drug,content
CHEMBL1195,"CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC_|_CAJIGINSTLKQMM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPOXYCAINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Propoxycaine']_|_[('PubChem', array(['11112410'], dtype=object)), ('Wikipedia', array(['Propoxycaine'], dtype=object)), ('drugbank', array(['DB09342'], dtype=object)), ('chEBI', array(['8496'], dtype=object))]_|_['CHEMBL1769']_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1231,"CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1_|_XIQVNETUBQGFHX-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYBUTYNIN_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Anturol' 'Contimin 2.5' 'Contimin 5' 'Cystrin' 'Ditropan' 'Ditropan xl'
 'Kentera' 'Kentera (previously oxybutynin nicobrand)' 'Lyrinel xl'
 'Oxybutynin' 'Oxytrol' 'Oxytrol for women' 'Promictuline' 'Urimin']_|_['Ditropan' 'Oxybutynin']_|_[('DailyMed', array(['oxybutynin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand'],
      dtype=object)), ('PubChem', array(['174006905', '50105262', '90341037'], dtype=object)), ('Wikipedia', array(['Oxybutynin'], dtype=object)), ('drugbank', array(['DB01062'], dtype=object)), ('chEBI', array(['7856'], dtype=object))]_|_['CHEMBL1133']_|_{'rows': array(['EFO_0006865', 'EFO_1000781', 'HP_0000103', 'MONDO_0024290',
       'EFO_0006865', 'EFO_0003956', 'EFO_0003918', 'HP_0000975',
       'EFO_0000512', 'HP_0002307', 'EFO_0009562', 'HP_0000020',
       'EFO_0001663', 'HP_0000011', 'HP_0000020', 'EFO_1000781',
       'EFO_0003877'], dtype=object), 'count': 17}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 11 investigational indications."
CHEMBL1637,"Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1_|_OKKDEIYWILRZIA-OSZBKLCCSA-N_|_Small molecule_|_False_|_GEMCITABINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL888_|_False_|_True_|_['Gemcitabine hydrochloride' 'Gemzar' 'Infugem']_|_['Gemcitabine (as hydrochloride)' 'Gemcitabine hcl'
 'Gemcitabine hydrochloride' 'Gemzar' 'LY-188011'
 'LY-188011 HYDROCHLORIDE' 'LY188011 HYDROCHLORIDE']_|_[('DailyMed', array(['gemcitabine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206197', '170465129'], dtype=object)), ('chEBI', array(['31647'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'MONDO_0008627', 'EFO_0006859', 'EFO_0000183',
       'Orphanet_145', 'EFO_0000574', 'EFO_0006475', 'EFO_0000681',
       'EFO_1000613', 'MONDO_0005184', 'EFO_0008528', 'EFO_0000616',
       'EFO_1000359', 'EFO_1000043', 'EFO_0000313', 'EFO_0001075',
       'EFO_0000096', 'EFO_0000565', 'MONDO_0011962', 'EFO_0000691',
       'MONDO_0002087', 'EFO_1000251', 'EFO_1001961', 'EFO_0007532',
       'MONDO_0004192', 'MONDO_0016537', 'EFO_0006861', 'EFO_0006738',
       'EFO_0000588', 'MONDO_0002158', 'MONDO_0015760', 'MONDO_0001056',
       'EFO_0000305', 'MONDO_0005411', 'EFO_0005537', 'MONDO_0004986',
       'EFO_1001951', 'MONDO_0007254', 'MONDO_0002974', 'MONDO_0002367',
       'MONDO_0004992', 'EFO_0001416', 'HP_0001907', 'EFO_0000466',
       'EFO_0004252', 'EFO_1001469', 'EFO_1001051', 'EFO_1001959',
       'MONDO_0008315', 'EFO_0001378', 'EFO_0003060', 'MONDO_0008903',
       'MONDO_0001187', 'EFO_0002618', 'MONDO_0002691'], dtype=object), 'count': 55}_|_[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229,ENSG00000167325,ENSG00000048392,ENSG00000171848]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 48 investigational indications."
CHEMBL1743017,"nan_|_nan_|_Antibody_|_False_|_FEZAKINUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fezakinumab' 'ILV-094']_|_nan_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000274', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000127318]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2104927,"CN(CCc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)[C@H](c1ccccc1)N1CCN(CC2CC2)CC1_|_HUTHJVYJUPXHDF-DEOSSOPVSA-N_|_Small molecule_|_False_|_FIGOPITANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIF 1149 BS' 'BIIF 1149 CL' 'BIIF-1149 BS' 'BIIF-1149-BS' 'Biif 1149'
 'Figopitant']_|_[('drugbank', array(['DB12122'], dtype=object))]_|_['CHEMBL3542235']_|_nan_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2105675,"CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1_|_DQJDBUPLRMRBAB-WZTVWXICSA-N_|_Small molecule_|_False_|_TAFAMIDIS MEGLUMINE_|_2011.0_|_4.0_|_CHEMBL2103837_|_False_|_True_|_['Vyndaqel']_|_['FX-1006A' 'Tafamidis meglumine']_|_[('DailyMed', array(['tafamidis%20meglumine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel'],
      dtype=object)), ('chEBI', array(['79345'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001875', 'EFO_0009562', 'EFO_0000318', 'MONDO_0019438',
       'EFO_0004129'], dtype=object), 'count': 5}_|_[ENSG00000118271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 2 investigational indications."
CHEMBL2107826,"O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21_|_DJXRIQMCROIRCZ-XOEOCAAJSA-N_|_Small molecule_|_False_|_VIBEGRON_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Gemtesa']_|_['KRP-114V' 'Mk4618' 'Vibegron']_|_[('drugbank', array(['DB14895'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006865', 'HP_0000020', 'EFO_0000555', 'EFO_0000537',
       'EFO_1000781'], dtype=object), 'count': 5}_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications."
CHEMBL2109177,nan_|_nan_|_Antibody_|_False_|_ODULIMOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Afolimomab' 'Odulimomab' 'anti-LFA1']_|_nan_|_nan_|_nan_|_[ENSG00000005844]_|_Antibody drug with a maximum clinical trial phase of III.
CHEMBL2346976,"CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1_|_JMEYDSHPKCSIJC-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD3514_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZD-3514' 'Azd 3514' 'Azd3514' 'CS-1443']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545096,"COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1.O=C(O)/C=C\C(=O)O_|_YUXMAKUNSXIEKN-BTJKTKAUSA-N_|_Small molecule_|_False_|_BGT-226_|_nan_|_2.0_|_CHEMBL3218578_|_False_|_False_|_[]_|_['BGT226' 'Bgt-226' 'NVP-BGT-226' 'NVP-BGT226']_|_[('chEBI', array(['71953'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0016063', 'MONDO_0004992', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545103,"nan_|_nan_|_Small molecule_|_False_|_AZD3199_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd3199']_|_nan_|_nan_|_{'rows': array(['HP_0006536', 'EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545145,"nan_|_nan_|_Small molecule_|_False_|_WX-554_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Wx-554']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545238,"nan_|_nan_|_Small molecule_|_False_|_CS-8080_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Cs-8080']_|_nan_|_nan_|_nan_|_[ENSG00000025434,ENSG00000131408]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545340,CNC(=O)COc1cccc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(F)(F)O4)n2)c1.O=C(O)c1ccc2ccccc2c1O_|_ILIHENOWEIBEQV-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-343_|_nan_|_2.0_|_CHEMBL2170582_|_False_|_False_|_[]_|_['R-343' 'R-940343' 'R940343']_|_nan_|_nan_|_nan_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL363648,"CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1_|_HEKAIDKUDLCBRU-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAK-715_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TAK 715' 'TAK-715' 'Tak-715']_|_[('PubChem', array(['103905024', '174006984'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707249,"nan_|_nan_|_Small molecule_|_False_|_ASM-024_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Asm-024']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}_|_[ENSG00000175344,ENSG00000181072,ENSG00000168539,ENSG00000133019,ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3910075,COc1ccc(C(=O)c2cn(C(C)C)c3ncnc(N)c23)cc1NC(=O)Nc1ccc(Cl)cc1Cl_|_VFCRSIORGUNNGT-UHFFFAOYSA-N_|_Small molecule_|_False_|_CE-245677_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ce 245677' 'Ce-245677']_|_nan_|_nan_|_nan_|_[ENSG00000120156]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989990,"nan_|_nan_|_Antibody_|_False_|_ISTIRATUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Istiratumab' 'MM-005' 'MM-141']_|_nan_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_0002618'], dtype=object), 'count': 2}_|_[ENSG00000065361,ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297785,"nan_|_nan_|_Antibody_|_False_|_VIBOSTOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-7684' 'MK7684' 'Mk-7684' 'TIGIT INHIBITOR MK-7684'
 'TIGIT-TARGETING AGENT MK-7684' 'Vibostolimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VIBOSTOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000756', 'EFO_0000702', 'MONDO_0001187',
       'EFO_0003060', 'EFO_0000681', 'EFO_0001642', 'EFO_1001951',
       'EFO_0008528', 'EFO_0000616'], dtype=object), 'count': 10}_|_[ENSG00000181847]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL466659,"O=[N+]([O-])OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-]_|_TZRXHJWUDPFEEY-UHFFFAOYSA-N_|_Small molecule_|_False_|_PENTAERYTHRITOL TETRANITRATE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Cardiacap' 'Mycardol' 'Peritrate' 'Peritrate sa']_|_['Pentaerithritol tetranitrate' 'Pentaerithrityl tetranitrate'
 'Pentaerythritol tetranitrate' 'Pentaerythrityl tetranitrate' 'Pentalong'
 'Pentanitrol']_|_[('PubChem', array(['144205177', '144212064', '29215318'], dtype=object)), ('Wikipedia', array(['Pentaerythritol_tetranitrate'], dtype=object)), ('drugbank', array(['DB06154'], dtype=object)), ('chEBI', array(['25879'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."
CHEMBL471737,"COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2_|_ACRHBAYQBXXRTO-OAQYLSRUSA-N_|_Small molecule_|_False_|_IVABRADINE_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Corlanor' 'Procoralan']_|_['Ivabradine' 'S-16257']_|_[('DailyMed', array(['ivabradine'], dtype=object)), ('PubChem', array(['50125937'], dtype=object)), ('Wikipedia', array(['Ivabradine'], dtype=object)), ('drugbank', array(['DB09083'], dtype=object)), ('chEBI', array(['85966'], dtype=object))]_|_['CHEMBL2145077']_|_{'rows': array(['EFO_1001207', 'EFO_0003144', 'EFO_0006834', 'EFO_0007372',
       'EFO_1000645', 'EFO_0003144', 'EFO_1000899', 'EFO_1001373',
       'EFO_0000574', 'EFO_0003913', 'EFO_0005252', 'HP_0001649',
       'EFO_0000401', 'EFO_0008586', 'EFO_0000373', 'EFO_0001645',
       'EFO_0000319', 'EFO_0000275', 'EFO_0005251', 'EFO_0000373',
       'EFO_0003913', 'MONDO_0004992'], dtype=object), 'count': 22}_|_[ENSG00000138622]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 18 investigational indications."
CHEMBL521851,"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1_|_LHNIIDJUOCFXAP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PICTILISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDC-0941' 'GDC 0941' 'GDC-0941' 'Pictilisib' 'Pictrelisib' 'Rg-7321']_|_[('PubChem', array(['103905592'], dtype=object)), ('drugbank', array(['DB11663'], dtype=object)), ('chEBI', array(['65326'], dtype=object))]_|_['CHEMBL4097197' 'CHEMBL1922096']_|_{'rows': array(['MONDO_0007254', 'EFO_0005952', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL524,"COc1ccc(OC)c(C(O)C(C)N)c1_|_WJAJPNHVVFWKKL-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHOXAMINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Methoxamine' 'NRL-001' 'NRL001' 'Nrl001' 'Vasoxyl']_|_[('PubChem', array(['90341132'], dtype=object)), ('Wikipedia', array(['Methoxamine'], dtype=object)), ('drugbank', array(['DB00723'], dtype=object)), ('chEBI', array(['6839'], dtype=object))]_|_['CHEMBL1201103']_|_{'rows': array(['EFO_0009523', 'EFO_0000319', 'EFO_0009523', 'HP_0000020'],
      dtype=object), 'count': 4}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 3 investigational indications."
CHEMBL5314392,"C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOc1ccc(-c2c(C#N)c(SCc3csc(-c4ccc(Cl)cc4)n3)nc(N3CCCC3)c2C#N)cc1_|_WESNEIGKOAXSGX-VXKWHMMOSA-N_|_Small molecule_|_False_|_BAY1067197_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY-10-67197' 'BAY-1067197' 'BAY10-67197' 'BAY1067197' 'Bay1067197'
 'Neladenoson bialanate' 'Neladenoson dalanate']_|_nan_|_nan_|_{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL5314401,"Cc1ncccc1C(=O)N1CCN(S(=O)(=O)c2ccc(C(F)(F)F)cc2)C[C@@H]1C_|_BLFJGFDZMABYMY-ZDUSSCGKSA-N_|_Small molecule_|_False_|_CNV2197944_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CNV2197944' 'Cnv-2197944' 'Cnv2197944']_|_nan_|_nan_|_{'rows': array(['EFO_1000783', 'MONDO_0041052'], dtype=object), 'count': 2}_|_[ENSG00000148408]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1090090,"NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F_|_FYSRKRZDBHOFAY-UHFFFAOYSA-N_|_Small molecule_|_False_|_VX-702_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['VX-702' 'Vx-702']_|_[('PubChem', array(['103905258', '137275870'], dtype=object)), ('drugbank', array(['DB05470'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200469,"CN(C)CCCN1c2ccccc2Sc2ccccc21.Cl_|_JIVSXRLRGOICGA-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROMAZINE HYDROCHLORIDE_|_1956.0_|_4.0_|_CHEMBL564_|_False_|_True_|_['Prazine' 'Promazine Granules' 'Promazine hydrochloride' 'Protactyl'
 'Sparine' 'Tranquazine' 'Verophene']_|_['NSC-17468' 'Promazine chloride' 'Promazine hcl'
 'Promazine hydrochloride']_|_[('PubChem', array(['144203786', '170464766', '26747628', '26747629', '50106839',
       '50106840', '50106841', '56422376', '57288080', '855749'],
      dtype=object)), ('chEBI', array(['8460'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL1200879,"CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[Na+]_|_KYITYFHKDODNCQ-UHFFFAOYSA-M_|_Small molecule_|_True_|_WARFARIN SODIUM_|_1954.0_|_4.0_|_CHEMBL1464_|_False_|_True_|_['Athrombin' 'Coumadin' 'Jantoven' 'Marevan' 'Panwarfin' 'Warfarin sodium']_|_['Aldocumar' 'Apo-warfarin' 'Prothromadin' 'Sodium warfarin'
 'Warfarin sodium' 'Warfarin sodium salt' 'Warfarinum natricum'
 'Zoocoumarin sodium salt']_|_[('DailyMed', array(['warfarin%20sodium'], dtype=object)), ('PubChem', array(['144211862', '50085469'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'HP_0004936', 'EFO_0003907', 'EFO_0000275',
       'EFO_0000612', 'EFO_0000685', 'EFO_0003827', 'HP_0001907',
       'EFO_0004239'], dtype=object), 'count': 9}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 7 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201746,"C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1_|_OGSBUKJUDHAQEA-WMCAAGNKSA-N_|_Small molecule_|_False_|_PRALATREXATE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Folotyn']_|_['NSC-754230' 'PDX' 'Pralatrexate']_|_[('DailyMed', array(['pralatrexate'], dtype=object)), ('PubChem', array(['144206459'], dtype=object)), ('Wikipedia', array(['Pralatrexate'], dtype=object)), ('drugbank', array(['DB06813'], dtype=object)), ('chEBI', array(['71223'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0002913', 'MONDO_0000430', 'EFO_1000785',
       'MONDO_0015760', 'MONDO_0002158', 'MONDO_0008903', 'MONDO_0002087',
       'EFO_0000574', 'EFO_0000305', 'EFO_0003060', 'EFO_0000616',
       'MONDO_0008170', 'EFO_0003032', 'EFO_0006859', 'MONDO_0019471',
       'EFO_0000211', 'MONDO_0004992', 'EFO_1001051'], dtype=object), 'count': 19}_|_[ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 14 investigational indications."
CHEMBL1721885,"Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1_|_CTNPALGJUAXMMC-PMFHANACSA-N_|_Small molecule_|_False_|_SU-014813_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SU-14813' 'Su-014813' 'Su-14813']_|_[('PubChem', array(['50100117'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003869'], dtype=object), 'count': 2}_|_[ENSG00000157404,ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1761322,"CCS(=O)(=O)CCCC12CCC(c3nnc(-c4ccccc4C(F)(F)F)n3C)(CC1)CC2_|_ORQZQBUNAMJFCY-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-0736_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK0736' 'Mk-0736' 'Mk0736']_|_[('drugbank', array(['DB15209'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003875', 'EFO_0000537'], dtype=object), 'count': 2}_|_[ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL197672,"C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)COc1c(F)c(F)cc(F)c1F_|_SCVHJVCATBPIHN-SJCJKPOMSA-N_|_Small molecule_|_False_|_EMRICASAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Emricasan' 'IDN 6556' 'IDN-6556' 'PF 03491390' 'PF-03491390' 'VAY-785'
 'VAY785']_|_[('drugbank', array(['DB05408'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010282', 'EFO_0000400', 'MONDO_0100096', 'EFO_1001249',
       'EFO_0001422', 'EFO_0004220', 'EFO_1001345', 'EFO_0001421'],
      dtype=object), 'count': 8}_|_[ENSG00000196954,ENSG00000132906,ENSG00000164305,ENSG00000137757,ENSG00000138794,ENSG00000165806,ENSG00000064012,ENSG00000137752,ENSG00000106144,ENSG00000003400,ENSG00000105141,ENSG00000204403]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL2103840,"CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12_|_PIMQWRZWLQKKBJ-SFHVURJKSA-N_|_Small molecule_|_False_|_DINACICLIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dinaciclib' 'Mk-7965' 'SCH 727965' 'SCH-727965' 'SCH727965']_|_[('drugbank', array(['DB12021'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006861', 'EFO_0000756', 'EFO_0000222', 'EFO_0000616',
       'EFO_0000095', 'MONDO_0001023', 'MONDO_0007254', 'EFO_0001378',
       'EFO_0000220'], dtype=object), 'count': 9}_|_[ENSG00000123374,ENSG00000170312,ENSG00000136807,ENSG00000164885]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2108660,"nan_|_nan_|_Antibody drug conjugate_|_False_|_TUCOTUZUMAB CELMOLEUKIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EMD 273066' 'EMD-273066' 'HUKS-IL2' 'KSA-INTERLEUKIN-2'
 'Tucotuzumab celmoleukin']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170'], dtype=object), 'count': 1}_|_[ENSG00000119888]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108887,"nan_|_nan_|_Antibody_|_False_|_AFELIMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Segard']_|_['Afelimomab' 'LU-54107' 'LU54107' 'MAK-195F']_|_nan_|_nan_|_{'rows': array(['EFO_0000540'], dtype=object), 'count': 1}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL229430,CC(=O)Nc1nc2c(Oc3cc(-c4ccc(C(F)(F)F)cc4)ncn3)cccc2s1_|_YUTIXVXZQIQWGY-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMG-517_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-517' 'Amg-517']_|_nan_|_nan_|_nan_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3039521,"CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CC[C@H](NC(=O)c5ccc(NCc6cnc7[nH]c(N)nc(=O)c7n6)cc5)C(=O)O)C(=O)O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1_|_KUZYSQSABONDME-QRLOMCMNSA-N_|_Unknown_|_False_|_VINTAFOLIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['EC-145' 'EC145' 'Vintafolide']_|_[('drugbank', array(['DB05168'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000571', 'EFO_0000616', 'EFO_0003869', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0008170'], dtype=object), 'count': 6}_|_[ENSG00000110195]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3545185,"O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1_|_DEVSOMFAQLZNKR-RJRFIUFISA-N_|_Small molecule_|_False_|_SELINEXOR_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Nexpovio' 'Xpovio']_|_['KPT-330' 'Selinexor']_|_[('DailyMed', array(['selinexor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio'],
      dtype=object)), ('drugbank', array(['DB11942'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0044903', 'EFO_0000574', 'EFO_0000702', 'MONDO_0008315',
       'EFO_0000182', 'EFO_1000581', 'EFO_0005537', 'EFO_0000681',
       'EFO_0000708', 'EFO_0000616', 'EFO_0003085', 'MONDO_0011962',
       'EFO_0007143', 'EFO_0001642', 'EFO_1000251', 'EFO_0000519',
       'EFO_0003060', 'EFO_0000339', 'EFO_0000096', 'EFO_0001075',
       'EFO_0000389', 'MONDO_0019460', 'MONDO_0007254', 'EFO_0001378',
       'MONDO_0100096', 'EFO_1001968', 'EFO_0000198', 'EFO_0004142',
       'EFO_0000220', 'MONDO_0004992', 'EFO_0002617', 'EFO_0000211',
       'EFO_1000657', 'EFO_0000691', 'MONDO_0000430', 'EFO_0000756',
       'MONDO_0019438', 'EFO_0008528', 'EFO_1001459', 'EFO_1001465',
       'EFO_0000707', 'EFO_0000222', 'EFO_0000403'], dtype=object), 'count': 43}_|_[ENSG00000082898]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 39 investigational indications."
CHEMBL3545415,"nan_|_nan_|_Protein_|_False_|_SMC021_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Smc021']_|_nan_|_nan_|_{'rows': array(['EFO_0003882', 'GO_0042697', 'MONDO_0005178', 'EFO_0003854'],
      dtype=object), 'count': 4}_|_[ENSG00000004948]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL356359,"CCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1_|_KVCSJPATKXABRQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIBOSEROD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Piboserod' 'SB-207266']_|_[('PubChem', array(['137275879'], dtype=object)), ('Wikipedia', array(['Piboserod'], dtype=object)), ('drugbank', array(['DB04873'], dtype=object))]_|_['CHEMBL2106927']_|_{'rows': array(['EFO_0000373', 'EFO_0000275'], dtype=object), 'count': 2}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297774,"nan_|_nan_|_Antibody_|_False_|_AMIVANTAMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Rybrevant']_|_['Amivantamab' 'Amivantamab vmjw' 'CNTO-4424' 'CNTO4424' 'JNJ 61186372'
 'JNJ-611' 'JNJ-61186372' 'JNJ-6372' 'Jnj 61186372' 'Jnj-61186372']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMIVANTAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'MONDO_0001056', 'EFO_0003060', 'MONDO_0004669',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000105976,ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 3 investigational indications."
CHEMBL4297880,"nan_|_nan_|_Protein_|_False_|_EVORPACEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALX-148' 'ALX148' 'Alx 148' 'Alx-148' 'Alx148' 'Evorpacept'
 'Lggl-alx-148' 'Sirpa variant alx148']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EVORPACEPT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'MONDO_0004992', 'EFO_0000181', 'EFO_0000616',
       'EFO_0000198', 'EFO_1001931', 'EFO_0005952', 'EFO_0000222'],
      dtype=object), 'count': 8}_|_[ENSG00000196776]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL468,"O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1_|_UEJJHQNACJXSKW-UHFFFAOYSA-N_|_Small molecule_|_True_|_THALIDOMIDE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Talidex' 'Thalidomide lipomed' 'Thalomid']_|_['.alpha.-phthalimidoglutarimide' 'Celgene' 'Contergan' 'Distaval' 'K-17'
 'Myrin' 'N-phthalylglutamic acid imide' 'NSC-527179' 'NSC-66847'
 'Neurosedyn' 'Pantosediv' 'Pharmion' 'Softenon' 'Thaled' 'Thalidomide'
 'Thalidomide ']_|_[('DailyMed', array(['thalidomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-lipomed'],
      dtype=object)), ('PubChem', array(['111716', '11532929', '124881523', '144210897', '170465323',
       '174007312', '26747126', '26751823', '50104514', '90341724'],
      dtype=object)), ('Wikipedia', array(['Thalidomide'], dtype=object)), ('drugbank', array(['DB01041'], dtype=object)), ('chEBI', array(['74947'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0005543', 'EFO_1000158', 'EFO_0000403',
       'EFO_1000613', 'EFO_0004142', 'EFO_0000191', 'EFO_0003060',
       'MONDO_0044903', 'MONDO_0002158', 'EFO_0003843', 'EFO_0001065',
       'MONDO_0008170', 'EFO_0006888', 'EFO_0000676', 'MONDO_0002087',
       'MONDO_0018364', 'EFO_0000389', 'MONDO_0019472', 'MONDO_0004975',
       'EFO_0000182', 'EFO_0000096', 'MONDO_0015564', 'MONDO_0017816',
       'EFO_0004268', 'EFO_0000474', 'EFO_0000681', 'EFO_0002430',
       'MONDO_0003196', 'EFO_0002939', 'EFO_1001767', 'MONDO_0019438',
       'HP_0003073', 'EFO_0000717', 'EFO_0006859', 'MONDO_0002367',
       'EFO_0000095', 'EFO_0000765', 'EFO_0005628', 'EFO_0009441',
       'EFO_0000756', 'EFO_1001875', 'MONDO_0004992', 'HP_0012735',
       'EFO_0000621', 'EFO_0000673', 'MONDO_0018906', 'EFO_1001951',
       'EFO_1001996', 'EFO_1001968', 'EFO_0000729', 'EFO_0000384',
       'EFO_0000574', 'MONDO_0008903', 'EFO_0000691', 'EFO_0000764',
       'MONDO_0019338', 'EFO_0000540', 'EFO_0005952', 'MONDO_0021063',
       'MONDO_0100096', 'MONDO_0001056', 'EFO_0000198', 'MONDO_0007254',
       'EFO_0005570', 'EFO_0000565', 'EFO_0003898', 'EFO_0001378',
       'Orphanet_848', 'EFO_0000183', 'EFO_0000616', 'EFO_0007160',
       'EFO_1001901', 'EFO_0007312', 'EFO_0000365', 'MONDO_0004976',
       'EFO_0000342', 'EFO_1000045', 'EFO_1000318', 'EFO_0003865',
       'EFO_0000768', 'MONDO_0019558', 'MONDO_0002691', 'MONDO_0007576',
       'EFO_1001469', 'EFO_0003047', 'MONDO_0008315'], dtype=object), 'count': 87}_|_[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for immune system disease and multiple myeloma and has 85 investigational indications. This drug has a black box warning from the FDA."
CHEMBL5314382,"NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O_|_HSXBEUMRBMAVDP-QKXVGOHISA-N_|_Protein_|_False_|_PASIREOTIDE PAMOATE_|_2014.0_|_4.0_|_CHEMBL3349607_|_False_|_True_|_['Signifor lar' 'Signifor lar kit']_|_['Pasireotide embonate']_|_nan_|_nan_|_{'rows': array(['EFO_1001485'], dtype=object), 'count': 1}_|_[ENSG00000139874,ENSG00000278195,ENSG00000180616,ENSG00000162009]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for acromegaly."
CHEMBL888,"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1_|_SDUQYLNIPVEERB-QPPQHZFASA-N_|_Small molecule_|_False_|_GEMCITABINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Gemzar']_|_['Gemcitabine' 'Gemzar' 'LY-188011' 'LY188011' 'NSC-613327']_|_[('PubChem', array(['124893555', '50113286'], dtype=object)), ('Wikipedia', array(['Gemcitabine'], dtype=object)), ('drugbank', array(['DB00441'], dtype=object)), ('chEBI', array(['175901'], dtype=object))]_|_['CHEMBL1637']_|_{'rows': array(['EFO_0000182', 'MONDO_0001657', 'EFO_0000255', 'EFO_0000574',
       'EFO_0000707', 'EFO_0000681', 'EFO_0006859', 'MONDO_0005184',
       'EFO_0008528', 'MONDO_0002367', 'MONDO_0015760', 'EFO_0001075',
       'EFO_1001961', 'MONDO_0005575', 'MONDO_0004192', 'EFO_0006861',
       'EFO_0006738', 'MONDO_0021117', 'EFO_0001061', 'EFO_0000183',
       'MONDO_0005411', 'MONDO_0018906', 'MONDO_0002158', 'EFO_0005537',
       'MONDO_0004986', 'EFO_0009708', 'MONDO_0007254', 'MONDO_0002974',
       'MONDO_0019472', 'MONDO_0002367', 'MONDO_0004992', 'EFO_0000565',
       'EFO_0004252', 'MONDO_0000430', 'EFO_1000359', 'MONDO_0004986',
       'MONDO_0001187', 'EFO_0002618', 'MONDO_0007576', 'EFO_0001075',
       'EFO_1001469', 'MONDO_0008627', 'EFO_0002913', 'EFO_0003060',
       'EFO_0000222', 'EFO_0000616', 'EFO_1000613', 'EFO_0009534',
       'MONDO_0002087', 'EFO_0000681', 'EFO_1000043', 'MONDO_0011719',
       'EFO_0000096', 'EFO_0003869', 'EFO_0003893', 'MONDO_0008315',
       'EFO_0001376', 'MONDO_0002087', 'MONDO_0011962', 'EFO_1001956',
       'EFO_0005230', 'EFO_0007532', 'MONDO_0016537', 'MONDO_0021054',
       'EFO_0002618', 'EFO_0000403', 'EFO_0000756', 'MONDO_0001056',
       'EFO_0000637', 'MONDO_0004192', 'EFO_0000564', 'MONDO_0009348',
       'EFO_0000181', 'MONDO_0002691', 'EFO_1001959', 'MONDO_0004992',
       'EFO_0005088', 'EFO_0010282', 'MONDO_0008170', 'EFO_0001378',
       'EFO_0000294', 'EFO_0006859', 'EFO_0000571', 'EFO_1000026',
       'MONDO_0001187', 'EFO_0006475', 'EFO_0000691', 'EFO_0000220',
       'EFO_0001416', 'MONDO_0007254', 'MONDO_0005411', 'EFO_0003050',
       'EFO_0000096', 'EFO_0003891', 'EFO_0000228', 'EFO_0000174',
       'MONDO_0011962', 'EFO_0000770', 'EFO_0003860', 'EFO_1000251',
       'EFO_1001951', 'MONDO_0002108', 'EFO_1000292', 'MONDO_0003059',
       'EFO_0003863', 'EFO_0000588', 'MONDO_0008627', 'EFO_0005952',
       'MONDO_0021063', 'MONDO_0015760', 'EFO_0000305', 'MONDO_0018364',
       'MONDO_0003060', 'EFO_0004252', 'EFO_0000305', 'MONDO_0008903',
       'EFO_0005537', 'EFO_0002939', 'MONDO_0001056', 'HP_0001907',
       'EFO_0000466', 'EFO_1001051', 'EFO_1000657', 'EFO_0000365',
       'EFO_0004606', 'EFO_0000313', 'EFO_1000251', 'MONDO_0008315',
       'EFO_0003060', 'EFO_1001100', 'EFO_1001968', 'MONDO_0008170',
       'EFO_0000183', 'EFO_0000574', 'Orphanet_145', 'EFO_0003032',
       'EFO_0008528', 'EFO_0000616', 'EFO_1000359', 'EFO_0000313',
       'EFO_0000565', 'EFO_0000211', 'EFO_0000691', 'EFO_1001961',
       'MONDO_0019471', 'EFO_0005221', 'EFO_0000702', 'MONDO_0002158',
       'EFO_0000514', 'EFO_1001951', 'EFO_0001416', 'EFO_1001469',
       'MONDO_0005184', 'EFO_0000708', 'EFO_0000588', 'MONDO_0002974',
       'EFO_0001378', 'MONDO_0008903', 'MONDO_0002691'], dtype=object), 'count': 159}_|_[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229,ENSG00000167325,ENSG00000048392,ENSG00000171848]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 9 approved and 132 investigational indications."
CHEMBL900,"Cc1ccccc1C(OCCN(C)C)c1ccccc1_|_QVYRGXJJSLMXQH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ORPHENADRINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Disipal' 'Invagesic' 'Mefenamine' 'Mialgin' 'Norflex' 'Norgesic'
 'Orphenadrin' 'Orphenadrine' 'Orphengesic']_|_[('PubChem', array(['124880989', '174006927', '90341796'], dtype=object)), ('Wikipedia', array(['Orphenadrine'], dtype=object)), ('drugbank', array(['DB01173'], dtype=object)), ('chEBI', array(['7789'], dtype=object))]_|_['CHEMBL1201023' 'CHEMBL1200395']_|_{'rows': array(['MONDO_0005180', 'EFO_0003843', 'HP_0003419'], dtype=object), 'count': 3}_|_[ENSG00000196639,ENSG00000103546,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for parkinson disease and pain and has 1 investigational indication."
CHEMBL1091,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_ALEXXDVDDISNDU-JZYPGELDSA-N_|_Small molecule_|_False_|_HYDROCORTISONE ACETATE_|_1951.0_|_4.0_|_nan_|_False_|_True_|_['Barquinol hc' 'Chloromycetin hydrocort' 'Colifoam' 'Cortef acetate'
 'Cortifoam' 'Cortril' 'Cortucid' 'Dricort' 'Epifoam' 'Framycort'
 'Fucidin h' 'Genticin hc' 'Gentisone hc' 'Gppe ear susp' 'Gppe eye crm'
 'Gppe foam aero' 'Hc45 hydrocort' 'Hemsol-hc' 'Hepacort plus' 'Hydrocal'
 'Hydrocortisone acetate' 'Hydrocortone' 'Lanacort' 'Micort-hc'
 'Neo-cortef' 'Orabase hca']_|_['Cortisol 21-acetate' 'Hydrocortisone 21-acetate'
 'Hydrocortisone Acetate' 'Hydrocortisone acetate' 'Hydrocortisoni acetas'
 'NSC-741']_|_[('DailyMed', array(['hydrocortisone%20acetate'], dtype=object)), ('PubChem', array(['56422202', '855532'], dtype=object)), ('drugbank', array(['DB14539'], dtype=object)), ('chEBI', array(['17609'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009552', 'EFO_0004208', 'EFO_0000274', 'HP_0000989',
       'MP_0001845', 'EFO_0000701', 'MONDO_0002050'], dtype=object), 'count': 7}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 3 approved and 4 investigational indications."
CHEMBL1200950,"C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2.[Br-]_|_GKEGFOKQMZHVOW-UHFFFAOYSA-M_|_Small molecule_|_False_|_CLIDINIUM BROMIDE_|_1982.0_|_4.0_|_CHEMBL620_|_False_|_True_|_['Quarzan']_|_['Clidinium bromide' 'NSC-756686' 'RO 2-3773' 'RO-2-3773' 'RO-23773']_|_[('DailyMed', array(['clidinium%20bromide'], dtype=object)), ('PubChem', array(['144204086', '170464768', '56423127', '855678'], dtype=object)), ('Wikipedia', array(['Clidinium_bromide'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease."
CHEMBL1201827,"nan_|_nan_|_Antibody_|_True_|_PANITUMUMAB_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Vectibix']_|_['ABX-EGF' 'Abenix' 'E7.6.3' 'L01xc08' 'Panitumumab']_|_[('DailyMed', array(['panitumumab'], dtype=object)), ('DrugCentral', array(['4955'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix'],
      dtype=object)), ('Wikipedia', array(['Panitumumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000707', 'MONDO_0007576', 'EFO_1000657', 'EFO_0001075',
       'EFO_0006859', 'MONDO_0008170', 'EFO_1000852', 'EFO_0000503',
       'EFO_0000681', 'EFO_0000365', 'MONDO_0021063', 'MONDO_0008903',
       'EFO_0000313', 'EFO_0005922', 'EFO_1000251', 'EFO_0002618',
       'MONDO_0005575', 'EFO_0005221', 'MONDO_0002158', 'MONDO_0002974',
       'EFO_0000616', 'MONDO_0008315', 'MONDO_0002367', 'EFO_0005537',
       'MONDO_0004992', 'MONDO_0001187', 'EFO_0004142', 'EFO_1001951',
       'EFO_0000181', 'EFO_1001512', 'MONDO_0007254', 'EFO_0002916',
       'EFO_0003060'], dtype=object), 'count': 33}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 27 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1336,"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1_|_MLDQJTXFUGDVEO-UHFFFAOYSA-N_|_Small molecule_|_False_|_SORAFENIB_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Nexavar']_|_['BAY 43-9006' 'BAY-43-9006' 'Sorafenib']_|_[('PubChem', array(['103904444', '124893321', '124893323', '50100118', '50112741'],
      dtype=object)), ('Wikipedia', array(['Sorafenib'], dtype=object)), ('drugbank', array(['DB00398'], dtype=object)), ('chEBI', array(['50924'], dtype=object))]_|_['CHEMBL1200485' 'CHEMBL4297490' 'CHEMBL1760433']_|_{'rows': array(['MONDO_0004192', 'EFO_0000691', 'EFO_0000673', 'EFO_0001061',
       'EFO_0000198', 'EFO_1001968', 'EFO_0000756', 'MONDO_0018531',
       'EFO_0000641', 'EFO_0004212', 'MONDO_0008170', 'EFO_0000365',
       'MONDO_0008903', 'EFO_0008524', 'EFO_0000756', 'MONDO_0008170',
       'EFO_0000691', 'EFO_0003060', 'EFO_0001361', 'EFO_1001968',
       'EFO_1001465', 'EFO_0003833', 'EFO_0000574', 'MONDO_0000831',
       'EFO_1000657', 'EFO_0002499', 'MONDO_0002108', 'EFO_0000588',
       'EFO_1001469', 'EFO_0000501', 'EFO_0000313', 'EFO_1000796',
       'EFO_0000702', 'MONDO_0002691', 'EFO_1001052', 'MONDO_0044937',
       'EFO_0003891', 'EFO_0000666', 'EFO_0000095', 'EFO_0001378',
       'EFO_0000224', 'EFO_0000196', 'MONDO_0008315', 'EFO_0002618',
       'MONDO_0004992', 'EFO_0003833', 'EFO_0000519', 'EFO_0002499',
       'EFO_0000640', 'EFO_0000565', 'EFO_0000221', 'MONDO_0007576',
       'MONDO_0011719', 'EFO_0009907', 'EFO_0000558', 'EFO_1001465',
       'EFO_0000621', 'EFO_0000702', 'EFO_1000158', 'EFO_0000681',
       'EFO_0000095', 'MONDO_0001187', 'EFO_1001901', 'MONDO_0002087',
       'EFO_1001346', 'EFO_0000222', 'EFO_1000657', 'EFO_0000501',
       'EFO_0003865', 'EFO_0003893', 'MONDO_0015277', 'MONDO_0001187',
       'EFO_0000403', 'MONDO_0002691', 'EFO_0003841', 'EFO_0000335',
       'EFO_0000637', 'MONDO_0011719', 'EFO_0000349', 'EFO_0006352',
       'EFO_0006861', 'EFO_0000389', 'EFO_0002501', 'MONDO_0007254',
       'MONDO_0002367', 'MONDO_0004992', 'EFO_0004142', 'EFO_0002918',
       'EFO_0000224', 'EFO_0007535', 'EFO_1000292', 'MONDO_0008315',
       'EFO_0000220', 'EFO_0000228', 'EFO_0000222', 'MONDO_0008903',
       'EFO_0002618', 'EFO_0000616', 'MONDO_0001056', 'EFO_1000613',
       'EFO_0003860', 'EFO_0000616', 'EFO_1000359', 'MONDO_0021063',
       'EFO_0005221', 'EFO_0002938', 'MONDO_0044926', 'EFO_0000707',
       'EFO_0002618', 'EFO_0000673', 'MONDO_0001056', 'EFO_0000339',
       'MONDO_0004986', 'EFO_0000641', 'EFO_0003060', 'EFO_0004284',
       'EFO_0001421', 'EFO_0000182', 'MONDO_0007254', 'EFO_0002501',
       'MONDO_0002108', 'EFO_0000222', 'EFO_1001951', 'MONDO_0002108',
       'EFO_0000182', 'EFO_0000588', 'EFO_0000519', 'MONDO_0002367',
       'EFO_0003086', 'EFO_0002892', 'EFO_0003060', 'EFO_0004252',
       'EFO_0000616', 'EFO_0000681', 'EFO_0005088', 'EFO_1001513',
       'EFO_0000637', 'EFO_0001378', 'EFO_0003871', 'EFO_0002892',
       'EFO_0004252', 'EFO_0003032', 'EFO_0000220', 'EFO_0000182',
       'MONDO_0002158'], dtype=object), 'count': 145}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025,ENSG00000132155,ENSG00000165731,ENSG00000157404,ENSG00000157764,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 112 investigational indications."
CHEMBL1371200,"C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)[O-].[K+]_|_JTZQCHFUGHIPDF-RYVBEKKQSA-M_|_Small molecule_|_False_|_CANRENOATE POTASSIUM_|_nan_|_4.0_|_CHEMBL1616951_|_False_|_True_|_['Soldactone' 'Spiroctan-m']_|_['Canrenoate potassium' 'Canrenone free acid potassium salt' 'Kanrenol'
 'NSC-757789' 'Potassium canrenoate' 'SC-14266']_|_[('PubChem', array(['144204351', '56463334'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0008585'], dtype=object), 'count': 2}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL1544,"N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O_|_AUYYCJSJGJYCDS-LBPRGKRZSA-N_|_Small molecule_|_True_|_LIOTHYRONINE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_['Cytomel' 'Tertroxin']_|_[""3,5,3'-triiodothyronine, l-"" 'Cyronine' 'Euthroid-0.5' 'Euthroid-1'
 'Euthroid-2' 'Euthroid-3'
 'Levothyroxine sodium related compound liothyronine' 'Liothyronine'
 'NSC-80203' 'Rathyronine' 'Rathyronine, (s)-' 'Thyrolar-0.25'
 'Thyrolar-0.5' 'Thyrolar-1' 'Thyrolar-2' 'Thyrolar-3' 'Thyrolar-5'
 'Triiodothyronine (T3 Or Liothyronine, Active) (6-11%)' 'Triostat']_|_[('PubChem', array(['11532858', '124877498', '144203580', '144212260', '26753840',
       '4253003'], dtype=object)), ('Wikipedia', array(['Triiodothyronine'], dtype=object)), ('drugbank', array(['DB00279'], dtype=object)), ('chEBI', array(['18258'], dtype=object))]_|_['CHEMBL2106622' 'CHEMBL2107398' 'CHEMBL1356342' 'CHEMBL1201119']_|_{'rows': array(['EFO_0003144', 'MONDO_0002050', 'EFO_1000931', 'EFO_0006859',
       'EFO_0004705', 'MONDO_0008315', 'EFO_0004705', 'EFO_0003929',
       'MONDO_0002009', 'EFO_0003840', 'MONDO_0007254', 'EFO_0000275',
       'HP_0030680', 'EFO_0003841', 'EFO_0005207', 'EFO_0006834',
       'EFO_1001465', 'HP_0030680', 'EFO_1002017', 'MONDO_0004985',
       'EFO_1001055', 'MONDO_0005301'], dtype=object), 'count': 22}_|_[ENSG00000126351,ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1628569,"NC(=O)c1ccc(F)c2c1C[C@@H](N(C1CCC1)C1CCC1)CO2_|_MQTUXRKNJYPMCG-CYBMUJFWSA-N_|_Small molecule_|_False_|_ROBALZOTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd-7371' 'NAD-299' 'Robalzotan']_|_[('drugbank', array(['DB06538'], dtype=object))]_|_nan_|_nan_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1963249,"C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1_|_WGYPAJVJMXQXTR-ABNZCKJZSA-N_|_Small molecule_|_False_|_ULIMORELIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['TZP-101 FREE BASE' 'Ulimorelin']_|_[('drugbank', array(['DB12128'], dtype=object))]_|_['CHEMBL1923502' 'CHEMBL3926779']_|_{'rows': array(['EFO_0010282', 'EFO_1000948', 'MONDO_0004567'], dtype=object), 'count': 3}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2108345,"nan_|_nan_|_Oligonucleotide_|_False_|_TRABEDERSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-12009 FREE ACID' 'Trabedersen']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0002499'], dtype=object), 'count': 2}_|_[ENSG00000092969]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109341,"nan_|_nan_|_Antibody_|_False_|_CCR5MAB004_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CCR5MAB004' 'Ccr5mab004']_|_nan_|_nan_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109366,"nan_|_nan_|_Antibody_|_False_|_ANTI-TAC 90 Y-HAT_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ANTI-TAC 90 Y-HAT' 'Anti-tac 90 y-hat']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0000183'], dtype=object), 'count': 2}_|_[ENSG00000134460]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2109595,"nan_|_nan_|_Antibody_|_False_|_AMG-157_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-157' 'Amg-157' 'MEDI-9929']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000145777]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL217899,"CCc1nn(C2CCCC2)c2c1CCn1c(-c3cccs3)nnc1-2_|_DHCOPPHTVOXDKU-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOFIMILAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-325,366' 'CP-325366' 'Tofimilast']_|_[('drugbank', array(['DB11681'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2331680,"CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1_|_RGJOJUGRHPQXGF-INIZCTEOSA-N_|_Small molecule_|_False_|_RG-7603_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GDC-0349' 'Rg-7603']_|_[('drugbank', array(['DB13072'], dtype=object))]_|_['CHEMBL2331681']_|_{'rows': array(['EFO_0005952'], dtype=object), 'count': 1}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2346738,"Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1_|_LZXMUJCJAWVHPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPRAGLURANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADX-48621' 'ADX48621' 'Adx48621' 'Dipraglurant']_|_[('drugbank', array(['DB12733'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'MONDO_0011728'], dtype=object), 'count': 2}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL272980,"Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1_|_HRNLUBSXIHFDHP-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOCETINOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MGCD-0103' 'MGCD0103' 'Mocetinostat']_|_[('PubChem', array(['137276026'], dtype=object)), ('Wikipedia', array(['Mocetinostat'], dtype=object)), ('drugbank', array(['DB11830'], dtype=object))]_|_['CHEMBL481122']_|_{'rows': array(['EFO_0000574', 'EFO_0000183', 'EFO_0003060', 'MONDO_0018906',
       'EFO_0008528', 'EFO_0000222', 'EFO_0000565', 'EFO_0000095',
       'EFO_0000616', 'EFO_0000198', 'EFO_0002918', 'EFO_0000199',
       'EFO_0000564', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0008903'],
      dtype=object), 'count': 16}_|_[ENSG00000196591,ENSG00000171720,ENSG00000147099,ENSG00000163517,ENSG00000116478]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications."
CHEMBL307429,"OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O_|_LXBIFEVIBLOUGU-JGWLITMVSA-N_|_Small molecule_|_False_|_DUVOGLUSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['1 deoxynojirimycin' '1,5-dideoxy-1,5-imino-'
 '1,5-dideoxy-1,5-imino-d-glucitol' '1-deoxynojirimycin' 'Bay-h-5595'
 'D-1-deoxynojirimycin' 'Deoxynojirimycin' 'Duvoglustat' 'Moranolin'
 'Moranoline' 'Nojirimycin, 1-deoxy-']_|_[('PubChem', array(['26752140'], dtype=object)), ('drugbank', array(['DB03206'], dtype=object)), ('chEBI', array(['44369'], dtype=object))]_|_['CHEMBL460785']_|_{'rows': array(['Orphanet_365'], dtype=object), 'count': 1}_|_[ENSG00000171298]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3137320,"Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1_|_HWGQMRYQVZSGDQ-HZPDHXFCSA-N_|_Small molecule_|_False_|_TALAZOPARIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BMN 673' 'BMN-673' 'LT-673' 'Talazoparib']_|_[('drugbank', array(['DB11760'], dtype=object))]_|_['CHEMBL3137318']_|_{'rows': array(['EFO_0000196', 'EFO_0008528', 'EFO_0005537', 'EFO_0003869',
       'EFO_0005537', 'Orphanet_145', 'EFO_0003869', 'MONDO_0008170',
       'EFO_0003060', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000519',
       'EFO_0000326', 'MONDO_0004992', 'EFO_0000708', 'EFO_1001901',
       'EFO_0000616', 'EFO_0003060', 'EFO_0000305', 'EFO_0000681',
       'EFO_0000239', 'EFO_0000616', 'EFO_0000565', 'MONDO_0007254',
       'EFO_1001951', 'EFO_0000702', 'EFO_0000673', 'MONDO_0008315',
       'EFO_0002618', 'EFO_0000222', 'MONDO_0002334', 'MONDO_0011962',
       'EFO_0003968'], dtype=object), 'count': 33}_|_[ENSG00000143799,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 27 investigational indications."
CHEMBL3989478,"CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O_|_RVBRTNPNFYFDMZ-SPIKMXEPSA-N_|_Small molecule_|_False_|_THIETHYLPERAZINE MALEATE_|_1961.0_|_4.0_|_CHEMBL1378_|_False_|_True_|_['Torecan']_|_['GS-95' 'NSC-130044' 'Thiethylperazine dimaleate'
 'Thiethylperazine maleate' 'Thietylperazine maleate']_|_nan_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL4650441,"nan_|_nan_|_Antibody_|_False_|_IMSIDOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ANB-019' 'ANB019' 'Anb019' 'Imsidolimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IMSIDOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003894', 'MONDO_0019269', 'EFO_0000676', 'EFO_1000710',
       'EFO_1000662', 'MONDO_0015597'], dtype=object), 'count': 6}_|_[ENSG00000115598,ENSG00000196083]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL5314374,"CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)[O-])[C@H]3OS(=O)(=O)[O-])[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)[O-])[C@H]1OS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]_|_MVPQUSQUURLQKF-MCPDASDXSA-E_|_Oligosaccharide_|_False_|_IDRAPARINUX SODIUM_|_nan_|_3.0_|_CHEMBL5314801_|_False_|_False_|_[]_|_['Idraparinux nonasodium salt' 'Idraparinux sodium' 'ORG-34006'
 'SANORG-34006' 'SANORG34006']_|_nan_|_nan_|_{'rows': array(['EFO_0003907', 'EFO_0003827', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000126218]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL762,"Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1_|_WYWIFABBXFUGLM-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYMETAZOLINE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Nasacon' 'Ocuclear' 'Operil' 'Oxymetazoline']_|_[('PubChem', array(['104171207', '11111570', '11111571', '11113337', '124880976',
       '124880979', '144203768', '170464916', '26751491', '26751492',
       '50100299', '50104031', '90341671'], dtype=object)), ('Wikipedia', array(['Oxymetazoline'], dtype=object)), ('drugbank', array(['DB00935'], dtype=object)), ('chEBI', array(['7862'], dtype=object))]_|_['CHEMBL1200791']_|_{'rows': array(['EFO_0009523', 'MONDO_0000728', 'EFO_0003956', 'MONDO_0001330',
       'HP_0010783', 'HP_0001742', 'EFO_0007141', 'HP_0010783',
       'EFO_0007214', 'EFO_0005854', 'EFO_1000760', 'EFO_0005252',
       'HP_0001742', 'EFO_0005751', 'EFO_0005854', 'MONDO_0001330',
       'EFO_0007486', 'EFO_0007214', 'EFO_0003956', 'EFO_1000760'],
      dtype=object), 'count': 20}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 8 approved and 10 investigational indications."
CHEMBL76222,"CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C_|_GTXSRFUZSLTDFX-HRCADAONSA-N_|_Small molecule_|_False_|_REBIMASTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS 275291-01' 'BMS-275291' 'BMS-275291-01' 'D-2163' 'D2163'
 'Rebimastat']_|_[('drugbank', array(['DB06573'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008903', 'MONDO_0007254', 'EFO_0000673', 'EFO_0000691'],
      dtype=object), 'count': 4}_|_[ENSG00000137745,ENSG00000118113,ENSG00000157227,ENSG00000100985,ENSG00000087245,ENSG00000196611]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL117287,"COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1_|_ZPMNHBXQOOVQJL-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRUCALOPRIDE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Resolor']_|_['Prucalopride' 'R-093877' 'R093877']_|_[('PubChem', array(['170466188', '174006285'], dtype=object)), ('drugbank', array(['DB06480'], dtype=object))]_|_['CHEMBL2105748' 'CHEMBL4757628' 'CHEMBL5199178']_|_{'rows': array(['EFO_0000555', 'MONDO_0004567', 'MONDO_0002203', 'EFO_0001421',
       'HP_0002019', 'EFO_0008533', 'HP_0002019', 'HP_0002590',
       'MONDO_0002050', 'HP_0002015'], dtype=object), 'count': 10}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for constipation disorder and constipation and has 7 investigational indications."
CHEMBL1200585,"C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O_|_ICMWWNHDUZJFDW-DHODBPELSA-N_|_Small molecule_|_True_|_OXYMETHOLONE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Anadrol-50' 'Anapolon 50']_|_['Anadrol' 'Anapolon' 'Anasteron' 'CI-406' 'HMD' 'NSC-26,198' 'NSC-26198'
 'Oximetholone' 'Oxymetholone' 'Oxymetholone ciii' 'Pardroyd']_|_[('PubChem', array(['144204682', '144207269', '170465403', '17388810'], dtype=object)), ('Wikipedia', array(['Oxymetholone'], dtype=object)), ('drugbank', array(['DB06412'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972. This drug has a black box warning from the FDA."
CHEMBL1201242,"CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21_|_UCEWGESNIULAGX-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDECAINIDE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Indecainide']_|_[('PubChem', array(['170465192'], dtype=object)), ('Wikipedia', array(['Indecainide'], dtype=object)), ('drugbank', array(['DB00192'], dtype=object))]_|_['CHEMBL1200341']_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989."
CHEMBL1251,"CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O_|_GJNXBNATEDXMAK-PFLSVRRQSA-N_|_Protein_|_False_|_GANIRELIX_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Ganirelix Acetate Injection']_|_[]_|_[('Wikipedia', array(['Ganirelix'], dtype=object)), ('drugbank', array(['DB06785'], dtype=object))]_|_['CHEMBL5314377']_|_{'rows': array(['EFO_1000859', 'EFO_0000660', 'EFO_1000645', 'EFO_0000545'],
      dtype=object), 'count': 4}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 investigational indications."
CHEMBL1276138,"O=C(c1ccc2nonc2c1)N1CCCCC1_|_XFVRBYKKGGDPAJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_FARAMPATOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CX 691' 'CX-691' 'CX691' 'Farampator' 'ORG 24448' 'ORG-24448'
 'SCH-900460']_|_[('drugbank', array(['DB15012'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0005090', 'MONDO_0002050'], dtype=object), 'count': 3}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1921847,"Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1_|_ZHPMYDSXGRRERG-DEOSSOPVSA-N_|_Small molecule_|_False_|_ATICAPRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Aticaprant' 'CERC-501' 'Cerc-501' 'JNJ-67953964-AAA' 'JSPA-0658'
 'JSPA0658' 'Jnj-67953964' 'LY-2456302' 'LY2456302' 'Ly2456302']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ATICAPRANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12341'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'MONDO_0002009', 'MONDO_0002009', 'EFO_0003768',
       'EFO_0009854'], dtype=object), 'count': 5}_|_[ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2103792,"Cc1cn([C@H]2C[C@H](OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP(O)(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O_|_OKYYOKGIPDRZJA-CPSXWDTOSA-N_|_Oligonucleotide_|_False_|_AGATOLIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Agatolimod' 'Cpg-10104' 'PF-3512676' 'Pf-3512676 free acid']_|_nan_|_['CHEMBL2103793']_|_{'rows': array(['EFO_0005952', 'EFO_0009441', 'EFO_0002913', 'EFO_0003869',
       'EFO_0000764', 'EFO_0000403', 'EFO_0001068', 'EFO_0000756',
       'EFO_0000574', 'EFO_0000681', 'EFO_1001051', 'HP_0100806',
       'EFO_0000096', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576',
       'EFO_0000313', 'EFO_0001068', 'MONDO_0008315', 'EFO_0000191',
       'EFO_0003060', 'EFO_1001469'], dtype=object), 'count': 22}_|_[ENSG00000239732]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications."
CHEMBL2108475,"nan_|_nan_|_Antibody_|_False_|_PRILIXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CEN 000029' 'CEN-000029' 'CEN000029' 'CM-MT412' 'CMT-412' 'MT-412'
 'Priliximab']_|_nan_|_nan_|_nan_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL219586,"Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)NCc1ccc(OC(C)(C)C(=O)O)cc1_|_ILUPZUOBHCUBKB-UHFFFAOYSA-N_|_Small molecule_|_False_|_GW590735_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW590735' 'Gw590735']_|_[('drugbank', array(['DB07215'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL258940,"CN1CCC(Nc2ncc3ncnc(Nc4ccc(F)c(Cl)c4)c3n2)CC1_|_FTFRZXFNZVCRSK-UHFFFAOYSA-N_|_Small molecule_|_False_|_FALNIDAMOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIBX 1382' 'BIBX-1382' 'Bibx 1382' 'Bibx-1382' 'Bibx1382' 'Falnidamol']_|_[('PubChem', array(['124892343', '26755049'], dtype=object)), ('drugbank', array(['DB12966'], dtype=object))]_|_['CHEMBL2136050']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL267936,"CNC1(C)C2CCC(C2)C1(C)C_|_IMYZQPCYWPFTAG-UHFFFAOYSA-N_|_Small molecule_|_False_|_MECAMYLAMINE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mecamylamine']_|_[('PubChem', array(['104171190', '144203749', '170465225', '26755706', '50111169',
       '90341710'], dtype=object)), ('drugbank', array(['DB00657'], dtype=object)), ('chEBI', array(['6706'], dtype=object))]_|_['CHEMBL1237082']_|_{'rows': array(['MONDO_0002009', 'MONDO_0007079', 'EFO_0003758', 'EFO_0000537',
       'MONDO_0002050', 'EFO_0003768', 'EFO_0009606', 'EFO_0001365',
       'HP_0001268'], dtype=object), 'count': 9}_|_[ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and is indicated for hypertension and has 8 investigational indications."
CHEMBL274070,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(N)cccc3nc2-1_|_FUXVKZWTXQUGMW-FQEVSTJZSA-N_|_Small molecule_|_False_|_9-AMINOCAMPTOTHECIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['9-amino-20(s)-camptothecin' '9-aminocamptothecin' 'Aminocamptothecin'
 'NSC-603071']_|_[('PubChem', array(['26725257', '483848'], dtype=object)), ('drugbank', array(['DB12515'], dtype=object)), ('chEBI', array(['80755'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'MONDO_0001056', 'EFO_0000574', 'EFO_0003893',
       'MONDO_0002367', 'MONDO_0004992', 'MONDO_0007576', 'MONDO_0008903',
       'EFO_0000222', 'EFO_0000220', 'MONDO_0002087'], dtype=object), 'count': 11}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL3544932,"CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1_|_WKDACQVEJIVHMZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAK-901_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Tak-901']_|_[('drugbank', array(['DB12756'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000222', 'EFO_0000095', 'EFO_0000198',
       'EFO_0001378', 'EFO_0002430', 'EFO_0009441', 'MONDO_0044903'],
      dtype=object), 'count': 8}_|_[ENSG00000178999]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 8 investigational indications."
CHEMBL3545073,"nan_|_nan_|_Small molecule_|_False_|_AMA0076_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMA-0076' 'Ama0076' 'PHP-201' 'PHP201' 'Sovesudil']_|_nan_|_nan_|_{'rows': array(['EFO_1001069', 'MONDO_0005041'], dtype=object), 'count': 2}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545209,"nan_|_nan_|_Small molecule_|_False_|_NKTR-171_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Nktr-171']_|_nan_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545263,"nan_|_nan_|_Small molecule_|_False_|_LGX-806_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Lgx-806' 'NVP-LGX806']_|_nan_|_nan_|_nan_|_[ENSG00000157764,ENSG00000132155]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3622533,"COc1ccc(-c2nc(N3CCOCC3)c3sc(CN(C)c4ncc(C(=O)NO)cn4)cc3n2)cn1_|_JOWXJLIFIIOYMS-UHFFFAOYSA-N_|_Small molecule_|_False_|_FIMEPINOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CUDC-907' 'CUDC907' 'Cudc 907' 'Cudc-907' 'Fimepinostat']_|_[('drugbank', array(['DB11891'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002108', 'EFO_0000574'], dtype=object), 'count': 2}_|_[ENSG00000171608,ENSG00000051382,ENSG00000121879,ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3833384,"nan_|_nan_|_Protein_|_False_|_EFLAPEGRASTIM_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Rolvedon']_|_['Eflapegrastim' 'HM-10460A' 'HM10460A' 'HNK-460' 'HNK460' 'SPI-2012'
 'SPL-2012']_|_nan_|_nan_|_{'rows': array(['MONDO_0001475', 'MONDO_0007254', 'EFO_0000574', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for neoplasm and has 3 investigational indications."
CHEMBL4297218,"CCOC(=O)Cn1nc(C(F)(F)F)cc1-c1ccc(-c2cccc(S(C)(=O)=O)c2)cc1_|_ZUMNJDGBYXHASJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROVAZOLAC_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALX-101' 'Rovazolac']_|_nan_|_nan_|_{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}_|_[ENSG00000025434,ENSG00000131408]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298128,"Cc1nn(C)cc1S(=O)(=O)NC(=O)c1ccc(-n2ccc(OCC(C)(C)C(F)(F)F)n2)nc1N1C[C@@H](C)CC1(C)C_|_MVRHVFSOIWFBTE-INIZCTEOSA-N_|_Small molecule_|_False_|_ELEXACAFTOR_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['3-PYRIDINECARBOXAMIDE, N-((1,3-DIMETHYL-1H-PYRAZOL-4-YL)SULFONYL)-6-(3-(3,3,3-TRIFLUORO-2,2-DIMETHYLPROPOXY)-1H-PYRAZOL-1-YL)-2-((4S)-2,2,4-TRIMETHYL-1-PYRROLIDINYL)-'
 'Elexacaftor' 'VX-445' 'Vx-445']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELEXACAFTOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15444'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and has 1 investigational indication."
CHEMBL4594242,"nan_|_nan_|_Protein_|_False_|_CALCITONIN_|_nan_|_4.0_|_nan_|_True_|_True_|_['Calcitare' 'Calsynar' 'Cibacalcin' 'Forcaltonin' 'Miacalcic']_|_['Calcitonin' 'Calcitonin, unspecified' 'Throcalcitonin']_|_nan_|_nan_|_{'rows': array(['EFO_1000950', 'EFO_0003854', 'MONDO_0002123'], dtype=object), 'count': 3}_|_[ENSG00000004948]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications. It was withdrawn in at least one region."
CHEMBL460785,"Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O_|_ZJIHMALTJRDNQI-VFQQELCFSA-N_|_Small molecule_|_False_|_DUVOGLUSTAT HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL307429_|_False_|_False_|_[]_|_['1 deoxynojirimycin hydrochloride' '1-deoxynojirimycin hydrochloride'
 'AT-2220' 'AT2220' 'Duvoglustat hcl' 'Duvoglustat hydrochloride'
 'Moranoline hydrochloride']_|_nan_|_nan_|_{'rows': array(['Orphanet_365'], dtype=object), 'count': 1}_|_[ENSG00000171298]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650288,"nan_|_nan_|_Antibody_|_False_|_FLYSYN_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['FLYSYN' 'Flysyn']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000122025]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL553,"C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1_|_AAKJLRGGTJKAMG-UHFFFAOYSA-N_|_Small molecule_|_False_|_ERLOTINIB_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Tarceva']_|_['CP-358,774' 'CP-358774' 'CP-35877401' 'Erlotinib' 'OSI-774' 'R-1415'
 'RG-1415' 'Ro-508231']_|_[('PubChem', array(['103905339', '124893165', '124893166', '144205755', '170465434',
       '26757996', '50100099', '85267493'], dtype=object)), ('Wikipedia', array(['Erlotinib'], dtype=object)), ('drugbank', array(['DB00530'], dtype=object)), ('chEBI', array(['114785'], dtype=object))]_|_['CHEMBL5220042' 'CHEMBL1079742']_|_{'rows': array(['EFO_0005537', 'EFO_0000632', 'EFO_0002501', 'MONDO_0007576',
       'MONDO_0002974', 'MONDO_0004992', 'EFO_0001422', 'MONDO_0044881',
       'EFO_0000616', 'EFO_0002429', 'EFO_0000588', 'MONDO_0021117',
       'EFO_0000514', 'EFO_0000305', 'EFO_0000519', 'MONDO_0000521',
       'EFO_0000681', 'MONDO_0008903', 'EFO_0000182', 'EFO_0004252',
       'EFO_0000198', 'EFO_0006859', 'MONDO_0008315', 'MONDO_0002898',
       'EFO_0000222', 'EFO_1000657', 'EFO_0003050', 'EFO_0000308',
       'EFO_0000676', 'EFO_0003893', 'EFO_0003868', 'EFO_1001951',
       'MONDO_0008170', 'MONDO_0018531', 'MONDO_0008903', 'MONDO_0016693',
       'MONDO_0002087', 'MONDO_0002691', 'MONDO_0016691', 'EFO_0003060',
       'EFO_0000708', 'MONDO_0002158', 'MONDO_0003060', 'EFO_0002618',
       'MONDO_0002158', 'EFO_0002501', 'EFO_0005577', 'EFO_1000581',
       'MONDO_0002898', 'EFO_0000313', 'MONDO_0003060', 'EFO_0003860',
       'EFO_1000026', 'EFO_1000158', 'EFO_0000571', 'EFO_1001465',
       'MONDO_0021063', 'MONDO_0003478', 'EFO_0000756', 'EFO_0003833',
       'MONDO_0007254', 'EFO_0002499', 'EFO_0009708', 'EFO_0000588',
       'EFO_0000571', 'MONDO_0021063', 'EFO_0000365', 'MONDO_0007254',
       'Orphanet_733', 'EFO_0000691', 'EFO_0001378', 'EFO_0000519',
       'EFO_0002916', 'EFO_0000182', 'EFO_0005221', 'EFO_1001901',
       'MONDO_0001187', 'EFO_0000707', 'EFO_1000657', 'EFO_1000028',
       'MONDO_0004986', 'MONDO_0011962', 'EFO_1001951', 'MONDO_0020634',
       'EFO_0010282', 'MONDO_0005411', 'MONDO_0003268', 'EFO_0000565',
       'EFO_0002618', 'EFO_0006859', 'EFO_0004220', 'MONDO_0002367',
       'EFO_0005567', 'EFO_0000181', 'EFO_1001465', 'EFO_0000616',
       'MONDO_0002367', 'EFO_1000359', 'MONDO_0003268', 'EFO_0007243',
       'MONDO_0001657', 'EFO_0002499', 'MONDO_0002691', 'MONDO_0044926',
       'EFO_0000756', 'EFO_1000158', 'EFO_0000181', 'Orphanet_733',
       'EFO_0003060', 'EFO_0000681', 'EFO_0003050', 'MONDO_0008315',
       'MONDO_0008170', 'MONDO_0001187', 'EFO_0000349', 'EFO_0000308',
       'MONDO_0004992', 'EFO_0000640', 'MONDO_0007576'], dtype=object), 'count': 119}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 105 investigational indications."
CHEMBL586702,"FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1_|_HGVNLRPZOWWDKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZSTK-474_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TCMDC-137004' 'Zstk-474' 'Zstk474']_|_[('drugbank', array(['DB12904'], dtype=object)), ('chEBI', array(['90545'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL87493,"CCNC(C)Cc1cccc(C(F)(F)F)c1_|_DBGIVFWFUFKIQN-UHFFFAOYSA-N_|_Small molecule_|_True_|_FENFLURAMINE_|_2020.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Acino' 'Brabafen' 'Fenfluramin' 'Fenfluramine' 'J5.760F' 'Obedrex'
 'Pesos' 'Phenfluramine' 'Ponderax pa' 'Rotondin' 'S-768' 'Z-008' 'Z008'
 'ZX-008' 'ZX008']_|_[('PubChem', array(['144205250', '29215428'], dtype=object)), ('Wikipedia', array(['Fenfluramine'], dtype=object)), ('drugbank', array(['DB00574'], dtype=object)), ('chEBI', array(['5000'], dtype=object))]_|_['CHEMBL2106217']_|_{'rows': array(['MONDO_0015643', 'EFO_0002610', 'MONDO_0100062', 'EFO_0000474',
       'HP_0001250', 'EFO_0001073'], dtype=object), 'count': 6}_|_[ENSG00000179546,ENSG00000147246,ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL940,"NCC1(CC(=O)O)CCCCC1_|_UGJMXCAKCUNAIE-UHFFFAOYSA-N_|_Small molecule_|_False_|_GABAPENTIN_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Gabapentin' 'Gralise' 'Neurontin']_|_['CI-945' 'DM-1796' 'GOE 3450' 'GOE-3450' 'Gabapentin' 'NSC-742194'
 'NSC-759254']_|_[('DailyMed', array(['gabapentin'], dtype=object)), ('PubChem', array(['104171164', '11112806', '11113327', '124880194', '144203708',
       '170464715', '50103936', '855579', '90340599'], dtype=object)), ('Wikipedia', array(['Gabapentin'], dtype=object)), ('drugbank', array(['DB00996'], dtype=object)), ('chEBI', array(['42797'], dtype=object))]_|_['CHEMBL542620']_|_{'rows': array(['EFO_0005687', 'EFO_1002028', 'HP_0000989', 'EFO_0000512',
       'MONDO_0041052', 'MONDO_0011382', 'HP_0003419', 'EFO_0005611',
       'HP_0002013', 'EFO_0003756', 'EFO_0007191', 'EFO_0003917',
       'EFO_0001422', 'HP_0008419', 'EFO_0005230', 'EFO_1001931',
       'MONDO_0002050', 'EFO_0004777', 'EFO_0005762', 'EFO_0008507',
       'EFO_0000546', 'HP_0012532', 'HP_0001250', 'EFO_0005323',
       'MONDO_0007079', 'EFO_0004710', 'EFO_0003890', 'EFO_0009267',
       'EFO_0003843', 'HP_0031217', 'MONDO_0007254', 'HP_0001337',
       'EFO_0000764', 'EFO_1001800', 'EFO_0004329', 'MONDO_0043510',
       'EFO_0006859', 'EFO_0006510', 'EFO_0003768', 'EFO_0004698',
       'EFO_0004143', 'MONDO_0004986', 'EFO_0004263', 'EFO_1001250',
       'HP_0000726', 'HP_0000360', 'EFO_0009430', 'EFO_0000474',
       'EFO_1000783', 'EFO_0005407', 'EFO_0004888', 'MONDO_0004992',
       'EFO_0008568', 'EFO_1001255', 'MONDO_0005090', 'MONDO_0005301',
       'EFO_1000971', 'MONDO_0008315', 'MONDO_0002038', 'EFO_0000279',
       'EFO_0008533', 'EFO_0004270', 'EFO_0003818', 'EFO_0004273',
       'EFO_1001898', 'EFO_0000519'], dtype=object), 'count': 66}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 61 investigational indications."
CHEMBL979,"CCCC(C)(COC(N)=O)COC(N)=O_|_NPPQSCRMBWNHMW-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPROBAMATE_|_1955.0_|_4.0_|_nan_|_True_|_True_|_['Amosene' 'Bamate' 'Equanil' 'Mepriam' 'Meprobamate' 'Meprospan'
 'Miltown' 'Neuramate' 'Tenavoid' 'Tranmep']_|_['Meprobamate' 'Meprobamate civ' 'NSC-30418']_|_[('DailyMed', array(['meprobamate'], dtype=object)), ('PubChem', array(['144204614', '144207530', '17389535'], dtype=object)), ('Wikipedia', array(['Meprobamate'], dtype=object)), ('drugbank', array(['DB00371'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006788', 'EFO_0005230'], dtype=object), 'count': 2}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for anxiety disorder and anxiety. It was withdrawn in at least one region."
CHEMBL107367,"Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1_|_ZZCHHVUQYRMYLW-HKBQPEDESA-N_|_Small molecule_|_False_|_FARGLITAZAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Farglitazar' 'G1-262570' 'GI-262570' 'GI-262570X' 'GI262570X' 'Gi262570']_|_[('PubChem', array(['144210538'], dtype=object)), ('Wikipedia', array(['Farglitazar'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001422'], dtype=object), 'count': 1}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL111659,"C#Cc1cncc([C@@H]2CCCN2C)c1_|_NUPUDYKEEJNZRG-LBPRGKRZSA-N_|_Small molecule_|_False_|_ALTINICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-5-ethynylnicotine' 'Altinicline' 'SIB-1508Y' 'SIB-1765F']_|_[('Wikipedia', array(['Altinicline'], dtype=object))]_|_['CHEMBL2146093']_|_nan_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL112,"CC(=O)Nc1ccc(O)cc1_|_RZVAJINKPMORJF-UHFFFAOYSA-N_|_Small molecule_|_True_|_ACETAMINOPHEN_|_1968.0_|_4.0_|_nan_|_False_|_True_|_['Abdine' 'Acephen' 'Acetaminophen' 'Alvedon' 'Angiers' 'Calpol'
 'Calpol six plus' 'Calpol six plus fastmelts' 'Child lemsip' 'Cupanol'
 'Dafalgan' 'Datril' 'Disprol' 'Disprol infant' 'Disprol jnr'
 'Disprol paed' 'Fennings' 'Galpamol' 'Hedex' 'Infadrops'
 ""Infants' feverall"" 'Injectapap' 'Junior parapaed' 'Mandanol' 'Medinol'
 'Medinol for children' 'Medinol over 6' 'Medinol under 6' 'Medised plain'
 'Miradol' 'Neopap' 'Ofirmev' 'Paldesic' 'Panadol' 'Panadol actifast'
 'Panadol actifast solb' 'Panadol advan' 'Panadol jnr' 'Panadol oa'
 'Panaleve' 'Panaleve 6 plus' 'Paracetamol' 'Paramin' 'Parapaed jnr'
 'Parapaed six plus' 'Paravict' 'Perfalgan' 'Phenaphen' 'Placidex'
 'Rimadol' 'Salzone' 'Tixymol' 'Tramil 500' 'Tylenol']_|_['Acetaminophen' 'Apap' 'Biocetamol' 'Doliprane' 'Efferalgan'
 'N-acetyl-p-aminophenol' 'NSC-109028' 'NSC-3991' 'P-hydroxy-acetanilid'
 'Paracetamol' 'Paracetamolum' 'Vermidon']_|_[('DailyMed', array(['acetaminophen'], dtype=object)), ('PubChem', array(['104171293', '11112253', '11114188', '124882135', '144209128',
       '144210420', '170466797', '17390068', '174007306', '26747171',
       '56422763'], dtype=object)), ('TG-GATEs', array(['1'], dtype=object)), ('Wikipedia', array(['Paracetamol'], dtype=object)), ('drugbank', array(['DB00316'], dtype=object)), ('chEBI', array(['46195'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'HP_0002315', 'HP_0002013', 'MONDO_0007915',
       'EFO_0000685', 'EFO_0000220', 'EFO_0002460', 'EFO_0005592',
       'EFO_1001139', 'MONDO_0005147', 'HP_0012076', 'HP_0011110',
       'EFO_0000384', 'EFO_0009615', 'Orphanet_365', 'EFO_0000540',
       'EFO_0000389', 'EFO_1000783', 'EFO_0010282', 'EFO_0003086',
       'MONDO_0005148', 'MONDO_0043510', 'HP_0002018', 'EFO_0003843',
       'HP_0000175', 'EFO_0000574', 'HP_0000989', 'HP_0002027',
       'MONDO_0005180', 'HP_0012115', 'EFO_0000095', 'EFO_0000544',
       'EFO_0000339', 'EFO_1001412', 'EFO_0000537', 'EFO_0000403',
       'EFO_0000222', 'MONDO_0007254', 'HP_0003419', 'HP_0001945',
       'EFO_0004599', 'EFO_0001378', 'EFO_0001068', 'EFO_0004209',
       'EFO_0004253', 'EFO_1000831', 'MONDO_0005301', 'EFO_0000618',
       'MONDO_0005041', 'EFO_0001073', 'EFO_0005230', 'MONDO_0002367',
       'HP_0100806', 'EFO_0004616', 'HP_0000545', 'EFO_0003060',
       'EFO_0004255', 'EFO_0000198', 'EFO_0000546', 'EFO_0004197',
       'EFO_1000249', 'EFO_1001216', 'EFO_0003931', 'EFO_0004888',
       'EFO_0009846', 'HP_0001643', 'EFO_0010072', 'EFO_0000616',
       'EFO_0007160', 'EFO_1001250', 'EFO_1000749', 'HP_0003418',
       'MONDO_0005277', 'EFO_1001476', 'EFO_0000668', 'EFO_0001074',
       'EFO_0000096', 'HP_0012228', 'EFO_0005856', 'EFO_0004269',
       'MONDO_0004992', 'HP_0012532', 'MONDO_0005178', 'EFO_0007486',
       'HP_0030833', 'EFO_0004273', 'HP_0100607', 'EFO_0000764',
       'EFO_0005762', 'HP_0008419', 'EFO_0005761', 'MP_0001914',
       'MONDO_0044917', 'EFO_0011023', 'EFO_0007359', 'MONDO_0100342',
       'MONDO_0009291', 'EFO_0005952', 'MONDO_0002258', 'MONDO_0017287',
       'EFO_0009267', 'EFO_1000786', 'MONDO_0024355', 'EFO_0801084',
       'EFO_0007214', 'EFO_0007328', 'EFO_1001898', 'EFO_0007444'],
      dtype=object), 'count': 108}_|_[ENSG00000196689,ENSG00000117480,ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 12 approved and 96 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1162175,"CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21_|_NXHAXEBZOXCDKD-XIXRRVGJSA-N_|_Small molecule_|_False_|_REGRELOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Regrelor']_|_[('drugbank', array(['DB05553'], dtype=object))]_|_['CHEMBL261244']_|_{'rows': array(['EFO_0001645', 'EFO_0000319'], dtype=object), 'count': 2}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1200541,"CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl.[Cl-].[Cl-]_|_DXUUXWKFVDVHIK-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMBENONIUM CHLORIDE_|_1956.0_|_4.0_|_CHEMBL1652_|_False_|_True_|_['Mytelase']_|_['Ambenonium chloride']_|_[('PubChem', array(['144205583', '170465386'], dtype=object)), ('chEBI', array(['2628'], dtype=object))]_|_nan_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL1200724,"CN[C@@H](C)[C@@H](O)c1ccccc1.Cl_|_BALXUFOVQVENIU-KXNXZCPBSA-N_|_Small molecule_|_False_|_PSEUDOEPHEDRINE HYDROCHLORIDE_|_1975.0_|_4.0_|_CHEMBL1590_|_False_|_True_|_['Actifed' 'Contac' 'Dimotane plus' 'Dimotane plus l.a.' 'Galpseud'
 'Galpseud plus' 'Novafed' 'Otrivine mu-cron'
 'Pseudoephedrine hydrochloride' 'Pseudophed' 'Sinutab' 'Sudafed'
 'Sudafed 12 hour' 'Sudafed 12 hr decongest' 'Sudafed 24 hour'
 'Sudafed plus' 'Sudafed-sa']_|_['Efidac 24' 'Galsud' 'NSC-106567' 'NSC-33634' 'Otrinol'
 'Pseudoephedrine hcl' 'Pseudoephedrine hydrochloride' 'Rhinalair']_|_[('DailyMed', array(['pseudoephedrine%20hydrochloride'], dtype=object)), ('PubChem', array(['50086711', '544025'], dtype=object)), ('chEBI', array(['8604'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003956', 'EFO_0007214', 'EFO_0005854', 'EFO_0003843',
       'HP_0001742', 'MONDO_0005271', 'EFO_0007486', 'EFO_0007328',
       'MONDO_0005277', 'MONDO_0024290', 'HP_0012735'], dtype=object), 'count': 11}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 10 approved and 1 investigational indication."
CHEMBL1200745,"C=CCOc1ccccc1OCC(O)CNC(C)C.Cl_|_COAJXCLTPGGDAJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXPRENOLOL HYDROCHLORIDE_|_1983.0_|_4.0_|_CHEMBL546_|_False_|_True_|_['Apsolox' 'Laracor' 'Oxyprenix excel 160' 'Paritane' 'Slow-pren'
 'Slow-trasicor' 'Trasicor' 'Trasicor ret']_|_['BA-39,089' 'BA-39089' 'Oxprenolol hcl' 'Oxprenolol hydrochloride']_|_[('PubChem', array(['144204107', '170464995', '56463641'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983."
CHEMBL1201486,"nan_|_nan_|_Small molecule_|_True_|_QUINIDINE POLYGALACTURONATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Cardioquin']_|_['Galactoquin' 'Naticardina' 'Quinidine polygalacturonate']_|_nan_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982. This drug has a black box warning from the FDA."
CHEMBL1201489,nan_|_nan_|_Protein_|_False_|_SERACTIDE ACETATE_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Acthar gel-synthetic']_|_['Seractide acetate' 'Seractide acetate hydrate']_|_nan_|_nan_|_nan_|_[ENSG00000185231]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1978.
CHEMBL1614710,"O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12_|_FGTCROZDHDSNIO-UHFFFAOYSA-N_|_Small molecule_|_False_|_OSI-930_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['OSI-930' 'Osi 930' 'Osi-930']_|_[('PubChem', array(['137276003'], dtype=object)), ('drugbank', array(['DB05913'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1743004,"nan_|_nan_|_Antibody_|_False_|_CRENEZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Crenezumab' 'MABT-5102A' 'MABT5102A' 'RG-7412' 'RG7412']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1743019,"nan_|_nan_|_Antibody_|_False_|_FIGITUMUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['871' 'CP-751' 'CP-751,871' 'CP-751871' 'Figitumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0006859', 'EFO_0000673', 'EFO_0000691', 'EFO_0003869',
       'EFO_0003050', 'EFO_0001378', 'EFO_0004142', 'EFO_0000702',
       'MONDO_0004992', 'MONDO_0021117', 'MONDO_0007254', 'EFO_0000707',
       'EFO_0000174', 'EFO_0003060'], dtype=object), 'count': 14}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."
CHEMBL1922673,"CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1.[Na+]_|_NOJNFULGOQGBKB-UHFFFAOYSA-M_|_Small molecule_|_False_|_FIBOFLAPON SODIUM_|_nan_|_3.0_|_CHEMBL1922660_|_False_|_False_|_[]_|_['AM-803 SODIUM' 'Am803 sodium' 'Fiboflapon sodium' 'GSK-2190915A'
 'GSK2190915A' 'SODIUM SALT']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_1001348', 'MONDO_0009061'], dtype=object), 'count': 3}_|_[ENSG00000132965]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1951575,"CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1_|_PFWVGKROPKKEDW-UHFFFAOYSA-N_|_Small molecule_|_False_|_VIDUPIPRANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 853' 'AMG-853' 'AMG853' 'Vidupiprant']_|_[('drugbank', array(['DB12272'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000183134,ENSG00000168229]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2068724,"CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]_|_BUVGWDNTAWHSKI-UHFFFAOYSA-L_|_Small molecule_|_False_|_ACAMPROSATE CALCIUM_|_2004.0_|_4.0_|_CHEMBL1201293_|_False_|_True_|_['Acamprosate calcium' 'Campral' 'Campral ec']_|_['Acamprosate calcium' 'NSC-759186' 'SN-102']_|_[('DailyMed', array(['acamprosate%20calcium'], dtype=object)), ('PubChem', array(['144206019', '144212923'], dtype=object)), ('chEBI', array(['51042'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2004 and is indicated for alcohol dependence."
CHEMBL2108350,"nan_|_nan_|_Protein_|_False_|_CONESTAT ALFA_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Ruconest']_|_['C1 esterase inhibitor' 'Complement c1 esterase inhibitor'
 'Conestat alfa' 'Recombinant human c1 inhibitor'
 'Recombinant human c1-inhibitor' 'Rhucin' 'Ruconest']_|_[('DrugCentral', array(['5152'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ruconest'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000508', 'MONDO_0100096', 'HP_0001919', 'EFO_0007224',
       'MONDO_0019623', 'EFO_0004599', 'EFO_0008586'], dtype=object), 'count': 7}_|_[ENSG00000149131]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for hereditary angioedema and has 6 investigational indications."
CHEMBL30,"CN/C(=N\CCSCc1nc[nH]c1C)NC#N_|_AQIXAKUUQRKLND-UHFFFAOYSA-N_|_Small molecule_|_False_|_CIMETIDINE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Acid-eze' 'Acitak 200' 'Acitak 400' 'Acitak 800' 'Brumetadina'
 'Cimetidine' 'Dyspamet' 'Galenamet' 'Kentamet' 'Peptimax 200'
 'Peptimax 400' 'Peptimax 800' 'Tagadine' 'Tagamet' 'Tagamet 100'
 'Tagamet hb' 'Tagamet hb 200' 'Ultec' 'Valmagen' 'Zita']_|_['Aciloc' 'Acinil' 'Brumetidina' 'Cimal' 'Cimetidine' 'Cimetidinum'
 'Gastromet' 'NSC-335308' 'SKF-92334' 'Stomedine' 'Ulcedin' 'Ulcimet'
 'Ulcomedina']_|_[('DailyMed', array(['cimetidine'], dtype=object)), ('PubChem', array(['104171130', '11113773', '11533056', '144203657', '144208358',
       '170464651', '17389962', '26747359', '26751957', '460110',
       '50104629', '56462993', '90341189'], dtype=object)), ('TG-GATEs', array(['35'], dtype=object)), ('Wikipedia', array(['Cimetidine'], dtype=object)), ('drugbank', array(['DB00501'], dtype=object)), ('chEBI', array(['3699'], dtype=object))]_|_['CHEMBL1201051']_|_{'rows': array(['MP_0001914', 'MONDO_0004976', 'EFO_0000341', 'MONDO_0011962',
       'EFO_0000544', 'HP_0002239', 'EFO_0000274', 'EFO_0004607',
       'EFO_1001892', 'HP_0004398', 'EFO_0003948', 'MONDO_0001676',
       'MONDO_0004658', 'MONDO_0043839'], dtype=object), 'count': 14}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 3 approved and 11 investigational indications."
CHEMBL3260567,"Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1_|_FJCDSQATIJKQKA-UHFFFAOYSA-N_|_Small molecule_|_False_|_VACTOSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ew-7197' 'TEW-7197' 'Tew 7197' 'Tew-7197' 'Vactosertib']_|_[('drugbank', array(['DB15310'], dtype=object))]_|_['CHEMBL3260908']_|_{'rows': array(['EFO_0000637', 'EFO_0003060', 'EFO_0002618', 'EFO_0009907',
       'EFO_0004251', 'EFO_0008528', 'EFO_0000198', 'EFO_0000616',
       'EFO_0003897', 'EFO_0001378', 'MONDO_0001056'], dtype=object), 'count': 11}_|_[ENSG00000106799]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL3544906,"C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1.Cl_|_ANFSNXAXVLRZCG-RSAXXLAASA-N_|_Small molecule_|_False_|_BENZPHETAMINE HYDROCHLORIDE_|_1960.0_|_4.0_|_CHEMBL3545985_|_False_|_True_|_['Benzphetamine hydrochloride' 'Didrex']_|_['Benzfetamine hydrochloride' 'Benzphetamine chloride' 'Benzphetamine hcl'
 'Benzphetamine hydrochloride' 'Benzphetamine hydrochloride ciii'
 'NSC-10937' 'U-0441']_|_[('DailyMed', array(['benzphetamine%20hydrochloride'], dtype=object)), ('chEBI', array(['59169'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for obesity."
CHEMBL3545131,"nan_|_nan_|_Antibody_|_False_|_ISATUXIMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Sarclisa']_|_['Isatuximab' 'Isatuximab irfc' 'SAR-650984' 'SAR650984']_|_[('DailyMed', array(['isatuximab-irfc'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'MONDO_0019438', 'EFO_0000220', 'EFO_0001642',
       'EFO_0000616', 'EFO_0001378', 'EFO_0005592', 'EFO_0000203',
       'EFO_0000222', 'EFO_1001264', 'EFO_0000540', 'EFO_0003073',
       'MONDO_0044881', 'MONDO_0044917', 'MONDO_0001705', 'EFO_0000403',
       'EFO_0000574'], dtype=object), 'count': 17}_|_[ENSG00000004468]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and multiple myeloma and has 15 investigational indications."
CHEMBL3894860,"CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1_|_PDGKHKMBHVFCMG-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRILACICLIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['G1T28' 'G1t28-1' 'Trilaciclib']_|_[('drugbank', array(['DB15442'], dtype=object))]_|_['CHEMBL4650272']_|_{'rows': array(['EFO_0003060', 'MONDO_0007254', 'EFO_0003869', 'EFO_0000702',
       'EFO_0003968', 'EFO_0005537', 'EFO_0000702'], dtype=object), 'count': 7}_|_[ENSG00000105810,ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for small cell lung carcinoma and has 6 investigational indications."
CHEMBL3989676,"CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O.O_|_CNDQSXOVEQXJOE-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYPHENBUTAZONE_|_1960.0_|_4.0_|_CHEMBL1228_|_True_|_True_|_['Oxyphenbutazone' 'Tandearil' 'Tanderil' 'Tanderil chloramphen']_|_['NSC-757261' 'Oxiphenbutazone' 'Oxyphenbutazone'
 'Oxyphenbutazone hydrate' 'Oxyphenbutazone monohydrate' 'Phlogase'
 'Phlogistol' 'Phlogont']_|_nan_|_nan_|_{'rows': array(['EFO_0005755', 'EFO_0005752', 'HP_0002829', 'HP_0003326'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications. It was withdrawn in at least one region."
CHEMBL4297456,"CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O_|_MMHDBUJXLOFTLC-WOYTXXSLSA-N_|_Protein_|_False_|_ATN-161_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATN 161' 'ATN-161' 'Ac-phscn-nh2' 'Atn-161']_|_nan_|_nan_|_{'rows': array(['EFO_1000158', 'EFO_0000681'], dtype=object), 'count': 2}_|_[ENSG00000150093,ENSG00000161638,ENSG00000259207,ENSG00000138448]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297530,"CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(=O)O_|_MRWFZSLZNUJVQW-DEOSSOPVSA-N_|_Small molecule_|_False_|_SAROGLITAZAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Saroglitazar']_|_[('drugbank', array(['DB13115'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001397', 'Orphanet_309005', 'EFO_0003095', 'EFO_1001486',
       'EFO_0001422', 'EFO_0001421', 'EFO_1001249', 'EFO_0003086'],
      dtype=object), 'count': 8}_|_[ENSG00000132170,ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL4297533,"CC(=O)O.CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O_|_MAYUSRUHXFWITM-GBRHMYBBSA-N_|_Protein_|_False_|_BREMELANOTIDE ACETATE_|_2019.0_|_4.0_|_CHEMBL2070241_|_False_|_True_|_['Vyleesi (autoinjector)']_|_['Bremelanotide acetate' 'PT 141' 'PT-141' 'Vyleesi']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BREMELANOTIDE%20ACETATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000677', 'EFO_0004714'], dtype=object), 'count': 2}_|_[ENSG00000166603]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for mental or behavioural disorder and sexual dysfunction."
CHEMBL4298037,"nan_|_nan_|_Antibody_|_False_|_RETIFANLIMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Zynyz']_|_['AEX-1188' 'AEX1188' 'INCMGA-00012' 'INCMGA-0012' 'INCMGA00012'
 'Incmga00012' 'MGA-012' 'MGA012' 'Mga012' 'Retifanlimab'
 'Retifanlimab-dlwr' 'Zynyz']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RETIFANLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0003060', 'MONDO_0004992', 'EFO_0000519',
       'EFO_0008528', 'MONDO_0005184', 'EFO_1001471', 'EFO_0005537',
       'EFO_0000756', 'EFO_0002618', 'MONDO_0008315', 'EFO_0000707',
       'MONDO_0007576', 'EFO_1000852', 'MONDO_0007254', 'EFO_0000691',
       'EFO_1001901', 'EFO_0006859', 'EFO_1001968', 'MONDO_0011962',
       'EFO_0000616'], dtype=object), 'count': 21}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 18 investigational indications."
CHEMBL507361,"O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F_|_SUDAHWBOROXANE-SECBINFHSA-N_|_Small molecule_|_False_|_MIRDAMETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mirdametinib' 'PD-0325901' 'Pd 0325901' 'Pd 03525901' 'Pd 901'
 'Pd-0325901']_|_[('PubChem', array(['144206915'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIRDAMETINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB07101'], dtype=object)), ('chEBI', array(['88249'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0018975', 'EFO_1001951',
       'EFO_0003060'], dtype=object), 'count': 5}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL919,"O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)([O-])[O-].[Na+].[Na+]_|_GQPXYJNXTAFDLT-UHFFFAOYSA-L_|_Small molecule_|_True_|_FOSPHENYTOIN SODIUM_|_1996.0_|_4.0_|_CHEMBL1201336_|_False_|_True_|_['Cerebyx' 'Fosphenytoin sodium' 'Pro-epanutin' 'Sesquient']_|_['ACC-9653-010' 'ACC-9653-010 (SODIUM SALT)' 'CI 982' 'CI-982'
 'Fosphenytoin disodium salt' 'Fosphenytoin sodium']_|_[('DailyMed', array(['fosphenytoin%20sodium'], dtype=object)), ('Wikipedia', array(['Fosphenytoin'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996. This drug has a black box warning from the FDA."
CHEMBL1088752,"Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1_|_KKYABQBFGDZVNQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOSMAPIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['FTX-1821' 'FTX1821' 'GSK-AHAB' 'GSKAHAB' 'GW-856553X' 'GW856553'
 'GW856553X' 'Gw-856553' 'Gw856553' 'Losmapimod']_|_[('Wikipedia', array(['Losmapimod'], dtype=object)), ('drugbank', array(['DB12270'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004236', 'Orphanet_269', 'EFO_0000319', 'MONDO_0100096',
       'EFO_0005762', 'EFO_0005672', 'EFO_0000685', 'EFO_0000341',
       'EFO_0003914', 'MONDO_0002009', 'Orphanet_309005'], dtype=object), 'count': 11}_|_[ENSG00000185386,ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL1200542,"CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C_|_VPGRYOFKCNULNK-ACXQXYJUSA-N_|_Small molecule_|_False_|_DESOXYCORTICOSTERONE ACETATE_|_1939.0_|_4.0_|_nan_|_False_|_True_|_['Doca' 'Percorten']_|_['11-deoxycorticosterone' '11-deoxycorticosterone acetate'
 '21-hydroxyprogesterone' 'Deoxycorticosterone'
 'Deoxycorticosterone acetate' 'Deoxycortone' 'Desoxycorticosterone'
 'Desoxycorticosterone acetate' 'Desoxycortone' 'Desoxycortone acetate'
 'NSC-11319' 'NSC-9567']_|_[('PubChem', array(['144204427', '170465334', '29215003', '56422097', '855662'],
      dtype=object)), ('drugbank', array(['DB06780'], dtype=object)), ('chEBI', array(['34671'], dtype=object))]_|_nan_|_nan_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939."
CHEMBL1201057,"CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)[O-].[Na+]_|_QXPBTTUOVWMPJN-QBNHLFMHSA-M_|_Small molecule_|_False_|_CILASTATIN SODIUM_|_1985.0_|_4.0_|_CHEMBL766_|_False_|_True_|_[]_|_['Cilastatin sodium' 'Cilastatin sodium salt' 'MK-791']_|_[('DailyMed', array(['cilastatin%20sodium'], dtype=object)), ('PubChem', array(['144206357', '49732002'], dtype=object)), ('chEBI', array(['59511'], dtype=object))]_|_nan_|_{'rows': array(['HP_0100806', 'EFO_0000544', 'EFO_0003103', 'EFO_0003106',
       'EFO_0000465'], dtype=object), 'count': 5}_|_[ENSG00000015413]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved indications."
CHEMBL1742997,"nan_|_nan_|_Antibody drug conjugate_|_False_|_CANTUZUMAB MERTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cantuzumab mertansine' 'HUC-242-DM1' 'HUC242-DM1' 'SB-408075']_|_nan_|_nan_|_nan_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000185499]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II."
CHEMBL2103862,"O=C(c1ccc(CN2CCOCC2)cc1)N1CCN(C2CC2)CC1_|_BGBVSGSIXIIREO-UHFFFAOYSA-N_|_Small molecule_|_False_|_BAVISANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bavisant' 'JNJ-31001074']_|_[('drugbank', array(['DB12299'], dtype=object))]_|_['CHEMBL3577957' 'CHEMBL2105715']_|_{'rows': array(['EFO_0003888', 'MONDO_0007079'], dtype=object), 'count': 2}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109137,"nan_|_nan_|_Protein_|_False_|_MOROCTOCOG ALFA_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Refacto af']_|_['Moroctocog alfa' 'Refacto' 'Refacto-af' 'Xyntha']_|_[('DrugCentral', array(['5166'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/refacto-af'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1999 and is indicated for hemophilia a."
CHEMBL2109634,nan_|_nan_|_Antibody_|_False_|_ONCOLYSIN S_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONCOLYSIN S']_|_nan_|_nan_|_nan_|_[ENSG00000149294]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2111083,"CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2_|_OANCEOSLKSTLTA-REWPJTCUSA-N_|_Small molecule_|_False_|_BEDORADRINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bedoradrine']_|_[('drugbank', array(['DB05590'], dtype=object))]_|_['CHEMBL2218893']_|_{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0008590'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL21731,"CNCCCC12CCC(c3ccccc31)c1ccccc12_|_QSLMDECMDJKHMQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_MAPROTILINE_|_1980.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BA-34,276 FREE BASE' 'BA-34,276 [AS HYDROCHLORIDE]' 'BA-34276 FREE BASE'
 'Maprotiline']_|_[('PubChem', array(['104171192', '11111502', '11112599', '11113802', '124880790',
       '124880792', '144203751', '170464778', '26751977', '50085871',
       '50104649', '90341780'], dtype=object)), ('Wikipedia', array(['Maprotiline'], dtype=object)), ('drugbank', array(['DB00934'], dtype=object)), ('chEBI', array(['6690'], dtype=object))]_|_['CHEMBL1237135']_|_{'rows': array(['EFO_0005230', 'MONDO_0002009', 'HP_0000726', 'MONDO_0002009',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0003833', 'EFO_0000519'],
      dtype=object), 'count': 8}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for major depressive disorder and depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL259571,"CC(C)c1c(O)cc(/C=C/c2ccccc2)cc1O_|_ZISJNXNHJRQYJO-CMDGGOBGSA-N_|_Small molecule_|_False_|_TAPINAROF_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Vtama']_|_['Benvitimod' 'GSK-2894512' 'GSK2894512' 'Tapinarof' 'Vtama' 'WBI-1001'
 'Wbi-1001']_|_[('drugbank', array(['DB06083'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000274'], dtype=object), 'count': 2}_|_[ENSG00000106546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 1 investigational indication."
CHEMBL301829,"O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O_|_NZQDWKCNBOELAI-KSFYIVLOSA-N_|_Small molecule_|_False_|_CP-195543_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-195,543' 'Cp-195,543' 'Cp-195543']_|_[('drugbank', array(['DB13053'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000213906,ENSG00000213903]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3334824,"CC(C)[C@@H](NC(=O)NCC(C)(C)O)C(=O)N1CC[C@](O)(c2ccc(Cl)cc2)C(C)(C)C1_|_GTDPZONCGOCXOD-JPYJTQIMSA-N_|_Small molecule_|_False_|_BMS-817399_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-817399' 'Bms-817399']_|_[('drugbank', array(['DB14941'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000163823]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545413,"Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1_|_BJCJYEYYYGBROF-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLUMATINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Flumatinib' 'Flumbatinib' 'HH-GV678' 'Hhgv-678']_|_[('drugbank', array(['DB11904'], dtype=object))]_|_['CHEMBL3901539']_|_{'rows': array(['EFO_0000220', 'EFO_0000339'], dtype=object), 'count': 2}_|_[ENSG00000097007]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3989909,"CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1.O=P(O)(O)O_|_XXEDEGOAYSGNPS-ZOWNYOTGSA-N_|_Small molecule_|_False_|_LENIOLISIB PHOSPHATE_|_2023.0_|_4.0_|_CHEMBL3643413_|_False_|_True_|_['Joenja']_|_['CDZ-173' 'CDZ-173-AZ' 'CDZ173' 'CDZ173-AZ' 'Cdz173' 'Joenja'
 'Leniolisib monophosphate' 'Leniolisib phosphate']_|_nan_|_nan_|_{'rows': array(['MONDO_0015517', 'EFO_0000699', 'MONDO_0003778'], dtype=object), 'count': 3}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for inborn error of immunity and has 2 investigational indications."
CHEMBL3989910,"O=C(O)c1ccc(-c2ccc3cc(O)ccc3n2)c(Cl)c1_|_BXSZILNGNMDGSL-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAVOSONSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cavosonstat' 'N-91115' 'N91115']_|_[('drugbank', array(['DB14775'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 3}_|_[ENSG00000197894]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL412262,"CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1_|_AXJQVVLKUYCICH-OAQYLSRUSA-N_|_Small molecule_|_False_|_IBIPINABANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-646256' 'Ibipinabant' 'SLV-319' 'Slv319']_|_[('drugbank', array(['DB12649'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297244,nan_|_nan_|_Oligonucleotide_|_False_|_DANVATIRSEN SODIUM_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['AZD9150 sodium' 'Danvatirsen pentadecasodium' 'Danvatirsen sodium']_|_nan_|_nan_|_nan_|_[ENSG00000168610]_|_Oligonucleotide drug.
CHEMBL4444976,"COc1cc(N2CCN(C(=O)Cn3nc(-c4ncc[nH]4)c4cccnc43)CC2)ccc1Cl_|_ZIMLRKWQDLVPEK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CCX354_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CCX354' 'CCX354-C' 'Ccx-354' 'Ccx354' 'GSK-2941266' 'GSK2941266']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000163823]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650485,"COc1ccc(F)cc1C(=O)NCc1ccc(-c2nn([C@@H](C)C(F)(F)F)c(N)c2C(N)=O)cc1_|_FWZAWAUZXYCBKZ-NSHDSACASA-N_|_Small molecule_|_False_|_PIRTOBRUTINIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Jaypirca']_|_['Jaypirca' 'LOXO-305' 'LY-3527727' 'LY3527727' 'Loxo-305' 'Pirtobrutinib'
 'RXC-005']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PIRTOBRUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001469', 'EFO_0000616', 'EFO_0000095', 'EFO_0000565',
       'EFO_0009441'], dtype=object), 'count': 5}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for mantle cell lymphoma and has 4 investigational indications."
CHEMBL567,"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1_|_RGCVKNLCSQQDEP-UHFFFAOYSA-N_|_Small molecule_|_True_|_PERPHENAZINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Chlorpiprazine' 'Decentan' 'Fentazin' 'Perphenazine'
 'Perphenazine Fendizoate' 'Trilafon' 'Trilafon-La']_|_['Etaperazine' 'NSC-150866' 'Perphenazine' 'Perphenazine fendizoate'
 'Perphenazine maleate']_|_[('DailyMed', array(['perphenazine'], dtype=object)), ('PubChem', array(['11111645', '11111646', '124881147', '144203784', '170464834',
       '26747080', '26747081', '50100322', '50104233', '50104234',
       '56422427', '57287811', '85231190', '856006', '90340948'],
      dtype=object)), ('Wikipedia', array(['Perphenazine'], dtype=object)), ('drugbank', array(['DB00850'], dtype=object)), ('chEBI', array(['8028'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002017', 'HP_0000713', 'EFO_0005230', 'MONDO_0005090',
       'EFO_0002610', 'MONDO_0002050', 'HP_0002140', 'HP_0000726',
       'EFO_0005407'], dtype=object), 'count': 9}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL570,"CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21_|_XSCGXQMFQXDFCW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIFLUPROMAZINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Fluopromazine' 'Nivoman' 'Vesprin' 'Vetame']_|_['Fluopromazine' 'Triflupromazine']_|_[('PubChem', array(['11111873', '11111874', '124881619', '50100355', '50104262',
       '90341005'], dtype=object)), ('Wikipedia', array(['Triflupromazine'], dtype=object)), ('drugbank', array(['DB00508'], dtype=object)), ('chEBI', array(['9711'], dtype=object))]_|_['CHEMBL1201102']_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for psychosis."
CHEMBL1201460,"nan_|_nan_|_Oligosaccharide_|_True_|_DALTEPARIN SODIUM_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Fragmin' 'Low liquemine']_|_['.alpha.-heparin' 'B01AB04' 'Boxol' 'Dalteparin' 'Dalteparin sodium'
 'FR-860' 'Fragmine' 'HEPARIN FRAGMENT KABI 2165' 'KABI-2165'
 'Low-liquemine']_|_[('DailyMed', array(['dalteparin%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0002618', 'EFO_0001378', 'HP_0001907',
       'EFO_1000954', 'MONDO_0043510', 'EFO_0004286', 'HP_0004419',
       'MONDO_0011382', 'MONDO_0008903', 'EFO_0000681', 'MONDO_0007254',
       'EFO_1001951', 'MONDO_0008315', 'HP_0004936', 'MONDO_0008170',
       'EFO_0009315', 'EFO_0002950', 'EFO_1000158', 'MONDO_0019514',
       'EFO_0003884', 'MONDO_0100096', 'EFO_0006834', 'EFO_1001459',
       'EFO_0003907'], dtype=object), 'count': 25}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201609,"nan_|_nan_|_Protein_|_False_|_CORTICOTROPIN ZINC HYDROXIDE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Cortrophin-zinc']_|_['Corticotrophin zinc hydroxide' 'Corticotropin zinc hydroxide'
 'Corticotropin-zinc hydroxide']_|_nan_|_nan_|_nan_|_[ENSG00000185231]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1955."
CHEMBL1201692,"nan_|_nan_|_Protein_|_False_|_FOLLITROPIN ALFA_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Bemfola' 'Gonal-f' 'Gonal-f rff' 'Gonal-f rff redi-ject' 'Ovaleap']_|_['Follitropin .alpha.' 'Follitropin alfa' 'Follitropin alpha' 'Gonal f'
 'Human FSH']_|_[('DrugCentral', array(['4928'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bemfola'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002775'], dtype=object), 'count': 1}_|_[ENSG00000170820]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for anovulation."
CHEMBL1201749,"CCCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_WYQPLTPSGFELIB-JTQPXKBDSA-N_|_Small molecule_|_False_|_DIFLUPREDNATE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Durezol']_|_['Difluprednate' 'W 6309' 'W-6309']_|_[('DailyMed', array(['difluprednate'], dtype=object)), ('PubChem', array(['144206181', '56422387', '856020'], dtype=object)), ('Wikipedia', array(['Difluprednate'], dtype=object)), ('drugbank', array(['DB06781'], dtype=object)), ('chEBI', array(['31485'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000811', 'EFO_1000906', 'EFO_1001231', 'EFO_1001082',
       'MP_0001845', 'MONDO_0005129'], dtype=object), 'count': 6}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for anterior uveitis and inflammation and has 4 investigational indications."
CHEMBL1215661,"N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12_|_AQRLDDAFYYAIJP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRUVANSERIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EMD 390920' 'EMD-281014' 'EMD-390920' 'EMD390920' 'LSN-2422347'
 'LSN2422347' 'LY-2420586' 'LY-2422347' 'LY-2422347 FREE BASE' 'LY2420586'
 'LY2422347' 'Ly2422347' 'Pruvanserin']_|_[('Wikipedia', array(['Pruvanserin'], dtype=object)), ('drugbank', array(['DB13094'], dtype=object))]_|_['CHEMBL2104980']_|_{'rows': array(['EFO_0008568'], dtype=object), 'count': 1}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1255582,"CCC1(c2c[nH]cn2)Cc2ccc(F)cc2C1_|_KXSUAWAUCNFBQJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_FIPAMEZOLE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fipamezole']_|_[('drugbank', array(['DB06585'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1257,"FC(F)OC(F)(F)C(F)Cl_|_JPGQOUSTVILISH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENFLURANE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Enflurane' 'Ethrane']_|_['ANESTHETIC COMPOUND NO. 347' 'Alyrane' 'Anesthetic Compound No. 347'
 'Compound 347' 'Efrane' 'Enflurane' 'Methylflurether' 'NSC-115944'
 'Ohio 347' 'R-E-235CA2']_|_[('PubChem', array(['144207364', '50112675'], dtype=object)), ('Wikipedia', array(['Enflurane'], dtype=object)), ('drugbank', array(['DB00228'], dtype=object)), ('chEBI', array(['4792'], dtype=object))]_|_nan_|_nan_|_[ENSG00000186795,ENSG00000100433,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000082482,ENSG00000145888,ENSG00000109738,ENSG00000169427,ENSG00000171303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972."
CHEMBL1484,"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1_|_ZBBHBTPTTSWHBA-UHFFFAOYSA-N_|_Small molecule_|_False_|_NICARDIPINE_|_1988.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Nicardipine' 'Nicardipine (stn)' 'Perpidine']_|_[('PubChem', array(['104171201', '124880905', '144203762', '170465173', '26755701',
       '26755702', '50111158', '50111159', '90340664'], dtype=object)), ('Wikipedia', array(['Nicardipine'], dtype=object)), ('drugbank', array(['DB00622'], dtype=object)), ('chEBI', array(['7550'], dtype=object))]_|_['CHEMBL1200326']_|_{'rows': array(['EFO_1000994', 'EFO_0000713', 'EFO_0000319', 'EFO_0009846',
       'EFO_0001645', 'EFO_0000668', 'EFO_0005669', 'EFO_0003833',
       'EFO_0000319', 'EFO_0000712', 'EFO_0000537', 'EFO_0000537',
       'EFO_0004282', 'EFO_0003843'], dtype=object), 'count': 14}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for cardiovascular disease and hypertension and has 12 investigational indications."
CHEMBL1504,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1_|_YNDXUCZADRHECN-JNQJZLCISA-N_|_Small molecule_|_False_|_TRIAMCINOLONE ACETONIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Adcortyl' 'Adcortyl in orabase' 'Allernaze' 'Aristocort' 'Aristocort a'
 'Aristogel' 'Audicort' 'Aureocort' 'Azmacort' 'Flutex' 'Gppe ear dps cap'
 'Gppe ear oint' 'Kenacort' 'Kenalog' 'Kenalog in orabase' 'Kenalog-10'
 'Kenalog-40' 'Kenalog-80' 'Kenalog-h' 'Nasacort'
 'Nasacort allergy 24 hour' 'Nasacort aq' 'Nasacort hfa' 'Nystadermal'
 'Oracort' 'Oralone' 'Pevaryl t.c.' 'Remiderm' 'Remotic' 'Silderm'
 'Tri-Nasal' 'Tri-adcortyl' 'Triacet' 'Triacort' 'Triamcinolone acetonide'
 'Triamcinolone acetonide in absorbase' 'Triatex' 'Triderm' 'Triesence'
 'Trivaris' 'Trymex' 'Vetalog' 'Xipere' 'Zilretta']_|_['FX-006' 'FX006' 'Kenacourt' 'NSC-21916' 'Triamcinolone Acetonide'
 'Triamcinolone acetonide']_|_[('DailyMed', array(['triamcinolone%20acetonide'], dtype=object)), ('PubChem', array(['144204436', '144208993', '144213331', '170464660', '29215012',
       '56423119', '855857'], dtype=object)), ('Wikipedia', array(['Triamcinolone_acetonide'], dtype=object)), ('chEBI', array(['71418'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004719', 'EFO_0003943', 'EFO_0003956', 'EFO_1000809',
       'EFO_0007363', 'EFO_0000497', 'MONDO_0004037', 'EFO_1001898',
       'EFO_1001494', 'EFO_0004229', 'MONDO_0002406', 'EFO_1000706',
       'MONDO_0002041', 'EFO_0003843', 'EFO_0009606', 'EFO_1001896',
       'EFO_0004208', 'EFO_1000680', 'MONDO_0005129', 'EFO_0010822',
       'EFO_1000941', 'EFO_1001250', 'EFO_1001222', 'MONDO_0007935',
       'EFO_0000685', 'EFO_0004683', 'EFO_1001157', 'MONDO_0004979',
       'EFO_0004616', 'EFO_0000701', 'HP_0001742', 'EFO_0008521',
       'EFO_1001231', 'HP_0030834', 'EFO_0004212', 'EFO_1000726',
       'EFO_1001129', 'MONDO_0003005', 'EFO_1001887', 'EFO_0008507',
       'EFO_0003770', 'MONDO_0018092', 'MONDO_0005041', 'HP_0012735',
       'EFO_1000786', 'MONDO_0002471', 'MONDO_0005301', 'MONDO_0002959',
       'EFO_0004238', 'EFO_1001435', 'EFO_0001365', 'EFO_0009485',
       'EFO_0007415', 'EFO_0008517', 'MONDO_0007254', 'MONDO_0002280',
       'MONDO_0004857', 'EFO_0004274', 'MONDO_0005178', 'EFO_0004192',
       'HP_0009588', 'EFO_1000049', 'EFO_0000274', 'EFO_0000546',
       'EFO_0005854', 'EFO_1001224'], dtype=object), 'count': 66}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 21 approved and 45 investigational indications."
CHEMBL150894,"CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCO)Cc1ccccc1-4)C(=O)NC3_|_MLIFNJABMANKEU-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEP-5214_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CEP-5214' 'CEP5214' 'Cep-5214']_|_nan_|_nan_|_nan_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL1643895,"Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21_|_NTHPAPBPFQJABD-LLVKDONJSA-N_|_Small molecule_|_False_|_RAMOSETRON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ramosetron']_|_[('PubChem', array(['50112691'], dtype=object)), ('Wikipedia', array(['Ramosetron'], dtype=object)), ('drugbank', array(['DB09290'], dtype=object))]_|_['CHEMBL3181841']_|_{'rows': array(['EFO_0004888', 'MONDO_0004992', 'HP_0002018', 'EFO_0006912',
       'MONDO_0001056', 'EFO_0000555', 'HP_0002013'], dtype=object), 'count': 7}_|_[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL1659,"CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_DBAKFASWICGISY-BTJKTKAUSA-N_|_Small molecule_|_False_|_CHLORPHENIRAMINE MALEATE_|_1950.0_|_4.0_|_CHEMBL505_|_False_|_True_|_['Allercalm allergy relief' 'Allerief' 'Alunex' 'Antagonate' 'Calimal'
 'Chlor-trimeton' 'Chlorphenamine' 'Chlorpheniramine maleate'
 'Efidac 24 chlorpheniramine maleate' 'Hayleve' 'Kloromin' 'Phenetron'
 'Piriject' 'Piriton' 'Piriton allergy' 'Pyridamal 100'
 'Rhino-syrup allergy' 'Rimarin' 'Teldrin']_|_['(+)-Chlorpheniramine Maleate' 'Chlorphenamine hydrogen maleate'
 'Chlorphenamine maleate' 'Chlorphenamini hydrogenomaleas'
 'Chlorpheniramine Maleate' 'Chlorpheniramine maleate'
 'Chlorprophenpyridamine maleate' 'Efidac' 'Histaspan' 'NSC-756684'
 'Neorestamin' 'Pyridamal' 'Synistamin']_|_[('DailyMed', array(['chlorpheniramine%20maleate'], dtype=object)), ('PubChem', array(['144209290', '144213766', '17389966', '26719778', '50106014',
       '50106015', '56422503'], dtype=object)), ('chEBI', array(['3645'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012735', 'HP_0002315', 'EFO_0007214', 'HP_0001742',
       'HP_0001945', 'EFO_0003956', 'MONDO_0002258', 'EFO_0005854',
       'HP_0003418', 'EFO_0003958', 'MONDO_0005271', 'EFO_0007486',
       'EFO_0003843'], dtype=object), 'count': 13}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 12 approved and 1 investigational indication."
CHEMBL1829433,"Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1_|_SMFXSYMLJDHGIE-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-4877_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-4877' 'AZD4877' 'Azd 4877' 'Azd-4877']_|_[('drugbank', array(['DB11671'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0005952', 'EFO_0000616', 'EFO_0000574',
       'EFO_0000313'], dtype=object), 'count': 5}_|_[ENSG00000138160]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL193482,"C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O_|_PROQIPRRNZUXQM-ZXXIGWHRSA-N_|_Small molecule_|_False_|_ESTRIOL_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Gynest' 'Incurin' 'Ortho-gynest' 'Ovestin']_|_['16.ALPHA.-HYDROXYESTRADIOL' '16.alpha.,17.beta.-estriol' 'Aacifemine'
 'Colpogyn' 'Estriol' 'Estriol acetate benzoate' 'Estriol propionate'
 'Estriol succinate' 'Incurin' 'NSC-12169' 'Oestriol' 'Trihydroxyestrin']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/incurin'],
      dtype=object)), ('PubChem', array(['11532998', '144205873', '144211921', '170465807'], dtype=object)), ('Wikipedia', array(['Estriol'], dtype=object)), ('drugbank', array(['DB04573'], dtype=object)), ('chEBI', array(['27974'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'EFO_0002950', 'GO_0042697', 'EFO_0008520',
       'EFO_1001271', 'EFO_0008522'], dtype=object), 'count': 6}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 investigational indications."
CHEMBL1976040,"C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1_|_BKWJAKQVGHWELA-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADAVOSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD 1775' 'AZD-1775' 'AZD1775' 'Adavosertib' 'Azd-1775' 'MK-1775'
 'MK1775']_|_[('PubChem', array(['103905025', '137276027'], dtype=object)), ('drugbank', array(['DB11740'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0003060', 'EFO_0001075', 'MONDO_0007254',
       'EFO_0000702', 'MONDO_0001187', 'EFO_1000131', 'MONDO_0044704',
       'EFO_1000043', 'EFO_0000349', 'EFO_0002939', 'MONDO_0002715',
       'EFO_0000616', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0006352',
       'EFO_0000503', 'EFO_0005537', 'EFO_1001960', 'EFO_0000519',
       'MONDO_0008903', 'EFO_0001378', 'EFO_1000251', 'EFO_0002618',
       'EFO_0000466', 'MONDO_0008315', 'EFO_0000707', 'MONDO_0002087',
       'MONDO_0008170'], dtype=object), 'count': 29}_|_[ENSG00000166483]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 29 investigational indications."
CHEMBL201960,"CCCC(C(=O)c1ccc(C)cc1)N1CCCC1_|_SWUVZKWCOBGPTH-UHFFFAOYSA-N_|_Small molecule_|_False_|_PYROVALERONE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['J8.659B' 'Pyrovalerone']_|_[('Wikipedia', array(['Pyrovalerone'], dtype=object))]_|_['CHEMBL2104793']_|_nan_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL2028852,"CC(=O)O.N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21_|_HKMZRZUEADSZDQ-DZJWSCHMSA-N_|_Protein_|_False_|_ICATIBANT ACETATE_|_2008.0_|_4.0_|_CHEMBL2028850_|_False_|_True_|_['Firazyr']_|_['HOE 140' 'HOE-140' 'Icatibant acetate']_|_[('DailyMed', array(['icatibant%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'MONDO_0019623', 'MP_0001845', 'EFO_0005532'],
      dtype=object), 'count': 4}_|_[ENSG00000168398]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for hereditary angioedema and angioedema and has 2 investigational indications."
CHEMBL2103852,"COc1cc([C@H]2C(C#N)=C(N)Oc3c2ccc(N)c3N)cc(Br)c1OC_|_JXONINOYTKKXQQ-CQSZACIVSA-N_|_Small molecule_|_False_|_CROLIBULIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Crolibulin' 'EPC 2407' 'EPC-2407' 'EPC2407']_|_[('drugbank', array(['DB12925'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'MONDO_0002108'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2105692,CC(C)OC(=O)COc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)c1_|_NVPXUFQLKWKBHK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAPRENEPAG ISOPROPYL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-04217329' 'Taprenepag isopropyl']_|_nan_|_nan_|_nan_|_[ENSG00000125384]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108222,"nan_|_nan_|_Unknown_|_False_|_ALOXIPRIN_|_nan_|_4.0_|_nan_|_False_|_True_|_['Palaprin fte']_|_['Alaprin' 'Aloxiprin' 'Paloxin' 'Polyoxyaluminium acetylsalicylate'
 'Polyoxyaluminum acetylsalicylate' 'Superpyrin']_|_[('DrugCentral', array(['4760'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001945', 'HP_0004419', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000073756,ENSG00000095303]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved indications."
CHEMBL2108767,"nan_|_nan_|_Antibody_|_False_|_RUPLIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Antova']_|_['BG-9588' 'BG9588' 'HU-5C8' 'Ruplizumab' 'hu5c8']_|_nan_|_nan_|_{'rows': array(['EFO_0005761'], dtype=object), 'count': 1}_|_[ENSG00000102245]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109435,"nan_|_nan_|_Antibody_|_False_|_HUA33_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HUA33' 'Hua33']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0004142'], dtype=object), 'count': 2}_|_[ENSG00000143167]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2110756,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC_|_BELMMAAWNYFCGF-PZXAHSFZSA-N_|_Small molecule_|_False_|_MITEMCINAL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mitemcinal']_|_[('drugbank', array(['DB06587'], dtype=object))]_|_['CHEMBL2105890']_|_{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}_|_[ENSG00000102539]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2165191,"Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1_|_IRTDIKMSKMREGO-OAHLLOKOSA-N_|_Small molecule_|_False_|_AZD-6482_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-6482' 'AZD6482' 'Azd 6482' 'Azd-6482']_|_[('drugbank', array(['DB14980'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002140'], dtype=object), 'count': 1}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2397751,"CCOC(=O)c1c(C)cc2nc(COC(=O)NCCO)n(-c3ccccc3S(=O)(=O)NC)c(=O)c2c1C_|_PMBUDILHPXTDNY-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAD448_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Sad448']_|_nan_|_nan_|_{'rows': array(['EFO_1001069'], dtype=object), 'count': 1}_|_[ENSG00000118432,ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3286830,"C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21_|_IIXWYSCJSQVBQM-LLVKDONJSA-N_|_Small molecule_|_False_|_LORLATINIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Lorbrena' 'Lorviqua']_|_['Lorlatinib' 'PF-06463922']_|_[('DailyMed', array(['lorlatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua'],
      dtype=object)), ('drugbank', array(['DB12130'], dtype=object))]_|_['CHEMBL4539157']_|_{'rows': array(['EFO_0000621', 'EFO_0003032', 'EFO_0003060', 'EFO_0003086',
       'EFO_0001421', 'EFO_0000502', 'EFO_0000574', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 9}_|_[ENSG00000171094,ENSG00000143924]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 5 investigational indications."
CHEMBL3301587,"nan_|_nan_|_Antibody_|_False_|_DURVALUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Imfinzi']_|_['Durvalumab' 'MEDI-4736' 'MEDI4736']_|_[('DailyMed', array(['durvalumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0001071', 'EFO_0000403', 'EFO_0000514',
       'MONDO_0008315', 'MONDO_0021117', 'EFO_0000198', 'EFO_0000181',
       'EFO_0000501', 'MONDO_0007254', 'EFO_0000588', 'EFO_0003869',
       'EFO_0000503', 'EFO_0003897', 'MONDO_0004986', 'EFO_0005537',
       'EFO_0000702', 'EFO_0000228', 'EFO_0000640', 'MONDO_0008903',
       'EFO_0002618', 'MONDO_0018906', 'EFO_0003060', 'EFO_0000707',
       'EFO_0001378', 'EFO_0000681', 'EFO_0001075', 'EFO_0000708',
       'EFO_0001642', 'EFO_0000313', 'EFO_0002430', 'EFO_0000691',
       'EFO_0003868', 'EFO_0005922', 'EFO_1000984', 'EFO_0009709',
       'EFO_1001931', 'MONDO_0005184', 'EFO_0000294', 'MONDO_0002974',
       'EFO_0003968', 'EFO_0000365', 'EFO_0000770', 'MONDO_0001056',
       'MONDO_0003001', 'EFO_0002913', 'EFO_0000222', 'EFO_0003863',
       'EFO_0000673', 'EFO_0000199', 'MONDO_0002898', 'MONDO_0003199',
       'EFO_0004230', 'EFO_0000182', 'EFO_0000519', 'EFO_1000251',
       'MONDO_0008170', 'EFO_1001961', 'EFO_1001951', 'EFO_0005221',
       'MONDO_0044903', 'EFO_0003891', 'EFO_0006859', 'MONDO_0021148',
       'EFO_0000571', 'MONDO_0021063', 'EFO_0000641', 'MONDO_0003059',
       'MONDO_0044704', 'EFO_0000095', 'EFO_0004284', 'MONDO_0005575',
       'EFO_0000348', 'MONDO_0011962', 'EFO_0002429', 'EFO_0008528',
       'EFO_1000657', 'MONDO_0003060', 'MONDO_0007576', 'EFO_0003050',
       'EFO_0005952', 'EFO_0000756', 'EFO_0000305', 'EFO_0000349',
       'MONDO_0004992', 'MONDO_0001187', 'EFO_0006738', 'EFO_0005220',
       'MONDO_0003002', 'EFO_0000574', 'MONDO_0002108', 'EFO_1001968'],
      dtype=object), 'count': 92}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 11 approved and 81 investigational indications."
CHEMBL3545039,"Cc1cc(Cl)cc2c1N(Cc1cccc(C(F)(F)F)c1)C(=O)C21NC(=O)NC1=O_|_DXDVSYALLVVBOV-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD1386_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD1386' 'Azd 1386' 'Azd-1386' 'Azd1386']_|_nan_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0012532', 'EFO_0005762'], dtype=object), 'count': 3}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3833386,"nan_|_nan_|_Cell_|_False_|_GALINPEPIMUT-S_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Galinpepimut-s' 'SLS-001']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000184937]_|_Cell drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4594568,"nan_|_nan_|_Unknown_|_False_|_KN-026_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anbenitamab' 'Anti-her2 bsab kn026' 'KN-026' 'KN026' 'Kn 026' 'Kn-026'
 'Kn026']_|_nan_|_nan_|_{'rows': array(['MONDO_0001056', 'MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000141736]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4650338,"CC#CC(=O)N1CC[C@@H](n2cc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)n[nH]c(=O)c32)C1_|_DNPOFZXZJJDQLB-MRXNPFEDSA-N_|_Small molecule_|_False_|_EDRALBRUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Edralbrutinib' 'SHR-1459' 'SHR1459' 'Shr1459' 'TG-1701' 'TG1701'
 'Tg 1701' 'Tg-1701']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EDRALBRUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000096', 'EFO_0004256', 'EFO_0004289', 'EFO_0003086',
       'EFO_0000616', 'EFO_0000095', 'EFO_0005809'], dtype=object), 'count': 7}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4802198,"nan_|_nan_|_Antibody_|_False_|_QUISOVALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AEVI-002' 'AEVI002' 'AVTX-002' 'AVTX002' 'Avtx-002' 'CERC-002' 'CERC002'
 'Cerc 002' 'Cerc-002' 'F-19' 'KHK-252067' 'MDGN-002' 'MDGN002' 'Mdgn-002'
 'Quisovalimab' 'SAR-252067' 'SAR252067']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/QUISOVALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000637', 'EFO_0000384', 'MONDO_0004979', 'MONDO_0100096',
       'EFO_0000729'], dtype=object), 'count': 5}_|_[ENSG00000125735]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL485629,"O=C(NC1CC1)c1cn(-c2cccc(C#Cc3ccc[n+]([O-])c3)c2)c2ncccc2c1=O_|_JJWKQXNHYDJXKF-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-0873_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-0873' 'MK0873' 'Mk-0873']_|_[('drugbank', array(['DB13029'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0000676', 'EFO_0000341'], dtype=object), 'count': 3}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL70,"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5_|_BQJCRHHNABKAKU-KBQPJGBKSA-N_|_Small molecule_|_True_|_MORPHINE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Anhydrous morphine' 'Avinza' 'Depodur'
 'Hydromorphone hydrochloride impurity, morphine-' 'IDS-NM-009'
 'Infumorph' 'Kadian' 'Morphia' 'Morphine' 'Morphine (anhydrous)'
 'Morphine anhydrous' 'Morphine extended release' 'Morphine polistirex'
 'Morphium' 'N02AA01' 'Nepenthe' 'Ospalivina']_|_[('Wikipedia', array(['Morphine'], dtype=object)), ('drugbank', array(['DB00295'], dtype=object)), ('chEBI', array(['17303'], dtype=object))]_|_['CHEMBL2096625' 'CHEMBL4068407' 'CHEMBL2103744' 'CHEMBL556578']_|_{'rows': array(['EFO_0801084', 'HP_0012532', 'EFO_0000768', 'EFO_0009688',
       'HP_0011110', 'HP_0003418', 'EFO_0000616', 'EFO_0000768',
       'EFO_0004240', 'EFO_0005611', 'EFO_0003890', 'EFO_0003931',
       'EFO_0000341', 'EFO_0005323', 'EFO_0004270', 'EFO_0003918',
       'EFO_0010702', 'EFO_0009513', 'EFO_0000222', 'HP_0000989',
       'HP_0002019', 'EFO_0020911', 'HP_0000989', 'EFO_1001412',
       'EFO_0009842', 'EFO_0003843', 'EFO_0003917', 'EFO_0003918',
       'EFO_0005611', 'MONDO_0004992', 'EFO_0009727', 'MONDO_0011382',
       'EFO_0008583', 'EFO_1001250', 'HP_0012532', 'EFO_0005799',
       'EFO_0003843', 'EFO_0004273', 'EFO_0000546', 'EFO_0002950',
       'EFO_0801084', 'EFO_0000612', 'EFO_0009492', 'EFO_0009314',
       'MONDO_0004992', 'EFO_0004253', 'EFO_0004616', 'EFO_0003843',
       'HP_0001822', 'HP_0003419', 'EFO_0010702', 'EFO_0005799',
       'EFO_0000341', 'MP_0001914', 'EFO_0009620', 'EFO_0005762',
       'MONDO_0008315', 'EFO_0001073', 'EFO_0005755', 'MONDO_0011382',
       'EFO_0001361', 'EFO_1001898', 'EFO_0005611'], dtype=object), 'count': 63}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 5 approved and 50 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1076903,"c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1_|_JQSHBVHOMNKWFT-DTORHVGOSA-N_|_Small molecule_|_False_|_VARENICLINE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CP-526,555' 'CP-526555' 'Varenicline']_|_[('Wikipedia', array(['Varenicline'], dtype=object)), ('chEBI', array(['84500'], dtype=object))]_|_['CHEMBL5303393' 'CHEMBL5316216']_|_{'rows': array(['MONDO_0007079', 'EFO_0002610', 'EFO_0004319', 'MONDO_0008903',
       'EFO_0005672', 'MONDO_0002491', 'Orphanet_98757', 'EFO_1000906',
       'EFO_0004329', 'EFO_0007191', 'MONDO_0004992', 'EFO_0003768',
       'MONDO_0007079', 'EFO_0001071', 'MONDO_0100339', 'EFO_0003890',
       'EFO_0004319', 'EFO_0004701', 'EFO_0003966', 'EFO_0003768',
       'MONDO_0005180', 'MONDO_0005090', 'EFO_0005411', 'EFO_1000906',
       'MONDO_0004975'], dtype=object), 'count': 25}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for nicotine dependence and eye disease and has 21 investigational indications."
CHEMBL1200501,"CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O_|_IKDXDQDKCZPQSZ-JHYYTBFNSA-N_|_Protein_|_False_|_GOSERELIN ACETATE_|_1989.0_|_4.0_|_CHEMBL1201247_|_False_|_True_|_['Novgos' 'Zoladex' 'Zoladex la']_|_['Fertilan' 'Goserelin Acetate' 'Goserelin acetate']_|_[('DailyMed', array(['goserelin%20acetate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006861', 'EFO_0000305', 'MONDO_0002087', 'MONDO_0008315',
       'GO_0042697', 'EFO_0001663', 'MONDO_0007254', 'MONDO_0008170',
       'EFO_0000313', 'MONDO_0002158', 'EFO_0000673', 'EFO_0000545',
       'MONDO_0000521', 'EFO_0000195'], dtype=object), 'count': 14}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 11 investigational indications."
CHEMBL1201284,"C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12_|_VDHAWDNDOKGFTD-MRXNPFEDSA-N_|_Small molecule_|_False_|_CINACALCET_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AMG 073' 'AMG-073' 'AMG073' 'Cinacalcet' 'KRN-1493' 'KRN1493']_|_[('PubChem', array(['124893630', '50125742'], dtype=object)), ('Wikipedia', array(['Cinacalcet'], dtype=object)), ('drugbank', array(['DB01012'], dtype=object)), ('chEBI', array(['48390'], dtype=object))]_|_['CHEMBL1200776']_|_{'rows': array(['EFO_1001173', 'EFO_1001152', 'HP_0003072', 'EFO_0003884',
       'EFO_0000673', 'EFO_0003884', 'EFO_0008506', 'EFO_0005754',
       'EFO_0001072', 'MONDO_0024300', 'EFO_1001173', 'EFO_0008519',
       'EFO_0000313', 'EFO_1000456', 'EFO_0008506'], dtype=object), 'count': 15}_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 7 approved and 8 investigational indications."
CHEMBL1201294,"CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1_|_HYPPXZBJBPSRLK-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENOXYLATE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Diphenoxylate' 'IDS-ND-016']_|_[('PubChem', array(['50113007'], dtype=object)), ('Wikipedia', array(['Diphenoxylate'], dtype=object)), ('drugbank', array(['DB01081'], dtype=object)), ('chEBI', array(['4639'], dtype=object))]_|_['CHEMBL1200665']_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1201666,"nan_|_nan_|_Protein_|_False_|_LEPIRUDIN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Refludan']_|_['Hirudin lepirudin' 'Lepirudin' 'Lepirudin Recombinant'
 'Lepirudin recombinant']_|_[('DrugCentral', array(['2995'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/refludan'],
      dtype=object)), ('Wikipedia', array(['Lepirudin'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001873', 'HP_0004419', 'MONDO_0000831', 'HP_0001907',
       'MONDO_0008903'], dtype=object), 'count': 5}_|_[ENSG00000180210]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 1 investigational indication."
CHEMBL1237132,"CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl_|_KPBZROQVTHLCDU-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLEVIDIPINE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Cleviprex']_|_['Clevidepine' 'Clevidepine butyrate' 'Clevidipine']_|_[('DailyMed', array(['clevidipine'], dtype=object)), ('PubChem', array(['170466066'], dtype=object)), ('drugbank', array(['DB04920'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001031', 'EFO_0000319', 'EFO_0004264', 'EFO_0000537',
       'EFO_0004273', 'EFO_0000712'], dtype=object), 'count': 6}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 5 investigational indications."
CHEMBL1580,"OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O_|_FPVKHBSQESCIEP-JQCXWYLXSA-N_|_Small molecule_|_True_|_PENTOSTATIN_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Nipent' 'Pentostatin']_|_['CI-825' 'Deoxycoformycin' 'NSC-218321' 'Nipent' 'PD 81565' 'PD-81565'
 'Pentostatin' 'YK-176']_|_[('DailyMed', array(['pentostatin'], dtype=object)), ('PubChem', array(['124893765', '144206967'], dtype=object)), ('Wikipedia', array(['Pentostatin'], dtype=object)), ('drugbank', array(['DB00552'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000574', 'MONDO_0013730', 'EFO_0000565',
       'MONDO_0002367', 'MONDO_0004992', 'EFO_0004599', 'MONDO_0011382',
       'EFO_0000095', 'EFO_1000956', 'EFO_0006927', 'MONDO_0002280',
       'MONDO_0020547'], dtype=object), 'count': 13}_|_[ENSG00000196839]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1581,"CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC_|_IPVQLZZIHOAWMC-QXKUPLGCSA-N_|_Small molecule_|_True_|_PERINDOPRIL_|_1993.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MCN-A-2833' 'Perindopril' 'S-9490']_|_[('PubChem', array(['144206638', '170464836', '56463760'], dtype=object)), ('Wikipedia', array(['Perindopril'], dtype=object)), ('drugbank', array(['DB00790'], dtype=object)), ('chEBI', array(['8024'], dtype=object))]_|_['CHEMBL3544986' 'CHEMBL1200343']_|_{'rows': array(['EFO_0001358', 'MONDO_0001134', 'EFO_0004701', 'EFO_0000537',
       'MONDO_0004975', 'EFO_0000319', 'MONDO_0007947', 'EFO_1000654',
       'EFO_0000612', 'MONDO_0005148', 'EFO_0000407', 'EFO_0001645',
       'EFO_0000537', 'MONDO_0007254', 'MONDO_0002491', 'EFO_0004214',
       'EFO_0000537'], dtype=object), 'count': 17}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1652,"CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl_|_OMHBPUNFVFNHJK-UHFFFAOYSA-P_|_Small molecule_|_False_|_AMBENONIUM_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ambenonium' 'Ambenonium cation' 'Ambenonium ion']_|_[('PubChem', array(['11113478', '26756578'], dtype=object)), ('Wikipedia', array(['Ambenonium_chloride'], dtype=object)), ('drugbank', array(['DB01122'], dtype=object)), ('chEBI', array(['2627'], dtype=object))]_|_['CHEMBL1200541']_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL17,"NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1_|_GJQPMPFPNINLKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_DICHLORPHENAMIDE_|_1958.0_|_4.0_|_nan_|_False_|_True_|_['Daranide' 'Keveyis' 'Oratrol']_|_['Dichlorphenamide' 'Diclofenamide']_|_[('DailyMed', array(['dichlorphenamide'], dtype=object)), ('PubChem', array(['11112264', '144203952', '56463645'], dtype=object)), ('Wikipedia', array(['Diclofenamide'], dtype=object)), ('drugbank', array(['DB01144'], dtype=object)), ('chEBI', array(['101085'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008223', 'MONDO_0008195', 'MONDO_0008224', 'MONDO_0005041'],
      dtype=object), 'count': 4}_|_[ENSG00000133742,ENSG00000074410,ENSG00000104267,ENSG00000167434]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and is indicated for glaucoma and has 3 investigational indications."
CHEMBL1742996,"nan_|_nan_|_Antibody_|_True_|_BRODALUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Kyntheum' 'Siliq']_|_['AMG 827' 'AMG-827' 'Brodalumab' 'KHK-4827' 'KHK4827']_|_[('DailyMed', array(['brodalumab'], dtype=object)), ('DrugCentral', array(['5179'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000540', 'EFO_0003778', 'EFO_0000384', 'MONDO_0004979',
       'MONDO_0015597', 'EFO_0000676', 'EFO_1000710', 'EFO_0003898',
       'EFO_0000717', 'EFO_1001494', 'EFO_0000685'], dtype=object), 'count': 11}_|_[ENSG00000177663]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2087337,"CC(C)n1c(=O)c(C(=O)N[C@H]2C[C@H]3CC[C@@H](C2)N3C[C@@H](O)CN(C)S(C)(=O)=O)cc2ccccc21_|_HXLOHDZQBKCUCR-WOZUAGRISA-N_|_Small molecule_|_False_|_VELUSETRAG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TD-5108' 'Velusetrag']_|_[('drugbank', array(['DB12702'], dtype=object))]_|_['CHEMBL2105660']_|_{'rows': array(['EFO_1000988', 'EFO_1000948', 'MONDO_0004975'], dtype=object), 'count': 3}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2105648,"CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21_|_YTFHCXIPDIHOIA-DHZHZOJOSA-N_|_Small molecule_|_True_|_PALOVAROTENE_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Sohonos']_|_['CLM-001' 'IPN-60120' 'IPN60120' 'Palovarotene' 'R-667' 'RG-667'
 'RO-3300074' 'RO3300074']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PALOVAROTENE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12320'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008153', 'EFO_1000906', 'MONDO_0007606'], dtype=object), 'count': 3}_|_[ENSG00000172819]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for fibrodysplasia ossificans progressiva and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108669,"nan_|_nan_|_Antibody drug conjugate_|_False_|_YTTRIUM Y 90 TACATUZUMAB TETRAXETAN_|_nan_|_2.0_|_nan_|_False_|_False_|_['Afp-cide']_|_['HAFP-31' 'Yttrium (90y) tacatuzumab tetraxetan'
 'Yttrium y 90 tacatuzumab tetraxetan']_|_nan_|_nan_|_nan_|_[ENSG00000081051]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II."
CHEMBL2109413,"nan_|_nan_|_Antibody_|_False_|_AS-1409_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AS-1409' 'As-1409' 'HUBC1-HUIL12']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000681'], dtype=object), 'count': 2}_|_[ENSG00000115414]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2219416,"C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5.O=C(O)C(=O)O_|_MNYIRXLCPODKLG-VUTNLTPYSA-N_|_Small molecule_|_False_|_NALOXEGOL OXALATE_|_2014.0_|_4.0_|_CHEMBL2219418_|_False_|_True_|_['Movantik' 'Moventig']_|_['AZ13337019 oxalate' 'NKTR-118 oxalate' 'Naloxegol oxalate']_|_[('DailyMed', array(['naloxegol%20oxalate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/moventig'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002203', 'EFO_0005611', 'HP_0002019', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved indications."
CHEMBL2336071,"CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1_|_KIHYPELVXPAIDH-HNSNBQBZSA-N_|_Small molecule_|_False_|_SIPONIMOD_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Mayzent']_|_['BAF-312' 'BAF312' 'Baf312' 'NVP-BAF312-NX' 'Siponimod']_|_[('DailyMed', array(['siponimod'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIPONIMOD/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12371'], dtype=object))]_|_['CHEMBL4298150']_|_{'rows': array(['EFO_0008522', 'EFO_0008522', 'EFO_0003840', 'EFO_0003929',
       'MONDO_0005301', 'EFO_0000398', 'EFO_0003929', 'EFO_0001421',
       'EFO_0003086', 'EFO_0000540', 'EFO_0003063', 'MONDO_0005301'],
      dtype=object), 'count': 12}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 6 investigational indications."
CHEMBL2369989,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)[N+](C)(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCC(=O)[O-])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)O_|_DUQRILZXKXSRIY-RUBJUKRASA-N_|_Protein_|_False_|_ATILMOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atilmotin' 'BAX-ACC-1638' 'MOT-288' 'OHM-11638']_|_nan_|_nan_|_nan_|_[ENSG00000102539]_|_Protein drug with a maximum clinical trial phase of II.
CHEMBL3039522,"CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12_|_PKWRMUKBEYJEIX-DXXQBUJASA-N_|_Small molecule_|_False_|_BIRINAPANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Birinapant' 'TL-32711' 'TL32711']_|_[('drugbank', array(['DB11782'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004197', 'EFO_0000222', 'MONDO_0004992', 'EFO_1001100',
       'EFO_0000181', 'EFO_1000251', 'MONDO_0002158', 'EFO_0000198',
       'MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 10}_|_[ENSG00000023445,ENSG00000110330]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL3142541,"CCCCOC(=O)c1ccc(N)cc1.CCCCOC(=O)c1ccc(N)cc1.O=[N+]([O-])c1cc([N+](=O)[O-])c(O)c([N+](=O)[O-])c1_|_ATAGSVCDFKGYPE-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUTAMBEN PICRATE_|_nan_|_4.0_|_CHEMBL127516_|_True_|_True_|_[]_|_['ABBOTT-34842' 'Butamben picrate']_|_[('chEBI', array(['86300'], dtype=object))]_|_nan_|_nan_|_[ENSG00000111199,ENSG00000104321]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL3544998,nan_|_nan_|_Small molecule_|_False_|_LY-3007113_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ly-3007113']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545097,"CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21_|_GYLDXIAOMVERTK-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAPANISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CB-228' 'INK-128' 'INK128' 'Ink-128' 'MLN-0128' 'MLN0128' 'Mln-0128'
 'Sapanisertib' 'TAK-228']_|_[('drugbank', array(['DB11836'], dtype=object))]_|_['CHEMBL3943182']_|_{'rows': array(['MONDO_0008315', 'EFO_0000616', 'EFO_0007416', 'EFO_1001968',
       'EFO_0004230', 'EFO_0000182', 'EFO_0000681', 'EFO_1000251',
       'MONDO_0007254', 'EFO_0000519', 'EFO_1001471', 'EFO_0001378',
       'EFO_0000708', 'EFO_1000045', 'MONDO_0004992', 'EFO_1000043',
       'EFO_0003060', 'EFO_0000209', 'EFO_0000466', 'EFO_0007532',
       'MONDO_0002108', 'EFO_0000574', 'EFO_0009441', 'EFO_1001465',
       'EFO_0003869'], dtype=object), 'count': 25}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 25 investigational indications."
CHEMBL3545125,"CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O_|_FTBQORVNHOIASH-CKYFFXLPSA-N_|_Small molecule_|_False_|_MIROGABALIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-200-0700' 'A200-0700' 'Mirogabalin']_|_[('drugbank', array(['DB11825'], dtype=object))]_|_['CHEMBL3545257']_|_{'rows': array(['EFO_1000783', 'EFO_0005687', 'MONDO_0041052', 'EFO_0005762'],
      dtype=object), 'count': 4}_|_[ENSG00000153956,ENSG00000007402]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3707293,"nan_|_nan_|_Small molecule_|_False_|_XEN-D0501_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Xen-d0501']_|_nan_|_nan_|_{'rows': array(['EFO_0000341', 'HP_0012735', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL392149,"OC[C@H]1O[C@@H](n2cnc3c(N[C@@H]4CCOC4)ncnc32)[C@H](O)[C@@H]1O_|_OESBDSFYJMDRJY-BAYCTPFLSA-N_|_Small molecule_|_False_|_TECADENOSON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CVT-510' 'Tecadenoson']_|_[('drugbank', array(['DB04954'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298004,"nan_|_nan_|_Antibody_|_False_|_VOPRATELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-icos agonist mab jtx-2011' 'JTX-2011' 'Jtx 2011' 'Jtx-2011'
 'Vopratelimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VOPRATELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000163600]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL482967,"Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1_|_GPSZYOIFQZPWEJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYC-116_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CYC-116' 'Cyc 116' 'Cyc-116']_|_[('PubChem', array(['103904403', '137276048'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL521686,"O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1_|_FDLYAMZZIXQODN-UHFFFAOYSA-N_|_Small molecule_|_False_|_OLAPARIB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Lynparza']_|_['AZ-2281' 'AZ2281' 'AZD-2281' 'AZD2281' 'KEYLYNK-010 COMPONENT OLAPARIB'
 'KU-0059436' 'KU-59436' 'NSC-747856' 'OLAPARIB COMPONENT OF KEYLYNK-010'
 'Olaparib']_|_[('DailyMed', array(['olaparib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza'],
      dtype=object)), ('PubChem', array(['124947876', '164339421', '174007124'], dtype=object)), ('Wikipedia', array(['Olaparib'], dtype=object)), ('drugbank', array(['DB09074'], dtype=object)), ('chEBI', array(['83766'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0100342', 'EFO_0000707', 'MONDO_0001056',
       'EFO_0005537', 'EFO_0000519', 'EFO_0003869', 'EFO_0000216',
       'EFO_0000702', 'EFO_0005221', 'MONDO_0008315', 'EFO_0006859',
       'EFO_1001951', 'EFO_0002618', 'EFO_0000294', 'EFO_0003825',
       'MONDO_0008903', 'EFO_1000251', 'EFO_0000174', 'EFO_0003860',
       'MONDO_0005184', 'EFO_0002617', 'EFO_0000389', 'EFO_0000514',
       'MONDO_0001187', 'EFO_0003060', 'EFO_0000574', 'MONDO_0003060',
       'MONDO_0007254', 'MONDO_0004986', 'EFO_0000095', 'MONDO_0004992',
       'EFO_0000503', 'EFO_0003968', 'EFO_1000984', 'EFO_0002918',
       'EFO_1001901', 'EFO_1001512', 'EFO_0003893', 'Orphanet_145',
       'EFO_0000305', 'EFO_0004230', 'MONDO_0002087', 'MONDO_0002715',
       'EFO_1000158', 'EFO_0001663', 'MONDO_0002158', 'EFO_0007532',
       'MONDO_0008170', 'MONDO_0003059', 'EFO_0001075', 'EFO_0009708',
       'MONDO_0011962', 'EFO_0000313', 'EFO_1001100', 'EFO_0000196',
       'EFO_0001061', 'EFO_0000673', 'EFO_0000588', 'EFO_0000637',
       'EFO_1001968', 'MONDO_0002974', 'EFO_0000181', 'MONDO_0002928',
       'EFO_0000691', 'MONDO_0018364', 'EFO_0000681', 'EFO_0001361'],
      dtype=object), 'count': 68}_|_[ENSG00000143799,ENSG00000041880,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 63 investigational indications."
CHEMBL5315050,"CC(=O)O.CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1_|_SVDWBHHCPXTODI-QIWYXCRTSA-N_|_Protein_|_False_|_ATOSIBAN ACETATE_|_2000.0_|_4.0_|_CHEMBL382301_|_False_|_True_|_['Tractocile']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tractocile'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003917'], dtype=object), 'count': 1}_|_[ENSG00000180914]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for premature birth."
CHEMBL68055,"CC1=C(c2ccc(O)cc2)[C@H](c2ccc(OCCN3CCCCC3)cc2)Oc2cc(O)ccc21_|_DUYNJNWVGIWJRI-LJAQVGFWSA-N_|_Small molecule_|_False_|_ACOLBIFENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Acolbifene' 'Em-652' 'SCH-57068' 'SCH57068']_|_nan_|_['CHEMBL2105965']_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1200586,"CCCNC(C)C(=O)Nc1ccccc1C.Cl_|_BJPJNTKRKALCPP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRILOCAINE HYDROCHLORIDE_|_1965.0_|_4.0_|_CHEMBL1194_|_False_|_True_|_['Citanest' 'Citanest plain' 'Citanest plain dental'
 'Prilocaine hydrochloride']_|_['ASTRA 1512' 'Citanest hydrochloride' 'L-67' 'NSC-758432'
 'Prilocaine hcl' 'Prilocaine hydrochloride' 'Propitocaine hydrochloride'
 'Xylonest']_|_[('DailyMed', array(['prilocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['11532855', '144204064', '170464697', '50106902'], dtype=object)), ('chEBI', array(['32053'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965."
CHEMBL1201476,"nan_|_nan_|_Oligosaccharide_|_True_|_ENOXAPARIN SODIUM_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Clexane' 'Enoxaparin sodium' 'Enoxaparin sodium (preservative free)'
 'Inhixa' 'Lovenox' 'Lovenox (preservative free)']_|_['Enoxaparin' 'Enoxaparin sodium' 'Enoxaparin sodium salt' 'Klexane'
 'PK 10169' 'PK-10169' 'RP 54563' 'RP-54563']_|_[('DailyMed', array(['enoxaparin%20sodium'], dtype=object)), ('DrugCentral', array(['4879'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0000616', 'EFO_0003964', 'MONDO_0008170',
       'EFO_0005681', 'EFO_0000495', 'EFO_0005672', 'EFO_0000702',
       'HP_0004936', 'HP_0004419', 'MP_0001914', 'EFO_0009314',
       'EFO_1001375', 'EFO_0004255', 'EFO_0003827', 'MONDO_0000831',
       'EFO_0000712', 'EFO_0000612', 'MONDO_0100096', 'EFO_1000954',
       'HP_0001907', 'MONDO_0021148', 'EFO_0003086', 'EFO_0003907',
       'EFO_0003060', 'EFO_0002916', 'EFO_0001422', 'EFO_0002618',
       'EFO_0001073', 'EFO_0008583', 'MONDO_0004992', 'EFO_0004286',
       'EFO_1000985', 'EFO_0008585', 'EFO_0000574', 'EFO_0000544'],
      dtype=object), 'count': 36}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 8 approved and 28 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1286,"CC[C@@H](C(N)=O)N1CCCC1=O_|_HPHUVLMMVZITSG-LURJTMIESA-N_|_Small molecule_|_False_|_LEVETIRACETAM_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Desitrend' 'Elepsia xr' 'Keppra' 'Keppra xr' 'Levetiracetam'
 'Levetiracetam in sodium chloride' 'Levetiracetam teva' 'Matever'
 'Spritam']_|_['AGB-101' 'Elepsia' 'Levetiracetam' 'Levetiracetam accord'
 'Levetiracetam actavis' 'Levetiracetam hospira' 'Levetiracetam sun'
 'Levetiracetam teva' 'Levetiracetame' 'N03AX14' 'NSC-760119' 'UCB 22059'
 'UCB L059' 'UCB-22059' 'UCB-L059']_|_[('DailyMed', array(['levetiracetam'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-teva'],
      dtype=object)), ('PubChem', array(['26719810', '90341134'], dtype=object)), ('Wikipedia', array(['Levetiracetam'], dtype=object)), ('drugbank', array(['DB01202'], dtype=object)), ('chEBI', array(['6437'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000473', 'EFO_0004270', 'EFO_0003833', 'MONDO_0005180',
       'MONDO_0007079', 'MONDO_0002046', 'EFO_0004777', 'MONDO_0010079',
       'EFO_0003108', 'EFO_0009562', 'MONDO_0005090', 'EFO_0000621',
       'EFO_1000904', 'EFO_0000712', 'HP_0001250', 'EFO_0002610',
       'EFO_0005543', 'HP_0000726', 'HP_0002069', 'EFO_0001358',
       'EFO_0004263', 'MONDO_0002050', 'MONDO_0015643', 'EFO_0005407',
       'EFO_0005230', 'EFO_0000326', 'EFO_0004280', 'EFO_0004262',
       'EFO_0004242', 'HP_0100543', 'MONDO_0004975', 'HP_0002121',
       'MONDO_0041052', 'HP_0007359', 'EFO_0007262', 'MONDO_0011382',
       'EFO_0005611', 'EFO_0000222', 'EFO_0000713', 'HP_0002381',
       'EFO_0008526', 'EFO_0000474', 'MONDO_0004985', 'EFO_0000519'],
      dtype=object), 'count': 44}_|_[ENSG00000159164,ENSG00000148408]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 39 investigational indications."
CHEMBL1433,"C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21_|_JBIWCJUYHHGXTC-AKNGSSGZSA-N_|_Small molecule_|_True_|_DOXYCYCLINE ANHYDROUS_|_1967.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Anhydrous doxycycline' 'Doxycycline (anhydrous)']_|_[('PubChem', array(['26755247', '90340791'], dtype=object)), ('Wikipedia', array(['Doxycycline'], dtype=object)), ('drugbank', array(['DB00254'], dtype=object)), ('chEBI', array(['50845'], dtype=object))]_|_['CHEMBL1200699' 'CHEMBL2364574' 'CHEMBL1256723' 'CHEMBL1200567'
 'CHEMBL2106418' 'CHEMBL3989740']_|_{'rows': array(['EFO_0008510', 'EFO_0002618', 'EFO_1001466', 'EFO_1000906',
       'EFO_0009536', 'EFO_1001896', 'EFO_0000341', 'EFO_0004214',
       'MONDO_0007039', 'EFO_0009659', 'EFO_0003102', 'MONDO_0018076',
       'EFO_0007470', 'EFO_0000662', 'EFO_0001068', 'EFO_0009425',
       'MONDO_0007947', 'EFO_0000778', 'EFO_0000574', 'EFO_1002047',
       'EFO_0007460', 'HP_0001250', 'EFO_1001466', 'MONDO_0004992',
       'EFO_0000729', 'EFO_1001898', 'EFO_0007205', 'EFO_1001788',
       'MONDO_0100096', 'MONDO_0009061', 'MONDO_0019438', 'MP_0001914',
       'EFO_0007430', 'EFO_0000612', 'EFO_1001051', 'MONDO_0004975',
       'MONDO_0005178', 'EFO_0002913', 'MONDO_0019180', 'EFO_0003770',
       'EFO_0007185', 'EFO_0000384', 'EFO_1001235', 'EFO_0000464',
       'EFO_0000199', 'EFO_0003894', 'EFO_0000756', 'EFO_0007205',
       'EFO_1001951', 'EFO_1001388', 'EFO_0000649', 'EFO_1000760',
       'EFO_0000274', 'EFO_0000544', 'MONDO_0002635', 'EFO_0000365',
       'EFO_0000771', 'MONDO_0005180', 'MONDO_0017816', 'EFO_0003878',
       'EFO_0005952', 'EFO_1000760', 'EFO_0009117', 'EFO_0008517',
       'HP_0000964', 'EFO_0007272', 'EFO_0007480', 'EFO_0000096',
       'EFO_0003106', 'EFO_0000649', 'EFO_0000544', 'EFO_1001459',
       'EFO_0000694', 'EFO_0001365', 'EFO_1001875', 'EFO_0007410',
       'DOID_7551', 'EFO_0003843', 'EFO_0003060', 'EFO_0005044',
       'EFO_0007504', 'EFO_1000785', 'EFO_0003894', 'MONDO_0100096',
       'EFO_0000768', 'EFO_0007357', 'EFO_0009637', 'EFO_1001444',
       'EFO_0002687'], dtype=object), 'count': 89}_|_[ENSG00000137745,ENSG00000118113,ENSG00000196611,ENSG00000137673]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 71 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1456,"COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2_|_RTGDFNSFWBGLEC-SYZQJQIISA-N_|_Small molecule_|_True_|_MYCOPHENOLATE MOFETIL_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Arzip' 'Cellcept' 'Myclausen' 'Mycophenolate mofetil' 'Myfenax']_|_['Myclausen' 'Mycophenolate mofetil'
 'Mycophenolic acid 2-(4-morpholinyl)ethyl ester' 'Mycophenylate mofetil'
 'NSC-724229' 'NSC-758905' 'RS-61443']_|_[('DailyMed', array(['mycophenolate%20mofetil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/myclausen'],
      dtype=object)), ('PubChem', array(['144205239', '170464859', '29215409'], dtype=object)), ('Wikipedia', array(['Mycophenolate_mofetil'], dtype=object)), ('drugbank', array(['DB00688'], dtype=object)), ('chEBI', array(['8764'], dtype=object))]_|_['CHEMBL1200955']_|_{'rows': array(['EFO_0000404', 'EFO_0000519', 'EFO_1000784', 'EFO_0004719',
       'EFO_1000309', 'EFO_0000220', 'MONDO_0019469', 'EFO_1000965',
       'EFO_0004826', 'MONDO_0002334', 'EFO_0000681', 'EFO_0000616',
       'EFO_0002618', 'EFO_0003777', 'MONDO_0002367', 'EFO_0000565',
       'MONDO_0044881', 'EFO_1001779', 'EFO_0000255', 'EFO_0000211',
       'MONDO_0021193', 'EFO_0003032', 'EFO_0004228', 'EFO_0004236',
       'EFO_1000560', 'MONDO_0000870', 'MONDO_0010518', 'Orphanet_79292',
       'EFO_0000676', 'EFO_0006803', 'EFO_0000319', 'MONDO_0015253',
       'EFO_0000389', 'EFO_1002048', 'EFO_0000339', 'EFO_1001857',
       'EFO_0006927', 'EFO_0004251', 'MONDO_0007915', 'MONDO_0001705',
       'EFO_0004256', 'HP_0001915', 'MONDO_0018906', 'MONDO_0019391',
       'EFO_0000574', 'HP_0001871', 'EFO_0004991', 'EFO_0000699',
       'EFO_0007196', 'EFO_0000764', 'EFO_0002428', 'EFO_0000318',
       'EFO_1001469', 'EFO_1001051', 'MONDO_0004976', 'DOID_13406',
       'Orphanet_848', 'EFO_0000621', 'MONDO_0019471', 'EFO_0003047',
       'MONDO_0013730', 'EFO_0000191', 'EFO_0004244', 'EFO_0005952',
       'EFO_0001365', 'HP_0002721', 'EFO_0000401', 'EFO_0003086',
       'EFO_1000785', 'MONDO_0005147', 'EFO_0004274', 'EFO_0000685',
       'MONDO_0044903', 'EFO_1001231', 'EFO_1001017', 'EFO_0000096',
       'EFO_1000680', 'MONDO_0015760', 'EFO_0000309', 'EFO_0000384',
       'EFO_0000198', 'EFO_0000537', 'EFO_0000182', 'EFO_0004255',
       'MONDO_0005301', 'EFO_0005297', 'MONDO_0009387', 'EFO_0001062',
       'EFO_0002430', 'EFO_0000095', 'EFO_0002429', 'MONDO_0000873',
       'EFO_0004194', 'EFO_0001378', 'MONDO_0015974', 'EFO_1000956',
       'MONDO_0009833', 'EFO_0003884', 'EFO_1000690', 'EFO_0001642',
       'EFO_1000318', 'MONDO_0100244', 'MONDO_0011382', 'EFO_0000222',
       'MONDO_0019472', 'EFO_0005140', 'EFO_0000717', 'EFO_1001345',
       'MONDO_0018923', 'EFO_0000702', 'EFO_0000403', 'EFO_0004599',
       'EFO_0009441', 'MONDO_0020547', 'EFO_0004254', 'EFO_0007187',
       'EFO_0007160', 'EFO_0000183', 'EFO_0007359', 'EFO_0005761',
       'EFO_0001421', 'EFO_1000102', 'EFO_0008507', 'MONDO_0019262',
       'EFO_1001465', 'MONDO_0004992'], dtype=object), 'count': 126}_|_[ENSG00000106348,ENSG00000178035]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 126 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1534525,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C.Cl.Cl_|_MTJLQTFHJIHXIX-GDUXWEAWSA-N_|_Small molecule_|_False_|_MIBEFRADIL DIHYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL45816_|_True_|_True_|_[]_|_['Mibefradil dihydrochloride' 'Mibefradil hydrochloride' 'RO 40-5967/001']_|_[('PubChem', array(['144204795', '170466110', '50106572'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997. It was withdrawn in at least one region."
CHEMBL1615439,"C[C@H]1[C@H](c2ccccc2)OCCN1C_|_MFOCDFTXLCYLKU-CMPLNLGQSA-N_|_Small molecule_|_False_|_PHENDIMETRAZINE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-169187' 'Phendimetrazine']_|_[('drugbank', array(['DB01579'], dtype=object)), ('chEBI', array(['8059'], dtype=object))]_|_['CHEMBL2062163']_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity."
CHEMBL1743031,"nan_|_nan_|_Antibody drug conjugate_|_False_|_INDATUXIMAB RAVTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BT-062' 'Indatuximab ravtansine']_|_nan_|_nan_|_{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}_|_[ENSG00000115884]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1952329,"CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1_|_MHXGEROHKGDZGO-UHFFFAOYSA-N_|_Small molecule_|_False_|_SGI-1776_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SGI-1776' 'Sgi-1776']_|_[('PubChem', array(['137276030'], dtype=object)), ('drugbank', array(['DB12494'], dtype=object))]_|_['CHEMBL1952141']_|_{'rows': array(['MONDO_0008315', 'EFO_0000565', 'EFO_0005952'], dtype=object), 'count': 3}_|_[ENSG00000137193,ENSG00000102096,ENSG00000198355]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL2103863,"CN(C)Cc1c(C(=O)NCCOc2ccc(C(=O)NO)cc2)oc2ccccc12_|_MAUCONCHVWBMHK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABEXINOSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Abexinostat' 'CRA 024781' 'CRA 24781' 'CRA-024781' 'PCI 24781'
 'PCI-24781' 'PZP-115891' 'PZP115891' 'S-78454' 'S78454']_|_[('drugbank', array(['DB12565'], dtype=object))]_|_['CHEMBL2105727']_|_{'rows': array(['MONDO_0018906', 'EFO_0005952', 'EFO_0000616', 'EFO_0000691',
       'EFO_0000681', 'EFO_0000183', 'EFO_0000403'], dtype=object), 'count': 7}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2107725,"Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)c4ccc(C(=N)N)cc4)c3Cl)c2n1_|_XUHBBTKJWIBQMY-MHZLTWQESA-N_|_Small molecule_|_False_|_ANATIBANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anatibant' 'Lf16-0687' 'XY-2405' 'XY2405']_|_[('drugbank', array(['DB05038'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168398]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL284838,"O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O_|_ULGNGSQNNMKROG-WOJBJXKFSA-N_|_Small molecule_|_False_|_K-134_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['K-134' 'OPC-33509']_|_[('drugbank', array(['DB12685'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003876'], dtype=object), 'count': 1}_|_[ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3137353,"nan_|_nan_|_Antibody_|_False_|_BIMAGRUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BYM-338' 'BYM338' 'Bimagrumab' 'O81t794r34']_|_nan_|_nan_|_{'rows': array(['EFO_1000653', 'HP_0004326', 'EFO_0009851', 'EFO_0007323',
       'EFO_0000341', 'MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 7}_|_[ENSG00000114739]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL3544958,nan_|_nan_|_Small molecule_|_False_|_CER-002_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Cer-002']_|_nan_|_nan_|_nan_|_[ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545235,"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCN1CC2(CC2)C2(C1)OCCO2_|_OXWUWXCJDBRCCG-UHFFFAOYSA-N_|_Small molecule_|_False_|_SIMOTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Sim-6802' 'Simotinib']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3746388,"Cn1cc(C(=O)O)c2ccc(N3CCC(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)CC3)cc21_|_RPVDFHPBGBMWID-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERN-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2562175' 'LY2562175' 'TERN-101' 'Tern-101']_|_nan_|_nan_|_{'rows': array(['EFO_1001249'], dtype=object), 'count': 1}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989716,"CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.O.O=S(=O)(O)c1ccc2ccccc2c1_|_GBKONKCASNNUQD-VGHSCWAPSA-N_|_Small molecule_|_True_|_PROPOXYPHENE NAPSYLATE_|_1971.0_|_4.0_|_CHEMBL1213351_|_True_|_True_|_['Darvon-n']_|_['D-propoxyphene napsylate hydrate' 'Dextropropoxyphene napsilate'
 'Propoxyphene napsylate' 'Propoxyphene napsylate cii'
 'Propoxyphene napsylate monohydrate']_|_[('DailyMed', array(['propoxyphene%20napsylate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1971 and is indicated for pain. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL404108,"Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1_|_KHPKQFYUPIUARC-UHFFFAOYSA-N_|_Small molecule_|_False_|_LUMIRACOXIB_|_2005.0_|_4.0_|_nan_|_True_|_True_|_['Prexige']_|_['COX-189' 'Lumiracoxib']_|_[('PubChem', array(['144207115', '170465597'], dtype=object)), ('Wikipedia', array(['Lumiracoxib'], dtype=object)), ('drugbank', array(['DB01283'], dtype=object)), ('chEBI', array(['73044'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0005178', 'EFO_0005755', 'EFO_0004616',
       'EFO_1000786'], dtype=object), 'count': 5}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for rheumatic disease and has 4 investigational indications. It was withdrawn in at least one region."
CHEMBL4297700,"nan_|_nan_|_Antibody_|_False_|_BIMEKIZUMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Bimzelx']_|_['Bimekizumab' 'UCB-4940' 'UCB4940' 'Ucb4940']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003898', 'EFO_0000540', 'EFO_1000747', 'EFO_0000676',
       'EFO_0000685', 'EFO_1000710', 'EFO_0003778'], dtype=object), 'count': 7}_|_[ENSG00000112116,ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 4 investigational indications."
CHEMBL434394,"OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1_|_KOHIRBRYDXPAMZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEBIVOLOL_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Hypoloc' 'Nebilet']_|_['Narbivolol' 'Nebivolol' 'R-65824' 'R65,824']_|_[('Wikipedia', array(['Nebivolol'], dtype=object)), ('drugbank', array(['DB04861'], dtype=object)), ('chEBI', array(['64019'], dtype=object))]_|_['CHEMBL1201731']_|_{'rows': array(['MONDO_0100096', 'EFO_0000537', 'EFO_0003882', 'MONDO_0001134',
       'EFO_0000537', 'MONDO_0007947', 'EFO_0000712', 'EFO_0000712',
       'EFO_0000768', 'EFO_0000319'], dtype=object), 'count': 10}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications."
CHEMBL4650326,"C(=C/c1cccs1)\c1cc[nH]n1_|_FOHWAQGURRYJFK-ONEGZZNKSA-N_|_Small molecule_|_False_|_TEREVALEFIM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ANG-3777' 'Ang-3777' 'BB3' 'Refanalin' 'SNV-003' 'Terevalefim']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEREVALEFIM/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0001919', 'MONDO_0002492'], dtype=object), 'count': 2}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL5315115,"nan_|_nan_|_Small molecule_|_False_|_LASOFOXIFENE TARTRATE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Fablyn']_|_['CB-336156EB' 'CP-336,156-CB' 'CP-336156' 'CP-336156-CB' 'Fablyn'
 'Lasofoxifene d-tartrate' 'Lasofoxifene tartrate' 'Oporia']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fablyn'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003854'], dtype=object), 'count': 1}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for postmenopausal osteoporosis."
CHEMBL539770,"CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C.Cl_|_RNGHAJVBYQPLAZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERODILINE HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL363295_|_True_|_True_|_['Micturin 12.5' 'Micturin 25']_|_['Terodiline hydrochloride']_|_[('PubChem', array(['144206962'], dtype=object))]_|_nan_|_nan_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984,ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in at least one region."
CHEMBL57242,"CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1_|_KGSXMPPBFPAXLY-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZILSARTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Azilsartan' 'TAK-536']_|_[('chEBI', array(['68850'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'MONDO_0005148', 'EFO_0000694', 'EFO_0000400',
       'MONDO_0001134', 'EFO_0000537'], dtype=object), 'count': 6}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL589586,"COC(=O)/C=C/C(=O)O_|_NKHAVTQWNUWKEO-NSCUHMNNSA-N_|_Small molecule_|_False_|_MONOMETHYL FUMARATE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Bafiertam']_|_['Fumaric acid monomethyl ester' 'Methyl Fumarate' 'Monomethyl fumarate'
 'NSC-523835']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MONOMETHYL%20FUMARATE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14219'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 2}_|_[ENSG00000079999]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for multiple sclerosis and has 1 investigational indication."
CHEMBL7413,"C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O_|_NZXKDOXHBHYTKP-UHFFFAOYSA-N_|_Small molecule_|_True_|_METHOHEXITAL_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Methohexital' 'Methohexital civ' 'Methohexitone']_|_[('Wikipedia', array(['Methohexital'], dtype=object)), ('drugbank', array(['DB00474'], dtype=object)), ('chEBI', array(['102216'], dtype=object))]_|_['CHEMBL30219']_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA."
CHEMBL750,"NS(=O)(=O)Cc1noc2ccccc12_|_UBQNRHZMVUUOMG-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZONISAMIDE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Zonegran' 'Zonisade' 'Zonisamide']_|_['AD-810' 'CI-912' 'Excegran' 'N03AX15' 'PD-110843' 'Zonisade'
 'Zonisamide']_|_[('DailyMed', array(['zonisamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zonegran'],
      dtype=object)), ('PubChem', array(['144205122', '49666067', '90341782'], dtype=object)), ('Wikipedia', array(['Zonisamide'], dtype=object)), ('drugbank', array(['DB00909'], dtype=object)), ('chEBI', array(['10127'], dtype=object))]_|_['CHEMBL1514931' 'CHEMBL1596271']_|_{'rows': array(['EFO_0004238', 'HP_0001250', 'EFO_0003768', 'EFO_0004319',
       'MONDO_0002046', 'EFO_0001073', 'MONDO_0005090', 'EFO_0003108',
       'EFO_0000474', 'EFO_0004566', 'HP_0007359', 'MONDO_0005180',
       'MONDO_0007079', 'EFO_0005203', 'EFO_0004263', 'EFO_1001254',
       'MONDO_0005277', 'EFO_0005411', 'EFO_0002610', 'EFO_1000877'],
      dtype=object), 'count': 20}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 16 investigational indications."
CHEMBL917,"O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F_|_ODKNJVUHOIMIIZ-RRKCRQDMSA-N_|_Small molecule_|_True_|_FLOXURIDINE_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['F.u.d.r.' 'Floxuridine' 'Fudr']_|_['5-Fluoro-2-deoxyuridine' '5-fudr' 'FUDR' 'Floxuridine'
 'Fluoruridine deoxyribose' 'NSC-27640']_|_[('DailyMed', array(['floxuridine'], dtype=object)), ('PubChem', array(['124886843', '144204443', '170465247', '29215018', '29215019',
       '50104188', '855946', '93576919'], dtype=object)), ('Wikipedia', array(['Floxuridine'], dtype=object)), ('drugbank', array(['DB00322'], dtype=object)), ('chEBI', array(['60761'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005221', 'EFO_0000365', 'MONDO_0001056', 'EFO_1001951',
       'EFO_0000503', 'MONDO_0021063', 'EFO_0000182', 'EFO_0004142',
       'MONDO_0002158', 'MONDO_0007576', 'MONDO_0002691', 'MONDO_0008170',
       'MONDO_0004992', 'MONDO_0002087', 'EFO_1001961', 'EFO_0004243',
       'EFO_1000657', 'EFO_0000616', 'MONDO_0011719'], dtype=object), 'count': 19}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for cancer and neoplasm and has 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL10188,"CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1_|_BIAVGWDGIJKWRM-FQEVSTJZSA-N_|_Small molecule_|_False_|_TALNETANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SB-2234' 'SB-223412' 'Sb-223412' 'Talnetant']_|_nan_|_['CHEMBL2146089']_|_{'rows': array(['EFO_0000555', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000169836]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1051,"CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O_|_GGXICVAJURFBLW-CEYXHVGTSA-N_|_Small molecule_|_False_|_LATANOPROST_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Latanoprost' 'Monopost' 'Xalatan' 'Xelpros']_|_['Iyuzeh' 'Latanoprost' 'Latanoprost (isopropyl ester)' 'PHXA-41' 'PHXA41'
 'T-2345' 'T2345' 'XA-41' 'XA41']_|_[('DailyMed', array(['latanoprost'], dtype=object)), ('PubChem', array(['26719861'], dtype=object)), ('Wikipedia', array(['Latanoprost'], dtype=object)), ('drugbank', array(['DB00654'], dtype=object)), ('chEBI', array(['6384'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005041', 'EFO_0004190', 'EFO_1001069', 'EFO_0004208',
       'EFO_0006862', 'EFO_0000537'], dtype=object), 'count': 6}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 2 investigational indications."
CHEMBL1088750,"CC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(C(=O)NCCN(C)C)cc21_|_IFGWYHGYNVGVRB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ARRY-797_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ARRY-371797' 'ARRY-797' 'Arry-797']_|_nan_|_nan_|_{'rows': array(['EFO_0000407', 'EFO_0003898', 'EFO_0010072', 'EFO_0000685',
       'EFO_0004616'], dtype=object), 'count': 5}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL1200326,"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl_|_AIKVCUNQWYTVTO-UHFFFAOYSA-N_|_Small molecule_|_False_|_NICARDIPINE HYDROCHLORIDE_|_1988.0_|_4.0_|_CHEMBL1484_|_False_|_True_|_['Cardene' 'Cardene sr' 'Nicardipine hydrochloride']_|_['Barizin' 'Cardepine' 'Dacarel' 'Lecibra' 'Lecibral' 'Lescodil' 'Loxen'
 'NSC-757855' 'Nerdipina' 'Nicant' 'Nicapress' 'Nicardal'
 'Nicardipine hcl' 'Nicardipine hydrochloride' 'Nicarpin' 'Nicodel'
 'Nimicor' 'Perdipina' 'Perdipine' 'RS-69216' 'RS-69216-XX-07-0'
 'RS-69216XX07-0' 'Ranvil' 'Ridene' 'Rycarden' 'Rydene' 'Vasodin'
 'Vasonase' 'YC-93']_|_[('DailyMed', array(['nicardipine%20hydrochloride'], dtype=object)), ('PubChem', array(['144212149', '26747578', '26747579', '50106640', '50106641',
       '50106642'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000994', 'EFO_0000319', 'EFO_0000537', 'EFO_0005669'],
      dtype=object), 'count': 4}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for hypertension and has 3 investigational indications."
CHEMBL1200383,"CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2.CS(=O)(=O)O_|_CPFJLLXFNPCTDW-BWSPSPBFSA-N_|_Small molecule_|_False_|_BENZTROPINE MESYLATE_|_1954.0_|_4.0_|_CHEMBL1201203_|_False_|_True_|_['Benztropine mesylate' 'Cogentin']_|_['Benzatropine mesilate' 'Benztropine mesilate' 'Benztropine mesylate'
 'Benztropine methanesulfonate' 'NSC-169913']_|_[('DailyMed', array(['benztropine%20mesylate'], dtype=object)), ('PubChem', array(['144203579'], dtype=object)), ('chEBI', array(['3049'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'HP_0003418', 'EFO_0009387'], dtype=object), 'count': 3}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for parkinson disease and has 2 investigational indications."
CHEMBL1201044,"Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1.Cl_|_ZIODNPFQZIHCOE-UHFFFAOYSA-N_|_Small molecule_|_False_|_DAPIPRAZOLE HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL1201216_|_False_|_True_|_['Dapiprazole hydrochloride']_|_['AF 2139' 'AF-2139' 'Dapiprazole hcl' 'Dapiprazole hydrochloride'
 'Dapiprazole monohydrochloride']_|_[('PubChem', array(['144206586', '170466549'], dtype=object))]_|_nan_|_{'rows': array(['HP_0011499', 'EFO_0004190'], dtype=object), 'count': 2}_|_[ENSG00000120907]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for mydriasis and open-angle glaucoma."
CHEMBL1201185,"CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O_|_PUDHBTGHUJUUFI-SCTWWAJVSA-N_|_Protein_|_False_|_LANREOTIDE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Somatuline autogel' 'Somatuline la']_|_['Angiopeptin' 'Lanreotide']_|_[('Wikipedia', array(['Lanreotide'], dtype=object))]_|_['CHEMBL1201184']_|_{'rows': array(['EFO_1001485', 'EFO_0004243', 'EFO_1001901', 'EFO_0000182',
       'EFO_1000852', 'HP_0002014', 'EFO_1001466', 'EFO_1001471',
       'EFO_1001769', 'EFO_1001307', 'EFO_1001095', 'EFO_1000852',
       'EFO_0009431', 'EFO_1000478', 'MONDO_0008315', 'MONDO_0024503',
       'EFO_1001496', 'MONDO_0004565', 'MONDO_0044937', 'HP_0003074',
       'EFO_1001485', 'EFO_0000616', 'EFO_0003769'], dtype=object), 'count': 23}_|_[ENSG00000180616,ENSG00000162009]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for acromegaly and carcinoid syndrome and has 21 investigational indications."
CHEMBL1214827,"CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O_|_IFRGXKKQHBVPCQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ONALESPIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATI-13387X' 'ATI13387X' 'At-13387' 'At13387' 'Onalespib']_|_[('drugbank', array(['DB06306'], dtype=object))]_|_['CHEMBL3301599']_|_{'rows': array(['MONDO_0007254', 'EFO_0003060', 'EFO_0003060', 'EFO_0000616',
       'EFO_0005537', 'MONDO_0008315'], dtype=object), 'count': 6}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1371,"O=c1[nH]c2cc(Cl)ccc2o1_|_TZFWDZFKRBELIQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORZOXAZONE_|_1958.0_|_4.0_|_nan_|_False_|_True_|_['Chlorzoxazone' 'Paraflex' 'Parafon Forte' 'Parafon forte dsc'
 'Parafon-Forte' 'Strifon forte dsc']_|_['Chlorzoxazone' 'NSC-26189']_|_[('DailyMed', array(['chlorzoxazone'], dtype=object)), ('PubChem', array(['11110945', '11110946', '144203656', '170464957', '50106005',
       '8139927', '85230968', '90340987'], dtype=object)), ('Wikipedia', array(['Chlorzoxazone'], dtype=object)), ('drugbank', array(['DB00356'], dtype=object)), ('chEBI', array(['3655'], dtype=object))]_|_nan_|_nan_|_[ENSG00000104783]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958."
CHEMBL1706,"Cl.c1ccc2c(CC3=NCCN3)cccc2c1_|_DJDFFEBSKJCGHC-UHFFFAOYSA-N_|_Small molecule_|_False_|_NAPHAZOLINE HYDROCHLORIDE_|_1971.0_|_4.0_|_CHEMBL761_|_False_|_True_|_['Albalon' 'Antistin-privine' 'Gppe nsl soln' 'Nafazair' 'Naphaz hcl'
 'Naphazoline hydrochloride' 'Naphcon forte' 'Opcon' 'Vasocon']_|_['NSC-35711' 'Naphazoline HCl' 'Naphazoline hcl'
 'Naphazoline hydrochloride' 'Naphazoline nitrate']_|_[('DailyMed', array(['naphazoline%20hydrochloride'], dtype=object)), ('PubChem', array(['56422379', '855777'], dtype=object)), ('chEBI', array(['7470'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000678', 'MP_0001845', 'HP_0001742', 'EFO_0007328',
       'EFO_0003956', 'EFO_0007214', 'EFO_0007486'], dtype=object), 'count': 7}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 4 approved and 3 investigational indications."
CHEMBL2037511,"CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C_|_UWHCWRQFNKUYCG-QUZACWSFSA-N_|_Small molecule_|_False_|_EPELSIBAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Epelsiban' 'GSK-557296' 'GSK557296' 'GSK557296B' 'Gsk557296']_|_[('drugbank', array(['DB11934'], dtype=object))]_|_['CHEMBL2105736']_|_{'rows': array(['EFO_1001757', 'EFO_0803321'], dtype=object), 'count': 2}_|_[ENSG00000180914]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108147,"nan_|_nan_|_Enzyme_|_False_|_STREPTOKINASE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Kabikinase']_|_['Streptokinase' 'Streptokinase c']_|_nan_|_nan_|_{'rows': array(['EFO_1000652', 'EFO_1001375', 'HP_0004419', 'EFO_0000612',
       'HP_0002140', 'EFO_0008583', 'HP_0004936'], dtype=object), 'count': 7}_|_[ENSG00000122194]_|_Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for recurrent thrombophlebitis and has 6 investigational indications."
CHEMBL2109321,"nan_|_nan_|_Antibody_|_False_|_CAROTUXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Carotuximab' 'DE-122' 'TRC-105' 'Trc105' 'c-SN6j']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000349', 'MONDO_0004992', 'EFO_1001968',
       'EFO_0000640', 'EFO_0002499', 'MONDO_0003268', 'EFO_0003968',
       'EFO_1001111', 'MONDO_0008903', 'EFO_0003060', 'EFO_1001465',
       'MONDO_0008315', 'EFO_0009708', 'EFO_0000681', 'EFO_0000519',
       'EFO_0002893', 'EFO_0001365', 'EFO_0000616', 'EFO_0002501',
       'EFO_0000182'], dtype=object), 'count': 21}_|_[ENSG00000106991]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications."
CHEMBL2109643,"nan_|_nan_|_Antibody_|_False_|_F19 131I_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BIBH-1' 'F19' 'F19 131i']_|_nan_|_nan_|_{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}_|_[ENSG00000078098]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2110580,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1_|_FIGNGSHKNAHTSH-JJMFXPFOSA-N_|_Small molecule_|_False_|_BERUBICIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Berubicin']_|_nan_|_['CHEMBL2103796']_|_{'rows': array(['EFO_0000519', 'MONDO_0100342', 'EFO_0000519', 'EFO_0005543',
       'EFO_0000313'], dtype=object), 'count': 5}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL218490,"CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21_|_IAVUPMFITXYVAF-XPUUQOCRSA-N_|_Small molecule_|_False_|_DORZOLAMIDE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Dorzant' 'Trusopt']_|_['Dorzolamide' 'Dorzolamide, trans-(-)-' 'MK-507' 'Trusopt']_|_[('Wikipedia', array(['Dorzolamide'], dtype=object)), ('drugbank', array(['DB00869'], dtype=object)), ('chEBI', array(['4702'], dtype=object))]_|_['CHEMBL1201162']_|_{'rows': array(['EFO_0004190', 'EFO_1001069', 'MONDO_0005041', 'MONDO_0005041',
       'EFO_0004190', 'EFO_0004683', 'EFO_1001069'], dtype=object), 'count': 7}_|_[ENSG00000104267]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 3 investigational indications."
CHEMBL259209,"CCN(CC)C(=O)C1(c2ccccc2)CC1CN_|_GJJFMKBJSRMPLA-UHFFFAOYSA-N_|_Small molecule_|_True_|_MILNACIPRAN_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Impulsor' 'Midalcipran' 'Milnacipran']_|_[('drugbank', array(['DB04896'], dtype=object))]_|_['CHEMBL4297064' 'CHEMBL3527085']_|_{'rows': array(['EFO_0005762', 'HP_0003419', 'EFO_0005687', 'MONDO_0002050',
       'EFO_0000555', 'HP_0003418', 'EFO_0003100', 'EFO_0005687',
       'MONDO_0002009'], dtype=object), 'count': 9}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL301742,"NC[C@H](CC(=O)O)c1ccc(Cl)cc1_|_KPYSYYIEGFHWSV-QMMMGPOBSA-N_|_Small molecule_|_False_|_ARBACLOFEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(r)-baclofen' 'Arbaclofen' 'Baclofen (r)-form' 'Baclofen, (r)-'
 'Baclofen, r(-)-' 'Baclofen, r-' 'D-baclofen' 'R-(-)-baclofen' 'STX-209'
 'STX209']_|_[('PubChem', array(['11113710'], dtype=object)), ('drugbank', array(['DB08891'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003756', 'MONDO_0010383', 'HP_0001257'], dtype=object), 'count': 3}_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3545168,"nan_|_nan_|_Small molecule_|_False_|_IMD-1041_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Imd-1041']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000104365]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545374,"nan_|_nan_|_Antibody_|_False_|_TREVOGRUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Human igg4 anti-myostatin mab' 'REGN-1033' 'REGN1033' 'SAR-391786'
 'SAR391786' 'Trevogrumab']_|_nan_|_nan_|_{'rows': array(['EFO_1000653', 'EFO_0007323'], dtype=object), 'count': 2}_|_[ENSG00000138379]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297884,"nan_|_nan_|_Antibody_|_False_|_PEPINEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-sema4d monoclonal antibody vx15/2503' 'Pepinemab' 'VX-15'
 'VX-152503' 'VX15' 'VX15/2503' 'Vx15/2503']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEPINEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0000616', 'EFO_0000181', 'EFO_0003060',
       'EFO_0000389', 'MONDO_0007254', 'EFO_0000637', 'MONDO_0007739',
       'MONDO_0005301'], dtype=object), 'count': 9}_|_[ENSG00000187764]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL450,"CCC1(CC)C(=O)NC(=O)N(C)C1=O_|_FWJKNZONDWOGMI-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHARBITAL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Gemonil']_|_['Endiemal' 'Metharbital' 'Metharbital ciii' 'Metharbitone' 'NSC-27156']_|_[('PubChem', array(['144206305'], dtype=object)), ('Wikipedia', array(['Metharbital'], dtype=object)), ('drugbank', array(['DB00463'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy."
CHEMBL4585668,"CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F_|_LOMMPXLFBTZENJ-ZACQAIPSSA-N_|_Small molecule_|_True_|_BELZUTIFAN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Welireg']_|_['Belzutifan' 'MK-6482' 'MK6482' 'Mk-6482' 'PT-2977' 'PT2977' 'Pt 2977'
 'Pt2977']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELZUTIFAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000045', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000681',
       'EFO_0003884', 'EFO_0001421', 'EFO_0000349', 'MONDO_0016748',
       'MONDO_0008667'], dtype=object), 'count': 9}_|_[ENSG00000116016]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL464,"CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C_|_HQMNCQVAMBCHCO-DJRRULDNSA-N_|_Small molecule_|_False_|_ETRETINATE_|_1986.0_|_4.0_|_nan_|_True_|_True_|_['Tegison' 'Tigason']_|_['Acitretin related compound b' 'Ethyl etrinoate' 'Etretinate'
 'NSC-297936' 'RO 10-9359' 'RO-10-9359' 'RO-109359']_|_[('PubChem', array(['144206054', '170465372', '50112753'], dtype=object)), ('Wikipedia', array(['Etretinate'], dtype=object)), ('chEBI', array(['4913'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}_|_[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for psoriasis. It was withdrawn in at least one region."
CHEMBL4650437,"nan_|_nan_|_Antibody_|_False_|_EBDAROKIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AK-101' 'AK101' 'Ak101' 'Ebdarokimab']_|_nan_|_nan_|_{'rows': array(['EFO_1001494', 'EFO_0000676'], dtype=object), 'count': 2}_|_[ENSG00000113302,ENSG00000110944,ENSG00000168811]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL582857,"COc1ccc(S(=O)(=O)N2C(=O)[C@@](c3ccccc3OC)(N3C[C@H](O)C[C@H]3C(=O)N(C)C)c3cc(Cl)ccc32)c(OC)c1_|_NJXZWIIMWNEOGJ-WEWKHQNJSA-N_|_Small molecule_|_False_|_NELIVAPTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nelivaptan' 'SR-149415' 'SSR-149,415' 'SSR-149415' 'SSR149415'
 'Ssr149415']_|_[('PubChem', array(['144210560'], dtype=object)), ('Wikipedia', array(['Nelivaptan'], dtype=object)), ('drugbank', array(['DB12643'], dtype=object))]_|_['CHEMBL1098000']_|_{'rows': array(['MONDO_0002050', 'EFO_0005230'], dtype=object), 'count': 2}_|_[ENSG00000198049]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL981,"CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O_|_MQOBSOSZFYZQOK-UHFFFAOYSA-N_|_Small molecule_|_False_|_FENOFIBRIC ACID_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Fenocor-67' 'Fenogal' 'Fibricor' 'Lipanthyl' 'Lipofen' 'Lofibra'
 'Supralip' 'Trilipix']_|_['Fenofibrate free acid' 'Fenofibrate related compound b'
 'Fenofibric acid' 'LF-153' 'NSC-281318' 'Procetofenic acid']_|_[('DailyMed', array(['fenofibric%20acid'], dtype=object)), ('drugbank', array(['DB13873'], dtype=object)), ('chEBI', array(['83469'], dtype=object))]_|_['CHEMBL1201745']_|_{'rows': array(['EFO_0000319', 'EFO_0004211', 'MONDO_0001751', 'HP_0003124',
       'EFO_0001645', 'MONDO_0007079', 'HP_0003124', 'Orphanet_309005',
       'EFO_0002939', 'Orphanet_79211', 'MONDO_0005148'], dtype=object), 'count': 11}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 8 investigational indications."
CHEMBL1200426,"CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1.Cl.O_|_RAOHHYUBMJLHNC-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHIXENE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201342_|_False_|_True_|_['Metixen' 'Tremaril' 'Tremarit' 'Tremonil' 'Trest']_|_['Anhydrous metixene hydrochloride' 'Methixene hcl'
 'Methixene hydrochloride' 'Methixene hydrochloride anhydrous'
 'Metixene hydrochloride' 'Metixene hydrochloride anhydrous' 'NSC-78194'
 'SJ 1977' 'SJ-1977']_|_[('PubChem', array(['56463218'], dtype=object)), ('chEBI', array(['51025'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200759,"Cl.O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1_|_TVWRQCIPWUCNMI-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANAGRELIDE HYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL760_|_False_|_True_|_['Agrelin' 'Agrylin' 'Anagrelide hydrochloride' 'Anagrelide mylan'
 'Xagrid']_|_['Anagrelide hcl' 'Anagrelide hydrochloride'
 'Anagrelide hydrochloride hydrate' 'Anagrelide hydrochloride monohydrate'
 'BL-4162A' 'BMY-26538-01' 'NSC-724577' 'NSC-759170' 'Thromboreductin']_|_[('DailyMed', array(['anagrelide%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/anagrelide-mylan'],
      dtype=object)), ('PubChem', array(['49681599'], dtype=object)), ('chEBI', array(['55345'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0000831', 'EFO_0000479', 'EFO_0004251', 'HP_0004419'],
      dtype=object), 'count': 4}_|_[ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved indications."
CHEMBL1200895,"NNCCc1ccccc1.O=S(=O)(O)O_|_RXBKMJIPNDOHFR-UHFFFAOYSA-N_|_Small molecule_|_True_|_PHENELZINE SULFATE_|_1961.0_|_4.0_|_CHEMBL1089_|_False_|_True_|_['Nardil' 'Phenelzine sulfate']_|_['NSC-170957' 'Phenelzine acid sulfate' 'Phenelzine sulfate'
 'Phenelzine sulphate']_|_[('DailyMed', array(['phenelzine%20sulfate'], dtype=object)), ('PubChem', array(['11533068', '144203787', '144207332', '170465229', '26747636',
       '26747637', '49681616', '50106853'], dtype=object)), ('chEBI', array(['8061'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000673', 'MONDO_0007254'], dtype=object), 'count': 2}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200984,"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=C(O)/C=C\C(=O)O_|_TZNOWAJJWCGILX-BTJKTKAUSA-N_|_Small molecule_|_False_|_AMLODIPINE MALEATE_|_2003.0_|_4.0_|_CHEMBL1491_|_False_|_True_|_['Amvaz']_|_['Amlodipine maleate' 'UK-48,340-11' 'UK-48340-11']_|_nan_|_nan_|_nan_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003."
CHEMBL1206245,"COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(OP(=O)(O)O)c2)c(OC)c1_|_LXENKEWVEVKKGV-BQYQJAHWSA-N_|_Small molecule_|_False_|_BRICICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Briciclib' 'ON 014185' 'ON-014185' 'ON014185' 'On-013105']_|_[('drugbank', array(['DB12004'], dtype=object))]_|_['CHEMBL3137303' 'CHEMBL1627071']_|_{'rows': array(['EFO_0000220', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000110092]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1316,"CC(C(=O)O)c1ccc2c(c1)[nH]c1ccc(Cl)cc12_|_PUXBGTOOZJQSKH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARPROFEN_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Rimadyl']_|_['Carprofen' 'Carprofen for veterinary use' 'NSC-297935' 'RO 20-5720/000'
 'Ro-205720000']_|_[('PubChem', array(['144204916', '170464799', '26748565', '50085988'], dtype=object)), ('Wikipedia', array(['Carprofen'], dtype=object)), ('drugbank', array(['DB00821'], dtype=object)), ('chEBI', array(['364453'], dtype=object))]_|_nan_|_nan_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987."
CHEMBL1513,"CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1_|_YOSHYTLCDANDAN-UHFFFAOYSA-N_|_Small molecule_|_True_|_IRBESARTAN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Aprovel' 'Avapro' 'Ifirmasta' 'Irbesartan' 'Karvea' 'Sabervel']_|_['BMS-186295' 'Irbesartan' 'Irbesartan bms' 'Irbesartan teva'
 'Irbesartan zentiva' 'NSC-758696' 'SR 47436' 'SR-47436' 'Sarbevel']_|_[('DailyMed', array(['irbesartan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/karvea'],
      dtype=object)), ('PubChem', array(['144204986', '170464670', '26719813', '26748950'], dtype=object)), ('Wikipedia', array(['Irbesartan'], dtype=object)), ('drugbank', array(['DB01029'], dtype=object)), ('chEBI', array(['5959'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007947', 'EFO_0003884', 'EFO_0004220', 'EFO_0004194',
       'EFO_0000373', 'MONDO_0100096', 'MONDO_0005148', 'EFO_0000694',
       'EFO_0000275', 'EFO_0000401', 'HP_0001919', 'EFO_0000319',
       'EFO_0003884', 'EFO_0004236', 'EFO_1001375', 'MONDO_0017314',
       'EFO_0000537', 'HP_0100806', 'EFO_0007243', 'HP_0003124',
       'MONDO_0001134'], dtype=object), 'count': 21}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1536,"C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]12_|_MECHNRXZTMCUDQ-RKHKHRCZSA-N_|_Small molecule_|_False_|_ERGOCALCIFEROL_|_1941.0_|_4.0_|_nan_|_False_|_True_|_['Calciferol' 'Calciferol in arach oil' 'Caltrate' 'D-forte' 'Deltalin'
 'Drisdol' 'Eciferol d2' 'Ergo-d2' 'Ergocalciferol' 'Ergoral d2' 'Lanes'
 'Oleovitamin D' 'Osto-d2' 'Sterogyl' 'Sterogyl 15h' 'Sterogyl-15'
 'Uvesterol d' 'Vitamin D 2' 'Vitamin d']_|_['Calciferol' 'Ergocalciferol' 'Ergocalciferolum' 'Ergorone' 'NSC-62792'
 'Oleovitamin d, synthetic' 'Ostelin' 'Viosterol' 'Viosterol in oil'
 'Vitamin d (ergocalciferol)' 'Vitamin d2']_|_[('DailyMed', array(['ergocalciferol'], dtype=object)), ('PubChem', array(['144205957', '144209546', '144213069', '57264355'], dtype=object)), ('Wikipedia', array(['Ergocalciferol'], dtype=object)), ('drugbank', array(['DB00153'], dtype=object)), ('chEBI', array(['28934'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007319', 'EFO_0000574', 'EFO_0003854', 'HP_0002901',
       'EFO_0007176', 'EFO_0004278', 'EFO_0008519', 'EFO_0000676',
       'EFO_0004593', 'EFO_0004288', 'EFO_0003917', 'MONDO_0002171',
       'EFO_0001378', 'EFO_0003834', 'EFO_0003882', 'HP_0002148',
       'MONDO_0005148', 'MONDO_0100096', 'Orphanet_309005', 'EFO_0004261',
       'EFO_0003762', 'HP_0000938', 'EFO_0000389', 'GO_0042697',
       'EFO_0009706', 'EFO_1001375', 'MONDO_0011962', 'MONDO_0024300',
       'HP_0003549', 'EFO_0004270', 'EFO_0009451', 'MONDO_0019019',
       'EFO_0009314', 'EFO_0003869', 'EFO_0003095', 'MONDO_0008315',
       'MONDO_0008903', 'EFO_0003843', 'EFO_0000673', 'MONDO_0007254',
       'EFO_0003767', 'EFO_0003144', 'EFO_0008572', 'EFO_0004247',
       'EFO_0005952', 'MONDO_0021063', 'MONDO_0004975', 'MONDO_0005277',
       'HP_0005521', 'EFO_1000049', 'EFO_0000764', 'EFO_1000783',
       'EFO_0004616', 'MONDO_0018076', 'EFO_0009516', 'EFO_1001951',
       'EFO_0005762', 'MONDO_0002974', 'EFO_0002614', 'EFO_0000660',
       'EFO_0003964', 'MONDO_0005147', 'EFO_1000653', 'EFO_1001494',
       'EFO_0003931', 'MONDO_0004992', 'EFO_0003047', 'EFO_1001792',
       'EFO_0007405', 'EFO_0003884', 'EFO_1001919', 'Orphanet_89936',
       'EFO_0001073', 'EFO_0000729', 'MONDO_0005301', 'MONDO_0004979',
       'MONDO_0011382', 'EFO_0000565', 'EFO_0004220', 'EFO_0002950',
       'EFO_0000384', 'EFO_0004192', 'EFO_0000400'], dtype=object), 'count': 83}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1941 and has 3 approved and 80 investigational indications."
CHEMBL2103758,"CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O_|_TZIRZGBAFTZREM-MKAGXXMWSA-N_|_Protein_|_True_|_PRAMLINTIDE_|_2005.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AC-0137' 'AC-137' 'AC0137' 'AC137' 'Pramlintide' 'Tripro-amylin']_|_[('drugbank', array(['DB01278'], dtype=object))]_|_['CHEMBL3833353']_|_{'rows': array(['EFO_0001073', 'EFO_0001073', 'MONDO_0005148', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0005147', 'MONDO_0005147'], dtype=object), 'count': 7}_|_[ENSG00000004948,ENSG00000132329,ENSG00000131477,ENSG00000122679]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for diabetes mellitus and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2104964,"Cc1ccc(S(=O)(=O)O)cc1.Clc1ccc(OC[C@H]2CCN2)cn1_|_JCPWIGCGJUGLJQ-OGFXRTJISA-N_|_Small molecule_|_False_|_TEBANICLINE TOSYLATE_|_nan_|_2.0_|_CHEMBL430497_|_False_|_False_|_[]_|_['A-165594' 'A-166594.47' 'A-16659447' 'ABT-165594' 'ABT-594'
 'Ebanicline tosylate' 'Tebanicline tosilate' 'Tebanicline tosylate']_|_nan_|_nan_|_nan_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2107779,"C/C(=N\NC(=N)N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(/C(C)=N/NC(=N)N)cc(/C(C)=N/NC(=N)N)c2)cc(/C(C)=N/NC(=N)N)c1_|_PWDYHMBTPGXCSN-VCBMUGGBSA-N_|_Small molecule_|_False_|_SEMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AXD-455' 'CNI-1493' 'CPSI-2364 FREE BASE' 'Cni-1493' 'Semapimod'
 'Semapimod hydrochloride' 'Semapimod tetrahydrochloride']_|_[('drugbank', array(['DB12094'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000384'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107831,"CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC_|_NOZIJMHMKORZBA-KJCUYJGMSA-N_|_Small molecule_|_False_|_LUSUTROMBOPAG_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Mulpleo (previously lusutrombopag shionogi)' 'Mulpleta' 'S-888711']_|_['Lusutrombopag' 'RSC888711' 'S-888711']_|_[('DailyMed', array(['lusutrombopag'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo'],
      dtype=object)), ('drugbank', array(['DB13125'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001873', 'EFO_0007160', 'MP_0001914'], dtype=object), 'count': 3}_|_[ENSG00000117400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for thrombocytopenia and hemorrhage and has 1 investigational indication."
CHEMBL2108252,"nan_|_nan_|_Antibody_|_False_|_APOLIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Remitogen smart1d10']_|_['Apolizumab' 'HU-1D10' 'HU1D10' 'Remitogen']_|_nan_|_nan_|_{'rows': array(['EFO_0000403', 'EFO_0000095', 'EFO_0000574', 'MONDO_0018906',
       'EFO_1001469'], dtype=object), 'count': 5}_|_[ENSG00000231679,ENSG00000198502,ENSG00000196126,ENSG00000227357]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2109410,"nan_|_nan_|_Antibody_|_False_|_TB-402_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TB-402' 'Tb-402']_|_nan_|_nan_|_{'rows': array(['EFO_0004286'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2181927,"CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2_|_BTBHLEZXCOBLCY-QGZVFWFLSA-N_|_Small molecule_|_False_|_FINERENONE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Kerendia']_|_['BAY 94-8862' 'BAY-94-8862' 'Bay94-8862' 'Finerenone']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'EFO_0003884', 'MONDO_0005148', 'EFO_0000319',
       'EFO_0003144'], dtype=object), 'count': 5}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications."
CHEMBL313971,"COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O_|_YKPUWZUDDOIDPM-VURMDHGXSA-N_|_Small molecule_|_False_|_ZUCAPSAICIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Civamide' 'Zucapsaicin']_|_[('PubChem', array(['11112338', '11113255', '11113512', '11113513', '124882262',
       '124882263', '26719735'], dtype=object)), ('drugbank', array(['DB09120'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'HP_0002829', 'EFO_0004616', 'HP_0003326',
       'EFO_0003843', 'MONDO_0041052'], dtype=object), 'count': 6}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3545414,"CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1_|_FYJROXRIVQPKRY-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIVOCERANIB MESYLATE_|_nan_|_3.0_|_CHEMBL3186534_|_False_|_False_|_['Aitan']_|_['Apatinib (registered name in China)' 'Apatinib mesylate'
 'Rivoceranib mesylate' 'YN-968D1' 'Yn-968d1']_|_nan_|_nan_|_{'rows': array(['EFO_1000359', 'EFO_0004252', 'EFO_0000231', 'MONDO_0007254',
       'EFO_0001061', 'EFO_0000756', 'EFO_0000702', 'MONDO_0008170',
       'EFO_0000178', 'EFO_0006859', 'EFO_1001968', 'EFO_0005221',
       'MONDO_0003060', 'MONDO_0002120', 'EFO_0004142', 'MONDO_0001056',
       'EFO_0003868', 'EFO_1001951', 'MONDO_0004992', 'EFO_0000182',
       'EFO_0000313', 'EFO_0000571', 'MONDO_0008903', 'EFO_1001961',
       'MONDO_0021063', 'EFO_1001956', 'EFO_0002939', 'EFO_0001071',
       'EFO_0005537', 'MONDO_0100342', 'EFO_0000199', 'MONDO_0002108',
       'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869',
       'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637',
       'EFO_0002916', 'EFO_0005543', 'EFO_0003897', 'EFO_0000181',
       'EFO_0000616', 'EFO_0005922', 'EFO_0000691', 'EFO_0000621',
       'EFO_0003893', 'MONDO_0018944', 'EFO_0000707', 'EFO_0000211',
       'MONDO_0007576', 'EFO_0002618', 'EFO_1002017', 'EFO_0009708',
       'EFO_0000365', 'EFO_0000574', 'EFO_0000503', 'EFO_0003860',
       'EFO_0000681', 'MONDO_0008315'], dtype=object), 'count': 62}_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 62 investigational indications."
CHEMBL3707398,"nan_|_nan_|_Small molecule_|_False_|_PAC-14028_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Asivatrep' 'Pac-14028']_|_nan_|_nan_|_{'rows': array(['HP_0000989', 'EFO_0000274', 'EFO_1000764', 'EFO_1000760'],
      dtype=object), 'count': 4}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL375611,"N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21_|_AVDUGNCTZRCAHH-MDASVERJSA-N_|_Small molecule_|_False_|_LY404039_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LY-404039' 'LY-404039, (-)-' 'LY404039' 'Ly 404039' 'Ly-404039'
 'Ly404039' 'Pomaglumetad']_|_nan_|_nan_|_nan_|_[ENSG00000164082,ENSG00000198822]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL38434,"Cc1c(-c2ccc(-c3ccccc3F)cc2)nc2ccc(F)cc2c1C(=O)O_|_PHEZJEYUWHETKO-UHFFFAOYSA-N_|_Small molecule_|_False_|_BREQUINAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Brequinar']_|_[('drugbank', array(['DB03523'], dtype=object))]_|_['CHEMBL300058']_|_{'rows': array(['MONDO_0100096', 'MONDO_0100096', 'EFO_0000222'], dtype=object), 'count': 3}_|_[ENSG00000102967]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3900554,"Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O_|_ZRYMMWAJAFUANM-INIZCTEOSA-N_|_Small molecule_|_False_|_BMS-986142_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bms-986142']_|_[('drugbank', array(['DB15291'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0005178'], dtype=object), 'count': 2}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594442,"Cc1cc(-c2nnc(N)nc2-c2ccc(F)cc2)cc(Cl)n1_|_NCWQLHHDGDXIJN-UHFFFAOYSA-N_|_Small molecule_|_False_|_IMARADENANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-4635' 'AZD4635' 'Azd 4635' 'Azd4635' 'HTL-1071' 'HTL1071'
 'Imaradenant']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL507282,"Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1_|_FPNPSEMJLALQSA-MIYUEGBISA-N_|_Small molecule_|_False_|_DENUFOSOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Denufosol']_|_[('drugbank', array(['DB04983'], dtype=object))]_|_['CHEMBL1767407']_|_{'rows': array(['EFO_0005773', 'MONDO_0009061', 'MONDO_0003005', 'EFO_1001417'],
      dtype=object), 'count': 4}_|_[ENSG00000175591]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5095022,"CC(C)S(=O)(=O)N[C@H]1COC[C@H]1Oc1ccc(-c2ccc(C#N)s2)cc1_|_TTYKUKSFWHEBLI-DLBZAZTESA-N_|_Small molecule_|_False_|_PESAMPATOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB-104' 'BIIB104' 'PF-04958242' 'PF-4958242' 'Pesampator'
 'Pf-04958242']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PESAMPATOR/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001176', 'EFO_0000677', 'MONDO_0005090', 'HP_0001268'],
      dtype=object), 'count': 4}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL514201,"C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl_|_ZMELOYOKMZBMRB-DLBZAZTESA-N_|_Small molecule_|_False_|_TALMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SCIO 469' 'SCIO-469' 'Scio-469' 'Talmapimod']_|_[('drugbank', array(['DB05412'], dtype=object)), ('chEBI', array(['90683'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0001378'], dtype=object), 'count': 2}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL818,"N=C(N)NCc1cccc(I)c1_|_PDWUPXJEEYOOTR-UHFFFAOYSA-N_|_Small molecule_|_False_|_IOBENGUANE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Iobenguane' 'Iobenguane (127-i)']_|_[('PubChem', array(['11111341', '90341658'], dtype=object)), ('Wikipedia', array(['Iobenguane'], dtype=object)), ('drugbank', array(['DB06704'], dtype=object))]_|_['CHEMBL1374843' 'CHEMBL1615777' 'CHEMBL3989511' 'CHEMBL4584538'
 'CHEMBL1615779' 'CHEMBL3989523' 'CHEMBL1255738']_|_{'rows': array(['MONDO_0024503', 'EFO_1000453', 'EFO_0000621', 'EFO_0003144',
       'EFO_0000621', 'EFO_0000373', 'EFO_1001901', 'EFO_0000239'],
      dtype=object), 'count': 8}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 5 investigational indications."
CHEMBL832,"O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1_|_MBGGBVCUIVRRBF-UHFFFAOYSA-N_|_Small molecule_|_False_|_SULFINPYRAZONE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Anturan' 'Anturane' 'Sulfinpyrazone']_|_['NSC-75925' 'Sulfinpyrazone' 'Sulphinpyrazone']_|_[('PubChem', array(['11112139', '124881954', '144203882', '170464677', '26747070',
       '46500625', '855982'], dtype=object)), ('Wikipedia', array(['Sulfinpyrazone'], dtype=object)), ('drugbank', array(['DB01138'], dtype=object)), ('chEBI', array(['9342'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004274'], dtype=object), 'count': 1}_|_[ENSG00000197891]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for gout."
CHEMBL957,"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO_|_GJPICJJJRGTNOD-UHFFFAOYSA-N_|_Small molecule_|_True_|_BOSENTAN_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Stayveer' 'Tracleer']_|_['Anhydrous bosentan' 'Bosentan' 'Bosentan anhydrous' 'Bosentan hydrate'
 'Bosentan monohydrate' 'RO 47-0203/029' 'RO-47-0203-029' 'RO-470203029']_|_[('DailyMed', array(['bosentan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/stayveer',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/tracleer'],
      dtype=object)), ('PubChem', array(['144205997', '170465245'], dtype=object)), ('Wikipedia', array(['Bosentan'], dtype=object)), ('drugbank', array(['DB00559'], dtype=object)), ('chEBI', array(['51450'], dtype=object))]_|_['CHEMBL175616']_|_{'rows': array(['EFO_0000768', 'EFO_0000537', 'EFO_0000373', 'EFO_1001103',
       'EFO_0003877', 'HP_0001945', 'EFO_0000616', 'EFO_1000809',
       'EFO_1001346', 'EFO_0001361', 'EFO_0009200', 'EFO_0001422',
       'EFO_0000717', 'MONDO_0004979', 'EFO_0002618', 'MONDO_0004933',
       'EFO_0000400', 'MONDO_0007172', 'MONDO_0005148', 'MONDO_0005149',
       'EFO_0005207', 'EFO_0005207', 'MONDO_0043839', 'EFO_0000341',
       'EFO_0000756', 'MONDO_0005041', 'EFO_0007372'], dtype=object), 'count': 27}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1037,"N=C(N)NCC1COC2(CCCCC2)O1_|_HPBNRIOWIXYZFK-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANADREL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Guanadrel' 'Hylorel']_|_[('Wikipedia', array(['Guanadrel'], dtype=object)), ('drugbank', array(['DB00226'], dtype=object)), ('chEBI', array(['5555'], dtype=object))]_|_['CHEMBL3184143']_|_nan_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200878,"CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C_|_TZIZWYVVGLXXFV-FLRHRWPCSA-N_|_Small molecule_|_False_|_TRIAMCINOLONE HEXACETONIDE_|_1969.0_|_4.0_|_nan_|_False_|_True_|_['Aristospan' 'Lederspan']_|_['CL 34433' 'CL-34433' 'TATBA' 'Triamcinolone hexacetonide']_|_[('PubChem', array(['144206532'], dtype=object)), ('chEBI', array(['9670'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'MONDO_0005178', 'EFO_0000685', 'EFO_0004616',
       'EFO_1000999'], dtype=object), 'count': 5}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and is indicated for osteoarthritis and has 4 investigational indications."
CHEMBL1201139,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C_|_RQZAXGRLVPAYTJ-GQFGMJRRSA-N_|_Small molecule_|_False_|_MEGESTROL ACETATE_|_1971.0_|_4.0_|_nan_|_False_|_True_|_['Megace' 'Megace es' 'Megestrol acetate' 'Ovaban']_|_['5071' 'BDH 1298' 'BDH-1298' 'Chronopil' 'Megesterol acetate' 'Megestrol'
 'Megestrol 17.alpha.-acetate' 'Megestrol acetate' 'NSC-71423' 'SC 10363'
 'SC-10363']_|_[('DailyMed', array(['megestrol%20acetate'], dtype=object)), ('PubChem', array(['144204020', '144212677', '170465406', '26719675', '56422102',
       '856018'], dtype=object)), ('drugbank', array(['DB00351'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0002715', 'MONDO_0002691', 'HP_0031217',
       'EFO_0004230', 'HP_0002039', 'EFO_1001512', 'HP_0004326',
       'EFO_0000765', 'MONDO_0004992', 'EFO_0007312', 'EFO_0006859',
       'MONDO_0011962', 'MONDO_0003778', 'MONDO_0007254', 'EFO_0000616',
       'EFO_0007532', 'MONDO_0024474', 'EFO_0003869', 'HP_0000726',
       'EFO_1000796'], dtype=object), 'count': 21}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 6 approved and 15 investigational indications."
CHEMBL1201173,"CC(=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C_|_GZENKSODFLBBHQ-ILSZZQPISA-N_|_Small molecule_|_False_|_MEDRYSONE_|_1969.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hydroxymesterone' 'Medrysone' 'NSC-63278' 'U-8471']_|_[('PubChem', array(['11533031', '144204077', '170465194', '56423131'], dtype=object)), ('Wikipedia', array(['Medrysone'], dtype=object)), ('drugbank', array(['DB00253'], dtype=object)), ('chEBI', array(['34829'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005752'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969 and is indicated for eye inflammation."
CHEMBL1201250,"CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O_|_JSZILQVIPPROJI-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZQUINAMIDE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benzchinamide' 'Benzquinamide' 'NSC-108159' 'NSC-169193' 'NSC-64375'
 'P-2647' 'Promecon']_|_[('PubChem', array(['170465138'], dtype=object)), ('Wikipedia', array(['Benzquinamide'], dtype=object)), ('drugbank', array(['DB00767'], dtype=object)), ('chEBI', array(['27662'], dtype=object))]_|_['CHEMBL1200707']_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974."
CHEMBL1201733,"Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl_|_MQHIQUBXFFAOMK-UHFFFAOYSA-N_|_Small molecule_|_True_|_PAZOPANIB HYDROCHLORIDE_|_2009.0_|_4.0_|_CHEMBL477772_|_False_|_True_|_['Votrient']_|_['GW-786034B' 'GW786034B' 'Pazopanib (as hydrochloride)' 'Pazopanib hcl'
 'Pazopanib hydrochloride' 'Pazopanib monohydrochloride']_|_[('DailyMed', array(['pazopanib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/votrient'],
      dtype=object)), ('chEBI', array(['71217'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'EFO_0000501',
       'MONDO_0001187', 'MONDO_0015277', 'EFO_1001465', 'MONDO_0008903',
       'EFO_1000613', 'MONDO_0004192', 'EFO_0000349', 'MONDO_0002158',
       'EFO_0003968', 'MONDO_0004986', 'EFO_0000588', 'EFO_0001663',
       'EFO_0000691', 'EFO_0000641', 'MONDO_0008315', 'EFO_0000640',
       'MONDO_0008667', 'MONDO_0007254', 'EFO_1001968', 'EFO_0000616',
       'EFO_0006861', 'EFO_0000335', 'EFO_0000389', 'MONDO_0008170'],
      dtype=object), 'count': 28}_|_[ENSG00000077782,ENSG00000113263,ENSG00000182866,ENSG00000068078,ENSG00000157404,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201833,"nan_|_nan_|_Antibody_|_True_|_GOLIMUMAB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Simponi']_|_['CNTO 148' 'CNTO-148' 'Golimumab']_|_[('DailyMed', array(['golimumab'], dtype=object)), ('DrugCentral', array(['4967'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/simponi'],
      dtype=object)), ('Wikipedia', array(['Golimumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0002609', 'EFO_0000706', 'EFO_0009672',
       'EFO_0000540', 'MONDO_0004979', 'EFO_0000729', 'MONDO_0019338',
       'EFO_0003898', 'MONDO_0005147', 'EFO_0003778', 'MONDO_0005178',
       'EFO_0000685', 'MONDO_0003937'], dtype=object), 'count': 14}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1518,"CCCc1cc(=O)[nH]c(=S)[nH]1_|_KNAHARQHSZJURB-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROPYLTHIOURACIL_|_1947.0_|_4.0_|_nan_|_False_|_True_|_['Propacil' 'Propylthiouracil' 'Prothyran' 'Thyreostat']_|_['NSC-6498' 'NSC-70461' 'Propylthiouracil' 'Thyreostat ii']_|_[('DailyMed', array(['propylthiouracil'], dtype=object)), ('PubChem', array(['11112111', '144204433', '144208939', '144210600', '170464965',
       '17389748', '174006773', '26751509', '855783'], dtype=object)), ('TG-GATEs', array(['29'], dtype=object)), ('Wikipedia', array(['Propylthiouracil'], dtype=object)), ('drugbank', array(['DB00550'], dtype=object)), ('chEBI', array(['8502'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009190', 'EFO_1001466', 'EFO_0009189', 'HP_0002140',
       'HP_0000820'], dtype=object), 'count': 5}_|_[ENSG00000115705,ENSG00000211452]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and is indicated for hyperthyroidism and abnormality of the thyroid gland and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1615438,"C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1_|_ZCGOMHNNNFPNMX-KYTRFIICSA-N_|_Small molecule_|_False_|_LEVOCABASTINE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Livostin direct']_|_['Levocabastine' 'R-50547']_|_[('drugbank', array(['DB01106'], dtype=object))]_|_['CHEMBL1237102']_|_{'rows': array(['EFO_1001417', 'EFO_0003956', 'HP_0001742', 'EFO_0005751',
       'EFO_1001417'], dtype=object), 'count': 5}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for nasal congestion and eye allergy and has 3 investigational indications."
CHEMBL1650595,"NCC(=O)Nc1ccc(-n2nc(C(F)(F)F)cc2-c2ccc3c(ccc4ccccc43)c2)cc1_|_YULUCECVQOCQFQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_AR-12_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AR-12' 'Ar-12' 'OSU-03012' 'Pdk1 inhibitor ar-12']_|_[('PubChem', array(['172131582'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000140992]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1743076,"nan_|_nan_|_Antibody_|_False_|_TADOCIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['C4G1' 'Tadocizumab' 'YM-337' 'YM337']_|_nan_|_nan_|_nan_|_[ENSG00000259207,ENSG00000005961]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL189475,"C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1_|_DDLPYOCJHQSVSZ-SSDOTTSWSA-N_|_Small molecule_|_False_|_LADARIXIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Df2156a' 'Ladarixin']_|_nan_|_['CHEMBL4442431']_|_{'rows': array(['EFO_0003060', 'MONDO_0005147', 'EFO_0007187'], dtype=object), 'count': 3}_|_[ENSG00000163464,ENSG00000180871]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1909283,"CC(NN)c1ccccc1_|_HHRZAEJMHSGZNP-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEBANAZINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Actamol' 'Mebanazine']_|_[('Wikipedia', array(['Mebanazine'], dtype=object)), ('drugbank', array(['DB09248'], dtype=object))]_|_['CHEMBL3186515']_|_nan_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2107801,"COc1cccc(-c2nccc3[nH]c(=O)c(-c4noc(C)n4)cc23)c1_|_JQOFKKWHXGQABB-UHFFFAOYSA-N_|_Small molecule_|_False_|_RESEQUINIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AVE-3933' 'Ac-3933' 'Radequinil' 'Resequinil' 'SX-3933']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108702,"nan_|_nan_|_Oligonucleotide_|_False_|_IMETELSTAT SODIUM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GRN-163L TRIDECASODIUM SALT' 'GRN163L' 'GRN163L TRIDECASODIUM SALT'
 'Imetelstat sodium']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0008903'],
      dtype=object), 'count': 4}_|_[ENSG00000164362]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2109047,"nan_|_nan_|_Protein_|_False_|_INTERFERON ALFA-N3_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.alpha.-interferons' 'Alferon' 'Alferon n' 'Interferon alfa-n3'
 'Interferon alpha-n3' 'Leukocyte interferon']_|_nan_|_nan_|_{'rows': array(['EFO_0000694', 'EFO_0000764'], dtype=object), 'count': 2}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 2 investigational indications."
CHEMBL2109574,"nan_|_nan_|_Antibody drug conjugate_|_False_|_ASG-5ME_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ASG-5ME' 'Asg-5me']_|_nan_|_nan_|_{'rows': array(['EFO_0001663'], dtype=object), 'count': 1}_|_[ENSG00000204385,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545365,"O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1_|_GNNDEPIMDAZHRQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALTIRATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Altiratinib' 'DCC-2701' 'DP-5164']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000120156,ENSG00000198400,ENSG00000148053,ENSG00000140538,ENSG00000128052,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL377300,"Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1_|_WCWUXEGQKLTGDX-LLVKDONJSA-N_|_Small molecule_|_False_|_BRIVANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-540215' 'Brivanib']_|_[('drugbank', array(['DB11958'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000313', 'EFO_1001951', 'EFO_0000616', 'EFO_0009708',
       'EFO_0000365', 'MONDO_0002974', 'EFO_0000182', 'MONDO_0002691',
       'MONDO_0004992', 'MONDO_0008170'], dtype=object), 'count': 10}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL3916243,"C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1_|_VLLFGVHGKLDDLW-SFHVURJKSA-N_|_Small molecule_|_False_|_ATABECESTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atabecestat' 'JNJ-54861911' 'JNJ-54861911-AAA' 'Jnj-54861911'
 'RSC- 385896' 'RSC-385896']_|_[('drugbank', array(['DB15307'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000186318]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297188,"Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1_|_HNFMVVHMKGFCMB-UHFFFAOYSA-N_|_Small molecule_|_False_|_MIRANSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARQ 092' 'ARQ 092 FREE BASE' 'ARQ-092' 'ARQ092' 'Arq-092' 'Miransertib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIRANSERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14982'], dtype=object))]_|_['CHEMBL4298151' 'CHEMBL4523032']_|_{'rows': array(['MONDO_0011962', 'EFO_0000616', 'EFO_0000616', 'MONDO_0008318',
       'EFO_0000574', 'MONDO_0008170'], dtype=object), 'count': 6}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4297661,"Cn1cnc([N+](=O)[O-])c1C[N+](C)(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(Cl)c(Br)c3)ncnc2cn1_|_MUJMYVFVAWFUJL-SNAWJCMRSA-O_|_Small molecule_|_False_|_TARLOXOTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tarloxotinib' 'Tarloxotinib cation' 'Tarloxotinib ion']_|_[('drugbank', array(['DB14944'], dtype=object))]_|_['CHEMBL4297662']_|_{'rows': array(['EFO_0000181', 'EFO_0003060', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297866,"C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1.O.O.O=C(O)/C=C\C(=O)O_|_QITOONQVTOGMOJ-IUJXYRIYSA-N_|_Small molecule_|_False_|_ABIVERTINIB MALEATE_|_nan_|_3.0_|_CHEMBL4297865_|_False_|_False_|_[]_|_['A-610MA' 'A610MA' 'AC-0010MA' 'AC0010MA' 'ACEA-100610MA' 'ACEA100610MA'
 'Abivertinib maleate' 'Abivertinib maleate dihydrate'
 'Ac0010 maleate dihydrate' 'Ac0010ma' 'EX-ACEA-0010MA' 'EX-ACEA0010MA'
 'Sti-5656']_|_nan_|_nan_|_{'rows': array(['EFO_0000096', 'EFO_0003060', 'MONDO_0100096'], dtype=object), 'count': 3}_|_[ENSG00000146648,ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4298213,"nan_|_nan_|_Antibody_|_False_|_VOLAGIDEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 477' 'AMG-477' 'REMD-477' 'Volagidemab']_|_nan_|_nan_|_{'rows': array(['HP_0003074', 'MONDO_0005148', 'MONDO_0005147'], dtype=object), 'count': 3}_|_[ENSG00000215644]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL449,"CCC(C)C1(CC)C(=O)NC(=O)NC1=O_|_ZRIHAIZYIMGOAB-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUTABARBITAL_|_1939.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Butabarbital' 'Butabarbital ciii' 'Butatab' 'Medarsed' 'Nilox'
 'Sec-butobarbitone' 'Secbutabarbital' 'Secbutobarbitone' 'Unicelles']_|_[('Wikipedia', array(['Butabarbital'], dtype=object)), ('drugbank', array(['DB00237'], dtype=object)), ('chEBI', array(['3228'], dtype=object))]_|_['CHEMBL1200982']_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939."
CHEMBL4594471,nan_|_nan_|_Protein_|_False_|_EFEPOETIN ALFA_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Efepoetin alfa']_|_nan_|_nan_|_nan_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of III.
CHEMBL5314387,"C[C@H](N)c1ccc([C@H](O)CNC(C)(C)C)cc1_|_KUHBBYPXWKYKKR-GXFFZTMASA-N_|_Small molecule_|_False_|_MK-1496_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mk-1496']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL728,"CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1_|_WIKYUJGCLQQFNW-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROCHLORPERAZINE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_['Compazine' 'Compro' 'Prochlorperazine' 'Stemetil eff']_|_['Prochlorperazine' 'Prochlorperazine mesilate'
 'Prochlorperazine mesylate']_|_[('DailyMed', array(['prochlorperazine'], dtype=object)), ('PubChem', array(['11111685', '11111686', '50100332', '50104093', '855827',
       '90341442'], dtype=object)), ('Wikipedia', array(['Prochlorperazine'], dtype=object)), ('drugbank', array(['DB00433'], dtype=object)), ('chEBI', array(['8435'], dtype=object))]_|_['CHEMBL1200587' 'CHEMBL1201154' 'CHEMBL1314751']_|_{'rows': array(['EFO_0006788', 'HP_0002018', 'EFO_0001378', 'EFO_0006911',
       'HP_0002017', 'MONDO_0005277', 'MONDO_0005090', 'EFO_0005407',
       'MONDO_0021148', 'HP_0002315', 'EFO_1001482'], dtype=object), 'count': 11}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL782,"CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1_|_JLRGJRBPOGGCBT-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLBUTAMIDE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_['Glyconon' 'Orinase' 'Pramidex' 'Rastinon' 'Tolbutamide']_|_['1-butyl-3-(p-tolylsulfonyl)urea' 'Arkozal' 'Butamide' 'Diabetamid'
 'Ipoglicone' 'NSC-23813' 'NSC-87833' 'Tolbutamide' 'Tolbutamidum'
 'Willbutamide']_|_[('PubChem', array(['11111858', '144203830', '144208810', '144213112', '170465238',
       '17389707', '26751511', '26751513', '50104069', '56436662',
       '855782'], dtype=object)), ('TG-GATEs', array(['114'], dtype=object)), ('Wikipedia', array(['Tolbutamide'], dtype=object)), ('drugbank', array(['DB01124'], dtype=object)), ('chEBI', array(['27999'], dtype=object))]_|_['CHEMBL1200874']_|_{'rows': array(['EFO_0000616', 'EFO_0600064', 'MONDO_0005148', 'EFO_0000574',
       'HP_0012532', 'MONDO_0004992', 'EFO_0000400', 'EFO_0004220'],
      dtype=object), 'count': 8}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 6 investigational indications."
CHEMBL82301,"COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C_|_CNPVJJQCETWNEU-CYFREDJKSA-N_|_Small molecule_|_False_|_VICRIVIROC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-7690' 'SCH-351125' 'SCH-417690 FREE BASE' 'SCH-D' 'Vicriviroc']_|_[('Wikipedia', array(['Vicriviroc'], dtype=object)), ('drugbank', array(['DB06652'], dtype=object))]_|_['CHEMBL2107384']_|_{'rows': array(['EFO_0004142', 'EFO_0000765', 'EFO_0000764', 'EFO_0000764'],
      dtype=object), 'count': 4}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1089636,"CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](OC(=O)CCC(=O)NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@@H](C(=O)O[C@H]4C[C@@]5(O)[C@@H](OC(=O)c6ccccc6)[C@@H]6[C@]7(OC(C)=O)CO[C@@H]7C[C@H](O)[C@@]6(C)C(=O)[C@H](OC(C)=O)C(=C4C)C5(C)C)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4ccc(O)cc4)C(=O)O)[C@@H](C)O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O_|_GBVKRUOMSUTVPW-AHNVSIPUSA-N_|_Protein_|_False_|_ANG1005_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ANG-1005' 'ANG1005' 'Ang1005' 'Paclitaxel trevatide']_|_nan_|_nan_|_{'rows': array(['MONDO_0100342', 'EFO_0000616', 'EFO_0000519', 'EFO_0003833'],
      dtype=object), 'count': 4}_|_[ENSG00000123384,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL1200638,"CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_SRGKFVAASLQVBO-DASCVMRKSA-N_|_Small molecule_|_False_|_DEXBROMPHENIRAMINE MALEATE_|_1963.0_|_4.0_|_CHEMBL1201287_|_False_|_True_|_['Disomer']_|_['Brompheniramine d-form maleate' 'Dexbrompheniramine fumarate'
 'Dexbrompheniramine maleate']_|_[('PubChem', array(['144205553', '170465028', '49681545', '50105972'], dtype=object)), ('chEBI', array(['59273'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003956'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1963 and is indicated for seasonal allergic rhinitis."
CHEMBL1200854,"CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1_|_VIQCGTZFEYDQMR-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLUPHENAZINE DECANOATE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Decazate' 'Fluphenazine decanoate' 'Modecate' 'Modecate conc'
 'Prolixin decanoate']_|_['Dapotum d' 'Fluphenazine decanoate' 'Fluphenazini decanoas' 'Lyogen'
 'Moditen depot' 'NSC-169510' 'QD-10733' 'SQ-10733']_|_[('DailyMed', array(['fluphenazine%20decanoate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972 and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200969,"C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CC[C@@H]12_|_JWJOTENAMICLJG-QWBYCMEYSA-N_|_Small molecule_|_False_|_DUTASTERIDE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Avodart' 'Dutasteride']_|_['Avolve' 'Duastride' 'Dutasteride' 'GG-745' 'GI 198745' 'GI-198745'
 'NSC-740477' 'NSC-759880']_|_[('DailyMed', array(['dutasteride'], dtype=object)), ('PubChem', array(['144205752'], dtype=object)), ('Wikipedia', array(['Dutasteride'], dtype=object)), ('drugbank', array(['DB01126'], dtype=object)), ('chEBI', array(['521033'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001663', 'MONDO_0002146', 'MONDO_0004976', 'EFO_0000284',
       'EFO_0003830', 'MONDO_0010735', 'MONDO_0004907', 'EFO_0004191',
       'MONDO_0100096', 'EFO_0000673', 'MONDO_0008315'], dtype=object), 'count': 11}_|_[ENSG00000145545,ENSG00000277893,ENSG00000128039]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 8 investigational indications."
CHEMBL1201101,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1_|_HPFVBGJFAYZEBE-ZLQWOROUSA-N_|_Small molecule_|_False_|_TESTOSTERONE CYPIONATE_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Andro-Cyp' 'Depandro' 'Depo-testosterone' 'Depotest'
 'Testosterone cypionate']_|_['Depo-Testadiol' 'NSC-9157'
 'Testosterone 17.beta.-cyclopentanepropionate' 'Testosterone cipionate'
 'Testosterone cyclopentylpropionate' 'Testosterone cypionate'
 'Testosterone cypionate ciii']_|_[('DailyMed', array(['testosterone%20cypionate'], dtype=object)), ('drugbank', array(['DB13943'], dtype=object)), ('chEBI', array(['9463'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000673', 'EFO_0000616', 'EFO_0004714', 'MONDO_0002146',
       'MONDO_0008315', 'EFO_1001078', 'EFO_1000783', 'EFO_0000196'],
      dtype=object), 'count': 8}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 3 approved and 5 investigational indications."
CHEMBL1201740,"Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O_|_YCBPQSYLYYBPDW-UHFFFAOYSA-N_|_Small molecule_|_True_|_NILOTINIB HYDROCHLORIDE MONOHYDRATE_|_2007.0_|_4.0_|_CHEMBL255863_|_False_|_True_|_['Tasigna']_|_['Nilotinib (as hydrochloride)' 'Nilotinib Hydrochloride Monohydrate'
 'Nilotinib hydrochloride' 'Nilotinib hydrochloride anhydrous'
 'Nilotinib hydrochloride hydrate' 'Nilotinib hydrochloride monohydrate']_|_[('DailyMed', array(['nilotinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0001075', 'EFO_1001512', 'EFO_0000616',
       'EFO_1000251', 'MONDO_0007254', 'EFO_0000339', 'EFO_0000717'],
      dtype=object), 'count': 8}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic myelogenous leukemia and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL123292,"C[C@@H]1C[C@@H]([C@H](O)CC2CC(=O)NC(=O)C2)C(=O)[C@@H](C)C1_|_YPHMISFOHDHNIV-FSZOTQKASA-N_|_Small molecule_|_False_|_CYCLOHEXIMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cicloheximide' 'Cycloheximide' 'GNF-Pf-5118' 'NSC-171' 'NSC-185'
 'TCMDC-125838' 'U-4527']_|_[('PubChem', array(['103076162', '124883128', '124883129', '144207129', '144208356',
       '144213954', '170466349', '17389082', '17389083', '26752000',
       '50104677', '56463698', '67121'], dtype=object)), ('Wikipedia', array(['Cycloheximide'], dtype=object)), ('chEBI', array(['27641'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1236107,"Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1_|_BCZUAADEACICHN-UHFFFAOYSA-N_|_Small molecule_|_False_|_SGX-523_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SGX-523' 'SGX523' 'Sgx-523']_|_[('PubChem', array(['137276007', '174006581'], dtype=object)), ('drugbank', array(['DB06314'], dtype=object)), ('chEBI', array(['90624'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1743025,"nan_|_nan_|_Antibody_|_False_|_GANTENERUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gantenerumab' 'R-04909832' 'R-1450' 'R04909832' 'R1450' 'RG-1450'
 'RO-4909832 R-1450' 'Ro-4909832']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1951071,"COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1.O=C(O)C(O)C(O)C(=O)O_|_FCSXYHUNDAXDRH-QVRIGTRMSA-N_|_Small molecule_|_False_|_ARFORMOTEROL TARTRATE_|_2006.0_|_4.0_|_CHEMBL1363_|_False_|_True_|_['Brovana']_|_['Arformoterol tartrate' 'Formoterol r,r-form l-tartrate']_|_nan_|_nan_|_{'rows': array(['EFO_0009661', 'EFO_0000341', 'EFO_0006505', 'EFO_0000464'],
      dtype=object), 'count': 4}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 1 investigational indication."
CHEMBL2105729,"CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O_|_YKGMKSIHIVVYKY-UHFFFAOYSA-N_|_Small molecule_|_False_|_DABRAFENIB MESYLATE_|_2013.0_|_4.0_|_CHEMBL2028663_|_False_|_True_|_['Tafinlar']_|_['Dabrafenib mesilate' 'Dabrafenib mesylate'
 'GSK-2118436 METHANESULFONATE SALT' 'GSK-2118436B'
 'GSK-2118436B MESYLATE' 'GSK-2118436B METHANESULFONATE SALT'
 'GSK2118436B' 'GSK2118436B, METHANE SULFONATE SALT'
 'METHANE SULFONATE SALT']_|_[('DailyMed', array(['dabrafenib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar'],
      dtype=object)), ('chEBI', array(['75048'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000926', 'EFO_0002892', 'MONDO_0002108', 'EFO_0001378',
       'EFO_0000389', 'EFO_0000756', 'EFO_0002617'], dtype=object), 'count': 7}_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 2 investigational indications."
CHEMBL2109562,"nan_|_nan_|_Antibody_|_False_|_CAL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CAL' 'Cal']_|_nan_|_nan_|_{'rows': array(['EFO_0000764', 'MONDO_0007254'], dtype=object), 'count': 2}_|_[ENSG00000087494]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2151197,"CCNC(=O)[C@H]1C[C@@](F)(c2ccc(CN3CCCC3)c(F)c2)C1_|_SXMBKHYDZOCBMT-PPUGGXLSSA-N_|_Small molecule_|_False_|_PF-03654746_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF 03654746' 'Pf-03654746']_|_[('drugbank', array(['DB12201'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854', 'EFO_0003888', 'MONDO_0004975', 'MONDO_0005090',
       'EFO_0004895'], dtype=object), 'count': 5}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2219776,"nan_|_nan_|_Oligonucleotide_|_False_|_CENERSEN SODIUM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cenersen sodium' 'EL-625' 'EL625' 'OL(1)P53']_|_nan_|_nan_|_{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}_|_[ENSG00000141510]_|_Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL25202,"CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21_|_MUTNCGKQJGXKEM-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAMIBAROTENE_|_2005.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AM-80' 'Am80' 'Amnoid' 'INNO-507' 'NSC-608000' 'OP-01' 'RR-110'
 'SY-1425' 'Sy-1425' 'TM-411' 'TOS-80T' 'Tamibarotene']_|_[('PubChem', array(['144206278', '170465883', '485050', '50125822'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAMIBAROTENE/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Tamibarotene'], dtype=object)), ('drugbank', array(['DB04942'], dtype=object)), ('chEBI', array(['32181'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000224', 'MONDO_0004975', 'EFO_0007527', 'EFO_0002618',
       'EFO_0000198', 'EFO_0005761', 'EFO_0000222', 'EFO_0000384'],
      dtype=object), 'count': 8}_|_[ENSG00000077092,ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 8 investigational indications."
CHEMBL3188386,"Cc1cc(-c2ncc(CC(=O)Nc3ccc(-c4cnccn4)cn3)cc2C)ccn1_|_XXYGTCZJJLTAGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_WNT-974_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LGK-974' 'LGK974' 'Lgk974' 'WNT-974' 'WNT974' 'Wnt-974' 'Wnt974']_|_[('PubChem', array(['174006720'], dtype=object)), ('drugbank', array(['DB12561'], dtype=object)), ('chEBI', array(['78030'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000707'], dtype=object), 'count': 1}_|_[ENSG00000102312]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545407,"O=[N+]([O-])OC[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O_|_AQLVRTWKJDTWQQ-SDBHATRESA-N_|_Small molecule_|_False_|_TRABODENOSON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['INNO-8875' 'Ino-8875' 'PJ-875' 'Trabodenoson']_|_[('drugbank', array(['DB13122'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001069', 'EFO_0004190'], dtype=object), 'count': 2}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3707227,"nan_|_nan_|_Antibody_|_False_|_ATEZOLIZUMAB_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Tecentriq']_|_['0ine2sfd9e' 'Anti-PD-L1' 'Anti-PDL1' 'Atezolizumab' 'MPDL-3280A'
 'MPDL3280A' 'RG-7446' 'RG7446']_|_[('DailyMed', array(['atezolizumab'], dtype=object)), ('DrugCentral', array(['5151'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000707', 'EFO_0003869', 'MONDO_0004992', 'EFO_1001465',
       'EFO_0007143', 'MONDO_0008315', 'EFO_0002617', 'EFO_0002918',
       'EFO_0000768', 'EFO_0001378', 'EFO_0004288', 'EFO_0000339',
       'MONDO_0005184', 'EFO_0006859', 'EFO_0005221', 'EFO_0000096',
       'EFO_1001951', 'EFO_0000199', 'EFO_0001061', 'EFO_0005922',
       'MONDO_0001187', 'EFO_1001100', 'EFO_0000640', 'MONDO_0021063',
       'MONDO_0044881', 'EFO_1000251', 'MONDO_0011962', 'EFO_0000503',
       'MONDO_0008170', 'MONDO_0003060', 'MONDO_0007576', 'EFO_0000196',
       'EFO_1001956', 'EFO_0008528', 'EFO_0000673', 'EFO_0000403',
       'MONDO_0002367', 'EFO_0000313', 'EFO_0000702', 'EFO_0005567',
       'EFO_0000691', 'EFO_1000657', 'EFO_0002618', 'EFO_1001961',
       'MONDO_0011719', 'EFO_0007532', 'EFO_0001075', 'EFO_1000613',
       'EFO_0000616', 'MONDO_0002158', 'EFO_0000095', 'EFO_0000588',
       'MONDO_0001056', 'MONDO_0007254', 'EFO_0000183', 'MONDO_0002898',
       'MONDO_0002691', 'EFO_0000770', 'EFO_0002892', 'EFO_1000601',
       'EFO_1001512', 'EFO_0009708', 'EFO_0003893', 'EFO_0000182',
       'EFO_0003863', 'EFO_0000181', 'MONDO_0001879', 'EFO_1001513',
       'EFO_0005537', 'EFO_0000305', 'MONDO_0100342', 'EFO_0000637',
       'EFO_0002916', 'EFO_0004142', 'EFO_1001051', 'EFO_0008528',
       'MONDO_0002974', 'EFO_0000756', 'EFO_0001642', 'EFO_0004284',
       'MONDO_0008903', 'MONDO_0002120', 'MONDO_0018906', 'MONDO_0004180',
       'EFO_0000198', 'EFO_0003060', 'EFO_0000574', 'EFO_0000389',
       'EFO_1000785', 'EFO_0000519', 'EFO_0000222', 'EFO_0000681',
       'EFO_0005952'], dtype=object), 'count': 93}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 11 approved and 82 investigational indications."
CHEMBL4297527,"O=C(Nc1c(Cl)c[n+]([O-])cc1Cl)c1ccc(OC(F)F)c2oc3ccncc3c12_|_IXQHNBONEVULTL-UHFFFAOYSA-N_|_Small molecule_|_False_|_REVAMILAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Revamilast']_|_[('drugbank', array(['DB11838'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297600,"NC(=O)c1ccn(-c2cnc(NC[C@]3(c4ncccc4F)C[C@H](F)C3)nc2)c1_|_MQXWPWOCXGARRK-HJGJAMNPSA-N_|_Small molecule_|_False_|_RELDESEMTIV_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CK-2127107' 'Ck-2127107' 'Reldesemtiv']_|_[('drugbank', array(['DB15256'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004976', 'EFO_0008525'], dtype=object), 'count': 3}_|_[ENSG00000130598,ENSG00000130595,ENSG00000101470]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297843,"nan_|_nan_|_Antibody_|_False_|_TORIPALIMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Loqtorzi']_|_['Anti-pd-i mab-shanghai junshi' 'CHS-007' 'JS-001' 'JS001' 'Js-001'
 'Js001' 'TAB-001' 'TAB001' 'Teriprizumab' 'Toripalimab' 'Treprizumab'
 'Tripleitriumab' 'Triprizumab' 'Tuoyi']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TORIPALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000569', 'EFO_0000178', 'EFO_0000691', 'EFO_0003897',
       'EFO_0000199', 'EFO_0008528', 'EFO_0003060', 'MONDO_0004986',
       'MONDO_0002974', 'EFO_0000707', 'EFO_0006859', 'EFO_1001972',
       'MONDO_0002691', 'MONDO_0001056', 'MONDO_0008903', 'MONDO_0007254',
       'EFO_0001416', 'EFO_1001968', 'EFO_0000503', 'EFO_0000702',
       'EFO_0005922', 'EFO_0004252', 'EFO_0002617', 'EFO_0003826',
       'MONDO_0005575', 'MONDO_0002108', 'MONDO_0011871', 'EFO_0000616',
       'EFO_0003891', 'MONDO_0021358', 'EFO_1001513', 'MONDO_0003060',
       'EFO_0000181', 'EFO_0000769', 'EFO_0000681', 'MONDO_0001187',
       'MONDO_0002120', 'EFO_0005221', 'EFO_0000756', 'EFO_1000657',
       'EFO_0002916', 'EFO_0000389', 'MONDO_0019472', 'MONDO_0007576',
       'EFO_0000182', 'MONDO_0000831', 'EFO_1000359', 'EFO_0000770',
       'MONDO_0004992', 'EFO_0003868', 'EFO_0005537', 'EFO_0000574',
       'EFO_1001961', 'EFO_0004288', 'EFO_1001951'], dtype=object), 'count': 55}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for niemann-pick disease type b and has 54 investigational indications."
CHEMBL4298113,nan_|_nan_|_Oligonucleotide_|_False_|_BAMOSIRAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bamosiran' 'SYL-040012' 'SYL040012' 'Syl040012']_|_nan_|_nan_|_nan_|_[ENSG00000169252]_|_Oligonucleotide drug with a maximum clinical trial phase of II.
CHEMBL5316167,"Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1_|_GBXJAPBXPROFPY-GOSISDBHSA-N_|_Small molecule_|_False_|_ARQ-736 FREE ACID_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL5314407']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000132155,ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL53366,"Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1_|_SQKXYSGRELMAAU-UHFFFAOYSA-N_|_Small molecule_|_False_|_IMIDAFENACIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Imidafenacin' 'KRP-197' 'ONO-8025' 'Staybla' 'Uritos']_|_[('drugbank', array(['DB09262'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000020', 'EFO_1000781', 'HP_0000103'], dtype=object), 'count': 3}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL551978,"CCOc1ccc(/C=C2\NCCc3cc(OCC)c(OCC)cc32)cc1OCC_|_OMFNSKIUKYOYRG-MOSHPQCFSA-N_|_Small molecule_|_False_|_DROTAVERINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dihydroethaverine' 'Dihydroisoperparine' 'Drotaverin' 'Drotaverine'
 'Drotin']_|_[('Wikipedia', array(['Drotaverine'], dtype=object)), ('drugbank', array(['DB06751'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010282', 'MONDO_0002887'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL848,"Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O_|_GOTYRUGSSMKFNF-UHFFFAOYSA-N_|_Small molecule_|_True_|_LENALIDOMIDE_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Revlimid']_|_['CC-5013' 'CDC-501' 'Lenalidomide' 'NSC-747972' 'SYP-1512']_|_[('DailyMed', array(['lenalidomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid'],
      dtype=object)), ('PubChem', array(['124893327', '124893328', '144206045', '170465201'], dtype=object)), ('Wikipedia', array(['Lenalidomide'], dtype=object)), ('drugbank', array(['DB00480'], dtype=object)), ('chEBI', array(['63791'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018906', 'MONDO_0100342', 'EFO_1000657', 'EFO_0000180',
       'EFO_1001779', 'MONDO_0002280', 'MONDO_0002158', 'EFO_0003758',
       'EFO_1001951', 'MONDO_0044903', 'MONDO_0004992', 'EFO_1001469',
       'MONDO_0002367', 'EFO_0000681', 'EFO_0000621', 'EFO_0000095',
       'EFO_0006475', 'HP_0004326', 'EFO_0000673', 'MONDO_0004095',
       'EFO_1001115', 'EFO_0000479', 'EFO_0000182', 'MONDO_0001187',
       'EFO_0000616', 'MONDO_0008170', 'EFO_1001465', 'EFO_0000384',
       'MONDO_0021063', 'EFO_0004142', 'EFO_0000403', 'EFO_0000209',
       'MONDO_0002087', 'EFO_0000183', 'EFO_0002892', 'EFO_1000630',
       'MONDO_0005184', 'EFO_0000222', 'EFO_1001938', 'MONDO_0019471',
       'EFO_1001998', 'EFO_0000191', 'EFO_0004272', 'MONDO_0008315',
       'EFO_0003060', 'MONDO_0017816', 'EFO_0000294', 'EFO_0002499',
       'MONDO_0001023', 'EFO_0000540', 'EFO_0000339', 'EFO_0000756',
       'EFO_0002430', 'EFO_0000574', 'EFO_0003841', 'MONDO_0044881',
       'EFO_1000026', 'EFO_0000707', 'EFO_0009708', 'EFO_0002618',
       'MONDO_0019438', 'EFO_0000196', 'EFO_0002913', 'MONDO_0015760',
       'EFO_0000096', 'EFO_0006738', 'MONDO_0002691', 'EFO_0000764',
       'MONDO_0004192', 'MONDO_0013730', 'EFO_0003073', 'EFO_1000158',
       'EFO_0000558', 'EFO_0000769', 'EFO_0000198', 'EFO_0004251',
       'EFO_0000211', 'MONDO_0002959', 'EFO_0001378', 'EFO_0009441',
       'EFO_0005952', 'EFO_0000309', 'MONDO_0006412', 'EFO_0002429',
       'EFO_0000565', 'EFO_0000220', 'MONDO_0000430', 'HP_0001871'],
      dtype=object), 'count': 88}_|_[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 82 investigational indications. This drug has a black box warning from the FDA."
CHEMBL88055,"Oc1ccc(C(O)C2CCCCN2)cc1O_|_IYMMESGOJVNCKV-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIMITEROL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Rimiterol']_|_nan_|_['CHEMBL2000813']_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for airway obstruction."
CHEMBL1094785,"COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1_|_IHOXNOQMRZISPV-YJYMSZOUSA-N_|_Small molecule_|_False_|_CARMOTEROL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CHF-4226' 'Carmoterol' 'Chf 4226' 'Quinoterol' 'TA-2005']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1117,"CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O_|_XDXDZDZNSLXDNA-TZNDIEGXSA-N_|_Small molecule_|_True_|_IDARUBICIN_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Idamycin' 'Idarubicin']_|_[('PubChem', array(['124891657', '50106402', '50106403', '50106404', '90340569'],
      dtype=object)), ('Wikipedia', array(['Idarubicin'], dtype=object)), ('drugbank', array(['DB01177'], dtype=object)), ('chEBI', array(['42068'], dtype=object))]_|_['CHEMBL1200976']_|_{'rows': array(['EFO_0002428', 'EFO_0000222', 'EFO_1001968', 'EFO_0000182',
       'EFO_0003025', 'EFO_0000339', 'MONDO_0004643', 'EFO_0000223',
       'EFO_0003027', 'EFO_0003811', 'EFO_0000616', 'MONDO_0001475',
       'EFO_0004251', 'EFO_0000220', 'EFO_0005952', 'EFO_0000565',
       'EFO_1001257', 'EFO_1000131', 'EFO_0000182', 'EFO_0000218',
       'EFO_0001378', 'MONDO_0002691', 'EFO_0000574', 'EFO_0003802',
       'EFO_0000221', 'EFO_0000224', 'EFO_0000222', 'MONDO_0000873',
       'EFO_1001779', 'EFO_0000198'], dtype=object), 'count': 30}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for acute myeloid leukemia and neoplasm and has 27 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200986,"CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1_|_GUTXTARXLVFHDK-UHFFFAOYSA-N_|_Small molecule_|_True_|_HALOPERIDOL DECANOATE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Haldol' 'Haldol Dec' 'Haloperidol decanoate']_|_['Halomonth' 'Haloperidol decanoate' 'R-13,672' 'R-13672']_|_[('DailyMed', array(['haloperidol%20decanoate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090', 'EFO_0009267'], dtype=object), 'count': 2}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for schizophrenia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201616,"nan_|_nan_|_Protein_|_False_|_SECRETIN SYNTHETIC PORCINE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Secreflo']_|_['Porcine secretin acetate salt' 'RG-1068'
 'Secretin (swine), acetate (salt)' 'Secretin porcine pentaacetate'
 'Secretin synthetic porcine']_|_nan_|_nan_|_{'rows': array(['EFO_0003758'], dtype=object), 'count': 1}_|_[ENSG00000080293]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2002 and has 1 investigational indication."
CHEMBL1653,"CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_SSOXZAQUVINQSA-BTJKTKAUSA-N_|_Small molecule_|_False_|_PHENIRAMINE MALEATE_|_1994.0_|_4.0_|_CHEMBL1193_|_False_|_True_|_['Avil ret' 'Daneral-sa']_|_['Antolozine' 'Daneral' 'Fervex' 'Inhiston' 'NSC-757270' 'Naphcon a'
 'PM-241' 'Pheniramine Maleate' 'Pheniramine hydrogen maleate'
 'Pheniramine maleate' 'Prophenpyridamine maleate' 'Trimeton' 'Trimetose']_|_[('DailyMed', array(['pheniramine%20maleate'], dtype=object)), ('PubChem', array(['144204739', '144208272', '170464902', '26747641', '50106867',
       '56422488', '93576675'], dtype=object)), ('chEBI', array(['31990'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007214', 'MONDO_0024355', 'EFO_0007328'], dtype=object), 'count': 3}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 investigational indications."
CHEMBL1709,"CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21.Cl_|_BLFQGGGGFNSJKA-XHXSRVRCSA-N_|_Small molecule_|_True_|_SERTRALINE HYDROCHLORIDE_|_1991.0_|_4.0_|_CHEMBL809_|_False_|_True_|_['Aremis' 'Besitron' 'Lustral' 'Sertraline hydrochloride' 'Zoloft']_|_['CP-51,974-1' 'CP-51974-1' 'NSC-746308' 'NSC-758948'
 'Sertraline (as hydrochloride)' 'Sertraline hcl'
 'Sertraline hydrochloride']_|_[('DailyMed', array(['sertraline%20hydrochloride'], dtype=object)), ('PubChem', array(['144204750', '170465121', '26719805', '26753298', '26753614',
       '49681568'], dtype=object)), ('chEBI', array(['9124'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'EFO_1001917', 'EFO_0001358', 'EFO_0004262',
       'MONDO_0007739', 'MONDO_0002009', 'MONDO_0002009', 'HP_0002315',
       'EFO_0004242', 'HP_0001249'], dtype=object), 'count': 10}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1742420,"CCOC(=O)NC(=N)c1ccc(OCc2cccc(COc3ccc(C(C)(C)c4ccc(O)cc4)cc3)c2)cc1_|_SBVYURPQULDJTI-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMELUBANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amelubant' 'BIIL 284' 'BIIL 284 BS' 'BIIL-284' 'BIIL-284BS' 'BIIL284 BS'
 'Biil 284 bs' 'LS-49968']_|_[('drugbank', array(['DB06248'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'EFO_0000685', 'EFO_0000341', 'MONDO_0004979'],
      dtype=object), 'count': 4}_|_[ENSG00000213903]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL20,"CC(=O)Nc1nnc(S(N)(=O)=O)s1_|_BZKPWHYZMXOIDC-UHFFFAOYSA-N_|_Small molecule_|_True_|_ACETAZOLAMIDE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_['Acetazolamide' 'Diamox' 'Diamox sr' 'Eytazox']_|_['Acetamox' 'Acetazolamide' 'Acetazolamidum' 'Atenezo' 'Defiltran' 'Didoc'
 'Diuriwas' 'Donmox' 'Edemox' 'Glaupax' 'L 579486' 'NSC-145177'
 'Nephramide' 'Phonurit']_|_[('DailyMed', array(['acetazolamide'], dtype=object)), ('PubChem', array(['11110757', '144208757', '144213090', '170464692', '26747033',
       '26751551', '50104152', '855900'], dtype=object)), ('TG-GATEs', array(['108'], dtype=object)), ('Wikipedia', array(['Acetazolamide'], dtype=object)), ('drugbank', array(['DB00819'], dtype=object)), ('chEBI', array(['27690'], dtype=object))]_|_['CHEMBL1200814' 'CHEMBL542496']_|_{'rows': array(['MONDO_0005301', 'EFO_0002617', 'MONDO_0005147', 'EFO_0003086',
       'Orphanet_37553', 'EFO_1000961', 'MONDO_0005041', 'EFO_1001065',
       'HP_0012532', 'HP_0002104', 'MONDO_0008315', 'EFO_0009373',
       'MONDO_0005090', 'EFO_0008526', 'EFO_0005252', 'MONDO_0003005',
       'EFO_1001132', 'EFO_0000182', 'EFO_1000782', 'EFO_0001361',
       'MONDO_0005041', 'EFO_0007231', 'EFO_0003144', 'EFO_0000702',
       'MONDO_0001744', 'EFO_0000712', 'EFO_0003918', 'EFO_0000373',
       'HP_0001250', 'MONDO_0001744', 'HP_0001250', 'EFO_0000474',
       'EFO_0009373', 'EFO_1001010'], dtype=object), 'count': 34}_|_[ENSG00000074410,ENSG00000167434,ENSG00000133742,ENSG00000104267]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 8 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103846,"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C_|_HKDLNTKNLJPAIY-WKWWZUSTSA-N_|_Small molecule_|_False_|_ULIPRISTAL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Uliprisnil' 'Ulipristal' 'Ulipristal acetate ulipristal']_|_[('drugbank', array(['DB08867'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001572', 'MONDO_0003061'], dtype=object), 'count': 2}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL2104793,"CCCC(C(=O)c1ccc(C)cc1)N1CCCC1.Cl_|_MWRACNBZNVAJHE-UHFFFAOYSA-N_|_Small molecule_|_False_|_PYROVALERONE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL201960_|_True_|_True_|_[]_|_['Centroton' 'F 1983' 'F-1983' 'Pyrovalerone hcl'
 'Pyrovalerone hydrochloride' 'SP-1059' 'Thymergix']_|_nan_|_nan_|_nan_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2105233,"C=CCC1(CC(C)O)C(=O)NC(=O)NC1=O_|_VNLMRPAWAMPLNZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROXIBARBAL_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Axeen' 'Centralgol' 'HH-184' 'Hydroxydial' 'Ipronal' 'Proxibarbal']_|_[('drugbank', array(['DB13253'], dtype=object))]_|_nan_|_nan_|_[ENSG00000002726,ENSG00000189221]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2107860,"nan_|_nan_|_Protein_|_False_|_TASPOGLUTIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BIM-51077' 'BIM51077' 'R-1583' 'R1583' 'RO-5073031' 'RO5073031'
 'Taspoglutide']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL354541,"O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1_|_MBBCVAKAJPKAKM-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOMITAPIDE_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Lojuxta']_|_['AEGR-733' 'BMS-201038' 'BMS-201038-01' 'Lomitapide']_|_[('drugbank', array(['DB08827'], dtype=object)), ('chEBI', array(['72297'], dtype=object))]_|_['CHEMBL2105662']_|_{'rows': array(['MONDO_0018328', 'MONDO_0018328', 'HP_0003124', 'MONDO_0021187',
       'EFO_0004911', 'EFO_0004911', 'EFO_0000319'], dtype=object), 'count': 7}_|_[ENSG00000138823,ENSG00000185624]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3674570,"CC1(C)CC=C(c2nc(C3CC(C)(C)OC(C)(C)C3)ccc2NC(=O)c2nc(C#N)c[nH]2)CC1_|_BNVPFDRNGHMRJS-UHFFFAOYSA-N_|_Small molecule_|_False_|_EDICOTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Edicotinib' 'JNJ-40346527' 'Jnj-40346527']_|_[('drugbank', array(['DB12504'], dtype=object))]_|_['CHEMBL4297225']_|_{'rows': array(['EFO_0000222', 'EFO_0000673', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000182578]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297320,"CCCCCCC(=O)N[C@@H]1CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2C[C@H](C(N)=O)NC(=O)[C@@H]2CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CCCC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O_|_HSHVZRILAMZYHY-WXSGKXQHSA-N_|_Protein_|_False_|_PL-3994_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pl-3994']_|_nan_|_nan_|_{'rows': array(['EFO_0003144', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000169418]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297845,"nan_|_nan_|_Unknown_|_False_|_TRU-015_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-5212374' 'Tru-015']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0000574', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000156738]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4298002,nan_|_nan_|_Antibody_|_False_|_ICHORCUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ichorcumab' 'JNJ-375' 'JNJ-64179375' 'JNJ-9375' 'Jnj-64179375']_|_nan_|_nan_|_nan_|_[ENSG00000180210]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL4751394,"NC(=O)c1ccc2nc(-c3ccc(C4(N)CCC4)cc3)c(-c3ccccc3)n2n1_|_JBGYKRAZYDNCNV-UHFFFAOYSA-N_|_Small molecule_|_False_|_BAY-1125976_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BAY-1125976' 'BAY1125976' 'Bay 1125976' 'Bay-1125976']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000142208,ENSG00000105221]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4802223,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1.CS(=O)(=O)O_|_MBIDSOMXPLCOHS-XNHQSDQCSA-N_|_Protein_|_False_|_LEUPROLIDE MESYLATE_|_2021.0_|_4.0_|_CHEMBL1201199_|_False_|_True_|_['Camcevi' 'Camcevi kit']_|_['Camcevi' 'Leuprorelin mesilate' 'Leuprorelin mesylate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/camcevi'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for prostate cancer."
CHEMBL5315093,"nan_|_nan_|_Unknown_|_False_|_AUTOLOGOUS CD34+ ENRICHED CELL FRACTION THAT CONTAINS CD34+ CELLS TRANSDUCED WITH RETROVIRAL VECTOR THAT ENCODES FOR THE HUMAN ADA CDNA SEQUENCE_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Strimvelis']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015974'], dtype=object), 'count': 1}_|_[ENSG00000196839]_|_Unknown drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for severe combined immunodeficiency."
CHEMBL53463,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1_|_AOJJSUZBOXZQNB-TZSSRYMLSA-N_|_Small molecule_|_False_|_DOXORUBICIN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Adriablastin' 'Adriamycin' 'Doxil' 'Doxorubicin'
 'Epirubicin hydrochloride impurity, doxorubicin-' 'Hydroxydaunorubicin'
 'NSC-123127' 'NSC-759155' 'Rubex' 'Valrubicin impurity, doxorubicin']_|_[('PubChem', array(['124886887', '124886893', '164339434'], dtype=object)), ('TG-GATEs', array(['149'], dtype=object)), ('Wikipedia', array(['Doxorubicin'], dtype=object)), ('drugbank', array(['DB00997'], dtype=object)), ('chEBI', array(['28748'], dtype=object))]_|_['CHEMBL359744' 'CHEMBL272706' 'CHEMBL216371']_|_{'rows': array(['MONDO_0002928', 'MONDO_0002974', 'EFO_0002618', 'EFO_0001378',
       'EFO_0004289', 'EFO_0000309', 'MONDO_0003175', 'EFO_0002918',
       'EFO_1001951', 'EFO_0005561', 'MONDO_0000873', 'EFO_0002617',
       'EFO_0000183', 'EFO_1000350', 'EFO_1000292', 'MONDO_0015760',
       'MONDO_0018531', 'EFO_0009708', 'EFO_0003060', 'MONDO_0004192',
       'MONDO_0004986', 'EFO_0007143', 'EFO_1000796', 'EFO_0005537',
       'MONDO_0018364', 'MONDO_0000870', 'EFO_0000096', 'EFO_0000095',
       'EFO_0003893', 'EFO_0000691', 'EFO_0000239', 'EFO_0000702',
       'EFO_0000094', 'MONDO_0017387', 'EFO_0000637', 'MONDO_0017816',
       'MONDO_0008170', 'MONDO_0000870', 'MONDO_0004986', 'MONDO_0005184',
       'EFO_0002913', 'EFO_0000313', 'EFO_0000220', 'EFO_0000403',
       'EFO_0000565', 'EFO_0000432', 'EFO_0000558', 'EFO_0000621',
       'EFO_0003032', 'EFO_0000760', 'EFO_1000131', 'Orphanet_145',
       'MONDO_0002367', 'EFO_0000569', 'EFO_0000702', 'MONDO_0100342',
       'EFO_0003833', 'EFO_0000220', 'EFO_0003869', 'EFO_0000502',
       'MONDO_0000873', 'MONDO_0019460', 'EFO_0000565', 'EFO_0000182',
       'EFO_0000222', 'EFO_1000984', 'EFO_1002017', 'EFO_1000158',
       'EFO_0005537', 'EFO_0000389', 'MONDO_0001187', 'EFO_0000502',
       'EFO_0000632', 'EFO_0000255', 'EFO_0004252', 'MONDO_0004992',
       'MONDO_0020077', 'EFO_0000248', 'HP_0001871', 'EFO_0003968',
       'EFO_0000209', 'EFO_0000630', 'MONDO_0002087', 'EFO_0000211',
       'EFO_0009708', 'EFO_0001378', 'MONDO_0008380', 'EFO_0006861',
       'EFO_0005952', 'EFO_0000574', 'EFO_1001100', 'EFO_0000503',
       'MONDO_0007576', 'MONDO_0015540', 'MONDO_0019004', 'MONDO_0018906',
       'EFO_1000251', 'MONDO_0008315', 'MONDO_0002691', 'EFO_0008528',
       'EFO_1001365', 'MONDO_0018906', 'MONDO_0018364', 'MONDO_0001056',
       'EFO_0000313', 'EFO_0000616', 'EFO_0006475', 'EFO_0003868',
       'MONDO_0016691', 'EFO_0000621', 'EFO_1000796', 'EFO_1001042',
       'MONDO_0011934', 'MONDO_0011962', 'EFO_0003060', 'EFO_1000292',
       'MONDO_0021117', 'EFO_0000223', 'EFO_0000681', 'EFO_0001376',
       'EFO_1000294', 'MONDO_0044917', 'MONDO_0021054', 'MONDO_0002974',
       'MONDO_0016717', 'EFO_0003869', 'MONDO_0000432', 'EFO_0006861',
       'EFO_0000198', 'EFO_0003085', 'EFO_0000305', 'EFO_0000437',
       'EFO_0000558', 'EFO_0003144', 'EFO_0000198', 'MONDO_0005094',
       'EFO_1000984', 'EFO_1000251', 'HP_0002017', 'EFO_0000309',
       'MONDO_0002730', 'MONDO_0002367', 'MONDO_0002158', 'MONDO_0008315',
       'MONDO_0004095', 'EFO_0000588', 'EFO_0000588', 'EFO_1000576',
       'MONDO_0002108', 'EFO_1001469', 'EFO_0000211', 'MONDO_0001475',
       'EFO_0000403', 'EFO_1001365', 'MONDO_0008903', 'EFO_0005952',
       'EFO_0000095', 'MONDO_0015540', 'EFO_0000519', 'MONDO_0008380',
       'EFO_0000174', 'EFO_0003032', 'EFO_0007160', 'EFO_0004230',
       'EFO_0000637', 'MONDO_0019004', 'MONDO_0007254', 'MONDO_0019472',
       'EFO_0003893', 'MONDO_0004992', 'MONDO_0002087', 'MONDO_0001187',
       'MONDO_0009348', 'EFO_0000673', 'EFO_0006475', 'MONDO_0044881',
       'MONDO_0001657', 'EFO_0000182', 'MONDO_0000430', 'EFO_1001968',
       'MONDO_0002158', 'MONDO_0007254', 'EFO_0009254', 'EFO_0000691',
       'EFO_0003968', 'MONDO_0004192', 'MONDO_0001056', 'MONDO_0004986',
       'EFO_0000183', 'EFO_1001469', 'MONDO_0015564', 'EFO_0005221',
       'EFO_0000096', 'MONDO_0002678', 'EFO_0000222', 'EFO_0000305',
       'MONDO_0004669', 'EFO_0000770', 'EFO_0001075', 'EFO_0000231',
       'EFO_0006859', 'EFO_0009907', 'EFO_0000174', 'EFO_1000581',
       'MONDO_0008170', 'MONDO_0002691', 'EFO_0000681', 'EFO_1001968',
       'MONDO_0009348', 'EFO_0002918', 'EFO_0000616', 'EFO_0002499',
       'MONDO_0011962', 'EFO_0000209', 'EFO_0000564', 'EFO_1001901',
       'EFO_1000595', 'EFO_0007532', 'MONDO_0019471', 'EFO_0001075',
       'EFO_1001100', 'EFO_0000564', 'EFO_0000094', 'EFO_0000765',
       'MONDO_0004658', 'EFO_0000574', 'MONDO_0044917'], dtype=object), 'count': 227}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 24 approved and 173 investigational indications."
CHEMBL558,"Cc1cccc(C)c1OCC(C)N_|_VLPIATFUUWWMKC-UHFFFAOYSA-N_|_Small molecule_|_True_|_MEXILETINE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(rs)-mexiletine' 'Dl-mexiletine' 'Mexiletine']_|_[('PubChem', array(['90341048'], dtype=object)), ('TG-GATEs', array(['103'], dtype=object)), ('Wikipedia', array(['Mexiletine'], dtype=object)), ('drugbank', array(['DB00379'], dtype=object)), ('chEBI', array(['6916'], dtype=object))]_|_['CHEMBL1200606']_|_{'rows': array(['MONDO_0016107', 'MONDO_0016120', 'EFO_0004278', 'EFO_0000612',
       'MONDO_0015626', 'HP_0004308', 'EFO_0004287', 'MONDO_0011728',
       'EFO_0004269', 'HP_0012532', 'Orphanet_273', 'EFO_0009387',
       'EFO_0000555'], dtype=object), 'count': 13}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL636,"CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1_|_XSVMFMHYUFZWBK-NSHDSACASA-N_|_Small molecule_|_False_|_RIVASTIGMINE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Alzest' 'Eluden' 'Erastig' 'Exelon' 'Kerstipon' 'Nimvastid' 'Prometax'
 'Rivastigmine' 'Somniton' 'Voleze']_|_['ENA-713' 'ENA-713D' 'ONO-2540' 'Rivastigmine' 'Rivastigmine hexal'
 'Rivastigmine sandoz' 'Rivastigmine teva' 'SDZ-212-713' 'SDZ-212713'
 'SDZ-ENA-713']_|_[('DailyMed', array(['rivastigmine'], dtype=object)), ('Wikipedia', array(['Rivastigmine'], dtype=object)), ('drugbank', array(['DB00989'], dtype=object)), ('chEBI', array(['8874'], dtype=object))]_|_['CHEMBL215645' 'CHEMBL1201092' 'CHEMBL3187096']_|_{'rows': array(['EFO_0003890', 'EFO_0004718', 'EFO_0005230', 'EFO_0004701',
       'MONDO_0004975', 'MONDO_0002050', 'EFO_0002610', 'MONDO_0005090',
       'MONDO_0043510', 'MONDO_0005180', 'EFO_0005252', 'EFO_0001064',
       'HP_0000726', 'MONDO_0002491', 'EFO_0004364', 'HP_0000726',
       'MONDO_0005180', 'HP_0100543', 'MONDO_0019037', 'EFO_0009267'],
      dtype=object), 'count': 20}_|_[ENSG00000114200,ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 15 investigational indications."
CHEMBL1095607,"Cn1c(=O)c2c(ncn2CCCNCC(O)c2cc(O)cc(O)c2)n(C)c1=O_|_WVLAAKXASPCBGT-UHFFFAOYSA-N_|_Small molecule_|_False_|_REPROTEROL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['D-1959' 'Reproterol']_|_[('drugbank', array(['DB12846'], dtype=object))]_|_['CHEMBL2104771']_|_{'rows': array(['HP_0006536', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 1 investigational indication."
CHEMBL1201155,"CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.O=C(O)CCC(=O)O_|_YQZBAXDVDZTKEQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOXAPINE SUCCINATE_|_1975.0_|_4.0_|_CHEMBL831_|_False_|_True_|_['Loxapac' 'Loxapine succinate' 'Loxitane']_|_['CL 71563' 'CL-71563' 'Loxapine succinate' 'NSC-759578']_|_[('PubChem', array(['11112040', '11112041', '124881879', '144203862', '170465094',
       '26719661', '26747560', '26747561', '49731997', '50106540',
       '85231309', '855705'], dtype=object)), ('chEBI', array(['6549'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975 and is indicated for schizophrenia. This drug has a black box warning from the FDA."
CHEMBL1201191,"O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1_|_ZKLPARSLTMPFCP-OAQYLSRUSA-N_|_Small molecule_|_False_|_LEVOCETIRIZINE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Xyzal']_|_['(-)-cetirizine' '(r)-cetirizine' 'Cetirizine (r)-form'
 'Cetirizine, (-)-' 'Cetirizine, (r)-' 'Levocetirizine' 'Xazal']_|_[('PubChem', array(['26719822', '49681558'], dtype=object)), ('Wikipedia', array(['Levocetirizine'], dtype=object)), ('drugbank', array(['DB06282'], dtype=object))]_|_['CHEMBL1201190']_|_{'rows': array(['EFO_0000274', 'EFO_1001417', 'EFO_0007533', 'EFO_0008521',
       'EFO_0000701', 'EFO_0005531', 'EFO_0005531', 'EFO_0003956',
       'EFO_0003956', 'Orphanet_79292', 'EFO_0005854', 'MONDO_0005271',
       'EFO_0008521', 'EFO_1001417', 'MONDO_0004979', 'EFO_0000401',
       'HP_0012735', 'HP_0000964', 'MONDO_0002406', 'EFO_0004142'],
      dtype=object), 'count': 20}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 14 investigational indications."
CHEMBL1201356,"CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1_|_UNBRKDKAWYKMIV-QWQRMKEZSA-N_|_Small molecule_|_False_|_METHYLERGONOVINE_|_1946.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ergotyl' 'Methylergometrine' 'Methylergonovine']_|_[('PubChem', array(['104171343', '144204360', '170465383', '26751766', '50104453',
       '90341291'], dtype=object)), ('Wikipedia', array(['Methylergometrine'], dtype=object)), ('drugbank', array(['DB00353'], dtype=object))]_|_['CHEMBL1200843']_|_{'rows': array(['MP_0001914'], dtype=object), 'count': 1}_|_[ENSG00000135914,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for hemorrhage."
CHEMBL1201463,"nan_|_nan_|_Small molecule_|_False_|_CODEINE POLISTIREX_|_1985.0_|_4.0_|_CHEMBL485_|_False_|_True_|_[]_|_['Codeine polistirex']_|_nan_|_nan_|_nan_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985."
CHEMBL1201497,"nan_|_nan_|_Protein_|_False_|_INSULIN GLARGINE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Abasaglar' 'Abasaglar kwikpen' 'Basaglar' 'Ins lantus'
 'Ins lantus opticlik' 'Ins lantus optiset' 'Ins lantus solostar' 'Lantus'
 'Lantus solostar' 'Toujeo' 'Toujeo (previously optisulin)'
 'Toujeo max solostar' 'Toujeo solostar']_|_['Basalin' 'Basalog' 'Galactus' 'Glargin' 'Glargine' 'Glaricon' 'HOE 71GT'
 'HOE 901' 'HOE-71GT' 'HOE-901' 'Insulin Glargine Recombinant'
 'Insulin glargine' 'Insulin glargine (lantus)'
 'Insulin glargine (sanofi)' 'Insulin glargine aglr'
 'Insulin glargine recombinant' 'Insulin glargine yfgn'
 'Insulin glargine-aglr' 'Insulin glargine-yfgn' 'LY-2963016' 'LY2963016'
 'Lantus r' 'Lusduna' 'MK-1293' 'MYL-1501D' 'Myl-1501d' 'Rezvoglar'
 'Rezvoglar kwikpen' 'Semglee']_|_[('DailyMed', array(['insulin%20glargine', 'insulin%20glargine%20recombinant'],
      dtype=object)), ('DrugCentral', array(['4901'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/toujeo-previously-optisulin'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000565', 'EFO_0000400', 'MONDO_0005148',
       'EFO_0003770', 'EFO_0008583', 'EFO_1000897', 'MONDO_0009061',
       'EFO_0001645', 'EFO_1001121', 'HP_0003124', 'MONDO_0005147',
       'EFO_0003914', 'HP_0003074', 'EFO_0000537'], dtype=object), 'count': 15}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 12 investigational indications."
CHEMBL1201639,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP BEEF_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Lente insulin']_|_['Insulin zinc susp beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1701,"CCOC(=O)C1(c2ccccc2)CCN(C)CC1.Cl_|_WCNLCIJMFAJCPX-UHFFFAOYSA-N_|_Small molecule_|_True_|_MEPERIDINE HYDROCHLORIDE_|_1942.0_|_4.0_|_CHEMBL607_|_False_|_True_|_['Demerol' 'Meperidine hydrochloride'
 'Meperidine hydrochloride preservative free' 'Pamergan' 'Pethidine'
 'Pethilorfan' 'Spasmodlin']_|_['Meperidine hcl' 'Meperidine hydrochloride'
 'Meperidine hydrochloride cii' 'NIH 10522' 'NSC-400479'
 'Pethidine hydrochloride' 'Pethidini hydrochloridum']_|_[('DailyMed', array(['meperidine%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0003890', 'EFO_0005251'], dtype=object), 'count': 3}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and is indicated for pain and drug dependence and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2031465,Cc1ccc(C(=O)NC2CC2)cc1-n1cnc2ccc(N3CCN(C)CC3)cc2c1=O_|_ZMAZXHICVRYLQN-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-6703_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZ-12012199' 'AZ12012199' 'AZD-6703' 'Azd 6703' 'Azd-6703' 'Azd6703']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2108078,"nan_|_nan_|_Protein_|_True_|_PARATHYROID HORMONE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Natpar' 'Preotact']_|_['ALX-1-11' 'ALX-111' 'ALX1-11' 'NPSP-558' 'NPSP558' 'Natpar' 'Natpara'
 'Parathormone (human recombinant)' 'Parathormonum' 'Parathyroid'
 'Parathyroid hormone' 'Parathyroid hormone (rdna)' 'Pth (1-84)'
 'Pth (1-84) human' 'Pth(1-84)']_|_[('DrugCentral', array(['4936'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/natpar',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/preotact'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008506', 'HP_0002901', 'EFO_0009451', 'EFO_0000676',
       'EFO_0003854', 'EFO_0003882'], dtype=object), 'count': 6}_|_[ENSG00000160801]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109552,"nan_|_nan_|_Antibody drug conjugate_|_False_|_YTTRIUM Y 90 CAPROMAB PENDETIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_['Oncoltad']_|_['90Y-CYT-356' 'CYT-356-90Y' 'CYT-356-Y-90' 'Cyt-356 90y'
 'Yttrium y 90 capromab pendetide']_|_nan_|_nan_|_nan_|_[ENSG00000086205]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II."
CHEMBL2111101,"CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1_|_RKEWSXXUOLRFBX-UHFFFAOYSA-N_|_Small molecule_|_True_|_PIMAVANSERIN_|_2016.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Pimavanserin']_|_[('drugbank', array(['DB05316'], dtype=object))]_|_['CHEMBL2448613' 'CHEMBL5177911']_|_{'rows': array(['EFO_0005772', 'EFO_0005407', 'EFO_0004895', 'MONDO_0005180',
       'EFO_0005407', 'MONDO_0002009', 'HP_0000738', 'MONDO_0004975',
       'MONDO_0005090', 'MONDO_0005090', 'MONDO_0005180'], dtype=object), 'count': 11}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3990012,"nan_|_nan_|_Protein_|_False_|_PEGAPAMODUTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2944876' 'LY2944876' 'Pegapamodutide']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL422872,"O=C(O)CSC(CCCc1ccccc1)c1ccc(OCc2ccc3ccccc3n2)cc1_|_JOIXGLLMSDPZDN-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-4769_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZ-12096971' 'AZD-4769' 'AZD4769' 'Azd 4769' 'Azd-4769' 'L-674573'
 'L674573']_|_nan_|_nan_|_nan_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL4297348,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(=O)O)C(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)O)[C@H](C)O)[C@H](C)O_|_HRMVIAFZYCCHGF-BMCUWHFPSA-N_|_Protein_|_False_|_BRIMAPITIDE, C-TERMINAL ACID_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AM-111' 'Am-111' 'Brimapitide, c-terminal acid' 'D-jnki-1'
 'Xg-102 c-terminal acid']_|_nan_|_nan_|_{'rows': array(['EFO_0004238'], dtype=object), 'count': 1}_|_[ENSG00000109339]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297507,"C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2_|_LOWWYYZBZNSPDT-ZBEGNZNMSA-N_|_Small molecule_|_False_|_DELGOCITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Delgocitinib' 'JTE-052' 'JTE-052A' 'LEO 124249' 'LEO 124249A'
 'LEO-124249' 'LEO-124249A']_|_nan_|_nan_|_{'rows': array(['EFO_0000274', 'HP_0000964', 'EFO_0000676', 'EFO_0004192',
       'MONDO_0019558'], dtype=object), 'count': 5}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297718,"nan_|_nan_|_Unknown_|_False_|_CD40 LIGAND_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-950' 'Cd40 ligand' 'Cd40 ligand recombinant'
 'Recombinant cd40-ligand' 'Recombinant human cd40 ligand'
 'Soluble cd154 recombinant']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000389'], dtype=object), 'count': 2}_|_[ENSG00000101017]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297888,"nan_|_nan_|_Antibody_|_False_|_SOTIGALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APX-005' 'APX-005M' 'APX005M' 'Apx005m' 'EPI-0050' 'Sotigalimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOTIGALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007576', 'MONDO_0008170', 'EFO_0000616', 'EFO_0002617',
       'EFO_1000657', 'EFO_1001968', 'EFO_0000756'], dtype=object), 'count': 7}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL440115,O=C(/C=C/c1c(-c2ccccc2)nn2ccccc12)N1CCCC[C@@H]1CCO_|_OPLOPFHUHFGKMJ-JXOMPUQVSA-N_|_Small molecule_|_False_|_FK453_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['FK-453' 'Fk453']_|_nan_|_nan_|_nan_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4594573,"nan_|_nan_|_Antibody_|_False_|_FEPIXNEBART_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fepixnebart' 'LY-3016859' 'LY3016859' 'Ly-3016859' 'Ly3016859']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FEPIXNEBART/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'HP_0003419', 'EFO_0005762', 'HP_0012532',
       'MONDO_0005178'], dtype=object), 'count': 5}_|_[ENSG00000163235,ENSG00000124882]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL462018,"CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23_|_URLYINUFLXOMHP-HTVVRFAVSA-N_|_Small molecule_|_False_|_TRICIRIBINE PHOSPHATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NSC-154020' 'NSC-280594' 'Phosphate salt of tricyclic nucleoside'
 'Triciribine' 'Triciribine phosphate' 'Vqd-002']_|_[('drugbank', array(['DB14636'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000565', 'MONDO_0008170'], dtype=object), 'count': 3}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650518,"nan_|_nan_|_Antibody_|_False_|_PLONMARLIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Plonmarlimab' 'TJ-003234' 'TJ003234' 'TJM-2' 'Tj 003234' 'Tj003234']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000164400]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5095028,"CC(C)N1C[C@@H]2C[C@H]1CN2c1ccc(Nc2ncc(-c3coc(C(N)=O)c3)n3ncnc23)cc1_|_YBFGSJUVEOYPIS-OALUTQOASA-N_|_Small molecule_|_False_|_GLPG-0259_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GLPG-0259' 'GLPG0259' 'Glpg-0259']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000089022]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL809,"CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21_|_VGKDLMBJGBXTGI-SJCJKPOMSA-N_|_Small molecule_|_True_|_SERTRALINE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Sertraline']_|_[('PubChem', array(['26753299', '29215139', '49665783', '50105682', '50105683',
       '50105684', '50105685', '90341218'], dtype=object)), ('Wikipedia', array(['Sertraline'], dtype=object)), ('drugbank', array(['DB01104'], dtype=object)), ('chEBI', array(['9123'], dtype=object))]_|_['CHEMBL1709']_|_{'rows': array(['MONDO_0002009', 'EFO_0003756', 'EFO_0003047', 'EFO_0004262',
       'EFO_0002610', 'EFO_0007453', 'EFO_0001073', 'HP_0000989',
       'EFO_0001358', 'EFO_0000519', 'MONDO_0010383', 'MONDO_0002050',
       'EFO_1001917', 'MONDO_0002046', 'EFO_1001917', 'MONDO_0043510',
       'EFO_1001892', 'EFO_0005230', 'HP_0002315', 'EFO_0004262',
       'EFO_0003890', 'EFO_0001358', 'EFO_0007211', 'EFO_0003758',
       'MONDO_0004985', 'MONDO_0007739', 'MONDO_0007079', 'MONDO_0002009',
       'MONDO_0005090', 'EFO_0004242', 'EFO_0004242', 'EFO_0000222',
       'HP_0001249', 'EFO_0004247', 'EFO_0004698', 'EFO_0000198',
       'MONDO_0002050', 'EFO_0007228', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0002009'], dtype=object), 'count': 41}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1007,"CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O_|_XLXSAKCOAKORKW-AQJXLSMYSA-N_|_Protein_|_False_|_GONADORELIN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Fertiral lh-rh' 'Relefact lh-rh']_|_['Gonadorelin' 'Gonadorelin decapeptide' 'Gonadotropin-releasing hormone'
 'Human gonadoliberin-i']_|_[('chEBI', array(['5520'], dtype=object))]_|_['CHEMBL1200516' 'CHEMBL1200511']_|_{'rows': array(['MONDO_0018555', 'EFO_0000673', 'EFO_0003882', 'EFO_0001663',
       'MONDO_0007254', 'EFO_0002610', 'MONDO_0018800', 'MONDO_0007254',
       'MONDO_0008315', 'MONDO_0008315', 'EFO_0000545', 'EFO_0000196',
       'EFO_0000512', 'MONDO_0002146'], dtype=object), 'count': 14}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 13 investigational indications."
CHEMBL1115,"CN(C)C(=O)Oc1ccc[n+](C)c1_|_RVOLLAQWKVFTGE-UHFFFAOYSA-N_|_Small molecule_|_True_|_PYRIDOSTIGMINE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mestinon' 'Pyridostigmine' 'Pyridostigmine cation' 'Pyridostigmine ion'
 'Regonol']_|_[('PubChem', array(['11111694', '90340824'], dtype=object)), ('Wikipedia', array(['Pyridostigmine'], dtype=object)), ('drugbank', array(['DB00545'], dtype=object)), ('chEBI', array(['8665'], dtype=object))]_|_['CHEMBL812' 'CHEMBL4303667']_|_{'rows': array(['EFO_0003144', 'EFO_0000764', 'MONDO_0100096', 'EFO_0005251',
       'MONDO_0004567', 'EFO_0004991', 'Orphanet_365', 'MONDO_0005180',
       'EFO_0004991', 'EFO_0005252', 'EFO_0005252', 'EFO_0000400',
       'MONDO_0009672', 'EFO_0005687', 'Orphanet_83419'], dtype=object), 'count': 15}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200534,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O.Cl_|_JXRAXHBVZQZSIC-JKVLGAQCSA-N_|_Small molecule_|_True_|_MOEXIPRIL HYDROCHLORIDE_|_1995.0_|_4.0_|_CHEMBL1165_|_False_|_True_|_['Moexipril hydrochloride' 'Perdix' 'Univasc']_|_['CI 925' 'CI-925' 'Moexipril hcl' 'Moexipril hydrochloride'
 'RS-10085-197' 'SPM 925' 'SPM-925']_|_[('DailyMed', array(['moexipril%20hydrochloride'], dtype=object)), ('PubChem', array(['144206143', '170465131'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for hypertension. This drug has a black box warning from the FDA."
CHEMBL1201210,"CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2_|_UVOIBTBFPOZKGP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPIOMAZINE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CB 1678' 'CB-1678' 'Dorevan' 'Dorevane' 'Indorm' 'Largon' 'Propavan'
 'Propiomazine' 'WY-1359']_|_[('Wikipedia', array(['Propiomazine'], dtype=object)), ('drugbank', array(['DB00777'], dtype=object)), ('chEBI', array(['8491'], dtype=object))]_|_['CHEMBL1201068']_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1201556,"nan_|_nan_|_Protein_|_False_|_BECAPLERMIN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Regranex']_|_['Becaplermin' 'GEM 21S' 'GEM-21S' 'Gemesis' 'Pdgf-2' 'Pdgf-bb' 'Pdgfb'
 'Platelet derived growth factor-bb'
 'Platelet-derived growth factor becaplermin' 'RWJ 60235' 'RWJ-60235'
 'Sh-polypeptide-59']_|_[('DailyMed', array(['becaplermin'], dtype=object)), ('DrugCentral', array(['4925'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/regranex'],
      dtype=object)), ('Wikipedia', array(['Becaplermin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001459', 'GO_0042060', 'HP_0200042', 'MONDO_0043839'],
      dtype=object), 'count': 4}_|_[ENSG00000113721,ENSG00000134853]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for wound healing and skin ulcer and has 2 investigational indications."
CHEMBL1237080,"CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2.Cl_|_QYZRTBKYBJRGJB-UHFFFAOYSA-N_|_Small molecule_|_False_|_GRANISETRON HYDROCHLORIDE_|_1993.0_|_4.0_|_CHEMBL289469_|_False_|_True_|_['Granisetron hydrochloride' 'Granisetron hydrochloride preservative free'
 'Granisol' 'Granisteron HCl' 'Kytril']_|_['BRL 43694A' 'BRL-43694A' 'Bema granisetron'
 'Granisetron (as hydrochloride)' 'Granisetron hcl'
 'Granisetron hydrochloride' 'NSC-759839']_|_[('DailyMed', array(['granisetron%20hydrochloride'], dtype=object)), ('PubChem', array(['124894588'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002017', 'MONDO_0004992', 'HP_0002018', 'EFO_0006911',
       'EFO_0000616', 'HP_0100806'], dtype=object), 'count': 6}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 5 approved and 1 investigational indication."
CHEMBL1495,"CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1_|_DUDKAZCAISNGQN-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYPHENCYCLIMINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Oxyphencyclimine']_|_[('drugbank', array(['DB00383'], dtype=object)), ('chEBI', array(['7868'], dtype=object))]_|_['CHEMBL1200891']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease."
CHEMBL2103829,"CN(C)C[C@@H]1CCCC[C@H]1c1cccc(O)c1_|_JIRYWFYYBBRJAN-ZFWWWQNUSA-N_|_Small molecule_|_False_|_FAXELADOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EM-906' 'EM906' 'Faxeladol' 'GCR-9905' 'GCR9905' 'GRT-TA300'
 'GRTA-0009906' 'GRTA-9906' 'GRTA0009906' 'GRTA9906' 'Grt9906']_|_nan_|_['CHEMBL3893776']_|_{'rows': array(['HP_0012532', 'EFO_0005762', 'EFO_0005687'], dtype=object), 'count': 3}_|_[ENSG00000108576,ENSG00000112038,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109295,"nan_|_nan_|_Antibody_|_False_|_ASCRINVACUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ascrinvacumab' 'PF-03446962']_|_nan_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_1001951', 'EFO_0000616', 'EFO_0000770'],
      dtype=object), 'count': 4}_|_[ENSG00000139567]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2109360,nan_|_nan_|_Antibody_|_False_|_AS-1403_|_nan_|_1.0_|_nan_|_False_|_False_|_['Therafab']_|_['AS-1403']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2364638,"C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F_|_DDOOFTLHJSMHLN-ZQHRPCGSSA-N_|_Small molecule_|_False_|_UBROGEPANT_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Ubrelvy']_|_['MK-1602' 'Ubrogepant' 'Ubrogepant anhydrous']_|_[('DailyMed', array(['ubrogepant'], dtype=object)), ('drugbank', array(['DB15328'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for migraine disorder."
CHEMBL3137321,"COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341_|_VPMRSLWWUXNYRY-NDOYXKHWSA-N_|_Small molecule_|_False_|_BENZHYDROCODONE_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benzhydrocodone']_|_[('drugbank', array(['DB15465'], dtype=object))]_|_['CHEMBL3137310']_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for pain."
CHEMBL3264610,"CC(C)[C@](O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1c[nH]nn1_|_ZBRAJOQFSNYJMF-SFHVURJKSA-N_|_Small molecule_|_False_|_SEVITERONEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Seviteronel' 'Vt-464']_|_[('drugbank', array(['DB12275'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0008315'],
      dtype=object), 'count': 4}_|_[ENSG00000148795,ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3545211,"CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1_|_OHCPNHFLPCVWRG-YQOGLFJVSA-N_|_Small molecule_|_False_|_SR16234_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL3545210']_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL384467,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO_|_UREBDLICKHMUKA-CXSFZGCWSA-N_|_Small molecule_|_False_|_DEXAMETHASONE_|_1958.0_|_4.0_|_nan_|_False_|_True_|_['Aeroseb-dex' 'Dalalone' 'Decaderm' 'Decadron' 'Decadron-75' 'Decaspray'
 'Dexacortisyl' 'Dexafree' 'Dexamethasone' 'Dexamethasone intensol'
 'Dexone' 'Dexone 0.5' 'Dexone 0.75' 'Dexone 1.5' 'Dexone 4' 'Dexsol'
 'Dextenza' 'Dexycu kit' 'Dropodex' 'Gppe ear spy' 'Hemady' 'Hexadrol'
 'Kortico Injection' 'Martapan' 'Maxidex' 'Maxitrol' 'Oradexon' 'Otomize'
 'Ozurdex' 'Sofradex' 'Spersadex comp' 'Tobradex']_|_['Decadron-LA' 'Dexacen-4' 'Dexacort' 'Dexair' 'Dexamethasone'
 'Dexamethasone metasulfobenzoate sodium' 'Dexamethasone palmitate'
 'Dexamethasone valerate' 'Dexycu' 'Fluormethylprednisolone' 'ISV-305'
 'Mymethasone' 'NSC-34521' 'Neodecadron' 'OTO-104']_|_[('DailyMed', array(['dexamethasone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ozurdex'],
      dtype=object)), ('PubChem', array(['144207320', '17389945', '26752876', '26752877', '26752878',
       '56314873', '56320685', '92119'], dtype=object)), ('Wikipedia', array(['Dexamethasone'], dtype=object)), ('drugbank', array(['DB01234'], dtype=object)), ('chEBI', array(['41879'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001663', 'EFO_0000546', 'EFO_0000224', 'EFO_0009449',
       'EFO_0003811', 'MONDO_0002331', 'EFO_1000657', 'MONDO_0019438',
       'EFO_1001267', 'EFO_1000941', 'EFO_1000694', 'EFO_0009456',
       'EFO_1000764', 'MONDO_0013730', 'EFO_0004237', 'EFO_1001231',
       'EFO_0000095', 'HP_0000265', 'EFO_0003932', 'MONDO_0004565',
       'EFO_0009491', 'MONDO_0002334', 'EFO_0002913', 'MONDO_0019460',
       'HP_0009926', 'EFO_0004888', 'MONDO_0044917', 'EFO_0000588',
       'EFO_1001469', 'EFO_0003025', 'HP_0011950', 'EFO_0000729',
       'EFO_0000673', 'EFO_0007405', 'EFO_1001012', 'EFO_0001642',
       'HP_0002901', 'EFO_0000373', 'EFO_0003917', 'EFO_1000879',
       'MONDO_0004658', 'HP_0002017', 'EFO_1001205', 'MONDO_0009348',
       'EFO_0006911', 'EFO_0009515', 'EFO_0000681', 'EFO_0001068',
       'MONDO_0018479', 'EFO_0003956', 'HP_0002013', 'EFO_0000309',
       'EFO_0003769', 'EFO_0004276', 'EFO_0007520', 'EFO_0006912',
       'MONDO_0015564', 'EFO_0004238', 'EFO_1000684', 'EFO_0003802',
       'EFO_0009536', 'EFO_0006862', 'EFO_0004255', 'EFO_0000565',
       'EFO_0006859', 'EFO_0007297', 'EFO_0000183', 'MONDO_0011962',
       'HP_0000486', 'EFO_0000616', 'EFO_0003106', 'EFO_0000223',
       'EFO_0003770', 'HP_0001094', 'HP_0030833', 'EFO_0000708',
       'MONDO_0004567', 'HP_0003072', 'EFO_0000384', 'EFO_0003918',
       'EFO_0008997', 'MONDO_0001280', 'EFO_0003103', 'MONDO_0015128',
       'MONDO_0002471', 'EFO_1001115', 'EFO_0009609', 'EFO_1001250',
       'HP_0002094', 'EFO_1000049', 'EFO_0004236', 'EFO_0009560',
       'EFO_1000965', 'MONDO_0001056', 'EFO_0007541', 'EFO_0009552',
       'EFO_0007537', 'EFO_0005752', 'EFO_0000182', 'EFO_0003893',
       'EFO_1001129', 'EFO_0003778', 'MONDO_0019472', 'HP_0000559',
       'EFO_1001417', 'MONDO_0007254', 'HP_0012378', 'EFO_0008517',
       'MONDO_0019338', 'EFO_0005221', 'MONDO_0017816', 'EFO_1001896',
       'MONDO_0002959', 'MONDO_0005301', 'EFO_0005319', 'MONDO_0008315',
       'MONDO_0005041', 'HP_0001742', 'EFO_0009430', 'EFO_0000274',
       'MONDO_0008170', 'MONDO_0007935', 'EFO_1000726', 'HP_0001873',
       'EFO_0004274', 'MONDO_0018076', 'EFO_0003032', 'EFO_1001494',
       'EFO_0000218', 'EFO_0003894', 'EFO_0005539', 'EFO_1001194',
       'EFO_0000676', 'MONDO_0006412', 'EFO_0005755', 'MONDO_0001572',
       'EFO_0000222', 'MONDO_0015540', 'EFO_0008520', 'MONDO_0004992',
       'EFO_0003073', 'EFO_0009441', 'EFO_0000221', 'EFO_0000613',
       'EFO_0009869', 'EFO_1001968', 'MONDO_0007576', 'EFO_1001435',
       'EFO_0007200', 'HP_0003418', 'EFO_0003027', 'MONDO_0000873',
       'MONDO_0002691', 'EFO_1000997', 'MONDO_0004979', 'MONDO_0008903',
       'EFO_0009507', 'EFO_1001801', 'EFO_0001422', 'EFO_0000540',
       'EFO_0007328', 'EFO_1001961', 'EFO_0000694', 'EFO_0000574',
       'EFO_0001063', 'HP_0011868', 'EFO_0007228', 'EFO_0003884',
       'EFO_0000209', 'EFO_0003966', 'MONDO_0001657', 'EFO_0000094',
       'EFO_0007231', 'EFO_0009104', 'MONDO_0005271', 'EFO_1000131',
       'EFO_0006475', 'EFO_0007257', 'EFO_0001378', 'MONDO_0002406',
       'MONDO_0001718', 'EFO_1001119', 'EFO_1002022', 'EFO_1000845',
       'EFO_0004616', 'EFO_0003869', 'EFO_0000544', 'EFO_0003843',
       'MONDO_0007079', 'EFO_0005207', 'Orphanet_1930', 'HP_0012532',
       'EFO_0005952', 'MONDO_0018896', 'MONDO_0018906', 'EFO_0000618',
       'EFO_1001909', 'EFO_0003060', 'HP_0001915', 'MONDO_0005178',
       'EFO_1001830', 'EFO_1001051', 'EFO_0000198', 'EFO_0007403',
       'MONDO_0100096', 'MONDO_0008728', 'EFO_0009448', 'EFO_0004208',
       'EFO_0004992', 'MONDO_0011382', 'EFO_0000365', 'MONDO_0005129',
       'EFO_0005570', 'EFO_0009708', 'EFO_0006738', 'EFO_1001951',
       'MONDO_0000465', 'MONDO_0000870', 'EFO_0000519', 'MONDO_0019091',
       'EFO_0007486', 'HP_0002015', 'EFO_0002618', 'EFO_1000811',
       'EFO_0004289', 'EFO_0002950', 'MP_0001845', 'EFO_0000220',
       'EFO_1001222', 'EFO_0005592', 'HP_0011110', 'EFO_0005558',
       'MONDO_0100130', 'EFO_1000986', 'MONDO_0044881', 'EFO_0000713',
       'EFO_0007149', 'EFO_0004272', 'EFO_0004274', 'MONDO_0002462',
       'EFO_0000211', 'EFO_1000039', 'EFO_1001176', 'MONDO_0100053',
       'MONDO_0003005', 'EFO_0000181', 'EFO_0000756', 'MONDO_0021148',
       'HP_0012424', 'EFO_1001157', 'EFO_0003898', 'EFO_0004252',
       'EFO_0007160', 'EFO_0004719', 'HP_0006536', 'EFO_0001365',
       'EFO_0004710', 'MONDO_0001705', 'EFO_0003144', 'HP_0100806',
       'MP_0001914', 'EFO_0007344', 'EFO_1000637', 'EFO_1001779',
       'EFO_0000691', 'EFO_0007141', 'EFO_1000797', 'EFO_0000305',
       'EFO_0000685', 'MONDO_0016226', 'EFO_0007355', 'MONDO_0011972',
       'EFO_1001216', 'EFO_0008528', 'EFO_1000749', 'MONDO_0005277',
       'EFO_0000537', 'HP_0004398', 'MONDO_0021108', 'MONDO_0020547',
       'EFO_0000403', 'EFO_0008571', 'EFO_0001075', 'EFO_0003957',
       'EFO_1001139', 'MONDO_0007915', 'MONDO_0019471', 'EFO_1000906',
       'HP_0002018', 'EFO_0004683', 'EFO_1000992', 'EFO_0002609',
       'EFO_0000096', 'EFO_1001875', 'EFO_0005854', 'MONDO_0001187',
       'EFO_1000318', 'EFO_0000702', 'HP_0002315', 'EFO_1001158'],
      dtype=object), 'count': 300}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 79 approved and 221 investigational indications."
CHEMBL4297383,"Fc1cc(-c2cccc(-c3nc[nH]n3)c2)cc(F)c1CNC1Cc2ccccc2C1_|_WIEDUMBCZQRGSY-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-1521498_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK1521498' 'Gsk-1521498' 'Gsk1521498']_|_[('drugbank', array(['DB12886'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297942,"nan_|_nan_|_Antibody_|_False_|_QUETMOLIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E-6011' 'E6011' 'Quetmolimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_1001486', 'EFO_0000384'], dtype=object), 'count': 3}_|_[ENSG00000006210]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL45305,"Cc1ccc(CNCC2(F)CCN(C(=O)c3ccc(F)c(Cl)c3)CC2)nc1_|_PKZXLMVXBZICTF-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEFIRADOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Befiradol' 'F-13640' 'F13640' 'NLX-112']_|_[('Wikipedia', array(['Befiradol'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004280'], dtype=object), 'count': 1}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594444,"C[C@H](O)c1nc(Cn2nc(-c3ccc(Cl)cc3)n(C[C@H](O)C(F)(F)F)c2=O)nn1-c1cccc(Cl)c1_|_AZXOTZCWQDJCLY-SJCJKPOMSA-N_|_Small molecule_|_False_|_PECAVAPTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 1753011' 'BAY-1753011' 'Bay 1753011' 'Pecavaptan']_|_nan_|_nan_|_{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}_|_[ENSG00000166148,ENSG00000126895]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL49,"O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1_|_QWCRAEMEVRGPNT-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUSPIRONE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BCI-024' 'Buspar' 'Buspirone' 'Gen-buspirone']_|_[('PubChem', array(['104171117', '11110857', '11112732', '11113821', '144203643',
       '144212688', '170464909', '26751994', '90340780'], dtype=object)), ('Wikipedia', array(['Buspirone'], dtype=object)), ('drugbank', array(['DB00490'], dtype=object)), ('chEBI', array(['3223'], dtype=object))]_|_['CHEMBL1200399']_|_{'rows': array(['EFO_0003756', 'EFO_0000717', 'EFO_0004714', 'MONDO_0005090',
       'MONDO_0002050', 'HP_0002104', 'EFO_0005230', 'MONDO_0005090',
       'EFO_1001919', 'MONDO_0002050', 'EFO_0007191', 'EFO_0008533',
       'EFO_1001892', 'EFO_1000948', 'EFO_0004888', 'EFO_0006788',
       'EFO_0002610', 'HP_0000726', 'EFO_0003758', 'EFO_0003888',
       'EFO_0004714', 'MONDO_0002009', 'MONDO_0005180', 'EFO_0005411',
       'HP_0002140', 'EFO_1001919'], dtype=object), 'count': 26}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 4 approved and 19 investigational indications."
CHEMBL536151,"O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O_|_CHILCFMQWMQVAL-UHFFFAOYSA-N_|_Small molecule_|_False_|_IMD-0354_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IMD-0354' 'Imd-0354' 'TCMDC-125465']_|_[('PubChem', array(['103904747', '29217569', '50111708'], dtype=object))]_|_nan_|_nan_|_[ENSG00000104365]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL1199324,"C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_BARDROPHSZEBKC-OITMNORJSA-N_|_Small molecule_|_False_|_FOSAPREPITANT_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Ivemend']_|_['Fosaprepitant' 'L-758298']_|_[('Wikipedia', array(['Fosaprepitant'], dtype=object)), ('drugbank', array(['DB06717'], dtype=object)), ('chEBI', array(['64321'], dtype=object))]_|_['CHEMBL1201782' 'CHEMBL1159797']_|_{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_0001378', 'EFO_0006911',
       'EFO_0004888', 'HP_0002017', 'MONDO_0043510', 'MONDO_0021148',
       'MONDO_0004992', 'EFO_0006911', 'EFO_0000691', 'HP_0002017',
       'EFO_0004252'], dtype=object), 'count': 13}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 9 investigational indications."
CHEMBL1200791,"Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl_|_BEEDODBODQVSIM-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYMETAZOLINE HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL762_|_False_|_True_|_['Afrazine' 'Ocuclear' 'Rhofade' 'Upneeq' 'Visine l.r.']_|_['Agn-199201' 'NSC-757254' 'Oximetazoline hydrochloride'
 'Oxymetazoline hcl' 'Oxymetazoline hydrochloride' 'SCH 9384' 'SCH-9384']_|_[('DailyMed', array(['oxymetazoline%20hydrochloride'], dtype=object)), ('PubChem', array(['26747607', '26747608', '50106757', '50106758', '50106759',
       '856146'], dtype=object)), ('chEBI', array(['7863'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854', 'HP_0001742', 'MONDO_0000728', 'MONDO_0001330',
       'HP_0010783', 'EFO_0007486', 'EFO_0007214', 'EFO_0007141',
       'EFO_0003956', 'EFO_1000760'], dtype=object), 'count': 10}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 3 investigational indications."
CHEMBL1201206,"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1_|_OWWLUIWOFHMHOQ-XGHATYIMSA-N_|_Small molecule_|_False_|_PIPECURONIUM_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Pipecuronium']_|_[('drugbank', array(['DB01338'], dtype=object)), ('chEBI', array(['8230'], dtype=object))]_|_['CHEMBL1200722']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990."
CHEMBL1266,"c1ccc2c(c1)CCCC2C1=NCCN1_|_BYJAVTDNIXVSPW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TETRAHYDROZOLINE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Caltheon' 'Tetrahydrozoline' 'Tetryzoline' 'Tyzine']_|_[('PubChem', array(['90341828'], dtype=object)), ('Wikipedia', array(['Tetrahydrozoline'], dtype=object)), ('drugbank', array(['DB06764'], dtype=object)), ('chEBI', array(['28674'], dtype=object))]_|_['CHEMBL1200413']_|_{'rows': array(['HP_0001742', 'EFO_1000906', 'EFO_0000678', 'MP_0001845',
       'EFO_0005751'], dtype=object), 'count': 5}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for nasal congestion and eye allergy and has 3 investigational indications."
CHEMBL1743067,"nan_|_nan_|_Antibody_|_False_|_SAMALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALXN-6000' 'ALXN6000' 'Samalizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000095', 'EFO_0001378', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000091972]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1900528,"C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12_|_LERNTVKEWCAPOY-DZZGSBJMSA-N_|_Small molecule_|_False_|_TIOTROPIUM_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Braltus' 'Spiriva' 'Spiriva respimat']_|_['Tiotropium' 'Tiotropium cation' 'Tiotropium ion']_|_[('PubChem', array(['50113015'], dtype=object)), ('drugbank', array(['DB01409'], dtype=object))]_|_['CHEMBL4440620' 'CHEMBL3545181']_|_{'rows': array(['EFO_1001919', 'HP_0006536', 'HP_0000083', 'MONDO_0009061',
       'EFO_0000616', 'EFO_0000341', 'MONDO_0004979', 'EFO_0006505',
       'EFO_0000341', 'EFO_0000464'], dtype=object), 'count': 10}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 5 investigational indications."
CHEMBL2105864,"COc1ccc(C[C@@H](CN[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](Cc2cccs2)NC(=O)CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](N)CCCNC(=N)N)cc1_|_IDXCXSCCZNCXCL-XMADEQCMSA-N_|_Protein_|_False_|_LABRADIMIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Labradimil' 'Lobradimil' 'RMP-7']_|_[('drugbank', array(['DB06549'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005543', 'EFO_1000158', 'EFO_0007228', 'EFO_0002939'],
      dtype=object), 'count': 4}_|_[ENSG00000168398]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2107355,"Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O_|_ZJIHMALTJRDNQI-OLALXQGDSA-N_|_Small molecule_|_False_|_MIGALASTAT HYDROCHLORIDE_|_2016.0_|_4.0_|_CHEMBL110458_|_False_|_True_|_['Galafold']_|_['AT-1001 (MIGALASTAT HYDROCHLORIDE)' 'Migalastat hcl'
 'Migalastat hydrochloride']_|_[('DailyMed', array(['migalastat%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/galafold'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010526'], dtype=object), 'count': 1}_|_[ENSG00000102393]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for fabry disease."
CHEMBL2107877,"nan_|_nan_|_Protein_|_False_|_BLISIBIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-623' 'AMG 623' 'AMG-623' 'Blisibimod']_|_nan_|_nan_|_{'rows': array(['EFO_0007160', 'EFO_0005297', 'EFO_0004194', 'MONDO_0007915',
       'EFO_1000784'], dtype=object), 'count': 5}_|_[ENSG00000102524]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2108045,nan_|_nan_|_Antibody_|_False_|_PRITUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pritumumab']_|_nan_|_nan_|_nan_|_[ENSG00000026025]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108572,"nan_|_nan_|_Protein_|_False_|_BALUGRASTIM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Balugrastim' 'CG-10639' 'CG10639']_|_nan_|_nan_|_{'rows': array(['MONDO_0001475', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109224,"nan_|_nan_|_Antibody_|_False_|_ROVELIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Leukarrest']_|_['HU-23F2G' 'HU23F2G' 'Rovelizumab']_|_nan_|_nan_|_nan_|_[ENSG00000005844,ENSG00000160255,ENSG00000169896]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL2109286,"nan_|_nan_|_Antibody drug conjugate_|_False_|_COLTUXIMAB RAVTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Coltuximab ravtansine' 'SAR-3419' 'SAR3419']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0000403', 'EFO_0000220'], dtype=object), 'count': 3}_|_[ENSG00000177455]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109544,nan_|_nan_|_Antibody_|_False_|_CDP-860_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDP-860']_|_nan_|_nan_|_nan_|_[ENSG00000113721]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL24778,"C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F_|_PNCPYILNMDWPEY-QGZVFWFLSA-N_|_Small molecule_|_False_|_SILODOSIN_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Rapaflo' 'Silodyx']_|_['KAD-3213' 'KMD-3213' 'Kso-0400' 'Rapilif' 'Silodal' 'Silodosin'
 'Silodyx' 'Urief' 'Urorec']_|_[('DailyMed', array(['silodosin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/silodyx'],
      dtype=object)), ('Wikipedia', array(['Silodosin'], dtype=object)), ('drugbank', array(['DB06207'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000284', 'EFO_0803321', 'MONDO_0008315', 'MONDO_0024647',
       'EFO_0004253', 'EFO_0003830'], dtype=object), 'count': 6}_|_[ENSG00000120907]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for benign prostatic hyperplasia and has 5 investigational indications."
CHEMBL260933,"CCCn1c(=O)c2[nH]c(-c3cnn(Cc4cccc(C(F)(F)F)c4)c3)nc2n(CC)c1=O_|_KOYXXLLNCXWUNF-UHFFFAOYSA-N_|_Small molecule_|_False_|_GS 6201_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CVT-6883' 'GS-6201' 'Gs 6201']_|_[('PubChem', array(['103905523', '174007167'], dtype=object)), ('drugbank', array(['DB05936'], dtype=object))]_|_nan_|_nan_|_[ENSG00000170425]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL325041,"CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O_|_GXJABQQUPOEUTA-RDJZCZTQSA-N_|_Small molecule_|_False_|_BORTEZOMIB_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Bortezomib accord' 'Velcade']_|_['Bortezomib' 'Bortezomib accord' 'Bortezomib hydrate' 'LDP-341'
 'NSC-681239' 'PS-341' 'Velcade']_|_[('DailyMed', array(['bortezomib'], dtype=object)), ('PubChem', array(['124950705', '144206183', '144206225', '170465087', '518755'],
      dtype=object)), ('Wikipedia', array(['Bortezomib'], dtype=object)), ('drugbank', array(['DB00188'], dtype=object)), ('chEBI', array(['52717'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001961', 'EFO_1000158', 'MONDO_0004192', 'MONDO_0002367',
       'MONDO_0003175', 'EFO_0000574', 'EFO_0000519', 'EFO_1001226',
       'MONDO_0008170', 'MONDO_0017816', 'EFO_0000588', 'EFO_0000096',
       'EFO_0000095', 'MONDO_0044917', 'MONDO_0016537', 'MONDO_0008627',
       'EFO_0000183', 'EFO_0001378', 'EFO_0003060', 'EFO_0000094',
       'EFO_0006859', 'EFO_0005952', 'EFO_0009441', 'EFO_0000339',
       'EFO_0000220', 'EFO_0000182', 'MONDO_0018922', 'EFO_0000681',
       'EFO_0003811', 'EFO_0000616', 'EFO_0004599', 'MONDO_0020547',
       'EFO_0000571', 'MONDO_0019460', 'EFO_0005543', 'EFO_0001642',
       'EFO_0003884', 'MONDO_0019471', 'MONDO_0001705', 'EFO_1001365',
       'EFO_0007183', 'EFO_1001968', 'EFO_0000209', 'EFO_0000198',
       'MONDO_0002974', 'MONDO_0007254', 'EFO_1001052', 'EFO_0000224',
       'MONDO_0015277', 'EFO_0000309', 'MONDO_0007576', 'EFO_1001875',
       'MONDO_0001056', 'EFO_0000641', 'EFO_0000501', 'MONDO_0019438',
       'EFO_0000621', 'MONDO_0004986', 'EFO_0002618', 'MONDO_0004992',
       'EFO_0003032', 'MONDO_0044881', 'MONDO_0009348', 'EFO_0000222',
       'EFO_0004252', 'EFO_0000191', 'EFO_1001051', 'EFO_1000785',
       'MONDO_0001187', 'EFO_0007160', 'EFO_0000255', 'EFO_0007332',
       'EFO_0000305', 'EFO_0000403', 'EFO_0003073', 'EFO_0000231',
       'EFO_0004289', 'EFO_0001663', 'MONDO_0008315', 'EFO_0006475',
       'EFO_1001469', 'EFO_0004256', 'EFO_0002428', 'EFO_0000211',
       'MONDO_0018906', 'EFO_0000565', 'MONDO_0002087', 'EFO_0002501',
       'EFO_1001465', 'EFO_0000756', 'MONDO_0002158', 'EFO_0000540',
       'EFO_0000707', 'EFO_0000691', 'MONDO_0015564', 'EFO_0006738',
       'MONDO_0013730', 'MONDO_0016145', 'MONDO_0008903', 'EFO_0002499',
       'EFO_0000673', 'EFO_1001951', 'MONDO_0000873', 'MONDO_0005184',
       'EFO_0000308'], dtype=object), 'count': 105}_|_[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 4 approved and 101 investigational indications."
CHEMBL3301582,"nan_|_nan_|_Antibody drug conjugate_|_False_|_POLATUZUMAB VEDOTIN_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Polivy']_|_['ACD-79B-VCMMAE' 'ACD-79BVCMMAE' 'ACD79B-VCMMAE' 'Anti-cd79b adc'
 'DCDS-4501A' 'DCDS4501A' 'FCU-2711' 'FCU2711' 'Polatuzumab vedotin'
 'Polatuzumab vedotin piiq' 'RG-7596' 'RG7596' 'RO-5541077-000'
 'RO-5541077000' 'RO5541077-000']_|_[('DailyMed', array(['polatuzumab%20vedotin-piiq'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/polivy'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018906', 'EFO_0000574', 'EFO_0000096', 'EFO_1001469',
       'EFO_0005952', 'EFO_0000403', 'EFO_0000095', 'MONDO_0004095',
       'EFO_0000616'], dtype=object), 'count': 9}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000007312]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 6 investigational indications."
CHEMBL3544911,"COc1cccc(OCCCN)c1-c1cc(Nc2cnc(C#N)cn2)n[nH]1_|_DOTGPNHGTYJDEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PREXASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2606368' 'LY2606368' 'Ly-2606368' 'Prexasertib']_|_[('drugbank', array(['DB12008'], dtype=object))]_|_['CHEMBL5305850']_|_{'rows': array(['EFO_0000616', 'MONDO_0001657', 'EFO_0009708', 'EFO_1001779',
       'MONDO_0004992', 'EFO_0000198', 'EFO_0000222', 'EFO_0004284',
       'EFO_1000158', 'MONDO_0008170', 'EFO_0004142', 'EFO_0000702',
       'EFO_0000708', 'EFO_0002939', 'MONDO_0007254', 'EFO_0003060'],
      dtype=object), 'count': 16}_|_[ENSG00000149554,ENSG00000183765]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications."
CHEMBL3545080,nan_|_nan_|_Small molecule_|_False_|_RG-7256_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PLX-3603' 'Rg-7256' 'Ro-5212054']_|_nan_|_nan_|_nan_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989408,"CC(C)Cc1ccc(C(C)C(=O)[O-])cc1.O.O.[Na+]_|_VTGPMVCGAVZLQI-UHFFFAOYSA-M_|_Small molecule_|_False_|_IBUPROFEN SODIUM_|_2012.0_|_4.0_|_CHEMBL521_|_False_|_True_|_['Advil' 'Ibuprofen sodium']_|_['Ibuprofen sodium' 'Ibuprofen sodium dihydrate'
 'Sodium ibuprofen dihydrate']_|_[('DailyMed', array(['ibuprofen%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2012 and has 1 investigational indication."
CHEMBL3989927,"O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1_|_IXZOHGPZAQLIBH-NRFANRHFSA-N_|_Small molecule_|_False_|_IBERDOMIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CC-220' 'Iberdomide']_|_[('drugbank', array(['DB12101'], dtype=object))]_|_['CHEMBL3989912']_|_{'rows': array(['EFO_0001378', 'EFO_0003073', 'EFO_0000574', 'MONDO_0018906',
       'HP_0000083', 'MONDO_0019338', 'EFO_0005952', 'EFO_0000403',
       'EFO_0001378', 'MONDO_0007915', 'EFO_0001421'], dtype=object), 'count': 11}_|_[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL3989937,"CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F.Cl.Cl.O_|_COWBUPJEEDYWKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAPMATINIB HYDROCHLORIDE_|_2020.0_|_4.0_|_CHEMBL3188267_|_False_|_True_|_['Tabrecta']_|_['Capmatinib hydrochloride' 'Capmatinib hydrochloride hydrate'
 'NVP-INC280-AAA']_|_[('DailyMed', array(['capmatinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for non-small cell lung carcinoma."
CHEMBL4297458,"Cc1nnn(C)c1-c1cnc2c3ccc(C(C)(C)O)cc3n([C@H](c3ccccc3)C3CCOCC3)c2c1_|_KGERZPVQIRYWRK-GDLZYMKVSA-N_|_Small molecule_|_False_|_EZOBRESIB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BMS-986158' 'Bet inhibitor bms-986158' 'Bms-986158' 'Ezobresib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EZOBRESIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15435'], dtype=object))]_|_['CHEMBL5185824']_|_{'rows': array(['EFO_0000574', 'EFO_0000616', 'EFO_0001378', 'MONDO_0044903'],
      dtype=object), 'count': 4}_|_[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL4298055,"nan_|_nan_|_Protein_|_False_|_ALDAFERMIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aldafermin' 'NGM-282' 'NGM282' 'Ngm282']_|_nan_|_nan_|_{'rows': array(['EFO_1001249', 'EFO_0004268', 'EFO_0000400', 'HP_0002019',
       'EFO_0003086', 'EFO_1001486', 'EFO_0001421'], dtype=object), 'count': 7}_|_[ENSG00000113578,ENSG00000134962,ENSG00000160867]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL436774,"CC(=O)N1CCC(NC(=O)NC23CC4CC(CC(C4)C2)C3)CC1_|_HUDQLWBKJOMXSZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_AR9281_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ar9281']_|_[('drugbank', array(['DB06345'], dtype=object))]_|_nan_|_nan_|_[ENSG00000120915]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4594518,"nan_|_nan_|_Antibody_|_False_|_LUTIKIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-1234138' 'ABT-981' 'Abt-981' 'Lutikizumab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUTIKIZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_0000616', 'EFO_1000710', 'EFO_0004616'],
      dtype=object), 'count': 4}_|_[ENSG00000125538,ENSG00000115008]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL460291,"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C_|_GKQPCPXONLDCMU-CCEZHUSRSA-N_|_Small molecule_|_False_|_LACIDIPINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Caldine' 'Molap' 'Motens']_|_[""3,3'-iminobispropylamine"" ""3,3'-iminodipropylamine""
 '4-azaheptamethylenediamine' ""Dipropylamine, 3,3'-diamino-""
 'Dipropylenetriamine' 'GR 43659X' 'GR-43659X' 'Lacidipine' 'NSC-7773']_|_[('PubChem', array(['144205727', '170465580'], dtype=object)), ('drugbank', array(['DB09236'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0003913', 'EFO_0000537'], dtype=object), 'count': 3}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL4650220,"Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12.Cl_|_VQDUWCSSPSOSNA-RYWNGCACSA-N_|_Small molecule_|_False_|_ZAVEGEPANT HYDROCHLORIDE_|_2023.0_|_4.0_|_CHEMBL2397415_|_False_|_True_|_['Zavzpret']_|_['BHV-3500 hydrochloride' 'BMS-742413 hydrochloride' 'BMS-742413-03'
 'Zavegepant hydrochloride' 'Zavzpret']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZAVEGEPANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for migraine disorder."
CHEMBL483465,"Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3_|_FARXPFGGGGLENU-UHFFFAOYSA-N_|_Small molecule_|_False_|_ELRAGLUSIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['9 ing 41' '9-ING-41' '9-ing-41' 'Elraglusib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELRAGLUSIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000691', 'EFO_0009708', 'MONDO_0100342', 'MONDO_0021117',
       'EFO_0003869', 'EFO_0000616', 'EFO_1000350', 'MONDO_0002367',
       'MONDO_0044903'], dtype=object), 'count': 9}_|_[ENSG00000082701]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL1201120,"CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1.Cl_|_WFBMIPUMYUHANP-UHFFFAOYSA-N_|_Small molecule_|_True_|_REMIFENTANIL HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL1005_|_False_|_True_|_['Ultiva']_|_['GI 87084B' 'GI-87084B' 'Remifentanil hcl' 'Remifentanil hydrochloride']_|_[('DailyMed', array(['remifentanil%20hydrochloride'], dtype=object)), ('chEBI', array(['32091'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996. This drug has a black box warning from the FDA."
CHEMBL1201538,"nan_|_nan_|_Protein_|_False_|_INSULIN LISPRO_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Admelog' 'Admelog solostar' 'Humalog' 'Humalog kwikpen' 'Humalog pen'
 'Humalog tempo pen' 'Ins humalog' 'Insulin lispro sanofi']_|_['Insulin Lispro Recombinant' 'Insulin lispro'
 'Insulin lispro recombinant' 'Lyumjev']_|_[('DailyMed', array(['insulin%20lispro', 'insulin%20lispro%20recombinant',
       'insulin%20lispro-aabc'], dtype=object)), ('DrugCentral', array(['5002'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/insulin-lispro-sanofi'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0003074', 'MONDO_0005147', 'EFO_0000400', 'MONDO_0005148'],
      dtype=object), 'count': 4}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for diabetes mellitus and has 3 investigational indications."
CHEMBL146095,"O=C(OCC(O)CO)c1ccccc1Nc1ccnc2cc(Cl)ccc12_|_GWOFUCIGLDBNKM-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLAFENINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Glafenin' 'Glafenine' 'Glaphenine' 'Glycerylaminophenaquine'
 'NSC-757808' 'R 1707' 'R-1707']_|_[('PubChem', array(['26748455'], dtype=object)), ('chEBI', array(['31653'], dtype=object))]_|_['CHEMBL1572751']_|_{'rows': array(['HP_0001945', 'EFO_0003843'], dtype=object), 'count': 2}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain. It was withdrawn in at least one region."
CHEMBL1643880,"O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O_|_AFUWQWYPPZFWCO-LBPRGKRZSA-N_|_Small molecule_|_False_|_PUMOSETRAG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DDP733' 'Pumosetrag']_|_[('drugbank', array(['DB12402'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003948', 'EFO_0000555'], dtype=object), 'count': 2}_|_[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2103799,"CC[C@H](C)CC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1_|_SDDSJMXGJNWMJY-BRHAQHMBSA-N_|_Small molecule_|_False_|_COBIPROSTONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cobiprostone' 'RU-8811' 'SPI-8811']_|_[('drugbank', array(['DB05514'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004607', 'EFO_0000666', 'EFO_1001904'], dtype=object), 'count': 3}_|_[ENSG00000114859]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2103847,"CC(C)C[C@@H](C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1)[C@H](O)C(=O)NO_|_FWFGIHPGRQZWIW-SQNIBIBYSA-N_|_Small molecule_|_False_|_TOSEDOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CHR 2797' 'CHR-2797' 'CHR2797' 'Tosedostat']_|_[('drugbank', array(['DB11781'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000222', 'EFO_0000198', 'EFO_0003060',
       'EFO_0002618'], dtype=object), 'count': 5}_|_[ENSG00000166825,ENSG00000141279,ENSG00000176393,ENSG00000164024,ENSG00000113441,ENSG00000123992,ENSG00000138792,ENSG00000108039,ENSG00000002549,ENSG00000111142,ENSG00000122121,ENSG00000164308,ENSG00000164307,ENSG00000172901,ENSG00000148120,ENSG00000172878,ENSG00000215440,ENSG00000142327,ENSG00000196236]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2103858,"COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)C[C@@H]1OC_|_VGDDOIZXGFJDRC-VJTSUQJLSA-N_|_Small molecule_|_False_|_NARONAPRIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATI-7505' 'ATI7505' 'Naronapride']_|_[('drugbank', array(['DB05542'], dtype=object))]_|_['CHEMBL2105706']_|_{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108025,nan_|_nan_|_Protein_|_False_|_DEPELESTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DX-890' 'Depelestat']_|_nan_|_nan_|_nan_|_[ENSG00000197561]_|_Protein drug with a maximum clinical trial phase of II.
CHEMBL2108287,"nan_|_nan_|_Oligonucleotide_|_False_|_APRINOCARSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Aprinocarsen' 'LY-900003' 'LY900003' 'Ly900003' 'Pkc-alpha']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000154229]_|_Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108305,"nan_|_nan_|_Protein_|_False_|_INSULIN TREGOPIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IN-105' 'Insulin tregopil']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109332,nan_|_nan_|_Antibody_|_False_|_MLNM-2201_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LDP-01' 'MLNM-2201']_|_nan_|_nan_|_nan_|_[ENSG00000160255]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL22108,"CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1_|_MVMQESMQSYOVGV-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIMETHINDENE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dimethpyrindene' 'Dimetindene' 'Feniallerg' 'Forhistal']_|_[('Wikipedia', array(['Dimetindene'], dtype=object)), ('drugbank', array(['DB08801'], dtype=object))]_|_['CHEMBL1870768']_|_{'rows': array(['EFO_0004269', 'MONDO_0005271', 'HP_0000989'], dtype=object), 'count': 3}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for allergic disease and pruritus and has 1 investigational indication."
CHEMBL24,"CC(C)NCC(O)COc1ccc(CC(N)=O)cc1_|_METKIMKYRPQLGS-UHFFFAOYSA-N_|_Small molecule_|_True_|_ATENOLOL_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Antipressan' 'Atenamin' 'Atenix-100' 'Atenix-25' 'Atenix-50' 'Atenolol'
 'Ibinolo' 'Kentol' 'Tenormin' 'Tenormin 25' 'Tenormin l.s.' 'Totamol'
 'Unibloc' 'Vasaten']_|_['Atenolol' 'Atenololum' 'Betacard' 'C07AB03' 'Corotenol' 'Duraatenolol'
 'Esatenolol' 'ICI 66,082' 'ICI 66082' 'ICI-66082' 'Juvental' 'Myocord'
 'NSC-757832' 'Novaten' 'Prenormine' 'Urosin']_|_[('DailyMed', array(['atenolol'], dtype=object)), ('PubChem', array(['144212743', '26751696', '50085956', '50104387', '855957',
       '90340978'], dtype=object)), ('Wikipedia', array(['Atenolol'], dtype=object)), ('drugbank', array(['DB00335'], dtype=object)), ('chEBI', array(['2904'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007947', 'EFO_0007372', 'EFO_0003882', 'EFO_0003896',
       'EFO_0000400', 'EFO_0003763', 'EFO_0003777', 'EFO_0000537',
       'EFO_1001375', 'EFO_0000319', 'EFO_0000612', 'EFO_1000645',
       'EFO_0000712', 'EFO_1000635', 'MONDO_0021661', 'EFO_0003144',
       'EFO_0000275', 'MONDO_0001134', 'EFO_0003913', 'EFO_0001358'],
      dtype=object), 'count': 20}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3186011,"COCC1(CO)C(=O)C2CCN1CC2_|_BGBNULCRKBVAKL-UHFFFAOYSA-N_|_Small molecule_|_False_|_EPRENETAPOPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['APR-246' 'Apr 246' 'Apr-246' 'Eprenetapopt' 'PRIMA-1Met']_|_[('PubChem', array(['174007096'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EPRENETAPOPT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11684'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000198', 'EFO_1001469', 'MONDO_0008170',
       'EFO_0002916', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000141510]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3707348,"CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12_|_WDENQIQQYWYTPO-IBGZPJMESA-N_|_Small molecule_|_False_|_ACALABRUTINIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Calquence']_|_['ACP-196' 'Acalabrutinib' 'Acp-196']_|_[('DailyMed', array(['acalabrutinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/calquence'],
      dtype=object)), ('drugbank', array(['DB11703'], dtype=object))]_|_['CHEMBL4594293']_|_{'rows': array(['MONDO_0001023', 'MONDO_0018906', 'EFO_0000565', 'EFO_0000095',
       'EFO_0000519', 'EFO_0000181', 'EFO_0001378', 'EFO_1001469',
       'EFO_0009441', 'EFO_0003060', 'MONDO_0020547', 'EFO_1001469',
       'MONDO_0100096', 'MONDO_0044881', 'EFO_1001890', 'EFO_0000616',
       'MONDO_0004992', 'EFO_0000096', 'EFO_0000095', 'EFO_0000574',
       'EFO_0000685', 'MONDO_0008170', 'EFO_0002618', 'EFO_0005741',
       'EFO_0005952', 'EFO_0000403'], dtype=object), 'count': 26}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 20 investigational indications."
CHEMBL4297214,"OC(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)(C(F)(F)F)C(F)(F)F_|_CYSJNTQNMDWAJV-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRALICIGUAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IW-1973' 'Praliciguat']_|_nan_|_nan_|_{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297778,"nan_|_nan_|_Antibody drug conjugate_|_False_|_LONCASTUXIMAB TESIRINE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Zynlonta']_|_['ADCT-402' 'ADCT-402 TESIRINE' 'Adct-402 tesirine'
 'Loncastuximab tesirine']_|_nan_|_nan_|_{'rows': array(['EFO_1001938', 'EFO_0000309', 'EFO_1001469', 'EFO_0009441',
       'EFO_0000096', 'EFO_0000616', 'EFO_0000220', 'MONDO_0018906',
       'EFO_0005952', 'EFO_0000403'], dtype=object), 'count': 10}_|_[ENSG00000177455]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 7 investigational indications."
CHEMBL4303241,"COc1cc(S(C)(=O)=O)ccc1Nc1nc2ccc(-c3ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc3)cn2n1_|_NRJKIOCCERLIDG-GOSISDBHSA-N_|_Small molecule_|_False_|_BAY-1161909_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-BAY-1161909' 'BAY 1161909' 'BAY1161909' 'Bay-1161909' 'Empesertib'
 'MPS1-IN-5']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000112742]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL445,"CNCCC=C1c2ccccc2CCc2ccccc21_|_PHVGLTMQBUFIQQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_NORTRIPTYLINE_|_1964.0_|_4.0_|_nan_|_False_|_True_|_['Allegron' 'Aventyl' 'Motipress' 'Motival']_|_['Desitriptilina' 'Lumbeck' 'NCI-169453' 'NSC-757234' 'Noramitriptyline'
 'Nortrilen' 'Nortriptyline' 'Pamelor' 'Sesaval']_|_[('PubChem', array(['11110653', '11110654', '124878449', '152146160', '26747092',
       '26747093', '4253930', '50100156', '50104257', '50104258',
       '90340759'], dtype=object)), ('Wikipedia', array(['Nortriptyline'], dtype=object)), ('drugbank', array(['DB00540'], dtype=object)), ('chEBI', array(['7640'], dtype=object))]_|_['CHEMBL1201156']_|_{'rows': array(['MONDO_0002009', 'EFO_0005230', 'EFO_1000948', 'EFO_0003948',
       'EFO_0000676', 'MONDO_0005090', 'MONDO_0002009', 'EFO_0008533',
       'EFO_0005279', 'EFO_0008524', 'HP_0000726', 'EFO_0000676',
       'EFO_0000555', 'MONDO_0002009', 'MONDO_0002050', 'EFO_0003768',
       'EFO_0000274'], dtype=object), 'count': 17}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4650373,"nan_|_nan_|_Unknown_|_False_|_APELIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apelin']_|_nan_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000134817]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL501259,"CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)(O)O)[C@@H]1OCC[C@@H](CCCCCCC)OC_|_BPSMYQFMCXXNPC-MFCPCZTFSA-N_|_Small molecule_|_False_|_ERITORAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['E5564' 'Eritoran']_|_[('Wikipedia', array(['Eritoran'], dtype=object)), ('drugbank', array(['DB04933'], dtype=object)), ('chEBI', array(['68609'], dtype=object))]_|_['CHEMBL3301672']_|_{'rows': array(['HP_0100806', 'EFO_0007328', 'EFO_0000565', 'EFO_0002614',
       'MONDO_0100096', 'EFO_0003106'], dtype=object), 'count': 6}_|_[ENSG00000136869,ENSG00000154589]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL5095035,"CNC(=O)c1cc(F)c(-c2nc3cc(C)ccn3c2C[C@H]2CN(C(=O)OC)CCO2)c(F)c1_|_SEHLMRJSQFAPCJ-HNNXBMFYSA-N_|_Small molecule_|_False_|_CAMLIPIXANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BLU-5937' 'Blu-5937' 'Camlipixant']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012735'], dtype=object), 'count': 1}_|_[ENSG00000109991]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL898,"O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O_|_HUPFGZXOMWLGNK-UHFFFAOYSA-N_|_Small molecule_|_True_|_DIFLUNISAL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Diflunisal' 'Dolobid' 'Dolobid 500']_|_['Diflunisal' 'NSC-756728']_|_[('DailyMed', array(['diflunisal'], dtype=object)), ('PubChem', array(['11112675', '124882514', '144204149', '170464956', '26746997',
       '855794'], dtype=object)), ('Wikipedia', array(['Diflunisal'], dtype=object)), ('drugbank', array(['DB00861'], dtype=object)), ('chEBI', array(['39669'], dtype=object))]_|_['CHEMBL4745456']_|_{'rows': array(['MONDO_0005148', 'EFO_0003843', 'HP_0001945', 'MONDO_0005178',
       'EFO_0000685', 'EFO_0004129'], dtype=object), 'count': 6}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL946,"CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1_|_SEBMTIQKRHYNIT-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZATADINE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Azatadine' 'Optimine' 'Trinalin']_|_[('PubChem', array(['144206535', '170464865'], dtype=object)), ('Wikipedia', array(['Azatadine'], dtype=object)), ('drugbank', array(['DB00719'], dtype=object)), ('chEBI', array(['2946'], dtype=object))]_|_['CHEMBL3544908']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977 and is indicated for allergic disease."
CHEMBL1200813,"CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1.Cl_|_KTUFKADDDORSSI-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACEBUTOLOL HYDROCHLORIDE_|_1984.0_|_4.0_|_CHEMBL642_|_False_|_True_|_['Acebut hcl' 'Acebutolol hydrochloride' 'Sectral' 'Sectral 200'
 'Sectral 400']_|_['Acebutolol hcl' 'Acebutolol hydrochloride' 'Acetanol' 'B 17803A'
 'B-17803A' 'IL-17803A' 'M&B 17803A' 'M&B-17803A' 'NSC-757412' 'Neptal'
 'Prent']_|_[('DailyMed', array(['acebutolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204184', '170465309', '56424136', '855517'], dtype=object)), ('chEBI', array(['2380'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'HP_0004308'], dtype=object), 'count': 2}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for hypertension and ventricular arrhythmia."
CHEMBL1200822,"CC(=O)O.O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F_|_RKXNZRPQSOPPRN-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLECAINIDE ACETATE_|_1985.0_|_4.0_|_CHEMBL652_|_False_|_True_|_['Flecainide acetate' 'Tambocor']_|_['Flecainide acetate' 'Flecainide monoacetate']_|_[('DailyMed', array(['flecainide%20acetate'], dtype=object)), ('PubChem', array(['144207406', '50106340', '56422486', '855927'], dtype=object)), ('chEBI', array(['5091'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004308', 'EFO_0003843', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000183873]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for ventricular arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200948,"CC(CN(C)C)CN1c2ccccc2CCc2ccccc21.O=C(O)/C=C\C(=O)O_|_YDGHCKHAXOUQOS-BTJKTKAUSA-N_|_Small molecule_|_True_|_TRIMIPRAMINE MALEATE_|_1979.0_|_4.0_|_CHEMBL644_|_False_|_True_|_['Surmontil' 'Trimipramine maleate']_|_['NSC-758386' 'Stangyl' 'Trimipramine maleate']_|_[('DailyMed', array(['trimipramine%20maleate'], dtype=object)), ('PubChem', array(['144204000', '170465260', '26732627', '26747677', '26747678',
       '50107079', '50107080', '50107081'], dtype=object)), ('chEBI', array(['35030'], dtype=object))]_|_nan_|_nan_|_[ENSG00000103546,ENSG00000196639,ENSG00000149295,ENSG00000102468,ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979. This drug has a black box warning from the FDA."
CHEMBL1200973,"C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1_|_UOACKFBJUYNSLK-XRKIENNPSA-N_|_Small molecule_|_True_|_ESTRADIOL CYPIONATE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Depo-estradiol' 'Estradiol cypionate']_|_['Estradiol 17.beta.-cyclopentanepropanoate' 'Estradiol cipionate'
 'Estradiol cypionate' 'NSC-3354']_|_[('DailyMed', array(['estradiol%20cypionate'], dtype=object)), ('PubChem', array(['144203554', '144205884', '144212135', '170464789', '46500620',
       '69855'], dtype=object)), ('drugbank', array(['DB13954'], dtype=object)), ('chEBI', array(['34745'], dtype=object))]_|_nan_|_nan_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979. This drug has a black box warning from the FDA."
CHEMBL1201089,"CN(C)CCOC(c1ccccc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_SPCKHVPPRJWQRZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENHYDRAMINE CITRATE_|_2005.0_|_4.0_|_CHEMBL657_|_False_|_True_|_[]_|_['Diphenhydramine' 'Diphenhydramine citrate'
 'Diphenhydramine laurylsulfate' 'Diphenhydramine tannate']_|_[('DailyMed', array(['diphenhydramine%20citrate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'EFO_0003938'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 2 investigational indications."
CHEMBL1201321,"N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1_|_UFIVBRCCIRTJTN-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIFENOXIN_|_1978.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acscn-9168' 'Difenoxin' 'Diphenoxylate related compound a'
 'Diphenoxylic acid' 'IDS-ND-007' 'Lyspafen' 'MCN-JR-15,403-11'
 'Mcn-jr 15403-11' 'R 15,403 [AS HYDROCHLORIDE]' 'R-15403']_|_[('Wikipedia', array(['Difenoxin'], dtype=object)), ('drugbank', array(['DB01501'], dtype=object)), ('chEBI', array(['4534'], dtype=object))]_|_['CHEMBL1200599']_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978."
CHEMBL134,"Clc1cccc(Cl)c1NC1=NCCN1_|_GJSURZIOUXUGAL-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLONIDINE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_['Catapres' 'Catapres-tts-1' 'Catapres-tts-2' 'Catapres-tts-3' 'Clonidine'
 'Nexiclon xr']_|_['Catapres' 'Catarpres-tts' 'Clonidine' 'Clonidine extended release'
 'Clorpres' 'Combipres' 'Duraclon' 'ST-155-BS' 'ST-155BS']_|_[('DailyMed', array(['clonidine'], dtype=object)), ('PubChem', array(['104171138', '11110984', '11110985', '11113648', '144203669',
       '170464900', '26751841', '90341662'], dtype=object)), ('Wikipedia', array(['Clonidine'], dtype=object)), ('drugbank', array(['DB00575'], dtype=object)), ('chEBI', array(['3757'], dtype=object))]_|_['CHEMBL1705']_|_{'rows': array(['EFO_0005762', 'MONDO_0005041', 'EFO_0002950', 'MONDO_0005299',
       'MONDO_0002959', 'EFO_0005230', 'MONDO_0005277', 'EFO_0007355',
       'EFO_0000274', 'HP_0002307', 'EFO_0002610', 'EFO_0001358',
       'MONDO_0043510', 'EFO_0005252', 'EFO_0003888', 'EFO_0003756',
       'EFO_0004240', 'EFO_0009676', 'MONDO_0004992', 'EFO_0005611',
       'EFO_0003843', 'EFO_0004273', 'EFO_1000783', 'MP_0001914',
       'EFO_0007191', 'EFO_0000537', 'EFO_0009267', 'EFO_0000537',
       'EFO_0003890', 'EFO_1000971', 'EFO_0003888', 'EFO_0005323',
       'EFO_1000645', 'EFO_0005799', 'HP_0003419', 'MONDO_0007254',
       'EFO_0009523', 'EFO_0003843', 'EFO_1001904', 'EFO_0000319'],
      dtype=object), 'count': 40}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1944698,"CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1_|_VXBAJLGYBMTJCY-NSCUHMNNSA-N_|_Small molecule_|_False_|_ZOTIRACICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EX45' 'Ex 45' 'SB-1317' 'SB1317' 'Sb-1317 free base' 'TG02' 'Tg-02'
 'Tg02' 'Zotiraciclib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZOTIRACICLIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4298173']_|_{'rows': array(['EFO_0000182', 'MONDO_0002334', 'EFO_0000616', 'EFO_0000095',
       'EFO_0000616', 'EFO_1001465', 'MONDO_0002334', 'EFO_0000519',
       'EFO_1000657'], dtype=object), 'count': 9}_|_[ENSG00000136807,ENSG00000170312,ENSG00000122025,ENSG00000096968,ENSG00000123374,ENSG00000134058]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL2107572,"COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1.Cl_|_YJXUXANREVNZLH-PFEQFJNWSA-N_|_Small molecule_|_False_|_TECALCET HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL292376_|_False_|_False_|_['Norcalin']_|_['KRN-568' 'NPS R-568' 'NPS-R-568' 'NPSR-568' 'R-568' 'Tecalcet hcl'
 'Tecalcet hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2107829,Cl.NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1_|_BPZWRYOUJMDQSY-PKLMIRHRSA-N_|_Small molecule_|_False_|_EMIXUSTAT HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL2107821_|_False_|_False_|_['Acu-4429 hcl']_|_['ACU-4429 HCL' 'ACU-4429 HYDROCHLORIDE' 'Emixustat hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000116745]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2109377,"nan_|_nan_|_Antibody_|_False_|_PAMREVLUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['FG-3019' 'Pamrevlumab']_|_nan_|_nan_|_{'rows': array(['EFO_0004239', 'EFO_0000400', 'EFO_0002618', 'EFO_0004236',
       'EFO_0000768', 'MONDO_0010679', 'MONDO_0100096'], dtype=object), 'count': 7}_|_[ENSG00000118523]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2109623,"nan_|_nan_|_Antibody_|_False_|_STX-100_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['STX-100' 'Stx-100']_|_nan_|_nan_|_{'rows': array(['EFO_0000768'], dtype=object), 'count': 1}_|_[ENSG00000138448,ENSG00000115221]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3544949,CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CCCCN)C(C)C)C(N)=O_|_VUYRSKROGTWHDC-HZGLMRDYSA-N_|_Protein_|_False_|_CTCE-9908_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CTCE 9908' 'Ctce-9908']_|_nan_|_nan_|_nan_|_[ENSG00000121966]_|_Protein drug with a maximum clinical trial phase of II.
CHEMBL3545394,nan_|_nan_|_Small molecule_|_False_|_DRF-10945_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Drf-10945']_|_nan_|_nan_|_nan_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3668014,"COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F_|_BMAAMIIYNNPHAB-UHFFFAOYSA-N_|_Small molecule_|_False_|_LINZAGOLIX_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['KLH-2109' 'Klh-2109' 'Linzagolix' 'OBE-2109' 'OBE2109']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINZAGOLIX/relevant/1/'],
      dtype=object))]_|_['CHEMBL4298171']_|_{'rows': array(['HP_0000131', 'HP_0000131', 'EFO_0001421', 'EFO_0000731',
       'EFO_0003086', 'EFO_0001065', 'EFO_0001065'], dtype=object), 'count': 7}_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for uterine leiomyoma and has 6 investigational indications."
CHEMBL3989986,"nan_|_nan_|_Antibody_|_True_|_RAVULIZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Ultomiris']_|_['ALXN-1210' 'ALXN1210' 'Ravulizumab' 'Ravulizumab cwvz']_|_[('DailyMed', array(['ravulizumab-cwvz'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007541', 'EFO_0000398', 'MONDO_0016244', 'MONDO_0004976',
       'EFO_0004610', 'MONDO_0001549', 'EFO_0000540', 'EFO_1000637',
       'MONDO_0019737', 'MONDO_0100244', 'EFO_0004991', 'EFO_0004256'],
      dtype=object), 'count': 12}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL493,"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12_|_OZVBMTJYIDMWIL-AYFBDAFISA-N_|_Small molecule_|_False_|_BROMOCRIPTINE_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Parlodel']_|_['2-bromo-.alpha.-ergocryptine' 'Bromergocryptine' 'Bromocriptine'
 'CB-154' 'Ergocryptine, 2-bromo-' 'SANDOZ 15-754']_|_[('PubChem', array(['144204458', '26751716', '26755307', '90340796'], dtype=object)), ('Wikipedia', array(['Bromocriptine'], dtype=object)), ('drugbank', array(['DB01200'], dtype=object)), ('chEBI', array(['3181'], dtype=object))]_|_['CHEMBL1255752' 'CHEMBL1200503']_|_{'rows': array(['EFO_0000232', 'MONDO_0005351', 'MONDO_0002146', 'EFO_0000545',
       'EFO_1001757', 'MONDO_0005180', 'MONDO_0005180', 'HP_0001249',
       'MONDO_0005148', 'MONDO_0004975', 'MONDO_0011972', 'MONDO_0005147',
       'EFO_0001073', 'EFO_1001485', 'EFO_0007319'], dtype=object), 'count': 15}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 7 investigational indications."
CHEMBL549344,"CCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O_|_YZOQZEXYFLXNKA-UHFFFAOYSA-N_|_Small molecule_|_False_|_CPG-52852_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cpg-52852' 'PF-4878691']_|_[('drugbank', array(['DB12476'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000389', 'EFO_0000616', 'EFO_0000756'], dtype=object), 'count': 3}_|_[ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL608,"CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1_|_FYPMFJGVHOHGLL-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROBUCOL_|_1977.0_|_4.0_|_nan_|_True_|_True_|_['Bisbid' 'Lorelco' 'Lurselle' 'Probucol' 'Sinlestal']_|_['DH-581' 'NSC-652160' 'NSC-86225' 'Probucol']_|_[('PubChem', array(['11112687', '123183', '124882521', '144204156', '170464772',
       '26748484', '50107410', '8139943'], dtype=object)), ('Wikipedia', array(['Probucol'], dtype=object)), ('drugbank', array(['DB01599'], dtype=object)), ('chEBI', array(['8427'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'MONDO_0021187', 'EFO_0004265', 'EFO_0000319'],
      dtype=object), 'count': 4}_|_[ENSG00000165029]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for cardiovascular disease and has 3 investigational indications. It was withdrawn in at least one region."
CHEMBL75133,"CC(/C=C/[C@@H]1C[C@]1(C)c1ccc2c(c1)C(C)(C)CCC2(C)C)=C\C(=O)O_|_BOOOLEGQBVUTKC-NVQSDHBMSA-N_|_Small molecule_|_False_|_IRX-4204_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGN-194204' 'AGN194204' 'Irx-4204' 'KB-145960' 'NRX-194204' 'NRX194204'
 'VTP-194204']_|_[('drugbank', array(['DB11806'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0005180'],
      dtype=object), 'count': 4}_|_[ENSG00000204231,ENSG00000143171,ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL91829,"CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1_|_ZCBUQCWBWNUWSU-SFHVURJKSA-N_|_Small molecule_|_False_|_RUBOXISTAURIN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Arxxant']_|_['LY-333531' 'Ly-333531' 'Ruboxistaurin']_|_[('PubChem', array(['50100106'], dtype=object)), ('Wikipedia', array(['Ruboxistaurin'], dtype=object)), ('drugbank', array(['DB11829'], dtype=object))]_|_['CHEMBL5307356' 'CHEMBL432130']_|_{'rows': array(['EFO_0003770', 'MONDO_0005147', 'EFO_1000783', 'EFO_0003144',
       'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 6}_|_[ENSG00000166501]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1201562,"nan_|_nan_|_Protein_|_False_|_INTERFERON BETA-1A_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Avonex' 'Rebif']_|_['Interferon beta-1a' 'SNG-001' 'SNG001' 'Sng001']_|_[('DailyMed', array(['interferon%20beta-1a'], dtype=object)), ('DrugCentral', array(['5139'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/avonex'],
      dtype=object)), ('Wikipedia', array(['Interferon_beta-1a'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000384', 'MONDO_0100130', 'EFO_1001373', 'EFO_0003929',
       'EFO_0000616', 'EFO_0000729', 'EFO_0000712', 'EFO_0003047',
       'EFO_0003106', 'MONDO_0004979', 'MONDO_0004975', 'EFO_1000868',
       'EFO_0007328', 'MONDO_0005301', 'MONDO_0100096', 'EFO_0000341'],
      dtype=object), 'count': 16}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for neoplasm and multiple sclerosis and has 14 investigational indications."
CHEMBL1201774,"C[C@H](O)[C@H](O)[C@H]1CNc2nc(N)[nH]c(=O)c2N1_|_FNKQXYHWGSIFBK-RPDRRWSUSA-N_|_Small molecule_|_False_|_SAPROPTERIN_|_2007.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['6r-bh4' 'Dapropterin' 'Daproterin' 'R-thbp' 'Sapropterin'
 'Tetrahydrobiopterin']_|_[('Wikipedia', array(['Tetrahydrobiopterin'], dtype=object)), ('drugbank', array(['DB00360'], dtype=object)), ('chEBI', array(['59560'], dtype=object))]_|_['CHEMBL1201775' 'CHEMBL1515624']_|_{'rows': array(['MONDO_0010298', 'MONDO_0005090', 'MONDO_0043771', 'EFO_0000537',
       'Orphanet_238583', 'EFO_0000181', 'EFO_0003884', 'EFO_0003144',
       'EFO_0001645', 'EFO_0003876', 'EFO_0003884', 'EFO_0000341',
       'EFO_0001361', 'EFO_0003758', 'MONDO_0004975', 'EFO_0005411',
       'MONDO_0043579', 'MONDO_0011382', 'MONDO_0009861', 'EFO_0000666',
       'MONDO_0009861', 'EFO_0001422', 'EFO_0000537'], dtype=object), 'count': 23}_|_[ENSG00000171759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hyperphenylalaninemia and phenylketonuria and has 20 investigational indications."
CHEMBL1624,"N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O_|_XUIIKFGFIJCVMT-LBPRGKRZSA-N_|_Small molecule_|_True_|_LEVOTHYROXINE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['L-thyroxine' 'Levothyroxin' 'Levothyroxine' 'NSC-36397'
 'Synthetic levothyroxine' 'Thyroxine, l-']_|_[('PubChem', array(['144205654', '144212473', '170465450', '26757755', '8139892'],
      dtype=object)), ('Wikipedia', array(['Levothyroxine'], dtype=object)), ('drugbank', array(['DB00451'], dtype=object)), ('chEBI', array(['18332'], dtype=object))]_|_['CHEMBL3989492' 'CHEMBL2103741' 'CHEMBL3989736']_|_{'rows': array(['Orphanet_309005', 'EFO_0000400', 'MONDO_0018612', 'EFO_0004705',
       'EFO_0002892', 'EFO_0004705', 'EFO_0004237', 'MONDO_0018612',
       'EFO_0003843', 'EFO_1002017', 'MONDO_0004985', 'EFO_0002950',
       'MONDO_0002108'], dtype=object), 'count': 13}_|_[ENSG00000126351,ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2107846,"nan_|_nan_|_Protein_|_False_|_DULANERMIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-951' 'APO2L/TRAIL' 'B lymphocyte stimulator (human)' 'Dulanermin']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0005952', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000104689,ENSG00000120889]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109036,"nan_|_nan_|_Antibody_|_False_|_IGOVOMAB_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Inadmacis-125' 'Indimacis 125']_|_['Igovomab' 'OC-125']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/indimacis-125'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003893', 'EFO_0006887'], dtype=object), 'count': 2}_|_[ENSG00000181143]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for ovarian neoplasm and radiologic finding."
CHEMBL2109281,"nan_|_nan_|_Antibody drug conjugate_|_False_|_RG-7600_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['DMOT4039A' 'RG-7600']_|_nan_|_nan_|_nan_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000102854]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I."
CHEMBL2109381,"nan_|_nan_|_Antibody_|_False_|_BHQ-880_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BHQ-880' 'BHQ880' 'Bhq-880']_|_nan_|_nan_|_{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}_|_[ENSG00000107984]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109450,"nan_|_nan_|_Antibody_|_False_|_AMG-811_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-811' 'Amg-811']_|_nan_|_nan_|_{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}_|_[ENSG00000111537]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL226267,"COc1ccc(-c2sc3cc(O)ccc3c2Oc2ccc(OCCN3CCCCC3)cc2)cc1_|_MCGDSOGUHLTADD-UHFFFAOYSA-N_|_Small molecule_|_False_|_ARZOXIFENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Arzoxifene' 'LY-353381' 'LY353381']_|_[('Wikipedia', array(['Arzoxifene'], dtype=object)), ('drugbank', array(['DB06249'], dtype=object))]_|_['CHEMBL2105949']_|_{'rows': array(['MONDO_0008170', 'MONDO_0007254', 'MONDO_0011962', 'EFO_0003854',
       'EFO_0003869', 'Orphanet_145', 'MONDO_0002087', 'EFO_0003882',
       'MONDO_0007254'], dtype=object), 'count': 9}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2364655,"nan_|_nan_|_Antibody_|_False_|_EVOLOCUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Repatha' 'Repatha sureclick']_|_['AMG-145' 'Evolocumab']_|_[('DailyMed', array(['evolocumab'], dtype=object)), ('DrugCentral', array(['5000'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/repatha'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0000319', 'EFO_0003144', 'MONDO_0018328',
       'HP_0003124', 'EFO_0000519', 'EFO_0003060', 'EFO_0008585',
       'EFO_0001645', 'HP_0003119', 'MONDO_0008903', 'Orphanet_79211',
       'MONDO_0100096', 'Orphanet_309005', 'EFO_0005672', 'EFO_0000612',
       'MONDO_0021187', 'HP_0100806', 'EFO_0004911'], dtype=object), 'count': 19}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 8 approved and 11 investigational indications."
CHEMBL2442750,"Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1_|_YOPFAMROKXHVCQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_QAV680_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NVP-QAV680' 'Nvp-qav-680' 'QAV680' 'QAV690 FREE ACID' 'Qav-680'
 'Qav-690 free acid' 'Qav680']_|_[('drugbank', array(['DB11658'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003956', 'EFO_0005854', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3408947,"COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2_|_DADASRPKWOGKCU-FVTQAUBDSA-N_|_Small molecule_|_False_|_OCIFISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ocifisertib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_['CHEMBL4297462']_|_{'rows': array(['EFO_0000616', 'MONDO_0008315', 'MONDO_0004992', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000142731]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3545063,"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.CS(=O)(=O)O_|_FUKSNUHSJBTCFJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_OSIMERTINIB MESYLATE_|_2015.0_|_4.0_|_CHEMBL3353410_|_False_|_True_|_['Tagrisso']_|_['AZD-9291 MESYLATE' 'AZD9291 mesylate' 'Mereletinib mesilate'
 'Mereletinib mesylate' 'Osimertinib mesilate' 'Osimertinib mesylate']_|_[('DailyMed', array(['osimertinib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0008903'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for non-small cell lung carcinoma and has 1 investigational indication."
CHEMBL3545166,"CS(=O)(=O)N(c1cc(F)cc(F)c1)C1CN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)C1_|_IQQBRKLVEALROM-UHFFFAOYSA-N_|_Small molecule_|_False_|_DRINABANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ave1625' 'Drinabant']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3833346,"nan_|_nan_|_Oligonucleotide_|_False_|_TOFERSEN_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Qalsody']_|_['BIIB-067' 'BIIB067' 'ISIS-SOD1Rx' 'Tofersen']_|_nan_|_nan_|_{'rows': array(['MONDO_0004976'], dtype=object), 'count': 1}_|_[ENSG00000142168]_|_Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for amyotrophic lateral sclerosis."
CHEMBL3942498,"C#CCNc1nc(-n2cncn2)nc(N)c1Br_|_OQCWNHHZPYJHQR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PBF-999_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PBF999' 'Pbf 999' 'Pbf-999']_|_nan_|_nan_|_{'rows': array(['MONDO_0007739', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000128271,ENSG00000112541]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3989509,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C.CC(O)C(=O)O_|_QNLDTXPVZPRSAM-UHFFFAOYSA-N_|_Small molecule_|_True_|_PENTAZOCINE LACTATE_|_1967.0_|_4.0_|_CHEMBL100116_|_False_|_True_|_['Talwin']_|_['Pentazocine lactate' 'Talwin (lactate)']_|_nan_|_nan_|_nan_|_[ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967. This drug has a black box warning from the FDA.
CHEMBL3989724,"CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl_|_ZIIJJOPLRSCQNX-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLURAZEPAM HYDROCHLORIDE_|_1970.0_|_4.0_|_CHEMBL968_|_False_|_True_|_['Dalmane' 'Flurazepam hydrochloride']_|_['Flurazepam' 'Flurazepam dihydrochloride' 'Flurazepam hydrochloride'
 'Flurazepam hydrochloride civ' 'NSC-78559' 'RO 5-6901' 'RO-5-6901']_|_[('DailyMed', array(['flurazepam%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970 and is indicated for insomnia. This drug has a black box warning from the FDA."
CHEMBL3989845,"CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O_|_BPQZYOJIXDMZSX-UHFFFAOYSA-N_|_Small molecule_|_True_|_IMIPRAMINE PAMOATE_|_1973.0_|_4.0_|_CHEMBL11_|_False_|_True_|_['Imipramine pamoate' 'Tofranil-pm']_|_['Imipramine embonate']_|_[('DailyMed', array(['imipramine%20pamoate'], dtype=object))]_|_nan_|_nan_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973. This drug has a black box warning from the FDA."
CHEMBL419213,"NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O_|_CZRQXSDBMCMPNJ-ZUIPZQNBSA-N_|_Small molecule_|_True_|_LISINOPRIL_|_1987.0_|_4.0_|_CHEMBL1237_|_False_|_True_|_['Acemin' 'Carace' 'Lisinopril' 'Lisopress' 'Prinivil' 'Qbrelis' 'Zestril']_|_['Lisinopril' 'Lisinopril dihydrate' 'Lisinopril hydrate' 'MK-521'
 'NSC-751176' 'NSC-758151' 'Ranolip']_|_[('DailyMed', array(['lisinopril'], dtype=object)), ('PubChem', array(['11113057', '170464907'], dtype=object)), ('chEBI', array(['6503'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000373', 'EFO_0000612', 'EFO_0000712',
       'EFO_0000400', 'EFO_0003144', 'EFO_0000319'], dtype=object), 'count': 7}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved indications. This drug has a black box warning from the FDA."
CHEMBL4297768,"nan_|_nan_|_Oligosaccharide_|_False_|_IDRABIOTAPARINUX SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Idrabiotaparinux sodium']_|_nan_|_nan_|_{'rows': array(['EFO_0003907', 'MONDO_0000831', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000126218]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4302409,"nan_|_nan_|_Protein_|_False_|_LUTETIUM OXODOTREOTIDE_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[]_|_nan_|_['CHEMBL4297545']_|_{'rows': array(['EFO_1000045', 'MONDO_0002120', 'EFO_0000305', 'MONDO_0020634',
       'EFO_0000621', 'MONDO_0016642', 'MONDO_0024503', 'EFO_1001901',
       'EFO_1001471', 'EFO_0007416'], dtype=object), 'count': 10}_|_[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for pancreatic neuroendocrine tumor and neuroendocrine neoplasm and has 8 investigational indications."
CHEMBL448343,"NC[C@@H](F)C[PH](=O)O_|_LJNUIEQATDYXJH-GSVOUGTGSA-N_|_Small molecule_|_False_|_LESOGABERAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-3355' 'AZD3355' 'Azd3355' 'Lesogaberan']_|_[('Wikipedia', array(['Lesogaberan'], dtype=object)), ('drugbank', array(['DB11920'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}_|_[ENSG00000136928,ENSG00000204681]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650332,"O=C([C@H](CO)c1ccccc1)N1CC2=C(C1)CN(S(=O)(=O)c1cnc3c(c1)OCCO3)C2_|_KZFFYEPYCVDOGE-LJQANCHMSA-N_|_Small molecule_|_False_|_ETAVOPIVAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Etavopivat' 'FT-4202' 'Ft-4202']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETAVOPIVAT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'MONDO_0011382'], dtype=object), 'count': 2}_|_[ENSG00000143627]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL495727,"O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1_|_LOLPPWBBNUVNQZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_AT-9283_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AT-9283' 'AT9283' 'At 9283' 'At-9283']_|_nan_|_['CHEMBL496311']_|_{'rows': array(['EFO_0001378', 'EFO_0000616', 'EFO_0005952', 'EFO_0000565'],
      dtype=object), 'count': 4}_|_[ENSG00000096968,ENSG00000087586,ENSG00000105639,ENSG00000097007,ENSG00000178999,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL5314357,"nan_|_nan_|_Antibody_|_False_|_ETARACIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Abegrin' 'Abegrin vitaxin']_|_['ETARATUZUMAB' 'Etaracizumab' 'HLM60' 'MEDI-522' 'Vitaxin']_|_nan_|_nan_|_{'rows': array(['EFO_0000676', 'MONDO_0008315', 'EFO_1001951', 'EFO_0002617',
       'EFO_0000685', 'EFO_0000756', 'MONDO_0004992', 'EFO_0000681'],
      dtype=object), 'count': 8}_|_[ENSG00000259207,ENSG00000138448]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL611,"COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC_|_VCKUSRYTPJJLNI-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERAZOSIN_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hytrin' 'Terazosabb' 'Terazosin']_|_[('PubChem', array(['174007477', '50085853', '855611', '90340975'], dtype=object)), ('Wikipedia', array(['Terazosin'], dtype=object)), ('drugbank', array(['DB01162'], dtype=object)), ('chEBI', array(['9445'], dtype=object))]_|_['CHEMBL1201091' 'CHEMBL3989562' 'CHEMBL1256665']_|_{'rows': array(['EFO_0003914', 'EFO_0000284', 'MONDO_0005180', 'HP_0000726',
       'MONDO_0005148', 'EFO_0000284', 'EFO_0000537', 'EFO_0001645',
       'EFO_0002615', 'HP_0003124'], dtype=object), 'count': 10}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for benign prostatic hyperplasia and has 8 investigational indications."
CHEMBL1090488,"C[C@@H]1CN(C(=O)[C@@H]2CN(C(C)(C)C)C[C@H]2c2ccc(F)cc2F)C[C@H](C)[C@@]1(O)c1ccccc1_|_WHPJOAUPIZDJNX-AGGGUQDCSA-N_|_Small molecule_|_False_|_PF-00446687_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-PF-00446687' 'Pf-00446687']_|_[('drugbank', array(['DB12517'], dtype=object))]_|_['CHEMBL1204059']_|_{'rows': array(['EFO_0004234', 'EFO_0004714'], dtype=object), 'count': 2}_|_[ENSG00000166603]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1200671,"CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O_|_FUCZIEGYURIPAY-CFWZQLQRSA-N_|_Protein_|_False_|_NAFARELIN ACETATE_|_1990.0_|_4.0_|_CHEMBL1201309_|_False_|_True_|_['Synarel']_|_['Nafarelin acetate' 'Nafarelin acetate anhydrous'
 'Nafarelin acetate hydrate' 'Nasanyl' 'RS-94991' 'RS-94991-298']_|_[('DailyMed', array(['nafarelin%20acetate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001065'], dtype=object), 'count': 1}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for endometriosis."
CHEMBL1201265,"C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)O)[C@@]2(C)C=CC(=O)C=C12_|_IMBXEJJVJRTNOW-XYMSELFBSA-N_|_Small molecule_|_False_|_METHYLPREDNISOLONE HEMISUCCINATE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Methylprednisolone hemisuccinate' 'Methylprednisolone succinate']_|_[('PubChem', array(['124896649'], dtype=object)), ('drugbank', array(['DB14644'], dtype=object))]_|_['CHEMBL1201081']_|_{'rows': array(['EFO_0003929', 'EFO_0000694', 'EFO_0000768', 'EFO_0008522',
       'MONDO_0007915', 'MONDO_0002280', 'EFO_0000095', 'EFO_0000685',
       'EFO_1001222', 'EFO_0000540', 'MONDO_0002135', 'MONDO_0002406',
       'MONDO_0005301', 'MONDO_0100096', 'MONDO_0013730', 'MONDO_0005301',
       'EFO_0000220', 'EFO_0003106', 'EFO_0003843', 'MONDO_0002462',
       'EFO_0003840', 'EFO_0000198', 'EFO_0004194', 'EFO_1001272',
       'EFO_0000574', 'MONDO_0004979', 'EFO_0004599', 'EFO_0000565',
       'EFO_0005952', 'EFO_0007359', 'EFO_0007332', 'EFO_0007537',
       'EFO_0004228', 'EFO_0001378', 'EFO_0000222', 'EFO_0000474',
       'EFO_0001063'], dtype=object), 'count': 37}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 8 approved and 29 investigational indications."
CHEMBL1201419,"nan_|_nan_|_Protein_|_False_|_LUTROPIN ALFA_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Luveris']_|_['ATC G03 GA GONADOTROPINS' 'Luteinising hormone'
 'Luteinising hormone (human)' 'Lutropin alfa']_|_[('DrugCentral', array(['4929'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/luveris'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000545', 'EFO_0008560', 'GO_0060279', 'MONDO_0002146'],
      dtype=object), 'count': 4}_|_[ENSG00000138039]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for female infertility and positive regulation of ovulation and has 2 investigational indications."
CHEMBL1201717,"nan_|_nan_|_Protein_|_False_|_MECASERMIN RINFABATE_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Iplex']_|_['Mecasermin Rinfabate Recombinant' 'Mecasermin rinfabate'
 'Mecasermin rinfabate recombinant' 'RHIGF-I/RHIGFBP-3']_|_[('DrugCentral', array(['5197'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_273', 'MONDO_0016107', 'MONDO_0009877', 'EFO_1001158'],
      dtype=object), 'count': 4}_|_[ENSG00000140443]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 investigational indications."
CHEMBL1230065,"CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C_|_GDTQLZHHDRRBEB-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-582949_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-582949' 'Bms 582949' 'Bms-582949' 'PS-540446' 'Ps-540446']_|_[('drugbank', array(['DB12696'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0004264', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1237102,"C[C@@H]1CN([C@H]2CC[C@](C#N)(c3ccc(F)cc3)CC2)CC[C@]1(C(=O)O)c1ccccc1.Cl_|_OICFWWJHIMKBCD-VALQNVSPSA-N_|_Small molecule_|_False_|_LEVOCABASTINE HYDROCHLORIDE_|_1993.0_|_4.0_|_CHEMBL1615438_|_False_|_True_|_['Livostin']_|_['Levocabastine hcl' 'Levocabastine hydrochloride' 'R 50,547' 'R-50547']_|_[('PubChem', array(['144204246', '170465061', '56463149'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001417'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993 and has 1 investigational indication."
CHEMBL1364144,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_PLBHSZGDDKCEHR-LFYFAGGJSA-N_|_Small molecule_|_False_|_METHYLPREDNISOLONE ACETATE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Depmedalone' 'Depo-medrol' 'Depo-medrone' 'M-predrol' 'Medrol acetate'
 'Methylprednisolone acetate' 'Neo-medrone']_|_['Methyl prednisolone acetate' 'Methylprednisolone 21-acetate'
 'Methylprednisolone acetate' 'NSC-48985']_|_[('DailyMed', array(['methylprednisolone%20acetate'], dtype=object)), ('PubChem', array(['144205275', '50085428'], dtype=object)), ('chEBI', array(['6889'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000941', 'EFO_1001222', 'EFO_0000565', 'EFO_1001896',
       'EFO_0003833', 'EFO_0004255', 'EFO_0003843', 'HP_0003419',
       'EFO_0005762', 'EFO_0004274', 'MONDO_0004979', 'EFO_1001178',
       'MONDO_0002041', 'MONDO_0002406', 'MONDO_0002280', 'EFO_0007405',
       'EFO_0000685', 'MONDO_0005178', 'EFO_1001231', 'HP_0012532',
       'EFO_0000574'], dtype=object), 'count': 21}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 13 approved and 8 investigational indications."
CHEMBL1764,"COc1ccc2c(c1)N(C[C@H](C)CN(C)C)c1ccccc1S2_|_VRQVVMDWGGWHTJ-CQSZACIVSA-N_|_Small molecule_|_False_|_LEVOMEPROMAZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Levomepromazine' 'Levoprome' 'Nirvan' 'Tisercin']_|_['CL 36467' 'CL 39743' 'CL-36467' 'CL-39743' 'Levomepromazine'
 'Methotrimeprazine' 'N05AA02' 'NSC-226516' 'Neozine' 'Nirvan' 'RP 7044'
 'RP-7044' 'SK&F 5116' 'SK&F-5116' 'XP-03' 'XP03']_|_[('Wikipedia', array(['Levomepromazine'], dtype=object)), ('drugbank', array(['DB01403'], dtype=object)), ('chEBI', array(['6838'], dtype=object))]_|_['CHEMBL2104973' 'CHEMBL1725730']_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0005407', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for psychosis and has 4 investigational indications."
CHEMBL1922235,"COc1ccc(C(=O)Nc2cccc(O)c2NC(=O)c2ccc(N3CCCN(C)CC3)cc2)cc1_|_IJNIQYINMSGIPS-UHFFFAOYSA-N_|_Small molecule_|_False_|_DAREXABAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Darexaban' 'Tanexaban' 'YM-150' 'YM150']_|_[('drugbank', array(['DB12289'], dtype=object))]_|_['CHEMBL1922345' 'CHEMBL3527359']_|_{'rows': array(['EFO_0004286', 'EFO_0000275', 'HP_0001907', 'EFO_0005672'],
      dtype=object), 'count': 4}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2019090,"CCc1c(C)cc(C(=O)NC2(C(=O)O)CCCCC2)c(=O)n1Cc1ccc(F)cc1_|_JIYXOJFSPOFZPY-UHFFFAOYSA-N_|_Small molecule_|_False_|_S-777469_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['S-777469']_|_nan_|_nan_|_{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}_|_[ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2104449,"CC(=O)N(O)CC1=C(n2ccccc2=O)c2cc(C(F)(F)F)ccc2OC1(C)C_|_FXRJKZVWFJSKGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_SARAKALIM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RS-91309' 'Sarakalim']_|_nan_|_nan_|_nan_|_[ENSG00000187486,ENSG00000069431,ENSG00000006071,ENSG00000121361]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2108658,"nan_|_nan_|_Antibody_|_False_|_TREMELIMUMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Imjudo']_|_['CP-675,206' 'CP-675206' 'PF-06753388' 'TICILIMUMAB' 'Tremelimumab'
 'Tremelimumab (genetical recombination)' 'Tremelimumab actl']_|_nan_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0000514', 'EFO_0000501', 'MONDO_0008315',
       'EFO_0000691', 'EFO_0000181', 'EFO_0000349', 'MONDO_0004992',
       'EFO_0003863', 'MONDO_0008903', 'EFO_0000503', 'EFO_0001075',
       'MONDO_0001187', 'EFO_0000681', 'EFO_0001378', 'MONDO_0002158',
       'EFO_0000702', 'EFO_0000764', 'EFO_0005221', 'EFO_0001642',
       'EFO_0000305', 'EFO_0003060', 'MONDO_0007576', 'EFO_1001100',
       'EFO_0005537', 'EFO_0000403', 'MONDO_0008170', 'MONDO_0003060',
       'EFO_0000365', 'MONDO_0003001', 'EFO_0000182', 'EFO_0003891',
       'MONDO_0002108', 'EFO_0000198', 'EFO_0000756', 'EFO_0008528',
       'EFO_0004142', 'MONDO_0044704', 'EFO_0000199', 'EFO_0000673',
       'EFO_0000574', 'EFO_1000251', 'EFO_0000616', 'EFO_0000389',
       'MONDO_0021148', 'EFO_0000641', 'MONDO_0005184', 'MONDO_0007254',
       'EFO_0000708', 'EFO_1001961', 'EFO_0004284', 'EFO_0000519',
       'EFO_0002618', 'EFO_0000588', 'MONDO_0001056', 'EFO_1001951',
       'EFO_1001968', 'EFO_0005220', 'MONDO_0003002'], dtype=object), 'count': 59}_|_[ENSG00000163599]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 56 investigational indications."
CHEMBL2109171,"nan_|_nan_|_Protein_|_False_|_DIBOTERMIN ALFA_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Inductos']_|_['Dibotermin' 'Dibotermin alfa' 'Inductos' 'Nebotermin' 'Rhbmp-2']_|_[('DrugCentral', array(['5024'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inductos'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004260', 'HP_0000689', 'EFO_0003931', 'EFO_0003957',
       'EFO_0003944', 'MONDO_0005178'], dtype=object), 'count': 6}_|_[ENSG00000107779,ENSG00000115170,ENSG00000121989,ENSG00000114739,ENSG00000138696,ENSG00000204217]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for bone disease and tibia fracture and has 4 investigational indications."
CHEMBL2109322,"nan_|_nan_|_Antibody_|_False_|_AMG-820_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-820' 'AMG820' 'Amg 820' 'Amg-820']_|_nan_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_1001951', 'EFO_0003060', 'MONDO_0004992'],
      dtype=object), 'count': 4}_|_[ENSG00000182578]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL2220486,"CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12_|_CUDVHEFYRIWYQD-UHFFFAOYSA-N_|_Small molecule_|_False_|_LUCITANIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AL-3810' 'Al-3810' 'CO-3810' 'E-3810' 'Lucitanib' 'S 80881' 'S-80881']_|_[('drugbank', array(['DB11845'], dtype=object)), ('chEBI', array(['65209'], dtype=object))]_|_['CHEMBL2180605']_|_{'rows': array(['EFO_0000702', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254',
       'MONDO_0021148', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000077782,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL235191,"CC(=O)Nc1ccc(C(=O)Nc2ccccc2N)cc1_|_VAZAPHZUAVEOMC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TACEDINALINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CI-994' 'GOE 5549' 'GOE-5549' 'PD 123654' 'PD-123654' 'Tacedinaline']_|_[('drugbank', array(['DB12291'], dtype=object)), ('chEBI', array(['90195'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'MONDO_0008903', 'EFO_0002618'], dtype=object), 'count': 3}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL294199,"COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O_|_YKPUWZUDDOIDPM-SOFGYWHQSA-N_|_Small molecule_|_False_|_CAPSAICIN_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Qutenza' 'Zacin' 'Zostrix' 'Zostrix hp']_|_['ALGRX 4975' 'ALGRX-4975' 'Ausanil' 'Axsain' 'Capsaicin' 'Capzasin-hp'
 'Cntx-4975' 'Dolenon' 'FEMA NO. 3404' 'Mioton' 'NGX-1998' 'NGX-4010'
 'NSC-56353' 'Ngx-1998' 'Ovocap' 'Ratden pe 40' 'Togarashi orenji'
 'Trans-capsaicin']_|_[('DailyMed', array(['capsaicin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza'],
      dtype=object)), ('PubChem', array(['104171351', '124883045', '124883047', '124883049', '124883050',
       '124890089', '144204368', '144207513', '17389996', '26747263',
       '26752818', '26752819', '26752820', '50105473', '56463572'],
      dtype=object)), ('Wikipedia', array(['Capsaicin'], dtype=object)), ('drugbank', array(['DB06774'], dtype=object)), ('chEBI', array(['3374'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000989', 'EFO_0001361', 'EFO_0000764', 'EFO_0003843',
       'EFO_0009364', 'MONDO_0043510', 'EFO_0006859', 'EFO_0009430',
       'EFO_0009387', 'EFO_0005762', 'HP_0002829', 'EFO_1000941',
       'MONDO_0041052', 'MONDO_0001583', 'EFO_1001434', 'HP_0003394',
       'HP_0002013', 'EFO_0003100', 'EFO_0006911', 'EFO_1001896',
       'EFO_1000783', 'EFO_0009619', 'EFO_0009625', 'EFO_0004616',
       'EFO_1001054', 'EFO_0003913', 'EFO_0000712', 'EFO_0006510',
       'MONDO_0005178', 'HP_0003418', 'MONDO_0005277', 'MONDO_0007254',
       'HP_0012735', 'EFO_0000319', 'EFO_0005856', 'EFO_0010582',
       'EFO_0009582', 'HP_0003326', 'MONDO_0004976'], dtype=object), 'count': 39}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 12 approved and 27 investigational indications."
CHEMBL3,"CN1CCC[C@H]1c1cccnc1_|_SNICXCGAKADSCV-JTQLQIEISA-N_|_Small molecule_|_False_|_NICOTINE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Habitrol' 'Nicabate' 'Nicoderm cq' 'Nicopass' 'Nicopatch'
 'Nicorette invisi' 'Nicotine' 'Nicotinell classic' 'Nicotinell support'
 'Nicotinell tts 10' 'Nicotinell tts 20' 'Nicotinell tts 30' 'Nicotrol'
 'Nicotrol Inhaler' 'Nicotrol NS' 'Niquitin' 'Niquitin clr'
 'Niquitin minis cherry' 'Niquitin minis mint' 'Niquitin minis orange'
 'Niquitin mint' 'Niquitin pre-quit' 'Niquitin strips mint' 'Prostep'
 'Stoppers' 'Stubit']_|_['Nicotine']_|_[('DailyMed', array(['nicotine'], dtype=object)), ('PubChem', array(['144209012', '144210494', '17389805', '26752744', '26752745',
       '26752746', '50105392', '50105393', '56314824', '90341453'],
      dtype=object)), ('Wikipedia', array(['Nicotine'], dtype=object)), ('drugbank', array(['DB00184'], dtype=object)), ('chEBI', array(['17688'], dtype=object))]_|_['CHEMBL3137669' 'CHEMBL1448280' 'CHEMBL3989563' 'CHEMBL151515'
 'CHEMBL3182465' 'CHEMBL225057' 'CHEMBL1201536']_|_{'rows': array(['HP_0100543', 'MONDO_0002050', 'MONDO_0005180', 'EFO_0003768',
       'EFO_0004329', 'EFO_0002610', 'MONDO_0004647', 'MONDO_0019338',
       'MONDO_0004938', 'EFO_0003888', 'EFO_0000691', 'EFO_0003144',
       'MONDO_0005090', 'EFO_0000341', 'MONDO_0008903', 'MONDO_0100096',
       'EFO_0000313', 'EFO_0001072', 'MONDO_0002050', 'EFO_0004319',
       'EFO_0000694', 'MONDO_0018076', 'DOID_13406', 'EFO_0004888',
       'EFO_0000546', 'EFO_0004318', 'EFO_0004318', 'MONDO_0002974',
       'EFO_0003768', 'EFO_0007191', 'EFO_0003768'], dtype=object), 'count': 31}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for nicotine dependence and has 30 investigational indications."
CHEMBL3133037,"Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C_|_POERAARDVFVDLO-QGZVFWFLSA-N_|_Small molecule_|_False_|_LEQ506_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LEQ-506' 'LEQ506' 'Leq 506' 'Leq506' 'NVP-LEQ506' 'Nvp-leq-506']_|_[('drugbank', array(['DB12857'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004193', 'EFO_0002939'], dtype=object), 'count': 2}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3301624,"CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O_|_HDHDTKMUACZDAA-PHNIDTBTSA-N_|_Protein_|_False_|_SETMELANOTIDE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Imcivree']_|_['BIM-22493' 'RM-493' 'Setmelanotide']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree'],
      dtype=object)), ('drugbank', array(['DB11700'], dtype=object))]_|_['CHEMBL4650273']_|_{'rows': array(['EFO_0001073', 'MONDO_0008300', 'EFO_0001073', 'HP_0000083',
       'EFO_0001074', 'MONDO_0015229'], dtype=object), 'count': 6}_|_[ENSG00000166603]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for obesity and has 4 investigational indications."
CHEMBL3545215,"CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21_|_JCINBYQJBYJGDM-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-911543_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bms-911543' 'JAK2 INHIBITOR BMS-911543']_|_[('drugbank', array(['DB12591'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707377,"C=C1C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]2(C)[C@@]1(OC(C)=O)C(C)=O_|_CKFBRGLGTWAVLG-GOMYTPFNSA-N_|_Small molecule_|_False_|_SEGESTERONE ACETATE_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Nestorone']_|_['Elcometrine' 'ST-1435' 'Segesterone acetate']_|_[('DailyMed', array(['segesterone%20acetate'], dtype=object)), ('drugbank', array(['DB14583'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018."
CHEMBL423,"CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1_|_NWIUTZDMDHAVTP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETAXOLOL_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Betoptic' 'Betoptic susp']_|_['ALO-140102 FREE BASE' 'Betaxolol' 'Betoptic' 'Kerledex' 'Kerlone'
 'SL-7521210 FREE BASE']_|_[('PubChem', array(['144203642', '170465448', '90341580'], dtype=object)), ('Wikipedia', array(['Betaxolol'], dtype=object)), ('drugbank', array(['DB00195'], dtype=object)), ('chEBI', array(['3082'], dtype=object))]_|_['CHEMBL1691']_|_{'rows': array(['EFO_0004190', 'EFO_0000537', 'EFO_0004190', 'EFO_0000319',
       'EFO_1001069', 'EFO_1001069', 'MONDO_0005041'], dtype=object), 'count': 7}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 2 investigational indications."
CHEMBL4297183,"CN1Cc2cc(Cl)ccc2-n2c(nnc2[C@H]2CC[C@H](Oc3ccccn3)CC2)C1_|_GMPZPHGHNDMRKL-RZDIXWSQSA-N_|_Small molecule_|_False_|_BALOVAPTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Balovaptan' 'RG-7314' 'RG7314' 'RO-5285119' 'RO5285119' 'Rg7314']_|_[('drugbank', array(['DB14823'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002140', 'EFO_0003756', 'EFO_0001358'], dtype=object), 'count': 3}_|_[ENSG00000166148]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297293,"Clc1ccc(-c2nn(Cc3ccccc3)c3c2CCNCC3)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_DIQZMBPDLFAJLK-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-18038683_|_nan_|_2.0_|_CHEMBL4205783_|_False_|_False_|_[]_|_['Jnj-18038683']_|_nan_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0004985'], dtype=object), 'count': 2}_|_[ENSG00000148680]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297416,"Cn1nccc1-c1ccc(Sc2cccc(C3(C(N)=O)CCOCC3)c2)cc1_|_DVNQWYLVSNPCJZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-4191834_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-04191834' 'Pf-4191834']_|_[('drugbank', array(['DB11645'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0004616'], dtype=object), 'count': 2}_|_[ENSG00000012779]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297555,"nan_|_nan_|_Unknown_|_False_|_RESIMMUNE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-dmdt390-bisfv(ucht1)' 'LAX-699' 'Resimmune']_|_nan_|_nan_|_{'rows': array(['EFO_1001051', 'EFO_0005592', 'EFO_1000785', 'EFO_0000756'],
      dtype=object), 'count': 4}_|_[ENSG00000167658,ENSG00000198851]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4650516,"nan_|_nan_|_Antibody_|_False_|_FINOTONLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Finotonlimab' 'SCT-I10A' 'Sct i10a' 'Sct-i10a']_|_nan_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_0000707', 'EFO_0000181', 'EFO_0000574'],
      dtype=object), 'count': 4}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5315120,"CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1.CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1.O.O.O_|_UIYFGCAQGONAMU-ZHQCGWDOSA-N_|_Small molecule_|_False_|_ODEVIXIBAT SESQUIHYDRATE_|_2021.0_|_4.0_|_CHEMBL4297588_|_False_|_True_|_['Bylvay']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000989', 'MONDO_0017290'], dtype=object), 'count': 2}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pruritus and familial intrahepatic cholestasis."
CHEMBL705,"CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1_|_SHGAZHPCJJPHSC-ZVCIMWCZSA-N_|_Small molecule_|_False_|_ALITRETINOIN_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Panretin' 'Toctino']_|_['9-cis retinoic acid' '9-cis-retinoic acid' 'AGN 192013' 'AGN-192013'
 'AGN192013' 'ALRT-1057' 'ALRT1057' 'Alitretinoin' 'BAL-4079' 'LG-100057'
 'LG100057' 'LGD-1057' 'LGD1057' 'NSC-659772' 'Panretin'
 'Retinoic acid 9-cis-form']_|_[('DailyMed', array(['alitretinoin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/panretin'],
      dtype=object)), ('PubChem', array(['144212512', '26755228', '26755229', '26755230'], dtype=object)), ('Wikipedia', array(['Alitretinoin'], dtype=object)), ('drugbank', array(['DB00523'], dtype=object)), ('chEBI', array(['50648'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000964', 'EFO_1000706', 'EFO_0003834', 'EFO_0000676',
       'EFO_1000726', 'EFO_0000558', 'MONDO_0007254', 'EFO_0000616'],
      dtype=object), 'count': 8}_|_[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 5 investigational indications."
CHEMBL1200715,"CC(CNC1CCCCC1)OC(=O)c1ccccc1.Cl_|_MTFCPNHRBINLRQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_HEXYLCAINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1197_|_False_|_True_|_['Cyclaine']_|_['Hexylcaine HCl' 'Hexylcaine hcl' 'Hexylcaine hydrochloride']_|_[('PubChem', array(['144204007', '170465088', '56463225'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200769,"CN(C)CCN(Cc1ccccc1)c1ccccn1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_GGRBYIUPUOYRLQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIPELENNAMINE CITRATE_|_1948.0_|_4.0_|_CHEMBL1241_|_False_|_True_|_[]_|_['NSC-757360' 'Tripelennamine citrate']_|_[('PubChem', array(['144205071', '170465118', '26749792'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1948."
CHEMBL1200963,"CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O_|_AQOKCDNYWBIDND-FTOWTWDKSA-N_|_Small molecule_|_False_|_BIMATOPROST_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Bimatoprost' 'Durysta' 'Latisse' 'Lumigan']_|_['AGN 192024' 'AGN-192024' 'Bimatoprost' 'Prostamide']_|_[('DailyMed', array(['bimatoprost'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan'],
      dtype=object)), ('Wikipedia', array(['Bimatoprost'], dtype=object)), ('drugbank', array(['DB00905'], dtype=object)), ('chEBI', array(['51230'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004208', 'EFO_0004191', 'EFO_0004192', 'MONDO_0005041',
       'EFO_1001069', 'MONDO_0003037', 'MONDO_0004907', 'MONDO_0018914',
       'EFO_0004190', 'EFO_1001466'], dtype=object), 'count': 10}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 5 investigational indications."
CHEMBL1201659,"nan_|_nan_|_Small molecule_|_False_|_CHLORPHENIRAMINE POLISTIREX_|_1984.0_|_4.0_|_CHEMBL505_|_False_|_True_|_[]_|_['Chlorpheniramine polistirex']_|_[('DailyMed', array(['chlorpheniramine%20polistirex'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984."
CHEMBL1650443,"Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O_|_IWYJYHUNXVAVAA-OAHLLOKOSA-N_|_Small molecule_|_False_|_TRELAGLIPTIN_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['SYR-472' 'Trelagliptin']_|_[('drugbank', array(['DB15323'], dtype=object))]_|_['CHEMBL1650457' 'CHEMBL2105754' 'CHEMBL1650456']_|_{'rows': array(['MONDO_0005148', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications."
CHEMBL1908397,"O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1_|_YYLKKYCXAOBSRM-JXMROGBWSA-N_|_Small molecule_|_False_|_KW-2449_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['KW-2449' 'Kw 2449' 'Kw-2449']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000097007,ENSG00000178999,ENSG00000122025,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2103794,"CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1.Cl_|_VFYAEUWJFGTGGO-GHTUPXNNSA-N_|_Small molecule_|_False_|_ANAMORELIN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL2110579_|_False_|_False_|_[]_|_['Anamorelin hcl' 'Anamorelin hydrochloride' 'Ono-7643' 'RC-1291 HCl']_|_nan_|_nan_|_{'rows': array(['HP_0004326', 'HP_0012378', 'EFO_0002618'], dtype=object), 'count': 3}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2107386,"CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1.O=S(=O)(O)O_|_NQRYCIGCIAWEIC-CKLVGUEFSA-N_|_Small molecule_|_True_|_VORAPAXAR SULFATE_|_2014.0_|_4.0_|_CHEMBL493982_|_False_|_True_|_['Zontivity']_|_['SCH 530348' 'SCH-530348' 'Vorapaxar sulfate']_|_[('DailyMed', array(['vorapaxar%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zontivity'],
      dtype=object)), ('chEBI', array(['83314'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0005672', 'EFO_0004265', 'EFO_0000612'],
      dtype=object), 'count': 4}_|_[ENSG00000181104]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2109458,"nan_|_nan_|_Antibody_|_False_|_AMG-108_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-108' 'Amg-108']_|_nan_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_0000400', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000115594]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2111112,"COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC_|_VBHQKCBVWWUUKN-KZNAEPCWSA-N_|_Small molecule_|_False_|_VERNAKALANT_|_2010.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Vernakalant']_|_[('drugbank', array(['DB06217'], dtype=object))]_|_['CHEMBL2107383']_|_{'rows': array(['EFO_0000275', 'EFO_0003911', 'EFO_0004269', 'EFO_0000275',
       'EFO_0003911'], dtype=object), 'count': 5}_|_[ENSG00000171385,ENSG00000130037,ENSG00000162989,ENSG00000120457,ENSG00000183873,ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for cardiac arrhythmia and atrial fibrillation and has 3 investigational indications."
CHEMBL2165615,"Cc1cnc(NC(=O)c2cc(Oc3cnc(C(=O)N(C)C)nc3)c3cc(C)oc3c2)cn1_|_MASKQITXHVYVFL-UHFFFAOYSA-N_|_Small molecule_|_False_|_NERIGLIATIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nerigliatin' 'PF-04937319' 'Pf-04937319']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object)), ('drugbank', array(['DB15009'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL225071,"Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1_|_IVTVGDXNLFLDRM-HNNXBMFYSA-N_|_Small molecule_|_False_|_RALTITREXED_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Tomudex']_|_['Raltitrexed' 'ZD-16' 'ZD-1694' 'ZD1694']_|_[('PubChem', array(['144205790', '144207198', '49681782', '499545'], dtype=object)), ('Wikipedia', array(['Raltitrexed'], dtype=object)), ('drugbank', array(['DB00293'], dtype=object)), ('chEBI', array(['5847'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005922', 'EFO_0000707', 'EFO_0002618', 'EFO_0000588',
       'MONDO_0002691', 'EFO_1001951', 'EFO_0000182', 'MONDO_0005575',
       'EFO_0004252', 'EFO_0000365', 'EFO_1000657', 'MONDO_0007576',
       'EFO_0004142', 'EFO_0000616', 'EFO_1000123', 'MONDO_0000870',
       'MONDO_0001056'], dtype=object), 'count': 17}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for neoplasm and has 16 investigational indications."
CHEMBL2396661,"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1_|_STUWGJZDJHPWGZ-LBPRGKRZSA-N_|_Small molecule_|_False_|_ALPELISIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Piqray' 'Vijoice']_|_['Alpelisib' 'BYL-719' 'BYL719' 'Byl-719' 'NVP-BYL719' 'Vijoice']_|_[('DailyMed', array(['alpelisib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/piqray'],
      dtype=object)), ('drugbank', array(['DB12015'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011962', 'EFO_0001421', 'EFO_0000181', 'EFO_1001951',
       'MONDO_0004992', 'MONDO_0007254', 'EFO_0001378', 'EFO_0005922',
       'EFO_1001931', 'EFO_0004284', 'EFO_0002618', 'EFO_1000657',
       'EFO_0000707', 'EFO_0005537', 'MONDO_0011719', 'MONDO_0044704',
       'EFO_0000305', 'MONDO_0001056', 'MONDO_0016642', 'EFO_0000616',
       'EFO_0003869', 'MONDO_0008170'], dtype=object), 'count': 22}_|_[ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 17 investigational indications."
CHEMBL244243,"C[C@@H](NC(=O)[C@@H](CC(=O)N1CCC(N2CCCCC2)CC1)N1C(=O)[C@@H](N2C(=O)OC[C@@H]2c2ccccc2)[C@H]1/C=C/c1ccccc1)c1cccc(C(F)(F)F)c1_|_ZPKHVQNRKMCYGL-AFAPVMNMSA-N_|_Small molecule_|_False_|_SRX246_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Srx246']_|_nan_|_nan_|_{'rows': array(['EFO_0001358', 'EFO_0004247', 'EFO_0005230', 'MONDO_0007739'],
      dtype=object), 'count': 4}_|_[ENSG00000166148]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3301601,"CN1C(N)=N[C@](C)(c2cc(NC(=O)c3ccc(F)cn3)ccc2F)CS1(=O)=O_|_YHYKUSGACIYRML-KRWDZBQOSA-N_|_Small molecule_|_False_|_VERUBECESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-8931' 'SCH 900931' 'SCH-900931' 'SCH900931' 'Verubecestat']_|_[('drugbank', array(['DB12285'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000186318]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3301622,"CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1_|_GYQYAJJFPNQOOW-UHFFFAOYSA-N_|_Small molecule_|_True_|_GILTERITINIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ASP-2215' 'ASP2215' 'Asp-2215' 'Gilteritinib']_|_[('drugbank', array(['DB12141'], dtype=object))]_|_['CHEMBL3301603' 'CHEMBL4524472']_|_{'rows': array(['EFO_1000131', 'EFO_0000198', 'EFO_0001421', 'EFO_0003060',
       'MONDO_0004643', 'EFO_0003086', 'EFO_0000222', 'EFO_0000616',
       'EFO_0000222'], dtype=object), 'count': 9}_|_[ENSG00000167601,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545163,"CCNC(=O)[C@H]1CC(n2ccc3c(NC(CC)Cc4sccc4Cl)ncnc32)[C@H](O)[C@@H]1O_|_CKQOOYMMAAPDKH-NXKGBEFYSA-N_|_Small molecule_|_False_|_AMP579_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amp579' 'RPR-100579']_|_nan_|_nan_|_nan_|_[ENSG00000128271,ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3545295,"nan_|_nan_|_Small molecule_|_False_|_AVE0847_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ave0847']_|_nan_|_nan_|_nan_|_[ENSG00000132170,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL4297457,"CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12.Cl_|_MQBBSMNIRWXALO-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-823778_|_nan_|_2.0_|_CHEMBL4301600_|_False_|_False_|_[]_|_['BMS-823778' 'Bms-823778']_|_nan_|_nan_|_{'rows': array(['EFO_0000319', 'MONDO_0005148', 'EFO_0000537', 'Orphanet_309005'],
      dtype=object), 'count': 4}_|_[ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297722,"nan_|_nan_|_Oligonucleotide_|_False_|_CEMDISIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AD-62643' 'AD-62643 FREE ACID' 'ALN-62643' 'ALN-62643 FREE ACID'
 'Cemdisiran' 'Cemdisiran sodium']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CEMDISIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004991', 'MONDO_0100244', 'MONDO_0100244', 'MONDO_0016244',
       'EFO_0004194'], dtype=object), 'count': 5}_|_[ENSG00000106804]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL688,"CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_IVLVTNPOHDFFCJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_FENTANYL CITRATE_|_1968.0_|_4.0_|_CHEMBL596_|_False_|_True_|_['Abstral' 'Actiq' 'Fentanyl' 'Fentanyl citrate'
 'Fentanyl citrate preservative free' 'Fentora' 'Instanyl' 'Lazanda'
 'Onsolis' 'Sublimaze' 'Sublimaze preservative free' 'Thalamonal']_|_['Fentanyl buccal' 'Fentanyl citrate' 'Fentanyl citrate cii' 'Instanyl'
 'Kw-2246' 'Leptanal' 'MCN-JR-4263-49' 'R-4263']_|_[('DailyMed', array(['fentanyl%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/instanyl'],
      dtype=object)), ('chEBI', array(['31602'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003419', 'MONDO_0005277', 'EFO_0003843', 'EFO_0005762',
       'EFO_0801084', 'EFO_0004244', 'HP_0002094', 'HP_0012532',
       'EFO_1001139', 'EFO_0009727', 'MONDO_0004992', 'EFO_0000546'],
      dtype=object), 'count': 12}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 4 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL7492,"COc1ccc(OC)c(Cc2cnc3nc(N)nc(N)c3c2C)c1_|_VJXSSYDSOJBUAV-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIRITREXIM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BW-301U' 'Bw 301u' 'Bw-301u' 'Piritrexim' 'TCMDC-137235']_|_[('drugbank', array(['DB03695'], dtype=object))]_|_['CHEMBL1712863']_|_{'rows': array(['MONDO_0001187', 'MONDO_0004192'], dtype=object), 'count': 2}_|_[ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1201728,"CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O=C(O)CCC(=O)O_|_ORUUBRMVQCKYHB-UHFFFAOYSA-N_|_Small molecule_|_True_|_DESVENLAFAXINE SUCCINATE_|_2008.0_|_4.0_|_CHEMBL1118_|_False_|_True_|_['Desvenlafaxine succinate' 'Pristiq']_|_['DVS-233' 'Desvenlafaxine succinate' 'Desvenlafaxine succinate anhydrous'
 'Desvenlafaxine succinate hydrate' 'Desvenlafaxine succinate monohydrate'
 'Dvs anhydrous' 'O-desmethyl venlafaxine succinate'
 'O-desmethylvenlafaxine succinate' 'WY-45233' 'WY45233']_|_[('DailyMed', array(['desvenlafaxine%20succinate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0005687', 'HP_0031217', 'MONDO_0002009',
       'GO_0042697', 'EFO_1000783', 'MONDO_0002050'], dtype=object), 'count': 7}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for major depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL15770,"CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1_|_MLKXDPUZXIRXEP-MFOYZWKCSA-N_|_Small molecule_|_True_|_SULINDAC_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Clinoril' 'Sulindac']_|_['Arthrocine' 'Artribid' 'MK-231' 'NSC-757344' 'Sulindac']_|_[('DailyMed', array(['sulindac'], dtype=object)), ('PubChem', array(['11111823', '11111824', '11114189', '124881496', '144203821',
       '144211735', '170464648', '26732639', '50106970', '85231236',
       '90341400'], dtype=object)), ('TG-GATEs', array(['100'], dtype=object)), ('Wikipedia', array(['Sulindac'], dtype=object)), ('drugbank', array(['DB00605'], dtype=object)), ('chEBI', array(['9352'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000389', 'MONDO_0021074', 'EFO_0004142', 'EFO_1001951',
       'MONDO_0007254', 'Orphanet_733', 'EFO_0000222', 'EFO_0009907',
       'EFO_0000181', 'MONDO_0005178', 'EFO_0005755', 'EFO_0000685',
       'MONDO_0010383', 'MONDO_0003937'], dtype=object), 'count': 14}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1688243,"CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C_|_ZMCJFJZOSKEMOM-DNKZPPIMSA-N_|_Small molecule_|_False_|_INCB-9471_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['INCB-009471' 'INCB009471' 'INCB9471' 'Incb-9471']_|_[('drugbank', array(['DB12960'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1743016,"nan_|_nan_|_Antibody_|_False_|_FARLETUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Farletuzumab' 'M3' 'MORAb-003']_|_nan_|_nan_|_{'rows': array(['MONDO_0002158', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000571',
       'EFO_1001100'], dtype=object), 'count': 5}_|_[ENSG00000110195]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL1817709,"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O_|_JCVQBJTWWDYUFQ-MRUTUVJXSA-N_|_Protein_|_False_|_SELEPRESSIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FE 202158' 'FE-202158' 'FE202158' 'Fe-202158' 'Selepressin']_|_[('drugbank', array(['DB12495'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006834'], dtype=object), 'count': 1}_|_[ENSG00000166148]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107771,"C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O_|_BHJIBOFHEFDSAU-LBPRGKRZSA-N_|_Small molecule_|_False_|_RALFINAMIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['FCE-26742A' 'NW1029' 'Nw-1029' 'PNU-0154339E' 'Priralfinamide'
 'Ralfinamide']_|_[('drugbank', array(['DB06649'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005762', 'EFO_0003843'], dtype=object), 'count': 2}_|_[ENSG00000069535,ENSG00000148408,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL237500,"CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C_|_LTXREWYXXSTFRX-QGZVFWFLSA-N_|_Small molecule_|_False_|_LINAGLIPTIN_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Tradjenta' 'Trajenta']_|_['BI 1356' 'BI 1356 BS' 'BI-1356' 'BI-1356-BS' 'BI-1356BS' 'BS 1356 BS'
 'BS-1356-BS' 'Linagliptin' 'Trazenta']_|_[('DailyMed', array(['linagliptin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta'],
      dtype=object)), ('Wikipedia', array(['Linagliptin'], dtype=object)), ('drugbank', array(['DB08882'], dtype=object)), ('chEBI', array(['68610'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0100096', 'EFO_0000537', 'EFO_0000503',
       'MONDO_0005090', 'MONDO_0005148', 'EFO_0002916', 'HP_0000083',
       'EFO_0000400', 'EFO_0000684'], dtype=object), 'count': 10}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 8 investigational indications."
CHEMBL2393130,"COc1cc(OC)c2c(=O)[nH]c(-c3cc(C)c(OCCO)c(C)c3)nc2c1_|_NETXMUIMUZJUTB-UHFFFAOYSA-N_|_Small molecule_|_False_|_APABETALONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Apabetalone' 'RVX-000222' 'RVX-208' 'RVX000222']_|_[('drugbank', array(['DB12000'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001645', 'MONDO_0010526', 'MONDO_0100096', 'EFO_0001361',
       'EFO_0000400', 'EFO_0003884'], dtype=object), 'count': 6}_|_[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL290194,"C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC_|_KSEYRUGYKHXGFW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALIZAPRIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Alizapride' 'Litican' 'Plitican' 'Superan' 'Vergentan']_|_[('Wikipedia', array(['Alizapride'], dtype=object)), ('drugbank', array(['DB01425'], dtype=object))]_|_['CHEMBL1896987']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3301600,"C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1.O=S(=O)(O)c1ccccc1_|_ABSXPNGWJFAPRT-UHFFFAOYSA-N_|_Small molecule_|_False_|_SPEBRUTINIB BESYLATE_|_nan_|_2.0_|_CHEMBL3301625_|_False_|_False_|_[]_|_['AVL-292' 'AVL-292 BESYLATE' 'CC-292' 'CC-292 BESYLATE' 'Spebrutinib'
 'Spebrutinib besilate' 'Spebrutinib besylate']_|_nan_|_nan_|_{'rows': array(['EFO_0000403', 'EFO_0000685', 'EFO_0000565'], dtype=object), 'count': 3}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL33986,"Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3_|_IFKLAQQSCNILHL-QHAWAJNXSA-N_|_Small molecule_|_True_|_BUTORPHANOL_|_1978.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Butorphanol' 'LEVO-BC-2627']_|_[('Wikipedia', array(['Butorphanol'], dtype=object)), ('chEBI', array(['3242'], dtype=object))]_|_['CHEMBL299400']_|_{'rows': array(['EFO_0003890', 'EFO_0003843', 'EFO_0005230'], dtype=object), 'count': 3}_|_[ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for drug dependence and pain and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL3639788,"O=C(Cc1cccc(OC(F)(F)F)c1)Nc1ccc(CCCCc2nnc(NC(=O)Cc3ccccn3)s2)nn1_|_PRAAPINBUWJLGA-UHFFFAOYSA-N_|_Small molecule_|_False_|_TELAGLENASTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CB-839' 'Telaglenastat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TELAGLENASTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15232'], dtype=object))]_|_['CHEMBL4594286']_|_{'rows': array(['EFO_0001061', 'EFO_0000349', 'EFO_0003060', 'EFO_0000681',
       'EFO_0000222', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000220',
       'EFO_0000272', 'EFO_0000198', 'EFO_0005537', 'EFO_0000616',
       'EFO_1001779', 'EFO_0001378', 'EFO_0000760'], dtype=object), 'count': 15}_|_[ENSG00000115419]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 14 investigational indications."
CHEMBL3833306,"nan_|_nan_|_Antibody drug conjugate_|_False_|_VANDORTUZUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DSTP3086S' 'MSTP2109A' 'RG-7450' 'RG7450' 'Vandortuzumab vedotin']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000164647,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989826,"COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.O=C(O)c1ccc(C(=O)O)cc1_|_BTEYIHUKHHAVAN-KDKWOIFOSA-N_|_Small molecule_|_False_|_OXYCODONE TEREPHTHALATE_|_1950.0_|_4.0_|_CHEMBL656_|_False_|_True_|_[]_|_['Oxycodone terephthalate']_|_[('DailyMed', array(['oxycodone%20terephthalate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950 and is indicated for pain."
CHEMBL4297864,"nan_|_nan_|_Antibody_|_False_|_CENDAKIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABT-308' 'Abt-308' 'CC-93538' 'Cendakimab' 'RPC-4046']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CENDAKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0004232', 'EFO_1001463'], dtype=object), 'count': 3}_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4650316,"C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO_|_GQCXHIKRWBIQMD-AKJBCIBTSA-N_|_Small molecule_|_False_|_GIREDESTRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GDC-9545' 'Gdc-9545' 'Giredestrant' 'RO-7197597' 'RO7197597']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GIREDESTRANT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011962', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL971,"CCCC(C)C1(CC)C(=O)N=C([O-])NC1=O.[Na+]_|_QGMRQYFBGABWDR-UHFFFAOYSA-M_|_Small molecule_|_False_|_PENTOBARBITAL SODIUM_|_1973.0_|_4.0_|_CHEMBL448_|_True_|_True_|_['Beuthanasia' 'Euthanase' 'Euthatal' 'Nembutal' 'Nembutal sodium'
 'Pentobarbital sodium' 'Pentobarbitone Sodium' 'Sagatal'
 'Sodium pentobarbital']_|_['Auropan' 'Barpental' 'Biosedan' 'Diabutal' 'Embutal' 'Entobar'
 'Etaminal sodium' 'Ethaminal sodium' 'Euthanyl' 'Euthatal' 'Isobarb'
 'Mebubarbital sodium' 'Mebumal sodium' 'NSC-10816' 'Napental' 'Narcoren'
 'Pacifan' 'Pental' 'Pentobarbital sodium' 'Pentobarbital sodium salt'
 'Pentobarbitone sodium' 'Pentonal' 'Pentone' 'Praecicalm'
 'Rs-pentobarbital sodium' 'Sagatal' 'Sodium ethaminal' 'Sodium nembutal'
 'Sodium pental' 'Sodium pentobarbitone' 'Sodium pentobarbiturate'
 'Sodium-pent' 'Soluble pentobarbital' 'Somnopentyl' 'Somnotol' 'Sopental'
 'Sotyl' 'V-pento' 'Vetbutal']_|_[('DailyMed', array(['pentobarbital%20sodium'], dtype=object)), ('chEBI', array(['7984'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973. It was withdrawn in at least one region."
CHEMBL1094,"NC(=O)OCC(COC(N)=O)c1ccccc1_|_WKGXYQFOCVYPAC-UHFFFAOYSA-N_|_Small molecule_|_True_|_FELBAMATE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Felbamate' 'Felbatol' 'Taloxa']_|_['ADD-03055' 'Felbamate' 'NSC-759866' 'W-554']_|_[('DailyMed', array(['felbamate'], dtype=object)), ('PubChem', array(['104171154', '11113343', '144203696', '144212685', '170465178',
       '50104096', '56422162', '855835', '90340922'], dtype=object)), ('Wikipedia', array(['Felbamate'], dtype=object)), ('drugbank', array(['DB00949'], dtype=object)), ('chEBI', array(['4995'], dtype=object))]_|_['CHEMBL2130858']_|_{'rows': array(['MONDO_0002280', 'MONDO_0004985', 'EFO_0000474', 'HP_0001250'],
      dtype=object), 'count': 4}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200480,"CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O_|_XQEJFZYLWPSJOV-XJQYZYIXSA-N_|_Protein_|_False_|_OCTREOTIDE ACETATE_|_1988.0_|_4.0_|_CHEMBL1680_|_False_|_True_|_['Bynfezia pen' 'Mycapssa' 'Octreotide acetate'
 'Octreotide acetate (preservative free)'
 'Octreotide acetate preservative free' 'Sandostatin' 'Sandostatin lar']_|_['Octreolin' 'Octreotide (as acetate)' 'Octreotide acetate'
 'SMS 201-995 AC' 'SMS-201-995 AC' 'SMS-201995-AC']_|_[('DailyMed', array(['octreotide%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mycapssa'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008300', 'EFO_1000852', 'EFO_1002048', 'EFO_1001901',
       'MONDO_0043579', 'EFO_0009708', 'EFO_0000616', 'HP_0002019',
       'MONDO_0004565', 'EFO_0003770', 'EFO_1001951', 'MONDO_0017611',
       'EFO_1001485', 'EFO_0002626', 'HP_0002014', 'EFO_0004243',
       'EFO_0001073', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0002691',
       'MONDO_0017182', 'EFO_0000574'], dtype=object), 'count': 22}_|_[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 18 investigational indications."
CHEMBL1200870,"CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.O=C(O)/C=C\C(=O)O_|_WLRMANUAADYWEA-NWASOUNVSA-N_|_Small molecule_|_False_|_TIMOLOL MALEATE_|_1978.0_|_4.0_|_CHEMBL499_|_False_|_True_|_['Blocadren' 'Istalol' 'Timolol maleate' 'Timoptic' 'Timoptic Xe'
 'Timoptic in ocudose' 'Timoptic-xe']_|_['Aquanil' 'NSC-757351' 'Ophtamolol' 'Timolol (as maleate)'
 'Timolol hydrogen maleate salt' 'Timolol maleate'
 'Timolol maleate, s-enantiomer' 'Timololi maleas' 'WP-934']_|_[('DailyMed', array(['timolol%20maleate'], dtype=object)), ('PubChem', array(['144212785', '56423148', '855659', '93576681'], dtype=object)), ('chEBI', array(['9600'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000879', 'MONDO_0005041', 'EFO_0000666', 'EFO_1001022',
       'EFO_0004190', 'EFO_1000809', 'EFO_1000635', 'EFO_1001069'],
      dtype=object), 'count': 8}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 3 approved and 5 investigational indications."
CHEMBL1201748,"CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C_|_BMQGVNUXMIRLCK-OAGWZNDDSA-N_|_Small molecule_|_True_|_CABAZITAXEL_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Cabazitaxel accord' 'Jevtana' 'Jevtana kit']_|_['Cabazitaxel' 'Cabazitaxel acetonate' 'Jevtana' 'NSC-761432' 'TXD 258'
 'TXD-258' 'TXD258' 'XRP 6258' 'XRP-6258' 'XRP6258']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord'],
      dtype=object)), ('Wikipedia', array(['Cabazitaxel'], dtype=object)), ('drugbank', array(['DB06772'], dtype=object)), ('chEBI', array(['63584'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003085', 'MONDO_0007254', 'EFO_0001663', 'EFO_0005088',
       'MONDO_0008315', 'EFO_0003060', 'EFO_0000326', 'EFO_1001094',
       'EFO_1000796', 'EFO_0006859', 'EFO_1000601', 'MONDO_0001657',
       'EFO_0000519', 'MONDO_0008170', 'EFO_0000702', 'EFO_0000181',
       'EFO_0000196', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0021259',
       'MONDO_0001056', 'MONDO_0004986', 'EFO_0000673', 'EFO_0000616',
       'EFO_0008528'], dtype=object), 'count': 25}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 7 approved and 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1237061,"O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Ca+2]_|_RHGYHLPFVJEAOC-FFNUKLMVSA-L_|_Small molecule_|_False_|_PITAVASTATIN CALCIUM_|_2009.0_|_4.0_|_CHEMBL1201753_|_False_|_True_|_['Livalo' 'Pitavastatin calcium']_|_['Itavastatin calcium' 'NK-104' 'Pitavastatin Calcium'
 'Pitavastatin calcium' 'Pitavastatin calcium salt']_|_[('DailyMed', array(['pitavastatin%20calcium'], dtype=object)), ('PubChem', array(['49681579'], dtype=object)), ('chEBI', array(['71258'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005', 'EFO_0004911', 'HP_0003124', 'MONDO_0021187',
       'HP_0003119'], dtype=object), 'count': 5}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 1 investigational indication."
CHEMBL1493,"Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O_|_SPIUTQOUKAMGCX-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLAVOXATE_|_1970.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bladuril' 'Flavoxate']_|_[('PubChem', array(['11112543'], dtype=object)), ('Wikipedia', array(['Flavoxate'], dtype=object)), ('drugbank', array(['DB01148'], dtype=object)), ('chEBI', array(['5088'], dtype=object))]_|_['CHEMBL1200875']_|_{'rows': array(['HP_0000020', 'EFO_0003830', 'EFO_0003901', 'EFO_0003878',
       'EFO_0003103', 'HP_0000103'], dtype=object), 'count': 6}_|_[ENSG00000205268,ENSG00000171408,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000113231,ENSG00000073417]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 6 approved indications."
CHEMBL1508,"CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21_|_WSEQXVZVJXJVFP-FQEVSTJZSA-N_|_Small molecule_|_True_|_ESCITALOPRAM_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Cipralex']_|_['Escitalopram' 'Esertia' 'Esitol' 'LU-26-054']_|_[('PubChem', array(['11110983', '11114081', '124879737', '50100207'], dtype=object)), ('Wikipedia', array(['Escitalopram'], dtype=object)), ('drugbank', array(['DB01175'], dtype=object)), ('chEBI', array(['36791'], dtype=object))]_|_['CHEMBL1200322']_|_{'rows': array(['MONDO_0005184', 'EFO_0000712', 'MONDO_0004992', 'EFO_0004262',
       'EFO_0003047', 'EFO_0001358', 'MONDO_0004985', 'EFO_1001892',
       'EFO_0000313', 'EFO_0003890', 'EFO_0009963', 'EFO_0002610',
       'HP_0002381', 'EFO_0004242', 'MONDO_0002009', 'EFO_1001908',
       'EFO_0005230', 'MONDO_0002009', 'EFO_0803321', 'MONDO_0004975',
       'MONDO_0002050', 'EFO_1001892', 'EFO_0003884', 'MONDO_0005149',
       'MONDO_0002491', 'MONDO_0002009', 'MONDO_0002050', 'HP_0012076',
       'EFO_0005687', 'EFO_1001917', 'HP_0000726', 'EFO_0010282',
       'EFO_1001919', 'MONDO_0002009', 'MONDO_0005090', 'EFO_0006788',
       'EFO_0000685', 'EFO_0000555'], dtype=object), 'count': 38}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1569,"Cl.NC12CC3CC(CC(C3)C1)C2_|_WOLHOYHSEKDWQH-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMANTADINE HYDROCHLORIDE_|_1968.0_|_4.0_|_CHEMBL660_|_False_|_True_|_['Amantadine hydrochloride' 'Gocovri' 'Lysovir' 'Mantadine' 'Osmolex er'
 'Symadine' 'Symmetrel']_|_['Adamantanamine hydrochloride' 'Amantadine hcl'
 'Amantadine hydrochloride' 'EXP-105-1' 'Mantadix' 'NSC-83653' 'Osmolex']_|_[('DailyMed', array(['amantadine%20hydrochloride'], dtype=object)), ('PubChem', array(['26747411', '26747412', '50105719', '50105720'], dtype=object)), ('chEBI', array(['2619'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328',
       'EFO_0003047', 'MONDO_0004976', 'MONDO_0005301', 'MONDO_0005090',
       'EFO_0000544', 'EFO_1001402', 'EFO_1000860', 'MONDO_0043510',
       'MONDO_0100096', 'MONDO_0005180', 'EFO_0005411'], dtype=object), 'count': 15}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 8 investigational indications."
CHEMBL159226,"CC(=O)Oc1cc(C(C)C)c(OCCN(C)C)cc1C_|_VRYMTAVOXVTQEF-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOXISYLYTE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Erecnos' 'Moxivig']_|_['Acetoxythymoxamine' 'Carlytene' 'Moxisylyte' 'Moxisylyte hcl'
 'Moxisylyte hydrochloride' 'NSC-170448' 'Thymoxamine' 'Thymoxamine hcl'
 'Thymoxamine hydrochloride']_|_[('PubChem', array(['11111464', '11111465', '90340735'], dtype=object)), ('TG-GATEs', array(['61'], dtype=object)), ('drugbank', array(['DB09205'], dtype=object))]_|_['CHEMBL1256739']_|_{'rows': array(['EFO_0000319', 'EFO_0004234'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and erectile dysfunction."
CHEMBL1698,"CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl_|_HEYVINCGKDONRU-UHFFFAOYSA-N_|_Small molecule_|_True_|_BUPROPION HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL894_|_False_|_True_|_['Bupropion hydrochloride' 'Forfivo xl' 'Wellbutrin' 'Wellbutrin 100'
 'Wellbutrin 75' 'Wellbutrin sr' 'Wellbutrin xl' 'Zyban']_|_['Amfebutamone hydrochloride' 'BW 323' 'BW-323' 'BW323' 'Bupropion HCl'
 'Bupropion hcl' 'Bupropion hydrochloride' 'Mysimba' 'NSC-315851']_|_[('DailyMed', array(['bupropion%20hydrochloride'], dtype=object)), ('PubChem', array(['144204172', '144212161', '170464747', '26747451', '49681824',
       '50105906', '573995', '855813'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005203', 'MONDO_0002009', 'MONDO_0002009', 'MONDO_0008903',
       'EFO_0003768', 'MONDO_0002050', 'EFO_0004319', 'MONDO_0007079',
       'EFO_0009963', 'EFO_0004318', 'EFO_0001073', 'MONDO_0010200',
       'MONDO_0007254', 'MONDO_0004985', 'EFO_0004247'], dtype=object), 'count': 15}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743260,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CC[Si](C)(C)C)cccc3nc2-1_|_SYXGVIWFCCQOEK-VWLOTQADSA-N_|_Small molecule_|_False_|_KARENITECIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Karenitecin']_|_nan_|_nan_|_{'rows': array(['EFO_0003833', 'EFO_1000158', 'EFO_0000756', 'MONDO_0008170',
       'MONDO_0008903', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1808388,"OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O_|_BTCRKOKVYTVOLU-SJSRKZJXSA-N_|_Small molecule_|_False_|_BEXAGLIFLOZIN_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Brenzavvy']_|_['Bexagliflozin' 'Brenzavvy' 'EGT-0001442' 'EGT-1442' 'EGT0001442'
 'EGT1442' 'THR-1442' 'THR1442']_|_[('drugbank', array(['DB12236'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0001134', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for type 2 diabetes mellitus and has 2 investigational indications."
CHEMBL2105581,"C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC_|_RYJXBGGBZJGVQF-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERALIPRIDE_|_1979.0_|_4.0_|_nan_|_True_|_True_|_['Agreal']_|_['Agradil' 'Veralipride']_|_[('PubChem', array(['144205502'], dtype=object)), ('drugbank', array(['DB13523'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for psychosis. It was withdrawn in at least one region."
CHEMBL2107387,"Br.Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1_|_VNGRUFUIHGGOOM-UHFFFAOYSA-N_|_Small molecule_|_True_|_VORTIOXETINE HYDROBROMIDE_|_2013.0_|_4.0_|_CHEMBL2104993_|_False_|_True_|_['Brintellix' 'Trintellix']_|_['Lu AA21004 (HBr)' 'Lu aa21004 hbr' 'Lu-aa21004 hydrobromide'
 'Vortioxetine hydrobromide']_|_[('DailyMed', array(['vortioxetine%20hydrobromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix'],
      dtype=object)), ('chEBI', array(['76015'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0002009'], dtype=object), 'count': 2}_|_[ENSG00000178394,ENSG00000108576,ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL2107861,"nan_|_nan_|_Antibody_|_False_|_ZALUTUMUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['2F8' 'HUMAX-EGFR, 2F8' 'HUMAX-EGFR-2F8' 'HuMax-EGFr' 'Zalutumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000707', 'EFO_0004284', 'EFO_0003060', 'EFO_0006859',
       'EFO_1001951'], dtype=object), 'count': 5}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2108354,"nan_|_nan_|_Antibody_|_False_|_UBLITUXIMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Briumvi']_|_['Briumvi' 'TG-1101' 'Ublituximab' 'Ublituximab xiiy' 'Ublituximab-xiiy']_|_nan_|_nan_|_{'rows': array(['MONDO_0005301', 'EFO_0009441', 'EFO_0004256', 'EFO_1001469',
       'MONDO_0018906', 'EFO_0000403', 'EFO_0003840', 'EFO_0003929',
       'EFO_0000095', 'EFO_0000096', 'EFO_0000540'], dtype=object), 'count': 11}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 8 investigational indications."
CHEMBL2108592,nan_|_nan_|_Antibody drug conjugate_|_False_|_EPITUMOMAB CITUXETAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Epitumomab cituxetan' 'Hmfg 1']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL29741,"CN(C)CCOc1ccccc1-c1nc(-c2ccccc2)no1_|_QZULPCPLWGCGSL-UHFFFAOYSA-N_|_Small molecule_|_False_|_IRAMPANEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIR 561' 'BIIR-561' 'BIIR-561 CL' 'Irampanel']_|_nan_|_nan_|_nan_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3301626,"Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1_|_UPZWINBEAHDTLA-UHFFFAOYSA-N_|_Small molecule_|_False_|_BASIMGLURANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Basimglurant' 'NOE-101' 'RG-7090' 'RO-4917523' 'RO4917523' 'Rg7090']_|_[('drugbank', array(['DB11833'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001734', 'EFO_1001219', 'MONDO_0002050', 'MONDO_0002009',
       'MONDO_0010383'], dtype=object), 'count': 5}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4297363,"CCOC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C12CCCCC2_|_QCYAXXZCQKMTMO-QFIPXVFZSA-N_|_Small molecule_|_False_|_UCB-1184197_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDP-323' 'CDP323' 'Cdp323' 'Ucb-1184197' 'Zaurategrast ethyl ester']_|_nan_|_nan_|_{'rows': array(['MONDO_0005301'], dtype=object), 'count': 1}_|_[ENSG00000115232]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297648,"[O-][n+]1cccc(-c2nc3c(Cl)cccc3cc2[C@@H](Nc2ncnc3cccnc23)C(F)(F)F)c1_|_LNLJHGXOFYUARS-OAQYLSRUSA-N_|_Small molecule_|_False_|_SELETALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Seletalisib' 'UCB-5857' 'UCB5857' 'Ucb5857']_|_[('drugbank', array(['DB12706'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000699', 'EFO_0000676'], dtype=object), 'count': 2}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL460,"CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2_|_KLPWJLBORRMFGK-UHFFFAOYSA-N_|_Small molecule_|_True_|_MOLINDONE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Moban' 'Molindone' 'Spn-810']_|_[('PubChem', array(['26755691', '50111112', '90341242'], dtype=object)), ('Wikipedia', array(['Molindone'], dtype=object)), ('drugbank', array(['DB01618'], dtype=object)), ('chEBI', array(['6965'], dtype=object))]_|_['CHEMBL1200419']_|_{'rows': array(['MONDO_0005090', 'EFO_0005407', 'EFO_0003888'], dtype=object), 'count': 3}_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for schizophrenia and psychosis and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL4802176,nan_|_nan_|_Unknown_|_False_|_ONO-5334_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONO-5334' 'Ono-5334']_|_nan_|_nan_|_nan_|_[ENSG00000143387]_|_Unknown drug with a maximum clinical trial phase of II.
CHEMBL481611,"CC(C)(F)C[C@H](N[C@@H](c1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1)C(F)(F)F)C(=O)NC1(C#N)CC1_|_FWIVDMJALNEADT-SFTDATJTSA-N_|_Small molecule_|_False_|_ODANACATIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-0822' 'MK0822' 'Odanacatib']_|_[('Wikipedia', array(['Odanacatib'], dtype=object)), ('drugbank', array(['DB06670'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003854', 'MONDO_0005178', 'MONDO_0008315', 'MONDO_0007254',
       'EFO_0003882', 'HP_0000083'], dtype=object), 'count': 6}_|_[ENSG00000143387]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL956,"CC(C(=O)O)c1ccc(C(=O)c2cccs2)cc1_|_MDKGKXOCJGEUJW-UHFFFAOYSA-N_|_Small molecule_|_False_|_SUPROFEN_|_1985.0_|_4.0_|_nan_|_True_|_True_|_['Profenal']_|_['NSC-303611' 'P-(2-thenoyl)hydratropic acid'
 'P-2-thenoylhydratropic acid' 'R-25,061' 'R-25061' 'Racemic suprofen'
 'Srendam' 'Sulproltin' 'Suprofen' 'Sutoprofen' 'TN-762' 'Topalgic']_|_[('PubChem', array(['144204194', '170465412', '26748525', '56463227'], dtype=object)), ('Wikipedia', array(['Suprofen'], dtype=object)), ('drugbank', array(['DB00870'], dtype=object)), ('chEBI', array(['9362'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for rheumatic disease. It was withdrawn in at least one region."
CHEMBL1200531,"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1.Cl_|_AQORHZJDCHLLJN-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALFENTANIL HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL634_|_False_|_True_|_['Alfenta' 'Alfentanil' 'Rapifen' 'Rapifen conc' 'Rapifen dilute'
 'Rapifen intensive care']_|_['Alfentanil hydrochloride' 'Alfentanil hydrochloride cii'
 'Alfentanil hydrochloride monohydrate' 'R 39,209' 'R 39209' 'R-39,209'
 'R-39209']_|_[('PubChem', array(['144206431', '85273815'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. This drug has a black box warning from the FDA."
CHEMBL148674,"CCc1c(C(=O)C(N)=O)c2c(OCC(=O)O)cccc2n1Cc1ccccc1_|_BHLXTPHDSZUFHR-UHFFFAOYSA-N_|_Small molecule_|_False_|_VARESPLADIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-315920' 'LY315920' 'Varepladib' 'Varespladib' 'Varespladib sodium']_|_[('PubChem', array(['174006184'], dtype=object)), ('Wikipedia', array(['Varespladib'], dtype=object)), ('drugbank', array(['DB11909'], dtype=object))]_|_['CHEMBL2107809']_|_{'rows': array(['EFO_0001645', 'MONDO_0100096', 'MONDO_0011382'], dtype=object), 'count': 3}_|_[ENSG00000188257]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1678,"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2.Cl_|_XWAIAVWHZJNZQQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DONEPEZIL HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL502_|_False_|_True_|_['Adlarity' 'Aricept' 'Aricept evess' 'Aricept odt'
 'Donepezil hydrochloride']_|_['Adlarity' 'BNAG' 'Donepezil hcl' 'Donepezil hydrochloride' 'E-2020'
 'E2020' 'NSC-737535' 'NSC-758882']_|_[('DailyMed', array(['donepezil%20hydrochloride'], dtype=object)), ('PubChem', array(['144206087', '170464858', '26719734', '49732006'], dtype=object)), ('chEBI', array(['4696'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0003758', 'EFO_1000158', 'EFO_0005762',
       'EFO_0009267', 'HP_0100543', 'MONDO_0002050', 'MONDO_0010726',
       'MONDO_0005277', 'EFO_0001064', 'HP_0000726', 'EFO_0004718'],
      dtype=object), 'count': 12}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for alzheimer disease and dementia and has 10 investigational indications."
CHEMBL1767408,"O=c1ccn([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1.[Na+].[Na+].[Na+].[Na+]_|_OWTGMPPCCUSXIP-FNXFGIETSA-J_|_Small molecule_|_False_|_DIQUAFOSOL TETRASODIUM_|_nan_|_3.0_|_CHEMBL221326_|_False_|_False_|_[]_|_['DE-089' 'Diquafosol sodium' 'Diquafosol tetrasodium'
 'Diquafosol tetrasodium salt' 'INS 365' 'INS365' 'KPY-998']_|_[('Wikipedia', array(['Diquafosol'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}_|_[ENSG00000171631,ENSG00000186912,ENSG00000175591,ENSG00000169860]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1946170,"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1_|_FNHKPVJBJVTLMP-UHFFFAOYSA-N_|_Small molecule_|_True_|_REGORAFENIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Stivarga']_|_['BAY 73-4506' 'BAY 73-4506 monohydrate' 'BAY-73-4506' 'BAY-734506'
 'Regorafenib' 'Regorafenib anhydrous' 'Regorafenib hydrate'
 'Regorafenib monohydrate']_|_[('DailyMed', array(['regorafenib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga'],
      dtype=object)), ('PubChem', array(['137275982'], dtype=object)), ('Wikipedia', array(['Regorafenib'], dtype=object)), ('drugbank', array(['DB08896'], dtype=object)), ('chEBI', array(['68647'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004142', 'EFO_1001961', 'MONDO_0021063', 'EFO_0000569',
       'EFO_0000616', 'EFO_0000222', 'EFO_0005540', 'EFO_0000691',
       'MONDO_0004992', 'MONDO_0007576', 'EFO_0002918', 'EFO_0000365',
       'EFO_0000637', 'EFO_0003893', 'EFO_0000756', 'EFO_1001949',
       'MONDO_0003060', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000702',
       'MONDO_0008170', 'EFO_1000350', 'EFO_0000681', 'EFO_0000519',
       'EFO_0005221', 'EFO_1001951', 'MONDO_0011719', 'MONDO_0001056',
       'EFO_0000389', 'MONDO_0002108', 'EFO_0002618', 'EFO_0009606',
       'EFO_0000231', 'EFO_0003968', 'EFO_1001968', 'EFO_1000657',
       'EFO_0001075', 'MONDO_0005575'], dtype=object), 'count': 38}_|_[ENSG00000165731,ENSG00000120156,ENSG00000077782,ENSG00000142627,ENSG00000185386,ENSG00000113721,ENSG00000134853,ENSG00000162733,ENSG00000157764,ENSG00000066468,ENSG00000132155,ENSG00000111816,ENSG00000157404,ENSG00000097007,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000198400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1969664,"N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1_|_BLTVBQXJFVRPFK-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-1080_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZ-11548415' 'AZD-1080' 'Azd-1080']_|_[('PubChem', array(['103905163'], dtype=object))]_|_nan_|_nan_|_[ENSG00000105723,ENSG00000082701]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL198362,"O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1_|_KGFYHTZWPPHNLQ-AWEZNQCLSA-N_|_Small molecule_|_True_|_RIVAROXABAN_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Xarelto']_|_['BAY 59-7939' 'BAY-59-7939' 'JNJ-39039039' 'JNJ39039039' 'Rivaroxaban']_|_[('DailyMed', array(['rivaroxaban'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto'],
      dtype=object)), ('Wikipedia', array(['Rivaroxaban'], dtype=object)), ('drugbank', array(['DB06228'], dtype=object)), ('chEBI', array(['68579'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002140', 'EFO_0003964', 'HP_0004419', 'EFO_0009314',
       'MONDO_0000831', 'EFO_0000612', 'EFO_0004265', 'EFO_0001378',
       'HP_0001907', 'EFO_0001645', 'MONDO_0100096', 'MP_0001914',
       'EFO_1000985', 'EFO_0003884', 'EFO_0003777', 'EFO_0009531',
       'EFO_0004286', 'HP_0004936', 'EFO_1001161', 'EFO_0003907',
       'HP_0000083', 'EFO_0001074', 'EFO_0000712', 'MONDO_0004992',
       'HP_0001873', 'EFO_0005672', 'EFO_0000694', 'EFO_0001422',
       'MONDO_0005148', 'EFO_0002689', 'EFO_0010680', 'EFO_0000275',
       'MONDO_0011382', 'EFO_0000616', 'EFO_0000266', 'EFO_0010726',
       'EFO_0000556', 'EFO_0003827'], dtype=object), 'count': 38}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 8 approved and 30 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2364609,"CN[C@]1(c2ccccc2Cl)CCCCC1=O.Cl_|_VCMGMSHEPQENPE-ZOWNYOTGSA-N_|_Small molecule_|_True_|_ESKETAMINE HYDROCHLORIDE_|_2019.0_|_4.0_|_CHEMBL395091_|_False_|_True_|_['Spravato']_|_['AM-101' 'Esketamine hydrochloride' 'Ketamine hydrochloride, (s)-'
 'Ketamine hydrochloride, s-' 'Ketanest s']_|_[('DailyMed', array(['esketamine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/spravato'],
      dtype=object)), ('chEBI', array(['60800'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0002050', 'EFO_0003843', 'HP_0000360',
       'MONDO_0002009'], dtype=object), 'count': 5}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for major depressive disorder and depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2364611,"Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1_|_IVRXNBXKWIJUQB-UHFFFAOYSA-N_|_Small molecule_|_False_|_GALUNISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Galunisertib' 'LY-2157299' 'LY2157299' 'Ly-2157299']_|_[('drugbank', array(['DB11911'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009708', 'EFO_0005537', 'EFO_0000519', 'EFO_0005543',
       'EFO_0000616', 'EFO_0004252', 'EFO_0002618', 'EFO_0000182',
       'EFO_1000657', 'EFO_0000198', 'MONDO_0008315', 'EFO_0003860'],
      dtype=object), 'count': 12}_|_[ENSG00000106799]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications."
CHEMBL296468,"CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1_|_OUSFTKFNBAZUKL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-387032_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BMS-387032' 'Bms-387032' 'Bms387032' 'SNS-032' 'Sns 032']_|_[('PubChem', array(['103905658', '137276011', '50100091'], dtype=object)), ('drugbank', array(['DB05969'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000616', 'EFO_0000095', 'EFO_1001469'],
      dtype=object), 'count': 4}_|_[ENSG00000134058,ENSG00000136807,ENSG00000123374]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL324547,"CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1_|_YDZYKNJZCVIKPP-VWLOTQADSA-N_|_Protein_|_False_|_NETAZEPIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Netazepide' 'Sograzepide' 'YF-476' 'Yf476']_|_[('drugbank', array(['DB12355'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001095', 'EFO_0004243', 'EFO_0000280', 'EFO_0007549',
       'EFO_0008533'], dtype=object), 'count': 5}_|_[ENSG00000110148]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3287735,"CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21_|_FKSFKBQGSFSOSM-QFIPXVFZSA-N_|_Small molecule_|_False_|_GSK2816126_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Gsk2816126']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000106462]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3360975,"CC(C)(O)c1cn(-c2ccc(-c3cccc(S(C)(=O)=O)c3)cc2)c(C(C)(C)c2ccccc2Cl)n1_|_JLPURTXCSILYLW-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-779788_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BMS 788' 'Bms-779788' 'EXEL 04286652' 'EXEL-04286652' 'XL 652' 'XL-014'
 'XL-652']_|_nan_|_nan_|_{'rows': array(['EFO_0003914'], dtype=object), 'count': 1}_|_[ENSG00000131408]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3544966,"O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1_|_QDITZBLZQQZVEE-YBEGLDIGSA-N_|_Small molecule_|_False_|_GSK-1059615_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GSK-615' 'GSK1059615' 'GSK615' 'Gsk-1059615']_|_[('drugbank', array(['DB11962'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545192,nan_|_nan_|_Antibody_|_False_|_MIRVETUXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['M-9346A' 'M9346A' 'Mirvetuximab']_|_nan_|_nan_|_nan_|_[ENSG00000110195]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL3707226,"nan_|_nan_|_Oligonucleotide_|_False_|_DEFIBROTIDE SODIUM_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Defitelio']_|_['Defibrotide sodium' 'JZP-381']_|_[('DailyMed', array(['defibrotide%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019514'], dtype=object), 'count': 1}_|_[ENSG00000122194]_|_Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for hepatic veno-occlusive disease."
CHEMBL3986824,"Nc1cncc(-c2cn3ccnc3c(Nc3ccc(N4CCN(C5COC5)CC4)cc3)n2)n1_|_XCIGZBVOUQVIPI-UHFFFAOYSA-N_|_Small molecule_|_False_|_LANRAPLENIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GS-SYK' 'Lanraplenib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LANRAPLENIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14770'], dtype=object))]_|_['CHEMBL4298174']_|_{'rows': array(['EFO_0003834', 'EFO_0000699', 'MONDO_0007915', 'EFO_0000222',
       'MP_0001845', 'MP_0001845'], dtype=object), 'count': 6}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4079239,"C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl_|_CWFVVQFVGMFTBD-SECBINFHSA-N_|_Small molecule_|_False_|_JNJ-54175446_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Jnj-54175446']_|_[('drugbank', array(['DB15358'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000089041]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4279455,"CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C_|_DXOJIXGRFSHVKA-BZVZGCBYSA-N_|_Small molecule_|_False_|_LAROTAXEL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Larotaxel' 'XRP-9881' 'XRP9881' 'Xrp9881']_|_[('drugbank', array(['DB12984'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000294', 'EFO_0003860', 'EFO_0003869', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297794,"nan_|_nan_|_Antibody_|_False_|_NEMOLIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CD14152' 'CIM-331' 'CIM331' 'Nemolizumab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NEMOLIZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0000717', 'MONDO_0021739', 'EFO_0000274'],
      dtype=object), 'count': 4}_|_[ENSG00000164509]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297935,"nan_|_nan_|_Unknown_|_False_|_RG-7841_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Anti-ly6e-vcmmae' 'DLYE-5953A' 'DLYE5953A' 'Dlye5953a' 'RG-7841'
 'RG7841' 'Rg 7841' 'Rg-7841']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000160932]_|_Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4298021,"nan_|_nan_|_Antibody_|_False_|_ZAGOTENEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-3303560' 'LY3303560' 'Ly3303560' 'Zagotenemab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZAGOTENEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005815', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000186868]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4298210,"nan_|_nan_|_Antibody_|_False_|_ISCALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CFZ-533' 'CFZ533' 'Iscalimab' 'NVP-CFZ533']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ISCALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000710', 'EFO_0000699', 'EFO_0004991', 'EFO_0005761',
       'MONDO_0005147', 'EFO_0004237', 'EFO_0004599', 'EFO_0000685',
       'EFO_0010134', 'MONDO_0007915'], dtype=object), 'count': 10}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL45816,"COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C_|_HBNPJJILLOYFJU-VMPREFPWSA-N_|_Small molecule_|_False_|_MIBEFRADIL_|_1997.0_|_4.0_|_nan_|_True_|_True_|_['Posicor 100' 'Posicor 50']_|_['Mibefradil' 'Posicor']_|_[('PubChem', array(['11111472', '26755047', '50110875', '90340964'], dtype=object)), ('Wikipedia', array(['Mibefradil'], dtype=object)), ('drugbank', array(['DB01388'], dtype=object)), ('chEBI', array(['6920'], dtype=object))]_|_['CHEMBL1256688' 'CHEMBL1534525' 'CHEMBL1421212']_|_{'rows': array(['EFO_0000519', 'EFO_1000158', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and has 2 investigational indications. It was withdrawn in at least one region."
CHEMBL595573,"O=C1O[C@]2(CC[C@H](C(=O)Nc3ccn(-c4ccccc4F)n3)CC2)c2cnccc21_|_RMYZIRFUCOMQRH-CAJLXGCNSA-N_|_Small molecule_|_False_|_MK-0557_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-0557' 'MK0557' 'Mk-0557' 'Mk0557']_|_[('drugbank', array(['DB12168'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000164129]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1084172,"O=C(O)C(c1ccccc1)(c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O_|_KLOLZALDXGTNQE-JIDHJSLPSA-N_|_Small molecule_|_False_|_VILANTEROL TRIFENATATE_|_2013.0_|_4.0_|_CHEMBL1198857_|_False_|_True_|_[]_|_['GW-642444M' 'GW642444M' 'Vilanterol (as trifenatate)'
 'Vilanterol trifenatate']_|_[('DailyMed', array(['vilanterol%20trifenatate'], dtype=object)), ('chEBI', array(['75040'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0000464', 'MONDO_0004979', 'EFO_0006505'],
      dtype=object), 'count': 4}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications."
CHEMBL11,"CN(C)CCCN1c2ccccc2CCc2ccccc21_|_BCGWQEUPMDMJNV-UHFFFAOYSA-N_|_Small molecule_|_True_|_IMIPRAMINE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Antideprin' 'Berkomine' 'Cristalia' 'Imipramine' 'Janimine'
 'Melipramine' 'NSC-169866' 'ORG-2463' 'Pramine' 'Presamine' 'Sermonil'
 'Tofranil' 'Tofranil-PM' 'Trimipramine maleate impurity, imipramine-']_|_[('PubChem', array(['104171178', '11111330', '11111331', '124880469', '144203725',
       '170464777', '26751600', '50100256', '50104254', '90341377'],
      dtype=object)), ('TG-GATEs', array(['69'], dtype=object)), ('Wikipedia', array(['Imipramine'], dtype=object)), ('drugbank', array(['DB00458'], dtype=object)), ('chEBI', array(['47499'], dtype=object))]_|_['CHEMBL1692' 'CHEMBL3989845']_|_{'rows': array(['MONDO_0002050', 'HP_0100749', 'EFO_0000519', 'EFO_0005230',
       'EFO_0009687', 'EFO_0004278', 'MONDO_0024290', 'EFO_0003948',
       'EFO_0004287', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0008623',
       'HP_0010992', 'MONDO_0007254', 'EFO_0000612', 'HP_0000726',
       'MONDO_0002009', 'EFO_0002496', 'HP_0003419', 'EFO_0010282'],
      dtype=object), 'count': 20}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1171754,"O=C(c1ccc(Oc2ccc(F)cc2)nc1)N1CCCN(C2CCC2)CC1_|_IQOWHZHNGJXGHG-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-39220675_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Jnj 39220675' 'Jnj-39220675']_|_[('drugbank', array(['DB12929'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200776,"C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl_|_QANQWUQOEJZMLL-PKLMIRHRSA-N_|_Small molecule_|_False_|_CINACALCET HYDROCHLORIDE_|_2004.0_|_4.0_|_CHEMBL1201284_|_False_|_True_|_['Mimpara' 'Sensipar']_|_['AMG-073' 'AMG-073 HCL' 'AMG073 HCL' 'AMG073 HYDROCHLORIDE'
 'Cinacalcet hcl' 'Cinacalcet hydrochloride']_|_[('DailyMed', array(['cinacalcet%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mimpara'],
      dtype=object)), ('PubChem', array(['144206207', '170465336'], dtype=object)), ('chEBI', array(['48391'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001173', 'HP_0003072', 'EFO_0000673', 'EFO_0000313',
       'EFO_0003884', 'EFO_1000456', 'EFO_0008506'], dtype=object), 'count': 7}_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 1 investigational indication."
CHEMBL1201262,"CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1_|_OCUJLLGVOUDECM-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPIVEFRIN_|_1980.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['DPE' 'Dipivalyl epinephrine' 'Dipivefrin' 'Dipivefrine']_|_[('Wikipedia', array(['Dipivefrine'], dtype=object)), ('drugbank', array(['DB00449'], dtype=object)), ('chEBI', array(['4646'], dtype=object))]_|_['CHEMBL1200833']_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for glaucoma."
CHEMBL1201513,"nan_|_nan_|_Oligosaccharide_|_False_|_HEPARIN CALCIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Calciparine' 'Uniparin ca']_|_['Ecasolv' 'Heparin calcium' 'Heparin calcium salt' 'Heparinum calcicum']_|_nan_|_nan_|_{'rows': array(['EFO_1000954', 'EFO_1000965'], dtype=object), 'count': 2}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 2 investigational indications."
CHEMBL1201828,"nan_|_nan_|_Antibody_|_True_|_ECULIZUMAB_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Soliris']_|_['5G1.1' 'ABP-959' 'Alexion' 'Eculizumab' 'Elizaria' 'H5G1-1' 'H5G1.1'
 'H5G1.1VHC+H5G1.1VLC' 'H5G11']_|_[('DailyMed', array(['eculizumab'], dtype=object)), ('DrugCentral', array(['4969'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/soliris'],
      dtype=object)), ('Wikipedia', array(['Eculizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'EFO_0001365', 'EFO_0004826', 'EFO_0007292',
       'MONDO_0100096', 'MONDO_0001549', 'EFO_0009473', 'EFO_1001311',
       'EFO_0004256', 'EFO_0004599', 'MONDO_0016244', 'EFO_0000668',
       'MONDO_0018922', 'MONDO_0019736', 'MONDO_0100244', 'EFO_0004991',
       'HP_0001873', 'EFO_0003884', 'MONDO_0018904', 'EFO_0000565',
       'EFO_0000398', 'EFO_0000540'], dtype=object), 'count': 22}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1722,"COC(=O)C(c1ccccc1)C1CCCCN1.Cl_|_JUMYIBMBTDDLNG-UHFFFAOYSA-N_|_Small molecule_|_True_|_METHYLPHENIDATE HYDROCHLORIDE_|_1955.0_|_4.0_|_CHEMBL796_|_False_|_True_|_['Adhansia xr' 'Aptensio xr' 'Concerta' 'Delmosart' 'Equasym' 'Equasym xl'
 'Jornay pm' 'Matoride xl' 'Medikinet' 'Medikinet xl' 'Metadate cd'
 'Metadate er' 'Methylin' 'Methylin er' 'Methylphenidate hydrochloride'
 'Quillichew er' 'Quillivant xr' 'Relexxii' 'Ritalin' 'Ritalin la'
 'Ritalin sr' 'Ritalin-sr' 'Tranquilyn' 'Xenidate xl']_|_['Aptensio' 'Aptensio xr' 'Foquest' 'Metadate' 'Methylphenidate HCl'
 'Methylphenidate hcl' 'Methylphenidate hydrochloride'
 'Methylphenidate hydrochloride cii' 'NSC-169868' 'Oros mph' 'Quillichew'
 'Quillivant' 'SPD-544' 'SPD544']_|_[('DailyMed', array(['methylphenidate%20hydrochloride'], dtype=object)), ('PubChem', array(['144204737', '144207507', '17389819'], dtype=object)), ('chEBI', array(['31836'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888', 'MONDO_0005090', 'EFO_0004216', 'MONDO_0004992',
       'EFO_0008568', 'HP_0012378', 'EFO_0003840', 'MONDO_0011184',
       'EFO_0003929', 'EFO_0003768', 'MONDO_0002050'], dtype=object), 'count': 11}_|_[ENSG00000103546,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743048,"nan_|_nan_|_Antibody_|_True_|_OBINUTUZUMAB_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Gazyvaro']_|_['AFUTUZUMAB' 'Afutuzumab' 'GA-101' 'GA101' 'Gazyva' 'HUMAB CD20'
 'HUMAB<CD20>' 'HUMABCD20' 'Obinutuzumab' 'R-7159' 'RG-7159' 'RO 5072759'
 'RO 5072759 HUMAB<CD20>' 'RO-5072759' 'RO-5072759 HUMAB<CD20>'
 'Ro5072759']_|_[('DailyMed', array(['obinutuzumab'], dtype=object)), ('DrugCentral', array(['4983'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001023', 'EFO_0005761', 'EFO_0000220', 'EFO_0004255',
       'EFO_1001469', 'EFO_0005952', 'EFO_1001951', 'EFO_0008528',
       'MONDO_0004992', 'EFO_0000574', 'MONDO_0018906', 'EFO_0009441',
       'EFO_0000565', 'EFO_0000403', 'MONDO_0007915', 'EFO_0003060',
       'MONDO_0013730', 'EFO_0004236', 'EFO_1001051', 'EFO_0003086',
       'EFO_0003884', 'EFO_0000309', 'EFO_0000095', 'EFO_0000096',
       'EFO_0000183', 'EFO_0000616', 'EFO_1000956'], dtype=object), 'count': 27}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2016681,"CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](C(=O)Nc2ccc(C(F)(F)F)cn2)CC1_|_WGEWUYACXPEFPO-AULYBMBSSA-N_|_Small molecule_|_False_|_VELNEPERIT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['S-2367' 'Velneperit']_|_[('drugbank', array(['DB12889'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000164129]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108027,"nan_|_nan_|_Protein_|_True_|_DULAGLUTIDE_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Trulicity']_|_['Dulaglutide' 'LY-2189265' 'LY2189265']_|_[('DailyMed', array(['dulaglutide'], dtype=object)), ('DrugCentral', array(['4885'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004319', 'MONDO_0005147', 'MONDO_0005148', 'EFO_0000400',
       'EFO_0003884', 'HP_0001959'], dtype=object), 'count': 6}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109664,"nan_|_nan_|_Antibody_|_False_|_ELDELUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-936557' 'Eldelumab' 'MDX-1100']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000384', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000169245]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2397415,"Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12_|_JJVAPHYEOZSKJZ-JGCGQSQUSA-N_|_Small molecule_|_False_|_ZAVEGEPANT_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BHV-3500' 'BMS-742413' 'BMS-742413-01' 'Vazegepant' 'Zavegepant']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZAVEGEPANT/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650220']_|_{'rows': array(['MONDO_0005277', 'MONDO_0004979', 'MONDO_0005277', 'MONDO_0100096'],
      dtype=object), 'count': 4}_|_[ENSG00000064989,ENSG00000132329]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for migraine disorder and has 3 investigational indications."
CHEMBL313972,"C[C@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1_|_HCZKYJDFEPMADG-TXEJJXNPSA-N_|_Small molecule_|_False_|_MASOPROCOL_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Actinex']_|_['CHX-100' 'Dihydronorguaiaretic acid' 'Dinorguaiaretic acid, dihydro-'
 'INSM-18' 'Insm-18' 'Insm18' 'MESO-NDGA' 'Masoprocol'
 'Meso-nordihydroguaiaretic acid' 'NSC-4291' 'NSC-682984'
 'Nordihydroguaiaretate' 'Nordihydroguaiaretic acid'
 'Nordihydroguiaretic acid' 'Oristar nhga']_|_[('PubChem', array(['11111540', '11111541', '124891671', '144203761', '50100292',
       '50106727', '50106728', '90341429'], dtype=object)), ('Wikipedia', array(['Masoprocol'], dtype=object)), ('drugbank', array(['DB00179'], dtype=object)), ('chEBI', array(['73468'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 2}_|_[ENSG00000140443,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 1 investigational indication."
CHEMBL346631,"CC(C)OCc1ccc2c(c1)c1c3c(c4c(c1n2CCCOC(=O)CN(C)C)Cc1ccccc1-4)C(=O)NC3_|_UHEBDUAFKQHUBV-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEP-7055_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CEP-7055' 'Cep-7055']_|_nan_|_nan_|_nan_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545010,"CCN1CCC(c2cccc(S(C)(=O)=O)c2F)CC1_|_UKUPJASJNQDHPH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ORDOPIDINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ACR-325' 'ACR325' 'Acr325' 'Ordopidine']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545159,"nan_|_nan_|_Small molecule_|_False_|_R-333_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['R-333']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000165025,ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545369,"NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1_|_FBKMWOJEPMPVTQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_EPACADOSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Epacadostat' 'INCB-024360' 'INCB024360']_|_[('drugbank', array(['DB11717'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000691', 'EFO_0000702', 'MONDO_0005184', 'MONDO_0002158',
       'EFO_0000196', 'Orphanet_145', 'MONDO_0008903', 'MONDO_0044881',
       'EFO_0000222', 'EFO_1000251', 'EFO_0003863', 'MONDO_0001187',
       'MONDO_0002087', 'EFO_0000181', 'EFO_0008528', 'EFO_0000616',
       'EFO_0006859', 'EFO_1000657', 'EFO_1001512', 'EFO_0003060',
       'EFO_0000756', 'EFO_0000574', 'MONDO_0011719', 'EFO_0000519',
       'EFO_0000681', 'EFO_1000576', 'MONDO_0008170', 'EFO_0000389',
       'EFO_0001075', 'EFO_0000198', 'MONDO_0011962'], dtype=object), 'count': 31}_|_[ENSG00000131203]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 31 investigational indications."
CHEMBL3545391,"CC#C[C@]1(O)CCC2C3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc4c(c3)OCO4)C[C@@]21C_|_DFELGYQKEOCHOA-RBXNTRDFSA-N_|_Small molecule_|_False_|_ORG-34517_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ORG 34517' 'ORG-34517' 'ORG34517' 'Org-34517' 'PT-150' 'PT150' 'Pt150'
 'SCH 900636' 'SCH-900636']_|_nan_|_nan_|_{'rows': array(['MONDO_0002050', 'MONDO_0007079', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3682589,"O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc3ccccc3c2C2CC2)cc1_|_CWEFDWIKLABKBX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ELISMETREP_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Elismetrep' 'MT-8554' 'Mt-8554']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELISMETREP/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15287'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000783', 'HP_0031217'], dtype=object), 'count': 2}_|_[ENSG00000144481]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3990033,"nan_|_nan_|_Oligonucleotide_|_False_|_INCLISIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ALN-60212' 'ALN-PCSSC' 'ALN-PSCsc' 'Inclisiran' 'Leqvio']_|_nan_|_nan_|_{'rows': array(['HP_0003124', 'EFO_0005672', 'EFO_0003086', 'EFO_0004911',
       'EFO_0000319', 'EFO_0003914', 'EFO_0001645', 'MONDO_0021187',
       'MONDO_0018328'], dtype=object), 'count': 9}_|_[ENSG00000169174]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL4210847,"CCOCCn1nc(C(=O)NS(C)(=O)=O)c2nc(N(C)CC)nc(Nc3cc(C)ccn3)c21_|_ZUHZNKJIJDAJFD-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-00489791_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-489,791' 'Pf-00489791' 'UK-489,791']_|_[('drugbank', array(['DB11736'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001361', 'EFO_0000401', 'EFO_1001145', 'EFO_0000537'],
      dtype=object), 'count': 4}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297184,"Cc1ccc(-c2nc(N)nc3c2nnn3Cc2cccc(CO[C@H]3CCOC3)n2)o1_|_KURQKNMKCGYWRJ-HNNXBMFYSA-N_|_Small molecule_|_False_|_CIFORADENANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CPI-444' 'Ciforadenant' 'V-81444' 'V81444']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CIFORADENANT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000681', 'EFO_0000616', 'EFO_0001378',
       'EFO_0003888', 'MONDO_0005180'], dtype=object), 'count': 6}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4297228,"nan_|_nan_|_Unknown_|_False_|_BRIVOLIGIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AYX-1' 'AYX1' 'Brivoligide']_|_nan_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000120738]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297345,"CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1.Cl_|_XROFSGVHHSJMMG-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADL-5747_|_nan_|_2.0_|_CHEMBL561339_|_False_|_False_|_[]_|_['ADL5747' 'Adl-5747' 'Adl5747']_|_nan_|_nan_|_{'rows': array(['MONDO_0041052', 'EFO_0004616'], dtype=object), 'count': 2}_|_[ENSG00000116329]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297750,"nan_|_nan_|_Antibody_|_False_|_FARICIMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Vabysmo']_|_['Faricimab' 'Faricimab svoa' 'Faricimab-svoa' 'RG7716' 'RG77161'
 'RO-6867461' 'RO6867461' 'Rg-7716' 'Ro6867461' 'Vabysmo' 'Y8ha1i28d3']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FARICIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000478', 'EFO_0009606', 'MONDO_0007935', 'EFO_0010977',
       'EFO_0001365', 'EFO_0005753', 'MONDO_0003005', 'EFO_0004683'],
      dtype=object), 'count': 8}_|_[ENSG00000112715,ENSG00000091879]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 5 approved and 3 investigational indications."
CHEMBL4303404,"Cc1noc2c1-c1ccccc1C(c1ccc(Cl)cc1)=N[C@H]2CC(N)=O_|_GCWIQUVXWZWCLE-INIZCTEOSA-N_|_Small molecule_|_False_|_PELABRESIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CPI-0610' 'CPI-232' 'CPI-267232' 'Cpi 0610' 'Cpi-0610'
 'Cpi-0610 anhydrous' 'Pelabresib' 'Pelabresib anhydrous'
 'Pelabresib monohydrate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PELABRESIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0044903', 'EFO_0002430', 'EFO_0002431', 'EFO_0000574',
       'EFO_0001378'], dtype=object), 'count': 5}_|_[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL482950,"CC[C@@H](C)Nc1nc(C)nc2c(-c3ccc(OC)nc3C)c(C)nn12_|_LBWQSAZEYIZZCE-SNVBAGLBSA-N_|_Small molecule_|_False_|_PEXACERFONT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-562086' 'Bms562086' 'CRF1 ANTAGONIST' 'Dpc-a69448' 'Pexacerfont']_|_[('drugbank', array(['DB12572'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0000555', 'EFO_1001892'], dtype=object), 'count': 3}_|_[ENSG00000120088]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL483321,"COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1_|_LLVZBTWPGQVVLW-SNAWJCMRSA-N_|_Small molecule_|_False_|_CP-724714_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-724,714' 'CP-724714' 'Cp-724714']_|_[('PubChem', array(['50100096'], dtype=object)), ('drugbank', array(['DB12302'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003869', 'MONDO_0007254', 'EFO_0009708'], dtype=object), 'count': 3}_|_[ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL517427,"COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1_|_FAIIFDPAEUKBEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_NILVADIPINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CL 287,389' 'CL-287,389' 'CL-287389' 'Dl-nilvadipine' 'Escor' 'FK 235'
 'FK-235' 'FR-34235' 'Nilvadipine' 'Nivadil' 'Nivadip' 'Nivadipine'
 'SK&F 102,362' 'SKF-102362']_|_[('PubChem', array(['144205992', '50112689'], dtype=object)), ('Wikipedia', array(['Nilvadipine'], dtype=object)), ('drugbank', array(['DB06712'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0000319'], dtype=object), 'count': 2}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL960,"Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1_|_VHOGYURTWQBHIL-UHFFFAOYSA-N_|_Small molecule_|_True_|_LEFLUNOMIDE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Arava' 'Leflunomide'
 'Leflunomide zentiva (previously leflunomide winthrop)']_|_['HWA-486' 'L04AA13' 'Leflunomide' 'Leflunomide medac'
 'Leflunomide ratiopharm' 'Leflunomide teva' 'Leflunomide winthrop'
 'NSC-677411' 'NSC-759864' 'Repso' 'SU-101' 'SU101' 'SULOL']_|_[('DailyMed', array(['leflunomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-zentiva'],
      dtype=object)), ('PubChem', array(['11111382', '11111383', '124880563', '124880568', '144203733',
       '144212190', '170464823', '174006674', '26746985', '26746986',
       '26746987', '50100264', '50104054', '50104055', '50104056',
       '56422128', '85231115', '855764', '90341277'], dtype=object)), ('Wikipedia', array(['Leflunomide'], dtype=object)), ('drugbank', array(['DB01097'], dtype=object)), ('chEBI', array(['6402'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'MONDO_0007915', 'EFO_0003778', 'EFO_0000764',
       'EFO_0005761', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000616',
       'EFO_0000540', 'EFO_0003073', 'MONDO_0100096', 'EFO_0004991',
       'EFO_1000965', 'MONDO_0016537', 'EFO_0008518', 'EFO_1000158',
       'EFO_1001231', 'EFO_0000685', 'MONDO_0020547', 'MONDO_0007254',
       'EFO_0007187', 'EFO_0000699'], dtype=object), 'count': 22}_|_[ENSG00000102967]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1133,"CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl_|_SWIJYDAEGSIQPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYBUTYNIN CHLORIDE_|_1975.0_|_4.0_|_CHEMBL1231_|_False_|_True_|_['Ditropan' 'Ditropan xl' 'Gelnique' 'Oxybutynin chloride']_|_['5058' 'MJ 4309-1' 'MJ-4309-1' 'NSC-759108' 'Oxybutynin chloride'
 'Oxybutynin hydrochloride' 'Pollakisu' 'Tropax']_|_[('DailyMed', array(['oxybutynin%20chloride'], dtype=object)), ('PubChem', array(['144204058', '50106787', '50106788', '56422498', '855604'],
      dtype=object)), ('chEBI', array(['7857'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006865', 'HP_0000020', 'EFO_0001663', 'EFO_1000781'],
      dtype=object), 'count': 4}_|_[ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and is indicated for urgency urinary incontinence and overactive bladder and has 2 investigational indications."
CHEMBL1201064,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_YRFXGQHBPBMFHW-SBTZIJSASA-N_|_Small molecule_|_False_|_FLUOROMETHOLONE ACETATE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Flarex']_|_['Fluorometholone 17-acetate' 'Fluorometholone acetate' 'NSC-47438'
 'U-17,323' 'U-17323']_|_[('DailyMed', array(['fluorometholone%20acetate'], dtype=object)), ('PubChem', array(['100431'], dtype=object)), ('chEBI', array(['78354'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986."
CHEMBL1289494,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC_|_SPMVMDHWKHCIDT-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIVOZANIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Fotivda']_|_['ASP-4130' 'AV-951' 'KIL8951' 'KRN-951' 'Kil-8951' 'Krn-951' 'Tivozanib']_|_[('PubChem', array(['124955473'], dtype=object)), ('Wikipedia', array(['Tivozanib'], dtype=object)), ('drugbank', array(['DB11800'], dtype=object))]_|_['CHEMBL2105756' 'CHEMBL3426917' 'CHEMBL4784300']_|_{'rows': array(['EFO_0005221', 'MONDO_0002158', 'EFO_0000681', 'EFO_0001421',
       'EFO_1001951', 'EFO_0000519', 'MONDO_0008315', 'EFO_0000182',
       'EFO_0000616', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001968',
       'MONDO_0007254', 'EFO_0000681', 'EFO_0003060'], dtype=object), 'count': 15}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157404,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for renal cell carcinoma and has 14 investigational indications."
CHEMBL1477,"COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1_|_SEERZIQQUAZTOL-ANMDKAQQSA-N_|_Small molecule_|_False_|_CERIVASTATIN_|_1997.0_|_4.0_|_nan_|_True_|_True_|_['Lipobay']_|_['Baycol' 'Cerivastatin' 'Lipobay']_|_[('PubChem', array(['50111694'], dtype=object)), ('Wikipedia', array(['Cerivastatin'], dtype=object)), ('drugbank', array(['DB00439'], dtype=object)), ('chEBI', array(['3558'], dtype=object))]_|_['CHEMBL1200563']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for cardiovascular disease. It was withdrawn in at least one region."
CHEMBL1715,"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl_|_GHUUBYQTCDQWRA-UHFFFAOYSA-N_|_Small molecule_|_True_|_PIOGLITAZONE HYDROCHLORIDE_|_1999.0_|_4.0_|_CHEMBL595_|_False_|_True_|_['Actos' 'Diabiom' 'Glidipion'
 'Glidipion (previously pioglitazone actavis group)' 'Glizofar'
 'Pioglitazone hydrochloride']_|_['Actos' 'NSC-758876' 'Pioglitazone (as hydrochloride)' 'Pioglitazone hcl'
 'Pioglitazone hydrochloride' 'Piomed' 'STR-001' 'U-72107A']_|_[('DailyMed', array(['pioglitazone%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/glidipion'],
      dtype=object)), ('PubChem', array(['144204993', '144210901', '170465116', '26748968', '49681546'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0002745', 'MONDO_0004976', 'EFO_0002618', 'MONDO_0005148',
       'EFO_0003095', 'EFO_0001421', 'EFO_0003884', 'MONDO_0002009',
       'EFO_0003060'], dtype=object), 'count': 9}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for type 2 diabetes mellitus and liver disease and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743041,"nan_|_nan_|_Antibody_|_False_|_MOGAMULIZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Poteligeo']_|_['AMG-761' 'KM-8761' 'KM8761' 'KW-0761' 'Mogamulizumab'
 'Mogamulizumab (genetical recombination)' 'Mogamulizumab kpkc']_|_[('DailyMed', array(['mogamulizumab-kpkc'], dtype=object)), ('DrugCentral', array(['5031'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000313', 'EFO_0000616', 'EFO_0002913', 'EFO_0007527',
       'EFO_1001051', 'MONDO_0004979', 'EFO_0003060', 'EFO_0000182',
       'MONDO_0019471', 'EFO_0000211', 'EFO_1000785'], dtype=object), 'count': 11}_|_[ENSG00000183813]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 8 investigational indications."
CHEMBL1774080,"O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)nc2N1_|_QGNOXTFZOLDODX-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-00217830_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['J2.975.999E' 'PF-00217830' 'PF-217830' 'Pf-00217830']_|_[('drugbank', array(['DB12998'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL178,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1_|_STQGQHZAVUOBTE-VGBVRHCVSA-N_|_Small molecule_|_True_|_DAUNORUBICIN_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Daunoxome']_|_['Cerubidine' 'Daunomycin' 'Daunorubicin' 'Daunoxome'
 'Epirubicin hydrochloride impurity, daunorubicin-' 'FI 6339' 'FI-6339'
 'NSC-83142' 'RP 13057' 'RP-13057' 'Valrubicin impurity, daunorubicin']_|_[('DailyMed', array(['daunorubicin'], dtype=object)), ('PubChem', array(['11114094', '144204447', '170465048', '29215022'], dtype=object)), ('Wikipedia', array(['Daunorubicin'], dtype=object)), ('drugbank', array(['DB00694'], dtype=object)), ('chEBI', array(['41977'], dtype=object))]_|_['CHEMBL1563' 'CHEMBL1200475']_|_{'rows': array(['MONDO_0044881', 'EFO_0000220', 'MONDO_0000873', 'EFO_0000558',
       'MONDO_0004643', 'EFO_0000565', 'EFO_0003028', 'EFO_0003811',
       'EFO_0004289', 'EFO_0004251', 'EFO_0000218', 'EFO_0000198',
       'EFO_0000209', 'MONDO_0044917', 'EFO_0003802', 'MONDO_0000870',
       'EFO_0000565', 'EFO_0000224', 'EFO_0003025', 'EFO_0000221',
       'MONDO_0000870', 'MONDO_0007254', 'EFO_0000691', 'EFO_0000094',
       'EFO_0003884', 'EFO_0000094', 'MONDO_0044917', 'MONDO_0044903',
       'EFO_0000222', 'EFO_0000574', 'EFO_0000616', 'EFO_0000565',
       'EFO_0000223', 'EFO_0004239', 'EFO_0004289', 'EFO_0000198',
       'EFO_0000479', 'EFO_0000220', 'EFO_0005952', 'EFO_0000222',
       'EFO_0000339', 'EFO_0003029', 'EFO_0000691', 'EFO_0002429',
       'EFO_0003027', 'EFO_0003802', 'EFO_1001779', 'EFO_1001052'],
      dtype=object), 'count': 48}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 3 approved and 41 investigational indications. This drug has a black box warning from the FDA."
CHEMBL178803,"CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1_|_XVGOZDAJGBALKS-UHFFFAOYSA-N_|_Small molecule_|_False_|_BLONANSERIN_|_2008.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AD-5423' 'Blonanserin' 'DSP-5423']_|_[('PubChem', array(['144206818'], dtype=object)), ('drugbank', array(['DB09223'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and has 1 investigational indication."
CHEMBL2106227,"CCNC1=Nc2ccc(Cl)cc2C(C)(c2ccccc2)O1_|_IBYCYJFUEJQSMK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETIFOXINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['36-801' 'Etifoxine' 'HOE 36801' 'HOE-36801']_|_[('drugbank', array(['DB08986'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108282,"nan_|_nan_|_Protein_|_False_|_CATRIDECACOG_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Novothirteen']_|_['Catridecacog' 'Novothirteen' 'Tretten']_|_[('DrugCentral', array(['5134'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/novothirteen'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_183654', 'MP_0001914', 'MONDO_0018029', 'MONDO_0002243'],
      dtype=object), 'count': 4}_|_[ENSG00000124491]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for rare genetic coagulation disorder and hemorrhage and has 2 investigational indications."
CHEMBL2109662,"nan_|_nan_|_Protein_|_False_|_DALANTERCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACE-041' 'Dalantercept' 'Delantercept']_|_nan_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_0000182', 'EFO_0004142', 'EFO_0000181',
       'EFO_0001378'], dtype=object), 'count': 5}_|_[ENSG00000163217,ENSG00000263761]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2336325,"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1_|_JUSFANSTBFGBAF-IRXDYDNUSA-N_|_Small molecule_|_False_|_VISTUSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-2014' 'AZD2014' 'Azd-2014' 'Vistusertib']_|_[('drugbank', array(['DB11925'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000707', 'MONDO_0004992', 'MONDO_0007254',
       'EFO_0005537', 'EFO_0000702', 'EFO_0003897', 'EFO_1000251',
       'MONDO_0016642', 'MONDO_0001187', 'EFO_0000708', 'MONDO_0008315',
       'EFO_0000519', 'EFO_0000349', 'EFO_0000228', 'EFO_0000503',
       'EFO_0003060', 'EFO_1001512', 'EFO_0000403', 'EFO_0007532',
       'Orphanet_145'], dtype=object), 'count': 21}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 21 investigational indications."
CHEMBL256147,"CNC(=N)NCCC[C@H](N)C(=O)O_|_NTNWOCRCBQPEKQ-YFKPBYRVSA-N_|_Small molecule_|_False_|_TILARGININE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['.omega.-n-methylarginine' 'L-NMMA' 'Ng-methylarginine'
 'Ng-monomethyl-l-arginine' 'Omega-n-methylarginine'
 'Omega-n-methylated arginine' 'Targinine' 'Tilarginine']_|_[('PubChem', array(['11111490', '11113694', '90340995'], dtype=object)), ('Wikipedia', array(['Methylarginine'], dtype=object)), ('drugbank', array(['DB11815'], dtype=object)), ('chEBI', array(['28229'], dtype=object))]_|_['CHEMBL3217190' 'CHEMBL1256175' 'CHEMBL1744478']_|_{'rows': array(['MONDO_0007254', 'EFO_0004272', 'EFO_1000859', 'EFO_0600064',
       'EFO_0000764', 'EFO_1000653', 'MONDO_0011382', 'MONDO_0021187',
       'HP_0031273', 'EFO_0009444'], dtype=object), 'count': 10}_|_[ENSG00000089250,ENSG00000007171,ENSG00000164867]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL3337527,"CCCCn1ccc(N2CCC(c3ccccc3)CC2)c(Cl)c1=O_|_HYOGJHCDLQSAHX-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-40411813_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADX-71149' 'Jnj-40411813']_|_[('drugbank', array(['DB12059'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'MONDO_0002009', 'MONDO_0005090', 'MONDO_0024417'],
      dtype=object), 'count': 4}_|_[ENSG00000164082]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL360328,"C[C@H]1CNCCc2ccc(Cl)cc21_|_XTTZERNUQAFMOF-QMMMGPOBSA-N_|_Small molecule_|_False_|_LORCASERIN_|_2012.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Lorcaserin']_|_[('PubChem', array(['144206569', '170466882'], dtype=object)), ('Wikipedia', array(['Lorcaserin'], dtype=object)), ('drugbank', array(['DB04871'], dtype=object)), ('chEBI', array(['65353'], dtype=object))]_|_['CHEMBL3527027' 'CHEMBL2095211']_|_{'rows': array(['EFO_0003100', 'EFO_0005611', 'EFO_0003768', 'EFO_0007191',
       'EFO_0003086', 'EFO_0003890', 'EFO_0001421', 'EFO_0004319',
       'EFO_0001073', 'EFO_0010702', 'EFO_0002610', 'EFO_0000319',
       'EFO_0001073'], dtype=object), 'count': 13}_|_[ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for obesity and has 12 investigational indications. It was withdrawn in at least one region."
CHEMBL37744,"CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1_|_OYPPVKRFBIWMSX-SXGWCWSVSA-N_|_Small molecule_|_False_|_ZIMELDINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Cis-zimelidine' 'Normud' 'Zelmid' 'Zimeldine' 'Zimelidine']_|_[('PubChem', array(['50104953', '90340829'], dtype=object)), ('Wikipedia', array(['Zimelidine'], dtype=object)), ('drugbank', array(['DB04832'], dtype=object))]_|_['CHEMBL2355333' 'CHEMBL1257002' 'CHEMBL1257115']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder."
CHEMBL3889654,"O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1_|_NYNZQNWKBKUAII-KBXCAEBGSA-N_|_Small molecule_|_False_|_LAROTRECTINIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ARRY-470' 'BAY-2757556' 'BAY2757556' 'LOXO-101' 'Larotrectinib'
 'Loxo-101']_|_[('drugbank', array(['DB14723'], dtype=object))]_|_['CHEMBL3989939']_|_{'rows': array(['EFO_0009708', 'MONDO_0002108', 'EFO_1000026', 'EFO_0000616',
       'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications."
CHEMBL4298095,"nan_|_nan_|_Antibody_|_False_|_NIMACIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JNJ-2463' 'JNJ2463' 'Nimacimab' 'RYI-018' 'RYI018' 'Ryi-018']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NIMACIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000948', 'EFO_0003095'], dtype=object), 'count': 2}_|_[ENSG00000118432]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4559134,"COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1_|_XIIOFHFUYBLOLW-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELPERCATINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Retevmo' 'Retsevmo']_|_['LOXO-292' 'LY-3527723' 'LY3527723' 'Loxo-292' 'Ret inhibitor loxo-292'
 'Selpercatinib']_|_[('DailyMed', array(['selpercatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SELPERCATINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000501', 'EFO_0001421', 'MONDO_0015277',
       'EFO_0000616', 'EFO_0003841', 'MONDO_0004992', 'HP_0000083',
       'EFO_0000641', 'MONDO_0002108'], dtype=object), 'count': 10}_|_[ENSG00000165731,ENSG00000170759,ENSG00000108091]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 7 approved and 3 investigational indications."
CHEMBL46516,"O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2_|_QOYHHIBFXOOADH-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLUSPIRILENE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Imap' 'Redeptin']_|_['Fluspirilene' 'Imap' 'MCN-JR-6218' 'R 6218' 'R-6218' 'Redeptin']_|_[('PubChem', array(['104171151', '11111163', '11112501', '11532937', '124880064',
       '124880066', '144203693', '170466307', '174006661', '26753577',
       '26753578', '50106303', '50106304', '56422781', '85231040',
       '90341058'], dtype=object)), ('Wikipedia', array(['Fluspirilene'], dtype=object)), ('drugbank', array(['DB04842'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005407', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."
CHEMBL5095030,"N=C(N)NCCC[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)c2ccc(F)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(N)=O)C(=O)N1)C(N)=O_|_JJVZSYKFCOBILL-DPNRMINZSA-N_|_Protein_|_False_|_MOTIXAFORTIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['4F-BENZOYL-TN-14003' '4F-benzoyl-TN14003' 'BKT-140' 'BKT140' 'BL-8040'
 'Bkt140' 'Bl 8040' 'Motixafortide' 'T140' 'TF 14016' 'TF-14016' 'TF14016']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOTIXAFORTIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0000616', 'EFO_0000220', 'EFO_0000503',
       'MONDO_0011382', 'EFO_0000339', 'EFO_0002916', 'HP_0001915',
       'EFO_0000222', 'EFO_0001378', 'EFO_0000183', 'MONDO_0000873'],
      dtype=object), 'count': 12}_|_[ENSG00000121966]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL5314395,"CC(C)(C)c1nnc([C@H]2O[C@@H](n3cnc4c(Nc5ccc(Cl)cc5F)ncnc43)[C@H](O)[C@@H]2O)o1_|_ZQYJPMPXQLNTPQ-QCUYGVNKSA-N_|_Small molecule_|_False_|_GW493838_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW-493838 X' 'GW-493838X' 'GW493838' 'Gw-493838' 'Gw493838']_|_nan_|_nan_|_{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL679,"CNC[C@H](O)c1ccc(O)c(O)c1_|_UCTWMZQNUQWSLP-VIFPVBQESA-N_|_Small molecule_|_False_|_EPINEPHRINE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Adren co' 'Adrenaclick' 'Adrenalin' 'Ana-Kit' 'Ana-guard' 'Anapen'
 'Anaphylactic shock drug kit' 'Asma-vydrin' 'Asthmahaler' 'Auvi-q'
 'Bronkaid mist' 'Brovon' 'Emerade' 'Epi e z pen jr' 'Epinephrine'
 'Epinephrine (copackaged)' 'Epipen' 'Epipen e z pen' 'Epipen jr'
 'Epipen jr.' 'Eppy' 'Gppe inh soln' 'Jext' 'Medihaler-epi' 'Primatene'
 'Primatene mist' 'Riddobron' 'Riddofan' 'Rybarvin' 'Simplene'
 'Soln made to rybarvin for' 'Sus-Phrine' 'Sus-Phrine Sulfite-Free'
 'Sus-phrine sulfite free' 'Symjepi' 'Twinject 0.15' 'Twinject 0.3']_|_['(-)-(r)-epinephrine' '(-)-epinephrine' 'Adrenaline' 'Adrenalinum'
 'Epinephrine' 'Epinephrine hcl' 'Epinephrine hydrochloride'
 'Epinephrinum' 'Glauposine' 'L-epinephrine hydrochloride'
 'Levo-methylaminoethanolcatechol' 'NSC-62786' 'Nephridine'
 'Racepinefrine hydrochloride, (r)-' 'Racepinefrine, (r)-'
 'Sus-phrine sulphite-free' 'Susphrine' 'Tonogen' 'Twinject']_|_[('DailyMed', array(['epinephrine'], dtype=object)), ('PubChem', array(['11111154', '144205115', '170464973', '26754418', '26754419',
       '26754420', '29215202', '90341589'], dtype=object)), ('Wikipedia', array(['Epinephrine'], dtype=object)), ('drugbank', array(['DB00668'], dtype=object)), ('chEBI', array(['28918'], dtype=object))]_|_['CHEMBL3183376' 'CHEMBL1256958' 'CHEMBL1200818' 'CHEMBL227634']_|_{'rows': array(['MONDO_0001056', 'MONDO_0003061', 'EFO_0000319', 'EFO_0005532',
       'HP_0002105', 'EFO_0003060', 'EFO_0007355', 'EFO_1001250',
       'MONDO_0007254', 'EFO_0004198', 'EFO_0000544', 'EFO_0003895',
       'EFO_0000400', 'HP_0002239', 'EFO_0003956', 'EFO_0004278',
       'EFO_0006834', 'EFO_0004209', 'MONDO_0004979', 'HP_0001742',
       'HP_0011950', 'EFO_0003843', 'EFO_0007149', 'EFO_1001087',
       'EFO_0005251', 'HP_0100543', 'EFO_0009676', 'EFO_0004287',
       'MONDO_0100053', 'HP_0011499', 'HP_0006536', 'EFO_0000546',
       'EFO_0004610', 'MP_0001914', 'EFO_0005854', 'HP_0012532',
       'EFO_0003843', 'EFO_0009492', 'EFO_1001139', 'MONDO_0005041',
       'MONDO_0005271', 'EFO_0003144', 'HP_0031273', 'EFO_0009840',
       'EFO_0009846', 'EFO_0005306', 'EFO_1001417', 'EFO_0005531',
       'EFO_0007486', 'EFO_0004278', 'MONDO_0002050', 'EFO_1001222',
       'EFO_0004616'], dtype=object), 'count': 53}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 19 approved and 34 investigational indications."
CHEMBL1090479,"CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1_|_QTBWCSQGBMPECM-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-1070916_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GSK 1070916A' 'GSK1070916' 'Gsk-1070916' 'Gsk-1070916a']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000178999,ENSG00000105146]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1095292,"CC[N+](C)(C)Cc1ccccc1Br.Cc1ccc(S(=O)(=O)[O-])cc1_|_KVWNWTZZBKCOPM-UHFFFAOYSA-M_|_Small molecule_|_False_|_BRETYLIUM TOSYLATE_|_1986.0_|_4.0_|_CHEMBL1199080_|_False_|_True_|_['Bretylium tosylate' 'Bretylol']_|_['ASL-603' 'Bretylium tosilate' 'Bretylium tosylate' 'NSC-62164']_|_[('PubChem', array(['11111997', '11111998', '50104303', '85231294', '855621'],
      dtype=object)), ('chEBI', array(['3173'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004287', 'HP_0004308', 'EFO_0004269'], dtype=object), 'count': 3}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications."
CHEMBL1200951,"CCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1_|_LRWSFOSWNAQHHW-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLUPHENAZINE ENANTHATE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Moditen enant' 'Prolixin enanthate']_|_['Flufenan' 'Fluphenazine enantate' 'Fluphenazine enanthate'
 'Fluphenazine maleate' 'Fluphenazini enantas' 'SQ 16,114' 'SQ 16144']_|_[('chEBI', array(['5125'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'EFO_0000676', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 5 investigational indications."
CHEMBL1201167,"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O_|_XCPXNPBILMXKNX-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARVEDILOL PHOSPHATE_|_2006.0_|_4.0_|_CHEMBL723_|_False_|_True_|_['Coreg cr']_|_['Carvedilol phosphate' 'Carvedilol phosphate hemihydrate'
 'Carvedilol phosphate hydrate' 'SK&F-105517-D' 'SKF 105517D'
 'SKF-105517D']_|_[('DailyMed', array(['carvedilol%20phosphate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000373', 'EFO_0000612', 'EFO_0000537'], dtype=object), 'count': 3}_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778,ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for myocardial infarction and hypertension and has 1 investigational indication."
CHEMBL1201863,"Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1_|_MJIHNNLFOKEZEW-RUZDIDTESA-N_|_Small molecule_|_False_|_DEXLANSOPRAZOLE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Dexilant' 'Dexilant solutab' 'Kapidex']_|_['(r)-lansoprazole' 'Dexlansoprazole' 'Kapidex' 'Lansoprazole r-form'
 'Lansoprazole, (r)-' 'NSC-758710' 'T-168390' 'TAK-390']_|_[('DailyMed', array(['dexlansoprazole'], dtype=object)), ('Wikipedia', array(['Dexlansoprazole'], dtype=object)), ('drugbank', array(['DB05351'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000280', 'EFO_0003948', 'EFO_1001095', 'HP_0004398',
       'HP_0100633'], dtype=object), 'count': 5}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 2 investigational indications."
CHEMBL250270,"COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1_|_ZDXUKAKRHYTAKV-UHFFFAOYSA-N_|_Small molecule_|_False_|_LERCANIDIPINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Lercanidipine' 'Lercanil']_|_[('PubChem', array(['50112745', '90340703'], dtype=object)), ('Wikipedia', array(['Lercanidipine'], dtype=object)), ('drugbank', array(['DB00528'], dtype=object))]_|_['CHEMBL2106419']_|_{'rows': array(['EFO_0000537', 'MONDO_0001134', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL3188267,"CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F_|_LIOLIMKSCNQPLV-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAPMATINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Capmatinib' 'INC-280' 'INC280' 'INCB-28060' 'INCB-28060 FREE BASE'
 'Incb-28060' 'NVP-INC280' 'NVP-INC280-NX' 'NYP-INC280-NX']_|_[('PubChem', array(['174006562'], dtype=object)), ('drugbank', array(['DB11791'], dtype=object))]_|_['CHEMBL3989937']_|_{'rows': array(['MONDO_0008903', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0002367',
       'EFO_0003060', 'MONDO_0004992', 'EFO_0000756', 'EFO_1001968',
       'EFO_0000519', 'EFO_0000389', 'EFO_0000616', 'EFO_0001421',
       'EFO_0003060'], dtype=object), 'count': 13}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 10 investigational indications."
CHEMBL3716057,"COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O_|_HLWURFKMDLAKOD-UHFFFAOYSA-N_|_Small molecule_|_False_|_GEFAPIXANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AF-219' 'Af-219' 'Gefapixant' 'R-1646' 'R1646' 'RG-1646' 'RG1646'
 'RO-4926219' 'RO4926219']_|_[('drugbank', array(['DB15097'], dtype=object))]_|_['CHEMBL4594278']_|_{'rows': array(['MONDO_0004979', 'EFO_0004616', 'HP_0012735', 'EFO_0000768',
       'HP_0000083', 'EFO_0008507', 'EFO_0003918'], dtype=object), 'count': 7}_|_[ENSG00000109991]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4094894,"CC(C)c1cccc([C@H](C)C2CC2)c1O_|_BMEARIQHWSVDBS-SNVBAGLBSA-N_|_Small molecule_|_False_|_CIPEPOFOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cipepofol' 'Ciprofol' 'HSK-3486' 'HSK-3486, (R)-' 'HSK3486' 'Hsk-3486'
 'Hsk3486']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'EFO_0003086'], dtype=object), 'count': 2}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4297837,"nan_|_nan_|_Antibody_|_False_|_TALACOTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CSL-362' 'CSL362' 'Csl362' 'JNJ-56022473' 'Jnj-56022473' 'Talacotuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000198', 'MONDO_0007915', 'EFO_0000222'], dtype=object), 'count': 3}_|_[ENSG00000292332,ENSG00000185291]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4790100,"Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1_|_JLRIJKVMMZEKDF-UHFFFAOYSA-N_|_Small molecule_|_False_|_AKN-028_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Akn-028']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL622,"CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3_|_NNYBQONXHNTVIJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_ETODOLAC_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Ebretin' 'Etodolac' 'Etolyn' 'Etopan xl' 'Lodine' 'Lodine sr'
 'Lodine xl' 'Ramodar']_|_['(rs)-etodolic acid' 'AY-24,236' 'AY-24-236' 'AY-24236' 'Eccoxolac'
 'Edolan' 'Etodolac' 'Etodolic acid' 'Flancox' 'Lodin xl' 'NIH-9918'
 'NSC-282126' 'Napilac' 'Tedolan' 'Ultradol' 'Zedolac']_|_[('DailyMed', array(['etodolac'], dtype=object)), ('PubChem', array(['144209416', '170464915', '174007213', '50105240', '56422166',
       '85231029', '855612', '90340662'], dtype=object)), ('Wikipedia', array(['Etodolac'], dtype=object)), ('drugbank', array(['DB00749'], dtype=object)), ('chEBI', array(['4909'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0003843', 'EFO_0000685', 'EFO_0002609',
       'EFO_0004142', 'EFO_0002970', 'EFO_0009582', 'EFO_0005755',
       'EFO_0000182', 'Orphanet_79292', 'MONDO_0005178', 'EFO_0003860'],
      dtype=object), 'count': 12}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL643,"CC(CN1c2ccccc2Sc2ccccc21)N(C)C_|_PWWVAXIEGOYWEE-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROMETHAZINE_|_1951.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dimapp' 'Diphergan' 'Fargan' 'NSC-30321' 'Phenergan' 'Proazamine'
 'Procit' 'Prometazin' 'Promethacon' 'Promethazine' 'Promethegan'
 'Protazine' 'Prothazin' 'RP-3277' 'Remsed' 'Vallergine' 'Zipan-25'
 'Zipan-50']_|_[('PubChem', array(['104171211', '124881100', '124881103', '144203778', '170465107',
       '26752304', '50105224', '90341785'], dtype=object)), ('TG-GATEs', array(['110'], dtype=object)), ('Wikipedia', array(['Promethazine'], dtype=object)), ('drugbank', array(['DB01069'], dtype=object)), ('chEBI', array(['8461'], dtype=object))]_|_['CHEMBL1200750']_|_{'rows': array(['EFO_0005230', 'HP_0002013', 'EFO_0003843', 'MONDO_0002050',
       'MONDO_0004900', 'MONDO_0005090', 'EFO_0005531', 'MONDO_0005271',
       'HP_0002017', 'EFO_1000971', 'EFO_0003843', 'HP_0000726',
       'EFO_0006928', 'EFO_0003956', 'MONDO_0005475', 'EFO_0004698',
       'MONDO_0100431', 'EFO_0000384', 'EFO_0000274', 'HP_0000989',
       'HP_0002018', 'MONDO_0005271', 'EFO_0006928', 'EFO_1000948',
       'EFO_0007141'], dtype=object), 'count': 25}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 9 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL75880,"C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1_|_CYXKNKQEMFBLER-UHFFFAOYSA-N_|_Small molecule_|_False_|_PERHEXILINE_|_1974.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Perhexiline']_|_[('PubChem', array(['174006795'], dtype=object)), ('TG-GATEs', array(['45'], dtype=object)), ('Wikipedia', array(['Perhexiline'], dtype=object)), ('drugbank', array(['DB01074'], dtype=object)), ('chEBI', array(['35553'], dtype=object))]_|_['CHEMBL1334033']_|_{'rows': array(['EFO_1000899', 'EFO_0003144', 'EFO_0000538', 'EFO_0000319',
       'EFO_1001458'], dtype=object), 'count': 5}_|_[ENSG00000157184,ENSG00000205560,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for cardiovascular disease and has 4 investigational indications."
CHEMBL1181731,"COCCOCCOCCOCCOC(=O)OC[n+]1ccc(N/C(=N/CCCCCCOc2ccc(Cl)cc2)NC#N)cc1_|_RXXJCNMVVRGOJB-UHFFFAOYSA-O_|_Small molecule_|_False_|_TEGLARINAD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Teglarinad cation' 'Teglarinad ion']_|_nan_|_['CHEMBL190412']_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000105835]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1190,"C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C_|_MTCUAOILFDZKCO-UHFFFAOYSA-N_|_Small molecule_|_False_|_DECAMETHONIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Decamethonium' 'Decamethonium cation' 'Decamethonium ion' 'Syncurine']_|_[('PubChem', array(['11111046', '11111047', '26756594', '90341654'], dtype=object)), ('drugbank', array(['DB01245'], dtype=object)), ('chEBI', array(['41934'], dtype=object))]_|_['CHEMBL1134']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200374,"C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12_|_BFYIZQONLCFLEV-DAELLWKTSA-N_|_Small molecule_|_False_|_EXEMESTANE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Aromasin' 'Exemestane']_|_['Exemestane' 'FCE-24304' 'FCE24304' 'NSC-758907' 'PNU-155971']_|_[('DailyMed', array(['exemestane'], dtype=object)), ('PubChem', array(['144205052', '170464628', '26719821', '49681613'], dtype=object)), ('Wikipedia', array(['Exemestane'], dtype=object)), ('drugbank', array(['DB00990'], dtype=object)), ('chEBI', array(['4953'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0011962', 'MONDO_0004658', 'EFO_0006861',
       'EFO_0005537', 'EFO_0000432', 'MONDO_0008315', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000305', 'EFO_1000098', 'MONDO_0008170',
       'EFO_0000574', 'EFO_0003869', 'MONDO_0004992'], dtype=object), 'count': 15}_|_[ENSG00000137869]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 10 investigational indications."
CHEMBL1200561,"COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC.CS(=O)(=O)O_|_VJECBOKJABCYMF-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXAZOSIN MESYLATE_|_1990.0_|_4.0_|_CHEMBL707_|_False_|_True_|_['Cardozin xl' 'Cardura' 'Cardura xl' 'Cascor' 'Colixil xl' 'Doxadura'
 'Doxazosin mesylate' 'Doxzogen xl' 'Larbex xl' 'Oxandosin xl'
 'Raporsin xl' 'Slocinx xl']_|_['Alfadil' 'Doxazosin (as mesilate)' 'Doxazosin mesilate'
 'Doxazosin mesylate' 'Doxazosin methanesulfonate' 'NSC-759284'
 'UK-33,274-27' 'UK-33274-27']_|_[('DailyMed', array(['doxazosin%20mesylate'], dtype=object)), ('PubChem', array(['144204347', '170465395', '50106256', '56422468', '85231302',
       '855527'], dtype=object)), ('chEBI', array(['4709'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000612', 'EFO_0000284'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved indications."
CHEMBL1213583,"C#C[C@]1(O)C=C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC_|_SIGSPDASOTUPFS-XUDSTZEESA-N_|_Small molecule_|_False_|_GESTODENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gestodene' 'SH B 331' 'SH-B-331']_|_[('PubChem', array(['144205785', '170466131'], dtype=object)), ('Wikipedia', array(['Gestodene'], dtype=object)), ('drugbank', array(['DB06730'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL1577,"CN1C(CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O_|_CESYKOGBSMNBPD-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHYCLOTHIAZIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Aquatensen' 'Enduron' 'Methyclothiazide']_|_['Methyclothiazide' 'NSC-110431']_|_[('PubChem', array(['144206003', '170465243', '92764517'], dtype=object)), ('Wikipedia', array(['Methyclothiazide'], dtype=object)), ('drugbank', array(['DB00232'], dtype=object)), ('chEBI', array(['6847'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for cardiovascular disease."
CHEMBL1697,"COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.Cl_|_HDRXZJPWHTXQRI-BHDTVMLSSA-N_|_Small molecule_|_False_|_DILTIAZEM HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL23_|_False_|_True_|_['Adizem-60' 'Adizem-sr' 'Adizem-xl' 'Angiozem 60' 'Angiozem cr 120'
 'Angiozem cr 90' 'Angitil sr 120' 'Angitil sr 180' 'Angitil sr 90'
 'Angitil xl 240' 'Angitil xl 300' 'Anoheal' 'Bi-carzem sr' 'Bi-carzem xl'
 'Britiazim' 'Calazem' 'Calcicard' 'Calcicard cr' 'Cardizem' 'Cardizem cd'
 'Cardizem la' 'Cardizem sr' 'Cartia xt' 'Dilacor xr' 'Dilcardia sr'
 'Dilcardia xl' 'Dilt-cd' 'Diltiazem hydrochloride'
 'Diltiazem hydrochloride in dextrose 5%' 'Diltzac' 'Dilzem sr 120'
 'Dilzem sr 60' 'Dilzem sr 90' 'Dilzem xl 120' 'Dilzem xl 180'
 'Dilzem xl 240' 'Disogram sr' 'Horizem sr 120' 'Horizem sr 60'
 'Horizem sr 90' 'Kentiazem' 'Kenzem sr' 'Optil' 'Optil sr 120'
 'Optil sr 180' 'Optil sr 90' 'Optil xl 240' 'Optil xl 300' 'Retalzem 60'
 'Slozem' 'Slozem 120' 'Slozem 180' 'Slozem 240' 'Taztia xt' 'Tiamex'
 'Tiazac' 'Tildiem' 'Tildiem la 200' 'Tildiem la 300' 'Tildiem ret 120'
 'Tildiem ret 90' 'Uard 120xl' 'Uard 180xl' 'Uard 240xl' 'Uard 300xl'
 'Viazem xl' 'Zemret 180 xl' 'Zemret 240 xl' 'Zemret 300 xl'
 'Zemtard 120 xl' 'Zemtard 180 xl' 'Zemtard 240 xl' 'Zemtard 300 xl'
 'Zildil sr']_|_['Adizem' 'Altiazem' 'CRD-401' 'Cartia' 'Deltazen' 'Diladel' 'Dilpral'
 'Dilrene' 'Diltiazem hcl' 'Diltiazem hydrochloride' 'Dilzem' 'Dilzene'
 'Masdil' 'NSC-759576' 'RG 83606' 'RG-83606' 'Taztia' 'Zilden']_|_[('DailyMed', array(['diltiazem%20hydrochloride'], dtype=object)), ('PubChem', array(['50106088', '56422509', '855699'], dtype=object)), ('chEBI', array(['645509'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012390', 'EFO_0000537', 'EFO_0003144', 'EFO_1001951',
       'EFO_0000701', 'EFO_0000275', 'EFO_0000764', 'EFO_0003913',
       'EFO_0004225', 'HP_0002019'], dtype=object), 'count': 10}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 4 approved and 6 investigational indications."
CHEMBL2108407,"nan_|_nan_|_Antibody_|_False_|_FARALIMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['64G12' 'Faralimomab']_|_nan_|_nan_|_nan_|_[ENSG00000197919,ENSG00000233816]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL3039530,"O=c1ccc2c([C@@H](O)CNCCCCCCOCC(F)(F)c3ccccc3)ccc(O)c2[nH]1_|_SFYAXIFVXBKRPK-QFIPXVFZSA-N_|_Small molecule_|_False_|_ABEDITEROL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abediterol' 'LAS-100977' 'LAS100977']_|_[('drugbank', array(['DB12100'], dtype=object))]_|_['CHEMBL3039510']_|_{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3182444,"O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1_|_LCVIRAZGMYMNNT-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-5108_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MK 5108' 'MK5108' 'Mk-5108' 'VX-689']_|_[('PubChem', array(['174006374'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL429736,"CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1_|_PLVGDGRBPMVYPB-FDUHJNRSSA-N_|_Small molecule_|_False_|_RETOSIBAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GSK-221149' 'GSK-221149A' 'GSK221149' 'GSK221149A' 'Retosiban']_|_[('drugbank', array(['DB11818'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003917'], dtype=object), 'count': 1}_|_[ENSG00000180914]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4298097,"nan_|_nan_|_Antibody_|_False_|_ROMILKIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Hutbti3_2_1' 'Romilkimab' 'SAR-156597' 'SAR156597' 'Sar156597']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROMILKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000717', 'EFO_0000768'], dtype=object), 'count': 2}_|_[ENSG00000169194,ENSG00000113520]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL472,"COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1_|_ZNNLBTZKUZBEKO-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLYBURIDE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Amglidia' 'Calabren' 'Daonil' 'Diabeta' 'Diabetamide 2.5'
 'Diabetamide 5' 'Euglucon' 'Gliken' 'Glyburide' 'Glyburide (micronized)'
 'Glynase' 'Glynase Prestab' 'Lederglib' 'Libanil' 'Malix' 'Micronase'
 'Semi-daonil']_|_['Cirara' 'Glibenclamide' 'Glibenclamidum' 'Glybenclamide' 'Glyburide'
 'HB 419' 'HB-419' 'NSC-759618' 'U-26,45' 'U-26,452' 'U-26452']_|_[('Wikipedia', array(['Glibenclamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia'],
      dtype=object)), ('TG-GATEs', array(['42'], dtype=object)), ('PubChem', array(['11111219', '11112597', '11113353', '144203709', '144211075',
       '170464964', '26747031', '26747032', '26751550', '50100249',
       '50104148', '50104149', '50104150', '50126365', '56422139',
       '85231061', '855894'], dtype=object)), ('DailyMed', array(['glyburide'], dtype=object)), ('drugbank', array(['DB01016'], dtype=object)), ('chEBI', array(['5441'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001919', 'HP_0002140', 'MONDO_0005148', 'EFO_0000712',
       'MONDO_0005147', 'EFO_0004593', 'MONDO_0043510', 'EFO_0000400',
       'EFO_0003913'], dtype=object), 'count': 9}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 7 investigational indications."
CHEMBL4802160,"COC[C@H]1CN(C(=O)[C@]2(F)CN(C3CCCC3)C[C@H]2c2ccc(OC)cc2)C[C@@H]1c1ccc(C(F)(F)F)cc1N1CCC(C(=O)O)CC1_|_MUNWOYRHJPWQNE-GMFUQMJFSA-N_|_Small molecule_|_False_|_DERSIMELAGON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dersimelagon' 'MT-7117' 'Mt-7117']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DERSIMELAGON/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802244']_|_{'rows': array(['EFO_1000753', 'MONDO_0001676', 'EFO_0000404', 'EFO_1000753',
       'EFO_0001421', 'MONDO_0001676', 'EFO_0003086'], dtype=object), 'count': 7}_|_[ENSG00000258839]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL5314366,"COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.O.O.O.[Mg+2]_|_ARGAGMTUBUKMOG-OXLUMUBXSA-N_|_Small molecule_|_False_|_ESOMEPRAZOLE MAGNESIUM_|_2001.0_|_4.0_|_CHEMBL1201320_|_False_|_True_|_['Emozul' 'Esomeprazole magnesium' 'Nexium' 'Nexium 24hr' 'Nexium control'
 'Nexium i.v.' 'Ventra']_|_['Esomeprazole (as magnesium)' 'Esomeprazole magnesium'
 'Esomeprazole magnesium hydrate' 'Esomeprazole magnesium trihydrate'
 'H199/18 MAGNESIUM TRIHYDRATE']_|_[('DailyMed', array(['esomeprazole%20magnesium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nexium-control'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009454', 'EFO_0010282', 'MONDO_0005178', 'EFO_0003948',
       'EFO_0007549', 'EFO_0004607', 'EFO_0000342', 'MONDO_0004247',
       'EFO_0003898', 'HP_0100633', 'MONDO_0005148', 'EFO_0008533',
       'EFO_0000685'], dtype=object), 'count': 13}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 8 approved and 5 investigational indications."
CHEMBL1743046,"nan_|_nan_|_Antibody_|_False_|_NARNATUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IMC RON-8' 'IMC-RON-8' 'IMC-RON8' 'Narnatumab' 'RON-8' 'RON8']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000164078]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1743056,"nan_|_nan_|_Antibody_|_False_|_PATECLIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MLTA-3698A' 'MLTA3698A' 'PRO-283698' 'PRO283698' 'Pateclizumab'
 'RG-7416' 'RG7415']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000226979]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107067,"CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C_|_UDSFVOAUHKGBEK-CNQKSJKFSA-N_|_Small molecule_|_True_|_TESTOSTERONE UNDECANOATE_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Aveed' 'Jatenzo' 'Kyzatrex' 'Nebido' 'Restandol' 'Restandol testocap'
 'Tlando' 'Undestor']_|_['Kyzatrex' 'MK-3033' 'ORG 538' 'ORG-538' 'TSX-011'
 'Testosterone 17.beta.-undecylate' 'Testosterone undecanoate'
 'Testosterone undecylate' 'Testosterone, undecanoate (ester)' 'Tlando']_|_[('DailyMed', array(['testosterone%20undecanoate'], dtype=object)), ('drugbank', array(['DB13946'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001919', 'EFO_0000681', 'EFO_1001078', 'EFO_0001645',
       'EFO_0008572', 'EFO_0000616', 'EFO_1001006', 'EFO_0009686',
       'MONDO_0002146', 'MONDO_0018555', 'MONDO_0008315', 'EFO_0004714'],
      dtype=object), 'count': 12}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2107872,"nan_|_nan_|_Protein_|_False_|_DELCASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-875944' 'Delcasertib' 'KAI-9803' 'Kai-9803']_|_nan_|_nan_|_{'rows': array(['EFO_0000612'], dtype=object), 'count': 1}_|_[ENSG00000163932]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109464,nan_|_nan_|_Antibody_|_False_|_CNTO-5825_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CNTO-5825' 'Cnto-5825']_|_nan_|_nan_|_nan_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2364617,"CC(=O)O.CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O_|_WVDSKQXKCDZXLH-OHIDFYLOSA-N_|_Small molecule_|_False_|_MACIMORELIN ACETATE_|_2017.0_|_4.0_|_CHEMBL278623_|_False_|_True_|_['Ghryvelin (previously macimorelin aeterna zentaris)' 'Macrilen']_|_['ARD 07' 'D-87575' 'EP 1572' 'Macimorelin acetate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ghryvelin-previously-macimorelin-aeterna-zentaris'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017."
CHEMBL3545257,"CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O.O=S(=O)(O)c1ccccc1_|_OKJXJRVWXYRSAN-TXULWXBWSA-N_|_Small molecule_|_False_|_MIROGABALIN BESYLATE_|_nan_|_-1.0_|_CHEMBL3545125_|_False_|_False_|_[]_|_['DS-5565' 'DS5565' 'Ds-5565' 'Mirogabalin' 'Mirogabalin besilate'
 'Mirogabalin besylate']_|_nan_|_nan_|_nan_|_[ENSG00000007402,ENSG00000153956]_|_Small molecule drug."
CHEMBL3707316,"nan_|_nan_|_Small molecule_|_False_|_ND0801_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nd0801']_|_nan_|_nan_|_{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4065122,"C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1_|_WNEODWDFDXWOLU-QHCPKHFHSA-N_|_Small molecule_|_False_|_FENEBRUTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fenebrutinib' 'G-02599853' 'G02599853' 'GDC-0853' 'Gdc-0853' 'RG-7845'
 'RG7845' 'RO-7010939' 'RO7010939']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FENEBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14785'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301', 'EFO_0003840', 'EFO_0005531', 'EFO_0005809',
       'MONDO_0007915', 'EFO_0000685'], dtype=object), 'count': 6}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4650406,"nan_|_nan_|_Antibody_|_False_|_LEVILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BCD-089' 'Bcd-089' 'Levilimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000160712]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL491473,"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1_|_XXJWYDDUDKYVKI-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEDIRANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Recentin']_|_['AZD-2171' 'AZD2171' 'Azd-2171' 'Cediranib' 'ZD-2171']_|_[('PubChem', array(['103905340', '137275941'], dtype=object)), ('drugbank', array(['DB04849'], dtype=object))]_|_['CHEMBL2103798']_|_{'rows': array(['EFO_1000657', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004992',
       'EFO_1001951', 'EFO_0000702', 'EFO_0006861', 'EFO_1001465',
       'EFO_0000681', 'EFO_0000222', 'EFO_0003893', 'MONDO_0002974',
       'EFO_0003060', 'EFO_0000770', 'MONDO_0002974', 'MONDO_0008903',
       'EFO_0000681', 'EFO_0000305', 'EFO_0000673', 'MONDO_0008903',
       'EFO_1001951', 'EFO_0003891', 'EFO_0000196', 'EFO_0000588',
       'EFO_0000673', 'EFO_0000616', 'EFO_0007143', 'MONDO_0002158',
       'EFO_0003833', 'EFO_0000389', 'EFO_0000519', 'EFO_0000349',
       'EFO_0003060', 'MONDO_0001056', 'MONDO_0011962', 'EFO_0002892',
       'EFO_0000182', 'EFO_0002617', 'MONDO_0007254', 'EFO_0000095',
       'MONDO_0008315', 'EFO_0000565', 'EFO_0000519', 'EFO_0009709',
       'MONDO_0002087'], dtype=object), 'count': 45}_|_[ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 39 investigational indications."
CHEMBL498,"CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1_|_RKWGIWYCVPQPMF-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORPROPAMIDE_|_1958.0_|_4.0_|_nan_|_False_|_True_|_['Chlorpropamide' 'Diabemide' 'Diabinese' 'Glucamide' 'Glymese' 'Melitase']_|_['Chlorpropamide' 'NSC-44634' 'NSC-626720']_|_[('PubChem', array(['11110918', '11110919', '144203653', '144208589', '144213106',
       '170464898', '17389965', '50103916', '56423142', '855559'],
      dtype=object)), ('TG-GATEs', array(['80'], dtype=object)), ('Wikipedia', array(['Chlorpropamide'], dtype=object)), ('drugbank', array(['DB00672'], dtype=object)), ('chEBI', array(['3650'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and is indicated for type 2 diabetes mellitus and diabetes mellitus."
CHEMBL5315123,"CC(=O)O.CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1_|_MZWHRPKAHCWTOI-KGURMGBCSA-N_|_Protein_|_False_|_DIFELIKEFALIN ACETATE_|_2021.0_|_4.0_|_CHEMBL3989915_|_False_|_True_|_['Kapruvia' 'Korsuva']_|_['Cr-845 acetate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'HP_0000989'], dtype=object), 'count': 2}_|_[ENSG00000082556]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for chronic kidney disease and pruritus."
CHEMBL539697,"CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1_|_KSGXQBZTULBEEQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_DABIGATRAN ETEXILATE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Pradaxa']_|_['BIBR 1048' 'BIBR 1048 BS RS1' 'BIBR-1048' 'BIBR-1048-BS-RS1'
 'Dabigatran etexilate' 'Dabigatran etexilate methanesulfonate']_|_[('PubChem', array(['170466107'], dtype=object)), ('Wikipedia', array(['Dabigatran'], dtype=object)), ('drugbank', array(['DB06695'], dtype=object)), ('chEBI', array(['70746'], dtype=object))]_|_['CHEMBL1615369']_|_{'rows': array(['EFO_0001645', 'HP_0000083', 'EFO_0000275', 'EFO_0010726',
       'HP_0001907', 'EFO_0003095', 'EFO_0000712', 'EFO_0003884',
       'EFO_0000275', 'EFO_0003827', 'EFO_0000712', 'EFO_1000652',
       'EFO_0003907', 'EFO_0004286', 'EFO_0004286', 'HP_0004936',
       'HP_0004419', 'HP_0001871', 'MONDO_0000831', 'EFO_0000673'],
      dtype=object), 'count': 20}_|_[ENSG00000180210]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 8 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL93,"CC(c1cc2ccccc2s1)N(O)C(N)=O_|_MWLSOWXNZPKENC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZILEUTON_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Zyflo' 'Zyflo cr']_|_['A-64077' 'ABBOTT-64077' 'NSC-730712' 'NSC-759277' 'Zileuton']_|_[('DailyMed', array(['zileuton'], dtype=object)), ('PubChem', array(['144205233', '144211465', '170465222', '174007276', '26719885',
       '29215400'], dtype=object)), ('Wikipedia', array(['Zileuton'], dtype=object)), ('drugbank', array(['DB00744'], dtype=object)), ('chEBI', array(['10112'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003768', 'MONDO_0008903', 'EFO_0000341', 'EFO_0000768',
       'EFO_0000339', 'MONDO_0011382', 'MONDO_0004979', 'EFO_0003894',
       'MP_0001845'], dtype=object), 'count': 9}_|_[ENSG00000012779]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for asthma and has 8 investigational indications."
CHEMBL1200497,CC(O)C(=O)O.CN1CCN(C(c2ccccc2)c2ccccc2)CC1_|_JOROEVAWQLGPFQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLIZINE LACTATE_|_1982.0_|_4.0_|_CHEMBL648_|_False_|_True_|_['Marezine']_|_['Cyclizine lactate']_|_nan_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200578,"Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)[O-].[Na+]_|_AIJQWRAOMFRHTQ-UHFFFAOYSA-M_|_Small molecule_|_False_|_THEOPHYLLINE SODIUM GLYCINATE_|_1982.0_|_4.0_|_CHEMBL1208646_|_False_|_True_|_['Asbron' 'Synophylate']_|_['Bronchoparat' 'Englate' 'Glycin theophyllinate' 'Glytheonate'
 'Panophylline' 'Theonate sodium' 'Theophylline sodium glycinate']_|_nan_|_nan_|_nan_|_[ENSG00000172572,ENSG00000152270,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201583,"nan_|_nan_|_Antibody_|_False_|_BEVACIZUMAB_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Avastin' 'Mvasi']_|_['12-IGG1' 'AVA-1' 'Abp-215' 'Alymsys' 'BAT-1706' 'BEVZ-92' 'BEVZ92'
 'BI 695502' 'BI695502' 'BS-503A' 'Bat 1706' 'Bat1706' 'Bevacizumab'
 'Bevacizumab (avastin)' 'Bevacizumab adcd' 'Bevacizumab awwb'
 'Bevacizumab beta' 'Bevacizumab biosimilar (abp-215)'
 'Bevacizumab biosimilar (amgen)' 'Bevacizumab biosimilar (fkb-238)'
 'Bevacizumab biosimilar (pfizer)' 'Bevacizumab bvzr' 'Bevacizumab maly'
 'Bevacizumab-adcd' 'Bevacizumab-awwb' 'Bevacizumab-bvzr'
 'Bevacizumab-maly' 'Bevax' 'Bi-695502' 'Bs-503' 'Byvasda' 'CHS-5217'
 'CT-16' 'CT-P16' 'CT-P16 (BIOSIMILAR OF BEVACIZUMAB)' 'Ct p16' 'Ct-16'
 'Ct-p16' 'FKB-238' 'Fkb 238' 'Fkb238' 'HLX-04' 'HLX04' 'Hlx 04' 'Ibi-305'
 'Ibi305' 'LY 01008' 'LY-01008' 'MB-02' 'Mvasi' 'Oyavas' 'PF-06439535'
 'Pf-06439535' 'Q-1101' 'Q1101' 'R-435' 'RG-435' 'RHUMAB-' 'RHUMAB-VEGF'
 'RO-4876646' 'Usp mab 002, monoclonal igg1' 'Vegzelma' 'Zirabev']_|_[('DailyMed', array(['bevacizumab', 'bevacizumab-awwb', 'bevacizumab-bvzr'],
      dtype=object)), ('DrugCentral', array(['4956'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mvasi'],
      dtype=object)), ('Wikipedia', array(['Bevacizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000326', 'EFO_0003050', 'MONDO_0005184', 'EFO_1000613',
       'EFO_0000174', 'EFO_1000796', 'EFO_0006859', 'EFO_0003828',
       'MONDO_0002158', 'MONDO_0008903', 'HP_0009588', 'MONDO_0004992',
       'EFO_0003016', 'EFO_1000052', 'MONDO_0002363', 'EFO_0007224',
       'MONDO_0018364', 'EFO_0001061', 'EFO_0002893', 'MONDO_0100342',
       'EFO_0002618', 'EFO_1000783', 'EFO_1001100', 'EFO_0003869',
       'EFO_0009708', 'EFO_0003106', 'EFO_0003884', 'EFO_0009637',
       'EFO_0000182', 'EFO_0008528', 'EFO_0004243', 'MONDO_0003060',
       'EFO_1001187', 'EFO_0003060', 'MONDO_0001187', 'EFO_0000756',
       'EFO_0000698', 'EFO_1000158', 'EFO_0000349', 'MONDO_0001280',
       'MONDO_0003005', 'EFO_1000657', 'MONDO_0011719', 'EFO_0009606',
       'EFO_0000770', 'MONDO_0020634', 'EFO_0000630', 'EFO_1001231',
       'EFO_0000571', 'EFO_0005537', 'HP_0001541', 'EFO_1001465',
       'EFO_0000678', 'EFO_0000095', 'EFO_1000895', 'EFO_1000984',
       'MONDO_0024677', 'EFO_0005577', 'EFO_0000305', 'EFO_0002087',
       'EFO_0000632', 'EFO_0001416', 'EFO_1000581', 'MONDO_0001576',
       'EFO_0000198', 'EFO_0002892', 'EFO_0000694', 'EFO_0000673',
       'EFO_0000564', 'MONDO_0018906', 'MONDO_0009937', 'EFO_0000588',
       'MONDO_0011962', 'EFO_1001951', 'MONDO_0044903', 'EFO_0000707',
       'MONDO_0008315', 'EFO_0000365', 'EFO_1001949', 'EFO_0009448',
       'MONDO_0002087', 'MONDO_0003268', 'MONDO_0002691', 'EFO_0003833',
       'EFO_0005543', 'EFO_0002499', 'EFO_0000503', 'EFO_0004212',
       'EFO_0004284', 'EFO_0002617', 'EFO_1001111', 'EFO_0005753',
       'EFO_0004264', 'MONDO_0044937', 'MP_0001914', 'EFO_0000335',
       'MONDO_0005575', 'EFO_0000640', 'MONDO_0002989', 'MONDO_0002108',
       'EFO_0007532', 'MONDO_0019472', 'EFO_0000519', 'EFO_1001961',
       'MONDO_0007254', 'EFO_0001376', 'EFO_0000574', 'EFO_0000248',
       'EFO_0001365', 'EFO_0000621', 'EFO_1000043', 'EFO_0001642',
       'EFO_0001065', 'MONDO_0002120', 'EFO_0000183', 'EFO_0004683',
       'EFO_0000348', 'EFO_0002916', 'EFO_0002918', 'EFO_0006772',
       'EFO_0000339', 'MONDO_0016700', 'EFO_0000569', 'EFO_1001471',
       'EFO_0005773', 'EFO_0002939', 'EFO_0000313', 'EFO_0005952',
       'EFO_1000809', 'EFO_0000096', 'EFO_0007143', 'MP_0001845',
       'EFO_0005221', 'EFO_1001158', 'EFO_0000272', 'EFO_0007416',
       'EFO_0001075', 'EFO_1001157', 'EFO_0009784', 'EFO_1001469',
       'EFO_1000026', 'EFO_1000475', 'EFO_1001968', 'MONDO_0008170',
       'EFO_0004252', 'EFO_0000232', 'EFO_0000514', 'EFO_0003839',
       'MONDO_0001657', 'EFO_0005567', 'MONDO_0021632', 'MONDO_0016642',
       'EFO_0000389', 'EFO_0000681', 'MONDO_0005041', 'EFO_1000028',
       'EFO_0000558', 'EFO_0000228', 'EFO_0000403', 'EFO_0004251',
       'EFO_1000823', 'MONDO_0018271', 'EFO_0010282', 'MONDO_0100096',
       'EFO_0000466', 'MONDO_0018092', 'MONDO_0008667', 'EFO_0001378',
       'EFO_0006861', 'EFO_1001901', 'EFO_0003893', 'EFO_0003770',
       'EFO_1001512', 'EFO_1001513', 'EFO_0000691', 'EFO_1000251',
       'EFO_0000565', 'EFO_0004142', 'MONDO_0007576', 'EFO_0000178',
       'MONDO_0005835', 'MONDO_0019297', 'EFO_0003860', 'MONDO_0007935',
       'EFO_0004256', 'MONDO_0021063', 'HP_0000545', 'EFO_0003968',
       'EFO_0000196', 'MONDO_0002974', 'EFO_0000760', 'MONDO_0019180',
       'EFO_0000702', 'EFO_0008626', 'MONDO_0002367', 'EFO_0002501',
       'EFO_0004288', 'MONDO_0005411', 'EFO_0000181', 'EFO_0000616',
       'MONDO_0043510', 'EFO_1000880', 'MONDO_0001056'], dtype=object), 'count': 203}_|_[ENSG00000112715]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 29 approved and 174 investigational indications."
CHEMBL1201620,"nan_|_nan_|_Protein_|_False_|_SOMATREM_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Protropin']_|_['Protropin (genentech)' 'Somatrem']_|_[('DrugCentral', array(['5042'], dtype=object)), ('Wikipedia', array(['Somatrem'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112964]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1985."
CHEMBL1428,"COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1_|_UIAGMCDKSXEBJQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_NIMODIPINE_|_1988.0_|_4.0_|_nan_|_False_|_True_|_['Nimodipine' 'Nimotop' 'Nymalize']_|_['Admon' 'BAY E 9736' 'BAY-E-9736' 'NSC-758476' 'Nemotan' 'Nimodipine'
 'Nimodipine ap' 'Periplum']_|_[('DailyMed', array(['nimodipine'], dtype=object)), ('PubChem', array(['104171194', '124880812', '124880816', '144203753', '170466561',
       '26747118', '26747119', '26747120', '26751792', '26751793',
       '50104485', '50104486', '50104487', '85231145', '90340912'],
      dtype=object)), ('Wikipedia', array(['Nimodipine'], dtype=object)), ('drugbank', array(['DB00393'], dtype=object)), ('chEBI', array(['7575'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002610', 'EFO_0003763', 'EFO_0000712', 'EFO_0008546',
       'HP_0009588', 'EFO_0000319', 'EFO_0003870', 'MONDO_0005090',
       'EFO_0009846', 'EFO_0000545', 'EFO_0000713'], dtype=object), 'count': 11}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for cardiovascular disease and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1535,"CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12_|_XXSMGPRMXLTPCZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYCHLOROQUINE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hydroxychloroquine' 'Polirreumin']_|_[('PubChem', array(['29215442'], dtype=object)), ('Wikipedia', array(['Hydroxychloroquine'], dtype=object)), ('drugbank', array(['DB01611'], dtype=object)), ('chEBI', array(['5801'], dtype=object))]_|_['CHEMBL1690']_|_{'rows': array(['DOID_13406', 'EFO_0000616', 'EFO_0002618', 'EFO_0009001',
       'EFO_0001068', 'EFO_0004244', 'MONDO_0005178', 'EFO_0007427',
       'MONDO_0004992', 'EFO_0007448', 'MONDO_0100096', 'EFO_0003840',
       'EFO_0000519', 'MONDO_0100130', 'EFO_1000158', 'EFO_0002689',
       'EFO_0000389', 'MONDO_0011705', 'EFO_0007328', 'EFO_1001951',
       'EFO_0000565', 'EFO_0003818', 'EFO_0004616', 'EFO_0000729',
       'MONDO_0005147', 'EFO_0007224', 'EFO_0001378', 'MONDO_0100096',
       'EFO_0003834', 'EFO_0000198', 'MONDO_0007915', 'EFO_0002614',
       'EFO_0001068', 'MONDO_0008315', 'EFO_0001663', 'EFO_0000694',
       'MONDO_0005148', 'EFO_0000228', 'EFO_0005221', 'MONDO_0010520',
       'EFO_0009686', 'MONDO_0007254', 'EFO_0000756', 'EFO_0002950',
       'MONDO_0013730', 'EFO_0004220', 'EFO_0000681', 'EFO_1000710',
       'EFO_0000095', 'EFO_0000685', 'EFO_0000389', 'MONDO_0007915',
       'EFO_0000637', 'EFO_0000384', 'EFO_0005221', 'Orphanet_912',
       'EFO_0000702', 'EFO_0007224', 'EFO_0005755', 'EFO_0000349',
       'EFO_0000685', 'EFO_0000691', 'EFO_1001209', 'MONDO_0015104',
       'EFO_0003047', 'EFO_0004244', 'EFO_0002618', 'HP_0001873',
       'EFO_0000668', 'EFO_0000222', 'EFO_0007541', 'EFO_0003106',
       'MONDO_0009061', 'MONDO_0008170', 'EFO_0004142', 'EFO_0000182',
       'EFO_0000699', 'EFO_0000764', 'EFO_1000954', 'EFO_1000726',
       'MONDO_0008903', 'MONDO_0019200', 'EFO_0000544', 'MONDO_0021117',
       'MONDO_0100342', 'EFO_1000637', 'EFO_0003060', 'EFO_0002689'],
      dtype=object), 'count': 88}_|_[ENSG00000239732,ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for malaria and rheumatoid arthritis and has 80 investigational indications."
CHEMBL169901,"N=C(N)N1CCc2ccccc2C1_|_JWPGJSVJDAJRLW-UHFFFAOYSA-N_|_Small molecule_|_False_|_DEBRISOQUIN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Debrisoquine']_|_[('PubChem', array(['11112418'], dtype=object)), ('Wikipedia', array(['Debrisoquine'], dtype=object)), ('drugbank', array(['DB04840'], dtype=object)), ('chEBI', array(['34665'], dtype=object))]_|_['CHEMBL3527581' 'CHEMBL1593558' 'CHEMBL1255735']_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for hypertension."
CHEMBL207433,"O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1_|_JYILLRHXRVTRSH-GFCCVEGCSA-N_|_Small molecule_|_False_|_SB-705498_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK705498' 'SB-705498' 'Sb-705498']_|_[('drugbank', array(['DB11883'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'EFO_0000555', 'EFO_0008521', 'EFO_0010072',
       'EFO_0000274'], dtype=object), 'count': 5}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2103857,"COc1ccc(F)cc1C[C@@](O)(C1CCOCC1)[C@@H]1CNCCO1_|_CPBHSHYQQLFAPW-ZWKOTPCHSA-N_|_Small molecule_|_False_|_EDIVOXETINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Edivoxetine' 'LY-2216684' 'LY-2216684 HYDROCHLORIDE' 'LY2216684']_|_[('drugbank', array(['DB09184'], dtype=object))]_|_['CHEMBL2105702']_|_{'rows': array(['EFO_0003888', 'MONDO_0002009'], dtype=object), 'count': 2}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2103869,"O=C(O)[C@@H]1C[C@H]2C[C@@H](Oc3cccc(Cl)c3-c3nnn[nH]3)CC[C@H]2CN1_|_LAKQPSQCICNZII-NOHGZBONSA-N_|_Small molecule_|_False_|_DASOLAMPANEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dasolampanel' 'NGX426']_|_nan_|_['CHEMBL3088054']_|_nan_|_[ENSG00000171189,ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2103884,"COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1_|_SWZXEVABPLUDIO-WSZYKNRRSA-N_|_Small molecule_|_False_|_OPROZOMIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONX 0912' 'ONX-0912' 'Oprozomib' 'Pr-047']_|_[('drugbank', array(['DB11991'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000182', 'MONDO_0004992', 'EFO_0009441',
       'EFO_0001378'], dtype=object), 'count': 5}_|_[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2106468,"CCN(CC)C(=O)CNC(=O)c1cc(OC)c(OC)c(OC)c1_|_NLRFFZRHTICQBO-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRICETAMIDE_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['R-548' 'Tricetamide']_|_nan_|_nan_|_nan_|_[ENSG00000162434,ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL2108470,"nan_|_nan_|_Unknown_|_False_|_MURELETECAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mag-camptothecin' 'Mag-cpt' 'Mureletecan' 'PNU-166148']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000198900]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109388,"nan_|_nan_|_Antibody_|_False_|_FUTUXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['992 DS' '992-DS' 'Futuximab' 'SYM-004' 'Sym004']_|_nan_|_nan_|_{'rows': array(['MONDO_0100342', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2110725,"CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32_|_NMDYYWFGPIMTKO-KLCPSUAYSA-N_|_Small molecule_|_False_|_VINFLUNINE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Vinflunine']_|_[('drugbank', array(['DB11641'], dtype=object)), ('chEBI', array(['90241'], dtype=object))]_|_['CHEMBL2105629']_|_{'rows': array(['MONDO_0001056', 'EFO_0008528', 'MONDO_0004992', 'EFO_0000702',
       'EFO_1001094', 'MONDO_0007254', 'EFO_0000616', 'EFO_0003060',
       'MONDO_0002038', 'MONDO_0008903', 'EFO_1000601', 'MONDO_0001187',
       'MONDO_0004986', 'EFO_0003863', 'MONDO_0008315'], dtype=object), 'count': 15}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 15 investigational indications."
CHEMBL240597,"C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C_|_RUDATBOHQWOJDD-BSWAIDMHSA-N_|_Small molecule_|_True_|_CHENODIOL_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Chendol 125' 'Chendol 250' 'Chenix' 'Chenocedon'
 'Chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau)'
 'Chenodiol' 'Chenofalk' 'Combidol' 'Lithofalk' 'Xenbilox']_|_['Anthropodeoxycholic acid' 'Anthropodesoxycholic acid'
 'Anthropododesoxycholic acid' 'Chendol' 'Chenic acid' 'Chenocol'
 'Chenodeoxycholate' 'Chenodeoxycholic acid' 'Chenodesoxycholic acid'
 'Chenodiol' 'Chenossil' 'Cholanorm' 'Fluibil' 'Gallodesoxycholic acid'
 'NSC-657949' 'NSC-757798']_|_[('DailyMed', array(['chenodiol'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant'],
      dtype=object)), ('PubChem', array(['144203963', '144207689', '26754178', '56463362'], dtype=object)), ('Wikipedia', array(['Chenodeoxycholic_acid'], dtype=object)), ('drugbank', array(['DB06777'], dtype=object)), ('chEBI', array(['16755'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001258', 'MONDO_0019052', 'EFO_0000555', 'MONDO_0008948'],
      dtype=object), 'count': 4}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for inborn errors of metabolism and cerebrotendinous xanthomatosis and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL240624,"COCCOc1ccc(N2CCN(CCn3ncc4c3nc(N)n3nc(-c5ccco5)nc43)CC2)cc1_|_DTYWJKSSUANMHD-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRELADENANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-3814' 'Preladenant' 'SCH 420814' 'SCH-420814' 'Sch-420814']_|_[('drugbank', array(['DB11864'], dtype=object))]_|_['CHEMBL540115']_|_{'rows': array(['EFO_0000616', 'MONDO_0005180', 'EFO_0001421'], dtype=object), 'count': 3}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL281398,"CC(C)(C)N/C(=N\C#N)Nc1cccc(/C(=C\CCCC(=O)O)c2cccnc2)c1_|_XUTLOCQNGLJNSA-RGVLZGJSSA-N_|_Small molecule_|_False_|_TERBOGREL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIBV 308 SE' 'BIBV-308-SE' 'BIBV-308SE' 'Terbogrel']_|_[('Wikipedia', array(['Terbogrel'], dtype=object)), ('drugbank', array(['DB12204'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}_|_[ENSG00000006638,ENSG00000059377]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL301265,"CCCN[C@H]1CCc2nc(N)sc2C1_|_FASDKYOPVNHBLU-ZETCQYMHSA-N_|_Small molecule_|_False_|_PRAMIPEXOLE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Mirapexin' 'Neliprax' 'Oprymea' 'Pipexus']_|_['Ctc-501' 'NSC-760426' 'Pramipexole' 'SUD-919CL2Y' 'SUD919CL2Y'
 'U-98528E']_|_[('PubChem', array(['144205998', '170465264', '50112695'], dtype=object)), ('Wikipedia', array(['Pramipexole'], dtype=object)), ('drugbank', array(['DB00413'], dtype=object)), ('chEBI', array(['8356'], dtype=object))]_|_['CHEMBL3143955' 'CHEMBL542257' 'CHEMBL3182733']_|_{'rows': array(['HP_0012532', 'EFO_0004270', 'EFO_0005411', 'MONDO_0004985',
       'EFO_0005203', 'EFO_0002610', 'MONDO_0005090', 'EFO_0003108',
       'MONDO_0002050', 'EFO_0005687', 'MONDO_0005180', 'MONDO_0002491',
       'EFO_1001412', 'EFO_0004270', 'EFO_0004895', 'MONDO_0002009',
       'EFO_0004242', 'MONDO_0004975', 'MONDO_0004976', 'MONDO_0005180',
       'MONDO_0004985'], dtype=object), 'count': 21}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome and has 17 investigational indications."
CHEMBL3707356,"nan_|_nan_|_Oligonucleotide_|_False_|_TIVANISIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SYL 1001' 'SYL-1001' 'SYL1001' 'Syl-1001' 'Tivanisiran']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIVANISIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'HP_0200026'], dtype=object), 'count': 2}_|_[ENSG00000196689]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3787344,"Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1_|_IOMMMLWIABWRKL-WUTDNEBXSA-N_|_Small molecule_|_False_|_NAZARTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EGF-816' 'EGF816' 'Egf816' 'NVP-EGF816-NX' 'Nazartinib']_|_nan_|_['CHEMBL4297222' 'CHEMBL3984979']_|_{'rows': array(['EFO_0000616', 'MONDO_0008903', 'EFO_1000849', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3989844,"C[C@H](N)Cc1ccccc1.O=C(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O_|_VHKVKWTWHZUFIA-DGOKBZBKSA-N_|_Small molecule_|_False_|_DEXTROAMPHETAMINE SACCHARATE_|_1996.0_|_4.0_|_CHEMBL612_|_False_|_True_|_[]_|_['D-amphetamine saccharate' 'Dexamfetamine hemisaccharate'
 'Dexamfetamine saccharate' 'Dexamfetaphine saccharate']_|_[('DailyMed', array(['dextroamphetamine%20saccharate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888', 'MONDO_0016158'], dtype=object), 'count': 2}_|_[ENSG00000142319,ENSG00000103546,ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome."
CHEMBL4297615,"CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1_|_ZQPDJCIXJHUERQ-QWRGUYRKSA-N_|_Small molecule_|_False_|_PARSACLISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['INCB-050465' 'INCB050465' 'Incb050465' 'Parsaclisib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PARSACLISIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14867'], dtype=object))]_|_['CHEMBL4298155']_|_{'rows': array(['EFO_0000574', 'EFO_0000211', 'MONDO_0000430', 'EFO_0004719',
       'MONDO_0007254', 'EFO_0000616', 'EFO_1001264', 'EFO_0000756',
       'MONDO_0011962', 'EFO_0000403', 'EFO_0000095', 'EFO_0004251',
       'EFO_0000616', 'MONDO_0018906', 'MONDO_0004992', 'EFO_1001469',
       'EFO_0000096', 'EFO_0000699'], dtype=object), 'count': 18}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications."
CHEMBL4802263,"nan_|_nan_|_Gene_|_False_|_CILTACABTAGENE AUTOLEUCEL_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Carvykti']_|_['Ciltacabtagene autoleucel' 'JNJ-68284528'
 'JNJ-68284528(LCAR-B38M CAR-T cells)']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CILTACABTAGENE%20AUTOLEUCEL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}_|_[ENSG00000048462]_|_Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for multiple myeloma."
CHEMBL514270,"COc1ccc(N2CCc3c(-n4ccc(N5CCNC5=O)n4)cc(C)nc32)c(C)c1_|_JFHJGXQFESYQGY-UHFFFAOYSA-N_|_Small molecule_|_False_|_EMICERFONT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Emicerfont' 'GW-876008' 'GW-876008X' 'GW876008' 'GW876008X' 'Gw876008']_|_[('drugbank', array(['DB12910'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555', 'EFO_1001917'], dtype=object), 'count': 2}_|_[ENSG00000120088]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL599,"Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1_|_ZRVUJXDFFKFLMG-UHFFFAOYSA-N_|_Small molecule_|_True_|_MELOXICAM_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Anjeso' 'Loxicom' 'Meloxicam' 'Mobic' 'Qmiiz odt' 'Vivlodex']_|_['Acticam' 'Contacera' 'Coxicam' 'Emdocam' 'Flexicam' 'Inflacam' 'Loxicom'
 'Melfax' 'Melosus' 'Melovem' 'Meloxicam' 'Meloxidolor' 'Meloxidyl'
 'Meloxivet' 'Meloxoral' 'Metacam' 'Movatec' 'N-1539' 'N1539' 'Recocam'
 'Revitacam' 'Rheumocam' 'UH-AC 62XX' 'UH-AC-62 XX' 'UHAC-62XX']_|_[('Wikipedia', array(['Meloxicam'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/loxicom'],
      dtype=object)), ('TG-GATEs', array(['124'], dtype=object)), ('PubChem', array(['144205287', '144206743', '144208887', '144213073', '170464857',
       '26747003', '50085983', '855815'], dtype=object)), ('DailyMed', array(['meloxicam'], dtype=object)), ('drugbank', array(['DB00814'], dtype=object)), ('chEBI', array(['6741'], dtype=object))]_|_['CHEMBL1898907' 'CHEMBL1256873']_|_{'rows': array(['HP_0030834', 'EFO_0003843', 'EFO_0000685', 'EFO_0002609',
       'EFO_0004616', 'MONDO_0005277', 'MONDO_0018076', 'MONDO_0002258',
       'MONDO_0005178', 'EFO_0000673', 'EFO_0010072', 'MONDO_0007915',
       'HP_0003419', 'EFO_0002950', 'EFO_0003898', 'HP_0100607',
       'EFO_0005755'], dtype=object), 'count': 17}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL965,"C[N+](C)(C)CCOC(N)=O_|_VPJXQGSRWJZDOB-UHFFFAOYSA-O_|_Small molecule_|_False_|_CARBAMOYLCHOLINE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Carbachol' 'Carbastat' 'Miostat']_|_[('PubChem', array(['11110943', '11110944', '26756576', '90341139'], dtype=object)), ('drugbank', array(['DB00411'], dtype=object))]_|_['CHEMBL14']_|_{'rows': array(['MONDO_0005129', 'HP_0000616', 'MONDO_0001330', 'MONDO_0005041'],
      dtype=object), 'count': 4}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved and 1 investigational indication."
CHEMBL1200904,"C#CCN(C)[C@H](C)Cc1ccccc1.Cl_|_IYETZZCWLLUHIJ-UTONKHPSSA-N_|_Small molecule_|_False_|_SELEGILINE HYDROCHLORIDE_|_1989.0_|_4.0_|_CHEMBL972_|_False_|_True_|_['Centrapryl 10' 'Centrapryl 5' 'Eldepryl' 'Selegiline hydrochloride'
 'Stilline 10' 'Stilline 5' 'Vivapryl' 'Zelapar']_|_['L-deprenyl' 'NSC-759259' 'Selegiline hcl' 'Selegiline hydrochloride']_|_[('DailyMed', array(['selegiline%20hydrochloride'], dtype=object)), ('PubChem', array(['144204123', '144212163', '170464993', '26719766', '56463000'],
      dtype=object)), ('chEBI', array(['9087'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0007191'], dtype=object), 'count': 2}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 2 investigational indications."
CHEMBL1201309,"CC(C)C[C@H](NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O_|_PPXLVGBVOZLEIW-ITQXDASVSA-N_|_Protein_|_False_|_NAFARELIN_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Lhrh, 6(d-nal(2))' 'Nafarelin']_|_[('Wikipedia', array(['Nafarelin'], dtype=object))]_|_['CHEMBL1200671']_|_{'rows': array(['EFO_0001065', 'EFO_0001065', 'EFO_0003843', 'EFO_0000545'],
      dtype=object), 'count': 4}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for endometriosis and has 3 investigational indications."
CHEMBL1201336,"O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O_|_XWLUWCNOOVRFPX-UHFFFAOYSA-N_|_Small molecule_|_True_|_FOSPHENYTOIN_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fosphenytoin' 'Np-06']_|_[('PubChem', array(['170465016'], dtype=object)), ('drugbank', array(['DB01320'], dtype=object)), ('chEBI', array(['5165'], dtype=object))]_|_['CHEMBL5205794' 'CHEMBL919']_|_{'rows': array(['EFO_0000474', 'EFO_0008526'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for epilepsy and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201542,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP EXTENDED PURIFIED BEEF_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Ultralente']_|_['Insulin zinc susp extended purified beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1411979,"CN(C)CCN(Cc1cccs1)c1ccccn1_|_HNJJXZKZRAWDPF-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHAPYRILENE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['A 3322' 'A-3322' 'Metapyrilene' 'Methapyrilene' 'Pyrinistol' 'Restryl'
 'Semikon' 'Sleepwell' 'Tenalin' 'Thionylan']_|_[('PubChem', array(['11111497', '11111498', '90341056'], dtype=object)), ('TG-GATEs', array(['25'], dtype=object)), ('drugbank', array(['DB04819'], dtype=object)), ('chEBI', array(['6820'], dtype=object))]_|_['CHEMBL1255739' 'CHEMBL3187246']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergic disease."
CHEMBL1667969,"O=c1[nH]ccc2cc(OC3CCNCC3)ccc12_|_IPEXHQGMTHOKQV-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAR-407899_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SAR-407899']_|_nan_|_['CHEMBL3545341']_|_{'rows': array(['EFO_0003884', 'EFO_0004234', 'EFO_0001645'], dtype=object), 'count': 3}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1742982,"nan_|_nan_|_Protein_|_False_|_AFLIBERCEPT_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Eylea' 'Zaltrap']_|_['ABP-938' 'AVE-0005' 'AVE0005' 'Aflibercept'
 'Aflibercept (genetical recombination)' 'Aflibercept beta'
 'Aflibercept biosimilar (amgen)' 'Aflibercept recombinant' 'BAY-86-5321'
 'BAY-865321' 'BAY86-5321' 'VEGF TRAP' 'Vegf trap-eye']_|_[('DailyMed', array(['aflibercept', 'ziv-aflibercept'], dtype=object)), ('DrugCentral', array(['4916'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eylea'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007310', 'EFO_0005753', 'EFO_1001951', 'EFO_1000657',
       'MONDO_0005041', 'MONDO_0004992', 'MONDO_0005575', 'EFO_1001060',
       'EFO_0004207', 'EFO_0004142', 'EFO_0000616', 'EFO_0000565',
       'EFO_0010977', 'EFO_1001158', 'EFO_0009606', 'EFO_0004243',
       'MONDO_0004986', 'MONDO_0003005', 'EFO_0000365', 'EFO_0000681',
       'EFO_0000702', 'EFO_0002617', 'EFO_0002499', 'EFO_0003770',
       'EFO_0000641', 'MONDO_0003268', 'EFO_0001365', 'EFO_0000574',
       'EFO_0003839', 'EFO_0008626', 'MONDO_0004192', 'EFO_0000756',
       'EFO_0002501', 'EFO_0000501', 'EFO_1001465', 'EFO_0003060',
       'EFO_0009784', 'EFO_1000880', 'EFO_0005952', 'EFO_1001512',
       'EFO_1001466', 'Orphanet_758', 'MONDO_0001576', 'EFO_0004683',
       'EFO_0000389', 'MONDO_0021063', 'EFO_1001157', 'EFO_0001378',
       'MONDO_0007254'], dtype=object), 'count': 49}_|_[ENSG00000119630,ENSG00000112715]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 13 approved and 36 investigational indications."
CHEMBL1743006,"nan_|_nan_|_Antibody_|_False_|_DALOTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dalotuzumab' 'MK 0646' 'MK-0646' 'MK0646']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_1000657', 'EFO_0003060', 'EFO_1001901',
       'MONDO_0008903', 'EFO_0003869', 'EFO_0001378', 'EFO_0000616',
       'EFO_1001951'], dtype=object), 'count': 9}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL182066,"O=C(Nc1ccc2nc(O)oc2c1)C(=O)N1CCC(Cc2ccc(F)cc2)CC1_|_GKGRZLGAQZPEHO-UHFFFAOYSA-N_|_Small molecule_|_False_|_RADIPRODIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RGH-896' 'Radiprodil' 'Rgh-896']_|_[('drugbank', array(['DB12260'], dtype=object))]_|_['CHEMBL1802037']_|_{'rows': array(['MONDO_0018097', 'EFO_0005762'], dtype=object), 'count': 2}_|_[ENSG00000176884,ENSG00000273079]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2105720,"O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12_|_FGQFOYHRJSUHMR-UHFFFAOYSA-N_|_Small molecule_|_True_|_LESINURAD_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Zurampic']_|_['Lesinurad' 'RDEA 594' 'RDEA-594' 'RDEA594']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zurampic'],
      dtype=object)), ('drugbank', array(['DB11560'], dtype=object))]_|_['CHEMBL2105716']_|_{'rows': array(['EFO_0009104', 'EFO_0004274'], dtype=object), 'count': 2}_|_[ENSG00000197891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hyperuricemia and gout. This drug has a black box warning from the FDA."
CHEMBL2178573,"Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1_|_LUUMLYXKTPBTQR-UHFFFAOYSA-N_|_Small molecule_|_False_|_ILACIRNON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CCX-140' 'CCX140' 'CCX140-B' 'Ccx140' 'Ilacirnon']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ILACIRNON/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650229']_|_{'rows': array(['HP_0000077', 'EFO_0000401', 'EFO_0004236', 'MONDO_0005148',
       'EFO_0004236', 'EFO_0000401', 'HP_0000077'], dtype=object), 'count': 7}_|_[ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3039508,"CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1.Cc1ccc(S(=O)(=O)O)cc1_|_WCYDLROFMZJJLE-RTMHEQJQSA-N_|_Small molecule_|_False_|_NALDEMEDINE TOSYLATE_|_2017.0_|_4.0_|_CHEMBL2105755_|_False_|_True_|_['Rizmoic' 'Symproic']_|_['Naldemedine tosilate' 'Naldemedine tosylate']_|_[('DailyMed', array(['naldemedine%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0002019', 'MONDO_0002203'], dtype=object), 'count': 3}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications."
CHEMBL3990025,"nan_|_nan_|_Antibody_|_False_|_OLENDALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALXN-1007' 'ALXN1007' 'ALXN1007 antibody' 'Alxn1007' 'Lendalizumab'
 'Olendalizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0004599', 'EFO_0002689'], dtype=object), 'count': 2}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297594,"CC(C)OCCn1c(=S)[nH]c(=O)c2[nH]ccc21_|_FVJCUZCRPIMVLB-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERDIPERSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZD-3241' 'AZD3241' 'Azd 3241' 'Azd3241' 'BHV-3241' 'BHV-3421'
 'Verdiperstat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VERDIPERSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12440'], dtype=object))]_|_['CHEMBL5191541']_|_{'rows': array(['EFO_1001050', 'MONDO_0010857', 'MONDO_0004976', 'MONDO_0005180'],
      dtype=object), 'count': 4}_|_[ENSG00000005381]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4594352,"CC[C@@]1(OC(=O)C(C)ON=C2c3cc([N+](=O)[O-])cc([N+](=O)[O-])c3-c3c2cc([N+](=O)[O-])cc3[N+](=O)[O-])C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1_|_JCCCLGDYMMTBPM-HXDHBHDHSA-N_|_Small molecule_|_False_|_TLC-388_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Lipotecan' 'Lipothecan free base' 'Tlc-388']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000182', 'EFO_0000681'], dtype=object), 'count': 3}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650299,"nan_|_nan_|_Oligosaccharide_|_False_|_HEPARIN_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['B01AB10' 'Heparin' 'Heparin porcine' 'Heparin porcine intestinal mucosa'
 'Heparin, porcine']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 2 investigational indications."
CHEMBL4650452,"nan_|_nan_|_Unknown_|_False_|_BNC-210_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BNC-210' 'BNC210' 'Bnc-210' 'Bnc210' 'Iw-2143']_|_nan_|_nan_|_{'rows': array(['EFO_0001358', 'HP_0000713', 'EFO_1001917'], dtype=object), 'count': 3}_|_[ENSG00000175344]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL594,"CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21_|_KBUZBQVCBVDWKX-UHFFFAOYSA-N_|_Small molecule_|_False_|_EMEDASTINE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Emadine' 'Emedastine']_|_[('PubChem', array(['50125935'], dtype=object)), ('Wikipedia', array(['Emedastine'], dtype=object)), ('drugbank', array(['DB01084'], dtype=object)), ('chEBI', array(['4779'], dtype=object))]_|_['CHEMBL2103739']_|_{'rows': array(['EFO_0007141', 'EFO_0005751'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for allergic conjunctivitis and eye allergy."
CHEMBL6622,"O=[N+]([O-])O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-]_|_MOYKHGMNXAOIAT-JGWLITMVSA-N_|_Small molecule_|_False_|_ISOSORBIDE DINITRATE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Angitak' 'Carvasin' 'Cedocard' 'Cedocard ret' 'Cedocard-10'
 'Cedocard-20' 'Cedocard-40' 'Cedocard-5' 'Dilatrate-sr' 'Imtack'
 'Iso mack' 'Isocard' 'Isoket 10' 'Isoket 20' 'Isoket 5' 'Isoket ret 20'
 'Isoket ret 40' 'Isordil' 'Isordil tembids' 'Isosorbide dinitrate'
 'Jeridin' 'Soni-slo' 'Sorbichew' 'Sorbid sa' 'Sorbid-20 sa'
 'Sorbid-40 sa' 'Sorbidilat' 'Sorbitrate' 'Vascardin']_|_['C01DA08' 'Diluted isosorbide dinitrate'
 'Diluted isosorbide dinitrate rs' 'Diluted-isosorbide dinitrate'
 'Isomannide dinitrate' 'Isomannide-dinitrate' 'Isosorbide dinitrate'
 'Isosorbide dinitrate, diluted' 'Isosorbide dinitrate, diluted-'
 'Isosorbidi dinitras dilutes' 'Isosorbidi dinitras dilutus' 'NSC-80038'
 'Sorbide nitrate']_|_[('DailyMed', array(['isosorbide%20dinitrate'], dtype=object)), ('PubChem', array(['144204870', '170464980', '57260297'], dtype=object)), ('drugbank', array(['DB00883'], dtype=object)), ('chEBI', array(['6061'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679', 'EFO_0001645', 'EFO_1001459', 'EFO_0000373',
       'EFO_0009552', 'EFO_1001375', 'EFO_0000319', 'EFO_0003913'],
      dtype=object), 'count': 8}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 4 approved and 4 investigational indications."
CHEMBL79261,"O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2cc(Cl)cc3c2OCCO3)CC1_|_LYXKFNHUJJDTIA-UHFFFAOYSA-N_|_Small molecule_|_False_|_DU 125530_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DU-125530' 'Du 125530' 'Du125530']_|_nan_|_nan_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL836,"CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1_|_DRHKJLXJIQTDTD-OAHLLOKOSA-N_|_Small molecule_|_False_|_TAMSULOSIN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['HGP-0412' 'HIP-1402' 'HIP1402' 'Tamsulon' 'Tamsulosin']_|_[('Wikipedia', array(['Tamsulosin'], dtype=object)), ('drugbank', array(['DB00706'], dtype=object)), ('chEBI', array(['9398'], dtype=object))]_|_['CHEMBL1200914']_|_{'rows': array(['HP_0000016', 'EFO_0005323', 'EFO_0005323', 'EFO_0004253',
       'EFO_0803321', 'EFO_1001228', 'EFO_0004234', 'MONDO_0024647',
       'EFO_0000284', 'HP_0000016', 'EFO_0000537', 'EFO_0000536',
       'EFO_0003830', 'HP_0000011', 'EFO_0001663', 'EFO_0000284',
       'MONDO_0008315'], dtype=object), 'count': 17}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for benign prostatic hyperplasia and prostate carcinoma and has 13 investigational indications."
CHEMBL1200961,"CN(C)CCC(c1ccc(Br)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_SRGKFVAASLQVBO-BTJKTKAUSA-N_|_Small molecule_|_False_|_BROMPHENIRAMINE MALEATE_|_1957.0_|_4.0_|_CHEMBL811_|_False_|_True_|_['Brompheniramine maleate' 'Dimegan' 'Dimetane' 'Dimetane-ten' 'Dimotane'
 'Dimotane l.a.']_|_['(+)-Brompheniramine Maleate' 'Brompheniramine fumarate'
 'Brompheniramine maleate' 'NSC-758652' 'Parabromdylamine maleate']_|_[('DailyMed', array(['brompheniramine%20maleate'], dtype=object)), ('PubChem', array(['26747454', '50105943', '56422493', '855910', '93576630'],
      dtype=object)), ('chEBI', array(['3184'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007214', 'HP_0001742', 'MONDO_0005271', 'EFO_0003956',
       'EFO_0007486', 'HP_0012735'], dtype=object), 'count': 6}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved indications."
CHEMBL1200967,"CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1.Cl_|_ZQDJSWUEGOYDGT-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMODIPHENHYDRAMINE HYDROCHLORIDE_|_1954.0_|_4.0_|_CHEMBL1201245_|_False_|_True_|_['Ambodryl']_|_['Bromazine' 'Bromodiphenhydramine hcl'
 'Bromodiphenhydramine hydrochloride' 'NSC-36113']_|_[('chEBI', array(['59178'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954."
CHEMBL1201022,"Cl.Nc1ccc(/N=N/c2ccccc2)c(N)n1_|_QQBPIHBUCMDKFG-GEEYTBSJSA-N_|_Small molecule_|_False_|_PHENAZOPYRIDINE HYDROCHLORIDE_|_1987.0_|_4.0_|_CHEMBL1242_|_False_|_True_|_['Pyridium' 'Uropyrine']_|_['NC 150' 'NC-150' 'NSC-1879' 'Phenazopyridine hcl'
 'Phenazopyridine hydrochloride' 'W 1655' 'W-1655']_|_[('PubChem', array(['17389769', '26748196', '26752976'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003103'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and has 1 investigational indication."
CHEMBL1429,"N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O_|_NFLWUMRGJYTJIN-PNIOQBSNSA-N_|_Protein_|_True_|_DESMOPRESSIN_|_1978.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Desmopressin' 'H01BA02' 'Ser-120' 'Ser120']_|_[('drugbank', array(['DB00035'], dtype=object)), ('chEBI', array(['4450'], dtype=object))]_|_['CHEMBL1200556']_|_{'rows': array(['EFO_0005669', 'MONDO_0004782', 'EFO_1000781', 'MP_0001914',
       'EFO_1001412', 'MONDO_0024290', 'MONDO_0004782', 'MONDO_0007254',
       'HP_0001742', 'MONDO_0024574', 'HP_0031364', 'MP_0001914',
       'MONDO_0024290', 'EFO_0009505', 'HP_0000863', 'MONDO_0008315',
       'EFO_0000537', 'EFO_0007344'], dtype=object), 'count': 18}_|_[ENSG00000126895,ENSG00000166148,ENSG00000198049]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743040,"nan_|_nan_|_Antibody_|_False_|_MILATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HLL1' 'IMMU-115' 'Milatuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0001378', 'EFO_0000574', 'EFO_0006738'],
      dtype=object), 'count': 4}_|_[ENSG00000019582]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1946618,"CN(CCO)C(=O)c1ccc(C(=C2CCN(Cc3cscn3)CC2)c2cccc3cccnc23)cc1_|_ZJKUETLEJYCOBO-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-7268_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZ-12488024' 'AZ12488024' 'AZD7268' 'Azd 7268' 'Azd-7268' 'Azd7268']_|_nan_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000116329]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2035874,"CC(C)c1cc(Oc2c(Br)cc(NC(=O)CC(=O)O)cc2Br)ccc1O_|_VPCSYAVXDAUHLT-UHFFFAOYSA-N_|_Small molecule_|_False_|_EPROTIROME_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bms-356384' 'Eprotirome' 'Kb-2115' 'Kb2115']_|_[('drugbank', array(['DB05035'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005', 'EFO_0004911', 'HP_0003124'], dtype=object), 'count': 3}_|_[ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2108061,"nan_|_nan_|_Antibody_|_False_|_VOLOCIXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['M-200' 'M200' 'Volociximab']_|_nan_|_nan_|_{'rows': array(['MONDO_0008903', 'EFO_0003060', 'EFO_0000756', 'EFO_0002618',
       'MONDO_0008170', 'EFO_0001365', 'EFO_1001100'], dtype=object), 'count': 7}_|_[ENSG00000150093,ENSG00000161638]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2109374,"nan_|_nan_|_Antibody_|_False_|_TRC-093_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MT-293' 'TRC-093' 'TRC093' 'Trc-093']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0009708'], dtype=object), 'count': 2}_|_[ENSG00000081052]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2109539,nan_|_nan_|_Antibody_|_False_|_RG-7652_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RG-7652']_|_nan_|_nan_|_nan_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109636,"nan_|_nan_|_Antibody_|_False_|_VILOBELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CACP 29' 'CACP29' 'IFX-1' 'Vilobelimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VILOBELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000710', 'EFO_1000784', 'HP_0000999', 'EFO_0006835',
       'MONDO_0100096', 'EFO_0005297', 'MONDO_0015492', 'EFO_0006834',
       'MP_0001845', 'HP_0100806', 'EFO_0000717'], dtype=object), 'count': 11}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL2110659,"O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1_|_DYJIKHYBKVODAC-ZDUSSCGKSA-N_|_Small molecule_|_False_|_APLINDORE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aplindore']_|_[('drugbank', array(['DB06620'], dtype=object))]_|_['CHEMBL2104864']_|_{'rows': array(['MONDO_0005180', 'EFO_0004270'], dtype=object), 'count': 2}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL223360,"Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1_|_MPVGZUGXCQEXTM-UHFFFAOYSA-N_|_Small molecule_|_False_|_LINIFANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-741439' 'ABT-869' 'AL-39324' 'Linifanib' 'RG-3635']_|_[('PubChem', array(['103904340', '137275904', '50100086'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_1000657', 'EFO_0000365', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000182', 'MONDO_0021063', 'EFO_0001065',
       'EFO_0001365', 'MONDO_0007254'], dtype=object), 'count': 10}_|_[ENSG00000182578,ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL300138,"Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21_|_AXRCEOKUDYDWLF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENZASTAURIN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Kinenza']_|_['DB-102' 'DB102' 'Enzastaurin' 'LY-317615' 'LY317615' 'Ly-317615']_|_[('PubChem', array(['137275839', '144206918', '170465609'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENZASTAURIN/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Enzastaurin'], dtype=object)), ('drugbank', array(['DB06486'], dtype=object))]_|_['CHEMBL2107337']_|_{'rows': array(['MONDO_0008315', 'EFO_0004288', 'EFO_1001465', 'EFO_0001378',
       'EFO_0002913', 'EFO_1001469', 'EFO_0009441', 'EFO_1001951',
       'EFO_0000096', 'EFO_1000158', 'MONDO_0018906', 'MONDO_0008315',
       'EFO_0003060', 'EFO_0000403', 'EFO_0000403', 'MONDO_0002087',
       'EFO_0004289', 'EFO_0000365', 'MONDO_0008170', 'MONDO_0020066',
       'MONDO_0004992', 'EFO_0003860', 'EFO_0005543', 'EFO_0000681',
       'EFO_1001100', 'EFO_0000519', 'MONDO_0100342', 'EFO_0000702',
       'MONDO_0008903', 'EFO_0005952', 'MONDO_0008903', 'EFO_0003869',
       'EFO_1000251', 'EFO_0000616', 'EFO_0003060', 'EFO_0000621',
       'EFO_0000519', 'EFO_0000574', 'EFO_0000326', 'MONDO_0008170',
       'EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 42}_|_[ENSG00000166501]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 37 investigational indications."
CHEMBL3544971,"C[C@H](N)Cc1ccccc1.C[C@H](N)Cc1ccccc1.O=S(=O)(O)O_|_PYHRZPFZZDCOPH-QXGOIDDHSA-N_|_Small molecule_|_True_|_DEXTROAMPHETAMINE SULFATE_|_1960.0_|_4.0_|_CHEMBL612_|_False_|_True_|_['Dexampex' 'Dexedrine' 'Dextroamphetamine sulfate' 'Dextrostat' 'Ferndex']_|_['Amphetamine sulfate, dextro' 'D-amphetamine hemisulfate salt'
 'Dexamfetamine sulfate' 'Dexamphetamine sulfate'
 'Dexamphetamine sulphate' 'Dextroamphetamine sulfate'
 'Dextroamphetamine sulfate cii' 'Dextroamphetamine sulphate' 'NSC-27104']_|_[('DailyMed', array(['dextroamphetamine%20sulfate'], dtype=object)), ('chEBI', array(['51064'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888', 'MONDO_0016158'], dtype=object), 'count': 2}_|_[ENSG00000165646,ENSG00000103546,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome. This drug has a black box warning from the FDA."
CHEMBL3545236,"nan_|_nan_|_Small molecule_|_False_|_BPI-9016_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BPI-9016M' 'Bpi-9016']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000105976,ENSG00000167601]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL4297517,"CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O_|_RLCLASQCAPXVLM-NSHDSACASA-N_|_Small molecule_|_True_|_MAVACAMTEN_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Camzyos']_|_['Camzyos' 'MYK-461' 'Mavacamten' 'Myk-461' 'SAR-439152']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MAVACAMTEN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14921'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000538', 'EFO_0003144', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000092054,ENSG00000197616,ENSG00000078814,ENSG00000160808,ENSG00000111245,ENSG00000106631,ENSG00000198336]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hypertrophic cardiomyopathy and cardiovascular disease and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL4298012,"nan_|_nan_|_Antibody_|_False_|_TESIDOLUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LFG-316' 'LFG316' 'Lfg316' 'NOV-4' 'Tesidolumab']_|_nan_|_nan_|_{'rows': array(['EFO_0001365', 'EFO_0004683', 'EFO_1001492', 'EFO_1000986'],
      dtype=object), 'count': 4}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4650296,"nan_|_nan_|_Unknown_|_False_|_BOS-589_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BOS-589' 'Bos-589' 'GSK3352589']_|_nan_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000165731]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL473,"CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1_|_IXTMWRCNAAVVAI-UHFFFAOYSA-N_|_Small molecule_|_True_|_DOFETILIDE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Dofetilide' 'Tikosyn']_|_['Dofetilide' 'UK-68,798' 'UK-68798']_|_[('DailyMed', array(['dofetilide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tikosyn'],
      dtype=object)), ('PubChem', array(['144205731', '170465418', '26757968'], dtype=object)), ('Wikipedia', array(['Dofetilide'], dtype=object)), ('drugbank', array(['DB00204'], dtype=object)), ('chEBI', array(['4681'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003911', 'EFO_0004269', 'EFO_0003144', 'HP_0001657',
       'HP_0004308', 'EFO_0000275'], dtype=object), 'count': 6}_|_[ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL592374,"Clc1ccc([C@]23CNC[C@H]2C3)cc1Cl_|_BSMNRYCSBFHEMQ-KCJUWKMLSA-N_|_Small molecule_|_False_|_AMITIFADINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amitifadine' 'DOV 21947' 'DOV-21,947' 'DOV-21947' 'EB1010']_|_[('Wikipedia', array(['Amitifadine'], dtype=object)), ('drugbank', array(['DB05964'], dtype=object))]_|_['CHEMBL1818442']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL595,"CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1_|_HYAFETHFCAUJAY-UHFFFAOYSA-N_|_Small molecule_|_True_|_PIOGLITAZONE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AD-4833' 'Actos' 'Duetact' 'Glustin' 'Pioglitazone' 'U-72107' 'Zactos']_|_[('PubChem', array(['137275816', '174007207', '26756476'], dtype=object)), ('Wikipedia', array(['Pioglitazone'], dtype=object)), ('drugbank', array(['DB01132'], dtype=object)), ('chEBI', array(['8228'], dtype=object))]_|_['CHEMBL1715']_|_{'rows': array(['EFO_0000756', 'EFO_0004265', 'EFO_0000712', 'EFO_0000400',
       'EFO_0000384', 'MONDO_0002108', 'MONDO_0008903', 'HP_0012115',
       'HP_0003124', 'EFO_0002546', 'EFO_0000544', 'HP_0002745',
       'EFO_0000339', 'MONDO_0005148', 'EFO_0003095', 'MONDO_0004975',
       'EFO_0003929', 'EFO_0001421', 'EFO_0000616', 'MONDO_0018305',
       'MONDO_0005148', 'EFO_0001361', 'MP_0001845', 'EFO_0001421',
       'MONDO_0004976', 'EFO_0003085', 'MONDO_0015339', 'MONDO_0100339',
       'EFO_0000707', 'EFO_1001249', 'EFO_0001073', 'EFO_0003884',
       'Orphanet_43', 'EFO_0000708', 'HP_0002745', 'EFO_0001645',
       'EFO_0003914', 'MONDO_0005301', 'MONDO_0008315', 'EFO_0002618',
       'MONDO_0007915', 'EFO_0000613', 'EFO_0000519', 'EFO_0003095',
       'EFO_0003047', 'EFO_1000948', 'EFO_0000537', 'EFO_0000685',
       'MONDO_0002009', 'EFO_0004272', 'HP_0100543', 'EFO_0002618',
       'EFO_0002499', 'EFO_0003756', 'MONDO_0001437', 'EFO_0005611',
       'EFO_0002614', 'EFO_0003060', 'MONDO_0009061', 'MONDO_0007079',
       'EFO_1001348', 'EFO_0000676', 'EFO_0005669', 'EFO_0000673',
       'EFO_0008620', 'EFO_0003060', 'MONDO_0004976', 'MONDO_0004979',
       'EFO_0000319', 'EFO_0000660', 'EFO_0000195', 'EFO_0003884',
       'HP_0001397', 'MONDO_0005180', 'EFO_0001378', 'MONDO_0016642',
       'EFO_0004220', 'MONDO_0005147', 'EFO_0000222', 'MONDO_0001657'],
      dtype=object), 'count': 80}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 74 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1173655,"CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1_|_ULXXDDBFHOBEHA-CWDCEQMOSA-N_|_Small molecule_|_False_|_AFATINIB_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Gilotrif' 'Giotrif']_|_['Afatinib' 'BIBW-2992' 'BIBW2992' 'Bibw 2992' 'NSC-750691' 'Tomtovok'
 'Tovok']_|_[('Wikipedia', array(['Afatinib'], dtype=object)), ('drugbank', array(['DB08916'], dtype=object)), ('chEBI', array(['61390'], dtype=object))]_|_['CHEMBL2105712']_|_{'rows': array(['EFO_0003869', 'MONDO_0021117', 'EFO_0000616', 'EFO_0000673',
       'MONDO_0001657', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378',
       'EFO_0004142', 'HP_0000083', 'EFO_0000707', 'EFO_0003859',
       'EFO_0006859', 'EFO_0000702', 'MONDO_0008978', 'MONDO_0007254',
       'EFO_0002618', 'EFO_0003863', 'EFO_0009709', 'MONDO_0004992',
       'EFO_0004284', 'EFO_0005543', 'EFO_1001956', 'EFO_0000181',
       'EFO_0000519', 'EFO_0001421', 'EFO_0005922', 'EFO_0001065',
       'EFO_0003060'], dtype=object), 'count': 29}_|_[ENSG00000146648,ENSG00000141736,ENSG00000178568]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 28 investigational indications."
CHEMBL1200618,"CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl_|_RRJFVPUCXDGFJB-UHFFFAOYSA-N_|_Small molecule_|_False_|_FEXOFENADINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL914_|_False_|_True_|_['Allegra' 'Allegra allergy' 'Allegra hives' ""Children's allegra allergy""
 ""Children's allegra hives""
 ""Children's fexofenadine hydrochloride allergy""
 ""Children's fexofenadine hydrochloride hives""
 'Fexofenadine hydrochloride' 'Fexofenadine hydrochloride allergy'
 'Fexofenadine hydrochloride hives' 'Telfast 120' 'Telfast 180'
 'Telfast 30']_|_['Fexofenadine hcl' 'Fexofenadine hydrochloride' 'MDL 16,455A'
 'MDL-16455A']_|_[('DailyMed', array(['fexofenadine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206676', '170464669', '26749923', '26753303', '50085984'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271', 'EFO_0004253', 'EFO_1001417', 'EFO_0005854',
       'EFO_0003956', 'EFO_0005531'], dtype=object), 'count': 6}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 2 investigational indications."
CHEMBL1201293,"CC(=O)NCCCS(=O)(=O)O_|_AFCGFAGUEYAMAO-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACAMPROSATE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acamprosate']_|_[('PubChem', array(['50112716'], dtype=object)), ('Wikipedia', array(['Acamprosate'], dtype=object)), ('drugbank', array(['DB00659'], dtype=object)), ('chEBI', array(['51041'], dtype=object))]_|_['CHEMBL2068724']_|_{'rows': array(['EFO_0003758', 'HP_0000360', 'MONDO_0007079', 'EFO_0005230',
       'EFO_0002610', 'HP_0000726', 'EFO_0003756', 'EFO_0005203',
       'MONDO_0002050', 'MONDO_0005090', 'MONDO_0010383', 'MONDO_0007079',
       'EFO_0004701'], dtype=object), 'count': 13}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for alcohol dependence and has 11 investigational indications."
CHEMBL1201664,"nan_|_nan_|_Protein_|_False_|_INSULIN ASPART PROTAMINE RECOMBINANT_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Insulin aspart protamine recombinant']_|_[('DailyMed', array(['insulin%20aspart%20protamine%20recombinant'], dtype=object))]_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2001."
CHEMBL1236682,"COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1_|_RDSACQWTXKSHJT-NSHDSACASA-N_|_Small molecule_|_False_|_REFAMETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 869766' 'BAY 8697661' 'BAY-86-9766' 'BAY-869766' 'BAY-8697661'
 'BAY86-9766' 'BAY869766' 'BAY8697661' 'Bay-86-9766' 'RDEA 119' 'RDEA-119'
 'Rdea119' 'Refametinib']_|_[('drugbank', array(['DB06309'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'MONDO_0003060', 'MONDO_0004992', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1743073,"nan_|_nan_|_Protein_|_False_|_SOTATERCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACE-001' 'ACE-011' 'ACE011' 'Sotatercept']_|_nan_|_nan_|_{'rows': array(['HP_0012410', 'EFO_0001378', 'MONDO_0044903', 'EFO_0004272',
       'EFO_0001361', 'MONDO_0016486', 'MONDO_0016487'], dtype=object), 'count': 7}_|_[ENSG00000122641]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2105711,"CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1.O_|_ZXOCGDDVNPDRIW-NHFZGCSJSA-N_|_Small molecule_|_False_|_TOFOGLIFLOZIN_|_2014.0_|_4.0_|_CHEMBL2110731_|_False_|_True_|_[]_|_['CSG452' 'Tofogliflozin' 'Tofogliflozin hydrate'
 'Tofogliflozin monohydrate']_|_[('Wikipedia', array(['Tofogliflozin'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_1001249'], dtype=object), 'count': 2}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 2 investigational indications."
CHEMBL2109193,"nan_|_nan_|_Antibody_|_False_|_GAVILIMOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABX-CBL' 'Gavilimomab']_|_nan_|_nan_|_{'rows': array(['MONDO_0013730'], dtype=object), 'count': 1}_|_[ENSG00000172270]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109328,"nan_|_nan_|_Antibody_|_False_|_IMC-EB10_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IMC-EB10' 'Imc-eb10']_|_nan_|_nan_|_{'rows': array(['MONDO_0004643'], dtype=object), 'count': 1}_|_[ENSG00000122025]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109338,nan_|_nan_|_Antibody_|_False_|_AMG-729_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-729']_|_nan_|_nan_|_nan_|_[ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2178422,"N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F_|_KRNAOFGYEFKHPB-ANJVHQHFSA-N_|_Small molecule_|_False_|_RIMEGEPANT_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BMS-927711' 'Bhv-3000' 'Rimegepant']_|_[('drugbank', array(['DB12457'], dtype=object))]_|_['CHEMBL2364629']_|_{'rows': array(['MONDO_0005277', 'EFO_0003843', 'EFO_0000676', 'EFO_0007486',
       'EFO_0005279', 'MONDO_0005277', 'EFO_1001219'], dtype=object), 'count': 7}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 6 investigational indications."
CHEMBL2361370,"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1.O=S(=O)(O)O_|_FEDSNBHHWZEYTP-ZFQYHYQMSA-N_|_Small molecule_|_False_|_PENBUTOLOL SULFATE_|_1987.0_|_4.0_|_CHEMBL1290_|_False_|_True_|_['Betapressin' 'Levatol']_|_['HOE 39-893D' 'HOE 893D' 'HOE-39-893D' 'HOE-893D' 'NSC-760043'
 'Penbutolol sulfate' 'Penbutolol sulphate']_|_[('PubChem', array(['144204192'], dtype=object))]_|_nan_|_nan_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987."
CHEMBL3039544,"nan_|_nan_|_Protein_|_False_|_TECEMOTIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_['Stimuvax']_|_['BLP-25' 'BLP25' 'BP-1-148' 'Blp 25' 'Blp-25 lipopeptide' 'EMD 531444'
 'Emepepimut-s' 'LIPOPEPTIDE BLP-25' 'Tecemotide']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0001378', 'MONDO_0008315', 'MONDO_0008903',
       'MONDO_0044937', 'EFO_1000657', 'MONDO_0007254', 'EFO_1001950'],
      dtype=object), 'count': 8}_|_[ENSG00000185499]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL3187365,"CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1_|_VSWBSWWIRNCQIJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_ASENAPINE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Secuado' 'Sycrest']_|_['Asenapine']_|_[('DailyMed', array(['asenapine'], dtype=object)), ('PubChem', array(['124899263'], dtype=object)), ('chEBI', array(['71255'], dtype=object))]_|_['CHEMBL3544974']_|_{'rows': array(['MONDO_0005090', 'EFO_0009963', 'HP_0025268', 'EFO_0005407',
       'EFO_0005411', 'EFO_0009963', 'MONDO_0004985', 'MONDO_0005090',
       'EFO_0005407'], dtype=object), 'count': 9}_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3301576,"nan_|_nan_|_Unknown_|_False_|_PEGPLERANIB SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_['Fovista']_|_['E-01AJ' 'E-10030' 'E01AJ' 'E10030' 'Pegpleranib sodium' 'X-01E' 'X01E']_|_nan_|_nan_|_{'rows': array(['MONDO_0008667', 'EFO_0001365'], dtype=object), 'count': 2}_|_[ENSG00000100311]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3301672,"CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)([O-])[O-])[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)([O-])[O-])[C@@H]1OCC[C@@H](CCCCCCC)OC.[Na+].[Na+].[Na+].[Na+]_|_FEMINZOAAWPBPP-RHMAUSBNSA-J_|_Small molecule_|_False_|_ERITORAN TETRASODIUM_|_nan_|_3.0_|_CHEMBL501259_|_False_|_False_|_[]_|_['B-1287' 'B1287' 'E-5564' 'E5564' 'Eritoran sodium'
 'Eritoran tetrasodium' 'Eritoran tetrasodium salt']_|_[('chEBI', array(['46692'], dtype=object))]_|_nan_|_{'rows': array(['HP_0100806', 'EFO_0000565'], dtype=object), 'count': 2}_|_[ENSG00000136869,ENSG00000154589]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3348963,"CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1.O=C(O)CNC(=O)c1ccccc1_|_XSFPZBUIBYMVEA-CELUQASASA-N_|_Small molecule_|_False_|_TELOTRISTAT ETIPRATE_|_2017.0_|_4.0_|_CHEMBL2105695_|_False_|_True_|_['Xermelo']_|_['LX1032 HIPPURATE' 'LX1606 HIPPURATE' 'Telotristat ethyl hippurate'
 'Telotristat etiprate']_|_[('DailyMed', array(['telotristat%20etiprate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xermelo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001901', 'HP_0002014', 'EFO_0004243'], dtype=object), 'count': 3}_|_[ENSG00000139287,ENSG00000129167]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications."
CHEMBL3707275,"nan_|_nan_|_Gene_|_False_|_VORETIGENE NEPARVOVEC_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Luxturna']_|_['AAV-2-HRPE65V2' 'AAV2-hRPE65v2' 'Luxturna' 'SPK-RPE65'
 'Voretigene neparvovec' 'Voretigene neparvovec rzyl'
 'Voretigene neparvovec-rzyl']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003966', 'HP_0000580', 'MONDO_0018998'], dtype=object), 'count': 3}_|_[ENSG00000116745]_|_Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications."
CHEMBL4073443,"Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1_|_HKTBYUWLRDZAJK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOMIVOSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EFT-508' 'Eft 508' 'Eft508' 'Tomivosertib' 'eFT508']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOMIVOSERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15219'], dtype=object))]_|_['CHEMBL4298140']_|_{'rows': array(['EFO_0000574', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0004992',
       'EFO_0000616', 'EFO_0003060', 'EFO_0000222', 'MONDO_0007254',
       'EFO_0000616'], dtype=object), 'count': 9}_|_[ENSG00000099875,ENSG00000079277]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL412309,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(O)cc1c2[Si](C)(C)C(C)(C)C_|_XUSKJHCMMWAAHV-SANMLTNESA-N_|_Small molecule_|_False_|_AR-67_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AR67' 'Ar-67' 'DB 67' 'DB-67' 'NSC-708298' 'Silatecan']_|_[('PubChem', array(['582483'], dtype=object)), ('drugbank', array(['DB12384'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000198', 'MONDO_0004992', 'EFO_1001465'],
      dtype=object), 'count': 4}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL414157,"CCCn1c(=O)c2[nH]c(C34CCC(CCC(=O)O)(CC3)CC4)nc2n(CCC)c1=O_|_ZWTVVWUOTJRXKM-UHFFFAOYSA-N_|_Small molecule_|_False_|_TONAPOFYLLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BG-9928' 'BG9928' 'Tonapofylline']_|_[('drugbank', array(['DB12569'], dtype=object))]_|_['CHEMBL535165']_|_{'rows': array(['EFO_0003144', 'HP_0000083', 'EFO_0000373', 'EFO_0001421'],
      dtype=object), 'count': 4}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4594419,"CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(C(C)(C)C)nn23)C1=O_|_CMVHFGNTABZQJU-HCXYKTFWSA-N_|_Small molecule_|_False_|_BMS-813160_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-813160' 'Bms 813160' 'Bms-813160']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'MONDO_0005184', 'EFO_0000536', 'EFO_0000401'],
      dtype=object), 'count': 4}_|_[ENSG00000160791,ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4650275,"nan_|_nan_|_Oligonucleotide_|_False_|_LUMASIRAN SODIUM_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Oxlumo']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oxlumo'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009823', 'MONDO_0002474'], dtype=object), 'count': 2}_|_[ENSG00000101323]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for primary hyperoxaluria type 1 and primary hyperoxaluria."
CHEMBL5314388,"CCN1CCC(Oc2c(C#N)ncc3[nH]c4ncccc4c23)CC1_|_XEZLBMHDUXSICI-UHFFFAOYSA-N_|_Small molecule_|_False_|_RG-7602_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GDC-0425' 'RG-7602' 'Rg-7602']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL5315119,"CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O_|_GJMQTRCDSIQEFK-SCDRJROZSA-N_|_Small molecule_|_True_|_UPADACITINIB HEMIHYDRATE_|_2019.0_|_4.0_|_CHEMBL3622821_|_False_|_True_|_['Rinvoq']_|_['Upadacitinib hydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000105639,ENSG00000096968,ENSG00000162434,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for rheumatoid arthritis. This drug has a black box warning from the FDA."
CHEMBL712,"COc1ccc(C2C(=O)c3ccccc3C2=O)cc1_|_XRCFXMGQEVUZFC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANISINDIONE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Miradon']_|_['Anisindione' 'NSC-759629']_|_[('PubChem', array(['144204923', '14729672', '170465379', '26748631', '50086377'],
      dtype=object)), ('Wikipedia', array(['Anisindione'], dtype=object)), ('drugbank', array(['DB01125'], dtype=object)), ('chEBI', array(['133809'], dtype=object))]_|_nan_|_nan_|_[ENSG00000115486]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957."
CHEMBL856,"CCC1(c2ccccc2)C(=O)NCNC1=O_|_DQMZLTXERSFNPB-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRIMIDONE_|_1954.0_|_4.0_|_nan_|_False_|_True_|_['Lepsiral' 'Liskantin' 'Mysoline' 'Neurosyn' 'Primidone']_|_['Lepimidin' 'NSC-41701' 'Primaclone' 'Primidone' 'Resimatil']_|_[('DailyMed', array(['primidone'], dtype=object)), ('PubChem', array(['104171217', '11111659', '11112270', '11113350', '144203789',
       '144209146', '144213511', '170464846', '17389534', '50104129',
       '50126364', '56324597', '855864', '90340844'], dtype=object)), ('Wikipedia', array(['Primidone'], dtype=object)), ('drugbank', array(['DB00794'], dtype=object)), ('chEBI', array(['8412'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0000474'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for epilepsy and has 1 investigational indication."
CHEMBL1097279,"CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])OP(=O)([O-])C(Cl)(Cl)P(=O)([O-])[O-])[C@@H](O)[C@H]1O.[Na+].[Na+].[Na+].[Na+]_|_COWWROCHWNGJHQ-OPKBHZIBSA-J_|_Small molecule_|_False_|_CANGRELOR TETRASODIUM_|_2015.0_|_4.0_|_CHEMBL334966_|_False_|_True_|_['Kengreal' 'Kengrexal']_|_['AR-C69931MX' 'Cangrelor tetrasodium' 'Cangrelor tetrasodium salt'
 'Kengrexal']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612', 'HP_0004419'], dtype=object), 'count': 2}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for myocardial infarction and recurrent thrombophlebitis."
CHEMBL1200338,"CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C.O_|_AFJCNBBHEVLGCZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PINACIDIL_|_1989.0_|_4.0_|_CHEMBL1159_|_False_|_True_|_['Pindac']_|_['NSC-759588' 'Pinacidil' 'Pinacidil hydrate' 'Pinacidil monohydrate']_|_[('PubChem', array(['144204505', '170465261', '56462991'], dtype=object)), ('Wikipedia', array(['Pinacidil'], dtype=object)), ('chEBI', array(['34923'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000187486,ENSG00000069431]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for hypertension."
CHEMBL1201346,"O=C(O)CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)O)c2)cc1_|_IPOKCKJONYRRHP-FMQUCBEESA-N_|_Small molecule_|_False_|_BALSALAZIDE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Balsalazide']_|_[('PubChem', array(['144205805', '170465305', '26758056'], dtype=object)), ('drugbank', array(['DB01014'], dtype=object)), ('chEBI', array(['267413'], dtype=object))]_|_['CHEMBL1200760']_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000132170,ENSG00000073756,ENSG00000095303,ENSG00000012779]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for ulcerative colitis."
CHEMBL1201577,"nan_|_nan_|_Antibody_|_True_|_CETUXIMAB_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Erbitux']_|_['ABP-494' 'C-225' 'C225' 'CMAB-009' 'CMAB009' 'Cetuximab'
 'Cetuximab (genetical recombination)' 'Cetuximab biosimilar (abp-494)'
 'IMC-225' 'IMC-C225' 'MOAB C225']_|_[('DailyMed', array(['cetuximab'], dtype=object)), ('DrugCentral', array(['4954'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux'],
      dtype=object)), ('Wikipedia', array(['Cetuximab'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001056', 'EFO_0007535', 'EFO_0005950', 'EFO_0000571',
       'MONDO_0002974', 'EFO_0000519', 'EFO_0000616', 'EFO_0009430',
       'MONDO_0007576', 'EFO_0004284', 'EFO_0004252', 'EFO_1001931',
       'MONDO_0002358', 'MONDO_0008315', 'EFO_0002916', 'EFO_1001949',
       'EFO_0000231', 'MONDO_0021074', 'EFO_0001061', 'EFO_0002938',
       'EFO_1001951', 'EFO_0000503', 'EFO_0003897', 'MONDO_0021355',
       'EFO_0004142', 'EFO_0005922', 'EFO_0003817', 'EFO_1000657',
       'MONDO_0004992', 'MONDO_0001187', 'EFO_0001378', 'MONDO_0021364',
       'EFO_0000182', 'MONDO_0002691', 'EFO_0003871', 'MONDO_0007254',
       'EFO_0003835', 'EFO_0000673', 'MONDO_0044926', 'EFO_0003060',
       'MONDO_0005575', 'MONDO_0008978', 'MONDO_0001879', 'EFO_0006352',
       'MONDO_0044704', 'EFO_0004198', 'EFO_0000181', 'MONDO_0021310',
       'EFO_0009708', 'EFO_0000365', 'MONDO_0100342', 'MONDO_0002087',
       'EFO_0003869', 'EFO_0002618', 'EFO_1001100', 'EFO_0000707',
       'MONDO_0005184', 'MONDO_0008903', 'MONDO_0011962', 'EFO_1000251',
       'EFO_0006859', 'MONDO_0001657', 'EFO_0002499', 'MONDO_0008170',
       'MONDO_0002038', 'MONDO_0021063', 'EFO_0000313', 'EFO_0000691',
       'EFO_0003891', 'EFO_0000228', 'EFO_1001998', 'EFO_0003868',
       'EFO_0005221', 'EFO_1001950'], dtype=object), 'count': 74}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 13 approved and 61 investigational indications. This drug has a black box warning from the FDA."
CHEMBL13,"COCCc1ccc(OCC(O)CNC(C)C)cc1_|_IUBSYMUCCVWXPE-UHFFFAOYSA-N_|_Small molecule_|_True_|_METOPROLOL_|_1978.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(rs)-metoprolol' 'Beatrolol' 'CGP-2175' 'Dl-metoprolol' 'Lopressidone'
 'Metoprolol' 'Metoprolol slow release' 'Seroken' 'Toprol-XL']_|_[('PubChem', array(['251919670'], dtype=object)), ('Wikipedia', array(['Metoprolol'], dtype=object)), ('drugbank', array(['DB00264'], dtype=object)), ('chEBI', array(['6904'], dtype=object))]_|_['CHEMBL1200337' 'CHEMBL1200840' 'CHEMBL2062335' 'CHEMBL545787'
 'CHEMBL3186768' 'CHEMBL2356097' 'CHEMBL3989566' 'CHEMBL1868892']_|_{'rows': array(['HP_0004308', 'EFO_0008585', 'EFO_0003913', 'EFO_0003144',
       'EFO_0001073', 'EFO_0008586', 'HP_0003124', 'EFO_0000712',
       'EFO_0003917', 'EFO_0000537', 'EFO_0000676', 'EFO_0000319',
       'EFO_0000275', 'EFO_0000612', 'EFO_0003777', 'EFO_0003913',
       'EFO_0000373', 'EFO_0000538', 'MONDO_0005148', 'EFO_0000266',
       'EFO_0003777', 'MONDO_0010679', 'EFO_0004287', 'Orphanet_79292',
       'EFO_0000712', 'EFO_0001068', 'EFO_0000275', 'EFO_0000764',
       'HP_0001653', 'Orphanet_848', 'EFO_0000275', 'EFO_0001645',
       'EFO_0000612', 'EFO_1002000', 'EFO_0000616', 'EFO_0003914',
       'EFO_0000537', 'EFO_0000341', 'EFO_0000274', 'EFO_0008583',
       'EFO_0000373', 'MONDO_0008300', 'EFO_0005306', 'EFO_0004278',
       'EFO_0000612', 'EFO_0003144', 'EFO_1000637', 'MONDO_0007254',
       'EFO_0003144', 'EFO_0000537', 'EFO_1000645'], dtype=object), 'count': 51}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 37 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1611,"O=C1N=C([O-])NC1(c1ccccc1)c1ccccc1.[Na+]_|_FJPYVLNWWICYDW-UHFFFAOYSA-M_|_Small molecule_|_True_|_PHENYTOIN SODIUM_|_1956.0_|_4.0_|_CHEMBL16_|_False_|_True_|_['Dilantin' 'Diphenylan sodium' 'Extended phenytoin sodium' 'Pentran'
 'Phenytek' 'Phenytex' 'Phenytoin sodium' 'Prompt phenytoin sodium']_|_['5,5-diphenylhydantoin sodium salt' 'Antisacer'
 'Diphenylhydantoin sodium' 'NSC-757274' 'Phenytoin Sodium'
 'Phenytoin sodium' 'Phenytoin sodium extended'
 'Phenytoin sodium for injection' 'Phenytoin sodium salt'
 'Phenytoin sodium, extended' 'Phenytoin sodium, prompt'
 'Phenytoin sodium,extended' 'Phenytoin sodium,prompt'
 'Phenytoinum natricum' 'Tacosal']_|_[('DailyMed', array(['phenytoin%20sodium'], dtype=object)), ('PubChem', array(['11112021', '144212655', '14742085', '26757853', '50106089',
       '85231301', '855788'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'EFO_0000474'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and is indicated for seizure and epilepsy. This drug has a black box warning from the FDA."
CHEMBL1655,"CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1_|_XFCLJVABOIYOMF-QPLCGJKRSA-N_|_Small molecule_|_True_|_TOREMIFENE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acapodene' 'Chlortamoxifen' 'Farestone' 'GTX-006' 'J33.157K'
 'Toremifene' 'Toremiphene']_|_[('PubChem', array(['29216214'], dtype=object)), ('Wikipedia', array(['Toremifene'], dtype=object)), ('drugbank', array(['DB00539'], dtype=object)), ('chEBI', array(['9635'], dtype=object))]_|_['CHEMBL1200675']_|_{'rows': array(['EFO_0009907', 'MONDO_0008315', 'EFO_0000616', 'EFO_0003931',
       'MONDO_0100096', 'EFO_0003869', 'EFO_0003882', 'EFO_1001366',
       'MONDO_0007254', 'MONDO_0007254', 'MONDO_0008170', 'EFO_0003869',
       'EFO_0000305', 'EFO_0002621', 'EFO_0003931'], dtype=object), 'count': 15}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1742994,"nan_|_nan_|_Antibody drug conjugate_|_True_|_BRENTUXIMAB VEDOTIN_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Adcetris']_|_['Brentuximab vedotin' 'Brentuximab vedotin brentuximab' 'CAC-10' 'CAC10'
 'CAC10-VCMMAE' 'Cac10-1006(4)' 'Cac10-vcmmae(4)'
 'Monoclonal antibody sgn-30' 'SGN-35' 'Sgn 30']_|_[('DailyMed', array(['brentuximab%20vedotin'], dtype=object)), ('DrugCentral', array(['4964'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000404', 'MONDO_0019473', 'EFO_0002913', 'EFO_0000095',
       'EFO_0000616', 'MONDO_0009348', 'EFO_0001642', 'EFO_0000565',
       'EFO_1000785', 'MONDO_0013730', 'EFO_0000096', 'EFO_0000764',
       'EFO_1001051', 'MONDO_0019471', 'MONDO_0018906', 'EFO_0000211',
       'EFO_0000514', 'EFO_0000222', 'EFO_0003032', 'EFO_0000574',
       'MONDO_0007915', 'EFO_0000183', 'EFO_0000403', 'EFO_0000588',
       'EFO_0007359', 'EFO_0005952'], dtype=object), 'count': 26}_|_[ENSG00000120949,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2107384,"COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C.O=C(O)/C=C\C(=O)O_|_GXINKQQWHLIBJA-UCIBKFKQSA-N_|_Small molecule_|_False_|_VICRIVIROC MALEATE_|_nan_|_3.0_|_CHEMBL82301_|_False_|_False_|_[]_|_['MK-4176' 'SCH 417690' 'SCH-417690' 'Sch417690' 'Vicriviroc maleate']_|_nan_|_nan_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108707,"nan_|_nan_|_Antibody_|_False_|_GLEMBATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CR-011' 'CR011' 'CR011-VCMMAE' 'Glembatumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'MONDO_0007254'], dtype=object), 'count': 2}_|_[ENSG00000136235]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109128,"nan_|_nan_|_Protein_|_False_|_LENOGRASTIM_|_nan_|_4.0_|_nan_|_False_|_True_|_['Granocyte-13' 'Granocyte-34']_|_['G-csf (cho cell derived)' 'Glycosylated recombinant g-csf' 'Granocyte'
 'Granulocyte colony-stimulating factor lenograstim' 'Lenograstim'
 'Lenograstim (genetical recombination)' 'Lenograstim rdna' 'Neutrogin'
 'RG-CSF']_|_[('DrugCentral', array(['5167'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008583', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000403',
       'EFO_0001378', 'EFO_0000222'], dtype=object), 'count': 6}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 5 investigational indications."
CHEMBL2109455,nan_|_nan_|_Antibody_|_False_|_AL-901_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AL-901']_|_nan_|_nan_|_nan_|_[ENSG00000211891]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109553,"nan_|_nan_|_Antibody_|_False_|_CYT-500 177LU_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CYT-500' 'Cyt-500 177lu']_|_nan_|_nan_|_{'rows': array(['EFO_0000196'], dtype=object), 'count': 1}_|_[ENSG00000086205]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL235668,"N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl_|_QQHMKNYGKVVGCZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIPIRACIL_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MA-1' 'TPI (freebase)' 'Tipiracil']_|_[('drugbank', array(['DB09343'], dtype=object))]_|_['CHEMBL65375']_|_{'rows': array(['EFO_0004252', 'EFO_0000365', 'MONDO_0001187', 'MONDO_0044937',
       'EFO_1001951', 'EFO_0003869', 'EFO_1001949', 'EFO_0005221',
       'EFO_1000657', 'EFO_0000616', 'EFO_0000365', 'MONDO_0021063',
       'EFO_0002618', 'EFO_0000708', 'MONDO_0001056', 'MONDO_0005575',
       'EFO_0003860', 'EFO_0004142', 'MONDO_0007254', 'EFO_1000657',
       'EFO_0000702'], dtype=object), 'count': 21}_|_[ENSG00000025708]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 20 investigational indications."
CHEMBL29919,"Nc1cnc(-c2cc(Cl)cc(Cl)c2Cl)c(N)n1_|_NNXUYJFHOVCRSM-UHFFFAOYSA-N_|_Small molecule_|_False_|_ELPETRIGINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Elpetrigine' 'JZP-4']_|_nan_|_nan_|_nan_|_[ENSG00000141837,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000136531,ENSG00000153253,ENSG00000148408]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3544944,O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12_|_JJWLXRKVUJDJKG-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-863233_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL3544943']_|_nan_|_[ENSG00000097046]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545305,"CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O_|_WZTIQQBMSJTRBR-WYKNNRPVSA-N_|_Protein_|_False_|_CIBINETIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARA 290' 'ARA-290' 'ARA290' 'Ara 290' 'Ara290' 'Cibinetide' 'Ph-bsp'
 'Phbsp']_|_[('drugbank', array(['DB13006'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000187266,ENSG00000100368]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545328,"O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1_|_ISOCDPQFIXDIMS-UHFFFAOYSA-N_|_Small molecule_|_False_|_XL-019_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['XL019' 'Xl-019']_|_nan_|_nan_|_{'rows': array(['EFO_0002429', 'MONDO_0044903', 'EFO_0000479'], dtype=object), 'count': 3}_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3989406,"C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O_|_MZYVOFLIPYDBGD-MLZQUWKJSA-N_|_Small molecule_|_True_|_ENALAPRILAT_|_1988.0_|_4.0_|_CHEMBL577_|_False_|_True_|_['Enalaprilat']_|_['Enalapril diacid dihydrate' 'Enalapril diacid dihydrate anhydrous'
 'Enalaprilat' 'Enalaprilat dihydrate' 'MK-422' 'NSC-760053'
 'Vasotec i.v.']_|_[('DailyMed', array(['enalaprilat'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000407', 'EFO_0006346', 'EFO_0000537'], dtype=object), 'count': 3}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989933,"N=C(N)NCCC[C@@H](N)C(=O)O.O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21_|_GVPVVOSNDUAUKM-YMQOIHNTSA-N_|_Small molecule_|_False_|_ETRASIMOD ARGININE_|_2023.0_|_4.0_|_CHEMBL3358920_|_False_|_True_|_['Velsipity']_|_['APD334 L-Arginine' 'Etrasimod arginine']_|_nan_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000170989,ENSG00000125910,ENSG00000180739]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for ulcerative colitis."
CHEMBL4163691,"C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccoc23)c1_|_LZMJNVRJMFMYQS-UHFFFAOYSA-N_|_Small molecule_|_False_|_POSELTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HM71224' 'Hm-71224' 'LY3337641' 'Ly3337641' 'Poseltinib']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297849,"C[C@@H]1CN(c2nc(-n3ccc(OCCC4(C(F)(F)F)CC4)n3)ccc2C(=O)NS(=O)(=O)c2ccccc2)C(C)(C)C1_|_IGEOJNMYRZUKIK-IBGZPJMESA-N_|_Small molecule_|_False_|_BAMOCAFTOR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bamocaftor' 'VX-659' 'VX659' 'Vx-659']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BAMOCAFTOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15177'], dtype=object))]_|_['CHEMBL4298159']_|_{'rows': array(['MONDO_0009061', 'MONDO_0009061'], dtype=object), 'count': 2}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL461101,"CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O_|_XDXWLKQMMKQXPV-QYQHSDTDSA-N_|_Small molecule_|_True_|_ELTROMBOPAG_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Revolade']_|_['Eltrombopag' 'SB497115']_|_[('Wikipedia', array(['Eltrombopag'], dtype=object)), ('drugbank', array(['DB06210'], dtype=object)), ('chEBI', array(['85010'], dtype=object))]_|_['CHEMBL461805' 'CHEMBL461806' 'CHEMBL3989691']_|_{'rows': array(['EFO_0000198', 'MONDO_0010518', 'EFO_0001421', 'HP_0001915',
       'EFO_0006927', 'EFO_0000637', 'EFO_0001422', 'EFO_0006927',
       'EFO_0000565', 'EFO_0007160', 'EFO_0007160', 'HP_0001873',
       'EFO_0004599', 'EFO_0001378', 'EFO_0000095', 'MONDO_0002245',
       'EFO_0000616', 'EFO_0003047', 'EFO_0004220', 'EFO_0000198',
       'MONDO_0019391', 'EFO_0000574', 'EFO_0004220', 'EFO_0000222',
       'EFO_0004272', 'MP_0001914', 'HP_0001873'], dtype=object), 'count': 27}_|_[ENSG00000117400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL477,"Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O_|_OIRDTQYFTABQOQ-KQYNXXCUSA-N_|_Small molecule_|_False_|_ADENOSINE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Adenocard' 'Adenocor' 'Adenoscan' 'Adenosine']_|_['9-.beta.-d-ribofuranosyladenine' 'Adenosine' 'NSC-7652' 'SR 96225'
 'SR-96225']_|_[('DailyMed', array(['adenosine'], dtype=object)), ('PubChem', array(['144204442', '170465447', '26751564', '50104175', '855932',
       '90341699'], dtype=object)), ('Wikipedia', array(['Adenosine'], dtype=object)), ('drugbank', array(['DB00640'], dtype=object)), ('chEBI', array(['16335'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000556', 'EFO_1001375', 'EFO_1001450', 'EFO_0008583',
       'EFO_1000637', 'EFO_0008585', 'MONDO_0006715', 'EFO_0003843',
       'EFO_0000318', 'EFO_0000612', 'EFO_0000275', 'EFO_0000095',
       'EFO_0009493', 'EFO_0001645', 'MONDO_0004992', 'EFO_0000319',
       'EFO_1002000', 'EFO_0003913', 'EFO_0000616', 'MP_0001845',
       'EFO_0005306'], dtype=object), 'count': 21}_|_[ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 18 investigational indications."
CHEMBL5095049,"C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_BAHHBHSHSRTKNK-BJILWQEISA-N_|_Small molecule_|_False_|_PACRITINIB CITRATE_|_2022.0_|_4.0_|_CHEMBL2035187_|_False_|_True_|_['Vonjo']_|_[]_|_nan_|_nan_|_{'rows': array(['EFO_0002429', 'EFO_0002430'], dtype=object), 'count': 2}_|_[ENSG00000122025,ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for polycythemia vera and primary myelofibrosis."
CHEMBL5314394,"COc1cc2c(cc1S(=O)(=O)c1ccc(OCc3ccc(Cl)cc3)cc1)CCN(C)CC2_|_HIBWHHQXUSKNOV-UHFFFAOYSA-N_|_Small molecule_|_False_|_SB-773812_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW773812' 'SB-737050-A' 'SB-773812' 'Sb-773812']_|_nan_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL967,"CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21_|_SEQDDYPDSLOBDC-UHFFFAOYSA-N_|_Small molecule_|_True_|_TEMAZEPAM_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Kentepam' 'Normison' 'Restoril' 'Temaz' 'Temazepam']_|_['(rs)-temazepam' 'NSC-246303' 'Temazepam' 'Temazepam civ' 'WY-3917']_|_[('DailyMed', array(['temazepam'], dtype=object)), ('PubChem', array(['144205223', '144207242', '29215382'], dtype=object)), ('Wikipedia', array(['Temazepam'], dtype=object)), ('drugbank', array(['DB00231'], dtype=object)), ('chEBI', array(['9435'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0005230', 'EFO_0000341', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090'], dtype=object), 'count': 6}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL113313,"CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O_|_KVLLHLWBPNCVNR-SKCUWOTOSA-N_|_Small molecule_|_False_|_CAPROMORELIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-424,391' 'CP-424391-18' 'Capimorelin' 'Capromorelin' 'Cp-424,391'
 'Cp-424391']_|_[('Wikipedia', array(['Capromorelin'], dtype=object)), ('drugbank', array(['DB15205'], dtype=object))]_|_nan_|_nan_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1200604,"CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1_|_BGDKAVGWHJFAGW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TROPICAMIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Mydriacyl' 'Mydriafair' 'Nods' 'Tropicacyl' 'Tropicamide']_|_['Bistropamide' 'NSC-757372' 'RO-1-7683' 'Tropicamide' 'Tropicamidum'
 'Visumidriatic']_|_[('DailyMed', array(['tropicamide'], dtype=object)), ('PubChem', array(['104171259', '144203848', '170464754', '26747134', '50086517',
       '50104635', '85231280', '90341160'], dtype=object)), ('Wikipedia', array(['Tropicamide'], dtype=object)), ('drugbank', array(['DB00809'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001069', 'EFO_0003966', 'MONDO_0001330', 'MONDO_0005180',
       'HP_0011499', 'HP_0002307'], dtype=object), 'count': 6}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for mydriasis and has 5 investigational indications."
CHEMBL1201103,"COc1ccc(OC)c(C(O)C(C)N)c1.Cl_|_YGRFXPCHZBRUKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHOXAMINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL524_|_False_|_True_|_['Vasoxine' 'Vasoxyl']_|_['Methoxamine hcl' 'Methoxamine hydrochloride' 'NSC-757102']_|_[('PubChem', array(['144204799', '26747569', '50106595', '56422119', '855753'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009523'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication."
CHEMBL1201201,"CN[C@@H](C)Cc1ccccc1_|_MYWUZJCMWCOHBA-VIFPVBQESA-N_|_Small molecule_|_True_|_METHAMPHETAMINE_|_1943.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(s)-phenylmethylaminopropane' 'J6.362B' 'Metamfetamine'
 'Methamphetamine' 'NSC-25115']_|_[('Wikipedia', array(['Methamphetamine'], dtype=object)), ('drugbank', array(['DB01577'], dtype=object)), ('chEBI', array(['6809'], dtype=object))]_|_['CHEMBL1200952']_|_{'rows': array(['EFO_0003888', 'EFO_0004701', 'EFO_0004242', 'EFO_0003888'],
      dtype=object), 'count': 4}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1232583,"COc1ccc(S(=O)(=O)n2cc(CCC(=O)O)c3cc(OC)ccc32)cc1_|_YMPALHOKRBVHOJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDEGLITAZAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Indeglitazar' 'PPM-204']_|_[('drugbank', array(['DB07724'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000132170,ENSG00000186951,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1561,"OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO_|_IBAQFPQHRJAVAV-ULAWRXDQSA-N_|_Small molecule_|_False_|_MIGLITOL_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Diastabol' 'Glyset' 'Miglitol']_|_['BAY M 1099' 'BAY-M-1099' 'Miglitol' 'NSC-758702']_|_[('DailyMed', array(['miglitol'], dtype=object)), ('PubChem', array(['144204989', '170465326', '26719889', '49681630'], dtype=object)), ('Wikipedia', array(['Miglitol'], dtype=object)), ('drugbank', array(['DB00491'], dtype=object)), ('chEBI', array(['6935'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000171298,ENSG00000257335]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 1 investigational indication."
CHEMBL160038,"O=C(Cc1ccccc1)c1cc(O)c(O)c([N+](=O)[O-])c1_|_MRFOLGFFTUGAEB-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEBICAPONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nebicapone']_|_[('drugbank', array(['DB14849'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000093010]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1950289,"O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1_|_IBGLGMOPHJQDJB-IHRRRGAJSA-N_|_Small molecule_|_False_|_TANZISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CC-930' 'JNK 930' 'JNK-930' 'JNK930' 'Tanzisertib']_|_[('drugbank', array(['DB11798'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000768'], dtype=object), 'count': 1}_|_[ENSG00000107643,ENSG00000050748,ENSG00000109339]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105618,"C=CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCCC4[C@H]3CC[C@@]21C_|_ATXHVCQZZJYMCF-XZCODKSBSA-N_|_Small molecule_|_False_|_ALLYLESTRENOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Gestanin']_|_['Allylestrenol' 'Allyloestrenol' 'NSC-37723' 'Perselin']_|_nan_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831,ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL2105664,"CC(OC(=O)c1ccc(Cc2c(O)c3ccccc3oc2=O)cc1)(C(F)(F)F)C(F)(F)F_|_QFLNTQDOVCLQKW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TECARFARIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ATI-5923' 'Tecarfarin']_|_[('drugbank', array(['DB12823'], dtype=object))]_|_['CHEMBL2105676']_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3545330,"c1cnc(NCc2ccc(CNc3ncccn3)cc2)nc1_|_PXZXYRKDDXKDTK-UHFFFAOYSA-N_|_Small molecule_|_False_|_MSX-122_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Msx 122' 'Msx-122']_|_[('drugbank', array(['DB12715'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000121966]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545427,"nan_|_nan_|_Small molecule_|_False_|_CM-082_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cm-082']_|_nan_|_nan_|_{'rows': array(['EFO_0001365', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000681', 'EFO_0000702'], dtype=object), 'count': 7}_|_[ENSG00000157404,ENSG00000122025,ENSG00000113721,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL3707400,"nan_|_nan_|_Small molecule_|_False_|_INDANTADOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Chf-3381 free base' 'Chf3381' 'Indantadol' 'V3381']_|_nan_|_nan_|_{'rows': array(['EFO_1000783', 'EFO_0005762', 'HP_0012735', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000189221,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3989887,"C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O_|_NWJQLQGQZSIBAF-MLAUYUEBSA-N_|_Small molecule_|_True_|_TACROLIMUS_|_1994.0_|_4.0_|_CHEMBL269732_|_False_|_True_|_['Adoport' 'Advagraf' 'Astagraf xl' 'Capexion' 'Envarsus' 'Envarsus xr'
 'Modigraf' 'Perixis' 'Prograf' 'Protopic' 'Tacni' 'Tacrolimus' 'Vivadex']_|_['FK 506' 'FK-506' 'FK506' 'FR-900506' 'FR900506' 'NSC-758659'
 'Tacrolimus' 'Tacrolimus hydrate' 'Tacrolimus monohydrate']_|_[('DailyMed', array(['tacrolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/protopic'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_0000540', 'HP_0000964'], dtype=object), 'count': 3}_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL3989967,"CNc1nc(-c2cccc(NC(=O)c3ccc(C(=O)OC)cc3)c2)c2cc(OC)c(OC)cc2n1_|_BBTFKAOFCSOZMB-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOTAMILAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E-6005' 'E6005' 'Lotamilast' 'RVT-501']_|_[('drugbank', array(['DB12776'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650393,"nan_|_nan_|_Antibody_|_False_|_EPCORITAMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Epkinly']_|_['Epcoritamab' 'Epcoritamab-bysp' 'Epkinly' 'GEN-3013' 'GEN3013']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EPCORITAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0000403', 'MONDO_0018906', 'EFO_0005952',
       'EFO_1001469', 'EFO_0000096', 'EFO_0000616'], dtype=object), 'count': 7}_|_[ENSG00000156738,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for diffuse large b-cell lymphoma and has 6 investigational indications."
CHEMBL471,"CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1_|_ZBMZVLHSJCTVON-UHFFFAOYSA-N_|_Small molecule_|_True_|_SOTALOL_|_1992.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betapace' 'C07AA07' 'Darob mite' 'Dl-sotalol' 'MJ-1999' 'Sorine'
 'Sotalol']_|_[('PubChem', array(['144203812', '26751989'], dtype=object)), ('Wikipedia', array(['Sotalol'], dtype=object)), ('drugbank', array(['DB00489'], dtype=object)), ('chEBI', array(['63622'], dtype=object))]_|_['CHEMBL1700']_|_{'rows': array(['HP_0004308', 'EFO_0004278', 'EFO_0000319', 'EFO_0000275',
       'EFO_0000612', 'EFO_0004287', 'EFO_0003144', 'EFO_0000275',
       'EFO_0005306'], dtype=object), 'count': 9}_|_[ENSG00000043591,ENSG00000055118,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and cardiovascular disease and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200710,"CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21.Cl_|_WIMWMKZEIBHDTH-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLOMIPRAMINE HYDROCHLORIDE_|_1989.0_|_4.0_|_CHEMBL415_|_False_|_True_|_['Anafranil' 'Anafranil sr' 'Chlorimipramine' 'Clomicalm'
 'Clomipramine hydrochloride' 'Tranquax']_|_['Clomipramine hcl' 'Clomipramine hydrochloride' 'G 34586' 'G-34586'
 'NSC-759323']_|_[('DailyMed', array(['clomipramine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/clomicalm'],
      dtype=object)), ('PubChem', array(['144212136', '26747483', '50106071', '56422907', '855785'],
      dtype=object)), ('chEBI', array(['3755'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'EFO_0004242'], dtype=object), 'count': 2}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for obsessive-compulsive disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201027,"C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.[Br-]_|_VPNYRYCIDCJBOM-UHFFFAOYSA-M_|_Small molecule_|_False_|_GLYCOPYRROLATE_|_1961.0_|_4.0_|_CHEMBL1201335_|_False_|_True_|_['Cuvposa' 'Dartisla odt' 'Glycopyrrolate' 'Glyrx-pf'
 'Lonhala magnair kit' 'Robinul' 'Robinul forte' 'Robinul fte' 'Seebri'
 'Seebri breezhaler' 'Sialanar']_|_['AD-237' 'AHR-504' 'CHF-5259' 'CHF5259' 'Glycopyrrolate'
 'Glycopyrrolate, erythro-' 'Glycopyrrone bromide'
 'Glycopyrronium (as bromide)' 'Glycopyrronium bromide' 'NSC-250836'
 'NSC-251251' 'NSC-251252' 'NVA-237' 'NVA237' 'Nodapton' 'ORG-NC-45'
 'PT-001' 'PT001' 'Robanul' 'Tarodyl' 'Tarodyn']_|_[('DailyMed', array(['glycopyrrolate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/sialanar'],
      dtype=object)), ('PubChem', array(['144206695', '144206696', '170465427', '85273808'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006505', 'MONDO_0004979', 'HP_0000975', 'HP_0002307',
       'EFO_0010282', 'MONDO_0002050', 'EFO_0000341', 'EFO_0009516',
       'EFO_0003086', 'HP_0006536'], dtype=object), 'count': 10}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 5 approved and 5 investigational indications."
CHEMBL1201032,"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12.O=C(O)c1ccccc1_|_JPRXYLQNJJVCMZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIZATRIPTAN BENZOATE_|_1998.0_|_4.0_|_CHEMBL905_|_False_|_True_|_['Maxalt' 'Maxalt-mlt' 'Rizatriptan benzoate']_|_['MK-0462' 'NSC-758919' 'Rizafilm' 'Rizatriptan benzoate']_|_[('DailyMed', array(['rizatriptan%20benzoate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100431', 'MONDO_0005277', 'MONDO_0005475'], dtype=object), 'count': 3}_|_[ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 2 investigational indications."
CHEMBL1201587,"nan_|_nan_|_Antibody_|_True_|_ALEMTUZUMAB_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Campath' 'Campath Mabcampath, Lemtrada' 'Campath mabcampath' 'Lemtrada'
 'Mabcampath']_|_['Alemtuzumab' 'Alemtuzumab (genetical recombination)' 'Allo 647'
 'CAMPATH-1H' 'GZ-402673' 'GZ402673' 'LDP-03']_|_[('DailyMed', array(['alemtuzumab'], dtype=object)), ('DrugCentral', array(['4909'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada'],
      dtype=object)), ('Wikipedia', array(['Alemtuzumab'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019469', 'EFO_1001996', 'EFO_0000183', 'EFO_0000211',
       'EFO_0000094', 'EFO_0000621', 'EFO_0003086', 'EFO_0000095',
       'EFO_0000403', 'EFO_0002428', 'EFO_1000785', 'EFO_0005952',
       'EFO_0003884', 'MONDO_0011382', 'EFO_0000685', 'MONDO_0015974',
       'EFO_1002048', 'EFO_0000384', 'MONDO_0008170', 'EFO_1001264',
       'EFO_0001378', 'EFO_1001257', 'MONDO_0005301', 'EFO_0004272',
       'EFO_0000220', 'MONDO_0000870', 'MONDO_0044348', 'EFO_0000222',
       'MONDO_0001023', 'MONDO_0021193', 'EFO_0007160', 'EFO_0000540',
       'MONDO_0019472', 'EFO_1000560', 'EFO_1000690', 'MONDO_0002087',
       'MONDO_0013730', 'MONDO_0015540', 'MONDO_0004992', 'MONDO_0017198',
       'EFO_0000209', 'HP_0001915', 'EFO_0000616', 'MONDO_0005147',
       'MONDO_0002158', 'EFO_0001642', 'MONDO_0019391', 'HP_0100727',
       'EFO_0000565', 'EFO_0006803', 'Orphanet_848', 'EFO_0000574',
       'EFO_0004289', 'MONDO_0044881', 'EFO_0003929', 'EFO_1001051',
       'EFO_0006927', 'EFO_0009441', 'MONDO_0018305', 'EFO_0000096',
       'EFO_0001421', 'EFO_0000198', 'EFO_0007323', 'EFO_0004599',
       'EFO_0000255', 'MONDO_0002367'], dtype=object), 'count': 66}_|_[ENSG00000169442]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 63 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1277001,"CC(C)S(=O)(=O)NC[C@H](C)c1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1_|_ULRDYYKSPCRXAJ-KRWDZBQOSA-N_|_Small molecule_|_False_|_MIBAMPATOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY 451395' 'LY-451395' 'LY451395' 'Mibampator']_|_[('drugbank', array(['DB12717'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1566,"C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O_|_XUFXOAAUWZOOIT-SXARVLRPSA-N_|_Oligosaccharide_|_False_|_ACARBOSE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Acarbose' 'Glucobay' 'Precose']_|_['Acarbose' 'BAY G 5421' 'BAY-G-5421' 'NSC-758915']_|_[('DailyMed', array(['acarbose'], dtype=object)), ('PubChem', array(['144205150', '170464784'], dtype=object)), ('TG-GATEs', array(['116'], dtype=object)), ('Wikipedia', array(['Acarbose'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007318', 'EFO_0000400', 'EFO_0000589', 'EFO_0004593',
       'EFO_0001645', 'HP_0003124', 'EFO_0005252', 'MONDO_0002367',
       'EFO_0003914', 'EFO_0001073', 'EFO_0000195', 'MONDO_0005148',
       'EFO_0000537', 'EFO_0003095'], dtype=object), 'count': 14}_|_[ENSG00000257335,ENSG00000243480]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 12 investigational indications."
CHEMBL2103830,"COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC_|_GKDRMWXFWHEQQT-UHFFFAOYSA-N_|_Small molecule_|_False_|_FOSTAMATINIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fostamatinib' 'R-788' 'R-788 FREE ACID' 'R-935788' 'R-935788 FREE ACID'
 'R788 FREE ACID' 'R935788 FREE ACID']_|_[('PubChem', array(['174006453'], dtype=object)), ('drugbank', array(['DB12010'], dtype=object))]_|_['CHEMBL3989516']_|_{'rows': array(['EFO_0000574', 'MONDO_0007915', 'MONDO_0100096', 'EFO_0004194',
       'EFO_0000685', 'MP_0001914', 'MONDO_0008170', 'EFO_0007160',
       'EFO_0000403', 'EFO_0003106', 'EFO_0001642', 'EFO_0007160',
       'MONDO_0044903', 'EFO_1000710', 'EFO_0000574', 'EFO_0000685',
       'EFO_0004194', 'EFO_1001264', 'EFO_1001264', 'HP_0001873'],
      dtype=object), 'count': 20}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 16 investigational indications."
CHEMBL2103870,"Cc1ccc(NC(=O)C2(c3ccc4c(c3)OC(F)(F)O4)CC2)nc1-c1cccc(C(=O)O)c1_|_UFSKUSARDNFIRC-UHFFFAOYSA-N_|_Small molecule_|_False_|_LUMACAFTOR_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Lumacaftor' 'VRT 826809' 'VRT-826809' 'VRT826809' 'VX 809' 'VX-809'
 'VX809']_|_[('DailyMed', array(['lumacaftor'], dtype=object)), ('drugbank', array(['DB09280'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'EFO_0001421'], dtype=object), 'count': 2}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for cystic fibrosis and has 1 investigational indication."
CHEMBL2107457,"COc1ccc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc1OC_|_QQQIECGTIMUVDS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ITOPRIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Itopride' 'NSC-759643']_|_[('drugbank', array(['DB04924'], dtype=object))]_|_['CHEMBL2139257']_|_{'rows': array(['EFO_0008533', 'EFO_0010282', 'HP_0002019', 'EFO_0008588',
       'EFO_1000948', 'EFO_0000555'], dtype=object), 'count': 6}_|_[ENSG00000087085,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2108248,nan_|_nan_|_Antibody drug conjugate_|_False_|_ANATUMOMAB MAFENATOX_|_nan_|_2.0_|_nan_|_False_|_False_|_['Anyara']_|_['ABR-214936' 'Anatumomab mafenatox' 'PNU-214936']_|_nan_|_nan_|_nan_|_[ENSG00000146242]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2108566,"nan_|_nan_|_Antibody_|_False_|_NERELIMOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Humicade']_|_['BAY X 1351' 'BAY-103356' 'BAY-X 1351' 'BAY-X-1351' 'BAYX-1351' 'CDP-571'
 'Nerelimomab' 'TNF MAB' 'TNF-MAB']_|_nan_|_nan_|_nan_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of III."
CHEMBL284092,"CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1_|_QOIGKGMMAGJZNZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_GEPIRONE_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ariza' 'BMY-13805' 'Gepirone' 'ORG-13011' 'Variza']_|_[('Wikipedia', array(['Gepirone'], dtype=object)), ('drugbank', array(['DB12184'], dtype=object))]_|_['CHEMBL1204187']_|_{'rows': array(['MONDO_0002009', 'EFO_0002610', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545174,"nan_|_nan_|_Small molecule_|_False_|_GSK2881078_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gsk2881078']_|_nan_|_nan_|_{'rows': array(['HP_0004326'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297352,"C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(Cl)cn3)CC2)NC(=O)NC1=O_|_SFJFBTPHDHUUPU-OAHLLOKOSA-N_|_Small molecule_|_False_|_AZD-1236_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD1236' 'Azd 1236' 'Azd-1236' 'Azd1236']_|_[('drugbank', array(['DB11961'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0009061'], dtype=object), 'count': 2}_|_[ENSG00000100985,ENSG00000262406]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL429910,"CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1_|_JVHXJTBJCFBINQ-ADAARDCZSA-N_|_Small molecule_|_False_|_DAPAGLIFLOZIN_|_2012.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BMS-512148' 'Dapagliflozin' 'LYN-045']_|_[('DailyMed', array(['dapagliflozin'], dtype=object)), ('Wikipedia', array(['Dapagliflozin'], dtype=object)), ('drugbank', array(['DB06292'], dtype=object)), ('chEBI', array(['85078'], dtype=object))]_|_['CHEMBL3125457' 'CHEMBL3125455' 'CHEMBL3125318' 'CHEMBL3125316'
 'CHEMBL3125317' 'CHEMBL2103802' 'CHEMBL3125456' 'CHEMBL3125458']_|_{'rows': array(['EFO_0001645', 'EFO_0000660', 'HP_0001919', 'EFO_1001375',
       'EFO_1000783', 'EFO_0000195', 'EFO_0000400', 'MONDO_0005148',
       'EFO_0001073', 'EFO_0000275', 'EFO_0002614', 'EFO_0004194',
       'EFO_0000612', 'MONDO_0007254', 'EFO_1002048', 'MONDO_0010526',
       'EFO_0002687', 'EFO_1000899', 'EFO_0009104', 'EFO_1001249',
       'EFO_0001663', 'MONDO_0100096', 'EFO_0003884', 'MONDO_0005147',
       'MONDO_0009067', 'HP_0001397', 'EFO_0003144', 'MONDO_0005147',
       'EFO_0001361', 'EFO_0000401', 'EFO_0002618', 'EFO_0003770',
       'EFO_0003940', 'EFO_0004285', 'MONDO_0005148', 'MONDO_0004975',
       'EFO_0001422', 'MONDO_0002050', 'HP_0001824', 'EFO_0003833',
       'EFO_0003144'], dtype=object), 'count': 41}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 37 investigational indications."
CHEMBL4650486,"nan_|_nan_|_Antibody_|_False_|_ZANSECIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-3127804' 'LY3127804' 'Ly3127804' 'Zansecimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANSECIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'MONDO_0100096', 'EFO_0003106', 'EFO_0000616',
       'EFO_1000637'], dtype=object), 'count': 5}_|_[ENSG00000091879]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL541758,Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)NC4(C(=O)N5CCN(C(=O)[C@@H](N)CCC[N+](C)(C)C)CC5)CCOCC4)c3Cl)c2n1.[Cl-]_|_ZNHJDJYKDVGQSH-JMAPEOGHSA-M_|_Small molecule_|_False_|_FASITIBANT CHLORIDE_|_nan_|_2.0_|_CHEMBL218427_|_False_|_False_|_[]_|_['Fasitibant chloride' 'Men16132']_|_nan_|_nan_|_nan_|_[ENSG00000168398]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL815,"CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O_|_PXGPLTODNUVGFL-YNNPMVKQSA-N_|_Small molecule_|_False_|_DINOPROST_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dinoprost' 'Pgf2a' 'Pgf2alpha' 'Prosmon' 'Prostaglandin f2-alpha'
 'Prostaglandin f2.alpha.' 'Prostaglandin f2alpha' 'U-14,583' 'U-14583']_|_[('PubChem', array(['144205330', '29216066'], dtype=object)), ('Wikipedia', array(['Prostaglandin_F2alpha'], dtype=object)), ('drugbank', array(['DB12789'], dtype=object)), ('chEBI', array(['15553'], dtype=object))]_|_['CHEMBL1200896']_|_nan_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200495,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)[O-].[Na+]_|_HHZQLQREDATOBM-CODXZCKSSA-M_|_Small molecule_|_False_|_HYDROCORTISONE SODIUM SUCCINATE_|_1955.0_|_4.0_|_CHEMBL977_|_False_|_True_|_['A-hydrocort' 'Hcss' 'Hydrocortisone sodium succinate' 'Solu-cortef']_|_['Cortisol 21-(sodium succinate)' 'Hydrocortisone 21-sodium succinate'
 'Hydrocortisone sodium succinate' 'Hydrocortisoni natrii succinas'
 'NSC-9152' 'SOLU-CORTEF']_|_[('DailyMed', array(['hydrocortisone%20sodium%20succinate'], dtype=object)), ('PubChem', array(['144207050', '170465053', '50106430', '855547'], dtype=object)), ('chEBI', array(['5782'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003032', 'EFO_0000403', 'EFO_0006834', 'EFO_0000565',
       'MONDO_0000870', 'EFO_0000220', 'EFO_0000309', 'MONDO_0004979'],
      dtype=object), 'count': 8}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for asthma and has 7 investigational indications."
CHEMBL1200906,"CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1.[Br-]_|_UKLQXHUGTKWPSR-UHFFFAOYSA-M_|_Small molecule_|_False_|_OXYPHENONIUM BROMIDE_|_1982.0_|_4.0_|_CHEMBL1201286_|_False_|_True_|_['Antrenyl']_|_['Antrenil' 'BA-5473' 'C-5473' 'NSC-759248' 'Oxifenon' 'Oxyfenon'
 'Oxyphenon' 'Oxyphenonium bromide' 'Spasmodin' 'Spasmophen']_|_[('PubChem', array(['144204402', '170465282', '56422900', '855750'], dtype=object)), ('Wikipedia', array(['Oxyphenonium_bromide'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201219,"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1_|_BGSZAXLLHYERSY-XQIGCQGXSA-N_|_Small molecule_|_True_|_VECURONIUM_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Vecuronium' 'Vecuronium cation' 'Vecuronium ion']_|_[('PubChem', array(['50112721'], dtype=object)), ('Wikipedia', array(['Vecuronium_bromide'], dtype=object)), ('drugbank', array(['DB01339'], dtype=object)), ('chEBI', array(['9939'], dtype=object))]_|_['CHEMBL1200629']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA."
CHEMBL1201342,"CN1CCCC(CC2c3ccccc3Sc3ccccc32)C1_|_MJFJKKXQDNNUJF-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHIXENE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Atosil' 'Methixene' 'Metixene']_|_[('Wikipedia', array(['Metixene'], dtype=object)), ('drugbank', array(['DB00340'], dtype=object)), ('chEBI', array(['51024'], dtype=object))]_|_['CHEMBL2359044' 'CHEMBL1200426']_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for parkinson disease."
CHEMBL1491,"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl_|_HTIQEAQVCYTUBX-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMLODIPINE_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Astudal 5' 'Istin' 'Norvas' 'Norvasc']_|_['Amlodipine' 'CKD-330 COMPONENT AMLODIPINE' 'HGP-0904' 'HGP0904']_|_[('PubChem', array(['124893198', '225144262', '29217715', '50111725'], dtype=object)), ('Wikipedia', array(['Amlodipine'], dtype=object)), ('drugbank', array(['DB00381'], dtype=object)), ('chEBI', array(['2668'], dtype=object))]_|_['CHEMBL1200402' 'CHEMBL4594262' 'CHEMBL1200984']_|_{'rows': array(['EFO_0000319', 'EFO_0000612', 'MONDO_0016486', 'HP_0000093',
       'EFO_0001421', 'EFO_1001145', 'HP_0003124', 'EFO_0004911',
       'EFO_0003144', 'MONDO_0000477', 'EFO_0000537', 'EFO_0000278',
       'MONDO_0021187', 'HP_0003124', 'EFO_0000373', 'Orphanet_79292',
       'EFO_0007148', 'EFO_0003086', 'EFO_0000612', 'MONDO_0001422',
       'MONDO_0002050', 'EFO_0000764', 'EFO_0003913', 'EFO_0000400',
       'EFO_0000537', 'EFO_0003144', 'EFO_1000013', 'EFO_0000537',
       'EFO_0000400', 'MONDO_0021187', 'EFO_0000373', 'MONDO_0005178',
       'MONDO_0005148', 'EFO_0004234', 'EFO_0001645', 'EFO_0000712',
       'MONDO_0001134', 'EFO_0003914', 'MONDO_0007254', 'EFO_1001375',
       'EFO_1001996', 'MONDO_0001134', 'EFO_0003777', 'EFO_0000538',
       'EFO_0001645', 'EFO_0004214'], dtype=object), 'count': 46}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 14 approved and 30 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1742408,c1ccc2c(c1)OC[C@H](CNCCCOc1ccc3c(c1)OCO3)O2_|_MEEQBDCQPIZMLY-HNNXBMFYSA-N_|_Small molecule_|_False_|_OSEMOZOTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MN-305' 'Mkc-242' 'Osemozotan']_|_nan_|_nan_|_nan_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III.
CHEMBL1743062,"nan_|_nan_|_Antibody_|_False_|_RAMUCIRUMAB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Cyramza']_|_['1121B' 'IMC-1121B' 'LY3009806' 'Ramucirumab']_|_[('DailyMed', array(['ramucirumab'], dtype=object)), ('DrugCentral', array(['4917'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000588', 'EFO_0000756', 'MONDO_0004992',
       'EFO_0000519', 'EFO_0004243', 'EFO_0000681', 'EFO_0008528',
       'EFO_0000708', 'EFO_1000895', 'MONDO_0003060', 'EFO_0000228',
       'EFO_0001376', 'EFO_1000657', 'EFO_0002916', 'EFO_0000503',
       'EFO_0003060', 'EFO_1001961', 'EFO_1001951', 'MONDO_0007254',
       'EFO_0000181', 'MONDO_0007576', 'MONDO_0021063', 'EFO_0000182',
       'MONDO_0008315', 'EFO_0000389', 'EFO_0000326', 'EFO_0003897',
       'EFO_1000576', 'MONDO_0005411', 'EFO_0005922', 'MONDO_0001056',
       'EFO_1001469', 'EFO_1000581', 'EFO_0005952', 'EFO_0000178',
       'EFO_0002618'], dtype=object), 'count': 37}_|_[ENSG00000128052]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 7 approved and 30 investigational indications."
CHEMBL181,"CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1_|_GDLBFKVLRPITMI-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIAZOXIDE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Diazoxide' 'Eudemine' 'Eudimine' 'Hyperstat' 'Mutabase' 'Proglycem']_|_['Diazoxide' 'Diazoxidum' 'Eudemine injection' 'Hypertonalum' 'NSC-64198'
 'NSC-76130' 'SCH 6783' 'SCH-6783' 'SRG 95213' 'SRG-95213']_|_[('DailyMed', array(['diazoxide'], dtype=object)), ('PubChem', array(['11111111', '11113823', '124879964', '144203683', '170465328',
       '26747146', '26751995', '50104671', '56422090', '855807'],
      dtype=object)), ('Wikipedia', array(['Diazoxide'], dtype=object)), ('drugbank', array(['DB01119'], dtype=object)), ('chEBI', array(['4495'], dtype=object))]_|_['CHEMBL4297276']_|_{'rows': array(['MONDO_0002177', 'EFO_0001073', 'MONDO_0002050', 'EFO_0004211',
       'HP_0001943', 'MONDO_0008300', 'EFO_0000537', 'MONDO_0005148',
       'MONDO_0024677', 'EFO_0001073'], dtype=object), 'count': 10}_|_[ENSG00000121361,ENSG00000187486]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved and 6 investigational indications."
CHEMBL1928262,"CCOc1ncc(S(=O)(=O)N2CCN(CC)CC2)cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1_|_YPFZMBHKIVDSNR-UHFFFAOYSA-N_|_Small molecule_|_False_|_GISADENAFIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gisadenafil' 'UK-369,003' 'UK-369003']_|_[('drugbank', array(['DB11902'], dtype=object))]_|_['CHEMBL2103843']_|_{'rows': array(['EFO_0000341', 'EFO_0000284', 'HP_0000802', 'EFO_1000781'],
      dtype=object), 'count': 4}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1980297,"Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12_|_WPHKIQPVPYJNAX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ILORASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Abt-348, a-968660']_|_['A-968660' 'A-968660.0' 'ABBOTT-968660' 'ABT-348' 'Abt-348' 'Ilorasertib']_|_[('PubChem', array(['103904272'], dtype=object)), ('drugbank', array(['DB11694'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586,ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2095212,"Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1_|_PBAPPPCECJKMCM-IBGZPJMESA-N_|_Small molecule_|_False_|_MIRABEGRON_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Betmiga' 'Myrbetriq' 'Myrbetriq granules']_|_['Betanis' 'Mirabegron' 'YM-178' 'YM178']_|_[('DailyMed', array(['mirabegron'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga'],
      dtype=object)), ('drugbank', array(['DB08893'], dtype=object)), ('chEBI', array(['65349'], dtype=object))]_|_['CHEMBL3542362']_|_{'rows': array(['EFO_0003086', 'EFO_0006865', 'EFO_0001421', 'EFO_0005669',
       'HP_0002571', 'HP_0000103', 'EFO_0004253', 'EFO_0000660',
       'EFO_1000781', 'EFO_0003896', 'EFO_1001121', 'EFO_1000869',
       'HP_0000020', 'HP_0000011', 'EFO_0003144', 'EFO_0003843'],
      dtype=object), 'count': 16}_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 12 investigational indications."
CHEMBL2104991,"Cl.c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2_|_PYPPENBDXAWXJC-QNTKWALQSA-N_|_Small molecule_|_False_|_VABICASERIN HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL2110670_|_False_|_False_|_[]_|_['SCA-136' 'Vabicaserin hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000147246,ENSG00000135914,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2108666,"nan_|_nan_|_Antibody drug conjugate_|_False_|_YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(sup 90)y-dota-hll2' '2F35K89X9W' '90Y-DOTA-HLL2' '90y-epratuzumab'
 'S9S0Y-DOTA-HLL2' 'Y-90-dota-hll2' 'Yttrium y 90 epratuzumab tetraxetan']_|_nan_|_nan_|_{'rows': array(['EFO_0000094', 'MONDO_0018906', 'EFO_0000403', 'EFO_0000096'],
      dtype=object), 'count': 4}_|_[ENSG00000012124]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2145077,"COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2.Cl_|_HLUKNZUABFFNQS-ZMBIFBSDSA-N_|_Small molecule_|_False_|_IVABRADINE HYDROCHLORIDE_|_2015.0_|_4.0_|_CHEMBL471737_|_False_|_True_|_['Corlanor' 'Ivabradine zentiva' 'Procoralan']_|_['AMG 998' 'AMG-998' 'Corlentor' 'Ivabradine hcl'
 'Ivabradine hydrochloride' 'S 16257' 'S-16257-2']_|_[('DailyMed', array(['ivabradine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-zentiva'],
      dtype=object)), ('PubChem', array(['144206355'], dtype=object)), ('chEBI', array(['85969'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'EFO_0000373', 'EFO_0003913'], dtype=object), 'count': 3}_|_[ENSG00000138622]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved indications."
CHEMBL2218894,"CC(C)n1c(/C=C/C(O)CC(O)CC(=O)[O-])c(-c2ccc(F)cc2)c2ccccc21.[Na+]_|_ZGGHKIMDNBDHJB-CALJPSDSSA-M_|_Small molecule_|_False_|_FLUVASTATIN SODIUM_|_1993.0_|_4.0_|_CHEMBL2220442_|_False_|_True_|_['Dorisin xl' 'Fluvastatin sodium' 'Lescol' 'Lescol xl' 'Luvinsta xl'
 'Nandovar xl' 'Pinmactil' 'Stefluvin xl']_|_['Almastatin' 'Canef' 'Cranoc' 'Fluindostatin' 'Fluvastatin sodium'
 'Fluvastatin sodium salt' 'Fractal' 'Lipaxan' 'Lochol' 'Locol' 'Primexin'
 'Vastin' 'XU 62-320' 'XU-62-320']_|_[('DailyMed', array(['fluvastatin%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004911', 'HP_0003124', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for familial hypercholesterolemia and hypercholesterolemia and has 1 investigational indication."
CHEMBL2387408,"CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(=O)O)CC(=O)O)c(OC)cc2[C@@H](c2ccccc2)N1_|_CZGVOBIGEBDYTP-VSGBNLITSA-N_|_Small molecule_|_False_|_LINERIXIBAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GSK2330672' 'Gsk-2330672' 'Gsk2330672' 'Linerixibat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINERIXIBAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11729'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'HP_0000989', 'MONDO_0019072', 'MONDO_0001751'],
      dtype=object), 'count': 4}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3181947,"Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.Nc1c(CC(=O)[O-])cccc1C(=O)c1ccc(Br)cc1.O.O.O.[Na+].[Na+]_|_PPOSVVJOVKVBPW-UHFFFAOYSA-L_|_Small molecule_|_False_|_BROMFENAC SODIUM_|_1997.0_|_4.0_|_CHEMBL1077_|_True_|_True_|_['Bromday' 'Bromfenac sodium' 'Bromsite' 'Prolensa' 'Xibrom' 'Yellox']_|_['AHR-10282B' 'Bromfenac monosodium salt'
 'Bromfenac monosodium salt sesquihydrate' 'Bromfenac sodium'
 'Bromfenac sodium hydrate' 'Bromfenac sodium sesquihydrate']_|_[('DailyMed', array(['bromfenac%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yellox'],
      dtype=object)), ('PubChem', array(['144205734', '170465189'], dtype=object)), ('chEBI', array(['59176'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005129', 'HP_0200026', 'EFO_0003843', 'MP_0001845'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved indications. It was withdrawn in at least one region."
CHEMBL3989943,"CS(=O)(=O)CCC#N_|_LQFRYKBDZNPJSW-UHFFFAOYSA-N_|_Small molecule_|_False_|_DAPANSUTRILE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dapansutrile' 'OLT-1177' 'OLT1177']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000756', 'EFO_1001165', 'EFO_0000612',
       'EFO_1001207'], dtype=object), 'count': 5}_|_[ENSG00000162711]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3989962,"NC(CO)(CO)CO.NC(CO)(CO)CO.Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1.O.O_|_DUORKVZYABUEHW-AHJYMZSGSA-N_|_Small molecule_|_False_|_PEMETREXED TROMETHAMINE_|_2022.0_|_4.0_|_CHEMBL225072_|_False_|_True_|_[]_|_['Pemetrexed ditrometamol' 'Pemetrexed tromethamine'
 'Pemetrexed tromethamine anhydrous']_|_nan_|_nan_|_{'rows': array(['EFO_0003050', 'EFO_0000228'], dtype=object), 'count': 2}_|_[ENSG00000159131,ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for large cell lung carcinoma and adenocarcinoma."
CHEMBL408,"Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2_|_GXPHKUHSUJUWKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_TROGLITAZONE_|_1997.0_|_4.0_|_nan_|_True_|_True_|_['Prelay' 'Rezulin' 'Romozin']_|_['CI-991' 'CS-045' 'GR-92132X' 'GR92132X' 'Rezulin' 'Troglitazone']_|_[('PubChem', array(['137275811', '144205672', '144210788', '170465091', '174007238',
       '26755242', '26755243', '26757864', '29216382'], dtype=object)), ('Wikipedia', array(['Troglitazone'], dtype=object)), ('drugbank', array(['DB00197'], dtype=object)), ('chEBI', array(['9753'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'EFO_0000691'], dtype=object), 'count': 2}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for diabetes mellitus and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL4297928,"nan_|_nan_|_Unknown_|_False_|_NOMACOPAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Coversin' 'Nomacopan' 'REV-576' 'REV-675' 'REV675' 'rEV576']_|_nan_|_nan_|_{'rows': array(['MONDO_0100244', 'EFO_0007187'], dtype=object), 'count': 2}_|_[ENSG00000213906,ENSG00000213903,ENSG00000106804]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL49429,"Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc32)c(Cl)c1_|_PPHTXRNHTVLQED-UHFFFAOYSA-N_|_Small molecule_|_False_|_LIXIVAPTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Lixar']_|_['CRTX 080' 'CRTX-080' 'CRTX080' 'Lixivaptan' 'VPA 985' 'VPA-985' 'VPA985'
 'Vpa-985' 'WAY-VPA-985']_|_[('Wikipedia', array(['Lixivaptan'], dtype=object)), ('drugbank', array(['DB06666'], dtype=object))]_|_['CHEMBL3526685']_|_{'rows': array(['EFO_0000373', 'HP_0002902', 'EFO_0008620', 'EFO_1001496'],
      dtype=object), 'count': 4}_|_[ENSG00000126895]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5316170,"CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4_|_GFNQJZFJGAULCC-BWENMZSBSA-N_|_Small molecule_|_False_|_CEP-2563_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL5314390']_|_nan_|_[ENSG00000122025,ENSG00000165731,ENSG00000113721,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675,ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL779,"CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O_|_WOXKDUGGOYFFRN-IIBYNOLFSA-N_|_Small molecule_|_False_|_TADALAFIL_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Adcirca' 'Adcirca (previously tadalafil lilly)' 'Cialis' 'Tadliq']_|_['IC-351' 'IC351' 'LY-450190' 'LY450190' 'NSC-750236' 'NSC-759172'
 'Tadalafil' 'Tadalafil mylan' 'Trans-tadalafil']_|_[('DailyMed', array(['tadalafil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adcirca'],
      dtype=object)), ('PubChem', array(['144206195', '170464819', '26719828', '49666420'], dtype=object)), ('Wikipedia', array(['Tadalafil'], dtype=object)), ('drugbank', array(['DB00820'], dtype=object)), ('chEBI', array(['71940'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0009200', 'EFO_0000284', 'EFO_0000616',
       'EFO_0004714', 'EFO_0004244', 'EFO_0001361', 'EFO_0002614',
       'MONDO_0000153', 'MONDO_0005148', 'EFO_0002499', 'EFO_0803321',
       'HP_0030680', 'HP_0000802', 'MONDO_0005149', 'EFO_0000373',
       'HP_0001952', 'EFO_0004284', 'EFO_1000948', 'EFO_0000181',
       'EFO_0004718', 'EFO_0003099', 'EFO_0004234', 'EFO_0002618',
       'EFO_0001073', 'MONDO_0010679', 'EFO_0000537', 'MONDO_0020121',
       'MONDO_0002009', 'EFO_0000712', 'EFO_0001378', 'EFO_0000717',
       'MONDO_0001134', 'HP_0200023', 'MONDO_0004992', 'EFO_0000519',
       'EFO_1001145'], dtype=object), 'count': 37}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 5 approved and 32 investigational indications."
CHEMBL1084617,"COc1cccc(C(=O)Nc2ccc(OCCN3CCOCC3)c(-c3ccnn3C)c2)c1_|_ZEOQUKRCASTCFR-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEMANOGREL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APD-791' 'APD791' 'Apd791' 'Temanogrel']_|_nan_|_['CHEMBL2105696']_|_{'rows': array(['EFO_0005672'], dtype=object), 'count': 1}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200425,"C#CCN(C)Cc1ccccc1.Cl_|_BCXCABRDBBWWGY-UHFFFAOYSA-N_|_Small molecule_|_False_|_PARGYLINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL673_|_False_|_True_|_['Eutonyl']_|_['A-19120' 'MO-911' 'NSC-43798' 'Pargyline hcl' 'Pargyline hydrochloride']_|_[('PubChem', array(['144203792', '144212995', '170465066', '50106924', '56422872',
       '855526'], dtype=object))]_|_nan_|_nan_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200781,"Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21_|_WIHMBLDNRMIGDW-UHFFFAOYSA-N_|_Small molecule_|_True_|_CITALOPRAM HYDROBROMIDE_|_1998.0_|_4.0_|_CHEMBL549_|_False_|_True_|_['Celexa' 'Cipramil' 'Citalopram hydrobromide' 'Paxoran']_|_['Citalopram (as hydrobromide)' 'Citalopram hbr' 'Citalopram hydrobromide'
 'LU 10-171-B' 'LU-10-171-B' 'NSC-758684']_|_[('DailyMed', array(['citalopram%20hydrobromide'], dtype=object)), ('PubChem', array(['26719710', '29215151', '46500388', '50106010', '50106011'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0031217', 'MONDO_0002009', 'EFO_0004262', 'EFO_0003758',
       'MONDO_0002009'], dtype=object), 'count': 5}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201061,"CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.Cl_|_OWNWYCOLFIFTLK-YDALLXLXSA-N_|_Small molecule_|_False_|_LEVALBUTEROL HYDROCHLORIDE_|_1999.0_|_4.0_|_CHEMBL1002_|_False_|_True_|_['Levalbuterol hydrochloride' 'Xopenex']_|_['Albuterol (r)-form hydrochloride' 'Albuterol hydrochloride, r-'
 'Levalbuterol hcl' 'Levalbuterol hydrochloride'
 'Levosalbutamol hydrochloride' 'NSC-759255']_|_[('DailyMed', array(['levalbuterol%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999 and is indicated for asthma."
CHEMBL1201505,"nan_|_nan_|_Unknown_|_False_|_FIBRINOLYSIN, HUMAN_|_1964.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fibrinolysin' 'Fibrinolysin (human)' 'Fibrinolysin human'
 'Fibrinolysin, human' 'Plasmin' 'Plasmin (bos taurus)' 'Plasmin (bovine)'
 'Plasmin (human)' 'Plasmin bovine' 'Thrombolysin.']_|_[('Wikipedia', array(['Fibrinolysin'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004419', 'MONDO_0020673', 'HP_0002140'], dtype=object), 'count': 3}_|_[ENSG00000171560,ENSG00000171564,ENSG00000171557]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for recurrent thrombophlebitis and has 2 investigational indications."
CHEMBL1711,"CC(C)NCC(O)c1ccc(O)c(O)c1.Cl_|_IROWCYIEJAOFOW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOPROTERENOL HYDROCHLORIDE_|_1956.0_|_4.0_|_CHEMBL434_|_False_|_True_|_['Aerolone' 'Imuprel' 'Isoprenaline' 'Isoproterenol hydrochloride'
 'Isuprel' 'Norisodrine aerotrol' 'Oriconazole' 'Vapo-iso']_|_['Aerotrol' 'Dl-isoprenaline hydrochloride' 'Euspiran' 'Isomenyl'
 'Isoprenaline hydrochloride' 'Isoprenaline hydrochloride, dl-'
 'Isopropylarterenol hydrochloride' 'Isoproterenol HCl'
 'Isoproterenol hcl' 'Isoproterenol hydrochloride' 'Isovon'
 'L-isoprenaline hydrochloride' 'Medihaler-Iso' 'Mistarel' 'NSC-37745'
 'NSC-89747' 'Suscardia']_|_[('DailyMed', array(['isoproterenol%20hydrochloride'], dtype=object)), ('PubChem', array(['144208470', '144210628', '17388957', '26747558', '26747559',
       '26752241', '50085961', '50106483', '50106527', '50106528',
       '56320927', '56320928'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000373'], dtype=object), 'count': 1}_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for congestive heart failure."
CHEMBL1717,"Cl.Clc1ccccc1CN1CCc2sccc2C1_|_MTKNGOHFNXIVOS-UHFFFAOYSA-N_|_Small molecule_|_True_|_TICLOPIDINE HYDROCHLORIDE_|_1991.0_|_4.0_|_CHEMBL833_|_False_|_True_|_['Ticlid' 'Ticlopidine hydrochloride' 'Tiklid']_|_['4-C-32' '53-32C' 'Ipaton' 'NSC-759165' 'Ticlopidine hcl'
 'Ticlopidine hydrochloride']_|_[('DailyMed', array(['ticlopidine%20hydrochloride'], dtype=object)), ('PubChem', array(['865815'], dtype=object)), ('chEBI', array(['9589'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'MONDO_0000831'], dtype=object), 'count': 2}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for stroke and thrombotic disease. This drug has a black box warning from the FDA."
CHEMBL180101,"CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1_|_CBQGYUDMJHNJBX-OALUTQOASA-N_|_Small molecule_|_False_|_ESREBOXETINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(s,s)-reboxetine' 'Esreboxetine' 'REBOXETINE' 'S,s-reboxetine']_|_[('PubChem', array(['11114256'], dtype=object)), ('drugbank', array(['DB12395'], dtype=object))]_|_['CHEMBL2103809']_|_{'rows': array(['EFO_0003843', 'EFO_0005687', 'EFO_1000783'], dtype=object), 'count': 3}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1983268,"CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1_|_HAYYBYPASCDWEQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENTRECTINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Rozlytrek']_|_['Entrectinib' 'NMS-E628' 'RXDX-101' 'Rxdx-101']_|_[('DailyMed', array(['entrectinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek'],
      dtype=object)), ('PubChem', array(['103905026'], dtype=object)), ('drugbank', array(['DB11986'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0001642', 'EFO_0000326', 'EFO_0003060',
       'EFO_0000389', 'EFO_0000616', 'EFO_0000222', 'EFO_0000553'],
      dtype=object), 'count': 8}_|_[ENSG00000047936,ENSG00000171094,ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 5 investigational indications."
CHEMBL2041933,"NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1_|_IAYGCINLNONXHY-LBPRGKRZSA-N_|_Small molecule_|_False_|_AZD-7762_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZD-7762' 'AZD7762' 'Azd 7762' 'Azd-7762']_|_[('PubChem', array(['124950686'], dtype=object)), ('drugbank', array(['DB12242'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL206253,"Cc1ccccc1-c1cc(N2CCN(C)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_WAXQNWCZJDTGBU-UHFFFAOYSA-N_|_Small molecule_|_False_|_NETUPITANT_|_2014.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Netupitant' 'RO 67-3189/000' 'RO-67-3189' 'RO-673189000']_|_[('DailyMed', array(['netupitant'], dtype=object)), ('drugbank', array(['DB09048'], dtype=object)), ('chEBI', array(['85155'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006911', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for chemotherapy-induced nausea and vomiting and has 1 investigational indication."
CHEMBL2097081,"nan_|_nan_|_Small molecule_|_True_|_NITROPRUSSIDE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Nitroprusside']_|_[('DrugCentral', array(['4631'], dtype=object)), ('PubChem', array(['29217813'], dtype=object)), ('chEBI', array(['7596'], dtype=object))]_|_['CHEMBL3183086' 'CHEMBL136478']_|_{'rows': array(['EFO_0001358', 'EFO_0000537', 'MP_0001914', 'EFO_0005251',
       'MONDO_0005090', 'EFO_1000653', 'MONDO_0002050', 'EFO_0008585',
       'EFO_0000373', 'EFO_0000612', 'EFO_1000645', 'EFO_0004272',
       'EFO_0005252', 'EFO_0000319', 'MP_0001845', 'EFO_0000537'],
      dtype=object), 'count': 16}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103795,"CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]_|_IHWFKDWIUSZLCJ-UHFFFAOYSA-M_|_Small molecule_|_True_|_AZILSARTAN KAMEDOXOMIL_|_2011.0_|_4.0_|_CHEMBL2028661_|_False_|_True_|_['Edarbi']_|_['Azilsartan kamedoxomil' 'Azilsartan medoxomil potassium' 'TAK-491']_|_[('DailyMed', array(['azilsartan%20kamedoxomil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi'],
      dtype=object)), ('chEBI', array(['68847'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000712'], dtype=object), 'count': 2}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hypertension and stroke. This drug has a black box warning from the FDA."
CHEMBL2109342,"nan_|_nan_|_Antibody_|_False_|_HGS-1025_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HGS-1025' 'Hgs-1025']_|_nan_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3414621,"CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1_|_NSQSAUGJQHDYNO-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAZEMETOSTAT_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['E-7438' 'E7438' 'EPZ-6438' 'EPZ6438' 'Tazemetostat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAZEMETOSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12887'], dtype=object))]_|_['CHEMBL4594260']_|_{'rows': array(['EFO_0005952', 'EFO_0000222', 'MONDO_0001187', 'EFO_0000181',
       'EFO_0000702', 'EFO_0000616', 'MONDO_0018906', 'EFO_0000196',
       'MONDO_0015760', 'MONDO_0018906', 'EFO_0002913', 'EFO_0000574',
       'EFO_0000096', 'EFO_0000403', 'EFO_0000691', 'EFO_0008528',
       'EFO_0001378', 'MONDO_0008315', 'MONDO_0017387', 'EFO_0000588',
       'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 22}_|_[ENSG00000106462]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 19 investigational indications."
CHEMBL3545057,"CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O_|_HPMZBILYSWLILX-UMDUKNJSSA-N_|_Small molecule_|_False_|_ACETYLDIGITOXIN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Acylanid']_|_['Acetyldigitoxin' 'Acetyldigitoxins .alpha.-form']_|_[('drugbank', array(['DB00511'], dtype=object)), ('chEBI', array(['53773'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease."
CHEMBL3545068,"COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21.Cl.Cl_|_STGQPVQAAFJJFX-UHFFFAOYSA-N_|_Small molecule_|_False_|_COPANLISIB HYDROCHLORIDE_|_2017.0_|_4.0_|_CHEMBL3218576_|_False_|_True_|_['Aliqopa']_|_['BAY 80-6946 DIHYDROCHLORIDE' 'BAY 84-1236' 'BAY-80-6946 DIHYDROCHLORIDE'
 'BAY-84-1236' 'Copanlisib hydrochloride'
 'Copanlisib hydrochloride hydrate']_|_[('DailyMed', array(['copanlisib%20dihydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005537', 'MONDO_0018906', 'EFO_0000305', 'EFO_1001051',
       'EFO_1001469', 'EFO_0000616', 'EFO_0000096', 'EFO_0000403',
       'EFO_0001378', 'EFO_0000183'], dtype=object), 'count': 10}_|_[ENSG00000121879,ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 8 investigational indications."
CHEMBL3545138,nan_|_nan_|_Small molecule_|_False_|_PRT-2607_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BIIB-057' 'P505-15' 'PRT-062607' 'Prt-2607']_|_nan_|_nan_|_nan_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545367,"Cc1ncc(OC[C@@]2(c3cccc(F)c3)C[C@H]2C(=O)Nc2ccc(F)cn2)c(C)n1_|_MUGXRYIUWFITCP-PGRDOPGGSA-N_|_Small molecule_|_False_|_LEMBOREXANT_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Dayvigo']_|_['E-2006' 'E2006' 'Lemborexant']_|_[('DailyMed', array(['lemborexant'], dtype=object)), ('drugbank', array(['DB11951'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0003918', 'MONDO_0007079', 'MONDO_0004975',
       'MONDO_0024361', 'EFO_0001421', 'EFO_0003086', 'EFO_0008568'],
      dtype=object), 'count': 8}_|_[ENSG00000121764,ENSG00000137252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for insomnia and has 7 investigational indications."
CHEMBL4297584,"CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1_|_HDXDQPRPFRKGKZ-INIZCTEOSA-N_|_Small molecule_|_False_|_TENALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tenalisib']_|_[('drugbank', array(['DB15295'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000211', 'EFO_0000574', 'MONDO_0007254', 'EFO_0001642',
       'EFO_0000095', 'MONDO_0009348', 'EFO_0005952'], dtype=object), 'count': 7}_|_[ENSG00000105851,ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4297611,"CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(-c2ccc(F)cc2)n1_|_YFHRCLAKZBDRHN-MRXNPFEDSA-N_|_Small molecule_|_False_|_VENGLUSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GENZ-682452' 'GZ-402671' 'GZ/SAR402671' 'GZ402671' 'Genz-682452'
 'Genz-682452-AA' 'Gz402671' 'Ibiglustat' 'SAR-402671' 'SAR402671'
 'Venglustat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VENGLUSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14966'], dtype=object))]_|_['CHEMBL4594270']_|_{'rows': array(['Orphanet_77259', 'MONDO_0018150', 'HP_0001300', 'HP_0001300',
       'EFO_1001496', 'EFO_1001496', 'EFO_0008615', 'MONDO_0010526',
       'MONDO_0005180', 'Orphanet_77261', 'MONDO_0018150',
       'MONDO_0010526'], dtype=object), 'count': 12}_|_[ENSG00000148154]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL4297638,"Cn1cc(-c2ccc(S(=O)(=O)[C@@H]3C[C@@H](C(=O)NC4(C#N)CC4)N(C(=O)C4(C(F)(F)F)CC4)C3)c(C(F)(F)F)c2)cn1_|_KXAAIORSMACJSI-AEFFLSMTSA-N_|_Small molecule_|_False_|_PETESICATIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Petesicatib' 'RG-7625' 'RG7625' 'RO-5459072' 'RO5459072' 'Rg7625'
 'Ro5459072']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PETESICATIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15297'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001060', 'EFO_0000699', 'EFO_0005809'], dtype=object), 'count': 3}_|_[ENSG00000163131]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297886,"nan_|_nan_|_Protein_|_False_|_ASUNERCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['APG-101' 'APG101' 'Apg101' 'Apocept' 'Asinercept' 'Asunercept' 'CAN-008']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'MONDO_0100096', 'EFO_0000198'], dtype=object), 'count': 3}_|_[ENSG00000117560]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4298098,"nan_|_nan_|_Antibody drug conjugate_|_False_|_TUSAMITAMAB RAVTANSINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Maytansin-loaded anti-ceacam5 mab' 'SAR-408701' 'SAR408701' 'Sar 408701'
 'Sar-408701' 'Sar408701' 'Tusamitamab ravtansine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TUSAMITAMAB%20RAVTANSINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000105388,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL866,"COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2_|_HPNSFSBZBAHARI-RUDMXATFSA-N_|_Small molecule_|_True_|_MYCOPHENOLIC ACID_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Mycophenolic acid' 'Myfortic']_|_['68618' 'Mycophenolate'
 'Mycophenolate mofetil impurity, mycophenolic acid-' 'Mycophenolic acid'
 'NSC-129185' 'RS-61443 [AS MOFETIL]']_|_[('PubChem', array(['11112696', '11112697', '11114111', '124882524', '124882525',
       '124882528', '124882529', '124882530', '144204161', '170465182',
       '26747168', '26752207', '26752208', '420202', '47193743',
       '50104875', '85148364'], dtype=object)), ('Wikipedia', array(['Mycophenolic_acid'], dtype=object)), ('drugbank', array(['DB01024'], dtype=object)), ('chEBI', array(['168396'], dtype=object))]_|_['CHEMBL2106643']_|_{'rows': array(['EFO_0004255', 'EFO_0005761', 'EFO_0005140', 'HP_0001871',
       'MONDO_0007915', 'EFO_0000717', 'EFO_0000384', 'EFO_1002048',
       'EFO_0003884', 'MONDO_0005147', 'EFO_0000540', 'EFO_0004599',
       'EFO_1000906', 'EFO_0000699', 'EFO_0003086', 'EFO_1000986',
       'MONDO_0005301', 'EFO_0000222', 'EFO_0003884', 'EFO_0004599',
       'MONDO_0013730', 'EFO_0005761'], dtype=object), 'count': 22}_|_[ENSG00000106348,ENSG00000178035]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1108,"O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1_|_RMEDXOLNCUSCGS-UHFFFAOYSA-N_|_Small molecule_|_True_|_DROPERIDOL_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['Dridol' 'Droleptan' 'Droperidol' 'Inapsine']_|_['Droperidol' 'MCN-JR-4749' 'NSC-169874' 'R-4749']_|_[('DailyMed', array(['droperidol'], dtype=object)), ('PubChem', array(['11112409', '124882342', '144204012', '170464722', '26719691',
       '26748461', '56463295', '855921'], dtype=object)), ('Wikipedia', array(['Droperidol'], dtype=object)), ('drugbank', array(['DB00450'], dtype=object)), ('chEBI', array(['4717'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0002017', 'EFO_0005407', 'EFO_0004888'],
      dtype=object), 'count': 4}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1164729,"Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O_|_BQSJTQLCZDPROO-UHFFFAOYSA-N_|_Small molecule_|_True_|_FEBUXOSTAT_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Adenuric' 'Febuxostat mylan' 'Uloric']_|_['Febuxostat' 'NSC-758874' 'TMX-67']_|_[('DailyMed', array(['febuxostat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan'],
      dtype=object)), ('PubChem', array(['124893781', '144206555', '170465220'], dtype=object)), ('Wikipedia', array(['Febuxostat'], dtype=object)), ('drugbank', array(['DB04854'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004253', 'EFO_0000537', 'EFO_1001479', 'EFO_0000319',
       'EFO_0004274', 'EFO_0003095', 'EFO_0003086', 'EFO_0003913',
       'EFO_0009104'], dtype=object), 'count': 9}_|_[ENSG00000158125]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for gout and hyperuricemia and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200377,"CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O_|_DYOBNLAYPQSBLB-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMPHETAMINE ASPARTATE_|_1996.0_|_4.0_|_CHEMBL405_|_False_|_True_|_[]_|_['Amfetamine aspartate' 'Amphetamine aspartate']_|_[('DailyMed', array(['amphetamine%20aspartate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 1 investigational indication."
CHEMBL1201653,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP PURIFIED PORK_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Lente' 'Lente iletin ii (pork)']_|_['Insulin zinc susp purified pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1589,"CC(=O)c1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1_|_VGZSUPCWNCWDAN-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACETOHEXAMIDE_|_1964.0_|_4.0_|_nan_|_False_|_True_|_['Acetohexamide' 'Dimelor' 'Dymelor']_|_['33006' 'Acetohexamide' 'NSC-759128']_|_[('PubChem', array(['11110689', '11112460', '144203618', '144209220', '144213052',
       '170465411', '17390067', '50105548', '56463352'], dtype=object)), ('Wikipedia', array(['Acetohexamide'], dtype=object)), ('drugbank', array(['DB00414'], dtype=object)), ('chEBI', array(['28052'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005129', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for diabetes mellitus and has 1 investigational indication."
CHEMBL1723,"COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC.Cl_|_YTNKWDJILNVLGX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALFUZOSIN HYDROCHLORIDE_|_2003.0_|_4.0_|_CHEMBL709_|_False_|_True_|_['Alfutral sr' 'Alfuzosin hydrochloride' 'Benestan' 'Benestan ret'
 'Besavar xl' 'Fuzatal xl' 'Kelanu xl' 'Urion s' 'Uroxatral' 'Vasran xl'
 'Xatral' 'Xatral sr' 'Zufal xl']_|_['Alfuzosin hcl' 'Alfuzosin hydrochloride' 'SL 77 499-10' 'SL-77-499-10'
 'SL-77499-10']_|_[('DailyMed', array(['alfuzosin%20hydrochloride'], dtype=object)), ('PubChem', array(['144204252', '170465022'], dtype=object)), ('chEBI', array(['32286'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000284', 'EFO_1001228', 'EFO_0004253'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 2 investigational indications."
CHEMBL1742423,"CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21_|_ACCMWZWAEFYUGZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BILASTINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ilaxten']_|_['Bilastine']_|_[('PubChem', array(['170466329'], dtype=object)), ('drugbank', array(['DB11591'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005751', 'MONDO_0005271', 'EFO_1001417', 'EFO_0003956',
       'EFO_0007141', 'EFO_1001881', 'EFO_0005531'], dtype=object), 'count': 7}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for eye allergy and allergic disease and has 5 investigational indications."
CHEMBL1743063,"nan_|_nan_|_Antibody_|_False_|_RILOTUMUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 102' 'AMG-102' 'Rilotumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'MONDO_0100342', 'EFO_0000681', 'EFO_0000708',
       'EFO_0000588', 'MONDO_0001056', 'MONDO_0008315', 'EFO_1001465'],
      dtype=object), 'count': 8}_|_[ENSG00000019991]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL1822792,"CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1_|_JGEBLDKNWBUGRZ-HXUWFJFHSA-N_|_Small molecule_|_False_|_MK-2461_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-2461' 'Mk-2461']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1852688,"CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1_|_QADPYRIHXKWUSV-UHFFFAOYSA-N_|_Small molecule_|_False_|_INFIGRATINIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BGJ-398' 'BGJ398' 'Bgj-398' 'Infigratinib' 'MVP-BGJ398' 'NVP-BGJ398']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/INFIGRATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11886'], dtype=object)), ('chEBI', array(['63451'], dtype=object))]_|_['CHEMBL1834657']_|_{'rows': array(['EFO_0001668', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0044704',
       'MONDO_0004992', 'MONDO_0007037', 'EFO_0005221', 'EFO_1002027',
       'EFO_0000519', 'EFO_0005221', 'EFO_0000616', 'EFO_1001961',
       'MONDO_0001187', 'MONDO_0011719', 'EFO_0000756', 'EFO_0001061'],
      dtype=object), 'count': 16}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 12 investigational indications."
CHEMBL2028019,"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1_|_KPWSJANDNDDRMB-QAQDUYKDSA-N_|_Small molecule_|_True_|_CARIPRAZINE_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Reagila']_|_['Cariprazine' 'Fri-7000188' 'GED-129' 'MP-214' 'RGH-188']_|_[('drugbank', array(['DB06016'], dtype=object))]_|_['CHEMBL2024517']_|_{'rows': array(['MONDO_0004985', 'EFO_0009963', 'MONDO_0004985', 'EFO_1001892',
       'EFO_0003756', 'MONDO_0002009', 'EFO_0009963', 'EFO_0005407',
       'MONDO_0005090', 'MONDO_0005090', 'MONDO_0002050'], dtype=object), 'count': 11}_|_[ENSG00000151577,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2043437,"CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1_|_SFNSLLSYNZWZQG-VQIMIIECSA-N_|_Small molecule_|_True_|_GLASDEGIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Glasdegib' 'PF-04449913' 'PF-4449913']_|_[('drugbank', array(['DB11978'], dtype=object))]_|_['CHEMBL4297534' 'CHEMBL2043440']_|_{'rows': array(['EFO_0000519', 'MONDO_0020547', 'MONDO_0004992', 'EFO_0000198',
       'EFO_0000222', 'EFO_1001968', 'EFO_0000616', 'EFO_0000222'],
      dtype=object), 'count': 8}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2110670,"c1cc2c3c(c1)[C@H]1CCC[C@H]1CN3CCNC2_|_NPTIPEQJIDTVKR-STQMWFEESA-N_|_Small molecule_|_False_|_VABICASERIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Vabicaserin']_|_[('drugbank', array(['DB12071'], dtype=object))]_|_['CHEMBL2104991' 'CHEMBL3126691']_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000135914,ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL232202,"OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O_|_BJRNKVDFDLYUGJ-RMPHRYRLSA-N_|_Small molecule_|_False_|_ARBUTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Arbutin' 'Arbutinum' 'Arbutoside' 'NSC-4036' 'Ursin']_|_[('PubChem', array(['144205062', '144212745', '170465722', '93576640'], dtype=object)), ('Wikipedia', array(['Arbutin'], dtype=object)), ('drugbank', array(['DB11217'], dtype=object)), ('chEBI', array(['18305'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003963'], dtype=object), 'count': 1}_|_[ENSG00000077498]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545029,"CN1CC2CCN(c3ccc(-c4ccc(-n5ncccc5=O)cc4)cc3)C2C1_|_GNIRITULTPTAQW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABT-288_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abt-288']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3678076,"CCCCOc1cccc(CCNCC(=O)N(C)C)c1_|_GRHBODILPPXVKN-UHFFFAOYSA-N_|_Small molecule_|_False_|_EVENAMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Evenamide' 'Nw-3509']_|_nan_|_['CHEMBL4286909']_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707320,"CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl_|_GYABBVHSRIHYJR-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALECTINIB HYDROCHLORIDE_|_2015.0_|_4.0_|_CHEMBL1738797_|_False_|_True_|_['Alecensa']_|_[]_|_[('DailyMed', array(['alectinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000171094,ENSG00000165731,ENSG00000143924]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for non-small cell lung carcinoma."
CHEMBL3833372,"nan_|_nan_|_Antibody_|_False_|_BRAZIKUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG-139' 'Brazikumab' 'MEDI-2070' 'MEDI2070']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}_|_[ENSG00000113302,ENSG00000110944]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3907479,"Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1_|_BEMNJULZEQTDJY-UHFFFAOYSA-N_|_Small molecule_|_False_|_FGFR INHIBITOR DEBIO 1347_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fgfr inhibitor debio 1347']_|_[('drugbank', array(['DB12903'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000068078,ENSG00000066468,ENSG00000077782]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3989562,"COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC.Cl.O.O_|_NZMOFYDMGFQZLS-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERAZOSIN HYDROCHLORIDE_|_1987.0_|_4.0_|_CHEMBL611_|_False_|_True_|_['Benph' 'Hytrin' 'Hytrin bph' 'Terazosin hydrochloride']_|_['ABBOTT-45975' 'ABBOTT-45975 ANHYDROUS' 'Heitrin' 'Hytracin' 'Itrin'
 'NSC-759168' 'Terazosin (as hydrochloride)' 'Terazosin hcl'
 'Terazosin hcl 2h20' 'Terazosin hydrochloride'
 'Terazosin hydrochloride anhydrous' 'Terazosin hydrochloride dihydrate'
 'Terazosin hydrochloride hydrate' 'Urodie']_|_[('DailyMed', array(['terazosin%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000726', 'EFO_0000284'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for benign prostatic hyperplasia and has 1 investigational indication."
CHEMBL4228124,"COc1ccc2c(c1)CC[C@H](CN(C)CC(=O)O)[C@@H]2c1ccccc1_|_UEBBYLJZCHTLEG-UTKZUKDTSA-N_|_Small molecule_|_False_|_ORG-25935_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ORG 25935' 'Org 25935' 'Org-25935' 'Org-25935 free base' 'SCH 900435'
 'SCH-900435' 'Sch 900435']_|_[('drugbank', array(['DB12220'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004262', 'MONDO_0005090', 'MONDO_0007079'], dtype=object), 'count': 3}_|_[ENSG00000196517]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297909,"nan_|_nan_|_Antibody_|_False_|_FAZPILODEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BFKB-8488A' 'BFKB8488A' 'Bfkb-8488a' 'Bfkb8488a' 'Fazpilodemab'
 'RG-7992' 'RG7992' 'RO-7040551' 'RO7040551']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FAZPILODEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003095', 'EFO_0002614', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000113578,ENSG00000134962]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297945,"nan_|_nan_|_Unknown_|_False_|_EFMOROCTOCOG ALFA_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Elocta']_|_['Efmoroctocog alfa' 'Efraloctocog alfa' 'Elocta' 'Eloctate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/elocta'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602', 'MONDO_0018660'], dtype=object), 'count': 2}_|_[ENSG00000185010]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hemophilia a and hemophilia."
CHEMBL4303201,"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1_|_KSMZEXLVHXZPEF-UHFFFAOYSA-N_|_Small molecule_|_False_|_CATEQUENTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AL 3818' 'AL-3818' 'AL3818' 'Al-3818' 'Anlotinib' 'Catequentinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CATEQUENTINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL5314570']_|_{'rows': array(['MONDO_0021117', 'EFO_0003108', 'EFO_0002618', 'EFO_0003860',
       'MONDO_0004992', 'EFO_0004252', 'EFO_0000564', 'EFO_0000756',
       'MONDO_0011962', 'EFO_0000333', 'MONDO_0005575', 'EFO_0001378',
       'EFO_1001512', 'EFO_0003869', 'EFO_1001951', 'EFO_0000174',
       'EFO_1000657', 'EFO_0000616', 'EFO_0005221', 'EFO_0000616',
       'MONDO_0002367', 'EFO_0000182', 'MONDO_0007254', 'MONDO_0024503',
       'MONDO_0008170', 'MONDO_0020547', 'EFO_0007143', 'EFO_0003818',
       'EFO_0000707', 'MONDO_0015277', 'EFO_0003060', 'EFO_0000403',
       'EFO_1001968', 'EFO_0000691', 'EFO_0003820', 'MONDO_0008903',
       'EFO_1000359', 'EFO_0000313', 'EFO_1001972', 'MONDO_0002108',
       'MONDO_0003060', 'EFO_0000574', 'MONDO_0011719', 'EFO_0001376',
       'MONDO_0002912', 'EFO_0002916', 'HP_0001410', 'MONDO_0100342',
       'EFO_0005537', 'MONDO_0007576', 'EFO_0000681', 'EFO_0001071',
       'EFO_0000702', 'MONDO_0002974', 'MONDO_0001056', 'EFO_0000621',
       'EFO_0005922', 'EFO_0000588', 'EFO_0000519', 'EFO_0000181'],
      dtype=object), 'count': 60}_|_[ENSG00000157404,ENSG00000113721,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 60 investigational indications."
CHEMBL52333,"CCCn1c(=O)c2nc(C34CC5CC(CC3C5)C4)[nH]c2n(CCC)c1=O_|_PJBFVWGQFLYWCB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROLOFYLLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['KW 3902' 'KW-3902' 'KW3902' 'MK-7418' 'Rolofylline']_|_[('PubChem', array(['137275983'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000373', 'EFO_0003144'], dtype=object), 'count': 2}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL592054,"Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1_|_ULVDFHLHKNJICZ-QCWLDUFUSA-N_|_Small molecule_|_False_|_IMIGLITAZAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Imiglitazar' 'TAK-559' 'Tak-559']_|_[('drugbank', array(['DB12511'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000186951,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL92,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C_|_ZDZOTLJHXYCWBA-VCVYQWHSSA-N_|_Small molecule_|_True_|_DOCETAXEL ANHYDROUS_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bind 014' 'CKD-810' 'Cabazitaxel metabolite (rp56976)'
 'Docetaxel accord' 'Docetaxel kabi' 'Docetaxel mylan' 'Docetaxel teva'
 'Docetaxel teva pharma' 'Docetaxel winthrop' 'Docetaxel, anhydrous'
 'NSC-628503' 'RP-56976' 'Rp56976' 'Taxotere']_|_[('PubChem', array(['124950708', '144206334', '144206639', '170464919', '494081'],
      dtype=object)), ('Wikipedia', array(['Docetaxel'], dtype=object)), ('drugbank', array(['DB01248'], dtype=object)), ('chEBI', array(['4672'], dtype=object))]_|_['CHEMBL3545252']_|_{'rows': array(['MONDO_0011719', 'HP_0002039', 'EFO_0000313', 'MONDO_0008315',
       'MONDO_0001187', 'EFO_0004281', 'MONDO_0021117', 'EFO_0007355',
       'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'EFO_0000181',
       'MONDO_0004986', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000673',
       'MONDO_0001528', 'EFO_0000432', 'HP_0004326', 'EFO_0001416',
       'MONDO_0003060', 'EFO_0009708', 'EFO_0006859', 'EFO_0004230',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0005271',
       'MONDO_0000521', 'MONDO_0002038', 'EFO_0003869', 'MONDO_0021310',
       'EFO_1000043', 'MONDO_0005575', 'EFO_0003891', 'MONDO_0004192',
       'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'Orphanet_145',
       'EFO_0001376', 'EFO_1000984', 'EFO_0005537', 'EFO_0003817',
       'EFO_0000616', 'MONDO_0001325', 'MONDO_0002120', 'EFO_0000174',
       'EFO_0000565', 'EFO_0000574', 'EFO_0000178', 'EFO_0003860',
       'EFO_0007362', 'EFO_0005570', 'EFO_0002916', 'EFO_0005088',
       'MONDO_0021063', 'EFO_0000503', 'EFO_0000571', 'EFO_0002938',
       'EFO_0006352', 'EFO_0000707', 'MONDO_0002158', 'EFO_0003897',
       'EFO_0000466', 'EFO_0003060', 'EFO_0002428', 'EFO_0000756',
       'EFO_0000198', 'EFO_0000199', 'MONDO_0004992', 'MONDO_0002974',
       'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0003865',
       'EFO_0000702', 'MONDO_0002367', 'EFO_0001663', 'EFO_0000637',
       'EFO_0002618', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0018364',
       'EFO_0008528', 'EFO_0000305', 'EFO_0003893', 'EFO_0006911',
       'EFO_0004284', 'HP_0012378', 'MONDO_0007254', 'MONDO_0001056',
       'EFO_0000228', 'MONDO_0011962', 'EFO_0000691', 'EFO_0000196',
       'MONDO_0007576', 'EFO_0000564', 'EFO_0005950', 'MONDO_0001475',
       'EFO_1000601', 'MONDO_0021355', 'MONDO_0004669', 'EFO_0000182',
       'EFO_0000708', 'EFO_0001075', 'EFO_0005577', 'EFO_1001931',
       'EFO_1001100', 'MONDO_0003199', 'EFO_1001214', 'EFO_0004252',
       'EFO_1000595', 'EFO_0003859', 'EFO_0001378', 'MONDO_0001402'],
      dtype=object), 'count': 116}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 20 approved and 96 investigational indications. This drug has a black box warning from the FDA."
CHEMBL103667,"Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1_|_MVCOAUNKQVWQHZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DORAMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIRB 796 BS' 'BIRB-796' 'BIRB-796 BS' 'Birb-796' 'Doramapimod']_|_[('PubChem', array(['103904828', '124950164', '144206937', '170466618', '50100090'],
      dtype=object)), ('drugbank', array(['DB03044'], dtype=object)), ('chEBI', array(['40953'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0000676'], dtype=object), 'count': 2}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1201011,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O.Cl_|_IBBLRJGOOANPTQ-JKVLGAQCSA-N_|_Small molecule_|_True_|_QUINAPRIL HYDROCHLORIDE_|_1991.0_|_4.0_|_CHEMBL1592_|_False_|_True_|_['Accupril' 'Accupro' 'Quinapril hydrochloride' 'Quinil']_|_['CI 906' 'CI-906' 'NSC-758222' 'Quinapril hcl' 'Quinapril hydrochloride']_|_[('DailyMed', array(['quinapril%20hydrochloride'], dtype=object)), ('PubChem', array(['144204934', '144207588', '170465312', '49648461'], dtype=object)), ('chEBI', array(['8714'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_1002048', 'EFO_0000712', 'EFO_0003144',
       'EFO_0000400'], dtype=object), 'count': 5}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved indications. This drug has a black box warning from the FDA."
CHEMBL1201130,"C[N+](C)(C)CC(=O)O.[Cl-]_|_HOPSCVCBEOCPJZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETAINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL95889_|_False_|_True_|_['Acidol pepsin' 'Cystadane']_|_['Betaine HCl' 'Betaine hcl' 'Betaine hydrochloride' 'Betainum muriaticum'
 'Lycine hydrochloride' 'NSC-32191' 'NSC-3976']_|_[('PubChem', array(['144204926', '144212459', '170464844', '26748661', '50105912',
       '56462965'], dtype=object))]_|_nan_|_nan_|_[ENSG00000145692,ENSG00000132840]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL1201643,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP PROMPT PURIFIED PORK_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Semilente']_|_['Insulin zinc susp prompt purified pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1237082,"CNC1(C)C2CCC(C2)C1(C)C.Cl_|_PKVZBNCYEICAQP-UHFFFAOYSA-N_|_Small molecule_|_False_|_MECAMYLAMINE HYDROCHLORIDE_|_1956.0_|_4.0_|_CHEMBL267936_|_False_|_True_|_['Inversine' 'Mecamylamine hydrochloride']_|_['Mecamylamine chloride' 'Mecamylamine hcl' 'Mecamylamine hydrochloride'
 'NSC-757086']_|_[('DailyMed', array(['mecamylamine%20hydrochloride'], dtype=object)), ('PubChem', array(['50106687', '50106688', '50106689'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and has 1 investigational indication."
CHEMBL1951914,"CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1_|_QOSMEMHKXNNIGG-SSEXGKCCSA-N_|_Small molecule_|_False_|_AZD5672_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-5672' 'AZD5672' 'Azd 5672' 'Azd-5672' 'Azd5672']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0003086'], dtype=object), 'count': 2}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108678,"nan_|_nan_|_Antibody_|_False_|_NESVACUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Regn910']_|_['Nesvacumab' 'REGN-910' 'REGN910']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0001365'], dtype=object), 'count': 2}_|_[ENSG00000091879]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108709,"nan_|_nan_|_Enzyme_|_False_|_COLLAGENASE CLOSTRIDIUM HISTOLYTICUM_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Santyl' 'Xiaflex' 'Xiapex']_|_['AA-4500' 'AA4500' 'Clostridial collagenase'
 'Clostridium histolyticum enzymes' 'Collagenase'
 'Collagenase (clostridium histolyticum)'
 'Collagenase clostridium histolyticum' 'Cordase' 'Iruxol' 'MZ-004'
 'Plaquase']_|_[('DailyMed', array(['collagenase%20clostridium%20histolyticum'], dtype=object)), ('DrugCentral', array(['5051'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xiapex'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0012227', 'HP_0200042', 'EFO_1000941', 'EFO_1001459',
       'EFO_0004229', 'EFO_1000466', 'EFO_0000759', 'EFO_1000438',
       'MONDO_0043839', 'EFO_1001434', 'EFO_0007067', 'HP_0003549',
       'EFO_0003899'], dtype=object), 'count': 13}_|_[ENSG00000164692,ENSG00000108821,ENSG00000139219,ENSG00000168542,ENSG00000187498,ENSG00000130635,ENSG00000142156,ENSG00000060718,ENSG00000204291,ENSG00000182871,ENSG00000171502,ENSG00000196739,ENSG00000215018,ENSG00000134871,ENSG00000204262,ENSG00000142173,ENSG00000204248,ENSG00000169031,ENSG00000080573,ENSG00000163359,ENSG00000081052,ENSG00000188153,ENSG00000172752,ENSG00000197565,ENSG00000206384]_|_Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 7 investigational indications."
CHEMBL3334624,"Cc1cc(C[C@@H](OC(=O)N2CCC(N3CCc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCOCC3)CC2)cc(C)c1O_|_HTLWMOKBJQKDIJ-WJOKGBTCSA-N_|_Small molecule_|_False_|_BI-44370_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI 44370 TA' 'BI-44370-BS' 'BI44370' 'Bi 44370 ta' 'Bi-44370'
 'J3.353.239C']_|_nan_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545403,"CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1_|_KLRRGBHZCJLIEL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-833923_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-833923' 'BMS-833923 DIMESYLATE MONOHYDRATE' 'Bms-833923' 'XL-139'
 'XL139']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_0002916', 'EFO_0003897', 'MONDO_0007187',
       'EFO_0000565', 'EFO_0004193', 'MONDO_0004992'], dtype=object), 'count': 7}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL377559,"C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2.Cl_|_OIRUWDYJGMHDHJ-AFXVCOSJSA-N_|_Small molecule_|_False_|_RETASPIMYCIN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL1184904_|_False_|_False_|_[]_|_['IPI-504' 'IPI-504 HYDROCHLORIDE' 'Retaspimycin hcl'
 'Retaspimycin hydrochloride']_|_[('chEBI', array(['71956'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0002617', 'MONDO_0008903', 'EFO_0000305',
       'EFO_0001378', 'MONDO_0011719', 'MONDO_0004992', 'MONDO_0007254',
       'EFO_0003085', 'EFO_0000673'], dtype=object), 'count': 10}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL3989686,"CN1CCCC[C@H]1CCc1ccccc1NC(=O)/C=C/c1ccccc1_|_UXIPFQUBOVWAQW-UEBLJOKOSA-N_|_Small molecule_|_False_|_IFERANSERIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Iferanserin' 'Ven-309']_|_[('drugbank', array(['DB11686'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009552'], dtype=object), 'count': 1}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297588,"CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(=O)O)c3ccc(O)cc3)cc2S(=O)(=O)N1_|_XULSCZPZVQIMFM-IPZQJPLYSA-N_|_Small molecule_|_False_|_ODEVIXIBAT_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['A-4250' 'A4250' 'AR-H064974' 'AZD-8294' 'AZD8294' 'Odevixibat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ODEVIXIBAT/relevant/1/'],
      dtype=object))]_|_['CHEMBL5315120']_|_{'rows': array(['MONDO_0007318', 'EFO_0004267', 'HP_0000989', 'MONDO_0017290',
       'MONDO_0001751', 'MONDO_0008867', 'EFO_1001249', 'MONDO_0019072'],
      dtype=object), 'count': 8}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pruritus and familial intrahepatic cholestasis and has 6 investigational indications."
CHEMBL4297828,"nan_|_nan_|_Unknown_|_False_|_SHR-1316_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Adebrelimab' 'HTI-1088' 'SHR-1316' 'Shr-1316']_|_nan_|_nan_|_{'rows': array(['EFO_0000707', 'EFO_0003893', 'MONDO_0007254', 'EFO_0003060',
       'MONDO_0004992', 'EFO_0000616', 'EFO_0000702', 'EFO_0000182'],
      dtype=object), 'count': 8}_|_[ENSG00000120217]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL4298077,"nan_|_nan_|_Antibody_|_False_|_PRASINEZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PRX002' 'Prasinezumab' 'Prx-002' 'Prx002' 'RG-7935' 'RG7935'
 'RO-7046015' 'RO7046015' 'Ro7046015']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PRASINEZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000145335]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL430497,"Clc1ccc(OC[C@H]2CCN2)cn1_|_MKTAGSRKQIGEBH-SSDOTTSWSA-N_|_Small molecule_|_False_|_TEBANICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tebanicline']_|_nan_|_['CHEMBL2104964' 'CHEMBL5303486']_|_nan_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4594550,"nan_|_nan_|_Antibody_|_False_|_SERPLULIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['HLX-10' 'HLX10' 'Hlx10' 'Serplulimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'HP_0001541', 'MONDO_0007254', 'MONDO_0002974',
       'EFO_0000503', 'MONDO_0021063', 'EFO_0003060', 'MONDO_0001056',
       'EFO_1001951', 'EFO_0000571', 'EFO_0000681', 'EFO_0000182',
       'MONDO_0002120', 'EFO_0005922', 'EFO_0004252', 'EFO_0000181',
       'EFO_0000702'], dtype=object), 'count': 17}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL493982,"CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1_|_ZBGXUVOIWDMMJE-QHNZEKIYSA-N_|_Small molecule_|_True_|_VORAPAXAR_|_2014.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['SCH-530348' 'Vorapaxar']_|_[('Wikipedia', array(['Vorapaxar'], dtype=object)), ('drugbank', array(['DB09030'], dtype=object)), ('chEBI', array(['82702'], dtype=object))]_|_['CHEMBL3542336' 'CHEMBL2107386']_|_{'rows': array(['EFO_0000712', 'HP_0004419', 'EFO_0000764', 'EFO_0005672',
       'EFO_0000612', 'EFO_0004265', 'MONDO_0002679'], dtype=object), 'count': 7}_|_[ENSG00000181104]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL516,"CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1_|_JJCFRYNCJDLXIK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYPROHEPTADINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ciprovit' 'Cyproheptadine']_|_[('PubChem', array(['104171133', '11110964', '11110965', '11113362', '124879679',
       '144203663', '170465127', '174007288', '26751603', '50100203',
       '50104260', '90341656'], dtype=object)), ('Wikipedia', array(['Cyproheptadine'], dtype=object)), ('drugbank', array(['DB00434'], dtype=object)), ('chEBI', array(['4046'], dtype=object))]_|_['CHEMBL1716']_|_{'rows': array(['MONDO_0004992', 'MONDO_0100096', 'HP_0002027', 'MONDO_0005271',
       'EFO_0005531', 'EFO_0007141', 'EFO_0000712', 'EFO_0003956',
       'HP_0001653', 'MONDO_0007079'], dtype=object), 'count': 10}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 6 investigational indications."
CHEMBL5314384,"C#CCOc1ccc(Nc2nc(Nc3ccc(C)c(S(=O)(=O)NC(=O)CC)c3)ncc2F)cc1_|_IGLNXKVGKIFNBQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-348_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['R-348']_|_nan_|_nan_|_{'rows': array(['MONDO_0020547', 'EFO_1000906'], dtype=object), 'count': 2}_|_[ENSG00000105639,ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL575448,"C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1_|_LQVXSNNAFNGRAH-QHCPKHFHSA-N_|_Small molecule_|_False_|_BMS-754807_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-754807' 'BMS754807' 'Bms 754807' 'Bms-754807']_|_[('PubChem', array(['164339435'], dtype=object)), ('drugbank', array(['DB15399'], dtype=object)), ('chEBI', array(['88339'], dtype=object))]_|_['CHEMBL2401777']_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000140443,ENSG00000171105]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL596802,"CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1_|_YGKUEOZJFIXDGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRIDOPIDINE_|_nan_|_3.0_|_nan_|_False_|_False_|_['Huntexil']_|_['ACR-16' 'ACR16' 'FR-310826' 'FR310826' 'Pridopidine']_|_[('drugbank', array(['DB11947'], dtype=object))]_|_['CHEMBL2105691']_|_{'rows': array(['MONDO_0007739', 'MONDO_0005180', 'MONDO_0004976'], dtype=object), 'count': 3}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL621,"O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12_|_PHLBKPHSAVXXEF-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRAZODONE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Desyrel' 'J10.767K' 'Trazodone' 'Trialodine' 'Trittico']_|_[('PubChem', array(['11111900', '11111901', '174007449', '90341328'], dtype=object)), ('Wikipedia', array(['Trazodone'], dtype=object)), ('drugbank', array(['DB00656'], dtype=object)), ('chEBI', array(['9654'], dtype=object))]_|_['CHEMBL1200798']_|_{'rows': array(['EFO_0007453', 'MONDO_0002009', 'EFO_0005230', 'MONDO_0002009',
       'EFO_0003918', 'MONDO_0005090', 'EFO_1000783', 'EFO_0008568',
       'MONDO_0004976', 'MONDO_0002050', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0007079', 'MONDO_0002050', 'MONDO_0004975', 'MONDO_0002009',
       'EFO_0004698'], dtype=object), 'count': 17}_|_[ENSG00000102468,ENSG00000147246,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for major depressive disorder and depressive disorder and has 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL923,"O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O_|_IIDJRNMFWXDHID-UHFFFAOYSA-N_|_Small molecule_|_False_|_RISEDRONIC ACID_|_1998.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Actonel' 'M05BA07' 'NE-58095' 'Ridron' 'Risedronate' 'Risedronic acid']_|_[('PubChem', array(['29216086'], dtype=object)), ('Wikipedia', array(['Risedronic_acid'], dtype=object)), ('drugbank', array(['DB00884'], dtype=object)), ('chEBI', array(['8869'], dtype=object))]_|_['CHEMBL4303174' 'CHEMBL3560765' 'CHEMBL1654']_|_{'rows': array(['MONDO_0005351', 'EFO_0003854', 'EFO_0000574', 'HP_0000938',
       'GO_0042697', 'EFO_1001919', 'EFO_0004260', 'EFO_0000196',
       'HP_0003418', 'MONDO_0021165', 'MONDO_0019019', 'MONDO_0000845',
       'EFO_0004261', 'EFO_0000565', 'EFO_0003854', 'EFO_0003882',
       'EFO_1001152', 'MONDO_0008315', 'EFO_0003882', 'MONDO_0021117'],
      dtype=object), 'count': 20}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 16 investigational indications."
CHEMBL1200413,"Cl.c1ccc2c(c1)CCCC2C1=NCCN1_|_BJORNXNYWNIWEY-UHFFFAOYSA-N_|_Small molecule_|_False_|_TETRAHYDROZOLINE HYDROCHLORIDE_|_1979.0_|_4.0_|_CHEMBL1266_|_False_|_True_|_['Tyzine']_|_['NSC-757339' 'Tetrahydrozoline hydrochloride' 'Tetrahydrozoline nitrate'
 'Tetryzoline' 'Tetryzoline hydrochloride']_|_[('PubChem', array(['170464943', '26747671', '50107052', '56424102', '855698'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000678', 'MP_0001845'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 2 investigational indications."
CHEMBL1200760,"O=C([O-])CCNC(=O)c1ccc(/N=N/c2ccc(O)c(C(=O)[O-])c2)cc1.[Na+].[Na+]_|_CKMOQBVBEGCJGW-LLIZZRELSA-L_|_Small molecule_|_False_|_BALSALAZIDE DISODIUM_|_2000.0_|_4.0_|_CHEMBL1201346_|_False_|_True_|_['Balsalazide disodium' 'Colazal' 'Colazide' 'Giazo']_|_['BX-661A' 'BX661A' 'Balsalazide disodium'
 'Balsalazide disodium anhydrous' 'Balsalazide disodium dihydrate'
 'Balsalazide disodium salt dihydrate' 'Balsalazide sodium' 'Balsalazine'
 'NSC-760046']_|_[('DailyMed', array(['balsalazide%20disodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000132170,ENSG00000073756,ENSG00000095303,ENSG00000012779]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for ulcerative colitis."
CHEMBL1471,"C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_ATALOFNDEOCMKK-OITMNORJSA-N_|_Small molecule_|_False_|_APREPITANT_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Aprepitant' 'Cinvanti' 'Emend']_|_['Aprepitant' 'L-754,030' 'MK-0869' 'MK-869' 'NSC-748825']_|_[('DailyMed', array(['aprepitant'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emend'],
      dtype=object)), ('Wikipedia', array(['Aprepitant'], dtype=object)), ('drugbank', array(['DB00673'], dtype=object)), ('chEBI', array(['499361'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006911', 'EFO_0005611', 'EFO_0002610', 'HP_0002017',
       'EFO_0000514', 'MONDO_0100096', 'HP_0000989', 'EFO_0000519',
       'HP_0002018', 'EFO_0004240', 'EFO_0003060', 'EFO_0007191',
       'EFO_0000182', 'EFO_0000764', 'EFO_0000222', 'EFO_1000948',
       'EFO_0001378', 'MONDO_0004992', 'HP_0002013', 'EFO_0003843',
       'MONDO_0007079', 'MONDO_0002009', 'EFO_0004888'], dtype=object), 'count': 23}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 17 investigational indications."
CHEMBL1823872,"C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O_|_NHXLMOGPVYXJNR-ATOGVRKGSA-N_|_Protein_|_False_|_SOMATOSTATIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SRIF-14' 'Somatostatin' 'Somatostatin-14']_|_[('drugbank', array(['DB09099'], dtype=object)), ('chEBI', array(['64628'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0004606', 'HP_0001399', 'EFO_0000666',
       'HP_0004398', 'EFO_1001496', 'EFO_1000045', 'EFO_1000652',
       'EFO_0004243', 'EFO_0000182', 'HP_0001943', 'EFO_0000673'],
      dtype=object), 'count': 12}_|_[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL2062335,"COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)C(O)C(O)C(=O)O_|_YGULWPYYGQCFMP-UHFFFAOYSA-N_|_Small molecule_|_True_|_METOPROLOL TARTRATE_|_1978.0_|_4.0_|_CHEMBL13_|_False_|_True_|_['Arbralene' 'Beloc cor' 'Betaloc' 'Betaloc s.a.' 'Lopresor' 'Lopresor sr'
 'Lopressor' 'Mepranix 100' 'Mepranix 50' 'Metoprolol tartrate' 'Tensomex'
 'Toprol xl']_|_['Beloc' 'CGP-2175E' 'Metoprolol hemitartrate' 'Metoprolol tartrate'
 'Metropress' 'NSC-757105' 'Prelis' 'Seloken' 'Selopral']_|_[('DailyMed', array(['metoprolol%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0003144', 'EFO_0000275', 'EFO_0003777',
       'EFO_0003913', 'EFO_0000612', 'EFO_0000712'], dtype=object), 'count': 7}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2105695,"CCOC(=O)[C@@H](N)Cc1ccc(-c2cc(O[C@H](c3ccc(Cl)cc3-n3ccc(C)n3)C(F)(F)F)nc(N)n2)cc1_|_MDSQOJYHHZBZKA-GBXCKJPGSA-N_|_Small molecule_|_False_|_TELOTRISTAT ETHYL_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Xermelo']_|_['LX 1032' 'LX 1606' 'LX-1032' 'LX-1606' 'LX1032' 'LX1606'
 'Telotristat ethyl']_|_[('drugbank', array(['DB12095'], dtype=object))]_|_['CHEMBL3348963']_|_{'rows': array(['EFO_0001421', 'EFO_1001901', 'EFO_1001901', 'EFO_1001769',
       'MONDO_0003060', 'HP_0002014', 'EFO_0004243', 'EFO_1000852'],
      dtype=object), 'count': 8}_|_[ENSG00000139287,ENSG00000129167]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 5 investigational indications."
CHEMBL2105759,"CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1_|_XUZMWHLSFXCVMG-UHFFFAOYSA-N_|_Small molecule_|_True_|_BARICITINIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Olumiant']_|_['Baricitinib' 'Baricitinib phosphate' 'Baricitinib phosphate salt'
 'INCB-028050' 'INCB028050' 'Incb-28050' 'LY-3009104' 'LY3009104']_|_[('DailyMed', array(['baricitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant'],
      dtype=object)), ('drugbank', array(['DB11817'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000699', 'EFO_1001486', 'EFO_0000783', 'EFO_0000694',
       'EFO_0004256', 'MONDO_0005147', 'EFO_1001231', 'EFO_0007160',
       'EFO_0000764', 'EFO_0000676', 'EFO_1001209', 'EFO_0000398',
       'EFO_0000401', 'MONDO_0007915', 'EFO_0000685', 'MONDO_0020547',
       'MONDO_0013730', 'EFO_0000540', 'EFO_1000726', 'EFO_0004192',
       'EFO_0003884', 'EFO_0000274', 'EFO_0004208', 'EFO_1001034',
       'EFO_1000668', 'EFO_0000557', 'EFO_0003106', 'EFO_0002609',
       'MONDO_0100096'], dtype=object), 'count': 29}_|_[ENSG00000096968,ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for rheumatoid arthritis and immune system disease and has 27 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108955,"nan_|_nan_|_Antibody_|_False_|_EDRECOLOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Panorex']_|_['17-1A' 'C-1' 'Edrecolomab' 'MAB-17-1A' 'Mab17-1a']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2181753,CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)NCc1ccccc1_|_OPXIRFWNLBDKQB-UHFFFAOYSA-N_|_Small molecule_|_False_|_AM-211_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AM211' 'Am-211']_|_nan_|_nan_|_nan_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2220442,"CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21_|_FJLGEFLZQAZZCD-VAWYXSNFSA-N_|_Small molecule_|_False_|_FLUVASTATIN_|_1993.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fluvas' 'Fluvastatin' 'NSC-758896']_|_[('chEBI', array(['38562'], dtype=object))]_|_['CHEMBL2218894']_|_{'rows': array(['HP_0003124', 'EFO_0004911', 'Orphanet_309005', 'EFO_0003047',
       'EFO_0004220', 'HP_0003124', 'EFO_0002689', 'HP_0000802',
       'EFO_0005543', 'MONDO_0008315', 'EFO_0000266', 'EFO_0000756',
       'MONDO_0007254', 'MONDO_0018965', 'EFO_0000319'], dtype=object), 'count': 15}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 12 investigational indications."
CHEMBL25263,"O=C(O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O_|_HZLAWYIBLZNRFZ-VXGBXAGGSA-N_|_Small molecule_|_False_|_MIRIDESAP_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CPHPC' 'Cphpc' 'GSK-2315698' 'GSK2315698' 'Gsk2315698' 'Miridesap'
 'RO-638695' 'Ro 63-8695']_|_[('Wikipedia', array(['CPHPC'], dtype=object)), ('drugbank', array(['DB13087'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_1001875', 'MONDO_0017816'], dtype=object), 'count': 3}_|_[ENSG00000132703]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3039517,"Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1_|_SYYBDNPGDKKJDU-ZDUSSCGKSA-N_|_Small molecule_|_False_|_RABUSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IC-83' 'LY-2603618' 'LY2603618' 'Ly-2603618' 'Rabusertib']_|_[('drugbank', array(['DB11662'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060', 'MONDO_0004992', 'EFO_0003860'],
      dtype=object), 'count': 4}_|_[ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3137313,"NC(=O)c1cccc([C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC2CCCCC2)C(=O)[C@@H](O)CO)c1_|_ATLYLVPZNWDJBW-KIHHCIJBSA-N_|_Small molecule_|_False_|_AXELOPRAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Axelopran' 'TD-1211']_|_[('drugbank', array(['DB12013'], dtype=object))]_|_['CHEMBL3137319' 'CHEMBL3895543']_|_{'rows': array(['HP_0002019'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3301625,"C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1_|_KXBDTLQSDKGAEB-UHFFFAOYSA-N_|_Small molecule_|_False_|_SPEBRUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AVL-292' 'Btk inhibitor cc-292' 'CC-292' 'Spebrutinib']_|_[('drugbank', array(['DB11764'], dtype=object))]_|_['CHEMBL3301600']_|_{'rows': array(['EFO_0000095', 'EFO_0000403', 'EFO_0009441', 'EFO_0000685',
       'EFO_0000565'], dtype=object), 'count': 5}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3545030,"nan_|_nan_|_Small molecule_|_False_|_JNJ-17216498_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Jnj-17216498']_|_nan_|_nan_|_{'rows': array(['MONDO_0021107'], dtype=object), 'count': 1}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3915620,"CC#C[C@@H](CC(=O)O)c1ccc(OCc2ccc(CN3CCC4(C=Cc5ccccc54)CC3)cc2)cc1_|_FHRWHNJJQGSCQC-LJAQVGFWSA-N_|_Small molecule_|_False_|_LY2881835_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LY-2881835' 'LY2881835' 'Ly2881835']_|_[('drugbank', array(['DB15046'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000126266]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989680,"COc1cccc(C2(O)CC(O)CCC2CN(C)C)c1_|_LQJLLAOISDVBJM-UHFFFAOYSA-N_|_Small molecule_|_False_|_AXOMADOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Axomadol' 'BN-110 FREE BASE' 'BN110 BASE' 'BN110 FREE BASE' 'En3324'
 'GRT-151 FREE BASE' 'GRT0151Y' 'GRT151 Base' 'GRT151 FREE BASE']_|_nan_|_['CHEMBL3976339']_|_{'rows': array(['HP_0003419', 'HP_0012532', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000112038,ENSG00000116329,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL419667,"COc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3[C@](O)(c3ccccc3Cl)[C@@H]2C(=O)N2CCC[C@H]2C(N)=O)cc1OC_|_CEBYCSRFKCEUSW-NAYZPBBASA-N_|_Small molecule_|_False_|_RELCOVAPTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Relcovaptan' 'SR 49059' 'SR49059' 'Sr-49059' 'TDI 0134' 'TDI-0134']_|_[('PubChem', array(['26753276'], dtype=object)), ('Wikipedia', array(['Relcovaptan'], dtype=object)), ('drugbank', array(['DB13929'], dtype=object))]_|_nan_|_nan_|_[ENSG00000166148,ENSG00000180914]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4297502,"C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC_|_TUWMKPVJGGWGNL-UHFFFAOYSA-N_|_Small molecule_|_False_|_AVORALSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Avoralstat' 'BCX-4161']_|_[('drugbank', array(['DB12120'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019623'], dtype=object), 'count': 1}_|_[ENSG00000164344]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4650487,"nan_|_nan_|_Antibody_|_False_|_TORUDOKIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-3375880' 'LY3375880' 'Ly3375880' 'Torudokimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}_|_[ENSG00000137033]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL473159,"Oc1cc(O)cc(O)c1_|_QCDYQQDYXPDABM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHLOROGLUCINOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Spasfon' 'Spasfon-lyoc']_|_['Benezene-1,3,5-triol' 'Dilospan s' 'NSC-1572' 'Phloroglucin'
 'Phloroglucinol' 'Sym-trihydroxybenzene']_|_[('PubChem', array(['29218028'], dtype=object)), ('Wikipedia', array(['Phloroglucinol'], dtype=object)), ('drugbank', array(['DB12944'], dtype=object)), ('chEBI', array(['16204'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for gastrointestinal disease."
CHEMBL539843,Cl.Cl.NC(=O)c1cnc2n1CCc1ccccc1C21CCNCC1_|_BOYLPLUVCXUHDJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_VAPITADINE DIHYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL369075_|_False_|_False_|_['Hivenyl']_|_['R-129160' 'R129160' 'Vapitadine dihydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL565612,"CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1_|_OAVGBZOFDPFGPJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SOTRASTAURIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AEB-071' 'AEB071' 'Aeb-071' 'NVP-AEB071' 'Sotrastaurin']_|_[('PubChem', array(['103905056'], dtype=object)), ('drugbank', array(['DB12369'], dtype=object)), ('chEBI', array(['90531'], dtype=object))]_|_['CHEMBL2105655']_|_{'rows': array(['EFO_0000403', 'EFO_0000729', 'EFO_0000574', 'EFO_0000676',
       'EFO_1001119'], dtype=object), 'count': 5}_|_[ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL669,"CN(C)CCC=C1c2ccccc2C=Cc2ccccc21_|_JURKNVYFZMSNLP-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLOBENZAPRINE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cyclobenzaprine' 'Flexeril' 'MK-130 (AS THE BASE)' 'TNX-102']_|_[('PubChem', array(['11110649', '11110650', '174007219', '4253288', '50108641',
       '50111010', '90340629'], dtype=object)), ('Wikipedia', array(['Cyclobenzaprine'], dtype=object)), ('drugbank', array(['DB00924'], dtype=object)), ('chEBI', array(['3996'], dtype=object))]_|_['CHEMBL1200636']_|_{'rows': array(['MONDO_0005277', 'EFO_0005687', 'HP_0003394', 'EFO_1000632',
       'EFO_0001422', 'EFO_0009488', 'HP_0003326', 'HP_0001257',
       'EFO_0003843', 'EFO_0001358', 'MONDO_0002050'], dtype=object), 'count': 11}_|_[ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 6 investigational indications."
CHEMBL84,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1_|_UCFGDBYHRUNTLO-QHCPKHFHSA-N_|_Small molecule_|_True_|_TOPOTECAN_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ff-10850 (liposomal topotecan)' 'Hycamptin' 'Hycamtin' 'NSC-609699'
 'NSC-641007' 'SKF-104864' 'Topotecan']_|_[('PubChem', array(['164339428'], dtype=object)), ('Wikipedia', array(['Topotecan'], dtype=object)), ('drugbank', array(['DB01030'], dtype=object)), ('chEBI', array(['63632'], dtype=object))]_|_['CHEMBL1607']_|_{'rows': array(['EFO_0003833', 'EFO_0008498', 'MONDO_0002158', 'EFO_0002087',
       'MONDO_0100342', 'MONDO_0008903', 'EFO_0002918', 'EFO_0002617',
       'EFO_0000613', 'EFO_1000158', 'EFO_0000466', 'MONDO_0004992',
       'EFO_0000519', 'MONDO_0008380', 'EFO_0000621', 'MONDO_0037745',
       'EFO_0002939', 'MONDO_0100096', 'EFO_0000630', 'EFO_0000702',
       'EFO_1001465', 'EFO_0001416', 'EFO_0003893', 'MONDO_0004992',
       'MONDO_0008170', 'EFO_0005543', 'MONDO_0002974', 'EFO_0001378',
       'EFO_0000502', 'EFO_1001042', 'EFO_0000565', 'EFO_1000251',
       'EFO_0000681', 'EFO_0003833', 'EFO_0000220', 'EFO_0000691',
       'EFO_0008524', 'MONDO_0019004', 'EFO_0000198', 'EFO_1001100',
       'EFO_0002501', 'MONDO_0007576', 'EFO_1000823', 'EFO_0005561',
       'EFO_0005537', 'EFO_0002428', 'EFO_0002499', 'MONDO_0007254',
       'EFO_0000174', 'EFO_1000657', 'EFO_0000326', 'EFO_0001061',
       'EFO_0001075', 'EFO_0000616', 'EFO_0005952', 'EFO_0000389',
       'EFO_0000313', 'EFO_0003060', 'EFO_0003851', 'EFO_0003060',
       'EFO_0000616', 'MONDO_0021063', 'EFO_0003869', 'EFO_0000574',
       'MONDO_0011962', 'EFO_0000702', 'MONDO_0006058', 'EFO_0000222',
       'EFO_1001331', 'EFO_0000621', 'MONDO_0018271', 'EFO_0003893',
       'MONDO_0002974', 'EFO_0007362', 'EFO_0003859', 'MONDO_0018364',
       'MONDO_0018364', 'EFO_1000895', 'MONDO_0008315', 'MONDO_0008170',
       'MONDO_0002380', 'MONDO_0002087', 'EFO_1000043'], dtype=object), 'count': 83}_|_[ENSG00000184428]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 75 investigational indications. This drug has a black box warning from the FDA."
CHEMBL895,"Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314_|_NETZHAKZCGBWSS-CEDHKZHLSA-N_|_Small molecule_|_False_|_NALBUPHINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Intapan' 'Nalbuphine' 'Nubain']_|_[('PubChem', array(['144205561'], dtype=object)), ('Wikipedia', array(['Nalbuphine'], dtype=object)), ('drugbank', array(['DB00844'], dtype=object)), ('chEBI', array(['7454'], dtype=object))]_|_['CHEMBL1396398' 'CHEMBL1201132']_|_{'rows': array(['HP_0000175', 'EFO_0005611', 'EFO_0000222', 'EFO_0003843',
       'EFO_1001250', 'EFO_0005323', 'HP_0000989', 'EFO_0009267',
       'EFO_0001421', 'EFO_0003843'], dtype=object), 'count': 10}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and has 8 investigational indications."
CHEMBL1200880,"COS(=O)(=O)[O-].C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1_|_BREMLQBSKCSNNH-UHFFFAOYSA-M_|_Small molecule_|_False_|_DIPHEMANIL METHYLSULFATE_|_1982.0_|_4.0_|_CHEMBL1201340_|_False_|_True_|_['Prantal']_|_['Diphemanil methylsulfate' 'Diphemanil methylsulphate'
 'Diphemanil metilsulfate' 'NSC-41725']_|_[('PubChem', array(['144203900', '170464876', '56463612'], dtype=object)), ('Wikipedia', array(['Diphemanil_metilsulfate'], dtype=object)), ('chEBI', array(['59782'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201420,"nan_|_nan_|_Enzyme_|_False_|_UROKINASE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Abbokinase' 'Kinlytic' 'Ukidan']_|_['Kinase (enzyme-activating), uro-' 'Urinary plasminogen activator'
 'Urokinase']_|_[('DrugCentral', array(['5109'], dtype=object)), ('Wikipedia', array(['Urokinase'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008585', 'EFO_0000712', 'EFO_0003827', 'EFO_0003097',
       'EFO_0009680', 'EFO_0000544', 'HP_0004419'], dtype=object), 'count': 7}_|_[ENSG00000122861]_|_Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for recurrent thrombophlebitis and has 6 investigational indications."
CHEMBL1201454,"nan_|_nan_|_Unknown_|_False_|_ALSEROXYLON_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Rautensin' 'Rauwiloid']_|_['Alseroxylon']_|_[('Wikipedia', array(['Alseroxylon'], dtype=object))]_|_nan_|_nan_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Unknown drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1213351,"CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C_|_XLMALTXPSGQGBX-GCJKJVERSA-N_|_Small molecule_|_True_|_PROPOXYPHENE_|_1957.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Algafan' 'D-propoxyphene' 'Depromic' 'Dextropropoxyphen'
 'Dextropropoxyphene' 'J5.928E' 'Levopropoxyphene' 'Propoxyphene'
 'Propoxyphene, d-' 'SK-65']_|_[('Wikipedia', array(['Dextropropoxyphene', 'Levopropoxyphene'], dtype=object)), ('drugbank', array(['DB00647'], dtype=object)), ('chEBI', array(['51173'], dtype=object))]_|_['CHEMBL3989716' 'CHEMBL1237104']_|_{'rows': array(['EFO_0003843', 'EFO_0003843', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for pain. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL13280,"CN1C(=O)CN=C(c2ccccc2F)c2cc([N+](=O)[O-])ccc21_|_PPTYJKAXVCCBDU-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLUNITRAZEPAM_|_nan_|_4.0_|_nan_|_True_|_True_|_['Rohypnol']_|_['Flunitrazepam' 'N05CD03' 'RO 5-4200' 'RO-5-4200' 'RO-54200']_|_[('Wikipedia', array(['Flunitrazepam'], dtype=object)), ('drugbank', array(['DB01544'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL13817,"CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12_|_UMUPQWIGCOZEOY-JOCHJYFZSA-N_|_Small molecule_|_False_|_IBUTAMOREN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ibutamoren' 'L-163,191' 'MK-677']_|_nan_|_['CHEMBL542653' 'CHEMBL2105872']_|_{'rows': array(['EFO_0005687'], dtype=object), 'count': 1}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1702,"CNCC[C@@H](Oc1ccccc1C)c1ccccc1.Cl_|_LUCXVPAZUDVVBT-UNTBIKODSA-N_|_Small molecule_|_True_|_ATOMOXETINE HYDROCHLORIDE_|_2002.0_|_4.0_|_CHEMBL641_|_False_|_True_|_['Atomoxetine hydrochloride' 'Strattera']_|_['Atomoxetine (as hydrochloride)' 'Atomoxetine hcl'
 'Atomoxetine hydrochloride' 'LY-139603' 'NSC-759104' 'Tomoxetine'
 'Tomoxetine hydrochloride']_|_[('DailyMed', array(['atomoxetine%20hydrochloride'], dtype=object)), ('PubChem', array(['144203843', '170465067', '49681605'], dtype=object)), ('chEBI', array(['331697'], dtype=object))]_|_nan_|_{'rows': array(['HP_0010865', 'EFO_0003918', 'EFO_0004701', 'EFO_0003888',
       'MONDO_0004975'], dtype=object), 'count': 5}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for attention deficit hyperactivity disorder and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743044,"nan_|_nan_|_Antibody_|_False_|_NAMILUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-hgm-csf igg1' 'MT-203' 'MT203' 'Namilumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0019338', 'EFO_0003898', 'EFO_0000676', 'EFO_0000685'],
      dtype=object), 'count': 4}_|_[ENSG00000164400]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1743079,"nan_|_nan_|_Antibody_|_False_|_TEPROTUMUMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Tepezza']_|_['Onilcamotide' 'R-1507' 'RG-1507' 'RG1507' 'RO-4858696' 'RO-4858696-000'
 'RO-4858696000' 'RO4858696' 'RO4858696-000' 'RV-001' 'RV-001 MONOCLONAL'
 'RV001' 'RV001 MONOCLONAL' 'Rhoc peptide vaccine rv001v' 'Tepezza'
 'Teprotumumab' 'Teprotumumab trbw']_|_[('DailyMed', array(['teprotumumab-trbw'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000616', 'EFO_0000540', 'MONDO_0007254',
       'EFO_1001466', 'EFO_0000404', 'EFO_0000691'], dtype=object), 'count': 7}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and graves ophthalmopathy and has 5 investigational indications."
CHEMBL2103851,"S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1_|_FOFDIMHVKGYHRU-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMUVATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amuvatinib' 'HPK 56' 'HPK-56' 'HPK56' 'MP 470' 'MP-470' 'MP470']_|_[('PubChem', array(['137276002'], dtype=object)), ('drugbank', array(['DB12742'], dtype=object))]_|_['CHEMBL4071984' 'CHEMBL4061772' 'CHEMBL4092757' 'CHEMBL2105685'
 'CHEMBL4063359' 'CHEMBL4099995' 'CHEMBL4085000']_|_{'rows': array(['EFO_0000616', 'EFO_0000702'], dtype=object), 'count': 2}_|_[ENSG00000105976,ENSG00000157404,ENSG00000122025,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2106615,"CC(=O)O.Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12_|_OMZAMQFQZMUNTP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BAZEDOXIFENE ACETATE_|_2009.0_|_4.0_|_CHEMBL46740_|_False_|_True_|_['Conbriza']_|_['Bazedoxifen acetate' 'Bazedoxifene acetate' 'Conbriza' 'Duavive'
 'WAY-140424']_|_[('DailyMed', array(['bazedoxifene%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza'],
      dtype=object)), ('PubChem', array(['144206564', '170466793'], dtype=object))]_|_nan_|_{'rows': array(['GO_0042697', 'EFO_0003929', 'EFO_0003882', 'EFO_0003854'],
      dtype=object), 'count': 4}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for postmenopausal osteoporosis and has 3 investigational indications."
CHEMBL2109477,"nan_|_nan_|_Antibody_|_False_|_SELICRELUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP 870,893' 'CP-870,893' 'CP-870893' 'RG-7876' 'RG7876' 'RO-7009789'
 'Selicrelumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001951', 'EFO_0000096', 'EFO_0003860',
       'EFO_0000756', 'MONDO_0007254'], dtype=object), 'count': 6}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL2109534,"nan_|_nan_|_Antibody_|_False_|_PF-03732010_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['P-cadherin antagonist pf-03732010' 'PF-03732010' 'PF03732010'
 'Pf-03732010']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000062038]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2151570,c1cc2cc(-c3ccc(O[C@H]4CN5CCC4CC5)nn3)ccc2[nH]1_|_LUKNJAQKVPBDSC-SFHVURJKSA-N_|_Small molecule_|_False_|_ABT-107_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ABT-PR1' 'Abt-107' 'Abt-107 free base']_|_nan_|_nan_|_nan_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545087,"nan_|_nan_|_Small molecule_|_False_|_GSK159802_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Gsk159802']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545395,"nan_|_nan_|_Small molecule_|_False_|_BI-811283_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bi-811283']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000178999]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL37676,"Cc1c(C)c2c(c(C)c1O)CCC(C)(C)O2_|_SEBPXHSZHLFWRL-UHFFFAOYSA-N_|_Small molecule_|_False_|_APC-100_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['2,2,5,7,9-pentamethyl-6-chromanol' 'APC-100' 'Apc-100' 'Chromane c1'
 'NSC-226236']_|_[('drugbank', array(['DB13111'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989855,"CN[C@@H](C)[C@@H](O)c1ccccc1.CN[C@@H](C)[C@@H](O)c1ccccc1.O=S(=O)(O)O_|_CAVQBDOACNULDN-NRCOEFLKSA-N_|_Small molecule_|_False_|_PSEUDOEPHEDRINE SULFATE_|_1963.0_|_4.0_|_CHEMBL1590_|_False_|_True_|_['Afrinol']_|_['D-pseudoephedrine sulfate' 'Pseudoephedrine sulfate'
 'Pseudoephedrine sulphate' 'SCH 4855' 'SCH-4855']_|_[('DailyMed', array(['pseudoephedrine%20sulfate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003956', 'EFO_0005854'], dtype=object), 'count': 2}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for seasonal allergic rhinitis and allergic rhinitis."
CHEMBL4297583,"Cc1nc2cc(C(=O)N(C)C)cc(O[C@H]3CCOc4cc(F)cc(F)c43)c2[nH]1_|_CLIQCDHNPDMGSL-HNNXBMFYSA-N_|_Small molecule_|_False_|_TEGOPRAZAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cj-12420' 'LXI-15028' 'Lxi-15028' 'Tegoprazan']_|_nan_|_nan_|_{'rows': array(['HP_0004398', 'EFO_0004607', 'EFO_1001355', 'EFO_1000961',
       'EFO_0003948', 'EFO_0001421'], dtype=object), 'count': 6}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4297804,"nan_|_nan_|_Unknown_|_False_|_PF-06263507_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pf-06263507']_|_nan_|_nan_|_nan_|_[ENSG00000146242,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Unknown drug with a maximum clinical trial phase of I."
CHEMBL4297949,"nan_|_nan_|_Protein_|_False_|_AVEXITIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Avexitide' 'Exendin (9-39)' 'Exendin (9-39) amide' 'Exendin 9-39'
 'Exendin(9-39)amide' 'Exendin-3 (9-39) amide']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AVEXITIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007318', 'MONDO_0017182', 'EFO_0001069', 'HP_0001943',
       'EFO_0001073', 'MONDO_0005148'], dtype=object), 'count': 6}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4298092,"nan_|_nan_|_Antibody_|_False_|_GLOFITAMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Columvi']_|_['Columvi' 'Glofitamab' 'Glofitamab-gxbm' 'RG-6026' 'RG6026' 'RO-7082859'
 'RO7082859' 'Ro7082859']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GLOFITAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000403', 'EFO_1001469', 'EFO_0000096', 'EFO_0000574',
       'EFO_0005952', 'EFO_0000616', 'MONDO_0018906'], dtype=object), 'count': 7}_|_[ENSG00000156738,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for diffuse large b-cell lymphoma and has 6 investigational indications."
CHEMBL4298138,"C[C@H]1CNC(=O)c2cnn3ccc(nc23)N[C@H](C)c2cc(F)ccc2O1_|_FIKPXCOQUIZNHB-WDEREUQCSA-N_|_Small molecule_|_False_|_REPOTRECTINIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Augtyro']_|_['Repotrectinib' 'TPX-0005' 'TRX-0005']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/REPOTRECTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000047936,ENSG00000124145,ENSG00000140538,ENSG00000148053,ENSG00000019582,ENSG00000198400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 investigational indications."
CHEMBL4594497,"nan_|_nan_|_Oligonucleotide_|_False_|_SEPOFARSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EW9I3PJC3R' 'QR-110' 'QR-110 FREE ACID' 'Qr-110' 'Sepofarsen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SEPOFARSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018998', 'EFO_0003966'], dtype=object), 'count': 2}_|_[ENSG00000198707]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4650495,"nan_|_nan_|_Protein_|_False_|_PEGSEBRENATIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NLY-01' 'NLY01' 'Nly-01' 'Nly01' 'Pegsebrenatide']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0005180'], dtype=object), 'count': 2}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL554,"CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1_|_BCFGMOOMADDAQU-UHFFFAOYSA-N_|_Small molecule_|_True_|_LAPATINIB_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Tyverb']_|_['GSK-572016' 'GW-2016' 'GW-572016' 'GW-572016X' 'GW572016' 'Lapatinib']_|_[('PubChem', array(['103905567', '103905568', '144206058', '170465125', '50100107'],
      dtype=object)), ('Wikipedia', array(['Lapatinib'], dtype=object)), ('drugbank', array(['DB01259'], dtype=object)), ('chEBI', array(['49603'], dtype=object))]_|_['CHEMBL1201179' 'CHEMBL3526325' 'CHEMBL1076241' 'CHEMBL1201183']_|_{'rows': array(['EFO_0000228', 'MONDO_0008315', 'EFO_0006859', 'EFO_0005543',
       'MONDO_0044926', 'EFO_0005774', 'EFO_1000478', 'EFO_1001465',
       'MONDO_0004986', 'EFO_0000707', 'MONDO_0004986', 'EFO_1001951',
       'EFO_1000294', 'EFO_1000158', 'EFO_1001512', 'MONDO_0004992',
       'MONDO_0007254', 'EFO_0005922', 'MONDO_0007576', 'EFO_0002618',
       'EFO_0005950', 'EFO_0003869', 'EFO_0000181', 'EFO_0003884',
       'MONDO_0011962', 'MONDO_0001056', 'EFO_1001968', 'EFO_0000365',
       'EFO_0006352', 'EFO_0002892', 'EFO_0002938', 'EFO_0003869',
       'EFO_0000616', 'EFO_1000294', 'EFO_0002618', 'EFO_0000305',
       'MONDO_0002974', 'MONDO_0002087', 'EFO_0000305', 'MONDO_0001187',
       'EFO_0000616', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0008170',
       'EFO_0000574', 'EFO_0006859', 'EFO_0006318', 'EFO_0000756',
       'MONDO_0007254', 'EFO_0006861', 'EFO_0000681', 'MONDO_0001657'],
      dtype=object), 'count': 52}_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA."
CHEMBL572284,"COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO_|_IXWNTLSTOZFSCM-YVACAVLKSA-N_|_Small molecule_|_False_|_OMBRABULIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AC7700' 'AVE-8062' 'AVE8062' 'Ave8062' 'Ombrabulin']_|_[('drugbank', array(['DB12882'], dtype=object))]_|_['CHEMBL585539']_|_{'rows': array(['EFO_0000691', 'EFO_0000616', 'EFO_0003060', 'MONDO_0008170'],
      dtype=object), 'count': 4}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL766,"CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O_|_DHSUYTOATWAVLW-WFVMDLQDSA-N_|_Small molecule_|_False_|_CILASTATIN_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cilastatin' 'Primaxin']_|_[('PubChem', array(['50125939'], dtype=object)), ('Wikipedia', array(['Cilastatin'], dtype=object)), ('drugbank', array(['DB01597'], dtype=object)), ('chEBI', array(['3697'], dtype=object))]_|_['CHEMBL1201057']_|_{'rows': array(['HP_0100806', 'EFO_0000544', 'EFO_0003103', 'EFO_1001141',
       'EFO_0003106', 'EFO_0000465', 'EFO_0000771', 'HP_0100806',
       'EFO_0003103', 'MONDO_0044881', 'EFO_1001865', 'EFO_0000544',
       'EFO_1001272', 'EFO_0003102'], dtype=object), 'count': 14}_|_[ENSG00000015413]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 9 investigational indications."
CHEMBL9298,"N#Cc1ccc(C2CCCc3cncn32)cc1_|_CLPFFLWZZBQMAO-UHFFFAOYSA-N_|_Small molecule_|_False_|_FADROZOLE_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['CGS-16949A' 'Fadrozole']_|_[('Wikipedia', array(['Fadrozole'], dtype=object))]_|_['CHEMBL468419']_|_nan_|_[ENSG00000137869]_|_Small molecule drug."
CHEMBL1120,"nan_|_nan_|_Small molecule_|_False_|_BISMUTH SUBSALICYLATE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Bismukote' 'Corrective Suspension' 'Gastro-Cote' 'Pepto-Bismol']_|_['Bismuth salicylate' 'Bismuth subsalicylate' 'NSC-759117']_|_[('PubChem', array(['144205951', '225144280', '29218057'], dtype=object)), ('Wikipedia', array(['Bismuth_subsalicylate'], dtype=object)), ('chEBI', array(['261649'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'HP_0002018', 'EFO_1000961', 'HP_0002014'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for nausea and diarrhea and has 2 investigational indications."
CHEMBL1201464,"nan_|_nan_|_Protein_|_False_|_CHORIOGONADOTROPIN ALFA_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Ovidrel' 'Ovitrelle']_|_['ATC CODE G03 GA GONADOTROPINS' 'Choriogonadotropin alfa'
 'Choriogonadotropin alpha' 'Choriongonadotropin alfa'
 'Chorionic gonadotrophin alfa' 'Fe-999302']_|_[('DailyMed', array(['choriogonadotropin%20alfa'], dtype=object)), ('DrugCentral', array(['5149'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ovitrelle'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011972', 'MONDO_0002146', 'EFO_0008560', 'EFO_0004266',
       'EFO_0001073', 'EFO_0000660', 'EFO_0000545', 'MONDO_0002775'],
      dtype=object), 'count': 8}_|_[ENSG00000138039]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 approved and 2 investigational indications."
CHEMBL1568698,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C_|_PGTVWKLGGCQMBR-FLBATMFCSA-N_|_Small molecule_|_False_|_GANAXOLONE_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Ztalmy']_|_['CCD 1042' 'CCD-1042' 'DEA NO. 2401' 'Ganaxolone' 'Ztalmy']_|_[('PubChem', array(['144205817', '170466317', '29217560', '50111707', '90341411'],
      dtype=object)), ('drugbank', array(['DB05087'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'EFO_0004263', 'MONDO_0010383', 'EFO_0001358',
       'MONDO_0018097', 'EFO_0000474', 'MONDO_0001734', 'EFO_0008526',
       'EFO_1000877', 'EFO_0004319'], dtype=object), 'count': 10}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 7 investigational indications."
CHEMBL1767164,"O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1_|_YANGEESWIGIKOP-UUWRZZSWSA-N_|_Small molecule_|_False_|_GSK-1004723_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK1004723' 'Gsk-1004723' 'Gsk1004723']_|_[('drugbank', array(['DB12806'], dtype=object))]_|_['CHEMBL3215857' 'CHEMBL1767170']_|_{'rows': array(['EFO_0003956', 'EFO_0005854'], dtype=object), 'count': 2}_|_[ENSG00000196639,ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2103791,"CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12_|_UAMAIHOEGLEXSV-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADIPIPLON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adipiplon' 'NG2-73']_|_[('drugbank', array(['DB06579'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108681,"nan_|_nan_|_Antibody_|_False_|_TILDRAKIZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Ilumetri' 'Ilumya']_|_['MK-3222' 'SCH-900222' 'Tildrakizumab' 'Tildrakizumab asmn']_|_[('DailyMed', array(['tildrakizumab-asmn'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000540', 'EFO_1001494', 'MONDO_0008315',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000113302,ENSG00000110944]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications."
CHEMBL2109480,"nan_|_nan_|_Antibody_|_False_|_AHN-12_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AHN-12' 'Ahn-12']_|_nan_|_nan_|_{'rows': array(['EFO_0000339', 'EFO_0000565', 'EFO_0000220', 'EFO_0000222',
       'EFO_0000198'], dtype=object), 'count': 5}_|_[ENSG00000081237]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications."
CHEMBL2109491,nan_|_nan_|_Antibody_|_False_|_COL-1_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['COL-1']_|_nan_|_nan_|_nan_|_[ENSG00000105388]_|_Antibody drug.
CHEMBL2165326,"NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1_|_DKULOVKANLVDEA-UHFFFAOYSA-N_|_Small molecule_|_False_|_APROCITENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACT-132577' 'Act-132577' 'Aprocitentan' 'Macitentan metabolite m6']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/APROCITENTAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15059'], dtype=object)), ('chEBI', array(['76609'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0003086', 'EFO_0001421', 'MONDO_0001134'],
      dtype=object), 'count': 4}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL243712,"CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC_|_NTJOBXMMWNYJFB-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMISULPRIDE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Barhemsys' 'Solian' 'Solian 100' 'Solian 200' 'Solian 400' 'Solian 50']_|_['APD-421' 'APD421' 'Aminosultopride' 'Amisulpride' 'DAN-2163' 'Deniban'
 'NSC-760085' 'Socian' 'Sulamid']_|_[('DailyMed', array(['amisulpride'], dtype=object)), ('PubChem', array(['124891581', '144206943', '170466480', '26719747', '26719748',
       '26753203'], dtype=object)), ('Wikipedia', array(['Amisulpride'], dtype=object)), ('drugbank', array(['DB06288'], dtype=object)), ('chEBI', array(['64045'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004888', 'MONDO_0005351', 'MONDO_0004985', 'EFO_0003884',
       'EFO_0006911', 'EFO_0005230', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0005407', 'HP_0002017',
       'EFO_0004242'], dtype=object), 'count': 13}_|_[ENSG00000149295,ENSG00000151577,ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 10 investigational indications."
CHEMBL3402762,"CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1_|_AHYMHWXQRWRBKT-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEPOTINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['EMD 1214063' 'EMD-1214063' 'EMD1214063' 'Emd-1214063' 'MSC-2156119'
 'MSC-2156119J' 'MSC2156119' 'Tepotinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPOTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15133'], dtype=object))]_|_['CHEMBL4594292']_|_{'rows': array(['EFO_0003833', 'EFO_0000616', 'EFO_0000571', 'EFO_0000616',
       'EFO_0001421', 'EFO_0000182', 'EFO_0003060', 'EFO_0004142',
       'EFO_0003060'], dtype=object), 'count': 9}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and non-small cell lung carcinoma and has 7 investigational indications."
CHEMBL3545000,"nan_|_nan_|_Small molecule_|_False_|_MK-2201_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mk-2201']_|_nan_|_nan_|_nan_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545346,"nan_|_nan_|_Small molecule_|_False_|_AZD2516_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd2516']_|_nan_|_nan_|_{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297779,"nan_|_nan_|_Oligonucleotide_|_False_|_LUMASIRAN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['AD-65585' 'ALN-65585' 'ALN-G01' 'ALN-GO1' 'Lumasiran']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUMASIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009823', 'EFO_0004253', 'MONDO_0002474'], dtype=object), 'count': 3}_|_[ENSG00000101323]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications."
CHEMBL4297784,"nan_|_nan_|_Antibody_|_False_|_FAVEZELIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Favezelimab' 'MK-4280' 'MK4280' 'Mavezelimab' 'Mk-4280']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FAVEZELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005952', 'MONDO_0001187', 'EFO_1001951', 'EFO_0000616',
       'EFO_0000756', 'EFO_0000183', 'EFO_0005922', 'EFO_0000702',
       'EFO_0008528', 'EFO_0003060', 'EFO_0000681'], dtype=object), 'count': 11}_|_[ENSG00000089692]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL4297950,"nan_|_nan_|_Protein_|_False_|_BENEGRASTIM_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Ryzneuta']_|_['Benegrastim' 'Efbemalenograstim alfa' 'F-627'
 'Rh g-csf fc fusion protein f-627']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616', 'MONDO_0001475'], dtype=object), 'count': 3}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for neoplasm and has 2 investigational indications."
CHEMBL4298111,"nan_|_nan_|_Unknown_|_False_|_APILIMOD MESYLATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apilimod bis-mesylate' 'Apilimod dimesylate' 'Apilimod mesilate'
 'Apilimod mesylate' 'STA 5326 MESYLATE' 'STA-5326 MESYLATE'
 'Sta 5326 mesilate' 'Sta 5326 mesylate' 'Sta-5326 mesilate'
 'Sta-5326 mesylate']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0000384'], dtype=object), 'count': 2}_|_[ENSG00000115020]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4650292,"nan_|_nan_|_Antibody_|_False_|_CDX-3379_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDX-3379' 'Cdx 3379' 'Cdx-3379' 'Cdx3379' 'KTN-3379' 'MEDI-3379']_|_nan_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0000756'], dtype=object), 'count': 2}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL49080,"CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1_|_STJMRWALKKWQGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLENBUTEROL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Spiropent' 'Spiropent mite']_|_['Clenbuterol' 'Clenbuterol hydrochloride' 'Contraspasmin' 'NAB 365'
 'NSC-758633' 'Planipart']_|_[('PubChem', array(['144205569', '170465955', '26756514', '29216418'], dtype=object)), ('Wikipedia', array(['Clenbuterol'], dtype=object)), ('drugbank', array(['DB01407'], dtype=object)), ('chEBI', array(['174690'], dtype=object))]_|_['CHEMBL1330729']_|_{'rows': array(['Orphanet_365', 'MONDO_0004976', 'MONDO_0005180', 'MONDO_0005148',
       'HP_0006536'], dtype=object), 'count': 5}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 4 investigational indications."
CHEMBL511,"COc1ccc(CN(CCN(C)C)c2ccccn2)cc1_|_YECBIJXISLIIDS-UHFFFAOYSA-N_|_Small molecule_|_False_|_PYRILAMINE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mepyramine' 'NSC-13136' 'Pyrilamine']_|_[('PubChem', array(['104171213', '11111639', '11111640', '11113355', '144203781',
       '144208176', '170464656', '17389532', '26751558', '50100317',
       '50104164', '90341279'], dtype=object)), ('Wikipedia', array(['Mepyramine'], dtype=object)), ('drugbank', array(['DB06691'], dtype=object)), ('chEBI', array(['6762'], dtype=object))]_|_['CHEMBL1201006']_|_{'rows': array(['HP_0000989', 'MONDO_0005271', 'EFO_0003956'], dtype=object), 'count': 3}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved indications."
CHEMBL926,"CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1_|_JRWZLRBJNMZMFE-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOBUTAMINE_|_1978.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['COMPOUND 81929' 'COMPOUND-81929' 'Dl-dobutamine' 'Dobutamine' 'Dobutrex'
 'Racemic dobutamine']_|_[('PubChem', array(['104171143', '144203677', '170465050', '26751752', '50104446',
       '90341592'], dtype=object)), ('Wikipedia', array(['Dobutamine'], dtype=object)), ('drugbank', array(['DB00841'], dtype=object)), ('chEBI', array(['4670'], dtype=object))]_|_['CHEMBL1200418' 'CHEMBL4297079']_|_{'rows': array(['EFO_0000373', 'EFO_0000319', 'MONDO_0043510', 'EFO_0004610',
       'EFO_0006834', 'EFO_0000319', 'EFO_0009516', 'EFO_0003144',
       'HP_0031273'], dtype=object), 'count': 9}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for congestive heart failure and cardiovascular disease and has 7 investigational indications."
CHEMBL997,"CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O_|_MPBVHIBUJCELCL-UHFFFAOYSA-N_|_Small molecule_|_False_|_IBANDRONIC ACID_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Bondronat' 'Bonviva' 'Iasibon' 'Quodixor']_|_['Bondenza' 'Boniva' 'Ibandronate' 'Ibandronic Acid' 'Ibandronic acid'
 'Ibandronic acid accord' 'Ibandronic acid sandoz' 'Ibandronic acid teva'
 'NSC-722623']_|_[('PubChem', array(['90340689'], dtype=object)), ('Wikipedia', array(['Ibandronic_acid'], dtype=object)), ('drugbank', array(['DB00710'], dtype=object))]_|_['CHEMBL1201008' 'CHEMBL3989569']_|_{'rows': array(['HP_0002027', 'EFO_0003854', 'EFO_0003820', 'EFO_0003854',
       'MONDO_0007254', 'EFO_0003882', 'EFO_0001642', 'EFO_0001378',
       'MONDO_0007254', 'EFO_0009708', 'EFO_0003843', 'EFO_0003843',
       'EFO_0004259', 'EFO_0003882', 'HP_0000938', 'EFO_0004260'],
      dtype=object), 'count': 16}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for postmenopausal osteoporosis and osteoporosis and has 12 investigational indications."
CHEMBL1005,"CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1_|_ZTVQQQVZCWLTDF-UHFFFAOYSA-N_|_Small molecule_|_True_|_REMIFENTANIL_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['GI 87084X' 'IDS-NR-005' 'Ramifentanyl' 'Remifentanil' 'Remifentanyl'
 'Ultiva' 'Ultiva-']_|_[('Wikipedia', array(['Remifentanil'], dtype=object)), ('drugbank', array(['DB00899'], dtype=object)), ('chEBI', array(['8802'], dtype=object))]_|_['CHEMBL1201120']_|_{'rows': array(['EFO_0000616', 'EFO_0004337', 'EFO_0000712', 'EFO_0003918',
       'EFO_0001074', 'MONDO_0021233', 'MONDO_0041052', 'EFO_0003833',
       'EFO_0003877', 'EFO_0005611', 'EFO_0010702', 'EFO_0009483',
       'HP_0002093', 'EFO_0003777', 'EFO_0003843', 'EFO_0009842',
       'EFO_0003917', 'EFO_0006834'], dtype=object), 'count': 18}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200613,"Cc1ccc(C(=O)c2ccc(CC(=O)[O-])n2C)cc1.[Na+]_|_QGUALMNFRILWRA-UHFFFAOYSA-M_|_Small molecule_|_True_|_TOLMETIN SODIUM_|_1976.0_|_4.0_|_CHEMBL1020_|_False_|_True_|_['Tolectin' 'Tolectin 600' 'Tolectin ds' 'Tolmetin sodium']_|_['MCN-2559-21-98' 'NSC-757341' 'Sodium tolmetin' 'Tolmetin sodium'
 'Tolmetin sodium anhydrous' 'Tolmetin sodium dihydrate'
 'Tolmetin sodium salt dihydrate']_|_[('DailyMed', array(['tolmetin%20sodium'], dtype=object)), ('PubChem', array(['26748279'], dtype=object)), ('chEBI', array(['9619'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0005178'], dtype=object), 'count': 2}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for rheumatoid arthritis and osteoarthritis. This drug has a black box warning from the FDA."
CHEMBL1201010,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_SYWHXTATXSMDSB-GSLJADNHSA-N_|_Small molecule_|_False_|_FLUDROCORTISONE ACETATE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Astonin' 'Florinef' 'Fludrocortisone acetate' 'Fludrocortone' 'Panotile']_|_['Fludrocortisone 21-acetate' 'Fludrocortisone acetate'
 'Fludrocortisoni acetas' 'Fluorhydrocortisone acetate'
 'Fluorocortisol acetate' 'NSC-15186' 'Scherofluron']_|_[('DailyMed', array(['fludrocortisone%20acetate'], dtype=object)), ('chEBI', array(['5102'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'EFO_1001176', 'MONDO_0015128', 'MONDO_0015898',
       'MONDO_0100096', 'EFO_0000694', 'MONDO_0005180', 'MONDO_0015129',
       'EFO_0006834', 'EFO_0000756', 'MONDO_0011972', 'MONDO_0018479'],
      dtype=object), 'count': 12}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 9 investigational indications."
CHEMBL1282,"CC(C)Cn1cnc2c(N)nc3ccccc3c21_|_DOUYETYNHWVLEO-UHFFFAOYSA-N_|_Small molecule_|_True_|_IMIQUIMOD_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Aldara' 'Imiquimod' 'Zyclara']_|_['Aldara' 'Imiquimod' 'NSC-369100' 'NSC-759651' 'R-837' 'S-26308' 'S26308'
 'Tmx-101']_|_[('DailyMed', array(['imiquimod'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aldara'],
      dtype=object)), ('PubChem', array(['144204536', '170464691', '174006731', '26752301', '865810'],
      dtype=object)), ('Wikipedia', array(['Imiquimod'], dtype=object)), ('drugbank', array(['DB00724'], dtype=object)), ('chEBI', array(['36704'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0024475', 'EFO_0000565', 'EFO_0000389', 'EFO_0002627',
       'EFO_0001061', 'EFO_0004197', 'EFO_1001968', 'EFO_0002913',
       'MONDO_0008094', 'EFO_0000707', 'EFO_0002499', 'EFO_0003868',
       'MONDO_0100342', 'EFO_1000026', 'EFO_0000220', 'EFO_0000095',
       'EFO_1000249', 'EFO_0007147', 'MONDO_0022394', 'MONDO_0002102',
       'EFO_0004193', 'EFO_0007444', 'EFO_0007328', 'MONDO_0002974',
       'EFO_0005222', 'MONDO_0021054', 'MONDO_0008315', 'EFO_0000756',
       'EFO_0002496', 'EFO_0000673', 'MONDO_0004992', 'MONDO_0008170',
       'EFO_1001361', 'EFO_0002939', 'MONDO_0002158', 'EFO_0001422',
       'MONDO_0005341', 'EFO_1000028', 'EFO_1002048', 'MONDO_0024474',
       'EFO_1001951', 'EFO_0000519', 'MONDO_0001657', 'EFO_1000635',
       'EFO_0001668', 'EFO_0000763', 'EFO_0003835', 'EFO_0005046',
       'EFO_0003060', 'EFO_0004212', 'MONDO_0007254', 'EFO_1000720',
       'EFO_1001051'], dtype=object), 'count': 53}_|_[ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 6 approved and 47 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1465,"CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O_|_DQDAYGNAKTZFIW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENPROCOUMON_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Liquamar' 'Marcoumar']_|_['BS-7565' 'Fencumar' 'Marcumar' 'Phenprocoumarol' 'Phenprocoumarole'
 'Phenprocoumon' 'Phenprocumone' 'RO-1-4849']_|_[('Wikipedia', array(['Phenprocoumon'], dtype=object)), ('drugbank', array(['DB00946'], dtype=object)), ('chEBI', array(['50438'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'HP_0004419', 'HP_0004936', 'EFO_0003907'],
      dtype=object), 'count': 4}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for recurrent thrombophlebitis and has 3 investigational indications."
CHEMBL2108332,nan_|_nan_|_Gene_|_False_|_BEPERMINOGENE PERPLASMID_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Beperminogene perplasmid']_|_nan_|_nan_|_nan_|_[ENSG00000105976]_|_Gene drug with a maximum clinical trial phase of II.
CHEMBL2108481,"nan_|_nan_|_Unknown_|_False_|_ANCROD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Acc-c' 'Ancrod' 'Arvin' 'Arwin' 'Ec 3.4.21.74' 'Protein c activator'
 'Proteinase, agkistrodon serine' 'Venombin-a' 'Viprinex']_|_nan_|_nan_|_{'rows': array(['HP_0004419'], dtype=object), 'count': 1}_|_[ENSG00000171560,ENSG00000171564,ENSG00000171557]_|_Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109330,"nan_|_nan_|_Antibody_|_False_|_IC14_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atibuclimab' 'IC-14' 'IC14' 'Ic14']_|_nan_|_nan_|_{'rows': array(['EFO_1000637', 'MONDO_0004976', 'MONDO_0100130', 'MONDO_0100096',
       'EFO_0005547'], dtype=object), 'count': 5}_|_[ENSG00000170458]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2109361,nan_|_nan_|_Antibody_|_False_|_PEMTUMOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Theragyn']_|_['Pemtumomab' 'RG-1549']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of III.
CHEMBL2109389,"nan_|_nan_|_Antibody_|_False_|_IMGATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GA-201' 'GA201' 'HUMA-B' 'HUMAB' 'HuMAB<EGFR>' 'Imgatuzumab' 'RG7160'
 'RO-5083945' 'RO5083945']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0000616', 'EFO_0003060', 'EFO_0006859'],
      dtype=object), 'count': 4}_|_[ENSG00000146648,ENSG00000203747]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2109492,"nan_|_nan_|_Antibody_|_False_|_MDX-1411_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MDX-1411' 'Mdx-1411']_|_nan_|_nan_|_{'rows': array(['EFO_1001469'], dtype=object), 'count': 1}_|_[ENSG00000125726]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2178578,"CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1_|_JRWROCIMSDXGOZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERCIRNON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CCX-282-B' 'CCX282' 'GSK-1605786' 'GSK1605786' 'Vercirnon' 'Verecimon']_|_[('drugbank', array(['DB15250'], dtype=object))]_|_['CHEMBL3039505']_|_{'rows': array(['EFO_0000729', 'EFO_0001060', 'EFO_0000384', 'EFO_0000384'],
      dtype=object), 'count': 4}_|_[ENSG00000173585]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2392545,"COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2c(n1)N(C1CCCC1)CC(F)(F)C(=O)N2C_|_GWRSATNRNFYMDI-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAK-960_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['TAK-960' 'TAK960' 'Tak-960']_|_nan_|_['CHEMBL5307337']_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3039539,"nan_|_nan_|_Antibody_|_False_|_OTLERTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Otlertuzumab' 'TRU-016']_|_nan_|_nan_|_{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}_|_[ENSG00000104894]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3219124,"COC[C@H](C)Oc1cc(Oc2cnc(C(=O)N3CCC3)cn2)cc(C(=O)Nc2cnc(C)cn2)c1_|_FJEJHJINOKKDCW-INIZCTEOSA-N_|_Small molecule_|_False_|_AZD-1656_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD1656' 'Azd 1656' 'Azd-1656' 'Azd1656']_|_[('drugbank', array(['DB14810'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'MONDO_0005148', 'MONDO_0100096'], dtype=object), 'count': 3}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545169,"CC(C)(C)OC(=O)NCCN1CC2CN(CCOc3ccc(C#N)cc3F)CC(C1)O2_|_BLLNYXOLLAVTRF-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD1305_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd 1305' 'Azd-1305' 'Azd1305']_|_nan_|_nan_|_{'rows': array(['EFO_0003911', 'EFO_0000275'], dtype=object), 'count': 2}_|_[ENSG00000055118,ENSG00000183873,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545300,"nan_|_nan_|_Small molecule_|_False_|_CP-459632_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Cp-459632']_|_nan_|_nan_|_nan_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000066056,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545378,"Cc1cc(Nc2cc(N3CC(F)(C4CC4)C3)nc(O[C@H]3CCN(C(=O)c4cc(Cl)ccc4F)C3)n2)n[nH]1_|_SLUHYAXFRJQTGB-KRWDZBQOSA-N_|_Small molecule_|_False_|_MK-6592_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mk-6592' 'VX-667']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL355200,"C#Cc1c[nH]c(=O)[nH]c1=O_|_JOZGNYDSEBIJDH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENILURACIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['776-C-85' '776C85' 'Eniluracil']_|_[('drugbank', array(['DB03516'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_1001951', 'EFO_0000365', 'EFO_0006859',
       'EFO_1000657', 'MONDO_0007254', 'MONDO_0021063', 'MONDO_0004992'],
      dtype=object), 'count': 8}_|_[ENSG00000188641]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL3644587,"O=c1[nH]nc2c3c(cccc13)N=C(CN1Cc3ccccc3C1)N2_|_JLFSBHQQXIAQEC-UHFFFAOYSA-N_|_Small molecule_|_False_|_2X-121_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['2X-121' '2x-121' 'E-7449' 'E7449' 'Parp inhibitor 2x-121' 'Stenoparib']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000305', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000107854,ENSG00000173273,ENSG00000143799,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3655081,"CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1_|_IUEWXNHSKRWHDY-PHIMTYICSA-N_|_Small molecule_|_True_|_ABROCITINIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Cibinqo']_|_['Abrocitinib' 'Cibinqo' 'PF-04965842' 'Pf-04965842']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo'],
      dtype=object)), ('drugbank', array(['DB14973'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019338', 'EFO_1001890', 'MONDO_0005147', 'EFO_1000704',
       'HP_0000964', 'EFO_0000676', 'EFO_0000274', 'EFO_0001421',
       'EFO_0003086'], dtype=object), 'count': 9}_|_[ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for eczematoid dermatitis and atopic eczema and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3707225,"nan_|_nan_|_Small molecule_|_False_|_GSK2798745_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gsk-2798745' 'Gsk2798745']_|_nan_|_nan_|_{'rows': array(['HP_0012735', 'MONDO_0003005', 'EFO_0000373', 'EFO_0003144',
       'EFO_1001134'], dtype=object), 'count': 5}_|_[ENSG00000111199]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3989698,"N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1.O=S(=O)(O)O_|_BKPRVQDIOGQWTG-ICOOEGOYSA-N_|_Small molecule_|_True_|_TRANYLCYPROMINE SULFATE_|_1961.0_|_4.0_|_CHEMBL3989843_|_False_|_True_|_['Parnate' 'Parstelin' 'Tranylcypromine sulfate']_|_['NSC-757342' 'Tranylcypromine sulfate' 'Tranylcypromine sulphate']_|_[('DailyMed', array(['tranylcypromine%20sulfate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1002014', 'MONDO_0002009'], dtype=object), 'count': 2}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for melancholia and major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL3989947,"CCCCCCCCCCCCCCOc1ccc(C(=O)OCC(=O)N(C)CC(=O)OCC)o1_|_FYJLDICZGDFWKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_OLUMACOSTAT GLASARETIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DRM-01B' 'DRM01B' 'DRMO1B' 'Olumacostat glasaretil']_|_[('drugbank', array(['DB12642'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003894'], dtype=object), 'count': 1}_|_[ENSG00000278540,ENSG00000076555]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3990042,"nan_|_nan_|_Antibody_|_False_|_GOSURANEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB092' 'BMS-986168' 'BMS-986168-01' 'Biib-092' 'Gosuranemab' 'IPN-007']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975', 'Orphanet_240071', 'MONDO_0019037'], dtype=object), 'count': 3}_|_[ENSG00000186868]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4296719,"O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O_|_DVJAMEIQRSHVKC-BDAKNGLRSA-N_|_Small molecule_|_False_|_DUTOGLIPTIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dutogliptin' 'PHX1149' 'Phx1149']_|_[('drugbank', array(['DB11723'], dtype=object))]_|_['CHEMBL4297203']_|_{'rows': array(['MONDO_0005148', 'MONDO_0005148', 'EFO_0008585'], dtype=object), 'count': 3}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4297711,"nan_|_nan_|_Protein_|_False_|_BULEVIRTIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Hepcludextm' 'Myrcludex']_|_['915207G' 'Bulevirtide' 'Hepcludex']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BULEVIRTIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000763', 'EFO_0008496', 'EFO_0007304', 'HP_0001392',
       'EFO_0004197'], dtype=object), 'count': 5}_|_[ENSG00000100652]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for viral disease and has 4 investigational indications."
CHEMBL4442620,"C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc(S(=N)(=O)C3CC3)cc2)ncc1C(F)(F)F_|_UELYDGOOJPRWGF-MFOHZAOFSA-N_|_Small molecule_|_False_|_RONICICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY10-00394' 'BAY1000394' 'Bay 1000394' 'Bay-1000394' 'Roniciclib']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000616', 'EFO_0000702'], dtype=object), 'count': 3}_|_[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4456085,"COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F_|_WNEILUNVMHVMPH-UHFFFAOYSA-N_|_Small molecule_|_False_|_BAY-1217389_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BAY-1217389' 'Bay-1217389']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000112742]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4518483,"N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1_|_HYBAKUMPISVZQP-DEOSSOPVSA-N_|_Small molecule_|_False_|_DANUGLIPRON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Danuglipron' 'PF-06882961' 'Pf-06882961']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANUGLIPRON/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650218']_|_{'rows': array(['MONDO_0005148', 'EFO_0003095', 'EFO_0003095', 'EFO_0001421',
       'EFO_0001073', 'MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 7}_|_[ENSG00000112164]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4650482,"nan_|_nan_|_Antibody_|_False_|_PIMIVALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JTX-4014' 'Jtx 4014' 'Jtx-4014' 'Pimivalimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PIMIVALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4802165,"nan_|_nan_|_Antibody_|_False_|_BEMARITUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bemarituzumab' 'FPA-144' 'FPA144' 'Fpa144']_|_nan_|_nan_|_{'rows': array(['MONDO_0001056', 'EFO_0000616', 'EFO_0003060', 'EFO_0000228',
       'MONDO_0007576'], dtype=object), 'count': 5}_|_[ENSG00000066468]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL521606,"CC(C)(C)NCC(O)COc1cccc2c1CC(O)C(O)C2_|_VWPOSFSPZNDTMJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_NADOLOL_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Corgard' 'Nadolol' 'Solgol']_|_['NSC-758430' 'Nadolol' 'SQ 11725' 'SQ-11725']_|_[('DailyMed', array(['nadolol'], dtype=object)), ('PubChem', array(['56463045'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_1000635', 'EFO_0000612', 'EFO_0003913',
       'EFO_0000319', 'EFO_0004319', 'EFO_0000537', 'EFO_0000712'],
      dtype=object), 'count': 8}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL714,"CC(C)(C)NCC(O)c1ccc(O)c(CO)c1_|_NDAUXUAQIAJITI-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALBUTEROL_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Aerolin' 'Aerolin 400' 'Aerolin auto' 'Airomir' 'Airsalb' 'Albuterol'
 'Asmasal clickhaler' 'Asmasal spacehaler' 'Asmaven' 'Asmavent'
 'Cobutolin' 'Combivent' 'Combivent udvs' 'Ipramol steri-neb' 'Kentamol'
 'Libetist' 'Maxivent' 'Proair Hfa' 'Proventil' 'Proventil Hfa' 'Rimasal'
 'Salamol e-breathe' 'Salapin' 'Salbulin novolizer' 'Salbuvent'
 'Salipraneb' 'Steri-neb salamol' 'Ventmax sr' 'Ventodisks' 'Ventolin'
 'Ventolin Hfa' 'Ventolin cr' 'Ventolin e-breathe' 'Volmax']_|_['Accuneb' 'Albuterol' 'Combivent' 'Duoneb' 'Etinoline' 'NSC-757417'
 'PROVENTIL-HFA' 'SCH 13949W' 'SCH-13949W' 'Salbutamol' 'Salbutamolum'
 'Ventoline' 'Volmax']_|_[('DailyMed', array(['albuterol'], dtype=object)), ('PubChem', array(['104171238', '144203817', '170465034', '50104505', '90340718',
       '90341530'], dtype=object)), ('Wikipedia', array(['Salbutamol'], dtype=object)), ('drugbank', array(['DB01001'], dtype=object)), ('chEBI', array(['2549'], dtype=object))]_|_['CHEMBL1437301' 'CHEMBL1201026' 'CHEMBL1441059']_|_{'rows': array(['EFO_1001919', 'EFO_0010581', 'EFO_0003818', 'MONDO_0005149',
       'MONDO_0004979', 'EFO_0001072', 'EFO_0008590', 'MONDO_0004979',
       'HP_0006536', 'MONDO_0002009', 'EFO_0003818', 'Orphanet_1764',
       'Orphanet_590', 'EFO_0000319', 'MONDO_0100130', 'EFO_0001361',
       'MONDO_0017147', 'HP_0011950', 'MONDO_0016575', 'EFO_0009686',
       'MONDO_0011705', 'EFO_0000373', 'HP_0012735', 'EFO_0008590',
       'MONDO_0004976', 'MONDO_0005271', 'Orphanet_365', 'EFO_0000400',
       'EFO_1001134', 'EFO_0009840', 'EFO_0003956', 'EFO_0000341',
       'EFO_0000768', 'EFO_0000341', 'HP_0002027'], dtype=object), 'count': 35}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 30 investigational indications. This drug has a black box warning from the FDA."
CHEMBL72,"CNCCCN1c2ccccc2CCc2ccccc21_|_HCYAFALTSJYZDH-UHFFFAOYSA-N_|_Small molecule_|_True_|_DESIPRAMINE_|_1964.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Desipramine' 'Imipramine, demethyl-' 'Monodemethylimipramine'
 'N-desmethylimipramine' 'Norimipramine']_|_[('PubChem', array(['11111066', '11111067', '174316136', '50100220', '50104283',
       '90341801'], dtype=object)), ('Wikipedia', array(['Desipramine'], dtype=object)), ('drugbank', array(['DB01151'], dtype=object)), ('chEBI', array(['47781'], dtype=object))]_|_['CHEMBL227644' 'CHEMBL1696']_|_{'rows': array(['MONDO_0002009', 'MONDO_0002009', 'EFO_0004234', 'EFO_0003918',
       'EFO_0002610', 'EFO_0001358', 'MONDO_0002050', 'MONDO_0007079',
       'HP_0011868', 'EFO_0000702', 'MONDO_0004992', 'MONDO_0010726',
       'MONDO_0002009', 'EFO_0003948', 'HP_0003418', 'MONDO_0002050'],
      dtype=object), 'count': 16}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and depressive disorder and has 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1004,"CN(C)CCOC(C)(c1ccccc1)c1ccccn1_|_HCFDWZZGGLSKEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXYLAMINE_|_1948.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Decapryn' 'Doxy-Sleep-Aid' 'Doxylamine' 'Unisom']_|_[('PubChem', array(['90340822'], dtype=object)), ('Wikipedia', array(['Doxylamine'], dtype=object)), ('drugbank', array(['DB00366'], dtype=object)), ('chEBI', array(['51380'], dtype=object))]_|_['CHEMBL1200392']_|_{'rows': array(['MONDO_0005271', 'EFO_0005854', 'HP_0002017', 'EFO_0000544'],
      dtype=object), 'count': 4}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for allergic disease and has 3 investigational indications."
CHEMBL1118,"CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1_|_KYYIDSXMWOZKMP-UHFFFAOYSA-N_|_Small molecule_|_True_|_DESVENLAFAXINE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Desvenlafaxine' 'Khedezla' 'Pristiq']_|_['D-veniz' 'Desvenlafaxine' 'Mdd-xr' 'Newven' 'O-desmethylvenlafaxine'
 'ODV']_|_[('DailyMed', array(['desvenlafaxine'], dtype=object)), ('Wikipedia', array(['Desvenlafaxine'], dtype=object)), ('drugbank', array(['DB06700'], dtype=object)), ('chEBI', array(['83527'], dtype=object))]_|_['CHEMBL3989861' 'CHEMBL1201728']_|_{'rows': array(['MONDO_0002009', 'EFO_0005687', 'MONDO_0002009', 'HP_0031217',
       'EFO_0004220', 'MONDO_0002009', 'MONDO_0002009', 'GO_0042697',
       'MONDO_0002050', 'EFO_1000783', 'EFO_0005687', 'MONDO_0002050',
       'MONDO_0002009'], dtype=object), 'count': 13}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for major depressive disorder and depressive disorder and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL12,"CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21_|_AAOVKJBEBIDNHE-UHFFFAOYSA-N_|_Small molecule_|_True_|_DIAZEPAM_|_1963.0_|_4.0_|_nan_|_False_|_True_|_['Alupram 10' 'Alupram 2' 'Alupram 5' 'Apozepam' 'Atensine' 'Dialar'
 'Dialar fte' 'Diastat' 'Diastat acudial' 'Diazepam' 'Diazepam intensol'
 'Dizac' 'E-Pam' 'Paxel' 'Q-pam' 'Relanium' 'Scriptopam' 'Serenack'
 'Solis' 'Stesolid' 'Tensium' 'Tranimul' 'Valclair' 'Valium' 'Valrelease'
 'Valtoco' 'Vivol']_|_['Ansiolisina' 'Centrazepam' 'Diacepin' 'Diazepam' 'Diazepam civ' 'LA III'
 'LA-III' 'NRL-1' 'NSC-169897' 'NSC-77518' 'Nrl-1' 'RO 5-2807' 'RO-5-2807'
 'RO-52807' 'Servizepam' 'Tranquase' 'WY-3467']_|_[('DailyMed', array(['diazepam'], dtype=object)), ('PubChem', array(['124893574', '144206622', '144209656', '170464626'], dtype=object)), ('TG-GATEs', array(['23'], dtype=object)), ('Wikipedia', array(['Diazepam'], dtype=object)), ('drugbank', array(['DB00829'], dtype=object)), ('chEBI', array(['49575'], dtype=object))]_|_['CHEMBL543191']_|_{'rows': array(['HP_0001250', 'HP_0003419', 'EFO_0005230', 'EFO_0000474',
       'EFO_0008526', 'MONDO_0002050', 'EFO_0003843', 'MONDO_0005090',
       'EFO_0006788', 'EFO_0000546', 'EFO_1001250', 'EFO_1000632',
       'HP_0000713', 'HP_0000726', 'EFO_0007498', 'EFO_1001010',
       'EFO_1000877'], dtype=object), 'count': 17}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200707,CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O.Cl_|_KZLNXGBVFTWMPS-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZQUINAMIDE HYDROCHLORIDE_|_1974.0_|_4.0_|_CHEMBL1201250_|_False_|_True_|_['Emete-con']_|_['Benzquinamide hcl']_|_nan_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974.
CHEMBL1200790,"CCC1(CC)C(=O)NCC(C)C1=O_|_SIDLZWOQUZRBRU-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHYPRYLON_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Noludar']_|_['Methyprylon' 'NSC-30442']_|_[('Wikipedia', array(['Methyprylon'], dtype=object)), ('drugbank', array(['DB01107'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200908,"CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_BDSYKGHYMJNPAB-LICBFIPMSA-N_|_Small molecule_|_False_|_HALOBETASOL PROPIONATE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_['Bryhali' 'Halobetasol propionate' 'Lexette' 'Ultravate']_|_['21-chloro diflorasone' 'BMY-30056' 'CGP-14,458' 'CGP-14458'
 'Halobetasol' 'Halobetasol propionate' 'IDP-122' 'Jemdel' 'Ulobetasol'
 'Ulobetasol propionate']_|_[('DailyMed', array(['halobetasol%20propionate'], dtype=object)), ('PubChem', array(['144206008'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000701', 'EFO_0000274', 'EFO_1001494', 'EFO_0000676'],
      dtype=object), 'count': 4}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved and 1 investigational indication."
CHEMBL1201237,"CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O_|_IXHBTMCLRNMKHZ-LBPRGKRZSA-N_|_Small molecule_|_False_|_LEVOBUNOLOL_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bunolol, (-)-' 'Bunolol, (s)-' 'Levobunolol']_|_[('PubChem', array(['11112712', '11112713'], dtype=object)), ('Wikipedia', array(['Levobunolol'], dtype=object)), ('drugbank', array(['DB01210'], dtype=object)), ('chEBI', array(['6438'], dtype=object))]_|_['CHEMBL1201177']_|_{'rows': array(['MONDO_0005041', 'MONDO_0005041'], dtype=object), 'count': 2}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for glaucoma."
CHEMBL1315867,"CC(C)(C)NCC(O)c1cc(O)cc(O)c1.CC(C)(C)NCC(O)c1cc(O)cc(O)c1.O=S(=O)(O)O_|_KFVSLSTULZVNPG-UHFFFAOYSA-N_|_Small molecule_|_True_|_TERBUTALINE SULFATE_|_1974.0_|_4.0_|_CHEMBL1760_|_False_|_True_|_['Brethaire' 'Brethine' 'Bricanyl' 'Bricanyl sa' 'Monovent' 'Monovent sa'
 'Terbasmin' 'Terbutaline sulfate']_|_['KWD 2019' 'KWD-2019' 'NSC-757336' 'Terbutaline sulfate'
 'Terbutaline sulphate']_|_[('DailyMed', array(['terbutaline%20sulfate'], dtype=object)), ('PubChem', array(['144204153', '170464990', '50107039'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0009661'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for asthma and bronchitis and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL175,"CC(C)Cc1ccc([C@H](C)C(=O)O)cc1_|_HEFNNWSXXWATRW-JTQLQIEISA-N_|_Small molecule_|_False_|_DEXIBUPROFEN_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Seractil']_|_['(s)-ibuprofen' 'Dexibuprofen' 'IBU-TAB' 'NSC-759814' 'Neoprofen' 'Rufen'
 'S-ibuprofen']_|_[('PubChem', array(['11111293', '11111294', '11112775', '144206692', '47193724',
       '50100253', '50106464', '85231335', '90340840'], dtype=object)), ('Wikipedia', array(['Dexibuprofen'], dtype=object)), ('drugbank', array(['DB09213'], dtype=object)), ('chEBI', array(['43415'], dtype=object))]_|_['CHEMBL1778537']_|_{'rows': array(['EFO_0005755', 'HP_0001945', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for rheumatic disease and has 2 investigational indications."
CHEMBL1779710,"CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F_|_LCDDAGSJHKEABN-MLGOLLRUSA-N_|_Small molecule_|_False_|_EVOGLIPTIN_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['DA-1229' 'DA1229' 'Da-1229' 'Evogliptin']_|_[('drugbank', array(['DB12625'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'MONDO_0005148', 'HP_0001410', 'EFO_0003086',
       'EFO_0009531'], dtype=object), 'count': 5}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 investigational indications."
CHEMBL1800955,"COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1_|_RFUBTTPMWSKEIW-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMECAMTIV MECARBIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CK-1827452' 'Omecamtiv mecarbil']_|_[('PubChem', array(['174007336'], dtype=object)), ('drugbank', array(['DB11816'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144'], dtype=object), 'count': 1}_|_[ENSG00000092054,ENSG00000197616,ENSG00000078814,ENSG00000160808,ENSG00000111245,ENSG00000106631,ENSG00000198336]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2107354,"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC.O.[Na+]_|_SARBMGXGWXCXFW-GJHVZSAVSA-M_|_Small molecule_|_False_|_MIFAMURTIDE_|_2009.0_|_4.0_|_CHEMBL2111100_|_False_|_True_|_['Mepact']_|_['L-MTP-PE' 'Mifamurtide' 'Mifamurtide sodium hydrate'
 'Mifamurtide sodium salt monohydrate' 'Sodium mifamurtide']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mepact'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002629', 'EFO_0000637', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000167207]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications."
CHEMBL2109365,nan_|_nan_|_Antibody_|_False_|_HUPAM4_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HUPAM4']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109593,"nan_|_nan_|_Antibody_|_False_|_FGI-101-1A6_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['FGI-101-1A6' 'Fgi-101-1a6']_|_nan_|_nan_|_{'rows': array(['EFO_0007328'], dtype=object), 'count': 1}_|_[ENSG00000074319]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL276711,"Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1_|_WUWDLXZGHZSWQZ-WQLSENKSSA-N_|_Small molecule_|_False_|_SEMAXANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['NSC-696819' 'SU-5416' 'SU005416' 'SU5416' 'Semaxanib' 'Semaxinib'
 'Su-5416']_|_[('PubChem', array(['124891688', '49674962', '50107014', '50107016', '525180',
       '56322916', '90341564'], dtype=object)), ('Wikipedia', array(['Semaxanib'], dtype=object)), ('drugbank', array(['DB06436'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000158', 'EFO_1000657', 'EFO_1001951', 'MONDO_0002974',
       'EFO_0001378', 'EFO_0000588', 'EFO_0000616', 'EFO_0006859',
       'MONDO_0007254', 'MONDO_0021063', 'EFO_0000389', 'EFO_0000681',
       'MONDO_0002367', 'EFO_0000756', 'EFO_0000365', 'EFO_0000691',
       'MONDO_0008315'], dtype=object), 'count': 17}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157404]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL3716365,"O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2_|_IRBAWVGZNJIROV-SFHVURJKSA-N_|_Small molecule_|_False_|_GLPG-1205_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Glpg-1205' 'Glpg1205']_|_[('drugbank', array(['DB15346'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000768'], dtype=object), 'count': 2}_|_[ENSG00000139572]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3833393,"nan_|_nan_|_Antibody_|_True_|_EMICIZUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Hemlibra']_|_['ACE-910' 'ACE910' 'Emicizumab' 'Emicizumab kxwh' 'Emicizumab-kxwh']_|_[('DailyMed', array(['emicizumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra'],
      dtype=object))]_|_nan_|_{'rows': array(['MP_0001914', 'MONDO_0010602'], dtype=object), 'count': 2}_|_[ENSG00000101981,ENSG00000126218]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for hemorrhage and hemophilia a. This drug has a black box warning from the FDA."
CHEMBL4091801,"CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2_|_YJCZPJQGFSSFOL-MNZPCBJKSA-N_|_Small molecule_|_False_|_APG115_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apg115']_|_nan_|_nan_|_{'rows': array(['EFO_0000569', 'EFO_1001779', 'MONDO_0004669', 'EFO_0004289',
       'EFO_0000574', 'EFO_0000621', 'EFO_0000222', 'EFO_0000198'],
      dtype=object), 'count': 8}_|_[ENSG00000141510,ENSG00000135679]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL4297538,"CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](CN2CCc3ncc(C(F)(F)F)cc3C2)(C(C)C)C1_|_UNVWTBOGMHPKJM-CWKRKGSWSA-N_|_Small molecule_|_False_|_MK-0812_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-0812' 'Mk0812']_|_[('drugbank', array(['DB11990'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594402,"CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(OCCOc5ccc6c7c5O[C@H]5[C@@]8(OC)CC[C@@]9(C[C@@H]8[C@](C)(O)C(C)(C)C)[C@@H](C6)N(CC6CC6)CC[C@]759)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5_|_LEQOVFCHMOTJKU-WJVXOHEGSA-N_|_Small molecule_|_False_|_ORP-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Buprenorphine dimer' 'Orp-101']_|_nan_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594579,"nan_|_nan_|_Antibody_|_False_|_FELZARTAMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Felzartamab' 'MOR-03087' 'MOR-202' 'MOR03087' 'Mor03087' 'Mor202'
 'TJ-202' 'TJ202']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'MONDO_0002462', 'MONDO_0007915', 'EFO_0004194',
       'EFO_0003086', 'EFO_0004254'], dtype=object), 'count': 6}_|_[ENSG00000004468]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL5314397,"Cc1ccc(C(=O)NC2CC2)cc1-n1ncc(C(=O)c2cccc(C#N)c2)c1N_|_VGUSQKZDZHAAEE-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACUMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Acumapimod' 'Bct-197']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL566757,"O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1_|_KPBNHDGDUADAGP-VAWYXSNFSA-N_|_Small molecule_|_False_|_DAPORINAD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APO 866' 'APO-866' 'APO866' 'Daporinad' 'FK 866' 'FK-866' 'FK866'
 'K 22.175']_|_[('drugbank', array(['DB12731'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000095', 'EFO_0002913'], dtype=object), 'count': 3}_|_[ENSG00000105835]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL589,"CCCN(CCC)CCc1cccc2c1CC(=O)N2_|_UHSKFQJFRQCDBE-UHFFFAOYSA-N_|_Small molecule_|_True_|_ROPINIROLE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Requip']_|_['NSC-758917' 'Requip' 'Ropinirole' 'SK&F 101468']_|_[('PubChem', array(['104171231', '11111741', '144203807', '170465139', '26750081',
       '90341563'], dtype=object)), ('Wikipedia', array(['Ropinirole'], dtype=object)), ('drugbank', array(['DB00268'], dtype=object)), ('chEBI', array(['8888'], dtype=object))]_|_['CHEMBL1200411']_|_{'rows': array(['EFO_0007319', 'MONDO_0005180', 'EFO_0005687', 'EFO_0002610',
       'MONDO_0009698', 'EFO_0000712', 'MONDO_0005180', 'EFO_0004270',
       'EFO_0004270'], dtype=object), 'count': 9}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL607,"CCOC(=O)C1(c2ccccc2)CCN(C)CC1_|_XADCESSVHJOZHK-UHFFFAOYSA-N_|_Small molecule_|_True_|_MEPERIDINE_|_1942.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['IDS-NP-001' 'Isonipecaine' 'Meperidine' 'Meperidol' 'Pethanol'
 'Pethidine' 'Pethidine dbl' 'Pethidineter' 'Renaudin']_|_[('Wikipedia', array(['Pethidine'], dtype=object)), ('drugbank', array(['DB00454'], dtype=object)), ('chEBI', array(['6754'], dtype=object))]_|_['CHEMBL429713' 'CHEMBL1701']_|_{'rows': array(['EFO_0004273', 'HP_0011868', 'EFO_0003843', 'EFO_0003843',
       'EFO_0003890', 'EFO_0005251', 'HP_0002140'], dtype=object), 'count': 7}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and is indicated for pain and drug dependence and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL887,"C#CCN[C@@H]1CCc2ccccc21_|_RUOKEQAAGRXIBM-GFCCVEGCSA-N_|_Small molecule_|_False_|_RASAGILINE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AGN-1135' 'Azilect' 'NSC-759639' 'Rasagiline' 'TV-1030']_|_[('Wikipedia', array(['Rasagiline'], dtype=object)), ('drugbank', array(['DB01367'], dtype=object)), ('chEBI', array(['63620'], dtype=object))]_|_['CHEMBL5315052' 'CHEMBL1201142']_|_{'rows': array(['MONDO_0019037', 'EFO_1001050', 'MONDO_0005180', 'EFO_0004270',
       'MONDO_0005180', 'MONDO_0005180', 'MONDO_0004976', 'MONDO_0004975'],
      dtype=object), 'count': 8}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for parkinson disease and has 5 investigational indications."
CHEMBL101253,"Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1_|_YCOYDOIWSSHVCK-UHFFFAOYSA-N_|_Small molecule_|_False_|_VATALANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BAY-86-5127' 'CGP-79787' 'K-222584' 'NVP-PTK787' 'PTK-787' 'PTK787'
 'Ptk-787' 'Vatalanib' 'Vatalanib succinate' 'ZK-222584' 'ZK222584']_|_[('PubChem', array(['103905548', '104171421', '144206361', '170466113', '50100112'],
      dtype=object)), ('Wikipedia', array(['Vatalanib'], dtype=object)), ('drugbank', array(['DB04879'], dtype=object)), ('chEBI', array(['90620'], dtype=object))]_|_['CHEMBL75232' 'CHEMBL2142861']_|_{'rows': array(['MONDO_0008667', 'EFO_0002618', 'MONDO_0002087', 'EFO_1000158',
       'EFO_0001378', 'EFO_0000588', 'EFO_1000657', 'MONDO_0002367',
       'MONDO_0011962', 'EFO_0002430', 'EFO_0004288', 'EFO_0000691',
       'EFO_0000519', 'EFO_0000339', 'EFO_0000222', 'MONDO_0002974',
       'EFO_0000403', 'EFO_0000389', 'EFO_0000756', 'MONDO_0007254',
       'MONDO_0008170', 'EFO_0009708', 'EFO_0003869', 'EFO_0000616',
       'MONDO_0008315', 'EFO_0003060', 'MONDO_0002158', 'EFO_0001365',
       'EFO_1001901', 'MONDO_0004992'], dtype=object), 'count': 30}_|_[ENSG00000157404,ENSG00000113721,ENSG00000134853,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications."
CHEMBL1101,"OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2_|_YSXKPIUOCJLQIE-UHFFFAOYSA-N_|_Small molecule_|_False_|_BIPERIDEN_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Akineton' 'Akineton-' 'Biperiden' 'Biperidenum' 'KL 373' 'NSC-759145']_|_[('PubChem', array(['124894170', '174006780', '90341640'], dtype=object)), ('Wikipedia', array(['Biperiden'], dtype=object)), ('drugbank', array(['DB00810'], dtype=object)), ('chEBI', array(['3112'], dtype=object))]_|_['CHEMBL1201035' 'CHEMBL1201067']_|_{'rows': array(['MONDO_0005180', 'EFO_0005230', 'EFO_0002610', 'HP_0000726',
       'MONDO_0043510', 'MONDO_0002050', 'MONDO_0005090'], dtype=object), 'count': 7}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for parkinson disease and has 6 investigational indications."
CHEMBL113051,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2/C=N/OC(C)(C)C_|_UIVFUQKYVFCEKJ-OPTOVBNMSA-N_|_Small molecule_|_False_|_GIMATECAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gimatecan']_|_[('PubChem', array(['170465615'], dtype=object)), ('drugbank', array(['DB06721'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_1000158', 'EFO_0000198', 'EFO_0002618',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1181829,"CN(c1ccc(Cl)cc1)c1cc[n+](Cc2ccc(-c3ccc(C[n+]4ccc(N(C)c5ccc(Cl)cc5)c5ccccc54)cc3)cc2)c2ccccc12_|_QGYGTMZEJNOHNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_RSM-932A CATION_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL192986']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000110721]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1200475,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_VNTHYLVDGVBPOU-QQYBVWGSSA-N_|_Small molecule_|_True_|_DAUNORUBICIN CITRATE_|_1996.0_|_4.0_|_CHEMBL178_|_False_|_True_|_['Daunoxome']_|_['Daunorubicin citrate' 'Daunorubicin citrate liposome'
 'Daunorubicin liposomal']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000691', 'EFO_0000565'], dtype=object), 'count': 3}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200560,"CC(=O)O.N=C(N)N/N=C/c1c(Cl)cccc1Cl_|_MCSPBPXATWBACD-GAYQJXMFSA-N_|_Small molecule_|_False_|_GUANABENZ ACETATE_|_1982.0_|_4.0_|_CHEMBL420_|_False_|_True_|_['Guanabenz acetate' 'Wytensin']_|_['Guanabenz acetate' 'Guanabenz monoacetate' 'NSC-757044' 'WY-8678'
 'WY-8678 ACETATE']_|_[('PubChem', array(['50106405'], dtype=object))]_|_nan_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1237,"NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O_|_RLAWWYSOJDYHDC-BZSNNMDCSA-N_|_Small molecule_|_True_|_LISINOPRIL ANHYDROUS_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Lisinopril anhydrous']_|_[('PubChem', array(['50085996'], dtype=object)), ('Wikipedia', array(['Lisinopril'], dtype=object)), ('drugbank', array(['DB00722'], dtype=object)), ('chEBI', array(['43755'], dtype=object))]_|_['CHEMBL419213' 'CHEMBL1729579']_|_{'rows': array(['EFO_0003144', 'EFO_0000319', 'EFO_0000279', 'EFO_0003896',
       'HP_0003124', 'EFO_0004264', 'EFO_0000537', 'EFO_0000400',
       'EFO_1000948', 'EFO_0000373', 'MONDO_0007915', 'EFO_0000612',
       'MONDO_0002474', 'EFO_0004236', 'EFO_0000712', 'MONDO_0001134',
       'EFO_0000537', 'EFO_0000612', 'MONDO_0002462', 'Orphanet_79292',
       'EFO_0000712', 'EFO_0000401', 'EFO_0000400', 'EFO_0008620',
       'EFO_0000318', 'MONDO_0007254', 'EFO_0000319', 'EFO_0000182',
       'EFO_0001645', 'EFO_0003914', 'EFO_1001375', 'EFO_1001249',
       'MONDO_0005148', 'EFO_0000373', 'EFO_0003144'], dtype=object), 'count': 35}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 7 approved and 28 investigational indications. This drug has a black box warning from the FDA."
CHEMBL12610,"CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12_|_CNBGNNVCVSKAQZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZYDAMINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Apo-benzydamine' 'Benzindamine' 'Benzydamine']_|_[('PubChem', array(['11112291', '160657813'], dtype=object)), ('Wikipedia', array(['Benzydamine'], dtype=object)), ('drugbank', array(['DB09084'], dtype=object))]_|_['CHEMBL1528134']_|_{'rows': array(['EFO_1001904', 'HP_0003326', 'EFO_0009688', 'EFO_1001904',
       'EFO_0005755', 'HP_0002829', 'EFO_0005757'], dtype=object), 'count': 7}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 2 investigational indications."
CHEMBL141305,"CC(=O)Oc1ccc(C(=C2CCCCC2)c2ccc(OC(C)=O)cc2)cc1_|_GVOUFPWUYJWQSK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLOFENIL_|_nan_|_4.0_|_nan_|_True_|_True_|_['Neoclym' 'Rehibin']_|_['Cyclofenil' 'F 6066' 'F-6066' 'ICI 48213' 'ICI-48213' 'NSC-86464'
 'Sexovid']_|_[('PubChem', array(['144205812', '170465970', '29217524'], dtype=object)), ('drugbank', array(['DB13472'], dtype=object))]_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1529,"Cl.OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1_|_AVZIYZHXZAYGJS-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENIDOL HYDROCHLORIDE_|_1967.0_|_4.0_|_CHEMBL936_|_False_|_True_|_['Vontrol']_|_['Cephadol' 'Diphenidol hcl' 'Diphenidol hydrochloride' 'NSC-23012'
 'SK&F 478-A' 'SK-478-A']_|_[('PubChem', array(['11533019', '85273789'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967."
CHEMBL1738697,"CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12_|_LGXVKMDGSIWEHL-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-00337210_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pf-00337210' 'Pf-337210']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1743043,"nan_|_nan_|_Antibody drug conjugate_|_True_|_MOXETUMOMAB PASUDOTOX_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Lumoxiti']_|_['CAT-8015' 'HA-22' 'HA22' 'Moxetumomab pasudotox'
 'Moxetumomab pasudotox tdfk']_|_[('DailyMed', array(['moxetumomab%20pasudotox-tdfk'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lumoxiti'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565', 'EFO_0000574', 'MONDO_0000870', 'EFO_0000616',
       'EFO_1000956', 'EFO_0005952', 'EFO_0000220', 'EFO_0000095'],
      dtype=object), 'count': 8}_|_[ENSG00000167658,ENSG00000012124]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for neoplasm and hairy cell leukemia and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103761,"COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@H]2CCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1_|_VXMOONUMYLCFJD-DHLKQENFSA-N_|_Small molecule_|_False_|_BARNIDIPINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Barnidipine' 'Barnidipine hydrochloride' 'Mepirodipine' 'Vasexten']_|_[('drugbank', array(['DB09227'], dtype=object))]_|_['CHEMBL2356712']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108667,"nan_|_nan_|_Antibody drug conjugate_|_True_|_YTTRIUM Y 90 IBRITUMOMAB TIUXETAN_|_2002.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(90)y-ibritumomab tiuxetan' '90y ibritumomab tiuxetan' '90y-ibritumomab'
 'Ibritumomab tiuxetan y-90' 'Ibritumomab tiuxetan yttrium y-90'
 'Yttrium y 90 ibritumomab tiuxetan' 'Yttrium y-90 ibritumomab tiuxetan']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0000183', 'EFO_0001378', 'EFO_0003032',
       'EFO_0000191', 'EFO_1001365', 'EFO_0009441', 'EFO_0000565',
       'EFO_0000403', 'EFO_0000309', 'EFO_1001469', 'MONDO_0000873',
       'EFO_0000574', 'EFO_0000095', 'EFO_0005952', 'EFO_0000096',
       'MONDO_0018906'], dtype=object), 'count': 17}_|_[ENSG00000156738]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109265,"nan_|_nan_|_Antibody_|_False_|_MOC31-PE_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MOC31-PE' 'Moc31-pe']_|_nan_|_nan_|_{'rows': array(['EFO_0000313'], dtype=object), 'count': 1}_|_[ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109401,"nan_|_nan_|_Antibody_|_False_|_AV-203_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AV-203' 'AV203' 'Av 203' 'Av-203' 'CAN-017']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109592,"nan_|_nan_|_Antibody_|_False_|_MEDI-500_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MEDI-500' 'Medi-500' 'T10B9']_|_nan_|_nan_|_nan_|_[ENSG00000211810,ENSG00000277734,ENSG00000278030,ENSG00000211699]_|_Antibody drug with a maximum clinical trial phase of III."
CHEMBL2143592,"Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl_|_PDYXPCKITKHFOZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-794833_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Bms-794833']_|_[('PubChem', array(['137276020'], dtype=object))]_|_nan_|_nan_|_[ENSG00000105976,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL230011,"Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1_|_UJIAQDJKSXQLIT-UHFFFAOYSA-N_|_Small molecule_|_False_|_TG100-115_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TG100-115' 'Tg100-115']_|_[('drugbank', array(['DB05552'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612'], dtype=object), 'count': 1}_|_[ENSG00000171608,ENSG00000105851]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL25336,"C(=N/NC1=NCCN1)\c1c2ccccc2c(/C=N/NC2=NCCN2)c2ccccc12_|_NJSMWLQOCQIOPE-OCHFTUDZSA-N_|_Small molecule_|_False_|_BISANTRENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bisantrene' 'NSC-337766']_|_nan_|_['CHEMBL3989424']_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000140718]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3137301,"CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O_|_PYNXFZCZUAOOQC-UTKZUKDTSA-N_|_Small molecule_|_False_|_SACUBITRIL_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AHU-377' 'AHU377' 'Sacubitril']_|_[('DailyMed', array(['sacubitril'], dtype=object)), ('drugbank', array(['DB09292'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'EFO_0007148', 'EFO_0000612', 'EFO_0008583',
       'MONDO_0001134', 'EFO_0004265', 'MONDO_0005149', 'EFO_0000538',
       'EFO_0000537', 'MONDO_0100096', 'EFO_0000373', 'EFO_0008585',
       'EFO_0005529'], dtype=object), 'count': 13}_|_[ENSG00000196549]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for heart failure and congestive heart failure and has 11 investigational indications."
CHEMBL3545408,O=C1c2ccccc2C(=O)N1[C@@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)C1O5_|_DHAITNWJDOSRBU-RCSSWNHXSA-N_|_Small molecule_|_False_|_NALTALIMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Naltalimide' 'TAK-363' 'TAK363' 'Trk-130']_|_nan_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3989920,"O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Na+]_|_NBDQGOCGYHMDSJ-NRFPMOEYSA-M_|_Small molecule_|_False_|_PITAVASTATIN SODIUM_|_2017.0_|_4.0_|_CHEMBL1201753_|_False_|_True_|_['Nikita']_|_[]_|_nan_|_nan_|_{'rows': array(['HP_0003119', 'MONDO_0021187'], dtype=object), 'count': 2}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for abnormal circulating lipid concentration and hyperlipidemia."
CHEMBL3989969,"C[C@@H](O)C(=N)NS(=O)(=O)c1cc(C(=O)C(C(=O)c2cc(F)ccc2F)=C2Nc3ccccc3N2)ccc1F_|_CWNLBPBIFALUQD-GFCCVEGCSA-N_|_Small molecule_|_False_|_OPIGOLIX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASP-1707' 'ASP1707' 'Opigolix' 'Opigolixum']_|_nan_|_nan_|_{'rows': array(['EFO_0001065', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL415606,"CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O_|_MEUCPCLKGZSHTA-XYAYPHGZSA-N_|_Protein_|_False_|_DEGARELIX_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Firmagon']_|_['Degarelix' 'FE200486 (AS ACETATE SALT)']_|_[('drugbank', array(['DB06699'], dtype=object))]_|_['CHEMBL2028987']_|_{'rows': array(['MONDO_0008315', 'EFO_0006861', 'MONDO_0021259', 'MONDO_0008315',
       'EFO_0001663', 'EFO_0000196', 'MONDO_0008315', 'EFO_0000228',
       'EFO_0000673', 'EFO_0000284', 'EFO_0001065', 'MONDO_0100096',
       'EFO_0008528', 'EFO_0001663', 'EFO_0000616', 'EFO_0000673',
       'MONDO_0007254', 'EFO_0000545'], dtype=object), 'count': 18}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 15 investigational indications."
CHEMBL4297258,"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C_|_GHKOONMJXNWOIW-UHFFFAOYSA-N_|_Small molecule_|_False_|_FIRMONERTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AST-2818' 'AST2818' 'Alflutinib' 'Firmonertinib' 'Furmonertinib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0008903', 'EFO_0000571', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297891,"nan_|_nan_|_Antibody_|_False_|_CUSATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Argx-110' 'Cusatuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000198', 'MONDO_0004992', 'EFO_0000222'],
      dtype=object), 'count': 4}_|_[ENSG00000125726]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL441,"CCCC(C)C1(CC)C(=O)NC(=S)NC1=O_|_IUJDSEJGGMCXSG-UHFFFAOYSA-N_|_Small molecule_|_False_|_THIOPENTAL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Thiopental' 'Thiopental ciii']_|_[('PubChem', array(['29215503'], dtype=object)), ('drugbank', array(['DB00599'], dtype=object)), ('chEBI', array(['102166'], dtype=object))]_|_['CHEMBL738']_|_{'rows': array(['EFO_0006834', 'EFO_0008526', 'HP_0000486', 'EFO_1001454',
       'MONDO_0043510'], dtype=object), 'count': 5}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 5 investigational indications."
CHEMBL4457723,"CC(C)N(C)[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NS(C)(=O)=O)C1_|_PJTGSIKANITYOO-RCOXNQKVSA-N_|_Small molecule_|_False_|_BMS-741672_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS 741672' 'Bms-741672' 'Bms741672']_|_nan_|_nan_|_{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}_|_[ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL452,"O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1_|_DGBIGWXXNGSACT-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLONAZEPAM_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Clonazepam' 'Klonopin' 'Klonopin rapidly disintegrating' 'Rivotril']_|_['Clonazepam' 'Clonazepam civ' 'NSC-179913' 'RO 5-4023' 'RO-5-4023'
 'RO-54023' 'Ravotril' 'Rivatril']_|_[('DailyMed', array(['clonazepam'], dtype=object)), ('Wikipedia', array(['Clonazepam'], dtype=object)), ('drugbank', array(['DB01068'], dtype=object)), ('chEBI', array(['3756'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474', 'EFO_0003843', 'EFO_0004262', 'HP_0001250',
       'EFO_0005230', 'EFO_0008526', 'EFO_1000850', 'EFO_0007262',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_0007191', 'HP_0000726',
       'EFO_0007462', 'EFO_0005762', 'EFO_1000924'], dtype=object), 'count': 15}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL672,"CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1_|_YMTINGFKWWXKFG-UHFFFAOYSA-N_|_Small molecule_|_False_|_FENOFIBRATE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Antara (micronized)' 'Fenofibrate' 'Fenofibrate (micronized)' 'Fenogal'
 'Fenoglide' 'Lipantil' 'Lipantil micro 200' 'Lipantil micro 267'
 'Lipantil micro 67' 'Lipidil' 'Lipofen' 'Supralip 160' 'Tricor'
 'Tricor (micronized)' 'Triglide']_|_['Fenofibrate' 'Fenofibrate delayed release' 'Fenofibrate micronized'
 'NSC-281319']_|_[('DailyMed', array(['fenofibrate'], dtype=object)), ('PubChem', array(['104171156', '11111181', '11111182', '124880099', '144203698',
       '144210471', '170464718', '174007303', '26746914', '26751450',
       '50103926', '56422492', '85231046', '855565', '90340778'],
      dtype=object)), ('TG-GATEs', array(['79'], dtype=object)), ('Wikipedia', array(['Fenofibrate'], dtype=object)), ('drugbank', array(['DB01039'], dtype=object)), ('chEBI', array(['5001'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'MONDO_0018473', 'EFO_0004268', 'HP_0003124',
       'EFO_1001486', 'MONDO_0007739', 'MONDO_0005148', 'MONDO_0007079',
       'EFO_0000195', 'EFO_0000319', 'MONDO_0021187', 'Orphanet_309005',
       'EFO_1000727', 'Orphanet_79211', 'EFO_0000589', 'EFO_0004211',
       'EFO_0000401', 'EFO_0001645', 'EFO_0000180', 'EFO_0001073',
       'EFO_0003914', 'EFO_0001378', 'MONDO_0037748', 'EFO_1001249',
       'EFO_0003767', 'HP_0003119', 'EFO_0009516', 'EFO_0004705',
       'EFO_0000537', 'EFO_0003770'], dtype=object), 'count': 30}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 24 investigational indications."
CHEMBL797,"CN1C(=O)CC(c2ccccc2)C1=O_|_WLWFNJKHKGIJNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENSUXIMIDE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Milontin']_|_['1-methyl-3-phenylsuccinimide' 'Epimid' 'Lifene' 'Milonton' 'Mirontin'
 'N-methyl-3-phenylpyrrolidinedione' 'NSC-760079' 'PM-334' 'Phensuximid'
 'Phensuximide' 'Racemic phensuximide' 'Succitimal']_|_[('PubChem', array(['144203933', '170465315', '56463169'], dtype=object)), ('Wikipedia', array(['Phensuximide'], dtype=object)), ('drugbank', array(['DB00832'], dtype=object)), ('chEBI', array(['8079'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for epilepsy."
CHEMBL83063,"CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1_|_IOVGROKTTNBUGK-UHFFFAOYSA-N_|_Small molecule_|_False_|_RITODRINE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['DU-21220' 'Ritodrine']_|_[('PubChem', array(['174007152'], dtype=object))]_|_['CHEMBL1367605']_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991."
CHEMBL962,"CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)[O-])O[C@H]2C[C@H]1O.[Na+]_|_LMHIPJMTZHDKEW-XQYLJSSYSA-M_|_Small molecule_|_False_|_EPOPROSTENOL SODIUM_|_1995.0_|_4.0_|_CHEMBL1139_|_False_|_True_|_['Epoprostenol sodium' 'Flolan' 'Veletri']_|_['Epoprostenol sodium' 'Epoprostenolsodium' 'Prostacyclin sodium salt'
 'Sodium prostacyclin' 'U-53,217A' 'U-53217A']_|_[('DailyMed', array(['epoprostenol%20sodium'], dtype=object)), ('PubChem', array(['144205984'], dtype=object)), ('Wikipedia', array(['Prostacyclin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for pulmonary arterial hypertension."
CHEMBL1200467,"O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1_|_ASDOKGIIKXGMNB-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYZINE PAMOATE_|_1959.0_|_4.0_|_CHEMBL896_|_False_|_True_|_['""hy-pam """"25""""""' 'Hy-Pam ""25""' 'Hydroxyzine pamoate' 'Vistaril']_|_['Hydroxyzine embonate' 'Hydroxyzine pamoate' 'NSC-757063']_|_[('DailyMed', array(['hydroxyzine%20pamoate'], dtype=object)), ('PubChem', array(['124886739', '26748082', '855631'], dtype=object)), ('chEBI', array(['31680'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004257', 'HP_0000989', 'EFO_0006788', 'EFO_0005531',
       'EFO_0000701'], dtype=object), 'count': 5}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 5 approved indications."
CHEMBL1201066,"COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1.Cl_|_QYRYFNHXARDNFZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_VENLAFAXINE HYDROCHLORIDE_|_1993.0_|_4.0_|_CHEMBL637_|_False_|_True_|_['Effexor' 'Effexor xr' 'Venlafaxine hydrochloride']_|_['NSC-745751' 'Venlafaxine (as hydrochloride)' 'Venlafaxine hcl'
 'Venlafaxine hydrochloride' 'WY-45,030' 'WY-45030']_|_[('DailyMed', array(['venlafaxine%20hydrochloride'], dtype=object)), ('PubChem', array(['144212825', '49681556'], dtype=object)), ('chEBI', array(['9944'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'MONDO_0002009', 'EFO_0006862', 'MONDO_0004985',
       'EFO_0009854', 'HP_0000726', 'HP_0031217', 'EFO_0005687',
       'MONDO_0004975', 'EFO_0006788', 'EFO_1001892', 'EFO_1001917',
       'EFO_0004242', 'EFO_0004262', 'EFO_0000673', 'MONDO_0007254',
       'MONDO_0005090', 'EFO_0003843', 'EFO_1001919', 'EFO_1002014',
       'MONDO_0002050', 'HP_0030833', 'EFO_0002610', 'EFO_0005230',
       'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'MONDO_0002009'],
      dtype=object), 'count': 28}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL129857,"COc1cccc2nc(-c3cccs3)nc(NN3C(=O)C=C(C)C3=O)c12_|_GZGLPBNOIFLLRE-UHFFFAOYSA-N_|_Small molecule_|_False_|_AS-602868_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['As-602868' 'SPC-839']_|_[('PubChem', array(['137275813', '26755375'], dtype=object))]_|_nan_|_nan_|_[ENSG00000122025,ENSG00000104365]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL1382,"Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1_|_OOGJQPCLVADCPB-HXUWFJFHSA-N_|_Small molecule_|_False_|_TOLTERODINE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Blerone xl' 'Detrusitol' 'Detrusitol xl' 'Efflosomyl xl' 'Inconex xl'
 'Mariosea xl' 'Neditol xl' 'Preblacon xl' 'Santizor xl']_|_['KABI 2234' 'KABI-2234' 'Tolterodine']_|_[('PubChem', array(['144205290', '170465337', '29215497', '49666284'], dtype=object)), ('Wikipedia', array(['Tolterodine'], dtype=object)), ('drugbank', array(['DB01036'], dtype=object)), ('chEBI', array(['9622'], dtype=object))]_|_['CHEMBL1200871' 'CHEMBL1722209']_|_{'rows': array(['EFO_0003843', 'HP_0000103', 'HP_0000020', 'EFO_0004253',
       'EFO_0006865', 'EFO_0005762', 'EFO_1000781', 'HP_0003419',
       'EFO_1000781', 'EFO_0004710'], dtype=object), 'count': 10}_|_[ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 6 investigational indications."
CHEMBL15677,"O=C(O)Cc1ccccc1Oc1ccc(Cl)cc1Cl_|_IDKAXRLETRCXKS-UHFFFAOYSA-N_|_Small molecule_|_False_|_FENCLOFENAC_|_1978.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Fenclofenac' 'R 67408' 'R-67408' 'RX 67408' 'RX-67408']_|_[('PubChem', array(['144206863'], dtype=object)), ('Wikipedia', array(['Fenclofenac'], dtype=object))]_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978. It was withdrawn in at least one region."
CHEMBL1614,"C[C@H]1O[C@@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3C[C@@H](O)[C@]3(C)[C@@H](C5=CC(=O)OC5)CC[C@]43O)C2)C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1_|_OBATZBGFDSVCJD-LALPQLPRSA-N_|_Small molecule_|_False_|_DESLANOSIDE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Cedilanid-d']_|_['Deacetylanatoside c' 'Desacetyl-lanatoside c' 'Deslanoside']_|_[('PubChem', array(['144205224', '170465236'], dtype=object)), ('Wikipedia', array(['Deslanoside'], dtype=object)), ('drugbank', array(['DB01078'], dtype=object)), ('chEBI', array(['31468'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease."
CHEMBL1685,"C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N_|_VTMVHDZWSFQSQP-VBNZEHGJSA-N_|_Small molecule_|_False_|_DEZOCINE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Dalgan']_|_['Dezocine' 'Docozine' 'Dozocine' 'WY-16,225' 'WY-16225']_|_[('Wikipedia', array(['Dezocine'], dtype=object)), ('drugbank', array(['DB01209'], dtype=object)), ('chEBI', array(['4474'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for pain."
CHEMBL1742428,"N#Cc1ccc(N2CCN(C(=O)COc3ccc4[nH]cc(CCN)c4c3)CC2)cc1_|_SOHCKWZVTCTQBG-UHFFFAOYSA-N_|_Small molecule_|_False_|_DONITRIPTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Donitriptan' 'Donitriptan hydrochloride' 'F-11356']_|_nan_|_nan_|_nan_|_[ENSG00000183134,ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1742466,"CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1_|_WMDSZGFJQKSLLH-RBBKRZOGSA-N_|_Small molecule_|_False_|_LANDIOLOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AOP-200704' 'AOP200704' 'LDLL-600' 'LDLL600' 'Landiolol' 'ONO-1101']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LANDIOLOL/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12212'], dtype=object))]_|_['CHEMBL2362410']_|_{'rows': array(['EFO_0004269', 'HP_0004755', 'EFO_0000319', 'EFO_0000275',
       'EFO_0009492', 'EFO_0003911', 'HP_0004755', 'EFO_0006834',
       'EFO_0000275', 'EFO_0003911'], dtype=object), 'count': 10}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL1743060,nan_|_nan_|_Antibody_|_False_|_RADRETUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Radretumab']_|_nan_|_nan_|_nan_|_[ENSG00000115414]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL1743085,"nan_|_nan_|_Antibody_|_False_|_URELUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-663513' 'Urelumab']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0005952', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0000756', 'EFO_0002618', 'EFO_0000096', 'EFO_1001465',
       'EFO_0003060', 'EFO_0000565'], dtype=object), 'count': 10}_|_[ENSG00000049249]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL1829335,"C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1_|_XUKROCVZGZNGSI-CQSZACIVSA-N_|_Small molecule_|_False_|_IRDABISANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CEP-26401' 'CEP26401' 'Cep 26401' 'Irdabisant']_|_[('drugbank', array(['DB12900'], dtype=object))]_|_['CHEMBL1813067']_|_{'rows': array(['HP_0100543'], dtype=object), 'count': 1}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108739,"nan_|_nan_|_Antibody_|_False_|_PLACULUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ART-621' 'ART-621 ( ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY)'
 'ART621' 'CEP-37247' 'PN-0621' 'PN0621' 'Placulumab']_|_nan_|_nan_|_{'rows': array(['HP_0011868', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109150,"nan_|_nan_|_Antibody_|_False_|_LINTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Zamyl']_|_['HUM-195' 'HUM195' 'Huma-195-Gelonin' 'Lintuzumab' 'SGN-33']_|_nan_|_nan_|_{'rows': array(['EFO_1001779', 'EFO_0000565', 'EFO_0000222', 'EFO_0001378',
       'EFO_0000198', 'MONDO_0001475'], dtype=object), 'count': 6}_|_[ENSG00000105383]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2218898,"CC[C@@H](C)[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CCSCC[C@@H](C(=O)N(C)[C@H](CO)CCCN)NC(=O)[C@H](CC(N)=O)NC1=O_|_UGNGRKKDUVKQDF-IHOMMZCZSA-N_|_Protein_|_False_|_BARUSIBAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Barusiban' 'Fe-200440']_|_[('drugbank', array(['DB12292'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000545'], dtype=object), 'count': 1}_|_[ENSG00000180914]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL320775,"Cc1ccc2nc(N)[nH]c(=O)c2c1Sc1ccncc1_|_XHWRWCSCBDLOLM-UHFFFAOYSA-N_|_Small molecule_|_False_|_NOLATREXED_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Nolatrexed']_|_[('PubChem', array(['50125758'], dtype=object)), ('drugbank', array(['DB12912'], dtype=object))]_|_['CHEMBL1983788' 'CHEMBL2356692']_|_{'rows': array(['MONDO_0002691'], dtype=object), 'count': 1}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL334966,"CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O_|_PAEBIVWUMLRPSK-IDTAVKCVSA-N_|_Small molecule_|_False_|_CANGRELOR_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AR-C69931XX' 'Cangrelor']_|_[('DailyMed', array(['cangrelor'], dtype=object)), ('drugbank', array(['DB06441'], dtype=object))]_|_['CHEMBL1097279']_|_{'rows': array(['EFO_0005672', 'HP_0004419', 'HP_0002140', 'EFO_0000556',
       'EFO_0008585', 'EFO_0001645', 'EFO_0000612', 'HP_0004419'],
      dtype=object), 'count': 8}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 6 investigational indications."
CHEMBL3545092,"nan_|_nan_|_Small molecule_|_False_|_CR 1447_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cr 1447']_|_nan_|_nan_|_nan_|_[ENSG00000169083,ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3545420,"CCNCc1cncc(-c2ccc3c(c2)/C(=C2/N=c4cc(F)cc(F)c4=N2)NN3)c1C_|_RBOKLZGCVRXGEP-XTQSDGFTSA-N_|_Small molecule_|_False_|_AG-24322_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AG-024322' 'Ag 024322' 'Ag-24322']_|_nan_|_nan_|_{'rows': array(['EFO_0005952'], dtype=object), 'count': 1}_|_[ENSG00000123374,ENSG00000170312,ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989694,"Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1.O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O_|_ZIMCQJVMPKQQPB-UHFFFAOYSA-N_|_Small molecule_|_True_|_OLANZAPINE PAMOATE_|_2009.0_|_4.0_|_CHEMBL715_|_False_|_True_|_['Zyprexa relprevv']_|_['Olanzapine (as embonate)' 'Olanzapine embonate' 'Olanzapine pamoate'
 'Olanzapine pamoate anhydrous' 'Olanzapine pamoate monohydrate'
 'Zypadhera']_|_[('DailyMed', array(['olanzapine%20pamoate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000147246,ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for schizophrenia. This drug has a black box warning from the FDA."
CHEMBL3990034,"nan_|_nan_|_Gene_|_False_|_FIDANACOGENE ELAPARVOVEC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Aav8 hfix19' 'Fidanacogene elaparvovec' 'PF-06838435'
 'Raav-spark100-hfix-padua' 'SPK 101' 'SPK-1001' 'SPK-9001'
 'SPK-FIX Padua' 'Spark 101']_|_nan_|_nan_|_{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Gene drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4071161,"CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1_|_SEJLPXCPMNSRAM-GOSISDBHSA-N_|_Small molecule_|_False_|_TIRABRUTINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Velexbru']_|_['GS-4059' 'Gs-4059' 'ONO-4059' 'ONO-4059(FREE BASE)' 'Ono-4059'
 'Tirabrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIRABRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15227'], dtype=object))]_|_['CHEMBL5314600']_|_{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_0000685', 'EFO_0000699',
       'EFO_0000095', 'EFO_0005531', 'MONDO_0004992'], dtype=object), 'count': 7}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 6 investigational indications."
CHEMBL4297558,"nan_|_nan_|_Antibody_|_False_|_INOTUZUMAB_|_nan_|_4.0_|_nan_|_False_|_True_|_['Besponsa']_|_['G544' 'Inotuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000220'], dtype=object), 'count': 1}_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of IV and has 1 investigational indication."
CHEMBL4297715,"nan_|_nan_|_Antibody_|_False_|_CAMRELIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Camrelizumab' 'Carilizumab' 'Carrelizumab' 'SHR-1210' 'Shr-1210']_|_nan_|_nan_|_{'rows': array(['EFO_0000637', 'MONDO_0008170', 'EFO_0005537', 'MONDO_0007254',
       'MONDO_0003060', 'MONDO_0021355', 'EFO_0004252', 'EFO_0000519',
       'EFO_1001012', 'MONDO_0001187', 'EFO_0002916', 'MONDO_0021117',
       'EFO_0000365', 'MONDO_0002120', 'EFO_0000708', 'EFO_0000707',
       'MONDO_0001056', 'EFO_1001961', 'MONDO_0009348', 'EFO_1000657',
       'EFO_1001951', 'MONDO_0008903', 'EFO_0000178', 'EFO_1001968',
       'MONDO_0005184', 'EFO_0003868', 'EFO_0005952', 'MONDO_0007576',
       'EFO_0000403', 'EFO_0000199', 'MONDO_0020669', 'EFO_0002618',
       'EFO_0004142', 'EFO_0003060', 'MONDO_0021063', 'MONDO_0005575',
       'EFO_0009637', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0019472',
       'EFO_0002938', 'EFO_0001061', 'EFO_0000182', 'EFO_0005221',
       'EFO_0000349', 'EFO_0001071', 'EFO_0000222', 'EFO_0000702',
       'MONDO_0002108', 'MONDO_0002974', 'MONDO_0011962', 'MONDO_0018944',
       'EFO_0000616', 'EFO_0000181', 'EFO_0000574', 'EFO_0003897',
       'EFO_0000211', 'EFO_0000294', 'EFO_1000796', 'EFO_0000503',
       'EFO_0000183', 'EFO_0000691', 'EFO_0000571', 'EFO_0005922'],
      dtype=object), 'count': 64}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 64 investigational indications."
CHEMBL4594271,"N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1_|_UXNXMBYCBRBRFD-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEROTRALSTAT_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BCX-7353' 'BCX7353' 'Bcx7353' 'Berotralstat']_|_nan_|_['CHEMBL4594272']_|_{'rows': array(['EFO_0005532', 'MONDO_0019623', 'MONDO_0019623'], dtype=object), 'count': 3}_|_[ENSG00000164344]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication."
CHEMBL4594602,"nan_|_nan_|_Antibody_|_False_|_LOMVASTOMIG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Lomvastomig' 'RO-7121661' 'RO7121661' 'Ro-7121661' 'Ro7121661']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0005922'], dtype=object), 'count': 2}_|_[ENSG00000135077,ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL631,"CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1_|_JWHAUXFOSRPERK-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROPAFENONE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['GNF-Pf-4594' 'Propafenon hexal' 'Propafenone' 'Rythmol']_|_[('PubChem', array(['104171212', '124881115', '144203779', '170464755', '26752315',
       '26752316', '50105251', '50105252', '90341088'], dtype=object)), ('Wikipedia', array(['Propafenone'], dtype=object)), ('drugbank', array(['DB01182'], dtype=object)), ('chEBI', array(['63619'], dtype=object))]_|_['CHEMBL1201063']_|_{'rows': array(['HP_0004308', 'EFO_0000275', 'EFO_0004278', 'EFO_0000612',
       'EFO_0003144', 'EFO_0004287', 'EFO_0004269', 'EFO_0000275'],
      dtype=object), 'count': 8}_|_[ENSG00000043591,ENSG00000169252,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL100116,"CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C_|_VOKSWYLNZZRQPF-UHFFFAOYSA-N_|_Small molecule_|_True_|_PENTAZOCINE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dl-pentazocine' 'NIH-7958' 'NSC-107430' 'Pentazocine' 'Pentazocine civ'
 'WIN 20,228' 'WIN-20228']_|_nan_|_['CHEMBL3989509' 'CHEMBL3989510']_|_{'rows': array(['MONDO_0004985', 'EFO_0003843', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for pain and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200485,"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1_|_IVDHYUQIDRJSTI-UHFFFAOYSA-N_|_Small molecule_|_False_|_SORAFENIB TOSYLATE_|_2005.0_|_4.0_|_CHEMBL1336_|_False_|_True_|_['Nexavar']_|_['BAY 54-9085' 'BAY-54-9085' 'Sorafenib tosilate' 'Sorafenib tosylate']_|_[('DailyMed', array(['sorafenib%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar'],
      dtype=object)), ('PubChem', array(['144206042', '170465175', '85147444'], dtype=object)), ('chEBI', array(['50928'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004192', 'MONDO_0011719', 'EFO_0000691', 'EFO_0000349',
       'EFO_0006352', 'EFO_1001968', 'EFO_0006861', 'EFO_0000756',
       'EFO_0000389', 'EFO_0002501', 'EFO_0000641', 'MONDO_0002367',
       'MONDO_0004992', 'MONDO_0008170', 'EFO_0000365', 'MONDO_0008903',
       'EFO_0007535', 'EFO_0000220', 'EFO_0002618', 'EFO_0000616',
       'EFO_1000613', 'EFO_1001465', 'EFO_1000657', 'MONDO_0021063',
       'EFO_0002938', 'MONDO_0044926', 'EFO_0002499', 'EFO_0000588',
       'EFO_1001469', 'EFO_0000501', 'EFO_0000673', 'MONDO_0002691',
       'EFO_1001052', 'MONDO_0044937', 'MONDO_0004986', 'EFO_0003060',
       'EFO_0001378', 'EFO_0000224', 'MONDO_0007254', 'MONDO_0008315',
       'MONDO_0002108', 'EFO_0003833', 'EFO_1001951', 'EFO_0000640',
       'EFO_0000182', 'EFO_0000519', 'EFO_0009907', 'EFO_0000702',
       'EFO_1000158', 'EFO_0000095', 'MONDO_0002087', 'EFO_0000681',
       'EFO_0000222', 'MONDO_0001187', 'EFO_0000403', 'EFO_0000637',
       'EFO_0003871', 'EFO_0000335', 'EFO_0002892', 'EFO_0003032',
       'MONDO_0002158'], dtype=object), 'count': 61}_|_[ENSG00000122025,ENSG00000132155,ENSG00000165731,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157764,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 7 approved and 54 investigational indications."
CHEMBL1201035,"Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2_|_RDNLAULGBSQZMP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BIPERIDEN HYDROCHLORIDE_|_1959.0_|_4.0_|_CHEMBL1101_|_False_|_True_|_['Akineton' 'Akineton ret']_|_['Akinophyl' 'Biperiden hcl' 'Biperiden hydrochloride'
 'Biperideni hydrochloridum' 'NSC-170950' 'NSC-84989' 'Tasmolin']_|_[('PubChem', array(['144206338', '144206615', '170465324'], dtype=object)), ('chEBI', array(['59171'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959."
CHEMBL1201177,"CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O.Cl_|_DNTDOBSIBZKFCP-YDALLXLXSA-N_|_Small molecule_|_False_|_LEVOBUNOLOL HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL1201237_|_False_|_True_|_['Akbeta' 'Betagan' 'Levobunolol hydrochloride']_|_['Levobunolol hcl' 'Levobunolol hydrochloride' 'NSC-759158' 'W 7000A'
 'W-7000A']_|_[('DailyMed', array(['levobunolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204168', '170464743', '56463666'], dtype=object)), ('chEBI', array(['6439'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for glaucoma."
CHEMBL1201347,"CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1_|_LKYQLAWMNBFNJT-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANILERIDINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Adopol' 'Alidine' 'Anileridine' 'Apidol' 'IDS-NA-012' 'Leritin'
 'Nipecotan']_|_[('PubChem', array(['170465266'], dtype=object)), ('Wikipedia', array(['Anileridine'], dtype=object)), ('drugbank', array(['DB00913'], dtype=object)), ('chEBI', array(['61203'], dtype=object))]_|_['CHEMBL1200543' 'CHEMBL1201047']_|_nan_|_[ENSG00000082556,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1509,"C[C@]12CCC(=O)C=C1[C@@H]1C[C@@H]1[C@H]1[C@@H]3[C@@H]4C[C@@H]4[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@@H]12_|_METQSPRSQINEEU-HXCATZOESA-N_|_Small molecule_|_False_|_DROSPIRENONE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Angeliq' 'Slynd']_|_['Drospirenone' 'NSC-760103' 'ZK 30595' 'ZK-30595']_|_[('DailyMed', array(['drospirenone'], dtype=object)), ('PubChem', array(['144205769', '170464870'], dtype=object)), ('Wikipedia', array(['Drospirenone'], dtype=object)), ('drugbank', array(['DB01395'], dtype=object)), ('chEBI', array(['50838'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000710', 'EFO_0000660', 'EFO_0003894', 'EFO_0005204',
       'MONDO_0004169', 'EFO_0005924', 'HP_0100607', 'MONDO_0002050'],
      dtype=object), 'count': 8}_|_[ENSG00000151623,ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for acne and has 7 investigational indications."
CHEMBL1650,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C_|_ITRJWOMZKQRYTA-RFZYENFJSA-N_|_Small molecule_|_False_|_CORTISONE ACETATE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_['Cortate' 'Cortelan' 'Cortisone acetate' 'Cortistab' 'Cortisyl' 'Cortone']_|_['Cortisone' 'Cortisone 21-acetate' 'Cortisone Acetate'
 'Cortisone acetate' 'Cortisone aceticum' 'NSC-49420']_|_[('PubChem', array(['144207031', '170464685', '29214995', '50103888', '855514',
       '90341460'], dtype=object)), ('drugbank', array(['DB01380'], dtype=object)), ('chEBI', array(['3897'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001896', 'HP_0004398', 'EFO_1001435', 'EFO_0004276',
       'EFO_1001205', 'EFO_0008997', 'EFO_1001119', 'EFO_1000764',
       'EFO_0007403', 'EFO_0000274', 'EFO_0007160', 'EFO_0000398',
       'EFO_1000694', 'EFO_0004255', 'EFO_0005752', 'EFO_1000039',
       'HP_0001094', 'HP_0003072', 'EFO_0000685', 'EFO_0003778',
       'MONDO_0008728', 'EFO_1000049', 'MONDO_0043579', 'MONDO_0007915',
       'MONDO_0005178', 'EFO_1001194', 'EFO_0003106', 'EFO_1000941',
       'EFO_0000565', 'EFO_0005319', 'HP_0001873', 'MONDO_0018479',
       'MONDO_0015128', 'EFO_0005558', 'EFO_1001250', 'EFO_0002609',
       'EFO_0004274', 'EFO_1000684', 'EFO_0005532', 'EFO_0009456',
       'EFO_0000574', 'EFO_0003063', 'HP_0001915', 'EFO_1000997',
       'MONDO_0004979', 'MONDO_0005271'], dtype=object), 'count': 46}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 44 approved and 2 investigational indications."
CHEMBL185,"O=c1[nH]cc(F)c(=O)[nH]1_|_GHASVSINZRGABV-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLUOROURACIL_|_1962.0_|_4.0_|_nan_|_False_|_True_|_['5.f.u.' 'Accusite' 'Actikerall' 'Adrucil' 'Carac' 'Efudex' 'Efudix'
 'Fluoro-uracil roche' 'Fluoroplex' 'Fluorouracil' 'Tolak']_|_['5 FU' '5-FU' '5-Fluorouracil' '5-fluoruracil' 'Fluorouracil'
 'Fluorouracilum' 'Fluorouricil' 'Fluracil' 'NSC-19893' 'Phthoruracil'
 'Queroplex' 'RO 2-9757' 'RO-2-9757' 'RO-29757']_|_[('DailyMed', array(['fluorouracil'], dtype=object)), ('PubChem', array(['104171158', '11111190', '124880118', '124880121', '144203701',
       '144209533', '144210432', '170464762', '17389875', '174007005',
       '26747342', '26752979', '50105574', '8139872', '82653', '85231050',
       '90341469'], dtype=object)), ('Wikipedia', array(['Fluorouracil'], dtype=object)), ('drugbank', array(['DB00544'], dtype=object)), ('chEBI', array(['46345'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'MONDO_0002691', 'EFO_1001959', 'EFO_1000720',
       'EFO_1001471', 'EFO_0000198', 'EFO_0004208', 'EFO_0007363',
       'EFO_0002617', 'EFO_1001365', 'EFO_0004252', 'EFO_0003060',
       'EFO_0005952', 'EFO_1000910', 'EFO_0005577', 'EFO_0000365',
       'EFO_1000657', 'EFO_0005221', 'EFO_1000251', 'EFO_1001951',
       'MONDO_0021063', 'EFO_0008528', 'EFO_0003866', 'MONDO_0002358',
       'EFO_0002938', 'EFO_0005950', 'EFO_0002618', 'MONDO_0002974',
       'MONDO_0002038', 'EFO_0004284', 'EFO_0000294', 'MONDO_0000831',
       'MONDO_0005184', 'MONDO_0004992', 'EFO_0000503', 'EFO_0003897',
       'EFO_0003869', 'EFO_0000698', 'EFO_0003859', 'EFO_1000292',
       'MONDO_0044937', 'EFO_0000199', 'EFO_0004288', 'MONDO_0004192',
       'EFO_1001512', 'EFO_0010282', 'MONDO_0001879', 'MONDO_0004986',
       'EFO_0000707', 'EFO_1001129', 'EFO_1001961', 'MONDO_0008170',
       'MONDO_0002087', 'EFO_1001949', 'EFO_0009259', 'EFO_1000028',
       'MONDO_0024475', 'EFO_0000178', 'EFO_0009708', 'EFO_0002496',
       'EFO_0003835', 'EFO_0000228', 'MONDO_0007254', 'MONDO_0003199',
       'EFO_0005537', 'EFO_0002428', 'MONDO_0003060', 'MONDO_0002367',
       'EFO_0000181', 'EFO_0000326', 'MONDO_0044704', 'EFO_0003100',
       'EFO_0000574', 'MONDO_0011719', 'EFO_1001901', 'MONDO_0007576',
       'EFO_0000389', 'MONDO_0002516', 'MONDO_0005575', 'EFO_0000197',
       'MONDO_0001187', 'MONDO_0002120', 'MONDO_0021355', 'EFO_1000359',
       'EFO_0003860', 'HP_0002745', 'MONDO_0005041', 'MONDO_0005835',
       'EFO_1001956', 'MONDO_0001056', 'EFO_0000616', 'EFO_0000565',
       'EFO_0003817', 'EFO_0001075', 'EFO_0002916', 'MONDO_0003059',
       'EFO_0008549', 'EFO_0001378', 'EFO_0000313', 'EFO_0000756',
       'EFO_1000984', 'EFO_0005570', 'EFO_0006859', 'EFO_1001100',
       'EFO_0000681', 'EFO_0003891', 'EFO_0004606', 'EFO_0005922',
       'EFO_0004193', 'EFO_0007416', 'EFO_0004142'], dtype=object), 'count': 111}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 6 approved and 105 investigational indications."
CHEMBL1967878,"Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1_|_KSOVGRCOLZZTPF-UHFFFAOYSA-N_|_Small molecule_|_False_|_CENISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AS 703569' 'AS-703569' 'AS703569' 'As-703569' 'As703569'
 'Aurora kinase inhibitor as703569' 'Cenisertib' 'R 763' 'R-763']_|_[('PubChem', array(['103904402', '103904437'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001642', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108673,"nan_|_nan_|_Antibody_|_False_|_VORSETUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Sgn-70, h1f6']_|_['H-1F6' 'SGN-70' 'Vorsetuzumab']_|_nan_|_nan_|_nan_|_[ENSG00000125726]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL2109364,nan_|_nan_|_Antibody_|_False_|_AR-20.5_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AR-20.5']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109598,"nan_|_nan_|_Antibody_|_False_|_BIIB-023_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB-023' 'Biib-023']_|_nan_|_nan_|_{'rows': array(['EFO_0005761', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000239697]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL25,"CC(=O)Oc1ccccc1C(=O)O_|_BSYNRYMUTXBXSQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ASPIRIN_|_1950.0_|_4.0_|_nan_|_False_|_True_|_['8-hour bayer' 'Acetosalic Acid' 'Acetylsalic acid'
 'Acetylsalicylic Acid' 'Alka rapid' 'Anadin all night' 'Angettes 75'
 'Aspirin' 'Aspro clr' 'Bayer extra strength aspirin for migraine pain'
 'Danamep' 'Disprin cv' 'Disprin direct' 'Durlaza' 'Ecotrin' 'Enprin'
 'Equi-Prin' 'Gencardia' 'Levius' 'Max strgh aspro clr' 'Measurin'
 'Micropirin ec' 'Nu-seals 300' 'Nu-seals 600' 'Nu-seals 75'
 'Nu-seals cardio 75' 'Paynocil' 'Platet' 'Platet 300' 'Postmi 300'
 'Postmi 75' 'Salicylic Acid Acetate' 'Vazalore']_|_['Acetyl salicylate' 'Acetylsalicylic Acid' 'Acetylsalicylic acid'
 'Acetylsalicylic acid (who-ip)' 'Acetylsalicylicum acidum'
 'Acidum acetylsalicylicum' 'Acidum acetylsalicylicum (who-ip)' 'Aspirin'
 'BAY1019036' 'Benzoic acid, 2-(acetyloxy)-' 'NSC-27223' 'NSC-406186']_|_[('DailyMed', array(['aspirin'], dtype=object)), ('PubChem', array(['144203627', '144209315', '144210466', '170465039', '17389202',
       '17390036', '174007205', '26747283', '26752858', '47193676',
       '50105490', '85230910', '87798', '90340586'], dtype=object)), ('TG-GATEs', array(['14'], dtype=object)), ('Wikipedia', array(['Aspirin'], dtype=object)), ('drugbank', array(['DB00945'], dtype=object)), ('chEBI', array(['15365'], dtype=object))]_|_['CHEMBL1697753' 'CHEMBL2296002']_|_{'rows': array(['EFO_0000495', 'MONDO_0007576', 'EFO_0000180', 'EFO_0001645',
       'Orphanet_733', 'EFO_0002615', 'EFO_0008586', 'EFO_0004607',
       'HP_0012042', 'EFO_0007328', 'MONDO_0002009', 'EFO_0003843',
       'MONDO_0004247', 'EFO_0000266', 'EFO_0003144', 'EFO_0000275',
       'EFO_0009364', 'HP_0012378', 'EFO_0003770', 'EFO_0000519',
       'MONDO_0005277', 'EFO_0003868', 'EFO_0000339', 'MONDO_0011962',
       'EFO_0004698', 'EFO_1001157', 'EFO_0003106', 'EFO_0005411',
       'EFO_1001161', 'MP_0001845', 'EFO_0003914', 'EFO_0003060',
       'EFO_0000571', 'MONDO_0005178', 'EFO_0004277', 'MONDO_0008170',
       'EFO_0009315', 'EFO_0008573', 'EFO_0000389', 'MONDO_0005090',
       'EFO_0010282', 'EFO_1000637', 'EFO_0003964', 'EFO_0000764',
       'EFO_1001951', 'HP_0002140', 'MONDO_0043839', 'MONDO_0005835',
       'MONDO_0010888', 'EFO_0005406', 'EFO_0003870', 'MONDO_0004979',
       'HP_0005521', 'EFO_0000319', 'EFO_0000195', 'MONDO_0007254',
       'MONDO_0021108', 'EFO_0001378', 'MONDO_0005129', 'EFO_0000673',
       'EFO_0000712', 'MP_0001914', 'EFO_0007443', 'EFO_0000266',
       'EFO_0003931', 'EFO_0009606', 'EFO_0001361', 'EFO_0000545',
       'HP_0100806', 'EFO_0000668', 'MONDO_0041052', 'EFO_0005856',
       'EFO_0007541', 'HP_0002239', 'MONDO_0018896', 'MONDO_0100096',
       'MONDO_0018076', 'EFO_0004610', 'MONDO_0001056', 'EFO_0004286',
       'HP_0002315', 'EFO_1000860', 'EFO_0000182', 'HP_0004398',
       'EFO_0000537', 'MONDO_0004985', 'EFO_0003893', 'EFO_0008585',
       'HP_0003326', 'EFO_0003764', 'EFO_0004259', 'EFO_0003913',
       'EFO_0000280', 'EFO_0009454', 'EFO_0000341', 'EFO_1001375',
       'HP_0003394', 'EFO_0007129', 'EFO_0000616', 'EFO_0003763',
       'EFO_0000707', 'EFO_0003875', 'EFO_0001663', 'EFO_0006859',
       'EFO_0003869', 'EFO_0002429', 'EFO_0003884', 'EFO_0004264',
       'EFO_1001154', 'EFO_0003777', 'EFO_0000400', 'EFO_0002950',
       'EFO_0000649', 'EFO_1000954', 'HP_0100607', 'EFO_0009854',
       'EFO_0000479', 'EFO_0000729', 'EFO_0009314', 'MONDO_0005301',
       'Orphanet_309005', 'EFO_0000556', 'EFO_0000684', 'EFO_1000657',
       'MONDO_0011382', 'EFO_1002022', 'EFO_0000538', 'EFO_0002618',
       'HP_0002745', 'EFO_0003762', 'EFO_0005407', 'EFO_0003768',
       'EFO_0000694', 'HP_0003418', 'EFO_0004252', 'EFO_0008583',
       'EFO_0009846', 'EFO_0000546', 'MONDO_0002679', 'HP_0000618',
       'EFO_0009686', 'HP_0004936', 'MONDO_0002974', 'MONDO_0021063',
       'MONDO_0007915', 'MONDO_0004992', 'HP_0001945', 'HP_0004419',
       'MONDO_0002258', 'EFO_0004265', 'MONDO_0008315', 'HP_0003419',
       'EFO_0010072', 'EFO_0000612', 'EFO_0005672', 'HP_0012228',
       'EFO_1001923', 'HP_0003124', 'MONDO_0005148', 'MONDO_0000831',
       'EFO_0004246', 'EFO_0007214', 'EFO_0004211'], dtype=object), 'count': 163}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 19 approved and 143 investigational indications."
CHEMBL264374,"CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O_|_IIBYAHWJQTYFKB-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEZAFIBRATE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Bezagen xl' 'Bezalip' 'Bezalip-mono' 'Fibrazate xl' 'Liparol xl'
 'Zimbacol xl']_|_['BM 15.075' 'BM-15.075' 'BM-15075' 'Bezafibrate' 'Bezatol sr'
 'NSC-758174']_|_[('PubChem', array(['11112764', '144204196', '144212162', '170465743', '26751546',
       '26751547', '56422496', '855877', '90341401'], dtype=object)), ('Wikipedia', array(['Bezafibrate'], dtype=object)), ('drugbank', array(['DB01393'], dtype=object)), ('chEBI', array(['47612'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0004985', 'EFO_0004268', 'EFO_0000198',
       'Orphanet_79211', 'MONDO_0044970', 'EFO_1001486', 'EFO_0000319'],
      dtype=object), 'count': 8}_|_[ENSG00000132170,ENSG00000186951,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 7 investigational indications."
CHEMBL3402567,"COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O.Cl_|_ICIJBYYMEBOTQP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ITX-5061_|_nan_|_2.0_|_CHEMBL1208829_|_False_|_False_|_[]_|_['ITX 5061' 'Itx 5061' 'Itx-5061' 'KC-706' 'KC706' 'Kc-706']_|_nan_|_nan_|_{'rows': array(['EFO_0004719', 'EFO_0003047'], dtype=object), 'count': 2}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545157,"O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1_|_PMJIHLSCWIDGMD-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIDEGLUSIB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Zentylor nypta']_|_['NP-031112' 'NP-12' 'NP031112' 'Np-031112' 'Tideglusib']_|_[('drugbank', array(['DB12129'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'Orphanet_273', 'MONDO_0016107', 'EFO_0003756',
       'MONDO_0004976'], dtype=object), 'count': 5}_|_[ENSG00000082701]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3545311,"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1_|_AILRADAXUVEEIR-UHFFFAOYSA-N_|_Small molecule_|_False_|_BRIGATINIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Alunbrig']_|_['AP-26113' 'AP26113' 'Ap-26113' 'Brigatinib']_|_[('DailyMed', array(['brigatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig'],
      dtype=object)), ('drugbank', array(['DB12267'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060', 'EFO_0003032'], dtype=object), 'count': 3}_|_[ENSG00000171094,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for neoplasm and non-small cell lung carcinoma and has 1 investigational indication."
CHEMBL3786673,"CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)c1ccccc1O_|_JQLBBYLGWHUHRW-KUBAVDMBSA-N_|_Small molecule_|_False_|_EDASALONEXENT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CAT 1004' 'CAT-1004' 'CAT1004' 'Cat 1004' 'Cat-1004' 'Edasalonexent']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EDASALONEXENT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15010'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000077150,ENSG00000109320,ENSG00000173039]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL402548,"CO[C@@H](C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1_|_XKFTZKGMDDZMJI-HSZRJFAPSA-N_|_Small molecule_|_False_|_DANUSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Danusertib' 'PHA-739358' 'Pha-739358']_|_[('drugbank', array(['DB11778'], dtype=object))]_|_['CHEMBL534499']_|_{'rows': array(['EFO_0001378', 'MONDO_0008315', 'EFO_0000565'], dtype=object), 'count': 3}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL405,"CC(N)Cc1ccccc1_|_KWTSXDURSIMDCE-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMPHETAMINE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Adzenys er' 'Adzenys xr-odt' 'Dyanavel xr']_|_['Amfetamin' 'Amfetamine' 'Amphetamine' 'Amphetamine, dl-' 'Dyanavel'
 'NSC-27159' 'Norephedrane']_|_[('DailyMed', array(['amphetamine'], dtype=object)), ('Wikipedia', array(['Adderall', 'Amphetamine'], dtype=object)), ('drugbank', array(['DB00182'], dtype=object)), ('chEBI', array(['2679'], dtype=object))]_|_['CHEMBL3250774' 'CHEMBL1200377' 'CHEMBL3250773' 'CHEMBL3250775'
 'CHEMBL554211' 'CHEMBL1200387' 'CHEMBL3250772' 'CHEMBL3250770'
 'CHEMBL3250771' 'CHEMBL501']_|_{'rows': array(['EFO_0003888', 'EFO_0001073', 'MONDO_0016158', 'EFO_0003925',
       'EFO_0003888', 'EFO_0003888', 'EFO_0002610', 'EFO_0002610'],
      dtype=object), 'count': 8}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297524,"Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1_|_DUPWHXBITIZIKZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_RADOTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IY5511' 'Radotinib']_|_[('drugbank', array(['DB12323'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0000339'], dtype=object), 'count': 2}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4297787,"nan_|_nan_|_Antibody_|_False_|_MONALIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IPH-2201 (ANTI-NKG2A)' 'IPH2201' 'Iph-2201' 'Iph2201' 'Monalizumab'
 'NN-8765' 'NN8765' 'NN8765-3658']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000095', 'MONDO_0007254', 'EFO_0004284',
       'EFO_0000616', 'EFO_0003060', 'EFO_0000707', 'EFO_0000702',
       'EFO_0000181', 'MONDO_0100096', 'MONDO_0021148', 'EFO_0000199'],
      dtype=object), 'count': 12}_|_[ENSG00000134545]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL4297926,"nan_|_nan_|_Unknown_|_False_|_CJM-112_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CJM-112' 'CJM112' 'Cjm 112' 'Cjm-112' 'Cjm112']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0003894', 'EFO_1000710', 'MONDO_0004979',
       'EFO_0000676'], dtype=object), 'count': 5}_|_[ENSG00000112115]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL475534,"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1_|_PVHUJELLJLJGLN-UHFFFAOYSA-N_|_Small molecule_|_False_|_NITRENDIPINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Baypress']_|_['BAY E 5009' 'BAY-E-5009' 'Bayotensin' 'Deiten' 'NSC-758466' 'Nidrel'
 'Nitrendipine' 'Nitrepin']_|_[('PubChem', array(['104171193', '124880808', '144203752', '170465897', '26751794',
       '26751795', '50104488', '85231144', '90341570'], dtype=object)), ('Wikipedia', array(['Nitrendipine'], dtype=object)), ('drugbank', array(['DB01054'], dtype=object)), ('chEBI', array(['7582'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 2}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL483158,"COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O_|_ZLHFILGSQDJULK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALISERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Alisertib' 'MLN 8237' 'MLN-8237' 'MLN8237' 'Mln-8237']_|_[('PubChem', array(['103905632', '137276087', '174006392'], dtype=object)), ('drugbank', array(['DB05220'], dtype=object))]_|_['CHEMBL2103871' 'CHEMBL3586471']_|_{'rows': array(['EFO_0001378', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000222',
       'EFO_1001469', 'MONDO_0008903', 'EFO_0006859', 'MONDO_0007254',
       'EFO_0000198', 'MONDO_0002158', 'EFO_0000574', 'EFO_0000211',
       'EFO_0000621', 'MONDO_0018906', 'EFO_0000181', 'MONDO_0002087',
       'EFO_0000702', 'EFO_0000305', 'EFO_0001075', 'EFO_0000673',
       'EFO_0000616', 'EFO_0000309', 'MONDO_0002516', 'EFO_0000403'],
      dtype=object), 'count': 24}_|_[ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications."
CHEMBL494,"CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O_|_HIFJCPQKFCZDDL-ACWOEMLNSA-N_|_Small molecule_|_False_|_ILOPROST_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Ventavis']_|_['Ciloprost' 'Endoprost' 'Ilomedin' 'Iloprost' 'ZK 00036374' 'ZK-00036374'
 'ZK-36374']_|_[('DailyMed', array(['iloprost'], dtype=object)), ('drugbank', array(['DB01088'], dtype=object)), ('chEBI', array(['63916'], dtype=object))]_|_['CHEMBL5315118']_|_{'rows': array(['EFO_0000341', 'EFO_0001071', 'MONDO_0005149', 'MONDO_0008903',
       'EFO_0006834', 'EFO_0000717', 'MONDO_0100130', 'EFO_0003943',
       'HP_0004419', 'MONDO_0004979', 'EFO_0009492', 'EFO_1001373',
       'EFO_0003884', 'EFO_0000612', 'EFO_0001361', 'EFO_1001145'],
      dtype=object), 'count': 16}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 13 investigational indications."
CHEMBL1193,"CN(C)CCC(c1ccccc1)c1ccccn1_|_IJHNSHDBIRRJRN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENIRAMINE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-47965' 'Pheniramine' 'Propheniramine' 'Prophenpyridamine' 'Pyriton'
 'Tripoton']_|_[('PubChem', array(['90341510'], dtype=object)), ('Wikipedia', array(['Pheniramine'], dtype=object)), ('drugbank', array(['DB01620'], dtype=object))]_|_['CHEMBL1596440' 'CHEMBL1580221' 'CHEMBL1653']_|_{'rows': array(['EFO_0007214', 'MONDO_0024355', 'MONDO_0005271', 'EFO_0007328',
       'EFO_0007214', 'HP_0000989'], dtype=object), 'count': 6}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for allergic disease and pruritus and has 3 investigational indications."
CHEMBL1200774,"C[C@]12C=CC(=O)C=C1[C@@H](F)C[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO_|_MYYIMZRZXIQBGI-HVIRSNARSA-N_|_Small molecule_|_False_|_FLUPREDNISOLONE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Alphadrol']_|_['Fluprednisolone' 'NSC-47439' 'U-7800']_|_[('PubChem', array(['144205251', '144206694', '170465086'], dtype=object)), ('Wikipedia', array(['Fluprednisolone'], dtype=object)), ('drugbank', array(['DB09378'], dtype=object)), ('chEBI', array(['34474'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200795,"CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O_|_PMGQWSIVQFOFOQ-YKVZVUFRSA-N_|_Small molecule_|_False_|_CLEMASTINE FUMARATE_|_1977.0_|_4.0_|_CHEMBL1626_|_False_|_True_|_['Clemastine fumarate' 'Tavegil' 'Tavist' 'Tavist-1']_|_['Clemastine fumarate' 'Clemastine hydrogen fumarate']_|_[('DailyMed', array(['clemastine%20fumarate'], dtype=object)), ('PubChem', array(['144204125', '170465318', '93576607'], dtype=object)), ('chEBI', array(['3739'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003840', 'MONDO_0005271', 'EFO_0005854', 'EFO_0005531',
       'EFO_0007214', 'EFO_0003956', 'EFO_0003929', 'MONDO_0005301'],
      dtype=object), 'count': 8}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 4 approved and 4 investigational indications."
CHEMBL1201764,"CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1_|_DCCSDBARQIPTGU-HSZRJFAPSA-N_|_Small molecule_|_False_|_FESOTERODINE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fesoterodine']_|_[('Wikipedia', array(['Fesoterodine'], dtype=object)), ('drugbank', array(['DB06702'], dtype=object))]_|_['CHEMBL1201765']_|_{'rows': array(['HP_0000103', 'HP_0000020', 'EFO_1000781', 'EFO_1001762',
       'HP_0000020', 'HP_0000011', 'EFO_1000781', 'EFO_0006865',
       'HP_0010992'], dtype=object), 'count': 9}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 5 investigational indications."
CHEMBL1743029,"nan_|_nan_|_Antibody_|_False_|_IBALIZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Trogarzo']_|_['HU5A8' 'Ibalizumab' 'Ibalizumab-uiyk' 'TNX-355']_|_[('DailyMed', array(['ibalizumab-uiyk'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trogarzo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000763', 'EFO_0000764', 'EFO_0000544', 'EFO_0000180'],
      dtype=object), 'count': 4}_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 1 investigational indication."
CHEMBL2103778,"Cc1nccn1C[C@H]1CCc2c(c3cccc4c3n2CCC4)C1=O_|_NCNFDKWULDWJDS-OAHLLOKOSA-N_|_Small molecule_|_False_|_CILANSETRON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cilansetron' 'KC-9946']_|_[('drugbank', array(['DB04885'], dtype=object))]_|_['CHEMBL2107807']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000166736,ENSG00000149305]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105890,"CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C(C)C)[C@H]2O)[C@@]2(C)CC(C)=C(O2)[C@H](C)C(=O)[C@]1(C)OC.O=C(O)/C=C/C(=O)O_|_IDLXWTNPDREJQZ-HSOMBQIOSA-N_|_Small molecule_|_False_|_MITEMCINAL FUMARATE_|_nan_|_2.0_|_CHEMBL2110756_|_False_|_False_|_[]_|_['115-8543 JAPAN' '115-8543-JAPAN' '5-1 UKIMA 5 CHOME' '5-1-UKIMA-5-CHOME'
 'GM-611' 'KITA-KU TOYKO' 'Mitemcinal fumarate']_|_nan_|_nan_|_{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}_|_[ENSG00000102539]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107383,"COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC.Cl_|_JMHYCBFEEFHTMK-IIUXMCBISA-N_|_Small molecule_|_False_|_VERNAKALANT HYDROCHLORIDE_|_2010.0_|_4.0_|_CHEMBL2111112_|_False_|_True_|_['Brinavess']_|_['Brinavess' 'Kynapid' 'RSD-1235' 'RSD1235' 'Vernakalant hcl'
 'Vernakalant hydrochloride']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0003911'], dtype=object), 'count': 2}_|_[ENSG00000055118,ENSG00000183873,ENSG00000171385,ENSG00000130037,ENSG00000162989,ENSG00000120457]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for atrial fibrillation and has 1 investigational indication."
CHEMBL2109522,nan_|_nan_|_Antibody_|_False_|_PF-03446879_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['PF-03446879']_|_nan_|_nan_|_nan_|_[ENSG00000138379]_|_Antibody drug.
CHEMBL220492,"CC1(C)O[C@@H]2[C@@H](CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@H]23)O1_|_KJADKKWYZYXHBB-XBWDGYHZSA-N_|_Small molecule_|_False_|_TOPIRAMATE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Epitomax' 'Eprontia' 'Qudexy xr' 'Topamax' 'Topamax sprinkle'
 'Topiramate' 'Trokendi xr']_|_['(-)-topiramate' 'Epitoma' 'Eprontia' 'MCN-4853' 'Qudexy' 'RWJ-17021'
 'RWJ-17021-000' 'Sincronil' 'Topamac' 'Topimax' 'Topina' 'Topiramate'
 'Topomax' 'USL-255' 'USL255']_|_[('DailyMed', array(['topiramate'], dtype=object)), ('PubChem', array(['144205025', '144212718', '170464746'], dtype=object)), ('Wikipedia', array(['Topiramate'], dtype=object)), ('drugbank', array(['DB00273'], dtype=object)), ('chEBI', array(['63631'], dtype=object))]_|_nan_|_{'rows': array(['HP_0011868', 'EFO_0007191', 'MONDO_0002046', 'EFO_0005203',
       'MONDO_0005180', 'EFO_0001073', 'EFO_1001176', 'MONDO_0021187',
       'EFO_0007262', 'EFO_0004211', 'EFO_0004895', 'EFO_0001063',
       'MONDO_0005299', 'HP_0000726', 'MONDO_0008300', 'HP_0002315',
       'EFO_0005204', 'MONDO_0005148', 'MONDO_0005277', 'EFO_0004263',
       'EFO_0000400', 'EFO_0004701', 'EFO_0004242', 'EFO_0001358',
       'EFO_0004329', 'EFO_0005230', 'EFO_0003768', 'HP_0100543',
       'EFO_0003843', 'EFO_0005207', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0004319', 'EFO_0001421', 'EFO_0004699', 'EFO_0000474',
       'EFO_0003108', 'EFO_0000195', 'MONDO_0016532', 'MONDO_0005301',
       'MONDO_0004985', 'EFO_0000537', 'HP_0001250', 'EFO_0005924',
       'EFO_0002610', 'MONDO_0007079'], dtype=object), 'count': 46}_|_[ENSG00000104267,ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000167434,ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 42 investigational indications."
CHEMBL3544964,"Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1_|_RZUOCXOYPYGSKL-GOSISDBHSA-N_|_Small molecule_|_False_|_RAVOXERTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GDC-0994' 'GDC0994' 'Gdc-0994' 'RG-7842' 'Ravoxertinib']_|_[('drugbank', array(['DB15281'], dtype=object))]_|_['CHEMBL4581802']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000100030,ENSG00000102882]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4069704,"CCOC(=O)[C@@H]1CC2(CCN(c3cc(O[C@H](c4ccc(Cl)cc4-c4ccccc4)C(F)(F)F)nc(N)n3)CC2)CN1_|_TZSZZENYCISATO-WIOPSUGQSA-N_|_Small molecule_|_False_|_RODATRISTAT ETHYL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['KAR-5585' 'KAR5585' 'Rodatristat ethyl']_|_nan_|_nan_|_{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}_|_[ENSG00000129167]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL408513,"O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO_|_NCNRHFGMJRPRSK-MDZDMXLPSA-N_|_Small molecule_|_False_|_BELINOSTAT_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Beleodaq']_|_['Belinostat' 'NSC-726630' 'NSC726630' 'PX-105684' 'PXD-101' 'PXD101']_|_[('DailyMed', array(['belinostat'], dtype=object)), ('Wikipedia', array(['Belinostat'], dtype=object)), ('drugbank', array(['DB05015'], dtype=object)), ('chEBI', array(['61076'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000309', 'EFO_0000403', 'EFO_1000131', 'MONDO_0015760',
       'EFO_0000616', 'EFO_0000588', 'MONDO_0002158', 'EFO_0003060',
       'EFO_0002913', 'MONDO_0000430', 'EFO_0000222', 'EFO_0005952',
       'EFO_0003032', 'EFO_1001469', 'EFO_0000183', 'EFO_0000228',
       'EFO_0000466', 'EFO_0001642', 'MONDO_0019471', 'MONDO_0004992',
       'EFO_1001968', 'EFO_0000313', 'EFO_0000198', 'MONDO_0002087',
       'EFO_0000211', 'EFO_1001051', 'EFO_1000581', 'EFO_0008528',
       'EFO_0000702', 'EFO_0001378', 'EFO_0000519', 'EFO_0000574',
       'EFO_0000182', 'EFO_1000576', 'MONDO_0018906', 'EFO_1000043'],
      dtype=object), 'count': 36}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 31 investigational indications."
CHEMBL4298084,"nan_|_nan_|_Antibody_|_False_|_ODRONEXTAMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Odronextamab' 'REGN-1979' 'REGN1979' 'Regn1979']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ODRONEXTAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004289', 'EFO_1001938', 'EFO_0000095', 'EFO_0000096'],
      dtype=object), 'count': 4}_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL433,"CCCC(CCC)C(=O)[O-].[Na+]_|_AEQFSUDEHCCHBT-UHFFFAOYSA-M_|_Small molecule_|_True_|_VALPROATE SODIUM_|_1996.0_|_4.0_|_CHEMBL109_|_False_|_True_|_['Delepsine' 'Depacon' 'Depakine' 'Depakote' 'Depakote CP' 'Depakote ER'
 'Epilim' 'Epilim 200' 'Epilim 500' 'Epilim chrono 200'
 'Epilim chrono 300' 'Epilim chrono 500' 'Epilim chronosphere' 'Epilim iv'
 'Episenta' 'Kentilim' 'Orfiril' 'Orlept' 'Valproate sodium']_|_['A-44090' 'ABBOTT 44090' 'ABBOTT-44090' 'KW-6066N' 'NSC-732626'
 'NSC-757376' 'Natrii valproas' 'Selenica' 'Sodium 2-propylpentanoate'
 'Sodium valproate' 'Valproate sodium' 'Valproic acid sodium salt (1:1)'
 'Valproic acid, sodium' 'Valproic acid, sodium salt']_|_[('DailyMed', array(['valproate%20sodium'], dtype=object)), ('PubChem', array(['11112073', '144212940', '50106736', '50112990', '57264447',
       '85231324'], dtype=object)), ('Wikipedia', array(['Sodium_valproate'], dtype=object)), ('chEBI', array(['9925'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079', 'EFO_0000474', 'EFO_0009963', 'EFO_0009430',
       'EFO_0003758', 'EFO_0000198', 'MONDO_0019188', 'MONDO_0005277',
       'HP_0001250', 'MONDO_0003478', 'EFO_0008526', 'MONDO_0043510',
       'EFO_0000519', 'MONDO_0010604', 'EFO_0004192', 'MONDO_0004976',
       'EFO_0008525', 'MONDO_0009293', 'EFO_0005762', 'EFO_0009267',
       'EFO_0000095', 'MONDO_0018105', 'HP_0000713', 'EFO_0000403',
       'MONDO_0004975', 'MONDO_0004985'], dtype=object), 'count': 26}_|_[ENSG00000112294]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for epilepsy and has 25 investigational indications. This drug has a black box warning from the FDA."
CHEMBL5314341,"nan_|_nan_|_Protein_|_False_|_GLUCAGON_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Glucagon' 'Gvoke hypopen' 'Ogluo']_|_['Baqsimi' 'Glucagen' 'Glucagon' 'Glucagon (recombinant dna origin)'
 'Glucagon recombinant' 'Glucagon, human' 'Glucagon, pig'
 'Glucagon, porcine']_|_[('DailyMed', array(['glucagon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'HP_0001943', 'EFO_0001073', 'MONDO_0005148',
       'MONDO_0017182', 'EFO_0007214', 'EFO_0007318', 'MONDO_0005147'],
      dtype=object), 'count': 8}_|_[ENSG00000215644]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for diabetes mellitus and hypoglycemia and has 6 investigational indications."
CHEMBL5314399,Cc1ccc(N2c3cccc(C(=O)Nc4ccc(OCC(F)(F)F)nc4)c3OC[C@@H]2CO)nc1_|_QZUCKCLSVBFSOS-INIZCTEOSA-N_|_Small molecule_|_False_|_JTS-653_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JTS653' 'Jts-653']_|_nan_|_nan_|_nan_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL690,"CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+]_|_VWBQYTRBTXKKOG-IYNICTALSA-M_|_Small molecule_|_False_|_PRAVASTATIN SODIUM_|_1991.0_|_4.0_|_CHEMBL1144_|_False_|_True_|_['Elisor' 'Lipemol' 'Liplat' 'Lipostat' 'Pravachol' 'Pravastatin sodium']_|_['CS-514' 'Dehypotin protect' 'Eptastatin sodium' 'NSC-759253'
 'Pravastatin sodium' 'SQ-31,000' 'SQ-31000']_|_[('DailyMed', array(['pravastatin%20sodium'], dtype=object)), ('PubChem', array(['144205027', '144210590', '26753280'], dtype=object)), ('chEBI', array(['8361'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0000400', 'MONDO_0005147', 'EFO_1000727',
       'EFO_0004255', 'EFO_0001645', 'EFO_0004911', 'EFO_0003914',
       'HP_0003124', 'Orphanet_79211', 'MONDO_0008903', 'EFO_0000565',
       'EFO_0000612', 'EFO_0000764', 'MONDO_0002691', 'EFO_0000180',
       'EFO_0004705', 'MONDO_0021661'], dtype=object), 'count': 18}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 8 investigational indications."
CHEMBL1179047,"CCN(CC)CCOC(=O)c1ccc(N)cc1Cl_|_VDANGULDQQJODZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLOROPROCAINE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['2-chloroprocaine' 'Chloroprocaine']_|_[('Wikipedia', array(['Chloroprocaine'], dtype=object)), ('drugbank', array(['DB01161'], dtype=object)), ('chEBI', array(['3636'], dtype=object))]_|_['CHEMBL944']_|_{'rows': array(['EFO_0003843', 'EFO_0003843', 'EFO_0002950', 'MONDO_0005129'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 4 investigational indications."
CHEMBL1200803,"O=C(O)CCC(=O)O.O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1_|_RXZMMZZRUPYENV-VROPFNGYSA-N_|_Small molecule_|_False_|_SOLIFENACIN SUCCINATE_|_2004.0_|_4.0_|_CHEMBL1734_|_False_|_True_|_['Solifenacin succinate' 'Vesicare' 'Vesicare ls']_|_['Solifenacin succinate' 'YM-67905' 'YM-905' 'YM67905' 'YM905']_|_[('DailyMed', array(['solifenacin%20succinate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000781', 'EFO_0000284', 'EFO_0006865'], dtype=object), 'count': 3}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for overactive bladder and urgency urinary incontinence and has 1 investigational indication."
CHEMBL1201150,"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O_|_PORMUFZNYQJOEI-UHFFFAOYSA-N_|_Small molecule_|_False_|_SUMATRIPTAN SUCCINATE_|_1992.0_|_4.0_|_CHEMBL128_|_False_|_True_|_['Alsuma' 'Imigran' 'Imigran 50' 'Imigran radis' 'Imigran recovery'
 'Imigran subject' 'Imitrex' 'Imitrex statdose' 'Migraitan'
 'Migraleve ultra' 'Onzetra xsail' 'Sumatriptan succinate'
 'Sumavel dosepro' 'Zecuity' 'Zembrace symtouch']_|_['GR 43175C' 'GR-43175C' 'NSC-760362' 'Sumatriptan (as succinate)'
 'Sumatriptan galpharm' 'Sumatriptan succinate' 'Treximet']_|_[('DailyMed', array(['sumatriptan%20succinate'], dtype=object)), ('PubChem', array(['49681638'], dtype=object)), ('chEBI', array(['64359'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005475', 'MONDO_0005277', 'MONDO_0100431'], dtype=object), 'count': 3}_|_[ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for migraine disorder and has 2 investigational indications."
CHEMBL1738889,"C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1_|_JNGVJMBLXIUVRD-SFHVURJKSA-N_|_Small molecule_|_False_|_ENOBOSARM_|_nan_|_3.0_|_nan_|_False_|_False_|_['Ostarine']_|_['Enobosarm' 'GTX-024' 'Gtx-024' 'MK-2866']_|_[('drugbank', array(['DB12078'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009851', 'HP_0004326', 'HP_0010992', 'MONDO_0007254',
       'EFO_0003060', 'EFO_0005537'], dtype=object), 'count': 6}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1910936,"O=C(CN1C(=O)C2(CCCC2)NC[C@H]1c1cc(F)cc(F)c1)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2ncccc21_|_AZAANWYREOQRFB-SETSBSEESA-N_|_Small molecule_|_False_|_MK3207_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK 3207' 'MK-3207' 'Mk-3207' 'Mk3207']_|_[('drugbank', array(['DB12424'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2007641,"nan_|_nan_|_Antibody_|_True_|_PERTUZUMAB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Omnitarg' 'Omnitarg Perjeta' 'Perjeta']_|_['Pertuzumab' 'Pertuzumab-zzxf' 'RG-1273' 'RHUMAB 2C4' 'RHUMAB-2C4']_|_[('DailyMed', array(['pertuzumab'], dtype=object)), ('DrugCentral', array(['4957'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta'],
      dtype=object)), ('Wikipedia', array(['Pertuzumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000294', 'EFO_0001642', 'EFO_1000657', 'MONDO_0007254',
       'MONDO_0002120', 'EFO_0000305', 'EFO_0001663', 'MONDO_0021063',
       'EFO_0006861', 'EFO_0002916', 'MONDO_0008170', 'EFO_0002618',
       'EFO_0009708', 'EFO_0000365', 'MONDO_0001056', 'MONDO_0008315',
       'MONDO_0004992', 'MONDO_0002158', 'EFO_0003869', 'MONDO_0002087',
       'EFO_1001951', 'EFO_0003968', 'EFO_0003060', 'EFO_1000984',
       'EFO_0000616', 'EFO_0005537'], dtype=object), 'count': 26}_|_[ENSG00000141736]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2104987,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC_|_CILIXQOJUNDIDU-ASQIGDHWSA-N_|_Protein_|_False_|_TEDUGLUTIDE_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Gattex kit' 'Revestive']_|_['ALX 0600' 'ALX-0600' 'Gattex' 'Revestive' 'Teduglutide'
 'Teduglutide (rdna origin)']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revestive'],
      dtype=object)), ('chEBI', array(['72305'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'MONDO_0021187', 'EFO_0001421', 'MONDO_0013730',
       'EFO_0000384', 'EFO_0003086', 'MONDO_0015183', 'EFO_0700081',
       'EFO_0008572', 'EFO_0009554'], dtype=object), 'count': 10}_|_[ENSG00000065325]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 7 investigational indications."
CHEMBL2107841,"nan_|_nan_|_Protein_|_True_|_ALBIGLUTIDE_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Eperzan']_|_['Albiglutide' 'Albiglutide (genetical recombination)' 'GSK-716155'
 'GSK716155' 'Tanzeum']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eperzan'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'EFO_0000400', 'EFO_0000373'],
      dtype=object), 'count': 4}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108742,"nan_|_nan_|_Antibody_|_False_|_SIPLIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MEDI-507' 'Siplizumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0000676', 'MONDO_0004992', 'EFO_0003086',
       'EFO_0000565', 'EFO_1002048', 'EFO_0000574', 'EFO_0003884',
       'MONDO_0005147', 'MONDO_0016537'], dtype=object), 'count': 10}_|_[ENSG00000116824]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL2110372,"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl_|_GGWBHVILAJZWKJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_RANITIDINE HYDROCHLORIDE_|_1983.0_|_4.0_|_CHEMBL1790041_|_False_|_True_|_['Azantac' 'Dumoran' 'Gavilast' 'Gavilast-p' 'Histac' 'Raciran 150'
 'Raciran 300' 'Ranicalm' 'Raniplex' 'Ranitic' 'Ranitidine hydrochloride'
 'Ranitil' 'Rantec' 'Ranzac' 'Vivatak' 'Zaedoc 150' 'Zaedoc 300' 'Zantac'
 'Zantac 150' 'Zantac 25' 'Zantac 300' 'Zantac 75' 'Zantac 75 dissolve'
 'Zantac 75 relief' 'Zantac 75 relief dissolve']_|_['AH 19065' 'AH-19065' 'Ranitidine hcl' 'Ranitidine hydrochloride'
 'Taladine']_|_[('DailyMed', array(['ranitidine%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004607', 'MONDO_0043839', 'EFO_0009454', 'EFO_0000764'],
      dtype=object), 'count': 4}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 3 approved and 1 investigational indication."
CHEMBL3707253,nan_|_nan_|_Antibody_|_False_|_BEVACIZUMAB 111IN_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Bevacizumab 111in' 'Bevacizumab in111']_|_nan_|_nan_|_nan_|_[ENSG00000112715]_|_Antibody drug.
CHEMBL3979920,"Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1_|_MJHOMTRKVMKCNE-NWDGAFQWSA-N_|_Small molecule_|_False_|_MIVAVOTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CB-659' 'Mivavotinib' 'TAK-659F']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIVAVOTINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4594253']_|_{'rows': array(['EFO_0000616', 'MONDO_0002334', 'EFO_0000616', 'MONDO_0002334',
       'EFO_0005952', 'EFO_0000222', 'EFO_0000403', 'EFO_0000574',
       'EFO_0000403', 'MONDO_0018906', 'EFO_0001075'], dtype=object), 'count': 11}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL4298006,"nan_|_nan_|_Antibody_|_False_|_ENVAFOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ASC-22' 'ASC22' 'Asc22' 'Envafolimab' 'KN-035' 'KN035' 'Kn 035' 'Kn035']_|_nan_|_nan_|_{'rows': array(['EFO_0004142', 'MONDO_0021117', 'EFO_0004252', 'MONDO_0011962',
       'EFO_0000616', 'EFO_0005922', 'MONDO_0007576', 'EFO_1001968',
       'EFO_0003060', 'EFO_0000182', 'EFO_0004288', 'MONDO_0004992',
       'MONDO_0021063', 'MONDO_0008170', 'MONDO_0002974', 'EFO_1000359',
       'EFO_0003891', 'MONDO_0007254', 'EFO_1001012', 'EFO_1000657',
       'EFO_0000180', 'EFO_0000503', 'MONDO_0003060', 'EFO_0004239',
       'EFO_1001951', 'EFO_0000764'], dtype=object), 'count': 26}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications."
CHEMBL4298117,"nan_|_nan_|_Antibody_|_False_|_ORILANOLIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALXN-1830' 'ALXN1830' 'Alxn1830' 'Orilanolimab' 'SYNT-001' 'SYNT001'
 'SYNT1001' 'Synt001']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ORILANOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004719', 'MONDO_0017287', 'EFO_0005809', 'EFO_0008601',
       'EFO_0004991', 'EFO_1001264'], dtype=object), 'count': 6}_|_[ENSG00000104870]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4594554,"nan_|_nan_|_Antibody_|_False_|_TAFOLECIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IBI-306' 'IBI306' 'Ibi306' 'Tafolecimab']_|_nan_|_nan_|_{'rows': array(['MONDO_0018328', 'EFO_0004911', 'HP_0003124'], dtype=object), 'count': 3}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL5315125,"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1.O_|_FQLHRUBTGKTKPZ-ZOWNYOTGSA-N_|_Small molecule_|_True_|_DUVELISIB MONOHYDRATE_|_2018.0_|_4.0_|_CHEMBL3039502_|_False_|_True_|_['Copiktra']_|_['Duvelisib hydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018906', 'EFO_0000095', 'EFO_0000574', 'EFO_0000096'],
      dtype=object), 'count': 4}_|_[ENSG00000105851,ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved indications. This drug has a black box warning from the FDA."
CHEMBL629,"CN(C)CCC=C1c2ccccc2CCc2ccccc21_|_KRMDCWKBEZIMAB-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMITRIPTYLINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amitid' 'Amitril' 'Amitriptyline' 'Damitriptyline' 'Elavil' 'Endep'
 'Etrafon-A' 'Etrafon-Forte' 'Flavyl' 'Laroxyl' 'Limbitrol'
 'Proheptadiene' 'Seroten' 'Triptanol']_|_[('PubChem', array(['11110782', '11110783', '124879280', '90340850'], dtype=object)), ('TG-GATEs', array(['70'], dtype=object)), ('Wikipedia', array(['Amitriptyline'], dtype=object)), ('drugbank', array(['DB00321'], dtype=object)), ('chEBI', array(['2666'], dtype=object))]_|_['CHEMBL1200964']_|_{'rows': array(['EFO_0007169', 'EFO_1000941', 'EFO_0003843', 'EFO_0005230',
       'EFO_1001800', 'EFO_0004698', 'EFO_0000400', 'MONDO_0005090',
       'EFO_0004244', 'HP_0002315', 'MONDO_0005277', 'EFO_0000512',
       'EFO_0004149', 'EFO_0009387', 'MONDO_0002050', 'EFO_0005762',
       'EFO_0005687', 'EFO_0010282', 'HP_0000989', 'EFO_0008507',
       'HP_0000726', 'MONDO_0016028', 'MONDO_0002009', 'MONDO_0002009',
       'MONDO_0002009'], dtype=object), 'count': 25}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for depressive disorder and major depressive disorder and has 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL864,"CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1_|_OJFSXZCBGQGRNV-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARBINOXAMINE_|_2003.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Carbinoxamine' 'Clistin' 'Palgic']_|_[('PubChem', array(['29217899'], dtype=object)), ('Wikipedia', array(['Carbinoxamine'], dtype=object)), ('drugbank', array(['DB00748'], dtype=object)), ('chEBI', array(['3398'], dtype=object))]_|_['CHEMBL1200974' 'CHEMBL1519829']_|_{'rows': array(['EFO_0007533', 'EFO_1001417', 'EFO_0003956', 'EFO_0005532',
       'EFO_0007141', 'MONDO_0005271', 'EFO_0005531'], dtype=object), 'count': 7}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved indications. It was withdrawn in at least one region."
CHEMBL894,"CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1_|_SNPPWIUOZRMYNY-UHFFFAOYSA-N_|_Small molecule_|_True_|_BUPROPION_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amfebutamone' 'Bupropion' 'Bupropion extended release'
 'Bupropion slow release' 'NSC-758686']_|_[('PubChem', array(['174006913', '90340803'], dtype=object)), ('Wikipedia', array(['Bupropion'], dtype=object)), ('drugbank', array(['DB01156'], dtype=object)), ('chEBI', array(['3219'], dtype=object))]_|_['CHEMBL1698' 'CHEMBL1201735']_|_{'rows': array(['EFO_0005203', 'MONDO_0002009', 'EFO_0003768', 'EFO_0004714',
       'MONDO_0002009', 'EFO_0006859', 'EFO_0001073', 'MONDO_0004975',
       'MONDO_0002491', 'MONDO_0008315', 'EFO_0009963', 'EFO_0000616',
       'EFO_0001073', 'MONDO_0002009', 'HP_0000726', 'MONDO_0004985',
       'MONDO_0007254', 'EFO_0009854', 'MONDO_0004985', 'EFO_0002610',
       'MONDO_0007739', 'MONDO_0005148', 'EFO_0003890', 'EFO_0000384',
       'EFO_0002617', 'EFO_0007191', 'EFO_0003060', 'EFO_0005230',
       'MONDO_0008903', 'EFO_0004319', 'MONDO_0002009', 'MONDO_0044970',
       'EFO_0004701', 'EFO_0003888', 'MONDO_0002050', 'EFO_0004319',
       'MONDO_0005090', 'MONDO_0002046', 'MONDO_0007079', 'EFO_0004318',
       'EFO_0000095', 'MONDO_0010200', 'MONDO_0002050', 'MONDO_0002009',
       'EFO_0003768', 'EFO_0004247', 'EFO_0004270'], dtype=object), 'count': 47}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 38 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1073,"Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1_|_ZJJXGWJIGJFDTL-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLIPIZIDE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Glibenese' 'Glipizide' 'Glucotrol' 'Glucotrol xl' 'Minodiab 2.5'
 'Minodiab 5']_|_['CP-28,720' 'CP-28720' 'Glipizide' 'Glipizide slow release' 'K 4024'
 'K-4024' 'NSC-759120']_|_[('DailyMed', array(['glipizide'], dtype=object)), ('PubChem', array(['11111214', '11112714', '144203707', '144212151', '170465089',
       '50104189', '56422485', '855947'], dtype=object)), ('Wikipedia', array(['Glipizide'], dtype=object)), ('drugbank', array(['DB01067'], dtype=object)), ('chEBI', array(['5384'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'MONDO_0005148', 'EFO_0003884', 'EFO_0000400'],
      dtype=object), 'count': 4}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 2 investigational indications."
CHEMBL1194666,"CCN(CC)C(C)C(=O)c1ccccc1_|_XXEPPPIWZFICOJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIETHYLPROPION_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.alpha.-benzoyltriethylamine' 'Amfepramone' 'Anfepramone' 'Anferpramon'
 'C06954' 'D07444' 'Diethylcathinone' 'Diethylpropion' 'J4.327C']_|_[('Wikipedia', array(['Amfepramone'], dtype=object)), ('drugbank', array(['DB00937'], dtype=object)), ('chEBI', array(['4530'], dtype=object))]_|_['CHEMBL1693']_|_{'rows': array(['EFO_0001073', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000103546,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for obesity."
CHEMBL1466,"O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O_|_DOBMPNYZJYQDGZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DICUMAROL_|_1944.0_|_4.0_|_nan_|_False_|_True_|_['Dicumarol']_|_['Bishydroxycoumarin' 'Dicoumarol' 'Dicoumarolum' 'Dicumarol' 'NSC-17860'
 'NSC-221570' 'NSC-41834']_|_[('PubChem', array(['11112184', '144203908', '170465275'], dtype=object)), ('Wikipedia', array(['Dicoumarol'], dtype=object)), ('drugbank', array(['DB00266'], dtype=object)), ('chEBI', array(['4513'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004419'], dtype=object), 'count': 1}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1944 and is indicated for recurrent thrombophlebitis."
CHEMBL1555,"Br.COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2_|_QORVDGQLPPAFRS-XPSHAMGMSA-N_|_Small molecule_|_False_|_GALANTAMINE HYDROBROMIDE_|_2001.0_|_4.0_|_CHEMBL659_|_False_|_True_|_['Galantamine hydrobromide' 'Razadyne' 'Razadyne er']_|_['(-)-galantamine hydrobromide' 'Galantamine hydrobromide'
 'Galanthamine hydrobromide' 'Jilkon hydrobromide'
 'Lycoremine hydrobromide' 'Nivalin' 'Nivaline' 'Tamilin']_|_[('DailyMed', array(['galantamine%20hydrobromide'], dtype=object)), ('PubChem', array(['26719770', '49681569'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0004718', 'HP_0000726', 'MONDO_0005090',
       'MONDO_0017276', 'HP_0100543', 'EFO_0000677'], dtype=object), 'count': 7}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for alzheimer disease and dementia and has 5 investigational indications."
CHEMBL181954,"CO[C@@H](Cc1ccc(OCCCOc2ccc(Oc3ccccc3)cc2)cc1)C(=O)O_|_OKJHGOPITGTTIM-DEOSSOPVSA-N_|_Small molecule_|_False_|_NAVEGLITAZAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-519818' 'LY-9818' 'LY519818' 'LY9818' 'Ly519818' 'Naveglitazar']_|_[('drugbank', array(['DB12662'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000186951,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108575,nan_|_nan_|_Antibody_|_False_|_ASELIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aselizumab']_|_nan_|_nan_|_nan_|_[ENSG00000188404]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108895,"nan_|_nan_|_Oligonucleotide_|_False_|_ALICAFORSEN SODIUM_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Alicaforsen' 'Alicaforsen nonadecasodium salt' 'Alicaforsen sodium'
 'ISIS 2302' 'ISIS-2302']_|_nan_|_nan_|_nan_|_[ENSG00000090339]_|_Oligonucleotide drug."
CHEMBL2109540,"nan_|_nan_|_Antibody_|_False_|_ALIROCUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Praluent']_|_['Alirocumab' 'REGN-727' 'REGN727' 'SAR-236553' 'SAR236553']_|_[('DailyMed', array(['alirocumab'], dtype=object)), ('DrugCentral', array(['5016'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/praluent'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'HP_0100806', 'EFO_0000319', 'EFO_0004911',
       'HP_0003124', 'HP_0003119', 'Orphanet_309005', 'EFO_0004255',
       'MONDO_0018328', 'EFO_0000400', 'EFO_0001645'], dtype=object), 'count': 11}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 6 investigational indications."
CHEMBL3544936,"nan_|_nan_|_Small molecule_|_False_|_XL-844_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Xl-844']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000095', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000149554,ENSG00000183765]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3545122,"CC(C)C[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@H](CC(C)C)C(=O)O)CSSC[C@@H](C(=O)N[C@H](C(=O)O)C(C)C)NC1=O_|_WGEWYYPHYMGJNT-HLHYUOOASA-N_|_Protein_|_False_|_DOLCANATIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dolcanatide' 'SP-333']_|_nan_|_nan_|_{'rows': array(['HP_0002019', 'EFO_1001951'], dtype=object), 'count': 2}_|_[ENSG00000070019]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545167,"nan_|_nan_|_Protein_|_False_|_FE 202767_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fe 202767']_|_nan_|_nan_|_{'rows': array(['EFO_0003917'], dtype=object), 'count': 1}_|_[ENSG00000180914]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3716552,"COc1cc(OCc2csc(-c3ccc(C(=O)N(C)C)cc3)n2)c2cc(-c3cn4nc(OC)sc4n3)oc2c1_|_KEEBLYWBELVGPQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-986141_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-986141' 'Bms-986141' 'UDM-003183']_|_[('drugbank', array(['DB14942'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001645', 'HP_0002140', 'EFO_0001421', 'MONDO_0000831'],
      dtype=object), 'count': 4}_|_[ENSG00000127533]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL372205,"C[C@H](CN(C(=O)c1ccc(C#N)cc1)c1ccccn1)N1CCN(c2cccc3c2OCCO3)CC1_|_NRPQELCNMADTOZ-OAQYLSRUSA-N_|_Small molecule_|_False_|_LECOZOTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Lecozotan']_|_[('drugbank', array(['DB12540'], dtype=object))]_|_['CHEMBL2107349']_|_{'rows': array(['MONDO_0004975', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication."
CHEMBL3989481,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O_|_GTPHQORJKFJIRB-JTQLPTLWSA-N_|_Protein_|_False_|_FRAKEFAMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bch-3963' 'Frakefamide' 'LEF-576' 'SPD-759' 'SPD759']_|_nan_|_nan_|_nan_|_[ENSG00000112038]_|_Protein drug with a maximum clinical trial phase of II.
CHEMBL4091374,"O=C(O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1_|_OQDQIFQRNZIEEJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_LANIFIBRANOR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IVA-337' 'IVA337' 'Iva337' 'Lanifibranor']_|_[('drugbank', array(['DB14801'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000404', 'EFO_0003095', 'EFO_1001249'], dtype=object), 'count': 3}_|_[ENSG00000132170,ENSG00000186951,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297859,"nan_|_nan_|_Antibody drug conjugate_|_False_|_AZINTUXIZUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abbv-838' 'Azintuxizumab vedotin']_|_nan_|_nan_|_{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}_|_[ENSG00000026751,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298176,"nan_|_nan_|_Antibody_|_False_|_GARETOSMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Garetosmab' 'REGN-2477' 'REGN2477']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GARETOSMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007606', 'EFO_0007323'], dtype=object), 'count': 2}_|_[ENSG00000122641]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4466233,"CC(=O)N1CCC(Nc2cc(C(=O)NC[C@H](O)CN3CCc4ccccc4C3)ncn2)CC1_|_JLCCNYVTIWRPIZ-NRFANRHFSA-N_|_Small molecule_|_False_|_PEMRAMETOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EPZ-015938' 'EPZ015938' 'GSK-3326595A' 'GSK3326595' 'Gsk 3326595'
 'Gsk-3326595' 'Gsk3326595' 'Pemrametostat']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000100462]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594348,"C=CC(=O)N1CCC[C@@H](c2ccc(C(N)=O)c3[nH]ccc23)C1_|_UNHZLHSLZZWMNP-LLVKDONJSA-N_|_Small molecule_|_False_|_ELSUBRUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-105' 'ABBV105' 'Elsubrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELSUBRUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4650421,"nan_|_nan_|_Unknown_|_False_|_RECOMBINANT HUMAN INTERLEUKIN-15_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Recombinant human il-15' 'Recombinant human interleukin-15' 'Rhil-15']_|_nan_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_0000565', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000147168,ENSG00000100385,ENSG00000134470]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL707,"COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC_|_RUZYUOTYCVRMRZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXAZOSIN_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['C02CA04' 'Cardura' 'Doxazosin' 'UK-33274']_|_[('PubChem', array(['124883384', '50105246', '90341261'], dtype=object)), ('Wikipedia', array(['Doxazosin'], dtype=object)), ('drugbank', array(['DB00590'], dtype=object)), ('chEBI', array(['4708'], dtype=object))]_|_['CHEMBL1200561']_|_{'rows': array(['EFO_0002610', 'EFO_0000537', 'EFO_0000284', 'HP_0003124',
       'EFO_0000400', 'EFO_0004234', 'EFO_0000537', 'EFO_0004253',
       'MONDO_0002491', 'EFO_0003144', 'EFO_1001375', 'EFO_0000612',
       'EFO_0001358', 'MONDO_0007079', 'EFO_0000612', 'EFO_0003777',
       'EFO_0003890', 'EFO_0000284', 'EFO_0003768'], dtype=object), 'count': 19}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved and 15 investigational indications."
CHEMBL94454,"CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1_|_PVLJETXTTWAYEW-UHFFFAOYSA-N_|_Small molecule_|_False_|_MIZOLASTINE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Mizollen']_|_['Mizolastine']_|_[('PubChem', array(['144206216', '170465604', '50125752'], dtype=object)), ('Wikipedia', array(['Mizolastine'], dtype=object)), ('drugbank', array(['DB12523'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for allergic disease."
CHEMBL1078178,"N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1_|_ZVHNDZWQTBEVRY-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOMELOTINIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CYT-0387' 'CYT-11387' 'CYT-387' 'CYT387' 'Cyt-387' 'GS-0387'
 'Momelotinib']_|_[('PubChem', array(['137275866'], dtype=object)), ('drugbank', array(['DB11763'], dtype=object))]_|_['CHEMBL2219411']_|_{'rows': array(['EFO_0000479', 'EFO_0002429', 'EFO_0000479', 'EFO_0002429',
       'EFO_0002430', 'EFO_0003060', 'MONDO_0044903', 'EFO_0002430',
       'MONDO_0005184'], dtype=object), 'count': 9}_|_[ENSG00000162434,ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 6 investigational indications."
CHEMBL1086,"CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1_|_PUFQVTATUTYEAL-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIBUCAINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cinchocaine' 'Dibucaine' 'NSC-159055']_|_[('PubChem', array(['11112228', '144203932', '170464829', '50100394', '50100395',
       '56424123', '855529'], dtype=object)), ('Wikipedia', array(['Cinchocaine'], dtype=object)), ('drugbank', array(['DB00527'], dtype=object)), ('chEBI', array(['247956'], dtype=object))]_|_['CHEMBL1200612']_|_{'rows': array(['EFO_0003958', 'EFO_0009552', 'HP_0000989'], dtype=object), 'count': 3}_|_[ENSG00000185313,ENSG00000183873]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved indications."
CHEMBL1200597,"CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C.Cl_|_LMWQQUMMGGIGJQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETIDOCAINE HYDROCHLORIDE_|_1976.0_|_4.0_|_CHEMBL492_|_False_|_True_|_['Duranest']_|_['Duranest hydrochloride' 'Etidocaine hcl' 'W-19053']_|_nan_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976."
CHEMBL1201151,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C_|_IMSSROKUHAOUJS-MJCUULBUSA-N_|_Small molecule_|_False_|_MESTRANOL_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['33355' 'EE-3ME' 'EE3 ME' 'EE3-ME' 'EE3ME' 'EEI3ME' 'Mestranol'
 'NSC-84032']_|_[('PubChem', array(['144204751', '144212154', '170465357', '29215140', '56422167',
       '8139980'], dtype=object)), ('Wikipedia', array(['Mestranol'], dtype=object)), ('drugbank', array(['DB01357'], dtype=object)), ('chEBI', array(['6784'], dtype=object))]_|_nan_|_nan_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL1201323,"NCCc1cc[nH]n1_|_JXDFEQONERDKSS-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETAZOLE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betazole']_|_[('PubChem', array(['11112911'], dtype=object)), ('Wikipedia', array(['Betazole'], dtype=object)), ('drugbank', array(['DB00272'], dtype=object)), ('chEBI', array(['59170'], dtype=object))]_|_['CHEMBL1200949' 'CHEMBL4303510']_|_nan_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201697,"nan_|_nan_|_Protein_|_False_|_LH (MENOTROPINS)_|_1975.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Human lh' 'Lh (menotropins)']_|_nan_|_nan_|_{'rows': array(['EFO_0000545'], dtype=object), 'count': 1}_|_[ENSG00000138039]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1975 and has 1 investigational indication."
CHEMBL1256175,"CC(=O)O.CNC(=N)NCCC[C@H](N)C(=O)O_|_IKPNWIGTWUZCKM-JEDNCBNOSA-N_|_Small molecule_|_False_|_TILARGININE ACETATE_|_nan_|_3.0_|_CHEMBL256147_|_False_|_False_|_[]_|_['ANO-1020' 'L-nmma acetate' 'Ng-methyl-l-arginine acetate salt'
 'Ng-methylarginine acetate' 'Ng-monomethyl-l-arginine acetate'
 'Targinine acetate' 'Tilarginine acetate']_|_[('PubChem', array(['144204797', '144207069', '144207127', '56463670'], dtype=object))]_|_nan_|_{'rows': array(['HP_0031273'], dtype=object), 'count': 1}_|_[ENSG00000089250,ENSG00000007171,ENSG00000164867]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1308,"Cc1cn[nH]c1_|_RIKMMFOAQPJVMX-UHFFFAOYSA-N_|_Small molecule_|_False_|_FOMEPIZOLE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Antizol' 'Fomepizole']_|_['4-MP' '4-methylpyrazole' 'Fomepizole' 'NSC-760365']_|_[('DailyMed', array(['fomepizole'], dtype=object)), ('PubChem', array(['11111426', '50111124', '90341211'], dtype=object)), ('Wikipedia', array(['Fomepizole'], dtype=object)), ('drugbank', array(['DB01213'], dtype=object)), ('chEBI', array(['5141'], dtype=object))]_|_['CHEMBL1256285']_|_{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}_|_[ENSG00000187758,ENSG00000196616,ENSG00000248144]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and has 1 investigational indication."
CHEMBL1542,"Cn1cnc([N+](=O)[O-])c1Sc1ncnc2[nH]cnc12_|_LMEKQMALGUDUQG-UHFFFAOYSA-N_|_Small molecule_|_True_|_AZATHIOPRINE_|_1968.0_|_4.0_|_nan_|_False_|_True_|_['Azamune' 'Azapress' 'Azasan' 'Azathioprine' 'Berkaprine' 'Immunoprin 50'
 'Imuran' 'Jayempi' 'Kentaprine' 'Oprisine 50']_|_['Azathioprine' 'Azathioprinum' 'BW-57-322' 'NSC-39084']_|_[('Wikipedia', array(['Azathioprine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi'],
      dtype=object)), ('TG-GATEs', array(['46'], dtype=object)), ('PubChem', array(['104171105', '11110740', '11110741', '124879189', '144203625',
       '144213985', '170464989', '17390031', '174006316', '26670994',
       '26747870', '26747871', '26747872', '26752814', '50105466',
       '50105467', '50105468', '85230906', '90340846'], dtype=object)), ('DailyMed', array(['azathioprine'], dtype=object)), ('drugbank', array(['DB00993'], dtype=object)), ('chEBI', array(['2948'], dtype=object))]_|_['CHEMBL1200400' 'CHEMBL3785814' 'CHEMBL3785780']_|_{'rows': array(['EFO_0000318', 'EFO_0005297', 'EFO_0003818', 'EFO_0003884',
       'EFO_0000729', 'EFO_0000222', 'MONDO_0007915', 'EFO_0005761',
       'EFO_0004826', 'EFO_0000384', 'HP_0001873', 'MONDO_0011382',
       'EFO_0000685', 'EFO_1001857', 'EFO_0004719', 'EFO_0000182',
       'EFO_0007208', 'EFO_0004274', 'EFO_0004244', 'EFO_0009448',
       'MONDO_0019249', 'EFO_0006803', 'EFO_0005676', 'EFO_0004256',
       'EFO_0007187', 'EFO_0003767', 'EFO_0000545', 'EFO_1000784',
       'EFO_0001423', 'EFO_0004991', 'EFO_1000749', 'HP_0000964',
       'EFO_0000768', 'EFO_0000540', 'EFO_0004194', 'EFO_0005531',
       'EFO_0000198', 'EFO_0000220'], dtype=object), 'count': 38}_|_[ENSG00000128059]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and is indicated for rheumatoid arthritis and immune system disease and has 36 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743080,"nan_|_nan_|_Antibody_|_False_|_TIGATUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anti-dr5 moab' 'Anti-trail-r2 moab' 'CS-1008' 'TRA-8' 'Tigatuzumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'MONDO_0008170', 'EFO_0000574', 'EFO_0003060',
       'EFO_0004142', 'EFO_0002618', 'EFO_0000182'], dtype=object), 'count': 7}_|_[ENSG00000120889]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL175247,"CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O_|_AHLBNYSZXLDEJQ-FWEHEUNISA-N_|_Small molecule_|_False_|_ORLISTAT_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Alli' 'Alli (previously orlistat gsk)' 'Beacita' 'Xenical']_|_['Lipstatin' 'NSC-758881' 'Orlipastat' 'Orlistat' 'RO 18-0647/002'
 'RO-180647-002' 'RO-180647002' 'Tetrahydrolipstatin']_|_[('DailyMed', array(['orlistat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alli'],
      dtype=object)), ('PubChem', array(['26719846', '29217614', '49681644', '93576635'], dtype=object)), ('Wikipedia', array(['Orlistat'], dtype=object)), ('drugbank', array(['DB01083'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000660', 'EFO_0000545', 'Orphanet_411', 'EFO_0000195',
       'EFO_0001073'], dtype=object), 'count': 5}_|_[ENSG00000175535,ENSG00000182333]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for obesity and has 4 investigational indications."
CHEMBL2108738,"nan_|_nan_|_Antibody_|_False_|_NIVOLUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Opdivo']_|_['BMS-936558' 'BMS-986298' 'MDX-1106' 'MDX1106' 'Nivolumab' 'ONO-4538']_|_[('DailyMed', array(['nivolumab'], dtype=object)), ('DrugCentral', array(['4923'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001657', 'EFO_0005221', 'MONDO_0002691', 'EFO_0000588',
       'EFO_1001972', 'EFO_1001949', 'EFO_0000183', 'EFO_0009709',
       'EFO_0005537', 'EFO_0000691', 'EFO_0001642', 'EFO_0003968',
       'EFO_1000657', 'MONDO_0007187', 'MONDO_0002158', 'EFO_0004243',
       'EFO_0004197', 'MONDO_0021148', 'EFO_0000096', 'EFO_0000365',
       'EFO_0000565', 'EFO_0000403', 'EFO_0000519', 'EFO_0006859',
       'EFO_0003891', 'MONDO_0002108', 'MONDO_0008170', 'EFO_0000198',
       'EFO_0000621', 'EFO_0000211', 'EFO_0000637', 'EFO_0000180',
       'EFO_0000305', 'EFO_1001469', 'MONDO_0021117', 'EFO_0003047',
       'MONDO_0007254', 'EFO_0001061', 'EFO_1001931', 'MONDO_0002928',
       'EFO_1001465', 'MONDO_0100342', 'EFO_1000613', 'EFO_0002617',
       'HP_0100806', 'EFO_0004252', 'EFO_0004142', 'EFO_0000708',
       'MONDO_0016642', 'EFO_0000616', 'MONDO_0002547', 'EFO_0000681',
       'MONDO_0015760', 'EFO_0000294', 'MONDO_0008315', 'MONDO_0000521',
       'MONDO_0002367', 'EFO_1001051', 'EFO_0000632', 'EFO_1000601',
       'MONDO_0100096', 'EFO_0009259', 'MONDO_0017582', 'EFO_0000389',
       'EFO_0000339', 'EFO_0005543', 'MONDO_0004992', 'EFO_0000770',
       'MONDO_0001187', 'EFO_0000220', 'EFO_0000571', 'MONDO_0024503',
       'EFO_0007532', 'HP_0002745', 'EFO_0008524', 'EFO_0007466',
       'EFO_0007541', 'EFO_1000984', 'EFO_1001950', 'EFO_0001416',
       'MONDO_0007576', 'EFO_0003833', 'EFO_0000181', 'MONDO_0044704',
       'EFO_0003032', 'EFO_0001376', 'EFO_1000251', 'EFO_0000228',
       'MONDO_0002087', 'MONDO_0005184', 'EFO_0000196', 'MONDO_0018906',
       'EFO_0002892', 'EFO_0003085', 'EFO_0000181', 'EFO_0000174',
       'EFO_1001951', 'EFO_0000564', 'MONDO_0011719', 'EFO_1001512',
       'MONDO_0002038', 'EFO_0000707', 'EFO_0003050', 'MONDO_0001056',
       'EFO_0005922', 'EFO_0004239', 'EFO_0000756', 'EFO_0001075',
       'EFO_0000199', 'EFO_1001471', 'EFO_0002916', 'EFO_0000182',
       'EFO_1000359', 'MONDO_0008903', 'MONDO_0002898', 'EFO_0000503',
       'EFO_0000326', 'EFO_0002918', 'EFO_0000514', 'MONDO_0002120',
       'EFO_0000349', 'EFO_1001968', 'EFO_0001378', 'MONDO_0003060',
       'EFO_0005952', 'EFO_0000702', 'MONDO_0020634', 'EFO_0003016',
       'EFO_0008528', 'MONDO_0004669', 'EFO_0000558', 'MONDO_0004986',
       'EFO_0000574', 'EFO_0000640', 'EFO_1000796', 'EFO_1000209',
       'EFO_0004193', 'EFO_0004284', 'MONDO_0000870', 'EFO_0000095',
       'EFO_0000673', 'EFO_0008585', 'EFO_0007304', 'MONDO_0004180',
       'EFO_0000313', 'MONDO_0021063', 'EFO_1000785', 'MONDO_0044881',
       'EFO_0003060', 'EFO_0003863', 'MONDO_0008978', 'EFO_0000335',
       'EFO_0000222', 'EFO_0002618', 'EFO_1000026', 'MONDO_0002974',
       'MONDO_0009348'], dtype=object), 'count': 157}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 23 approved and 134 investigational indications."
CHEMBL266125,"Cc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1_|_YQYSVMKCMIUCHY-WJOKGBTCSA-N_|_Small molecule_|_False_|_IBODUTANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ibodutant' 'Men15596']_|_[('drugbank', array(['DB12042'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000075073]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL282724,"Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2_|_PHWXUGHIIBDVKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_SITAXENTAN_|_2006.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['IPI-1040' 'Sitaxentan' 'Sitaxsentan' 'TBC-11251']_|_[('PubChem', array(['170465720'], dtype=object)), ('Wikipedia', array(['Sitaxentan'], dtype=object)), ('drugbank', array(['DB06268'], dtype=object))]_|_['CHEMBL2105740']_|_{'rows': array(['MONDO_0005149', 'EFO_0000537', 'HP_0000093', 'EFO_1000899',
       'EFO_0001361', 'MONDO_0004979', 'EFO_0003884', 'MONDO_0005149'],
      dtype=object), 'count': 8}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for hypertension and pulmonary hypertension and has 6 investigational indications. It was withdrawn in at least one region."
CHEMBL297302,"O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1_|_FEBOTPHFXYHVPL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENPERIDOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Anquil' 'Benquil']_|_['Benperidol' 'MCN-JR-4584' 'NSC-170982' 'R-4584']_|_[('PubChem', array(['11112508', '144204068', '170466409', '56463215'], dtype=object)), ('Wikipedia', array(['Benperidol'], dtype=object)), ('drugbank', array(['DB12867'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0005407'], dtype=object), 'count': 5}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."
CHEMBL299400,"O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3_|_GMTYREVWZXJPLF-SXWPHCFWSA-N_|_Small molecule_|_True_|_BUTORPHANOL TARTRATE_|_1978.0_|_4.0_|_CHEMBL33986_|_False_|_True_|_['Butorphanol tartrate' 'Butorphanol tartrate preservative free' 'Stadol'
 'Stadol ns' 'Stadol preservative free' 'Torbugesic' 'Torbutrol']_|_['Butorphanol tartrate' 'Butorphanol tartrate civ' 'Dolorex'
 'LEVO-BC-2627 TARTRATE' 'Torbugesic' 'Torbutrol']_|_[('DailyMed', array(['butorphanol%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003890'], dtype=object), 'count': 1}_|_[ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978 and is indicated for drug dependence. This drug has a black box warning from the FDA."
CHEMBL3623290,"COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C_|_MXDSJQHFFDGFDK-CYBMUJFWSA-N_|_Small molecule_|_False_|_AZD-3759_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD3759' 'Azd 3759' 'Azd-3759' 'Azd3759' 'Zorifertinib']_|_[('drugbank', array(['DB14795'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989958,"N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1_|_WIJZXSAJMHAVGX-DHLKQENFSA-N_|_Small molecule_|_True_|_IVOSIDENIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Tibsovo']_|_['AG-120' 'Ivosidenib']_|_[('DailyMed', array(['ivosidenib'], dtype=object)), ('drugbank', array(['DB14568'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005184', 'EFO_0000333', 'EFO_0000616', 'EFO_0000198',
       'EFO_0005221', 'EFO_0001421', 'EFO_0003891', 'EFO_0005543',
       'EFO_0000222', 'MONDO_0004992'], dtype=object), 'count': 10}_|_[ENSG00000138413]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4164059,"Cl.Clc1ccc(CCCOCCCN2CCCCC2)cc1_|_XLFKECRRMPOAQS-UHFFFAOYSA-N_|_Small molecule_|_False_|_PITOLISANT HYDROCHLORIDE_|_2019.0_|_4.0_|_CHEMBL462605_|_False_|_True_|_['Ozawade' 'Wakix']_|_['Ciproxidine' 'Pitolisant hydrochloride']_|_[('DailyMed', array(['pitolisant%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PITOLISANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005246', 'MONDO_0016158'], dtype=object), 'count': 2}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for hypersomnia and narcolepsy-cataplexy syndrome."
CHEMBL4297596,"Cn1c(=O)oc2cc(-n3cc(C(=O)O)c(=O)n([C@@H]4CCc5c4cccc5C(F)(F)F)c3=O)ccc21_|_JDARDSVOVYVQST-MRXNPFEDSA-N_|_Small molecule_|_False_|_FULACIMSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY-1142524' 'BAY1142524' 'Bay1142524' 'Fulacimstat']_|_[('drugbank', array(['DB15085'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612', 'EFO_0000401', 'EFO_0003144'], dtype=object), 'count': 3}_|_[ENSG00000092009]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL435,"NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O_|_JZUFKLXOESDKRF-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROCHLOROTHIAZIDE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Apo-hydro' 'Esidrex' 'Esidrix' 'Hydro-d' 'Hydrochlorothiazide'
 'Hydrochlorothiazide intensol' 'Hydrodiuril' 'Hydrosaluric' 'Microzide'
 'Oretic' 'Zide']_|_['Apresazide' 'Carozide' 'Chlorosulthiadil' 'Copalia-hct' 'Dafiro-hct'
 'Dihydrochlorurite' 'Exforge-hct' 'Hctz' 'Hidrotiazida'
 'Hydrochlorothiaizide' 'Hydrochlorothiazide' 'Hydrochlorothiazidum'
 'Idrotiazide' 'Imprida-hct' 'Lotensin hct' 'Megadiuril' 'NSC-53477'
 'Newtolide' 'Pantemon' 'Rasilez-hct' 'SU-5879' 'Servithiazid' 'Unipres'
 'Vetidrex']_|_[('DailyMed', array(['hydrochlorothiazide'], dtype=object)), ('PubChem', array(['103995', '11111269', '11111270', '144208763', '144210612',
       '170465005', '17389854', '26746944', '50103978', '85231074',
       '855646'], dtype=object)), ('Wikipedia', array(['Hydrochlorothiazide'], dtype=object)), ('drugbank', array(['DB00999'], dtype=object)), ('chEBI', array(['5778'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001422', 'EFO_0003913', 'EFO_0000537', 'EFO_0000319',
       'EFO_0000400', 'Orphanet_79292', 'MONDO_0005148', 'EFO_0003884',
       'EFO_0000668', 'EFO_0004278', 'EFO_0009373', 'EFO_0001645',
       'EFO_0000612', 'HP_0003124', 'EFO_0004255', 'EFO_0003914',
       'EFO_0003144', 'EFO_0004253', 'EFO_0000195', 'MONDO_0001134',
       'EFO_1001496', 'EFO_0003086', 'EFO_0000668', 'EFO_0000373',
       'MONDO_0002462'], dtype=object), 'count': 25}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 12 approved and 13 investigational indications."
CHEMBL4650333,"COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC_|_JHJNPOSPVGRIAN-SFHVURJKSA-N_|_Small molecule_|_False_|_SERALUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GB-002' 'GB002' 'Gb002' 'PK-10571' 'Seralutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SERALUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001361', 'MONDO_0005149'], dtype=object), 'count': 2}_|_[ENSG00000157404,ENSG00000182578,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4650472,"nan_|_nan_|_Antibody_|_False_|_PUCOTENLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['HX-008' 'HX008' 'Hx 008' 'Hx008' 'Pucotenlimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000182', 'MONDO_0001056', 'EFO_0000616',
       'MONDO_0001187', 'MONDO_0002108', 'EFO_0003060'], dtype=object), 'count': 7}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL708,"O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1_|_MVWVFYHBGMAFLY-UHFFFAOYSA-N_|_Small molecule_|_True_|_ZIPRASIDONE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CP-88059' 'Geodon' 'Zipradon' 'Ziprasidone']_|_[('PubChem', array(['144205747', '144207074', '170465342', '26719835'], dtype=object)), ('Wikipedia', array(['Ziprasidone'], dtype=object)), ('drugbank', array(['DB00246'], dtype=object)), ('chEBI', array(['10119'], dtype=object))]_|_['CHEMBL1712' 'CHEMBL1200997' 'CHEMBL3989833' 'CHEMBL1375743']_|_{'rows': array(['EFO_1001917', 'EFO_0005411', 'MONDO_0005090', 'EFO_0005230',
       'EFO_0009963', 'MONDO_0004985', 'MONDO_0004985', 'MONDO_0005090',
       'HP_0012076', 'MONDO_0004985', 'EFO_0004247', 'EFO_0005306',
       'HP_0000713', 'EFO_1001141', 'HP_0000726', 'EFO_0003890',
       'EFO_0005407', 'MONDO_0002050', 'EFO_0004269', 'EFO_0003758',
       'EFO_0005611', 'EFO_0000319', 'MONDO_0005090', 'MONDO_0002009'],
      dtype=object), 'count': 24}_|_[ENSG00000147246,ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 8 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL93747,"O=C1NC(=O)C(Cc2ccc3cc(OCc4ccccc4F)ccc3c2)S1_|_PKWDZWYVIHVNKS-UHFFFAOYSA-N_|_Small molecule_|_False_|_NETOGLITAZONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MCC 555' 'MCC555' 'Mcc-555' 'Netoglitazone' 'PGX-510' 'RWJ-241947']_|_[('drugbank', array(['DB09199'], dtype=object))]_|_nan_|_nan_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1200396,"CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl_|_SIEYLFHKZGLBNX-UHFFFAOYSA-N_|_Small molecule_|_True_|_BUPIVACAINE HYDROCHLORIDE_|_1972.0_|_4.0_|_CHEMBL1098_|_False_|_True_|_['Bupivac hcl' 'Bupivacaine hydrochloride' 'Bupivacaine hydrochloride kit'
 'Bupivacaine hydrochloride preservative free' 'Marcain' 'Marcaine'
 'Marcaine hydrochloride' 'Marcaine hydrochloride preservative free'
 'Sensorcaine' 'Xaracoll']_|_['AH-2250' 'Bupivacaine hcl' 'Bupivacaine hydrochloride'
 'Bupivacaine hydrochloride hydrate'
 'Bupivacaine hydrochloride monohydrate' 'Bupivacaine hydrochloride rs'
 'Bupivacaini hydrochloridum' 'Carbostesin' 'LAC-43' 'NSC-758631'
 'WIN 11,318' 'WIN-11318' 'Xaracoll']_|_[('DailyMed', array(['bupivacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['26748842', '56463371'], dtype=object)), ('chEBI', array(['31322'], dtype=object))]_|_nan_|_{'rows': array(['HP_0031217', 'MONDO_0002087', 'EFO_0004616', 'MONDO_0005277',
       'MONDO_0007254', 'HP_0000023', 'MONDO_0041052', 'HP_0012532',
       'EFO_0009552', 'HP_0000175', 'EFO_1001087', 'EFO_0000546',
       'EFO_0003843', 'EFO_0000764', 'MONDO_0004992', 'MONDO_0002959',
       'HP_0001822'], dtype=object), 'count': 17}_|_[ENSG00000007314]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and has 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200624,"C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C_|_ONKUMRGIYFNPJW-KIEAKMPYSA-N_|_Small molecule_|_False_|_ETHYNODIOL DIACETATE_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Femulen']_|_['Ethynodiol diacetate' 'Etynodiol' 'Etynodiol acetate'
 'Etynodiol diacetate' 'NSC-759288' 'SC 11800' 'SC-11800']_|_[('DailyMed', array(['ethynodiol%20diacetate'], dtype=object)), ('PubChem', array(['144205886', '144206477', '170464933', '29217896'], dtype=object)), ('drugbank', array(['DB00823'], dtype=object)), ('chEBI', array(['31580'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1966."
CHEMBL1200675,"CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_IWEQQRMGNVVKQW-OQKDUQJOSA-N_|_Small molecule_|_True_|_TOREMIFENE CITRATE_|_1996.0_|_4.0_|_CHEMBL1655_|_False_|_True_|_['Fareston']_|_['FC-1157A' 'NSC-613680' 'Toremifene citrate']_|_[('DailyMed', array(['toremifene%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fareston'],
      dtype=object)), ('PubChem', array(['144205430', '144212057', '486747', '49681796', '50085986'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003931', 'EFO_0003869', 'EFO_0000305', 'EFO_0003882',
       'MONDO_0007254'], dtype=object), 'count': 5}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200695,"CC(N)C(O)c1ccccc1.Cl_|_DYWNLSQWJMTVGJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENYLPROPANOLAMINE HYDROCHLORIDE_|_1958.0_|_4.0_|_CHEMBL61006_|_True_|_True_|_['Dexatrim' 'Dimotapp' 'Dimotapp l.a.' 'Eskornade' 'Procol' 'Propagest'
 'Sine-off' 'Triogesic' 'Triominic']_|_['NSC-23798' 'Norephedrine hydrochloride' 'Phenylpropanolamine chloride'
 'Phenylpropanolamine hcl' 'Phenylpropanolamine hydrochloride'
 'Propadrine hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000120907,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958. It was withdrawn in at least one region."
CHEMBL1200833,"CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1.Cl_|_VKFAUCPBMAGVRG-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPIVEFRIN HYDROCHLORIDE_|_1980.0_|_4.0_|_CHEMBL1201262_|_False_|_True_|_['Akpro' 'Dipivefrin hydrochloride' 'Propine']_|_['Dipivefrin hcl' 'Dipivefrin hydrochloride' 'Dipivefrine hydrochloride']_|_[('PubChem', array(['144204226', '56463529'], dtype=object)), ('chEBI', array(['4647'], dtype=object))]_|_nan_|_nan_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980."
CHEMBL1201635,nan_|_nan_|_Protein_|_False_|_INSULIN SUSP ISOPHANE BEEF/PORK_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Nph iletin i (beef-pork)']_|_['Insulin susp isophane beef/pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1966.
CHEMBL1230609,"COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1_|_CXQHYVUVSFXTMY-UHFFFAOYSA-N_|_Small molecule_|_False_|_FORETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EXEL-2880' 'Foretinib' 'GSK-089' 'GSK-1363089' 'GSK-1363089G' 'GSK089'
 'GSK1363089G' 'Gsk-1363089' 'Gsk1363089' 'XL-880' 'XL880']_|_[('PubChem', array(['137275948'], dtype=object)), ('drugbank', array(['DB12307'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000182', 'EFO_0005950', 'MONDO_0008903',
       'EFO_0000616', 'EFO_0000681', 'MONDO_0004992'], dtype=object), 'count': 7}_|_[ENSG00000113721,ENSG00000134853,ENSG00000120156,ENSG00000122025,ENSG00000105976,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL1743052,"nan_|_nan_|_Antibody drug conjugate_|_False_|_OPORTUZUMAB MONATOX_|_nan_|_3.0_|_nan_|_False_|_False_|_['Proxinium' 'Proxinium, Vicinium' 'Vicineum' 'Vicinium']_|_['4D5MOCB-ETA' 'Oportuzumab monatox' 'VB4-845' 'XD60E5X7FI']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OPORTUZUMAB%20MONATOX/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000294', 'MONDO_0001187', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000119888]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1769,"CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC.Cl_|_GITPCGSPKUQZTE-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPOXYCAINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1195_|_False_|_True_|_[]_|_['NSC-760044' 'Propoxycaine HCl' 'Propoxycaine hcl'
 'Propoxycaine hydrochloride']_|_[('PubChem', array(['144204013', '56463554'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1773,"CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F_|_GAGWJHPBXLXJQN-UORFTKCHSA-N_|_Small molecule_|_True_|_CAPECITABINE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Capecitabine' 'Xeloda']_|_['Capecitabine' 'Capecitabine accord' 'Capecitabine medac'
 'Capecitabine sun' 'Capecitabine teva' 'Capecitibine' 'Capecytabine'
 'Capiibine' 'Captabin' 'Ecansya' 'NSC-759853' 'RO 09-1978/000'
 'RO-09-1978000' 'RO-091978000' 'Xeloda']_|_[('DailyMed', array(['capecitabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda'],
      dtype=object)), ('PubChem', array(['144205751', '170464779'], dtype=object)), ('Wikipedia', array(['Capecitabine'], dtype=object)), ('drugbank', array(['DB01101'], dtype=object)), ('chEBI', array(['31348'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_0001075', 'EFO_0007456', 'EFO_0002938',
       'EFO_1001893', 'EFO_1001901', 'EFO_0005774', 'EFO_0000181',
       'EFO_0002617', 'EFO_0003897', 'MONDO_0005575', 'EFO_0005540',
       'EFO_0004252', 'EFO_0006352', 'EFO_0005922', 'MONDO_0002691',
       'MONDO_0002165', 'MONDO_0001056', 'MONDO_0002158', 'EFO_1001471',
       'EFO_0003860', 'MONDO_0001657', 'EFO_0003869', 'EFO_1001949',
       'EFO_1000158', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0005221',
       'EFO_0004288', 'MONDO_0005184', 'EFO_0006859', 'EFO_0005543',
       'MONDO_0002974', 'EFO_0000588', 'MONDO_0100342', 'EFO_1000251',
       'EFO_1000657', 'MONDO_0001879', 'MONDO_0002087', 'EFO_0003891',
       'EFO_0000681', 'MONDO_0002367', 'EFO_0009259', 'EFO_1000984',
       'EFO_0000178', 'EFO_0008528', 'EFO_0004142', 'EFO_0005537',
       'EFO_0003060', 'EFO_0002618', 'MONDO_0008315', 'EFO_1001956',
       'MONDO_0004992', 'EFO_0000616', 'MONDO_0002108', 'MONDO_0044926',
       'MONDO_0007576', 'EFO_1000294', 'EFO_0000228', 'EFO_0007416',
       'EFO_0000389', 'EFO_0000365', 'EFO_0000707', 'EFO_1000045',
       'EFO_0000305', 'MONDO_0021063', 'EFO_0000503', 'EFO_0000519',
       'EFO_0004284', 'EFO_0009708', 'MONDO_0005411', 'EFO_1001951',
       'EFO_1001961', 'MONDO_0003060', 'EFO_0005952', 'EFO_0002916',
       'EFO_0000313', 'EFO_0006861', 'EFO_0000756', 'MONDO_0008170',
       'EFO_0003865', 'MONDO_0002898', 'MONDO_0002120', 'MONDO_0044937'],
      dtype=object), 'count': 84}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 16 approved and 68 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108429,"nan_|_nan_|_Antibody_|_False_|_MEPOLIZUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Bosatria' 'Nucala']_|_['Mepolizumab' 'SB-240563']_|_[('DailyMed', array(['mepolizumab'], dtype=object)), ('DrugCentral', array(['5061'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nucala'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004232', 'EFO_0005297', 'EFO_0005531', 'EFO_0000341',
       'MONDO_0004979', 'EFO_0007208', 'EFO_0000274', 'EFO_1000024',
       'HP_0001880', 'HP_0006536', 'EFO_1001467', 'EFO_0006803',
       'EFO_1000391'], dtype=object), 'count': 13}_|_[ENSG00000113525]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 8 investigational indications."
CHEMBL2109356,"nan_|_nan_|_Antibody_|_False_|_BIIB-022_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BIIB-022' 'Biib 022' 'Biib-022']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060', 'EFO_0000182'], dtype=object), 'count': 3}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL215645,"CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1.O=C(O)C(O)C(O)C(=O)O_|_GWHQHAUAXRMMOT-MERQFXBCSA-N_|_Small molecule_|_False_|_RIVASTIGMINE TARTRATE_|_1998.0_|_4.0_|_CHEMBL636_|_False_|_True_|_['Exelon' 'Rivastigmine tartrate']_|_['ENA 713' 'Rivastigmine Tartrate' 'Rivastigmine actavis'
 'Rivastigmine bitartrate' 'Rivastigmine hydrogen tartrate'
 'Rivastigmine hydrogentartrate' 'Rivastigmine tartrate' 'Sdz-ena 713']_|_[('DailyMed', array(['rivastigmine%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/exelon'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000726', 'MONDO_0005180', 'EFO_0005252'], dtype=object), 'count': 3}_|_[ENSG00000114200,ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for dementia and parkinson disease and has 1 investigational indication."
CHEMBL3039556,"nan_|_nan_|_Oligonucleotide_|_False_|_APATORSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apatorsen' 'OGX-427']_|_nan_|_nan_|_{'rows': array(['EFO_0000708', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0002618',
       'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000106211]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3301580,"nan_|_nan_|_Antibody_|_False_|_FLETIKUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-IL-20' 'Fletikumab' 'NNC-0109-0012' 'NNC01 09-0012' 'NNC0109-0012']_|_nan_|_nan_|_{'rows': array(['MP_0001845', 'EFO_0000685', 'EFO_0000676'], dtype=object), 'count': 3}_|_[ENSG00000162891]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL389621,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO_|_JYGXADMDTFJGBT-VWUMJDOOSA-N_|_Small molecule_|_False_|_HYDROCORTISONE_|_1952.0_|_4.0_|_nan_|_False_|_True_|_['Acetasol hc' 'Acticort' 'Aeroseb-hc' 'Ala-cort' 'Ala-scalp'
 'Alkindi sprinkle' 'Alphaderm' 'Anflam' 'Anucort-Hc' 'Anugesic hc'
 'Anusol hc' 'Anusol plus hc' 'Anusol soothing relief' 'Anusol-Hc'
 'Balneol-hc' 'Beta-hc' 'Calmurid hc' 'Canesten hc' 'Cetacort' 'Cipro hc'
 'Cobadex' 'Colocort' 'Corlan' 'Cort-dome' 'Cortef' 'Cortenem' 'Cortenema'
 'Cortril' 'Daktacort' 'Daktacort hydrocort' 'Derma care hydrocort'
 'Dermacort' 'Dermaspray demang' 'Dioderm' 'Dome-cort' 'Econacort'
 'Efcortelan p' 'Eldecort' 'Epicort' 'Eurax-hc' 'Eurax-hydrocort'
 'Evacort' 'Exe-cort' 'Flexicort' 'Germoloids hc' 'Glycort' 'Gregoderm'
 'H-cort' 'Hc #1' 'Hc #4' 'Hc (hydrocortisone)' 'Hi-cor' 'Hydro-rx'
 'Hydrocort in calamine oily' 'Hydrocort in cetomacrogol for a'
 'Hydrocort in wte soft paraf' 'Hydrocortisone'
 'Hydrocortisone in absorbase' 'Hydrocortone' 'Hydroderm' 'Hydroderm hc'
 'Hytone' 'Jungle for' 'Locoid' 'Medicort' 'Mildison lipocream'
 'Nogenic hc' 'Nutracort' 'Nybadex' 'Nystaform-hc' 'Otoseptil' 'Otosporin'
 'Penecort' 'Perinal' 'Plenadren' 'Proctocort' 'Proctocream hc'
 'Proctofoam hc' 'Proctosedyl' 'Quinocort' 'Sential hc' 'Stie-cort'
 'Synacort' 'Terra-cortril nystatin' 'Texacort' 'Timocort' 'Timodine'
 'Topisone' 'Tri-cicatrin' 'Uniroid' 'Uniroid hc' 'Xyloproct' 'Zenoxone']_|_['Cor-Oticin' 'Cortifoam' 'Cortisol' 'FLEXICORT' 'Hydrocortisone'
 'Micort-HC' 'NSC-10483' 'Neo-Cortef' 'Ophthocort' 'Terra-Cortril'
 'U-Cort']_|_[('DailyMed', array(['hydrocortisone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/plenadren'],
      dtype=object)), ('PubChem', array(['144204434', '144208013', '170464635', '26751519', '26751520',
       '29215010', '56422453', '75748', '85148352', '855803', '90341326'],
      dtype=object)), ('Wikipedia', array(['Cortisol'], dtype=object)), ('drugbank', array(['DB00741'], dtype=object)), ('chEBI', array(['17650'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004251', 'EFO_1001222', 'MONDO_0019460', 'EFO_0000221',
       'MONDO_0100096', 'MONDO_0004979', 'MONDO_0000873', 'EFO_0005251',
       'EFO_0000574', 'MONDO_0022096', 'EFO_0003843', 'MONDO_0018479',
       'EFO_0000278', 'EFO_0000223', 'EFO_0003027', 'EFO_0003811',
       'EFO_0000673', 'EFO_0000094', 'EFO_0000565', 'EFO_0000274',
       'EFO_1000796', 'EFO_1001435', 'EFO_0000403', 'EFO_0000764',
       'MONDO_0015540', 'EFO_0007541', 'EFO_0009492', 'HP_0012076',
       'EFO_1000764', 'EFO_0001379', 'EFO_0001072', 'EFO_0003032',
       'EFO_0000546', 'MONDO_0000870', 'EFO_0000198', 'MONDO_0003937',
       'EFO_0000384', 'EFO_0009444', 'EFO_0000685', 'EFO_0000220',
       'HP_0000964', 'EFO_0005687', 'MONDO_0008728', 'EFO_1001779',
       'EFO_0000612', 'EFO_0000756', 'MONDO_0015129', 'EFO_0001378',
       'MONDO_0005178', 'MONDO_0005147', 'MONDO_0002471', 'EFO_0001073',
       'MONDO_0002406', 'EFO_0003768', 'EFO_0003025', 'MONDO_0007079',
       'HP_0001742', 'HP_0100806', 'EFO_0000544', 'EFO_0005752',
       'EFO_0000209', 'EFO_0005611', 'EFO_1000158', 'MP_0001845',
       'EFO_0007141', 'EFO_0000676', 'MONDO_0015128', 'HP_0000989',
       'EFO_0003106', 'EFO_0009560', 'EFO_0000701', 'EFO_0006834',
       'MONDO_0004992', 'MONDO_0019091', 'EFO_0009552', 'EFO_0000275',
       'EFO_0002609', 'EFO_0001422', 'EFO_0000218', 'EFO_1001494',
       'EFO_0003778', 'EFO_0009491', 'EFO_0004192', 'EFO_0005539',
       'EFO_1001818', 'EFO_0003144', 'EFO_0007359', 'MONDO_0008315',
       'EFO_0010702', 'EFO_1001908', 'EFO_0007328', 'EFO_1001347',
       'EFO_0002614', 'EFO_0000729', 'EFO_1000697', 'EFO_0003802',
       'EFO_0000222'], dtype=object), 'count': 97}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 35 approved and 62 investigational indications."
CHEMBL408194,"COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C_|_RFTSSZJZXOSICM-GRSHGNNSSA-N_|_Small molecule_|_False_|_OBATOCLAX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GX15-070' 'Obatoclax']_|_[('drugbank', array(['DB12191'], dtype=object))]_|_['CHEMBL2107358']_|_{'rows': array(['EFO_1001469', 'EFO_0000702', 'MONDO_0001023', 'EFO_0000702',
       'EFO_0000222', 'EFO_0000183', 'EFO_0000095', 'MONDO_0044903',
       'EFO_0000198', 'EFO_0001378', 'EFO_0001642', 'MONDO_0008903',
       'EFO_0002617', 'EFO_0000403', 'MONDO_0018906'], dtype=object), 'count': 15}_|_[ENSG00000143384,ENSG00000171552,ENSG00000258643,ENSG00000129473,ENSG00000140379,ENSG00000137875,ENSG00000171791]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications."
CHEMBL4303214,"CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12_|_BALLNEJQLSTPIO-UHFFFAOYSA-N_|_Small molecule_|_False_|_FRUQUINTINIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Fruzaqla']_|_['Fruquintinib' 'HMPL-013' 'HMPL013' 'Hmpl-013']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FRUQUINTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001968', 'EFO_0002618', 'EFO_1001951',
       'EFO_1000657', 'MONDO_0001056', 'EFO_0003897', 'MONDO_0007254',
       'MONDO_0011962', 'EFO_0001421', 'EFO_0003060', 'MONDO_0021063',
       'EFO_0000365', 'MONDO_0008903', 'EFO_0003086', 'EFO_0005922',
       'MONDO_0004992', 'EFO_0000681', 'EFO_0004142'], dtype=object), 'count': 19}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 16 investigational indications."
CHEMBL4650827,"CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C_|_FRVSRBKUQZKTOW-YOCNBXQISA-N_|_Small molecule_|_False_|_REVUMENIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Revumenib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_['CHEMBL4650278']_|_{'rows': array(['EFO_0000565', 'EFO_0000222', 'EFO_0000220', 'EFO_1001951',
       'EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000133895,ENSG00000118058]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL776,"CC(C)NCC(O)c1cc(O)cc(O)c1_|_LMOINURANNBYCM-UHFFFAOYSA-N_|_Small molecule_|_False_|_METAPROTERENOL_|_1973.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Metaproterenol' 'Orciprenaline']_|_[('PubChem', array(['26748125', '90340962'], dtype=object)), ('Wikipedia', array(['Orciprenaline'], dtype=object)), ('drugbank', array(['DB00816'], dtype=object)), ('chEBI', array(['6792'], dtype=object))]_|_['CHEMBL1200812' 'CHEMBL1568057' 'CHEMBL2164775' 'CHEMBL1628446']_|_{'rows': array(['HP_0006536', 'EFO_0003890', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for airway obstruction and asthma and has 1 investigational indication."
CHEMBL1200343,"CC(C)(C)N.CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC_|_IYNMDWMQHSMDDE-MHXJNQAMSA-N_|_Small molecule_|_True_|_PERINDOPRIL ERBUMINE_|_1993.0_|_4.0_|_CHEMBL1581_|_False_|_True_|_['Aceon' 'Coversyl' 'Perindopril erbumine']_|_['MCN-A-2833-109' 'NSC-758929' 'Perindopril erbumine'
 'Perindopril tert-butylamine' 'S-9490-3']_|_[('DailyMed', array(['perindopril%20erbumine'], dtype=object)), ('chEBI', array(['8025'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612', 'MONDO_0001134', 'EFO_0001645', 'EFO_0000537'],
      dtype=object), 'count': 4}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201162,"CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl_|_OSRUSFPMRGDLAG-QMGYSKNISA-N_|_Small molecule_|_False_|_DORZOLAMIDE HYDROCHLORIDE_|_1994.0_|_4.0_|_CHEMBL218490_|_False_|_True_|_['Cosopt Pf' 'Dorzolamide hydrochloride' 'Trusopt']_|_['Dorzolamide (as hydrochloride)' 'Dorzolamide hcl'
 'Dorzolamide hydrochloride' 'MK-507']_|_[('DailyMed', array(['dorzolamide%20hydrochloride'], dtype=object)), ('PubChem', array(['170465119', '56463558'], dtype=object)), ('chEBI', array(['4703'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004190', 'MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 3}_|_[ENSG00000104267]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved indications."
CHEMBL1201286,"CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)C1CCCCC1_|_GFRUPHOKLBPHTQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYPHENONIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Oxyphenonium' 'Oxyphenonium cation' 'Oxyphenonium ion']_|_[('drugbank', array(['DB00219'], dtype=object))]_|_['CHEMBL1200906']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease."
CHEMBL1230607,"CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C_|_HUXYBQXJVXOMKX-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHA-793887_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PHA-793887' 'Pha-793887']_|_[('PubChem', array(['137276012'], dtype=object)), ('drugbank', array(['DB12686'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1237023,"nan_|_nan_|_Antibody_|_False_|_DENOSUMAB_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Prolia' 'Prolia, Ranmark Xgeva' 'Prolia, xgeva' 'Xgeva']_|_['AMG 162' 'AMG-162' 'Denosumab' 'Denosumab biosimilar (ql-1206)'
 'Denosumab biosimilar tk-006' 'QL-1206' 'QL1206' 'Ql1206' 'TK-006'
 'TK006']_|_[('DailyMed', array(['denosumab'], dtype=object)), ('DrugCentral', array(['4965'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/prolia'],
      dtype=object)), ('Wikipedia', array(['Denosumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000305', 'MONDO_0000837', 'MONDO_0005271', 'EFO_0000400',
       'EFO_0007176', 'EFO_0000685', 'EFO_1000318', 'EFO_0000756',
       'MONDO_0002171', 'EFO_0009870', 'EFO_0000616', 'EFO_1000984',
       'EFO_1000786', 'EFO_0000681', 'EFO_0001378', 'MONDO_0005351',
       'EFO_0004248', 'EFO_0009708', 'MONDO_0002108', 'EFO_0003060',
       'EFO_0000637', 'EFO_0004274', 'MONDO_0008903', 'EFO_0003882',
       'EFO_0000389', 'EFO_0003854', 'EFO_0003931', 'MONDO_0007254',
       'MONDO_0019019', 'HP_0003072', 'EFO_0000384', 'MONDO_0000845',
       'EFO_1001951', 'EFO_0004260', 'EFO_0000313', 'EFO_0000266',
       'EFO_0003086', 'MONDO_0008315', 'EFO_0001075', 'EFO_0003869',
       'HP_0000938'], dtype=object), 'count': 41}_|_[ENSG00000120659]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 11 approved and 30 investigational indications."
CHEMBL1334033,"C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1.O=C(O)/C=C\C(=O)O_|_JDZOTSLZMQDFLG-BTJKTKAUSA-N_|_Small molecule_|_False_|_PERHEXILINE MALEATE_|_1974.0_|_4.0_|_CHEMBL75880_|_True_|_True_|_['Pexid' 'Pexsig']_|_['NSC-758409' 'Perhexiline maleate' 'Perhexilinum']_|_[('PubChem', array(['144204948', '170466435', '26748746', '56422147', '855892'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000205560,ENSG00000198793,ENSG00000157184]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. It was withdrawn in at least one region."
CHEMBL1795071,"N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O_|_JFMWPOCYMYGEDM-XFULWGLBSA-N_|_Small molecule_|_True_|_RUXOLITINIB PHOSPHATE_|_2011.0_|_4.0_|_CHEMBL1789941_|_False_|_True_|_['Jakafi' 'Jakavi' 'Opzelura']_|_['INCB-018424 PHOSPHATE' 'INCB-018424 SALT' 'INCB-18424 PHOSPHATE'
 'INCB018424 PHOSPHATE' 'INCB018424 SALT' 'Opzelura'
 'Ruxolitinib (as phosphate)' 'Ruxolitinib monophosphate'
 'Ruxolitinib phosphate']_|_[('DailyMed', array(['ruxolitinib%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi'],
      dtype=object)), ('chEBI', array(['66917'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001068', 'EFO_0000222', 'EFO_0004192', 'HP_0011974',
       'EFO_0004251', 'EFO_0002430', 'EFO_0000220', 'EFO_0000676',
       'EFO_0000095', 'MONDO_0013730', 'MONDO_0002158', 'EFO_0000466',
       'EFO_0005537', 'EFO_0000274', 'EFO_0002429'], dtype=object), 'count': 15}_|_[ENSG00000162434,ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1915540,"CN[C@@H]1CCN(c2cc(NCC3CC3)nc(N)n2)C1_|_ISBHYKVAFKTATD-SNVBAGLBSA-N_|_Small molecule_|_False_|_ADRIFORANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adriforant' 'NVP-ZPL389-NX' 'PF-03893787' 'PF-3893787' 'Pf-03893787'
 'ZPL-389' 'ZPL-389-NX' 'ZPL-3893787' 'ZPL389-NX']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ADRIFORANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15027'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'HP_0011123', 'EFO_0000274', 'EFO_0000676'],
      dtype=object), 'count': 4}_|_[ENSG00000134489]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2108375,nan_|_nan_|_Enzyme_|_False_|_DUTEPLASE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Duteplase']_|_nan_|_nan_|_nan_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2109452,"nan_|_nan_|_Antibody_|_False_|_MEDI-4212_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MEDI-4212' 'MEDI4212' 'Medi-4212']_|_nan_|_nan_|_{'rows': array(['EFO_0005854', 'EFO_0000274'], dtype=object), 'count': 2}_|_[ENSG00000211891]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2109586,"nan_|_nan_|_Antibody_|_False_|_AMG-780_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-780' 'Amg 780' 'Amg-780']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000154188,ENSG00000091879]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL284348,"Nc1ccncc1_|_NUKYPUAOHBNCPY-UHFFFAOYSA-N_|_Small molecule_|_False_|_DALFAMPRIDINE_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Ampyra' 'Ampyra Extended Release' 'Fampridine accord' 'Fampyra']_|_['Dalfampridine' 'EL-970' 'Fampridine' 'Fampridine (4-aminopyridine)'
 'NSC-15041']_|_[('DailyMed', array(['dalfampridine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord'],
      dtype=object)), ('PubChem', array(['104171097', '11110683', '11113806', '124879040', '124879042',
       '136964060', '144203616', '144207991', '170466526', '26747141',
       '26751980', '26751983', '50104658', '8139900', '90341267'],
      dtype=object)), ('Wikipedia', array(['4-Aminopyridine'], dtype=object)), ('drugbank', array(['DB06637'], dtype=object)), ('chEBI', array(['34385'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000632', 'HP_0000083', 'HP_0002140', 'MONDO_0005301',
       'EFO_0003918', 'EFO_0008522', 'EFO_0009602', 'EFO_0000712',
       'EFO_0003782', 'EFO_0007292', 'EFO_0009490', 'Orphanet_83419',
       'EFO_1001919', 'EFO_0004335', 'EFO_0007405', 'EFO_0003929',
       'HP_0001257'], dtype=object), 'count': 17}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for multiple sclerosis and has 16 investigational indications."
CHEMBL3137326,"[2H]C([2H])([2H])Oc1cc2c(cc1OC([2H])([2H])[2H])C1CC(=O)C(CC(C)C)CN1CC2_|_MKJIEFSOBYUXJB-LIJFRPJRSA-N_|_Small molecule_|_True_|_DEUTETRABENAZINE_|_2017.0_|_4.0_|_CHEMBL117785_|_False_|_True_|_['Austedo']_|_['Deutetrabenazine' 'Dutetrabenazine' 'SD-809']_|_[('DailyMed', array(['deutetrabenazine'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000632', 'MONDO_0007739', 'EFO_0004895', 'MONDO_0003441',
       'EFO_0004280', 'EFO_0004152'], dtype=object), 'count': 6}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for huntington disease and chorea and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3244648,"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1.[Na+].[Na+]_|_DASQOOZCTWOQPA-GXKRWWSZSA-L_|_Small molecule_|_True_|_METHOTREXATE SODIUM_|_1953.0_|_4.0_|_CHEMBL34259_|_False_|_True_|_['Abitrexate' 'Folex' 'Folex pfs' 'Methotrexate lpf'
 'Methotrexate preservative free' 'Methotrexate sodium'
 'Methotrexate sodium preservative free' 'Mexate' 'Mexate-aq'
 'Mexate-aq preserved' 'Trexall' 'Xatmep']_|_['ADX-2191 SODIUM' 'Disodium methotrexate' 'Methotrexate (as disodium)'
 'Methotrexate disodium' 'Methotrexate disodium salt'
 'Methotrexate sodium' 'Methotrexate sodium salt'
 'Methotrexate, sodium salt']_|_[('DailyMed', array(['methotrexate%20sodium'], dtype=object)), ('chEBI', array(['50679'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005856', 'MONDO_0002041', 'EFO_0000676', 'EFO_0000220',
       'EFO_0000685', 'EFO_1001012', 'EFO_0002609', 'MONDO_0008903',
       'MONDO_0007254', 'EFO_0000232', 'EFO_0005952', 'EFO_0002893'],
      dtype=object), 'count': 12}_|_[ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 11 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL3544945,"nan_|_nan_|_Small molecule_|_False_|_SAR-113945_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Sar-113945']_|_nan_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_0004616'], dtype=object), 'count': 2}_|_[ENSG00000104365]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545176,"nan_|_nan_|_Small molecule_|_False_|_DB959_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Db959' 'T3D-959']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000112033,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3813842,"CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12_|_LGWACEZVCMBSKW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PAXALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['G-02441729' 'G02441729' 'GDC-0084' 'GDC0084' 'Paxalisib' 'Rg-7666']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PAXALISIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15186'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_1000158', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL416146,"Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1_|_MNJVRJDLRVPLFE-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETORICOXIB_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Arcoxia']_|_['Etoricoxib' 'L-791456' 'MK-0663']_|_[('PubChem', array(['144205759', '170465621', '26758000'], dtype=object)), ('Wikipedia', array(['Etoricoxib'], dtype=object)), ('drugbank', array(['DB01628'], dtype=object)), ('chEBI', array(['6339'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'HP_0003419', 'EFO_0003820', 'EFO_0003898',
       'MONDO_0005178', 'EFO_0003843', 'MONDO_0008315', 'EFO_0000546',
       'EFO_0000685', 'EFO_0005755', 'MONDO_0018076', 'EFO_0010072',
       'EFO_0004616', 'EFO_0000764', 'HP_0100607'], dtype=object), 'count': 15}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for rheumatic disease and has 14 investigational indications."
CHEMBL429,"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1_|_SGUAFYQXFOLMHL-UHFFFAOYSA-N_|_Small molecule_|_False_|_LABETALOL_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AH-5158A FREE BASE' 'Ibidomide' 'Labetalol' 'Normodyne' 'Normozide'
 'SCH-15719W FREE BASE' 'Trandate']_|_[('PubChem', array(['90341718'], dtype=object)), ('TG-GATEs', array(['40'], dtype=object)), ('Wikipedia', array(['Labetalol'], dtype=object)), ('drugbank', array(['DB00598'], dtype=object)), ('chEBI', array(['6343'], dtype=object))]_|_['CHEMBL1200323']_|_{'rows': array(['EFO_0000319', 'EFO_0003843', 'EFO_0000668', 'EFO_0005251',
       'EFO_0002610', 'EFO_0000537', 'EFO_0000537', 'EFO_0005669',
       'EFO_0000712', 'EFO_0007486', 'EFO_0000668', 'EFO_0003768'],
      dtype=object), 'count': 12}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and hypertension and has 10 investigational indications."
CHEMBL4297423,"Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)NCCCN1CCN(C)CC1)c1nnc(C)n1-2_|_PKQXLRYFPSZKDU-QFIPXVFZSA-N_|_Small molecule_|_False_|_RO-6870810_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['(S)-JQ35' 'BET INHIBITOR TEN-010' 'Bet inhibitor ro6870810'
 'Jq-35, (s)-' 'RO6870810' 'Rg 6146' 'Ro-6870810' 'Ro6870810']_|_[('drugbank', array(['DB15151'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000616', 'EFO_0000222', 'EFO_0000198'],
      dtype=object), 'count': 4}_|_[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL4298009,"nan_|_nan_|_Antibody_|_False_|_IERAMILIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Humanised imp-701' 'Ieramilimab' 'LAG-525' 'LAG525' 'Lag 525' 'Lag525'
 'NVP-LAG525']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IERAMILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0005537', 'EFO_0000616', 'EFO_0000756'],
      dtype=object), 'count': 4}_|_[ENSG00000089692]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4298198,"nan_|_nan_|_Oligonucleotide_|_False_|_VUPANORSEN SODIUM_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AKCEA-ANGPTL3-LRx salt' 'ISIS 703802 salt' 'Vupanorsen sodium']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VUPANORSEN%20SODIUM/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021187'], dtype=object), 'count': 1}_|_[ENSG00000141505,ENSG00000132855]_|_Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4594350,"C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N_|_PEMUGDMSUDYLHU-ZEQRLZLVSA-N_|_Small molecule_|_False_|_ADAGRASIB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Krazati']_|_['Adagrasib' 'Kras g12c inhibitor mrtx849' 'Krazati' 'MRTX-849' 'MRTX849'
 'Mrtx-849' 'Mrtx849']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ADAGRASIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060', 'EFO_1001951', 'MONDO_0008903',
       'EFO_0009709', 'MONDO_0021063', 'EFO_0002618'], dtype=object), 'count': 7}_|_[ENSG00000133703]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for neoplasm and non-small cell lung carcinoma and has 5 investigational indications."
CHEMBL462605,"Clc1ccc(CCCOCCCN2CCCCC2)cc1_|_NNACHAUCXXVJSP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PITOLISANT_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Wakix' 'Wakix, europe']_|_['BF-2.649' 'BF-2649' 'BF2.649' 'Bf2.649' 'HBS-101' 'Pitolisant'
 'Tiprolisant']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PITOLISANT/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Pitolisant'], dtype=object)), ('drugbank', array(['DB11642'], dtype=object))]_|_['CHEMBL4164059']_|_{'rows': array(['EFO_0003890', 'MONDO_0018044', 'MONDO_0008300', 'MONDO_0005090',
       'EFO_0003086', 'EFO_0005246', 'MONDO_0016158', 'MONDO_0016158',
       'MONDO_0021107', 'MONDO_0005180', 'MONDO_0007079'], dtype=object), 'count': 11}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for hypersomnia and narcolepsy-cataplexy syndrome and has 9 investigational indications."
CHEMBL545437,"CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2.Cl_|_NQIZCDQCNYCVAS-RQBPZYBGSA-N_|_Small molecule_|_False_|_AMIBEGRON HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL1193948_|_False_|_False_|_[]_|_['Amibegron hcl' 'Amibegron hydrochloride' 'SR-58611A' 'SR58611A'
 'Sr-58611a']_|_[('Wikipedia', array(['Amibegron'], dtype=object))]_|_nan_|_nan_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL651,"CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1_|_USSIQXCVUWKGNF-UHFFFAOYSA-N_|_Small molecule_|_True_|_METHADONE_|_1947.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amidone' 'Diaminon' 'Dl-methadone' 'Dolophin' 'Dolophine' 'Heptadon'
 'Heptadone' 'IDS-NM-002' 'Metasedin' 'Methadone' 'Methadose' 'Phenadone'
 'Phy' 'Physeptone' 'Symoron' 'Westadone']_|_[('Wikipedia', array(['Methadone'], dtype=object)), ('drugbank', array(['DB00333'], dtype=object)), ('chEBI', array(['6807'], dtype=object))]_|_['CHEMBL1200825']_|_{'rows': array(['EFO_0005611', 'MONDO_0041052', 'EFO_0003843', 'EFO_0003843',
       'EFO_0004240', 'EFO_0010702', 'EFO_0801084', 'EFO_0000764',
       'EFO_0003890', 'HP_0012532', 'EFO_0003917', 'HP_0008419',
       'EFO_0004273', 'EFO_0005611', 'EFO_0003047', 'EFO_0003884',
       'EFO_0005799', 'EFO_0000180', 'EFO_0003890', 'MONDO_0004992',
       'EFO_0000764', 'EFO_0004270', 'EFO_0005762', 'EFO_0002610',
       'EFO_0003100'], dtype=object), 'count': 25}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 3 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL92401,"CC(C)NNC(=O)c1ccncc1_|_NYMGNSNKLVNMIA-UHFFFAOYSA-N_|_Small molecule_|_False_|_IPRONIAZID_|_nan_|_4.0_|_nan_|_False_|_True_|_['Marsilid']_|_['Iproniazid' 'Iproniazide']_|_[('PubChem', array(['11111333', '11111334', '50111104', '90341605'], dtype=object)), ('TG-GATEs', array(['62'], dtype=object)), ('Wikipedia', array(['Iproniazid'], dtype=object)), ('drugbank', array(['DB04818'], dtype=object)), ('chEBI', array(['5958'], dtype=object))]_|_['CHEMBL1256361' 'CHEMBL1534878']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder."
CHEMBL977,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC(=O)O_|_VWQWXZAWFPZJDA-CGVGKPPMSA-N_|_Small molecule_|_False_|_HYDROCORTISONE HEMISUCCINATE ANHYDROUS_|_1955.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hydrocortisone Hemisuccinate' 'Hydrocortisone hemisuccinate anhydrous'
 'Hydrocortisone succinate' 'NSC-7576' 'Oristar hcshs']_|_[('PubChem', array(['56422426', '855704'], dtype=object)), ('drugbank', array(['DB14545'], dtype=object)), ('chEBI', array(['31677'], dtype=object))]_|_['CHEMBL3989663' 'CHEMBL1200495']_|_{'rows': array(['EFO_0000403', 'EFO_0003032', 'EFO_0006834', 'EFO_0000565',
       'MONDO_0000870', 'EFO_0000220', 'EFO_0000309', 'MONDO_0004979'],
      dtype=object), 'count': 8}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for asthma and has 7 investigational indications."
CHEMBL1198855,"CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F_|_FQJISUPNMFRIFZ-HXUWFJFHSA-N_|_Small molecule_|_False_|_RONACALERET_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ronacaleret' 'Sb-751689']_|_[('drugbank', array(['DB05255'], dtype=object))]_|_['CHEMBL1083998']_|_{'rows': array(['EFO_0003931', 'EFO_0003882'], dtype=object), 'count': 2}_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1200,"CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N_|_CMHHMUWAYWTMGS-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENOXINATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benoxinate' 'Conjucain' 'Dorsacain' 'Monofree oxybuprocaine'
 'Oxybucaine' 'Oxybuprocaine']_|_[('PubChem', array(['11112575', '56320722'], dtype=object)), ('Wikipedia', array(['Oxybuprocaine'], dtype=object)), ('drugbank', array(['DB00892'], dtype=object)), ('chEBI', array(['309594'], dtype=object))]_|_['CHEMBL1200654']_|_{'rows': array(['HP_0000989'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for pruritus."
CHEMBL1201002,"CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2.Cl_|_FYBXRCFPOTXTJF-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARTEOLOL HYDROCHLORIDE_|_1988.0_|_4.0_|_CHEMBL839_|_False_|_True_|_['Carteolol hydrochloride' 'Cartrol' 'Ocupress' 'Teoptic']_|_['ABBOTT-43326' 'Carteolol hcl' 'Carteolol hydrochloride' 'NSC-300906'
 'OPC-1085']_|_[('DailyMed', array(['carteolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204205', '170465122', '56463040'], dtype=object)), ('chEBI', array(['3438'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004190'], dtype=object), 'count': 1}_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and is indicated for open-angle glaucoma."
CHEMBL1201202,"CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)O)[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)O)[C@H]3NS(=O)(=O)O)[C@H](O)[C@H]2OS(=O)(=O)O)[C@H](O)[C@H]1NS(=O)(=O)O_|_KANJSNBRCNMZMV-ABRZTLGGSA-N_|_Oligosaccharide_|_True_|_FONDAPARINUX_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fondaparinux']_|_[('Wikipedia', array(['Fondaparinux'], dtype=object)), ('drugbank', array(['DB00569'], dtype=object)), ('chEBI', array(['61033'], dtype=object))]_|_['CHEMBL1200644']_|_{'rows': array(['HP_0001907', 'EFO_0000275', 'EFO_0003907', 'EFO_0000612',
       'EFO_0004286', 'EFO_0007541', 'EFO_0001074', 'EFO_0005672',
       'HP_0004419', 'HP_0004936', 'EFO_0004286', 'HP_0001873',
       'EFO_0003827', 'MONDO_0100096', 'HP_0000083', 'EFO_1000985',
       'EFO_0009686', 'HP_0001907', 'EFO_0001075', 'HP_0004936'],
      dtype=object), 'count': 20}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201821,"nan_|_nan_|_Protein_|_False_|_PALIFERMIN_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Kepivance']_|_['Palifermin']_|_[('DailyMed', array(['palifermin'], dtype=object)), ('DrugCentral', array(['4804'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kepivance'],
      dtype=object)), ('Wikipedia', array(['Palifermin'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000574', 'MONDO_0004992', 'MONDO_0005301',
       'EFO_0000707', 'EFO_0000764', 'EFO_0004276', 'MONDO_0015760',
       'EFO_0005555', 'EFO_0006475', 'EFO_1001904', 'EFO_0000198',
       'EFO_0005952', 'EFO_0009688', 'EFO_0000222', 'MONDO_0013730',
       'EFO_1001898', 'MONDO_0044881', 'EFO_0000565', 'EFO_0000183',
       'EFO_0004599', 'EFO_1001451', 'MONDO_0021193', 'EFO_0001378',
       'EFO_0006859', 'EFO_1000690', 'MONDO_0004907', 'MONDO_0021063'],
      dtype=object), 'count': 28}_|_[ENSG00000066468]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 25 investigational indications."
CHEMBL1237119,"CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O_|_PAJMKGZZBBTTOY-ZFORQUDYSA-N_|_Small molecule_|_False_|_TREPROSTINIL_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Remodulin' 'Tyvaso' 'Tyvaso dpi']_|_['15-AU-81' '15AU81' 'L-606' 'LRX -15' 'LRX-15' 'Rumodolin' 'Treprostinil'
 'UT-15' 'Uniprost']_|_[('DailyMed', array(['treprostinil'], dtype=object)), ('drugbank', array(['DB00374'], dtype=object)), ('chEBI', array(['50861'], dtype=object))]_|_['CHEMBL561157' 'CHEMBL2107815']_|_{'rows': array(['MONDO_0005149', 'MONDO_0005149', 'MONDO_0005147', 'EFO_0000768',
       'EFO_0000717', 'EFO_0000341', 'MONDO_0001999', 'MONDO_0100130',
       'EFO_1001145', 'EFO_0000556', 'EFO_1001103', 'EFO_0003875',
       'EFO_0002687', 'EFO_0001361', 'EFO_0001361', 'EFO_0005207',
       'EFO_1001459', 'HP_0004419', 'EFO_0000717'], dtype=object), 'count': 19}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 15 investigational indications."
CHEMBL1409,"COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1.O=C(O)/C=C\C(=O)O_|_LFMYNZPAVPMEGP-PIDGMYBPSA-N_|_Small molecule_|_True_|_FLUVOXAMINE MALEATE_|_1994.0_|_4.0_|_CHEMBL814_|_False_|_True_|_['Faverin 100' 'Faverin 50' 'Floxyfral' 'Fluvoxamine maleate' 'Luvox'
 'Luvox cr']_|_['DU-23000' 'DU23000' 'Faverin' 'Fevarin' 'Fluvoxamine hydrogenmaleate'
 'Fluvoxamine maleate' 'NSC-759602']_|_[('DailyMed', array(['fluvoxamine%20maleate'], dtype=object)), ('PubChem', array(['50106274', '50106275', '93576625'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000694', 'EFO_0004262', 'MONDO_0100096', 'EFO_0004242'],
      dtype=object), 'count': 4}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for obsessive-compulsive disorder and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1476022,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C_|_IIVBFTNIGYRNQY-YQLZSBIMSA-N_|_Small molecule_|_False_|_NOMEGESTROL ACETATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Nomac' 'Nomegestrol acetate' 'ORG 10486-0' 'ORG-10486-0' 'TX 066'
 'TX-066' 'Zoely']_|_[('PubChem', array(['56463139'], dtype=object)), ('drugbank', array(['DB13981'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301', 'EFO_0000660', 'HP_0100607'], dtype=object), 'count': 3}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1628227,"CN(C)CCC=C1c2ccccc2COc2ccccc21_|_ODQWQRRAPPTVAG-UHFFFAOYSA-N_|_Small molecule_|_True_|_DOXEPIN_|_1969.0_|_4.0_|_nan_|_False_|_True_|_['Sinepin' 'Sinequan']_|_['Doxepin' 'P-3693A' 'Zonalon']_|_[('PubChem', array(['174006603'], dtype=object)), ('TG-GATEs', array(['39'], dtype=object)), ('drugbank', array(['DB01142'], dtype=object)), ('chEBI', array(['4710'], dtype=object))]_|_['CHEMBL1628234']_|_{'rows': array(['MONDO_0007079', 'EFO_0005230', 'EFO_0005531', 'EFO_0004698',
       'EFO_1001904', 'MONDO_0005090', 'MONDO_0004985', 'HP_0000989',
       'EFO_0008568', 'EFO_0003843', 'HP_0000726', 'MONDO_0002009',
       'MONDO_0002009', 'EFO_0000555', 'MONDO_0007254', 'MONDO_0002050',
       'EFO_0000274'], dtype=object), 'count': 17}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 7 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1921976,"CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1_|_OZPFIJIOIVJZMN-SFHVURJKSA-N_|_Small molecule_|_False_|_ORTERONEL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Orteronel' 'TAK-700']_|_[('Wikipedia', array(['Orteronel'], dtype=object)), ('drugbank', array(['DB12066'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000673'],
      dtype=object), 'count': 4}_|_[ENSG00000148795]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2107888,nan_|_nan_|_Antibody_|_False_|_TALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['C21/AL-90' 'HU-901' 'TNX-901' 'Talizumab']_|_nan_|_nan_|_nan_|_[ENSG00000211891]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108427,"nan_|_nan_|_Protein_|_False_|_MENOTROPINS_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Humegon' 'Menopur' 'Merional' 'Normegon' 'Pergonal' 'Pergonal low lh']_|_['FSH' 'Follotropin' 'HMG' 'Human follicle stimulating hormone'
 'Menotrophin' 'Menotropins']_|_[('DailyMed', array(['menotropins%20(fsh;lh)'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002950', 'MONDO_0002146', 'EFO_0008560', 'EFO_0000279',
       'MONDO_0002259', 'MONDO_0018800', 'EFO_0000660', 'EFO_0000545'],
      dtype=object), 'count': 8}_|_[ENSG00000170820,ENSG00000138039]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 8 investigational indications."
CHEMBL211471,"CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1.COS(=O)(=O)[O-]_|_OSZNNLWOYWAHSS-UHFFFAOYSA-M_|_Small molecule_|_False_|_NEOSTIGMINE METHYLSULFATE_|_2013.0_|_4.0_|_CHEMBL278020_|_False_|_True_|_['Bloxiverz' 'Neostigmine methylsulfate' 'Robinul-neostig']_|_['Intrastigmina' 'NSC-93753' 'Neostigmine methyl sulfate'
 'Neostigmine methylsulfate' 'Neostigmine methylsulphate'
 'Neostigmine metilsulfate' 'Neostigmini metilsulfas' 'Syntostigmin']_|_[('DailyMed', array(['neostigmine%20methylsulfate'], dtype=object)), ('PubChem', array(['56422780', '855838'], dtype=object)), ('chEBI', array(['7516'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004991', 'HP_0025267'], dtype=object), 'count': 2}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for myasthenia gravis and has 1 investigational indication."
CHEMBL303960,"COCc1cccc(C[C@H](O)/C=C/[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(=O)OC)c1_|_FBQUXLIJKPWCAO-AZIFJQEOSA-N_|_Small molecule_|_False_|_RIVENPROST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-ono-4819' 'ONO-4819' 'Rivenprost']_|_nan_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000171522]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3187812,"CC(=O)S[C@H](C(=O)N[C@H]1Cc2ccccc2[C@H]2CCC[C@@H](C(=O)O)N2C1=O)C(C)C_|_FXKFFTMLFPWYFH-RDGPPVDQSA-N_|_Small molecule_|_False_|_ILEPATRIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AVE-7688' 'AVE7688' 'Ave7688' 'Ilepatril']_|_[('PubChem', array(['144210558'], dtype=object)), ('drugbank', array(['DB06604'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000196549,ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545038,nan_|_nan_|_Small molecule_|_False_|_S-237648_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['S-237648']_|_nan_|_nan_|_nan_|_[ENSG00000164129]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545201,nan_|_nan_|_Small molecule_|_False_|_TA-5493_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ta-5493']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989409,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](COP(=O)(O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O_|_XTAUIEMSNCLHEG-GGVFYUGVSA-N_|_Protein_|_False_|_FORIGERIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_['Lupuzor']_|_['Forigerimod' 'IPP 201101' 'IPP-201101' 'IPP201101' 'Rigerimod']_|_nan_|_['CHEMBL3989801']_|_{'rows': array(['MONDO_0007915', 'MONDO_0007915'], dtype=object), 'count': 2}_|_[ENSG00000109971]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication."
CHEMBL3989923,"O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.O=C([O-])C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1.[Mg+2]_|_MPAZKXHCZWDZDY-FFNUKLMVSA-L_|_Small molecule_|_False_|_PITAVASTATIN MAGNESIUM_|_2017.0_|_4.0_|_CHEMBL1201753_|_False_|_True_|_['Zypitamag']_|_[]_|_[('DailyMed', array(['pitavastatin%20magnesium'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003119', 'MONDO_0021187', 'HP_0003124'], dtype=object), 'count': 3}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications."
CHEMBL3991927,COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1_|_OCKHRKSTDPOHEN-BQYQJAHWSA-N_|_Small molecule_|_False_|_HMN-214_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Hmn-214' 'IVX-214']_|_nan_|_nan_|_nan_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4650336,"COc1ccc([C@H]2c3[nH]c4ccc(Cl)cc4c3CCN2C(=O)Oc2ccc(Cl)cc2)cc1_|_SRSHBZRURUNOSM-DEOSSOPVSA-N_|_Small molecule_|_False_|_EMVODODSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Emvododstat' 'PTC299' 'Ptc-299' 'Ptc299']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EMVODODSTAT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'MONDO_0100096', 'MONDO_0007254', 'EFO_0000222',
       'MONDO_0007039'], dtype=object), 'count': 5}_|_[ENSG00000102967]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4650342,"CCCN1C[C@H](CSCC(=O)NCCCC[C@@H](NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(CCC)C2)C(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc3ccc(O)cc3)NC2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21_|_WLBJBODHTIKYSL-JFPOTJHNSA-N_|_Unknown_|_False_|_ONZIGOLIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIM-23A760' 'Dopastatin' 'Onzigolide' 'TBR-760' 'Tbr-760']_|_nan_|_nan_|_{'rows': array(['EFO_1000478'], dtype=object), 'count': 1}_|_[ENSG00000149295,ENSG00000180616,ENSG00000162009]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650476,"nan_|_nan_|_Oligonucleotide_|_False_|_COFIRASERSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cofirasersen' 'ION-827359' 'IONIS-ENACRX' 'Ion-827359' 'Ionis-enacrx']_|_nan_|_nan_|_{'rows': array(['EFO_0006505', 'MONDO_0009061'], dtype=object), 'count': 2}_|_[ENSG00000166828,ENSG00000111319,ENSG00000168447]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5303393,"O=C(O)C(O)C(O)C(=O)O.c1cnc2cc3c(cc2n1)[C@@H]1CNC[C@H]3C1_|_TWYFGYXQSYOKLK-UFIFRZAQSA-N_|_Small molecule_|_False_|_VARENICLINE TARTRATE_|_2006.0_|_4.0_|_CHEMBL1076903_|_False_|_True_|_['Champix' 'Chantix' 'Tyrvaya']_|_['CP-526,555-18' 'CP-526555-18' 'Tyrvaya' 'Varenicline tartrate']_|_[('DailyMed', array(['varenicline%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/champix'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004319', 'EFO_0003768', 'EFO_1000906', 'MONDO_0007079'],
      dtype=object), 'count': 4}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 investigational indications."
CHEMBL5314385,"CCc1ccc(CSc2ccc(NS(=O)(=O)c3ccc(C)c(C(=O)O)c3)cc2)cc1_|_VRAPCAZHERPDQO-UHFFFAOYSA-N_|_Small molecule_|_False_|_CP-778875_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-778,875' 'CP-778875' 'Cp-778875']_|_nan_|_nan_|_{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL778,"Cc1cccc([C@H](C)c2c[nH]cn2)c1C_|_CUHVIMMYOGQXCV-NSHDSACASA-N_|_Small molecule_|_False_|_DEXMEDETOMIDINE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dexmedetomidine' 'MPV-1440' 'Medetomidine, (s)-']_|_[('PubChem', array(['11114268'], dtype=object)), ('Wikipedia', array(['Dexmedetomidine'], dtype=object)), ('drugbank', array(['DB00633'], dtype=object)), ('chEBI', array(['4466'], dtype=object))]_|_['CHEMBL2106195']_|_{'rows': array(['EFO_0003843', 'EFO_0003918', 'EFO_0002460', 'EFO_1002048',
       'MONDO_0007172', 'MONDO_0005129', 'HP_0030834', 'EFO_0006834',
       'EFO_0005774', 'EFO_0004698', 'EFO_0003777', 'EFO_0009516',
       'EFO_0001074', 'EFO_0005279', 'MONDO_0004976', 'EFO_0005251',
       'HP_0000713', 'MP_0001845', 'EFO_0003957', 'EFO_0001645',
       'EFO_0000275', 'EFO_0001073', 'EFO_0003843', 'EFO_0004888',
       'EFO_1000391', 'MONDO_0007254', 'HP_0012532', 'EFO_0000668',
       'MONDO_0005090', 'EFO_0005207', 'MONDO_0001056', 'HP_0012735',
       'HP_0001919', 'EFO_0005762', 'EFO_0005323', 'HP_0002093',
       'EFO_0003833', 'EFO_0005411', 'EFO_0002950', 'EFO_0000474',
       'EFO_0005230', 'EFO_0009267', 'EFO_0000239', 'EFO_0002610',
       'MONDO_0002258', 'EFO_0000546', 'MONDO_0005149', 'MONDO_0003544',
       'EFO_0004273', 'EFO_1001210', 'HP_0000713', 'HP_0100543',
       'MONDO_0004975', 'EFO_0000537', 'EFO_0009267', 'EFO_0000677',
       'EFO_0009620', 'EFO_0009686', 'MONDO_0005299', 'MONDO_0043510',
       'MONDO_0004992', 'HP_0000175', 'EFO_0005611', 'EFO_0003756',
       'EFO_0010282', 'EFO_0003931', 'EFO_0000713', 'MONDO_0043510',
       'EFO_1001884', 'EFO_0004264', 'EFO_1001454', 'HP_0001337',
       'HP_0002315', 'HP_0000023'], dtype=object), 'count': 74}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 73 investigational indications."
CHEMBL1186579,"C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5_|_JVLBPIPGETUEET-GAAHOAFPSA-O_|_Small molecule_|_False_|_METHYLNALTREXONE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MRZ-2663' 'Methylnaltrexone' 'Methylnaltrexone cation'
 'Methylnaltrexone ion']_|_[('Wikipedia', array(['Methylnaltrexone'], dtype=object))]_|_['CHEMBL470617' 'CHEMBL1201770']_|_{'rows': array(['EFO_0002618', 'MONDO_0004565', 'EFO_1000948', 'EFO_0003086',
       'HP_0002019', 'EFO_0005611', 'EFO_0005611', 'HP_0001410',
       'MONDO_0004567', 'HP_0033454', 'EFO_1000652', 'MONDO_0004567',
       'HP_0002019'], dtype=object), 'count': 13}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and opioid dependence and has 10 investigational indications."
CHEMBL1231124,"Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1_|_PDOQBOJDRPLBQU-QMMMGPOBSA-N_|_Small molecule_|_False_|_AZD-1480_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-1480' 'AZD1480' 'Azd 1480' 'Azd-1480']_|_[('drugbank', array(['DB12588'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001056', 'EFO_0000479', 'EFO_0003060', 'EFO_0002430',
       'MONDO_0004992', 'EFO_0000182'], dtype=object), 'count': 6}_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL2103831,"COc1ccc2cc([C@H](C)C(=O)OCCCCO[N+](=O)[O-])ccc2c1_|_AKFJWRDCWYYTIG-ZDUSSCGKSA-N_|_Small molecule_|_False_|_NAPROXCINOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AR-P900758XX' 'AZD-3582' 'AZD3582' 'HCT 3012' 'HCT-3012' 'HCT3012'
 'Naproxcinod' 'Naproxen-n-butyl nitrate' 'Nitronaproxen']_|_[('drugbank', array(['DB06682'], dtype=object)), ('chEBI', array(['76254'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_1002048', 'EFO_1000786', 'EFO_0001421',
       'EFO_0005755'], dtype=object), 'count': 5}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2103882,"O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12_|_UCEQXRCJXIVODC-PMACEKPBSA-N_|_Small molecule_|_False_|_TIVANTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ARQ 197' 'ARQ-197' 'Arq-197' 'Tivantinib']_|_[('drugbank', array(['DB12200'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0005537', 'EFO_0000182', 'MONDO_0004992',
       'EFO_0000770', 'EFO_0000514', 'MONDO_0002691', 'EFO_0000616',
       'EFO_0003860', 'EFO_0000702', 'MONDO_0007576', 'EFO_0000640',
       'EFO_0000673', 'MONDO_0001056', 'EFO_0001378', 'EFO_0000181'],
      dtype=object), 'count': 16}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications."
CHEMBL2107339,"CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1.O=C(O)/C=C\C(=O)O_|_RPUBHMMISKEXSR-MLCLTIQSSA-N_|_Small molecule_|_False_|_ESMIRTAZAPINE MALEATE_|_nan_|_3.0_|_CHEMBL1366933_|_False_|_False_|_[]_|_['Esmirtazapine maleate' 'Mirtazapine maleate, (s)-' 'ORG 50081'
 'ORG-50081' 'Org-50081']_|_nan_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 2}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000196639,ENSG00000147246,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2107777,"CCOc1ccc2c(c1)[C@]1(CC[C@H](CCN3CCOCC3)CC1)C(=O)N2S(=O)(=O)c1ccc(C(=O)NC(C)(C)C)cc1OC_|_CDSBFDCCJJDFCV-CKZSCMLPSA-N_|_Small molecule_|_False_|_SATAVAPTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Aquilda']_|_['SR 121463' 'SR 121463A' 'SR 121463B' 'SR-121463' 'SR-121463A'
 'SR-121463B' 'SR121463B' 'SR121463F' 'Satavaptan'
 'Satavaptan monophosphate' 'Satavaptan phosphate' 'Sr121463']_|_nan_|_nan_|_{'rows': array(['HP_0001541', 'HP_0002902', 'EFO_0001422', 'EFO_1000982'],
      dtype=object), 'count': 4}_|_[ENSG00000126895]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL274654,"Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O_|_NHFDRBXTEDBWCZ-ZROIWOOFSA-N_|_Small molecule_|_False_|_ORANTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['NSC-702827' 'Orantinib' 'SU-6668' 'Su-6668' 'TSU-68']_|_[('PubChem', array(['527809'], dtype=object)), ('drugbank', array(['DB12072'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_1001951', 'EFO_0000182', 'MONDO_0008903',
       'MONDO_0008315', 'EFO_0000616', 'EFO_0002618', 'MONDO_0007254',
       'MONDO_0001056', 'MONDO_0002367'], dtype=object), 'count': 10}_|_[ENSG00000113721,ENSG00000134853,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL3813873,"FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1_|_JGWRKYUXBBNENE-UHFFFAOYSA-N_|_Small molecule_|_True_|_PEXIDARTINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CML-261' 'PLX-3397' 'PLX3397' 'Pexidartinib' 'Plx-3397']_|_[('drugbank', array(['DB12978'], dtype=object))]_|_['CHEMBL3989973']_|_{'rows': array(['EFO_0000183', 'MONDO_0008315', 'MONDO_0011719', 'EFO_0000519',
       'EFO_0001421', 'EFO_0000222', 'MONDO_0002171', 'EFO_1000562',
       'EFO_0002617', 'EFO_1001106', 'EFO_0003968', 'EFO_0000685',
       'EFO_0000760', 'EFO_0000756', 'EFO_0000616', 'EFO_0005537',
       'EFO_0000673', 'MONDO_0007254'], dtype=object), 'count': 18}_|_[ENSG00000182578,ENSG00000157404,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for tenosynovial giant cell tumor and neoplasm and has 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989496,"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1.O_|_XPYQFIISZQCINN-QVXDJYSKSA-N_|_Small molecule_|_False_|_TEZACITABINE_|_nan_|_2.0_|_CHEMBL2105467_|_False_|_False_|_[]_|_['Anhydrous' 'FMDC' 'MDL 101,731' 'Tezacitabine'
 'Tezacitabine monohydrate']_|_nan_|_nan_|_nan_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3989794,"CCOC(=O)[C@H](CCCc1ccccc1)C1(C(=O)N[C@H]2CCc3ccccc3N(CC(=O)O)C2=O)CCCC1_|_FVWPYVZWVOLAOP-DQEYMECFSA-N_|_Small molecule_|_False_|_DAGLUTRIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Daglutril' 'SLV-306' 'SLV306']_|_nan_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000117298,ENSG00000196549]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989819,CCCn1c(=O)c2nc([C@H]3C[C@H]4C[C@@H]3[C@@H]3O[C@H]43)[nH]c2n(CCC)c1=O_|_OQCJPFYWFGUHIN-GJKBLCTNSA-N_|_Small molecule_|_False_|_NAXIFYLLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BG-9719' 'BG9719' 'CVT-124' 'Naxifylline']_|_nan_|_nan_|_nan_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL404849,"CCCCCCCCNC(C)C(O)c1ccc(SC(C)C)cc1_|_BFCDFTHTSVTWOG-UHFFFAOYSA-N_|_Small molecule_|_False_|_SULOCTIDIL_|_1979.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Bemperil' 'CP-556S' 'Cerebro' 'Circleton' 'Dulasi' 'Duloctil' 'Euvasal'
 'Fluversin' 'Fluvisco' 'Hemoantin' 'Iangene' 'Loctidon' 'Locton'
 'MJF 12637' 'MJF-12637' 'Octamet' 'Polivasal' 'Sudil' 'Suloctidil'
 'Sulocton' 'Sulodene']_|_[('PubChem', array(['104171389', '144204409', '170466521', '26748521'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for cardiovascular disease. It was withdrawn in at least one region."
CHEMBL4594301,"COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21.O=S(=O)(O)c1ccccc1_|_QMTKNJZIWGTNTE-LMOVPXPDSA-N_|_Small molecule_|_True_|_REMIMAZOLAM BESYLATE_|_2020.0_|_4.0_|_CHEMBL4297526_|_False_|_True_|_['Byfavo']_|_['BIPRAZINE PF' 'CNS 7056 besylate' 'CNS 7056B' 'CNS-7056 BESYLATE'
 'CNS-7056B' 'GW-502056X' 'GW502056X' 'ONO-2745BS' 'ONO-IN-251' 'RF-10007'
 'RF10007' 'Remimazolam besilate' 'Remimazolam besylate' 'SP148.5']_|_[('DailyMed', array(['remimazolam%20besylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/REMIMAZOLAM%20BESYLATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009868', 'EFO_0003843'], dtype=object), 'count': 2}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL479527,"CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC_|_CMSGWTNRGKRWGS-NQIIRXRSSA-N_|_Small molecule_|_False_|_TORCETRAPIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CP-529,414' 'CP-529414' 'Torcetrapib']_|_[('Wikipedia', array(['Torcetrapib'], dtype=object)), ('drugbank', array(['DB06281'], dtype=object)), ('chEBI', array(['49203'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021187', 'MONDO_0018473', 'EFO_0001645', 'HP_0003124',
       'Orphanet_413', 'EFO_0004211', 'Orphanet_79211', 'EFO_0004911',
       'Orphanet_309005'], dtype=object), 'count': 9}_|_[ENSG00000087237]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL5314377,"CC(=O)O.CC(=O)O.CC/N=C(\NCC)NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN/C(=N/CC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O_|_OVBICQMTCPFEBS-SATRDZAXSA-N_|_Protein_|_False_|_GANIRELIX ACETATE_|_1999.0_|_4.0_|_CHEMBL1251_|_False_|_True_|_['Ganirelix acetate' 'Orgalutran']_|_['Ganirelix' 'Ganirelix acetate' 'Ganirest' 'RS-26306' 'RS-26306-298']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ganirelix-gedeon-richter'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000859', 'EFO_0000660', 'EFO_1000645', 'EFO_0000545'],
      dtype=object), 'count': 4}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 investigational indications."
CHEMBL53292,"Cc1cc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)no1_|_YYUAYBYLJSNDCX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOXICAM_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Isoxicam' 'NSC-758436' 'W 8495' 'W-8495']_|_[('PubChem', array(['11112741', '144204185', '170466334', '26747065', '855966'],
      dtype=object)), ('drugbank', array(['DB08942'], dtype=object)), ('chEBI', array(['76163'], dtype=object))]_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1025,"CC(C)OP(=O)(F)OC(C)C_|_MUCZHBLJLSDCSD-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOFLUROPHATE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Floropryl']_|_['Dyflos' 'Fluostigmine' 'Isoflurophate' 'NSC-727370']_|_[('PubChem', array(['144206196', '50113285'], dtype=object)), ('Wikipedia', array(['Diisopropyl_fluorophosphate'], dtype=object)), ('drugbank', array(['DB00677'], dtype=object)), ('chEBI', array(['17941'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for glaucoma."
CHEMBL1174,"N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O_|_CZKPOZZJODAYPZ-LROMGURASA-N_|_Protein_|_False_|_EPTIFIBATIDE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Eptifibatide' 'Eptifibatide accord' 'Integrilin']_|_['Eptifibatide' 'Integrelin']_|_[('DailyMed', array(['eptifibatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord'],
      dtype=object)), ('PubChem', array(['144206056', '170465043'], dtype=object)), ('Wikipedia', array(['Eptifibatide'], dtype=object)), ('chEBI', array(['291902'], dtype=object))]_|_['CHEMBL4068311']_|_{'rows': array(['MONDO_0011382', 'EFO_0000612', 'EFO_0000319', 'EFO_0001645',
       'EFO_0000712', 'HP_0002140', 'EFO_0005672', 'EFO_0008583',
       'EFO_0006834', 'EFO_0003106', 'HP_0004419', 'EFO_0008585',
       'EFO_0004277'], dtype=object), 'count': 13}_|_[ENSG00000259207,ENSG00000005961]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 9 investigational indications."
CHEMBL1201515,"nan_|_nan_|_Protein_|_False_|_PEGVISOMANT_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Somavert']_|_['B-2036-PEG' 'B2036-PEG' 'Pegvisomant' 'Pegwisomant' 'Somavent' 'Trovert']_|_[('DailyMed', array(['pegvisomant'], dtype=object)), ('DrugCentral', array(['5015'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/somavert'],
      dtype=object)), ('Wikipedia', array(['Pegvisomant'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000691', 'EFO_0003869', 'MONDO_0018919', 'MONDO_0021117',
       'EFO_1001485', 'EFO_0009607', 'EFO_0000673', 'EFO_0004142',
       'MONDO_0008274'], dtype=object), 'count': 9}_|_[ENSG00000112964]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for acromegaly and has 8 investigational indications."
CHEMBL1201735,"Br.CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1_|_WSTCENNATOVXKQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_BUPROPION HYDROBROMIDE_|_2008.0_|_4.0_|_CHEMBL894_|_False_|_True_|_['Aplenzin']_|_['BVF-033' 'Bupropion hbr' 'Bupropion hydrobromide']_|_[('DailyMed', array(['bupropion%20hydrobromide'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL1215923,"O=C(O)Cc1cccc(-c2cc(CCCCCCc3ccc(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)c(-c4cccc(CC(=O)O)c4)c3)ccc2O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)c1_|_RYWCQJDEHXJHRI-XJMXIVSISA-N_|_Small molecule_|_False_|_BIMOSIAMOSE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bimosiamose' 'TBC-1269']_|_[('PubChem', array(['124894548', '144206811'], dtype=object)), ('drugbank', array(['DB06197'], dtype=object))]_|_['CHEMBL2146099']_|_{'rows': array(['EFO_0000341', 'EFO_0000676'], dtype=object), 'count': 2}_|_[ENSG00000188404,ENSG00000007908,ENSG00000174175]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1278146,"CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O_|_GKEYKDOLBLYGRB-LGMDPLHJSA-N_|_Small molecule_|_False_|_FAMITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Famitinib' 'SHR-1020' 'SHR1020' 'Shr-1020']_|_[('drugbank', array(['DB11741'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0024503', 'EFO_0003869', 'EFO_0003060', 'EFO_0000756',
       'EFO_0004252', 'EFO_0005537', 'EFO_0002618', 'EFO_0000681',
       'EFO_0001071', 'EFO_0005922', 'EFO_1001961', 'MONDO_0002974',
       'MONDO_0011719', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0000365'], dtype=object), 'count': 17}_|_[ENSG00000128052,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000037280,ENSG00000102755,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL1387,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C(CCC(=O)C4)[C@H]3CC[C@@]21C_|_ICTXHFFSOAJUMG-SLHNCBLASA-N_|_Small molecule_|_False_|_NORETHYNODREL_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Enidrel' 'NSC-15432' 'Norethynodrel' 'Noretynodrel' 'SC-4642']_|_[('PubChem', array(['11533052', '144203910'], dtype=object)), ('Wikipedia', array(['Norethynodrel'], dtype=object)), ('drugbank', array(['DB09371'], dtype=object)), ('chEBI', array(['34895'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL166863,"CC1(C)OC(c2ccc(S(N)(=O)=O)cc2)=C(c2cccc(F)c2)C1=O_|_IJWPAFMIFNSIGD-UHFFFAOYSA-N_|_Small molecule_|_False_|_POLMACOXIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CG-100649' 'CG100649' 'Polmacoxib']_|_[('drugbank', array(['DB12399'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000786', 'MONDO_0005178', 'EFO_0005755', 'EFO_0004616'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000133742,ENSG00000104267]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL1672054,"CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1_|_XGGTZCKQRWXCHW-WMTVXVAQSA-N_|_Small molecule_|_False_|_CASOPITANT_|_nan_|_3.0_|_nan_|_False_|_False_|_['Rezonic' 'Zunrisa']_|_['Casopitant' 'GW-679769' 'GW679769' 'Gw679769']_|_[('drugbank', array(['DB06634'], dtype=object))]_|_['CHEMBL3542382' 'CHEMBL2107320']_|_{'rows': array(['HP_0002017', 'EFO_0006911', 'HP_0002018', 'HP_0002013',
       'EFO_0004888', 'MONDO_0002009', 'EFO_1000781', 'EFO_0008533',
       'EFO_0004698'], dtype=object), 'count': 9}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL1712842,"CC(=O)O.CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1_|_COBIOCPXKOZHSU-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPAZINE ACETATE_|_nan_|_4.0_|_CHEMBL395110_|_True_|_True_|_[]_|_['Mepazine acetate' 'NND 1964' 'Pecazine acetate']_|_[('PubChem', array(['49645132'], dtype=object))]_|_nan_|_nan_|_[ENSG00000172175]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1743089,"nan_|_nan_|_Antibody_|_False_|_VESENCUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MNRP-1685A' 'MNRP1685A' 'RG-7347' 'Vesencumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000099250]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107371,"CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NC4CCCC4)ncnc32)[C@H](O)[C@@H]1O_|_GWVQGVCXFNYGFP-PFHKOEEOSA-N_|_Small molecule_|_False_|_SELODENOSON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DTI-0009' 'GR-56072' 'GR56072' 'RG-14202' 'Selodenoson']_|_nan_|_nan_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108250,"nan_|_nan_|_Enzyme_|_False_|_ANISTREPLASE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Eminase']_|_['APSAC' 'Anistreplase' 'BRL 26921' 'BRL-26921']_|_nan_|_nan_|_{'rows': array(['HP_0004419'], dtype=object), 'count': 1}_|_[ENSG00000122194]_|_Enzyme drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis."
CHEMBL2108319,"nan_|_nan_|_Protein_|_False_|_SIMOCTOCOG ALFA_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Vihuma']_|_['Human-cl rh fviii' 'Nuwiq' 'Simoctocog alfa']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vihuma'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia a."
CHEMBL2108403,nan_|_nan_|_Antibody_|_False_|_EPITUMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Epitumomab']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109268,"nan_|_nan_|_Antibody drug conjugate_|_False_|_NARATUXIMAB EMTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DEBIO-1562' 'IMGN-529' 'IMGN529' 'Imgn 529' 'Imgn529' 'K7153a-smcc-dm1'
 'Naratuximab emtansine']_|_nan_|_nan_|_{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}_|_[ENSG00000104894]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109310,"nan_|_nan_|_Antibody_|_False_|_8H9 131I_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['8H9' '8h9 131i']_|_nan_|_nan_|_{'rows': array(['EFO_1001012', 'MONDO_0002087', 'EFO_0000621', 'EFO_1000026'],
      dtype=object), 'count': 4}_|_[ENSG00000103855]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3544910,"nan_|_nan_|_Small molecule_|_False_|_MOTEXAFIN GADOLINIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_['Xcytrin']_|_['API-GP3' 'FP-GP1' 'GD-TEXAPHYRIN' 'Gd texaphyrin' 'Gd-Tex'
 'Motexafin gadolinium' 'Motexafin gadolinium anhydrous'
 'Motexafin gadolinium hydrate' 'NSC-695238' 'PCI-0120'
 'gadolinium texaphyrin']_|_[('chEBI', array(['50161'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009708', 'EFO_0000095', 'EFO_1000158', 'EFO_0000681',
       'EFO_0000632', 'EFO_0000228', 'EFO_0005952', 'EFO_0000519',
       'EFO_0002618', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001378',
       'EFO_0003863', 'MONDO_0005411', 'MONDO_0002367', 'EFO_1001465',
       'EFO_0003833'], dtype=object), 'count': 17}_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848,ENSG00000198431]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL3828074,"CCc1nc2c(C)cc(N3CCN(CC(=O)N4CC(O)C4)CC3)cn2c1N(C)c1nc(-c2ccc(F)cc2)c(C#N)s1_|_REQQVBGILUTQNN-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZIRITAXESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['G-451990' 'G451990' 'GLPG-1690' 'GLPG1690' 'Glpg1690' 'Ziritaxestat'
 'Ziritaxestatn']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZIRITAXESTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15403'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000768', 'EFO_0006890', 'EFO_0000717'], dtype=object), 'count': 3}_|_[ENSG00000136960]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL395110,"CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1_|_CBHCDHNUZWWAPP-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPAZINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['III-2318' 'Lacumin' 'Mepasin' 'Mepazin' 'Mepazine base' 'Meprazine'
 'Mesapin' 'Nothiazine' 'P-391' 'Pacatal' 'Pacatal base' 'Pacatol'
 'Pakatal' 'Paxital' 'Pecatal' 'Pecazine']_|_[('PubChem', array(['144205395', '29216162'], dtype=object))]_|_['CHEMBL1712842']_|_nan_|_[ENSG00000172175]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL426559,"CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3_|_NXFFJDQHYLNEJK-CYBMUJFWSA-N_|_Small molecule_|_False_|_LAROPIPRANT_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Cordaptive' 'Laropiprant' 'MK-0524']_|_[('Wikipedia', array(['Laropiprant'], dtype=object)), ('drugbank', array(['DB11629'], dtype=object))]_|_['CHEMBL218415' 'CHEMBL375527']_|_{'rows': array(['Orphanet_309005', 'EFO_0004911', 'Orphanet_79211', 'HP_0003124',
       'EFO_1000760', 'MONDO_0005148', 'HP_0031284', 'MONDO_0021187'],
      dtype=object), 'count': 8}_|_[ENSG00000168229]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications. It was withdrawn in at least one region."
CHEMBL4297270,"Cc1noc(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)c1NC(=O)O[C@H](C)c1ccccc1_|_GQBRZBHEPUQRPL-LJQANCHMSA-N_|_Small molecule_|_False_|_BMS-986020_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AP-3152 FREE ACID' 'Bms-986020']_|_[('drugbank', array(['DB14948'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001993', 'EFO_0000768'], dtype=object), 'count': 2}_|_[ENSG00000198121]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4298192,"nan_|_nan_|_Oligonucleotide_|_False_|_SUVODIRSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMTR0139' 'Suvodirsen' 'WLS-4176' 'WV-3473' 'WVE-210201' 'Wve-210201']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SUVODIRSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4535757,"C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1_|_NXQKSXLFSAEQCZ-SFHVURJKSA-N_|_Small molecule_|_False_|_SOTORASIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Lumakras' 'Lumykras']_|_['AMG-510' 'AMG510' 'Kras g12c inhibitor 9'
 'Kras mutant-targeting amg 510' 'Sotorasib']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOTORASIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000571', 'EFO_0003060', 'MONDO_0008903', 'EFO_0001075',
       'EFO_1001512', 'EFO_0001421', 'EFO_1000251', 'EFO_0002618',
       'EFO_0000365', 'EFO_0000616'], dtype=object), 'count': 10}_|_[ENSG00000133703]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 8 investigational indications."
CHEMBL494089,"CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21_|_KGPGFQWBCSZGEL-ZDUSSCGKSA-N_|_Small molecule_|_False_|_GSK-690693_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GSK 690693' 'GSK690693' 'Gsk-690693']_|_[('drugbank', array(['DB12745'], dtype=object)), ('chEBI', array(['90677'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000142875,ENSG00000072062,ENSG00000165059,ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL632,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO_|_UREBDLICKHMUKA-DVTGEIKXSA-N_|_Small molecule_|_False_|_BETAMETHASONE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_['Alphatrex' 'Betasolan' 'Betatrex' 'Betnelan' 'Celestone' 'Dermabet'
 'Uticort']_|_['BETA-VAL' 'Betamethasone' 'Betatrex' 'Dermabet' 'Flubenisolone'
 'Lotrisone' 'NSC-39470' 'SCH 4831' 'SCH-4831' 'Taclonex' 'Uticort'
 'VISUBETA']_|_[('PubChem', array(['144205668', '144211772', '170465027', '26757820', '46500420',
       '56320847'], dtype=object)), ('Wikipedia', array(['Betamethasone'], dtype=object)), ('drugbank', array(['DB00443'], dtype=object)), ('chEBI', array(['3077'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271', 'MONDO_0009971', 'EFO_1000644', 'HP_0011868',
       'EFO_0008517', 'HP_0030833', 'EFO_0004209', 'EFO_1000637',
       'EFO_1000906', 'HP_0012735', 'EFO_0009840', 'HP_0000964',
       'EFO_0004143', 'MONDO_0003005', 'EFO_0002950', 'EFO_0000232',
       'EFO_0005854', 'EFO_0003917', 'MONDO_0005041', 'HP_0006536',
       'EFO_0000676', 'EFO_0000274', 'EFO_0004274', 'HP_0001742',
       'MONDO_0002258', 'EFO_1001157', 'EFO_0005752', 'EFO_0009552',
       'EFO_1001077', 'EFO_1001494', 'EFO_0000756', 'HP_0011950'],
      dtype=object), 'count': 32}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 4 approved and 28 investigational indications."
CHEMBL1116,"Cl.O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12_|_BKXVVCILCIUCLG-UHFFFAOYSA-N_|_Small molecule_|_True_|_RALOXIFENE HYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL81_|_False_|_True_|_['Evirex' 'Evista' 'Optruma' 'Ostiral' 'Raloxifene hydrochloride'
 'Razylan']_|_['Keoxifene hydrochloride' 'LY-156758' 'LY156758' 'NSC-706725'
 'Raloxifene hcl' 'Raloxifene hydrochloride' 'Raloxifene teva']_|_[('DailyMed', array(['raloxifene%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evista'],
      dtype=object)), ('PubChem', array(['144203806', '144212686', '170465341', '26753259', '26753260',
       '50106949', '50106950', '56320710', '56324093'], dtype=object)), ('chEBI', array(['50740'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000673', 'EFO_0003854', 'EFO_0003882'],
      dtype=object), 'count': 4}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200411,"CCCN(CCC)CCc1cccc2c1CC(=O)N2.Cl_|_XDXHAEQXIBQUEZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_ROPINIROLE HYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL589_|_False_|_True_|_['Adartrel' 'Aimpart xl' 'Clevor' 'Ipinnia xl' 'Ralnea xl' 'Raponer xl'
 'Repinex xl' 'Requip' 'Requip xl' 'Ropilynz xl'
 'Ropinirole hydrochloride' 'Spiroco xl']_|_['Ropinirole (as hydrochloride)' 'Ropinirole hcl'
 'Ropinirole hydrochloride' 'SK&F 101468-A' 'SK&F-101468-A']_|_[('DailyMed', array(['ropinirole%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/clevor'],
      dtype=object)), ('PubChem', array(['50107005'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0004270'], dtype=object), 'count': 2}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for parkinson disease and restless legs syndrome. This drug has a black box warning from the FDA."
CHEMBL1201212,"COc1ccc(OC)c(C(O)CNC(=O)CN)c1_|_PTKSEFOSCHHMPD-UHFFFAOYSA-N_|_Small molecule_|_True_|_MIDODRINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Midodrine' 'ST 1085' 'ST-1085']_|_[('drugbank', array(['DB00211'], dtype=object)), ('chEBI', array(['6933'], dtype=object))]_|_['CHEMBL1200461']_|_{'rows': array(['EFO_1001346', 'EFO_1001919', 'EFO_0005251', 'EFO_0000319',
       'EFO_0006834', 'EFO_0000712', 'HP_0002140', 'EFO_0005252',
       'HP_0001541', 'EFO_0006834', 'HP_0100806', 'EFO_0005252'],
      dtype=object), 'count': 12}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for cardiovascular disease and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL131,"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO_|_OIGNJSKKLXVSLS-VWUMJDOOSA-N_|_Small molecule_|_False_|_PREDNISOLONE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Cortalone' 'Dekotil' 'Delta-cortef' 'Deltacortril' 'Deltalone'
 'Dilacort' 'Equisolon' 'Fernisolone-p' 'Hydeltra' 'Meti-derm'
 'Meticortelone' 'Pevanti' 'Precortisyl' 'Precortisyl fte' 'Prednisolone'
 'Prelone' 'Scheriproct' 'Servisone' 'Sterane']_|_['Desowen' 'Hydeltra-Tba' 'Meticortelone' 'NSC-9120' 'NSC-9900'
 'Neo-Delta-Cortef' 'Poly-Pred' 'Pred-G' 'Prednisolone' 'Servisone'
 'Tridesilon' 'Verdeso']_|_[('DailyMed', array(['prednisolone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/equisolon'],
      dtype=object)), ('PubChem', array(['144204880', '144208871', '144213304', '170464732', '50085972'],
      dtype=object)), ('Wikipedia', array(['Prednisolone'], dtype=object)), ('drugbank', array(['DB00860'], dtype=object)), ('chEBI', array(['8378'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0000873', 'MONDO_0015128', 'EFO_0005319', 'EFO_0007486',
       'HP_0001742', 'EFO_0005558', 'EFO_0008997', 'EFO_1001345',
       'EFO_0004254', 'EFO_1001321', 'HP_0002315', 'EFO_0000341',
       'EFO_1001205', 'EFO_0004190', 'MONDO_0018906', 'EFO_1001968',
       'EFO_0000768', 'EFO_0000565', 'EFO_0005297', 'HP_0001915',
       'EFO_0000222', 'EFO_0003872', 'EFO_0000182', 'EFO_1001139',
       'EFO_0000183', 'EFO_0001663', 'EFO_0007257', 'EFO_0009609',
       'EFO_0000685', 'EFO_0005854', 'HP_0003072', 'EFO_0000545',
       'EFO_1001896', 'EFO_1001231', 'EFO_1001069', 'MONDO_0005090',
       'EFO_0007537', 'MONDO_0009348', 'MONDO_0005129', 'EFO_0003938',
       'EFO_1000684', 'EFO_0007427', 'EFO_0000699', 'EFO_0004236',
       'EFO_0004194', 'MONDO_0015540', 'EFO_0009456', 'EFO_0000274',
       'MONDO_0004992', 'EFO_0004274', 'EFO_0000196', 'EFO_0000384',
       'EFO_0004237', 'EFO_0003106', 'HP_0002140', 'EFO_1001857',
       'EFO_0000209', 'EFO_0003884', 'EFO_1000941', 'MONDO_0004750',
       'MONDO_0019338', 'EFO_0007520', 'EFO_0000764', 'MONDO_0002462',
       'EFO_0004246', 'MONDO_0001705', 'EFO_0001378', 'MP_0001845',
       'EFO_0000255', 'EFO_1001194', 'EFO_0003778', 'EFO_1000764',
       'HP_0004398', 'EFO_0000211', 'EFO_0003898', 'EFO_1001110',
       'EFO_0000318', 'EFO_1001467', 'EFO_0000096', 'EFO_1000694',
       'HP_0001873', 'EFO_0002609', 'MONDO_0013730', 'EFO_0007227',
       'EFO_1001176', 'EFO_0009491', 'EFO_0000676', 'MONDO_0005178',
       'MONDO_0007254', 'EFO_0000398', 'EFO_0004826', 'MONDO_0005148',
       'EFO_1000726', 'EFO_1000680', 'MONDO_0007915', 'EFO_0000220',
       'EFO_0003086', 'EFO_0004616', 'EFO_0000717', 'EFO_1001051',
       'MONDO_0010679', 'EFO_1000997', 'EFO_0007141', 'EFO_0000673',
       'MONDO_0018097', 'EFO_0001054', 'EFO_0001365', 'EFO_1000954',
       'MONDO_0004979', 'EFO_0000756', 'EFO_0005761', 'MONDO_0008315',
       'MONDO_0005271', 'EFO_1001222', 'EFO_0003032', 'MONDO_0100096',
       'HP_0012424', 'EFO_0007160', 'EFO_1000784', 'EFO_0007208',
       'HP_0001094', 'EFO_0009449', 'EFO_1001209', 'EFO_1000749',
       'HP_0000964', 'EFO_0001060', 'MONDO_0008867', 'EFO_0005752',
       'EFO_1001887', 'EFO_0004255', 'EFO_1000049', 'EFO_0005952',
       'EFO_1000635', 'EFO_0000712', 'EFO_1001435', 'EFO_1001264',
       'MONDO_0018896', 'MONDO_0005301', 'MONDO_0005041', 'EFO_1001119',
       'EFO_0000574', 'EFO_0000729', 'MONDO_0008728', 'EFO_0007405',
       'MONDO_0020290', 'EFO_0007403', 'EFO_1001888', 'EFO_0007140',
       'MONDO_0001280', 'EFO_0000759', 'EFO_0009552', 'EFO_0000403',
       'EFO_1001077', 'EFO_0008518', 'EFO_0007167', 'MONDO_0009387',
       'EFO_1000039'], dtype=object), 'count': 157}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 58 approved and 99 investigational indications."
CHEMBL1434513,"NC[C@H](O)c1ccc(O)c(O)c1.O.O=C(O)C(O)C(O)C(=O)O_|_LNBCGLZYLJMGKP-JZGIKJSDSA-N_|_Small molecule_|_True_|_NOREPINEPHRINE BITARTRATE_|_1950.0_|_4.0_|_CHEMBL1437_|_False_|_True_|_['Adrenor' 'Aktamin' 'Levarterenol Bitartrate' 'Levophed' 'Noradrenaline'
 'Norepinephrine bitartrate' 'Norepinephrine bitartrate in 5% dextrose']_|_['Aktamin' 'Arterenol, tartrate, monohydrate' 'Binodrenal'
 'Levarterenol bitartrate' 'NSC-169106' 'Noradrenaline'
 'Noradrenaline (as tartrate)' 'Noradrenaline bitartrate'
 'Noradrenaline tartrate' 'Norepinephrine' 'Norepinephrine bitartrate'
 'Norepinephrine bitartrate monohydrate' 'Norepinephrine d-bitartrate'
 'Norepinephrine hydrochloride']_|_[('DailyMed', array(['norepinephrine%20bitartrate'], dtype=object)), ('PubChem', array(['56463315'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'HP_0100806', 'MONDO_0001382', 'EFO_0005251',
       'EFO_0004610', 'HP_0002140', 'EFO_0007450', 'EFO_0002497',
       'MONDO_0008867'], dtype=object), 'count': 9}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1742995,"nan_|_nan_|_Antibody_|_False_|_BRIAKINUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Ozespa']_|_['A-796874.0' 'ABT-874' 'BSF 415977' 'BSF-415977' 'Briakinumab' 'J-695'
 'J-695 BSF-415977 LU-415977 WAY-165772 A-796874.0' 'J695' 'LU 415977'
 'LU-415977' 'WAY-165772']_|_nan_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000384', 'EFO_0000540', 'MONDO_0005301'],
      dtype=object), 'count': 4}_|_[ENSG00000113302,ENSG00000110944,ENSG00000168811]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2062262,"C[C@H](N)[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O_|_VENXSELNXQXCNT-YDYUUSCQSA-N_|_Small molecule_|_False_|_METARAMINOL BITARTRATE_|_1954.0_|_4.0_|_CHEMBL1201319_|_False_|_True_|_['Aramine' 'Metaraminol bitartrate']_|_['Metaradrine bitartrate' 'Metaraminol bitartrate'
 'Metaraminol hydrochloride' 'Metaraminol hydrochloride, (-)-'
 'Metaraminol tartrate' 'NSC-758425']_|_nan_|_nan_|_nan_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954."
CHEMBL2105721,"CC(C)[C@@]1(C(=O)N[C@H]2CC(=O)O[C@]2(O)CF)CC(c2nccc3ccccc23)=NO1_|_VYFGDLGHHBUDTQ-ZLGUVYLKSA-N_|_Small molecule_|_False_|_NIVOCASAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GS-9450' 'LB-84451' 'LB84451' 'Nivocasan']_|_[('drugbank', array(['DB12720'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003047', 'EFO_1001249'], dtype=object), 'count': 2}_|_[ENSG00000137752,ENSG00000064012,ENSG00000132906]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108316,"nan_|_nan_|_Oligonucleotide_|_False_|_EDIFOLIGIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Edifoligide']_|_nan_|_nan_|_nan_|_[ENSG00000101412,ENSG00000007968,ENSG00000112242,ENSG00000205250,ENSG00000133740,ENSG00000169016,ENSG00000165891,ENSG00000129173]_|_Oligonucleotide drug with a maximum clinical trial phase of II."
CHEMBL2108348,"nan_|_nan_|_Protein_|_False_|_NONACOG BETA PEGOL_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Refixia']_|_['Nonacog beta pegol' 'Rebinyn' 'Refixia']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/refixia'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia b."
CHEMBL2108357,"nan_|_nan_|_Antibody_|_False_|_EPRATUZUMAB 90Y_|_nan_|_3.0_|_nan_|_False_|_False_|_['Lymphocide']_|_['AMG-412' 'Epratuzumab 90y' 'HLL2']_|_nan_|_nan_|_{'rows': array(['EFO_1001938'], dtype=object), 'count': 1}_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2147777,"Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1_|_WGRQANOPCQRCME-PMACEKPBSA-N_|_Small molecule_|_False_|_TENELIGLIPTIN_|_2012.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MP-513' 'Teneligliptin']_|_[('drugbank', array(['DB11950'], dtype=object))]_|_['CHEMBL2147708']_|_{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 2 investigational indications."
CHEMBL221692,"Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1_|_IUVSEUFHPNITEQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADOPRAZINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adoprazine' 'SLV-313']_|_nan_|_['CHEMBL4751170']_|_nan_|_[ENSG00000151577,ENSG00000178394,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3185463,"CN1CCN(c2ccccc2/C=C2\SCCN(c3ccc(Cl)c(Cl)c3)C2=O)CC1_|_LHYMPSWMHXUWSK-STZFKDTASA-N_|_Small molecule_|_False_|_ELZASONAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Elzasonan']_|_[('PubChem', array(['144210759'], dtype=object))]_|_['CHEMBL3989903' 'CHEMBL3989805']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3286580,"Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1_|_YBAWYTYNMZWMMJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_IDALOPIRDINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Idalopirdine' 'LU AE-58054' 'LU-AE-58054' 'LU-AE58054' 'LY-483518'
 'LY483518' 'Lu AE58054' 'Lu-ae58054' 'SGS-518' 'SGS518']_|_[('drugbank', array(['DB11957'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'HP_0100543', 'MONDO_0005090'], dtype=object), 'count': 3}_|_[ENSG00000158748]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3590106,"CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1_|_KSERXGMCDHOLSS-LJQANCHMSA-N_|_Small molecule_|_False_|_ULIXERTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BVD-ERK' 'Bvd-523' 'Ulixertinib' 'VRT-752271']_|_[('drugbank', array(['DB13930'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000616', 'EFO_0002618', 'EFO_0000198',
       'EFO_0000326'], dtype=object), 'count': 5}_|_[ENSG00000102882,ENSG00000100030]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4279047,"C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F_|_QCZAWDGAVJMPTA-RNFRBKRXSA-N_|_Small molecule_|_False_|_VORASIDENIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AG-881' 'Ag-881' 'Vorasidenib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VORASIDENIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4594378']_|_{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_0001421', 'EFO_0000272',
       'EFO_0000326'], dtype=object), 'count': 5}_|_[ENSG00000138413,ENSG00000182054]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297770,"nan_|_nan_|_Oligonucleotide_|_False_|_INOTERSEN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['GSK-2998728' 'ISIS 420915' 'ISIS-420915' 'Inotersen']_|_nan_|_nan_|_{'rows': array(['EFO_1001875', 'EFO_0004129'], dtype=object), 'count': 2}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL4297777,"nan_|_nan_|_Unknown_|_False_|_LMB-100_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-msln-pe24 cfp lmb-100' 'LMB-100' 'Lmb 100' 'Lmb-100' 'RG-7787'
 'RG7787' 'RO-6927005' 'RO6927005' 'Ro6927005']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000571', 'EFO_0000588', 'EFO_0003860'],
      dtype=object), 'count': 4}_|_[ENSG00000102854,ENSG00000167658]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297939,"nan_|_nan_|_Antibody drug conjugate_|_False_|_DATOPOTAMAB DERUXTECAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ADC DS-1062A' 'DS-1062' 'DS-1062a' 'DS1062' 'Dato-DXd'
 'Datopotamab deruxtecan' 'Ds-1062' 'Ds-1062a']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DATOPOTAMAB%20DERUXTECAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008903', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616',
       'EFO_0003869', 'EFO_0003968', 'EFO_0005537'], dtype=object), 'count': 7}_|_[ENSG00000198900,ENSG00000184292]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4298178,"nan_|_nan_|_Antibody drug conjugate_|_False_|_TRASTUZUMAB DUOCARMAZINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SYD-985' 'SYD985' 'Trastuzumab duocarmazine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRASTUZUMAB%20DUOCARMAZINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0001056', 'EFO_0004243', 'EFO_0001075',
       'EFO_0000616', 'EFO_0003968', 'MONDO_0011962', 'MONDO_0001187',
       'MONDO_0021251', 'EFO_0005537'], dtype=object), 'count': 10}_|_[ENSG00000141736]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL4298209,"nan_|_nan_|_Antibody drug conjugate_|_True_|_BELANTAMAB MAFODOTIN_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Blenrep']_|_['Belantamab mafodotin' 'Belantamab mafodotin blmf' 'GSK-2857916'
 'GSK2857916']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELANTAMAB%20MAFODOTIN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019438', 'EFO_0000403', 'EFO_0000616', 'EFO_0001378'],
      dtype=object), 'count': 4}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000048462]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and multiple myeloma and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4802129,"C[C@@H]1NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N2_|_MKXOUIKTXREBLX-NDKBASPVSA-N_|_Protein_|_False_|_BALIXAFORTIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Balixafortide' 'POL-6326' 'POL6326' 'Pol6326']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BALIXAFORTIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005809', 'EFO_0000616', 'EFO_0000339', 'EFO_0000612',
       'EFO_0000198', 'EFO_0000222', 'MONDO_0007254', 'EFO_0001378',
       'EFO_0000095'], dtype=object), 'count': 9}_|_[ENSG00000121966]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL48582,"CS(=O)(=O)O.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O_|_YKOCHIUQOBQIAC-YDALLXLXSA-N_|_Small molecule_|_False_|_SAFINAMIDE MESYLATE_|_2015.0_|_4.0_|_CHEMBL396778_|_False_|_True_|_['Xadago']_|_['EMD 1195686' 'NW 1015' 'NW-1015' 'PNU 151774E' 'PNU-151774E'
 'Safinamide mesilate' 'Safinamide mesylate' 'Safinamide methanesulfonate'
 'Safinamide methansulfonate']_|_[('DailyMed', array(['safinamide%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xadago'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for parkinson disease."
CHEMBL521589,"CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1_|_ANZXOIAKUNOVQU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BAMBUTEROL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bambuterol']_|_[('PubChem', array(['56463628'], dtype=object)), ('Wikipedia', array(['Bambuterol'], dtype=object)), ('drugbank', array(['DB01408'], dtype=object)), ('chEBI', array(['553827'], dtype=object))]_|_['CHEMBL1603534']_|_{'rows': array(['HP_0006536', 'EFO_0001361'], dtype=object), 'count': 2}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL897,"CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1_|_DBABZHXKTCFAPX-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROBENECID_|_1951.0_|_4.0_|_nan_|_False_|_True_|_['Benemid' 'Benuryl' 'Probalan' 'Probampicin' 'Probecid' 'Probenecid']_|_['HC 5006' 'NSC-18786' 'P-(dipropylsulfamoyl)benzoic acid' 'Probenate'
 'Probenecid' 'Probenecidum']_|_[('DailyMed', array(['probenecid'], dtype=object)), ('PubChem', array(['11112135', '144203879', '144209308', '144213245', '170464839',
       '17389752', '26747055', '26747056', '26751571', '50100375',
       '56424104', '855953'], dtype=object)), ('Wikipedia', array(['Probenecid'], dtype=object)), ('drugbank', array(['DB01032'], dtype=object)), ('chEBI', array(['8426'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0004248', 'EFO_0004274', 'EFO_0000544',
       'MONDO_0007079', 'MONDO_0001314', 'EFO_0003144', 'MONDO_0043510',
       'MONDO_0005148', 'EFO_0003103', 'EFO_1001207', 'EFO_0005222',
       'EFO_1000025', 'EFO_0000616', 'EFO_0001073', 'EFO_0003035'],
      dtype=object), 'count': 16}_|_[ENSG00000149452,ENSG00000197901,ENSG00000168065]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for gout and has 15 investigational indications."
CHEMBL1200787,"CC(COc1ccccc1)N(CCCl)Cc1ccccc1.Cl_|_VBCPVIWPDJVHAN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENOXYBENZAMINE HYDROCHLORIDE_|_1953.0_|_4.0_|_CHEMBL753_|_False_|_True_|_['Dibenyline' 'Dibenzyline' 'Phenoxybenzamine hydrochloride']_|_['Bensylyte hydrochloride' 'Dibenzylin' 'Dibenzyline chloride'
 'Dibenzyline hydrochloride' 'Dibenzyran' 'NSC-37448'
 'Phenoxybenzamine chloride' 'Phenoxybenzamine hcl'
 'Phenoxybenzamine hydrochloride']_|_[('DailyMed', array(['phenoxybenzamine%20hydrochloride'], dtype=object)), ('PubChem', array(['144208786', '144213295', '17389764', '26747462', '26752311',
       '50105976', '855636'], dtype=object)), ('chEBI', array(['8078'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000239'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma."
CHEMBL1201037,"Cl.NCCCC(N)(C(=O)O)C(F)F.O_|_FJPAMFNRCFEGSD-UHFFFAOYSA-N_|_Small molecule_|_False_|_EFLORNITHINE HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL830_|_False_|_True_|_['Ornidyl' 'Vaniqa']_|_['Dfmo hcl' 'Difluromethylornithine' 'Eflornithine hcl'
 'Eflornithine hydrochloride' 'Eflornithine hydrochloride monohydrate'
 'MDL 71,782 A' 'MDL-71782-A' 'MDL-71782A' 'NSC-270295' 'NSC-337250'
 'RMI-71782-A']_|_[('DailyMed', array(['eflornithine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_733', 'EFO_0000621'], dtype=object), 'count': 2}_|_[ENSG00000115758]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 2 investigational indications."
CHEMBL1201168,"Cc1cc(C(=O)NNCc2ccccc2)no1_|_XKFPYPQQHFEXRZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_ISOCARBOXAZID_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Marplan']_|_['Enerzer' 'Isocarboxazid' 'NSC-169893' 'RO 5-0831' 'RO-5-0831']_|_[('DailyMed', array(['isocarboxazid'], dtype=object)), ('PubChem', array(['11112152', '144203887', '56463226'], dtype=object)), ('Wikipedia', array(['Isocarboxazid'], dtype=object)), ('drugbank', array(['DB01247'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0002009', 'MONDO_0004975'], dtype=object), 'count': 3}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for major depressive disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201630,"nan_|_nan_|_Protein_|_False_|_INSULIN PURIFIED PORK_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Iletin ii' 'Regular iletin ii (pork)' 'Regular purified pork insulin'
 'Velosulin']_|_['Insulin (pork)' 'Insulin purified pork']_|_nan_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for diabetes mellitus."
CHEMBL1201640,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP EXTENDED BEEF_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Ultralente insulin']_|_['Insulin zinc susp extended beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1256958,"CNC[C@H](O)c1ccc(O)c(O)c1.O=C(O)C(O)C(O)C(=O)O_|_YLXIPWWIOISBDD-FVGYRXGTSA-N_|_Small molecule_|_False_|_EPINEPHRINE BITARTRATE_|_1965.0_|_4.0_|_CHEMBL679_|_False_|_True_|_['Bronitin mist' 'Medihaler-epi']_|_['(-)-Epinephrine Bitartrate' 'Adrenalin tartrate'
 'Adrenaline (as tartrate)' 'Adrenaline acid tartrate'
 'Adrenaline bitartate' 'Adrenaline bitartrate' 'Epinephrine bitartrate'
 'Epinephrine d-bitartrate' 'Epinephrine hydrogen tartrate'
 'Epinephrine tartrate' 'Epinephrini hydrogenotartras'
 'L-epinephrine hydrogen tartrate' 'NSC-756755']_|_[('DailyMed', array(['epinephrine%20bitartrate'], dtype=object)), ('PubChem', array(['11532860', '50106283'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1965 and is indicated for pain."
CHEMBL1431,"CN(C)C(=N)NC(=N)N_|_XZWYZXLIPXDOLR-UHFFFAOYSA-N_|_Small molecule_|_True_|_METFORMIN_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['LA-6023' 'Metformin' 'Metformin extended release']_|_[('PubChem', array(['11112469', '137275802', '144212687', '174006543'], dtype=object)), ('TG-GATEs', array(['53'], dtype=object)), ('Wikipedia', array(['Metformin'], dtype=object)), ('drugbank', array(['DB00331'], dtype=object)), ('chEBI', array(['6801'], dtype=object))]_|_['CHEMBL3094198' 'CHEMBL1703']_|_{'rows': array(['EFO_0000685', 'EFO_0002617', 'MONDO_0044704', 'EFO_0005537',
       'MONDO_0007254', 'EFO_0002618', 'HP_0000842', 'MONDO_0005090',
       'EFO_0004214', 'HP_0003124', 'MONDO_0100096', 'MONDO_0010383',
       'MONDO_0018906', 'MONDO_0005299', 'EFO_0008522', 'EFO_0000571',
       'MONDO_0001941', 'EFO_0001378', 'EFO_0003095', 'MONDO_0010679',
       'EFO_0000403', 'EFO_0000182', 'MONDO_0007254', 'EFO_0000673',
       'EFO_1001951', 'MP_0001845', 'EFO_0005687', 'MONDO_0018875',
       'EFO_1001496', 'HP_0002745', 'EFO_0000432', 'EFO_0000660',
       'EFO_0000275', 'EFO_0003914', 'MONDO_0011382', 'MONDO_0021063',
       'HP_0003419', 'MONDO_0019391', 'EFO_0001071', 'MONDO_0019353',
       'EFO_0004593', 'EFO_0000305', 'EFO_0005411', 'EFO_0003968',
       'MONDO_0005148', 'MONDO_0004782', 'EFO_0000673', 'EFO_0000676',
       'EFO_0002687', 'EFO_0003884', 'EFO_0000341', 'EFO_0003770',
       'EFO_0003060', 'EFO_0009516', 'EFO_1001121', 'EFO_0000537',
       'EFO_0000702', 'EFO_0000199', 'EFO_0004208', 'EFO_0004616',
       'MONDO_0002158', 'MONDO_0008315', 'Orphanet_309005', 'EFO_0002950',
       'EFO_0000756', 'EFO_1001892', 'EFO_0000365', 'MONDO_0021350',
       'EFO_1001512', 'EFO_0004265', 'EFO_0009637', 'HP_0100543',
       'EFO_0000181', 'EFO_0003767', 'EFO_0000095', 'MONDO_0002108',
       'EFO_0000400', 'EFO_0000280', 'EFO_1000043', 'EFO_0004566',
       'EFO_0005672', 'MONDO_0004658', 'EFO_0000694', 'MONDO_0011962',
       'EFO_1000359', 'EFO_1001492', 'HP_0002910', 'EFO_0008520',
       'MONDO_0002009', 'EFO_0004364', 'EFO_0000729', 'EFO_1001459',
       'EFO_1000710', 'EFO_0008520', 'EFO_0003144', 'EFO_0001663',
       'EFO_0000474', 'EFO_0004142', 'EFO_0006859', 'EFO_0000519',
       'EFO_0000196', 'MONDO_0008903', 'MONDO_0019338', 'MONDO_0005180',
       'EFO_0000228', 'HP_0001268', 'MONDO_0004992', 'MONDO_0005178',
       'EFO_0000195', 'EFO_0001416', 'EFO_0003884', 'EFO_0006859',
       'EFO_0001645', 'EFO_0000466', 'EFO_0000313', 'EFO_0003060',
       'EFO_0005922', 'EFO_0001054', 'EFO_0001361', 'EFO_0004593',
       'EFO_0000308', 'Orphanet_733', 'MONDO_0005301', 'EFO_0000707',
       'MONDO_0005277', 'EFO_1001249', 'EFO_0000616', 'EFO_0003963',
       'HP_0001541', 'MONDO_0020121', 'EFO_0002618', 'MONDO_0008170',
       'MONDO_0002974', 'HP_0001397', 'EFO_0005762', 'MONDO_0008315',
       'EFO_0003050', 'EFO_0000571', 'EFO_0001068', 'EFO_0003863',
       'EFO_0000649', 'MONDO_0002691', 'MONDO_0005147', 'EFO_0000545',
       'EFO_0001378', 'EFO_1001207', 'MONDO_0005184', 'EFO_0000348',
       'EFO_1000045', 'EFO_0003940', 'EFO_0003144', 'MONDO_0017975',
       'EFO_0003918', 'EFO_0002546', 'EFO_0000195', 'EFO_1001901',
       'EFO_0003868', 'EFO_0003876', 'MONDO_0001187', 'EFO_0000199',
       'HP_0012115', 'EFO_1000783', 'MONDO_0015229', 'MONDO_0007739',
       'EFO_1000657', 'MONDO_0005041', 'EFO_0001663', 'EFO_0000220',
       'EFO_1000286', 'EFO_0000400', 'EFO_0000589', 'EFO_0001075',
       'MONDO_0018076', 'MONDO_0021063', 'MONDO_0002087', 'EFO_0001073',
       'MONDO_0017276', 'MONDO_0004985', 'EFO_0000660', 'EFO_0008522',
       'EFO_0000764', 'EFO_0003833', 'EFO_1000632', 'EFO_0001073',
       'EFO_0003100', 'HP_0001249', 'EFO_1001465', 'EFO_0000319',
       'EFO_0000616', 'EFO_1001348', 'MONDO_0005148', 'EFO_0002614'],
      dtype=object), 'count': 192}_|_[ENSG00000115159,ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 181 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1703,"CN(C)C(=N)NC(=N)N.Cl_|_OETHQSJEHLVLGH-UHFFFAOYSA-N_|_Small molecule_|_True_|_METFORMIN HYDROCHLORIDE_|_1995.0_|_4.0_|_CHEMBL1431_|_False_|_True_|_['Bolamyn sr' 'Diagemet xl' 'Fortamet' 'Glucamet 500' 'Glucamet 850'
 'Glucient sr' 'Glucophage' 'Glucophage sr' 'Glucophage xr' 'Glumetza'
 'Glyformin' 'Janumet' 'Ledermetin' 'Metabet sr' 'Metformin hydrochloride'
 'Metsol' 'Milform' 'Orabet' 'Riomet' 'Riomet er' 'Sukkarto sr']_|_['Apophage' 'Benofomin' 'Diabefagos' 'Diabex' 'EX-404' 'EX404'
 'Glucaminol' 'LA-6023' 'Metformin hcl' 'Metformin hydrochloride'
 'NSC-91485' 'Neodipa' 'Siamformet' 'Walaphage']_|_[('DailyMed', array(['metformin%20hydrochloride'], dtype=object)), ('PubChem', array(['11532867', '144204049', '170464804', '26749076', '85273756'],
      dtype=object)), ('chEBI', array(['6802'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0000571', 'EFO_0008520', 'MONDO_0007254',
       'EFO_0002618', 'HP_0000842', 'EFO_0000199', 'MONDO_0005184',
       'EFO_0000348', 'EFO_0004208', 'EFO_1001459', 'EFO_0004616',
       'EFO_0003144', 'MONDO_0005299', 'MONDO_0002158', 'EFO_0000195',
       'EFO_0001663', 'EFO_0003868', 'EFO_0006859', 'MONDO_0008315',
       'EFO_1000783', 'EFO_0001378', 'EFO_0000400', 'EFO_1001512',
       'MONDO_0002087', 'MP_0001845', 'EFO_0009637', 'EFO_0000432',
       'EFO_0000660', 'EFO_0008522', 'EFO_0000466', 'EFO_0003060',
       'MONDO_0021063', 'EFO_0001073', 'EFO_0004593', 'EFO_0001071',
       'MONDO_0019391', 'EFO_1000043', 'MONDO_0019353', 'EFO_1001465',
       'EFO_0000616', 'MONDO_0005148', 'HP_0001541', 'EFO_0000673'],
      dtype=object), 'count': 44}_|_[ENSG00000115159,ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 42 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2105738,"C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12_|_PAFKTGFSEFKSQG-PAASFTFBSA-N_|_Small molecule_|_False_|_GALETERONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Galeterone' 'TOK 001' 'TOK-001' 'VN 124' 'VN-124' 'VN/124' 'VN/124-1']_|_[('drugbank', array(['DB12415'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_1000359'], dtype=object), 'count': 2}_|_[ENSG00000169083,ENSG00000148795]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2424780,"CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2_|_VFOKSTCIRGDTBR-UHFFFAOYSA-N_|_Small molecule_|_False_|_VESATOLIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GS-9620' 'Vesatolimod']_|_[('drugbank', array(['DB12687'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_0003047', 'EFO_0000180', 'EFO_0004239',
       'EFO_0000765', 'EFO_0004197'], dtype=object), 'count': 6}_|_[ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3039502,"C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1_|_SJVQHLPISAIATJ-ZDUSSCGKSA-N_|_Small molecule_|_True_|_DUVELISIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Duvelisib' 'INK-1197' 'IPI-145']_|_[('DailyMed', array(['duvelisib'], dtype=object)), ('drugbank', array(['DB11952'], dtype=object))]_|_['CHEMBL5315125']_|_{'rows': array(['EFO_0000574', 'MONDO_0004979', 'EFO_0000095', 'EFO_0000685',
       'EFO_0000181', 'EFO_0000574', 'EFO_0000095', 'MONDO_0100096',
       'EFO_0000403', 'EFO_1001051', 'MONDO_0018906', 'EFO_0000220',
       'EFO_0001421', 'EFO_1000785', 'MONDO_0004992', 'MONDO_0044881',
       'EFO_0000096', 'EFO_0000756', 'EFO_0000211', 'EFO_0000616',
       'EFO_0000565', 'MONDO_0018906', 'EFO_0005952'], dtype=object), 'count': 23}_|_[ENSG00000171608,ENSG00000105851]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3039526,"CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1.CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1.O=C(O)CCC(=O)O_|_MSOIHUHNGPOCTH-UHFFFAOYSA-N_|_Small molecule_|_False_|_LASMIDITAN SUCCINATE_|_2020.0_|_4.0_|_CHEMBL3039520_|_False_|_True_|_['Rayvow' 'Reyvow']_|_['LY-573144' 'LY-683974' 'LY683974' 'Lasmiditan hemisuccinate'
 'Lasmiditan succinate']_|_[('DailyMed', array(['lasmiditan%20succinate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rayvow'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000179097]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for migraine disorder."
CHEMBL3301581,"nan_|_nan_|_Protein_|_True_|_ABALOPARATIDE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Eladynos' 'Tymlos']_|_['Abaloparatide' 'BA-058' 'BA058' 'BIM-44058']_|_[('DailyMed', array(['abaloparatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003931', 'EFO_0003882', 'EFO_0003854'], dtype=object), 'count': 3}_|_[ENSG00000160801]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for osteoporosis and postmenopausal osteoporosis and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL3545070,"nan_|_nan_|_Enzyme_|_False_|_VONAPANITASE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PRT-201' 'PRT201' 'Pancreatic elastase 1' 'Vonapanitase']_|_nan_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0004265'], dtype=object), 'count': 2}_|_[ENSG00000049540]_|_Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3545072,"nan_|_nan_|_Antibody_|_False_|_LANDOGROZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-myostatin antibody' 'LY-2495655' 'LY2495655' 'Landogrozumab']_|_nan_|_nan_|_{'rows': array(['HP_0003202', 'EFO_0002970', 'MONDO_0004992', 'EFO_0002618'],
      dtype=object), 'count': 4}_|_[ENSG00000138379]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3545270,"nan_|_nan_|_Small molecule_|_False_|_LY2969822_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ly2969822']_|_nan_|_nan_|_nan_|_[ENSG00000164082,ENSG00000198822]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3707328,"nan_|_nan_|_Antibody_|_False_|_GALCANEZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Emgality']_|_['Galcanezumab' 'Galcanezumab gnlm' 'LY-2951742' 'LY2951742']_|_[('DailyMed', array(['galcanezumab-gnlm'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emgality'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0004616', 'MONDO_0005277'], dtype=object), 'count': 3}_|_[ENSG00000110680,ENSG00000175868]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 2 investigational indications."
CHEMBL3900409,"Cn1c(=O)oc2ccc(-c3ccc(C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)cc3)cc21_|_AEXFXNFMSAAELR-RXVVDRJESA-N_|_Small molecule_|_False_|_BRENSOCATIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZD 7986' 'AZD-7986' 'AZD7986' 'Azd-7986' 'Azd7986' 'Brensocatib'
 'INS-1007' 'INS1007']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BRENSOCATIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15638'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'EFO_0003086', 'HP_0002110', 'MONDO_0100096',
       'MONDO_0004822', 'EFO_0001421'], dtype=object), 'count': 6}_|_[ENSG00000109861]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL3989559,"COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[n-]2)c1OC.O.[Na+]_|_CGJRLPRCWSHOFU-UHFFFAOYSA-N_|_Small molecule_|_False_|_PANTOPRAZOLE SODIUM_|_2000.0_|_4.0_|_CHEMBL1502_|_False_|_True_|_['Pantoprazole sodium' 'Pantozol control' 'Protonix' 'Protonix iv']_|_['Controloc control' 'Pantoprazole (as sodium)' 'Pantoprazole sodium'
 'Pantoprazole sodium hydrate' 'Pantoprazole sodium sesquihydrate'
 'Pantozol control' 'Somac control']_|_[('DailyMed', array(['pantoprazole%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pantozol-control'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003948', 'EFO_0007549', 'HP_0100633', 'Orphanet_79292',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 2 investigational indications."
CHEMBL4297721,"nan_|_nan_|_Unknown_|_False_|_CDX-1140_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDX-1140' 'CDX1140' 'Cdx 1140' 'Cdx-1140']_|_nan_|_nan_|_{'rows': array(['EFO_0005221', 'EFO_0000756', 'EFO_0006859', 'EFO_0003060',
       'MONDO_0001056', 'EFO_0000182', 'EFO_0005540', 'EFO_0000305',
       'EFO_0000681', 'EFO_0002618', 'EFO_1001951', 'EFO_0000616',
       'EFO_0002617', 'MONDO_0007576', 'MONDO_0008170', 'MONDO_0007254',
       'MONDO_0002158', 'EFO_0000403', 'EFO_1001469'], dtype=object), 'count': 19}_|_[ENSG00000101017]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 19 investigational indications."
CHEMBL4297754,"nan_|_nan_|_Oligonucleotide_|_False_|_FITUSIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ALN-57213' 'ALN-AT3SC' 'Aln-at3sc' 'Fitusiran']_|_nan_|_nan_|_{'rows': array(['MONDO_0018660', 'MONDO_0010602', 'MONDO_0010604'], dtype=object), 'count': 3}_|_[ENSG00000117601]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4298023,"nan_|_nan_|_Unknown_|_False_|_M-1095_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALX-0761' 'ALX0761' 'M-1095' 'M1095' 'Sonelokimab']_|_nan_|_nan_|_{'rows': array(['EFO_0003778', 'EFO_0000676', 'EFO_1000710'], dtype=object), 'count': 3}_|_[ENSG00000112116,ENSG00000112115]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4594292,"CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1.Cl.O_|_KZVOMLRKFJUTLK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEPOTINIB HYDROCHLORIDE_|_2021.0_|_4.0_|_CHEMBL3402762_|_False_|_True_|_['Tepmetko']_|_['MSC2156119J' 'Msc2156119j' 'Tepotinib hydrochloride'
 'Tepotinib hydrochloride hydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPOTINIB%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and has 1 investigational indication."
CHEMBL488436,"Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C_|_WJRRGYBTGDJBFX-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-5438_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZD-5438' 'Azd 5438' 'Azd-5438']_|_nan_|_['CHEMBL454649']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL730,"O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-]_|_SNIOPGDIGTZGOP-UHFFFAOYSA-N_|_Small molecule_|_True_|_NITROGLYCERIN_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Coro-nitro' 'Deponit 10' 'Deponit 5' 'Glytrin' 'Gonitro' 'Lenitral 7.5'
 'Minitran' 'Minitran 10' 'Minitran 15' 'Minitran 5' 'Natirose'
 'Nitriderm tts' 'Nitro iv' 'Nitro-bid' 'Nitro-dur' 'Nitro-mack ret'
 'Nitrocine' 'Nitrocontin continus' 'Nitroglycerin' 'Nitrol'
 'Nitrolingual' 'Nitrolingual pumpspray' 'Nitromin' 'Nitromist' 'Nitronal'
 'Nitrostat' 'Percutol' 'Rectiv' 'Rectogesic' 'Suscard buccal' 'Sustac'
 'Transderm-nitro' 'Transiderm-nitro 10' 'Transiderm-nitro 5' 'Tridil'
 'Trintek 10' 'Trintek 15' 'Trintek 5']_|_['C01DA02' 'Chlormethine oxide hydrochloride' 'Diluted nitroglycerin'
 'Glonoinum' 'Glyceryl Trinitrate' 'Glyceryl trinitrate'
 'Glyceryl trinitrate solution' 'Imx-150' 'Mechlorethamine oxide hcl'
 'Mitomen' 'Mustron' 'Nitora' 'Nitroglycerin' 'Nitroglycerin tablets'
 'Nitromin hydrochloride' 'Transderm-Nitro' 'Trinitrin'
 'Trinitrin tablets' 'Trinitrine']_|_[('DailyMed', array(['nitroglycerin'], dtype=object)), ('Wikipedia', array(['Nitroglycerin'], dtype=object)), ('drugbank', array(['DB00727'], dtype=object)), ('chEBI', array(['28787'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001993', 'EFO_1000783', 'EFO_1000657', 'EFO_0004234',
       'EFO_0000537', 'EFO_1001375', 'MONDO_0005149', 'EFO_0003913',
       'EFO_0009660', 'EFO_0000319', 'EFO_0000685', 'EFO_0000373',
       'HP_0031273', 'MP_0001845', 'EFO_1001951', 'EFO_0000612',
       'HP_0031217', 'EFO_0003882', 'EFO_1001395', 'EFO_0009552',
       'MONDO_0004857', 'EFO_1001145', 'EFO_0002687', 'EFO_0004265',
       'MONDO_0008903', 'HP_0000938', 'EFO_0000546', 'EFO_0001645',
       'EFO_0000544', 'EFO_0003144', 'EFO_0009846', 'EFO_0003843',
       'EFO_0000712', 'EFO_0005251', 'EFO_0003060'], dtype=object), 'count': 35}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 26 investigational indications. This drug has a black box warning from the FDA."
CHEMBL772,"COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC_|_QEVHRUUCFGRFIF-MDEJGZGSSA-N_|_Small molecule_|_False_|_RESERPINE_|_1960.0_|_4.0_|_nan_|_True_|_True_|_['Hiserpia' 'Rau-sed' 'Reserpine' 'Sandril' 'Serpalan' 'Serpanray'
 'Serpasil' 'Serpate' 'Serpivite']_|_['Apoplon' 'ENT-50146' 'NSC-237659' 'NSC-59272' 'Reserpine' 'Reserpinum']_|_[('PubChem', array(['107574', '144204658', '144209593', '144210855', '170465405',
       '17389743', '26752948', '50105550', '50105551', '50105552',
       '50105553', '56463068', '90341213'], dtype=object)), ('Wikipedia', array(['Reserpine'], dtype=object)), ('drugbank', array(['DB00206'], dtype=object)), ('chEBI', array(['28487'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002610', 'EFO_0003914', 'EFO_0001361', 'MONDO_0005148',
       'EFO_0000537', 'EFO_0003777', 'EFO_0003763', 'EFO_0001645',
       'EFO_0004701', 'HP_0003124'], dtype=object), 'count': 10}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for hypertension and has 9 investigational indications. It was withdrawn in at least one region."
CHEMBL995,"CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[n-]2)cc1.[K+]_|_OXCMYAYHXIHQOA-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOSARTAN POTASSIUM_|_1995.0_|_4.0_|_CHEMBL191_|_False_|_True_|_['Cozaar' 'Losaprex' 'Losartan potassium']_|_['Aradois' 'Cozaar' 'DU PONT-753' 'DUP 753' 'DUP-753' 'DUP753' 'E-3340'
 'Hyzaar' 'L-158086' 'Losacar' 'Losartan monopotassium salt'
 'Losartan potassium' 'Losata' 'MK-0954' 'MK0954' 'Nu-lotan'
 'Presartan-50' 'Tancin' 'Zaart']_|_[('DailyMed', array(['losartan%20potassium'], dtype=object)), ('PubChem', array(['49665951', '49681581'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'HP_0000093', 'EFO_0004232', 'MONDO_0005184',
       'EFO_0002618', 'EFO_0000537', 'MONDO_0001134', 'EFO_0000668',
       'EFO_0003095', 'EFO_0003896', 'MONDO_0007947', 'EFO_0000712',
       'EFO_0003884'], dtype=object), 'count': 13}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1068,"NC(=O)N1c2ccccc2CC(=O)c2ccccc21_|_CTRLABGOLIVAIY-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXCARBAZEPINE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Oxcarbazepine' 'Oxtellar xr' 'Trileptal']_|_['GP-47680' 'KIN-493' 'NSC-758693' 'Oxcarbamazepine' 'Oxcarbazepine'
 'SPN-804']_|_[('DailyMed', array(['oxcarbazepine'], dtype=object)), ('PubChem', array(['144204534', '170464811', '174006287', '26719673', '26747194',
       '50085868', '866068'], dtype=object)), ('Wikipedia', array(['Oxcarbazepine'], dtype=object)), ('drugbank', array(['DB00776'], dtype=object)), ('chEBI', array(['7824'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090', 'HP_0000713', 'EFO_0005230', 'HP_0000726',
       'MONDO_0004992', 'EFO_0005762', 'MONDO_0002050', 'EFO_0000474',
       'MONDO_0005301', 'EFO_0003015', 'HP_0001250', 'EFO_0004263'],
      dtype=object), 'count': 12}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for epilepsy and seizure and has 10 investigational indications."
CHEMBL1200562,"CCCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_FZCHYNWYXKICIO-FZNHGJLXSA-N_|_Small molecule_|_False_|_HYDROCORTISONE VALERATE_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Hydrocortisone valerate' 'Westcort']_|_['Cortisol 17-valerate' 'Hydrocortisone 17-valerate'
 'Hydrocortisone valerate' 'NSC-759133']_|_[('DailyMed', array(['hydrocortisone%20valerate'], dtype=object)), ('PubChem', array(['144204404', '170464775', '56422095', '855996'], dtype=object)), ('drugbank', array(['DB14544'], dtype=object)), ('chEBI', array(['50865'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978."
CHEMBL1201153,"CCC(NC(C)C)C(O)c1ccc(O)c(O)c1.CS(=O)(=O)O_|_SOYAGMVKMXZVNZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOETHARINE MESYLATE_|_1984.0_|_4.0_|_CHEMBL1201213_|_False_|_True_|_['Bronchilator' 'Bronkometer' 'Isoetharine mesylate']_|_['Isoetarine mesilate' 'Isoetharine mesilate' 'Isoetharine mesylate'
 'NSC-759286']_|_[('PubChem', array(['144204319', '50106482', '56422893', '85231307', '856022'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984."
CHEMBL1265,"COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2_|_LZCDAPDGXCYOEH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADAPALENE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Adapalene' 'Differin']_|_['Adapalene' 'CD 271' 'CD-271' 'Differin']_|_[('DailyMed', array(['adapalene'], dtype=object)), ('PubChem', array(['144205789', '170464674', '174006867', '26758039'], dtype=object)), ('Wikipedia', array(['Adapalene'], dtype=object)), ('drugbank', array(['DB00210'], dtype=object)), ('chEBI', array(['31174'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007375', 'EFO_0000701', 'EFO_0003894'], dtype=object), 'count': 3}_|_[ENSG00000172819,ENSG00000077092,ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for acne and has 2 investigational indications."
CHEMBL1294,"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12_|_LOUPRKONTZGTKE-LHHVKLHASA-N_|_Small molecule_|_True_|_QUINIDINE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(8r,9s)-quinidine' '.beta.-quinidine' 'Conquinine' 'Kinidin' 'Pitayine'
 'Quinidine']_|_[('PubChem', array(['17389531', '56320931', '56320932'], dtype=object)), ('drugbank', array(['DB00908'], dtype=object)), ('chEBI', array(['28593'], dtype=object))]_|_['CHEMBL2068675' 'CHEMBL3707183' 'CHEMBL1435413' 'CHEMBL1200437'
 'CHEMBL2165709']_|_{'rows': array(['EFO_0001068', 'EFO_0004278', 'HP_0004308', 'EFO_0004287',
       'HP_0002019', 'EFO_0000275', 'MONDO_0100096', 'EFO_0004269',
       'MONDO_0004976', 'EFO_1001413', 'MONDO_0002050', 'EFO_0000612',
       'MONDO_0004976', 'MONDO_0005277', 'MONDO_0002009', 'MONDO_0005301',
       'EFO_1001249', 'EFO_0003758', 'EFO_0004197'], dtype=object), 'count': 19}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1546,"CC(N)Cc1ccc(O)cc1_|_GIKNHHRFLCDOEU-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYAMPHETAMINE_|_1969.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dl-4-hydroxyamphetamine' 'Dl-p-hydroxyamphetamine' 'Hydroxyamfetamine'
 'Hydroxyamphetamine' 'NSC-170995' 'Norveritol' 'P-hydroxyamphetamine'
 'Phenol, p-(2-aminopropyl)-' 'Pulsoton' 'Racemic p-hydroxyamphetamine']_|_[('Wikipedia', array(['Hydroxyamfetamine'], dtype=object)), ('drugbank', array(['DB09352'], dtype=object))]_|_['CHEMBL1200705']_|_nan_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969."
CHEMBL1563,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl_|_GUGHGUXZJWAIAS-QQYBVWGSSA-N_|_Small molecule_|_True_|_DAUNORUBICIN HYDROCHLORIDE_|_1979.0_|_4.0_|_CHEMBL178_|_False_|_True_|_['Cerubidine' 'Daunorubicin hydrochloride']_|_['Daunorubicin (as hydrochloride)' 'Daunorubicin hcl'
 'Daunorubicin hydrochloride' 'FI 6339 HYDROCHLORIDE'
 'FI 6339 [AS THE BASE]' 'FI-6339' 'FI-6339 HYDROCHLORIDE' 'NDC 0082-4155'
 'NDC-0082-4155' 'NSC-82151' 'RP 13057 HYDROCHLORIDE'
 'RP 13057 [AS THE BASE)' 'RP-13057' 'RP-13057 HYDROCHLORIDE']_|_[('DailyMed', array(['daunorubicin%20hydrochloride'], dtype=object)), ('PubChem', array(['144208357', '17389073', '85273781', '855543'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000220', 'EFO_0000565', 'EFO_0000223',
       'EFO_0003028', 'EFO_0000209', 'EFO_0003811', 'EFO_0004251',
       'EFO_0000218', 'EFO_0000198', 'EFO_0004289', 'MONDO_0000870',
       'EFO_0000224', 'EFO_0003025', 'EFO_0000222', 'EFO_0000221',
       'EFO_0003029', 'EFO_0000691', 'EFO_0003027', 'EFO_0003802',
       'EFO_1001052', 'EFO_1001779', 'EFO_0000094', 'MONDO_0044917'],
      dtype=object), 'count': 24}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for lymphoid leukemia and has 23 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1614702,COc1cc2c(cc1C(=O)N1CCC(Cc3ccc(F)cc3)CC1)c(C(=O)C(=O)N(C)C)cn2C_|_JBNWDYGOTHQHOZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SCIO-323_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SCIO-323' 'Scio-323']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1676,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF_|_XTULMSXFIHGYFS-VLSRWLAYSA-N_|_Small molecule_|_False_|_FLUTICASONE FUROATE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Arnuity ellipta' 'Avamys' 'Flonase sensimist allergy relief'
 'Relvar ellipta' 'Trelegy ellipta' 'Veramyst']_|_['Allermist' 'Ennhale' 'Fluticasone furoate' 'Furamist' 'GSK 685 698'
 'GSK-685968' 'GSK685968' 'GW-685698X' 'GW685698X']_|_[('DailyMed', array(['fluticasone%20furoate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/avamys'],
      dtype=object)), ('Wikipedia', array(['Fluticasone_furoate'], dtype=object)), ('drugbank', array(['DB08906'], dtype=object)), ('chEBI', array(['74899'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0008521', 'MONDO_0004979', 'EFO_0007533',
       'HP_0001742', 'HP_0006536', 'EFO_1001417', 'EFO_0005854',
       'EFO_0003956'], dtype=object), 'count': 9}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 7 approved and 2 investigational indications."
CHEMBL1724,"C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1.[Br-]_|_JRRNZNSGDSFFIR-UHFFFAOYSA-M_|_Small molecule_|_False_|_MEPENZOLATE BROMIDE_|_1956.0_|_4.0_|_CHEMBL524004_|_False_|_True_|_['Cantil']_|_['AN-6437' 'FT-0671006' 'Glycophenylate' 'HY-17585' 'Mepenzolate'
 'Mepenzolate Bromide' 'Mepenzolate bromide' 'Mepenzolate methylbromide'
 'Mepenzolone bromide' 'NSC-4358']_|_[('PubChem', array(['144203918', '170465214', '26748120', '49648464'], dtype=object))]_|_nan_|_nan_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL1742999,"nan_|_nan_|_Antibody_|_False_|_CARLUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CNTO 888' 'CNTO-888' 'Carlumab']_|_nan_|_nan_|_{'rows': array(['EFO_0009448', 'MONDO_0008315', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000108691]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1908360,"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C_|_HKVAMNSJSFKALM-GKUWKFKPSA-N_|_Small molecule_|_True_|_EVEROLIMUS_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Afinitor' 'Afinitor disperz' 'Certican' 'Votubia' 'Zortress']_|_['40-o-(2-hydroxyethyl)-rapamycin' 'Everolimus' 'RAD 666' 'RAD-001'
 'RAD-666' 'RAD001' 'SDZ-RAD' 'Sdz rad']_|_[('DailyMed', array(['everolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/votubia'],
      dtype=object)), ('PubChem', array(['144206063'], dtype=object)), ('drugbank', array(['DB01590'], dtype=object)), ('chEBI', array(['68478'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001871', 'EFO_0004224', 'EFO_0002618', 'EFO_0000339',
       'EFO_0000519', 'EFO_0000349', 'MONDO_0001422', 'EFO_0000691',
       'MONDO_0017623', 'EFO_0000770', 'EFO_0002499', 'EFO_0000326',
       'EFO_1000312', 'MONDO_0015277', 'MONDO_0007576', 'EFO_0000365',
       'EFO_0002916', 'EFO_0005220', 'EFO_0003060', 'MONDO_0018975',
       'EFO_1000630', 'MONDO_0100342', 'EFO_0003897', 'MONDO_0002898',
       'EFO_1000634', 'EFO_0003833', 'MONDO_0011962', 'MONDO_0002120',
       'MONDO_0018076', 'MONDO_0007039', 'EFO_0000231', 'EFO_0002913',
       'EFO_0000574', 'EFO_0003047', 'EFO_0000272', 'MONDO_0000873',
       'EFO_0000474', 'MONDO_0002367', 'EFO_0009708', 'EFO_0005672',
       'MONDO_0001056', 'EFO_0000632', 'EFO_0000222', 'EFO_0001365',
       'EFO_0008620', 'MONDO_0008280', 'EFO_0004243', 'MONDO_0008170',
       'MONDO_0024503', 'EFO_1002048', 'EFO_0001071', 'MONDO_0021054',
       'EFO_1001496', 'EFO_1000852', 'MONDO_0009348', 'MONDO_0002087',
       'MONDO_0003268', 'EFO_0000702', 'EFO_0004599', 'MONDO_0013730',
       'EFO_0002617', 'EFO_0000403', 'EFO_1000601', 'MONDO_0008903',
       'EFO_1001469', 'EFO_0000183', 'EFO_0003884', 'EFO_0000565',
       'EFO_0005537', 'EFO_0007331', 'EFO_0000630', 'MONDO_0007254',
       'MONDO_0003478', 'EFO_0005952', 'EFO_0000637', 'MONDO_0002974',
       'EFO_0009441', 'EFO_0000182', 'HP_0009720', 'MONDO_0020732',
       'EFO_0000544', 'EFO_1001231', 'EFO_1001901', 'EFO_0003860',
       'EFO_0006861', 'MONDO_0018364', 'EFO_0000228', 'EFO_0000558',
       'MONDO_0001187', 'EFO_1001968', 'MONDO_0021063', 'EFO_0004289',
       'EFO_0005221', 'MONDO_0004992', 'EFO_0004252', 'EFO_0001378',
       'MONDO_0011719', 'EFO_1000045', 'MONDO_0016586', 'EFO_0000313',
       'MONDO_0011705', 'EFO_0006859', 'MONDO_0002715', 'EFO_0001376',
       'EFO_0003086', 'EFO_0000333', 'MONDO_0002108', 'MONDO_0002158',
       'EFO_0005543', 'EFO_0001062', 'EFO_0002626', 'EFO_0000181',
       'MONDO_0002603', 'MONDO_0001734', 'MONDO_0002691', 'MONDO_0008315',
       'EFO_0000514', 'EFO_0000305', 'EFO_1000158', 'MONDO_0020290',
       'EFO_0000760', 'EFO_1000026', 'EFO_0000540', 'MONDO_0016642',
       'EFO_1001951', 'MONDO_0016693', 'EFO_0000616', 'EFO_0003869',
       'EFO_0000681', 'EFO_0000220', 'EFO_0000198', 'MONDO_0005411',
       'EFO_0000389', 'EFO_0000588'], dtype=object), 'count': 134}_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 19 approved and 115 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103879,"CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O_|_RVAQIUULWULRNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_GANETESPIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ganetespib' 'STA 9090' 'STA-9090']_|_[('drugbank', array(['DB12047'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0001056', 'EFO_0000702', 'MONDO_0008903',
       'EFO_0000673', 'EFO_0006861', 'MONDO_0021063', 'MONDO_0011719',
       'EFO_0002916', 'EFO_0003060', 'EFO_0001378', 'MONDO_0007254',
       'EFO_1000657', 'MONDO_0002158', 'EFO_0000182', 'EFO_0000198',
       'MONDO_0008170', 'EFO_0000756', 'EFO_0000222', 'EFO_0000571',
       'EFO_0000760', 'EFO_0003968', 'EFO_0000770', 'EFO_0005537'],
      dtype=object), 'count': 24}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications."
CHEMBL2108568,"nan_|_nan_|_Protein_|_False_|_TREBANANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 386' 'AMG-386' 'Trebananib']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000673', 'EFO_1001465', 'EFO_0000632',
       'MONDO_0002158', 'EFO_0008528', 'EFO_0000616', 'EFO_0003060',
       'EFO_0000182', 'MONDO_0007254', 'MONDO_0002087', 'EFO_1000158',
       'EFO_0000681', 'EFO_0003968'], dtype=object), 'count': 14}_|_[ENSG00000091879,ENSG00000154188]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."
CHEMBL2109354,"nan_|_nan_|_Antibody_|_False_|_MONO-DGA-RFB4_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MONO-DGA-RFB4' 'Mono-dga-rfb4']_|_nan_|_nan_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109481,nan_|_nan_|_Antibody_|_False_|_ICM3_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ICM3']_|_nan_|_nan_|_nan_|_[ENSG00000076662]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL24828,"COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1_|_UHTHHESEBZOYNR-UHFFFAOYSA-N_|_Small molecule_|_True_|_VANDETANIB_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Caprelsa' 'Zactima']_|_['GNF-PF-2188' 'NSC-744325' 'NSC-760766' 'Vandetanib' 'ZD-64' 'ZD-6474'
 'ZD6474']_|_[('DailyMed', array(['vandetanib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa'],
      dtype=object)), ('PubChem', array(['103905338', '124893338', '144206064', '170465617', '50100123',
       '50112766'], dtype=object)), ('Wikipedia', array(['Vandetanib'], dtype=object)), ('drugbank', array(['DB05294'], dtype=object)), ('chEBI', array(['49960'], dtype=object))]_|_['CHEMBL533849']_|_{'rows': array(['EFO_0000588', 'MONDO_0008627', 'EFO_1001951', 'MONDO_0100342',
       'EFO_0009708', 'EFO_0000349', 'EFO_0000641', 'MONDO_0008315',
       'MONDO_0007254', 'EFO_0001663', 'EFO_0000182', 'EFO_0007535',
       'MONDO_0002367', 'EFO_0000702', 'MONDO_0008903', 'EFO_1000026',
       'EFO_0003060', 'EFO_0003869', 'EFO_0002501', 'EFO_1000657',
       'EFO_0002916', 'MONDO_0011719', 'EFO_0000519', 'EFO_0003897',
       'MONDO_0001187', 'MONDO_0008170', 'EFO_0001378', 'MONDO_0002108',
       'EFO_0006859', 'EFO_1000158', 'EFO_0002499', 'MONDO_0004992',
       'MONDO_0015277', 'EFO_0000501', 'MONDO_0002087', 'EFO_0000222',
       'EFO_0000630', 'MONDO_0004192', 'MONDO_0001056', 'EFO_0002618',
       'MONDO_0002158', 'EFO_0000616', 'EFO_0000181', 'EFO_1001465',
       'EFO_0000621', 'EFO_0002892', 'EFO_0003841', 'EFO_0000365'],
      dtype=object), 'count': 48}_|_[ENSG00000197122,ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361,ENSG00000142627,ENSG00000133216,ENSG00000145242,ENSG00000116106,ENSG00000070886,ENSG00000080224,ENSG00000135333,ENSG00000182580,ENSG00000044524,ENSG00000154928,ENSG00000196411,ENSG00000146904,ENSG00000106123,ENSG00000183317,ENSG00000120156,ENSG00000165731,ENSG00000101213,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 7 approved and 41 investigational indications. This drug has a black box warning from the FDA."
CHEMBL267044,"CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC_|_BGRJTUBHPOOWDU-NSHDSACASA-N_|_Small molecule_|_False_|_LEVOSULPIRIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-sulpiride' 'L-sulpiride' 'Lesuride' 'Levobren' 'Levopraid'
 'Levopride' 'Levosulpiride' 'S-(-)-sulpiride' 'Sulpiride l-form'
 'Sulpiride, (-)-' 'Sulpiride, (s)-']_|_[('PubChem', array(['11112626', '11113767', '170465834', '26719874', '50104627'],
      dtype=object)), ('Wikipedia', array(['Levosulpiride'], dtype=object)), ('chEBI', array(['64119'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005407', 'EFO_0008533', 'HP_0000713'], dtype=object), 'count': 3}_|_[ENSG00000164270,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3707378,nan_|_nan_|_Small molecule_|_False_|_CB-189625_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['CB-625' 'Cb-189625']_|_nan_|_nan_|_nan_|_[ENSG00000104321]_|_Small molecule drug.
CHEMBL3989917,"Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)([O-])O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_HZIYEEMJNBKMJH-UHFFFAOYSA-N_|_Small molecule_|_False_|_FOSNETUPITANT_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['07-PNET' 'Fosnetupitant']_|_[('drugbank', array(['DB14019'], dtype=object))]_|_['CHEMBL3989919']_|_{'rows': array(['EFO_0006911', 'HP_0002013'], dtype=object), 'count': 2}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chemotherapy-induced nausea and vomiting and vomiting."
CHEMBL4297477,"Cn1cc(Nc2nccc(N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1_|_BUWBRTXGQRBBHG-MJBXVCDLSA-N_|_Small molecule_|_False_|_BREPOCITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Brepocitinib' 'PF-06700841' 'Pf-06700841']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BREPOCITINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15003'], dtype=object))]_|_['CHEMBL4298160']_|_{'rows': array(['EFO_0000384', 'EFO_0000540', 'EFO_1000710', 'EFO_0003778',
       'EFO_0000540', 'EFO_0000274', 'EFO_0000398', 'EFO_0000676',
       'EFO_0000729', 'MONDO_0007915', 'EFO_0004192', 'EFO_0003086',
       'EFO_1002028'], dtype=object), 'count': 13}_|_[ENSG00000105397,ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL4303389,"C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1_|_UQTPDWDAYHAZNT-AWEZNQCLSA-N_|_Small molecule_|_False_|_NS-018_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ilginatinib' 'NS-018' 'Ns-018']_|_nan_|_nan_|_{'rows': array(['EFO_0002430', 'MONDO_0044903'], dtype=object), 'count': 2}_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL440498,"O=C(NO)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1_|_ROSNVSQTEGHUKU-UHFFFAOYSA-N_|_Small molecule_|_False_|_CTS-1027_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cts-1027' 'RO-1130830' 'RS-130830']_|_[('drugbank', array(['DB08490'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004220', 'EFO_0003047'], dtype=object), 'count': 2}_|_[ENSG00000149968,ENSG00000157227,ENSG00000087245,ENSG00000100985,ENSG00000137745,ENSG00000262406,ENSG00000118113]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594248,"CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O)C(C)C_|_LDVRMNJZLWXJPL-JKQNMTHDSA-N_|_Protein_|_False_|_CALCITONIN HUMAN_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Cibacalcin']_|_['Calcitonin (human synthetic)']_|_nan_|_nan_|_{'rows': array(['EFO_0005754'], dtype=object), 'count': 1}_|_[ENSG00000004948]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for parathyroid disease."
CHEMBL4594611,"nan_|_nan_|_Antibody drug conjugate_|_False_|_PATRITUMAB DERUXTECAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Patritumab deruxtecan' 'U3 1402' 'U3-1402' 'U3-1402A' 'U31402']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PATRITUMAB%20DERUXTECAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000065361,ENSG00000198900]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4650387,"nan_|_nan_|_Protein_|_False_|_CDX-301_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amg-949' 'CDX-301' 'Cdx 301' 'Cdx-301']_|_nan_|_nan_|_{'rows': array(['EFO_0005221', 'MONDO_0008315', 'EFO_0006859', 'EFO_0002617',
       'MONDO_0007254', 'MONDO_0001056', 'EFO_0000182', 'EFO_0003060',
       'EFO_0000681', 'EFO_0000574', 'EFO_0002618', 'MONDO_0007576',
       'EFO_1001951', 'MONDO_0008170', 'EFO_0000756', 'MONDO_0002158',
       'EFO_1001469', 'EFO_0000403'], dtype=object), 'count': 18}_|_[ENSG00000122025]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications."
CHEMBL896,"OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1_|_ZQDWXGKKHFNSQK-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYZINE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Atarax' 'Ataraxoid' 'Hydroxyzine' 'Marex' 'NSC-169188' 'Orgatrax'
 'Tran-q' 'Tranquizine' 'U.c.b-4492']_|_[('PubChem', array(['144207118', '170464958'], dtype=object)), ('TG-GATEs', array(['71'], dtype=object)), ('Wikipedia', array(['Hydroxyzine'], dtype=object)), ('drugbank', array(['DB00557'], dtype=object)), ('chEBI', array(['5818'], dtype=object))]_|_['CHEMBL1201007' 'CHEMBL3186993' 'CHEMBL1200467']_|_{'rows': array(['EFO_0004257', 'HP_0000989', 'HP_0000726', 'EFO_0006788',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_0005531', 'EFO_0005230',
       'EFO_0000701'], dtype=object), 'count': 9}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 6 approved and 3 investigational indications."
CHEMBL998,"CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1_|_JCCNYMKQOSZNPW-UHFFFAOYSA-N_|_Small molecule_|_False_|_LORATADINE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Alavert' ""Children's claritin"" 'Claritin' 'Claritin hives relief'
 'Claritin hives relief reditab' 'Claritin reditabs' 'Clarityn'
 'Clarityn rapide' 'Clarityne' 'Hay-rite' 'Loratadine'
 'Loratadine redidose' 'Roletra']_|_['BAY76-2211' 'Claritin-D' 'Loratadine' 'NSC-758628' 'SCH 29851'
 'SCH-29851']_|_[('DailyMed', array(['loratadine'], dtype=object)), ('PubChem', array(['104171183', '11111394', '11113345', '124880597', '124880599',
       '144203736', '144211849', '170464867', '26719690', '26747010',
       '26751528', '50104102', '535878', '56424146', '85231118', '855843',
       '90340694'], dtype=object)), ('Wikipedia', array(['Loratadine'], dtype=object)), ('drugbank', array(['DB00455'], dtype=object))]_|_['CHEMBL4092143']_|_{'rows': array(['EFO_0004232', 'HP_0003418', 'EFO_0001378', 'EFO_0005531',
       'MONDO_0004979', 'EFO_0000685', 'MONDO_0005271', 'EFO_0003956',
       'MONDO_0011705', 'MONDO_0005301', 'MONDO_0007254', 'HP_0000989',
       'EFO_1001417', 'MONDO_0100096', 'EFO_0005854', 'EFO_0000574',
       'EFO_0000274'], dtype=object), 'count': 17}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 11 investigational indications."
CHEMBL1200644,"CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]_|_XEKSTYNIJLDDAZ-JASSWCPGSA-D_|_Oligosaccharide_|_True_|_FONDAPARINUX SODIUM_|_2001.0_|_4.0_|_CHEMBL1201202_|_False_|_True_|_['Arixtra' 'Fondaparinux sodium']_|_['Fondaparin sodium' 'Fondaparinux sodium' 'Fondaparinux sodium for assay'
 'Fondaparinux sodium identification' 'IC-851589' 'ORG 31540' 'ORG-31540'
 'Quixidar' 'SR 90107A' 'SR-90107A']_|_[('DailyMed', array(['fondaparinux%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0001907', 'HP_0000083', 'EFO_0000612', 'EFO_0003907',
       'EFO_0004286', 'EFO_1000985', 'EFO_0003827', 'HP_0004936'],
      dtype=object), 'count': 8}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201244,"C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1_|_YXRDKMPIGHSVRX-OOJCLDBCSA-N_|_Small molecule_|_False_|_ROCURONIUM_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Rocuronium' 'Rocuronium cation' 'Rocuronium ion']_|_[('PubChem', array(['50112687'], dtype=object)), ('Wikipedia', array(['Rocuronium_bromide'], dtype=object)), ('drugbank', array(['DB00728'], dtype=object)), ('chEBI', array(['8884'], dtype=object))]_|_['CHEMBL1200648']_|_{'rows': array(['EFO_0007490', 'EFO_0009492', 'EFO_0003843', 'EFO_0010581',
       'EFO_0003931', 'EFO_0009492', 'HP_0003326', 'EFO_0003086',
       'HP_0003418', 'MONDO_0008315', 'EFO_0002618', 'MONDO_0021117'],
      dtype=object), 'count': 12}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 11 investigational indications."
CHEMBL1714,"CNC1(c2ccccc2Cl)CCCCC1=O.Cl_|_VCMGMSHEPQENPE-UHFFFAOYSA-N_|_Small molecule_|_False_|_KETAMINE HYDROCHLORIDE_|_1970.0_|_4.0_|_CHEMBL742_|_False_|_True_|_['Anaket-V' 'Ketalar' 'Ketamine hydrochloride' 'Ketanest' 'Ketavet'
 'Vetalar']_|_['CI-581' 'CL 369' 'CL-369' 'CN-52,372-2' 'CN-52372-2' 'CN-523722'
 'Ketamine (as hydrochloride)' 'Ketamine hcl' 'Ketamine hydrochloride'
 'Ketamine hydrochloride ciii' 'Ketamini hydrochloridum' 'Special k'
 'Vetalar']_|_[('DailyMed', array(['ketamine%20hydrochloride'], dtype=object)), ('chEBI', array(['650657'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000546', 'EFO_0003931', 'EFO_0000713', 'MONDO_0007079',
       'EFO_0007430', 'MONDO_0002009', 'EFO_0009854', 'EFO_0005611',
       'EFO_0002610', 'HP_0000360', 'MONDO_0004992', 'EFO_1000391',
       'EFO_0004321', 'HP_0000989', 'EFO_0000474', 'HP_0000713',
       'MONDO_0002050', 'HP_0100543', 'MONDO_0005351', 'EFO_0004320',
       'EFO_0009963', 'EFO_0003015', 'MONDO_0004985', 'EFO_1001884'],
      dtype=object), 'count': 24}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 24 investigational indications."
CHEMBL1743000,"nan_|_nan_|_Antibody drug conjugate_|_False_|_CITATUZUMAB BOGATOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Citatuzumab bogatox' 'VB6-845']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000119888]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL203567,"Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1_|_IJDQETGUEUJVTB-HNNXBMFYSA-N_|_Small molecule_|_False_|_RO-3201195_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ro-3201195' 'SYD003' 'Syd-003']_|_[('drugbank', array(['DB08424'], dtype=object)), ('chEBI', array(['45116'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL2103802,"CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1.C[C@H](O)CO.O_|_GOADIQFWSVMMRJ-UPGAGZFNSA-N_|_Small molecule_|_False_|_DAPAGLIFLOZIN PROPANEDIOL_|_2012.0_|_4.0_|_CHEMBL429910_|_False_|_True_|_['Farxiga' 'Forxiga']_|_['BMS-512148-05']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga'],
      dtype=object)), ('chEBI', array(['85079'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for heart failure and type 2 diabetes mellitus and has 1 investigational indication."
CHEMBL2103815,"CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C_|_NYGCNONRVCGHAT-UFIKZEAMSA-N_|_Protein_|_False_|_LARAZOTIDE ACETATE_|_nan_|_3.0_|_CHEMBL2105646_|_False_|_False_|_[]_|_['AT-1001' 'AT-1001 (LARAZOTIDE ACETATE)' 'Larazotide acetate']_|_nan_|_nan_|_{'rows': array(['EFO_0001060'], dtype=object), 'count': 1}_|_[ENSG00000117971,ENSG00000080644]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109249,"nan_|_nan_|_Antibody_|_False_|_AMG-557_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-557' 'Amg-557' 'MEDI-5872' 'Medi 5872' 'Prezalumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0000699', 'EFO_0003834', 'EFO_0000676'],
      dtype=object), 'count': 4}_|_[ENSG00000160223]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2109621,"nan_|_nan_|_Antibody_|_False_|_ABITUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALD403' 'Abituzumab' 'DI 17E6' 'DI-17E6' 'DI17E6' 'EMD 525797'
 'EMD-525797']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0004244', 'EFO_0000717', 'MONDO_0008315',
       'EFO_1001951'], dtype=object), 'count': 5}_|_[ENSG00000150093,ENSG00000138448,ENSG00000115221,ENSG00000259207,ENSG00000105855,ENSG00000082781]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2110579,"CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)C(C)(C)N)C1_|_VQPFSIRUEPQQPP-MXBOTTGLSA-N_|_Small molecule_|_False_|_ANAMORELIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anamorelin' 'RC-1291' 'ST-1291']_|_[('drugbank', array(['DB06645'], dtype=object))]_|_['CHEMBL2103794']_|_{'rows': array(['HP_0004326', 'HP_0012378', 'EFO_0002618', 'HP_0004326',
       'EFO_0003060'], dtype=object), 'count': 5}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL232201,"CCc1oc2ccccc2c1C(=O)c1cc(I)c(O)c(I)c1_|_CZCHIEJNWPNBDE-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZIODARONE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Amplivix' 'Benziodarone' 'L 2329' 'L-2329' 'NSC-82133']_|_[('PubChem', array(['144205346', '170465852', '29216089'], dtype=object)), ('TG-GATEs', array(['130'], dtype=object)), ('Wikipedia', array(['Benziodarone'], dtype=object)), ('drugbank', array(['DB13277'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000198668]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region."
CHEMBL2326966,"N=C(N)NCCC[C@H](NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)[O-]_|_SVNJBEMPMKWDCO-KCHLEUMXSA-N_|_Small molecule_|_False_|_SF-1126_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SF 1126' 'SF-1126' 'SF-1126 INNER SALT' 'Sf-1126']_|_nan_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0000182', 'MONDO_0004992', 'EFO_0000621'],
      dtype=object), 'count': 4}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3545117,nan_|_nan_|_Small molecule_|_False_|_AVE-9940_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ave-9940']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545237,"C#C[C@]1(O)CCC2C3CCC4CC(O)CC[C@]4(C)C3CC[C@@]21C_|_CKAXZOYFIHQCBN-UQOAMHMYSA-N_|_Small molecule_|_False_|_HE3235_|_nan_|_1.0_|_nan_|_False_|_False_|_['Apotone']_|_['Apoptone' 'HE-3235' 'He 3235' 'He3235']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3707247,"CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N_|_XRVDGNKRPOAQTN-FQEVSTJZSA-N_|_Small molecule_|_False_|_OZANIMOD_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ozanimod' 'RPC-1063' 'RPC1063']_|_[('drugbank', array(['DB12612'], dtype=object))]_|_['CHEMBL3707246']_|_{'rows': array(['EFO_0000729', 'MONDO_0100096', 'EFO_0001421', 'EFO_0000384',
       'MONDO_0005301', 'MONDO_0005301', 'EFO_0000729', 'EFO_0000540',
       'EFO_0003929'], dtype=object), 'count': 9}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 5 investigational indications."
CHEMBL4297873,"nan_|_nan_|_Protein_|_False_|_ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Advate']_|_['Advate' 'Antihemophilic factor, human recombinant' 'BAY 14-2222'
 'BAY 81-8973' 'BAY W 6240' 'BAY-14-2222' 'BAY-81-8973' 'BAY-W-6240'
 'BAY81-8973' 'Bay81-8973' 'Factor viii (rdna)' 'Factor viii octocog alfa'
 'Factor viii, recombinant' 'Octocog alfa']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/advate'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602', 'Orphanet_903'], dtype=object), 'count': 2}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for hemophilia a and has 1 investigational indication."
CHEMBL435191,"O=C1c2c(c3c4ccc(O)cc4n([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c3[nH]c4cc(O)ccc4c23)C(=O)N1NC(CO)CO_|_QMVPQBFHUJZJCS-NTKFZFFISA-N_|_Small molecule_|_False_|_EDOTECARIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Edotecarin' 'J-107088' 'PF-804950']_|_[('drugbank', array(['DB04882'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000519', 'EFO_0003897'], dtype=object), 'count': 3}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4435170,"[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC_|_BZZKEPGENYLQSC-FIBGUPNXSA-N_|_Small molecule_|_False_|_DEUCRAVACITINIB_|_2022.0_|_4.0_|_CHEMBL4596392_|_False_|_True_|_['Sotyktu']_|_['BMS-986165' 'Bms-986165' 'Deucravacitinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DEUCRAVACITINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003778', 'EFO_0003834', 'EFO_0000729', 'EFO_0000540',
       'HP_0000999', 'EFO_0003086', 'EFO_0000676', 'MONDO_0007915',
       'EFO_0004192', 'EFO_0005761', 'HP_0001410', 'MP_0001845'],
      dtype=object), 'count': 12}_|_[ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 11 investigational indications."
CHEMBL4594547,"nan_|_nan_|_Antibody_|_False_|_TEMELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GNBAC1' 'Gnbac1' 'Temelimab']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 3}_|_[ENSG00000242950]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650321,"C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1_|_MZPVEMOYADUARK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ORELABRUTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Innobruka']_|_['ICP-022' 'ICP022' 'Icp-022' 'Orelabrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ORELABRUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000096', 'MONDO_0018906', 'EFO_1001469', 'EFO_0007160',
       'MONDO_0007915', 'EFO_0000616', 'EFO_0000403', 'EFO_0003929',
       'EFO_0009441', 'EFO_0000095', 'EFO_0000183', 'EFO_0001421',
       'MONDO_0004992'], dtype=object), 'count': 13}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL4650365,"C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F_|_WDHOIABIERMLGY-CMJOXMDJSA-N_|_Small molecule_|_False_|_CAMIZESTRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZ-14066724' 'AZ14066724' 'AZD-9833' 'AZD9833' 'Azd9833' 'Camizestrant']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CAMIZESTRANT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'MONDO_0007254', 'EFO_0003869'], dtype=object), 'count': 3}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4802239,"C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C.O=C(O)CCC(=O)O_|_YXYAEUMTJQGKHS-UHFFFAOYSA-N_|_Small molecule_|_True_|_MOBOCERTINIB SUCCINATE_|_2021.0_|_4.0_|_CHEMBL4650319_|_False_|_True_|_['Exkivity']_|_[]_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for non-small cell lung carcinoma. This drug has a black box warning from the FDA."
CHEMBL1175,"CNCC[C@H](Oc1cccc2ccccc12)c1cccs1_|_ZEUITGRIYCTCEM-KRWDZBQOSA-N_|_Small molecule_|_True_|_DULOXETINE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cymbalta' 'Duloxetine' 'LY-248686' 'LY248686']_|_[('PubChem', array(['124893161', '26719725', '26757978', '49681583'], dtype=object)), ('Wikipedia', array(['Duloxetine'], dtype=object)), ('drugbank', array(['DB00476'], dtype=object)), ('chEBI', array(['36795'], dtype=object))]_|_['CHEMBL1200328']_|_{'rows': array(['MONDO_0005301', 'HP_0012532', 'EFO_0005762', 'HP_0000020',
       'EFO_0001358', 'EFO_0001358', 'EFO_0005687', 'MONDO_0002009',
       'EFO_0000400', 'EFO_0005762', 'MONDO_0005180', 'MONDO_0005178',
       'EFO_0003888', 'HP_0010992', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0002009', 'MONDO_0002050', 'HP_0003418', 'EFO_0006788',
       'EFO_1000783', 'EFO_0004701', 'EFO_0005687', 'EFO_0005230',
       'EFO_0000712', 'EFO_0007169', 'HP_0030834', 'EFO_0005230',
       'EFO_1001951', 'MONDO_0001583', 'MONDO_0002009', 'MONDO_0005090',
       'EFO_0004244', 'EFO_0004540', 'HP_0000020', 'HP_0003326',
       'EFO_1001951', 'HP_0003419', 'HP_0100543', 'MONDO_0005301',
       'EFO_0003843', 'EFO_0003843', 'EFO_0003100', 'EFO_0004616',
       'MONDO_0007079', 'EFO_1001892', 'MONDO_0005178', 'MONDO_0002050',
       'EFO_1000783', 'EFO_0000401', 'EFO_0002970'], dtype=object), 'count': 51}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 38 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200819,"CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC.Cl_|_GDWDBGSWGNEMGJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ARTICAINE HYDROCHLORIDE_|_2000.0_|_4.0_|_CHEMBL1093_|_False_|_True_|_[]_|_['40 045' 'Articaine hcl' 'Articaine hydrochloride'
 'Carticaine hydrochloride' 'HOE 045' 'HOE-045' 'HOE-40045' 'Ubistesine'
 'Ultracain']_|_[('DailyMed', array(['articaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204160', '170464825', '56463593'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000."
CHEMBL1200875,"Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O.Cl_|_XOEVKNFZUQEERE-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLAVOXATE HYDROCHLORIDE_|_1970.0_|_4.0_|_CHEMBL1493_|_False_|_True_|_['Flavoxate hydrochloride' 'Urispas' 'Urispas 200']_|_['DW-61' 'Flavoxate' 'Flavoxate hcl' 'Flavoxate hydrochloride'
 'NSC-114649']_|_[('DailyMed', array(['flavoxate%20hydrochloride'], dtype=object)), ('PubChem', array(['144204088', '170466285'], dtype=object)), ('chEBI', array(['5089'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003830', 'EFO_0003901', 'EFO_0003878', 'EFO_0003103'],
      dtype=object), 'count': 4}_|_[ENSG00000205268,ENSG00000171408,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000113231,ENSG00000073417]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 4 approved indications."
CHEMBL1201099,"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O=P(O)(O)O_|_JPGKFBXFEQWCAI-CCLYOLAMSA-N_|_Small molecule_|_False_|_CODEINE PHOSPHATE_|_1952.0_|_4.0_|_CHEMBL485_|_False_|_True_|_['Bepro' 'Evacode' 'Galcodine']_|_['Codeine phosphate' 'Codeine phosphate anhydrous' 'Codeine phosphate bp'
 'Codeine phosphate cii' 'Codeine phosphate hemihydrate'
 'Codeine phosphate hydrate' 'Codeini phosphas' 'Methylmorphine']_|_[('DailyMed', array(['codeine%20phosphate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'HP_0012735', 'EFO_0003890', 'HP_0003394',
       'EFO_0003843', 'EFO_0000764', 'HP_0011868'], dtype=object), 'count': 7}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 4 approved and 3 investigational indications."
CHEMBL1201132,"Cl.Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314_|_YZLZPSJXMWGIFH-BCXQGASESA-N_|_Small molecule_|_True_|_NALBUPHINE HYDROCHLORIDE_|_1979.0_|_4.0_|_CHEMBL895_|_False_|_True_|_['Nalbuphine' 'Nalbuphine hydrochloride' 'Nubain']_|_['EN-2234A' 'NSC-757829' 'Nalbufine hydrochloride' 'Nalbuphine hcl'
 'Nalbuphine hydrochloride']_|_[('DailyMed', array(['nalbuphine%20hydrochloride'], dtype=object)), ('PubChem', array(['56463337'], dtype=object)), ('chEBI', array(['7455'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000175', 'EFO_0005611', 'EFO_0000222', 'EFO_0003843',
       'EFO_1001250', 'EFO_0005323', 'HP_0000989', 'EFO_0009267',
       'EFO_0001421'], dtype=object), 'count': 9}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for pain and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1437,"NC[C@H](O)c1ccc(O)c(O)c1_|_SFLSHLFXELFNJZ-QMMMGPOBSA-N_|_Small molecule_|_False_|_NOREPINEPHRINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-noradrenaline' 'Levarterenol' 'Levophed' 'NSC-757246'
 'Nor adrenalin' 'Norepinephrine' 'R-norepinephrine']_|_[('PubChem', array(['144212261', '26754493', '26754494', '29215339', '50109852',
       '50109853', '57288371', '90341660'], dtype=object)), ('Wikipedia', array(['Norepinephrine'], dtype=object)), ('drugbank', array(['DB00368'], dtype=object)), ('chEBI', array(['18357'], dtype=object))]_|_['CHEMBL1356607' 'CHEMBL5087452' 'CHEMBL3273169' 'CHEMBL2311152'
 'CHEMBL3248963' 'CHEMBL2130595' 'CHEMBL1434513']_|_{'rows': array(['EFO_0005207', 'EFO_0000319', 'MONDO_0043771', 'HP_0031273',
       'EFO_0005251', 'EFO_0005252', 'HP_0002140', 'EFO_0004610',
       'MONDO_0002050', 'HP_0002140', 'EFO_0002497', 'EFO_0001073',
       'MONDO_0008867', 'EFO_0003777', 'HP_0100806', 'HP_0100806',
       'MONDO_0001382', 'MONDO_0043510', 'EFO_0005251', 'MP_0001845',
       'EFO_0000319', 'EFO_0007450', 'HP_0100543', 'EFO_0006834'],
      dtype=object), 'count': 24}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 approved and 19 investigational indications."
CHEMBL160,"C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C_|_PMATZTZNYRCHOR-CGLBZJNRSA-N_|_Protein_|_True_|_CYCLOSPORINE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Capimune' 'Capsorin' 'Cequa' 'Cyclosporine' 'Deximune' 'Gengraf'
 'Ikervis' 'Neoral' 'Optimmune' 'Restasis' 'Restasis multidose'
 'Sandimmun' 'Sandimmune' 'Sangcya' 'Vanquoral' 'Verkazia']_|_['27-400' 'ANTIBIOTIC S-7481F1' 'Atopica' 'Ciclosporin' 'Ciclosporin a'
 'Ciclosporinum' 'Cyclosporin' 'Cyclosporin a' 'Cyclosporine'
 'Cyclosporine a' 'Cyclosporine microemulsion' 'Cyclosporine, modified'
 'Equoral' 'Mitogard' 'NSC-290193' 'Neoplanta' 'Neurostat' 'OL-27-400'
 'Ramihyphin a' 'SANG-35' 'SDZ-OXL-400' 'Vevye' 'Zinograf me']_|_[('Wikipedia', array(['Ciclosporin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ikervis'],
      dtype=object)), ('TG-GATEs', array(['142'], dtype=object)), ('PubChem', array(['11532934', '144204218', '144212166', '170466812', '26757675',
       '56422786'], dtype=object)), ('DailyMed', array(['cyclosporine'], dtype=object)), ('drugbank', array(['DB00091'], dtype=object)), ('chEBI', array(['4031'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000389', 'MP_0001845', 'EFO_1001478', 'EFO_0000565',
       'EFO_0000685', 'EFO_0000274', 'EFO_0000681', 'EFO_0000783',
       'EFO_0000183', 'HP_0009926', 'EFO_0003777', 'MONDO_0019469',
       'EFO_0004599', 'EFO_0000400', 'EFO_0000365', 'EFO_1000785',
       'EFO_0004254', 'EFO_0003884', 'EFO_1001365', 'MONDO_0001475',
       'EFO_0000574', 'MONDO_0013730', 'EFO_1001231', 'MONDO_0018906',
       'MONDO_0021193', 'EFO_1001264', 'MONDO_0007254', 'EFO_0008507',
       'EFO_0009464', 'HP_0000964', 'EFO_0009492', 'EFO_1000560',
       'EFO_0000220', 'MONDO_0020547', 'EFO_0002687', 'EFO_0007141',
       'EFO_1001051', 'EFO_0004236', 'EFO_0005676', 'EFO_0009609',
       'EFO_0003966', 'EFO_0001054', 'EFO_0000694', 'MONDO_0005041',
       'MONDO_0019249', 'MONDO_0001705', 'EFO_0007160', 'MONDO_0018305',
       'EFO_0003780', 'MONDO_0008315', 'EFO_0004220', 'EFO_0000649',
       'EFO_0000222', 'MONDO_0004992', 'EFO_0005761', 'EFO_0000616',
       'MONDO_0008380', 'MONDO_0018896', 'EFO_0007527', 'EFO_0000341',
       'EFO_0003047', 'Orphanet_848', 'EFO_0000198', 'EFO_0000621',
       'EFO_0000540', 'EFO_0006927', 'EFO_0003818', 'MONDO_0019019',
       'EFO_0004214', 'EFO_1001413', 'EFO_1000690', 'EFO_0008583',
       'EFO_0000557', 'MONDO_0015540', 'EFO_0000544', 'EFO_0002428',
       'EFO_0001642', 'EFO_0000691', 'EFO_0009708', 'MONDO_0011382',
       'MONDO_0002898', 'EFO_0003833', 'EFO_0000612', 'MONDO_0009387',
       'EFO_0007157', 'MONDO_0002158', 'MONDO_0005148', 'EFO_0000403',
       'EFO_0000764', 'EFO_0000339', 'MONDO_0019623', 'EFO_1000906',
       'HP_0001915', 'EFO_0003086', 'EFO_0004276', 'MONDO_0044881',
       'EFO_1001951', 'EFO_0005952', 'MONDO_0100096', 'EFO_1002048',
       'EFO_0000678', 'MONDO_0018904', 'MONDO_0008170', 'EFO_0000182',
       'EFO_0001378', 'EFO_0000095', 'EFO_1001469', 'MONDO_0043510',
       'MONDO_0004768', 'MONDO_0002367', 'MONDO_0020077', 'MONDO_0018923',
       'EFO_0000309', 'MONDO_0000870', 'EFO_1001156', 'MONDO_0005147',
       'MONDO_0010788', 'EFO_0000676', 'MONDO_0020290', 'EFO_0007359',
       'MONDO_0000873', 'EFO_0001421', 'EFO_0007183', 'EFO_0004286',
       'EFO_1000102', 'EFO_0005531', 'MONDO_0019391', 'EFO_0009441',
       'HP_0001919'], dtype=object), 'count': 129}_|_[ENSG00000196262]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 7 approved and 122 investigational indications. This drug has a black box warning from the FDA."
CHEMBL180022,"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C_|_JWNPDZNEKVCWMY-VQHVLOKHSA-N_|_Small molecule_|_False_|_NERATINIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CDP-820' 'HKI-272' 'Neratinib' 'WAY-179272']_|_[('PubChem', array(['124950160'], dtype=object)), ('Wikipedia', array(['Neratinib'], dtype=object)), ('drugbank', array(['DB11828'], dtype=object))]_|_['CHEMBL3989921']_|_{'rows': array(['EFO_0000339', 'MONDO_0007254', 'EFO_0000313', 'EFO_0003869',
       'EFO_1001951', 'EFO_0000305', 'EFO_0000673', 'EFO_0003060',
       'EFO_1000294', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0007254',
       'EFO_0000182', 'EFO_0000519', 'EFO_0003891', 'EFO_0003968',
       'EFO_0000616', 'MONDO_0008170', 'EFO_0000553', 'EFO_0005537',
       'EFO_0000305'], dtype=object), 'count': 21}_|_[ENSG00000178568,ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 19 investigational indications."
CHEMBL1829174,"Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1_|_BZCALJIHZVNMGJ-HSZRJFAPSA-N_|_Small molecule_|_False_|_FASIGLIFAM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fasiglifam' 'Fasiglifam hemihydrate' 'Fasiglifam hydrate' 'TAK-875'
 'TAK875' 'Tak-875 anhydrous']_|_[('drugbank', array(['DB12491'], dtype=object))]_|_['CHEMBL2047171' 'CHEMBL2047159']_|_{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000126266]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108081,"nan_|_nan_|_Protein_|_False_|_TRAFERMIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CAB-2001' 'Trafermin']_|_nan_|_nan_|_{'rows': array(['EFO_0000649', 'EFO_0009472', 'EFO_1001459', 'HP_0200042'],
      dtype=object), 'count': 4}_|_[ENSG00000066468]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2109482,"nan_|_nan_|_Antibody_|_False_|_BI-505_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI-505' 'Bi-505']_|_nan_|_nan_|_{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}_|_[ENSG00000090339]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109513,"nan_|_nan_|_Antibody_|_False_|_PD-360324_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PD-360324' 'Pd-360324']_|_nan_|_nan_|_{'rows': array(['EFO_0001075', 'MONDO_0004992', 'EFO_1000251', 'EFO_0000685',
       'EFO_0003834', 'DOID_13406'], dtype=object), 'count': 6}_|_[ENSG00000184371]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL2109607,"nan_|_nan_|_Antibody_|_False_|_MEDI-8968_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MEDI-8968' 'Medi-8968']_|_nan_|_nan_|_{'rows': array(['EFO_1000710', 'EFO_0000341'], dtype=object), 'count': 2}_|_[ENSG00000115594]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2325014,"Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl_|_ZYSCOUXLBXGGIM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-05089771_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-05089771']_|_[('drugbank', array(['DB14856'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0010072', 'EFO_1000783', 'MONDO_0016028'],
      dtype=object), 'count': 4}_|_[ENSG00000169432]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL236593,"O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1_|_CGDZXLJGHVKVIE-DNVCBOLYSA-N_|_Small molecule_|_False_|_TELCAGEPANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-0974' 'MK0974' 'Mk-0974' 'Telcagepant']_|_[('Wikipedia', array(['Telcagepant'], dtype=object)), ('drugbank', array(['DB12228'], dtype=object))]_|_['CHEMBL2105656']_|_{'rows': array(['MONDO_0005277', 'MONDO_0005277'], dtype=object), 'count': 2}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 1 investigational indication."
CHEMBL3544941,nan_|_nan_|_Small molecule_|_False_|_RG7185_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['RO5271983' 'Rg7185']_|_nan_|_nan_|_nan_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545396,"COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1_|_CSGQVNMSRKWUSH-IAGOWNOFSA-N_|_Small molecule_|_False_|_BMS-690514_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bms 6690514' 'Bms 690514' 'Bms-690514']_|_[('drugbank', array(['DB11665'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0003060', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000141736,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000178568,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3707383,"nan_|_nan_|_Oligonucleotide_|_False_|_MONGERSEN SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GED-0301' 'GED-0301 SODIUM' 'Mongersen sodium']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000384'], dtype=object), 'count': 2}_|_[ENSG00000101665]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL382277,NC(=O)C1CCCC2c3cc(Cl)ccc3NC12_|_NYORQUCSPQVLTE-UHFFFAOYSA-N_|_Small molecule_|_False_|_EX-527_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ex-527']_|_nan_|_nan_|_nan_|_[ENSG00000096717]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3908979,"COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc32)ncc1C#N_|_BHKDKKZMPODMIQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_FGF401_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FGF-401' 'Fgf401' 'Roblitinib']_|_nan_|_nan_|_{'rows': array(['EFO_0000182'], dtype=object), 'count': 1}_|_[ENSG00000160867]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4175981,"CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21_|_ACSQLTBPYZSGBA-GMXVVIOVSA-N_|_Small molecule_|_False_|_OLORINAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APD-371' 'APD371' 'Apd371' 'Olorinab']_|_[('drugbank', array(['DB14998'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002027', 'EFO_0000384', 'EFO_0000555'], dtype=object), 'count': 3}_|_[ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL428647,"CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O_|_RCINICONZNJXQF-MZXODVADSA-N_|_Small molecule_|_True_|_PACLITAXEL_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Abraxane' 'Apealea' 'Pacitaxel' 'Paclitaxel' 'Paxene' 'Taxol'
 'Taxol 100']_|_['(-)-paclitaxel' 'ABI-007' 'ABI-007 COMPONENT PACLITAXEL' 'BMS 181339-01'
 'BMS-181339-01' 'Capxol' 'Cyclopax' 'DHP 107' 'DHP-107' 'Ebetaxel'
 'Empac' 'Endotag 1' 'Genaxol' 'Genetaxyl' 'Genexol' 'Genexol-pm'
 'Intaxel' 'Lep-etu' 'MBT 0206' 'MBT-0206' 'Mitotax' 'NK 105' 'NK-105'
 'NSC-125973' 'Oncogel' 'Onxal' 'Onxol' 'Pacliex' 'Paclitaxel'
 'Paclitaxel (taxus canadensis)' 'Paclitaxol' 'Plaxicel' 'QW-8184'
 'Taxalbin' 'Taxol' 'Taxol a' 'Taxus' 'Taxus liberte' 'Taxus stent'
 'Tocosol paclitaxel' 'Yewtaxan']_|_[('DailyMed', array(['paclitaxel'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/apealea'],
      dtype=object)), ('PubChem', array(['124893045', '144205660', '418145', '56463361'], dtype=object)), ('drugbank', array(['DB01229'], dtype=object)), ('chEBI', array(['45863'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003869', 'EFO_1000984', 'EFO_0000616', 'EFO_1000350',
       'MONDO_0021043', 'EFO_1000043', 'MONDO_0008315', 'EFO_0002938',
       'EFO_0004243', 'EFO_1001931', 'MONDO_0002158', 'MONDO_0003060',
       'EFO_0006818', 'EFO_0002892', 'MONDO_0001187', 'EFO_0006352',
       'EFO_0007535', 'EFO_0000685', 'EFO_0003860', 'EFO_0006859',
       'MONDO_0018364', 'EFO_0003893', 'MONDO_0004658', 'EFO_0001061',
       'EFO_0002916', 'EFO_0000308', 'EFO_0000305', 'EFO_0005952',
       'EFO_0003859', 'EFO_0009708', 'MONDO_0004669', 'EFO_0000702',
       'MONDO_0044704', 'MONDO_0021148', 'MONDO_0021657', 'EFO_0000514',
       'EFO_0000519', 'MONDO_0005184', 'EFO_0000180', 'EFO_0000294',
       'EFO_0004272', 'EFO_1000796', 'EFO_0000466', 'MONDO_0005271',
       'MONDO_0003751', 'EFO_1000576', 'EFO_1001100', 'MONDO_0021251',
       'EFO_1000158', 'EFO_1000294', 'EFO_0000503', 'MONDO_0004192',
       'MONDO_0011719', 'EFO_0000558', 'EFO_0003868', 'EFO_0005567',
       'EFO_1001951', 'EFO_0006772', 'EFO_1000251', 'EFO_0004224',
       'EFO_1000613', 'EFO_0003826', 'EFO_0000182', 'EFO_0000588',
       'MONDO_0001879', 'EFO_0004149', 'EFO_1001968', 'MONDO_0007576',
       'MONDO_0002108', 'MONDO_0004992', 'EFO_0000707', 'EFO_0000691',
       'EFO_0005537', 'EFO_0003863', 'EFO_0000556', 'EFO_0001075',
       'MONDO_0001402', 'EFO_1001961', 'MONDO_0008170', 'MONDO_0002367',
       'EFO_0000574', 'MONDO_0002715', 'MONDO_0002120', 'EFO_1001512',
       'EFO_0000183', 'EFO_1001331', 'EFO_0001378', 'EFO_0005088',
       'EFO_0003060', 'MONDO_0022394', 'EFO_0003050', 'EFO_0001642',
       'MONDO_0002691', 'MONDO_0021355', 'EFO_0006861', 'EFO_0003875',
       'EFO_1001471', 'EFO_0000199', 'EFO_0004265', 'MONDO_0005411',
       'EFO_0000181', 'MONDO_0002974', 'EFO_0003968', 'EFO_0004284',
       'EFO_0001416', 'EFO_0002617', 'MONDO_0001528', 'EFO_0005221',
       'EFO_0000565', 'EFO_0010282', 'EFO_0004281', 'MONDO_0008903',
       'EFO_0004142', 'EFO_0000389', 'EFO_0008524', 'EFO_1000052',
       'EFO_0000228', 'EFO_0003833', 'EFO_1000657', 'EFO_0000764',
       'MONDO_0002601', 'EFO_0000681', 'MONDO_0004986', 'MONDO_0001056',
       'EFO_0007532', 'EFO_0000178', 'MONDO_0044926', 'MONDO_0011962',
       'EFO_0000313', 'Orphanet_145', 'EFO_0000432', 'MONDO_0018944',
       'EFO_0000284', 'EFO_1001465', 'MONDO_0001325', 'EFO_0000676',
       'EFO_0002496', 'EFO_0000708', 'EFO_0005922', 'EFO_0004230',
       'EFO_0008528', 'MONDO_0021117', 'EFO_1000359', 'EFO_0000673',
       'EFO_0003843', 'EFO_0000095', 'MONDO_0007254', 'MONDO_0002087',
       'EFO_0002618', 'EFO_0006318', 'EFO_0004252', 'EFO_0000756',
       'EFO_0003100', 'EFO_1000581', 'MONDO_0100342', 'EFO_0003897',
       'EFO_0000571', 'EFO_0000365'], dtype=object), 'count': 158}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 12 approved and 146 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4298062,"nan_|_nan_|_Oligonucleotide_|_False_|_VILTOLARSEN_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Viltepso']_|_['NCNP-01' 'NS-065' 'NS-065/NCNP-01' 'Ns-065/ncnp-01' 'Viltolarsen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VILTOLARSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0020121', 'MONDO_0010679'], dtype=object), 'count': 2}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for muscular dystrophy and duchenne muscular dystrophy."
CHEMBL4298179,"nan_|_nan_|_Oligonucleotide_|_False_|_TEPRASIRAN SODIUM_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Teprasiran sodium']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPRASIRAN%20SODIUM/relevant/1/'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000141510]_|_Oligonucleotide drug with a maximum clinical trial phase of I."
CHEMBL4594394,"O=C([O-])CCCO.O=C([O-])CCCO.[Mg+2]_|_QWZIZKOBUUSCLO-UHFFFAOYSA-L_|_Small molecule_|_False_|_MAGNESIUM OXYBATE_|_2020.0_|_4.0_|_CHEMBL1342_|_False_|_True_|_[]_|_['Oxybate magnesium']_|_[('DailyMed', array(['magnesium%20oxybate'], dtype=object))]_|_nan_|_nan_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020."
CHEMBL4650438,"nan_|_nan_|_Oligonucleotide_|_False_|_OLEZARSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AKCEA-APOCIII-LRx' 'Akcea-apociii-lrx' 'IONIS- APOCIII-LRx'
 'IONIS-APOCIII-LRX' 'ISIS 678354' 'ISIS-678354' 'ISIS-APOCIII-LRX'
 'Olezarsen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLEZARSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004211', 'EFO_0000319'], dtype=object), 'count': 2}_|_[ENSG00000110245]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL494753,"C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O_|_JKKFKPJIXZFSSB-CBZIJGRNSA-N_|_Small molecule_|_True_|_ESTRONE SULFURIC ACID_|_1977.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Estrone Sulphate']_|_[('PubChem', array(['11112590'], dtype=object)), ('Wikipedia', array(['Estrone_sulfate'], dtype=object)), ('drugbank', array(['DB04574'], dtype=object)), ('chEBI', array(['17474'], dtype=object))]_|_['CHEMBL1200980' 'CHEMBL1546237' 'CHEMBL2106240']_|_{'rows': array(['EFO_1000096', 'GO_0042697', 'EFO_0004266', 'MONDO_0002146',
       'EFO_0003882'], dtype=object), 'count': 5}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA."
CHEMBL634,"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1_|_IDBPHNDTYPBSNI-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALFENTANIL_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Afentanyl' 'Alfentanil' 'Alfentanyl' 'IDS-NA-014' 'R-39209' 'R-39209-']_|_[('Wikipedia', array(['Alfentanil'], dtype=object)), ('drugbank', array(['DB00802'], dtype=object)), ('chEBI', array(['2569'], dtype=object))]_|_['CHEMBL1200531']_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. This drug has a black box warning from the FDA."
CHEMBL1096979,"NC(CO)C(=O)NNCc1ccc(O)c(O)c1O_|_BNQDCRGUHNALGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENSERAZIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benserazide' 'Benserazide (as hydrochloride)' 'Benserazide hcl'
 'Benserazide hydrochloride' 'NSC-755907' 'RO 4-4602' 'RO-4-4602'
 'Serazide']_|_[('PubChem', array(['174006784', '90341370'], dtype=object)), ('Wikipedia', array(['Benserazide'], dtype=object)), ('drugbank', array(['DB12783'], dtype=object)), ('chEBI', array(['64187'], dtype=object))]_|_['CHEMBL1255778']_|_{'rows': array(['EFO_0004270', 'MONDO_0005180'], dtype=object), 'count': 2}_|_[ENSG00000132437]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL1200692,"CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1_|_UQGKUQLKSCSZGY-UHFFFAOYSA-N_|_Small molecule_|_True_|_OLMESARTAN MEDOXOMIL_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Benicar' 'Olmesartan medoxomil' 'Olmetec']_|_['CS-866' 'NSC-758924' 'Olmesartan medoxomil']_|_[('DailyMed', array(['olmesartan%20medoxomil'], dtype=object)), ('PubChem', array(['144204998', '26748978'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002462', 'EFO_0000401', 'EFO_0000712', 'EFO_0000400',
       'EFO_0000319', 'EFO_0003086', 'EFO_0000537', 'MONDO_0001134',
       'EFO_0000612', 'EFO_0003144', 'EFO_0003914', 'HP_0000093'],
      dtype=object), 'count': 12}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743083,"nan_|_nan_|_Antibody_|_False_|_TREGALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BT-061' 'Tregalizumab']_|_nan_|_nan_|_{'rows': array(['EFO_1001494', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1763,"NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O_|_DMDGGSIALPNSEE-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROFLUMETHIAZIDE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Diucardin' 'Hydrenox' 'Hydroflumethiazide' 'Saluron']_|_['Hydroflumethiazide' 'NSC-44627']_|_[('PubChem', array(['11112295', '144203973', '170465082', '26747027', '56422879',
       '855883'], dtype=object)), ('Wikipedia', array(['Hydroflumethiazide'], dtype=object)), ('drugbank', array(['DB00774'], dtype=object)), ('chEBI', array(['5784'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for cardiovascular disease."
CHEMBL207538,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C_|_AURFZBICLPNKBZ-SYBPFIFISA-N_|_Small molecule_|_True_|_BREXANOLONE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Zulresso']_|_['Allopregnan-3.alpha.-ol-20-one' 'Allopregnanolone'
 'Allotetrahydroprogesterone' 'Brexanolone' 'SAGE-547' 'SGE-102']_|_[('DailyMed', array(['brexanolone'], dtype=object)), ('PubChem', array(['144205595', '26756639'], dtype=object)), ('drugbank', array(['DB11859'], dtype=object)), ('chEBI', array(['50169'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0007453', 'MONDO_0002050', 'MONDO_0043510',
       'HP_0000360', 'EFO_0008526', 'EFO_0005407', 'EFO_0003108',
       'EFO_0001358', 'MONDO_0007079', 'MONDO_0002009'], dtype=object), 'count': 11}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2106829,"Cc1ccccc1-n1c(C)nc2ccccc2c1=O.Cl_|_KJUHIXIWKSVBKB-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHAQUALONE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL282052_|_True_|_True_|_[]_|_['Methaqualone hcl' 'Methaqualone hydrochloride' 'NSC-75892']_|_nan_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2108326,"nan_|_nan_|_Oligonucleotide_|_False_|_ALICAFORSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Alicaforsen']_|_nan_|_nan_|_{'rows': array(['EFO_0003767', 'EFO_0000729', 'EFO_0000384', 'EFO_0003921'],
      dtype=object), 'count': 4}_|_[ENSG00000090339]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2218893,"CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2.CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2.O=S(=O)(O)O_|_VPCOODFYDJWLHD-YMZXMBPUSA-N_|_Small molecule_|_False_|_BEDORADRINE SULFATE_|_nan_|_2.0_|_CHEMBL2111083_|_False_|_False_|_[]_|_['Bedoradrine sulfate' 'Bedoradrine sulphate' 'KUR-1246' 'MN-221']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0008590'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2368861,"CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl_|_UAIXRPCCYXNJMQ-HPRIMLMLSA-N_|_Small molecule_|_True_|_BUPRENORPHINE HYDROCHLORIDE_|_1981.0_|_4.0_|_CHEMBL511142_|_False_|_True_|_['Belbuca' 'Buprenex' 'Buprenorphine hydrochloride' 'Espranor' 'Gabup'
 'Natzon' 'Prefibin' 'Probuphine' 'Sixmo' 'Subutex']_|_['Anorfin' 'Buprederm' 'Buprenorphine hcl' 'Buprenorphine hydrochloride'
 'Buprenorphine hydrochloride ciii' 'Buprex' 'CL 112,302' 'CL-112302'
 'Finibron' 'Lepetan' 'M-6029' 'NIH 8805' 'NIH-8805' 'Nopan'
 'RX 6029-M HCL' 'RX-6029-M HCL' 'SCH-028444' 'UM 952' 'UM-952'
 'Vetergesic']_|_[('DailyMed', array(['buprenorphine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005611', 'EFO_0003890'], dtype=object), 'count': 2}_|_[ENSG00000082556,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for opioid dependence and drug dependence. This drug has a black box warning from the FDA."
CHEMBL3542265,"CC(C)OC(=O)N[C@H]1Cc2c(n(Cc3ccccn3)c3ccc(C#N)cc23)C1_|_IHIWYQYVBNODSV-KRWDZBQOSA-N_|_Small molecule_|_False_|_LY2452473_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2452473' 'LY2452473' 'Ly2452473' 'OPK-88004' 'TT-701']_|_[('drugbank', array(['DB12573'], dtype=object))]_|_['CHEMBL3542296']_|_{'rows': array(['MONDO_0008315', 'EFO_0004234', 'EFO_0000284'], dtype=object), 'count': 3}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL376897,"C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12_|_LZCOQTDXKCNBEE-IKIFYQGPSA-N_|_Small molecule_|_False_|_METHSCOPOLAMINE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-n-methylscopolamine' 'Methscopolamine cation' 'Methscopolamine ion'
 'Methylscopolamine' 'N-methylhyoscine' 'N-methylscopolamine']_|_[('Wikipedia', array(['Methylscopolamine_bromide'], dtype=object)), ('drugbank', array(['DB11315'], dtype=object))]_|_['CHEMBL1506225' 'CHEMBL1354199']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and is indicated for gastrointestinal disease."
CHEMBL4298195,"nan_|_nan_|_Antibody_|_False_|_NARSOPLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Masp-2 antibody' 'Narsoplimab' 'OMS-721' 'OMS00620646' 'OMS620646'
 'OMS721']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NARSOPLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0016244', 'EFO_0005761', 'MONDO_0100096', 'EFO_0004194'],
      dtype=object), 'count': 4}_|_[ENSG00000009724]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL504652,"c1cncc(N2CCC3(CCCN3)C2)c1_|_NXIPMBQVNTWEEX-UHFFFAOYSA-N_|_Small molecule_|_False_|_TC-2216_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['TC-2216' 'Tc-2216']_|_nan_|_nan_|_{'rows': array(['MONDO_0002050', 'EFO_0005230'], dtype=object), 'count': 2}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL598172,"COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C_|_COSPVUFTLGQDQL-UHFFFAOYSA-N_|_Small molecule_|_False_|_NELOTANSERIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APD-125' 'APD125' 'Apd-125' 'Nelotanserin']_|_[('drugbank', array(['DB12555'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'HP_0000738', 'EFO_0006792'], dtype=object), 'count': 3}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL95,"Nc1c2c(nc3ccccc13)CCCC2_|_YLJREFDVOIBQDA-UHFFFAOYSA-N_|_Small molecule_|_False_|_TACRINE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Tacrinal' 'Tacrine']_|_[('PubChem', array(['104171104', '11110734', '11113824', '124879172', '124879174',
       '144203624', '144212594', '170465420', '26755281', '90341647'],
      dtype=object)), ('TG-GATEs', array(['60'], dtype=object)), ('Wikipedia', array(['Tacrine'], dtype=object)), ('drugbank', array(['DB00382'], dtype=object)), ('chEBI', array(['45980'], dtype=object))]_|_['CHEMBL1677' 'CHEMBL1337960']_|_{'rows': array(['EFO_0002610', 'HP_0000726'], dtype=object), 'count': 2}_|_[ENSG00000114200,ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for dementia and has 1 investigational indication."
CHEMBL1200379,"Cl.Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1_|_OTQYGBJVDRBCHC-UHFFFAOYSA-N_|_Small molecule_|_False_|_APRACLONIDINE HYDROCHLORIDE_|_1987.0_|_4.0_|_CHEMBL647_|_False_|_True_|_['Apraclonidine hydrochloride' 'Iopidine']_|_['AL-02145' 'AL02145' 'Aplonidine hydrochloride' 'Apraclonidine hcl'
 'Apraclonidine hydrochloride']_|_[('DailyMed', array(['apraclonidine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204758', '50105753'], dtype=object)), ('chEBI', array(['2789'], dtype=object))]_|_nan_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987."
CHEMBL1201203,"CN1[C@@H]2CC[C@H]1C[C@@H](OC(c1ccccc1)c1ccccc1)C2_|_GIJXKZJWITVLHI-PMOLBWCYSA-N_|_Small molecule_|_False_|_BENZTROPINE_|_1954.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benzatropine' 'Benztropine' 'Cobrentin' 'NK-02']_|_[('PubChem', array(['144204856', '144205248', '29215426'], dtype=object)), ('Wikipedia', array(['Benzatropine'], dtype=object)), ('drugbank', array(['DB00245'], dtype=object)), ('chEBI', array(['3048'], dtype=object))]_|_['CHEMBL1200383']_|_{'rows': array(['EFO_0005279', 'EFO_0002610', 'HP_0003418', 'MONDO_0005180',
       'MONDO_0005180', 'HP_0011868', 'EFO_0009387'], dtype=object), 'count': 7}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for parkinson disease and has 5 investigational indications."
CHEMBL1233528,"CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C_|_SXNJFOWDRLKDSF-STROYTFGSA-N_|_Small molecule_|_False_|_VOLASERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BI 6727' 'BI-6727' 'BI6727' 'Bi-6727' 'Volasertib']_|_[('drugbank', array(['DB12062'], dtype=object))]_|_['CHEMBL2105742']_|_{'rows': array(['EFO_0000221', 'EFO_1001257', 'EFO_0003060', 'EFO_0002913',
       'EFO_0000198', 'EFO_0000574', 'EFO_0000616', 'EFO_0003893',
       'EFO_0000565', 'EFO_0000222', 'MONDO_0000430'], dtype=object), 'count': 11}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL1451,"C[C@]12C=CC(=O)C=C1CC[C@H]1[C@@H]3C[C@@H](O)[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@]12F_|_GFNANZIMVAIWHM-OBYCQNJPSA-N_|_Small molecule_|_False_|_TRIAMCINOLONE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Aristocort' 'Aristocort A' 'Delphicort' 'Kenacort' 'Kenalog'
 'Triamcinolone' 'Volon']_|_['Fluoxiprednisolone' 'NSC-13397' 'Triamcinolone']_|_[('PubChem', array(['144204885', '144210498', '170465188', '26751455', '47193900',
       '50103941', '50103942', '77851', '855586', '90341396'],
      dtype=object)), ('Wikipedia', array(['Triamcinolone'], dtype=object)), ('drugbank', array(['DB00620'], dtype=object)), ('chEBI', array(['9667'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005762', 'EFO_0000274', 'EFO_0007486', 'EFO_1000391',
       'EFO_0005752', 'HP_0002027', 'EFO_0005854', 'MONDO_0005178',
       'EFO_1000786', 'HP_0001742', 'HP_0006536', 'EFO_1000662',
       'EFO_1001157', 'EFO_1001492', 'EFO_1000879', 'MONDO_0003005',
       'MONDO_0002959', 'EFO_0000701', 'EFO_0004683', 'EFO_0003843',
       'EFO_0001365', 'EFO_0004208', 'EFO_1001250', 'EFO_0004212',
       'EFO_0004264', 'EFO_0003963', 'HP_0030834', 'EFO_0009552',
       'EFO_0004616', 'EFO_1001417', 'EFO_0000342', 'EFO_1001077',
       'EFO_0000341', 'EFO_1000809', 'EFO_0000676', 'EFO_0008517',
       'EFO_0003770', 'EFO_0000756', 'EFO_0004192'], dtype=object), 'count': 39}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 5 approved and 34 investigational indications."
CHEMBL1516474,"CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12.O=C(O)/C=C\C(=O)O_|_CPDDZSSEAVLMRY-FEQFWAPWSA-N_|_Small molecule_|_False_|_TEGASEROD MALEATE_|_2002.0_|_4.0_|_CHEMBL76370_|_True_|_True_|_['Zelmac' 'Zelnorm']_|_['HTF 919' 'HTF-919' 'NSC-760425' 'Tegaserod maleate']_|_[('DailyMed', array(['tegaserod%20maleate'], dtype=object)), ('PubChem', array(['26748994'], dtype=object)), ('chEBI', array(['51044'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555', 'MONDO_0002203'], dtype=object), 'count': 2}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for irritable bowel syndrome and constipation disorder. It was withdrawn in at least one region."
CHEMBL1574,"CC(C)(N)Cc1ccccc1_|_DHHVAGZRUROJKS-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENTERMINE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Duromine' 'Ionamin' 'Phentermine resin 30' 'Phentermine resin complex']_|_['NSC-759163' 'Phentermine' 'Phentermine resin' 'Qsiva']_|_[('Wikipedia', array(['Phentermine'], dtype=object)), ('drugbank', array(['DB00191'], dtype=object)), ('chEBI', array(['8080'], dtype=object))]_|_['CHEMBL1200912']_|_{'rows': array(['EFO_0001074', 'EFO_0003890', 'EFO_0001073', 'EFO_0005204',
       'EFO_0001421', 'EFO_0003086', 'EFO_0000400', 'EFO_0001073'],
      dtype=object), 'count': 8}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for obesity and has 6 investigational indications."
CHEMBL1873475,"C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1_|_XYFPWWZEPKGCCK-GOSISDBHSA-N_|_Small molecule_|_False_|_IBRUTINIB_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Imbruvica']_|_['CRA-032765' 'Ibrutinib' 'PC-32765' 'PCI 32765' 'PCI-32765'
 'PCI-32765-00']_|_[('DailyMed', array(['ibrutinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica'],
      dtype=object)), ('PubChem', array(['124898784'], dtype=object)), ('drugbank', array(['DB09053'], dtype=object)), ('chEBI', array(['76612'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001469', 'MONDO_0100096', 'EFO_0000183', 'EFO_0007359',
       'EFO_0001421', 'EFO_1000560', 'EFO_0000403', 'MONDO_0007576',
       'MONDO_0021063', 'EFO_0000220', 'EFO_0000096', 'EFO_1001890',
       'EFO_0000222', 'EFO_0001642', 'EFO_0005952', 'EFO_0003060',
       'MONDO_0007254', 'EFO_1001264', 'EFO_0001378', 'MONDO_0044881',
       'EFO_0000181', 'EFO_1000630', 'EFO_0000574', 'EFO_0000616',
       'EFO_0000389', 'EFO_0000198', 'EFO_0009441', 'EFO_0004243',
       'MONDO_0008903', 'MONDO_0001023', 'MONDO_0100053', 'EFO_0000309',
       'MONDO_0009348', 'EFO_0004289', 'EFO_0000519', 'MONDO_0008315',
       'EFO_0002617', 'EFO_0000095', 'MONDO_0020547', 'EFO_0002616',
       'MONDO_0018906', 'EFO_1001875', 'MONDO_0004992', 'MONDO_0013730',
       'EFO_0000565', 'EFO_1001951', 'EFO_1000956', 'EFO_0000681'],
      dtype=object), 'count': 48}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 42 investigational indications."
CHEMBL2105667,"Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_XWNBGDJPEXZSQM-VZOBGQTKSA-N_|_Small molecule_|_False_|_ORVEPITANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW-823296X' 'GW823296X' 'Gw-823296' 'Gw823296' 'Orvepitant']_|_[('drugbank', array(['DB12427'], dtype=object))]_|_['CHEMBL2105668']_|_{'rows': array(['MONDO_0002009', 'HP_0012735', 'MONDO_0002050', 'EFO_0001358'],
      dtype=object), 'count': 4}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2109084,"nan_|_nan_|_Enzyme_|_False_|_DESMOTEPLASE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Desmoteplase' 'Dspa desmoteplase' 'RDSPA ALPHA 1']_|_nan_|_nan_|_{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}_|_[ENSG00000122194]_|_Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2146146,"CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O=S(=O)(O)O_|_VJFQPODMEGSXHC-RIMUKSHESA-N_|_Small molecule_|_False_|_ATROPINE SULFATE_|_1960.0_|_4.0_|_CHEMBL517712_|_False_|_True_|_['Atropine' 'Atropine sulfate' 'Atropine sulfate ansyr plastic syringe'
 'Atropine sulfate lifeshield abboject syringe' 'Isopto atropine']_|_['Atropine sulfate' 'Atropine sulfate anhydrous'
 'Atropine sulfate hydrate' 'Atropine sulfate monohydrate'
 'Atropine sulphate' 'Atropini sulfas' 'Atropinum sulphuricum' 'Atropt'
 'NSC-26671' 'NSC-755889' 'SYD-101']_|_[('DailyMed', array(['atropine%20sulfate'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000545', 'HP_0004398', 'EFO_0005854', 'EFO_0003956',
       'MONDO_0005180', 'EFO_0010581', 'EFO_0005323', 'HP_0011499'],
      dtype=object), 'count': 8}_|_[ENSG00000168539,ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 5 approved and 3 investigational indications."
CHEMBL245030,CCOC(=O)c1ccc2[nH]c3c(OC)c4[nH]c5ccc(C(=O)OCC)cc5c4cc3c2c1_|_BMTPVPNVQOYGAP-UHFFFAOYSA-N_|_Small molecule_|_False_|_SR-13668_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SR-13668' 'SR13668' 'Sr-13668']_|_nan_|_nan_|_nan_|_[ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL259972,"COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1_|_DJEIHHYCDCTAAH-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOFEZOLAC_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mofezolac']_|_[('PubChem', array(['144206111', '50112817'], dtype=object))]_|_nan_|_nan_|_[ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994."
CHEMBL286738,"NS(=O)(=O)Oc1ccc2c3c(c(=O)oc2c1)CCCCC3_|_DSLPMJSGSBLWRE-UHFFFAOYSA-N_|_Small molecule_|_False_|_IROSUSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['667 COUMATE' '667-COUMATE' 'BN 83495' 'BN-83495' 'BN83495' 'Irosustat'
 'STX 64' 'STX-64' 'STX64']_|_[('drugbank', array(['DB02292'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0008315'],
      dtype=object), 'count': 4}_|_[ENSG00000101846]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3544986,"CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC.N=C(N)NCCC[C@H](N)C(=O)O_|_RYCSJJXKEWBUTI-YDYAIEMNSA-N_|_Small molecule_|_False_|_PERINDOPRIL ARGININE_|_2015.0_|_4.0_|_CHEMBL1581_|_False_|_True_|_[]_|_['Perindopril arginine']_|_[('DailyMed', array(['perindopril%20arginine'], dtype=object)), ('chEBI', array(['77655'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0004214'], dtype=object), 'count': 2}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hypertension and has 1 investigational indication."
CHEMBL3545307,"Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1_|_QHADVLVFMKEIIP-UHFFFAOYSA-N_|_Small molecule_|_False_|_MERESTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2801653' 'LY2801653' 'Ly-2801653' 'Merestinib']_|_[('drugbank', array(['DB12381'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000389', 'MONDO_0003060', 'EFO_0003060', 'EFO_1001469',
       'EFO_0002618', 'EFO_1001951', 'MONDO_0004992', 'MONDO_0007254'],
      dtype=object), 'count': 8}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL3545412,"nan_|_nan_|_Small molecule_|_False_|_K-877_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['K-877']_|_nan_|_nan_|_{'rows': array(['EFO_0004211', 'EFO_0003095', 'MONDO_0021187', 'HP_0003124',
       'Orphanet_309005', 'EFO_1001249'], dtype=object), 'count': 6}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3697617,"Cc1cc(Oc2ncccc2C(F)(F)F)ccc1-c1c(C)c(=O)[nH]c(=O)n1C_|_AKQXQLUNFKDZBN-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAVAPADON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CVL-751' 'Cvl-751' 'PF-06649751' 'Pf-06649751' 'Tavapadon']_|_[('drugbank', array(['DB14899'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0001421', 'EFO_0003086'], dtype=object), 'count': 3}_|_[ENSG00000184845,ENSG00000169676]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3989693,"CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.O=C(O)C(O)C(O)C(=O)O_|_VNVNZKCCDVFGAP-NMFAMCKASA-N_|_Small molecule_|_False_|_LEVALBUTEROL TARTRATE_|_2005.0_|_4.0_|_CHEMBL1002_|_False_|_True_|_['Xopenex hfa']_|_['Levalbuterol tartrate' 'Levosalbutamol tartrate']_|_[('DailyMed', array(['levalbuterol%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2005 and has 1 investigational indication."
CHEMBL3989908,"CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1_|_DYLUUSLLRIQKOE-UHFFFAOYSA-N_|_Small molecule_|_True_|_ENASIDENIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AG-221' 'Ag 221' 'CC-90007 Free Base' 'Enasidenib']_|_[('drugbank', array(['DB13874'], dtype=object))]_|_['CHEMBL3989931']_|_{'rows': array(['EFO_0000222', 'EFO_0000565', 'MONDO_0044881', 'EFO_0000616',
       'EFO_1001779', 'EFO_0001378', 'MONDO_0004992', 'EFO_0001421',
       'EFO_0000198', 'EFO_0000222'], dtype=object), 'count': 10}_|_[ENSG00000182054]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297436,"Cc1nc(-c2cccnc2)sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1_|_LAMQVIQMVKWXOC-UHFFFAOYSA-N_|_Small molecule_|_False_|_SRT-2104_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SRT2104' 'Srt-2104' 'Srt2104']_|_[('drugbank', array(['DB12186'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000096', 'EFO_0000341', 'EFO_0000676', 'EFO_0009851',
       'HP_0100806', 'EFO_0000729', 'MONDO_0005148'], dtype=object), 'count': 7}_|_[ENSG00000096717]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4297452,"C[N+](C)(C)CCO.[O-]c1ccc(Cc2cc3cccccc-3c2)cc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O_|_UKOOBSDARBTSHN-NGOMLPPMSA-M_|_Small molecule_|_False_|_YM-543_|_nan_|_2.0_|_CHEMBL2397450_|_False_|_False_|_[]_|_['ASP-543' 'YM 543' 'YM543' 'Ym-543' 'Ym543']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297549,"nan_|_nan_|_Protein_|_False_|_HUMAN C1-ESTERASE INHIBITOR_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Cinryze']_|_['Berinert' 'C1 inhibitor human' 'C1-inhibitor, plasma derived' 'Cinryze'
 'Human c1-esterase inhibitor' 'RVG-19303']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cinryze'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1002048', 'EFO_0005532', 'EFO_0003884', 'MONDO_0100096',
       'MONDO_0019623', 'EFO_0004256'], dtype=object), 'count': 6}_|_[ENSG00000088926,ENSG00000182326,ENSG00000131187,ENSG00000164344]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hereditary angioedema and has 5 investigational indications."
CHEMBL4650293,"nan_|_nan_|_Antibody drug conjugate_|_False_|_APRUTUMAB IXADOTIN_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Aprutumab ixadotin' 'BAY 1187982' 'BAY-1187982' 'BAY1187982']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000066468,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL513922,"CCN(Cc1ccccc1)C(=O)Cn1c(=O)n(C)c2cnc(-c3ccccc3)nc21_|_NBMBIEOUVBHEBM-UHFFFAOYSA-N_|_Small molecule_|_False_|_EMAPUNIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AC-5216' 'Emapunil' 'XBD-173' 'XBD173']_|_[('drugbank', array(['DB12666'], dtype=object))]_|_['CHEMBL2206281']_|_{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}_|_[ENSG00000100300]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL527,"CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O_|_QYSPLQLAKJAUJT-UHFFFAOYSA-N_|_Small molecule_|_True_|_PIROXICAM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Brexidol' 'Feldene' 'Feldene 20' 'Feldene p' 'Flamatrol' 'Kentene'
 'Larapam' 'Piroflam 10' 'Piroflam 20' 'Piroxicam' 'Pirozip 10'
 'Pirozip 20']_|_['CP-16,171' 'CP-16171' 'NSC-666076' 'Piroxicam']_|_[('DailyMed', array(['piroxicam'], dtype=object)), ('PubChem', array(['11111641', '11111642', '11113322', '124881135', '144203782',
       '144207349', '170464817', '26746904', '26751443', '50085963',
       '50103896', '511550', '856007', '859011'], dtype=object)), ('Wikipedia', array(['Piroxicam'], dtype=object)), ('drugbank', array(['DB00554'], dtype=object)), ('chEBI', array(['8249'], dtype=object))]_|_['CHEMBL2106953' 'CHEMBL1418195']_|_{'rows': array(['EFO_0000685', 'EFO_0005752', 'HP_0002829', 'EFO_1001896',
       'MONDO_0005178', 'EFO_1001412', 'EFO_0004616', 'EFO_0003843',
       'EFO_0005755', 'HP_0003326'], dtype=object), 'count': 10}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200989,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H]([C@@H](O)C[C@@]21C)[C@@]1(C)C=CC(=O)C=C1C[C@H]3Cl_|_DJHCCTTVDRAMEH-DUUJBDRPSA-N_|_Small molecule_|_False_|_ALCLOMETASONE DIPROPIONATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Aclovate' 'Alclometasone dipropionate' 'Modrasone']_|_['Alclometasone' 'Alclometasone 17,21-dipropionate'
 'Alclometasone dipropionate' 'NSC-758914' 'SCH 22219' 'SCH-22219']_|_[('DailyMed', array(['alclometasone%20dipropionate'], dtype=object)), ('PubChem', array(['144204277'], dtype=object)), ('chEBI', array(['31184'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000701', 'EFO_0005752'], dtype=object), 'count': 3}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for skin disease and eye inflammation and has 1 investigational indication."
CHEMBL1201572,"nan_|_nan_|_Protein_|_True_|_ETANERCEPT_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Benepali' 'Enbrel']_|_['Chs-0214' 'Davictrel' 'Dwp-422' 'Enia-11' 'Erelzi' 'Etanercept'
 'Etanercept (enbrel)' 'Etanercept biosimilar (gp-2015)'
 'Etanercept biosimilar (sandoz)' 'Etanercept biosimilar (sb-4)'
 'Etanercept szzs' 'Etanercept ykro' 'Etanercept-szzs' 'Etanercept-ykro'
 'Eticovo' 'GP-2015' 'GP2015' 'GP2015C' 'HD203' 'Hd-203' 'L04ab01'
 'LBEC0101' 'Lbec-0101' 'RHU TNFR:FC' 'RHU-TNFR:FC' 'TNFR-IMMUNOADHESIN'
 'Tunex']_|_[('DailyMed', array(['etanercept'], dtype=object)), ('DrugCentral', array(['4978'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/benepali'],
      dtype=object)), ('Wikipedia', array(['Etanercept'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002039', 'MONDO_0004979', 'MONDO_0003937', 'EFO_0009688',
       'MONDO_0013730', 'EFO_0003884', 'EFO_0003778', 'EFO_0005279',
       'EFO_0004208', 'EFO_0005297', 'MONDO_0019391', 'EFO_0007323',
       'EFO_0000616', 'EFO_1000726', 'HP_0100727', 'EFO_0004719',
       'MONDO_0005147', 'EFO_0005761', 'EFO_0000713', 'EFO_0004246',
       'MONDO_0024280', 'HP_0000360', 'EFO_0000341', 'HP_0011868',
       'HP_0004326', 'EFO_0000398', 'MONDO_0017816', 'EFO_0002609',
       'EFO_1001494', 'EFO_0009448', 'EFO_0003898', 'EFO_0000565',
       'EFO_0000685', 'EFO_0000699', 'EFO_0002687', 'EFO_0007430',
       'EFO_0003106', 'EFO_0000764', 'EFO_0000095', 'MONDO_0008315',
       'MONDO_0004975', 'EFO_0000540', 'EFO_0000198', 'MP_0001845',
       'EFO_0003834', 'EFO_0000195', 'EFO_0004599', 'EFO_0008997',
       'EFO_1000710', 'EFO_0008518', 'EFO_0000676', 'MONDO_0002959',
       'EFO_0004276'], dtype=object), 'count': 53}_|_[ENSG00000232810]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 8 approved and 45 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1237022,"nan_|_nan_|_Antibody_|_True_|_TOCILIZUMAB_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Actemra' 'Actemra roactemra' 'Roactemra']_|_['ATLIZUMAB' 'Actemra' 'BAT-1806' 'BAT1806' 'Bat1806' 'MRA' 'MSB-11456'
 'MSB11456' 'R-1569' 'RG-1569' 'RHPM-1' 'RO-4877533' 'Tocilizumab'
 'Tocilizumab biosimilar (bat-1806)' 'Tocilizumab biosimilar (msb11456)']_|_[('DailyMed', array(['tocilizumab'], dtype=object)), ('DrugCentral', array(['4933'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra'],
      dtype=object)), ('Wikipedia', array(['Tocilizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001513', 'EFO_0000565', 'MONDO_0000845',
       'EFO_0000540', 'EFO_0000095', 'EFO_1000926', 'EFO_0000222',
       'EFO_0000702', 'EFO_0007328', 'EFO_0000094', 'EFO_0003818',
       'EFO_0008586', 'EFO_0003780', 'EFO_0000685', 'EFO_1000986',
       'EFO_1001469', 'EFO_0000474', 'EFO_0004256', 'HP_0001945',
       'EFO_0008518', 'EFO_0007135', 'EFO_0004991', 'EFO_0008528',
       'EFO_1000637', 'EFO_1001165', 'MONDO_0007915', 'EFO_0007541',
       'EFO_0000519', 'EFO_0003106', 'MONDO_0005147', 'EFO_1001119',
       'MONDO_0015564', 'EFO_0001378', 'MONDO_0007254', 'EFO_1001231',
       'EFO_0000717', 'EFO_0000673', 'EFO_1001951', 'EFO_1001148',
       'EFO_0000403', 'EFO_0000764', 'EFO_0000694', 'EFO_1001806',
       'MONDO_0013730', 'EFO_0002609', 'EFO_0003060', 'MONDO_0002009',
       'EFO_0000756', 'MONDO_0004976', 'EFO_0000220', 'EFO_0003898',
       'EFO_0000398', 'EFO_1001209', 'EFO_0000182', 'MONDO_0008170',
       'MONDO_0044881', 'EFO_1001857', 'MONDO_0005090', 'MONDO_0018088',
       'EFO_0002618', 'EFO_0000574', 'EFO_1001466', 'EFO_0001361',
       'EFO_0004599', 'EFO_0000096', 'MONDO_0001187', 'EFO_0005952',
       'MONDO_0018906', 'EFO_0003884', 'MONDO_0100096', 'EFO_0009730',
       'MONDO_0015540'], dtype=object), 'count': 73}_|_[ENSG00000160712]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 6 approved and 67 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1571,"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2(C)OC(=O)CC[C@@H]12_|_BPEWUONYVDABNZ-DZBHQSCQSA-N_|_Small molecule_|_False_|_TESTOLACTONE_|_1969.0_|_4.0_|_nan_|_False_|_True_|_['Fludestrin' 'Teslac']_|_['NSC-23759' 'SQ 9538' 'SQ-9538' 'Teolit' 'Testolactone'
 'Testolactone ciii']_|_[('PubChem', array(['144205129', '85554'], dtype=object)), ('Wikipedia', array(['Testolactone'], dtype=object)), ('drugbank', array(['DB00894'], dtype=object)), ('chEBI', array(['9460'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0000088'], dtype=object), 'count': 1}_|_[ENSG00000137869]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969 and has 1 investigational indication."
CHEMBL1743070,"nan_|_nan_|_Antibody_|_False_|_SILTUXIMAB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Sylvant']_|_['CLLB8' 'CNTO-328' 'Siltuximab']_|_[('DailyMed', array(['siltuximab'], dtype=object)), ('DrugCentral', array(['4977'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565', 'EFO_0000673', 'EFO_0005952', 'EFO_0001663',
       'MONDO_0100096', 'MONDO_0005147', 'EFO_0000540', 'EFO_0000222',
       'EFO_0000198', 'EFO_0000203', 'EFO_0000681', 'MONDO_0015564',
       'MONDO_0008315', 'MONDO_0005090', 'EFO_1001332', 'EFO_0001378',
       'MONDO_0002367'], dtype=object), 'count': 17}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 14 investigational indications."
CHEMBL17976,"C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@@H]41)O2_|_DSDNAKHZNJAGHN-MXTYGGKSSA-N_|_Small molecule_|_False_|_RESINIFERATOXIN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Neuroclastin']_|_['Lopain' 'MTX-71' 'Mtx-071' 'RTX' 'Resiniferatoxin']_|_[('PubChem', array(['26755740'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RESINIFERATOXIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06515'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010582', 'EFO_0003843', 'EFO_0801084', 'EFO_0004616'],
      dtype=object), 'count': 4}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL1923502,"C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1.Cl.O_|_ZWIXEQBDJMFCMN-DHHNQDMHSA-N_|_Small molecule_|_False_|_ULIMORELIN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL1963249_|_False_|_False_|_[]_|_['TZP-101' 'Ulimorelin hydrochloride'
 'Ulimorelin hydrochloride monohydrate']_|_nan_|_nan_|_{'rows': array(['EFO_1000948', 'MONDO_0004567'], dtype=object), 'count': 2}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2104967,"CCOCc1cc(OC)c(-c2ccc(C[C@H](NC(=O)c3c(F)cccc3F)C(=O)O)cc2)c(OC)c1_|_YLFZHHDVRSYTKT-NRFANRHFSA-N_|_Small molecule_|_False_|_FIRATEGRAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Firategrast' 'SB-683699']_|_[('drugbank', array(['DB12732'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 2}_|_[ENSG00000150093,ENSG00000115232,ENSG00000139626]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2107341,"OCCOCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1_|_NKZTZAQIKKGTDB-QPLCGJKRSA-N_|_Small molecule_|_False_|_FISPEMIFENE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fispemifene' 'HM-101' 'HM-101a']_|_[('drugbank', array(['DB06640'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004234', 'MONDO_0002146', 'EFO_0004714', 'MONDO_0018555'],
      dtype=object), 'count': 4}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2108752,"nan_|_nan_|_Unknown_|_False_|_PEGAPTANIB OCTASODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Pegaptanib octasodium']_|_[('DrugCentral', array(['4905'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004683'], dtype=object), 'count': 1}_|_[ENSG00000112715]_|_Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109205,"nan_|_nan_|_Protein_|_False_|_COAGULATION FACTOR IX RECOMBINANT HUMAN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Benefix' 'Rixubis']_|_['Coagulation factor ix recombinant human' 'Factor ix,recombinant'
 'Nonacog alfa' 'Nonacog gamma' 'Recombinant factor ix']_|_[('DrugCentral', array(['5163'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/benefix',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/rixubis'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for hemophilia b."
CHEMBL2109390,"nan_|_nan_|_Antibody_|_False_|_MAB-425_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MAB-425' 'Mab-425']_|_nan_|_nan_|_{'rows': array(['EFO_0000326'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109399,"nan_|_nan_|_Antibody drug conjugate_|_False_|_T-DM1_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['T-DM1' 'T-dm1']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000141736]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109449,"nan_|_nan_|_Antibody_|_False_|_MEDI-570_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MEDI-570' 'Medi 570' 'Medi-570']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000163600]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL257704,"CN(C)CCO/N=C(/C=C/c1ccc(O)cc1)c1ccccc1F_|_VAIOZOCLKVMIMN-PRJWTAEASA-N_|_Small molecule_|_False_|_EPLIVANSERIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Eplivanserin' 'SR-46349' 'SR46349']_|_[('drugbank', array(['DB12177'], dtype=object))]_|_['CHEMBL2103845']_|_{'rows': array(['EFO_0008568', 'EFO_0004698'], dtype=object), 'count': 2}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3329435,"Cc1nc2c(N3CCNCC3)cccc2n1S(=O)(=O)c1ccccc1_|_MAYQIFVKVAUMPD-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-05212377_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-05212377' 'PF-5212377' 'Pf-05212377' 'SAM-760' 'WYE-103760']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000158748]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545036,"Cc1cc(C)c(N)c(C#Cc2cccc(F)c2)n1_|_MEDCLNYIYBERKO-UHFFFAOYSA-N_|_Small molecule_|_False_|_RASEGLURANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADX-10059' 'ADX10059' 'Adx-10059' 'Adx10059' 'Raseglurant']_|_nan_|_['CHEMBL3894333']_|_{'rows': array(['EFO_0003948', 'MONDO_0005277'], dtype=object), 'count': 2}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545104,"nan_|_nan_|_Protein_|_False_|_MODIMELANOTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABT-719' 'Ap-214' 'Ap214' 'Modimelanotide' 'ZP-1480' 'ZP1480']_|_nan_|_nan_|_{'rows': array(['EFO_0001666', 'HP_0001919'], dtype=object), 'count': 2}_|_[ENSG00000258839,ENSG00000124089]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545147,nan_|_nan_|_Small molecule_|_False_|_IMD-2560_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Imd-2560']_|_nan_|_nan_|_nan_|_[ENSG00000104365]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545268,nan_|_nan_|_Small molecule_|_False_|_MLN3126_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mln3126']_|_nan_|_nan_|_nan_|_[ENSG00000173585]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545359,nan_|_nan_|_Small molecule_|_False_|_ARRY-300_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Arry-300' 'MET-300']_|_nan_|_nan_|_nan_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707266,"CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1.O=C(O)CCC(=O)O_|_NHANOMFABJQAAH-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIBOCICLIB SUCCINATE_|_2017.0_|_4.0_|_CHEMBL3545110_|_False_|_True_|_['Kisqali']_|_['Birociclib' 'LEE-011-BBA' 'LEE011-BBA' 'Ribociclib succinate']_|_[('DailyMed', array(['ribociclib%20succinate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000305', 'EFO_0003869', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000105810,ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved indications."
CHEMBL3989988,"nan_|_nan_|_Antibody_|_False_|_MODOTUXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['1024 DS' '1024-DS' 'Modotuximab' 'Zatuximab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL406381,"CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl_|_VPBYZLCHOKSGRX-UHFFFAOYSA-N_|_Small molecule_|_False_|_KRN-633_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['K00589A' 'KRN-633' 'KRN633' 'Krn-633']_|_[('PubChem', array(['174006598'], dtype=object))]_|_nan_|_nan_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL4594330,"nan_|_nan_|_Antibody_|_False_|_DAXDILIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Daxdilimab' 'HZN-7734' 'MEDI-7734' 'MEDI7734' 'Medi 7734' 'Medi7734'
 'VIB7734' 'Vib-7734' 'Vib7734']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DAXDILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004610', 'MONDO_0019558', 'MONDO_0020122', 'EFO_0005809',
       'EFO_0005761', 'EFO_0004192', 'MONDO_0007915'], dtype=object), 'count': 7}_|_[ENSG00000239961]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4594393,"O=C([O-])CCCO.O=C([O-])CCCO.[Ca+2]_|_AZRRVLSHRWGNRS-UHFFFAOYSA-L_|_Small molecule_|_False_|_CALCIUM OXYBATE_|_2020.0_|_4.0_|_CHEMBL1342_|_False_|_True_|_[]_|_['Oxybate calcium']_|_[('DailyMed', array(['calcium%20oxybate'], dtype=object))]_|_nan_|_nan_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020."
CHEMBL4802159,"N#Cc1ccc(N2C[C@H](N)C[C@H](C(F)(F)F)C2)c2cccnc12_|_BJXYHBKEQFQVES-NWDGAFQWSA-N_|_Small molecule_|_False_|_ENPATORAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Enpatoran' 'M-5049' 'M5049']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENPATORAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007915', 'MONDO_0100096', 'EFO_0000398', 'MONDO_0100096',
       'EFO_0003834'], dtype=object), 'count': 5}_|_[ENSG00000101916,ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL53418,"O=C1c2cccc(O)c2C(=O)c2c(O)cccc21_|_QBPFLULOKWLNNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_DANTHRON_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Chrysazin' 'Danthron' 'Dantron' 'NSC-38626' 'NSC-646568'
 'Pilules vinchy n.f.']_|_[('PubChem', array(['144204673', '144208184', '170465532', '17389963', '26747347',
       '73151', '8139970'], dtype=object)), ('Wikipedia', array(['Dantron'], dtype=object)), ('drugbank', array(['DB04816'], dtype=object)), ('chEBI', array(['3682'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002019'], dtype=object), 'count': 1}_|_[ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for constipation. It was withdrawn in at least one region."
CHEMBL1000,"O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1_|_ZKLPARSLTMPFCP-UHFFFAOYSA-N_|_Small molecule_|_False_|_CETIRIZINE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AC-170' 'Cetiderm' 'Cetirizine']_|_[('PubChem', array(['174007233', '90341832'], dtype=object)), ('Wikipedia', array(['Cetirizine'], dtype=object)), ('drugbank', array(['DB00341'], dtype=object)), ('chEBI', array(['3561'], dtype=object))]_|_['CHEMBL1201113' 'CHEMBL1607273']_|_{'rows': array(['EFO_0008521', 'HP_0000989', 'EFO_0004256', 'EFO_1001417',
       'MONDO_0005271', 'EFO_1001417', 'EFO_0005854', 'HP_0001742',
       'HP_0000989', 'MONDO_0005277', 'EFO_1000749', 'EFO_0007141',
       'MONDO_0005271', 'EFO_0004191', 'MONDO_0009291', 'EFO_0007141',
       'EFO_0005751', 'MONDO_0005301', 'EFO_0003956', 'HP_0000964',
       'MONDO_0002406', 'EFO_0005531', 'EFO_0000274', 'EFO_0005854',
       'EFO_0003956', 'EFO_0003830'], dtype=object), 'count': 26}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 9 approved and 17 investigational indications."
CHEMBL1922660,"CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1_|_DFQGDHBGRSTTHX-UHFFFAOYSA-N_|_Small molecule_|_False_|_FIBOFLAPON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AM-803' 'Am803' 'Fiboflapon' 'GSK-2190915' 'GSK2190915' 'GSK2190915B']_|_[('drugbank', array(['DB06346'], dtype=object))]_|_['CHEMBL1922673']_|_{'rows': array(['MONDO_0004979', 'EFO_1001348', 'MONDO_0009061', 'MONDO_0004979'],
      dtype=object), 'count': 4}_|_[ENSG00000132965]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1951143,"CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1_|_AMEROGPZOLAFBN-UHFFFAOYSA-N_|_Small molecule_|_False_|_FIMASARTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fimasartan']_|_[('drugbank', array(['DB09279'], dtype=object))]_|_['CHEMBL1951146']_|_{'rows': array(['MONDO_0001134', 'EFO_0000537', 'EFO_0003086', 'MONDO_0021187',
       'EFO_0000319'], dtype=object), 'count': 5}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2105756,"COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O_|_RQXMKRRBJITKRN-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIVOZANIB HYDROCHLORIDE_|_2017.0_|_4.0_|_CHEMBL1289494_|_False_|_True_|_['Fotivda']_|_['(tivozanib hydrochloride hydrate' 'AV-951' 'Tivozanib hydrochloride'
 'Tivozanib hydrochloride monohydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fotivda'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0001421', 'EFO_0000681'], dtype=object), 'count': 3}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000157404,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for renal cell carcinoma and has 2 investigational indications."
CHEMBL289469,"CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2_|_MFWNKCLOYSRHCJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_GRANISETRON_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Kytril' 'Sancuso' 'Sustol']_|_['APF-530' 'APF530' 'BRL 43694' 'BRL-43694' 'Granisetron' 'LY-278584']_|_[('DailyMed', array(['granisetron'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso'],
      dtype=object)), ('PubChem', array(['90340785'], dtype=object))]_|_['CHEMBL1237080']_|_{'rows': array(['MONDO_0004992', 'HP_0000989', 'HP_0002018', 'HP_0002018',
       'EFO_0001061', 'MONDO_0100342', 'EFO_0000616', 'EFO_0007359',
       'HP_0002017', 'EFO_0000182', 'EFO_0006911', 'HP_0002013',
       'MONDO_0004992', 'EFO_0000574', 'HP_0002017', 'EFO_0006911',
       'EFO_0000616', 'EFO_0004888', 'HP_0100806', 'EFO_1000948'],
      dtype=object), 'count': 20}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 8 investigational indications."
CHEMBL3039525,"CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1_|_UQRCJCNVNUFYDX-UHFFFAOYSA-N_|_Small molecule_|_False_|_GOLVATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E-7050' 'E7050' 'Golvatinib']_|_[('drugbank', array(['DB11977'], dtype=object))]_|_['CHEMBL3039500']_|_{'rows': array(['MONDO_0004992', 'EFO_0000181', 'MONDO_0001056', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000128052,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3039598,"CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C_|_BIDNLKIUORFRQP-XYGFDPSESA-N_|_Small molecule_|_True_|_FOSINOPRIL_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Monopril']_|_['C09AA09' 'Fosenopril' 'Fosinopril' 'SQ-28555']_|_[('drugbank', array(['DB00492'], dtype=object))]_|_['CHEMBL3039596']_|_{'rows': array(['EFO_0000319', 'EFO_0000537', 'EFO_0003144', 'EFO_0003777',
       'EFO_0000401', 'EFO_0000537'], dtype=object), 'count': 6}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3833344,"nan_|_nan_|_Antibody_|_False_|_GANCOTAMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gancotamab' 'MM-302']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000141736,ENSG00000131747]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297302,"CCS(=O)(=O)c1ccc(Oc2cc(O[C@@H](C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1.CS(=O)(=O)O_|_PIDNRTWDGDJKSQ-UQKRIMTDSA-N_|_Small molecule_|_False_|_MK-0941_|_nan_|_2.0_|_CHEMBL3580737_|_False_|_False_|_[]_|_['MK0941' 'Mk-0941' 'Mk0941']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297713,"nan_|_nan_|_Antibody_|_False_|_CABIRALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cabiralizumab' 'Fpa-008' 'Fpa008']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_1000359', 'EFO_0000211', 'EFO_0000181',
       'EFO_0002618', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000182'],
      dtype=object), 'count': 8}_|_[ENSG00000182578]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL4297732,"nan_|_nan_|_Antibody_|_False_|_ZILTIVEKIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['COR-001' 'COR001' 'Cor-001' 'Ziltivekimab']_|_nan_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0003144', 'EFO_0004272'], dtype=object), 'count': 3}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4301162,"COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1_|_UBZPNQRBUOBBLN-PWRODBHTSA-O_|_Small molecule_|_False_|_SERDEXMETHYLPHENIDATE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Serdexmethylphenidate']_|_nan_|_['CHEMBL4298139']_|_{'rows': array(['EFO_0003888', 'MONDO_0018044'], dtype=object), 'count': 2}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder and has 1 investigational indication."
CHEMBL4594457,"nan_|_nan_|_Unknown_|_False_|_AL-78898A_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(trp(me)4)-ac-compstatin' '4(1mew)' 'AL-78898A' 'Al-78898a'
 'Compstatin analog 4(1mew)' 'POT-4' 'Pot-4']_|_nan_|_nan_|_{'rows': array(['EFO_0001365', 'EFO_1001492'], dtype=object), 'count': 2}_|_[ENSG00000125730]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5095032,"Cl.O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12_|_CMRLNEYJEPELSM-BTQNPOSSSA-N_|_Small molecule_|_False_|_FACINICLINE HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL2151439_|_False_|_False_|_[]_|_['Facinicline hydrochloride' 'MEM 3454' 'MEM-3454' 'MEM3454' 'RG-3487'
 'RG3487' 'Rg3487']_|_nan_|_nan_|_{'rows': array(['MONDO_0005090', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000175344,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL52885,"Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21_|_OVSKGTONMLKNPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENMD-981693_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ENMD 981693' 'ENMD-2076' 'ENMD-981693' 'Enmd-2076 free base'
 'Enmd-981693' 'MKC-1' 'Mkc 1' 'R-440' 'RO 31-7453' 'RO-31-7453'
 'Ro-317453']_|_[('drugbank', array(['DB05608'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0003060', 'EFO_0002618', 'MONDO_0007254',
       'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000113721,ENSG00000134853,ENSG00000087586,ENSG00000122025,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL916,"CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O_|_COKMIXFXJJXBQG-NRFANRHFSA-N_|_Small molecule_|_False_|_TIROFIBAN_|_1998.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Aggrastat' 'Agrastat' 'L-700462' 'MK-383' 'Tirofiban']_|_[('Wikipedia', array(['Tirofiban'], dtype=object)), ('drugbank', array(['DB00775'], dtype=object)), ('chEBI', array(['9605'], dtype=object))]_|_['CHEMBL3189072' 'CHEMBL1704']_|_{'rows': array(['MONDO_0100096', 'EFO_0004286', 'EFO_0000612', 'HP_0004419',
       'EFO_0007541', 'EFO_0001645', 'EFO_0000712', 'EFO_0005672',
       'EFO_0009686', 'HP_0002140', 'EFO_0008583', 'EFO_0000612',
       'HP_0000083'], dtype=object), 'count': 13}_|_[ENSG00000259207,ENSG00000005961]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for myocardial infarction and recurrent thrombophlebitis and has 11 investigational indications."
CHEMBL1170,"CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C_|_PDMMFKSKQVNJMI-BLQWBTBKSA-N_|_Small molecule_|_False_|_TESTOSTERONE PROPIONATE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_['Testosterone propionate']_|_['NRB-03689' 'NSC-9166' 'Orchisterone' 'Testosteron 17-propionate'
 'Testosterone 17.beta.-propionate' 'Testosterone Propionate'
 'Testosterone propionate' 'Testosterone propionate ciii'
 'Testosteroni propionas' 'Virormone']_|_[('PubChem', array(['11112138', '144203881', '144212587', '170464835', '56463044'],
      dtype=object)), ('drugbank', array(['DB01420'], dtype=object)), ('chEBI', array(['9466'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001271'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and has 1 investigational indication."
CHEMBL1200367,"CCOP(=O)(OCC)SCC[N+](C)(C)C.[I-]_|_OVXQHPWHMXOFRD-UHFFFAOYSA-M_|_Small molecule_|_False_|_ECHOTHIOPHATE IODIDE_|_1960.0_|_4.0_|_CHEMBL1201341_|_False_|_True_|_['Phospholine iodide']_|_['217-MI' 'Echodide' 'Echothiophate iodide' 'Ecostigmine iodide'
 'Ecothiopate iodide']_|_[('chEBI', array(['59849'], dtype=object))]_|_nan_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1201178,"CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN_|_CETWSOHVEGTIBR-FORAGAHYSA-N_|_Small molecule_|_True_|_LISDEXAMFETAMINE DIMESYLATE_|_2007.0_|_4.0_|_CHEMBL1201222_|_False_|_True_|_['Elvanse' 'Elvanse adult' 'Vyvanse']_|_['Lisdexamfetamine dimesilate' 'Lisdexamfetamine dimesylate'
 'Lisdexamfetamine dimethanesulfonate' 'Lisdexamfetamine mesilate'
 'Lisdexamphetamine dimesilate' 'NRP-104' 'NRP104' 'SPD-489' 'SPD489'
 'Tyvense']_|_[('DailyMed', array(['lisdexamfetamine%20dimesylate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'MONDO_0002009', 'EFO_0005203', 'MONDO_0002277',
       'MONDO_0005090', 'EFO_0005924', 'EFO_0004698', 'EFO_0003890',
       'EFO_0005204', 'MONDO_0005041', 'EFO_0003888'], dtype=object), 'count': 11}_|_[ENSG00000103546,ENSG00000165646,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201260,"C/N=C(\NC)NCc1ccccc1_|_NIVZHWNOUVJHKV-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETHANIDINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betanidine' 'Bethanidine']_|_[('Wikipedia', array(['Bethanidine'], dtype=object)), ('drugbank', array(['DB00217'], dtype=object)), ('chEBI', array(['37937'], dtype=object))]_|_['CHEMBL2110368']_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for hypertension."
CHEMBL1201340,"C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1_|_LCTZPQRFOZKZNK-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHEMANIL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Diphemanil' 'Diphemanil cation' 'Diphemanil ion']_|_[('PubChem', array(['11112168'], dtype=object)), ('drugbank', array(['DB13720'], dtype=object))]_|_['CHEMBL1200880']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease."
CHEMBL1255794,"CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2_|_GWNOTCOIYUNTQP-FQLXRVMXSA-N_|_Small molecule_|_False_|_APLAVIROC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AK-602' 'Aplaviroc' 'GSK-873140' 'GW-873140' 'GW873140']_|_[('drugbank', array(['DB06497'], dtype=object))]_|_['CHEMBL1668019']_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1425,"Sc1ncnc2nc[nH]c12_|_GLVAUDGFNGKCSF-UHFFFAOYSA-N_|_Small molecule_|_False_|_MERCAPTOPURINE ANHYDROUS_|_1953.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mercaptopurine anhydrous']_|_[('PubChem', array(['124891196', '144204709', '144209789', '170464985', '174006957',
       '26748122', '49675007', '50086850', '538245'], dtype=object)), ('Wikipedia', array(['Mercaptopurine'], dtype=object)), ('drugbank', array(['DB01033'], dtype=object)), ('chEBI', array(['2208'], dtype=object))]_|_['CHEMBL1200751']_|_{'rows': array(['MONDO_0000873', 'EFO_0000309', 'EFO_0000565', 'EFO_0000574',
       'MONDO_0044917', 'MONDO_0019460', 'EFO_0000224', 'EFO_0003833',
       'EFO_0004289', 'MONDO_0003268', 'EFO_0002501', 'EFO_0000729',
       'MONDO_0000870', 'EFO_0000209', 'EFO_0000616', 'EFO_0000222',
       'EFO_0000094', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872',
       'EFO_0002499', 'EFO_1000318', 'EFO_0000220'], dtype=object), 'count': 23}_|_[ENSG00000128059]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 5 approved and 18 investigational indications."
CHEMBL14370,"CCOc1ccccc1OC(c1ccccc1)C1CNCCO1_|_CBQGYUDMJHNJBX-UHFFFAOYSA-N_|_Small molecule_|_False_|_REBOXETINE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Edronax']_|_['Reboxetine']_|_[('Wikipedia', array(['Reboxetine'], dtype=object))]_|_['CHEMBL2146087']_|_{'rows': array(['MONDO_0002009', 'EFO_0003888', 'EFO_0005230', 'EFO_0005687',
       'HP_0000726', 'EFO_0003843', 'HP_0012378', 'EFO_0001358',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_1000783', 'MONDO_0002009'],
      dtype=object), 'count': 12}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for major depressive disorder and depressive disorder and has 10 investigational indications."
CHEMBL1514,"CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1_|_XBMIVRRWGCYBTQ-AVRDEDQJSA-N_|_Small molecule_|_False_|_LEVOMETHADYL ACETATE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Orlaam']_|_['LAA-M' 'LAAM' 'Levacetylmethadol' 'Levo-alphacetylmethadol'
 'Levoacetyl methadol' 'Levomethadyl acetate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orlaam'],
      dtype=object)), ('Wikipedia', array(['Levacetylmethadol'], dtype=object)), ('drugbank', array(['DB01227'], dtype=object)), ('chEBI', array(['6441'], dtype=object))]_|_['CHEMBL1200817']_|_{'rows': array(['EFO_0005611', 'EFO_0003890'], dtype=object), 'count': 2}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for opioid dependence and drug dependence."
CHEMBL1742981,"nan_|_nan_|_Antibody_|_False_|_ABAGOVOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACA-125' 'Abagovomab' 'MEN-2234']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'MONDO_0002158', 'MONDO_0002087'], dtype=object), 'count': 3}_|_[ENSG00000181143]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1800159,"CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1_|_AOMXMOCNKJTRQP-UHFFFAOYSA-N_|_Small molecule_|_False_|_RELUGOLIX_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Orgovyx']_|_['Relugolix' 'TAK-385' 'Tak-385']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orgovyx'],
      dtype=object)), ('drugbank', array(['DB11853'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000731', 'EFO_0000196', 'EFO_0000673', 'MONDO_0008315',
       'EFO_0001065', 'EFO_0003843', 'MONDO_0008315', 'EFO_0000616'],
      dtype=object), 'count': 8}_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 4 investigational indications."
CHEMBL2105872,"CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12.CS(=O)(=O)O_|_DUGMCDWNXXFHDE-VZYDHVRKSA-N_|_Small molecule_|_False_|_IBUTAMOREN MESYLATE_|_nan_|_2.0_|_CHEMBL13817_|_False_|_False_|_[]_|_['Ibutamoren mesilate' 'Ibutamoren mesylate' 'MK-0677' 'MK-677']_|_nan_|_nan_|_{'rows': array(['EFO_0005687'], dtype=object), 'count': 1}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107786,Cc1ccc2c(c1CCC(=O)O)CC[C@@H](NS(=O)(=O)c1ccc(Cl)cc1)C2_|_HWEOXFSBSQIWSY-MRXNPFEDSA-N_|_Small molecule_|_False_|_TERUTROBAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Triplion']_|_['S18886' 'Terutroban']_|_nan_|_nan_|_nan_|_[ENSG00000006638]_|_Small molecule drug with a maximum clinical trial phase of III.
CHEMBL2108029,"nan_|_nan_|_Antibody_|_False_|_ERTUMAXOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Rexomun']_|_['Ertumaxomab']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000141736,ENSG00000198851]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109124,"nan_|_nan_|_Antibody drug conjugate_|_False_|_DORLIMOMAB ARITOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dorlimomab aritox' 'MDX-RA' 'ST-1 4197X-RA']_|_nan_|_nan_|_nan_|_[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II."
CHEMBL2364648,"nan_|_nan_|_Antibody_|_False_|_GUSELKUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Tremfya']_|_['CNTO 1959' 'CNTO-1959' 'Guselkumab']_|_[('DailyMed', array(['guselkumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008573', 'EFO_0000676', 'EFO_0000540', 'MONDO_0015597',
       'EFO_0000685', 'EFO_0005761', 'MONDO_0100017', 'EFO_1001494',
       'EFO_1001209', 'Orphanet_733', 'EFO_1000710', 'EFO_0000384',
       'EFO_0000717', 'EFO_0001060', 'EFO_0003778', 'EFO_0000729',
       'EFO_0002609'], dtype=object), 'count': 17}_|_[ENSG00000113302,ENSG00000110944]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 12 investigational indications."
CHEMBL277062,"O=C1CN=C(c2ccccn2)c2cc(Br)ccc2N1_|_VMIYHDSEFNYJSL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMAZEPAM_|_nan_|_4.0_|_nan_|_False_|_True_|_['Lexotan']_|_['Bromazepam' 'Bromazepam civ' 'Lexatin' 'Lexotanil' 'NSC-140669'
 'RO 5-3350' 'RO-5-3350']_|_[('Wikipedia', array(['Bromazepam'], dtype=object)), ('drugbank', array(['DB01558'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090'],
      dtype=object), 'count': 4}_|_[ENSG00000151834]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anxiety and has 3 investigational indications."
CHEMBL3092650,"O=C1CCCN1c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1_|_YFRBKEVUUCQYOW-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK239512_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-239512A' 'GSK239512' 'Gsk-239512' 'Gsk239512']_|_[('drugbank', array(['DB15120'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0003929', 'MONDO_0005301', 'MONDO_0005090',
       'HP_0000726'], dtype=object), 'count': 5}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3188034,"Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl.O_|_CUZMOIXUFHOLLN-UMVVUDSKSA-N_|_Small molecule_|_False_|_TRIPROLIDINE HYDROCHLORIDE_|_1983.0_|_4.0_|_CHEMBL855_|_False_|_True_|_['Actidil' 'Myidyl' 'Pro-actidil' 'Triprolidine hydrochloride']_|_['NSC-757361' 'Triprolidine hcl' 'Triprolidine hydrochloride']_|_[('DailyMed', array(['triprolidine%20hydrochloride'], dtype=object)), ('PubChem', array(['144208046'], dtype=object)), ('chEBI', array(['32265'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001742', 'EFO_0005854', 'EFO_0007214', 'EFO_0003956'],
      dtype=object), 'count': 4}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 4 approved indications."
CHEMBL3707277,"nan_|_nan_|_Antibody drug conjugate_|_False_|_DEPATUXIZUMAB MAFODOTIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABT-414' 'Abt-414' 'Depatuxizumab mafodotin']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_1001465', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000146648]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3786343,"C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1_|_FDMQDKQUTRLUBU-UHFFFAOYSA-N_|_Small molecule_|_False_|_OLMUTINIB_|_2016.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BI 1482694' 'BI-1482694' 'HM-61713' 'HM61713' 'Hm-61713' 'Olmutinib']_|_[('drugbank', array(['DB13164'], dtype=object))]_|_['CHEMBL3989930']_|_{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 2 investigational indications."
CHEMBL4297521,"COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(C(F)(F)F)nc2s1_|_DCXFIOLWWRXEQH-SSDOTTSWSA-N_|_Small molecule_|_False_|_PADSEVONIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Padsevonil' 'UCB-0942' 'UCB-1415943-000' 'UCB0942' 'UCB1415943-000'
 'Ucb0942']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PADSEVONIL/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14977'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'HP_0001250', 'EFO_0000474', 'EFO_0004263'],
      dtype=object), 'count': 4}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000159164,ENSG00000185518,ENSG00000122012]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5314405,COC(=O)/C(=C/c1cc(OC)cc(OC)c1)c1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1_|_IVAQJHSXBVHUQT-ZVHZXABRSA-N_|_Small molecule_|_False_|_CLX-0921_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Clx-0921' 'THR-0921']_|_nan_|_nan_|_nan_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1040,"C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12_|_JWUBBDSIWDLEOM-DTOXIADCSA-N_|_Small molecule_|_False_|_CALCIFEDIOL ANHYDROUS_|_1980.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Calcifediol' 'Calcifediol, anhydrous' 'Calcifediol,anhydrous']_|_[('PubChem', array(['144205540', '26754888', '50110817'], dtype=object)), ('drugbank', array(['DB00146'], dtype=object)), ('chEBI', array(['17933'], dtype=object))]_|_['CHEMBL3544909' 'CHEMBL4594399']_|_{'rows': array(['EFO_0003884', 'MONDO_0100096', 'HP_0001919', 'EFO_0005754',
       'EFO_0003918', 'EFO_0000612', 'EFO_1001173', 'EFO_0003762'],
      dtype=object), 'count': 8}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved and 5 investigational indications."
CHEMBL1201129,"Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1_|_XAUDJQYHKZQPEU-KVQBGUIXSA-N_|_Small molecule_|_False_|_DECITABINE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Dacogen' 'Decitabine']_|_[""2'-deoxy-5-azacytidine"" 'DAC' 'Decitabine' 'NSC-127716']_|_[('DailyMed', array(['decitabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen'],
      dtype=object)), ('PubChem', array(['144205864', '170465126', '47211573', '56324652', '57260149'],
      dtype=object)), ('Wikipedia', array(['Decitabine'], dtype=object)), ('drugbank', array(['DB01262'], dtype=object)), ('chEBI', array(['50131'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000096', 'EFO_0000224', 'EFO_0000403', 'EFO_0000326',
       'EFO_0000220', 'MONDO_0011382', 'MONDO_0003660', 'MONDO_0007254',
       'EFO_0000198', 'EFO_0002913', 'EFO_1000131', 'MONDO_0000870',
       'EFO_0003869', 'EFO_0000621', 'MONDO_0004643', 'EFO_1001996',
       'EFO_0003811', 'EFO_1001830', 'MONDO_0003659', 'EFO_0000756',
       'EFO_0007160', 'MONDO_0019472', 'EFO_0000183', 'EFO_0000641',
       'EFO_0002428', 'EFO_0004251', 'EFO_0003060', 'EFO_0004599',
       'MONDO_0008170', 'EFO_0002617', 'EFO_0005537', 'MONDO_0013730',
       'EFO_0000681', 'EFO_0000501', 'EFO_0001663', 'HP_0001915',
       'MONDO_0002158', 'EFO_0000196', 'EFO_0000180', 'EFO_0000211',
       'MONDO_0002280', 'EFO_0005952', 'EFO_0000565', 'EFO_0006859',
       'EFO_0000616', 'EFO_1001779', 'EFO_0000339', 'EFO_0001642',
       'HP_0001873', 'EFO_0000222', 'MONDO_0004992', 'EFO_0002939',
       'EFO_0000389', 'MONDO_0002087', 'MONDO_0000430', 'EFO_0001378',
       'EFO_0000574', 'EFO_0005922', 'EFO_0000309', 'EFO_1001469',
       'MONDO_0100096'], dtype=object), 'count': 61}_|_[ENSG00000130816,ENSG00000119772]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 7 approved and 54 investigational indications."
CHEMBL1201179,"CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1.O_|_XNRVGTHNYCNCFF-UHFFFAOYSA-N_|_Small molecule_|_True_|_LAPATINIB DITOSYLATE_|_2007.0_|_4.0_|_CHEMBL554_|_False_|_True_|_['Tykerb' 'Tyverb']_|_['GW-572016F' 'GW572016F' 'Lapatinib'
 'Lapatinib ditoluenesulfonate monohydrate' 'Lapatinib ditosylate'
 'Lapatinib ditosylate anhydrous' 'Lapatinib ditosylate monohydrate'
 'Lapatinib tosilate' 'Lapatinib tosilate hydrate' 'Tycerb']_|_[('DailyMed', array(['lapatinib%20ditosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0002892', 'MONDO_0008315', 'EFO_0002938', 'MONDO_0044926',
       'EFO_0000616', 'EFO_1001465', 'EFO_0000305', 'MONDO_0004986',
       'MONDO_0001187', 'EFO_1000294', 'EFO_1000158', 'EFO_1001512',
       'EFO_0000574', 'EFO_0006859', 'MONDO_0007254', 'EFO_0002618',
       'EFO_0006861', 'EFO_0003869', 'EFO_0006352'], dtype=object), 'count': 19}_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 15 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201320,"COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1_|_SUBDBMMJDZJVOS-DEOSSOPVSA-N_|_Small molecule_|_False_|_ESOMEPRAZOLE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['A02BC05' 'Esomeprazole' 'Inexium paranova' 'Omeprazole s-form'
 'Omeprazole, (s)-']_|_[('Wikipedia', array(['Esomeprazole'], dtype=object)), ('drugbank', array(['DB00736'], dtype=object)), ('chEBI', array(['50275'], dtype=object))]_|_['CHEMBL1200470' 'CHEMBL2146140' 'CHEMBL5279304' 'CHEMBL2105642'
 'CHEMBL5314366']_|_{'rows': array(['EFO_0008533', 'EFO_0000342', 'EFO_0004607', 'EFO_0000337',
       'EFO_0003948', 'EFO_1001095', 'EFO_0009454', 'MONDO_0005178',
       'HP_0004398', 'EFO_0000574', 'EFO_0004607', 'HP_0002239',
       'EFO_0007549', 'EFO_0009454', 'EFO_0003948', 'MONDO_0004247',
       'EFO_0004232', 'EFO_0002609', 'MONDO_0004247', 'EFO_0008533',
       'EFO_0003869', 'MONDO_0009061', 'MONDO_0007576', 'MP_0001914',
       'EFO_0000217', 'MONDO_0004979', 'EFO_0000668', 'EFO_0005762',
       'EFO_0000616', 'EFO_0003948', 'EFO_0001361', 'MONDO_0005148',
       'EFO_0007549', 'EFO_0010282', 'MONDO_0005178', 'EFO_0003948',
       'EFO_0010282', 'EFO_0004239', 'EFO_0004607', 'MONDO_0043839',
       'EFO_0003758', 'HP_0002018', 'EFO_0003898', 'HP_0100633',
       'EFO_0009454', 'EFO_0000685', 'EFO_0004607', 'EFO_0003756',
       'EFO_1000961'], dtype=object), 'count': 49}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 8 approved and 34 investigational indications."
CHEMBL1201574,"nan_|_nan_|_Unknown_|_True_|_ONABOTULINUMTOXINA_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Botox' 'Botox Cosmetic' 'Botox/botox cosmetic']_|_['Bontoxilysin' 'Botulin' 'Botulinum neurotoxin' 'Botulinum toxin'
 'Botulinum toxin type a purified neurotoxin complex' 'Onabotulinumtoxina'
 'RTI-150' 'RTI150']_|_[('DailyMed', array(['onabotulinumtoxina'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005279', 'EFO_1001896', 'EFO_1001887', 'HP_0030834',
       'EFO_0003897', 'EFO_1001434', 'EFO_1001466', 'MONDO_0011728',
       'EFO_0009550', 'EFO_0005422', 'EFO_1001993', 'Orphanet_93955',
       'EFO_0008521', 'MONDO_0005180', 'HP_0012532', 'HP_0000565',
       'EFO_0001073', 'HP_0002307', 'EFO_0003899', 'MONDO_0043839',
       'EFO_0000618', 'HP_0003419', 'HP_0000020', 'HP_0001347',
       'HP_0012390', 'HP_0000016', 'EFO_1000781', 'EFO_1000999',
       'EFO_0004212', 'EFO_0009523', 'HP_0000473', 'EFO_1000657',
       'EFO_1000391', 'EFO_0005762', 'EFO_1000948', 'HP_0000726',
       'EFO_1001054', 'EFO_0003877', 'EFO_0004234', 'MONDO_0005178',
       'MONDO_0005301', 'MONDO_0043510', 'EFO_0009453', 'HP_0001257',
       'EFO_0004270', 'EFO_0009619', 'HP_0002315', 'HP_0000989',
       'EFO_0003894', 'HP_0010992', 'EFO_0004616', 'MONDO_0004001',
       'EFO_0000275', 'EFO_0007159', 'EFO_1001250', 'EFO_0002618',
       'MONDO_0000485', 'HP_0000486', 'EFO_1000632', 'EFO_1001092',
       'MONDO_0002050', 'EFO_0002970', 'EFO_0000284', 'EFO_0004143',
       'EFO_0004273', 'HP_0001337', 'EFO_0002916', 'MONDO_0002471',
       'HP_0009926', 'EFO_0004269', 'EFO_1001866', 'EFO_1001219',
       'HP_0012228', 'EFO_0005306', 'EFO_0009846', 'EFO_0009625',
       'EFO_0000546', 'EFO_1000850', 'EFO_0004191', 'HP_0000975',
       'MONDO_0041052', 'EFO_0003911', 'EFO_0006865', 'EFO_0009430',
       'EFO_0003830', 'MONDO_0005277', 'HP_0003549', 'EFO_0003108',
       'HP_0000011', 'EFO_0000712', 'EFO_0007507', 'EFO_0006346',
       'EFO_1001919', 'HP_0001605', 'MONDO_0002009', 'EFO_0008507',
       'EFO_0803321', 'EFO_1001909', 'EFO_1001494', 'EFO_1001145',
       'HP_0032252', 'EFO_0001074', 'EFO_0003843', 'EFO_1000906',
       'MONDO_0002507'], dtype=object), 'count': 105}_|_[ENSG00000132639]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 104 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201628,nan_|_nan_|_Protein_|_False_|_INSULIN SUSP PROTAMINE ZINC BEEF/PORK_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Protamine zinc & iletin i (beef-pork)']_|_['Insulin susp protamine zinc beef/pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1966.
CHEMBL1214124,"N#Cc1ccccc1-c1cc(-c2ccccn2)cn(-c2ccccc2)c1=O_|_PRMWGUBFXWROHD-UHFFFAOYSA-N_|_Small molecule_|_True_|_PERAMPANEL_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Fycompa']_|_['E-2007' 'E2007' 'ER-155055-90' 'Perampanel']_|_[('DailyMed', array(['perampanel'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa'],
      dtype=object)), ('Wikipedia', array(['Perampanel'], dtype=object)), ('drugbank', array(['DB08883'], dtype=object)), ('chEBI', array(['71013'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001358', 'HP_0002069', 'EFO_0004263', 'EFO_0003108',
       'MONDO_0004985', 'EFO_0007262', 'EFO_0009430', 'HP_0001250',
       'MONDO_0004976', 'MONDO_0800207', 'MONDO_0002009', 'MONDO_0005277',
       'MONDO_0005180', 'EFO_0000474', 'MONDO_0007079', 'HP_0000473',
       'EFO_1000783', 'MONDO_0016532'], dtype=object), 'count': 18}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 15 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1241,"CN(C)CCN(Cc1ccccc1)c1ccccn1_|_UFLGIAIHIAPJJC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIPELENNAMINE_|_1948.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-118946' 'PBZ' 'PBZ-SR' 'Tripelennamine']_|_[('Wikipedia', array(['Tripelennamine'], dtype=object)), ('drugbank', array(['DB00792'], dtype=object)), ('chEBI', array(['9741'], dtype=object))]_|_['CHEMBL1200769' 'CHEMBL1200446']_|_{'rows': array(['MONDO_0005271', 'HP_0000989'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for allergic disease and pruritus."
CHEMBL1258006,"O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc2ccccc2o1_|_OXKRFEWMSWPKKV-GHTZIAJQSA-N_|_Small molecule_|_False_|_BRADANICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATA-101' 'Bradanicline' 'TC 5619' 'TC-5619']_|_[('drugbank', array(['DB06090'], dtype=object))]_|_['CHEMBL3137311']_|_{'rows': array(['MONDO_0005090', 'EFO_0003888', 'HP_0012735'], dtype=object), 'count': 3}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2016893,"Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1_|_IKBSEBRGSVFUHM-UHFFFAOYSA-N_|_Small molecule_|_False_|_XL-418_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['XL418' 'Xl-418']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000175634,ENSG00000108443]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2104993,"Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1_|_YQNWZWMKLDQSAC-UHFFFAOYSA-N_|_Small molecule_|_True_|_VORTIOXETINE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Brintellix']_|_['LU AA21004' 'LU-AA21004' 'LUAA21004' 'Vortioxetine']_|_[('drugbank', array(['DB09068'], dtype=object)), ('chEBI', array(['76016'], dtype=object))]_|_['CHEMBL5314578' 'CHEMBL2107387' 'CHEMBL3260563' 'CHEMBL2204360']_|_{'rows': array(['MONDO_0004985', 'MONDO_0002009', 'MONDO_0002009', 'MONDO_0002050',
       'MONDO_0002009', 'EFO_0005203', 'EFO_0003888', 'EFO_0001421',
       'EFO_0006788', 'EFO_1001892', 'MONDO_0002009', 'MONDO_0002009'],
      dtype=object), 'count': 12}_|_[ENSG00000178394,ENSG00000108576,ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109590,"nan_|_nan_|_Antibody_|_False_|_GSK-1995057_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GSK-1995057' 'Gsk-1995057']_|_nan_|_nan_|_{'rows': array(['EFO_0000684'], dtype=object), 'count': 1}_|_[ENSG00000067182]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3218578,"COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1_|_BMMXYEBLEBULND-UHFFFAOYSA-N_|_Small molecule_|_False_|_BGT-226_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BGT-226' 'NVP-BGT226']_|_[('chEBI', array(['71967'], dtype=object))]_|_['CHEMBL3545096']_|_{'rows': array(['MONDO_0016063', 'MONDO_0007254', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3544922,"nan_|_nan_|_Antibody_|_False_|_OPICINUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-LINGO' 'BIIB-033' 'BIIB033' 'Opicinumab']_|_nan_|_nan_|_{'rows': array(['EFO_0003929', 'MONDO_0005301', 'EFO_0007405'], dtype=object), 'count': 3}_|_[ENSG00000169783]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545252,"CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C.O.O.O_|_XCDIRYDKECHIPE-QHEQPUDQSA-N_|_Small molecule_|_True_|_DOCETAXEL_|_1996.0_|_4.0_|_CHEMBL92_|_False_|_True_|_['Docefrez' 'Docetaxel'
 'Docetaxel zentiva (previously docetaxel winthrop)' 'Taxceus' 'Taxotere']_|_['Docetaxel' 'Docetaxel (as trihydrate)' 'Docetaxel hydrate'
 'Docetaxel trihydrate' 'RP 56976' 'RP-56976' 'XRP6976']_|_[('DailyMed', array(['docetaxel'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva-previously-docetaxel-winthrop'],
      dtype=object)), ('chEBI', array(['59809'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011719', 'HP_0002039', 'EFO_0000313', 'MONDO_0008315',
       'MONDO_0001187', 'EFO_0004281', 'MONDO_0021117', 'EFO_0007355',
       'EFO_0003866', 'EFO_0002617', 'EFO_0005922', 'EFO_0000181',
       'MONDO_0004986', 'MONDO_0002358', 'MONDO_0008170', 'EFO_0000673',
       'MONDO_0001528', 'EFO_0000432', 'HP_0004326', 'EFO_0001416',
       'MONDO_0003060', 'EFO_0009708', 'EFO_0006859', 'EFO_0004230',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_1001951', 'MONDO_0005271',
       'MONDO_0002038', 'MONDO_0000521', 'EFO_0003869', 'MONDO_0021310',
       'EFO_1000043', 'MONDO_0005575', 'EFO_0003891', 'MONDO_0004192',
       'EFO_0010282', 'EFO_1000613', 'EFO_1001968', 'Orphanet_145',
       'EFO_0001376', 'EFO_1000984', 'EFO_0005537', 'EFO_0003817',
       'EFO_0000616', 'MONDO_0001325', 'MONDO_0002120', 'EFO_0000174',
       'EFO_0000565', 'EFO_0000574', 'EFO_0000178', 'EFO_0003860',
       'EFO_0007362', 'EFO_0005570', 'EFO_0002916', 'EFO_0005088',
       'MONDO_0021063', 'EFO_0000503', 'EFO_0002938', 'EFO_0000571',
       'EFO_0006352', 'EFO_0000707', 'EFO_0003897', 'MONDO_0002158',
       'EFO_0000466', 'EFO_0003060', 'EFO_0002428', 'EFO_0000756',
       'EFO_0000198', 'EFO_0000199', 'MONDO_0002974', 'MONDO_0004992',
       'EFO_0006861', 'EFO_0000681', 'EFO_0003863', 'EFO_0003865',
       'EFO_0000702', 'MONDO_0002367', 'EFO_0001663', 'EFO_0000637',
       'EFO_0002618', 'MONDO_0002087', 'MONDO_0002691', 'MONDO_0018364',
       'EFO_0008528', 'EFO_0000305', 'EFO_0003893', 'EFO_0006911',
       'EFO_0004284', 'HP_0012378', 'MONDO_0007254', 'MONDO_0001056',
       'MONDO_0011962', 'EFO_0000228', 'EFO_0000691', 'EFO_0000196',
       'MONDO_0007576', 'EFO_0000564', 'EFO_0005950', 'MONDO_0001475',
       'EFO_1000601', 'MONDO_0021355', 'MONDO_0004669', 'EFO_0000182',
       'EFO_0000708', 'EFO_0001075', 'MONDO_0003199', 'EFO_1001931',
       'EFO_0005577', 'EFO_1001100', 'EFO_1001214', 'EFO_0004252',
       'EFO_0003859', 'EFO_1000595', 'EFO_0001378', 'MONDO_0001402'],
      dtype=object), 'count': 116}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 20 approved and 96 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989520,NCCc1c[nH]cn1.O=P(O)(O)O.O=P(O)(O)O_|_ZHIBQGJKHVBLJJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_HISTAMINE PHOSPHATE_|_1939.0_|_4.0_|_CHEMBL90_|_False_|_True_|_['Histamine phosphate']_|_['Histamine phosphate']_|_nan_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939. This drug has a black box warning from the FDA.
CHEMBL405130,COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC_|_HOZUXBLMYUPGPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_WHI-P131_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['JANEX-1' 'Janex 1' 'WHI-P131' 'Whi-p131']_|_nan_|_['CHEMBL555201']_|_nan_|_[ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL411907,"C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C_|_QIUASFSNWYMDFS-NILGECQDSA-N_|_Small molecule_|_False_|_SONOLISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PX-866' 'Px-866' 'Sonolisib']_|_[('drugbank', array(['DB12601'], dtype=object)), ('chEBI', array(['65345'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000519'],
      dtype=object), 'count': 4}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL41306,"CSc1cccc(N(C)C(=N)Nc2cc(SC)ccc2Cl)c1_|_JHVHEDNLONERHY-UHFFFAOYSA-N_|_Small molecule_|_False_|_CNS-5161_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Cns 5161' 'Cns-5161']_|_[('drugbank', array(['DB05824'], dtype=object))]_|_['CHEMBL1079972']_|_nan_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug."
CHEMBL4297666,"CC(C)OC(=O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1_|_VIQCWEGEHRBLAC-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMIDENEPAG ISOPROPYL_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Omlonti']_|_['DE-117' 'De-117' 'Omidenepag isopropyl']_|_[('drugbank', array(['DB15071'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001069', 'EFO_0004190', 'MONDO_0005041'], dtype=object), 'count': 3}_|_[ENSG00000125384]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for ocular hypertension and open-angle glaucoma and has 1 investigational indication."
CHEMBL4594357,"nan_|_nan_|_Antibody_|_False_|_IANALUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ianalumab' 'NVP-VAY736' 'VAY-736' 'VAY736' 'Vay736']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IANALUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000768', 'EFO_0005809', 'EFO_0000699', 'EFO_0005676',
       'EFO_1001264', 'EFO_0000685', 'MONDO_0018906', 'MONDO_0005301',
       'EFO_1001469', 'EFO_1000630', 'EFO_0000616', 'EFO_0007160',
       'MONDO_0007915', 'EFO_0000095', 'EFO_0000403', 'EFO_0004719',
       'EFO_0005761'], dtype=object), 'count': 17}_|_[ENSG00000159958]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL4650392,"nan_|_nan_|_Antibody_|_False_|_DOMVANALIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AB-154' 'AB154' 'Ab154' 'Domvanalimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DOMVANALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000616', 'EFO_0000228', 'MONDO_0002691',
       'EFO_0003060', 'MONDO_0004992', 'EFO_0000519'], dtype=object), 'count': 7}_|_[ENSG00000181847]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4650469,"nan_|_nan_|_Antibody_|_False_|_DEPEMOKIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AQ-82742999' 'AQ82742999' 'Depemokimab' 'GSK-3511294' 'GSK3511294'
 'Gsk3511294']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DEPEMOKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005297', 'EFO_1001467', 'EFO_1000391', 'MONDO_0004979'],
      dtype=object), 'count': 4}_|_[ENSG00000113525]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL61780,"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO_|_TUYWTLTWNJOZNY-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEZOSENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Veletri']_|_['ACT-050089' 'Ro 61-0612' 'Ro-610612' 'Tezosentan']_|_[('Wikipedia', array(['Tezosentan'], dtype=object)), ('drugbank', array(['DB06558'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001361', 'EFO_0003144'], dtype=object), 'count': 2}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL655,"Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2_|_DDLIGBOFAVUZHB-UHFFFAOYSA-N_|_Small molecule_|_True_|_MIDAZOLAM_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Midazolam in 0.8% sodium chloride' 'Midazolam in 0.9% sodium chloride'
 'Nayzilam']_|_['Midazolam' 'Midazolam civ' 'USL-261' 'USL261']_|_[('DailyMed', array(['midazolam'], dtype=object)), ('PubChem', array(['50113067'], dtype=object)), ('Wikipedia', array(['Midazolam'], dtype=object)), ('drugbank', array(['DB00683'], dtype=object)), ('chEBI', array(['6931'], dtype=object))]_|_['CHEMBL2106922' 'CHEMBL1200420']_|_{'rows': array(['EFO_0009686', 'EFO_0005741', 'MONDO_0043510', 'HP_0000083',
       'EFO_1001413', 'EFO_1001884', 'EFO_0000685', 'EFO_0003929',
       'EFO_0001073', 'MONDO_0002050', 'MONDO_0004992', 'EFO_0009854',
       'EFO_0000544', 'EFO_0000384', 'EFO_0007157', 'EFO_0006834',
       'EFO_0004272', 'EFO_0008525', 'MONDO_0002009', 'EFO_1002048',
       'EFO_0007328', 'HP_0000989', 'EFO_0003869', 'MONDO_0002009',
       'EFO_0003914', 'EFO_0009708', 'EFO_0003103', 'EFO_0003890',
       'MONDO_0004985', 'EFO_1000049', 'MONDO_0005148', 'EFO_0000616',
       'MONDO_0005148', 'EFO_0005251', 'EFO_1001494', 'EFO_1001454',
       'EFO_0003144', 'HP_0030833', 'EFO_0003060', 'EFO_0003854',
       'EFO_0000701', 'EFO_0000545', 'EFO_0004242', 'EFO_0000546',
       'EFO_0006911', 'EFO_0009267', 'EFO_0005230', 'EFO_0001422',
       'EFO_0000756', 'MONDO_0044970', 'MONDO_0011719', 'EFO_0000537',
       'HP_0002140', 'EFO_0000095', 'HP_0001250', 'HP_0012532',
       'EFO_0004888', 'EFO_0003015', 'MONDO_0011382', 'MONDO_0018076',
       'EFO_1001884', 'EFO_0003768', 'EFO_0000676', 'HP_0001623',
       'EFO_0000662', 'EFO_1001328', 'HP_0011110', 'MONDO_0002050',
       'EFO_1001249', 'MONDO_0005129', 'EFO_0001378', 'EFO_0004320',
       'MONDO_0007606', 'EFO_1001454', 'EFO_0002617', 'EFO_0003931',
       'EFO_0009513', 'EFO_0003047', 'EFO_0000588', 'MONDO_0007254',
       'HP_0100806', 'EFO_0004220', 'MONDO_0004975', 'MONDO_0005180',
       'EFO_0002610', 'MONDO_0004976', 'EFO_0000274', 'HP_0012076',
       'EFO_0000274', 'EFO_0003758', 'MONDO_0100096', 'EFO_0003863',
       'EFO_0000713', 'HP_0003419', 'EFO_0001068', 'EFO_0000764',
       'EFO_0000616', 'EFO_0000319', 'EFO_0008526', 'HP_0000726',
       'EFO_0004239', 'EFO_0003843', 'EFO_0000222', 'EFO_0005411',
       'EFO_0000618', 'EFO_0000474', 'EFO_0008526', 'MONDO_0005090',
       'MONDO_0004985', 'EFO_0005952', 'EFO_0005762', 'EFO_0000729',
       'MP_0001914', 'MONDO_0018076', 'EFO_0001065', 'MONDO_0008315',
       'EFO_0001358', 'EFO_0000673', 'HP_0000023', 'HP_0012735'],
      dtype=object), 'count': 120}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 112 investigational indications. This drug has a black box warning from the FDA."
CHEMBL787,"CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1_|_UCHDWCPVSPXUMX-TZIWLTJVSA-N_|_Small molecule_|_True_|_MONTELUKAST_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Singulair']_|_['Brondilat' 'MK-476' 'Montelukast']_|_[('Wikipedia', array(['Montelukast'], dtype=object)), ('drugbank', array(['DB00471'], dtype=object)), ('chEBI', array(['50730'], dtype=object))]_|_['CHEMBL1200681']_|_{'rows': array(['HP_0040187', 'EFO_0007183', 'EFO_1001417', 'EFO_0003918',
       'MONDO_0011382', 'EFO_0003917', 'EFO_0000694', 'HP_0012735',
       'EFO_0000540', 'HP_0011950', 'EFO_0003843', 'EFO_0004227',
       'EFO_0003877', 'EFO_0000684', 'EFO_0000222', 'EFO_0003956',
       'MONDO_0100096', 'MONDO_0004979', 'EFO_0008521', 'EFO_0001378',
       'EFO_0000220', 'EFO_0003060', 'EFO_0004232', 'EFO_0000341',
       'EFO_1001417', 'EFO_0000764', 'EFO_1001249', 'EFO_0008590',
       'EFO_0000685', 'EFO_0000401', 'HP_0100806', 'EFO_0003956',
       'MONDO_0004979', 'EFO_0005854', 'EFO_0005854', 'MONDO_0004975',
       'MONDO_0019091', 'EFO_0004232', 'HP_0006536', 'EFO_0009715'],
      dtype=object), 'count': 40}_|_[ENSG00000173198]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL821,"N=C(N)N_|_ZRALSGWEFCBTJO-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANIDINE_|_1939.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Guanidine']_|_[('Wikipedia', array(['Guanidine'], dtype=object)), ('drugbank', array(['DB00536'], dtype=object)), ('chEBI', array(['42820'], dtype=object))]_|_['CHEMBL1200728' 'CHEMBL3187576']_|_{'rows': array(['EFO_0009708', 'EFO_0008524', 'EFO_1001901', 'HP_0001324',
       'EFO_0004991'], dtype=object), 'count': 5}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 3 approved and 2 investigational indications."
CHEMBL91397,"Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1_|_WUZYKBABMWJHDL-UHFFFAOYSA-N_|_Small molecule_|_False_|_RUPATADINE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Rupatadine' 'UR-12592']_|_[('Wikipedia', array(['Rupatadine'], dtype=object)), ('drugbank', array(['DB11614'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271', 'EFO_0000685', 'EFO_0005531', 'EFO_0009001',
       'EFO_1001881'], dtype=object), 'count': 5}_|_[ENSG00000196639,ENSG00000169403]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 investigational indications."
CHEMBL944,"CCN(CC)CCOC(=O)c1ccc(N)cc1Cl.Cl_|_SZKQYDBPUCZLRX-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLOROPROCAINE HYDROCHLORIDE_|_1955.0_|_4.0_|_CHEMBL1179047_|_False_|_True_|_['Ampres' 'Chloroprocaine hydrochloride' 'Clorotekal' 'Nesacaine'
 'Nesacaine-mpf']_|_['Chloroprocaine HCl' 'Chloroprocaine hcl' 'Chloroprocaine hydrochloride'
 'Chlorprocaine chloride' 'Iheezo']_|_[('DailyMed', array(['chloroprocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206478'], dtype=object)), ('chEBI', array(['3637'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and has 1 investigational indication."
CHEMBL1082462,"CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N_|_VQKSCYBKUIDZEI-STQMWFEESA-N_|_Small molecule_|_False_|_DBPR-108_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DBPR-108' 'Dbpr-108' 'Prusogliptin']_|_nan_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0003086', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1200959,"CN1CCC(CN2c3ccccc3Sc3ccccc32)C1_|_HTMIBDQKFHUPSX-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHDILAZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Tacaryl']_|_['Methdilazine']_|_[('Wikipedia', array(['Methdilazine'], dtype=object)), ('drugbank', array(['DB00902'], dtype=object)), ('chEBI', array(['6823'], dtype=object))]_|_['CHEMBL1200532']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease."
CHEMBL1341,"COC(F)(F)C(Cl)Cl_|_RFKMCNOHBTXSMU-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHOXYFLURANE_|_nan_|_4.0_|_nan_|_True_|_True_|_['Metofane' 'Penthrane' 'Pentrane']_|_['Analgizer' 'Anecotan' 'DA-759' 'Inhalan' 'Methoxiflurane'
 'Methoxy flurane' 'Methoxyflurane' 'NSC-110432' 'Penthrox']_|_[('Wikipedia', array(['Methoxyflurane'], dtype=object)), ('drugbank', array(['DB01028'], dtype=object)), ('chEBI', array(['6843'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'MONDO_0004992', 'HP_0001945', 'EFO_0000546'],
      dtype=object), 'count': 4}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000145888,ENSG00000109738]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 2 investigational indications. It was withdrawn in at least one region."
CHEMBL2051955,"C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1_|_WHXMKTBCFHIYNQ-SECBINFHSA-N_|_Small molecule_|_False_|_LEVOSIMENDAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(-)-OR-1259' '(r)-simendan' 'Levosimendan' 'NSC-759644' 'OR-1259'
 'Simendan, (r)-']_|_[('PubChem', array(['144205744', '170466128', '170466129'], dtype=object)), ('drugbank', array(['DB00922'], dtype=object)), ('chEBI', array(['50567'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000373', 'MP_0001914', 'HP_0001919', 'EFO_0000712',
       'EFO_0003764', 'EFO_0008585', 'EFO_0005207', 'EFO_0001645',
       'EFO_0000319', 'EFO_0000694', 'EFO_0003144', 'EFO_0002970',
       'MONDO_0004976', 'HP_0031273', 'EFO_0006834'], dtype=object), 'count': 15}_|_[ENSG00000114854,ENSG00000129991,ENSG00000118194,ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications."
CHEMBL2105635,"CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@H](C)O)[C@H](C)O_|_SLYFITHISHUGLZ-LWZDQURMSA-N_|_Protein_|_False_|_DAVALINTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AC-2307' 'AC2307' 'Ac2307' 'Davalintide']_|_nan_|_['CHEMBL2105636']_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000064989,ENSG00000004948,ENSG00000132329]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107328,"CCC(CC)COC(=O)[C@@H]1C[C@H]2C[C@@H](Oc3cccc(Cl)c3-c3nnn[nH]3)CC[C@H]2CN1_|_HPBRMCFZIGUGTK-ZMMAXQRCSA-N_|_Small molecule_|_False_|_DASOLAMPANEL ETIBUTIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dasolampanel etibutil' 'LY-545694' 'Ly545694']_|_[('drugbank', array(['DB12049'], dtype=object))]_|_['CHEMBL2107327']_|_{'rows': array(['EFO_1000783'], dtype=object), 'count': 1}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108413,"nan_|_nan_|_Antibody_|_False_|_BIVATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bivatuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0003869', 'EFO_0000707', 'EFO_0004284'], dtype=object), 'count': 3}_|_[ENSG00000026508]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109363,nan_|_nan_|_Antibody_|_False_|_BRE-3 90Y_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BRE-3' 'Bre-3 90y']_|_nan_|_nan_|_nan_|_[ENSG00000140545]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL247951,"CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O_|_ZHKNLJLMDFQVHJ-RUZDIDTESA-N_|_Small molecule_|_False_|_PEMAFIBRATE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(R)-K-13675' 'K-13675, (r)-' 'Pemafibrate']_|_[('drugbank', array(['DB15212'], dtype=object))]_|_nan_|_nan_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017."
CHEMBL3545398,"nan_|_nan_|_Small molecule_|_False_|_PG-760564_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pg-760564']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707357,"nan_|_nan_|_Antibody_|_False_|_BROLUCIZUMAB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Beovu']_|_['Brolucizumab' 'Brolucizumab dbll' 'ESBA-1008' 'ESBA1008' 'RTH-258'
 'RTH258']_|_[('DailyMed', array(['brolucizumab-dbll'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/beovu'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001157', 'EFO_0004683', 'MONDO_0003005', 'EFO_0001365',
       'EFO_0005753'], dtype=object), 'count': 5}_|_[ENSG00000112715]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for wet macular degeneration and ocular vascular disease and has 3 investigational indications."
CHEMBL3989824,"CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1.Cl.Cl.O.O_|_MEUAAEMCZUPORO-LRSHZYOCSA-N_|_Small molecule_|_True_|_THIOTHIXENE HYDROCHLORIDE_|_1970.0_|_4.0_|_CHEMBL1201_|_False_|_True_|_['Navane' 'Thiothixene hydrochloride' 'Thiothixene hydrochloride intensol']_|_['CP-12,252-1' 'CP-122521' 'Thiothixene dihydrochloride'
 'Thiothixene hcl h20' 'Thiothixene hydrochloride'
 'Tiotixene hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970. This drug has a black box warning from the FDA."
CHEMBL4080062,"O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12_|_JNLSTLQFDDAULK-UHFFFAOYSA-N_|_Small molecule_|_False_|_BFH-772_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BFH-722' 'BFH-772' 'BFH722' 'BFH772' 'Bfh-772' 'Bfh772']_|_nan_|_nan_|_{'rows': array(['EFO_1000760'], dtype=object), 'count': 1}_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297323,"CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O_|_VZRIKWNVDCTBTF-BKGFHLQYSA-N_|_Protein_|_False_|_PZ-128_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Palmitate-kksralf-nh2' 'Pz-128']_|_[('drugbank', array(['DB11839'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001645'], dtype=object), 'count': 1}_|_[ENSG00000181104]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297563,"nan_|_nan_|_Antibody_|_False_|_PACMILIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CX-072' 'CX-072 PROBODY' 'CX072' 'Cx 072' 'Cx-072' 'Pacmilimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PACMILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0002617', 'EFO_0000574', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL5314410,"C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4C[C@H]5CCN(C)[C@H]5C4)cc23)c1_|_FSXCKIBROURMFT-VGSWGCGISA-N_|_Small molecule_|_False_|_THELIATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HMPL-309' 'Hmpl-309' 'Theliatinib' 'Xiliertinib']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1084546,"CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O_|_MZDKLVOWGIOKTN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-00562271_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PF 562271' 'PF-562271' 'Pf-00562271' 'Pf-562271 besilate']_|_[('PubChem', array(['103905684'], dtype=object))]_|_['CHEMBL2430359']_|_nan_|_[ENSG00000169398]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL11662,"O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1_|_SHZKQBHERIJWAO-AATRIKPKSA-N_|_Small molecule_|_False_|_OZAGREL_|_1988.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['KCT-0809' 'Ozagrel' 'Ozagrel sodium']_|_[('Wikipedia', array(['Ozagrel'], dtype=object)), ('drugbank', array(['DB12017'], dtype=object))]_|_['CHEMBL1715705' 'CHEMBL542549']_|_{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}_|_[ENSG00000059377]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and has 1 investigational indication."
CHEMBL1200334,"CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2.Cl_|_GAQAKFHSULJNAK-UHFFFAOYSA-N_|_Small molecule_|_True_|_MORICIZINE HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL1075_|_False_|_True_|_['Ethmozine']_|_['Moracizine hydrochloride' 'Moricizine hcl' 'Moricizine hydrochloride']_|_[('PubChem', array(['144204173', '170465141', '24840971', '856698'], dtype=object)), ('chEBI', array(['60937'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. This drug has a black box warning from the FDA."
CHEMBL1201573,"nan_|_nan_|_Protein_|_True_|_OPRELVEKIN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Neumega']_|_['Interleukin-11 (2-178)' 'Oprelvekin']_|_[('DrugCentral', array(['5026'], dtype=object)), ('Wikipedia', array(['Oprelvekin'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_903', 'EFO_0000191', 'EFO_0000095', 'EFO_0000339',
       'MONDO_0018906', 'MONDO_0010602', 'EFO_0009441', 'HP_0001873',
       'EFO_0000616'], dtype=object), 'count': 9}_|_[ENSG00000137070]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for thrombocytopenia and neoplasm and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1395,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O_|_GCKMFJBGXUYNAG-HLXURNFRSA-N_|_Small molecule_|_False_|_METHYLTESTOSTERONE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Android 10' 'Android 25' 'Android 5' 'Metandren' 'Methitest'
 'Methyltestosterone' 'Oreton' 'Oreton methyl' 'Perandren' 'Plex hormone'
 'Potensan fte' 'Testovis' 'Testred' 'Virilon']_|_['17-methyltestosterone' 'CDB-110' 'L 589.372' 'L-589.372' 'L-589372'
 'Methyltestosterone' 'Methyltestosterone ciii' 'NSC-139965' 'NSC-9701'
 'Oxandrolone impurity, methyltestosterone-' 'RU 24400' 'RU-24400'
 'U-2842']_|_[('DailyMed', array(['methyltestosterone'], dtype=object)), ('PubChem', array(['144206712', '144206713', '144214019', '170464631', '17388912',
       '26719668', '56463771'], dtype=object)), ('TG-GATEs', array(['41'], dtype=object)), ('Wikipedia', array(['Methyltestosterone'], dtype=object)), ('drugbank', array(['DB06710'], dtype=object)), ('chEBI', array(['27436'], dtype=object))]_|_nan_|_{'rows': array(['GO_0042697', 'MONDO_0007254', 'MONDO_0002146', 'EFO_1001078'],
      dtype=object), 'count': 4}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 1 investigational indication."
CHEMBL1743036,"nan_|_nan_|_Antibody_|_False_|_LEXATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ETR2-ST01' 'HGS-1018' 'HGS-ETR2' 'HGS1018' 'Lexatumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000174', 'EFO_0002918', 'EFO_0000637', 'EFO_0000621'],
      dtype=object), 'count': 4}_|_[ENSG00000120889]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL197194,"COc1cccc(-c2ccc(NC(=O)C3=C(C(=O)O)CCC3)c(F)c2)c1_|_XPRDUGXOWVXZLL-UHFFFAOYSA-N_|_Small molecule_|_False_|_VIDOFLUDIMUS_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['4SC-101' 'IMU-838' 'Imu-838' 'NSC-717824' 'SC-12267' 'SC12267'
 'Vidofludimus']_|_[('PubChem', array(['174007069'], dtype=object)), ('drugbank', array(['DB15446'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0004268',
       'EFO_0003767', 'EFO_0003929', 'EFO_0000729'], dtype=object), 'count': 7}_|_[ENSG00000102967]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2108034,"nan_|_nan_|_Protein_|_False_|_IBOCTADEKIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Iboctadekin' 'Ifn-gamma-inducing factor' 'Il-1 gamma' 'Il-18'
 'Interferon gamma-inducing factor' 'Interleukin-1 gamma' 'Interleukin-18'
 'SB-485232']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0000756', 'EFO_0000574', 'MONDO_0004992'],
      dtype=object), 'count': 4}_|_[ENSG00000115607,ENSG00000115604]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2108184,"nan_|_nan_|_Small molecule_|_False_|_CROFELEMER_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Fulyzaq' 'Mytesi']_|_['Crofelemer' 'NP-303' 'SP-303' 'TRN-002']_|_[('DailyMed', array(['crofelemer'], dtype=object)), ('DrugCentral', array(['4744'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002014', 'EFO_0000555', 'MONDO_0007254', 'EFO_0000765'],
      dtype=object), 'count': 4}_|_[ENSG00000001626,ENSG00000131620]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for diarrhea and aids and has 2 investigational indications."
CHEMBL2219422,"Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl_|_AFJRDFWMXUECEW-LBPRGKRZSA-N_|_Small molecule_|_False_|_AFURESERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASB-183' 'ASB183' 'Afuresertib' 'GSK-2110183' 'GSK-2110183C'
 'GSK2110183' 'GSK2110183C' 'Gsk-2110183']_|_[('drugbank', array(['DB11648'], dtype=object))]_|_['CHEMBL2219423']_|_{'rows': array(['MONDO_0008170', 'MONDO_0008315', 'EFO_0001378', 'MONDO_0007254',
       'EFO_0000616', 'MONDO_0004992', 'EFO_1000318'], dtype=object), 'count': 7}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL2219773,"nan_|_nan_|_Oligonucleotide_|_False_|_CUSTIRSEN SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Custirsen sodium' 'ISIS 112989' 'ISIS-112989' 'OGX-011' 'Ogx 011']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0007254', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000120885]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3137318,"Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1_|_QUQKKHBYEFLEHK-QNBGGDODSA-N_|_Small molecule_|_False_|_TALAZOPARIB TOSYLATE_|_2018.0_|_4.0_|_CHEMBL3137320_|_False_|_True_|_['Talzenna']_|_['BMN 673ts' 'BMN-673TS' 'Talazoparib tosilate' 'Talazoparib tosylate']_|_[('DailyMed', array(['talazoparib%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0003060', 'EFO_0000222',
       'EFO_0000305', 'EFO_0003869', 'EFO_0005537'], dtype=object), 'count': 7}_|_[ENSG00000129484,ENSG00000143799]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 4 investigational indications."
CHEMBL32800,"CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1_|_LSLYOANBFKQKPT-UHFFFAOYSA-N_|_Small molecule_|_False_|_FENOTEROL_|_nan_|_4.0_|_nan_|_True_|_True_|_['Berodual' 'Berodual n' 'Berotec' 'Berotec 100' 'Berotec 200' 'Duovent']_|_['Airum' 'Dosberotec' 'Fenoterol' 'Fenoterol hbr' 'Fenoterol hydrobromide'
 'NSC-757811' 'Partusisten' 'TH 1165A' 'TH 1165A FREE BASE'
 'TH 1165A [AS HYDROBROMIDE SALT]' 'TH-1165' 'TH-1165A'
 'TH-1165A FREE BASE']_|_[('PubChem', array(['90340690'], dtype=object)), ('Wikipedia', array(['Fenoterol'], dtype=object)), ('drugbank', array(['DB01288'], dtype=object)), ('chEBI', array(['149226'], dtype=object))]_|_['CHEMBL537445']_|_{'rows': array(['EFO_0000373', 'HP_0006536', 'MONDO_0004979', 'EFO_0000341'],
      dtype=object), 'count': 4}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for airway obstruction and has 3 investigational indications. It was withdrawn in at least one region."
CHEMBL3545043,"CC(C)Oc1ccc(S(=O)(=O)N2CCN(c3ccc(-c4ncco4)c(OCC(=O)O)c3)CC2)cc1_|_ZMZNWNTZRWXTJU-UHFFFAOYSA-N_|_Small molecule_|_False_|_ASAPIPRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Asapiprant' 'BGE175' 'Bge 175' 'Bge-175' 'S-555739']_|_nan_|_nan_|_{'rows': array(['EFO_0003956', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000168229]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3545203,nan_|_nan_|_Small molecule_|_False_|_RG7342_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['RO6806127' 'Rg7342']_|_nan_|_nan_|_nan_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL397420,"CC(=O)CC(c1ccc([N+](=O)[O-])cc1)c1c(O)c2ccccc2oc1=O_|_VABCILAOYCMVPS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACENOCOUMAROL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Sinthrome']_|_['Acenocoumarin' 'Acenocoumarol' 'Mini-sintrom' 'NSC-760052' 'Nicoumalone']_|_[('PubChem', array(['144203981', '170465636'], dtype=object)), ('Wikipedia', array(['Acenocoumarol'], dtype=object)), ('drugbank', array(['DB01418'], dtype=object)), ('chEBI', array(['53766'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003827', 'EFO_0000275', 'EFO_0000756', 'HP_0004419'],
      dtype=object), 'count': 4}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 3 investigational indications."
CHEMBL3989569,"CCCCCN(C)CCC(O)(P(=O)([O-])O)P(=O)(O)O.O.[Na+]_|_VBDRTGFACFYFCT-UHFFFAOYSA-M_|_Small molecule_|_False_|_IBANDRONATE SODIUM_|_2003.0_|_4.0_|_CHEMBL997_|_False_|_True_|_['Boniva' 'Ibandronate sodium' 'Ibandronic acid accord']_|_['BM 21.0955 NA H20' 'BM-21.0955' 'BM-210955'
 'Ibandronate monosodium monohydrate' 'Ibandronate sodium'
 'Ibandronate sodium hydrate' 'Ibandronate sodium monohydrate'
 'Ibandronic acid sodium salt' 'Ibandronic acid sodium salt monohydrate'
 'Ibandronic sodium monohydrate' 'NSC-759815']_|_[('DailyMed', array(['ibandronate%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ibandronic-acid-accord'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003854', 'MONDO_0007254', 'EFO_0003843', 'EFO_0003882',
       'HP_0000938'], dtype=object), 'count': 5}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for postmenopausal osteoporosis and osteoporosis and has 3 investigational indications."
CHEMBL4297856,"nan_|_nan_|_Antibody_|_False_|_ZIMBERELIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AB-122' 'AB122' 'Ab-122' 'Ab122' 'GLS-010' 'Gls-010' 'WBP-3055'
 'WBP3055' 'Zimberelimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZIMBERELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000228', 'MONDO_0002691', 'EFO_1000657', 'MONDO_0007254',
       'EFO_0000181', 'MONDO_0005184', 'MONDO_0009348', 'EFO_0000196',
       'EFO_0000348', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0000616',
       'EFO_0000756', 'EFO_0001061', 'EFO_0003085', 'MONDO_0002974',
       'EFO_0000673', 'EFO_1000359', 'EFO_0003060', 'EFO_0000519'],
      dtype=object), 'count': 20}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications."
CHEMBL4303729,"O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12_|_YYACLQUDUDXAPA-MRXNPFEDSA-N_|_Small molecule_|_False_|_PLIXORAFENIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FORE-8394' 'FORE8394' 'PLX8394' 'Plixorafenib' 'Plx 8394' 'Plx-8394']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000756', 'MONDO_0004992', 'HP_0100727',
       'EFO_0005221', 'EFO_1000956', 'MONDO_0002108', 'EFO_1001951',
       'EFO_0000616'], dtype=object), 'count': 9}_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL4567446,"COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2c(cnn2C(C)C)C3)cc(-c2ccc(C(=O)O)cc2)n1_|_LXZMHBHEXAELHH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLESACOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Clesacostat' 'PF-05221304' 'PF05221304' 'Pf-05221304']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CLESACOSTAT/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650217']_|_{'rows': array(['EFO_0003095', 'EFO_0003095', 'EFO_0001421', 'EFO_1001249'],
      dtype=object), 'count': 4}_|_[ENSG00000278540,ENSG00000076555]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4594511,"nan_|_nan_|_Oligonucleotide_|_False_|_VUTRISIRAN_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Amvuttra']_|_['ALN-65492' 'ALN-TTRSC02' 'Votrisiran' 'Vutrisiran']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VUTRISIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001875', 'EFO_0004129', 'EFO_0009562'], dtype=object), 'count': 3}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for familial amyloid neuropathy and polyneuropathy and has 1 investigational indication."
CHEMBL4594569,"nan_|_nan_|_Antibody_|_False_|_AMLITELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amlitelimab' 'KY-1005' 'KY-1005-2D10' 'KY1005' 'KY1005-2D10' 'Ky-1005'
 'Ky1005' 'SAR-445229' 'SAR445229']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMLITELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000964', 'MONDO_0004979', 'EFO_0000274', 'EFO_0005809',
       'EFO_0000540'], dtype=object), 'count': 5}_|_[ENSG00000117586]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4650411,"nan_|_nan_|_Antibody_|_False_|_OCIPERLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BGB-A1217' 'Bgb-a1217' 'Ociperlimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OCIPERLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000182', 'EFO_0000403', 'EFO_0000702',
       'EFO_0005922', 'MONDO_0004992', 'MONDO_0002974', 'MONDO_0007254',
       'EFO_0003060'], dtype=object), 'count': 9}_|_[ENSG00000181847]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL1200837,"CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1.Cl_|_CHDPSNLJFOQTRK-LMOVPXPDSA-N_|_Small molecule_|_False_|_LEVOBETAXOLOL HYDROCHLORIDE_|_2000.0_|_4.0_|_CHEMBL1201274_|_False_|_True_|_['Betaxon']_|_['AL-1577A' 'AL1577A' 'Levobetaxolol hcl' 'Levobetaxolol hydrochloride']_|_[('chEBI', array(['59256'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 2}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications."
CHEMBL1201743,"Cl.N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2_|_TUAZNHHHYVBVBR-NHKADLRUSA-N_|_Small molecule_|_False_|_SAXAGLIPTIN HYDROCHLORIDE_|_2009.0_|_4.0_|_CHEMBL385517_|_False_|_True_|_['Onglyza']_|_['Saxagliptin HCl' 'Saxagliptin hcl' 'Saxagliptin hydrochloride']_|_[('DailyMed', array(['saxagliptin%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for type 2 diabetes mellitus."
CHEMBL1668019,"CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl_|_QNNBMSGFNQRUEH-PQQSRXGVSA-N_|_Small molecule_|_False_|_APLAVIROC HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL1255794_|_False_|_False_|_[]_|_['Aplaviroc hcl' 'Aplaviroc hydrochloride' 'GW-873140A' 'GW873140A']_|_[('PubChem', array(['144210531'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108612,"nan_|_nan_|_Antibody_|_False_|_IRATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Iratumumab' 'MDX-060']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000183', 'EFO_0001642'], dtype=object), 'count': 3}_|_[ENSG00000120949]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109271,"nan_|_nan_|_Antibody_|_False_|_MDX-210_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['520C9XH22' 'MDX-210']_|_nan_|_nan_|_nan_|_[ENSG00000150337,ENSG00000141736]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL2109468,nan_|_nan_|_Antibody_|_False_|_HUMAX-IL15_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HUMAX-IL15']_|_nan_|_nan_|_nan_|_[ENSG00000004468]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2178579,"O=C(Nc1ccc(Cl)c(S(=O)(=O)N2CCNCC2)c1O)Nc1cccc(F)c1Cl_|_YQYFEGTYCUQBEI-UHFFFAOYSA-N_|_Small molecule_|_False_|_ELUBRIXIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Elubrixin' 'SB-656933' 'SB-656933-AAF' 'SB656933' 'Sb-656933']_|_[('drugbank', array(['DB12135'], dtype=object))]_|_['CHEMBL3039524']_|_{'rows': array(['EFO_0000341', 'EFO_0000729', 'EFO_0000341', 'MONDO_0009061'],
      dtype=object), 'count': 4}_|_[ENSG00000180871]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545402,"nan_|_nan_|_Small molecule_|_False_|_XL-820_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Xl-820']_|_nan_|_nan_|_{'rows': array(['MONDO_0011719', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3707235,"N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O_|_ZWPRRQZNBDYKLH-VIFPVBQESA-N_|_Small molecule_|_False_|_GEMIGLIPTIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gemigliptin' 'LC-15-0444' 'LC-150444' 'LC15-0444']_|_[('drugbank', array(['DB12412'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0000400', 'MONDO_0005148', 'EFO_0001421',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297624,"CCOC(=O)C12CCC(NCC(=O)N3C[C@@H](F)C[C@H]3C#N)(CC1)CC2_|_AKFNKZFJBFQFAA-DIOPXHOYSA-N_|_Small molecule_|_False_|_BISEGLIPTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bisegliptin' 'KRP-104' 'Krp-104']_|_[('drugbank', array(['DB06127'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297797,"nan_|_nan_|_Unknown_|_False_|_NNC0114-0006_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NN-8828' 'NN-9828' 'Nnc0114-0006']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147'], dtype=object), 'count': 1}_|_[ENSG00000138684]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297833,"nan_|_nan_|_Antibody_|_False_|_MEZAGITAMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mezagitamab' 'TAK-079' 'TAK079' 'Tak-079']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MEZAGITAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0004991', 'MONDO_0002462', 'EFO_0000616',
       'EFO_0005809', 'EFO_0007160', 'EFO_0005140', 'MONDO_0007915'],
      dtype=object), 'count': 8}_|_[ENSG00000004468]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL4303596,"C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1_|_KWRYMZHCQIOOEB-LBPRGKRZSA-N_|_Small molecule_|_False_|_AMG-319_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG319' 'Amg-319' 'J3.391.906I']_|_nan_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0000181', 'EFO_1001469', 'EFO_0000403',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4594492,"nan_|_nan_|_Oligonucleotide_|_False_|_REVUSIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AD-51547' 'Revusiran']_|_nan_|_nan_|_{'rows': array(['EFO_0004129'], dtype=object), 'count': 1}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL5315055,"C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl.O.O_|_XOBQQQVDLSMXCE-JVRGSUDVSA-N_|_Small molecule_|_False_|_NALMEFENE HYDROCHLORIDE DIHYDRATE_|_2013.0_|_4.0_|_CHEMBL982_|_False_|_True_|_['Selincro']_|_['Nalmefene hydrochloride hydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/selincro'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for alcohol dependence."
CHEMBL593430,"C[C@H]1CC(CN)(CC(=O)O)C[C@@H]1C_|_IUVMAUQEZFTTFB-YUMQZZPRSA-N_|_Small molecule_|_False_|_ATAGABALIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atagabalin' 'PD 0200390' 'PD-0200,390' 'PD-0200390' 'PD0200390']_|_[('Wikipedia', array(['Atagabalin'], dtype=object)), ('drugbank', array(['DB12032'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL635,"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2C(=O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)CO_|_XOFYZVNMUHMLCC-ZPOLXVRWSA-N_|_Small molecule_|_False_|_PREDNISONE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Cortan' 'Cortancyl' 'Decortisyl' 'Delta-dome' 'Deltasone' 'Fernisone'
 'Liquid pred' 'Lodotra' 'Meticorten' 'Orasone' 'Paracort' 'Prednicen-m'
 'Prednisone' 'Prednisone intensol' 'Rayos' 'Servisone' 'Sterapred']_|_['3en3hg4wsw' 'Decortin' 'Dehydrocortisone' 'Metacortandracin' 'NSC-10023'
 'Prednisone' 'Prednisone anhydrous' 'Prednisone tablets' 'Supercortil']_|_[('DailyMed', array(['prednisone'], dtype=object)), ('PubChem', array(['144204565', '144208762', '144210516', '170464847', '17389753',
       '50085971', '56314869', '75351'], dtype=object)), ('Wikipedia', array(['Prednisone'], dtype=object)), ('drugbank', array(['DB00635'], dtype=object)), ('chEBI', array(['8382'], dtype=object))]_|_nan_|_{'rows': array(['DOID_13406', 'EFO_0000318', 'Orphanet_77260', 'MP_0001845',
       'MONDO_0019391', 'EFO_0005319', 'EFO_1001194', 'EFO_0005531',
       'EFO_0003898', 'EFO_0005854', 'MONDO_0015760', 'MONDO_0019338',
       'EFO_1001435', 'EFO_0000616', 'EFO_1001968', 'EFO_0003956',
       'EFO_0004826', 'EFO_0008997', 'EFO_1001896', 'MONDO_0003937',
       'EFO_0007403', 'EFO_0002609', 'MONDO_0008315', 'EFO_0003777',
       'EFO_0003778', 'EFO_1000318', 'EFO_0005761', 'MONDO_0009061',
       'EFO_0000764', 'MONDO_0018896', 'EFO_1001264', 'EFO_0000565',
       'EFO_0000196', 'EFO_0004274', 'EFO_0001378', 'EFO_1000997',
       'EFO_1000965', 'EFO_1000131', 'EFO_0000403', 'EFO_0007405',
       'MONDO_0008903', 'EFO_0004991', 'HP_0001094', 'EFO_0002428',
       'EFO_0000222', 'EFO_1001205', 'HP_0012424', 'EFO_0000309',
       'EFO_0004228', 'MONDO_0016537', 'EFO_0007427', 'EFO_0005856',
       'EFO_0007187', 'MONDO_0018906', 'EFO_0008518', 'MONDO_0044903',
       'HP_0001952', 'EFO_0004256', 'EFO_0009456', 'EFO_0000691',
       'EFO_0009448', 'MONDO_0004979', 'EFO_0007141', 'MONDO_0015540',
       'EFO_1000784', 'MONDO_0017719', 'EFO_0005952', 'HP_0001871',
       'EFO_0000198', 'MONDO_0004992', 'EFO_0005801', 'EFO_0000209',
       'EFO_0004236', 'EFO_0007313', 'EFO_0000211', 'EFO_0007537',
       'EFO_0002430', 'EFO_0000183', 'MONDO_0018998', 'MONDO_0013730',
       'EFO_0007486', 'EFO_1001383', 'MONDO_0015564', 'MONDO_0000873',
       'EFO_0000557', 'EFO_1001051', 'EFO_0004254', 'MONDO_0004976',
       'EFO_0007160', 'HP_0012410', 'EFO_0003833', 'EFO_1001467',
       'EFO_0003032', 'MONDO_0005301', 'EFO_0009491', 'EFO_0007167',
       'MONDO_0001085', 'EFO_0000398', 'EFO_0000096', 'EFO_0008590',
       'EFO_0003818', 'EFO_0007541', 'HP_0003072', 'EFO_0009609',
       'EFO_1001417', 'EFO_1000684', 'EFO_0004719', 'MONDO_0002280',
       'EFO_0001663', 'MONDO_0000870', 'EFO_1001413', 'EFO_0003086',
       'MONDO_0000432', 'EFO_0001379', 'EFO_0002626', 'EFO_0004599',
       'EFO_1001345', 'EFO_0000729', 'EFO_0000094', 'EFO_0007498',
       'EFO_0003144', 'EFO_1001466', 'EFO_1001469', 'EFO_0004238',
       'EFO_0007168', 'EFO_0007520', 'MONDO_0017287', 'EFO_0000220',
       'MONDO_0004095', 'EFO_1000635', 'EFO_0000479', 'EFO_1001176',
       'MONDO_0018150', 'EFO_0005558', 'EFO_1000049', 'EFO_0000768',
       'MONDO_0005271', 'EFO_0000255', 'EFO_0006803', 'MONDO_0001280',
       'MONDO_0008728', 'EFO_0000574', 'MONDO_0005178', 'EFO_1000694',
       'EFO_1000391', 'EFO_1000986', 'EFO_1000158', 'EFO_0003047',
       'EFO_0009538', 'EFO_0003063', 'HP_0002043', 'EFO_1001857',
       'MONDO_0010602', 'EFO_1000749', 'EFO_0003884', 'MONDO_0004975',
       'EFO_0002429', 'EFO_0001063', 'EFO_0000756', 'MONDO_0044881',
       'HP_0001915', 'EFO_0003106', 'MONDO_0002471', 'HP_0001873',
       'EFO_0004289', 'MONDO_0000430', 'MONDO_0002367', 'EFO_0004194',
       'MONDO_0010079', 'EFO_1001209', 'HP_0004398', 'MONDO_0007915',
       'EFO_0003929', 'EFO_0000673', 'EFO_1001119', 'MONDO_0015128',
       'EFO_0005539', 'MONDO_0009348', 'MONDO_0017276', 'EFO_1000764',
       'HP_0011868', 'EFO_0005297', 'EFO_1001492', 'EFO_0005140',
       'MONDO_0010679', 'MONDO_0007254', 'EFO_0000274', 'EFO_0000676',
       'EFO_1000941', 'EFO_0000373', 'EFO_0004276', 'EFO_0000384',
       'MONDO_0018076', 'EFO_0003843', 'EFO_1001365', 'MONDO_0005148',
       'EFO_0004255', 'EFO_0000095', 'MONDO_0100096', 'EFO_0000182',
       'EFO_0008517', 'EFO_1001231', 'EFO_0004251', 'MONDO_0018848',
       'EFO_1001222', 'EFO_0007208', 'EFO_0009449', 'MONDO_0019471',
       'EFO_0000621', 'EFO_0003060', 'MONDO_0044917', 'EFO_0000685',
       'EFO_0000341', 'MONDO_0020547', 'MONDO_0011719', 'EFO_1000039',
       'EFO_0000765', 'EFO_0007257', 'EFO_0005676'], dtype=object), 'count': 219}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 72 approved and 147 investigational indications."
CHEMBL1200437,"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO_|_XHKUDCCTVQUHJQ-LCYSNFERSA-N_|_Small molecule_|_True_|_QUINIDINE GLUCONATE_|_1950.0_|_4.0_|_CHEMBL1294_|_False_|_True_|_['Duraquin' 'Quinact' 'Quinaglute' 'Quinalan' 'Quinatime'
 'Quinidine gluconate']_|_['Dura-tab' 'Gluconic acid quinidine salt' 'Gluquinate' 'NSC-757297'
 'Quinidine gluconate' 'Quinidine mono-d-gluconate'
 'Quinidine monogluconate, d-']_|_[('DailyMed', array(['quinidine%20gluconate'], dtype=object)), ('chEBI', array(['27502'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001068', 'HP_0004308'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for malaria and ventricular arrhythmia. This drug has a black box warning from the FDA."
CHEMBL1200980,"C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O_|_HZEQBCVBILBTEP-ZFINNJDLSA-N_|_Small molecule_|_True_|_ESTROPIPATE_|_1977.0_|_4.0_|_CHEMBL494753_|_False_|_True_|_['Estropipate' 'Harmogen' 'Ogen' 'Ogen .625' 'Ogen 1.25' 'Ogen 2.5'
 'Ogen 5' 'Ortho-est']_|_['Estrone sulfate piperazine salt' 'Estropipate' 'NSC-758912'
 'Piperazine estrone sulfate' 'Piperazine estrone sulphate'
 'Sulestrex piperazine']_|_[('DailyMed', array(['estropipate'], dtype=object)), ('PubChem', array(['144206901', '26750028', '56463533'], dtype=object)), ('Wikipedia', array(['Estropipate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000096', 'GO_0042697', 'EFO_0004266', 'MONDO_0002146',
       'EFO_0003882'], dtype=object), 'count': 5}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA."
CHEMBL1201124,"NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O_|_BWHLPLXXIDYSNW-UHFFFAOYSA-N_|_Small molecule_|_True_|_KETOROLAC TROMETHAMINE_|_1989.0_|_4.0_|_CHEMBL469_|_False_|_True_|_['Acular' 'Acular ls' 'Acular preservative free' 'Acuvail'
 'Ketorolac tromethamine' 'Sprix' 'Toradol']_|_['Dolac' 'Ketorolac trometamol' 'Ketorolac tromethamine' 'Lixidol'
 'NSC-758637' 'Tarasyn']_|_[('DailyMed', array(['ketorolac%20tromethamine'], dtype=object)), ('PubChem', array(['124881877', '26747544', '49681816', '50106489', '8139924'],
      dtype=object)), ('chEBI', array(['6130'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003777', 'MONDO_0005129', 'EFO_1000859', 'MONDO_0005184',
       'EFO_1001139', 'MONDO_0005277', 'EFO_1001412', 'MP_0001845',
       'EFO_0003843', 'EFO_1001178', 'HP_0003418', 'EFO_0005854',
       'EFO_0004253', 'MONDO_0003005', 'HP_0200026'], dtype=object), 'count': 15}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201247,"CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O_|_BLCLNMBMMGCOAS-URPVMXJPSA-N_|_Protein_|_False_|_GOSERELIN_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Goserelin' 'Goserelin acetate' 'ICI 118,630' 'ICI-118630']_|_[('Wikipedia', array(['Goserelin'], dtype=object)), ('drugbank', array(['DB00014'], dtype=object))]_|_['CHEMBL1200501']_|_{'rows': array(['EFO_0006861', 'MONDO_0002087', 'MONDO_0008315', 'EFO_0001663',
       'EFO_0001663', 'MONDO_0008170', 'EFO_0000313', 'EFO_0000195',
       'MONDO_0007254', 'MONDO_0002158', 'EFO_0000545', 'MONDO_0000521',
       'EFO_0000305', 'EFO_0000196', 'GO_0042697', 'MONDO_0007254',
       'MONDO_0008170', 'MONDO_0008315', 'EFO_0001065', 'EFO_0000616',
       'EFO_1001757', 'EFO_0000305', 'EFO_0000731', 'EFO_0000673',
       'EFO_0000545', 'HP_0008209', 'EFO_0000673', 'EFO_0003869',
       'EFO_0000183', 'EFO_0000195', 'EFO_0000553', 'MONDO_0004669'],
      dtype=object), 'count': 32}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 4 approved and 23 investigational indications."
CHEMBL1201341,"CCOP(=O)(OCC)SCC[N+](C)(C)C_|_BJOLKYGKSZKIGU-UHFFFAOYSA-N_|_Small molecule_|_False_|_ECHOTHIOPHATE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Echothiophate' 'Echothiophate cation' 'Echothiophate ion' 'Ecothiopate'
 'Ecothiopate cation']_|_[('Wikipedia', array(['Echothiophate'], dtype=object)), ('drugbank', array(['DB01057'], dtype=object)), ('chEBI', array(['4753'], dtype=object))]_|_['CHEMBL1200367']_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for glaucoma."
CHEMBL1255901,"C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2_|_ZRJBHWIHUMBLCN-HZRLMBICSA-N_|_Small molecule_|_False_|_HUPERZINE A_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-huperzine a' '(-)-selagine' 'Huperzine a' 'L-huperzine a' 'Selagine']_|_nan_|_nan_|_{'rows': array(['MONDO_0002491', 'MONDO_0004975', 'EFO_0002610', 'MONDO_0043510'],
      dtype=object), 'count': 4}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1291,"CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C_|_BQIPXWYNLPYNHW-UHFFFAOYSA-N_|_Small molecule_|_False_|_METIPRANOLOL_|_1989.0_|_4.0_|_nan_|_True_|_True_|_['Glauline']_|_['BM-01.004' 'BM-01004' 'BM01.004' 'D,l-metipranolol' 'Metipranolol'
 'Optipranolol' 'VUAB-6453' 'VUAB6453' 'VUAB6453 (SPOFA)']_|_[('PubChem', array(['144205272', '29215465'], dtype=object)), ('Wikipedia', array(['Metipranolol'], dtype=object)), ('drugbank', array(['DB01214'], dtype=object)), ('chEBI', array(['6897'], dtype=object))]_|_['CHEMBL1200947']_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for glaucoma."
CHEMBL1520,"CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12_|_SECKRCOLJRRGGV-UHFFFAOYSA-N_|_Small molecule_|_False_|_VARDENAFIL_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Levitra']_|_['BAY-389456' 'BAY38-9456' 'Vardenafil' 'Vivanza']_|_[('Wikipedia', array(['Vardenafil'], dtype=object)), ('drugbank', array(['DB00862'], dtype=object)), ('chEBI', array(['46295'], dtype=object))]_|_['CHEMBL2106480' 'CHEMBL1874590' 'CHEMBL1339']_|_{'rows': array(['HP_0000360', 'EFO_0002687', 'EFO_0004234', 'HP_0000802',
       'MONDO_0009061', 'EFO_1001145', 'EFO_0004234', 'EFO_1000781',
       'EFO_0000284', 'MONDO_0005149'], dtype=object), 'count': 10}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for erectile dysfunction and impotence and has 7 investigational indications."
CHEMBL1626570,"COS(=O)(=O)[O-].C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1_|_NSILVESQCSUIAJ-UHFFFAOYSA-M_|_Small molecule_|_False_|_HEXOCYCLIUM METHYLSULFATE_|_1982.0_|_4.0_|_CHEMBL1201325_|_False_|_True_|_['Tral']_|_['Hexocyclium methyl sulfate' 'Hexocyclium methylsulfate'
 'Hexocyclium methylsulphate' 'Hexocyclium metilsulfate'
 'Hexocyclium metilsulphate' 'NSC-30256']_|_[('PubChem', array(['144206775'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL2068839,"Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1_|_RECBFDWSXWAXHY-IAGOWNOFSA-N_|_Small molecule_|_False_|_RISLENEMDAZ_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CERC-301' 'Cerc-301' 'MK-0657' 'MK-0657, (-)-' 'Rislenemdaz'
 'Rislenemdaz, (-)-']_|_[('drugbank', array(['DB12063'], dtype=object))]_|_['CHEMBL2036513']_|_{'rows': array(['MONDO_0002050', 'MONDO_0002009'], dtype=object), 'count': 2}_|_[ENSG00000176884,ENSG00000273079]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3112866,"C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1_|_UAXHPOBBKRWJGA-ZDUSSCGKSA-N_|_Small molecule_|_False_|_SAR-260301_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SAR-260301' 'SAR260301' 'Sar-260301']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000051382]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL319144,"O=P(O)(O)C(O)(Cc1cnc2ccccn12)P(=O)(O)O_|_VMMKGHQPQIEGSQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_MINODRONIC ACID_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Minodronate' 'Minodronic acid' 'NSC-725590' 'ONO-5920' 'YM 529' 'YM-529'
 'YM529']_|_[('PubChem', array(['144206806'], dtype=object)), ('Wikipedia', array(['Minodronic_acid'], dtype=object)), ('drugbank', array(['DB06548'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003854', 'EFO_0003882'], dtype=object), 'count': 2}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 2 investigational indications."
CHEMBL3545231,"c1ccc(-c2nnc(O[C@@H]3C4CC5C[C@H]3CN(C5)C4)s2)cc1_|_QZDCYUCETTWCMO-CDFKWJNJSA-N_|_Small molecule_|_False_|_ABT-126_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABT-126' 'Abt-126' 'Nelonicline']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545411,"nan_|_nan_|_Unknown_|_False_|_MF101_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Mf101']_|_nan_|_nan_|_{'rows': array(['GO_0042697', 'HP_0031217'], dtype=object), 'count': 2}_|_[ENSG00000140009]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4206033,"C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1_|_RNMAUIMMNAHKQR-QFBILLFUSA-N_|_Small molecule_|_False_|_BAY1436032_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Bay1436032']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000222'], dtype=object), 'count': 2}_|_[ENSG00000138413]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL445813,"O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl_|_OVPNQJVDAFNBDN-UHFFFAOYSA-N_|_Small molecule_|_False_|_AT-7519_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AT 7519' 'AT-7519' 'AT7519' 'At-7519' 'Cdki at7519']_|_[('PubChem', array(['137275934', '137275935'], dtype=object)), ('drugbank', array(['DB08142'], dtype=object))]_|_['CHEMBL497478']_|_{'rows': array(['EFO_0000616', 'EFO_0001378', 'EFO_1001469', 'EFO_0000095',
       'EFO_0000574'], dtype=object), 'count': 5}_|_[ENSG00000170312,ENSG00000135446,ENSG00000123374,ENSG00000164885,ENSG00000105810,ENSG00000134058,ENSG00000250506,ENSG00000102225,ENSG00000117266,ENSG00000132964,ENSG00000059758,ENSG00000248333,ENSG00000138395,ENSG00000155111,ENSG00000058091,ENSG00000136807,ENSG00000185324,ENSG00000065883,ENSG00000156345,ENSG00000167258]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4594275,"N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1_|_NLFLXLJXEIUQDL-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUSACITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASN-002' 'ASN002' 'Asn-002' 'Asn002' 'EN-3351' 'EN3351' 'Gusacitinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GUSACITINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4594276']_|_{'rows': array(['EFO_0005809', 'MONDO_0002334', 'EFO_0005809', 'MONDO_0002406',
       'MONDO_0002334', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000403',
       'EFO_0000274'], dtype=object), 'count': 9}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397,ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL568,"O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O_|_ADIMAYPTOBDMTL-UHFFFAOYSA-N_|_Small molecule_|_True_|_OXAZEPAM_|_1965.0_|_4.0_|_nan_|_False_|_True_|_['Lederpam' 'Oxazepam' 'Serax' 'Serenid fte' 'Zaxopam']_|_['J3.308A' 'NSC-169448' 'Oxazepam' 'Oxazepam civ' 'Oxozepam'
 'Temazepam impurity, oxazepam-' 'WY-3498']_|_[('DailyMed', array(['oxazepam'], dtype=object)), ('PubChem', array(['144205125', '144206372', '144207898', '144213809', '29215230'],
      dtype=object)), ('Wikipedia', array(['Oxazepam'], dtype=object)), ('drugbank', array(['DB00842'], dtype=object)), ('chEBI', array(['7823'], dtype=object))]_|_['CHEMBL3251468']_|_{'rows': array(['HP_0000713', 'EFO_0003768', 'HP_0000726', 'EFO_0006788',
       'MONDO_0002050', 'MONDO_0005090', 'EFO_0000764', 'EFO_0005230'],
      dtype=object), 'count': 8}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL577,"C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O_|_LZFZMUMEGBBDTC-QEJZJMRPSA-N_|_Small molecule_|_False_|_ENALAPRILAT ANHYDROUS_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Enalaprilat anhydrous' 'MK-421']_|_[('Wikipedia', array(['Enalaprilat'], dtype=object)), ('drugbank', array(['DB09477'], dtype=object)), ('chEBI', array(['4786'], dtype=object))]_|_['CHEMBL3989406']_|_{'rows': array(['EFO_0000407', 'EFO_0006346', 'EFO_0000537'], dtype=object), 'count': 3}_|_[ENSG00000159640]_|_Small molecule drug and has 3 investigational indications."
CHEMBL1171837,"Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12_|_PHXJVRSECIGDHY-UHFFFAOYSA-N_|_Small molecule_|_True_|_PONATINIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Iclusig']_|_['AP-24534' 'AP24534' 'Ponatinib']_|_[('PubChem', array(['137275996'], dtype=object)), ('Wikipedia', array(['Ponatinib'], dtype=object)), ('drugbank', array(['DB08901'], dtype=object)), ('chEBI', array(['78543'], dtype=object))]_|_['CHEMBL2105708']_|_{'rows': array(['EFO_0000222', 'EFO_0000571', 'EFO_0000198', 'EFO_0003841',
       'MONDO_0015277', 'EFO_0000339', 'EFO_0000519', 'EFO_0000222',
       'EFO_0000339', 'EFO_0000702', 'EFO_0000565', 'EFO_1000131',
       'EFO_0000616', 'EFO_0000220', 'EFO_0003060', 'MONDO_0004992',
       'EFO_1000131', 'MONDO_0011719', 'EFO_0000220'], dtype=object), 'count': 19}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for chronic myelogenous leukemia and acute lymphoblastic leukemia and has 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200907,"C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C#N)C[C@]35C)[C@@H]1CC[C@@H]2O_|_KVJXBPDAXMEYOA-CXANFOAXSA-N_|_Small molecule_|_False_|_TRILOSTANE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Modrastane' 'Modrenal']_|_['Desopan' 'NSC-758904' 'Trilostane' 'WIN 24,540' 'WIN-24540']_|_[('PubChem', array(['144206007', '144212723', '170465836'], dtype=object)), ('Wikipedia', array(['Trilostane'], dtype=object)), ('drugbank', array(['DB01108'], dtype=object)), ('chEBI', array(['32260'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005539', 'EFO_0000673'], dtype=object), 'count': 2}_|_[ENSG00000203859]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for adrenal gland disease and has 1 investigational indication."
CHEMBL1201837,"nan_|_nan_|_Protein_|_True_|_ECALLANTIDE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['DX-88' 'Ecallantide' 'Escallantide']_|_[('DailyMed', array(['ecallantide'], dtype=object)), ('DrugCentral', array(['4846'], dtype=object)), ('Wikipedia', array(['Ecallantide'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005532', 'MONDO_0019623'], dtype=object), 'count': 2}_|_[ENSG00000164344]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for hereditary angioedema and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1908318,"CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CNC(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1c[nH]c3ccccc13)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2_|_NGCNKEZHGRXHNL-WVWQGFTISA-N_|_Protein_|_False_|_NEPADUTANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nepadutant']_|_[('drugbank', array(['DB12538'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002027'], dtype=object), 'count': 1}_|_[ENSG00000075073]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2103836,"CCC[C@@H](C)C[C@H](N)CC(=O)O_|_JXEHXYFSIOYTAH-SFYZADRCSA-N_|_Small molecule_|_False_|_IMAGABALIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Imagabalin' 'PD 0332334' 'PD-0332334' 'PD0332334' 'PF-00195889']_|_[('drugbank', array(['DB12105'], dtype=object))]_|_['CHEMBL2105673']_|_{'rows': array(['EFO_1001892', 'HP_0000083', 'EFO_0005230'], dtype=object), 'count': 3}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2108312,"nan_|_nan_|_Protein_|_False_|_OZARELIX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['D-63153' 'D63153' 'Ozarelix']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000284'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108675,"nan_|_nan_|_Antibody_|_False_|_DUPILUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Dupixent' 'Regn668, sar231893']_|_['Dupilumab' 'REGN-668' 'REGN668' 'SAR-231893' 'SAR231893']_|_[('DailyMed', array(['dupilumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007425', 'EFO_0007141', 'EFO_0007140', 'EFO_0007187',
       'EFO_0000729', 'HP_0000964', 'EFO_0003060', 'EFO_0000274',
       'EFO_0000341', 'EFO_1000391', 'EFO_0004212', 'EFO_1001881',
       'MONDO_0004979', 'MONDO_0100096', 'MONDO_0002406', 'EFO_0005531',
       'EFO_0004192', 'HP_0000989', 'EFO_0000684', 'EFO_0005532',
       'HP_0100582', 'EFO_0004232', 'MONDO_0009735', 'EFO_1001361',
       'EFO_0007486', 'EFO_0005854', 'MONDO_0008315', 'EFO_1000740',
       'EFO_0000701'], dtype=object), 'count': 29}_|_[ENSG00000077238]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 25 investigational indications."
CHEMBL2108806,"nan_|_nan_|_Oligosaccharide_|_False_|_BEMIPARIN SODIUM_|_nan_|_4.0_|_nan_|_False_|_True_|_['Zibor']_|_['Badyket' 'Bemiparin sodium' 'Hibor' 'Zivor']_|_nan_|_nan_|_{'rows': array(['EFO_0003907', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL214268,"O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1_|_IPKZCLGGYKRDES-ZDUSSCGKSA-N_|_Small molecule_|_False_|_PHA-543613_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['J3.179.420J' 'PHA-543,613' 'PHA-543613' 'Pha-00543613' 'Pha-543613']_|_[('PubChem', array(['144210766'], dtype=object)), ('Wikipedia', array(['PHA-543,613'], dtype=object))]_|_nan_|_nan_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL2356097,"COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O_|_RGHAZVBIOOEVQX-UHFFFAOYSA-N_|_Small molecule_|_True_|_METOPROLOL SUCCINATE_|_1992.0_|_4.0_|_CHEMBL13_|_False_|_True_|_['Kapspargo sprinkle' 'Metoprolol succinate' 'Toprol Xl' 'Toprol-xl']_|_['H 93/26 SUCCINATE' 'Metoprolol hemisuccinate' 'Metoprolol succinate'
 'Seloken-zok' 'Selozok']_|_[('DailyMed', array(['metoprolol%20succinate'], dtype=object)), ('PubChem', array(['144206706'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679', 'EFO_0000341', 'EFO_0000537', 'EFO_0003913',
       'EFO_0000712', 'EFO_0000612', 'HP_0001653', 'EFO_0000275',
       'EFO_0000266', 'EFO_0003144', 'EFO_0000538', 'EFO_0000373',
       'Orphanet_79292'], dtype=object), 'count': 13}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL315795,"Cc1ncsc1CCCl_|_PCLITLDOTJTVDJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOMETHIAZOLE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Heminevrin']_|_['Chlormethiazole' 'Clomethiazole' 'Distraneurine' 'SCTZ [AS EDISYLATE]']_|_[('PubChem', array(['11113756', '144204482', '170466516', '26751938', '90341262'],
      dtype=object)), ('Wikipedia', array(['Clomethiazole'], dtype=object)), ('drugbank', array(['DB06470'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090'],
      dtype=object), 'count': 4}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications."
CHEMBL3545419,"nan_|_nan_|_Antibody_|_False_|_TELISOTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABT-700' 'Abt-700' 'Telisotuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989862,"C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)OCC(=O)NCC(F)(F)C(F)(F)F)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_SVCSMAZYWOQCBW-NVJMFHFGSA-N_|_Small molecule_|_False_|_PEFCALCITOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['M-5181' 'M-518101' 'M5181' 'M518101' 'Pefcalcitol']_|_[('drugbank', array(['DB11786'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4303323,"C[C@H](Nc1ncnc2[nH]cnc12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1_|_DOCINCLJNAXZQF-LBPRGKRZSA-N_|_Small molecule_|_False_|_ACALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Acalisib' 'CAL-120' 'CAL120' 'GS-9820' 'GS9820' 'Gs-9820']_|_nan_|_nan_|_{'rows': array(['EFO_0001642'], dtype=object), 'count': 1}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594403,"CC1=CN2CCS(=O)(=O)N=C2C(c2ccc(OC3CCCCC3)cc2)=N1_|_PXJBHEHFVQVDDS-UHFFFAOYSA-N_|_Small molecule_|_False_|_OSAVAMPATOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Osavampator' 'Tak-653']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650369,"nan_|_nan_|_Antibody_|_False_|_ABELACIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Abelacimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0004286'], dtype=object), 'count': 2}_|_[ENSG00000088926]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL515387,"O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1_|_QWEWGXUTRTXFRF-KBPBESRZSA-N_|_Small molecule_|_False_|_GOSOGLIPTIN_|_2016.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Gosogliptin' 'PF-00734200' 'PF-734,200' 'PF-734200']_|_[('drugbank', array(['DB08382'], dtype=object))]_|_['CHEMBL3526419']_|_{'rows': array(['EFO_0003884', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 2 investigational indications."
CHEMBL5314381,"CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.O=S(=O)(O)OC[C@H]1O[C@@](COS(=O)(=O)O)(O[C@H]2O[C@H](COS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@@H](OS(=O)(=O)O)[C@@H]1OS(=O)(=O)O_|_BCPSLKYBXGKPIW-RTXWKGGWSA-N_|_Small molecule_|_False_|_IRINOTECAN SUCROSOFATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Irinotecan sucrosofate' 'MM-398' 'PEP-02']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'MONDO_0004992', 'EFO_1000657', 'EFO_0000616',
       'EFO_0002618'], dtype=object), 'count': 5}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL563251,"CN1C[C@@H]2[C@H](C1)[C@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1_|_KYLOBHXXQOZRKK-FICVDOATSA-N_|_Small molecule_|_False_|_PF-03463275_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-03463275' 'Pf-3463275']_|_[('drugbank', array(['DB11993'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000196517]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL61006,"CC(N)C(O)c1ccccc1_|_DLNKOYKMWOXYQA-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENYLPROPANOLAMINE_|_1958.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Fansia' 'NSC-9920' 'Norephedrine' 'Phenylfenesin' 'Phenylpropanolamine'
 'Propadrine' 'Rinexin']_|_nan_|_['CHEMBL1200695' 'CHEMBL2146104' 'CHEMBL1201535']_|_{'rows': array(['HP_0001742'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958 and is indicated for nasal congestion. It was withdrawn in at least one region."
CHEMBL1200342,"CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_HYRKAAMZBDSJFJ-LFDBJOOHSA-N_|_Small molecule_|_False_|_PARAMETHASONE ACETATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Haldrone']_|_['Dillar' 'Paramethasone' 'Paramethasone 21-acetate'
 'Paramethasone acetate']_|_[('PubChem', array(['144206683'], dtype=object)), ('drugbank', array(['DB14657'], dtype=object)), ('chEBI', array(['31963'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200479,"CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1.Cl_|_GUBNMFJOJGDCEL-UHFFFAOYSA-N_|_Small molecule_|_False_|_DICYCLOMINE HYDROCHLORIDE_|_1950.0_|_4.0_|_CHEMBL1123_|_False_|_True_|_['Bentyl' 'Bentyl preservative free'
 'Dicyclomine Hydrochloride (Preservative-Free)'
 'Dicyclomine hydrochloride'
 'Dicyclomine hydrochloride (preservative free)' 'Merbentyl'
 'Merbentyl 20']_|_['Bentylol' 'Dicyclomine hcl' 'Dicyclomine hydrochloride'
 'Dicycloverine hydrochloride' 'Kolantyl hydrochloride' 'NSC-404381'
 'Wyovin']_|_[('DailyMed', array(['dicyclomine%20hydrochloride'], dtype=object)), ('PubChem', array(['26747501', '26747502', '50106212', '50106213', '50106214',
       '56423126', '855865'], dtype=object)), ('chEBI', array(['4515'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950 and is indicated for irritable bowel syndrome."
CHEMBL1200807,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC_|_ISHXLNHNDMZNMC-VTKCIJPMSA-N_|_Small molecule_|_False_|_NORELGESTROMIN_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Deacetylnorgestimate' 'Norelgestromin' 'RWJ-10553']_|_[('DailyMed', array(['norelgestromin'], dtype=object)), ('PubChem', array(['144206200'], dtype=object)), ('Wikipedia', array(['Norelgestromin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'HP_0100608', 'EFO_0002950'], dtype=object), 'count': 3}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 investigational indications."
CHEMBL1201629,"nan_|_nan_|_Protein_|_False_|_INSULIN PURIFIED BEEF_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Regular iletin ii']_|_['(beef) insulin' 'Bovine insulin highly purified' 'Bovine insulinum'
 'Insulin (beef)' 'Insulin (bison bonasus)' 'Insulin beef'
 'Insulin bovine' 'Insulin purified beef' 'Insulin, regular, beef'
 'Insulin,lente,beef' 'Insulin,nph,beef' 'Insulin,semilente,beef'
 'Insulin,ultralente,beef']_|_[('DrugCentral', array(['5192'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for diabetes mellitus."
CHEMBL1237024,"nan_|_nan_|_Cell_|_False_|_SIPULEUCEL-T_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['APC-8015' 'APC8015' 'Sipuleucel-t']_|_[('Wikipedia', array(['Sipuleucel-T'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0008315', 'EFO_0000673', 'EFO_0000196'],
      dtype=object), 'count': 4}_|_[ENSG00000014257]_|_Cell drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and prostate cancer and has 2 investigational indications."
CHEMBL1303,"CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1_|_KFQYTPMOWPVWEJ-INIZCTEOSA-N_|_Small molecule_|_False_|_ROTIGOTINE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Leganto' 'Neupro']_|_['Leganto' 'Rotigotine' 'SPM 962' 'SPM-962']_|_[('DailyMed', array(['rotigotine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/leganto'],
      dtype=object)), ('PubChem', array(['144206180', '170465204', '50113269'], dtype=object)), ('Wikipedia', array(['Rotigotine'], dtype=object)), ('drugbank', array(['DB05271'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003890', 'MONDO_0004975', 'MONDO_0005180', 'EFO_0004270',
       'EFO_0005687', 'EFO_0000712'], dtype=object), 'count': 6}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for parkinson disease and restless legs syndrome and has 4 investigational indications."
CHEMBL2027925,Nc1c(Cl)cc(-c2nn(C3CCN(CCc4ccccc4)CC3)c(=O)o2)c2c1OCCO2_|_MDBNTXARNGRHEV-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAPESEROD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Capeserod' 'SL650155' 'Sl65.0155']_|_nan_|_['CHEMBL2022742']_|_nan_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108185,"nan_|_nan_|_Protein_|_False_|_CORIFOLLITROPIN ALFA_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Elonva']_|_['Corifollitropin alfa' 'MK-8962' 'ORG 36286' 'ORG-36286' 'SCH 900962'
 'SCH-900962']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/elonva'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018555', 'GO_0060279', 'EFO_0000545'], dtype=object), 'count': 3}_|_[ENSG00000170820]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for positive regulation of ovulation and has 2 investigational indications."
CHEMBL2108492,"nan_|_nan_|_Protein_|_False_|_INSULIN ZINC, EXTENDED_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ins humulin zn' 'Ins ultrat' 'Ins ultrat mc']_|_['Crystalline (aqueous suspension)' 'Insulin zinc injection'
 'Insulin zinc injection, crystalline (aqueous suspension)'
 'Insulin zinc suspension ' 'Insulin zinc suspension (crystalline)'
 'Insulin zinc, extended']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV."
CHEMBL2108591,nan_|_nan_|_Antibody_|_False_|_ELSILIMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['B-e8']_|_['Anti-il-6 mab b-e8' 'Antibody b-e8' 'Elsilimomab' 'Mab b-e8']_|_nan_|_nan_|_nan_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109284,nan_|_nan_|_Antibody_|_False_|_CMB-401_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CMB-401' 'HCTMO1-CALICHEAMICIN']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109642,"nan_|_nan_|_Antibody_|_False_|_A33 131I_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A33' 'A33 131i']_|_nan_|_nan_|_{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}_|_[ENSG00000143167]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL21333,"O=C(Nc1cccc2c(=O)cc(-c3nnn[nH]3)oc12)c1ccc(OCCCCc2ccccc2)cc1_|_NBQKINXMPLXUET-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRANLUKAST_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Azlaire' 'CCN 00401' 'CCN-00401' 'ONO 1078' 'ONO-1078' 'Pranlukast'
 'RS 411' 'RS-411' 'SB 205312' 'SB-205312']_|_[('PubChem', array(['144206505'], dtype=object)), ('Wikipedia', array(['Pranlukast'], dtype=object)), ('drugbank', array(['DB01411'], dtype=object))]_|_['CHEMBL3810125']_|_{'rows': array(['EFO_0003956', 'HP_0006536', 'EFO_0007486'], dtype=object), 'count': 3}_|_[ENSG00000173198]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 investigational indications."
CHEMBL2364612,"O=C(CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O)OCCCCO[N+](=O)[O-]_|_LOVMMUBRQUFEAH-UIEAZXIASA-N_|_Small molecule_|_False_|_LATANOPROSTENE BUNOD_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Vesneo' 'Vyzulta']_|_['BOL-303259-X' 'Bol-303259-x' 'Latanoprostene bunod' 'NCX 116' 'NCX-116'
 'NCX116' 'PF-3187207']_|_[('DailyMed', array(['latanoprostene%20bunod'], dtype=object)), ('drugbank', array(['DB11660'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005041', 'EFO_0004190', 'EFO_1001069'], dtype=object), 'count': 3}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications."
CHEMBL3218576,"COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21_|_PZBCKZWLPGJMAO-UHFFFAOYSA-N_|_Small molecule_|_False_|_COPANLISIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BAY 80-6946' 'BAY-80-6946' 'BAY80-6946' 'Bay-80-6946' 'Copanlisib']_|_[('drugbank', array(['DB12483'], dtype=object))]_|_['CHEMBL3545068']_|_{'rows': array(['EFO_0000403', 'EFO_0000616', 'EFO_0000403', 'MONDO_0018906',
       'EFO_0001378', 'EFO_0005537', 'EFO_0000574', 'MONDO_0018906',
       'EFO_0000305', 'EFO_0000305', 'MONDO_0007254', 'EFO_1001469',
       'EFO_0000220', 'EFO_0005221', 'EFO_0000183', 'EFO_0003060',
       'EFO_0000096', 'EFO_0008528', 'HP_0000083', 'EFO_0000616',
       'EFO_0000096', 'EFO_0005952', 'EFO_0000707', 'MONDO_0021063',
       'EFO_0004606', 'EFO_0007532', 'MONDO_0008315', 'EFO_1001051',
       'EFO_1001469', 'EFO_0000095'], dtype=object), 'count': 30}_|_[ENSG00000171608,ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 26 investigational indications."
CHEMBL3785197,"CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC_|_NRWORBQAOQVYBJ-GJZUVCINSA-N_|_Small molecule_|_False_|_OBICETRAPIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG-899' 'DEZ-001' 'Obicetrapib' 'TA-8995' 'Ta-8995']_|_[('drugbank', array(['DB14890'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005', 'EFO_0000319', 'MONDO_0004975'], dtype=object), 'count': 3}_|_[ENSG00000087237]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3990038,"nan_|_nan_|_Antibody_|_False_|_FLOTETUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Flotetuzumab' 'MGD-006' 'MGD006' 'RES-234' 'RES234' 'S-80880' 'S80880']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000292332,ENSG00000185291,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4101807,"CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O_|_FWCVZAQENIZVMY-UHFFFAOYSA-N_|_Small molecule_|_False_|_VOXELOTOR_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Oxbryta']_|_['GBT-440' 'GBT440' 'GTX-011' 'Gbt440' 'Voxelotor']_|_[('DailyMed', array(['voxelotor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta'],
      dtype=object)), ('drugbank', array(['DB14975'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'MONDO_0002280', 'EFO_0004272', 'EFO_0001421',
       'EFO_0000768', 'EFO_0004610', 'MONDO_0011382'], dtype=object), 'count': 7}_|_[ENSG00000206172,ENSG00000188536,ENSG00000244734]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications."
CHEMBL4297181,"CO[C@@H](C)Cn1c(=O)n(C)c2cnc3ccc(-c4cncc(C(C)(C)O)c4)cc3c21_|_ACCFLVVUVBJNGT-AWEZNQCLSA-N_|_Small molecule_|_False_|_SAMOTOLISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY 3023414' 'LY-3023414' 'LY3023414' 'Ly-3023414' 'Samotolisib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SAMOTOLISIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12167'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003869', 'MONDO_0008315', 'EFO_0005952', 'EFO_0009708',
       'EFO_0004142', 'EFO_0000616', 'MONDO_0005184', 'MONDO_0007254',
       'EFO_0000588', 'MONDO_0011962', 'EFO_0003060'], dtype=object), 'count': 11}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL4297572,"nan_|_nan_|_Unknown_|_False_|_ABBV-3373_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-3373' 'Abbv-3373']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000113580,ENSG00000232810]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297580,"nan_|_nan_|_Antibody_|_False_|_ETOKIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ANB-020' 'ANB020' 'Anb020' 'Etokimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETOKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000274', 'EFO_0007425', 'EFO_0007486',
       'HP_0011123'], dtype=object), 'count': 5}_|_[ENSG00000137033]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4297729,"nan_|_nan_|_Antibody_|_False_|_COSIBELIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CK-301' 'Ck-301' 'Cosibelimab' 'TG-1501' 'Tg-1501']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/COSIBELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4298197,"nan_|_nan_|_Oligonucleotide_|_False_|_VUPANORSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AKCEA-ANGPTL3-LRx' 'ISIS 703802' 'ISIS-703802' 'Vupanorsen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VUPANORSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0020088', 'MONDO_0018328', 'MONDO_0021187'], dtype=object), 'count': 3}_|_[ENSG00000132855,ENSG00000141505]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL448,"CCCC(C)C1(CC)C(=O)NC(=O)NC1=O_|_WEXRUCMBJFQVBZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PENTOBARBITAL_|_1973.0_|_4.0_|_nan_|_True_|_True_|_['Nembutal']_|_['Mebubarbital' 'Mebumal' 'NSC-28708' 'Pentobarbital'
 'Pentobarbital calcium' 'Pentobarbital cii' 'Pentobarbitone']_|_[('PubChem', array(['144205108', '26750091'], dtype=object)), ('Wikipedia', array(['Pentobarbital'], dtype=object)), ('drugbank', array(['DB00312'], dtype=object)), ('chEBI', array(['7983'], dtype=object))]_|_['CHEMBL971']_|_{'rows': array(['EFO_0003890', 'EFO_0008526', 'EFO_0004698', 'EFO_0003777',
       'MONDO_0043510'], dtype=object), 'count': 5}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for insomnia and has 4 investigational indications. It was withdrawn in at least one region."
CHEMBL4594584,"nan_|_nan_|_Unknown_|_False_|_ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Adynovi']_|_['Adynovate' 'Adynovi'
 'Antihemophilic factor, pegylated (mw 20000) human sequence recombinant'
 'Pegylated recombinant factor viii' 'Pegylated rfviii'
 'Rurioctocog alfa pegol']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Unknown drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hemophilia a."
CHEMBL4650434,"nan_|_nan_|_Antibody_|_False_|_ENIBARCIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adrecizumab' 'Enibarcimab' 'HAM-8101' 'HAM8101']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0003144', 'EFO_0006834'], dtype=object), 'count': 3}_|_[ENSG00000148926]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL5267842,"N#Cc1cccc(-c2ccc3ncc(-c4cc(F)cc(F)c4)c(N4CCC(N)CC4)c3c2)c1O_|_GHILNKWBALQPDP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PALTUSOTINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CRN-00808' 'CRN00808' 'Crn00808' 'Paltusotine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PALTUSOTINE/relevant/1/'],
      dtype=object))]_|_['CHEMBL5314560']_|_{'rows': array(['EFO_1001485', 'EFO_1000852', 'EFO_1001485', 'EFO_1001901',
       'EFO_1000852', 'EFO_1001901'], dtype=object), 'count': 6}_|_[ENSG00000180616]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL553025,"CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2_|_GBABOYUKABKIAF-IELIFDKJSA-N_|_Small molecule_|_True_|_VINORELBINE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-760087' 'Navelbin' 'Vinorelbine' 'Vinorelbine Base']_|_[('PubChem', array(['124893200', '29217724', '50111727'], dtype=object)), ('drugbank', array(['DB00361'], dtype=object)), ('chEBI', array(['480999'], dtype=object))]_|_['CHEMBL538943']_|_{'rows': array(['EFO_0000437', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0021063', 'EFO_0004284', 'EFO_0002918',
       'MONDO_0004992', 'EFO_1000895', 'EFO_0003869', 'EFO_0000313',
       'EFO_0000770', 'EFO_0003050', 'EFO_1000026', 'EFO_0003032',
       'EFO_0000437', 'EFO_0000571', 'MONDO_0007254', 'EFO_0000313',
       'MONDO_0002367', 'MONDO_0021117', 'MONDO_0008315', 'EFO_0000616',
       'EFO_0000621', 'EFO_0000616', 'EFO_0005537', 'EFO_0005952',
       'EFO_0000248', 'EFO_1000158', 'EFO_0003869', 'EFO_0000403',
       'EFO_0001071', 'MONDO_0008903', 'MONDO_0002158', 'EFO_0000389',
       'EFO_0000248', 'EFO_0002617', 'EFO_0000571', 'EFO_0003060',
       'EFO_0000211', 'EFO_0000691', 'EFO_0001378', 'EFO_0000691',
       'EFO_0006861', 'MONDO_0002974', 'EFO_0000588', 'MONDO_0009348',
       'EFO_0000183', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0008903',
       'EFO_0000183', 'EFO_0000702', 'MONDO_0001187', 'EFO_0005922',
       'EFO_0000565', 'EFO_1000294', 'EFO_0001416', 'MONDO_0001402',
       'MONDO_0011962', 'EFO_0005952', 'EFO_0000574', 'MONDO_0007254'],
      dtype=object), 'count': 64}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for cancer and neoplasm and has 52 investigational indications. This drug has a black box warning from the FDA."
CHEMBL565,"CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1_|_KNHUKKLJHYUCFP-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOFIBRATE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Atromid-s' 'Clofibrate']_|_['AY-61123' 'Chlorfenisate' 'Clofibrate'
 'Ethyl p-chlorophenoxyisobutyrate' 'ICI 28257' 'ICI-28257' 'NSC-79389']_|_[('PubChem', array(['11110971', '119396', '124879709', '144203667', '144209612',
       '170465329', '50106069', '57260455', '85230976', '90341380'],
      dtype=object)), ('TG-GATEs', array(['6'], dtype=object)), ('Wikipedia', array(['Clofibrate'], dtype=object)), ('drugbank', array(['DB00636'], dtype=object)), ('chEBI', array(['3750'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001375', 'EFO_0000612', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL592435,"OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1_|_RBZNJGHIKXAKQE-UHFFFAOYSA-N_|_Small molecule_|_False_|_DERENOFYLLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Derenofylline' 'SLV-320' 'SLV320' 'Slv320']_|_nan_|_nan_|_{'rows': array(['EFO_0000373'], dtype=object), 'count': 1}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL74355,"COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC_|_HXTGXYRHXAGCFP-OAQYLSRUSA-N_|_Small molecule_|_False_|_VOLINANSERIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['M-100907' 'M100907' 'MDL-100.907' 'MDL-100907' 'MDL100.907' 'Mdl-100907'
 'Volinanserin']_|_[('PubChem', array(['144210564'], dtype=object)), ('Wikipedia', array(['Volinanserin'], dtype=object))]_|_['CHEMBL5173614' 'CHEMBL5189294']_|_{'rows': array(['MONDO_0002050', 'EFO_0008568'], dtype=object), 'count': 2}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL744,"Nc1nc2ccc(OC(F)(F)F)cc2s1_|_FTALBRSUTCGOEG-UHFFFAOYSA-N_|_Small molecule_|_False_|_RILUZOLE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Exservan' 'Rilutek' 'Riluzole' 'Riluzole zentiva' 'Teglutik'
 'Tiglutik kit']_|_['BHV-0223' 'NSC-753433' 'NSC-759823' 'RP 54274' 'RP-54274' 'Riluzole'
 'Tiglutik']_|_[('DailyMed', array(['riluzole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/riluzole-zentiva'],
      dtype=object)), ('PubChem', array(['104171227', '11111723', '11113346', '124881305', '144203803',
       '170464928', '26751529', '50104104', '85231207', '855844',
       '90341557'], dtype=object)), ('Wikipedia', array(['Riluzole'], dtype=object)), ('drugbank', array(['DB00740'], dtype=object)), ('chEBI', array(['8863'], dtype=object))]_|_['CHEMBL1531817']_|_{'rows': array(['EFO_0001358', 'EFO_0003100', 'MONDO_0004976', 'MONDO_0007739',
       'MONDO_0005301', 'MONDO_0004985', 'HP_0002196', 'MONDO_0002050',
       'EFO_0000275', 'MONDO_0007254', 'MONDO_0019037', 'MONDO_0008458',
       'EFO_1001919', 'MONDO_0002009', 'EFO_1001050', 'EFO_0003756',
       'EFO_0008522', 'EFO_0008525', 'EFO_0000389', 'MONDO_0016163',
       'MONDO_0000437', 'MONDO_0004975', 'EFO_0004242'], dtype=object), 'count': 23}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for amyotrophic lateral sclerosis and has 22 investigational indications."
CHEMBL817,"Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1_|_OUDSBRTVNLOZBN-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLAZAMIDE_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Tolazamide' 'Tolinase']_|_['NSC-70762' 'Tolazamide' 'U-17835']_|_[('PubChem', array(['11111870', '124881598', '144203832', '144208705', '144210734',
       '170465136', '26747047', '26751566', '50104182', '56422126',
       '85231252', '855941'], dtype=object)), ('Wikipedia', array(['Tolazamide'], dtype=object)), ('drugbank', array(['DB00839'], dtype=object)), ('chEBI', array(['9613'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and is indicated for diabetes mellitus and type 2 diabetes mellitus."
CHEMBL1200843,"CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1.O=C(O)/C=C\C(=O)O_|_NOFOWWRHEPHDCY-DAUURJMHSA-N_|_Small molecule_|_False_|_METHYLERGONOVINE MALEATE_|_1946.0_|_4.0_|_CHEMBL1201356_|_False_|_True_|_['Methergine' 'Methylergonovine maleate']_|_['Methylergometrine maleate' 'Methylergonovine maleate'
 'Methylergonovinium bimaleate' 'NSC-757104']_|_[('DailyMed', array(['methylergonovine%20maleate'], dtype=object)), ('PubChem', array(['93576602'], dtype=object))]_|_nan_|_{'rows': array(['MP_0001914'], dtype=object), 'count': 1}_|_[ENSG00000135914,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for hemorrhage."
CHEMBL1201319,"C[C@H](N)[C@H](O)c1cccc(O)c1_|_WXFIGDLSSYIKKV-RCOVLWMOSA-N_|_Small molecule_|_False_|_METARAMINOL_|_1954.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Metaraminol']_|_[('Wikipedia', array(['Metaraminol'], dtype=object)), ('drugbank', array(['DB00610'], dtype=object)), ('chEBI', array(['6794'], dtype=object))]_|_['CHEMBL4303541' 'CHEMBL2062262' 'CHEMBL3184244' 'CHEMBL2062343']_|_{'rows': array(['EFO_0000668', 'EFO_0005251', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL1201752,"C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1_|_FABUFPQFXZVHFB-PVYNADRNSA-N_|_Small molecule_|_True_|_IXABEPILONE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Ixempra' 'Ixempra kit']_|_['Azaepothilone b' 'BMS 247550-01' 'BMS-247550' 'BMS-247550-01'
 'Ixabepilone' 'Ixempra' 'NSC-747973']_|_[('Wikipedia', array(['Ixabepilone'], dtype=object)), ('drugbank', array(['DB04845'], dtype=object)), ('chEBI', array(['63605'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'MONDO_0004992', 'MONDO_0004192', 'EFO_1001968',
       'EFO_0000182', 'EFO_0003897', 'EFO_1001465', 'EFO_0005221',
       'EFO_1000613', 'MONDO_0005411', 'MONDO_0007254', 'EFO_0006861',
       'MONDO_0044926', 'EFO_0000305', 'EFO_0007532', 'EFO_1001469',
       'MONDO_0011962', 'MONDO_0004986', 'EFO_0000403', 'EFO_0000349',
       'EFO_0000565', 'EFO_0000309', 'MONDO_0008903', 'EFO_0002499',
       'EFO_0000681', 'EFO_0003869', 'MONDO_0018906', 'EFO_0000673',
       'EFO_0000616', 'MONDO_0002158', 'EFO_0002938', 'EFO_0003871',
       'EFO_0002618', 'EFO_0003032', 'EFO_0000574', 'EFO_0003060',
       'EFO_0006859', 'MONDO_0002087', 'MONDO_0008170', 'EFO_0006352',
       'EFO_0007535', 'EFO_1001951', 'MONDO_0008315'], dtype=object), 'count': 43}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 38 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1345,"N=C(N)NCCN1CCCCCCC1.O=S(=O)(O)O_|_YUFWAVFNITUSHI-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANETHIDINE MONOSULFATE_|_1960.0_|_4.0_|_CHEMBL765_|_False_|_True_|_['Ganda' 'Guanethidine monosulfate' 'Ismelin' 'Ismeline' 'Lotens']_|_['Guanethidine monosulfate' 'Guanethidine monosulphate']_|_[('PubChem', array(['26748068'], dtype=object)), ('chEBI', array(['51016'], dtype=object))]_|_nan_|_nan_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1595,"COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341_|_RBOXVHNMENFORY-DNJOTXNNSA-N_|_Small molecule_|_False_|_DIHYDROCODEINE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.alpha.-hydrocodol' '8,14-dihydroneopine' 'Codhydrine' 'Dehacodin'
 'Dh-codeine' 'Dihydrocodeine' 'IDS-ND-008(SECT.2)' 'NSC-231319'
 'Novicondin' 'Rapacodin' 'Remedacen']_|_[('Wikipedia', array(['Dihydrocodeine'], dtype=object)), ('drugbank', array(['DB01551'], dtype=object))]_|_['CHEMBL2062266']_|_{'rows': array(['EFO_0003843', 'EFO_0003843'], dtype=object), 'count': 2}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and is indicated for pain."
CHEMBL1614650,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](N)CC3_|_ZVYVPGLRVWUPMP-FYSMJZIKSA-N_|_Small molecule_|_False_|_EXATECAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DX-8951' 'Exatecan']_|_[('Wikipedia', array(['Exatecan'], dtype=object)), ('drugbank', array(['DB12185'], dtype=object))]_|_['CHEMBL3989759']_|_{'rows': array(['MONDO_0008315', 'EFO_0000565', 'MONDO_0002158', 'EFO_0002618',
       'MONDO_0008170', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002691',
       'EFO_1000158', 'MONDO_0002974', 'EFO_0000691', 'EFO_0000616',
       'EFO_0000198', 'MONDO_0007254', 'EFO_0000574'], dtype=object), 'count': 15}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications."
CHEMBL1693,"CCN(CC)C(C)C(=O)c1ccccc1.Cl_|_ICFXZZFWRWNZMA-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIETHYLPROPION HYDROCHLORIDE_|_1959.0_|_4.0_|_CHEMBL1194666_|_False_|_True_|_['Apisate' 'Diethylpropion hydrochloride' 'Tenuate' 'Tenuate dospan'
 'Tepanil' 'Tepanil ten-tab']_|_['Amfepramone hydrochloride' 'Anorex' 'D03801' 'Diethylpropion HCl'
 'Diethylpropion hcl' 'Diethylpropion hydrochloride'
 'Diethylpropion hydrochloride civ' 'Dobesin' 'Moderatan' 'Prefamone'
 'Regenon']_|_[('DailyMed', array(['diethylpropion%20hydrochloride'], dtype=object)), ('PubChem', array(['170464650'], dtype=object)), ('chEBI', array(['643703'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for obesity."
CHEMBL1742984,"nan_|_nan_|_Antibody_|_False_|_AMATUXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amatuximab' 'MORAb-009']_|_nan_|_nan_|_{'rows': array(['EFO_0000588', 'MONDO_0004992', 'EFO_0000770', 'EFO_0002618'],
      dtype=object), 'count': 4}_|_[ENSG00000102854]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1743012,"nan_|_nan_|_Antibody_|_False_|_ENOKIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['7F3COM-2H2' '7f3com2h2' 'Enokizumab' 'MEDI 528' 'MEDI-528']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000145839]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL19236,"COc1nc(C)nc(Cl)c1NC1=NCCN1_|_WPNJAUFVNXKLIM-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOXONIDINE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Fisiotens' 'Normatens' 'Physiotens']_|_['BDF-5896' 'BDF5896' 'BE-5895' 'BE5895' 'LY-326869' 'LY326869'
 'Moxonidine']_|_[('PubChem', array(['11111430', '11111431', '144203741', '170466534', '85148350',
       '90341434'], dtype=object)), ('Wikipedia', array(['Moxonidine'], dtype=object)), ('drugbank', array(['DB09242'], dtype=object)), ('chEBI', array(['7009'], dtype=object))]_|_['CHEMBL1256287']_|_{'rows': array(['EFO_0000537', 'EFO_0005252', 'EFO_0003777'], dtype=object), 'count': 3}_|_[ENSG00000010322]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for hypertension and has 2 investigational indications."
CHEMBL1950649,"CCNC(=O)[C@H]1O[C@@H](n2cnc3c(N)nc(C#CC[C@H]4CC[C@H](C(=O)OC)CC4)nc32)[C@H](O)[C@@H]1O_|_FLEVIENZILQUKB-XTWQNQIISA-N_|_Small molecule_|_False_|_APADENOSON_|_nan_|_3.0_|_nan_|_False_|_False_|_['Stedivaze']_|_['Apadenoson' 'BMS-068645' 'BMS068645' 'Bms-068645' 'DWH-146E']_|_[('drugbank', array(['DB05009'], dtype=object))]_|_nan_|_nan_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL2108041,"nan_|_nan_|_Antibody_|_False_|_OCRELIZUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Ocrevus']_|_['2H7' 'Ocrelizumab' 'PR-070769' 'PR070769' 'R-1594' 'RG-1594']_|_[('DailyMed', array(['ocrelizumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301', 'EFO_0003929', 'EFO_0005952', 'EFO_0003840',
       'EFO_0000540', 'MONDO_0007915', 'EFO_0008520', 'EFO_0000685',
       'EFO_0007332'], dtype=object), 'count': 9}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 4 investigational indications."
CHEMBL2110618,CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(C(=O)OC[C@H](COC(=O)N(Cc2cccc[n+]2CC)C(=O)c2ccccc2OC)OC)CC1_|_HGOAIWZFTWACBD-RRHRGVEJSA-O_|_Small molecule_|_False_|_MINOPAFANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E-5880' 'Minopafant']_|_nan_|_['CHEMBL2104419']_|_nan_|_[ENSG00000169403]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL216981,"CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1_|_RXIUEIPPLAFSDF-CYBMUJFWSA-N_|_Small molecule_|_False_|_NAVARIXIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-7123' 'Navarixin' 'PS-291822' 'PS291822' 'SCH-527123' 'SCH527123']_|_nan_|_['CHEMBL2103864']_|_{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0000676'], dtype=object), 'count': 3}_|_[ENSG00000180871,ENSG00000163464]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL266497,"O=C1NC(=O)[C@@]2(CCOc3ccc(F)cc32)N1_|_LXANPKRCLVQAOG-NSHDSACASA-N_|_Small molecule_|_False_|_SORBINIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CP-45,634' 'CP-45634' 'NSC-355082' 'Sorbinil']_|_[('PubChem', array(['144205232', '170466611', '29215399'], dtype=object)), ('drugbank', array(['DB02712'], dtype=object)), ('chEBI', array(['102029'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003770'], dtype=object), 'count': 1}_|_[ENSG00000085662]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL271227,"CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)C(c4cccnc4)=CC[C@@H]32)C1_|_UVIQSJCZCSLXRZ-UBUQANBQSA-N_|_Small molecule_|_False_|_ABIRATERONE ACETATE_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Abiraterone krka' 'Yonsa' 'Zytiga']_|_['Abiraterone acetate' 'CB-7630' 'CB7630' 'NSC-748121' 'NSC-749227']_|_[('DailyMed', array(['abiraterone%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/abiraterone-krka',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/zytiga'],
      dtype=object)), ('PubChem', array(['144207138'], dtype=object)), ('chEBI', array(['68639'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'MONDO_0018479', 'EFO_0003826', 'MONDO_0007254',
       'MONDO_0008728', 'EFO_0001663', 'HP_0000083', 'EFO_0003060',
       'EFO_0000196', 'EFO_0000673', 'EFO_0001421', 'MONDO_0008315'],
      dtype=object), 'count': 12}_|_[ENSG00000148795]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 8 investigational indications."
CHEMBL3184143,"N=C(N)NCC1COC2(CCCCC2)O1.N=C(N)NCC1COC2(CCCCC2)O1.O=S(=O)(O)O_|_RTEVGQJRTFFMLL-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANADREL SULFATE_|_1982.0_|_4.0_|_CHEMBL1037_|_False_|_True_|_['Hylorel']_|_['CL-1388R' 'Guanadrel sulfate' 'Guanadrel sulphate' 'NSC-760062'
 'U-28,288D' 'U-28288D']_|_[('PubChem', array(['144204146'], dtype=object)), ('chEBI', array(['5556'], dtype=object))]_|_nan_|_nan_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL3359265,"Cc1nc2ccc(C(=O)N3CCC4(CC3)CC(=O)c3c(cnn3C(C)C)C4)cc2[nH]1_|_BDXXSFOJPYSYOC-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-05175157_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-05175157']_|_[('drugbank', array(['DB12096'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003894', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000278540,ENSG00000076555]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL362558,"O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2_|_HRJWTAWVFDCTGO-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY-2090314_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2090314' 'LY2090314' 'Ly 2090314' 'Ly-2090314']_|_[('PubChem', array(['103905564'], dtype=object)), ('drugbank', array(['DB11913'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000565', 'EFO_0002618'], dtype=object), 'count': 3}_|_[ENSG00000082701,ENSG00000105723]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3707278,"nan_|_nan_|_Antibody_|_False_|_CROTEDUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Crotedumab' 'REGN-1193' 'REGN1193']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000215644]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL405821,"NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1_|_SCTZUZTYRMOMKT-UHFFFAOYSA-N_|_Small molecule_|_False_|_SENICAPOC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ICA-17043' 'PF-05416266' 'Senicapoc']_|_[('drugbank', array(['DB06280'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000694', 'MONDO_0100096', 'MONDO_0004979', 'MONDO_0011382'],
      dtype=object), 'count': 4}_|_[ENSG00000104783]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297182,"COCCN1C(=O)O[C@@]2(C[C@H]3O[C@]2(C)n2c4ccccc4c4c5c(c6c7ccccc7n3c6c42)C(=O)NC5)C1=O_|_SHWPFRVVBIKGAT-LYWBODIJSA-N_|_Small molecule_|_False_|_PEGCANTRATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CT-327' 'CT327' 'Ct-327' 'Pegcantratinib' 'SNA-120' 'Sna-120']_|_nan_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_0000676', 'EFO_0005762', 'EFO_1001494'],
      dtype=object), 'count': 4}_|_[ENSG00000198400]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297427,"O[C@]1(c2ncccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl_|_MQWMHMZNBGQNMT-XHNJZIHCSA-N_|_Small molecule_|_False_|_SCH-486757_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SCH 486757' 'SCH486757' 'Sch 486757' 'Sch-486757']_|_[('drugbank', array(['DB12782'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012735'], dtype=object), 'count': 1}_|_[ENSG00000125510]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4740383,"Cc1c(C#N)cccc1-c1cc(-c2cn(Cc3cccc(C(C)(C)O)n3)nn2)nc(N)n1_|_BUXIAWLTBSXYSW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETRUMADENANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AB-928' 'AB928' 'Ab928' 'Etrumadenant']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETRUMADENANT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0000616', 'EFO_1000657', 'EFO_0000673',
       'EFO_0003085', 'EFO_0000196', 'EFO_0003060', 'MONDO_0008315'],
      dtype=object), 'count': 8}_|_[ENSG00000170425,ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL522038,"CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N\O)cc1)C1CCCCC1_|_ZXIBCJHYVWYIKI-PZJWPPBQSA-N_|_Small molecule_|_False_|_XIMELAGATRAN_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Exanta' 'H 376/95' 'Ximelagatran']_|_[('PubChem', array(['144207182'], dtype=object)), ('Wikipedia', array(['Ximelagatran'], dtype=object)), ('drugbank', array(['DB04898'], dtype=object)), ('chEBI', array(['65172'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001907', 'HP_0004419', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000180210]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for recurrent thrombophlebitis and has 2 investigational indications. It was withdrawn in at least one region."
CHEMBL796,"COC(=O)C(c1ccccc1)C1CCCCN1_|_DUGOZIWVEXMGBE-UHFFFAOYSA-N_|_Small molecule_|_True_|_METHYLPHENIDATE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Concerta' 'Cotempla xr-odt' 'Daytrana']_|_['Concerta' 'Methylin' 'Methylphenidate'
 'Methylphenidate extended release' 'Prc-063' 'Threo-dl-methylphenidate']_|_[('DailyMed', array(['methylphenidate'], dtype=object)), ('Wikipedia', array(['Methylphenidate'], dtype=object)), ('drugbank', array(['DB00422'], dtype=object)), ('chEBI', array(['84276'], dtype=object))]_|_['CHEMBL1722']_|_{'rows': array(['HP_0000726', 'EFO_0009267', 'MONDO_0005180', 'EFO_0001642',
       'MONDO_0004992', 'EFO_0008568', 'MONDO_0008315', 'EFO_0003768',
       'MONDO_0007079', 'EFO_0003840', 'MONDO_0011184', 'MONDO_0011382',
       'MONDO_0002050', 'EFO_0001663', 'EFO_0005252', 'MONDO_0004992',
       'EFO_0005203', 'EFO_0007625', 'EFO_0003890', 'MONDO_0005090',
       'HP_0012378', 'MONDO_0043510', 'EFO_0001358', 'MONDO_0004985',
       'EFO_0003833', 'EFO_0004701', 'EFO_0002610', 'MONDO_0002050',
       'HP_0012378', 'EFO_0003888', 'MONDO_0004975', 'EFO_0005323',
       'EFO_0003888', 'EFO_0004216', 'HP_0012532', 'MONDO_0016158',
       'MONDO_0005301', 'EFO_0005611', 'EFO_0003768', 'EFO_0003929',
       'MONDO_0002009', 'EFO_0003843'], dtype=object), 'count': 42}_|_[ENSG00000103546,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for attention deficit hyperactivity disorder and narcolepsy-cataplexy syndrome and has 36 investigational indications. This drug has a black box warning from the FDA."
CHEMBL98,"O=C(CCCCCCC(=O)Nc1ccccc1)NO_|_WAEXFXRVDQXREF-UHFFFAOYSA-N_|_Small molecule_|_False_|_VORINOSTAT_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Zolinza']_|_['MK-0683' 'MK0683' 'NSC-701852' 'NSC-748799' 'NSC-759852'
 'Suberoylanilide hydroxamic acid' 'Vorinostat']_|_[('DailyMed', array(['vorinostat'], dtype=object)), ('PubChem', array(['104171411', '124893442', '144206158', '144207172', '170465180',
       '49645508', '50113029'], dtype=object)), ('Wikipedia', array(['Vorinostat'], dtype=object)), ('drugbank', array(['DB02546'], dtype=object)), ('chEBI', array(['45716'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'MONDO_0004992', 'EFO_0002913', 'EFO_0000096',
       'EFO_0000691', 'MONDO_0008903', 'EFO_0000220', 'EFO_0000191',
       'EFO_0003828', 'EFO_0006352', 'EFO_1000026', 'MONDO_0004975',
       'MONDO_0015760', 'EFO_0000616', 'EFO_1001830', 'EFO_0004198',
       'EFO_0000574', 'EFO_0000621', 'EFO_1001110', 'MONDO_0002158',
       'EFO_0000641', 'EFO_0003833', 'MONDO_0003268', 'EFO_0007535',
       'MONDO_0007254', 'MONDO_0005090', 'EFO_0000309', 'MONDO_0011382',
       'EFO_0000365', 'EFO_0000565', 'EFO_0000222', 'MONDO_0019460',
       'EFO_0000764', 'EFO_0000224', 'EFO_1001380', 'MONDO_0008315',
       'EFO_0003060', 'MONDO_0001657', 'EFO_0005774', 'EFO_0000349',
       'EFO_0002429', 'EFO_0000180', 'EFO_0002939', 'EFO_0000211',
       'MONDO_0007576', 'EFO_0000198', 'EFO_0000519', 'EFO_1000785',
       'EFO_0003893', 'EFO_0000479', 'EFO_0000339', 'MONDO_0015277',
       'EFO_1001968', 'MONDO_0018364', 'EFO_0002618', 'EFO_0003869',
       'MONDO_0044926', 'EFO_1000657', 'EFO_0000183', 'EFO_0000702',
       'EFO_1001465', 'EFO_0002938', 'EFO_1001469', 'EFO_0004289',
       'MONDO_0018906', 'EFO_1000309', 'MONDO_0001879', 'EFO_0000756',
       'MONDO_0002087', 'EFO_0001378', 'EFO_0000588', 'EFO_0000681',
       'MONDO_0021063', 'MONDO_0008170', 'MONDO_0000873', 'EFO_0000095',
       'MONDO_0002691', 'EFO_0002501', 'EFO_0000673', 'MONDO_0001056',
       'EFO_0000384', 'EFO_0000770', 'EFO_0000403', 'EFO_0002499',
       'MONDO_0004986', 'EFO_0005952', 'EFO_1001051', 'EFO_0006861',
       'MONDO_0000870'], dtype=object), 'count': 89}_|_[ENSG00000094631,ENSG00000116478,ENSG00000196591,ENSG00000171720]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 85 investigational indications."
CHEMBL1113,"Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2_|_QWGDMFLQWFTERH-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMOXAPINE_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Amoxapine' 'Asendin' 'Asendis' 'Defanyl']_|_['Amoxapine' 'CL 67,772' 'CL 67772' 'CL-67,772' 'CL-67772' 'NSC-759559']_|_[('DailyMed', array(['amoxapine'], dtype=object)), ('PubChem', array(['104171096', '11110675', '11110676', '124879022', '124879024',
       '144203615', '144212669', '170465376', '26747067', '26751577',
       '50100159', '50104205', '50104206', '85230879', '855963',
       '90341240'], dtype=object)), ('Wikipedia', array(['Amoxapine'], dtype=object)), ('drugbank', array(['DB00543'], dtype=object)), ('chEBI', array(['2675'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000108576,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL1201570,"nan_|_nan_|_Protein_|_False_|_ANAKINRA_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Kineret']_|_['AMG-719' 'Alta-2530' 'Alta2530' 'Anakinra'
 'Interleukin-1 receptor antagonist anakinra' 'Osp-101']_|_[('DailyMed', array(['anakinra'], dtype=object)), ('DrugCentral', array(['5017'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kineret'],
      dtype=object)), ('Wikipedia', array(['Anakinra'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009672', 'EFO_0000540', 'EFO_0004274', 'MONDO_0005301',
       'EFO_0004227', 'EFO_0009609', 'EFO_0000398', 'MONDO_0004979',
       'EFO_0000685', 'EFO_0004246', 'MONDO_0007254', 'EFO_0001378',
       'EFO_0002609', 'EFO_0007328', 'EFO_0003073', 'EFO_0007427',
       'EFO_1001806', 'EFO_0000694', 'EFO_0000764', 'EFO_0009507',
       'EFO_0000096', 'MONDO_0008315', 'EFO_1000637', 'MONDO_0019338',
       'EFO_0000660', 'MONDO_0043510', 'EFO_0001065', 'EFO_0003884',
       'EFO_0007135', 'MONDO_0100096', 'MONDO_0005178', 'EFO_0003843',
       'EFO_0000095', 'MONDO_0005147', 'EFO_1000657', 'MONDO_0011776',
       'EFO_0004238', 'EFO_1001209', 'EFO_1000668', 'EFO_0009536',
       'MONDO_0005149', 'EFO_0004540', 'EFO_0005669', 'EFO_0007323',
       'Orphanet_47045', 'EFO_0003144', 'EFO_0000400', 'HP_0001943',
       'MONDO_0004976', 'EFO_0000195', 'EFO_1000710', 'EFO_1001345',
       'EFO_0000544', 'MONDO_0018088', 'EFO_0008583', 'EFO_1001231',
       'EFO_0000616', 'MONDO_0018305', 'EFO_0001361', 'EFO_0002618',
       'EFO_0003106'], dtype=object), 'count': 61}_|_[ENSG00000115594]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 57 investigational indications."
CHEMBL1684,"NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O_|_HDWIHXWEUNVBIY-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENDROFLUMETHIAZIDE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Aprinox' 'Berkozide' 'Centyl' 'Naturetin-10' 'Naturetin-2.5'
 'Naturetin-5' 'Neo-bendromax 2.5' 'Neo-bendromax 5' 'Neo-naclex'
 'Urizide']_|_['Bendrofluazide' 'Bendroflumethiazide' 'Benzydroflumethiazide'
 'NSC-758229']_|_[('DailyMed', array(['bendroflumethiazide'], dtype=object)), ('PubChem', array(['124883448', '144203916', '170465156', '26747201', '56422088',
       '855628'], dtype=object)), ('Wikipedia', array(['Bendroflumethiazide'], dtype=object)), ('drugbank', array(['DB00436'], dtype=object)), ('chEBI', array(['3013'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0000537', 'EFO_0003144'], dtype=object), 'count': 3}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for cardiovascular disease and hypertension and has 1 investigational indication."
CHEMBL1743035,"nan_|_nan_|_Antibody_|_False_|_LEBRIKIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Lebrikizumab' 'MILR-1444A' 'MILR1444A' 'PRO-301444' 'PRO-301444 RG-3637'
 'PRO301444' 'RG-3637']_|_nan_|_nan_|_{'rows': array(['EFO_0000768', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000274'],
      dtype=object), 'count': 4}_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL189,"Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1_|_PZRHRDRVRGEVNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_MILRINONE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Milrila' 'Milrinone' 'NSC-760072' 'WIN 47,203-2' 'WIN-47203-2']_|_[('PubChem', array(['11111460', '11111461', '11114110', '11532967', '124880718',
       '144205666', '144214030', '170465221', '26757809', '49681694',
       '50104873', '90341667'], dtype=object)), ('Wikipedia', array(['Milrinone'], dtype=object)), ('drugbank', array(['DB00235'], dtype=object)), ('chEBI', array(['50693'], dtype=object))]_|_['CHEMBL1200977']_|_{'rows': array(['MONDO_0005149', 'EFO_0002687', 'EFO_0000319', 'EFO_0000713',
       'EFO_0005207', 'EFO_0003144', 'EFO_0006834', 'EFO_1000994',
       'EFO_0003144', 'EFO_0009846', 'HP_0004308', 'HP_0030680'],
      dtype=object), 'count': 12}_|_[ENSG00000172572]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 approved and 9 investigational indications."
CHEMBL2103796,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl_|_GPMIHHFZKBVWAZ-LMMKTYIZSA-N_|_Small molecule_|_False_|_BERUBICIN HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL2110580_|_False_|_False_|_[]_|_['Berubicin hcl' 'Berubicin hydrochloride' 'RTA 744' 'RTA-744' 'WP-744'
 'WP744']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'MONDO_0100342', 'EFO_0005543', 'EFO_0000313'],
      dtype=object), 'count': 4}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL258805,"COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2_|_QNUKRWAIZMBVCU-WCIBSUBMSA-N_|_Small molecule_|_False_|_SU-9516_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SU-9516' 'Su-9516' 'Su9516']_|_[('PubChem', array(['124891674', '124891675', '26753623', '26753624', '29215168',
       '49674687', '90341527'], dtype=object)), ('drugbank', array(['DB03428'], dtype=object))]_|_nan_|_nan_|_[ENSG00000123374]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL279260,C[C@H](Cc1c[nH]c2c(OCC(=O)O)cccc12)NC[C@H](O)c1cccc(Cl)c1_|_FHEYFIGWYQJVDR-ACJLOTCBSA-N_|_Small molecule_|_False_|_RAFABEGRON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AD-9677' 'Aj-9677' 'Rafabegron' 'TAK-677']_|_nan_|_nan_|_nan_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL304902,"CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1_|_KAAZGXDPUNNEFN-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOTHIAPINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Clothiapine' 'Clotiapine' 'Entumin' 'HF-2159']_|_[('PubChem', array(['144205332', '170465938', '26754613', '29216068'], dtype=object)), ('Wikipedia', array(['Clotiapine'], dtype=object)), ('drugbank', array(['DB13256'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000069696,ENSG00000135914,ENSG00000102468,ENSG00000147246,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for psychosis."
CHEMBL3137304,"Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](O)(C(F)(F)F)CC[C@@]21Cc1ccccc1_|_QJJBNCHSWFGXML-KEKPKEOLSA-N_|_Small molecule_|_False_|_DAGROCORAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dagrocorat' 'PF-00251802' 'PF-0251802' 'PF-802']_|_[('drugbank', array(['DB14676'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3183740,"NC(=O)Cn1c(=O)cc(CCN2CCN(c3nccc4sccc34)CC2)c2ccc(F)cc21_|_JDLYOFUDIKMYBL-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRELANSERIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SL-650472' 'SL65.0472' 'Sl650472' 'Trelanserin']_|_[('PubChem', array(['144210557'], dtype=object))]_|_nan_|_nan_|_[ENSG00000135312,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3617964,"Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1_|_QNQZWEGMKJBHEM-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALVELESTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-9668' 'AZD9668' 'Alvelestat' 'Azd9668' 'MPH-966' 'MPH966' 'Mph966']_|_[('drugbank', array(['DB11863'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0044881', 'HP_0002110', 'EFO_0000341', 'MONDO_0009061',
       'MONDO_0100096'], dtype=object), 'count': 5}_|_[ENSG00000197561]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3833353,"CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O_|_DTPWZYSUQQHRKD-VIUAGAKSSA-N_|_Protein_|_True_|_PRAMLINTIDE ACETATE_|_2005.0_|_4.0_|_CHEMBL2103758_|_False_|_True_|_['Symlin' 'Symlinpen']_|_['AC0-137' 'AC0137' 'Pramlintide acetate' 'Pramlintide acetate anhydrous'
 'Pramlintide acetate hydrate' 'Tripro-amylin acetate'
 'Tripro-amylin acetate hydrate']_|_nan_|_nan_|_{'rows': array(['EFO_0001073', 'MONDO_0005148', 'MONDO_0005147'], dtype=object), 'count': 3}_|_[ENSG00000004948,ENSG00000132329,ENSG00000131477,ENSG00000122679]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989740,"CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O_|_HALQELOKLVRWRI-VDBOFHIQSA-N_|_Small molecule_|_True_|_DOXYCYCLINE HYCLATE_|_1967.0_|_4.0_|_CHEMBL1433_|_False_|_True_|_['Acticlate' 'Acticlate cap' 'Alodox' 'Atridox' 'Cyclodox' 'Demix 100'
 'Demix 50' 'Doryx' 'Doryx mpc' 'Doxatet' 'Doxy 100' 'Doxy 200'
 'Doxy-Caps' 'Doxy-lemmon' 'Doxychel hyclate' 'Doxycycline hyclate'
 'Doxylar' 'Lymepak' 'Nordox' 'Periostat' 'Ramysis' 'Vibra-tabs'
 'Vibramycin' 'Vibramycin 50' 'Vibramycin Hyclate' 'Vibramycin acne pack'
 'Vibramycin-d' 'Vibrox']_|_['Azudoxat' 'Clinofug' 'Diocimex' 'Doxicrisol' 'Doxycycline hyclate'
 'Doxycycline hydrochloride hemiethanolate hemihydrate'
 'Doxycycline hydrochloride hydrate' 'Doxycyclini hyclas' 'Doxyprex'
 'Duradoxal' 'Granudoxy' 'Mespafin' 'Monodoks' 'NSC-741421' 'Retens'
 'Ronaxan' 'Spanor' 'Tetraclean' 'Tetradox' 'Unacil' 'Vibraveineuse'
 'Vibravenos' 'Zadorin']_|_[('DailyMed', array(['doxycycline%20hyclate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001365', 'EFO_1001896', 'EFO_1000760', 'MONDO_0019180',
       'EFO_0000649', 'EFO_0003894', 'EFO_1001466', 'EFO_0007205',
       'EFO_1001898'], dtype=object), 'count': 9}_|_[ENSG00000196611,ENSG00000118113,ENSG00000137673,ENSG00000137745]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for acne and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL399510,"CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC_|_GIYAQDDTCWHPPL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMOPRIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bromopride' 'Movipride' 'NSC-758391']_|_[('PubChem', array(['104171315', '11112553', '144204094', '170466299', '56463076'],
      dtype=object)), ('Wikipedia', array(['Bromopride'], dtype=object)), ('drugbank', array(['DB09018'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008533', 'EFO_0010282'], dtype=object), 'count': 2}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL406,"CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1_|_NDDAHWYSQHTHNT-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDAPAMIDE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Cardide sr' 'Ethibide xl' 'Indapamide' 'Indaxa 2.5' 'Indipam xl' 'Lozol'
 'Mapemid xl' 'Natrilix' 'Natrilix sr' 'Nindaxa 2.5' 'Opumide 2.5'
 'Rawel xl' 'Tensaid xl' 'Varbim xl']_|_['Arifon' 'Bajaten' 'Damide' 'Flubest' 'Fludex' 'Fludin' 'Flupamid'
 'Indaflex' 'Indamide' 'Indamol' 'Indapamide' 'Ipamix' 'KYD-041' 'Lorvas'
 'NSC-757075' 'Natrix' 'Noranat' 'S-1520' 'SE-1520' 'Tandix' 'Tertensif'
 'Veroxil']_|_[('DailyMed', array(['indapamide'], dtype=object)), ('PubChem', array(['124883405', '144204326', '144206733', '144213004', '170465366',
       '26747199', '56422467', '855885'], dtype=object)), ('Wikipedia', array(['Indapamide'], dtype=object)), ('drugbank', array(['DB00808'], dtype=object)), ('chEBI', array(['5893'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000668', 'MONDO_0005148', 'EFO_0000537', 'MONDO_0001134',
       'EFO_0003840', 'EFO_0000373', 'EFO_0000319'], dtype=object), 'count': 7}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 4 approved and 3 investigational indications."
CHEMBL426161,"COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1_|_WPOXAFXHRJYEIC-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZM-475271_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azm 475271' 'Azm-475271' 'M-475271']_|_nan_|_nan_|_nan_|_[ENSG00000097007,ENSG00000197122]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4297658,"O=C(O)[C@@H]1CCCN1.OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O_|_TUVGWWULBZIUBS-FVYIYGEMSA-N_|_Small molecule_|_False_|_IPRAGLIFLOZIN L-PROLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ipragliflozin l-proline']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4594304,"Cn1cc(S(=O)(=O)[C@@](C)(F)C2CCN(C(=O)Nc3ccon3)CC2)c(C(F)F)n1_|_NREKKBAMVWQRES-MRXNPFEDSA-N_|_Small molecule_|_False_|_DANICAMTIV_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Danicamtiv' 'MYK-491' 'MYK491' 'Myk-491' 'SAR-440181' 'SAR440181']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANICAMTIV/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'EFO_0000407'], dtype=object), 'count': 2}_|_[ENSG00000092054,ENSG00000197616,ENSG00000078814,ENSG00000160808,ENSG00000111245,ENSG00000106631,ENSG00000198336]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL475251,"COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC_|_NHHQJBCNYHBUSI-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-406_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['R-406' 'R940406' 'Tamatinib']_|_[('PubChem', array(['103904600', '137275829', '99460878'], dtype=object)), ('drugbank', array(['DB07159'], dtype=object))]_|_nan_|_nan_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL525610,"CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C_|_OGBMKVWORPGQRR-UMXFMPSGSA-N_|_Protein_|_True_|_TERIPARATIDE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Bonsity' 'Forsteo' 'Forteo' 'Teriparatide sun']_|_['(1-34)-human parathyroid hormone' '1-34-human pth'
 'Human parathyroid hormone 1-34' 'LY 333334' 'LY-333334' 'LY333334'
 'Pth (1-34)' 'Teriparatide' 'Teriparatide rdna' 'ZT-034']_|_[('DailyMed', array(['teriparatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/teriparatide-sun'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003854', 'EFO_0003964', 'EFO_0003957', 'HP_0000938',
       'EFO_0009451', 'MONDO_0019019', 'EFO_0003931', 'EFO_0004616',
       'EFO_1001378', 'HP_0002901', 'HP_0003418', 'EFO_0003882'],
      dtype=object), 'count': 12}_|_[ENSG00000160801]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for postmenopausal osteoporosis and osteoporosis and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL61593,"NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O_|_BOCUKUHCLICSIY-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLOTHIAZIDE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Anhydron' 'Fluidil']_|_['35483' 'Cyclothiazide' 'NSC-758431']_|_[('PubChem', array(['144203675', '170465274', '26751850', '50104549', '50104550',
       '56424127', '85230990'], dtype=object)), ('Wikipedia', array(['Cyclothiazide'], dtype=object)), ('drugbank', array(['DB00606'], dtype=object)), ('chEBI', array(['31448'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for cardiovascular disease."
CHEMBL1200891,"CN1CCCN=C1COC(=O)C(O)(c1ccccc1)C1CCCCC1.Cl_|_WXAYTPABEADAAB-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYPHENCYCLIMINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1495_|_False_|_True_|_['Daricon']_|_['NSC-528449' 'Oxiphencyclimine chloride' 'Oxyphencyclimine hcl'
 'Oxyphencyclimine hydrochloride']_|_[('PubChem', array(['144204969', '170465276', '26748867', '56422213', '855685'],
      dtype=object)), ('Wikipedia', array(['Oxyphencyclimine'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201174,"N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O_|_GQPYTJVDPQTBQC-KLQYNRQASA-N_|_Small molecule_|_False_|_SITAGLIPTIN PHOSPHATE_|_2006.0_|_4.0_|_CHEMBL1422_|_False_|_True_|_['Janumet Xr' 'Januvia' 'Xelevia']_|_['Glactiv' 'MK-0431' 'MK0431' 'ONO-5435' 'Sitagliptin monophosphate'
 'Sitagliptin monophosphate anhydrous'
 'Sitagliptin monophosphate monohydrate' 'Sitagliptin phosphate'
 'Sitagliptin phosphate anhydrous' 'Sitagliptin phosphate hydrate'
 'Sitagliptin phosphate monohydrate']_|_[('DailyMed', array(['sitagliptin%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xelevia'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612', 'MONDO_0005148', 'EFO_0000400', 'HP_0000083',
       'MONDO_0021187', 'EFO_0000712'], dtype=object), 'count': 6}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 2 investigational indications."
CHEMBL1201207,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O_|_VQODGRNSFPNSQE-DVTGEIKXSA-N_|_Small molecule_|_False_|_BETAMETHASONE PHOSPHORIC ACID_|_1965.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betamethasone phosphate' 'Betamethasone phosphoric acid']_|_[('drugbank', array(['DB14669'], dtype=object)), ('chEBI', array(['68603'], dtype=object))]_|_['CHEMBL1200762']_|_{'rows': array(['MONDO_0005178', 'EFO_1000906', 'EFO_1001434', 'EFO_0000729',
       'EFO_1001097', 'EFO_1001909', 'EFO_0002950', 'HP_0003419'],
      dtype=object), 'count': 8}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for ulcerative colitis and has 7 investigational indications."
CHEMBL1201770,"C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]_|_IFGIYSGOEZJNBE-KNLJMPJLSA-N_|_Small molecule_|_False_|_METHYLNALTREXONE BROMIDE_|_2008.0_|_4.0_|_CHEMBL1186579_|_False_|_True_|_['Relistor']_|_['MOA728' 'MRZ 2663BR' 'MRZ-2663BR' 'MRZ2663BR' 'Methylnaltrexone bromide'
 'Moa-728' 'N-methylnaltrexone bromide' 'Naltrexone methobromide'
 'Naltrexone methylbromide']_|_[('DailyMed', array(['methylnaltrexone%20bromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/relistor'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0002618', 'HP_0002019', 'EFO_0005611', 'MONDO_0004567'],
      dtype=object), 'count': 4}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and opioid dependence and has 2 investigational indications."
CHEMBL2062264,"CNC[C@H](O)c1cccc(O)c1.O=C(O)C(O)C(O)C(=O)O_|_NHKOTKKHHYKARN-FVGYRXGTSA-N_|_Small molecule_|_False_|_PHENYLEPHRINE BITARTRATE_|_1973.0_|_4.0_|_CHEMBL1215_|_False_|_True_|_[]_|_['Phenylephrine acid tartrate' 'Phenylephrine bitartrate'
 'Phenylephrine hydrogen tartrate']_|_nan_|_nan_|_{'rows': array(['HP_0012735', 'HP_0001742', 'EFO_0007214', 'HP_0002315'],
      dtype=object), 'count': 4}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 4 approved indications."
CHEMBL22242,"CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC_|_GUJRSXAPGDDABA-NSHDSACASA-N_|_Small molecule_|_False_|_REMOXIPRIDE_|_1990.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['A 33547' 'A-33547' 'FLA 731' 'FLA-731(-)' 'Remoxipride' 'Roxiam']_|_[('PubChem', array(['11112836', '11113786', '144204485', '170466425', '26751966'],
      dtype=object)), ('Wikipedia', array(['Remoxipride'], dtype=object)), ('drugbank', array(['DB00409'], dtype=object))]_|_['CHEMBL1899328' 'CHEMBL3989556']_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for psychosis. It was withdrawn in at least one region."
CHEMBL3544963,"nan_|_nan_|_Small molecule_|_False_|_DS-3078A_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ds-3078a']_|_nan_|_nan_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545065,"CN(C)C(C(=O)Nc1ccc2c(=O)[nH]ccc2c1)c1ccsc1_|_VDYRZXYYQMMFJW-UHFFFAOYSA-N_|_Small molecule_|_False_|_VEROSUDIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AR-12286' 'AR-12286 FREE BASE' 'Ar-12286' 'Verosudil']_|_nan_|_['CHEMBL3545124']_|_{'rows': array(['MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 2}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3989971,"CC[C@H]1C[C@@H](C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2NC(C)=O)[C@@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O_|_LYSYOXNOOPBOSC-NGSKMYNLSA-N_|_Small molecule_|_False_|_UPROLESELAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GMI-1271' 'GMI-1271 FREE ACID' 'Uproleselan']_|_[('drugbank', array(['DB14829'], dtype=object))]_|_['CHEMBL3989975']_|_{'rows': array(['EFO_0003907', 'EFO_0001378', 'EFO_0000222', 'MONDO_0100096'],
      dtype=object), 'count': 4}_|_[ENSG00000007908]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL418995,"O=C(O)CCCCCCNC1c2ccccc2CCc2ccccc21_|_ONNOFKFOZAJDHT-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMINEPTINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Amineptin' 'Amineptine' 'Dea no. 1219']_|_[('PubChem', array(['144206864'], dtype=object)), ('Wikipedia', array(['Amineptine'], dtype=object)), ('drugbank', array(['DB04836'], dtype=object)), ('chEBI', array(['32499'], dtype=object))]_|_['CHEMBL1697712']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000149295,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder. It was withdrawn in at least one region."
CHEMBL4297564,"nan_|_nan_|_Oligonucleotide_|_False_|_COBITOLIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cobitolimod']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/COBITOLIMOD/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000239732]_|_Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297911,"nan_|_nan_|_Antibody_|_False_|_SPESOLIMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Spevigo']_|_['BI 655130' 'BI-655130' 'BI655130' 'Bi655130' 'Spesolimab'
 'Spesolimab sbzo']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SPESOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015597', 'MP_0001845', 'EFO_0000274', 'EFO_1000710',
       'MONDO_0009735', 'EFO_0000540', 'EFO_0000676', 'EFO_0000729',
       'EFO_0000384'], dtype=object), 'count': 9}_|_[ENSG00000115598,ENSG00000196083]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 6 investigational indications."
CHEMBL451887,"CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1_|_BLMPQMFVWMYDKT-NZTKNTHTSA-N_|_Protein_|_False_|_CARFILZOMIB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Kyprolis']_|_['Carfilzomib' 'NSC-758252' 'PR-171']_|_[('DailyMed', array(['carfilzomib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis'],
      dtype=object)), ('PubChem', array(['124955654', '144206630', '170466878'], dtype=object)), ('drugbank', array(['DB08889'], dtype=object)), ('chEBI', array(['65347'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009441', 'MONDO_0004992', 'MONDO_0002120', 'EFO_1000785',
       'MONDO_0018906', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000574',
       'EFO_0000616', 'EFO_0000095', 'MONDO_0002367', 'EFO_0000220',
       'EFO_0000702', 'EFO_0000096', 'EFO_0005952', 'EFO_1001469',
       'EFO_0000183', 'EFO_0000222', 'EFO_0006475', 'EFO_0006738',
       'EFO_0000211', 'MONDO_0001023', 'MONDO_0017816', 'EFO_0000565',
       'MONDO_0020547', 'EFO_0000403', 'EFO_1001875', 'EFO_1001051'],
      dtype=object), 'count': 28}_|_[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 25 investigational indications."
CHEMBL4594446,"O=C(c1cc(Cl)c(O)c(Cl)c1)N1CS(=O)(=O)c2ccccc21_|_VOFLAIHEELWYGO-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOTINURAD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dotinurad' 'FYU-981' 'Fyu-981']_|_nan_|_nan_|_{'rows': array(['EFO_0009104', 'HP_0000083', 'EFO_0004274'], dtype=object), 'count': 3}_|_[ENSG00000197891]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4594603,"nan_|_nan_|_Unknown_|_False_|_LONOCTOCOG ALFA_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Afstyla']_|_['Afstyla' 'CSL-627' 'CSL627' 'Lonoctocog alfa' 'Rviii-singlechain']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/afstyla'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Unknown drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for hemophilia a."
CHEMBL4594608,"nan_|_nan_|_Antibody_|_False_|_AXATILIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Axatilimab' 'SNDX-6352' 'Sndx-6352' 'UCB-6352' 'UCB6352']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AXATILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005221', 'MONDO_0020547', 'EFO_0009709', 'EFO_0009448',
       'EFO_0005537', 'EFO_0000183', 'EFO_0000616'], dtype=object), 'count': 7}_|_[ENSG00000182578]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL5095025,"Cn1/c(=N\C#N)n(-c2ccc(C(C)(C)C#N)nc2)c2c3cc(-c4cnc(N)c(C(F)(F)F)c4)ccc3ncc21_|_VJLRLTSXTLICIR-AUGOTPMTSA-N_|_Small molecule_|_False_|_PANULISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['P-7170' 'P7170' 'Panulisib']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000139567,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL515271,Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1_|_TVKGTSHBQZEFEE-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-112_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['R-112' 'R-921218']_|_nan_|_nan_|_nan_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1201048,"CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CC[C@H]4CC(=O)[C@H](C)C[C@]4(C)[C@H]3CC[C@]12C_|_NOTIQUSPUUHHEH-UXOVVSIBSA-N_|_Small molecule_|_False_|_DROMOSTANOLONE PROPIONATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Drolban' 'Masteril']_|_['32379' 'Dromostanolone propionate' 'Drostanolone propionate' 'Masterid'
 'Masteron' 'NSC-12198' 'NSC-1298' 'Permastril']_|_[('drugbank', array(['DB14655'], dtype=object)), ('chEBI', array(['31523'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201217,"CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1_|_BZEWSEKUUPWQDQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DYCLONINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dyclonine']_|_[('PubChem', array(['11112403', '50100427'], dtype=object)), ('Wikipedia', array(['Dyclonine'], dtype=object)), ('drugbank', array(['DB00645'], dtype=object)), ('chEBI', array(['4724'], dtype=object))]_|_['CHEMBL1200478']_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1482,"CC(C[N+](C)(C)C)OC(N)=O_|_NZUPCNDJBJXXRF-UHFFFAOYSA-O_|_Small molecule_|_False_|_BETHANECHOL_|_1948.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bethanechol']_|_[('PubChem', array(['124879661', '26756574', '90341349'], dtype=object)), ('Wikipedia', array(['Bethanechol'], dtype=object)), ('drugbank', array(['DB01019'], dtype=object)), ('chEBI', array(['3084'], dtype=object))]_|_['CHEMBL1768']_|_{'rows': array(['EFO_0004232', 'HP_0000016', 'EFO_0002618', 'MONDO_0005148'],
      dtype=object), 'count': 4}_|_[ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for urinary retention and has 3 investigational indications."
CHEMBL207197,"NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(N2Cc3ccccc3NC2=O)CC1)C(=O)N1CCN(c2ccncc2)CC1_|_ITIXDWVDFFXNEG-JHOUSYSJSA-N_|_Small molecule_|_False_|_OLCEGEPANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIBN 4096 BS' 'BIBN-4096 BS' 'BIBN-4096BS' 'Bibn 4096 bs' 'Bibn-4096bs'
 'Olcegepant']_|_[('drugbank', array(['DB04869'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107815,"CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)O)c3C[C@H]2C[C@H]1O.OCCNCCO_|_RHWRWEUCEXUUAV-ZSESPEEFSA-N_|_Small molecule_|_False_|_TREPROSTINIL DIOLAMINE_|_2013.0_|_4.0_|_CHEMBL1237119_|_False_|_True_|_['Orenitram' 'Ut-15c']_|_['Treprostinil diethanolamine' 'Treprostinil diolamin'
 'Treprostinil diolamine' 'UT-15C']_|_[('DailyMed', array(['treprostinil%20diolamine'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000717', 'EFO_0001361'], dtype=object), 'count': 2}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 2 investigational indications."
CHEMBL2403108,"Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1_|_VERWOWGGCGHDQE-UHFFFAOYSA-N_|_Small molecule_|_False_|_CERITINIB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Zykadia']_|_['Ceritinib' 'Ceritinib[mi]' 'LDK-378' 'LDK378' 'NVP-LDK-378-NX'
 'NVP-LDK378-NX']_|_[('DailyMed', array(['ceritinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia'],
      dtype=object)), ('drugbank', array(['DB09063'], dtype=object)), ('chEBI', array(['78432'], dtype=object))]_|_['CHEMBL4476089' 'CHEMBL4468931' 'CHEMBL4542506']_|_{'rows': array(['EFO_0000756', 'EFO_0003032', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000519', 'EFO_0000389', 'EFO_1001968', 'EFO_0001421',
       'MONDO_0015798', 'EFO_0000621', 'EFO_0005221', 'MONDO_0002108',
       'EFO_0000616'], dtype=object), 'count': 13}_|_[ENSG00000171094,ENSG00000181163,ENSG00000143924]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 10 investigational indications."
CHEMBL253969,"NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1_|_HXHAJRMTJXHJJZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_OSI-632_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-547,632' 'CP-547632' 'CP-632' 'Cp-547,632' 'OSI-632' 'Osi-632'
 'PAN 90806' 'PAN-90806' 'PAN90806']_|_[('PubChem', array(['103905622', '137275944'], dtype=object)), ('drugbank', array(['DB12962'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021117', 'MONDO_0002158', 'EFO_0003770', 'EFO_0001365',
       'MONDO_0008170', 'MONDO_0002087'], dtype=object), 'count': 6}_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL306280,"CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(F)c(F)cc3nc2-1_|_LFQCJSBXBZRMTN-OAQYLSRUSA-N_|_Small molecule_|_False_|_DIFLOMOTECAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Diflomotecan']_|_nan_|_nan_|_{'rows': array(['EFO_0000702'], dtype=object), 'count': 1}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3137336,"Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl_|_AXTAPYRUEKNRBA-JTQLQIEISA-N_|_Small molecule_|_False_|_UPROSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Akt inhibitor gsk-2141795' 'Akt inhibitor gsk2141795' 'GSK-2141795C'
 'GSK2141795' 'GSK2141795C' 'Gsk-2141795' 'Uprosertib']_|_[('drugbank', array(['DB11969'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0001378', 'EFO_0000756', 'EFO_0000616',
       'MONDO_0002974', 'MONDO_0004992', 'EFO_0005537'], dtype=object), 'count': 7}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL3545243,"nan_|_nan_|_Small molecule_|_False_|_AS-703988_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['As-703988' 'MSC-2015103B']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3589904,"COc1ccc(Cl)c(-c2ccc(NC(=O)c3ccnn3C)nc2N)c1_|_ZRJGMDIPCQOGNI-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-04531083_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-4531083' 'Pf-04531083']_|_[('drugbank', array(['DB12468'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012532', 'EFO_0010072'], dtype=object), 'count': 2}_|_[ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3707250,"nan_|_nan_|_Small molecule_|_False_|_CP-601927_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-601,927' 'Cp-601927']_|_nan_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707324,"nan_|_nan_|_Antibody_|_False_|_UTOMILUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PF-05082566' 'PF-5082566' 'Utomilumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000403', 'MONDO_0018906', 'EFO_0000616', 'MONDO_0004992',
       'EFO_1000294', 'EFO_0001075', 'EFO_0000096', 'EFO_0005537',
       'EFO_0000365', 'EFO_0000196', 'MONDO_0007254'], dtype=object), 'count': 11}_|_[ENSG00000049249]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL3990044,"nan_|_nan_|_Antibody_|_False_|_RELATLIMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BMS-986016' 'Relatlimab' 'Relatlimab rmbw' 'Relatlimab-rmbw']_|_nan_|_nan_|_{'rows': array(['MONDO_0008978', 'MONDO_0007576', 'EFO_1001950', 'EFO_0000756',
       'EFO_0000403', 'EFO_1001465', 'EFO_0000181', 'MONDO_0001056',
       'EFO_0000574', 'MONDO_0018906', 'EFO_0003060', 'MONDO_0004992',
       'EFO_1001951', 'EFO_0000222', 'EFO_1001968', 'MONDO_0044881',
       'EFO_0000519', 'EFO_0004142', 'EFO_0000616', 'EFO_0000681',
       'EFO_0000707', 'EFO_0002617', 'EFO_0000365', 'EFO_0003016',
       'EFO_0001378', 'EFO_0000182', 'EFO_0000389', 'EFO_0004193'],
      dtype=object), 'count': 28}_|_[ENSG00000089692]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 28 investigational indications."
CHEMBL476323,"Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1_|_DDDZBLNULGDPGA-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-0249_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-0249' 'MK0249' 'Mk-0249']_|_[('drugbank', array(['DB11910'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888', 'HP_0000726', 'EFO_0003918', 'MONDO_0005090',
       'MONDO_0004975'], dtype=object), 'count': 5}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4871106,"NC(=O)c1cccc2c(N[C@H](CN3CCC3)c3ccc(Cl)c(C(F)(F)F)c3)ncnc12_|_HXAUJHZZPCBFPN-QGZVFWFLSA-N_|_Small molecule_|_False_|_MSC-2363318A_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['M-2698' 'M2698' 'MSC-2363318A' 'MSC2363318A' 'Msc-2363318a']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000175634,ENSG00000108443,ENSG00000142208,ENSG00000117020]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL6995,"CC(=O)Nc1ccc(OCC(O)CNC(C)C)cc1_|_DURULFYMVIFBIR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRACTOLOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Eraldin']_|_['AY-21,011' 'AY-21011' 'Dalzic' 'I.C.I. 50,172' 'I.C.I.-50,172'
 'ICI-50172' 'Practolol'
 '[3-(4-Acetylamino-Phenoxy)-2-Hydroxy-Propyl]-Isopropyl-Ammonium']_|_[('PubChem', array(['144204479', '170466619', '56463034'], dtype=object)), ('Wikipedia', array(['Practolol'], dtype=object)), ('drugbank', array(['DB01297'], dtype=object)), ('chEBI', array(['258351'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."
CHEMBL1193948,"CCOC(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1cccc(Cl)c1)CC2_|_RDJQCOBTKKAQAH-FPOVZHCZSA-N_|_Small molecule_|_False_|_AMIBEGRON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Amibegron' 'SR-58611' 'SR58611']_|_[('drugbank', array(['DB05395'], dtype=object))]_|_['CHEMBL545437']_|_{'rows': array(['EFO_0005230', 'MONDO_0002050', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1200681,"CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+]_|_LBFBRXGCXUHRJY-HKHDRNBDSA-M_|_Small molecule_|_True_|_MONTELUKAST SODIUM_|_1998.0_|_4.0_|_CHEMBL787_|_False_|_True_|_['Montelukast sodium' 'Singulair']_|_['MK-476' 'Montelukast (as sodium)' 'Montelukast monosodium salt'
 'Montelukast sodium' 'NSC-759107']_|_[('DailyMed', array(['montelukast%20sodium'], dtype=object)), ('PubChem', array(['144205750', '170465230', '56320471'], dtype=object)), ('chEBI', array(['6993'], dtype=object))]_|_nan_|_{'rows': array(['HP_0040187', 'EFO_0005854', 'EFO_0007183', 'EFO_0003956',
       'HP_0011950', 'EFO_1001417', 'EFO_0000341', 'EFO_0004232',
       'EFO_0008521', 'MONDO_0004979', 'HP_0100806'], dtype=object), 'count': 11}_|_[ENSG00000173198]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1287935,"CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1_|_VKHVAUKFLBBZFJ-SFHVURJKSA-N_|_Small molecule_|_False_|_VERUCERFONT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-561,679' 'GSK-561679' 'GSK-561679A' 'GSK561679' 'GSK561679A'
 'NBI-77860' 'Verucerfont']_|_[('drugbank', array(['DB12512'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079', 'MONDO_0018479', 'EFO_0000555', 'EFO_0001358',
       'EFO_1001917', 'MONDO_0002009'], dtype=object), 'count': 6}_|_[ENSG00000120088]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL1393,"CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12_|_LXMSZDCAJNLERA-ZHYRCANASA-N_|_Small molecule_|_True_|_SPIRONOLACTONE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Abbolactone' 'Aldactone' 'Carospir' 'Diatensec' 'Gx spironol'
 'Laractone' 'Spiretic' 'Spiroctan 100' 'Spiroctan 25' 'Spiroctan 50'
 'Spironolactone' 'Spironolactone ceva' 'Spirospare 100' 'Spirospare 25']_|_['NSC-150399' 'SC-9420' 'Spironolactone' 'Spironolactone ceva'
 'Spironolactonum' 'Verospirone']_|_[('DailyMed', array(['spironolactone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/spironolactone-ceva'],
      dtype=object)), ('PubChem', array(['144206598', '144212471', '26757816', '47193741'], dtype=object)), ('Wikipedia', array(['Spironolactone'], dtype=object)), ('drugbank', array(['DB00421'], dtype=object)), ('chEBI', array(['9241'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001397', 'EFO_0000401', 'EFO_0000537', 'MONDO_0010679',
       'EFO_0003894', 'EFO_0000400', 'EFO_0000275', 'EFO_1000899',
       'EFO_0008586', 'EFO_0000319', 'EFO_0001422', 'EFO_0000373',
       'EFO_0001361', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000266',
       'HP_0001919', 'EFO_0000668', 'EFO_0001365', 'EFO_1001249',
       'MONDO_0007079', 'EFO_0000612', 'EFO_0000621', 'EFO_0000222',
       'EFO_0004255', 'EFO_0000685', 'EFO_0008585', 'EFO_0003144',
       'Orphanet_247', 'EFO_0000318', 'MONDO_0001134', 'EFO_0003884',
       'MONDO_0000088', 'EFO_0000694', 'MONDO_0100096', 'EFO_0003963',
       'HP_0012424', 'EFO_0005669', 'EFO_0000660', 'EFO_1001496'],
      dtype=object), 'count': 40}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 8 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1510,"CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12_|_PWVXXGRKLHYWKM-LJQANCHMSA-N_|_Small molecule_|_False_|_ELETRIPTAN_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Relpax']_|_['Eletriptan' 'UK-116,044' 'UK-116,044-04 FREE BASE'
 'UK-116,044-04 [AS HYDROBROMIDE)' 'UK-116044' 'UK-116044-04'
 'UK-116044-04 FREE BASE']_|_[('PubChem', array(['144206290', '170465317', '50125841'], dtype=object)), ('Wikipedia', array(['Eletriptan'], dtype=object)), ('drugbank', array(['DB00216'], dtype=object)), ('chEBI', array(['50922'], dtype=object))]_|_['CHEMBL1201003']_|_{'rows': array(['MONDO_0005475', 'MONDO_0100431', 'MONDO_0005277', 'MONDO_0005277'],
      dtype=object), 'count': 4}_|_[ENSG00000135312,ENSG00000179546,ENSG00000179097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for migraine disorder and has 2 investigational indications."
CHEMBL1767407,"Nc1ccn([C@H]2C[C@H](O)[C@@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)O2)c(=O)n1.[Na+].[Na+].[Na+].[Na+]_|_PASYJVRFGUDDEW-WMUGRWSXSA-J_|_Small molecule_|_False_|_DENUFOSOL TETRASODIUM_|_nan_|_3.0_|_CHEMBL507282_|_False_|_False_|_[]_|_['Denufosol tetrasodium' 'Denufosol tetrasodium salt' 'INS-37217'
 'INS37217']_|_nan_|_nan_|_{'rows': array(['EFO_0005773', 'MONDO_0009061', 'MONDO_0003005', 'EFO_1001417'],
      dtype=object), 'count': 4}_|_[ENSG00000175591]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL189963,"CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O_|_AHJRHEGDXFFMBM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PALBOCICLIB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Ibrance']_|_['PD-0332991' 'Palbociclib']_|_[('DailyMed', array(['palbociclib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance'],
      dtype=object)), ('PubChem', array(['103905660', '103905661', '137275973'], dtype=object)), ('drugbank', array(['DB09073'], dtype=object)), ('chEBI', array(['85993'], dtype=object))]_|_['CHEMBL2364621' 'CHEMBL3962672']_|_{'rows': array(['EFO_0008528', 'MONDO_0008170', 'EFO_0003060', 'EFO_1001950',
       'EFO_0006318', 'EFO_0001378', 'EFO_0001075', 'EFO_0000349',
       'EFO_0000569', 'EFO_0000616', 'EFO_0000182', 'MONDO_0007254',
       'EFO_0005952', 'MONDO_0008978', 'EFO_0000574', 'EFO_1000294',
       'MONDO_0008315', 'EFO_0000228', 'EFO_0000632', 'EFO_0002626',
       'EFO_1000251', 'EFO_0004252', 'MONDO_0005184', 'EFO_0002618',
       'EFO_1001469', 'EFO_0000707', 'EFO_0000305', 'EFO_0000220',
       'EFO_0000222', 'EFO_0000174', 'EFO_0003085', 'MONDO_0004992',
       'EFO_1000045', 'EFO_0000630', 'Orphanet_145', 'EFO_0000637',
       'EFO_0000181', 'MONDO_0011962', 'EFO_0003869', 'EFO_0000616',
       'MONDO_0100096', 'EFO_0000708', 'EFO_0005922', 'EFO_0003086',
       'EFO_0000519', 'EFO_1001512', 'EFO_0006859', 'EFO_0000681',
       'EFO_1001968', 'MONDO_0008903', 'EFO_0000756'], dtype=object), 'count': 51}_|_[ENSG00000110092,ENSG00000105810,ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 45 investigational indications."
CHEMBL2029988,"COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC_|_DKNUPRMJNUQNHR-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEP-32496_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AB-024' 'AC-013773' 'Agerafenib' 'CEP-32496' 'Cep-32496' 'RXDX-105'
 'Rxdx 105']_|_[('drugbank', array(['DB15068'], dtype=object))]_|_['CHEMBL3309923']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000165731,ENSG00000157764,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105748,"COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1.O=C(O)CCC(=O)O_|_QZRSNVSQLGRAID-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRUCALOPRIDE SUCCINATE_|_2009.0_|_4.0_|_CHEMBL117287_|_False_|_True_|_['Motegrity' 'Resolor']_|_['Prucalopride (as succinate)' 'Prucalopride succinate' 'R-108512']_|_[('DailyMed', array(['prucalopride%20succinate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/resolor'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002203', 'HP_0002019'], dtype=object), 'count': 2}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for constipation disorder and constipation."
CHEMBL2108583,"nan_|_nan_|_Protein_|_False_|_CINTREDEKIN BESUDOTOX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cintredekin besudotox' 'IL-13-PE38' 'IL13-PE38' 'IL13-PE38QQR']_|_nan_|_nan_|_{'rows': array(['EFO_0003833', 'EFO_0002501', 'EFO_1000158', 'EFO_0000519',
       'EFO_0000630', 'EFO_0002499', 'MONDO_0100342', 'EFO_0005543'],
      dtype=object), 'count': 8}_|_[ENSG00000077238,ENSG00000131724,ENSG00000123496]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL2109573,"nan_|_nan_|_Antibody_|_False_|_GSK-249320_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-249320' 'Gsk-249320']_|_nan_|_nan_|_{'rows': array(['EFO_0000712'], dtype=object), 'count': 1}_|_[ENSG00000105695]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL227529,"Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1_|_KEJICOXJTRHYAK-XFULWGLBSA-N_|_Small molecule_|_False_|_ALOGLIPTIN BENZOATE_|_2013.0_|_4.0_|_CHEMBL376359_|_False_|_True_|_['Nesina' 'Vipidia']_|_['Alogliptin (as benzoate)' 'Alogliptin benzoate' 'SYR 322' 'SYR-322']_|_[('DailyMed', array(['alogliptin%20benzoate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vipidia'],
      dtype=object)), ('chEBI', array(['72324'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for type 2 diabetes mellitus."
CHEMBL257978,Cc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O_|_FOYWMEJSRSBQGB-UHFFFAOYSA-N_|_Small molecule_|_False_|_DABUZALGRON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dabuzalgron' 'Ro 115-1240' 'Ro-115-1240']_|_nan_|_['CHEMBL2107325']_|_nan_|_[ENSG00000120907]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL314437,"CCC1(c2cccc(O)c2)CCCCN(C)C1_|_JLICHNCFTLFZJN-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPTAZINOL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['IL-22811' 'Meptazinol']_|_[('Wikipedia', array(['Meptazinol'], dtype=object)), ('drugbank', array(['DB13478'], dtype=object))]_|_['CHEMBL1477274']_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for pain."
CHEMBL3707446,"C[C@@H]1O[C@@H](O[C@@H]2[C@@H](NC(=O)c3cc(=O)[nH]c(=O)[nH]3)C[C@@H](C(=O)NCCNC(=O)COCCOCC(=O)Nc3cc(S(=O)(=O)O)cc4cc(S(=O)(=O)O)cc(S(=O)(=O)O)c34)C[C@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2OC(=O)c2ccccc2)[C@@H](O)[C@H](O)[C@@H]1O_|_VXBNTHRZPJLRSS-PTCSXESPSA-N_|_Small molecule_|_False_|_RIVIPANSEL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GMI-1070' 'PF-06460031' 'Rivipansel']_|_[('drugbank', array(['DB12778'], dtype=object))]_|_['CHEMBL3833316']_|_{'rows': array(['EFO_0001421', 'MONDO_0011382', 'MONDO_0011382', 'EFO_0003086'],
      dtype=object), 'count': 4}_|_[ENSG00000007908,ENSG00000188404,ENSG00000174175]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3989677,"COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O.O=C(O)C(O)C(O)C(=O)O_|_IUAXSWPNEQYKDR-GXTZACRKSA-N_|_Small molecule_|_True_|_HYDROCODONE BITARTRATE_|_1943.0_|_4.0_|_CHEMBL1457_|_False_|_True_|_['Hysingla' 'Hysingla er' 'Vantrela er' 'Zohydro er']_|_['CEP-33237' 'Dihydrocodeinone bitartrate' 'Hycodan'
 'Hydrocodone bitartrate' 'Hydrocodone bitartrate cii'
 'Hydrocodone bitartrate hemipentahydrate' 'Hydrocodone tartrate'
 'Vantrela' 'Zohydro']_|_[('DailyMed', array(['hydrocodone%20bitartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001250', 'EFO_0003843', 'EFO_0001421', 'EFO_0003890',
       'EFO_0005762', 'EFO_0003086', 'HP_0012532', 'MONDO_0005178',
       'EFO_0000546', 'HP_0003419'], dtype=object), 'count': 10}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and is indicated for pain and drug dependence and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989873,"CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4ccc(I)cc4)ncnc32)[C@H](O)[C@@H]1O_|_JTZRECOPNKCRTE-MOROJQBDSA-N_|_Small molecule_|_False_|_PICLIDENOSON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ALB-7208' 'CF-101' 'CF101' 'Cf101' 'IB-MECA' 'Piclidenoson']_|_nan_|_nan_|_{'rows': array(['EFO_0004616', 'EFO_1000906', 'EFO_0000685', 'EFO_1000986',
       'EFO_0000676', 'MONDO_0005041', 'MONDO_0100096', 'EFO_1001069',
       'EFO_1001119'], dtype=object), 'count': 9}_|_[ENSG00000282608]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL41194,"CCCc1nc2c(n1Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CCCC2_|_KCTFTBCZZUBAKN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRATOSARTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DA-727' 'DA727' 'KT3-671' 'Kt-3671' 'Pratosartan']_|_[('chEBI', array(['32041'], dtype=object))]_|_nan_|_nan_|_[ENSG00000197901,ENSG00000144891,ENSG00000197891,ENSG00000149452]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4298185,"nan_|_nan_|_Protein_|_False_|_LONAPEGSOMATROPIN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Skytrofa' 'Skytrofa (previously lonapegsomatropin ascendis pharma)'
 'Stem-stat ortho']_|_['ACP-011' 'Lonapegsomatropin' 'Lonapegsomatropin tcgd' 'TRANSCONPEG-HGH'
 'TransConPEG hGh' 'rhGH-PEG']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LONAPEGSOMATROPIN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019499', 'EFO_1001109', 'MONDO_0005178'], dtype=object), 'count': 3}_|_[ENSG00000112964]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pituitary dwarfism and has 2 investigational indications."
CHEMBL444929,"CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O_|_UIRKNQLZZXALBI-MSVGPLKSSA-N_|_Small molecule_|_False_|_SQUALAMINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Squalamine']_|_[('Wikipedia', array(['Squalamine'], dtype=object)), ('drugbank', array(['DB06461'], dtype=object)), ('chEBI', array(['80765'], dtype=object))]_|_['CHEMBL3989689' 'CHEMBL2386601']_|_{'rows': array(['MONDO_0008315', 'MONDO_0008170', 'EFO_0009606', 'EFO_0001365',
       'EFO_0003770'], dtype=object), 'count': 5}_|_[ENSG00000066230]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4594549,"nan_|_nan_|_Antibody_|_False_|_PIMURUTAMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HLX-07' 'HLX07' 'Hlx07' 'Pimurutamab']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0005922', 'EFO_0003060', 'EFO_0000182',
       'EFO_0004252', 'EFO_0000616', 'EFO_0000702', 'EFO_0000181'],
      dtype=object), 'count': 8}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL4650473,"nan_|_nan_|_Unknown_|_False_|_IBI-939_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IBI-939' 'IBI939' 'Ibi 939' 'Ibi-939' 'Ibi939' 'Tamgiblimab']_|_nan_|_nan_|_{'rows': array(['MONDO_0008903', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000181847]_|_Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL48361,"Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21_|_YBSJFWOBGCMAKL-UHFFFAOYSA-N_|_Small molecule_|_False_|_DABIGATRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Pradaxa']_|_['BIBR 953 ZW' 'BIBR-953' 'BIBR-953-ZW' 'Dabigatran'
 'Pradaxa (dabigatran)']_|_[('PubChem', array(['174006835'], dtype=object)), ('Wikipedia', array(['Dabigatran'], dtype=object)), ('drugbank', array(['DB14726'], dtype=object)), ('chEBI', array(['70752'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0000712', 'Orphanet_136', 'EFO_0000546',
       'EFO_1001413', 'EFO_0010680', 'HP_0002140', 'HP_0001907',
       'EFO_0004286', 'HP_0000083', 'MP_0001914'], dtype=object), 'count': 11}_|_[ENSG00000180210]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL514800,"CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC_|_IMOZEMNVLZVGJZ-QGZVFWFLSA-N_|_Small molecule_|_False_|_APREMILAST_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Otezla']_|_['Apremilast' 'CC-10004' 'CC10004']_|_[('DailyMed', array(['apremilast'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/otezla'],
      dtype=object)), ('drugbank', array(['DB05676'], dtype=object)), ('chEBI', array(['78540'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015597', 'EFO_0003894', 'EFO_1000710', 'MONDO_0002406',
       'HP_0000964', 'MONDO_0019558', 'MONDO_0007079', 'EFO_0000729',
       'EFO_0000685', 'EFO_0003106', 'MONDO_0100096', 'EFO_0003898',
       'EFO_1000760', 'EFO_0003778', 'EFO_0007328', 'EFO_1000726',
       'EFO_0003830', 'EFO_1000668', 'HP_0000155', 'EFO_1000694',
       'EFO_0000676', 'EFO_0003780', 'EFO_1001231', 'EFO_0008517',
       'EFO_0004208', 'EFO_0000540', 'EFO_0000274', 'EFO_0000398',
       'EFO_0004274'], dtype=object), 'count': 29}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 24 investigational indications."
CHEMBL559180,"CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1.Cl_|_QVPSGVSNYPRFAS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOXSUPRINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL1197051_|_False_|_True_|_['Defencin' 'Duvadilan' 'Duvadilan ret']_|_['Dilavase' 'Duviculine' 'Isoxsuprine hcl' 'Isoxsuprine hydrochloride'
 'NSC-757067' 'Navilox' 'Suprilent' 'Vadosilan' 'Vasotran']_|_[('PubChem', array(['144204018', '170465968', '26748094', '56422878', '855622'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."
CHEMBL1161,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl_|_WOFMFGQZHJDGCX-ZULDAHANSA-N_|_Small molecule_|_False_|_MOMETASONE FUROATE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Asmanex hfa' 'Asmanex twisthaler' 'Elocon' 'Mometasone furoate'
 'Nasonex' 'Nasonex 24hr allergy' 'Sinuva']_|_['LAS-41002' 'LAS41002' 'LYR-210' 'LYR210' 'Lyr-210' 'Mometasone furoate'
 'Mometasone furoate anhydrous' 'Mometasone furoate hydrate'
 'Mometasone furoate monohydrate' 'Monovo' 'NSC-746171' 'NSC-760077'
 'Nasonex' 'SCH 32088' 'SCH-32088']_|_[('DailyMed', array(['mometasone%20furoate'], dtype=object)), ('PubChem', array(['144204256', '170464666', '56463118'], dtype=object)), ('Wikipedia', array(['Mometasone_furoate'], dtype=object)), ('drugbank', array(['DB14512'], dtype=object)), ('chEBI', array(['47564'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'HP_0001742', 'EFO_0000676', 'EFO_0004232',
       'HP_0100582', 'EFO_0007486', 'MONDO_0004979', 'EFO_0007415',
       'EFO_1000391', 'HP_0006536', 'EFO_1001919', 'EFO_0000274',
       'MONDO_0011382', 'EFO_0003918', 'MONDO_0005271', 'MONDO_0043771',
       'EFO_1001417', 'EFO_0003956', 'EFO_0002460', 'EFO_0004192',
       'MONDO_0007254', 'EFO_0007187', 'MONDO_0100096', 'EFO_0005854',
       'EFO_0000701', 'EFO_1001494'], dtype=object), 'count': 26}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 8 approved and 18 investigational indications."
CHEMBL1200690,"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O_|_BJFIDCADFRDPIO-DZCXQCEKSA-N_|_Protein_|_False_|_LYPRESSIN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Diapid']_|_['8-l-lysinevasopressin' 'L-8' 'Lypressin' 'Lysine vasopressin'
 'Vasopressin pig' 'Vasopressin, 8-l-lysine']_|_[('PubChem', array(['144206455', '144206977'], dtype=object)), ('drugbank', array(['DB14642'], dtype=object))]_|_nan_|_nan_|_[ENSG00000126895,ENSG00000166148,ENSG00000198049]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201470,"nan_|_nan_|_Small molecule_|_False_|_HYDROCODONE POLISTIREX_|_1987.0_|_4.0_|_CHEMBL1457_|_False_|_True_|_[]_|_['Hydrocodone polistirex']_|_[('DailyMed', array(['hydrocodone%20polistirex'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987."
CHEMBL1201483,nan_|_nan_|_Small molecule_|_False_|_PSEUDOEPHEDRINE POLISTIREX_|_1987.0_|_4.0_|_CHEMBL1590_|_False_|_True_|_['Pseudo-12']_|_['Pseudoephedrine polistirex']_|_nan_|_nan_|_nan_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1272,"CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O_|_FAEKWTJYAYMJKF-QHCPKHFHSA-N_|_Small molecule_|_False_|_REPAGLINIDE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Enyglid' 'Novonorm' 'Prandin' 'Repaglinide' 'Repaglinide krka']_|_['A10BX02' 'AG-EE 623 ZW' 'AG-EE-623-ZW' 'AG-EE-623ZW' 'AGEE-623ZW'
 'NSC-759893' 'Prandin' 'Repaglinide']_|_[('DailyMed', array(['repaglinide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka'],
      dtype=object)), ('PubChem', array(['11112894', '144204272', '26719812', '49648522'], dtype=object)), ('Wikipedia', array(['Repaglinide'], dtype=object)), ('drugbank', array(['DB00912'], dtype=object)), ('chEBI', array(['8805'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0044970', 'EFO_0001068', 'EFO_0000616', 'EFO_0000400',
       'EFO_0001645', 'MONDO_0005148', 'HP_0003124', 'MONDO_0011719',
       'MONDO_0009061', 'MONDO_0008315', 'EFO_0003914', 'MONDO_0005180',
       'EFO_0000685', 'EFO_0000537'], dtype=object), 'count': 14}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 12 investigational indications."
CHEMBL1628234,"CN(C)CCC=C1c2ccccc2COc2ccccc21.Cl_|_MHNSPTUQQIYJOT-UHFFFAOYSA-N_|_Small molecule_|_True_|_DOXEPIN HYDROCHLORIDE_|_1969.0_|_4.0_|_CHEMBL1628227_|_False_|_True_|_['Adapin' 'Doxepin hydrochloride' 'Quitaxon' 'Silenor' 'Sinequan' 'Xepin'
 'Zonalon']_|_['Doxepin hcl' 'Doxepin hydrochloride' 'NSC-108160' 'P-3693A']_|_[('DailyMed', array(['doxepin%20hydrochloride'], dtype=object)), ('PubChem', array(['26719773', '26748009'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079', 'EFO_0003843', 'EFO_0004698', 'MONDO_0002009',
       'EFO_1001904', 'EFO_0000274', 'MONDO_0004985'], dtype=object), 'count': 7}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL168815,"CC1OC2(CS1)CN1CCC2CC1_|_WUTYZMFRCNBCHQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEVIMELINE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cevimeline']_|_nan_|_['CHEMBL2218917']_|_{'rows': array(['EFO_0009869', 'EFO_0009869'], dtype=object), 'count': 2}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for xerostomia and has 1 investigational indication."
CHEMBL1743047,"nan_|_nan_|_Antibody_|_True_|_NECITUMUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Portrazza']_|_['11F8' 'IMC-11F8' 'Necitumumab' 'Portrazza']_|_[('DailyMed', array(['necitumumab'], dtype=object)), ('DrugCentral', array(['5071'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/portrazza'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000708', 'EFO_0000616', 'EFO_0000707', 'EFO_0003060',
       'EFO_0009708'], dtype=object), 'count': 5}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and non-small cell lung carcinoma and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1751,"C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O_|_LTMHDMANZUZIPE-PUGKRICDSA-N_|_Small molecule_|_False_|_DIGOXIN_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Digamex' 'Digoxin' 'Digoxin pediatric' 'Lanoxicaps' 'Lanoxin'
 'Lanoxin pediatric' 'Lanoxin-125' 'Lanoxin-pg' 'Vanoxin']_|_['Digoxin' 'Digoxinum' 'Dynamos' 'Fargoxin' 'Lanocardin' 'Mapluxin'
 'NSC-95100' 'Natigoxin' 'Rougoxin' 'Stillacor-' 'Toloxin' 'Vanoxin']_|_[('DailyMed', array(['digoxin'], dtype=object)), ('PubChem', array(['11533002', '144204576', '144208876', '144213367', '17389540',
       '26752810', '49718191', '50105460', '56422204'], dtype=object)), ('Wikipedia', array(['Digoxin'], dtype=object)), ('drugbank', array(['DB00390'], dtype=object)), ('chEBI', array(['4551'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000359', 'EFO_1001249', 'EFO_0006911', 'MONDO_0002009',
       'EFO_0000616', 'EFO_0003047', 'EFO_0000400', 'EFO_0000222',
       'MP_0001845', 'EFO_0001062', 'MONDO_0008667', 'EFO_0000764',
       'EFO_0003890', 'MONDO_0001134', 'EFO_0000474', 'EFO_0000373',
       'EFO_0000685', 'EFO_0001073', 'EFO_0000558', 'EFO_0006859',
       'EFO_0003869', 'MONDO_0002050', 'EFO_0003060', 'EFO_0007328',
       'HP_0004755', 'EFO_0000198', 'EFO_0000544', 'EFO_0000275',
       'EFO_0003144', 'EFO_0000756', 'MONDO_0008315', 'MONDO_0019623',
       'EFO_0000319', 'EFO_0002496', 'MONDO_0005148', 'EFO_0003843',
       'MONDO_0007254', 'EFO_0004239'], dtype=object), 'count': 38}_|_[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 34 investigational indications."
CHEMBL2108054,"nan_|_nan_|_Protein_|_False_|_TADEKINIG ALFA_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Tadekinig alfa']_|_nan_|_nan_|_{'rows': array(['EFO_0007135', 'MONDO_0015540'], dtype=object), 'count': 2}_|_[ENSG00000150782]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108266,nan_|_nan_|_Antibody_|_False_|_CEDELIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cedelizumab' 'ORTHOCLONE OKT4 A' 'RWJ 49004' 'RWJ-49004']_|_nan_|_nan_|_nan_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109065,"nan_|_nan_|_Protein_|_False_|_DROTRECOGIN ALFA (ACTIVATED)_|_2001.0_|_4.0_|_nan_|_True_|_True_|_['Xigris']_|_['Activated protein c' 'Drotrecogin alfa' 'Drotrecogin alfa (activated)'
 'Drotrecogin alfa activated' 'Drotrecogin alfa, activated'
 'Drotrecogin-alfa' 'LY-203638' 'LY203638']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xigris'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005251', 'EFO_0006834', 'HP_0100806', 'EFO_0003827',
       'HP_0002140', 'EFO_0000712', 'EFO_0003884', 'MONDO_0100130',
       'EFO_1001373', 'HP_0004419'], dtype=object), 'count': 10}_|_[ENSG00000185010,ENSG00000198734]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 7 investigational indications. It was withdrawn in at least one region."
CHEMBL2109402,"nan_|_nan_|_Antibody_|_False_|_MM-121_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MM-121' 'Mm-121' 'SAR-256212']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0008170', 'MONDO_0002087', 'EFO_0000616',
       'EFO_0003060', 'MONDO_0004992', 'MONDO_0002158'], dtype=object), 'count': 7}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL2109630,nan_|_nan_|_Antibody_|_False_|_BC8 131I_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BC8' 'Bc8 131i']_|_nan_|_nan_|_nan_|_[ENSG00000081237]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL3039596,"CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)[O-])C(C)C.[Na+]_|_TVTJZMHAIQQZTL-WATAJHSMSA-M_|_Small molecule_|_True_|_FOSINOPRIL SODIUM_|_1991.0_|_4.0_|_CHEMBL3039598_|_False_|_True_|_['Fosinopril sodium' 'Fositens' 'Fozitec' 'Monopril' 'Staril']_|_['Fosenopril sodium' 'Fosinopril sodium' 'Fosinopril sodium salt'
 'SQ 28555' 'SQ-28555']_|_[('DailyMed', array(['fosinopril%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0003144'], dtype=object), 'count': 2}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for hypertension and heart failure. This drug has a black box warning from the FDA."
CHEMBL3137316,"Cc1ncccc1NC(=O)c1ccc2c(c1)CC[C@@H]1C[C@@](OP(=O)(O)O)(C(F)(F)F)CC[C@@]21Cc1ccccc1_|_BVXLAHSJXXSWFF-KEKPKEOLSA-N_|_Small molecule_|_False_|_FOSDAGROCORAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fosdagrocorat' 'PF-04171327']_|_[('drugbank', array(['DB12198'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3234035,"CCCCCCC(C)(C)c1cc(O)c([C@H]2CC(=O)[C@H]3C[C@@H]2C3(C)C)c(OC(=O)/C=C/C(=O)O)c1_|_GSTZHANFXAKPSE-MXTREEOPSA-N_|_Small molecule_|_False_|_PRS-211375_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cannabinor' 'Cannabinor, (-)-' 'PRS-211,375' 'Prs-211375']_|_[('drugbank', array(['DB05048'], dtype=object))]_|_nan_|_nan_|_[ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3989949,"NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl_|_GFHAXPJGXSQLPT-VIFPVBQESA-N_|_Small molecule_|_False_|_CENOBAMATE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Ontozry' 'Xcopri']_|_['Cenobamate' 'YKP-3089' 'YKP3089']_|_[('DailyMed', array(['cenobamate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry'],
      dtype=object)), ('drugbank', array(['DB06119'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474', 'HP_0001250', 'EFO_0001421', 'EFO_0004263',
       'HP_0007359'], dtype=object), 'count': 5}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 2 investigational indications."
CHEMBL413,"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C_|_QFJCIRLUMZQUOT-HPLJOQBZSA-N_|_Small molecule_|_True_|_SIROLIMUS_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Fyarro' 'Hyftor' 'Rapamune' 'Sirolimus']_|_['AY-22989' 'Fyarro' 'Hyftor' 'L04AA10' 'NSC-226080' 'Npc-12g' 'Rapalimus'
 'Rapamycin' 'SM-88 COMPONENT SIROLIMUS' 'Sirolimus' 'WY-090217']_|_[('DailyMed', array(['sirolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rapamune'],
      dtype=object)), ('PubChem', array(['124886754', '144204421', '144206303', '50103901'], dtype=object)), ('Wikipedia', array(['Sirolimus'], dtype=object)), ('drugbank', array(['DB00877'], dtype=object)), ('chEBI', array(['9168'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1002048', 'Orphanet_77260', 'EFO_0007323', 'EFO_0000760',
       'MONDO_0004976', 'EFO_1001465', 'MONDO_0002898', 'MONDO_0018848',
       'Orphanet_365', 'MONDO_0002280', 'EFO_1000749', 'EFO_1000475',
       'EFO_0000519', 'EFO_0000514', 'EFO_1000637', 'EFO_1001968',
       'EFO_0000182', 'MONDO_0007079', 'HP_0001915', 'EFO_0008620',
       'Orphanet_122', 'Orphanet_733', 'EFO_0000637', 'MONDO_0011705',
       'EFO_0000180', 'EFO_1000986', 'MONDO_0000873', 'MONDO_0007915',
       'HP_0003124', 'EFO_0000681', 'EFO_1000906', 'EFO_0000565',
       'EFO_0008514', 'MONDO_0005147', 'EFO_0001421', 'EFO_0001365',
       'EFO_0000220', 'EFO_0003086', 'EFO_0004610', 'EFO_0000699',
       'EFO_0008517', 'EFO_0003144', 'MONDO_0018975', 'Orphanet_848',
       'EFO_0001378', 'EFO_0000183', 'HP_0002721', 'EFO_0002913',
       'MONDO_0021121', 'EFO_0000095', 'EFO_0001075', 'EFO_0000717',
       'EFO_1001119', 'MONDO_0017719', 'EFO_0006475', 'EFO_1001492',
       'EFO_0004236', 'MONDO_0011382', 'EFO_0003060', 'EFO_1001469',
       'MONDO_0002691', 'MONDO_0100096', 'EFO_1000811', 'EFO_0003929',
       'EFO_0000198', 'MONDO_0044881', 'EFO_0000196', 'HP_0001871',
       'EFO_0004194', 'EFO_0000222', 'MONDO_0019313', 'EFO_0007328',
       'MONDO_0001718', 'MONDO_0016471', 'EFO_1001466', 'EFO_0000574',
       'EFO_0003870', 'EFO_1001050', 'MONDO_0007254', 'MONDO_0002177',
       'MONDO_0015974', 'EFO_0000571', 'EFO_0000401', 'EFO_0000174',
       'EFO_1001996', 'EFO_0002618', 'EFO_0000540', 'EFO_0003966',
       'EFO_0009661', 'EFO_0003770', 'EFO_0005952', 'MONDO_0004986',
       'EFO_1000251', 'EFO_0000708', 'EFO_0000339', 'EFO_1001496',
       'EFO_0002424', 'MONDO_0018150', 'MONDO_0008501', 'MONDO_0019338',
       'EFO_0006927', 'MONDO_0001187', 'Orphanet_46724', 'EFO_0000621',
       'EFO_1000312', 'EFO_0000702', 'EFO_0004208', 'EFO_1000464',
       'MONDO_0018531', 'EFO_0004599', 'EFO_0010134', 'EFO_0009708',
       'MONDO_0002108', 'EFO_0000616', 'EFO_0009259', 'EFO_1000657',
       'EFO_0005761', 'MONDO_0004992', 'MONDO_0013730', 'MONDO_0005180',
       'MONDO_0008094', 'EFO_1001264', 'EFO_1000158', 'MONDO_0020547',
       'EFO_0004683', 'MONDO_0017276', 'EFO_0003884', 'HP_0001626',
       'MONDO_0002050', 'EFO_0000537', 'MONDO_0018305', 'EFO_1000653',
       'EFO_1001761', 'MONDO_0008903', 'EFO_0000691', 'MONDO_0005149',
       'EFO_0000403', 'MONDO_0001734', 'EFO_0006888', 'MONDO_0019391',
       'MONDO_0008315', 'MONDO_0015564', 'EFO_0009907'], dtype=object), 'count': 143}_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 138 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297229,"nan_|_nan_|_Unknown_|_True_|_PRABOTULINUMTOXIN A_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Jeuveau']_|_['ABP 450' 'ABP-450' 'ABP450' 'Botulinum toxin type a complex' 'DWP-450'
 'DWP450' 'Prabotulinumtoxin a' 'Prabotulinumtoxina'
 'Prabotulinumtoxina xvfs']_|_[('DailyMed', array(['prabotulinumtoxina-xvfs'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005422', 'MONDO_0005277', 'HP_0000473'], dtype=object), 'count': 3}_|_[ENSG00000132639]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for skin aging and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297536,"nan_|_nan_|_Oligonucleotide_|_False_|_PATISIRAN SODIUM_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Onpattro']_|_[]_|_[('DailyMed', array(['patisiran%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onpattro'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018634', 'EFO_0004129', 'EFO_0009562', 'EFO_1001875'],
      dtype=object), 'count': 4}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved indications."
CHEMBL4594214,"CSCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N2)NC(=O)[C@H](CSSC[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC3=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O_|_BPKIMPVREBSLAJ-QTBYCLKRSA-N_|_Protein_|_False_|_ZICONOTIDE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.omega.-conotoxin m viia' 'SNX-111' 'Ziconotide']_|_nan_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0001945'], dtype=object), 'count': 2}_|_[ENSG00000148408]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications."
CHEMBL506871,"C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1_|_JNAHVYVRKWKWKQ-CYBMUJFWSA-N_|_Small molecule_|_False_|_VELIPARIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABT-888' 'PARP-1 INHIBITOR ABT-888' 'Veliparib']_|_[('drugbank', array(['DB07232'], dtype=object)), ('chEBI', array(['62880'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002617', 'MONDO_0007254', 'MONDO_0008315', 'MONDO_0008170',
       'EFO_0000616', 'EFO_0006861', 'EFO_0000708', 'EFO_0005537',
       'Orphanet_145', 'MONDO_0002898', 'MONDO_0015760', 'EFO_0001075',
       'EFO_0000305', 'MONDO_0001056', 'EFO_1000158', 'EFO_0000182',
       'EFO_0000519', 'EFO_0002618', 'EFO_0005088', 'EFO_1000657',
       'EFO_1001951', 'MONDO_0004992', 'EFO_0000466', 'EFO_0005952',
       'EFO_0000702', 'EFO_1001465', 'EFO_0002499', 'MONDO_0002158',
       'EFO_1001469', 'EFO_0001663', 'EFO_0003060', 'EFO_0000574',
       'EFO_0006772', 'EFO_0003968'], dtype=object), 'count': 34}_|_[ENSG00000143799,ENSG00000041880,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 34 investigational indications."
CHEMBL5315078,"nan_|_nan_|_Unknown_|_False_|_EPTACOG BETA (ACTIVATED)_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Cevenfacta']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cevenfacta'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604', 'MONDO_0010602'], dtype=object), 'count': 2}_|_[ENSG00000057593]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for hemophilia b and hemophilia a."
CHEMBL941,"Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1_|_KTUFNOKKBVMGRW-UHFFFAOYSA-N_|_Small molecule_|_False_|_IMATINIB_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Glamox' 'Gleevec' 'Imatinib' 'NSC-743414' 'NSC-759854' 'STI-571']_|_[('PubChem', array(['103905596', '124892207', '124892208', '124892209', '26755316',
       '29215405', '50100104'], dtype=object)), ('Wikipedia', array(['Imatinib'], dtype=object)), ('drugbank', array(['DB00619'], dtype=object)), ('chEBI', array(['45783'], dtype=object))]_|_['CHEMBL2386595' 'CHEMBL1642']_|_{'rows': array(['EFO_0004288', 'EFO_0006861', 'MONDO_0002108', 'EFO_0000717',
       'EFO_0000760', 'EFO_1001361', 'MONDO_0005575', 'EFO_0003032',
       'EFO_0003106', 'EFO_0001361', 'MONDO_0011934', 'EFO_0000756',
       'MONDO_0004979', 'MONDO_0004643', 'EFO_0007328', 'EFO_0000181',
       'EFO_0000685', 'MONDO_0008978', 'EFO_0004198', 'EFO_0000717',
       'EFO_0000220', 'MONDO_0005301', 'MONDO_0018975', 'MONDO_0005147',
       'EFO_1001465', 'MONDO_0002108', 'EFO_0000702', 'EFO_0002429',
       'HP_0001880', 'MONDO_0013730', 'EFO_0000588', 'EFO_0009907',
       'EFO_1000729', 'MONDO_0100096', 'EFO_0000339', 'MONDO_0004992',
       'EFO_0002617', 'MONDO_0021063', 'MONDO_0005149', 'MONDO_0011962',
       'MONDO_0009937', 'EFO_0000691', 'MONDO_0008170', 'EFO_1000657',
       'EFO_1000895', 'MONDO_0008903', 'MONDO_0007254', 'EFO_0000641',
       'MONDO_0100096', 'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715',
       'EFO_0000313', 'EFO_0009907', 'EFO_0000209', 'MONDO_0007254',
       'EFO_1000613', 'MONDO_0001056', 'EFO_0000756', 'MONDO_0018076',
       'EFO_1001471', 'EFO_1000359', 'EFO_0000389', 'MONDO_0008903',
       'EFO_0000333', 'EFO_0000768', 'EFO_0003060', 'EFO_0004683',
       'EFO_0001361', 'MONDO_0000870', 'EFO_0006859', 'EFO_0000519',
       'EFO_0000497', 'EFO_0000094', 'EFO_0005952', 'EFO_0001422',
       'EFO_0000616', 'MONDO_0011719', 'MONDO_0011382', 'EFO_0007444',
       'MONDO_0008315', 'EFO_0000339', 'EFO_0002087', 'MONDO_0004992',
       'MONDO_0002367', 'MONDO_0002087', 'EFO_1000158', 'EFO_1001951',
       'EFO_0000519', 'MONDO_0005149', 'MONDO_0000873', 'MONDO_0013730',
       'MONDO_0044881', 'MONDO_0011719', 'MONDO_0011705', 'MONDO_0002158',
       'EFO_0000503', 'EFO_1001467', 'EFO_0000712', 'EFO_1001814',
       'EFO_1001467', 'EFO_0000673', 'EFO_0000658', 'EFO_1000576',
       'EFO_0000691', 'EFO_1001993', 'EFO_0002430', 'EFO_0000365',
       'EFO_0000222', 'EFO_0004610', 'EFO_0001376', 'EFO_0003956',
       'MONDO_0044917', 'EFO_0002428', 'EFO_0000616', 'MONDO_0020547',
       'EFO_0000565', 'EFO_0005952', 'EFO_1001919', 'EFO_0004289',
       'EFO_0000220', 'EFO_0000349', 'MONDO_0000873', 'EFO_0000565',
       'EFO_0000574', 'EFO_0003897', 'EFO_0000222'], dtype=object), 'count': 127}_|_[ENSG00000157404,ENSG00000097007,ENSG00000186716,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 110 investigational indications."
CHEMBL112797,"CCCCP(=O)(O)CCCN_|_ONNMDRQRSGKZCN-UHFFFAOYSA-N_|_Small molecule_|_False_|_SGS-742_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CGP-36742' 'LU-AE-58479' 'SGS742' 'Sgs 742' 'Sgs-742' 'Sgs742']_|_[('drugbank', array(['DB05010'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200778,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl_|_BIFMNMPSIYHKDN-FJXQXJEOSA-N_|_Small molecule_|_False_|_DEXRAZOXANE HYDROCHLORIDE_|_1995.0_|_4.0_|_CHEMBL1738_|_False_|_True_|_['Dexrazoxane hydrochloride' 'Savene' 'Totect' 'Zinecard']_|_['ADR-529 HYDROCHLORIDE' 'Cardioxan' 'Dexrazoxane hcl'
 'Dexrazoxane hydrochloride' 'ICRF-187 HYDROCHLORIDE'
 'Razoxane hydrochloride, (s)-' 'Savene']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/savene'],
      dtype=object)), ('chEBI', array(['50224'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000318', 'EFO_0000691', 'MONDO_0000870', 'EFO_1000984',
       'EFO_0000621', 'EFO_0000574', 'EFO_0000502', 'EFO_0000565',
       'MONDO_0007254', 'EFO_0000222', 'EFO_0000209', 'EFO_0000616',
       'EFO_1000158'], dtype=object), 'count': 13}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 11 investigational indications."
CHEMBL1200935,"Br.NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1_|_UQAVIASOPREUIT-VQIWEWKSSA-N_|_Small molecule_|_False_|_DARIFENACIN HYDROBROMIDE_|_2004.0_|_4.0_|_CHEMBL1346_|_False_|_True_|_['Darifenacin hydrobromide' 'Emselex' 'Enablex']_|_['Darifenacin hbr' 'Darifenacin hydrobromide' 'UK-88525-04 (HYDROBROMIDE)'
 'Uk-88525-04 (hbr)']_|_[('DailyMed', array(['darifenacin%20hydrobromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emselex'],
      dtype=object)), ('PubChem', array(['144206189', '170465079'], dtype=object)), ('chEBI', array(['31455'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006865', 'EFO_1000781'], dtype=object), 'count': 2}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for urgency urinary incontinence and overactive bladder."
CHEMBL1201229,"CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1_|_RWZVPVOZTJJMNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_DEMECARIUM_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Demecarium' 'Demecarium cation' 'Demecarium ion']_|_[('drugbank', array(['DB00944'], dtype=object)), ('chEBI', array(['59719'], dtype=object))]_|_['CHEMBL1200514']_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for glaucoma."
CHEMBL1207366,"O=C(O)C1C/C(=C2/CCN(c3ccccc3)C2=O)c2ccc(Cl)cc2N1_|_XDKRVNKVAKCFGW-FOCLMDBBSA-N_|_Small molecule_|_False_|_GW468816_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW468816' 'Gw-468816' 'Gw468816']_|_nan_|_['CHEMBL400007']_|_{'rows': array(['EFO_0003768'], dtype=object), 'count': 1}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1224,"Cc1ccc(/C(=C\CN2CCCC2)c2cccc(/C=C/C(=O)O)n2)cc1_|_PWACSDKDOHSSQD-IUTFFREVSA-N_|_Small molecule_|_False_|_ACRIVASTINE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Benadryl allgy relief plus decongest' 'Semprex']_|_['Acrivastine' 'BW 825C' 'BW-825C']_|_[('PubChem', array(['144206566'], dtype=object)), ('Wikipedia', array(['Acrivastine'], dtype=object)), ('drugbank', array(['DB09488'], dtype=object)), ('chEBI', array(['83168'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994 and is indicated for allergic disease."
CHEMBL1980391,"COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2_|_UOVCGJXDGOGOCZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_RG-1530_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['R-1530' 'RG-1530' 'Rg-1530']_|_[('PubChem', array(['103905607'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000122025,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000087586,ENSG00000142731,ENSG00000077782,ENSG00000113721,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2104386,"CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O_|_NSQLIUXCMFBZME-MPVJKSABSA-N_|_Protein_|_False_|_CARPERITIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Atrial natriuretic peptide' 'Atrial natriuretic peptide carperitide'
 'Carperitide' 'SUN 4936' 'SUN-4936']_|_nan_|_nan_|_nan_|_[ENSG00000159899,ENSG00000169418,ENSG00000113389]_|_Protein drug with a maximum clinical trial phase of III."
CHEMBL2106841,"CCCCCC(C)C(C)c1cc(O)c2c(c1)OC(C)(C)C=C2c1ccncc1_|_YHUDSHIRWOVVCV-UHFFFAOYSA-N_|_Small molecule_|_False_|_NONABINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BRL 4664' 'Brl-4664' 'Nonabine']_|_nan_|_nan_|_nan_|_[ENSG00000118432,ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2108080,"nan_|_nan_|_Oligosaccharide_|_False_|_PARNAPARIN SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fluxum' 'Lowepa' 'Minidalton' 'OP 21-23' 'OP-21-23' 'OP-2123'
 'Parnaparin sodium' 'Tromboparin']_|_nan_|_nan_|_{'rows': array(['HP_0004418', 'EFO_0000545'], dtype=object), 'count': 2}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108489,nan_|_nan_|_Antibody_|_False_|_KELIXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IDEC CE-9.1' 'IDEC-CE9.1' 'Keliximab' 'SB-210396']_|_nan_|_nan_|_nan_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108581,"nan_|_nan_|_Antibody_|_False_|_CATUMAXOMAB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Removab']_|_['Catumaxomab']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/removab'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_1000251', 'HP_0001541', 'MONDO_0004992',
       'MONDO_0001187', 'EFO_1001100', 'EFO_0003897', 'EFO_0000294',
       'EFO_0000503', 'EFO_0000616'], dtype=object), 'count': 10}_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 7 investigational indications."
CHEMBL3137347,"nan_|_nan_|_Antibody_|_False_|_VARLILUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDX-1127' 'Varlilumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000756', 'EFO_0003060', 'EFO_1001956',
       'EFO_0000632', 'EFO_0000519', 'EFO_0003863', 'EFO_0000272',
       'EFO_0000681', 'EFO_0000630'], dtype=object), 'count': 10}_|_[ENSG00000139193]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL3545239,"nan_|_nan_|_Small molecule_|_False_|_PF-05019702_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PRA-027' 'Pf-05019702' 'WAY-257027']_|_nan_|_nan_|_{'rows': array(['EFO_0000731'], dtype=object), 'count': 1}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL427216,"Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1_|_BOVGTQGAOIONJV-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLICLAZIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Bilxona' 'Dacadis mr' 'Diaglyk' 'Diamicron' 'Diamicron mr' 'Edicil'
 'Glimil' 'Nazdol mr' 'Vamju' 'Vitile xl' 'Ziclaseg' 'Zicron' 'Zicron pr']_|_['Gliclazide' 'Glimicron' 'J3.151H' 'NSC-758673' 'S-1702' 'S-852'
 'SE 1702' 'SE-1702']_|_[('PubChem', array(['144204141', '170465698', '26748918', '26748919', '26748920',
       '49646130'], dtype=object)), ('Wikipedia', array(['Gliclazide'], dtype=object)), ('drugbank', array(['DB01120'], dtype=object)), ('chEBI', array(['31654'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474', 'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 2 investigational indications."
CHEMBL429317,"Cc1cc(/C(=C/Nc2ccc(Cl)cc2)C(=O)Nc2ccc(Cl)cc2)on1_|_VMAKIACTLSBBIY-BOPFTXTBSA-N_|_Small molecule_|_False_|_AVL-3288_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Anvylic-3288' 'Avl-3288' 'CCMI' 'UCI-4083' 'XY-4083']_|_nan_|_nan_|_{'rows': array(['EFO_0005411', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL4583691,"Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1_|_UEPXBTCUIIGYCY-UHFFFAOYSA-N_|_Small molecule_|_False_|_LXH254_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LXH-254' 'LXH254' 'Lxh 254' 'Lxh254' 'Naporafenib'
 'PAN-RAF INHIBITOR LXH254']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000756'], dtype=object), 'count': 2}_|_[ENSG00000132155,ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594355,"nan_|_nan_|_Unknown_|_False_|_APL-501_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APL-501' 'Apl-501' 'CBT-501' 'GB-226' 'GB226' 'Gb226' 'Genolimzumab'
 'Geptanolimab']_|_nan_|_nan_|_{'rows': array(['EFO_1001938', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0000211',
       'EFO_0007143', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000188389]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4802221,"nan_|_nan_|_Antibody_|_False_|_SOCAZOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anti-PD-L1 SH1E2' 'SH1E2' 'STI-A1014' 'Socazolimab' 'ZKAB-001' 'ZKAB001'
 'Zkab001']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOCAZOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_0000637', 'MONDO_0002974', 'EFO_0002617',
       'EFO_0000616', 'EFO_0008528', 'MONDO_0003060'], dtype=object), 'count': 7}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL508102,"CCOC(=O)n1ccn(C)c1=S_|_CFOYWRHIYXMDOT-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARBIMAZOLE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Neo-mercazole 20' 'Neo-mercazole 5']_|_['Athyromazole' 'Carbimazol henning' 'Carbimazole' 'NSC-758966']_|_[('PubChem', array(['11112670', '144204147', '144212637', '170465583', '26749040'],
      dtype=object)), ('Wikipedia', array(['Carbimazole'], dtype=object)), ('drugbank', array(['DB00389'], dtype=object)), ('chEBI', array(['617099'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009190', 'HP_0000820'], dtype=object), 'count': 2}_|_[ENSG00000115705]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for abnormality of the thyroid gland and has 1 investigational indication."
CHEMBL5315069,"nan_|_nan_|_Protein_|_False_|_DAMOCTOCOG ALFA PEGOL_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Jivi']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jivi'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for hemophilia a."
CHEMBL597,"Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1_|_MRBDMNSDAVCSSF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENTOLAMINE_|_1952.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Phentolamin' 'Phentolamine']_|_[('PubChem', array(['104171285', '11112200', '124882050', '124882053', '144203915',
       '170464866', '26751465', '26751466', '26751467', '50085867',
       '50100389', '50100390', '50103967', '860967', '90341742'],
      dtype=object)), ('Wikipedia', array(['Phentolamine'], dtype=object)), ('drugbank', array(['DB00692'], dtype=object)), ('chEBI', array(['8081'], dtype=object))]_|_['CHEMBL1204146' 'CHEMBL1200873']_|_{'rows': array(['MONDO_0008315', 'EFO_0000239', 'EFO_0000319', 'EFO_0001073',
       'EFO_0001073', 'HP_0001943', 'HP_0011499', 'EFO_0000319',
       'MONDO_0001330'], dtype=object), 'count': 9}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for adrenal gland pheochromocytoma and cardiovascular disease and has 6 investigational indications."
CHEMBL1089318,"Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n1_|_ASOADIZOVZTJSR-UHFFFAOYSA-N_|_Small molecule_|_False_|_OPICAPONE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Ongentys' 'Ontilyv']_|_['BIA 9-1067' 'BIA-9-1067' 'BIA-91067' 'Ongentys' 'Opicapone']_|_[('DailyMed', array(['opicapone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv'],
      dtype=object)), ('drugbank', array(['DB11632'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000093010]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for parkinson disease."
CHEMBL1201631,"nan_|_nan_|_Protein_|_True_|_INSULIN HUMAN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Actrapid' 'Afrezza' 'Exubera' 'Humulin br' 'Humulin r'
 'Humulin r kwikpen' 'Humulin r pen' 'Inpremzia' 'Ins humulin r' 'Insuman'
 'Insuman infusat' 'Myxredlin' 'Novolin r' 'Velosulin Br Human'
 'Velosulin br']_|_['Biosulin r' 'Capsulin' 'Exubera (inhaled insulin human)'
 'High molecular weight insulin human' 'Human insulin' 'Humulin' 'Insulin'
 'Insulin (human)' 'Insulin Recombinant Human' 'Insulin human'
 'Insulin human (biosynthesis)' 'Insulin human (synthesis)'
 'Insulin human lente' 'Insulin human nph' 'Insulin human rdna'
 'Insulin human regular' 'Insulin human regular (rdna)'
 'Insulin human semisynthetic' 'Insulin human, rdna origin'
 'Insulin recombinant human' 'Insulin recombinant purified human'
 'Insulin reconbinanet human' 'Insulin semi synthetic human'
 'Insulin semisynthetic human' 'Insulin, human'
 'Insulin,regular,human buffered' 'Insulin,ultralente,human'
 'Regular insulin, human' 'Viatab']_|_[('DailyMed', array(['insulin%20human', 'insulin%20recombinant%20human'], dtype=object)), ('DrugCentral', array(['5003'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/actrapid',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/inpremzia',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/insuman'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021187', 'HP_0003074', 'EFO_1000783', 'EFO_0000401',
       'HP_0000842', 'EFO_1001050', 'EFO_0009492', 'EFO_0007430',
       'MONDO_0005148', 'HP_0003124', 'MONDO_0005041', 'HP_0001919',
       'EFO_0003840', 'EFO_0001358', 'EFO_0009267', 'EFO_0002614',
       'EFO_0000400', 'HP_0002140', 'EFO_0000373', 'EFO_0000712',
       'EFO_1000906', 'EFO_0001645', 'HP_0100543', 'MONDO_0002009',
       'EFO_0003768', 'EFO_0003917', 'EFO_1000653', 'EFO_0005672',
       'EFO_0008583', 'EFO_0003929', 'MONDO_0005180', 'EFO_0003914',
       'EFO_0003843', 'MONDO_0005147', 'EFO_1000985', 'EFO_0001073',
       'MONDO_0100096', 'EFO_0004143', 'MONDO_0002146', 'EFO_0000612',
       'EFO_0000546', 'MONDO_0018555', 'EFO_0006834', 'MONDO_0005090',
       'EFO_0003095', 'EFO_0004593', 'EFO_0009516', 'EFO_0000537',
       'HP_0001943', 'MONDO_0004985', 'HP_0002153'], dtype=object), 'count': 51}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 49 investigational indications. This drug has a black box warning from the FDA."
CHEMBL139835,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C_|_UWFYSQMTEOIJJG-FDTZYFLXSA-N_|_Small molecule_|_False_|_CYPROTERONE ACETATE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Androcur' 'Androcur 10' 'Cyprostat' 'Diane']_|_['Cyproterone' 'Cyproterone 17.alpha.-acetate' 'Cyproterone acetate'
 'NSC-81430' 'SH 714' 'SH-714' 'SH714']_|_[('PubChem', array(['144204615', '144208884', '144213258', '170465682', '17389953',
       '26752883', '46500455', '49737417', '90340797'], dtype=object)), ('drugbank', array(['DB04839'], dtype=object)), ('chEBI', array(['50743'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0003894', 'EFO_0001065', 'EFO_0000673',
       'EFO_0000536', 'GO_0042697', 'HP_0031217', 'EFO_0000660'],
      dtype=object), 'count': 8}_|_[ENSG00000082175,ENSG00000113580,ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications."
CHEMBL1689,"Cl.c1ccc(CC2=NCCN2)cc1_|_RHTNTTODYGNRSP-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLAZOLINE HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL770_|_False_|_True_|_['Benzidazol' 'Priscol' 'Priscoline']_|_['Benzazoline hydrochloride' 'NSC-757353' 'TCMDC-125842' 'Tolazoline HCl'
 'Tolazoline hcl' 'Tolazoline hydrochloride']_|_[('PubChem', array(['144203890', '14742771', '170465219', '26748277'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985."
CHEMBL1742993,"nan_|_nan_|_Antibody_|_False_|_BLOSOZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Blosozumab' 'LY-2541546' 'LY2541546']_|_nan_|_nan_|_{'rows': array(['EFO_0003854', 'EFO_0003882'], dtype=object), 'count': 2}_|_[ENSG00000167941]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2103793,"Cc1cn([C@H]2C[C@H](OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4ccc(N)nc4=O)C[C@@H]3OP([O-])(=S)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]_|_QUWFSKKBMDKAHK-SBOJBMMISA-A_|_Oligonucleotide_|_False_|_AGATOLIMOD SODIUM_|_nan_|_3.0_|_CHEMBL2103792_|_False_|_False_|_[]_|_['Agatolimod sodium' 'Agatolimod tricosasodium salt' 'CPG 7909' 'CPG-7909'
 'PF-03512676' 'PF-3512676' 'Vaximmune']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0009441', 'EFO_0002913', 'EFO_0003869',
       'EFO_0000764', 'EFO_0000403', 'EFO_0001068', 'EFO_0000756',
       'EFO_0000574', 'EFO_0000681', 'EFO_1001051', 'HP_0100806',
       'EFO_0000096', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0007576',
       'EFO_0000313', 'MONDO_0008315', 'EFO_0000191', 'EFO_0003060',
       'EFO_1001469'], dtype=object), 'count': 21}_|_[ENSG00000239732]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 21 investigational indications."
CHEMBL2105712,"CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O_|_USNRYVNRPYXCSP-JUGPPOIOSA-N_|_Small molecule_|_False_|_AFATINIB DIMALEATE_|_2013.0_|_4.0_|_CHEMBL1173655_|_False_|_True_|_['Gilotrif' 'Giotrif']_|_['Afatinib dimaleate' 'Afatinib maleate' 'BIBW-2992 MA2' 'BIBW-2992-MA2'
 'BIBW-2992MA2' 'BIBW2992 MA2' 'BIBW2992-MA2']_|_[('DailyMed', array(['afatinib%20dimaleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif'],
      dtype=object)), ('chEBI', array(['76003'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0001378'], dtype=object), 'count': 2}_|_[ENSG00000141736,ENSG00000178568,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for non-small cell lung carcinoma and has 1 investigational indication."
CHEMBL2106643,"COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)[O-])C(=O)OC2.[Na+]_|_DOZYTHNHLLSNIK-JOKMOOFLSA-M_|_Small molecule_|_True_|_MYCOPHENOLATE SODIUM_|_2004.0_|_4.0_|_CHEMBL866_|_False_|_True_|_['Ceptava' 'Myfortic']_|_['ERL 080' 'ERL-080' 'Mycophenolate sodium'
 'Mycophenolic acid sodium salt' 'Mycophenolic sod' 'NSC-116072'
 'Sodium mycophenalate']_|_[('DailyMed', array(['mycophenolic%20sodium'], dtype=object)), ('chEBI', array(['67155'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000699', 'EFO_0005140', 'EFO_0005761', 'HP_0001871',
       'MONDO_0005301', 'EFO_1002048', 'EFO_0003884', 'EFO_0004599',
       'EFO_0003086'], dtype=object), 'count': 9}_|_[ENSG00000106348,ENSG00000178035]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for multiple sclerosis and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108680,"nan_|_nan_|_Antibody_|_False_|_PIDILIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Ct-011']_|_['CT-011' 'Pidilizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000673', 'EFO_0004220', 'EFO_0000681', 'EFO_0000574',
       'EFO_0000403', 'EFO_0000182', 'EFO_0001378', 'EFO_0000756',
       'EFO_0002618'], dtype=object), 'count': 9}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL2109520,nan_|_nan_|_Antibody_|_False_|_ONCOLYSIN M_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONCOLYSIN M']_|_nan_|_nan_|_nan_|_[ENSG00000105383]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2360580,"CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1.Cl.Cl_|_SDBHDSZKNVDKNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUCLIZINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201271_|_False_|_True_|_['Bucladin-s' 'Equivert']_|_['Aphilan' 'Buclina' 'Buclizine dihydrochloride' 'Buclizine hcl'
 'Buclizine hydrochloride' 'Buclodin' 'Longifene' 'NSC-25141' 'Softran'
 'UCB 4445' 'UCB-4445']_|_[('PubChem', array(['144203574'], dtype=object)), ('chEBI', array(['61193'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL3407547,"COc1ccccc1[C@H](Cn1c(=O)n(C(C)(C)C(=O)O)c(=O)c2c(C)c(-c3ncco3)sc21)OC1CCOCC1_|_ZZWWXIBKLBMSCS-FQEVSTJZSA-N_|_Small molecule_|_False_|_FIRSOCOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Firsocostat' 'GS-0976' 'GS-ACC' 'Gs-0976' 'ND-630' 'Ndi-010976']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FIRSOCOSTAT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001249', 'MONDO_0019052'], dtype=object), 'count': 2}_|_[ENSG00000278540,ENSG00000076555]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545264,"CC(Oc1ccc2[nH]nc(/C=C/c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl_|_GKJCVYLDJWTWQU-DUXPYHPUSA-N_|_Small molecule_|_False_|_LY-2874455_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LY2874455' 'Ly-2874455']_|_nan_|_nan_|_nan_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3833304,"nan_|_nan_|_Antibody_|_False_|_TOSITUMOMAB 131I_|_nan_|_3.0_|_nan_|_False_|_False_|_['Bexxar']_|_['Tositumomab (131I)' 'Tositumomab 131i'
 'Tositumomab/iodine (131i) tositumomab']_|_nan_|_nan_|_{'rows': array(['EFO_0000403', 'EFO_0001378', 'MONDO_0000873', 'EFO_0000574',
       'EFO_0009441', 'EFO_0000096', 'EFO_0005952', 'EFO_0000191',
       'MONDO_0018906', 'EFO_1001469', 'EFO_0003032', 'EFO_0000183',
       'EFO_0000309', 'EFO_0000095'], dtype=object), 'count': 14}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."
CHEMBL4297255,"COC(=O)C1(OC(=O)c2cncn2[C@H](C)c2ccccc2)CC1_|_DRAFVCKNYNQOKR-GFCCVEGCSA-N_|_Small molecule_|_False_|_ABP-700_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abp-700']_|_[('drugbank', array(['DB15411'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4297504,"CO[C@@H]1[C@H](OC(=O)/C=C/c2ccc(OCCN(C)C)cc2)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C_|_ZEZFKUBILQRZCK-MJSCXXSSSA-N_|_Small molecule_|_False_|_BELORANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Beloranib' 'ZGN-433' 'ZGN-440' 'Zgn-433' 'Zgn-440']_|_[('drugbank', array(['DB12671'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'MONDO_0008300'], dtype=object), 'count': 2}_|_[ENSG00000111142]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL452461,"O=c1c2c(c1=O)N(CCP(=O)(O)O)CCCN2_|_BDABGOLMYNHHTR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PERZINFOTEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EAA-090' 'Perzinfotel']_|_[('drugbank', array(['DB12365'], dtype=object))]_|_nan_|_nan_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4594395,"O=C([O-])CCCO.[K+]_|_TXSIWDVUJVMMKM-UHFFFAOYSA-M_|_Small molecule_|_False_|_POTASSIUM OXYBATE_|_2020.0_|_4.0_|_CHEMBL1342_|_False_|_True_|_[]_|_['Oxybate potassium']_|_[('DailyMed', array(['potassium%20oxybate'], dtype=object))]_|_nan_|_nan_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020."
CHEMBL4650483,"nan_|_nan_|_Antibody_|_False_|_ERFONRILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Erfonrilimab' 'KN-046' 'KN046' 'Kn 046' 'Kn046']_|_nan_|_nan_|_{'rows': array(['MONDO_0005184', 'EFO_0000574', 'EFO_0000616', 'EFO_0003060',
       'EFO_0005922', 'EFO_0005537', 'EFO_1000576', 'EFO_0002618',
       'EFO_0000182'], dtype=object), 'count': 9}_|_[ENSG00000120217,ENSG00000163599]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL5315049,"N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O=C(O)/C=C\C(=O)O_|_YRKLLQIZVVYDQY-YLGLLLDBSA-N_|_Small molecule_|_False_|_SITAGLIPTIN FUMARATE_|_2021.0_|_4.0_|_CHEMBL1422_|_False_|_True_|_['Sitagliptin sun']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-sun'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for type 2 diabetes mellitus."
CHEMBL562668,"CCNC1(C(N)=O)CCN(c2ncnc3c2nc(-c2ccccc2Cl)n3-c2ccc(Cl)cc2)CC1_|_UNAZAADNBYXMIV-UHFFFAOYSA-N_|_Small molecule_|_False_|_OTENABANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CP-945,598' 'CP-945598' 'CP-945598-01' 'Cp-945598' 'Otenabant'
 'Otenabant hydrochloride']_|_[('Wikipedia', array(['Otenabant'], dtype=object)), ('drugbank', array(['DB11745'], dtype=object))]_|_['CHEMBL2103817' 'CHEMBL3526399']_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL58,"O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21_|_KKZJGLLVHKMTCM-UHFFFAOYSA-N_|_Small molecule_|_True_|_MITOXANTRONE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Mitoxantrone HCl' 'Novantrone']_|_['Misostol' 'Mitoxantrone' 'NSC-279836' 'Novantrone']_|_[('PubChem', array(['11111482', '11111483', '142727', '162108252', '50111146',
       '85856281', '90341083', '92763439'], dtype=object)), ('Wikipedia', array(['Mitoxantrone'], dtype=object)), ('drugbank', array(['DB01204'], dtype=object)), ('chEBI', array(['50729'], dtype=object))]_|_['CHEMBL1200827' 'CHEMBL1417019']_|_{'rows': array(['MONDO_0019472', 'EFO_0000182', 'MONDO_0005301', 'EFO_1001469',
       'EFO_0000403', 'EFO_1000359', 'MONDO_0008170', 'EFO_0003843',
       'EFO_0000220', 'EFO_0004289', 'EFO_0000198', 'EFO_0001378',
       'EFO_0000616', 'EFO_0004289', 'EFO_0003929', 'EFO_0000222',
       'EFO_1001830', 'EFO_0008522', 'EFO_0000565', 'EFO_0000224',
       'EFO_0000339', 'MONDO_0008315', 'EFO_1001968', 'MONDO_0007254',
       'EFO_0000574', 'EFO_0006859', 'MONDO_0007254', 'EFO_0004256',
       'EFO_0004252', 'EFO_0000326', 'MONDO_0019472', 'EFO_0000222',
       'MONDO_0001023', 'MONDO_0005301', 'MONDO_0019460', 'EFO_1001052',
       'EFO_0000574', 'MONDO_0015760', 'EFO_0000211', 'MONDO_0018906',
       'EFO_0004251', 'EFO_0000673', 'EFO_0000196', 'EFO_0000221',
       'EFO_1001469', 'EFO_0005952', 'MONDO_0004992', 'EFO_0000095',
       'MONDO_0008315', 'EFO_0001378', 'EFO_0000178', 'EFO_0000403',
       'EFO_1000286', 'EFO_0000211', 'EFO_0000616', 'MONDO_0000873',
       'EFO_0001663'], dtype=object), 'count': 57}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 48 investigational indications. This drug has a black box warning from the FDA."
CHEMBL9960,"CC[C@H](NC(=O)c1cc(-c2ccccc2)nc2ccccc12)c1ccccc1_|_MXNGYQJJYRVGGJ-QFIPXVFZSA-N_|_Small molecule_|_False_|_AZD-7624_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-7624' 'Azd 7624' 'Azd-7624']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341', 'MP_0001845'], dtype=object), 'count': 3}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1014,"CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1_|_GHOSNRCGJFBJIB-UHFFFAOYSA-N_|_Small molecule_|_True_|_CANDESARTAN CILEXETIL_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Amias' 'Atacand' 'Candesartan cilexetil' 'Ratacand']_|_['Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester'
 'Candesartan cilexetil' 'NSC-758697' 'TCV-116']_|_[('DailyMed', array(['candesartan%20cilexetil'], dtype=object)), ('PubChem', array(['144212519', '26748952'], dtype=object)), ('drugbank', array(['DB00796'], dtype=object)), ('chEBI', array(['3348'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0000319', 'EFO_0003913', 'MONDO_0005147',
       'EFO_0000612', 'EFO_0000537', 'MONDO_0043510', 'EFO_0003144',
       'EFO_0001645', 'HP_0000093', 'EFO_1001150', 'HP_0003124',
       'MONDO_0007254', 'EFO_0000373', 'EFO_0000400', 'EFO_0003914',
       'MONDO_0001134', 'MONDO_0005148', 'EFO_1001153', 'MONDO_0100096',
       'EFO_0000712'], dtype=object), 'count': 21}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 7 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1123,"CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1_|_CURUTKGFNZGFSE-UHFFFAOYSA-N_|_Small molecule_|_False_|_DICYCLOMINE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bentyl' 'Dicyclomine' 'Dicycloverine' 'Dicymine' 'Kolantyl']_|_[('PubChem', array(['11111098', '11112188', '144207120', '170464896', '50100226',
       '50104289', '90341021'], dtype=object)), ('Wikipedia', array(['Dicycloverine'], dtype=object)), ('drugbank', array(['DB00804'], dtype=object)), ('chEBI', array(['4514'], dtype=object))]_|_['CHEMBL1200479']_|_{'rows': array(['EFO_0010282', 'EFO_0000555'], dtype=object), 'count': 2}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for gastrointestinal disease and irritable bowel syndrome."
CHEMBL1139,"CCCCC[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)O[C@H]2C[C@H]1O_|_KAQKFAOMNZTLHT-OZUDYXHBSA-N_|_Small molecule_|_False_|_EPOPROSTENOL_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ACT-385781A' 'Epoprostenol' 'Flolan' 'PG-I2' 'Pgi2' 'Pgx' 'Prostacyclin'
 'Prostaglandin i2' 'Prostaglandin x' 'U-53,217' 'U-53217']_|_[('PubChem', array(['26754811', '50112680'], dtype=object)), ('drugbank', array(['DB01240'], dtype=object)), ('chEBI', array(['15552'], dtype=object))]_|_['CHEMBL962']_|_{'rows': array(['EFO_0002687', 'HP_0004419', 'MONDO_0005149', 'EFO_0001361',
       'EFO_0000713', 'MONDO_0043510', 'MONDO_0100096', 'EFO_0001361'],
      dtype=object), 'count': 8}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for recurrent thrombophlebitis and pulmonary arterial hypertension and has 6 investigational indications."
CHEMBL1187833,"OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2_|_FVTWTVQXNAJTQP-UHFFFAOYSA-N_|_Small molecule_|_False_|_UMECLIDINIUM_|_2013.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['GSK-573719' 'GSK573719' 'Umeclidinium' 'Umeclidinium cation'
 'Umeclidinium ion']_|_[('drugbank', array(['DB09076'], dtype=object))]_|_['CHEMBL523299']_|_{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0000464', 'HP_0006536',
       'EFO_0000341', 'MONDO_0004979', 'HP_0000975', 'EFO_0006505'],
      dtype=object), 'count': 8}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 4 investigational indications."
CHEMBL1200402,"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=S(=O)(O)c1ccccc1_|_ZPBWCRDSRKPIDG-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMLODIPINE BESYLATE_|_1992.0_|_4.0_|_CHEMBL1491_|_False_|_True_|_['Amlodipine besylate' 'Norliqva' 'Norvasc']_|_['Amlodipine (as besilate)' 'Amlodipine benzenesulfonate'
 'Amlodipine besilate' 'Amlodipine besylate' 'Amlor' 'Antacal'
 'Lodipressin' 'Monopina' 'NSC-758922' 'Norliqva' 'UK-48,340-26'
 'UK-48340-26']_|_[('DailyMed', array(['amlodipine%20besylate'], dtype=object)), ('PubChem', array(['144205078', '144207025', '26749852'], dtype=object)), ('chEBI', array(['2669'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'EFO_0003144', 'EFO_0000612', 'HP_0000093',
       'EFO_0004911', 'EFO_1000013', 'MONDO_0005178', 'MONDO_0021187',
       'EFO_0000373', 'EFO_0000537', 'EFO_0000712', 'MONDO_0001134',
       'HP_0003124', 'Orphanet_79292', 'EFO_0003913', 'EFO_0001645'],
      dtype=object), 'count': 16}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 13 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200789,"O=P([O-])(O)OCC(Cl)(Cl)Cl.[Na+]_|_WFKJEZKHPGDCRK-UHFFFAOYSA-M_|_Small molecule_|_False_|_TRICLOFOS SODIUM_|_1982.0_|_4.0_|_CHEMBL1201317_|_False_|_True_|_['Triclos']_|_['SCH 10159' 'SCH-10159' 'Trichloroethyl phosphate sodium'
 'Triclofos monosodium salt' 'Triclofos sodium' 'Tricloryl']_|_nan_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201014,"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]_|_VJZLQIPZNBPASX-OJJGEMKLSA-L_|_Small molecule_|_False_|_PREDNISOLONE SODIUM PHOSPHATE_|_1973.0_|_4.0_|_CHEMBL1201231_|_False_|_True_|_['Codelsol' 'Cortisate' 'Hydeltrasol' 'Inflamase' 'Inflamase forte'
 'Inflamase mild' 'Metreton' 'Orapred' 'Orapred odt' 'Pediapred' 'Predair'
 'Predair forte' 'Prednisolone sodium phosphate' 'Predsol' 'Predsol-n']_|_['NSC-759187' 'Prednisolone 21-disodium phosphate'
 'Prednisolone sodium phosphate' 'Prednisoloni natrii phosphas']_|_[('DailyMed', array(['prednisolone%20sodium%20phosphate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301', 'MONDO_0002280', 'EFO_1001231', 'EFO_0007126',
       'MP_0001845', 'EFO_0003929', 'MONDO_0004979', 'EFO_0000768',
       'EFO_1001226', 'EFO_0000341', 'HP_0000559', 'EFO_0009448',
       'EFO_0000565', 'EFO_0005854', 'EFO_0007141', 'EFO_0004255',
       'EFO_0007415'], dtype=object), 'count': 17}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 14 approved and 3 investigational indications."
CHEMBL1201063,"CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1.Cl_|_XWIHRGFIPXWGEF-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROPAFENONE HYDROCHLORIDE_|_1989.0_|_4.0_|_CHEMBL631_|_False_|_True_|_['Arythmol' 'Propafenone hydrochloride' 'Rythmol' 'Rythmol sr' 'Rytmonorm']_|_['NSC-758640' 'Propafenone hcl' 'Propafenone hydrochloride']_|_[('DailyMed', array(['propafenone%20hydrochloride'], dtype=object)), ('PubChem', array(['26747617', '26747618', '50106779', '50106780', '50106781',
       '56422489', '855997'], dtype=object)), ('chEBI', array(['8466'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004308', 'EFO_0000275', 'EFO_0003144'], dtype=object), 'count': 3}_|_[ENSG00000043591,ENSG00000169252,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for ventricular arrhythmia and atrial fibrillation and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1398126,"Cl.N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.O.O_|_LTKVFMLMEYCWMK-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMILORIDE HYDROCHLORIDE_|_1981.0_|_4.0_|_CHEMBL945_|_False_|_True_|_['Amilamont' 'Amiloride hydrochloride' 'Amilospare 5' 'Amoride' 'Berkamil'
 'Midamor']_|_['Amiloride hcl' 'Amiloride hydrochloride'
 'Amiloride hydrochloride anhydrous' 'Amiloride hydrochloride dehydrate'
 'Amiloride hydrochloride dihydrate' 'Amiloridi hydrochloridum'
 'Amipramidine' 'Anhydrous amiloride hydrochloride' 'NSC-755847']_|_[('DailyMed', array(['amiloride%20hydrochloride'], dtype=object)), ('PubChem', array(['11113002'], dtype=object)), ('chEBI', array(['2640'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004269', 'MONDO_0009061', 'EFO_0000537', 'EFO_0000373'],
      dtype=object), 'count': 4}_|_[ENSG00000111319,ENSG00000168447,ENSG00000166828]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1684950,"CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1_|_IQIKXZMPPBEWAD-CQSZACIVSA-N_|_Small molecule_|_False_|_SUVECALTAMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CX-8998' 'Cx-8998' 'JZP-385' 'JZP385' 'MK-8998' 'Mk-8998'
 'Suvecaltamide']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SUVECALTAMIDE/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802242']_|_{'rows': array(['MONDO_0005090', 'EFO_0003108', 'EFO_0000474', 'EFO_0003108'],
      dtype=object), 'count': 4}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1743057,"nan_|_nan_|_Protein_|_False_|_PEGSUNERCEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pegsunercept' 'STNF-RI']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000232810]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1755,"Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2_|_IKENVDNFQMCRTR-UHFFFAOYSA-N_|_Small molecule_|_False_|_CONIVAPTAN_|_2005.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Conivaptan']_|_[('Wikipedia', array(['Conivaptan'], dtype=object)), ('drugbank', array(['DB00872'], dtype=object)), ('chEBI', array(['681850'], dtype=object))]_|_['CHEMBL1201108']_|_{'rows': array(['HP_0002902', 'MONDO_0043510', 'HP_0002902', 'EFO_0003144',
       'EFO_0001422', 'EFO_0001421', 'EFO_0003144', 'EFO_0000319'],
      dtype=object), 'count': 8}_|_[ENSG00000126895,ENSG00000166148]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for heart failure and cardiovascular disease and has 5 investigational indications."
CHEMBL2108628,"nan_|_nan_|_Small molecule_|_False_|_PACLITAXEL POLIGLUMEX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CT-2103' 'L-polyglutamic paclitaxel' 'Opaxio' 'PG-TXL'
 'Paclitaxel conjugate with poly-l-glutamic acid' 'Paclitaxel poliglumex']_|_nan_|_nan_|_{'rows': array(['EFO_0006772', 'MONDO_0008170', 'MONDO_0002158', 'MONDO_0008315',
       'EFO_0000466', 'MONDO_0005575', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0003060', 'MONDO_0002087', 'EFO_0003833', 'EFO_0000673',
       'MONDO_0008903', 'EFO_0000707'], dtype=object), 'count': 14}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."
CHEMBL2109298,"nan_|_nan_|_Antibody_|_False_|_MEDI-3617_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MEDI-3617' 'MEDI3617' 'Medi 3617' 'Medi-3617']_|_nan_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000091879]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2109653,"nan_|_nan_|_Antibody_|_False_|_BERMEKIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Xilonix']_|_['Bermekimab' 'CA-18C3' 'CV-18C3' 'MaBp1' 'RA-18C3' 'T2-18C3']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BERMEKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_1000710', 'EFO_0000676',
       'EFO_0003894', 'EFO_0000717', 'EFO_0000274', 'MP_0001845',
       'MONDO_0005148', 'EFO_0000365', 'HP_0000999'], dtype=object), 'count': 11}_|_[ENSG00000115008]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL3139186,"Cc1nc(N2CCN(C)CC2)c2nc(-c3ccccc3Cl)n(C3CCOCC3)c2n1_|_UCMNDPDJRSEZPL-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY2828360_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2828360' 'LY2828360' 'Ly2828360']_|_nan_|_['CHEMBL3092901']_|_{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}_|_[ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3234237,"Fc1ccc(CN2CCC(Nc3ccc(C(F)(F)F)nn3)CC2)cc1F_|_UVUYWJWYRLJHEN-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-37822681_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JNJ-37822681' 'Jnj-37822681']_|_[('drugbank', array(['DB12579'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL34124,"COc1ccc2c(c1OCc1ccccc1)C[C@@H](C(=O)O)N(C(=O)C(c1ccccc1)c1ccccc1)C2_|_GHBCIXGRCZIPNQ-MHZLTWQESA-N_|_Small molecule_|_False_|_OLODANRIGAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EMA-401' 'EMA401' 'Ema401' 'Olodanrigan' 'PD-126055']_|_nan_|_['CHEMBL157510']_|_{'rows': array(['EFO_1000783', 'MONDO_0041052'], dtype=object), 'count': 2}_|_[ENSG00000180772]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3544994,"nan_|_nan_|_Oligonucleotide_|_False_|_VOLANESORSEN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['ISIS 304801' 'ISIS 304801 FREE ACID' 'ISIS-304801' 'Volanesorsen'
 'free acid']_|_nan_|_nan_|_{'rows': array(['EFO_0004211', 'MONDO_0020088', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000110245]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL3586404,"CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1_|_UFKLYTOEMRFKAD-SHTZXODSSA-N_|_Small molecule_|_False_|_ONATASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATG-008' 'ATG008' 'CC-223' 'CC223' 'Cc-223' 'Onatasertib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ONATASERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12570'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001901', 'EFO_0001378', 'EFO_0003060', 'EFO_0000519',
       'EFO_0000182', 'EFO_0000616', 'EFO_0000403', 'MONDO_0007254'],
      dtype=object), 'count': 8}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL3916929,"CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2_|_MBKYLPOPYYLTNW-ZDUSSCGKSA-N_|_Small molecule_|_False_|_BALCINRENONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-9977' 'AZD9977' 'Azd 9977' 'Azd-9977' 'Azd9977' 'Balcinrenone']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('drugbank', array(['DB15418'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0003086', 'EFO_0003144'], dtype=object), 'count': 3}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4066936,"COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N_|_QZFHIXARHDBPBY-UHFFFAOYSA-N_|_Small molecule_|_True_|_VERICIGUAT_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Verquvo']_|_['BAY 1021189' 'BAY-1021189' 'MK-1242' 'Vericiguat']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VERICIGUAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15456'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0000195', 'EFO_0003144', 'EFO_0001645'],
      dtype=object), 'count': 4}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cardiovascular disease and heart failure and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL419792,"CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1_|_RKZSNTNMEFVBDT-MRVPVSSYSA-N_|_Small molecule_|_False_|_SUMANIROLE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PNU-95666E' 'Pnu-95666' 'Sumanirole']_|_[('Wikipedia', array(['Sumanirole'], dtype=object)), ('drugbank', array(['DB06477'], dtype=object))]_|_['CHEMBL5071215']_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297865,"C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)c(F)c3)nc3[nH]ccc23)c1_|_UOFYSRZSLXWIQB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABIVERTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A610' 'AC-0010' 'AC0010' 'ACEA100610' 'Abivertinib' 'Ac0010' 'Avitinib'
 'EX-ACEA0010']_|_[('drugbank', array(['DB15327'], dtype=object))]_|_['CHEMBL4297866' 'CHEMBL5307684']_|_{'rows': array(['EFO_0000096', 'MONDO_0100096', 'EFO_0003060', 'MONDO_0100096',
       'EFO_0003060', 'MONDO_0008315'], dtype=object), 'count': 6}_|_[ENSG00000010671,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4298127,"nan_|_nan_|_Unknown_|_False_|_VRC-01LS_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['VRC-01LS' 'VRC01LS' 'Vrc-01ls' 'Vrc-hivmab080-00-ab' 'Vrc01ls']_|_nan_|_nan_|_{'rows': array(['EFO_0000180', 'EFO_0000764'], dtype=object), 'count': 2}_|_[ENSG00000010610]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4298134,"nan_|_nan_|_Antibody_|_False_|_OBEXELIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Obexelimab' 'XMAB-5871' 'XMAB5871' 'Xmab5871']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_1001264', 'MONDO_0017287'], dtype=object), 'count': 3}_|_[ENSG00000072694,ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL452231,"COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O_|_NRUKOCRGYNPUPR-QBPJDGROSA-N_|_Small molecule_|_True_|_TENIPOSIDE_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Vumon']_|_['NSC-122819' 'Teniposide' 'VM-26' 'VM26']_|_[('drugbank', array(['DB00444'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000220', 'EFO_0000574', 'EFO_0000565'],
      dtype=object), 'count': 4}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL5316169,O=C(N[C@@H](Cc1ccc(OCc2ccc3ccc(F)cc3n2)cc1)C(=O)O)c1ccc2ccccc2n1_|_XBKBJNOSNDZQGN-MHZLTWQESA-N_|_Small molecule_|_False_|_CR-3465 FREE ACID_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL5314389']_|_nan_|_[ENSG00000173198]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL715,"Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1_|_KVWDHTXUZHCGIO-UHFFFAOYSA-N_|_Small molecule_|_True_|_OLANZAPINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Arkolamyl' 'Olanzapine' 'Olanzapine mylan' 'Zalasta' 'Zyprexa'
 'Zyprexa zydis']_|_['LY-170053' 'LY170053' 'Olansek' 'Olanzapine' 'Olanzapine apotex'
 'Olanzapine cipla' 'Olanzapine glenmark' 'Olanzapine mylan'
 'Olanzapine teva' 'Olazax' 'Olazax disperzi' 'Zyprexa velotab']_|_[('DailyMed', array(['olanzapine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-mylan'],
      dtype=object)), ('PubChem', array(['144205109', '170465009', '174006883', '26719852', '26750094',
       '29215187', '49666419'], dtype=object)), ('Wikipedia', array(['Olanzapine'], dtype=object)), ('drugbank', array(['DB00334'], dtype=object)), ('chEBI', array(['7735'], dtype=object))]_|_['CHEMBL3989694']_|_{'rows': array(['Orphanet_79292', 'EFO_0005088', 'HP_0012076', 'HP_0001249',
       'MONDO_0002009', 'EFO_0004699', 'EFO_0000616', 'MONDO_0002009',
       'EFO_0010702', 'MONDO_0005351', 'HP_0000726', 'HP_0002039',
       'EFO_0009963', 'MONDO_0007079', 'MONDO_0002009', 'EFO_0005407',
       'MONDO_0044881', 'HP_0002013', 'EFO_0004888', 'EFO_0003758',
       'EFO_0005230', 'EFO_0004247', 'MONDO_0004985', 'HP_0001824',
       'HP_0002018', 'EFO_0006911', 'MONDO_0021148', 'EFO_0004566',
       'MONDO_0002050', 'EFO_0005411', 'HP_0000713', 'EFO_0009854',
       'EFO_0005203', 'EFO_1000904', 'EFO_0003852', 'EFO_0009267',
       'HP_0002017', 'MONDO_0004976', 'MONDO_0005090', 'MONDO_0005090',
       'MONDO_0007739'], dtype=object), 'count': 41}_|_[ENSG00000102468,ENSG00000147246,ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL90,"NCCc1c[nH]cn1_|_NTYJJOPFIAHURM-UHFFFAOYSA-N_|_Small molecule_|_True_|_HISTAMINE_|_1939.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.beta.-aminoethylglyoxaline' 'Ergamine' 'Ergotidine' 'Histamine'
 'NSC-33792']_|_[('PubChem', array(['104171171', '11111275', '124880328', '144203717', '170465001',
       '26753351', '26753352', '8139979', '90341171'], dtype=object)), ('Wikipedia', array(['Histamine'], dtype=object)), ('drugbank', array(['DB05381'], dtype=object)), ('chEBI', array(['18295'], dtype=object))]_|_['CHEMBL1533310' 'CHEMBL544208' 'CHEMBL3989520' 'CHEMBL535166']_|_{'rows': array(['MONDO_0005271', 'MONDO_0004979', 'EFO_0000678', 'MONDO_0002367',
       'MP_0001845', 'EFO_0005854', 'EFO_0000389', 'EFO_0000565',
       'EFO_0000222', 'EFO_0004616', 'EFO_0000616', 'EFO_0005952',
       'EFO_0003956', 'MONDO_0005301'], dtype=object), 'count': 14}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and is indicated for acute myeloid leukemia and neoplasm and has 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1042,"C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]12_|_QYSXJUFSXHHAJI-YRZJJWOYSA-N_|_Small molecule_|_False_|_CHOLECALCIFEROL_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Accrete d3' 'Aciferol d3' 'Adcal-d3' 'Aviticol' 'Bio-vitamin d3'
 'Biolife vitamin d3' 'Cacit d3' 'Calceos' 'Calci-d' 'Calcichew d3'
 'Calcichew d3 fte' 'Calcichew d3 once daily' 'Caldrink d3' 'Calfovit d3'
 'Colecal d3' 'Colecalciferol' 'Colekal-d3' 'Colevit d3' 'Cubicole d3'
 'D-max' 'D-tracetten' 'D-vit3' 'D3 lemon melts' 'D3-50' 'Dekristol'
 'Desunin' 'Dihydrocholesterol' 'Dlux 400' 'E-d3' 'Evacal d3'
 'Fultium daily d3' 'Fultium-d3' 'Hux d3' 'Invita d3' 'Iso d3'
 'Kora liquid' 'Natecal d3' ""Nature's remedy vitamin d3"" 'Neo-d' 'Nphd3'
 'Osteocaps d3' 'Plenachol' 'Pro d3' 'Pro d3 folic' 'Pro d3 forte'
 'Royalvit d3' 'Stexerol-d3' 'Stivit-d3' 'Sunvit-d3 1,000'
 'Sunvit-d3 10,000' 'Sunvit-d3 2,000' 'Sunvit-d3 20,000' 'Sunvit-d3 3,000'
 'Sunvit-d3 400' 'Sunvit-d3 5,000' 'Sunvit-d3 50,000' 'Sunvit-d3 800'
 'Synervit-d3' 'Theical d-3' 'Thorens' 'Vigantol' 'Vigantoletten'
 'Vigantoletten 500' 'Vit d3 streuli' 'Vita-d3' 'Vitamin D 3' 'Zymad']_|_['7-dehydrocholesterol, activated' 'AK R215 COMPONENT COLECALCIFEROL'
 'AK-R215 COMPONENT COLECALCIFEROL' 'Cholecalciferol' 'Colecalciferol'
 'Colecalciferolum' 'Delsterol' 'Delta-d' 'Deparal' 'Ebivit' 'NSC-375571'
 'Provitina' 'Ricketon' 'Vitamin d' 'Vitamin d (cholecalciferol)'
 'Vitamin d assay system suitability' 'Vitamin d-3' 'Vitamin d3'
 'Vitamin d3 (as cholecalciferol)']_|_[('DailyMed', array(['cholecalciferol'], dtype=object)), ('PubChem', array(['144205131', '144209744', '17388665', '26754459', '29215239'],
      dtype=object)), ('Wikipedia', array(['Cholecalciferol'], dtype=object)), ('drugbank', array(['DB00169'], dtype=object)), ('chEBI', array(['28940'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002508', 'EFO_0003929', 'MONDO_0003778', 'EFO_0003917',
       'EFO_0005406', 'MONDO_0008315', 'EFO_0000365', 'MONDO_0005301',
       'MONDO_0004979', 'MONDO_0008170', 'MONDO_0007915', 'EFO_0000765',
       'EFO_0000616', 'EFO_0003047', 'EFO_0000660', 'MONDO_0005271',
       'EFO_0001073', 'MONDO_0007254', 'EFO_0003767', 'EFO_0009516',
       'EFO_0003884', 'EFO_0007141', 'EFO_0002950', 'EFO_0005531',
       'HP_0100543', 'EFO_0000432', 'EFO_0007328', 'MONDO_0002898',
       'EFO_0003854', 'EFO_0000274', 'EFO_0000694', 'EFO_0000676',
       'MONDO_0004647', 'MONDO_0021063', 'EFO_0005681', 'Orphanet_145',
       'EFO_0004272', 'EFO_0002609', 'EFO_0000400', 'MONDO_0004992',
       'EFO_0008572', 'Orphanet_309005', 'EFO_0000222', 'MONDO_0011382',
       'EFO_0000474', 'EFO_0007405', 'EFO_0000764', 'MONDO_0005148',
       'EFO_0000729', 'EFO_1000049', 'MONDO_0002050', 'EFO_0000544',
       'EFO_0000095', 'EFO_0009686', 'EFO_0003762', 'EFO_0003106',
       'MONDO_0005180', 'EFO_0000756', 'HP_0001891', 'EFO_0000180',
       'EFO_1000961', 'MONDO_0002363', 'HP_0000938', 'EFO_0000319',
       'EFO_0004593', 'EFO_0003931', 'HP_0001742', 'MONDO_0005090',
       'MONDO_0002146', 'MONDO_0018975', 'EFO_0000341', 'EFO_0004261',
       'EFO_1001951', 'MONDO_0100096', 'EFO_0000403', 'EFO_0007214',
       'EFO_0003964', 'EFO_1000653', 'EFO_0002546', 'EFO_0000555',
       'EFO_0000519', 'MONDO_0044881', 'EFO_0003944', 'EFO_0003758',
       'MONDO_0018076', 'EFO_0002496', 'EFO_0008506', 'MONDO_0021187',
       'HP_0011950', 'EFO_1001121', 'EFO_0004248', 'EFO_0003095',
       'MONDO_0005147', 'EFO_0000384', 'EFO_0000196', 'EFO_1000657',
       'EFO_0000280', 'EFO_0003882', 'EFO_0005411', 'EFO_0000195',
       'EFO_0003144', 'EFO_0000673', 'Orphanet_43', 'EFO_0003103'],
      dtype=object), 'count': 104}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 101 investigational indications."
CHEMBL1079175,"NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1_|_ULDXWLCXEDXJGE-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-2206_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-2206' 'MK2206' 'Mk-2206']_|_[('PubChem', array(['124897541', '124897542', '144206919', '170466896'], dtype=object)), ('chEBI', array(['67271'], dtype=object))]_|_['CHEMBL4635254']_|_{'rows': array(['MONDO_0008903', 'EFO_0000756', 'EFO_0005221', 'MONDO_0011962',
       'EFO_0001663', 'EFO_0000308', 'EFO_0000403', 'MONDO_0005411',
       'MONDO_0021063', 'MONDO_0004992', 'EFO_0000681', 'MONDO_0007254',
       'EFO_0004252', 'EFO_0000095', 'EFO_0000305', 'EFO_0003060',
       'EFO_0000181', 'EFO_0006861', 'EFO_1000657', 'EFO_0000182',
       'MONDO_0100342', 'EFO_0000616', 'EFO_0003050', 'EFO_0005537'],
      dtype=object), 'count': 24}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 24 investigational indications."
CHEMBL1112,"O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1_|_CEUORZQYGODEFX-UHFFFAOYSA-N_|_Small molecule_|_True_|_ARIPIPRAZOLE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Abilify' 'Abilify maintena' 'Abilify maintena kit' 'Abilify mycite kit'
 'Aripiprazole'
 'Aripiprazole mylan pharma (previously aripiprazole pharmathen)']_|_['Abilify mycite' 'Aripiprazole' 'Aripiprex' 'NSC-759266' 'OPC-14597'
 'OPC-31']_|_[('DailyMed', array(['aripiprazole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma'],
      dtype=object)), ('PubChem', array(['144205281', '170465392', '174006897', '26719891', '29215485',
       '49666418'], dtype=object)), ('Wikipedia', array(['Aripiprazole'], dtype=object)), ('drugbank', array(['DB01238'], dtype=object)), ('chEBI', array(['31236'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000726', 'EFO_0004895', 'MONDO_0000594', 'MONDO_0010383',
       'MONDO_0004985', 'EFO_0003756', 'EFO_0004242', 'MONDO_0002009',
       'EFO_0005407', 'EFO_0003757', 'MONDO_0005090', 'HP_0012167',
       'EFO_0009963', 'EFO_0002610', 'EFO_0003758', 'MONDO_0004975',
       'EFO_0005230', 'EFO_0004701', 'MONDO_0002050', 'MONDO_0007079',
       'EFO_0007453', 'EFO_0003888', 'EFO_0005411', 'MONDO_0002009',
       'MONDO_0005351', 'EFO_0003015', 'EFO_0001358', 'HP_0000713'],
      dtype=object), 'count': 28}_|_[ENSG00000149295,ENSG00000102468,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 11 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1166,"CC1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1_|_KXNPVXPOPUZYGB-IOVMHBDKSA-N_|_Small molecule_|_False_|_ARGATROBAN_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Acova' 'Argatroban' 'Argatroban in dextrose'
 'Argatroban in sodium chloride']_|_['Argatroban' 'Argatroban anhydrous' 'Argatroban hydrate'
 'Argatroban monohydrate' 'Argipidine' 'DK-7419' 'GN-1600' 'GN1600'
 'MCI-9038' 'MD-805']_|_[('DailyMed', array(['argatroban'], dtype=object)), ('Wikipedia', array(['Argatroban'], dtype=object)), ('drugbank', array(['DB00278'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004419', 'HP_0002140', 'HP_0001873', 'EFO_1000985',
       'MONDO_0002243', 'MONDO_0000831'], dtype=object), 'count': 6}_|_[ENSG00000180210]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 3 investigational indications."
CHEMBL1200802,"C=CCC1(C(C)CC)C(=O)NC(=O)NC1=O_|_BJVVMKUXKQHWJK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TALBUTAL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Lotusate']_|_['Talbutal']_|_[('PubChem', array(['170465408'], dtype=object)), ('Wikipedia', array(['Talbutal'], dtype=object)), ('drugbank', array(['DB00306'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201,"CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1_|_GFBKORZTTCHDGY-UWVJOHFNSA-N_|_Small molecule_|_True_|_THIOTHIXENE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Navane' 'Orbinamon' 'Thiothixene']_|_['(z)-thiothixene' 'CP-12252-1' 'Cis-thiothixene' 'NSC-108165' 'P-4657 B'
 'P-4657B' 'Thiothixene' 'Thiothixene cis-isomer' 'Tiotixene']_|_[('DailyMed', array(['thiothixene'], dtype=object)), ('PubChem', array(['11532885', '50111253'], dtype=object)), ('Wikipedia', array(['Thiothixene'], dtype=object)), ('drugbank', array(['DB01623'], dtype=object))]_|_['CHEMBL1200902' 'CHEMBL3989824']_|_{'rows': array(['EFO_0005407', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for psychosis and schizophrenia. This drug has a black box warning from the FDA."
CHEMBL1201184,"CC(=O)O.CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O_|_DEXPIBGCLCPUHE-UISHROKMSA-N_|_Protein_|_False_|_LANREOTIDE ACETATE_|_2007.0_|_4.0_|_CHEMBL1201185_|_False_|_True_|_['Somatuline depot']_|_['BIM-23014C' 'Lanreotide acetate' 'Somatuline' 'Somatuline lp']_|_[('DailyMed', array(['lanreotide%20acetate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001485', 'EFO_1000852'], dtype=object), 'count': 2}_|_[ENSG00000180616,ENSG00000162009]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for acromegaly and carcinoid syndrome."
CHEMBL1201439,"nan_|_nan_|_Antibody_|_True_|_BASILIXIMAB_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Simulect']_|_['Basiliximab' 'CHI-621' 'SDZ-CHI-621']_|_[('DailyMed', array(['basiliximab'], dtype=object)), ('DrugCentral', array(['4940'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/simulect'],
      dtype=object)), ('Wikipedia', array(['Basiliximab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'MONDO_0013730', 'EFO_0000183', 'EFO_1000794',
       'EFO_0004236', 'EFO_0000616', 'EFO_0003884', 'MONDO_0018923',
       'MONDO_0019472', 'EFO_0010134', 'EFO_1001226', 'EFO_1001231',
       'EFO_0002687', 'EFO_0000544', 'EFO_0000464', 'EFO_0004599',
       'EFO_0000729', 'EFO_0001378', 'EFO_0000540', 'MONDO_0005147',
       'MONDO_0004976', 'EFO_0003086', 'EFO_0000519'], dtype=object), 'count': 23}_|_[ENSG00000134460,ENSG00000147168,ENSG00000100385]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for kidney transplant and immune system disease and has 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1254682,"C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13_|_OZYUPQUCAUTOBP-QXAKKESOSA-N_|_Small molecule_|_False_|_LEVALLORPHAN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Levallorphan' 'Lorfan' 'Naloxiphan']_|_[('PubChem', array(['144205558', '170465778'], dtype=object)), ('Wikipedia', array(['Levallorphan'], dtype=object)), ('drugbank', array(['DB00504'], dtype=object)), ('chEBI', array(['6431'], dtype=object))]_|_['CHEMBL2062276']_|_nan_|_[ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1533,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3C(=C)C[C@@]21CC_|_RPLCPCMSCLEKRS-BPIQYHPVSA-N_|_Small molecule_|_False_|_DESOGESTREL_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Aizea' 'Cerazette' 'Cerelle' 'Desomono' 'Feanolla' 'Nacrez' 'Zelleta']_|_['Desogestrel' 'Mircette' 'ORG 2969' 'ORG-2969']_|_[('DailyMed', array(['desogestrel'], dtype=object)), ('PubChem', array(['144206006', '50112703'], dtype=object)), ('Wikipedia', array(['Desogestrel'], dtype=object)), ('drugbank', array(['DB00304'], dtype=object)), ('chEBI', array(['4453'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000660', 'EFO_0010269', 'Orphanet_661', 'MP_0001914'],
      dtype=object), 'count': 4}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 investigational indications."
CHEMBL1614713,"c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1_|_XDJCLCLBSGGNKS-UHFFFAOYSA-N_|_Small molecule_|_False_|_CC-401_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CC-401' 'Cc-401']_|_[('drugbank', array(['DB12432'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004643'], dtype=object), 'count': 1}_|_[ENSG00000107643,ENSG00000050748,ENSG00000109339]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1614766,"O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F_|_FIMYFEGKMOCQKT-UHFFFAOYSA-N_|_Small molecule_|_False_|_RO-4987655_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CH-4987655' 'RO4987655' 'Ro 4987655' 'Ro-4987655']_|_[('drugbank', array(['DB12933'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL17157,"CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1_|_GUGOEEXESWIERI-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERFENADINE_|_1985.0_|_4.0_|_nan_|_True_|_True_|_['Antihistamine' 'Histafen' 'Histafen 120' 'Seldane' 'Terfenor'
 'Terfenor fte' 'Terfex' 'Terfinax 120' 'Terfinax 60' 'Triludan'
 'Triludan fte']_|_['NSC-665802' 'NSC-758627' 'RMI 9918' 'RMI-9918' 'Terfenadine']_|_[('PubChem', array(['104171258', '144203846', '144203847', '170465598', '26752308',
       '50105228', '56422373', '85231279', '855647', '90341346'],
      dtype=object)), ('Wikipedia', array(['Terfenadine'], dtype=object)), ('drugbank', array(['DB00342'], dtype=object)), ('chEBI', array(['9453'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007425', 'MONDO_0005271', 'EFO_0003869', 'MONDO_0004979',
       'EFO_0007304', 'EFO_0004197', 'EFO_0000403', 'EFO_0003840',
       'MONDO_0005301'], dtype=object), 'count': 9}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for allergic disease and has 8 investigational indications. It was withdrawn in at least one region."
CHEMBL1743024,"nan_|_nan_|_Antibody_|_False_|_GANITUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 479' 'AMG-479' 'AMG479' 'Ganitumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0003060',
       'EFO_0000174', 'EFO_0003893', 'EFO_0002918', 'EFO_0000691',
       'EFO_0002618', 'EFO_0003968', 'EFO_0000616', 'EFO_0005537'],
      dtype=object), 'count': 12}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL1743030,"nan_|_nan_|_Antibody_|_False_|_ICRUCUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IMC 18F1' 'IMC-18F1' 'IMC18F1' 'Icrucumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0021063', 'EFO_0000616', 'EFO_1000657'],
      dtype=object), 'count': 4}_|_[ENSG00000102755]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1743038,"nan_|_nan_|_Antibody_|_False_|_LUCATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CHIR-12.12' 'HCD-122' 'HCD122' 'Lucatumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0001378', 'MONDO_0018906', 'EFO_0000183',
       'EFO_0000095'], dtype=object), 'count': 5}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1752,"Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O_|_KSCFJBIXMNOVSH-UHFFFAOYSA-N_|_Small molecule_|_False_|_DYPHYLLINE_|_1951.0_|_4.0_|_nan_|_False_|_True_|_['Dilor' 'Dilor-400' 'Lufyllin' 'Neothylline']_|_['Diprophylline' 'Dyphilline' 'Dyphylline' 'Glyphylline' 'NSC-14305']_|_[('PubChem', array(['144203995', '170465316', '174006928', '56422180', '855557'],
      dtype=object)), ('Wikipedia', array(['Dyphylline'], dtype=object)), ('drugbank', array(['DB00651'], dtype=object)), ('chEBI', array(['4728'], dtype=object))]_|_nan_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000172572]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for airway obstruction."
CHEMBL2106370,"COc1ccnc(C[S+]([O-])c2nc3cc(-n4cccc4)ccc3[nH]2)c1C_|_HRRXCXABAPSOCP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ILAPRAZOLE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ilaprazole' 'Noltec']_|_[('drugbank', array(['DB11964'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003948', 'MP_0001914', 'HP_0004398', 'EFO_0004607'],
      dtype=object), 'count': 4}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2107823,"Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1_|_SQSZANZGUXWJEA-UHFFFAOYSA-N_|_Small molecule_|_False_|_GANDOTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gandotinib' 'LY-2784544' 'LY2784544' 'Ly-2784544' 'Ly2784544']_|_[('drugbank', array(['DB13040'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2146140,"COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.O.O.O.O.[Sr+2]_|_NCGHIAKEJNQSMS-QLGOZJDFSA-N_|_Small molecule_|_False_|_ESOMEPRAZOLE STRONTIUM_|_2013.0_|_4.0_|_CHEMBL1201320_|_False_|_True_|_['Esomeprazole strontium']_|_['Esomeprazole strontium' 'FM-0F67' 'FM0F67' 'HIP-1601' 'Hip1601'
 'S-omeprazole strontium hydrate']_|_[('DailyMed', array(['esomeprazole%20strontium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009454', 'EFO_0004607', 'EFO_0003948', 'EFO_0007549'],
      dtype=object), 'count': 4}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved indications."
CHEMBL2216859,"CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1_|_MCIDWGZGWVSZMK-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEMIRALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-2269557' 'GSK-2269557 FREE BASE' 'GSK-2269557A' 'GSK2269557A'
 'Nemiralisib']_|_nan_|_['CHEMBL5314409' 'CHEMBL4297193']_|_{'rows': array(['EFO_0000341', 'EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545141,"nan_|_nan_|_Small molecule_|_False_|_RP-6530_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Rp-6530']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0002913'], dtype=object), 'count': 2}_|_[ENSG00000105851,ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3545354,"nan_|_nan_|_Small molecule_|_False_|_CAFUSERTIB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Cafusertib']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL4297520,"CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1_|_OKFDRAHPFKMAJH-UHFFFAOYSA-N_|_Small molecule_|_False_|_OGLEMILAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GRC 3845' 'Oglemilast']_|_[('drugbank', array(['DB12375'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297651,CO[C@@H]1[C@H](OC(=O)N2CC(CCN3CCOCC3)C2)CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C_|_QJWJPMLDQYEPPW-AUKZVGPFSA-N_|_Small molecule_|_False_|_ACLIMOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aclimostat' 'ZGN-1061' 'Zgn-1061']_|_nan_|_nan_|_nan_|_[ENSG00000111142]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4298101,"nan_|_nan_|_Antibody drug conjugate_|_False_|_LADIRATUZUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ladiratuzumab vedotin' 'SGN-LIV1A' 'Sgn-liv1a']_|_nan_|_nan_|_{'rows': array(['EFO_0003968', 'EFO_0003869', 'EFO_0005537', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000141424,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4298189,"nan_|_nan_|_Gene_|_False_|_ELADOCAGENE EXUPARVOVEC_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Upstaza']_|_['AGIL-AADC' 'Eladocagene exuparvovec']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELADOCAGENE%20EXUPARVOVEC/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004736'], dtype=object), 'count': 1}_|_[ENSG00000132437]_|_Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for inborn disorder of amino acid metabolism."
CHEMBL4594460,"nan_|_nan_|_Antibody_|_False_|_TEGOPRUBART_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AT-1501' 'At-1501' 'Tegoprubart']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004976', 'EFO_0004194', 'EFO_0005809', 'MONDO_0005147'],
      dtype=object), 'count': 4}_|_[ENSG00000102245]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4802163,"CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1_|_VQIIUJSNIKEMCK-MHZLTWQESA-N_|_Small molecule_|_False_|_NEZULCITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nezulcitinib' 'TD-0903' 'THRX-136377' 'Td-0903']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NEZULCITINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0004610'], dtype=object), 'count': 2}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5315324,"Cc1ccsc1C(=O)Nc1cc(CN2CCN(C(=O)CO)CC2)ccc1/C=C/c1n[nH]c2ccccc12_|_HHCSNTXVZDWIGT-CMDGGOBGSA-N_|_Small molecule_|_False_|_KW-2450 FREE BASE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL5283463']_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000171105,ENSG00000140443]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1072,"CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1_|_MAEIEVLCKWDQJH-UHFFFAOYSA-N_|_Small molecule_|_True_|_BUMETANIDE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Betinex' 'Bumetanide' 'Bumex' 'Burinex' 'Lixil']_|_['Bumetanide' 'RO 10-6338' 'RO-10-6338' 'RO-106338' 'S-95008.' 'S95008.']_|_[('DailyMed', array(['bumetanide'], dtype=object)), ('PubChem', array(['11110843', '11110844', '144203639', '170464735', '26746951',
       '26751481', '50103991', '56424138', '855675'], dtype=object)), ('Wikipedia', array(['Bumetanide'], dtype=object)), ('drugbank', array(['DB00887'], dtype=object)), ('chEBI', array(['3213'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'EFO_0003086', 'MONDO_0005148', 'EFO_0003758',
       'EFO_0003756', 'EFO_0000373', 'EFO_0004255', 'EFO_0003144',
       'MONDO_0008223', 'EFO_0000319', 'EFO_0000182', 'EFO_0003884'],
      dtype=object), 'count': 12}_|_[ENSG00000074803]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL109480,"C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O_|_AYUNIORJHRXIBJ-TXHRRWQRSA-N_|_Small molecule_|_False_|_TANESPIMYCIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['17-AAG' '17aag' 'BMS-722782' 'CNF-1010' 'CNF1010' 'KOS-953' 'NSC-330507'
 'Tanespimycin']_|_[('PubChem', array(['144205607', '26756800', '26756801', '574817'], dtype=object)), ('Wikipedia', array(['Tanespimycin'], dtype=object)), ('drugbank', array(['DB05134'], dtype=object)), ('chEBI', array(['64153'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565', 'MONDO_0001187', 'MONDO_0002367', 'EFO_0002428',
       'MONDO_0008903', 'EFO_1000785', 'EFO_0000333', 'EFO_0000616',
       'EFO_0009441', 'EFO_0000403', 'EFO_0001378', 'EFO_0000183',
       'MONDO_0015277', 'EFO_0000637', 'MONDO_0018906', 'MONDO_0001056',
       'MONDO_0019471', 'MONDO_0000873', 'EFO_1001365', 'EFO_0000255',
       'EFO_0000191', 'EFO_0000309', 'EFO_0000574', 'EFO_0006859',
       'EFO_0000641', 'EFO_0000673', 'MONDO_0004992', 'EFO_1001951',
       'EFO_0000756', 'EFO_0000095', 'EFO_0003032', 'MONDO_0001023',
       'EFO_1001051', 'EFO_0000389', 'MONDO_0007254', 'MONDO_0008315',
       'MONDO_0008170', 'EFO_1001469'], dtype=object), 'count': 38}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 38 investigational indications."
CHEMBL1190199,"CN(C(=O)C(c1ccccc1)c1ccccc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1_|_JHLHNYVMZCADTC-LOSJGSFVSA-N_|_Small molecule_|_False_|_ASIMADOLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Asimadoline' 'EMD-61753']_|_[('Wikipedia', array(['Asimadoline'], dtype=object)), ('drugbank', array(['DB05104'], dtype=object))]_|_['CHEMBL540342']_|_{'rows': array(['EFO_0000555', 'MONDO_0004567'], dtype=object), 'count': 2}_|_[ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1201533,"nan_|_nan_|_Protein_|_False_|_THYROTROPIN ALFA_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Thyrogen']_|_['GX-30' 'Thyrotropin alfa' 'Thyrotropin alpha']_|_[('DailyMed', array(['thyrotropin%20alfa'], dtype=object)), ('DrugCentral', array(['4930'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000501', 'MONDO_0002108', 'EFO_1001062', 'EFO_0002892',
       'EFO_0003841', 'EFO_0000641', 'EFO_0004237'], dtype=object), 'count': 7}_|_[ENSG00000165409]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 3 investigational indications."
CHEMBL1201584,"nan_|_nan_|_Antibody_|_False_|_ABCIXIMAB_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Reopro']_|_['Abciximab' 'Abciximab (genetical recombination)' 'C7E3']_|_[('DrugCentral', array(['4950'], dtype=object)), ('Wikipedia', array(['Abciximab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008583', 'EFO_0003913', 'MONDO_0005299', 'EFO_0000712',
       'EFO_0002615', 'HP_0004419', 'EFO_0008585', 'EFO_0000612',
       'EFO_1000985'], dtype=object), 'count': 9}_|_[ENSG00000259207,ENSG00000005961,ENSG00000138448]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for recurrent thrombophlebitis and intermediate coronary syndrome and has 7 investigational indications."
CHEMBL1208646,"Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCC(=O)O_|_HXSKWEQQPCKYIF-UHFFFAOYSA-N_|_Small molecule_|_False_|_THEOPHYLLINE GLYCINATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[]_|_nan_|_['CHEMBL1200578']_|_nan_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1256842,"CN1Cc2c(N)cccc2C(c2ccccc2)C1.O=C(O)/C=C\C(=O)O_|_GEOCVSMCLVIOEV-BTJKTKAUSA-N_|_Small molecule_|_False_|_NOMIFENSINE MALEATE_|_1984.0_|_4.0_|_CHEMBL273575_|_True_|_True_|_[]_|_['HOE 984' 'HOE-984' 'Hostalival' 'NSC-289114'
 'Nomifensine hydrogen maleate' 'Nomifensine maleate' 'Psicronizer']_|_[('PubChem', array(['170466450', '26747597', '26747598', '50106723', '50106724',
       '50106725', '855660', '93576623'], dtype=object))]_|_nan_|_nan_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. It was withdrawn in at least one region."
CHEMBL1742983,nan_|_nan_|_Antibody_|_False_|_ALACIZUMAB PEGOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Alacizumab pegol' 'CDP-791' 'g165 DFM-PEG']_|_nan_|_nan_|_nan_|_[ENSG00000128052]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL190083,"C[C@@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1_|_SYTBZMRGLBWNTM-SNVBAGLBSA-N_|_Small molecule_|_False_|_TARENFLURBIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['E-7869' 'Flurbiprofen, (r)-' 'MPC-7869' 'R-flurbiprofen' 'Tarenflurbil']_|_[('PubChem', array(['11112562', '11114208', '520769', '520770'], dtype=object)), ('drugbank', array(['DB05289'], dtype=object)), ('chEBI', array(['38666'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'HP_0000726', 'MONDO_0004975'], dtype=object), 'count': 3}_|_[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1908394,"C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F_|_ZHJGWYRLJUCMRT-QGZVFWFLSA-N_|_Small molecule_|_False_|_GSK-461364_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GSK-461364A' 'GSK461364' 'Gsk 461364' 'Gsk-461364']_|_nan_|_nan_|_{'rows': array(['EFO_0005952'], dtype=object), 'count': 1}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2107857,"nan_|_nan_|_Protein_|_True_|_METRELEPTIN_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Myalepta']_|_['Leptin (human), n-methionyl-' 'Metreleptin' 'Myalept'
 'N-methionylleptin (human)' 'R-METHULEPTIN']_|_[('DailyMed', array(['metreleptin'], dtype=object)), ('DrugCentral', array(['4826'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'EFO_0003095', 'EFO_0002614', 'EFO_0001421',
       'MONDO_0020088', 'EFO_1000728', 'MONDO_0005147', 'EFO_0002756',
       'EFO_0000195', 'EFO_1001348', 'EFO_0010269', 'EFO_1000727'],
      dtype=object), 'count': 12}_|_[ENSG00000116678]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109151,"nan_|_nan_|_Antibody_|_False_|_LUMILIXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gomiliximab' 'IDEC-152' 'Lumiliximab' 'P5E8 SI-3401 GOMILIXIMAB'
 'Primatized anti-cd23' 'ST-152']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000095', 'EFO_0000565'], dtype=object), 'count': 3}_|_[ENSG00000104921]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2140408,"Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1_|_IVUGFMLRJOCGAS-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMG-900_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-900' 'AMG900' 'Amg 900' 'Amg-900']_|_[('PubChem', array(['137275938'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'MONDO_0004643'], dtype=object), 'count': 2}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL296913,"CCC(=O)[N-]S(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1.[Na+]_|_HQPVVKXJNZEAFW-UHFFFAOYSA-M_|_Small molecule_|_False_|_PARECOXIB SODIUM_|_2002.0_|_4.0_|_CHEMBL1206690_|_False_|_True_|_['Dynastat']_|_['Parecoxib sodium' 'Parecoxib sodium salt' 'SC-69124A']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dynastat'],
      dtype=object)), ('PubChem', array(['144206591'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'MONDO_0005178'], dtype=object), 'count': 2}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for pain and has 1 investigational indication."
CHEMBL3183075,"CNC(=C[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1_|_SGXXNSQHWDMGGP-UHFFFAOYSA-N_|_Small molecule_|_False_|_NIZATIDINE_|_1988.0_|_4.0_|_nan_|_False_|_True_|_['Axid' 'Axid ar' 'Nizatidine' 'Zinga 150' 'Zinga 300']_|_['Acinon' 'LY 139037' 'LY-139037' 'NSC-759289' 'Nizatidine']_|_[('DailyMed', array(['nizatidine'], dtype=object)), ('PubChem', array(['144204242', '144211911', '170464780'], dtype=object)), ('drugbank', array(['DB00585'], dtype=object)), ('chEBI', array(['7601'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000948', 'EFO_0000217', 'HP_0004398', 'EFO_0003948',
       'HP_0100633', 'EFO_0004607'], dtype=object), 'count': 6}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 2 investigational indications."
CHEMBL3301595,"N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21_|_SRPXSILJHWNFMK-MEDUHNTESA-N_|_Small molecule_|_False_|_DASOTRALINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(1r,4s)-trans-norsertraline' 'Dasotraline'
 'Norsertraline, (1r,4s)-trans-' 'SEP-225289']_|_[('drugbank', array(['DB12305'], dtype=object))]_|_['CHEMBL3301596']_|_{'rows': array(['MONDO_0002009', 'EFO_0005203', 'EFO_0003888'], dtype=object), 'count': 3}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL35,"NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl_|_ZZUFCTLCJUWOSV-UHFFFAOYSA-N_|_Small molecule_|_True_|_FUROSEMIDE_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Aluzine 20' 'Aluzine 40' 'Aluzine 500' 'Aquamed' 'Disal' 'Diuresal'
 'Dryptal' 'Froop' 'Frumax' 'Frumil' 'Frusemide' 'Frusetic' 'Frusid'
 'Frusol' 'Furosemide' 'Hydroled' 'Lasix' 'Lasix ret' 'Rusyde'
 'Tenkofruse']_|_['Frusemide' 'Furoscix' 'Furosemide' 'Furosemidum' 'LB-502' 'Logirene'
 'Marsemide' 'Mirfat' 'NSC-269420' 'Oedemex']_|_[('DailyMed', array(['furosemide'], dtype=object)), ('PubChem', array(['11112125', '144203873', '144209411', '144213288', '170464879',
       '17389872', '47193739'], dtype=object)), ('TG-GATEs', array(['78'], dtype=object)), ('Wikipedia', array(['Furosemide'], dtype=object)), ('drugbank', array(['DB00695'], dtype=object)), ('chEBI', array(['47426'], dtype=object))]_|_['CHEMBL1788133']_|_{'rows': array(['EFO_0002617', 'MONDO_0019091', 'MONDO_0005090', 'EFO_0001422',
       'EFO_0000400', 'EFO_0009373', 'EFO_0000319', 'HP_0003124',
       'HP_0011950', 'MONDO_0004992', 'EFO_0000565', 'EFO_0000341',
       'EFO_1000391', 'EFO_0009840', 'EFO_0000373', 'EFO_0003086',
       'EFO_0008583', 'MONDO_0001134', 'EFO_0009662', 'EFO_1001134',
       'EFO_0000668', 'HP_0002094', 'EFO_1002048', 'EFO_0003827',
       'EFO_0003144', 'EFO_0004610', 'EFO_0003917', 'EFO_0001645',
       'EFO_0000222', 'EFO_0003914', 'MONDO_0005148', 'MONDO_0024664',
       'EFO_0000537', 'EFO_0004255', 'EFO_0003818', 'HP_0001919',
       'EFO_0002496', 'EFO_0003884', 'EFO_0004253'], dtype=object), 'count': 39}_|_[ENSG00000074803]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 7 approved and 32 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3544988,"O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O_|_RUEYEZADQJCKGV-UHFFFAOYSA-N_|_Small molecule_|_True_|_DAPRODUSTAT_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Jesduvroq']_|_['Daprodustat' 'GSK-1278863' 'GSK1278863' 'Jesduvroq']_|_[('drugbank', array(['DB11682'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0003875', 'EFO_0000546', 'MONDO_0002280',
       'EFO_0004272'], dtype=object), 'count': 5}_|_[ENSG00000269858,ENSG00000178467,ENSG00000135766,ENSG00000129521]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545386,"nan_|_nan_|_Small molecule_|_False_|_BI113823_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Bi113823']_|_nan_|_nan_|_{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}_|_[ENSG00000100739]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3646118,"O=c1c(-n2ccnn2)c[nH]n1-c1cc(N2CCOCC2)ncn1_|_IJMBOKOTALXLKS-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOLIDUSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 85-3934' 'BAY-85-3934' 'Molidustat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOLIDUSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15642'], dtype=object))]_|_['CHEMBL3931782']_|_{'rows': array(['EFO_0004272', 'EFO_0004272'], dtype=object), 'count': 2}_|_[ENSG00000269858,ENSG00000129521,ENSG00000135766]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication."
CHEMBL3702854,"CC(C)(/C=C(\C#N)C(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3F)c3c(N)ncnc32)C1)N1CCN(C2COC2)CC1_|_LCFFREMLXLZNHE-GBOLQPHISA-N_|_Small molecule_|_False_|_RILZABRUTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PRN1008' 'Prn-1008' 'Prn1008' 'Rilzabrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RILZABRUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_1001264', 'MP_0001845', 'MONDO_0004979',
       'EFO_0005531', 'MONDO_0017287', 'EFO_1000749', 'EFO_0007160',
       'EFO_0005809', 'EFO_0004719'], dtype=object), 'count': 10}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL3991065,"C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F_|_QIVUCLWGARAQIO-OLIXTKCUSA-N_|_Small molecule_|_False_|_ATOGEPANT_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Qulipta']_|_['AGN-241689' 'Atogepant' 'MK-8031']_|_nan_|_['CHEMBL3981883']_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for migraine disorder."
CHEMBL4297646,"Fc1cc(F)c(OCc2ccccc2C2CCNCC2)c(F)c1_|_TZIALEBTHQWNAO-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMPRELOXETINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ampreloxetine' 'TD-9855' 'Td-9855']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMPRELOXETINE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15348'], dtype=object))]_|_['CHEMBL4594277']_|_{'rows': array(['MONDO_0005180', 'EFO_0003888', 'EFO_0005252', 'EFO_1001050',
       'EFO_0005252', 'EFO_0005687'], dtype=object), 'count': 6}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4297838,"nan_|_nan_|_Unknown_|_False_|_TILSOTOLIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IMO-2125' 'Tilsotolimod']_|_nan_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0000616', 'EFO_0000756', 'MONDO_0004992'],
      dtype=object), 'count': 4}_|_[ENSG00000239732]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL450044,"CCOC(=O)OC[C@H]1O[C@@H](Oc2ccccc2Cc2ccc(OC)cc2)[C@H](O)[C@@H](O)[C@@H]1O_|_QLXKHBNJTPICNF-QMCAAQAGSA-N_|_Small molecule_|_False_|_SERGLIFLOZIN ETABONATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW-869682X' 'GW-869683X' 'GW869682X' 'Sergliflozin' 'Sergliflozin a'
 'Sergliflozin etabonate']_|_nan_|_nan_|_nan_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4582651,"CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1_|_GBLBJPZSROAGMF-RWYJCYHVSA-N_|_Small molecule_|_False_|_PRALSETINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Gavreto']_|_['BLU-123244' 'BLU-667' 'BLU123244' 'Blu-667' 'Pralsetinib' 'X-581238'
 'X581238']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PRALSETINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015277', 'EFO_0000616', 'MONDO_0004992', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000165731,ENSG00000108091,ENSG00000170759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved indications."
CHEMBL4651002,"Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12_|_BOOMBLZEOHXPPX-BQYQJAHWSA-N_|_Small molecule_|_False_|_SAFUSIDENIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Safusidenib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_['CHEMBL4650282']_|_{'rows': array(['EFO_0000616', 'EFO_0005543'], dtype=object), 'count': 2}_|_[ENSG00000138413]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL488,"CCC1(c2ccc(N)cc2)CCC(=O)NC1=O_|_ROBVIMPUHSLWNV-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMINOGLUTETHIMIDE_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Cytadren' 'Orimeten']_|_['Aminoglutethimide' 'Cytadren' 'NSC-330915']_|_[('PubChem', array(['144203957', '144213805', '170465259', '174007456', '26747446',
       '459146', '46500462', '50105852', '85230926', '90340970'],
      dtype=object)), ('Wikipedia', array(['Aminoglutethimide'], dtype=object)), ('drugbank', array(['DB00357'], dtype=object)), ('chEBI', array(['2654'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000137869,ENSG00000140459]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for neoplasm and has 2 investigational indications."
CHEMBL1121,"CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O_|_IZTQOLKUZKXIRV-YRVFCXMDSA-N_|_Protein_|_False_|_SINCALIDE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Kinevac']_|_['Cck c-terminal octapeptide' 'Cck-8' 'Cholecystokinin'
 'Cholecystokinin c-terminal octapeptide' 'Pancreozymin' 'SQ 19844'
 'SQ-19844' 'Sincalide']_|_[('DailyMed', array(['sincalide'], dtype=object)), ('PubChem', array(['144206508', '144207030'], dtype=object)), ('Wikipedia', array(['Sincalide'], dtype=object)), ('drugbank', array(['DB09142'], dtype=object))]_|_nan_|_nan_|_[ENSG00000163394]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1976."
CHEMBL1200862,"C[C@](N)(Cc1ccc(O)cc1)C(=O)O_|_NHTGHBARYWONDQ-JTQLQIEISA-N_|_Small molecule_|_False_|_METYROSINE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Demser']_|_['L-588357-0' 'MK-781' 'Metirosine' 'Metyrosine' 'Racemetirosine, (s)-']_|_[('DailyMed', array(['metyrosine'], dtype=object)), ('PubChem', array(['170465112', '29215162', '50106644', '50106645', '50106646',
       '90341393'], dtype=object)), ('Wikipedia', array(['Metirosine'], dtype=object)), ('drugbank', array(['DB00765'], dtype=object)), ('chEBI', array(['6912'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000239', 'EFO_0000537', 'EFO_0005407', 'EFO_0000174'],
      dtype=object), 'count': 4}_|_[ENSG00000180176]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for adrenal gland pheochromocytoma and hypertension and has 2 investigational indications."
CHEMBL1354199,"C[N+]1(C)[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12.[Br-]_|_CXYRUNPLKGGUJF-RAFJPFSSSA-M_|_Small molecule_|_False_|_METHSCOPOLAMINE BROMIDE_|_1953.0_|_4.0_|_CHEMBL376897_|_False_|_True_|_['Methscopolamine bromide' 'Pamine' 'Pamine forte']_|_['(-)-Scopolamine Methyl Bromide' 'Epoxytropine tropate methylbromide'
 'Holopon' 'Hyoscine methobromide' 'Methscopolamine bromide'
 'Methylscopolamine bromide' 'N-methylscopolamine bromide'
 'N-methylscopolamine methylsulfate' 'NSC-120606'
 'Scopolamine methyl bromide' 'Scopolamine methylbromide']_|_[('DailyMed', array(['methscopolamine%20bromide'], dtype=object)), ('PubChem', array(['11532979', '144203588', '170464623'], dtype=object)), ('chEBI', array(['61276'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953."
CHEMBL1739,"COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3.[I-].[I-]_|_DIGFQJFCDPKEPF-OIUSMDOTSA-L_|_Small molecule_|_False_|_METOCURINE IODIDE_|_1982.0_|_4.0_|_CHEMBL1259_|_False_|_True_|_['Metubine iodide']_|_['Dimethyl tubocurarine iodide' 'Dimethylchondrocurarine iodide'
 'Dimethyltubocurarinium iodide' 'Metocurine iodide' 'NSC-36388']_|_[('PubChem', array(['144206308', '170465111'], dtype=object)), ('drugbank', array(['DB00416'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1773683,"CCS(=O)(=O)c1ccc2oc(-c3ccc4ccccc4c3)nc2c1_|_KSGCNXAZROJSNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_EZUTROMID_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMN 195' 'BMN-195' 'BMN195' 'Ezutromid' 'SMT-C1100' 'SMTC-1100'
 'Smt c1100']_|_[('drugbank', array(['DB12888'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}_|_[ENSG00000152818]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1908376,"C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/C=C/C(O)(CC)CC)CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_LVLLALCJVJNGQQ-SEODYNFXSA-N_|_Small molecule_|_False_|_SEOCALCITOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CB-1089' 'Eb-1089' 'Seocalcitol']_|_[('drugbank', array(['DB04258'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182'], dtype=object), 'count': 1}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL19299,"CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1_|_YMBXTVYHTMGZDW-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOXOPROFEN_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Loxoprofen' 'Loxoprofen acid' 'Loxoprofen sodium']_|_[('PubChem', array(['144203729', '170465808', '50106490', '85231106', '90341428'],
      dtype=object)), ('Wikipedia', array(['Loxoprofen'], dtype=object)), ('drugbank', array(['DB09212'], dtype=object)), ('chEBI', array(['76172'], dtype=object))]_|_['CHEMBL66552']_|_{'rows': array(['HP_0002829', 'HP_0003326', 'EFO_0000685', 'EFO_0002970',
       'EFO_0003843', 'HP_0030833', 'HP_0003419'], dtype=object), 'count': 7}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 investigational indications."
CHEMBL2018096,"OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O_|_AHFWIQIYAXSLBA-RQXATKFSSA-N_|_Small molecule_|_False_|_IPRAGLIFLOZIN_|_2014.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ASP-1941' 'Ipragliflozin']_|_[('drugbank', array(['DB11698'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 investigational indications."
CHEMBL2109093,"nan_|_nan_|_Protein_|_False_|_EPOETIN DELTA_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Dynepo']_|_['Epoetin delta' 'GA-EPO' 'HMR-4396' 'HMR4396']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dynepo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 2}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for chronic kidney disease and anemia (phenotype)."
CHEMBL2109406,"nan_|_nan_|_Antibody_|_False_|_PATRITUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 888' 'Patritumab' 'U3-1287']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PATRITUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0003060', 'EFO_0004284', 'EFO_0003968',
       'EFO_0000616', 'EFO_0005537'], dtype=object), 'count': 6}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2178570,"CC(=O)Nc1ccc(O)cc1OC[C@@](C)(O)CNC1CCN(Cc2ccc(Cl)cc2)CC1_|_RKWKLTLIBREDHD-DEOSSOPVSA-N_|_Small molecule_|_False_|_AZD4818_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-4818' 'AZD4818' 'Azd 4818' 'Azd-4818' 'Azd4818']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000163823]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2218896,"CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)C1CCC(=O)CC21_|_GECBBEABIDMGGL-UHFFFAOYSA-N_|_Small molecule_|_False_|_NABILONE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Cesamet']_|_['CPD 109514' 'CPD-109514' 'Nabilone']_|_[('DailyMed', array(['nabilone'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005687', 'EFO_0004320', 'EFO_0005762', 'EFO_0004242',
       'HP_0002018', 'EFO_0007191', 'EFO_1000783', 'HP_0001257',
       'EFO_0001073', 'MONDO_0004992', 'EFO_0004888', 'HP_0002017',
       'MONDO_0005180'], dtype=object), 'count': 13}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 9 investigational indications."
CHEMBL284121,"C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)CC#CC(C)(C)O)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_JKFZMIQMKFWJAY-RQJQXFIZSA-N_|_Small molecule_|_False_|_ILX23-7553_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BXL 353' 'BXL-353' 'ILEX-23-7553' 'ILX-23-7553' 'ILX-237553' 'ILX7553'
 'Ilx 237553' 'Ilx23-7553' 'Ro-23-7553']_|_nan_|_nan_|_nan_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545050,"nan_|_nan_|_Small molecule_|_False_|_BMS-817378_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Bms-817378']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545200,"nan_|_nan_|_Small molecule_|_False_|_S-222611_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['S-222611']_|_nan_|_nan_|_nan_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545259,"nan_|_nan_|_Antibody_|_False_|_VANUCIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['C0u97738ae' 'RG-7221' 'RG7221' 'RO-5520985' 'RO5520985' 'Vanucizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 2}_|_[ENSG00000091879,ENSG00000112715]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3707315,"nan_|_nan_|_Small molecule_|_False_|_D-3263_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['D 3263' 'D-3263' 'D-3263 (FREE BASE)']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000144481]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3936761,"C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1_|_RNOAOAWBMHREKO-QFIPXVFZSA-N_|_Small molecule_|_False_|_ZANUBRUTINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Brukinsa']_|_['BGB-3111' 'Bgb-3111' 'Zanubrutinib']_|_[('DailyMed', array(['zanubrutinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANUBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15035'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015540', 'EFO_0004256', 'EFO_0000096', 'MONDO_0004992',
       'EFO_0003086', 'EFO_0005761', 'EFO_1001469', 'EFO_0009441',
       'EFO_1000630', 'EFO_0000095', 'MONDO_0018906', 'MONDO_0017287',
       'EFO_0000403', 'EFO_1001264', 'EFO_0000616', 'MONDO_0015564',
       'MONDO_0100096', 'EFO_0007160', 'EFO_0000565', 'EFO_0000574'],
      dtype=object), 'count': 20}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 16 investigational indications."
CHEMBL409,"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1_|_LKJPYSCBVHEWIU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BICALUTAMIDE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Bicalutamide' 'Calutide' 'Casodex' 'Cosudex' 'Kalumid']_|_['Bicalutamide' 'Casodex' 'ICI 176,334' 'ICI-176334' 'ICI176,334-1'
 'NSC-759816']_|_[('DailyMed', array(['bicalutamide'], dtype=object)), ('PubChem', array(['26719836'], dtype=object)), ('drugbank', array(['DB01128'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000196', 'MONDO_0002087', 'MONDO_0001187', 'EFO_0000313',
       'EFO_0000673', 'EFO_0003869', 'MONDO_0008315', 'MONDO_0000088',
       'MONDO_0002158', 'EFO_0000694', 'MONDO_0008170', 'EFO_0000305',
       'MONDO_0100096', 'EFO_0001663', 'HP_0000771', 'EFO_0000616',
       'MONDO_0004669', 'MONDO_0007254'], dtype=object), 'count': 18}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for carcinoma and neoplasm and has 16 investigational indications."
CHEMBL4650501,"nan_|_nan_|_Unknown_|_False_|_PF-4136309_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['INCB-8761' 'INCB8761' 'PF-04136309' 'PF-4136309' 'Pf-04136309'
 'Pf-4136309']_|_nan_|_nan_|_{'rows': array(['MONDO_0005184', 'EFO_0004220', 'EFO_0003860', 'EFO_0004616'],
      dtype=object), 'count': 4}_|_[ENSG00000121807]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL480,"Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1_|_MJIHNNLFOKEZEW-UHFFFAOYSA-N_|_Small molecule_|_False_|_LANSOPRAZOLE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Lansoprazole' 'Opiren' 'Prevacid' 'Prevacid 24 hr'
 'Prevacid Delayed Release' 'Prevacid Solutab' 'Prevacid iv' 'Zoton']_|_['A-65006' 'AG-1749' 'Agopton' 'Lansoprazole' 'Lansox' 'Lanzoprazole'
 'Lanzor' 'Limpidex' 'NSC-758638' 'Ogast' 'Ogastoro' 'Prevonco' 'Takepron']_|_[('DailyMed', array(['lansoprazole'], dtype=object)), ('PubChem', array(['11111389', '11111390', '124880589', '124880592', '144203735',
       '144211340', '170464649', '174007196', '26719660', '26747053',
       '50104195', '50104197', '56422192', '57287635', '85231117',
       '855954', '90341606'], dtype=object)), ('Wikipedia', array(['Lansoprazole'], dtype=object)), ('drugbank', array(['DB00448'], dtype=object)), ('chEBI', array(['6375'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0009454', 'MONDO_0011962', 'EFO_0000768',
       'EFO_0000095', 'EFO_1001355', 'EFO_0003843', 'EFO_0000574',
       'EFO_0000616', 'EFO_0003917', 'EFO_0004274', 'EFO_1001095',
       'MONDO_0005178', 'EFO_0007456', 'EFO_0003948', 'MONDO_0005147',
       'EFO_1000657', 'EFO_0004607', 'HP_0004398', 'EFO_1000961',
       'MONDO_0002974', 'MONDO_0009061', 'EFO_0000217', 'EFO_0004232'],
      dtype=object), 'count': 24}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 4 approved and 20 investigational indications."
CHEMBL639,"CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1_|_MBUVEWMHONZEQD-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZELASTINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Azelastine' 'NSC-758971']_|_[('Wikipedia', array(['Azelastine'], dtype=object)), ('drugbank', array(['DB00972'], dtype=object)), ('chEBI', array(['2950'], dtype=object))]_|_['CHEMBL1200809']_|_{'rows': array(['HP_0001742', 'MONDO_0005271', 'EFO_0005854', 'EFO_0005751',
       'EFO_0005854', 'EFO_0009364', 'EFO_0003956', 'HP_0001742',
       'EFO_1001417', 'EFO_1001417', 'EFO_0003956', 'EFO_0007533',
       'EFO_0007141'], dtype=object), 'count': 13}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 4 investigational indications."
CHEMBL717,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C_|_PSGAAPLEWMOORI-PEINSRQWSA-N_|_Small molecule_|_True_|_MEDROXYPROGESTERONE ACETATE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Adgyn medro' 'Amen' 'Climanor' 'Curretab' 'Cycrin' 'Depo-progevera'
 'Depo-provera' 'Depo-provera oncology' 'Depo-subq provera 104' 'Farlutal'
 'Farlutal 100' 'Farlutal 200' 'Farlutal 250' 'Farlutal 500' 'Lunelle'
 'Medroxyprogesterone acetate' 'Provera' 'Sayana press']_|_['Amen' 'Depot-medroxyprogesterone acetate' 'Farlutal inyectable'
 'G03AC06' 'Medroxiprogesterone acetate' 'Medroxyprogesterone'
 'Medroxyprogesterone 17-acetate' 'Medroxyprogesterone Acetate'
 'Medroxyprogesterone acetate' 'Medroxyprogesteroni acetas' 'NSC-21171'
 'NSC-26386' 'NSC-27408' 'Prempro' 'Provera' 'TV-46046']_|_[('DailyMed', array(['medroxyprogesterone%20acetate'], dtype=object)), ('PubChem', array(['144204872', '144207339', '170464622', '17388931', '26751478',
       '56422500', '855664'], dtype=object)), ('Wikipedia', array(['Medroxyprogesterone_acetate'], dtype=object)), ('drugbank', array(['DB00603'], dtype=object)), ('chEBI', array(['6716'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011962', 'EFO_0000536', 'MONDO_0007915', 'EFO_0000198',
       'EFO_0000537', 'EFO_0000545', 'EFO_0000400', 'EFO_0000616',
       'HP_0031217', 'GO_0042697', 'HP_0000132', 'EFO_0001065',
       'EFO_1001375', 'EFO_0000764', 'EFO_0000180', 'HP_0008209',
       'EFO_0003843', 'EFO_0000681', 'EFO_0003882', 'MONDO_0019499',
       'EFO_0002890', 'MP_0001914', 'MONDO_0002367', 'EFO_0000673',
       'MONDO_0000831', 'EFO_0001645', 'HP_0003124', 'EFO_0004230',
       'EFO_0003877', 'EFO_0003777', 'MONDO_0004975', 'EFO_0002950'],
      dtype=object), 'count': 32}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 6 approved and 26 investigational indications. This drug has a black box warning from the FDA."
CHEMBL983,"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]_|_YOEWQQVKRJEPAE-UHFFFAOYSA-L_|_Small molecule_|_True_|_SUCCINYLCHOLINE CHLORIDE_|_1952.0_|_4.0_|_CHEMBL703_|_False_|_True_|_['Anectine' 'Quelicin' 'Quelicin preservative free' 'Scoline'
 'Succinylcholine chloride' 'Sucostrin' 'Suxamethonium Chloride']_|_['Choline chloride succinate (2:1)' 'NSC-49132' 'Succinylcholine chloride'
 'Suxamethone' 'Suxamethonii chloridum' 'Suxamethonium chloride'
 'Suxamethonium chloride dihydrate' 'Suxamethonium chloride hydrate']_|_[('DailyMed', array(['succinylcholine%20chloride'], dtype=object)), ('PubChem', array(['144204820', '170464625', '50106980'], dtype=object)), ('Wikipedia', array(['Suxamethonium_chloride'], dtype=object)), ('chEBI', array(['61219'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1952. This drug has a black box warning from the FDA."
CHEMBL1180725,"CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C_|_VVWYOYDLCMFIEM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPANTHELINE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Propantheline' 'Propantheline cation' 'Propantheline ion']_|_[('PubChem', array(['11111683', '11112101', '90340675'], dtype=object)), ('drugbank', array(['DB00782'], dtype=object)), ('chEBI', array(['8481'], dtype=object))]_|_['CHEMBL1240']_|_{'rows': array(['MONDO_0004247', 'EFO_0010282', 'EFO_1000781'], dtype=object), 'count': 3}_|_[ENSG00000133019,ENSG00000168539,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for peptic ulcer disease and gastrointestinal disease and has 1 investigational indication."
CHEMBL1200686,"CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC_|_KASDHRXLYQOAKZ-XDSKOBMDSA-N_|_Small molecule_|_True_|_PIMECROLIMUS_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Elidel']_|_['(-)-pimecrolimus' 'Pimecrolimus' 'SDZ ASM 981' 'SDZ ASM-981'
 'SDZ-ASM 981' 'SDZ-ASM-981']_|_[('DailyMed', array(['pimecrolimus'], dtype=object)), ('Wikipedia', array(['Pimecrolimus'], dtype=object)), ('drugbank', array(['DB00337'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'MONDO_0009735', 'EFO_0000274', 'EFO_1000726',
       'EFO_1000764', 'HP_0000964', 'MONDO_0002406', 'EFO_1000724',
       'EFO_1001305', 'EFO_0004208', 'EFO_0008517'], dtype=object), 'count': 11}_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for atopic eczema and eczematoid dermatitis and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200953,"CCCC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_FOGXJPFPZOHSQS-AYVLZSQQSA-N_|_Small molecule_|_False_|_HYDROCORTISONE PROBUTATE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Pandel']_|_['Hydrocortisone buteprate' 'Hydrocortisone butyrate propionate'
 'Hydrocortisone probutat' 'Hydrocortisone probutate' 'TS 408' 'TS-408']_|_[('PubChem', array(['144206491'], dtype=object)), ('drugbank', array(['DB14543'], dtype=object)), ('chEBI', array(['31675'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000701'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for skin disease."
CHEMBL1549,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1_|_DLVOSEUFIRPIRM-KAQKJVHQSA-N_|_Small molecule_|_False_|_HYDROCORTISONE CYPIONATE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Cortef']_|_['Hydrocortisone Cypionate' 'Hydrocortisone cipionate'
 'Hydrocortisone cyclopentylpropionate' 'Hydrocortisone cypionate'
 'NSC-10721']_|_[('PubChem', array(['75847'], dtype=object)), ('drugbank', array(['DB14541'], dtype=object)), ('chEBI', array(['5783'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015129'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and has 1 investigational indication."
CHEMBL1587,"CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O_|_CYLWJCABXYDINA-UHFFFAOYSA-N_|_Small molecule_|_False_|_POLYTHIAZIDE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_['Nephril' 'Renese']_|_['NSC-108161' 'P-2525' 'Polythiazide']_|_[('PubChem', array(['144206688', '170465068'], dtype=object)), ('Wikipedia', array(['Polythiazide'], dtype=object)), ('drugbank', array(['DB01324'], dtype=object)), ('chEBI', array(['8327'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and is indicated for cardiovascular disease."
CHEMBL1639,"COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC_|_UXOWGYHJODZGMF-QORCZRPOSA-N_|_Small molecule_|_True_|_ALISKIREN_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Rasilez']_|_['Aliskiren' 'SPP-100' 'SPP100']_|_[('Wikipedia', array(['Aliskiren'], dtype=object)), ('drugbank', array(['DB09026'], dtype=object)), ('chEBI', array(['601027'], dtype=object))]_|_['CHEMBL559358' 'CHEMBL1667' 'CHEMBL3545059' 'CHEMBL3508698']_|_{'rows': array(['EFO_0000537', 'EFO_0000275', 'EFO_0000537', 'EFO_0000400',
       'EFO_0003884', 'MONDO_0001134', 'MONDO_0005148', 'EFO_0000712',
       'EFO_0000319', 'MONDO_0007947', 'EFO_0000401', 'EFO_0004194',
       'EFO_0003144', 'EFO_0000373', 'EFO_0003086', 'EFO_0005672',
       'MONDO_0021661', 'EFO_0003914', 'EFO_0003896', 'EFO_0000612'],
      dtype=object), 'count': 20}_|_[ENSG00000143839]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743003,"nan_|_nan_|_Antibody_|_False_|_CONATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 655' 'AMG-655' 'Conatumumab' 'TRAIL-R2 MAB' 'TRAIL-R2-MAB'
 'TRAIL-R2MAB XG1-048' 'XG1-048']_|_nan_|_nan_|_{'rows': array(['EFO_0000183', 'EFO_0003060', 'EFO_0002618', 'EFO_1001469',
       'EFO_0000403', 'EFO_1001968', 'MONDO_0008170', 'MONDO_0002158'],
      dtype=object), 'count': 8}_|_[ENSG00000120889]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL1940832,"O=CNc1cc([C@@H](O)CNCCc2ccc(NC[C@H](O)c3ccccc3)cc2)ccc1O_|_BMKINZUHKYLSKI-DQEYMECFSA-N_|_Small molecule_|_False_|_MILVETEROL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-159797' 'GSK159797' 'Gsk159797' 'Milveterol' 'TD3327']_|_nan_|_['CHEMBL2107356']_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108280,"nan_|_nan_|_Oligonucleotide_|_False_|_CENERSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cenersen']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000198'], dtype=object), 'count': 2}_|_[ENSG00000141510]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545106,"nan_|_nan_|_Protein_|_False_|_TM30339_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tm30339']_|_nan_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000204174]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3833321,"nan_|_nan_|_Antibody_|_False_|_LECANEMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Leqembi']_|_['BAN-2401' 'BAN2401' 'Ban 2401' 'Lecanemab' 'Lecanemab irmb'
 'Lecanemab-irmb' 'Leqembi']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for alzheimer disease."
CHEMBL3989754,"CC(C(=O)[O-])c1ccc(-c2ccccc2)c(F)c1.O.O.[Na+]_|_GNMBMOULKUXEQF-UHFFFAOYSA-M_|_Small molecule_|_False_|_FLURBIPROFEN SODIUM_|_1986.0_|_4.0_|_CHEMBL563_|_False_|_True_|_['Ansaid' 'Flurbiprofen sodium' 'Occufen' 'Ocufen' 'Zepolas']_|_['Flurbiprofen sodium' 'Flurbiprofen sodium anhydrous'
 'Flurbiprofen sodium dihydrate']_|_[('DailyMed', array(['flurbiprofen%20sodium'], dtype=object))]_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986."
CHEMBL4297846,"nan_|_nan_|_Antibody_|_False_|_SEMZUVOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Db4c7 mab' 'Mab db4c7' 'Semzuvolimab' 'Semzuvolimab ' 'UB-421'
 'UB-421 (DB4C7 MAB)' 'UB421' 'Ub-421']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000180', 'EFO_0000544', 'EFO_0005809'], dtype=object), 'count': 3}_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4301600,"CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12_|_PTIFVLOBVCIMKL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-823778_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL4297457']_|_{'rows': array(['EFO_0000319', 'MONDO_0005148', 'Orphanet_309005', 'EFO_0000537'],
      dtype=object), 'count': 4}_|_[ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL434,"CC(C)NCC(O)c1ccc(O)c(O)c1_|_JWZZKOKVBUJMES-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOPROTERENOL_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['A-21' 'Aleudrin' 'Aludrine' 'Asiprenol' 'Asmalar' 'Assiprenol'
 'Bellasthman' 'Isonorin' 'Isoprenaline' 'Isopropydrin' 'Isoproterenol'
 'Isoproterenol dl-form' 'Isorenin' 'Isupren' 'NSC-33791' 'NSC-9975'
 'Neo-epinine' 'Neodrenal' 'Novodrin' 'Proternol' 'Respifral' 'Saventrine'
 'Vapo-n-iso']_|_[('PubChem', array(['104171176', '144203723', '170464679', '26752240', '50104946',
       '50111114', '90340610'], dtype=object)), ('Wikipedia', array(['Isoprenaline'], dtype=object)), ('drugbank', array(['DB01064'], dtype=object)), ('chEBI', array(['64317'], dtype=object))]_|_['CHEMBL3989521' 'CHEMBL1711']_|_{'rows': array(['EFO_0000319', 'EFO_0000373', 'EFO_1000645', 'EFO_0000275',
       'EFO_0000759', 'EFO_0001073', 'EFO_0005252', 'EFO_0004253',
       'HP_0006536'], dtype=object), 'count': 9}_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 6 investigational indications."
CHEMBL4594254,"C(=C/[C@H]1CCNC1)\c1cncnc1_|_FNEHSHNEXMPCLJ-VWCDRPFISA-N_|_Small molecule_|_False_|_SIMPINICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['OC-02' 'Oc-02' 'Simpinicline' 'TC-6499' 'TC-6499-12' 'TC6499' 'Tc-6499']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMPINICLINE/relevant/1/'],
      dtype=object))]_|_['CHEMBL4594377']_|_{'rows': array(['EFO_1000906', 'EFO_1000948', 'EFO_0000555', 'EFO_1000906'],
      dtype=object), 'count': 4}_|_[ENSG00000160716,ENSG00000101204,ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4596972,"c1cnc2ccc(Nc3nc(NC4CC4)c4nc[nH]c4n3)cc2c1_|_QUTFBURLXCODBH-UHFFFAOYSA-N_|_Small molecule_|_False_|_PUQUITINIB MESYLATE DIHYDRATE_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Puquitinib dimesylate dihydrate' 'Puquitinib mesylate dihydrate'
 'Xc-302']_|_nan_|_['CHEMBL4545915']_|_nan_|_[ENSG00000128052,ENSG00000113721,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL587723,"CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1_|_OONFNUWBHFSNBT-HXUWFJFHSA-N_|_Small molecule_|_False_|_AEE-788_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AEE-788' 'AEE788' 'Aee 788' 'Aee-788' 'GNF-PF-5343' 'NVP-AEE-788'
 'NVP-AEE788']_|_[('Wikipedia', array(['AEE788'], dtype=object)), ('drugbank', array(['DB12558'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000519', 'EFO_1000158'], dtype=object), 'count': 3}_|_[ENSG00000102755,ENSG00000146648,ENSG00000141736,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1071,"O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1_|_OFPXSFXSNFPTHF-UHFFFAOYSA-N_|_Small molecule_|_True_|_OXAPROZIN_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Daypro' 'Oxaprozin']_|_['NSC-310839' 'Oxaprozin' 'WY-21,743' 'WY-21743']_|_[('DailyMed', array(['oxaprozin'], dtype=object)), ('PubChem', array(['11110656', '11110657', '144203610', '170464987', '26719634',
       '26747622', '4254158', '455291', '50106813', '50106814',
       '85230870', '90340983'], dtype=object)), ('Wikipedia', array(['Oxaprozin'], dtype=object)), ('drugbank', array(['DB00991'], dtype=object)), ('chEBI', array(['7822'], dtype=object))]_|_['CHEMBL1200463']_|_{'rows': array(['EFO_0000685', 'MONDO_0005178', 'EFO_0002609', 'EFO_0005755'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 4 approved indications. This drug has a black box warning from the FDA."
CHEMBL1201170,"O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]_|_WJSIUCDMWSDDCE-UHFFFAOYSA-K_|_Small molecule_|_True_|_LITHIUM CITRATE ANHYDROUS_|_1980.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Citric acid trilithium salt']_|_[('Wikipedia', array(['Lithium_citrate'], dtype=object)), ('drugbank', array(['DB14507'], dtype=object)), ('chEBI', array(['64735'], dtype=object))]_|_['CHEMBL2103738']_|_{'rows': array(['EFO_0009963'], dtype=object), 'count': 1}_|_[ENSG00000133731,ENSG00000105723,ENSG00000082701]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for bipolar i disorder. This drug has a black box warning from the FDA."
CHEMBL1201716,"nan_|_nan_|_Protein_|_False_|_MECASERMIN_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Increlex']_|_['CEP-151' 'Cg-gf2' 'Cg-igf-1' 'Igf-1-ec' 'Igf-1ec'
 'Insulin-like growth factor 1' 'Insulin-like growth factor i'
 'Mecasermin' 'Mechano growth factor' 'Pv-802' 'Pv802' 'Rh-oligopeptide-2'
 'Sh-oligopeptide-2' 'Somatomedin c' 'Somatomedin c, human' 'Vexxon-igf-1']_|_[('DailyMed', array(['mecasermin%20recombinant'], dtype=object)), ('DrugCentral', array(['5009'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/increlex'],
      dtype=object)), ('Wikipedia', array(['Mecasermin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004260', 'EFO_1001348', 'EFO_0000400', 'MONDO_0002177',
       'MONDO_0010726', 'EFO_1001158', 'EFO_0000384', 'EFO_0004705',
       'MONDO_0005301', 'MONDO_0005351', 'EFO_1001434', 'MONDO_0015892',
       'MONDO_0004976', 'MONDO_0018997', 'MONDO_0009877', 'HP_0001510'],
      dtype=object), 'count': 16}_|_[ENSG00000140443]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 approved and 12 investigational indications."
CHEMBL163,"CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1_|_NCDNCNXCDXHOMX-XGKFQTDJSA-N_|_Small molecule_|_True_|_RITONAVIR_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Norvir' 'Ritonavir']_|_['A-84538' 'ABBOTT-84538' 'ABT-538' 'Empetus' 'NSC-693184' 'Norvir'
 'Ritomune' 'Ritonavir' 'Ritonavir related compounds mixture'
 'Ritonavirum' 'Ritovir' 'Viekirax' 'Viriton']_|_[('DailyMed', array(['ritonavir'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/norvir'],
      dtype=object)), ('PubChem', array(['144206522', '144206981', '170464891', '26719904', '29215414'],
      dtype=object)), ('Wikipedia', array(['Ritonavir'], dtype=object)), ('drugbank', array(['DB00503'], dtype=object)), ('chEBI', array(['45409'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000558', 'EFO_0000691', 'EFO_0002950', 'EFO_0004234',
       'EFO_0003106', 'EFO_0000765', 'EFO_0001068', 'EFO_0000519',
       'EFO_0004220', 'EFO_0009708', 'EFO_0007328', 'MONDO_0004976',
       'EFO_0000764', 'EFO_0003086', 'EFO_0001361', 'EFO_0000694',
       'MONDO_0100116', 'EFO_0003047', 'EFO_0000763', 'EFO_0003835',
       'MONDO_0100096', 'EFO_0000180', 'EFO_0007224', 'MONDO_0018076',
       'EFO_0007386', 'EFO_0001421', 'EFO_0004197', 'EFO_0000537',
       'MONDO_0004992', 'EFO_0000544', 'EFO_1000637', 'EFO_0002614',
       'EFO_0007304', 'EFO_0000673'], dtype=object), 'count': 34}_|_[ENSG00000160868,ENSG00000106258,ENSG00000021461,ENSG00000160870]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 29 investigational indications. This drug has a black box warning from the FDA."
CHEMBL191413,"CC(C)Cc1ccc([C@@H](C)C(=O)NS(C)(=O)=O)cc1_|_KQDRVXQXKZXMHP-LLVKDONJSA-N_|_Small molecule_|_False_|_REPARIXIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DF 1681Y' 'DF-1681Y' 'DF1681Y' 'Df-1681y' 'Reparixin' 'Repertaxin']_|_[('PubChem', array(['144205825'], dtype=object)), ('drugbank', array(['DB12614'], dtype=object))]_|_['CHEMBL1527147']_|_{'rows': array(['MONDO_0005147', 'MONDO_0100096', 'EFO_0002687', 'MONDO_0007254',
       'EFO_0000342', 'EFO_0007541', 'EFO_0003106', 'MONDO_0100130'],
      dtype=object), 'count': 8}_|_[ENSG00000180871,ENSG00000163464]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL2103975,"CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(N)=O)NC1=O_|_SWXOGPJRIDTIRL-KTJGOPLGSA-N_|_Protein_|_False_|_VAPREOTIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_['Sanvar']_|_['BMY-41606' 'Bmy-41606' 'DP-05-094' 'RC-160' 'Vapreotide'
 'Vapreotide acetate']_|_nan_|_['CHEMBL2218872']_|_{'rows': array(['EFO_0005323'], dtype=object), 'count': 1}_|_[ENSG00000162009,ENSG00000180616,ENSG00000278195]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108187,nan_|_nan_|_Antibody_|_False_|_CLENOLIXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CE9.GAMMA.4PE' 'CE9?4PE' 'Clenoliximab' 'IDEC-151' 'IDEC151']_|_nan_|_nan_|_nan_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL220808,"Fc1ccc(-c2cncc(CNC[C@H]3CCc4ccccc4O3)c2)cc1_|_HKFMQJUJWSFOLY-OAQYLSRUSA-N_|_Small molecule_|_False_|_SARIZOTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['EMD-77697' 'Sarizotan']_|_[('drugbank', array(['DB06454'], dtype=object))]_|_['CHEMBL2146110']_|_{'rows': array(['MONDO_0010726', 'EFO_0004280', 'MONDO_0005180', 'EFO_0004280'],
      dtype=object), 'count': 4}_|_[ENSG00000149295,ENSG00000069696,ENSG00000151577,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2364659,"nan_|_nan_|_Antibody_|_False_|_ONTUXIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MORAB-004' 'Ontecizumab' 'Ontuxizumab']_|_nan_|_nan_|_{'rows': array(['EFO_1001968', 'EFO_0000616', 'EFO_0002617'], dtype=object), 'count': 3}_|_[ENSG00000174807]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL306823,"O=C([O-])C(Cl)Cl.[Na+]_|_LUPNKHXLFSSUGS-UHFFFAOYSA-M_|_Small molecule_|_False_|_SODIUM DICHLOROACETATE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['CMI X-11S' 'CPC-211' 'DCA' 'Dca sodium' 'NSC-744479'
 'Sodium dichloroacetate']_|_[('PubChem', array(['144207122', '144211711', '50112986'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019169', 'EFO_0003777', 'EFO_1000036', 'EFO_0001361',
       'EFO_0000519', 'EFO_0000181', 'MONDO_0007254', 'MONDO_0008903'],
      dtype=object), 'count': 8}_|_[ENSG00000005882,ENSG00000067992,ENSG00000004799,ENSG00000152256]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 8 investigational indications."
CHEMBL3237547,"O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F_|_VUDZSIYXZUYWSC-DBRKOABJSA-N_|_Small molecule_|_False_|_CEDAZURIDINE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ASTX-727 COMPONENT CEDAZURIDINE' 'ASTX727 COMPONENT CEDAZURIDINE'
 'Cedazuridine' 'E-7727' 'E7727']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CEDAZURIDINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005537', 'EFO_0000198', 'EFO_0001663', 'EFO_0000222',
       'EFO_0000211', 'EFO_0000616', 'EFO_0000339', 'EFO_1001779'],
      dtype=object), 'count': 8}_|_[ENSG00000158825]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for myelodysplastic syndrome and has 7 investigational indications."
CHEMBL3264002,"CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F_|_LMMJFBMMJUMSJS-UHFFFAOYSA-N_|_Small molecule_|_False_|_AVUTOMETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Avutometinib' 'CH-5126766' 'CH5126766' 'CKI-27' 'R-7304' 'RG-7304'
 'Rg-7304' 'Ro 5126766' 'Ro-5126766' 'VS-6766']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AVUTOMETINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15254'], dtype=object)), ('chEBI', array(['78825'], dtype=object))]_|_['CHEMBL3264004']_|_{'rows': array(['MONDO_0008170', 'EFO_0000466', 'EFO_0002618', 'EFO_0000616',
       'EFO_0000616', 'MONDO_0007254', 'MONDO_0021148', 'EFO_0003060',
       'EFO_0001378', 'EFO_0000519'], dtype=object), 'count': 10}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL3545317,nan_|_nan_|_Antibody_|_False_|_REFANEZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK249320' 'Refanezumab']_|_nan_|_nan_|_nan_|_[ENSG00000105695]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL3989691,"CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO.NCCO_|_PLILLUUXAVKBPY-SBIAVEDLSA-N_|_Small molecule_|_True_|_ELTROMBOPAG OLAMINE_|_2008.0_|_4.0_|_CHEMBL461101_|_False_|_True_|_['Promacta' 'Promacta kit' 'Revolade']_|_['Eltrombopag (as olamine)' 'Eltrombopag compd with 2-aminoethanol (1:2)'
 'Eltrombopag olamine' 'SB-497115-GR']_|_[('DailyMed', array(['eltrombopag%20olamine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revolade'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0006927', 'EFO_0004220', 'EFO_0007160',
       'HP_0001873'], dtype=object), 'count': 5}_|_[ENSG00000117400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL4297674,"CC#CC(=O)N[C@H]1CCCN(c2c(F)cc(C(N)=O)c3[nH]c(C)c(C)c23)C1_|_VJPPLCNBDLZIFG-ZDUSSCGKSA-N_|_Small molecule_|_False_|_BRANEBRUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-986195' 'Bms-986195' 'Branebrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BRANEBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15347'], dtype=object))]_|_['CHEMBL4639484']_|_{'rows': array(['MONDO_0002334', 'EFO_0005809', 'EFO_0000274', 'EFO_0000685'],
      dtype=object), 'count': 4}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297748,"nan_|_nan_|_Protein_|_False_|_ONVITRELIN UCALONTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EP-100' 'EP-100 (PEPTIDE)' 'EP100' 'Ep 100' 'Ep-100'
 'Onvitrelin ucalontide']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297879,"nan_|_nan_|_Protein_|_False_|_.ALPHA.1-PROTEINASE INHIBITOR HUMAN_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Respreeza']_|_['.alpha.-1 protease inhibitor' '.alpha.1-antitrypsin'
 '.alpha.1-proteinase inhibitor human' 'Alfa1 antitrypsin'
 'Alpha 1-antitrypsin' 'Alpha-1 protease inhibitor'
 'Alpha-1 proteinase inhibitor (human)' 'Alpha-1-antiproteinase'
 'Alpha-1-antitrypsin' 'Alpha1-proteinase inhibitor'
 'Alpha1-proteinase inhibitor (human)' 'Aralast' 'Atc-b02ab02' 'Glassia'
 'Human alpha1-proteinase inhibitor' 'Prolastin' 'Prolastin-c' 'Zemaira']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza'],
      dtype=object))]_|_nan_|_{'rows': array(['MP_0001845', 'MONDO_0020547', 'EFO_0000342', 'EFO_0000341',
       'EFO_0008583', 'EFO_0003818', 'MP_0001914', 'MONDO_0100096',
       'Orphanet_60', 'MONDO_0009061', 'MONDO_0013730', 'EFO_0000508',
       'MONDO_0005147'], dtype=object), 'count': 13}_|_[ENSG00000197561]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 10 investigational indications."
CHEMBL431,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2_|_HRWCVUIFMSZDJS-SZMVWBNQSA-N_|_Small molecule_|_False_|_SPIRAPRIL_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Spirapril']_|_[('Wikipedia', array(['Spirapril'], dtype=object)), ('drugbank', array(['DB01348'], dtype=object))]_|_['CHEMBL1200831']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994 and is indicated for cardiovascular disease."
CHEMBL431733,"CNC(=O)[C@H]1O[C@@H](n2cnc3c(NCc4cccc(I)c4)nc(Cl)nc32)[C@H](O)[C@@H]1O_|_IPSYPUKKXMNCNQ-PFHKOEEOSA-N_|_Small molecule_|_False_|_NAMODENOSON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CF-102' 'CF102' 'CI-IB-MECA' 'CL-IB-MECA' 'Cf102' 'Chloro-ib-meca'
 'Namodenoson']_|_[('PubChem', array(['26752072', '56463287'], dtype=object)), ('drugbank', array(['DB12885'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004220', 'EFO_0000182', 'EFO_0003095', 'EFO_1001249'],
      dtype=object), 'count': 4}_|_[ENSG00000282608]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4594575,"nan_|_nan_|_Antibody_|_False_|_SABATOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MBG-453' 'MBG453' 'Mbg 453' 'Mbg453' 'NVP-MBG453' 'Sabatolimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SABATOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'MONDO_0044903', 'EFO_0000616', 'EFO_0005809',
       'EFO_0000198', 'EFO_0000222', 'EFO_1001779', 'MONDO_0004992'],
      dtype=object), 'count': 8}_|_[ENSG00000135077]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL4650423,"nan_|_nan_|_Antibody_|_False_|_DANBURSTOTUG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Danburstotug' 'IMC-001' 'Imc-001' 'STI-3031' 'Sti-3031']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANBURSTOTUG/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0019472', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL591501,"CCCOCCn1c(=O)c(N2CCN(CCO)CC2)nc2cnc(-c3ccc(OC)nc3)cc21_|_MNLNAGRCHNMKKJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-03049423_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-03049423']_|_nan_|_nan_|_{'rows': array(['HP_0002140'], dtype=object), 'count': 1}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1083390,"O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1_|_JJZFWROHYSMCMU-UHFFFAOYSA-N_|_Small molecule_|_False_|_INTEPIRDINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GSK-742457' 'GSK742457' 'Intepirdine' 'RVT-101' 'SB-742457' 'Sb-742457']_|_[('Wikipedia', array(['SB-742,457'], dtype=object)), ('drugbank', array(['DB12680'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'HP_0000726'], dtype=object), 'count': 2}_|_[ENSG00000158748]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1200622,"C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@]12C_|_BPKAHTKRCLCHEA-UBFJEZKGSA-N_|_Small molecule_|_False_|_PARICALCITOL_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Paricalcitol' 'Zemplar']_|_['COMPOUND 49510' 'COMPOUND-49510' 'Paricalcitol']_|_[('DailyMed', array(['paricalcitol'], dtype=object)), ('PubChem', array(['144206540'], dtype=object)), ('Wikipedia', array(['Paricalcitol'], dtype=object)), ('drugbank', array(['DB00910'], dtype=object)), ('chEBI', array(['7931'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000342', 'MONDO_0005184', 'EFO_0003086',
       'MONDO_0007254', 'MONDO_0008315', 'EFO_0001378', 'EFO_0000401',
       'MONDO_0005148', 'HP_0002901', 'EFO_0004194', 'EFO_0003896',
       'EFO_1000657', 'EFO_0002618', 'HP_0000093', 'EFO_1001173',
       'EFO_1000359', 'EFO_0005754', 'EFO_0008506', 'EFO_0004285',
       'EFO_0003884'], dtype=object), 'count': 21}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 18 investigational indications."
CHEMBL1505,"CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12_|_WKEMJKQOLOHJLZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALMOTRIPTAN_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Almotriptan' 'LAS 31416' 'LAS-31416' 'NSC-760092']_|_[('PubChem', array(['170465288', '174006290', '26748976'], dtype=object)), ('Wikipedia', array(['Almotriptan'], dtype=object)), ('drugbank', array(['DB00918'], dtype=object)), ('chEBI', array(['520985'], dtype=object))]_|_['CHEMBL1200521']_|_{'rows': array(['MONDO_0005277', 'MONDO_0005277'], dtype=object), 'count': 2}_|_[ENSG00000179097,ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for migraine disorder."
CHEMBL1713,"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21.Cl_|_FBSMERQALIEGJT-UHFFFAOYSA-N_|_Small molecule_|_True_|_CHLORPROMAZINE HYDROCHLORIDE_|_1957.0_|_4.0_|_CHEMBL71_|_False_|_True_|_['Chloractil' 'Chlorazine' 'Chlorpromazine hydrochloride'
 'Chlorpromazine hydrochloride intensol' 'Largactil' 'Largactil fte'
 'Promapar' 'Rimazine' 'Sonazine' 'Thorazine']_|_['Chlorpromazine HCl' 'Chlorpromazine hcl' 'Chlorpromazine hydrochloride'
 'Chlorpromazini hydrochloridum' 'Klorproman' 'Marazine' 'NSC-17479'
 'Nci-c05210' 'Norcozine']_|_[('DailyMed', array(['chlorpromazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144210835', '14743551', '26751622', '50106001', '50125717',
       '56422870', '855926'], dtype=object)), ('chEBI', array(['3649'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957. This drug has a black box warning from the FDA."
CHEMBL1750,"Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F_|_WDDPHFBMKLOVOX-AYQXTPAHSA-N_|_Small molecule_|_False_|_CLOFARABINE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Clolar' 'Evoltra']_|_['Clofarabine' 'Clolar' 'NSC-759857']_|_[('DailyMed', array(['clofarabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra'],
      dtype=object)), ('PubChem', array(['144205735', '170465145'], dtype=object)), ('Wikipedia', array(['Clofarabine'], dtype=object)), ('drugbank', array(['DB00631'], dtype=object)), ('chEBI', array(['681569'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0017198', 'EFO_0000574', 'MONDO_0000873', 'EFO_0000220',
       'EFO_1001779', 'MONDO_0015760', 'EFO_0000222', 'MONDO_0013730',
       'EFO_1000318', 'EFO_0000095', 'EFO_0005803', 'EFO_0000183',
       'EFO_0001378', 'EFO_0005952', 'EFO_0000198', 'EFO_0000096',
       'EFO_0000339', 'EFO_0004289', 'MONDO_0004992', 'EFO_0000565',
       'EFO_0000616', 'EFO_0000224'], dtype=object), 'count': 22}_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848,ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 17 investigational indications."
CHEMBL1779046,"O=C(O[C@H]1CN2CCC1CC2)N(Cc1cc(F)c(F)c(F)c1)c1cccc(F)c1_|_UXZDMXYRRQJIBJ-IBGZPJMESA-N_|_Small molecule_|_False_|_TARAFENACIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Svt-40776' 'Tarafenacin']_|_nan_|_nan_|_{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1812161,"CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O_|_LNOVHERIIMJMDG-XZXLULOTSA-N_|_Small molecule_|_False_|_VATIQUINONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(R)-Alpha-Tocotrienol Quinone' '.alpha.-tocotrienol quinone'
 'Alpha tocotrienol quinone' 'Alpha-tocotrienol quinone' 'EPI-743'
 'PTC-743' 'PTC743' 'Vatiquinone']_|_[('drugbank', array(['DB11917'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004895', 'MONDO_0005180', 'EFO_0004145', 'EFO_0003756',
       'MONDO_0009723', 'MONDO_0044970', 'MONDO_0100339', 'MONDO_0010726',
       'EFO_1001254'], dtype=object), 'count': 9}_|_[ENSG00000181019]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2105107,"C[C@H](CC#CC(C)(C)O)[C@H]1CC[C@@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C_|_HHGRMHMXKPQNGF-WNSNRMDMSA-N_|_Small molecule_|_False_|_INECALCITOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Inecalcitol' 'TX-522' 'Tx-522']_|_[('drugbank', array(['DB04796'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000339', 'EFO_0000222'], dtype=object), 'count': 2}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109637,"nan_|_nan_|_Antibody_|_False_|_HUHMFG1_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AS-1402' 'AS1402' 'HUHMFG1' 'Huhmfg1' 'MOAB HuHMFG1' 'R1550' 'Therex'
 'humanized IgG1 monoclonal antibody'
 'humanized human milk fat globule-1 monoclonal antibody']_|_nan_|_nan_|_{'rows': array(['EFO_0000305', 'MONDO_0007254'], dtype=object), 'count': 2}_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2365940,"C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c1ccccc1)c1ccccc1)C2_|_BKLAJZNVMHLXAP-AGYIDARRSA-N_|_Small molecule_|_False_|_DAROTROPIUM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Darotropium cation' 'Darotropium ion']_|_nan_|_['CHEMBL2308782']_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL308148,"CC(=O)NC1(c2ccccc2)CCN(CC[C@H](CN(C)C(=O)c2ccccc2)c2ccc(Cl)c(Cl)c2)CC1_|_PGKXDIMONUAMFR-AREMUKBSSA-N_|_Small molecule_|_False_|_SAREDUTANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Saredutant' 'Sr-48968']_|_[('Wikipedia', array(['Saredutant'], dtype=object)), ('drugbank', array(['DB06660'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'MONDO_0002009', 'EFO_0005230'], dtype=object), 'count': 3}_|_[ENSG00000075073]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3181841,"Cl.Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21_|_XIXYTCLDXQRHJO-RFVHGSKJSA-N_|_Small molecule_|_False_|_RAMOSETRON HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL1643895_|_False_|_False_|_[]_|_['(r)-(-)-ramosetron hydrochloride' 'Irribow' 'Ramosetron hydrochloride'
 'YM-060' 'YM060' 'Ym060']_|_[('PubChem', array(['144205994', '170465928'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3301589,"nan_|_nan_|_Antibody drug conjugate_|_True_|_ENFORTUMAB VEDOTIN_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Padcev']_|_['AGS-22CE' 'AGS-22M6E' 'AGS-22ME' 'AGS-22MSE' 'ASG-22ME' 'Asg-22ce'
 'Enfortumab vedotin' 'Enfortumab vedotin ejfv']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/padcev'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000601', 'MONDO_0004180', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0003863', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0008528',
       'MONDO_0005184'], dtype=object), 'count': 9}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000143217]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL339427,"COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C_|_JFJZZMVDLULRGK-URLMMPGGSA-O_|_Small molecule_|_False_|_TUBOCURARINE_|_1945.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['D-tubocurarine' 'Tubocurarine' 'Tubocurarine cation' 'Tubocurarine ion']_|_[('PubChem', array(['26756599'], dtype=object)), ('drugbank', array(['DB01199'], dtype=object)), ('chEBI', array(['9774'], dtype=object))]_|_['CHEMBL292280' 'CHEMBL3989821' 'CHEMBL1687']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945."
CHEMBL34259,"CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1_|_FBOZXECLQNJBKD-ZDUSSCGKSA-N_|_Small molecule_|_True_|_METHOTREXATE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_['Amethopterin' 'Ebetrex' 'Emtexate high-pot' 'Emtexate pf' 'Folex'
 'Maxtrex' 'Methotrexate' 'Metoject' 'Nordimet' 'Otrexup' 'Otrexup pfs'
 'Rasuvo' 'Reditrex' 'Rheumatrex' 'Trexall' 'Zlatal']_|_['(r)-methotrexate' 'ADX-2191' 'Abitrexate' 'Amethopterin' 'CL 14377'
 'CL-14377' 'D-amethopterin' 'D-methotrexate' 'EMT-25299' 'Folex'
 'Jylamvo' 'Methotrexate' 'Methotrexate, (r)-' 'Methotrexate, d-'
 'Methotrexatum' 'Methylaminopterin' 'Mexate' 'Mexate-AQ' 'NSC-740'
 'R-9985' 'R-methotrexate' 'TCMDC-123832' 'TCMDC-125488' 'TCMDC-125858'
 'Trexall']_|_[('DailyMed', array(['methotrexate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet'],
      dtype=object)), ('PubChem', array(['11113978', '124886991', '144204495', '144210589', '170464688',
       '26752120', '26752121', '26752122', '50104777', '50104778',
       '56463665', '67627', '90340825'], dtype=object)), ('Wikipedia', array(['Methotrexate'], dtype=object)), ('drugbank', array(['DB00563'], dtype=object)), ('chEBI', array(['44185'], dtype=object))]_|_['CHEMBL4572304' 'CHEMBL3244648' 'CHEMBL1376974']_|_{'rows': array(['MONDO_0019460', 'EFO_0000221', 'EFO_1000785', 'EFO_0000717',
       'EFO_0000339', 'MONDO_0019338', 'EFO_0002609', 'EFO_0004192',
       'EFO_0000224', 'MONDO_0019469', 'EFO_0003027', 'EFO_0003811',
       'EFO_0006859', 'EFO_1001469', 'MONDO_0021054', 'EFO_0000232',
       'MONDO_0004979', 'EFO_0000574', 'MONDO_0015540', 'EFO_0000220',
       'EFO_0000384', 'EFO_0004208', 'EFO_0000389', 'EFO_0002609',
       'MONDO_0004192', 'EFO_0000255', 'EFO_0000096', 'EFO_0000612',
       'MONDO_0005178', 'EFO_1001486', 'EFO_1000131', 'EFO_0006475',
       'MONDO_0011382', 'EFO_1001471', 'EFO_0009784', 'EFO_1001365',
       'MONDO_0004986', 'HP_0012410', 'EFO_0000274', 'EFO_1000309',
       'MONDO_0010518', 'EFO_0000094', 'EFO_1001012', 'EFO_0000095',
       'EFO_0003025', 'MONDO_0005090', 'EFO_0007187', 'MONDO_0100096',
       'EFO_0000209', 'EFO_0000198', 'EFO_0000676', 'MONDO_0015253',
       'EFO_0001642', 'EFO_0000729', 'HP_0001915', 'MONDO_0009833',
       'EFO_0009441', 'MONDO_0007254', 'EFO_0005531', 'EFO_0004284',
       'EFO_0000616', 'EFO_0000305', 'MONDO_0002041', 'MONDO_0000873',
       'EFO_0001068', 'EFO_0000540', 'MONDO_0018848', 'MP_0001845',
       'EFO_0003060', 'MONDO_0018944', 'MONDO_0008903', 'MONDO_0008170',
       'EFO_0003032', 'EFO_0002893', 'MONDO_0005575', 'EFO_0000181',
       'EFO_1001779', 'EFO_0005297', 'EFO_0008528', 'MONDO_0017198',
       'MONDO_0003005', 'MONDO_0019200', 'EFO_0003898', 'EFO_1001209',
       'EFO_0005952', 'EFO_0000770', 'EFO_1000318', 'EFO_0003802',
       'EFO_0002939', 'MONDO_0001187', 'MONDO_0044917', 'EFO_0002428',
       'MONDO_0019471', 'EFO_0000685', 'EFO_0000191', 'EFO_0000707',
       'EFO_0000565', 'EFO_1001494', 'EFO_0000637', 'EFO_0000223',
       'MONDO_0016717', 'MONDO_0100244', 'MONDO_0044881', 'EFO_1000298',
       'MONDO_0005301', 'EFO_0002430', 'EFO_0000557', 'EFO_0000691',
       'MONDO_0007254', 'EFO_0003869', 'EFO_0000403', 'MONDO_0024280',
       'MONDO_0002367', 'EFO_0000588', 'EFO_1001951', 'EFO_0005856',
       'EFO_0004599', 'EFO_0009708', 'MONDO_0002038', 'MONDO_0013730',
       'EFO_0006803', 'EFO_0000676', 'EFO_0000764', 'EFO_0002429',
       'EFO_0006927', 'MONDO_0002974', 'EFO_1001012', 'EFO_0000309',
       'EFO_0001075', 'EFO_0004289', 'MONDO_0001657', 'MONDO_0000159',
       'EFO_0000685', 'MONDO_0015974', 'MONDO_0018975', 'MONDO_0004992',
       'EFO_1000956', 'EFO_0003833', 'MONDO_0020077', 'EFO_1001231',
       'EFO_0000183', 'EFO_0005952', 'MONDO_0019391', 'EFO_0000211',
       'MONDO_0000870', 'EFO_0006818', 'EFO_0004991', 'EFO_0003778',
       'EFO_1000158', 'EFO_1001176', 'EFO_1000986', 'EFO_1001051',
       'EFO_0005235', 'EFO_0001645', 'EFO_0000319', 'EFO_1001129',
       'EFO_0000220', 'EFO_0004251', 'EFO_1001830', 'EFO_0000218',
       'EFO_0002893', 'EFO_0000222', 'MONDO_0007915', 'MONDO_0003478',
       'EFO_0009907', 'MONDO_0044903', 'MONDO_0019472', 'EFO_0000621',
       'EFO_0001378', 'MONDO_0018906', 'EFO_0000398'], dtype=object), 'count': 171}_|_[ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 22 approved and 143 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3544992,nan_|_nan_|_Antibody_|_False_|_DENINTUZUMAB_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Denintuzumab' 'HBU-12' 'hBU12']_|_nan_|_nan_|_nan_|_[ENSG00000177455]_|_Antibody drug.
CHEMBL3545101,"nan_|_nan_|_Small molecule_|_False_|_KRP203_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Krp203']_|_nan_|_nan_|_{'rows': array(['EFO_0001642', 'EFO_0000729', 'EFO_0003834'], dtype=object), 'count': 3}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545164,"C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1_|_SXWHYTICXCLKDG-GFCCVEGCSA-N_|_Small molecule_|_False_|_AZD2066_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd 2066' 'Azd-2066' 'Azd2066']_|_[('drugbank', array(['DB12644'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0003948', 'EFO_1000783', 'HP_0012532',
       'EFO_0005762', 'EFO_0003843'], dtype=object), 'count': 6}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3545366,"CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21_|_RGHYDLZMTYDBDT-UHFFFAOYSA-N_|_Small molecule_|_False_|_VOXTALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SAR-245409' 'SAR245409' 'Voxtalisib' 'XL-765' 'XL765']_|_[('drugbank', array(['DB12400'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0003268',
       'EFO_0000756', 'EFO_0000095', 'EFO_0000574', 'EFO_1001469',
       'EFO_1001951', 'EFO_0000519', 'MONDO_0004992', 'MONDO_0008170'],
      dtype=object), 'count': 12}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications."
CHEMBL3590187,"CCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C_|_GPNHMOZDMYNCPO-PDUMRIMRSA-N_|_Small molecule_|_False_|_CLASCOTERONE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Breezula' 'Winlevi']_|_['CB-03-01' 'Cb-03-01' 'Clascoterone' 'Cortexolone 17.alpha.-propionate'
 'Cortodoxone 17.alpha.-propionate']_|_[('drugbank', array(['DB12499'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004191', 'EFO_0003894'], dtype=object), 'count': 2}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for acne and has 1 investigational indication."
CHEMBL3818875,"CNc1nc(C)nc(N[C@H]2CCC[C@@H](C(=O)NCc3ccc(C#N)cc3C(F)(F)F)C2)n1_|_LQHDJQIMETZMPH-ZBFHGGJFSA-N_|_Small molecule_|_False_|_GSK2256294_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-2256294' 'GSK-2256294A' 'Gsk2256294']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000120915]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3833374,"nan_|_nan_|_Antibody_|_False_|_ANDECALIXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Andecaliximab' 'GS-5745' 'GS5745']_|_nan_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0000685', 'EFO_0000384', 'EFO_0000729',
       'MONDO_0009061', 'EFO_0000503'], dtype=object), 'count': 6}_|_[ENSG00000100985]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3989558,"CCC(CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1.O=C(O)/C=C\C(=O)O_|_LWYXFDXUMVEZKS-TZTNOGQLSA-N_|_Small molecule_|_False_|_METHYSERGIDE MALEATE_|_1962.0_|_4.0_|_CHEMBL485253_|_False_|_True_|_['Sansert']_|_['Methysergide hydrogen maleate' 'Methysergide maleate' 'NSC-759143']_|_nan_|_nan_|_nan_|_[ENSG00000178394,ENSG00000147246,ENSG00000135914]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962."
CHEMBL3989830,"CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1.Cl.O_|_KFNNPQDSPLWLCX-UHFFFAOYSA-N_|_Small molecule_|_False_|_SIBUTRAMINE HYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL1419_|_True_|_True_|_['Meridia']_|_['BTS 54524' 'BTS-54524' 'NSC-758928' 'Sibutramine hcl'
 'Sibutramine hydrochloride' 'Sibutramine hydrochloride civ'
 'Sibutramine hydrochloride hydrate'
 'Sibutramine hydrochloride monohydrate']_|_nan_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL420,"N=C(N)N/N=C/c1c(Cl)cccc1Cl_|_WDZVGELJXXEGPV-YIXHJXPBSA-N_|_Small molecule_|_False_|_GUANABENZ_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Guanabenz' 'NSC-68982' 'WY-8678']_|_[('PubChem', array(['26751943', '50104618', '50104619', '90341577'], dtype=object)), ('Wikipedia', array(['Guanabenz'], dtype=object)), ('chEBI', array(['5553'], dtype=object))]_|_['CHEMBL1200560']_|_{'rows': array(['EFO_0003929'], dtype=object), 'count': 1}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication."
CHEMBL4297223,"O.O.O.O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1.O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1.O=S(=O)(O)O_|_DMRIPASJCJRBMV-UHFFFAOYSA-N_|_Small molecule_|_False_|_MITAPIVAT SULFATE_|_2022.0_|_4.0_|_CHEMBL4299940_|_False_|_True_|_['Pyrukynd']_|_['AG-348 HEMISULFATE SESQUIHYDRATE' 'AG-348 sulfate hydrate'
 'Mitapivat sulfate' 'Pyrukynd']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0003689', 'MONDO_0002280', 'EFO_0000508'], dtype=object), 'count': 3}_|_[ENSG00000143627]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved indications."
CHEMBL4297256,"CC(C)(C(=O)NC1C2CC3CC1CC(C(N)=O)(C3)C2)N1CCN(c2ccc(C(F)(F)F)cn2)CC1_|_CLHMYBJIOZXCEX-QIGVQZHLSA-N_|_Small molecule_|_False_|_ABT-384_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abt-384']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297993,"nan_|_nan_|_Unknown_|_False_|_EMD-1201081_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Emd-1201081' 'HYB-2055' 'IMO-2055' 'Imo-2055' 'Imoxine']_|_nan_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_0003060', 'EFO_1001951'], dtype=object), 'count': 3}_|_[ENSG00000239732]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL461522,"Cc1c(N(C)CS(=O)(=O)O)c(=O)n(-c2ccccc2)n1C_|_LVWZTYCIRDMTEY-UHFFFAOYSA-N_|_Small molecule_|_False_|_METAMIZOLE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Metamizole' 'Methamizole-']_|_[('drugbank', array(['DB04817'], dtype=object)), ('chEBI', array(['62088'], dtype=object))]_|_['CHEMBL487894' 'CHEMBL3989803']_|_{'rows': array(['HP_0100806', 'MONDO_0005277', 'EFO_0003843', 'HP_0001945',
       'EFO_1001463', 'HP_0012532'], dtype=object), 'count': 6}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 4 investigational indications."
CHEMBL4802209,"nan_|_nan_|_Unknown_|_False_|_INCB-086550_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['INCB-086550' 'INCB086550' 'Incb 086550' 'Incb-086550' 'Incb086550']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000120217]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL571209,"Cn1cc(C[C@@H](N)C(=O)O)c2ccccc21_|_ZADWXFSZEAPBJS-SNVBAGLBSA-N_|_Small molecule_|_False_|_INDOXIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['1-methyltryptophan, d-' 'D-1-methyltryptophan' 'D-1MT' 'Indoximod'
 'N-1-methyl-d-tryptophan' 'NLG-8189' 'NSC-721782']_|_[('PubChem', array(['536240'], dtype=object)), ('drugbank', array(['DB12827'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_1000028', 'MONDO_0007254', 'EFO_0002617',
       'EFO_0002939', 'EFO_0003060', 'EFO_0000616', 'EFO_0000222',
       'EFO_1001465', 'EFO_0000196'], dtype=object), 'count': 10}_|_[ENSG00000198793,ENSG00000141564,ENSG00000167965]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL807,"CC12CC3CC(C)(C1)CC(N)(C3)C2_|_BUGYDGFZZOZRHP-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEMANTINE_|_2003.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['D-145' 'DRG-0267' 'Memantine' 'NSC-757843' 'Namenda']_|_[('PubChem', array(['104171191', '144203750', '170464999', '26751885', '50104569',
       '90341818'], dtype=object)), ('Wikipedia', array(['Memantine'], dtype=object)), ('drugbank', array(['DB01043'], dtype=object)), ('chEBI', array(['64312'], dtype=object))]_|_['CHEMBL1882685' 'CHEMBL1699']_|_{'rows': array(['EFO_0000326', 'HP_0012167', 'MONDO_0005180', 'MONDO_0004985',
       'MONDO_0004975', 'EFO_0009386', 'MONDO_0004992', 'EFO_0005611',
       'EFO_0003890', 'EFO_0003758', 'MONDO_0004976', 'MONDO_0007079',
       'HP_0100543', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0007328',
       'MONDO_0017276', 'MONDO_0002009', 'EFO_0003757', 'EFO_0000519',
       'HP_0002140', 'MONDO_0005277', 'EFO_0003833', 'MONDO_0011382',
       'HP_0001268', 'EFO_0005411', 'MONDO_0002046', 'EFO_0001073',
       'EFO_0004699', 'MONDO_0002491', 'EFO_1001801', 'EFO_0004240',
       'MONDO_0004681', 'MONDO_0007739', 'MONDO_0007915', 'EFO_0005407',
       'EFO_0005230', 'EFO_0003768', 'EFO_0003758', 'EFO_0004329',
       'HP_0000726', 'EFO_0003843', 'MONDO_0004976', 'MONDO_0010383',
       'HP_0000726', 'MONDO_0004975', 'EFO_0004242', 'HP_0012228',
       'MONDO_0005301', 'EFO_0004190', 'EFO_1001465', 'EFO_0005762',
       'EFO_0003756', 'EFO_0002610', 'EFO_0005687'], dtype=object), 'count': 55}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and dementia and has 51 investigational indications."
CHEMBL1034,"O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+]_|_KPHWPUGNDIVLNH-UHFFFAOYSA-M_|_Small molecule_|_True_|_DICLOFENAC SODIUM_|_1988.0_|_4.0_|_CHEMBL139_|_False_|_True_|_['Acoflam' 'Acoflam ret' 'Acoflam sr' 'Arthronac' 'Arthrotec 50'
 'Arthrotec 75' 'Closteril 100' 'Defanac' 'Defanac retard' 'Defanac sr'
 'Dexomon ret' 'Dexomon sr' 'Diclofenac sodium' 'Dicloflex'
 'Dicloflex ret' 'Dicloflex sr' 'Diclomax ret' 'Diclomax sr'
 'Diclotard 100 mr' 'Diclotard 75 mr' 'Diclovol' 'Diclovol ret'
 'Diclovol sr' 'Diclozip 25' 'Diclozip 50' 'Difenor xl' 'Digenac xl 100'
 'Dyloject' 'Econac' 'Econac sr' 'Econac xl' 'Enstar sr' 'Enstar xl'
 'Enzed' 'Fenactol' 'Fenactol ret' 'Fenactol sr' 'Flamatak mr' 'Flamrase'
 'Flamrase sr' 'Flexotard mr' 'Isclofen' 'Lofensaid 25' 'Lofensaid 50'
 'Lofensaid ret 100' 'Lofensaid ret 75' 'Masidemen' 'Misofen' 'Mobigel'
 'Mobigel paineze' 'Motifene' 'Pennsaid' 'Rheumatac ret 75' 'Rhumalgan'
 'Rhumalgan cr 100' 'Rhumalgan cr 75' 'Rhumalgan sr' 'Rhumalgan xl'
 'Slofenac' 'Solaraze' 'Valdic 100 ret' 'Valdic 75 ret' 'Valenac'
 'Volraman' 'Volsaid ret 100' 'Volsaid ret 75' 'Voltaren'
 'Voltaren arthritis pain' 'Voltaren emulgel' 'Voltaren ret' 'Voltaren-xr'
 'Voltarene' 'Voltarene emulgel' 'Voltarene l.p.' 'Voltarene ret'
 'Voltarol' 'Voltarol 12 hour emulgel p' 'Voltarol active'
 'Voltarol emulgel' 'Voltarol emulgel p' 'Voltarol gel patch'
 'Voltarol ophtha' 'Voltarol pain-eze emulgel' 'Voltarol ret'
 'Voltarol sr']_|_['Abitren' 'Benfofen' 'Dealgic' 'Deflamat' 'Delphinac'
 'Diclofenac diethylamine' 'Diclofenac diethylamine salt'
 'Diclofenac diethylammonium' 'Diclofenac diethylammonium salt'
 'Diclofenac sod' 'Diclofenac sodium' 'Diclofenac sodium salt' 'Diclomax'
 'Diclophenac sodium' 'Diclophlogont' 'Dicloreum' 'Duravolten' 'Ecofenac'
 'Effekton' 'GP 45840' 'GP-45840' 'Lexobene' 'NSC-756725' 'Neriodin'
 'Novapirina' 'Primofenac' 'Prophenatin' 'Rewodina' 'Sodium diclofenac'
 'Voldal' 'Xenid']_|_[('DailyMed', array(['diclofenac%20sodium'], dtype=object)), ('PubChem', array(['11111091', '11112998', '144204321', '144210585', '170464642',
       '26747983', '50106220', '56422389', '85231008', '855544',
       '90341049'], dtype=object)), ('chEBI', array(['4509'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009560', 'EFO_0010072', 'EFO_0002970', 'EFO_0004616',
       'EFO_0000685', 'MONDO_0001187', 'EFO_0000649', 'MP_0001914',
       'MONDO_0005178', 'MONDO_0002959', 'EFO_0009582', 'HP_0003419',
       'EFO_0004272', 'EFO_0004607', 'MP_0001845', 'EFO_0003958',
       'EFO_0003843', 'HP_0012532', 'EFO_0004274', 'EFO_0002496',
       'HP_0011868'], dtype=object), 'count': 21}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200654,"CCCCOc1cc(C(=O)OCCN(CC)CC)ccc1N.Cl_|_PRGUDWLMFLCODA-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENOXINATE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1200_|_False_|_True_|_['Benoxinate hydrochloride']_|_['Benoxinate hcl' 'Benoxinate hydrochloride' 'NSC-759847'
 'Oxibuprocaine chloride' 'Oxybuprocaine hcl'
 'Oxybuprocaine hydrochloride']_|_[('DailyMed', array(['benoxinate%20hydrochloride'], dtype=object)), ('PubChem', array(['144204104', '170464771', '56463336'], dtype=object)), ('chEBI', array(['31260'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201012,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1_|_POPFMWWJOGLOIF-XWCQMRHXSA-N_|_Small molecule_|_False_|_FLURANDRENOLIDE_|_1965.0_|_4.0_|_nan_|_False_|_True_|_['Cordran' 'Cordran sp' 'Flurandrenolide' 'Haelan' 'Haelan-c' 'Haelan-x']_|_['33379' 'Fludroxicortide' 'Fludroxycortide' 'Flurandrenolide'
 'Flurandrenolone' 'NSC-757869']_|_[('DailyMed', array(['flurandrenolide'], dtype=object)), ('PubChem', array(['144204060', '144212928', '170465298', '56424122', '855862'],
      dtype=object)), ('Wikipedia', array(['Fludroxycortide'], dtype=object)), ('drugbank', array(['DB00846'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000701', 'EFO_0003884'], dtype=object), 'count': 2}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for skin disease and has 1 investigational indication."
CHEMBL1201634,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP PURIFIED BEEF/PORK_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Lentard']_|_['Insulin zinc susp purified beef/pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201662,"nan_|_nan_|_Protein_|_False_|_DESIRUDIN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Iprivask' 'Revasc']_|_['63-desulfohirudin' '63-desulfohirudin (recombinant)' 'CGP 39393'
 'CGP-39393' 'Desirudin' 'Desirudin recombinant' 'Hirudin desirudin'
 'Revasc']_|_[('DrugCentral', array(['2990'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/revasc'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003907', 'HP_0004936', 'HP_0004419'], dtype=object), 'count': 3}_|_[ENSG00000180210]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved indications."
CHEMBL1201773,"CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2.Cl_|_JALHGCPDPSNJNY-UHFFFAOYSA-N_|_Small molecule_|_True_|_PRASUGREL HYDROCHLORIDE_|_2009.0_|_4.0_|_CHEMBL1201772_|_False_|_True_|_['Effient' 'Efient']_|_['LY640315' 'Prasu doc' 'Prasugrel hcl' 'Prasugrel hydrochloride']_|_[('DailyMed', array(['prasugrel%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/efient'],
      dtype=object)), ('PubChem', array(['144207170', '170465441'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612', 'EFO_0005672', 'MP_0001914'], dtype=object), 'count': 3}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL1201825,"nan_|_nan_|_Antibody_|_True_|_RANIBIZUMAB_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Lucentis']_|_['BCD-300' 'Byooviz' 'Cimerli' 'FAB-12 VARIANT Y0317' 'FYB-201' 'FYB201'
 'PF-582' 'Pf-582 (ranibizumab biosimilar)' 'Pf582' 'QL-1205' 'QL1205'
 'RG-3645' 'RHUFAB' 'Ranibizumab' 'Ranibizumab biosimilar pf582'
 'Ranibizumab eqrn' 'Ranibizumab nuna' 'Ranibizumab-eqrn'
 'Ranibizumab-nuna' 'SB-11' 'SB11 (RANIBIZUMAB BIOSIMILAR)' 'Susvimo']_|_[('DailyMed', array(['ranibizumab'], dtype=object)), ('DrugCentral', array(['4971'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lucentis'],
      dtype=object)), ('Wikipedia', array(['Ranibizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001158', 'MONDO_0008380', 'EFO_0004190', 'EFO_0004207',
       'EFO_0009606', 'EFO_1000880', 'EFO_1001157', 'EFO_0003770',
       'HP_0000545', 'MONDO_0001576', 'EFO_1001060', 'EFO_0010977',
       'EFO_0000400', 'EFO_0005753', 'HP_0000573', 'EFO_0001365',
       'MONDO_0001941', 'EFO_0003839', 'MONDO_0007935', 'EFO_0000678',
       'HP_0000545', 'MONDO_0005041', 'EFO_1000805', 'MONDO_0020204',
       'EFO_1000809', 'EFO_0007310', 'MONDO_0008667', 'EFO_0004683',
       'EFO_0009784', 'EFO_0005773', 'MONDO_0003005'], dtype=object), 'count': 31}_|_[ENSG00000112715]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 8 approved and 23 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1237026,"nan_|_nan_|_Protein_|_False_|_TESAMORELIN_|_2010.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['TH-9507' 'TH9507' 'Tesamorelin']_|_[('DrugCentral', array(['4170'], dtype=object))]_|_['CHEMBL2111290']_|_{'rows': array(['EFO_0000341', 'EFO_1001348', 'EFO_1001348', 'EFO_0000764',
       'MONDO_0005148', 'HP_0100543'], dtype=object), 'count': 6}_|_[ENSG00000106128]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for hiv-associated lipodystrophy syndrome and has 5 investigational indications."
CHEMBL1254025,"CO/N=C1/C[C@@H](CO)N(C(=O)c2ccc(-c3ccccc3C)cc2)C1_|_OLUJSZLBWZWGJT-HGBKYHTQSA-N_|_Small molecule_|_False_|_NOLASIBAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Erlosiban' 'Nolasiban' 'OBE-001' 'Obe001']_|_nan_|_nan_|_{'rows': array(['EFO_0003917', 'EFO_0000545'], dtype=object), 'count': 2}_|_[ENSG00000180914]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1269258,"CC(C)N(Cc1ccccc1)C(=O)CN1C(=O)[C@@H](Cc2c[nH]c3ccccc23)c2nnc(-c3ccccc3)n2-c2ccccc21_|_UBNMGTSDHSQBEL-PMERELPUSA-N_|_Small molecule_|_False_|_CE-326597_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CE-326,597' 'Ce-326,597' 'Ce-326597']_|_[('drugbank', array(['DB12694'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000163394]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1311,"O=[N+]([O-])O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O_|_YWXYYJSYQOXTPL-SLPGGIOYSA-N_|_Small molecule_|_False_|_ISOSORBIDE MONONITRATE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Angeze 10' 'Angeze 20' 'Angeze 40' 'Angeze sr 40' 'Angeze sr 60'
 'Angitate' 'Astrodur mr' 'Carmil xl' 'Chemydur 60 xl' 'Cibral 10'
 'Cibral 20' 'Cibral 40' 'Cibral xl 60' 'Dynamin' 'Dynamin xl 25'
 'Dynamin xl 50' 'Elantan 10' 'Elantan 20' 'Elantan 40' 'Elantan la 25'
 'Elantan la 50' 'Eumon 40 xl' 'Eumon 60 xl' 'Imdur' 'Imo la' 'Isib 20'
 'Isib 40' 'Isib 50 xl' 'Isib 60 xl' 'Ismo' 'Ismo 10' 'Ismo 20' 'Ismo 40'
 'Ismo ret' 'Isodur' 'Isodur 25 xl' 'Isodur 50 xl'
 'Isosorbide mononitrate' 'Isotard 25 xl' 'Isotard 40 xl' 'Isotard 50 xl'
 'Isotard 60 xl' 'Isotrate' 'Ketanodur' 'Mcr 50' 'Modisal 40 xl'
 'Modisal 60 xl' 'Modisal la 25' 'Modisal la 50' 'Monigen xl 60' 'Monit'
 'Monit ls' 'Monit sr' 'Monit xl 60' 'Mono-cedocard 10' 'Mono-cedocard 20'
 'Mono-cedocard 40' 'Monodur' 'Monoket' 'Monomax sr 40' 'Monomax sr 60'
 'Monomax xl' 'Monomil xl' 'Monosorb xl 60' 'Pertil ret' 'Phasonit la 50'
 'Relosorb xl' 'Slomon xl 60' 'Tardisc xl' 'Tenkosorb' 'Trangina xl'
 'Vasotrate 60 sr' 'Xismox xl 60' 'Zemon 40 xl' 'Zemon 60 xl' 'Ziotan xl']_|_['1,1-diureidisobutane' 'AHR-4698' 'BM 22.145' 'BM 22.145IS 5-MNAHR-4698'
 'BM-22-145' 'BM-22.145' 'BM-22145' 'Corangin'
 'Diluted isosorbide mononitrate' 'IS 5-MN' 'IS-5-MN' 'IS-5MN'
 'Iso-5-mononitrate' 'Isobutyldiurea' 'Isobutylenediurea'
 'Isosorbide 5-mononitrate' 'Isosorbide 5-nitrate'
 'Isosorbide dinitrate isosorbide-5-mononitrate' 'Isosorbide mononitrate'
 'Isosorbide-5-mononitrate' 'Monocord' 'NSC-758619']_|_[('DailyMed', array(['isosorbide%20mononitrate'], dtype=object)), ('PubChem', array(['144205134'], dtype=object)), ('Wikipedia', array(['Isosorbide_mononitrate'], dtype=object)), ('drugbank', array(['DB01020'], dtype=object)), ('chEBI', array(['6062'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003913', 'EFO_0000537', 'EFO_0002950', 'EFO_0001645',
       'HP_0001788', 'EFO_0004264', 'EFO_0000319', 'EFO_0007401',
       'EFO_0000712', 'EFO_0003144', 'HP_0012390'], dtype=object), 'count': 11}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 8 investigational indications."
CHEMBL2108334,"nan_|_nan_|_Protein_|_False_|_EPTACOG ALFA (ACTIVATED)_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Novoseven']_|_['Activated recombinant human factor vii'
 'Coagulation factor viia (recombinant)'
 'Coagulation factor viia recombinant human' 'Eptacog alfa'
 'Eptacog alfa (activated)' 'Recombinant activated factor vii']_|_[('DrugCentral', array(['5159'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002243', 'MP_0001914', 'MONDO_0010604', 'EFO_1000025',
       'EFO_0005669', 'MONDO_0010602', 'MONDO_0100326', 'MONDO_0002244',
       'MONDO_0018660', 'EFO_0000551'], dtype=object), 'count': 10}_|_[ENSG00000057593]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 5 investigational indications."
CHEMBL2109393,nan_|_nan_|_Antibody_|_False_|_RG-7160_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RG-7160']_|_nan_|_nan_|_nan_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL321582,"CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N_|_FBMYKMYQHCBIGU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUCINDOLOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bucindolol']_|_[('PubChem', array(['144206141', '170466320', '50112957'], dtype=object)), ('drugbank', array(['DB12752'], dtype=object))]_|_['CHEMBL2107546']_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545093,"nan_|_nan_|_Small molecule_|_False_|_ZYH7_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Zyh7']_|_nan_|_nan_|_{'rows': array(['EFO_0004211', 'Orphanet_309005'], dtype=object), 'count': 2}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545334,nan_|_nan_|_Small molecule_|_False_|_AVE8134_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ave8134']_|_nan_|_nan_|_nan_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3746329,"O=C(O)C1(Sc2ccnc3ccc(Br)cc23)CCC1_|_QGBWIYLNOBYNDL-UHFFFAOYSA-N_|_Small molecule_|_False_|_SHR-4640_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ruzinurad' 'SHR-4640' 'SHR4640' 'Shr-4640' 'Shr4640']_|_nan_|_nan_|_{'rows': array(['EFO_0009104', 'EFO_0001421', 'EFO_0004274'], dtype=object), 'count': 3}_|_[ENSG00000197891]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4650340,"O=C(O)c1cccc(CN2CN(C3CCCCC3)C3(CCN(CCCC(=O)c4ccccc4)CC3)C2=O)c1_|_BDXJYAAYLZTLEK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRAZPIROBEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TAK-906' 'TAK906' 'Tak-906' 'Trazpiroben']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRAZPIROBEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0011024', 'EFO_1000948'], dtype=object), 'count': 2}_|_[ENSG00000149295,ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5095029,"CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2C[C@@H]3C[C@H]2CN3c2cc(C(F)(F)F)ncn2)(C(C)C)C1_|_MCRWZBYTLVCCJJ-DKALBXGISA-N_|_Small molecule_|_False_|_PF-04634817_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-04634817']_|_nan_|_nan_|_{'rows': array(['EFO_0000401', 'HP_0000083'], dtype=object), 'count': 2}_|_[ENSG00000160791,ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL770,"c1ccc(CC2=NCCN2)cc1_|_JIVZKJJQOZQXQB-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLAZOLINE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-35110' 'Priscoline' 'Tolazine' 'Tolazoline']_|_[('PubChem', array(['11112156'], dtype=object)), ('Wikipedia', array(['Tolazoline'], dtype=object)), ('drugbank', array(['DB00797'], dtype=object)), ('chEBI', array(['28502'], dtype=object))]_|_['CHEMBL1689']_|_{'rows': array(['HP_0003326', 'HP_0002829', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000196639,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved indications."
CHEMBL829,"CC(CN(C)C)CN1c2ccccc2Sc2ccccc21_|_ZZHLYYDVIOPZBE-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHYLPROMAZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Alimemazine' 'BAYER-1219' 'Dl-trimeprazine' 'Methylpromazine' 'RP-6549'
 'Temaril' 'Trimeprazine']_|_[('Wikipedia', array(['Alimemazine'], dtype=object)), ('drugbank', array(['DB01246'], dtype=object)), ('chEBI', array(['9725'], dtype=object))]_|_['CHEMBL3989885' 'CHEMBL4785767' 'CHEMBL1713082']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease."
CHEMBL84158,"CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC_|_JTVPZMFULRWINT-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIAPRIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['NSC-758225' 'Tiapride']_|_[('PubChem', array(['11111853', '11111854'], dtype=object)), ('Wikipedia', array(['Tiapride'], dtype=object)), ('drugbank', array(['DB13025'], dtype=object))]_|_['CHEMBL1256772']_|_{'rows': array(['EFO_0005407', 'EFO_0004895', 'EFO_0005230', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090', 'MONDO_0007739'], dtype=object), 'count': 7}_|_[ENSG00000149295,ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL89598,"C=CC(N)CCC(=O)O_|_PJDFLNIOAUIZSL-UHFFFAOYSA-N_|_Small molecule_|_True_|_VIGABATRIN_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Kigabeq' 'Sabril']_|_['5-hexenoic acid, 4-amino-' 'CPP-109' 'Gamma vinyl gaba'
 'Gamma-vinyl gaba' 'MDL 71,754' 'MDL-71754' 'RMI-71754' 'Vigabatrin'
 'Vinyl gamma-aminobutyric acid']_|_[('DailyMed', array(['vigabatrin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq'],
      dtype=object)), ('PubChem', array(['104171263', '144203852', '26747129', '26751903', '50104581',
       '50104582', '50104583', '85231284', '90340732'], dtype=object)), ('Wikipedia', array(['Vigabatrin'], dtype=object)), ('drugbank', array(['DB01080'], dtype=object)), ('chEBI', array(['63638'], dtype=object))]_|_['CHEMBL4303352']_|_{'rows': array(['MONDO_0001734', 'EFO_1000877', 'EFO_0004263', 'EFO_0004701',
       'HP_0011097', 'EFO_0001073', 'MONDO_0007079', 'EFO_0004895',
       'MONDO_0100062', 'MONDO_0018097', 'EFO_0000474', 'EFO_0002610'],
      dtype=object), 'count': 12}_|_[ENSG00000183044]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1089221,"O=C(O)COc1nn(Cc2ccccc2)c2ccccc12_|_BYFMCKSPFYVMOU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENDAZAC_|_1984.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['AF 1934 [LYSINE]' 'Bendazac' 'Bindazac' 'Iwazac']_|_[('PubChem', array(['50112715'], dtype=object)), ('TG-GATEs', array(['129'], dtype=object)), ('Wikipedia', array(['Bendazac'], dtype=object)), ('drugbank', array(['DB13501'], dtype=object)), ('chEBI', array(['31257'], dtype=object))]_|_['CHEMBL3189046' 'CHEMBL1089222']_|_{'rows': array(['EFO_0005752', 'HP_0003326', 'HP_0002829'], dtype=object), 'count': 3}_|_[ENSG00000158125]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved indications. It was withdrawn in at least one region."
CHEMBL1199307,"CN(CCCCCCN(C)C(=O)Oc1ccc[n+](C)c1)C(=O)Oc1ccc[n+](C)c1_|_AHZBEVXBKNYXPU-UHFFFAOYSA-N_|_Small molecule_|_False_|_DISTIGMINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Distigmine' 'Distigmine cation' 'Distigmine ion']_|_[('drugbank', array(['DB13694'], dtype=object)), ('chEBI', array(['80756'], dtype=object))]_|_['CHEMBL1098285']_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL1200418,"CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1.Cl_|_BQKADKWNRWCIJL-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOBUTAMINE HYDROCHLORIDE_|_1978.0_|_4.0_|_CHEMBL926_|_False_|_True_|_['Dobutamine hydrochloride' 'Dobutrex' 'Posiject']_|_['46236' 'Dl-dobutamine hydrochloride' 'Dobutamine hcl'
 'Dobutamine hydrochloride' 'NSC-299583']_|_[('PubChem', array(['46500392', '50106131', '50106132', '56320684'], dtype=object)), ('chEBI', array(['4671'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000373', 'EFO_0000319'], dtype=object), 'count': 2}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for congestive heart failure and has 1 investigational indication."
CHEMBL1200703,"CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1.Cl_|_DMLFJMQTNDSRFU-UHFFFAOYSA-N_|_Small molecule_|_True_|_CHLORDIAZEPOXIDE HYDROCHLORIDE_|_1960.0_|_4.0_|_CHEMBL451_|_False_|_True_|_['A-poxide' 'Chlordiazachel' 'Chlordiazepoxide hydrochloride' 'Librium'
 'Lygen' 'Tropium']_|_['Chlordiazepoxide hcl' 'Chlordiazepoxide hydrochloride'
 'Clopoxide chloride' 'NSC-115748' 'RO 5-0690' 'RO-5-0690']_|_[('DailyMed', array(['chlordiazepoxide%20hydrochloride'], dtype=object)), ('chEBI', array(['3612'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA."
CHEMBL1201146,"C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C_|_IMONTRJLAWHYGT-ZCPXKWAGSA-N_|_Small molecule_|_False_|_NORETHINDRONE ACETATE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Aygestin' 'Norethidrone Acetate' 'Norethindrone acetate' 'Norlutate']_|_['NSC-22844' 'Norethindrone acetate' 'Norethisteron acetate'
 'Norethisterone 17-acetate' 'Norethisterone acetate'
 'Norethisteroni acetas' 'Norethynyltestosterone' 'Norlutin acetate'
 'SH-420']_|_[('DailyMed', array(['norethindrone%20acetate'], dtype=object)), ('PubChem', array(['144206922', '29215468'], dtype=object)), ('Wikipedia', array(['Norethisterone_acetate'], dtype=object)), ('chEBI', array(['7628'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000574', 'EFO_0002950', 'EFO_0001065',
       'MP_0001914', 'EFO_0003894', 'MONDO_0002146', 'EFO_0000731',
       'MONDO_0009061', 'EFO_0003843', 'GO_0042697'], dtype=object), 'count': 11}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 8 investigational indications."
CHEMBL1255739,"CN(C)CCN(Cc1cccs1)c1ccccn1.Cl_|_BONORRGKLJBGRV-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHAPYRILENE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL1411979_|_True_|_True_|_[]_|_['Methapyrilene hcl' 'Methapyrilene hydrochloride' 'NSC-758410'
 'Thenylpyramine hydrochloride']_|_[('PubChem', array(['11533035', '144204808', '144208332', '170465531', '26747593',
       '50106697', '56422381'], dtype=object)), ('chEBI', array(['38213'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1389,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC_|_WWYNJERNGUHSAO-XUDSTZEESA-N_|_Small molecule_|_False_|_LEVONORGESTREL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Athentia next' 'Emerres' 'Emerres una' 'Ezinelle' 'Fallback solo'
 'Her style' 'Isteranda' 'Jadelle' 'Jaydess' 'Kyleena' 'Levonelle'
 'Levonelle one step' 'Levonelle-2' 'Levonorgestrel' 'Levosert' 'Liletta'
 'Microval' 'Mirena' 'Norgeston' 'Norplant' 'Norplant Ii'
 'Norplant System' 'Opcicon one-step' 'Ovrette' 'Plan B' 'Plan b one-step'
 'Postinor-2' 'Skyla' 'Upostelle']_|_['BAY86-5028' 'Levonorgestrel' 'Levonorgestrelum' 'NSC-744007'
 'Norgestrel (-)-form' 'Norgestrel, (-)-' 'WY-5104']_|_[('DailyMed', array(['levonorgestrel'], dtype=object)), ('PubChem', array(['11532896', '144205146', '144210070', '144213960', '170465033',
       '26719646', '29215264', '56422866'], dtype=object)), ('Wikipedia', array(['Levonorgestrel', 'Norgestrel'], dtype=object)), ('drugbank', array(['DB00367'], dtype=object)), ('chEBI', array(['6443'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000132', 'MP_0001914', 'EFO_0000180', 'MONDO_0005351',
       'EFO_0001065', 'MONDO_0005148', 'MONDO_0005277', 'EFO_0000764',
       'EFO_0001075', 'EFO_1001757', 'MONDO_0004992', 'HP_0100607',
       'EFO_0004220', 'EFO_0000095', 'EFO_0004239', 'EFO_0002950',
       'EFO_1001249', 'EFO_0003843', 'HP_0000938'], dtype=object), 'count': 19}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for menorrhagia and has 18 investigational indications."
CHEMBL1800807,"COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C_|_MZZLGJHLQGUVPN-HAWMADMCSA-N_|_Small molecule_|_False_|_ANACETRAPIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anacetrapib' 'MK-0859' 'MK0859']_|_[('Wikipedia', array(['Anacetrapib'], dtype=object)), ('drugbank', array(['DB06630'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005', 'MONDO_0018328', 'EFO_0004911', 'EFO_0001645',
       'HP_0003124', 'EFO_0000319', 'MONDO_0021187'], dtype=object), 'count': 7}_|_[ENSG00000087237]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2107361,"Cc1cc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)sc1CC[C@@H]1CNc2nc(N)[nH]c(=O)c2C1_|_QXOPTIPQEVJERB-JQWIXIFHSA-N_|_Small molecule_|_False_|_PELITREXOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AG-2037' 'AG2037' 'Pelitrexol']_|_[('drugbank', array(['DB12757'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004142', 'MONDO_0021117', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000159131]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2108040,nan_|_nan_|_Protein_|_False_|_MIROCOCEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APT 070' 'APT-070' 'Mirococept']_|_nan_|_nan_|_nan_|_[ENSG00000203710]_|_Protein drug with a maximum clinical trial phase of II.
CHEMBL2109469,"nan_|_nan_|_Antibody_|_False_|_AFASEVIKUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Afasevikumab' 'MCAF-5352A' 'MCAF5352A' 'NI-1401' 'RG-7624' 'RG7624'
 'RO-5553110' 'RO5553110']_|_nan_|_nan_|_nan_|_[ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL2111084,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccccc1c2CCNC(C)C_|_LNHWXBUNXOXMRL-VWLOTQADSA-N_|_Small molecule_|_False_|_BELOTECAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Belotecan']_|_[('drugbank', array(['DB12459'], dtype=object))]_|_['CHEMBL2107315']_|_{'rows': array(['MONDO_0008903', 'EFO_0000616', 'EFO_0000702', 'EFO_0003060',
       'MONDO_0008170', 'MONDO_0002974'], dtype=object), 'count': 6}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL248702,"CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1_|_DBGIVFWFUFKIQN-VIFPVBQESA-N_|_Small molecule_|_False_|_DEXFENFLURAMINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['D-fenfluramine' 'Dexfenfluramine' 'Fenfluramine d-form' 'Isolipan'
 'J13.711A' 'S 5614']_|_[('Wikipedia', array(['Dexfenfluramine'], dtype=object)), ('drugbank', array(['DB01191'], dtype=object)), ('chEBI', array(['439329'], dtype=object))]_|_['CHEMBL1887891']_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for obesity."
CHEMBL266510,"COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(C(F)(F)F)ccc21_|_ULYONBAOIMCNEH-HNNXBMFYSA-N_|_Small molecule_|_False_|_FLINDOKALNER_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-204352' 'BMS-204352-01' 'Flindokalner']_|_nan_|_nan_|_nan_|_[ENSG00000075043,ENSG00000184156,ENSG00000185760,ENSG00000156113,ENSG00000117013]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL3544953,"nan_|_nan_|_Small molecule_|_False_|_SAF312_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Saf312']_|_nan_|_nan_|_{'rows': array(['HP_0200026', 'EFO_0003843', 'HP_0000011'], dtype=object), 'count': 3}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545385,"nan_|_nan_|_Small molecule_|_False_|_WX-037_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Wx-037']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989911,"CC(O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)CCCNC(=O)CCCN(CC(N)=O)C(=O)[C@H](Cc2ccccc2)NC1=O_|_ABFNTRQPWNXUHA-NNIYEDDKSA-N_|_Protein_|_False_|_VELDOREOTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['COR-005' 'DG-3173' 'DG3173' 'Dg3173' 'PTR 3173' 'PTR-3173' 'Somatoprim'
 'Veldoreotide']_|_nan_|_nan_|_{'rows': array(['EFO_1001485'], dtype=object), 'count': 1}_|_[ENSG00000162009,ENSG00000132671,ENSG00000180616]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989929,"CCCCc1nc(-c2ccc(OCCCN(CC)CC)cc2)cn1-c1ccc(Oc2ccc(Cl)cc2)cc1_|_KJNNWYBAOPXVJY-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZELIRAGON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Azeliragon' 'PF-04494700' 'TTP-488' 'TTP448' 'TTP488']_|_[('drugbank', array(['DB12689'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0002618', 'MONDO_0100096', 'MONDO_0002158',
       'EFO_0000401', 'MONDO_0008170', 'MONDO_0004975'], dtype=object), 'count': 7}_|_[ENSG00000204305]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4297534,"CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O_|_VJCVKWFBWAVYOC-UIXXXISESA-N_|_Small molecule_|_True_|_GLASDEGIB MALEATE_|_2018.0_|_4.0_|_CHEMBL2043437_|_False_|_True_|_['Daurismo']_|_['Glasdegib maleate' 'PF-04449913 MALEATE']_|_[('DailyMed', array(['glasdegib%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/daurismo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA."
CHEMBL4297730,"nan_|_nan_|_Antibody_|_False_|_CONCIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anti-TFPI' 'Concizumab' 'MAB-2021' 'NN-7415' 'NN7415'
 'NNC 0172-0000-2021' 'NNC-0172-0000-2021' 'mAb2021']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CONCIZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604', 'MONDO_0010602'], dtype=object), 'count': 2}_|_[ENSG00000003436]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4594273,"CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1.Cl.Cl_|_XGFHYCAZOCBCRQ-FBHGDYMESA-N_|_Small molecule_|_False_|_ELACESTRANT HYDROCHLORIDE_|_2023.0_|_4.0_|_CHEMBL4297509_|_False_|_True_|_['Orserdu']_|_['Elacestrant dihydrochloride' 'Elacestrant hydrochloride' 'Orserdu'
 'RAD1901 hydrochloride']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELACESTRANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0006861', 'EFO_0003869'], dtype=object), 'count': 2}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for male breast carcinoma and breast neoplasm."
CHEMBL4650273,"CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](C)NC1=O.CC(=O)O.CC(=O)O_|_GOOYENKUPOAYOV-KMKYJKQVSA-N_|_Protein_|_False_|_SETMELANOTIDE ACETATE_|_2020.0_|_4.0_|_CHEMBL3301624_|_False_|_True_|_['Imcivree']_|_[]_|_nan_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000166603]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for obesity."
CHEMBL517,"CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C_|_UVTNFZQICZKOEM-UHFFFAOYSA-N_|_Small molecule_|_True_|_DISOPYRAMIDE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(rs)-disopyramide' 'Dicorantil' 'Disopyramide' 'Dl-disopyramide'
 'H-3292' 'Isorythm' 'Lispine' 'Norpace' 'Ritmilen' 'Rythmodan p'
 'SC-7031' 'Searle-703']_|_[('PubChem', array(['144204278', '170464947', '174006632', '50106174', '85148360',
       '85231006', '90340571', '90341382'], dtype=object)), ('TG-GATEs', array(['102'], dtype=object)), ('Wikipedia', array(['Disopyramide'], dtype=object)), ('drugbank', array(['DB00280'], dtype=object)), ('chEBI', array(['4657'], dtype=object))]_|_['CHEMBL1201020']_|_{'rows': array(['HP_0004308', 'EFO_0004269', 'EFO_0000275', 'EFO_0004269',
       'EFO_0003144', 'EFO_0000275'], dtype=object), 'count': 6}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL570015,"COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1_|_JFHROPTYMMSOLG-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-256066_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK256066' 'Gsk-256066']_|_[('drugbank', array(['DB12137'], dtype=object))]_|_['CHEMBL5307584']_|_{'rows': array(['EFO_0003956', 'EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL572878,"Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1_|_GCIKSSRWRFVXBI-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOZASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-045' 'MK-0457' 'Tozasertib' 'VX-68' 'VX-680']_|_[('PubChem', array(['103905648', '137275826', '162108261', '164339430', '49645761',
       '50100121'], dtype=object))]_|_['CHEMBL2105657']_|_{'rows': array(['EFO_1001951', 'EFO_0003060', 'MONDO_0004992', 'EFO_0004289',
       'EFO_0000339', 'EFO_0000220', 'EFO_0000198', 'EFO_0000565'],
      dtype=object), 'count': 8}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL1095777,"CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2_|_QZZUEBNBZAPZLX-QFIPXVFZSA-N_|_Small molecule_|_False_|_INDACATEROL_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Indacaterol' 'Indacterol' 'Onbrez' 'QAB-149' 'QAB149' 'QABI49']_|_[('Wikipedia', array(['Indacaterol'], dtype=object)), ('drugbank', array(['DB05039'], dtype=object)), ('chEBI', array(['68575'], dtype=object))]_|_['CHEMBL1789842' 'CHEMBL3527369' 'CHEMBL4297657']_|_{'rows': array(['HP_0006536', 'EFO_0006505', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0000464', 'MONDO_0004979', 'EFO_0000341', 'EFO_0003144',
       'MONDO_0004979'], dtype=object), 'count': 9}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 4 investigational indications."
CHEMBL1195136,"CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1_|_AVDSOVJPJZVBTC-CTYIDZIISA-N_|_Small molecule_|_False_|_SNX 5422_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-04929113' 'Pf-4929113' 'Snx 5422' 'Snx-5422']_|_[('drugbank', array(['DB06070'], dtype=object))]_|_['CHEMBL553939']_|_{'rows': array(['EFO_0000574', 'MONDO_0004992', 'MONDO_0044881', 'EFO_0000565'],
      dtype=object), 'count': 4}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1200689,"[N]=O_|_MWUXSHHQAYIFBG-UHFFFAOYSA-N_|_Small molecule_|_False_|_NITRIC OXIDE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Genosyl' 'Inomax']_|_['Amidogen, oxo-' 'Inovent' 'Nitric oxide' 'Nitric oxide trimer'
 'Nitrogen oxide (no)' 'Nitrosyl radical' 'OHM-11771']_|_[('DailyMed', array(['nitric%20oxide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inomax'],
      dtype=object)), ('Wikipedia', array(['Nitric_oxide', 'Nitroxyl'], dtype=object)), ('drugbank', array(['DB00435'], dtype=object)), ('chEBI', array(['16480'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011382', 'EFO_0000341', 'EFO_1001375', 'EFO_0000373',
       'EFO_0004272', 'EFO_1001923', 'MONDO_0005299', 'MONDO_0005149',
       'EFO_0000544', 'MONDO_0100096', 'EFO_0004278', 'EFO_0009444',
       'EFO_0000694', 'EFO_0007512', 'MONDO_0019091', 'EFO_0009447',
       'EFO_0007486', 'EFO_0005762', 'EFO_0005611', 'HP_0100806',
       'EFO_0008585', 'EFO_0005046', 'MONDO_0043510', 'EFO_1001399',
       'EFO_1000644', 'EFO_1001951', 'MONDO_0009061', 'EFO_1000637',
       'EFO_0003827', 'HP_0011950', 'EFO_1001459', 'EFO_0003917',
       'EFO_0007067', 'MONDO_0004992', 'EFO_0009492', 'EFO_0000684',
       'EFO_0009686', 'EFO_0008583', 'EFO_0005207', 'EFO_0003106',
       'HP_0001919', 'EFO_0001068', 'MP_0001845', 'EFO_0003818',
       'EFO_0007541', 'EFO_0002687', 'HP_0002093', 'EFO_1001103',
       'EFO_0000712', 'HP_0002094', 'HP_0200042', 'EFO_0000768',
       'EFO_0001361', 'EFO_0007224'], dtype=object), 'count': 54}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 5 approved and 49 investigational indications."
CHEMBL1200797,"nan_|_nan_|_Small molecule_|_False_|_TECHNETIUM TC 99M SUCCIMER_|_1982.0_|_4.0_|_CHEMBL2110572_|_False_|_True_|_['Mpi dmsa kidney reagent' 'Nephroscan']_|_['99mtc-dmsa' 'Nephroscan' 'Tc-99m dmsa' 'Technetium (99Mtc) Succimer'
 'Technetium (99mtc) dimercaptosuccinic acid for injection'
 'Technetium (99mtc) succimer' 'Technetium tc 99m succimer'
 'Technetium tc-99m succimer' 'Technetium-99 dimercaptosuccinate'
 'Technetium-99-dmsa']_|_nan_|_nan_|_nan_|_[ENSG00000175899]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201554,"nan_|_nan_|_Protein_|_False_|_ANTITHROMBIN ALFA_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Atryn']_|_['Antithrombin (recombinant)' 'Antithrombin alfa'
 'Antithrombin iii,recombinant' 'Human anti-thrombin-iii' 'KW-3357']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/atryn'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000668', 'HP_0001976', 'HP_0005521'], dtype=object), 'count': 3}_|_[ENSG00000180210,ENSG00000126218]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for reduced antithrombin iii activity and has 2 investigational indications."
CHEMBL1620,"CN(C)CCOC(c1ccccc1)c1ccccc1.Cl_|_PCHPORCSPXIHLZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENHYDRAMINE HYDROCHLORIDE_|_1946.0_|_4.0_|_CHEMBL657_|_False_|_True_|_['Alledryl' 'Antitussive' 'Beldin' 'Belix' 'Benadryl'
 'Benadryl preservative free' 'Benylin' 'Caladryl' 'Coltex' 'Dibenil'
 'Diphen' 'Diphenhydramine hydrochloride'
 'Diphenhydramine hydrochloride preservative free' 'Dreemon' 'Dytuss'
 'Fedril' 'Gppe cough expect paed' 'Gppe oral soln' 'Histergan'
 'Hydramine' 'Medinex' 'Nightcalm' 'Nytol' 'Nytol one-a-night' 'Paxidorm'
 'Silphen' 'Sleepia' 'Syntedril' 'Tixylix catarrh' 'Vicks formula 44']_|_['Dimedrol' 'Diphenhydramine HCl' 'Diphenhydramine hcl'
 'Diphenhydramine hydrochloride' 'NSC-33299']_|_[('DailyMed', array(['diphenhydramine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206544', '144208670', '144210928', '26719640', '26747495',
       '26747496', '26751624', '50106145', '50106146', '50106147',
       '543925', '56422455', '855936'], dtype=object)), ('chEBI', array(['4637'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271', 'EFO_0006928', 'EFO_0004255', 'EFO_0009516',
       'MONDO_0007915', 'EFO_0005252', 'EFO_1000783', 'HP_0002017',
       'HP_0002018', 'HP_0002315', 'EFO_0000701', 'EFO_0005761',
       'EFO_0009847', 'MONDO_0002258', 'EFO_0000403', 'MONDO_0002367',
       'HP_0002013', 'HP_0000989', 'EFO_0003958', 'EFO_0004698',
       'EFO_0000095', 'EFO_0003843', 'HP_0001742', 'EFO_1000657',
       'HP_0001945', 'EFO_0005854', 'EFO_0007214', 'MONDO_0007254',
       'EFO_0003956', 'HP_0012735'], dtype=object), 'count': 30}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 18 approved and 12 investigational indications."
CHEMBL2105749,"NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3.O=C(O)C[C@H](O)C(=O)O_|_RARHXUAUPNYAJF-QSYGGRRVSA-N_|_Small molecule_|_False_|_SAMIDORPHAN L-MALATE_|_2021.0_|_4.0_|_CHEMBL426084_|_False_|_True_|_[]_|_['RDC-0313-02' 'Samidorphan l-malate' 'Samidorphan malate']_|_nan_|_nan_|_{'rows': array(['EFO_0009963', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000082556,ENSG00000112038,ENSG00000116329]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for bipolar i disorder and schizophrenia."
CHEMBL2105842,"CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3C=C(C)C4=Cc5c(cnn5-c5ccccc5)C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_RKHQGWMMUURILY-UHRZLXHJSA-N_|_Small molecule_|_False_|_CORTIVAZOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Altim']_|_['Cortivazol' 'NSC-80998']_|_[('drugbank', array(['DB13003'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV and has 1 investigational indication."
CHEMBL2109369,nan_|_nan_|_Antibody_|_False_|_90Y-CT84.66_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['90Y-CT84.66']_|_nan_|_nan_|_nan_|_[ENSG00000105388]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109459,nan_|_nan_|_Antibody_|_False_|_CDP-484_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CDP-484']_|_nan_|_nan_|_nan_|_[ENSG00000125538]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109479,nan_|_nan_|_Antibody_|_False_|_PF-03475952_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['PF-03475952']_|_nan_|_nan_|_nan_|_[ENSG00000026508]_|_Antibody drug.
CHEMBL2359670,"CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2.O=C(O)CC(O)C(=O)O.O=C(O)CC(O)C(=O)O_|_GTHHLZDYRHLACN-UHFFFAOYSA-N_|_Small molecule_|_False_|_THIETHYLPERAZINE MALATE_|_1961.0_|_4.0_|_CHEMBL1378_|_False_|_True_|_['Torecan']_|_['Thiethylperazine dimalate' 'Thiethylperazine malate'
 'Thietylperazine malate']_|_[('PubChem', array(['144204335'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL3189072,"CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O.Cl.O_|_HWAAPJPFZPHHBC-FGJQBABTSA-N_|_Small molecule_|_False_|_TIROFIBAN HYDROCHLORIDE_|_1998.0_|_4.0_|_CHEMBL916_|_False_|_True_|_['Aggrastat']_|_['L-700,462' 'L-700462' 'MK-383' 'Tirofiban hcl' 'Tirofiban hydrochloride'
 'Tirofiban hydrochloride anhydrous']_|_[('DailyMed', array(['tirofiban%20hydrochloride'], dtype=object)), ('PubChem', array(['144206533', '170465092'], dtype=object)), ('chEBI', array(['9606'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000612'], dtype=object), 'count': 1}_|_[ENSG00000259207,ENSG00000005961]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998 and is indicated for myocardial infarction."
CHEMBL3349001,"CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1_|_GYCPCOJTCINIFZ-OXJNMPFZSA-N_|_Small molecule_|_False_|_AVN-944_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AVN 944' 'AVN944' 'Avn-944' 'Avn944']_|_nan_|_nan_|_{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}_|_[ENSG00000106348,ENSG00000178035]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL338975,"CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C.O=C(O)c1ccccc1O_|_HZOTZTANVBDFOF-PBCQUBLHSA-N_|_Small molecule_|_False_|_PHYSOSTIGMINE SALICYLATE_|_nan_|_4.0_|_CHEMBL94_|_False_|_True_|_[]_|_['Eserine salicylate' 'NSC-757275' 'Physostigmine monosalicylate'
 'Physostigmine salicylate' 'Physostigmini salicylas']_|_[('PubChem', array(['855875'], dtype=object)), ('chEBI', array(['48883'], dtype=object))]_|_nan_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL3544954,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1_|_OOUACICUAVTCEC-LZHWUUGESA-N_|_Protein_|_False_|_ZOPTARELIN DOXORUBICIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AN-152' 'Aezs-108' 'Zoptarelin doxorubicin']_|_nan_|_['CHEMBL3989956']_|_{'rows': array(['MONDO_0007254', 'MONDO_0011962', 'EFO_0008528'], dtype=object), 'count': 3}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3545278,"CCCCCS(=O)(=O)NC(=O)c1ccc2nc(C)n(Cc3ccc(Cl)cc3Cl)c2c1_|_UYGZODVVDUIDDQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ATX08-001_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atx08-001' 'FK-614' 'FK614']_|_[('drugbank', array(['DB12557'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'MONDO_0041052'], dtype=object), 'count': 2}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545347,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O_|_PVHLMTREZMEJCG-GDTLVBQBSA-N_|_Protein_|_False_|_TXA127_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['5-ile-angiotensin-(1-7)' 'Angiotensin (1-7)' 'Angiotensin 1-7'
 'Angiotensin fragment 1-7' 'Angiotensin peptide (1-7)'
 'Angiotensin-(1-7)' 'Asp-arg-val-tyr-ile-his-pro' 'Bf-angiotensin 1-7'
 'Human angiotensin ii (1-7)' 'Sh-heptapeptide-13' 'TXA-127' 'TXA127'
 'Txa127']_|_[('drugbank', array(['DB11720'], dtype=object)), ('chEBI', array(['55438'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0000616', 'EFO_0003144', 'MONDO_0004992',
       'EFO_0000537', 'EFO_0001073', 'EFO_0000764', 'MONDO_0100096',
       'EFO_0004265', 'EFO_0009686'], dtype=object), 'count': 10}_|_[ENSG00000130368]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL3545350,"Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1_|_BOVUHBFXPNLTKF-UHFFFAOYSA-N_|_Small molecule_|_False_|_EVT-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Evt-101']_|_nan_|_['CHEMBL3545349']_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000176884,ENSG00000273079]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3833389,"C[C@@H](CC(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1)N1CCOCC1_|_XHKXWINHANRSNT-NRFANRHFSA-N_|_Small molecule_|_False_|_DEXTROMORAMIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acscn-9613' 'Alcoid' 'Dextromoramide' 'IDS-ND-003' 'Jetrium' 'Linfadol'
 'MCP-875' 'Moramide' 'Narcolo' 'Palfadonna' 'R-875' 'Racemoramide, (s)-'
 'SKF-5137' 'Troxilan' 'Yetrium']_|_nan_|_['CHEMBL3833311']_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for pain."
CHEMBL4297650,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CO)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](N)CC(=O)O)C(C)C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N1CCC[C@@H]1C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(N)=O)[C@H](C)O)[C@H](C)O_|_BAAXVYBAMNDCIB-BMCUWHFPSA-N_|_Protein_|_False_|_BRIMAPITIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Brimapitide' 'Xg-102']_|_[('drugbank', array(['DB15231'], dtype=object))]_|_nan_|_{'rows': array(['MP_0001845'], dtype=object), 'count': 1}_|_[ENSG00000109339]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297680,"nan_|_nan_|_Unknown_|_False_|_1018 ISS_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['1018 ISS' '1018 iss' 'CPG-1018' 'Cpg 1018'
 'Cpg oligonucleotide 1018 iss' 'Iss 1018'
 'Iss 1018 cpg oligodeoxynucleotide' 'Iss-1018']_|_nan_|_nan_|_{'rows': array(['EFO_0004197', 'EFO_0005952', 'EFO_0000764', 'MONDO_0100096',
       'EFO_0004142'], dtype=object), 'count': 5}_|_[ENSG00000239732]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4594594,"nan_|_nan_|_Antibody_|_False_|_ITEPEKIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Itepekimab' 'REGN-3500' 'REGN3500' 'Regn3500' 'SAR-440340' 'SAR440340'
 'Sar440340']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ITEPEKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0000274'], dtype=object), 'count': 3}_|_[ENSG00000137033]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL5315075,"nan_|_nan_|_Protein_|_False_|_SUSOCTOCOG ALFA_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Obizur']_|_['BAX-802' 'BAX802' 'Susoctocog alfa']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/obizur'],
      dtype=object))]_|_nan_|_{'rows': array(['MP_0001914', 'MONDO_0010602'], dtype=object), 'count': 2}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for hemorrhage and hemophilia a."
CHEMBL644,"CC(CN(C)C)CN1c2ccccc2CCc2ccccc21_|_ZSCDBOWYZJWBIY-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRIMIPRAMINE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['7162 RP' '7162-RP' 'IL 6001' 'IL-6001' 'Surmontil' 'Trimeproprimine'
 'Trimipramine']_|_[('PubChem', array(['50111256', '90341093'], dtype=object)), ('Wikipedia', array(['Trimipramine'], dtype=object)), ('drugbank', array(['DB00726'], dtype=object)), ('chEBI', array(['9738'], dtype=object))]_|_['CHEMBL1200948']_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002009', 'MONDO_0005090',
       'MONDO_0002050'], dtype=object), 'count': 5}_|_[ENSG00000196639,ENSG00000149295,ENSG00000102468,ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000147246,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for major depressive disorder and depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL742,"CNC1(c2ccccc2Cl)CCCCC1=O_|_YQEZLKZALYSWHR-UHFFFAOYSA-N_|_Small molecule_|_False_|_KETAMINE_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['Ketalar']_|_['Anaket v' 'Calypsol' 'Clorketam 1000' 'Dl-ketamine' 'Imalgene 1000'
 'Ketamine' 'Ketasol 100' 'NSC-70151' 'Narketan' 'PMI-150' 'Tekam'
 'Ursotamin' 'Vetaket']_|_[('PubChem', array(['144205256', '29215438', '56424156'], dtype=object)), ('Wikipedia', array(['Esketamine', 'Ketamine'], dtype=object)), ('drugbank', array(['DB01221'], dtype=object)), ('chEBI', array(['6121'], dtype=object))]_|_['CHEMBL1714']_|_{'rows': array(['EFO_0001358', 'EFO_1001998', 'HP_0012532', 'EFO_0003768',
       'EFO_0007224', 'EFO_0000713', 'EFO_0003756', 'MONDO_0002009',
       'MONDO_0007079', 'EFO_0001074', 'EFO_0002460', 'MONDO_0002009',
       'EFO_0009854', 'EFO_1001412', 'EFO_0000512', 'EFO_0000546',
       'EFO_0004320', 'EFO_1001898', 'EFO_0003890', 'MONDO_0005129',
       'HP_0002315', 'EFO_0005279', 'EFO_0009963', 'EFO_0000712',
       'EFO_0008526', 'MONDO_0002009', 'EFO_0007191', 'MONDO_0010726',
       'EFO_0009513', 'HP_0012378', 'EFO_0003957', 'MONDO_0007079',
       'EFO_0000713', 'MONDO_0011382', 'EFO_0007430', 'EFO_0005762',
       'HP_0000486', 'EFO_0009552', 'EFO_0004242', 'EFO_1000391',
       'EFO_0000474', 'EFO_1001917', 'EFO_0004321', 'EFO_0005323',
       'MONDO_0008903', 'EFO_1000637', 'EFO_0007453', 'MONDO_0004992',
       'MONDO_0005351', 'EFO_0009267', 'EFO_0004320', 'EFO_0801084',
       'MONDO_0004985', 'HP_0012076', 'EFO_0000677', 'MONDO_0002050',
       'MONDO_0002038', 'MONDO_0002070', 'HP_0100806', 'EFO_0009854',
       'EFO_0005611', 'EFO_0002610', 'HP_0000360', 'EFO_0003843',
       'HP_0100543', 'HP_0000989', 'MONDO_0002050', 'EFO_0007149',
       'EFO_0008590', 'MONDO_0007254', 'MONDO_0043510', 'EFO_0009686',
       'EFO_0009492', 'EFO_1001210', 'MONDO_0100096', 'EFO_0006834',
       'EFO_0002610', 'EFO_0000546', 'EFO_0005611', 'EFO_0003931',
       'MONDO_0002258', 'EFO_0009620', 'EFO_0003931', 'HP_0002140',
       'MONDO_0004992', 'MONDO_0005090', 'EFO_0000474', 'HP_0000713',
       'HP_0100543', 'MONDO_0004985', 'EFO_0003015', 'MONDO_0024417',
       'EFO_0000694', 'EFO_1001884'], dtype=object), 'count': 94}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 83 investigational indications."
CHEMBL1096882,"Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O_|_GIUYCYHIANZCFB-FJFJXFQQSA-N_|_Small molecule_|_True_|_FLUDARABINE PHOSPHATE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Fludara' 'Fludarabine phosphate' 'Oforta']_|_['2-f-ara-amp' '2-f-araa' '2-fluoro ara-a' '2-fluorovidarabine'
 'Fludarabine' ""Fludarabine 5'-monophosphate"" 'Fludarabine monophosphate'
 'Fludarabine phosphate' 'Fluradosa' 'NSC-118218' 'NSC-118218H'
 'NSC-312887' 'NSC-328002']_|_[('DailyMed', array(['fludarabine%20phosphate'], dtype=object)), ('chEBI', array(['63599'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000691', 'EFO_0000403', 'EFO_0000221', 'HP_0001871',
       'EFO_0009709', 'EFO_0000209', 'EFO_0003027', 'EFO_0003811',
       'EFO_0004599', 'EFO_0004256', 'EFO_1000292', 'MONDO_0008170',
       'EFO_0009441', 'EFO_0003778', 'MONDO_0021063', 'EFO_0004251',
       'EFO_0000309', 'MONDO_0002334', 'MONDO_0015760', 'EFO_0001642',
       'EFO_0005952', 'EFO_1000690', 'EFO_0000389', 'EFO_0000220',
       'MONDO_0001023', 'EFO_0003802', 'EFO_0000255', 'EFO_0000621',
       'MONDO_0004992', 'EFO_0000196', 'HP_0001915', 'Orphanet_848',
       'MONDO_0019391', 'EFO_0000339', 'MONDO_0009348', 'MONDO_0021193',
       'EFO_0003032', 'HP_0012410', 'EFO_0006927', 'EFO_0005761',
       'MONDO_0007576', 'EFO_1001257', 'MONDO_0015277', 'EFO_1000560',
       'EFO_0003025', 'MONDO_0002691', 'EFO_0004272', 'EFO_0000222',
       'EFO_0000095', 'EFO_1001779', 'EFO_0000349', 'EFO_0000182',
       'EFO_0000096', 'MONDO_0018906', 'MONDO_0015253', 'MONDO_0009833',
       'MONDO_0019469', 'EFO_0006803', 'EFO_0002617', 'EFO_0001075',
       'MONDO_0011382', 'EFO_0000565', 'MONDO_0015974', 'EFO_0000540',
       'EFO_0000708', 'EFO_0009708', 'MONDO_0019460', 'MONDO_0002158',
       'MONDO_0017198', 'EFO_1001051', 'EFO_0000519', 'EFO_0001378',
       'MONDO_0008903', 'EFO_0000384', 'MONDO_0000159', 'EFO_1001465',
       'EFO_0000574', 'EFO_1000131', 'EFO_0003869', 'EFO_1001996',
       'MONDO_0044881', 'MONDO_0008315', 'EFO_0000223', 'EFO_0000174',
       'MONDO_0100244', 'MONDO_0002898', 'EFO_1000309', 'EFO_0004252',
       'EFO_0000183', 'EFO_0000685', 'EFO_0000616', 'EFO_0003865',
       'MONDO_0000870', 'EFO_0000637', 'EFO_1002048', 'MONDO_0020077',
       'EFO_0000211', 'EFO_0006475', 'EFO_0002429', 'EFO_1001469',
       'EFO_0006859', 'EFO_0000588', 'EFO_0000094', 'MONDO_0002108',
       'EFO_0000218', 'EFO_0000198', 'MONDO_0002087', 'EFO_0002428',
       'MONDO_0010518', 'MONDO_0013730', 'MONDO_0018922', 'EFO_1000956',
       'EFO_0003060', 'MONDO_0044903', 'EFO_0000717', 'EFO_0001061',
       'EFO_0000681', 'EFO_0000756', 'MONDO_0005184', 'EFO_1000318',
       'HP_0100727', 'MONDO_0019472', 'MONDO_0018305', 'MONDO_0002367',
       'HP_0002721', 'EFO_0002430', 'EFO_1001938', 'EFO_0005803',
       'EFO_0000571', 'EFO_0004289', 'MONDO_0005301', 'EFO_0000676',
       'EFO_1000785', 'MONDO_0000873', 'MONDO_0019471', 'MONDO_0007915',
       'EFO_1000102', 'EFO_0000326', 'EFO_0000191', 'MONDO_0007254',
       'MONDO_0001657'], dtype=object), 'count': 141}_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848,ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 138 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200694,"FCOC(C(F)(F)F)C(F)(F)F_|_DFEYYRMXOJXZRJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SEVOFLURANE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Sevoflurane' 'Sevohale (previously known as sevocalm)' 'Sojourn'
 'Ultane']_|_['MR-6S4' 'MR6S4' 'NSC-760367' 'Sevocalm' 'Sevoflo' 'Sevoflurane'
 'Sevorane']_|_[('DailyMed', array(['sevoflurane'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/sevohale-previously-known-sevocalm'],
      dtype=object)), ('PubChem', array(['144205978', '50112674'], dtype=object)), ('Wikipedia', array(['Sevoflurane'], dtype=object)), ('drugbank', array(['DB01236'], dtype=object)), ('chEBI', array(['9130'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009267', 'EFO_0003870', 'EFO_0000713', 'EFO_0001074',
       'MONDO_0021698', 'EFO_0005207', 'EFO_1001328', 'EFO_0009686',
       'HP_0011110', 'HP_0003418', 'EFO_0003884', 'EFO_0001073',
       'EFO_0003843', 'EFO_0002687', 'MONDO_0007254', 'MONDO_0007576',
       'EFO_0003777', 'EFO_0005323', 'HP_0001919', 'MONDO_0100096',
       'EFO_0001645', 'EFO_0008583', 'MONDO_0004992', 'EFO_0005611',
       'EFO_1002048', 'EFO_0000694', 'MONDO_0043510', 'MP_0001845',
       'EFO_0006834', 'EFO_1000637', 'EFO_1001951', 'MONDO_0021117',
       'EFO_1001884'], dtype=object), 'count': 33}_|_[ENSG00000145888,ENSG00000109738,ENSG00000100433,ENSG00000186795,ENSG00000082482,ENSG00000169427,ENSG00000171303,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 33 investigational indications."
CHEMBL1200920,"CCC(NC(C)C)C(O)c1ccc(O)c(O)c1.Cl_|_MUFDLGGSOCHQOC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOETHARINE HYDROCHLORIDE_|_1979.0_|_4.0_|_CHEMBL1201213_|_False_|_True_|_['Beta-2' 'Bronkosol' 'Isoetharine hydrochloride'
 'Isoetharine hydrochloride s/f' 'Numotac']_|_['Asthmalitan' 'Dl-isoetharine hydrochloride' 'Isoetarine hydrochloride'
 'Isoetharine hcl' 'Isoetharine hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979."
CHEMBL1201192,"NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1_|_YFGHCGITMMYXAQ-LJQANCHMSA-N_|_Small molecule_|_False_|_ARMODAFINIL_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Armodafinil' 'Nuvigil']_|_['Armodafinil' 'CEP-10952' 'CEP-10953' 'CRL-40982' 'Modafinil, (r)-'
 'NSC-751850' 'NSC-758711' 'R-(-)-modafinil']_|_[('DailyMed', array(['armodafinil'], dtype=object)), ('Wikipedia', array(['Armodafinil'], dtype=object)), ('drugbank', array(['DB06413'], dtype=object)), ('chEBI', array(['77590'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100342', 'HP_0012378', 'EFO_0003060', 'MONDO_0021107',
       'EFO_0003888', 'MONDO_0007576', 'MONDO_0005090', 'EFO_0006859',
       'MONDO_0016158', 'EFO_0001073', 'EFO_0008568', 'MONDO_0002050',
       'EFO_0004698', 'MONDO_0043510', 'EFO_0003918', 'EFO_0005246',
       'EFO_0000712', 'EFO_0000616', 'MONDO_0005301'], dtype=object), 'count': 19}_|_[ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 14 investigational indications."
CHEMBL1201448,"nan_|_nan_|_Oligosaccharide_|_False_|_ARDEPARIN SODIUM_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Normiflo']_|_['Ardeparin sodium' 'Ardeparin sodium salt' 'RD-11885' 'WY-90493 RD'
 'WY-90493-RD']_|_[('Wikipedia', array(['Ardeparin_sodium'], dtype=object))]_|_nan_|_nan_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV that was first approved in 1997."
CHEMBL1237105,"CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO_|_UMMADZJLZAPZAW-XOWPVRJPSA-N_|_Small molecule_|_True_|_CARBOPROST TROMETHAMINE_|_1979.0_|_4.0_|_CHEMBL1237122_|_False_|_True_|_['Hemabate']_|_['Carboprost trometamol' 'Carboprost trometanol' 'Carboprost tromethamine'
 'Carboprost tromethamine salt' 'U-32,921E' 'U-32921E']_|_[('DailyMed', array(['carboprost%20tromethamine'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000731', 'EFO_0009579', 'MP_0001914'], dtype=object), 'count': 3}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for postpartum hemorrhage and hemorrhage and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1276308,"CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C_|_VKHAHZOOUSRJNA-GCNJZUOMSA-N_|_Small molecule_|_True_|_MIFEPRISTONE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Korlym' 'Mifegyne' 'Mifeprex']_|_['Mifepristone' 'NSC-759862' 'RU 38486' 'RU 486' 'RU-38486' 'RU-486'
 'RU486']_|_[('DailyMed', array(['mifepristone'], dtype=object)), ('PubChem', array(['11533034', '144204503', '144212158', '170465151', '26752198',
       '26752199', '50104862', '50104863', '50124354', '56424093',
       '90341299'], dtype=object)), ('drugbank', array(['DB00834'], dtype=object)), ('chEBI', array(['50692'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001110', 'MONDO_0002050', 'MONDO_0001572', 'EFO_0000764',
       'MONDO_0007254', 'EFO_0006861', 'EFO_0003060', 'MONDO_0004975',
       'EFO_1001757', 'EFO_0000400', 'MONDO_0002158', 'HP_0012076',
       'EFO_0001358', 'MONDO_0007079', 'MONDO_0011962', 'EFO_1001255',
       'MONDO_0002046', 'MONDO_0016642', 'EFO_0009784', 'MONDO_0002087',
       'EFO_0000432', 'EFO_0000673', 'EFO_0003047', 'EFO_0003099',
       'EFO_0001065', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0007430',
       'MONDO_0002009', 'EFO_0002610', 'EFO_0002950', 'EFO_0000731',
       'MONDO_0004985', 'HP_0005268', 'EFO_0003768', 'EFO_0005230'],
      dtype=object), 'count': 36}_|_[ENSG00000082175,ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for cushing syndrome and has 35 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2048028,"CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1_|_JFOZKMSJYSPYLN-QHCPKHFHSA-N_|_Small molecule_|_False_|_LIFITEGRAST_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Xiidra']_|_['Lifitegrast' 'SAR 1118' 'SAR-1118' 'SHP-606' 'SHP606']_|_[('DailyMed', array(['lifitegrast'], dtype=object)), ('drugbank', array(['DB11611'], dtype=object))]_|_['CHEMBL2048409' 'CHEMBL2048410']_|_{'rows': array(['EFO_0003966', 'EFO_0007141', 'MONDO_0013730', 'EFO_1000906'],
      dtype=object), 'count': 4}_|_[ENSG00000005844,ENSG00000160255]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for eye disease and dry eye syndrome and has 2 investigational indications."
CHEMBL2107863,"nan_|_nan_|_Unknown_|_False_|_RINDOPEPIMUT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CDX-110' 'PF-04948568' 'PF-04948568 (FORMERLY CDX-110)' 'Rindopepimut']_|_nan_|_nan_|_{'rows': array(['EFO_1001465', 'MONDO_0100342', 'MONDO_0001657'], dtype=object), 'count': 3}_|_[ENSG00000146648]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2108339,"nan_|_nan_|_Protein_|_False_|_EGAPTIVON PEGOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARC-1779' 'ARC1779' 'Arc1779' 'Egaptivon pegol']_|_nan_|_nan_|_{'rows': array(['MONDO_0018896', 'Orphanet_903', 'MONDO_0000831'], dtype=object), 'count': 3}_|_[ENSG00000110799]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2177390,"CC(C)NC[C@@H](C(=O)N1CCN(c2ncnc3c2[C@H](C)C[C@H]3O)CC1)c1ccc(Cl)cc1_|_GRZXWCHAXNAUHY-NSISKUIASA-N_|_Small molecule_|_False_|_IPATASERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GDC-0068' 'Ipatasertib' 'RG-7440' 'RG7440' 'Rg-7440']_|_[('drugbank', array(['DB11743'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0001075',
       'MONDO_0001056', 'MONDO_0004992', 'MONDO_0008170', 'EFO_0003893',
       'EFO_0003869', 'MONDO_0011962', 'EFO_0000616', 'EFO_0005537',
       'EFO_0000503', 'EFO_0003060', 'EFO_1001512', 'EFO_1000251'],
      dtype=object), 'count': 16}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications."
CHEMBL2368924,"CS(=O)(=O)O.O.O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12_|_QTFFGPOXNNGTGZ-LIFGOUTFSA-N_|_Small molecule_|_False_|_DOLASETRON MESYLATE_|_1997.0_|_4.0_|_CHEMBL2368925_|_False_|_True_|_['Anzemet']_|_['Dolasetron mesilate' 'Dolasetron mesilate monohydrate'
 'Dolasetron mesylate' 'Dolasetron mesylate anhydrous'
 'Dolasetron mesylate monohydrate' 'Dolasetron methanesulfonate'
 'MDL 73,147EF' 'MDL-73147EF']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0004888', 'HP_0002017'], dtype=object), 'count': 3}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved indications."
CHEMBL27,"CC(C)NCC(O)COc1cccc2ccccc12_|_AQHHHDLHHXJYJD-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROPRANOLOL_|_1967.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.beta.-propranolol' 'AY-64043-' 'Betalong' 'Dl-propranolol' 'Euprovasin'
 'Inderal' 'Inderide-40/25' 'Inderide-80/25' 'Propranolol' 'Proprasylyt'
 'Reducor']_|_[('PubChem', array(['124881056', '26751802', '26755283', '50104497', '90341556'],
      dtype=object)), ('Wikipedia', array(['Propranolol'], dtype=object)), ('drugbank', array(['DB00571'], dtype=object)), ('chEBI', array(['8499'], dtype=object))]_|_['CHEMBL1671']_|_{'rows': array(['EFO_0000712', 'EFO_0001663', 'EFO_0000341', 'EFO_0005230',
       'EFO_0005687', 'EFO_0009516', 'EFO_0000612', 'MONDO_0004938',
       'EFO_0000389', 'EFO_0004319', 'EFO_0009545', 'EFO_1000911',
       'HP_0001943', 'EFO_0005252', 'EFO_0001358', 'EFO_0005537',
       'EFO_0000712', 'EFO_0001422', 'MONDO_0043510', 'EFO_0003756',
       'MONDO_0001187', 'EFO_0003913', 'EFO_0001365', 'EFO_1001375',
       'MONDO_0021661', 'EFO_0004329', 'EFO_0001073', 'EFO_0000182',
       'MONDO_0018089', 'HP_0004755', 'EFO_0005223', 'HP_0001279',
       'EFO_0001072', 'MONDO_0005475', 'MONDO_0001056', 'EFO_1001450',
       'HP_0030834', 'EFO_1000645', 'EFO_0002610', 'EFO_1001158',
       'MONDO_0019297', 'EFO_0000666', 'MONDO_0005147', 'EFO_0005251',
       'EFO_0003968', 'EFO_0004280', 'EFO_0000681', 'EFO_0001422',
       'EFO_1001968', 'EFO_0003882', 'MONDO_0005277', 'EFO_0004269',
       'MONDO_0100431', 'MONDO_0002363', 'EFO_0003918', 'MONDO_0004979',
       'MONDO_0005277', 'MONDO_0005148', 'MONDO_0002009', 'EFO_0001378',
       'EFO_0004262', 'EFO_0004142', 'EFO_0000546', 'EFO_0009444',
       'EFO_1001884', 'HP_0002315', 'EFO_0001358', 'HP_0001541',
       'EFO_0000558', 'MONDO_0031037', 'MONDO_0008315', 'EFO_0000537',
       'EFO_0003843', 'EFO_0003086', 'HP_0001636', 'MONDO_0011382',
       'EFO_0002610', 'EFO_0000537', 'EFO_1000635', 'EFO_0004287',
       'HP_0003419', 'MONDO_0007254', 'MONDO_0007947', 'EFO_0004278',
       'EFO_1000635', 'MONDO_0019180', 'EFO_0000756', 'EFO_0000319',
       'EFO_0003860'], dtype=object), 'count': 89}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 9 approved and 77 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545090,nan_|_nan_|_Small molecule_|_False_|_RXDX-103_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Rxdx-103']_|_nan_|_nan_|_nan_|_[ENSG00000097046]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545186,"Cc1cc2c(CCc3sc(-c4ccc(C(F)(F)F)cc4)nc3C(C)C)noc2cc1OCC(=O)O_|_WWKYLBGQYALEDL-UHFFFAOYSA-N_|_Small molecule_|_False_|_FONADELPAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fonadelpar' 'NPS-005' 'SJP-0035']_|_nan_|_nan_|_{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}_|_[ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL420762,"Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(N(C)C)c3ccccc32)cc1_|_WRNXUQJJCIZICJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOZAVAPTAN_|_2006.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mozavaptan' 'Mozavaptane']_|_[('PubChem', array(['170466304'], dtype=object)), ('Wikipedia', array(['Mozavaptan'], dtype=object))]_|_['CHEMBL5087555']_|_nan_|_[ENSG00000126895]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006."
CHEMBL4297511,"N[C@@H](CCS(=O)(=O)O)CSSC[C@@H](N)CCS(=O)(=O)O_|_HJPXZXVKLGEMGP-YUMQZZPRSA-N_|_Small molecule_|_False_|_FIRIBASTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Firibastat' 'QGC001' 'Qgc-001' 'Qgc001' 'RB-150']_|_[('drugbank', array(['DB13107'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001134', 'EFO_0003144', 'EFO_1002048', 'EFO_0000537',
       'EFO_0000612'], dtype=object), 'count': 5}_|_[ENSG00000138792]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4594440,"Fc1cc(F)c2c(c1)C[C@@H](n1c(CCNCc3ccccc3)c[nH]c1=S)CO2_|_ZSSLCFLHEFXANG-GOSISDBHSA-N_|_Small molecule_|_False_|_ZAMICASTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Zamicastat']_|_nan_|_nan_|_{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}_|_[ENSG00000123454]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594517,"nan_|_nan_|_Antibody_|_False_|_GILORALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-927' 'Abbv-927' 'Giloralimab' 'PR-1614645']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0002618', 'MONDO_0007254', 'EFO_0006859'],
      dtype=object), 'count': 4}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL5095024,"C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1_|_BRZCZOWSDKKGGK-UHFFFAOYSA-N_|_Small molecule_|_False_|_MP-412_|_nan_|_1.0_|_CHEMBL5095492_|_False_|_False_|_[]_|_['AV-412' 'Mp 412' 'Mp-412']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL73234,"CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1_|_CFJMRBQWBDQYMK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARBETAPENTANE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Pentoxyverine']_|_[('PubChem', array(['11113506', '144204460', '170465562', '26751724', '50104415',
       '50104416', '90340636'], dtype=object)), ('Wikipedia', array(['Pentoxyverine'], dtype=object)), ('drugbank', array(['DB11186'], dtype=object))]_|_['CHEMBL1256696']_|_{'rows': array(['EFO_0007486', 'HP_0012735'], dtype=object), 'count': 2}_|_[ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for sinusitis and cough."
CHEMBL1200464,"CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N.Cl_|_BFUUJUGQJUTPAF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPARACAINE HYDROCHLORIDE_|_1953.0_|_4.0_|_CHEMBL1196_|_False_|_True_|_['Alcaine' 'Kainair' 'Ophthaine' 'Ophthetic' 'Paracaine'
 'Proparacaine hydrochloride']_|_['Ak-taine' 'NSC-759896' 'Proparacaine hcl' 'Proparacaine hydrochloride'
 'Proxymetacaine' 'Proxymetacaine hydrochloride']_|_[('DailyMed', array(['proparacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144207096', '170465400', '56320661'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953."
CHEMBL1200645,"COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O_|_LIQODXNTTZAGID-OCBXBXKTSA-N_|_Small molecule_|_False_|_ETOPOSIDE PHOSPHATE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Etopophos' 'Etopophos preservative free']_|_['BMY 40481' 'BMY-40481' 'Etoposide phosphate' 'VP-16' 'VP16' 'Vepeside']_|_nan_|_nan_|_{'rows': array(['EFO_0000621', 'EFO_0000183', 'MONDO_0002158', 'EFO_0000502',
       'EFO_0000094', 'EFO_0000574', 'EFO_0002939', 'EFO_1000158',
       'EFO_0000096', 'MONDO_0000873', 'EFO_0005952', 'EFO_0000222',
       'EFO_0000220', 'MONDO_0009348', 'EFO_0000565', 'EFO_0000313',
       'EFO_0002918', 'MONDO_0002087', 'MONDO_0100342', 'EFO_0002501',
       'MONDO_0008170', 'EFO_0001378', 'MONDO_0008903'], dtype=object), 'count': 23}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 23 investigational indications."
CHEMBL1200705,"Br.CC(N)Cc1ccc(O)cc1_|_RZCJLMTXBMNRAD-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYAMPHETAMINE HYDROBROMIDE_|_1969.0_|_4.0_|_CHEMBL1546_|_False_|_True_|_['Paredrine']_|_['Hydroxyamfetamine hbr' 'Hydroxyamfetamine hydrobromide'
 'Hydroxyamphetamine hbr' 'Hydroxyamphetamine hydrobromide'
 'Hyroxyamfetamine hydrobromide' 'NSC-61065' 'Oxamphetamine hydrobromide'
 'Phenol, 4-(2-aminopropyl)-, hbr']_|_[('DailyMed', array(['hydroxyamphetamine%20hydrobromide'], dtype=object)), ('PubChem', array(['124752968', '124752971', '144205040', '26749172'], dtype=object))]_|_nan_|_nan_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969."
CHEMBL1200841,"CCN(CC)CCOC(=O)c1ccc(N)cc1.Cl_|_HCBIBCJNVBAKAB-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROCAINE HYDROCHLORIDE_|_1954.0_|_4.0_|_CHEMBL569_|_False_|_True_|_['Novocain' 'Pasconeural n' 'Procaine hydrochloride']_|_['Anestil' 'Enpro' 'Jenacaine' 'Medaject' 'NSC-757280' 'Naucaine'
 'Neocaine' 'Omnicain' 'Planocaine' 'Procaine hcl'
 'Procaine hydrochloride' 'Procaini hydrochloridum' 'Rocain' 'SP-01A'
 'SP01A' 'Sp01a' 'Syntocain']_|_[('PubChem', array(['144203799', '144212431', '170464937', '50085977', '50106847'],
      dtype=object)), ('chEBI', array(['8431'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and has 1 investigational indication."
CHEMBL1201199,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1_|_GFIJNRVAKGFPGQ-LIJARHBVSA-N_|_Protein_|_False_|_LEUPROLIDE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-leuprolide' 'ABBOTT-43818 FREE BASE' 'CKD-841' 'Leuporelin'
 'Leuprolide' 'Leuprorelin' 'Leuprorelin slow release' 'NSC-377526'
 'TAP-144 FREE BASE']_|_[('Wikipedia', array(['Leuprorelin'], dtype=object)), ('drugbank', array(['DB00007'], dtype=object)), ('chEBI', array(['6427'], dtype=object))]_|_['CHEMBL1200775' 'CHEMBL4802223']_|_{'rows': array(['EFO_0009029', 'EFO_0000731', 'MONDO_0004975', 'EFO_0004248',
       'EFO_0000616', 'MONDO_0000521', 'EFO_0005204', 'MONDO_0008170',
       'EFO_0000731', 'MONDO_0000088', 'EFO_0003869', 'EFO_0000756',
       'EFO_0000764', 'MONDO_0008315', 'EFO_0000673', 'MONDO_0004992',
       'EFO_0003843', 'EFO_0001065', 'EFO_0001065', 'EFO_0000545',
       'MONDO_0008315', 'HP_0100543', 'EFO_0001378', 'MONDO_0008315',
       'EFO_0000537', 'MONDO_0003061', 'MONDO_0007254', 'GO_0042697',
       'EFO_0009006', 'MONDO_0000521', 'EFO_0001073', 'EFO_1001469',
       'MONDO_0007254', 'EFO_0000673', 'EFO_0000196', 'EFO_0001073',
       'EFO_0000183', 'EFO_0001663', 'EFO_0001663', 'EFO_0000196',
       'MONDO_0002146', 'EFO_0007453'], dtype=object), 'count': 42}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 7 approved and 30 investigational indications."
CHEMBL1201561,"nan_|_nan_|_Protein_|_True_|_PEGINTERFERON ALFA-2B_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Peg-Intron' 'Pegintron']_|_['Peg-interferon alfa-2b' 'Pegifn alfa-2b' 'Peginterferon alfa-2b'
 'Peginterferon-alfa-2b' 'Pegylated interferon alpha 2b' 'Sylatron']_|_[('DrugCentral', array(['5164'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pegintron'],
      dtype=object)), ('Wikipedia', array(['Peginterferon_alfa-2b'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006859', 'EFO_0002430', 'EFO_0005221', 'EFO_0000681',
       'EFO_0000565', 'EFO_0005543', 'EFO_0000756', 'EFO_1001469',
       'EFO_0000182', 'MONDO_0002974', 'EFO_0001378', 'MONDO_0018975',
       'HP_0012115', 'EFO_0004239', 'EFO_0002617', 'EFO_0004220',
       'EFO_0000765', 'EFO_0009708', 'EFO_0000479', 'MONDO_0008170',
       'EFO_0000707', 'EFO_0000637', 'MONDO_0005301', 'MONDO_0002367',
       'EFO_1000209', 'MONDO_0002158', 'EFO_0000658', 'MONDO_0019471',
       'EFO_0000616', 'MONDO_0016691', 'MONDO_0002087', 'EFO_0004243',
       'EFO_0001642', 'EFO_0001422', 'MONDO_0004992', 'EFO_0003047',
       'EFO_0000764', 'EFO_0007304', 'EFO_0002429', 'EFO_0000389',
       'EFO_0000180', 'EFO_0000339', 'EFO_0009259'], dtype=object), 'count': 43}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 approved and 37 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201593,"nan_|_nan_|_Enzyme_|_False_|_ALTEPLASE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Actilyse' 'Actilyse cathflo' 'Activase' 'Cathflo activase']_|_['Alteplase' 'Alteplase (genetical recombination)'
 'Alteplase for injection' 'Alteplase, recombinant'
 'Alteplase,recombinant' 'Ec 3.4.21.68' 'RT-PA'
 'Tissue plasminogen activator alteplase']_|_[('DailyMed', array(['alteplase'], dtype=object)), ('DrugCentral', array(['5141'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009680', 'EFO_1000637', 'EFO_0001365', 'EFO_0003966',
       'MONDO_0000831', 'EFO_0003907', 'EFO_0000616', 'MONDO_0005299',
       'EFO_0000712', 'MONDO_0100096', 'HP_0004418', 'EFO_0000618',
       'EFO_0003827', 'MONDO_0002679', 'EFO_0000713', 'EFO_0003913',
       'EFO_1001375', 'HP_0000573', 'HP_0004419', 'EFO_0003144',
       'EFO_1001753', 'EFO_1001154', 'EFO_1001157', 'HP_0002140',
       'EFO_0009661', 'EFO_0000694', 'MP_0001914', 'EFO_0000612',
       'EFO_0000544', 'EFO_0003030', 'EFO_0005669', 'MONDO_0020673',
       'EFO_0003097', 'EFO_0000373', 'MONDO_0004992', 'HP_0000016'],
      dtype=object), 'count': 36}_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 28 investigational indications."
CHEMBL1222883,"CN1C(=O)CC[C@H]1C(=O)NCc1cccc(C(F)(F)F)c1Cl_|_BJEMSIVBBUBXMZ-JTQLQIEISA-N_|_Small molecule_|_False_|_GSK1482160_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GSK1482160' 'Gsk-1482160' 'Gsk1482160']_|_nan_|_['CHEMBL5204842']_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000089041]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1240967,"CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1_|_YPHDIMUXXABSSO-YTTGMZPUSA-N_|_Small molecule_|_False_|_PF-00610355_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF - 00610355' 'PF-610355' 'Pf-00610355']_|_[('drugbank', array(['DB11871'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979', 'EFO_0003818'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1272307,"Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1_|_ZJXIUGNEAIHSBI-IBGZPJMESA-N_|_Small molecule_|_False_|_SB-649868_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK649868' 'SB-649868' 'Sb-649868']_|_[('Wikipedia', array(['SB-649,868'], dtype=object)), ('drugbank', array(['DB14822'], dtype=object))]_|_['CHEMBL3527302']_|_{'rows': array(['EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 2}_|_[ENSG00000121764,ENSG00000137252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1819077,"CCC(CC)Nc1c2c(nc3c(-c4ccc(OC)cc4Cl)c(C)nn13)CCC2_|_LDIOUQIXNSSOGU-UHFFFAOYSA-N_|_Small molecule_|_False_|_ONO-2333MS_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ono-2333ms']_|_nan_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000120088]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2106068,"CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1.Cl_|_IJFUJIFSUKPWCZ-SQMFDTLJSA-N_|_Small molecule_|_False_|_ATRASENTAN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL9194_|_False_|_False_|_[]_|_['A-127722' 'A-147627.1' 'ABBOT-147627' 'ABT-627' 'Atrasentan hcl'
 'Atrasentan hydrochloride']_|_nan_|_nan_|_{'rows': array(['MONDO_0002367', 'MONDO_0008315', 'EFO_1000158', 'MONDO_0002087',
       'MONDO_0002158', 'MONDO_0008170'], dtype=object), 'count': 6}_|_[ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2107358,"COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O_|_ZFKXDVMHNXPEIY-PEZBNFGJSA-N_|_Small molecule_|_False_|_OBATOCLAX MESYLATE_|_nan_|_3.0_|_CHEMBL408194_|_False_|_False_|_[]_|_['GX-15-070MS' 'GX15-070MS' 'Obatoclax' 'Obatoclax mesilate'
 'Obatoclax mesylate']_|_nan_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0001378', 'EFO_0001642', 'EFO_1001469',
       'EFO_0000702', 'MONDO_0008903', 'MONDO_0001023', 'EFO_0002617',
       'EFO_0000403', 'EFO_0000183', 'EFO_0000095', 'MONDO_0018906',
       'MONDO_0044903'], dtype=object), 'count': 13}_|_[ENSG00000171791,ENSG00000140379,ENSG00000137875,ENSG00000258643,ENSG00000129473,ENSG00000143384,ENSG00000171552]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL2109103,"nan_|_nan_|_Antibody_|_False_|_BERTILIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bertilimumab' 'CAT-213' 'ICO-008']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0007187'], dtype=object), 'count': 2}_|_[ENSG00000172156]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109264,"nan_|_nan_|_Antibody_|_False_|_SOLITOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MT110' 'Solitomab']_|_nan_|_nan_|_nan_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL2355051,"CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1_|_GKIRPKYJQBWNGO-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOMIPHENE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Clomifene' 'Clomiphene']_|_[('PubChem', array(['144206661', '170464951'], dtype=object)), ('drugbank', array(['DB00882'], dtype=object)), ('chEBI', array(['3752'], dtype=object))]_|_['CHEMBL3185958']_|_{'rows': array(['MONDO_0002775', 'EFO_0000660', 'EFO_0000279', 'EFO_0000731',
       'EFO_0000512', 'EFO_0001073', 'EFO_1001485', 'EFO_0008560',
       'EFO_0000660', 'EFO_0000545', 'MONDO_0002146', 'MONDO_0018555',
       'EFO_0000545', 'MP_0001914', 'EFO_0008560'], dtype=object), 'count': 15}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 3 approved and 12 investigational indications."
CHEMBL3545135,"nan_|_nan_|_Small molecule_|_False_|_NV-128_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Nv-128']_|_nan_|_nan_|_nan_|_[ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545355,"COc1ccc(C2=C(Cc3ccc(OCCN4CCCCC4)cc3)c3ccc(O)cc3OC2)cc1_|_ZUDXUNPSRMREOJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHF4227_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Chf4227']_|_nan_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3984441,"Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C_|_VQYYQSZNRVQLIS-UHFFFAOYSA-N_|_Small molecule_|_False_|_NINGETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CT-053 FREE BASE' 'CT-053-PTSA FREE BASE' 'CT053PTSA FREE BASE'
 'Ningetinib']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000153208,ENSG00000128052,ENSG00000167601,ENSG00000122025,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989954,"C=C1CC[C@H]2[C@H](CN)[C@@H]([C@@]3(C)CC[C@H](O)C[C@@H]3CO)CC[C@]12C_|_MDEJTPWQNNMAQF-BVMLLJBZSA-N_|_Small molecule_|_False_|_ROSIPTOR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AQX-1125' 'AQX-1125 free base' 'Aqx-1125' 'Rosiptor']_|_[('drugbank', array(['DB13012'], dtype=object))]_|_['CHEMBL3989953']_|_{'rows': array(['EFO_0000341', 'EFO_1000869', 'EFO_0000274', 'EFO_0008507'],
      dtype=object), 'count': 4}_|_[ENSG00000168918]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297619,"O=C(O)CNC(=O)c1c(O)cc(CCc2ccccc2)n2ncnc12_|_NALAUGMPMIVAOW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENARODUSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Enarodustat' 'JTZ-951' 'Jtz-951']_|_[('drugbank', array(['DB14985'], dtype=object))]_|_['CHEMBL4166742']_|_{'rows': array(['EFO_0003884'], dtype=object), 'count': 1}_|_[ENSG00000135766]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297633,"CC(C)OC(=O)CCC[C@H]1CC[C@@H]2[C@@H](/C=C/[C@@H](O)COc3cc(F)ccc3F)[C@H](O)C[C@@H]2OC1_|_BKVUSNOUTQMSBE-XCMGCKIWSA-N_|_Small molecule_|_False_|_SEPETAPROST_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DE-126' 'ONO-9054' 'Ono-9054' 'STN-1012600' 'STN1012600' 'Sepetaprost']_|_[('drugbank', array(['DB12043'], dtype=object))]_|_nan_|_nan_|_[ENSG00000050628,ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL4297636,"C/C=C\C[C@@H](C/C=C\NC(=O)[C@@H](NC(=O)/C=C\C=C/C(C)=C/[C@H](C)[C@@H]1CC=C(OC)C(=O)O1)C(C)(C)C)OC(N)=O_|_IEKGSKLKBICCHQ-BDOJOPHNSA-N_|_Small molecule_|_False_|_PLOCABULIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['J3.348.355D' 'PM-060184' 'PM060184' 'Plocabulin' 'Pm 060184' 'Pm060184']_|_[('drugbank', array(['DB13137'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005575', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297878,"nan_|_nan_|_Antibody_|_False_|_LIRENTELIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AK-002' 'AK002' 'Ak002' 'Antolimab' 'Lirentelimab'
 'Monoclonal antibody ak002']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LIRENTELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0011024', 'EFO_0004232', 'EFO_0007141', 'EFO_0005531',
       'EFO_0005531', 'MONDO_0016586', 'EFO_0000274', 'MONDO_0004627',
       'EFO_1000886', 'EFO_0009450'], dtype=object), 'count': 10}_|_[ENSG00000105366]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL431770,"CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O_|_IQVRBWUUXZMOPW-PKNBQFBNSA-N_|_Small molecule_|_False_|_ISTRADEFYLLINE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Nourianz']_|_['Istradefylline' 'KW-6002' 'Nouriast']_|_[('DailyMed', array(['istradefylline'], dtype=object)), ('PubChem', array(['170466116'], dtype=object)), ('Wikipedia', array(['Istradefylline'], dtype=object)), ('drugbank', array(['DB11757'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004976', 'EFO_0003890', 'MONDO_0005180', 'EFO_0001421'],
      dtype=object), 'count': 4}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for parkinson disease and has 3 investigational indications."
CHEMBL4459585,"Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1_|_XPLZTJWZDBFWDE-OYOVHJISSA-N_|_Small molecule_|_False_|_ROPSACITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-06826647' 'Pf-06826647' 'Ropsacitinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROPSACITINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000710', 'EFO_0000729', 'EFO_0003767', 'EFO_0000676'],
      dtype=object), 'count': 4}_|_[ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4594310,"nan_|_nan_|_Antibody_|_False_|_NIPOCALIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['JNJ-80202135' 'M-281' 'M281' 'Nipocalimab']_|_nan_|_nan_|_{'rows': array(['EFO_1001264', 'EFO_0004991', 'EFO_0000699', 'EFO_1000937',
       'MONDO_0007915', 'EFO_1000868', 'EFO_0005761', 'EFO_0000783',
       'EFO_0000685'], dtype=object), 'count': 9}_|_[ENSG00000104870]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL4594539,"nan_|_nan_|_Protein_|_False_|_TRENIBOTULINUMTOXINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AGN-151586' 'BoNT/E' 'Bontoxilysin-e' 'Botulinum neurotoxin type e'
 'Botulinum toxin type e' 'EB-001' 'Eb-001' 'Trenibotulinumtoxine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRENIBOTULINUMTOXINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000132639]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL506569,"CC(=O)O[C@H]1C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)O[C@H](C)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O_|_JAYAGJDXJIDEKI-PTGWOZRBSA-N_|_Small molecule_|_False_|_LANATOSIDE C_|_nan_|_4.0_|_nan_|_False_|_True_|_['Cedilanid']_|_['Allocor' 'Celadigal' 'Cetosanol' 'Digilanogen c' 'Isolanid' 'Isolanide'
 'Lanatigen c' 'Lanatoside c' 'Lanatoside c jp 17' 'Lanimerck'
 'NSC-119991' 'NSC-7533']_|_[('PubChem', array(['144204914'], dtype=object)), ('Wikipedia', array(['Lanatoside_C'], dtype=object)), ('drugbank', array(['DB13467'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."
CHEMBL5095021,COc1ccc(CC(=O)O)cc1Oc1ccc(NC(=O)C(C)(C)C)cc1CSC(C)(C)C_|_SDHFXINHZHARIB-UHFFFAOYSA-N_|_Small molecule_|_False_|_AM-461_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AM461' 'Am-461']_|_nan_|_nan_|_nan_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL71,"CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21_|_ZPEIMTDSQAKGNT-UHFFFAOYSA-N_|_Small molecule_|_True_|_CHLORPROMAZINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Elmarin' 'Largactil' 'Megaphen' 'Thorazine']_|_['Aminazine' 'Chlorpromazine' 'Chlorpromazine hibenzate'
 'Chlorpromazine phenolphthalinate' 'Chlorpromazine tannate'
 'Chlorpromazinum' 'Esmind' 'Fenactil' 'J2.794D' 'Largactilothiazine'
 'NSC-167745' 'NSC-226514' 'Novomazina' 'Propaphenin' 'SKF-2601A'
 'Sanopron' 'Sonazine' 'Wintermin']_|_[('PubChem', array(['104171139', '11110990', '11110991', '124879752', '124879754',
       '124879757', '144203671', '152146164', '170465371', '26747094',
       '26747095', '26751620', '26751621', '50100209', '50104291',
       '57287810', '90340916'], dtype=object)), ('TG-GATEs', array(['16'], dtype=object)), ('Wikipedia', array(['Chlorpromazine'], dtype=object)), ('drugbank', array(['DB00477'], dtype=object)), ('chEBI', array(['3647'], dtype=object))]_|_['CHEMBL1713']_|_{'rows': array(['EFO_0009267', 'HP_0002017', 'MONDO_0021063', 'EFO_0000519',
       'EFO_0004216', 'EFO_0005407', 'MONDO_0005090', 'MONDO_0100096',
       'MONDO_0037939', 'EFO_0000677', 'EFO_0005799'], dtype=object), 'count': 11}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1059,"CC(C)C[C@H](CN)CC(=O)O_|_AYXYPKUFHZROOJ-ZETCQYMHSA-N_|_Small molecule_|_False_|_PREGABALIN_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Alzain' 'Axalid' 'Lecaent' 'Lyrica' 'Lyrica cr' 'Pregabalin'
 'Pregabalin mylan' 'Rewisca']_|_['CI-1008' 'NSC-759256' 'PD-144723' 'Pregabalin' 'Pregabalin mylan'
 'Pregabalin sandoz' 'Pregabalin sandoz gmbh' 'Pregabalin zentiva'
 'Vronogabic' 'YNP-1807']_|_[('DailyMed', array(['pregabalin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-mylan'],
      dtype=object)), ('PubChem', array(['144205028'], dtype=object)), ('Wikipedia', array(['Pregabalin'], dtype=object)), ('drugbank', array(['DB00230'], dtype=object)), ('chEBI', array(['64356'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000783', 'HP_0002018', 'EFO_0006510', 'MONDO_0005277',
       'HP_0002069', 'EFO_1000877', 'EFO_0000400', 'MONDO_0007079',
       'EFO_0009558', 'EFO_0006788', 'EFO_0002950', 'EFO_1001892',
       'EFO_0000474', 'HP_0012532', 'EFO_1000906', 'EFO_0000342',
       'HP_0012735', 'HP_0000726', 'EFO_0003108', 'EFO_1001998',
       'EFO_0003931', 'EFO_0009846', 'EFO_0009430', 'EFO_0004270',
       'HP_0000989', 'EFO_0005230', 'HP_0008419', 'EFO_0005762',
       'EFO_0005687', 'HP_0007359', 'EFO_0003100', 'MONDO_0004892',
       'EFO_0004149', 'MONDO_0002959', 'MONDO_0005090', 'MONDO_0002050',
       'HP_0001250', 'EFO_1000781', 'EFO_0000707', 'EFO_0003830',
       'MONDO_0007254', 'MONDO_0005178', 'EFO_0007191', 'EFO_0004257',
       'EFO_1001919', 'EFO_1001884', 'EFO_0004698', 'EFO_1001931',
       'EFO_0003768', 'EFO_0005611', 'MONDO_0041052', 'EFO_0000555',
       'EFO_0003843', 'EFO_0004263'], dtype=object), 'count': 54}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 9 approved and 45 investigational indications."
CHEMBL1095,"CCN1C(=O)NC(c2ccccc2)C1=O_|_SZQIFWWUIBRPBZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETHOTOIN_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Peganone']_|_['Accenon' 'Ethotoin' 'NSC-760074']_|_[('PubChem', array(['144203934', '56463534'], dtype=object)), ('Wikipedia', array(['Ethotoin'], dtype=object)), ('drugbank', array(['DB00754'], dtype=object)), ('chEBI', array(['4888'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'EFO_0000474'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for seizure and epilepsy."
CHEMBL1200556,"CC(=O)O.N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O_|_MLSVJHOYXJGGTR-IFHOVBQLSA-N_|_Protein_|_True_|_DESMOPRESSIN ACETATE_|_1978.0_|_4.0_|_CHEMBL1429_|_False_|_True_|_['Concentraid' 'Ddavp' 'Ddavp (needs no refrigeration)' 'Desmomelt'
 'Desmopressin acetate' 'Desmopressin acetate (needs no refrigeration)'
 'Desmopressin acetate preservative free' 'Desmospray' 'Desmotabs'
 'Minirin' 'Nocdurna' 'Noctiva' 'Nocutil' 'Noqdirna' 'Octim' 'Octostim'
 'Presinex' 'Stimate' 'Stimate (needs no refrigeration)']_|_['Anhydrous desmopressin acetate' 'Desmopressin acetate'
 'Desmopressin acetate anhydrous' 'Desmopressin acetate hydrate'
 'Desmopressin acetate trihydrate']_|_[('DailyMed', array(['desmopressin%20acetate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009505', 'EFO_0005669', 'HP_0000863', 'MONDO_0024290',
       'EFO_0000537', 'MONDO_0004782', 'HP_0001742', 'MONDO_0024574',
       'HP_0031364', 'MP_0001914'], dtype=object), 'count': 10}_|_[ENSG00000126895,ENSG00000166148,ENSG00000198049]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201039,"NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O_|_NDTSRXAMMQDVSW-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZTHIAZIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Aquatag' 'Benzthiazide' 'Exna' 'Fovane' 'Urese']_|_['Benzothiazide' 'Benzthiazide' 'NSC-755902']_|_[('PubChem', array(['11112238', '124882104', '144203938', '170465246', '26747882',
       '855918'], dtype=object)), ('Wikipedia', array(['Benzthiazide'], dtype=object)), ('drugbank', array(['DB00562'], dtype=object)), ('chEBI', array(['3047'], dtype=object))]_|_nan_|_nan_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1201335,"C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1_|_ANGKOCUUWGHLCE-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLYCOPYRRONIUM_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Glycopyrrolate cation' 'Glycopyrrolate ion' 'Glycopyrronium'
 'Glycopyrronium cation' 'Glycopyrronium ion' 'Glycopyrronium, erythro-']_|_[('Wikipedia', array(['Glycopyrronium_bromide'], dtype=object)), ('drugbank', array(['DB00986'], dtype=object))]_|_['CHEMBL3707243' 'CHEMBL1201027']_|_{'rows': array(['MONDO_0004979', 'EFO_0010282', 'EFO_0004269', 'EFO_0000341',
       'MONDO_0004247', 'HP_0006536', 'EFO_0006505', 'MONDO_0004979',
       'EFO_1000632', 'HP_0000975', 'HP_0002307', 'MONDO_0002050',
       'EFO_0000341', 'HP_0000975', 'HP_0000975', 'EFO_0000341',
       'EFO_0009516', 'MONDO_0100096', 'EFO_0003086'], dtype=object), 'count': 19}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 9 approved and 8 investigational indications."
CHEMBL1201546,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP PURIFIED BEEF_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Lente iletin ii']_|_['Insulin zinc susp purified beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL1201610,"nan_|_nan_|_Protein_|_False_|_CORTICOTROPIN_|_1950.0_|_4.0_|_nan_|_False_|_True_|_['Acth' 'Acthar' 'Acthar gel' 'Adrenocorticotropic Hormone'
 'Adrenocorticotropin' 'Adrenomone' 'Corticotropin' 'H.p. acthar gel'
 'Purified cortrophin gel']_|_['Adrenocorticotrophin' 'Adrenocorticotropic hormone' 'Corticotrophin'
 'Corticotropin' 'Corticotropin (acth)' 'Corticotropin in gelatin matrix'
 'Corticotropin, repository' 'Cortigel' 'Cortrophin']_|_nan_|_nan_|_{'rows': array(['EFO_0003929', 'EFO_0000685', 'EFO_0008520', 'EFO_1001129',
       'EFO_0000474', 'EFO_0008522', 'MONDO_0004976', 'MONDO_0005301',
       'MONDO_0018097', 'EFO_0000401', 'MONDO_0001718', 'EFO_1001231',
       'EFO_0000398', 'EFO_0007405', 'EFO_0000660', 'MONDO_0002462',
       'MONDO_0019338', 'EFO_0004254', 'EFO_0003884', 'EFO_0004255',
       'EFO_0003086', 'MONDO_0005277'], dtype=object), 'count': 22}_|_[ENSG00000185231]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for multiple sclerosis and west syndrome and has 20 investigational indications."
CHEMBL146032,"CC(=O)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C(F)(F)C(F)(F)F)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1_|_VHZPUDNSVGRVMB-RXDLHWJPSA-N_|_Small molecule_|_False_|_LONAPRISAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY86-5044' 'Lonaprisan' 'ZK 230211' 'ZK-230211' 'ZK230211' 'Zk-230211']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1743032,"nan_|_nan_|_Antibody_|_False_|_INTETUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CNTO 095' 'CNTO 95' 'CNTO-095' 'CNTO-95' 'Intetumumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000673'], dtype=object), 'count': 2}_|_[ENSG00000138448,ENSG00000082781,ENSG00000259207]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1743068,"nan_|_nan_|_Antibody_|_False_|_SECUKINUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Cosentyx']_|_['AIN-457' 'AIN457' 'AIN457A' 'Cosentyx' 'Secukinumab']_|_[('DailyMed', array(['secukinumab'], dtype=object)), ('DrugCentral', array(['4934'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008518', 'MONDO_0100017', 'EFO_0005761', 'EFO_1000906',
       'EFO_0004192', 'EFO_1000738', 'EFO_1001209', 'EFO_0000685',
       'EFO_1001231', 'MONDO_0005301', 'MONDO_0005178', 'EFO_0003778',
       'MONDO_0019558', 'EFO_0009856', 'EFO_0000540', 'EFO_1000710',
       'MONDO_0005147', 'EFO_1001494', 'EFO_1001466', 'EFO_0000384',
       'HP_0000999', 'EFO_1001434', 'MONDO_0100096', 'EFO_0003929',
       'EFO_0003780', 'MONDO_0004979', 'EFO_1000760', 'EFO_0000274',
       'EFO_0000706', 'EFO_0000676', 'EFO_0003898'], dtype=object), 'count': 31}_|_[ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 25 investigational indications."
CHEMBL1834657,"CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O_|_GUQNHCGYHLSITB-UHFFFAOYSA-N_|_Small molecule_|_False_|_INFIGRATINIB PHOSPHATE_|_2021.0_|_4.0_|_CHEMBL1852688_|_False_|_True_|_['Truseltiq']_|_['BGJ-398 phosphate' 'Infigratinib monophosphate' 'Infigratinib phosphate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/INFIGRATINIB%20PHOSPHATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0005221', 'EFO_1001961'], dtype=object), 'count': 3}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for cholangiocarcinoma and intrahepatic cholangiocarcinoma and has 1 investigational indication."
CHEMBL2107308,"COc1cc(O)c(C(=O)Nc2nc(C(=O)NCCN(C(C)C)C(C)C)cs2)cc1OC.Cl.O.O.O_|_NPTDXIXCQCFGKC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACOTIAMIDE HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL2107723_|_False_|_False_|_[]_|_['Acotiamide hydrochloride' 'Acotiamide hydrochloride hydrate'
 'Acotiamide hydrochloride trihydrate' 'YM-443' 'YM443' 'Z-338']_|_nan_|_nan_|_{'rows': array(['EFO_0008533'], dtype=object), 'count': 1}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108730,"nan_|_nan_|_Antibody_|_True_|_SARILUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Kevzara']_|_['REG-N88' 'REGN-88' 'REGN88' 'SAR-153191' 'SAR153191' 'Sarilumab']_|_[('DailyMed', array(['sarilumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000694', 'EFO_0000540', 'EFO_1001231', 'EFO_0000685',
       'EFO_0008518', 'MONDO_0100096', 'MONDO_0016586', 'EFO_0002609',
       'EFO_0003106', 'MONDO_0008903', 'MONDO_0008315', 'EFO_0007328',
       'EFO_1001361', 'EFO_1001209', 'EFO_0003898', 'EFO_0000756'],
      dtype=object), 'count': 16}_|_[ENSG00000160712]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for immune system disease and rheumatoid arthritis and has 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109257,nan_|_nan_|_Antibody_|_False_|_IMC-1C11_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IMC-1C11']_|_nan_|_nan_|_nan_|_[ENSG00000128052]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL261244,"CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)([O-])[O-])[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21.[Na+].[Na+]_|_MKQKPLQMNCXTJE-VEZQGTPESA-L_|_Small molecule_|_False_|_REGRELOR DISODIUM_|_nan_|_2.0_|_CHEMBL1162175_|_False_|_False_|_[]_|_['INS-50589' 'INS50589' 'Regrelor disodium']_|_nan_|_nan_|_{'rows': array(['EFO_0001645', 'EFO_0000319'], dtype=object), 'count': 2}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3137310,"COc1ccc2c3c1O[C@H]1C(OC(=O)c4ccccc4)=CC[C@@H]4[C@@H](C2)N(C)CC[C@@]341.Cl_|_VVCUIDHKAHHSAN-JJHQWJQCSA-N_|_Small molecule_|_False_|_BENZHYDROCODONE HYDROCHLORIDE_|_2018.0_|_4.0_|_CHEMBL3137321_|_False_|_True_|_[]_|_['Benzhydrocodone hydrochloride' 'KP-201' 'KP201']_|_[('DailyMed', array(['benzhydrocodone%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for pain."
CHEMBL3544917,"C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)[C@@H](C)O_|_GIBQQARAXHVEGD-BSOLPCOYSA-N_|_Protein_|_False_|_RAPASTINEL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GLYX-13' 'Rapastinel' 'Rapastinelum' 'Tppt-amide']_|_[('drugbank', array(['DB11801'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0004242'], dtype=object), 'count': 2}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3644672,"COc1c(OC[C@H](O)CN2CCOCC2)ccc2c1N=C(NC(=O)c1cccnc1C)N1CCN=C21_|_JGNRMIWLBBNSMU-QGZVFWFLSA-N_|_Small molecule_|_False_|_BAY-1082439_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BAY1082439' 'Bay 1082439' 'Bay-1082439']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000051382,ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989869,"CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1_|_KYJWUPZPSXZEPG-NTISSMGPSA-N_|_Small molecule_|_False_|_UMBRALISIB TOSYLATE_|_2021.0_|_4.0_|_CHEMBL3948730_|_False_|_True_|_['Ukoniq']_|_['RP-5307' 'TGR-1202' 'TGR-1202 (4-METHYLBENZENESULFONATE)' 'Tgr-1202'
 'Umbralisib tosylate']_|_nan_|_nan_|_{'rows': array(['MONDO_0044903', 'MONDO_0001056', 'EFO_0000095', 'EFO_1000630',
       'MONDO_0018906', 'MONDO_0007576', 'EFO_1001469', 'EFO_0002618',
       'EFO_1001951', 'MONDO_0011719', 'EFO_0000183', 'EFO_0000403',
       'EFO_1000657', 'EFO_0002429', 'EFO_0000211'], dtype=object), 'count': 15}_|_[ENSG00000097007,ENSG00000213923,ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for marginal zone b-cell lymphoma and follicular lymphoma and has 13 investigational indications."
CHEMBL3990014,"nan_|_nan_|_Antibody_|_False_|_MIRIKIZUMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Omvoh']_|_['LY-3074828' 'LY3074828' 'Mirikizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0000676', 'EFO_0000729'], dtype=object), 'count': 3}_|_[ENSG00000113302,ENSG00000110944]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for ulcerative colitis and has 2 investigational indications."
CHEMBL421,"O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O_|_NCEXYHBECQHGNR-QZQOTICOSA-N_|_Small molecule_|_False_|_SULFASALAZINE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_['Azulfidine' 'Azulfidine EN' 'Azulfidine en-tabs' 'Colizine' 'S.a.s.-500'
 'Salazopyrin' 'Salazopyrin e.c.' 'Salazopyrin-en' 'Salazosulfapyridine'
 'Salicylazosulfapyridine' 'Sulfasalazine' 'Ucine']_|_['Azulfidine' 'Benzosulfa' 'NSC-203730' 'NSC-667219' 'SAS-500'
 'Salazosulfapyridine' 'Salicylazosulfapyridine' 'Sulfasalazine'
 'Sulfasalazinum' 'Sulfasalazopyridine' 'Sulphasalazine']_|_[('DailyMed', array(['sulfasalazine'], dtype=object)), ('PubChem', array(['144204588', '144208437', '144210859', '170464716', '17389737',
       '26747277'], dtype=object)), ('TG-GATEs', array(['34'], dtype=object)), ('Wikipedia', array(['Sulfasalazine'], dtype=object)), ('drugbank', array(['DB00795'], dtype=object)), ('chEBI', array(['9334'], dtype=object))]_|_['CHEMBL3765414' 'CHEMBL2311115']_|_{'rows': array(['EFO_0000222', 'EFO_0000685', 'EFO_0006911', 'MONDO_0004565',
       'EFO_0004268', 'EFO_0003917', 'EFO_0003898', 'EFO_0003778',
       'EFO_0000519', 'EFO_0002609', 'EFO_0001361', 'EFO_0003102',
       'EFO_0004149', 'EFO_0000729'], dtype=object), 'count': 14}_|_[ENSG00000073756,ENSG00000095303,ENSG00000012779]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 11 investigational indications."
CHEMBL4250860,"CC(=O)c1nn(CC(=O)N2C[C@H](F)C[C@H]2C(=O)Nc2cccc(Br)n2)c2ccc(-c3cnc(C)nc3)cc12_|_PIBARDGJJAGJAJ-NQIIRXRSSA-N_|_Small molecule_|_False_|_DANICOPAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACH-0144471' 'ACH-4471' 'Ach-0144471' 'Danicopan']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DANICOPAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15401'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0001421', 'MONDO_0100244', 'EFO_1001492',
       'MONDO_0019736', 'MONDO_0100244', 'EFO_0003086'], dtype=object), 'count': 7}_|_[ENSG00000197766]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4297861,"nan_|_nan_|_Antibody_|_False_|_NEIHULIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abgn-168h' 'Neihulizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0003778', 'EFO_0000676', 'EFO_0004599',
       'MONDO_0013730'], dtype=object), 'count': 5}_|_[ENSG00000110876]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4298169,"O=C(O)c1cc(F)c2nc(N3[C@@H]4CC[C@H]3C[C@@H](OCc3c(-c5ccccc5OC(F)(F)F)noc3C3CC3)C4)sc2c1_|_VYLOOGHLKSNNEK-PIIMJCKOSA-N_|_Small molecule_|_False_|_TROPIFEXOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LJN-452' 'LJN452' 'NVP-LJN452-NXA' 'Tropifexor']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TROPIFEXOR/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001249', 'EFO_0003095', 'EFO_1001486'], dtype=object), 'count': 3}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL5314801,"CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@@H](C(=O)O)[C@@H](O[C@H]3O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]4O[C@H](C(=O)O)[C@@H](O[C@H]5O[C@H](COS(=O)(=O)O)[C@@H](OC)[C@H](OC)[C@H]5OC)[C@H](OC)[C@H]4OC)[C@H](OS(=O)(=O)O)[C@H]3OS(=O)(=O)O)[C@H](OC)[C@H]2OC)[C@H](OS(=O)(=O)O)[C@H]1OS(=O)(=O)O_|_AJBMORBNKXNZSF-COSHMZDQSA-N_|_Oligosaccharide_|_False_|_IDRAPARINUX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SR 34006' 'SR-34006' 'Sr34006']_|_nan_|_['CHEMBL5314374']_|_{'rows': array(['EFO_0003907', 'EFO_0003827', 'EFO_0003827', 'EFO_0000275'],
      dtype=object), 'count': 4}_|_[ENSG00000126218]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1102,"CCC1(c2ccccc2)CCC(=O)NC1=O_|_JMBQKKAJIKAWKF-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLUTETHIMIDE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Doriden' 'Glutethimide']_|_['Elrodorm' 'Glutethimide' 'NSC-95239' 'Noxyron' 'Rigenox' 'Sarodormin']_|_[('PubChem', array(['144205194', '170465223', '29215340'], dtype=object)), ('Wikipedia', array(['Glutethimide'], dtype=object)), ('drugbank', array(['DB01437'], dtype=object)), ('chEBI', array(['5439'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976."
CHEMBL1201317,"O=P(O)(O)OCC(Cl)(Cl)Cl_|_YYQRGCZGSFRBAM-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRICLOFOS_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Neguvon' 'Tri-beta-chloroethylphosphate' 'Triclofos']_|_[('Wikipedia', array(['Triclofos'], dtype=object)), ('drugbank', array(['DB06753'], dtype=object)), ('chEBI', array(['9695'], dtype=object))]_|_['CHEMBL1200789']_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1615025,"Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21_|_RCLQNICOARASSR-SECBINFHSA-N_|_Small molecule_|_False_|_TAK-733_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mek inhibitor tak-733' 'TAK-733' 'TAK733' 'Tak 733' 'Tak-733']_|_[('drugbank', array(['DB12241'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002617', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2028850,"N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21_|_QURWXBZNHXJZBE-SKXRKSCCSA-N_|_Protein_|_False_|_ICATIBANT_|_2008.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['HOE-140' 'Icatibant']_|_[('drugbank', array(['DB06196'], dtype=object))]_|_['CHEMBL2028852']_|_{'rows': array(['EFO_0000694', 'MONDO_0044970', 'EFO_1000999', 'EFO_0005251',
       'MONDO_0100096', 'MONDO_0100096', 'MONDO_0019623', 'MONDO_0019623',
       'EFO_0005532', 'MP_0001845', 'EFO_0003144', 'EFO_0005532'],
      dtype=object), 'count': 12}_|_[ENSG00000168398]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for hereditary angioedema and angioedema and has 9 investigational indications."
CHEMBL2105694,"COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C_|_JVBGZFRPTRKSBB-MJBQOYBXSA-N_|_Small molecule_|_False_|_TELAPRISTONE ACETATE_|_nan_|_3.0_|_nan_|_False_|_False_|_['Proellex' 'Proellextm' 'Progenta']_|_['CDB-4124' 'RU 44675' 'RU-44675' 'Telapristone acetate' 'ZPV-200']_|_[('drugbank', array(['DB05253'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'MONDO_0007254', 'EFO_0001065', 'EFO_0003086',
       'EFO_0000731', 'EFO_0010269'], dtype=object), 'count': 6}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2105704,"COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O_|_HWLFIUUAYLEFCT-UHFFFAOYSA-N_|_Small molecule_|_False_|_LENVATINIB MESYLATE_|_2015.0_|_4.0_|_CHEMBL1289601_|_False_|_True_|_['Kisplyx' 'Lenvima']_|_['E-7080 MESYLATE' 'E7080' 'E7080 MESYLATE' 'Lenvatinib mesilate'
 'Lenvatinib mesylate' 'Lenvatinib methanesulfonate']_|_[('DailyMed', array(['lenvatinib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kisplyx'],
      dtype=object)), ('chEBI', array(['85995'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0003060', 'EFO_1001961', 'MONDO_0004992', 'EFO_0000681',
       'EFO_0003060', 'EFO_0002892', 'MONDO_0005184', 'MONDO_0002108',
       'EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 10}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 7 investigational indications."
CHEMBL2109529,nan_|_nan_|_Antibody_|_False_|_MU-BC-1_|_nan_|_1.0_|_nan_|_False_|_False_|_['Angiomab']_|_['MU-BC-1']_|_nan_|_nan_|_nan_|_[ENSG00000115414]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109585,"nan_|_nan_|_Antibody_|_False_|_LY-2382770_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2382770' 'LY2382770' 'Ly-2382770']_|_nan_|_nan_|_{'rows': array(['EFO_0000401'], dtype=object), 'count': 1}_|_[ENSG00000105329]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3899477,"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc2c(c(Nc3ccccc3S(=O)(=O)NC(C)C)n1)CCN2_|_NPJCURIANJMFEO-UHFFFAOYSA-N_|_Small molecule_|_False_|_CONTELTINIB _|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Conteltinib ']_|_nan_|_nan_|_{'rows': array(['EFO_1000359', 'EFO_0003060'], dtype=object), 'count': 2}_|_[ENSG00000169398,ENSG00000140443,ENSG00000171094,ENSG00000120899]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3977543,"Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12_|_KVCQTKNUUQOELD-UHFFFAOYSA-N_|_Small molecule_|_False_|_BELVARAFENIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Belvarafenib']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000132155,ENSG00000157764,ENSG00000078061]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL398707,"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5_|_WVLOADHCBXTIJK-YNHQPCIGSA-N_|_Small molecule_|_False_|_HYDROMORPHONE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dilaudid' 'Dilaudid-HP' 'Dimorphone' 'Hydromorphon' 'Hydromorphone'
 'IDS-NH-004' 'Jurnista' 'N02AA03' 'NSC-19046' 'Novolaudon' 'Palladone']_|_[('Wikipedia', array(['Hydromorphone'], dtype=object)), ('drugbank', array(['DB00327'], dtype=object)), ('chEBI', array(['5790'], dtype=object))]_|_['CHEMBL3989585' 'CHEMBL1237055']_|_{'rows': array(['EFO_1000786', 'HP_0012532', 'EFO_0010702', 'EFO_0001421',
       'HP_0003419', 'EFO_0801084', 'EFO_0005611', 'EFO_0004616',
       'EFO_0003890', 'EFO_0003843', 'HP_0002019', 'EFO_0004616',
       'MONDO_0004567', 'HP_0003418', 'EFO_1000786', 'EFO_0000546',
       'EFO_0004240', 'MONDO_0002367', 'EFO_0801084', 'EFO_1001898',
       'EFO_0003843', 'MONDO_0011382', 'HP_0012532'], dtype=object), 'count': 23}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for drug dependence and pain and has 16 investigational indications."
CHEMBL4216467,"CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21_|_CEFJVGZHQAGLHS-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIPRETINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Qinlock']_|_['DCC-2618' 'Dcc-2618' 'Ripretinib']_|_[('DailyMed', array(['ripretinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock'],
      dtype=object)), ('drugbank', array(['DB14840'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0011719'], dtype=object), 'count': 2}_|_[ENSG00000134853,ENSG00000157404]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and gastrointestinal stromal tumor."
CHEMBL465,"CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21_|_CYQFCXCEBYINGO-IAGOWNOFSA-N_|_Small molecule_|_False_|_DRONABINOL_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Dronabinol' 'Marinol' 'Syndros']_|_['.delta.-9-tetrahydrocannabinol' '.delta.1-thc'
 '.delta.9-tetrahydrocannabinol' '.delta.9-thc' 'ABBOTT 40566'
 'ABBOTT-40566' 'Delta-9-tetrahydrocannabinol' 'Delta-9-thc' 'Dronabinol'
 'J882F' 'NSC-134454' 'QCD 84924' 'QCD-84924' 'SP 104' 'SP-104'
 'Tetrahydrocannabinol' 'Tetrahydrocannabinols (-)-trans-.delta.9-form']_|_[('DailyMed', array(['dronabinol'], dtype=object)), ('PubChem', array(['144206169'], dtype=object)), ('Wikipedia', array(['Tetrahydrocannabinol'], dtype=object)), ('drugbank', array(['DB00470'], dtype=object)), ('chEBI', array(['66964'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_0003778', 'MONDO_0005301', 'EFO_0007191',
       'EFO_0001358', 'HP_0002018', 'MONDO_0005475', 'EFO_0006911',
       'HP_0100543', 'HP_0003040', 'EFO_0004895', 'HP_0002039',
       'EFO_0003890', 'EFO_0003918', 'EFO_0004329', 'MONDO_0004976',
       'MONDO_0004992', 'HP_0002017', 'MONDO_0011382', 'EFO_0000555',
       'EFO_0003756', 'HP_0012532', 'HP_0012167', 'HP_0000726',
       'HP_0000473', 'EFO_0003843', 'MONDO_0007079', 'MONDO_0004985',
       'MONDO_0005351', 'MONDO_0005090', 'EFO_0005762', 'MONDO_0005148',
       'EFO_0005611', 'EFO_0003108', 'EFO_0004616', 'MONDO_0100431'],
      dtype=object), 'count': 36}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 5 approved and 31 investigational indications."
CHEMBL569713,"CN1[C@@H]2C[C@@H](OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@@H]1O[C@@H]12_|_STECJAGHUSJQJN-FWXGHANASA-N_|_Small molecule_|_False_|_SCOPOLAMINE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Isoptpo Hyoscine' 'Scopolamine' 'Transderm scop']_|_['Scopolamine']_|_[('DailyMed', array(['scopolamine'], dtype=object)), ('drugbank', array(['DB00747'], dtype=object)), ('chEBI', array(['16794'], dtype=object))]_|_['CHEMBL2251240' 'CHEMBL3185877' 'CHEMBL1530287' 'CHEMBL1877254']_|_{'rows': array(['HP_0002027', 'EFO_1001412', 'HP_0002018', 'EFO_0006928',
       'EFO_1001917', 'MONDO_0004985', 'EFO_0003843', 'EFO_0006928',
       'MONDO_0002009', 'HP_0002017', 'MONDO_0002050', 'MONDO_0002009',
       'HP_0002307', 'HP_0000726', 'EFO_0000544', 'MONDO_0004976',
       'EFO_0003843', 'EFO_0004888', 'MONDO_0004975'], dtype=object), 'count': 19}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 4 approved and 14 investigational indications."
CHEMBL1093,"CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC_|_QTGIAADRBBLJGA-UHFFFAOYSA-N_|_Small molecule_|_False_|_ARTICAINE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['40 045' '40-045' 'Articaine' 'Carticaine' 'HOE 045' 'HOE-045'
 'Septocaine']_|_[('Wikipedia', array(['Articaine'], dtype=object)), ('drugbank', array(['DB09009'], dtype=object))]_|_['CHEMBL1200819']_|_{'rows': array(['EFO_1001139', 'EFO_1002048', 'EFO_0000649', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 investigational indications."
CHEMBL1200419,"CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2.Cl_|_GQWNECFJGBQMBO-UHFFFAOYSA-N_|_Small molecule_|_True_|_MOLINDONE HYDROCHLORIDE_|_1974.0_|_4.0_|_CHEMBL460_|_False_|_True_|_['Moban' 'Molindone hydrochloride']_|_['EN-1733A' 'Molindone hcl' 'Molindone hydrochloride']_|_[('DailyMed', array(['molindone%20hydrochloride'], dtype=object)), ('PubChem', array(['144204130', '170465047', '26753596', '49648854'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for schizophrenia. This drug has a black box warning from the FDA."
CHEMBL1200444,"CC(=O)O.CC(C)(C)NCC(O)c1ccc(O)c(CO)n1_|_QSXMZJGGEWYVCN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIRBUTEROL ACETATE_|_1986.0_|_4.0_|_CHEMBL1094966_|_False_|_True_|_['Maxair']_|_['CP-24,314-14' 'CP-24314-14' 'Pirbuterol acetate'
 'Pirbuterol monoacetate' 'Spirolair']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for asthma."
CHEMBL1200487,"C=C(CC)C(=O)c1ccc(OCC(=O)[O-])c(Cl)c1Cl.[Na+]_|_CWCSCNSKBSCYCS-UHFFFAOYSA-M_|_Small molecule_|_False_|_ETHACRYNATE SODIUM_|_1967.0_|_4.0_|_CHEMBL456_|_False_|_True_|_['Edecrin' 'Ethacrynate sodium']_|_['Etacrynate sodium' 'Ethacrynate sodium' 'Ethacrynic acid sodium salt'
 'Sodium etacrynate' 'Sodium ethacrynate']_|_[('DailyMed', array(['ethacrynate%20sodium'], dtype=object))]_|_nan_|_nan_|_[ENSG00000074803]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967."
CHEMBL1200699,"C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O_|_XQTWDDCIUJNLTR-CVHRZJFOSA-N_|_Small molecule_|_False_|_DOXYCYCLINE_|_1967.0_|_4.0_|_CHEMBL1433_|_False_|_True_|_['Doxirobe' 'Doxychel' 'Doxycycline' 'Monodox' 'Oracea' 'Vibramycin']_|_['Doxirobe' 'Doxycycline' 'Doxycycline monohydrate' 'Doxylin' 'GS-3065'
 'Supracyclin' 'Xyrosa']_|_[('DailyMed', array(['doxycycline'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/doxirobe'],
      dtype=object)), ('chEBI', array(['60648'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008510', 'EFO_1001466', 'EFO_0002618', 'EFO_1000906',
       'EFO_0009536', 'EFO_0000341', 'EFO_0004214', 'MONDO_0007039',
       'EFO_0009659', 'EFO_0003102', 'MONDO_0018076', 'EFO_0001068',
       'EFO_0000662', 'EFO_0009425', 'EFO_0007470', 'MONDO_0007947',
       'EFO_0000778', 'EFO_0000574', 'EFO_1002047', 'EFO_0007460',
       'HP_0001250', 'MONDO_0004992', 'EFO_0000729', 'EFO_0007205',
       'EFO_1001788', 'MONDO_0100096', 'MONDO_0009061', 'MONDO_0019438',
       'MP_0001914', 'EFO_0007430', 'EFO_0000612', 'EFO_1001051',
       'MONDO_0004975', 'MONDO_0005178', 'EFO_0002913', 'EFO_0003770',
       'EFO_0007185', 'EFO_0000384', 'EFO_1001235', 'EFO_0000464',
       'EFO_0000199', 'EFO_0003894', 'EFO_0000756', 'EFO_1001951',
       'EFO_1001388', 'EFO_0000649', 'EFO_1000760', 'EFO_0000274',
       'MONDO_0002635', 'EFO_0000365', 'EFO_0000771', 'MONDO_0005180',
       'MONDO_0017816', 'EFO_0003878', 'EFO_0005952', 'EFO_0009117',
       'HP_0000964', 'EFO_0008517', 'EFO_0007272', 'EFO_0007480',
       'EFO_0000096', 'EFO_0003106', 'EFO_0000544', 'EFO_1001459',
       'EFO_1001875', 'EFO_0007410', 'EFO_0003843', 'DOID_7551',
       'EFO_0003060', 'EFO_0005044', 'EFO_0007504', 'EFO_1000785',
       'EFO_0000768', 'EFO_0007357', 'EFO_0009637', 'EFO_1001444',
       'EFO_0002687'], dtype=object), 'count': 77}_|_[ENSG00000137673,ENSG00000137745,ENSG00000118113,ENSG00000196611]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 15 approved and 62 investigational indications."
CHEMBL1200982,"CCC(C)C1(CC)C(=O)[N-]C(=O)NC1=O.[Na+]_|_QORQZMBCPRBCAB-UHFFFAOYSA-M_|_Small molecule_|_False_|_BUTABARBITAL SODIUM_|_1939.0_|_4.0_|_CHEMBL449_|_False_|_True_|_['Butabarb' 'Butabarbital' 'Butabarbital sodium' 'Butalan' 'Buticaps'
 'Butisol sodium' 'Sarisol' 'Sarisol no. 1' 'Sarisol no. 2'
 'Sodium butabarbital']_|_['Astrudion' 'Butabarbital sodium' 'Butabarbital sodium salt' 'Loubarb'
 'Mebutal' 'NSC-11778' 'Secbutabarbital sodium']_|_nan_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1939."
CHEMBL1201149,"Cl.O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5_|_RHBRMCOKKKZVRY-ITLPAZOVSA-N_|_Small molecule_|_True_|_NALTREXONE HYDROCHLORIDE_|_1984.0_|_4.0_|_CHEMBL19019_|_False_|_True_|_['Adepend' 'Depade' 'Nalorex' 'Naltrexone hydrochloride' 'Opizone' 'Revia']_|_['EN-1639A' 'EN-1639A (AS HYDROCHLORIDE)' 'Naltrexone hcl'
 'Naltrexone hydrochloride' 'Trexan']_|_[('DailyMed', array(['naltrexone%20hydrochloride'], dtype=object)), ('PubChem', array(['56422210', '855955'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005203', 'HP_0100716', 'MONDO_0100096', 'MONDO_0015626',
       'EFO_0005611', 'HP_0012532', 'EFO_0010702', 'EFO_0003843',
       'EFO_0004701', 'EFO_0004329'], dtype=object), 'count': 10}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for pain and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201264,"CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21_|_GZHFODJQISUKAY-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHANTHELINE_|_1951.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Methantheline' 'Methantheline cation' 'Methantheline ion'
 'Methanthelinium']_|_[('PubChem', array(['11112123'], dtype=object)), ('Wikipedia', array(['Methantheline'], dtype=object)), ('drugbank', array(['DB00940'], dtype=object)), ('chEBI', array(['6817'], dtype=object))]_|_['CHEMBL1200988']_|_{'rows': array(['HP_0000011', 'EFO_0010282'], dtype=object), 'count': 2}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for gastrointestinal disease and has 1 investigational indication."
CHEMBL1269102,"CC(C)C[C@@H]1NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O_|_VYCMAAOURFJIHD-AOYLRGCGSA-N_|_Protein_|_False_|_BQ-123_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BQ-123' 'BQ123' 'Bq-123' 'Cyclo(d-trp-d-asp-pro-d-val-leu)']_|_[('Wikipedia', array(['BQ-123'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001645', 'EFO_0000319', 'EFO_0002687', 'EFO_0003144',
       'EFO_0008585', 'MONDO_0005149'], dtype=object), 'count': 6}_|_[ENSG00000151617]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL12856,"Nc1cc(-c2ccncc2)c[nH]c1=O_|_RNLQIBCLLYYYFJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_INAMRINONE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amcoral' 'Amrinone' 'C01CE01' 'Cartonic' 'Cordemcura' 'Inamrinone'
 'NSC-759805' 'Vesistol' 'WIN 40680' 'WIN-40680' 'Wincoram']_|_[('PubChem', array(['11112811', '11533005', '124882647', '144205663', '144212164',
       '170465367', '26750001', '26757798', '56424028'], dtype=object)), ('Wikipedia', array(['Amrinone'], dtype=object)), ('drugbank', array(['DB01427'], dtype=object))]_|_['CHEMBL2096642']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000172572]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for cardiovascular disease."
CHEMBL1519,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21_|_VXFJYXUZANRPDJ-WTNASJBWSA-N_|_Small molecule_|_True_|_TRANDOLAPRIL_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Gopten' 'Mavik' 'Odrik' 'Trandolapril']_|_['Indolapril' 'NSC-758939' 'RU 44570' 'RU-44570' 'Trandolapril']_|_[('DailyMed', array(['trandolapril'], dtype=object)), ('PubChem', array(['144205006', '144206703', '90340949'], dtype=object)), ('Wikipedia', array(['Trandolapril'], dtype=object)), ('drugbank', array(['DB00519'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0003144', 'EFO_0000537', 'EFO_0000612'],
      dtype=object), 'count': 4}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved indications. This drug has a black box warning from the FDA."
CHEMBL1788132,"CC(Oc1c(Cl)cccc1Cl)C1=NCCN1.Cl_|_DWWHMKBNNNZGHF-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOFEXIDINE HYDROCHLORIDE_|_2018.0_|_4.0_|_CHEMBL17860_|_False_|_True_|_['Britlofex' 'Lucemyra']_|_['Lofexidine hcl' 'Lofexidine hydrochloride' 'MDL 14,042' 'MDL-14042'
 'NSC-759654']_|_nan_|_nan_|_{'rows': array(['EFO_0005800', 'EFO_0005611'], dtype=object), 'count': 2}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for substance withdrawal syndrome and has 1 investigational indication."
CHEMBL2105395,"OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1_|_LUMKNAVTFCDUIE-VHXPQNKSSA-N_|_Small molecule_|_True_|_OSPEMIFENE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Osphena' 'Senshio']_|_['(deaminohydroxy) toremifene' 'FC-1271' 'FC-1271A' 'Ospemifene'
 'Tore iii']_|_[('DailyMed', array(['ospemifene'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/senshio'],
      dtype=object)), ('Wikipedia', array(['Ospemifene'], dtype=object)), ('drugbank', array(['DB04938'], dtype=object)), ('chEBI', array(['73275'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001271', 'EFO_0000512', 'HP_0030016', 'GO_0042697',
       'EFO_1000096'], dtype=object), 'count': 5}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2105662,"CS(=O)(=O)O.O=C(NC1CCN(CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c3ccccc32)CC1)c1ccccc1-c1ccc(C(F)(F)F)cc1_|_QKVKOFVWUHNEBX-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOMITAPIDE MESYLATE_|_2012.0_|_4.0_|_CHEMBL354541_|_False_|_True_|_['Juxtapid' 'Lojuxta']_|_['AEGR-733' 'AEGR-733 MESYLATE' 'Aegr-733 mesilate' 'BMS-201038'
 'BMS-201038-04' 'Lomitapide mesilate' 'Lomitapide mesylate']_|_[('DailyMed', array(['lomitapide%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta'],
      dtype=object)), ('chEBI', array(['72299'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018328', 'HP_0003124', 'MONDO_0021187', 'EFO_0004911'],
      dtype=object), 'count': 4}_|_[ENSG00000138823,ENSG00000185624]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2107832,"O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F_|_VIUAUNHCRHHYNE-JTQLQIEISA-N_|_Small molecule_|_False_|_PIMASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Msc1936369a; as703026; emd 1036239']_|_['AS 703026' 'AS-703026' 'AS703026' 'As-703026' 'EMD 1036239'
 'EMD-1036239' 'G-02443714' 'MSC-1936369A' 'MSC-1936369B' 'MSC1936369A'
 'Msc-1936369' 'Pimasertib']_|_[('drugbank', array(['DB14904'], dtype=object))]_|_['CHEMBL4297676']_|_{'rows': array(['EFO_0000389', 'EFO_0000756', 'EFO_0000641', 'EFO_0003060',
       'MONDO_0008170', 'EFO_1001951', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0000182', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0016691',
       'EFO_0000222', 'EFO_0002618'], dtype=object), 'count': 14}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications."
CHEMBL2108718,"nan_|_nan_|_Oligosaccharide_|_False_|_SEMULOPARIN SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AVE-5026' 'Semuloparin sodium']_|_nan_|_nan_|_{'rows': array(['HP_0004936', 'EFO_0004286'], dtype=object), 'count': 2}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109266,"nan_|_nan_|_Antibody drug conjugate_|_False_|_AVE-9633_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AVE-9633' 'Ave-9633' 'HUMY9-6']_|_nan_|_nan_|_{'rows': array(['MONDO_0004643'], dtype=object), 'count': 1}_|_[ENSG00000105383]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109584,"nan_|_nan_|_Antibody_|_False_|_F16SIP 131I_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['F16SIP' 'F16sip 131i']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000041982]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2360079,"CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O_|_NUKVZKPNSKJGBK-SPIKMXEPSA-N_|_Small molecule_|_False_|_ACETOPHENAZINE MALEATE_|_1961.0_|_4.0_|_CHEMBL1085_|_False_|_True_|_['Tindal']_|_['Acephenazine dimaleate' 'Acetophenazine dimaleate'
 'Acetophenazine maleate' 'NSC-169180' 'NSC-70600' 'SCH 6673' 'SCH-6673']_|_[('PubChem', array(['144206283'], dtype=object)), ('chEBI', array(['2402'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL3186534,"N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1_|_WPEWQEMJFLWMLV-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIVOCERANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Apatinib' 'Apatinib free base' 'Rivoceranib' 'YN968D1'
 'YN968D1 FREE BASE']_|_[('PubChem', array(['124955476'], dtype=object)), ('drugbank', array(['DB14765'], dtype=object))]_|_['CHEMBL3545414']_|_{'rows': array(['EFO_1000359', 'EFO_0004252', 'EFO_0000231', 'MONDO_0007254',
       'EFO_0000231', 'EFO_0001061', 'EFO_0000756', 'EFO_0000702',
       'EFO_0000178', 'MONDO_0008170', 'EFO_0006859', 'EFO_1001968',
       'EFO_0005221', 'MONDO_0003060', 'MONDO_0002120', 'EFO_0004142',
       'EFO_0000616', 'MONDO_0001056', 'EFO_0003868', 'EFO_1001951',
       'MONDO_0004992', 'MONDO_0011719', 'EFO_0000182', 'EFO_0000313',
       'EFO_0000571', 'MONDO_0008903', 'EFO_1001961', 'MONDO_0021063',
       'EFO_1001956', 'EFO_0002939', 'EFO_0001071', 'EFO_0005537',
       'MONDO_0100342', 'EFO_0000503', 'EFO_0000199', 'MONDO_0002108',
       'EFO_0004284', 'EFO_0003060', 'MONDO_0005575', 'EFO_0003869',
       'HP_0001541', 'MONDO_0002974', 'EFO_0003891', 'EFO_0000637',
       'EFO_0002916', 'EFO_0000182', 'EFO_0005543', 'EFO_0003897',
       'EFO_0000181', 'EFO_0000616', 'EFO_0005922', 'EFO_0000691',
       'EFO_0003893', 'EFO_0000621', 'MONDO_0018944', 'EFO_0000707',
       'EFO_0000211', 'MONDO_0007576', 'EFO_0002618', 'EFO_1002017',
       'EFO_0009708', 'EFO_0000365', 'EFO_0000574', 'EFO_0000503',
       'EFO_0003860', 'EFO_0000681', 'MONDO_0008315'], dtype=object), 'count': 67}_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 64 investigational indications."
CHEMBL3545423,"NC1CCCN(c2c(/C=C3/SC(=O)NC3=O)cccc2-c2ccccc2)C1_|_MCUJKPPARUPFJM-LDADJPATSA-N_|_Small molecule_|_False_|_AZD-1208_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Azd 1208' 'Azd-1208']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'MONDO_0004992', 'EFO_0000222'], dtype=object), 'count': 3}_|_[ENSG00000137193,ENSG00000102096,ENSG00000198355]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3786098,"C=CC(=O)N1C[C@H](COc2nc(Nc3cnn(C)c3)nc3[nH]cc(Cl)c23)[C@@H](OC)C1_|_ODMXWZROLKITMS-RISCZKNCSA-N_|_Small molecule_|_False_|_PF-06459988_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-06459988' 'Pf-06459988']_|_[('drugbank', array(['DB14768'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3822773,"O=C(O)c1ccc([C@H]2C[C@@H]2c2ccc(OCc3c(-c4c(Cl)cccc4Cl)noc3C3CC3)cc2Cl)cc1_|_XBUXXJUEBFDQHD-NHCUHLMSSA-N_|_Small molecule_|_False_|_PX-102_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Px-102' 'Px-104']_|_[('drugbank', array(['DB15416'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003095'], dtype=object), 'count': 1}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3833343,"nan_|_nan_|_Antibody_|_False_|_VOBARILIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALX-0061' 'ALX0061' 'Vobarilizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0007915'], dtype=object), 'count': 2}_|_[ENSG00000160712]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3916700,"COc1cc(NC(=O)OCCN(C)[C@H]2CC[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12_|_SNXJYSXRLKUBSZ-WBXFWKJNSA-N_|_Small molecule_|_False_|_LAS190792_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Azd 8999' 'LAS-190792' 'Las190792']_|_nan_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000169252,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3989556,"CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC.Cl.O_|_SPFVHFBNXPARTR-IDMXKUIJSA-N_|_Small molecule_|_False_|_REMOXIPRIDE HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL22242_|_True_|_True_|_['Roxiam' 'Roxiam ir']_|_['(-)-FLA-731' 'A 33547.HCL.H20' 'FLA 731(-)' 'FLA-731' 'Remoxipride hcl'
 'Remoxipride hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. It was withdrawn in at least one region."
CHEMBL4116008,"CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1_|_BGLPECHZZQDNCD-UHFFFAOYSA-N_|_Small molecule_|_False_|_CERDULATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cerdulatinib' 'PRT-062070' 'Prt-2070' 'RVT-502']_|_[('drugbank', array(['DB15499'], dtype=object))]_|_['CHEMBL3991929']_|_{'rows': array(['EFO_0004208', 'EFO_0000095', 'MONDO_0019473', 'MONDO_0018906'],
      dtype=object), 'count': 4}_|_[ENSG00000162434,ENSG00000165025,ENSG00000105397,ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297329,"C[C@]1(O)C[C@@](N)(c2ccc(-c3nc4n(c3-c3ccccc3)COc3ccncc3-4)cc2)C1_|_AIFGVDXMHWGOGJ-DIVCQZSQSA-N_|_Small molecule_|_False_|_PIFUSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pifusertib' 'TAS 117' 'Tas-117']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('drugbank', array(['DB15054'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297344,"FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1_|_OZOGDCZJYVSUBR-UHFFFAOYSA-N_|_Small molecule_|_False_|_OBEFAZIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABX-464' 'ABX464' 'Abx 464' 'Abx-464' 'Abx464' 'Obefazimod' 'SPL-464']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OBEFAZIMOD/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14828'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_0000685', 'MONDO_0100096', 'EFO_0000729',
       'EFO_0000384'], dtype=object), 'count': 5}_|_[ENSG00000114503,ENSG00000136937]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297775,"nan_|_nan_|_Unknown_|_False_|_KAI-1678_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['KP-1678' 'Kai-1678']_|_nan_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_1001919', 'MONDO_0041052'], dtype=object), 'count': 3}_|_[ENSG00000171132]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL435224,"COc1cccc([C@H]2O[C@H](CC(=O)N3CCC(CC(=O)O)CC3)C(=O)N(CC(C)(C)COC(C)=O)c3ccc(Cl)cc32)c1OC_|_CMLUGNQVANVZHY-POURPWNDSA-N_|_Small molecule_|_False_|_LAPAQUISTAT ACETATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Lapaquistat acetate' 'TAK 475' 'TAK-475']_|_nan_|_nan_|_{'rows': array(['MONDO_0021187', 'Orphanet_309005', 'HP_0003124', 'MONDO_0005148'],
      dtype=object), 'count': 4}_|_[ENSG00000079459]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4594447,"CCCNCCOc1cc(F)cc(S(C)(=O)=O)c1_|_OSBPYFBXSLJHCR-UHFFFAOYSA-N_|_Small molecule_|_False_|_MESDOPETAM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IRL-790' 'IRL790' 'Irl790' 'Mesdopetam']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650334,"C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1_|_CMLVKUWQFZQPPS-YUNKPMOVSA-N_|_Small molecule_|_False_|_ALDUMASTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aldumastat' 'G-504572' 'G504572' 'GLPG-1972' 'GLPG1972' 'Glpg1972'
 'S-201086' 'S201086']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ALDUMASTAT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}_|_[ENSG00000154736]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL513994,N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F_|_IENZFHBNCRQMNP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRX-08066_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL4297322']_|_nan_|_[ENSG00000135914]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL5314398,O=C(Nc1cccc2cnccc12)N[C@@H]1CC2(CCC2)Oc2ccc(F)cc21_|_JADKHWDNSKIILG-LJQANCHMSA-N_|_Small molecule_|_False_|_GRC-6211_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GRC6211' 'Grc-6211']_|_nan_|_nan_|_nan_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL56564,"CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)c1c[nH]c3ccccc13)C2_|_ZNRGQMMCGHDTEI-ITGUQSILSA-N_|_Small molecule_|_False_|_TROPISETRON_|_nan_|_4.0_|_nan_|_False_|_True_|_['Navoban']_|_['ICS-205-930' 'NSC-759842' 'Novaban' 'SDZ-ICS-930' 'Tropisetron'
 'Tropisetron (as hydrochloride)' 'Tropisetron hcl'
 'Tropisetron hydrochloride' 'Tropisetron monohydrochloride']_|_[('PubChem', array(['26755041'], dtype=object)), ('drugbank', array(['DB11699'], dtype=object)), ('chEBI', array(['32269'], dtype=object))]_|_['CHEMBL3348564' 'CHEMBL2130744']_|_{'rows': array(['EFO_0006911', 'HP_0002017', 'EFO_0003843', 'HP_0002018'],
      dtype=object), 'count': 4}_|_[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for chemotherapy-induced nausea and vomiting and nausea and has 2 investigational indications."
CHEMBL709,"COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC_|_WNMJYKCGWZFFKR-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALFUZOSIN_|_2003.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Alfuzosin' 'NSC-760065' 'Uroxatral']_|_[('PubChem', array(['174007387', '26719847', '26749009', '26749010', '50107503',
       '50107504', '90341616'], dtype=object)), ('Wikipedia', array(['Alfuzosin'], dtype=object)), ('drugbank', array(['DB00346'], dtype=object)), ('chEBI', array(['51141'], dtype=object))]_|_['CHEMBL1723']_|_{'rows': array(['EFO_0000284', 'HP_0002019', 'EFO_0003830', 'EFO_0000284',
       'MONDO_0005301', 'EFO_1001228', 'EFO_0004253', 'HP_0000016',
       'HP_0000011', 'EFO_0004253'], dtype=object), 'count': 10}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for benign prostatic hyperplasia and has 7 investigational indications."
CHEMBL1087,"Cc1cccc(C)c1NC(=O)C1CCCCN1C_|_INWLQCZOYSRPNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPIVACAINE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[""1-methyl-2',6'-pipecoloxylidide"" ""2',6'-pipecoloxylidide, 1-methyl-""
 'APF-135' 'Carbocaine' 'Carboplyin dental' 'Dl-mepivacaine' 'Mepisv'
 'Mepivacaine' 'Polocaine' 'Polocaine-Mpf' 'Tevacaine']_|_[('Wikipedia', array(['Mepivacaine'], dtype=object)), ('drugbank', array(['DB00961'], dtype=object)), ('chEBI', array(['6759'], dtype=object))]_|_['CHEMBL1200440']_|_{'rows': array(['MONDO_0004001', 'EFO_0004616', 'EFO_1000786', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 investigational indications."
CHEMBL1200648,"C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1.[Br-]_|_OYTJKRAYGYRUJK-FMCCZJBLSA-M_|_Small molecule_|_False_|_ROCURONIUM BROMIDE_|_1994.0_|_4.0_|_CHEMBL1201244_|_False_|_True_|_['Esmeron' 'Rocuronium bromide' 'Zemuron']_|_['ORG 9426' 'ORG-9426' 'Rocuronium bromide']_|_[('DailyMed', array(['rocuronium%20bromide'], dtype=object)), ('PubChem', array(['144205990'], dtype=object)), ('chEBI', array(['8885'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007490', 'EFO_0009492', 'HP_0003418'], dtype=object), 'count': 3}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 investigational indications."
CHEMBL1201180,"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl.OCCN1CCCC1_|_DCERVXIINVUMKU-UHFFFAOYSA-N_|_Small molecule_|_True_|_DICLOFENAC EPOLAMINE_|_2007.0_|_4.0_|_CHEMBL139_|_False_|_True_|_['Flector' 'Flector Patch' 'Licart']_|_['Diclofenac epolamine' 'Diclofenac epolaminum']_|_[('DailyMed', array(['diclofenac%20epolamine'], dtype=object)), ('chEBI', array(['48296'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0009582', 'EFO_0003843', 'EFO_1000652'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for sprain and pain and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743050,"nan_|_nan_|_Antibody_|_False_|_OLOKIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CDP-6038' 'CDP6038' 'Olokizumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000384', 'EFO_0000540', 'EFO_0000685',
       'MONDO_0005178'], dtype=object), 'count': 5}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL18,"CCOc1ccc2nc(S(N)(=O)=O)sc2c1_|_OUZWUKMCLIBBOG-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETHOXZOLAMIDE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Cardrase' 'Ethamide']_|_['Ethoxzolamide' 'NSC-10679']_|_[('PubChem', array(['144204399', '170465083', '56422188', '855751'], dtype=object)), ('Wikipedia', array(['Ethoxzolamide'], dtype=object)), ('drugbank', array(['DB00311'], dtype=object)), ('chEBI', array(['101096'], dtype=object))]_|_nan_|_nan_|_[ENSG00000104267,ENSG00000168748,ENSG00000133742,ENSG00000164879,ENSG00000131686,ENSG00000074410,ENSG00000118298,ENSG00000107159,ENSG00000167434,ENSG00000185015,ENSG00000169239,ENSG00000174990]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1933350,"CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12_|_FYRJJCYFYLLOSC-LXFBAYGMSA-N_|_Small molecule_|_False_|_MK-3577_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-3577']_|_[('drugbank', array(['DB14957'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000215644]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1947204,"C=CC(=O)Nc1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1_|_MVZGYPSXNDCANY-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALLITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALL-3' 'AST-1306' 'Allitinib' 'Als 1306' 'Ast 1306' 'Ast-1306' 'Ast1306']_|_nan_|_['CHEMBL4779286']_|_{'rows': array(['MONDO_0008903'], dtype=object), 'count': 1}_|_[ENSG00000141736,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2103736,"CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.CC(C(=O)[O-])c1cccc(Oc2ccccc2)c1.O.O.[Ca+2]_|_LZPBLUATTGKZBH-UHFFFAOYSA-L_|_Small molecule_|_True_|_FENOPROFEN CALCIUM_|_1976.0_|_4.0_|_CHEMBL1297_|_False_|_True_|_['Fenoprofen calcium' 'Nalfon']_|_['69323' 'Fenoprofen calcium' 'Fenoprofen calcium salt dihydrate'
 'Fenopron' 'Fepron' 'Feprona' 'Nalgesic']_|_[('DailyMed', array(['fenoprofen%20calcium'], dtype=object)), ('chEBI', array(['5005'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for osteoarthritis and rheumatoid arthritis. This drug has a black box warning from the FDA."
CHEMBL2109528,"nan_|_nan_|_Antibody_|_False_|_FASINUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fasinumab' 'REGN-475' 'REGN475' 'SAR-164877' 'SAR164877']_|_nan_|_nan_|_{'rows': array(['HP_0003418', 'HP_0011868', 'EFO_1000786', 'EFO_0004616',
       'HP_0003419', 'MONDO_0005178', 'HP_0002027'], dtype=object), 'count': 7}_|_[ENSG00000134259]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2109589,"nan_|_nan_|_Antibody_|_False_|_L19TNFA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['L19TNFA' 'L19tnfa']_|_nan_|_nan_|_{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}_|_[ENSG00000115414]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2153191,"CCCSc1nc(N2CCC[C@@H](CC(=O)O)C2)ccc1C(=O)NC1CCCCC1_|_NCDZABJPWMBMIQ-INIZCTEOSA-N_|_Small molecule_|_False_|_AZD-4017_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-4017' 'AZD4017' 'Azd 4017' 'Azd-4017']_|_[('drugbank', array(['DB14875'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_1001132', 'EFO_1001110', 'EFO_1001069',
       'EFO_0001073'], dtype=object), 'count': 5}_|_[ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3039498,"CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1_|_HZVLFTCYCLXTGV-UHFFFAOYSA-N_|_Small molecule_|_False_|_GRAPIPRANT_|_2018.0_|_2.0_|_nan_|_False_|_False_|_['Galliprant']_|_['423' 'AAT-007' 'CJ 023423' 'CJ-023' 'CJ-023423' 'Cj-023,423'
 'Grapiprant' 'MR-10A7' 'MR10A7' 'RQ-00000007' 'RQ-7']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/galliprant'],
      dtype=object)), ('drugbank', array(['DB12836'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0005178', 'EFO_0000305', 'EFO_1001951'],
      dtype=object), 'count': 4}_|_[ENSG00000171522]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) that was first approved in 2018 and has 4 investigational indications."
CHEMBL3137331,"CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1_|_FWLMVFUGMHIOAA-UHFFFAOYSA-N_|_Small molecule_|_False_|_DEFACTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Defactinib' 'PF-04554878' 'VS-6063' 'Vs-6063']_|_[('drugbank', array(['DB12282'], dtype=object))]_|_['CHEMBL3137305']_|_{'rows': array(['MONDO_0005184', 'EFO_0000466', 'EFO_0002618', 'EFO_0001378',
       'EFO_0000770', 'MONDO_0021148', 'EFO_0003060', 'MONDO_0004992',
       'MONDO_0008170', 'EFO_0000770', 'MONDO_0008170', 'EFO_0000519'],
      dtype=object), 'count': 12}_|_[ENSG00000120899,ENSG00000169398]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL3545165,"O=C1Nc2ccccc2C(c2ccccc2)N1C1CCN(Cc2cccc(OC(F)(F)F)c2)CC1_|_IJUMFEAYOMCXAQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_AFACIFENACIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Afacifenacin' 'NS-986' 'Smp-986']_|_nan_|_nan_|_{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}_|_[ENSG00000185313,ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984,ENSG00000168356]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545279,"Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N.Cl.Cl_|_WFIOHOJEIMQCEG-UHFFFAOYSA-N_|_Small molecule_|_False_|_EFATUTAZONE HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL3545280_|_False_|_False_|_[]_|_['CS-7017' 'Efatutazone dihydrochloride' 'Efatutazone hydrochloride'
 'Inolitazone dihydrochloride' 'RS5444']_|_nan_|_nan_|_nan_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3931971,"COC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(NS(=O)(=O)O)cc1)c1csc(-c2cccs2)n1_|_KWJDHELCGJFUHW-SFTDATJTSA-N_|_Small molecule_|_False_|_RAZUPROTAFIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AKB-9778' 'Razuprotafib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RAZUPROTAFIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001157', 'EFO_0003770', 'MONDO_0005041'], dtype=object), 'count': 3}_|_[ENSG00000127329]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297625,"CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2_|_XFJAMQQAAMJFGB-ZQGJOIPISA-N_|_Small molecule_|_False_|_LICOGLIFLOZIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LIK-066' 'LIK066' 'Licogliflozin' 'Lik066']_|_[('drugbank', array(['DB15048'], dtype=object))]_|_['CHEMBL4762033']_|_{'rows': array(['EFO_0003086', 'EFO_0000660', 'EFO_0001073', 'MONDO_0005148',
       'EFO_0003095'], dtype=object), 'count': 5}_|_[ENSG00000100170,ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL431651,"CCCOc1ccc2c(c1)[C@@H](c1ccc(OC)cc1OCCO)[C@H](C(=O)O)[C@H]2c1ccc2c(c1)OCO2_|_GLCKXJLCYIJMRB-UPRLRBBYSA-N_|_Small molecule_|_False_|_ENRASENTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Enrasentan' 'SB-217242' 'Sb-217242']_|_[('drugbank', array(['DB06460'], dtype=object))]_|_nan_|_nan_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL432162,"Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2_|_ADXGNEYLLLSOAR-UHFFFAOYSA-N_|_Small molecule_|_False_|_TASOSARTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ANA-756' 'Tasosartan' 'WAY-ANA-756']_|_[('drugbank', array(['DB01349'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594341,"nan_|_nan_|_Antibody_|_False_|_VIXARELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['30C6 [N73D) IgG4P.agly/IgG1' 'BIIB-069' 'BIIB069' 'KPL-716' 'Kpl-716'
 'Vixarelimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VIXARELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000989'], dtype=object), 'count': 1}_|_[ENSG00000145623]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594454,"C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12.Cl.O.O_|_CMDJNMACGABCKQ-XVSRHIFFSA-N_|_Small molecule_|_False_|_RIPASUDIL HYDROCHLORIDE DIHYDRATE_|_nan_|_2.0_|_CHEMBL3426621_|_False_|_False_|_[]_|_['Glanatec' 'K-115' 'K-115-R' 'Ripasudil hydrochloride dihydrate'
 'Ripasudil hydrochloride hydrate']_|_nan_|_nan_|_{'rows': array(['MONDO_0005321'], dtype=object), 'count': 1}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650286,"Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(C(=O)N2CCN(C3COC3)CC2)CC1_|_QAYHKBLKSXWOEO-UHFFFAOYSA-N_|_Small molecule_|_False_|_M4344_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Gartisertib' 'M 4344' 'M-4344' 'M4344' 'VX-803']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000175054]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL46618,"COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1_|_PFGVNLZDWRZPJW-OPAMFIHVSA-N_|_Small molecule_|_False_|_OTAMIXABAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['FXV-673' 'Fxv673' 'Otamixaban' 'RPR-130673' 'RPR130673' 'XRP-0673'
 'XRP0673']_|_[('Wikipedia', array(['Otamixaban'], dtype=object)), ('drugbank', array(['DB06635'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0001421', 'EFO_0001645', 'EFO_0005672'],
      dtype=object), 'count': 4}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL492,"CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C_|_VTUSIVBDOCDNHS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETIDOCAINE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Etidocaine' 'W-19053' 'W-19053 [AS HYDROCHLORIDE]']_|_[('PubChem', array(['144206521'], dtype=object)), ('Wikipedia', array(['Etidocaine'], dtype=object)), ('drugbank', array(['DB08987'], dtype=object)), ('chEBI', array(['4904'], dtype=object))]_|_['CHEMBL1200597']_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976."
CHEMBL526,"CC(C)c1cccc(C(C)C)c1O_|_OLBCVFGFOZPWHH-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPOFOL_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Diprivan' 'Disoprivan' 'Propofol' 'Rapinovet']_|_['Disoprofol' 'Fresofol' 'ICI 35,868' 'ICI 35-868' 'ICI-35868' 'ICI35,868'
 'Lipuro' 'NSC-5105' 'Phenol, 2,6-bis(1-methylethyl)' 'Propofol']_|_[('DailyMed', array(['propofol'], dtype=object)), ('PubChem', array(['104171149', '11111121', '11111122', '124879991', '144203685',
       '144208569', '144213542', '170464994', '17389856', '26747380',
       '47193694', '50105615', '90341256'], dtype=object)), ('Wikipedia', array(['Propofol'], dtype=object)), ('drugbank', array(['DB00818'], dtype=object)), ('chEBI', array(['44915'], dtype=object))]_|_['CHEMBL356637' 'CHEMBL154232']_|_{'rows': array(['EFO_0004698', 'EFO_0000713', 'EFO_0003918', 'EFO_0003870',
       'EFO_0004259', 'EFO_0004888', 'HP_0000989', 'EFO_0001074',
       'EFO_0003855', 'EFO_0005251', 'EFO_0007355', 'MONDO_0002009',
       'EFO_0006834', 'HP_0011110', 'HP_0003418', 'EFO_0002618',
       'EFO_0003884', 'MONDO_0002050', 'EFO_0003917', 'EFO_0002687',
       'HP_0000713', 'EFO_0009267', 'EFO_0004273', 'MONDO_0007576',
       'EFO_1001210', 'EFO_0000662', 'MONDO_0043510', 'EFO_0001073',
       'EFO_0001422', 'HP_0100806', 'EFO_0000616', 'EFO_0009854',
       'EFO_0000537', 'EFO_0003869', 'EFO_0000712', 'HP_0031273',
       'HP_0002093', 'EFO_0007490', 'HP_0000486', 'EFO_0003843',
       'MONDO_0005277', 'EFO_0000546', 'EFO_0000565', 'EFO_1000644',
       'MP_0001845', 'MONDO_0004992', 'EFO_1002048', 'EFO_0000694',
       'EFO_0008526', 'EFO_1000637', 'EFO_1001951', 'EFO_0003777',
       'EFO_1001454', 'EFO_0001645', 'MONDO_0021117'], dtype=object), 'count': 55}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 55 investigational indications."
CHEMBL547,"CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1_|_SHGAZHPCJJPHSC-XFYACQKRSA-N_|_Small molecule_|_True_|_ISOTRETINOIN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Absorica' 'Absorica ld' 'Accutane' 'Amnesteem' 'Claravis' 'Isotrex'
 'Myorisan' 'Roaccutane' 'Sotret' 'Zenatane']_|_['13 Cis-Retinoic Acid' '13-cis-retinoic acid' 'Isotretinoin' 'NSC-758156'
 'PAT-001' 'RO 4-3780' 'RO-4-3780' 'RO-43780' 'Retinoic acid 13-cis-form'
 'Retinoic acid, 13-cis-' 'Vitamin a acid, 13-cis']_|_[('DailyMed', array(['isotretinoin'], dtype=object)), ('PubChem', array(['144207291', '26747659', '26753641', '26753642', '26753643',
       '26753644', '47193696', '50106981', '90341473'], dtype=object)), ('Wikipedia', array(['Isotretinoin'], dtype=object)), ('drugbank', array(['DB00982'], dtype=object)), ('chEBI', array(['6067'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000632', 'EFO_0000180', 'EFO_0000616',
       'EFO_0000565', 'EFO_1001051', 'EFO_0000544', 'MONDO_0008315',
       'EFO_0002501', 'EFO_0000464', 'EFO_0000339', 'EFO_0001378',
       'MONDO_0002974', 'EFO_1000309', 'MONDO_0008903', 'EFO_0004236',
       'EFO_1000760', 'MONDO_0003268', 'EFO_0000519', 'EFO_1001465',
       'EFO_0000403', 'EFO_0007512', 'EFO_0000198', 'MONDO_0002367',
       'EFO_0000309', 'EFO_0002499', 'EFO_0003833', 'EFO_0000183',
       'EFO_0000621', 'EFO_1000690', 'EFO_0002496', 'EFO_1001006',
       'EFO_1000158', 'MONDO_0000870', 'MONDO_0000873', 'EFO_0000502',
       'MONDO_0007254', 'EFO_0000681', 'EFO_0002939', 'EFO_0000222',
       'EFO_0006859', 'EFO_1000910', 'EFO_0000224', 'EFO_0000279',
       'EFO_0003894', 'MONDO_0006058', 'MONDO_0019269', 'MONDO_0004975'],
      dtype=object), 'count': 48}_|_[ENSG00000172819,ENSG00000077092,ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for acne and has 47 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200563,"COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c1-c1ccc(F)cc1.[Na+]_|_GPUADMRJQVPIAS-QCVDVZFFSA-M_|_Small molecule_|_False_|_CERIVASTATIN SODIUM_|_1997.0_|_4.0_|_CHEMBL1477_|_True_|_True_|_['Baycol']_|_['BAY W 6228' 'BAY-W-6228' 'Cerivastatin sodium'
 'Cerivastatin sodium salt']_|_[('PubChem', array(['144205797', '170465109', '251919809', '49681715'], dtype=object)), ('chEBI', array(['3559'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997. It was withdrawn in at least one region."
CHEMBL1200762,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]_|_PLCQGRYPOISRTQ-LWCNAHDDSA-L_|_Small molecule_|_False_|_BETAMETHASONE SODIUM PHOSPHATE_|_1965.0_|_4.0_|_CHEMBL1201207_|_False_|_True_|_['Betam-ophtal' 'Betamethasone sodium phosphate' 'Betnesol' 'Betnesol-n'
 'Celestone' 'Vistamethasone' 'Vistamethasone n']_|_['Betamethasone 21-phosphate disodium salt'
 'Betamethasone disodium phosphate' 'Betamethasone sodium phosphate'
 'NSC-90616']_|_[('PubChem', array(['144212784'], dtype=object)), ('chEBI', array(['3078'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'MONDO_0005178', 'EFO_1001434', 'EFO_0000729',
       'EFO_1001097', 'HP_0003419'], dtype=object), 'count': 6}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for ulcerative colitis and has 5 investigational indications."
CHEMBL1200826,"O=C([O-])[O-].[Li+].[Li+]_|_XGZVUEUWXADBQD-UHFFFAOYSA-L_|_Small molecule_|_True_|_LITHIUM CARBONATE_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['Camcolit 250' 'Camcolit 400' 'Eskalith' 'Eskalith cr' 'Liskonum'
 'Lithane' 'Lithium carbonate' 'Lithobid' 'Lithonate' 'Lithotabs' 'Phasal']_|_['CP-15,467-61' 'CP-15467-61' 'CP-1546761' 'Carbonic acid, dilithium salt'
 'Lithii carbonas' 'Lithium carbonate' 'Lithium carbonicum' 'NSC-16895']_|_[('DailyMed', array(['lithium%20carbonate'], dtype=object)), ('DrugCentral', array(['4207'], dtype=object)), ('PubChem', array(['8139879'], dtype=object)), ('Wikipedia', array(['Lithium_carbonate'], dtype=object)), ('drugbank', array(['DB14509'], dtype=object)), ('chEBI', array(['6504'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079', 'MONDO_0005090', 'EFO_0004216', 'EFO_0000712',
       'EFO_0009963', 'MONDO_0008315', 'EFO_1002017', 'MONDO_0015277',
       'EFO_0011023', 'EFO_1000158', 'MONDO_0001475', 'MONDO_0002050',
       'MONDO_0005301', 'MONDO_0018982', 'EFO_1001901', 'MONDO_0017276',
       'MONDO_0004976', 'HP_0000726', 'MONDO_0019037', 'MONDO_0002009',
       'MONDO_0007739', 'MONDO_0001657', 'EFO_0000702', 'Orphanet_733',
       'MONDO_0018696', 'EFO_0003931', 'MONDO_0005180', 'EFO_0002615',
       'EFO_1001919', 'MONDO_0008458', 'EFO_1001050', 'EFO_0009854',
       'MONDO_0004975', 'EFO_0003756', 'MONDO_0008119', 'EFO_0003015',
       'MONDO_0004985', 'Orphanet_98757', 'MONDO_0002009', 'EFO_0005230'],
      dtype=object), 'count': 40}_|_[ENSG00000133731,ENSG00000105723,ENSG00000082701]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 4 approved and 36 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1256841,"O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1_|_NOIIUHRQUVNIDD-UHFFFAOYSA-N_|_Small molecule_|_False_|_NIALAMIDE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['NSC-124514' 'Nialamide' 'Niamid']_|_[('PubChem', array(['11111522', '11111523', '144203759', '170466097', '50104074',
       '56422110', '85231151', '855800', '90341025'], dtype=object)), ('drugbank', array(['DB04820'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder. It was withdrawn in at least one region."
CHEMBL139,"O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl_|_DCOPUUMXTXDBNB-UHFFFAOYSA-N_|_Small molecule_|_True_|_DICLOFENAC_|_1988.0_|_4.0_|_nan_|_False_|_True_|_['Cambia' 'Voltaren' 'Voltaren Ophthalmic' 'Voltaren Xr' 'Zorvolex'
 'Zorvolex capsules']_|_['Arthrotec' 'Cataflam' 'Diclofenac' 'Diclofenac acid'
 'Diclofenac free acid' 'LAS-41007' 'LAS41007' 'Las41007' 'Solaraze'
 'Voltaren' 'Voltaren-XR']_|_[('DailyMed', array(['diclofenac'], dtype=object)), ('PubChem', array(['24424557'], dtype=object)), ('TG-GATEs', array(['19'], dtype=object)), ('Wikipedia', array(['Diclofenac'], dtype=object)), ('drugbank', array(['DB00586'], dtype=object)), ('chEBI', array(['47381'], dtype=object))]_|_['CHEMBL1201180' 'CHEMBL3350449' 'CHEMBL1034' 'CHEMBL1200804']_|_{'rows': array(['MP_0001845', 'EFO_1000786', 'EFO_0000685', 'MONDO_0005277',
       'EFO_0009582', 'EFO_0003898', 'EFO_0004607', 'HP_0100607',
       'HP_0003326', 'EFO_0010072', 'EFO_0004616', 'MONDO_0001187',
       'EFO_1000652', 'EFO_0004616', 'EFO_1001139', 'EFO_0003843',
       'EFO_0000649', 'MONDO_0005178', 'MP_0001845', 'EFO_0003843',
       'EFO_0004274', 'EFO_0009582', 'EFO_1000720', 'MONDO_0007254',
       'EFO_0000685', 'EFO_1001412', 'EFO_0003843', 'MONDO_0005129',
       'EFO_0010072', 'MONDO_0005277', 'EFO_0003931', 'EFO_1001366',
       'EFO_0000545', 'MONDO_0005178', 'MONDO_0005178', 'HP_0003419',
       'EFO_0004272', 'EFO_0010072', 'EFO_0000685', 'EFO_0000546',
       'EFO_0003843', 'EFO_0002496', 'EFO_0002496', 'EFO_0009582',
       'MONDO_0002050', 'EFO_0009560', 'EFO_0000616', 'EFO_0002970',
       'EFO_0000649', 'EFO_0009454', 'MP_0001914', 'HP_0002829',
       'MONDO_0002959', 'MONDO_0002887', 'EFO_0004193', 'HP_0100607',
       'EFO_0005755', 'EFO_0003958', 'HP_0012532', 'EFO_0005752',
       'EFO_0000313', 'HP_0011868', 'EFO_0003827'], dtype=object), 'count': 63}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 16 approved and 35 investigational indications. This drug has a black box warning from the FDA."
CHEMBL149082,"NCCCS(=O)(=O)O_|_SNKZJIOFVMKAOJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRAMIPROSATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['3-aminopropane sulfonic acid' 'Acamprosate related compound a'
 'Homotaurine' 'NC-758' 'NSC-77071' 'Tramiprosate']_|_[('PubChem', array(['8139961', '90340792'], dtype=object)), ('Wikipedia', array(['Homotaurine'], dtype=object)), ('drugbank', array(['DB06527'], dtype=object)), ('chEBI', array(['1457'], dtype=object))]_|_['CHEMBL1256473' 'CHEMBL1256024']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1649931,"CC(=O)N[C@@H](CCN1[C@@H]2CC[C@H]1C[C@@H](n1c(C)nc3c1CCN(C(=O)C(C)C)C3)C2)c1cccc(F)c1_|_QETUKYDWZIRTEI-QUMGSSFMSA-N_|_Small molecule_|_False_|_PF-232798_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-232798' 'Pf-00232798' 'Pf-232798']_|_[('drugbank', array(['DB14813'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764'], dtype=object), 'count': 1}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL197669,CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1_|_CYYQMAWUIRPCNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ST1535_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ct-1500' 'ST-1535' 'St1535']_|_nan_|_nan_|_nan_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2103824,"CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1_|_BJBCSGQLZQGGIQ-QGZVFWFLSA-N_|_Small molecule_|_False_|_ARHALOFENATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Arhalofenate' 'CB-102' 'CB102' 'JNJ-39659100' 'M-102' 'M102' 'MBX-102']_|_[('drugbank', array(['DB11811'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004274', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000197891,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2105737,"Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1_|_VZZJRYRQSPEMTK-CALCHBBNSA-N_|_Small molecule_|_True_|_SONIDEGIB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Erismodegib' 'LDE 225' 'LDE-225' 'LDE225' 'NVP-LDE 225' 'NVP-LDE-225'
 'NVP-LDE225' 'Sonidegib']_|_[('drugbank', array(['DB09143'], dtype=object))]_|_['CHEMBL3137317']_|_{'rows': array(['EFO_0004193', 'EFO_0002618', 'EFO_0004193', 'MONDO_0008315',
       'EFO_0000616', 'EFO_0000182', 'EFO_0001378', 'MONDO_0007254',
       'EFO_0003869', 'MONDO_0007576', 'MONDO_0008170', 'EFO_0001421',
       'MONDO_0005341', 'EFO_0002939', 'MONDO_0013730', 'EFO_0000565'],
      dtype=object), 'count': 16}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for basal cell carcinoma and neoplasm and has 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109457,"nan_|_nan_|_Antibody_|_False_|_LIGELIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ligelizumab' 'QGE-031' 'QGE031']_|_nan_|_nan_|_{'rows': array(['EFO_0007187', 'MONDO_0004979', 'EFO_1001890', 'EFO_0005531',
       'MONDO_0005271', 'EFO_0000274', 'EFO_1001881', 'EFO_0007425'],
      dtype=object), 'count': 8}_|_[ENSG00000211891]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL2205230,"CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1_|_ZADWXQMNNVICKB-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAK-441_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Tak-441']_|_nan_|_nan_|_{'rows': array(['EFO_0004193'], dtype=object), 'count': 1}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2448612,"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21.O=C(O)C(O)C(O)C(=O)O_|_CJMJLDQKTOJACI-SEUSHGJOSA-N_|_Small molecule_|_True_|_ERGOTAMINE TARTRATE_|_1948.0_|_4.0_|_CHEMBL442_|_False_|_True_|_['Cafergot' 'Ergomar' 'Ergostat' 'Femergin' 'Gynergen' 'Lingraine'
 'Medihaler ergotamine' 'Migril' 'Wigrettes']_|_['Ergotamine bitartrate' 'Ergotamine d-tartrate' 'Ergotamine tartrate'
 'Ergotamini tartras' 'Gotamine tartrate' 'NSC-41869']_|_[('DailyMed', array(['ergotamine%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'HP_0002315'], dtype=object), 'count': 2}_|_[ENSG00000179546,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for migraine disorder and headache. This drug has a black box warning from the FDA."
CHEMBL3039553,nan_|_nan_|_Oligonucleotide_|_False_|_APATORSEN SODIUM_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Apatorsen sodium' 'OGX-427']_|_nan_|_nan_|_nan_|_[ENSG00000106211]_|_Oligonucleotide drug.
CHEMBL3306803,"CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12_|_HOIIHACBCFLJET-SFTDATJTSA-N_|_Small molecule_|_True_|_LUMATEPERONE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ITI 007' 'ITI-007' 'ITI-722' 'ITI007' 'Lumateperone']_|_[('drugbank', array(['DB06077'], dtype=object))]_|_['CHEMBL3233142']_|_{'rows': array(['MONDO_0002009', 'MONDO_0005090', 'HP_0012076', 'EFO_0005407',
       'MONDO_0004975', 'MONDO_0004985', 'MONDO_0005090'], dtype=object), 'count': 7}_|_[ENSG00000102468,ENSG00000149295,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for schizophrenia and psychosis and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3663929,"C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1_|_QKDCLUARMDUUKN-XMMPIXPASA-N_|_Small molecule_|_False_|_NAQUOTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ASP-8273' 'ASP8273' 'Naquotinib']_|_[('drugbank', array(['DB12036'], dtype=object))]_|_['CHEMBL3707350']_|_{'rows': array(['EFO_0003060', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3833373,"nan_|_nan_|_Antibody_|_False_|_AVELUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Bavencio']_|_['Avelumab' 'MSB-0010682' 'MSB0010682' 'MSB0010718C' 'Msb-0010718c']_|_[('DailyMed', array(['avelumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100342', 'EFO_0000574', 'EFO_0001668', 'MONDO_0008170',
       'EFO_0004142', 'EFO_1000158', 'MONDO_0011962', 'EFO_1001951',
       'EFO_0000349', 'EFO_0006859', 'MONDO_0008315', 'EFO_0000181',
       'MONDO_0016642', 'EFO_0000707', 'EFO_1001471', 'EFO_0000339',
       'EFO_0000637', 'MONDO_0005184', 'MONDO_0004992', 'MONDO_0002087',
       'EFO_0000222', 'MONDO_0021063', 'EFO_0000182', 'EFO_0002618',
       'EFO_0000403', 'EFO_0000365', 'EFO_0000616', 'EFO_0000231',
       'EFO_0000096', 'MONDO_0007254', 'MONDO_0018906', 'EFO_0005537',
       'EFO_0003968', 'MONDO_0002898', 'EFO_0003869', 'MONDO_0004986',
       'MONDO_0002120', 'EFO_0000588', 'EFO_0000228', 'EFO_0004252',
       'MONDO_0044903', 'EFO_0000519', 'EFO_0001378', 'MONDO_0002158',
       'EFO_1000581', 'EFO_0000503', 'MONDO_0001187', 'EFO_1000576',
       'EFO_0002890', 'EFO_0003863', 'EFO_0000564', 'EFO_0000681',
       'MONDO_0018944', 'EFO_0000756', 'EFO_0008528', 'EFO_1000657',
       'EFO_0005922', 'MONDO_0008978', 'EFO_0005952', 'EFO_0008528',
       'EFO_0000196', 'EFO_0000183', 'EFO_0003060', 'EFO_1001901',
       'EFO_0000702'], dtype=object), 'count': 65}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 60 investigational indications."
CHEMBL4204794,"Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1_|_DWYRIWUZIJHQKQ-SANMLTNESA-N_|_Small molecule_|_False_|_AVAPRITINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Ayvakit' 'Ayvakyt']_|_['70C366' 'Avapritinib' 'BLU-285' 'C-366' 'X-720776' 'X720776']_|_[('DailyMed', array(['avapritinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt'],
      dtype=object)), ('drugbank', array(['DB15233'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000326', 'EFO_0007359', 'MONDO_0011719', 'EFO_0000616',
       'MONDO_0004992', 'MONDO_0016586'], dtype=object), 'count': 6}_|_[ENSG00000134853,ENSG00000157404]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 3 investigational indications."
CHEMBL4297813,"nan_|_nan_|_Unknown_|_False_|_PRI-724_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(S,S)-ICG-001' 'Foscenvivint' 'PRI-724' 'PRI724' 'Pri-724']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000365', 'EFO_0000222', 'EFO_0000339'],
      dtype=object), 'count': 4}_|_[ENSG00000005339,ENSG00000168036]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL580,"O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O_|_DIWRORZWFLOCLC-UHFFFAOYSA-N_|_Small molecule_|_True_|_LORAZEPAM_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Abbloraz' 'Ativan' 'Loraz' 'Lorazepam' 'Lorazepam intensol'
 'Lorazepam preservative free' 'Loreev xr' 'Temesta']_|_['Lorazepam' 'Lorazepam civ' 'NSC-289758' 'WY-4036']_|_[('DailyMed', array(['lorazepam'], dtype=object)), ('PubChem', array(['144205222', '29215381'], dtype=object)), ('Wikipedia', array(['Lorazepam'], dtype=object)), ('drugbank', array(['DB00186'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009267', 'EFO_0005411', 'EFO_0008526', 'MONDO_0002009',
       'HP_0000713', 'MONDO_0007079', 'HP_0000726', 'MONDO_0002009',
       'EFO_0002610', 'EFO_0009692', 'EFO_0004701', 'EFO_0000474',
       'EFO_0003890', 'EFO_0001064', 'EFO_0005230', 'MONDO_0005090',
       'MONDO_0004900', 'EFO_0004777', 'MONDO_0004975', 'EFO_0006788',
       'EFO_1000690', 'MONDO_0002050', 'EFO_0004242', 'HP_0001250',
       'EFO_1000924', 'EFO_0003843', 'EFO_1001146'], dtype=object), 'count': 27}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL659,"COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2_|_ASUTZQLVASHGKV-JDFRZJQESA-N_|_Small molecule_|_False_|_GALANTAMINE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Acumor xl' 'Consion xl' 'Elmino xl' 'Galsya xl' 'Galzemic xl'
 'Gatalin xl' 'Gazylan xl' 'Lotprosin xl' 'Luventa xl' 'Reminyl'
 'Reminyl xl' 'Zeebral xl']_|_['(-)-galantamine' '(-)-galanthamine' 'Galantamine' 'Galanthamine'
 'NSC-100058' 'Razadyne']_|_[('PubChem', array(['104171341', '144204358', '26751839'], dtype=object)), ('Wikipedia', array(['Galantamine'], dtype=object)), ('drugbank', array(['DB00674'], dtype=object)), ('chEBI', array(['42944'], dtype=object))]_|_['CHEMBL4467191' 'CHEMBL1555' 'CHEMBL3099484']_|_{'rows': array(['EFO_0001072', 'EFO_0005230', 'MONDO_0005090', 'EFO_0000713',
       'EFO_0006792', 'EFO_0004718', 'HP_0000726', 'EFO_0005252',
       'EFO_0003758', 'MONDO_0002050', 'Orphanet_79292', 'MONDO_0005090',
       'MONDO_0004975', 'EFO_0001073', 'MONDO_0004975', 'EFO_0003768',
       'EFO_0004718', 'HP_0000726', 'EFO_0000764', 'MONDO_0017276',
       'HP_0100543', 'EFO_0005411', 'EFO_0002610', 'EFO_0000677'],
      dtype=object), 'count': 24}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for dementia and alzheimer disease and has 19 investigational indications."
CHEMBL70972,"CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O_|_ZBVKEHDGYSLCCC-UHFFFAOYSA-N_|_Small molecule_|_False_|_SERATRODAST_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['A-73001' 'AA-2414' 'ABBOTT 73001' 'ABBOTT-73001' 'ABT-001' 'Bronica'
 'NSC-759640' 'Seratrodast']_|_[('PubChem', array(['144206327', '170465940', '50125893'], dtype=object)), ('drugbank', array(['DB06739'], dtype=object))]_|_nan_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000006638]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication."
CHEMBL1079742,"C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl_|_GTTBEUCJPZQMDZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ERLOTINIB HYDROCHLORIDE_|_2004.0_|_4.0_|_CHEMBL553_|_False_|_True_|_['Erlotinib hydrochloride' 'Tarceva']_|_['CP-358' 'CP-358,774-01' 'CP-358774-01' 'Erlotinib hcl'
 'Erlotinib hydrochloride' 'OSI-774']_|_[('DailyMed', array(['erlotinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva'],
      dtype=object)), ('PubChem', array(['534851'], dtype=object)), ('chEBI', array(['53509'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0005537', 'EFO_0002501', 'EFO_0000632',
       'MONDO_0003060', 'EFO_0002618', 'EFO_0000691', 'MONDO_0005411',
       'MONDO_0002158', 'MONDO_0007576', 'MONDO_0002974', 'EFO_0005567',
       'EFO_0000181', 'EFO_0005221', 'MONDO_0004992', 'MONDO_0002367',
       'MONDO_0001187', 'EFO_0001422', 'EFO_0000616', 'MONDO_0003268',
       'EFO_0000519', 'EFO_1001465', 'EFO_0000305', 'EFO_1000657',
       'MONDO_0021063', 'MONDO_0000521', 'MONDO_0004986', 'MONDO_0008903',
       'MONDO_0044926', 'EFO_0000182', 'EFO_1000158', 'EFO_0006859',
       'MONDO_0008315', 'MONDO_0002898', 'Orphanet_733', 'MONDO_0011962',
       'EFO_0000681', 'EFO_0003050', 'EFO_0000756', 'EFO_0003833',
       'MONDO_0007254', 'EFO_0002499', 'EFO_1001951', 'MONDO_0008170',
       'EFO_0000588', 'MONDO_0020634', 'EFO_0000308', 'EFO_0000571',
       'EFO_0000640', 'EFO_0000365', 'MONDO_0002087', 'MONDO_0002691',
       'EFO_0000708'], dtype=object), 'count': 53}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 52 investigational indications."
CHEMBL1083993,"CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1.Cl_|_ITPDYQOUSLNIHG-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMIODARONE HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL633_|_False_|_True_|_['Amidox' 'Amiodarone hydrochloride' 'Amyben' 'Cordarone' 'Cordarone x'
 'Cordarone x 100' 'Cordarone x 200' 'Darmil' 'Nexterone' 'Pacerone']_|_['Amiodar' 'Amiodarone' 'Amiodarone hcl' 'Amiodarone hydrochloride'
 'L-3428' 'Miodaron' 'NSC-343341' 'NSC-85442' 'Ortacrone' 'Ritmocardyl'
 'SK&F-33134-A' 'SKF 33134-A' 'SKF-33134-A' 'Trangorex' 'VF-236']_|_[('DailyMed', array(['amiodarone%20hydrochloride'], dtype=object)), ('PubChem', array(['144207027', '144210713', '26747445', '50105848', '50105849',
       '50105850', '552042', '56422901', '855533'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0004287', 'MONDO_0019438', 'EFO_0005529',
       'EFO_0003144', 'EFO_0005306', 'HP_0004308'], dtype=object), 'count': 7}_|_[ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL110458,"OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O_|_LXBIFEVIBLOUGU-DPYQTVNSSA-N_|_Small molecule_|_False_|_MIGALASTAT_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['At-1001, gr-181314a' 'Galafold']_|_['Migalastat']_|_[('PubChem', array(['11114003'], dtype=object)), ('drugbank', array(['DB05018'], dtype=object))]_|_['CHEMBL2107355']_|_{'rows': array(['MONDO_0010526', 'MONDO_0010526'], dtype=object), 'count': 2}_|_[ENSG00000102393]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for fabry disease and has 1 investigational indication."
CHEMBL1200443,"nan_|_nan_|_Small molecule_|_False_|_MERETHOXYLLINE PROCAINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Merethoxyline procaine' 'Merethoxylline procaine'
 'Procaine merethoxylline']_|_[('DrugCentral', array(['4992'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL1200949,"Cl.NCCc1cc[nH]n1_|_HLJRAERMLKNULP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETAZOLE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201323_|_False_|_True_|_['Histalog']_|_['Ametazole' 'Betazole dihydrochloride' 'Betazole hcl'
 'Betazole hydrochloride' 'Betazolium chloride' 'NSC-759872']_|_[('PubChem', array(['144204280', '170465002', '56463652'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1560,"C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O_|_FAKRSMQSSFJEIM-RQJHMYQMSA-N_|_Small molecule_|_True_|_CAPTOPRIL_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Acepril' 'Capoten' 'Captomex' 'Captopril' 'Ecopace' 'Hyteneze 12.5'
 'Hyteneze 25' 'Hyteneze 50' 'Kaplon' 'Lopril' 'Noyada' 'Tensobon']_|_['Apopril' 'C09AA01' 'Capoten' 'Captomax' 'Captopril' 'Captoprilum'
 'Farcopril' 'Garranil' 'Hypopress' 'Mepha' 'NSC-757419' 'SA-333'
 'SQ -14225' 'SQ 14,225' 'SQ-14225' 'Tensiomin' 'Zapto']_|_[('DailyMed', array(['captopril'], dtype=object)), ('PubChem', array(['11110941', '144204441', '170464644', '26747043', '26751563',
       '50104171', '50104172', '50104173', '50104174', '56422201',
       '855925', '90340865'], dtype=object)), ('TG-GATEs', array(['94'], dtype=object)), ('Wikipedia', array(['Captopril'], dtype=object)), ('drugbank', array(['DB01197'], dtype=object)), ('chEBI', array(['3380'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755', 'EFO_0003106', 'EFO_0000537', 'EFO_0000373',
       'EFO_1002048', 'EFO_0002430', 'EFO_0001361', 'MONDO_0005148',
       'EFO_0000519', 'EFO_0003777', 'EFO_0000616', 'EFO_0000612',
       'MONDO_0100096', 'EFO_0000401', 'EFO_0000319', 'EFO_0003144',
       'EFO_0003770'], dtype=object), 'count': 17}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 9 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1691,"CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1.Cl_|_CHDPSNLJFOQTRK-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETAXOLOL HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL423_|_False_|_True_|_['Betaxolol' 'Betaxolol hydrochloride' 'Betoptic' 'Betoptic s' 'Kerlone']_|_['ALO 1401-02' 'ALO-1401-02' 'ALO-140102' 'Betaxolol hcl'
 'Betaxolol hydrochloride' 'NSC-760048' 'SL 75.212-10' 'SL-75.212-10'
 'SL-75212-10' 'SL-7521210']_|_[('DailyMed', array(['betaxolol%20hydrochloride'], dtype=object)), ('PubChem', array(['26663050', '50105931', '855778'], dtype=object)), ('chEBI', array(['643228'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004190', 'EFO_0000537', 'EFO_1001069'], dtype=object), 'count': 3}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved indications."
CHEMBL1743013,"nan_|_nan_|_Antibody_|_False_|_ENSITUXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ensituximab' 'NEO-101' 'NEO-102' 'NPC-1C']_|_nan_|_nan_|_{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}_|_[ENSG00000215182]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1743020,"nan_|_nan_|_Antibody_|_False_|_FORALUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Foralumab' 'NI-0401' 'TZLS-401']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0008520', 'EFO_0008522', 'EFO_0004599',
       'MONDO_0100096'], dtype=object), 'count': 5}_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2104765,"C[C@H](O)C(=O)[C@@]1(C)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3CC[C@@]21C_|_JUNDJWOLDSCTFK-MTZCLOFQSA-N_|_Small molecule_|_False_|_TRIMEGESTONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['RU 27987' 'RU-27987' 'Trimegestone']_|_[('drugbank', array(['DB13129'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002950'], dtype=object), 'count': 1}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2104864,O=C(O)/C=C/C(=O)O.O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CO3)N1_|_GELJVTSEGKGLDF-QDSMGTAFSA-N_|_Small molecule_|_False_|_APLINDORE FUMARATE_|_nan_|_2.0_|_CHEMBL2110659_|_False_|_False_|_[]_|_['Aplindore fumarate' 'DAB-452' 'Palindore' 'Palindore fumarate']_|_nan_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108058,"nan_|_nan_|_Protein_|_False_|_VANUTIDE CRIDIFICAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ACC-001' 'Vanutide cridificar']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108557,"nan_|_nan_|_Protein_|_False_|_TELBERMIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RH VEGF' 'RH-VEGF' 'RHVEG-F' 'RHVEGF' 'SNN0029' 'Telbermin' 'Vegf-a165'
 'Vegf165']_|_nan_|_nan_|_{'rows': array(['EFO_1001459', 'MONDO_0004976'], dtype=object), 'count': 2}_|_[ENSG00000102755,ENSG00000128052]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2358147,"CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O_|_TVPJGGZLZLUPOB-SPIKMXEPSA-N_|_Small molecule_|_False_|_CARPHENAZINE MALEATE_|_1982.0_|_4.0_|_CHEMBL1201328_|_False_|_True_|_['Proketazine']_|_['Carfenazine maleate' 'Carphenazine' 'Carphenazine dimaleate'
 'Carphenazine maleate' 'NSC-71755' 'WY-2445']_|_[('PubChem', array(['144206284'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295,ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL3590674,"O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1_|_AGPIHNZOZNKRGT-CYBMUJFWSA-N_|_Small molecule_|_False_|_ABT-639_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abt-639' 'Abt-639 free base']_|_[('drugbank', array(['DB15055'], dtype=object))]_|_['CHEMBL3589557']_|_{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}_|_[ENSG00000196557]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4541964,"O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1_|_LTSUMTMGJHPGFX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZATOLMILAST_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BPN-14770' 'BPN14770' 'Bpn14770' 'Zatolmilast']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZATOLMILAST/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002039', 'MONDO_0004975', 'MONDO_0010383'], dtype=object), 'count': 3}_|_[ENSG00000113448]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4594401,"CC1=NN(c2ccc3c(c2)CCCC3)C(=O)/C1=N\Nc1cccc(-c2ccc(C(=O)O)o2)c1O_|_BDGGFTDRPHKXFC-QYQHSDTDSA-N_|_Small molecule_|_False_|_RAFUTROMBOPAG_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Hetrombopag' 'Rafutrombopag' 'SHR-8735' 'SHR8735']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0000198', 'HP_0001915', 'EFO_0007160',
       'HP_0001873', 'MONDO_0007254'], dtype=object), 'count': 6}_|_[ENSG00000117400]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4594448,"CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@H](c2ccc(C(=O)O)cc2)C1_|_RENRQMCACQEWFC-UGKGYDQZSA-N_|_Small molecule_|_False_|_IPTACOPAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Iptacopan' 'LNP-023' 'LNP023' 'Lnp023' 'NVP-LNP023' 'NVP-LNP023-NX']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IPTACOPAN/relevant/1/'],
      dtype=object))]_|_['CHEMBL4643495' 'CHEMBL5095401']_|_{'rows': array(['EFO_0004254', 'EFO_0005761', 'MONDO_0100244', 'HP_0000077',
       'MONDO_0002462', 'EFO_0001365', 'HP_0000077', 'EFO_0001421',
       'MONDO_0100244', 'MONDO_0018904', 'EFO_0004194', 'MONDO_0002462',
       'MONDO_0016244', 'MONDO_0100244'], dtype=object), 'count': 14}_|_[ENSG00000243649]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL5095451,"nan_|_nan_|_Gene_|_False_|_ETRANACOGENE DEZAPARVOVEC_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AAV5-hFIXco-Padua' 'AMT-061' 'Etranacogene dezaparvovec'
 'Etranacogene dezaparvovec-dlrb' 'Hemgenix']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETRANACOGENE%20DEZAPARVOVEC/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Gene drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL6,"COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1_|_CGIGDMFJXJATDK-UHFFFAOYSA-N_|_Small molecule_|_True_|_INDOMETHACIN_|_1965.0_|_4.0_|_nan_|_False_|_True_|_['Artracin' 'Artracin sr' 'Berlind 75 ret' 'Flexin-25 continus'
 'Flexin-50 continus' 'Flexin-75 continus' 'Imbrilon' 'Indo-lemmon'
 'Indo-paed' 'Indocid ret' 'Indocid-r' 'Indocin' 'Indocin sr' 'Indoderm'
 'Indoflex' 'Indolar' 'Indolar sr' 'Indomax-25' 'Indomax-75 sr'
 'Indomethacin' 'Indomod' 'Indoptol' 'Indotard mr 75' 'Ledmecin'
 'Maximet sr' 'Mobilan' 'Pardelprin mr' 'Rheumacin la' 'Rimacid'
 'Slo-indo' 'Tivorbex']_|_['Aconip' 'Durametacin' 'Indometacin' 'Indometacin farnesil'
 'Indometacinum' 'Indomethacin' 'NSC-757061' 'NSC-77541' 'Reumacide']_|_[('DailyMed', array(['indomethacin'], dtype=object)), ('PubChem', array(['11111328', '11111329', '11113361', '124880453', '124880455',
       '124880457', '124880458', '144206660', '144208989', '144210586',
       '170464705', '17389851', '174007200', '26747086', '26747087',
       '26751593', '50100255', '50104238', '50104239', '50126367',
       '56422212', '85231093', '856012', '90340917'], dtype=object)), ('TG-GATEs', array(['15'], dtype=object)), ('Wikipedia', array(['Indometacin'], dtype=object)), ('drugbank', array(['DB00328'], dtype=object)), ('chEBI', array(['49662'], dtype=object))]_|_['CHEMBL2028292' 'CHEMBL3989410' 'CHEMBL4590319']_|_{'rows': array(['MONDO_0003937', 'EFO_0000278', 'EFO_0005755', 'MONDO_0004979',
       'EFO_1001412', 'EFO_0000199', 'EFO_0000685', 'EFO_1000652',
       'EFO_0010072', 'MONDO_0004975', 'MONDO_0100096', 'HP_0002829',
       'EFO_1000318', 'EFO_0005252', 'MONDO_0007254', 'EFO_0003843',
       'MP_0001914', 'Orphanet_79292', 'EFO_0003898', 'EFO_0003917',
       'MP_0001845', 'EFO_0000181', 'MONDO_0024475', 'EFO_0000196',
       'EFO_0000342', 'MONDO_0005178', 'HP_0001643', 'EFO_0000319',
       'HP_0003326', 'EFO_0004274', 'EFO_0005752', 'MP_0001845',
       'MONDO_0008315', 'EFO_0000389', 'EFO_0000673'], dtype=object), 'count': 35}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 12 approved and 23 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1173055,"CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1_|_HMABYWSNWIZPAG-UHFFFAOYSA-N_|_Small molecule_|_False_|_RUCAPARIB_|_2016.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AG-014699' 'AG-14447' 'Rucaparib']_|_[('PubChem', array(['103905261', '137276017', '174006354'], dtype=object)), ('drugbank', array(['DB12332'], dtype=object))]_|_['CHEMBL2105733' 'CHEMBL3833368']_|_{'rows': array(['EFO_0003060', 'MONDO_0002087', 'MONDO_0002158', 'MONDO_0004992',
       'MONDO_0008170', 'EFO_0000616', 'MONDO_0007254', 'EFO_0003893',
       'MONDO_0008315', 'EFO_0000702', 'MONDO_0008170', 'MONDO_0001056',
       'MONDO_0003060', 'EFO_0000616', 'EFO_0000616', 'Orphanet_145',
       'MONDO_0002974', 'EFO_0002618', 'MONDO_0005184', 'EFO_1000613',
       'EFO_0000564', 'EFO_0000673', 'MONDO_0011962', 'EFO_0001075',
       'EFO_0000588'], dtype=object), 'count': 25}_|_[ENSG00000143799,ENSG00000041880,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 5 approved and 19 investigational indications."
CHEMBL1201248,"COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC_|_YXSLJKQTIDHPOT-LJCJQEJUSA-N_|_Small molecule_|_False_|_CISATRACURIUM_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Nimbex']_|_['Cisatracurium' 'Cisatracurium cation' 'Cisatracurium ion']_|_[('Wikipedia', array(['Cisatracurium_besilate'], dtype=object)), ('drugbank', array(['DB00565'], dtype=object))]_|_['CHEMBL1200641']_|_{'rows': array(['EFO_1000637'], dtype=object), 'count': 1}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication."
CHEMBL1201468,"nan_|_nan_|_Unknown_|_True_|_ESTROGENS, ESTERIFIED_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Amnestrogen' 'Esterified estrogens' 'Estratab' 'Evex' 'Femogen' 'Menest']_|_['Esterified estrogens' 'Estrogens esterified' 'Estrogens, esterified'
 'Estrogens,esterified']_|_[('DailyMed', array(['estrogens,%20esterified'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000096', 'GO_0042697', 'EFO_0004266', 'MONDO_0002146',
       'MONDO_0007254'], dtype=object), 'count': 5}_|_[ENSG00000140009,ENSG00000091831]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved indications. This drug has a black box warning from the FDA."
CHEMBL1201772,"CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2_|_DTGLZDAWLRGWQN-UHFFFAOYSA-N_|_Small molecule_|_True_|_PRASUGREL_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Efient']_|_['LY-640315' 'NSC-759625' 'Prasugrel']_|_[('PubChem', array(['124899264', '174006898'], dtype=object)), ('Wikipedia', array(['Prasugrel'], dtype=object)), ('drugbank', array(['DB06209'], dtype=object)), ('chEBI', array(['87723'], dtype=object))]_|_['CHEMBL1201773']_|_{'rows': array(['EFO_0003777', 'EFO_0000612', 'EFO_0000612', 'MONDO_0004979',
       'EFO_0008585', 'MP_0001914', 'EFO_0003884', 'EFO_0000275',
       'EFO_0000764', 'EFO_0003106', 'HP_0004419', 'MONDO_0011382',
       'EFO_0007328', 'EFO_0005672', 'EFO_0001645', 'MONDO_0100096',
       'EFO_0005672'], dtype=object), 'count': 17}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1234354,"COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1_|_XDLYKKIQACFMJG-WKILWMFISA-N_|_Small molecule_|_False_|_PF-04691502_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-04691502' 'PF-4691502' 'Pf-04691502']_|_[('drugbank', array(['DB11974'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003869', 'MONDO_0007254', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1423,"O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1_|_YVUQSNJEYSNKRX-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIMOZIDE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Orap' 'Pimozide']_|_['MCN-JR-6238' 'NSC-170984' 'Pimozide' 'R 623' 'R 6238' 'R-623' 'R-6238']_|_[('DailyMed', array(['pimozide'], dtype=object)), ('PubChem', array(['104171210', '11111615', '11112507', '11113804', '124881071',
       '124881072', '124881075', '124881079', '144116849', '144203775',
       '144211903', '170464864', '26747138', '26751488', '26751978',
       '26751979', '50104653', '563187', '56422165', '85231181', '855710',
       '90341263'], dtype=object)), ('Wikipedia', array(['Pimozide'], dtype=object)), ('drugbank', array(['DB01100'], dtype=object)), ('chEBI', array(['8212'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090', 'EFO_0005230', 'HP_0000726', 'HP_0100033',
       'MONDO_0002050', 'EFO_0005407', 'MONDO_0004976', 'EFO_0004895'],
      dtype=object), 'count': 8}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 5 investigational indications."
CHEMBL1515,"Cn1ccnc1S_|_PMRYVIKBURPHAH-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHIMAZOLE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_['Favistan' 'Methimazole' 'Tapazole']_|_['Mercaptizole' 'Methimazole' 'NSC-38608' 'Thiamazole']_|_[('DailyMed', array(['methimazole'], dtype=object)), ('PubChem', array(['11112158', '144203892', '144208539', '144210850', '170464856',
       '57299280', '8139973'], dtype=object)), ('TG-GATEs', array(['57'], dtype=object)), ('Wikipedia', array(['Methimazole'], dtype=object)), ('drugbank', array(['DB00763'], dtype=object)), ('chEBI', array(['50673'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000820', 'EFO_0000519', 'EFO_1001466', 'EFO_1001465',
       'EFO_0000398', 'EFO_0009189'], dtype=object), 'count': 6}_|_[ENSG00000115705]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for abnormality of the thyroid gland and hyperthyroidism and has 4 investigational indications."
CHEMBL1683544,"C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C.CS(=O)(=O)O_|_QAMYWGZHLCQOOJ-WRNBYXCMSA-N_|_Small molecule_|_False_|_ERIBULIN MESYLATE_|_2010.0_|_4.0_|_CHEMBL1683590_|_False_|_True_|_['Halaven']_|_['E-7389' 'E7389' 'Eribulin (as mesylate)' 'Eribulin mesilate'
 'Eribulin mesylate' 'Eribulin monomethanesulfonate' 'Halaven']_|_[('DailyMed', array(['eribulin%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/halaven'],
      dtype=object)), ('chEBI', array(['70710'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000616', 'MONDO_0001187', 'EFO_0000569',
       'EFO_0008528', 'MONDO_0004992', 'MONDO_0004669', 'EFO_0000574',
       'EFO_0006859', 'EFO_0000637', 'EFO_1001968', 'MONDO_0004192',
       'EFO_0000673', 'EFO_0006861', 'MONDO_0021632', 'EFO_1000613',
       'MONDO_0002974', 'EFO_0003869', 'EFO_0000305', 'MONDO_0007254',
       'EFO_0005537', 'MONDO_0008315'], dtype=object), 'count': 22}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 4 approved and 18 investigational indications."
CHEMBL1729,"COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC_|_DCSUBABJRXZOMT-UHFFFAOYSA-N_|_Small molecule_|_True_|_CISAPRIDE_|_1993.0_|_4.0_|_nan_|_True_|_True_|_['Alimix' 'Prepulsid' 'Prepulsid quicklet' 'Propulsid'
 'Propulsid quicksolv']_|_['Cisapride' 'Cisapride monohydrate' 'Propulsid' 'R-51,619' 'R-51619']_|_[('PubChem', array(['144204250', '170465200'], dtype=object)), ('Wikipedia', array(['Cisapride'], dtype=object))]_|_['CHEMBL1200788']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993 and is indicated for gastrointestinal disease. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1743065,nan_|_nan_|_Antibody_|_False_|_ROLEDUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Roledumab']_|_nan_|_nan_|_nan_|_[ENSG00000187010]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL1789941,"N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1_|_HFNKQEVNSGCOJV-OAHLLOKOSA-N_|_Small molecule_|_True_|_RUXOLITINIB_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Jakavi']_|_['INC-424' 'INC424' 'INCB-018424' 'INCB-18424' 'INCB018424' 'Ruxolitinib']_|_[('Wikipedia', array(['Ruxolitinib'], dtype=object)), ('drugbank', array(['DB08877'], dtype=object)), ('chEBI', array(['66919'], dtype=object))]_|_['CHEMBL1795071' 'CHEMBL4594382' 'CHEMBL4594381']_|_{'rows': array(['EFO_0004192', 'EFO_0003086', 'EFO_0000222', 'HP_0011974',
       'EFO_0000181', 'EFO_0000685', 'EFO_0000220', 'EFO_1000710',
       'HP_0004326', 'EFO_0000616', 'EFO_0003060', 'MONDO_0021739',
       'EFO_0000339', 'EFO_0000574', 'MONDO_0002158', 'MONDO_0019469',
       'EFO_0000305', 'MONDO_0002406', 'EFO_0002618', 'EFO_0000274',
       'EFO_0001068', 'EFO_1001951', 'EFO_0002430', 'EFO_0004208',
       'EFO_1000738', 'EFO_1000984', 'EFO_0004192', 'EFO_0000676',
       'EFO_0002429', 'MONDO_0044903', 'EFO_0003106', 'EFO_0000676',
       'HP_0000964', 'EFO_0000274', 'EFO_1000764', 'EFO_0004272',
       'EFO_0000222', 'EFO_1001467', 'MONDO_0008903', 'EFO_1001806',
       'EFO_1000724', 'EFO_1000726', 'EFO_0000095', 'EFO_0001378',
       'EFO_0000565', 'EFO_0000694', 'EFO_1001779', 'EFO_0000479',
       'MONDO_0009348', 'EFO_0004251', 'EFO_0001421', 'MONDO_0013730',
       'MONDO_0007254', 'EFO_0000220', 'EFO_0000466', 'EFO_0007183',
       'MONDO_0100096', 'EFO_0004256', 'EFO_0002430', 'MONDO_0020547',
       'EFO_0004192', 'MONDO_0004992', 'EFO_0000209', 'EFO_0004192',
       'EFO_0001642', 'EFO_0004251', 'EFO_0005952', 'EFO_0000764',
       'MONDO_0005184', 'EFO_0000519', 'MONDO_0019558', 'MONDO_0013730',
       'EFO_0000095', 'EFO_0004599', 'EFO_0000183', 'MONDO_0008315',
       'EFO_0005537', 'MONDO_0015540', 'MONDO_0016486', 'EFO_0002429'],
      dtype=object), 'count': 80}_|_[ENSG00000162434,ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 8 approved and 68 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1823817,"COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O_|_FUCKCIVGBCBZNP-MRXNPFEDSA-N_|_Small molecule_|_False_|_CE-224535_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CE 224,535' 'CE-224,535' 'CE224535' 'Ce 224535' 'Ce-224535']_|_[('drugbank', array(['DB12113'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_0000685'], dtype=object), 'count': 2}_|_[ENSG00000089041]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2104981,"COCCN1CCC(N(Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C(=O)Cn2c(SCc3cccc(F)c3F)cc(=O)c3ccccc32)CC1_|_NNBGCSGCRSCFEA-UHFFFAOYSA-N_|_Small molecule_|_False_|_RILAPLADIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Rilapladib' 'SB-659032']_|_[('drugbank', array(['DB05119'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0003914'], dtype=object), 'count': 2}_|_[ENSG00000146070]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2107333,"COC(=O)/C=C/C(=O)OC_|_LDCRTTXIJACKKU-ONEGZZNKSA-N_|_Small molecule_|_False_|_DIMETHYL FUMARATE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Dimethyl fumarate neuraxpharm' 'Tecfidera']_|_['AZL 0 211089' 'AZL O 211089' 'AZL-0211089' 'AZL-O-211089' 'BG 00012'
 'BG 12' 'BG-00012' 'BG-12' 'BG00012' 'Dimethyl fumar' 'Dimethyl fumarate'
 'FAG-201' 'FP-187' 'FP187' 'Fumaric acid dimethyl ester' 'LAS-41008'
 'LAS41008' 'Las41008' 'NSC-167432' 'NSC-25942' 'Panaclar']_|_[('DailyMed', array(['dimethyl%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-neuraxpharm'],
      dtype=object)), ('drugbank', array(['DB08908'], dtype=object)), ('chEBI', array(['76004'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0003778', 'EFO_0000540', 'EFO_1001465',
       'EFO_0005669', 'EFO_0003918', 'EFO_0000095', 'HP_0002140',
       'EFO_0002913', 'EFO_0000685', 'EFO_0003929', 'EFO_0003840',
       'EFO_0000694', 'MONDO_0005301', 'EFO_0008520'], dtype=object), 'count': 15}_|_[ENSG00000079999]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 12 investigational indications."
CHEMBL2107873,"nan_|_nan_|_Protein_|_False_|_VONICOG ALFA_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Veyvondi']_|_['BAX 111' 'BAX-111' 'Von willebrand factor (recombinant)' 'Vonicog alfa'
 'Vonvendi']_|_[('DrugCentral', array(['5173'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_903'], dtype=object), 'count': 1}_|_[ENSG00000110799]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for von willebrand disease."
CHEMBL2108278,"nan_|_nan_|_Oligonucleotide_|_False_|_ETEPLIRSEN_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Exondys 51']_|_['AVI-4658' 'Eteplirsen']_|_[('DailyMed', array(['eteplirsen'], dtype=object)), ('DrugCentral', array(['5182'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679', 'MONDO_0020121'], dtype=object), 'count': 2}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for duchenne muscular dystrophy and muscular dystrophy."
CHEMBL2109092,"nan_|_nan_|_Protein_|_False_|_EPOETIN BETA_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Neorecormon' 'Neorecormon 1000' 'Neorecormon 10000' 'Neorecormon 2000'
 'Neorecormon 20000' 'Neorecormon 3000' 'Neorecormon 30000'
 'Neorecormon 4000' 'Neorecormon 500' 'Neorecormon 5000'
 'Neorecormon 6000' 'Recormon 1000' 'Recormon 10000' 'Recormon 2000'
 'Recormon 5000' 'Recormon s 1000' 'Recormon s 10000' 'Recormon s 2000'
 'Recormon s 5000']_|_['BM 06.019' 'EPOCH' 'Epoetin' 'Epoetin beta' 'Erythropoietin'
 'Erythropoietin for bioassays']_|_[('DrugCentral', array(['5160'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001919', 'EFO_1002048', 'EFO_0000712', 'EFO_0001068',
       'MONDO_0043510', 'EFO_0000198', 'EFO_1001330', 'MP_0001914',
       'EFO_0004247', 'MONDO_0005180', 'EFO_0000183', 'MONDO_0004976',
       'EFO_1000632', 'MONDO_0002135', 'EFO_0004220', 'MONDO_0008170',
       'EFO_1001375', 'EFO_0004272', 'EFO_1001779', 'EFO_1000824',
       'EFO_0003964', 'EFO_0001061', 'HP_0002140', 'EFO_0000713',
       'MONDO_0005301', 'EFO_0008583', 'MONDO_0004992', 'EFO_1001100',
       'EFO_0003928', 'EFO_0000403', 'MONDO_0003608', 'EFO_0003884',
       'EFO_0000612', 'MONDO_0005299', 'EFO_0002687', 'EFO_0000574',
       'MONDO_0002158', 'EFO_0005676', 'EFO_0007405', 'HP_0001919',
       'EFO_0003917', 'EFO_0006859', 'EFO_0004273', 'EFO_1000809',
       'EFO_0000546', 'EFO_0004599'], dtype=object), 'count': 46}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for anemia (phenotype) and chronic kidney disease and has 44 investigational indications."
CHEMBL2109440,"nan_|_nan_|_Antibody_|_False_|_LY-2787106_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LY-2787106' 'LY2787106' 'Ly-2787106']_|_nan_|_nan_|_{'rows': array(['EFO_0004272'], dtype=object), 'count': 1}_|_[ENSG00000105697]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2110585,"CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1_|_GWEJFLVSOGNLSS-WPFOTENUSA-N_|_Small molecule_|_False_|_EZATIOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ezatiostat' 'TLK-199']_|_[('drugbank', array(['DB05460'], dtype=object))]_|_['CHEMBL2103810']_|_{'rows': array(['MONDO_0001475', 'EFO_0000198', 'EFO_0000198'], dtype=object), 'count': 3}_|_[ENSG00000084207]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2110900,"CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1_|_USRHYDPUVLEVMC-FQEVSTJZSA-N_|_Small molecule_|_False_|_DAPOXETINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dapoxetine' 'Kutub' 'LY-210448']_|_[('PubChem', array(['170466555'], dtype=object)), ('drugbank', array(['DB04884'], dtype=object))]_|_['CHEMBL2106574']_|_{'rows': array(['EFO_0004714', 'EFO_0803321', 'EFO_0004234'], dtype=object), 'count': 3}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications."
CHEMBL2304041,"C=CC[C@H]1C(=O)C(C)(C)[C@@H](O)CC(=O)O[C@H](c2ccc3sc(C)nc3c2)C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@@H]1O_|_BFZKMNSQCNVFGM-UCEYFQQTSA-N_|_Small molecule_|_False_|_SAGOPILONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY86-5302' 'DE-03757' 'Sagopilone' 'ZK 219477' 'ZK-219477' 'ZK-EPO'
 'Zk219477']_|_[('drugbank', array(['DB12391'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'MONDO_0007254', 'EFO_0003893', 'EFO_1000158',
       'EFO_0003060', 'EFO_0000616', 'EFO_0000756', 'EFO_0003869',
       'EFO_0000702', 'MONDO_0008315'], dtype=object), 'count': 10}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL2364629,"N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F.N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F.O.O.O.O=S(=O)(O)O_|_SOGUOEZRYKUOHR-CQZKMDJHSA-N_|_Small molecule_|_False_|_RIMEGEPANT SULFATE_|_2020.0_|_4.0_|_CHEMBL2178422_|_False_|_True_|_['Nurtec odt' 'Vydura']_|_['Rimegepant sulfate']_|_[('DailyMed', array(['rimegepant%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vydura'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000064989]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for migraine disorder."
CHEMBL2402737,"COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F_|_TVTXCJFHQKSQQM-LJQIRTBHSA-N_|_Small molecule_|_False_|_IDASANUTLIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Idasanutlin' 'RG-7388' 'RG7388' 'RO-5503781' 'RO5503781']_|_[('drugbank', array(['DB12325'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000403', 'EFO_1001951', 'MONDO_0018906',
       'MONDO_0007254', 'EFO_0000616', 'EFO_0002429', 'EFO_0000222',
       'EFO_0000519', 'EFO_0000479', 'EFO_0005952'], dtype=object), 'count': 11}_|_[ENSG00000141510,ENSG00000135679]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL265502,"Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1_|_FIAFUQMPZJWCLV-UHFFFAOYSA-N_|_Small molecule_|_False_|_SURAMIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['FARMA-939' 'Farma' 'Fourneau' 'Metaret' 'NSC-34936' 'Naganol' 'Suramin'
 'Suramine']_|_[('PubChem', array(['11114098', '124887029', '144205598', '170466101', '26752197',
       '26756673', '50104860', '544513', '90341387'], dtype=object)), ('Wikipedia', array(['Suramin'], dtype=object)), ('drugbank', array(['DB04786'], dtype=object)), ('chEBI', array(['45906'], dtype=object))]_|_['CHEMBL413376']_|_{'rows': array(['MONDO_0008315', 'EFO_0000681', 'MONDO_0007254', 'DOID_10113',
       'EFO_1000796', 'EFO_0003060', 'HP_0001919', 'EFO_0000673',
       'MONDO_0001187', 'EFO_0005044', 'EFO_0007294', 'EFO_0003756',
       'EFO_0001378', 'EFO_0003060', 'EFO_1000158', 'EFO_1001951'],
      dtype=object), 'count': 16}_|_[ENSG00000113578]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications."
CHEMBL3039513,"CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F_|_ASUGUQWIHMTFJL-QGZVFWFLSA-N_|_Small molecule_|_False_|_DECERNOTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adelatinib' 'Decernotinib' 'VRT-831509' 'VX-509']_|_[('drugbank', array(['DB12566'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3187246,"CN(C)CCN(Cc1cccs1)c1ccccn1.CN(C)CCN(Cc1cccs1)c1ccccn1.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O_|_OLGIEIJNOQGBSS-VQYXCCSOSA-N_|_Small molecule_|_False_|_METHAPYRILENE FUMARATE_|_nan_|_4.0_|_CHEMBL1411979_|_True_|_True_|_[]_|_['Methapyrilene fumarate']_|_[('PubChem', array(['144213936'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL345524,"O=C(OCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1ccccc1Nc1ccnc2cc(C(F)(F)F)ccc12_|_NWGGKKGAFZIVBJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANTRAFENINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Antrafenine']_|_[('Wikipedia', array(['Antrafenine'], dtype=object)), ('drugbank', array(['DB01419'], dtype=object))]_|_nan_|_nan_|_[ENSG00000107317]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL3544913,"NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1_|_JESCETIFNOFKEU-SJORKVTESA-N_|_Small molecule_|_False_|_VIXOTRIGINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BIIB-074' 'BIIB074' 'CNV-1014802' 'CNV1014802' 'GSK-1014802'
 'GSK1014802' 'Raxatrigine' 'Vixotrigine']_|_[('drugbank', array(['DB11706'], dtype=object))]_|_['CHEMBL3544912']_|_{'rows': array(['MONDO_0004985', 'MONDO_0016028', 'MONDO_0002959', 'EFO_1001219',
       'EFO_1000783', 'EFO_0005762'], dtype=object), 'count': 6}_|_[ENSG00000169432]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3545154,"C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1_|_LPFWVDIFUFFKJU-UHFFFAOYSA-N_|_Small molecule_|_False_|_POZIOTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['HM 781-36' 'HM 781-36B' 'HM-781-36' 'HM-781-36B' 'HM781-36B'
 'Hm-781-36b' 'NOV-1201' 'NOV-120101' 'Poziotinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/POZIOTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12114'], dtype=object))]_|_['CHEMBL5095402']_|_{'rows': array(['EFO_0000616', 'MONDO_0001056', 'EFO_0004284', 'EFO_0005922',
       'MONDO_0007254', 'EFO_0003060', 'EFO_0000571', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 9}_|_[ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL3545199,"nan_|_nan_|_Small molecule_|_False_|_RG-7741_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GDC-0575' 'Rg-7741']_|_nan_|_nan_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3639728,"COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1_|_NSMOZFXKTHCPTQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PLX-5622_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PLX-5622' 'PLX5622' 'Plx-5622']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000182578]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989510,"CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C.Cl_|_OQGYMIIFOSJQSF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PENTAZOCINE HYDROCHLORIDE_|_1969.0_|_4.0_|_CHEMBL100116_|_False_|_True_|_['Sosegon' 'Talwin 50']_|_['Pentazocine hcl' 'Pentazocine hydrochloride']_|_nan_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1969 and is indicated for pain."
CHEMBL4112930,"C[C@]12CCCN1CC1=NNC(=O)c3cc(F)cc4[nH]c2c1c34_|_DENYZIUJOTUUNY-MRXNPFEDSA-N_|_Small molecule_|_False_|_PAMIPARIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BGB-290' 'Bgb-290' 'Pamiparib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PAMIPARIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14769'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000181', 'MONDO_0008170', 'MONDO_0008315', 'MONDO_0001056',
       'EFO_0003060', 'EFO_1000158', 'MONDO_0004992', 'MONDO_0007254',
       'MONDO_0003060', 'EFO_0000702', 'EFO_0000616', 'EFO_0000519'],
      dtype=object), 'count': 12}_|_[ENSG00000143799,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL4297556,"nan_|_nan_|_Unknown_|_False_|_MM-111_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mm 111' 'Mm-111']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000141736,ENSG00000065361]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297831,"nan_|_nan_|_Antibody_|_False_|_SPARTALIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ANTI-PD1 MONOCLONAL ANTIBODY PDR001' 'NVP-LZV184' 'PDR-001' 'PDR001'
 'Pdr001' 'Spartalizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000389', 'EFO_0001378', 'MONDO_0007254', 'EFO_0000756',
       'MONDO_0005184', 'EFO_0005537', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0000681', 'MONDO_0011719', 'EFO_0000181', 'EFO_0003060',
       'MONDO_0001056', 'EFO_0005922', 'MONDO_0008903', 'EFO_0000182',
       'EFO_0004252', 'EFO_0000574', 'MONDO_0002120'], dtype=object), 'count': 19}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications."
CHEMBL4297844,"nan_|_nan_|_Antibody drug conjugate_|_True_|_TRASTUZUMAB DERUXTECAN_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Enhertu']_|_['DS-8201' 'DS-8201a' 'Ds-8201a' 'Trastuzumab deruxtecan'
 'Trastuzumab deruxtecan nxki' 'Trastuzumab deruxtecan-nxki']_|_[('DailyMed', array(['fam-trastuzumab%20deruxtecan-nxki'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003869', 'EFO_0003060', 'EFO_0000616', 'EFO_0004142',
       'MONDO_0005575', 'EFO_0008549', 'EFO_1001951', 'EFO_0000503',
       'EFO_1000984', 'MONDO_0007254', 'EFO_0009708', 'EFO_0000637',
       'EFO_0000305', 'MONDO_0001056', 'MONDO_0004992'], dtype=object), 'count': 15}_|_[ENSG00000198900,ENSG00000141736]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297986,"nan_|_nan_|_Unknown_|_False_|_COAGULATION FACTOR IX HUMAN_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Nonafact']_|_['Coagulation factor ix human' 'Human coagulation factor ix']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nonafact'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Unknown drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for hemophilia b."
CHEMBL4298024,"nan_|_nan_|_Protein_|_False_|_BINTRAFUSP ALFA_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['8L9YQ2N6PA' 'Bintrafusp alfa' 'M-7824' 'M7824' 'MSB-0011359C'
 'MSB0011359C' 'Msb0011359c']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BINTRAFUSP%20ALFA/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001879', 'MONDO_0001325', 'EFO_0003869', 'EFO_0000196',
       'EFO_0000588', 'EFO_0000702', 'MONDO_0007254', 'MONDO_0002974',
       'EFO_1001968', 'MONDO_0001528', 'EFO_0000181', 'MONDO_0008315',
       'EFO_0003863', 'MONDO_0008903', 'EFO_1000581', 'EFO_0000305',
       'EFO_0000365', 'EFO_1001961', 'MONDO_0008170', 'EFO_0001416',
       'EFO_0005537', 'MONDO_0001056', 'EFO_0002618', 'EFO_0005221',
       'EFO_0000616', 'EFO_0003060', 'EFO_0002916', 'EFO_0001663',
       'MONDO_0001402', 'MONDO_0021063', 'EFO_1001931', 'EFO_0000558'],
      dtype=object), 'count': 32}_|_[ENSG00000120217,ENSG00000105329,ENSG00000092969,ENSG00000119699]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 32 investigational indications."
CHEMBL521,"CC(C)Cc1ccc(C(C)C(=O)O)cc1_|_HEFNNWSXXWATRW-UHFFFAOYSA-N_|_Small molecule_|_True_|_IBUPROFEN_|_1974.0_|_4.0_|_nan_|_False_|_True_|_['Aches-n-pain' 'Advil' 'Advil liqui-gels' 'Advil migraine liqui-gels'
 'Anadin joint pain' 'Anadin liquifast' 'Anadin period pain relief'
 'Anadin ultra' 'Apsifen' 'Apsifen-f' 'Arthrofen 200' 'Arthrofen 400'
 'Arthrofen 600' 'Brufen ret' 'Caldolor' 'Cap-profen' ""Children's advil""
 ""Children's advil-flavored"" ""Children's elixsure"" ""Children's ibuprofen""
 ""Children's motrin"" 'Co-op' 'Codafen continus' 'Cuprofen for child'
 'Cuprofen plus' 'Deep relief' 'Ebufac' 'Femafen' 'Fenbid' 'Fenbid fte'
 'Fenpaed' 'Feverfen' 'Fleximex' 'Ibu-slo' 'Ibu-tab' 'Ibu-tab 200'
 'Ibucalm' 'Ibuderm' 'Ibufac' 'Ibugel' 'Ibugel fte' 'Ibular' 'Ibuleve'
 'Ibumed' 'Ibumetin' 'Ibumousse' 'Ibuprin' 'Ibuprofen' 'Ibuprohm'
 'Ibuspray' 'Ibutime' 'Inabrin' ""Infant's advil"" 'Inoven' 'Isisfen'
 'Junifen' 'Junior strength advil' 'Junior strength ibuprofen'
 'Junior strength motrin' 'Lidifen' 'Lidifen-f' 'Lobufen' 'Mandafen'
 'Manorfen' 'Maxa-gesic' 'Medipren' 'Midol' 'Midol liquid gels' 'Migrafen'
 'Motrin' 'Motrin ib' 'Motrin migraine pain' 'Novaprin' 'Nuprin'
 'Nurofen 400' 'Nurofen back pain sr' 'Nurofen child' 'Nurofen for child'
 'Nurofen plus' 'Nurofen recovery' 'Nurofen sinus' 'Nurofen solb'
 'Orbifen' 'Pacifene' 'Paxofen' 'Pedea' 'Pediatric advil' 'Phensic'
 'Phor pain' 'Phorpain' 'Phorpain max strgh' 'Profen' 'Proflex'
 'Proflex sr' 'Relcofen' 'Rimafen' 'Rufen' 'Seclodin' 'Suspren'
 'Tab-profen']_|_['Burana' 'IB-100' 'IP-82' 'Ibuprofen' 'Ibuprofenum' 'M01AE01'
 'NSC-256857' 'RD 13621' 'U-18,573' 'U-18573']_|_[('Wikipedia', array(['Ibuprofen'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pedea'],
      dtype=object)), ('TG-GATEs', array(['72'], dtype=object)), ('PubChem', array(['104171175', '124880372', '124880375', '138460', '144203721',
       '144208582', '144213146', '170464979', '174007269', '26747223',
       '26747224', '26752326', '50105276', '50105277', '50105278',
       '56422436', '85231082', '855602', '90341584'], dtype=object)), ('DailyMed', array(['ibuprofen'], dtype=object)), ('drugbank', array(['DB01050'], dtype=object)), ('chEBI', array(['5855'], dtype=object))]_|_['CHEMBL4594450' 'CHEMBL5201530' 'CHEMBL1201141' 'CHEMBL3989408'
 'CHEMBL1241153']_|_{'rows': array(['EFO_0002609', 'EFO_0007328', 'EFO_0009582', 'EFO_1000652',
       'EFO_0003931', 'HP_0003326', 'MONDO_0002009', 'EFO_0000546',
       'HP_0012228', 'EFO_0003869', 'HP_0004398', 'EFO_0009615',
       'EFO_0005252', 'HP_0003419', 'EFO_0002970', 'MONDO_0004975',
       'HP_0002315', 'EFO_1001158', 'EFO_0000685', 'EFO_0009516',
       'EFO_0009846', 'EFO_0001068', 'EFO_0003917', 'EFO_1000632',
       'EFO_0000537', 'EFO_0005854', 'EFO_0003843', 'MONDO_0024290',
       'EFO_0006803', 'EFO_0005279', 'EFO_0003938', 'EFO_0007214',
       'HP_0001643', 'EFO_0000649', 'EFO_0004263', 'EFO_0003918',
       'EFO_0003843', 'EFO_0004209', 'MONDO_0002367', 'EFO_0003958',
       'HP_0001945', 'HP_0100543', 'EFO_0010072', 'EFO_0003944',
       'EFO_0000706', 'EFO_0004616', 'EFO_0005856', 'MONDO_0007254',
       'EFO_1000843', 'EFO_0000464', 'MONDO_0019091', 'EFO_1000637',
       'EFO_1001139', 'MONDO_0005301', 'MP_0001914', 'HP_0012532',
       'EFO_0000544', 'MONDO_0005147', 'EFO_0006834', 'EFO_0000668',
       'MONDO_0005277', 'EFO_0003843', 'HP_0030833', 'MONDO_0010679',
       'HP_0003418', 'EFO_0005755', 'HP_0001643', 'EFO_1000782',
       'EFO_0007486', 'EFO_0000764', 'EFO_1000854', 'MONDO_0005178',
       'MONDO_0100342', 'EFO_0009610', 'MONDO_0009291', 'MONDO_0002258',
       'EFO_1001216', 'EFO_0000319', 'EFO_0005757', 'HP_0100607',
       'MONDO_0018076', 'MONDO_0018305', 'HP_0002829'], dtype=object), 'count': 83}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 21 approved and 61 investigational indications. This drug has a black box warning from the FDA."
CHEMBL578390,"CCCCCCCCC/C(=C\C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(=O)O_|_AALSSIXXBDPENJ-FYWRMAATSA-N_|_Small molecule_|_False_|_APX-3330_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APX 3330' 'APX-3330' 'APX3330' 'Apx-3330' 'Apx3330' 'E 3330' 'E-3330']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000100823]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL603,"COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12_|_YEEZWCHGZNKEEK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZAFIRLUKAST_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Accolate' 'Zafirlukast']_|_['ICI 204,219' 'ICI-204219' 'Ici-204,219' 'Zafirlukast']_|_[('DailyMed', array(['zafirlukast'], dtype=object)), ('PubChem', array(['144205729', '170464673', '26719823', '26757966', '49681658'],
      dtype=object)), ('Wikipedia', array(['Zafirlukast'], dtype=object)), ('drugbank', array(['DB00549'], dtype=object)), ('chEBI', array(['10100'], dtype=object))]_|_nan_|_{'rows': array(['HP_0006536', 'MONDO_0007254', 'MONDO_0004979', 'MONDO_0008170'],
      dtype=object), 'count': 4}_|_[ENSG00000173198]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for airway obstruction and asthma and has 2 investigational indications."
CHEMBL1194,"CCCNC(C)C(=O)Nc1ccccc1C_|_MVFGUOIZUNYYSO-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRILOCAINE_|_1965.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ASTRA-1512' 'ASTRA-1515' 'Citanest' 'NSC-40027' 'Prilocaine'
 'Propitocaine']_|_[('DailyMed', array(['prilocaine'], dtype=object)), ('PubChem', array(['90341069'], dtype=object)), ('Wikipedia', array(['Prilocaine'], dtype=object)), ('drugbank', array(['DB00750'], dtype=object)), ('chEBI', array(['8404'], dtype=object))]_|_['CHEMBL1200586']_|_{'rows': array(['MONDO_0041052', 'EFO_0002950', 'EFO_0000707', 'EFO_0003843',
       'HP_0012532', 'EFO_0803321', 'EFO_0002496', 'EFO_0000701'],
      dtype=object), 'count': 8}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for pain and has 7 investigational indications."
CHEMBL1201236,"C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O_|_TZFNLOMSOLWIDK-JTQLQIEISA-N_|_Small molecule_|_False_|_CARBIDOPA ANHYDROUS_|_1975.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Carbidopa, l- anhydrous']_|_[('PubChem', array(['11113507', '144204461', '26749935', '29215028', '50104417',
       '50104418', '8139862', '93576631'], dtype=object)), ('Wikipedia', array(['Carbidopa'], dtype=object)), ('drugbank', array(['DB00190'], dtype=object)), ('chEBI', array(['39585'], dtype=object))]_|_['CHEMBL1200748']_|_{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0003770', 'EFO_1001402',
       'EFO_0002610', 'Orphanet_1764', 'EFO_0000546', 'EFO_0003768',
       'MONDO_0018910', 'MONDO_0005301', 'MONDO_0007113', 'HP_0002381',
       'EFO_0005252', 'EFO_0005687', 'MONDO_0004979', 'HP_0012532',
       'MONDO_0005180', 'HP_0003418', 'EFO_0000537', 'MONDO_0019200',
       'MONDO_0005090', 'EFO_0003888', 'MONDO_0001020', 'EFO_1001175',
       'EFO_0003843', 'MONDO_0004976', 'EFO_0001365'], dtype=object), 'count': 27}_|_[ENSG00000132437]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 23 investigational indications."
CHEMBL1201608,"nan_|_nan_|_Antibody_|_True_|_MUROMONAB-CD3_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Orthoclone okt3']_|_['Anticd3' 'L04AA02' 'Macs gmp cd3 pure' 'Muromomab' 'Muromonab'
 'Muromonab cd3' 'Muromonab-cd3' 'OKT-3' 'OKT3']_|_[('DrugCentral', array(['5177'], dtype=object)), ('Wikipedia', array(['Muromonab-CD3'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002367', 'MONDO_0004992', 'EFO_0000756', 'EFO_0000616',
       'EFO_0000389', 'EFO_0000540', 'EFO_1000158', 'EFO_1001249',
       'EFO_0003865', 'EFO_0000729'], dtype=object), 'count': 10}_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for immune system disease and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201759,"O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1_|_UDGHXQPQKQPSBB-BOXHHOBZSA-N_|_Small molecule_|_False_|_BEPOTASTINE BESYLATE_|_2009.0_|_4.0_|_CHEMBL1201758_|_False_|_True_|_['Bepreve']_|_['BB' 'Bepotastine Besilate' 'Bepotastine benzenesulfonate salt'
 'Bepotastine besilate' 'Bepotastine besylate' 'TAU-284' 'Talion']_|_[('DailyMed', array(['bepotastine%20besilate'], dtype=object)), ('chEBI', array(['31281'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001417', 'EFO_0007141', 'HP_0000989'], dtype=object), 'count': 3}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for allergic conjunctivitis and pruritus and has 1 investigational indication."
CHEMBL1770248,"CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1_|_MCIACXAZCBVDEE-CUUWFGFTSA-N_|_Small molecule_|_False_|_ERTUGLIFLOZIN_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Steglatro']_|_['Ertugliflozin' 'MK-8835' 'PF-04971729' 'PF-04971729-00' 'PF04971729'
 'Pf-04971729']_|_[('DailyMed', array(['ertugliflozin'], dtype=object)), ('drugbank', array(['DB11827'], dtype=object))]_|_['CHEMBL3526992' 'CHEMBL5315054']_|_{'rows': array(['MONDO_0005148', 'MONDO_0005148', 'EFO_0000400', 'EFO_0003144'],
      dtype=object), 'count': 4}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 1 investigational indication."
CHEMBL2103825,"CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1_|_MVCQKIKWYUURMU-UHFFFAOYSA-N_|_Small molecule_|_False_|_CETILISTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATL-962' 'Cetilistat']_|_[('drugbank', array(['DB06586'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000182333,ENSG00000175535]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105629,"CC[C@]12C=CCN3CC[C@@]4(c5cc([C@@]6(C(=O)OC)C[C@@H]7C[C@@H](C(C)(F)F)CN(Cc8c6[nH]c6ccccc86)C7)c(OC)cc5N(C)[C@H]4[C@@](O)(C(=O)OC)[C@@H]1OC(C)=O)[C@@H]32.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O_|_YIHUEPHBPPAAHH-PEPODRRYSA-N_|_Small molecule_|_False_|_VINFLUNINE DITARTRATE_|_2009.0_|_4.0_|_CHEMBL2110725_|_False_|_True_|_['Javlor']_|_['BMS-710485' 'F-12158' 'Vinflunine bitartrate' 'Vinflunine ditartrate'
 'Vinflunine tartrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/javlor'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009."
CHEMBL2108720,"nan_|_nan_|_Antibody_|_False_|_OXELUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HUMAB OX-40L' 'HUMAB OX40L' 'Humab ox 40l' 'Oxelumab' 'R-4930'
 'R-4930 HUMAB OX40L' 'R-4930 HUMABOX40L' 'R4930' 'RO-49-89991'
 'RO-4989991' 'RO4989991']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000117586]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109485,nan_|_nan_|_Antibody_|_False_|_ONCOLYSIN CD6_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONCOLYSIN CD6']_|_nan_|_nan_|_nan_|_[ENSG00000013725]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2386889,"Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1_|_GMIZZEXBPRLVIV-SECBINFHSA-N_|_Small molecule_|_False_|_SCH-900776_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-8776' 'Mk-8776' 'SCH 900776' 'SCH-900776' 'Sch-900776']_|_[('drugbank', array(['DB11899'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000183', 'EFO_0000220', 'EFO_0000222', 'EFO_0000339',
       'EFO_0005952'], dtype=object), 'count': 5}_|_[ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL332750,"CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC_|_XDBHURGONHZNJF-UHFFFAOYSA-N_|_Small molecule_|_False_|_TETOMILAST_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['OPC-6535' 'Tetomilast']_|_[('drugbank', array(['DB05298'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0000729', 'EFO_0000384'], dtype=object), 'count': 3}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3544989,"nan_|_nan_|_Oligonucleotide_|_False_|_VOLANESORSEN SODIUM_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Waylivra']_|_['ISIS 304801' 'ISIS 304801 SODIUM SALT' 'ISIS-304801 SODIUM'
 'ISIS-304801 SODIUM SALT' 'Volanesorsen sodium' 'salt']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/waylivra'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000727', 'MONDO_0009387'], dtype=object), 'count': 2}_|_[ENSG00000110245]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for familial lipoprotein lipase deficiency and has 1 investigational indication."
CHEMBL3642985,"Cc1nc(C#Cc2ccc(-c3cc(F)cc(C#N)c3)nc2)cs1_|_SYOSUEIMOYEGKU-UHFFFAOYSA-N_|_Small molecule_|_False_|_STX107_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Stx107']_|_nan_|_nan_|_{'rows': array(['MONDO_0010383'], dtype=object), 'count': 1}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL373742,"N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O_|_KBZOIRJILGZLEJ-LGYYRGKSSA-N_|_Protein_|_False_|_VASOPRESSIN_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Beta-Hypophamine' 'Leiormone' 'Pitressin' 'Vasophysin' 'Vasostrict']_|_['Arginine Vasopressin' 'Arginine vasopressin' 'Argipressin or lypressin'
 'Vasopressin' 'Vasopressin injection' 'Vasopressin, unspecified']_|_[('DailyMed', array(['vasopressin'], dtype=object)), ('PubChem', array(['144206588', '29218064'], dtype=object)), ('chEBI', array(['34543'], dtype=object))]_|_['CHEMBL2360839']_|_{'rows': array(['MONDO_0003061', 'EFO_0003756', 'EFO_1001255', 'EFO_0003843',
       'EFO_0009637', 'MONDO_0001572', 'EFO_0004610', 'EFO_0003758',
       'MONDO_0002009', 'MONDO_0005149', 'EFO_0004278', 'EFO_0006834',
       'EFO_0003777', 'EFO_0005251', 'EFO_0009492', 'MONDO_0004782',
       'EFO_0005207', 'HP_0031273', 'HP_0100806'], dtype=object), 'count': 19}_|_[ENSG00000126895,ENSG00000166148,ENSG00000198049]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes insipidus and sepsis and has 17 investigational indications."
CHEMBL3989566,COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)/C=C/C(=O)O_|_BRIPGNJWPCKDQZ-WXXKFALUSA-N_|_Small molecule_|_False_|_METOPROLOL FUMARATE_|_1989.0_|_4.0_|_CHEMBL13_|_False_|_True_|_['Lopressor' 'Metoros' 'Metoros ls']_|_['CGP 2175C' 'CGP-2175C' 'Metoprolol fumarate']_|_nan_|_nan_|_nan_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989.
CHEMBL3991932,"Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1_|_LNMRSSIMGCDUTP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PEXMETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARRY-614' 'Arry-614' 'Pexmetinib']_|_nan_|_nan_|_{'rows': array(['EFO_0000198'], dtype=object), 'count': 1}_|_[ENSG00000112062,ENSG00000120156]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297830,"nan_|_nan_|_Protein_|_False_|_SOMATROGON_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Ngenla']_|_['Ctp-somatropin fusion protein' 'MOD-4023' 'MOD4023' 'Mod-4023'
 'Somatrogon' 'Somatropin-ctp fusion protein']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001109'], dtype=object), 'count': 1}_|_[ENSG00000112964]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for pituitary dwarfism."
CHEMBL4298088,"nan_|_nan_|_Antibody drug conjugate_|_False_|_CETUXIMAB SAROTALOCAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASP-1929' 'Cetuximab sarotalocan' 'Cetuximab sarotalocan sodium'
 'Cetuximab-IRDye-700DX' 'Cetuximab-irdye 700dx conjugate' 'RM-1929']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CETUXIMAB%20SAROTALOCAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298119,"nan_|_nan_|_Antibody_|_False_|_OLINVACIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Olinvacimab' 'TTAC-0001' 'Tanibirumab' 'Ttac-0001']_|_nan_|_nan_|_{'rows': array(['EFO_0005537', 'MONDO_0007254', 'EFO_0000519'], dtype=object), 'count': 3}_|_[ENSG00000128052]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL447955,"C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_FLNYCRJBCNNHRH-OIYLJQICSA-N_|_Small molecule_|_False_|_SERLOPITANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-0594' 'Serlopitant' 'VPD-737' 'Vpd-737']_|_[('drugbank', array(['DB12973'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000989', 'EFO_1000690'], dtype=object), 'count': 2}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4594565,"nan_|_nan_|_Protein_|_False_|_PABINAFUSP ALFA_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['JR-141' 'JR141' 'Jr-141' 'Pabinafusp alfa']_|_nan_|_nan_|_{'rows': array(['MONDO_0010674'], dtype=object), 'count': 1}_|_[ENSG00000072274,ENSG00000106327]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4650298,"nan_|_nan_|_Unknown_|_False_|_PLB1003_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PLB1003' 'Plb1003']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000171094,ENSG00000143924]_|_Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL59,"NCCc1ccc(O)c(O)c1_|_VYFYYTLLBUKUHU-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOPAMINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['A-dopamine' 'Dobutamine a' 'Dopamine' 'Intropin' 'Medopa' 'NSC-173182'
 'Oxytyramine']_|_[('PubChem', array(['104171172', '11111282', '124880336', '124880337', '124880340',
       '144203718', '170464942', '26750067', '26753786', '26753787',
       '50107800', '57288369', '90341661'], dtype=object)), ('Wikipedia', array(['Dopamine'], dtype=object)), ('drugbank', array(['DB00988'], dtype=object)), ('chEBI', array(['18243'], dtype=object))]_|_['CHEMBL3247442' 'CHEMBL1557']_|_{'rows': array(['EFO_0000400', 'EFO_0005207', 'EFO_0003917', 'EFO_0006834',
       'MONDO_0002050', 'EFO_0003144', 'MONDO_0005180', 'EFO_0000612',
       'HP_0031273', 'MONDO_0005180', 'EFO_0000373', 'HP_0100543',
       'EFO_0000319', 'EFO_1002048'], dtype=object), 'count': 14}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 9 investigational indications."
CHEMBL657,"CN(C)CCOC(c1ccccc1)c1ccccc1_|_ZZVUWRFHKOJYTH-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENHYDRAMINE_|_1946.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Antitussive' 'Beldin' 'Belix' 'Benadryl' 'Benylin' 'Dibenil' 'Diphen'
 'Diphenhdyra' 'Diphenhydramine' 'Hydramine' 'Restamin' 'Silphen']_|_[('PubChem', array(['104171144', '11111059', '11111060', '124879862', '124879863',
       '144203678', '170466857', '26751623', '50100219', '50104292',
       '85148365', '90341811'], dtype=object)), ('Wikipedia', array(['Diphenhydramine'], dtype=object)), ('drugbank', array(['DB01075'], dtype=object)), ('chEBI', array(['4636'], dtype=object))]_|_['CHEMBL1620' 'CHEMBL1201089']_|_{'rows': array(['MONDO_0005271', 'MONDO_0007915', 'EFO_0005592', 'EFO_0000220',
       'MONDO_0011962', 'EFO_0000384', 'MONDO_0005277', 'EFO_0005761',
       'MONDO_0002009', 'MONDO_0007915', 'Orphanet_365', 'EFO_0005252',
       'EFO_1000783', 'EFO_0004270', 'EFO_0000540', 'EFO_0000616',
       'MP_0001845', 'EFO_0005761', 'Orphanet_60', 'EFO_0003086',
       'EFO_0003758', 'MONDO_0002367', 'EFO_0000403', 'EFO_0000574',
       'HP_0002013', 'EFO_0005230', 'HP_0000989', 'EFO_0006890',
       'EFO_0003958', 'EFO_0004698', 'EFO_0009688', 'EFO_0000095',
       'EFO_0004239', 'EFO_0008521', 'HP_0001742', 'EFO_0000222',
       'EFO_0005531', 'EFO_1000657', 'HP_0001945', 'EFO_0003938',
       'EFO_0009104', 'MONDO_0008903', 'EFO_0005854', 'EFO_0004599',
       'EFO_0001378', 'MONDO_0001056', 'MONDO_0007254', 'HP_0012735',
       'MONDO_0005271', 'MONDO_0008315', 'EFO_0003060', 'EFO_0006928',
       'MONDO_0007079', 'EFO_0004255', 'EFO_0000198', 'MONDO_0002050',
       'EFO_0009516', 'EFO_1001904', 'HP_0002017', 'EFO_0007160',
       'HP_0002018', 'HP_0002315', 'EFO_0000701', 'HP_0000726',
       'EFO_0009847', 'MONDO_0002258', 'EFO_0002610', 'EFO_0000403',
       'EFO_0000096', 'EFO_0000681', 'MONDO_0004658', 'MONDO_0004992',
       'MONDO_0005090', 'EFO_0003843', 'HP_0000989', 'EFO_0007359',
       'MONDO_0044917', 'EFO_0005952', 'MONDO_0017287', 'EFO_0000274',
       'EFO_0007214', 'EFO_0003956', 'EFO_0008520', 'EFO_0003843',
       'HP_0012735'], dtype=object), 'count': 85}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 19 approved and 63 investigational indications."
CHEMBL1172,"Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1_|_JAUOIFJMECXRGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_DESLORATADINE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Aerius' 'Clarinex' 'Desloratadine' 'Midetorin' 'Neoclarityn']_|_['Allex' 'Azomyr' 'Dasselta' 'Denosin' 'Descarboethoxyloratadine'
 'Desloratadine' 'Desloratadine actavis' 'Desloratadine teva'
 'Loratadine related compound a' 'Loratadine related compound a rs'
 'NSC-759824' 'Opulis' 'SCH 34117' 'SCH-34117']_|_[('DailyMed', array(['desloratadine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn'],
      dtype=object)), ('PubChem', array(['144205127', '14742700', '170464781', '26719697', '26754458',
       '29215232', '50086379'], dtype=object)), ('Wikipedia', array(['Desloratadine'], dtype=object)), ('drugbank', array(['DB00967'], dtype=object)), ('chEBI', array(['291342'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003956', 'EFO_0007214', 'EFO_0005854', 'MONDO_0002406',
       'EFO_0007141', 'HP_0000989', 'HP_0000964', 'MONDO_0005271',
       'EFO_0003060', 'EFO_1001417', 'EFO_0005531', 'EFO_0008520',
       'Orphanet_79292', 'EFO_0000274'], dtype=object), 'count': 14}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 9 investigational indications."
CHEMBL1200490,"CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O_|_SBNPWPIBESPSIF-MHWMIDJBSA-N_|_Protein_|_False_|_CETRORELIX_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Cetrotide']_|_['Cetrorelix']_|_[('Wikipedia', array(['Cetrorelix'], dtype=object)), ('drugbank', array(['DB00050'], dtype=object)), ('chEBI', array(['59224'], dtype=object))]_|_['CHEMBL2103735']_|_{'rows': array(['EFO_0000545', 'MONDO_0011972', 'EFO_0000685', 'EFO_0001065',
       'EFO_0000284', 'EFO_0000545', 'EFO_0000660'], dtype=object), 'count': 7}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 investigational indications."
CHEMBL1200782,"C[C@H](N)Cc1ccccc1.O=C(O)CCCCC(=O)O_|_OFCJKOOVFDGTLY-QRPNPIFTSA-N_|_Small molecule_|_False_|_DEXTROAMPHETAMINE ADIPATE_|_1975.0_|_4.0_|_CHEMBL612_|_False_|_True_|_[]_|_['D-amphetamine adipate' 'Dextroamphetamine adipate']_|_nan_|_nan_|_nan_|_[ENSG00000142319,ENSG00000103546,ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975."
CHEMBL1200978,"O=[As]O[As]=O_|_IKWTVSLWAPBBKU-UHFFFAOYSA-N_|_Small molecule_|_True_|_ARSENIC TRIOXIDE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Arsenic trioxide mylan' 'Trisenox']_|_['Arseneous anhydride' 'Arseneous oxide' 'Arsenic oxide'
 'Arsenic oxide (as4o6)' 'Arsenic sesquioxide' 'Arsenic trioxide'
 'Arsenicum album' 'Arsenous oxide' 'Diarsenic trioxide' 'NSC-759274'
 'NSC-92859' 'Tetraarsenic hexaoxide' 'White arsenic']_|_[('DailyMed', array(['arsenic%20trioxide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/arsenic-trioxide-mylan'],
      dtype=object)), ('PubChem', array(['26758061'], dtype=object)), ('Wikipedia', array(['Arsenic_trioxide'], dtype=object)), ('drugbank', array(['DB01169'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_1001512', 'EFO_0003060', 'EFO_0000479',
       'MONDO_0002974', 'EFO_0000339', 'MONDO_0020547', 'EFO_0000222',
       'EFO_0002429', 'MONDO_0004992', 'EFO_1001951', 'EFO_1000158',
       'EFO_0000095', 'MONDO_0008627', 'MONDO_0007254', 'EFO_0000565',
       'EFO_0000616', 'EFO_0000765', 'EFO_0000224', 'EFO_1001465',
       'EFO_0000702', 'MONDO_0007915', 'EFO_0000574', 'MONDO_0002367',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_0000621', 'MONDO_0002691',
       'EFO_0001378', 'EFO_0002430', 'MONDO_0044903', 'EFO_0002617',
       'MONDO_0004192', 'MONDO_0004986', 'EFO_0002618', 'EFO_0000198',
       'MONDO_0005341', 'MONDO_0001657'], dtype=object), 'count': 38}_|_[ENSG00000198431]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 35 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201325,"C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1_|_ZRYHPQCHHOKSMD-UHFFFAOYSA-N_|_Small molecule_|_False_|_HEXOCYCLIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hexocyclium' 'Hexocyclium cation' 'Hexocyclium ion']_|_[('Wikipedia', array(['Hexocyclium'], dtype=object)), ('drugbank', array(['DB06787'], dtype=object)), ('chEBI', array(['5707'], dtype=object))]_|_['CHEMBL1626570']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease."
CHEMBL190412,"COCCOCCOCCOCCOC(=O)OC[n+]1ccc(N/C(=N/C#N)NCCCCCCOc2ccc(Cl)cc2)cc1.[Cl-]_|_DAHMXVAETAAQOZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEGLARINAD CHLORIDE_|_nan_|_2.0_|_CHEMBL1181731_|_False_|_False_|_[]_|_['EB-1627' 'EB1627' 'GMX-1777' 'GMX1777' 'Teglarinad chloride']_|_nan_|_nan_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000105835]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2017974,"Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1_|_CWHUFRVAEUJCEF-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUPARLISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BKM-120' 'BKM-120NX' 'BKM120-NX' 'Bkm-120' 'Buparlisib' 'NVP-BKM-120'
 'NVP-BKM120']_|_[('PubChem', array(['137275918'], dtype=object)), ('drugbank', array(['DB11666'], dtype=object)), ('chEBI', array(['71954'], dtype=object))]_|_['CHEMBL2364604']_|_{'rows': array(['EFO_1000581', 'MONDO_0044903', 'EFO_0000519', 'EFO_0000403',
       'EFO_0000565', 'EFO_0000702', 'EFO_0003060', 'EFO_0000095',
       'MONDO_0018906', 'MONDO_0008903', 'MONDO_0011719', 'MONDO_0007576',
       'MONDO_0007254', 'EFO_0006859', 'MONDO_0002108', 'EFO_0001421',
       'EFO_1001469', 'EFO_0003086', 'EFO_1001951', 'EFO_0000756',
       'EFO_0000616', 'EFO_0003869', 'MONDO_0011962', 'MONDO_0002974',
       'EFO_0000181', 'MONDO_0008315'], dtype=object), 'count': 26}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications."
CHEMBL2105741,"CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1.C[S+](C)[O-]_|_OQUFJVRYDFIQBW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRAMETINIB DIMETHYL SULFOXIDE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Mekinist']_|_['GSK-1120212B' 'GSK1120212B' 'Trametinib dimethyl sulfoxide']_|_[('DailyMed', array(['trametinib%20dimethyl%20sulfoxide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist'],
      dtype=object)), ('chEBI', array(['75991'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002617', 'MONDO_0004992', 'MONDO_0002108', 'EFO_1000926',
       'MONDO_0008903', 'EFO_0001378', 'EFO_0000389'], dtype=object), 'count': 7}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 3 investigational indications."
CHEMBL2108292,"nan_|_nan_|_Protein_|_False_|_EPTACOG ALFA PEGOL (ACTIVATED)_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Activated recombinant human factor vii, long acting'
 'Eptacog alfa pegol (activated)']_|_nan_|_nan_|_{'rows': array(['MONDO_0010604', 'MONDO_0010602'], dtype=object), 'count': 2}_|_[ENSG00000057593]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109467,"nan_|_nan_|_Antibody_|_False_|_ORDESEKIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 714' 'AMG-714' 'AMG714' 'Amg 714' 'HuMax-IL-15' 'Humax il15'
 'Humax-il 15' 'MAb146B7' 'Ordesekimab' 'PRV-015' 'Prv-015']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ORDESEKIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0004208', 'EFO_0001060', 'EFO_0000685',
       'EFO_0005809'], dtype=object), 'count': 5}_|_[ENSG00000164136]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2110731,"CCc1ccc(Cc2ccc3c(c2)[C@]2(OC3)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1_|_VWVKUNOPTJGDOB-BDHVOXNPSA-N_|_Small molecule_|_False_|_TOFOGLIFLOZIN ANHYDROUS_|_2014.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CSG-452' 'R-7201' 'RO-4998452' 'RO4998452']_|_[('drugbank', array(['DB11824'], dtype=object))]_|_['CHEMBL2105711']_|_{'rows': array(['MONDO_0005148', 'EFO_1001249'], dtype=object), 'count': 2}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 2 investigational indications."
CHEMBL289480,"C1COC(NC(C2CC2)C2CC2)=N1_|_CQXADFVORZEARL-UHFFFAOYSA-N_|_Small molecule_|_False_|_RILMENIDINE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hyperium' 'Rilmenidine']_|_[('PubChem', array(['104171229', '11111726', '11111727', '11113329', '124881316',
       '144203805', '170466278', '50103956', '510678', '85231209',
       '90340708'], dtype=object)), ('Wikipedia', array(['Rilmenidine'], dtype=object)), ('drugbank', array(['DB11738'], dtype=object)), ('chEBI', array(['8862'], dtype=object))]_|_['CHEMBL1256674']_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000010322]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and has 1 investigational indication."
CHEMBL398338,CC(C)(C)c1ccc2c(c1)CC[C@H]2NC(=O)Nc1cccc2[nH]ncc12_|_TYOYXJNGINZFET-GOSISDBHSA-N_|_Small molecule_|_False_|_ABT-102_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ABT-102' 'Abt-102']_|_nan_|_nan_|_nan_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL4297460,"CCOc1cc([C@@H](CS(C)(=O)=O)N2Cc3cccc(NC(=O)C4CC4)c3C2=O)ccc1OC_|_QDZOBXFRIVOQBR-LJQANCHMSA-N_|_Small molecule_|_False_|_DOVRAMILAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CC-11050' 'CC11050' 'Cc-11050' 'Dovramilast']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018076', 'EFO_0003834'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297537,"nan_|_nan_|_Oligonucleotide_|_True_|_INOTERSEN SODIUM_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Tegsedi']_|_[]_|_[('DailyMed', array(['inotersen%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tegsedi'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004129', 'EFO_1001875', 'EFO_0009562'], dtype=object), 'count': 3}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL4297862,"nan_|_nan_|_Protein_|_True_|_BOTULINUM TOXIN TYPE A_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Nuceiva']_|_['Agn-151607' 'Ant-1401' 'Ant-1403' 'Botulift' 'Botulinum a toxin'
 'Botulinum toxin type a' 'Btx-a' 'Cunox' 'Neuronox' 'RTI-150' 'RTI150']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nuceiva'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_93955', 'EFO_0009846', 'HP_0000473', 'MONDO_0005277',
       'HP_0000975', 'EFO_1000781', 'EFO_0005422', 'EFO_0006865',
       'EFO_1000999'], dtype=object), 'count': 9}_|_[ENSG00000132639]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4298191,"nan_|_nan_|_Antibody_|_False_|_SASANLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PF-06801591' 'RN-888' 'Sasanlimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SASANLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0008528', 'MONDO_0001187', 'EFO_0000616',
       'EFO_0000673', 'EFO_0009708'], dtype=object), 'count': 6}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL53,"CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3_|_VMWNQDUVQKEIOC-CYBMUJFWSA-N_|_Small molecule_|_False_|_APOMORPHINE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['6a.beta.-aporphine-10,11-diol' 'APL-130277' 'Apomorphine' 'Apomorphinum'
 'VR-040' 'VR040']_|_[('PubChem', array(['11114270', '144204518', '170465297', '26752261'], dtype=object)), ('Wikipedia', array(['Apomorphine'], dtype=object)), ('drugbank', array(['DB00714'], dtype=object)), ('chEBI', array(['48538'], dtype=object))]_|_['CHEMBL3187985' 'CHEMBL1256708' 'CHEMBL1616' 'CHEMBL5314363']_|_{'rows': array(['EFO_0004234', 'HP_0000802', 'MONDO_0005180', 'MONDO_0005180',
       'MONDO_0007079', 'EFO_0000616', 'MONDO_0043510', 'HP_0000738',
       'EFO_0003882'], dtype=object), 'count': 9}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 5 investigational indications."
CHEMBL1200430,"CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12_|_FHXBMXJMKMWVRG-SLHNCBLASA-N_|_Small molecule_|_True_|_ESTRADIOL ACETATE_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Femring' 'Femtrace']_|_['E3A' 'ESTRADIOL-3-ACETATE' 'Estradiol 3-acetate' 'Estradiol acetate']_|_[('DailyMed', array(['estradiol%20acetate'], dtype=object)), ('PubChem', array(['144204912', '170465258'], dtype=object)), ('drugbank', array(['DB13952'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000096', 'GO_0042697'], dtype=object), 'count': 2}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for atrophy and menopause. This drug has a black box warning from the FDA."
CHEMBL1200733,"FC(F)OC(F)C(F)(F)F_|_DPYMFVXJLLWWEU-UHFFFAOYSA-N_|_Small molecule_|_False_|_DESFLURANE_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Suprane']_|_['Desflurane' 'I-653']_|_[('DailyMed', array(['desflurane'], dtype=object)), ('Wikipedia', array(['Desflurane'], dtype=object)), ('drugbank', array(['DB01189'], dtype=object)), ('chEBI', array(['4445'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005323', 'EFO_1002048'], dtype=object), 'count': 2}_|_[ENSG00000169427,ENSG00000186795,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000171303,ENSG00000145888,ENSG00000109738,ENSG00000082482,ENSG00000100433]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 2 investigational indications."
CHEMBL1237065,"COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl_|_PPKXEPBICJTCRU-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRAMADOL HYDROCHLORIDE_|_1995.0_|_4.0_|_CHEMBL1237044_|_False_|_True_|_['Aceon' 'Conzip' 'Dromadol sr' 'Dromadol xl' 'Invodol sr' 'Larapam sr'
 'Mabron' 'Maneo' 'Marol' 'Maxitram sr' 'Nobligan ret' 'Oldaram' 'Qdolo'
 'Rybix odt' 'Ryzolt' 'Tilodol sr' 'Tradorec xl' 'Tramacet'
 'Tramadol hydrochloride' 'Tramake' 'Tramake insts' 'Tramquel sr'
 'Tramulief sr' 'Ultram' 'Ultram er' 'Zamadol' 'Zamadol 24hr'
 'Zamadol melt' 'Zamadol sr' 'Zeridame sr' 'Zydol' 'Zydol sr' 'Zydol xl']_|_['Amadol' 'CG-315' 'CG-315E' 'Contramal' 'NIH-10969' 'NSC-759105'
 'Tradonal' 'Tramadol hcl' 'Tramadol hydrochloride'
 'Tramadol hydrochloride civ' 'Tramal' 'U-26,225A' 'U-26225A' 'Zamudol'
 'Zertane']_|_[('DailyMed', array(['tramadol%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012532', 'EFO_0010072', 'HP_0003419', 'EFO_0803321',
       'EFO_0003843', 'EFO_0003890', 'MONDO_0004992'], dtype=object), 'count': 7}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1642,"CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1_|_YLMAHDNUQAMNNX-UHFFFAOYSA-N_|_Small molecule_|_False_|_IMATINIB MESYLATE_|_2001.0_|_4.0_|_CHEMBL941_|_False_|_True_|_['Gleevec' 'Glivec' 'Imatinib accord' 'Imatinib mesylate']_|_['Gleevec' 'Imatinib (as mesilate)' 'Imatinib accord' 'Imatinib medac'
 'Imatinib mesilate' 'Imatinib mesylate' 'Imatinib methane sulfonate'
 'Imatinib methanesulfonate' 'NSC-716051' 'QTI-571' 'QTI571' 'Qti571'
 'STI 571' 'STI-571' 'STI571']_|_[('DailyMed', array(['imatinib%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-accord'],
      dtype=object)), ('PubChem', array(['144205237', '170465393', '49681833'], dtype=object)), ('chEBI', array(['31690'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006861', 'EFO_0000389', 'MONDO_0008903', 'EFO_0000333',
       'EFO_0000768', 'EFO_0003060', 'EFO_0000760', 'EFO_1001361',
       'EFO_0004683', 'EFO_0001361', 'MONDO_0011934', 'MONDO_0000870',
       'MONDO_0004979', 'EFO_0006859', 'EFO_0000094', 'EFO_0005952',
       'EFO_0000616', 'EFO_0004198', 'MONDO_0011382', 'MONDO_0011719',
       'MONDO_0008315', 'EFO_0000339', 'EFO_0000717', 'EFO_0000220',
       'MONDO_0004992', 'MONDO_0002367', 'MONDO_0002087', 'EFO_1000158',
       'MONDO_0005301', 'EFO_0000519', 'MONDO_0018975', 'MONDO_0005147',
       'EFO_1001951', 'EFO_1001465', 'MONDO_0002108', 'MONDO_0011705',
       'MONDO_0002158', 'EFO_0000702', 'EFO_0002429', 'HP_0001880',
       'MONDO_0013730', 'EFO_0000588', 'EFO_0009907', 'EFO_1000729',
       'EFO_0000503', 'EFO_1001467', 'EFO_1001814', 'EFO_0000673',
       'EFO_0000658', 'EFO_1001993', 'MONDO_0021063', 'MONDO_0005149',
       'EFO_0002430', 'MONDO_0011962', 'MONDO_0009937', 'EFO_0000222',
       'EFO_0000691', 'MONDO_0008170', 'EFO_0001376', 'EFO_1000657',
       'MONDO_0044917', 'EFO_0002428', 'MONDO_0020547', 'MONDO_0100096',
       'EFO_0002618', 'MONDO_0018364', 'MONDO_0002715', 'EFO_0000313',
       'EFO_0004289', 'MONDO_0000873', 'EFO_0000209', 'MONDO_0007254',
       'EFO_0000565', 'EFO_1000613', 'EFO_0000574', 'MONDO_0001056',
       'EFO_0000756', 'EFO_1001471'], dtype=object), 'count': 78}_|_[ENSG00000097007,ENSG00000186716,ENSG00000113721,ENSG00000157404]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for chronic myelogenous leukemia and has 77 investigational indications."
CHEMBL1743001,"nan_|_nan_|_Antibody_|_False_|_CIXUTUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cixutumumab' 'IMC-A12' 'NSC-742460']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_0003050', 'EFO_0000756', 'EFO_0000571',
       'MONDO_0008903', 'MONDO_0021063', 'EFO_1001951', 'EFO_0003060',
       'EFO_0000588', 'EFO_1001968', 'EFO_0000181', 'EFO_1000796',
       'EFO_1000657', 'MONDO_0008315', 'EFO_0006859', 'EFO_0002618',
       'EFO_0006861', 'EFO_0000437', 'EFO_0000637', 'MONDO_0007254',
       'EFO_0000182', 'EFO_0000673', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0000248', 'EFO_1000294'], dtype=object), 'count': 26}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 26 investigational indications."
CHEMBL1743072,"nan_|_nan_|_Antibody_|_False_|_SOLANEZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-2062430' 'LY2062430' 'Solanezumab']_|_nan_|_nan_|_{'rows': array(['HP_0100543', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1743077,nan_|_nan_|_Antibody_|_False_|_TENATUMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ST-2146' 'Tenatumomab']_|_nan_|_nan_|_nan_|_[ENSG00000041982]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL1950651,"COC(=O)N1CCC(CC#Cc2nc(N)c3ncn([C@@H]4O[C@H](C(=O)NC5CC5)[C@@H](O)[C@H]4O)c3n2)CC1_|_SQJXTUJMBYVDBB-RQXXJAGISA-N_|_Small molecule_|_False_|_EVODENOSON_|_nan_|_2.0_|_nan_|_False_|_False_|_['Atl313, de-112']_|_['ATL-313' 'ATL313' 'Atl313' 'DE-112' 'Evodenoson']_|_[('drugbank', array(['DB12295'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004190', 'EFO_1001069'], dtype=object), 'count': 2}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2103826,"CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)O_|_DWLTUUXCVGVRAV-XWRHUKJGSA-N_|_Protein_|_False_|_DAVUNETIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AL-108' 'AL-208' 'Davunetide']_|_[('drugbank', array(['DB12613'], dtype=object))]_|_nan_|_{'rows': array(['HP_0100543', 'MONDO_0019037', 'MONDO_0005090'], dtype=object), 'count': 3}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2105527,"CN1C(=O)CN=C(C2=CCCCC2)c2cc(Cl)ccc21_|_IQWYAQCHYZHJOS-UHFFFAOYSA-N_|_Small molecule_|_False_|_TETRAZEPAM_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['CB 4261' 'CB-4261' 'Myolastan' 'Tetrazepam']_|_[('drugbank', array(['DB13324'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2109337,"nan_|_nan_|_Antibody_|_False_|_MDX-1342_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MDX-1342' 'Mdx-1342']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0000095'], dtype=object), 'count': 2}_|_[ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL218291,"O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12_|_IWKXDMQDITUYRK-KUBHLMPHSA-N_|_Small molecule_|_False_|_FORODESINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BCX-1777' 'Forodesine' 'Immucillin h' 'Mundesine' 'NSC-717904']_|_[('Wikipedia', array(['Forodesine'], dtype=object)), ('drugbank', array(['DB06185'], dtype=object)), ('chEBI', array(['43362'], dtype=object))]_|_['CHEMBL550755' 'CHEMBL1213652']_|_{'rows': array(['EFO_0000574', 'EFO_0002913', 'EFO_0000095', 'MONDO_0000430',
       'EFO_0000094', 'EFO_0000095', 'EFO_0000565', 'EFO_0004289',
       'EFO_0000574', 'MONDO_0004992'], dtype=object), 'count': 10}_|_[ENSG00000198805]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL292376,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1_|_ZVQUCWXZCKWZBP-CQSZACIVSA-N_|_Small molecule_|_False_|_TECALCET_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tecalcet']_|_nan_|_['CHEMBL2107572']_|_nan_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3137332,"Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F_|_GFPPXZDRVCSVNR-UHFFFAOYSA-N_|_Small molecule_|_False_|_FEVIPIPRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fevipiprant' 'NVP-QAW039' 'QAW-039' 'QAW039']_|_[('drugbank', array(['DB12011'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000083', 'EFO_0005854', 'HP_0001880', 'EFO_1000391',
       'EFO_0001421', 'EFO_0000274', 'MONDO_0004979', 'EFO_0000341'],
      dtype=object), 'count': 8}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL388590,"CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1_|_WHQCHUCQKNIQEC-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZBROMARONE_|_nan_|_4.0_|_nan_|_True_|_True_|_['Desuric' 'Narcaricin mite']_|_['Benzbromaron' 'Benzbromarone' 'Benzpromarone' 'L-2214' 'MJ 10061'
 'MJ-10061' 'NSC-85433' 'Uroleap']_|_[('PubChem', array(['11110651', '122758', '144203592', '170465792', '24424558',
       '26664708', '4253342', '50103990', '56422114', '855676'],
      dtype=object)), ('TG-GATEs', array(['21'], dtype=object)), ('Wikipedia', array(['Benzbromarone'], dtype=object)), ('drugbank', array(['DB12319'], dtype=object)), ('chEBI', array(['3023'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0017147', 'EFO_0004274', 'EFO_0009104'], dtype=object), 'count': 3}_|_[ENSG00000197891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gout and has 2 investigational indications. It was withdrawn in at least one region."
CHEMBL4204869,"C[C@H]1OC[C@]2(c3cc(NC(=O)c4cnc(C(F)F)cn4)ccc3F)N=C(N)SC[C@H]12_|_AACUJFVOHGRMTR-DPXNYUHVSA-N_|_Small molecule_|_False_|_ELENBECESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['E-2609' 'E2609' 'Elenbecestat']_|_[('drugbank', array(['DB15391'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000186318]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297788,"nan_|_nan_|_Antibody_|_False_|_MOSUNETUZUMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Lunsumio']_|_['BTCT-4465A' 'BTCT4465A' 'Mosunetuzumab' 'Mosunetuzumab axgb'
 'Mosunetuzumab-axgb' 'RG-7828' 'RG7828' 'RO-7030816' 'RO7030816']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOSUNETUZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0000183', 'MONDO_0002334', 'MONDO_0007915',
       'EFO_0000403', 'MONDO_0018906', 'EFO_0000096', 'EFO_0000095'],
      dtype=object), 'count': 8}_|_[ENSG00000156738,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for follicular lymphoma and neoplasm of mature b-cells and has 6 investigational indications."
CHEMBL4298005,"nan_|_nan_|_Unknown_|_False_|_MITIGLINIDE CALCIUM DIHYDRATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Glufast' 'KAD-1229' 'Kad-1229' 'Mitiglinide calcium dihydrate'
 'Mitiglinide calcium hydrate' 'Mitiglinide calcium salt dihydrate'
 'S-21403']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000187486,ENSG00000006071]_|_Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4563522,"CCCC[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(N)=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O_|_AVYLMJODKHVQHD-WFOXQDBGSA-N_|_Protein_|_False_|_FE 203799_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fe 203799']_|_nan_|_nan_|_{'rows': array(['MONDO_0015183', 'EFO_0001421', 'EFO_0003884', 'MONDO_0013730'],
      dtype=object), 'count': 4}_|_[ENSG00000065325]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL49120,"CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1_|_IFPPYSWJNWHOLQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PD-0166285_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PD-0166285' 'TCMDC-140940']_|_[('PubChem', array(['103905313', '137275855', '307078458'], dtype=object))]_|_['CHEMBL3545196']_|_nan_|_[ENSG00000077782,ENSG00000197122,ENSG00000146648,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL567303,Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1_|_WYJCYXOCHXWTHG-UHFFFAOYSA-N_|_Small molecule_|_False_|_PALOSURAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Act-058362' 'Palosuran']_|_nan_|_['CHEMBL1164032']_|_nan_|_[ENSG00000181408]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL591,"C#CC(O)(/C=C/Cl)CC_|_ZEHYJZXQEQOSON-AATRIKPKSA-N_|_Small molecule_|_False_|_ETHCHLORVYNOL_|_1961.0_|_4.0_|_nan_|_False_|_True_|_['Ethchlorvynol' 'Placidyl']_|_['Alvinol' 'Arvynol' 'Ethchlorvynol' 'Ethchlorvynol civ' 'NSC-30372'
 'Normoson' 'Nostel' 'Roeridorm' 'Serenesil' 'Serensil']_|_[('Wikipedia', array(['Ethchlorvynol'], dtype=object)), ('drugbank', array(['DB00189'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL1201535,"nan_|_nan_|_Small molecule_|_False_|_PHENYLPROPANOLAMINE POLISTIREX_|_1984.0_|_4.0_|_CHEMBL61006_|_True_|_True_|_[]_|_['Phenylpropanolamine polistirex']_|_nan_|_nan_|_nan_|_[ENSG00000120907,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. It was withdrawn in at least one region."
CHEMBL1229517,"CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F_|_GPXBXXGIAQBQNI-UHFFFAOYSA-N_|_Small molecule_|_False_|_VEMURAFENIB_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Zelboraf']_|_['PLX-4032' 'PLX4032' 'RG 7204' 'RG-7204' 'RO 5185426' 'RO-51-85426'
 'RO-5185426' 'Vemurafenib']_|_[('DailyMed', array(['vemurafenib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf'],
      dtype=object)), ('Wikipedia', array(['Vemurafenib'], dtype=object)), ('drugbank', array(['DB08881'], dtype=object)), ('chEBI', array(['63637'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000326', 'EFO_0001642', 'MONDO_0002108',
       'EFO_1000209', 'EFO_1000956', 'EFO_0000756', 'MONDO_0002898',
       'EFO_0000222', 'HP_0100727', 'EFO_0002892', 'EFO_0000365',
       'MONDO_0004992', 'EFO_0002618', 'EFO_0002617', 'EFO_0001378',
       'EFO_0003060', 'EFO_0000574', 'EFO_0000389', 'EFO_1000318',
       'EFO_1001951'], dtype=object), 'count': 21}_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 5 approved and 16 investigational indications."
CHEMBL1305,"c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1_|_REYFJDPCWQRWAA-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANTAZOLINE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Antaz sulf' 'Vasocon-a']_|_['Antazoline' 'Atazoline' 'Vasocon-A']_|_[('PubChem', array(['11112519', '11113348', '124882433', '50100471', '50100472'],
      dtype=object)), ('Wikipedia', array(['Antazoline'], dtype=object)), ('drugbank', array(['DB08799'], dtype=object)), ('chEBI', array(['84115'], dtype=object))]_|_['CHEMBL1256819' 'CHEMBL1200550']_|_{'rows': array(['EFO_0000678', 'MP_0001845', 'HP_0001742', 'MONDO_0005271'],
      dtype=object), 'count': 4}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for nasal congestion and allergic disease and has 2 investigational indications."
CHEMBL1722209,"Cc1ccc(O)c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)c1.O=C(O)C(O)C(O)C(=O)O_|_TWHNMSJGYKMTRB-VEIFNGETSA-N_|_Small molecule_|_False_|_TOLTERODINE TARTRATE_|_1998.0_|_4.0_|_CHEMBL1382_|_False_|_True_|_['Detrol' 'Detrol la' 'Tolterodine tartrate']_|_['PNU-200583E' 'Tolterodine l-tartrate' 'Tolterodine tartrate']_|_[('DailyMed', array(['tolterodine%20tartrate'], dtype=object)), ('PubChem', array(['49681822'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006865', 'EFO_1000781'], dtype=object), 'count': 2}_|_[ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for urgency urinary incontinence and overactive bladder."
CHEMBL2105467,"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1_|_GFFXZLZWLOBBLO-ASKVSEFXSA-N_|_Small molecule_|_False_|_TEZACITABINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FMD-C' 'KW-2331' 'MDL-101731' 'Tezacitabine']_|_[('drugbank', array(['DB06433'], dtype=object))]_|_['CHEMBL3989496']_|_{'rows': array(['MONDO_0004992', 'EFO_0004142', 'EFO_0000228', 'EFO_0003897',
       'EFO_0002916'], dtype=object), 'count': 5}_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2109256,"nan_|_nan_|_Antibody_|_False_|_SGN-30_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SGN-30' 'Sgn-30']_|_nan_|_nan_|_{'rows': array(['EFO_0002913', 'EFO_0000558', 'EFO_0000183', 'EFO_0000574',
       'EFO_0003032', 'EFO_0001642'], dtype=object), 'count': 6}_|_[ENSG00000120949]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2109427,"nan_|_nan_|_Antibody_|_False_|_ZOLBETUXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Claudiximab' 'IMAB-362' 'IMAB362' 'Zolbetuximab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZOLBETUXIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000066405]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109484,"nan_|_nan_|_Antibody_|_False_|_BB-10901_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BB-10901' 'Bb-10901' 'HUN901-DM1']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000702'], dtype=object), 'count': 2}_|_[ENSG00000149294]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3301603,"CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O_|_UJOUWHLYTQFUCU-WXXKFALUSA-N_|_Small molecule_|_True_|_GILTERITINIB FUMARATE_|_2018.0_|_4.0_|_CHEMBL3301622_|_False_|_True_|_['Xospata']_|_['ASP-2215 HEMIFUMARATE' 'ASP2215 hemifumarate' 'Gilteritinib fumarate'
 'Gilteritinib hemifumarate']_|_[('DailyMed', array(['gilteritinib%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xospata'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004643', 'EFO_0000222'], dtype=object), 'count': 2}_|_[ENSG00000122025,ENSG00000167601]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for myeloid leukemia and acute myeloid leukemia. This drug has a black box warning from the FDA."
CHEMBL3545189,"nan_|_nan_|_Antibody_|_False_|_LANADELUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Takhzyro']_|_['DX-2930' 'Lanadelumab' 'Lanadelumab flyo' 'Lanadelumab-flyo' 'SHP-643'
 'Tak-743']_|_[('DailyMed', array(['landelumab-flyo'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000546', 'EFO_0005532', 'EFO_0005251', 'MONDO_0019623',
       'MONDO_0100096'], dtype=object), 'count': 5}_|_[ENSG00000164344]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for hereditary angioedema and has 4 investigational indications."
CHEMBL3707183,"C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12.O.O.O=S(=O)(O)O_|_ZHNFLHYOFXQIOW-AHSOWCEXSA-N_|_Small molecule_|_True_|_QUINIDINE SULFATE_|_1962.0_|_4.0_|_CHEMBL1294_|_False_|_True_|_['Cin-quin' 'Quinicardine' 'Quinidex' 'Quinidine sulfate' 'Quinora']_|_['AVP-786 COMPONENT QUINIDINE SULFATE' 'NSC-10004'
 'QUINIDINE SULFATE COMPONENT OF AVP-786' 'Quinidex extentabs'
 'Quinidine sulfate' 'Quinidine sulfate anhydrous'
 'Quinidine sulfate dihydrate' 'Quinidine sulfate hydrate'
 'Quinidine sulphate' 'Quinidine sulphate anhydrous'
 'Quinidine sulphate dihydrate' 'Quinidine, sulfate (2:1) (salt)'
 'Quinidini sulfas']_|_[('DailyMed', array(['quinidine%20sulfate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004976', 'EFO_0003758'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL408403,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O_|_CZGUSIXMZVURDU-JZXHSEFVSA-N_|_Protein_|_False_|_ANGIOTENSIN II_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['5-l-isoleucineangiotensin ii' 'Angiotensin ii'
 'Angiotensin ii (human type)' 'Angiotensin ii human'
 'Asp-arg-val-tyr-ile-his-pro-phe' 'Delivert' 'LJPC-501']_|_[('PubChem', array(['50112427'], dtype=object)), ('drugbank', array(['DB11842'], dtype=object)), ('chEBI', array(['2719'], dtype=object))]_|_['CHEMBL4303682' 'CHEMBL3989932']_|_{'rows': array(['EFO_1000645', 'EFO_0000319', 'MONDO_0001382', 'EFO_0005251',
       'EFO_0006834', 'EFO_0006834', 'EFO_0000537', 'HP_0031273'],
      dtype=object), 'count': 8}_|_[ENSG00000144891]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 4 investigational indications."
CHEMBL4297863,"nan_|_nan_|_Antibody_|_False_|_REMTOLUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-1230717' 'ABT-122' 'Abt-122' 'Remtolumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0003778'], dtype=object), 'count': 2}_|_[ENSG00000232810,ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594470,"nan_|_nan_|_Unknown_|_False_|_CVX-060_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CVX-060' 'CVX060' 'Cvx-060' 'PF-04856884' 'PF04856884' 'Pf-04856884']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0000681', 'EFO_0000313'], dtype=object), 'count': 3}_|_[ENSG00000091879]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4594531,"nan_|_nan_|_Unknown_|_False_|_BI-836826_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI 836826' 'BI-836826' 'Bi 836826' 'Bi-836826' 'Mab 37.1']_|_nan_|_nan_|_{'rows': array(['EFO_0000403', 'EFO_0000095', 'EFO_0005952'], dtype=object), 'count': 3}_|_[ENSG00000104894]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL482767,"O=C(Nc1cccc(Cl)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1_|_FAYAUAZLLLJJGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_SNS-314_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SNS-314' 'Sns 314' 'Sns-314']_|_[('PubChem', array(['103905586', '124950687'], dtype=object)), ('drugbank', array(['DB06134'], dtype=object))]_|_['CHEMBL518051']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL5314411,"C#Cc1cccc(Nc2ncnc3cc(OC)c(NC(=O)N4CCN(CC)CC4)cc23)c1_|_DQAZPZIYEOGZAF-UHFFFAOYSA-N_|_Small molecule_|_False_|_EPITINIB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Epitinib' 'HMPL-813' 'Hmpl-813']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL799,"O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1_|_RRGUKTPIGVIEKM-UHFFFAOYSA-N_|_Small molecule_|_True_|_CILOSTAZOL_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Cilostazol' 'Pletal']_|_['Cilostazol' 'NSC-758936' 'OPC-13013' 'OPC-21']_|_[('DailyMed', array(['cilostazol'], dtype=object)), ('PubChem', array(['104171123', '11110906', '11113335', '124879546', '144203649',
       '170465347', '174007041', '26719653', '26719654', '26746958',
       '26746959', '50100194', '50103999', '50104000', '56463107',
       '85230957', '855683', '90341176'], dtype=object)), ('Wikipedia', array(['Cilostazol'], dtype=object)), ('drugbank', array(['DB01166'], dtype=object)), ('chEBI', array(['31401'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0003914', 'EFO_0003843', 'MONDO_0005178',
       'HP_0004419', 'EFO_0003144', 'EFO_0001645', 'EFO_0008493',
       'EFO_0000712', 'EFO_0004265', 'EFO_0003876', 'HP_0100543',
       'Orphanet_136', 'EFO_0003875', 'EFO_0000319', 'HP_0001397',
       'EFO_0003763', 'MONDO_0002679'], dtype=object), 'count': 18}_|_[ENSG00000172572]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for recurrent thrombophlebitis and has 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL8030,"Cc1cccc(Oc2cnc(=O)[nH]c2)c1_|_HJQILFPVRNHTIG-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLIMIDONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-26,154' 'CP-26154' 'MLR-1023' 'Mlr-1023' 'NSC-314335' 'Tolimidone']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000254087]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL841,"CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1_|_RDOIQAHITMMDAJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOPERAMIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Imodium' 'Loperamide']_|_[('PubChem', array(['104171181', '11111380', '11112740', '11113732', '124880549',
       '124880551', '124880553', '144203731', '170464852', '26751916',
       '26751917', '50104594', '50104595', '90340730'], dtype=object)), ('Wikipedia', array(['Loperamide'], dtype=object)), ('drugbank', array(['DB00836'], dtype=object)), ('chEBI', array(['6532'], dtype=object))]_|_['CHEMBL1707']_|_{'rows': array(['EFO_0000305', 'MONDO_0004565', 'EFO_0009130', 'EFO_0003060',
       'MONDO_0004992', 'HP_0002014', 'EFO_0003869', 'HP_0002014',
       'EFO_0003843', 'EFO_0009523', 'MONDO_0007254', 'HP_0000964',
       'EFO_0000512'], dtype=object), 'count': 13}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diarrhea and has 12 investigational indications."
CHEMBL94081,"C=CCOc1ccc(CC(=O)O)cc1Cl_|_ARHWPKZXBHOEEE-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALCLOFENAC_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Alclofenac' 'W 7320']_|_[('PubChem', array(['144205279', '29215481'], dtype=object)), ('Wikipedia', array(['Alclofenac'], dtype=object)), ('drugbank', array(['DB13167'], dtype=object)), ('chEBI', array(['31183'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease. It was withdrawn in at least one region."
CHEMBL953,"CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1_|_JRURYQJSLYLRLN-BJMVGYQFSA-N_|_Small molecule_|_False_|_ENTACAPONE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Comtan' 'Comtess' 'Entacapone' 'Entacapone orion']_|_['Entacapone' 'Entacapone orion' 'Entacapone teva' 'OR-611']_|_[('DailyMed', array(['entacapone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-orion'],
      dtype=object)), ('PubChem', array(['144205737', '170464850', '26757974'], dtype=object)), ('Wikipedia', array(['Entacapone'], dtype=object)), ('drugbank', array(['DB00494'], dtype=object)), ('chEBI', array(['4798'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002610', 'EFO_0000474', 'MONDO_0005180', 'MONDO_0011719',
       'EFO_0001073', 'EFO_0004701'], dtype=object), 'count': 6}_|_[ENSG00000093010]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for parkinson disease and has 5 investigational indications."
CHEMBL1023,"C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C_|_NAVMQTYZDKMPEU-UHFFFAOYSA-N_|_Small molecule_|_True_|_BEXAROTENE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Bexarotene' 'Targretin' 'Targretine']_|_['Bexarotene' 'LG-100069' 'LG100069' 'LGD-1069' 'LGD1069' 'NSC-747528']_|_[('DailyMed', array(['bexarotene'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/targretin'],
      dtype=object)), ('PubChem', array(['124893633', '144206219', '144212724', '170465308', '50125754'],
      dtype=object)), ('Wikipedia', array(['Bexarotene'], dtype=object)), ('drugbank', array(['DB00307'], dtype=object)), ('chEBI', array(['50859'], dtype=object))]_|_['CHEMBL5290401']_|_{'rows': array(['EFO_0004192', 'EFO_0000676', 'EFO_0000565', 'MONDO_0005090',
       'EFO_0000574', 'EFO_1001051', 'EFO_0002913', 'HP_0100543',
       'EFO_0000222', 'MONDO_0020077', 'EFO_0003060', 'EFO_1001110',
       'MONDO_0004975', 'EFO_0000198', 'MONDO_0008903', 'EFO_1000785',
       'EFO_0005411', 'EFO_1000747', 'EFO_0005537', 'EFO_0000616',
       'MONDO_0002108', 'EFO_0001378', 'MONDO_0015760', 'EFO_0003032',
       'EFO_0000432', 'MONDO_0007254'], dtype=object), 'count': 26}_|_[ENSG00000204231,ENSG00000143171,ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 23 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200386,"CCOC(=O)O[C@]1(C(=O)COC(=O)CC)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_FNPXMHRZILFCKX-KAJVQRHHSA-N_|_Small molecule_|_False_|_PREDNICARBATE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Dermatop' 'Dermatop e emollient' 'Prednicarbate']_|_['HOE 777' 'HOE-777' 'LAS-189961' 'LAS-41003 COMPONENT PREDNICARBATE'
 'LAS189961' 'NSC-760042' 'Prednicarbate' 'S 77 0777' 'S-77 0777'
 'S-77-0777' 'S-770777']_|_[('DailyMed', array(['prednicarbate'], dtype=object)), ('PubChem', array(['144204238', '56463553'], dtype=object)), ('Wikipedia', array(['Prednicarbate'], dtype=object)), ('drugbank', array(['DB01130'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002026', 'EFO_0000676', 'EFO_0000701', 'HP_0000964',
       'EFO_0007512'], dtype=object), 'count': 5}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for skin disease and has 4 investigational indications."
CHEMBL1200805,"COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.O=C(O)CC(O)C(=O)O_|_IUSFTUWHKCSCDY-BHDTVMLSSA-N_|_Small molecule_|_False_|_DILTIAZEM MALATE_|_1996.0_|_4.0_|_CHEMBL23_|_False_|_True_|_['Tiamate']_|_['Diltiazem malate' 'MK-793']_|_nan_|_nan_|_nan_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996."
CHEMBL1201193,"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C_|_LEBVLXFERQHONN-INIZCTEOSA-N_|_Small molecule_|_False_|_LEVOBUPIVACAINE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-bupivacaine' '(s)-bupivacaine' 'Bupivacaine (-)-form'
 'Bupivacaine, (-)-' 'Bupivacaine, (s)-' 'L-bupivacaine' 'Levobupivacaine'
 'Novabupi']_|_[('PubChem', array(['11112642', '29215441'], dtype=object)), ('Wikipedia', array(['Levobupivacaine'], dtype=object)), ('drugbank', array(['DB01002'], dtype=object)), ('chEBI', array(['6149'], dtype=object))]_|_['CHEMBL1200749']_|_{'rows': array(['HP_0002027', 'EFO_0005323', 'EFO_0002950', 'EFO_0000616',
       'EFO_0003843', 'EFO_0003843', 'HP_0000175', 'HP_0003418',
       'EFO_0002950'], dtype=object), 'count': 9}_|_[ENSG00000007314]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 7 investigational indications."
CHEMBL1201656,"nan_|_nan_|_Protein_|_False_|_INSULIN SUSP ISOPHANE PURIFIED PORK_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Insulin insulatard nph nordisk' 'Nph iletin ii (pork)'
 'Nph purified pork isophane insulin']_|_['Insulin susp isophane purified pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1979."
CHEMBL1201835,"nan_|_nan_|_Antibody_|_False_|_USTEKINUMAB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Stelara' 'Stelera']_|_['CNTO 1275' 'CNTO-1275' 'TT-20' 'Ustekinumab' 'Ustekinumab ']_|_[('DailyMed', array(['ustekinumab'], dtype=object)), ('DrugCentral', array(['4966'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/stelara'],
      dtype=object)), ('Wikipedia', array(['Ustekinumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000540', 'EFO_1001486', 'MONDO_0007915', 'EFO_1001494',
       'MONDO_0019269', 'MONDO_0002334', 'EFO_0000685', 'EFO_1000710',
       'EFO_0000384', 'EFO_1001209', 'EFO_0007187', 'EFO_0000729',
       'EFO_0003780', 'MONDO_0013730', 'EFO_0003898', 'EFO_1001231',
       'MONDO_0019338', 'EFO_0003921', 'MONDO_0005147', 'MONDO_0005301',
       'EFO_0003872', 'EFO_0000676', 'EFO_0000398', 'EFO_0000274',
       'EFO_0002609', 'EFO_0003778', 'EFO_1001857'], dtype=object), 'count': 27}_|_[ENSG00000113302,ENSG00000110944,ENSG00000168811]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 21 investigational indications."
CHEMBL1370,"CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1_|_VOVIALXJUBGFJZ-KWVAZRHASA-N_|_Small molecule_|_True_|_BUDESONIDE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Aircort' 'Budeflam aquanase' 'Budelin novolizer' 'Budenofalk'
 'Budesonide' 'Cortiment' 'Duoresp spiromax' 'Entocort' 'Entocort cr'
 'Entocort ec' 'Jorveza' 'Ortikos' 'Preferid' 'Pulmaxan' 'Pulmicort'
 'Pulmicort flexhaler' 'Pulmicort l.s.' 'Pulmicort respules' 'Rhinocort'
 'Rhinocort allergy' 'Rhinocort aqua' 'Rhinocort aqua 64' 'Symbicort'
 'Tarpeyo' 'Uceris']_|_['Budesonide' 'MAP-0010' 'MAP0010' 'NSC-757788' 'R01AD05' 'S-1320']_|_[('DailyMed', array(['budesonide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jorveza'],
      dtype=object)), ('PubChem', array(['56422168', '855541', '90341081'], dtype=object)), ('Wikipedia', array(['Budesonide'], dtype=object)), ('drugbank', array(['DB01222'], dtype=object)), ('chEBI', array(['3207'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'HP_0025267', 'HP_0002014', 'EFO_1000391',
       'EFO_1001223', 'HP_0001742', 'EFO_0000464', 'EFO_0009544',
       'MONDO_0013730', 'EFO_0004194', 'EFO_1001486', 'EFO_0005854',
       'EFO_1001295', 'EFO_0004232', 'EFO_0003918', 'EFO_1000637',
       'EFO_1000782', 'EFO_0000684', 'EFO_0007140', 'MONDO_0100096',
       'EFO_1001294', 'EFO_0000384', 'EFO_0007183', 'EFO_0000341',
       'EFO_0000694', 'EFO_0000729', 'EFO_0007486', 'MONDO_0019091',
       'EFO_0004268', 'EFO_1001411', 'EFO_0008572', 'MONDO_0005271',
       'EFO_0000756', 'EFO_0005628', 'EFO_0003956', 'HP_0002043',
       'EFO_0004599', 'MONDO_0020547', 'MONDO_0008903', 'EFO_0006505',
       'EFO_1001417', 'EFO_0008590', 'EFO_0001378', 'HP_0006536',
       'MONDO_0004979', 'EFO_0005676', 'EFO_1001293'], dtype=object), 'count': 47}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 12 approved and 35 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1734,"O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1_|_FBOUYBDGKBSUES-VXKWHMMOSA-N_|_Small molecule_|_False_|_SOLIFENACIN_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Vesicare']_|_['NSC-759144' 'Solifenacin']_|_[('PubChem', array(['50113280'], dtype=object)), ('Wikipedia', array(['Solifenacin'], dtype=object)), ('drugbank', array(['DB01591'], dtype=object))]_|_['CHEMBL1200803' 'CHEMBL2361425']_|_{'rows': array(['EFO_0006865', 'EFO_0000284', 'EFO_1000781', 'EFO_1000781',
       'HP_0000020', 'EFO_0006865', 'HP_0000103', 'EFO_0000284'],
      dtype=object), 'count': 8}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 3 investigational indications."
CHEMBL2108318,"nan_|_nan_|_Protein_|_False_|_ELSIGLUTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Elsiglutide' 'ZP-1846' 'ZP1846' 'Zp1846']_|_nan_|_nan_|_{'rows': array(['HP_0002014'], dtype=object), 'count': 1}_|_[ENSG00000065325]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108811,"nan_|_nan_|_Antibody_|_False_|_VISILIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Nuvion']_|_['HUM-291' 'Visilizumab' 'huM291']_|_nan_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0000384', 'EFO_0000729', 'EFO_0000222',
       'EFO_0000574'], dtype=object), 'count': 5}_|_[ENSG00000198851]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2141296,"CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O_|_MXAYKZJJDUDWDS-LBPRGKRZSA-N_|_Small molecule_|_False_|_IXAZOMIB_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ninlaro']_|_['Ixazomib' 'MLN-2238' 'MLN-9708 FREE BASE' 'MLN2238']_|_[('PubChem', array(['124955652'], dtype=object)), ('drugbank', array(['DB09570'], dtype=object))]_|_['CHEMBL5171825']_|_{'rows': array(['EFO_1001264', 'EFO_0000565', 'EFO_0000220', 'EFO_0009441',
       'MONDO_0019438', 'MONDO_0044881', 'EFO_0001378', 'EFO_0005537',
       'EFO_0005761', 'EFO_0000681', 'EFO_0006738', 'EFO_0000764',
       'MONDO_0004992', 'EFO_0000574', 'EFO_0000616', 'EFO_0007160',
       'EFO_1001469', 'EFO_0000222', 'MONDO_0000873', 'EFO_0003884',
       'MONDO_0018906'], dtype=object), 'count': 21}_|_[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 19 investigational indications."
CHEMBL21536,"CCCCCCOc1nsnc1C1=CCCN(C)C1_|_JOLJIIDDOBNFHW-UHFFFAOYSA-N_|_Small molecule_|_False_|_XANOMELINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-246708' 'LY-246708 FREE BASE' 'LY246708' 'Xanomeline']_|_[('Wikipedia', array(['Xanomeline'], dtype=object)), ('drugbank', array(['DB15357'], dtype=object)), ('chEBI', array(['10056'], dtype=object))]_|_['CHEMBL2336050' 'CHEMBL73149']_|_{'rows': array(['MONDO_0005090', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000168539,ENSG00000180720]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2179105,"C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc2c(cnn2C2CCOCC2)c(=O)[nH]1_|_IWXUVYOOUMLUTQ-CZUORRHYSA-N_|_Small molecule_|_False_|_EDELINONTRINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Edelinontrine' 'Pf-04447943']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object)), ('drugbank', array(['DB11953'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000160191]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3039511,"COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(C(N)=O)cn1_|_ZGCYVRNZWGUXNQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEVENOPRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ADL-5945' 'ADL5945' 'Bevenopran' 'CB-5945' 'CB5-945' 'CB5945']_|_[('drugbank', array(['DB12464'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002019', 'EFO_0003086'], dtype=object), 'count': 2}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3187723,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21_|_ACWZRVQXLIRSDF-UHFFFAOYSA-N_|_Small molecule_|_False_|_BINIMETINIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Mektovi']_|_['ARRY 438162' 'ARRY-162' 'ARRY-438162' 'Binimetinib' 'MEK-162' 'MEK162'
 'Mek-162' 'NVP-MEK162']_|_[('DailyMed', array(['binimetinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi'],
      dtype=object)), ('PubChem', array(['174006430'], dtype=object)), ('drugbank', array(['DB11967'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0003060', 'EFO_0000389', 'EFO_0002617',
       'EFO_1000251', 'EFO_1001959', 'MONDO_0004992', 'MONDO_0007254',
       'MONDO_0021063', 'EFO_1000956', 'MONDO_0008170', 'MONDO_0011719',
       'EFO_0002503', 'EFO_0003833', 'EFO_0005537', 'EFO_0002892',
       'EFO_0002618', 'EFO_1000657', 'EFO_0000565', 'EFO_0000305',
       'EFO_0009259', 'EFO_0000685', 'EFO_0001075', 'EFO_1001951',
       'MONDO_0002158', 'MONDO_0003060', 'EFO_1001512', 'EFO_0000756',
       'EFO_0003891', 'EFO_0000616', 'MONDO_0008903', 'EFO_0004606',
       'EFO_0001378', 'MONDO_0002087'], dtype=object), 'count': 34}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 29 investigational indications."
CHEMBL3545216,"nan_|_nan_|_Small molecule_|_False_|_FX-005_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fx-005']_|_nan_|_nan_|_{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545283,"CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C1CO_|_QLUYMIVVAYRECT-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIVICICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['P 276-00 free base' 'P-276-00 free base' 'P276-00' 'Riviciclib']_|_nan_|_nan_|_nan_|_[ENSG00000136807,ENSG00000135446,ENSG00000170312]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3545349,"Cc1nccn1Cc1cc(-c2ccc(F)c(C(F)F)c2)cnn1.Cl.Cl_|_OJBLXSPBJMGZDN-UHFFFAOYSA-N_|_Small molecule_|_False_|_EVT-101_|_nan_|_2.0_|_CHEMBL3545350_|_False_|_False_|_[]_|_['Evt-101' 'Evt101']_|_[('drugbank', array(['DB05956'], dtype=object))]_|_nan_|_nan_|_[ENSG00000176884,ENSG00000273079]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3577124,"CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1_|_HHCBMISMPSAZBF-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY-3009120_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['DP-4978' 'LY3009120' 'Ly-3009120' 'Pan-raf inhibitor ly3009120']_|_nan_|_nan_|_{'rows': array(['EFO_0004142', 'EFO_0009708', 'EFO_0003060', 'EFO_0000756'],
      dtype=object), 'count': 4}_|_[ENSG00000132155,ENSG00000157764,ENSG00000078061]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL3707330,"C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.O_|_GZQWMYVDLCUBQX-WVZIYJGPSA-N_|_Small molecule_|_False_|_ROLAPITANT HYDROCHLORIDE_|_2015.0_|_4.0_|_CHEMBL3707331_|_False_|_True_|_['Varubi' 'Varuby']_|_['Rolapitant hcl h20' 'Rolapitant hydrochloride'
 'Rolapitant hydrochloride monohydrate' 'SCH-619734' 'SCH619734']_|_[('DailyMed', array(['rolapitant%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/varuby'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0006911', 'EFO_0000691'], dtype=object), 'count': 2}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for chemotherapy-induced nausea and vomiting and has 1 investigational indication."
CHEMBL4289017,"CC(=O)NCC(=O)N1[C@@H]2CC[C@H]1c1ccc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)cc12_|_RYYNGWLOYLRZLK-RBUKOAKNSA-N_|_Small molecule_|_False_|_PF-03814735_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PF 03814735' 'PF 3814735' 'PF-3814735' 'Pf-03814735']_|_[('drugbank', array(['DB13059'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000087586,ENSG00000178999]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4650277,"CC(C)(C)NCCNc1ccc(C2=NN=C(C(F)(F)F)C2)nc1C1CCN(c2ncnc3c2C(C)(C)C(=O)N3)CC1_|_UVKWCPOZHXNKAZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAS0612_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['TAS0612' 'Tas0612']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000175634,ENSG00000108443,ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000177189,ENSG00000071242,ENSG00000072133,ENSG00000117676]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL479,"CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2_|_KLBQZWRITKRQQV-UHFFFAOYSA-N_|_Small molecule_|_True_|_THIORIDAZINE_|_1962.0_|_4.0_|_nan_|_True_|_True_|_['Mellaril-s' 'Melleril' 'Rideril']_|_['Dl-thioridazine' 'Mellaril' 'Mellerette' 'Novoridazine' 'Sonapax'
 'TP-21' 'Thioridazine' 'Thioridazine prolongatum' 'Thioril']_|_[('PubChem', array(['104171257', '124881748', '144203845', '170465080', '174006671',
       '26752322', '50105272', '90341630'], dtype=object)), ('TG-GATEs', array(['38'], dtype=object)), ('Wikipedia', array(['Thioridazine'], dtype=object)), ('drugbank', array(['DB00679'], dtype=object)), ('chEBI', array(['9566'], dtype=object))]_|_['CHEMBL1200916']_|_{'rows': array(['EFO_0000222', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090', 'EFO_0005407'], dtype=object), 'count': 6}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for psychosis and has 5 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL501867,"CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O_|_AQTQHPDCURKLKT-JKDPCDLQSA-N_|_Small molecule_|_True_|_VINCRISTINE SULFATE_|_1963.0_|_4.0_|_CHEMBL90555_|_False_|_True_|_['Kyocristine' 'Leurocristine Sulfate' 'Marqibo kit' 'Oncovin' 'Vincasar'
 'Vincasar pfs' 'Vincrex' 'Vincristine sulfate' 'Vincristine sulfate pfs']_|_['37231' 'Kyocristine' 'LILLY-37231' 'Marqibo' 'NSC-67574' 'Novopharm'
 'Vincristine sulfate' 'Vincristine sulfate liposome'
 'Vincristine sulphate' 'Vincristini sulfas' 'Vincrisul']_|_[('PubChem', array(['112141'], dtype=object)), ('chEBI', array(['79401'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000174', 'EFO_0000272', 'EFO_0000094', 'MONDO_0009348',
       'EFO_0000248', 'EFO_0000220', 'MONDO_0008380', 'MONDO_0018975',
       'EFO_0006859', 'EFO_1001469', 'EFO_0000558', 'EFO_0000183',
       'EFO_0002939', 'EFO_0004289', 'EFO_0003032', 'EFO_0000502',
       'EFO_0000756', 'EFO_0000211', 'EFO_0000565', 'EFO_1001042',
       'EFO_0000096', 'MONDO_0008903', 'MONDO_0002367', 'EFO_1000131',
       'EFO_0000616', 'EFO_0001378', 'EFO_0005235', 'EFO_1000292',
       'EFO_0000621', 'MONDO_0000430', 'EFO_1001951', 'EFO_0000095',
       'MONDO_0000870', 'EFO_0000209', 'MONDO_0018906', 'MONDO_0015540',
       'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'MONDO_0002974',
       'EFO_1000158', 'HP_0001871', 'EFO_0000588', 'EFO_0000403',
       'MONDO_0000873', 'EFO_0000222', 'EFO_1001365', 'EFO_0000574',
       'MONDO_0018271', 'EFO_0009441', 'MONDO_0019004', 'EFO_0003833',
       'EFO_0000309', 'MONDO_0019471', 'EFO_0000765', 'EFO_0002918',
       'MONDO_0044917', 'EFO_0000437'], dtype=object), 'count': 58}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 58 investigational indications. This drug has a black box warning from the FDA."
CHEMBL839,"CC(C)(C)NCC(O)COc1cccc2c1CCC(=O)N2_|_LWAFSWPYPHEXKX-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARTEOLOL_|_1988.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Carteolol' 'Cartrol' 'Ocupress']_|_[('Wikipedia', array(['Carteolol'], dtype=object)), ('drugbank', array(['DB00521'], dtype=object)), ('chEBI', array(['3437'], dtype=object))]_|_['CHEMBL1201002']_|_{'rows': array(['EFO_0004190', 'MONDO_0005041', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 3 approved indications."
CHEMBL1200511,"CC(=O)O.CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O_|_NGCGMRBZPXEPOZ-HBBGHHHDSA-N_|_Protein_|_False_|_GONADORELIN ACETATE_|_1989.0_|_4.0_|_CHEMBL1007_|_False_|_True_|_['Cystorelin' 'Factrel' 'GnRH' 'Gonadotropin Releasing Hormone'
 'Lh Releasing Factor' 'Lutrelef' 'Lutrepulse kit']_|_['ABBOTT-41070' 'Fertagyl' 'Gonadorelin acetate'
 'Gonadorelin acetate anhydrous' 'Gonadorelin acetate mixture'
 'Gonadorelin diacetate' 'Hypocrine' 'Luteinizing'
 'Luteinizing hormone-releasing factor diacetate tetrahydrate']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0018555', 'EFO_0000673', 'EFO_0001663',
       'MONDO_0008315', 'EFO_0000545', 'MONDO_0018800', 'EFO_0000196',
       'EFO_0000512', 'MONDO_0002146'], dtype=object), 'count': 10}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 10 investigational indications."
CHEMBL1200592,"CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C_|_VVOIQBFMTVCINR-WWMZEODYSA-N_|_Small molecule_|_False_|_DESOXYCORTICOSTERONE PIVALATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Percorten' 'Zycortal']_|_['Desoxycorticosterone pivalate' 'Desoxycorticosterone trimethylacetate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/zycortal'],
      dtype=object)), ('PubChem', array(['144205152'], dtype=object)), ('drugbank', array(['DB01134'], dtype=object)), ('chEBI', array(['50782'], dtype=object))]_|_nan_|_nan_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200964,"CN(C)CCC=C1c2ccccc2CCc2ccccc21.Cl_|_KFYRPLNVJVHZGT-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMITRIPTYLINE HYDROCHLORIDE_|_1961.0_|_4.0_|_CHEMBL629_|_False_|_True_|_['Amitid' 'Amitril' 'Amitriptyline hydrochloride' 'Cytriptyline' 'Domical'
 'Elavil' 'Endep' 'Lentizol' 'Limbitrol 5' 'Saroten' 'Saroten retard'
 'Triptafen' 'Triptafen-m' 'Tryptizol' 'Tryptizol-75']_|_['Amitriptyline hcl' 'Amitriptyline hydrochloride'
 'Amitriptylini hydrochloridum' 'Etravil' 'NIH 10794' 'NSC-104210'
 'Novoprotect' 'Syneudon']_|_[('DailyMed', array(['amitriptyline%20hydrochloride'], dtype=object)), ('PubChem', array(['144206673', '144208476', '144213917', '170464758', '17389180',
       '26747443', '26751626', '49816669', '50105841', '855970'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000989', 'MONDO_0016028', 'MONDO_0002009', 'EFO_0009387'],
      dtype=object), 'count': 4}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201108,"Cc1nc2c([nH]1)-c1ccccc1N(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)CC2.Cl_|_BTYHAFSDANBVMJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CONIVAPTAN HYDROCHLORIDE_|_2005.0_|_4.0_|_CHEMBL1755_|_False_|_True_|_['Vaprisol']_|_['CI-1025' 'Conivaptan hcl' 'Conivaptan hydrochloride' 'YM-087' 'YM087']_|_[('chEBI', array(['31430'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'HP_0002902', 'EFO_0001421'], dtype=object), 'count': 3}_|_[ENSG00000166148,ENSG00000126895]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for heart failure and has 2 investigational indications."
CHEMBL1201534,"nan_|_nan_|_Unknown_|_False_|_DANAPAROID SODIUM_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Orgaran']_|_['Danaparoid' 'Danaparoid sodium' 'ORG 10172' 'ORG-10172'
 'Sodium danaparoid']_|_nan_|_nan_|_{'rows': array(['HP_0004419', 'HP_0001873'], dtype=object), 'count': 2}_|_[ENSG00000117601]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for recurrent thrombophlebitis and has 1 investigational indication."
CHEMBL1201765,"CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1.O=C(O)/C=C/C(=O)O_|_MWHXMIASLKXGBU-RNCYCKTQSA-N_|_Small molecule_|_False_|_FESOTERODINE FUMARATE_|_2007.0_|_4.0_|_CHEMBL1201764_|_False_|_True_|_['Fesoterodine fumarate' 'Toviaz']_|_['Fesoterodine fumarate' 'SPM 8272' 'SPM 907' 'SPM-8272' 'SPM-907']_|_[('DailyMed', array(['fesoterodine%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/toviaz'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000781', 'HP_0000020', 'EFO_0006865'], dtype=object), 'count': 3}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for overactive bladder and urgency urinary incontinence and has 1 investigational indication."
CHEMBL1204165,"C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1.Cl_|_WQVZLXWQESQGIF-WJKBNZMCSA-N_|_Small molecule_|_False_|_DILEVALOL HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL27193_|_True_|_True_|_[]_|_['Dilevalol hcl' 'Dilevalol hydrochloride' 'SCH 19927' 'SCH-19927']_|_nan_|_nan_|_nan_|_[ENSG00000169252,ENSG00000043591,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990. It was withdrawn in at least one region."
CHEMBL1255840,"CC1(C)CCC(NC(=O)[C@@H](N)CCC(=O)O)CC1_|_VCRGLZYPNNAVRP-JTQLQIEISA-N_|_Small molecule_|_False_|_NEBOGLAMINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cr2249' 'Neboglamine' 'Nebostinel' 'XY-2401']_|_[('PubChem', array(['144204806', '50106666', '90341776'], dtype=object))]_|_nan_|_nan_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1378,"CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2_|_XCTYLCDETUVOIP-UHFFFAOYSA-N_|_Small molecule_|_False_|_THIETHYLPERAZINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Thiethylperazine' 'Torecan']_|_[('Wikipedia', array(['Thiethylperazine'], dtype=object)), ('drugbank', array(['DB00372'], dtype=object)), ('chEBI', array(['9544'], dtype=object))]_|_['CHEMBL2359670' 'CHEMBL3989478' 'CHEMBL1326247' 'CHEMBL1201074'
 'CHEMBL1200856']_|_{'rows': array(['MONDO_0004975', 'MONDO_0005271', 'HP_0000023'], dtype=object), 'count': 3}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for allergic disease and has 2 investigational indications."
CHEMBL13828,"O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1_|_BAINIUMDFURPJM-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXATOMIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Tinset']_|_['Celtect' 'Cobiona' 'Dasten' 'NSC-309710' 'Oxatomide' 'R 35,443'
 'R-35443']_|_[('PubChem', array(['11111579', '144203770', '170466059', '50100302', '50106789',
       '50106790', '85231171', '855791'], dtype=object)), ('Wikipedia', array(['Oxatomide'], dtype=object)), ('drugbank', array(['DB12877'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271', 'MONDO_0010679'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for allergic disease and has 1 investigational indication."
CHEMBL1567328,"COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Mg+2]_|_KWORUUGOSLYAGD-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMEPRAZOLE MAGNESIUM_|_2003.0_|_4.0_|_CHEMBL1503_|_False_|_True_|_['Omeprazole magnesium' 'Prilosec' 'Prilosec otc']_|_['H 168/68 MAGNESIUM' 'Omeprazole (as magnesium)' 'Omeprazole magnesium'
 'Omeprazole magnesium salt']_|_[('DailyMed', array(['omeprazole%20magnesium'], dtype=object)), ('PubChem', array(['49665950', '49681830'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003 and has 1 investigational indication."
CHEMBL2074972,"COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1_|_QZVNQOLPLYWLHQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENIDIPINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Benidipine' 'Benidipine hydrochloride']_|_nan_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2107729,"O=C(Nc1ccc(S(=O)(=O)N2CCOCC2)cc1)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Cl)s1_|_PQHLRGARXNPFCF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ATACIGUAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ataciguat']_|_[('PubChem', array(['144206754', '170466340'], dtype=object)), ('drugbank', array(['DB12805'], dtype=object))]_|_['CHEMBL4079827']_|_{'rows': array(['EFO_0003876', 'EFO_0000266', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2107821,"NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1_|_WJIGGYYSZBWCGC-MRXNPFEDSA-N_|_Small molecule_|_False_|_EMIXUSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_['Acu-4429']_|_['ACU-4429' 'Emixustat']_|_[('drugbank', array(['DB12608'], dtype=object))]_|_['CHEMBL2107829']_|_{'rows': array(['EFO_1001492', 'MONDO_0019353'], dtype=object), 'count': 2}_|_[ENSG00000116745]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109247,nan_|_nan_|_Antibody_|_False_|_LBY-135_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LBY-135' 'LBY135' 'Lby 135']_|_nan_|_nan_|_nan_|_[ENSG00000120889]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109352,"nan_|_nan_|_Antibody_|_False_|_BL22_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BL22' 'Bl22' 'CAT-3888']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_1000956', 'EFO_0000565'], dtype=object), 'count': 3}_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL278398,"CN1CCC2=C(C1)C(c1ccccc1)c1ccccc12_|_ISFHAYSTHMVOJR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENINDAMINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['NU-1504' 'Nolahist' 'Phenindamine' 'Thephorin']_|_[('Wikipedia', array(['Phenindamine'], dtype=object)), ('drugbank', array(['DB01619'], dtype=object)), ('chEBI', array(['8065'], dtype=object))]_|_['CHEMBL2107213']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergic disease."
CHEMBL3358920,"O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21_|_MVGWUTBTXDYMND-QGZVFWFLSA-N_|_Small molecule_|_False_|_ETRASIMOD_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['APD-334' 'APD-334(FREE ACID)' 'APD334' 'Apd334' 'Etrasimod']_|_[('drugbank', array(['DB14766'], dtype=object))]_|_['CHEMBL3989933']_|_{'rows': array(['EFO_0004232', 'EFO_0003767', 'EFO_0000274', 'EFO_0000384',
       'EFO_1001486', 'EFO_0000729', 'HP_0000999', 'EFO_0000729',
       'EFO_0004192'], dtype=object), 'count': 9}_|_[ENSG00000170989,ENSG00000125910,ENSG00000180739]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for ulcerative colitis and has 8 investigational indications."
CHEMBL3989695,"CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O_|_CDQVVPUXSPZONN-WPPLYIOHSA-N_|_Small molecule_|_False_|_REGADENOSON_|_2008.0_|_4.0_|_CHEMBL317052_|_False_|_True_|_['Lexiscan' 'Rapiscan']_|_['CVT-3146' 'Rapiscan' 'Regadenoson' 'Regadenoson hydrate'
 'Regadenoson monohydrate']_|_[('DailyMed', array(['regadenoson'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008 and is indicated for cardiovascular disease."
CHEMBL3990028,"nan_|_nan_|_Antibody_|_False_|_BLESELUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASKP-1240' 'ASKP1240' 'Bleselumab']_|_nan_|_nan_|_{'rows': array(['EFO_0004236', 'EFO_0000676'], dtype=object), 'count': 2}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL424133,"Cc1ccc(Cn2nc(CCCc3ccc(OC(C)(C)C(=O)O)cc3)nc2O)cc1_|_PNHFDVSKDSLUFH-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY-518674_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['KB-68984' 'LY-674' 'LY518674' 'Ly-518674']_|_[('drugbank', array(['DB12988'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003124', 'EFO_0000537', 'EFO_0000195'], dtype=object), 'count': 3}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297526,"COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21_|_CYHWMBVXXDIZNZ-KRWDZBQOSA-N_|_Small molecule_|_True_|_REMIMAZOLAM_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Byfavo']_|_['CNS 7056' 'CNS-7056' 'Cns 7056' 'ONO-2745' 'Remimazolam']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/REMIMAZOLAM/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12404'], dtype=object))]_|_['CHEMBL4297324' 'CHEMBL4594301']_|_{'rows': array(['EFO_0003890', 'EFO_0009868', 'MONDO_0000870', 'EFO_0001421',
       'EFO_0003843'], dtype=object), 'count': 5}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sedation and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL46423,"CC(C)c1cccc(C(C)C)c1NC(=O)NCC1(c2ccc(N(C)C)cc2)CCCC1_|_PKKNCEXEVUFFFI-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEVANIMIBE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nevanimibe' 'PD 132301' 'PD-132301']_|_nan_|_['CHEMBL542103']_|_{'rows': array(['EFO_1000796', 'MONDO_0018479', 'EFO_0003099'], dtype=object), 'count': 3}_|_[ENSG00000057252]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650278,"CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O_|_AXNUWYROYVRYIM-OQIJCFCCSA-N_|_Small molecule_|_False_|_SNDX-5613_|_nan_|_1.0_|_CHEMBL4650827_|_False_|_False_|_[]_|_['Revumenib sesquifumarate' 'SNDX-50613' 'SNDX-5613' 'SNDX50613'
 'SNDX5613' 'Sndx 5613' 'Sndx-5613']_|_nan_|_nan_|_{'rows': array(['EFO_0000565', 'EFO_0000222', 'EFO_0000220', 'EFO_1001951'],
      dtype=object), 'count': 4}_|_[ENSG00000133895,ENSG00000118058]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL481958,"CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl_|_BHMLHEQFWVQAJS-IITOGVPQSA-N_|_Small molecule_|_False_|_AMRUBICIN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL1186894_|_False_|_False_|_[]_|_['Amrubicin hydrochloride' 'Calsed' 'SM 5887' 'SM-5887']_|_nan_|_nan_|_{'rows': array(['MONDO_0008903', 'EFO_0000702'], dtype=object), 'count': 2}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL494480,"CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3cccc(O)c32)cc1_|_OPIKUXLJQFYMSC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADL-5859_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adl-5859']_|_[('PubChem', array(['174006844'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0004616', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000116329]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1079,"Clc1ccc2nsnc2c1NC1=NCCN1_|_XFYDIVBRZNQMJC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIZANIDINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Tizanidine' 'Zanaflex']_|_[('PubChem', array(['144205429', '170465419', '26754628', '29216212', '29216213',
       '90340638'], dtype=object)), ('Wikipedia', array(['Tizanidine'], dtype=object)), ('drugbank', array(['DB00697'], dtype=object)), ('chEBI', array(['63629'], dtype=object))]_|_['CHEMBL1200329']_|_{'rows': array(['EFO_0003843', 'HP_0001257', 'EFO_0000756', 'MONDO_0043510',
       'MONDO_0100431', 'HP_0001257', 'MONDO_0005475', 'MONDO_0002959'],
      dtype=object), 'count': 8}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for spasticity and has 7 investigational indications."
CHEMBL1200436,"C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O_|_QSLJIVKCVHQPLV-PEMPUTJUSA-N_|_Small molecule_|_True_|_OXANDROLONE_|_1964.0_|_4.0_|_nan_|_False_|_True_|_['Anavar' 'Oxandrin' 'Oxandrolone']_|_['Lonavar' 'NSC-67068' 'Oxandrolone' 'Oxandrolone ciii' 'Provitar'
 'SC 11585' 'SC-11585' 'Vasorome']_|_[('DailyMed', array(['oxandrolone'], dtype=object)), ('Wikipedia', array(['Oxandrolone'], dtype=object)), ('drugbank', array(['DB00621'], dtype=object)), ('chEBI', array(['7820'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001006', 'MONDO_0019391', 'EFO_0007067', 'EFO_0000616',
       'EFO_0000546', 'EFO_0008572', 'EFO_1001250', 'EFO_0009516',
       'MONDO_0019499'], dtype=object), 'count': 9}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200817,"CC[C@H](OC(C)=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1.Cl_|_UXBPQRGCVJOTNT-COBSGTNCSA-N_|_Small molecule_|_False_|_LEVOMETHADYL ACETATE HYDROCHLORIDE_|_1993.0_|_4.0_|_CHEMBL1514_|_False_|_True_|_['Orlaam']_|_['LAAM' 'Levacetylmethadol hydrochloride' 'Levomethadyl acetate hcl'
 'Levomethadyl acetate hydrochloride' 'MK-790' 'MK790']_|_[('PubChem', array(['85273814'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993."
CHEMBL1201134,"CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1_|_WGFOBBZOWHGYQH-MXHNKVEKSA-N_|_Small molecule_|_False_|_LUBIPROSTONE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Amitiza']_|_['Lubiprostone' 'RU-0211']_|_[('DailyMed', array(['lubiprostone'], dtype=object)), ('PubChem', array(['144206539'], dtype=object)), ('Wikipedia', array(['Lubiprostone'], dtype=object)), ('drugbank', array(['DB01046'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002203', 'HP_0002019', 'EFO_0000555', 'EFO_0000764',
       'EFO_0003095', 'HP_0012532'], dtype=object), 'count': 6}_|_[ENSG00000114859]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 2 investigational indications."
CHEMBL1201668,"nan_|_nan_|_Protein_|_False_|_NESIRITIDE_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Natrecor']_|_['Bnp-32' 'Brain natriuretic peptide 32' 'C01DX19' 'Nesiritide'
 'Nesiritide Recombinant' 'Nesiritide recombinant']_|_[('Wikipedia', array(['Nesiritide'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'EFO_0000319', 'EFO_0000537', 'EFO_0000373',
       'EFO_0000701', 'EFO_0000756', 'EFO_0008583', 'EFO_0003086',
       'EFO_0000318', 'EFO_0000400', 'EFO_0003144', 'EFO_0005672',
       'EFO_0000612', 'HP_0000842', 'EFO_1002048', 'HP_0030680',
       'HP_0001919', 'HP_0002094'], dtype=object), 'count': 18}_|_[ENSG00000169418]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for cardiovascular disease and has 17 investigational indications."
CHEMBL1206232,"COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O_|_WDOGQTQEKVLZIJ-WAYWQWQTSA-N_|_Small molecule_|_False_|_FOSBRETABULIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Combretastatin a-4 phosphate' 'Combretastatin a4 phosphate'
 'Fosbretabulin' 'Phosbretabulin']_|_[('drugbank', array(['DB12577'], dtype=object))]_|_['CHEMBL2105643' 'CHEMBL1972559' 'CHEMBL289351' 'CHEMBL263994']_|_{'rows': array(['MONDO_0002108', 'MONDO_0008170', 'EFO_0000616', 'EFO_0000616',
       'EFO_0004683', 'EFO_1001901', 'MONDO_0004992', 'MONDO_0008170',
       'EFO_1001901', 'EFO_0006859'], dtype=object), 'count': 10}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL1375743,"Cl.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1_|_ZCBZSCBNOOIHFP-UHFFFAOYSA-N_|_Small molecule_|_True_|_ZIPRASIDONE HYDROCHLORIDE_|_2001.0_|_4.0_|_CHEMBL708_|_False_|_True_|_['Geodon' 'Zeldox' 'Ziprasidone hydrochloride']_|_['CP-88,059-1' 'CP-88059-1' 'CP-880591' 'Ziprasidone hydrochloride'
 'Ziprasidone hydrochloride hydrate'
 'Ziprasidone hydrochloride monohydrate']_|_[('DailyMed', array(['ziprasidone%20hydrochloride'], dtype=object)), ('PubChem', array(['90340940'], dtype=object)), ('chEBI', array(['32314'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005306', 'MONDO_0005090', 'HP_0000713', 'EFO_0009963',
       'MONDO_0004985', 'EFO_0004269'], dtype=object), 'count': 6}_|_[ENSG00000147246,ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 approved indications. This drug has a black box warning from the FDA."
CHEMBL1521,"CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1_|_HUNXMJYCHXQEGX-UHFFFAOYSA-N_|_Small molecule_|_True_|_ZALEPLON_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Sonata' 'Zaleplon']_|_['CL 284,846' 'CL-284846' 'L-846' 'L846' 'LJC 10846' 'LJC-10846'
 'LJC10846' 'SKP-1041' 'ZAL-846' 'Zaleplon' 'Zaleplon civ' 'Zerene']_|_[('DailyMed', array(['zaleplon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sonata'],
      dtype=object)), ('PubChem', array(['144205425', '170465168', '26719706', '29216208'], dtype=object)), ('Wikipedia', array(['Zaleplon'], dtype=object)), ('drugbank', array(['DB00962'], dtype=object)), ('chEBI', array(['10102'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0005230', 'HP_0000726', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000022355,ENSG00000113327,ENSG00000163288]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for insomnia and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1614701,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21_|_CYOHGALHFOKKQC-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELUMETINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ARRY-142886' 'ARRY-886' 'AZD-6244' 'AZD6244' 'Azd-6244' 'Selumetinib']_|_[('PubChem', array(['144206913', '170466898', '174006431'], dtype=object)), ('drugbank', array(['DB11689'], dtype=object)), ('chEBI', array(['90227'], dtype=object))]_|_['CHEMBL2105684']_|_{'rows': array(['EFO_0000389', 'EFO_0003144', 'EFO_0000272', 'EFO_0000501',
       'EFO_0000403', 'EFO_0001075', 'EFO_0009254', 'EFO_0003060',
       'EFO_1001956', 'MONDO_0018975', 'EFO_0000756', 'MONDO_0001187',
       'EFO_0008514', 'EFO_0000365', 'MONDO_0018975', 'MONDO_0002367',
       'MONDO_0007254', 'MONDO_0003060', 'EFO_0000558', 'EFO_0002617',
       'EFO_1001951', 'EFO_0000339', 'EFO_0000228', 'EFO_1001950',
       'EFO_0000220', 'EFO_0001378', 'EFO_1000251', 'MONDO_0004992',
       'EFO_0002618', 'EFO_0000503', 'EFO_0005221', 'EFO_0002618',
       'MONDO_0016691', 'EFO_0000707', 'EFO_0005537', 'EFO_0000616',
       'EFO_0000182', 'EFO_1001968', 'EFO_0000641', 'EFO_0000708',
       'EFO_0000760', 'EFO_0004606', 'EFO_0000389', 'MONDO_0005411',
       'EFO_0004142', 'EFO_0000658', 'EFO_1000657', 'EFO_1001512',
       'EFO_0002617', 'MONDO_0021063', 'MONDO_0002108', 'MONDO_0018531',
       'MONDO_0008903'], dtype=object), 'count': 53}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 48 investigational indications."
CHEMBL17350,"C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1_|_QEMSVZNTSXPFJA-HNAYVOBHSA-N_|_Small molecule_|_False_|_TRAXOPRODIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-101,606' 'CP-101606' 'Cp-101,606' 'Traxoprodil']_|_[('Wikipedia', array(['Traxoprodil'], dtype=object))]_|_['CHEMBL3989673']_|_{'rows': array(['MONDO_0005180', 'EFO_0000712', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000176884,ENSG00000273079]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL20684,"COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1_|_URCVCIZFVQDVPM-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABT-751_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Abt-751' 'E 7010' 'E-7010' 'NSC-742134']_|_[('drugbank', array(['DB12254'], dtype=object))]_|_['CHEMBL1830238']_|_{'rows': array(['EFO_0000681', 'EFO_0001642', 'EFO_1001951', 'EFO_0000621',
       'MONDO_0008315', 'MONDO_0007254', 'MONDO_0000870', 'EFO_0003060'],
      dtype=object), 'count': 8}_|_[ENSG00000188229,ENSG00000101162,ENSG00000258947,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000173213]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL2107773,"Cc1cc(OCC(=O)O)c(C)cc1CCN[C@@H](C)[C@H](O)c1ccc(O)cc1_|_VMMYRRFPMAGXNP-BTYIYWSLSA-N_|_Small molecule_|_False_|_RITOBEGRON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['KUC-7483' 'Kuc-7483' 'Ritobegron']_|_[('drugbank', array(['DB12080'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000781', 'HP_0000011'], dtype=object), 'count': 2}_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108817,"nan_|_nan_|_Antibody_|_False_|_YTTRIUM Y 90 EPRATUZUMAB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['90Y-HLL2' '90Y_HLL2' 'Epratuzumab (y 90)' 'S9S0Y-HLL2'
 'Yttrium y 90 epratuzumab' 'Yttrium y-90 epratuzumab']_|_nan_|_nan_|_nan_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of I."
CHEMBL2109494,"nan_|_nan_|_Antibody_|_False_|_A27.15_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['A27.15']_|_nan_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0000565', 'EFO_0001378', 'EFO_0002428'],
      dtype=object), 'count': 4}_|_[ENSG00000072274]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL2110954,"CC1(C)CC(C)(C)CC(C)(N)C1_|_OGZQTTHDGQBLBT-UHFFFAOYSA-N_|_Small molecule_|_False_|_NERAMEXANE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Neramexane']_|_[('drugbank', array(['DB04926'], dtype=object))]_|_['CHEMBL2106798']_|_{'rows': array(['MONDO_0004975', 'HP_0000360', 'HP_0000360'], dtype=object), 'count': 3}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000174343,ENSG00000129749]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3186993,"Cl.Cl.OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1_|_ANOMHKZSQFYSBR-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYZINE HYDROCHLORIDE_|_1956.0_|_4.0_|_CHEMBL896_|_False_|_True_|_['Atarax' 'Hydroxyzine' 'Hydroxyzine hydrochloride' 'Orgatrax' 'Ucerax'
 'Vistaril']_|_['Hydroxizine chloride' 'Hydroxyzine dihydrochloride'
 'Hydroxyzine hydrochloride']_|_[('DailyMed', array(['hydroxyzine%20hydrochloride'], dtype=object)), ('PubChem', array(['26752325'], dtype=object)), ('chEBI', array(['5819'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL3219616,"CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21_|_ZBVPUFSKFGYNLC-FIDNPTQWSA-N_|_Small molecule_|_False_|_CP-866087_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-866,087' 'Cp-866,087' 'Cp-866087']_|_[('drugbank', array(['DB12196'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'EFO_0004714', 'MONDO_0007079'], dtype=object), 'count': 3}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545241,"Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1_|_DCRWIATZWHLIPN-UHFFFAOYSA-N_|_Small molecule_|_False_|_AC-430_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AC430' 'Ac-430']_|_[('drugbank', array(['DB12535'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3586573,"CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21_|_GMYLVKUGJMYTFB-UHFFFAOYSA-N_|_Small molecule_|_False_|_CC-115_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cc-115']_|_[('drugbank', array(['DB12740'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009708', 'EFO_0000095', 'EFO_0000181', 'EFO_0000519',
       'EFO_0000637', 'MONDO_0008315'], dtype=object), 'count': 6}_|_[ENSG00000253729,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4208229,"O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1_|_VOVZXURTCKPRDQ-CQSZACIVSA-N_|_Small molecule_|_False_|_ASCIMINIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ABL-001' 'ABL001' 'ABL001-NX' 'Abl-001' 'Asciminib' 'NVP-ABL001']_|_[('drugbank', array(['DB12597'], dtype=object))]_|_['CHEMBL4297220']_|_{'rows': array(['EFO_1000131', 'EFO_0003086', 'EFO_0000616', 'MONDO_0003060',
       'EFO_0000220', 'EFO_0000339', 'EFO_0000339'], dtype=object), 'count': 7}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 4 investigational indications."
CHEMBL4297608,"C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)[C@@H](OCCCO)[C@@H]1O_|_FZEXGDDBXLBRTD-AYIMTCTASA-N_|_Small molecule_|_False_|_ELDECALCITOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ed-71' 'Eldecalcitol']_|_[('drugbank', array(['DB05295'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003882'], dtype=object), 'count': 1}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL454,"C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O_|_UZVHFVZFNXBMQJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUTALBITAL_|_1983.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Alisobumal' 'Allylbarbituric acid' 'Butalbital' 'Butalbital ciii'
 'Itobarbital' 'Tetrallobarbital']_|_[('DailyMed', array(['butalbital'], dtype=object)), ('Wikipedia', array(['Butalbital'], dtype=object)), ('drugbank', array(['DB00241'], dtype=object)), ('chEBI', array(['102524'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for migraine disorder."
CHEMBL4650436,"nan_|_nan_|_Unknown_|_False_|_AGN-211745_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGN 211745' 'AGN-211745' 'AGN-745' 'Agn 211745' 'Agn-211745' 'SIRNA-027']_|_nan_|_nan_|_{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}_|_[ENSG00000102755]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL529437,"COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C.Cl_|_PIQVDUKEQYOJNR-VZXSFKIWSA-N_|_Small molecule_|_True_|_COCAINE HYDROCHLORIDE_|_2017.0_|_4.0_|_CHEMBL370805_|_False_|_True_|_['Goprelto' 'Numbrino']_|_['Cocaine hcl' 'Cocaine hydrochloride' 'Cocaine hydrochloride cii'
 'Cocaine muriate' 'Cocainum muriaticum' 'MCV 4526' 'NIH 8211' 'NSC-25263'
 'RX-0041-002']_|_[('DailyMed', array(['cocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206436'], dtype=object)), ('chEBI', array(['613010'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002610'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL569,"CCN(CC)CCOC(=O)c1ccc(N)cc1_|_MFDFERRIHVXMIY-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROCAINE_|_1954.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-169497' 'Novocain' 'Procaine']_|_[('PubChem', array(['11111696', '11111697', '90341175'], dtype=object)), ('Wikipedia', array(['Procaine'], dtype=object)), ('drugbank', array(['DB00721'], dtype=object)), ('chEBI', array(['8430'], dtype=object))]_|_['CHEMBL1200841']_|_{'rows': array(['EFO_0000764', 'EFO_0009552', 'EFO_0003102'], dtype=object), 'count': 3}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for hemorrhoid and has 2 investigational indications."
CHEMBL591118,"COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](N3C[C@@H](CF)CC3=O)CN1CC2_|_GUYMHFIHHOEFOA-ZCPGHIKRSA-N_|_Small molecule_|_False_|_CARMEGLIPTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Carmegliptin' 'R-1579' 'R1579' 'RO-4876904' 'RO4876904']_|_[('drugbank', array(['DB12268'], dtype=object))]_|_['CHEMBL2105633']_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200509,"CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1_|_OWAUGAMNPZHEOJ-YKZVIGSYSA-N_|_Protein_|_False_|_HISTRELIN ACETATE_|_1991.0_|_4.0_|_CHEMBL1201255_|_False_|_True_|_['Supprelin' 'Supprelin la' 'Vantas']_|_['Histrelin acetate']_|_[('DailyMed', array(['histrelin%20acetate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000673'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for prostate cancer and prostate adenocarcinoma."
CHEMBL1201065,"C=CCC1(C(C)CCC)C(=O)[N-]C(=S)NC1=O.[Na+]_|_LYZGJWXNOGIVQA-UHFFFAOYSA-M_|_Small molecule_|_False_|_THIAMYLAL SODIUM_|_1982.0_|_4.0_|_CHEMBL440_|_False_|_True_|_['Surital']_|_['NSC-759558' 'Sodium thiamylal' 'Thiamylal sodium'
 'Thiamylal sodium salt']_|_[('PubChem', array(['144205070', '26749789'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201068,"CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2.Cl_|_UGVNGSMLNPWNNA-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPIOMAZINE HYDROCHLORIDE_|_1960.0_|_4.0_|_CHEMBL1201210_|_False_|_True_|_['Largon']_|_['Propiomazine hcl' 'Propiomazine hydrochloride']_|_[('chEBI', array(['8492'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1201532,"nan_|_nan_|_Unknown_|_False_|_THYROTROPIN_|_1953.0_|_4.0_|_nan_|_False_|_True_|_['Thytropar']_|_['Thyrotrophin' 'Thyrotropin' 'Thyrotropin (bovine)']_|_nan_|_nan_|_{'rows': array(['EFO_0006859', 'EFO_0000641', 'EFO_0000501'], dtype=object), 'count': 3}_|_[ENSG00000165409]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 3 investigational indications."
CHEMBL1201836,"nan_|_nan_|_Antibody_|_True_|_OFATUMUMAB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Arzerra' 'Kesimpta']_|_['2F2' 'GSK-1841157' 'GSK1841157' 'GSKI841157' 'HUMAX-CD20'
 'HUMAX-CD20 2F2' 'HUMAX-CD20, 2F2' 'HUMAX-CD20-2F2' 'Ofatumumab']_|_[('DailyMed', array(['ofatumumab'], dtype=object)), ('DrugCentral', array(['4951'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta'],
      dtype=object)), ('Wikipedia', array(['Ofatumumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004255', 'MONDO_0005301', 'EFO_0000574', 'EFO_0004256',
       'MONDO_0020547', 'EFO_0003929', 'MONDO_0001023', 'EFO_0000183',
       'EFO_1000749', 'EFO_0000756', 'EFO_1001469', 'EFO_0000565',
       'EFO_0000685', 'EFO_0000540', 'EFO_0004289', 'EFO_0009441',
       'EFO_0000309', 'EFO_0000403', 'MONDO_0018906', 'MONDO_0004992',
       'MONDO_0000873', 'MONDO_0000870', 'EFO_0000765', 'EFO_0000616',
       'EFO_0000095', 'EFO_0004719', 'EFO_0005952', 'EFO_0000220'],
      dtype=object), 'count': 28}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1614707,"FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1_|_ZTFBIUXIQYRUNT-MDWZMJQESA-N_|_Small molecule_|_False_|_MUBRITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mubritinib' 'TAK-165']_|_[('drugbank', array(['DB12682'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003860', 'EFO_0003893', 'EFO_0003865', 'MONDO_0021117',
       'EFO_0003869'], dtype=object), 'count': 5}_|_[ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1716,"CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl_|_ZPMVNZLARAEGHB-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYPROHEPTADINE HYDROCHLORIDE_|_1961.0_|_4.0_|_CHEMBL516_|_False_|_True_|_['Cyproheptadine Hydrocloride' 'Cyproheptadine hydrochloride' 'Periactin']_|_['Cyproheptadine HCl' 'Cyproheptadine hcl' 'Cyproheptadine hydrochloride'
 'Cyproheptadine hydrochloride hydrate'
 'Cyproheptadine hydrochloride sesquihydrate' 'NSC-169911' 'NSC-759282'
 'Periactine' 'Peritol']_|_[('DailyMed', array(['cyproheptadine%20hydrochloride'], dtype=object)), ('PubChem', array(['50105994', '50105995', '56422142', '855651'], dtype=object)), ('chEBI', array(['59695'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0005531', 'EFO_0007141', 'EFO_0003956'],
      dtype=object), 'count': 4}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 1 investigational indication."
CHEMBL1789842,"CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2.O=C(O)/C=C\C(=O)O_|_IREJFXIHXRZFER-PCBAQXHCSA-N_|_Small molecule_|_False_|_INDACATEROL MALEATE_|_2009.0_|_4.0_|_CHEMBL1095777_|_False_|_True_|_['Arcapta neohaler' 'Onbrez breezhaler']_|_['Indacaterol (as maleate)' 'Indacaterol maleate' 'Indacterol maleate'
 'QAB-149-AFA' 'QAB149-AFA']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onbrez-breezhaler'],
      dtype=object)), ('chEBI', array(['68573'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006505', 'EFO_0000341', 'MONDO_0004979', 'EFO_0000464'],
      dtype=object), 'count': 4}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 1 investigational indication."
CHEMBL2108051,"nan_|_nan_|_Antibody_|_False_|_STAMULUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MYO-029' 'Stamulumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0016971', 'MONDO_0010311', 'Orphanet_269'], dtype=object), 'count': 3}_|_[ENSG00000138379]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109614,"nan_|_nan_|_Antibody_|_False_|_MEDI-5117_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MEDI-5117' 'Medi 5117' 'Medi-5117']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2181929,"CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(c2ccc(F)cc2)C1=O_|_AZNHWXAFPBYFGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_MT-3995_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apararenone' 'MT-3995' 'Mt-3995']_|_[('drugbank', array(['DB15024'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'EFO_1001249'], dtype=object), 'count': 2}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL220491,"CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(S(N)(=O)=O)cc21_|_HCRKCZRJWPKOAR-JTQLQIEISA-N_|_Small molecule_|_False_|_BRINZOLAMIDE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Azopt']_|_['AL-4862' 'Azopt' 'Brinzolamide' 'NSC-760050']_|_[('DailyMed', array(['brinzolamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/azopt'],
      dtype=object)), ('PubChem', array(['170464926', '56463043'], dtype=object)), ('Wikipedia', array(['Brinzolamide'], dtype=object)), ('drugbank', array(['DB01194'], dtype=object)), ('chEBI', array(['3176'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004190', 'EFO_0009784', 'MONDO_0005041', 'EFO_1001069'],
      dtype=object), 'count': 4}_|_[ENSG00000104267]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 1 investigational indication."
CHEMBL2206292,"CC(C)CNC(=O)[C@H]1C[C@@](F)(c2ccc(CN3CCCC3)c(F)c2)C1_|_DJRDLCHHQYHQQK-UKIBZPOASA-N_|_Small molecule_|_False_|_PF-03654764_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-03654764']_|_[('drugbank', array(['DB12360'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2218861,"CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21_|_GDFGTRDCCWFXTG-UHFFFAOYSA-N_|_Small molecule_|_False_|_QUINAGOLIDE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Quinagolide']_|_nan_|_['CHEMBL5316219']_|_{'rows': array(['MONDO_0011972'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2004 and has 1 investigational indication."
CHEMBL2364624,"O=C(O)C[C@H]1CC[C@H](c2ccc(-c3ccc(Nc4ccc(C(F)(F)F)nc4)cn3)cc2)CC1_|_GXALXAKNHIROPE-QAQDUYKDSA-N_|_Small molecule_|_False_|_PRADIGASTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LCQ-908-NXA' 'LCQ-908NXA' 'LCQ908-NXA' 'Lcq-908'
 'Lcq908 - dgat-1-inhibitor' 'Pradigastat']_|_[('drugbank', array(['DB12866'], dtype=object))]_|_['CHEMBL2364625']_|_{'rows': array(['EFO_0003095', 'EFO_0001421', 'MONDO_0037748', 'EFO_0003086',
       'HP_0002019', 'MONDO_0005148', 'EFO_0003047'], dtype=object), 'count': 7}_|_[ENSG00000185000]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL277474,"Cc1cc(=O)n(-c2ccccc2)n1C_|_VEQOALNAAJBPNY-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANTIPYRINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Antipyrin' 'Antipyrine' 'Antipyrinum' 'NSC-7945' 'Phenazon' 'Phenazone']_|_[('PubChem', array(['104171279', '11112159', '144203893', '144208798', '144213343',
       '170465510', '26753718', '56320742'], dtype=object)), ('Wikipedia', array(['Phenazone'], dtype=object)), ('drugbank', array(['DB01435'], dtype=object)), ('chEBI', array(['31225'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'HP_0001945', 'HP_0100607', 'EFO_0004992',
       'EFO_0003843'], dtype=object), 'count': 5}_|_[ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for fever and pain and has 3 investigational indications."
CHEMBL3301611,"Nc1ccncc1N.O=P(O)(O)O_|_KAICRBBQCRKMPO-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMIFAMPRIDINE PHOSPHATE_|_2009.0_|_4.0_|_CHEMBL354077_|_False_|_True_|_['Firdapse' 'Firdapse (previously zenas)']_|_['3,4-DAPP' 'Amifampridine phosphate' 'DAPP' 'Zenas']_|_[('DailyMed', array(['amifampridine%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008525', 'EFO_0004991', 'MONDO_0015263', 'EFO_0020094',
       'EFO_0004991', 'EFO_0009851'], dtype=object), 'count': 6}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for lambert-eaton myasthenic syndrome and myasthenia gravis and has 4 investigational indications."
CHEMBL3545046,"nan_|_nan_|_Small molecule_|_False_|_GSK2849466_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Gsk2849466']_|_nan_|_nan_|_{'rows': array(['HP_0004326'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3707325,"nan_|_nan_|_Antibody_|_False_|_LENZILUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['KB-003' 'KB003' 'Lenzilumab']_|_nan_|_nan_|_{'rows': array(['EFO_0003106', 'EFO_0000096', 'EFO_1001779', 'MONDO_0004979',
       'EFO_0000685', 'MONDO_0100096'], dtype=object), 'count': 6}_|_[ENSG00000164400]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4297240,"nan_|_nan_|_Gene_|_False_|_ONASEMNOGENE ABEPARVOVEC_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Zolgensma']_|_['AVXS-101' 'Onasemnogene abeparvovec' 'Zolgensma']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_83419', 'EFO_0008525', 'MONDO_0009669', 'MONDO_0009673'],
      dtype=object), 'count': 4}_|_[ENSG00000172062,ENSG00000205571]_|_Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for proximal spinal muscular atrophy type 3 and spinal muscular atrophy and has 2 investigational indications."
CHEMBL4297505,"CCc1cc(-c2noc(-c3cc(OC)nc(C4CCCC4)c3)n2)cc(C)c1OC[C@@H](O)CO_|_KJKKMMMRWISKRF-FQEVSTJZSA-N_|_Small molecule_|_False_|_CENERIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACT-334441' 'ACT334441' 'Act-334441' 'Cenerimod']_|_[('drugbank', array(['DB12705'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'MONDO_0007915', 'EFO_0001421'], dtype=object), 'count': 3}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297883,"nan_|_nan_|_Antibody_|_False_|_IVUXOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anti-ox40 antibody pf-04518600' 'Ivuxolimab' 'PF-04518600' 'PF-8600'
 'PF04518600' 'Pf-04518600' 'Pf04518600']_|_nan_|_nan_|_{'rows': array(['MONDO_0018906', 'EFO_0000349', 'MONDO_0004992', 'EFO_0000222',
       'EFO_0005537', 'EFO_0000616', 'EFO_0000196'], dtype=object), 'count': 7}_|_[ENSG00000186827]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4297919,"nan_|_nan_|_Unknown_|_False_|_PAROXETINE HYDROCHLORIDE HEMIHYDRATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BRL29060A' 'Brl29060a' 'Paroxetine hydrochloride'
 'Paroxetine hydrochloride hemihydrate' 'Paroxetine hydrochloride hydrate']_|_nan_|_nan_|_{'rows': array(['EFO_1001917'], dtype=object), 'count': 1}_|_[ENSG00000108576]_|_Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297938,"nan_|_nan_|_Antibody drug conjugate_|_False_|_LIFASTUZUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DNIB-0600A' 'DNIB0600A' 'Dnib0600a' 'Lifastuzumab vedotin' 'NAPI3B'
 'RG-7599']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0008170'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000157765]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL450940,"C=Cc1cc(O)cc2nc(-c3ccc(O)c(F)c3)oc12_|_MQIMZDXIAHJKQP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRINABEREL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ERB-041' 'PF-00913086' 'Prinaberel']_|_[('drugbank', array(['DB06832'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001657', 'EFO_0001065', 'EFO_0000384'], dtype=object), 'count': 3}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650337,"CNC[C@@H]1OCCc2ccsc21_|_ABDDQTDRAHXHOC-QMMMGPOBSA-N_|_Small molecule_|_False_|_ULOTARONT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SEP-363856' 'SEP-856' 'Sep-363856' 'Ulotaront']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ULOTARONT/relevant/1/'],
      dtype=object))]_|_['CHEMBL5314561']_|_{'rows': array(['MONDO_0005090', 'MONDO_0005090', 'MONDO_0005180', 'EFO_1001892',
       'MONDO_0005180', 'MONDO_0002009', 'MONDO_0002009', 'MONDO_0016158',
       'MONDO_0002009', 'MONDO_0016158'], dtype=object), 'count': 10}_|_[ENSG00000146399,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL467399,"COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc32)c1C_|_QULDDKSCVCJTPV-UHFFFAOYSA-N_|_Small molecule_|_False_|_BIIB021_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB 021' 'BIIB-021' 'Biib021' 'CNF2024' 'Cnf-2024' 'Cnf2024']_|_[('PubChem', array(['124954167'], dtype=object)), ('drugbank', array(['DB12359'], dtype=object)), ('chEBI', array(['90687'], dtype=object))]_|_['CHEMBL3526911' 'CHEMBL557165']_|_{'rows': array(['EFO_0000616', 'EFO_0000574', 'MONDO_0011719', 'MONDO_0007254',
       'EFO_0000095'], dtype=object), 'count': 5}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL535,"CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C_|_WINHZLLDWRZWRT-ATVHPVEESA-N_|_Small molecule_|_True_|_SUNITINIB_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Sunitinib accord' 'Sutent']_|_['NSC-736511' 'NSC-750690' 'SU-011248' 'SU-11248' 'SU011248' 'Sunitinib'
 'Sutent']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord'],
      dtype=object)), ('PubChem', array(['124893176', '26758053', '50100120'], dtype=object)), ('Wikipedia', array(['Sunitinib'], dtype=object)), ('drugbank', array(['DB01268'], dtype=object)), ('chEBI', array(['38940'], dtype=object))]_|_['CHEMBL3109278' 'CHEMBL3542310' 'CHEMBL1567']_|_{'rows': array(['EFO_0000222', 'EFO_0000313', 'MONDO_0003268', 'EFO_0000181',
       'EFO_0005221', 'EFO_0000228', 'EFO_1000251', 'MONDO_0002367',
       'EFO_0002499', 'EFO_0006861', 'EFO_0000349', 'EFO_1000045',
       'MONDO_0001056', 'MONDO_0044926', 'EFO_1000581', 'EFO_0000702',
       'MONDO_0004192', 'EFO_0000640', 'EFO_0000641', 'EFO_0003869',
       'EFO_0000514', 'EFO_0000673', 'EFO_0007331', 'EFO_0002617',
       'MONDO_0015277', 'EFO_0000294', 'EFO_0000095', 'EFO_0000673',
       'EFO_1001901', 'EFO_0000220', 'EFO_0000403', 'MONDO_0002367',
       'EFO_1000045', 'EFO_0003869', 'EFO_0003897', 'MONDO_0011719',
       'MONDO_0002691', 'EFO_0000702', 'EFO_0003833', 'EFO_0003897',
       'EFO_0003060', 'MONDO_0007254', 'EFO_0004142', 'EFO_0000519',
       'EFO_0008528', 'EFO_0006352', 'EFO_0001378', 'EFO_0000182',
       'EFO_0002618', 'MONDO_0008170', 'MONDO_0002087', 'EFO_0000756',
       'MONDO_0007254', 'EFO_0000239', 'MONDO_0008667', 'EFO_0000616',
       'EFO_0007416', 'EFO_0000558', 'MONDO_0008667', 'MONDO_0008903',
       'EFO_0000514', 'EFO_0000222', 'EFO_0000640', 'EFO_0000519',
       'EFO_0000349', 'MONDO_0002158', 'MONDO_0007576', 'EFO_0003060',
       'EFO_0004243', 'MONDO_0002158', 'EFO_1001951', 'EFO_1000984',
       'MONDO_0001187', 'EFO_1000796', 'MONDO_0008903', 'EFO_0000616',
       'EFO_1000576', 'EFO_0003863', 'EFO_1001465', 'EFO_0000501',
       'EFO_0000196', 'EFO_0002618', 'MONDO_0008315', 'EFO_1001951',
       'MONDO_0002087', 'EFO_0003865', 'EFO_0000632', 'EFO_0000681',
       'EFO_0000588', 'EFO_0007243', 'EFO_0004252', 'HP_0001541',
       'EFO_0000691', 'EFO_0000182', 'EFO_0000637', 'MONDO_0018364',
       'EFO_1001465', 'EFO_1001968', 'EFO_0007143', 'EFO_0002938',
       'EFO_1001968', 'MONDO_0008315', 'EFO_1001901', 'MONDO_0001187',
       'EFO_0007416', 'MONDO_0004992', 'EFO_0000681', 'MONDO_0011719',
       'MONDO_0004992', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0002892',
       'EFO_1000576', 'EFO_0002617'], dtype=object), 'count': 114}_|_[ENSG00000037280,ENSG00000128052,ENSG00000165731,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000182578,ENSG00000122025,ENSG00000102755]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 8 approved and 86 investigational indications. This drug has a black box warning from the FDA."
CHEMBL117785,"COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2_|_MKJIEFSOBYUXJB-UHFFFAOYSA-N_|_Small molecule_|_True_|_TETRABENAZINE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Nitoman' 'Revocon' 'Tetmodis' 'Tetrabenazine' 'Xenazine' 'Xenazine 25']_|_['NSC-169886' 'RO 1-9569' 'RO-1-9569' 'RO-19569' 'Tetrabenazine']_|_[('DailyMed', array(['tetrabenazine'], dtype=object)), ('PubChem', array(['144205356', '170464675', '29216102', '50086515', '90341774'],
      dtype=object)), ('Wikipedia', array(['Tetrabenazine'], dtype=object)), ('drugbank', array(['DB04844'], dtype=object)), ('chEBI', array(['64028'], dtype=object))]_|_['CHEMBL3137326']_|_{'rows': array(['EFO_1000632', 'MONDO_0007739', 'MONDO_0007739', 'EFO_0004895',
       'MONDO_0003441', 'EFO_0004280', 'EFO_0004152', 'EFO_0004895',
       'EFO_0004280', 'EFO_0004152'], dtype=object), 'count': 10}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for huntington disease and chorea and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200392,"CN(C)CCOC(C)(c1ccccc1)c1ccccn1.O=C(O)CCC(=O)O_|_KBAUFVUYFNWQFM-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXYLAMINE SUCCINATE_|_1948.0_|_4.0_|_CHEMBL1004_|_False_|_True_|_['Decapryn' 'Doxy-sleep-aid' 'Doxylamine succinate' 'Unisom']_|_['Alsodorm' 'Donormil' 'Donormyl' 'Dormidina'
 'Doxylamine hydrogen succinate' 'Doxylamine succinate' 'Gittalun'
 'Hoggar n' 'Meraprina' 'NSC-74772']_|_[('DailyMed', array(['doxylamine%20succinate'], dtype=object)), ('PubChem', array(['144207064', '144209276', '144213178', '170465171', '26747491',
       '50106112', '56423151', '855569'], dtype=object)), ('chEBI', array(['82461'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854', 'HP_0002017', 'EFO_0000544'], dtype=object), 'count': 3}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 3 investigational indications."
CHEMBL1200477,"O=c1[n-]cnc2[nH]ncc12.[Na+]_|_PTJRZVJXXNYNLN-UHFFFAOYSA-M_|_Small molecule_|_False_|_ALLOPURINOL SODIUM_|_1996.0_|_4.0_|_CHEMBL1467_|_False_|_True_|_['Allopurinol sodium' 'Aloprim']_|_['Allopurinol sodium' 'Allopurinol sodium salt' 'NSC-108836']_|_[('DailyMed', array(['allopurinol%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001793'], dtype=object), 'count': 1}_|_[ENSG00000158125]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1996 and has 1 investigational indication."
CHEMBL1200521,"CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12.O=C(O)CC(O)C(=O)O_|_QHATUKWEVNMHRY-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALMOTRIPTAN MALATE_|_2001.0_|_4.0_|_CHEMBL1505_|_False_|_True_|_['Almotriptan malate' 'Axert']_|_['Almogran' 'Almotriptan d,l-hydrogenmalate' 'Almotriptan malate'
 'Almotriptan maleate' 'LAS 31416 D,L-MALATE ACID' 'LAS-31416'
 'LAS-31416 D,L-MALATE ACID' 'LAS-31416-D,L-MALATE-ACID' 'PNU-180638E']_|_[('DailyMed', array(['almotriptan%20malate'], dtype=object)), ('chEBI', array(['53781'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000179097,ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for migraine disorder."
CHEMBL1200755,"CCNCC.CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O_|_FHDKSYKZXIFRKJ-CBCFNHQSSA-N_|_Protein_|_False_|_CERULETIDE DIETHYLAMINE_|_1982.0_|_4.0_|_CHEMBL1201355_|_False_|_True_|_['Tymtran']_|_['Caerulein diethylamine' 'Ceosunin' 'Ceruletide diethylamine'
 'Ceruletide diethylamine salt' 'Takus']_|_[('chEBI', array(['59223'], dtype=object))]_|_nan_|_nan_|_[ENSG00000163394]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201232,"CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C_|_JTPUMZTWMWIVPA-UHFFFAOYSA-O_|_Small molecule_|_False_|_ISOPROPAMIDE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Isopropamide' 'Isopropamide cation' 'Isopropamide ion']_|_[('PubChem', array(['11112197', '144203913', '170465291'], dtype=object)), ('Wikipedia', array(['Isopropamide'], dtype=object)), ('drugbank', array(['DB01625'], dtype=object)), ('chEBI', array(['6043'], dtype=object))]_|_['CHEMBL1200347']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for gastrointestinal disease."
CHEMBL136478,"nan_|_nan_|_Small molecule_|_True_|_SODIUM NITROPRUSSIDE_|_1981.0_|_4.0_|_CHEMBL2097081_|_False_|_True_|_['Nipride' 'Nitropress' 'Sodium nitroprusside']_|_['NSC-755844' 'Nipruss' 'Nitroprusside sodium' 'Sodium nitroferricyanide'
 'Sodium nitroprusside' 'Sodium nitroprusside anhydrous'
 'Sodium nitroprusside dihydrate' 'Sodium nitroprusside hydrate']_|_[('DailyMed', array(['sodium%20nitroprusside'], dtype=object)), ('Wikipedia', array(['Sodium_nitroprusside'], dtype=object)), ('chEBI', array(['29321'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'MP_0001914', 'EFO_0004272', 'MONDO_0005090',
       'EFO_1000653', 'EFO_0000373', 'EFO_0008585', 'EFO_0000319',
       'MP_0001845', 'EFO_0001358'], dtype=object), 'count': 10}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for hemorrhage and congestive heart failure and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL193,"COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]_|_HYIMSNHJOBLJNT-UHFFFAOYSA-N_|_Small molecule_|_False_|_NIFEDIPINE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Adalat' 'Adalat a.r.' 'Adalat cc' 'Adalat ic' 'Adalat la 20'
 'Adalat la 30' 'Adalat la 60' 'Adalat ret' 'Adalate lp' 'Adanif xl'
 'Adipine mr 10' 'Adipine mr 20' 'Adipine xl' 'Afeditab cr' 'Angiopine 10'
 'Angiopine 40 la' 'Angiopine 5' 'Angiopine mr 10' 'Angiopine mr 20'
 'Calanif' 'Calchan mr 10' 'Calchan mr 20' 'Calcilat' 'Cardilate mr'
 'Coracten sr' 'Coracten xl' 'Coroday mr' 'Fortipine la40'
 'Genalat 10 ret' 'Genalat 20 ret' 'Hypolar ret 10' 'Hypolar ret 20'
 'Hypolar xl 30' 'Kentipine' 'Kentipine mr 10' 'Kentipine mr 20'
 'Neozipine xl' 'Nife-wolff' 'Nifedipine' 'Nifedipress mr 10'
 'Nifedipress mr 20' 'Nifedotard 20 mr' 'Nifelease' 'Nifensar xl'
 'Nifopress mr' 'Nifopress ret' 'Nimodrel mr 10' 'Nimodrel mr 20'
 'Nimodrel xl' 'Nivaten ret' 'Procardia' 'Procardia xl'
 'Slofedipine xl 30' 'Slofedipine xl 60' 'Tensipine mr 10'
 'Tensipine mr 20' 'Unipine xl' 'Valni 20 ret' 'Valni xl' 'Vasad']_|_['BAY A 1040' 'BAY-A-1040' 'Coracten' 'NSC-757242' 'Nifedipine'
 'Nifedipine hydrochloride' 'Nifedipine slow release' 'Nifedipinum']_|_[('DailyMed', array(['nifedipine'], dtype=object)), ('PubChem', array(['104171202', '11111548', '11111549', '11113899', '124880908',
       '124880909', '124880910', '124880913', '144203763', '144207502',
       '170465006', '17388858', '26747150', '26747151', '26752059',
       '26752060', '50100293', '50104712', '50104713', '50104714',
       '85231157', '90341123'], dtype=object)), ('TG-GATEs', array(['91'], dtype=object)), ('Wikipedia', array(['Nifedipine'], dtype=object)), ('drugbank', array(['DB01115'], dtype=object)), ('chEBI', array(['7565'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018479', 'HP_0000093', 'EFO_1001145', 'EFO_0000401',
       'EFO_0003917', 'EFO_1001375', 'EFO_0003890', 'EFO_0004263',
       'EFO_0009660', 'EFO_0007442', 'HP_0012390', 'MONDO_0005149',
       'EFO_0000319', 'EFO_0003884', 'EFO_0004225', 'EFO_0000668',
       'EFO_0000537', 'EFO_0004253'], dtype=object), 'count': 18}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 15 investigational indications."
CHEMBL2021430,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]_|_PLCQGRYPOISRTQ-FCJDYXGNSA-L_|_Small molecule_|_False_|_DEXAMETHASONE SODIUM PHOSPHATE_|_1959.0_|_4.0_|_CHEMBL1201302_|_False_|_True_|_['Decadron' 'Dexacen-4' 'Dexacort' 'Dexair' 'Dexamethasone'
 'Dexamethasone sodium phosphate'
 'Dexamethasone sodium phosphate preservative free' 'Hexadrol' 'Maxidex']_|_['Dexamethasone 21-phosphate disodium salt'
 'Dexamethasone sodium phosphate' 'NSC-756722' 'TLC-399' 'TLC399' 'Tlc399']_|_[('DailyMed', array(['dexamethasone%20sodium%20phosphate'], dtype=object)), ('PubChem', array(['144206732', '144212903'], dtype=object)), ('chEBI', array(['4462'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_1000941', 'MONDO_0007915', 'EFO_0000556',
       'EFO_0007328', 'MONDO_0008728', 'EFO_0009609', 'EFO_0004719',
       'EFO_1000039', 'EFO_1000764', 'EFO_1000997', 'EFO_1001896',
       'EFO_0000574', 'HP_0001915', 'EFO_0001642', 'EFO_1001051',
       'HP_0012424', 'EFO_0005558', 'HP_0001873', 'EFO_0007257',
       'MONDO_0100096', 'EFO_1002022', 'EFO_0004276', 'EFO_1001250',
       'EFO_0006738', 'EFO_0005319', 'MP_0001845', 'EFO_0000729',
       'EFO_1000049', 'EFO_0007141', 'EFO_0009491', 'EFO_0001378',
       'EFO_0003929', 'EFO_0004265', 'EFO_0007490', 'EFO_0008997',
       'EFO_1000845', 'EFO_1001194', 'MONDO_0005178', 'EFO_0007403',
       'EFO_0007520', 'EFO_0004255', 'EFO_0004274', 'MONDO_0015128',
       'EFO_1000684', 'EFO_1001119', 'EFO_0003778', 'EFO_0003898',
       'EFO_0000694', 'EFO_0000565', 'MONDO_0019338', 'EFO_0003956',
       'EFO_0003106', 'EFO_0000685', 'EFO_1001222', 'EFO_0000384',
       'EFO_0009456', 'HP_0004398', 'HP_0003072', 'EFO_0002609',
       'EFO_0000676', 'EFO_0007405', 'EFO_0009449', 'EFO_0005854',
       'HP_0001094', 'EFO_1001205', 'MONDO_0001280', 'EFO_1000694',
       'HP_0003040', 'EFO_0007160', 'EFO_1001435', 'EFO_0000274'],
      dtype=object), 'count': 72}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 60 approved and 12 investigational indications."
CHEMBL2103735,"CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O_|_KFEFLCOCAHJBEA-ANRVCLKPSA-N_|_Protein_|_False_|_CETRORELIX ACETATE_|_1999.0_|_4.0_|_CHEMBL1200490_|_False_|_True_|_['Cetrotide']_|_['Cetrorelix acetate' 'Cetrotide acetate' 'D-20761' 'NS-75A'
 'SB-075 ACETATE']_|_[('DailyMed', array(['cetrorelix%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cetrotide'],
      dtype=object)), ('chEBI', array(['31387'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000545', 'EFO_0000660'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications."
CHEMBL2103855,"Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(C[C@H](N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1_|_NCLGDOBQAWBXRA-PGRDOPGGSA-N_|_Small molecule_|_False_|_TELOTRISTAT_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['LP 778902' 'LP-778902' 'Telotristat']_|_[('drugbank', array(['DB14218'], dtype=object))]_|_['CHEMBL4796268']_|_{'rows': array(['EFO_1001901', 'EFO_0000729', 'EFO_1000852', 'EFO_0001421',
       'EFO_0003086'], dtype=object), 'count': 5}_|_[ENSG00000139287,ENSG00000129167]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 5 investigational indications."
CHEMBL2104986,"Cc1ccc(Sc2ccccc2C2CCNCC2)cc1_|_CVASBKDYSQKLSO-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEDATIOXETINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LU AA24530' 'LU-AA24530' 'LUAA24530' 'Lu aa24530' 'Tedatioxetine']_|_[('drugbank', array(['DB12641'], dtype=object))]_|_['CHEMBL2107377']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000102468,ENSG00000142319,ENSG00000147246,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084,ENSG00000108576,ENSG00000120907]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105728,"CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1_|_DYNHJHQFHQTFTP-UHFFFAOYSA-N_|_Small molecule_|_False_|_CRENOLANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ARO 002' 'ARO-002' 'CP 868596' 'CP-868,596' 'CP-868596' 'Crenolanib']_|_[('drugbank', array(['DB11832'], dtype=object))]_|_['CHEMBL2146086']_|_{'rows': array(['EFO_0005543', 'EFO_1000026', 'MONDO_0011719', 'EFO_0000616',
       'EFO_0000222', 'EFO_0000222', 'EFO_0000503', 'MONDO_0011719',
       'EFO_0000519'], dtype=object), 'count': 9}_|_[ENSG00000113721,ENSG00000134853,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2105754,"Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O.O=C(O)CCC(=O)O_|_OGCNTTUPLQTBJI-XFULWGLBSA-N_|_Small molecule_|_False_|_TRELAGLIPTIN SUCCINATE_|_2015.0_|_4.0_|_CHEMBL1650443_|_False_|_True_|_[]_|_['SYR-111472 SUCCINATE' 'SYR-472' 'SYR111472 SUCCINATE'
 'Trelagliptin succinate' 'Zafatek']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications."
CHEMBL2107866,"nan_|_nan_|_Protein_|_False_|_PEGINESATIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_['Hematide']_|_['AF-37702' 'AF37702' 'Peginesatide']_|_[('DrugCentral', array(['4234'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004272'], dtype=object), 'count': 1}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108072,nan_|_nan_|_Enzyme_|_False_|_PAMITEPLASE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pamiteplase' 'Solinase']_|_nan_|_nan_|_nan_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2108735,"nan_|_nan_|_Oligonucleotide_|_False_|_DRISAPERSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Drisapersen' 'GSK-2402968' 'GSK-2402968A' 'GSK2402968' 'GSK2402968A'
 'Gsk 2402968a' 'H51AON23' 'PRO-051' 'PRO051']_|_nan_|_nan_|_{'rows': array(['MONDO_0020121', 'MONDO_0010679'], dtype=object), 'count': 2}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109379,"nan_|_nan_|_Antibody_|_False_|_NI-0801_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NI-0801' 'Ni-0801']_|_nan_|_nan_|_{'rows': array(['EFO_1000668', 'EFO_1001486'], dtype=object), 'count': 2}_|_[ENSG00000169245]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL222460,O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO_|_QESHSZWKJULSAR-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-223131_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bms-223131']_|_nan_|_nan_|_nan_|_[ENSG00000156113]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL23,"COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1_|_HSUGRBWQSSZJOP-RTWAWAEBSA-N_|_Small molecule_|_False_|_DILTIAZEM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cardizem' 'Dilt-CD' 'Diltiazem' 'Diltiazem extended release' 'Diltzac'
 'Ditiaz' 'Surazem' 'Tiamate' 'Tiazac']_|_[('PubChem', array(['11113366', '144204449', '170464699', '26751609', '26751610',
       '50104266', '50104267', '50104268', '50104269', '90341257'],
      dtype=object)), ('TG-GATEs', array(['92'], dtype=object)), ('Wikipedia', array(['Diltiazem'], dtype=object)), ('drugbank', array(['DB00343'], dtype=object)), ('chEBI', array(['101278'], dtype=object))]_|_['CHEMBL1697' 'CHEMBL1200805']_|_{'rows': array(['EFO_0004888', 'EFO_0002687', 'EFO_0000701', 'MONDO_0000831',
       'EFO_1001375', 'EFO_0000195', 'HP_0003124', 'EFO_0000537',
       'EFO_0003890', 'EFO_0000537', 'EFO_0009660', 'EFO_0000538',
       'EFO_0003144', 'EFO_0000275', 'EFO_1001951', 'EFO_0009552',
       'EFO_0007328', 'EFO_0004225', 'EFO_0001645', 'MONDO_0004992',
       'EFO_0003914', 'HP_0012390', 'EFO_0000319', 'EFO_0000275',
       'MONDO_0005148', 'EFO_0005251', 'HP_0012390', 'MONDO_0100096',
       'EFO_0000764', 'EFO_0003913', 'HP_0002019'], dtype=object), 'count': 31}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 6 approved and 25 investigational indications."
CHEMBL3137345,"nan_|_nan_|_Antibody_|_False_|_DULIGOTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Duligotumab' 'Duligotuzumab' 'MEHD-7945A' 'MEHD7945A' 'RG-7597' 'RG7597']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001951', 'EFO_0006859'], dtype=object), 'count': 3}_|_[ENSG00000065361,ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545110,"CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1_|_RHXHGRAEPCAFML-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIBOCICLIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['LEE-011' 'LEE-011A' 'LEE011' 'LEE011A' 'Lee-011' 'NVP-LEE011'
 'Ribociclib']_|_[('drugbank', array(['DB11730'], dtype=object))]_|_['CHEMBL4468983' 'CHEMBL3707266']_|_{'rows': array(['MONDO_0002158', 'MONDO_0007254', 'EFO_0003085', 'EFO_0000616',
       'MONDO_0044903', 'EFO_0000569', 'EFO_0000519', 'EFO_0002499',
       'EFO_0000182', 'EFO_0005701', 'EFO_1001968', 'EFO_0000220',
       'EFO_0000574', 'EFO_0000313', 'EFO_0000181', 'EFO_0001075',
       'EFO_0000305', 'EFO_0000196', 'EFO_1001901', 'MONDO_0004992',
       'EFO_0000305', 'EFO_0002626', 'EFO_0003869', 'EFO_1001100',
       'EFO_0000756', 'EFO_0000616', 'EFO_0003859', 'EFO_1000251',
       'EFO_0003869', 'MONDO_0002601', 'EFO_0003086', 'EFO_0005220',
       'EFO_1000026', 'EFO_0003060', 'MONDO_0008315', 'MONDO_0008170',
       'MONDO_0007254', 'EFO_0000621'], dtype=object), 'count': 38}_|_[ENSG00000135446,ENSG00000105810]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 34 investigational indications."
CHEMBL3545985,"C[C@@H](Cc1ccccc1)N(C)Cc1ccccc1_|_YXKTVDFXDRQTKV-HNNXBMFYSA-N_|_Small molecule_|_False_|_BENZPHETAMINE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benzfetamine']_|_[('drugbank', array(['DB00865'], dtype=object)), ('chEBI', array(['3044'], dtype=object))]_|_['CHEMBL3544906']_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for obesity."
CHEMBL3707229,"nan_|_nan_|_Antibody_|_False_|_TEZEPELUMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Tezspire']_|_['AMG 157' 'MEDI19929' 'Tezepelumab']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005531', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000274',
       'HP_0006536', 'EFO_0004232', 'MONDO_0005271'], dtype=object), 'count': 7}_|_[ENSG00000145777]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for asthma and airway obstruction and has 5 investigational indications."
CHEMBL4297560,"nan_|_nan_|_Antibody_|_False_|_GATIPOTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gatipotuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297581,"nan_|_nan_|_Oligonucleotide_|_False_|_TOMINERSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ISIS-443139 FREE ACID' 'Ionis httrx' 'Isis 443139' 'RG-6042 FREE ACID'
 'RG6042' 'RG6042 FREE ACID' 'Rg6042' 'Ro7234292' 'Tominersen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOMINERSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0006835', 'MP_0001845', 'MONDO_0015492', 'MONDO_0007739',
       'EFO_1000710'], dtype=object), 'count': 5}_|_[ENSG00000197386]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297616,"NC(=O)[C@](O)(CNc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F)C(F)(F)F_|_YWQFJNWMWZMXRW-HXUWFJFHSA-N_|_Small molecule_|_False_|_OLINCIGUAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IW-1701' 'IW1701' 'Iw-1701' 'Olinciguat']_|_[('drugbank', array(['DB15238'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002571', 'MONDO_0011382'], dtype=object), 'count': 2}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297832,"nan_|_nan_|_Antibody_|_False_|_SUTIMLIMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Enjaymo']_|_['BIVV009' 'Bivv-009' 'Enjaymo' 'Sutimlimab' 'Sutimlimab jome'
 'Sutimlimab-jome' 'TNT-009' 'TNT009']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007160', 'EFO_0000540', 'EFO_1001264', 'MONDO_0018922',
       'EFO_0009473'], dtype=object), 'count': 5}_|_[ENSG00000182326]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 4 approved and 1 investigational indication."
CHEMBL4594605,"nan_|_nan_|_Unknown_|_False_|_OMFILOCTOCOG ALFA_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Omfiloctocog alfa' 'SCT-800' 'SCT800' 'Sct800']_|_nan_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4650461,"nan_|_nan_|_Unknown_|_False_|_CSL-324_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anumigilimab' 'CSL-324' 'CSL324' 'Csl 324' 'Csl-324' 'Csl324']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096'], dtype=object), 'count': 1}_|_[ENSG00000119535]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL5095492,"C=CC(=O)Nc1cc(C#CC(C)(C)N2CCN(C)CC2)cc2ncnc(Nc3ccc(F)c(Cl)c3)c12_|_JZDDKMMYGMSSFH-UHFFFAOYSA-N_|_Small molecule_|_False_|_MP-412_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL5095024']_|_{'rows': array(['MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL511142,"CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5_|_RMRJXGBAOAMLHD-CTAPUXPBSA-N_|_Small molecule_|_True_|_BUPRENORPHINE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Bupeaze' 'Buplast' 'Butec' 'Butrans' 'Hapoctasin' 'Panitaz' 'Prenotrix'
 'Reletrans' 'Sevodyne' 'Sublocade' 'Temgesic' 'Tephine' 'Transtec']_|_['ALKS-5461 COMPONENT BUPRENORPHINE' 'Brixadi' 'Buprenorphin'
 'Buprenorphine' 'Suboxone']_|_[('DailyMed', array(['buprenorphine'], dtype=object))]_|_['CHEMBL2368861']_|_{'rows': array(['EFO_0005799', 'EFO_0003047', 'EFO_0020911', 'MONDO_0002491',
       'HP_0003419', 'HP_0003418', 'EFO_0001358', 'EFO_0005611',
       'EFO_0000764', 'EFO_0010702', 'EFO_0010072', 'EFO_1001250',
       'EFO_0005611', 'EFO_0003843', 'EFO_0000181', 'MONDO_0002050',
       'EFO_0005762', 'HP_0012532', 'HP_0008419', 'EFO_0003890',
       'EFO_0002610', 'EFO_0004240', 'EFO_0004701', 'MONDO_0002009',
       'EFO_0003890', 'EFO_0005800', 'MONDO_0005090', 'MONDO_0011382',
       'MONDO_0005178', 'EFO_0005612'], dtype=object), 'count': 30}_|_[ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL604710,"O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1_|_VCPMZDWBEWTGNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_Z160_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-6721' 'MK6721' 'NMED-160' 'NP-118809' 'Z-160' 'Z160']_|_[('drugbank', array(['DB12743'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002959', 'MONDO_0041052'], dtype=object), 'count': 2}_|_[ENSG00000148408]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL633,"CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1_|_IYIKLHRQXLHMJQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMIODARONE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amiodarone' 'Cordarone' 'L-3428' 'Pacerone' 'SKF 33134-A']_|_[('PubChem', array(['104171110', '11110784', '11110785', '124879287', '144203634',
       '170464920', '26751596', '26751597', '50100172', '90341282'],
      dtype=object)), ('TG-GATEs', array(['33'], dtype=object)), ('Wikipedia', array(['Amiodarone'], dtype=object)), ('drugbank', array(['DB01118'], dtype=object)), ('chEBI', array(['2663'], dtype=object))]_|_['CHEMBL1083993']_|_{'rows': array(['EFO_0004269', 'EFO_0004287', 'EFO_0007243', 'EFO_0000373',
       'HP_0004755', 'EFO_0001645', 'MONDO_0100096', 'EFO_0000275',
       'EFO_0005529', 'MONDO_0019438', 'EFO_0003911', 'EFO_0005306',
       'EFO_0000612', 'EFO_0009492', 'EFO_0004287', 'EFO_0003144',
       'EFO_0004278', 'EFO_0005306', 'HP_0004308', 'EFO_0000275',
       'HP_0004308', 'EFO_0000318'], dtype=object), 'count': 22}_|_[ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL86,"CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC_|_TTWJBBZEZQICBI-UHFFFAOYSA-N_|_Small molecule_|_True_|_METOCLOPRAMIDE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Clopra' 'Clopra-""Yellow""' 'Elieten' 'Maxolon' 'Methoxyclopramide'
 'Metoclopramide' 'Reglan' 'Terperan']_|_[('PubChem', array(['11111421', '11111422', '144203739', '170464848', '26751627',
       '90341551'], dtype=object)), ('Wikipedia', array(['Metoclopramide'], dtype=object)), ('drugbank', array(['DB01233'], dtype=object)), ('chEBI', array(['107736'], dtype=object))]_|_['CHEMBL1200940' 'CHEMBL1256771']_|_{'rows': array(['HP_0002039', 'HP_0002239', 'EFO_1002048', 'HP_0002017',
       'EFO_1000948', 'HP_0002315', 'HP_0001943', 'HP_0002013',
       'MONDO_0004992', 'EFO_0004888', 'EFO_0003843', 'EFO_0005252',
       'HP_0100806', 'EFO_1000949', 'EFO_0000198', 'EFO_1000948',
       'HP_0002013', 'HP_0002017', 'EFO_1001463', 'EFO_0000764',
       'EFO_1000971', 'EFO_0006911', 'EFO_0000616', 'EFO_1000645',
       'MONDO_0005277', 'EFO_0010282', 'MONDO_0004565', 'EFO_0000546'],
      dtype=object), 'count': 28}_|_[ENSG00000149295,ENSG00000166736,ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200970,"CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21.Cl_|_VXPCQISYVPFYRK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETHOPROPAZINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1206_|_False_|_True_|_['Parsidol']_|_['Ethopropazine hcl' 'Ethopropazine hydrochloride' 'NSC-169467'
 'NSC-64074' 'Profenamine' 'Profenamine hibenzate'
 'Profenamine hydrochloride' 'Prophenamine hydrochloride']_|_[('PubChem', array(['144204047', '170465065', '26748043', '26748044'], dtype=object)), ('chEBI', array(['31568'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201213,"CCC(NC(C)C)C(O)c1ccc(O)c(O)c1_|_HUYWAWARQUIQLE-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOETHARINE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dilabron' 'Etyprenaline' 'Isoetarine' 'Isoetharine' 'Neoisuprel'
 'WIN 3406' 'WIN-3046' 'WIN-3406' 'WIN3406']_|_[('PubChem', array(['90341304'], dtype=object)), ('Wikipedia', array(['Isoetarine'], dtype=object)), ('drugbank', array(['DB00221'], dtype=object)), ('chEBI', array(['6005'], dtype=object))]_|_['CHEMBL1200920' 'CHEMBL1201153']_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for airway obstruction."
CHEMBL1201288,"O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1_|_OZOMQRBLCMDCEG-VIZOYTHASA-N_|_Small molecule_|_True_|_DANTROLENE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['2-methylbenzoic acid anilide' 'BAS-305' 'BAS-3050' 'BAS-3050F' 'Bebenil'
 'Dantrolene' 'F-368' 'Mebenil' 'NSC-227402' 'NSC-26404'
 'O-methylbenzanilide' 'O-toluanilide' 'SHA-458100']_|_[('PubChem', array(['26756482', '26756773'], dtype=object)), ('TG-GATEs', array(['119'], dtype=object)), ('Wikipedia', array(['Dantrolene'], dtype=object)), ('drugbank', array(['DB01219'], dtype=object))]_|_['CHEMBL2067986' 'CHEMBL928']_|_{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0020003', 'MONDO_0005301',
       'EFO_1000632', 'HP_0001257', 'EFO_0000546', 'EFO_0005306',
       'HP_0001945', 'EFO_1001340', 'MONDO_0018105', 'MONDO_0005301',
       'HP_0001945'], dtype=object), 'count': 13}_|_[ENSG00000198838,ENSG00000196218]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201560,"nan_|_nan_|_Protein_|_True_|_PEGINTERFERON ALFA-2A_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Pegasys' 'Roferon-A']_|_['Peg-interferon alfa 2a' 'Peg-interferon alfa-2a'
 'Peginterferon .alpha.-2a' 'Peginterferon alfa' 'Peginterferon alfa-2a'
 'Peginterferon-alfa-2a' 'Pegyinterferon-alfa-2a'
 'Pegylated interferon alfa-2a' 'Pegylated interferon alpha 2a'
 'Pegylated-interferon alfa 2a' 'Pegylated-interferon-alfa-2a'
 'RO 25-8310/000' 'RO-258310000']_|_[('DailyMed', array(['peginterferon%20alfa-2a'], dtype=object)), ('DrugCentral', array(['5158'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys'],
      dtype=object)), ('Wikipedia', array(['Peginterferon_alfa-2a'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002430', 'HP_0012115', 'HP_0001873', 'EFO_0004197',
       'EFO_0002429', 'EFO_0001378', 'MONDO_0002050', 'EFO_0000479',
       'MONDO_0021063', 'EFO_0004239', 'EFO_0000756', 'EFO_0001422',
       'MONDO_0007254', 'EFO_1000026', 'MONDO_0002367', 'MONDO_0044903',
       'EFO_0000544', 'EFO_0000182', 'EFO_0008496', 'EFO_0000095',
       'EFO_0000339', 'EFO_0007304', 'EFO_0000764', 'EFO_0004220',
       'EFO_0003047', 'MONDO_0004992', 'EFO_1000874', 'EFO_0000616'],
      dtype=object), 'count': 28}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 23 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1279,"CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1_|_XPSQPHWEGNHMSK-SECBINFHSA-N_|_Small molecule_|_False_|_FROVATRIPTAN_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Migard' 'Mylatrip']_|_['Allergo filmtabletten' 'Frova' 'Frovatriptan']_|_[('Wikipedia', array(['Frovatriptan'], dtype=object)), ('drugbank', array(['DB00998'], dtype=object))]_|_['CHEMBL1200371' 'CHEMBL2138684']_|_{'rows': array(['MONDO_0005277', 'MONDO_0005277', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for migraine disorder and has 1 investigational indication."
CHEMBL1743078,"nan_|_nan_|_Antibody_|_False_|_TEPLIZUMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Tzield']_|_['HOKT3-GAMMA-1 (ALA-ALA)' 'HUMANIZED OKT3' 'Humanzied OKT3' 'MGA-031'
 'MGA031' 'Teplizumab' 'Teplizumab mzwv' 'Teplizumab-mzwv' 'Tzield'
 'hOKT3 gamma 1 (Ala-Ala)']_|_nan_|_nan_|_{'rows': array(['EFO_0002546', 'MONDO_0005147', 'EFO_0000676'], dtype=object), 'count': 3}_|_[ENSG00000198851]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for type 1 diabetes mellitus and has 2 investigational indications."
CHEMBL2103743,"C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_SYIKUFDOYJFGBQ-YLAFAASESA-N_|_Small molecule_|_True_|_TOFACITINIB CITRATE_|_2012.0_|_4.0_|_CHEMBL221959_|_False_|_True_|_['Xeljanz' 'Xeljanz xr']_|_['CP-690,550-10' 'CP-690550-10' 'Cp-690550 citrate'
 'Tasocitinib monocitrate' 'Tofacitinib citrate' 'Tofacitinib monocitrate']_|_[('DailyMed', array(['tofacitinib%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz'],
      dtype=object)), ('chEBI', array(['71197'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019558', 'EFO_0003898', 'EFO_0003778', 'MONDO_0007915',
       'EFO_0000274', 'EFO_0000685'], dtype=object), 'count': 6}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2107312,"CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C_|_JXTAALBWJQJLGN-KSSFIOAISA-N_|_Small molecule_|_False_|_ARBACLOFEN PLACARBIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Arbaclofen placarbil' 'XP-19986' 'XP19986']_|_[('drugbank', array(['DB08892'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003418', 'MONDO_0005301', 'HP_0001257', 'MONDO_0007079',
       'EFO_0003948'], dtype=object), 'count': 5}_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2109250,"nan_|_nan_|_Antibody_|_False_|_TGN-1412_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CD28-SUPERMAB' 'TAB-08' 'TGN-1412' 'Tab08' 'Tgn-1412' 'Tgn1412'
 'Theralizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0007915', 'EFO_0000685', 'EFO_1001494'],
      dtype=object), 'count': 4}_|_[ENSG00000178562]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2109348,"nan_|_nan_|_Antibody_|_False_|_LFB-R603_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LFB-R603' 'Lfb-r603']_|_nan_|_nan_|_{'rows': array(['EFO_0000095'], dtype=object), 'count': 1}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2311030,"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O.CS(=O)(=O)O_|_PBKVEOSEPXMKDN-LZHUFOCISA-N_|_Unknown_|_False_|_ERGOLOID MESYLATES_|_1953.0_|_4.0_|_CHEMBL2364968_|_False_|_True_|_['Alkergot' 'Circanol' 'Deapril-st' 'Ergoloid mesylates' 'Gerimal'
 'Hydergine' 'Hydergine lc' 'Hydrogenated ergot alkaloids']_|_['Co-dergocrine mesilate' 'Co-dergocrine mesylate' 'Codergocrine mesilate'
 'Dihydroergotoxine mesilate' 'Dihydroergotoxine mesylate'
 'Dihydroergotoxine methanesulfonate' 'Dihydrogenated ergot alkaloids'
 'Ergoloid mesilates' 'Ergoloid mesylates' 'Hydrogenated ergot alkaloids']_|_[('DailyMed', array(['ergoloid%20mesylates'], dtype=object)), ('DrugCentral', array(['5035'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004718', 'EFO_0000319', 'MONDO_0010383'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845,ENSG00000135312,ENSG00000178394]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL3527000,"O=c1[nH]nc2c3c(cccc13)Oc1ccc(CN3CCC(O)CC3)cc1-2_|_HAVFFEMDLROBGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_E-7016_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E 7016' 'E-7016' 'E7016' 'GPI-21016']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000143799,ENSG00000041880,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545261,"nan_|_nan_|_Antibody_|_False_|_BRONTICTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Brontictuzumab' 'OMP-52M51']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000148400]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3989801,"CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](COP(=O)(O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O_|_AAYJNPGTWYJOET-VURLEEIPSA-N_|_Protein_|_False_|_FORIGERIMOD ACETATE_|_nan_|_3.0_|_CHEMBL3989409_|_False_|_False_|_['Lupuzor']_|_['CEP-33457' 'Forigerimod acetate' 'IPP 201101' 'P-140' 'P140']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000109971]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL413376,"Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)[O-])c3cc(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)[O-])c5cc(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c45)ccc3C)c2)c1.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]_|_VAPNKLKDKUDFHK-UHFFFAOYSA-H_|_Small molecule_|_False_|_SURAMIN HEXASODIUM_|_nan_|_3.0_|_CHEMBL265502_|_False_|_False_|_[]_|_['BAY-205' 'BAYER-205' 'CI-1003' 'FOURNEAU 309' 'FOURNEAU-309' 'NF-060'
 'NSC-758165' 'Nagananinum' 'Naphuride' 'Suramin hexasodium'
 'Suramin sodium' 'Suraminum natricum']_|_[('PubChem', array(['11112082', '124881892', '26747683', '26753666', '85231329'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000681', 'MONDO_0007254', 'DOID_10113',
       'EFO_1000796', 'HP_0001919', 'EFO_0000673', 'MONDO_0001187',
       'EFO_0005044', 'EFO_0007294', 'EFO_0003756', 'EFO_0001378',
       'EFO_0003060', 'EFO_1000158', 'EFO_1001951'], dtype=object), 'count': 15}_|_[ENSG00000113578]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 15 investigational indications."
CHEMBL4297599,"N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O_|_PVPJTBAEAQVTPN-HRAQMCAYSA-N_|_Small molecule_|_False_|_ASPACYTARABINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aspacytarabine' 'Astarabine' 'BST-236' 'Bst-236']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ASPACYTARABINE/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802250']_|_{'rows': array(['EFO_0000198', 'EFO_0000222', 'EFO_0000198', 'EFO_0000220',
       'EFO_0000222'], dtype=object), 'count': 5}_|_[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297764,"nan_|_nan_|_Unknown_|_False_|_HETROMBOPAG OLAMINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Hetrombopag diolamine' 'Hetrombopag ethanolamine' 'Hetrombopag olamine'
 'Rafutrombopag olamine' 'SHR-8735 OLAMINE' 'SHR8735 OLAMINE']_|_nan_|_nan_|_{'rows': array(['EFO_0007160', 'EFO_0006927', 'HP_0001915'], dtype=object), 'count': 3}_|_[ENSG00000117400]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4650374,"nan_|_nan_|_Unknown_|_False_|_APG-2575_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APG-2575' 'APG2575' 'Apg-2575' 'Apg2575' 'Lisaftoclax']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000220', 'EFO_1001875', 'EFO_0009441',
       'EFO_0004289', 'EFO_0000095', 'EFO_0000621', 'MONDO_0004992',
       'EFO_0000222', 'MONDO_0007254'], dtype=object), 'count': 10}_|_[ENSG00000171791]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL4650509,"nan_|_nan_|_Antibody_|_False_|_MIBAVADEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mibavademab' 'REGN-4461' 'REGN4461' 'Regn4461']_|_nan_|_nan_|_{'rows': array(['MONDO_0027766', 'MONDO_0020088'], dtype=object), 'count': 2}_|_[ENSG00000116678]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5314409,"CC(C)N1CCN(Cc2cnc(-c3cc(-c4cccc5[nH]ccc45)cc4[nH]ncc34)o2)CC1.Cl_|_GECUEJGEJLAXQA-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-2269557_|_nan_|_2.0_|_CHEMBL2216859_|_False_|_False_|_[]_|_['GSK-2269557' 'GSK2269557' 'Gsk-2269557' 'Nemiralisib hydrochloride']_|_nan_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL658,"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1_|_GGCSSNBKKAUURC-UHFFFAOYSA-N_|_Small molecule_|_True_|_SUFENTANIL_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['IDS-NS-001' 'R 30,730' 'R-30730' 'Sufentanil' 'Sufentanyl']_|_[('Wikipedia', array(['Sufentanil'], dtype=object)), ('drugbank', array(['DB00708'], dtype=object)), ('chEBI', array(['9316'], dtype=object))]_|_['CHEMBL1201163' 'CHEMBL4747678']_|_{'rows': array(['EFO_1001139', 'EFO_0003843', 'EFO_0009267', 'HP_0012532',
       'EFO_0002950', 'HP_0003418', 'EFO_0003843', 'EFO_0000546'],
      dtype=object), 'count': 8}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for pain and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL76688,"CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1_|_BTGNGJJLZOIYID-UHFFFAOYSA-N_|_Small molecule_|_False_|_SIVELESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-544349' 'LY544349' 'ONO-5046' 'Sivelestat']_|_[('Wikipedia', array(['Sivelestat'], dtype=object)), ('drugbank', array(['DB12863'], dtype=object))]_|_['CHEMBL3182314' 'CHEMBL2107493']_|_{'rows': array(['EFO_0000694'], dtype=object), 'count': 1}_|_[ENSG00000197561]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1200405,"CS(=O)(=O)O.Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1_|_HODFCFXCOMKRCG-UHFFFAOYSA-N_|_Small molecule_|_False_|_BITOLTEROL MESYLATE_|_1984.0_|_4.0_|_CHEMBL1201295_|_False_|_True_|_['Tornalate']_|_['Bitolterol mesilate' 'Bitolterol mesylate' 'Bitolterol methanesulfonate'
 'WIN 32,784' 'WIN-32784']_|_[('chEBI', array(['3134'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984."
CHEMBL1201154,"CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1.O=S(=O)(O)CCS(=O)(=O)O_|_SWOUGRBFXFILIB-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROCHLORPERAZINE EDISYLATE_|_1957.0_|_4.0_|_CHEMBL728_|_False_|_True_|_['Compazine' 'Prochlorperazine edisylate']_|_['NSC-757299' 'Prochlorperazine edisilate' 'Prochlorperazine edisylate'
 'Prochlorperazine edisylate salt' 'Prochlorperazine ethanedisulfonate']_|_[('DailyMed', array(['prochlorperazine%20edisylate'], dtype=object)), ('PubChem', array(['26748222', '56422461'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957. This drug has a black box warning from the FDA."
CHEMBL1201187,"Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1_|_GSNHKUDZZFZSJB-QYOOZWMWSA-N_|_Small molecule_|_True_|_MARAVIROC_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Celsentri' 'Selzentry']_|_['Maraviroc' 'Rel-Maraviroc' 'UK-427857' 'Uk-427,857']_|_[('DailyMed', array(['maraviroc'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/celsentri'],
      dtype=object)), ('Wikipedia', array(['Maraviroc'], dtype=object)), ('drugbank', array(['DB04835'], dtype=object)), ('chEBI', array(['63608'], dtype=object))]_|_['CHEMBL4476214' 'CHEMBL4586236']_|_{'rows': array(['EFO_0000198', 'MONDO_0100096', 'EFO_0000685', 'EFO_0000403',
       'EFO_0000183', 'EFO_0000544', 'EFO_0000339', 'EFO_0002608',
       'MONDO_0018906', 'MONDO_0044881', 'EFO_0000095', 'EFO_0000765',
       'EFO_0000558', 'EFO_0000712', 'MONDO_0013730', 'EFO_0004211',
       'EFO_0000763', 'EFO_0000180', 'HP_0100543', 'EFO_0000764',
       'MONDO_0021094'], dtype=object), 'count': 21}_|_[ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1621597,"CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2_|_OEXHQOGQTVQTAT-BHIXFJMTSA-N_|_Small molecule_|_False_|_IPRATROPIUM_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ipratropium' 'Ipratropium cation' 'Ipratropium ion']_|_[('drugbank', array(['DB00332'], dtype=object))]_|_['CHEMBL1464005' 'CHEMBL2134724' 'CHEMBL3085123']_|_{'rows': array(['MONDO_0005180', 'EFO_0000341', 'HP_0002307', 'EFO_0008590',
       'EFO_0006505', 'MONDO_0004979', 'HP_0001742', 'EFO_0000464',
       'Orphanet_1764', 'EFO_0003956', 'EFO_0001361', 'EFO_0000341',
       'EFO_0007214', 'HP_0006536', 'EFO_0000274'], dtype=object), 'count': 15}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 6 investigational indications."
CHEMBL2107856,"nan_|_nan_|_Oligonucleotide_|_False_|_IMETELSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GRN-163L' 'GRN163L' 'Imetelstat']_|_nan_|_nan_|_{'rows': array(['MONDO_0044903', 'EFO_0000479', 'EFO_0000621', 'EFO_0001378',
       'EFO_0003060', 'MONDO_0007254', 'EFO_0000198', 'EFO_0000574',
       'EFO_0002429'], dtype=object), 'count': 9}_|_[ENSG00000164362]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2108358,"nan_|_nan_|_Protein_|_False_|_SERELAXIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Human relaxin 2 (relaxin h2)' 'Human relaxin recombinant' 'RLX-030'
 'RLX030' 'Recombinant human relaxin' 'Serelaxin']_|_nan_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0000668', 'EFO_0001645', 'EFO_0003144',
       'EFO_0000319', 'EFO_0003884'], dtype=object), 'count': 6}_|_[ENSG00000133105,ENSG00000171509]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2109384,"nan_|_nan_|_Antibody_|_False_|_DEMCIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Demcizumab' 'OMP-21M18']_|_nan_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_1001951', 'EFO_0003060', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000128917]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL249856,"CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1_|_ZJKNESGOIKRXQY-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENOXIMONE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Perfan']_|_['Enoximone' 'MDL 17,043' 'MDL-17043']_|_[('PubChem', array(['11111134', '144203688', '170466419', '50106183', '56320891',
       '56320892', '85231030', '90340640'], dtype=object)), ('Wikipedia', array(['Enoximone'], dtype=object)), ('drugbank', array(['DB04880'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0001645', 'EFO_0000373'], dtype=object), 'count': 3}_|_[ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL278703,"Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1_|_XIESSJVMWNJCGZ-VKJFTORMSA-N_|_Small molecule_|_False_|_ERTEBEREL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Erteberel' 'LY-500307' 'LY500307' 'Serba-1']_|_[('drugbank', array(['DB07933'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090', 'EFO_0000284'], dtype=object), 'count': 2}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL289228,"Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C_|_PLHJCIYEEKOWNM-HHHXNRCGSA-N_|_Small molecule_|_False_|_TIPIFARNIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['NSC-702818' 'R-11577' 'R-115777' 'R115777' 'Tipifarnib' 'Zarnestra']_|_[('Wikipedia', array(['Tipifarnib'], dtype=object)), ('drugbank', array(['DB04960'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005235', 'EFO_0000565', 'EFO_0002430', 'MONDO_0002108',
       'MONDO_0001187', 'EFO_0000305', 'EFO_0000218', 'EFO_1001951',
       'EFO_0002429', 'EFO_1000984', 'EFO_0003869', 'EFO_0001378',
       'EFO_1001779', 'MONDO_0008315', 'EFO_0000616', 'EFO_0002618',
       'EFO_0003028', 'EFO_1000309', 'MONDO_0004992', 'EFO_0000632',
       'MONDO_0008903', 'MONDO_0007254', 'EFO_0002428', 'EFO_0006861',
       'EFO_1000158', 'EFO_0000756', 'EFO_0003060', 'EFO_0000198',
       'EFO_0002939', 'EFO_0008528', 'EFO_0000479', 'EFO_0003027',
       'MONDO_0019469', 'MONDO_0021633', 'EFO_0000222', 'EFO_0000223',
       'EFO_0000095', 'EFO_1001465', 'EFO_0000181', 'EFO_1001469',
       'EFO_1001933', 'EFO_0000519', 'MONDO_0021310', 'EFO_0000339'],
      dtype=object), 'count': 44}_|_[ENSG00000168522,ENSG00000257365]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 44 investigational indications."
CHEMBL3301604,"O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1_|_NPDKXVKJRHPDQT-IYARVYRRSA-N_|_Small molecule_|_False_|_RALINEPAG_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['APD-811' 'APD811' 'Ralinepag']_|_[('drugbank', array(['DB12462'], dtype=object))]_|_['CHEMBL3961431']_|_{'rows': array(['EFO_0001361'], dtype=object), 'count': 1}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3545139,nan_|_nan_|_Small molecule_|_False_|_PS-516895_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ps-516895']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL38943,"Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3)nc2C)ccc1OCC(=O)O_|_YDBLKRPLXZNVNB-UHFFFAOYSA-N_|_Small molecule_|_False_|_GW501516_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cardarine' 'GSK-516' 'GW-1516' 'GW501516' 'Gw-501516' 'Gw501516']_|_[('PubChem', array(['137275846', '99460836'], dtype=object)), ('Wikipedia', array(['GW501516'], dtype=object)), ('drugbank', array(['DB05416'], dtype=object)), ('chEBI', array(['73726'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}_|_[ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297356,"CCCCOc1nc(N)c2[nH]c(=O)n(CCCN(CCCN3CCOCC3)Cc3cccc(CC(=O)OC)c3)c2n1_|_FEFIBEHSXLKJGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-8848_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD8848' 'Azd 8848' 'Azd-8848' 'Azd8848' 'DSP-3025' 'Dsp-3025']_|_[('drugbank', array(['DB14868'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}_|_[ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL442,"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21_|_XCGSFFUVFURLIX-VFGNJEKYSA-N_|_Small molecule_|_True_|_ERGOTAMINE_|_1948.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ergotamine' 'Ergotamine Tartrate' 'NSC-95090']_|_[('Wikipedia', array(['Ergotamine'], dtype=object)), ('drugbank', array(['DB00696'], dtype=object)), ('chEBI', array(['64318'], dtype=object))]_|_['CHEMBL2448612' 'CHEMBL1743258' 'CHEMBL2131781']_|_{'rows': array(['MONDO_0005277', 'MONDO_0005277', 'HP_0002315', 'EFO_0005252'],
      dtype=object), 'count': 4}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and is indicated for migraine disorder and headache and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL4650281,"C=CC(=O)N[C@H]1C=C(C)c2c(-c3cnc4ccccc4c3)c3c(N)ncnc3n2C1_|_MKCYPWYURWOKST-INIZCTEOSA-N_|_Small molecule_|_False_|_CLN-081_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CLN-081' 'CLN081' 'Cln 081' 'Cln-081' 'TAS-6417' 'TAS6417' 'TPC-064'
 'TPC064' 'Zipalertinib']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4650318,"COc1nc(C(=O)NC[C@](C)(O)C(F)(F)F)c(N)cc1C(F)(F)F_|_USHQRIKZLHNPQR-JTQLQIEISA-N_|_Small molecule_|_False_|_ICENTICAFTOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Icenticaftor' 'QBW-251' 'QBW251' 'Qbw251']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ICENTICAFTOR/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0001399', 'EFO_0000341', 'MONDO_0004822', 'MONDO_0009061'],
      dtype=object), 'count': 4}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4650413,"nan_|_nan_|_Oligonucleotide_|_False_|_OLPASIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 890' 'AMG-890' 'Amg 890' 'Olpasiran']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLPASIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0003914', 'EFO_0001421', 'EFO_0000319'],
      dtype=object), 'count': 4}_|_[ENSG00000198670]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL57997,"Nc1sc2c(c1C(=O)c1ccc(Cl)cc1)CCCC2_|_OTZVBZFYMFTYKH-UHFFFAOYSA-N_|_Small molecule_|_False_|_T-62_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['T-62']_|_[('PubChem', array(['29217669'], dtype=object)), ('drugbank', array(['DB12919'], dtype=object))]_|_['CHEMBL203347']_|_{'rows': array(['MONDO_0041052'], dtype=object), 'count': 1}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL603469,"C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O_|_UIARLYUEJFELEN-LROUJFHJSA-N_|_Small molecule_|_False_|_LESTAURTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-154475' 'A-154475.0' 'CEP-701' 'Cep-701' 'KT-555' 'KT-5555' 'KT5555'
 'Lestaurtinib' 'SP-924' 'SP924' 'SPM-924']_|_[('PubChem', array(['144206186', '50113274'], dtype=object)), ('Wikipedia', array(['Lestaurtinib'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0002429', 'EFO_0000479', 'EFO_0000222',
       'EFO_0000621', 'MONDO_0008315', 'MONDO_0044903', 'EFO_0000676',
       'EFO_0000565'], dtype=object), 'count': 9}_|_[ENSG00000096968,ENSG00000165731,ENSG00000122025,ENSG00000140538,ENSG00000198400,ENSG00000148053]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL73451,"c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2_|_HOKDBMAJZXIPGC-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEQUITAZINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Primalan']_|_['Kitazemin' 'Mequitazine' 'NSC-303612']_|_[('PubChem', array(['144207197', '170465794', '26665232', '453325', '56320321'],
      dtype=object)), ('drugbank', array(['DB01071'], dtype=object)), ('chEBI', array(['31821'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for allergic disease."
CHEMBL94,"CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C_|_PIJVFDBKTWXHHD-HIFRSBDPSA-N_|_Small molecule_|_False_|_PHYSOSTIGMINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-physostigmine' 'Cogmine' 'Eserin' 'Eserine' 'Eserinum' 'MCV-4484'
 'NSC-30782' 'Physostigmine']_|_[('PubChem', array(['144204779', '144211908', '170465757', '26753571', '26753572',
       '50085948', '50106262', '50106263', '90340907'], dtype=object)), ('Wikipedia', array(['Physostigmine'], dtype=object)), ('drugbank', array(['DB00981'], dtype=object)), ('chEBI', array(['27953'], dtype=object))]_|_['CHEMBL338975' 'CHEMBL537674' 'CHEMBL2105891']_|_{'rows': array(['EFO_0002614', 'EFO_0009267', 'EFO_0003843', 'MONDO_0005041'],
      dtype=object), 'count': 4}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for glaucoma and has 3 investigational indications."
CHEMBL95889,"C[N+](C)(C)CC(=O)O_|_KWIUHFFTVRNATP-UHFFFAOYSA-O_|_Small molecule_|_False_|_BETAINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Amversio' 'Cystadane']_|_['Abromine' 'Betaine' 'Betaine anhydrous' 'Betaine, anhydrous' 'Cystadane'
 'FEMA NO. 4223' 'NSC-166511']_|_[('DailyMed', array(['betaine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amversio'],
      dtype=object)), ('PubChem', array(['11110845', '174007375', '90341438'], dtype=object)), ('drugbank', array(['DB04455'], dtype=object)), ('chEBI', array(['41139'], dtype=object))]_|_['CHEMBL1201130']_|_{'rows': array(['EFO_1001249', 'EFO_0004248', 'EFO_0009869', 'MONDO_0004737',
       'MONDO_0002009', 'EFO_0003047', 'EFO_0004220', 'EFO_0001073',
       'MONDO_0002474'], dtype=object), 'count': 9}_|_[ENSG00000145692,ENSG00000132840]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for homocystinuria and major depressive disorder and has 7 investigational indications."
CHEMBL1200623,"CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C_|_AOXRBFRFYPMWLR-XGXHKTLJSA-N_|_Small molecule_|_False_|_ETHYLESTRENOL_|_1964.0_|_4.0_|_nan_|_False_|_True_|_['Maxibolin']_|_['Durabolin-o' 'Duraboral' 'Ethylestrenol' 'Ethylnandrol' 'Ethyloestrenol'
 'NSC-37726' 'Orabolin']_|_[('PubChem', array(['144206065', '170465211', '50112767'], dtype=object)), ('Wikipedia', array(['Ethylestrenol'], dtype=object)), ('drugbank', array(['DB01493'], dtype=object)), ('chEBI', array(['31578'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1964."
CHEMBL1200809,"CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl_|_YEJAJYAHJQIWNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZELASTINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL639_|_False_|_True_|_['Astelin' 'Astepro' 'Astepro allergy' 'Azelastine hydrochloride'
 ""Children's astepro allergy"" 'Optilast' 'Optivar' 'Rhinolast'
 'Rhinolast allergy']_|_['A-5610' 'Azelastine hcl' 'Azelastine hydrochloride' 'E-0659' 'W-2979M']_|_[('DailyMed', array(['azelastine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205022', '170465172', '26749052', '49681818'], dtype=object)), ('chEBI', array(['2951'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001742', 'EFO_0005854', 'EFO_0009364', 'EFO_1001417',
       'EFO_0003956', 'EFO_0007533', 'EFO_0007141'], dtype=object), 'count': 7}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 1 investigational indication."
CHEMBL1200873,"CS(=O)(=O)O.Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1_|_OGIYDFVHFQEFKQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENTOLAMINE MESYLATE_|_1952.0_|_4.0_|_CHEMBL597_|_False_|_True_|_['Oraverse' 'Phentolamine mesylate' 'Regitine' 'Rogitine']_|_['Mesylate phentolamine' 'NV-101' 'Phentolamine mesilate'
 'Phentolamine mesylate' 'Phentolamine methanesulfonate']_|_[('DailyMed', array(['phentolamine%20mesylate'], dtype=object)), ('PubChem', array(['11112076', '50106870', '56423107', '85231326', '855630'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000239', 'EFO_0000319', 'EFO_0001073'],
      dtype=object), 'count': 4}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and is indicated for adrenal gland pheochromocytoma and has 3 investigational indications."
CHEMBL1200874,"CCCCNC(=O)[N-]S(=O)(=O)c1ccc(C)cc1.[Na+]_|_QKHDBRQBSNZFAK-UHFFFAOYSA-M_|_Small molecule_|_False_|_TOLBUTAMIDE SODIUM, STERILE_|_1961.0_|_4.0_|_CHEMBL782_|_False_|_True_|_['Orinase diagnostic']_|_['Sodium tolbutamide' 'Tolbutamide sodium' 'Tolbutamide sodium salt'
 'Tolbutamide sodium, sterile']_|_nan_|_nan_|_nan_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961."
CHEMBL1200896,"CCCCC[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O.NC(CO)(CO)CO_|_IYGXEHDCSOYNKY-RZHHZEQLSA-N_|_Small molecule_|_False_|_DINOPROST TROMETHAMINE_|_1982.0_|_4.0_|_CHEMBL815_|_False_|_True_|_['Dinoprost Trometamol' 'Lutalyse' 'PGF2A' 'Prostaglandin F 2 Alpha'
 'Prostin f2 alpha']_|_['Dinoprost trometamol' 'Dinoprost tromethamine' 'NSC-196515' 'PGF2A THAM'
 'PGF2ALPHA THAM' 'U-14,583E' 'U-14-583E' 'U-14583E']_|_[('PubChem', array(['11532973'], dtype=object)), ('drugbank', array(['DB01160'], dtype=object)), ('chEBI', array(['31502'], dtype=object))]_|_nan_|_nan_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201549,"nan_|_nan_|_Protein_|_False_|_TERIPARATIDE ACETATE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Parathar']_|_['Ak-159' 'Ak159' 'HPTH 1-34' 'HPTH 1-34 (ACETATE SALT)' 'HPTH-1-34'
 'Teriparatide acetate' 'Teriparatide acetate hydrate']_|_nan_|_nan_|_{'rows': array(['EFO_0003882', 'MONDO_0018923', 'EFO_1001494', 'EFO_0003854',
       'EFO_0009451'], dtype=object), 'count': 5}_|_[ENSG00000160801]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 investigational indications."
CHEMBL1219,"COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C_|_YREYEVIYCVEVJK-UHFFFAOYSA-N_|_Small molecule_|_False_|_RABEPRAZOLE_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Aciphex' 'E-3810 (PPI)' 'E3810' 'Eraloc' 'LY-307640' 'LY307640'
 'Ly-307640' 'Pariprazole' 'Rabeprazole']_|_[('Wikipedia', array(['Rabeprazole'], dtype=object)), ('drugbank', array(['DB01129'], dtype=object)), ('chEBI', array(['8768'], dtype=object))]_|_['CHEMBL4303515' 'CHEMBL1200930']_|_{'rows': array(['MONDO_0004976', 'EFO_0008533', 'EFO_0004607', 'EFO_0000574',
       'EFO_1001355', 'EFO_0003763', 'EFO_0007549', 'MONDO_0004992',
       'EFO_1000961', 'HP_0002239', 'EFO_1001095', 'EFO_0004607',
       'EFO_1000961', 'EFO_0003948', 'EFO_0003948', 'EFO_0001642',
       'EFO_0005741', 'HP_0004398'], dtype=object), 'count': 18}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 12 investigational indications."
CHEMBL1405,"C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O_|_DNXHEGUUPJUMQT-CBZIJGRNSA-N_|_Small molecule_|_False_|_ESTRONE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Estrogenic substance' 'Estrone' 'Natural estrogenic substance-estrone'
 'Oestrone' 'Theelin']_|_['1,3,5-estratrien-3-ol-17-one' 'Estradiol metabolite e1' 'Estrone'
 'Follicular hormone' 'Follicular-hormone' 'Folliculin' 'Folliculinum'
 'Ketohydroxyestrin' 'NSC-9699' 'Oestrone' 'Theelin' 'Thelykinin'
 'Tokokin' 'WAY 164397']_|_[('PubChem', array(['11111162', '11112119', '144207116', '144208573', '144213953',
       '170465020', '26751561', '26751562', '50104169', '56423156',
       '855919', '90340856'], dtype=object)), ('Wikipedia', array(['Estrone'], dtype=object)), ('drugbank', array(['DB00655'], dtype=object)), ('chEBI', array(['17263'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004169', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 2 investigational indications."
CHEMBL1422,"N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F_|_MFFMDFFZMYYVKS-SECBINFHSA-N_|_Small molecule_|_False_|_SITAGLIPTIN_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Januvia']_|_['LEZ-763' 'LEZ763' 'MK-0431' 'Sitagliptin']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SITAGLIPTIN/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Sitagliptin'], dtype=object)), ('drugbank', array(['DB01261'], dtype=object)), ('chEBI', array(['40237'], dtype=object))]_|_['CHEMBL1201174' 'CHEMBL539077' 'CHEMBL393336' 'CHEMBL5315049']_|_{'rows': array(['EFO_1001459', 'EFO_1001121', 'EFO_0000400', 'MONDO_0005147',
       'EFO_0002546', 'EFO_0000712', 'EFO_0003884', 'MONDO_0005148',
       'HP_0000083', 'MONDO_0013730', 'EFO_0000180', 'EFO_0003095',
       'HP_0001952', 'EFO_0000612', 'EFO_0004599', 'EFO_0001073',
       'MONDO_0005148', 'MONDO_0009061', 'EFO_0000373', 'MONDO_0021187',
       'EFO_0000400', 'EFO_0003047', 'EFO_0000182', 'MONDO_0021187',
       'MONDO_0005148', 'MONDO_0100096', 'EFO_0000676', 'EFO_0008583'],
      dtype=object), 'count': 28}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 4 approved and 23 investigational indications."
CHEMBL1445,"C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_YLRFCQOZQXIBAB-RBZZARIASA-N_|_Small molecule_|_False_|_FLUOXYMESTERONE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_['Android-f' 'Androxy' 'Fluoxymesterone' 'Halotestin' 'Ora-testryl']_|_['Fluoximesterone' 'Fluoxymesterone' 'Fluoxymesterone ciii' 'NSC-10704'
 'NSC-12165']_|_[('PubChem', array(['144206709', '144208052', '17388998', '56422069'], dtype=object)), ('Wikipedia', array(['Fluoxymesterone'], dtype=object)), ('drugbank', array(['DB01185'], dtype=object)), ('chEBI', array(['5120'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001078', 'MONDO_0007254', 'MONDO_0002146', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 3 approved and 1 investigational indication."
CHEMBL1528134,"CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12.Cl_|_HNNIWKQLJSNAEQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENZYDAMINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL12610_|_False_|_True_|_['Difflam' 'Difflam-p' 'Lozamine']_|_['AF-864' 'Benzidamine hydrochloride' 'Benzydamine hcl'
 'Benzydamine hydrochloride' 'NSC-759276']_|_[('PubChem', array(['144203971', '170465576', '49665028'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001904', 'EFO_0009688'], dtype=object), 'count': 2}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL1720,"Cl.O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2_|_OLDRWYVIKMSFFB-SSPJITILSA-N_|_Small molecule_|_False_|_PALONOSETRON HYDROCHLORIDE_|_2003.0_|_4.0_|_CHEMBL1189679_|_False_|_True_|_['Aloxi' 'Palonosetron hospira' 'Palonosetron hydrochloride']_|_['Palonocetron hydrochloride' 'Palonosetron (as hydrochloride)'
 'Palonosetron hcl' 'Palonosetron hydrochloride' 'RS-25259-197']_|_[('DailyMed', array(['palonosetron%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/palonosetron-hospira'],
      dtype=object)), ('PubChem', array(['144205974', '170465300'], dtype=object)), ('chEBI', array(['85157'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004888', 'HP_0002013', 'HP_0002018', 'EFO_0006911',
       'MONDO_0004992', 'HP_0002017'], dtype=object), 'count': 6}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved indications."
CHEMBL1743034,"nan_|_nan_|_Antibody_|_False_|_IXEKIZUMAB_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Taltz']_|_['Ixekizumab' 'LY-2439821' 'LY2439821']_|_[('DailyMed', array(['ixekizumab'], dtype=object)), ('DrugCentral', array(['5083'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/taltz'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0006818', 'MONDO_0002009', 'MONDO_0005147', 'EFO_0003898',
       'EFO_0007187', 'EFO_0003778', 'MONDO_0100096', 'EFO_0000540',
       'HP_0000999', 'EFO_0009856', 'EFO_0000676', 'EFO_1001494',
       'MONDO_0100017', 'EFO_0000685'], dtype=object), 'count': 14}_|_[ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 4 approved and 10 investigational indications."
CHEMBL2103868,"COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O_|_HFCFMRYTXDINDK-WNQIDUERSA-N_|_Small molecule_|_True_|_CABOZANTINIB S-MALATE_|_2012.0_|_4.0_|_CHEMBL2105717_|_False_|_True_|_['Cabometyx' 'Cometriq']_|_['BMS-907351' 'Cabozantinib malate' 'Cabozantinib s-malate' 'XL-184'
 'XL184']_|_[('DailyMed', array(['cabozantinib%20s-malate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cabometyx'],
      dtype=object)), ('chEBI', array(['72319'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_0000519', 'EFO_0001075', 'MONDO_0004992',
       'EFO_0000326', 'EFO_0000272', 'EFO_0000501', 'EFO_0000637',
       'EFO_0000673', 'EFO_1001465', 'EFO_0000641', 'EFO_0003968',
       'EFO_0000239', 'EFO_0002892', 'EFO_0000640', 'EFO_0000182',
       'MONDO_0002108', 'EFO_1000251', 'EFO_0000616', 'EFO_1001512',
       'EFO_0007532', 'EFO_0000305', 'EFO_0008524', 'EFO_0004252',
       'EFO_0000349', 'EFO_0003060'], dtype=object), 'count': 26}_|_[ENSG00000128052,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 7 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108784,nan_|_nan_|_Antibody_|_False_|_ZIRALIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABX-RB2' 'Ziralimumab']_|_nan_|_nan_|_nan_|_[ENSG00000172270]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108893,"nan_|_nan_|_Enzyme_|_False_|_ALFIMEPRASE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Alfimeprase']_|_nan_|_nan_|_{'rows': array(['HP_0002140', 'HP_0004936', 'MONDO_0000831'], dtype=object), 'count': 3}_|_[ENSG00000171560,ENSG00000171564,ENSG00000171557]_|_Enzyme drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2219774,"nan_|_nan_|_Oligonucleotide_|_False_|_GATAPARSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gataparsen' 'LY-2181308' 'LY2181308']_|_nan_|_['CHEMBL2219775']_|_{'rows': array(['EFO_0000182', 'MONDO_0008315', 'EFO_0000222', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000089685]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2381848,"CCC[C@H](Oc1cc(C)c(-n2cc(C(F)(F)F)cn2)c(C)c1)c1ccc(C(=O)NCCC(=O)O)cc1_|_IBDYYOQKQCCSDP-QFIPXVFZSA-N_|_Small molecule_|_False_|_PF-06291874_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-06291874' 'Pf-06291874']_|_[('drugbank', array(['DB15065'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000215644]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2386081,"O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2_|_IHAXLPDVOWLUOS-UHFFFAOYSA-N_|_Small molecule_|_False_|_SETIPIPRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACT-129968' 'KYTH-105' 'Setipiprant']_|_[('drugbank', array(['DB12562'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'MONDO_0004907', 'EFO_0003956'], dtype=object), 'count': 3}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL341812,"CC(C)Cc1ccc(CC(=O)O)cc1_|_CYWFCPPBTWOZSF-UHFFFAOYSA-N_|_Small molecule_|_False_|_IBUFENAC_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['(p-isobutylphenyl)acetic acid' 'Ibufenac' 'NSC-99976' 'RD 11654'
 'RD-11654']_|_[('PubChem', array(['170465922', '29216132'], dtype=object)), ('chEBI', array(['76158'], dtype=object))]_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL3545220,"nan_|_nan_|_Small molecule_|_False_|_LY2590443_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ly2590443']_|_nan_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000148680]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707290,"C=C(CCCCCCCCCCCCCCCc1nnn[nH]1)NS(=O)(=O)CCCC(=O)NCCOCCOCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)N[C@@H](CCCCNC(=O)CSC[C@H](N)C(=O)O)C(N)=O)C(=O)O)C(=O)O_|_NAKSIOUBFDBTSW-ITMZJIMRSA-N_|_Small molecule_|_False_|_SOMAPACITAN_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Sogroya']_|_['NN-8640' 'NN8640' 'NNC-0195-0092' 'NNC0195-0092' 'Somapacitan'
 'Somapacitan beco']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001109'], dtype=object), 'count': 1}_|_[ENSG00000112964]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for pituitary dwarfism."
CHEMBL4206492,"O=c1[nH]c(Cc2ccccn2)nc2c1cnn2C1CCOCC1_|_BZTIJCSHNVZMES-UHFFFAOYSA-N_|_Small molecule_|_False_|_OSORESNONTRINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI 409306' 'BI-409306' 'Bi 409306' 'Osoresnontrine' 'SUB 166499']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0000677', 'MONDO_0005090'], dtype=object), 'count': 3}_|_[ENSG00000160191]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297998,"nan_|_nan_|_Antibody_|_False_|_LACUTAMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IPH-4102' 'IPH4102' 'Iph4102' 'Lacutamab']_|_nan_|_nan_|_{'rows': array(['EFO_0002913', 'EFO_0000211'], dtype=object), 'count': 2}_|_[ENSG00000240403]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594258,"CCCC[C@](C)(CO)Nc1nc(N)nc2cc(F)cnc12_|_HTCJUBZBSJQWBW-CQSZACIVSA-N_|_Small molecule_|_False_|_SELGANTOLIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GS-9688' 'Gs-9688' 'Selgantolimod']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SELGANTOLIMOD/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004197', 'EFO_0004239'], dtype=object), 'count': 2}_|_[ENSG00000101916]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594445,"CNCc1cn(S(=O)(=O)c2cccc(F)c2)c(-c2ccc(F)cc2F)c1OC_|_OUNXGNDVWVPCOL-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABEPRAZAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Abeprazan' 'DWP-14012' 'DWP14012' 'Dwp14012' 'Fexuprazan']_|_nan_|_nan_|_{'rows': array(['HP_0004398', 'EFO_0000337', 'EFO_1001095', 'EFO_0003948'],
      dtype=object), 'count': 4}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4594485,"nan_|_nan_|_Oligonucleotide_|_False_|_OLAPTESED PEGOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NOX-A12 FREE ACID' 'Olaptesed pegol']_|_nan_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_0000519'], dtype=object), 'count': 2}_|_[ENSG00000107562]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5095027,CCP(=S)(Oc1ccc([N+](=O)[O-])cc1Cl)OC(C)C_|_QINWTFKFPMRNJP-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMS405_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Oms405']_|_nan_|_nan_|_nan_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL524004,"C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1_|_GKNPSSNBBWDAGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPENZOLATE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mepenzolate' 'Mepenzolate bromide free base' 'Mepenzolate cation'
 'Mepenzolate ion']_|_[('Wikipedia', array(['Mepenzolate'], dtype=object)), ('drugbank', array(['DB04843'], dtype=object))]_|_['CHEMBL1724']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for gastrointestinal disease."
CHEMBL546,"C=CCOc1ccccc1OCC(O)CNC(C)C_|_CEMAWMOMDPGJMB-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXPRENOLOL_|_1983.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Oxprenolol']_|_[('Wikipedia', array(['Oxprenolol'], dtype=object)), ('drugbank', array(['DB01580'], dtype=object))]_|_['CHEMBL1200745' 'CHEMBL3245937']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for cardiovascular disease."
CHEMBL963,"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5_|_UQCNKQCJZOAFTQ-ISWURRPUSA-N_|_Small molecule_|_True_|_OXYMORPHONE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['14-hydroxydihydromorphinone' '7,8-dihydro-14-hydroxymorphinone'
 'Dihydroxymorphinone' 'IDS-NO-003' 'NIH 10323' 'NSC-19045' 'Numorphan'
 'Opana' 'Oxycodone hydrochloride impurity, oxymorphone-' 'Oxymorphone'
 'Oxymorphone cii']_|_[('Wikipedia', array(['Oxymorphone'], dtype=object)), ('drugbank', array(['DB01192'], dtype=object)), ('chEBI', array(['7865'], dtype=object))]_|_['CHEMBL1200794']_|_{'rows': array(['EFO_0003843', 'HP_0012532', 'HP_0012532', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for pain and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1096146,"CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C_|_LPAUOXUZGSBGDU-STDDISTJSA-N_|_Small molecule_|_False_|_PONESIMOD_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Ponvory']_|_['ACT-128800' 'Ponesimod']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory'],
      dtype=object)), ('drugbank', array(['DB12016'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301', 'EFO_0000676', 'MONDO_0020547', 'EFO_0000540',
       'EFO_0003929'], dtype=object), 'count': 5}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications."
CHEMBL1097999,"CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\[C@@H](C)[C@H](C)OC2=O_|_MWUFVYLAWAXDHQ-HMNLTAHHSA-N_|_Small molecule_|_False_|_E-6201_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E-6201' 'E6201' 'ER-806201']_|_[('drugbank', array(['DB11687'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001494', 'EFO_0000616', 'EFO_0000676'], dtype=object), 'count': 3}_|_[ENSG00000169032,ENSG00000095015]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1200988,"CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc21.[Br-]_|_PQMWYJDJHJQZDE-UHFFFAOYSA-M_|_Small molecule_|_False_|_METHANTHELINE BROMIDE_|_1951.0_|_4.0_|_CHEMBL1201264_|_False_|_True_|_['Banthine']_|_['Dixamone bromide' 'Methantheline bromide' 'Methanthelinium bromide'
 'NSC-32145' 'Vagantin']_|_[('PubChem', array(['144203871', '170465350', '56463185'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951."
CHEMBL1201461,"nan_|_nan_|_Small molecule_|_False_|_DEXTROMETHORPHAN POLISTIREX_|_1982.0_|_4.0_|_CHEMBL52440_|_False_|_True_|_['Delsym' 'Dextromethorphan polistirex']_|_['Dextromethorphan polistirex' 'NSC-751452']_|_[('DailyMed', array(['dextromethorphan%20polistirex'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003756'], dtype=object), 'count': 1}_|_[ENSG00000147955,ENSG00000183454]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication."
CHEMBL1742998,"nan_|_nan_|_Antibody drug conjugate_|_False_|_CANTUZUMAB RAVTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cantuzumab ravtansine' 'HUC242-DM4' 'IMGN-242' 'IMGN242']_|_nan_|_nan_|_{'rows': array(['EFO_0002618', 'MONDO_0001056', 'EFO_0000365'], dtype=object), 'count': 3}_|_[ENSG00000185499]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL19019,"O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5_|_DQCKKXVULJGBQN-XFWGSAIBSA-N_|_Small molecule_|_True_|_NALTREXONE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Celupan' 'Trexal' 'Trexan' 'Vivitrol']_|_['EN-1639A' 'EN-1639A FREE BASE' 'EN-1639A [AS HYDROCHLORIDE]'
 'NSC-758439' 'Naltrexone' 'Revia']_|_[('DailyMed', array(['naltrexone'], dtype=object)), ('PubChem', array(['144205560', '170465207'], dtype=object)), ('drugbank', array(['DB00704'], dtype=object)), ('chEBI', array(['7465'], dtype=object))]_|_['CHEMBL1201149' 'CHEMBL4303313']_|_{'rows': array(['EFO_0005203', 'EFO_0007224', 'MONDO_0002009', 'EFO_1000906',
       'MONDO_0002050', 'MONDO_0100096', 'MONDO_0005301', 'EFO_0001358',
       'EFO_0000274', 'MONDO_0000594', 'EFO_0003843', 'EFO_0004329',
       'EFO_0000764', 'EFO_0005687', 'MONDO_0015626', 'EFO_0005611',
       'EFO_0002610', 'EFO_0005924', 'MONDO_0100096', 'EFO_0010702',
       'MONDO_0005351', 'EFO_1000783', 'EFO_0003843', 'EFO_1000637',
       'MONDO_0005277', 'EFO_0004701', 'EFO_0000676', 'HP_0012076',
       'EFO_0003768', 'EFO_0004242', 'MONDO_0002009', 'MONDO_0007254',
       'HP_0100716', 'MONDO_0021698', 'HP_0012532', 'HP_0012532',
       'HP_0012167', 'EFO_0003890', 'EFO_0005204', 'EFO_0004699',
       'EFO_0004329', 'HP_0012378', 'EFO_0004240', 'EFO_0001065',
       'EFO_0008507', 'EFO_0007191', 'EFO_0005611', 'EFO_0000729',
       'MONDO_0007079', 'EFO_0010702', 'EFO_0001073', 'EFO_0004701',
       'MONDO_0005090', 'MONDO_0002046', 'HP_0003419', 'EFO_0000694',
       'EFO_0000384'], dtype=object), 'count': 57}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 52 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1914489,"CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O_|_JWYIGNODXSRKGP-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD1981_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-1981' 'Azd 1981' 'Azd-1981' 'Azd1981']_|_[('drugbank', array(['DB11946'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341', 'EFO_0000545'], dtype=object), 'count': 3}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2107881,"nan_|_nan_|_Protein_|_False_|_REGRAMOSTIM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GM-CSF' 'GM-CSF (CHO CELL)' 'GMC 89-107' 'GMC-89-107'
 'Leucotropin glycoform gmc 89-107' 'RHGM-C' 'RHGM-CSF' 'Regramostim']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000403', 'MONDO_0100342', 'MONDO_0002367',
       'MONDO_0004992', 'EFO_0000519', 'EFO_0000180', 'EFO_0003060',
       'EFO_0001378', 'EFO_0000764', 'EFO_0000574', 'EFO_1001951',
       'EFO_0000770', 'EFO_0007149', 'EFO_0000365', 'EFO_0000389',
       'EFO_0004265', 'EFO_0000681', 'EFO_0000756', 'MONDO_0021063',
       'MONDO_0008315', 'MONDO_0007254', 'EFO_1001923', 'EFO_0000309',
       'EFO_0004252', 'MONDO_0001437', 'MONDO_0008903', 'EFO_0000621'],
      dtype=object), 'count': 28}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications."
CHEMBL2108493,"nan_|_nan_|_Protein_|_False_|_INSULIN ZINC, PROMPT_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ins semit mc']_|_['Amorphous (aqueous suspension)' 'Insulin zinc injection'
 'Insulin zinc injection, amorphous (aqueous suspension)'
 'Insulin zinc suspension ' 'Insulin zinc suspension (amorphous)'
 'Insulin zinc, prompt']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV."
CHEMBL2108967,nan_|_nan_|_Antibody_|_False_|_LERDELIMUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Trabio']_|_['CAT-152' 'Lerdelimumab' 'TRABIO']_|_nan_|_nan_|_nan_|_[ENSG00000092969]_|_Antibody drug with a maximum clinical trial phase of III.
CHEMBL2109555,nan_|_nan_|_Antibody_|_False_|_MDX-070_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MDX-070']_|_nan_|_nan_|_nan_|_[ENSG00000086205]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109615,"nan_|_nan_|_Antibody_|_False_|_MRA 003 US_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MRA 003 US' 'Mra 003 us']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL271220,CCOC[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2_|_SLKURXRZHJOZOD-RUZDIDTESA-N_|_Small molecule_|_False_|_CORT 108297_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ADS-108297' 'CORT-108297' 'Cort 108297']_|_nan_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL312443,"Oc1noc2c1CCNC2_|_ZXRVKCBLGJOCEE-UHFFFAOYSA-N_|_Small molecule_|_False_|_GABOXADOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gaboxadol' 'LU 02-030' 'LU-02-030' 'LU-02030' 'MK-0928' 'NSC-759585']_|_[('PubChem', array(['104171241', '11111836', '11111837', '11113715', '170466512',
       '90341079'], dtype=object)), ('Wikipedia', array(['Gaboxadol'], dtype=object)), ('drugbank', array(['DB06554'], dtype=object)), ('chEBI', array(['34373'], dtype=object))]_|_['CHEMBL1255746']_|_{'rows': array(['MONDO_0010383', 'MONDO_0007113', 'EFO_0004698', 'MONDO_0002009'],
      dtype=object), 'count': 4}_|_[ENSG00000022355,ENSG00000145864,ENSG00000166206,ENSG00000109158,ENSG00000011677,ENSG00000163288,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3301612,"COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1_|_CMJCXYNUCSMDBY-ZDUSSCGKSA-N_|_Small molecule_|_False_|_ENCORAFENIB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Braftovi']_|_['Encorafenib' 'Lgx-818' 'Lgx818' 'NVP-LGX-818-NXA' 'NVP-LGX818'
 'NVP-LGX818-NXA']_|_[('DailyMed', array(['encorafenib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi'],
      dtype=object)), ('drugbank', array(['DB11718'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_1001951', 'EFO_0000365', 'EFO_0000756',
       'EFO_0002617', 'EFO_0009259', 'EFO_0002618', 'EFO_1000657',
       'EFO_1000956', 'EFO_0000389', 'EFO_0001378', 'EFO_0004142',
       'EFO_0003060', 'EFO_0002892', 'EFO_0003891', 'EFO_1001949',
       'MONDO_0005184', 'EFO_0000616'], dtype=object), 'count': 18}_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 8 approved and 10 investigational indications."
CHEMBL3545333,"CN1C(=O)C(F)=C[C@]2(C)C3CC[C@@]4(C)C(CC[C@@H]4C(=O)NCc4nc5ncccc5[nH]4)C3CCC12_|_GBEUKTWTUSPHEE-PAWGCEJPSA-N_|_Small molecule_|_False_|_MK-0773_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-0773' 'PF-05314882']_|_nan_|_nan_|_{'rows': array(['EFO_1000653'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3833357,"nan_|_nan_|_Antibody_|_False_|_BEGELOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Begedina']_|_['BT 5/9' 'Begelomab' 'SAND-26']_|_nan_|_nan_|_{'rows': array(['EFO_0000540', 'MONDO_0013730'], dtype=object), 'count': 2}_|_[ENSG00000197635]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3990000,"nan_|_nan_|_Antibody_|_False_|_TIBULIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-3090106' 'LY3090106' 'Tibulizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0000699'], dtype=object), 'count': 2}_|_[ENSG00000112115,ENSG00000102524]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4078588,"Cc1ccc(Cc2cc3c(=O)n([C@H]4CCCC[C@@H]4O)cnc3c3ccccc23)cn1_|_JUVQLZBJFOGEEO-GOTSBHOMSA-N_|_Small molecule_|_False_|_MK-7622_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK7622' 'Mk-7622']_|_[('drugbank', array(['DB12897'], dtype=object))]_|_['CHEMBL4216833']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297236,"nan_|_nan_|_Gene_|_False_|_LISOCABTAGENE MARALEUCEL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Breyanzi' 'JCAR-017' 'JCAR017' 'Lisocabtagene maraleucel']_|_nan_|_nan_|_{'rows': array(['MONDO_0018906', 'EFO_0000095', 'EFO_1001469', 'EFO_0000220',
       'EFO_0005952', 'EFO_0000403'], dtype=object), 'count': 6}_|_[ENSG00000177455]_|_Gene drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4297523,"COc1ccc2[nH]cc(CCNC(=O)c3cc(=O)cco3)c2c1_|_PNTNBIHOAPJYDB-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIROMELATINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NEU-P-11' 'NEU-P11' 'Neu-p11' 'Piromelatine']_|_[('drugbank', array(['DB12288'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0004698'], dtype=object), 'count': 2}_|_[ENSG00000168412,ENSG00000134640]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4298193,"nan_|_nan_|_Oligonucleotide_|_False_|_SUVODIRSEN SODIUM_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BMTR0139 SODIUM' 'Suvodirsen sodium' 'WLS-4176 SODIUM' 'WV3473']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SUVODIRSEN%20SODIUM/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4650256,"nan_|_nan_|_Antibody_|_False_|_ZANIDATAMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ZW-25' 'Zanidatamab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANIDATAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0003060',
       'EFO_0003891', 'EFO_0003968', 'MONDO_0007254', 'EFO_0005537'],
      dtype=object), 'count': 8}_|_[ENSG00000141736]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL59356,"C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O_|_MMSNEKOTSJRTRI-LLVKDONJSA-N_|_Small molecule_|_False_|_ATRELEUTON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-85761' 'A-85761.0' 'ABBOTT-85761' 'ABT-761' 'Atreleuton' 'VIA-2291']_|_[('drugbank', array(['DB12758'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005672', 'EFO_0003914', 'EFO_0001645'], dtype=object), 'count': 3}_|_[ENSG00000012779]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL701,"NCC(CC(=O)O)c1ccc(Cl)cc1_|_KPYSYYIEGFHWSV-UHFFFAOYSA-N_|_Small molecule_|_True_|_BACLOFEN_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Baclofen' 'Baclospas-10' 'Fleqsuvy' 'Gablofen' 'Kemstro' 'Lioresal'
 'Lioresal intrath' 'Lyflex' 'Lyvispah' 'Ozobax']_|_['(rs)-baclofen' 'BA-34,647' 'BA-34647' 'Baclofen' 'Fleqsuvy' 'Lyvispah'
 'NSC-755906']_|_[('DailyMed', array(['baclofen'], dtype=object)), ('PubChem', array(['104171115', '124879423', '124879424', '170465099', '26751712',
       '50104402', '85230940', '855960', '90341690'], dtype=object)), ('Wikipedia', array(['Baclofen'], dtype=object)), ('drugbank', array(['DB00181'], dtype=object)), ('chEBI', array(['2972'], dtype=object))]_|_['CHEMBL1897150']_|_{'rows': array(['MONDO_0015626', 'EFO_0001073', 'EFO_0009488', 'MONDO_0043510',
       'EFO_0007191', 'EFO_0003768', 'EFO_0000512', 'MONDO_0008840',
       'EFO_1001919', 'MONDO_0010383', 'EFO_0004777', 'EFO_0003758',
       'MONDO_0005301', 'HP_0001257', 'EFO_0000182', 'EFO_1000632',
       'HP_0002063', 'EFO_1000802', 'EFO_0003948', 'EFO_0003890',
       'EFO_0003843', 'EFO_0002610', 'MONDO_0007079'], dtype=object), 'count': 23}_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1086218,"C/C=C/C[C@@H](C)C(=O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C_|_YJDYDFNKCBANTM-QCWCSKBGSA-N_|_Protein_|_False_|_VALSPODAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PSC 833' 'SDZ PSC 833' 'SDZ-PSC 833' 'Valspodar']_|_[('drugbank', array(['DB11869'], dtype=object)), ('chEBI', array(['8985'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000218', 'EFO_0000223', 'EFO_0003027', 'EFO_0003025',
       'EFO_0000691', 'EFO_0000565', 'EFO_0003028', 'EFO_0003029',
       'EFO_0000681', 'EFO_0009708', 'MONDO_0007254', 'EFO_0004251',
       'EFO_0000198', 'MONDO_0008170', 'EFO_0001378', 'EFO_0000574',
       'EFO_0003865', 'EFO_0000221'], dtype=object), 'count': 18}_|_[ENSG00000085563]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications."
CHEMBL1090173,"O=C(CO)N1CCC(c2n[nH]c(-c3ccc(Cl)cc3)c2-c2ccncn2)CC1_|_CATQHDWESBRRQA-UHFFFAOYSA-N_|_Small molecule_|_False_|_SD-0006_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SD-0006' 'SD-06' 'SD0006' 'Sd-0006']_|_[('PubChem', array(['174007108'], dtype=object)), ('drugbank', array(['DB07943'], dtype=object)), ('chEBI', array(['82712'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL1200463,"O=C([O-])CCc1nc(-c2ccccc2)c(-c2ccccc2)o1.[K+]_|_QTAQWNSMRSLSCG-UHFFFAOYSA-M_|_Small molecule_|_True_|_OXAPROZIN POTASSIUM_|_2002.0_|_4.0_|_CHEMBL1071_|_False_|_True_|_['Daypro alta']_|_['Oxaprozin potassium']_|_nan_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002. This drug has a black box warning from the FDA."
CHEMBL1200761,"COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1_|_BFPSDSIWYFKGBC-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLOROTRIANISENE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Chlorotrianisene' 'Tace']_|_['Chlorotrianisene' 'Chlortrianisestrol' 'NSC-10108' 'Trianisestrol']_|_[('PubChem', array(['104171308', '11112416', '11532856', '124882352', '144204017',
       '144209559', '144213214', '170465394', '17389725', '26747338'],
      dtype=object)), ('Wikipedia', array(['Chlorotrianisene'], dtype=object)), ('drugbank', array(['DB00269'], dtype=object)), ('chEBI', array(['3641'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'MONDO_0002691'], dtype=object), 'count': 2}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 2 investigational indications."
CHEMBL1200983,"nan_|_nan_|_Small molecule_|_True_|_GALLIUM NITRATE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Ganite']_|_['Gallium nitrate' 'Gallium nitrate (anhydrous)'
 'Gallium nitrate anhydrous' 'Gallium nitrate nonahydrate' 'NSC-15200'
 'Nitric acid, gallium salt']_|_[('DailyMed', array(['gallium%20nitrate'], dtype=object)), ('DrugCentral', array(['5115'], dtype=object)), ('Wikipedia', array(['Gallium_nitrate'], dtype=object))]_|_['CHEMBL1697699']_|_{'rows': array(['EFO_0009429', 'EFO_0000574', 'EFO_0000691', 'EFO_0000621',
       'EFO_1000158', 'MONDO_0009061', 'EFO_0005952'], dtype=object), 'count': 7}_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201052,"CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21.O=S(=O)(O)c1ccccc1_|_CRJHBCPQHRVYBS-UHFFFAOYSA-N_|_Small molecule_|_True_|_MESORIDAZINE BESYLATE_|_1970.0_|_4.0_|_CHEMBL1088_|_False_|_True_|_['Serentil']_|_['Mesoridazine benzenesulfonate' 'Mesoridazine besilate'
 'Mesoridazine besylate' 'NSC-760073']_|_[('PubChem', array(['26719781', '85273786'], dtype=object)), ('chEBI', array(['6781'], dtype=object))]_|_nan_|_nan_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970. This drug has a black box warning from the FDA."
CHEMBL1201353,"CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1_|_SOYKEARSMXGVTM-HNNXBMFYSA-N_|_Small molecule_|_False_|_DEXCHLORPHENIRAMINE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Chlorphenamine, (s)-' 'Chlorpheniramine d-form' 'Chlorpheniramine, (s)-'
 'Chlorpheniramine, d-' 'Dapriton' 'Dexchlorpheniramine']_|_[('PubChem', array(['29216403', '90340867'], dtype=object)), ('Wikipedia', array(['Dexchlorpheniramine'], dtype=object)), ('drugbank', array(['DB13679'], dtype=object)), ('chEBI', array(['4464'], dtype=object))]_|_['CHEMBL1200927' 'CHEMBL3183101']_|_{'rows': array(['EFO_0005531', 'EFO_1001417', 'EFO_0007141', 'MONDO_0005271',
       'EFO_0005854', 'EFO_0003958', 'MONDO_0005301', 'MONDO_0005271',
       'EFO_0003956', 'EFO_0005532', 'EFO_0007533'], dtype=object), 'count': 11}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 8 approved and 3 investigational indications."
CHEMBL1201509,"nan_|_nan_|_Protein_|_False_|_GONADOTROPIN, CHORIONIC_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['A.p.l.' 'Choragon' 'Chorionic gonadotropin'
 'Equine Chorionic Gonadotropin' 'Follutein' 'Gonadotraphon lh'
 'Human Chorionic Gonadotropin' 'Pregnyl' 'Profasi' 'Profast' 'Progestyl']_|_['Choriogonadotropin beta' 'Chorionic gonadotrophin'
 'Gonadotropin, chorionic']_|_[('DailyMed', array(['gonadotropin,%20chorionic'], dtype=object)), ('DrugCentral', array(['5196'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018555', 'MONDO_0002259', 'EFO_0000545', 'EFO_0002950',
       'MONDO_0007254', 'MONDO_0002146', 'MONDO_0002775', 'EFO_1001006',
       'EFO_0004599', 'EFO_0000279', 'EFO_0000660'], dtype=object), 'count': 11}_|_[ENSG00000138039]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 11 investigational indications."
CHEMBL1201541,nan_|_nan_|_Protein_|_False_|_INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Protamine zinc and iletin ii' 'Protamine zinc insulin']_|_['Insulin susp protamine zinc purified beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL1201823,"nan_|_nan_|_Protein_|_False_|_ABATACEPT_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Orencia' 'Orencia clickject']_|_['Abatacept' 'Abatacept (genetical recombination)' 'Abatacept recombinant'
 'BMS-188667' 'CTLA4-IGG4M' 'RG-1046' 'RG-2077']_|_[('DailyMed', array(['abatacept'], dtype=object)), ('DrugCentral', array(['5089'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orencia'],
      dtype=object)), ('Wikipedia', array(['Abatacept'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001148', 'MONDO_0100096', 'EFO_0004192', 'EFO_0009609',
       'EFO_0004255', 'EFO_1001494', 'MONDO_0013730', 'EFO_0004599',
       'EFO_0000699', 'MONDO_0020547', 'EFO_0000729', 'EFO_0000384',
       'MONDO_0019338', 'EFO_1001996', 'MONDO_0017287', 'EFO_0003780',
       'EFO_1001231', 'EFO_0005297', 'EFO_1001209', 'EFO_0004991',
       'EFO_0004208', 'EFO_0000685', 'EFO_0003929', 'MONDO_0005301',
       'EFO_0000404', 'MONDO_0019080', 'EFO_0000537', 'EFO_0000540',
       'MONDO_0005147', 'MONDO_0007915', 'EFO_0008518', 'EFO_0007425',
       'EFO_0009730', 'EFO_0003898', 'EFO_0003778', 'EFO_1001857',
       'EFO_0000398', 'EFO_0005761', 'EFO_0001378', 'EFO_0000676',
       'EFO_0004826', 'EFO_0002609'], dtype=object), 'count': 42}_|_[ENSG00000121594,ENSG00000114013]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 5 approved and 37 investigational indications."
CHEMBL1399,"CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1_|_YBBLVLTVTVSKRW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANASTROZOLE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Anastrozole' 'Arimidex' 'Nastrosa']_|_['Anastrozole' 'Arimidex' 'ICI D1033' 'ICI-D1033' 'NSC-719344'
 'NSC-759855' 'Rvg-106400' 'ZD-1033' 'ZD1033']_|_[('DailyMed', array(['anastrozole'], dtype=object)), ('PubChem', array(['144205791', '144213873', '170464923', '174007355', '26719808'],
      dtype=object)), ('Wikipedia', array(['Anastrozole'], dtype=object)), ('drugbank', array(['DB01217'], dtype=object)), ('chEBI', array(['2704'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011962', 'EFO_0005537', 'EFO_0001361', 'EFO_0000195',
       'EFO_0000313', 'EFO_0003869', 'EFO_0000553', 'EFO_1001006',
       'MONDO_0002775', 'EFO_0000432', 'MONDO_0004992', 'EFO_0000537',
       'MONDO_0018800', 'EFO_0001065', 'MONDO_0000088', 'EFO_0000616',
       'EFO_0001380', 'MONDO_0008170', 'EFO_0006861', 'MONDO_0018919',
       'EFO_1001512', 'MONDO_0002146', 'HP_0000771', 'EFO_1001100',
       'EFO_0000305', 'MONDO_0007254'], dtype=object), 'count': 26}_|_[ENSG00000137869]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 21 investigational indications."
CHEMBL14935,"O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1_|_ZXFRFPSZAKNPQQ-YTWAJWBKSA-N_|_Small molecule_|_False_|_TEZAMPANEL ANHYDROUS_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-293,558' 'LY-293558' 'NGX-424' 'NGX424' 'Tezampanel anhydrous']_|_[('drugbank', array(['DB06354'], dtype=object))]_|_['CHEMBL3989703']_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873,ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1621,"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O_|_PMXMIIMHBWHSKN-UHFFFAOYSA-N_|_Small molecule_|_True_|_PALIPERIDONE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Invega' 'Paliperidone' 'Trevicta' 'Xeplion']_|_['9-hydroxyrisperidone' 'NSC-759623' 'Paliperidone' 'R-76477' 'RO-76477'
 'RO76477' 'Risperidone impurity, 9-hydroxyrisperidone-']_|_[('DailyMed', array(['paliperidone'], dtype=object)), ('PubChem', array(['90341688'], dtype=object)), ('Wikipedia', array(['Paliperidone'], dtype=object)), ('drugbank', array(['DB01267'], dtype=object)), ('chEBI', array(['83804'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004242', 'EFO_0005230', 'EFO_0003758', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090', 'MONDO_0004985', 'EFO_0005407',
       'EFO_0005411'], dtype=object), 'count': 9}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743049,"nan_|_nan_|_Antibody_|_False_|_OLARATUMAB_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Lartruvo']_|_['IMC-3G3' 'IMC3G3' 'Olaratumab']_|_[('DrugCentral', array(['5183'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lartruvo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000564', 'MONDO_0008315', 'EFO_1001968', 'EFO_0000691',
       'EFO_0000519', 'EFO_0003893', 'EFO_0003060', 'MONDO_0011719',
       'EFO_0000616', 'EFO_0002618', 'EFO_0009708'], dtype=object), 'count': 11}_|_[ENSG00000134853]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 8 investigational indications."
CHEMBL2079588,"CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1_|_QFCXANHHBCGMAS-UHFFFAOYSA-N_|_Small molecule_|_False_|_TELATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 57-9352' 'BAY-579352' 'Bay-57-9352' 'Telatinib']_|_[('PubChem', array(['124955475'], dtype=object)), ('drugbank', array(['DB15393'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0001056'], dtype=object), 'count': 2}_|_[ENSG00000113721,ENSG00000128052,ENSG00000157404,ENSG00000037280]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2103744,"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O.O.O.O.O.O=S(=O)(O)O_|_GRVOTVYEFDAHCL-RTSZDRIGSA-N_|_Small molecule_|_True_|_MORPHINE SULFATE_|_1984.0_|_4.0_|_CHEMBL70_|_False_|_True_|_['Arymo er' 'Astramorph pf' 'Avinza' 'Depodur' 'Duramorph pf' 'Duromorph'
 'Filnarine sr' 'Infumorph' 'Kadian' 'Moraxen' 'Morcap sr' 'Morphabond'
 'Morphabond er' 'Morphgesic sr' 'Morphine sulfate'
 'Morphine sulfate (autoinjector)' 'Ms contin' 'Mst continus' 'Oramorph'
 'Oramorph sr' 'Oramorph udv' 'Rhotard' 'Sevredol' 'Srm-rhotard' 'Zomorph']_|_['Arymo' 'Astramorph' 'Dolcontin' 'Kapanol' 'Morcap' 'Morphine sulfate'
 'Morphine sulfate anhydrous' 'Morphine sulfate cii'
 'Morphine sulfate hydrate' 'Morphine sulfate pentahydrate'
 'Morphine sulfate,anhydrous' 'Morphine sulphate'
 'Morphine sulphate anhydrous' 'Morphine sulphate pentahydrate'
 'Morphini sulfas' 'Moscontin' 'NSC-11441']_|_[('DailyMed', array(['morphine%20sulfate'], dtype=object)), ('PubChem', array(['144206414'], dtype=object)), ('chEBI', array(['50731'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010702', 'EFO_0000768', 'EFO_0004616', 'HP_0001822',
       'HP_0003419', 'HP_0012532', 'EFO_0020911', 'EFO_0005799',
       'HP_0000989', 'EFO_0003843', 'EFO_0003918', 'EFO_0801084',
       'EFO_0000612', 'EFO_0001361', 'MONDO_0004992', 'EFO_0005611',
       'EFO_0003890', 'MONDO_0011382'], dtype=object), 'count': 18}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 5 approved and 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108589,"nan_|_nan_|_Antibody_|_False_|_CLAZAKIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ALD-518' 'ALD518' 'BMS-945429' 'Clazakizumab']_|_nan_|_nan_|_{'rows': array(['HP_0004326', 'HP_0012378', 'MONDO_0100096', 'EFO_1001904',
       'EFO_0000384', 'EFO_0000685', 'MONDO_0004979', 'EFO_0004599',
       'EFO_0003778', 'MP_0001845'], dtype=object), 'count': 10}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL2109046,"nan_|_nan_|_Protein_|_False_|_INSULIN, PROTAMINE ZINC_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ins hypurin bov prot zn' 'Ins prot zn bp']_|_['Insulin zinc protamine injection (aqueous suspension)'
 'Insulin, protamine zinc' 'Protamine zinc insulin'
 'Protamine zinc insulin injection']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV."
CHEMBL2109396,"nan_|_nan_|_Antibody_|_False_|_AMG-888_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-888' 'Amg-888' 'U3-1287']_|_nan_|_nan_|_{'rows': array(['EFO_0000691', 'EFO_0003060', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0000574', 'EFO_0000313'], dtype=object), 'count': 6}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL2109608,"nan_|_nan_|_Antibody_|_False_|_L19IL2_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['L19IL2' 'L19il2']_|_nan_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0000616', 'EFO_0002618', 'EFO_0000756'],
      dtype=object), 'count': 4}_|_[ENSG00000115414]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2110737,"CCCC(=O)O[C@H]1CN2CC[C@H](O)[C@@H]2[C@@H](O)[C@@H]1O_|_HTJGLYIJVSDQAE-VWNXEWBOSA-N_|_Small molecule_|_False_|_CELGOSIVIR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Celgosivir']_|_[('drugbank', array(['DB06580'], dtype=object))]_|_['CHEMBL2105801']_|_{'rows': array(['EFO_0000764', 'EFO_0004220', 'EFO_0005547'], dtype=object), 'count': 3}_|_[ENSG00000257335,ENSG00000171298,ENSG00000090402,ENSG00000257743]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2146883,"O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1_|_BSMCAPRUBJMWDF-KRWDZBQOSA-N_|_Small molecule_|_False_|_COBIMETINIB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Cotellic']_|_['Cobimetinib' 'GDC-0973' 'Gdc 0623' 'Gdc 0973' 'Gdc-0623' 'RG 7420'
 'RG-7420' 'RG7420' 'Rg-7420' 'Rg-7421' 'XL-518' 'Xl 518' 'Xl518']_|_[('drugbank', array(['DB05239'], dtype=object))]_|_['CHEMBL2364607' 'CHEMBL3526209']_|_{'rows': array(['MONDO_0008170', 'EFO_1001779', 'EFO_0001642', 'EFO_1001956',
       'EFO_1000209', 'EFO_0000756', 'EFO_0003060', 'EFO_0000756',
       'MONDO_0002898', 'Orphanet_46724', 'EFO_0002892', 'EFO_1001951',
       'EFO_0002916', 'EFO_0001378', 'EFO_0000305', 'MONDO_0005184',
       'EFO_0000222', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0000616',
       'EFO_0000389', 'EFO_0000503', 'EFO_0002617', 'EFO_0000691',
       'EFO_0002617'], dtype=object), 'count': 25}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 21 investigational indications."
CHEMBL3120215,"COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12_|_JROFGZPOBKIAEW-HAQNSBGRSA-N_|_Small molecule_|_False_|_OSI-027_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AEVI-006' 'ASP 7486' 'ASP-7486' 'ASP7486' 'CERC 006' 'CERC-006'
 'CERC006' 'OSI-027' 'OSI027' 'Osi 027' 'Osi-027']_|_[('drugbank', array(['DB12387'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'MONDO_0019313'], dtype=object), 'count': 2}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3137349,"nan_|_nan_|_Antibody_|_False_|_BOCOCIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bococizumab' 'PF-04950615' 'RN-316' 'RN316']_|_nan_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0004911', 'MONDO_0021187', 'HP_0003124'],
      dtype=object), 'count': 4}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3235279,"N#Cc1c(N)nc(SCc2csc(-c3ccc(Cl)cc3)n2)c(C#N)c1-c1ccc(OCCO)cc1_|_CITWCLNVRIKQAF-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAPADENOSON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 68-4986' 'BAY-68-4986' 'Bay-684986' 'Capadenoson']_|_nan_|_nan_|_{'rows': array(['EFO_0003913', 'EFO_0000275'], dtype=object), 'count': 2}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545054,"nan_|_nan_|_Small molecule_|_False_|_INCB-40093_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['INCB-040093' 'Incb-40093']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000183'], dtype=object), 'count': 2}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545142,nan_|_nan_|_Small molecule_|_False_|_OLOCROLIMUS_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Sar-943']_|_nan_|_nan_|_nan_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707353,nan_|_nan_|_Small molecule_|_False_|_RG7893_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GDC-0276' 'Rg7893']_|_nan_|_nan_|_nan_|_[ENSG00000169432]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989932,"CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O_|_VBTZKFAHKJXHBA-PIONDTTLSA-N_|_Protein_|_False_|_ANGIOTENSIN II ACETATE_|_2017.0_|_4.0_|_CHEMBL408403_|_False_|_True_|_['Giapreza']_|_['Angiotensin ii acetate' 'Angiotensin ii acetate human'
 'Angiotensin ii triacetate' 'Human angiotensin ii acetate salt']_|_[('DailyMed', array(['angiotensin%20ii%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005251', 'EFO_0006834', 'HP_0031273'], dtype=object), 'count': 3}_|_[ENSG00000144891]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved indications."
CHEMBL41355,"CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)cc1N_|_PCOBBVZJEWWZFR-UHFFFAOYSA-N_|_Small molecule_|_True_|_EZOGABINE_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Potiga' 'Trobalt']_|_['AWD-21360' 'AWD21-360' 'D-23129' 'Ezogabine' 'GKE-841' 'GW-582892X'
 'GW582892X' 'Retigabine' 'WAY-143841']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trobalt'],
      dtype=object)), ('PubChem', array(['174006313'], dtype=object)), ('Wikipedia', array(['Retigabine'], dtype=object)), ('drugbank', array(['DB04953'], dtype=object)), ('chEBI', array(['68584'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474', 'MONDO_0002009', 'MONDO_0004976', 'MONDO_0002050',
       'MONDO_0041052', 'HP_0001250'], dtype=object), 'count': 6}_|_[ENSG00000053918,ENSG00000075043,ENSG00000184156,ENSG00000185760,ENSG00000117013]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for epilepsy and seizure and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297091,"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341.O.O.O.O=S(=O)(O)O_|_BOLDZXRCJAJADM-AAXBYHQXSA-N_|_Small molecule_|_True_|_CODEINE SULFATE_|_2009.0_|_4.0_|_CHEMBL485_|_False_|_True_|_['Codeine sulfate']_|_['Codeine sulfate' 'Codeine sulfate anhydrous' 'Codeine sulfate cii'
 'Codeine sulfate trihydrate' 'Codeine sulphate']_|_[('DailyMed', array(['codeine%20sulfate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0003890'], dtype=object), 'count': 2}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for pain and drug dependence. This drug has a black box warning from the FDA."
CHEMBL4297525,"NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1_|_KUBPNVYPKPWGRJ-LIVOIKKVSA-N_|_Small molecule_|_False_|_RELAMORELIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BIM-28131' 'BIM28131' 'Relamorelin']_|_[('drugbank', array(['DB12678'], dtype=object))]_|_nan_|_nan_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL4298205,"nan_|_nan_|_Antibody_|_False_|_ETIGILIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Etigilimab' 'OMP-313M32']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ETIGILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0008170'], dtype=object), 'count': 2}_|_[ENSG00000181847]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594472,"nan_|_nan_|_Unknown_|_False_|_EMB-01_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bafisontamab' 'EMB-01' 'Emb-01' 'Emb01' 'Fit-013a']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000105976,ENSG00000146648]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594578,"nan_|_nan_|_Antibody_|_False_|_TEBOTELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mgd 013' 'Mgd-013' 'Mgd013' 'Mgd013 (pd-1 x lag-3)' 'Tebotelimab']_|_nan_|_nan_|_{'rows': array(['MONDO_0003060', 'MONDO_0007254', 'EFO_1001512', 'EFO_0000182',
       'MONDO_0001056', 'EFO_0000181'], dtype=object), 'count': 6}_|_[ENSG00000089692,ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4594612,"nan_|_nan_|_Antibody_|_False_|_BEPRANEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bepranemab' 'UCB-0107' 'UCB0107' 'Ucb0107']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BEPRANEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'MONDO_0019037'], dtype=object), 'count': 2}_|_[ENSG00000186868]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5314403,"COc1cc(Cl)ccc1CCNC(=O)c1ccc(Oc2cc3c(cc2Cl)[C@@H](C(=O)O)CCO3)cc1_|_QIDYUNXQPQEJEC-IBGZPJMESA-N_|_Small molecule_|_False_|_ARRY-502_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARRY-502' 'ARRY502' 'Arry-502']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL607707,"CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C_|_WVUNYSQLFKLYNI-AATRIKPKSA-N_|_Small molecule_|_False_|_PELITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EKB-569' 'Pelitinib' 'WAY-EKB-569']_|_[('PubChem', array(['50100098'], dtype=object)), ('drugbank', array(['DB05524'], dtype=object)), ('chEBI', array(['38927'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000657', 'EFO_0003060', 'EFO_0000616', 'EFO_0004288'],
      dtype=object), 'count': 4}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1197,"CC(CNC1CCCCC1)OC(=O)c1ccccc1_|_DKLKMKYDWHYZTD-UHFFFAOYSA-N_|_Small molecule_|_False_|_HEXYLCAINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cyclaine' 'Hexylcaine' 'Osmocaine']_|_[('Wikipedia', array(['Hexylcaine'], dtype=object)), ('drugbank', array(['DB00473'], dtype=object)), ('chEBI', array(['34791'], dtype=object))]_|_['CHEMBL1200715']_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200641,"COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1_|_XXZSQOVSEBAPGS-DONVQRBFSA-L_|_Small molecule_|_False_|_CISATRACURIUM BESYLATE_|_1995.0_|_4.0_|_CHEMBL1201248_|_False_|_True_|_['Cisatracurium besylate' 'Cisatracurium besylate preservative free'
 'Nimbex' 'Nimbex preservative free']_|_['51 W89' '51-W-89' '51-W89' '51W-89' '51W89'
 'Cisatracurium (as besilate)' 'Cisatracurium besilate'
 'Cisatracurium besylate']_|_[('DailyMed', array(['cisatracurium%20besylate'], dtype=object)), ('PubChem', array(['11113043'], dtype=object)), ('chEBI', array(['3721'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000637'], dtype=object), 'count': 1}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and has 1 investigational indication."
CHEMBL1201334,"CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O_|_VXKHXGOKWPXYNA-PGBVPBMZSA-N_|_Protein_|_False_|_TRIPTORELIN_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Decapeptyl' 'Decapeptyl sr' 'Gonapeptyl depot']_|_['AY-25650' 'Arvekap' 'CL 118,532' 'CL-118532' 'Triptodur' 'Triptorelin'
 'Tryptorelin' 'WY-42462']_|_[('PubChem', array(['50112597'], dtype=object)), ('Wikipedia', array(['Triptorelin'], dtype=object)), ('drugbank', array(['DB06825'], dtype=object)), ('chEBI', array(['63633'], dtype=object))]_|_['CHEMBL1200554']_|_{'rows': array(['EFO_0000196', 'MONDO_0011972', 'MONDO_0000088', 'EFO_0000196',
       'EFO_0000574', 'MONDO_0008315', 'EFO_0001663', 'MONDO_0000088',
       'EFO_0001663', 'EFO_0000616', 'MONDO_0008170', 'EFO_0000180',
       'EFO_1001757', 'EFO_0009029', 'MONDO_0007254', 'EFO_0001065',
       'EFO_0009029', 'MONDO_0008315', 'EFO_0000545', 'EFO_0000673',
       'EFO_0000305', 'EFO_0000673', 'EFO_0001065', 'MONDO_0004669',
       'MONDO_0007254'], dtype=object), 'count': 25}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 6 approved and 17 investigational indications."
CHEMBL1201414,"nan_|_nan_|_Oligosaccharide_|_True_|_TINZAPARIN SODIUM_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Innohep' 'Logiparin']_|_['LNH-1' 'LNH1' 'Tinzaparin' 'Tinzaparin na' 'Tinzaparin sodium'
 'Tinzaparin sodium, porcine']_|_[('Wikipedia', array(['Tinzaparin_sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003907', 'EFO_0000365', 'EFO_0003106', 'HP_0002140',
       'MONDO_0002367', 'EFO_0001378', 'MONDO_0100096', 'EFO_0003060',
       'HP_0001907', 'HP_0004419', 'MONDO_0008170'], dtype=object), 'count': 11}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for deep vein thrombosis and recurrent thrombophlebitis and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201564,"nan_|_nan_|_Protein_|_False_|_INTERFERON GAMMA-1B_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Actimmune' 'Immukin']_|_['Ifn-.gamma.' 'Ifn-.gamma.1b' 'Imifn' 'Immune ifn'
 'Interferon .gamma.-1b' 'Interferon gama-1b' 'Interferon gamma'
 'Interferon gamma-1b' 'Interferon gamma-1b, recombinant'
 'Interferon gamma-1b,recomb.' 'Interferon gamma-2a' 'Interferon-.gamma.'
 'Interferon-.gamma. (human)']_|_[('DailyMed', array(['interferon%20gamma-1b'], dtype=object)), ('Wikipedia', array(['Interferon-gamma'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001231', 'MONDO_0018305', 'EFO_0000588', 'EFO_0000574',
       'EFO_0002918', 'EFO_0009869', 'MONDO_0009061', 'EFO_0000676',
       'EFO_0000616', 'MONDO_0018364', 'MONDO_0007254', 'EFO_0007386',
       'EFO_0000174', 'MONDO_0002158', 'EFO_0007460', 'EFO_0000756',
       'EFO_0005952', 'MONDO_0017198', 'EFO_0009448', 'MONDO_0002087',
       'EFO_1001359', 'EFO_0000637', 'EFO_0000764', 'MONDO_0004580',
       'EFO_0000621', 'Orphanet_53', 'EFO_0000389', 'EFO_1001865',
       'EFO_1001051', 'EFO_0009429', 'EFO_0004220', 'EFO_0001422',
       'EFO_0003830', 'EFO_0001378', 'EFO_1000811', 'EFO_0000768',
       'EFO_0007228', 'EFO_1001282', 'EFO_0007183', 'EFO_0000565',
       'MONDO_0008315', 'EFO_0007147', 'EFO_0007157', 'MONDO_0100339',
       'MONDO_0008170'], dtype=object), 'count': 45}_|_[ENSG00000159128,ENSG00000027697]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 41 investigational indications."
CHEMBL1201606,"nan_|_nan_|_Antibody drug conjugate_|_False_|_IBRITUMOMAB TIUXETAN_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Zevalin' 'Zevalin Kit-Indium-111']_|_['IDEC-129' 'IDEC-IN2B8' 'IDEC-Y2B8' 'IDEC-Y2B8 IDEC-129'
 'Ibritumomab tiuxetan']_|_[('DailyMed', array(['ibritumomab%20tiuxetan'], dtype=object)), ('DrugCentral', array(['4984'], dtype=object)), ('Wikipedia', array(['Ibritumomab_tiuxetan'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0000183', 'EFO_0000095', 'EFO_0000191',
       'EFO_0009441', 'EFO_0000565', 'EFO_0000096', 'EFO_0001378',
       'EFO_0000403', 'EFO_0000574', 'MONDO_0018906', 'EFO_1001365',
       'EFO_0000309', 'EFO_0005952', 'EFO_1001469', 'MONDO_0000873'],
      dtype=object), 'count': 16}_|_[ENSG00000156738]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 16 investigational indications."
CHEMBL1201830,"nan_|_nan_|_Protein_|_False_|_RILONACEPT_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Arcalyst' 'Rilonacept regeneron (previously arcalyst)']_|_['IL-1 TRAP' 'IL-1-TRAP' 'INTERLEUKIN-1 TRAP' 'KPL-914' 'Kpl-914'
 'Rilonacept']_|_[('DrugCentral', array(['5105'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rilonacept-regeneron-previously-arcalyst'],
      dtype=object)), ('Wikipedia', array(['Rilonacept'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000404', 'EFO_0000540', 'Orphanet_47045', 'EFO_1001881',
       'MONDO_0016168', 'EFO_0007427', 'EFO_0002609', 'EFO_0004274',
       'MONDO_0018088', 'EFO_0004238', 'MONDO_0008633', 'MONDO_0005147',
       'EFO_1001345'], dtype=object), 'count': 13}_|_[ENSG00000125538]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 approved and 8 investigational indications."
CHEMBL134713,"COc1ccc(/C=C2\CCCN=C2c2cccnc2)c(OC)c1_|_RPYWXZCFYPVCNQ-RVDMUPIBSA-N_|_Small molecule_|_False_|_GTS-21_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['3-(2,4-Dimethoxybenzylidene)Anabaseine'
 'Dimethoxybenzylidene anabaseine' 'Dmxb-a' 'Gts-21']_|_[('drugbank', array(['DB05708'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003768', 'EFO_0001073', 'EFO_0003758', 'EFO_0005411',
       'MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 6}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL1388,"Oc1ccc(OCc2ccccc2)cc1_|_VYQNWZOUAUKGHI-UHFFFAOYSA-N_|_Small molecule_|_False_|_MONOBENZONE_|_1952.0_|_4.0_|_nan_|_False_|_True_|_['Benoquin']_|_['Monobenzone' 'Monobenzyl ether of hydroquinone' 'NSC-2132'
 'P-(benzyloxy)phenol' 'P-benzyloxyphenol']_|_[('PubChem', array(['11112252', '144203947', '144208345', '170464724', '174006811'],
      dtype=object)), ('Wikipedia', array(['Monobenzone'], dtype=object)), ('drugbank', array(['DB00600'], dtype=object)), ('chEBI', array(['34380'], dtype=object))]_|_nan_|_nan_|_[ENSG00000077498]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1952."
CHEMBL1512580,"FC(F)(F)c1cccc(C2=CCN(CCc3ccc4ccccc4c3)CC2)c1_|_WJJYZXPHLSLMGE-UHFFFAOYSA-N_|_Small molecule_|_False_|_XALIPRODEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SR 57746' 'SR-57746' 'Xaliproden']_|_[('PubChem', array(['50112828', '50112829'], dtype=object)), ('drugbank', array(['DB06393'], dtype=object)), ('chEBI', array(['48520'], dtype=object))]_|_['CHEMBL3183486']_|_{'rows': array(['MONDO_0004975', 'EFO_0004142'], dtype=object), 'count': 2}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2107869,"nan_|_nan_|_Protein_|_False_|_INSULIN DEGLUDEC_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Ins tresiba' 'Tresiba']_|_['Insulin degludec' 'NN-1250' 'NN1250']_|_[('DailyMed', array(['insulin%20degludec'], dtype=object)), ('DrugCentral', array(['4960'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for diabetes mellitus and has 2 investigational indications."
CHEMBL2107911,"nan_|_nan_|_Protein_|_False_|_ONERCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Onercept' 'R-HTBP-1']_|_nan_|_nan_|_{'rows': array(['EFO_0003778'], dtype=object), 'count': 1}_|_[ENSG00000232810]_|_Protein drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2107917,"nan_|_nan_|_Antibody_|_False_|_OREGOVOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Ovarex']_|_['Oregovamab' 'Oregovomab' 'mAb-B43.13']_|_nan_|_nan_|_{'rows': array(['MONDO_0002087', 'EFO_0003893', 'MONDO_0008170', 'EFO_0001075',
       'MONDO_0002158'], dtype=object), 'count': 5}_|_[ENSG00000181143]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2108286,"nan_|_nan_|_Protein_|_False_|_TUROCTOCOG ALFA_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Novoeight']_|_['NN-7008' 'NN7008' 'Novoeight' 'Turoctocog alfa']_|_[('DrugCentral', array(['5019'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/novoeight'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for hemophilia a."
CHEMBL2109545,"nan_|_nan_|_Antibody_|_False_|_TB-403_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RG-7334' 'RO-5323441' 'TB-403' 'TB403' 'THR-317' 'Tb-403' 'Thr 317']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000119630]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2141712,"COc1ccc(COc2cc3oc(=O)c4cc(C(C)O)ccc4c3cc2OC)cc1_|_YEAHTLOYHVWAKW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PALOMID-529_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['P-529' 'P529' 'PALOMID-529' 'Palomid 529' 'Palomid-529' 'SG 00529'
 'SG-00529']_|_[('PubChem', array(['137275969'], dtype=object)), ('drugbank', array(['DB12812'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2360464,"Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc3)c2c(=O)[nH]1.[Na+].[Na+]_|_NYDXNILOWQXUOF-GXKRWWSZSA-L_|_Small molecule_|_False_|_PEMETREXED DISODIUM_|_2004.0_|_4.0_|_CHEMBL225072_|_False_|_True_|_['Alimta']_|_['LY-231514 DISODIUM SALT' 'LY231514 DISODIUM SALT' 'Pemetrexed disodium'
 'Pemetrexed disodium heptahydrate' 'Pemetrexed sodium hydrate'
 'Pemetrexed sodium salt']_|_[('DailyMed', array(['pemetrexed%20disodium'], dtype=object)), ('PubChem', array(['144206040'], dtype=object)), ('chEBI', array(['63722'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003050', 'MONDO_0011962', 'MONDO_0002158', 'MONDO_0008315',
       'EFO_1001951', 'EFO_0000308', 'EFO_0000365', 'EFO_0008528',
       'EFO_0000571', 'EFO_0006859', 'EFO_0002618', 'MONDO_0021117',
       'MONDO_0004192', 'MONDO_0008903', 'EFO_0003060', 'EFO_0000708',
       'EFO_0000574', 'MONDO_0000521', 'MONDO_0004992', 'MONDO_0002087',
       'MONDO_0018944', 'MONDO_0007254', 'EFO_0003860', 'MONDO_0001187',
       'MONDO_0008170', 'MONDO_0002974', 'EFO_0000691', 'MONDO_0001056',
       'EFO_0009708', 'EFO_1000576', 'EFO_0000770', 'EFO_0000588',
       'EFO_0003863', 'EFO_1000581', 'EFO_0000616'], dtype=object), 'count': 35}_|_[ENSG00000176890,ENSG00000159131,ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for non-small cell lung carcinoma and has 34 investigational indications."
CHEMBL3544975,"COc1cc(N)c(Cl)cc1C(=O)NCC1CCN(CC[C@H](OC(N)=O)c2ccc(F)cc2)CC1_|_KGMMSPVVHZGPHL-NRFANRHFSA-N_|_Small molecule_|_False_|_RELENOPRIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Relenopride' 'YKP-10811' 'YKP10811']_|_[('drugbank', array(['DB12798'], dtype=object))]_|_['CHEMBL3544976']_|_{'rows': array(['HP_0002019'], dtype=object), 'count': 1}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545027,"COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1_|_MMNNTJYFHUDSKL-UHFFFAOYSA-N_|_Small molecule_|_False_|_XL-281_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-908662' 'Bms-908662 free base' 'EXEL-2819' 'Xl 281' 'Xl-281']_|_[('drugbank', array(['DB12854'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000641', 'EFO_1001951', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000132155,ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3545274,"CC(C)(C)n1nnc2c3c(ccc21)C1=CC(=O)CC[C@@]1(CCOc1ccccc1)C3_|_LYLIIGQPIKTONH-RUZDIDTESA-N_|_Small molecule_|_False_|_MK-6913_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-6913']_|_nan_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3545360,"COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1_|_MGGBYMDAPCCKCT-UHFFFAOYSA-N_|_Small molecule_|_False_|_ASP-3026_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ASP3026' 'Asp 3026' 'Asp-3026']_|_[('drugbank', array(['DB12729'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000096', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000171094]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3989843,"N[C@@H]1C[C@H]1c1ccccc1.N[C@H]1C[C@@H]1c1ccccc1_|_IGLYMJRIWWIQQE-QUOODJBBSA-N_|_Small molecule_|_True_|_TRANYLCYPROMINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-80664' 'Tranylcypromine']_|_nan_|_['CHEMBL3989698']_|_{'rows': array(['MONDO_0002009', 'EFO_0005230', 'MONDO_0002009', 'HP_0000726',
       'EFO_1002014', 'EFO_0000198', 'MONDO_0002009', 'EFO_0000222',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0005252'], dtype=object), 'count': 11}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989870,"CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1_|_JZCWLJDSIRUGIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_BERZOSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Berzosertib' 'M-6620' 'M6620' 'VE-822' 'VX-970' 'VX970' 'Vx-970']_|_[('drugbank', array(['DB11794'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001075', 'EFO_1000251', 'EFO_0000199', 'EFO_0003060',
       'EFO_0000702', 'EFO_0006352', 'EFO_0002618', 'EFO_0000564',
       'EFO_0000616', 'EFO_0000196', 'MONDO_0008170', 'EFO_0003893',
       'EFO_0001416', 'EFO_0000365', 'EFO_1001960', 'MONDO_0044704',
       'EFO_0005537'], dtype=object), 'count': 17}_|_[ENSG00000175054]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 17 investigational indications."
CHEMBL3989885,"CC(CN(C)C)CN1c2ccccc2Sc2ccccc21.CC(CN(C)C)CN1c2ccccc2Sc2ccccc21.O=C(O)C(O)C(O)C(=O)O_|_AJZJIYUOOJLBAU-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIMEPRAZINE TARTRATE_|_1982.0_|_4.0_|_CHEMBL829_|_False_|_True_|_['Temaril' 'Trimeprazine tartrate' 'Vallergan' 'Vallergan fte']_|_['Alimemazine hemitartrate' 'Alimemazine tartrate'
 'Methylpromazine tartrate' 'NSC-17475' 'NSC-757358' 'Panectyl' 'Repeltin'
 'Theralene' 'Trimeprazine hemitartrate' 'Trimeprazine tartrate']_|_nan_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL4297315,"N=C(N)c1ccc2nc(-c3cc(CC(=O)N[C@@H](CC(=O)O)C(=O)O)cc(-c4cc(S(N)(=O)=O)ccc4O)c3O)[nH]c2c1_|_WDJHHCAKBRKCLW-IBGZPJMESA-N_|_Small molecule_|_False_|_PCI-27483_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cra-027483' 'Pci-27483']_|_[('drugbank', array(['DB13000'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}_|_[ENSG00000057593]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297442,"OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@H](n3cc(-c4cccc(F)c4)nn3)[C@H]2O)[C@H](O)[C@@H](n2cc(-c3cccc(F)c3)nn2)[C@H]1O_|_YGIDGBAHDZEYMT-MQFIMZJJSA-N_|_Small molecule_|_False_|_OLITIGALTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GB-0139' 'GB0139' 'Olitigaltin' 'TD-139' 'TD139' 'Td 139' 'Td-139'
 'Td139']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLITIGALTIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12895'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000768', 'MONDO_0100096', 'EFO_0006890'], dtype=object), 'count': 3}_|_[ENSG00000131981]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297447,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)O_|_XIEWFECSPPTVQN-KMIMAYJXSA-N_|_Protein_|_False_|_TRV-120027_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Sar-val-tyr-ile-his-pro-d-ala-oh' 'TRV 027' 'TRV-027' 'TRV027'
 'Trv-120027' 'Trv027' 'Trv120027']_|_[('drugbank', array(['DB12199'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0003144'], dtype=object), 'count': 2}_|_[ENSG00000144891]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297522,"CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21_|_HCDMJFOHIXMBOV-UHFFFAOYSA-N_|_Small molecule_|_False_|_PEMIGATINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Pemazyre']_|_['Fgfr inhibitor incb054828' 'INCB054828' 'Incb-054828' 'Incb054828'
 'Pemigatinib']_|_[('DailyMed', array(['pemigatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEMIGATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15102'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003863', 'EFO_0000616', 'EFO_0003060', 'EFO_1001961',
       'EFO_0008528', 'EFO_0000519', 'EFO_0004251', 'MONDO_0004992',
       'MONDO_0007254', 'EFO_1001951', 'MONDO_0011962', 'EFO_0000222',
       'EFO_0002618', 'EFO_0005221', 'MONDO_0001187'], dtype=object), 'count': 15}_|_[ENSG00000077782,ENSG00000066468,ENSG00000068078]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 11 investigational indications."
CHEMBL4298167,"O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O_|_BFENHEAPFWQJFL-BTJKTKAUSA-N_|_Small molecule_|_False_|_FILGOTINIB MALEATE_|_2020.0_|_4.0_|_CHEMBL3301607_|_False_|_True_|_['Jyseleca']_|_['Filgotinib maleate' 'GS-6034']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000162434,ENSG00000105397,ENSG00000096968,ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for rheumatoid arthritis."
CHEMBL4650294,nan_|_nan_|_Antibody_|_False_|_IMALUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAX-069' 'BAX-69' 'BAX69' 'Imalumab']_|_nan_|_nan_|_nan_|_[ENSG00000240972]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL4650424,"nan_|_nan_|_Protein_|_False_|_SVN53-67/M57-KLH PEPTIDE VACCINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Survaxm' 'Svn53-67/m57-klh peptide vaccine']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_1001465', 'EFO_0006475', 'EFO_0001378'],
      dtype=object), 'count': 4}_|_[ENSG00000089685]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL485253,"CCC(CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1_|_KPJZHOPZRAFDTN-NQUBZZJWSA-N_|_Small molecule_|_False_|_METHYSERGIDE_|_1962.0_|_4.0_|_nan_|_False_|_True_|_['Deseril']_|_['Methysergide']_|_[('drugbank', array(['DB00247'], dtype=object)), ('chEBI', array(['584020'], dtype=object))]_|_['CHEMBL3989558']_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000147246,ENSG00000135914,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962 and is indicated for migraine disorder."
CHEMBL502097,"COCCO[C@@H]1[C@H](SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)([O-])OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](OCCOC)[C@@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cnc4c(N)ncnc43)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)([O-])OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2O)[C@@H](COP(=O)([O-])S[C@H]2[C@@H](OCCOC)[C@H](n3cc(C)c(N)nc3=O)O[C@@H]2COP(=O)([O-])S[C@H]2[C@@H](OCCOC)[C@H](n3cnc4c(=O)[nH]c(N)nc43)O[C@@H]2CO)O[C@H]1n1cc(C)c(N)nc1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]_|_OSGPYAHSKOGBFY-KMHHXCEHSA-A_|_Oligonucleotide_|_True_|_MIPOMERSEN SODIUM_|_2013.0_|_4.0_|_CHEMBL2219536_|_False_|_True_|_['Kynamro']_|_['ISIS 301012' 'ISIS-301012' 'Mipomersen sodium' 'Mipomersen sodium salt']_|_[('DailyMed', array(['mipomersen%20sodium'], dtype=object)), ('Wikipedia', array(['Mipomersen'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004911', 'HP_0003124'], dtype=object), 'count': 2}_|_[ENSG00000084674]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL93645,"O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl_|_MNIPYSSQXLZQLJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACECLOFENAC_|_nan_|_4.0_|_nan_|_False_|_True_|_['Gerbin' 'Preservex']_|_['Aceclofenac' 'Aceclofenac betadex']_|_[('PubChem', array(['11112873', '144204261', '170465979', '50085951'], dtype=object)), ('Wikipedia', array(['Aceclofenac'], dtype=object)), ('drugbank', array(['DB06736'], dtype=object)), ('chEBI', array(['31159'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003326', 'MONDO_0003937', 'EFO_0005755', 'MONDO_0005178',
       'EFO_0000685', 'EFO_1001139', 'HP_0002829'], dtype=object), 'count': 7}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 6 approved and 1 investigational indication."
CHEMBL938,"CNCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C_|_PFGWGEPQIUAZME-NXSMLHPHSA-N_|_Protein_|_False_|_SARALASIN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['1-sar-8-ala-angiotensin ii' 'Sar-arg-val-tyr-val-his-pro-ala'
 'Saralasin']_|_[('Wikipedia', array(['Saralasin'], dtype=object)), ('drugbank', array(['DB06763'], dtype=object))]_|_['CHEMBL1200670']_|_nan_|_[ENSG00000144891]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1002,"CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1_|_NDAUXUAQIAJITI-LBPRGKRZSA-N_|_Small molecule_|_False_|_LEVOSALBUTAMOL_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ASF-1096' 'Albuterol (r)-form' 'Levalbuterol' 'Levosalbutamol'
 'R-salbutamol' 'Xopenex']_|_[('PubChem', array(['11111805', '11111806', '11112645', '11113612'], dtype=object)), ('Wikipedia', array(['Levosalbutamol'], dtype=object)), ('drugbank', array(['DB13139'], dtype=object)), ('chEBI', array(['8746'], dtype=object))]_|_['CHEMBL3989693' 'CHEMBL1201061' 'CHEMBL3989589']_|_{'rows': array(['MONDO_0004979', 'MONDO_0004979', 'MONDO_0004979', 'EFO_0000341'],
      dtype=object), 'count': 4}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for asthma and has 2 investigational indications."
CHEMBL1095032,"O=C([C@H](O)CS(=O)(=O)c1ccc2cc(Cl)ccc2c1)N1CCC(N2CCCNC2=O)CC1_|_GEHAEMCVKDPMKO-HXUWFJFHSA-N_|_Small molecule_|_False_|_LETAXABAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Letaxaban' 'TAK 442' 'TAK-442' 'TAK442']_|_[('drugbank', array(['DB11984'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004286', 'EFO_0005672'], dtype=object), 'count': 2}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1255654,"CCCCNc1ccc(C(=O)OCCN(C)C)cc1.Cl_|_PPWHTZKZQNXVAE-UHFFFAOYSA-N_|_Small molecule_|_False_|_TETRACAINE HYDROCHLORIDE_|_2016.0_|_4.0_|_CHEMBL698_|_False_|_True_|_['Anethaine' 'Locan' 'Tetracaine hydrochloride']_|_['Amethocaine hydrochloride' 'Butethanol' 'Curtacain' 'Dicainum'
 'Menonasal' 'NSC-757337' 'Pantocaine' 'Tetocaine' 'Tetraca'
 'Tetracaine hcl' 'Tetracaine hydrochloride' 'Tetracaini hydrochloridum']_|_[('DailyMed', array(['tetracaine%20hydrochloride'], dtype=object)), ('PubChem', array(['11533049', '144203841', '170465190', '26747689', '26747690',
       '50107143', '50107144', '50107145', '85273695'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016."
CHEMBL1562610,"Cc1ccc(Cl)c(Nc2ccccc2C(=O)[O-])c1Cl.O.[Na+]_|_QHJLLDJTVQAFAN-UHFFFAOYSA-M_|_Small molecule_|_True_|_MECLOFENAMATE SODIUM_|_1980.0_|_4.0_|_CHEMBL509_|_False_|_True_|_['Meclodium' 'Meclofenamate sodium' 'Meclomen']_|_['CL-583.NA SALT' 'Meclofenamate sodium' 'Meclofenamate sodium anhydrous'
 'Meclofenamate sodium hydrate' 'Meclofenamic acid sodium' 'NSC-757088'
 'Sodium meclofenamate' 'Sodium meclofenamate monohydrate']_|_[('DailyMed', array(['meclofenamate%20sodium'], dtype=object)), ('PubChem', array(['11112978', '144204315', '170464886', '85273783'], dtype=object)), ('chEBI', array(['76232'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'HP_0001945', 'EFO_0000685', 'EFO_0002609',
       'HP_0100607'], dtype=object), 'count': 5}_|_[ENSG00000012779,ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 5 approved indications. This drug has a black box warning from the FDA."
CHEMBL1742461,"O=C(C[S+]([O-])Cc1ccco1)NC/C=C\COc1cc(CN2CCCCC2)ccn1_|_KMZQAVXSMUKBPD-DJWKRKHSSA-N_|_Small molecule_|_False_|_LAFUTIDINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Lafutidine']_|_[('PubChem', array(['144205732', '170465978'], dtype=object)), ('drugbank', array(['DB12770'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004398', 'EFO_0003948', 'EFO_0000337', 'EFO_0009454'],
      dtype=object), 'count': 4}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL1760,"CC(C)(C)NCC(O)c1cc(O)cc(O)c1_|_XWTYSIMOBUGWOL-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERBUTALINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Asthmasian' 'Brethaire' 'Brethine' 'Bricanyl' 'Terbutalin' 'Terbutaline']_|_[('PubChem', array(['90341646'], dtype=object)), ('Wikipedia', array(['Terbutaline'], dtype=object)), ('drugbank', array(['DB00871'], dtype=object)), ('chEBI', array(['9449'], dtype=object))]_|_['CHEMBL1315867' 'CHEMBL1160544']_|_{'rows': array(['HP_0006536', 'EFO_0000341', 'MONDO_0004979', 'EFO_0000341',
       'EFO_0009661', 'EFO_0007160', 'EFO_0005762', 'MONDO_0004979',
       'MONDO_0005147'], dtype=object), 'count': 9}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 approved and 5 investigational indications."
CHEMBL1908373,"CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1_|_IEXUMDBQLIVNHZ-YOUGDJEHSA-N_|_Small molecule_|_False_|_ONAPRISTONE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Onapristone' 'ZK-299' 'ZK-98299' 'ZK299' 'Zk-98299' 'Zk98299']_|_[('drugbank', array(['DB12637'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0007254', 'EFO_0000196'], dtype=object), 'count': 3}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications."
CHEMBL2012520,"CC(C)(Cc1ccc(Oc2ccc(C(N)=O)cn2)cc1)NC[C@H](O)COc1cccc2[nH]c3ccccc3c12_|_RBSGUQYXRDKPAE-QFIPXVFZSA-N_|_Small molecule_|_False_|_LY377604_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-377604' 'Ly-377604' 'Ly377604']_|_[('drugbank', array(['DB12858'], dtype=object))]_|_['CHEMBL2012522' 'CHEMBL2012521']_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105345,"CCCOC(=O)Cc1ccc(OCC(=O)N(CC)CC)c(OC)c1_|_KEJXLQUPYHWCNM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPANIDID_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['BAYER 1420' 'BAYER-1420' 'FBA 1420' 'FBA-1420' 'Propanidid' 'TH-2180'
 'WH 5668' 'WH-5668']_|_[('PubChem', array(['144206858'], dtype=object)), ('drugbank', array(['DB13234'], dtype=object))]_|_nan_|_nan_|_[ENSG00000114200,ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2105762,"CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2_|_MKMPWKUAHLTIBJ-ISTRZQFTSA-N_|_Small molecule_|_False_|_OMARIGLIPTIN_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MK-3102' 'Omarigliptin']_|_[('drugbank', array(['DB11992'], dtype=object))]_|_['CHEMBL3234203']_|_{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 2 investigational indications."
CHEMBL2105763,"Cn1cc(CNCC2CCN(c3ncc(C(=O)NO)cn3)CC2)c2ccccc21_|_PAWIYAYFNXQGAP-UHFFFAOYSA-N_|_Small molecule_|_False_|_QUISINOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JNJ 26481585' 'JNJ-26481585' 'Quisinostat']_|_[('drugbank', array(['DB12985'], dtype=object))]_|_['CHEMBL3039527']_|_{'rows': array(['EFO_0002913', 'MONDO_0008170', 'EFO_0000574'], dtype=object), 'count': 3}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2108342,"nan_|_nan_|_Antibody_|_False_|_GEMTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gemtuzumab' 'Hp 67.6']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000105383]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108576,"nan_|_nan_|_Antibody_|_False_|_BAPINEUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['3D-6' 'AAB-001' 'AAB-001, Humanized 3D-6 Monoclonal Antibody'
 'Bapineuzumab' 'HUMANIZED 3D-6 MONOCLONAL ANTIBODY']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108683,"nan_|_nan_|_Unknown_|_False_|_ENTOLIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_['Cblb502']_|_['CBLB-502' 'CBLB502' 'Entolimod']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001951', 'EFO_0003890'], dtype=object), 'count': 3}_|_[ENSG00000187554]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109583,"nan_|_nan_|_Antibody_|_False_|_F16IL2_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['F16IL2' 'F16il2']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_1001471', 'MONDO_0007254', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000041982]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2110727,"CCCCOCCOc1ccc(-c2ccc3c(c2)/C=C(/C(=O)Nc2ccc([S@@+]([O-])Cc4cncn4CCC)cc2)CCCN3CC(C)C)cc1_|_PNDKCRDVVKJPKG-WHERJAGFSA-N_|_Small molecule_|_False_|_CENICRIVIROC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cenicriviroc' 'TAK-652' 'TBR-652']_|_[('drugbank', array(['DB11758'], dtype=object))]_|_['CHEMBL2105686']_|_{'rows': array(['EFO_1001249', 'MONDO_0100096', 'EFO_0003095', 'EFO_0000180',
       'EFO_0000180', 'EFO_0000544', 'EFO_0001421', 'EFO_0000764',
       'EFO_0004268'], dtype=object), 'count': 9}_|_[ENSG00000121807,ENSG00000160791]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2216870,"CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1_|_IFSDAJWBUCMOAH-HNNXBMFYSA-N_|_Small molecule_|_True_|_IDELALISIB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Zydelig']_|_['CAL-101' 'GS-1101' 'GS-11CAL-101' 'Idelalisib']_|_[('DailyMed', array(['idelalisib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig'],
      dtype=object)), ('drugbank', array(['DB09054'], dtype=object)), ('chEBI', array(['82701'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000183', 'EFO_1001469', 'MONDO_0005184', 'MONDO_0018906',
       'MONDO_0044903', 'EFO_0000095', 'EFO_0005854', 'EFO_0000616',
       'MONDO_0004992', 'EFO_0000574', 'EFO_0000403', 'EFO_0000222',
       'EFO_0001378', 'MONDO_0000432', 'EFO_0009441', 'EFO_1001875',
       'EFO_0000096', 'EFO_0005952', 'EFO_0000220'], dtype=object), 'count': 19}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 5 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL262075,"CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1_|_CBIAWPMZSFFRGN-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDIPLON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CL-285489' 'Calenthys' 'Indiplon' 'NBI-34060']_|_[('PubChem', array(['174006212'], dtype=object)), ('Wikipedia', array(['Indiplon'], dtype=object)), ('drugbank', array(['DB12590'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'MONDO_0002050'], dtype=object), 'count': 2}_|_[ENSG00000022355]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3545373,"nan_|_nan_|_Antibody_|_False_|_ENOBLITUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Enoblituzumab' 'MGA-271' 'MGA271']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000756', 'EFO_0000181'], dtype=object), 'count': 3}_|_[ENSG00000103855]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL364804,"CCOc1ccc(-c2nn3ncccc3c2-c2ccc(S(C)(=O)=O)cc2)cc1_|_NXMZBNYLCVTRGB-UHFFFAOYSA-N_|_Small molecule_|_False_|_GW-406381_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gw 406381' 'Gw-406381' 'Gw406381']_|_[('drugbank', array(['DB12009'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010072', 'EFO_0004616', 'EFO_0000685', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3989798,"COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O_|_RATSWNOMCHFQGJ-XODSYJLDSA-N_|_Small molecule_|_False_|_FORMOTEROL FUMARATE_|_2001.0_|_4.0_|_CHEMBL1256786_|_False_|_True_|_['Atimos modulite' 'Foradil' 'Foradil certihaler' 'Oxis 12' 'Oxis 6'
 'Perforomist']_|_['Atock' 'BD 40A' 'BD-40A' 'CGP 25827A' 'CGP-25827A' 'Eformoterol'
 'Fomoterol fumarate' 'Foraseq' 'Formoterol fumarate'
 'Formoterol fumarate (superceded)' 'Formoterol fumarate anhydrous'
 'Formoterol fumarate dihydrate' 'Formoterol fumarate hydrate'
 'Formoterol hemifumarate' 'NSC-299587' 'Oxeze' 'YM-08316']_|_[('DailyMed', array(['formoterol%20fumarate', 'formoterol%20fumarate%20dihydrate'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0006536', 'EFO_0007183', 'EFO_0009661', 'MONDO_0100096',
       'EFO_1000637', 'HP_0002110', 'MONDO_0005271', 'MONDO_0008903',
       'EFO_0000341', 'EFO_0006505', 'EFO_0003768', 'EFO_0000464',
       'MONDO_0004979'], dtype=object), 'count': 13}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 9 investigational indications."
CHEMBL3989805,"CN1CCN(c2ccccc2/C=C2\SCCN(c3ccc(Cl)c(Cl)c3)C2=O)CC1.Cl_|_NMTRXBJYASHMND-UXTSPRGOSA-N_|_Small molecule_|_False_|_ELZASONAN HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL3185463_|_False_|_False_|_[]_|_['CP-448,187-01' 'Cp-448187-01' 'Elzasonan hcl' 'Elzasonan hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4089083,"O/N=c1\cc(-c2cc3sccc3cn2)oc2ccc(CCCN3CCOCC3)cc12_|_ZTEDNASHAWNBKQ-NCELDCMTSA-N_|_Small molecule_|_False_|_FOLIGLURAX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DT-1687' 'DT1687' 'Foliglurax' 'PXT-002331' 'PXT002331' 'Pxt002331']_|_[('drugbank', array(['DB15292'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000124493]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4110551,"COC(=O)NCCCn1nc([C@@H](C)N(C(=O)[C@H]2CNCCO2)C2CC2)c2ccc(C)nc21_|_GRTDDIZIUSADLD-CRAIPNDOSA-N_|_Small molecule_|_False_|_SPH-3127_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SPH-3127' 'SPH3127' 'Sph-3127' 'Sph3127']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000401', 'MONDO_0001134', 'EFO_0000537'],
      dtype=object), 'count': 4}_|_[ENSG00000143839]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297312,"COC[C@@]1(C)CCCN2CCc3c(oc4ccccc34)[C@@H]21_|_OCUKPFWNSAAHRP-QZTJIDSGSA-N_|_Small molecule_|_False_|_ORM-12741_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DB-105' 'ORM-10921' 'Orm-12741']_|_[('drugbank', array(['DB12057'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000184160]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298047,"nan_|_nan_|_Antibody_|_False_|_TAFASITAMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Minjuvi' 'Monjuvi' 'Monjuvi (tafasitamab-cxix) for injection']_|_['MOR-00208' 'MOR00208' 'MOR208' 'Mor-208' 'Mor00208' 'Tafasitamab'
 'Tafasitamab cxix' 'XmAb5574' 'Xmab-5574' 'Xmab5574']_|_[('DailyMed', array(['tafasitamab-cxix'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_1001469', 'MONDO_0001023', 'EFO_0000574',
       'EFO_0000096', 'MONDO_0018906', 'EFO_0000403', 'EFO_0005952',
       'EFO_0000616', 'EFO_0000220'], dtype=object), 'count': 10}_|_[ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 7 investigational indications."
CHEMBL4594566,"nan_|_nan_|_Antibody_|_False_|_ONGERICIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['JS 002' 'JS-002' 'Js002' 'Ongericimab']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0004911', 'Orphanet_79211', 'HP_0003124',
       'MONDO_0021187'], dtype=object), 'count': 5}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL515966,"COc1ccc(C(C)C)cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1_|_XPNMCDYOYIKVGB-CONSDPRKSA-N_|_Small molecule_|_False_|_EZLOPITANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CJ-11, 974' 'CJ-11,974' 'Cj-11974' 'Ezlopitant']_|_[('Wikipedia', array(['Ezlopitant'], dtype=object))]_|_nan_|_nan_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL5315052,"C#CCN[C@@H]1CCc2ccccc21.C#CCN[C@@H]1CCc2ccccc21.O=C(O)C(O)C(O)C(=O)O_|_YGKHOZXCTLKSLJ-IUWNWRFPSA-N_|_Small molecule_|_False_|_RASAGILINE TARTRATE_|_2016.0_|_4.0_|_CHEMBL887_|_False_|_True_|_['Rasagiline mylan']_|_['Rasagiline hemitartrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-mylan'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for parkinson disease."
CHEMBL561157,"CCCCC[C@H](O)CC[C@@H]1[C@H]2Cc3cccc(OCC(=O)[O-])c3C[C@H]2C[C@H]1O.[Na+]_|_IQKAWAUTOKVMLE-ZSESPEEFSA-M_|_Small molecule_|_False_|_TREPROSTINIL SODIUM_|_2020.0_|_4.0_|_CHEMBL1237119_|_False_|_True_|_['Remodulin' 'Trepulmix' 'Tyvaso']_|_['Treprostinil Sodium' 'Treprostinil sodium' 'Treprostinil sodium salt']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trepulmix'],
      dtype=object)), ('chEBI', array(['50863'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005149'], dtype=object), 'count': 1}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for pulmonary hypertension."
CHEMBL578,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O_|_GBXSMTUPTTWBMN-XIRDDKMYSA-N_|_Small molecule_|_True_|_ENALAPRIL_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['C09AA02' 'Enalapril' 'Lexxel' 'Olinapril' 'Vaseretic' 'Vasotec']_|_[('PubChem', array(['11112847', '144204423', '170464969', '29214998'], dtype=object)), ('TG-GATEs', array(['95'], dtype=object)), ('Wikipedia', array(['Enalapril'], dtype=object)), ('drugbank', array(['DB00584'], dtype=object)), ('chEBI', array(['4784'], dtype=object))]_|_['CHEMBL1200659']_|_{'rows': array(['HP_0000093', 'EFO_0000537', 'EFO_1001482', 'EFO_0003144',
       'EFO_0001378', 'EFO_0000668', 'EFO_0003884', 'EFO_0003106',
       'EFO_1001375', 'EFO_0000280', 'MONDO_0005147', 'EFO_0007328',
       'EFO_0003144', 'EFO_0000756', 'EFO_0000373', 'MONDO_0004992',
       'EFO_0008585', 'EFO_0005529', 'MONDO_0100096', 'EFO_0005669',
       'EFO_0000318', 'EFO_0000222', 'MONDO_0018638', 'EFO_0004289',
       'EFO_0000712', 'EFO_0000537', 'EFO_0004194', 'MONDO_0001134',
       'EFO_0004234', 'EFO_0000319', 'EFO_0000556', 'EFO_0000373',
       'EFO_0000685', 'EFO_0003777'], dtype=object), 'count': 34}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 30 investigational indications. This drug has a black box warning from the FDA."
CHEMBL61872,"CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3_|_JACAAXNEHGBPOQ-LLVKDONJSA-N_|_Small molecule_|_False_|_TALAMPANEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-talampanel' 'GYKI-53773' 'LY-300164' 'Ly300164' 'Talampanel']_|_[('Wikipedia', array(['Talampanel'], dtype=object)), ('drugbank', array(['DB04982'], dtype=object)), ('chEBI', array(['34992'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002501', 'MONDO_0005180', 'MONDO_0004976', 'EFO_0000630',
       'EFO_1000158', 'EFO_0000474', 'EFO_0000519', 'EFO_0002499'],
      dtype=object), 'count': 8}_|_[ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL1162,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C_|_VIKNJXKGJWUCNN-XGXHKTLJSA-N_|_Small molecule_|_True_|_NORETHINDRONE_|_1962.0_|_4.0_|_nan_|_False_|_True_|_['Aygestin' 'Camila' 'Errin' 'Heather' 'Incassia' 'Jencycla' 'Menzol'
 'Micronor' 'Micronor hrt' 'Nor-qd' 'Norethidrone' 'Norethindrone'
 'Noriday' 'Norlutin' 'Primolut n' 'Utovlan']_|_['Activella' 'Anovule' 'Aygestin' 'Calluna vulgaris'
 'Calluna vulgaris whole' 'Combipatch' 'Femhrt' 'Gestest' 'Heather whole'
 'NSC-9564' 'Norethindrone' 'Norethisteron' 'Norethisterone'
 'Norethisteronum' 'Norlutate' 'SC-4640' 'Triella']_|_[('DailyMed', array(['norethindrone'], dtype=object)), ('PubChem', array(['144204875', '144212744', '170464683', '49647479'], dtype=object)), ('Wikipedia', array(['Norethisterone'], dtype=object)), ('drugbank', array(['DB00717'], dtype=object)), ('chEBI', array(['7627'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0002687', 'HP_0100607', 'EFO_0003929',
       'EFO_0008520', 'GO_0042697', 'EFO_0001065', 'EFO_0003843',
       'EFO_0004714', 'EFO_0000616', 'EFO_0008522', 'EFO_0009006',
       'EFO_0003047'], dtype=object), 'count': 13}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and has 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200470,"COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.[Na+]_|_RYXPMWYHEBGTRV-JIDHJSLPSA-N_|_Small molecule_|_False_|_ESOMEPRAZOLE SODIUM_|_2005.0_|_4.0_|_CHEMBL1201320_|_False_|_True_|_['Esomeprazole sodium' 'Nexium iv']_|_['Esomeprazole (as sodium)' 'Esomeprazole sodium' 'H199/18 SODIUM']_|_[('DailyMed', array(['esomeprazole%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004247', 'EFO_0003948', 'EFO_0004607'], dtype=object), 'count': 3}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for gastroesophageal reflux disease and duodenal ulcer and has 1 investigational indication."
CHEMBL1200599,"Cl.N#CC(CCN1CCC(C(=O)O)(c2ccccc2)CC1)(c1ccccc1)c1ccccc1_|_VMIZTXDGZPTKIK-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIFENOXIN HYDROCHLORIDE_|_1978.0_|_4.0_|_CHEMBL1201321_|_False_|_True_|_[]_|_['Difenoxin hcl' 'Difenoxine hydrochloride' 'R 15,403' 'R-15403']_|_[('DailyMed', array(['difenoxin%20hydrochloride'], dtype=object)), ('chEBI', array(['59790'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1978."
CHEMBL1200877,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C_|_JWRMHDSINXPDHB-OJAGFMMFSA-N_|_Small molecule_|_False_|_FLUMETHASONE PIVALATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Locorten' 'Locorten-vioform']_|_['Flumetasone pivalate' 'Flumethasone 21-pivalate' 'Flumethasone pivalate'
 'NSC-107680']_|_[('PubChem', array(['56423133', '855730'], dtype=object)), ('chEBI', array(['31620'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201006,"COc1ccc(CN(CCN(C)C)c2ccccn2)cc1.O=C(O)/C=C\C(=O)O_|_JXYWFNAQESKDNC-BTJKTKAUSA-N_|_Small molecule_|_False_|_PYRILAMINE MALEATE_|_1973.0_|_4.0_|_CHEMBL511_|_False_|_True_|_['Pyrilamine maleate']_|_['Antamine' 'Anthisan' 'Dorantamin' 'Enrumay' 'Histalon' 'Histan'
 'Histapyran' 'Histatex' 'Mepyramine maleate' 'NSC-3604' 'Neo-antergan'
 'Paraminyl' 'Parmal' 'Pyramal' 'Pyrilamine maleate' 'Stamine' 'Stangen'
 'Thylogen']_|_[('PubChem', array(['144207712', '26747601', '26747602', '50106737', '50106738',
       '50106739', '56422415', '855902', '93576628'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003956'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973 and is indicated for seasonal allergic rhinitis."
CHEMBL1231160,"NS(=O)(=O)OC[C@@H]1C[C@@H](n2ccc3c(N[C@H]4CCc5ccccc54)ncnc32)C[C@@H]1O_|_MPUQHZXIXSTTDU-QXGSTGNESA-N_|_Small molecule_|_False_|_PEVONEDISTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MLN 4924' 'MLN-4924' 'MLN-4924003' 'MLN4924' 'Pevonedistat']_|_[('drugbank', array(['DB11759'], dtype=object))]_|_['CHEMBL2364622']_|_{'rows': array(['EFO_0000403', 'EFO_0001378', 'EFO_0000182', 'EFO_0003060',
       'EFO_0000220', 'MONDO_0004992', 'EFO_0002617', 'EFO_0000588',
       'EFO_0000616', 'EFO_0000222', 'EFO_0000198', 'EFO_1001961',
       'EFO_1001779'], dtype=object), 'count': 13}_|_[ENSG00000144744,ENSG00000159593]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL1290,"CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1_|_KQXKVJAGOJTNJS-HNNXBMFYSA-N_|_Small molecule_|_False_|_PENBUTOLOL_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Levatol' 'Penbutolol']_|_[('Wikipedia', array(['Penbutolol'], dtype=object)), ('drugbank', array(['DB01359'], dtype=object)), ('chEBI', array(['7954'], dtype=object))]_|_['CHEMBL1200363' 'CHEMBL2361370']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for cardiovascular disease."
CHEMBL16,"O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1_|_CXOFVDLJLONNDW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENYTOIN_|_1953.0_|_4.0_|_nan_|_False_|_True_|_['Dilabid' 'Dilantin' 'Dilantin-125' 'Dilantin-30' 'Diphenylhydantoin'
 'Hydantol' 'Phentytoin' 'Phenytoin']_|_['Diphenylhydantoin' 'Epamin' 'Lepitoin' 'NSC-8722' 'Phenytek' 'Phenytex'
 'Phenytoin' 'Phenytoinum' 'SM-88 COMPONENT PHENYTOIN' 'Zentropil']_|_[('DailyMed', array(['phenytoin'], dtype=object)), ('PubChem', array(['11111069', '11532994', '124879886', '124886706', '144204412',
       '144209497', '144210601', '170464785', '17389903', '26753026',
       '26753027', '26753028', '50106148', '56423134', '85230999',
       '90340679', '90341165'], dtype=object)), ('TG-GATEs', array(['26'], dtype=object)), ('Wikipedia', array(['Phenytoin'], dtype=object)), ('drugbank', array(['DB00252'], dtype=object)), ('chEBI', array(['8107'], dtype=object))]_|_['CHEMBL3274483' 'CHEMBL553532' 'CHEMBL1611' 'CHEMBL3786353'
 'CHEMBL4764504']_|_{'rows': array(['EFO_0007405', 'EFO_0005230', 'EFO_0000565', 'EFO_0000474',
       'EFO_0002618', 'EFO_0004272', 'EFO_1001996', 'MONDO_0002050',
       'MONDO_0005090', 'HP_0001250', 'EFO_0000174', 'EFO_0000621',
       'EFO_0000546', 'EFO_0000474', 'HP_0001250', 'HP_0000726',
       'EFO_0009562', 'EFO_0000574', 'EFO_0000540', 'MONDO_0011382',
       'EFO_0002610'], dtype=object), 'count': 21}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for epilepsy and seizure and has 17 investigational indications."
CHEMBL1695,"Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C.Cl_|_YUKARLAABCGMCN-PKLMIRHRSA-N_|_Small molecule_|_False_|_TIAGABINE HYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL1027_|_False_|_True_|_['Gabitril' 'Tiagabine hydrochloride']_|_['ABBOTT-70569 HYDROCHLORIDE' 'ABBOTT-70569.1' 'ABBOTT-70569.HCL'
 'ABBOTT-705691' 'ABT-569' 'Abbott-70569' 'Abbott-70569.1' 'Gabatril'
 'NNC-05-0328' 'NNC-050328' 'NO-05-0328' 'NO-050328' 'Tiagabine hcl'
 'Tiagabine hydrochloride']_|_[('DailyMed', array(['tiagabine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205798', '170465153', '49681547'], dtype=object)), ('chEBI', array(['85388'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001892', 'HP_0001250', 'EFO_0005230'], dtype=object), 'count': 3}_|_[ENSG00000157103]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for seizure and has 2 investigational indications."
CHEMBL1743058,"nan_|_nan_|_Antibody_|_False_|_PONEZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-04360365' 'Ponezumab' 'RN-1219']_|_nan_|_nan_|_{'rows': array(['EFO_0006790', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2103837,"O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1_|_TXEIIPDJKFWEEC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAFAMIDIS_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Vyndamax' 'Vyndaqel']_|_['FX-1005' 'FX-1006' 'FX1006' 'Tafamidis']_|_[('DailyMed', array(['tafamidis'], dtype=object)), ('drugbank', array(['DB11644'], dtype=object)), ('chEBI', array(['78538'], dtype=object))]_|_['CHEMBL2105675']_|_{'rows': array(['EFO_1001875', 'EFO_0009562', 'EFO_0000318', 'EFO_0000318',
       'MONDO_0019438', 'EFO_0004129', 'EFO_0004129', 'EFO_1001875'],
      dtype=object), 'count': 8}_|_[ENSG00000118271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 3 investigational indications."
CHEMBL2105722,"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C_|_KZUIYQJTUIACIG-YBZCJVABSA-N_|_Small molecule_|_False_|_NOMEGESTROL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Nomegestrol']_|_[('drugbank', array(['DB11636'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL2108567,"nan_|_nan_|_Antibody_|_False_|_TANEZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PF-04383119' 'PF-4383119' 'RN-624' 'RN624' 'Tanezumab']_|_nan_|_nan_|_{'rows': array(['EFO_1000786', 'EFO_1000869', 'EFO_0000342', 'EFO_0004616',
       'MONDO_0041052', 'HP_0001945', 'HP_0003419', 'EFO_0003830',
       'EFO_1000783', 'MONDO_0005178', 'HP_0012532', 'EFO_0001065',
       'EFO_0003843'], dtype=object), 'count': 13}_|_[ENSG00000134259]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL2218917,"CC1OC2(CS1)CN1CCC2CC1.Cl.O_|_JKJRNPOQQPBPOV-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEVIMELINE HYDROCHLORIDE_|_2000.0_|_4.0_|_CHEMBL168815_|_False_|_True_|_['Cevimeline' 'Cevimeline hydrochloride' 'Evoxac']_|_['AF-102B' 'AF102B' 'Cevimeline hcl' 'Cevimeline hydrochloride'
 'Cevimeline hydrochloride hemihydrate' 'Cevimeline hydrochloride hydrate'
 'FKS-508' 'SND-5008' 'SNI-2011' 'SNK-508' 'Saligren']_|_[('DailyMed', array(['cevimeline%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009869'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for xerostomia."
CHEMBL23293,"CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O_|_WUILNKCFCLNXOK-CFBAGHHKSA-N_|_Small molecule_|_False_|_SALIRASIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FTS' 'Salirasib']_|_[('PubChem', array(['11111197', '50106301', '50106302', '520931', '85231054'],
      dtype=object)), ('drugbank', array(['DB12681'], dtype=object))]_|_nan_|_nan_|_[ENSG00000174775,ENSG00000213281,ENSG00000133703]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL256997,"O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1_|_OOUGLTULBSNHNF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ATALUREN_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Translarna']_|_['Ataluren' 'PTC-124' 'PTC124' 'Translarna']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/translarna'],
      dtype=object)), ('PubChem', array(['144206184', '170466862', '85852879', '87334013', '99460885'],
      dtype=object)), ('Wikipedia', array(['Ataluren'], dtype=object)), ('drugbank', array(['DB05016'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'MONDO_0010602', 'MONDO_0010679', 'MONDO_0019172',
       'MONDO_0010311', 'MONDO_0010604', 'EFO_0000474'], dtype=object), 'count': 7}_|_[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for duchenne muscular dystrophy and becker muscular dystrophy and has 5 investigational indications."
CHEMBL3039515,"CCCCC1(CCCC)CN(c2ccccc2)c2cc(SC)c(OCC(=O)N[C@@H](C(=O)NCC(=O)O)c3ccccc3)cc2S(=O)(=O)C1_|_XFLQIRAKKLNXRQ-UUWRZZSWSA-N_|_Small molecule_|_False_|_ELOBIXIBAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-3309' 'A3309' 'AZD-7806' 'AZD7806' 'Elobixibat']_|_[('drugbank', array(['DB12486'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001249', 'Orphanet_309005', 'HP_0002019'], dtype=object), 'count': 3}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3137351,"nan_|_nan_|_Antibody_|_False_|_ABRILUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 181' 'AMG-181' 'Abrilumab' 'MEDI-7183' 'MEDI7183']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}_|_[ENSG00000115232,ENSG00000139626]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3301607,"O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1_|_RIJLVEAXPNLDTC-UHFFFAOYSA-N_|_Small molecule_|_False_|_FILGOTINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Filgotinib' 'G-146034' 'G146034' 'GLPG0634' 'GS-6034 FREE BASE'
 'Glpg-0634']_|_[('drugbank', array(['DB14845'], dtype=object))]_|_['CHEMBL3301602' 'CHEMBL4298167']_|_{'rows': array(['EFO_0003086', 'EFO_0003767', 'EFO_0003834', 'EFO_0000699',
       'MONDO_0007915', 'EFO_0003778', 'EFO_0000384', 'EFO_0000729',
       'EFO_0000685', 'EFO_1001231', 'EFO_0000685', 'EFO_0003898',
       'EFO_0000540'], dtype=object), 'count': 13}_|_[ENSG00000105397,ENSG00000096968,ENSG00000105639,ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for rheumatoid arthritis and immune system disease and has 11 investigational indications."
CHEMBL3707375,"CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F_|_JVCPIJKPAKAIIP-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMISELIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['2240442' 'Amiselimod']_|_nan_|_['CHEMBL3707374']_|_{'rows': array(['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000729',
       'EFO_0000384', 'MONDO_0007915'], dtype=object), 'count': 6}_|_[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3990032,"nan_|_nan_|_Antibody drug conjugate_|_False_|_TELISOTUZUMAB VEDOTIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABBV-399' 'ABT-399' 'Abbv 399' 'Abt-700-vcmmae' 'PR-1420682'
 'Telisotuzumab vedotin']_|_nan_|_nan_|_{'rows': array(['EFO_0000708', 'EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000105976,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL414357,"CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O_|_HTQBXNHDCUEHJF-XWLPCZSASA-N_|_Protein_|_True_|_EXENATIDE_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Bydureon' 'Bydureon bcise' 'Bydureon pen' 'Byetta']_|_['AC 2993' 'AC-002993' 'AC-2993' 'AC-2993A' 'AC-2993LAR' 'AC002993'
 'AC2993' 'AC2993A' 'DA-3091' 'EXENDIN-4' 'Exenatide'
 'Exenatide Synthetic' 'Exenatide synthetic' 'Exendin 4' 'ITCA-650'
 'LY-2148568' 'LY2148568']_|_[('DailyMed', array(['exenatide%20synthetic'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003095', 'EFO_0001645', 'MONDO_0005147', 'HP_0002140',
       'HP_0000083', 'EFO_0001073', 'EFO_1001050', 'EFO_0007318',
       'EFO_0004319', 'EFO_0001074', 'HP_0001824', 'EFO_0008493',
       'EFO_0000712', 'EFO_0008583', 'MONDO_0005148', 'MONDO_0007079',
       'EFO_0000400', 'EFO_1001121', 'EFO_0002610', 'EFO_0000612',
       'EFO_0000660', 'MONDO_0005180', 'HP_0003074'], dtype=object), 'count': 23}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL42,"CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1_|_QZUDBNBUXVUHMW-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLOZAPINE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Clozapine' 'Clozaril' 'Fazaclo odt' 'Versacloz' 'Zaponex']_|_['Clozapine' 'Clozapine (caraco)' 'Clozapine (clozaril)'
 'Clozapine (fazaclo)' 'Clozapine (ivax)' 'Clozapine (mylan)'
 'Clozapine (teva)' 'Clozapine (udl)' 'Clozapine (versacloz)'
 'Clozapine resolution mixture' 'HF 1854' 'HF-1854' 'Leponex' 'NSC-757429']_|_[('DailyMed', array(['clozapine'], dtype=object)), ('PubChem', array(['104171134', '11110967', '11110968', '11113341', '124879684',
       '124879686', '124879688', '124879690', '124879691', '144203664',
       '170464853', '26747001', '26751524', '50104084', '50104086',
       '56422144', '85230974', '855811', '90341777'], dtype=object)), ('Wikipedia', array(['Clozapine'], dtype=object)), ('drugbank', array(['DB00363'], dtype=object)), ('chEBI', array(['3766'], dtype=object))]_|_['CHEMBL538973']_|_{'rows': array(['EFO_0005407', 'EFO_0005230', 'MONDO_0004985', 'HP_0000726',
       'EFO_0003852', 'MONDO_0005090', 'MONDO_0002050', 'HP_0001249',
       'EFO_0005411'], dtype=object), 'count': 9}_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297852,"nan_|_nan_|_Protein_|_False_|_CENEGERMIN_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Oxervate']_|_['Cenegermin' 'Cenegermin bkbj']_|_[('DailyMed', array(['cenegermin-bkbj'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'EFO_0003966', 'EFO_0009449'], dtype=object), 'count': 3}_|_[ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for eye disease and keratitis and has 1 investigational indication."
CHEMBL4297877,"nan_|_nan_|_Antibody_|_False_|_BALSTILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AGEN-2034' 'AGEN2034' 'Agen2034' 'Balstilimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BALSTILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000294', 'EFO_1001931', 'EFO_0004142', 'EFO_0003968',
       'MONDO_0002974', 'EFO_0002618', 'MONDO_0008170', 'EFO_0001668',
       'MONDO_0011962', 'EFO_0000756', 'EFO_1001968', 'EFO_0000616',
       'EFO_1001951', 'EFO_1000026', 'MONDO_0005184', 'EFO_0003060',
       'EFO_0000574'], dtype=object), 'count': 17}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL443684,"CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1_|_JLYAXFNOILIKPP-KXQOOQHDSA-N_|_Small molecule_|_False_|_NAVITOCLAX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-855071.0' 'ABT-263' 'Navitoclax']_|_[('drugbank', array(['DB12340'], dtype=object))]_|_['CHEMBL2105690']_|_{'rows': array(['EFO_0000198', 'MONDO_0008315', 'MONDO_0000873', 'EFO_1001469',
       'MONDO_0008170', 'EFO_0000220', 'EFO_0004251', 'EFO_0000616',
       'EFO_0000095', 'EFO_0000702', 'EFO_0000403', 'EFO_0000222',
       'EFO_0001642', 'EFO_0003060', 'MONDO_0004992', 'EFO_0002430'],
      dtype=object), 'count': 16}_|_[ENSG00000171552,ENSG00000258643,ENSG00000129473,ENSG00000171791]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 16 investigational indications."
CHEMBL456,"C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl_|_AVOLMBLBETYQHX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETHACRYNIC ACID_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Edecrin' 'Ethacrynic acid' 'Hydromedin' 'Reomax']_|_['Etacrynic acid' 'Ethacrynate' 'Ethacrynic acid' 'MK-595' 'NSC-624008'
 'NSC-85791']_|_[('DailyMed', array(['ethacrynic%20acid'], dtype=object)), ('PubChem', array(['104171276', '11112144', '122995', '124881977', '124881979',
       '144203886', '144208300', '170465426', '17389016', '26746983',
       '26746984', '50100377', '855762', '92763949'], dtype=object)), ('Wikipedia', array(['Etacrynic_acid'], dtype=object)), ('drugbank', array(['DB00903'], dtype=object)), ('chEBI', array(['4876'], dtype=object))]_|_['CHEMBL1200487']_|_{'rows': array(['EFO_1001134', 'MONDO_0001187', 'EFO_0004255', 'EFO_0000319',
       'EFO_0009690', 'MONDO_0005041', 'EFO_0001422', 'EFO_0000373'],
      dtype=object), 'count': 8}_|_[ENSG00000074803]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 6 approved and 2 investigational indications."
CHEMBL4650522,"nan_|_nan_|_Unknown_|_False_|_ORN-0829 HYDRATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ORN-0829 HYDRATE' 'ORN0829 HYDRATE' 'Orn-0829 hydrate' 'Ts-142']_|_nan_|_nan_|_{'rows': array(['EFO_0003918', 'EFO_0001421', 'EFO_0004698'], dtype=object), 'count': 3}_|_[ENSG00000137252,ENSG00000121764]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL5314391,"CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1_|_DMQYDVBIPXAAJA-VHXPQNKSSA-N_|_Small molecule_|_False_|_XL-999_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['XL-999' 'Xl 999' 'Xl-999']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0000222', 'EFO_0000681', 'EFO_0003060',
       'MONDO_0008170', 'MONDO_0004992', 'EFO_0001378'], dtype=object), 'count': 7}_|_[ENSG00000122025,ENSG00000157404,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL723,"COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12_|_OGHNVEJMJSYVRP-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARVEDILOL_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Carvedilol' 'Coreg' 'Coreg CR' 'Eucardic 12.5' 'Eucardic 25'
 'Eucardic 3.125' 'Eucardic 6.25']_|_['BM 14.190' 'BM-14-190' 'BM-14.190' 'BM-14190' 'C07AG02' 'Carvedilol'
 'Coronis' 'DQ-2466' 'Dilatrend' 'Dimitone' 'Eucardic' 'Korvasan' 'Kredex'
 'NSC-758694' 'SKF-105517' 'Talliton']_|_[('DailyMed', array(['carvedilol'], dtype=object)), ('PubChem', array(['26719722', '26719723', '50112972', '50112973', '90341342'],
      dtype=object)), ('Wikipedia', array(['Carvedilol'], dtype=object)), ('drugbank', array(['DB01136'], dtype=object)), ('chEBI', array(['3441'], dtype=object))]_|_['CHEMBL1201167' 'CHEMBL1437006']_|_{'rows': array(['MONDO_0001134', 'EFO_0002610', 'EFO_0003896', 'EFO_0000612',
       'EFO_0004264', 'EFO_0001378', 'EFO_0000537', 'EFO_0000373',
       'EFO_0000275', 'EFO_0000666', 'HP_0003124', 'EFO_0000612',
       'MONDO_0008315', 'EFO_0003913', 'EFO_0009545', 'EFO_0000537',
       'EFO_0000373', 'EFO_0001358', 'EFO_0003144', 'MONDO_0005149',
       'EFO_0003086', 'EFO_0000222', 'EFO_0004289', 'EFO_0000318',
       'EFO_0000319', 'EFO_0001645', 'EFO_0003914', 'EFO_0000474',
       'MONDO_0007254', 'MONDO_0004992', 'MONDO_0005148', 'EFO_0000519',
       'HP_0001943', 'EFO_0001361'], dtype=object), 'count': 34}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 27 investigational indications."
CHEMBL833,"Clc1ccccc1CN1CCc2sccc2C1_|_PHWBOXQYWZNQIN-UHFFFAOYSA-N_|_Small molecule_|_True_|_TICLOPIDINE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ticlopidin-puren' 'Ticlopidine']_|_[('PubChem', array(['104171328', '11112786', '124882626', '144204209', '170464698',
       '26751617', '50085878'], dtype=object)), ('TG-GATEs', array(['146'], dtype=object)), ('Wikipedia', array(['Ticlopidine'], dtype=object)), ('drugbank', array(['DB00208'], dtype=object)), ('chEBI', array(['9588'], dtype=object))]_|_['CHEMBL1717']_|_{'rows': array(['HP_0004419', 'EFO_0000712', 'EFO_0004265', 'MONDO_0000831',
       'EFO_0002615'], dtype=object), 'count': 5}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1078685,"N#Cc1cc(-c2n[nH]c(-c3ccncc3)n2)ccn1_|_UBVZQGOVTLIHLH-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOPIROXOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FYX-051' 'Topiroxostat']_|_[('drugbank', array(['DB01685'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'EFO_0009104'], dtype=object), 'count': 2}_|_[ENSG00000158125]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1200434,"C[N+](C)(C)CCO.Cn1c(=O)c2[n-]cnc2n(C)c1=O_|_RLANKEDHRWMNRO-UHFFFAOYSA-M_|_Small molecule_|_False_|_OXTRIPHYLLINE_|_1981.0_|_4.0_|_CHEMBL190_|_False_|_True_|_['Choledyl' 'Choledyl sa' 'Oxtriphylline' 'Oxtriphylline pediatric'
 'Sabidal']_|_['Choline theophyllinate' 'Choline theophylline' 'Cholinophyllin'
 'NSC-760431' 'Oxtriphylline' 'Theocolin']_|_[('DrugCentral', array(['4390'], dtype=object)), ('Wikipedia', array(['Choline_theophyllinate'], dtype=object)), ('drugbank', array(['DB01303'], dtype=object))]_|_nan_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000172572,ENSG00000152270,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for airway obstruction."
CHEMBL1201227,"OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1_|_SWRUZBWLEWHWRI-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCRIMINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cycrimine']_|_[('Wikipedia', array(['Cycrimine'], dtype=object)), ('drugbank', array(['DB00942'], dtype=object)), ('chEBI', array(['59692'], dtype=object))]_|_['CHEMBL1200828']_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201355,"CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O_|_YRALAIOMGQZKOW-HYAOXDFASA-N_|_Protein_|_False_|_CERULETIDE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Caerulein' 'Cerulein' 'Ceruletide']_|_[('Wikipedia', array(['Ceruletide'], dtype=object)), ('drugbank', array(['DB00403'], dtype=object)), ('chEBI', array(['59219'], dtype=object))]_|_['CHEMBL1200755']_|_nan_|_[ENSG00000163394]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201580,"nan_|_nan_|_Antibody_|_True_|_ADALIMUMAB_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Amgevita' 'Humira']_|_['AVT-02' 'Abp-501' 'Abrilada' 'Adalimumab' 'Adalimumab (abbvie)'
 'Adalimumab (genetical recombination)' 'Adalimumab (humira)'
 'Adalimumab aacf' 'Adalimumab adaz' 'Adalimumab adbm' 'Adalimumab afzb'
 'Adalimumab aqvh' 'Adalimumab atto' 'Adalimumab beta'
 'Adalimumab biosimilar (alvotech)' 'Adalimumab biosimilar (amgen)'
 'Adalimumab biosimilar (avt02)' 'Adalimumab biosimilar (celltrion)'
 'Adalimumab biosimilar (ct-p17)' 'Adalimumab biosimilar (fkb-327)'
 'Adalimumab biosimilar (msb11022)' 'Adalimumab biosimilar (mylan)'
 'Adalimumab biosimilar (pfizer)' 'Adalimumab biosimilar (sandoz)'
 'Adalimumab biosimilar (yusimry)' 'Adalimumab biosimilar (zrc-3197)'
 'Adalimumab bwwd' 'Adalimumab fkjp' 'Adalimumab-aacf' 'Adalimumab-aaty'
 'Adalimumab-adaz' 'Adalimumab-adbm' 'Adalimumab-afzb' 'Adalimumab-aqvh'
 'Adalimumab-atto' 'Adalimumab-bwwd' 'Adalimumab-fkjp' 'Amjevita'
 'Amsparity' 'Avt02' 'BI695501' 'Bcd-057' 'Bi 695501' 'Bi-695501' 'CT-P17'
 'Chs-1420' 'Cyltezo' 'D2E7' 'Exemptia' 'FKB-327' 'FKB327' 'GP2017'
 'Gp-2017' 'HLX-03' 'HLX03' 'Hadlima' 'Hulio' 'Hyrimoz' 'Idacio'
 'LU-200134' 'LU200134' 'M-923' 'M923' 'MSB-11022' 'MSB11022' 'Ons-3010'
 'Pf-06410293' 'Trudexa' 'Yuflyma' 'Yusimry' 'ZRC-3197' 'ZRC3197']_|_[('DailyMed', array(['adalimumab'], dtype=object)), ('DrugCentral', array(['4904'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita'],
      dtype=object)), ('Wikipedia', array(['Adalimumab'], dtype=object))]_|_nan_|_{'rows': array(['MP_0001845', 'EFO_0003780', 'EFO_0000685', 'EFO_0003898',
       'EFO_1001209', 'MONDO_0009735', 'MONDO_0002108', 'EFO_0008507',
       'MONDO_0100096', 'EFO_0003872', 'MONDO_0019338', 'MONDO_0009661',
       'HP_0011868', 'EFO_0000729', 'EFO_0004616', 'EFO_0002609',
       'HP_0000999', 'EFO_0004236', 'MONDO_0010674', 'MONDO_0004979',
       'EFO_0000540', 'MONDO_0005178', 'EFO_1001231', 'EFO_0000676',
       'EFO_0000384', 'EFO_0004229', 'EFO_1000710', 'EFO_0003767',
       'EFO_0003778', 'EFO_0004683', 'EFO_1000941', 'EFO_0005856'],
      dtype=object), 'count': 32}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 9 approved and 23 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1277072,"Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2_|_MCTXSDCWFQAGFS-UEXNTNOUSA-N_|_Small molecule_|_False_|_HENATINIB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Henatinib']_|_[('drugbank', array(['DB13019'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1366933,"CN1CCN2c3ncccc3Cc3ccccc3[C@H]2C1_|_RONZAEMNMFQXRA-MRXNPFEDSA-N_|_Small molecule_|_False_|_ESMIRTAZAPINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(s)-6-azamianserin' '(s)-mirtazapine' '(s)-org 3770' 'Esmirtazapine'
 'Mirtazapine, (s)-' 'ORG-44-20']_|_[('PubChem', array(['11114267'], dtype=object)), ('drugbank', array(['DB06678'], dtype=object))]_|_['CHEMBL2107339']_|_{'rows': array(['EFO_0004698', 'EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 3}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000196639,ENSG00000147246,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1464,"CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O_|_PJVWKTKQMONHTI-UHFFFAOYSA-N_|_Small molecule_|_True_|_WARFARIN_|_1954.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-59813' 'Warfarin']_|_[('PubChem', array(['144206736', '144209380', '144210849', '174006926', '26748308',
       '26754489'], dtype=object)), ('Wikipedia', array(['Warfarin'], dtype=object)), ('drugbank', array(['DB00682'], dtype=object)), ('chEBI', array(['87732'], dtype=object))]_|_['CHEMBL1200879' 'CHEMBL1200772']_|_{'rows': array(['EFO_0000275', 'HP_0004419', 'EFO_0003764', 'EFO_0006911',
       'EFO_0003875', 'EFO_0002950', 'HP_0004936', 'EFO_0000685',
       'EFO_0003929', 'EFO_0004286', 'EFO_0002689', 'EFO_0003827',
       'MONDO_0002009', 'EFO_0000275', 'EFO_0000319', 'EFO_1001161',
       'HP_0001907', 'EFO_0004616', 'EFO_0003911', 'EFO_0000274',
       'EFO_0000712', 'EFO_0003907', 'EFO_0000574', 'EFO_0004277',
       'EFO_0000612', 'EFO_0009708', 'EFO_1001249', 'HP_0002140',
       'EFO_0000612', 'EFO_0001073', 'HP_0001907', 'EFO_0004239',
       'HP_0004936', 'EFO_0003914', 'EFO_0000384', 'HP_0004936',
       'MONDO_0008315', 'EFO_0000616', 'EFO_0000712', 'HP_0004418',
       'EFO_0000685', 'EFO_0001422', 'MONDO_0001134', 'EFO_0004211',
       'MONDO_0004992', 'EFO_0001361', 'EFO_0003907', 'EFO_0000673',
       'EFO_0003777', 'EFO_0000275', 'MP_0001914', 'MONDO_0005149',
       'EFO_0000756', 'EFO_0000266', 'MONDO_0005180', 'EFO_0003144',
       'HP_0001907', 'EFO_0000474', 'EFO_0000400', 'EFO_0000768',
       'MONDO_0000831', 'MONDO_0004975', 'EFO_0000676', 'EFO_1000781',
       'HP_0001873', 'EFO_0000729', 'MONDO_0002679', 'EFO_1001375',
       'EFO_0001642', 'EFO_0002618', 'MONDO_0005148', 'EFO_0003827'],
      dtype=object), 'count': 72}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and has 9 approved and 60 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1643,"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1_|_IWUCXVSUMQZMFG-AFCXAGJDSA-N_|_Small molecule_|_True_|_RIBAVIRIN_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Copegus' 'Rebetol' 'Ribapak' 'Ribasphere' 'Ribavarin' 'Ribavirin'
 'Ribofluranosyl Carboxamide' 'Tribavirin' 'Viramid' 'Virazid' 'Virazole']_|_['Cotronak' 'NSC-163039' 'Ribavirin' 'Ribavirin biopartners'
 'Ribavirin mylan' 'Ribavirin teva' 'SCH 18908' 'SCH-18908' 'Tribavirin']_|_[('DailyMed', array(['ribavirin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rebetol'],
      dtype=object)), ('PubChem', array(['144203810', '144208165', '170464657', '17389529', '50105410',
       '50105411', '50105412', '50105413', '8139972', '90341426'],
      dtype=object)), ('Wikipedia', array(['Ribavirin'], dtype=object)), ('drugbank', array(['DB00811'], dtype=object)), ('chEBI', array(['63580'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001422', 'EFO_0000764', 'EFO_0006890', 'EFO_0000616',
       'EFO_0000222', 'MONDO_0100096', 'HP_0001873', 'HP_0012115',
       'EFO_0007299', 'EFO_0004220', 'EFO_0000694', 'EFO_0003047',
       'EFO_0007328', 'EFO_0007338', 'EFO_1001413', 'MONDO_0002050',
       'EFO_0004197', 'EFO_0007332', 'MONDO_0005147', 'MONDO_0007254',
       'EFO_0000544', 'EFO_0004239', 'EFO_0007304', 'EFO_0000763'],
      dtype=object), 'count': 24}_|_[ENSG00000106348]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 4 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1683,"CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_BMCQMVFGOVHVNG-TUFAYURCSA-N_|_Small molecule_|_False_|_HYDROCORTISONE BUTYRATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Hydrocortisone butyrate' 'Locoid' 'Locoid c' 'Locoid crelo'
 'Locoid lipocream']_|_['Cortisol 17-butyrate' 'Hydrocortisone 17-butyrate'
 'Hydrocortisone butyrate' 'Hydrocortisone-17-butyrate' 'NSC-758433']_|_[('DailyMed', array(['hydrocortisone%20butyrate'], dtype=object)), ('PubChem', array(['11533027', '144204950', '170465456', '56422894'], dtype=object)), ('Wikipedia', array(['Hydrocortisone_17-butyrate'], dtype=object)), ('drugbank', array(['DB14540'], dtype=object)), ('chEBI', array(['31674'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000764', 'EFO_1001494', 'EFO_0000701', 'EFO_0000274'],
      dtype=object), 'count': 4}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 approved and 1 investigational indication."
CHEMBL187709,"CCN(CC)CCOc1ccc(C(O)(Cc2ccc(Cl)cc2)c2ccc(C)cc2)cc1_|_SYHDSBBKRLVLFF-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIPARANOL_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['NSC-65345' 'Triparanol']_|_[('PubChem', array(['144205821', '170466640', '29217665', '50111719'], dtype=object))]_|_nan_|_nan_|_[ENSG00000116133]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2180604,"Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1_|_DZFZXPPHBWCXPQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAK-593_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['TAK 593' 'TAK-593' 'Tak-593']_|_[('drugbank', array(['DB13093'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL230158,"CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1_|_JWHYSEDOYMYMNM-QGZVFWFLSA-N_|_Small molecule_|_False_|_SELADELPAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MBX-8025' 'Mbx-8025' 'RWJ-800025' 'Seladelpar']_|_[('drugbank', array(['DB12390'], dtype=object))]_|_['CHEMBL5303479' 'CHEMBL3989960']_|_{'rows': array(['EFO_0004268', 'MONDO_0021187', 'MONDO_0018328', 'EFO_1001249',
       'EFO_0001421', 'EFO_1001486'], dtype=object), 'count': 6}_|_[ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3301627,"CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1.Cl.Cl_|_VFRAXTZDILCRKY-OWRGXFNZSA-N_|_Small molecule_|_True_|_TENAPANOR HYDROCHLORIDE_|_2019.0_|_4.0_|_CHEMBL3304485_|_False_|_True_|_['Ibsrela']_|_['AZD-1722 HYDROCHLORIDE' 'AZD1722' 'AZD1722 hydrochloride' 'RDX-5791'
 'RDX5791' 'Tenapanor dihydrochloride' 'Tenapanor hydrochloride']_|_[('DailyMed', array(['tenapanor%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'MONDO_0002203', 'EFO_0000555', 'HP_0002905'],
      dtype=object), 'count': 4}_|_[ENSG00000066230]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for constipation disorder and irritable bowel syndrome and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545114,nan_|_nan_|_Small molecule_|_False_|_KD3010_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Kd3010']_|_nan_|_nan_|_nan_|_[ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545153,"nan_|_nan_|_Small molecule_|_False_|_DE-104_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['De-104']_|_nan_|_nan_|_{'rows': array(['EFO_1001069', 'EFO_0004190'], dtype=object), 'count': 2}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3707355,"nan_|_nan_|_Small molecule_|_False_|_AZD8108_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Azd8108']_|_nan_|_nan_|_nan_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3707404,"nan_|_nan_|_Antibody_|_False_|_LUMRETUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Lumretuzumab' 'RG-7116' 'RG7116' 'RO-5479599' 'RO5479599']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0003060', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL415049,"CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O_|_GBJVVSCPOBPEIT-UHFFFAOYSA-N_|_Small molecule_|_False_|_BARASERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZD 1152' 'AZD-1152' 'AZD1152' 'Azd-1152' 'Barasertib'
 'Barasertib (who-dd)']_|_[('PubChem', array(['103905346'], dtype=object)), ('drugbank', array(['DB11747'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004643', 'EFO_0000574', 'EFO_0000222'],
      dtype=object), 'count': 4}_|_[ENSG00000178999]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4205783,"Clc1ccc(-c2nn(Cc3ccccc3)c3c2CCNCC3)cc1_|_UKJPMZGILXATGT-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-18038683_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL4297293']_|_{'rows': array(['MONDO_0002009', 'MONDO_0004985'], dtype=object), 'count': 2}_|_[ENSG00000148680]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297245,"nan_|_nan_|_Antibody_|_False_|_DONANEMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Donanemab' 'LY 3002813' 'LY-3002813' 'LY3002813']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DONANEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297399,"O=C(Nc1ncc(SCCN2CCCC2)s1)[C@]1(c2ccc(S(=O)(=O)C3CC3)cc2)C[C@H]1C1CCCCC1_|_QIIVJLHCZUTGSD-CUBQBAPOSA-N_|_Small molecule_|_False_|_LY-2608204_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Globalagliatin' 'LY2608204' 'Ly-2608204' 'Ly2608204' 'Sy-004']_|_[('drugbank', array(['DB12284'], dtype=object))]_|_['CHEMBL5095182']_|_{'rows': array(['MONDO_0005148', 'HP_0003074'], dtype=object), 'count': 2}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297918,"nan_|_nan_|_Antibody_|_False_|_SETRUSUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BPS-804' 'BPS804' 'Bps804' 'MOR05813' 'Setrusumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0019019', 'EFO_0003086', 'MONDO_0018570'], dtype=object), 'count': 3}_|_[ENSG00000167941]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4594557,"nan_|_nan_|_Unknown_|_False_|_EFTILAGIMOD ALFA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Eftilagimod alfa' 'IMP321' 'Immufact' 'Imp321']_|_nan_|_nan_|_{'rows': array(['EFO_0000681', 'MONDO_0007254', 'EFO_0000756', 'EFO_0000389'],
      dtype=object), 'count': 4}_|_[ENSG00000089692]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4802262,"nan_|_nan_|_Gene_|_False_|_ATIDARSAGENE AUTOTEMCEL_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Libmeldy']_|_['Atidarsagene autotemcel' 'OTL-200']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ATIDARSAGENE%20AUTOTEMCEL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018868'], dtype=object), 'count': 1}_|_[ENSG00000100299]_|_Gene drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for metachromatic leukodystrophy."
CHEMBL5095034,"CS(=O)(=O)N1CCC(c2ccc(-c3ncc4nccnc4c3NC[C@@H]3CNCCO3)cc2)CC1_|_BRCHZKBUGSKTND-FQEVSTJZSA-N_|_Small molecule_|_False_|_SOVLEPLENIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['HMPL523' 'Hmpl 523' 'Hmpl-523' 'Sovleplenib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0007160', 'EFO_0000685', 'EFO_0000222',
       'EFO_1001264', 'EFO_0000616', 'MONDO_0004992', 'EFO_0005952'],
      dtype=object), 'count': 8}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL550,"CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C_|_QCHFTSOMWOSFHM-WPRPVWTQSA-N_|_Small molecule_|_False_|_PILOCARPINE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_['Ocusert pilo-20' 'Ocusert pilo-40']_|_['Ocucarpine' 'Pilocarpine' 'Pilocarpinum' 'Pilocarpol' 'Pilokarpin'
 'Spersacarpine' 'Syncarpine']_|_[('PubChem', array(['11113352', '170464845', '26751548', '50104139', '90340957',
       '90341610'], dtype=object)), ('Wikipedia', array(['Pilocarpine'], dtype=object)), ('drugbank', array(['DB01085'], dtype=object)), ('chEBI', array(['8207'], dtype=object))]_|_['CHEMBL2139597' 'CHEMBL1200330' 'CHEMBL1213136']_|_{'rows': array(['EFO_1000906', 'MONDO_0001330', 'EFO_0006859', 'MONDO_0001330',
       'EFO_0004190', 'HP_0000545', 'HP_0000616', 'EFO_0000699',
       'EFO_1001069', 'HP_0000020', 'EFO_0009869', 'MONDO_0005041',
       'MONDO_0001744'], dtype=object), 'count': 13}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 7 approved and 5 investigational indications."
CHEMBL573352,"C#C[C@@]1(O)[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@@H]1O_|_JFIWEPHGRUDAJN-DYUFWOLASA-N_|_Small molecule_|_False_|_TAS-106_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[""2'-C-Ethynylcytidine"" ""3'-C-Ethynylcytidine"" 'Tas 106' 'Tas-106']_|_[('drugbank', array(['DB06656'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0006859'], dtype=object), 'count': 2}_|_[ENSG00000068654,ENSG00000148606,ENSG00000181222]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1106,"NC1=NCC2c3ccccc3Cc3ccccc3N12_|_WHWZLSFABNNENI-UHFFFAOYSA-N_|_Small molecule_|_False_|_EPINASTINE_|_2003.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Elestat' 'Epinastine' 'Purivist' 'WAL-801']_|_[('PubChem', array(['29217549', '50111706', '90340676'], dtype=object)), ('Wikipedia', array(['Epinastine'], dtype=object)), ('drugbank', array(['DB00751'], dtype=object)), ('chEBI', array(['51032'], dtype=object))]_|_['CHEMBL1200491']_|_{'rows': array(['EFO_0003956', 'EFO_0005854', 'EFO_1001417', 'EFO_0005751',
       'EFO_0007141', 'MONDO_0005271'], dtype=object), 'count': 6}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 3 investigational indications."
CHEMBL1237104,"CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C.Cl_|_QMQBBUPJKANITL-MYXGOWFTSA-N_|_Small molecule_|_True_|_PROPOXYPHENE HYDROCHLORIDE_|_1957.0_|_4.0_|_CHEMBL1213351_|_True_|_True_|_['Darvon' 'Dolene' 'Doloxene' 'Kesso-gesic' 'Prophene 65'
 'Propoxyphene hydrochloride' 'Propoxyphene hydrochloride 65']_|_['Algaphan' 'Deprancol' 'Dextro propoxyphene hydrochloride'
 'Dextropropoxiphene chloride' 'Dextropropoxyphene'
 'Dextropropoxyphene hydrochloride' 'Femadol' 'Harmar' 'Propoxyphene hcl'
 'Propoxyphene hydrochloride' 'Propoxyphene hydrochloride cii'
 'Proxagesic']_|_[('PubChem', array(['144206413'], dtype=object)), ('chEBI', array(['8498'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for pain. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL127071,"Cc1ncccc1OC[C@@H]1CCCN1_|_YRVIKLBSVVNSHF-JTQLQIEISA-N_|_Small molecule_|_False_|_POZANICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-87089.0' 'A-870890' 'ABT-089' 'Pozanicline']_|_[('Wikipedia', array(['A-84,543'], dtype=object)), ('drugbank', array(['DB05458'], dtype=object))]_|_['CHEMBL2105650']_|_{'rows': array(['EFO_0003768', 'EFO_0003888', 'MONDO_0004975'], dtype=object), 'count': 3}_|_[ENSG00000160716,ENSG00000101204,ENSG00000169684,ENSG00000147434]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1692,"CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl_|_XZZXIYZZBJDEEP-UHFFFAOYSA-N_|_Small molecule_|_True_|_IMIPRAMINE HYDROCHLORIDE_|_1959.0_|_4.0_|_CHEMBL11_|_False_|_True_|_['Imipramine hydrochloride' 'Janimine' 'Pramine' 'Praminil' 'Presamine'
 'Sarimp' 'Tofranil']_|_['G-22355' 'Imidobenzyle' 'Imipramine HCl' 'Imipramine hcl'
 'Imipramine hydrochloride' 'Imipramine hydrochloride rs'
 'Imipramini hydrochloridum' 'Imizine' 'NSC-114900' 'Pryleugan']_|_[('DailyMed', array(['imipramine%20hydrochloride'], dtype=object)), ('PubChem', array(['144211734', '26747552', '26747553', '26751601', '50106516',
       '50106517', '50106518', '56422890', '855555'], dtype=object)), ('chEBI', array(['5882'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'MONDO_0024290', 'MONDO_0002050'], dtype=object), 'count': 3}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for enuresis and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL17860,"CC(Oc1c(Cl)cccc1Cl)C1=NCCN1_|_KSMAGQUYOIHWFS-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOFEXIDINE_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Lofexidine']_|_[('PubChem', array(['170466275'], dtype=object)), ('Wikipedia', array(['Lofexidine'], dtype=object)), ('drugbank', array(['DB04948'], dtype=object)), ('chEBI', array(['51368'], dtype=object))]_|_['CHEMBL1788132']_|_{'rows': array(['EFO_0005800', 'EFO_0003890', 'HP_0001399', 'EFO_0004240',
       'EFO_0010702', 'EFO_0005611', 'EFO_0002610', 'EFO_0007191',
       'EFO_0005611'], dtype=object), 'count': 9}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for substance withdrawal syndrome and drug dependence and has 6 investigational indications."
CHEMBL189171,"COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1_|_FSQKKOOTNAMONP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACEMETACIN_|_nan_|_4.0_|_nan_|_False_|_True_|_['Emflex']_|_['Acemetacin' 'NSC-757413' 'Rantudil']_|_[('PubChem', array(['11112782', '124882621', '144207022', '170466043', '174007220',
       '26746953', '855677'], dtype=object)), ('Wikipedia', array(['Acemetacin'], dtype=object)), ('drugbank', array(['DB13783'], dtype=object)), ('chEBI', array(['31162'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease."
CHEMBL1921904,"C[C@@](C(=O)O[C@H]1C[N+]2(CCc3ccc(F)cc3)CCC1CC2)(c1ccccc1)N1CCCCC1_|_FNYFFCOCVNTJCD-NNMXADRKSA-N_|_Small molecule_|_False_|_AZD-9164_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD9164' 'Azd 9164' 'Azd-9164' 'Azd9164' 'J3.232.015E']_|_[('drugbank', array(['DB12115'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2103828,"CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F_|_LGSDFTPAICUONK-UHFFFAOYSA-N_|_Small molecule_|_False_|_ELINOGREL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Elinogrel' 'PRT 060128' 'PRT-060128' 'Prt060128']_|_[('drugbank', array(['DB06350'], dtype=object))]_|_['CHEMBL2105641']_|_{'rows': array(['EFO_0000612', 'EFO_0003086'], dtype=object), 'count': 2}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2105671,"O=C(O)C(O)C(O)C(=O)O.OC[C@H]1CNC[C@@H](O)[C@@H]1O_|_ULBPPCHRAVUQMC-RWOHWRPJSA-N_|_Small molecule_|_False_|_AFEGOSTAT TARTRATE_|_nan_|_2.0_|_CHEMBL206468_|_False_|_False_|_[]_|_['AT-2101' 'AT2101' 'Afegostat tartrate' 'HGT-3410' 'Isofagomine tartrate'
 'Plicera']_|_nan_|_nan_|_{'rows': array(['MONDO_0018150'], dtype=object), 'count': 1}_|_[ENSG00000177628]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108208,nan_|_nan_|_Protein_|_False_|_LENERCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Lenercept' 'RO 45-2081' 'RO-45-2081' 'Ro-452081']_|_nan_|_nan_|_nan_|_[ENSG00000232810]_|_Protein drug with a maximum clinical trial phase of III.
CHEMBL2109343,"nan_|_nan_|_Antibody_|_False_|_LERONLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Leronlimab' 'PRO 140' 'PRO-140' 'PRO140']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LERONLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0013730', 'MONDO_0100096', 'EFO_0003869', 'EFO_1001951',
       'EFO_0000616', 'EFO_0000764', 'EFO_1001249', 'EFO_0000180'],
      dtype=object), 'count': 8}_|_[ENSG00000160791]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL3184679,"COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1_|_VRQMAABPASPXMW-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-4547_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABSK-091' 'ABSK091' 'AZD-4547' 'Azd 4547' 'Azd-4547' 'Azd4547'
 'KB-74810']_|_[('PubChem', array(['174006594'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000228', 'MONDO_0001056', 'MONDO_0004992', 'EFO_0000707',
       'EFO_0000708', 'MONDO_0007254', 'EFO_0003060', 'EFO_0008528',
       'EFO_0000326', 'EFO_0001378', 'MONDO_0001187'], dtype=object), 'count': 11}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL3261331,"CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O_|_FDBYIYFVSAHJLY-UHFFFAOYSA-N_|_Small molecule_|_False_|_RESMETIROM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MGL-3196' 'Mgl-3196' 'Resmetirom' 'VIA-3196']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RESMETIROM/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12914'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003119', 'HP_0003124', 'EFO_1001249', 'EFO_0004911',
       'EFO_0003095'], dtype=object), 'count': 5}_|_[ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL3301609,"Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1_|_FCRFVPZAXGJLPW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOREFORANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JNJ-38518168' 'Jnj-38518168' 'Toreforant']_|_[('drugbank', array(['DB12522'], dtype=object))]_|_['CHEMBL3301614']_|_{'rows': array(['EFO_0000685', 'EFO_0000685', 'EFO_0000676', 'MONDO_0004979',
       'EFO_0001421'], dtype=object), 'count': 5}_|_[ENSG00000134489]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL345237,"O=C1c2ccccc2OC=C(Cl)N1CCCCN1CC=C(c2ccccn2)CC1_|_URMTUEWUIGOJBW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PICLOZOTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Piclozotan' 'SUN-N-4057' 'Sun-n4057']_|_[('drugbank', array(['DB12361'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0000712'], dtype=object), 'count': 2}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545233,"CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(-c2ccccc2)nc2ccccc12)c1ccccc1_|_QYTBBBAHNIWFOD-NRFANRHFSA-N_|_Small molecule_|_False_|_PAVINETANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZ-12472520' 'AZ12472520' 'AZ124752520' 'AZ4901' 'AZD-4901' 'AZD2624'
 'AZD4901' 'Azd 2624' 'Azd 4901' 'Azd-2624' 'Azd2624' 'MLE-4901' 'MLE4901'
 'Pavinetant']_|_[('drugbank', array(['DB11692'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090', 'HP_0031284', 'EFO_0000660'], dtype=object), 'count': 3}_|_[ENSG00000169836]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3649803,"CCOc1cc(CN2CCOCC2)cc2[nH]c(=O)c3c(c12)NCCC3_|_WBBZUHMHBSXBDT-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMELPARIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL5314421']_|_{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}_|_[ENSG00000143799]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3951811,"CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl_|_BCSHRERPHLTPEE-NRFANRHFSA-N_|_Small molecule_|_False_|_CEP-37440_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Alk-fak inhibitor cep-37440' 'Cep-37440']_|_[('drugbank', array(['DB13060'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000169398,ENSG00000171094]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989977,"nan_|_nan_|_Antibody_|_False_|_EMAPALUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Gamifant']_|_['Emapalumab' 'Emapalumab lzsg' 'NI-0501']_|_[('DailyMed', array(['emapalumab-lzsg'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001806', 'Orphanet_158038', 'MONDO_0100096', 'EFO_0000540',
       'EFO_0007135', 'MONDO_0007915', 'EFO_0004599', 'MONDO_0015540',
       'MONDO_0018305'], dtype=object), 'count': 9}_|_[ENSG00000111537]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications."
CHEMBL3989989,"nan_|_nan_|_Gene_|_True_|_AXICABTAGENE CILOLEUCEL_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Yescarta']_|_['Axicabtagene ciloleucel' 'KTE-C19' 'Yescarta']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001642', 'MONDO_0018906', 'EFO_1001469', 'EFO_0000574',
       'EFO_0000403', 'EFO_0000096'], dtype=object), 'count': 6}_|_[ENSG00000177455]_|_Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL459324,"CC(=O)Oc1ccc2c3c1O[C@H]1[C@@H](OC(C)=O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341_|_GVGLGOZIDCSQPN-PVHGPHFFSA-N_|_Small molecule_|_False_|_DIACETYLMORPHINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Diacetylmorphine' 'IDS-NH-001' 'IDS-NH-001(SECT.3)' 'J6.494G']_|_[('PubChem', array(['144206165'], dtype=object)), ('Wikipedia', array(['Heroin'], dtype=object)), ('drugbank', array(['DB01452'], dtype=object)), ('chEBI', array(['27808'], dtype=object))]_|_['CHEMBL2106627']_|_{'rows': array(['EFO_0003890', 'EFO_0010702', 'EFO_0004240', 'EFO_0005611'],
      dtype=object), 'count': 4}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for drug dependence and has 3 investigational indications."
CHEMBL4594333,"nan_|_nan_|_Gene_|_False_|_ELIVALDOGENE AUTOTEMCEL_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Skysona']_|_['Elivaldogene autotemcel' 'Lenti-D Drug substance']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/skysona'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELIVALDOGENE%20AUTOTEMCEL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_43'], dtype=object), 'count': 1}_|_[ENSG00000101986]_|_Gene drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for x-linked adrenoleukodystrophy."
CHEMBL4650272,"CN1CCN(c2ccc(Nc3ncc4cc5n(c4n3)C3(CCCCC3)CNC5=O)nc2)CC1.Cl.Cl_|_BRCYOXKEDFAUSA-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRILACICLIB DIHYDROCHLORIDE_|_2021.0_|_4.0_|_CHEMBL3894860_|_False_|_True_|_['Cosela']_|_[]_|_nan_|_nan_|_{'rows': array(['EFO_0000702'], dtype=object), 'count': 1}_|_[ENSG00000105810,ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for small cell lung carcinoma."
CHEMBL4802222,"nan_|_nan_|_Unknown_|_False_|_OSTABOLIN-C_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ostabolin-c' 'PTH-1-31 CYCLIC' 'ZT-031' 'Zt-031']_|_nan_|_nan_|_{'rows': array(['EFO_0003964'], dtype=object), 'count': 1}_|_[ENSG00000160801]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL515606,"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@@H](C(=O)O)N2C1=O_|_HHHKFGXWKKUNCY-FHWLQOOXSA-N_|_Small molecule_|_False_|_CILAZAPRIL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Vascace']_|_['Anhydrous cilazapril' 'Cilazapril' 'Cilazapril anhydrous'
 'Cilazapril hydrate' 'Cilazapril monohydrate' 'Cilazaprilum' 'Initiss'
 'Justor' 'RO 31-2848/006' 'RO-312848006']_|_[('PubChem', array(['144206524'], dtype=object)), ('Wikipedia', array(['Cilazapril'], dtype=object)), ('drugbank', array(['DB01340'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."
CHEMBL566315,"CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12_|_ZXERDUOLZKYMJM-ZWECCWDJSA-N_|_Small molecule_|_True_|_OBETICHOLIC ACID_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Ocaliva']_|_['6-ecdca' '6-ethylchenodeoxycholic acid' 'DSP-1747' 'INT-747'
 'Obeticholic acid']_|_[('DailyMed', array(['obeticholic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva'],
      dtype=object)), ('drugbank', array(['DB05990'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001486', 'MONDO_0020088', 'Orphanet_733', 'EFO_1001345',
       'EFO_0004268', 'HP_0002014', 'MONDO_0001751', 'EFO_0001421',
       'EFO_0000280', 'EFO_1001249', 'EFO_0003095', 'EFO_0004267',
       'HP_0030151', 'EFO_0001073', 'HP_0000989'], dtype=object), 'count': 15}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL711,"O=C1c2ccccc2C(=O)C1c1ccccc1_|_NFBAXHOPROOJAW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENINDIONE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Dindevan' 'Hedulin']_|_['Danilone' 'NSC-41693' 'Phenindione' 'Phenylindanedione']_|_[('PubChem', array(['11112218', '11532881', '144203926', '170465130', '26748198',
       '26748199', '50107356', '50107357', '56423141'], dtype=object)), ('Wikipedia', array(['Phenindione'], dtype=object)), ('drugbank', array(['DB00498'], dtype=object)), ('chEBI', array(['8066'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004419', 'EFO_0002950'], dtype=object), 'count': 2}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for recurrent thrombophlebitis and has 1 investigational indication."
CHEMBL85,"Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2_|_RAPZEAPATHNIPO-UHFFFAOYSA-N_|_Small molecule_|_True_|_RISPERIDONE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Okedi' 'Perseris kit' 'Risperdal' 'Risperdal Consta Long Acting'
 'Risperdal M' 'Risperdal M-Tab' 'Risperdal consta' 'Risperdal quicklet'
 'Risperidone']_|_['LY-03004' 'LY03004' 'N05AX08' 'NSC-759895' 'Perseris' 'R 64 766'
 'R-64,766' 'R-64-766' 'R-64766' 'RCN-3028' 'RCN3028' 'Risperidone'
 'Rykindo' 'Uzedy']_|_[('DailyMed', array(['risperidone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/okedi'],
      dtype=object)), ('PubChem', array(['104171228', '11111724', '11111725', '124881313', '124881314',
       '144203804', '170464925', '26719830', '26753640', '49666400',
       '50106974', '50106975', '50123965', '85231208'], dtype=object)), ('Wikipedia', array(['Risperidone'], dtype=object)), ('drugbank', array(['DB00734'], dtype=object)), ('chEBI', array(['8871'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004895', 'EFO_0003852', 'EFO_0003758', 'HP_0000726',
       'EFO_0005407', 'EFO_0003757', 'EFO_0002610', 'EFO_0003015',
       'HP_0001249', 'MONDO_0002009', 'MONDO_0005090', 'EFO_0009963',
       'HP_0010865', 'EFO_0003756', 'MONDO_0002009', 'MONDO_0002050',
       'MONDO_0004985', 'EFO_0004701', 'EFO_0005411', 'EFO_0005230',
       'EFO_0004718', 'EFO_0001358', 'MONDO_0007739', 'Orphanet_79292',
       'EFO_0004242', 'MONDO_0004975', 'EFO_1000904', 'EFO_0003890',
       'EFO_0004216', 'MONDO_0001087', 'EFO_0010642', 'MONDO_0010726',
       'EFO_0005611'], dtype=object), 'count': 33}_|_[ENSG00000102468,ENSG00000147246,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 25 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1016,"CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1_|_HTQMVQVXFRQIKW-UHFFFAOYSA-N_|_Small molecule_|_False_|_CANDESARTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Blopress' 'CV-11974' 'Candemore' 'Candesartan'
 'Candesartan cilexetil related compound g' 'NSC-759858']_|_[('PubChem', array(['144206031', '170466386', '50112728'], dtype=object)), ('Wikipedia', array(['Candesartan'], dtype=object)), ('drugbank', array(['DB13919'], dtype=object)), ('chEBI', array(['3347'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000373', 'MONDO_0005277', 'EFO_0003896',
       'EFO_0002610', 'EFO_0003100', 'MONDO_0100431', 'EFO_0000694',
       'MONDO_0004985', 'MONDO_0005147', 'EFO_0003047', 'MONDO_0005148',
       'EFO_0003144', 'MONDO_0005475', 'EFO_0000407', 'EFO_0000319',
       'EFO_0000275', 'EFO_0000280', 'EFO_0003777', 'MONDO_0001134',
       'EFO_0004701', 'MONDO_0002491', 'EFO_0008573', 'EFO_0000538',
       'HP_0100543', 'EFO_0000537', 'EFO_0000266'], dtype=object), 'count': 27}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 27 investigational indications."
CHEMBL1084173,"O=C(O)/C(=C/c1ccccc1)c1ccccc1.OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O_|_KAMFDHLRBHTIMJ-AZDLLSQWSA-N_|_Small molecule_|_False_|_VILANTEROL .ALPHA.-PHENYL CINNAMATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW-642444H' 'GW642444H' 'Gw642444h'
 'Vilanterol .alpha.-phenyl cinnamate']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200799,"CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O_|_MKPLKVHSHYCHOC-AHTXBMBWSA-N_|_Small molecule_|_False_|_TRAVOPROST_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Izba' 'Travatan' 'Travatan z' 'Travoprost']_|_['AL-6221' 'NSC-760366' 'Otx-tp' 'Travoprost']_|_[('DailyMed', array(['travoprost'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/travatan'],
      dtype=object)), ('Wikipedia', array(['Travoprost'], dtype=object)), ('drugbank', array(['DB00287'], dtype=object)), ('chEBI', array(['746859'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001069', 'EFO_0004190', 'EFO_0004235', 'MONDO_0005041'],
      dtype=object), 'count': 4}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 1 investigational indication."
CHEMBL1201642,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP PROMPT BEEF_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Semilente insulin']_|_['Insulin zinc susp prompt beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201729,"CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1.Cl_|_DWKVCQXJYURSIQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_DRONEDARONE HYDROCHLORIDE_|_2009.0_|_4.0_|_CHEMBL184412_|_False_|_True_|_['Multaq']_|_['Dronedarone hcl' 'Dronedarone hydrochloride' 'SR-33598B' 'SR33598B']_|_[('DailyMed', array(['dronedarone%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000138622,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000123700]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2009 and is indicated for atrial fibrillation. This drug has a black box warning from the FDA."
CHEMBL1628688,"COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1_|_FJHHZXWJVIEFGJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZIBOTENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ZD-4054' 'ZD4054' 'Zibotentan']_|_[('drugbank', array(['DB06629'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'MONDO_0008315', 'EFO_0004265', 'EFO_0003876',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000673', 'MONDO_0008170',
       'EFO_0001422', 'MONDO_0007254', 'EFO_0003884', 'EFO_0001421',
       'EFO_0009708'], dtype=object), 'count': 13}_|_[ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL1672627,O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1_|_XUYURJQIMYCWBB-UHFFFAOYSA-N_|_Small molecule_|_False_|_LAS101057_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LAS-101057' 'Las101057']_|_nan_|_nan_|_nan_|_[ENSG00000170425]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1690,"CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O_|_JCBIVZZPXRZKTI-UHFFFAOYSA-N_|_Small molecule_|_False_|_HYDROXYCHLOROQUINE SULFATE_|_1955.0_|_4.0_|_CHEMBL1535_|_False_|_True_|_['Ercoquin' 'Hydroxychloroquine sulfate' 'Oxichlorochine' 'Plaquenil'
 'Quensyl' 'Quinoric']_|_['Ercoquin' 'Hydroxychloroquine Sulfate' 'Hydroxychloroquine sulfate'
 'Hydroxychloroquine sulphate' 'NSC-4375' 'Oxichlorochine sulfate'
 'Oxiklorin' 'Quensyl' 'TCMDC-123987']_|_[('DailyMed', array(['hydroxychloroquine%20sulfate'], dtype=object)), ('PubChem', array(['144205260', '170464696', '26748879'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0007224', 'EFO_0002618', 'EFO_0001068',
       'EFO_0004244', 'EFO_0005221', 'EFO_0003834', 'MONDO_0007915',
       'EFO_0005755', 'MONDO_0100096', 'MONDO_0010520', 'EFO_0002689',
       'EFO_0000389', 'EFO_0003818'], dtype=object), 'count': 14}_|_[ENSG00000239732,ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for rheumatoid arthritis and malaria and has 12 investigational indications."
CHEMBL1887891,"CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1.Cl_|_ZXKXJHAOUFHNAS-FVGYRXGTSA-N_|_Small molecule_|_False_|_DEXFENFLURAMINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL248702_|_True_|_True_|_['Adifax']_|_['Adipomin' 'D-fenfluramine hydrochloride' 'Dexfenfluramine hcl'
 'Dexfenfluramine hydrochloride' 'Fenfluramine d-form hydrochloride'
 'Glypolix' 'Isomeride' 'S 5614 HCL' 'S-5614 HCL']_|_[('PubChem', array(['144206417', '170465626', '85273812'], dtype=object)), ('chEBI', array(['59730'], dtype=object))]_|_nan_|_nan_|_[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2062163,"C[C@H]1[C@H](c2ccccc2)OCCN1C.O=C(O)C(O)C(O)C(=O)O_|_VEPOHXYIFQMVHW-XOZOLZJESA-N_|_Small molecule_|_False_|_PHENDIMETRAZINE TARTRATE_|_1976.0_|_4.0_|_CHEMBL1615439_|_False_|_True_|_['Adphen' 'Alphazine' 'Bontril' 'Bontril pdm' 'Cam-metrazine' 'Di-metrex'
 'Melfiat' 'Melfiat-105' 'Metra' 'Phenazine' 'Phenazine-35'
 'Phendimetrazine tartrate' 'Plegine' 'Sprx-105' 'Sprx-3' 'Statobex'
 'Statobex-g' 'X-trozine' 'X-trozine l.a.']_|_['Adipost' 'Appecon' 'Azophenylene' 'NSC-13157'
 'Phendimetrazine bitartrate' 'Phendimetrazine hydrogen tartrate'
 'Phendimetrazine tartrate' 'Phendimetrazine tartrate ciii']_|_[('DailyMed', array(['phendimetrazine%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for obesity."
CHEMBL2103876,"Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1_|_VJGFOYBQOIPQFY-XMMPIXPASA-N_|_Small molecule_|_False_|_MAPRACORAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BOL-303242-X' 'BOL-303242X' 'Mapracorat' 'ZK 245186' 'ZK-245186'
 'ZK245186' 'Zk-245186']_|_[('drugbank', array(['DB12041'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_1000906', 'EFO_0003966', 'EFO_0007141',
       'EFO_0000274', 'MONDO_0005129'], dtype=object), 'count': 6}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2103878,"NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1_|_QWNDOCKIKKQJNN-UHFFFAOYSA-N_|_Small molecule_|_False_|_ODELEPRAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2196044' 'LY2196044' 'Ly2196044' 'Odelepran' 'Ondelopran']_|_[('drugbank', array(['DB12585'], dtype=object))]_|_['CHEMBL2105746']_|_{'rows': array(['MONDO_0007079'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2104969,"O=C(O)c1ccc(CCCc2c(CCNS(=O)(=O)Cc3ccccc3C(F)(F)F)n(C(c3ccccc3)c3ccccc3)c3ccc(Cl)cc23)cc1_|_NHHBNHIPCSPSHQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_GIRIPLADIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Giripladib' 'PLA-695']_|_[('drugbank', array(['DB15426'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0005178'], dtype=object), 'count': 2}_|_[ENSG00000116711]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2106217,"CCNC(C)Cc1cccc(C(F)(F)F)c1.Cl_|_ZXKXJHAOUFHNAS-UHFFFAOYSA-N_|_Small molecule_|_True_|_FENFLURAMINE HYDROCHLORIDE_|_2020.0_|_4.0_|_CHEMBL87493_|_True_|_True_|_['Fintepla' 'Ponderax' 'Ponderax pacaps']_|_['AHR-3002' 'Dl-fenfluramine hydrochloride' 'Fenfluramine hcl'
 'Fenfluramine hydrochloride' 'Ganal' 'HHR-965']_|_[('DailyMed', array(['fenfluramine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fintepla'],
      dtype=object)), ('chEBI', array(['59729'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015643', 'HP_0001250'], dtype=object), 'count': 2}_|_[ENSG00000147955,ENSG00000179546,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for seizure and has 1 investigational indication. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL2109293,"nan_|_nan_|_Antibody_|_False_|_KRN-330_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['KRN-330' 'Krn 330' 'Krn-330' 'Krn330']_|_nan_|_nan_|_{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}_|_[ENSG00000143167]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109411,nan_|_nan_|_Antibody_|_False_|_RG-7444_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['RG-7444']_|_nan_|_nan_|_nan_|_[ENSG00000068078]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109466,"nan_|_nan_|_Antibody_|_False_|_TNX-650_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TNX-650' 'Tnx-650']_|_nan_|_nan_|_{'rows': array(['EFO_0000183'], dtype=object), 'count': 1}_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL211456,"CN[C@@H](C)[C@H](O)c1ccccc1_|_KWGRBVOPPLSCSI-WPRPVWTQSA-N_|_Small molecule_|_False_|_EPHEDRINE_|_2016.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['(-)-ephedrine' 'Ephedrine' 'Ephedrine, anhydrous'
 'Ephedrinum, anhydrous' 'L-ephedrine' 'NSC-170951' 'NSC-8971' 'Xenadrine']_|_[('PubChem', array(['124892369'], dtype=object)), ('Wikipedia', array(['Ephedrine'], dtype=object)), ('drugbank', array(['DB01364'], dtype=object)), ('chEBI', array(['15407'], dtype=object))]_|_['CHEMBL2146102' 'CHEMBL1523964' 'CHEMBL526872']_|_{'rows': array(['EFO_0001073', 'HP_0001742', 'EFO_0007214', 'EFO_0003956',
       'EFO_0005251', 'EFO_0003843', 'MP_0001914', 'HP_0001742',
       'EFO_0005251', 'MONDO_0004979', 'EFO_0000319', 'EFO_0000668',
       'MONDO_0004979', 'EFO_0009314', 'EFO_0005251', 'HP_0100543'],
      dtype=object), 'count': 16}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 7 approved and 6 investigational indications. It was withdrawn in at least one region."
CHEMBL228814,"Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1_|_QJZRFPJCWMNVAV-HHHXNRCGSA-N_|_Small molecule_|_False_|_ISPINESIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ispinesib']_|_[('drugbank', array(['DB06188'], dtype=object))]_|_['CHEMBL2347651']_|_{'rows': array(['MONDO_0004992', 'EFO_0003869', 'EFO_0000681', 'EFO_1000657',
       'MONDO_0008170', 'MONDO_0002691', 'EFO_0000673', 'MONDO_0021063',
       'EFO_0003060', 'EFO_0000389'], dtype=object), 'count': 10}_|_[ENSG00000138160]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL348475,"COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2_|_LGGHDPFKSSRQNS-UHFFFAOYSA-N_|_Small molecule_|_False_|_TARIQUIDAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Tariquidar' 'XR-9576' 'XR9576']_|_[('PubChem', array(['174006280'], dtype=object)), ('Wikipedia', array(['Tariquidar'], dtype=object)), ('drugbank', array(['DB06240'], dtype=object))]_|_['CHEMBL1214643']_|_{'rows': array(['EFO_1000796', 'MONDO_0008170', 'MONDO_0007254', 'MONDO_0008903',
       'EFO_0005762', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000085563]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3545196,"CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1.Cl.Cl_|_NADLBPWBFGTESN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PD-0166285_|_nan_|_1.0_|_CHEMBL49120_|_False_|_False_|_[]_|_['Pd-0166285']_|_nan_|_nan_|_nan_|_[ENSG00000077782,ENSG00000197122,ENSG00000146648,ENSG00000113721]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545222,"nan_|_nan_|_Small molecule_|_False_|_AZD8683_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd8683']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707245,"O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1_|_YHGSTSNEOJUIRN-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMIDENEPAG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Omidenepag' 'UR-7276']_|_nan_|_nan_|_{'rows': array(['MONDO_0005041'], dtype=object), 'count': 1}_|_[ENSG00000125384]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707280,"nan_|_nan_|_Antibody_|_False_|_CG250 111IN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CG250' 'Cg250 (111in)' 'Cg250 111in']_|_nan_|_nan_|_{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}_|_[ENSG00000107159]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3969876,COCCCCn1c(C(=O)N(CC(C)C)[C@@H]2CNC[C@H](C(=O)N3CCOCC3)C2)nc2ccccc21.Cl_|_PUXOYQIZZIWCHH-NSLUPJTDSA-N_|_Small molecule_|_False_|_IMARIKIREN HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL3990145_|_False_|_False_|_[]_|_['Imarikiren hydrochloride' 'TAK-272' 'Tak-272']_|_nan_|_nan_|_nan_|_[ENSG00000143839]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297969,"nan_|_nan_|_Antibody_|_False_|_FELADILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['3359609' 'Feladilimab' 'GSK-3359609' 'GSK-609' 'GSK3359609'
 'Gsk 3359609' 'Gsk3359609']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FELADILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0005950', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000163600]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297971,"nan_|_nan_|_Protein_|_False_|_PEPTIDE YY HUMAN (3-36)_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gt-001' 'Human peptide yy (3-36)' 'Peptide yy (3-36)'
 'Peptide yy human (3-36)' 'Pyy 3-36' 'Pyy(3-36)' 'Pyy3-36']_|_nan_|_nan_|_{'rows': array(['EFO_0005203', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000185149]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL439338,"CC(C)(C)c1nc(N2CCN(CCCSc3nccc(O)n3)CC2)cc(C(F)(F)F)n1_|_KXVAICSRMHXLJN-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABT-925_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-437203' 'Abt-925']_|_nan_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594316,"nan_|_nan_|_Antibody_|_False_|_CROVALIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Crovalimab' 'RG-6107' 'RG6107' 'RO-7112689' 'RO7112689' 'Ro7112689'
 'SKY-59' 'SKY59']_|_nan_|_nan_|_{'rows': array(['MONDO_0016244', 'MONDO_0100244', 'MONDO_0011382', 'EFO_0007292'],
      dtype=object), 'count': 4}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL1017,"CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1_|_RMMXLENWKUUMAY-UHFFFAOYSA-N_|_Small molecule_|_True_|_TELMISARTAN_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Micardis' 'Telmisartan' 'Tolura']_|_['BIBR 277 SE' 'BIBR-277' 'BIBR-277 SE' 'BIBR-277-SE' 'BIBR-277SE'
 'C09CA07' 'Kinzalmono' 'Pritor' 'Semintra' 'Telmisartan'
 'Telmisartan actavis' 'Telmisartan teva']_|_[('DailyMed', array(['telmisartan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/micardis'],
      dtype=object)), ('PubChem', array(['137275807', '144205005', '170464873', '26719833', '26749005',
       '49648460'], dtype=object)), ('Wikipedia', array(['Telmisartan'], dtype=object)), ('drugbank', array(['DB00966'], dtype=object)), ('chEBI', array(['9434'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'Orphanet_309005', 'EFO_0000612', 'EFO_0000764',
       'EFO_0000694', 'EFO_0008620', 'EFO_0000401', 'EFO_0005762',
       'EFO_0000712', 'MONDO_0100096', 'EFO_0004285', 'EFO_0003918',
       'EFO_0003777', 'EFO_0000537', 'EFO_0000319', 'MONDO_0005148',
       'MONDO_0001134', 'EFO_0003884', 'EFO_0000180', 'MONDO_0004975'],
      dtype=object), 'count': 20}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 15 investigational indications. This drug has a black box warning from the FDA."
CHEMBL111,"Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1_|_JZCPYUJPEARBJL-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIMONABANT_|_2006.0_|_4.0_|_nan_|_True_|_True_|_['Acomplia' 'Zimulti']_|_['Rimonabant' 'SR-14171' 'SR-141716' 'SR-141716A' 'SR141716' 'Zimulti']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zimulti'],
      dtype=object)), ('PubChem', array(['144205753', '170465599', '26757994'], dtype=object)), ('Wikipedia', array(['Rimonabant'], dtype=object)), ('drugbank', array(['DB06155'], dtype=object)), ('chEBI', array(['34967'], dtype=object))]_|_['CHEMBL558598']_|_{'rows': array(['EFO_0001073', 'EFO_0004329', 'EFO_0003843', 'EFO_1001919',
       'HP_0001397', 'EFO_1001121', 'MONDO_0008300', 'EFO_0004319',
       'EFO_0009086', 'HP_0001824', 'EFO_0007191', 'MONDO_0021661',
       'MONDO_0005148', 'Orphanet_309005', 'EFO_0000319', 'EFO_0003768',
       'EFO_0000195'], dtype=object), 'count': 17}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for obesity and has 16 investigational indications. It was withdrawn in at least one region."
CHEMBL1111,"COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O_|_OUJTZYPIHDYQMC-LJQANCHMSA-N_|_Small molecule_|_True_|_AMBRISENTAN_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Ambrisentan mylan' 'Letairis' 'Volibris']_|_['Ambrisentan' 'GSK-1325760' 'GSK-1325760A' 'GSK1325760' 'GSK1325760A'
 'LU-208075']_|_[('DailyMed', array(['ambrisentan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ambrisentan-mylan'],
      dtype=object)), ('PubChem', array(['144205520', '170465143'], dtype=object)), ('Wikipedia', array(['Ambrisentan'], dtype=object)), ('drugbank', array(['DB06403'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004933', 'EFO_0001361', 'EFO_0000768', 'EFO_0000537',
       'EFO_1000782', 'MONDO_0100096', 'EFO_0004264', 'MONDO_0011382',
       'MONDO_0004979', 'MONDO_0005149'], dtype=object), 'count': 10}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1184,"CC(=O)OCC[N+](C)(C)C.[Cl-]_|_JUGOREOARAHOCO-UHFFFAOYSA-M_|_Small molecule_|_False_|_ACETYLCHOLINE CHLORIDE_|_1973.0_|_4.0_|_CHEMBL667_|_False_|_True_|_['Miochol' 'Miochol-e' 'Miphtel']_|_['Acetylcholine' 'Acetylcholine Chloride' 'Acetylcholine chloride'
 'Acetylcholine chloride for injection' 'Choline acetate (ester) chloride'
 'Miochol' 'Miochol-E' 'NSC-755845']_|_[('PubChem', array(['11532873', '170464783', '26747837'], dtype=object)), ('chEBI', array(['2417'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000616', 'MONDO_0005129'], dtype=object), 'count': 2}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for miosis and cataract."
CHEMBL1200977,"CC(O)C(=O)O.Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1_|_VWUPWEAFIOQCGF-UHFFFAOYSA-N_|_Small molecule_|_False_|_MILRINONE LACTATE_|_1987.0_|_4.0_|_CHEMBL189_|_False_|_True_|_['Milrinone lactate' 'Primacor']_|_['Milrinone lactate']_|_[('DailyMed', array(['milrinone%20lactate'], dtype=object)), ('chEBI', array(['34850'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'HP_0004308'], dtype=object), 'count': 2}_|_[ENSG00000172572]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for heart failure and ventricular arrhythmia."
CHEMBL1201013,"O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]_|_ZJEFYLVGGFISGT-VRZXRVJBSA-L_|_Small molecule_|_False_|_OLSALAZINE SODIUM_|_1990.0_|_4.0_|_CHEMBL425_|_False_|_True_|_['Dipentum']_|_['Ads' 'Azodisal sodium' 'CJ 91B' 'CJ-91B' 'Disodium azodisalicylate'
 'Olsalazine disodium salt' 'Olsalazine sodium' 'Sodium azodisalicylate'
 'Sodium olsalazine']_|_[('DailyMed', array(['olsalazine%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000012779,ENSG00000132170,ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for ulcerative colitis."
CHEMBL1201159,"CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.Cl_|_LHCBOXPPRUIAQT-UHFFFAOYSA-N_|_Small molecule_|_True_|_FENTANYL HYDROCHLORIDE_|_2006.0_|_4.0_|_CHEMBL596_|_False_|_True_|_['Ionsys']_|_['Fentanyl hcl' 'Fentanyl hydrochloride']_|_nan_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006 and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1565476,"CCCC1C(=O)N2C(N(C)C)=Nc3ccc(C)cc3N2C1=O_|_MPHPHYZQRGLTBO-UHFFFAOYSA-N_|_Small molecule_|_False_|_APAZONE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Rheumox' 'Rheumox 600']_|_['AHR-3018' 'Apazone' 'Apazone dihydrate' 'Azapropazone'
 'Azapropazone dihydrate' 'Cinnopropazone' 'MI-85' 'MI-85DI' 'NSC-102824'
 'Prolixan']_|_[('PubChem', array(['144204120', '56463151'], dtype=object)), ('chEBI', array(['38010'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease."
CHEMBL1567,"CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O_|_LBWFXVZLPYTWQI-IPOVEDGCSA-N_|_Small molecule_|_True_|_SUNITINIB MALATE_|_2006.0_|_4.0_|_CHEMBL535_|_False_|_True_|_['Sunitinib malate' 'Sutent']_|_['PHA-290940AD' 'SU-010398' 'SU-011248 L-MALATE SALT' 'SU010398'
 'SU011248 L-MALATE SALT' 'Sunitinib l-malate' 'Sunitinib malate' 'Sutent']_|_[('DailyMed', array(['sunitinib%20malate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000514', 'EFO_0000222', 'MONDO_0003268', 'MONDO_0002158',
       'EFO_1000984', 'MONDO_0002367', 'EFO_0002499', 'EFO_1000576',
       'EFO_0006861', 'EFO_0000349', 'MONDO_0044926', 'EFO_0000641',
       'EFO_0002618', 'MONDO_0004192', 'EFO_0000501', 'EFO_0000640',
       'EFO_0007331', 'MONDO_0008315', 'EFO_1001951', 'EFO_0002617',
       'EFO_0003865', 'EFO_0000681', 'EFO_0000588', 'EFO_0000632',
       'MONDO_0015277', 'EFO_0000095', 'EFO_0000673', 'EFO_0000182',
       'EFO_1001465', 'MONDO_0018364', 'EFO_1001968', 'EFO_0000220',
       'EFO_1000045', 'EFO_0000403', 'EFO_0003869', 'EFO_0003897',
       'EFO_0002938', 'MONDO_0011719', 'MONDO_0002691', 'EFO_0000702',
       'EFO_1001901', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0003060',
       'MONDO_0007576', 'MONDO_0007254', 'MONDO_0004986', 'EFO_0000519',
       'EFO_0001378', 'EFO_0006352', 'MONDO_0002087', 'MONDO_0008667',
       'EFO_0000616', 'EFO_0007416', 'EFO_0000558', 'MONDO_0008903'],
      dtype=object), 'count': 56}_|_[ENSG00000122025,ENSG00000165731,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 50 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1615372,"Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1_|_NEKCRUIRPWNMLK-SCIYSFAVSA-N_|_Small molecule_|_True_|_LURASIDONE HYDROCHLORIDE_|_2010.0_|_4.0_|_CHEMBL1237021_|_False_|_True_|_['Latuda']_|_['Lurasidone hcl' 'Lurasidone hydrochloride' 'SM-13496']_|_[('DailyMed', array(['lurasidone%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/latuda'],
      dtype=object)), ('chEBI', array(['70732'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009963', 'MONDO_0005090', 'MONDO_0004985'], dtype=object), 'count': 3}_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL1696,"CNCCCN1c2ccccc2CCc2ccccc21.Cl_|_XAEWZDYWZHIUCT-UHFFFAOYSA-N_|_Small molecule_|_True_|_DESIPRAMINE HYDROCHLORIDE_|_1964.0_|_4.0_|_CHEMBL72_|_False_|_True_|_['Desipramine hydrochloride' 'Norpramin' 'Pertofran' 'Pertofrane']_|_['18-8181' 'DMI' 'Desipramine hcl' 'Desipramine hydrochloride' 'EX 4355'
 'EX-4355' 'G-35020' 'JB-8181' 'NSC-114901' 'RMI 9,384A' 'RMI-9384A']_|_[('DailyMed', array(['desipramine%20hydrochloride'], dtype=object)), ('PubChem', array(['144203680', '170465424', '26732610', '26747493', '26747494',
       '50106122', '50106123', '50106124', '855832', '858256'],
      dtype=object)), ('chEBI', array(['4449'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'HP_0003418', 'EFO_0000702', 'MONDO_0002050'],
      dtype=object), 'count': 4}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1718,"C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl_|_RGPDIGOSVORSAK-STHHAXOLSA-N_|_Small molecule_|_False_|_NALOXONE HYDROCHLORIDE_|_1971.0_|_4.0_|_CHEMBL80_|_False_|_True_|_['Evzio' 'Evzio (autoinjector)' 'Kloxxado' 'Nalone' 'Naloxone'
 'Naloxone hydrochloride' 'Naloxone hydrochloride (autoinjector)' 'Narcan'
 'Narcan neonatal' 'Narconil' 'Prenoxad' 'Zimhi']_|_['Anhydrous naloxone hydrochloride' 'EN-15304' 'NIH 7890' 'NSC-757109'
 'Naloxone hcl' 'Naloxone hydrochloride'
 'Naloxone hydrochloride anhydrous' 'Naloxoni hydrochloridum anhydrous'
 'Narcanti']_|_[('DailyMed', array(['naloxone%20hydrochloride'], dtype=object)), ('PubChem', array(['11532915'], dtype=object)), ('chEBI', array(['31892'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0006834', 'MONDO_0002009', 'EFO_0005611',
       'HP_0002019', 'MONDO_0004565', 'EFO_0004699'], dtype=object), 'count': 7}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 3 approved and 4 investigational indications."
CHEMBL283120,"COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC_|_YJGVMLPVUAXIQN-HAEOHBJNSA-N_|_Small molecule_|_False_|_AXL-1717_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AXL-1717' 'Axl-1717' 'Axl1717' 'NSC-36407' 'Picropodophyllin'
 'Picropodophyllotoxin' 'Podophyllotoxin picropodophyllin']_|_[('PubChem', array(['29216394'], dtype=object)), ('drugbank', array(['DB12802'], dtype=object)), ('chEBI', array(['75251'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002501', 'EFO_0000616', 'EFO_0002499', 'EFO_0000571',
       'EFO_1001465', 'EFO_0003060', 'EFO_0001642', 'EFO_0000707'],
      dtype=object), 'count': 8}_|_[ENSG00000140443]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL295698,"CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1_|_XMAYWYJOQHXEEK-ZEQKJWHPSA-N_|_Small molecule_|_True_|_LEVOKETOCONAZOLE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Extina' 'Ketosidin' 'Ketozole' 'Nizoral' 'Nizoral A-D' 'Panfungol'
 'Recorlev' 'Xolegel']_|_['(-)-(2s,4r)-ketoconazole' '2s,4r ketoconazole' '2s,4r-ketoconazole'
 'COR-003' 'COR003' 'DIO-902' 'Ketoconazole, (2s,4r)-' 'Levoketoconazole'
 'Nizoral' 'Normocort' 'R-41400']_|_[('PubChem', array(['11111347', '11112822', '124882653', '124882654'], dtype=object)), ('drugbank', array(['DB05667'], dtype=object)), ('chEBI', array(['47518'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005539', 'MONDO_0005148', 'EFO_0003099', 'EFO_1000797',
       'EFO_1001110'], dtype=object), 'count': 5}_|_[ENSG00000179142,ENSG00000140459,ENSG00000160882,ENSG00000148795]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3137317,"Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O_|_RWIVSVMMGFFZIJ-VWDRLOGHSA-N_|_Small molecule_|_True_|_SONIDEGIB PHOSPHATE_|_2015.0_|_4.0_|_CHEMBL2105737_|_False_|_True_|_['Odomzo']_|_['Erismodegib phosphate' 'Sonidegib diphosphate' 'Sonidegib phosphate']_|_[('DailyMed', array(['sonidegib%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/odomzo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004193'], dtype=object), 'count': 1}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for basal cell carcinoma. This drug has a black box warning from the FDA."
CHEMBL3545100,"nan_|_nan_|_Small molecule_|_False_|_ASP7991_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Asp7991']_|_nan_|_nan_|_{'rows': array(['EFO_1001173'], dtype=object), 'count': 1}_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545184,"CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O_|_ANIAZGVDEUQPRI-ZJQCGQFWSA-N_|_Protein_|_False_|_VELCALCETIDE_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Parsabiv']_|_['AMG-416' 'Amg416' 'Etelcalcetide' 'KAI-4169' 'ONO-5163' 'Telcalcetide'
 'Velcalcetide']_|_[('DailyMed', array(['etelcalcetide'], dtype=object)), ('drugbank', array(['DB12865'], dtype=object))]_|_['CHEMBL3545183']_|_{'rows': array(['EFO_1001173', 'EFO_0003884', 'EFO_0005754', 'EFO_1001173',
       'EFO_0003884'], dtype=object), 'count': 5}_|_[ENSG00000036828]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 1 investigational indication."
CHEMBL3653256,"COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1_|_AGBSXNCBIWWLHD-FQEVSTJZSA-N_|_Small molecule_|_False_|_SIREMADLIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HDM-201' 'HDM201' 'Hdm 201' 'NVP-HDM 201' 'Siremadlin']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIREMADLIN/relevant/1/'],
      dtype=object))]_|_['CHEMBL5095424']_|_{'rows': array(['EFO_0001421', 'EFO_0000616', 'MONDO_0044903', 'EFO_0000616',
       'EFO_0000569', 'EFO_1001968', 'EFO_0000222'], dtype=object), 'count': 7}_|_[ENSG00000141510,ENSG00000135679]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4297528,"Cc1cn2nc(-c3cc(=O)n4cc(N5CCNC6(CC6)C5)ccc4n3)cc(C)c2n1_|_ASKZRYGFUPSJPN-UHFFFAOYSA-N_|_Small molecule_|_False_|_RISDIPLAM_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Evrysdi']_|_['RG-7916' 'RG7916' 'RO-7034067' 'RO7034067' 'Risdiplam']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RISDIPLAM/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15305'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008525', 'EFO_1000096'], dtype=object), 'count': 2}_|_[ENSG00000205571]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for spinal muscular atrophy and atrophy."
CHEMBL43,"COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12_|_XCPGHVQEEXUHNC-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMSACRINE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acridinylanisidide' 'Amekrin' 'Amsacrine' 'Amsidil' 'Amsidine' 'CI-880'
 'Lamasine' 'M-AMSA' 'NCI-249992' 'NSC-156303' 'NSC-249992' 'SN-11841'
 'SN-21429']_|_[('PubChem', array(['11110803', '137181', '50110958'], dtype=object)), ('Wikipedia', array(['Amsacrine'], dtype=object)), ('drugbank', array(['DB00276'], dtype=object)), ('chEBI', array(['2687'], dtype=object))]_|_['CHEMBL1256655' 'CHEMBL3229103' 'CHEMBL540070']_|_{'rows': array(['EFO_0000222', 'EFO_0000616', 'EFO_0000565', 'EFO_0000198'],
      dtype=object), 'count': 4}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for neoplasm and has 3 investigational indications."
CHEMBL496102,"COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1_|_HEAIZQNMNCHNFD-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMG-208_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-208' 'Amg 208' 'Amg-208' 'Amg208']_|_[('PubChem', array(['174006590'], dtype=object)), ('drugbank', array(['DB08079'], dtype=object)), ('chEBI', array(['90626'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5314402,"O=C(N[C@@H]1C2CCN(CC2)[C@H]1Cc1cccnc1)c1cc(F)cc(F)c1_|_UAKZGMMGIMKFMV-RBUKOAKNSA-N_|_Small molecule_|_False_|_TC-6987_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TC-6987' 'Tc-6987']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL110691,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C_|_QMBJSIBWORFWQT-DFXBJWIESA-N_|_Small molecule_|_False_|_CHLORMADINONE ACETATE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Chlormadinone' 'Chlormadinone acetate' 'Lutoral' 'NSC-92338' 'Normenon'
 'RS-1280']_|_[('PubChem', array(['144204432', '144207863', '170465776', '29215009', '56422443',
       '855775'], dtype=object)), ('chEBI', array(['31394'], dtype=object))]_|_nan_|_nan_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1200339,"CNC[C@H](O)c1cccc(O)c1.Cl_|_OCYSGIYOVXAGKQ-FVGYRXGTSA-N_|_Small molecule_|_False_|_PHENYLEPHRINE HYDROCHLORIDE_|_1952.0_|_4.0_|_CHEMBL1215_|_False_|_True_|_['Biorphen' 'Fenilfar' 'Fenox' 'Mydfrin' 'Nazex' 'Neosynephrine'
 'Nurofen sinus pain relief' 'Phenylephrine hydrochloride' 'Prefrin'
 'Vazculep']_|_['Metaoxedrine chloride' 'NSC-757273' 'Phenylephrine HCl'
 'Phenylephrine hydrochloride']_|_[('DailyMed', array(['phenylephrine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204448', '144208459', '144213163', '170465356', '26751602',
       '50106782', '855560'], dtype=object)), ('chEBI', array(['8094'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007486', 'HP_0000989', 'EFO_0004269', 'HP_0001742',
       'EFO_0004610', 'EFO_0006834', 'EFO_0007214', 'EFO_0007533',
       'EFO_0008521', 'EFO_0000319', 'EFO_0000178', 'EFO_0000544',
       'EFO_0005251', 'MONDO_0024355', 'EFO_0003956', 'EFO_0009552',
       'MONDO_0005129', 'MONDO_0005271'], dtype=object), 'count': 18}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 9 approved and 9 investigational indications."
CHEMBL122,"CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1_|_RZJQGNCSTQAWON-UHFFFAOYSA-N_|_Small molecule_|_True_|_ROFECOXIB_|_1999.0_|_4.0_|_nan_|_True_|_True_|_['Vioxx']_|_['M01AH02' 'MK-0966' 'MK-966' 'MK0966' 'NSC-720256' 'NSC-758705'
 'Rofecoxib' 'TRM-201' 'TRM201']_|_[('PubChem', array(['144204983', '174007305', '26748942', '49665949', '535364'],
      dtype=object)), ('Wikipedia', array(['Rofecoxib'], dtype=object)), ('drugbank', array(['DB00533'], dtype=object)), ('chEBI', array(['8887'], dtype=object))]_|_['CHEMBL5171570' 'CHEMBL4465601']_|_{'rows': array(['EFO_0005755', 'MONDO_0005178', 'EFO_0003833', 'MONDO_0008315',
       'EFO_0005406', 'EFO_0005543', 'EFO_0004616', 'EFO_0003843',
       'EFO_0003897', 'EFO_1001951', 'EFO_0003060', 'MONDO_0004975',
       'HP_0003040'], dtype=object), 'count': 13}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for rheumatic disease and has 12 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1743064,"nan_|_nan_|_Antibody_|_False_|_ROBATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['19D12' 'Robatumumab' 'SCH 717454' 'SCH-717454']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1981592,"CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)O_|_VBUWHHLIZKOSMS-RIWXPGAOSA-N_|_Protein_|_False_|_AVIPTADIL_|_nan_|_3.0_|_nan_|_False_|_False_|_['Samiairtm' 'Samiviptm' 'Samivirtm' 'Zyesami']_|_['Aviptadil' 'Aviptadil acetate' 'Vip human vip']_|_[('PubChem', array(['124893751'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AVIPTADIL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0004610', 'EFO_1000637', 'MONDO_0100096'],
      dtype=object), 'count': 4}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL206468,"OC[C@H]1CNC[C@@H](O)[C@@H]1O_|_QPYJXFZUIJOGNX-HSUXUTPPSA-N_|_Small molecule_|_False_|_AFEGOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Afegostat' 'Isofagomine']_|_[('PubChem', array(['85267413'], dtype=object)), ('drugbank', array(['DB04545'], dtype=object))]_|_['CHEMBL2105671']_|_{'rows': array(['MONDO_0018150'], dtype=object), 'count': 1}_|_[ENSG00000177628]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2105719,"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1.O_|_BSPLGGCPNTZPIH-IPZCTEOASA-N_|_Small molecule_|_False_|_DACOMITINIB_|_2018.0_|_4.0_|_CHEMBL2110732_|_False_|_True_|_['Vizimpro']_|_['Dacomitinib' 'Dacomitinib hydrate' 'Dacomitinib monohydrate'
 'PF-00299804-03']_|_[('DailyMed', array(['dacomitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008903', 'EFO_0000616', 'EFO_1001951', 'MONDO_0001657',
       'EFO_1001094', 'MONDO_0004992', 'EFO_0001421', 'EFO_0000181',
       'EFO_0000707', 'EFO_0003060'], dtype=object), 'count': 10}_|_[ENSG00000141736,ENSG00000146648,ENSG00000178568]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 7 investigational indications."
CHEMBL2107760,"COc1ccccc1Oc1c(NS(=O)(=O)/C=C/c2ccccc2)nc(-c2ncccn2)nc1OC_|_LONWRQOYFPYMQD-DTQAZKPQSA-N_|_Small molecule_|_False_|_NEBENTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HE-11' 'Nebentan' 'Nebentan potassium' 'YM-598' 'Ym598']_|_nan_|_nan_|_{'rows': array(['EFO_0000673', 'MONDO_0008315'], dtype=object), 'count': 2}_|_[ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2107762,"CCCN(c1ccncc1F)n1cc(C)c2ccccc21_|_BTDHTARYCBHHPJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_NERISPIRDINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HP-184' 'HP184' 'Nerispirdine' 'Nerispirdine hydrochloride']_|_[('drugbank', array(['DB12714'], dtype=object))]_|_['CHEMBL3585642']_|_{'rows': array(['MONDO_0005301', 'EFO_1001919'], dtype=object), 'count': 2}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109487,nan_|_nan_|_Antibody_|_False_|_RG-1512_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RG-1512']_|_nan_|_nan_|_nan_|_[ENSG00000174175]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109527,"nan_|_nan_|_Antibody_|_False_|_MEDI-578_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MEDI-578' 'Medi-578']_|_nan_|_nan_|_{'rows': array(['EFO_0003843', 'MONDO_0005178'], dtype=object), 'count': 2}_|_[ENSG00000134259]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2109587,nan_|_nan_|_Antibody_|_False_|_AZ9773_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZ-9773' 'AZ9773']_|_nan_|_nan_|_nan_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL288441,"COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl_|_UBPYILGKFZZVDX-UHFFFAOYSA-N_|_Small molecule_|_False_|_BOSUTINIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Bosulif']_|_['Bosutinib' 'SK-606' 'SKI-606']_|_[('PubChem', array(['124950167'], dtype=object)), ('Wikipedia', array(['Bosutinib'], dtype=object)), ('drugbank', array(['DB06616'], dtype=object)), ('chEBI', array(['39112'], dtype=object))]_|_['CHEMBL2095206' 'CHEMBL2131134']_|_{'rows': array(['EFO_0000222', 'MONDO_0002974', 'MONDO_0004643', 'EFO_1000131',
       'EFO_0002618', 'EFO_0000616', 'EFO_1001496', 'MONDO_0002087',
       'EFO_1000581', 'MONDO_0007254', 'EFO_0000519', 'EFO_0000339',
       'EFO_0000565', 'EFO_0003060', 'MONDO_0001187', 'MONDO_0002586',
       'HP_0000726', 'EFO_0000305', 'EFO_0000588', 'EFO_0000220',
       'MONDO_0004976', 'MONDO_0008170', 'EFO_0000339'], dtype=object), 'count': 23}_|_[ENSG00000197122,ENSG00000101336,ENSG00000097007,ENSG00000186716,ENSG00000254087]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for myeloid leukemia and chronic myelogenous leukemia and has 21 investigational indications."
CHEMBL3039538,"nan_|_nan_|_Protein_|_False_|_TRENONACOG ALFA_|_nan_|_3.0_|_nan_|_False_|_False_|_['Ixinity[tm]']_|_['IB-1001' 'IB1001' 'Trenonacog alfa']_|_nan_|_nan_|_{'rows': array(['MONDO_0008840', 'MONDO_0010006', 'MONDO_0018982', 'MONDO_0010604',
       'MONDO_0010100'], dtype=object), 'count': 5}_|_[ENSG00000101981]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4298093,"nan_|_nan_|_Antibody_|_False_|_SEMORINEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MTAU-9937A' 'MTAU9937A' 'RO-7105705' 'RO7105705' 'Ro7105705'
 'Semorinemab']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000186868]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298102,"nan_|_nan_|_Antibody_|_False_|_VUNAKIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['SHR-1314' 'Shr-1314' 'Vunakizumab']_|_nan_|_nan_|_{'rows': array(['EFO_1001466', 'EFO_0003778', 'EFO_0000676', 'EFO_0003898',
       'EFO_0005761'], dtype=object), 'count': 5}_|_[ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4650426,"nan_|_nan_|_Protein_|_False_|_PEGENZILEUKIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Il-2 variant thor-707' 'Pegenzileukin' 'SAR-444245' 'SAR444245'
 'THOR-707' 'THOR707' 'Thor 707' 'Thor-707']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEGENZILEUKIN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009708', 'EFO_0001378', 'MONDO_0009348', 'EFO_0000181',
       'EFO_0000403', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000147168,ENSG00000100385]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL517712,"CN1[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2_|_RKUNBYITZUJHSG-SPUOUPEWSA-N_|_Small molecule_|_False_|_ATROPINE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Atroject' 'Atropen' 'Atrophate' 'Atropine' 'Atropine (autoinjector)'
 'Isopto Atropine']_|_['Atropine' 'Atropinum' 'Dl-hyoscyamine']_|_[('DailyMed', array(['atropine'], dtype=object)), ('PubChem', array(['11533003', '144204367', '144205143', '144207685', '56422449'],
      dtype=object)), ('drugbank', array(['DB00572'], dtype=object)), ('chEBI', array(['16684'], dtype=object))]_|_['CHEMBL1200752' 'CHEMBL2146146' 'CHEMBL3185794' 'CHEMBL3182372']_|_{'rows': array(['HP_0000545', 'HP_0002315', 'EFO_1001865', 'EFO_0008546',
       'EFO_0004209', 'HP_0001943', 'EFO_0002614', 'HP_0000545',
       'HP_0004398', 'MONDO_0007254', 'EFO_0004207', 'MONDO_0005180',
       'EFO_0005252', 'EFO_0003956', 'MONDO_0004976', 'EFO_0005323',
       'EFO_0009314', 'MONDO_0001020', 'EFO_0010282', 'EFO_0003843',
       'EFO_1001109', 'HP_0011499', 'EFO_0009492', 'HP_0012803',
       'MP_0001914', 'EFO_1000645', 'EFO_0005854', 'HP_0001662',
       'EFO_0003956', 'EFO_1001121', 'HP_0000486', 'EFO_0010581',
       'HP_0011499'], dtype=object), 'count': 33}_|_[ENSG00000181072,ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 7 approved and 24 investigational indications."
CHEMBL585902,Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O_|_RQVKVJIRFKVPBF-VWLOTQADSA-N_|_Small molecule_|_False_|_AMG-548_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-548' 'Amg-548']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL68117,"CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC_|_XZAFZXJXZHRNAQ-STQMWFEESA-N_|_Small molecule_|_False_|_VOSAROXIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AG-7352' 'SNS-595' 'SPC-595' 'Vosaroxin']_|_[('drugbank', array(['DB11999'], dtype=object))]_|_['CHEMBL543336']_|_{'rows': array(['EFO_0000565', 'EFO_0000220', 'EFO_0003060', 'EFO_0000702',
       'EFO_0000339', 'EFO_0000198', 'EFO_0000616', 'EFO_0000222'],
      dtype=object), 'count': 8}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL75753,"O=C(NCCNCC(O)COc1ccc(O)cc1)N1CCOCC1_|_DXPOSRCHIDYWHW-UHFFFAOYSA-N_|_Small molecule_|_False_|_XAMOTEROL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['ICI-118,587' 'ICI-118587' 'Xamoterol']_|_[('PubChem', array(['104171266', '144203855'], dtype=object)), ('Wikipedia', array(['Xamoterol'], dtype=object)), ('drugbank', array(['DB13781'], dtype=object)), ('chEBI', array(['10055'], dtype=object))]_|_['CHEMBL1329567' 'CHEMBL1256945' 'CHEMBL2104466']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease."
CHEMBL945,"N=C(N)NC(=O)c1nc(Cl)c(N)nc1N_|_XSDQTOBWRPYKKA-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMILORIDE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amiclaran' 'Amiloride' 'Hydro-Ride' 'Midamor']_|_[('PubChem', array(['104171108', '11110775', '11113372', '124879259', '124879263',
       '144203631', '170465124', '26751628', '26751629', '49645530',
       '90341609'], dtype=object)), ('Wikipedia', array(['Amiloride'], dtype=object)), ('drugbank', array(['DB00594'], dtype=object)), ('chEBI', array(['2639'], dtype=object))]_|_['CHEMBL1398126' 'CHEMBL1201085' 'CHEMBL540851']_|_{'rows': array(['EFO_0000537', 'EFO_0000319', 'MONDO_0009061', 'EFO_0003144',
       'EFO_0008519', 'EFO_0000373', 'EFO_0003888', 'EFO_0001645',
       'EFO_0007405', 'EFO_0004269', 'EFO_0008522', 'MONDO_0005475',
       'MONDO_0009061', 'EFO_0000537', 'HP_0011096'], dtype=object), 'count': 15}_|_[ENSG00000111319,ENSG00000168447,ENSG00000166828]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL984,"COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2.[Cl-].[Cl-]_|_WMSYWJSZGVOIJW-ONUALHDOSA-L_|_Small molecule_|_False_|_MIVACURIUM CHLORIDE_|_1992.0_|_4.0_|_CHEMBL1182833_|_False_|_True_|_['Mivacron' 'Mivacurium chloride']_|_['BW B109OU DICHLORIDE' 'BW-1090U DICHLORIDE' 'BW-B109OU'
 'BW-B109OU DICHLORIDE' 'BWB109OU' 'MIVACURIUM CHLORIDE'
 'Mivacurium chloride' 'mivacurium']_|_[('PubChem', array(['144206026'], dtype=object)), ('Wikipedia', array(['Mivacurium_chloride'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001410'], dtype=object), 'count': 1}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and has 1 investigational indication."
CHEMBL1184904,"C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2_|_OAKGNIRUXAZDQF-TXHRRWQRSA-N_|_Small molecule_|_False_|_RETASPIMYCIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IPI-504' 'Retaspimycin']_|_[('drugbank', array(['DB05626'], dtype=object)), ('chEBI', array(['71975'], dtype=object))]_|_['CHEMBL377559']_|_{'rows': array(['EFO_0003060', 'EFO_0002617', 'MONDO_0008903', 'EFO_0000305',
       'MONDO_0011719', 'EFO_0001378', 'MONDO_0004992', 'MONDO_0007254',
       'EFO_0003085', 'EFO_0000673'], dtype=object), 'count': 10}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL1186894,"CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O_|_VJZITPJGSQKZMX-XDPRQOKASA-N_|_Small molecule_|_False_|_AMRUBICIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Amrubicin']_|_[('Wikipedia', array(['Amrubicin'], dtype=object)), ('drugbank', array(['DB06263'], dtype=object))]_|_['CHEMBL481958']_|_{'rows': array(['EFO_0001378', 'MONDO_0007254', 'MONDO_0008903', 'EFO_0000702',
       'EFO_1000576', 'EFO_0000616', 'EFO_1000581', 'EFO_0000702',
       'EFO_1001968', 'MONDO_0001187', 'MONDO_0008903'], dtype=object), 'count': 11}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL1200472,"Fc1ccccc1C1=NCC(=S)N(CC(F)(F)F)c2ccc(Cl)cc21_|_IKMPWMZBZSAONZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_QUAZEPAM_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Doral']_|_['NSC-309702' 'Quazepam' 'Quazepam civ' 'SCH 16134' 'SCH-16134']_|_[('DailyMed', array(['quazepam'], dtype=object)), ('Wikipedia', array(['Quazepam'], dtype=object)), ('drugbank', array(['DB01589'], dtype=object)), ('chEBI', array(['8694'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for insomnia. This drug has a black box warning from the FDA."
CHEMBL1201003,"Br.CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12_|_UTINOWOSWSPFLJ-FSRHSHDFSA-N_|_Small molecule_|_False_|_ELETRIPTAN HYDROBROMIDE_|_2002.0_|_4.0_|_CHEMBL1510_|_False_|_True_|_['Relpax']_|_['Eletriptan hbr' 'Eletriptan hydrobromide' 'NSC-759258' 'UK-116,044-04'
 'UK-116044-04']_|_[('DailyMed', array(['eletriptan%20hydrobromide'], dtype=object)), ('chEBI', array(['61176'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000135312,ENSG00000179546,ENSG00000179097]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2002 and is indicated for migraine disorder."
CHEMBL1201109,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1_|_WBGKWQHBNHJJPZ-LECWWXJVSA-N_|_Small molecule_|_False_|_DESONIDE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Desonate' 'Desonide' 'Desowen' 'Tridesilon' 'Verdeso']_|_['D-2083' 'D2083' 'Desonate' 'Desonide' 'NSC-759226']_|_[('DailyMed', array(['desonide'], dtype=object)), ('PubChem', array(['144206156', '170464832'], dtype=object)), ('Wikipedia', array(['Desonide'], dtype=object)), ('drugbank', array(['DB01260'], dtype=object)), ('chEBI', array(['204734'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_0005752', 'EFO_0000701'], dtype=object), 'count': 3}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved indications."
CHEMBL1201163,"CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_OJCZPLDERGDQRJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_SUFENTANIL CITRATE_|_1984.0_|_4.0_|_CHEMBL658_|_False_|_True_|_['Dsuvia' 'Dzuveo' 'Sufenta' 'Sufenta preservative free' 'Sufental'
 'Sufentanil citrate']_|_['R 33800' 'R-33800' 'Sufentanil citrate' 'Sufentanil citrate cii']_|_[('DailyMed', array(['sufentanil%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dzuveo'],
      dtype=object)), ('PubChem', array(['144206432', '85273816'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for pain. This drug has a black box warning from the FDA."
CHEMBL124162,"CCC(=O)O[C@]1(CC)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1_|_YCNIQYLWIPCLNY-QHCPKHFHSA-N_|_Small molecule_|_False_|_CAMPTOTHECIN-20-O-PROPIONATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Camptothecin-20-o-propionate']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000702', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1743011,nan_|_nan_|_Antibody_|_False_|_ENAVATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Enavatuzumab' 'PDL 192' 'PDL-192']_|_nan_|_nan_|_nan_|_[ENSG00000006327]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL1823681,"CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1_|_NULMGOSOSZBEQL-QMMMGPOBSA-N_|_Small molecule_|_False_|_ETILEVODOPA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Etilevodopa' 'L-dopa ethyl ester' 'TV-1203']_|_[('drugbank', array(['DB06535'], dtype=object))]_|_nan_|_nan_|_[ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL20883,"O=c1[nH]c(=O)n(C2CCCO2)cc1F_|_WFWLQNSHRPWKFK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEGAFUR_|_nan_|_4.0_|_nan_|_False_|_True_|_['Citofur' 'Uftoral']_|_['Atillon' 'BMS-200604' 'Coparogin' 'Exonal' 'FT-207' 'Fental' 'Franrose'
 'Ftorafur' 'Fulaid' 'Fulfeel' 'Furafluor' 'Furofutran' 'Futraful'
 'J356.722B' 'Lamar' 'Lifril' 'MJF-12264' 'NSC-148958' 'Neberk'
 'Nitobanil' 'Sinoflurol' 'Sunfural' 'Tefsiel c' 'Tegafur'
 'Tegafur-uracil' 'Youfuding']_|_[('PubChem', array(['144205202', '144212129', '170465809', '26754499', '29215356',
       '56422217', '8139878'], dtype=object)), ('Wikipedia', array(['Tegafur'], dtype=object)), ('drugbank', array(['DB09256'], dtype=object)), ('chEBI', array(['32188'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0007576', 'EFO_0000182', 'MONDO_0007254',
       'MONDO_0004992', 'EFO_0000199', 'MONDO_0001187', 'EFO_0003891',
       'MONDO_0003060', 'EFO_0000228', 'MONDO_0002974', 'MONDO_0021355',
       'EFO_0003860', 'EFO_0003086', 'MONDO_0002120', 'EFO_1001951',
       'MONDO_0005184', 'MONDO_0044937', 'EFO_0001421', 'EFO_1001901',
       'EFO_0000702', 'EFO_0003060', 'EFO_0000365', 'EFO_0005922',
       'EFO_0004142', 'EFO_0003897', 'EFO_0003869', 'EFO_0000503',
       'EFO_0000181', 'EFO_1000359', 'EFO_1000657', 'EFO_1000045',
       'MONDO_0005575', 'EFO_0005221', 'EFO_0000178', 'MONDO_0001056',
       'EFO_0004252', 'EFO_0002916', 'EFO_0006859', 'EFO_0002618',
       'EFO_1001956'], dtype=object), 'count': 41}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 39 investigational indications."
CHEMBL2103849,"CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1_|_IYFNEFQTYQPVOC-UHFFFAOYSA-N_|_Small molecule_|_False_|_UDENAFIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DA-8159' 'Udenafil' 'Zydena']_|_[('drugbank', array(['DB06267'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000899', 'EFO_0003777', 'EFO_0001421', 'EFO_0001361',
       'EFO_1001145', 'MONDO_0004975', 'EFO_0004234', 'EFO_0004718',
       'EFO_1001207'], dtype=object), 'count': 9}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL2105684,"Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21.O=S(=O)(O)O_|_GRKFGZYYYYISDX-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELUMETINIB SULFATE_|_2020.0_|_4.0_|_CHEMBL1614701_|_False_|_True_|_['Koselugo']_|_['AZD-6244 HYD-SULFATE' 'AZD-6244 HYDROGEN SULFATE' 'AZD6244 HYD-SULFATE'
 'AZD6244 HYDROGEN SULFATE' 'Azd-6244 hydrogen sulphate'
 'Azd6244 hydrogen sulphate' 'Selumetinib sulfate' 'Selumetinib sulphate']_|_[('DailyMed', array(['selumetinib%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000272', 'EFO_0001075', 'EFO_1001512', 'EFO_0002617',
       'EFO_1000251', 'EFO_0008514', 'EFO_0002618', 'MONDO_0018975',
       'EFO_0000389'], dtype=object), 'count': 9}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neurofibromatosis and neurofibromatosis type 1 and has 7 investigational indications."
CHEMBL2107834,"COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N_|_WXXSNCNJFUAIDG-UHFFFAOYSA-N_|_Small molecule_|_True_|_RIOCIGUAT_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Adempas' 'Bay 63-2521']_|_['BAY 63-2521' 'BAY-63-2521' 'Riociguat']_|_[('DailyMed', array(['riociguat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adempas'],
      dtype=object)), ('drugbank', array(['DB08931'], dtype=object)), ('chEBI', array(['76018'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001361', 'EFO_1001993', 'EFO_0000764', 'EFO_1001145',
       'EFO_0000537', 'MONDO_0005149', 'EFO_0000717', 'MONDO_0011382',
       'MONDO_0043839', 'HP_0002140', 'MONDO_0009061', 'EFO_0001645'],
      dtype=object), 'count': 12}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 3 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109308,nan_|_nan_|_Antibody_|_False_|_ONCOLYSIN B_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONCOLYSIN B']_|_nan_|_nan_|_nan_|_[ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2364618,"CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1_|_ORDHXXHTBUZRCN-NTEUORMPSA-N_|_Small molecule_|_False_|_MAVATREP_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JNJ-39439335' 'Mavatrep']_|_[('drugbank', array(['DB12875'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545321,"nan_|_nan_|_Small molecule_|_False_|_NMS-1116354_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Nms-1116354']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000097046]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3581647,"Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2_|_GNMUEVRJHCWKTO-FQEVSTJZSA-N_|_Small molecule_|_False_|_BIRABRESIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Birabresib' 'MK-8628' 'OTX-015' 'OTX-015 ANHYDROUS' 'OTX015'
 'OTX015 ANHYDROUS' 'Y-803 anhydrous']_|_[('drugbank', array(['DB15189'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0000222', 'MONDO_0008315', 'EFO_0000403',
       'MONDO_0005184', 'MONDO_0007254', 'EFO_0003060'], dtype=object), 'count': 7}_|_[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL3608680,"Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1_|_PPSNFPASKFYPMN-SECBINFHSA-N_|_Small molecule_|_False_|_FEZOLINETANT_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Veozah']_|_['A-2693' 'A2693' 'AS-3472693-00' 'AS3472693-00' 'ES-256364' 'ESN-364'
 'ESN364' 'Esn364' 'Fezolinetant' 'Veozah']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FEZOLINETANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15669'], dtype=object))]_|_nan_|_{'rows': array(['HP_0031217', 'EFO_0003086', 'EFO_0001421'], dtype=object), 'count': 3}_|_[ENSG00000169836]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for hot flashes and has 2 investigational indications."
CHEMBL3989865,"C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@H]([C@@H]1OC(=O)CCCCCCC)[C@@](C)(OC(C)=O)C[C@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)[C@@]1(O)[C@H]2OC(=O)[C@@]1(C)O_|_UPYNTAIBQVNPIH-ODMLWHIESA-N_|_Small molecule_|_False_|_MIPSAGARGIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['G-202' 'Mipsagargin']_|_[('drugbank', array(['DB11813'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_0000519', 'EFO_0000673', 'MONDO_0008315',
       'EFO_0000616', 'EFO_0000349'], dtype=object), 'count': 6}_|_[ENSG00000074370,ENSG00000196296,ENSG00000174437]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3989939,"O=C(Nc1cnn2ccc(N3CCC[C@@H]3c3cc(F)ccc3F)nc12)N1CC[C@H](O)C1.O=S(=O)(O)O_|_PXHANKVTFWSDSG-QLOBERJESA-N_|_Small molecule_|_False_|_LAROTRECTINIB SULFATE_|_2018.0_|_4.0_|_CHEMBL3889654_|_False_|_True_|_['Vitrakvi']_|_['ARRY-470 SULFATE' 'LOXO-101 sulfate' 'Larotrectinib sulfate']_|_[('DailyMed', array(['larotrectinib%20sulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009708', 'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications."
CHEMBL3990016,"nan_|_nan_|_Antibody_|_False_|_OLECLUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MEDI-9447' 'MEDI9447' 'Oleclumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0003060', 'EFO_0003869', 'MONDO_0007254',
       'MONDO_0004992', 'EFO_0000616', 'MONDO_0001187'], dtype=object), 'count': 7}_|_[ENSG00000135318]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4297793,"nan_|_nan_|_Protein_|_False_|_NANGIBOTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LR-12' 'Motrem' 'Nangibotide']_|_nan_|_nan_|_{'rows': array(['EFO_0006834', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000124731]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4298129,"nan_|_nan_|_Unknown_|_False_|_HUMAN COAGULATION FACTOR VIII/VON WILLEBRAND FACTOR COMPLEX_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Voncento']_|_['Human coagulation factor viii/von willebrand factor complex' 'Wilate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/voncento'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602', 'Orphanet_903'], dtype=object), 'count': 2}_|_[ENSG00000110799,ENSG00000185010]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for hemophilia a and von willebrand disease."
CHEMBL4594567,"nan_|_nan_|_Antibody_|_False_|_ROCATINLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 451' 'AMG-451' 'AMG451' 'KHK-4083' 'KHK4083' 'KLK4083' 'Khk-4083'
 'Khk4083' 'Rocatinlimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROCATINLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000274'], dtype=object), 'count': 2}_|_[ENSG00000186827]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL5095033,"COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1_|_BRKWREZNORONDU-UHFFFAOYSA-N_|_Small molecule_|_False_|_IBCASERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CS-2164' 'CS2164' 'Chiauranib' 'Cs-2164' 'Ibcasertib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005537', 'EFO_0005952', 'EFO_0000182', 'EFO_0000702',
       'EFO_0000616', 'MONDO_0008170', 'EFO_1001968'], dtype=object), 'count': 7}_|_[ENSG00000178999,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL5314348,"nan_|_nan_|_Protein_|_False_|_BIVALIRUDIN_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Angiomax' 'Angiomax rtu' 'Angiox' 'Bivalirudin'
 'Bivalirudin in 0.9% sodium chloride']_|_['BG-8967' 'BG8967' 'Bivalirudin']_|_[('DailyMed', array(['bivalirudin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/angiox'],
      dtype=object))]_|_['CHEMBL5314353']_|_{'rows': array(['HP_0004419', 'EFO_0005672', 'HP_0001871', 'EFO_0008583',
       'EFO_0000266', 'HP_0001873', 'EFO_0000713', 'EFO_0001645',
       'EFO_0003777', 'MP_0001914', 'EFO_1000985', 'EFO_0003907',
       'EFO_0000612', 'EFO_0000319', 'MONDO_0000831'], dtype=object), 'count': 15}_|_[ENSG00000180210]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 10 investigational indications."
CHEMBL58323,"COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1_|_VPPJLAIAVCUEMN-GFCCVEGCSA-N_|_Small molecule_|_False_|_LACOSAMIDE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Lacosamide' 'Vimpat']_|_['(r)-lacosamide 1' 'ADD 243037' 'ADD-243037' 'ADD243037' 'Erlosamide'
 'Lacosamide' 'Lacosamide cv' 'Motpoly' 'SPM 927' 'SPM-927' 'SPM927']_|_[('DailyMed', array(['lacosamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat'],
      dtype=object)), ('PubChem', array(['170466190'], dtype=object)), ('Wikipedia', array(['Lacosamide'], dtype=object)), ('drugbank', array(['DB06218'], dtype=object))]_|_['CHEMBL1213900']_|_{'rows': array(['EFO_0005543', 'EFO_0003833', 'EFO_0000474', 'MONDO_0007571',
       'EFO_0005230', 'HP_0001250', 'EFO_0005762', 'MONDO_0002050',
       'EFO_0008526', 'EFO_0005687', 'MONDO_0005090', 'MONDO_0004976',
       'EFO_0000326', 'MONDO_0041052', 'MONDO_0005277', 'MONDO_0007079',
       'MONDO_0005178', 'HP_0000726', 'EFO_0004263', 'EFO_0003086',
       'HP_0011868', 'EFO_1000783'], dtype=object), 'count': 22}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for epilepsy and seizure and has 20 investigational indications."
CHEMBL83,"CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1_|_NKANXQFJJICGDU-QPLCGJKRSA-N_|_Small molecule_|_True_|_TAMOXIFEN_|_1977.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ICI-46474' 'ICI-47699' 'Mammaton' 'NSC-727681' 'Nolvadex' 'Novaldex'
 'Soltamox' 'Tamoplex' 'Tamoxifen']_|_[('PubChem', array(['11113844', '144208441', '144210857', '26752017', '26752018',
       '50104683', '50104684', '50104685', '50104686', '56320712',
       '90340643'], dtype=object)), ('TG-GATEs', array(['54'], dtype=object)), ('Wikipedia', array(['Tamoxifen'], dtype=object)), ('drugbank', array(['DB00675'], dtype=object)), ('chEBI', array(['41774'], dtype=object))]_|_['CHEMBL786']_|_{'rows': array(['MONDO_0007254', 'GO_0042697', 'MONDO_0001187', 'MONDO_0010679',
       'EFO_0003869', 'EFO_0009907', 'MONDO_0002158', 'EFO_0003843',
       'HP_0100543', 'EFO_0000305', 'EFO_0000616', 'EFO_1000294',
       'EFO_0000536', 'EFO_0000294', 'MONDO_0011962', 'EFO_0000545',
       'EFO_0004248', 'EFO_0000519', 'MONDO_0018364', 'HP_0000771',
       'EFO_0000305', 'EFO_0003833', 'EFO_0009708', 'EFO_1000158',
       'MONDO_0002087', 'EFO_1001512', 'EFO_0000389', 'MONDO_0002691',
       'EFO_0004220', 'MONDO_0004985', 'EFO_1001901', 'EFO_0000232',
       'MONDO_0008170', 'MONDO_0019180', 'MONDO_0018848', 'EFO_0000764',
       'EFO_0005543', 'EFO_0006861', 'EFO_0000637', 'EFO_0000616',
       'MONDO_0008315', 'EFO_0001075', 'EFO_1000251', 'MONDO_0007254',
       'EFO_1001375', 'EFO_0007532', 'MONDO_0100096', 'MONDO_0004992',
       'EFO_0000432', 'Orphanet_145', 'EFO_0000537', 'MONDO_0004976',
       'EFO_1000984', 'EFO_0001416'], dtype=object), 'count': 54}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 49 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1026,"CS(=O)(=O)O.Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1_|_CVKUMNRCIJMVAR-UHFFFAOYSA-N_|_Small molecule_|_False_|_FENOLDOPAM MESYLATE_|_1997.0_|_4.0_|_CHEMBL588_|_False_|_True_|_['Corlopam' 'Fenoldopam mesylate']_|_['Fendolopam mesylate' 'Fenoldopam mesilate' 'Fenoldopam mesylate'
 'Fenoldopam methanesulfonate' 'NSC-759860' 'SK&F 82526-J' 'SK&F-82526J'
 'SK-82526-J']_|_[('DailyMed', array(['fenoldopam%20mesylate'], dtype=object)), ('PubChem', array(['49681595'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'HP_0001919'], dtype=object), 'count': 2}_|_[ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and has 1 investigational indication."
CHEMBL1077896,"CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C_|_ZKMNUMMKYBVTFN-HNNXBMFYSA-N_|_Small molecule_|_False_|_ROPIVACAINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ropivacaine' 'Ropivicaine' 'TLC-590' 'TLC590' 'Tlc590']_|_[('PubChem', array(['26758019'], dtype=object)), ('Wikipedia', array(['Ropivacaine'], dtype=object)), ('drugbank', array(['DB00296'], dtype=object)), ('chEBI', array(['8890'], dtype=object))]_|_['CHEMBL1889140']_|_{'rows': array(['EFO_0003843', 'HP_0012532', 'EFO_0007355', 'MONDO_0005178',
       'EFO_0003869', 'MONDO_0001572', 'EFO_0003931', 'EFO_0009507',
       'EFO_0002950', 'EFO_0009620', 'MONDO_0001056', 'HP_0003040',
       'MONDO_0004992', 'HP_0003470', 'EFO_0009676', 'EFO_0001358',
       'MONDO_0008170', 'EFO_0005251', 'EFO_0006859', 'HP_0000138',
       'MONDO_0007254', 'HP_0030834', 'HP_0000023', 'HP_0000023',
       'EFO_0007149', 'EFO_0003843', 'HP_0002027', 'HP_0001822',
       'HP_0002017', 'MONDO_0005178', 'EFO_0007486', 'EFO_1001909',
       'HP_0001822', 'EFO_0004616', 'EFO_1001250'], dtype=object), 'count': 35}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 32 investigational indications."
CHEMBL1200420,"Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.Cl_|_PLYSCVSCYOQVRP-UHFFFAOYSA-N_|_Small molecule_|_True_|_MIDAZOLAM HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL655_|_False_|_True_|_['Buccolam' 'Dormicum' 'Hypnovel' 'Midazolam hydrochloride'
 'Midazolam hydrochloride (autoinjector)'
 'Midazolam hydrochloride preservative free' 'Midozalam hydrochloride'
 'Rocam' 'Seizalam' 'Versed']_|_['Midazolam hcl' 'Midazolam hydrochloride' 'Midazolam hydrochloride civ'
 'NSC-751451' 'RO 21-3981/003' 'RO-213981001' 'Ro-213981-003' 'SHP-615'
 'SHP615']_|_[('DailyMed', array(['midazolam%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam'],
      dtype=object)), ('PubChem', array(['144206166', '170465015', '49731994'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0000274', 'EFO_0008526', 'MONDO_0005148',
       'EFO_0000618', 'EFO_0000662', 'EFO_0000616', 'MONDO_0002050',
       'MONDO_0018076', 'MONDO_0004985', 'EFO_1001454', 'EFO_1001884'],
      dtype=object), 'count': 12}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for amnesia and has 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201102,"CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21.Cl_|_FTNWXGFYRHWUKG-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIFLUPROMAZINE HYDROCHLORIDE_|_1957.0_|_4.0_|_CHEMBL570_|_False_|_True_|_['Vesprin']_|_['MC-4703' 'NSC-14959' 'NSC-17473' 'Triflupromazine hcl'
 'Triflupromazine hydrochloride']_|_[('PubChem', array(['144204828', '170465325', '26747673', '26747674', '50107065',
       '50107066', '50107067', '540840', '541291', '56422371', '57288079',
       '855673'], dtype=object)), ('chEBI', array(['9712'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957."
CHEMBL1201165,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC5CCCC5)ccc4[C@H]3CC[C@@]21C_|_PWZUUYSISTUNDW-VAFBSOEGSA-N_|_Small molecule_|_False_|_QUINESTROL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Estrovis']_|_['NSC-759637' 'Quinestrol' 'W 3566' 'W-3566']_|_[('PubChem', array(['11532988', '144205893', '170465054', '29217904', '56422146'],
      dtype=object)), ('Wikipedia', array(['Quinestrol'], dtype=object)), ('drugbank', array(['DB04575'], dtype=object)), ('chEBI', array(['8716'], dtype=object))]_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201349,"C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21_|_HDZAQYPYABGTCL-UHFFFAOYSA-N_|_Small molecule_|_False_|_HEXAFLUORENIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hexafluorenium' 'Hexafluorenium cation' 'Hexafluorenium ion'
 'Hexafluronium']_|_[('drugbank', array(['DB00941'], dtype=object))]_|_['CHEMBL1200933']_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201776,"CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C_|_KWTWDQCKEHXFFR-SMDDNHRTSA-N_|_Small molecule_|_True_|_TAPENTADOL_|_2008.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BN 200 (BASE)' 'BN-200' 'CG-5503' 'CG5503' 'CG5503 (BASE)' 'CG5503 IR'
 'NSC-759619' 'Tapentadol']_|_[('Wikipedia', array(['Tapentadol'], dtype=object)), ('drugbank', array(['DB06204'], dtype=object))]_|_['CHEMBL1201777']_|_{'rows': array(['EFO_0003843', 'MONDO_0005178', 'MONDO_0001583', 'EFO_0005762',
       'HP_0001822', 'EFO_0003843', 'EFO_0004616', 'EFO_1000999',
       'HP_0003418', 'HP_0012532', 'EFO_0005762', 'EFO_1000786',
       'EFO_0000616', 'HP_0003419', 'HP_0003419', 'HP_0012532',
       'EFO_1000783'], dtype=object), 'count': 17}_|_[ENSG00000103546,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1346,"NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1_|_HXGBXQDTNZMWGS-RUZDIDTESA-N_|_Small molecule_|_False_|_DARIFENACIN_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Darifenacin' 'Darifenacin extended release' 'Enablex' 'UK-88525']_|_[('PubChem', array(['50113277'], dtype=object)), ('Wikipedia', array(['Darifenacin'], dtype=object)), ('drugbank', array(['DB00496'], dtype=object)), ('chEBI', array(['391960'], dtype=object))]_|_['CHEMBL1200935']_|_{'rows': array(['HP_0000020', 'HP_0000103', 'EFO_1000781', 'EFO_0006865',
       'EFO_1000781'], dtype=object), 'count': 5}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 1 investigational indication."
CHEMBL1738,"C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1_|_BMKDZUISNHGIBY-ZETCQYMHSA-N_|_Small molecule_|_False_|_DEXRAZOXANE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Cardioxane']_|_['ADR-529' 'Dexrazoxane' 'ICRF-187' 'NSC-169780' 'Razoxane, (s)-'
 'Razoxane, d-']_|_[('PubChem', array(['144205809', '170464709', '442425'], dtype=object)), ('Wikipedia', array(['Dexrazoxane'], dtype=object)), ('drugbank', array(['DB00380'], dtype=object)), ('chEBI', array(['50223'], dtype=object))]_|_['CHEMBL1200778']_|_{'rows': array(['EFO_0000502', 'EFO_0000691', 'EFO_1001968', 'MONDO_0000870',
       'EFO_1000292', 'MONDO_0005301', 'EFO_0000502', 'EFO_0000565',
       'EFO_0000616', 'EFO_0000174', 'EFO_1000158', 'EFO_0000209',
       'EFO_0000318', 'HP_0030680', 'EFO_0000637', 'EFO_0000220',
       'EFO_1000984', 'EFO_0000621', 'EFO_0000621', 'EFO_0000574',
       'EFO_0000198', 'MONDO_0004992', 'EFO_0000222', 'MONDO_0007254',
       'EFO_0000222', 'EFO_0002918'], dtype=object), 'count': 26}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiomyopathy and breast cancer and has 24 investigational indications."
CHEMBL1743033,"nan_|_nan_|_Antibody_|_False_|_ITOLIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMAB-600' 'Bmab 600' 'EQ-001' 'EQ001' 'Itolizumab' 'T1h']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ITOLIZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'MP_0001845', 'EFO_0005809', 'MONDO_0100096',
       'MONDO_0013730', 'EFO_0004599'], dtype=object), 'count': 6}_|_[ENSG00000013725]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL188952,"CC(C(=O)O)c1ccc(N2CC=CC2)c(Cl)c1_|_PIDSZXPFGCURGN-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIRPROFEN_|_1987.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Pirprofen' 'Racemic pirprofen' 'Rangasil 400' 'Rengasil' 'SU 21524'
 'SU-21524' 'Seflenyl']_|_[('Wikipedia', array(['Pirprofen'], dtype=object)), ('drugbank', array(['DB13722'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1987 and is indicated for rheumatic disease. It was withdrawn in at least one region."
CHEMBL2104954,"COc1cc2c(Nc3ccc(Sc4nccn4C)c(Cl)c3)c(C#N)cnc2cc1N1CCC(N2CCCC2)CC1_|_CVAKNHIXTWLGJO-UHFFFAOYSA-N_|_Small molecule_|_False_|_BALAMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Balamapimod' 'MKI-833']_|_nan_|_nan_|_nan_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2106419,"COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1.Cl_|_WMFYOYKPJLRMJI-UHFFFAOYSA-N_|_Small molecule_|_False_|_LERCANIDIPINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL250270_|_False_|_True_|_['Zanidip']_|_['Lercanidipine hcl' 'Lercanidipine hydrochloride' 'REC-15/2375']_|_[('PubChem', array(['144206046', '170465587'], dtype=object))]_|_nan_|_nan_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL2108705,"nan_|_nan_|_Unknown_|_False_|_ASTUPROTIMUT-R_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Astuprotimut r' 'Astuprotimut-r' 'GSK-1572932A' 'GSK-249553'
 'GSK1572932A' 'Hp3tut3x8x' 'MAGE-A3' 'Mage a3 protein'
 'Mage a3 recombinant protein' 'Mage-a3 asci'
 'Mage-a3 recombinant protein' 'SB-249553' 'Zastumotide']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000389', 'EFO_0000181', 'EFO_0000756',
       'EFO_0003060', 'MONDO_0001187'], dtype=object), 'count': 6}_|_[ENSG00000221867]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3305985,"C=CC[N@@+]12CC[C@@]34c5ccccc5N5/C=C6/[C@H]7C[C@H]8[C@@]9(CC[N@@+]8(CC=C)C/C7=C/CO)c7ccccc7N(/C=C(/[C@@H](C[C@@H]31)/C(=C\CO)C2)[C@H]54)[C@@H]69_|_MUQUYTSLDVKIOF-CHJKCJHBSA-N_|_Small molecule_|_False_|_ALCURONIUM_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Alcuronium' 'Alcuronium cation' 'Alcuronium ion' 'Diallylnortoxiferine'
 ""N,n'-diallylnortoxiferinium""]_|_[('drugbank', array(['DB13648'], dtype=object)), ('chEBI', array(['55313'], dtype=object))]_|_['CHEMBL3188339']_|_nan_|_[ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL3306918,"CC(C)n1c(=O)c(C(=O)NCCCN2CCCCC2)c(O)c2ccsc21_|_SCHKZZSVELPJKU-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRX-03140_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Prx-03140']_|_[('drugbank', array(['DB05596'], dtype=object))]_|_['CHEMBL3291085']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3334567,"C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21_|_XYDNMOZJKOGZLS-NSHDSACASA-N_|_Small molecule_|_False_|_SAVOLITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZD-6094' 'AZD6094' 'Azd-6094' 'HMPL-504' 'Savolitinib' 'Volitinib']_|_[('drugbank', array(['DB12048'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003863', 'EFO_0000313', 'EFO_1000657', 'EFO_0003060',
       'EFO_0000681', 'MONDO_0004992', 'MONDO_0001056', 'EFO_0000503',
       'MONDO_0008903', 'MONDO_0008315', 'EFO_0000640', 'EFO_0000616',
       'EFO_1001951', 'EFO_1001949'], dtype=object), 'count': 14}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."
CHEMBL3545006,"nan_|_nan_|_Small molecule_|_False_|_PWT-33587_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pwt-33587']_|_nan_|_nan_|_nan_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3545280,"Cc1cc(Oc2ccc3nc(COc4ccc(CC5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N_|_JCYNMRJCUYVDBC-UHFFFAOYSA-N_|_Small molecule_|_False_|_EFATUTAZONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Efatutazone' 'Inolitazone']_|_[('drugbank', array(['DB11894'], dtype=object))]_|_['CHEMBL3545279']_|_{'rows': array(['MONDO_0004992', 'EFO_1001951', 'EFO_0000616', 'EFO_0000569',
       'EFO_0003060', 'EFO_0001378', 'MONDO_0002108', 'EFO_0000365'],
      dtype=object), 'count': 8}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL3545393,"nan_|_nan_|_Small molecule_|_False_|_XL550_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CS-3150' 'Esaxerenone' 'XL-550' 'Xl550']_|_nan_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000401', 'MONDO_0001422', 'MONDO_0001134'],
      dtype=object), 'count': 4}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3989516,"COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)([O-])[O-])C(=O)C(C)(C)O4)n2)cc(OC)c1OC.O.O.O.O.O.O.[Na+].[Na+]_|_ZQGJCHHKJNSPMS-UHFFFAOYSA-L_|_Small molecule_|_False_|_FOSTAMATINIB DISODIUM_|_2018.0_|_4.0_|_CHEMBL2103830_|_False_|_True_|_['Tavalisse' 'Tavlesse']_|_['Fostamatinib disodium' 'Fostamatinib disodium hexahydrate'
 'Fostamatinib disodium salt hexahydrate' 'Fostamatinib sodium hydrate'
 'R-788 SODIUM' 'R-788 SODIUM HYDRATE' 'R-935788 SODIUM'
 'R-935788 SODIUM HYDRATE' 'R788 SODIUM' 'R788 SODIUM HYDRATE'
 'R935788 SODIUM' 'R935788 SODIUM HYDRATE']_|_[('DailyMed', array(['fostamatinib%20disodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007160', 'MONDO_0007915', 'EFO_0000574', 'EFO_0000685',
       'EFO_0004194', 'HP_0001873', 'EFO_1001264'], dtype=object), 'count': 7}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for autoimmune thrombocytopenic purpura and thrombocytopenia and has 5 investigational indications."
CHEMBL4217292,"N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1_|_LSYANGLAZUZYFX-UHFFFAOYSA-N_|_Small molecule_|_False_|_APINOCALTAMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ACT-709478' 'Act-709478' 'Apinocaltamide']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_['CHEMBL4204434']_|_{'rows': array(['MONDO_0015643', 'HP_0001250'], dtype=object), 'count': 2}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297723,"nan_|_nan_|_Antibody_|_False_|_CEMIPLIMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Libtayo']_|_['Cemiplimab' 'Cemiplimab rwlc' 'REGN-2810' 'REGN2810' 'Regn2810']_|_[('DailyMed', array(['cemiplimab-rwlc'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'MONDO_0007254', 'EFO_0000096', 'MONDO_0002158',
       'EFO_1001951', 'EFO_1000026', 'MONDO_0002898', 'EFO_0001378',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000707', 'MONDO_0008903',
       'EFO_0004197', 'EFO_0000764', 'MONDO_0044926', 'MONDO_0002974',
       'EFO_0005537', 'EFO_0006859', 'MONDO_0001187', 'EFO_0004193',
       'EFO_0000616', 'EFO_0000681', 'EFO_0000181', 'EFO_0003085',
       'MONDO_0021063', 'EFO_0000756', 'EFO_0003863', 'EFO_0002618',
       'EFO_0000183', 'MONDO_0008170', 'EFO_1001051', 'MONDO_0008315',
       'EFO_1001471', 'EFO_0009709', 'EFO_0000574', 'EFO_0003968',
       'MONDO_0001056'], dtype=object), 'count': 37}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 31 investigational indications."
CHEMBL4297808,"nan_|_nan_|_Antibody_|_False_|_DAZUKIBART_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dazukibart' 'PF-06823859' 'PF06823859' 'Pf-06823859']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DAZUKIBART/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0000783', 'EFO_0000398', 'EFO_0003834'],
      dtype=object), 'count': 4}_|_[ENSG00000171855]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4650301,"CC(C)[C@H](N)C(=O)NCCCS(=O)(=O)O_|_NRZRFNYKMSAZBI-ZETCQYMHSA-N_|_Small molecule_|_False_|_VALILTRAMIPROSATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ALZ-801' 'Alz-801' 'BLU-8499' 'BLU8499' 'NRM-8499' 'NRM8499'
 'Valiltramiprosate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VALILTRAMIPROSATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL495,"CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O_|_GMVPRGQOIOIIMI-DWKJAMRDSA-N_|_Small molecule_|_True_|_ALPROSTADIL_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Alprostadil' 'Caverject' 'Caverject impulse' 'Edex' 'Prostin vr'
 'Prostin vr pediatric' 'Viridal 10' 'Viridal 20' 'Viridal 5'
 'Viridal duo' 'Vitaros']_|_['Alprostadil' 'NSC-165559' 'ONO-1608' 'Pge1' 'Prostaglandin e1'
 'U-10,136' 'U-10136']_|_[('DailyMed', array(['alprostadil'], dtype=object)), ('PubChem', array(['144204033', '49681576'], dtype=object)), ('Wikipedia', array(['Prostaglandin_E1'], dtype=object)), ('drugbank', array(['DB00770'], dtype=object)), ('chEBI', array(['15544'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001919', 'EFO_0000319', 'MONDO_0008315', 'EFO_0004714',
       'EFO_1000809', 'EFO_0004234', 'EFO_0009606', 'MONDO_0100096',
       'EFO_0003144', 'HP_0001643', 'EFO_0004265', 'EFO_0003875',
       'MONDO_0100130', 'EFO_1000820'], dtype=object), 'count': 14}_|_[ENSG00000160951,ENSG00000125384]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL502,"COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2_|_ADEBPBSSDYVVLD-UHFFFAOYSA-N_|_Small molecule_|_False_|_DONEPEZIL_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Aricept' 'D-797' 'Donaz' 'Donepezil' 'E-2020']_|_[('PubChem', array(['50112790'], dtype=object)), ('Wikipedia', array(['Donepezil'], dtype=object)), ('drugbank', array(['DB00843'], dtype=object)), ('chEBI', array(['53289'], dtype=object))]_|_['CHEMBL2171854' 'CHEMBL1678' 'CHEMBL2337271']_|_{'rows': array(['EFO_0000546', 'EFO_0003756', 'HP_0002381', 'HP_0100543',
       'EFO_0009267', 'EFO_0009386', 'MONDO_0005180', 'EFO_0000712',
       'MONDO_0010726', 'EFO_0001064', 'EFO_0004718', 'MONDO_0001020',
       'MONDO_0004992', 'MONDO_0004975', 'EFO_1000158', 'EFO_0009267',
       'MONDO_0002050', 'EFO_0000701', 'MONDO_0004975', 'HP_0000016',
       'MONDO_0005301', 'EFO_0005230', 'MONDO_0005148', 'MONDO_0010383',
       'MONDO_0002050', 'Orphanet_240071', 'EFO_0005762', 'EFO_0003768',
       'HP_0100543', 'EFO_0003758', 'EFO_0005762', 'EFO_0004718',
       'HP_0000726', 'EFO_1001176', 'MONDO_0005090', 'HP_0002140',
       'MONDO_0005277', 'EFO_0002610', 'HP_0000726'], dtype=object), 'count': 39}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for alzheimer disease and dementia and has 33 investigational indications."
CHEMBL5315053,"Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1.O_|_NBNBOZLBWLNZHB-ZOWNYOTGSA-N_|_Small molecule_|_False_|_PEMETREXED MONOHYDRATE_|_2016.0_|_4.0_|_CHEMBL225072_|_False_|_True_|_['Armisarte (previously pemetrexed actavis)']_|_['Armisarte' 'Pemetrexed diacid monohydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/armisarte'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000588'], dtype=object), 'count': 2}_|_[ENSG00000176890,ENSG00000228716,ENSG00000159131]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for non-small cell lung carcinoma and mesothelioma."
CHEMBL54349,"CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12_|_JRTIDHTUMYMPRU-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALPIDEM_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Alpidem' 'SL 80.0342-00' 'SL-80.0342-00']_|_[('PubChem', array(['144207142', '170466634'], dtype=object)), ('Wikipedia', array(['Alpidem'], dtype=object))]_|_nan_|_nan_|_[ENSG00000100300]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL564,"CN(C)CCCN1c2ccccc2Sc2ccccc21_|_ZGUGWUXLJSTTMA-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROMAZINE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Combelen' 'NSC-31447' 'Promazine']_|_[('PubChem', array(['11111651', '11111652', '124881158', '50100325', '50104276',
       '90341344'], dtype=object)), ('Wikipedia', array(['Promazine'], dtype=object)), ('drugbank', array(['DB00420'], dtype=object)), ('chEBI', array(['8459'], dtype=object))]_|_['CHEMBL1200469']_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for psychosis."
CHEMBL831,"CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1_|_XJGVXQDUIWGIRW-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOXAPINE_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Adasuve']_|_['CL 62,362' 'CL-62362' 'Loxapac' 'Loxapine' 'Loxitane' 'SUM 3170'
 'SUM-3170']_|_[('DailyMed', array(['loxapine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve'],
      dtype=object)), ('PubChem', array(['50103874', '50104024', '50104025', '50104026', '90341467'],
      dtype=object)), ('Wikipedia', array(['Loxapine'], dtype=object)), ('drugbank', array(['DB00408'], dtype=object)), ('chEBI', array(['50841'], dtype=object))]_|_['CHEMBL1201155' 'CHEMBL1201060']_|_{'rows': array(['EFO_0000341', 'HP_0000713', 'MONDO_0005090', 'MONDO_0004979',
       'EFO_0009267', 'MONDO_0005090', 'EFO_0005407', 'EFO_0003768',
       'MONDO_0004985', 'MONDO_0005277', 'EFO_0005762', 'EFO_0009963',
       'EFO_0005230'], dtype=object), 'count': 13}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL982,"C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5_|_WJBLNOPPDWQMCH-MBPVOVBZSA-N_|_Small molecule_|_False_|_NALMEFENE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Selincro']_|_['JF-1' 'JKB-121' 'Nalmefene' 'Nalmetrene' 'ORF 1167' 'ORF 11676'
 'ORF-1167' 'ORF-11676' 'Revex' 'SRD-174' 'SRD174']_|_[('PubChem', array(['144204424', '170465281', '50103951', '855608'], dtype=object)), ('Wikipedia', array(['Nalmefene'], dtype=object)), ('drugbank', array(['DB06230'], dtype=object)), ('chEBI', array(['7457'], dtype=object))]_|_['CHEMBL5315055' 'CHEMBL1201152']_|_{'rows': array(['EFO_0004699', 'EFO_0000274', 'MONDO_0007079', 'MONDO_0007079',
       'EFO_0005611', 'EFO_0004319', 'EFO_1001249', 'MONDO_0007079',
       'EFO_0003890', 'EFO_0003086', 'EFO_0005611'], dtype=object), 'count': 11}_|_[ENSG00000116329,ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for alcohol dependence and has 8 investigational indications."
CHEMBL10878,"COc1ccc2cccc(CCNC(C)=O)c2c1_|_YJYPHIXNFHFHND-UHFFFAOYSA-N_|_Small molecule_|_False_|_AGOMELATINE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Thymanax' 'Valdoxan']_|_['Agomelatine' 'S-20098' 'S20098' 'Thymanax']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax'],
      dtype=object)), ('PubChem', array(['170466417', '174006904'], dtype=object)), ('Wikipedia', array(['Agomelatine'], dtype=object)), ('drugbank', array(['DB06594'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004242', 'MONDO_0002050', 'EFO_0005230', 'MONDO_0002009',
       'HP_0000726', 'MONDO_0005090', 'MONDO_0002009'], dtype=object), 'count': 7}_|_[ENSG00000168412,ENSG00000134640,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for depressive disorder and major depressive disorder and has 4 investigational indications."
CHEMBL1200550,"O=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1_|_DUIGUKRYYAGJAF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANTAZOLINE PHOSPHATE_|_1994.0_|_4.0_|_CHEMBL1305_|_False_|_True_|_[]_|_['Antazoline phosphate' 'NSC-755865']_|_[('PubChem', array(['26747864', '26747865', '50107311', '56422487', '855846'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994."
CHEMBL1200606,"Cc1cccc(C)c1OCC(C)N.Cl_|_NFEIBWMZVIVJLQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_MEXILETINE HYDROCHLORIDE_|_1985.0_|_4.0_|_CHEMBL558_|_False_|_True_|_['Mexiletine hydrochloride' 'Mexitil' 'Mexitil p.l.' 'Namuscla']_|_['KO 1173 CL' 'KO-1173' 'KO-1173 CL' 'KO-1173-CL' 'Katen' 'Mexiletine hcl'
 'Mexiletine hydrochloride' 'NSC-758639']_|_[('DailyMed', array(['mexiletine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/namuscla'],
      dtype=object)), ('PubChem', array(['144204800', '144204801', '170464740', '26732616', '26747574',
       '50106611'], dtype=object)), ('chEBI', array(['6917'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0016120', 'HP_0004308', 'EFO_0009387'], dtype=object), 'count': 3}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for myotonic syndrome and ventricular arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200890,"COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl_|_MUZQPDBAOYKNLO-RKXJKUSZSA-N_|_Small molecule_|_True_|_OXYCODONE HYDROCHLORIDE_|_1950.0_|_4.0_|_CHEMBL656_|_True_|_True_|_['Abtard' 'Candox' 'Carexil' 'Dolocodon pr' 'Leveraxo' 'Longtec' 'Lynlor'
 'Oxaydo' 'Oxecta' 'Oxeltra' 'Oxycodone hydrochloride' 'Oxycontin'
 'Oxylan' 'Oxynorm' 'Reltebon' 'Roxicodone' 'Roxybond' 'Shortec'
 'Zomestine']_|_['Anhydrous oxycodone hydrochloride' 'Endocodone' 'Oxecta' 'Oxycodone hcl'
 'Oxycodone hydrochloride' 'Oxycodone hydrochloride cii']_|_[('DailyMed', array(['oxycodone%20hydrochloride'], dtype=object)), ('chEBI', array(['7859'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003890', 'EFO_0004616', 'HP_0003419', 'EFO_1000786',
       'HP_0012532', 'EFO_0003843'], dtype=object), 'count': 6}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 3 approved and 3 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1201141,"CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O_|_IHHXIUAEPKVVII-ZSCHJXSPSA-N_|_Small molecule_|_False_|_IBUPROFEN LYSINE_|_2006.0_|_4.0_|_CHEMBL521_|_False_|_True_|_['Feminax express' 'Ibuprofen lysine' 'Neoprofen' 'Nurofen advance'
 'Nurofen max strgth mig pain' 'Nurofen migraine pain'
 'Nurofen tension headache']_|_['Arfen' 'Dolormin' 'Ibuprofen l-lysine' 'Ibuprofen lysinate'
 'Ibuprofen lysine' 'Imbun' 'Lisiprofen' 'Saren' 'Solufenum' 'Soluphene']_|_[('DailyMed', array(['ibuprofen%20lysine'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001643'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006 and is indicated for patent ductus arteriosus."
CHEMBL1201557,"nan_|_nan_|_Protein_|_True_|_INTERFERON ALFACON-1_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Infergen']_|_['Interferon alfacon-1' 'Rsifn-co']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/infergen'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007328', 'MONDO_0100096', 'EFO_0000616', 'EFO_0003047',
       'EFO_0004220'], dtype=object), 'count': 5}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for neoplasm and chronic hepatitis c virus infection and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201571,"nan_|_nan_|_Protein_|_False_|_ALEFACEPT_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Amevive']_|_['Alefacept' 'BG-9273' 'BG-9712' 'BG9273' 'BG9712'
 'Human lfa-3igg fusion protein' 'LFA-3CD2' 'LFA-3TIP' 'LFA3TIP']_|_[('DrugCentral', array(['5088'], dtype=object)), ('Wikipedia', array(['Alefacept'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000540', 'EFO_1000726', 'EFO_0000676', 'MONDO_0020547',
       'MONDO_0005147', 'MONDO_0015597', 'EFO_0000574', 'HP_0001915',
       'EFO_1002048', 'EFO_0003778'], dtype=object), 'count': 10}_|_[ENSG00000116824]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and has 9 investigational indications."
CHEMBL1201619,"nan_|_nan_|_Unknown_|_False_|_APROTININ_|_1993.0_|_4.0_|_nan_|_True_|_True_|_['Trasylol']_|_['Aprotinin' 'Aprotinin (bovine)' 'Aprotinin (synthetic)'
 'Aprotinin biosynthetic' 'Aprotinin bovine'
 'Aprotinin concentrated solution' 'BAYER A 128' 'BAYER-A-128'
 'BAYERA-128' 'Bovine aprotinin' 'Fibrinolysis inhibitor' 'RIKER 52G'
 'RIKER-52G' 'RP 9921' 'RP-9921']_|_[('DrugCentral', array(['4839'], dtype=object)), ('Wikipedia', array(['Aprotinin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000278', 'MONDO_0007254', 'MP_0001914'], dtype=object), 'count': 3}_|_[ENSG00000122194,ENSG00000164344]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for hemorrhage and has 2 investigational indications. It was withdrawn in at least one region."
CHEMBL190461,"C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O_|_QHMBSVQNZZTUGM-ZWKOTPCHSA-N_|_Small molecule_|_False_|_CANNABIDIOL_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Epidiolex' 'Epidyolex']_|_['(-)-cannabidiol' '(-)-cbd' '(-)-trans-cannabidiol'
 '.delta.1(2)-trans-cannabidiol' 'BTX-1204' 'BTX-1503' 'CBD' 'Cannabidiol'
 'Cannabidiol solution' 'Cardiolrx' 'GWP-42003' 'GWP-42003-P' 'GWP42003'
 'GWP42003-P']_|_[('DailyMed', array(['cannabidiol'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex'],
      dtype=object)), ('drugbank', array(['DB09061'], dtype=object)), ('chEBI', array(['69478'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0005762', 'MONDO_0007739', 'EFO_1001917',
       'EFO_0000474', 'MONDO_0008300', 'EFO_0000519', 'HP_0002829',
       'EFO_0005230', 'MONDO_0004976', 'EFO_0004242', 'MONDO_0010726',
       'EFO_0005411', 'EFO_0008507', 'MONDO_0005351', 'EFO_0001358',
       'EFO_0010072', 'EFO_0003756', 'EFO_0010702', 'EFO_0000384',
       'EFO_0008526', 'EFO_0007427', 'HP_0001249', 'EFO_0004599',
       'HP_0001397', 'EFO_0005676', 'MONDO_0011728', 'EFO_0000764',
       'EFO_1000783', 'EFO_0002610', 'EFO_0003843', 'EFO_0007191',
       'MONDO_0013730', 'MONDO_0008501', 'MONDO_0005090', 'EFO_0003108',
       'MONDO_0002959', 'EFO_0005407', 'HP_0100543', 'EFO_0003778',
       'HP_0000938', 'EFO_0003890', 'MONDO_0016532', 'EFO_0000180',
       'MONDO_0010826', 'EFO_0003758', 'HP_0012532', 'MONDO_0100062',
       'HP_0012167', 'MONDO_0018097', 'Orphanet_93955', 'EFO_0000537',
       'MONDO_0005277', 'EFO_0000546', 'EFO_0000673', 'MONDO_0007079',
       'EFO_0008568', 'EFO_0000729', 'EFO_0004698', 'EFO_0004616',
       'EFO_0005611', 'EFO_0005687', 'EFO_0003086', 'MONDO_0010383',
       'EFO_1000634', 'MONDO_0008903', 'HP_0001250', 'MONDO_0007254',
       'EFO_0003100', 'EFO_0000616', 'EFO_0004895', 'MONDO_0004985',
       'EFO_0009609', 'EFO_0003768', 'MONDO_0100096', 'EFO_0003144'],
      dtype=object), 'count': 76}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 4 approved and 71 investigational indications."
CHEMBL2103875,"CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1_|_LIRYPHYGHXZJBZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRAMETINIB_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Mekinist']_|_['GSK-1120212' 'GSK1120212' 'JTP 74057' 'JTP-74057' 'TMT-212' 'TMT212'
 'Tmt212' 'Trametinib']_|_[('PubChem', array(['137276024'], dtype=object)), ('drugbank', array(['DB08911'], dtype=object)), ('chEBI', array(['75998'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011719', 'MONDO_0008315', 'EFO_0002618', 'EFO_1000926',
       'MONDO_0015523', 'EFO_0000196', 'EFO_1000657', 'EFO_0000182',
       'EFO_0000222', 'MONDO_0004976', 'MONDO_0100342', 'MONDO_0008903',
       'EFO_0000565', 'MONDO_0004992', 'EFO_0003060', 'EFO_0000756',
       'EFO_0001378', 'MONDO_0017795', 'EFO_0002617', 'EFO_1001968',
       'EFO_0005221', 'EFO_1001951', 'MONDO_0021063', 'EFO_1000209',
       'HP_0100727', 'EFO_0003868', 'MONDO_0002974', 'MONDO_0005184',
       'EFO_1000849', 'EFO_1000760', 'MONDO_0007254', 'EFO_0000571',
       'MONDO_0001056', 'EFO_0005537', 'EFO_0000616', 'EFO_0000389',
       'EFO_0000501', 'EFO_0000641', 'MONDO_0002108', 'MONDO_0016642',
       'EFO_0000365', 'EFO_0006772'], dtype=object), 'count': 42}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 42 investigational indications."
CHEMBL2111097,"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl_|_HTIQEAQVCYTUBX-KRWDZBQOSA-N_|_Small molecule_|_False_|_LEVAMLODIPINE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amlodipine, (s)-' 'Levamlodipine' 'S-amlodipine']_|_[('drugbank', array(['DB09237'], dtype=object)), ('chEBI', array(['53796'], dtype=object))]_|_['CHEMBL2107350' 'CHEMBL4594288']_|_{'rows': array(['EFO_0000537', 'EFO_0000537', 'EFO_0000319', 'EFO_0000537'],
      dtype=object), 'count': 4}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for cardiovascular disease and hypertension and has 2 investigational indications."
CHEMBL219916,"O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1_|_FGXWKSZFVQUSTL-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOMPERIDONE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Domilium' 'Evoxin' 'Motilium' 'Motilium 10' 'Motilium instants'
 'Vivadone']_|_['Domperidone' 'NSC-299589' 'NSC-759575' 'R 33,812' 'R-33812']_|_[('PubChem', array(['11111029', '124878657', '124878660', '124878661', '124878664',
       '144203607', '147912', '170465594', '174006911', '26746912',
       '26746913', '26751449', '4254117', '46500486', '50103922',
       '50103923', '50103924', '50103925', '50109475', '85230869',
       '855562', '90341791'], dtype=object)), ('Wikipedia', array(['Domperidone'], dtype=object)), ('drugbank', array(['DB01184'], dtype=object)), ('chEBI', array(['31515'], dtype=object))]_|_['CHEMBL4594380' 'CHEMBL3436365']_|_{'rows': array(['EFO_0003948', 'MONDO_0005180', 'EFO_0003917', 'EFO_1000948',
       'EFO_0003929', 'EFO_0003840', 'EFO_1000948', 'EFO_0008533',
       'EFO_1001463', 'EFO_0010282'], dtype=object), 'count': 10}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and has 9 investigational indications."
CHEMBL22055,"CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1_|_UCQSBGOFELXYIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_SUFUGOLIX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Sufugolix' 'TAK-013' 'Tak-013']_|_[('drugbank', array(['DB06494'], dtype=object))]_|_nan_|_nan_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2387080,"Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1_|_BEUQXVWXFDOSAQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TASELISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GDC-0032' 'RG-7604' 'Taselisib']_|_[('drugbank', array(['DB12108'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008903', 'EFO_0000708', 'EFO_0005952', 'MONDO_0007254',
       'EFO_0005537', 'EFO_0001378'], dtype=object), 'count': 6}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL313006,"CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1_|_YZQLWPMZQVHJED-UHFFFAOYSA-N_|_Small molecule_|_False_|_DALCETRAPIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dalcetrapib' 'JTT-705' 'RO-4607381' 'RO4607381']_|_[('Wikipedia', array(['Dalcetrapib'], dtype=object)), ('drugbank', array(['DB12181'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005672', 'MONDO_0100096', 'EFO_0000319', 'EFO_0001645',
       'MONDO_0021187', 'EFO_0004265', 'Orphanet_309005', 'HP_0003119'],
      dtype=object), 'count': 8}_|_[ENSG00000087237]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL3545249,nan_|_nan_|_Small molecule_|_False_|_GLPG-0555_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Glpg-0555']_|_nan_|_nan_|_nan_|_[ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3940890,"Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F_|_WBFUHHBPNXWNCC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACORAMIDIS_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AG-10' 'AG10' 'Acoramidis']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ACORAMIDIS/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650226']_|_{'rows': array(['EFO_0004129', 'EFO_1001875', 'EFO_0004129'], dtype=object), 'count': 3}_|_[ENSG00000118271]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3989968,"CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1_|_VFBILHPIHUPBPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIFAMILAST_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Difamilast' 'OPA-15406']_|_[('drugbank', array(['DB14987'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297762,"nan_|_nan_|_Oligonucleotide_|_False_|_GOLODIRSEN_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Vyondys 53']_|_['Golodirsen' 'NG-12-0163' 'SRP-4053']_|_[('DailyMed', array(['golodirsen'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GOLODIRSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0020121', 'MONDO_0010679'], dtype=object), 'count': 2}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for muscular dystrophy and duchenne muscular dystrophy."
CHEMBL451930,"CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O_|_UUSZLLQJYRSZIS-LXNNNBEUSA-N_|_Small molecule_|_False_|_PLITIDEPSIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Aplidine' 'Plitidepsin']_|_[('drugbank', array(['DB04977'], dtype=object)), ('chEBI', array(['90205'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000616', 'MONDO_0044903', 'EFO_0001378',
       'EFO_0000574', 'EFO_0003085', 'MONDO_0100096'], dtype=object), 'count': 7}_|_[ENSG00000101210]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4650492,"nan_|_nan_|_Antibody_|_False_|_UNASNEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MT-3921' 'MT3921' 'Mt-3921' 'Unasnemab' 'rH116A3']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/UNASNEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001919'], dtype=object), 'count': 1}_|_[ENSG00000182175]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL490029,"CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O_|_STWITCBWQHTJFJ-XMMPIXPASA-N_|_Small molecule_|_False_|_MK-0533_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-0533' 'MK0533' 'Mk-0533']_|_[('drugbank', array(['DB15242'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL531,"CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21_|_YEHCICAEULNIGD-MZMPZRCHSA-N_|_Small molecule_|_False_|_PERGOLIDE_|_1988.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Pergolide']_|_[('PubChem', array(['104171354', '26754330', '26754331', '90341767'], dtype=object)), ('Wikipedia', array(['Pergolide'], dtype=object)), ('drugbank', array(['DB01186'], dtype=object)), ('chEBI', array(['63617'], dtype=object))]_|_['CHEMBL1275']_|_{'rows': array(['MONDO_0005180', 'EFO_0002610'], dtype=object), 'count': 2}_|_[ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for parkinson disease and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL60889,"CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1_|_YPELFRMCRYSPKZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOSAPRIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Mosapride' 'Mosart']_|_[('PubChem', array(['174006284', '29216210', '50110109'], dtype=object)), ('Wikipedia', array(['Mosapride'], dtype=object)), ('drugbank', array(['DB11675'], dtype=object))]_|_['CHEMBL1733174']_|_{'rows': array(['MONDO_0004567', 'EFO_0010282', 'EFO_0008533', 'HP_0002014',
       'EFO_0000555', 'EFO_0008533', 'EFO_0000217', 'HP_0002019'],
      dtype=object), 'count': 8}_|_[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084,ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL623,"CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1_|_VRBKIVRKKCLPHA-UHFFFAOYSA-N_|_Small molecule_|_True_|_NEFAZODONE_|_1994.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Nefazodone']_|_[('PubChem', array(['29217604', '49666410', '50111710'], dtype=object)), ('Wikipedia', array(['Nefazodone'], dtype=object)), ('drugbank', array(['DB01149'], dtype=object)), ('chEBI', array(['7494'], dtype=object))]_|_['CHEMBL1200492']_|_{'rows': array(['EFO_0007191', 'EFO_0002610', 'MONDO_0002009', 'MONDO_0002009'],
      dtype=object), 'count': 4}_|_[ENSG00000108576,ENSG00000147246,ENSG00000103546,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL697,"CN1C(=O)CC(C)(c2ccccc2)C1=O_|_AJXPJJZHWIXJCJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHSUXIMIDE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Celontin']_|_['Mesuximide' 'Methsuximide' 'NSC-760075']_|_[('DailyMed', array(['methsuximide'], dtype=object)), ('PubChem', array(['144207162'], dtype=object)), ('Wikipedia', array(['Mesuximide'], dtype=object)), ('drugbank', array(['DB05246'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'EFO_0000474'], dtype=object), 'count': 2}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for seizure and epilepsy."
CHEMBL765,"N=C(N)NCCN1CCCCCCC1_|_ACGDKVXYNVEAGU-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANETHIDINE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Esimil' 'Guanethidine' 'Ismelin']_|_[('PubChem', array(['11112157'], dtype=object)), ('Wikipedia', array(['Guanethidine'], dtype=object)), ('drugbank', array(['DB01170'], dtype=object)), ('chEBI', array(['5557'], dtype=object))]_|_['CHEMBL2051958' 'CHEMBL1345' 'CHEMBL3560112']_|_{'rows': array(['EFO_0000537', 'MONDO_0005041'], dtype=object), 'count': 2}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for hypertension and glaucoma."
CHEMBL114551,"CC(=N)NCCSCC[C@H](N)C(=O)O_|_MOLOJNHYNHBPCW-ZETCQYMHSA-N_|_Small molecule_|_False_|_GW-274150_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW274150' 'Gw-274150']_|_[('drugbank', array(['DB12237'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'EFO_0000685', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000007171]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1200514,"CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1.[Br-].[Br-]_|_YHKBUDZECQDYBR-UHFFFAOYSA-L_|_Small molecule_|_False_|_DEMECARIUM BROMIDE_|_1959.0_|_4.0_|_CHEMBL1201229_|_False_|_True_|_['Humorsol' 'Tosmilen']_|_['BC-48' 'Demecarium bromide' 'Demekastigmine bromide']_|_[('PubChem', array(['57265778'], dtype=object)), ('Wikipedia', array(['Demecarium_bromide'], dtype=object)), ('chEBI', array(['4391'], dtype=object))]_|_nan_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959."
CHEMBL1201142,"C#CCN[C@@H]1CCc2ccccc21.CS(=O)(=O)O_|_JDBJJCWRXSVHOQ-UTONKHPSSA-N_|_Small molecule_|_False_|_RASAGILINE MESYLATE_|_2006.0_|_4.0_|_CHEMBL887_|_False_|_True_|_['Azilect' 'Rasagiline mesylate']_|_['Agilect' 'Azilect' 'Rasagiline (as mesilate)' 'Rasagiline mesilate'
 'Rasagiline mesylate' 'Rasagline ratiopharm' 'TVP-1012']_|_[('DailyMed', array(['rasagiline%20mesylate'], dtype=object)), ('PubChem', array(['144206188', '170465410'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001050', 'MONDO_0005180'], dtype=object), 'count': 2}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for parkinson disease and has 1 investigational indication."
CHEMBL1201657,"nan_|_nan_|_Oligosaccharide_|_False_|_HEPARIN SODIUM_|_1939.0_|_4.0_|_nan_|_False_|_True_|_['Heparin lock flush' 'Heparin sodium' 'Heparin sodium preservative free'
 'Lipo-hepin' 'Liquaemin lock flush' 'Liquaemin sodium'
 'Liquaemin sodium preservative free' 'Multiparin' 'Panheprin' 'Pump-hep'
 'Sodium heparin' 'Thrombophob' 'Unihep' 'Uniparin' 'Uniparin fte']_|_['Crude heparin' 'Crude heparin porcine' 'Heparin sodium'
 'Heparin sodium porcine' 'Heparin sodium unfractionated'
 'Heparin sodium, porcine' 'Heparinum natricum' 'Liquemin sodium'
 'S01XA14']_|_[('DailyMed', array(['heparin%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'HP_0000083', 'EFO_0001645', 'HP_0004936',
       'EFO_0003964', 'EFO_0003106', 'EFO_0000668', 'HP_0001907',
       'EFO_1000985', 'MONDO_0004992', 'EFO_1001904', 'EFO_0003103',
       'EFO_0002950', 'EFO_0000712', 'EFO_0003033', 'EFO_0000365',
       'EFO_0004610', 'EFO_0003907', 'EFO_0008507', 'EFO_0000713',
       'EFO_0000612', 'MONDO_0002243', 'EFO_0003777', 'EFO_0001073',
       'HP_0001919', 'EFO_0000616', 'EFO_1000637', 'EFO_0008585',
       'MP_0001914', 'EFO_0006834', 'EFO_0000319', 'HP_0100806',
       'EFO_1001129', 'HP_0031273', 'EFO_0000275', 'HP_0004418',
       'EFO_0003913', 'EFO_1001375', 'EFO_0003884', 'EFO_0004286',
       'EFO_0003827', 'EFO_0000546', 'MONDO_0021148', 'MONDO_0100096',
       'EFO_1001951', 'EFO_0000544', 'EFO_0000266', 'EFO_0003060',
       'MONDO_0005148', 'EFO_0008583', 'EFO_0000771', 'EFO_1002048',
       'EFO_0009516', 'EFO_0000545', 'EFO_0000694', 'MONDO_0000831',
       'EFO_0005672'], dtype=object), 'count': 57}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 5 approved and 52 investigational indications."
CHEMBL1269025,"CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1_|_HGVDHZBSSITLCT-JLJPHGGASA-N_|_Small molecule_|_True_|_EDOXABAN_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Lixiana']_|_['DU-176' 'Edoxaban']_|_[('drugbank', array(['DB09075'], dtype=object)), ('chEBI', array(['85973'], dtype=object))]_|_['CHEMBL3542264' 'CHEMBL2105682']_|_{'rows': array(['EFO_0004286', 'EFO_0004265', 'EFO_0003827', 'EFO_0000712',
       'EFO_0008583', 'EFO_0000266', 'EFO_0000694', 'EFO_0009314',
       'EFO_0000275', 'HP_0004419', 'MONDO_0100096', 'EFO_0001645',
       'MP_0001914', 'EFO_0003907', 'EFO_0000712', 'EFO_0003777',
       'MONDO_0000831', 'EFO_0001422', 'EFO_0004286', 'HP_0002140',
       'EFO_0000275'], dtype=object), 'count': 21}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 6 approved and 15 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1705,"Cl.Clc1cccc(Cl)c1NC1=NCCN1_|_ZNIFSRGNXRYGHF-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLONIDINE HYDROCHLORIDE_|_1974.0_|_4.0_|_CHEMBL134_|_False_|_True_|_['Catapres' 'Catapres p.l.' 'Catapres tts 1' 'Catapres tts 2'
 'Catapres tts 3' 'Clonidine hydrochloride' 'Dixarit' 'Duraclon' 'Jenloga'
 'Kapvay']_|_['Clonidine hcl' 'Clonidine hydrochloride' 'Dichloranilino imidazolin'
 'NSC-756699' 'ST-155']_|_[('DailyMed', array(['clonidine%20hydrochloride'], dtype=object)), ('PubChem', array(['144211869', '26719783', '50106022'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0000537', 'EFO_0003888'], dtype=object), 'count': 3}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for hypertension and attention deficit hyperactivity disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1742990,"nan_|_nan_|_Protein_|_True_|_BELATACEPT_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Nujolix' 'Nulojix']_|_['BMS-224818' 'Belatacept' 'LEA29Y']_|_[('DailyMed', array(['belatacept'], dtype=object)), ('DrugCentral', array(['5091'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nulojix'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0010134', 'HP_0000093', 'EFO_0000540', 'EFO_0004599',
       'EFO_0000685', 'EFO_0003884', 'MONDO_0005147'], dtype=object), 'count': 7}_|_[ENSG00000121594,ENSG00000114013]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for kidney transplant and immune system disease and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL184999,CC(C)OC(=O)CCC/C=C\CC[C@H]1[C@@H](O)CO[C@@H]1/C=C/[C@@H](O)COc1cccc(Cl)c1_|_SGNMBLPAWMQIHK-LYTYUWFYSA-N_|_Small molecule_|_False_|_AL-12182_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AL-12182' 'Al-12182']_|_nan_|_nan_|_nan_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL185073,"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1_|_GVEAYVLWDAFXET-XGHATYIMSA-N_|_Small molecule_|_False_|_PANCURONIUM_|_1972.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Pancuronium' 'Pavulon']_|_[('PubChem', array(['50104094', '90341747'], dtype=object)), ('Wikipedia', array(['Pancuronium_bromide'], dtype=object)), ('drugbank', array(['DB01337'], dtype=object)), ('chEBI', array(['7907'], dtype=object))]_|_['CHEMBL1200757']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972."
CHEMBL2028665,"CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O_|_UAOCLDQAQNNEAX-ABMICEGHSA-N_|_Small molecule_|_False_|_REMOGLIFLOZIN ETABONATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BHV-091009' 'GSK-189075' 'GSK-189075A' 'GSK189075A' 'Gsk189075'
 'Remogliflozin etabonate']_|_[('drugbank', array(['DB12935'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2095206,"COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O_|_BXPOSPOKHGNMEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BOSUTINIB MONOHYDRATE_|_2012.0_|_4.0_|_CHEMBL288441_|_False_|_True_|_['Bosulif']_|_['Bosutinib (as monohydrate)' 'Bosutinib hydrate']_|_[('DailyMed', array(['bosutinib%20monohydrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif'],
      dtype=object)), ('chEBI', array(['68533'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'MONDO_0004643', 'EFO_0000339'], dtype=object), 'count': 3}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for myeloid leukemia and chronic myelogenous leukemia and has 1 investigational indication."
CHEMBL2103864,"CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1.O_|_AFTCWZSEWTXWTL-BTQNPOSSSA-N_|_Small molecule_|_False_|_NAVARIXIN_|_nan_|_2.0_|_CHEMBL216981_|_False_|_False_|_[]_|_['Mk-7123' 'Navarixin' 'Navarixin monohydrate' 'PS291822' 'SCH 527123'
 'SCH527123']_|_nan_|_nan_|_nan_|_[ENSG00000180871,ENSG00000163464]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2111290,"nan_|_nan_|_Protein_|_False_|_TESAMORELIN ACETATE_|_2010.0_|_4.0_|_CHEMBL1237026_|_False_|_True_|_['Egrifta']_|_['TH9507' 'Tesamorelin acetate']_|_nan_|_nan_|_{'rows': array(['EFO_1001348'], dtype=object), 'count': 1}_|_[ENSG00000106128]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2010 and is indicated for hiv-associated lipodystrophy syndrome."
CHEMBL218166,"O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1_|_CYGODHVAJQTCBG-UHFFFAOYSA-N_|_Small molecule_|_False_|_BIFEPRUNOX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bifeprunox']_|_[('Wikipedia', array(['Bifeprunox'], dtype=object)), ('drugbank', array(['DB04888'], dtype=object))]_|_['CHEMBL2107317']_|_{'rows': array(['MONDO_0004985', 'MONDO_0005090', 'EFO_0009963', 'MONDO_0004975',
       'MONDO_0002050', 'EFO_0005411'], dtype=object), 'count': 6}_|_[ENSG00000178394,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3544974,"CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O_|_GMDCDXMAFMEDAG-BTJKTKAUSA-N_|_Small molecule_|_True_|_ASENAPINE MALEATE_|_2009.0_|_4.0_|_CHEMBL3187365_|_False_|_True_|_['Saphris' 'Sycrest']_|_['Asenapine (as maleate)' 'Asenapine maleate' 'ORG 5222' 'ORG-5222']_|_[('DailyMed', array(['asenapine%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sycrest'],
      dtype=object)), ('drugbank', array(['DB06216'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090', 'HP_0025268', 'EFO_0005407', 'EFO_0005411',
       'EFO_0009963', 'MONDO_0004985'], dtype=object), 'count': 6}_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545004,"nan_|_nan_|_Small molecule_|_False_|_PL-225B_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pl-225b']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000140443]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545071,"nan_|_nan_|_Antibody_|_False_|_SERIBANTUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MM121' 'SAR256212' 'Seribantumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0002618'], dtype=object), 'count': 2}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545085,"CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1_|_ALKJNCZNEOTEMP-UHFFFAOYSA-N_|_Small molecule_|_False_|_XL-228_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Exel-2280' 'XL228' 'Xl-228']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000220', 'EFO_0000574', 'EFO_0000339'],
      dtype=object), 'count': 4}_|_[ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000140443,ENSG00000097007]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL3545298,"nan_|_nan_|_Small molecule_|_False_|_AZD-6918_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Azd-6918']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3707319,"nan_|_nan_|_Small molecule_|_False_|_GRC-15300_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Grc-15300' 'SAR-292833']_|_nan_|_nan_|_{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}_|_[ENSG00000167723]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3833308,"nan_|_nan_|_Antibody_|_False_|_LITIFILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['24F4A' 'BIIB-059' 'BIIB059' 'Biib 059' 'Biib059' 'Litifilimab'
 'anti-BDCA2']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LITIFILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003834', 'MONDO_0007915', 'EFO_0005809'], dtype=object), 'count': 3}_|_[ENSG00000198178]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3984425,"C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1_|_XUMALORDVCFWKV-IBGZPJMESA-N_|_Small molecule_|_False_|_EGANELISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Eganelisib' 'IPI-549' 'Ipi-549' 'Pi3k-gamma inhibitor ipi-549']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EGANELISIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105851]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297220,"Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1_|_HGCOOPLEWPBLOY-PFEQFJNWSA-N_|_Small molecule_|_False_|_ASCIMINIB HYDROCHLORIDE_|_2021.0_|_4.0_|_CHEMBL4208229_|_False_|_True_|_['Scemblix']_|_['ABL001-AAA' 'Asciminib hydrochloride' 'Scemblix']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000131', 'EFO_0000339'], dtype=object), 'count': 2}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for blast phase chronic myelogenous leukemia, bcr-abl1 positive and chronic myelogenous leukemia."
CHEMBL4297326,"COc1cccc(C(=O)Nc2ccc3c(c2)CCN(C(=O)Oc2ccccc2)C3)c1-c1ccc(C(F)(F)F)cc1_|_AZUIUVJESCFSLJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SLX-4090_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['KD-026' 'Slx-4090']_|_[('drugbank', array(['DB05678'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'Orphanet_411', 'EFO_0004211', 'MONDO_0021187'],
      dtype=object), 'count': 4}_|_[ENSG00000138823,ENSG00000185624]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297741,"nan_|_nan_|_Unknown_|_False_|_DASIGLUCAGON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dasiglucagon' 'ZP-4207' 'ZP-GA-1' 'ZP4207']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0007318', 'MONDO_0017182', 'HP_0001943'],
      dtype=object), 'count': 4}_|_[ENSG00000215644]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297820,"nan_|_nan_|_Antibody_|_False_|_ROZANOLIXIZUMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Rystiggo']_|_['Rozanolixizumab' 'UCB-7665' 'UCB7665' 'Ucb7665']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ROZANOLIXIZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007160', 'HP_0001873', 'EFO_1000868', 'EFO_0005687',
       'EFO_0004991'], dtype=object), 'count': 5}_|_[ENSG00000104870]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for myasthenia gravis and has 4 investigational indications."
CHEMBL4298050,"nan_|_nan_|_Antibody_|_False_|_TIRAGOLUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MTIG-7192A' 'MTIG7192A' 'Mtig 7192a' 'Mtig7192a' 'RG-6058' 'RG6058'
 'RO-7092284' 'RO7092284' 'Tiragolumab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIRAGOLUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018906', 'MONDO_0004992', 'MONDO_0002974', 'EFO_1000657',
       'EFO_1001513', 'EFO_0000616', 'EFO_0000707', 'EFO_0000702',
       'EFO_0000756', 'EFO_0008528', 'EFO_0000181', 'EFO_0005537',
       'EFO_0003060', 'MONDO_0001187', 'EFO_0005922', 'EFO_0000199',
       'EFO_0000681', 'MONDO_0011962', 'EFO_0000503', 'EFO_0000182',
       'EFO_0002916', 'EFO_0000389', 'EFO_0003863', 'MONDO_0007576'],
      dtype=object), 'count': 24}_|_[ENSG00000181847]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications."
CHEMBL4298089,"nan_|_nan_|_Antibody_|_False_|_CODRITUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Codrituzumab' 'GC-33' 'GC33' 'RG-7686' 'RO5137382' 'Ro5137382']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000182'], dtype=object), 'count': 2}_|_[ENSG00000147257]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594385,"nan_|_nan_|_Antibody_|_False_|_ASTEGOLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG-282' 'AMG282' 'Astegolimab' 'MSTT-1041A' 'MSTT1041A' 'Mstt1041a'
 'RG-6149' 'RG6149' 'RO-7187807']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ASTEGOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341', 'MONDO_0100096', 'EFO_0000274'],
      dtype=object), 'count': 4}_|_[ENSG00000196083,ENSG00000115602]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5095303,"nan_|_nan_|_Oligonucleotide_|_False_|_VUTRISIRAN SODIUM_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Amvuttra']_|_['ALN-TTRSC02' 'Amvuttra' 'Votrisiran sodium']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/amvuttra'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004129', 'EFO_0009562'], dtype=object), 'count': 2}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for familial amyloid neuropathy and polyneuropathy."
CHEMBL560993,"Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O_|_FATGTHLOZSXOBC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIMAPIPRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CHF-6532' 'OC-000459' 'OC000459' 'OC459' 'Oc-459' 'Oc000459' 'Odc-9101'
 'Timapiprant']_|_[('drugbank', array(['DB11900'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_0005854', 'EFO_0004232', 'MONDO_0004979'],
      dtype=object), 'count': 4}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL970,"O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F_|_WYCLKVQLVUQKNZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_HALAZEPAM_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Paxipam']_|_['Halazepam' 'Halazepam civ' 'SCH 12041' 'SCH-12041']_|_[('Wikipedia', array(['Halazepam'], dtype=object)), ('drugbank', array(['DB00801'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for anxiety."
CHEMBL1096380,"CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O_|_UNRCMCRRFYFGFX-TYPNBTCFSA-N_|_Small molecule_|_False_|_PLINABULIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['NPI-2358' 'Plinabulin']_|_[('drugbank', array(['DB05992'], dtype=object))]_|_['CHEMBL4063810']_|_{'rows': array(['EFO_0001378', 'MONDO_0001475', 'EFO_0003060', 'MONDO_0004992',
       'EFO_0000702'], dtype=object), 'count': 5}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL1198857,"OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O_|_DAFYYTQWSAWIGS-DEOSSOPVSA-N_|_Small molecule_|_False_|_VILANTEROL_|_2013.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['GW-642444' 'GW-642444X' 'GW642444' 'GW642444X' 'Vilanterol']_|_[('drugbank', array(['DB09082'], dtype=object)), ('chEBI', array(['75037'], dtype=object))]_|_['CHEMBL1084172' 'CHEMBL1084647']_|_{'rows': array(['EFO_0000341', 'EFO_0000464', 'MONDO_0004979', 'MONDO_0004979',
       'EFO_0000341', 'EFO_0006505'], dtype=object), 'count': 6}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 2 investigational indications."
CHEMBL1200322,"CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O_|_KTGRHKOEFSJQNS-BDQAORGHSA-N_|_Small molecule_|_True_|_ESCITALOPRAM OXALATE_|_2002.0_|_4.0_|_CHEMBL1508_|_False_|_True_|_['Escitalopram oxalate' 'Lexapro']_|_['Citalopram oxalate, (s)-' 'Escitalopram (as oxalate)'
 'Escitalopram oxalate' 'LU 26-054-0' 'LU-26-054-0' 'LU-26-054-O'
 'NSC-758934']_|_[('DailyMed', array(['escitalopram%20oxalate'], dtype=object)), ('PubChem', array(['144205088', '170465453', '26749920', '49681820'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_1001919', 'EFO_0004262', 'EFO_0006788',
       'MONDO_0002009', 'EFO_0000555', 'EFO_1001892', 'MONDO_0002050'],
      dtype=object), 'count': 8}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200409,"CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl.O_|_YECIFGHRMFEPJK-UHFFFAOYSA-N_|_Small molecule_|_True_|_LIDOCAINE HYDROCHLORIDE_|_1948.0_|_4.0_|_CHEMBL79_|_False_|_True_|_['Akten' 'Alphacaine hydrochloride' 'Anestacon' 'Anodesyn' 'Bismodyne'
 'Bradosol plus' 'Calgel' 'Co-phenylcaine fte' 'Denela' 'Dequaspray'
 'Emla' 'Germoloids' 'Germoloids complete' 'Glydo' 'Hemocane' 'Iglu'
 'Instillagel' 'Laryng-o-jet kit' 'Laryngojet'
 'Laryngotracheal anesthesia kit' 'Lido hcl' 'Lidocaine hydrochloride'
 'Lidocaine hydrochloride preservative free'
 'Lidocaine hydrochloride viscous' 'Lidocaine viscous' 'Lidocaton'
 'Lidopen' 'Lignokent' 'Lignospan special' 'Lignostab' 'Lignostab a 100'
 'Lignostab n' 'Lignostab-a' 'Lta ii kit' 'Medijel' 'Oragard'
 'Pediatric lta kit' 'Preparation h' 'Rexocaine' 'Versatis' 'Xylocaine'
 'Xylocaine dental' 'Xylocaine preservative free' 'Xylocaine viscous'
 'Xylotox e80' 'Zingo']_|_['Anhydrous lidocaine hydrochloride' 'Lidocaine hcl'
 'Lidocaine hydrochloride' 'Lidocaine hydrochloride anhydrous'
 'Lidocaine hydrochloride monohydrate' 'Lidocaine hydrochloride usp'
 'Lidocaini hydrochloridum' 'Lignocaine (as hydrochloride)'
 'Lignocaine hydrochloride' 'NSC-757420' 'Xylocaine hydrochloride']_|_[('DailyMed', array(['lidocaine%20hydrochloride'], dtype=object)), ('PubChem', array(['56422178'], dtype=object)), ('chEBI', array(['60791'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0003843', 'MONDO_0004992', 'MONDO_0005277',
       'MONDO_0002691', 'EFO_0007490', 'EFO_1001250', 'HP_0012532',
       'HP_0003418', 'HP_0000989', 'EFO_0002950', 'EFO_0001663',
       'EFO_0009552', 'EFO_0000546', 'EFO_0000400', 'EFO_0002618',
       'HP_0002315', 'EFO_1001898', 'EFO_1001996'], dtype=object), 'count': 19}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 3 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200598,"CC/C(=C(/CC)c1ccc(OP(=O)(O)O)cc1)c1ccc(OP(=O)(O)O)cc1_|_NLORYLAYLIXTID-ISLYRVAYSA-N_|_Small molecule_|_False_|_DIETHYLSTILBESTROL DIPHOSPHATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Fosfestrol' 'Stilphostrol']_|_['Diethylstilbestrol diphosphate' 'Fosfestrol']_|_[('PubChem', array(['144206347', '50125929'], dtype=object)), ('chEBI', array(['4532'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for neoplasm."
CHEMBL1200773,"Cc1cccc(C)c1NC(=O)C(C)N.Cl_|_AMZACPWEJDQXGW-UHFFFAOYSA-N_|_Small molecule_|_True_|_TOCAINIDE HYDROCHLORIDE_|_1984.0_|_4.0_|_CHEMBL1762_|_False_|_True_|_['Tonocard' 'Xylotocan']_|_['Tocainide hcl' 'Tocainide hydrochloride' 'Tocainide monohydrochloride']_|_[('PubChem', array(['144204283', '170465114'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA."
CHEMBL1442422,"CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21_|_QPGGEKPRGVJKQB-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIBENZEPIN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dibenzepin']_|_[('PubChem', array(['26754618', '29216076'], dtype=object)), ('drugbank', array(['DB13225'], dtype=object))]_|_['CHEMBL2104287']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000196639,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder."
CHEMBL1489,"Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1_|_NMUSYJAQQFHJEW-KVTDHHQDSA-N_|_Small molecule_|_False_|_AZACITIDINE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Azacitidine' 'Azacitidine accord' 'Onureg' 'Vidaza']_|_['5-azacitidine' 'Azacitidine' 'Ladakamycin' 'NSC-102816' 'U-18,496'
 'U-18496' 'Vidaza']_|_[('DailyMed', array(['azacitidine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-accord'],
      dtype=object)), ('PubChem', array(['124890084', '144204583', '144213302', '170465076', '17390033',
       '26752817', '50105470', '50105471', '50122846', '56320704',
       '56323580', '90341307'], dtype=object)), ('Wikipedia', array(['Azacitidine'], dtype=object)), ('drugbank', array(['DB00928'], dtype=object)), ('chEBI', array(['2038'], dtype=object))]_|_['CHEMBL3250420' 'CHEMBL3250421']_|_{'rows': array(['MONDO_0007576', 'EFO_1001951', 'MONDO_0018906', 'EFO_0000221',
       'EFO_0000403', 'EFO_0006861', 'MONDO_0008170', 'EFO_0000389',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000339', 'EFO_0000569',
       'MONDO_0044903', 'EFO_0005952', 'MONDO_0018076', 'EFO_0006859',
       'MONDO_0003478', 'EFO_1001257', 'EFO_0003869', 'EFO_0003833',
       'EFO_1001779', 'EFO_0000681', 'MONDO_0009348', 'EFO_0000707',
       'Orphanet_848', 'EFO_0003811', 'EFO_0001642', 'MONDO_0020077',
       'EFO_0001378', 'EFO_0000209', 'MONDO_0044881', 'EFO_0000326',
       'EFO_1000028', 'MONDO_0021063', 'EFO_0000574', 'EFO_0002617',
       'EFO_0002618', 'EFO_0000220', 'MONDO_0007254', 'MONDO_0000430',
       'EFO_0000673', 'EFO_0004251', 'EFO_1000657', 'EFO_0000637',
       'EFO_0004252', 'EFO_0000181', 'EFO_0000222', 'EFO_0000183',
       'MONDO_0019469', 'EFO_0000198', 'MONDO_0013730', 'HP_0001873',
       'EFO_0004289', 'EFO_0000255', 'MONDO_0008315', 'MONDO_0002492',
       'MONDO_0002280', 'MONDO_0016586', 'EFO_0000565', 'EFO_0000095',
       'EFO_0000616', 'MONDO_0016486', 'EFO_0000211', 'MONDO_0005184'],
      dtype=object), 'count': 64}_|_[ENSG00000119772,ENSG00000130816]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 56 investigational indications."
CHEMBL1628502,"CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C_|_TZDUHAJSIBHXDL-UHFFFAOYSA-N_|_Small molecule_|_False_|_GABAPENTIN ENACARBIL_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Horizant']_|_['ASP-8825' 'ASP8825' 'GSK1838262' 'Gabapentin enacarbil'
 'Gabapentin encarbil' 'Gsk-1838262' 'XP 13512' 'XP-13512' 'XP13512']_|_[('DailyMed', array(['gabapentin%20enacarbil'], dtype=object)), ('drugbank', array(['DB08872'], dtype=object)), ('chEBI', array(['68840'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0009430', 'EFO_1000783', 'MONDO_0007079',
       'EFO_0004270', 'MONDO_0005277'], dtype=object), 'count': 6}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for neuralgia and restless legs syndrome and has 4 investigational indications."
CHEMBL1737,"CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_DEIYFTQMQPDXOT-UHFFFAOYSA-N_|_Small molecule_|_False_|_SILDENAFIL CITRATE_|_1998.0_|_4.0_|_CHEMBL192_|_False_|_True_|_['Mysildecard' 'Revatio' 'Sildenafil citrate' 'Viagra']_|_['Liqrev' 'NSC-744009' 'NSC-758669' 'Sildenafil (as citrate)'
 'Sildenafil citrate' 'UK-92,480-10' 'UK-92480-10']_|_[('DailyMed', array(['sildenafil%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mysildecard'],
      dtype=object)), ('PubChem', array(['144205270', '170465285'], dtype=object)), ('Wikipedia', array(['Sildenafil'], dtype=object)), ('chEBI', array(['58987'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0006058', 'EFO_0000341', 'MONDO_0008315', 'EFO_1001893',
       'EFO_1001103', 'EFO_1001145', 'MONDO_0005149', 'EFO_0009441',
       'EFO_0003144', 'EFO_1001017', 'EFO_1001827', 'EFO_0003833',
       'EFO_0000404', 'MONDO_0043510', 'EFO_0000668', 'EFO_0000519',
       'EFO_0000545', 'MONDO_0100096', 'EFO_0000464', 'EFO_1001986',
       'EFO_0003047', 'HP_0100607', 'EFO_1000824', 'EFO_0000537',
       'EFO_0001365', 'EFO_0011023', 'EFO_0000616', 'EFO_0004234',
       'EFO_0000495', 'EFO_0000712', 'EFO_0001361', 'EFO_1001134'],
      dtype=object), 'count': 32}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 28 investigational indications."
CHEMBL190333,"OCCC#Cc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1CCCc1ccccc1_|_QSUSKMBNZQHHPA-UHFFFAOYSA-N_|_Small molecule_|_False_|_RWJ-67657_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['JNJ-3026582' 'JNJ3026582' 'RWJ-67657' 'RWJ67657' 'Rwj-67657']_|_[('PubChem', array(['137275843'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112062,ENSG00000185386]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL2103784,"CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C_|_ZOEFCCMDUURGSE-SQKVDDBVSA-N_|_Protein_|_False_|_COSYNTROPIN_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['Cortrosyn' 'Cosyntropin' 'Synacthen' 'Synacthen depot']_|_['Corticotropin tetracosapeptide' 'Cosyntropin' 'Cosyntropin acetate'
 'Cosyntropin hexaacetate' 'Tetracosactide' 'Tetracosactide acetate'
 'Tetracosactide hexaacetate' 'Tetracosactide hexacetate' 'Tetracosactrin'
 'Vicotrope']_|_[('DailyMed', array(['cosyntropin'], dtype=object)), ('drugbank', array(['DB01284'], dtype=object)), ('chEBI', array(['3901'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0004254', 'MONDO_0100062', 'EFO_0005539'],
      dtype=object), 'count': 4}_|_[ENSG00000185231]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 4 investigational indications."
CHEMBL2108038,"nan_|_nan_|_Antibody_|_False_|_MATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EMD-72000' 'Matuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0008170'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108426,nan_|_nan_|_Enzyme_|_False_|_MONTEPLASE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cleactor' 'Monteplase']_|_nan_|_nan_|_nan_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of III.
CHEMBL2109474,nan_|_nan_|_Antibody_|_False_|_TRX-1_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TRX-1']_|_nan_|_nan_|_nan_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2111286,"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Bi+3]_|_XAUTYMZTJWXZHZ-UHFFFAOYSA-K_|_Small molecule_|_False_|_RANITIDINE BISMUTH CITRATE_|_1996.0_|_4.0_|_CHEMBL1790041_|_False_|_True_|_['Pylorid' 'Tritec']_|_['GR 122311X' 'GR-122311X' 'Ranitidine bismuth citrate'
 'Ranitidine bismutrex']_|_nan_|_nan_|_{'rows': array(['EFO_1000961', 'EFO_0003948', 'HP_0004398'], dtype=object), 'count': 3}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for gastroesophageal reflux disease and peptic ulcer and has 1 investigational indication."
CHEMBL2367706,"O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O_|_JTZPPHUZZDKEOC-RBQAPOGLSA-A_|_Unknown_|_False_|_SUCRALFATE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Antepsin' 'Carafate' 'Sucralfate' 'Ulcerlmin']_|_['Sucralfate']_|_[('DailyMed', array(['sucralfate'], dtype=object)), ('DrugCentral', array(['4106'], dtype=object))]_|_['CHEMBL3989780']_|_{'rows': array(['MP_0001914', 'EFO_0003948', 'HP_0100633', 'EFO_0004607',
       'HP_0004398', 'EFO_0004232'], dtype=object), 'count': 6}_|_[ENSG00000256713]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 3 investigational indications."
CHEMBL30219,"C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]_|_KDXZREBVGAGZHS-UHFFFAOYSA-M_|_Small molecule_|_True_|_METHOHEXITAL SODIUM_|_1960.0_|_4.0_|_CHEMBL7413_|_False_|_True_|_['Brevimytal' 'Brevital' 'Brevital sodium' 'Brietal' 'Brietal sod'
 'Methohexitone']_|_['Enallynymal sodium' 'Methohexital sodium' 'Methohexital sodium salt'
 'Sodium methohexital']_|_[('DailyMed', array(['methohexital%20sodium'], dtype=object)), ('chEBI', array(['6834'], dtype=object))]_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960. This drug has a black box warning from the FDA."
CHEMBL3039520,"CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1_|_XEDHVZKDSYZQBF-UHFFFAOYSA-N_|_Small molecule_|_False_|_LASMIDITAN_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['COL-144' 'LY573144' 'Lasmiditan']_|_[('drugbank', array(['DB11732'], dtype=object))]_|_['CHEMBL3039526']_|_{'rows': array(['MONDO_0005277', 'EFO_0003890', 'MONDO_0005277'], dtype=object), 'count': 3}_|_[ENSG00000179097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 1 investigational indication."
CHEMBL306700,"CCOc1ccccc1OCC1CNCCO1_|_YWPHCCPCQOJSGZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_VILOXAZINE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Viloxazin' 'Viloxazine']_|_[('Wikipedia', array(['Viloxazine'], dtype=object)), ('drugbank', array(['DB09185'], dtype=object))]_|_['CHEMBL2106483']_|_{'rows': array(['MONDO_0002009', 'EFO_0003888'], dtype=object), 'count': 2}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for major depressive disorder and attention deficit hyperactivity disorder. This drug has a black box warning from the FDA."
CHEMBL3137354,nan_|_nan_|_Antibody_|_False_|_LULIZUMAB PEGOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-931699' 'Lulizumab pegol']_|_nan_|_nan_|_nan_|_[ENSG00000178562]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL3545155,"COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1_|_ZXBFYBLSJMEBEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_JI-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Angiogenesis inhibitor ji-101' 'CGI-1842' 'JI-101' 'Ji-101']_|_[('drugbank', array(['DB12744'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021063', 'MONDO_0008170', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000113721,ENSG00000128052,ENSG00000196411]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL383322,"CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O_|_BXNMTOQRYBFHNZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_RESIQUIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CD-11301' 'CD11301' 'R-848' 'Resiquimod' 'S-28463']_|_[('Wikipedia', array(['Resiquimod'], dtype=object)), ('drugbank', array(['DB06530'], dtype=object)), ('chEBI', array(['36706'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002913', 'EFO_0000756', 'EFO_0000632', 'EFO_0000519',
       'EFO_0002496', 'EFO_0007328', 'EFO_0004193', 'MONDO_0004992',
       'EFO_0000389', 'EFO_0002617', 'EFO_0002499', 'EFO_0004197'],
      dtype=object), 'count': 12}_|_[ENSG00000196664,ENSG00000101916]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications."
CHEMBL3989992,"nan_|_nan_|_Protein_|_False_|_PEGILODECAKIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AM-0010' 'AM0010' 'LY-3500518' 'LY3500518' 'Pegilodecakin']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0002618'], dtype=object), 'count': 2}_|_[ENSG00000243646,ENSG00000110324]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4285417,"C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1_|_OHUHVTCQTUDPIJ-JYCIKRDWSA-N_|_Small molecule_|_False_|_CERALASERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZD6738' 'Atr kinase inhibitor azd6738' 'Azd 6738' 'Azd-6738'
 'Ceralasertib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CERALASERTIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0003059', 'EFO_0000707', 'EFO_0000181', 'MONDO_0008170',
       'EFO_0000616', 'EFO_0000637', 'EFO_0000756', 'MONDO_0001023',
       'EFO_0005537', 'MONDO_0008315', 'EFO_0000228', 'MONDO_0004992',
       'EFO_0000313', 'EFO_0000403', 'EFO_0000702', 'EFO_0003869',
       'EFO_0000305', 'MONDO_0007254', 'EFO_0000095', 'EFO_0003060'],
      dtype=object), 'count': 20}_|_[ENSG00000175054]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications."
CHEMBL4297551,"nan_|_nan_|_Protein_|_False_|_EFGARTIGIMOD ALFA_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Vyvgart']_|_['ARGX-113' 'Argx-113' 'Efgartigimod' 'Efgartigimod alfa'
 'Efgartigimod alfa fcab' 'Efgartigimod alfa-fcab'
 'Efgartigimod alfa-qvfc' 'Vyvgart']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EFGARTIGIMOD%20ALFA/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005809', 'EFO_0000699', 'MONDO_0017287', 'EFO_0004991',
       'EFO_1000645', 'EFO_0003086', 'EFO_0007187', 'EFO_0007160',
       'EFO_0007292', 'EFO_0009538', 'EFO_0000540', 'EFO_0005761'],
      dtype=object), 'count': 12}_|_[ENSG00000104870]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for myasthenia gravis and immune system disease and has 10 investigational indications."
CHEMBL4297635,"CCCCCc1cccc(CC(=O)O)c1_|_PEGQOIGYZLJMIB-UHFFFAOYSA-N_|_Small molecule_|_False_|_SETOGEPRAM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fezagepras' 'Pbi-4050' 'Setogepram']_|_[('drugbank', array(['DB15447'], dtype=object))]_|_['CHEMBL4799780']_|_{'rows': array(['HP_0001987'], dtype=object), 'count': 1}_|_[ENSG00000126266,ENSG00000139572]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297841,"nan_|_nan_|_Antibody drug conjugate_|_True_|_TISOTUMAB VEDOTIN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Tivdak']_|_['GCT1015-04' 'HuMax-TF-ADC' 'IGG1-1015-011-1006' 'TF-011-MMAE'
 'Tisotumab vedotin' 'Tisotumab vedotin tftv']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TISOTUMAB%20VEDOTIN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002087', 'MONDO_0002158', 'MONDO_0002974', 'MONDO_0008170',
       'MONDO_0004992', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000117525,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4298016,"nan_|_nan_|_Antibody_|_False_|_FROVOCIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Frovocimab' 'LY-3015014' 'LY3015014' 'Ly3015014']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FROVOCIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0003124', 'MONDO_0021187'], dtype=object), 'count': 2}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4298139,"COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1C(=O)OC[n+]1cccc(C(=O)N[C@@H](CO)C(=O)O)c1.[Cl-]_|_GONQEUJYYMYNMN-HWAJWLCKSA-N_|_Small molecule_|_False_|_SERDEXMETHYLPHENIDATE CHLORIDE_|_2021.0_|_4.0_|_CHEMBL4301162_|_False_|_True_|_[]_|_['KP415 Cl' 'Serdexmethylphenidate chloride']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SERDEXMETHYLPHENIDATE%20CHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder."
CHEMBL1094636,"NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12_|_PCHKPVIQAHNQLW-CQSZACIVSA-N_|_Small molecule_|_False_|_NIRAPARIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Zejula']_|_['JNJ-64091742' 'MK-4827' 'MK4827' 'Niraparib' 'ZL-2306']_|_[('drugbank', array(['DB11793'], dtype=object))]_|_['CHEMBL3989922']_|_{'rows': array(['EFO_0004230', 'EFO_0003869', 'MONDO_0008315', 'EFO_0001075',
       'EFO_0003893', 'EFO_0001075', 'EFO_0000181', 'EFO_0000702',
       'EFO_0001663', 'EFO_0000174', 'EFO_1001512', 'MONDO_0004992',
       'MONDO_0011962', 'EFO_1000465', 'EFO_0006859', 'MONDO_0002158',
       'EFO_1000657', 'EFO_0000707', 'EFO_0000616', 'MONDO_0008903',
       'MONDO_0002974', 'EFO_0003060', 'MONDO_0003060', 'EFO_0003893',
       'EFO_1000251', 'EFO_0000196', 'EFO_0000564', 'MONDO_0007254',
       'EFO_0002617', 'EFO_0000574', 'EFO_0000095', 'MONDO_0002087',
       'EFO_1000294', 'EFO_0003863', 'MONDO_0001056', 'EFO_0002618',
       'EFO_1001100', 'MONDO_0005184', 'EFO_0000588', 'Orphanet_145',
       'EFO_0000673', 'MONDO_0008170', 'EFO_0000519', 'EFO_0008528',
       'EFO_0003891', 'EFO_0001061', 'EFO_0000365', 'MONDO_0001187'],
      dtype=object), 'count': 48}_|_[ENSG00000129484,ENSG00000143799]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 6 approved and 42 investigational indications."
CHEMBL1200665,"CCOC(=O)C1(c2ccccc2)CCN(CCC(C#N)(c2ccccc2)c2ccccc2)CC1.Cl_|_SHTAFWKOISOCBI-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENOXYLATE HYDROCHLORIDE_|_1960.0_|_4.0_|_CHEMBL1201294_|_False_|_True_|_[]_|_['Diphenoxylate HCl' 'Diphenoxylate hcl' 'Diphenoxylate hydrochloride'
 'Diphenoxylate hydrochloride cii' 'Diphenoxylati hydrochloridum'
 'R-1132 (ANTIPERISTALTIC)']_|_[('DailyMed', array(['diphenoxylate%20hydrochloride'], dtype=object)), ('PubChem', array(['144206146', '144206378', '170465332', '49681550'], dtype=object)), ('chEBI', array(['59784'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1564,"CN1CCC(OC(c2ccccc2)c2ccccc2)CC1.Cl_|_LPRLDRXGWKXRMQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENYLPYRALINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1492_|_False_|_True_|_['Hispril' 'Histryl' 'Histryl paed' 'Lergoban']_|_['Diaminophen' 'Diamiphen' 'Diamiphene' 'Diaphen' 'Diphenylpyraline HCl'
 'Diphenylpyraline hcl' 'Diphenylpyraline hydrochloride'
 'Diphenylpyraline teoclate' 'NSC-16338' 'NSC-61825']_|_[('PubChem', array(['11532996', '144203970', '170464816', '26748003', '26748004'],
      dtype=object)), ('chEBI', array(['31508'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL159,"CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1_|_JXLYSJRDGCGARV-CFWMRBGOSA-N_|_Small molecule_|_False_|_VINBLASTINE_|_1965.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-47842' 'Velban' 'Vinblastine' '[3H]-Vinblastine']_|_[('Wikipedia', array(['Vinblastine'], dtype=object)), ('drugbank', array(['DB00570'], dtype=object))]_|_['CHEMBL378544']_|_{'rows': array(['EFO_0000588', 'MONDO_0018975', 'EFO_0000681', 'EFO_0000574',
       'EFO_0000691', 'MONDO_0002898', 'MONDO_0009348', 'EFO_0000220',
       'MONDO_0001187', 'MONDO_0008170', 'EFO_0000574', 'EFO_0000222',
       'MONDO_0004192', 'EFO_0004281', 'MONDO_0004986', 'EFO_0006818',
       'MONDO_0003751', 'MONDO_0008315', 'MONDO_0009348', 'EFO_0000183',
       'EFO_0000183', 'EFO_1000318', 'EFO_0000565', 'EFO_0002617',
       'EFO_0000389', 'EFO_0000616', 'EFO_0003833', 'EFO_0005543',
       'EFO_0000389', 'EFO_0000211', 'MONDO_0002041', 'MONDO_0008315',
       'MONDO_0008903', 'MONDO_0002367', 'MONDO_0004986', 'EFO_0000756',
       'MONDO_0001187', 'EFO_1000158', 'EFO_0000756', 'MONDO_0008903',
       'EFO_0009907', 'EFO_0004281', 'EFO_0001642', 'MONDO_0004192',
       'EFO_0008528', 'MONDO_0002974', 'EFO_0000403'], dtype=object), 'count': 47}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 6 approved and 36 investigational indications."
CHEMBL1743007,"nan_|_nan_|_Antibody_|_False_|_DARATUMUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Darzalex']_|_['3003-005' 'Daratumumab' 'Daratumumab-fihj' 'Darzalex' 'HUMAX-CD 38'
 'HuMax-CD38']_|_[('DailyMed', array(['daratumumab'], dtype=object)), ('DrugCentral', array(['5063'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002462', 'EFO_0001378', 'EFO_0005952', 'EFO_0000574',
       'MONDO_0007915', 'EFO_0006475', 'EFO_0005761', 'MONDO_0018906',
       'EFO_0004256', 'EFO_0000198', 'EFO_0003060', 'EFO_1001875',
       'EFO_0000220', 'EFO_0007160', 'EFO_1001469', 'HP_0001915',
       'EFO_0000616', 'EFO_0000349', 'EFO_0003073', 'EFO_0000540',
       'MONDO_0018904', 'EFO_1001115', 'EFO_0009441', 'EFO_0000519',
       'EFO_0000203', 'EFO_0000209', 'MONDO_0019438', 'EFO_0004255',
       'EFO_0000183', 'EFO_1001051', 'EFO_0000673', 'MONDO_0004992',
       'EFO_1001951', 'EFO_0000403', 'EFO_0000095', 'EFO_0004599',
       'EFO_0000222', 'EFO_0006738', 'MONDO_0004975', 'EFO_0005558',
       'MONDO_0008315'], dtype=object), 'count': 41}_|_[ENSG00000004468]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 38 investigational indications."
CHEMBL2104391,"CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O_|_UGOZVNFCFYTPAZ-IOXYNQHNSA-N_|_Protein_|_False_|_INSULIN DETEMIR_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Ins levemir' 'Levemir' 'Levemir flexpen' 'Levemir flextouch'
 'Levemir innolet' 'Levemir penfill']_|_['Detemir' 'Insulin detemir' 'Insulin,detemir,human' 'NN-304']_|_[('DailyMed', array(['insulin%20detemir%20recombinant'], dtype=object)), ('DrugCentral', array(['4985'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/levemir'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'MONDO_0005148', 'MONDO_0005147', 'MONDO_0009061',
       'EFO_0000400', 'EFO_0000537', 'EFO_0001645', 'HP_0003124'],
      dtype=object), 'count': 8}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 5 investigational indications."
CHEMBL2108785,"nan_|_nan_|_Antibody drug conjugate_|_False_|_ZOLIMOMAB ARITOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['H-65-RTA' 'H-65RTA' 'H65-RTA' 'Orthozyme cd 5 plus' 'Xoma zyme h 65'
 'ZX-CD5' 'Zolimomab aritox']_|_nan_|_nan_|_nan_|_[ENSG00000110448]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II."
CHEMBL2109191,"nan_|_nan_|_Antibody_|_False_|_GALIXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Galiximab' 'IDEC-114']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0005952'], dtype=object), 'count': 2}_|_[ENSG00000121594]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2165620,"O=C(O)c1ccc(NC(=O)[C@H](CC2CCCC2)n2cnc(C(F)(F)F)c2)nc1_|_GKMLFBRLRVQVJO-ZDUSSCGKSA-N_|_Small molecule_|_False_|_PF-04991532_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pf-04991532']_|_[('drugbank', array(['DB11765'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL259084,"O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1_|_HHFBDROWDBDFBR-UHFFFAOYSA-N_|_Small molecule_|_False_|_MLN-8054_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MLN 8054' 'MLN-8054' 'Mln-8054' 'Mln8054']_|_[('PubChem', array(['103904597', '174006403', '50100109'], dtype=object)), ('drugbank', array(['DB13061'], dtype=object))]_|_['CHEMBL3586469']_|_{'rows': array(['EFO_0003869', 'EFO_0003860', 'MONDO_0004992', 'EFO_0004288'],
      dtype=object), 'count': 4}_|_[ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL282052,"Cc1ccccc1-n1c(C)nc2ccccc2c1=O_|_JEYCTXHKTXCGPB-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHAQUALONE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['CI-705' 'CN 38703' 'CN-38703' 'Methaqualone' 'Methaqualoneinone'
 'Metolquizolone' 'NSC-111388' 'NSC-111388-' 'NSC-126877' 'NSC-631628'
 'QZ-2' 'R-148' 'TR-495']_|_[('PubChem', array(['144206055', '144206422', '24804237'], dtype=object)), ('Wikipedia', array(['Methaqualone'], dtype=object)), ('drugbank', array(['DB04833'], dtype=object)), ('chEBI', array(['6821'], dtype=object))]_|_['CHEMBL2106829']_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL291657,"C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1_|_IEAKXXNRGSLYTQ-DEOSSOPVSA-N_|_Small molecule_|_False_|_CRINECERFONT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['06-RORI' 'Crinecerfont' 'NBI-74788' 'Nbi-74788' 'SSR125543' 'Ssr 125543'
 'Ssr-125543' 'Ssr125543']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CRINECERFONT/relevant/1/'],
      dtype=object)), ('chEBI', array(['34969'], dtype=object))]_|_['CHEMBL1628268']_|_{'rows': array(['MONDO_0002050', 'MONDO_0018479'], dtype=object), 'count': 2}_|_[ENSG00000120088]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL296522,"COc1cc(N)c(Cl)cc1C(=O)NC1CCN2CCCC1C2_|_GZSKEXSLDPEFPT-UHFFFAOYSA-N_|_Small molecule_|_False_|_RENZAPRIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ATL-1251' 'Renzapride']_|_nan_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000164270,ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3039540,"nan_|_nan_|_Antibody_|_True_|_ADUCANUMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Aduhelm']_|_['Aducanumab' 'Aducanumab avwa' 'BIIB-037' 'BIIB037']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975', 'HP_0000726'], dtype=object), 'count': 2}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alzheimer disease and dementia. This drug has a black box warning from the FDA."
CHEMBL3039547,"nan_|_nan_|_Gene_|_False_|_PEXASTIMOGENE DEVACIREPVEC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['JX-594' 'Pexastimogene devacirepvec']_|_nan_|_nan_|_{'rows': array(['EFO_0009709', 'EFO_0002617', 'EFO_0000681', 'EFO_0000182',
       'MONDO_0008170', 'EFO_0000756', 'EFO_0000616', 'EFO_0000365',
       'EFO_1001951'], dtype=object), 'count': 9}_|_[ENSG00000164400]_|_Gene drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL3301606,"CC1(C)CN(C(=O)c2ccc(-c3cccc4nc(NC(=O)C5CC5)nn34)cc2)C1_|_MPYACSQFXVMWNO-UHFFFAOYSA-N_|_Small molecule_|_False_|_SOLCITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['G-154578' 'G154578' 'GLPG-0778' 'GLPG-0788' 'GLPG0778' 'GSK-2586184'
 'GSK-2586184A' 'GSK2586184A' 'Glpg-0778' 'Gsk-2586184' 'Solcitinib']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0000676', 'EFO_0000729'], dtype=object), 'count': 3}_|_[ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545011,O[C@@H]1[C@H](O)[C@@H](CSc2ccccc2F)O[C@H]1n1cnc2c(N[C@@H]3CCC[C@H]3O)ncnc21_|_IZRXENCTXNMAMI-DIJFLQFKSA-N_|_Small molecule_|_False_|_GS-9667_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CVT 3619' 'CVT-3619' 'Gs-9667']_|_nan_|_nan_|_nan_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545371,"nan_|_nan_|_Antibody drug conjugate_|_False_|_DENINTUZUMAB MAFODOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Denintuzumab mafodotin' 'SGN-19A' 'SGN-CD19A']_|_nan_|_nan_|_{'rows': array(['EFO_1001469', 'EFO_0000220', 'EFO_0000403', 'EFO_0000309',
       'MONDO_0018906'], dtype=object), 'count': 5}_|_[ENSG00000177455]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL360055,"CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC_|_OZLPUNFFCJDMJD-UHFFFAOYSA-N_|_Small molecule_|_False_|_GALLAMINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Gallamine']_|_[('PubChem', array(['11111237', '11111238', '124880248', '26756602', '90341095'],
      dtype=object))]_|_['CHEMBL1200993']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL396778,"C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O_|_NEMGRZFTLSKBAP-LBPRGKRZSA-N_|_Small molecule_|_False_|_SAFINAMIDE_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Xadago']_|_['EMD 1195686' 'EMD-1195686' 'Safinamide']_|_[('Wikipedia', array(['Safinamide'], dtype=object)), ('drugbank', array(['DB06654'], dtype=object))]_|_['CHEMBL48582']_|_{'rows': array(['EFO_1001050', 'EFO_0001421', 'MONDO_0005180', 'EFO_0003086',
       'MONDO_0005180'], dtype=object), 'count': 5}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for parkinson disease and has 3 investigational indications."
CHEMBL3989401,"NCCC(O)(P(=O)([O-])O)P(=O)([O-])O.O.O.O.O.O.[Na+].[Na+]_|_CZYWHNTUXNGDGR-UHFFFAOYSA-L_|_Small molecule_|_False_|_PAMIDRONATE DISODIUM_|_1991.0_|_4.0_|_CHEMBL834_|_False_|_True_|_['Aredia' 'Pamidronate disodium']_|_['CGP 23339AE' 'CGP-23339AE' 'Disodium pamidronate' 'Pamidronate disodium'
 'Pamidronate disodium hydrate' 'Pamidronate disodium pentahydrate']_|_[('DailyMed', array(['pamidronate%20disodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001164', 'EFO_0001378', 'MONDO_0007254', 'MONDO_0019019'],
      dtype=object), 'count': 4}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 investigational indications."
CHEMBL4167360,"Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1_|_DCGDPJCUIKLTDU-QWQRMKEZSA-N_|_Small molecule_|_False_|_IDH305_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Idh305']_|_nan_|_nan_|_{'rows': array(['EFO_0005543', 'EFO_0000222', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000138413]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL454138,"CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21_|_INASOKQDNHHMRE-UHFFFAOYSA-N_|_Small molecule_|_False_|_TUROFEXORATE ISOPROPYL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FXR-450' 'Turofexorate isopropyl' 'WAY-362450' 'XL-335' 'XL335']_|_[('PubChem', array(['137275949'], dtype=object)), ('drugbank', array(['DB12719'], dtype=object))]_|_nan_|_nan_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL5095031,"CCCCCCN(CCOc1ccc(CCCCNC(=N)NC(=O)c2nc(Cl)c(N)nc2N)cc1)C[C@H](O)C(O)[C@H](O)[C@H](O)CO_|_HBZAZSCNDMDWEU-GNZRQIOVSA-N_|_Small molecule_|_False_|_IDREVLORIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GS-560876' 'GS-5737' 'Idrevloride' 'P-1037' 'VRT-1499138' 'VX-371']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IDREVLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000684', 'MONDO_0016575', 'MONDO_0009061'], dtype=object), 'count': 3}_|_[ENSG00000111319,ENSG00000168447,ENSG00000166828]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL572881,"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21_|_RAHBGWKEPAQNFF-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOTESANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 706' 'AMG-706' 'Motesanib']_|_[('PubChem', array(['137276049', '50100087'], dtype=object)), ('drugbank', array(['DB05575'], dtype=object)), ('chEBI', array(['51098'], dtype=object))]_|_['CHEMBL2107357']_|_{'rows': array(['MONDO_0007254', 'MONDO_0021063', 'MONDO_0008903', 'MONDO_0007254',
       'EFO_1000657', 'MONDO_0007576', 'MONDO_0002087', 'EFO_0003060',
       'MONDO_0008170', 'MONDO_0011719', 'EFO_0002618', 'EFO_0000616',
       'EFO_0007331', 'EFO_0003060', 'MONDO_0002158', 'MONDO_0002108',
       'EFO_0004243', 'EFO_0000574', 'MONDO_0016537'], dtype=object), 'count': 19}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000165731]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications."
CHEMBL10316,"c1ccc2c(c1)OCC(C1=NCCN1)O2_|_HPMRFMKYPGXPEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_IDAZOXAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dl-idazoxan' 'Idazoxan' 'NSC-759867' 'RX-781094' 'Racemic idazoxan']_|_[('PubChem', array(['104171177', '144203724', '170466595', '26751897', '90341761'],
      dtype=object)), ('Wikipedia', array(['Idazoxan'], dtype=object)), ('drugbank', array(['DB12551'], dtype=object)), ('chEBI', array(['5862'], dtype=object))]_|_['CHEMBL543467']_|_{'rows': array(['MONDO_0002009', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1200629,"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1.[Br-]_|_VEPSYABRBFXYIB-PWXDFCLTSA-M_|_Small molecule_|_True_|_VECURONIUM BROMIDE_|_1984.0_|_4.0_|_CHEMBL1201219_|_False_|_True_|_['Musculax' 'Norcuron' 'Vecuronium bromide']_|_['NSC-759184' 'ORG NC 45' 'ORG-NC 45'
 'Pancuronium bromide impurity, vecuronium bromide -' 'Vecuronium bromide']_|_[('DailyMed', array(['vecuronium%20bromide'], dtype=object)), ('PubChem', array(['144206024', '170465295'], dtype=object)), ('chEBI', array(['9940'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984. This drug has a black box warning from the FDA."
CHEMBL1201568,"nan_|_nan_|_Protein_|_False_|_PEGFILGRASTIM_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Fulphila' 'Neulasta' 'Neulasta sureclick']_|_['B-12019' 'B12019' 'Cegfila' 'Chs-1701' 'Fulphila' 'Fylnetra'
 'Granulocyte colony-stimulating factor pegfilgrastim' 'Hsp-130'
 'LA EP 2006' 'LA EP-2006' 'La-ep2006' 'Lupifil-p' 'MYL-1401H' 'Msb-11455'
 'Msb11455' 'Neupopeg' 'Nyvepria' 'Peg-filgrastim' 'Pegfilgrastim'
 'Pegfilgrastim (neulasta)' 'Pegfilgrastim apgf'
 'Pegfilgrastim biosimilar (lupin)' 'Pegfilgrastim biosimilar (pfizer)'
 'Pegfilgrastim biosimilar (sandoz)' 'Pegfilgrastim biosimilar - lupin'
 'Pegfilgrastim bmez' 'Pegfilgrastim cbqv' 'Pegfilgrastim for bioassay'
 'Pegfilgrastim fpgk' 'Pegfilgrastim jmdb' 'Pegfilgrastim pbbk'
 'Pegfilgrastim-apgf' 'Pegfilgrastim-bmez' 'Pegfilgrastim-cbqv'
 'Pegfilgrastim-fpgk' 'Pegfilgrastim-jmdb' 'Pegfilgrastim-ljfd'
 'Pegfilgrastim-pbbk' 'Pelmeg' 'Pf-06881894' 'Ql-0605' 'Ql0605'
 'Stimufend' 'TPI-120' 'Udenyca' 'Ziextenzo']_|_[('DailyMed', array(['pegfilgrastim', 'pegfilgrastim-bmez', 'pegfilgrastim-cbqv',
       'pegfilgrastim-jmdb'], dtype=object)), ('DrugCentral', array(['4986'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fulphila-0'],
      dtype=object)), ('Wikipedia', array(['Pegfilgrastim'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007532', 'EFO_0000183', 'EFO_0000544', 'MONDO_0001657',
       'MONDO_0004192', 'EFO_0000756', 'EFO_0000621', 'EFO_0006861',
       'MONDO_0008315', 'MONDO_0004643', 'EFO_0000305', 'EFO_0000702',
       'EFO_0000096', 'EFO_0000181', 'EFO_1000796', 'MONDO_0018906',
       'EFO_0000222', 'EFO_0006859', 'EFO_0000198', 'MONDO_0002087',
       'MONDO_0001056', 'MONDO_0008380', 'EFO_0004252', 'EFO_1001469',
       'EFO_0003060', 'MONDO_0001187', 'EFO_1001951', 'MONDO_0007254',
       'EFO_1000657', 'EFO_0003869', 'EFO_0002913', 'EFO_0000211',
       'EFO_0000574', 'EFO_0008528', 'EFO_0001645', 'MONDO_0001475',
       'EFO_0000403', 'MONDO_0002158', 'EFO_0000514', 'MONDO_0005147',
       'MONDO_0009348', 'MONDO_0002974', 'EFO_0000196', 'MONDO_0008170',
       'EFO_0002939', 'EFO_0000691', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0002618', 'EFO_0007416', 'EFO_0000220', 'EFO_0005537',
       'MONDO_0008903', 'EFO_0001642', 'MONDO_0021063', 'MONDO_0006058',
       'EFO_0005952', 'MONDO_0007576', 'MONDO_0004986', 'EFO_0000637',
       'EFO_0000571', 'EFO_0000681', 'EFO_0000565', 'HP_0001915',
       'EFO_0001378'], dtype=object), 'count': 65}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 4 approved and 61 investigational indications."
CHEMBL1201576,"nan_|_nan_|_Antibody_|_True_|_RITUXIMAB_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Mabthera' 'Mabthera rituxan' 'Rituxan' 'Ruxience']_|_['ABP-798' 'ABP798' 'BI695500' 'Bi 695500' 'Bi-695500' 'Blitzima' 'CT-P10'
 'Gp2013' 'HS-006' 'HS-006 (RITUXIMAB BIOSIMILAR)' 'HS006' 'IDEC-102'
 'IDEC-C2B8' 'Mk-8808' 'Pf-05280586' 'R-105 IDEC-102' 'RG-105'
 'RHCACD20MA' 'Riabni' 'Ritemvia' 'Rituximab'
 'Rituximab (genetical recombination)' 'Rituximab (rituxan)'
 'Rituximab abbs' 'Rituximab arrx' 'Rituximab biosimilar (amgen)'
 'Rituximab biosimilar (celltrion)' 'Rituximab biosimilar (pfizer)'
 'Rituximab biosimilar - celltrion' 'Rituximab biosimilar -merck'
 'Rituximab pvvr' 'Rituximab-abbs' 'Rituximab-arrx'
 'Rituximab-boehringer ingelheim' 'Rituximab-ct-p10' 'Rituximab-pfizer'
 'Rituximab-pvvr' 'Ruxience' 'SAIT-101' 'SAIT101' 'Truxima' 'Tuxella'
 'Usp mab 001, monoclonal igg1' 'Zuberitamab']_|_[('DailyMed', array(['rituximab', 'rituximab-abbs', 'rituximab-pvvr'], dtype=object)), ('DrugCentral', array(['4975'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ruxience'],
      dtype=object)), ('Wikipedia', array(['Rituximab'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002334', 'EFO_0008518', 'EFO_0000309', 'EFO_0003032',
       'EFO_0009441', 'Orphanet_365', 'EFO_0007187', 'MONDO_0007915',
       'EFO_0003840', 'EFO_0000191', 'EFO_1001938', 'EFO_0009538',
       'EFO_0000707', 'EFO_0004244', 'MONDO_0004095', 'EFO_0004540',
       'EFO_0002617', 'MONDO_0010602', 'EFO_1000783', 'MONDO_0011382',
       'EFO_1000868', 'MONDO_0002462', 'EFO_0000220', 'EFO_1001264',
       'MONDO_0001437', 'MONDO_0019391', 'EFO_0003884', 'EFO_0000198',
       'EFO_0003898', 'HP_0000093', 'EFO_0000339', 'EFO_0004288',
       'MONDO_0044881', 'EFO_0007316', 'EFO_0003144', 'MONDO_0000873',
       'MONDO_0019338', 'EFO_0008522', 'MONDO_0004992', 'EFO_0000621',
       'EFO_0004254', 'MONDO_0017719', 'EFO_0000209', 'EFO_0000772',
       'HP_0001871', 'EFO_1000956', 'EFO_0000729', 'EFO_0004255',
       'EFO_0004256', 'EFO_0003086', 'EFO_0000222', 'EFO_0007332',
       'EFO_0000095', 'EFO_0000540', 'EFO_0000183', 'EFO_0009562',
       'EFO_0004236', 'EFO_0003778', 'EFO_0005297', 'EFO_0000389',
       'EFO_0002689', 'MONDO_0021117', 'MONDO_0018906', 'EFO_1002048',
       'MONDO_0013730', 'EFO_0008610', 'EFO_0005761', 'EFO_0003780',
       'EFO_1000749', 'EFO_0005140', 'MONDO_0000432', 'EFO_0005952',
       'EFO_0004826', 'EFO_0000255', 'EFO_0006803', 'EFO_1001161',
       'EFO_0004719', 'MONDO_0001718', 'EFO_0004145', 'MONDO_0015760',
       'MONDO_0005090', 'EFO_0004289', 'EFO_0000616', 'EFO_1000131',
       'MONDO_0000870', 'EFO_0006803', 'HP_0001915', 'MONDO_0015564',
       'EFO_1001051', 'MONDO_0016537', 'EFO_0003100', 'MONDO_0005147',
       'EFO_0005531', 'EFO_0004599', 'MONDO_0018922', 'MONDO_0008315',
       'MONDO_0018904', 'EFO_1001486', 'MONDO_0009348', 'MONDO_0018896',
       'EFO_0007160', 'EFO_0000565', 'EFO_0001378', 'HP_0002196',
       'EFO_0007498', 'EFO_1000784', 'MONDO_0017276', 'EFO_0003860',
       'EFO_1000318', 'EFO_0000096', 'EFO_0000403', 'EFO_1001469',
       'EFO_1000630', 'EFO_0000574', 'EFO_0000717', 'MONDO_0044917',
       'EFO_0003897', 'MONDO_0020547', 'EFO_0000557', 'EFO_0000699',
       'MONDO_0001023', 'EFO_0000094', 'EFO_0004991', 'EFO_0000685',
       'EFO_0000384', 'EFO_0009606', 'EFO_0003869', 'EFO_0003929',
       'EFO_0001423', 'EFO_0007359', 'EFO_1001779', 'EFO_0007208',
       'EFO_0003818', 'EFO_1001383', 'EFO_0008520', 'EFO_0001642',
       'MONDO_0005301', 'MONDO_0001549', 'EFO_0000765', 'EFO_0000768',
       'EFO_1001466', 'EFO_1001365'], dtype=object), 'count': 142}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 13 approved and 129 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201745,"CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)[O-].C[N+](C)(C)CCO_|_JWAZHODZSADEHB-UHFFFAOYSA-M_|_Small molecule_|_False_|_CHOLINE FENOFIBRATE_|_2008.0_|_4.0_|_CHEMBL981_|_False_|_True_|_['Trilipix']_|_['ABT-335' 'Choline fenofibrate' 'Fenofibric acid choline salt']_|_[('DailyMed', array(['choline%20fenofibrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0001645', 'HP_0003124', 'Orphanet_309005',
       'Orphanet_79211'], dtype=object), 'count': 5}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 4 investigational indications."
CHEMBL1324,"Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1_|_MIQPIUSUKVNLNT-UHFFFAOYSA-N_|_Small molecule_|_True_|_TOLCAPONE_|_1997.0_|_4.0_|_nan_|_True_|_True_|_['Tasmar' 'Tolcapone']_|_['RO 40-7592' 'RO-40-7592' 'RO-407592' 'Tolcapone']_|_[('DailyMed', array(['tolcapone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tasmar'],
      dtype=object)), ('PubChem', array(['144206516', '144212731', '170465081', '50126317'], dtype=object)), ('Wikipedia', array(['Tolcapone'], dtype=object)), ('drugbank', array(['DB00323'], dtype=object)), ('chEBI', array(['63630'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001399', 'EFO_0002610', 'EFO_0003768', 'MONDO_0043510',
       'MONDO_0005180', 'EFO_0007046', 'MONDO_0005090', 'MONDO_0007079',
       'EFO_0004242', 'EFO_0003096', 'EFO_0004699', 'MONDO_0002046',
       'EFO_0000621'], dtype=object), 'count': 13}_|_[ENSG00000093010]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hepatic failure and parkinson disease and has 11 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL2062266,"COc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@H]4[C@@H](C2)N(C)CC[C@@]341.O=C(O)C(O)C(O)C(=O)O_|_ZGSZBVAEVPSPFM-FFHNEAJVSA-N_|_Small molecule_|_False_|_DIHYDROCODEINE BITARTRATE_|_1983.0_|_4.0_|_CHEMBL1595_|_False_|_True_|_[]_|_['Codeine, dihydro-, tartrate (1:1)' 'DF 118' 'DF-118'
 'Dihydrocodeine bitartrate' 'Dihydrocodeine bitartrate cii'
 'Dihydrocodeine hydrogen tartrate' 'Dihydrocodeine phosphate'
 'Dihydrocodeine tartrate' 'Dihydroneopine' 'Drocode' 'NSC-117857']_|_[('DailyMed', array(['dihydrocodeine%20bitartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983 and is indicated for pain."
CHEMBL2093999,"C[C@]12CCC(=NOCCN)C[C@@H]1C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12_|_MPYLDWFDPHRTEG-IFVNMTGRSA-N_|_Small molecule_|_False_|_ISTAROXIME_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(E,Z)-Istaroxime' 'Istaroxime' 'PST-2744']_|_nan_|_nan_|_{'rows': array(['HP_0031273', 'EFO_0003144', 'EFO_0000373'], dtype=object), 'count': 3}_|_[ENSG00000174437,ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2108459,"nan_|_nan_|_Antibody_|_False_|_FONTOLIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fontolizumab' 'HUZAF']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000111537]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109334,"nan_|_nan_|_Antibody_|_False_|_INEBILIZUMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Uplizna']_|_['Inebilizumab' 'Inebilizumab cdon' 'MEDI-551' 'MEDI551']_|_[('DailyMed', array(['inebilizumab-cdon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/uplizna'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004256', 'EFO_0000095', 'EFO_0000717', 'EFO_0000540',
       'EFO_1001993', 'MONDO_0005301', 'EFO_0001378', 'MONDO_0017287',
       'MONDO_0004992', 'EFO_0004991', 'EFO_0007332', 'EFO_0000574',
       'EFO_0001642', 'EFO_0000403'], dtype=object), 'count': 14}_|_[ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neuromyelitis optica and immune system disease and has 12 investigational indications."
CHEMBL2109488,"nan_|_nan_|_Antibody_|_False_|_INCLACUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Inclacumab' 'LC-1004-002' 'LC1004-002' 'RG1512' 'RO-4905417' 'RO4905417']_|_nan_|_nan_|_{'rows': array(['EFO_0000612', 'EFO_0004265', 'EFO_0001645'], dtype=object), 'count': 3}_|_[ENSG00000174175]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2109610,"nan_|_nan_|_Antibody_|_False_|_HUMIK-BETA-1_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HUMIK-BETA-1' 'Humik-beta-1']_|_nan_|_nan_|_{'rows': array(['MONDO_0019469', 'EFO_0001060', 'EFO_0007316'], dtype=object), 'count': 3}_|_[ENSG00000100385]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3545082,nan_|_nan_|_Small molecule_|_False_|_RG-7376_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PLX-5568' 'Rg-7376']_|_nan_|_nan_|_nan_|_[ENSG00000132155]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL660,"NC12CC3CC(CC(C3)C1)C2_|_DKNWSYNQZKUICI-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMANTADINE_|_1968.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amantadine' 'Amantidine' 'NSC-341865' 'Symadine' 'Symmetrel'
 'TCMDC-125869']_|_[('PubChem', array(['104171100', '11110715', '124879107', '144203619', '170464860',
       '26755640', '26755641', '50110918', '50110919', '90340894'],
      dtype=object)), ('Wikipedia', array(['Amantadine'], dtype=object)), ('drugbank', array(['DB00915'], dtype=object)), ('chEBI', array(['2618'], dtype=object))]_|_['CHEMBL465617' 'CHEMBL1569' 'CHEMBL1445834']_|_{'rows': array(['EFO_0003843', 'MONDO_0005090', 'EFO_0000712', 'EFO_0002610',
       'MONDO_0002679', 'EFO_0003047', 'MONDO_0004976', 'MONDO_0005301',
       'MONDO_0005090', 'EFO_0007328', 'EFO_0000544', 'EFO_1001402',
       'EFO_0003888', 'MONDO_0005180', 'MONDO_0043510', 'EFO_0005411',
       'MONDO_0005301', 'MONDO_0005148', 'EFO_0004220', 'EFO_0000544',
       'EFO_1001175', 'EFO_0004247', 'HP_0001300', 'EFO_0007328',
       'EFO_1000860', 'MONDO_0100096', 'MONDO_0043510', 'MONDO_0100096',
       'MONDO_0005180', 'EFO_0005411'], dtype=object), 'count': 30}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 7 approved and 20 investigational indications."
CHEMBL1200682,"O=C([O-])CCCO.[Na+]_|_XYGBKMMCQDZQOZ-UHFFFAOYSA-M_|_Small molecule_|_True_|_SODIUM OXYBATE_|_2002.0_|_4.0_|_CHEMBL1342_|_False_|_True_|_['Xyrem']_|_['.gamma.-hydroxybutyrate sodium salt' 'Catabate' 'Lumryz' 'NSC-84223'
 'Oxybate sodium' 'Sodium oxybat' 'Sodium oxybate' 'Sodium oxybutyrate'
 'WY-3478']_|_[('Wikipedia', array(['Sodium_oxybate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem'],
      dtype=object)), ('DrugCentral', array(['4566'], dtype=object)), ('PubChem', array(['144206424'], dtype=object)), ('DailyMed', array(['sodium%20oxybate'], dtype=object)), ('drugbank', array(['DB09072'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018044', 'EFO_0003108', 'EFO_0008568', 'MONDO_0021107',
       'EFO_0005203', 'HP_0001337', 'MONDO_0005180', 'EFO_0003843',
       'MONDO_0000485', 'MONDO_0016241', 'EFO_0005687', 'MONDO_0016158'],
      dtype=object), 'count': 12}_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for narcolepsy and narcolepsy-cataplexy syndrome and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201467,"nan_|_nan_|_Small molecule_|_True_|_SYNTHETIC CONJUGATED ESTROGENS, B_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Enjuvia']_|_['CE-10' 'Estrogens, conjugated synthetic b'
 'Estrogens,conjugated synthetic b' 'Synthetic conjugated estrogens, b']_|_[('DailyMed', array(['estrogens,%20conjugated%20synthetic%20b'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000096', 'GO_0042697'], dtype=object), 'count': 2}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for atrophy and menopause. This drug has a black box warning from the FDA."
CHEMBL1551,"C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C_|_RUDATBOHQWOJDD-UZVSRGJWSA-N_|_Small molecule_|_False_|_URSODIOL_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Actigall' 'Cholurso' 'Destolit' 'Urdox' 'Urso 250' 'Urso forte'
 'Ursodiol' 'Ursofalk' 'Ursogal']_|_['NSC-683769' 'Ursodeoxycholate' 'Ursodeoxycholic acid'
 'Ursodesoxycholic acid' 'Ursodiol' 'Ursonorm']_|_[('DailyMed', array(['ursodiol'], dtype=object)), ('PubChem', array(['11532904'], dtype=object)), ('Wikipedia', array(['Ursodiol'], dtype=object)), ('drugbank', array(['DB01586'], dtype=object)), ('chEBI', array(['9907'], dtype=object))]_|_['CHEMBL2028234']_|_{'rows': array(['MONDO_0005148', 'MONDO_0007739', 'MONDO_0001751', 'EFO_0000400',
       'EFO_1001951', 'EFO_0004268', 'EFO_0003095', 'EFO_0000685',
       'HP_0002910', 'HP_0001952', 'EFO_1001068', 'Orphanet_733',
       'MONDO_0100096', 'MONDO_0005180', 'MONDO_0019072', 'EFO_0001422',
       'EFO_0004220', 'EFO_0007304', 'EFO_0004799', 'EFO_0000373',
       'EFO_0001073', 'EFO_1001486', 'EFO_0001421', 'MP_0001845',
       'EFO_0002950', 'EFO_0004228', 'EFO_0004267'], dtype=object), 'count': 27}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for primary biliary cirrhosis and biliary liver cirrhosis and has 25 investigational indications."
CHEMBL1790041,"CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1_|_VMXUWOKSQNHOCA-UHFFFAOYSA-N_|_Small molecule_|_False_|_RANITIDINE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-757851' 'Ranitidine' 'Tritec' 'Zantac']_|_[('PubChem', array(['170465134'], dtype=object)), ('TG-GATEs', array(['86'], dtype=object)), ('Wikipedia', array(['Ranitidine'], dtype=object)), ('drugbank', array(['DB00863'], dtype=object))]_|_['CHEMBL2110372' 'CHEMBL2111286']_|_{'rows': array(['EFO_0003948', 'HP_0004398', 'EFO_0009454', 'MONDO_0015277',
       'Orphanet_2314', 'EFO_0003948', 'HP_0012735', 'MONDO_0005301',
       'EFO_0005592', 'HP_0004398', 'EFO_0009579', 'EFO_0000540',
       'EFO_0005252', 'EFO_1000961', 'EFO_0004607', 'MONDO_0004992',
       'MONDO_0044917', 'EFO_1001095', 'MONDO_0043839', 'MONDO_0007254',
       'EFO_0000280', 'EFO_0000681', 'MONDO_0004658', 'EFO_0009454',
       'EFO_0000764'], dtype=object), 'count': 25}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 18 investigational indications."
CHEMBL1963683,"CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(F)(F)COc2ccccc2)[C@H](O)C[C@@H]1O_|_WSNODXPBBALQOF-VEJSHDCNSA-N_|_Small molecule_|_False_|_TAFLUPROST_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Saflutan' 'Zioptan']_|_['AFP-168' 'MK-2452' 'Tafluprost']_|_[('DailyMed', array(['tafluprost'], dtype=object)), ('Wikipedia', array(['Tafluprost'], dtype=object)), ('drugbank', array(['DB08819'], dtype=object)), ('chEBI', array(['66899'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001069', 'EFO_0004190', 'MONDO_0005041'], dtype=object), 'count': 3}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved indications."
CHEMBL2005186,"CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1_|_GKHIVNAUVKXIIY-UHFFFAOYSA-N_|_Small molecule_|_False_|_BELUMOSUDIL_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Belumosudil' 'KD-025' 'KD025' 'Rock2 inhibitor kd025' 'SLx-2119'
 'Slx-2119 free base']_|_[('PubChem', array(['103905007'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELUMOSUDIL/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802130']_|_{'rows': array(['EFO_0000404', 'MONDO_0013730', 'EFO_0005809', 'EFO_0001421',
       'EFO_1001494', 'EFO_0000768', 'EFO_0005809', 'MONDO_0020547',
       'EFO_0000540', 'EFO_0000676', 'MONDO_0013730', 'EFO_1001951'],
      dtype=object), 'count': 12}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for graft versus host disease and immune system disease and has 9 investigational indications."
CHEMBL206815,"CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)[C@H]1C(=O)NO_|_MAVDNGWEBZTACC-HNNXBMFYSA-N_|_Small molecule_|_False_|_APRATASTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apratastat' 'TMI-005' 'TMI-05']_|_[('drugbank', array(['DB13020'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000137745,ENSG00000151694]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108380,"nan_|_nan_|_Protein_|_False_|_LIATERMIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gdnf liatermin' 'Liatermin' 'R-methugdnf']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000151892]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109512,"nan_|_nan_|_Antibody_|_False_|_MCS-110_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MCS-110' 'Mcs-110']_|_nan_|_nan_|_{'rows': array(['MONDO_0001056', 'MONDO_0007254', 'EFO_0000756'], dtype=object), 'count': 3}_|_[ENSG00000184371]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2316582,"Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1_|_TZKBVRDEOITLRB-UHFFFAOYSA-N_|_Small molecule_|_False_|_OLVEREMBATINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['D-824' 'D-824 DIMESYLATE' 'GZD-824' 'GZD-824 DIMESYLATE' 'HQP-1351'
 'HQP-1351 DIMESYLATE' 'HQP1351' 'HQP1351 DIMESYLATE' 'Hqp1351'
 'Olverembatinib' 'Olverembatinib dimesylate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLVEREMBATINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000339', 'EFO_0000220', 'MONDO_0011719'],
      dtype=object), 'count': 4}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL267495,"CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5_|_XGZZHZMWIXFATA-UEZBDDGYSA-N_|_Small molecule_|_False_|_NALFURAFINE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MT-9938' 'Nalfurafine']_|_[('drugbank', array(['DB13471'], dtype=object))]_|_['CHEMBL490665']_|_{'rows': array(['EFO_0003884', 'EFO_0001421'], dtype=object), 'count': 2}_|_[ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 2 investigational indications."
CHEMBL3545059,"COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC.O=C(O)/C=C/C(=O)O_|_KLRSDBSKUSSCGU-KRQUFFFQSA-N_|_Small molecule_|_True_|_ALISKIREN FUMARATE_|_2007.0_|_4.0_|_CHEMBL1639_|_False_|_True_|_['Rasilez' 'Tekturna']_|_['Aliskiren fumarate' 'Aliskiren hemifumarate' 'NSC-759185' 'SPP-100B'
 'SPP100']_|_[('DailyMed', array(['aliskiren%20hemifumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez'],
      dtype=object)), ('chEBI', array(['53777'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000712'], dtype=object), 'count': 2}_|_[ENSG00000143839]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hypertension and stroke. This drug has a black box warning from the FDA."
CHEMBL359744,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl_|_MWWSFMDVAYGXBV-RUELKSSGSA-N_|_Small molecule_|_True_|_DOXORUBICIN HYDROCHLORIDE_|_1974.0_|_4.0_|_CHEMBL53463_|_False_|_True_|_['Adriamycin' 'Adriamycin Rdf' 'Adriamycin pfs' 'Caelyx'
 'Caelyx pegylated liposomal' 'Doxil' 'Doxil (liposomal)'
 'Doxorubicin hydrochloride' 'Doxorubicin hydrochloride (liposomal)'
 'Myocet' 'Rubex']_|_['Adriablastina cs' 'Adriamycin, hydrochloride' 'Doxorubicin HCl'
 'Doxorubicin citrate' 'Doxorubicin citric acid salt' 'Doxorubicin hcl'
 'Doxorubicin hydrochloride'
 'Doxorubicin liposomal complex of the hydrochloride'
 'Doxorubicini hydrochloridum' 'Hydroxydaunomycin hydrochloride'
 'Liposomal doxorubicin hydrochloride']_|_[('DailyMed', array(['doxorubicin%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/caelyx-pegylated-liposomal'],
      dtype=object)), ('PubChem', array(['144203601', '144205614', '144209681', '170465451', '17389199',
       '49681823', '49718188', '50126368', '855944'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000796', 'MONDO_0002974', 'EFO_0001378', 'EFO_1001042',
       'MONDO_0011934', 'MONDO_0003175', 'EFO_1001951', 'EFO_1000292',
       'EFO_0005561', 'EFO_0003060', 'EFO_0000223', 'EFO_0000183',
       'EFO_1000294', 'EFO_0001376', 'MONDO_0021054', 'EFO_0003869',
       'EFO_0006861', 'MONDO_0004986', 'EFO_0007143', 'EFO_0000437',
       'MONDO_0018364', 'EFO_0003144', 'EFO_0000198', 'MONDO_0005094',
       'EFO_1000984', 'EFO_0000095', 'EFO_0003893', 'EFO_0000691',
       'EFO_0000239', 'EFO_0000702', 'EFO_0000309', 'MONDO_0002367',
       'EFO_0000094', 'MONDO_0008315', 'MONDO_0017387', 'MONDO_0008170',
       'MONDO_0000870', 'EFO_0000588', 'EFO_0000220', 'EFO_0000565',
       'EFO_0000211', 'EFO_0000558', 'EFO_0000403', 'EFO_1001365',
       'MONDO_0008903', 'EFO_0003032', 'EFO_0000760', 'EFO_1000131',
       'EFO_0000174', 'EFO_0000569', 'EFO_0007160', 'EFO_0000637',
       'MONDO_0004992', 'MONDO_0009348', 'MONDO_0000873', 'EFO_0006475',
       'MONDO_0007254', 'MONDO_0002158', 'EFO_0000182', 'EFO_0003968',
       'EFO_0000222', 'MONDO_0004192', 'EFO_1002017', 'EFO_1000158',
       'MONDO_0004986', 'EFO_1001469', 'EFO_0005537', 'MONDO_0001187',
       'EFO_0000096', 'EFO_0000502', 'MONDO_0002678', 'EFO_0000305',
       'MONDO_0020077', 'EFO_0000248', 'MONDO_0002087', 'EFO_0009708',
       'EFO_0006859', 'MONDO_0008380', 'EFO_0005952', 'EFO_1001100',
       'EFO_0000681', 'EFO_1001968', 'MONDO_0015540', 'MONDO_0007576',
       'EFO_0002918', 'EFO_0000616', 'MONDO_0018906', 'MONDO_0019004',
       'EFO_1000251', 'EFO_0000209', 'MONDO_0002691', 'MONDO_0011962',
       'EFO_1000595', 'EFO_0007532', 'EFO_0001075', 'MONDO_0001056',
       'EFO_0000313', 'EFO_0000564', 'EFO_0000765', 'EFO_0000574',
       'MONDO_0004658', 'EFO_0000621', 'MONDO_0044917'], dtype=object), 'count': 103}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 22 approved and 81 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3833319,"CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1_|_FYDWDCIFZSGNBU-UHFFFAOYSA-N_|_Small molecule_|_False_|_REVEFENACIN_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Yupelri']_|_['GSK-1160724' 'GSK1160724' 'Revefenacin' 'TD-4208']_|_[('DailyMed', array(['revefenacin'], dtype=object)), ('drugbank', array(['DB11855'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0000341', 'HP_0006536', 'EFO_0003086'],
      dtype=object), 'count': 4}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chronic obstructive pulmonary disease and airway obstruction and has 2 investigational indications."
CHEMBL3989834,"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC_|_YBWLTKFZAOSWSM-UHFFFAOYSA-N_|_Small molecule_|_False_|_AVOSENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Avosentan' 'RO 67-0565' 'RO-67-0565' 'Ro670565' 'SPP-301' 'SPP301']_|_nan_|_nan_|_{'rows': array(['EFO_0000401'], dtype=object), 'count': 1}_|_[ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297064,"CCN(CC)C(=O)C1(c2ccccc2)CC1CN.Cl_|_XNCDYJFPRPDERF-UHFFFAOYSA-N_|_Small molecule_|_True_|_MILNACIPRAN HYDROCHLORIDE_|_2009.0_|_4.0_|_CHEMBL259209_|_False_|_True_|_['Dalcipran' 'Ixel' 'Milnacipran hydrochloride' 'Savella' 'Toledomin']_|_['Milnacipran hcl' 'Milnacipran hydrochloride' 'NSC-759806']_|_[('DailyMed', array(['milnacipran%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003418', 'EFO_0005687'], dtype=object), 'count': 2}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for fibromyalgia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL492399,"COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1_|_SNHCRNMVYDHVDT-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERUBULIN_|_nan_|_2.0_|_nan_|_False_|_False_|_['Azixa']_|_['MPC-6827' 'MX-128495' 'Verubulin']_|_[('drugbank', array(['DB05585'], dtype=object))]_|_['CHEMBL3910844' 'CHEMBL2105697']_|_{'rows': array(['EFO_0000616', 'EFO_0000519', 'EFO_0003833'], dtype=object), 'count': 3}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL5315087,"nan_|_nan_|_Unknown_|_False_|_PROTEIN C CONCENTRATE (HUMAN)_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Ceprotin']_|_['Human protein c' 'Protein c' 'Protein c (coagulation inhibitor)'
 'Protein c (homo sapiens)' 'Protein c human' 'Protexel']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009316', 'EFO_1001913', 'HP_0004419'], dtype=object), 'count': 3}_|_[ENSG00000115718]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved indications."
CHEMBL558752,"Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21_|_YABJJWZLRMPFSI-UHFFFAOYSA-N_|_Small molecule_|_False_|_RAF-265_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CHIR-265' 'NVP-RAF265' 'RAF265' 'Raf 265' 'Raf-265']_|_[('PubChem', array(['137275908', '50100093'], dtype=object)), ('drugbank', array(['DB05984'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000128052,ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL585,"Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1_|_FNYLWPVRPXGIIP-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRIAMTERENE_|_1964.0_|_4.0_|_nan_|_False_|_True_|_['Dyrenium' 'Dytac']_|_['NSC-639359' 'NSC-77625' 'SK&F 8542' 'SK&F-8542' 'SK-8542' 'Triamterene']_|_[('DailyMed', array(['triamterene'], dtype=object)), ('PubChem', array(['104171252', '11111878', '11111879', '124881638', '124881640',
       '144203834', '144209219', '144213150', '170464706', '17389703',
       '26747035', '26751552', '50100356', '50104154', '50104155',
       '85231255', '855896', '90341047'], dtype=object)), ('TG-GATEs', array(['101'], dtype=object)), ('Wikipedia', array(['Triamterene'], dtype=object)), ('drugbank', array(['DB00384'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0003914', 'EFO_0001422', 'EFO_0004255',
       'MONDO_0005148', 'EFO_0009452', 'EFO_0000668', 'EFO_0000373',
       'EFO_0004278', 'EFO_0009373', 'EFO_0001645', 'HP_0003124',
       'EFO_0000319'], dtype=object), 'count': 13}_|_[ENSG00000111319,ENSG00000168447,ENSG00000166828]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and has 8 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL76370,"CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12_|_IKBKZGMPCYNSLU-RGVLZGJSSA-N_|_Small molecule_|_False_|_TEGASEROD_|_2002.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['HTF 919' 'SDZ-HTF-919' 'Tegaserod']_|_[('PubChem', array(['144205034', '170466887', '26749090'], dtype=object)), ('Wikipedia', array(['Tegaserod'], dtype=object)), ('drugbank', array(['DB01079'], dtype=object)), ('chEBI', array(['51043'], dtype=object))]_|_['CHEMBL533819' 'CHEMBL1516474' 'CHEMBL4303321']_|_{'rows': array(['EFO_0008533', 'HP_0002019', 'EFO_0000555', 'MONDO_0002203',
       'EFO_0003948'], dtype=object), 'count': 5}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 3 approved and 2 investigational indications. It was withdrawn in at least one region."
CHEMBL846,"C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_GMRQFYUYWCNGIN-NKMMMXOESA-N_|_Small molecule_|_False_|_CALCITRIOL_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Calcijex' 'Calcitriol' 'Dihydroxycholecalciferol' 'Dihydroxyvitamin D 3'
 'Rocaltrol' 'Silkis' 'Topitriol' 'Vectical']_|_['1,25-dihydroxy vitamin d3' '1,25-dihydroxyvitamin d3'
 '1,25-hydroxylated vitamin d' '1alpha,25-dihydroxycholecalciferol'
 '1alpha,25-dihydroxyvitamin d3' 'Calcitriol' 'RO 21-5535' 'RO-21-5535'
 'RO-215535']_|_[('DailyMed', array(['calcitriol'], dtype=object)), ('PubChem', array(['144205541', '26719902', '50110818'], dtype=object)), ('Wikipedia', array(['Calcitriol'], dtype=object)), ('drugbank', array(['DB00136'], dtype=object)), ('chEBI', array(['17823'], dtype=object))]_|_['CHEMBL578780']_|_{'rows': array(['EFO_1001121', 'EFO_0002424', 'EFO_1001152', 'EFO_0000537',
       'EFO_0003884', 'MONDO_0100096', 'EFO_0000401', 'EFO_0003888',
       'MONDO_0008315', 'Orphanet_733', 'HP_0002901', 'HP_0100806',
       'EFO_0003854', 'EFO_0003868', 'EFO_0005221', 'MONDO_0024300',
       'EFO_0002617', 'EFO_0003882', 'EFO_0009451', 'EFO_1001494',
       'MONDO_0005147', 'Orphanet_89936', 'EFO_0003869', 'EFO_1000158',
       'MONDO_0007915', 'HP_0001919', 'EFO_0000673', 'EFO_0000616',
       'EFO_0000676', 'EFO_0002618', 'EFO_1001006', 'EFO_0000384',
       'MONDO_0017198', 'EFO_0004193', 'MONDO_0007254', 'EFO_0003060',
       'EFO_0000198'], dtype=object), 'count': 37}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 5 approved and 32 investigational indications."
CHEMBL1064,"CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21_|_RYMZZMVNJRMUDD-HGQWONQESA-N_|_Small molecule_|_False_|_SIMVASTATIN_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Flolipid' 'Lacersa' 'Ranzolont' 'Simvador' 'Simvastatin' 'Zocor'
 'Zocor heart-pro']_|_['C10AA01' 'MK-0733' 'MK-733' 'NSC-758706' 'Simvastatin'
 'Simvastatin hydroxy acid' 'Synvinolin']_|_[('DailyMed', array(['simvastatin'], dtype=object)), ('PubChem', array(['144204247', '144210718', '164339438', '170464984', '496592',
       '50086525'], dtype=object)), ('TG-GATEs', array(['117'], dtype=object)), ('Wikipedia', array(['Simvastatin'], dtype=object)), ('drugbank', array(['DB00641'], dtype=object)), ('chEBI', array(['9150'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000359', 'EFO_0000713', 'EFO_0009441', 'EFO_0003060',
       'EFO_0004264', 'EFO_0007405', 'EFO_0004319', 'HP_0012532',
       'HP_0002140', 'EFO_0002618', 'MONDO_0005147', 'EFO_0004911',
       'EFO_0008522', 'EFO_0006834', 'EFO_0000474', 'EFO_0007328',
       'EFO_0000685', 'MONDO_0100096', 'EFO_0004268', 'EFO_0003770',
       'EFO_0000764', 'EFO_0001645', 'EFO_0005669', 'MONDO_0008903',
       'EFO_0004208', 'EFO_0008583', 'EFO_0003884', 'EFO_1001898',
       'EFO_0009783', 'EFO_1001782', 'MONDO_0010035', 'EFO_1001343',
       'EFO_0000731', 'EFO_1001466', 'EFO_0000195', 'EFO_1001951',
       'MONDO_0018997', 'EFO_0005672', 'EFO_0000712', 'EFO_0000666',
       'MONDO_0004985', 'EFO_0008568', 'EFO_0001663', 'EFO_0000182',
       'MONDO_0007915', 'MONDO_0004992', 'EFO_0004192', 'HP_0003119',
       'EFO_0000649', 'MONDO_0010557', 'MONDO_0001187', 'MONDO_0005180',
       'EFO_0600064', 'EFO_0000341', 'EFO_0001378', 'EFO_0000660',
       'EFO_0003106', 'EFO_1001231', 'MONDO_0005277', 'HP_0003124',
       'EFO_0000266', 'EFO_0001361', 'MONDO_0021118', 'EFO_0000702',
       'MP_0001845', 'EFO_1001375', 'EFO_0000407', 'EFO_0000612',
       'EFO_0000537', 'MONDO_0002009', 'EFO_0007486', 'EFO_0000574',
       'EFO_0004211', 'MONDO_0005301', 'MONDO_0008170', 'EFO_0003144',
       'MONDO_0005149', 'MONDO_0008315', 'EFO_1000652', 'EFO_0000401',
       'MONDO_0004979', 'MONDO_0001056', 'EFO_0000095', 'MONDO_0007254',
       'MONDO_0009061', 'MONDO_0011382', 'EFO_0000275', 'EFO_0000342',
       'EFO_0000319', 'EFO_0003914', 'HP_0100806', 'MONDO_0005148',
       'MONDO_0001134', 'Orphanet_309005', 'EFO_0004265',
       'Orphanet_79211', 'EFO_0000305', 'EFO_1001121', 'EFO_1000657',
       'EFO_0003876', 'EFO_0004197', 'MONDO_0004975', 'MONDO_0021187',
       'EFO_0001422', 'EFO_0003929', 'EFO_0009854', 'EFO_0000400'],
      dtype=object), 'count': 107}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 97 investigational indications."
CHEMBL1199080,"CC[N+](C)(C)Cc1ccccc1Br_|_AAQOQKQBGPPFNS-UHFFFAOYSA-N_|_Small molecule_|_False_|_BRETYLIUM_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bretylium' 'Bretylium cation' 'Bretylium ion']_|_[('PubChem', array(['50113154', '50113155'], dtype=object)), ('Wikipedia', array(['Bretylium'], dtype=object)), ('drugbank', array(['DB01158'], dtype=object)), ('chEBI', array(['3172'], dtype=object))]_|_['CHEMBL1095292']_|_{'rows': array(['EFO_0004269', 'EFO_0004287', 'HP_0004308'], dtype=object), 'count': 3}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications."
CHEMBL1200387,"CC(N)Cc1ccccc1.O=C(O)CCCCC(=O)O_|_OFCJKOOVFDGTLY-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMPHETAMINE ADIPATE_|_1975.0_|_4.0_|_CHEMBL405_|_False_|_True_|_[]_|_['Amphetamine adipate']_|_nan_|_nan_|_nan_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975."
CHEMBL1200412,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1_|_UBWXUGDQUBIEIZ-QNTYDACNSA-N_|_Small molecule_|_False_|_NANDROLONE PHENPROPIONATE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Durabolin' 'Nandrolone phenpropionate']_|_['Nandrolone phenpropionate' 'Nandrolone phenylpropionate'
 'Norandrostenolone phenylpropionate' 'Nortestosterone furanpropionate'
 'Nortestosterone phenylpropionate']_|_[('PubChem', array(['144206893', '170465193'], dtype=object)), ('drugbank', array(['DB00984'], dtype=object)), ('chEBI', array(['7468'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959."
CHEMBL1200483,"CC1NCCOC1c1ccccc1.Cl_|_VJNXVAVKCZJOFQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENMETRAZINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201208_|_False_|_True_|_['Preludin']_|_['NSC-405728' 'Phenmetraline hydrochloride' 'Phenmetrazine chloride'
 'Phenmetrazine hcl' 'Phenmetrazine hydrochloride']_|_[('PubChem', array(['144205719', '170465166'], dtype=object)), ('chEBI', array(['8068'], dtype=object))]_|_nan_|_nan_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200600,"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_FAOZLTXFLGPHNG-KNAQIMQKSA-N_|_Small molecule_|_False_|_FLUOROMETHOLONE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Fluaton' 'Fluor-op' 'Fml forte' 'Fml fte' 'Fml-neo' 'Oxylone']_|_['Fluorometholone' 'NSC-33001']_|_[('DailyMed', array(['fluorometholone'], dtype=object)), ('PubChem', array(['144203991', '144212910', '170464629', '56422125', '855588',
       '91286'], dtype=object)), ('Wikipedia', array(['Fluorometholone'], dtype=object)), ('drugbank', array(['DB00324'], dtype=object)), ('chEBI', array(['31625'], dtype=object))]_|_nan_|_{'rows': array(['MP_0001845', 'HP_0007957', 'EFO_0005752', 'EFO_1000906',
       'EFO_0009552', 'EFO_0003894'], dtype=object), 'count': 6}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 4 approved and 2 investigational indications."
CHEMBL1200810,"C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](C)C(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_HKXBNHCUPKIYDM-CGMHZMFXSA-N_|_Small molecule_|_False_|_DOXERCALCIFEROL_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Doxercalciferol' 'Hectorol']_|_['1-.alpha.-hydroxyergocalciferol' '1-alpha-hydroxyergocalciferol'
 '1-hydroxyergocalciferol' '1.alpha.-hydroxyergocalciferol'
 '1.alpha.-hydroxyvitamin d2' 'Doxercalciferol' 'GZ427397' 'TSA-840']_|_[('DailyMed', array(['doxercalciferol'], dtype=object)), ('PubChem', array(['144206531'], dtype=object)), ('Wikipedia', array(['Doxercalciferol'], dtype=object)), ('drugbank', array(['DB06410'], dtype=object)), ('chEBI', array(['4712'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001173', 'EFO_0003884', 'EFO_0000676', 'MONDO_0008315',
       'EFO_0000616', 'EFO_0005754'], dtype=object), 'count': 6}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 3 investigational indications."
CHEMBL1743088,"nan_|_nan_|_Antibody_|_False_|_VELTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HA20' 'IMMU-106' 'Veltuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0000220', 'EFO_0000095', 'EFO_0007160',
       'EFO_0000685', 'EFO_0000403', 'EFO_0000574', 'MONDO_0018906',
       'MONDO_0000432'], dtype=object), 'count': 9}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL1766582,Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21_|_RQHSAIGGUWVOBG-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-1487_|_nan_|_1.0_|_CHEMBL1230122_|_False_|_False_|_[]_|_['R 1487' 'R-1487']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2109090,nan_|_nan_|_Antibody_|_False_|_ENLIMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI-RR-0001' 'BIRR-0001' 'Enlimomab']_|_nan_|_nan_|_nan_|_[ENSG00000090339]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109408,"nan_|_nan_|_Antibody_|_False_|_LAMPALIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AFD' 'Anti-fD' 'FCFD-4514S' 'FCFD4514S' 'Lampalizumab' 'RG-7417'
 'RG7417' 'Sn578b8z9q' 'anti-FACTOR-D']_|_nan_|_nan_|_{'rows': array(['EFO_1001492'], dtype=object), 'count': 1}_|_[ENSG00000197766]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109571,"nan_|_nan_|_Antibody_|_False_|_AMG-167_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-167' 'Amg-167']_|_nan_|_nan_|_{'rows': array(['HP_0000938'], dtype=object), 'count': 1}_|_[ENSG00000167941]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2110572,nan_|_nan_|_Small molecule_|_False_|_TECHNETIUM SUCCIMER_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[]_|_nan_|_['CHEMBL1200797']_|_nan_|_[ENSG00000175899]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL2110588,"CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2_|_FJZZPCZKBUKGGU-AUSIDOKSSA-N_|_Small molecule_|_False_|_ELIGLUSTAT_|_2014.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Eliglustat' 'GENZ 99067' 'GENZ-99067']_|_[('drugbank', array(['DB09039'], dtype=object)), ('chEBI', array(['82752'], dtype=object))]_|_['CHEMBL4297066']_|_{'rows': array(['MONDO_0044881', 'MONDO_0018150', 'MONDO_0018150',
       'Orphanet_77261', 'Orphanet_77259'], dtype=object), 'count': 5}_|_[ENSG00000148154]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 1 investigational indication."
CHEMBL3545183,"CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O.Cl_|_KHQMSZGKHGQUHG-WZDHWKSBSA-N_|_Protein_|_False_|_ETELCALCETIDE HYDROCHLORIDE_|_2016.0_|_4.0_|_CHEMBL3545184_|_False_|_True_|_['Parsabiv']_|_['AMG 416' 'Etelcalcetide hydrochloride' 'KAI-4169 HCl'
 'Telcalcetide hydrochloride' 'Velcalcetide hydrochloride']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001173', 'EFO_0003884'], dtype=object), 'count': 2}_|_[ENSG00000036828]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for secondary hyperparathyroidism and chronic kidney disease."
CHEMBL3622820,"N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1_|_KTBSXLIQKWEBRB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ITACITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['INCB-039110' 'INCB039110' 'Incb-039110' 'Incb-39110' 'Itacitinib']_|_[('drugbank', array(['DB12154'], dtype=object))]_|_['CHEMBL3948879' 'CHEMBL3707409' 'CHEMBL3947131']_|_{'rows': array(['MONDO_0009348', 'EFO_0000540', 'MONDO_0013730', 'MONDO_0015540',
       'MONDO_0044881', 'MONDO_0008903', 'EFO_0000183', 'EFO_0000403',
       'MONDO_0020547', 'EFO_0000717', 'MONDO_0011962', 'EFO_0002618',
       'EFO_0000182', 'EFO_0004251', 'EFO_0000616', 'EFO_0000756',
       'MONDO_0044903', 'EFO_0003060', 'EFO_0007183', 'EFO_0004599',
       'EFO_0000676', 'HP_0000989', 'EFO_0005803', 'EFO_0000729',
       'MONDO_0007254', 'EFO_0000574', 'MONDO_0004992', 'EFO_1000560',
       'EFO_0007183', 'EFO_0000685'], dtype=object), 'count': 30}_|_[ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 29 investigational indications."
CHEMBL393220,"CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]_|_FQCKMBLVYCEXJB-MNSAWQCASA-L_|_Small molecule_|_False_|_ATORVASTATIN CALCIUM_|_1996.0_|_4.0_|_CHEMBL1487_|_False_|_True_|_['Atorvastatin calcium' 'Lipitor']_|_['Atorvastatin calcium' 'Atorvastatin calcium (anhydrous)'
 'Atorvastatin calcium anhydrous' 'Atorvastatin calcium hydrate'
 'Atorvastatin calcium salt anhydrous'
 'Atorvastatin calcium salt trihydrate' 'Atorvastatin calcium trihydrate'
 'CI-981' 'NSC-758617']_|_[('DailyMed', array(['atorvastatin%20calcium'], dtype=object)), ('PubChem', array(['144205238', '144212690', '170465113'], dtype=object)), ('chEBI', array(['50686'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018473', 'EFO_0001422', 'EFO_0003767', 'EFO_0009426',
       'EFO_0000198', 'EFO_0007328', 'EFO_0007129', 'EFO_0008568',
       'EFO_0000612', 'MONDO_0019338', 'EFO_0003086', 'MONDO_0005301',
       'EFO_0005672', 'MONDO_0002679', 'EFO_1001771', 'EFO_0008586',
       'EFO_0000275', 'EFO_0000196', 'EFO_0001361', 'MONDO_0021661',
       'EFO_0003095', 'EFO_0000764', 'EFO_0000676', 'MONDO_0013730',
       'MONDO_0018076', 'MONDO_0018373', 'EFO_0003869', 'EFO_0006818',
       'EFO_0004616', 'HP_0003119', 'EFO_0000616', 'EFO_0000685',
       'EFO_0009783', 'MONDO_0002492', 'HP_0100543', 'MONDO_0001444',
       'EFO_0000319', 'MONDO_0005147', 'EFO_0000180', 'EFO_0000222',
       'EFO_0007160', 'EFO_0008583', 'EFO_0003884', 'MONDO_0007254',
       'EFO_0000712', 'MONDO_0008315', 'EFO_0000519', 'EFO_0004208',
       'HP_0003124', 'EFO_0004264', 'MONDO_0004782', 'EFO_0003913',
       'EFO_1000984', 'EFO_1001993', 'EFO_0000660', 'Orphanet_79211',
       'EFO_0000538', 'EFO_0001645', 'Orphanet_413', 'EFO_0005952',
       'EFO_0000373', 'MONDO_0043510', 'MONDO_0001134', 'EFO_0004211',
       'MONDO_0011962', 'EFO_0000537', 'EFO_0000673', 'EFO_0008585',
       'EFO_1001249', 'EFO_0000384', 'EFO_0003144', 'EFO_0000318',
       'MONDO_0004992', 'EFO_0004255', 'EFO_1001466', 'EFO_0003870',
       'MONDO_0005835', 'EFO_0004246', 'EFO_0000649', 'EFO_0000574',
       'EFO_0004252', 'EFO_0003929', 'EFO_0004236', 'EFO_0001073',
       'EFO_0000365', 'EFO_0000681', 'Orphanet_309005', 'EFO_0000400',
       'EFO_0001378', 'EFO_0004286', 'EFO_0003914', 'EFO_0003047',
       'HP_0100806', 'EFO_0001365', 'EFO_0000668', 'EFO_0004911',
       'EFO_1001801', 'EFO_0000474', 'EFO_0004194', 'EFO_0003918',
       'EFO_0000195', 'HP_0000083', 'MONDO_0004975', 'MONDO_0004979',
       'MONDO_0005148', 'MONDO_0100096', 'MONDO_0021187', 'EFO_0000565',
       'MONDO_0007915', 'MONDO_0002050', 'HP_0001647', 'MONDO_0011382'],
      dtype=object), 'count': 112}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 13 approved and 99 investigational indications."
CHEMBL3989410,"COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]_|_UHYAQBLOGVNWNT-UHFFFAOYSA-M_|_Small molecule_|_False_|_INDOMETHACIN SODIUM_|_1985.0_|_4.0_|_CHEMBL6_|_False_|_True_|_['Indocin' 'Indomethacin sodium']_|_['Indometacin sodium' 'Indometacin sodium hydrate'
 'Indometacin sodium trihydrate' 'Indomethacin sodium'
 'Indomethacin sodium anhydrous' 'Indomethacin sodium salt trihydrate'
 'Indomethacin sodium trihydrate' 'Sodium indomethacin'
 'Sodium indomethacin trihydrate']_|_nan_|_nan_|_{'rows': array(['MP_0001845'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and has 1 investigational indication."
CHEMBL407,"CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2_|_OFBIFZUFASYYRE-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLUMAZENIL_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Anexate' 'Flumazenil' 'Flumazepil' 'Mazicon' 'Romazicon']_|_['Flumazenil' 'Flumazepil' 'Lanexat' 'Mazicon' 'NSC-759193'
 'RO 15-1788/000' 'RO-15-1788' 'RO-151788' 'RO-151788000' 'RO-1722'
 'RO-41-8157']_|_[('DailyMed', array(['flumazenil'], dtype=object)), ('PubChem', array(['104171157', '11111184', '11114035', '11532958', '170464960',
       '26719655', '26752172', '26752173', '50104818', '56422177',
       '85231047', '90341071'], dtype=object)), ('Wikipedia', array(['Flumazenil'], dtype=object)), ('drugbank', array(['DB01205'], dtype=object)), ('chEBI', array(['5103'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018044', 'MONDO_0021107', 'EFO_0003890', 'MONDO_0007079',
       'EFO_0004242', 'MONDO_0005180', 'MONDO_0010383', 'EFO_0004698',
       'EFO_1001884', 'EFO_0005230'], dtype=object), 'count': 10}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4081711,"CC[C@@H]1[C@H](F)C(=O)N[C@@H]1COc1nccc2cc(C(N)=O)c(OC)cc12_|_JKDGKIBAOAFRPJ-ZBINZKHDSA-N_|_Small molecule_|_False_|_ZIMLOVISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-06650833' 'Pf 06650833' 'Pf-06650833' 'Zimlovisertib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZIMLOVISERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15143'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_1000710', 'EFO_0000685', 'MONDO_0100096',
       'EFO_1000637'], dtype=object), 'count': 5}_|_[ENSG00000198001]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4117187,"COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br_|_GWCYPEHWIZXYFZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_MASUPIRDINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Masupirdine' 'SUVN-502' 'Suvn-502']_|_[('drugbank', array(['DB06140'], dtype=object))]_|_['CHEMBL4082473']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000158748]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4297734,"nan_|_nan_|_Antibody_|_False_|_CRIZANLIZUMAB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Adakveo']_|_['Crizanlizumab' 'Crizanlizumab tmca' 'NVP-LXI-262' 'NVP-LXI262' 'SEG-101'
 'SEG101' 'SEL-G1' 'SelG1' 'Selg1']_|_[('DailyMed', array(['crizanlizumab-tmca'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adakveo'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011382', 'MONDO_0100096', 'MONDO_0044903', 'HP_0200023'],
      dtype=object), 'count': 4}_|_[ENSG00000174175]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for sickle cell anemia and has 3 investigational indications."
CHEMBL4297743,"nan_|_nan_|_Antibody_|_False_|_ELEZANUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABT-555' 'AE12-1Y-QL' 'Abt-555' 'Elezanumab' 'PR-1432051']_|_nan_|_nan_|_{'rows': array(['HP_0002140', 'MONDO_0005301', 'EFO_1001919'], dtype=object), 'count': 3}_|_[ENSG00000182175]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297985,"nan_|_nan_|_Antibody_|_False_|_MAGROLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Hu5F9-G4' 'Hu5f9 g4' 'Hu5f9-g4' 'Magrolimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MAGROLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005537', 'EFO_0000198', 'MONDO_0008170', 'EFO_1001951',
       'EFO_0008528', 'EFO_0001378', 'EFO_0000181', 'EFO_1001051',
       'EFO_0000616', 'MONDO_0001187', 'MONDO_0004992', 'EFO_0005952',
       'EFO_0000403', 'MONDO_0001657', 'EFO_0001642', 'MONDO_0009348',
       'EFO_1000785', 'EFO_0000222'], dtype=object), 'count': 18}_|_[ENSG00000196776]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 18 investigational indications."
CHEMBL4303379,"C[C@H](N)C(=O)N[C@@]1(C(=O)O)C[C@@H](Sc2nnc[nH]2)[C@H]2[C@H](C(=O)O)[C@H]21_|_BBGHHIUQOKQCBW-LDZWZCGGSA-N_|_Small molecule_|_False_|_LY2979165_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HY-13239' 'LY-2979165' 'Ly2979165']_|_nan_|_nan_|_{'rows': array(['MONDO_0004985'], dtype=object), 'count': 1}_|_[ENSG00000164082]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4650419,"nan_|_nan_|_Antibody_|_False_|_QUAVONLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-1308' 'MK-1308A COMPONENT QUAVONLIMAB' 'Quavonlimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/QUAVONLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000681', 'EFO_0000182', 'EFO_0000756',
       'EFO_1001951', 'EFO_0000702', 'EFO_0003060'], dtype=object), 'count': 7}_|_[ENSG00000163599]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL513,"O=NN(CCCl)C(=O)NCCCl_|_DLGOEMSEDOSKAD-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARMUSTINE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Bicnu' 'Carmustine obvius' 'Gliadel']_|_['BCNU' 'Becenun' 'Bischloroethyl nitrosourea' 'Camustine' 'Carmubris'
 'Carmustine' 'DTI-015' 'FDA-0345' 'NSC-409962' 'SK-27702' 'SRI-1720']_|_[('DailyMed', array(['carmustine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-obvius'],
      dtype=object)), ('PubChem', array(['11110902', '124879537', '144203648', '170464880', '174007319',
       '26747453', '26753530', '479311', '50105925', '57264377',
       '85230955', '90341293'], dtype=object)), ('Wikipedia', array(['Carmustine'], dtype=object)), ('drugbank', array(['DB00262'], dtype=object)), ('chEBI', array(['3423'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002913', 'EFO_0005543', 'EFO_1001469', 'EFO_0000565',
       'EFO_0000756', 'MONDO_0005184', 'EFO_1001051', 'EFO_0004256',
       'Orphanet_145', 'EFO_0003929', 'EFO_0000216', 'EFO_0000621',
       'EFO_0000096', 'EFO_0000519', 'EFO_1001465', 'EFO_1000785',
       'EFO_0000305', 'EFO_0000095', 'MONDO_0008170', 'EFO_0007498',
       'EFO_1000028', 'EFO_0002939', 'EFO_0005952', 'MONDO_0008315',
       'EFO_0001378', 'EFO_0000211', 'MONDO_0100342', 'EFO_1000158',
       'EFO_0000616', 'MONDO_0018906', 'HP_0001871', 'MONDO_0007254',
       'EFO_0004991', 'EFO_0000574', 'EFO_0006475', 'EFO_0000389',
       'EFO_0000691', 'EFO_0000183', 'EFO_0002501', 'EFO_0009538',
       'MONDO_0001657', 'EFO_1001383', 'EFO_0002499', 'EFO_0000272',
       'EFO_0000403', 'MONDO_0003268', 'EFO_1001951', 'EFO_0004599',
       'EFO_0003833'], dtype=object), 'count': 49}_|_[ENSG00000104687]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 12 approved and 37 investigational indications."
CHEMBL5315054,"CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1.O=C1CC[C@@H](C(=O)O)N1_|_YHIUPZFKHZTLSH-LXYIGGQGSA-N_|_Small molecule_|_False_|_ERTUGLIFLOZIN PIDOLATE_|_2018.0_|_4.0_|_CHEMBL1770248_|_False_|_True_|_['Steglatro']_|_['Ertugliflozin l-pyroglutamic acid']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/steglatro'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for type 2 diabetes mellitus."
CHEMBL606,"CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC_|_OJLOPKGSLYJEMD-URPKTTJQSA-N_|_Small molecule_|_True_|_MISOPROSTOL_|_1988.0_|_4.0_|_nan_|_False_|_True_|_['Cytotec' 'Misoprostol' 'Mysodelle' 'Topogyne']_|_['Misoprostol' 'SC-29333']_|_[('DailyMed', array(['misoprostol'], dtype=object)), ('PubChem', array(['11532984', '144205563', '26755780', '26755781'], dtype=object)), ('Wikipedia', array(['Misoprostol'], dtype=object)), ('drugbank', array(['DB00929'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001255', 'EFO_0000668', 'EFO_0004607', 'MONDO_0004247',
       'EFO_0009579', 'EFO_0000731', 'MONDO_0000931', 'HP_0000132',
       'EFO_0000544', 'EFO_0002950', 'EFO_0003843', 'EFO_1001249',
       'MONDO_0001572', 'EFO_0009454', 'MONDO_0005178', 'MONDO_0003061',
       'EFO_0009846', 'EFO_0003898', 'HP_0004398', 'EFO_0001073',
       'MP_0001914', 'EFO_1000874', 'EFO_0003948', 'EFO_1001799',
       'EFO_0003917'], dtype=object), 'count': 25}_|_[ENSG00000050628]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 7 approved and 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL628,"CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O_|_BYPFEZZEUUWMEJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PENTOXIFYLLINE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_['Neotren mr' 'Pentoxifylline' 'Pentoxil' 'Trental' 'Trental 100'
 'Trental 400']_|_['BL 191' 'BL-191' 'C04AD03' 'NSC-637086' 'NSC-758481' 'Oxpentifylline'
 'Oxypentifylline' 'Pentoxifylline' 'Pentoxiphyllin']_|_[('DailyMed', array(['pentoxifylline'], dtype=object)), ('PubChem', array(['11111613', '11111614', '124881066', '144203774', '170465384',
       '26719692', '26747196', '50085870', '50105176', '85231180',
       '857899', '90341235'], dtype=object)), ('Wikipedia', array(['Pentoxifylline'], dtype=object)), ('drugbank', array(['DB00806'], dtype=object)), ('chEBI', array(['7986'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_1001249', 'EFO_0000278', 'MONDO_0021681',
       'MONDO_0004985', 'MONDO_0100096', 'MONDO_0002050', 'MONDO_0010679',
       'EFO_0001065', 'EFO_0000545', 'EFO_0004272', 'EFO_1001346',
       'EFO_0003780', 'MONDO_0008867', 'EFO_1001345', 'EFO_0003767',
       'HP_0001919', 'EFO_0006890', 'EFO_0003928', 'EFO_1001486',
       'EFO_0000319', 'EFO_0005046', 'EFO_1000158', 'EFO_0003869',
       'EFO_0005774', 'MONDO_0018373', 'MONDO_0002462', 'EFO_0003060',
       'EFO_0004255', 'EFO_0000384', 'EFO_0003884', 'EFO_0005044',
       'EFO_0004284', 'HP_0001643', 'HP_0001397', 'MONDO_0005090',
       'EFO_1000844', 'MONDO_0002009', 'EFO_0007444', 'HP_0040187',
       'EFO_0001645', 'EFO_0004259', 'EFO_0005672', 'EFO_0000474',
       'HP_0001399', 'EFO_0000401', 'MONDO_0004992', 'EFO_0000546',
       'EFO_0001422', 'EFO_0000220', 'EFO_1000652', 'DOID_13406'],
      dtype=object), 'count': 52}_|_[ENSG00000170425,ENSG00000128271,ENSG00000138735,ENSG00000065989,ENSG00000172572,ENSG00000139053,ENSG00000185527,ENSG00000186642,ENSG00000205268,ENSG00000115252,ENSG00000160191,ENSG00000133256,ENSG00000113448,ENSG00000184588,ENSG00000156973,ENSG00000132915,ENSG00000152270,ENSG00000095464,ENSG00000113231,ENSG00000112541,ENSG00000123360,ENSG00000105650,ENSG00000154678,ENSG00000073417,ENSG00000171408]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and has 51 investigational indications."
CHEMBL748,"C[n+]1ccccc1/C=N/O.[Cl-]_|_HIGSLXSBYYMVKI-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRALIDOXIME CHLORIDE_|_1964.0_|_4.0_|_CHEMBL1420_|_False_|_True_|_['2-Pam' 'Contrathion' 'Duodote' 'Pralidoxime chloride'
 'Pralidoxime chloride (autoinjector)' 'Protopam' 'Protopam chloride']_|_['2-PAM' '2-PAM CHLORIDE' '2-PAM Chloride' 'NSC-164614'
 'Pralidoxime chloride' 'Protopam']_|_[('DailyMed', array(['pralidoxime%20chloride'], dtype=object)), ('PubChem', array(['11533058', '144203867', '170465059', '56422221'], dtype=object)), ('chEBI', array(['8355'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008546', 'EFO_0004991'], dtype=object), 'count': 2}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for poisoning and myasthenia gravis."
CHEMBL1085,"CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2_|_WNTYBHLDCKXEOT-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACETOPHENAZINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acetophenazine' 'Tindal']_|_[('PubChem', array(['50125831'], dtype=object)), ('Wikipedia', array(['Acetophenazine'], dtype=object)), ('drugbank', array(['DB01063'], dtype=object)), ('chEBI', array(['2401'], dtype=object))]_|_['CHEMBL2360079']_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and is indicated for psychosis."
CHEMBL1200947,"CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C.Cl_|_BLWNYSZZZWQCKO-UHFFFAOYSA-N_|_Small molecule_|_False_|_METIPRANOLOL HYDROCHLORIDE_|_1989.0_|_4.0_|_CHEMBL1291_|_True_|_True_|_['Metipranolol' 'Optipranolol']_|_['Betamann' 'Metipranolol hcl']_|_[('chEBI', array(['34845'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989. It was withdrawn in at least one region."
CHEMBL1201302,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O_|_VQODGRNSFPNSQE-CXSFZGCWSA-N_|_Small molecule_|_False_|_DEXAMETHASONE PHOSPHORIC ACID_|_1959.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dexamethasone phosphate' 'Dexamethasone phosphoric acid']_|_[('chEBI', array(['68637'], dtype=object))]_|_['CHEMBL1200637' 'CHEMBL2021430']_|_{'rows': array(['MONDO_0004979', 'EFO_1000941', 'MONDO_0007915', 'EFO_0000556',
       'EFO_0007328', 'MONDO_0008728', 'EFO_0009609', 'EFO_0004719',
       'EFO_1000039', 'EFO_1000764', 'MONDO_0005129', 'EFO_1000997',
       'EFO_1001896', 'EFO_0000574', 'HP_0001915', 'EFO_0001642',
       'EFO_1001051', 'HP_0012424', 'EFO_0005558', 'HP_0001873',
       'EFO_0007257', 'MONDO_0100096', 'EFO_1002022', 'EFO_0004276',
       'EFO_1001250', 'EFO_0006738', 'EFO_0005319', 'MP_0001845',
       'EFO_0000729', 'EFO_1000049', 'EFO_0007141', 'EFO_0009491',
       'EFO_0001378', 'MONDO_0003005', 'EFO_0003929', 'MONDO_0001718',
       'EFO_0004265', 'EFO_1000906', 'EFO_0007490', 'EFO_0008997',
       'EFO_1000845', 'EFO_1000811', 'MONDO_0005178', 'EFO_1001194',
       'EFO_0007403', 'EFO_0007520', 'EFO_0004255', 'EFO_0004274',
       'MONDO_0015128', 'EFO_1000684', 'EFO_1001119', 'EFO_0003778',
       'EFO_0003898', 'EFO_0000694', 'EFO_0000565', 'MONDO_0019338',
       'EFO_0003956', 'EFO_0003106', 'EFO_0000685', 'EFO_0009560',
       'EFO_0000384', 'EFO_1001222', 'EFO_0009456', 'HP_0004398',
       'HP_0003072', 'EFO_0002609', 'EFO_0000676', 'EFO_0007405',
       'EFO_0009449', 'EFO_0005854', 'HP_0001094', 'EFO_1001205',
       'MONDO_0001280', 'HP_0003040', 'EFO_1000694', 'EFO_0007160',
       'EFO_1001435', 'EFO_0000274'], dtype=object), 'count': 78}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 60 approved and 18 investigational indications."
CHEMBL1201891,"CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C_|_FBHSPRKOSMHSIF-GRMWVWQJSA-N_|_Small molecule_|_False_|_DEFLAZACORT_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Calcort' 'Emflaza' 'Zamene']_|_['Deflazacort' 'MDL 458' 'MDL-458' 'MDL458']_|_[('DailyMed', array(['deflazacort'], dtype=object)), ('PubChem', array(['144206059', '144211732', '170466610'], dtype=object)), ('drugbank', array(['DB11921'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0020121', 'EFO_0001421', 'MONDO_0016971', 'EFO_0003086',
       'EFO_0007140', 'MONDO_0010679'], dtype=object), 'count': 6}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for muscular dystrophy and duchenne muscular dystrophy and has 4 investigational indications."
CHEMBL1275868,"CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1_|_ZKFQEACEUNWPMT-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZELNIDIPINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Azelnidipine' 'Calblock']_|_[('PubChem', array(['144205993', '170465756', '174006618', '50112690'], dtype=object)), ('drugbank', array(['DB09230'], dtype=object))]_|_nan_|_nan_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL142703,"N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2_|_SYOKIDBDQMKNDQ-XWTIBIIYSA-N_|_Small molecule_|_False_|_VILDAGLIPTIN_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Galvus' 'Xiliarx']_|_['LAF 237' 'LAF-237' 'LAF237' 'NVP-LAF 237' 'NVP-LAF237' 'Vildagliptin'
 'Vitagliptin']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xiliarx'],
      dtype=object)), ('Wikipedia', array(['Vildagliptin'], dtype=object)), ('drugbank', array(['DB04876'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004593', 'MONDO_0005147', 'EFO_1001121', 'MONDO_0005148',
       'EFO_0000400', 'MONDO_0002009', 'EFO_0002546'], dtype=object), 'count': 7}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 5 investigational indications."
CHEMBL1742985,"nan_|_nan_|_Antibody_|_False_|_ANRUKINZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anrukinzumab' 'IMA-638']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000729'], dtype=object), 'count': 2}_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2035187,"C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2_|_HWXVIOGONBBTBY-ONEGZZNKSA-N_|_Small molecule_|_False_|_PACRITINIB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ONX-0803' 'Pacritinib' 'SB-1518' 'SB1518' 'Sb-1518']_|_[('drugbank', array(['DB11697'], dtype=object))]_|_['CHEMBL5095049']_|_{'rows': array(['EFO_0000616', 'MONDO_0100096', 'EFO_0004251', 'EFO_0002429',
       'EFO_1001469', 'MONDO_0007254', 'EFO_0002430', 'EFO_0002430',
       'MONDO_0013730', 'EFO_1001951', 'EFO_0000222', 'EFO_0001421',
       'EFO_0003060', 'EFO_0000095', 'MONDO_0044903', 'EFO_0000183',
       'EFO_0000565', 'MONDO_0008315'], dtype=object), 'count': 18}_|_[ENSG00000122025,ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 15 investigational indications."
CHEMBL2108356,"nan_|_nan_|_Protein_|_False_|_PEGDINETANIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Angiocept' 'BMS-844203' 'CT-322' 'Ct-322' 'Pegdinetanib'
 'VEGFR-2 INHIBITOR PEPTIDE CT-322']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000616', 'EFO_0000519',
       'EFO_0000365'], dtype=object), 'count': 5}_|_[ENSG00000128052]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2108734,"nan_|_nan_|_Antibody_|_False_|_FLANVOTUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['20-D-7S' '20D7S' 'Flanvotumab' 'IMC-20D7S' 'IMC20D7S']_|_nan_|_nan_|_{'rows': array(['EFO_0000756'], dtype=object), 'count': 1}_|_[ENSG00000107165]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109259,nan_|_nan_|_Antibody_|_False_|_IGN-101_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IGN-101']_|_nan_|_nan_|_nan_|_[ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of III.
CHEMBL2109677,"nan_|_nan_|_Antibody_|_False_|_HUJ591 111IN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HUJ591' 'Huj591 (111in)' 'Huj591 111in']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000086205]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2364653,"nan_|_nan_|_Antibody_|_False_|_ANIFROLUMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Saphnelo']_|_['Anifrolumab' 'Anifrolumab fnia' 'MEDI-546']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001993', 'MONDO_0007915', 'EFO_0000699', 'EFO_0000540',
       'EFO_0004208', 'EFO_0000717', 'EFO_0000685', 'EFO_0005761'],
      dtype=object), 'count': 8}_|_[ENSG00000142166]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for systemic lupus erythematosus and immune system disease and has 6 investigational indications."
CHEMBL260538,"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C_|_OOLLAFOLCSJHRE-ZHAKMVSLSA-N_|_Small molecule_|_False_|_ULIPRISTAL ACETATE_|_2009.0_|_4.0_|_nan_|_True_|_True_|_['Ella' 'Ellaone' 'Esmya']_|_['CDB-2914' 'PGL-4001' 'RTI-3021-012' 'Ulipristal acet'
 'Ulipristal acetate' 'Ulipristal acetate ' 'VA-2914' 'VA2914']_|_[('DailyMed', array(['ulipristal%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/esmya'],
      dtype=object)), ('Wikipedia', array(['Ulipristal_acetate'], dtype=object)), ('chEBI', array(['71025'], dtype=object))]_|_nan_|_{'rows': array(['GO_0042697', 'EFO_0009520', 'MONDO_0007309', 'HP_0000131',
       'MONDO_0004169', 'EFO_1001757', 'MONDO_0001572', 'MP_0001914',
       'MONDO_0007254', 'EFO_0000731', 'MONDO_0002050'], dtype=object), 'count': 11}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 approved and 7 investigational indications. It was withdrawn in at least one region."
CHEMBL270995,"Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1_|_LTEJRLHKIYCEOX-OCCSQVGLSA-N_|_Small molecule_|_False_|_BRIVANIB ALANINATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-582664' 'BMS-582664-02' 'Brivanib alaninate'
 'Brivanib l-alanine ester']_|_[('drugbank', array(['DB11865'], dtype=object))]_|_['CHEMBL3526472']_|_{'rows': array(['EFO_0000182', 'MONDO_0004992', 'EFO_0000681', 'EFO_0000616',
       'EFO_1001951'], dtype=object), 'count': 5}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL28218,"O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1_|_RKLNONIVDFXQRX-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMPERIDOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Impromen']_|_['Bromperidol' 'NSC-759275' 'R 11,333' 'R-11333']_|_[('PubChem', array(['11112600', '144204116', '170465873', '56463221'], dtype=object)), ('Wikipedia', array(['Bromperidol'], dtype=object)), ('drugbank', array(['DB12401'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'EFO_0005407',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."
CHEMBL3184799,"CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O_|_DNKCFBJMFIUNRS-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPHENTERMINE SULFATE_|_1951.0_|_4.0_|_CHEMBL1201234_|_False_|_True_|_['Wyamine sulfate']_|_['Mephentermine sulfate' 'Mephentermine sulfate dihydrate'
 'Mephentermine sulphate' 'Mephine' 'NSC-758424' 'Wyamine'
 'Wyamine sulphate']_|_[('PubChem', array(['144204052', '170465271'], dtype=object))]_|_nan_|_nan_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951."
CHEMBL3989833,"CS(=O)(=O)O.O.O.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1_|_WLQZEFFFIUHSJB-UHFFFAOYSA-N_|_Small molecule_|_True_|_ZIPRASIDONE MESYLATE_|_2002.0_|_4.0_|_CHEMBL708_|_False_|_True_|_['Geodon']_|_['CP-88, 059-27' 'CP-88,059-27' 'CP-88059-27' 'CP-8805927' 'NSC-760351'
 'Ziprasidone mesilate' 'Ziprasidone mesilate trihydrate'
 'Ziprasidone mesylate' 'Ziprasidone mesylate anhydrous']_|_[('DailyMed', array(['ziprasidone%20mesylate'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004985', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000102468,ENSG00000149295,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for bipolar disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL425,"O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O_|_QQBDLJCYGRGAKP-FOCLMDBBSA-N_|_Small molecule_|_False_|_OLSALAZINE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['C. i. mordant yellow 5' 'Dipentum' 'Olsalazine']_|_[('PubChem', array(['50125747'], dtype=object)), ('drugbank', array(['DB01250'], dtype=object))]_|_['CHEMBL1201013']_|_{'rows': array(['EFO_0003898', 'EFO_0000729'], dtype=object), 'count': 2}_|_[ENSG00000012779,ENSG00000132170,ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for ulcerative colitis and has 1 investigational indication."
CHEMBL4297322,"N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F.O=C(O)/C=C/C(=O)O_|_RPYIKXHIQXRXEM-WLHGVMLRSA-N_|_Small molecule_|_False_|_PRX-08066_|_nan_|_2.0_|_CHEMBL513994_|_False_|_False_|_[]_|_['Prx-08066']_|_[('drugbank', array(['DB05607'], dtype=object))]_|_nan_|_nan_|_[ENSG00000135914]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4297800,"nan_|_nan_|_Protein_|_False_|_PEGTEOGRASTIM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Neulapeg' 'Pegteograstim']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297892,"nan_|_nan_|_Antibody drug conjugate_|_False_|_ANVATABART OPADOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARX-788' 'ARX788' 'ARX788 ADC' 'Anvatabart opadotin'
 'Anvatabart opafidotin' 'Arx 788' 'Arx-788' 'Arx788']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ANVATABART%20OPADOTIN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0003968',
       'EFO_0003869', 'EFO_0005537'], dtype=object), 'count': 6}_|_[ENSG00000141736,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4594272,"Cl.Cl.N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1_|_XFZLBLTUANGZBD-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEROTRALSTAT HYDROCHLORIDE_|_2020.0_|_4.0_|_CHEMBL4594271_|_False_|_True_|_['Orladeyo']_|_['BCX7353.2HCl' 'Berotralstat dihydrochloride'
 'Berotralstat hydrochloride']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BEROTRALSTAT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005532', 'MONDO_0019623'], dtype=object), 'count': 2}_|_[ENSG00000164344]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hereditary angioedema and has 1 investigational indication."
CHEMBL4650285,"Cn1nccc1Nc1nccc(-c2cc3c(s2)C(C)(C)N(CCN2CCOCC2)C3=O)n1_|_JNPRPMBJODOFEC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TEMUTERKIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-3214996' 'LY3214996' 'Ly 3214996' 'Ly3214996' 'Temuterkib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEMUTERKIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802243']_|_{'rows': array(['EFO_0000616', 'MONDO_0005184', 'EFO_0002618', 'EFO_0000616',
       'EFO_0000222', 'MONDO_0004992', 'EFO_0000519'], dtype=object), 'count': 7}_|_[ENSG00000102882,ENSG00000100030]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL468419,"Cl.N#Cc1ccc(C2CCCc3cncn32)cc1_|_UKCVAQGKEOJTSR-UHFFFAOYSA-N_|_Small molecule_|_False_|_FADROZOLE HYDROCHLORIDE_|_nan_|_-1.0_|_CHEMBL9298_|_False_|_False_|_[]_|_['Afema' 'CGS 16949A' 'CGS-16949A' 'Fadrozole hcl'
 'Fadrozole hydrochloride']_|_[('PubChem', array(['144213918'], dtype=object))]_|_nan_|_nan_|_[ENSG00000137869]_|_Small molecule drug."
CHEMBL481,"CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC_|_UWKQSNNFCGGAFS-XIFFEERXSA-N_|_Small molecule_|_True_|_IRINOTECAN_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Biotecan' 'Camptosar' 'Irinotecan' 'NSC-728073']_|_[('PubChem', array(['124893595'], dtype=object)), ('Wikipedia', array(['Irinotecan'], dtype=object)), ('drugbank', array(['DB00762'], dtype=object)), ('chEBI', array(['80630'], dtype=object))]_|_['CHEMBL541887' 'CHEMBL1200512' 'CHEMBL3989514']_|_{'rows': array(['EFO_1000359', 'EFO_1001901', 'MONDO_0002120', 'EFO_1001013',
       'EFO_0002618', 'EFO_0001075', 'MONDO_0004669', 'EFO_0000681',
       'EFO_0002617', 'EFO_0000707', 'EFO_0005543', 'EFO_0000178',
       'EFO_1000350', 'EFO_1000292', 'MONDO_0008315', 'EFO_0003893',
       'EFO_0000309', 'EFO_0003833', 'MONDO_0002120', 'EFO_0002501',
       'EFO_0000565', 'EFO_1000475', 'MONDO_0018364', 'EFO_0003860',
       'EFO_1001051', 'MONDO_0008170', 'MONDO_0021063', 'EFO_0000702',
       'EFO_0000326', 'MONDO_0007576', 'MONDO_0008903', 'MONDO_0008903',
       'EFO_0000621', 'HP_0002014', 'MONDO_0004992', 'EFO_0006352',
       'MONDO_0003060', 'EFO_1000359', 'EFO_0002918', 'EFO_1000158',
       'MONDO_0002974', 'EFO_0000174', 'MONDO_0044937', 'EFO_0004243',
       'MONDO_0002367', 'EFO_0009708', 'EFO_1001961', 'MONDO_0001475',
       'EFO_1000251', 'MONDO_0005575', 'EFO_0003968', 'MONDO_0044937',
       'EFO_0002939', 'EFO_0000632', 'MONDO_0005411', 'MONDO_0002087',
       'MONDO_0024503', 'EFO_1000895', 'EFO_0005952', 'EFO_1000657',
       'EFO_0003869', 'MONDO_0001325', 'EFO_0001416', 'MONDO_0005184',
       'EFO_1001951', 'EFO_0003891', 'EFO_0002499', 'EFO_1000785',
       'EFO_1001469', 'EFO_0000502', 'MONDO_0001187', 'MONDO_0001879',
       'EFO_0000389', 'EFO_1001365', 'EFO_0002618', 'EFO_0000502',
       'EFO_0000637', 'EFO_1001471', 'EFO_0000691', 'EFO_0006859',
       'EFO_0002939', 'EFO_0000616', 'EFO_1001949', 'MONDO_0005184',
       'EFO_0000691', 'EFO_0000616', 'EFO_0000503', 'EFO_0000174',
       'EFO_0003032', 'EFO_0002499', 'EFO_0000365', 'EFO_0005221',
       'EFO_0004142', 'EFO_0000588', 'MONDO_0021633', 'MONDO_0018271',
       'EFO_0007416', 'EFO_0000255', 'MONDO_0021063', 'EFO_0001075',
       'EFO_1000657', 'MONDO_0002367', 'MONDO_0002158', 'EFO_1001512',
       'EFO_0000313', 'EFO_1000292', 'EFO_0000707', 'EFO_0000403',
       'EFO_0000228', 'MONDO_0100342', 'EFO_0000574', 'MONDO_0016717',
       'EFO_0000365', 'EFO_1000407', 'MONDO_0044926', 'MONDO_0000873',
       'EFO_0002938', 'MONDO_0001056', 'MONDO_0002165', 'MONDO_0002537',
       'EFO_0002918', 'EFO_0002501', 'EFO_0005537', 'MONDO_0002974',
       'EFO_0004193', 'MONDO_0002087', 'EFO_0008549', 'EFO_0000519',
       'EFO_0003860', 'EFO_0000437', 'EFO_1000475', 'EFO_0004288',
       'MONDO_0003060', 'MONDO_0008170', 'EFO_0000191', 'EFO_0001061',
       'MONDO_0007254', 'EFO_1001465', 'EFO_0003060', 'MONDO_0020634',
       'EFO_0000702', 'EFO_0002916', 'EFO_0000313', 'EFO_0000519',
       'MONDO_0007576', 'MONDO_0019004', 'EFO_0000621', 'EFO_1000026',
       'EFO_0005537', 'MONDO_0100342', 'MONDO_0001657', 'EFO_0000095',
       'MONDO_0002158', 'MONDO_0019471', 'EFO_0000503', 'MONDO_0016717',
       'EFO_0007535', 'MONDO_0011719', 'EFO_0000182', 'EFO_0000574',
       'MONDO_0003196', 'EFO_0000183', 'EFO_0003897', 'EFO_0000197',
       'EFO_0005922', 'EFO_0006859', 'MONDO_0002691', 'Orphanet_145',
       'EFO_1000158', 'EFO_0004142', 'MONDO_0006058', 'EFO_1001465',
       'MONDO_0021117', 'EFO_1001951', 'EFO_0001071', 'EFO_0000248',
       'EFO_0000178', 'MONDO_0018906', 'MONDO_0004192', 'MONDO_0004992',
       'EFO_1001512', 'MONDO_0007254', 'EFO_0000565', 'MONDO_0002691',
       'EFO_0003060', 'MONDO_0001056'], dtype=object), 'count': 186}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 148 investigational indications. This drug has a black box warning from the FDA."
CHEMBL592,"CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13_|_JAQUASYNZVUNQP-USXIJHARSA-N_|_Small molecule_|_True_|_LEVORPHANOL_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Aromarone' 'IDS-NL-007' 'Levorphan' 'Levorphanol' 'RO 1-5431']_|_[('Wikipedia', array(['Levorphanol'], dtype=object)), ('drugbank', array(['DB00854'], dtype=object)), ('chEBI', array(['6444'], dtype=object))]_|_['CHEMBL1628243' 'CHEMBL2062261' 'CHEMBL3989768' 'CHEMBL3249801']_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991 and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL760,"O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1_|_OTBXOEAOVRKTNQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANAGRELIDE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Agrylin' 'Anagrelide' 'Xagrid']_|_[('PubChem', array(['124892336', '26755034'], dtype=object)), ('Wikipedia', array(['Anagrelide'], dtype=object)), ('drugbank', array(['DB00261'], dtype=object)), ('chEBI', array(['142290'], dtype=object))]_|_['CHEMBL1200759']_|_{'rows': array(['EFO_0004251', 'EFO_0000479', 'EFO_0002429', 'MONDO_0000831',
       'EFO_0000479', 'EFO_0004251', 'HP_0004419', 'EFO_0000616'],
      dtype=object), 'count': 8}_|_[ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 3 investigational indications."
CHEMBL1200399,"Cl.O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1_|_RICLFGYGYQXUFH-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUSPIRONE HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL49_|_False_|_True_|_['Buspar' 'Buspirone hydrochloride']_|_['APD-405' 'APD405' 'Buspirone hcl' 'Buspirone hydrochloride' 'MJ 9022-1'
 'MJ-9022-1' 'NSC-751138' 'NSC-759571']_|_[('DailyMed', array(['buspirone%20hydrochloride'], dtype=object)), ('PubChem', array(['11533010', '50105965', '56422091'], dtype=object)), ('chEBI', array(['3224'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006788', 'MONDO_0005090', 'EFO_0004714', 'EFO_0005411',
       'MONDO_0002050', 'EFO_1001892', 'EFO_0004888', 'EFO_1001919'],
      dtype=object), 'count': 8}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 5 investigational indications."
CHEMBL1200515,"COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5ccccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC_|_CVBMAZKKCSYWQR-WCGOZPBSSA-N_|_Small molecule_|_False_|_DESERPIDINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Harmonyl']_|_['Deserpidine' 'Deserpidine, (-)-' 'Halmonyl' 'NSC-72138' 'Recanescin']_|_[('PubChem', array(['144206199', '144206653', '50113288'], dtype=object)), ('Wikipedia', array(['Deserpidine'], dtype=object)), ('drugbank', array(['DB01089'], dtype=object)), ('chEBI', array(['27478'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for hypertension."
CHEMBL1200993,"CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]_|_REEUVFCVXKWOFE-UHFFFAOYSA-K_|_Small molecule_|_False_|_GALLAMINE TRIETHIODIDE_|_1982.0_|_4.0_|_CHEMBL360055_|_False_|_True_|_['Benzcurine Iodide' 'Flaxedil' 'Gallomone Triethiodide' 'Relaxan']_|_['Benzcurine iodide' 'Gallamine triethiodide' 'Gallamini triethiodidum'
 'Gallamone triethiodide' 'NSC-102690' 'Remyolan' 'Syncurarine']_|_[('PubChem', array(['144205593', '170465398', '50106346', '57264265'], dtype=object)), ('Wikipedia', array(['Gallamine_triethiodide'], dtype=object)), ('drugbank', array(['DB00483'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201023,"Cc1ccccc1C(OCCN(C)C)c1ccccc1.Cl_|_UQZKYYIKWZOKKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_ORPHENADRINE HYDROCHLORIDE_|_1957.0_|_4.0_|_CHEMBL900_|_False_|_True_|_['Biorphen' 'Disipal']_|_['Mephenamin' 'NSC-82357' 'Orphenadrine (chloride)'
 'Orphenadrine Chloride' 'Orphenadrine hcl' 'Orphenadrine hydrochloride']_|_[('PubChem', array(['144212244', '26752324', '50106731', '56422385', '855661'],
      dtype=object)), ('chEBI', array(['60902'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000196639,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for parkinson disease."
CHEMBL1240,"CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C.[Br-]_|_XLBIBBZXLMYSFF-UHFFFAOYSA-M_|_Small molecule_|_False_|_PROPANTHELINE BROMIDE_|_1953.0_|_4.0_|_CHEMBL1180725_|_False_|_True_|_['Pro-banthine' 'Propantheline bromide']_|_['NSC-757294' 'Propantheline Bromide' 'Propantheline bromide']_|_[('PubChem', array(['144204817', '144212648', '170464881', '26747652', '50106913',
       '56422773', '855578'], dtype=object)), ('Wikipedia', array(['Propantheline_bromide'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004247', 'EFO_1000781'], dtype=object), 'count': 2}_|_[ENSG00000133019,ENSG00000168539,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for peptic ulcer disease and has 1 investigational indication."
CHEMBL14376,"COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1_|_XMXHEBAFVSFQEX-UHFFFAOYSA-N_|_Small molecule_|_True_|_ILOPERIDONE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Fanapt' 'Iloperidone']_|_['HP 873' 'HP-873' 'Iloperidone']_|_[('DailyMed', array(['iloperidone'], dtype=object)), ('PubChem', array(['124899318', '144207159', '170465198'], dtype=object)), ('Wikipedia', array(['Iloperidone'], dtype=object)), ('drugbank', array(['DB04946'], dtype=object)), ('chEBI', array(['65173'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005407', 'EFO_0001421', 'EFO_0009963', 'EFO_0001358',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for psychosis and schizophrenia and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1645462,"Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12_|_LUJZZYWHBDHDQX-QFIPXVFZSA-N_|_Small molecule_|_False_|_AC-480_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AC-480' 'AC480' 'Ac-480' 'BMS-599626' 'Bms 599626']_|_[('drugbank', array(['DB12318'], dtype=object))]_|_['CHEMBL5307497']_|_{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_0005543'], dtype=object), 'count': 3}_|_[ENSG00000146648,ENSG00000141736,ENSG00000178568]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL2103827,"N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1_|_QXWYKJLNLSIPIN-JGVFFNPUSA-N_|_Small molecule_|_True_|_DROXIDOPA_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Northera']_|_['DOPS' 'Droxidopa' 'L-DOPS' 'L-threo-dops']_|_[('DailyMed', array(['droxidopa'], dtype=object)), ('drugbank', array(['DB06262'], dtype=object)), ('chEBI', array(['31524'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005687', 'MONDO_0005180', 'EFO_1000645', 'EFO_1001050',
       'EFO_0005251', 'EFO_0005252', 'EFO_0003888', 'EFO_0000319'],
      dtype=object), 'count': 8}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103838,"Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F_|_ORVNHOYNEHYKJG-UHFFFAOYSA-N_|_Small molecule_|_False_|_DILMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dilmapimod' 'Gw-681323' 'SB-681323' 'SB681323']_|_[('drugbank', array(['DB12140'], dtype=object))]_|_['CHEMBL2105674']_|_{'rows': array(['EFO_0004610', 'EFO_0001645', 'EFO_0005762', 'EFO_0000341',
       'EFO_0000685'], dtype=object), 'count': 5}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2107979,"nan_|_nan_|_Antibody_|_False_|_PEXELIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['5G1.1-SC' 'H-5G1.1 SCFV' 'H5G1.1 SCFV' 'H5G1.1 SCFV (CDR)' 'Pexelizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0008583', 'EFO_0001645'], dtype=object), 'count': 2}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108370,"nan_|_nan_|_Antibody_|_False_|_INOLIMOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Leucotac']_|_['BT-563' 'Inolimomab' 'Leukotac']_|_nan_|_nan_|_{'rows': array(['MONDO_0013730'], dtype=object), 'count': 1}_|_[ENSG00000134460]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108501,"nan_|_nan_|_Antibody_|_False_|_LABETUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Cea-Cide']_|_['HMN-14' 'Labetuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_1000657', 'EFO_1001951', 'MONDO_0007254', 'EFO_0000365',
       'EFO_0004142', 'MONDO_0021063', 'EFO_0003860'], dtype=object), 'count': 7}_|_[ENSG00000105388]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL2109665,"nan_|_nan_|_Antibody_|_False_|_OCARATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AME-133v' 'LY2469298' 'Ocaratuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2151439,"O=C(N[C@@H]1CN2CCC1CC2)c1n[nH]c2ccccc12_|_TXCYUSKWBHUVEP-CYBMUJFWSA-N_|_Small molecule_|_False_|_FACINICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MEM 3454 FREE BASE' 'MEM-3454 FREE BASE' 'MEM3454 FREE BASE'
 'RG-3487 FREE BASE' 'RG3487 FREE BASE' 'RO-5313534 FREE BASE']_|_[('drugbank', array(['DB05586'], dtype=object))]_|_['CHEMBL5095032']_|_{'rows': array(['MONDO_0005090', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000166736,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084,ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL231779,"COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1_|_QNZCBYKSOIHPEH-UHFFFAOYSA-N_|_Small molecule_|_True_|_APIXABAN_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Eliquis']_|_['Apixaban' 'BMS-562247' 'BMS-562247-01']_|_[('DailyMed', array(['apixaban'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis'],
      dtype=object)), ('PubChem', array(['174006823'], dtype=object)), ('Wikipedia', array(['Apixaban'], dtype=object)), ('drugbank', array(['DB06605'], dtype=object)), ('chEBI', array(['72296'], dtype=object))]_|_['CHEMBL3526474']_|_{'rows': array(['EFO_0003884', 'EFO_0009314', 'EFO_0003144', 'EFO_0000266',
       'MONDO_0000831', 'EFO_1002000', 'MONDO_0004992', 'HP_0002140',
       'EFO_0000275', 'EFO_0004286', 'EFO_0003907', 'MP_0001914',
       'HP_0000083', 'EFO_0000556', 'EFO_0004255', 'EFO_0003827',
       'EFO_0001422', 'EFO_0003911', 'MONDO_0011382', 'EFO_0005672',
       'HP_0001907', 'EFO_0000220', 'EFO_0010680', 'HP_0004419',
       'HP_0004936', 'HP_0001655', 'EFO_0000712', 'MONDO_0100096'],
      dtype=object), 'count': 28}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 8 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2402904,"COC(=O)N1CCC(CN2CCC(CNC(=O)c3cccc4[nH]c(C(C)C)nc34)CC2)CC1_|_MZOITCJKGUIQEI-UHFFFAOYSA-N_|_Small molecule_|_False_|_FELCISETRAG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Felcisetrag' 'TAK-954' 'TD-8954' 'THRX-149699' 'Tak-954' 'Td-8954']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FELCISETRAG/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12725'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000948', 'EFO_0001421', 'EFO_0003086', 'HP_0011024'],
      dtype=object), 'count': 4}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL252164,"CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1_|_NDAZATDQFDPQBD-UHFFFAOYSA-N_|_Small molecule_|_False_|_LUMINESPIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Luminespib' 'NVP-AUY-922' 'NVP-AUY922' 'NVP-AUY922-NX' 'VER-52296']_|_[('PubChem', array(['124954168'], dtype=object)), ('Wikipedia', array(['NVP-AUY922'], dtype=object)), ('chEBI', array(['83656'], dtype=object))]_|_['CHEMBL3137334']_|_{'rows': array(['EFO_0000574', 'EFO_0000571', 'EFO_0003060', 'EFO_0000708',
       'EFO_0000616', 'MONDO_0001056', 'EFO_0001378', 'EFO_0000365',
       'EFO_0004251', 'MONDO_0011719', 'MONDO_0021063', 'EFO_1000657',
       'MONDO_0007254'], dtype=object), 'count': 13}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 13 investigational indications."
CHEMBL273575,"CN1Cc2c(N)cccc2C(c2ccccc2)C1_|_XXPANQJNYNUNES-UHFFFAOYSA-N_|_Small molecule_|_False_|_NOMIFENSINE_|_1984.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Linamiphen' 'Nomifensin' 'Nomifensine']_|_[('PubChem', array(['144212072', '50105261', '90340560'], dtype=object)), ('Wikipedia', array(['Nomifensine'], dtype=object)), ('drugbank', array(['DB04821'], dtype=object)), ('chEBI', array(['116225'], dtype=object))]_|_['CHEMBL1256842']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for major depressive disorder."
CHEMBL3188551,"Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F_|_XTKLTGBKIDQGQL-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-2636771_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-2636771' 'GSK2636771' 'Gsk 2636771' 'Gsk-2636771']_|_[('PubChem', array(['174006492'], dtype=object)), ('drugbank', array(['DB11795'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000503', 'MONDO_0004992', 'EFO_0002617',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000051382]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3348923,"C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1_|_VWMJHAFYPMOMGF-ZCFIWIBFSA-N_|_Small molecule_|_False_|_TOVORAFENIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BIIB-024' 'BIIB024' 'Biib-024' 'DAY-101' 'DAY101' 'MLN-2480' 'Mln-2480'
 'TAK-580' 'Tak 580' 'Tak-580' 'Tovorafenib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOVORAFENIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15266'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000756', 'EFO_0000616', 'EFO_0002617',
       'EFO_1001951', 'EFO_1000209', 'MONDO_0016691', 'EFO_1000318',
       'EFO_0000641', 'EFO_0002618', 'EFO_0003060'], dtype=object), 'count': 11}_|_[ENSG00000132155,ENSG00000157764,ENSG00000078061]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL3544908,"CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O_|_SGHXFFAHXTZRQM-SPIKMXEPSA-N_|_Small molecule_|_False_|_AZATADINE MALEATE_|_1977.0_|_4.0_|_CHEMBL946_|_False_|_True_|_['Lergocil' 'Optimine']_|_['Azatadine dimaleate' 'Azatadine maleate' 'NSC-759874' 'SCH 10649'
 'SCH-10649']_|_[('chEBI', array(['2947'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977."
CHEMBL3545193,"nan_|_nan_|_Small molecule_|_False_|_MSC-2364447_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Msc-2364447']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989803,"Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C.O.[Na+]_|_UNZIDPIPYUMVPA-UHFFFAOYSA-M_|_Small molecule_|_False_|_DIPYRONE_|_nan_|_4.0_|_CHEMBL461522_|_True_|_True_|_[]_|_['Analgin' 'Dipyrone' 'Dipyrone anhydrous' 'Metamizol'
 'Metamizol monohydrate' 'Metamizole sodium'
 'Metamizole sodium (anhydrous)' 'Metamizole sodium hydrate'
 'Metamizole sodium monohydrate' 'Metamizolum natricum anhydricum'
 'Methampyrone' 'NSC-73205' 'NSC-758445'
 'Noramidopyrine methanesulfonate sodium' 'Novalgin' 'Sulpyrine'
 'Sulpyrine hydrate']_|_nan_|_nan_|_{'rows': array(['HP_0100806', 'MONDO_0005277', 'EFO_0003843', 'HP_0001945',
       'EFO_1001463', 'HP_0012532'], dtype=object), 'count': 6}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pain and fever and has 4 investigational indications. It was withdrawn in at least one region."
CHEMBL4297300,"CN1CCN(C(=O)C2C(C(=O)O)[C@H]3CC[C@@H]2O3)CC1_|_JUQMLSGOTNKJKI-IZUQBHJASA-N_|_Small molecule_|_False_|_LB-100_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LB 100' 'Lb-100']_|_[('drugbank', array(['DB15412'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000632', 'EFO_1001968', 'EFO_0000198',
       'EFO_0000702', 'EFO_0000519'], dtype=object), 'count': 6}_|_[ENSG00000113575,ENSG00000104695,ENSG00000011485]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL4297894,"nan_|_nan_|_Unknown_|_False_|_ASP-8374_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ASP-8374' 'ASP8374' 'Asp 8374' 'Asp-8374' 'Asp8374' 'PTZ-201']_|_nan_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000181847]_|_Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL4298013,"nan_|_nan_|_Antibody_|_False_|_ELGEMTUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['69745p00p9' 'Elgemtumab' 'LJM-716' 'LJM716' 'Ljm716' 'NOV-6']_|_nan_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0005922', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4558324,"C=CC(=O)Nc1cc(Nc2nccc(-n3cc(CN(C)C)c(-c4ccccc4)n3)n2)c(OC)cc1N1CCOCC1_|_RRMJMHOQSALEJJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_LAZERTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['C-18112003-G' 'GNS-1480' 'GNS1480' 'JNJ-73841937-AAA' 'Lazertinib'
 'YH-25448' 'YH25448' 'Yh25448']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LAZERTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021117', 'EFO_0003060', 'MONDO_0004992', 'EFO_0001421',
       'EFO_0000616', 'MONDO_0008903'], dtype=object), 'count': 6}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL459505,"CCC(CC)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1_|_SNFYYXUGUBUECJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TALAROZOLE_|_nan_|_2.0_|_nan_|_False_|_False_|_['Rambazole']_|_['R-115866' 'R115866' 'Talarozole']_|_[('drugbank', array(['DB13083'], dtype=object))]_|_nan_|_{'rows': array(['MP_0001845', 'EFO_0000676', 'EFO_0003894'], dtype=object), 'count': 3}_|_[ENSG00000095596]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650297,"nan_|_nan_|_Unknown_|_False_|_HMPL-453_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HMPL-453' 'Hmpl-453']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000588', 'MONDO_0003059'], dtype=object), 'count': 3}_|_[ENSG00000077782,ENSG00000068078,ENSG00000066468]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650313,"Cc1cc(S(=O)(=O)Nc2cscn2)c(F)cc1N(C)[C@H]1CCN(Cc2ccccc2)C1_|_UCSHINHOAVARGQ-SFHVURJKSA-N_|_Small molecule_|_False_|_ZANDATRIGINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NBI-921352' 'Nbi-921352' 'XEN-901' 'XEN901' 'Xen901' 'Zandatrigine']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196876]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL5314649,"C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C.Cc1ccc(S(=O)(=O)O)cc1_|_YOZLVAFWYLSRRN-VZXYPILPSA-N_|_Small molecule_|_True_|_RITLECITINIB TOSYLATE_|_2023.0_|_4.0_|_CHEMBL4085457_|_False_|_True_|_['Litfulo']_|_['Pf-06651600 tosylate' 'Ritlecitinib tosilate' 'Ritlecitinib toslate']_|_nan_|_nan_|_{'rows': array(['EFO_0004192'], dtype=object), 'count': 1}_|_[ENSG00000113263,ENSG00000102010,ENSG00000135605,ENSG00000074966,ENSG00000010671,ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for alopecia areata. This drug has a black box warning from the FDA."
CHEMBL5315080,"nan_|_nan_|_Protein_|_False_|_BULEVIRTIDE ACETATE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Hepcludex']_|_[]_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007304'], dtype=object), 'count': 1}_|_[ENSG00000100652]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for hepatitis d virus infection."
CHEMBL563646,"CC(C)(C)c1ccc(CN(Cc2cccc(OCC(=O)O)c2)S(=O)(=O)c2cccnc2)cc1_|_WOHRHWDYFNWPNG-UHFFFAOYSA-N_|_Small molecule_|_False_|_EVATANEPAG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CP-533,536' 'CP-533536' 'Evatanepag']_|_[('drugbank', array(['DB12022'], dtype=object))]_|_['CHEMBL2105672']_|_{'rows': array(['EFO_0003944'], dtype=object), 'count': 1}_|_[ENSG00000125384]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL574738,"CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1_|_ODPGGGTTYSGTGO-UHFFFAOYSA-N_|_Small molecule_|_False_|_AST-487_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AST-487' 'Ast-487' 'NVP-AST-487' 'NVP-AST487']_|_[('PubChem', array(['103905682', '50100088'], dtype=object))]_|_nan_|_nan_|_[ENSG00000165731,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL803,"Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1_|_UHDGCWIWMRVCDJ-CCXZUQQUSA-N_|_Small molecule_|_True_|_CYTARABINE_|_1969.0_|_4.0_|_nan_|_False_|_True_|_['Alexan' 'Alexan 100' 'Cytarabine' 'Cytosar' 'Cytosar-u' 'Depocyt'
 'Depocyte' 'Tarabine Pfs']_|_['Ara-c' 'Ara-cytidine' 'Arabinocytosine' 'Arabinosyl cytosine'
 'Aracytidine' 'Aracytin' 'Aracytine' 'Cytarabine' 'Cytarabine liposome'
 'Cytarabinoside' 'Cytarabinum' 'NSC-287459' 'Spongocytidine' 'U 19920a'
 'U-19,920' 'U-19920']_|_[('DailyMed', array(['cytarabine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/depocyte'],
      dtype=object)), ('PubChem', array(['131404637', '144204754', '144212288', '26719755', '29215144',
       '47193873', '90341066'], dtype=object)), ('Wikipedia', array(['Cytarabine'], dtype=object)), ('drugbank', array(['DB00987'], dtype=object)), ('chEBI', array(['28680'], dtype=object))]_|_['CHEMBL1256472']_|_{'rows': array(['MONDO_0044881', 'MONDO_0044917', 'EFO_0000339', 'EFO_1001779',
       'EFO_0000220', 'EFO_0000309', 'MONDO_0019460', 'EFO_0003811',
       'EFO_1000781', 'MONDO_0001475', 'MONDO_0000831', 'EFO_0003028',
       'EFO_0000096', 'MONDO_0007915', 'EFO_0000095', 'EFO_0003025',
       'EFO_0000519', 'EFO_0007498', 'EFO_1001257', 'MONDO_0008315',
       'EFO_0003851', 'EFO_0000691', 'EFO_0000094', 'EFO_0000211',
       'MONDO_0044903', 'MONDO_0018906', 'EFO_0000223', 'EFO_0003802',
       'EFO_0002939', 'EFO_0000574', 'MONDO_0000870', 'EFO_0004991',
       'EFO_0003086', 'EFO_0006475', 'EFO_0003833', 'MONDO_0004992',
       'EFO_0003029', 'EFO_0004191', 'EFO_0001378', 'EFO_0002429',
       'EFO_0009538', 'EFO_1001052', 'MONDO_0013730', 'EFO_1001365',
       'EFO_0002428', 'EFO_1000131', 'EFO_1001012', 'EFO_1000823',
       'EFO_0000183', 'MONDO_0000873', 'MONDO_0009348', 'EFO_0004256',
       'EFO_0000616', 'EFO_0003929', 'EFO_0000198', 'EFO_1000318',
       'EFO_0000209', 'EFO_0000218', 'EFO_0000756', 'EFO_0000403',
       'EFO_0000221', 'EFO_1000158', 'EFO_0000222', 'EFO_1000309',
       'MONDO_0019471', 'EFO_0003884', 'EFO_0004289', 'EFO_0003027',
       'EFO_0000222', 'EFO_0001068', 'MONDO_0007254', 'EFO_0000224',
       'EFO_1001469', 'EFO_1000286', 'EFO_0003032', 'EFO_0000479',
       'EFO_0004251', 'EFO_0000565', 'EFO_0005952', 'EFO_1001383',
       'MONDO_0008170'], dtype=object), 'count': 81}_|_[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1969 and has 11 approved and 70 investigational indications. This drug has a black box warning from the FDA."
CHEMBL978,"CC(=O)OC(C)C[N+](C)(C)C_|_NZWOPGCLSHLLPA-UHFFFAOYSA-N_|_Small molecule_|_True_|_METHACHOLINE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Methacholine' 'Methacholine cation' 'Methacholine ion' 'Provocholine']_|_[('PubChem', array(['90340728'], dtype=object)), ('Wikipedia', array(['Methacholine'], dtype=object)), ('drugbank', array(['DB06709'], dtype=object)), ('chEBI', array(['6804'], dtype=object))]_|_['CHEMBL1200764' 'CHEMBL12137' 'CHEMBL2106885']_|_{'rows': array(['MONDO_0004979', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for asthma and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1009,"N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O_|_WTDRDQBEARUVNC-LURJTMIESA-N_|_Small molecule_|_False_|_LEVODOPA_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['Bendopa' 'Brocadopa' 'Dopar' 'Inbrija' 'Larodopa']_|_['Bendopa' 'Cvt-301' 'Levodopa' 'Levodopa component of carbilev'
 'Levodopa component of parcopa' 'Levodopa component of sinemet'
 'Levodopum' 'NSC-118381' 'V-1512']_|_[('DailyMed', array(['levodopa'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija'],
      dtype=object)), ('PubChem', array(['104171278', '11111115', '11112155', '11532916', '144203889',
       '26753566', '90341430'], dtype=object)), ('Wikipedia', array(['L-DOPA'], dtype=object)), ('drugbank', array(['DB01235'], dtype=object)), ('chEBI', array(['15765'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004270', 'EFO_0003770', 'EFO_1001919', 'EFO_0003768',
       'MONDO_0043209', 'MONDO_0018910', 'MONDO_0005180', 'EFO_0000712',
       'EFO_0004895', 'HP_0002381', 'EFO_0005252', 'MONDO_0004979',
       'HP_0012532', 'EFO_0002610', 'HP_0003418', 'EFO_0001358',
       'MONDO_0043510', 'MONDO_0019200', 'MONDO_0005090', 'MONDO_0001020',
       'EFO_0003843', 'MONDO_0004976', 'EFO_0001365', 'EFO_0003756',
       'MONDO_0007113'], dtype=object), 'count': 25}_|_[ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for parkinson disease and has 24 investigational indications."
CHEMBL1082407,"CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F_|_WXCXUHSOUPDCQV-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENZALUTAMIDE_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Xtandi']_|_['Enzalutamide' 'MDV-3100' 'MDV3100' 'Mdv 3100']_|_[('DailyMed', array(['enzalutamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi'],
      dtype=object)), ('PubChem', array(['137275964'], dtype=object)), ('drugbank', array(['DB08899'], dtype=object)), ('chEBI', array(['68534'], dtype=object))]_|_['CHEMBL4594421']_|_{'rows': array(['EFO_1001469', 'EFO_0007532', 'EFO_0001421', 'MONDO_0008315',
       'EFO_0001663', 'MONDO_0008315', 'EFO_0000349', 'EFO_0003086',
       'MONDO_0004992', 'MONDO_0008315', 'MONDO_0008170', 'MONDO_0100096',
       'EFO_0000616', 'EFO_0000673', 'EFO_0000196', 'EFO_0002618',
       'EFO_0000182', 'EFO_0000616', 'MONDO_0100096', 'EFO_0005537',
       'MONDO_0001187', 'EFO_0000313', 'MONDO_0007254'], dtype=object), 'count': 23}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 17 investigational indications."
CHEMBL1200595,"CC(C)(N)Cc1ccc(Cl)cc1.Cl_|_WEJDYJKJPUPMLH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORPHENTERMINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201269_|_True_|_True_|_['Pre-sate']_|_['Chlorphentermine hcl' 'Chlorphentermine hydrochloride' 'NSC-76098'
 'S-62' 'W 2426' 'W-2426']_|_[('PubChem', array(['144205357', '170465307'], dtype=object))]_|_nan_|_nan_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982. It was withdrawn in at least one region."
CHEMBL1200934,"C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C/C(=N/O)CC[C@@H]4[C@H]3CC[C@@]21CC_|_KIQQMECNKUGGKA-NMYWJIRASA-N_|_Small molecule_|_False_|_NORGESTIMATE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dexnorgestrel acetime' 'NSC-759159' 'Norgestimate' 'ORF 10131'
 'ORF-10131' 'RWJ 10131' 'RWJ-10131']_|_[('DailyMed', array(['norgestimate'], dtype=object)), ('PubChem', array(['144206364', '170464733', '50125945'], dtype=object)), ('Wikipedia', array(['Norgestimate'], dtype=object)), ('drugbank', array(['DB00957'], dtype=object)), ('chEBI', array(['50815'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018075', 'EFO_0003894', 'MONDO_0009061', 'HP_0100608',
       'EFO_0003882', 'EFO_0003047', 'EFO_0000764', 'MONDO_0005277'],
      dtype=object), 'count': 8}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for acne and has 7 investigational indications."
CHEMBL1201287,"CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1_|_ZDIGNSYAACHWNL-HNNXBMFYSA-N_|_Small molecule_|_False_|_DEXBROMPHENIRAMINE_|_1963.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Brompheniramine d-form' 'Brompheniramine, (s)-' 'Dexbrompheniramine']_|_[('PubChem', array(['29216402', '90341837'], dtype=object)), ('Wikipedia', array(['Dexbrompheniramine'], dtype=object)), ('drugbank', array(['DB00405'], dtype=object)), ('chEBI', array(['59269'], dtype=object))]_|_['CHEMBL1200638']_|_{'rows': array(['MONDO_0005271', 'EFO_0003956'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for allergic disease and seasonal allergic rhinitis."
CHEMBL1280,"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC.Cl_|_DOQPXTMNIUCOSY-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERAPAMIL HYDROCHLORIDE_|_1981.0_|_4.0_|_CHEMBL6966_|_False_|_True_|_['Berkatens' 'Calan' 'Calan sr' 'Cordilox' 'Cordilox i.v.'
 'Cordilox mr 240' 'Covera-hs' 'Ethimil mr 240' 'Geangin'
 'Half securon sr' 'Isoptin' 'Isoptin Sr' 'Manidon sr' 'Ranvera mr'
 'Securon' 'Securon iv' 'Securon mid' 'Securon sr' 'Univer' 'Vera-til sr'
 'Verapamil hydrochloride' 'Verapress mr 240' 'Verelan' 'Verelan pm'
 'Vertab sr 240' 'Zolvera']_|_['CP-16533-1' 'LU-20175' 'NSC-272366' 'NSC-657799' 'Verapamil hcl'
 'Verapamil hydrochloride' 'Verapamili hydrochloridum']_|_[('DailyMed', array(['verapamil%20hydrochloride'], dtype=object)), ('PubChem', array(['144208378', '17388668', '26747697', '26747698', '49718106',
       '50107178', '50107179', '50107180', '507863', '856000'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0004269', 'EFO_0000400', 'EFO_0003144',
       'EFO_0000183', 'EFO_0000275', 'EFO_0000537'], dtype=object), 'count': 7}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 4 investigational indications."
CHEMBL15870,"CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1_|_RJMIEHBSYVWVIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDOPROFEN_|_1979.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Bor-ind' 'Flosin' 'Flosint' 'Indoprofen' 'Isindone' 'K 4277' 'K-4277'
 'NSC-757065' 'Praxis' 'Reumofene']_|_[('PubChem', array(['11532964', '144204869', '26748086'], dtype=object)), ('Wikipedia', array(['Indoprofen'], dtype=object)), ('drugbank', array(['DB08951'], dtype=object)), ('chEBI', array(['76162'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979 and is indicated for rheumatic disease. It was withdrawn in at least one region."
CHEMBL1716091,"CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3_|_NNYBQONXHNTVIJ-QGZVFWFLSA-N_|_Small molecule_|_False_|_SDX-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-(r)-etodolac' '(-)-etodolac' 'Etodolac, (-)-' 'Etodolac, (r)-'
 'KS-1056' 'R-etodolac' 'RAK-593' 'SDX-101' 'Sdx-101']_|_[('PubChem', array(['11112763'], dtype=object)), ('chEBI', array(['60370'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0001378'], dtype=object), 'count': 2}_|_[ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2096642,CC(O)C(=O)O.Nc1cc(-c2ccncc2)c[nH]c1=O_|_DOSIONJFGDSKCQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_INAMRINONE LACTATE_|_1984.0_|_4.0_|_CHEMBL12856_|_False_|_True_|_['Amrinone lactate' 'Inocor']_|_['Inamrinone lactate']_|_nan_|_nan_|_nan_|_[ENSG00000172572]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984.
CHEMBL2107890,nan_|_nan_|_Antibody drug conjugate_|_False_|_TAPLITUMOMAB PAPTOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Taplitumomab paptox']_|_nan_|_nan_|_nan_|_[ENSG00000177455]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2138684,"CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1.O.O=C(O)CCC(=O)O_|_CUETXFMONOSVJA-KLQYNRQASA-N_|_Small molecule_|_False_|_FROVATRIPTAN SUCCINATE_|_2001.0_|_4.0_|_CHEMBL1279_|_False_|_True_|_['Frova' 'Frovatriptan succinate']_|_['Frovatriptan succinate' 'Frovatriptan succinate hydrate' 'Frovelan'
 'Miguard' 'NSC-760422' 'SB 209509 AX' 'SB 209509-AX' 'SB-209509-AX'
 'SB-209509AX' 'VML 251' 'VML-251']_|_[('DailyMed', array(['frovatriptan%20succinate'], dtype=object)), ('PubChem', array(['124894597', '144207155'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for migraine disorder."
CHEMBL23261,"COc1cc(OC)nc(O[C@H](C(=O)O)C(OC)(c2ccccc2)c2ccccc2)n1_|_FEJVSJIALLTFRP-LJQANCHMSA-N_|_Small molecule_|_False_|_DARUSENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Darusentan' 'HMR-4005' 'LU-135252' 'Lu-135252']_|_[('PubChem', array(['170466416'], dtype=object)), ('Wikipedia', array(['Darusentan'], dtype=object)), ('drugbank', array(['DB04883'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000151617,ENSG00000136160]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3039507,"CCOc1ccc(Cc2cc([C@@H]3O[C@H](SC)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1_|_QKDRXGFQVGOQKS-CRSSMBPESA-N_|_Small molecule_|_False_|_SOTAGLIFLOZIN_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Inpefa' 'Zynquista']_|_['Inpefa' 'LP-802034' 'LX-4211' 'LX4211' 'Sar-439954' 'Sar439954'
 'Sotagliflozin']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista'],
      dtype=object)), ('drugbank', array(['DB12713'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'MONDO_0005148', 'EFO_0004252', 'MONDO_0005147',
       'EFO_0003144', 'EFO_0003884', 'EFO_0003086', 'EFO_0001421'],
      dtype=object), 'count': 8}_|_[ENSG00000100170,ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 approved and 2 investigational indications."
CHEMBL3137308,"NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2_|_DREIJXJRTLTGJC-ZLBJMMTISA-N_|_Small molecule_|_False_|_PEFICITINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ASP-015K' 'ASP015K' 'Asp-015k' 'JNJ-54781532' 'Peficitinib']_|_nan_|_['CHEMBL3137329']_|_{'rows': array(['EFO_0003086', 'EFO_0000676', 'EFO_0000540', 'EFO_0001421',
       'EFO_0000729', 'EFO_0000685'], dtype=object), 'count': 6}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 6 investigational indications."
CHEMBL3545058,"N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+]_|_ANMYAHDLKVNJJO-CURYUGHLSA-M_|_Small molecule_|_False_|_DEXTROTHYROXINE SODIUM_|_1967.0_|_4.0_|_CHEMBL559_|_False_|_True_|_['Choloxin']_|_['Anhydrous dextrothyroxine sodium' 'D-thyroxine sodium salt'
 'Dextrothyroxine sodium' 'Dextrothyroxine sodium anhydrous'
 'Dextrothyroxine sodium hydrate' 'Monosodium d-thyroxine hydrate'
 'Sodium dextrothyroxine']_|_nan_|_nan_|_{'rows': array(['EFO_1001375', 'EFO_0000612'], dtype=object), 'count': 2}_|_[ENSG00000126351,ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 2 investigational indications."
CHEMBL384304,"COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N_|_JRNJNYBQQYBCLE-UHFFFAOYSA-N_|_Small molecule_|_False_|_RG-547_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['R 547' 'R-547' 'RG-547' 'RO4584820' 'Rg-547' 'Ro 4584820' 'Ro-4584820']_|_[('drugbank', array(['DB08094'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000123374,ENSG00000135446,ENSG00000170312]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989703,"O.O=C(O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1_|_LNDYQNTTYXLTNH-RTBBDAMFSA-N_|_Small molecule_|_False_|_TEZAMPANEL_|_nan_|_2.0_|_CHEMBL14935_|_False_|_False_|_[]_|_['LY293558' 'Tezampanel' 'Tezampanel hydrate']_|_nan_|_nan_|_nan_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3989919,"Cc1ccccc1-c1cc(N2CC[N+](C)(COP(=O)(O)O)CC2)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl.[Cl-]_|_LBTQUZNIWCWBNN-UHFFFAOYSA-N_|_Small molecule_|_False_|_FOSNETUPITANT CHLORIDE HYDROCHLORIDE_|_2018.0_|_4.0_|_CHEMBL3989917_|_False_|_True_|_[]_|_['08-PNET' 'Fosnetupitant chloride' 'Fosnetupitant chloride hydrochloride'
 'Fosnetupitant dihydrochloride']_|_[('DailyMed', array(['fosnetupitant%20chloride%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006911', 'HP_0002013'], dtype=object), 'count': 2}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for chemotherapy-induced nausea and vomiting and vomiting."
CHEMBL3989973,"Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1_|_CJLUYLRKLUYCEK-UHFFFAOYSA-N_|_Small molecule_|_True_|_PEXIDARTINIB HYDROCHLORIDE_|_2019.0_|_4.0_|_CHEMBL3813873_|_False_|_True_|_['Turalio']_|_['FP-113' 'PLX-3397 HCL' 'PLX3397 HCl' 'Pexidartinib hydrochloride']_|_nan_|_nan_|_{'rows': array(['EFO_1000562'], dtype=object), 'count': 1}_|_[ENSG00000182578,ENSG00000122025,ENSG00000157404]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for tenosynovial giant cell tumor. This drug has a black box warning from the FDA."
CHEMBL4085457,"C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C_|_CBRJPFGIXUFMTM-WDEREUQCSA-N_|_Small molecule_|_True_|_RITLECITINIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['PF-06651600' 'Pf-06651600' 'Ritlecitinib']_|_[('drugbank', array(['DB14924'], dtype=object))]_|_['CHEMBL5314649']_|_{'rows': array(['EFO_1001051', 'EFO_0000384', 'EFO_0004192', 'EFO_1000785',
       'EFO_0001421', 'EFO_0001060', 'EFO_0000729', 'EFO_0003086',
       'EFO_0004208', 'MONDO_0005147', 'EFO_0004192', 'EFO_0000685',
       'EFO_1002028'], dtype=object), 'count': 13}_|_[ENSG00000113263,ENSG00000102010,ENSG00000135605,ENSG00000074966,ENSG00000010671,ENSG00000105639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for alopecia areata and has 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4116649,"NCc1cc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)nc(C(F)(F)F)c1_|_ODGXXYXJORZPHE-ZIAGYGMSSA-N_|_Small molecule_|_False_|_LENUMLOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Lenumlostat' 'PAT-1251' 'Pat-1251']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_['CHEMBL4528871' 'CHEMBL4543285' 'CHEMBL4079398']_|_{'rows': array(['EFO_0006890'], dtype=object), 'count': 1}_|_[ENSG00000134013]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297260,"CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@@H](C(=O)N(C)[C@H](C(N)=O)[C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@H](C(C)C)NC1=O_|_MUSGYEMSJUFFHT-UWABRSFTSA-N_|_Protein_|_False_|_AMY-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amy 101' 'Amy-101' 'Compstatin 40' 'Compstatin analog peptide cp40']_|_nan_|_nan_|_{'rows': array(['MONDO_0002508'], dtype=object), 'count': 1}_|_[ENSG00000125730]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297571,"nan_|_nan_|_Antibody_|_False_|_PENPULIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AK-105' 'AK105' 'Ak-105' 'Ak105' 'Penpulimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PENPULIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_0000182', 'MONDO_0004992', 'EFO_0005922',
       'EFO_0000181', 'EFO_0003060', 'EFO_0003108', 'MONDO_0002108',
       'EFO_0000183', 'EFO_0003860', 'EFO_1000359', 'EFO_0000616',
       'EFO_0003869', 'MONDO_0007254', 'EFO_0004252', 'EFO_0000708',
       'EFO_0000574', 'EFO_1000657', 'EFO_0000178', 'EFO_0000519',
       'MONDO_0002974', 'MONDO_0008903', 'EFO_0000403', 'MONDO_0001056',
       'EFO_1001951'], dtype=object), 'count': 25}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications."
CHEMBL522302,"COc1ccc(-n2nnnc2C(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1_|_XILNRORTJVDYRH-HKUYNNGSSA-N_|_Small molecule_|_False_|_VOFOPITANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GR-205171' 'GR205171' 'Gr-205171' 'Vofopitant']_|_[('drugbank', array(['DB12436'], dtype=object))]_|_['CHEMBL557983']_|_{'rows': array(['EFO_0008568', 'MONDO_0004985', 'EFO_0001358'], dtype=object), 'count': 3}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL562318,"Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1_|_AZEXWHKOMMASPA-UHFFFAOYSA-N_|_Small molecule_|_False_|_MARDEPODECT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MP-10' 'Mardepodect' 'PF-02545920' 'PF-2545920']_|_[('PubChem', array(['165222673', '174006264'], dtype=object)), ('drugbank', array(['DB08387'], dtype=object))]_|_['CHEMBL1684440' 'CHEMBL5306001']_|_{'rows': array(['MONDO_0007739', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000112541]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1089,"NNCCc1ccccc1_|_RMUCZJUITONUFY-UHFFFAOYSA-N_|_Small molecule_|_True_|_PHENELZINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Nardil' 'Phenelzine']_|_[('PubChem', array(['11111653', '11111654', '174006798', '50111200', '90341694'],
      dtype=object)), ('Wikipedia', array(['Phenelzine'], dtype=object)), ('drugbank', array(['DB00780'], dtype=object)), ('chEBI', array(['8060'], dtype=object))]_|_['CHEMBL1200895']_|_{'rows': array(['EFO_0000673', 'MONDO_0007254', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1171829,"C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F_|_YUUGYIUSCYNSQR-LBPRGKRZSA-N_|_Small molecule_|_False_|_BITOPERTIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bitopertin' 'DISC-1459' 'Paliflutine' 'R-1678' 'RG-1678' 'RO-4917838'
 'RO-4917939' 'RO4917838']_|_[('drugbank', array(['DB12426'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004242', 'MONDO_0005090', 'MONDO_0015253', 'Orphanet_848',
       'MONDO_0001676'], dtype=object), 'count': 5}_|_[ENSG00000196517]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL1189679,"O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2_|_CPZBLNMUGSZIPR-NVXWUHKLSA-N_|_Small molecule_|_False_|_PALONOSETRON_|_2003.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-palonosetron' 'Aurothioglucose' 'NSC-743769' 'Palonosetron'
 'Palonosetron, (3as, 3s)-']_|_[('Wikipedia', array(['Palonosetron'], dtype=object)), ('drugbank', array(['DB00377'], dtype=object)), ('chEBI', array(['85161'], dtype=object))]_|_['CHEMBL1720']_|_{'rows': array(['EFO_0004888', 'MONDO_0004992', 'EFO_0003869', 'HP_0002013',
       'HP_0002018', 'EFO_0006911', 'EFO_0000756', 'MONDO_0004992',
       'HP_0002013', 'HP_0000486', 'EFO_0001378', 'MONDO_0001657',
       'EFO_0000616', 'HP_0002018', 'MONDO_0001056', 'EFO_0006911',
       'EFO_0004888', 'HP_0002017', 'HP_0002017', 'MONDO_0100342'],
      dtype=object), 'count': 20}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 12 investigational indications."
CHEMBL1200347,"CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C.[I-]_|_BFSMWENDZZIWPW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOPROPAMIDE IODIDE_|_1957.0_|_4.0_|_CHEMBL1201232_|_False_|_True_|_['Darbid']_|_['Dipramid' 'Dipramide' 'Isamid' 'Isopropamide (as iodide)'
 'Isopropamide iodide' 'Isoproponum iodide' 'Marygin-m' 'NSC-15521'
 'Piaccamide' 'Priamide' 'Priazimide' 'SKF-4740' 'Sanulcin' 'Tyrimide']_|_[('PubChem', array(['11532965', '56424103'], dtype=object))]_|_nan_|_nan_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957."
CHEMBL1259,"COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3_|_JFXBEKISTKFVAB-AJQTZOPKSA-N_|_Small molecule_|_False_|_METOCURINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dimethyl tubocurarine' 'Dimethyltubocurarine' 'Dimethyltubocurarinium'
 'Metocurine' 'Metocurine cation' 'Metocurine ion']_|_[('Wikipedia', array(['Metocurine'], dtype=object)), ('drugbank', array(['DB01336'], dtype=object)), ('chEBI', array(['6900'], dtype=object))]_|_['CHEMBL1739' 'CHEMBL2105841']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1511,"CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C_|_RSEPBGGWRJCQGY-RBRWEJTLSA-N_|_Small molecule_|_True_|_ESTRADIOL VALERATE_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Climaval' 'Delestrogen' 'Estradiol valerate' 'Femtab' 'Progynon depot'
 'Progynon-depot-10' 'Progynova']_|_['.beta.-estradiol 17-valerate' 'Estradiol 17-valerate'
 'Estradiol Valerate' 'Estradiol valerate' 'NSC-17590'
 'Oestradiol valerate']_|_[('DailyMed', array(['estradiol%20valerate'], dtype=object)), ('PubChem', array(['144204865', '56422428', '855707'], dtype=object)), ('drugbank', array(['DB13956'], dtype=object)), ('chEBI', array(['31561'], dtype=object))]_|_nan_|_{'rows': array(['HP_0100608', 'EFO_0000660', 'EFO_1001271', 'HP_0000132',
       'MONDO_0002146', 'EFO_1000096', 'EFO_0000545', 'HP_0100607',
       'GO_0042697', 'HP_0008209', 'EFO_0004266'], dtype=object), 'count': 11}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2105643,"COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)(O)O.NC(CO)(CO)CO_|_FIDMEHCRMLKKPZ-YSMBQZINSA-N_|_Small molecule_|_False_|_FOSBRETABULIN TROMETHAMINE_|_nan_|_2.0_|_CHEMBL1206232_|_False_|_False_|_['Zybrestat']_|_['Fosbretabulin tromethamine']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_1001901'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109253,"nan_|_nan_|_Antibody_|_False_|_HOKT3_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['HOKT3' 'Hokt3']_|_nan_|_nan_|_{'rows': array(['EFO_0003778', 'MONDO_0005147'], dtype=object), 'count': 2}_|_[ENSG00000198851]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109572,nan_|_nan_|_Antibody_|_False_|_ANTI-SCLEROSTIN_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ANTI-SCLEROSTIN']_|_nan_|_nan_|_nan_|_[ENSG00000167941]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2133806,"Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1_|_JRWCBEOAFGHNNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-38877605_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['JNJ-38877605' 'Jnj-38877605']_|_[('PubChem', array(['137276033'], dtype=object)), ('drugbank', array(['DB13113'], dtype=object))]_|_['CHEMBL5275126']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2263632,"COc1cccc(-c2cc(F)c(Nc3ncccc3C(=O)O)c(F)c2)c1_|_OMPATGZMNFWVOH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ASLAN-003_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASLAN-003' 'ASLAN003' 'Aslan-003' 'Aslan003' 'Farudodstat']_|_nan_|_nan_|_{'rows': array(['EFO_0004192', 'EFO_0000222'], dtype=object), 'count': 2}_|_[ENSG00000102967]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3039582,"CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C_|_OWMZNFCDEHGFEP-NFBCVYDUSA-N_|_Protein_|_False_|_SECRETIN_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Secretin-ferring']_|_['Secretin' 'Secretin (human, porcine, etc.)' 'Secretin, unspecified']_|_nan_|_nan_|_{'rows': array(['MONDO_0005090', 'EFO_0000278', 'EFO_0008533', 'EFO_0003758',
       'EFO_0000342', 'EFO_0001073'], dtype=object), 'count': 6}_|_[ENSG00000080293]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 investigational indications."
CHEMBL3301588,"nan_|_nan_|_Antibody_|_False_|_TAREXTUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['OMP-59R5' 'Tarextumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_0002618', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000074181,ENSG00000134250]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545040,"CC(C)(C)OC(=O)NCCN1CC2CN(C[C@H](O)COc3ccc(C#N)cc3)CC(C1)O2_|_JRHUUZPSMQIWBQ-PELRDEGISA-N_|_Small molecule_|_False_|_AZD7009_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd7009']_|_nan_|_nan_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000183873,ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545162,"nan_|_nan_|_Small molecule_|_False_|_PBF-680_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pbf-680']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545432,"CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1_|_MBOMYENWWXQSNW-AWEZNQCLSA-N_|_Small molecule_|_False_|_IXAZOMIB CITRATE_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Ninlaro']_|_['Ixazomib citrate' 'MLN-9708' 'MLN9708']_|_[('DailyMed', array(['ixazomib%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ninlaro'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000220', 'MONDO_0019438', 'EFO_0009441', 'EFO_0000222',
       'EFO_0000558', 'EFO_0000574', 'MONDO_0004992', 'EFO_0006738',
       'MONDO_0007254', 'EFO_0000519', 'MONDO_0000873', 'MONDO_0020547',
       'EFO_1001469', 'EFO_0001378', 'EFO_0006475'], dtype=object), 'count': 15}_|_[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for multiple myeloma and has 14 investigational indications."
CHEMBL3657311,"COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc(C(F)(F)F)c(Oc2cccc3c2C(=O)N(C)C3)n1_|_ULMMVBPTWVRPSI-UHFFFAOYSA-N_|_Small molecule_|_False_|_IFEBEMTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI853520' 'Bi 853520' 'Bi-853520' 'IN-10018' 'IN10018' 'Ifebemtinib']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0008170', 'EFO_0002618', 'MONDO_0001056',
       'EFO_0002617'], dtype=object), 'count': 5}_|_[ENSG00000169398]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3989915,"CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1_|_FWMNVWWHGCHHJJ-SKKKGAJSSA-N_|_Protein_|_False_|_DIFELIKEFALIN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['4-PIPERIDINECARBOXYLIC ACID, N1-(D-PHENYLALANYL-D-PHENYLALANYL-D-LEUCYL-D-LYSYL)-4-AMINO-'
 'CR-845' 'CR845' 'Difelikefalin' 'FE-202845' 'FE202845' 'MR-13A9'
 'MR13A9']_|_[('drugbank', array(['DB11938'], dtype=object))]_|_['CHEMBL5315123']_|_{'rows': array(['HP_0000989', 'EFO_0003884', 'HP_0000989', 'EFO_0003843',
       'MONDO_0005178'], dtype=object), 'count': 5}_|_[ENSG00000082556]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for chronic kidney disease and pruritus and has 3 investigational indications."
CHEMBL3990011,"nan_|_nan_|_Antibody drug conjugate_|_False_|_ROVALPITUZUMAB TESIRINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Rovalpituzumab tesirine' 'SC-002' 'SC-16LD6.5' 'SC0002' 'Sc 002']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000616', 'EFO_0000702'], dtype=object), 'count': 3}_|_[ENSG00000090932]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297289,"CN1CCN(C(=O)[C@H](CCCN[C@@H]2C[C@H]2c2ccc(F)cc2)NC(=O)c2ccc(-n3ccnn3)cc2)CC1_|_KQKBMHGOHXOHTD-KKUQBAQOSA-N_|_Small molecule_|_False_|_BOMEDEMSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bomedemstat' 'IMG-7289' 'Img-7289']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BOMEDEMSTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15126'], dtype=object))]_|_['CHEMBL5095405']_|_{'rows': array(['EFO_0000616', 'EFO_0000222', 'EFO_0000616', 'EFO_0000198',
       'EFO_0002429', 'EFO_0000702', 'EFO_0000479', 'MONDO_0044903'],
      dtype=object), 'count': 8}_|_[ENSG00000004487]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4297590,"COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1_|_NBGABHGMJVIVBW-QHCPKHFHSA-N_|_Small molecule_|_False_|_DARIDOREXANT_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ACT-541468' 'Act-541468' 'DEA NO. 2410' 'Daridorexant' 'Nemorexant']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DARIDOREXANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15031'], dtype=object))]_|_['CHEMBL4650216']_|_{'rows': array(['EFO_0001358', 'EFO_0004698', 'EFO_0001421', 'HP_0000083',
       'EFO_0000341', 'EFO_0004698', 'EFO_0003918'], dtype=object), 'count': 7}_|_[ENSG00000137252,ENSG00000121764]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for insomnia and has 6 investigational indications."
CHEMBL4297955,"nan_|_nan_|_Protein_|_False_|_FOLLITROPIN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['F.s.h.-p injectable' 'Follicle stimulating hormone' 'Follitropin'
 'Follitropin (pig)' 'Follitropin epsilon' 'Follitropin gamma'
 'Follitropin porcine' 'Follotropin recombinant' 'Folltropin-v'
 'Fsh (menotropins)' 'Menotropins (fsh)' 'Super-ov']_|_nan_|_nan_|_{'rows': array(['MONDO_0018555', 'EFO_0008560', 'EFO_0000660', 'EFO_0004266',
       'MONDO_0002146', 'EFO_0004248', 'MONDO_0002775', 'EFO_0000545'],
      dtype=object), 'count': 8}_|_[ENSG00000170820]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 4 investigational indications."
CHEMBL4298090,"nan_|_nan_|_Protein_|_False_|_SIMLUKAFUSP ALFA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FAP-IL-2V' 'FAP-IL2V FP RO6874281' 'FAP-IL2v' 'RG-7461' 'RG7461'
 'RO-6874281' 'RO6874281' 'Ro6874281' 'Simlukafusp alfa']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMLUKAFUSP%20ALFA/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_0002617', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000078098,ENSG00000147168,ENSG00000100385]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL452076,"COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC/C=C/c2ccccc2)C1c1cccc([N+](=O)[O-])c1_|_KJEBULYHNRNJTE-DHZHZOJOSA-N_|_Small molecule_|_False_|_CILNIDIPINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Atelec' 'Cilnidipine' 'Cinalong' 'FRC-8653' 'Siscard']_|_[('PubChem', array(['144205554', '170465867', '26755677', '50111041', '90341030'],
      dtype=object)), ('drugbank', array(['DB09232'], dtype=object)), ('chEBI', array(['31399'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_1001496', 'EFO_0000537'], dtype=object), 'count': 3}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL511115,"COc1ccc([C@]2(C#N)CC[C@@H](C(=O)O)CC2)cc1OC1CCCC1_|_CFBUZOUXXHZCFB-OYOVHJISSA-N_|_Small molecule_|_False_|_CILOMILAST_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ariflo' 'Cilomilast' 'SB 207499' 'SB-207499' 'SB207499']_|_[('PubChem', array(['144206070'], dtype=object)), ('Wikipedia', array(['Cilomilast'], dtype=object)), ('drugbank', array(['DB03849'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL695,"CN1C(=O)OC(C)(C)C1=O_|_IRYJRGCIQBGHIV-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIMETHADIONE_|_1946.0_|_4.0_|_nan_|_False_|_True_|_['Tridione']_|_['A 2297' 'Absentol' 'Epidione' 'J2.519D' 'Minoaleviatin' 'NSC-15799'
 'NSC-169503' 'Tridone' 'Trimethadione' 'Trimethadionum' 'Troxidone']_|_[('PubChem', array(['11112276', '144203959', '144207429'], dtype=object)), ('TG-GATEs', array(['122'], dtype=object)), ('Wikipedia', array(['Trimethadione'], dtype=object)), ('drugbank', array(['DB00347'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for epilepsy."
CHEMBL99946,"CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN_|_GJJFMKBJSRMPLA-DZGCQCFKSA-N_|_Small molecule_|_True_|_LEVOMILNACIPRAN_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Fetzima']_|_['(1s,2r)-milnacipran' 'F 2695' 'F-2695' 'F2695' 'Levomilnacipran'
 'Milnacipran, (1s,2r)-']_|_[('drugbank', array(['DB08918'], dtype=object))]_|_['CHEMBL2105732']_|_{'rows': array(['MONDO_0002009', 'MONDO_0002009', 'EFO_0005687', 'EFO_0003768',
       'HP_0002140', 'MONDO_0002009', 'MONDO_0002009'], dtype=object), 'count': 7}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and fibromyalgia and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL101,"CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O_|_VYMDGNCVAMGZFE-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENYLBUTAZONE_|_1980.0_|_4.0_|_nan_|_True_|_True_|_['Antadol' 'Azolid' 'Butacote' 'Butaject' 'Butazolidin' 'Elmedal'
 'Equiphar' 'Phenylbutazone' 'Pro-Bute']_|_['Ambene' 'Artrizin' 'Bizolin' 'Butadion' 'Butadiona' 'Butapirazol'
 'Butatron' 'Butoz' 'Buzon' 'Diphebuzol' 'Diphenylbutazone' 'Ecobutazone'
 'Equipalazone' 'Exrheudon n' 'Fenibutazona' 'Fenibutol' 'Fenylbutazon'
 'Flexazone' 'G-13871' 'Intrabutazone' 'Intrazone' 'Mepha-butazon'
 'NSC-25134' 'Phebuzine' 'Phenylbutazone' 'Phenyzene' 'R-3-ZON'
 'Robizone-v' 'Shigrodin' 'Tevcodyne' 'Uzone' 'Zolaphen']_|_[('PubChem', array(['104171220', '104171221', '11111674', '144203793', '144203794',
       '144209007', '144213080', '170465040', '17389760', '26747057',
       '26751573', '50104199', '56436656', '85231197', '855958',
       '90341773'], dtype=object)), ('TG-GATEs', array(['11'], dtype=object)), ('Wikipedia', array(['Phenylbutazone'], dtype=object)), ('drugbank', array(['DB00812'], dtype=object)), ('chEBI', array(['48574'], dtype=object))]_|_['CHEMBL3137687']_|_{'rows': array(['EFO_0005755', 'HP_0003326', 'HP_0002829'], dtype=object), 'count': 3}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved indications. It was withdrawn in at least one region."
CHEMBL1027,"Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C_|_PBJUNZJWGZTSKL-MRXNPFEDSA-N_|_Small molecule_|_False_|_TIAGABINE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Gabitril']_|_['A-70569-1' 'ABBOTT-70569' 'ABBOTT-70569 FREE BASE' 'ABBOTT-70569-1'
 'ABBOTT-705691 FREE BASE' 'ABT-569' 'ABT-569 FREE BASE' 'Gabitril'
 'NNC-05-0328' 'NNC-050328 FREE BASE' 'NO-05-0328' 'NO-050328 FREE BASE'
 'Tiagabine']_|_[('PubChem', array(['26758048'], dtype=object)), ('Wikipedia', array(['Tiagabine'], dtype=object)), ('drugbank', array(['DB00906'], dtype=object)), ('chEBI', array(['9586'], dtype=object))]_|_['CHEMBL1695']_|_{'rows': array(['EFO_1001892', 'MONDO_0005090', 'EFO_0000474', 'HP_0001250',
       'EFO_0002610', 'EFO_0003918', 'MONDO_0007079', 'EFO_0005230',
       'EFO_0005230'], dtype=object), 'count': 9}_|_[ENSG00000157103]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for epilepsy and seizure and has 6 investigational indications."
CHEMBL1054,"NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O_|_LMJSLTNSBFUCMU-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRICHLORMETHIAZIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Metahydrin' 'Naqua' 'Trichlorex' 'Trichlormas' 'Trichlormethiazide']_|_['NSC-61560' 'Trichlormethiazide' 'Trichloromethiazide']_|_[('PubChem', array(['144203972', '170464812', '56422224', '855703'], dtype=object)), ('Wikipedia', array(['Trichlormethiazide'], dtype=object)), ('drugbank', array(['DB01021'], dtype=object)), ('chEBI', array(['9683'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960 and is indicated for cardiovascular disease."
CHEMBL1075,"CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2_|_FUBVWMNBEHXPSU-UHFFFAOYSA-N_|_Small molecule_|_True_|_MORICIZINE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['EN-313' 'EN-313 FREE BASE' 'Ethmozine' 'Moracizine' 'Moricizine']_|_[('PubChem', array(['11112721', '174006664', '50086819'], dtype=object)), ('Wikipedia', array(['Moracizine'], dtype=object)), ('drugbank', array(['DB00680'], dtype=object)), ('chEBI', array(['6997'], dtype=object))]_|_['CHEMBL1200334']_|_{'rows': array(['EFO_0000275', 'EFO_0004269'], dtype=object), 'count': 2}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for cardiac arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1138,"O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1_|_OLNTVTPDXPETLC-XPWALMASSA-N_|_Small molecule_|_False_|_EZETIMIBE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Ezetimibe' 'Ezetrol' 'Zetia']_|_['Ezetimibe' 'MK0653' 'NSC-758923' 'SCH-58235' 'SCH58235']_|_[('DailyMed', array(['ezetimibe'], dtype=object)), ('PubChem', array(['144204996', '170465013', '26719841'], dtype=object)), ('Wikipedia', array(['Ezetimibe'], dtype=object)), ('drugbank', array(['DB00973'], dtype=object)), ('chEBI', array(['49040'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021187', 'EFO_0007304', 'EFO_0000764', 'EFO_0000195',
       'MONDO_0019052', 'EFO_0000537', 'MONDO_0008315', 'EFO_0001645',
       'HP_0003124', 'EFO_0004220', 'EFO_0000266', 'Orphanet_309005',
       'EFO_0003914', 'EFO_0004211', 'EFO_0003095', 'EFO_0004911',
       'EFO_0000612', 'EFO_0000319', 'MONDO_0005148', 'MONDO_0018328',
       'EFO_0000400'], dtype=object), 'count': 21}_|_[ENSG00000015520]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 5 approved and 16 investigational indications."
CHEMBL1200750,"CC(CN1c2ccccc2Sc2ccccc21)N(C)C.Cl_|_XXPDBLUZJRXNNZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROMETHAZINE HYDROCHLORIDE_|_1951.0_|_4.0_|_CHEMBL643_|_False_|_True_|_['Mymethazine fortis' 'Phenergan' 'Phenergan nightime' 'Phenhalal'
 'Phensedyl' 'Prometh fortis' 'Prometh plain' 'Promethacon' 'Promethazine'
 'Promethazine hydrochloride' 'Promethazine hydrochloride plain'
 'Promethazine plain' 'Promethegan' 'Q-mazine' 'Remsed' 'Sarantihist'
 'Sominex' 'Zipan-25' 'Zipan-50']_|_['Promethazine hydrochloride']_|_[('DailyMed', array(['promethazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144209462', '144213195', '26747605', '26747606', '26752305',
       '50106751', '50106752', '50106753', '56422196', '567521', '855711'],
      dtype=object)), ('chEBI', array(['8462'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0006928', 'EFO_0003956', 'MONDO_0005475',
       'EFO_0004698', 'MONDO_0100431', 'EFO_0000274', 'EFO_0005531',
       'MONDO_0005271', 'HP_0002017', 'EFO_1000971', 'EFO_0007141'],
      dtype=object), 'count': 12}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 7 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1215331,"N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl_|_XNULRSOGWPFPBL-REWPJTCUSA-N_|_Small molecule_|_False_|_PF-03882845_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PF-3882845' 'Pf-03882845']_|_[('drugbank', array(['DB11814'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL1237055,"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5.Cl_|_XHILEZUETWRSHC-NRGUFEMZSA-N_|_Small molecule_|_True_|_HYDROMORPHONE HYDROCHLORIDE_|_1984.0_|_4.0_|_CHEMBL398707_|_False_|_True_|_['Dilaudid' 'Dilaudid-hp' 'Exalgo' 'Hydromorphone hydrochloride'
 'Palladone' 'Palladone-sr']_|_['Dihydromorphinone hydrochloride' 'Hydromorphone HCl' 'Hydromorphone hcl'
 'Hydromorphone hydrochloride' 'Hydromorphone hydrochloride cii'
 'NSC-117862']_|_[('DailyMed', array(['hydromorphone%20hydrochloride'], dtype=object)), ('chEBI', array(['5791'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003418', 'EFO_0001421', 'EFO_0801084', 'EFO_1000786',
       'EFO_0004616', 'EFO_0003890', 'EFO_0003843', 'HP_0012532'],
      dtype=object), 'count': 8}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for drug dependence and pain and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1256786,"COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1_|_BPZSYCZIITTYBL-UHFFFAOYSA-N_|_Small molecule_|_False_|_FORMOTEROL_|_2001.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Foradil' 'Formoterol']_|_[('PubChem', array(['50125837'], dtype=object)), ('drugbank', array(['DB00983'], dtype=object)), ('chEBI', array(['63082'], dtype=object))]_|_['CHEMBL2133469' 'CHEMBL1893395' 'CHEMBL3989798']_|_{'rows': array(['HP_0006536', 'MONDO_0004979', 'EFO_0000341', 'EFO_1000637',
       'MONDO_0005271', 'HP_0002110', 'MONDO_0008903', 'EFO_0003768',
       'EFO_0009661', 'MONDO_0004975', 'MONDO_0100096', 'HP_0006536',
       'MONDO_0004979', 'EFO_0006505', 'EFO_0000341', 'EFO_0000464',
       'EFO_0007183'], dtype=object), 'count': 17}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 5 approved and 12 investigational indications."
CHEMBL1257015,"COc1ccc(C(=O)NCc2cccnc2)cc1C(=O)NCc1cccnc1_|_KYWCWBXGRWWINE-UHFFFAOYSA-N_|_Small molecule_|_False_|_PICOTAMIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['G-137' 'NSC-304384' 'Picotamide']_|_[('PubChem', array(['11111675', '50106897', '85231198', '90341089'], dtype=object)), ('drugbank', array(['DB13327'], dtype=object))]_|_['CHEMBL1317747']_|_{'rows': array(['HP_0004419'], dtype=object), 'count': 1}_|_[ENSG00000059377,ENSG00000006638]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis."
CHEMBL1743066,"nan_|_nan_|_Antibody_|_False_|_RONTALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RG-7415' 'RHUMAB IFNALPHA' 'RHUMAB-IFNALPHA' 'Rontalizumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000120235,ENSG00000120242,ENSG00000147873,ENSG00000186803,ENSG00000188379,ENSG00000197919,ENSG00000233816,ENSG00000214042,ENSG00000137080,ENSG00000147885,ENSG00000228083,ENSG00000234829,ENSG00000236637]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2040682,"CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C_|_LUKZNWIVRBCLON-GXOBDPJESA-N_|_Small molecule_|_False_|_CICLESONIDE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Alvesco' 'Alvesco 160' 'Alvesco 80' 'Aservo equihaler' 'Omnaris'
 'Zetonna']_|_['BI54903' 'Ciclesonide' 'RPR-251526' 'RPR251526']_|_[('DailyMed', array(['ciclesonide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/aservo-equihaler'],
      dtype=object)), ('PubChem', array(['144206039'], dtype=object)), ('drugbank', array(['DB01410'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0003956', 'EFO_1000024', 'MONDO_0005271',
       'HP_0006536', 'HP_0001742', 'EFO_0005854', 'MONDO_0004979',
       'EFO_1001417', 'EFO_0000341'], dtype=object), 'count': 10}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 6 approved and 4 investigational indications."
CHEMBL2103832,"CN1CCN(c2cccc3[nH]c(=O)oc23)CC1_|_YVPUUUDAZYFFQT-UHFFFAOYSA-N_|_Small molecule_|_False_|_PARDOPRUNOX_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DU 126891' 'DU-126891' 'DU126891' 'Pardoprunox' 'SLV 308' 'SLV-308'
 'SLV308']_|_[('drugbank', array(['DB12061'], dtype=object))]_|_['CHEMBL2105649']_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000178394,ENSG00000149295,ENSG00000151577]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2103842,"C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1_|_UWXSAYUXVSFDBQ-CYBMUJFWSA-N_|_Small molecule_|_False_|_VARLITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AR-00334543' 'ARRY-334543' 'ARRY-543' 'ASLAN-001' 'ASLAN001'
 'Varlitinib']_|_[('drugbank', array(['DB05944'], dtype=object))]_|_['CHEMBL2105679']_|_{'rows': array(['EFO_0000182', 'MONDO_0001056', 'EFO_0000616', 'EFO_0005221',
       'MONDO_0003060', 'MONDO_0004992', 'MONDO_0007254', 'EFO_0002618'],
      dtype=object), 'count': 8}_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL2108973,"nan_|_nan_|_Protein_|_False_|_INSULIN HUMAN, ISOPHANE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Insulin human, isophane']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of III."
CHEMBL2109460,"nan_|_nan_|_Antibody_|_False_|_SCH-708980_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SCH-708980' 'Sch-708980']_|_nan_|_nan_|_{'rows': array(['EFO_0005044'], dtype=object), 'count': 1}_|_[ENSG00000136634]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109470,"nan_|_nan_|_Antibody_|_False_|_PERAKIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Perakizumab' 'RG-4934' 'RG4934' 'RO-5310074' 'RO5310074']_|_nan_|_nan_|_{'rows': array(['EFO_0003778'], dtype=object), 'count': 1}_|_[ENSG00000112115]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2178100,"CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(CO)c1ccccc1_|_VAJGULUVTFDTAS-GOSISDBHSA-N_|_Small molecule_|_False_|_GLPG0492_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['(-)-GLPG-0492' 'DT-200' 'G 100192' 'GLPG0492' 'Glpg-0492' 'Glpg0492']_|_[('drugbank', array(['DB12461'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3188993,"O=C(O)/C=C/C(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1_|_ZTHJULTYCAQOIJ-WXXKFALUSA-N_|_Small molecule_|_True_|_QUETIAPINE FUMARATE_|_1997.0_|_4.0_|_CHEMBL716_|_False_|_True_|_['Quetiapine fumarate' 'Seroquel' 'Seroquel xr']_|_['FK-947E' 'FK947E' 'ICI 204,636' 'ICI-204636' 'Quetiapine (as fumarate)'
 'Quetiapine fumarate' 'Quetiapine hemifumarate' 'Utapine' 'ZD-5077'
 'ZD5077' 'ZM 204,636' 'ZM-204636']_|_[('DailyMed', array(['quetiapine%20fumarate'], dtype=object)), ('PubChem', array(['144212683'], dtype=object)), ('chEBI', array(['8708'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0005301', 'EFO_1001892', 'EFO_0005411',
       'EFO_0009963', 'EFO_1001917', 'MONDO_0002046', 'HP_0000713',
       'EFO_0004242', 'MONDO_0005090', 'EFO_0005407', 'EFO_0005230',
       'EFO_0009964', 'MONDO_0002050', 'HP_0000726', 'Orphanet_79292',
       'MONDO_0004985', 'HP_0012076', 'EFO_0004257', 'EFO_0001358',
       'MONDO_0002009', 'MONDO_0007079'], dtype=object), 'count': 22}_|_[ENSG00000102468,ENSG00000149295,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3544923,"nan_|_nan_|_Antibody drug conjugate_|_False_|_LABETUZUMAB GOVITECAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-ceacam5-sn 38' 'IMMU-130' 'Labetuzumab govitecan']_|_nan_|_nan_|_{'rows': array(['MONDO_0021063', 'EFO_1000657'], dtype=object), 'count': 2}_|_[ENSG00000105388]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL356388,"CCOC(=O)c1cnc2c(cnn2CC)c1NN=C(C)C_|_OPQRBXUBWHDHPQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETAZOLATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EHT-0202' 'Etazolate' 'SQ-20009']_|_[('PubChem', array(['11111137', '11113501', '124880016', '90341463'], dtype=object)), ('Wikipedia', array(['Etazolate'], dtype=object))]_|_['CHEMBL1256671']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000166206]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3905910,"CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO_|_MRPGRAKIAJJGMM-OCCSQVGLSA-N_|_Small molecule_|_False_|_VORUCICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['P-1446' 'P1446a-05' 'Voruciclib']_|_[('drugbank', array(['DB15157'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000095', 'MONDO_0044881', 'MONDO_0004992'],
      dtype=object), 'count': 4}_|_[ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL41,"CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1_|_RTHCYVBBDHJXIQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLUOXETINE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fluoxetin ratiopharm' 'Fluoxetine' 'Fluval' 'NSC-283480' 'NSC-758685'
 'Prozac' 'Sarafem' 'Symbyax']_|_[('PubChem', array(['104171153', '144203695', '170465374', '26751973', '26755310',
       '50104648', '90341619'], dtype=object)), ('Wikipedia', array(['Fluoxetine'], dtype=object)), ('drugbank', array(['DB00472'], dtype=object)), ('chEBI', array(['86990'], dtype=object))]_|_['CHEMBL1201082']_|_{'rows': array(['HP_0002140', 'EFO_0004262', 'MONDO_0002050', 'EFO_0003768',
       'MONDO_0024290', 'HP_0011868', 'MONDO_0005147', 'EFO_1001917',
       'EFO_1001050', 'EFO_0001361', 'HP_0000726', 'HP_0100543',
       'EFO_0001073', 'MONDO_0021632', 'EFO_0000694', 'MONDO_0002009',
       'EFO_0000712', 'EFO_0003948', 'MONDO_0004985', 'MONDO_0002009',
       'EFO_0003758', 'MONDO_0005090', 'EFO_0002610', 'MONDO_0100096',
       'EFO_0005230', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004985',
       'EFO_0009854', 'EFO_0008623', 'EFO_0000546', 'EFO_0004242',
       'EFO_0007328', 'EFO_0009963', 'MONDO_0002009', 'EFO_0008522',
       'EFO_0001358', 'EFO_0000474', 'EFO_0005669', 'MONDO_0002050',
       'EFO_0007191', 'EFO_0004242'], dtype=object), 'count': 42}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 approved and 36 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297744,"nan_|_nan_|_Unknown_|_False_|_ELX-02_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ELX-02' 'Elx-02' 'Exaluren' 'NB-124']_|_nan_|_nan_|_{'rows': array(['EFO_0000508', 'MONDO_0009061', 'MONDO_0016239', 'EFO_0003086',
       'MONDO_0018965'], dtype=object), 'count': 5}_|_[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4297829,"nan_|_nan_|_Antibody_|_False_|_SINTILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Tyvyt']_|_['ANTI-PD-1 MONOCLONAL ANTIBODY IBI308' 'IBI-308' 'IBI308' 'Ibi308'
 'Sintilimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SINTILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003897', 'EFO_0000178', 'EFO_0000702', 'EFO_1000359',
       'EFO_0004252', 'EFO_1001951', 'MONDO_0011962', 'EFO_0000183',
       'EFO_0000707', 'EFO_0000211', 'EFO_0003060', 'EFO_0000621',
       'EFO_0000348', 'EFO_0000255', 'MONDO_0003060', 'EFO_0000616',
       'EFO_0002618', 'EFO_0000349', 'EFO_1001972', 'MONDO_0004669',
       'EFO_0000313', 'EFO_0002916', 'EFO_0000199', 'MONDO_0002974',
       'MONDO_0019472', 'MONDO_0008903', 'MONDO_0008170', 'EFO_0000519',
       'EFO_0000182', 'EFO_1001968', 'EFO_0003860', 'EFO_1001961',
       'EFO_1000657', 'MONDO_0004992', 'EFO_0002913', 'EFO_0000365',
       'EFO_1001901', 'EFO_0004142', 'EFO_0000574', 'MONDO_0001056',
       'MONDO_0007254', 'EFO_0005570', 'EFO_0003968', 'MONDO_0021117',
       'MONDO_0002120', 'EFO_0005221', 'EFO_0001416', 'EFO_0000588',
       'MONDO_0009348', 'EFO_0000691', 'EFO_0000181', 'EFO_0000503',
       'MONDO_0005411', 'EFO_0005922', 'MONDO_0044704', 'EFO_0000403',
       'EFO_0000681'], dtype=object), 'count': 57}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 57 investigational indications."
CHEMBL4297876,"nan_|_nan_|_Antibody_|_False_|_ZALIFRELIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGEN1884' 'Agen-1884' 'Agen1884' 'Ugn-301' 'Zalifrelimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZALIFRELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000294', 'MONDO_0004992', 'EFO_0003060', 'EFO_1000026',
       'EFO_0000616', 'EFO_0003968', 'EFO_1001968', 'MONDO_0005184',
       'MONDO_0002974'], dtype=object), 'count': 9}_|_[ENSG00000163599]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL4298150,"CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.O=C(O)/C=C/C(=O)O_|_JNLIKIBISICTMS-PEJBKAKVSA-N_|_Small molecule_|_False_|_SIPONIMOD FUMARIC ACID_|_2019.0_|_4.0_|_CHEMBL2336071_|_False_|_True_|_['Mayzent']_|_['NVP-BAF312-AEA' 'Siponimod fumarate' 'Siponimod hemifumarate'
 'Siponimod hemifumaric acid']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mayzent'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIPONIMOD%20FUMARIC%20ACID/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008522', 'EFO_0003840', 'EFO_0003929', 'MONDO_0005301'],
      dtype=object), 'count': 4}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved indications."
CHEMBL435381,"COc1ccc(-c2c(Cl)ncn2-c2ccc(S(N)(=O)=O)cc2)cc1F_|_KYXDNECMRLFQMZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CIMICOXIB_|_2011.0_|_2.0_|_nan_|_False_|_False_|_['Cimalgex']_|_['Cimalgex' 'Cimicoxib' 'Cimicoxib (ema epar: veterinary)']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/cimalgex'],
      dtype=object)), ('drugbank', array(['DB05095'], dtype=object)), ('chEBI', array(['76127'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of II that was first approved in 2011 and has 1 investigational indication."
CHEMBL451,"CNC1=Nc2ccc(Cl)cc2C(c2ccccc2)=[N+]([O-])C1_|_ANTSCNMPPGJYLG-UHFFFAOYSA-N_|_Small molecule_|_True_|_CHLORDIAZEPOXIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Clopoxide' 'Librelease' 'Libritabs' 'Librium' 'Sarlib' 'Trakipeal'
 'Zeisin']_|_['A-Poxide' 'Chlordiazachel' 'Chlordiazepoxide' 'Chlordiazepoxide civ'
 'Clopoxide' 'Librium' 'Lygen']_|_[('DailyMed', array(['chlordiazepoxide'], dtype=object)), ('PubChem', array(['144205120', '144205121', '49648393'], dtype=object)), ('Wikipedia', array(['Chlordiazepoxide'], dtype=object)), ('drugbank', array(['DB00475'], dtype=object)), ('chEBI', array(['3611'], dtype=object))]_|_['CHEMBL1200703']_|_{'rows': array(['EFO_0005230', 'EFO_0006788', 'MONDO_0007079', 'EFO_0004777',
       'MONDO_0002009'], dtype=object), 'count': 5}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL455136,"CNC(=O)[C@@H](c1ccccc1)N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(C(F)(F)F)cc1_|_DKMACHNQISHMDN-RPLLCQBOSA-N_|_Small molecule_|_False_|_ALMOREXANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACT-078573' 'Almorexant']_|_[('Wikipedia', array(['Almorexant'], dtype=object)), ('drugbank', array(['DB06673'], dtype=object))]_|_['CHEMBL3542330']_|_{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}_|_[ENSG00000137252,ENSG00000121764]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4594455,"nan_|_nan_|_Unknown_|_False_|_AGS-16C3F_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADC AGS-16C3F' 'AGS-16C3F' 'Ags-16c3f' 'Ags-16c3f (anti-enpp3 antibody)']_|_nan_|_nan_|_{'rows': array(['EFO_0000349', 'EFO_0000681'], dtype=object), 'count': 2}_|_[ENSG00000154269,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL500,"CC(C)NCC(O)COc1cccc2[nH]ccc12_|_JZQKKSLKJUAGIC-UHFFFAOYSA-N_|_Small molecule_|_False_|_PINDOLOL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Betadren' 'Pindolol' 'Visken']_|_['(rs)-pindolol' 'Apo-pindol' 'Betapindol' 'Blocklin-l' 'Calvisken'
 'Carvisken' 'Decreten' 'Dl-lb-46' 'Dl-pindolol' 'Durapindol'
 'Glauco-visken' 'LB-46' 'NSC-757276' 'Pectobloc' 'Pinbetol' 'Pindolol'
 'Prinodolol' 'Pynastin']_|_[('DailyMed', array(['pindolol'], dtype=object)), ('PubChem', array(['104171209', '144203772', '170464892', '26747148', '26747149',
       '26752014', '50104680', '50104681', '85231175', '855790',
       '90341348'], dtype=object)), ('Wikipedia', array(['Pindolol'], dtype=object)), ('drugbank', array(['DB00960'], dtype=object)), ('chEBI', array(['8214'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'MONDO_0002009', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL559,"N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O_|_XUIIKFGFIJCVMT-GFCCVEGCSA-N_|_Small molecule_|_False_|_DEXTROTHYROXINE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Thyroxine']_|_['Choloxin' 'D-thyroxine' 'Dextrothyroxine' 'Liotrix']_|_[('PubChem', array(['11112110'], dtype=object)), ('Wikipedia', array(['Dextrothyroxine'], dtype=object)), ('drugbank', array(['DB00509'], dtype=object)), ('chEBI', array(['30659'], dtype=object))]_|_['CHEMBL1200777' 'CHEMBL3545058']_|_{'rows': array(['EFO_0000319', 'EFO_1001375', 'EFO_0000612', 'EFO_0001064'],
      dtype=object), 'count': 4}_|_[ENSG00000126351,ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for cardiovascular disease and has 3 investigational indications."
CHEMBL661,"Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2_|_VREFGVBLTWBCJP-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALPRAZOLAM_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Alprazolam' 'Niravam' 'Xanax' 'Xanax xr']_|_['Alprazolam' 'Alprazolam civ' 'NSC-760140' 'U 31,889' 'U-31,889'
 'U-31889']_|_[('DailyMed', array(['alprazolam'], dtype=object)), ('PubChem', array(['144205245', '26719699', '29215419'], dtype=object)), ('Wikipedia', array(['Alprazolam'], dtype=object)), ('drugbank', array(['DB00404'], dtype=object)), ('chEBI', array(['2611'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006788', 'MONDO_0005147', 'EFO_0003890', 'EFO_0000474',
       'EFO_1001917', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_1001892', 'HP_0001250', 'EFO_0004262', 'EFO_0001358',
       'HP_0000726', 'MONDO_0005277', 'EFO_1001884', 'MONDO_0004979'],
      dtype=object), 'count': 16}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL834,"NCCC(O)(P(=O)(O)O)P(=O)(O)O_|_WRUUGTRCQOWXEG-UHFFFAOYSA-N_|_Small molecule_|_False_|_PAMIDRONIC ACID_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CGP-23339AE' 'Pamidronate' 'Pamidronic Acid' 'Pamidronic acid'
 'Ribodroat']_|_[('PubChem', array(['144205217', '170464689', '29215372', '29217620'], dtype=object)), ('Wikipedia', array(['Pamidronic_acid'], dtype=object)), ('drugbank', array(['DB00282'], dtype=object))]_|_['CHEMBL676' 'CHEMBL3989401']_|_{'rows': array(['EFO_1001164', 'EFO_0001378', 'MONDO_0007254', 'EFO_0003882',
       'MONDO_0007254', 'HP_0003419', 'EFO_0001378', 'MONDO_0019019',
       'EFO_0004260'], dtype=object), 'count': 9}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and is indicated for bone disease and has 6 investigational indications."
CHEMBL855,"Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1_|_CBEQULMOCCWAQT-WOJGMQOQSA-N_|_Small molecule_|_False_|_TRIPROLIDINE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Actahist' 'Actidil' 'Actifed' 'Allerfed' 'Corphed' 'Histafed' 'Myfed'
 'Myidyl' 'Trilitron' 'Triphed' 'Triprolidine']_|_[('PubChem', array(['144204470', '170464931', '26751829', '50104523', '50104524',
       '50104525', '90341007'], dtype=object)), ('Wikipedia', array(['Triprolidine'], dtype=object)), ('drugbank', array(['DB00427'], dtype=object)), ('chEBI', array(['84116'], dtype=object))]_|_['CHEMBL1200450' 'CHEMBL3188034']_|_{'rows': array(['HP_0001742', 'MONDO_0005271', 'EFO_0005854', 'EFO_0007214',
       'EFO_0003956'], dtype=object), 'count': 5}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved indications."
CHEMBL105442,"O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl_|_GFMMXOIFOQCCGU-UHFFFAOYSA-N_|_Small molecule_|_False_|_CI-1040_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CI-1040' 'Ci 1040' 'Ci-1040' 'PD-18435' 'PD-184352']_|_[('PubChem', array(['144206914', '170466835', '174006413'], dtype=object)), ('drugbank', array(['DB12429'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_0003860', 'EFO_1001951', 'EFO_0004142',
       'MONDO_0007254', 'MONDO_0008903', 'EFO_0003060', 'EFO_0003869'],
      dtype=object), 'count': 8}_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL1200748,"C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O_|_QTAOMKOIBXZKND-PPHPATTJSA-N_|_Small molecule_|_False_|_CARBIDOPA_|_1975.0_|_4.0_|_CHEMBL1201236_|_False_|_True_|_['Carbidopa' 'Lodosyn']_|_['Carbidopa' 'Carbidopa component of carbilev'
 'Carbidopa component of parcopa' 'Carbidopa component of sinemet'
 'Carbidopa hydrate' 'Carbidopa monohydrate' 'Carbidopum monohydrate'
 'Lodosyn' 'MK-486' 'NSC-751137' 'NSC-758190']_|_[('DailyMed', array(['carbidopa'], dtype=object)), ('chEBI', array(['3395'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0003770', 'Orphanet_1764',
       'EFO_0002610', 'EFO_1001402', 'EFO_0000546', 'EFO_0003768',
       'MONDO_0018910', 'MONDO_0007113', 'MONDO_0005301', 'HP_0002381',
       'EFO_0005252', 'EFO_0005687', 'MONDO_0004979', 'HP_0012532',
       'MONDO_0005180', 'HP_0003418', 'EFO_0000537', 'MONDO_0019200',
       'MONDO_0005090', 'MONDO_0001020', 'EFO_1001175', 'EFO_0003888',
       'EFO_0003843', 'MONDO_0004976', 'EFO_0001365'], dtype=object), 'count': 27}_|_[ENSG00000132437]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 23 investigational indications."
CHEMBL1200831,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CC2(C[C@H]1C(=O)O)SCCS2.Cl_|_CLDOLNORSLLQDI-OOAIBONUSA-N_|_Small molecule_|_False_|_SPIRAPRIL HYDROCHLORIDE_|_1994.0_|_4.0_|_CHEMBL431_|_False_|_True_|_['Renormax']_|_['SCH 33844' 'SCH-33844' 'Spirapril hcl' 'Spirapril hydrochloride']_|_[('PubChem', array(['144206534'], dtype=object))]_|_nan_|_nan_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994."
CHEMBL1201329,"O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1_|_CHQOEHPMXSHGCL-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIMETHAPHAN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Trimetaphan' 'Trimethaphan' 'Trimethaphan cation' 'Trimethaphan ion']_|_[('drugbank', array(['DB01116'], dtype=object)), ('chEBI', array(['9728'], dtype=object))]_|_['CHEMBL1245']_|_{'rows': array(['EFO_0000537', 'EFO_0002614'], dtype=object), 'count': 2}_|_[ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for hypertension and has 1 investigational indication."
CHEMBL1318287,"C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1.O=C([O-])[C@H](O)[C@@H](O)C(=O)O.O=C([O-])[C@H](O)[C@@H](O)C(=O)O_|_HSMKTIKKPMTUQH-WBPXWQEISA-L_|_Small molecule_|_False_|_PENTOLINIUM TARTRATE_|_1982.0_|_4.0_|_CHEMBL1271_|_False_|_True_|_['Ansolysen']_|_['NSC-759890' 'Pentolinium tartrate' 'Pentolonium tartrate'
 'Pentolonum bitartrate']_|_[('PubChem', array(['50106735', '90341731'], dtype=object)), ('chEBI', array(['55326'], dtype=object))]_|_nan_|_nan_|_[ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1614652,"O=C1c2ccccc2S(=O)(=O)N1CCCCNC[C@H]1CCc2ccccc2O1_|_YGYBFMRFXNDIPO-QGZVFWFLSA-N_|_Small molecule_|_False_|_REPINOTAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Repinotan']_|_[('Wikipedia', array(['Repinotan'], dtype=object)), ('drugbank', array(['DB06506'], dtype=object))]_|_nan_|_nan_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1743086,"nan_|_nan_|_Antibody_|_False_|_VATELIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GBR 500' 'GBR-500' 'SAR-339658' 'SAR339658' 'Vatelizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0003929'], dtype=object), 'count': 2}_|_[ENSG00000164171]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1933349,"COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1_|_DNTVJEMGHBIUMW-IBGZPJMESA-N_|_Small molecule_|_False_|_MK-0893_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-0893' 'Mk-0893' 'Mk0893']_|_[('drugbank', array(['DB12044'], dtype=object))]_|_['CHEMBL2159354']_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000215644]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109465,"nan_|_nan_|_Antibody_|_False_|_QAX-576_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dectrekumab' 'QAX-576' 'Qax-576' 'Qax576']_|_nan_|_nan_|_{'rows': array(['EFO_0005854', 'EFO_0004212', 'EFO_0009448', 'EFO_0004232',
       'EFO_0000768', 'MONDO_0004979', 'EFO_0000384', 'EFO_0000717'],
      dtype=object), 'count': 8}_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL2109495,"nan_|_nan_|_Antibody_|_False_|_E2.3_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['E2.3']_|_nan_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0000565', 'EFO_0001378', 'EFO_0002428'],
      dtype=object), 'count': 4}_|_[ENSG00000072274,ENSG00000106327]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."
CHEMBL2111100,"CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC_|_JMUHBNWAORSSBD-WKYWBUFDSA-N_|_Small molecule_|_False_|_MIFAMURTIDE ACID_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CGP-19835' 'Mifamurtide free acid anhydrous']_|_nan_|_['CHEMBL2107354']_|_{'rows': array(['MONDO_0002629', 'EFO_0000637', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000167207]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved indications."
CHEMBL3545108,"O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl_|_HSQAARMBHJCUOK-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD9056_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD9056' 'Azd 9056' 'Azd-9056' 'Azd9056']_|_[('drugbank', array(['DB12594'], dtype=object))]_|_['CHEMBL3415305']_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000089041]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3686884,"CNC(=O)n1ccc2cc(Oc3ccnc(NC(=O)c4ccc(C5CCN(CCO)CC5)cc4)c3)c(OCCOC)cc21_|_IBHOLSBDZMIPPT-UHFFFAOYSA-N_|_Small molecule_|_False_|_E-7090_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E 7090' 'E-7090' 'E7090' 'Tasurgratinib']_|_nan_|_nan_|_{'rows': array(['EFO_0005221', 'EFO_0003869', 'EFO_0001421', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000077782,ENSG00000068078,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3707359,"nan_|_nan_|_Unknown_|_False_|_DAXIBOTULINUMTOXINA_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Daxxify']_|_['Daxibotulinumtoxina' 'RTI-150' 'RTI150' 'RTT150']_|_nan_|_nan_|_{'rows': array(['HP_0000473', 'EFO_0005422'], dtype=object), 'count': 2}_|_[ENSG00000132639]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for skin aging and has 1 investigational indication."
CHEMBL395091,"CN[C@]1(c2ccccc2Cl)CCCCC1=O_|_YQEZLKZALYSWHR-ZDUSSCGKSA-N_|_Small molecule_|_True_|_ESKETAMINE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-ketamine' 'Esketamine' 'Jnj-54135419' 'Keta-s' 'Ketamine, (s)-'
 'Ketamine, s-' 'Ketaved' 'L-ketamine' 'S-(-)-ketamine' 'S-ketamine']_|_[('PubChem', array(['144206757'], dtype=object)), ('drugbank', array(['DB11823'], dtype=object)), ('chEBI', array(['60799'], dtype=object))]_|_['CHEMBL2364609']_|_{'rows': array(['MONDO_0002050', 'EFO_0003843', 'MONDO_0002050', 'MONDO_0002009',
       'EFO_0003086', 'MONDO_0002009', 'MONDO_0002009', 'EFO_0003890',
       'EFO_0801084', 'EFO_0005854', 'EFO_0003843', 'HP_0000360',
       'EFO_0009267', 'EFO_0001421', 'EFO_0006834', 'MONDO_0002009'],
      dtype=object), 'count': 16}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for depressive disorder and major depressive disorder and has 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297643,"Cc1cccc(/C=N/Nc2cc(N3CCOCC3)nc(OCCc3ccccn3)n2)c1_|_HSKAZIJJKRAJAV-KOEQRZSOSA-N_|_Small molecule_|_False_|_APILIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apilimod' 'STA 5326' 'STA-5326' 'Sta-5326']_|_[('drugbank', array(['DB05611'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'MONDO_0015517', 'EFO_0000384'], dtype=object), 'count': 3}_|_[ENSG00000115020]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL642,"CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1_|_GOEMGAFJFRBGGG-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACEBUTOLOL_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acebutolol' 'C07AB04' 'Sectral']_|_[('Wikipedia', array(['Acebutolol'], dtype=object)), ('drugbank', array(['DB01193'], dtype=object)), ('chEBI', array(['2379'], dtype=object))]_|_['CHEMBL1200813']_|_{'rows': array(['HP_0004308', 'EFO_0003777', 'EFO_0000537', 'EFO_0000537',
       'EFO_0000319', 'EFO_1000635'], dtype=object), 'count': 6}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 approved and 3 investigational indications."
CHEMBL105060,"CN(C(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)[C@@H](/C=C/C(=O)N[C@@H]1CCCCNC1=O)Cc1ccc(Cl)c(Cl)c1_|_BHCJHYIMNHXLOM-WVDRJWPYSA-N_|_Small molecule_|_False_|_DNK333_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dnk333']_|_nan_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0000274', 'EFO_0000555'], dtype=object), 'count': 3}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1069,"CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C_|_ACWBQPMHZXGDFX-QFIPXVFZSA-N_|_Small molecule_|_True_|_VALSARTAN_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Diovan' 'Exforge' 'Prexxartan' 'Valsartan']_|_['CGP 48933' 'CGP-48933' 'NSC-758927' 'Valsartan']_|_[('DailyMed', array(['valsartan'], dtype=object)), ('PubChem', array(['26719825'], dtype=object)), ('Wikipedia', array(['Valsartan'], dtype=object)), ('drugbank', array(['DB00177'], dtype=object)), ('chEBI', array(['9927'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0004265', 'EFO_0008583', 'HP_0003124',
       'EFO_0008586', 'EFO_0007148', 'EFO_0000195', 'EFO_0005672',
       'MONDO_0005149', 'EFO_0003086', 'EFO_0000538', 'EFO_0000373',
       'EFO_0005529', 'EFO_0000401', 'Orphanet_309005', 'MONDO_0100096',
       'EFO_0000694', 'EFO_0008585', 'EFO_0001645', 'EFO_0000319',
       'EFO_0000712', 'EFO_0003914', 'EFO_0000400', 'MONDO_0005148',
       'EFO_0000612', 'EFO_0003144', 'EFO_0003884', 'MONDO_0001134',
       'MONDO_0018965', 'EFO_0000537'], dtype=object), 'count': 30}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1088,"CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21_|_SLVMESMUVMCQIY-UHFFFAOYSA-N_|_Small molecule_|_True_|_MESORIDAZINE_|_1970.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mesoridazine' 'NC-123' 'NSC-186066' 'Serentil' 'TPS-23'
 'Thioridazine-2-sulfoxide']_|_[('PubChem', array(['144203603', '144205571', '170465272', '26756521', '447728'],
      dtype=object)), ('Wikipedia', array(['Mesoridazine'], dtype=object)), ('drugbank', array(['DB00933'], dtype=object)), ('chEBI', array(['6780'], dtype=object))]_|_['CHEMBL1201052']_|_{'rows': array(['EFO_0005407'], dtype=object), 'count': 1}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1970 and is indicated for psychosis. This drug has a black box warning from the FDA."
CHEMBL1200955,"COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2.Cl_|_OWLCGJBUTJXNOF-HDNKIUSMSA-N_|_Small molecule_|_True_|_MYCOPHENOLATE MOFETIL HYDROCHLORIDE_|_1998.0_|_4.0_|_CHEMBL1456_|_False_|_True_|_['Cellcept' 'Mycophenolate mofetil hydrochloride']_|_['Mycophenolate mofetil hcl' 'Mycophenolate mofetil hydrochloride'
 'RS-61443-190']_|_[('DailyMed', array(['mycophenolate%20mofetil%20hydrochloride'], dtype=object))]_|_nan_|_nan_|_[ENSG00000106348,ENSG00000178035]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998. This drug has a black box warning from the FDA."
CHEMBL1201566,"nan_|_nan_|_Protein_|_True_|_DARBEPOETIN ALFA_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Aranesp' 'Aranesp sureclick']_|_['Darbepoetin' 'Darbepoetin alfa' 'Darbepoetin alfa,recombinant' 'KRN-321'
 'KRN321' 'NESP' 'Nespo']_|_[('DailyMed', array(['darbepoetin%20alfa'], dtype=object)), ('DrugCentral', array(['5157'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aranesp'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0001298', 'EFO_0000095', 'EFO_0004272', 'EFO_0000198',
       'EFO_0000574', 'EFO_0001642', 'MONDO_0002280', 'EFO_0000565',
       'MONDO_0007254', 'EFO_0000222', 'MONDO_0043510', 'EFO_0000702',
       'EFO_0003884', 'EFO_0003086', 'EFO_0000612', 'HP_0001919',
       'MONDO_0005299', 'MONDO_0003002', 'MONDO_0004992', 'EFO_0008583',
       'EFO_0000403'], dtype=object), 'count': 21}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743071,"nan_|_nan_|_Antibody_|_False_|_SIRUKUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CNTO 136' 'CNTO-136' 'Sirukumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0000540', 'MONDO_0004979', 'EFO_1001209',
       'MONDO_0100096', 'EFO_0003834', 'EFO_0008518', 'EFO_0005761',
       'EFO_0000685', 'MONDO_0002009'], dtype=object), 'count': 10}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL188185,"CCCC(=O)N1CCCN(c2nc(N)c3cc(OC)c(OC)cc3n2)CC1_|_RHLJLALHBZGAFM-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUNAZOSIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bunazosin' 'Bunazosin hydrochloride']_|_[('Wikipedia', array(['Bunazosin'], dtype=object)), ('drugbank', array(['DB12230'], dtype=object))]_|_['CHEMBL3182014']_|_nan_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL2095208,"CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1_|_ZCIGNRJZKPOIKD-CQXVEOKZSA-N_|_Small molecule_|_False_|_COBICISTAT_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Tybost']_|_['Cobicistat' 'Cobicistat on silicon dioxide' 'Cobicistat, (r,r,s)-'
 'GS-9350']_|_[('DailyMed', array(['cobicistat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tybost'],
      dtype=object)), ('drugbank', array(['DB09065'], dtype=object)), ('chEBI', array(['72291'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000765', 'EFO_0007448', 'MONDO_0004992', 'EFO_0001068',
       'EFO_0000764', 'EFO_0000220', 'EFO_0000544', 'MONDO_0100096',
       'MONDO_0005184', 'EFO_0002614', 'EFO_0003060', 'EFO_0000180'],
      dtype=object), 'count': 12}_|_[ENSG00000160868,ENSG00000106258,ENSG00000021461,ENSG00000160870]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 9 investigational indications."
CHEMBL312448,"Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1_|_HUCJFAOMUPXHDK-UHFFFAOYSA-N_|_Small molecule_|_False_|_XYLOMETAZOLINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Balminil' 'Xylometazoline']_|_[('PubChem', array(['11111974', '11111975', '174007471', '50100368', '50104259',
       '90340774'], dtype=object)), ('Wikipedia', array(['Xylometazoline'], dtype=object)), ('drugbank', array(['DB06694'], dtype=object)), ('chEBI', array(['10082'], dtype=object))]_|_['CHEMBL1256400']_|_{'rows': array(['HP_0001742', 'EFO_0005751', 'EFO_0007214'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for nasal congestion and eye allergy and has 1 investigational indication."
CHEMBL3707326,"nan_|_nan_|_Antibody_|_False_|_BUROSUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Crysvita']_|_['Burosumab' 'Burosumab twza' 'KRN-23' 'KRN23']_|_[('DailyMed', array(['burosumab-twza'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0000845', 'EFO_1002027', 'Orphanet_89936', 'EFO_0004260',
       'MONDO_0024300', 'HP_0002148'], dtype=object), 'count': 6}_|_[ENSG00000118972]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 3 investigational indications."
CHEMBL398435,"CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1_|_OEKWJQXRCDYSHL-FNOIDJSQSA-N_|_Small molecule_|_True_|_TICAGRELOR_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Brilinta' 'Brilique']_|_['AR-C126532XX' 'AZD-6140' 'AZD6140' 'Possia' 'Ticagrelor']_|_[('DailyMed', array(['ticagrelor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/brilique'],
      dtype=object)), ('Wikipedia', array(['Ticagrelor'], dtype=object)), ('drugbank', array(['DB08816'], dtype=object)), ('chEBI', array(['68558'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008585', 'EFO_0003884', 'EFO_0003870', 'EFO_0002615',
       'EFO_0000341', 'EFO_0008586', 'EFO_0000266', 'EFO_0000612',
       'EFO_0008583', 'EFO_0007328', 'EFO_0003086', 'EFO_0005672',
       'MONDO_0011382', 'MONDO_0000831', 'EFO_0003106', 'EFO_0004214',
       'EFO_0000556', 'EFO_0003875', 'MONDO_0005148', 'EFO_0003913',
       'EFO_0000275', 'EFO_0004265', 'EFO_0000319', 'EFO_0000712',
       'HP_0004419', 'MONDO_0100096', 'HP_0002140', 'EFO_0001645'],
      dtype=object), 'count': 28}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 9 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4209157,"O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1_|_NGFFVZQXSRKHBM-FKBYEOEOSA-N_|_Small molecule_|_False_|_LIFIRAFENIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BGB-283' 'Beigene-283' 'Bgb 283' 'Bgb-283' 'Lifirafenib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LIFIRAFENIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14773'], dtype=object))]_|_['CHEMBL4298146']_|_{'rows': array(['EFO_0000616', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication."
CHEMBL4297566,"nan_|_nan_|_Oligonucleotide_|_False_|_CASIMERSEN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Amondys 45']_|_['Casimersen' 'EXON-45: NG-12-0064' 'SRP-4045']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CASIMERSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010679', 'MONDO_0020121'], dtype=object), 'count': 2}_|_[ENSG00000198947]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for duchenne muscular dystrophy and muscular dystrophy."
CHEMBL4297694,"nan_|_nan_|_Protein_|_False_|_ANFIBATIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Agkisacucetin' 'Anfibatide']_|_nan_|_nan_|_{'rows': array(['EFO_0000612', 'MONDO_0019740'], dtype=object), 'count': 2}_|_[ENSG00000185245]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297840,"nan_|_nan_|_Antibody_|_False_|_TISLELIZUMAB_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['BGB-A317' 'BGN-1' 'BGN1' 'Bgb-a317' 'JHL-2108' 'JHL2108' 'Tislelizumab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TISLELIZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019472', 'EFO_0005952', 'EFO_0000294', 'MONDO_0002974',
       'EFO_0005922', 'EFO_0000616', 'EFO_0004142', 'EFO_0000199',
       'EFO_0005221', 'EFO_0000707', 'MONDO_0021063', 'EFO_0000365',
       'EFO_0000272', 'MONDO_0002367', 'EFO_0000574', 'EFO_0000182',
       'EFO_1000350', 'EFO_1000657', 'EFO_1001961', 'EFO_0002609',
       'EFO_0003860', 'MONDO_0008170', 'EFO_0000183', 'MONDO_0011962',
       'EFO_0000211', 'MONDO_0001056', 'EFO_0000403', 'MONDO_0007576',
       'MONDO_0007254', 'MONDO_0002691', 'EFO_0000681', 'EFO_0001416',
       'MONDO_0002108', 'EFO_0008528', 'EFO_0004252', 'EFO_0000708',
       'EFO_0003060', 'EFO_0005537', 'MONDO_0003060', 'MONDO_0015760',
       'MONDO_0001187', 'MONDO_0004986', 'EFO_0000756', 'MONDO_0009348',
       'EFO_0000313', 'EFO_0003891', 'HP_0001541', 'EFO_0000702',
       'EFO_0002618', 'MONDO_0008315', 'EFO_1001951', 'EFO_0006859',
       'MONDO_0008903', 'EFO_0004244', 'EFO_0000181', 'MONDO_0005184',
       'MONDO_0005575', 'EFO_0000519', 'EFO_0000503', 'MONDO_0004992',
       'EFO_0000632', 'EFO_0000565'], dtype=object), 'count': 62}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and cancer and has 60 investigational indications."
CHEMBL456237,"Fc1ccc(-c2c3cccc(C(F)(F)F)c3nn2Cc2ccc(F)cc2Cl)cc1_|_KYWWJENKIMRJBI-UHFFFAOYSA-N_|_Small molecule_|_False_|_LXR-623_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Lx-623' 'Lx623' 'Lxr-623' 'WAY-252623' 'Way252623']_|_nan_|_nan_|_nan_|_[ENSG00000131408,ENSG00000025434]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL5283463,"Cc1ccc(S(=O)(=O)O)cc1.Cc1ccsc1C(=O)Nc1cc(CN2CCN(C(=O)CO)CC2)ccc1/C=C/c1n[nH]c2ccccc12_|_SIJKXSMUXNJNQM-HRNDJLQDSA-N_|_Small molecule_|_False_|_KW-2450_|_nan_|_2.0_|_CHEMBL5315324_|_False_|_False_|_[]_|_['KW-2450' 'Kw-2450']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000171105,ENSG00000140443]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL911,"Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1_|_ZAFYATHCZYHLPB-UHFFFAOYSA-N_|_Small molecule_|_True_|_ZOLPIDEM_|_1992.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ambien' 'Sanval' 'Zolpidem' 'Zolpidem civ']_|_[('PubChem', array(['144205024', '170465242', '26749064'], dtype=object)), ('Wikipedia', array(['Zolpidem'], dtype=object)), ('drugbank', array(['DB00425'], dtype=object)), ('chEBI', array(['10125'], dtype=object))]_|_['CHEMBL3989820' 'CHEMBL1723343']_|_{'rows': array(['MONDO_0005180', 'EFO_0004698', 'EFO_0003888', 'MONDO_0000477',
       'MONDO_0005090', 'EFO_0007191', 'EFO_0003758', 'EFO_0000673',
       'EFO_0001073', 'EFO_0003890', 'EFO_0008568', 'EFO_0005230',
       'HP_0000726', 'EFO_0008568', 'EFO_0004698', 'HP_0003419',
       'MONDO_0002050'], dtype=object), 'count': 17}_|_[ENSG00000022355,ENSG00000113327,ENSG00000163288]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL928,"O=C1CN(/N=C/c2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)[N-]1.[Na+]_|_KSRLIXGNPXAZHD-HAZZGOGXSA-M_|_Small molecule_|_True_|_DANTROLENE SODIUM_|_1974.0_|_4.0_|_CHEMBL1201288_|_False_|_True_|_['Dantrium' 'Dantrolene sodium' 'Revonto' 'Ryanodex']_|_['Dantamacrin' 'Dantrolen' 'Dantrolene sodium'
 'Dantrolene sodium heptahydrate' 'Dantrolene sodium hydrate'
 'Dantrolene sodium salt hemiheptahydrate' 'F-440' 'NSC-758403']_|_[('DailyMed', array(['dantrolene%20sodium'], dtype=object)), ('PubChem', array(['50106202'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_1001919', 'EFO_0020003', 'EFO_1000632',
       'HP_0001257', 'EFO_1001340', 'MONDO_0018105', 'MONDO_0005301',
       'HP_0001945'], dtype=object), 'count': 9}_|_[ENSG00000196218,ENSG00000198838]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1079593,"O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1[C@@H]1CCOc2c(F)cccc21_|_DBXGGXLBTWZXBB-MRXNPFEDSA-N_|_Small molecule_|_False_|_VS-5584_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['VS-5584' 'Vs 5584' 'Vs-5584']_|_nan_|_nan_|_{'rows': array(['EFO_0000588', 'EFO_0000574'], dtype=object), 'count': 2}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL1100,"CCC1(C)OC(=O)N(C)C1=O_|_VQASKUSHBVDKGU-UHFFFAOYSA-N_|_Small molecule_|_False_|_PARAMETHADIONE_|_1949.0_|_4.0_|_nan_|_False_|_True_|_['Paradione']_|_['Isoethadione' 'NSC-760129' 'Paramethadione']_|_[('Wikipedia', array(['Paramethadione'], dtype=object)), ('drugbank', array(['DB00617'], dtype=object)), ('chEBI', array(['7921'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1949 and is indicated for epilepsy."
CHEMBL1200764,"CC(=O)OC(C)C[N+](C)(C)C.[Cl-]_|_JHPHVAVFUYTVCL-UHFFFAOYSA-M_|_Small molecule_|_True_|_METHACHOLINE CHLORIDE_|_1986.0_|_4.0_|_CHEMBL978_|_False_|_True_|_['Provocholine']_|_['Methacholine chloride' 'NSC-757090']_|_[('DailyMed', array(['methacholine%20chloride'], dtype=object)), ('PubChem', array(['144203899', '170464971', '50105745', '56423647', '855729'],
      dtype=object)), ('chEBI', array(['50142'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for asthma. This drug has a black box warning from the FDA."
CHEMBL124660,"COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1_|_UXXQOJXBIDBUAC-UHFFFAOYSA-N_|_Small molecule_|_False_|_TANDUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CT 53518' 'CT-53518' 'CT53518' 'MLN-518' 'Mln-0518' 'NSC-759851'
 'Tandutinib']_|_[('PubChem', array(['103905342', '124950156', '144206917', '170466826', '50100108'],
      dtype=object)), ('drugbank', array(['DB05465'], dtype=object)), ('chEBI', array(['90237'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001465', 'EFO_0002501', 'EFO_0002499', 'EFO_0000222',
       'EFO_0000349', 'EFO_0000630', 'EFO_0000198', 'EFO_0000519'],
      dtype=object), 'count': 8}_|_[ENSG00000157404,ENSG00000113721,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL1457,"COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314_|_LLPOLZWFYMWNKH-CMKMFDCUSA-N_|_Small molecule_|_True_|_HYDROCODONE_|_1943.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hydrocodone']_|_[('PubChem', array(['29215221'], dtype=object)), ('Wikipedia', array(['Hydrocodone'], dtype=object)), ('drugbank', array(['DB00956'], dtype=object)), ('chEBI', array(['5779'], dtype=object))]_|_['CHEMBL3989677' 'CHEMBL1201470' 'CHEMBL3182640' 'CHEMBL2062267'
 'CHEMBL2135756']_|_{'rows': array(['EFO_0003843', 'HP_0002013', 'EFO_0005762', 'EFO_0003086',
       'MONDO_0005178', 'EFO_0009615', 'MONDO_0005178', 'EFO_0000546',
       'HP_0003419', 'HP_0012532', 'EFO_1001250', 'EFO_0003843',
       'EFO_0001421', 'EFO_0003890', 'EFO_0003966', 'HP_0003419',
       'HP_0012532', 'HP_0012735', 'HP_0002018'], dtype=object), 'count': 19}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1943 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1463345,"C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]21CCC(=O)O1_|_UJVLDDZCTMKXJK-WNHSNXHDSA-N_|_Small molecule_|_False_|_CANRENONE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Canrenone' 'NSC-261713' 'SC-9376' 'Spironolactone metabolite m1'
 'Spironolactone related compound a']_|_[('PubChem', array(['144205004', '170466206', '49646110'], dtype=object)), ('drugbank', array(['DB12221'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region."
CHEMBL1480,"CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl_|_RZTAMFZIAATZDJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_FELODIPINE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Cabren' 'Cardioplen xl' 'Felodipine' 'Felogen xl' 'Felotens xl'
 'Folpik xl' 'Keloc sr' 'Neofel xl' 'Parmid xl' 'Pinefeld xl' 'Plendil'
 'Preslow' 'Vascalpha']_|_['C08CA02' 'Felodipine' 'H 154/82' 'H-154/82' 'NSC-760343']_|_[('DailyMed', array(['felodipine'], dtype=object)), ('PubChem', array(['124880165', '144203706', '170464849', '17405071', '50106289',
       '50106290', '85231057', '90340828'], dtype=object)), ('Wikipedia', array(['Felodipine'], dtype=object)), ('drugbank', array(['DB01023'], dtype=object)), ('chEBI', array(['585948'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'EFO_0000400', 'EFO_0000537', 'EFO_0000319',
       'MONDO_0005148', 'EFO_0001645', 'HP_0003124'], dtype=object), 'count': 7}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 4 investigational indications."
CHEMBL154,"COc1ccc2cc([C@H](C)C(=O)O)ccc2c1_|_CMWTZPSULFXXJA-VIFPVBQESA-N_|_Small molecule_|_True_|_NAPROXEN_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Aleve' 'Anaprox' 'Arthrosin 250' 'Arthrosin 250 ec' 'Arthrosin 500'
 'Arthrosin 500 ec' 'Condrotec' 'Ec-naprosyn' 'Equiproxen' 'Feminax ultra'
 'Grenoxal' 'Kenosyn' 'Laraflex' 'Napratec op' 'Naprosyn' 'Naprosyn 375'
 'Naprosyn ec' 'Naproxen' 'Nycopren' 'Pranoxen continus' 'Prosaid'
 'Rheuflex 250' 'Rheuflex 500' 'Rimoxyn' 'Stirlescent' 'Timpron'
 'Timpron 250 ec' 'Timpron 500 ec' 'Valrox' 'Vimovo']_|_['Aleve' 'Anaprox' 'NSC-750183' 'NSC-757239' 'Naprelan' 'Naproxen'
 'PN400 COMPONENT NAPROXEN' 'RS-3540']_|_[('DailyMed', array(['naproxen'], dtype=object)), ('PubChem', array(['11112669', '144212270', '26755231', '90341518'], dtype=object)), ('TG-GATEs', array(['73'], dtype=object)), ('Wikipedia', array(['Naproxen'], dtype=object)), ('drugbank', array(['DB00788'], dtype=object)), ('chEBI', array(['7476'], dtype=object))]_|_['CHEMBL1200806']_|_{'rows': array(['HP_0003418', 'MONDO_0005277', 'EFO_0005856', 'EFO_0010072',
       'EFO_0004616', 'MONDO_0007254', 'EFO_0002609', 'MONDO_0002471',
       'HP_0003418', 'MONDO_0005178', 'MONDO_0005301', 'EFO_0009637',
       'EFO_1000786', 'MONDO_0004975', 'EFO_0009454', 'EFO_0000673',
       'EFO_0007214', 'EFO_0005755', 'MONDO_0002471', 'EFO_0004607',
       'MONDO_0005835', 'HP_0002315', 'MONDO_0005277', 'EFO_1001434',
       'MONDO_0003937', 'MP_0001845', 'EFO_0000685', 'MONDO_0004857',
       'MONDO_0010870', 'HP_0003326', 'EFO_0004616', 'EFO_0003898',
       'MONDO_0100096', 'HP_0003419', 'MONDO_0002258', 'EFO_0000685',
       'EFO_0004274', 'MONDO_0005178', 'EFO_0003843', 'EFO_0003898',
       'EFO_0002609', 'MONDO_0004975', 'EFO_0000546', 'HP_0002315',
       'EFO_0005757', 'HP_0002829', 'EFO_1000941', 'HP_0100607',
       'EFO_0009454', 'EFO_0004274', 'HP_0001945', 'EFO_0005762',
       'EFO_0003843', 'EFO_0010072', 'HP_0100607', 'EFO_0009846',
       'HP_0004398', 'MONDO_0003937'], dtype=object), 'count': 58}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 25 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2035185,"C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1_|_NNXDIGHYPZHXTR-ONEGZZNKSA-N_|_Small molecule_|_False_|_CT-1578_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CT-1578' 'Ct-1578' 'ONX 0805' 'ONX-0805' 'SB-1578' 'SB1578' 'Sb1578']_|_[('drugbank', array(['DB15294'], dtype=object))]_|_nan_|_nan_|_[ENSG00000122025,ENSG00000096968,ENSG00000182578]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL2109633,"nan_|_nan_|_Antibody drug conjugate_|_False_|_IMGN-388_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IMGN-388' 'Imgn-388']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000138448]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2364639,"COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2_|_GEJDGVNQKABXKG-CFKGEZKQSA-N_|_Small molecule_|_True_|_VALBENAZINE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mt-5199' 'NBI-98854' 'Valbenazine']_|_[('drugbank', array(['DB11915'], dtype=object))]_|_['CHEMBL3707248']_|_{'rows': array(['MONDO_0007739', 'HP_0012167', 'EFO_0004895', 'EFO_0004280',
       'EFO_0004280', 'MONDO_0005090'], dtype=object), 'count': 6}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for movement disorder and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3039504,"CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1_|_MMMVNAGRWOJNMW-FJBFXRHMSA-N_|_Small molecule_|_False_|_NINTEDANIB ESYLATE_|_2014.0_|_4.0_|_CHEMBL502835_|_False_|_True_|_['Ofev']_|_['Nintedanib esilate' 'Nintedanib esylate' 'Nintedanib ethanesulfonate']_|_[('DailyMed', array(['nintedanib%20esylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ofev'],
      dtype=object)), ('chEBI', array(['85170'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000768', 'EFO_0000717'], dtype=object), 'count': 2}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for idiopathic pulmonary fibrosis and systemic scleroderma."
CHEMBL3544947,"CC(C)(C(N)=O)C1CCN(CCC2(c3ccc(Cl)c(Cl)c3)CN(C(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CCO2)CC1_|_ZLNYUCXXSDDIFU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BURAPITANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Burapitant' 'SSR-240600' 'SSR240600C' 'Ssr240600']_|_nan_|_nan_|_{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545337,"CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23.Cl.Cl.O_|_XJYNBZQTAZDMHZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_C-1311_|_nan_|_2.0_|_CHEMBL338604_|_False_|_False_|_['Symadex']_|_['C 1311' 'C-1311' 'NSC-645809' 'Xls-002']_|_nan_|_nan_|_nan_|_[ENSG00000131747,ENSG00000077097,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3707314,"nan_|_nan_|_Protein_|_False_|_METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Mircera']_|_['Methoxy polyethylene glycol-epoetin beta' 'Pegzerepoetin alfa' 'R-744'
 'R744']_|_[('DailyMed', array(['methoxy%20polyethylene%20glycol-epoetin%20beta'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mircera'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'MONDO_0002280', 'EFO_0004272', 'EFO_0003086'],
      dtype=object), 'count': 4}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 1 investigational indication."
CHEMBL3920982,"O=C(O)c1ccc(C2(NC(=O)C3CC4(CCN3Cc3ccc(C(F)(F)F)cc3)CC4)CC2)cc1_|_CADWTPLFEZSAHM-UHFFFAOYSA-N_|_Small molecule_|_False_|_VORBIPIPRANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CR-6086' 'CR6086' 'Cr 6086' 'Cr-6086' 'Cr6086' 'Vorbipiprant']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000171522]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL426084,"NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3_|_RYIDHLJADOKWFM-MAODMQOUSA-N_|_Small molecule_|_False_|_SAMIDORPHAN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ALKS 33' 'ALKS-33' 'ALKS-5461 COMPONENT SAMIDORPHAN' 'Alks-33'
 'RDC-0313' 'RDC-0313-00' 'Samidorphan']_|_[('drugbank', array(['DB12543'], dtype=object))]_|_['CHEMBL2105749' 'CHEMBL471243']_|_{'rows': array(['EFO_0009963', 'EFO_0002610', 'MONDO_0005090', 'MONDO_0005090',
       'EFO_0005203', 'MONDO_0007079'], dtype=object), 'count': 6}_|_[ENSG00000112038,ENSG00000116329,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for bipolar i disorder and schizophrenia and has 4 investigational indications."
CHEMBL4303669,"O.O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O_|_FUXFIVRTGHOMSO-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZOLEDRONIC ACID_|_2001.0_|_4.0_|_CHEMBL924_|_False_|_True_|_['Aclasta' 'Reclast' 'Zerlinda' 'Zoledronic acid' 'Zometa']_|_['AK-156' 'CGP 42446' 'CGP-42446' 'CGP-42446A' 'NSC-721517'
 'Zoladrona acid mylan' 'Zoledronate hydrate' 'Zoledronic'
 'Zoledronic acid' 'Zoledronic acid accord' 'Zoledronic acid hydrate'
 'Zoledronic acid medac' 'Zoledronic acid monohydrate'
 'Zoledronic acid teva']_|_[('DailyMed', array(['zoledronic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aclasta'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000228', 'EFO_0000588', 'EFO_0003820', 'EFO_0000564',
       'EFO_0004259', 'EFO_0001416', 'MONDO_0008310', 'EFO_0003863',
       'EFO_0005952', 'EFO_0003843', 'EFO_1001998', 'MONDO_0011382',
       'EFO_1001147', 'EFO_0004252', 'EFO_1001919', 'GO_0042697',
       'EFO_0000691', 'EFO_0003060', 'EFO_0003882', 'EFO_0003869',
       'EFO_0000681', 'EFO_0003854', 'EFO_0000196', 'MONDO_0019019',
       'MONDO_0021165', 'MONDO_0044903', 'MONDO_0002974', 'EFO_0002430',
       'MONDO_0008315', 'MONDO_0002171', 'EFO_0003931', 'EFO_0000685',
       'EFO_0000673', 'EFO_0009708', 'EFO_0001365', 'MONDO_0008903',
       'HP_0000938', 'EFO_0000182', 'MONDO_0020732', 'EFO_0001663',
       'EFO_0009870', 'EFO_0000637', 'Orphanet_848', 'HP_0003419',
       'EFO_0001378', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000333',
       'EFO_0000432', 'EFO_0000621', 'EFO_0004260', 'MONDO_0002367',
       'EFO_0000174', 'EFO_0004261', 'EFO_1000786'], dtype=object), 'count': 55}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 12 approved and 43 investigational indications."
CHEMBL43064,"C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1_|_DERZBLKQOCDDDZ-JLHYYAGUSA-N_|_Small molecule_|_False_|_CINNARIZINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Marzine r.f.' 'Mylan travel sickness' 'Stugeron' 'Stugeron fte']_|_['516 MD' '516-MD' 'Aplactan' 'Aplexal' 'Artate' 'Carecin' 'Cerebolan'
 'Cerepar' 'Cinaperazine' 'Cinarizine' 'Cinazyn' 'Cinnacet' 'Cinnageron'
 'Cinnarizine' 'Cinnipirine' 'Corathiem' 'Denapol' 'Dimitron' 'Eglen'
 'Folcodal' 'Giganten' 'Glanil' 'Hilactan' 'Ixertol' 'Katoseran' 'Labyrin'
 'Midronal' 'Mitronal' 'NSC-758400' 'Olamin' 'Processine' 'R 1575' 'R 516'
 'R-1575' 'R-516' 'Sedatromin' 'Sepan' 'Siptazin' 'Spaderizine' 'Stugeron'
 'Stunarone' 'Stutgeron' 'Stutgin']_|_[('PubChem', array(['144203660', '170465920', '50103929', '56422441', '85231348',
       '855570', '90340734'], dtype=object)), ('Wikipedia', array(['Cinnarizine'], dtype=object)), ('chEBI', array(['31403'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002321'], dtype=object), 'count': 1}_|_[ENSG00000196639,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for vertigo."
CHEMBL561339,"CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1_|_ALGHKWSXJUQNJJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ADL-5747_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL4297345']_|_{'rows': array(['MONDO_0041052', 'EFO_0004616'], dtype=object), 'count': 2}_|_[ENSG00000116329]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL905,"CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12_|_ULFRLSNUDGIQQP-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIZATRIPTAN_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Maxalt']_|_['L-705126' 'MK-462' 'MK-462 FREE BASE' 'Maxalt' 'Maxalt-Mlt'
 'Rizatriptan']_|_[('PubChem', array(['144205087', '174007052'], dtype=object)), ('Wikipedia', array(['Rizatriptan'], dtype=object)), ('drugbank', array(['DB00953'], dtype=object)), ('chEBI', array(['48273'], dtype=object))]_|_['CHEMBL1201032' 'CHEMBL3989629']_|_{'rows': array(['MONDO_0005277', 'MONDO_0100431', 'MONDO_0005277', 'MONDO_0005475'],
      dtype=object), 'count': 4}_|_[ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 2 investigational indications."
CHEMBL1082607,"O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O_|_XTZNCVSCVHTPAI-UHFFFAOYSA-N_|_Small molecule_|_True_|_SALMETEROL XINAFOATE_|_1994.0_|_4.0_|_CHEMBL1263_|_False_|_True_|_['Serevent']_|_['GR 33343 G' 'GR-33343 G' 'GR-33343X' 'LIPO-202'
 'Salmeterol 1-hydroxy-2-naphthoate' 'Salmeterol xinafoate']_|_[('DailyMed', array(['salmeterol%20xinafoate'], dtype=object)), ('PubChem', array(['144204822', '170465397', '26753648', '29215171', '50107004',
       '56320805', '56320806', '90341116'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'EFO_0006505', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0007183', 'EFO_0000464'], dtype=object), 'count': 6}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1088751,"CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1_|_KCAJXIDMCNPGHZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PH-797804_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PH-797804' 'PHA-797804' 'Ph-797804']_|_[('PubChem', array(['103905624', '137276009'], dtype=object)), ('drugbank', array(['DB07941'], dtype=object)), ('chEBI', array(['82715'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0005178', 'MONDO_0041052', 'EFO_0003843',
       'EFO_0000685'], dtype=object), 'count': 5}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1339,"CCCc1nc(C)c2c(O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12.Cl_|_XCMULUAPJXCOHI-UHFFFAOYSA-N_|_Small molecule_|_False_|_VARDENAFIL HYDROCHLORIDE_|_2003.0_|_4.0_|_CHEMBL1520_|_False_|_True_|_['Levitra' 'Staxyn' 'Vardenafil hydrochloride' 'Vivanza']_|_['BAY 38-9456' 'BAY-38-9456' 'Nuviva' 'Vardenafil hcl'
 'Vardenafil hydrochloride' 'Vardenafil hydrochloride anhydrous'
 'Vardenafil hydrochloride hydrate' 'Vardenafil hydrochloride trihydrate'
 'Vardenafil monohydrochloride']_|_[('DailyMed', array(['vardenafil%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vivanza'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000802', 'EFO_0004234'], dtype=object), 'count': 2}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for impotence and erectile dysfunction."
CHEMBL1601669,"C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_OFHCOWSQAMBJIW-AVJTYSNKSA-N_|_Small molecule_|_False_|_ALFACALCIDOL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Alfa d' 'Etalpha' 'One-alpha']_|_['.alpha.-calcidol' '1-alpha-vitamin d' '1-hydroxycholecalciferol'
 '1-hydroxyvitamin d3' '1.alpha-hydroxycholecalciferol' '1.alpha.(oh)d3'
 '1.alpha.-hydroxycholecalciferol' '1.alpha.-hydroxyvitamin d3'
 'Alfacalcidol' 'Alfarol' 'Alpha d3' 'Alphacalcidol' 'Alpharol' 'Alsiodol'
 'Bondiol' 'Einsalpha' 'Oxydevit' 'Tevabone' 'Un alfa' 'Un alpha']_|_[('PubChem', array(['50125753'], dtype=object)), ('drugbank', array(['DB01436'], dtype=object)), ('chEBI', array(['31186'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003882', 'EFO_0004273', 'EFO_0004278', 'EFO_0004710',
       'EFO_0003837', 'EFO_0003854', 'EFO_1002048', 'EFO_0000660',
       'EFO_0002970'], dtype=object), 'count': 9}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications."
CHEMBL1743037,"nan_|_nan_|_Antibody drug conjugate_|_False_|_LORVOTUZUMAB MERTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HUN901-DM1, BB-10901' 'IMGN-901' 'Lorvotuzumab mertansine']_|_nan_|_nan_|_{'rows': array(['EFO_0000565', 'MONDO_0006058', 'EFO_0000702', 'EFO_0002918',
       'EFO_0001378', 'EFO_0000760', 'EFO_0001376', 'EFO_0000621'],
      dtype=object), 'count': 8}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000149294]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL190,"Cn1c(=O)c2[nH]cnc2n(C)c1=O_|_ZFXYFBGIUFBOJW-UHFFFAOYSA-N_|_Small molecule_|_False_|_THEOPHYLLINE_|_1940.0_|_4.0_|_nan_|_False_|_True_|_['Accurbron' 'Aerolate' 'Aerolate iii' 'Aerolate jr' 'Aerolate sr'
 'Aquaphyllin' 'Bronkodyl' 'Duraphyl' 'Elixicon' 'Elixomin' 'Elixophyllin'
 'Elixophyllin sr' 'Labid' 'Lanophyllin' 'Lasma' 'Nuelin' 'Nuelin sa'
 'Nuelin sa-250' 'Pro-vent' 'Quibron' 'Quibron-t' 'Quibron-t/sr' 'Respbid'
 'Slo-bid' 'Slo-phyllin' 'Somophyllin-crt' 'Somophyllin-t' 'Sustaire'
 'T-phyl' 'Theo-24' 'Theo-dur' 'Theobid' 'Theobid jr.' 'Theochron'
 'Theocin' 'Theoclear l.a.-130' 'Theoclear l.a.-260' 'Theoclear-100'
 'Theoclear-200' 'Theoclear-80' 'Theograd' 'Theolair' 'Theolair-sr'
 'Theolixir' 'Theophyl' 'Theophyl-225' 'Theophyl-sr' 'Theophylline'
 'Theophylline-sr' 'Theovent' 'Uni-dur' 'Uniphyl' 'Uniphyllin continus']_|_['Dimethylxanthine' 'Doxophylline metabolite m3' 'NSC-2066' 'NSC-757346'
 'Theophylline' 'Theophylline anhydrous'
 'Theophylline melting point standard' 'Theophylline monohydrate'
 'Theophylline, anhydrous' 'Theophylline,anhydrous']_|_[('DailyMed', array(['theophylline'], dtype=object)), ('PubChem', array(['104171361', '144204378', '144209573', '144210348', '170466874',
       '17389715', '174007168', '50103998', '56463437', '68760', '855679',
       '90341676'], dtype=object)), ('TG-GATEs', array(['96'], dtype=object)), ('Wikipedia', array(['Theophylline'], dtype=object)), ('drugbank', array(['DB00277'], dtype=object)), ('chEBI', array(['28177'], dtype=object))]_|_['CHEMBL1355736' 'CHEMBL1200434' 'CHEMBL2104089' 'CHEMBL2107084'
 'CHEMBL1370561']_|_{'rows': array(['MONDO_0019992', 'HP_0001919', 'EFO_1000782', 'MONDO_0007078',
       'HP_0002104', 'Orphanet_665', 'EFO_0003060', 'EFO_0000222',
       'MONDO_0001187', 'HP_0002315', 'HP_0006536', 'EFO_0000565',
       'EFO_0009492', 'EFO_0001361', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0003917', 'MONDO_0002009', 'EFO_0001361', 'HP_0006536',
       'HP_0006536', 'EFO_0000763', 'EFO_0006505', 'EFO_0009686',
       'EFO_1000782', 'HP_0006536', 'MONDO_0002050', 'EFO_0003086',
       'EFO_0005207', 'MONDO_0004979', 'EFO_0003884', 'EFO_0001663'],
      dtype=object), 'count': 32}_|_[ENSG00000172572,ENSG00000152270,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1940 and has 3 approved and 25 investigational indications."
CHEMBL2107016,"CN1C(=O)C[C@@H](C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N2CCC[C@H]2C(N)=O)NC1=O_|_LQZAIAZUDWIVPM-SRVKXCTJSA-N_|_Protein_|_False_|_TALTIRELIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TA-0910' 'Taltirelin']_|_[('PubChem', array(['144206235'], dtype=object))]_|_nan_|_nan_|_[ENSG00000174417]_|_Protein drug with a maximum clinical trial phase of II."
CHEMBL2107818,"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1_|_OBMJQRLIQQTJLR-USGQOSEYSA-N_|_Small molecule_|_False_|_ALDOXORUBICIN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Inno-206']_|_['Aldoxorubicin' 'Doxo-emch' 'Doxorubicin-emch']_|_[('drugbank', array(['DB06013'], dtype=object))]_|_['CHEMBL2107827']_|_{'rows': array(['EFO_0000182', 'EFO_0000702', 'EFO_0003060', 'MONDO_0008978',
       'EFO_0000519', 'MONDO_0005184', 'EFO_0002618', 'EFO_0000616',
       'MONDO_0007254', 'EFO_0000707', 'EFO_1001968'], dtype=object), 'count': 11}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL2108790,"nan_|_nan_|_Antibody drug conjugate_|_False_|_TELIMOMAB ARITOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['T-101' 'T101' 'Telimomab aritox']_|_nan_|_nan_|_{'rows': array(['EFO_0004197'], dtype=object), 'count': 1}_|_[ENSG00000110448]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707380,nan_|_nan_|_Small molecule_|_False_|_RG6029_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['GDC-0310' 'Rg6029']_|_nan_|_nan_|_nan_|_[ENSG00000169432]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3945728,"O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1_|_SQZJGTOZFRNWCX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ELCUBRAGISTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABX-1431' 'ABX1431' 'Abx-1431' 'Elcubragistat']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004895', 'EFO_0008533', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000074416]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3989972,"COc1cn(-c2ccc(-n3cccn3)cc2F)nc(-c2ccnn2-c2ccccc2)c1=O_|_KVHRYLNQDWXAGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_BALIPODECT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Balipodect' 'TAK-063']_|_[('drugbank', array(['DB14774'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000112541]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297431,"CCOc1ccc(Cc2cc([C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1F_|_HYTPDMFFHVZBOR-VNXMGFANSA-N_|_Small molecule_|_False_|_HENAGLIFLOZIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Henagliflozin' 'SHR-3824' 'SHR3824' 'Shr3824']_|_[('drugbank', array(['DB11939'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0001421', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4594217,"Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O_|_RCCZPUWDQVUJAB-FVYJGOGTSA-N_|_Small molecule_|_True_|_CANAGLIFLOZIN_|_2011.0_|_4.0_|_CHEMBL2048484_|_False_|_True_|_['Invokana']_|_['Canagliflozin' 'Canagliflozin hemihydrate' 'Canagliflozin hydrate'
 'JNJ-24831754-ZAE' 'JNJ-28431754-AAA']_|_[('DailyMed', array(['canagliflozin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/invokana'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0000401', 'HP_0000083', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0007254', 'EFO_0003144', 'EFO_0001073',
       'EFO_0000660'], dtype=object), 'count': 9}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL476960,"OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O_|_FZNCGRZWXLXZSZ-CIQUZCHMSA-N_|_Small molecule_|_False_|_VOGLIBOSE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['A-71100' 'AO-128' 'Voglibose']_|_[('PubChem', array(['144205773', '170465993'], dtype=object)), ('Wikipedia', array(['Voglibose'], dtype=object)), ('drugbank', array(['DB04878'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000257335,ENSG00000171298,ENSG00000090402,ENSG00000257743]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 2 investigational indications."
CHEMBL557555,"CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O_|_KPSRODZRAIWAKH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CIPROFIBRATE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Modalim']_|_['Ciprofibrate' 'NSC-759617' 'WIN 35833' 'WIN-35833']_|_[('PubChem', array(['144205674', '144208557', '144213157', '170466356', '26757866',
       '50105908', '56463556', '85230953', '90340632'], dtype=object)), ('Wikipedia', array(['Ciprofibrate'], dtype=object)), ('drugbank', array(['DB09064'], dtype=object)), ('chEBI', array(['50867'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and is indicated for cardiovascular disease."
CHEMBL641,"CNCC[C@@H](Oc1ccccc1C)c1ccccc1_|_VHGCDTVCOLNTBX-QGZVFWFLSA-N_|_Small molecule_|_True_|_ATOMOXETINE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Atomoxetine' 'Strattera']_|_[('PubChem', array(['11114266'], dtype=object)), ('Wikipedia', array(['Atomoxetine'], dtype=object)), ('drugbank', array(['DB00289'], dtype=object)), ('chEBI', array(['127342'], dtype=object))]_|_['CHEMBL1702']_|_{'rows': array(['EFO_1001917', 'HP_0010865', 'EFO_0004895', 'EFO_0003758',
       'MONDO_0007079', 'EFO_0003918', 'EFO_0003888', 'MONDO_0002491',
       'EFO_0003768', 'EFO_0005611', 'EFO_0004701', 'HP_0100543',
       'EFO_1000645', 'MONDO_0004992', 'EFO_0003918', 'EFO_0002610',
       'EFO_0005252', 'MONDO_0005147', 'MONDO_0005180', 'EFO_0004701',
       'EFO_0003888', 'MONDO_0004975', 'EFO_0003877', 'EFO_0007191',
       'MONDO_0005090'], dtype=object), 'count': 25}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for attention deficit hyperactivity disorder and has 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL677,"C[C@H](N)[C@H](O)c1ccc(O)c(O)c1_|_GEFQWZLICWMTKF-CDUCUWFYSA-N_|_Small molecule_|_False_|_LEVONORDEFRIN_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-cobefrin' 'BA 2818' 'BA-2818' 'Corbadrine'
 'L-.alpha.-methylnoradrenaline' 'L-nordefrin'
 'L-norephedrine, 3,4-dihydroxy-' 'Levonordefrin' 'NSC-757084'
 'Neo-Cobefrin' 'Nordefrin' 'Nordefrin (-)-form' 'Nordefrin, l-']_|_[('PubChem', array(['11111073', '11112447', '144205604', '170464794'], dtype=object)), ('Wikipedia', array(['Levonordefrin'], dtype=object)), ('drugbank', array(['DB06707'], dtype=object)), ('chEBI', array(['10304'], dtype=object))]_|_nan_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1096,"CC(C)c1ccc2oc3nc(N)c(C(=O)O)cc3c(=O)c2c1_|_SGRYPYWGNKJSDL-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMLEXANOX_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Amlexanox' 'Aphthasol']_|_['AA-673' 'Amlexanox' 'Amoxanox' 'Aphtheal' 'CHX 3673' 'CHX-3673' 'Elics'
 'Solfa']_|_[('PubChem', array(['124893315', '144206029', '170465365', '26719859', '50112726'],
      dtype=object)), ('Wikipedia', array(['Amlexanox'], dtype=object)), ('drugbank', array(['DB01025'], dtype=object)), ('chEBI', array(['31205'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001904', 'HP_0006536'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for airway obstruction and has 1 investigational indication."
CHEMBL1200382,"CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1.Cl.O_|_UEECHQPWQHYEDE-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEPRIDIL HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL1008_|_False_|_True_|_['Bepadin' 'Vascor']_|_['Bepridil hydrochloride' 'Bepridil hydrochloride hydrate' 'CERM 1978'
 'CERM-1978' 'Cordium' 'NSC-758390' 'Unicordium']_|_[('chEBI', array(['52715'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990."
CHEMBL1200670,"CC(=O)O.CNCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C)C(C)C.O_|_YBZYNINTWCLDQA-UHKVWXOHSA-N_|_Protein_|_False_|_SARALASIN ACETATE_|_1982.0_|_4.0_|_CHEMBL938_|_False_|_True_|_['Sarenin']_|_['P-113' 'Saralasin acetate' 'Saralasin hydrated acetate']_|_[('Wikipedia', array(['Saralasin'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144891]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201234,"CNC(C)(C)Cc1ccccc1_|_RXQCGGRTAILOIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPHENTERMINE_|_1951.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mephentermine']_|_[('PubChem', array(['11112475'], dtype=object)), ('Wikipedia', array(['Mephentermine'], dtype=object)), ('drugbank', array(['DB01365'], dtype=object)), ('chEBI', array(['6755'], dtype=object))]_|_['CHEMBL1200996' 'CHEMBL3184799']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for cardiovascular disease."
CHEMBL1230314,"C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O_|_AJIPIJNNOJSSQC-NYLIRDPKSA-N_|_Small molecule_|_False_|_ESTETROL_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['15.alpha.-hydroxyestriol' 'E-4' 'E4' 'Estetrol' 'Estetrol (anhydrous)'
 'Estetrol (e4)' 'Estetrol (hydrous)' 'Estetrol anhydrous'
 'Estetrol hydrate' 'Estetrol monohydrate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ESTETROL/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12235'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000673', 'EFO_0009520', 'GO_0042697', 'MONDO_0100096',
       'EFO_1001240', 'EFO_0003869', 'EFO_0002950', 'MONDO_0007254',
       'HP_0031217'], dtype=object), 'count': 9}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for pregnancy and has 8 investigational indications."
CHEMBL1700,"CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1.Cl_|_VIDRYROWYFWGSY-UHFFFAOYSA-N_|_Small molecule_|_True_|_SOTALOL HYDROCHLORIDE_|_1992.0_|_4.0_|_CHEMBL471_|_False_|_True_|_['Beta-cardone' 'Betapace' 'Betapace af' 'Sorine' 'Sotacor' 'Sotalex'
 'Sotalol hydrochloride' 'Sotylize']_|_['DL-MJ-1999' 'Darob' 'MJ 1999' 'MJ-1999' 'NSC-337251' 'NSC-760358'
 'Sotalol hcl' 'Sotalol hydrochloride']_|_[('DailyMed', array(['sotalol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204819', '26719708', '46500431', '50106953'], dtype=object)), ('chEBI', array(['9207'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004308', 'EFO_0003144', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000055118,ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for ventricular arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL192986,"CN(c1ccc(Cl)cc1)c1cc[n+](Cc2ccc(-c3ccc(C[n+]4ccc(N(C)c5ccc(Cl)cc5)c5ccccc54)cc3)cc2)c2ccccc12.[Br-].[Br-]_|_DGBVSSXGHKAASQ-UHFFFAOYSA-L_|_Small molecule_|_False_|_RSM-932A_|_nan_|_1.0_|_CHEMBL1181829_|_False_|_False_|_[]_|_['RSM 932A' 'Tcd-717']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000110721]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2105458,"CN1CCC(N(Cc2cccs2)c2ccccc2)CC1_|_KLOHYVOVXOUKQI-UHFFFAOYSA-N_|_Small molecule_|_False_|_THENALIDINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Thenaldine' 'Thenalidine' 'Thenophenopiperidine']_|_[('PubChem', array(['144206868'], dtype=object)), ('drugbank', array(['DB04826'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000989', 'MONDO_0005271'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pruritus and allergic disease. It was withdrawn in at least one region."
CHEMBL2108063,"nan_|_nan_|_Antibody_|_False_|_ZANOLIMUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Humax-cd4']_|_['HuMax-CD4' 'MDX-016' 'Zanolimumab']_|_nan_|_nan_|_{'rows': array(['EFO_1001051', 'EFO_0000574', 'EFO_0000685', 'EFO_1000785',
       'EFO_0002913'], dtype=object), 'count': 5}_|_[ENSG00000010610]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2108818,"nan_|_nan_|_Antibody_|_False_|_YTTRIUM Y 90 LABETUZUMAB_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['90Y-HMN-14' 'Labetuzumab 90y' 'S9S0Y-HMN-14' 'Yttrium y 90 labetuzumab'
 'Yttrium y-90 labetuzumab']_|_nan_|_nan_|_nan_|_[ENSG00000105388]_|_Antibody drug."
CHEMBL3990004,"nan_|_nan_|_Unknown_|_False_|_BIROPEPIMUT-S_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Biropepimut s' 'Biropepimut-s' 'GL-0817'
 'MAGE-A3 Trojan Peptide Vaccine']_|_nan_|_nan_|_{'rows': array(['EFO_0000199'], dtype=object), 'count': 1}_|_[ENSG00000221867]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297492,"CCC[C@H](C)Oc1nc(N)c2[nH]c(=O)n(CCCCCN3CCCCC3)c2n1_|_LFMPVTVPXHNXOT-HNNXBMFYSA-N_|_Small molecule_|_False_|_GSK-2245035_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-2245035' 'GSK2245035' 'Gsk-2245035' 'Gsk2245035']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000196664]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297688,"nan_|_nan_|_Unknown_|_False_|_ADU-S100_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADU-S100' 'Adu s100' 'Adu-s100' 'CDN AGONIST ADU-S100' 'MIW815' 'MW-815'
 'Miw815']_|_nan_|_nan_|_{'rows': array(['EFO_0006859', 'EFO_0000574'], dtype=object), 'count': 2}_|_[ENSG00000184584]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297968,"nan_|_nan_|_Unknown_|_False_|_GSK-3174998_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-3174998' 'GSK3174998' 'Gsk 3174998' 'Gsk-3174998' 'Gsk3174998']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000186827]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594253,"Cn1cc(-c2nc(N[C@@H]3CCCC[C@@H]3N)c(F)c3c2C(=O)NC3)cn1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_ZVPYVZMKBQYKQG-ZVWHLABXSA-N_|_Small molecule_|_False_|_MIVAVOTINIB CITRATE_|_nan_|_2.0_|_CHEMBL3979920_|_False_|_False_|_[]_|_['Mivavotinib citrate' 'TAK-659' 'Tak 659' 'Tak-659']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MIVAVOTINIB%20CITRATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002334', 'EFO_0000616', 'EFO_0000222', 'EFO_0005952',
       'EFO_0000574', 'EFO_0000403', 'MONDO_0018906'], dtype=object), 'count': 7}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4594546,"nan_|_nan_|_Antibody_|_False_|_TELAZORLIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GBR 830' 'GBR-830' 'GBR830' 'Gbr 830' 'ISB 830' 'ISB-830' 'Telazorlimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000274'], dtype=object), 'count': 1}_|_[ENSG00000186827]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL503,"CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21_|_PCZOHLXUXFIOCF-BXMDZJJMSA-N_|_Small molecule_|_False_|_LOVASTATIN_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Altoprev' 'Lovastatin' 'Mevacor' 'Mevinacor' 'Mevinacor 10'
 'Mevinacor 40']_|_['6.alpha.-methylcompactin' 'C10AA02' 'L-154803' 'Lovastatin' 'MK-803'
 'Mevinolin' 'Mevlor' 'Monacolin k' 'NSC-758662'
 'Simvastatin impurity, lovastatin-' 'Sivlor']_|_[('DailyMed', array(['lovastatin'], dtype=object)), ('PubChem', array(['144204439', '144208673', '144210588', '170464913', '17389841',
       '26751557', '496591', '49732779', '855905'], dtype=object)), ('Wikipedia', array(['Lovastatin'], dtype=object)), ('drugbank', array(['DB00227'], dtype=object)), ('chEBI', array(['40303'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0021661', 'MONDO_0010726', 'MONDO_0004979', 'EFO_0003777',
       'EFO_0000319', 'EFO_1001375', 'EFO_0003914', 'EFO_1000757',
       'EFO_0000764', 'MONDO_0010383', 'EFO_0000222', 'Orphanet_309005',
       'Orphanet_46724', 'EFO_0000589', 'EFO_0001645', 'EFO_0004705',
       'MONDO_0008170', 'MONDO_0008315', 'MONDO_0004681', 'MP_0001845',
       'MONDO_0005180', 'EFO_1000860', 'HP_0100543', 'EFO_0000756',
       'MONDO_0018975', 'MONDO_0008948', 'EFO_0000712', 'EFO_0002615',
       'EFO_0000341', 'HP_0003124', 'EFO_0000685', 'EFO_0003876',
       'MONDO_0007254'], dtype=object), 'count': 33}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 6 approved and 27 investigational indications."
CHEMBL551064,Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1_|_USVCWSAJUAARAL-MEMLXQNLSA-N_|_Small molecule_|_False_|_AEW-541_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AEW 541' 'Aew-541' 'NVP-AEW 541' 'NVP-AEW541']_|_nan_|_nan_|_nan_|_[ENSG00000140443]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL620,"C[N+]12CCC(CC1)C(OC(=O)C(O)(c1ccccc1)c1ccccc1)C2_|_HOOSGZJRQIVJSZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLIDINIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Clidinium' 'Clidinium cation' 'Clidinium ion']_|_nan_|_['CHEMBL1200950']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for gastrointestinal disease."
CHEMBL88712,"O=C(O)[C@@H](c1ccc(OCc2ccc3ccccc3n2)cc1)C1CCCC1_|_ZEYYDOLCHFETHQ-JOCHJYFZSA-N_|_Small molecule_|_False_|_VELIFLAPON_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BAY X 1005' 'BAY X-1005' 'BAY-X-005' 'BAY-X-1005' 'DG-031' 'Veliflapon']_|_nan_|_nan_|_{'rows': array(['EFO_0005672'], dtype=object), 'count': 1}_|_[ENSG00000132965]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL908,"CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21_|_WSPOMRSOLSGNFJ-AUWJEWJLSA-N_|_Small molecule_|_False_|_CHLORPROTHIXENE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Taractan' 'Truxal']_|_['Chlorprothixene' 'N-714' 'N-714RO 4-0403' 'NSC-18720' 'RO 4-0403'
 'RO-4-0403' 'RO-40403']_|_[('PubChem', array(['26665646', '29217891'], dtype=object)), ('Wikipedia', array(['Chlorprothixene'], dtype=object)), ('drugbank', array(['DB01239'], dtype=object)), ('chEBI', array(['50931'], dtype=object))]_|_['CHEMBL1256658']_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0005407', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for psychosis and has 4 investigational indications."
CHEMBL96172,"C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC1_|_XOZIUKBZLSUILX-GIQCAXHBSA-N_|_Small molecule_|_False_|_EPOTHILONE D_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-desoxyepothilone b' '12,13-desoxyepothilone b'
 '12,13-desoxyepothilone b, cis' 'Desoxyepothilone b' 'Epothilone d'
 'KOS-862' 'NSC-703147' 'R-1492' 'R1492']_|_[('PubChem', array(['527930'], dtype=object)), ('drugbank', array(['DB01873'], dtype=object)), ('chEBI', array(['29579'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1001951', 'MONDO_0008903', 'MONDO_0008315',
       'MONDO_0007254'], dtype=object), 'count': 5}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1200794,"CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl_|_BCGJBQBWUGVESK-KCTCKCTRSA-N_|_Small molecule_|_True_|_OXYMORPHONE HYDROCHLORIDE_|_1959.0_|_4.0_|_CHEMBL963_|_False_|_True_|_['Numorphan' 'Opana' 'Opana er' 'Oxymorphone hydrochloride']_|_['Oxymorphone hcl' 'Oxymorphone hydrochloride']_|_[('DailyMed', array(['oxymorphone%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0012532'], dtype=object), 'count': 2}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for pain and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200933,"C[N+](C)(CCCCCC[N+](C)(C)C1c2ccccc2-c2ccccc21)C1c2ccccc2-c2ccccc21.[Br-].[Br-]_|_WDEFPRUEZRUYNW-UHFFFAOYSA-L_|_Small molecule_|_False_|_HEXAFLUORENIUM BROMIDE_|_1982.0_|_4.0_|_CHEMBL1201349_|_False_|_True_|_['Mylaxen']_|_['Hexafluorenium bromide' 'Hexaflurone bromide' 'Hexafluronium bromide'
 'NSC-19477']_|_[('PubChem', array(['144206765'], dtype=object))]_|_nan_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200974,"CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_GVNWHCVWDRNXAZ-BTJKTKAUSA-N_|_Small molecule_|_False_|_CARBINOXAMINE MALEATE_|_2003.0_|_4.0_|_CHEMBL864_|_False_|_True_|_['Carbinoxamine maleate' 'Clistin' 'Davenol' 'Karbinal er']_|_['Carbinoxamine maleate' 'NSC-62362']_|_[('DailyMed', array(['carbinoxamine%20maleate'], dtype=object)), ('PubChem', array(['144205889', '170465237', '26749308', '93576626'], dtype=object)), ('chEBI', array(['31353'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007533', 'EFO_1001417', 'EFO_0003956', 'EFO_0005532',
       'EFO_0007141', 'EFO_0005531'], dtype=object), 'count': 6}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved indications."
CHEMBL1201047,"CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.Cl_|_UDUQHZSAAWGSPJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANILERIDINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201347_|_False_|_True_|_['Leritine']_|_['Aldine' 'Anileridine dihydrochloride' 'Anileridine hcl'
 'Anileridine hydrochloride' 'Anileridine hydrochloride cii' 'Apodol'
 'Leritine dihydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000082556,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201558,"nan_|_nan_|_Protein_|_True_|_INTERFERON ALFA-2B_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Intron a' 'Intron-A' 'Introna' 'Viraferon']_|_['Interferon alfa-2b' 'SCH 30500' 'SCH-30500']_|_[('DailyMed', array(['interferon%20alfa-2b'], dtype=object)), ('DrugCentral', array(['5205'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/introna'],
      dtype=object)), ('Wikipedia', array(['Interferon_alfa-2b'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000182', 'EFO_1000956', 'EFO_0001668',
       'MONDO_0024503', 'EFO_0000616', 'EFO_1000131', 'EFO_0000756',
       'MONDO_0100096', 'EFO_0000339', 'EFO_0000673', 'EFO_0000764',
       'EFO_0000681', 'EFO_0009708', 'EFO_0000349', 'EFO_0001378',
       'MONDO_0044881', 'MONDO_0004992', 'MONDO_0008315', 'EFO_0002618',
       'MONDO_0019471', 'EFO_0007147', 'MONDO_0002367', 'EFO_0004220',
       'EFO_0004197', 'EFO_0004243', 'EFO_0001422', 'EFO_0003047',
       'MONDO_0018906', 'EFO_0003869', 'EFO_0000389', 'EFO_0000565',
       'EFO_0004239', 'MONDO_0007254', 'MONDO_0002691', 'MONDO_0004658',
       'EFO_0000558'], dtype=object), 'count': 37}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 16 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL14,"C[N+](C)(C)CCOC(N)=O.[Cl-]_|_AIXAANGOTKPUOY-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARBACHOL_|_1972.0_|_4.0_|_CHEMBL965_|_False_|_True_|_['Carbachol' 'Carbastat' 'Doryl' 'Miostat']_|_['Carbachol' 'Carbachol chloride' 'Carbacholine Chloride'
 'Carbacholine chloride' 'Carbamoylcholine chloride' 'NSC-32865']_|_[('DailyMed', array(['carbachol'], dtype=object)), ('PubChem', array(['144205582', '170464972', '26747465', '50105987', '56463323'],
      dtype=object)), ('Wikipedia', array(['Carbachol'], dtype=object)), ('chEBI', array(['3385'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005129', 'HP_0000616', 'MONDO_0001330', 'MONDO_0005041'],
      dtype=object), 'count': 4}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 3 approved and 1 investigational indication."
CHEMBL1421,"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1_|_ZBNZXTGUTAYRHI-UHFFFAOYSA-N_|_Small molecule_|_False_|_DASATINIB_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Dasatinib' 'Dasatinib accordpharma' 'Sprycel']_|_['BMS-354825' 'BMS-354825 HYDRATE' 'BMS-354825-03' 'Dasatinib'
 'Dasatinib hydrate' 'Dasatinib monohydrate' 'NSC-759877']_|_[('DailyMed', array(['dasatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accordpharma'],
      dtype=object)), ('PubChem', array(['103905543', '124893650', '124893651', '124893652', '144206289',
       '164339436', '170465390', '50100097', '50125840'], dtype=object)), ('Wikipedia', array(['Dasatinib'], dtype=object)), ('drugbank', array(['DB01254'], dtype=object)), ('chEBI', array(['49375'], dtype=object))]_|_['CHEMBL5314601']_|_{'rows': array(['EFO_0000768', 'EFO_0000616', 'EFO_1000956', 'EFO_0000255',
       'EFO_0003884', 'MONDO_0019469', 'MONDO_0011719', 'EFO_0000191',
       'EFO_0000588', 'MONDO_0019472', 'EFO_1001469', 'EFO_0002429',
       'EFO_1000475', 'MONDO_0004975', 'MONDO_0018906', 'EFO_0000770',
       'EFO_1001951', 'EFO_0000702', 'MONDO_0000870', 'EFO_0000095',
       'MONDO_0002087', 'EFO_0006859', 'MONDO_0004992', 'EFO_0005774',
       'EFO_0000708', 'MONDO_0000873', 'EFO_1000131', 'MONDO_0100096',
       'MONDO_0008903', 'EFO_0000309', 'EFO_1001465', 'EFO_0002617',
       'MONDO_0016586', 'EFO_0000183', 'EFO_0003869', 'EFO_0000220',
       'EFO_0000621', 'MONDO_0004643', 'MONDO_0021063', 'EFO_1000026',
       'EFO_0000565', 'EFO_0002618', 'MONDO_0011962', 'EFO_0000764',
       'EFO_0000339', 'EFO_0000707', 'EFO_0000181', 'EFO_0001073',
       'EFO_0000673', 'EFO_0002918', 'EFO_0000196', 'EFO_0003032',
       'EFO_0000180', 'EFO_1001993', 'EFO_0000389', 'EFO_0001378',
       'EFO_0000182', 'EFO_0000403', 'EFO_1000158', 'MONDO_0008315',
       'EFO_0009441', 'EFO_0000756', 'EFO_0000574', 'EFO_0004289',
       'MONDO_0100342', 'EFO_0000211', 'EFO_1001051', 'EFO_0000198',
       'EFO_0003833', 'EFO_0005952', 'EFO_1000657', 'EFO_0003060',
       'EFO_0000222', 'EFO_1000654', 'MONDO_0008170', 'EFO_1000785',
       'EFO_0000305', 'MONDO_0019471', 'EFO_0004289', 'EFO_0000519',
       'MONDO_0003175', 'EFO_0005221', 'EFO_0000616', 'MONDO_0007254',
       'MONDO_0002158'], dtype=object), 'count': 85}_|_[ENSG00000142627,ENSG00000113721,ENSG00000157404,ENSG00000097007,ENSG00000186716,ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 9 approved and 76 investigational indications."
CHEMBL1503,"COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1_|_SUBDBMMJDZJVOS-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMEPRAZOLE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Antra' 'Losec' 'Losec mups' 'Mezzopram' 'Mopral' 'Omeprazole' 'Omeran'
 'Prilosec' 'Zanprol']_|_['H 168/68' 'H-168/68' 'NSC-751450' 'NSC-759192' 'Omeprazole']_|_[('DailyMed', array(['omeprazole'], dtype=object)), ('PubChem', array(['104171331', '11112840', '124882676', '124882677', '144204237',
       '144207707', '170465443', '174007234', '26751452', '26751453',
       '50103932', '56422106', '855576'], dtype=object)), ('TG-GATEs', array(['12'], dtype=object)), ('Wikipedia', array(['Omeprazole'], dtype=object)), ('drugbank', array(['DB00338'], dtype=object)), ('chEBI', array(['77260'], dtype=object))]_|_['CHEMBL2105294' 'CHEMBL1567328']_|_{'rows': array(['MONDO_0001056', 'MONDO_0015277', 'EFO_0000191', 'EFO_1001095',
       'EFO_0003948', 'HP_0001601', 'EFO_0005741', 'MONDO_0004247',
       'EFO_0000676', 'MONDO_0009061', 'EFO_0003929', 'MONDO_0007254',
       'EFO_0003843', 'EFO_0000280', 'EFO_0000217', 'MONDO_0043839',
       'EFO_0009130', 'EFO_1001951', 'EFO_0003756', 'EFO_0004272',
       'EFO_0002617', 'EFO_0008533', 'EFO_0009784', 'EFO_0000768',
       'EFO_0000181', 'EFO_0004607', 'EFO_0000616', 'EFO_0007231',
       'MONDO_0024475', 'MP_0001914', 'EFO_0003100', 'HP_0002239',
       'EFO_0000274', 'MONDO_0004975', 'EFO_0000199', 'EFO_0000546',
       'EFO_1000961', 'EFO_0004239', 'EFO_0008525', 'EFO_0000685',
       'EFO_0007549', 'EFO_0003948', 'HP_0012735', 'MONDO_0005041',
       'EFO_0000729', 'HP_0002239', 'MONDO_0001684', 'HP_0004398',
       'EFO_0000764', 'EFO_0003898', 'EFO_0000341', 'EFO_0006859',
       'HP_0100633', 'MONDO_0008315', 'EFO_0000384', 'EFO_0000180',
       'EFO_0000574', 'EFO_0009454', 'EFO_0000673', 'EFO_0000756',
       'MONDO_0044970', 'EFO_0004234', 'MONDO_0003523', 'EFO_0000305',
       'EFO_0000400', 'EFO_0002618', 'EFO_0004220', 'MONDO_0005148',
       'HP_0032252', 'MONDO_0005178', 'EFO_0000544', 'HP_0012532',
       'EFO_0003047', 'MONDO_0005147', 'MONDO_0004992'], dtype=object), 'count': 75}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 7 approved and 67 investigational indications."
CHEMBL1592,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O_|_JSDRRTOADPPCHY-HSQYWUDLSA-N_|_Small molecule_|_True_|_QUINAPRIL_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['C09AA06' 'CI-906' 'Quinapril']_|_[('Wikipedia', array(['Quinapril'], dtype=object)), ('drugbank', array(['DB00881'], dtype=object)), ('chEBI', array(['8713'], dtype=object))]_|_['CHEMBL1201011']_|_{'rows': array(['EFO_0000319', 'MONDO_0005147', 'EFO_0000537', 'EFO_1002048',
       'EFO_0000712', 'EFO_0003144', 'EFO_0000400'], dtype=object), 'count': 7}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1699,"CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl_|_LDDHMLJTFXJGPI-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEMANTINE HYDROCHLORIDE_|_2003.0_|_4.0_|_CHEMBL807_|_False_|_True_|_['Akatinol' 'Ebixa' 'Marixino' 'Memantine' 'Memantine hydrochloride'
 'Memantine merz' 'Memantine mylan' 'Namenda' 'Namenda xr' 'Nemdatine'
 'Valios']_|_['Acrescent' 'Auxura' 'Balaxur' 'FP-01' 'Memantine accord' 'Memantine hcl'
 'Memantine hydrochloride' 'Memantine lek' 'Memantine merz'
 'Memantine mylan' 'Memantine ratiopharm' 'Memary' 'NSC-102290'
 'SUN-Y7017']_|_[('DailyMed', array(['memantine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-merz',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/memantine-mylan'],
      dtype=object)), ('PubChem', array(['26747595', '50106707', '50106708', '57260151'], dtype=object)), ('chEBI', array(['64323'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004699', 'EFO_0000326', 'EFO_1001801', 'MONDO_0004681',
       'MONDO_0004975', 'EFO_0003758', 'HP_0000726', 'MONDO_0004976',
       'EFO_0007328', 'MONDO_0017276', 'EFO_0003757', 'EFO_1001465',
       'EFO_0003833', 'MONDO_0011382'], dtype=object), 'count': 14}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for alzheimer disease and dementia and has 12 investigational indications."
CHEMBL1742992,"nan_|_nan_|_Antibody_|_True_|_BLINATUMOMAB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Blincyto']_|_['Blinatumomab' 'Blincyto' 'MEDI-538' 'MT-103']_|_[('DailyMed', array(['blinatumomab'], dtype=object)), ('DrugCentral', array(['4915'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0004289', 'EFO_0000565', 'EFO_0005952',
       'EFO_0001642', 'EFO_0000616', 'EFO_0004289', 'EFO_0000574',
       'EFO_0000403', 'EFO_0000094', 'EFO_0001378', 'MONDO_0000873',
       'EFO_0000220', 'EFO_0000209', 'EFO_0000309'], dtype=object), 'count': 15}_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000177455]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2104992,"CS(=O)(=O)O.Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_BHECXGHXWKHZOY-DXPOFMJKSA-N_|_Small molecule_|_False_|_VESTIPITANT MESYLATE_|_nan_|_2.0_|_CHEMBL522987_|_False_|_False_|_[]_|_['GW-597588B' 'GW-597599B' 'GW597588B' 'GW597599B' 'Vestipitant mesilate'
 'Vestipitant mesylate']_|_nan_|_nan_|_nan_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2108313,"nan_|_nan_|_Protein_|_False_|_CONBERCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Conbercept' 'KH-902']_|_nan_|_nan_|_{'rows': array(['EFO_0004683', 'MONDO_0008380', 'EFO_0001365', 'EFO_1001157',
       'EFO_1000880', 'EFO_0004207'], dtype=object), 'count': 6}_|_[ENSG00000119630,ENSG00000112715,ENSG00000173511,ENSG00000150630]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2109058,"nan_|_nan_|_Oligonucleotide_|_False_|_EDIFOLIGIDE SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CG-T003' 'CGT-003' 'CGT003' 'E2f duplex decoy'
 'E2f duplex decoy (trivial name)' 'Edifoligide sodium']_|_nan_|_nan_|_{'rows': array(['EFO_0001645'], dtype=object), 'count': 1}_|_[ENSG00000101412,ENSG00000007968,ENSG00000112242,ENSG00000205250,ENSG00000133740,ENSG00000169016,ENSG00000165891,ENSG00000129173]_|_Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL225072,"Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1_|_WBXPDJSOTKVWSJ-ZDUSSCGKSA-N_|_Small molecule_|_False_|_PEMETREXED_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Alimta' 'Pemfexy']_|_['LY-2315' 'LY-231514' 'LY231514' 'NSC-698037' 'Pemetrexed']_|_[('PubChem', array(['124893263', '124950689', '525786'], dtype=object)), ('Wikipedia', array(['Pemetrexed'], dtype=object)), ('drugbank', array(['DB00642'], dtype=object)), ('chEBI', array(['63616'], dtype=object))]_|_['CHEMBL2360464' 'CHEMBL5315053' 'CHEMBL3989962']_|_{'rows': array(['MONDO_0011962', 'MONDO_0007254', 'EFO_1001901', 'EFO_0000574',
       'EFO_0001075', 'EFO_0006859', 'EFO_1001951', 'MONDO_0001187',
       'EFO_1001951', 'EFO_0003863', 'MONDO_0002158', 'EFO_0000365',
       'EFO_0008528', 'MONDO_0008315', 'EFO_0002617', 'EFO_0006859',
       'EFO_0002618', 'EFO_0000708', 'MONDO_0021117', 'MONDO_0004192',
       'MONDO_0001056', 'EFO_0003060', 'EFO_0000708', 'EFO_0003897',
       'MONDO_0002586', 'MONDO_0007576', 'MONDO_0000521', 'EFO_0003060',
       'MONDO_0002087', 'MONDO_0008315', 'MONDO_0001187', 'EFO_0000707',
       'MONDO_0008170', 'EFO_0005952', 'MONDO_0021117', 'EFO_0002618',
       'MONDO_0008170', 'MONDO_0001056', 'EFO_0009708', 'EFO_1000576',
       'MONDO_0002974', 'EFO_0000588', 'EFO_0000588', 'EFO_1000251',
       'EFO_0000616', 'EFO_0003863', 'EFO_0002916', 'EFO_0000228',
       'MONDO_0011962', 'EFO_0000637', 'EFO_0003050', 'MONDO_0002691',
       'MONDO_0100342', 'EFO_0000308', 'EFO_0000681', 'EFO_0005537',
       'EFO_0000228', 'MONDO_0008978', 'MONDO_0008903', 'EFO_1000657',
       'EFO_0000691', 'EFO_0000571', 'EFO_0003050', 'EFO_0008528',
       'EFO_1001012', 'EFO_0000313', 'MONDO_0008903', 'EFO_0005567',
       'EFO_0004252', 'EFO_0000403', 'EFO_1000581', 'EFO_0000574',
       'EFO_0000389', 'MONDO_0004992', 'EFO_0000702', 'MONDO_0044903',
       'MONDO_0002158', 'MONDO_0004992', 'MONDO_0018944', 'EFO_0003860',
       'EFO_0004142', 'MONDO_0007254', 'EFO_0000178', 'MONDO_0002108',
       'EFO_0003869', 'MONDO_0002087', 'EFO_0006861', 'EFO_0002939',
       'EFO_0000691', 'EFO_0000181', 'MONDO_0002974', 'EFO_0009708',
       'EFO_0000588', 'EFO_0003050', 'EFO_0000770', 'EFO_0004284',
       'EFO_0003060', 'MONDO_0003060', 'EFO_0001416', 'EFO_0000571',
       'EFO_0000770', 'EFO_1000581', 'EFO_0000616'], dtype=object), 'count': 103}_|_[ENSG00000159131,ENSG00000176890,ENSG00000228716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 8 approved and 82 investigational indications."
CHEMBL2408045,"CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1_|_DFJSJLGUIXFDJP-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAPITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-8931' 'AZD8931' 'Azd-8931' 'Sapitinib']_|_[('PubChem', array(['174006599'], dtype=object)), ('drugbank', array(['DB12183'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000365', 'MONDO_0007254', 'EFO_0003869',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000141736,ENSG00000065361,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3545248,"nan_|_nan_|_Small molecule_|_False_|_DS-7423_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ds-7423']_|_nan_|_nan_|_{'rows': array(['MONDO_0011962', 'EFO_1001951'], dtype=object), 'count': 2}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3707224,"CCOC(=O)C[N+]1(C)CC[C@@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1_|_SEVCTUCCZYBJER-BSJAROSPSA-N_|_Small molecule_|_False_|_SOFPIRONIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bbi-4000 ion' 'Sofpironium cation']_|_nan_|_['CHEMBL3707223']_|_{'rows': array(['HP_0000975'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3707347,"CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O_|_YYBOLPLTQDKXPM-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERINURAD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RDEA-3170' 'RDEA3170' 'Verinurad']_|_[('drugbank', array(['DB11873'], dtype=object))]_|_['CHEMBL5170470']_|_{'rows': array(['EFO_0003884', 'EFO_0003144', 'EFO_0004274', 'EFO_0009104'],
      dtype=object), 'count': 4}_|_[ENSG00000197891]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4088896,"C[C@H](CN1CCOCC1)n1/c(=N\C(N)=O)[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc21_|_YPCLDHGBEKZGEB-RUDKWAFVSA-N_|_Small molecule_|_False_|_LY2623091_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ly-2623091' 'Ly2623091']_|_[('drugbank', array(['DB15367'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'MONDO_0001134'], dtype=object), 'count': 2}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594456,"nan_|_nan_|_Antibody_|_False_|_CADONILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AK-104' 'AK104' 'Ak-104' 'Ak104' 'Cadonilimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CADONILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000519', 'EFO_0001061', 'MONDO_0001056',
       'MONDO_0002974', 'MONDO_0004992', 'EFO_1001968', 'EFO_0004252',
       'EFO_0001416', 'EFO_1001951', 'EFO_0002618', 'EFO_0000681',
       'EFO_0000349', 'EFO_0000616', 'EFO_0003060', 'MONDO_0003060',
       'EFO_0000211', 'MONDO_0044937', 'MONDO_0008903', 'EFO_0005922',
       'EFO_0000756', 'EFO_0000182', 'EFO_1001961', 'EFO_1000657'],
      dtype=object), 'count': 24}_|_[ENSG00000163599,ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications."
CHEMBL843,"CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_SUFUKZSWUHZXAV-BTJKTKAUSA-N_|_Small molecule_|_True_|_ROSIGLITAZONE MALEATE_|_1999.0_|_4.0_|_CHEMBL121_|_True_|_True_|_['Avandia' 'Rosiglitazone maleate']_|_['Avandia' 'BRL-49653' 'BRL-49653-C' 'BRL-49653C' 'NSC-717764'
 'Rosiglitazone maleate' 'Rosiglitzazone maleate']_|_[('DailyMed', array(['rosiglitazone%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/avandia'],
      dtype=object)), ('PubChem', array(['144212684', '49681563'], dtype=object)), ('chEBI', array(['8892'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002745', 'EFO_0000691', 'EFO_0003914', 'EFO_0000400',
       'MONDO_0005148', 'EFO_1000158', 'EFO_0000764', 'EFO_1001110',
       'EFO_0006859', 'EFO_0002614', 'EFO_0000373', 'EFO_1001249'],
      dtype=object), 'count': 12}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 10 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1165,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O_|_UWWDHYUMIORJTA-HSQYWUDLSA-N_|_Small molecule_|_True_|_MOEXIPRIL_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Moexipril' 'RS-10085' 'Uniretic' 'Univasc']_|_[('Wikipedia', array(['Moexipril'], dtype=object)), ('drugbank', array(['DB00691'], dtype=object)), ('chEBI', array(['6960'], dtype=object))]_|_['CHEMBL1200534']_|_{'rows': array(['EFO_0000319', 'EFO_1001486', 'EFO_0000537'], dtype=object), 'count': 3}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for cardiovascular disease and hypertension and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201255,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1cn(Cc2ccccc2)cn1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1_|_HHXHVIJIIXKSOE-QILQGKCVSA-N_|_Protein_|_False_|_HISTRELIN_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Histrelin' 'ORF 17070' 'ORF 17070RWJ 17070' 'ORF-17070' 'RWJ 17070'
 'RWJ-17070']_|_[('Wikipedia', array(['Histrelin'], dtype=object)), ('chEBI', array(['5739'], dtype=object))]_|_['CHEMBL1200509']_|_{'rows': array(['EFO_0000196', 'MONDO_0008315', 'EFO_0000616', 'EFO_0009029',
       'EFO_0000673', 'EFO_0000673'], dtype=object), 'count': 6}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved and 3 investigational indications."
CHEMBL1237135,"CNCCCC12CCC(c3ccccc31)c1ccccc12.Cl_|_NZDMFGKECODQRY-UHFFFAOYSA-N_|_Small molecule_|_True_|_MAPROTILINE HYDROCHLORIDE_|_1980.0_|_4.0_|_CHEMBL21731_|_False_|_True_|_['Ludiomil' 'Maprotiline hydrochloride']_|_['BA-34,276' 'BA-34276' 'Maprotiline hcl' 'Maprotiline hydrochloride'
 'NSC-757085']_|_[('PubChem', array(['144211309', '14743087', '152146163', '26719700', '26747580',
       '26747581', '50106647', '50106648', '56422491', '855591'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL1242,"Nc1ccc(/N=N/c2ccccc2)c(N)n1_|_QPFYXYFORQJZEC-FOCLMDBBSA-N_|_Small molecule_|_False_|_PHENAZOPYRIDINE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-145895' 'Phenazopyridine']_|_[('PubChem', array(['104171363'], dtype=object)), ('Wikipedia', array(['Phenazopyridine'], dtype=object)), ('drugbank', array(['DB01438'], dtype=object))]_|_['CHEMBL1201022']_|_{'rows': array(['EFO_0003103', 'HP_0000016', 'EFO_0003843', 'EFO_0003901'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 investigational indications."
CHEMBL1278,"CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1_|_AMKVXSZCKVJAGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_NARATRIPTAN_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Amerge' 'Naratriptan']_|_['Amerge' 'Naratriptan']_|_[('Wikipedia', array(['Naratriptan'], dtype=object)), ('drugbank', array(['DB00952'], dtype=object)), ('chEBI', array(['7478'], dtype=object))]_|_['CHEMBL1200601']_|_{'rows': array(['MONDO_0005277', 'HP_0002315', 'MONDO_0005277'], dtype=object), 'count': 3}_|_[ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication."
CHEMBL1516,"CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1_|_VTRAEEWXHOVJFV-UHFFFAOYSA-N_|_Small molecule_|_False_|_OLMESARTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['NSC-759810' 'Olmesartan' 'Olmesartan medoxomil impurity, olmesartan-'
 'RNH-6270']_|_[('PubChem', array(['174007156', '26719844'], dtype=object)), ('Wikipedia', array(['Olmesartan'], dtype=object)), ('drugbank', array(['DB00275'], dtype=object)), ('chEBI', array(['48416'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'MONDO_0001134', 'EFO_0000537', 'MONDO_0100096',
       'EFO_0000694', 'EFO_0000712'], dtype=object), 'count': 6}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1742471,NC(N)=Nc1nc(CSCCN/C=N/S(=O)(=O)c2ccc(Br)cc2)cs1_|_ZQHFZHPUZXNPMF-UHFFFAOYSA-N_|_Small molecule_|_False_|_EBROTIDINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Ebrotidine']_|_nan_|_nan_|_nan_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.
CHEMBL1742986,"nan_|_nan_|_Protein_|_False_|_ATACICEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Atacicept' 'TACI-FC5' 'TACI-IG']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915', 'EFO_0005761', 'EFO_0004194', 'EFO_0007405',
       'EFO_0000685', 'MONDO_0005301'], dtype=object), 'count': 6}_|_[ENSG00000102524,ENSG00000161955]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1783256,"CCCNC(=O)c1nnc2c(-c3cc(OC)ccc3OC)cccc2c1N_|_NVWCZRPXYVDQEE-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD6280_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZD6280' 'Azd-6280' 'Azd6280']_|_[('drugbank', array(['DB12210'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}_|_[ENSG00000011677,ENSG00000151834]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1909286,"CC(COc1ccccc1)NN_|_QNEXFJFTGQBXBJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENOXYPROPAZINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Fenoxypropazine' 'Phenoxypropazine']_|_[('PubChem', array(['144206870'], dtype=object)), ('Wikipedia', array(['Phenoxypropazine'], dtype=object)), ('drugbank', array(['DB09251'], dtype=object))]_|_['CHEMBL4303424']_|_nan_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL2109412,"nan_|_nan_|_Antibody_|_False_|_L19SIP 131I_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['L19SIP' 'L19sip 131i']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000115414]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109433,"nan_|_nan_|_Antibody_|_False_|_OTILIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GSK-3196165' 'GSK3196165' 'MOR-103' 'MOR103' 'Otilimab']_|_nan_|_nan_|_{'rows': array(['EFO_0000694', 'MONDO_0005178', 'EFO_0000685', 'MONDO_0005301'],
      dtype=object), 'count': 4}_|_[ENSG00000164400]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2109635,"nan_|_nan_|_Antibody drug conjugate_|_False_|_SAR-566658_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SAR-566658' 'SAR566658' 'Sar 566658' 'Sar-566658' 'huDS6-DM4']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000185499]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2204263,"O=C(CNC(=O)c1cccc(C(F)(F)F)c1)NC1CN([C@H]2CC[C@@](O)(c3cncs3)CC2)C1_|_CFKBNYUHQSQBSX-CYWCHRQTSA-N_|_Small molecule_|_False_|_JNJ-41443532_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Jnj-41443532']_|_[('drugbank', array(['DB12632'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL267431,"COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C_|_GJMNAFGEUJBOCE-MEQIQULJSA-N_|_Small molecule_|_False_|_ASOPRISNIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Asoprisnil' 'BAY86-5294' 'J-867' 'J867']_|_[('Wikipedia', array(['Asoprisnil'], dtype=object)), ('drugbank', array(['DB06680'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001572', 'HP_0000132', 'GO_0042697', 'EFO_0000731',
       'EFO_0001065', 'HP_0100608'], dtype=object), 'count': 6}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3039543,"nan_|_nan_|_Antibody_|_False_|_ULOCUPLUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-936564' 'MDX-1338' 'Ulocuplumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0018906', 'EFO_0000222', 'EFO_0000565', 'EFO_0009441',
       'EFO_0000616', 'EFO_0001378', 'EFO_0000095'], dtype=object), 'count': 7}_|_[ENSG00000121966]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL3544983,"COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1_|_HVXKQKFEHMGHSL-QKDCVEJESA-N_|_Small molecule_|_False_|_TESEVATINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['EXEL-7647' 'KD-019' 'KD-020' 'KD019' 'Tesevatinib' 'XL647' 'Xl-647']_|_[('drugbank', array(['DB11973'], dtype=object))]_|_['CHEMBL3544982']_|_{'rows': array(['MONDO_0007254', 'MONDO_0009889', 'EFO_0003060', 'EFO_0000519',
       'EFO_1001496', 'EFO_0003833', 'MONDO_0004992'], dtype=object), 'count': 7}_|_[ENSG00000141736,ENSG00000146648,ENSG00000196411]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL3622821,"CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12_|_WYQFJHHDOKWSHR-MNOVXSKESA-N_|_Small molecule_|_True_|_UPADACITINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ABT-494' 'Upadacitinib' 'Upadacitinib anhydrous']_|_[('DailyMed', array(['upadacitinib'], dtype=object)), ('drugbank', array(['DB15091'], dtype=object))]_|_['CHEMBL3707269' 'CHEMBL5315119']_|_{'rows': array(['EFO_0000274', 'EFO_0003778', 'EFO_0000540', 'EFO_0000384',
       'EFO_1000710', 'EFO_0002609', 'EFO_0000685', 'EFO_1001209',
       'EFO_0000729', 'EFO_0004208', 'EFO_0000685', 'MONDO_0007915',
       'EFO_0003898'], dtype=object), 'count': 13}_|_[ENSG00000105397,ENSG00000105639,ENSG00000096968,ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for rheumatoid arthritis and has 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297216,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O_|_QAFZLTVOFJHYDF-UHFFFAOYSA-N_|_Small molecule_|_True_|_FEDRATINIB HYDROCHLORIDE_|_2019.0_|_4.0_|_CHEMBL1287853_|_False_|_True_|_['Inrebic']_|_['Fedratinib hydrochloride' 'SAR302503A']_|_[('DailyMed', array(['fedratinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0002430', 'HP_0011974', 'EFO_0004251'], dtype=object), 'count': 3}_|_[ENSG00000096968,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL4297574,"nan_|_nan_|_Oligonucleotide_|_False_|_TEPRASIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['I5-NP' 'I5NP' 'QPI-1002' 'Qpi-1002' 'Teprasiran']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEPRASIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0001919'], dtype=object), 'count': 1}_|_[ENSG00000141510]_|_Oligonucleotide drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL471498,"O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1_|_WPGGHFDDFPHPOB-BBWFWOEESA-N_|_Small molecule_|_False_|_MITIGLINIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Mitiglinide']_|_[('Wikipedia', array(['Mitiglinide'], dtype=object)), ('drugbank', array(['DB01252'], dtype=object))]_|_['CHEMBL1603301']_|_{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL574737,"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O_|_PBCZSGKMGDDXIJ-KRUBCLEUSA-N_|_Small molecule_|_False_|_UCN-01_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['7-hydroxystaurosporine' 'KRX-0601' 'KW-2401' 'NSC-638850' 'UCN-01'
 'UCN-02' 'Ucn 01' 'Ucn-01']_|_nan_|_nan_|_{'rows': array(['MONDO_0002158', 'EFO_1001013', 'EFO_0000756', 'EFO_1001512',
       'EFO_0003025', 'MONDO_0007254', 'EFO_0000209', 'MONDO_0004669',
       'EFO_0003027', 'MONDO_0002087', 'EFO_0000198', 'MONDO_0002367',
       'EFO_0007535', 'EFO_0000224', 'MONDO_0011719', 'EFO_1000407',
       'MONDO_0008315', 'MONDO_0003196', 'MONDO_0044926', 'EFO_0003060',
       'EFO_0000339', 'EFO_0002938', 'MONDO_0002537', 'MONDO_0018364',
       'EFO_0005537', 'MONDO_0002974', 'EFO_0004193', 'MONDO_0001879',
       'EFO_0000616', 'EFO_0000221', 'EFO_0006352', 'MONDO_0001056',
       'MONDO_0007576', 'EFO_0003028', 'EFO_0000702', 'MONDO_0005411',
       'EFO_0000218', 'EFO_0000574', 'MONDO_0008170', 'EFO_0002618',
       'EFO_0000223', 'EFO_0000673', 'EFO_0000565'], dtype=object), 'count': 43}_|_[ENSG00000140992,ENSG00000123374,ENSG00000135446,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675,ENSG00000105810,ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 43 investigational indications."
CHEMBL726,"OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1_|_PLDUPXSUYLZYBN-UHFFFAOYSA-N_|_Small molecule_|_False_|_FLUPHENAZINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fluphenazine' 'NSC-62323' 'Permitil' 'Prolixin']_|_[('PubChem', array(['104171155', '11111179', '11111180', '144203697', '170465375',
       '26751625', '50100242', '50104297', '57287813', '90341540'],
      dtype=object)), ('TG-GATEs', array(['37'], dtype=object)), ('Wikipedia', array(['Fluphenazine'], dtype=object)), ('drugbank', array(['DB00623'], dtype=object)), ('chEBI', array(['5123'], dtype=object))]_|_['CHEMBL1200792' 'CHEMBL1448187']_|_{'rows': array(['MONDO_0005090', 'EFO_0000677', 'EFO_0005407', 'EFO_0001378'],
      dtype=object), 'count': 4}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for mental or behavioural disorder and psychosis and has 2 investigational indications."
CHEMBL814,"COCCCC/C(=N\OCCN)c1ccc(C(F)(F)F)cc1_|_CJOFXWAVKWHTFT-XSFVSMFZSA-N_|_Small molecule_|_True_|_FLUVOXAMINE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fluvoxamine' 'N06AB08']_|_[('PubChem', array(['104171369', '144204388', '170464809', '26751469', '50103976',
       '90340960'], dtype=object)), ('Wikipedia', array(['Fluvoxamine'], dtype=object)), ('drugbank', array(['DB00176'], dtype=object)), ('chEBI', array(['5138'], dtype=object))]_|_['CHEMBL1409']_|_{'rows': array(['EFO_1001916', 'EFO_1001917', 'EFO_0000694', 'MONDO_0100096',
       'EFO_0003758', 'EFO_0004262', 'MONDO_0002009', 'EFO_0005230',
       'MONDO_0005090', 'EFO_0004242', 'EFO_0000616', 'EFO_0004242',
       'MONDO_0002050', 'HP_0000726', 'MONDO_0100096', 'EFO_1001892',
       'EFO_0000694', 'EFO_1002014'], dtype=object), 'count': 18}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL87992,"CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc21_|_QIALRBLEEWJACW-INIZCTEOSA-N_|_Small molecule_|_False_|_ESLICARBAZEPINE ACETATE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Aptiom' 'Erelib' 'Pazzul' 'Stedesa' 'Zebinix']_|_['BIA 2-093' 'BIA-2-093' 'BIA-2093' 'Eslicarbazepine acetate'
 'SEP - 0002093' 'SEP-0002093']_|_[('DailyMed', array(['eslicarbazepine%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix'],
      dtype=object)), ('PubChem', array(['29217508', '90341297'], dtype=object)), ('drugbank', array(['DB09119'], dtype=object)), ('chEBI', array(['87016'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0041052', 'EFO_0005762', 'EFO_1000877', 'EFO_0005687',
       'HP_0001250', 'EFO_0000474', 'EFO_0009963', 'EFO_0004263',
       'MONDO_0005277', 'EFO_1000783'], dtype=object), 'count': 10}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for seizure and epilepsy and has 8 investigational indications."
CHEMBL936,"OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1_|_OGAKLTJNUQRZJU-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENIDOL_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Vontrol']_|_['Difenidol' 'Difenidol hydrochloride' 'Diphenidol' 'SK&F 478' 'SK&F-478'
 'SK-478' 'Vontrol']_|_[('PubChem', array(['11112531', '144206624', '170465280', '50100475'], dtype=object)), ('Wikipedia', array(['Diphenidol'], dtype=object)), ('drugbank', array(['DB01231'], dtype=object)), ('chEBI', array(['4638'], dtype=object))]_|_['CHEMBL2105784' 'CHEMBL1529']_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967."
CHEMBL1201087,"C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21_|_KORNTPPJEAJQIU-KJXAQDMKSA-N_|_Small molecule_|_False_|_CABERGOLINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Cabaser' 'Cabergoline' 'Dostinex' 'Velactis']_|_['Cabergoline' 'FCE 21336' 'FCE-21336' 'Velactis']_|_[('DailyMed', array(['cabergoline'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/velactis'],
      dtype=object)), ('PubChem', array(['144206142', '170464667'], dtype=object)), ('Wikipedia', array(['Cabergoline'], dtype=object)), ('drugbank', array(['DB00248'], dtype=object)), ('chEBI', array(['3286'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'EFO_0000545', 'EFO_0000512', 'MONDO_0002491',
       'MONDO_0007254', 'EFO_1001110', 'MONDO_0005180', 'EFO_0001073',
       'EFO_0002610', 'MONDO_0011972', 'EFO_0004270', 'EFO_1000979',
       'EFO_0001065'], dtype=object), 'count': 13}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for parkinson disease and hypothalamic neoplasm and has 11 investigational indications."
CHEMBL1228,"CCCCC1C(=O)N(c2ccccc2)N(c2ccc(O)cc2)C1=O_|_HFHZKZSRXITVMK-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYPHENBUTAZONE ANHYDROUS_|_1960.0_|_4.0_|_nan_|_True_|_True_|_['Oxyphenbutazone' 'Tandearil']_|_['Californit' 'Crovaril' 'Flogitolo' 'Flogoril' 'Frabel' 'G-27202'
 'NSC-526053' 'Neo-farmadol' 'Oxalid' 'Oxyphenbutazone' 'RO-04-4410'
 'Rapostan' 'Reozon' 'Suganril' 'Visubutina']_|_[('PubChem', array(['144203965', '170465310', '26748182', '56463172'], dtype=object)), ('Wikipedia', array(['Oxyphenbutazone'], dtype=object)), ('drugbank', array(['DB03585'], dtype=object)), ('chEBI', array(['76258'], dtype=object))]_|_['CHEMBL3989676']_|_{'rows': array(['EFO_0005755', 'EFO_0005752', 'HP_0002829', 'HP_0003326'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 approved indications."
CHEMBL1297,"CC(C(=O)O)c1cccc(Oc2ccccc2)c1_|_RDJGLLICXDHJDY-UHFFFAOYSA-N_|_Small molecule_|_True_|_FENOPROFEN_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Progesic']_|_['53858' 'Fenoprofen' 'LILLY-53858' 'NSC-757813' 'Nalfon']_|_[('Wikipedia', array(['Fenoprofen'], dtype=object)), ('drugbank', array(['DB00573'], dtype=object)), ('chEBI', array(['5004'], dtype=object))]_|_['CHEMBL2068720' 'CHEMBL2103736' 'CHEMBL138241']_|_{'rows': array(['MONDO_0005178', 'EFO_0000685', 'EFO_0005755'], dtype=object), 'count': 3}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL1738797,"CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O_|_KDGFLJKFZUIJMX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALECTINIB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Alecensa']_|_['AF-802' 'AF802' 'Alectinib' 'CH-5424802' 'CH5424802' 'RO-5424802'
 'RO5424802']_|_[('PubChem', array(['174006440'], dtype=object)), ('drugbank', array(['DB11363'], dtype=object))]_|_['CHEMBL3707320']_|_{'rows': array(['EFO_0001421', 'EFO_0000756', 'EFO_0000641', 'MONDO_0004992',
       'EFO_0001642', 'EFO_0000691', 'EFO_0003032', 'EFO_0005221',
       'EFO_0003826', 'EFO_0003893', 'EFO_0004142', 'EFO_0000326',
       'MONDO_0021117', 'EFO_0003833', 'EFO_1000849', 'EFO_0000616',
       'EFO_0003860', 'EFO_1001901', 'EFO_0003060', 'EFO_0000519',
       'EFO_0003060', 'EFO_0004284'], dtype=object), 'count': 22}_|_[ENSG00000171094,ENSG00000143924,ENSG00000165731]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 19 investigational indications."
CHEMBL1835207,"CCOc1ccc(-c2cc(C)cn2-c2ccc(S(N)(=O)=O)cc2)cc1_|_JTMITOKKUMVWRT-UHFFFAOYSA-N_|_Small molecule_|_False_|_APRICOXIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apricoxib' 'CS-706' 'R-109339' 'TG-01' 'TG01']_|_[('drugbank', array(['DB12378'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_0003060', 'MONDO_0007254', 'EFO_0001378'],
      dtype=object), 'count': 4}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2107759,"CCC(=O)O[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)C2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](CC(=O)OC(C)(C)C)c4ccco4)C(C)=C([C@@H](O)C(=O)[C@@]21C)C3(C)C_|_GJQWFXNJAXOCBV-XVGNUGADSA-N_|_Small molecule_|_False_|_MILATAXEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MAC-321' 'Milataxel']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0004288', 'EFO_1000657', 'EFO_0000588'],
      dtype=object), 'count': 4}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2108508,"nan_|_nan_|_Protein_|_True_|_INTERFERON ALFA-2A_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['INTERFERON ALFA-2A' 'Interferon alfa-2a'
 'Interferon alfa-2a (genetical recombination)' 'RO 22-8181' 'RO-22-8181'
 'RO-228181']_|_nan_|_nan_|_{'rows': array(['EFO_0003047', 'MONDO_0004992', 'EFO_1000956', 'EFO_1001156',
       'MONDO_0002367', 'EFO_0003780', 'EFO_0000676', 'EFO_0000681',
       'EFO_0001378', 'EFO_0004220', 'EFO_0000756', 'EFO_0000220',
       'EFO_0000616', 'EFO_0000764', 'EFO_0002617', 'EFO_0000574'],
      dtype=object), 'count': 16}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for cancer and neoplasm and has 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108593,"nan_|_nan_|_Protein_|_False_|_EPOETIN ZETA_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Retacrit']_|_['Epoetin' 'Epoetin zeta' 'Erythropoietin' 'Erythropoietin for bioassays']_|_[('DrugCentral', array(['5170'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001459', 'EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 3}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic kidney disease and anemia (phenotype) and has 1 investigational indication."
CHEMBL2109511,"nan_|_nan_|_Antibody_|_False_|_ONTAMALIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ontamalimab' 'PF-00547659' 'SHP-647' 'SHP647' 'Shp647']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}_|_[ENSG00000099866]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2219425,"CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21_|_DDINXHAORAAYAD-UHFFFAOYSA-N_|_Small molecule_|_True_|_ARIPIPRAZOLE LAUROXIL_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Aristada' 'Aristada initio kit']_|_['ALKS 9072' 'ALKS-9070' 'ALKS-9072' 'Aripiprazole lauroxil'
 'Aristada initio' 'RDC-3317' 'RDC3317']_|_[('DailyMed', array(['aripiprazole%20lauroxil'], dtype=object)), ('drugbank', array(['DB14185'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005411', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000178394,ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for schizophrenia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL270190,"C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1_|_UPNUIXSCZBYVBB-JVFUWBCBSA-N_|_Small molecule_|_True_|_ALVIMOPAN_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Entereg']_|_['ADL 8-2698' 'ADL-8-2698' 'Alvimopan' 'Alvimopan anhydrous'
 'Alvimopan dihydrate' 'Anhydrous alvimopan' 'LY-246736'
 'LY-246736 DIHYDRATE' 'LY246736']_|_[('DailyMed', array(['alvimopan'], dtype=object)), ('Wikipedia', array(['Alvimopan'], dtype=object)), ('drugbank', array(['DB06274'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004567', 'MONDO_0002087', 'MONDO_0008170', 'MONDO_0002158',
       'MONDO_0001187', 'HP_0002019'], dtype=object), 'count': 6}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for constipation and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3084748,"O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1.[Cl-]_|_RVCSYOQWLPPAOA-QKYUOBHYSA-M_|_Small molecule_|_False_|_TROSPIUM CHLORIDE_|_2004.0_|_4.0_|_CHEMBL1888176_|_False_|_True_|_['Flotros' 'Regurin' 'Regurin xl' 'Sanctura' 'Sanctura xr' 'Spasmo-lyt'
 'Trospium chloride' 'Uraplex']_|_['IP-631' 'IP631' 'Relaspium' 'Spasmex' 'Spasmolyt' 'Trospium chloride']_|_[('DailyMed', array(['trospium%20chloride'], dtype=object)), ('PubChem', array(['144205995', '170464918'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006865', 'EFO_0000341', 'EFO_1000781', 'MONDO_0005090'],
      dtype=object), 'count': 4}_|_[ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for urgency urinary incontinence and overactive bladder and has 2 investigational indications."
CHEMBL333021,"c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1_|_VOYMOBPSYVKQGF-UHFFFAOYSA-N_|_Small molecule_|_False_|_L-21649_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['L-21649']_|_nan_|_nan_|_nan_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL371405,"C[C@@]12OC(=O)[C@]1([C@@H](O)[C@@H]1C=CCCC1)NC(=O)[C@@H]2CCCl_|_NGWSFRIPKNWYAO-SHTIJGAHSA-N_|_Small molecule_|_False_|_MARIZOMIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Marizomib' 'NPI-0052' 'Salinosporamide a']_|_[('Wikipedia', array(['Salinosporamide_A'], dtype=object)), ('drugbank', array(['DB11762'], dtype=object)), ('chEBI', array(['48045'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000028', 'EFO_0000519', 'MONDO_0016700', 'EFO_0001378',
       'MONDO_0004992', 'EFO_0000574'], dtype=object), 'count': 6}_|_[ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL406050,"CCC(C)SSc1ncc[nH]1_|_BPBPYQWMFCTCNG-UHFFFAOYSA-N_|_Small molecule_|_False_|_PX-12_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Px-12']_|_[('PubChem', array(['174006855'], dtype=object)), ('drugbank', array(['DB05448'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003860'], dtype=object), 'count': 1}_|_[ENSG00000136810]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL411,"CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1_|_RGLYKWWBQGJZGM-ISLYRVAYSA-N_|_Small molecule_|_False_|_DIETHYLSTILBESTROL_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Apstil' 'Diethylstilbestrol' 'Distilbene' 'Stilbestrol' 'Stilbetin'
 'Stilboesterol' 'Tampovagan']_|_['Cyren a' 'Diethylstilbestrol' 'Estrobene' 'Estrogenine' 'Estromenin'
 'Fonatol' 'NSC-3070' 'New-estranol 1' 'Palestrol' 'Stilbestro'
 'Stilbestroform' 'Stilbestrol' 'Stilboestrol' 'Synestrin' 'Synthestrin']_|_[('PubChem', array(['11532921', '144209605', '144210844', '17389919', '26747240',
       '26752777'], dtype=object)), ('Wikipedia', array(['Diethylstilbestrol'], dtype=object)), ('drugbank', array(['DB00255'], dtype=object)), ('chEBI', array(['41922'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 2}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for neoplasm and has 1 investigational indication."
CHEMBL4297789,"nan_|_nan_|_Unknown_|_False_|_MT-3724_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mt-3724']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'EFO_0000403', 'EFO_0004289', 'EFO_0000095'],
      dtype=object), 'count': 4}_|_[ENSG00000168028,ENSG00000177954,ENSG00000137154,ENSG00000140988,ENSG00000149273,ENSG00000145425,ENSG00000198034,ENSG00000129824,ENSG00000083845,ENSG00000171863,ENSG00000142937,ENSG00000170889,ENSG00000124614,ENSG00000142534,ENSG00000112306,ENSG00000110700,ENSG00000164587,ENSG00000115268,ENSG00000134419,ENSG00000105193,ENSG00000182774,ENSG00000231500,ENSG00000105372,ENSG00000008988,ENSG00000171858,ENSG00000186468,ENSG00000138326,ENSG00000118181,ENSG00000197728,ENSG00000143947,ENSG00000233927,ENSG00000213741,ENSG00000149806,ENSG00000100316,ENSG00000174444,ENSG00000122406,ENSG00000089009,ENSG00000147604,ENSG00000148303,ENSG00000161016,ENSG00000163682,ENSG00000147403,ENSG00000198755,ENSG00000142676,ENSG00000197958,ENSG00000167526,ENSG00000142541,ENSG00000188846,ENSG00000174748,ENSG00000265681,ENSG00000063177,ENSG00000105640,ENSG00000108298,ENSG00000122026,ENSG00000116251,ENSG00000125691,ENSG00000198242,ENSG00000114391,ENSG00000161970,ENSG00000131469,ENSG00000166441,ENSG00000108107,ENSG00000162244,ENSG00000156482,ENSG00000071082,ENSG00000144713,ENSG00000109475,ENSG00000136942,ENSG00000182899,ENSG00000130255,ENSG00000241343,ENSG00000145592,ENSG00000197756,ENSG00000172809,ENSG00000198918,ENSG00000229117,ENSG00000089157,ENSG00000137818,ENSG00000156738]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4298025,"nan_|_nan_|_Antibody_|_False_|_ZENOCUTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MCLA-128' 'MCLA128' 'Mcla 128' 'Mcla-128' 'Zenocutuzumab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZENOCUTUZUMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 2}_|_[ENSG00000141736,ENSG00000065361]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594251,"CS(=O)(=O)O.CS(=O)(=O)O.Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1_|_QQDRLKRHJOAQDC-FBHGDYMESA-N_|_Small molecule_|_False_|_NETARSUDIL DIMESYLATE_|_2017.0_|_4.0_|_CHEMBL4594250_|_False_|_True_|_['Rhokiinsa' 'Rhopressa']_|_['AR-13324' 'Netarsudil dimesylate' 'Netarsudil mesilate'
 'Netarsudil mesylate']_|_[('DailyMed', array(['netarsudil%20dimesylate', 'netarsudil%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004190', 'EFO_1001069'], dtype=object), 'count': 2}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for open-angle glaucoma and ocular hypertension."
CHEMBL4594334,"nan_|_nan_|_Oligonucleotide_|_False_|_EPLONTERSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AKCEA-TTR-LRx' 'Akcea ttr lrx' 'Akcea-ttr-lrx' 'Eplontersen'
 'ION-682884' 'ION-682884 FREE ACID' 'IONIS-TTR-LRx'
 'ISIS-682884 FREE ACID' 'Ion-ttr-lrx']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EPLONTERSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004129', 'EFO_1001875'], dtype=object), 'count': 2}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL46,"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O_|_FELGMEQIXOGIFQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ONDANSETRON_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Ondansetron' 'Zofran' 'Zofran odt' 'Zuplenz']_|_['A04AA01' 'Desmethylondansetron' 'EUR-1025' 'GR-38032' 'GR-38032F'
 'NSC-757870' 'Ondansetron' 'Zofran']_|_[('DailyMed', array(['ondansetron'], dtype=object)), ('PubChem', array(['124893606', '144206599', '170464701'], dtype=object)), ('Wikipedia', array(['Ondansetron'], dtype=object)), ('drugbank', array(['DB00904'], dtype=object)), ('chEBI', array(['7773'], dtype=object))]_|_['CHEMBL1487310' 'CHEMBL1201111' 'CHEMBL3186492']_|_{'rows': array(['EFO_0006911', 'EFO_0004888', 'EFO_0003843', 'EFO_0004701',
       'HP_0002018', 'HP_0002094', 'MONDO_0005090', 'EFO_0003843',
       'MONDO_0004992', 'HP_0002013', 'HP_0002017', 'EFO_0002618',
       'HP_0011110', 'MONDO_0007079', 'HP_0002017', 'Orphanet_79292',
       'EFO_0002610', 'MONDO_0100342', 'EFO_0005611', 'EFO_0000096',
       'EFO_0006911', 'EFO_0003869', 'MONDO_0004992', 'EFO_1000948',
       'HP_0002013', 'MONDO_0002046', 'EFO_0001061', 'MONDO_0021148',
       'EFO_1001463', 'HP_0002018', 'EFO_0005762', 'EFO_0003768',
       'EFO_0005774', 'EFO_0000764', 'HP_0000726', 'HP_0001082',
       'EFO_0011023', 'EFO_0004242', 'EFO_0005952', 'MONDO_0007254',
       'EFO_0006912', 'EFO_0007386', 'EFO_0000555', 'MONDO_0043510',
       'EFO_0000691', 'HP_0000738', 'EFO_0005251', 'EFO_0004888'],
      dtype=object), 'count': 48}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 7 approved and 35 investigational indications."
CHEMBL4650514,"nan_|_nan_|_Antibody_|_False_|_BATOCLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Batoclimab' 'HBM-9161' 'HBM9161' 'HL161BKN' 'RVT-1401' 'RVT1401'
 'Rvt-1401']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BATOCLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005809', 'EFO_1001466', 'EFO_1000749', 'EFO_0004237',
       'EFO_1001264', 'EFO_0009538', 'EFO_0004256', 'EFO_0004991',
       'EFO_0007160'], dtype=object), 'count': 9}_|_[ENSG00000104870]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL489095,"C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1_|_RZKDEGZIFSJVNA-IBGZPJMESA-N_|_Small molecule_|_False_|_CAMICINAL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Camicinal' 'GSK-962040' 'GSK-962040B' 'GSK962040' 'GSK962040B'
 'Gsk962040']_|_[('drugbank', array(['DB12567'], dtype=object))]_|_['CHEMBL489679']_|_{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}_|_[ENSG00000102539]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL499,"CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1_|_BLJRIMJGRPQVNF-JTQLQIEISA-N_|_Small molecule_|_False_|_TIMOLOL_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Betim' 'Betimol' 'Blocadren' 'Glau-opt' 'Glaucol' 'Nyogel' 'Timolol'
 'Timoptic' 'Tiopex']_|_['Blocadren' 'Istalol' 'Timolol' 'Timolol anhydrous' 'Timolol hemihydrate'
 'Timoptic' 'Timoptic-XE']_|_[('DailyMed', array(['timolol'], dtype=object)), ('PubChem', array(['104171325', '11111904', '11112709', '11113334', '144204165',
       '170465062', '90341807'], dtype=object)), ('Wikipedia', array(['Timolol'], dtype=object)), ('drugbank', array(['DB00373'], dtype=object)), ('chEBI', array(['9599'], dtype=object))]_|_['CHEMBL1200870']_|_{'rows': array(['EFO_0000319', 'MONDO_0005041', 'EFO_1001022', 'EFO_0000666',
       'EFO_1000809', 'EFO_1000635', 'EFO_0000756', 'MONDO_0005041',
       'EFO_1000635', 'EFO_1001069', 'EFO_1000879', 'EFO_0004190',
       'EFO_0000546', 'MONDO_0005277', 'EFO_0004190', 'EFO_0004235',
       'EFO_0004683', 'EFO_1001923', 'EFO_1001069', 'MONDO_0019180'],
      dtype=object), 'count': 20}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 13 investigational indications."
CHEMBL545315,"C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1.Cl.Cl_|_JZZFDCXSFTVOJY-UHFFFAOYSA-N_|_Small molecule_|_False_|_CANERTINIB DIHYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL31965_|_False_|_False_|_[]_|_['CI-1033' 'Canertinib dihydrochloride' 'Canertinib hydrochloride'
 'PD-0183805' 'PD-0183805-002B' 'PD-183805' 'SN-26606']_|_nan_|_nan_|_{'rows': array(['EFO_0003869', 'MONDO_0021117', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000141736,ENSG00000178568,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL650,"C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12_|_VHRSUDSXCMQTMA-PJHHCJLFSA-N_|_Small molecule_|_False_|_METHYLPREDNISOLONE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Medrol' 'Medrone' 'Methylprednisolone']_|_['6-methyl-prednisolone' '6-methylprednisolone' 'J3.872E'
 'Methylprednisolone' 'NSC-19987' 'U-67,590A']_|_[('DailyMed', array(['methylprednisolone'], dtype=object)), ('PubChem', array(['144203927', '144212335', '170465051', '56424125', '82706',
       '855789'], dtype=object)), ('Wikipedia', array(['Methylprednisolone'], dtype=object)), ('drugbank', array(['DB00959'], dtype=object)), ('chEBI', array(['6888'], dtype=object))]_|_['CHEMBL1200844']_|_{'rows': array(['Orphanet_77260', 'EFO_1000905', 'EFO_0004143', 'EFO_0000768',
       'EFO_0003898', 'EFO_1000391', 'HP_0002027', 'MONDO_0007915',
       'EFO_0004256', 'EFO_1000965', 'EFO_0007224', 'MONDO_0011972',
       'EFO_0000684', 'HP_0002015', 'EFO_0000403', 'MONDO_0018896',
       'EFO_0003777', 'EFO_0000662', 'MONDO_0002135', 'EFO_0007160',
       'EFO_0004826', 'EFO_0007405', 'EFO_1001919', 'EFO_0000729',
       'EFO_0004194', 'MONDO_0019391', 'EFO_0007149', 'EFO_0003840',
       'EFO_1000784', 'EFO_0003914', 'EFO_0001379', 'EFO_0003060',
       'EFO_0009104', 'EFO_0003103', 'EFO_0009609', 'EFO_0007537',
       'MONDO_0013730', 'MP_0001845', 'MONDO_0016537', 'EFO_1000941',
       'EFO_0005761', 'EFO_1001806', 'EFO_0003884', 'EFO_0001378',
       'HP_0002140', 'HP_0001915', 'EFO_0004991', 'EFO_0000209',
       'EFO_1001435', 'MONDO_0004750', 'EFO_1001466', 'EFO_0003872',
       'EFO_0003843', 'EFO_0005297', 'HP_0001873', 'HP_0030834',
       'MONDO_0002471', 'EFO_0003929', 'MONDO_0017719', 'MONDO_0020077',
       'MONDO_0100096', 'EFO_0000255', 'EFO_0000211', 'EFO_0000685',
       'EFO_0009373', 'MONDO_0015540', 'MONDO_0019091', 'EFO_0003106',
       'EFO_0000546', 'MONDO_0017287', 'MONDO_0004979', 'EFO_0000565',
       'MONDO_0004976', 'MONDO_0004992', 'EFO_1001345', 'EFO_0005952',
       'MONDO_0005301', 'EFO_0000694', 'EFO_0002428', 'MONDO_0005277',
       'MONDO_0000870', 'EFO_0004254', 'EFO_0003778', 'EFO_0000540',
       'MONDO_0008315', 'EFO_0003032', 'EFO_1001119', 'EFO_0004251',
       'MONDO_0009348', 'EFO_0000717', 'EFO_0000557', 'EFO_0004599',
       'EFO_0002609', 'EFO_0000341', 'EFO_1001909', 'EFO_0000198',
       'EFO_0000706', 'EFO_0004145', 'EFO_1000637', 'MONDO_0100339',
       'MONDO_0018150', 'EFO_1002048', 'EFO_0000574', 'MONDO_0007254',
       'EFO_0007498', 'EFO_1000809', 'EFO_0000274', 'MONDO_0002158',
       'EFO_1001254', 'EFO_0000616', 'EFO_0000196', 'EFO_0009492',
       'HP_0002576', 'MONDO_0044881', 'EFO_0007295', 'EFO_0000756',
       'EFO_1001365', 'EFO_0003086', 'MONDO_0016226', 'MONDO_0005180',
       'EFO_0004255', 'MONDO_0100062', 'EFO_0000220', 'MONDO_0009387',
       'MONDO_0008170', 'EFO_0000095', 'MONDO_0020547', 'MONDO_0017276',
       'EFO_0003894', 'EFO_0004278', 'EFO_1001801', 'EFO_0007448',
       'MONDO_0005178', 'HP_0100543', 'EFO_0001642', 'EFO_0000712',
       'EFO_0000309', 'EFO_0006862', 'MONDO_0018923', 'EFO_0007167',
       'EFO_0000384', 'EFO_0003957', 'EFO_0004246', 'MONDO_0000873',
       'EFO_0007486', 'EFO_0008520', 'MONDO_0100130', 'EFO_1001139',
       'MONDO_0002959'], dtype=object), 'count': 149}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 17 approved and 132 investigational indications."
CHEMBL806,"CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1_|_MKXKFYHWDHIYRV-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLUTAMIDE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Chimax' 'Drogenil' 'Eulexin' 'Flutamide']_|_['Flutamide' 'NSC-215876' 'SCH 13521' 'SCH-13521']_|_[('DailyMed', array(['flutamide'], dtype=object)), ('PubChem', array(['104171162', '11111202', '11111203', '11532925', '124880151',
       '124880153', '144203705', '144209367', '144210854', '170464921',
       '17388997', '174007322', '26747365', '26747366', '26753014',
       '26753015', '49675006', '50105597', '50105598', '50105599',
       '50105600', '85231055', '90341271'], dtype=object)), ('TG-GATEs', array(['44'], dtype=object)), ('Wikipedia', array(['Flutamide'], dtype=object)), ('drugbank', array(['DB00499'], dtype=object)), ('chEBI', array(['5132'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000196', 'EFO_0000313', 'MONDO_0008170',
       'EFO_0000673', 'EFO_0000660', 'MONDO_0008315', 'EFO_0001663'],
      dtype=object), 'count': 8}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 5 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL842,"NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O_|_JBMKAUGHUNFTOL-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLOROTHIAZIDE_|_1958.0_|_4.0_|_nan_|_False_|_True_|_['Chlorothiazide' 'Diuril' 'Saluric']_|_['Chlorothiazide' 'Chlorthiazide'
 'Hydrochlorothiazide impurity, chlorothiazide-' 'NSC-25693']_|_[('DailyMed', array(['chlorothiazide'], dtype=object)), ('PubChem', array(['11110950', '11110951', '144203658', '144208170', '170465303',
       '17389544', '50105505', '855976'], dtype=object)), ('Wikipedia', array(['Chlorothiazide'], dtype=object)), ('drugbank', array(['DB00880'], dtype=object)), ('chEBI', array(['3640'], dtype=object))]_|_['CHEMBL1200616']_|_{'rows': array(['EFO_0003777', 'EFO_0003914', 'MONDO_0002462', 'EFO_0004255',
       'EFO_0000319', 'EFO_0000537', 'MONDO_0005148', 'EFO_0009373',
       'EFO_0003884', 'EFO_0001645', 'EFO_0000373', 'EFO_0000668',
       'HP_0003124'], dtype=object), 'count': 13}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1958 and has 8 approved and 5 investigational indications."
CHEMBL924,"O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O_|_XRASPMIURGNCCH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZOLEDRONIC ACID ANHYDROUS_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Reclast' 'Zometa']_|_['CGP-42446' 'Zometa']_|_[('PubChem', array(['144205292', '174006914', '29215499'], dtype=object)), ('Wikipedia', array(['Zoledronic_acid'], dtype=object)), ('drugbank', array(['DB00399'], dtype=object)), ('chEBI', array(['46557'], dtype=object))]_|_['CHEMBL3989655' 'CHEMBL4303669' 'CHEMBL4746555' 'CHEMBL2103912']_|_{'rows': array(['EFO_0000228', 'EFO_0000588', 'EFO_0003820', 'EFO_0000564',
       'EFO_0004259', 'MONDO_0008310', 'EFO_0001416', 'EFO_0003863',
       'EFO_0005952', 'EFO_0003843', 'EFO_1001998', 'MONDO_0011382',
       'EFO_1001147', 'EFO_0004252', 'EFO_1001919', 'GO_0042697',
       'EFO_0003060', 'EFO_0003882', 'EFO_0000691', 'EFO_0003869',
       'EFO_0000681', 'EFO_0000196', 'EFO_0003854', 'MONDO_0019019',
       'MONDO_0021165', 'MONDO_0008315', 'MONDO_0002974', 'EFO_0002430',
       'MONDO_0044903', 'MONDO_0002171', 'EFO_0003931', 'EFO_0000685',
       'EFO_0000673', 'EFO_0009708', 'EFO_0001365', 'MONDO_0008903',
       'HP_0000938', 'EFO_0000182', 'EFO_0001663', 'EFO_0000637',
       'EFO_0009870', 'EFO_0001378', 'Orphanet_848', 'MONDO_0020732',
       'HP_0003419', 'EFO_0006738', 'MONDO_0007254', 'EFO_0000333',
       'EFO_0000432', 'EFO_0004260', 'EFO_0000621', 'MONDO_0002367',
       'EFO_0000174', 'EFO_0004261', 'EFO_1000786'], dtype=object), 'count': 55}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 12 approved and 43 investigational indications."
CHEMBL972,"C#CCN(C)[C@H](C)Cc1ccccc1_|_MEZLKOACVSPNER-GFCCVEGCSA-N_|_Small molecule_|_True_|_SELEGILINE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Eldepryl' 'Emsam' 'Zelapar']_|_['Eldepryl' 'L-selegiline' 'Selegiline' 'Zelapar']_|_[('DailyMed', array(['selegiline'], dtype=object)), ('PubChem', array(['11113910', '26752066'], dtype=object)), ('Wikipedia', array(['Selegiline'], dtype=object)), ('drugbank', array(['DB01037'], dtype=object)), ('chEBI', array(['9086'], dtype=object))]_|_['CHEMBL1200904' 'CHEMBL5194110']_|_{'rows': array(['EFO_0002610', 'MONDO_0002009', 'EFO_0004701', 'EFO_0000673',
       'MONDO_0005180', 'MONDO_0005090', 'EFO_0003768', 'MONDO_0004975',
       'MONDO_0002050', 'EFO_0007191', 'MONDO_0002009', 'HP_0012076'],
      dtype=object), 'count': 12}_|_[ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and is indicated for major depressive disorder and parkinson disease and has 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL107430,"CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl_|_PNAWUIKCVQSLFG-UHFFFAOYSA-N_|_Small molecule_|_False_|_NRX195183_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGN 195183' 'AGN-195183' 'IRX5183' 'Irx-5183' 'NRX-195183' 'NRX195183'
 'Nrx195183' 'VTP-195183' 'VTP-5183']_|_[('drugbank', array(['DB05653'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000224'], dtype=object), 'count': 1}_|_[ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1148,"Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1_|_NGBFQHCMQULJNZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TORSEMIDE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Demadex' 'Soaanz' 'Torem 10' 'Torem 2.5' 'Torem 5' 'Torsemide' 'Upcard']_|_['AC-4464' 'AC4464' 'BM-02.015' 'BM-02015' 'BM02.015' 'Luprac'
 'Torasemide' 'Torasemide anhydrous' 'Torsemide' 'Upcard']_|_[('DailyMed', array(['torsemide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/upcard'],
      dtype=object)), ('PubChem', array(['11112793', '144204213', '170465279', '26719820', '26748988',
       '49665992', '49666477'], dtype=object)), ('Wikipedia', array(['Torasemide'], dtype=object)), ('drugbank', array(['DB00214'], dtype=object)), ('chEBI', array(['9637'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0000612', 'EFO_0000373', 'EFO_0003144',
       'EFO_0000319', 'MONDO_0005148', 'EFO_0000668', 'EFO_0000537'],
      dtype=object), 'count': 8}_|_[ENSG00000074803]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 6 approved and 2 investigational indications."
CHEMBL1200554,"CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O_|_ZBVJFYPGLGEMIN-OYLNGHKZSA-N_|_Protein_|_False_|_TRIPTORELIN PAMOATE_|_2000.0_|_4.0_|_CHEMBL1201334_|_False_|_True_|_['Trelstar' 'Triptodur kit']_|_['Salvacyl' 'Triptorelin (as embonate)' 'Triptorelin embonate'
 'Triptorelin pamoate']_|_[('DailyMed', array(['triptorelin%20pamoate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000196', 'EFO_0001065', 'MONDO_0008315', 'EFO_0001663',
       'MONDO_0000088', 'EFO_0000673', 'EFO_0009029', 'MONDO_0007254'],
      dtype=object), 'count': 8}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 3 investigational indications."
CHEMBL1201082,"CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl_|_GIYXAJPCNFJEHY-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLUOXETINE HYDROCHLORIDE_|_1987.0_|_4.0_|_CHEMBL41_|_False_|_True_|_['Felicium' 'Fluoxetine' 'Fluoxetine hydrochloride' 'Olena' 'Oxactin'
 'Prozac' 'Prozac 60' 'Prozac weekly' 'Prozep' 'Prozit' 'Ranflutin'
 'Reconcile' 'Sarafem' 'Selfemra']_|_['Adofen' 'Fluctin' 'Fluneurin' 'Fluox-puren' 'Fluoxeren'
 'Fluoxetine (as hydrochloride)' 'Fluoxetine hydrochloride' 'Flusol'
 'Fluxet' 'Fontex' 'Foxetin' 'LY-110140' 'LY110140' 'Lovan' 'Reconcile']_|_[('DailyMed', array(['fluoxetine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/veterinary/EPAR/reconcile'],
      dtype=object)), ('PubChem', array(['144207380', '26747522', '26747523', '50106352', '50106353',
       '50106354', '56422172', '855820'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0004242', 'EFO_0004262', 'EFO_0009963',
       'MONDO_0004985', 'MONDO_0002009', 'MONDO_0002050'], dtype=object), 'count': 7}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 4 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201488,"nan_|_nan_|_Protein_|_False_|_SECRETIN SYNTHETIC HUMAN_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Chirhostim']_|_['Human secretin' 'Secretin (human)' 'Secretin (human), acetate (salt)'
 'Secretin Synthetic Human' 'Secretin acetate human' 'Secretin human'
 'Secretin human acetate' 'Secretin human pentaacetate'
 'Secretin synthetic human' 'Synthetic human secretin']_|_[('DailyMed', array(['secretin%20synthetic%20human'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004242', 'EFO_0003758'], dtype=object), 'count': 2}_|_[ENSG00000080293]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 2 investigational indications."
CHEMBL1201641,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Humulin u']_|_['Insulin zinc susp extended recombinant human']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1987.
CHEMBL1337,"O=C1CCCC(=O)C1C(=O)c1ccc(C(F)(F)F)cc1[N+](=O)[O-]_|_OUBCNLGXQFSTLU-UHFFFAOYSA-N_|_Small molecule_|_False_|_NITISINONE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Nityr' 'Orfadin']_|_['Nitisinone' 'SC-0735']_|_[('DailyMed', array(['nitisinone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nityr'],
      dtype=object)), ('PubChem', array(['174007248'], dtype=object)), ('Wikipedia', array(['Nitisinone'], dtype=object)), ('drugbank', array(['DB00348'], dtype=object)), ('chEBI', array(['50378'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004741', 'MONDO_0008753', 'MONDO_0043209'], dtype=object), 'count': 3}_|_[ENSG00000158104]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for tyrosinemia and has 2 investigational indications."
CHEMBL1417019,"Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21_|_ZAHQPTJLOCWVPG-UHFFFAOYSA-N_|_Small molecule_|_True_|_MITOXANTRONE HYDROCHLORIDE_|_1987.0_|_4.0_|_CHEMBL58_|_False_|_True_|_['Mitoxantrone hydrochloride' 'Novantrone']_|_['CL 232,315' 'CL-232315' 'Mitoxantrone Dihcl'
 'Mitoxantrone Dihydrochloride' 'Mitoxantrone dihydrochloride'
 'Mitoxantrone hcl' 'Mitoxantrone hydrochloride' 'Mitozantrone'
 'NSC-301739']_|_[('PubChem', array(['144203748', '170465183', '26747571', '26747572', '26747573',
       '50106605'], dtype=object)), ('chEBI', array(['50727'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015760', 'MONDO_0019472', 'EFO_0000182', 'MONDO_0005301',
       'EFO_0000211', 'MONDO_0008170', 'EFO_0003843', 'EFO_0000220',
       'MONDO_0018906', 'EFO_0000198', 'EFO_0000616', 'EFO_0004251',
       'EFO_0000673', 'EFO_0004289', 'EFO_0003929', 'EFO_0000196',
       'EFO_0000222', 'EFO_0000221', 'EFO_1001469', 'EFO_0005952',
       'EFO_1001830', 'EFO_0008522', 'EFO_0000565', 'MONDO_0004992',
       'EFO_0000224', 'EFO_0000339', 'EFO_0000095', 'MONDO_0008315',
       'MONDO_0008315', 'EFO_0001378', 'EFO_0000178', 'EFO_0000574',
       'EFO_0000403', 'EFO_0006859', 'MONDO_0007254', 'EFO_1000286',
       'MONDO_0001023', 'MONDO_0019460', 'MONDO_0000873', 'EFO_1001052',
       'EFO_0001663'], dtype=object), 'count': 41}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 5 approved and 36 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1418176,"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O_|_XWALNWXLMVGSFR-HLXURNFRSA-N_|_Small molecule_|_False_|_METHANDROSTENOLONE_|_nan_|_4.0_|_nan_|_True_|_True_|_['Dianabol']_|_['Metandienone' 'Methandienone' 'Methandrostenolone' 'NSC-42722' 'Nerobol'
 'Perbolin']_|_[('PubChem', array(['144205200', '170466069', '29215353'], dtype=object)), ('Wikipedia', array(['Methandrostenolone'], dtype=object)), ('drugbank', array(['DB13586'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1654,"O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+]_|_DRFDPXKCEWYIAW-UHFFFAOYSA-M_|_Small molecule_|_False_|_RISEDRONATE SODIUM_|_1998.0_|_4.0_|_CHEMBL923_|_False_|_True_|_['Actonel' 'Atelvia' 'Risedronate sodium']_|_['NE-58095' 'NE-58095 ANHYDROUS' 'NSC-722598' 'NSC-759280'
 'Risedronate monosodium' 'Risedronate sodium'
 'Risedronate sodium anhydrous' 'Risedronic acid monosodium salt']_|_[('DailyMed', array(['risedronate%20sodium'], dtype=object)), ('PubChem', array(['174006918'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005351', 'MONDO_0021165', 'EFO_0003854', 'EFO_0000574',
       'MONDO_0019019', 'EFO_0000565', 'EFO_0003882'], dtype=object), 'count': 7}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 3 approved and 4 investigational indications."
CHEMBL1671,"CC(C)NCC(O)COc1cccc2ccccc12.Cl_|_ZMRUPTIKESYGQW-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROPRANOLOL HYDROCHLORIDE_|_1967.0_|_4.0_|_CHEMBL27_|_False_|_True_|_['Angilol' 'Apsolol' 'Avlocardyl' 'Bedranol' 'Bedranol s.r.' 'Berkolol'
 'Beta-prograne mr' 'Betadur cr' 'Cardinol' 'Dupromex'
 'Half beta-prograne mr' 'Half propanix la' 'Half propatard la'
 'Half-beprane cr' 'Half-betadur cr' 'Half-inderal la' 'Hemangeol'
 'Hemangiol' 'Inderal' 'Inderal la' 'Innopran xl' 'Lederpronol'
 'Lopranol la' 'Probeta la' 'Propanix la' 'Propanix-10' 'Propanix-160'
 'Propanix-160 sr' 'Propanix-40' 'Propanix-80' 'Propatard la'
 'Propranolol hydrochloride' 'Propranolol hydrochloride intensol'
 'Rapranol sr' 'Sagittol' 'Slo-blok' 'Slo-pro' 'Sloprolol' 'Syprol'
 'Tesnol']_|_['AY 64043' 'AY-64043' 'ICI 45520' 'ICI-45520' 'NSC-91523'
 'Propranolol hydrochloride']_|_[('DailyMed', array(['propranolol%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol'],
      dtype=object)), ('PubChem', array(['144209084', '144213222', '17389750', '26732618', '26747603',
       '26747604', '26751803', '46500341', '50106744', '50106745',
       '50106746'], dtype=object)), ('chEBI', array(['8500'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001187', 'EFO_0003913', 'EFO_1001968', 'HP_0001636',
       'MONDO_0021661', 'EFO_0000712', 'EFO_0004269', 'MONDO_0005277',
       'EFO_0001073', 'MONDO_0018089', 'EFO_0001663', 'MONDO_0005148',
       'EFO_1001450', 'EFO_0002610', 'EFO_0000389', 'EFO_0004142',
       'EFO_0009444', 'EFO_0009545', 'EFO_0001358', 'EFO_0004280',
       'EFO_1000635', 'EFO_0001422', 'EFO_0000537', 'EFO_0003860'],
      dtype=object), 'count': 24}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 8 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1708,"Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1_|_GELRVIPPMNMYGS-RVXRQPKJSA-N_|_Small molecule_|_True_|_PAROXETINE HYDROCHLORIDE_|_1992.0_|_4.0_|_CHEMBL490_|_False_|_True_|_['Paroxetine hydrochloride' 'Paxil' 'Paxil cr' 'Seroxat']_|_['NSC-758654' 'Paroxetine HCl' 'Paroxetine hydrochloride'
 'Paroxetine hydrochloride anhydrous']_|_[('DailyMed', array(['paroxetine%20hydrochloride'], dtype=object)), ('PubChem', array(['26753519', '85273719'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0006788', 'EFO_0001358', 'EFO_0004262',
       'EFO_0803321', 'MONDO_0002009', 'EFO_0005230', 'MONDO_0002050',
       'EFO_1001917', 'EFO_0004242'], dtype=object), 'count': 10}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103739,"CCOCCn1c(N2CCCN(C)CC2)nc2ccccc21.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O_|_FWLKKPKZQYVAFR-LVEZLNDCSA-N_|_Small molecule_|_False_|_EMEDASTINE DIFUMARATE_|_1997.0_|_4.0_|_CHEMBL594_|_False_|_True_|_['Emadine']_|_['AL-3432A' 'Emedastine difumarate' 'Emedastine fumarate' 'KB-2413'
 'LY-188695' 'Ly188695' 'Rapimine']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/emadine'],
      dtype=object)), ('PubChem', array(['144206353', '170465197'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007141'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for allergic conjunctivitis."
CHEMBL2109327,"nan_|_nan_|_Antibody_|_False_|_CSL-360_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CSL-360' 'Csl-360']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000292332,ENSG00000185291]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109498,"nan_|_nan_|_Antibody_|_False_|_IPH-2101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['1-7F9' 'IHP-2101' 'IPH-2101' 'IPH2101' 'Iph-2101']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0001378'], dtype=object), 'count': 2}_|_[ENSG00000278731,ENSG00000275546,ENSG00000276731,ENSG00000276011,ENSG00000275407,ENSG00000275914,ENSG00000125498,ENSG00000243772]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2110581,"Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O_|_PRYZSLKPMFOUNL-MHIBGBBJSA-N_|_Oligonucleotide_|_False_|_BEVASIRANIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bevasiranib']_|_nan_|_['CHEMBL2103797']_|_{'rows': array(['EFO_0001365', 'EFO_0009606'], dtype=object), 'count': 2}_|_[ENSG00000164342,ENSG00000112715]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL315838,"COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1_|_PJWPNDMDCLXCOM-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENCAINIDE_|_1986.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Encainide']_|_[('drugbank', array(['DB01228'], dtype=object)), ('chEBI', array(['4788'], dtype=object))]_|_['CHEMBL2106155']_|_{'rows': array(['EFO_0004269'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986 and is indicated for cardiac arrhythmia."
CHEMBL3349607,"NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O_|_VMZMNAABQBOLAK-DBILLSOUSA-N_|_Protein_|_False_|_PASIREOTIDE_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Signifor']_|_['Pasireotide' 'SOM 230' 'SOM-230' 'SOM230']_|_[('drugbank', array(['DB06663'], dtype=object)), ('chEBI', array(['72312'], dtype=object))]_|_['CHEMBL5314380' 'CHEMBL5316227' 'CHEMBL5314382']_|_{'rows': array(['MONDO_0016642', 'EFO_0000182', 'MONDO_0004992', 'EFO_0003843',
       'EFO_0001378', 'EFO_1001485', 'EFO_0007331', 'EFO_0004243',
       'EFO_0000673', 'HP_0003074', 'EFO_0000432', 'EFO_0001642',
       'EFO_1001110', 'EFO_1001471', 'EFO_1000581', 'EFO_0005323',
       'EFO_0008549', 'EFO_1001901', 'EFO_0000702', 'MONDO_0002108',
       'EFO_0002618', 'MONDO_0015277', 'MONDO_0007254', 'EFO_1001256',
       'EFO_0003086', 'EFO_1001485', 'MONDO_0024503', 'EFO_0000232',
       'EFO_0001071', 'EFO_0003099', 'EFO_1001307', 'MONDO_0008315'],
      dtype=object), 'count': 32}_|_[ENSG00000139874,ENSG00000162009,ENSG00000278195,ENSG00000180616]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for acromegaly and has 31 investigational indications."
CHEMBL3426621,"C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12_|_QSKQVZWVLOIIEV-NSHDSACASA-N_|_Small molecule_|_False_|_RIPASUDIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ripasudil']_|_[('drugbank', array(['DB13165'], dtype=object))]_|_['CHEMBL4594454']_|_{'rows': array(['MONDO_0005041', 'Orphanet_98974', 'MONDO_0005321', 'EFO_1000879',
       'EFO_1001158'], dtype=object), 'count': 5}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL3545111,"nan_|_nan_|_Small molecule_|_False_|_HEMAY-022_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Hemay-022']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3545148,nan_|_nan_|_Small molecule_|_False_|_PHE377_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Phe377']_|_nan_|_nan_|_nan_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545351,"Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O_|_HQLHZNDJQSRKDT-UHFFFAOYSA-N_|_Small molecule_|_False_|_AV-101_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['4-chlorokynurenine' '4-cl-kyn' 'Av-101' 'J578.071C'
 'L-4-chlorokynurenine' 'L-4-cl-kyn']_|_nan_|_nan_|_{'rows': array(['MONDO_0002050', 'MONDO_0002009', 'EFO_0001361', 'EFO_0005762'],
      dtype=object), 'count': 4}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3707313,"CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1_|_MFBCDACCJCDGBA-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIFAROTENE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Aklief']_|_['CD-5789' 'CD5789' 'Trifarotene']_|_[('DailyMed', array(['trifarotene'], dtype=object)), ('drugbank', array(['DB12808'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'MONDO_0017778', 'EFO_0003894'], dtype=object), 'count': 3}_|_[ENSG00000172819]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for acne and has 2 investigational indications."
CHEMBL3833320,"nan_|_nan_|_Antibody_|_False_|_EPTINEZUMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Vyepti']_|_['ALD-403' 'ALD403' 'Eptinezumab']_|_[('DailyMed', array(['eptinezumab-jjmr'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'EFO_0003843'], dtype=object), 'count': 2}_|_[ENSG00000110680,ENSG00000175868]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for migraine disorder and has 1 investigational indication."
CHEMBL4298194,"nan_|_nan_|_Gene_|_False_|_GIROCTOCOGENE FITELPARVOVEC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Giroctocogene fitelparvovec' 'PF-07055480' 'SB-525']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GIROCTOCOGENE%20FITELPARVOVEC/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Gene drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4650274,"nan_|_nan_|_Unknown_|_False_|_DASIGLUCAGON HYDROCHLORIDE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Zegalogue' 'Zegalogue (autoinjector)']_|_[]_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'HP_0001943'], dtype=object), 'count': 2}_|_[ENSG00000215644]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for type 1 diabetes mellitus and hypoglycemia."
CHEMBL4761468,"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C4CC4)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C_|_DOEOECWDNSEFDN-UHFFFAOYSA-N_|_Small molecule_|_False_|_AUMOLERTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Ameile' 'Amerol']_|_['Almonertinib' 'Ameile' 'Amerol' 'Aumolertinib' 'EQ-143' 'EQ143'
 'Egfr t790m inhibitor hs-10296' 'HS-10206' 'HS-10296' 'Hs 10296'
 'Hs-10296']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AUMOLERTINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL5095491']_|_{'rows': array(['EFO_0001421', 'EFO_0000707', 'MONDO_0008903', 'EFO_0000313',
       'EFO_0000571', 'EFO_0000616', 'EFO_0003060', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 9}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL5095052,"nan_|_nan_|_Oligonucleotide_|_False_|_INCLISIRAN SODIUM_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Leqvio']_|_['Leqvio sodium']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'EFO_0004911'], dtype=object), 'count': 2}_|_[ENSG00000169174]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for atherosclerosis and familial hypercholesterolemia."
CHEMBL552212,"CCC[C@H](Nc1nc(-c2ccc(NC(=O)NCC)c(OC)c2)ncc1C)c1cccnc1_|_MTJHLONVHHPNSI-IBGZPJMESA-N_|_Small molecule_|_False_|_LEXIBULIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CYT 997' 'CYT-997' 'CYT997' 'Lexibulin']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000519'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL65375,"Cl.N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl_|_KGHYQYACJRXCAT-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIPIRACIL HYDROCHLORIDE_|_2015.0_|_4.0_|_CHEMBL235668_|_False_|_True_|_[]_|_['TAS-1-462' 'TPI' 'Tipiracil hydrochloride']_|_[('DailyMed', array(['tipiracil%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0044937', 'EFO_1000657', 'EFO_0000365'], dtype=object), 'count': 3}_|_[ENSG00000025708]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for colorectal adenocarcinoma and has 2 investigational indications."
CHEMBL675,"NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.[Na+]_|_CAKRAHQRJGUPIG-UHFFFAOYSA-M_|_Small molecule_|_False_|_ALENDRONATE SODIUM_|_1995.0_|_4.0_|_CHEMBL870_|_False_|_True_|_['Alendronate sodium' 'Binosto' 'Fosamax']_|_['Adrovance' 'Alendronate (as sodium)' 'Alendronate sodium'
 'Alendronate sodium hydrate' 'Alendronate sodium trihydrate'
 'Alendronic acid monosodium salt trihydrate' 'Fosavance' 'G-704,650'
 'G-704650' 'MK-217' 'NSC-722597' 'NSC-758931' 'Sodium alendronate'
 'Sodium alendronate trihydrate' 'Vantavo']_|_[('DailyMed', array(['alendronate%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0003762', 'EFO_0003854', 'EFO_0003882',
       'EFO_0000589', 'EFO_0004261'], dtype=object), 'count': 6}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 4 approved and 2 investigational indications."
CHEMBL696,"CCC1(C)CC(=O)NC1=O_|_HAPOVYFOVVWLRS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETHOSUXIMIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Emeside' 'Ethosuximide' 'Suxinutin' 'Zarontin']_|_['CI-366' 'CN-10,395' 'CN-10395' 'Ethosuximide' 'Ethosuximidum'
 'NSC-64013' 'PM-671' 'Pyknolepsinum']_|_[('DailyMed', array(['ethosuximide'], dtype=object)), ('PubChem', array(['144203921', '170464802', '174006922', '26747515', '26747516',
       '50106318', '50106319', '85231037', '90340672'], dtype=object)), ('Wikipedia', array(['Ethosuximide'], dtype=object)), ('drugbank', array(['DB00593'], dtype=object)), ('chEBI', array(['4887'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474', 'MONDO_0002050', 'EFO_1001998', 'HP_0001250',
       'EFO_0000555', 'EFO_0005762', 'MONDO_0005277', 'MONDO_0010826'],
      dtype=object), 'count': 8}_|_[ENSG00000196557,ENSG00000006283,ENSG00000100346]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for epilepsy and has 7 investigational indications."
CHEMBL107,"COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2_|_IAKHMKGGTNLKSZ-INIZCTEOSA-N_|_Small molecule_|_False_|_COLCHICINE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_['Colchicine' 'Colcrys' 'Gloperba' 'Mitigare']_|_['(-)-colchicine' 'Colchcine' 'Colchicine' 'Colchicinum' 'Colchineos'
 'Colchisol' 'Lodoco' 'NSC-757']_|_[('DailyMed', array(['colchicine'], dtype=object)), ('PubChem', array(['104219585', '11114044', '144204498', '144208745', '144210899',
       '170465011', '17389095', '17389096', '26752175', '26752176',
       '49718107', '50085974', '50104821', '50104822', '50113684',
       '50113685', '50113686', '67636', '90340644'], dtype=object)), ('TG-GATEs', array(['113'], dtype=object)), ('Wikipedia', array(['Colchicine'], dtype=object)), ('chEBI', array(['27882'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0007541', 'EFO_0003884', 'EFO_0004220',
       'EFO_0000401', 'EFO_0003818', 'EFO_0008586', 'EFO_0000551',
       'EFO_0000537', 'EFO_0007427', 'EFO_0005672', 'MONDO_0004976',
       'EFO_0004616', 'EFO_0003780', 'EFO_0000694', 'EFO_0001422',
       'EFO_0003777', 'EFO_0004274', 'EFO_0003144', 'EFO_1001486',
       'EFO_0005221', 'EFO_0006803', 'EFO_0007224', 'EFO_0000275',
       'MONDO_0004979', 'MONDO_0100096', 'EFO_0000319', 'MONDO_0018088',
       'EFO_0008585', 'EFO_0003863', 'EFO_0001645', 'EFO_0004264',
       'EFO_0003914', 'EFO_0003938', 'EFO_0000612', 'EFO_1001404',
       'EFO_0009609', 'EFO_0000616', 'EFO_1001129', 'EFO_0002687',
       'EFO_0004269', 'MONDO_0008315'], dtype=object), 'count': 42}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and is indicated for gout and familial mediterranean fever and has 40 investigational indications."
CHEMBL113,"Cn1c(=O)c2c(ncn2C)n(C)c1=O_|_RYYVLZVUVIJVGH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAFFEINE_|_1948.0_|_4.0_|_nan_|_False_|_True_|_['Nodoz' 'Pro-plus' 'Yeast-vite' 'Zanthine']_|_['Anhydrous caffeine' 'Cafcit' 'Caffeine' 'Caffeine anhydrous'
 'Caffeine melting point standard' 'Caffeinum' 'Coffeine' 'Coffeinum'
 'Durvitan' 'FEMA NO. 2224' 'Guaranine' 'Methyltheobromine' 'NSC-5036'
 'Synalgos' 'Theine' 'Vivarin']_|_[('DailyMed', array(['caffeine'], dtype=object)), ('PubChem', array(['104171124', '11110908', '124879556', '144208883', '144210330',
       '17389997', '26732615', '26752751', '49718178', '50105397',
       '50105398', '90341215'], dtype=object)), ('TG-GATEs', array(['97'], dtype=object)), ('Wikipedia', array(['Caffeine', 'Caffeine_(data_page)'], dtype=object)), ('drugbank', array(['DB00201'], dtype=object)), ('chEBI', array(['27732'], dtype=object))]_|_['CHEMBL1200569']_|_{'rows': array(['EFO_0005741', 'HP_0012228', 'MONDO_0007079', 'EFO_0002610',
       'EFO_0003843', 'EFO_0005252', 'MONDO_0100096', 'EFO_1001249',
       'EFO_0003929', 'EFO_0003888', 'EFO_0004714', 'EFO_0001421',
       'EFO_1001158', 'MONDO_0005299', 'MONDO_0005180', 'EFO_0004272',
       'EFO_0002617', 'EFO_0000685', 'MONDO_0100431', 'MONDO_0004938',
       'EFO_0000764', 'EFO_0004220', 'EFO_0000274', 'EFO_0009708',
       'HP_0002094', 'EFO_0009692', 'MONDO_0004976', 'MONDO_0021107',
       'MONDO_0001020', 'HP_0002315', 'EFO_0009444', 'EFO_0000384',
       'MONDO_0008315', 'EFO_0007214', 'MONDO_0004567', 'EFO_0000305',
       'HP_0002104', 'EFO_0001645', 'HP_0030833', 'EFO_0001072',
       'MONDO_0005475', 'EFO_0000756', 'EFO_0003917', 'MONDO_0044970',
       'EFO_0001073', 'MONDO_0005277', 'EFO_0000275', 'EFO_1001919',
       'EFO_0010072', 'EFO_0000676', 'EFO_0600064', 'MONDO_0019091',
       'HP_0002104', 'MONDO_0005148', 'HP_0001298', 'EFO_0000729',
       'EFO_0003843', 'HP_0100607', 'EFO_0000616', 'HP_0012532',
       'HP_0003418', 'EFO_0003876', 'HP_0003419', 'MONDO_0004975'],
      dtype=object), 'count': 64}_|_[ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 4 approved and 59 investigational indications."
CHEMBL1200449,"CC(=O)OCC(=O)[C@@]1(O)[C@H](OC(C)=O)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_XGMPVBXKDAHORN-RBWIMXSLSA-N_|_Small molecule_|_False_|_TRIAMCINOLONE DIACETATE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Aristocort' 'Kenacort' 'Triamcinolone diacetate']_|_['Aristocort forte' 'NSC-757356' 'Orion' 'Polcortolon' 'Tedarol'
 'Triamcinolone 16,21-diacetate' 'Triamcinolone diacetate']_|_[('PubChem', array(['144206670', '170464837'], dtype=object)), ('chEBI', array(['9669'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959."
CHEMBL1200503,"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CS(=O)(=O)O_|_NOJMTMIRQRDZMT-GSPXQYRGSA-N_|_Small molecule_|_False_|_BROMOCRIPTINE MESYLATE_|_1978.0_|_4.0_|_CHEMBL493_|_False_|_True_|_['Bromocriptine mesylate' 'Cycloset' 'Parlodel']_|_['2-bromoergocryptine mesylate' 'Bromocriptine mesilate'
 'Bromocriptine mesylate' 'Bromocriptine methanesulfonate' 'CB-154'
 'CB-154 MESYLATE' 'Cb-154 mesilate' 'NSC-755915']_|_[('DailyMed', array(['bromocriptine%20mesylate'], dtype=object)), ('PubChem', array(['144213902', '442420', '50105911'], dtype=object)), ('chEBI', array(['3182'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000232', 'MONDO_0005148', 'MONDO_0002146', 'EFO_0000545',
       'EFO_1001485', 'MONDO_0005180', 'EFO_0007319'], dtype=object), 'count': 7}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 7 approved indications."
CHEMBL1200545,"CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_BOBLHFUVNSFZPJ-JOYXJVLSSA-N_|_Small molecule_|_False_|_DIFLORASONE DIACETATE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Diflorasone diacetate' 'Florone' 'Florone e' 'Psorcon' 'Psorcon e']_|_['Diflorasone' 'Diflorasone diacetate' 'Murode' 'U-34,865' 'U-34865']_|_[('DailyMed', array(['diflorasone%20diacetate'], dtype=object)), ('PubChem', array(['144204426', '170465294', '29215002', '56422226', '855657'],
      dtype=object)), ('chEBI', array(['31483'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000701'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977 and is indicated for skin disease."
CHEMBL1201780,"NC(=O)N[C@@H](CCC(=O)O)C(=O)O_|_LCQLHJZYVOQKHU-VKHMYHEASA-N_|_Small molecule_|_False_|_CARGLUMIC ACID_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Carbaglu' 'Ucedane']_|_['Carglumic acid' 'N-carbamyl-l-glutamic acid' 'NSC-760124' 'OE 312'
 'OE 312 (LABORATORY CODE DESIGNATION)' 'OE-312']_|_[('DailyMed', array(['carglumic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ucedane'],
      dtype=object)), ('PubChem', array(['144206097', '170466164'], dtype=object)), ('Wikipedia', array(['Carglumic_acid'], dtype=object)), ('drugbank', array(['DB06775'], dtype=object)), ('chEBI', array(['71028'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011628', 'Orphanet_927', 'MONDO_0019052', 'HP_0001987',
       'MONDO_0004736'], dtype=object), 'count': 5}_|_[ENSG00000021826]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 2 investigational indications."
CHEMBL1213252,"O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O_|_XDDJGVMJFWAHJX-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLORAZEPIC ACID_|_1972.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['4306-CB FREE ACID' 'ABBOTT-35616 FREE ACID' 'Chlorazepate' 'Clorazepate'
 'Clorazepic acid']_|_[('drugbank', array(['DB00628'], dtype=object)), ('chEBI', array(['3761'], dtype=object))]_|_['CHEMBL2096631' 'CHEMBL2106085']_|_{'rows': array(['HP_0001250', 'EFO_0006788', 'EFO_0005230'], dtype=object), 'count': 3}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1743039,"nan_|_nan_|_Antibody_|_False_|_MAVRILIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CAM-3001' 'CAM3001' 'KPL-301' 'Mavrilimumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0100096', 'EFO_1001209'], dtype=object), 'count': 3}_|_[ENSG00000198223,ENSG00000292357,ENSG00000100368]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1908391,"Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1_|_WJEOLQLKVOPQFV-UHFFFAOYSA-N_|_Small molecule_|_False_|_MASITINIB_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Kinavet' 'Masivet']_|_['AB-1010' 'AB1010' 'Ab-1010' 'Masican' 'Masitinib' 'Masiviera']_|_[('PubChem', array(['124950163', '99460877'], dtype=object)), ('drugbank', array(['DB11526'], dtype=object)), ('chEBI', array(['63450'], dtype=object))]_|_['CHEMBL5315058']_|_{'rows': array(['EFO_0002618', 'EFO_0002617', 'MONDO_0004975', 'MONDO_0004979',
       'MONDO_0100096', 'EFO_0000616', 'MONDO_0008315', 'MONDO_0008170',
       'EFO_0003840', 'EFO_0000685', 'EFO_0009001', 'EFO_0001378',
       'MONDO_0011719', 'MONDO_0004976', 'EFO_0000676', 'MONDO_0016586',
       'MONDO_0005301'], dtype=object), 'count': 17}_|_[ENSG00000068078,ENSG00000157404,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for neoplasm and has 16 investigational indications."
CHEMBL2103810,"CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1.Cl_|_XJDYQYNYISTAMO-GFDYFVENSA-N_|_Small molecule_|_False_|_EZATIOSTAT HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL2110585_|_False_|_False_|_['Telintra']_|_['Ezatiostat hcl' 'Ezatiostat hydrochloride' 'TER-199' 'TER199'
 'TLK-199 HYDROCHLORIDE' 'TLK199']_|_nan_|_nan_|_{'rows': array(['MONDO_0001475', 'EFO_0000198'], dtype=object), 'count': 2}_|_[ENSG00000084207]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108985,"nan_|_nan_|_Oligonucleotide_|_False_|_APRINOCARSEN SODIUM_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Aprinocarsen nonadecasodium salt' 'Aprinocarsen sodium' 'ISIS 5321'
 'ISIS-5321']_|_nan_|_nan_|_nan_|_[ENSG00000154229]_|_Oligonucleotide drug."
CHEMBL2146110,"Cl.Fc1ccc(-c2cncc(CNC[C@H]3CCc4ccccc4O3)c2)cc1_|_QDLVYMYXOLGZOD-ZMBIFBSDSA-N_|_Small molecule_|_False_|_SARIZOTAN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL220808_|_False_|_False_|_[]_|_['EMD 128130' 'EMD-128130' 'Emd128130' 'Sarizotan hcl'
 'Sarizotan hydrochloride']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0004280'], dtype=object), 'count': 2}_|_[ENSG00000149295,ENSG00000069696,ENSG00000151577,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3301618,"CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1_|_QSPOQCXMGPDIHI-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOTOLIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Motolimod' 'VTX-2337' 'VTX-378']_|_[('drugbank', array(['DB12303'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007535', 'EFO_0000707', 'MONDO_0044926', 'MONDO_0008170',
       'EFO_0002938', 'EFO_0006352', 'EFO_0000574', 'MONDO_0002158',
       'EFO_0000181', 'EFO_0003871'], dtype=object), 'count': 10}_|_[ENSG00000101916]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL3544968,"nan_|_nan_|_Small molecule_|_False_|_GSK-610677_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Gsk-610677']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL44657,"COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O_|_VJJPUSNTGOMMGY-MRVIYFEKSA-N_|_Small molecule_|_True_|_ETOPOSIDE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Etoposide' 'Toposar' 'Vepesid']_|_['Etoposide' 'Etoposide resolution mixture' 'Etoposidum' 'NSC-141540'
 'Sintopozid' 'VP-16-213']_|_[('DailyMed', array(['etoposide'], dtype=object)), ('PubChem', array(['164339423', '56463308'], dtype=object)), ('TG-GATEs', array(['131'], dtype=object)), ('Wikipedia', array(['Etoposide'], dtype=object)), ('drugbank', array(['DB00773'], dtype=object)), ('chEBI', array(['4911'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008524', 'EFO_0005235', 'EFO_0000191', 'EFO_0000094',
       'EFO_0009441', 'EFO_0003811', 'MONDO_0002158', 'MONDO_0004992',
       'MONDO_0015760', 'MONDO_0001475', 'EFO_1000437', 'MONDO_0016717',
       'EFO_0000502', 'EFO_0000621', 'EFO_0003025', 'EFO_0000221',
       'EFO_1000564', 'MONDO_0002601', 'EFO_0005952', 'EFO_0004281',
       'MONDO_0013730', 'EFO_0000209', 'MONDO_0006058', 'EFO_0000637',
       'EFO_0000223', 'EFO_0003802', 'EFO_0000211', 'MONDO_0021657',
       'MONDO_0019472', 'EFO_0006475', 'EFO_0000180', 'EFO_0000616',
       'EFO_0004289', 'MONDO_0021193', 'MONDO_0001056', 'MONDO_0002367',
       'MONDO_0005575', 'EFO_1001052', 'EFO_0000558', 'EFO_0000174',
       'MONDO_0018906', 'MONDO_0008380', 'EFO_0004256', 'EFO_1000574',
       'EFO_0000702', 'MONDO_0008170', 'EFO_0000095', 'EFO_0000313',
       'EFO_0000632', 'MONDO_0020077', 'MONDO_0009348', 'EFO_0000248',
       'EFO_0000630', 'EFO_1001469', 'EFO_0000198', 'EFO_0000220',
       'EFO_1001365', 'MONDO_0003478', 'HP_0001871', 'MONDO_0003001',
       'EFO_0000519', 'EFO_1001465', 'EFO_0007362', 'EFO_0003032',
       'EFO_0003060', 'MONDO_0002087', 'EFO_1001383', 'EFO_1001968',
       'EFO_1000581', 'EFO_0003027', 'MONDO_0016691', 'EFO_0004251',
       'MONDO_0003751', 'EFO_0003028', 'EFO_0007416', 'MONDO_0015540',
       'EFO_0000437', 'MONDO_0024503', 'MONDO_0044917', 'EFO_0007498',
       'EFO_0000309', 'EFO_1000292', 'EFO_0000339', 'EFO_0003833',
       'MONDO_0002730', 'MONDO_0004095', 'MONDO_0019004', 'MONDO_0000870',
       'EFO_0000514', 'EFO_0000691', 'EFO_1000415', 'MONDO_0000873',
       'EFO_0002626', 'EFO_0001061', 'EFO_0004991', 'EFO_0002618',
       'MONDO_0015564', 'EFO_0000182', 'MONDO_0016700', 'EFO_0003029',
       'EFO_0009538', 'EFO_0004599', 'EFO_1001779', 'EFO_0000222',
       'MONDO_0002120', 'EFO_1000026', 'MONDO_0001657', 'MONDO_0100096',
       'MONDO_0044881', 'MONDO_0008903', 'EFO_0009254', 'MONDO_0007254',
       'EFO_1000796', 'EFO_0003929', 'EFO_0000565', 'EFO_0000218',
       'EFO_0000183', 'MONDO_0018944', 'EFO_1000028', 'MONDO_0021364',
       'EFO_0005088', 'EFO_1001471', 'EFO_0000574', 'EFO_0002939',
       'EFO_0001378', 'EFO_0005543', 'EFO_0002499', 'EFO_0002918',
       'EFO_0000571', 'EFO_0000403', 'MONDO_0019471', 'EFO_0002501',
       'EFO_0002428', 'EFO_0000765', 'EFO_0000708', 'MONDO_0008315',
       'EFO_1000158', 'EFO_0000096'], dtype=object), 'count': 138}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 5 approved and 133 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4594598,"nan_|_nan_|_Unknown_|_False_|_EFTRENONACOG ALFA_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Alprolix']_|_['Alprolix' 'BIIB-029' 'Eftrenonacog alfa' 'Rfixfc']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604', 'MONDO_0018660'], dtype=object), 'count': 2}_|_[ENSG00000101981]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for hemophilia b and has 1 investigational indication."
CHEMBL5314551,"nan_|_nan_|_Antibody_|_False_|_ADAKITUG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A33 124i' 'Adakitug' 'BMS-986253' 'BMS-986253-01' 'BMS986253'
 'Bms 986253' 'HuMax-IL8' 'Humax-il-8' 'Humax-il8' 'Humax-inflam'
 'MDX-018' 'aIL8']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ADAKITUG/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_1001950', 'MONDO_0004992', 'EFO_0002618',
       'EFO_0000181', 'EFO_0000756', 'EFO_0000198', 'EFO_0000673',
       'EFO_0000182', 'EFO_0000616'], dtype=object), 'count': 10}_|_[ENSG00000169429]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL544665,"CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1.Cl_|_SWZTYAVBMYWFGS-UHFFFAOYSA-N_|_Small molecule_|_False_|_FINGOLIMOD HYDROCHLORIDE_|_2010.0_|_4.0_|_CHEMBL314854_|_False_|_True_|_['Gilenya']_|_['FTY-720 HYDROCHLORIDE' 'FTY720' 'FTY720 HYDROCHLORIDE'
 'Fingolimod (as hydrochloride)' 'Fingolimod hcl'
 'Fingolimod hydrochlorid' 'Fingolimod hydrochloride' 'Gilenia']_|_[('DailyMed', array(['fingolimod%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gilenya'],
      dtype=object)), ('chEBI', array(['63112'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'MONDO_0004976', 'EFO_0000305', 'MONDO_0005301'],
      dtype=object), 'count': 4}_|_[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for multiple sclerosis and has 3 investigational indications."
CHEMBL648,"CN1CCN(C(c2ccccc2)c2ccccc2)CC1_|_UVKZSORBKUEBAZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLIZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Cyclizine' 'Marezine' 'NSC-26608']_|_[('PubChem', array(['11112316', '124882239', '26747952'], dtype=object)), ('Wikipedia', array(['Cyclizine'], dtype=object)), ('drugbank', array(['DB01176'], dtype=object)), ('chEBI', array(['3994'], dtype=object))]_|_['CHEMBL1324714' 'CHEMBL3189137' 'CHEMBL1200497']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease."
CHEMBL989,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1_|_FEBLZLNTKCEFIT-VSXGLTOVSA-N_|_Small molecule_|_False_|_FLUOCINOLONE ACETONIDE_|_1963.0_|_4.0_|_nan_|_False_|_True_|_['Capex' 'Derma-smoothe/fs' 'Dermotic' 'Fluocet' 'Fluocinolone acetonide'
 'Fluonid' 'Fluotrex' 'Iluvien' 'Retisert' 'Synalar' 'Synalar fte'
 'Synalar-c' 'Synalar-hp' 'Synalar-n' 'Synandone' 'Yutiq']_|_['Flucinolone acetonide' 'Fluocinolide (acetate)' 'Fluocinolone'
 'Fluocinolone acetonide' 'NSC-92339' 'Oto-synalar']_|_[('DailyMed', array(['fluocinolone%20acetonide'], dtype=object)), ('PubChem', array(['144204420', '144212681', '170464630', '29214997', '398387',
       '56422130', '855535'], dtype=object)), ('Wikipedia', array(['Fluocinolone_acetonide'], dtype=object)), ('drugbank', array(['DB00591'], dtype=object)), ('chEBI', array(['31623'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000764', 'EFO_0009560', 'EFO_0005741', 'EFO_0009552',
       'EFO_0000701', 'EFO_1000986', 'EFO_1000811', 'EFO_0000274',
       'EFO_1001119', 'EFO_0003963', 'EFO_0000676', 'EFO_1001231',
       'EFO_0005752', 'MONDO_0005041', 'MONDO_0003005', 'EFO_0009606',
       'EFO_0003839', 'EFO_0001365'], dtype=object), 'count': 18}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 10 approved and 8 investigational indications."
CHEMBL1200749,"CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl_|_SIEYLFHKZGLBNX-NTISSMGPSA-N_|_Small molecule_|_False_|_LEVOBUPIVACAINE HYDROCHLORIDE_|_1999.0_|_4.0_|_CHEMBL1201193_|_False_|_True_|_['Chirocaine' 'Levobupivac']_|_['Bupivacaine (-)-form hydrochloride' 'CHIROCAINE' 'Levobupivacaine hcl'
 'Levobupivacaine hydrochloride']_|_[('PubChem', array(['144205259', '170465452'], dtype=object)), ('chEBI', array(['31772'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0002950'], dtype=object), 'count': 2}_|_[ENSG00000007314]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications."
CHEMBL1201565,"nan_|_nan_|_Protein_|_False_|_EPOETIN ALFA_|_1989.0_|_4.0_|_nan_|_False_|_True_|_['Abseamed' 'Binocrit' 'Epogen' 'Eprex' 'Procrit']_|_['EPO' 'Epoetin' 'Epoetin alfa' 'Erythropoietin'
 'Erythropoietin for bioassays']_|_[('DailyMed', array(['epoetin%20alfa-epbx'], dtype=object)), ('DrugCentral', array(['4995'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/abseamed'],
      dtype=object)), ('Wikipedia', array(['Epoetin_alfa'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0003884', 'EFO_0000764', 'HP_0012378',
       'EFO_0003047', 'EFO_0000612', 'MONDO_0007254', 'EFO_0009492',
       'EFO_0003917', 'EFO_1001459', 'EFO_0002618', 'EFO_0001645',
       'EFO_0004272', 'EFO_0003100', 'MONDO_0004992', 'EFO_0001663',
       'EFO_1001100', 'MONDO_0011382', 'EFO_0006859', 'EFO_1001779',
       'MONDO_0100339', 'MONDO_0043510', 'MONDO_0002280', 'EFO_0009909',
       'EFO_0001416', 'EFO_0000712', 'MONDO_0008903', 'MONDO_0001240',
       'EFO_0000198', 'Orphanet_848', 'EFO_0003890', 'EFO_0008585',
       'MONDO_0005299', 'EFO_0000222', 'EFO_0009446', 'HP_0004936'],
      dtype=object), 'count': 36}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 5 approved and 31 investigational indications."
CHEMBL1263,"OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O_|_GIIZNNXWQWCKIB-UHFFFAOYSA-N_|_Small molecule_|_True_|_SALMETEROL_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Beglan' 'Neovent' 'Serevent' 'Soltel' 'Vertine']_|_['Cryogenine' 'GR 33343 X' 'GR-33343-X' 'GR-33343X' 'NSC-272693' 'SN408D'
 'Salmaterol' 'Salmeterol' 'Serevent']_|_[('PubChem', array(['144207133', '26719802'], dtype=object)), ('Wikipedia', array(['Salmeterol'], dtype=object)), ('drugbank', array(['DB00938'], dtype=object)), ('chEBI', array(['64064'], dtype=object))]_|_['CHEMBL3126379' 'CHEMBL1082607']_|_{'rows': array(['MONDO_0004979', 'EFO_0001073', 'EFO_1001919', 'EFO_0006505',
       'HP_0006536', 'EFO_0000341', 'EFO_0000464', 'MONDO_0004979',
       'EFO_0006505', 'EFO_0007183', 'EFO_0000341', 'EFO_0000464'],
      dtype=object), 'count': 12}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 5 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1364551,"Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1.Cl.Cl_|_GNUCGROXDZMCJI-UHFFFAOYSA-N_|_Small molecule_|_False_|_MINAPRINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL278819_|_True_|_True_|_['Cantor']_|_['30038-CB' '30038CB' 'Minaprine dihydrochloride' 'Minaprine hcl'
 'Minaprine hydrochloride' 'NSC-305742']_|_[('PubChem', array(['144204908', '170466172', '26748498'], dtype=object)), ('chEBI', array(['51040'], dtype=object))]_|_nan_|_nan_|_[ENSG00000189221,ENSG00000149295,ENSG00000184845,ENSG00000168539,ENSG00000135914,ENSG00000102468,ENSG00000147246,ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1472,"NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1_|_XNSAINXGIQZQOO-SRVKXCTJSA-N_|_Protein_|_False_|_PROTIRELIN_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Thypinone' 'Thyrel trh' 'Trh-cambridge']_|_['5-oxo-pro-his-pro-nh2' 'A-38579' 'ABBOTT-38579' 'Lopremone' 'NSC-760113'
 'Protirelin' 'Protirelin tartrate' 'Protirelin, synthetic' 'Relefact trh'
 'SYNTHETIC TRH' 'Synthetic TRH' 'Thyroid releasing hormone'
 'Thyroliberin' 'Thyrotropin releasing hormone'
 'Thyrotropin-releasing factor' 'Thyrotropin-releasing hormone']_|_[('PubChem', array(['144205492', '29216304'], dtype=object)), ('Wikipedia', array(['Thyrotropin-releasing_hormone'], dtype=object)), ('drugbank', array(['DB09421'], dtype=object)), ('chEBI', array(['35940'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000637', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000174417]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 2 investigational indications."
CHEMBL1530428,"CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_AKUJBENLRBOFTD-RPRRAYFGSA-N_|_Small molecule_|_False_|_DEXAMETHASONE ACETATE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Decadron-la' 'Dexamethasone acetate']_|_['Dectancyl' 'Dexamethasone 21-acetate' 'Dexamethasone acetate'
 'Dexamethasone acetate anhydrous' 'Dexamethasone acetate monohydrate'
 'Dexamethasoni acetas' 'Dexamethasoni acetas monohydrate'
 'Fortecortin (crystal suspension)' 'NSC-39471']_|_[('PubChem', array(['144204050', '144206481', '170466872', '56423129', '855773'],
      dtype=object)), ('drugbank', array(['DB14649'], dtype=object)), ('chEBI', array(['4463'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565', 'EFO_0000574', 'EFO_0001378', 'EFO_1000652',
       'EFO_1001216'], dtype=object), 'count': 5}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 5 investigational indications."
CHEMBL1557,"Cl.NCCc1ccc(O)c(O)c1_|_CTENFNNZBMHDDG-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOPAMINE HYDROCHLORIDE_|_1974.0_|_4.0_|_CHEMBL59_|_False_|_True_|_['Dopamin-Natterman' 'Dopamine hydrochloride' 'Dopmin' 'Dynatra'
 'Intropin' 'Sabax Dopamin' 'Selectajet']_|_['ASL-279' 'Cardiosteril' 'Dopamine hcl' 'Dopamine hydrochloride'
 'Dopamini hydrochloridum' 'Inotropin' 'NSC-169105' 'Tensamin']_|_[('DailyMed', array(['dopamine%20hydrochloride'], dtype=object)), ('PubChem', array(['11532883', '144208216', '26747527', '26747528', '50106387',
       '50106388', '56424030'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0000612', 'EFO_0000373', 'EFO_1002048'],
      dtype=object), 'count': 4}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and has 3 approved and 1 investigational indication."
CHEMBL1795072,"nan_|_nan_|_Protein_|_True_|_ZICONOTIDE ACETATE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Prialt']_|_['Ziconotide acetate']_|_[('DailyMed', array(['ziconotide%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/prialt'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000148408]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2004. This drug has a black box warning from the FDA."
CHEMBL2108672,"nan_|_nan_|_Antibody drug conjugate_|_False_|_VORSETUZUMAB MAFODOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_['Sgn-75']_|_['SGN-75' 'Vorsetuzumab mafodotin']_|_nan_|_nan_|_{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}_|_[ENSG00000125726]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109355,"nan_|_nan_|_Antibody_|_False_|_DUSIGITUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dusigitumab' 'MEDI-573' 'MEDI573']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0004992', 'EFO_0000182'], dtype=object), 'count': 3}_|_[ENSG00000167244,ENSG00000017427]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2109447,"nan_|_nan_|_Antibody_|_False_|_LYM-1_|_nan_|_3.0_|_nan_|_False_|_False_|_['Oncolym']_|_['LYM-1' 'Lym-1']_|_nan_|_nan_|_{'rows': array(['EFO_0000574'], dtype=object), 'count': 1}_|_[ENSG00000196126]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2109613,"nan_|_nan_|_Antibody_|_False_|_PF-04236921_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF 4236921' 'PF-04236921' 'PF-4236921' 'Pf-04236921']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'MONDO_0007915'], dtype=object), 'count': 2}_|_[ENSG00000136244]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109622,"nan_|_nan_|_Antibody_|_False_|_PF-04605412_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PF-04605412' 'PF04605412' 'Pf 04605412' 'Pf-04605412']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000161638]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2110368,"C/N=C(\NC)NCc1ccccc1.C/N=C(\NC)NCc1ccccc1.O=S(=O)(O)O_|_YTIJUXVIZLYQTB-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETHANIDINE SULFATE_|_1982.0_|_4.0_|_CHEMBL1201260_|_False_|_True_|_['Bendogen' 'Esbatal' 'Tenathan']_|_['BW-467-C-60' 'Betanidine sulfate' 'Betanidine sulphate'
 'Bethanidine sulfate' 'Bethanidine sulphate' 'NSC-106563']_|_[('chEBI', array(['31279'], dtype=object))]_|_nan_|_nan_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL2151572,"O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1_|_SSRDSYXGYPJKRR-ZDUSSCGKSA-N_|_Small molecule_|_False_|_ENCENICLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['EVP-6124' 'Encenicline' 'Evp-6124' 'MT-4666' 'MT4666']_|_[('drugbank', array(['DB11726'], dtype=object))]_|_['CHEMBL3137323']_|_{'rows': array(['HP_0000726', 'EFO_0005411', 'HP_0100543', 'EFO_0003086',
       'MONDO_0004975', 'MONDO_0005090', 'EFO_0001421', 'MONDO_0005090',
       'MONDO_0004975'], dtype=object), 'count': 9}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL240163,"C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23_|_XAGMUUZPGZWTRP-ZETCQYMHSA-N_|_Small molecule_|_False_|_PAZUFLOXACIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Pazufloxacin' 'T-3761']_|_[('PubChem', array(['144206084', '170465985', '26719888', '49681761', '50112787'],
      dtype=object)), ('drugbank', array(['DB11774'], dtype=object))]_|_['CHEMBL3764913']_|_{'rows': array(['EFO_0004992', 'EFO_0000771', 'EFO_1000829'], dtype=object), 'count': 3}_|_[ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3137352,"nan_|_nan_|_Antibody_|_False_|_RALPANCIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-05335810' 'RN-317' 'RN317' 'Ralpancizumab']_|_nan_|_nan_|_{'rows': array(['HP_0003124'], dtype=object), 'count': 1}_|_[ENSG00000169174]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3304485,"CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1_|_DNHPDWGIXIMXSA-CXNSMIOJSA-N_|_Small molecule_|_True_|_TENAPANOR_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AZD-1722' 'KHK-7791' 'Khk7791' 'Tenapanor']_|_[('drugbank', array(['DB11761'], dtype=object))]_|_['CHEMBL3301627']_|_{'rows': array(['EFO_0003884', 'EFO_0000555', 'MONDO_0002203', 'HP_0002905',
       'EFO_0000555', 'HP_0002905', 'HP_0002019'], dtype=object), 'count': 7}_|_[ENSG00000066230]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL38380,"O=S(=O)(c1cccc2cnccc12)N1CCCNCC1_|_NGOGFTYYXHNFQH-UHFFFAOYSA-N_|_Small molecule_|_False_|_FASUDIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AT 877' 'AT-877' 'Fasudil' 'HA 1077' 'HA-1077' 'NSC-759827' 'ZK-258594']_|_[('PubChem', array(['103905389', '103905390', '104171358', '11113364', '124883255',
       '124883258', '124883259', '26751605', '92708292'], dtype=object)), ('Wikipedia', array(['Fasudil'], dtype=object)), ('drugbank', array(['DB08162'], dtype=object))]_|_['CHEMBL4459126' 'CHEMBL541388' 'CHEMBL4435188']_|_{'rows': array(['MONDO_0004976', 'EFO_0000319', 'EFO_0000319', 'EFO_1001157',
       'EFO_0002615', 'EFO_1001158', 'HP_0000726'], dtype=object), 'count': 7}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL3989987,"nan_|_nan_|_Oligonucleotide_|_False_|_PATISIRAN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['ALN-18328' 'ALN-TTR02' 'Genz-438027' 'Patisiran' 'SAR-438037']_|_nan_|_nan_|_{'rows': array(['EFO_0004129', 'EFO_1000783', 'EFO_1001875'], dtype=object), 'count': 3}_|_[ENSG00000118271]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications."
CHEMBL4594463,"nan_|_nan_|_Antibody_|_False_|_AVDORALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-c5ar-215' 'Avdoralimab' 'IPH-5401' 'Iph5401' 'NN-8210'
 'NNC-0215-0384']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0100096', 'EFO_0007187'], dtype=object), 'count': 3}_|_[ENSG00000197405]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL501,"CC(N)Cc1ccccc1.O=S(=O)(O)O_|_SOFQDLYSFOWTJX-UHFFFAOYSA-N_|_Small molecule_|_True_|_AMPHETAMINE SULFATE_|_1960.0_|_4.0_|_CHEMBL405_|_False_|_True_|_['Amphetamine sulfate' 'Evekeo' 'Evekeo odt']_|_['Amfetamine sulfate' 'Amfetamine sulphate' 'Amphetamine Sulfate'
 'Amphetamine sulfate' 'Astedin' 'Benzedrine' 'Dl-amphetamine sulfate'
 'Dl-amphetamine sulphate' 'NSC-170999']_|_[('DailyMed', array(['amphetamine%20sulfate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'MONDO_0016158', 'EFO_0003888', 'EFO_0002610'],
      dtype=object), 'count': 4}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL5314386,"Cc1c(O)ccc2c1OC[C@@H](c1ccc(O)cc1)[C@H]2c1ccc(O)cc1_|_QVCAATSEPLQVBX-FPOVZHCZSA-N_|_Small molecule_|_False_|_ME-344_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Me 344' 'Me-344']_|_nan_|_nan_|_{'rows': array(['EFO_0000305', 'EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 3}_|_[ENSG00000198695,ENSG00000130414,ENSG00000110717,ENSG00000212907,ENSG00000184983,ENSG00000198888,ENSG00000165264,ENSG00000189043,ENSG00000174886,ENSG00000099795,ENSG00000198763,ENSG00000158864,ENSG00000198786,ENSG00000119421,ENSG00000136521,ENSG00000198886,ENSG00000198840,ENSG00000004779,ENSG00000125356,ENSG00000164258,ENSG00000119013,ENSG00000109390,ENSG00000131495,ENSG00000168653,ENSG00000115286,ENSG00000145494,ENSG00000183648,ENSG00000213619,ENSG00000170906,ENSG00000065518,ENSG00000166136,ENSG00000090266,ENSG00000267855,ENSG00000151366,ENSG00000140990,ENSG00000178127,ENSG00000023228,ENSG00000167792,ENSG00000160194,ENSG00000128609,ENSG00000139180,ENSG00000164182,ENSG00000178057,ENSG00000185633,ENSG00000147123,ENSG00000123545,ENSG00000186010,ENSG00000184752,ENSG00000137806,ENSG00000147684]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL592445,"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1_|_DWZAEMINVBZMHQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_GEDATOLISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gedatolisib' 'PF-05212384' 'PKI-587']_|_[('drugbank', array(['DB11896'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'MONDO_0004992', 'EFO_0005537', 'EFO_0004230',
       'EFO_0003060', 'EFO_0000222', 'MONDO_0007254', 'EFO_0000616'],
      dtype=object), 'count': 8}_|_[ENSG00000198793,ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL103,"CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C_|_RJKFOVLPORLFTN-LEKSSAKUSA-N_|_Small molecule_|_True_|_PROGESTERONE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Crinone' 'Cyclogest' 'Endometrin' 'Gesterol' 'Lutigest' 'Milprosa'
 'Prochieve' 'Progesta-care' 'Progestasert' 'Progesterone' 'Progestin'
 'Prometrium' 'Regumate' 'Serenity for women' 'Syngestrone' 'Utrogestan']_|_['NSC-64377' 'NSC-9704' 'Progesterone' 'Progesterone, micronized'
 'Progesteronum' 'U 3672']_|_[('DailyMed', array(['progesterone'], dtype=object)), ('PubChem', array(['144206708', '144208990', '144210627', '17388760', '17389514',
       '26719639', '26751485', '26751486', '50104004', '50104005',
       '50104007', '56424141', '75083', '855688', '90340816'],
      dtype=object)), ('Wikipedia', array(['Progesterone'], dtype=object)), ('drugbank', array(['DB00396'], dtype=object)), ('chEBI', array(['17026'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000938', 'MONDO_0005351', 'MONDO_0005147', 'MONDO_0022394',
       'EFO_0010269', 'MP_0001914', 'EFO_1000623', 'EFO_0000731',
       'EFO_1000098', 'EFO_0000474', 'EFO_0005204', 'EFO_0002950',
       'EFO_0001645', 'EFO_0003869', 'EFO_0000400', 'EFO_0000180',
       'EFO_0007453', 'EFO_0000668', 'MONDO_0100096', 'MONDO_0007254',
       'EFO_0003917', 'MONDO_0004975', 'EFO_1000645', 'EFO_0004701',
       'EFO_0008560', 'EFO_0000537', 'MONDO_0011972', 'EFO_0007442',
       'EFO_0007191', 'EFO_1000985', 'EFO_0003768', 'EFO_0000660',
       'EFO_1001465', 'EFO_0000545', 'MONDO_0000831', 'MONDO_0043510',
       'MONDO_0011962', 'EFO_1001375', 'EFO_0003882', 'EFO_0001072',
       'GO_0042697', 'HP_0003124', 'EFO_0002610', 'EFO_0003893'],
      dtype=object), 'count': 44}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 3 approved and 41 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1189432,"CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21_|_JBIMVDZLSHOPLA-LSCVHKIXSA-N_|_Small molecule_|_False_|_OLOPATADINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Opatanol']_|_['AL-4943A' 'Olopatadine']_|_[('Wikipedia', array(['Olopatadine'], dtype=object)), ('drugbank', array(['DB00768'], dtype=object))]_|_['CHEMBL1719']_|_{'rows': array(['EFO_0005854', 'EFO_1001417', 'EFO_0007141', 'EFO_0003956',
       'EFO_0005751', 'HP_0001742', 'HP_0000989', 'EFO_0003956',
       'EFO_0007141', 'EFO_0005854'], dtype=object), 'count': 10}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 6 approved and 4 investigational indications."
CHEMBL1200527,"COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1_|_XXZSQOVSEBAPGS-UHFFFAOYSA-L_|_Small molecule_|_False_|_ATRACURIUM BESYLATE_|_1983.0_|_4.0_|_CHEMBL1360_|_False_|_True_|_['Atracurium Besilate' 'Atracurium besylate'
 'Atracurium besylate preservative free' 'Tracrium'
 'Tracrium preservative free']_|_['Atracurium besilate' 'Atracurium besylate' 'Atracurium dibesylate'
 'BW 33A' 'BW-33A' 'NSC-760047']_|_[('DailyMed', array(['atracurium%20besylate'], dtype=object)), ('PubChem', array(['144204341', '174006843'], dtype=object)), ('drugbank', array(['DB00732'], dtype=object)), ('chEBI', array(['2915'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983."
CHEMBL1200775,"CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1_|_RGLRXNKKBLIBQS-XNHQSDQCSA-N_|_Protein_|_False_|_LEUPROLIDE ACETATE_|_1985.0_|_4.0_|_CHEMBL1201199_|_False_|_True_|_['Carcinil' 'Eligard' 'Eligard kit' 'Fensolvi kit' 'Leuprolide acetate'
 'Leuprorelin' 'Lupron' 'Lupron Depot Ped' 'Lupron depot'
 'Lupron depot-ped' 'Lupron depot-ped kit' 'Lutrate depot kit' 'Viadur']_|_['A-43818' 'ABBOTT-43818' 'Carcinil' 'Enantone' 'Fensolvi' 'Leuplin'
 'Leuporelin acetate' 'Leuprolide acetate' 'Leuprolide monoacetate'
 'Leuprorelin acetate' 'Lucrin' 'Lupaneta' 'Lutrate depot' 'Prostap'
 'TAP-144' 'Tap-144-sr' 'Trenantone']_|_[('DailyMed', array(['leuprolide%20acetate'], dtype=object)), ('PubChem', array(['144207056'], dtype=object)), ('chEBI', array(['63597'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009029', 'EFO_0001378', 'MONDO_0004975', 'EFO_0004248',
       'EFO_0005204', 'EFO_0000731', 'EFO_0000537', 'MONDO_0000088',
       'MONDO_0000521', 'EFO_0003869', 'EFO_1001469', 'MONDO_0007254',
       'MONDO_0008315', 'EFO_0000673', 'MONDO_0004992', 'EFO_0001073',
       'EFO_0000183', 'EFO_0001663', 'EFO_0001065', 'EFO_0000196',
       'HP_0100543', 'EFO_0007453'], dtype=object), 'count': 22}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 6 approved and 16 investigational indications."
CHEMBL1200975,"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C_|_SXYZQZLHAIHKKY-GSTUPEFVSA-N_|_Small molecule_|_False_|_CLOCORTOLONE PIVALATE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Cloderm']_|_['Clocortolone 21-pivalate' 'Clocortolone pivalate' 'SH 863' 'SH-863']_|_[('DailyMed', array(['clocortolone%20pivalate'], dtype=object)), ('PubChem', array(['144204183', '56463639'], dtype=object)), ('chEBI', array(['59583'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977."
CHEMBL1201655,nan_|_nan_|_Protein_|_False_|_INSULIN SUSP ISOPHANE PURIFIED BEEF_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Nph iletin ii']_|_['Insulin susp isophane purified beef']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1980.
CHEMBL18116,"Cc1cccc(N2CC(CO)OC2=O)c1_|_MXUNKHLAEDCYJL-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLOXATONE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Humoryl' 'Toloxatone']_|_[('Wikipedia', array(['Toloxatone'], dtype=object)), ('drugbank', array(['DB09245'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000189221]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and has 1 investigational indication."
CHEMBL2105717,"COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC_|_ONIQOQHATWINJY-UHFFFAOYSA-N_|_Small molecule_|_True_|_CABOZANTINIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Cabometyx' 'Cometriq']_|_['BMS-907351' 'BMS-907351 FREE BASE' 'Cabozantinib' 'XL-184'
 'XL-184 FREE BASE' 'XL184']_|_[('PubChem', array(['137276008'], dtype=object)), ('drugbank', array(['DB08875'], dtype=object)), ('chEBI', array(['72317'], dtype=object))]_|_['CHEMBL2103868']_|_{'rows': array(['EFO_0000519', 'EFO_0001075', 'MONDO_0004992', 'EFO_0000501',
       'EFO_1001949', 'EFO_0000640', 'EFO_0001421', 'EFO_0003968',
       'EFO_0000239', 'EFO_0000640', 'EFO_0000313', 'EFO_0000616',
       'EFO_1001512', 'EFO_0007532', 'EFO_0000681', 'EFO_0003060',
       'MONDO_0007254', 'EFO_1001968', 'MONDO_0002974', 'EFO_0003060',
       'EFO_0005220', 'EFO_1001951', 'EFO_0000326', 'EFO_0000272',
       'EFO_0000616', 'EFO_0000673', 'EFO_1000796', 'EFO_1001465',
       'EFO_0000389', 'MONDO_0002120', 'MONDO_0002108', 'EFO_0000182',
       'EFO_0004243', 'EFO_0002618', 'EFO_1000251', 'EFO_0000305',
       'EFO_1000657', 'MONDO_0011719', 'EFO_0004252', 'EFO_0008528',
       'EFO_0000349', 'EFO_0000641', 'EFO_0000222', 'EFO_0002617',
       'EFO_1000613', 'MONDO_0001187', 'MONDO_0004669', 'EFO_0000637',
       'EFO_0000519', 'EFO_1001465', 'EFO_0003016', 'EFO_0000756',
       'EFO_0000641', 'EFO_0000182', 'EFO_0002892', 'EFO_0001378',
       'MONDO_0008315', 'MONDO_0002108', 'EFO_0000637', 'MONDO_0004986',
       'EFO_0000707', 'EFO_0000349', 'MONDO_0002367', 'EFO_0000681',
       'MONDO_0016642', 'MONDO_0004992', 'EFO_0000501', 'EFO_0003863',
       'EFO_0000335', 'EFO_0008524', 'EFO_0000673', 'EFO_1001901',
       'EFO_0002499', 'MONDO_0015277', 'EFO_1001961'], dtype=object), 'count': 75}_|_[ENSG00000105976,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 9 approved and 61 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108713,"nan_|_nan_|_Antibody_|_False_|_IODINE I 124 GIRENTUXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Redectane']_|_['124ICG250' 'Girentuximab i-124' 'Girentuximab iodine-124'
 'Iodine (124i) girentuximab' 'Iodine i 124 girentuximab' 'cG250 (124I)']_|_nan_|_nan_|_nan_|_[ENSG00000107159]_|_Antibody drug with a maximum clinical trial phase of III."
CHEMBL2110732,"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1_|_LVXJQMNHJWSHET-AATRIKPKSA-N_|_Small molecule_|_False_|_DACOMITINIB ANHYDROUS_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dacomitinib anhydrous' 'Pf-00299804']_|_[('drugbank', array(['DB11963'], dtype=object))]_|_['CHEMBL2105719']_|_{'rows': array(['MONDO_0008903', 'EFO_0000616', 'MONDO_0008903', 'EFO_0003060',
       'EFO_0004284', 'MONDO_0001657', 'EFO_1001951', 'EFO_0009708',
       'MONDO_0004992', 'EFO_0000707', 'EFO_0000181', 'EFO_0000519',
       'EFO_0000616', 'EFO_0003833', 'EFO_1001094', 'EFO_0000313',
       'EFO_0001421', 'EFO_0003060', 'EFO_0000181', 'EFO_0005570'],
      dtype=object), 'count': 20}_|_[ENSG00000146648,ENSG00000141736,ENSG00000178568]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 16 investigational indications."
CHEMBL2219418,"C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](OCCOCCOCCOCCOCCOCCOCCOC)CC[C@@]3(O)[C@H]1C5_|_XNKCCCKFOQNXKV-ZRSCBOBOSA-N_|_Small molecule_|_False_|_NALOXEGOL_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Moventig']_|_['AZ-13337019' 'NKTR-118' 'Naloxegol']_|_[('drugbank', array(['DB09049'], dtype=object)), ('chEBI', array(['82975'], dtype=object))]_|_['CHEMBL2219416']_|_{'rows': array(['HP_0002019', 'MONDO_0002203', 'MONDO_0043510', 'EFO_0005611',
       'EFO_0003060', 'EFO_0005611', 'HP_0002019', 'MONDO_0004567',
       'EFO_0003843'], dtype=object), 'count': 9}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 4 investigational indications."
CHEMBL296419,"COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1_|_GXDALQBWZGODGZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ASTEMIZOLE_|_1988.0_|_4.0_|_nan_|_True_|_True_|_['Hismanal' 'Pollon-eze']_|_['Astemizole' 'GNF-Pf-2461' 'NSC-329963' 'NSC-759570' 'R 43,512']_|_[('PubChem', array(['104171329', '11112828', '124882660', '124882662', '144204231',
       '144207293', '170465888', '26746979', '26751496', '26751497',
       '56422418', '855746'], dtype=object)), ('Wikipedia', array(['Astemizole'], dtype=object)), ('drugbank', array(['DB00637'], dtype=object)), ('chEBI', array(['2896'], dtype=object))]_|_['CHEMBL1788122']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988 and is indicated for allergic disease. It was withdrawn in at least one region."
CHEMBL304087,"COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1_|_JBPUGFODGPKTDW-SFHVURJKSA-N_|_Small molecule_|_False_|_MERIMEPODIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Merimepodib' 'VI-21,497' 'VI-21497' 'VX-497']_|_[('drugbank', array(['DB04862'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096'], dtype=object), 'count': 1}_|_[ENSG00000106348]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3087515,"COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1_|_ZFPZEYHRWGMJCV-ZHALLVOQSA-N_|_Small molecule_|_False_|_MAVOGLURANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AFQ-056' 'AFQ056' 'Mavoglurant']_|_[('drugbank', array(['DB13004'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007739', 'EFO_0001421', 'EFO_0002610', 'EFO_0004329',
       'MONDO_0007079', 'EFO_0003086', 'MONDO_0010383', 'EFO_0004242',
       'EFO_0004152', 'MONDO_0005180', 'EFO_0003948'], dtype=object), 'count': 11}_|_[ENSG00000168959]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL314854,"CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1_|_KKGQTZUTZRNORY-UHFFFAOYSA-N_|_Small molecule_|_False_|_FINGOLIMOD_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Gilenya']_|_['FTY-720' 'Fingolimod']_|_[('Wikipedia', array(['Fingolimod'], dtype=object)), ('drugbank', array(['DB08868'], dtype=object)), ('chEBI', array(['63115'], dtype=object))]_|_['CHEMBL5095050' 'CHEMBL544665' 'CHEMBL3526818']_|_{'rows': array(['EFO_0008520', 'EFO_0000540', 'EFO_0002499', 'EFO_1000868',
       'MONDO_0010726', 'HP_0000083', 'MONDO_0005090', 'EFO_1001231',
       'MONDO_0004979', 'EFO_0000712', 'EFO_0007405', 'MONDO_0100096',
       'EFO_0003840', 'EFO_0003929', 'EFO_0000519', 'MONDO_0004976',
       'MONDO_0005301', 'EFO_0000305', 'EFO_0003929', 'MONDO_0005301'],
      dtype=object), 'count': 20}_|_[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for immune system disease and multiple sclerosis and has 18 investigational indications."
CHEMBL3545262,"nan_|_nan_|_Antibody drug conjugate_|_True_|_SACITUZUMAB GOVITECAN_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Trodelvy']_|_['HRS7-SN38' 'HRS7-SN38-ANTIBODY-DRUG-CONJUGATE' 'IMMU-132'
 'Sacituzumab govitecan' 'Sacituzumab govitecan hziy']_|_[('DailyMed', array(['sacituzumab%20govitecan-hziy'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000519', 'EFO_0003863', 'MONDO_0004986', 'MONDO_0004992',
       'MONDO_0007254', 'EFO_0008528', 'EFO_1001512', 'EFO_0005537',
       'EFO_0003869', 'EFO_0000702', 'MONDO_0008315', 'EFO_0003060',
       'EFO_0000616', 'MONDO_0004669', 'MONDO_0001187', 'MONDO_0002974'],
      dtype=object), 'count': 16}_|_[ENSG00000184292,ENSG00000198900]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 5 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3597971,"Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1_|_SQOCEMCKYDVLMM-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELTOREXANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['JNJ-42847922' 'MIN-202' 'Seltorexant']_|_nan_|_['CHEMBL4780973']_|_{'rows': array(['EFO_0003086', 'EFO_0004698', 'MONDO_0004975', 'MONDO_0002009',
       'EFO_0003918', 'EFO_0001421'], dtype=object), 'count': 6}_|_[ENSG00000137252]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4297905,nan_|_nan_|_Antibody_|_False_|_OSOCIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 1213790' 'BAY-1213790' 'Bay1213790' 'Osocimab']_|_nan_|_nan_|_nan_|_[ENSG00000088926]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL4594230,"nan_|_nan_|_Protein_|_False_|_LIPEGFILGRASTIM_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Lonquex']_|_['Lipegfilgrastim' 'XM-22' 'XM22']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000174', 'EFO_0000574', 'MONDO_0001475'],
      dtype=object), 'count': 4}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for neoplasm and neutropenia and has 2 investigational indications."
CHEMBL4594287,"COc1cc2c(cc1OC)-c1c/c(=N\c3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2_|_CSOBIBXVIYAXFM-BYNJWEBRSA-N_|_Small molecule_|_False_|_ENSIFENTRINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ensifentrine' 'Ls-193,855' 'Ls-193855' 'RPL-554' 'RPL554']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENSIFENTRINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000341', 'MONDO_0009061', 'MONDO_0004979'],
      dtype=object), 'count': 4}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4650470,"nan_|_nan_|_Protein_|_False_|_EFPEGLENATIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Efpeglenatide' 'HM-11260C' 'HM11260C' 'Hm11260c' 'Langlenatide'
 'SAR-439977' 'SAR439977']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EFPEGLENATIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0001073', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL469,"O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O_|_OZWKMVRBQXNZKK-UHFFFAOYSA-N_|_Small molecule_|_True_|_KETOROLAC_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ketorolac']_|_[('PubChem', array(['174007295', '90341692'], dtype=object)), ('Wikipedia', array(['Ketorolac'], dtype=object)), ('drugbank', array(['DB00465'], dtype=object)), ('chEBI', array(['76223'], dtype=object))]_|_['CHEMBL1201124']_|_{'rows': array(['EFO_0003777', 'EFO_0005755', 'EFO_0003869', 'HP_0003418',
       'HP_0011110', 'EFO_1001178', 'EFO_0003843', 'EFO_0008571',
       'EFO_1001250', 'HP_0002315', 'EFO_0000649', 'MONDO_0003005',
       'EFO_0000668', 'EFO_0004616', 'EFO_1001158', 'MP_0001845',
       'HP_0200026', 'EFO_0000546', 'EFO_0009676', 'HP_0002015',
       'EFO_1001412', 'EFO_0004273', 'EFO_0003843', 'MONDO_0005277',
       'MONDO_0005129', 'HP_0002027', 'MONDO_0005184', 'EFO_1000859',
       'EFO_1001139', 'MONDO_0005277', 'EFO_1001412', 'EFO_1000652',
       'HP_0012532', 'MP_0001845', 'EFO_0009444', 'HP_0003418',
       'MONDO_0002087', 'EFO_0005752', 'MONDO_0005129', 'HP_0000616',
       'EFO_0005854', 'MONDO_0008170', 'EFO_0004253', 'EFO_0003770',
       'EFO_0004253', 'MONDO_0002158', 'MONDO_0002367'], dtype=object), 'count': 47}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 6 approved and 39 investigational indications. This drug has a black box warning from the FDA."
CHEMBL505,"CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1_|_SOYKEARSMXGVTM-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORPHENIRAMINE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Antagonate' 'Chlor-Trimeton' 'Chlorphenamine' 'Chlorpheniramine'
 'Isoclor' 'Kloromin' 'Phenetron' 'Teldrin']_|_[('PubChem', array(['174006626', '174007153', '50110994', '90340572'], dtype=object)), ('TG-GATEs', array(['90'], dtype=object)), ('Wikipedia', array(['Chlorphenamine'], dtype=object)), ('drugbank', array(['DB01114'], dtype=object)), ('chEBI', array(['52010'], dtype=object))]_|_['CHEMBL1201659' 'CHEMBL180454' 'CHEMBL1659']_|_{'rows': array(['EFO_0007328', 'EFO_0005854', 'MONDO_0005271', 'HP_0003418',
       'EFO_0003843', 'HP_0012735', 'HP_0002315', 'MONDO_0005271',
       'EFO_0007214', 'HP_0001742', 'HP_0001945', 'EFO_0003956',
       'EFO_0003956', 'MONDO_0002258', 'EFO_0003958', 'EFO_0007486',
       'EFO_0004239'], dtype=object), 'count': 17}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 12 approved and 4 investigational indications."
CHEMBL5314363,"CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl.Cl.O_|_BOQNMOQMVACUOG-BXUUEFRQSA-N_|_Small molecule_|_False_|_APOMORPHINE HYDROCHLORIDE_|_2001.0_|_4.0_|_CHEMBL53_|_False_|_True_|_['Apo-go' 'Apo-go pen' 'Apo-go pfs' 'Apokyn' 'Apomorph hcl' 'Britaject'
 'Dacepton' 'Diagesil' 'Diamorph hcl' 'Diamorph roche'
 'Diamorph,cocaine,chlorpromazine' 'Diaphine' 'Kynmobi' 'Uprima']_|_['Apokinon' 'Apomine' 'Apomorphine hcl' 'Apomorphine hydrochloride'
 'Apomorphine hydrochloride hemihydrate'
 'Apomorphine hydrochloride hydrate' 'Apomorphinum muriaticum'
 'Diamorphine hydrochloride ' 'Ixense' 'Kw-6500' 'NSC-11442' 'NSC-755875'
 'Taluvian']_|_[('DailyMed', array(['apomorphine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/uprima'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000802', 'MONDO_0005180', 'EFO_0000616', 'EFO_0003882'],
      dtype=object), 'count': 4}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for impotence and parkinson disease and has 2 investigational indications."
CHEMBL761,"c1ccc2c(CC3=NCCN3)cccc2c1_|_CNIIGCLFLJGOGP-UHFFFAOYSA-N_|_Small molecule_|_False_|_NAPHAZOLINE_|_1971.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Nafazair' 'Nafazolin' 'Naphazoline']_|_[('PubChem', array(['11112411', '26751615'], dtype=object)), ('Wikipedia', array(['Naphazoline'], dtype=object)), ('drugbank', array(['DB06711'], dtype=object))]_|_['CHEMBL1706']_|_{'rows': array(['EFO_0007214', 'EFO_0000678', 'MP_0001845', 'EFO_0007141',
       'EFO_0000616', 'HP_0001742', 'EFO_0007328', 'EFO_0003822',
       'EFO_0003956', 'EFO_0005751', 'EFO_0007214', 'EFO_0007486',
       'HP_0001742'], dtype=object), 'count': 13}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 7 investigational indications."
CHEMBL878,"Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C_|_AQCHWTWZEMGIFD-UHFFFAOYSA-N_|_Small molecule_|_False_|_METOLAZONE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Diulo' 'Metenix' 'Metolazone' 'Mykrox' 'Xuret' 'Zaroxolyn']_|_['Metazoline' 'Metolazone' 'Metozalone' 'NSC-759581' 'Normelan' 'Oldren'
 'SR 720-22' 'SR-720-22']_|_[('DailyMed', array(['metolazone'], dtype=object)), ('PubChem', array(['144203737', '144207075', '170464665', '26747536', '26747537',
       '26753589', '26753590', '56463247'], dtype=object)), ('Wikipedia', array(['Metolazone'], dtype=object)), ('drugbank', array(['DB00524'], dtype=object)), ('chEBI', array(['64354'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0003144', 'EFO_0003884', 'EFO_0000373',
       'EFO_0000537', 'EFO_0000668'], dtype=object), 'count': 6}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 5 approved and 1 investigational indication."
CHEMBL969,"O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1_|_MWQCHHACWWAQLJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRAZEPAM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Centrax' 'Demetrin' 'Prazepam']_|_['NSC-277179' 'Prazepam' 'Prazepam civ' 'W 4020' 'W-4020']_|_[('PubChem', array(['144206168', '144207274', '50113069'], dtype=object)), ('Wikipedia', array(['Prazepam'], dtype=object)), ('drugbank', array(['DB01588'], dtype=object)), ('chEBI', array(['8362'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for anxiety."
CHEMBL119385,"O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl_|_VEPKQEUBKLEPRA-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEFLAMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['745' 'Neflamapimod' 'VD-31' 'VD-31,745' 'VD-31745' 'VRT-031745' 'VX-745'
 'Vx-745']_|_[('PubChem', array(['103905630', '124950172', '174006470', '50100122'], dtype=object)), ('drugbank', array(['DB07138'], dtype=object)), ('chEBI', array(['90528'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000726', 'MONDO_0007739', 'HP_0100543', 'MONDO_0004975'],
      dtype=object), 'count': 4}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1200848,"CCCCCC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C_|_DOMWKUIIPQCAJU-LJHIYBGHSA-N_|_Small molecule_|_False_|_HYDROXYPROGESTERONE CAPROATE_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Delalutin' 'Hydroxyprogesterone caproate' 'Makena'
 'Makena (autoinjector)' 'Makena preservative free' 'Proluton depot']_|_['17-ohpc' '17.alpha.-caproyloxy-p4' 'Depo-proluton' 'Hormofort'
 'Hydroxyprogesterone' 'Hydroxyprogesterone caproate'
 'Hydroxyprogesterone hexanoate' 'Hylutin' 'NSC-17592'
 'Oxiprogesterone caproate' 'Pharlon' 'Primolut depot' 'Procyte depo'
 'Proge' 'Syngynon' 'Teralutil']_|_[('DailyMed', array(['hydroxyprogesterone%20caproate'], dtype=object)), ('PubChem', array(['144207051', '144212650', '170465210', '56424128', '855528'],
      dtype=object)), ('drugbank', array(['DB06789'], dtype=object)), ('chEBI', array(['5812'], dtype=object))]_|_['CHEMBL3526451']_|_{'rows': array(['EFO_0002950', 'EFO_0003917'], dtype=object), 'count': 2}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and is indicated for premature birth and has 1 investigational indication."
CHEMBL1201421,"nan_|_nan_|_Unknown_|_False_|_PEGAPTANIB SODIUM_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Macugen']_|_['EYE-001' 'EYE001' 'EYEOO1' 'NX-1838' 'NX1838' 'Pegaptanib na'
 'Pegaptanib sodium']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/macugen'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007935', 'MONDO_0003005', 'EFO_1001157', 'EFO_0001365',
       'EFO_0004683', 'MONDO_0008667', 'EFO_0009606'], dtype=object), 'count': 7}_|_[ENSG00000112715]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for wet macular degeneration and has 6 investigational indications."
CHEMBL1252,"CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O_|_AIWRTTMUVOZGPW-HSPKUQOVSA-N_|_Protein_|_True_|_ABARELIX_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Plenaxis']_|_['Abarelix' 'PPI-149' 'Plenaxis' 'R-382' 'R-3827' 'R382' 'R3827']_|_[('Wikipedia', array(['Abarelix'], dtype=object)), ('drugbank', array(['DB00106'], dtype=object)), ('chEBI', array(['337298'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for neoplasm and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1502,"COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC_|_IQPSEEYGBUAQFF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PANTOPRAZOLE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Pantoloc control' 'Protium' 'Protium i.v.']_|_['Altopan' 'BY 1023' 'BY-1023' 'BY1023' 'NSC-759257' 'Pantocid' 'Pantoloc'
 'Pantoprazole' 'Pantozol' 'Protonix' 'SK&F 96022' 'SK&F-96022' 'SK-96022'
 'SKF-96022' 'Zovanta']_|_[('PubChem', array(['144205030', '170466337', '174007264', '26749082'], dtype=object)), ('Wikipedia', array(['Pantoprazole'], dtype=object)), ('drugbank', array(['DB00213'], dtype=object)), ('chEBI', array(['7915'], dtype=object))]_|_['CHEMBL5307366' 'CHEMBL3989559']_|_{'rows': array(['EFO_0003948', 'EFO_0000771', 'HP_0002239', 'MONDO_0008315',
       'EFO_0007549', 'MONDO_0043839', 'EFO_0000616', 'HP_0100633',
       'EFO_0007549', 'EFO_0009454', 'HP_0004398', 'MONDO_0005301',
       'EFO_0000400', 'EFO_0003948', 'EFO_1000961', 'EFO_0005672',
       'EFO_0004607', 'MONDO_0003523', 'MONDO_0005090', 'MONDO_0005148',
       'EFO_0007157', 'HP_0100633', 'MONDO_0005147', 'EFO_1001355',
       'Orphanet_79292', 'MP_0001914', 'EFO_0000280', 'EFO_0009544',
       'EFO_0000373'], dtype=object), 'count': 29}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 26 investigational indications."
CHEMBL1631540,"Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1_|_ANGUXJDGJCHGOG-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK163090_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK163090' 'Gsk163090']_|_nan_|_['CHEMBL3215829']_|_{'rows': array(['MONDO_0002050', 'MONDO_0002009'], dtype=object), 'count': 2}_|_[ENSG00000178394,ENSG00000108576,ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1743015,"nan_|_nan_|_Antibody_|_False_|_ETROLIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Anti-.beta.7' 'Anti-Beta7' 'Anti-Beta7 Pro145223' 'Etrolizumab'
 'PRO-145223' 'PRO145223' 'RG-7413' 'RHUMAB-BETA7' 'Rhumab .beta.7'
 'rhuMAb beta7']_|_nan_|_nan_|_{'rows': array(['EFO_0000384', 'EFO_0000729'], dtype=object), 'count': 2}_|_[ENSG00000139626]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1889140,"CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C.Cl_|_NDNSIBYYUOEUSV-RSAXXLAASA-N_|_Small molecule_|_False_|_ROPIVACAINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL1077896_|_False_|_True_|_['Naropin' 'Ropivacaine hydrochloride']_|_['Ropivacaine hcl' 'Ropivacaine hydrochloride'
 'Ropivacaine hydrochloride hydrate'
 'Ropivacaine hydrochloride monohydrate']_|_[('DailyMed', array(['ropivacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205774', '170465120', '49681555'], dtype=object)), ('chEBI', array(['60803'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009676', 'EFO_0003931', 'EFO_0003843', 'EFO_0006859',
       'HP_0000023', 'MONDO_0005178', 'HP_0001822'], dtype=object), 'count': 7}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for pain and has 6 investigational indications."
CHEMBL1911882,CN(CCCNCc1ccc2c(c1)OCO2)c1nc(-n2ccnc2)ns1_|_ZJFFPGMGWOEQLF-UHFFFAOYSA-N_|_Small molecule_|_False_|_KD7040_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Kd7040']_|_nan_|_nan_|_nan_|_[ENSG00000007171]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL2108296,nan_|_nan_|_Oligonucleotide_|_False_|_AGANIRSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aganirsen' 'Gs-101']_|_nan_|_nan_|_nan_|_[ENSG00000169047]_|_Oligonucleotide drug with a maximum clinical trial phase of II.
CHEMBL217092,"CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1_|_OUKYUETWWIPKQR-UHFFFAOYSA-N_|_Small molecule_|_False_|_SARACATINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZ-10353926' 'AZD-0530' 'AZD0530' 'Azd-0530' 'Saracatinib']_|_[('PubChem', array(['137275842', '164339484'], dtype=object)), ('drugbank', array(['DB11805'], dtype=object))]_|_['CHEMBL2105677']_|_{'rows': array(['EFO_0006861', 'EFO_0000637', 'MONDO_0021063', 'MONDO_0011705',
       'EFO_0000616', 'MONDO_0007606', 'EFO_0000365', 'MONDO_0008315',
       'MONDO_0002158', 'EFO_1000581', 'EFO_0002618', 'MONDO_0007254',
       'EFO_0004329', 'MONDO_0008170', 'MONDO_0007079', 'EFO_0003060',
       'MONDO_0004992', 'EFO_0000756', 'EFO_1000657', 'MONDO_0004975'],
      dtype=object), 'count': 20}_|_[ENSG00000097007,ENSG00000197122]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications."
CHEMBL253371,"CCN(CCCc1ccccc1)CCCc1ccccc1_|_ZPFXAOWNKLFJDN-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALVERINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Alverine' 'Phenpropamine']_|_[('PubChem', array(['50103849', '50104229', '50104230'], dtype=object)), ('Wikipedia', array(['Alverine'], dtype=object)), ('drugbank', array(['DB01616'], dtype=object)), ('chEBI', array(['518413'], dtype=object))]_|_['CHEMBL1408594']_|_{'rows': array(['EFO_0010282', 'EFO_0000666'], dtype=object), 'count': 2}_|_[ENSG00000101076,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and has 1 investigational indication."
CHEMBL3039558,"nan_|_nan_|_Small molecule_|_False_|_ETIRINOTECAN PEGOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Etirinotecan pegol' 'NKTR-102']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0002499', 'EFO_0002501', 'EFO_0003060',
       'EFO_0000519', 'MONDO_0008170', 'MONDO_0007254', 'EFO_1001951',
       'EFO_0000616'], dtype=object), 'count': 9}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL3182621,"Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O_|_RWEVIPRMPFNTLO-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-8330_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ARRY-424704' 'ARRY-704' 'AZD-8330' 'Azd 8330' 'Azd-8330' 'Azd8330']_|_[('PubChem', array(['174006482'], dtype=object)), ('drugbank', array(['DB06061'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3260505,"CCc1cnc(N2CCC(c3nc(COc4ccc(-n5cnnn5)cc4)cs3)CC2)nc1_|_NFTMKHWBOINJGM-UHFFFAOYSA-N_|_Small molecule_|_False_|_MBX-2982_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mbx-2982']_|_[('drugbank', array(['DB12345'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000147262]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL329123,"CCCc1c(OCCCOc2cc(O)c(-c3ccc(F)cc3)cc2CC)cccc1Oc1ccccc1C(=O)O_|_YFIZRWPXUYFCSN-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETALOCIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Etalocib' 'LY-193111' 'LY-293111' 'LY293111' 'Ly-293111' 'Ly293111'
 'VML 295']_|_[('Wikipedia', array(['Etalocib'], dtype=object)), ('drugbank', array(['DB12850'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000213903,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3544943,Cl.O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12_|_UNDKJUKLBNARIZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-863233_|_nan_|_2.0_|_CHEMBL3544944_|_False_|_False_|_[]_|_['Bms-863233' 'XL-413']_|_nan_|_nan_|_nan_|_[ENSG00000097046]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3545384,nan_|_nan_|_Small molecule_|_False_|_SB-85635_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Sb-85635']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3559672,"nan_|_nan_|_Unknown_|_False_|_RAUWOLFIA SERPENTINA_|_1954.0_|_4.0_|_nan_|_False_|_True_|_['Hiwolfia' 'Hyserpin' 'Koglucoid' 'Raudixin' 'Rauserpin' 'Rauval'
 'Rauwolfia serpentina' 'Wolfina']_|_['Rauvolfia serpentina root' 'Rauwolfia alkaloids'
 'Rauwolfia alkaloids, whole root' 'Rauwolfia serpentina'
 'Rauwolfia serpentina alseroxylon']_|_nan_|_nan_|_{'rows': array(['EFO_0003777', 'EFO_0000537'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1954 and is indicated for hypertension and has 1 investigational indication."
CHEMBL4475463,"O=C(O)c1ccc2c(c1)CCCC(c1ccc(Cl)cc1Cl)=C2c1ccc(O[C@H]2CCN(CCCF)C2)cc1_|_KISZAGQTIXIVAR-VWLOTQADSA-N_|_Small molecule_|_False_|_AMCENESTRANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Amcenestrant' 'SAR-439859' 'SAR439859' 'Sar439859']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/AMCENESTRANT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0003968', 'EFO_0005537', 'EFO_0003869'],
      dtype=object), 'count': 4}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4650323,"C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccc32)C1_|_KOEUOFPEZFUWRF-LJQANCHMSA-N_|_Small molecule_|_False_|_TOLEBRUTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['PRN-2246' 'PRN2246' 'SAR-442168' 'SAR442168' 'Sar442168' 'Tolebrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOLEBRUTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0008520', 'EFO_0008522', 'MONDO_0005301'],
      dtype=object), 'count': 4}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5315048,"nan_|_nan_|_Protein_|_True_|_ZILUCOPLAN SODIUM_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Zilbrysq']_|_[]_|_nan_|_nan_|_{'rows': array(['EFO_0004991'], dtype=object), 'count': 1}_|_[ENSG00000106804]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2023 and is indicated for myasthenia gravis. This drug has a black box warning from the FDA."
CHEMBL605846,"COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1_|_COUYJEVMBVSIHV-SFHVURJKSA-N_|_Small molecule_|_False_|_OLODATEROL_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Striverdi respimat']_|_['BI 1744' 'Olodaterol']_|_[('Wikipedia', array(['Olodaterol'], dtype=object)), ('drugbank', array(['DB09080'], dtype=object)), ('chEBI', array(['82700'], dtype=object))]_|_['CHEMBL2105743']_|_{'rows': array(['EFO_0006505', 'MONDO_0004979', 'EFO_0000341', 'EFO_0000464',
       'HP_0006536', 'EFO_0001421', 'EFO_0000341'], dtype=object), 'count': 7}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 3 investigational indications."
CHEMBL94657,"C/C(=C\c1csc(C)n1)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1_|_QXRSDHAAWVKZLJ-PVYNADRNSA-N_|_Small molecule_|_False_|_PATUPILONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(-)-epothilone b' 'EPO 906' 'EPO 906A' 'EPO-906' 'EPO-906A' 'EPO906'
 'EPO906A' 'Epithilone b' 'Epo b' 'Epothilone b' 'GNF-PF-193' 'Patupilone']_|_[('PubChem', array(['50125842', '520207'], dtype=object)), ('drugbank', array(['DB03010'], dtype=object)), ('chEBI', array(['31550'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0000182', 'EFO_0003865', 'EFO_0004243',
       'EFO_0000673', 'MONDO_0004992', 'EFO_0000756', 'MONDO_0007254',
       'EFO_0003060', 'EFO_0003869', 'EFO_0000616', 'MONDO_0002158',
       'MONDO_0008315', 'EFO_0000519', 'EFO_0004288', 'EFO_1001100',
       'MONDO_0021063'], dtype=object), 'count': 17}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."
CHEMBL1200400,"Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[n-]c12.[Na+]_|_WISNYKIQFMKSDQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_AZATHIOPRINE SODIUM_|_1974.0_|_4.0_|_CHEMBL1542_|_False_|_True_|_['Azathioprine sodium' 'Imuran']_|_['Azathioprine sodium' 'Azathioprine sodium salt']_|_[('DailyMed', array(['azathioprine%20sodium'], dtype=object))]_|_nan_|_nan_|_[ENSG00000128059]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. This drug has a black box warning from the FDA."
CHEMBL1201051,"CN/C(=N\CCSCc1nc[nH]c1C)NC#N.Cl_|_QJHCNBWLPSXHBL-UHFFFAOYSA-N_|_Small molecule_|_False_|_CIMETIDINE HYDROCHLORIDE_|_1977.0_|_4.0_|_CHEMBL30_|_False_|_True_|_['Cimetidine hydrochloride' 'Tagamet']_|_['Cimetidine hcl' 'Cimetidine hydrochloride']_|_[('chEBI', array(['50362'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1977."
CHEMBL1201245,"CN(C)CCOC(c1ccccc1)c1ccc(Br)cc1_|_NUNIWXHYABYXKF-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMODIPHENHYDRAMINE_|_1954.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['4-bromodiphen hydramine' 'Bromazine' 'Bromodiphenhydramine' 'Deserol'
 'Histabromamine' 'Neo-benadryl']_|_[('PubChem', array(['170465292'], dtype=object)), ('Wikipedia', array(['Bromazine'], dtype=object)), ('drugbank', array(['DB01237'], dtype=object)), ('chEBI', array(['59177'], dtype=object))]_|_['CHEMBL1200967']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and is indicated for allergic disease."
CHEMBL1201775,"C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1.Cl.Cl_|_RKSUYBCOVNCALL-NTVURLEBSA-N_|_Small molecule_|_False_|_SAPROPTERIN DIHYDROCHLORIDE_|_2007.0_|_4.0_|_CHEMBL1201774_|_False_|_True_|_['Kuvan' 'Sapropterin dipharma']_|_['Biopten' 'Dapropterin hydrochloride' 'Phenoptin' 'SUN-0588'
 'SUN-0588 (SHIRATORI)' 'Sapropterin dihydrochloride'
 'Sapropterin hydrochloride' 'T-1401' 'T1401' 'T1401 (BIOMARIN)']_|_[('DailyMed', array(['sapropterin%20dihydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/sapropterin-dipharma'],
      dtype=object)), ('PubChem', array(['144205335'], dtype=object)), ('chEBI', array(['32120'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003876', 'MONDO_0005090', 'EFO_0000537', 'EFO_0001361',
       'EFO_0005411', 'MONDO_0011382', 'Orphanet_238583', 'MONDO_0009861',
       'EFO_0000181', 'EFO_0003884', 'EFO_0001645'], dtype=object), 'count': 11}_|_[ENSG00000171759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hyperphenylalaninemia and phenylketonuria and has 9 investigational indications."
CHEMBL1523964,"CN[C@@H](C)[C@H](O)c1ccccc1.CN[C@@H](C)[C@H](O)c1ccccc1.O=S(=O)(O)O_|_CAVQBDOACNULDN-KHFUBBAMSA-N_|_Small molecule_|_False_|_EPHEDRINE SULFATE_|_2016.0_|_4.0_|_CHEMBL211456_|_False_|_True_|_['Akovaz' 'Corphedra' 'Emerphed' 'Expansyl' 'Franol plus' 'Franol-plus']_|_['Ephedrine sulfate' 'Ephedrine sulphate' 'Ephedrini sulfas']_|_[('DailyMed', array(['ephedrine%20sulfate'], dtype=object)), ('PubChem', array(['50106282'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0005251'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for asthma and hypotension."
CHEMBL1730601,"Oc1cc(O)c(Cl)cn1_|_ZPLQIPFOCGIIHV-UHFFFAOYSA-N_|_Small molecule_|_False_|_GIMERACIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gimeracil' 'Gimestat']_|_[('PubChem', array(['144206214', '170466048', '50125750'], dtype=object)), ('drugbank', array(['DB09257'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000503', 'EFO_1001951', 'EFO_0000182', 'MONDO_0007254',
       'EFO_0006859', 'MONDO_0003060', 'EFO_0000228', 'MONDO_0002974',
       'EFO_0003860', 'MONDO_0002120', 'EFO_0003086', 'EFO_0001421',
       'MONDO_0005184', 'EFO_0000702', 'EFO_0000365', 'MONDO_0001056',
       'EFO_0005922', 'EFO_0004142', 'MONDO_0044937', 'MONDO_0007576',
       'EFO_0003060', 'EFO_0003897', 'EFO_0004252', 'EFO_0000181',
       'EFO_1000359', 'EFO_0000616', 'MONDO_0005575', 'EFO_0005221',
       'EFO_0000178', 'EFO_0003869', 'MONDO_0004992', 'EFO_1000657',
       'EFO_0002916', 'EFO_0002618'], dtype=object), 'count': 34}_|_[ENSG00000188641]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 34 investigational indications."
CHEMBL187927,"c1cnc2c(c1)O[C@H]1CCN3CC[C@@]1(C2)C3_|_SUPRUPHAEXPGPF-QWHCGFSZSA-N_|_Small molecule_|_False_|_DIANICLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dianicline' 'SSR-591813' 'SSR591813']_|_[('drugbank', array(['DB12125'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003768'], dtype=object), 'count': 1}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2105705,"C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C/C=C/S(=O)(=O)C(C)(C)C)=CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_RFQHCLMGLJGZNV-UXXOMSPDSA-N_|_Small molecule_|_False_|_LUNACALCIPOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CTA-018' 'CTA018' 'Lunacalcipol']_|_nan_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0000676', 'EFO_0009909', 'EFO_1001173'],
      dtype=object), 'count': 4}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2108674,"nan_|_nan_|_Protein_|_False_|_RAMATERCEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_['Ace-031']_|_['ACE-031' 'Ramatercept']_|_nan_|_nan_|_{'rows': array(['HP_0003202', 'MONDO_0010679'], dtype=object), 'count': 2}_|_[ENSG00000138379]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108968,"nan_|_nan_|_Protein_|_False_|_INSULIN [INJECTION], BIPHASIC_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ins rapit mc']_|_['Biphasic insulin injection' 'Insulin [injection], biphasic']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV."
CHEMBL2109391,"nan_|_nan_|_Antibody_|_False_|_MDX-447_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['EMD-82633' 'MDX-447' 'Mdx-447']_|_nan_|_nan_|_{'rows': array(['EFO_1000158'], dtype=object), 'count': 1}_|_[ENSG00000150337,ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109530,"nan_|_nan_|_Antibody_|_False_|_ASK-8007_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASK-8007' 'Ask-8007']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000118785]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109559,"nan_|_nan_|_Antibody_|_False_|_J591 177LU_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['177 LU-J591' 'HUJ591-GS' 'J591 177lu']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000086205]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2179529,"O=C(c1ccc(Cl)o1)N1CC2CNCC2C1_|_GTUIQNHJSXQMKW-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD1446_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-1446' 'AZD1446 HCL' 'Azd 1446' 'Azd1446' 'Azd1446 free base'
 'TC-6683' 'TC6683' 'TC6683 HCL']_|_nan_|_nan_|_{'rows': array(['HP_0100543', 'MONDO_0004975', 'EFO_0003888'], dtype=object), 'count': 3}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL220360,"C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1_|_QLYKJCMUNUWAGO-GAJHUEQPSA-N_|_Small molecule_|_False_|_TARANABANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK-0364' 'MK-0634' 'Mk-0364' 'Mk0364' 'Taranabant']_|_[('drugbank', array(['DB06624'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0003768', 'HP_0000020', 'EFO_0001073'],
      dtype=object), 'count': 4}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL254219,"C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5CC[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O_|_WDJUZGPOPHTGOT-XUDUSOBPSA-N_|_Small molecule_|_False_|_DIGITOXIN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Crystodigin' 'Digimerck' 'Nativelle digitaline']_|_['CRYSTODIGIN' 'Cristapurat' 'Digitalin, crystalline' 'Digitophyllin'
 'Digitoxin' 'Digitoxinum' 'Digitoxoside' 'Glucodigin' 'Lanatoxin'
 'NSC-7529' 'Purpurid' 'Tradigal']_|_[('PubChem', array(['11533060', '144205212', '144212586', '170464713', '26754428',
       '26754429'], dtype=object)), ('Wikipedia', array(['Digitoxin'], dtype=object)), ('drugbank', array(['DB01396'], dtype=object)), ('chEBI', array(['28544'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'MONDO_0009061'], dtype=object), 'count': 2}_|_[ENSG00000163399,ENSG00000129244,ENSG00000143153,ENSG00000018625,ENSG00000069849,ENSG00000105409,ENSG00000132681,ENSG00000137731]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL3545181,"C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12.O.[Br-]_|_MQLXPRBEAHBZTK-SEINRUQRSA-M_|_Small molecule_|_False_|_TIOTROPIUM BROMIDE_|_2004.0_|_4.0_|_CHEMBL1900528_|_False_|_True_|_['Spiriva' 'Spiriva respimat']_|_['BA 679 BR' 'BA-679 BR' 'BA-679-BR' 'BA-679BR' 'Tiotropium bromide'
 'Tiotropium bromide anhydrous' 'Tiotropium bromide hydrate'
 'Tiotropium bromide monohydrate']_|_[('DailyMed', array(['tiotropium%20bromide'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001919', 'HP_0006536', 'HP_0000083', 'MONDO_0009061',
       'EFO_0000616', 'MONDO_0004979', 'EFO_0006505', 'EFO_0000341',
       'EFO_0000464'], dtype=object), 'count': 9}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 5 approved and 4 investigational indications."
CHEMBL3545247,"nan_|_nan_|_Small molecule_|_False_|_CAL-263_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Cal-263']_|_nan_|_nan_|_{'rows': array(['EFO_0005854'], dtype=object), 'count': 1}_|_[ENSG00000171608,ENSG00000105851]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545291,"CN(C)C(=O)CCn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccncc1_|_IURMHZBQEYNQOH-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-39393406_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Jnj-39393406']_|_[('drugbank', array(['DB11867'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'EFO_0004319', 'MONDO_0005090'], dtype=object), 'count': 3}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3785909,"COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(-c5cnn(C)c5)cn34)c(=O)c2c1_|_DWHXUGDWKAIASB-CQSZACIVSA-N_|_Small molecule_|_False_|_AMG-337_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 337' 'Amg-337']_|_[('drugbank', array(['DB15639'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003897', 'EFO_0008498', 'MONDO_0004992'],
      dtype=object), 'count': 4}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3989922,"Cc1ccc(S(=O)(=O)O)cc1.NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12.O_|_ACNPUCQQZDAPJH-FMOMHUKBSA-N_|_Small molecule_|_False_|_NIRAPARIB TOSYLATE MONOHYDRATE_|_2017.0_|_4.0_|_CHEMBL1094636_|_False_|_True_|_['Zejula']_|_['Niraparib tosilate hydrate' 'Niraparib tosylate'
 'Niraparib tosylate monohydrate']_|_[('DailyMed', array(['niraparib%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zejula'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001075', 'EFO_0003893', 'EFO_0000564', 'EFO_1000251',
       'EFO_1001100'], dtype=object), 'count': 5}_|_[ENSG00000129484,ENSG00000143799]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 4 approved and 1 investigational indication."
CHEMBL4297589,"CCCCOC(=O)N1CCN(C(=O)[C@H](CP(=O)(O)O)NC(=O)c2cc(N3CC[C@H](OC)C3)nc(-c3ccccc3)n2)CC1_|_FYXHWMQPCJOJCH-GMAHTHKFSA-N_|_Small molecule_|_False_|_SELATOGREL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACT-246475' 'Act-246475' 'Selatogrel']_|_[('drugbank', array(['DB15163'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0008583', 'EFO_0001645'], dtype=object), 'count': 3}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297871,"nan_|_nan_|_Antibody drug conjugate_|_False_|_CAMIDANLUMAB TESIRINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADCT-301' 'ADCT-301 TESIRINE' 'ADCT301' 'Adct 301' 'Adct 502'
 'Adct-301 tesirine' 'Camidanlumab tesirine']_|_nan_|_nan_|_{'rows': array(['EFO_0004251', 'EFO_0000183', 'EFO_0000220', 'EFO_0000198',
       'EFO_0000222', 'EFO_0005952'], dtype=object), 'count': 6}_|_[ENSG00000134460]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL43452,"Nc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O_|_UVSMNLNDYGZFPF-UHFFFAOYSA-N_|_Small molecule_|_True_|_POMALIDOMIDE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Imnovid' 'Imnovid (previously pomalidomide celgene)' 'Pomalyst']_|_['Actimid' 'CC-4047' 'IMID 3' 'IMID-3' 'Pomalidomide']_|_[('DailyMed', array(['pomalidomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid'],
      dtype=object)), ('PubChem', array(['174007398'], dtype=object)), ('Wikipedia', array(['Pomalidomide'], dtype=object)), ('drugbank', array(['DB08910'], dtype=object)), ('chEBI', array(['72690'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003073', 'EFO_0009441', 'EFO_0005952', 'MONDO_0019180',
       'MONDO_0015564', 'MONDO_0017816', 'EFO_0002618', 'EFO_0002430',
       'EFO_0006475', 'EFO_0000717', 'EFO_0002939', 'EFO_0002429',
       'EFO_0004251', 'EFO_0000616', 'EFO_0000702', 'EFO_0001378',
       'EFO_0000403', 'EFO_0000540', 'EFO_0000558', 'EFO_0004244',
       'MONDO_0008315', 'EFO_1001968', 'EFO_0000183', 'EFO_0000309',
       'MONDO_0019438', 'MONDO_0013730', 'EFO_0009448', 'EFO_0006738',
       'MONDO_0044903', 'MONDO_0011382'], dtype=object), 'count': 30}_|_[ENSG00000113851,ENSG00000167986,ENSG00000139842,ENSG00000100387]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for multiple myeloma and immune system disease and has 28 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4594331,"nan_|_nan_|_Protein_|_False_|_DAZODALIBEP_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dazodalibep' 'MEDI-4920' 'MEDI4920' 'Medi 4920' 'VIB-4920' 'VIB4920'
 'Vib4920']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DAZODALIBEP/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007160', 'EFO_0005809', 'EFO_0000685', 'EFO_0000699',
       'EFO_0005761'], dtype=object), 'count': 5}_|_[ENSG00000102245]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL686,"Cc1cccc(Nc2ccccc2C(=O)O)c1C_|_HYYBABOKPJLUIN-UHFFFAOYSA-N_|_Small molecule_|_True_|_MEFENAMIC ACID_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Contraflam' 'Dysman-250' 'Dysman-500' 'Mefenamic acid' 'Meflam 250'
 'Meflam 500' 'Mendys' 'Opustan 250' 'Opustan 500' 'Ponstan' 'Ponstan fte'
 'Ponstel']_|_['CI-473' 'CN-35355' 'Gardan' 'INF-3355' 'J2.344B' 'M01AG01' 'Mefenamate'
 'Mefenamic acid' 'Mefenaminic acid' 'Mephenamic acid' 'Mephenaminic acid'
 'NSC-94437']_|_[('DailyMed', array(['mefenamic%20acid'], dtype=object)), ('PubChem', array(['104171280', '11112163', '124882006', '144203895', '144212300',
       '170464813', '26746974', '26751493', '56422190', '855723'],
      dtype=object)), ('TG-GATEs', array(['84'], dtype=object)), ('Wikipedia', array(['Mefenamic_acid'], dtype=object)), ('drugbank', array(['DB00784'], dtype=object)), ('chEBI', array(['6717'], dtype=object))]_|_nan_|_{'rows': array(['HP_0100607', 'EFO_0005755', 'EFO_0003843', 'EFO_0000400',
       'MP_0001914'], dtype=object), 'count': 5}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for dysmenorrhea and rheumatic disease and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1110,"Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O_|_JSWZEAMFRNKZNL-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALOSETRON_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['A03AE01' 'Alosetron' 'Lotronex']_|_[('Wikipedia', array(['Alosetron'], dtype=object)), ('drugbank', array(['DB00969'], dtype=object)), ('chEBI', array(['253342'], dtype=object))]_|_['CHEMBL1200885']_|_{'rows': array(['EFO_0010282', 'EFO_0000555', 'EFO_0000555'], dtype=object), 'count': 3}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for gastrointestinal disease and irritable bowel syndrome and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1194325,"O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1_|_ASMXXROZKSBQIH-VITNCHFBSA-N_|_Small molecule_|_False_|_ACLIDINIUM_|_2012.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Aclidinium' 'Aclidinium cation' 'Aclidinium ion']_|_[('drugbank', array(['DB08897'], dtype=object)), ('chEBI', array(['65346'], dtype=object))]_|_['CHEMBL551466']_|_{'rows': array(['EFO_0000464', 'EFO_0000341', 'EFO_0006505', 'MONDO_0004979',
       'HP_0006536', 'EFO_0000341', 'EFO_0003768'], dtype=object), 'count': 7}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 2 investigational indications."
CHEMBL1201328,"CCC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2_|_XZSMZRXAEFNJCU-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARPHENAZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Carfenazine' 'Carphenazine']_|_[('PubChem', array(['50125832'], dtype=object)), ('Wikipedia', array(['Carfenazine'], dtype=object)), ('drugbank', array(['DB01038'], dtype=object))]_|_['CHEMBL2358147']_|_nan_|_[ENSG00000149295,ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1342,"O=C(O)CCCO_|_SJZRECIVHVDYJC-UHFFFAOYSA-N_|_Small molecule_|_True_|_OXYBATE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['.gamma.-hydroxybutyrate' 'Gamma hydroxybutyrate' 'Gamma-hydroxybutyrate'
 'Oxybate' 'Xyrem']_|_[('Wikipedia', array(['Gamma-Hydroxybutyric_acid'], dtype=object)), ('drugbank', array(['DB01440'], dtype=object)), ('chEBI', array(['30830'], dtype=object))]_|_['CHEMBL1200682' 'CHEMBL4594393' 'CHEMBL4594395' 'CHEMBL4594394']_|_{'rows': array(['MONDO_0018044', 'EFO_0003108', 'EFO_0008568', 'MONDO_0021107',
       'EFO_0005203', 'HP_0001337', 'EFO_0003843', 'MONDO_0016241',
       'MONDO_0000485', 'MONDO_0005180', 'EFO_0005687', 'MONDO_0016158'],
      dtype=object), 'count': 12}_|_[ENSG00000204681,ENSG00000136928]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for narcolepsy and narcolepsy-cataplexy syndrome and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1372,"N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O_|_YPZRWBKMTBYPTK-BJDJZHNGSA-N_|_Small molecule_|_False_|_OXIGLUTATIONE_|_2008.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Glutathione disulfide' 'Oxiglutatione']_|_[('DailyMed', array(['glutathione%20disulfide'], dtype=object)), ('PubChem', array(['144206973', '26754399', '29215201'], dtype=object)), ('Wikipedia', array(['Glutathione_disulfide'], dtype=object)), ('drugbank', array(['DB03310'], dtype=object)), ('chEBI', array(['17858'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000565', 'MONDO_0008170', 'MONDO_0007254',
       'EFO_0000198'], dtype=object), 'count': 5}_|_[ENSG00000104687]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 5 investigational indications."
CHEMBL1492500,"CN(C)CC/C=C1\c2ccccc2CSc2ccccc21_|_PHTUQLWOUWZIMZ-GZTJUZNOSA-N_|_Small molecule_|_False_|_DOTHIEPIN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dosulepin' 'Dothiepin' 'Dothirpin']_|_[('PubChem', array(['11112454'], dtype=object)), ('drugbank', array(['DB09167'], dtype=object)), ('chEBI', array(['36803'], dtype=object))]_|_['CHEMBL1711280']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder."
CHEMBL1950554,"Nc1nc(N/N=C/C2CCCCC2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O_|_XJFMHMFFBSOEPR-DNZQAUTHSA-N_|_Small molecule_|_False_|_BINODENOSON_|_nan_|_3.0_|_nan_|_False_|_False_|_['Corvue']_|_['Binodenoson' 'MRE-0470' 'MRE0470' 'Wrc0470']_|_[('drugbank', array(['DB04853'], dtype=object))]_|_nan_|_nan_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL2109138,nan_|_nan_|_Antibody_|_False_|_MOROLIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Morolimumab']_|_nan_|_nan_|_nan_|_[ENSG00000187010]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2443262,"COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1_|_DMNOVGJWPASQDL-OAQYLSRUSA-N_|_Small molecule_|_True_|_OLICERIDINE_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Olinvyk' 'Olynvik']_|_['Oliceridine' 'TRV-130' 'TRV130']_|_[('drugbank', array(['DB14881'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for pain. This drug has a black box warning from the FDA."
CHEMBL3301578,"nan_|_nan_|_Antibody_|_False_|_EMIBETUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['C-8H241' 'Emibetuzumab' 'LA480' 'LY-2875358' 'LY2875358' 'La-480']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992', 'MONDO_0001056'], dtype=object), 'count': 3}_|_[ENSG00000105976]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545327,"nan_|_nan_|_Small molecule_|_False_|_TTP-607_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ttp-607']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000574'], dtype=object), 'count': 2}_|_[ENSG00000178999,ENSG00000105146,ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3707397,nan_|_nan_|_Small molecule_|_False_|_MR-1817_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mr-1817']_|_nan_|_nan_|_nan_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3764045,"CNC(=O)c1cc2c(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)ccnc2cc1OC_|_ORRNXRYWGDUDOG-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAS-115_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pamufetinib' 'Tas-115']_|_nan_|_nan_|_nan_|_[ENSG00000128052,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL382301,"CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1_|_VWXRQYYUEIYXCZ-OBIMUBPZSA-N_|_Protein_|_False_|_ATOSIBAN_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Tractocile']_|_['Antocile' 'Antocin' 'Antocin ii' 'Atosiban' 'CAP-449' 'CAP-476'
 'CAP-581' 'F-314' 'ORF 22164' 'ORF-22164' 'RW-22164' 'RWJ 22164'
 'RWJ-22164' 'Tractocil']_|_[('PubChem', array(['144207023', '29217473'], dtype=object)), ('drugbank', array(['DB09059'], dtype=object))]_|_['CHEMBL5315050']_|_{'rows': array(['EFO_0003917', 'EFO_0003917', 'EFO_0001065'], dtype=object), 'count': 3}_|_[ENSG00000180914]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for premature birth and has 2 investigational indications."
CHEMBL415,"CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21_|_GDLIGKIOYRNHDA-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLOMIPRAMINE_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['3-chloro-iminodibenzyl' 'Anafranil' 'Anapramine' 'Chlorimipramine'
 'Clomicalm' 'Clomipramine' 'NSC-169865']_|_[('PubChem', array(['104171137', '11110978', '11110979', '11113368', '124879726',
       '144203668', '170464702', '26751616', '50100206', '50104278',
       '90340575'], dtype=object)), ('TG-GATEs', array(['121'], dtype=object)), ('Wikipedia', array(['Clomipramine'], dtype=object)), ('drugbank', array(['DB01242'], dtype=object)), ('chEBI', array(['47780'], dtype=object))]_|_['CHEMBL1200710']_|_{'rows': array(['MONDO_0002050', 'EFO_0005230', 'HP_0000726', 'EFO_0004242',
       'EFO_0004242', 'MONDO_0002009', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0803321'], dtype=object), 'count': 9}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL483254,"Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1_|_FPOHNWQLNRZRFC-ZHACJKMWSA-N_|_Small molecule_|_True_|_PANOBINOSTAT_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Farydak']_|_['LBH-589' 'LBH589' 'Panobinostat' 'Panobinostat hydrate']_|_[('drugbank', array(['DB06603'], dtype=object)), ('chEBI', array(['85990'], dtype=object))]_|_['CHEMBL3545368']_|_{'rows': array(['EFO_0002892', 'EFO_0000349', 'EFO_0003060', 'EFO_0000673',
       'EFO_0004252', 'MONDO_0007254', 'EFO_1000026', 'EFO_0002617',
       'MONDO_0001056', 'EFO_0000519', 'EFO_0006475', 'EFO_0000403',
       'EFO_0000681', 'EFO_0000574', 'EFO_0000756', 'EFO_0002618',
       'EFO_1001469', 'EFO_0009441', 'EFO_0001378', 'EFO_0000220',
       'EFO_0002429', 'EFO_0002430', 'EFO_0000616', 'EFO_0000565',
       'EFO_0006738', 'MONDO_0020547', 'MONDO_0011382', 'MONDO_0002898',
       'MONDO_0044881', 'EFO_0001378', 'EFO_0000183', 'MONDO_0004992',
       'MONDO_0044903', 'EFO_0005952', 'EFO_1001901', 'EFO_0000339',
       'EFO_1001951', 'EFO_0000764', 'EFO_0000198', 'EFO_0000182',
       'MONDO_0100342', 'EFO_1000657', 'EFO_0005543', 'EFO_0000222',
       'MONDO_0008903', 'MONDO_0008315', 'MONDO_0002691', 'MONDO_0009348',
       'MONDO_0021063', 'EFO_1001779', 'EFO_0002913', 'MONDO_0013730'],
      dtype=object), 'count': 52}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 49 investigational indications. This drug has a black box warning from the FDA."
CHEMBL506981,"COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12_|_DYLJVOXRWLXDIG-UHFFFAOYSA-N_|_Small molecule_|_False_|_REMINERTANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Meclinertant' 'Reminertant' 'SR-48692' 'Sr48692']_|_[('PubChem', array(['124950704'], dtype=object)), ('drugbank', array(['DB06455'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000702'], dtype=object), 'count': 1}_|_[ENSG00000101188]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL607400,"CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1_|_MSYKRHVOOPPJKU-BDAKNGLRSA-N_|_Small molecule_|_False_|_BRIVARACETAM_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Briviact' 'Briviact (in italy:  nubriveo)']_|_['Brivaracetam' 'UCB 34714' 'UCB-34714']_|_[('DailyMed', array(['brivaracetam'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo'],
      dtype=object)), ('Wikipedia', array(['Brivaracetam'], dtype=object)), ('drugbank', array(['DB05541'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_308', 'EFO_1001919', 'EFO_0000474', 'EFO_0003833',
       'HP_0001250', 'MONDO_0041052', 'HP_0007359'], dtype=object), 'count': 7}_|_[ENSG00000159164]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 4 investigational indications."
CHEMBL77305,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1_|_VHXNKPBCCMUMSW-FQEVSTJZSA-N_|_Small molecule_|_False_|_RUBITECAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['9-nc' '9-nitro-20(s)-camptothecin' '9-nitro-20-(s)-camptothecin'
 '9-nitrocamptothecin' 'RFS 2000' 'RFS-2000' 'RFS2000' 'Rubitecan']_|_[('PubChem', array(['144206150', '50113013'], dtype=object)), ('Wikipedia', array(['Rubitecan'], dtype=object)), ('drugbank', array(['DB06159'], dtype=object)), ('chEBI', array(['90225'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001187', 'MONDO_0011962', 'MONDO_0004192', 'EFO_0000389',
       'MONDO_0008170', 'MONDO_0008903', 'EFO_0000616', 'MONDO_0002087',
       'EFO_0002618', 'MONDO_0007254', 'EFO_1001951', 'EFO_1000158'],
      dtype=object), 'count': 12}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 12 investigational indications."
CHEMBL1008,"CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1_|_UIEATEWHFDRYRU-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEPRIDIL_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bepadin' 'Bepridil' 'Vascor']_|_[('PubChem', array(['104171114', '124879417', '124879419', '144203640', '170465240',
       '26755663', '26755664', '50110980', '90341574'], dtype=object)), ('Wikipedia', array(['Bepridil'], dtype=object)), ('drugbank', array(['DB01244'], dtype=object)), ('chEBI', array(['3061'], dtype=object))]_|_['CHEMBL1257078' 'CHEMBL1200382']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for cardiovascular disease."
CHEMBL119625,"O=C(O)Cn1c(=O)c(=O)[nH]c2cc([N+](=O)[O-])c(-n3ccnc3)cc21_|_SPXYHZRWPRQLNS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZONAMPANEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['YM 872 ANHYDROUS' 'YM-872' 'YM-872 ANHYDROUS' 'YM872' 'YM872 ANHYDROUS'
 'Ym 872' 'Zonampanel' 'Zonampanel anhydrous' 'Zonampanel monohydrate']_|_nan_|_nan_|_{'rows': array(['HP_0002140', 'EFO_0000712'], dtype=object), 'count': 2}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1200494,"Cl.N=C(N)NC(=O)Cc1c(Cl)cccc1Cl_|_DGFYECXYGUIODH-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANFACINE HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL862_|_False_|_True_|_['Akfen' 'Estulic' 'Guanfacine hydrochloride' 'Intuniv' 'Tenex']_|_['BS 100-141' 'BS-100-141' 'Guafacine hydrochloride' 'Guanfacine hcl'
 'Guanfacine hydrochloride' 'SPD503']_|_[('DailyMed', array(['guanfacine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/intuniv'],
      dtype=object)), ('PubChem', array(['11532959', '144203710', '170465381', '50106306', '56422899'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0003888'], dtype=object), 'count': 2}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for hypertension and attention deficit hyperactivity disorder."
CHEMBL1200538,"CC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_AKUJBENLRBOFTD-QZIXMDIESA-N_|_Small molecule_|_False_|_BETAMETHASONE ACETATE_|_1965.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betamethasone 21-acetate' 'Betamethasone acetate' 'NSC-759196']_|_[('chEBI', array(['31275'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'MONDO_0002280', 'EFO_1001434', 'MONDO_0004979',
       'EFO_1001222', 'EFO_0000729', 'EFO_0004255', 'HP_0003419',
       'MONDO_0002406'], dtype=object), 'count': 9}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 6 approved and 3 investigational indications."
CHEMBL1201119,"N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+]_|_SBXXSUDPJJJJLC-YDALLXLXSA-M_|_Small molecule_|_True_|_LIOTHYRONINE SODIUM_|_1956.0_|_4.0_|_CHEMBL1544_|_False_|_True_|_['Cynomel' 'Cytomel' 'Liothyronine sodium' 'Tertroxin' 'Thybon'
 'Triiodothyronine' 'Triiodothyronine,evans' 'Triostat']_|_['Basoprocin' 'Cytobin' 'Ibiothyron' 'L-triiodothyronine hydrochloride'
 'L-triiodothyronine sodium salt' 'Liothyronine hydrochloride'
 'Liothyronine sodium' 'Liothyronine sodium salt' 'Liotrix (t3)'
 'Lyothyronin' 'NSC-758175' 'NSC-80774' 'Rathyronine hydrochloride, (s)-'
 'Rathyronine sodium, (s)-' 'T3 sodium salt'
 'Triiodothyronine sodium salt' 'Triiodothyronine sodium, levo']_|_[('DailyMed', array(['liothyronine%20sodium'], dtype=object)), ('PubChem', array(['144212831', '855617'], dtype=object)), ('Wikipedia', array(['Liothyronine'], dtype=object)), ('chEBI', array(['6484'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003841', 'EFO_0006859', 'EFO_0004705', 'MONDO_0008315',
       'EFO_0005207', 'HP_0030680', 'EFO_1002017', 'MONDO_0005301',
       'EFO_1001055'], dtype=object), 'count': 9}_|_[ENSG00000126351,ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1956 and has 4 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201540,"nan_|_nan_|_Protein_|_False_|_INSULIN SUSP ISOPHANE RECOMBINANT HUMAN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Humulin n' 'Novolin n']_|_['Insulin susp isophane recombinant human']_|_[('DailyMed', array(['insulin%20susp%20isophane%20recombinant%20human'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'MONDO_0005147', 'HP_0003074', 'MONDO_0005148',
       'EFO_0000537', 'EFO_0001645', 'HP_0003124', 'EFO_0000400'],
      dtype=object), 'count': 8}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 8 investigational indications."
CHEMBL1479,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C_|_POZRVZJJTULAOH-LHZXLZLDSA-N_|_Small molecule_|_True_|_DANAZOL_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Danazol' 'Danocrine']_|_['Danazol' 'NSC-270916' 'WIN 17,757' 'WIN-17757']_|_[('DailyMed', array(['danazol'], dtype=object)), ('PubChem', array(['144205667', '144212257', '170464884', '26757819', '49648394'],
      dtype=object)), ('TG-GATEs', array(['127'], dtype=object)), ('Wikipedia', array(['Danazol'], dtype=object)), ('drugbank', array(['DB01406'], dtype=object)), ('chEBI', array(['4315'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001366', 'EFO_0007160', 'MONDO_0018896', 'EFO_0001065',
       'EFO_0000545', 'EFO_0000198', 'MONDO_0015780', 'MONDO_0011962',
       'MONDO_0019098', 'HP_0001915', 'EFO_0003014', 'MONDO_0019391'],
      dtype=object), 'count': 12}_|_[ENSG00000082175,ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for endometriosis and breast fibrocystic disease and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1501,"CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C_|_WJOHZNCJWYWUJD-IUGZLZTKSA-N_|_Small molecule_|_True_|_FLUOCINONIDE_|_1971.0_|_4.0_|_nan_|_False_|_True_|_['Fluocinonide' 'Fluocinonide emulsified base' 'Lidex' 'Lidex-e' 'Metosyn'
 'Metosyn fapg' 'Vanos']_|_['Fluocinolide' 'Fluocinonide' 'NSC-101791']_|_[('DailyMed', array(['fluocinonide'], dtype=object)), ('PubChem', array(['144203989', '170464717', '855724'], dtype=object)), ('Wikipedia', array(['Fluocinonide'], dtype=object)), ('drugbank', array(['DB01047'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000305', 'EFO_0000274', 'EFO_0009552', 'EFO_0000676',
       'EFO_0000701'], dtype=object), 'count': 5}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and is indicated for hemorrhoid and skin disease and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1761,"Cl.OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1_|_ZFSPFXJSEHCTTR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROCYCLIDINE HYDROCHLORIDE_|_1955.0_|_4.0_|_CHEMBL86715_|_False_|_True_|_['Arpicolin' 'Kemadrin' 'Muscinil']_|_['NSC-757293' 'Procyclidine HCl' 'Procyclidine hcl'
 'Procyclidine hydrochloride']_|_[('PubChem', array(['144204059', '170464805', '26748224', '26748225', '50107359',
       '50107360', '56424071', '856015'], dtype=object)), ('Wikipedia', array(['Procyclidine'], dtype=object)), ('chEBI', array(['8449'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955."
CHEMBL1762621,"COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2_|_WPTTVJLTNAWYAO-KPOXMGGZSA-N_|_Small molecule_|_False_|_BARDOXOLONE METHYL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bardoxolone methyl' 'Bardoxolone methyl ester' 'CDDO-METHYL ESTER'
 'CDDO-Me' 'NSC 713200' 'NSC-713200' 'RTA 402' 'RTA-402' 'RTA402'
 'Rta-402']_|_[('PubChem', array(['144206780', '532003'], dtype=object)), ('drugbank', array(['DB05983'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005149', 'EFO_0000756', 'MONDO_0100096', 'EFO_0000401',
       'EFO_0003884', 'EFO_0002618', 'MONDO_0018965', 'EFO_0001642',
       'EFO_0001421', 'EFO_0001361', 'EFO_1001496'], dtype=object), 'count': 11}_|_[ENSG00000132170,ENSG00000104365,ENSG00000116044,ENSG00000079999]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL2062257,"Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O_|_QZHBYNSSDLTCRG-UHFFFAOYSA-N_|_Small molecule_|_False_|_BRIMONIDINE TARTRATE_|_1996.0_|_4.0_|_CHEMBL844_|_False_|_True_|_['Alphagan' 'Alphagan p' 'Brimonidine tartrate' 'Brymont' 'Lumify'
 'Mirvaso' 'Qoliana']_|_['AGN 190342-LF' 'AGN-190342-LF' 'AGN-190342LF' 'Brimonidine d-tartrate'
 'Brimonidine tartrate' 'Bromoxidine tartrate' 'Cd-07805' 'OCU-300'
 'OCU300' 'UK-14304-18' 'UK-1430418']_|_[('DailyMed', array(['brimonidine%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mirvaso'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'EFO_0004190', 'MONDO_0021698', 'EFO_0000537',
       'EFO_1001893', 'MONDO_0001330', 'MONDO_0005041', 'EFO_0003822',
       'HP_0000951', 'EFO_1000879', 'HP_0010783', 'EFO_1000760',
       'HP_0031284', 'EFO_1001069', 'EFO_0007141'], dtype=object), 'count': 15}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 8 investigational indications."
CHEMBL2095211,"C[C@H]1CNCCc2ccc(Cl)cc21.Cl_|_ITIHHRMYZPNGRC-QRPNPIFTSA-N_|_Small molecule_|_False_|_LORCASERIN HYDROCHLORIDE_|_2012.0_|_4.0_|_CHEMBL360328_|_False_|_True_|_['Belviq' 'Belviq xr']_|_['APD-356' 'APD356' 'Lorcaserin hcl' 'Lorcaserin hydrochloride' 'Lorqess']_|_[('chEBI', array(['65350'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004319', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 2 investigational indications."
CHEMBL2108677,"nan_|_nan_|_Protein_|_False_|_PEGINTERFERON BETA-1A_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Biib017' 'Plegridy']_|_['BIIB-017' 'BIIB017' 'Peginterferon beta' 'Peginterferon beta-1a']_|_[('DailyMed', array(['peginterferon%20beta-1a'], dtype=object)), ('DrugCentral', array(['5137'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000083', 'MONDO_0005301', 'EFO_0000616', 'EFO_0003929'],
      dtype=object), 'count': 4}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for multiple sclerosis and neoplasm and has 2 investigational indications."
CHEMBL2109095,nan_|_nan_|_Antibody_|_False_|_ERLIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Erlizumab' 'RHUMAB CD18' 'RHUMAB-CD18']_|_nan_|_nan_|_nan_|_[ENSG00000160255]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2134724,"CC(C)[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-]_|_KEWHKYJURDBRMN-XSAPEOHZSA-M_|_Small molecule_|_False_|_IPRATROPIUM BROMIDE_|_1986.0_|_4.0_|_CHEMBL1621597_|_False_|_True_|_['Atrovent' 'Atrovent aerocaps' 'Atrovent fte' 'Atrovent hfa'
 'Atrovent udvs' 'Ipratrop' 'Ipratrop steripoule' 'Ipratropium bromide'
 'Respontin' 'Rinatec' 'Tropiovent']_|_['Ipratropium bromide' 'Ipratropium bromide anhydrous'
 'Ipratropium bromide hydrate' 'Ipratropium bromide monohydrate'
 'NSC-759613' 'SCH 1000-BR-MONOHYDRATE' 'SCH-1000-BR-']_|_[('DailyMed', array(['ipratropium%20bromide'], dtype=object)), ('PubChem', array(['56462997'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_1764', 'MONDO_0005180', 'EFO_0003956', 'HP_0002307',
       'EFO_0001361', 'EFO_0000341', 'EFO_0006505', 'HP_0006536',
       'EFO_0007214', 'EFO_0000274', 'MONDO_0004979', 'EFO_0000464',
       'HP_0001742'], dtype=object), 'count': 13}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 4 investigational indications."
CHEMBL3109738,"COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3_|_JXDYOSVKVSQGJM-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-26483327_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['JNJ 26483327' 'JNJ-26483327' 'Jnj-26483327']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000197122,ENSG00000178568,ENSG00000182866,ENSG00000254087,ENSG00000010810,ENSG00000037280,ENSG00000146648,ENSG00000176105,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3234681,CC(C)(C)NC(=O)c1nn(-c2ccc(F)cc2F)c2c1[C@H]1CC[C@@H]2C1_|_NTPZXHMTJGOMCJ-WDEREUQCSA-N_|_Small molecule_|_False_|_TEDALINAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GRC10693' 'Grc-10693' 'Tedalinab']_|_nan_|_nan_|_nan_|_[ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3673452,"COc1ccc(COc2ccc(Cn3c(N)nc4cc(-c5cnn(C)c5)cnc43)cc2OC)cc1_|_HVRWZFQFSQUILC-UHFFFAOYSA-N_|_Small molecule_|_False_|_GZ-389988_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GZ-389988' 'GZ389988' 'Gz-389988' 'Gz389988']_|_nan_|_nan_|_{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}_|_[ENSG00000198400]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298126,"nan_|_nan_|_Unknown_|_False_|_VON WILLEBRAND FACTOR HUMAN_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Human von willebrand factor' 'Von willebrand factor'
 'Von willebrand factor (human)' 'Von willebrand factor human'
 'Von willebrand factor, human' ""Von willebrand's factor""]_|_nan_|_nan_|_{'rows': array(['MONDO_0024574', 'Orphanet_903', 'MP_0001914', 'EFO_0009579'],
      dtype=object), 'count': 4}_|_[ENSG00000110799]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) and is indicated for hemorrhage and has 3 investigational indications."
CHEMBL4298211,"nan_|_nan_|_Protein_|_True_|_PEGCETACOPLAN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Aspaveli' 'Empaveli']_|_['APL-2' 'Pegcetacoplan' 'Syfovre']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEGCETACOPLAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019737', 'MONDO_0100244', 'MONDO_0004976', 'EFO_0000540',
       'EFO_1001492', 'MONDO_0018922', 'MONDO_0019736', 'MONDO_0100244',
       'EFO_0001365'], dtype=object), 'count': 9}_|_[ENSG00000125730]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for paroxysmal nocturnal hemoglobinuria and immune system disease and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4299940,"O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1_|_XAYGBKHKBBXDAK-UHFFFAOYSA-N_|_Small molecule_|_False_|_MITAPIVAT_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AG-348' 'Ag-348' 'Mitapivat' 'Pkr-in-1']_|_nan_|_['CHEMBL4297223']_|_{'rows': array(['MONDO_0003689', 'MONDO_0002280', 'Orphanet_846', 'EFO_0000508',
       'EFO_0004272', 'MONDO_0011382', 'EFO_1001996', 'Orphanet_848',
       'EFO_0001421'], dtype=object), 'count': 9}_|_[ENSG00000143627]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 6 investigational indications."
CHEMBL4650276,"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(OC[C@@H](O)CO)cc1_|_KRBMOYIWQCZVHA-INIZCTEOSA-N_|_Small molecule_|_False_|_SHR3680_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Rezvilutamide' 'SHR3680' 'Shr3680']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0001421',
       'EFO_0005537'], dtype=object), 'count': 5}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4650989,"C[C@@H](N)COc1ccc(-c2cnc3ccc(N[C@H](C)c4cccc(F)c4)nn23)cc1_|_HEVHTYMYEMEBPX-HZPDHXFCSA-N_|_Small molecule_|_False_|_TALETRECTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AB-106' 'Ab-106' 'DS-6051' 'DS-6051a' 'Taletrectinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TALETRECTINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650361']_|_{'rows': array(['EFO_0003060', 'EFO_0000616', 'MONDO_0004992', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000047936,ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL561132,CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1_|_JTCAGRAKUAAYDY-OAHLLOKOSA-N_|_Small molecule_|_False_|_MK-7246_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MK-7246' 'MK7246']_|_nan_|_['CHEMBL2093879']_|_nan_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL1095097,"COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13_|_JUKPWJGBANNWMW-VWBFHTRKSA-N_|_Small molecule_|_False_|_EPLERENONE_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Eplerenone' 'Inspra']_|_['Eplerenone' 'SC-66110' 'SC-6611O']_|_[('DailyMed', array(['eplerenone'], dtype=object)), ('PubChem', array(['144205299', '170465283', '26754514'], dtype=object)), ('Wikipedia', array(['Eplerenone'], dtype=object)), ('drugbank', array(['DB00700'], dtype=object)), ('chEBI', array(['31547'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000401', 'EFO_0003884', 'EFO_0000612', 'EFO_0008519',
       'EFO_0000275', 'MONDO_0010679', 'EFO_0009784', 'EFO_0003144',
       'MONDO_0005148', 'EFO_0000537', 'EFO_0000318', 'EFO_0000319',
       'MONDO_0007254', 'EFO_0000712', 'MONDO_0001134', 'EFO_0000373'],
      dtype=object), 'count': 16}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 10 investigational indications."
CHEMBL1200543,"CCOC(=O)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1.O=P(O)(O)O_|_FLQCEKVTYABVSH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANILERIDINE PHOSPHATE_|_1982.0_|_4.0_|_CHEMBL1201347_|_False_|_True_|_['Leritine']_|_['Anileridine phosphate' 'Leritine phosphate']_|_nan_|_nan_|_nan_|_[ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200853,"CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C_|_JGMOKGBVKVMRFX-HQZYFCCVSA-N_|_Small molecule_|_False_|_DYDROGESTERONE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Duphaston' 'Duphaston-hrt' 'Gynorest']_|_['Dydrogesterone' 'Isopregnenone' 'NSC-92336']_|_[('PubChem', array(['144203980', '170465104', '56463092'], dtype=object)), ('drugbank', array(['DB00378'], dtype=object)), ('chEBI', array(['31527'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008560', 'EFO_0000660', 'EFO_0003917', 'EFO_0002950',
       'HP_0000138', 'EFO_0000545', 'EFO_1000954', 'GO_0042697'],
      dtype=object), 'count': 8}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 8 investigational indications."
CHEMBL1201115,"COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl_|_GEKNCWBANDDJJL-UHFFFAOYSA-N_|_Small molecule_|_False_|_ESMOLOL HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL768_|_True_|_True_|_['Brevibloc' 'Esmolol hydrochloride']_|_['ASL-8052' 'Esmolol hcl' 'Esmolol hydrochloride']_|_[('DailyMed', array(['esmolol%20hydrochloride'], dtype=object)), ('PubChem', array(['144207045', '170465277', '49681641'], dtype=object)), ('chEBI', array(['4857'], dtype=object))]_|_nan_|_{'rows': array(['HP_0100543', 'EFO_0000537', 'HP_0000138', 'EFO_1001459',
       'EFO_0006834'], dtype=object), 'count': 5}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for hypertension and has 4 investigational indications. It was withdrawn in at least one region."
CHEMBL1289926,"CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1_|_RITAVMQDGBJQJZ-FMIVXFBMSA-N_|_Small molecule_|_False_|_AXITINIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Inlyta']_|_['AG-013736' 'AG-13736' 'Axitinib' 'NSC-757441']_|_[('DailyMed', array(['axitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta'],
      dtype=object)), ('PubChem', array(['124950168', '144207146', '170466656'], dtype=object)), ('Wikipedia', array(['Axitinib'], dtype=object)), ('drugbank', array(['DB06626'], dtype=object)), ('chEBI', array(['66910'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004142', 'MONDO_0004669', 'EFO_0000673', 'EFO_0000198',
       'EFO_0000616', 'MONDO_0011719', 'MONDO_0011962', 'MONDO_0002367',
       'EFO_1001951', 'EFO_0009708', 'EFO_0003860', 'EFO_0003841',
       'EFO_1001465', 'EFO_0003060', 'EFO_0000231', 'EFO_1001968',
       'EFO_0003865', 'EFO_0000681', 'EFO_0004198', 'EFO_1000131',
       'EFO_0000222', 'EFO_1001513', 'EFO_0004252', 'EFO_0000640',
       'EFO_0000313', 'MONDO_0005184', 'EFO_0000181', 'EFO_0000349',
       'EFO_0000770', 'EFO_1000796', 'EFO_0002890', 'EFO_0003869',
       'EFO_0004243', 'EFO_0007143', 'EFO_0003891', 'MONDO_0008315',
       'EFO_0000756', 'EFO_0000519', 'MONDO_0016238', 'MONDO_0004992',
       'MONDO_0001056', 'EFO_0001065', 'EFO_0000182'], dtype=object), 'count': 43}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 6 approved and 37 investigational indications."
CHEMBL1616951,"C[C@]12CCC(=O)C=C1C=C[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@@]2(O)CCC(=O)O_|_PBKZPPIHUVSDNM-WNHSNXHDSA-N_|_Small molecule_|_False_|_CANRENOATE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Canrenoic acid']_|_[('drugbank', array(['DB09015'], dtype=object)), ('chEBI', array(['50156'], dtype=object))]_|_['CHEMBL1371200']_|_{'rows': array(['EFO_0000319', 'EFO_0008585'], dtype=object), 'count': 2}_|_[ENSG00000151623]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL1668,"COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC_|_SZLZWPPUNLXJEA-QEGASFHISA-N_|_Small molecule_|_False_|_RESCINNAMINE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_['Cinnasil' 'Moderil']_|_['Apoterin s' 'Cartric' 'Cinnaloid' 'NSC-15628' 'Rescinnamine' 'Rescisan'
 'Resealoid' 'Reserpinine' 'Scinnamina' 'Tsuruselpi s']_|_[('PubChem', array(['56463114'], dtype=object)), ('Wikipedia', array(['Rescinnamine'], dtype=object)), ('chEBI', array(['28572'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956 and is indicated for hypertension."
CHEMBL1743026,"nan_|_nan_|_Antibody_|_False_|_GEVOKIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gevokizumab' 'VPM-087' 'VPM087' 'XOMA 052' 'XOMA-052']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'HP_0000999', 'MONDO_0021063', 'EFO_0009672',
       'EFO_0003780', 'MONDO_0001718', 'MONDO_0005147', 'MONDO_0005178',
       'EFO_0003894', 'EFO_0000685', 'EFO_1001231'], dtype=object), 'count': 11}_|_[ENSG00000125538]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL2024517,"CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1.Cl_|_GPPJWWMREQHLQT-BHQIMSFRSA-N_|_Small molecule_|_True_|_CARIPRAZINE HYDROCHLORIDE_|_2015.0_|_4.0_|_CHEMBL2028019_|_False_|_True_|_['Reagila' 'Vraylar']_|_['Cariprazine hcl' 'Cariprazine hydrochloride' 'RGH-188 HCL']_|_[('DailyMed', array(['cariprazine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/reagila'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004985', 'EFO_0009963', 'MONDO_0005090'], dtype=object), 'count': 3}_|_[ENSG00000151577,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL2107546,"CC(C)(Cc1c[nH]c2ccccc12)NCC(O)COc1ccccc1C#N.Cl_|_NCEAPFRHADKEHP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUCINDOLOL HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL321582_|_False_|_False_|_[]_|_['Bucindolol hcl' 'Bucindolol hydrochloride' 'Gencaro' 'MJ 13,105-1'
 'MJ-13105-1']_|_nan_|_nan_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109478,"nan_|_nan_|_Antibody_|_False_|_DAPIROLIZUMAB PEGOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CDP-7657' 'CDP7657' 'Cdp-7657' 'Dapirolizumab pegol']_|_nan_|_nan_|_{'rows': array(['MONDO_0007915'], dtype=object), 'count': 1}_|_[ENSG00000102245]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL221959,"C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12_|_UJLAWZDWDVHWOW-YPMHNXCESA-N_|_Small molecule_|_True_|_TOFACITINIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['550' 'CP 690550' 'CP- 690 550' 'CP-690' 'CP-690,550'
 'CP-690,550 FREE BASE' 'CP-690-550' 'CP-690550' 'CP-690550 FREE BASE'
 'CP690,550' 'CP690550' 'Cp-690 free base' 'Tofacitinib']_|_[('PubChem', array(['124939204', '50100095'], dtype=object)), ('Wikipedia', array(['Tofacitinib'], dtype=object)), ('drugbank', array(['DB08895'], dtype=object)), ('chEBI', array(['71200'], dtype=object))]_|_['CHEMBL2103743']_|_{'rows': array(['MONDO_0019472', 'EFO_0003778', 'EFO_0000274', 'EFO_0003884',
       'EFO_0000398', 'MONDO_0018305', 'MONDO_0019338', 'EFO_0000274',
       'EFO_1001857', 'EFO_0000783', 'EFO_1000704', 'EFO_0000546',
       'EFO_0003921', 'MONDO_0007915', 'EFO_0008518', 'EFO_0003898',
       'EFO_0000699', 'EFO_0002609', 'EFO_1000906', 'EFO_0003778',
       'EFO_0000676', 'MONDO_0100096', 'EFO_0003834', 'EFO_0000729',
       'EFO_0003106', 'EFO_0000685', 'EFO_0004991', 'EFO_0001064',
       'MONDO_0019558', 'EFO_1001494', 'EFO_0000685', 'EFO_0000519',
       'EFO_0000384', 'EFO_0003872', 'MONDO_0007915', 'EFO_0004192',
       'EFO_0000717', 'EFO_0003898', 'EFO_0003086', 'EFO_0000540'],
      dtype=object), 'count': 40}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for psoriatic arthritis and rheumatoid arthritis and has 38 investigational indications. This drug has a black box warning from the FDA."
CHEMBL315985,"NC(=O)N1c2ccccc2C[C@H](O)c2ccccc21_|_BMPDWHIDQYTSHX-AWEZNQCLSA-N_|_Small molecule_|_False_|_ESLICARBAZEPINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Erelib' 'Pazzul' 'Stedesa']_|_['(s)-licarbazepine' 'BIA 2-194' 'BIA-2-194' 'BIA-2194' 'CGP-13751'
 'Eslicarbazepine' 'Licarbazepine, (s)-']_|_[('drugbank', array(['DB14575'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for epilepsy."
CHEMBL3186492,"Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl.O.O_|_VRSLTNZJOUZKLX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ONDANSETRON HYDROCHLORIDE_|_1991.0_|_4.0_|_CHEMBL46_|_False_|_True_|_['Demorem' 'Ondansetron hydrochloride'
 'Ondansetron hydrochloride preservative free' 'Ondemet' 'Setofilm'
 'Zofran' 'Zofran preservative free']_|_['GR 38032F' 'GR-38032F' 'NSC-665799' 'Odansetron hydrochloride'
 'Ondansetron (as hydrochloride)' 'Ondansetron hcl'
 'Ondansetron hydrochloride' 'Ondansetron hydrochloride dihydrate'
 'Ondansetron hydrochloride hydrate' 'Ondansetron monohydrochloride'
 'SN 307' 'SN-307' 'Zophren']_|_[('DailyMed', array(['ondansetron%20hydrochloride'], dtype=object)), ('PubChem', array(['144206896'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004888', 'EFO_0006911', 'EFO_0011023', 'MONDO_0004992',
       'HP_0002018', 'EFO_0003843', 'EFO_0007386', 'HP_0002013',
       'HP_0002017', 'Orphanet_79292'], dtype=object), 'count': 10}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 6 approved and 4 investigational indications."
CHEMBL3545013,"nan_|_nan_|_Small molecule_|_False_|_APN1125_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Apn1125']_|_nan_|_nan_|_{'rows': array(['MONDO_0005090'], dtype=object), 'count': 1}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3581693,"CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl_|_BURHGPHDEVGCEZ-KJGLQBJMSA-N_|_Small molecule_|_False_|_BRILANESTRANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARN-810' 'Brilanestrant' 'GDC-0810' 'Gdc-0810' 'RG-6046' 'RG6046']_|_[('drugbank', array(['DB12253'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4071864,"CN1C(=O)[C@@H](NC(=O)c2n[nH]c(Cc3ccccc3)n2)COc2ccccc21_|_LYPAFUINURXJSG-AWEZNQCLSA-N_|_Small molecule_|_False_|_GSK2982772_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gsk2982772']_|_nan_|_nan_|_{'rows': array(['EFO_0003767', 'EFO_0000540', 'EFO_0000729', 'EFO_0000676',
       'EFO_0000685'], dtype=object), 'count': 5}_|_[ENSG00000137275]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4297739,"nan_|_nan_|_Oligonucleotide_|_False_|_DANVATIRSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD 9150' 'AZD-9150' 'AZD9150' 'Azd9150' 'Danvatirsen' 'ISIS-481464'
 'ISIS-STAT3RX']_|_nan_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_0000403', 'EFO_0000616', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0001187', 'EFO_0000181'], dtype=object), 'count': 7}_|_[ENSG00000168610]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4594260,"Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1_|_UQRICAQPWZSJNF-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAZEMETOSTAT HYDROBROMIDE_|_2020.0_|_4.0_|_CHEMBL3414621_|_False_|_True_|_['Tazverik']_|_['E-7438 HYDROBROMIDE' 'EPZ-6438 HYDROBROMIDE' 'EPZ-6438 MONOHYDROBROMIDE'
 'EZ-438' 'EZ438' 'Tazemetostat hydrobromide'
 'Tazemetostat monohydrobromide']_|_[('DailyMed', array(['tazemetostat%20hydrobromide'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAZEMETOSTAT%20HYDROBROMIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000691', 'MONDO_0008315', 'EFO_0000702', 'EFO_0000616',
       'MONDO_0018906'], dtype=object), 'count': 5}_|_[ENSG00000106462]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for sarcoma and follicular lymphoma and has 3 investigational indications."
CHEMBL4647810,"C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1_|_YBXRSCXGRPSTMW-CYBMUJFWSA-N_|_Small molecule_|_False_|_ELIMUSERTIB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BAY-1895344' 'Elimusertib']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_1001469', 'EFO_0000616'], dtype=object), 'count': 3}_|_[ENSG00000175054]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL4650319,"C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C_|_AZSRSNUQCUDCGG-UHFFFAOYSA-N_|_Small molecule_|_True_|_MOBOCERTINIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AP-32788' 'AP32788' 'Mobocertinib' 'TAK-788' 'Tak-788']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MOBOCERTINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802239']_|_{'rows': array(['EFO_0003086', 'EFO_0001421', 'EFO_0003060', 'EFO_0000616',
       'EFO_0003060'], dtype=object), 'count': 5}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for non-small cell lung carcinoma and neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL485,"COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341_|_OROGSEYTTFOCAN-DNJOTXNNSA-N_|_Small molecule_|_True_|_CODEINE_|_1952.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Codeine' 'Codeine monohydrate' 'Codeinum' 'Codeinum monohydricum'
 'Dea no. 9050' 'IDS-NC-005(SECT.-2)']_|_[('PubChem', array(['144207280'], dtype=object)), ('Wikipedia', array(['Codeine'], dtype=object)), ('drugbank', array(['DB00318'], dtype=object)), ('chEBI', array(['16714'], dtype=object))]_|_['CHEMBL4297091' 'CHEMBL1257022' 'CHEMBL1159819' 'CHEMBL284671'
 'CHEMBL369475' 'CHEMBL1201463' 'CHEMBL1201099']_|_{'rows': array(['HP_0000545', 'HP_0002019', 'EFO_0003890', 'MONDO_0005277',
       'EFO_0003843', 'HP_0030833', 'HP_0003394', 'EFO_0003843',
       'EFO_0000764', 'EFO_0010072', 'MONDO_0011382', 'HP_0012735',
       'EFO_0003843', 'HP_0012735', 'EFO_0003890', 'HP_0011868',
       'MONDO_0005178'], dtype=object), 'count': 17}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 5 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL533,"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1_|_ALOBUEHUHMBRLE-UHFFFAOYSA-N_|_Small molecule_|_True_|_IBUTILIDE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ibutilide']_|_[('Wikipedia', array(['Ibutilide'], dtype=object)), ('drugbank', array(['DB00308'], dtype=object)), ('chEBI', array(['5856'], dtype=object))]_|_['CHEMBL3187455' 'CHEMBL2355456']_|_{'rows': array(['EFO_0004269'], dtype=object), 'count': 1}_|_[ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995 and is indicated for cardiac arrhythmia. This drug has a black box warning from the FDA."
CHEMBL548,"CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O_|_XEYBRNLFEZDVAW-ARSRFYASSA-N_|_Small molecule_|_False_|_DINOPROSTONE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Cervidil' 'Prepidil' 'Propess' 'Prostin e2']_|_['Dinoprostone' 'Dinoprostone beta-cyclodextrin clathrate' 'Enzaprost e'
 'Minprostin e2' 'NSC-165560' 'NSC-196514' 'Prostaglandin e2' 'U-12,062'
 'U-12062']_|_[('DailyMed', array(['dinoprostone'], dtype=object)), ('PubChem', array(['144204747', '170465000', '26753268', '26753269', '26753270',
       '50105679'], dtype=object)), ('Wikipedia', array(['Prostaglandin_E2'], dtype=object)), ('drugbank', array(['DB00917'], dtype=object)), ('chEBI', array(['15551'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001799', 'EFO_0002950', 'MONDO_0003061', 'EFO_0003843',
       'EFO_0000495'], dtype=object), 'count': 5}_|_[ENSG00000160951,ENSG00000171522,ENSG00000125384,ENSG00000050628]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 investigational indications."
CHEMBL588,"Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1_|_TVURRHSHRRELCG-UHFFFAOYSA-N_|_Small molecule_|_False_|_FENOLDOPAM_|_1997.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Carlacor' 'Fenoldopam' 'SK&F-82526' 'SK-82526']_|_[('PubChem', array(['104171160', '144203703', '170465321', '26752227', '50104923',
       '90340762'], dtype=object)), ('Wikipedia', array(['Fenoldopam'], dtype=object)), ('drugbank', array(['DB00800'], dtype=object)), ('chEBI', array(['5002'], dtype=object))]_|_['CHEMBL1256646' 'CHEMBL1026']_|_{'rows': array(['EFO_0000537', 'HP_0001919', 'EFO_0000537', 'EFO_0000319',
       'EFO_1002048', 'HP_0001919'], dtype=object), 'count': 6}_|_[ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and cardiovascular disease and has 4 investigational indications."
CHEMBL605,"CCN(CC)CCNC(=O)c1ccc(N)cc1.Cl_|_ABTXGJFUQRCPNH-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROCAINAMIDE HYDROCHLORIDE_|_1950.0_|_4.0_|_CHEMBL640_|_False_|_True_|_['Biocoryl' 'Novocainamid' 'Procainamide hydrochloride' 'Procan'
 'Procan sr' 'Procanbid' 'Procapan' 'Pronestyl' 'Pronestyl-sr']_|_['Amidoprocaine' 'Cardiorytmin' 'NSC-757279' 'Procainamide HCl'
 'Procainamide hcl' 'Procainamide hydrochloride'
 'Procainamidi hydrochloridum']_|_[('DailyMed', array(['procainamide%20hydrochloride'], dtype=object)), ('PubChem', array(['144210053', '26747643', '50106886', '56423113', '855728'],
      dtype=object)), ('chEBI', array(['8429'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004308', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL654,"CN1CCN2c3ncccc3Cc3ccccc3C2C1_|_RONZAEMNMFQXRA-UHFFFAOYSA-N_|_Small molecule_|_True_|_MIRTAZAPINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Mirtazapine' 'Remeron' 'Remeron soltab' 'Zispin']_|_['6-azamianserin' 'Avanza' 'Mirataz' 'Mirtazapin' 'Mirtazapine'
 'Mirtazapine anhydrous' 'Norset' 'ORG 3770' 'ORG-3770' 'Promyrtil'
 'Rexer']_|_[('DailyMed', array(['mirtazapine'], dtype=object)), ('PubChem', array(['144204516', '29215050', '49648465'], dtype=object)), ('Wikipedia', array(['Mirtazapine'], dtype=object)), ('drugbank', array(['DB00370'], dtype=object)), ('chEBI', array(['6950'], dtype=object))]_|_['CHEMBL5315116']_|_{'rows': array(['HP_0004326', 'HP_0002039', 'EFO_0005687', 'EFO_0002610',
       'MONDO_0002050', 'EFO_0004240', 'EFO_0004888', 'MONDO_0005090',
       'HP_0000726', 'MONDO_0007079', 'EFO_0005230', 'MONDO_0002491',
       'MONDO_0005351', 'HP_0001824', 'EFO_0004698', 'MONDO_0002009',
       'EFO_0003890', 'EFO_0003918', 'EFO_0004701', 'EFO_0000326',
       'EFO_0006911', 'MONDO_0002009', 'EFO_0003756'], dtype=object), 'count': 23}_|_[ENSG00000102468,ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL738,"CCCC(C)C1(CC)C(=O)[N-]C(=S)NC1=O.[Na+]_|_AWLILQARPMWUHA-UHFFFAOYSA-M_|_Small molecule_|_False_|_THIOPENTAL SODIUM_|_1982.0_|_4.0_|_CHEMBL441_|_False_|_True_|_['Intraval' 'Intraval sod' 'Penthiobarbital' 'Pentothal' 'Thiomebumal'
 'Thionembutal' 'Thiopentone' 'Trapanal']_|_['Farmotal' 'Hypnostan' 'Leopental' 'NSC-759557' 'Nesdonal'
 'Penthiobarbital sodium' 'Ravonal' 'Sodium pentothal' 'Sodium thiopental'
 'Thiomebumal sodium' 'Thiopental Sodium' 'Thiopental sodium'
 'Thiopentalum natricum' 'Thiopentobarbitone sodium' 'Thiopentone'
 'Thiopentone sodium' 'Trapanal']_|_[('PubChem', array(['144205294', '170464734', '26749790'], dtype=object)), ('Wikipedia', array(['Sodium_thiopental'], dtype=object)), ('chEBI', array(['9561'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001454'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication."
CHEMBL939,"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1_|_XGALLCVXEZPNRQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_GEFITINIB_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Iressa']_|_['Gefitinib' 'Iressa' 'NSC-759856' 'ZD-1839' 'ZD1839']_|_[('DailyMed', array(['gefitinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/iressa'],
      dtype=object)), ('PubChem', array(['103905343', '103905344', '124892204', '124892206', '137275808',
       '144205236', '170464828', '29215403', '50100103'], dtype=object)), ('Wikipedia', array(['Gefitinib'], dtype=object)), ('drugbank', array(['DB00317'], dtype=object)), ('chEBI', array(['49668'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000514', 'EFO_0000702', 'EFO_0000182', 'EFO_0003869',
       'EFO_0000222', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000708',
       'MONDO_0008315', 'EFO_0000196', 'MONDO_0007254', 'EFO_0000616',
       'EFO_1000158', 'MONDO_0002367', 'EFO_0000313', 'MONDO_0004992',
       'EFO_0004252', 'EFO_0000681', 'EFO_0003859', 'EFO_0000588',
       'EFO_0002618', 'EFO_1001951', 'EFO_0000571', 'EFO_0000691',
       'EFO_0000181', 'MONDO_0004192', 'MONDO_0002158', 'EFO_0001071',
       'MONDO_0004669', 'EFO_0000308', 'EFO_0000707', 'EFO_0000519',
       'MONDO_0021117', 'EFO_0006861', 'EFO_0000621', 'MONDO_0002898',
       'MONDO_0002087', 'MONDO_0002974', 'MONDO_0007576', 'EFO_1000251',
       'MONDO_0008903', 'EFO_1001100', 'EFO_0006859', 'EFO_1001465',
       'EFO_0000178', 'EFO_0004284', 'MONDO_0008170', 'EFO_0003897'],
      dtype=object), 'count': 48}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 45 investigational indications."
CHEMBL1091644,"C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1_|_PKCDDUHJAFVJJB-VLZXCDOPSA-N_|_Small molecule_|_False_|_LINSITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ASP-7487' 'Linsitinib' 'OSI-906' 'OSI-906AA']_|_[('drugbank', array(['DB06075'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_1001951', 'EFO_0000702', 'EFO_0000174',
       'EFO_0006859', 'MONDO_0002898', 'EFO_0000181', 'EFO_0003060',
       'EFO_0000673', 'MONDO_0007254', 'EFO_0000182', 'EFO_1000796',
       'EFO_0000616'], dtype=object), 'count': 13}_|_[ENSG00000140443,ENSG00000171105]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL1200798,"Cl.O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12_|_OHHDIOKRWWOXMT-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRAZODONE HYDROCHLORIDE_|_1981.0_|_4.0_|_CHEMBL621_|_False_|_True_|_['Desyrel' 'Molipaxin' 'Molipaxin cr' 'Oleptro' 'Trazodone hydrochloride'
 'Trialodine']_|_['AF-1161' 'NSC-292811' 'Trazodone hcl' 'Trazodone hydrochloride']_|_[('DailyMed', array(['trazodone%20hydrochloride'], dtype=object)), ('PubChem', array(['124891691', '144203837', '144213002', '170465234', '26747679',
       '50107085', '56423658', '855917'], dtype=object)), ('chEBI', array(['9655'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004976', 'MONDO_0002050', 'MONDO_0002009', 'MONDO_0002009'],
      dtype=object), 'count': 4}_|_[ENSG00000102468,ENSG00000147246,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for depressive disorder and major depressive disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1200828,"Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1_|_WBCWFMFZMRFRLT-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCRIMINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201227_|_False_|_True_|_['Pagitane']_|_['Cycrimine HCl' 'Cycrimine hcl' 'Cycrimine hydrochloride' 'NSC-169452']_|_[('chEBI', array(['59693'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201496,"nan_|_nan_|_Protein_|_False_|_INSULIN ASPART_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Fiasp' 'Fiasp flextouch' 'Fiasp penfill' 'Ins novorapid' 'Novolog'
 'Novolog flexpen' 'Novolog flextouch' 'Novolog innolet' 'Novolog penfill']_|_['B28-ASP-INSULIN' 'INA-X14' 'INSULIN X14' 'Insulin aspart']_|_[('DailyMed', array(['insulin%20aspart', 'insulin%20aspart%20recombinant'], dtype=object)), ('DrugCentral', array(['4981'], dtype=object)), ('Wikipedia', array(['Insulin_aspart'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000565', 'EFO_0003914', 'EFO_0000400',
       'MONDO_0005148', 'EFO_0004593', 'MONDO_0004975', 'EFO_0000537',
       'EFO_0001645', 'MONDO_0005147', 'HP_0003124', 'MONDO_0009061'],
      dtype=object), 'count': 12}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for diabetes mellitus and has 11 investigational indications."
CHEMBL1201832,"nan_|_nan_|_Protein_|_False_|_ROMIPLOSTIM_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Nplate']_|_['AMG 531' 'Romiplate' 'Romiplostim']_|_[('DailyMed', array(['romiplostim'], dtype=object)), ('DrugCentral', array(['4996'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nplate'],
      dtype=object)), ('Wikipedia', array(['Romiplostim'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010518', 'MONDO_0018896', 'HP_0001873', 'EFO_0000198',
       'MP_0001914', 'MONDO_0008170', 'EFO_0000519', 'EFO_0000313',
       'HP_0001915', 'MONDO_0004992', 'EFO_0006927', 'EFO_0000574',
       'EFO_0007160', 'EFO_0005952', 'MONDO_0043768'], dtype=object), 'count': 15}_|_[ENSG00000117400]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 12 investigational indications."
CHEMBL1237123,"COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC_|_GBLRQXKSCRCLBZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXACURIUM_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Doxacurium cation' 'Doxacurium ion']_|_[('drugbank', array(['DB01135'], dtype=object)), ('chEBI', array(['4706'], dtype=object))]_|_['CHEMBL1237099']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991."
CHEMBL1271,"C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1_|_XSBSKEQEUFOSDD-UHFFFAOYSA-N_|_Small molecule_|_False_|_PENTOLINIUM_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ansolysen' 'Pentolinium' 'Pentolinium cation' 'Pentolinium ion'
 'Pentolonium']_|_[('Wikipedia', array(['Pentolinium'], dtype=object)), ('drugbank', array(['DB01090'], dtype=object)), ('chEBI', array(['347401'], dtype=object))]_|_['CHEMBL118902' 'CHEMBL1356989' 'CHEMBL1318287']_|_nan_|_[ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1487,"CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O_|_XUKUURHRXDUEBC-KAYWLYCHSA-N_|_Small molecule_|_False_|_ATORVASTATIN_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Cardyl' 'Lipitor' 'Prevencor' 'Sortis' 'Tahor' 'Zarator']_|_['Atorvastatin']_|_[('PubChem', array(['124892211', '144212734', '29215408'], dtype=object)), ('Wikipedia', array(['Atorvastatin'], dtype=object)), ('drugbank', array(['DB01076'], dtype=object)), ('chEBI', array(['39548'], dtype=object))]_|_['CHEMBL393220' 'CHEMBL1790017' 'CHEMBL3349878']_|_{'rows': array(['MONDO_0011382', 'EFO_0003767', 'EFO_0009426', 'EFO_0004211',
       'EFO_0008568', 'EFO_0000612', 'EFO_0003086', 'MONDO_0019338',
       'MONDO_0005301', 'EFO_0008586', 'Orphanet_309005', 'EFO_1001771',
       'EFO_0000275', 'EFO_0000196', 'EFO_0001361', 'EFO_0000764',
       'EFO_0003914', 'MONDO_0018076', 'EFO_0004911', 'EFO_0003869',
       'EFO_0006818', 'EFO_0004616', 'EFO_0000616', 'EFO_0000685',
       'EFO_0009783', 'MONDO_0002492', 'HP_0100543', 'MONDO_0001444',
       'EFO_0000319', 'EFO_0000180', 'MONDO_0008315', 'EFO_0000519',
       'EFO_0000319', 'MONDO_0004782', 'EFO_0003913', 'EFO_0000660',
       'Orphanet_79211', 'EFO_0000538', 'EFO_0001645', 'EFO_0000373',
       'MONDO_0043510', 'EFO_0004211', 'MONDO_0011962', 'EFO_0000195',
       'EFO_0000673', 'EFO_1001249', 'EFO_0000384', 'EFO_0003047',
       'EFO_0000318', 'MONDO_0004992', 'EFO_1001466', 'EFO_0003870',
       'EFO_0000649', 'EFO_0000574', 'EFO_0004252', 'EFO_0001073',
       'EFO_0000681', 'EFO_0001378', 'Orphanet_309005', 'EFO_0003914',
       'EFO_0001365', 'EFO_0000668', 'EFO_0004911', 'EFO_0004194',
       'EFO_0003918', 'EFO_0000195', 'EFO_0000649', 'EFO_0000565',
       'MONDO_0021187', 'MONDO_0007915', 'EFO_0001645', 'MONDO_0018473',
       'EFO_0001422', 'EFO_0000198', 'EFO_0007328', 'EFO_0007129',
       'EFO_0005672', 'MONDO_0002679', 'HP_0003124', 'MONDO_0021661',
       'EFO_0003095', 'EFO_0000676', 'MONDO_0013730', 'MONDO_0018373',
       'MONDO_0021187', 'HP_0003119', 'MONDO_0005147', 'EFO_0000222',
       'EFO_0007160', 'EFO_0008583', 'EFO_0003884', 'MONDO_0007254',
       'EFO_0000712', 'EFO_0004208', 'HP_0003124', 'EFO_0004264',
       'EFO_1000984', 'EFO_1001993', 'EFO_0005952', 'Orphanet_413',
       'MONDO_0001134', 'MONDO_0007254', 'EFO_0000537', 'MONDO_0005148',
       'EFO_0008585', 'EFO_0003144', 'HP_0001258', 'EFO_0004255',
       'MONDO_0005835', 'EFO_0004246', 'EFO_0000400', 'EFO_0003929',
       'EFO_0000365', 'EFO_0004236', 'EFO_0007243', 'EFO_0004286',
       'EFO_0003047', 'HP_0100806', 'Orphanet_79211', 'EFO_1001801',
       'EFO_0000474', 'HP_0000083', 'MONDO_0004979', 'MONDO_0005148',
       'MONDO_0004975', 'MONDO_0100096', 'MONDO_0002050', 'HP_0001647',
       'EFO_0000400'], dtype=object), 'count': 129}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 14 approved and 106 investigational indications."
CHEMBL1651534,"O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1_|_BATCTBJIJJEPHM-UHFFFAOYSA-N_|_Small molecule_|_False_|_REDAFAMDASTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-04457845' 'PF-4457845' 'Pf-04457845' 'Redafamdastat']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-129'], dtype=object)), ('Wikipedia', array(['PF-04457845'], dtype=object)), ('drugbank', array(['DB12012'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004616', 'EFO_0007191', 'HP_0012532', 'EFO_0001358',
       'EFO_0004895'], dtype=object), 'count': 5}_|_[ENSG00000117480]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1738699,"Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1_|_YVPGZQLRPAGKLA-UHFFFAOYSA-N_|_Small molecule_|_False_|_N6022_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['N-6022' 'N6022']_|_[('drugbank', array(['DB12206'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'MONDO_0009061'], dtype=object), 'count': 2}_|_[ENSG00000197894]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1922094,"Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12_|_YOVVNQKCSKSHKT-HNNXBMFYSA-N_|_Small molecule_|_False_|_APITOLISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apitolisib' 'G-038390' 'G-038390.1' 'GDC-0980' 'GDC-0980.1' 'Gne-390'
 'RG-7422' 'RG7422' 'Rg-7422']_|_[('drugbank', array(['DB12180'], dtype=object))]_|_['CHEMBL1922103' 'CHEMBL1922106']_|_{'rows': array(['MONDO_0004992', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0007254',
       'EFO_0000681', 'EFO_1001512'], dtype=object), 'count': 6}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL2010872,"CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3_|_AEULIVPVIDOLIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_CEP-11981_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BOL-303213X' 'CEP-11981' 'CEP11981' 'Cep 11981' 'Cep-11981']_|_nan_|_nan_|_{'rows': array(['EFO_0000196', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000120156,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2070241,"CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O_|_FFHBJDQSGDNCIV-MFVUMRCOSA-N_|_Protein_|_False_|_BREMELANOTIDE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Bremelanotide']_|_['Bremelanotide' 'PT-141' 'PT-141 FREE BASE']_|_[('drugbank', array(['DB11653'], dtype=object))]_|_['CHEMBL4297533']_|_{'rows': array(['EFO_0000677', 'EFO_0004714', 'EFO_0003086', 'EFO_0004714',
       'HP_0002018'], dtype=object), 'count': 5}_|_[ENSG00000166603]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for mental or behavioural disorder and sexual dysfunction and has 3 investigational indications."
CHEMBL2103839,"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C_|_BUROJSBIWGDYCN-GAUTUEMISA-N_|_Small molecule_|_False_|_RIDAFOROLIMUS_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AP 23573' 'AP-23573' 'AP23573' 'MK-8669' 'MK8669' 'Ridaforolimus']_|_[('drugbank', array(['DB06233'], dtype=object)), ('chEBI', array(['79700'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000569', 'MONDO_0008315', 'EFO_0003869', 'MONDO_0021054',
       'EFO_0001378', 'EFO_0002430', 'EFO_0000637', 'EFO_1001968',
       'EFO_1001465', 'EFO_0000574', 'MONDO_0011962', 'EFO_0003060',
       'EFO_0000198', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0000691', 'EFO_0000565', 'EFO_0000564'], dtype=object), 'count': 19}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications."
CHEMBL2105160,"C[C@@H](N/C(=N\C#N)Nc1ccc(C#N)cc1)C(C)(C)C_|_PGYDRGZVXVVZQC-LLVKDONJSA-N_|_Small molecule_|_False_|_NAMINIDIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-234303' 'BMS-234303-01' 'Naminidil' 'Naminidil, (r)-']_|_nan_|_nan_|_nan_|_[ENSG00000187486,ENSG00000069431,ENSG00000006071,ENSG00000121361]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2108341,nan_|_nan_|_Antibody_|_False_|_SONTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AS-1402' 'HUHMFG-1' 'Sontuzumab']_|_nan_|_nan_|_nan_|_[ENSG00000185499]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109428,"nan_|_nan_|_Antibody_|_False_|_TRX-518_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['TRX-518' 'Trx-518']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'MONDO_0008315', 'MONDO_0007254', 'EFO_0000756',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000186891]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications."
CHEMBL2109616,"nan_|_nan_|_Antibody_|_False_|_ABX-IL8_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABX-IL8' 'Abx-il8']_|_nan_|_nan_|_{'rows': array(['EFO_0006505'], dtype=object), 'count': 1}_|_[ENSG00000169429]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2111051,"C#CCO[C@H]1CN2CCC1CC2_|_XVFJONKUSLSKSW-JTQLQIEISA-N_|_Small molecule_|_False_|_TALSACLIDINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Talsaclidine']_|_[('drugbank', array(['DB12287'], dtype=object))]_|_['CHEMBL2107204']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL219410,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3cnnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C_|_CGTADGCBEXYWNE-JUKNQOCSSA-N_|_Small molecule_|_False_|_ZOTAROLIMUS_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABT-578' 'Mdt-4107' 'Zotarolimus']_|_nan_|_nan_|_nan_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of III.
CHEMBL282686,"CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O_|_CXGTZJYQWSUFET-IBGZPJMESA-N_|_Small molecule_|_False_|_TESAGLITAZAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AR-H-039242' 'AR-H039242XX' 'AZ-242' 'Az-242' 'BR-44608' 'Tesaglitazar']_|_[('drugbank', array(['DB06536'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000186951,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3184437,"OCc1ccc(Cl)cc1Cl_|_DBHODFSFBXJZNY-UHFFFAOYSA-N_|_Small molecule_|_False_|_DICHLOROBENZYL ALCOHOL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dichlorobenzyl alcohol' 'Dybenal' 'NSC-15635'
 'Oxiconazole related compound d' 'Rapidosept']_|_[('PubChem', array(['144211212', '170465574'], dtype=object)), ('drugbank', array(['DB13269'], dtype=object)), ('chEBI', array(['48220'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL4105630,"C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1_|_HARRKNSQXBRBGZ-GVKWWOCJSA-N_|_Small molecule_|_True_|_ZURANOLONE_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Zurzuvae']_|_['S-812217' 'SAGE-217' 'SGE-797' 'Sage-217' 'Zuranolone']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZURANOLONE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15490'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007453', 'MONDO_0002009', 'EFO_0003108', 'MONDO_0005180',
       'MONDO_0002050', 'EFO_0004247'], dtype=object), 'count': 6}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for postpartum depression and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4298199,"nan_|_nan_|_Gene_|_False_|_IDECABTAGENE VICLEUCEL_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Abecma']_|_['Anti-bcma car t cell' 'BB-2121' 'Ide-cel' 'Idecabtagene vicleucel'
 'bb2121']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/abecma'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IDECABTAGENE%20VICLEUCEL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0010283', 'HP_0001871', 'EFO_0000200', 'Orphanet_2442',
       'MONDO_0002243', 'MONDO_0021334', 'EFO_0004264', 'EFO_0001378',
       'EFO_0007326', 'MONDO_0003159', 'EFO_0000319', 'EFO_0000203',
       'EFO_0000616', 'EFO_0000540'], dtype=object), 'count': 14}_|_[ENSG00000048462]_|_Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 14 approved indications."
CHEMBL435298,"C[C@H](C(=O)O)c1ccc(-c2ccccc2)c(F)c1_|_SYTBZMRGLBWNTM-JTQLQIEISA-N_|_Small molecule_|_False_|_ESFLURBIPROFEN_|_2015.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BTS 24332' 'BTS-24332' 'Esflurbiprofen' 'Flurbiprofen, (s)-']_|_[('PubChem', array(['47193727'], dtype=object)), ('chEBI', array(['42446'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002829', 'HP_0003326', 'EFO_0009582'], dtype=object), 'count': 3}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 investigational indications."
CHEMBL4594326,"nan_|_nan_|_Antibody_|_False_|_APITEGROMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Apitegromab' 'SRK-015' 'Srk-015']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/APITEGROMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009673', 'MONDO_0009672', 'EFO_0008525', 'EFO_1000096',
       'HP_0003202'], dtype=object), 'count': 5}_|_[ENSG00000138379]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL5314408,"CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1_|_MVWATCATLSSVBH-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD-0424_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZD0424' 'Azd-0424']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000197122,ENSG00000097007]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL544,"COc1ccc(O)cc1_|_NWVVVBRKAWDGAB-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEQUINOL_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['4-hydroxyanisole' '4-methoxyphenol' '4ha' 'BMS-181158'
 'Hqmme; hydroxyquinone methyl ether' 'Leucobasal' 'Leucodine b'
 'Mechinolum' 'Menthyl anthranilate' 'Mequinol' 'NSC-4960'
 'Novo-dermoquinona' 'P-guaiacol' 'P-hydroxyanisole']_|_[('PubChem', array(['144204676', '144209565', '144213193', '170464687', '17389832',
       '50105587', '71152', '85272557'], dtype=object)), ('Wikipedia', array(['Mequinol'], dtype=object)), ('drugbank', array(['DB09516'], dtype=object)), ('chEBI', array(['69441'], dtype=object))]_|_nan_|_nan_|_[ENSG00000077498]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999."
CHEMBL861,"CCC1(c2ccccc2)NC(=O)N(C)C1=O_|_GMHKMTDVRCWUDX-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPHENYTOIN_|_1946.0_|_4.0_|_nan_|_False_|_True_|_['Mesantoin']_|_['Mephenytoin' 'Methoin' 'NSC-34652']_|_[('PubChem', array(['56463168'], dtype=object)), ('Wikipedia', array(['Mephenytoin'], dtype=object)), ('drugbank', array(['DB00532'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for epilepsy."
CHEMBL1200329,"Cl.Clc1ccc2nsnc2c1NC1=NCCN1_|_ZWUKMNZJRDGCTQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIZANIDINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL1079_|_False_|_True_|_['Sirdalud' 'Sirdalud mr' 'Tizanidine hydrochloride' 'Zanaflex']_|_['AN-021' 'AN021' 'DS 103-282' 'DS-103-282'
 'Tizanidine (as hydrochloride)' 'Tizanidine hcl'
 'Tizanidine hydrochloride']_|_[('DailyMed', array(['tizanidine%20hydrochloride'], dtype=object)), ('PubChem', array(['56320475'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0043510', 'MONDO_0100431', 'HP_0001257', 'MONDO_0005475',
       'MONDO_0002959'], dtype=object), 'count': 5}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for spasticity and has 4 investigational indications."
CHEMBL1200500,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C_|_KUVIULQEHSCUHY-XYWKZLDCSA-N_|_Small molecule_|_False_|_BECLOMETHASONE DIPROPIONATE_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Aerobec 100' 'Aerobec 50' 'Aerobec fte 250' 'Asmabec clickhaler'
 'Asmabec spacehaler' 'Beclazone 100' 'Beclazone 100 e-breathe'
 'Beclazone 200' 'Beclazone 250' 'Beclazone 250 e-breathe' 'Beclazone 50'
 'Beclazone 50 e-breathe' 'Becloaqua 50' 'Becloforte'
 'Becloforte e-breathe' 'Becloforte integra' 'Becloforte-vm'
 'Beclomet diprop' 'Beclomet hayfever' 'Beclomist' 'Beclotaide'
 'Beclovent' 'Becodisks' 'Beconase' 'Beconase aq' 'Becotide'
 'Becotide 100' 'Becotide 100 e-breathe' 'Becotide 200' 'Becotide 50'
 'Becotide 50 e-breathe' 'Clenil modulite' 'Clipper' 'Filair 100'
 'Filair 50' 'Filair fte' 'Fostair' 'Fostair nexthaler' 'Nasobec aq'
 'Nasobec hayfever' 'Propaderm' 'Propaderm fte' 'Propaderm-a'
 'Propaderm-c' 'Pulvinal beclomet' 'Qnasl' 'Qvar 100' 'Qvar 100 e-breathe'
 'Qvar 40' 'Qvar 50' 'Qvar 50 e-breathe' 'Qvar 80' 'Qvar redihaler'
 'Rino clenil' 'Vancenase' 'Vancenase aq' 'Vancenase pockethaler'
 'Vanceril' 'Vanceril double strength' 'Ventide' 'Vivabec'
 'Zonivent aquanasal']_|_['Beclometasone' 'Beclometasone dipropionate' 'Beclomethasone'
 'Beclomethasone dipropionate' 'NSC-755901' 'SCH 18020W' 'SCH 8020W'
 'SCH-18020W' 'SGX-201' 'SGX-202' 'SGX-203']_|_[('DailyMed', array(['beclomethasone%20dipropionate',
       'beclomethasone%20dipropionate%20monohydrate'], dtype=object)), ('PubChem', array(['144206719', '56463541'], dtype=object)), ('Wikipedia', array(['Beclometasone_dipropionate'], dtype=object)), ('drugbank', array(['DB00394'], dtype=object)), ('chEBI', array(['3002'], dtype=object))]_|_nan_|_{'rows': array(['HP_0006536', 'EFO_0000702', 'EFO_0003956', 'EFO_0005854',
       'MONDO_0004979', 'EFO_0007227', 'MONDO_0019091', 'HP_0002110',
       'MONDO_0043579', 'EFO_1000391', 'EFO_1001417', 'EFO_0004599',
       'EFO_1000702', 'EFO_1000644', 'EFO_0000768', 'HP_0001742',
       'MONDO_0013730', 'MONDO_0020547', 'EFO_0000544', 'EFO_0007486',
       'EFO_0004232', 'MONDO_0100096', 'EFO_0000341'], dtype=object), 'count': 23}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 6 approved and 17 investigational indications."
CHEMBL1201352,"C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1_|_HTIKWNNIPGXLGM-YLINKJIISA-N_|_Small molecule_|_False_|_RAPACURONIUM_|_1999.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Rapacuronium' 'Rapacuronium cation' 'Rapacuronium ion']_|_[('Wikipedia', array(['Rapacuronium'], dtype=object)), ('drugbank', array(['DB04834'], dtype=object))]_|_['CHEMBL1200549']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999."
CHEMBL1201607,"nan_|_nan_|_Antibody_|_True_|_NATALIZUMAB_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Tysabri']_|_['AN100226M' 'ANTEGRAN' 'Antegren' 'Natalizumab']_|_[('DailyMed', array(['natalizumab'], dtype=object)), ('DrugCentral', array(['4970'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri'],
      dtype=object)), ('Wikipedia', array(['Natalizumab'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0008522', 'MONDO_0005090', 'EFO_0000637',
       'MONDO_0005301', 'MP_0001845', 'MONDO_0011382', 'EFO_0000685',
       'EFO_0000384', 'EFO_0004599', 'EFO_0000540', 'EFO_0003929',
       'EFO_0001378', 'EFO_0008520', 'EFO_0007323', 'HP_0002140'],
      dtype=object), 'count': 16}_|_[ENSG00000150093,ENSG00000115232,ENSG00000139626]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1648,"COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12_|_HMJIYCCIJYRONP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISRADIPINE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_['Dynacirc' 'Dynacirc cr' 'Isradipine' 'Prescal']_|_['Isradipine' 'Isrodipine' 'NSC-759892' 'PN 200-110' 'PN-200-110']_|_[('DailyMed', array(['isradipine'], dtype=object)), ('PubChem', array(['144204241', '170465070'], dtype=object)), ('Wikipedia', array(['Isradipine'], dtype=object)), ('drugbank', array(['DB00270'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003890', 'EFO_0004319', 'EFO_0000537', 'EFO_0005611',
       'EFO_0000319', 'EFO_0003768', 'MONDO_0005180', 'MONDO_0004985'],
      dtype=object), 'count': 8}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for hypertension and cardiovascular disease and has 6 investigational indications."
CHEMBL1743023,"nan_|_nan_|_Antibody_|_False_|_FULRANUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMG 403' 'AMG-403' 'AMG403' 'Fulranumab' 'JNJ 42160443' 'JNJ-42160443']_|_nan_|_nan_|_{'rows': array(['EFO_1000783', 'EFO_0003843', 'MONDO_0005178', 'HP_0012532',
       'EFO_1000869', 'HP_0003419'], dtype=object), 'count': 6}_|_[ENSG00000134259]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1743051,"nan_|_nan_|_Antibody_|_False_|_ONARTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['METMA-B' 'Metmab' 'Onartuzumab' 'PRO-143966' 'PRO-143996' 'PRO143966'
 'RO-5490258' 'RO5490258']_|_nan_|_nan_|_{'rows': array(['EFO_0000182', 'MONDO_0008903', 'MONDO_0004992', 'MONDO_0001056',
       'MONDO_0007254', 'EFO_0000519', 'EFO_0003060', 'EFO_0000616',
       'EFO_1001951'], dtype=object), 'count': 9}_|_[ENSG00000105976]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL19,"CC(=O)/N=c1/sc(S(N)(=O)=O)nn1C_|_FLOSMHQXBMRNHR-QPJJXVBHSA-N_|_Small molecule_|_False_|_METHAZOLAMIDE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Methazolamide' 'Neptazane']_|_['L-584601' 'Methazolamide' 'Methenamide' 'NSC-758426' 'Neptazaneat'
 'VVP-808' 'VVP808']_|_[('DailyMed', array(['methazolamide'], dtype=object)), ('PubChem', array(['11112413', '56422398', '855821'], dtype=object)), ('Wikipedia', array(['Methazolamide'], dtype=object)), ('chEBI', array(['6822'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005041', 'EFO_1000782', 'EFO_0004190', 'MONDO_0002974'],
      dtype=object), 'count': 4}_|_[ENSG00000168748,ENSG00000133742,ENSG00000104267,ENSG00000167434]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for glaucoma and open-angle glaucoma and has 2 investigational indications."
CHEMBL204021,"CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2_|_WDPFJWLDPVQCAJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DARAPLADIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Darapladib' 'SB-480848']_|_[('drugbank', array(['DB06311'], dtype=object))]_|_['CHEMBL3793364']_|_{'rows': array(['EFO_0005672', 'EFO_0003914', 'EFO_0003770'], dtype=object), 'count': 3}_|_[ENSG00000146070]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2105682,"CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1_|_ZLFZITWZOYXXAW-QXXZOGQOSA-N_|_Small molecule_|_True_|_EDOXABAN TOSYLATE_|_2015.0_|_4.0_|_CHEMBL1269025_|_False_|_True_|_['Roteas' 'Savaysa']_|_['DU-176B' 'Edoxaban tosilate' 'Edoxaban tosylate']_|_[('DailyMed', array(['edoxaban%20tosylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/roteas'],
      dtype=object)), ('chEBI', array(['85975'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003827', 'EFO_0003907', 'EFO_0000712', 'MONDO_0000831',
       'EFO_0004286', 'EFO_0000275'], dtype=object), 'count': 6}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2110814,"CNCCC(c1cccc(F)c1)c1cccc(F)c1_|_MUGNLPWYHGOJEG-UHFFFAOYSA-N_|_Small molecule_|_False_|_DELUCEMINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Delucemine']_|_nan_|_['CHEMBL2106165']_|_nan_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2111110,"C1CCC2(C1)[C@H]1CN(CC3CC3)C[C@@H]2CN(CC2CC2)C1_|_CTIRHWCPXYGDGF-HDICACEKSA-N_|_Small molecule_|_False_|_TEDISAMIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['KC-8857' 'KC8857' 'Tedisamil']_|_nan_|_['CHEMBL2107378']_|_{'rows': array(['EFO_0003911', 'EFO_0004269', 'EFO_0000275'], dtype=object), 'count': 3}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL344159,"Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1_|_GYHCTFXIZSNGJT-UHFFFAOYSA-N_|_Small molecule_|_True_|_TOLVAPTAN_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Jinarc' 'Jynarque' 'Samsca']_|_['OPC-41061' 'OPC-41061(TOLVAPTAN)' 'Tolvaptan']_|_[('DailyMed', array(['tolvaptan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc'],
      dtype=object)), ('PubChem', array(['124894207', '144206807'], dtype=object)), ('Wikipedia', array(['Tolvaptan'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_1001496', 'EFO_0001422', 'EFO_1001771',
       'EFO_0000313', 'HP_0002094', 'EFO_0008620', 'EFO_1000982',
       'EFO_0003884', 'HP_0002902', 'EFO_0003086', 'EFO_0000373',
       'EFO_0003144', 'EFO_0004253'], dtype=object), 'count': 14}_|_[ENSG00000126895]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545299,nan_|_nan_|_Small molecule_|_False_|_BMS-698769_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Bms-698769']_|_nan_|_nan_|_nan_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL395429,"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O_|_XNOPRXBHLZRZKH-DSZYJQQASA-N_|_Protein_|_True_|_OXYTOCIN_|_1980.0_|_4.0_|_nan_|_False_|_True_|_['Orasthin' 'Oxytocin' 'Pitocin' 'Syntocinon' 'Syntometrine']_|_['Alpha-hypophamine' 'Endopituitrina' 'Intertocine s' 'Oxytocin'
 'Oxytocinum' 'TNX-1900' 'TNX1900' 'TTA-121']_|_[('DailyMed', array(['oxytocin'], dtype=object)), ('PubChem', array(['50112429'], dtype=object)), ('chEBI', array(['7872'], dtype=object))]_|_['CHEMBL3185709']_|_{'rows': array(['EFO_0002610', 'EFO_1000948', 'MONDO_0007079', 'EFO_0001073',
       'EFO_0004242', 'MONDO_0100096', 'EFO_0003918', 'EFO_0003758',
       'MONDO_0005090', 'EFO_0000668', 'MONDO_0017276', 'EFO_0004714',
       'EFO_0004616', 'EFO_0010702', 'EFO_0003756', 'EFO_0005411',
       'EFO_0009579', 'HP_0000360', 'MONDO_0002009', 'MP_0001845',
       'EFO_0004566', 'MONDO_0008300', 'EFO_0003888', 'MONDO_0002025',
       'EFO_0004247', 'EFO_0000612', 'MONDO_0005351', 'EFO_0005611',
       'EFO_0004777', 'EFO_1001271', 'MONDO_0002050', 'HP_0012532',
       'EFO_1000911', 'EFO_1001863', 'EFO_0000432', 'EFO_0003877',
       'EFO_0003843', 'EFO_1000096', 'EFO_0001072', 'EFO_0005762',
       'EFO_1001917', 'EFO_0001358', 'EFO_0003890', 'MONDO_0004782',
       'EFO_0005203', 'MONDO_0002491', 'EFO_0010642', 'EFO_0004269',
       'MONDO_0010383', 'MP_0001914'], dtype=object), 'count': 50}_|_[ENSG00000180914]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and is indicated for uterine inertia and hemorrhage and has 48 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4802152,"O=C(c1cc(Cn2c(=O)[nH]c(=O)c3c(F)cccc32)ccc1F)N1CCN(c2ncccn2)CC1_|_VBTUJTGLLREMNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_SENAPARIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IMP-4297' 'IMP4297' 'Imp4297' 'Senaparib']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'MONDO_0004992', 'EFO_0000616', 'MONDO_0008170',
       'MONDO_0007254', 'MONDO_0008315'], dtype=object), 'count': 6}_|_[ENSG00000129484,ENSG00000143799]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL509,"Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl_|_SBDNJUWAMKYJOX-UHFFFAOYSA-N_|_Small molecule_|_True_|_MECLOFENAMIC ACID_|_1980.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CI-583' 'CL-583' 'INF 4668' 'INF-4668' 'Meclodium' 'Meclofenamate'
 'Meclofenamic acid' 'Meclomen' 'NSC-95309']_|_[('PubChem', array(['24424562', '26751537', '90341585'], dtype=object)), ('Wikipedia', array(['Meclofenamic_acid'], dtype=object)), ('drugbank', array(['DB00939'], dtype=object)), ('chEBI', array(['6710'], dtype=object))]_|_['CHEMBL1562610' 'CHEMBL876']_|_{'rows': array(['HP_0003326', 'MONDO_0005178', 'EFO_0005755', 'HP_0001945',
       'EFO_0000685', 'HP_0002829', 'EFO_0002609', 'HP_0100607'],
      dtype=object), 'count': 8}_|_[ENSG00000012779,ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 8 approved indications. This drug has a black box warning from the FDA."
CHEMBL518924,"NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21_|_WVLHHLRVNDMIAR-IBGZPJMESA-N_|_Small molecule_|_False_|_MAVORIXAFOR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AMD-070' 'AMD-11070' 'AMD070' 'AMD11070' 'Amd 070'
 'Cxcr4 inhibitor x4p-001' 'Mavorixafor' 'X 4P-001' 'X4P-001' 'X4p001']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MAVORIXAFOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB05501'], dtype=object))]_|_['CHEMBL4203190']_|_{'rows': array(['EFO_0009441', 'EFO_0000756', 'EFO_0000616', 'EFO_0000764',
       'MONDO_0007254', 'MONDO_0001475', 'EFO_0000349'], dtype=object), 'count': 7}_|_[ENSG00000121966]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL931,"FC(F)(F)C(Cl)Br_|_BCQZXOMGPXTTIC-UHFFFAOYSA-N_|_Small molecule_|_False_|_HALOTHANE_|_1958.0_|_4.0_|_nan_|_False_|_True_|_['Fluothane' 'Halothane' 'Rhidialothan']_|_['FREON 123B1' 'Halothane' 'Halothanum' 'NSC-143490']_|_[('PubChem', array(['144204584', '144208048', '170464645', '17388981'], dtype=object)), ('Wikipedia', array(['Halothane'], dtype=object)), ('drugbank', array(['DB01159'], dtype=object)), ('chEBI', array(['5615'], dtype=object))]_|_['CHEMBL3250431']_|_nan_|_[ENSG00000169427,ENSG00000082482,ENSG00000186795,ENSG00000145888,ENSG00000109738,ENSG00000100433,ENSG00000171303,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958."
CHEMBL9967,"CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc32)CC1_|_RMHMFHUVIITRHF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIRENZEPINE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Gastri p' 'Gastrozepin']_|_['ACI-91' 'Pirenzepine']_|_[('PubChem', array(['104171218', '11111661', '11111662', '11113363', '144203790',
       '170465793', '26751604', '90341394'], dtype=object)), ('Wikipedia', array(['Pirenzepine'], dtype=object)), ('drugbank', array(['DB00670'], dtype=object)), ('chEBI', array(['8247'], dtype=object))]_|_['CHEMBL1257024' 'CHEMBL1531864']_|_{'rows': array(['EFO_0003948', 'HP_0004398'], dtype=object), 'count': 2}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastroesophageal reflux disease and peptic ulcer."
CHEMBL1200492,"CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl_|_DYCKFEBIOUQECE-UHFFFAOYSA-N_|_Small molecule_|_True_|_NEFAZODONE HYDROCHLORIDE_|_1994.0_|_4.0_|_CHEMBL623_|_True_|_True_|_['Dutonin' 'Nefazodone hydrochloride' 'Serzone']_|_['BMY 13754' 'BMY-13754' 'MJ 13,754-1' 'MJ-13754-1' 'NSC-760344'
 'Nefazodone hcl' 'Nefazodone hydrochloride']_|_[('DailyMed', array(['nefazodone%20hydrochloride'], dtype=object)), ('PubChem', array(['144205288', '144207123', '170465078', '26719737', '49681554'],
      dtype=object)), ('chEBI', array(['7495'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000147246,ENSG00000103546,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994 and is indicated for major depressive disorder. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1200666,"C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@@H](O)C4CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O_|_LWQQLNNNIPYSNX-UROSTWAQSA-N_|_Small molecule_|_False_|_CALCIPOTRIENE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Calcipotriene' 'Dovobet' 'Dovonex' 'Enstilar' 'Sorilux' 'Xamiol']_|_['Calcipotriene' 'Calcipotriene hydrate' 'Calcipotriene monohydrate'
 'Calcipotriol' 'Calcipotriol anhydrous' 'Calcipotriol hydrate'
 'Calcipotriol monohydrate' 'Calciptriol' 'MC 903' 'MC-903' 'PRI-2201']_|_[('DailyMed', array(['calcipotriene', 'calcipotriene%20hydrate'], dtype=object)), ('PubChem', array(['144206022', '170464710', '49681738', '50112719'], dtype=object)), ('drugbank', array(['DB02300'], dtype=object)), ('chEBI', array(['50749'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000707', 'MONDO_0043771', 'EFO_1001361', 'EFO_0003894',
       'EFO_1001993', 'EFO_0004208', 'EFO_1001494', 'EFO_0000701',
       'HP_0000964', 'EFO_0000274', 'EFO_0000676', 'EFO_0002496'],
      dtype=object), 'count': 12}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for psoriasis vulgaris and psoriasis and has 10 investigational indications."
CHEMBL1201271,"CC(C)(C)c1ccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)cc1_|_MOYGZHXDRJNJEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUCLIZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Buclizine']_|_[('Wikipedia', array(['Buclizine'], dtype=object)), ('drugbank', array(['DB00354'], dtype=object)), ('chEBI', array(['3205'], dtype=object))]_|_['CHEMBL2360580' 'CHEMBL1200403']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease."
CHEMBL1201477,"nan_|_nan_|_Small molecule_|_False_|_POLYESTRADIOL PHOSPHATE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Estradurin' 'Polyest phos']_|_['Estradiol phosphate polymer' 'LEO 114' 'LEO-114'
 'Polyestradiol phos phosphate' 'Polyestradiol phosphate']_|_[('DrugCentral', array(['3482'], dtype=object)), ('Wikipedia', array(['Polyestradiol_phosphate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1957 and is indicated for neoplasm."
CHEMBL1201536,"nan_|_nan_|_Small molecule_|_False_|_NICOTINE POLACRILEX_|_1984.0_|_4.0_|_CHEMBL3_|_False_|_True_|_['Commit' 'Nicorette' 'Nicorette (mint)' 'Nicotine polacrilex' 'Thrive']_|_['Nicotine polacrilex']_|_[('DailyMed', array(['nicotine%20polacrilex'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004318', 'MONDO_0002050', 'EFO_0003768'], dtype=object), 'count': 3}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 3 investigational indications."
CHEMBL127516,"CCCCOC(=O)c1ccc(N)cc1_|_IUWVALYLNVXWKX-UHFFFAOYSA-N_|_Small molecule_|_False_|_BUTAMBEN_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Butamben' 'Butyl aminobenzoate' 'Butyl p-aminobenzoate' 'Butyl paba'
 'NSC-128464' 'P-aminobenzoic acid butyl ester']_|_[('PubChem', array(['104171291', '11112245', '11532999', '144203943', '144207576',
       '170465735', '17389507'], dtype=object)), ('Wikipedia', array(['Butamben'], dtype=object)), ('drugbank', array(['DB11148'], dtype=object)), ('chEBI', array(['3231'], dtype=object))]_|_['CHEMBL3142541']_|_nan_|_[ENSG00000111199,ENSG00000104321]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL193240,"O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1_|_MNDBXUUTURYVHR-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROFLUMILAST_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Daliresp' 'Daxas' 'Zoryve']_|_['Arq-151' 'B-9302-107' 'B9302-107' 'BY-217' 'BY217' 'BYK-20869'
 'BYK20869' 'Roflumilast' 'Zoryve']_|_[('DailyMed', array(['roflumilast'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/daxas'],
      dtype=object)), ('PubChem', array(['165222658', '174007051'], dtype=object)), ('Wikipedia', array(['Roflumilast'], dtype=object)), ('drugbank', array(['DB01656'], dtype=object)), ('chEBI', array(['47657'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006505', 'MONDO_0002009', 'HP_0006536', 'EFO_0000274',
       'EFO_1000760', 'EFO_0000401', 'EFO_0003095', 'HP_0000726',
       'MONDO_0010383', 'MONDO_0004979', 'EFO_0000676', 'MONDO_0002406',
       'EFO_0000341', 'MONDO_0005090', 'EFO_0000574', 'MONDO_0100130',
       'HP_0002110', 'EFO_0003100', 'MONDO_0004992', 'EFO_0001073',
       'EFO_0000618', 'MONDO_0005148'], dtype=object), 'count': 22}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 19 investigational indications."
CHEMBL2103873,"CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1_|_JGCMEBMXRHSZKX-UHFFFAOYSA-N_|_Small molecule_|_True_|_MACITENTAN_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Opsumit']_|_['ACT 064992' 'ACT-064992' 'Macitentan']_|_[('DailyMed', array(['macitentan'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit'],
      dtype=object)), ('drugbank', array(['DB08932'], dtype=object)), ('chEBI', array(['76607'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005207', 'MONDO_0005149', 'EFO_0003144', 'EFO_0000537',
       'EFO_0000519', 'EFO_0000717', 'EFO_0000768', 'MONDO_0043839',
       'EFO_0001361'], dtype=object), 'count': 9}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108712,"nan_|_nan_|_Small molecule_|_False_|_PLOVAMER ACETATE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CO-14' 'PI-2301' 'Pi-2301 acetate' 'Plovamer acetate']_|_nan_|_nan_|_{'rows': array(['EFO_0003929'], dtype=object), 'count': 1}_|_[ENSG00000196126]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL27759,"Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1_|_INVTYAOGFAGBOE-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENTINOSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Entinostat' 'MS-27-275' 'MS-275' 'MS-275-27' 'SNDX-275']_|_[('PubChem', array(['137275820', '29217590', '529250'], dtype=object)), ('Wikipedia', array(['Entinostat'], dtype=object)), ('drugbank', array(['DB11841'], dtype=object))]_|_['CHEMBL3093129']_|_{'rows': array(['MONDO_0001879', 'MONDO_0001325', 'EFO_0000349', 'EFO_0000222',
       'EFO_0000756', 'EFO_0002618', 'EFO_0006861', 'MONDO_0008170',
       'EFO_0002916', 'EFO_1000657', 'EFO_0003086', 'EFO_0000681',
       'EFO_0000673', 'EFO_0000305', 'MONDO_0021063', 'MONDO_0002367',
       'MONDO_0002158', 'MONDO_0001528', 'EFO_0000198', 'EFO_1001951',
       'EFO_0005537', 'EFO_0003869', 'MONDO_0007254', 'MONDO_0004992',
       'MONDO_0002974', 'MONDO_0002087', 'EFO_0000326', 'EFO_0000183',
       'MONDO_0001187', 'EFO_1001901', 'EFO_0000616', 'MONDO_0001402',
       'EFO_0003060', 'EFO_0000574', 'EFO_1001931'], dtype=object), 'count': 35}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 35 investigational indications."
CHEMBL3114577,"NCC(=O)Nc1cncc(-c2nn3c(=O)cc(N4CCNCC4)nc3s2)c1_|_LTVKZVGAALCRFW-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZALUNFIBAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['RUC-4' 'Zalunfiban']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZALUNFIBAN/relevant/1/'],
      dtype=object))]_|_['CHEMBL4802247']_|_{'rows': array(['EFO_0001645', 'EFO_0008585', 'EFO_0008585'], dtype=object), 'count': 3}_|_[ENSG00000259207,ENSG00000005961]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL31965,"C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1_|_OMZCMEYTWSXEPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CANERTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CI-1033' 'Canertinib']_|_[('PubChem', array(['124894124', '144206912', '174006548', '50100094'], dtype=object)), ('Wikipedia', array(['Canertinib'], dtype=object)), ('drugbank', array(['DB05424'], dtype=object)), ('chEBI', array(['61399'], dtype=object))]_|_['CHEMBL545315']_|_{'rows': array(['EFO_0003869', 'MONDO_0021117', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000146648,ENSG00000178568,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL3301675,"C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC(=O)[C@@H]2CSSC[C@H](N)C(=O)N[C@H]3CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)CSSC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC3=O)C(=O)N2_|_KXGCNMMJRFDFNR-WDRJZQOASA-N_|_Protein_|_True_|_LINACLOTIDE_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Constella' 'Linzess']_|_['ASP-0456' 'ASP0456' 'Linaclotide' 'MD-1100']_|_[('DailyMed', array(['linaclotide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/constella'],
      dtype=object)), ('drugbank', array(['DB08890'], dtype=object)), ('chEBI', array(['68551'], dtype=object))]_|_['CHEMBL3301676']_|_{'rows': array(['EFO_0000555', 'HP_0002019', 'MONDO_0002203', 'EFO_0005406',
       'EFO_0000555', 'HP_0002019', 'EFO_1001951'], dtype=object), 'count': 7}_|_[ENSG00000070019]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297576,"nan_|_nan_|_Protein_|_False_|_EFINOPEGDUTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Efinopegdutide' 'HM-12525A' 'HM12525A' 'JNJ-64565111' 'Jnj-64565111']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EFINOPEGDUTIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0003884', 'EFO_1001249', 'EFO_0001073'],
      dtype=object), 'count': 4}_|_[ENSG00000215644,ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297627,"C[C@@H]1CCc2ncc(F)cc2[C@H]2CCCN2c2ccn3ncc(c3n2)C(=O)N1_|_OEBIHOVSAMBXIB-SJKOYZFVSA-N_|_Small molecule_|_False_|_SELITRECTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LOXO-195' 'Loxo-195' 'Selitrectinib']_|_[('drugbank', array(['DB14896'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000198400,ENSG00000148053,ENSG00000140538]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297776,"nan_|_nan_|_Unknown_|_False_|_LEFITOLIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Lefitolimod' 'MGN-1703' 'TLR9 AGONIST MGN1703']_|_nan_|_nan_|_{'rows': array(['EFO_0000180'], dtype=object), 'count': 1}_|_[ENSG00000239732]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594535,"nan_|_nan_|_Antibody_|_False_|_SUGEMALIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CS-1001' 'CS1001' 'Cs1001' 'Sugemalimab' 'WBP-315' 'WBP315']_|_nan_|_nan_|_{'rows': array(['EFO_0000702', 'EFO_0000503', 'EFO_0000574', 'EFO_0003060',
       'MONDO_0004992', 'EFO_0000183', 'EFO_0000616', 'MONDO_0019472',
       'EFO_0000182'], dtype=object), 'count': 9}_|_[ENSG00000120217]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL4650279,"C=CC(=O)Nc1cc2c(Nc3ccc(OCc4ccccn4)c(Cl)c3)ncnc2cc1OCCN1CCOCC1_|_HIBPKFXWOPYJPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TUXOBERTINIB_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BDTX-189' 'BDTX189' 'Bdtx-189' 'Bdtx189' 'Tuxobertinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TUXOBERTINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4650395,"nan_|_nan_|_Antibody_|_False_|_GLENZOCIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ACT-017' 'ACT017' 'Glenzocimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GLENZOCIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0002140', 'EFO_0000712', 'MONDO_0005299'], dtype=object), 'count': 3}_|_[ENSG00000088053]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL52440,"COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3_|_MKXZASYAUGDDCJ-NJAFHUGGSA-N_|_Small molecule_|_False_|_DEXTROMETHORPHAN_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dextromethorphan' 'Dimetane-DX' 'NSC-751452']_|_[('PubChem', array(['11111057', '50100218'], dtype=object)), ('Wikipedia', array(['Dextromethorphan'], dtype=object)), ('drugbank', array(['DB00514'], dtype=object))]_|_['CHEMBL1201461' 'CHEMBL3989946' 'CHEMBL3989940' 'CHEMBL1201004'
 'CHEMBL1256818']_|_{'rows': array(['MONDO_0002009', 'EFO_0007486', 'EFO_0000384', 'EFO_0005611',
       'EFO_0001068', 'MONDO_0004985', 'MONDO_0004976', 'HP_0012735',
       'EFO_0005772', 'EFO_0005762', 'EFO_0002460', 'EFO_0003843',
       'MONDO_0008315', 'EFO_0000764', 'EFO_0001062', 'EFO_0003100',
       'EFO_0003929', 'MONDO_0005180', 'MONDO_0010726', 'MONDO_0005148',
       'MONDO_0005277', 'EFO_0009854', 'HP_0000093', 'MONDO_0004976',
       'EFO_0000616', 'MONDO_0005148', 'HP_0100543', 'EFO_0003758',
       'EFO_0003890', 'EFO_0007214', 'EFO_0007214', 'EFO_0000756',
       'EFO_0002617', 'EFO_0009430', 'MONDO_0044970', 'MONDO_0005271',
       'EFO_1000783', 'MONDO_0002009', 'HP_0001945', 'EFO_0003756',
       'MONDO_0004975', 'EFO_0009692', 'MONDO_0005090', 'EFO_0000729',
       'EFO_0000616', 'EFO_0005687', 'EFO_0009708', 'MONDO_0002050',
       'EFO_0000555', 'HP_0002315', 'HP_0001742', 'HP_0012735',
       'EFO_0000676', 'EFO_0001663', 'MONDO_0005301'], dtype=object), 'count': 55}_|_[ENSG00000147955,ENSG00000183454]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 7 approved and 45 investigational indications."
CHEMBL5314342,"nan_|_nan_|_Protein_|_False_|_GLUCAGON HYDROCHLORIDE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Glucagon chloride' 'Glucagon hcl' 'Glucagon hydrochloride'
 'Glucagon, monohydrochloride']_|_[('DailyMed', array(['glucagon%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'HP_0001943', 'EFO_0000400'],
      dtype=object), 'count': 4}_|_[ENSG00000215644]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 4 investigational indications."
CHEMBL549,"CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21_|_WSEQXVZVJXJVFP-UHFFFAOYSA-N_|_Small molecule_|_True_|_CITALOPRAM_|_1998.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Celexa' 'Citadur' 'Citalopram']_|_[('PubChem', array(['174007166', '50104852', '90340852'], dtype=object)), ('Wikipedia', array(['Citalopram'], dtype=object)), ('drugbank', array(['DB00215'], dtype=object)), ('chEBI', array(['77397'], dtype=object))]_|_['CHEMBL1628605' 'CHEMBL1200781']_|_{'rows': array(['MONDO_0002050', 'MONDO_0004985', 'HP_0000713', 'EFO_0005230',
       'MONDO_0002009', 'MONDO_0005180', 'MONDO_0002009', 'HP_0031217',
       'EFO_0004262', 'EFO_0005672', 'EFO_0003758', 'MONDO_0005090',
       'EFO_0000712', 'MONDO_0002009', 'EFO_0004242', 'EFO_0002610',
       'EFO_0003756', 'HP_0000726', 'MONDO_0002009', 'EFO_0000555',
       'MONDO_0007079', 'MONDO_0002046', 'EFO_0005611'], dtype=object), 'count': 23}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for depressive disorder and major depressive disorder and has 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL612,"C[C@H](N)Cc1ccccc1_|_KWTSXDURSIMDCE-QMMMGPOBSA-N_|_Small molecule_|_True_|_DEXTROAMPHETAMINE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Dexedrine' 'Dextrostat' 'Xelstrym']_|_['Amfetamine, (s)-' 'Amphetamine, d-' 'D-amphetamine' 'Dexamfetamine'
 'Dexampex' 'Dexamphetamine' 'Dexedrine' 'Dexidrine' 'Dextroamphetamine'
 'Dextrostat' 'Ferndex' 'NSC-73713' 'Xelstrym']_|_[('PubChem', array(['50113060'], dtype=object)), ('Wikipedia', array(['Dextroamphetamine'], dtype=object)), ('drugbank', array(['DB01576'], dtype=object)), ('chEBI', array(['4469'], dtype=object))]_|_['CHEMBL1200782' 'CHEMBL287386' 'CHEMBL2106669' 'CHEMBL3544971'
 'CHEMBL3989844']_|_{'rows': array(['EFO_0005611', 'MONDO_0004985', 'EFO_0000712', 'EFO_0003888',
       'EFO_0005543', 'MONDO_0016158', 'MONDO_0016158', 'EFO_0002610',
       'EFO_0003888', 'MONDO_0005301', 'MONDO_0005090', 'EFO_0003888',
       'EFO_0003890', 'EFO_0004701', 'MONDO_0002277', 'EFO_0001358'],
      dtype=object), 'count': 16}_|_[ENSG00000103546,ENSG00000142319,ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL637,"COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1_|_PNVNVHUZROJLTJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_VENLAFAXINE_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Alventa xl' 'Amphero xl' 'Bonilux xl' 'Depefex xl' 'Efexor' 'Efexor xl'
 'Foraven xl' 'Mentaven xl' 'Politid xl' 'Ranfaxine xl' 'Rodomel xl'
 'Sunveniz xl' 'Tardcaps xl' 'Tifaxin xl' 'Tonpular xl' 'Trixat xl'
 'Vaxalin xl' 'Venaxx xl' 'Venlablue xl' 'Venladex xl' 'Venlalic xl'
 'Venlaneo xl' 'Vensir xl' 'Vexarin xl' 'Viepax' 'Viepax xl' 'Winfex xl']_|_['Efectin' 'Effexor' 'Kanghong' 'NSC-758676' 'Trevilor' 'Velafax'
 'Venlafaxine' 'Venlor']_|_[('PubChem', array(['144204978', '170465123', '174007175', '26748923', '90341232'],
      dtype=object)), ('Wikipedia', array(['Venlafaxine'], dtype=object)), ('drugbank', array(['DB00285'], dtype=object)), ('chEBI', array(['9943'], dtype=object))]_|_['CHEMBL1201066' 'CHEMBL3133301' 'CHEMBL5095051']_|_{'rows': array(['MONDO_0005180', 'EFO_0006788', 'MONDO_0002050', 'MONDO_0002009',
       'EFO_0006862', 'MONDO_0004985', 'EFO_0009854', 'HP_0000726',
       'HP_0031217', 'MONDO_0002009', 'EFO_0005687', 'MONDO_0004975',
       'EFO_0006788', 'EFO_1001892', 'EFO_1001917', 'EFO_0004242',
       'EFO_0004262', 'EFO_0000673', 'MONDO_0007254', 'MONDO_0005090',
       'MONDO_0002009', 'EFO_0003843', 'MONDO_0002050', 'EFO_1002014',
       'EFO_1001919', 'HP_0030833', 'EFO_0002610', 'EFO_0005230',
       'MONDO_0008315', 'EFO_0003918', 'EFO_0005762', 'MONDO_0002009',
       'MONDO_0002009'], dtype=object), 'count': 33}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 7 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1131,"COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C_|_IHUNBGSDBOWDMA-AQFIFDHZSA-N_|_Small molecule_|_True_|_ACITRETIN_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Acitretin' 'Neotigason' 'Soriatane']_|_['Acitretin' 'Etretin' 'RO 10-1670' 'RO 10-1670/000' 'RO-101670000']_|_[('DailyMed', array(['acitretin'], dtype=object)), ('PubChem', array(['144205565', '26756475', '29216416', '49640651'], dtype=object)), ('Wikipedia', array(['Acitretin'], dtype=object)), ('drugbank', array(['DB00459'], dtype=object)), ('chEBI', array(['50173'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001494', 'EFO_0000676', 'MONDO_0002406', 'EFO_0000764',
       'EFO_0000756', 'MONDO_0004975'], dtype=object), 'count': 6}_|_[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for psoriasis vulgaris and psoriasis and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200446,"CN(C)CCN(Cc1ccccc1)c1ccccn1.Cl_|_FSSICIQKZGUEAE-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIPELENNAMINE HYDROCHLORIDE_|_1948.0_|_4.0_|_CHEMBL1241_|_False_|_True_|_['Pbz-sr' 'Tripelennamine hydrochloride']_|_['Azaron' 'Dehistin' 'NSC-409943' 'Pyribenzamine'
 'Tripelennamine chloride' 'Tripelennamine hcl'
 'Tripelennamine hydrochloride' 'Vetibenzamina']_|_[('PubChem', array(['26719674', '56424144', '855583'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1948."
CHEMBL1200635,"CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C.Cl_|_AKQNAIYKSALPKV-OYHXESGYSA-N_|_Small molecule_|_False_|_HYDROCORTAMATE HYDROCHLORIDE_|_1956.0_|_4.0_|_CHEMBL1201263_|_False_|_True_|_['Magnacort']_|_['Hydrocortamate chloride' 'Hydrocortamate hcl'
 'Hydrocortamate hydrochloride' 'NSC-12884']_|_[('chEBI', array(['50854'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL1200732,"CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C_|_ILKJAFIWWBXGDU-MOGDOJJUSA-N_|_Small molecule_|_False_|_AMCINONIDE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Amcinonide' 'Cyclocort']_|_['Amcinonide' 'CL 34699' 'CL-34699' 'NSC-758620']_|_[('DailyMed', array(['amcinonide'], dtype=object)), ('PubChem', array(['144204964', '56423154', '855515'], dtype=object)), ('Wikipedia', array(['Amcinonide'], dtype=object)), ('drugbank', array(['DB00288'], dtype=object)), ('chEBI', array(['31199'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1979."
CHEMBL1269597,"C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C_|_AQHMBDAHQGYLIU-XNFHFXFQSA-N_|_Protein_|_False_|_SCY 635_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SCY-635' 'Scy 635']_|_[('drugbank', array(['DB12451'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004220', 'EFO_0003047'], dtype=object), 'count': 2}_|_[ENSG00000196262]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1367605,"CC(NCCc1ccc(O)cc1)C(O)c1ccc(O)cc1.Cl_|_IDLSITKDRVDKRV-UHFFFAOYSA-N_|_Small molecule_|_False_|_RITODRINE HYDROCHLORIDE_|_1991.0_|_4.0_|_CHEMBL83063_|_False_|_True_|_['Ritodrine hydrochloride' 'Yutopar']_|_['Luteonin' 'NSC-291565' 'Ritodrine hcl' 'Ritodrine hydrochloride']_|_[('PubChem', array(['26748517', '856010'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991."
CHEMBL1590,"CN[C@@H](C)[C@@H](O)c1ccccc1_|_KWGRBVOPPLSCSI-WCBMZHEXSA-N_|_Small molecule_|_False_|_PSEUDOEPHEDRINE_|_1963.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acunaso' 'Isoephedrine, d-' 'Neodurasina' 'Pseudoephedrine'
 'Pseudoephedrine polistirex']_|_[('PubChem', array(['11111142'], dtype=object)), ('Wikipedia', array(['Pseudoephedrine'], dtype=object)), ('drugbank', array(['DB00852'], dtype=object)), ('chEBI', array(['51209'], dtype=object))]_|_['CHEMBL1200724' 'CHEMBL1201483' 'CHEMBL3989855']_|_{'rows': array(['EFO_0003843', 'EFO_0005854', 'EFO_1001417', 'EFO_0007533',
       'MONDO_0005271', 'EFO_0007328', 'MONDO_0005277', 'EFO_0003956',
       'MONDO_0024290', 'HP_0012735', 'HP_0001742', 'EFO_0005252',
       'EFO_0003956', 'EFO_1001050', 'EFO_0005854', 'EFO_0007214',
       'HP_0001742', 'EFO_0003956', 'MONDO_0024355', 'MP_0001845',
       'EFO_0008521', 'EFO_0007486', 'EFO_0005854', 'MONDO_0005271',
       'HP_0012735', 'EFO_0007214'], dtype=object), 'count': 26}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and has 10 approved and 10 investigational indications."
CHEMBL1743069,"nan_|_nan_|_Antibody_|_False_|_SIFALIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MDX-1103' 'MEDI-545' 'Sifalimumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000398', 'MONDO_0007915'], dtype=object), 'count': 3}_|_[ENSG00000120235,ENSG00000120242,ENSG00000147873,ENSG00000186803,ENSG00000188379,ENSG00000197919,ENSG00000233816,ENSG00000214042,ENSG00000137080,ENSG00000147885,ENSG00000228083,ENSG00000234829,ENSG00000236637]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1743087,"nan_|_nan_|_Antibody_|_False_|_VEDOLIZUMAB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Entyvio']_|_['LDP-02' 'LDP02' 'MLN-0002' 'MLN-02' 'MLN0002' 'MLN02' 'Vedolizumab']_|_[('DailyMed', array(['vedolizumab'], dtype=object)), ('DrugCentral', array(['4982'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000544', 'EFO_0000764', 'EFO_0000729', 'EFO_0000756',
       'EFO_0003767', 'EFO_0001060', 'EFO_0000180', 'EFO_0003872',
       'MONDO_0005147', 'EFO_0000384', 'EFO_0000540'], dtype=object), 'count': 11}_|_[ENSG00000115232,ENSG00000139626]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 8 investigational indications."
CHEMBL2028663,"CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1_|_BFSMGDJOXZAERB-UHFFFAOYSA-N_|_Small molecule_|_False_|_DABRAFENIB_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Tafinlar']_|_['Dabrafenib' 'GSK-2118436' 'GSK-2118436A' 'GSK2118436A' 'Gsk2118436']_|_[('drugbank', array(['DB08912'], dtype=object)), ('chEBI', array(['75045'], dtype=object))]_|_['CHEMBL2105729']_|_{'rows': array(['EFO_0002892', 'EFO_1000926', 'EFO_0003833', 'EFO_0003086',
       'EFO_0002892', 'MONDO_0002108', 'EFO_0003060', 'MONDO_0008903',
       'MONDO_0002108', 'EFO_0002617', 'EFO_0002617', 'EFO_1000926',
       'EFO_0000389', 'MONDO_0100342', 'EFO_0000501', 'EFO_0000756',
       'EFO_0000641', 'MONDO_0017795', 'EFO_0000616', 'EFO_0001378',
       'MONDO_0004992', 'EFO_0001421', 'EFO_0001378', 'EFO_0006772',
       'EFO_0000389', 'EFO_0000756', 'EFO_1000209'], dtype=object), 'count': 27}_|_[ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 7 approved and 19 investigational indications."
CHEMBL2103772,"CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1_|_ODUOJXZPIYUATO-UHFFFAOYSA-N_|_Small molecule_|_False_|_RACECADOTRIL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Hidrasec']_|_['Acetorphan' 'NSC-759828' 'Racecadotril' 'Tiorfan' 'Tiorfix']_|_[('PubChem', array(['174006909'], dtype=object)), ('drugbank', array(['DB11696'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002014', 'EFO_1001306'], dtype=object), 'count': 2}_|_[ENSG00000196549]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL2106003,CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1.O=C(O)/C=C\C(=O)O_|_QIQWRCNAPQJQLL-COALEZEGSA-N_|_Small molecule_|_False_|_CIPRALISANT MALEATE_|_nan_|_1.0_|_CHEMBL278462_|_False_|_False_|_[]_|_['Cipralisant maleate' 'GT-2331' 'Gt2331']_|_nan_|_nan_|_nan_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2108585,"nan_|_nan_|_Gene_|_False_|_CONTUSUGENE LADENOVEC_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AD5CMV-P53' 'Contusugene ladenovec' 'INGN 201' 'INGN-201']_|_nan_|_nan_|_{'rows': array(['EFO_1000158', 'MONDO_0002691', 'MONDO_0008903', 'MONDO_0002087',
       'MONDO_0007254', 'EFO_0006859', 'MONDO_0004986', 'MONDO_0008170',
       'EFO_0003060'], dtype=object), 'count': 9}_|_[ENSG00000141510]_|_Gene drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL2109263,"nan_|_nan_|_Antibody_|_False_|_ING-1_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HEMAB' 'ING-1' 'Ing-1']_|_nan_|_nan_|_{'rows': array(['EFO_0000228'], dtype=object), 'count': 1}_|_[ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109600,"nan_|_nan_|_Antibody_|_False_|_RO-5458640_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['RG-7212' 'RO-5458640' 'Ro-5458640']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000239697]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109629,"nan_|_nan_|_Antibody drug conjugate_|_False_|_ANETUMAB RAVTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anetumab ravtansine' 'BAY 94-9343' 'BAY-94-9343' 'BAY-949343'
 'BAY94-9343']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000770', 'EFO_0002618', 'MONDO_0004992',
       'EFO_0000616', 'EFO_0003893', 'MONDO_0021117', 'EFO_0000588'],
      dtype=object), 'count': 8}_|_[ENSG00000102854]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL2364626,"CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21_|_XPPBBJCBDOEXDN-UHFFFAOYSA-N_|_Small molecule_|_False_|_RALIMETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LSN-2322600 FREE BASE' 'LSN2322600 FREE BASE' 'LY-2228820' 'LY2228820'
 'LY22288220' 'Ly-2228820' 'Ralimetinib']_|_[('drugbank', array(['DB11787'], dtype=object))]_|_['CHEMBL2364627']_|_{'rows': array(['MONDO_0008170', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0000519',
       'MONDO_0007254'], dtype=object), 'count': 5}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2448613,"CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.O=C(O)C(O)C(O)C(=O)O_|_RGSULKHNAKTFIZ-UHFFFAOYSA-N_|_Small molecule_|_True_|_PIMAVANSERIN TARTRATE_|_2016.0_|_4.0_|_CHEMBL2111101_|_False_|_True_|_['Nuplazid']_|_['ACP-103' 'Pimavanserin tartrate']_|_[('DailyMed', array(['pimavanserin%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005407', 'HP_0000738', 'MONDO_0004975', 'MONDO_0005090',
       'MONDO_0005180'], dtype=object), 'count': 5}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3651966,"C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1_|_VRQXRVAKPDCRCI-ZNMIVQPWSA-N_|_Small molecule_|_False_|_LGH-447_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LGH-447' 'LGH447' 'Lgh-447' 'NVP-LGH477' 'PIM 447' 'PIM-447'
 'Pim kinase inhibitor lgh447']_|_[('drugbank', array(['DB14943'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'MONDO_0044903', 'EFO_0001378'], dtype=object), 'count': 3}_|_[ENSG00000137193,ENSG00000102096,ENSG00000198355]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3707396,nan_|_nan_|_Small molecule_|_False_|_EVT401_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Evt401']_|_nan_|_nan_|_nan_|_[ENSG00000089041]_|_Small molecule drug.
CHEMBL383824,"CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O_|_KUFRQPKVAWMTJO-LMZWQJSESA-N_|_Small molecule_|_False_|_ALVESPIMYCIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Alvespimycin' 'NSC-707545']_|_[('Wikipedia', array(['17-Dimethylaminoethylamino-17-demethoxygeldanamycin'],
      dtype=object)), ('drugbank', array(['DB12442'], dtype=object)), ('chEBI', array(['65324'], dtype=object))]_|_['CHEMBL2105630']_|_{'rows': array(['MONDO_0001023', 'EFO_0000095', 'EFO_0000616', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000080824,ENSG00000096384]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3989821,"COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C.Cl.O.O.O.O.O.[Cl-]_|_WMIZITXEJNQAQK-GGDSLZADSA-N_|_Small molecule_|_False_|_TUBOCURARINE CHLORIDE_|_1945.0_|_4.0_|_CHEMBL339427_|_False_|_True_|_['Jexin' 'Tubarine' 'Tubocurarine chloride']_|_['Curare' 'NSC-757362' 'Tubaine' 'Tubarine pentahydrate'
 'Tubocurarine chloride' 'Tubocurarine chloride anhydrous'
 'Tubocurarine chloride, anhydrous' 'Tubocurarini chloridum']_|_nan_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945."
CHEMBL3990145,COCCCCn1c(C(=O)N(CC(C)C)[C@@H]2CNC[C@H](C(=O)N3CCOCC3)C2)nc2ccccc21_|_RHIBAIKQWJNESW-YADHBBJMSA-N_|_Small molecule_|_False_|_IMARIKIREN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Imarikiren']_|_nan_|_['CHEMBL3969876']_|_nan_|_[ENSG00000143839]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4297163,"nan_|_nan_|_Oligosaccharide_|_False_|_MUPARFOSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Muparfostat' 'PI-88']_|_nan_|_['CHEMBL4297162']_|_{'rows': array(['EFO_0003060', 'MONDO_0008903', 'EFO_0000389', 'EFO_0000756',
       'EFO_0000182', 'MONDO_0008315'], dtype=object), 'count': 6}_|_[ENSG00000113578,ENSG00000138685,ENSG00000112715,ENSG00000173083]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4297185,"CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1_|_BLIJXOOIHRSQRB-PXYINDEMSA-N_|_Small molecule_|_False_|_DAROLUTAMIDE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Nubeqa']_|_['BAY 1841788' 'BAY-1841788' 'BAY1841788' 'Darolutamide' 'ODM-201'
 'Odm-201']_|_[('DailyMed', array(['darolutamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa'],
      dtype=object)), ('drugbank', array(['DB12941'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0001663', 'MONDO_0007254', 'MONDO_0008315',
       'EFO_0000196', 'MONDO_0004992', 'EFO_0000673', 'MONDO_0021259',
       'MONDO_0004669', 'MONDO_0000521'], dtype=object), 'count': 10}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 7 approved and 3 investigational indications."
CHEMBL4297440,"COc1ccc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)cc1NC(N)=O_|_FSXLOWIFSZNIMV-UHFFFAOYSA-N_|_Small molecule_|_False_|_T-900607_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['T 900607' 'T-900607' 'T900607']_|_[('drugbank', array(['DB12068'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002691', 'EFO_0005952', 'EFO_0000182', 'MONDO_0001056',
       'EFO_0003893'], dtype=object), 'count': 5}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4592045,"CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1_|_CQOJHAJWCDJEAT-UHFFFAOYSA-N_|_Small molecule_|_False_|_NAVACAPRANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BTRX-335140' 'Btrx-335140' 'CYM-53093' 'Navacaprant']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_['CHEMBL4455146']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650282,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12_|_UPPAAWQBZQBNIE-USRGLUTNSA-N_|_Small molecule_|_False_|_DS-1001B_|_nan_|_2.0_|_CHEMBL4651002_|_False_|_False_|_[]_|_['DS-1001b' 'Ds-1001b']_|_nan_|_nan_|_nan_|_[ENSG00000138413]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL4650295,"nan_|_nan_|_Cell_|_False_|_AMG553_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG553' 'Amg553']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000122025]_|_Cell drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL489,"CC/C(=C(\c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1_|_TXUZVZSFRXZGTL-QPLCGJKRSA-N_|_Small molecule_|_False_|_AFIMOXIFENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['4-Hydroxytamoxifen' '4-OHT' 'Afimoxifene']_|_[('PubChem', array(['11532960', '144208141', '26757818', '56422185'], dtype=object)), ('Wikipedia', array(['Afimoxifene'], dtype=object)), ('drugbank', array(['DB04468'], dtype=object)), ('chEBI', array(['44616'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000432', 'EFO_1001366'], dtype=object), 'count': 3}_|_[ENSG00000196482,ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL5314383,C[C@@H]1CN(C(=O)CN2CC(C)(C)OC[C@H]2C(=O)Nc2cc(Cl)cc3c2[nH]c2cnccc23)C[C@H](C)O1_|_BQBAVNBXWBYXIF-DMPWYTOCSA-N_|_Small molecule_|_False_|_MLN-0415_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mln-0415']_|_nan_|_nan_|_nan_|_[ENSG00000104365]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL571948,"C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1_|_JTVBXQAYBIJXRP-SNVBAGLBSA-N_|_Small molecule_|_False_|_Y-39983_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Y-39983']_|_nan_|_['CHEMBL3794409']_|_nan_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL681,"CCOC(=O)c1cncn1[C@H](C)c1ccccc1_|_NPUKDXXFDDZOKR-LLVKDONJSA-N_|_Small molecule_|_False_|_ETOMIDATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Amidate' 'Etomidate']_|_['Etomidate' 'Hypnomidate' 'NSC-759160']_|_[('DailyMed', array(['etomidate'], dtype=object)), ('PubChem', array(['11114097'], dtype=object)), ('drugbank', array(['DB00292'], dtype=object)), ('chEBI', array(['4910'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000712', 'EFO_0009686'], dtype=object), 'count': 3}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications."
CHEMBL914,"CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1_|_RWTNPBWLLIMQHL-UHFFFAOYSA-N_|_Small molecule_|_False_|_FEXOFENADINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Allegra' 'Fexofenadine']_|_[('PubChem', array(['50105687', '90341422'], dtype=object)), ('Wikipedia', array(['Fexofenadine'], dtype=object)), ('drugbank', array(['DB00950'], dtype=object)), ('chEBI', array(['5050'], dtype=object))]_|_['CHEMBL1200618']_|_{'rows': array(['EFO_0000401', 'EFO_0003060', 'EFO_0004253', 'MONDO_0005271',
       'MONDO_0005271', 'EFO_0000274', 'HP_0000989', 'EFO_1001417',
       'EFO_0009373', 'EFO_0003956', 'EFO_0005531', 'EFO_0003956',
       'MONDO_0004979', 'EFO_0000685', 'EFO_0005854', 'EFO_0000673',
       'EFO_0003948', 'EFO_1001417'], dtype=object), 'count': 18}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 13 investigational indications."
CHEMBL118,"Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1_|_RZEKVGVHFLEQIL-UHFFFAOYSA-N_|_Small molecule_|_True_|_CELECOXIB_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Celebra' 'Celebrex' 'Celecoxib' 'Elyxyb' 'Onsenal']_|_['Celecoxib' 'DFN-15' 'DFN15' 'NSC-719627' 'NSC-758624' 'SC-58635']_|_[('DailyMed', array(['celecoxib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onsenal'],
      dtype=object)), ('PubChem', array(['144204686', '144209162', '144210916', '170464693', '17389545',
       '26747363', '49665790', '49666478', '535138'], dtype=object)), ('Wikipedia', array(['Celecoxib'], dtype=object)), ('drugbank', array(['DB00482'], dtype=object)), ('chEBI', array(['41423'], dtype=object))]_|_['CHEMBL395268' 'CHEMBL1801594']_|_{'rows': array(['EFO_0003843', 'HP_0012532', 'MONDO_0005090', 'EFO_1001893',
       'MP_0001914', 'MONDO_0001657', 'EFO_0005279', 'EFO_0009606',
       'EFO_0000546', 'EFO_0002496', 'EFO_0004239', 'EFO_0004251',
       'EFO_0000284', 'EFO_0003868', 'MONDO_0018975', 'EFO_0005252',
       'EFO_0005406', 'EFO_0004616', 'HP_0100607', 'MONDO_0042487',
       'EFO_0001075', 'MONDO_0018076', 'MONDO_0004976', 'MONDO_0011705',
       'MONDO_0004247', 'MONDO_0002087', 'HP_0004398', 'EFO_0000668',
       'EFO_0004142', 'EFO_0000616', 'MP_0001845', 'MONDO_0002363',
       'EFO_0000681', 'EFO_0001073', 'MONDO_0002974', 'EFO_0007328',
       'EFO_0000621', 'MONDO_0004985', 'EFO_0004242', 'EFO_0000685',
       'EFO_1001904', 'EFO_0002939', 'MONDO_0021056', 'EFO_0005543',
       'EFO_0004288', 'HP_0003418', 'EFO_0001416', 'MONDO_0008170',
       'EFO_0007453', 'MONDO_0021063', 'MONDO_0007254', 'EFO_0004252',
       'EFO_1001950', 'EFO_0008525', 'EFO_0000673', 'EFO_0010072',
       'MONDO_0002258', 'EFO_0003893', 'EFO_0000691', 'MONDO_0010200',
       'MONDO_0001187', 'EFO_0000305', 'EFO_0005537', 'EFO_0005669',
       'MONDO_0044937', 'EFO_0002609', 'MONDO_0002715', 'MONDO_0004975',
       'EFO_0005755', 'EFO_0000203', 'EFO_0002618', 'HP_0011110',
       'MONDO_0007576', 'EFO_1001250', 'MONDO_0005178', 'MONDO_0004992',
       'EFO_0003898', 'MONDO_0002050', 'MONDO_0003937', 'EFO_0004274',
       'EFO_0009625', 'EFO_0003931', 'EFO_0004142', 'EFO_0001072',
       'EFO_0000199', 'EFO_0000537', 'EFO_0000756', 'EFO_0003869',
       'EFO_0000365', 'MONDO_0002009', 'EFO_1001951', 'EFO_0005762',
       'Orphanet_733', 'MONDO_0008903', 'EFO_1000786', 'EFO_0003060',
       'MONDO_0100096', 'MONDO_0005277', 'EFO_0000712', 'MONDO_0002691',
       'EFO_1000158', 'EFO_1001466', 'EFO_0006859', 'MONDO_0024475',
       'MONDO_0008315', 'EFO_0000519', 'EFO_0001668', 'EFO_0003768',
       'HP_0003419', 'EFO_1000657', 'MONDO_0004658', 'EFO_0001378',
       'EFO_0000182'], dtype=object), 'count': 113}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 18 approved and 95 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200461,"COc1ccc(OC)c(C(O)CNC(=O)CN)c1.Cl_|_MGCQZNBCJBRZDT-UHFFFAOYSA-N_|_Small molecule_|_True_|_MIDODRINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL1201212_|_False_|_True_|_['Bramox' 'Gutron' 'Midodrine hydrochloride' 'Midon' 'Orvaten'
 'Proamatine']_|_['A-4020 LINZ' 'Amatine' 'Hipertan' 'Metligine' 'Midodrine hcl'
 'Midodrine hydrochloride' 'Midodrine monohydrochloride' 'NSC-758429'
 'ST 1085 HYDROCHLORIDE' 'ST 1085 [AS THE BASE]' 'ST-1085' 'ST-1085 BASE'
 'ST-1085 HYDROCHLORIDE' 'ST-PETER-224' 'ST. PETER 224'
 'ST1085 HYDROCHLORIDE']_|_[('DailyMed', array(['midodrine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204080', '144213040', '170464672', '56320803'], dtype=object)), ('chEBI', array(['31847'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0006834', 'HP_0100806', 'EFO_0005252'],
      dtype=object), 'count': 4}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200728,"Cl.N=C(N)N_|_PJJJBBJSCAKJQF-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANIDINE HYDROCHLORIDE_|_1939.0_|_4.0_|_CHEMBL821_|_False_|_True_|_['Guanidine hydrochloride']_|_['Guanidine HCl' 'Guanidine hydrochloride']_|_[('chEBI', array(['32735'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008524', 'HP_0001324', 'EFO_0004991'], dtype=object), 'count': 3}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 3 approved indications."
CHEMBL1201216,"Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1_|_RFWZESUMWJKKRN-UHFFFAOYSA-N_|_Small molecule_|_False_|_DAPIPRAZOLE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dapiprazole']_|_[('Wikipedia', array(['Dapiprazole'], dtype=object)), ('drugbank', array(['DB00298'], dtype=object)), ('chEBI', array(['51066'], dtype=object))]_|_['CHEMBL1201044']_|_{'rows': array(['HP_0011499', 'EFO_0004190', 'MONDO_0005041'], dtype=object), 'count': 3}_|_[ENSG00000120907]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 3 approved indications."
CHEMBL1201563,"nan_|_nan_|_Protein_|_False_|_INTERFERON BETA-1B_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Betaseron' 'Extavia']_|_['BAY 86-5046' 'BAY-86-5046' 'Interferon beta-1b']_|_[('DailyMed', array(['interferon%20beta-1b'], dtype=object)), ('DrugCentral', array(['5140'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/extavia'],
      dtype=object)), ('Wikipedia', array(['Interferon_beta-1b'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000764', 'MONDO_0100096', 'MONDO_0005301',
       'MONDO_0100116', 'EFO_0000318', 'EFO_0003929'], dtype=object), 'count': 7}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for neoplasm and multiple sclerosis and has 5 investigational indications."
CHEMBL1201611,"nan_|_nan_|_Protein_|_False_|_INSULIN LISPRO PROTAMINE RECOMBINANT_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Insulin lispro protamine recombinant']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 2 investigational indications."
CHEMBL1201834,"nan_|_nan_|_Antibody_|_False_|_CANAKINUMAB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Ilaris']_|_['ACZ-885' 'ACZ885' 'Canakinumab']_|_[('DailyMed', array(['canakinumab'], dtype=object)), ('DrugCentral', array(['4952'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris'],
      dtype=object)), ('Wikipedia', array(['Canakinumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001365', 'EFO_0004616', 'MONDO_0011776', 'MONDO_0005178',
       'EFO_0001071', 'EFO_1000906', 'MONDO_0018088', 'EFO_0008518',
       'MONDO_0005184', 'EFO_0000756', 'MONDO_0017708', 'EFO_0000275',
       'EFO_0004274', 'EFO_0004265', 'EFO_0000341', 'EFO_0004274',
       'EFO_0004246', 'MONDO_0005148', 'EFO_1001345', 'MONDO_0005147',
       'EFO_0003914', 'EFO_0002609', 'MONDO_0007254', 'EFO_0000540',
       'EFO_0000681', 'EFO_0004214', 'MONDO_0008633', 'EFO_1001165',
       'HP_0000999', 'HP_0001945', 'EFO_1001478', 'MONDO_0016168',
       'EFO_0003106', 'MONDO_0008903', 'EFO_0003780', 'DOID_13406',
       'EFO_0000685', 'EFO_0003060', 'HP_0001943', 'MONDO_0011382',
       'MONDO_0100096', 'EFO_0007135', 'EFO_0000198'], dtype=object), 'count': 43}_|_[ENSG00000125538]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 8 approved and 35 investigational indications."
CHEMBL1592101,"nan_|_nan_|_Small molecule_|_False_|_BISMUTH SUBGALLATE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Basic bismuth gallate' 'Bismuth subgallate'
 'Gallic acid bismuth basic salt']_|_[('PubChem', array(['144205941', '29218038'], dtype=object)), ('chEBI', array(['31292'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009669'], dtype=object), 'count': 1}_|_[ENSG00000131187]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for flatulence."
CHEMBL1657,"CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1_|_OGQICQVSFDPSEI-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAZAROTENE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Arazlo' 'Avage' 'Fabior' 'Tazorac' 'Zorac']_|_['AGN 190168' 'AGN-190168' 'Idp-123' 'Tazarotene']_|_[('DailyMed', array(['tazarotene'], dtype=object)), ('PubChem', array(['144206075', '170464671', '174006350', '50112778'], dtype=object)), ('Wikipedia', array(['Tazarotene'], dtype=object)), ('drugbank', array(['DB00799'], dtype=object)), ('chEBI', array(['32184'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003894', 'EFO_0009259', 'Orphanet_183469', 'EFO_1001494',
       'EFO_0002913', 'EFO_0000701', 'EFO_0000676'], dtype=object), 'count': 7}_|_[ENSG00000172819,ENSG00000077092,ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 3 investigational indications."
CHEMBL2104955,"C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CC)CC[C@@H]23)C[C@H]1O_|_QSLUXQQUPXBIHH-YHSKWIAJSA-N_|_Small molecule_|_False_|_BECOCALCIDIOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['2MBisP' 'Becocalcidiol' 'DP-006' 'DP006' 'QRX 101' 'QRX-101' 'QRX101'
 'Qrx-101']_|_[('drugbank', array(['DB04891'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676'], dtype=object), 'count': 1}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108151,nan_|_nan_|_Antibody drug conjugate_|_False_|_NACOLOMAB TAFENATOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Nacolomab tafenatox']_|_nan_|_nan_|_nan_|_[ENSG00000146242]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II.
CHEMBL2109556,"nan_|_nan_|_Antibody drug conjugate_|_False_|_MLN-2704_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MLN-2704' 'MLN-591DM1' 'Mln-2704']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000673'], dtype=object), 'count': 2}_|_[ENSG00000086205]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL269732,"C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC_|_QJJXYPPXXYFBGM-LFZNUXCKSA-N_|_Small molecule_|_True_|_TACROLIMUS ANHYDROUS_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Prograf' 'Protopic' 'Tacrolimus']_|_['Anhydrous tacrolimus' 'FK-506' 'FR-900506' 'Fujimycin' 'Prograph'
 'Tacro' 'Tacrolimus anhydrous' 'Tacrolimus, anhydrous' 'Tsukubaenolide']_|_[('PubChem', array(['144205609', '50111459'], dtype=object)), ('drugbank', array(['DB00864'], dtype=object)), ('chEBI', array(['61049'], dtype=object))]_|_['CHEMBL3989887']_|_{'rows': array(['EFO_0006344', 'EFO_1000794', 'EFO_0000274', 'EFO_1000309',
       'MONDO_0018906', 'MONDO_0019469', 'MONDO_0002334', 'EFO_0000274',
       'EFO_0004254', 'EFO_0000183', 'EFO_0002687', 'EFO_0004251',
       'HP_0001399', 'EFO_0003777', 'EFO_0000701', 'MONDO_0004979',
       'EFO_1000690', 'EFO_0000198', 'EFO_0001423', 'EFO_0000400',
       'EFO_0008517', 'MONDO_0100096', 'EFO_1002048', 'EFO_0003834',
       'EFO_0000255', 'EFO_0000403', 'EFO_0000211', 'MONDO_0004992',
       'EFO_1001993', 'MONDO_0021193', 'EFO_0004194', 'EFO_0003032',
       'HP_0012410', 'MONDO_0005147', 'EFO_0000574', 'EFO_0001378',
       'EFO_0006475', 'EFO_0003884', 'MONDO_0010518', 'EFO_0000729',
       'EFO_0000546', 'EFO_0000220', 'EFO_0003047', 'MONDO_0000873',
       'MONDO_0015253', 'EFO_0009441', 'MONDO_0009833', 'HP_0003124',
       'EFO_0006803', 'EFO_0000676', 'EFO_0002428', 'EFO_0005676',
       'MONDO_0004768', 'EFO_0004991', 'EFO_0004236', 'EFO_0000339',
       'EFO_0000544', 'EFO_0000685', 'EFO_0009510', 'EFO_0006927',
       'EFO_1001020', 'EFO_1001051', 'MONDO_0013730', 'EFO_1000131',
       'MONDO_0004976', 'EFO_0007183', 'Orphanet_848', 'EFO_0000621',
       'MONDO_0019471', 'EFO_0000191', 'EFO_0000309', 'EFO_0003818',
       'EFO_0001361', 'EFO_0000540', 'MONDO_0005301', 'EFO_0003086',
       'EFO_1000764', 'MONDO_0100244', 'MONDO_0044881', 'EFO_1001469',
       'MONDO_0008315', 'EFO_0000222', 'EFO_1000785', 'EFO_1001413',
       'EFO_0007141', 'EFO_0003872', 'MONDO_0044903', 'EFO_0009373',
       'MONDO_0000870', 'EFO_0004255', 'EFO_0000096', 'MONDO_0015760',
       'EFO_0000691', 'EFO_1001996', 'EFO_0000095', 'MONDO_0002898',
       'EFO_0004599', 'EFO_0002430', 'EFO_0000512', 'EFO_0005803',
       'EFO_0007157', 'MONDO_0004907', 'EFO_0004208', 'EFO_0002429',
       'EFO_0004220', 'EFO_0001365', 'EFO_0000717', 'MONDO_0000159',
       'MONDO_0015974', 'EFO_0005761', 'HP_0001915', 'EFO_1000956',
       'MONDO_0020077', 'EFO_0007160', 'EFO_0000616', 'MONDO_0019297',
       'EFO_0000565', 'EFO_1000318', 'MONDO_0020547', 'EFO_1000652',
       'MONDO_0019472', 'EFO_0000545', 'EFO_0004192', 'HP_0000964',
       'MONDO_0018923', 'EFO_0005952', 'EFO_0000384', 'EFO_0001642',
       'MONDO_0011382', 'EFO_0000182', 'EFO_0001421', 'HP_0002721',
       'EFO_0004286', 'EFO_1001779', 'EFO_1000623', 'EFO_0000699',
       'MONDO_0002367'], dtype=object), 'count': 137}_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 134 investigational indications. This drug has a black box warning from the FDA."
CHEMBL278623,"CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O_|_UJVDJAPJQWZRFR-DHIUTWEWSA-N_|_Small molecule_|_False_|_MACIMORELIN_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Macrilen' 'Solorel']_|_['AEZS-130' 'ARD-07' 'ARD07' 'Ard-07' 'EP-01572' 'EP-1572' 'EP01572'
 'EP1572' 'JMV 1843' 'JMV-1843' 'Macimorelin']_|_[('drugbank', array(['DB13074'], dtype=object))]_|_['CHEMBL2364617']_|_{'rows': array(['HP_0004326'], dtype=object), 'count': 1}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and has 1 investigational indication."
CHEMBL289351,"COc1ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)cc1OP(=O)([O-])[O-].[Na+].[Na+]_|_VXNQMUVMEIGUJW-XNOMRPDFSA-L_|_Small molecule_|_False_|_FOSBRETABULIN DISODIUM_|_nan_|_2.0_|_CHEMBL1206232_|_False_|_False_|_[]_|_['CA 4P' 'CA-4DP' 'CA4DP' 'Fosbretabulin disodium'
 'Fosbretabulin disodium salt']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0004683', 'MONDO_0004992', 'EFO_0006859'],
      dtype=object), 'count': 4}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3113974,"CS(=O)(=O)Nc1ccc(C(=O)O[C@@H](Cc2c(Cl)c[n+]([O-])cc2Cl)c2ccc(OC(F)F)c(OCC3CC3)c2)cc1OCC1CC1_|_VCFBPAOSTLMYIV-SANMLTNESA-N_|_Small molecule_|_False_|_TRANIMILAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CHF6001' 'Chf-6001' 'Chf6001' 'J3.309.618F' 'Tanimilast' 'Tranimilast']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TRANIMILAST/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12800'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545213,"N#CC(c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1)c1nc2ccccc2s1_|_XCPPIJCBCWUBNT-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENTAMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AS602801' 'As-602801' 'Bentamapimod' 'PGL-5001' 'PGL5001']_|_nan_|_nan_|_{'rows': array(['EFO_0001065'], dtype=object), 'count': 1}_|_[ENSG00000107643,ENSG00000109339,ENSG00000050748]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989868,"Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1_|_SDEAXTCZPQIFQM-UHFFFAOYSA-N_|_Small molecule_|_False_|_TUCATINIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Tukysa']_|_['ARRY-380' 'Irbinitinib' 'MK-7119' 'ONT-380' 'Ont-380' 'Tucatinib']_|_[('DailyMed', array(['tucatinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa'],
      dtype=object)), ('drugbank', array(['DB11652'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009708', 'EFO_0000339', 'EFO_0001421', 'EFO_0004142',
       'EFO_0000305', 'EFO_1000294', 'EFO_0003060', 'EFO_0000616',
       'MONDO_0001056', 'EFO_0003869', 'MONDO_0004992', 'EFO_0000182',
       'EFO_0003968', 'EFO_0005537', 'MONDO_0007254', 'EFO_1001951'],
      dtype=object), 'count': 16}_|_[ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 9 approved and 7 investigational indications."
CHEMBL4297579,"nan_|_nan_|_Gene_|_False_|_VALOCTOCOGENE ROXAPARVOVEC_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Roctavian']_|_['BMN-270' 'BMN270' 'Valoctocogene roxaparvovec']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Gene drug with a maximum clinical trial phase of IV that was first approved in 2022 and has 1 investigational indication."
CHEMBL4297839,"nan_|_nan_|_Protein_|_True_|_TIRZEPATIDE_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Mounjaro']_|_['LY-3298176' 'LY3298176' 'Ly3298176' 'Mounjaro' 'Tirzepatide']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'MONDO_0018105', 'MONDO_0005148', 'EFO_1001249',
       'EFO_0000400', 'EFO_0001073'], dtype=object), 'count': 6}_|_[ENSG00000010310,ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297850,"nan_|_nan_|_Antibody_|_False_|_XENTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI 836845' 'BI-836845' 'Bi 836845' 'Xentuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000673', 'EFO_0003869', 'MONDO_0008315',
       'EFO_0003060'], dtype=object), 'count': 5}_|_[ENSG00000017427,ENSG00000167244]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4650349,"O=C(c1ccc(F)cc1)c1ccccc1N[C@@H](Cc1ccc(OCCn2c3ccccc3c3ccccc32)cc1)C(=O)O_|_QNLWMPLUWMWDMQ-YTTGMZPUSA-N_|_Small molecule_|_False_|_CHIGLITAZAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CS 038' 'CS-038' 'Carfloglitazar, (s)-' 'Chiglitazar']_|_nan_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0001421', 'EFO_1001249', 'MONDO_0005148'],
      dtype=object), 'count': 4}_|_[ENSG00000132170,ENSG00000186951,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4650402,"nan_|_nan_|_Antibody_|_False_|_POSDINEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['JNJ-63733657' 'Jnj-63733657' 'Posdinemab' 'Posdinemab ']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000186868]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL471897,"Cc1cc(OCP2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)cc(C)c1Cc1ccc(O)c(C(C)C)c1_|_LGGPZDRLTDGYSQ-GYKKGXIBSA-N_|_Small molecule_|_False_|_MB07811_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MB-07811' 'MB07811' 'Mb-07811' 'Mb07811' 'VK2809' 'Vk-2809']_|_nan_|_['CHEMBL1162981']_|_{'rows': array(['MONDO_0021187', 'HP_0003124', 'EFO_1001249'], dtype=object), 'count': 3}_|_[ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL90555,"CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1_|_OGWKCGZFUXNPDA-XQKSVPLYSA-N_|_Small molecule_|_True_|_VINCRISTINE_|_1963.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['22-oxovincaleukoblastine' 'Leucristine' 'Leurocristine' 'Oncotcs'
 'Tecnocris' 'Vincaleukoblastine, 22-oxo-' 'Vincristin' 'Vincristine'
 'Vinkristin']_|_[('PubChem', array(['124892473', '144205620', '170465186'], dtype=object)), ('chEBI', array(['28445'], dtype=object))]_|_['CHEMBL501867']_|_{'rows': array(['EFO_0000174', 'MONDO_0009348', 'MONDO_0000870', 'EFO_0000248',
       'EFO_0000220', 'MONDO_0008380', 'EFO_1000292', 'EFO_0000183',
       'MONDO_0015760', 'EFO_0000094', 'MONDO_0016717', 'EFO_0000616',
       'EFO_1001469', 'EFO_0000183', 'EFO_0002939', 'EFO_0004289',
       'EFO_0000255', 'EFO_0000502', 'EFO_0003833', 'EFO_0000211',
       'EFO_0002918', 'EFO_0005952', 'EFO_0000096', 'MONDO_0008903',
       'EFO_1000131', 'EFO_0000180', 'EFO_0005235', 'EFO_0000502',
       'EFO_1000292', 'EFO_1000635', 'EFO_0002499', 'MONDO_0008380',
       'EFO_0000209', 'EFO_1001951', 'EFO_0000095', 'MONDO_0018906',
       'MONDO_0015540', 'EFO_0000095', 'MONDO_0044881', 'MONDO_0002974',
       'EFO_1000796', 'EFO_0007160', 'MONDO_0003478', 'HP_0001871',
       'EFO_0002939', 'MONDO_0000873', 'EFO_0000574', 'MONDO_0018271',
       'MONDO_0019004', 'EFO_0003833', 'EFO_0000309', 'EFO_0000222',
       'EFO_0000437', 'EFO_0000272', 'EFO_1001469', 'EFO_0000309',
       'EFO_0000211', 'EFO_0000094', 'MONDO_0000873', 'EFO_0009254',
       'EFO_0004289', 'MONDO_0044917', 'MONDO_0018975', 'MONDO_0000432',
       'EFO_0006859', 'EFO_1001365', 'EFO_0000198', 'EFO_0000558',
       'EFO_0000248', 'EFO_0000437', 'EFO_0000565', 'EFO_0001378',
       'EFO_0003032', 'MONDO_0004095', 'EFO_0000519', 'EFO_0000220',
       'EFO_1000158', 'EFO_0000756', 'EFO_0000565', 'EFO_1001042',
       'EFO_0009708', 'EFO_0000621', 'MONDO_0002367', 'EFO_0003032',
       'EFO_0000616', 'MONDO_0016700', 'EFO_0001378', 'MONDO_0019004',
       'EFO_0000621', 'MONDO_0001657', 'MONDO_0000430', 'EFO_0000403',
       'EFO_0000574', 'EFO_0000702', 'EFO_0000637', 'MONDO_0000870',
       'EFO_0000209', 'EFO_1000318', 'MONDO_0018944', 'MONDO_0015564',
       'EFO_0005952', 'EFO_0000313', 'EFO_0000691', 'EFO_1000158',
       'EFO_0000588', 'EFO_0000403', 'MONDO_0009348', 'MONDO_0006058',
       'EFO_0000222', 'EFO_1001830', 'EFO_1001365', 'EFO_0009441',
       'MONDO_0018906', 'EFO_0000691', 'MONDO_0019471', 'EFO_0000096',
       'EFO_0000765', 'EFO_0002918', 'EFO_0000174', 'MONDO_0044917'],
      dtype=object), 'count': 120}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1963 and is indicated for neoplasm and has 90 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1128,"CC[N+](C)(C)c1cccc(O)c1.[Cl-]_|_BXKDSDJJOVIHMX-UHFFFAOYSA-N_|_Small molecule_|_False_|_EDROPHONIUM CHLORIDE_|_1951.0_|_4.0_|_CHEMBL1104_|_False_|_True_|_['Camsilon' 'Edrophonium chloride'
 'Edrophonium chloride preservative free' 'Enlon' 'Reversol' 'Tensilon'
 'Tensilon preservative free']_|_['Antirex' 'Edrophone chloride' 'Edrophonii chloridum'
 'Edrophonium Chloride' 'Edrophonium chloride' 'NSC-759577']_|_[('PubChem', array(['144203689', '170464801', '26747508', '26747509', '50106293',
       '50106294', '50106295', '56422101', '855983'], dtype=object)), ('Wikipedia', array(['Edrophonium'], dtype=object)), ('chEBI', array(['4759'], dtype=object))]_|_nan_|_nan_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951."
CHEMBL1200636,"CN(C)CCC=C1c2ccccc2C=Cc2ccccc21.Cl_|_VXEAYBOGHINOKW-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLOBENZAPRINE HYDROCHLORIDE_|_1977.0_|_4.0_|_CHEMBL669_|_False_|_True_|_['Amrix' 'Cyclobenzaprine hydrochloride' 'Flexeril']_|_['Cyclobenzaprine hcl' 'Cyclobenzaprine hydrochloride' 'MK-130'
 'MK-130 HYDROCHLORIDE' 'MK-130 [AS THE BASE]' 'NSC-169900' 'NSC-173379'
 'NSC-78206']_|_[('DailyMed', array(['cyclobenzaprine%20hydrochloride'], dtype=object)), ('PubChem', array(['124891634', '144203591', '170464953', '26748730', '26748731',
       '50106063', '50107452', '50107453', '551139', '56463037'],
      dtype=object)), ('chEBI', array(['3997'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'HP_0003394', 'EFO_1000632', 'EFO_0009488',
       'HP_0003326', 'HP_0001257'], dtype=object), 'count': 6}_|_[ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 5 approved and 1 investigational indication."
CHEMBL1200930,"COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C.[Na+]_|_KRCQSTCYZUOBHN-UHFFFAOYSA-N_|_Small molecule_|_False_|_RABEPRAZOLE SODIUM_|_1999.0_|_4.0_|_CHEMBL1219_|_False_|_True_|_['Aciphex' 'Aciphex sprinkle' 'Pariet' 'Rabeprazole sodium']_|_['E-3810' 'E-3810 SODIUM' 'Idiazole' 'LY-307640' 'LY-307640 SODIUM'
 'LY307640 SODIUM' 'NSC-759270' 'Rabeprazole na' 'Rabeprazole sodium'
 'Rabeprazole sodium salt' 'Sodium rabeprazole']_|_[('DailyMed', array(['rabeprazole%20sodium'], dtype=object)), ('PubChem', array(['144205289', '144212634', '170464736', '49666380'], dtype=object)), ('chEBI', array(['8769'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004607', 'EFO_1001355', 'EFO_0003763', 'EFO_0007549',
       'EFO_0003948', 'EFO_1000961', 'EFO_1001095'], dtype=object), 'count': 7}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 4 investigational indications."
CHEMBL1373,"NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1_|_YFGHCGITMMYXAQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_MODAFINIL_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Modafinil' 'Provigil']_|_['CEP 1538' 'CEP-1538' 'CRC-40476' 'CRL 40476' 'CRL-40476' 'DEP-1538'
 'Modafinil' 'Modafinil civ' 'Modaphonil' 'Modiodal' 'NSC-751178'
 'NSC-759110' 'THN-102 COMPONENT MODAFINIL' 'THN102 COMPONENT MODAFINIL']_|_[('DailyMed', array(['modafinil'], dtype=object)), ('PubChem', array(['144205023', '170465042', '26719679', '26749058', '26753746'],
      dtype=object)), ('Wikipedia', array(['Modafinil'], dtype=object)), ('drugbank', array(['DB00745'], dtype=object)), ('chEBI', array(['77585'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0003925', 'EFO_0003768', 'HP_0100543',
       'EFO_0002610', 'EFO_0007454', 'MONDO_0002050', 'MONDO_0005180',
       'EFO_0008568', 'EFO_0005411', 'EFO_0005252', 'HP_0000360',
       'EFO_0003833', 'EFO_0004701', 'MONDO_0008170', 'HP_0003419',
       'EFO_0005611', 'EFO_0002617', 'MONDO_0004975', 'EFO_0003877',
       'EFO_0003918', 'MONDO_0002491', 'EFO_0001358', 'EFO_0000712',
       'MONDO_0016158', 'EFO_0000756', 'MONDO_0005090', 'HP_0002015',
       'EFO_0003890', 'MONDO_0021107', 'HP_0012378', 'MONDO_0007079',
       'MONDO_0005301', 'EFO_0003888', 'EFO_0000174', 'MONDO_0002009'],
      dtype=object), 'count': 36}_|_[ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 4 approved and 32 investigational indications."
CHEMBL1743027,"nan_|_nan_|_Antibody_|_False_|_GIRENTUXIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Rencarex']_|_['CA9-SCAN CG250' 'CG-250' 'CG250' 'Girentuximab' 'WX-G250']_|_nan_|_nan_|_{'rows': array(['EFO_0000681', 'MONDO_0002367', 'EFO_0000349'], dtype=object), 'count': 3}_|_[ENSG00000107159]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1743075,"nan_|_nan_|_Antibody_|_False_|_TABALUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-2127399' 'LY2127399' 'Tabalumab']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000685', 'EFO_0003884', 'MONDO_0007915',
       'EFO_0003929'], dtype=object), 'count': 5}_|_[ENSG00000102524]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL2109509,"nan_|_nan_|_Antibody_|_False_|_HCBE-11_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HCBE-11' 'Hcbe-11']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000111321]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2364574,"C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc([O-])c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.[Ca+2]_|_GJPGCACMCURAKH-YQCFNCLSSA-L_|_Small molecule_|_False_|_DOXYCYCLINE CALCIUM_|_1974.0_|_4.0_|_CHEMBL1433_|_False_|_True_|_['Vibramycin']_|_['Doxycycline calcium']_|_nan_|_nan_|_{'rows': array(['EFO_0003102'], dtype=object), 'count': 1}_|_[ENSG00000196611,ENSG00000118113,ENSG00000137745,ENSG00000137673]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and has 1 investigational indication."
CHEMBL3128043,"Cc1nc(Nc2n[nH]c3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1_|_AYCPARAPKDAOEN-LJQANCHMSA-N_|_Small molecule_|_False_|_PF-03758309_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PF-03758309' 'PF-3758309' 'Pf-03758309']_|_[('drugbank', array(['DB11775'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000130669]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3301583,"nan_|_nan_|_Unknown_|_False_|_ANDEXANET ALFA_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Ondexxya']_|_['Andexanet alfa' 'Andexxa' 'PRT-064445' 'PRT-4445' 'PRT064445'
 'rfXa Inhibitor Antidote']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0020003', 'MP_0001914'], dtype=object), 'count': 2}_|_[ENSG00000003436]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for drug toxicity and has 1 investigational indication."
CHEMBL3646221,"O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O_|_JGRXMPYUTJLTKT-UHFFFAOYSA-N_|_Small molecule_|_False_|_VADADUSTAT_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['AKB-6548' 'B-506' 'B506' 'PG-1016548' 'PG1016548' 'Vadadustat']_|_[('drugbank', array(['DB12255'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 3}_|_[ENSG00000129521,ENSG00000269858,ENSG00000135766]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for anemia (phenotype) and has 2 investigational indications."
CHEMBL422,"CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1_|_ZEWQUBUPAILYHI-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRIFLUOPERAZINE_|_1959.0_|_4.0_|_nan_|_False_|_True_|_['Amylozine' 'Stelazine' 'Stelazine fte']_|_['Apo-trifluoperazine' 'Flurazine' 'NSC-17474' 'NSC-46061' 'RP-7623'
 'Trifluoperazine']_|_[('PubChem', array(['11110644', '11110645', '124877144', '124877145', '174006276',
       '26751598', '26751599', '4252673', '50100152', '50104251',
       '50104252', '50104253', '57287812', '90341087', '92763314'],
      dtype=object)), ('Wikipedia', array(['Trifluoperazine'], dtype=object)), ('drugbank', array(['DB00831'], dtype=object)), ('chEBI', array(['45951'], dtype=object))]_|_['CHEMBL1726794' 'CHEMBL1257040' 'CHEMBL1710']_|_{'rows': array(['EFO_0005407', 'EFO_0006788', 'MONDO_0005090', 'EFO_0000677'],
      dtype=object), 'count': 4}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 4 approved indications. This drug has a black box warning from the FDA."
CHEMBL4297147,"CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1_|_BVUSNQJCSYDJJG-UHFFFAOYSA-N_|_Small molecule_|_True_|_HALOPERIDOL LACTATE_|_1967.0_|_4.0_|_CHEMBL54_|_False_|_True_|_['Haldol' 'Haloperidol intensol' 'Haloperidol lactate']_|_['Haloperidol lactate']_|_[('DailyMed', array(['haloperidol%20lactate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005411', 'MONDO_0005090', 'HP_0000713'], dtype=object), 'count': 3}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for schizophrenia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297649,"CC(C)COc1cc(F)cc(-c2ccc(C(=O)NS(=O)(=O)c3ccccc3)c(N3C[C@@H](C)CC3(C)C)n2)c1_|_NHOUNZMCSIHKHJ-FQEVSTJZSA-N_|_Small molecule_|_False_|_OLACAFTOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Olacaftor' 'VX-440' 'Vx-440']_|_nan_|_nan_|_{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297966,"nan_|_nan_|_Antibody_|_False_|_DEZAMIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti - sap mab' 'Dezamizumab' 'GSK-2398852' 'GSK2398852' 'Gsk2398852'
 'anti-SAP mAb']_|_nan_|_nan_|_{'rows': array(['MONDO_0017816', 'EFO_1001875'], dtype=object), 'count': 2}_|_[ENSG00000132703]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL440,"C=CCC1(C(C)CCC)C(=O)NC(=S)NC1=O_|_XLOMZPUITCYLMJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_THIAMYLAL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-120815' 'Thiamylal']_|_[('Wikipedia', array(['Thiamylal'], dtype=object)), ('drugbank', array(['DB01154'], dtype=object)), ('chEBI', array(['9536'], dtype=object))]_|_['CHEMBL1201065']_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL4594250,"Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1_|_OURRXQUGYQRVML-AREMUKBSSA-N_|_Small molecule_|_False_|_NETARSUDIL_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AR-11324 FREE BASE' 'AR-13324' 'Netarsudil']_|_nan_|_['CHEMBL4594251' 'CHEMBL4796289']_|_{'rows': array(['MONDO_0005321', 'Orphanet_98974', 'EFO_0004190', 'EFO_0004190',
       'MONDO_0005041', 'EFO_1001069', 'EFO_1000879'], dtype=object), 'count': 7}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for open-angle glaucoma and ocular hypertension and has 5 investigational indications."
CHEMBL4594262,"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl.O=C(O)c1ccccc1_|_RVPCEXXEUXIPEO-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMLODIPINE BENZOATE_|_2019.0_|_4.0_|_CHEMBL1491_|_False_|_True_|_['Katerzia']_|_[]_|_[('DailyMed', array(['amlodipine%20benzoate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hypertension."
CHEMBL4594558,"nan_|_nan_|_Antibody_|_False_|_RAGIFILIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGEN-1876' 'AGEN1876' 'CM-701' 'CM701' 'INCAGN-01876' 'INCAGN01876'
 'Incagn01876' 'Ragifilimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RAGIFILIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000707', 'EFO_0000519', 'EFO_0006859', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000186891]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL512351,"COc1ccc(NC(=O)c2ccc(C(=N)N(C)C)cc2)c(C(=O)Nc2ccc(Cl)cn2)c1_|_XHOLNRLADUSQLD-UHFFFAOYSA-N_|_Small molecule_|_True_|_BETRIXABAN_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Bevyxxa']_|_['Betrixaban' 'Betrixaban maleate' 'PRT-054021' 'PRT054021']_|_[('Wikipedia', array(['Betrixaban'], dtype=object)), ('drugbank', array(['DB12364'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'EFO_0001421', 'EFO_0003911', 'HP_0001907',
       'EFO_0004286', 'EFO_0003086', 'MP_0001914', 'HP_0004419'],
      dtype=object), 'count': 8}_|_[ENSG00000126218]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for venous thromboembolism and recurrent thrombophlebitis and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1134,"C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C.[Br-].[Br-]_|_HLXQFVXURMXRPU-UHFFFAOYSA-L_|_Small molecule_|_False_|_DECAMETHONIUM BROMIDE_|_1982.0_|_4.0_|_CHEMBL1190_|_False_|_True_|_['Syncurine']_|_['Decamethonium Bromide' 'Decamethonium bromide' 'Decamethonium diiodide'
 'Decamethonium iodide' 'NSC-23004']_|_[('PubChem', array(['144205588', '170465349', '50106154', '855712'], dtype=object)), ('Wikipedia', array(['Decamethonium'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200722,"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H](N3CC[N+](C)(C)CC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CC[N+](C)(C)CC1.[Br-].[Br-]_|_TXWBOBJCRVVBJF-YTGGZNJNSA-L_|_Small molecule_|_False_|_PIPECURONIUM BROMIDE_|_1990.0_|_4.0_|_CHEMBL1201206_|_False_|_True_|_['Arduan']_|_['Pipecurium bromide' 'Pipecuronium bromide'
 'Pipecuronium bromide anhydrous' 'Pipecuronium bromide dihydrate'
 'Pipecuronium bromide hydrate' 'RGH 1106' 'RGH-1106']_|_[('Wikipedia', array(['Pipecuronium_bromide'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990."
CHEMBL1201338,"CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1_|_SKYSRIRYMSLOIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLOPENTOLATE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bell pentolate' 'Cyclopentolate']_|_[('drugbank', array(['DB00979'], dtype=object)), ('chEBI', array(['4024'], dtype=object))]_|_['CHEMBL1200473']_|_{'rows': array(['HP_0000616', 'HP_0000545', 'HP_0011499'], dtype=object), 'count': 3}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for mydriasis and has 2 investigational indications."
CHEMBL1206,"CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21_|_CDOZDBSBBXSXLB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ETHOPROPAZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ethopropazine' 'Parsidol' 'Profenamine']_|_[('PubChem', array(['90341779'], dtype=object)), ('Wikipedia', array(['Profenamine'], dtype=object)), ('drugbank', array(['DB00392'], dtype=object)), ('chEBI', array(['313639'], dtype=object))]_|_['CHEMBL1200970']_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for parkinson disease."
CHEMBL12713,"O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1_|_GZKLJWGUPQBVJQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SERTINDOLE_|_1996.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['LU 23-174' 'LU-23-174' 'Serdolect' 'Sertindole' 'Zerdol']_|_[('PubChem', array(['144206958', '144206971', '170465613'], dtype=object)), ('Wikipedia', array(['Sertindole'], dtype=object)), ('drugbank', array(['DB06144'], dtype=object)), ('chEBI', array(['9122'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'MONDO_0005090',
       'EFO_0005407', 'HP_0100543'], dtype=object), 'count': 6}_|_[ENSG00000149295,ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for psychosis and has 5 investigational indications. It was withdrawn in at least one region."
CHEMBL1680,"C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O_|_DEQANNDTNATYII-OULOTJBUSA-N_|_Protein_|_False_|_OCTREOTIDE_|_1988.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Octreotide' 'SMS 201-995' 'SMS-201-995' 'SMS-995' 'SMS995']_|_[('PubChem', array(['50126343'], dtype=object)), ('Wikipedia', array(['Octreotide'], dtype=object)), ('drugbank', array(['DB00104'], dtype=object))]_|_['CHEMBL3545066' 'CHEMBL1200480' 'CHEMBL2105834']_|_{'rows': array(['EFO_0000544', 'EFO_0000182', 'EFO_1000852', 'MONDO_0005277',
       'EFO_1001496', 'MONDO_0004565', 'EFO_0000768', 'EFO_1000852',
       'EFO_1001951', 'EFO_0005252', 'MONDO_0017611', 'EFO_1000045',
       'MONDO_0019180', 'EFO_0002626', 'HP_0002014', 'EFO_0000616',
       'EFO_0007331', 'MONDO_0024503', 'MONDO_0016642', 'EFO_0001073',
       'MONDO_0007254', 'EFO_1001485', 'EFO_1001901', 'MONDO_0017182',
       'EFO_0000574', 'HP_0002239', 'EFO_0000555', 'HP_0002014',
       'MONDO_0002120', 'MONDO_0008300', 'EFO_1002048', 'EFO_1001901',
       'EFO_0004243', 'EFO_0009708', 'EFO_1000581', 'EFO_0000616',
       'MONDO_0043579', 'HP_0002019', 'MONDO_0007254', 'EFO_1001780',
       'EFO_0003770', 'EFO_1001485', 'EFO_0002618', 'EFO_1001485',
       'EFO_0004243', 'MONDO_0004992', 'MONDO_0024503', 'EFO_0001073',
       'MONDO_0008315', 'MONDO_0002691', 'MONDO_0008315', 'MONDO_0004565'],
      dtype=object), 'count': 52}_|_[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 4 approved and 41 investigational indications."
CHEMBL2109204,"nan_|_nan_|_Oligosaccharide_|_False_|_NADROPARIN CALCIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CY 216' 'CY-216' 'Fraxiparin' 'Fraxiparina' 'Fraxiparine' 'Nadroparin'
 'Nadroparin calcium' 'Seleparina' 'Ultraparina']_|_[('DrugCentral', array(['5162'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004936', 'EFO_0004286', 'EFO_0009315', 'HP_0004419',
       'EFO_0003907', 'MONDO_0008903'], dtype=object), 'count': 6}_|_[ENSG00000117601]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2109500,"nan_|_nan_|_Antibody_|_False_|_LIRILUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-KIR Antibody' 'BMS-986015' 'BMS-986015-01' 'BMS-98601501'
 'IPH-2102' 'IPH2102' 'Lirilumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000181', 'MONDO_0004992', 'MONDO_0001187',
       'EFO_0005952', 'EFO_0000095', 'EFO_0001378', 'EFO_0000183',
       'EFO_0000565', 'EFO_0000222'], dtype=object), 'count': 10}_|_[ENSG00000243772,ENSG00000125498,ENSG00000278731,ENSG00000275546,ENSG00000276731,ENSG00000276011,ENSG00000275407,ENSG00000275914]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL2109531,"nan_|_nan_|_Antibody_|_False_|_MEDI-6469_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['9b12, a murine igg1 antibody' 'MEDI-6469' 'MEDI6469' 'Medi 6469'
 'Medi-6469']_|_nan_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0006859', 'EFO_0004142', 'EFO_0000574',
       'EFO_0000196', 'MONDO_0007254'], dtype=object), 'count': 6}_|_[ENSG00000186827]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL2364605,"CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12_|_CSMVOZKEWSOFER-RQNOJGIXSA-N_|_Small molecule_|_False_|_CEBRANOPADOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cebranopadol' 'GRT-6005' 'GRT6005']_|_[('drugbank', array(['DB12830'], dtype=object))]_|_['CHEMBL3325957']_|_{'rows': array(['MONDO_0001583', 'EFO_0004616', 'HP_0003419', 'EFO_0003890',
       'EFO_0003843'], dtype=object), 'count': 5}_|_[ENSG00000125510,ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL26,"CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC_|_BGRJTUBHPOOWDU-UHFFFAOYSA-N_|_Small molecule_|_False_|_SULPIRIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Dolmatil']_|_['N05AL01' 'NSC-757850' 'RD-1403' 'Sulpiride']_|_[('PubChem', array(['144212522', '50104625'], dtype=object)), ('TG-GATEs', array(['115'], dtype=object)), ('Wikipedia', array(['Sulpiride'], dtype=object)), ('drugbank', array(['DB00391'], dtype=object)), ('chEBI', array(['32168'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0005407', 'MONDO_0002050',
       'MONDO_0005090'], dtype=object), 'count': 5}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."
CHEMBL284483,"OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)[C@H](O)[C@@H]1O_|_YOOVTUPUBVHMPG-LODYRLCVSA-N_|_Small molecule_|_False_|_COFORMYCIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Coformycin' 'NSC-277817']_|_[('chEBI', array(['16213'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565'], dtype=object), 'count': 1}_|_[ENSG00000196839]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL325424,"Cc1cccc(-c2ccc3c(c2)c(C(=O)C(=O)O)cn3Cc2ccc(C(C)(C)C)cc2)c1_|_HSXLMAFNWCSZGP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALEPLASININ_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aleplasinin' 'PAZ-417']_|_[('drugbank', array(['DB12635'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000106366]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3408248,"C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12_|_LMJFJIDLEAWOQJ-CQSZACIVSA-N_|_Small molecule_|_False_|_AZD-8186_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZD8186' 'Azd 8186' 'Azd-8186']_|_[('drugbank', array(['DB15029'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000196', 'MONDO_0008315', 'EFO_0005537', 'MONDO_0007254',
       'MONDO_0001056', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000171608,ENSG00000051382]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 6 investigational indications."
CHEMBL3545017,"O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1_|_FBCQEUMZZNVQKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_GTX-758_|_nan_|_2.0_|_nan_|_False_|_False_|_['Capesaris']_|_['Gtx 758' 'Gtx-758']_|_[('drugbank', array(['DB14969'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707311,"CCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@@]21C_|_AJAMXPWEAPICIM-XCAPYKEYSA-N_|_Small molecule_|_False_|_VAMOROLONE_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Agamree']_|_['9,11-dehydro dexamethasone' '9,11-dehydrodexamethasone acetate' 'VBP-15'
 'Vamorolone' 'Vamorolone acetate' 'Vbp-15 free alcohol']_|_nan_|_nan_|_{'rows': array(['EFO_0000729', 'MONDO_0010679', 'MONDO_0010311'], dtype=object), 'count': 3}_|_[ENSG00000151623,ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for duchenne muscular dystrophy and becker muscular dystrophy and has 1 investigational indication."
CHEMBL3989514,"CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O_|_KLEAIHJJLUAXIQ-JDRGBKBRSA-N_|_Small molecule_|_True_|_IRINOTECAN HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL481_|_False_|_True_|_['Campto' 'Camptosar' 'Irinotecan hydrochloride' 'Onivyde'
 'Onivyde pegylated liposomal (previously known as onivyde)']_|_['CPT-11' 'DQ-2805' 'Irinotecan hydrochloride'
 'Irinotecan hydrochloride anhydrous' 'Irinotecan hydrochloride hydrate'
 'Irinotecan hydrochloride trihydrate'
 'Irinotecan monohydrochloride trihydrate' 'NSC-759878' 'U-101,440E'
 'U-101440E']_|_[('DailyMed', array(['irinotecan%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-liposomal'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000359', 'EFO_1001013', 'EFO_0001075', 'EFO_1000657',
       'MONDO_0002367', 'MONDO_0002158', 'EFO_0002618', 'EFO_1001512',
       'MONDO_0004669', 'EFO_0000313', 'EFO_1000292', 'EFO_0000681',
       'EFO_0002617', 'EFO_0000403', 'EFO_0000228', 'EFO_0000574',
       'EFO_0000707', 'EFO_0000365', 'EFO_1000407', 'MONDO_0008315',
       'MONDO_0002120', 'MONDO_0044926', 'EFO_0000309', 'MONDO_0000873',
       'EFO_0002938', 'MONDO_0001056', 'MONDO_0002537', 'MONDO_0018364',
       'EFO_0003860', 'EFO_1001051', 'EFO_0002501', 'MONDO_0008170',
       'MONDO_0021063', 'MONDO_0007576', 'MONDO_0002974', 'MONDO_0008903',
       'HP_0002014', 'EFO_0000621', 'EFO_0004193', 'EFO_0006352',
       'EFO_0002918', 'EFO_0000437', 'EFO_1000475', 'MONDO_0003060',
       'EFO_0000191', 'EFO_1001465', 'EFO_0004243', 'MONDO_0020634',
       'MONDO_0001475', 'EFO_1000251', 'EFO_0000702', 'EFO_0000519',
       'MONDO_0044937', 'EFO_0005537', 'MONDO_0100342', 'MONDO_0005411',
       'EFO_0000632', 'MONDO_0002087', 'MONDO_0001325', 'EFO_0000095',
       'EFO_1001951', 'MONDO_0019471', 'MONDO_0016717', 'EFO_0007535',
       'EFO_1000785', 'MONDO_0011719', 'EFO_1001469', 'MONDO_0001187',
       'MONDO_0003196', 'MONDO_0001879', 'EFO_0000183', 'EFO_0000389',
       'EFO_1001365', 'EFO_0000502', 'EFO_0000637', 'EFO_1001471',
       'EFO_0006859', 'MONDO_0002691', 'EFO_0002939', 'EFO_1000158',
       'EFO_0004142', 'MONDO_0005184', 'EFO_0000691', 'EFO_0000616',
       'EFO_0000503', 'EFO_0000174', 'EFO_0000248', 'EFO_0001071',
       'EFO_0003032', 'EFO_0002499', 'EFO_0000178', 'MONDO_0021633',
       'MONDO_0004192', 'MONDO_0004992', 'MONDO_0018271', 'MONDO_0018906',
       'MONDO_0007254', 'EFO_0000565', 'EFO_0003060', 'EFO_0000255'],
      dtype=object), 'count': 100}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 5 approved and 95 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297621,"C[C@@H](N[C@H]1CCN(c2ccc(CC(=O)O)cc2)C1)c1cccc2ccccc12_|_RZNUIYPHQFXBAN-XLIONFOSSA-N_|_Small molecule_|_False_|_EVOCALCET_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Evocalcet' 'KHK-7580' 'KHK7580' 'Khk7580' 'MT-4580']_|_[('drugbank', array(['DB12388'], dtype=object))]_|_['CHEMBL4128835']_|_{'rows': array(['EFO_1001173', 'EFO_0008506'], dtype=object), 'count': 2}_|_[ENSG00000036828]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4297644,"Cc1n[nH]cc1-c1cc2nc([C@@H]3CC4CCN3CC4)[nH]c(=O)c2s1_|_XGVXKJKTISMIOW-ZDUSSCGKSA-N_|_Small molecule_|_False_|_SIMUROSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Simurosertib' 'TAK-931' 'TAK931F' 'Tak 931' 'Tak-931']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMUROSERTIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000097046]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL439849,"N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1_|_SGEGOXDYSFKCPT-UHFFFAOYSA-N_|_Small molecule_|_True_|_VILAZODONE_|_2011.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['EMD 515259' 'EMD-515259' 'EMD-68-843' 'Vilazodone']_|_[('Wikipedia', array(['Vilazodone'], dtype=object)), ('drugbank', array(['DB06684'], dtype=object)), ('chEBI', array(['70707'], dtype=object))]_|_['CHEMBL1615374']_|_{'rows': array(['EFO_0001358', 'EFO_1001892', 'MONDO_0002009', 'MONDO_0002009',
       'EFO_0001072', 'EFO_0007191', 'MONDO_0002009'], dtype=object), 'count': 7}_|_[ENSG00000178394,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for major depressive disorder and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4650283,"CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C_|_HJFSVYUFOXAVAA-YUAYGMJFSA-N_|_Small molecule_|_False_|_FF-10101_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['FF-10101' 'FLT3-IN-1' 'Ff-10101']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4650289,"nan_|_nan_|_Unknown_|_False_|_KBP5209_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['KBP5209' 'Kbp5209']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000141736,ENSG00000146648,ENSG00000178568,ENSG00000065361]_|_Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL490,"Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1_|_AHOUBRCZNHFOSL-YOEHRIQHSA-N_|_Small molecule_|_True_|_PAROXETINE_|_1992.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)3s,4r-paroxetine' 'Arketis' 'Arotin' 'BRL 29060' 'BRL-29060'
 'Besitram' 'Casbol' 'Daparox' 'Fg-7051' 'Frosinor' 'Motivan' 'Parogen'
 'Paroxetine' 'Paxil' 'Paxpar' 'Pexeva' 'Xetanor']_|_[('PubChem', array(['144206674', '170465075', '26752262', '29215051', '50104978',
       '50104979', '50104980', '50104981', '90341371'], dtype=object)), ('Wikipedia', array(['Paroxetine'], dtype=object)), ('drugbank', array(['DB00715'], dtype=object)), ('chEBI', array(['7936'], dtype=object))]_|_['CHEMBL1449490' 'CHEMBL1200609' 'CHEMBL1708' 'CHEMBL1256912'
 'CHEMBL3133300' 'CHEMBL1628650']_|_{'rows': array(['MONDO_0005180', 'EFO_0006788', 'EFO_0000612', 'EFO_1001917',
       'EFO_0004242', 'EFO_1001892', 'EFO_1001917', 'GO_0042697',
       'MONDO_0002050', 'EFO_0005762', 'HP_0000726', 'EFO_0005230',
       'HP_0031217', 'EFO_0004262', 'EFO_0005687', 'EFO_0004242',
       'EFO_0001358', 'MONDO_0002009', 'EFO_0803321', 'EFO_0005230',
       'EFO_0001358', 'MONDO_0002009', 'EFO_0803321', 'MONDO_0002009',
       'MONDO_0002009', 'MONDO_0004985', 'HP_0000360', 'MONDO_0005090',
       'EFO_0004220', 'MONDO_0007079', 'MONDO_0002050', 'EFO_1001917',
       'EFO_0006788', 'EFO_0004262', 'EFO_0004262', 'EFO_0004242',
       'EFO_1001872', 'MONDO_0002775', 'EFO_0001358', 'EFO_0000685',
       'EFO_0000768', 'MONDO_0002009'], dtype=object), 'count': 42}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 8 approved and 25 investigational indications. This drug has a black box warning from the FDA."
CHEMBL786,"CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_FQZYTYWMLGAPFJ-OQKDUQJOSA-N_|_Small molecule_|_True_|_TAMOXIFEN CITRATE_|_1977.0_|_4.0_|_CHEMBL83_|_False_|_True_|_['Emblon' 'Fentamox 10' 'Fentamox 20' 'Kentadex' 'Kessar' 'Kessar 10'
 'Kessar 20' 'Noltam' 'Nolvadex' 'Nolvadex d' 'Nolvadex fte'
 'Oestrifen-10' 'Oestrifen-20' 'Oestrifen-40' 'Soltamox' 'Tamofen'
 'Tamoxifen citrate' 'Zynoplex']_|_['I.C.I.46474 CITRATE' 'ICI 46,474' 'ICI-46474' 'Kessar' 'NSC-180973'
 'NSC-757345' 'Nourytam' 'Tamofene' 'Tamoxifen citrate'
 'Tamoxifeni citras' 'Tomaxasta' 'Zemide' 'Zitazonium']_|_[('DailyMed', array(['tamoxifen%20citrate'], dtype=object)), ('PubChem', array(['11112087', '11112088', '124881893', '144204489', '144209268',
       '144210594', '170465425', '17389724', '26747686', '26747687',
       '26747688', '26752019', '447264', '49816809', '50107133',
       '85231332'], dtype=object)), ('chEBI', array(['9397'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001187', 'GO_0042697', 'MONDO_0010679', 'EFO_0003869',
       'EFO_0009907', 'MONDO_0002158', 'EFO_0003843', 'HP_0100543',
       'EFO_1000294', 'EFO_0000536', 'MONDO_0011962', 'EFO_0000294',
       'EFO_0000545', 'EFO_0004248', 'EFO_0000519', 'MONDO_0018364',
       'HP_0000771', 'EFO_0000305', 'EFO_0003833', 'EFO_0009708',
       'EFO_1000158', 'EFO_1001512', 'MONDO_0002087', 'EFO_0000389',
       'MONDO_0002691', 'EFO_0004220', 'MONDO_0004985', 'EFO_1001901',
       'EFO_0000232', 'MONDO_0008170', 'EFO_0000616', 'MONDO_0018848',
       'EFO_0000764', 'EFO_0005543', 'EFO_0006861', 'EFO_0000637',
       'EFO_0001075', 'MONDO_0008315', 'MONDO_0019180', 'EFO_1000251',
       'MONDO_0007254', 'EFO_1001375', 'EFO_0007532', 'MONDO_0004992',
       'MONDO_0100096', 'EFO_0000432', 'Orphanet_145', 'EFO_0000537',
       'MONDO_0004976', 'EFO_1000984', 'EFO_0001416'], dtype=object), 'count': 51}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 4 approved and 47 investigational indications. This drug has a black box warning from the FDA."
CHEMBL80,"C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5_|_UZHSEJADLWPNLE-GRGSLBFTSA-N_|_Small molecule_|_False_|_NALOXONE_|_1971.0_|_4.0_|_nan_|_False_|_True_|_['Nalone' 'Narcan' 'Narcanti']_|_['Dbl naloxone' 'NSC-70413' 'Naloxone' 'Suboxone']_|_[('PubChem', array(['144205559', '170465008'], dtype=object)), ('Wikipedia', array(['Naloxone'], dtype=object)), ('drugbank', array(['DB01183'], dtype=object)), ('chEBI', array(['7459'], dtype=object))]_|_['CHEMBL5315056' 'CHEMBL3186613' 'CHEMBL1718' 'CHEMBL1512507']_|_{'rows': array(['MONDO_0018555', 'EFO_0003843', 'EFO_0003047', 'MONDO_0005147',
       'MONDO_0001583', 'HP_0000989', 'EFO_0005611', 'EFO_0010702',
       'EFO_0005203', 'EFO_0004270', 'EFO_1001051', 'EFO_0006834',
       'HP_0012532', 'EFO_1000785', 'EFO_0005611', 'MONDO_0004565',
       'EFO_0001073', 'EFO_0004699', 'HP_0003419', 'MONDO_0002009',
       'EFO_0005762', 'EFO_0005611', 'EFO_0004240', 'EFO_0000474',
       'HP_0002019', 'MONDO_0005178', 'HP_0002019', 'EFO_0003843',
       'EFO_0000555', 'EFO_0005800', 'MONDO_0004565', 'EFO_0003890',
       'MONDO_0005180', 'EFO_0005612'], dtype=object), 'count': 34}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 29 investigational indications."
CHEMBL1200940,"CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC.Cl.O_|_KJBLQGHJOCAOJP-UHFFFAOYSA-N_|_Small molecule_|_True_|_METOCLOPRAMIDE HYDROCHLORIDE_|_1979.0_|_4.0_|_CHEMBL86_|_False_|_True_|_['""clopra-""""yellow""""""' 'Clopra' 'Clopra-""Yellow""' 'Gastrese l.a.'
 'Gastrobid continus' 'Gastroflux' 'Gastromax' 'Gimoti' 'Maxolon'
 'Maxolon sr' 'Metoclomex' 'Metoclopramide hydrochloride'
 'Metoclopramide intensol' 'Metox' 'Metozolv odt' 'Metramid' 'Mygdalon'
 'Parmid' 'Primperan' 'Reglan' 'Reglan odt']_|_['AHR-3070-C' 'Metipamid' 'Metoclopramide dihydrochloride monohydrate'
 'Metoclopramide hcl monohydrate' 'Metoclopramide hydrochloride'
 'Metoclopramide hydrochloride monohydrate'
 'Metoclopramide monohydrochloride monohydrate'
 'Metoclopramidi hydrochloridum' 'NSC-757117']_|_[('DailyMed', array(['metoclopramide%20hydrochloride'], dtype=object)), ('chEBI', array(['6899'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'HP_0002039', 'EFO_1002048', 'EFO_0004888',
       'EFO_1000948', 'HP_0002013', 'HP_0002017'], dtype=object), 'count': 7}_|_[ENSG00000149295,ENSG00000166736,ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 7 approved indications. This drug has a black box warning from the FDA."
CHEMBL1684984,"CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21_|_JEGHXKRHKHPBJD-UHFFFAOYSA-N_|_Small molecule_|_False_|_IZORLISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CH-5132799' 'CH5132799' 'Ch 5132799' 'Izorlisib' 'PA-799' 'PA799'
 'Pa-799']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object)), ('drugbank', array(['DB13051'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1743008,"nan_|_nan_|_Antibody_|_False_|_DROZITUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ANTI-DR5' 'ANTI-DR5 RHUMAB-DR5' 'Drozitumab' 'PRO-95780' 'RHUMAB DR5'
 'RHUMAB-DR5' 'Usp mab 003, monoclonal igg1']_|_nan_|_nan_|_{'rows': array(['EFO_0000333', 'EFO_0005952', 'EFO_0003060', 'EFO_1001951'],
      dtype=object), 'count': 4}_|_[ENSG00000120889]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1744447,"CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]_|_LALFOYNTGMUKGG-BGRFNVSISA-L_|_Small molecule_|_False_|_ROSUVASTATIN CALCIUM_|_2003.0_|_4.0_|_CHEMBL1496_|_False_|_True_|_['Crestor' 'Ezallor' 'Ezallor sprinkle' 'Rosuvastatin calcium']_|_['Fortius' 'NSC-747274' 'NSC-758930' 'Rostar' 'Rosuvastatin (as calcium)'
 'Rosuvastatin calcium' 'Rosuvastatin calcium salt'
 'Rosuvastatin hemicalcium' 'Rozavel' 'S-4522' 'Suvikan' 'ZD-4522'
 'ZD-4522 (CALCIUM SALT)' 'ZD-4522 CALCIUM' 'ZD4522 (CALCIUM SALT)'
 'ZD4522 CALCIUM']_|_[('DailyMed', array(['rosuvastatin%20calcium'], dtype=object)), ('chEBI', array(['77249'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0003144', 'Orphanet_79211', 'EFO_0003914',
       'EFO_0004911', 'EFO_0005672', 'EFO_0001645', 'EFO_0000400',
       'MONDO_0018473', 'Orphanet_309005', 'MONDO_0005148', 'EFO_0004211',
       'EFO_0000537', 'EFO_0000616', 'MONDO_0021187', 'HP_0003124',
       'EFO_0004239'], dtype=object), 'count': 17}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 approved and 11 investigational indications."
CHEMBL2109248,nan_|_nan_|_Antibody_|_False_|_APOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Apomab']_|_[]_|_nan_|_nan_|_nan_|_[ENSG00000120889]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109326,"nan_|_nan_|_Antibody_|_False_|_MIK-BETA-1_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MIK-BETA-1' 'Mik-beta-1']_|_nan_|_nan_|_{'rows': array(['EFO_0000565'], dtype=object), 'count': 1}_|_[ENSG00000100385]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2364968,"CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12.CCC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12_|_ZQLJWTRXKINMIN-BEJKIDSHSA-N_|_Unknown_|_False_|_ERGOLOID_|_1953.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[]_|_nan_|_['CHEMBL2311030']_|_{'rows': array(['EFO_0004718', 'EFO_0000319', 'MONDO_0010383'], dtype=object), 'count': 3}_|_[ENSG00000178394,ENSG00000135312,ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL3545370,"nan_|_nan_|_Antibody_|_False_|_EMACTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['7i1955n5wx' 'CXD-301' 'CXD301' 'Emactuzumab' 'RG-7155' 'RG7155'
 'RO-5509554' 'RO5509554' 'RO5509554 (ANTI-CSF-R1)']_|_nan_|_nan_|_{'rows': array(['EFO_0005952', 'MONDO_0004992', 'MONDO_0002171', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000182578]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3707393,"N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1.O=P(O)(O)O_|_FMCPYRDGUZBOJZ-BTQNPOSSSA-N_|_Small molecule_|_False_|_OSILODROSTAT PHOSPHATE_|_2020.0_|_4.0_|_CHEMBL3099695_|_False_|_True_|_['Isturisa']_|_['LCI699-AZA' 'Osilodrostat phosphate']_|_[('DailyMed', array(['osilodrostat%20phosphate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/isturisa'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003099', 'EFO_1001110'], dtype=object), 'count': 2}_|_[ENSG00000160882]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for cushing syndrome and pituitary-dependent cushing's disease."
CHEMBL4297422,"CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@@H]1C(=O)Nc2ccccc2-c2ccccc21_|_OJPLJFIFUQPSJR-INIZCTEOSA-N_|_Small molecule_|_False_|_RG-4733_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['RO 4929097' 'RO-4929097' 'Rg 4733' 'Rg-4733' 'Ro4929097']_|_[('drugbank', array(['DB11870'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000365', 'EFO_1000251', 'MONDO_0021063', 'EFO_0000616',
       'EFO_0000756', 'EFO_0001378', 'EFO_0001075', 'EFO_0000673',
       'EFO_0002501', 'EFO_0000349', 'EFO_0005537', 'EFO_1001465',
       'EFO_0000389', 'EFO_1000657', 'EFO_0006861', 'EFO_0002499',
       'MONDO_0007254', 'EFO_0003060'], dtype=object), 'count': 18}_|_[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications."
CHEMBL4297508,"CC(C)C[C@@H](C(=O)Nc1ccn(C[C@@H](O)CO)n1)N1CC(Oc2ccccc2Cl)=CC1=O_|_HMUMWSORCUWQJO-QAPCUYQASA-N_|_Small molecule_|_False_|_DORZAGLIATIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dorzagliatin' 'HMS-5552' 'HMS5552' 'Hms5552' 'RO-5305552' 'RO5305552'
 'Sinogliatin']_|_[('drugbank', array(['DB15123'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001952', 'MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 3}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1200406,"CN(C)CCOC(c1ccccc1)c1ccccc1.Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O_|_NFLLKCVHYJRNRH-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIMENHYDRINATE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Antemin' 'Dimenhydrinate' 'Dramamine' 'Vertigo-vomex s']_|_['Chloranautine' 'Dimenhydrinate' 'NSC-117855']_|_[('DailyMed', array(['dimenhydrinate'], dtype=object)), ('DrugCentral', array(['901'], dtype=object)), ('PubChem', array(['11112942', '144207521', '17389041', '26747407'], dtype=object)), ('Wikipedia', array(['Dimenhydrinate'], dtype=object)), ('drugbank', array(['DB00985'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002321', 'EFO_0004888', 'MONDO_0005271'], dtype=object), 'count': 3}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for allergic disease and has 2 investigational indications."
CHEMBL1201117,"COc1ccccc1OCC(O)COC(N)=O_|_GNXFOGHNGIVQEH-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHOCARBAMOL_|_1957.0_|_4.0_|_nan_|_False_|_True_|_['Delaxin' 'Forbaxin' 'Methocarbamol' 'Miolaxin' 'Neuraxin' 'Robaxin'
 'Robaxin-750']_|_['Methocarbamol' 'NSC-170960']_|_[('DailyMed', array(['methocarbamol'], dtype=object)), ('PubChem', array(['144204005', '170464808', '174006834', '26747217', '26747218',
       '56422407', '855587'], dtype=object)), ('Wikipedia', array(['Methocarbamol'], dtype=object)), ('drugbank', array(['DB00423'], dtype=object)), ('chEBI', array(['77498'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0001422'], dtype=object), 'count': 2}_|_[ENSG00000133742]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 2 investigational indications."
CHEMBL1201520,"nan_|_nan_|_Unknown_|_False_|_UROFOLLITROPIN_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Bravelle' 'Fertinex' 'Fostimon' 'Gonadotraphon fsh' 'Metrodin'
 'Metrodin high purity' 'Orgafol' 'Urofollitrophin']_|_['Fertinorm' 'Follitropin human' 'Urofollitrophin' 'Urofollitropin']_|_[('Wikipedia', array(['Urofollitropin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008560', 'EFO_0000279', 'EFO_0004248', 'MONDO_0002775',
       'EFO_0000545'], dtype=object), 'count': 5}_|_[ENSG00000170820]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 5 investigational indications."
CHEMBL1314751,"CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O_|_DSKIOWHQLUWFLG-SPIKMXEPSA-N_|_Small molecule_|_True_|_PROCHLORPERAZINE MALEATE_|_1956.0_|_4.0_|_CHEMBL728_|_False_|_True_|_['Buccastem' 'Buccastem m' 'Compazine' 'Prochlorperazine maleate'
 'Procomp' 'Proziere' 'Vertigon']_|_['Prochlorperazine dimaleate' 'Prochlorperazine maleate']_|_[('DailyMed', array(['prochlorperazine%20maleate'], dtype=object)), ('PubChem', array(['144207071', '170464761', '50106935'], dtype=object)), ('chEBI', array(['8436'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956. This drug has a black box warning from the FDA."
CHEMBL1444,"N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1_|_HPJKCIUCZWXJDR-UHFFFAOYSA-N_|_Small molecule_|_False_|_LETROZOLE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Femara' 'Letrozole']_|_['CGS 20267' 'CGS-20267' 'Letrozole' 'NSC-759652']_|_[('DailyMed', array(['letrozole'], dtype=object)), ('PubChem', array(['11112889', '124882709', '144204270', '144213877'], dtype=object)), ('Wikipedia', array(['Letrozole'], dtype=object)), ('drugbank', array(['DB01006'], dtype=object)), ('chEBI', array(['6413'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001510', 'EFO_0009708', 'EFO_0000279', 'MONDO_0011972',
       'GO_0042697', 'EFO_0000616', 'MONDO_0018555', 'EFO_1001346',
       'MONDO_0011962', 'EFO_0008509', 'EFO_0000305', 'MONDO_0002715',
       'MONDO_0002775', 'MONDO_0008170', 'EFO_0000466', 'EFO_0000313',
       'EFO_0001065', 'EFO_1001512', 'EFO_0001075', 'EFO_0003833',
       'EFO_0004248', 'EFO_0003060', 'EFO_0000660', 'EFO_0003859',
       'EFO_0005952', 'EFO_0000588', 'EFO_0000432', 'EFO_0000545',
       'EFO_1000251', 'EFO_1000984', 'EFO_0000731', 'EFO_0002950',
       'EFO_0003869', 'EFO_1001757', 'EFO_0000564', 'EFO_0004230',
       'MONDO_0011705', 'HP_0005268', 'Orphanet_145', 'MONDO_0002158',
       'EFO_0003968', 'EFO_0000553', 'MONDO_0007254', 'EFO_0005537',
       'MONDO_0002087', 'EFO_0003882', 'EFO_0001416'], dtype=object), 'count': 47}_|_[ENSG00000137869]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 4 approved and 43 investigational indications."
CHEMBL1742991,"nan_|_nan_|_Antibody_|_False_|_BENRALIZUMAB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Fasenra']_|_['BIW-8405' 'Benralizumab' 'MEDI-563']_|_[('DailyMed', array(['benralizumab'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/fasenra'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0007187', 'HP_0002110', 'EFO_0004232', 'EFO_0007486',
       'MONDO_0021739', 'EFO_0000274', 'MONDO_0004979', 'HP_0001871',
       'EFO_1000391', 'EFO_0005531', 'EFO_0000341', 'EFO_1001467',
       'HP_0006536'], dtype=object), 'count': 13}_|_[ENSG00000091181]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for asthma and airway obstruction and has 11 investigational indications."
CHEMBL1766,"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO_|_VWVSBHGCDBMOOT-IIEHVVJPSA-N_|_Small molecule_|_False_|_DESOXIMETASONE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_['Desoximetasone' 'Stiedex' 'Stiedex lp' 'Stiedex lpn' 'Topicort'
 'Topicort lp']_|_['A-41-304' 'A-41304' 'Desoximetasone' 'Desoxymethasone' 'HOE 304'
 'HOE-304' 'J83.644C' 'NSC-759189' 'R 2113' 'R-2113']_|_[('DailyMed', array(['desoximetasone'], dtype=object)), ('PubChem', array(['144204440', '170464795', '29215017', '56423147', '855924'],
      dtype=object)), ('Wikipedia', array(['Desoximetasone'], dtype=object)), ('drugbank', array(['DB00547'], dtype=object)), ('chEBI', array(['691037'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_1001494', 'EFO_0000701'], dtype=object), 'count': 3}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 3 approved indications."
CHEMBL262747,"CC(=O)Nc1ccc(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(C)=O)C(=O)N[C@H](Cc2ccc(NC(C)=O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(N)=O)cc1_|_ZWNUQDJANZGVFO-YHSALVGYSA-N_|_Protein_|_False_|_ACYLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Acyline' 'MER-104']_|_[('drugbank', array(['DB11906'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002146'], dtype=object), 'count': 1}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL276520,"c1ccc2c(CCC3CCNCC3)c[nH]c2c1_|_SADQVAVFGNTEOD-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDALPINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Indalpine' 'LM-5008']_|_[('Wikipedia', array(['Indalpine'], dtype=object)), ('drugbank', array(['DB08953'], dtype=object))]_|_['CHEMBL2362557']_|_nan_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL3039518,"COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12_|_URWYQGVSPQJGGB-DHUJRADRSA-N_|_Small molecule_|_False_|_BATEFENTEROL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Batefenterol' 'GSK-961081' 'GSK-961081A' 'GSK961081' 'GSK961081A'
 'TD-5959']_|_[('drugbank', array(['DB12526'], dtype=object))]_|_['CHEMBL3039512']_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000169252,ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545083,"COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1_|_XLSYZSRXVVCHLS-UHFFFAOYSA-N_|_Small molecule_|_False_|_RGB-286638_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['RGB 286638' 'Rgb-286638']_|_nan_|_nan_|_{'rows': array(['EFO_0001642'], dtype=object), 'count': 1}_|_[ENSG00000134058,ENSG00000170312,ENSG00000136807,ENSG00000123374,ENSG00000164885,ENSG00000135446]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545368,"CC(O)C(=O)O.Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1_|_XVDWNSFFSMWXJJ-ASTDGNLGSA-N_|_Small molecule_|_True_|_PANOBINOSTAT LACTATE_|_2015.0_|_4.0_|_CHEMBL483254_|_False_|_True_|_['Farydak']_|_['Panobinostat lactate' 'Panobinostat lactate anhydrous']_|_[('DailyMed', array(['panobinostat%20lactate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/farydak'],
      dtype=object)), ('chEBI', array(['85991'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378'], dtype=object), 'count': 1}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015 and is indicated for multiple myeloma. This drug has a black box warning from the FDA."
CHEMBL3545372,"nan_|_nan_|_Antibody drug conjugate_|_False_|_SOFITUZUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-MUC16 ADC' 'DMUC-5754A' 'DMUC5754A' 'RG-7458' 'Sofituzumab vedotin']_|_nan_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0002618'], dtype=object), 'count': 2}_|_[ENSG00000181143,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3644252,"Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)n1_|_JUPOTOIJLKDAPF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ARRY-382_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Arry-382']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000182578]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3669417,"N#Cc1ccc2c(c1)[C@H]1CCCN(C(=O)c3ccc4[nH]cnc4c3)[C@H]1C2_|_VVZNCSHIBODHMZ-UZLBHIALSA-N_|_Small molecule_|_False_|_BI-187004_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bi 187004' 'Bi-187004']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL369075,"NC(=O)c1cnc2n1CCc1ccccc1C21CCNCC1_|_VQWGYPVNVICKFC-UHFFFAOYSA-N_|_Small molecule_|_False_|_VAPITADINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Vapitadine']_|_[('drugbank', array(['DB05738'], dtype=object))]_|_['CHEMBL539843' 'CHEMBL1203919']_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3912251,"Cc1cc(C(=O)O)ccc1COc1cc2c(cc1N(CC(C)C)S(=O)(=O)c1nccs1)CCC2_|_ALLLQQUASFFEKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ONO-8539_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ONO-8539' 'Ono-8539']_|_[('drugbank', array(['DB15325'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003948', 'EFO_1000781'], dtype=object), 'count': 2}_|_[ENSG00000160951]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3989936,"C[C@]12C[C@H](c3ccc(S(C)(=O)=O)cc3)C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C(F)(F)C(F)(F)F_|_JUFWQQVHQFDUOD-ANRPBIDPSA-N_|_Small molecule_|_False_|_VILAPRISAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BAY-1002670' 'BAY1002670' 'Vilaprisan']_|_[('drugbank', array(['DB11971'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001065', 'MONDO_0001572', 'EFO_0000731'], dtype=object), 'count': 3}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4084119,"CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O_|_YSDQQAXHVYUZIW-QCIJIYAXSA-N_|_Protein_|_True_|_LIRAGLUTIDE_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Saxenda' 'Victoza']_|_['Liraglutide' 'Liraglutide (rdna origin)' 'NN-2211' 'NN-9924' 'NN2211'
 'NN9924' 'NNC 90-1170' 'NNC-90-1170']_|_[('DailyMed', array(['liraglutide', 'liraglutide%20recombinant'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015183', 'MONDO_0005148', 'EFO_0002546', 'EFO_0005935',
       'EFO_0001073', 'MONDO_0004975', 'EFO_0003921', 'MONDO_0002009',
       'EFO_0004319', 'EFO_0003144', 'HP_0003074', 'EFO_0000400',
       'EFO_0003877', 'HP_0001824', 'EFO_1001121', 'MONDO_0005180',
       'MONDO_0004985', 'EFO_0000401', 'EFO_0000195', 'EFO_1001249',
       'Orphanet_552', 'EFO_0005203', 'EFO_0005611', 'MONDO_0005147'],
      dtype=object), 'count': 24}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 5 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297631,"CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c21_|_RRTPWQXEERTRRK-UHFFFAOYSA-N_|_Small molecule_|_False_|_TELRATOLIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['3M-052' 'MEDI9197' 'Medi 9197' 'Medi-9197' 'Medi9197' 'Telratolimod']_|_nan_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_0000180', 'EFO_0002913'], dtype=object), 'count': 3}_|_[ENSG00000196664,ENSG00000101916]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297684,"nan_|_nan_|_Protein_|_False_|_ABICIPAR PEGOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AGN-150998' 'Abicipar pegol' 'Agn-150998' 'MP-0112' 'MP-0260' 'MP0112'
 'Mp0112' 'P7FHD7AG35' 'Vegf-a binding darpin']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ABICIPAR%20PEGOL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004683', 'MONDO_0003005', 'EFO_0009606', 'EFO_0005753',
       'EFO_0001365'], dtype=object), 'count': 5}_|_[ENSG00000112715]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297717,"nan_|_nan_|_Unknown_|_False_|_CD24FC_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cd24fc' 'Cd24igg1fc' 'Efprezimod alfa' 'MK-7110' 'Saccovid']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0100096', 'EFO_0002617'], dtype=object), 'count': 3}_|_[ENSG00000204389,ENSG00000204388,ENSG00000142512,ENSG00000189403,ENSG00000080824,ENSG00000096384]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4650280,"Cc1cnc(NC2CCOCC2)nc1-n1cnc(C(=O)N[C@H](CN)c2cc(F)cc(Cl)c2)c1_|_PWHIUQBBGPGFFV-GOSISDBHSA-N_|_Small molecule_|_False_|_ASN007_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ASN007' 'Asn007']_|_nan_|_nan_|_nan_|_[ENSG00000102882,ENSG00000100030]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL4802150,"Nc1cc(S(=O)(=O)c2ccc(OC(F)(F)F)cc2)cnc1-c1nnc(CO)o1_|_WOXOLLSAICIZNO-UHFFFAOYSA-N_|_Small molecule_|_False_|_NAVOCAFTOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-3067' 'Abbv-3067' 'GLPG-3067' 'GLPG3067' 'Navocaftor']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NAVOCAFTOR/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL49642,"O=C(Nc1ccncc1)C(=O)c1cn(Cc2ccc(Cl)cc2)c2ccccc12_|_SOLIIYNRSAWTSQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDIBULIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['D-24851' 'Indibulin' 'ZIO-301']_|_[('PubChem', array(['174007308'], dtype=object)), ('drugbank', array(['DB06169'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004992', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL54,"O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1_|_LNEPOXFFQSENCJ-UHFFFAOYSA-N_|_Small molecule_|_True_|_HALOPERIDOL_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Dolpin' 'Dozic' 'Fortunan' 'Haldol' 'Haldol solutab' 'Haloperidol'
 'Kentace' 'Keselen' 'Serenace']_|_['Haloperidol' 'Haloperidol decanoate impurity, haloperidol-'
 'MCN-JR-1625' 'NSC-170973' 'NSC-615296' 'R-1625']_|_[('DailyMed', array(['haloperidol'], dtype=object)), ('PubChem', array(['104171168', '11111260', '11112116', '11113356', '124880286',
       '124880288', '124880291', '124880292', '144203713', '144210793',
       '170464841', '26747061', '26747062', '26751574', '26751575',
       '487337', '50100251', '50104201', '50104202', '56422397',
       '85231072', '855969', '90341418'], dtype=object)), ('TG-GATEs', array(['36'], dtype=object)), ('Wikipedia', array(['Haloperidol'], dtype=object)), ('drugbank', array(['DB00502'], dtype=object)), ('chEBI', array(['5613'], dtype=object))]_|_['CHEMBL2096643' 'CHEMBL4297147' 'CHEMBL1160253' 'CHEMBL545608'
 'CHEMBL2234294']_|_{'rows': array(['MONDO_0005090', 'EFO_0005407', 'EFO_0005411', 'EFO_0005230',
       'EFO_0009267', 'EFO_0005323', 'HP_0000713', 'EFO_0000677',
       'MONDO_0004985', 'EFO_0004895', 'MONDO_0007739', 'MONDO_0002050',
       'HP_0002018', 'EFO_0005411', 'EFO_0004701', 'EFO_0004247',
       'EFO_0004216', 'EFO_0003768', 'MONDO_0005090', 'HP_0000713',
       'HP_0000726', 'EFO_0009954', 'MONDO_0004975', 'HP_0100033',
       'EFO_0003015'], dtype=object), 'count': 25}_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA."
CHEMBL727,"Nc1nc2[nH]cnc2c(=S)[nH]1_|_WYWHKKSPHMUBEB-UHFFFAOYSA-N_|_Small molecule_|_False_|_THIOGUANINE_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Lanvis' 'Tabloid' 'Thioguanine']_|_['NSC-752' 'NSC-76504' 'Thioguanine' 'Thioguanine anhydrous'
 'Thioguanine hemihydrate' 'Thioguanine, anhydrous' 'Tioguanine'
 'Tioguanine hemihydrate']_|_[('PubChem', array(['144204586', '144206735', '144209599', '144210595', '170464908',
       '174007001', '26748270', '538243', '57260104', '57264437'],
      dtype=object)), ('Wikipedia', array(['Tioguanine'], dtype=object)), ('drugbank', array(['DB00352'], dtype=object)), ('chEBI', array(['9555'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000183', 'EFO_0003027', 'EFO_0000519', 'EFO_0000198',
       'EFO_0003811', 'MONDO_0001657', 'EFO_0000565', 'EFO_0000209',
       'EFO_0003025', 'MONDO_0000873', 'EFO_0003833', 'EFO_0004251',
       'EFO_0000574', 'EFO_1000318', 'EFO_0005952', 'EFO_0003029',
       'EFO_0000616', 'MONDO_0000870', 'EFO_0000220', 'EFO_0000222',
       'EFO_0000223', 'EFO_0000218', 'EFO_0004289', 'EFO_1001779',
       'EFO_0000221', 'EFO_0003802', 'MONDO_0044917'], dtype=object), 'count': 27}_|_[ENSG00000106348,ENSG00000178035]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and is indicated for neoplasm and has 26 investigational indications."
CHEMBL838,"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O_|_XPCFTKFZXHTYIP-PMACEKPBSA-N_|_Small molecule_|_True_|_BENAZEPRIL_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Benazepril' 'Benazepril sandoz' 'Briem' 'C09AA07' 'CGS-14824A'
 'Cibacen ws' 'Cibacene' 'Forteekor' 'Lotensin' 'Lotrel']_|_[('Wikipedia', array(['Benazepril'], dtype=object)), ('drugbank', array(['DB00542'], dtype=object)), ('chEBI', array(['3011'], dtype=object))]_|_['CHEMBL1694']_|_{'rows': array(['EFO_1002048', 'EFO_0000712', 'EFO_0000319', 'EFO_0001645',
       'HP_0003124', 'EFO_0003086', 'EFO_0000400', 'EFO_0003914',
       'MONDO_0010520', 'Orphanet_79292', 'MONDO_0007915', 'EFO_1000965',
       'MONDO_0005148', 'EFO_0000400', 'EFO_0000537', 'EFO_0000537',
       'MONDO_0018965'], dtype=object), 'count': 17}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 5 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1018,"C/C=C(C(=C/C)/c1ccc(O)cc1)\c1ccc(O)cc1_|_NFDFQCUYFHCNBW-SCGPFSFSSA-N_|_Small molecule_|_False_|_DIENESTROL_|_1947.0_|_4.0_|_nan_|_False_|_True_|_['Dienestrol' 'Estraguard' 'Hormofemin']_|_['.alpha.-dienestrol diacetate' 'Cycladiene' 'Dehydrostilbestrol'
 'Dienestrol' 'Dienestrol diacetate, .alpha.-' 'Dienestrol trans-form'
 'Dienestrol, .alpha.-' 'Dienoestrol' 'Dienol' 'Dinovex' 'Estragard'
 'Estroral' 'Follidiene' 'Gynefollin' 'NSC-59809' 'Oestrasid'
 'Oestrodiene' 'Oestroral' 'Restrol' 'Retalon']_|_[('PubChem', array(['124883370', '144203929', '170465362', '26746961', '56422141',
       '855694'], dtype=object)), ('Wikipedia', array(['Dienestrol'], dtype=object)), ('drugbank', array(['DB00890'], dtype=object))]_|_nan_|_nan_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1947."
CHEMBL1021,"NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N_|_QEFAQIPZVLVERP-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEPAFENAC_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Ilevro' 'Nepafenac' 'Nevanac']_|_['AHR-9434' 'AL-6515' 'Nepafenac']_|_[('DailyMed', array(['nepafenac'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac'],
      dtype=object)), ('PubChem', array(['124896627', '144206538', '170465203'], dtype=object)), ('Wikipedia', array(['Nepafenac'], dtype=object)), ('drugbank', array(['DB06802'], dtype=object)), ('chEBI', array(['75922'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000616', 'MONDO_0005129', 'MONDO_0003005', 'EFO_0005752',
       'MP_0001845', 'EFO_0003843'], dtype=object), 'count': 6}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 4 approved and 2 investigational indications."
CHEMBL1200516,"CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O.Cl_|_UPRWQSQENCASAD-HBBGHHHDSA-N_|_Protein_|_False_|_GONADORELIN HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1007_|_False_|_True_|_['Factrel']_|_['AY-24,031' 'AY-24031' 'Gonadorelin hcl' 'Gonadorelin hydrochloride'
 'Luteinizing hormone-releasing factor dihydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200804,"O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[K+]_|_KXZOIWWTXOCYKR-UHFFFAOYSA-M_|_Small molecule_|_True_|_DICLOFENAC POTASSIUM_|_1993.0_|_4.0_|_CHEMBL139_|_False_|_True_|_['Cambia' 'Cataflam' 'Diclofenac potassium' 'Voltarol joint pain'
 'Voltarol pain-eze' 'Voltarol pain-eze extra strgh' 'Voltarol rapid'
 'Zipsor']_|_['CGP 45840B' 'CGP-45840B' 'Diclofenac potassium'
 'Diclofenac potassium salt' 'Potassium diclofenac']_|_[('DailyMed', array(['diclofenac%20potassium'], dtype=object)), ('chEBI', array(['4508'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_1001139', 'EFO_0003843', 'HP_0100607',
       'EFO_0010072', 'MONDO_0005178', 'EFO_0009454', 'MONDO_0005277'],
      dtype=object), 'count': 8}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and has 4 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201438,"nan_|_nan_|_Protein_|_True_|_ALDESLEUKIN_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Proleukin']_|_['Aldesleukin' 'Human interleukin-2' 'Human interleukin-2 125-serine'
 'ILT-101' 'Il2 (2-133) c125s' 'Ilt-101' 'Ilt-101 (low dose il-2)'
 'Interleukin 2' 'Interleukin-2' 'Interleukin-2 aldesleukin'
 'Interleukin-2(2-133),125-ser' 'Recombinant interleukin-2 human']_|_[('DailyMed', array(['aldesleukin'], dtype=object)), ('DrugCentral', array(['5011'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000564', 'EFO_0000673', 'EFO_1000954', 'EFO_0005672',
       'EFO_0003780', 'EFO_0000565', 'EFO_0000616', 'EFO_0000389',
       'EFO_0000223', 'EFO_0009709', 'EFO_0009708', 'EFO_0004251',
       'EFO_0000222', 'EFO_0004599', 'EFO_0001062', 'EFO_0003811',
       'EFO_0004719', 'EFO_0000783', 'MONDO_0100096', 'EFO_0000691',
       'EFO_0002617', 'EFO_1000251', 'EFO_0003865', 'EFO_0000403',
       'MONDO_0020547', 'MONDO_0004975', 'EFO_0000313', 'MONDO_0001187',
       'EFO_0000681', 'EFO_0003025', 'EFO_0001378', 'MONDO_0002367',
       'EFO_0000220', 'EFO_1001375', 'EFO_0000729', 'MONDO_0007915',
       'EFO_1001051', 'EFO_0005531', 'EFO_0008518', 'EFO_0000339',
       'EFO_0000588', 'MONDO_0007254', 'MONDO_0002108', 'MONDO_0007576',
       'EFO_0000574', 'MONDO_0024475', 'EFO_0000182', 'MONDO_0002087',
       'MONDO_0019956', 'EFO_0000765', 'EFO_0000699', 'EFO_1001148',
       'EFO_0001061', 'EFO_0000180', 'EFO_1001806', 'EFO_1000984',
       'EFO_0000183', 'EFO_0001075', 'MONDO_0013730', 'MONDO_0002158',
       'MONDO_0018906', 'MONDO_0008170', 'EFO_1000158', 'EFO_0000398',
       'MONDO_0004992', 'EFO_0008528', 'EFO_0004255', 'EFO_1000131',
       'EFO_0000198', 'MONDO_0008903', 'MONDO_0020077', 'EFO_0003060',
       'EFO_0000095', 'EFO_1001471', 'MONDO_0008315', 'EFO_0000571',
       'MONDO_0044881', 'EFO_0003869', 'EFO_0006861', 'EFO_0005846',
       'EFO_1000785', 'EFO_0005952', 'EFO_0000756', 'EFO_0003029',
       'EFO_0007141', 'EFO_0000309', 'EFO_0000621', 'EFO_0000349',
       'EFO_0001668', 'MONDO_0002691', 'MONDO_0004976', 'EFO_0003027',
       'MONDO_0002898', 'EFO_0000764', 'HP_0001871', 'EFO_0004192',
       'EFO_0002428', 'EFO_0001376', 'EFO_0000218', 'EFO_0000384',
       'EFO_0000708', 'EFO_0006859', 'EFO_0003893', 'EFO_0003047',
       'EFO_1001951', 'EFO_1001264', 'EFO_1001779', 'EFO_0000096',
       'MONDO_0010518', 'EFO_0003802', 'EFO_1001465', 'MONDO_0005147',
       'EFO_0000221'], dtype=object), 'count': 113}_|_[ENSG00000134460,ENSG00000147168,ENSG00000100385]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 5 approved and 108 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1558,"COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl_|_WFXFYZULCQKPIP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRAZOSIN HYDROCHLORIDE_|_1976.0_|_4.0_|_CHEMBL2_|_False_|_True_|_['Alphavase 0.5' 'Alphavase 1' 'Alphavase 2' 'Alphavase 5' 'Hypovase'
 'Hypovase b.d.' 'Kentovace' 'Minipress' 'Minipress xl'
 'Prazosin hydrochloride']_|_['CP-12,299-1' 'CP-12299-1' 'NSC-292810' 'Prazosin hcl'
 'Prazosin hydrochloride']_|_[('DailyMed', array(['prazosin%20hydrochloride'], dtype=object)), ('PubChem', array(['26747647', '26747648', '50106894', '50106895', '50106896',
       '56462999', '572084', '855727'], dtype=object)), ('chEBI', array(['8365'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for hypertension and diabetes mellitus."
CHEMBL1568057,"CC(C)NCC(O)c1cc(O)cc(O)c1.CC(C)NCC(O)c1cc(O)cc(O)c1.O=S(=O)(O)O_|_MKFFGUZYVNDHIH-UHFFFAOYSA-N_|_Small molecule_|_False_|_METAPROTERENOL SULFATE_|_1973.0_|_4.0_|_CHEMBL776_|_True_|_True_|_['Alupent' 'Alupent obstetric' 'Metaproterenol sulfate' 'Prometa']_|_['Metaproterenol sulfate' 'Metaproterenol sulphate'
 'Orciprenaline sulfate' 'Orciprenaline sulphate' 'TH-152']_|_[('PubChem', array(['170466142', '50106554'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003890', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for asthma and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL1615779,"N=C(N)NCc1cccc([131I])c1_|_PDWUPXJEEYOOTR-JRGAVVOBSA-N_|_Small molecule_|_False_|_IOBENGUANE I 131_|_2018.0_|_4.0_|_CHEMBL818_|_False_|_True_|_['Azedra']_|_['(131i)-mibg' '131 i-mibg' '131i-mibg' '3-iodobenzylguanidine (131i)'
 '3-iodobenzylguanidine, i-131' 'I-131 metaiodobenzylguanidine'
 'Iobenguane (131 i)' 'Iobenguane (131i)' 'Iobenguane i 131'
 'Iobenguane, i-131' 'Iodine (131i) iobenguane' 'M131ibg'
 'Metaiodobenzylguanidine i-131' 'Mibg i-131']_|_[('DailyMed', array(['iobenguane%20i-131'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0024503', 'EFO_1000453', 'EFO_0000621', 'EFO_0000239'],
      dtype=object), 'count': 4}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 1 investigational indication."
CHEMBL1743054,"nan_|_nan_|_Antibody_|_False_|_OZORALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATN 103' 'ATN-103' 'Ozoralizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000685'], dtype=object), 'count': 1}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1762,"Cc1cccc(C)c1NC(=O)C(C)N_|_BUJAGSGYPOAWEI-UHFFFAOYSA-N_|_Small molecule_|_True_|_TOCAINIDE_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Tocainide' 'W-36095']_|_[('PubChem', array(['90341559'], dtype=object)), ('Wikipedia', array(['Tocainide'], dtype=object)), ('drugbank', array(['DB01056'], dtype=object)), ('chEBI', array(['9611'], dtype=object))]_|_['CHEMBL1200773']_|_{'rows': array(['EFO_0004269'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for cardiac arrhythmia. This drug has a black box warning from the FDA."
CHEMBL189676,"CCc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1_|_HMXDWDSNPRNUKI-UHFFFAOYSA-N_|_Small molecule_|_False_|_SURINABANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SR-147778' 'Sr147778' 'Surinabant']_|_[('PubChem', array(['144210559'], dtype=object)), ('Wikipedia', array(['Surinabant'], dtype=object)), ('drugbank', array(['DB13070'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'EFO_0004319'], dtype=object), 'count': 2}_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2096631,"O=C([O-])C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O.[K+].[K+].[OH-]_|_QCHSEDTUUKDTIG-UHFFFAOYSA-L_|_Small molecule_|_True_|_CLORAZEPATE DIPOTASSIUM_|_1972.0_|_4.0_|_CHEMBL1213252_|_False_|_True_|_['Clorazepate dipotassium' 'Gen-xene' 'Tranxene' 'Tranxene sd']_|_['4306 CB' '4306-CB' '4306CB' 'AB 35616' 'ABBOTT-35616' 'CB 4306'
 'CM 4306' 'Clorazepate dipotassium' 'Clorazepate dipotassium civ'
 'Clorazepic acid dipotassium salt' 'Dipotassium clorazepate'
 'Potassium Clorazepate' 'TR 19119']_|_[('DailyMed', array(['clorazepate%20dipotassium'], dtype=object)), ('chEBI', array(['3762'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001250', 'EFO_0006788'], dtype=object), 'count': 2}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for seizure and anxiety disorder. This drug has a black box warning from the FDA."
CHEMBL2108328,"nan_|_nan_|_Protein_|_False_|_AMILOMOTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amilomotide' 'CAD-106' 'CAD106' 'Cad106']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000142192]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108986,"nan_|_nan_|_Protein_|_False_|_ARGIPRESSIN TANNATE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Argipressin' 'Argipressin tannate' 'CI-107']_|_nan_|_nan_|_nan_|_[ENSG00000126895,ENSG00000166148,ENSG00000198049]_|_Protein drug with a maximum clinical trial phase of IV."
CHEMBL2109434,"nan_|_nan_|_Antibody_|_False_|_IMC-GP100_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['IMC-GP100']_|_nan_|_nan_|_nan_|_[ENSG00000185664,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug."
CHEMBL2109475,"nan_|_nan_|_Antibody_|_False_|_PG-102_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PG-102' 'Pg-102']_|_nan_|_nan_|_{'rows': array(['EFO_0003778'], dtype=object), 'count': 1}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2355456,"CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.CCCCCCCN(CC)CCCC(O)c1ccc(NS(C)(=O)=O)cc1.O=C(O)/C=C/C(=O)O_|_PCIOHQNIRPWFMV-WXXKFALUSA-N_|_Small molecule_|_True_|_IBUTILIDE FUMARATE_|_1995.0_|_4.0_|_CHEMBL533_|_False_|_True_|_['Corvert' 'Ibutilide fumarate']_|_['Ibutilide fumarate' 'U-70226E']_|_[('DailyMed', array(['ibutilide%20fumarate'], dtype=object)), ('PubChem', array(['144206557'], dtype=object))]_|_nan_|_nan_|_[ENSG00000055118]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1995. This drug has a black box warning from the FDA."
CHEMBL317052,"CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1_|_LZPZPHGJDAGEJZ-AKAIJSEGSA-N_|_Small molecule_|_False_|_REGADENOSON ANHYDROUS_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Lexiscan']_|_['Regadenoson anhydrous']_|_[('PubChem', array(['170465244'], dtype=object)), ('drugbank', array(['DB06213'], dtype=object))]_|_['CHEMBL3989695']_|_{'rows': array(['EFO_0001645', 'EFO_1001154', 'EFO_0000319', 'MONDO_0011382'],
      dtype=object), 'count': 4}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and is indicated for cardiovascular disease and has 3 investigational indications."
CHEMBL3360203,"COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1_|_QINPEPAQOBZPOF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PILARALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pilaralisib' 'SAR-245408' 'SAR245408' 'Sar-245408' 'XL-147' 'XL147']_|_[('drugbank', array(['DB11772'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000519', 'EFO_0004230', 'EFO_0003060',
       'MONDO_0011962', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0007254'],
      dtype=object), 'count': 8}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."
CHEMBL3545137,"Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1_|_YFNWWNRZJGMDBR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-00477736_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PF-00477736' 'PF-477736' 'PF477736' 'Pf 477736' 'Pf-00477736']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000149554]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545191,"nan_|_nan_|_Antibody_|_False_|_EVINACUMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Evkeeza']_|_['Evinacumab' 'Evinacumab dgnb' 'REGN-1500' 'REGN1500']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evkeeza'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0003124', 'EFO_0000589', 'EFO_0000319', 'EFO_0004911',
       'EFO_0004211', 'MONDO_0018328'], dtype=object), 'count': 6}_|_[ENSG00000132855]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 2 investigational indications."
CHEMBL3545343,"nan_|_nan_|_Small molecule_|_False_|_ADC3680_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ADC3680B' 'Adc3680']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707395,"CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1_|_AFLFKFHDSCQHOL-IZZDOVSWSA-N_|_Small molecule_|_False_|_ELAFIBRANOR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Elafibranor' 'GFT-505' 'GFT505' 'Gft505']_|_[('drugbank', array(['DB05187'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001486', 'EFO_0003095', 'EFO_0004268', 'MONDO_0005148',
       'EFO_1001248', 'EFO_0001421'], dtype=object), 'count': 6}_|_[ENSG00000186951,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL400599,"CC(Cc1cccc(C(F)(F)F)c1)NCCOC(=O)c1ccccc1_|_CJAVTWRYCDNHSM-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENFLUOREX_|_1974.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Benfluorex' 'Mediaxal' 'NSC-757396']_|_[('PubChem', array(['56320700'], dtype=object)), ('Wikipedia', array(['Benfluorex'], dtype=object)), ('drugbank', array(['DB09022'], dtype=object))]_|_['CHEMBL1412305']_|_{'rows': array(['EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000057252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for diabetes mellitus and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL4297213,"CC(=O)O.CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C_|_LBIUKNXYUXOWFF-CRYSLBJVSA-N_|_Protein_|_False_|_AFAMELANOTIDE ACETATE_|_2014.0_|_4.0_|_CHEMBL441738_|_False_|_True_|_['Scenesse']_|_['A-melanotropin, 4(nle)-7(d-phe)' 'Afamelanotide acetate'
 'Afamelanotide triacetate' 'CUV1647 ACETATE']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000258839]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2014."
CHEMBL4297562,"nan_|_nan_|_Unknown_|_False_|_DKN-01_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DKN-01' 'DKN01' 'Dkn 01' 'Dkn-01' 'LY-2812176' 'LY2812176' 'Sirexatamab']_|_nan_|_nan_|_{'rows': array(['EFO_0001378', 'MONDO_0008315', 'EFO_0000182', 'MONDO_0011962',
       'MONDO_0003060'], dtype=object), 'count': 5}_|_[ENSG00000107984]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4594462,"nan_|_nan_|_Protein_|_False_|_BATIRAXCEPT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AVB S6 500' 'AVB-500' 'AVB-S6-500' 'AVBS6500' 'Aravive-S6' 'Avb-s6-500'
 'Axl fc fusion protein avb-s6-500' 'Batiraxcept' 'Ruga-S6' 'S6-500c']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BATIRAXCEPT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008528', 'EFO_0000616', 'MONDO_0002715', 'EFO_0003893',
       'EFO_0000349', 'MONDO_0008170', 'EFO_0004194'], dtype=object), 'count': 7}_|_[ENSG00000183087]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4650478,"nan_|_nan_|_Oligonucleotide_|_False_|_SAPABLURSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['IONIS-TMPRSS6-LRx' 'ISIS 702843' 'ISIS-702843' 'Ionis tmprss6-lrx'
 'Sapablursen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SAPABLURSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001996', 'Orphanet_848', 'MONDO_0016487', 'EFO_0002429'],
      dtype=object), 'count': 4}_|_[ENSG00000187045]_|_Oligonucleotide drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL5314393,"CC(C)(CN1CCN(C2=Nc3ccccc3Oc3ccccc32)CC1)C(=O)O_|_UEFWDVMEDFCHGW-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY2624803_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DB-7' 'HY-10275' 'LY2624803' 'Ly-2624803' 'Ly2624803']_|_nan_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0008568'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1055,"NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl_|_JIVPVXMEBJLZRO-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORTHALIDONE_|_1960.0_|_4.0_|_nan_|_False_|_True_|_['Chlorthalidone' 'Hygroton' 'Thalitone']_|_['Chlortalidone' 'Chlortalidonum' 'Chlorthalidone' 'G-33182' 'NSC-69200'
 'Natriuran' 'Phthalamudine']_|_[('DailyMed', array(['chlorthalidone'], dtype=object)), ('PubChem', array(['11532862', '170464745', '26747917'], dtype=object)), ('Wikipedia', array(['Chlortalidone'], dtype=object)), ('drugbank', array(['DB00310'], dtype=object)), ('chEBI', array(['3654'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004255', 'EFO_0000537', 'HP_0003124', 'EFO_0003144',
       'EFO_0000400', 'EFO_0003777', 'EFO_0003763', 'EFO_0004278',
       'EFO_0001645', 'MONDO_0005147', 'MONDO_0001134', 'EFO_0003914',
       'EFO_1001375', 'EFO_0000319', 'EFO_0000612', 'MONDO_0005148',
       'MONDO_0002462', 'EFO_0000373', 'EFO_0003884', 'EFO_0000668',
       'EFO_0003913'], dtype=object), 'count': 21}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 9 approved and 12 investigational indications."
CHEMBL1200806,"COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+]_|_CDBRNDSHEYLDJV-FVGYRXGTSA-M_|_Small molecule_|_True_|_NAPROXEN SODIUM_|_1980.0_|_4.0_|_CHEMBL154_|_False_|_True_|_['Aleve' 'Anaprox' 'Anaprox ds' 'Naprelan' 'Naproxen sodium' 'Synflex']_|_['BAY-117031' 'BAY117031' 'BAYH6689' 'Naproxen sodium'
 'Naproxen sodium anhydrous' 'Naproxen sodium salt' 'RS-3650']_|_[('DailyMed', array(['naproxen%20sodium'], dtype=object)), ('PubChem', array(['11112047', '11113013', '144204325', '170465301', '50106619',
       '85231338', '855887'], dtype=object)), ('chEBI', array(['7477'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003898', 'EFO_0009454', 'MONDO_0002258', 'EFO_0010072',
       'EFO_0003843', 'EFO_0004274', 'MONDO_0005178', 'EFO_0004616',
       'EFO_0002609', 'MONDO_0004975', 'HP_0002315', 'MONDO_0005277',
       'MONDO_0002471', 'MONDO_0003937', 'EFO_1001434', 'HP_0003418',
       'EFO_0000685', 'EFO_1000941', 'HP_0100607'], dtype=object), 'count': 19}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 14 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1256717,"Cc1cc(C)c(NC(=O)C[C@H](CC(=O)O)c2cccc3ccccc23)c(C(=O)N2CCC3(CCCC3)CC2)c1_|_MFOOVZCXWVAWOV-RUZDIDTESA-N_|_Small molecule_|_False_|_ITRIGLUMIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cr-2945' 'Itriglumide']_|_[('PubChem', array(['50111121'], dtype=object))]_|_['CHEMBL1335406']_|_nan_|_[ENSG00000110148]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL128748,"COc1ccc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(OC)c(OC)c2)cc1OC_|_ZMGUKFHHNQMKJI-CIOHCNBKSA-N_|_Small molecule_|_False_|_DIMETHYLCURCUMIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASCJ-9' 'CHC-004' 'Dimethylcurcumin' 'GO-Y-025' 'Go-Y025']_|_[('drugbank', array(['DB06133'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003894'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1522,"CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1_|_GBBSUAFBMRNDJC-INIZCTEOSA-N_|_Small molecule_|_True_|_ESZOPICLONE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Eszopiclone' 'Lunesta']_|_['(S)-ZOPICLONE' '(S)-Zopiclone' 'Estorra' 'Eszopiclon' 'Eszopiclone'
 'Eszopiclone civ' 'GSK-1755165' 'Zopiclone s-form']_|_[('DailyMed', array(['eszopiclone'], dtype=object)), ('PubChem', array(['144205286', '170465445', '29215492', '49666409'], dtype=object)), ('Wikipedia', array(['Eszopiclone'], dtype=object)), ('drugbank', array(['DB00402'], dtype=object)), ('chEBI', array(['53760'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_1001892', 'EFO_0007191', 'EFO_0003918'],
      dtype=object), 'count': 4}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for insomnia and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL208427,"O=C(O)c1cccc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)c1_|_LLDXOPKUNJTIRF-QFIPXVFZSA-N_|_Small molecule_|_False_|_SOLABEGRON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gw427353' 'Solabegron']_|_[('drugbank', array(['DB06190'], dtype=object))]_|_['CHEMBL2107299']_|_{'rows': array(['EFO_1000781'], dtype=object), 'count': 1}_|_[ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108018,"nan_|_nan_|_Antibody_|_False_|_ADECATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adecatumumab' 'MT-201']_|_nan_|_nan_|_{'rows': array(['EFO_1001951'], dtype=object), 'count': 1}_|_[ENSG00000119888]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2108309,"nan_|_nan_|_Oligonucleotide_|_False_|_CUSTIRSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Custirsen' 'ISIS-112989 FREE ACID' 'OGX-011 FREE ACID']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0008315', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000120885]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2109582,nan_|_nan_|_Antibody_|_False_|_81C6 131I_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['81C6' '81c6 131i']_|_nan_|_nan_|_nan_|_[ENSG00000041982]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL269864,"O=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12_|_AFNHHLILYQEHKK-BDAKNGLRSA-N_|_Small molecule_|_False_|_ULODESINE_|_nan_|_2.0_|_nan_|_False_|_False_|_['Bcx-4208']_|_['BCX-3408' 'BCX4208' 'Dadme-immucillin h' 'R-3421' 'Ulodesine']_|_[('drugbank', array(['DB12353'], dtype=object))]_|_['CHEMBL2107835' 'CHEMBL1213653']_|_{'rows': array(['MONDO_0005178', 'EFO_0004274', 'EFO_0009104'], dtype=object), 'count': 3}_|_[ENSG00000198805]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL281764,"CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N_|_WURGZWOTGMLDJP-ZCYANPAGSA-N_|_Small molecule_|_False_|_TABIMORELIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NN-703' 'NNC-26-0703' 'Nn703' 'Tabimorelin']_|_[('PubChem', array(['26753275'], dtype=object))]_|_nan_|_nan_|_[ENSG00000160868,ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3125702,"CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1_|_DRLCSJFKKILATL-YWCVFVGNSA-N_|_Small molecule_|_False_|_NAVTEMADLIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG 232' 'AMG-232' 'Amg 232' 'KRT-232' 'Krt-232'
 'Mdm2 inhibitor amg-232' 'Navtemadlin']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NAVTEMADLIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15299'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000339', 'EFO_1001471', 'EFO_0000222', 'EFO_0006738',
       'EFO_0002429', 'EFO_0000702', 'EFO_0004251', 'EFO_0003060',
       'MONDO_0004992', 'EFO_1001465', 'EFO_0001378', 'EFO_0000479',
       'MONDO_0011962', 'EFO_0000616', 'MONDO_0044903', 'EFO_1001968',
       'EFO_0000756', 'EFO_0002430'], dtype=object), 'count': 18}_|_[ENSG00000141510,ENSG00000135679]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 18 investigational indications."
CHEMBL328190,"Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1_|_GXESHMAMLJKROZ-IAPPQJPRSA-N_|_Small molecule_|_False_|_LASOFOXIFENE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Lasofoxifene']_|_[('Wikipedia', array(['Lasofoxifene'], dtype=object)), ('drugbank', array(['DB06202'], dtype=object))]_|_['CHEMBL5307767' 'CHEMBL2113354']_|_{'rows': array(['EFO_0003882', 'EFO_0003968', 'MONDO_0007254', 'EFO_0005537'],
      dtype=object), 'count': 4}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 4 investigational indications."
CHEMBL3544914,"CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO_|_MJUVRTYWUMPBTR-MRXNPFEDSA-N_|_Small molecule_|_False_|_TEZACAFTOR_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Tezacaftor' 'VX-661']_|_[('drugbank', array(['DB11712'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for cystic fibrosis."
CHEMBL3545335,"Cc1cc(C(=O)Nc2cc(Nc3ccc4c(/C=C/c5ccccn5)n[nH]c4c3)ccc2F)n(C)n1_|_JXSVVZKPEDIRTN-DHZHZOJOSA-N_|_Small molecule_|_False_|_AG-13958_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AG 13958' 'Ag-13958']_|_nan_|_['CHEMBL3922529']_|_nan_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3545383,"nan_|_nan_|_Small molecule_|_False_|_RG-7167_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Rg-7167']_|_nan_|_nan_|_nan_|_[ENSG00000126934,ENSG00000169032]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL386630,"C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O_|_MUMGGOZAMZWBJJ-DYKIIFRCSA-N_|_Small molecule_|_True_|_TESTOSTERONE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Androderm' 'Androgel' 'Androgel 1%' 'Andropatch' 'Axiron' 'Fortesta'
 'Intrinsa' 'Natesto' 'Striant' 'Striant sr' 'Testim' 'Testim 1%'
 'Testoderm' 'Testoderm tts' 'Testogel' 'Testopatch' 'Testopel' 'Testoral'
 'Testosterone' 'Tostran' 'Vogelxo']_|_['Android-t' 'Androlan' 'Delatestryl' 'Homosterone' 'Livensa' 'NSC-9700'
 'TESTIM' 'Testiculosterone' 'Testosterone' 'Testosterone ciii'
 'Virosterone']_|_[('DailyMed', array(['testosterone'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/intrinsa'],
      dtype=object)), ('PubChem', array(['144207887', '17389513', '50085980', '56462804'], dtype=object)), ('Wikipedia', array(['Testosterone'], dtype=object)), ('drugbank', array(['DB00624'], dtype=object)), ('chEBI', array(['17347'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000545', 'HP_0001510', 'EFO_0004234', 'EFO_1001919',
       'MONDO_0018555', 'MONDO_0005301', 'EFO_0000660', 'EFO_0003964',
       'EFO_0001073', 'EFO_0003884', 'EFO_0003843', 'EFO_0002970',
       'EFO_0000195', 'HP_0030016', 'EFO_0005088', 'MONDO_0004992',
       'Orphanet_325690', 'EFO_0000196', 'MONDO_0005351', 'EFO_1001006',
       'EFO_0003144', 'MONDO_0008315', 'EFO_1001078', 'EFO_1000859',
       'EFO_0001645', 'EFO_0001663', 'HP_0003549', 'Orphanet_145',
       'EFO_0004714', 'MONDO_0018800', 'GO_0042697', 'MONDO_0002146',
       'EFO_1000653', 'HP_0000044', 'EFO_0000765', 'EFO_0002614',
       'EFO_0000616'], dtype=object), 'count': 37}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 7 approved and 29 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3989948,"CC#Cc1cncc(-c2ccc3c(c2)[C@@]2(N=C(C)C(N)=N2)[C@]2(CC[C@H](OC)CC2)C3)c1_|_WKDNQONLGXOZRG-HRNNMHKYSA-N_|_Small molecule_|_False_|_LANABECESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AZD-3293' 'AZD3293' 'LY-3314814' 'LY3314814' 'Lanabecestat']_|_[('drugbank', array(['DB14814'], dtype=object))]_|_['CHEMBL3989942']_|_{'rows': array(['EFO_0001421', 'MONDO_0004975', 'HP_0000083'], dtype=object), 'count': 3}_|_[ENSG00000186318]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297296,"C/C1=C/C[C@@H](/C(C)=C/c2csc(C)n2)OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C1_|_XAYAKDZVINDZGB-BMVMHAJPSA-N_|_Small molecule_|_False_|_KOS-1584_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(e)-9,10-dehydroepothilone d' '(e)-9,10-didehydroepothilone d'
 '9,10-trans-dehydroepothilone d' 'Dehydelone' 'Kos-1584' 'R-1645' 'R1645']_|_[('drugbank', array(['DB05903'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297622,"C[C@@H]1OC(=O)N[C@@H]1C(=O)N[C@@H](Cc1cscn1)C(=O)N1CCC[C@H]1C_|_WTXWDXWZGJGIHV-URBCHYCLSA-N_|_Small molecule_|_False_|_ROVATIRELIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['KPS-0373' 'Kps-0373' 'Rovatirelin' 'S-0373']_|_[('drugbank', array(['DB15338'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0000437'], dtype=object), 'count': 1}_|_[ENSG00000174417]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL499915,"CC1(C)[C@@H](OC(=O)CCC(=O)O)CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@@](C)(C(=O)O)CC[C@]5(C)CC[C@@]4(C)[C@]3(C)CC[C@@H]12_|_OBZHEBDUNPOCJG-WBXJDKIVSA-N_|_Small molecule_|_False_|_CARBENOXOLONE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Carbenoxolone']_|_[('Wikipedia', array(['Carbenoxolone'], dtype=object)), ('drugbank', array(['DB02329'], dtype=object))]_|_['CHEMBL1697717']_|_{'rows': array(['EFO_0003948', 'HP_0004398'], dtype=object), 'count': 2}_|_[ENSG00000176387,ENSG00000117594]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastroesophageal reflux disease and peptic ulcer."
CHEMBL645,"CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1_|_VHYCDWMUTMEGQY-UHFFFAOYSA-N_|_Small molecule_|_False_|_BISOPROLOL_|_1992.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bisoprolol' 'CL 297,939' 'CL-297939' 'EMD 33 512' 'EMD-33-512' 'Zebeta'
 'Ziac']_|_[('PubChem', array(['174007419', '26751965', '29215032', '50104637', '90341096'],
      dtype=object)), ('Wikipedia', array(['Bisoprolol'], dtype=object)), ('drugbank', array(['DB00612'], dtype=object)), ('chEBI', array(['3127'], dtype=object))]_|_['CHEMBL1200708' 'CHEMBL1472989']_|_{'rows': array(['Orphanet_79292', 'EFO_0000537', 'MONDO_0010679', 'MP_0001914',
       'EFO_0000319', 'MONDO_0017147', 'MONDO_0007254', 'EFO_0005672',
       'EFO_0000537', 'EFO_0001645', 'EFO_0000275'], dtype=object), 'count': 11}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for cardiovascular disease and hypertension and has 9 investigational indications."
CHEMBL75435,"C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1_|_DKYWVDODHFEZIM-NSHDSACASA-N_|_Small molecule_|_False_|_DEXKETOPROFEN_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Keral']_|_['(s)-ketoprofen' 'Arveles' 'Dexketoprofen' 'Ketoprofen, (s)-']_|_[('PubChem', array(['26754382', '26754383', '56320640'], dtype=object)), ('drugbank', array(['DB09214'], dtype=object)), ('chEBI', array(['76128'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002829', 'HP_0003419', 'EFO_0003843', 'HP_0003326',
       'EFO_0005755'], dtype=object), 'count': 5}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 2 investigational indications."
CHEMBL109648,"COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccnc(-c3nnn[nH]3)c2)nc1OCCO_|_LFWCJABOXHSRGC-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLAZOSENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Pivlaz']_|_['ACT-108475' 'AXV-034343' 'AXV-343434' 'Axv-034' 'Clazosentan'
 'RO-61-1790' 'Ro 61-1790' 'VML-588']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CLAZOSENTAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06677'], dtype=object))]_|_['CHEMBL5314590']_|_{'rows': array(['EFO_0000713', 'EFO_0000713'], dtype=object), 'count': 2}_|_[ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1200517,"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O_|_ADYPXRFPBQGGAH-UMYZUSPBSA-N_|_Small molecule_|_True_|_DIHYDROERGOTAMINE MESYLATE_|_1946.0_|_4.0_|_CHEMBL1732_|_False_|_True_|_['D.h.e. 45' 'Diergo' 'Dihydergot' 'Dihydroergotamine mesylate' 'Tonopan'
 'Trudhesa']_|_['DHE-45' 'Dihydroergotamine Methanesulfonate'
 'Dihydroergotamine mesilate' 'Dihydroergotamine mesylate'
 'Dihydroergotamine methanesulfonate' 'Migranal' 'NSC-759848']_|_[('DailyMed', array(['dihydroergotamine%20mesylate'], dtype=object)), ('PubChem', array(['50106120'], dtype=object)), ('chEBI', array(['59756'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946 and is indicated for migraine disorder. This drug has a black box warning from the FDA."
CHEMBL1200617,"CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_QTTRZHGPGKRAFB-OOKHYKNYSA-N_|_Small molecule_|_False_|_RIMEXOLONE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Vexol']_|_['ORG 6216' 'ORG-6216' 'Rimexolon' 'Rimexolone']_|_[('PubChem', array(['56463550'], dtype=object)), ('Wikipedia', array(['Rimexolone'], dtype=object)), ('drugbank', array(['DB00896'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000906', 'EFO_0005752'], dtype=object), 'count': 2}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for eye inflammation and has 1 investigational indication."
CHEMBL1201567,"nan_|_nan_|_Protein_|_False_|_FILGRASTIM_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Accofil' 'Neupogen' 'Neupogen 30' 'Neupogen 48' 'Nivestim' 'Zarzio']_|_['Filgrastim' 'Filgrastim for bioassay'
 'Granulocyte colony-stimulating factor filgrastim' 'KRN-8601' 'MBRI-9901'
 'R-METHUG-CSF' 'TX-01' 'TX01' 'XM-02' 'XM02']_|_[('DailyMed', array(['filgrastim', 'filgrastim-aafi', 'filgrastim-sndz',
       'tbo-filgrastim'], dtype=object)), ('DrugCentral', array(['4987'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim'],
      dtype=object)), ('Wikipedia', array(['Filgrastim'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007532', 'MONDO_0008867', 'MONDO_0004992', 'EFO_0001422',
       'EFO_0009708', 'EFO_0000565', 'EFO_0001421', 'EFO_0000223',
       'EFO_1001469', 'MONDO_0004643', 'EFO_0003833', 'EFO_0004272',
       'MONDO_0015760', 'EFO_0003811', 'MONDO_0007576', 'MONDO_0002334',
       'EFO_0002918', 'EFO_0000574', 'GO_0042697', 'EFO_0003060',
       'EFO_0000612', 'EFO_0003929', 'EFO_0000183', 'EFO_0000545',
       'EFO_0000239', 'EFO_0000637', 'MONDO_0008315', 'EFO_0005537',
       'EFO_0003869', 'EFO_0008583', 'EFO_0000621', 'EFO_1001779',
       'MONDO_0011382', 'EFO_0000221', 'EFO_0003802', 'MONDO_0002087',
       'EFO_0001642', 'EFO_0000095', 'MONDO_0004986', 'HP_0001871',
       'EFO_0003032', 'EFO_0000616', 'EFO_0004142', 'MONDO_0002974',
       'Orphanet_848', 'EFO_0005529', 'Orphanet_303', 'EFO_1001345',
       'MONDO_0003783', 'EFO_0000313', 'EFO_1001968', 'EFO_1001365',
       'MONDO_0002691', 'MONDO_0009348', 'EFO_0004991', 'EFO_0004251',
       'EFO_0000209', 'EFO_0000096', 'EFO_0000182', 'HP_0031217',
       'MONDO_0008903', 'MONDO_0019460', 'EFO_0000220', 'EFO_0000196',
       'EFO_1001465', 'HP_0008209', 'EFO_0001378', 'MONDO_0019391',
       'EFO_1000749', 'EFO_0006803', 'EFO_0000760', 'EFO_0007416',
       'EFO_0006927', 'EFO_0000717', 'EFO_0000702', 'EFO_0005952',
       'EFO_0003928', 'EFO_0003029', 'MONDO_0003751', 'EFO_0007362',
       'HP_0001399', 'HP_0001945', 'EFO_0000544', 'MONDO_0004192',
       'MONDO_0001475', 'MONDO_0005180', 'MONDO_0013730', 'EFO_1000131',
       'EFO_0000339', 'EFO_0000222', 'EFO_0001376', 'EFO_0000502',
       'MONDO_0018906', 'EFO_0006475', 'EFO_0009441', 'EFO_0000384',
       'MONDO_0002158', 'EFO_0000407', 'EFO_0000218', 'EFO_0000466',
       'EFO_0002428', 'EFO_1001951', 'EFO_0003875', 'MONDO_0007915',
       'MONDO_0005301', 'EFO_0000691', 'MONDO_0007254', 'EFO_1000796',
       'EFO_0003025', 'EFO_0002939', 'HP_0002721', 'MONDO_0001056',
       'MONDO_0001657', 'MONDO_0000870', 'EFO_0004145', 'MONDO_0008170',
       'EFO_1000984', 'EFO_0004256', 'EFO_0000211', 'MONDO_0019438',
       'EFO_0004281', 'EFO_0007498', 'EFO_1001042', 'MONDO_0005147',
       'EFO_0002618', 'MONDO_0008380', 'EFO_0004252', 'MONDO_0004975',
       'EFO_0000309', 'MONDO_0016700', 'EFO_0000712', 'EFO_0006859',
       'MONDO_0020077', 'HP_0002140', 'EFO_0000764', 'EFO_0000174',
       'EFO_0000191', 'EFO_0003968', 'EFO_0001645', 'EFO_0000094',
       'MONDO_0044903', 'HP_0012410', 'EFO_0008585', 'EFO_0000514',
       'EFO_0002430', 'EFO_1000318', 'EFO_0003893', 'MONDO_0011962',
       'EFO_0000198', 'MONDO_0015974', 'EFO_0000389', 'EFO_0005235',
       'EFO_0001065', 'EFO_0000403', 'MONDO_0008978', 'EFO_1000158',
       'EFO_0000756', 'EFO_0000181', 'MONDO_0006058', 'EFO_0004265',
       'MONDO_0002367', 'MONDO_0044881', 'EFO_0006861', 'EFO_0007359',
       'EFO_0003027', 'MONDO_0000873', 'MONDO_0019471', 'EFO_0000681',
       'EFO_0000224', 'HP_0001915', 'MONDO_0004976', 'EFO_1000043',
       'MONDO_0001187', 'EFO_1000632'], dtype=object), 'count': 174}_|_[ENSG00000119535]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 170 investigational indications."
CHEMBL1448187,"Cl.Cl.OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1_|_MBHNWCYEGXQEIT-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLUPHENAZINE HYDROCHLORIDE_|_1959.0_|_4.0_|_CHEMBL726_|_False_|_True_|_['Fluphenazine hydrochloride' 'Moditen' 'Permitil' 'Prolixin']_|_['Anatensol' 'Dapotum' 'Fluphenazine dihydrochloride' 'Fluphenazine hcl'
 'Fluphenazine hydrochloride' 'Fluphenazini hydrochloridum' 'NSC-179197'
 'SQUIBB 4918']_|_[('DailyMed', array(['fluphenazine%20hydrochloride'], dtype=object)), ('PubChem', array(['26747520', '26747521', '50106350'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000677', 'EFO_0001378'], dtype=object), 'count': 2}_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and is indicated for mental or behavioural disorder and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1512,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1_|_XSFJVAJPIHIPKU-XWCQMRHXSA-N_|_Small molecule_|_False_|_FLUNISOLIDE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Aerobid' 'Aerospan hfa' 'Flunisolide' 'Nasalide' 'Nasarel' 'Syntaris'
 'Syntaris hayfever']_|_['Flunisolide' 'Flunisolide anhydrous' 'Flunisolide hemihydrate'
 'NSC-757871' 'RS-3999']_|_[('DailyMed', array(['flunisolide'], dtype=object)), ('PubChem', array(['144204276', '170465331', '56463079'], dtype=object)), ('Wikipedia', array(['Flunisolide'], dtype=object)), ('drugbank', array(['DB00180'], dtype=object)), ('chEBI', array(['5106'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0008521', 'EFO_1001417', 'HP_0006536',
       'HP_0001742'], dtype=object), 'count': 5}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 1 investigational indication."
CHEMBL1743053,"nan_|_nan_|_Antibody_|_False_|_OTELIXIZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CHAGLY CD3' 'CHAGLYCD-3' 'ChAglyCD' 'Chaglycd3' 'Otelixizumab' 'TRX-4'
 'TRX4']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_1001466', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000198851]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2105743,"COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl_|_KCEHVJZZIGJAAW-FERBBOLQSA-N_|_Small molecule_|_False_|_OLODATEROL HYDROCHLORIDE_|_2014.0_|_4.0_|_CHEMBL605846_|_False_|_True_|_['Striverdi respimat']_|_['BI 1744 CL' 'BI-1744 CL' 'BI-1744-CL' 'Olodaterol hydrochloride']_|_[('DailyMed', array(['olodaterol%20hydrochloride'], dtype=object)), ('chEBI', array(['83309'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006505', 'EFO_0000341', 'EFO_0000464'], dtype=object), 'count': 3}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved indications."
CHEMBL2108569,"nan_|_nan_|_Protein_|_False_|_INSULIN PEGLISPRO_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Insulin peglispro' 'LY-2605541' 'LY2605541']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109385,"nan_|_nan_|_Antibody_|_False_|_ENOTICUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Enoticumab' 'REGN-421' 'REGN421']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000128917]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2146102,"CN[C@@H](C)[C@H](O)c1ccccc1.Cl_|_BALXUFOVQVENIU-GNAZCLTHSA-N_|_Small molecule_|_False_|_EPHEDRINE HYDROCHLORIDE_|_2021.0_|_4.0_|_CHEMBL211456_|_False_|_True_|_['Amesec' 'Asmapax' 'Bronchipax' 'C.a.m.' 'Do-do' 'Ephed hcl'
 'Ephed in nor saline' 'Expurhin' 'Franol' 'Haymine' 'Rezipres' 'Secron'
 'Tabasan' 'Taumasthman' 'Tedral' 'Tedral sa']_|_['(-)-ephedrine hydrochloride' 'Ephedrine hcl' 'Ephedrine hydrochloride'
 'Ephedrini hydrochloridum' 'L-ephedrine hydrochloride' 'NSC-759611']_|_[('PubChem', array(['144204863', '170465509'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001742', 'EFO_0005251', 'EFO_0007214', 'EFO_0003956',
       'MONDO_0004979'], dtype=object), 'count': 5}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 5 approved indications."
CHEMBL278819,"Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1_|_LDMWSLGGVTVJPG-UHFFFAOYSA-N_|_Small molecule_|_False_|_MINAPRINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['AGR-1240' 'Brantur' 'CB-30038' 'Cantor' 'Minaprine']_|_[('PubChem', array(['11112706'], dtype=object)), ('Wikipedia', array(['Minaprine'], dtype=object)), ('drugbank', array(['DB00805'], dtype=object)), ('chEBI', array(['51038'], dtype=object))]_|_['CHEMBL536932' 'CHEMBL1364551']_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000168539,ENSG00000087085,ENSG00000149295,ENSG00000184845,ENSG00000189221,ENSG00000135914,ENSG00000102468,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for major depressive disorder. It was withdrawn in at least one region."
CHEMBL338604,"CCN(CC)CCNc1ccc2ncn3c4ccc(O)cc4c(=O)c1c23_|_CUNDRHORZHFPLY-UHFFFAOYSA-N_|_Small molecule_|_False_|_C-1311_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NSC-645809']_|_nan_|_['CHEMBL3545337' 'CHEMBL2002951']_|_nan_|_[ENSG00000131747,ENSG00000077097,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3545401,"nan_|_nan_|_Small molecule_|_False_|_X-82_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['X-82']_|_nan_|_nan_|_{'rows': array(['EFO_0001365', 'EFO_0000228', 'EFO_0000616', 'EFO_0003860'],
      dtype=object), 'count': 4}_|_[ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3580737,"CCS(=O)(=O)c1ccc(Oc2cc(O[C@@H](C)CO)cc(C(=O)Nc3ccn(C)n3)c2)cn1_|_KJSGTWFWVTYPFZ-AWEZNQCLSA-N_|_Small molecule_|_False_|_MK-0941_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL4297302']_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000106633]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3692206,"Cc1cc(Nc2nc(CC3(C(=O)O)CCN(C(=O)c4cccc(Cl)c4Cl)CC3)ccc2F)n[nH]1_|_PLAVWQHGBMTMFR-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAS-119_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Tas 119' 'Tas-119']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000087586]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3916717,"Cc1cc(F)c(C(=O)Nc2cccc(-c3nncn3C(C)C)n2)cc1-n1cnc(C2CC2)c1_|_YIDDLAAKOYYGJG-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELONSERTIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GS-4997' 'Gs-4997' 'Selonsertib']_|_[('drugbank', array(['DB14916'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003095', 'EFO_1001249', 'EFO_0000401', 'EFO_1001345',
       'EFO_0001361'], dtype=object), 'count': 5}_|_[ENSG00000197442]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297066,"CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2.O=C(O)C(O)C(O)C(=O)O_|_KUBARPMUNHKBIQ-ZBPSDVLKSA-N_|_Small molecule_|_False_|_ELIGLUSTAT TARTRATE_|_2014.0_|_4.0_|_CHEMBL2110588_|_False_|_True_|_['Cerdelga']_|_['Eliglustat hemitartrate' 'Eliglustat tartrate' 'GENZ 112638'
 'GENZ-112638']_|_[('DailyMed', array(['eliglustat%20tartrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018150'], dtype=object), 'count': 1}_|_[ENSG00000148154]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2014 and is indicated for gaucher disease."
CHEMBL4297593,"CONC(=N)c1ccc(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)c2cc(Cl)cc(OC(F)F)c2)cc1_|_XSNMGLZVFNDDPW-ZWKOTPCHSA-N_|_Small molecule_|_False_|_ATECEGATRAN METOXIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-0837' 'AZD0837' 'Atecegatran fexenetil' 'Atecegatran metoxil'
 'Azd 0837' 'Azd0837']_|_[('drugbank', array(['DB12507'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275'], dtype=object), 'count': 1}_|_[ENSG00000180210]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297923,"nan_|_nan_|_Protein_|_False_|_RASDEGAFUSP ALFA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDX-1401' 'Cdx-1401' 'Rasdegafusp alfa']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000389', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000054219,ENSG00000184033,ENSG00000268651]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4650214,"CN1CCC(c2ccccc2CC(C)(C)Nc2nc(N3CCOCC3)nc(-n3c(C(F)F)nc4ccccc43)n2)CC1_|_WPFUFWIHMYZXSF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZANDELISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACC-524' 'ME-401' 'Me-401' 'PW-143' 'PWT-143' 'PWT143' 'Pwt-143'
 'Zandelisib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZANDELISIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000096', 'EFO_0000403', 'EFO_0004289', 'EFO_1001469',
       'MONDO_0004992', 'MONDO_0018906', 'EFO_0000095'], dtype=object), 'count': 7}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL573677,"C[C@H](CCOc1cccc(CC(=O)O)c1)N(Cc1cccc(C(F)(F)F)c1Cl)CC(c1ccccc1)c1ccccc1_|_ZLJZDYOBXVOTSA-XMMPIXPASA-N_|_Small molecule_|_False_|_ABEQUOLIXRON_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Abequolixron' 'RGX-104' 'Rgx-104' 'SB-742881']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ABEQUOLIXRON/relevant/1/'],
      dtype=object))]_|_['CHEMBL5303417' 'CHEMBL5095408']_|_{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_0003060', 'MONDO_0011962'],
      dtype=object), 'count': 4}_|_[ENSG00000025434,ENSG00000131408]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL640,"CCN(CC)CCNC(=O)c1ccc(N)cc1_|_REQCZEXYDRLIBE-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROCAINAMIDE_|_1950.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-27461' 'Novocainamide' 'Procainamide' 'Procan' 'Procanbid'
 'Procapan' 'Pronestyl' 'Pronestyl-SR' 'Sp 100 (pharmaceutical)']_|_[('PubChem', array(['11111690', '11111691', '144203797', '170464952', '26751611',
       '90340905'], dtype=object)), ('Wikipedia', array(['Procainamide'], dtype=object)), ('drugbank', array(['DB01035'], dtype=object)), ('chEBI', array(['8428'], dtype=object))]_|_['CHEMBL605']_|_{'rows': array(['EFO_0004278', 'HP_0004308', 'EFO_0000612', 'EFO_0004269',
       'EFO_0003144', 'EFO_0004287', 'EFO_0000275', 'EFO_0000275',
       'EFO_0004269'], dtype=object), 'count': 9}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1152,"CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_LRJOMUJRLNCICJ-JZYPGELDSA-N_|_Small molecule_|_False_|_PREDNISOLONE ACETATE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_['Econopred' 'Flo-pred' 'Meticortelone' 'Omnipred' 'Pred forte' 'Pred fte'
 'Pred mild' 'Prednisolone acetate' 'Sterane' 'Ultracortenol']_|_['NSC-10966' 'Prednisolone 21-acetate' 'Prednisolone Acetate'
 'Prednisolone acetate' 'Prednisoloni acetas']_|_[('DailyMed', array(['prednisolone%20acetate'], dtype=object)), ('PubChem', array(['144204881', '170464632', '56422451', '855649'], dtype=object)), ('drugbank', array(['DB15566'], dtype=object)), ('chEBI', array(['8380'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007141', 'EFO_1000811', 'EFO_1001157', 'HP_0011868',
       'EFO_1001231', 'HP_0003419', 'MONDO_0005129', 'MONDO_0005301',
       'MP_0001845', 'EFO_1001888', 'EFO_1000997', 'MONDO_0003005',
       'HP_0000559', 'MONDO_0002280'], dtype=object), 'count': 14}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and has 5 approved and 9 investigational indications."
CHEMBL1197051,"CC(COc1ccccc1)NC(C)C(O)c1ccc(O)cc1_|_BMUKKTUHUDJSNZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOXSUPRINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dilator' 'Isoxsuprine']_|_[('Wikipedia', array(['Isoxsuprine'], dtype=object))]_|_['CHEMBL559180']_|_{'rows': array(['EFO_0000319', 'MONDO_0005301'], dtype=object), 'count': 2}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL1200772,"CC(=O)CC(c1ccccc1)c1c([O-])c2ccccc2oc1=O.[K+]_|_WSHYKIAQCMIPTB-UHFFFAOYSA-M_|_Small molecule_|_False_|_WARFARIN POTASSIUM_|_1982.0_|_4.0_|_CHEMBL1464_|_False_|_True_|_['Athrombin-k']_|_['Potassium warfarin' 'Warfarin potassium' 'Warfarin-potassium']_|_[('PubChem', array(['144205190', '170464790'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'HP_0001907', 'HP_0004936'], dtype=object), 'count': 3}_|_[ENSG00000167397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications."
CHEMBL1201644,"nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP RECOMBINANT HUMAN_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Humulin l' 'Novolin l']_|_['Insulin zinc susp recombinant human']_|_nan_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1985 and has 1 investigational indication."
CHEMBL1201754,"NC(=O)c1cn(Cc2c(F)cccc2F)nn1_|_POGQSBRIGCQNEG-UHFFFAOYSA-N_|_Small molecule_|_False_|_RUFINAMIDE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Banzel' 'Inovelon' 'Rufinamide']_|_['60231/4' 'CGP 33101' 'CGP-33101' 'E-2080' 'E2080' 'RUF 331' 'RUF-331'
 'Rufinamide']_|_[('DailyMed', array(['rufinamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon'],
      dtype=object)), ('PubChem', array(['170465202', '29217641', '50111716', '56320687', '90341717'],
      dtype=object)), ('Wikipedia', array(['Rufinamide'], dtype=object)), ('drugbank', array(['DB06201'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0001250', 'EFO_0000474', 'MONDO_0016532'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 3 approved and 1 investigational indication."
CHEMBL1236962,"COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F_|_CGBJSGAELGCMKE-UHFFFAOYSA-N_|_Small molecule_|_False_|_OMIPALISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-2126458' 'GSK2126458' 'Gsk-2126458' 'Omipalisib']_|_[('drugbank', array(['DB12703'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000768', 'MONDO_0004992'], dtype=object), 'count': 3}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1420,"C[n+]1ccccc1C=NO_|_JBKPUQTUERUYQE-UHFFFAOYSA-O_|_Small molecule_|_False_|_PRALIDOXIME_|_1964.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Atnaa' 'Duodote' 'Pralidoxime' 'Pralidoxime cation' 'Pralidoxime ion']_|_[('PubChem', array(['11112108'], dtype=object)), ('Wikipedia', array(['Pralidoxime'], dtype=object)), ('drugbank', array(['DB00733'], dtype=object)), ('chEBI', array(['8354'], dtype=object))]_|_['CHEMBL3335073' 'CHEMBL748' 'CHEMBL2104739' 'CHEMBL14577']_|_{'rows': array(['EFO_0008546', 'EFO_0010581', 'EFO_0008546', 'EFO_0004991'],
      dtype=object), 'count': 4}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for poisoning and myasthenia gravis and has 2 investigational indications."
CHEMBL1694,"CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O.Cl_|_VPSRQEHTHIMDQM-FKLPMGAJSA-N_|_Small molecule_|_True_|_BENAZEPRIL HYDROCHLORIDE_|_1991.0_|_4.0_|_CHEMBL838_|_False_|_True_|_['Benazepril hydrochloride' 'Cibacen' 'Lotensin']_|_['Benazepril hcl' 'Benazepril hydrochloride' 'CGS 14824A HCL' 'CGS-14824A'
 'CGS-14824A HCL' 'NSC-758920']_|_[('DailyMed', array(['benazepril%20hydrochloride'], dtype=object)), ('PubChem', array(['144204994', '170465003', '49648469'], dtype=object)), ('chEBI', array(['3012'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010520', 'Orphanet_79292', 'EFO_1002048', 'EFO_0000712',
       'EFO_1000965', 'EFO_0000400', 'EFO_0000537', 'EFO_0003086'],
      dtype=object), 'count': 8}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103881,"CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C_|_IMYZQPCYWPFTAG-NGZCFLSTSA-N_|_Small molecule_|_False_|_DEXMECAMYLAMINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dexmecamylamine' 'NIH-11008' 'TC-5214' 'Tc-5214']_|_[('drugbank', array(['DB11807'], dtype=object))]_|_['CHEMBL2105753']_|_{'rows': array(['MONDO_0002009', 'EFO_0003086', 'EFO_0000537', 'EFO_0003890',
       'HP_0000975', 'EFO_1000781'], dtype=object), 'count': 6}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL2105710,"CCCCC[C@H](O)c1ccc(N2C(=O)CC[C@@H]2COCc2ccc(C(=O)OC(C)C)s2)cc1_|_MSIIJNOQQWRTFC-GGAORHGYSA-N_|_Small molecule_|_False_|_SIMENEPAG ISOPROPYL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGN-210669' 'Simenepag isopropyl']_|_[('drugbank', array(['DB12977'], dtype=object))]_|_nan_|_nan_|_[ENSG00000125384]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2105747,"COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12_|_XNBRWUQWSKXMPW-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOZADENANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-2A (3)' 'A2A (3)' 'A2A-(3)' 'RO-4494351' 'RO-4494351-000'
 'RO-4494351-002' 'RO-4494351000' 'RO4494351' 'RO4494351-000'
 'RO4494351-002' 'SYN-115' 'SYN115' 'Tozadenant']_|_[('drugbank', array(['DB12203'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'MONDO_0005180', 'EFO_0002610'], dtype=object), 'count': 3}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2108336,"nan_|_nan_|_Protein_|_False_|_LIXISENATIDE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Adlyxin' 'Lyxumia']_|_['AVE 010' 'AVE-0010' 'AVE-010' 'AVE0010' 'Lixisenatide' 'ZP 10' 'ZP-10']_|_[('DailyMed', array(['lixisenatide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400', 'MONDO_0005147', 'EFO_0005672', 'MONDO_0005180',
       'MONDO_0005148'], dtype=object), 'count': 5}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 3 investigational indications."
CHEMBL225157,"CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl_|_LEEIJTHMHDMWLJ-CQSZACIVSA-N_|_Small molecule_|_False_|_RESATORVID_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cli-095' 'Resatorvid' 'TAK-242' 'Tak-242']_|_[('drugbank', array(['DB05943'], dtype=object))]_|_['CHEMBL3527013']_|_{'rows': array(['EFO_0007949', 'HP_0100806'], dtype=object), 'count': 2}_|_[ENSG00000136869]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL38,"CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1_|_SHGAZHPCJJPHSC-YCNIQYBTSA-N_|_Small molecule_|_True_|_TRETINOIN_|_1971.0_|_4.0_|_nan_|_False_|_True_|_['Acticin' 'Altreno' 'Atralin' 'Avita' 'Renova' 'Retin-a' 'Retin-a micro'
 'Retin-a-micro' 'Tretin-X' 'Tretinoin' 'Vesanoid']_|_['Aberel' 'All-trans retinoic acid' 'All-trans-retinoic acid' 'Eudyna'
 'Kerlocal' 'NSC-122758' 'Oristar rna' 'Retin a' 'Retinoic acid'
 'Tretinoin']_|_[('DailyMed', array(['tretinoin'], dtype=object)), ('PubChem', array(['104171346', '124882949', '124882951', '124882956', '124882957',
       '144204363', '144209528', '144210625', '170465045', '26746936',
       '29214999', '416403', '50103969', '50103970', '50126361',
       '50126362', '56422209', '85231340', '855632', '90341365'],
      dtype=object)), ('Wikipedia', array(['Retinoic_acid', 'Tretinoin'], dtype=object)), ('drugbank', array(['DB00755'], dtype=object)), ('chEBI', array(['15367'], dtype=object))]_|_['CHEMBL2051965']_|_{'rows': array(['EFO_0000621', 'EFO_0007160', 'EFO_0000231', 'EFO_0002618',
       'EFO_0000198', 'EFO_0000616', 'EFO_0003060', 'HP_0001065',
       'EFO_0000389', 'EFO_0000464', 'EFO_0004268', 'EFO_0000673',
       'EFO_0004193', 'MONDO_0002280', 'MONDO_0044881', 'EFO_0001378',
       'EFO_0000702', 'EFO_0000574', 'EFO_0004826', 'EFO_0003963',
       'EFO_0000222', 'EFO_1000760', 'EFO_0003758', 'MONDO_0004976',
       'MONDO_0019289', 'MONDO_0008903', 'EFO_0000224', 'EFO_0003869',
       'EFO_0002496', 'EFO_0000756', 'MONDO_0007254', 'EFO_0000707',
       'EFO_0000565', 'MONDO_0002367', 'EFO_0003894', 'MONDO_0019098',
       'EFO_0004251', 'HP_0003124', 'MONDO_0100096', 'MONDO_0020077'],
      dtype=object), 'count': 40}_|_[ENSG00000172819,ENSG00000077092,ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1971 and has 5 approved and 35 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3833329,"nan_|_nan_|_Antibody_|_False_|_ERENUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Aimovig']_|_['AMG 334' 'AMG-334' 'Erenumab' 'Erenumab aooe']_|_[('DailyMed', array(['erenumab-aooe'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003913', 'EFO_1001219', 'MONDO_0005277', 'EFO_0004149',
       'EFO_0005279'], dtype=object), 'count': 5}_|_[ENSG00000064989]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 4 investigational indications."
CHEMBL3989690,"CCOC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C_|_VCVWXKKWDOJNIT-ZOMKSWQUSA-N_|_Small molecule_|_False_|_TESOFENSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NS 2330' 'NS-2330' 'Ns2330' 'Tesofensine']_|_[('drugbank', array(['DB06156'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073', 'MONDO_0005148', 'MONDO_0008300', 'MONDO_0005180',
       'MONDO_0004975'], dtype=object), 'count': 5}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3989914,"COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1_|_YRCHYHRCBXNYNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_GLESATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Glesatinib' 'MG-90265' 'MG-90265X' 'MG90265' 'MG90265H9' 'MG90265X'
 'MG90265gly' 'MGCD-265' 'MGCD265' 'Mgcd-265']_|_[('drugbank', array(['DB06302'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000120156,ENSG00000164078,ENSG00000105976,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4130229,"Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1_|_ZQOBVMHBVWNVBG-UHFFFAOYSA-N_|_Small molecule_|_False_|_VODOBATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['K-0706' 'K0706' 'Sco-088' 'Vodobatinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VODOBATINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005180', 'MONDO_0004643', 'HP_0000726', 'EFO_0000339',
       'EFO_0005772'], dtype=object), 'count': 5}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL4297385,"COC[C@@H]1[C@@H](c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H]1N2C_|_PGYDXVBZYKQYCS-VPWBDBDCSA-N_|_Small molecule_|_False_|_NS-2359_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-372,475' 'GSK-372475' 'GSK372475' 'Gsk372475' 'NS2359' 'Ns-2359'
 'Ns2359']_|_[('drugbank', array(['DB05805'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002610', 'EFO_0003888', 'MONDO_0002050'], dtype=object), 'count': 3}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297441,"CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@@H](C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@]4(OC(C)=O)CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)[C@@H](NC(=O)c1ccccc1)c1ccccc1_|_LRCZQSDQZJBHAF-PUBGEWHCSA-N_|_Small molecule_|_False_|_PACLITAXEL DOCOSAHEXAENOIC ACID_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Dha paclitaxel' 'Dha-paclitaxel' 'Paclitaxel docosahexaenoic acid'
 'Paclitaxel-dha' 'Taxoprexin']_|_[('drugbank', array(['DB05297'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003060', 'EFO_0000182', 'EFO_0002617'], dtype=object), 'count': 3}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297887,"nan_|_nan_|_Unknown_|_False_|_GSK-2586881_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['APN-01' 'APN01' 'Alunacedase alfa' 'Apn01' 'GSK-2586881' 'Gsk-2586881'
 'Gsk2586881']_|_nan_|_nan_|_{'rows': array(['EFO_0001361', 'EFO_0004610', 'MONDO_0100096'], dtype=object), 'count': 3}_|_[ENSG00000135744]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4594618,"nan_|_nan_|_Gene_|_False_|_BREXUCABTAGENE AUTOLEUCEL_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Tecartus']_|_['Brexucabtagene autoleucel' 'KTE-X19']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BREXUCABTAGENE%20AUTOLEUCEL/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001642', 'EFO_0000095', 'EFO_0000220', 'EFO_0000616',
       'EFO_1001469'], dtype=object), 'count': 5}_|_[ENSG00000177455]_|_Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for mantle cell lymphoma and has 4 investigational indications."
CHEMBL4594730,"nan_|_nan_|_Small molecule_|_False_|_VIPIVOTIDE TETRAXETAN LUTETIUM_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[]_|_nan_|_['CHEMBL4594406']_|_{'rows': array(['MONDO_0008315', 'MONDO_0008315', 'MONDO_0021259', 'EFO_0000616',
       'EFO_0001663', 'EFO_0003863', 'EFO_0000673'], dtype=object), 'count': 7}_|_[ENSG00000086205]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for prostate cancer and prostate neoplasm and has 5 investigational indications."
CHEMBL550781,"CCCCCN(CCCOC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc(Cl)c(Cl)c1_|_QNQZBKQEIFTHFZ-GOSISDBHSA-N_|_Small molecule_|_False_|_DEXLOXIGLUMIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CR-2017' 'Dexloxiglumide' 'Loxiglumide (r)-form' 'Loxiglumide, (r)-']_|_[('Wikipedia', array(['Dexloxiglumide'], dtype=object)), ('drugbank', array(['DB04856'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555', 'EFO_0008533'], dtype=object), 'count': 2}_|_[ENSG00000163394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1077,"Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1_|_ZBPLOVFIXSTCRZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMFENAC_|_1997.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Bromfenac' 'ISV-303']_|_[('PubChem', array(['26757971'], dtype=object)), ('Wikipedia', array(['Bromfenac'], dtype=object)), ('drugbank', array(['DB00963'], dtype=object)), ('chEBI', array(['240107'], dtype=object))]_|_['CHEMBL751' 'CHEMBL3181947']_|_{'rows': array(['EFO_0001365', 'HP_0200026', 'MONDO_0005129', 'MP_0001845',
       'MONDO_0001330', 'EFO_0003843', 'MONDO_0005129', 'EFO_0005752',
       'MP_0001845', 'MONDO_0007935', 'EFO_1000906', 'EFO_0007141'],
      dtype=object), 'count': 12}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 7 investigational indications."
CHEMBL1159650,"CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_CBGUOGMQLZIXBE-XGQKBEPLSA-N_|_Small molecule_|_True_|_CLOBETASOL PROPIONATE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Clarelux' 'Clobaderm' 'Clobetasol propionate'
 'Clobetasol propionate (emollient)' 'Clobex' 'Cormax' 'Dermovate'
 'Dermovate nn' 'Embeline' 'Embeline e' 'Etrivex' 'Impeklo' 'Impoyz'
 'Olux' 'Olux e' 'Temovate' 'Temovate e']_|_['CCI 4725' 'CCI-4725' 'Clobecort amex' 'Clobetasol'
 'Clobetasol 17-propionate' 'Clobetasol propionate' 'Dovate' 'GR 2/925'
 'NSC-758634' 'Psorex']_|_[('DailyMed', array(['clobetasol%20propionate'], dtype=object)), ('PubChem', array(['144204967', '170465385', '56422175', '855884'], dtype=object)), ('Wikipedia', array(['Clobetasol_propionate'], dtype=object)), ('drugbank', array(['DB01013'], dtype=object)), ('chEBI', array(['31414'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004192', 'EFO_1000657', 'EFO_1000726', 'EFO_1001347',
       'EFO_1000623', 'EFO_0000274', 'EFO_0004775', 'MONDO_0013730',
       'EFO_1001494', 'EFO_0000685', 'EFO_0007187', 'EFO_0000676',
       'EFO_1001993', 'MONDO_0020547', 'EFO_1001949', 'EFO_1000764',
       'EFO_0000701', 'MONDO_0005129', 'EFO_1000724', 'EFO_0008517',
       'EFO_1001395'], dtype=object), 'count': 21}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200721,"C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)([O-])[O-].[Na+].[Na+]_|_IIUMCNJTGSMNRO-VVSKJQCTSA-L_|_Small molecule_|_False_|_ESTRAMUSTINE PHOSPHATE SODIUM_|_1981.0_|_4.0_|_CHEMBL1756_|_False_|_True_|_['Emcyt']_|_['Estramustine 17-(dihydrogenphosphate) disodium salt anhydrous'
 'Estramustine 17-(dihydrogenphosphate) disodium salt monohydrate'
 'Estramustine phosphate sodium' 'Estramustine phosphate sodium hydrate'
 'Estramustine phosphate sodium monohydrate'
 'Estramustine sodium phosphate' 'RO 21-8837/001' 'RO-218837-001']_|_[('DailyMed', array(['estramustine%20phosphate%20sodium'], dtype=object)), ('PubChem', array(['144206926'], dtype=object)), ('chEBI', array(['31562'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000673', 'MONDO_0008315', 'EFO_0000574', 'MONDO_0002367',
       'MONDO_0007254', 'EFO_0000313'], dtype=object), 'count': 6}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for carcinoma and has 5 investigational indications."
CHEMBL1201148,"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO_|_PIDANAQULIKBQS-RNUIGHNZSA-N_|_Small molecule_|_False_|_MEPREDNISONE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Betapar']_|_['Meprednisone' 'NSC-527579' 'SCH 4358' 'SCH-4358']_|_[('PubChem', array(['144207161', '170465165'], dtype=object)), ('Wikipedia', array(['Meprednisone'], dtype=object)), ('drugbank', array(['DB09383'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and has 1 investigational indication."
CHEMBL1256696,"CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_AKJDEXBCRLOVTH-UHFFFAOYSA-N_|_Small molecule_|_False_|_CARBETAPENTANE CITRATE_|_nan_|_4.0_|_CHEMBL73234_|_True_|_True_|_[]_|_['Carbetapentane citrate' 'Loucarbate' 'NSC-757833' 'Pentoxyverine'
 'Pentoxyverine citrate' 'Pentoxyverine hydrogen citrate']_|_[('PubChem', array(['11112007', '11113006', '124881868', '26747484', '26747485',
       '46500452', '50106075', '85231297', '85273776'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007486'], dtype=object), 'count': 1}_|_[ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for sinusitis. It was withdrawn in at least one region."
CHEMBL13376,"COc1ccc2c(C(=O)c3ccc(Cl)cc3)c(C)n(CC(=O)O)c2c1_|_DGMZLCLHHVYDIS-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOMETACIN_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['C 1656' 'C-1656' 'Clometacin' 'Mindolic acid' 'R 3959' 'R-3959']_|_[('PubChem', array(['144206860'], dtype=object))]_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL184412,"CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1_|_ZQTNQVWKHCQYLQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_DRONEDARONE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dronedarone' 'SR-33589' 'SR33589']_|_[('PubChem', array(['144206559', '170465064'], dtype=object)), ('Wikipedia', array(['Dronedarone'], dtype=object)), ('drugbank', array(['DB04855'], dtype=object)), ('chEBI', array(['50659'], dtype=object))]_|_['CHEMBL1201729']_|_{'rows': array(['EFO_0000275', 'EFO_0000373', 'EFO_0004269', 'EFO_0003911',
       'EFO_0000275'], dtype=object), 'count': 5}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313,ENSG00000123700,ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001,ENSG00000138622]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for atrial fibrillation and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2,"COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC_|_IENZQIKPVFGBNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRAZOSIN_|_1976.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CP-12299' 'CP-122991' 'Prazosin']_|_[('PubChem', array(['11112649', '11112650', '11113367', '124882482', '124882484',
       '124882486', '124882487', '144207195', '170465415', '26751613',
       '26751614', '50100502', '50104272', '50104273', '50104274',
       '50104275', '90340959'], dtype=object)), ('Wikipedia', array(['Prazosin'], dtype=object)), ('drugbank', array(['DB00457'], dtype=object)), ('chEBI', array(['8364'], dtype=object))]_|_['CHEMBL1558' 'CHEMBL1347191']_|_{'rows': array(['EFO_0004777', 'EFO_0004701', 'EFO_0000537', 'EFO_0000537',
       'EFO_0003768', 'EFO_0000400', 'MONDO_0100096', 'EFO_0005230',
       'MONDO_0007079', 'HP_0000011', 'EFO_0001358', 'EFO_0004253'],
      dtype=object), 'count': 12}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and is indicated for hypertension and diabetes mellitus and has 9 investigational indications."
CHEMBL2105661,"CCNCCS(=O)(=O)NC[C@@]1(c2ccccc2)SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C_|_YVAFBXLHPINSIK-QHCPKHFHSA-N_|_Small molecule_|_False_|_LITRONESIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['KF 89617' 'KF-89617' 'KF89617' 'LY 2523355' 'LY-2523355' 'LY2523355'
 'Litronesib']_|_[('drugbank', array(['DB11861'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0003060', 'MONDO_0007254', 'EFO_0000565',
       'EFO_0000702', 'EFO_0000616', 'MONDO_0001056', 'MONDO_0008315',
       'EFO_0006859', 'MONDO_0007576', 'MONDO_0008170', 'MONDO_0004992'],
      dtype=object), 'count': 12}_|_[ENSG00000138160]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 12 investigational indications."
CHEMBL2105683,"COc1ccc2cc([C@H](C)C(=O)OCCS(C)(=O)=O)ccc2c1_|_JGBUBSOKFSVXKS-LBPRGKRZSA-N_|_Small molecule_|_False_|_NAPROXEN ETEMESIL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LT-NS001' 'MX-1094' 'Naproxen etemesil']_|_[('drugbank', array(['DB12398'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178'], dtype=object), 'count': 1}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107360,"CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(CCN1CCC(c3noc4cc(F)ccc34)CC1)c2=O_|_VOMKSBFLAZZBOW-UHFFFAOYSA-N_|_Small molecule_|_True_|_PALIPERIDONE PALMITATE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Byannli (previously paliperidone janssen-cilag international)'
 'Invega sustenna' 'Invega trinza']_|_['JNS-010' 'JNS010' 'Paliperidone palmitate' 'Palperidone palmitate'
 'R-092670' 'R092670' 'RO-92670' 'RO92670']_|_[('DailyMed', array(['paliperidone%20palmitate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/byannli-previously-paliperidone-janssen-cilag-international'],
      dtype=object)), ('chEBI', array(['83808'], dtype=object))]_|_['CHEMBL4745890']_|_{'rows': array(['MONDO_0005090', 'EFO_0005411'], dtype=object), 'count': 2}_|_[ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for schizophrenia and schizoaffective disorder. This drug has a black box warning from the FDA."
CHEMBL2108167,nan_|_nan_|_Antibody_|_False_|_VEPALIMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Vapantix' 'Vepalimomab']_|_nan_|_nan_|_nan_|_[ENSG00000131471]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109325,"nan_|_nan_|_Antibody_|_False_|_AMG-191_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AMG-191' 'Amg-191']_|_nan_|_nan_|_{'rows': array(['MONDO_0015974'], dtype=object), 'count': 1}_|_[ENSG00000157404]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109486,nan_|_nan_|_Antibody_|_False_|_CDP-850_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CDP-850']_|_nan_|_nan_|_nan_|_[ENSG00000007908]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2338329,"Cc1nc(C(=O)NCC(=O)O)c(O)c2ccc(Oc3ccccc3)cc12_|_YOZBGTLTNGAVFU-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROXADUSTAT_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Evrenzo']_|_['ASP-1517' 'ASP1517' 'FG-4592' 'FG4592' 'Roxadustat']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo'],
      dtype=object)), ('PubChem', array(['174006837'], dtype=object)), ('drugbank', array(['DB04847'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0004272', 'EFO_0003086', 'EFO_0008585',
       'EFO_0003884'], dtype=object), 'count': 5}_|_[ENSG00000269858,ENSG00000178467,ENSG00000135766,ENSG00000129521]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for anemia (phenotype) and chronic kidney disease and has 3 investigational indications."
CHEMBL2354773,"nan_|_nan_|_Small molecule_|_False_|_AUROTHIOGLUCOSE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Aureotan 100' 'Solganal']_|_['(1-thio-d-glucopyranosato)gold' 'Aureotan' 'Aurothioglucose' 'Aurumine'
 'Authron' 'Brenol' 'Glysanol b' 'Gold thioglucose'
 'Gold, (1-thio-d-glucopyranosato)-' 'NSC-759601' 'Oronol' 'Solganal b']_|_[('DrugCentral', array(['4349'], dtype=object)), ('PubChem', array(['144205102'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000198431]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for rheumatic disease."
CHEMBL3421729,"C[C@H]1c2cccc(CCC(C)(C)O)c2C[C@H](CO)N1C(=O)Cc1c(Cl)cccc1Cl_|_XHCSBQBBGNQINS-DOTOQJQBSA-N_|_Small molecule_|_False_|_MEVIDALEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-3154207' 'LY3154207' 'Ly3154207' 'Mevidalen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MEVIDALEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'MONDO_0005180', 'EFO_0006792'], dtype=object), 'count': 3}_|_[ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545323,"nan_|_nan_|_Small molecule_|_False_|_PWT-33579_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pwt-33579']_|_nan_|_nan_|_nan_|_[ENSG00000198793,ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3666807,"C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2c(cnn2-c2cccc(C(=O)N[C@@H]3CCOC3)c2)c1)c1ccc2c(c1)OCCO2_|_ZZWJKLGCDHYVMB-BWGXUDETSA-N_|_Small molecule_|_False_|_VELSECORAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-7594' 'AZD7594' 'Azd 7594' 'Azd7594' 'Velsecorat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VELSECORAT/relevant/1/'],
      dtype=object))]_|_['CHEMBL4093501']_|_{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3707246,"CC(C)Oc1ccc(-c2nc(-c3cccc4c3CC[C@@H]4NCCO)no2)cc1C#N.Cl_|_HAOOCAKHSFYDBU-BDQAORGHSA-N_|_Small molecule_|_False_|_OZANIMOD HYDROCHLORIDE_|_2020.0_|_4.0_|_CHEMBL3707247_|_False_|_True_|_['Zeposia']_|_['Ozanimod hydrochloride' 'RPC-1063 HCL' 'RPC1063 HCL']_|_[('DailyMed', array(['ozanimod%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005301', 'EFO_0000729', 'EFO_0003929'], dtype=object), 'count': 3}_|_[ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved indications."
CHEMBL3960488,"Cn1cc(-c2ccc(=O)n(Cc3cccc(-c4ncc(OCCN5CCOCC5)cn4)c3)n2)cn1_|_CIUKPBWULKEZMF-UHFFFAOYSA-N_|_Small molecule_|_False_|_EMD-1204831_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Emd-1204831']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3989555,"Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1.Cl.Cl.O_|_KDLHYOMCWBWLMM-UHFFFAOYSA-N_|_Small molecule_|_False_|_MECLIZINE HYDROCHLORIDE_|_1957.0_|_4.0_|_CHEMBL1623_|_False_|_True_|_['Ancoloxin' 'Antivert' 'Meclizine hydrochloride' 'Sea-legs' 'Traveleeze']_|_['Agyrax' 'Ancolan' 'Anhydrous meclozine hydrochloride' 'Bonamine'
 'Meclizine dihydrochloride monohydrate' 'Meclizine hcl'
 'Meclizine hydrochloride' 'Meclizine hydrochloride anhydrous'
 'Meclizine monohydrochloride' 'Meclozine dihydrochloride'
 'Meclozine hydrochloride' 'Meclozine hydrochloride monohydrate'
 'Meclozine monohydrochloride' 'NSC-28728' 'NSC-757094' 'Postafen'
 'UCB-5062']_|_[('DailyMed', array(['meclizine%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002013', 'EFO_0006928', 'HP_0002321', 'HP_0002018',
       'HP_0002017'], dtype=object), 'count': 5}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 5 approved indications."
CHEMBL3989767,"CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O_|_BBBFJLBPOGFECG-VJVYQDLKSA-N_|_Protein_|_False_|_CALCITONIN SALMON_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Calcimar' 'Calcitonin-salmon' 'Forcaltonin' 'Fortical' 'Miacalcin']_|_['Calcitonin (salmon synthetic)' 'Calcitonin salmon'
 'Calcitonin salmon recombinant']_|_[('DailyMed', array(['calcitonin%20salmon', 'calcitonin%20salmon%20recombinant'],
      dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/forcaltonin'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004261', 'GO_0042697', 'EFO_0003854', 'EFO_0005754',
       'HP_0000938', 'HP_0003072', 'EFO_0003882'], dtype=object), 'count': 7}_|_[ENSG00000004948]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 4 approved and 3 investigational indications."
CHEMBL4298067,"nan_|_nan_|_Antibody_|_False_|_TOMARALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['OPN-305' 'Opn 305' 'Opn-305' 'Tomaralimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOMARALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198'], dtype=object), 'count': 1}_|_[ENSG00000137462]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL559478,"O=C(Oc1ccc(Br)cc1)N1CCN2CCC1CC2_|_RXLOZRCLQMJJLC-UHFFFAOYSA-N_|_Small molecule_|_False_|_SSR180711_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['J2.849.107G' 'SSR-180,711' 'SSR-180711' 'SSR180711C' 'Ssr180711']_|_[('PubChem', array(['144210561'], dtype=object))]_|_['CHEMBL3235499']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1200323,"CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.Cl_|_WQVZLXWQESQGIF-UHFFFAOYSA-N_|_Small molecule_|_False_|_LABETALOL HYDROCHLORIDE_|_1984.0_|_4.0_|_CHEMBL429_|_False_|_True_|_['Labetalol Hydrocloride' 'Labetalol hydrochloride'
 'Labetalol hydrochloride in dextrose'
 'Labetalol hydrochloride in sodium chloride' 'Labrocol' 'Normodyne'
 'Trandate']_|_['AH 5158A' 'AH-5158A' 'AH-5158A HYDROCHLORIDE' 'Ibidomide hydrochloride'
 'Labetalol hcl' 'Labetalol hydrochloride' 'NSC-290312' 'SCH 15719W'
 'SCH-15719W' 'SCH-15719W HYDROCHLORIDE']_|_[('DailyMed', array(['labetalol%20hydrochloride'], dtype=object)), ('PubChem', array(['144204174', '144213042', '26747550', '50106500', '56422413',
       '855542'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0005669', 'EFO_0000668'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000150594,ENSG00000043591,ENSG00000169252,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for hypertension and has 2 investigational indications."
CHEMBL1200616,"NS(=O)(=O)c1cc2c(cc1Cl)N=C[N-]S2(=O)=O.[Na+]_|_CPIWHAFLBZQYLQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLOROTHIAZIDE SODIUM_|_1958.0_|_4.0_|_CHEMBL842_|_False_|_True_|_['Chlorothiazide sodium' 'Diuril']_|_['Chlorothiazide sodium' 'Chlorothiazide sodium salt']_|_[('DailyMed', array(['chlorothiazide%20sodium'], dtype=object))]_|_nan_|_nan_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1958."
CHEMBL1200751,"O.S=c1[nH]cnc2nc[nH]c12_|_WFFQYWAAEWLHJC-UHFFFAOYSA-N_|_Small molecule_|_False_|_MERCAPTOPURINE_|_1953.0_|_4.0_|_CHEMBL1425_|_False_|_True_|_['Mercaptopurine' 'Puri-nethol' 'Purinethol' 'Purixan' 'Xaluprine'
 'Xaluprine (previously mercaptopurine nova laboratories)']_|_['6-mercaptopurine monohydrate' 'Mercaptopurine' 'Mercaptopurine hydrate'
 'Mercaptopurinum' 'NSC-755' 'NSC-759614']_|_[('DailyMed', array(['mercaptopurine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xaluprine'],
      dtype=object)), ('PubChem', array(['103804943', '57260342'], dtype=object)), ('chEBI', array(['31822'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0000873', 'EFO_0000309', 'MONDO_0044917', 'MONDO_0019460',
       'EFO_0000574', 'EFO_0000565', 'EFO_0000224', 'EFO_0003833',
       'EFO_0004289', 'MONDO_0003268', 'EFO_0002501', 'EFO_0000729',
       'MONDO_0000870', 'EFO_0000616', 'EFO_0000209', 'EFO_0000222',
       'EFO_0000094', 'EFO_0000519', 'EFO_0000384', 'EFO_0003872',
       'EFO_0002499', 'EFO_1000318', 'EFO_0000220'], dtype=object), 'count': 23}_|_[ENSG00000128059]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 5 approved and 18 investigational indications."
CHEMBL1201831,"nan_|_nan_|_Antibody_|_True_|_CERTOLIZUMAB PEGOL_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Cimzia']_|_['CDP 870' 'CDP-870' 'CDP870' 'Certolizumab pegol' 'PHA-738144']_|_[('DailyMed', array(['certolizumab%20pegol'], dtype=object)), ('DrugCentral', array(['4968'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia'],
      dtype=object)), ('Wikipedia', array(['Certolizumab_pegol'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000540', 'EFO_0000384', 'MP_0001845', 'EFO_0000685',
       'EFO_0003898', 'EFO_0002609', 'EFO_0000676', 'EFO_0000729',
       'EFO_0003778', 'EFO_1000869'], dtype=object), 'count': 10}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1472989,"CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1.CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1.O=C(O)/C=C/C(=O)O_|_VMDFASMUILANOL-WXXKFALUSA-N_|_Small molecule_|_False_|_BISOPROLOL FUMARATE_|_1992.0_|_4.0_|_CHEMBL645_|_False_|_True_|_['Bipranix' 'Bisoprolol fumarate' 'Cardicor' 'Concor' 'Congescor' 'Emcor'
 'Emcor ls' 'Isoten mitis' 'Monocor' 'Soloc' 'Soprol' 'Vivacor' 'Zebeta']_|_['Bisoprolol fumarate' 'Bisoprolol hemifumarate' 'CL 297,939' 'CL-297939'
 'Detensiel' 'EMD-33-512' 'EMD-33512' 'Emconcor' 'Euradal' 'Isoten'
 'Speridol']_|_[('DailyMed', array(['bisoprolol%20fumarate'], dtype=object)), ('PubChem', array(['144204814', '144206959', '170464815', '26753629'], dtype=object)), ('chEBI', array(['3128'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_79292', 'MONDO_0010679', 'EFO_0005672', 'EFO_0000537'],
      dtype=object), 'count': 4}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for hypertension and has 3 investigational indications."
CHEMBL1726,"COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]_|_VKQFCGNPDRICFG-UHFFFAOYSA-N_|_Small molecule_|_False_|_NISOLDIPINE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Nisoldipine' 'Sular' 'Syscor mr 10' 'Syscor mr 20' 'Syscor mr 30']_|_['BAY K 5552' 'BAY-K-5552' 'Baymycard' 'Geomatrix 16e' 'NSC-759106'
 'Nisoldipin' 'Nisoldipine' 'Nisoldipine (stn)']_|_[('DailyMed', array(['nisoldipine'], dtype=object)), ('PubChem', array(['144205804', '144212682', '170465320', '26758055'], dtype=object)), ('Wikipedia', array(['Nisoldipine'], dtype=object)), ('drugbank', array(['DB00401'], dtype=object)), ('chEBI', array(['76917'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000319'], dtype=object), 'count': 2}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and is indicated for hypertension and cardiovascular disease."
CHEMBL2107844,nan_|_nan_|_Protein_|_False_|_BRIOBACEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BR-3-FC' 'BR3-FC' 'Briobacept' 'SS-79']_|_nan_|_nan_|_nan_|_[ENSG00000102524]_|_Protein drug with a maximum clinical trial phase of II.
CHEMBL2108258,nan_|_nan_|_Antibody_|_False_|_ATOROLIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atorolimumab']_|_nan_|_nan_|_nan_|_[ENSG00000187010]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108791,"nan_|_nan_|_Enzyme_|_False_|_TENECTEPLASE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Metalyse']_|_['Rhtnk-tpa' 'TNK-TPA' 'Tenecteplase']_|_[('DailyMed', array(['tenecteplase'], dtype=object)), ('DrugCentral', array(['5066'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/metalyse'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003827', 'EFO_0009637', 'MONDO_0002679', 'EFO_0000712',
       'EFO_0008585', 'HP_0002140', 'EFO_0008583', 'HP_0004419',
       'EFO_1000637', 'EFO_0000612', 'EFO_0000618', 'MONDO_0005299',
       'MONDO_0000831', 'EFO_0004278', 'EFO_1001154'], dtype=object), 'count': 15}_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 4 approved and 11 investigational indications."
CHEMBL2109255,"nan_|_nan_|_Antibody_|_False_|_HEFI-1_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['HEFI-1' 'Hefi-1']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000120949]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2109282,"nan_|_nan_|_Antibody drug conjugate_|_False_|_RG-7636_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['DEDN-6526A' 'RG-7636']_|_nan_|_nan_|_nan_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000136160]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I."
CHEMBL325109,"COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1_|_BVPWJMCABCPUQY-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLEBOPRIDE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Clanzoflat']_|_['Amicos' 'Clanzol' 'Clast' 'Clebopride' 'Clebopride hydrogen malate'
 'Clebopride malate' 'Cleprid' 'LAS 9273' 'LAS-9273' 'Motilex']_|_[('PubChem', array(['11112867'], dtype=object)), ('Wikipedia', array(['Clebopride'], dtype=object)), ('drugbank', array(['DB13511'], dtype=object))]_|_['CHEMBL1599248']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000164270,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for gastrointestinal disease."
CHEMBL350775,"COc1cc(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCc2cccnc2)CCCc2cccnc2)cc(OC)c1OC_|_CGVWPQOFHSAKRR-NDEPHWFRSA-N_|_Small molecule_|_False_|_BIRICODAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Biricodar']_|_[('Wikipedia', array(['Biricodar'], dtype=object)), ('drugbank', array(['DB04851'], dtype=object))]_|_['CHEMBL2104406']_|_{'rows': array(['MONDO_0008903'], dtype=object), 'count': 1}_|_[ENSG00000085563,ENSG00000103222]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL354077,"Nc1ccncc1N_|_OYTKINVCDFNREN-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMIFAMPRIDINE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Ruzurgi']_|_['3,4-DAP' '3,4-Diammoniopyridinium' '4-DAP' 'Amifampridine' 'DAP'
 'Dynamine' 'NSC-521760' 'Pyridine-3,4-Diamine']_|_[('PubChem', array(['144206108', '170466846', '50112814', '51088028', '56323425'],
      dtype=object)), ('Wikipedia', array(['3,4-Diaminopyridine'], dtype=object)), ('drugbank', array(['DB11640'], dtype=object))]_|_['CHEMBL3301611']_|_{'rows': array(['EFO_0008525', 'EFO_0004991', 'MONDO_0005301', 'EFO_0005542',
       'EFO_0004991', 'EFO_0004991', 'MONDO_0015263', 'EFO_0020094',
       'EFO_0004991', 'EFO_0020094', 'EFO_0009851'], dtype=object), 'count': 11}_|_[ENSG00000053918,ENSG00000171385,ENSG00000055118,ENSG00000177301,ENSG00000111262,ENSG00000075043,ENSG00000184156,ENSG00000104848,ENSG00000185760,ENSG00000117013,ENSG00000143473,ENSG00000182255,ENSG00000130037,ENSG00000177272,ENSG00000151079,ENSG00000129159,ENSG00000184408,ENSG00000182674,ENSG00000116396,ENSG00000131398,ENSG00000158445,ENSG00000143105,ENSG00000164794,ENSG00000140015,ENSG00000171126,ENSG00000168418,ENSG00000168263,ENSG00000124134,ENSG00000183960,ENSG00000166006,ENSG00000170745,ENSG00000173826,ENSG00000162975,ENSG00000184611,ENSG00000102057,ENSG00000026559,ENSG00000178342,ENSG00000135519,ENSG00000156486,ENSG00000089558]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for myasthenia gravis and lambert-eaton myasthenic syndrome and has 6 investigational indications."
CHEMBL3544991,"nan_|_nan_|_Antibody_|_False_|_DOMAGROZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Domagrozumab' 'PF-06252616']_|_nan_|_nan_|_{'rows': array(['MONDO_0010679'], dtype=object), 'count': 1}_|_[ENSG00000138379]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545074,nan_|_nan_|_Small molecule_|_False_|_LEO-15520_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Leo-15520']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707248,"COc1cc2c(cc1OC)[C@H]1C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CC2.Cc1ccc(S(=O)(=O)O)cc1.Cc1ccc(S(=O)(=O)O)cc1_|_BXGKAGLZHGYAMW-TZYFFPFWSA-N_|_Small molecule_|_True_|_VALBENAZINE TOSYLATE_|_2017.0_|_4.0_|_CHEMBL2364639_|_False_|_True_|_['Ingrezza']_|_['NBI-98854' 'Valbenazine ditosylate' 'Valbenazine tosilate'
 'Valbenazine tosylate']_|_[('DailyMed', array(['valbenazine%20tosylate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004280'], dtype=object), 'count': 1}_|_[ENSG00000165646]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for movement disorder. This drug has a black box warning from the FDA."
CHEMBL3707365,"nan_|_nan_|_Oligosaccharide_|_False_|_BEMIPARIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bemiparin']_|_[('DrugCentral', array(['4840'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001422', 'HP_0000083', 'EFO_0000702', 'EFO_1001459',
       'MONDO_0100096', 'HP_0004419'], dtype=object), 'count': 6}_|_[ENSG00000126218]_|_Oligosaccharide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4298123,"nan_|_nan_|_Antibody_|_False_|_COBOLIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cobolimab' 'TSR-022' 'Tsr 022' 'Tsr-022' 'WBP-296A']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/COBOLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002691', 'EFO_0000616', 'EFO_0000756', 'EFO_0003060'],
      dtype=object), 'count': 4}_|_[ENSG00000135077]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4594424,"CC(C)C[C@H]1NC(=O)[C@@H](C)N(C)C(=O)[C@H](C2CC2)NC[C@@H](C)Oc2ccccc2CC[C@H](C)NC1=O_|_HIIMPSTXUQUYOO-FPJBJBNZSA-N_|_Protein_|_False_|_TZP-102_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TZP-102' 'Tzp-102']_|_nan_|_nan_|_{'rows': array(['EFO_1000948'], dtype=object), 'count': 1}_|_[ENSG00000121853]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL482968,"Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1_|_BLQYVHBZHAISJM-CMDGGOBGSA-N_|_Small molecule_|_False_|_ENMD-2076_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ENMD-2076' 'Enmd 2076' 'Enmd-2076']_|_nan_|_['CHEMBL3237191']_|_{'rows': array(['EFO_0001642', 'MONDO_0004992', 'EFO_0000348', 'MONDO_0002087',
       'EFO_1001968', 'EFO_1000251', 'MONDO_0008170', 'MONDO_0007254',
       'EFO_0001378', 'EFO_0000182'], dtype=object), 'count': 10}_|_[ENSG00000182578,ENSG00000178999,ENSG00000068078,ENSG00000157404,ENSG00000122025,ENSG00000087586,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL5095023,N#C/C(=C\C=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1_|_DTCCYSMPUUYHOF-LHQXNBGVSA-N_|_Small molecule_|_False_|_LS-104_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ls-104' 'Tyrene cr-4']_|_nan_|_nan_|_nan_|_[ENSG00000096968]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL534,"CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1_|_ZCVMWBYGMWKGHF-UHFFFAOYSA-N_|_Small molecule_|_False_|_KETOTIFEN_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(R)-Ketotifen' 'Ketotifen']_|_[('PubChem', array(['104171180', '11111350', '11111351', '11113338', '144203727',
       '170465378', '26751502', '50100258', '50104048', '90341121'],
      dtype=object)), ('Wikipedia', array(['Ketotifen'], dtype=object)), ('drugbank', array(['DB00920'], dtype=object))]_|_['CHEMBL1885671' 'CHEMBL1633']_|_{'rows': array(['EFO_1001417', 'EFO_0005687', 'MONDO_0002406', 'MONDO_0005271',
       'EFO_0008533', 'EFO_0007141', 'HP_0012532', 'EFO_0004149',
       'EFO_1001417', 'EFO_0007141', 'EFO_0000274', 'MONDO_0100096',
       'HP_0001371', 'EFO_0003931', 'EFO_0007425', 'EFO_0005751'],
      dtype=object), 'count': 16}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for allergic disease and eye allergy and has 12 investigational indications."
CHEMBL647,"Nc1cc(Cl)c(N=C2NCCN2)c(Cl)c1_|_IEJXVRYNEISIKR-UHFFFAOYSA-N_|_Small molecule_|_False_|_APRACLONIDINE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Iopidine']_|_['Apraclonidine']_|_[('PubChem', array(['11110712', '50110931', '90341674'], dtype=object)), ('Wikipedia', array(['Apraclonidine'], dtype=object)), ('drugbank', array(['DB00964'], dtype=object)), ('chEBI', array(['2788'], dtype=object))]_|_['CHEMBL1200379']_|_{'rows': array(['MONDO_0005041', 'EFO_0004991'], dtype=object), 'count': 2}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for glaucoma and has 1 investigational indication."
CHEMBL1083385,"COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.O=S(=O)(O)O_|_FDEODCTUSIWGLK-RSAXXLAASA-N_|_Small molecule_|_True_|_CLOPIDOGREL BISULFATE_|_1997.0_|_4.0_|_CHEMBL1771_|_False_|_True_|_['Clopidogrel bisulfate' 'Iscover' 'Plavix']_|_['Clopidogrel (as bisulfate)' 'Clopidogrel (as hydrogen sulfate)'
 'Clopidogrel bisulfate' 'Clopidogrel bisulphate' 'Clopidogrel bms'
 'Clopidogrel hydrogen sulfate' 'Clopidogrel hydrogen sulphate'
 'Clopidogrel ratiopharm' 'Clopidogrel sulfate' 'Clopidogrel teva'
 'Clopidogrel zentiva' 'Clopidogrel-bgr' 'Clopidogrel-bms' 'Isocover'
 'Pidogrel' 'SR 25990C' 'SR-25990C']_|_[('DailyMed', array(['clopidogrel%20bisulfate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/iscover'],
      dtype=object)), ('PubChem', array(['144205123', '170465231'], dtype=object)), ('chEBI', array(['3759'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005672', 'EFO_0004265', 'EFO_0000612', 'EFO_0001645',
       'EFO_0003869', 'HP_0002239', 'EFO_0000712', 'HP_0002140',
       'EFO_1000985', 'EFO_0000556'], dtype=object), 'count': 10}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 6 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1130,"C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O_|_ZWAOHEXOSAUJHY-ZIYNGMLESA-N_|_Small molecule_|_False_|_DOXIFLURIDINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_[""5'-Deoxy-5-Fluorouridine"" 'Capecitabine related compound b'
 'Doxifluridine' 'Flutron' 'Fulturon' 'Furtulon' 'NSC-758890' 'RO 219738'
 'RO-219738']_|_[('PubChem', array(['144204782', '170465861', '29215154', '50106323', '50106324',
       '56320807', '56322615', '90341388'], dtype=object)), ('drugbank', array(['DB12947'], dtype=object)), ('chEBI', array(['31521'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001056'], dtype=object), 'count': 1}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1200478,"CCCCOc1ccc(C(=O)CCN2CCCCC2)cc1.Cl_|_KNZADIMHVBBPOA-UHFFFAOYSA-N_|_Small molecule_|_False_|_DYCLONINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201217_|_False_|_True_|_['Dyclone']_|_['Dyclocaine' 'Dyclonine HCl' 'Dyclonine hcl' 'Dyclonine hydrochloride'
 'NSC-23018']_|_[('DailyMed', array(['dyclonine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204010', '170464776', '26748011', '26748012', '50107329',
       '50107330', '56422189', '855952'], dtype=object)), ('chEBI', array(['4725'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200976,"CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl_|_JVHPTYWUBOQMBP-RVFAQHLVSA-N_|_Small molecule_|_True_|_IDARUBICIN HYDROCHLORIDE_|_1990.0_|_4.0_|_CHEMBL1117_|_False_|_True_|_['Idamycin' 'Idamycin pfs' 'Idarubicin hydrochloride'
 'Idarubicin hydrochloride pfs' 'Zavedos']_|_['IMI 30' 'IMI-30' 'Idarubicin hcl' 'Idarubicin hydrochloride'
 'NSC-256439']_|_[('DailyMed', array(['idarubicin%20hydrochloride'], dtype=object)), ('PubChem', array(['144204787', '170464627', '49681632'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000182', 'MONDO_0004643'], dtype=object), 'count': 3}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for acute myeloid leukemia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201613,"nan_|_nan_|_Protein_|_False_|_INSULIN GLULISINE_|_2004.0_|_4.0_|_nan_|_False_|_True_|_['Apidra' 'Apidra solostar' 'Ins apidra' 'Ins apidra opticlik'
 'Ins apidra optiset' 'Ins apidra solostar']_|_['Glulisine apidra' 'HMR 1964' 'HMR-1964' 'HMR1964'
 'Insulin Glulisine Recombinant' 'Insulin glulisine'
 'Insulin glulisine recombinant' 'Insulin, glulisine, human'
 'Insulin,glulisine,human']_|_[('DailyMed', array(['insulin%20glulisine%20recombinant'], dtype=object)), ('DrugCentral', array(['5057'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/apidra'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0001064', 'EFO_0000400', 'EFO_0008583',
       'MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 6}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and is indicated for diabetes mellitus and has 5 investigational indications."
CHEMBL1607,"CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl_|_DGHHQBMTXTWTJV-BQAIUKQQSA-N_|_Small molecule_|_True_|_TOPOTECAN HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL84_|_False_|_True_|_['Hycamptin' 'Hycamtin' 'Potactasol' 'Topotecan' 'Topotecan hydrochloride']_|_['Evotopin' 'NSC-759263' 'Nogitecan hydrochloride' 'SK&F S-104864-A'
 'SK&F-S-104864A' 'SK-S-104864-A' 'Topotecan'
 'Topotecan (as hydrochloride)' 'Topotecan actavis' 'Topotecan hcl'
 'Topotecan hospira' 'Topotecan hydrochloride' 'Topotecan teva']_|_[('DailyMed', array(['topotecan%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin'],
      dtype=object)), ('PubChem', array(['144205031', '170465137', '26749084', '4254372', '49681835',
       '50107520', '580652'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003833', 'EFO_0008498', 'MONDO_0002158', 'EFO_0002087',
       'MONDO_0100342', 'MONDO_0008903', 'EFO_0002918', 'EFO_0002617',
       'EFO_0000613', 'EFO_1000158', 'EFO_0000466', 'EFO_0000519',
       'EFO_0000621', 'MONDO_0008380', 'MONDO_0037745', 'EFO_0002939',
       'MONDO_0100096', 'EFO_0000630', 'EFO_1001465', 'EFO_0000702',
       'EFO_0001416', 'EFO_0003893', 'MONDO_0004992', 'EFO_0005543',
       'EFO_0001378', 'EFO_0000502', 'EFO_1001042', 'EFO_0000565',
       'EFO_1000251', 'EFO_0000681', 'EFO_0000220', 'EFO_0000691',
       'EFO_0008524', 'MONDO_0019004', 'EFO_0000198', 'EFO_1001100',
       'EFO_0002501', 'MONDO_0007576', 'EFO_1000823', 'EFO_0005561',
       'EFO_0005537', 'EFO_0002428', 'EFO_0002499', 'MONDO_0007254',
       'EFO_0000174', 'EFO_1000657', 'EFO_0000326', 'EFO_0001075',
       'EFO_0001061', 'EFO_0000616', 'EFO_0005952', 'EFO_0000389',
       'EFO_0000313', 'EFO_0003060', 'EFO_0003851', 'EFO_0003869',
       'MONDO_0021063', 'EFO_0000574', 'MONDO_0011962', 'MONDO_0006058',
       'EFO_0000222', 'EFO_1001331', 'MONDO_0018271', 'MONDO_0002974',
       'EFO_0007362', 'MONDO_0018364', 'EFO_1000895', 'MONDO_0008170',
       'MONDO_0008315', 'MONDO_0002380', 'MONDO_0002087', 'EFO_1000043'],
      dtype=object), 'count': 72}_|_[ENSG00000184428]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 7 approved and 65 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743045,"nan_|_nan_|_Antibody drug conjugate_|_False_|_NAPTUMOMAB ESTAFENATOX_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABR-217620' 'ANYARA' 'ANYARA TTS CD3' 'Naptumomab estafenatox' 'TTS CD3'
 'TTS-CD3']_|_nan_|_nan_|_{'rows': array(['EFO_0000681', 'EFO_0008528', 'EFO_0003060'], dtype=object), 'count': 3}_|_[ENSG00000146242]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL209821,"CC(=O)Nc1cccc(N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2)c1_|_SPWZXWDPAWDKQE-UHFFFAOYSA-N_|_Small molecule_|_False_|_NALUZOTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Naluzotan' 'PRX-00023']_|_[('drugbank', array(['DB05562'], dtype=object))]_|_['CHEMBL2105647']_|_{'rows': array(['MONDO_0002009', 'EFO_0000773', 'EFO_0005230'], dtype=object), 'count': 3}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2104984,"Cc1cc(SCc2sc(-c3ccc(C(F)(F)F)cc3F)nc2C)ccc1OC(C)(C)C(=O)O_|_ZUGQWAYOWCBWGM-UHFFFAOYSA-N_|_Small molecule_|_False_|_SODELGLITAZAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW-677954' 'GW677954' 'Sodelglitazar']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000195'], dtype=object), 'count': 2}_|_[ENSG00000132170,ENSG00000186951,ENSG00000112033]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2356023,"CC(C)[C@@H](C)/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C[C@@H](O)CC[C@@H]3C)CCC[C@]12C_|_ILYCWAKSDCYMBB-OPCMSESCSA-N_|_Small molecule_|_False_|_DIHYDROTACHYSTEROL_|_nan_|_4.0_|_nan_|_False_|_True_|_['A.t. 10' 'Dihydral' 'Dygratyl' 'Tachyrol']_|_['Dichysterol' 'Dihydrotachysterol' 'Dihydrotachysterol 2'
 'Dihydrotachysterol2' 'Tachysterol dihydro derivative' 'Vitamin d1']_|_[('PubChem', array(['144205894'], dtype=object)), ('drugbank', array(['DB01070'], dtype=object)), ('chEBI', array(['4591'], dtype=object))]_|_nan_|_nan_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV."
CHEMBL238804,"CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(-c2ccccc2)n1_|_QXWZQTURMXZVHJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELEXIPAG_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Uptravi']_|_['ACT-293987' 'NS-304' 'Selexipag']_|_[('DailyMed', array(['selexipag'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi'],
      dtype=object)), ('drugbank', array(['DB11362'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0017147', 'EFO_0001361', 'MONDO_0005149', 'HP_0004419'],
      dtype=object), 'count': 4}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved indications."
CHEMBL24072,"CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1_|_IFFPICMESYHZPQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRENYLAMINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['B-436' 'Prenylamine' 'Prenylamine lactate']_|_[('Wikipedia', array(['Prenylamine'], dtype=object)), ('drugbank', array(['DB04825'], dtype=object))]_|_['CHEMBL1367944']_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000183873,ENSG00000198668]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for cardiovascular disease. It was withdrawn in at least one region."
CHEMBL3545035,"COCCCN1CC[C@@H](CNC(=O)c2cc(Cl)c(N)c3c2OC(C)(C)C3)[C@H](O)C1_|_FOUUNSGQVBGYQM-SUMWQHHRSA-N_|_Small molecule_|_False_|_REVEXEPRIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-revexepride' 'R-149402' 'R149402' 'Revexepride' 'SPD-557' 'SPD557'
 'Ssp-002358']_|_nan_|_nan_|_{'rows': array(['EFO_0003948'], dtype=object), 'count': 1}_|_[ENSG00000164270]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3935857,"Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1_|_BLGWHBSBBJNKJO-UHFFFAOYSA-N_|_Small molecule_|_False_|_SERABELISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGN-PC-0DB6FL' 'INK1117' 'Ink-1117' 'MLN-1117' 'MLN1117' 'Mln-1117'
 'Serabelisib' 'TAK-117' 'Tak-117']_|_[('drugbank', array(['DB14935'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000681', 'EFO_0003060', 'EFO_0000616',
       'EFO_0004230'], dtype=object), 'count': 5}_|_[ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3963485,"COCc1c(-c2cc3cc(C)cc(OC)c3s2)c2c(N)ncnn2c1CN1CCNC(=O)C1_|_HNLRRJSKGXOYNO-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROGARATINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY-1163877' 'Bay-1163877' 'Rogaratinib']_|_[('drugbank', array(['DB15078'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0004992', 'EFO_0008528', 'EFO_0000616',
       'MONDO_0001187', 'EFO_0003060'], dtype=object), 'count': 6}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3989768,"CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O.O.O=C(O)C(O)C(O)C(=O)O_|_UMZNDVASJKIQCB-SODJFYQGSA-N_|_Small molecule_|_True_|_LEVORPHANOL TARTRATE_|_1991.0_|_4.0_|_CHEMBL592_|_False_|_True_|_['Dromoran' 'Levo-dromoran' 'Levorphanol tartrate']_|_['Levorphanol tartrate' 'Levorphanol tartrate anhydrous'
 'Levorphanol tartrate dihydrate' 'NSC-91012']_|_[('DailyMed', array(['levorphanol%20tartrate'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991. This drug has a black box warning from the FDA."
CHEMBL4297294,"O=C(Nc1cnccc1Cl)N1CCN(Cc2ccc3c(c2)OC(F)(F)O3)CC1_|_YWGYNGCRVZLMCS-UHFFFAOYSA-N_|_Small molecule_|_False_|_JNJ-42165279_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Jnj-42165279']_|_[('drugbank', array(['DB15173'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003756', 'EFO_1001908'], dtype=object), 'count': 2}_|_[ENSG00000117480]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297604,"O=C(O)c1ccc(CN2C[C@@H]3C[C@H]2CN3Cc2ccc(Oc3ccc(-c4ncco4)cc3)cc2)cc1_|_GERJIEKMNDGSCS-DQEYMECFSA-N_|_Small molecule_|_False_|_ACEBILUSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Acebilustat' 'CTX-4430' 'Ctx-4430' 'EP-501']_|_[('drugbank', array(['DB15385'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'MONDO_0019297', 'EFO_0003894', 'MONDO_0100096'],
      dtype=object), 'count': 4}_|_[ENSG00000111144]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297809,"nan_|_nan_|_Antibody_|_True_|_ELRANATAMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Elrexfio']_|_['Elranatamab' 'PF-06863135' 'Pf-06863135' 'RN-613' 'RN613']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELRANATAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000048462,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for multiple myeloma and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL523299,"OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]_|_PEJHHXHHNGORMP-UHFFFAOYSA-M_|_Small molecule_|_False_|_UMECLIDINIUM BROMIDE_|_2013.0_|_4.0_|_CHEMBL1187833_|_False_|_True_|_['Incruse ellipta' 'Incruse ellipta (previously incruse)'
 'Rolufta ellipta (previously rolufta)']_|_['Anoro ellipta' 'GSK-573719A' 'GSK573719A' 'Umeclidinium brom'
 'Umeclidinium bromide']_|_[('DailyMed', array(['umeclidinium%20bromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta-previously-incruse',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/rolufta-ellipta'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000464', 'HP_0006536', 'EFO_0000341', 'MONDO_0004979',
       'EFO_0006505'], dtype=object), 'count': 5}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 4 approved and 1 investigational indication."
CHEMBL5314389,O=C(N[C@@H](Cc1ccc(OCc2ccc3ccc(F)cc3n2)cc1)C(=O)[O-])c1ccc2ccccc2n1.[Na+]_|_KGZGMOFDZSCICN-YCBFMBTMSA-M_|_Small molecule_|_False_|_CR-3465_|_nan_|_1.0_|_CHEMBL5316169_|_False_|_False_|_[]_|_['CR3465' 'Cr-3465']_|_nan_|_nan_|_nan_|_[ENSG00000173198]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL698,"CCCCNc1ccc(C(=O)OCCN(C)C)cc1_|_GKCBAIGFKIBETG-UHFFFAOYSA-N_|_Small molecule_|_False_|_TETRACAINE_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Ametop' 'Dicaine' 'Pontocaine']_|_['Amethocaine' 'Tetracaine']_|_[('DailyMed', array(['tetracaine'], dtype=object)), ('PubChem', array(['11111916', '11111917', '50111267', '90340576'], dtype=object)), ('Wikipedia', array(['Tetracaine'], dtype=object)), ('drugbank', array(['DB09085'], dtype=object)), ('chEBI', array(['9468'], dtype=object))]_|_['CHEMBL1255654']_|_{'rows': array(['EFO_0000701', 'EFO_1001054', 'EFO_0004616', 'EFO_1001434',
       'HP_0000989', 'MONDO_0005129', 'EFO_0009552', 'EFO_1001178',
       'EFO_0003843', 'EFO_0004143', 'MONDO_0041052', 'EFO_0000546'],
      dtype=object), 'count': 12}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 9 investigational indications."
CHEMBL710,"CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C_|_DBEPLOCGEIEOCV-WSBQPABSSA-N_|_Small molecule_|_False_|_FINASTERIDE_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Aindeem' 'Finasteride' 'Propecia' 'Proscar' 'Prostide']_|_['Finasteride' 'MK-906' 'NSC-741485' 'NSC-759318']_|_[('DailyMed', array(['finasteride'], dtype=object)), ('PubChem', array(['144204268', '144208704', '144213061', '170464818', '26719811',
       '26753508', '26753509', '49666458'], dtype=object)), ('Wikipedia', array(['Finasteride'], dtype=object)), ('drugbank', array(['DB01216'], dtype=object)), ('chEBI', array(['5062'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003839', 'EFO_0004191', 'EFO_0000673', 'EFO_0000284',
       'MONDO_0008315', 'EFO_0000536', 'MONDO_0004907', 'MONDO_0002146',
       'MONDO_0003037', 'EFO_0003894', 'EFO_0001663', 'EFO_0003060'],
      dtype=object), 'count': 12}_|_[ENSG00000277893]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 6 approved and 6 investigational indications."
CHEMBL741,"Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1_|_PYZRQGJRPPTADH-UHFFFAOYSA-N_|_Small molecule_|_True_|_LAMOTRIGINE_|_1994.0_|_4.0_|_nan_|_False_|_True_|_['Lamictal' 'Lamictal cd' 'Lamictal odt' 'Lamictal xr' 'Lamotrigine']_|_['BW 430C' 'BW-430C' 'Lamotrigine' 'NSC-759171']_|_[('DailyMed', array(['lamotrigine'], dtype=object)), ('PubChem', array(['11113342', '144203730', '170465024', '174006315', '26719658',
       '50104089', '56423136', '85231112', '855818', '90341162'],
      dtype=object)), ('Wikipedia', array(['Lamotrigine'], dtype=object)), ('drugbank', array(['DB00555'], dtype=object)), ('chEBI', array(['6367'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'HP_0001250', 'EFO_0003890', 'MONDO_0005090',
       'MONDO_0041052', 'EFO_0000474', 'MONDO_0016532', 'EFO_0009963',
       'MONDO_0007079', 'HP_0000726', 'EFO_0002610', 'MONDO_0010826',
       'EFO_0003843', 'MONDO_0002050', 'EFO_0000677', 'EFO_0003100',
       'HP_0002069', 'EFO_0005230', 'EFO_0001073', 'EFO_0005203',
       'HP_0100543', 'MONDO_0004985', 'EFO_0005611', 'EFO_0004263',
       'Orphanet_79292', 'EFO_0008522', 'MONDO_0018975', 'EFO_0007262',
       'EFO_0003929', 'EFO_0004247', 'MONDO_0002009'], dtype=object), 'count': 31}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 10 approved and 21 investigational indications. This drug has a black box warning from the FDA."
CHEMBL753,"CC(COc1ccccc1)N(CCCl)Cc1ccccc1_|_QZVCTJOXCFMACW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENOXYBENZAMINE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bensylyt' 'Benzylyt' 'Dibenylin' 'Phenoxybenzamine']_|_[('PubChem', array(['104171113', '124879342', '124879343', '144203638', '170465147',
       '174007411', '26752309', '26752310', '90341231'], dtype=object)), ('Wikipedia', array(['Phenoxybenzamine'], dtype=object)), ('drugbank', array(['DB00925'], dtype=object)), ('chEBI', array(['8077'], dtype=object))]_|_['CHEMBL1200787']_|_{'rows': array(['EFO_0005207', 'EFO_0000239', 'EFO_0000319'], dtype=object), 'count': 3}_|_[ENSG00000120907,ENSG00000150594,ENSG00000184160,ENSG00000171873,ENSG00000170214,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and is indicated for adrenal gland pheochromocytoma and cardiovascular disease and has 1 investigational indication."
CHEMBL1200549,"C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1.[Br-]_|_LVQTUXZKLGXYIU-GWSNJHLMSA-M_|_Small molecule_|_False_|_RAPACURONIUM BROMIDE_|_1999.0_|_4.0_|_CHEMBL1201352_|_True_|_True_|_['Raplon']_|_['ORG 9487' 'ORG-9487' 'Rapacuronium bromide']_|_[('PubChem', array(['144206855'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999. It was withdrawn in at least one region."
CHEMBL1201490,"nan_|_nan_|_Protein_|_False_|_SERMORELIN ACETATE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_['Geref']_|_['Groliberin' 'Sermorelin' 'Sermorelin acetate']_|_[('Wikipedia', array(['Sermorelin'], dtype=object))]_|_nan_|_nan_|_[ENSG00000106128]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1990."
CHEMBL1201539,"nan_|_nan_|_Protein_|_False_|_INSULIN PORK_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Iletin i' 'Insulin' 'Regular insulin']_|_['Insulin porcine' 'Insulin porcine insulin' 'Insulin pork']_|_[('DrugCentral', array(['5191'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002614', 'MONDO_0005148', 'MONDO_0005147', 'EFO_0003931',
       'EFO_0001645', 'EFO_0000400'], dtype=object), 'count': 6}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 6 investigational indications."
CHEMBL1245,"CC1(C)C2CCC1(CS(=O)(=O)[O-])C(=O)C2.O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1_|_HALWUDBBYKMYPW-UHFFFAOYSA-M_|_Small molecule_|_False_|_TRIMETHAPHAN CAMSYLATE_|_1982.0_|_4.0_|_CHEMBL1201329_|_False_|_True_|_['Arfonad']_|_['NU-2222' 'Trimetaphan camsilate' 'Trimetaphan camsylate'
 'Trimethaphan Camsylate' 'Trimethaphan camphorsulfonate'
 'Trimethaphan camsylate']_|_[('Wikipedia', array(['Trimetaphan_camsilate'], dtype=object))]_|_nan_|_nan_|_[ENSG00000117971,ENSG00000080644]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1287853,"Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1_|_JOOXLOJCABQBSG-UHFFFAOYSA-N_|_Small molecule_|_True_|_FEDRATINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Fedratinib' 'SAR-302503' 'SAR302503' 'Sar-302503' 'TG-101348' 'TG101348']_|_[('drugbank', array(['DB12500'], dtype=object))]_|_['CHEMBL4297216']_|_{'rows': array(['EFO_0004251', 'EFO_0000198', 'EFO_0000616', 'EFO_0001421',
       'EFO_1000179', 'EFO_0002430', 'EFO_0002430', 'HP_0011974',
       'MONDO_0044903', 'EFO_0003086', 'EFO_0004251'], dtype=object), 'count': 11}_|_[ENSG00000096968,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1370561,"Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN_|_FQPFAHBPWDRTLU-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMINOPHYLLINE_|_1940.0_|_4.0_|_CHEMBL190_|_False_|_True_|_['Aminophyllin' 'Aminophylline' 'Aminophylline In Sodium Chloride'
 'Aminophylline dye free' 'Ammophyllin' 'Amnivent-225 sr'
 'Amnivent-350 sr' 'Peterphyllin' 'Phyllocontin' 'Somophyllin'
 'Somophyllin-df' 'Truphylline']_|_['Aminophylline' 'Aminophyllinum' 'Cardophyllin' 'Linampheta' 'NSC-7919'
 'Syntophyllin' 'Theophyllamine' 'Theophylline ethylenediamine'
 'Theophylline-ethylenediamine']_|_[('DailyMed', array(['aminophylline'], dtype=object)), ('PubChem', array(['11111990', '11111991', '50105733', '85231291'], dtype=object)), ('drugbank', array(['DB01223'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001919', 'HP_0002315', 'EFO_1000782', 'HP_0006536',
       'EFO_0009492', 'MONDO_0004979', 'EFO_0003917', 'EFO_0001361',
       'MONDO_0001187'], dtype=object), 'count': 9}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650,ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271,ENSG00000172572,ENSG00000152270]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1940 and is indicated for airway obstruction and asthma and has 7 investigational indications."
CHEMBL1481,"CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O_|_WIGIZIANZCJQQY-RUCARUNLSA-N_|_Small molecule_|_False_|_GLIMEPIRIDE_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Amaryl' 'Glimepiride' 'Niddaryl']_|_['Amaryl' 'Glimepiride' 'HOE 490' 'HOE-490' 'NSC-759809']_|_[('DailyMed', array(['glimepiride'], dtype=object)), ('PubChem', array(['144204264', '170464966', '49648856'], dtype=object)), ('Wikipedia', array(['Glimepiride'], dtype=object)), ('drugbank', array(['DB00222'], dtype=object)), ('chEBI', array(['5383'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003914', 'MONDO_0005148', 'EFO_0000400', 'Orphanet_552',
       'EFO_0000537', 'EFO_0001645', 'HP_0003124'], dtype=object), 'count': 7}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 4 investigational indications."
CHEMBL1742988,"nan_|_nan_|_Protein_|_False_|_BAMINERCEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BG 9924' 'BG-9924' 'BG9924' 'Baminercept' 'Baminercept alfa' 'TT-47']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0008522', 'EFO_0000699', 'EFO_0004220'],
      dtype=object), 'count': 4}_|_[ENSG00000226979,ENSG00000227507,ENSG00000125735]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL194378,"CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12_|_QVDSEJDULKLHCG-UHFFFAOYSA-N_|_Small molecule_|_False_|_PSILOCYBINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CY 39' 'CY-39' 'Indocybin' 'Psilocybin' 'Psilocybine' 'Teonanacatl']_|_[('PubChem', array(['144206451'], dtype=object)), ('Wikipedia', array(['Psilocybin'], dtype=object)), ('drugbank', array(['DB11664'], dtype=object)), ('chEBI', array(['8614'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'HP_0002315', 'MONDO_0002334', 'EFO_0005230',
       'MONDO_0002050', 'EFO_0003843', 'EFO_0000546', 'EFO_0009854',
       'EFO_1001454', 'EFO_0005687', 'EFO_0003768', 'MONDO_0002009',
       'MONDO_0005351', 'EFO_0010702', 'MONDO_0044881', 'MONDO_0004985',
       'EFO_0008510', 'EFO_0004701', 'MONDO_0007079', 'EFO_0002610',
       'MONDO_0005277', 'EFO_0004242', 'EFO_0001358', 'HP_0003419'],
      dtype=object), 'count': 24}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 24 investigational indications."
CHEMBL2087361,"C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1_|_QQLKULDARVNMAL-UHFFFAOYSA-N_|_Small molecule_|_False_|_ICOTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BPI-2009H' 'Bpi-2009' 'Icotinib']_|_[('drugbank', array(['DB11737'], dtype=object))]_|_['CHEMBL4297665']_|_{'rows': array(['EFO_0000708', 'MONDO_0008903', 'EFO_0000616', 'MONDO_0007254',
       'EFO_0003060', 'EFO_0004252', 'EFO_0002618', 'EFO_1000849',
       'MONDO_0007576', 'EFO_0005922', 'EFO_0000313', 'EFO_0000676',
       'EFO_0000571'], dtype=object), 'count': 13}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL2103738,"O.O.O.O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Li+].[Li+].[Li+]_|_HXGWMCJZLNWEBC-UHFFFAOYSA-K_|_Small molecule_|_True_|_LITHIUM CITRATE_|_1980.0_|_4.0_|_CHEMBL1201170_|_False_|_True_|_['Li-liquid' 'Litarex' 'Lithium citrate']_|_['Lithium (as citrate)' 'Lithium citrate' 'Lithonate s' 'NSC-758700']_|_[('DrugCentral', array(['4512'], dtype=object)), ('chEBI', array(['64754'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009963'], dtype=object), 'count': 1}_|_[ENSG00000133731,ENSG00000105723,ENSG00000082701]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1980 and is indicated for bipolar i disorder. This drug has a black box warning from the FDA."
CHEMBL2109606,"nan_|_nan_|_Antibody_|_False_|_GSK-1070806_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-1070806' 'Gsk-1070806']_|_nan_|_nan_|_{'rows': array(['EFO_0003767', 'EFO_0003780', 'EFO_0000400', 'EFO_0000384',
       'EFO_0000274'], dtype=object), 'count': 5}_|_[ENSG00000150782]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL232943,"COC(=O)c1c(Cl)cccc1-c1ccc([C@@H](C)NC(=O)C2(NC(=O)C(F)(F)F)CC2)c(F)c1_|_WZZIQHIQMWJNLU-LLVKDONJSA-N_|_Small molecule_|_False_|_MK0686_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-0686' 'MK0686' 'Mk0686']_|_[('drugbank', array(['DB12563'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0041052', 'MONDO_0005178', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000100739]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3353541,"C[C@]1(C(=O)N(CCCC(=O)O)Cc2cccc(Cl)c2)CCN1C(=O)c1csc2ccccc12_|_MPMKMQHJHDHPBE-RUZDIDTESA-N_|_Small molecule_|_False_|_GLPG-0974_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GLPG-0974' 'GLPG0974' 'Glpg-0974' 'Glpg0974']_|_[('drugbank', array(['DB15406'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000126262]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545146,nan_|_nan_|_Small molecule_|_False_|_SRX251_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Srx251']_|_nan_|_nan_|_nan_|_[ENSG00000166148]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3707318,"nan_|_nan_|_Small molecule_|_False_|_GRC-17536_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Grc-17536']_|_nan_|_nan_|_{'rows': array(['EFO_1000783'], dtype=object), 'count': 1}_|_[ENSG00000104321]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3945199,"CC(C)(O)c1cn(-c2ccc(-c3cc(F)c(CO)c(S(C)(=O)=O)c3)cc2F)c(C(C)(C)c2c(Cl)cccc2Cl)n1_|_HNAJDMYOTDNOBK-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-852927_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Bms-852927' 'EXEL-04541041' 'XL-041' 'XL-652']_|_nan_|_nan_|_{'rows': array(['HP_0003124'], dtype=object), 'count': 1}_|_[ENSG00000131408,ENSG00000025434]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4297860,"nan_|_nan_|_Antibody_|_False_|_TILAVONEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-8E12' 'Abbv-8e12' 'Tilavonemab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TILAVONEMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019037', 'MONDO_0004975', 'EFO_0005772'], dtype=object), 'count': 3}_|_[ENSG00000186868]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL444172,"O[C@@H](COc1cccc2ncccc12)CN1CCN([C@@H]2c3ccccc3[C@@H]3[C@H](c4ccccc42)C3(F)F)CC1_|_IHOVFYSQUDPMCN-DBEBIPAYSA-N_|_Small molecule_|_False_|_ZOSUQUIDAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Zosuquidar']_|_[('Wikipedia', array(['Zosuquidar'], dtype=object)), ('drugbank', array(['DB06191'], dtype=object))]_|_['CHEMBL2074689']_|_{'rows': array(['EFO_0000565', 'EFO_0000198', 'EFO_0000565'], dtype=object), 'count': 3}_|_[ENSG00000085563]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL487,"CC/C(=C(/c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1_|_ZQZFYGIXNQKOAV-OCEACIFDSA-N_|_Small molecule_|_False_|_DROLOXIFENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['3-hydroxytamoxifen' 'Droloxifene' 'E-Droloxifene' 'FK-435' 'Fk-435'
 'K-060' 'K-21060E' 'K060' 'K060E']_|_[('chEBI', array(['34731'], dtype=object))]_|_['CHEMBL2105786']_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III."
CHEMBL5095026,"C[C@@H](NCc1nc2ccc(Oc3cc(F)c(F)c(F)c3)nc2n1C1CCC1)C(N)=O_|_HHXCJIMPEJSJTG-SNVBAGLBSA-N_|_Small molecule_|_False_|_DSP-2230_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Dsp-2230']_|_nan_|_nan_|_nan_|_[ENSG00000169432,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL519504,"CO[C@@H](Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)c2ccsc12)C(=O)O_|_DAYKLWSKQJBGCS-NRFANRHFSA-N_|_Small molecule_|_False_|_ALEGLITAZAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Aleglitazar' 'R-1439' 'R1439' 'RO-0728804' 'RO0728804' 'Ro-0728804']_|_[('Wikipedia', array(['Aleglitazar'], dtype=object)), ('drugbank', array(['DB08915'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000186951,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1200332,"CNCCCC1c2ccccc2C=Cc2ccccc21.Cl_|_OGQDIIKRQRZXJH-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROTRIPTYLINE HYDROCHLORIDE_|_1967.0_|_4.0_|_CHEMBL668_|_False_|_True_|_['Concordin-10' 'Concordin-5' 'Protriptyline hydrochloride' 'Vivactil']_|_['MK-240' 'NSC-169912' 'Protriptyline hcl' 'Protriptyline hydrochloride']_|_[('DailyMed', array(['protriptyline%20hydrochloride'], dtype=object)), ('PubChem', array(['144203795', '170465077', '50106858', '50106859', '56422215',
       '855990'], dtype=object)), ('chEBI', array(['8598'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967 and is indicated for depressive disorder. This drug has a black box warning from the FDA."
CHEMBL1200609,"CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1_|_SHIJTGJXUHTGGZ-RVXRQPKJSA-N_|_Small molecule_|_True_|_PAROXETINE MESYLATE_|_2003.0_|_4.0_|_CHEMBL490_|_False_|_True_|_['Brisdelle' 'Pexeva']_|_['Mesafem' 'PO-T.MES' 'POT.MES' 'Paroxetine mesilate'
 'Paroxetine mesylate' 'Paroxetine methanesulfonate'
 'Paroxetine methanesulphonate']_|_[('DailyMed', array(['paroxetine%20mesylate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001917', 'GO_0042697', 'EFO_0006788', 'MONDO_0002009',
       'EFO_0004242', 'HP_0031217', 'EFO_0001358', 'EFO_0004262'],
      dtype=object), 'count': 8}_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201782,"CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_VRQHBYGYXDWZDL-OOZCZQCLSA-N_|_Small molecule_|_False_|_FOSAPREPITANT DIMEGLUMINE_|_2008.0_|_4.0_|_CHEMBL1199324_|_False_|_True_|_['Emend' 'Fosaprepitant dimeglumine' 'Ivemend']_|_['Fosaprepitant (as dimeglumine)' 'Fosaprepitant dimeglumine'
 'Fosaprepitant meglumine' 'MK-0517']_|_[('DailyMed', array(['fosaprepitant%20dimeglumine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend'],
      dtype=object)), ('chEBI', array(['64311'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004888', 'HP_0002017', 'MONDO_0004992', 'EFO_0006911',
       'EFO_0000691'], dtype=object), 'count': 5}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 1 investigational indication."
CHEMBL1743018,"nan_|_nan_|_Antibody_|_False_|_FICLATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AV 299' 'AV-299' 'Ficlatuzumab' 'SCH 900105' 'SCH-900105']_|_nan_|_nan_|_{'rows': array(['EFO_0000181', 'EFO_0000707', 'EFO_0001378', 'EFO_0000519',
       'EFO_0002618', 'EFO_0003060', 'EFO_0000222'], dtype=object), 'count': 7}_|_[ENSG00000019991]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL1963681,"COc1ccc(CNc2nc(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl_|_WEAJZXNPAWBCOA-INIZCTEOSA-N_|_Small molecule_|_False_|_AVANAFIL_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Spedra' 'Stendra']_|_['Avanafil' 'TA-1790']_|_[('DailyMed', array(['avanafil'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/spedra'],
      dtype=object)), ('PubChem', array(['165222624'], dtype=object)), ('Wikipedia', array(['Avanafil'], dtype=object)), ('drugbank', array(['DB06237'], dtype=object)), ('chEBI', array(['66876'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004234', 'HP_0000802', 'EFO_0003086'], dtype=object), 'count': 3}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for erectile dysfunction and impotence and has 1 investigational indication."
CHEMBL2028661,"CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1_|_QJFSABGVXDWMIW-UHFFFAOYSA-N_|_Small molecule_|_True_|_AZILSARTAN MEDOXOMIL_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Edarbi']_|_['AR-14' 'Azilsartan medoxomil' 'Ipreziv' 'TAK 491' 'TAK-491']_|_[('drugbank', array(['DB08822'], dtype=object)), ('chEBI', array(['68845'], dtype=object))]_|_['CHEMBL2103795']_|_{'rows': array(['EFO_0000319', 'EFO_0000537', 'MONDO_0001134', 'EFO_0000712',
       'EFO_0000537'], dtype=object), 'count': 5}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for hypertension and stroke and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2079130,"CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1_|_BFDBKMOZYNOTPK-UHFFFAOYSA-N_|_Small molecule_|_False_|_VONOPRAZAN_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Takecab' 'Vocinti']_|_['TAK-438' 'Vonoprazan']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VONOPRAZAN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB11739'], dtype=object))]_|_['CHEMBL2064032']_|_{'rows': array(['EFO_0009454', 'MONDO_0001409', 'HP_0004398', 'MONDO_0001409',
       'EFO_0003948', 'EFO_0003948', 'EFO_1000961', 'EFO_0004607',
       'EFO_1000961'], dtype=object), 'count': 9}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for peptic ulcer and gastroesophageal reflux disease and has 5 investigational indications."
CHEMBL2105740,"Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+]_|_MDTNUYUCUYPIHE-UHFFFAOYSA-N_|_Small molecule_|_False_|_SITAXENTAN SODIUM_|_2006.0_|_4.0_|_CHEMBL282724_|_True_|_True_|_['Thelin']_|_['Sitaxentan sodium' 'Sitaxsentan sodium salt' 'TBC-11251 SODIUM'
 'TBC-11251NA' 'TBC-11251Z']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/thelin'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000899', 'MONDO_0005149'], dtype=object), 'count': 2}_|_[ENSG00000136160,ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for pulmonary hypertension and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL2105857,"CC[C@@]1(OC(=O)[C@@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=S)Nc2ccc(O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)[C@@H]3O)cc2)C(C)C)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1_|_SLOJCSGNHWIKIG-JNYZSSQASA-N_|_Small molecule_|_False_|_AFELETECAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Afeletecan']_|_nan_|_['CHEMBL4297664']_|_{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2106483,"CCOc1ccccc1OCC1CNCCO1.Cl_|_HJOCKFVCMLCPTP-UHFFFAOYSA-N_|_Small molecule_|_True_|_VILOXAZINE HYDROCHLORIDE_|_2021.0_|_4.0_|_CHEMBL306700_|_False_|_True_|_['Qelbree' 'Vivalan']_|_['ICI 58,834' 'ICI-58834' 'SPN-812' 'Spn-812' 'Viloxazine hcl'
 'Viloxazine hydrochloride']_|_[('PubChem', array(['170466300'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA."
CHEMBL2108228,nan_|_nan_|_Antibody_|_False_|_BECTUMOMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Lymphoscan']_|_['Bectumomab' 'IMMU-LL2' 'Technetium tc 99m bectumomab']_|_nan_|_nan_|_nan_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of III.
CHEMBL2108401,nan_|_nan_|_Antibody_|_False_|_ENLIMOMAB PEGOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIRR-1' 'Enlimomab pegol' 'R6.5']_|_nan_|_nan_|_nan_|_[ENSG00000090339]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2109283,nan_|_nan_|_Antibody drug conjugate_|_False_|_BICIROMAB BRALLOBARBITAL_|_nan_|_1.0_|_nan_|_False_|_False_|_['Fibriscint']_|_['Biciromab brallobarbital' 'T2G1S']_|_nan_|_nan_|_nan_|_[ENSG00000171564]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I.
CHEMBL2109309,"nan_|_nan_|_Antibody_|_False_|_RHIGM12B7_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['RHIGM12B7' 'Rhigm12b7']_|_nan_|_nan_|_{'rows': array(['EFO_0000389'], dtype=object), 'count': 1}_|_[ENSG00000197646]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109624,"nan_|_nan_|_Antibody_|_False_|_CAPLACIZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Cablivi']_|_['ALX-0081' 'Caplacizumab' 'Caplacizumab yhdp']_|_[('DailyMed', array(['caplacizumab-yhdp'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019740', 'MONDO_0018896', 'HP_0004419'], dtype=object), 'count': 3}_|_[ENSG00000110799]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved indications."
CHEMBL2151437,"c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2_|_OCKIPDMKGPYYJS-ZDUSSCGKSA-N_|_Small molecule_|_False_|_AZD0328_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-0328' 'AZD0328' 'Azd 0328' 'Azd-0328' 'Azd0328']_|_[('drugbank', array(['DB12145'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL340978,"CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1_|_MITFXPHMIHQXPI-UHFFFAOYSA-N_|_Small molecule_|_False_|_BENOXAPROFEN_|_1982.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Benoxaprofen' 'COMPD 90459' 'COMPOUND 90459' 'Coxigon' 'NSC-299582'
 'Opren']_|_[('Wikipedia', array(['Benoxaprofen'], dtype=object)), ('drugbank', array(['DB04812'], dtype=object)), ('chEBI', array(['76114'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755'], dtype=object), 'count': 1}_|_[ENSG00000108839]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for rheumatic disease. It was withdrawn in at least one region."
CHEMBL3545225,"nan_|_nan_|_Small molecule_|_False_|_INCB-047986_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Incb-047986' 'Incb-47986']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0000198', 'EFO_0000183', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3545341,"Cl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12_|_KMNVOGVCCZNVNU-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAR-407899_|_nan_|_2.0_|_CHEMBL1667969_|_False_|_False_|_[]_|_['SAR-407899' 'SAR407899' 'Sar-407899']_|_nan_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0004234', 'EFO_0001645'], dtype=object), 'count': 3}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545389,"nan_|_nan_|_Small molecule_|_False_|_LY2245461_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ly2245461']_|_nan_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3643413,"CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1_|_MWKYMZXCGYXLPL-ZDUSSCGKSA-N_|_Small molecule_|_False_|_LENIOLISIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CDZ-173-NX' 'CDZ173-NX' 'Cdz-173 free base' 'Cdz173 free base'
 'Leniolisib']_|_nan_|_['CHEMBL3989909']_|_{'rows': array(['MONDO_0015517', 'EFO_0000699', 'MONDO_0003778'], dtype=object), 'count': 3}_|_[ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for inborn error of immunity and has 2 investigational indications."
CHEMBL3707228,"nan_|_nan_|_Antibody_|_False_|_PLOZALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HU-1D9' 'MLN-1202' 'MLN1202' 'Plozalizumab' 'hu1D9']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0000401', 'MONDO_0005301', 'EFO_0003914',
       'EFO_0000319'], dtype=object), 'count': 5}_|_[ENSG00000121807]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3989872,"C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O_|_DVBUEXCIEIAXPM-PJUQSVSOSA-N_|_Protein_|_False_|_APIMOSTINEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Apimostinel' 'NRX-1074' 'NRX1074' 'Nrx-1074']_|_[('drugbank', array(['DB11784'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0005090'], dtype=object), 'count': 2}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297187,"COCCNCCc1cccc(Nc2ncc3c(n2)-c2ccccc2[C@H](c2ccccc2F)C3)c1_|_KPJDVVCDVBFRMU-AREMUKBSSA-N_|_Small molecule_|_False_|_DERAZANTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARQ 087' 'ARQ087' 'Arq-087' 'Derazantinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DERAZANTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14889'], dtype=object))]_|_['CHEMBL4298156']_|_{'rows': array(['EFO_0000616', 'EFO_0000616', 'EFO_1001961', 'EFO_0008528',
       'EFO_0000503'], dtype=object), 'count': 5}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297287,"COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1_|_ABEJDMOBAFLQNJ-NHCUHLMSSA-N_|_Small molecule_|_False_|_HT-0712_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BLX-028914' 'Blx-028914' 'Ht-0712' 'IPL-455903' 'OX-914']_|_[('drugbank', array(['DB11650'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854', 'EFO_0001072'], dtype=object), 'count': 2}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297311,"COc1cc(Cl)ccc1[C@H]1c2[nH]c3cccc(F)c3c2C2(CC2)CN1C(C)=O_|_ZBQMTQGDBFZUBG-NRFANRHFSA-N_|_Small molecule_|_False_|_ONO-2952_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ono-2952']_|_[('drugbank', array(['DB14802'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000100300]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297462,"COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@@H](C)O[C@@H](C)C5)cc4)n[nH]c3c1)C(=O)N2.O=C(O)/C=C/C(=O)O_|_AQCDFVLWUWJREO-WQVJSASDSA-N_|_Small molecule_|_False_|_CFI-400945_|_nan_|_2.0_|_CHEMBL3408947_|_False_|_False_|_[]_|_['CFI-400945' 'CFI-400945 FUMARATE' 'Cfi 400945' 'Cfi-400945'
 'Cfi-400945 fumarate' 'Ocifisertib fumarate']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0004992', 'MONDO_0007254'], dtype=object), 'count': 3}_|_[ENSG00000142731]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297613,"O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1_|_KZSKGLFYQAYZCO-UHFFFAOYSA-N_|_Small molecule_|_False_|_CILOFEXOR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cilofexor' 'GS 9674' 'GS-9674' 'Gs-9674' 'PX-104' 'PX104']_|_[('drugbank', array(['DB15168'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001249', 'EFO_0004268', 'EFO_1001486'], dtype=object), 'count': 3}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297640,"NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O_|_QLRRJMOBVVGXEJ-XHSDSOJGSA-N_|_Small molecule_|_False_|_VECABRUTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB-062' 'BSK-4841' 'FP-0182' 'FP0182' 'SNS-062' 'Sns-062'
 'Vecabrutinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VECABRUTINIB/relevant/1/'],
      dtype=object))]_|_['CHEMBL4298148']_|_{'rows': array(['EFO_0000616', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 1 investigational indication."
CHEMBL4303187,"CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1_|_RGYQPQARIQKJKH-UHFFFAOYSA-N_|_Small molecule_|_False_|_SETANAXIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GKT-137831' 'GKT-831' 'Setanaxib']_|_nan_|_nan_|_{'rows': array(['EFO_1001486', 'EFO_0000181', 'EFO_0000768'], dtype=object), 'count': 3}_|_[ENSG00000007952,ENSG00000086991]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL502182,"COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+]_|_DQYGXRQUFSRDCH-UQIIZPHYSA-M_|_Small molecule_|_False_|_ELAGOLIX SODIUM_|_2018.0_|_4.0_|_CHEMBL1208155_|_False_|_True_|_['Orilissa']_|_['Elagolix sodium' 'Elagolix sodium salt' 'NBI-56418 NA' 'NBI-56418-NA'
 'Orlissa']_|_[('DailyMed', array(['elagolix%20sodium'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001065'], dtype=object), 'count': 1}_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for endometriosis."
CHEMBL1020,"Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1_|_UPSPUYADGBWSHF-UHFFFAOYSA-N_|_Small molecule_|_True_|_TOLMETIN_|_1976.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['MCN-2559' 'Tolectin' 'Tolmetin']_|_[('Wikipedia', array(['Tolmetin'], dtype=object)), ('drugbank', array(['DB00500'], dtype=object)), ('chEBI', array(['71941'], dtype=object))]_|_['CHEMBL1556918' 'CHEMBL1200613' 'CHEMBL1437585']_|_{'rows': array(['HP_0002829', 'HP_0003326', 'EFO_0005755', 'EFO_0000685',
       'MONDO_0005178'], dtype=object), 'count': 5}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 5 approved indications. This drug has a black box warning from the FDA."
CHEMBL1200987,"CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O_|_DJSLTDBPKHORNY-XMMWENQYSA-N_|_Small molecule_|_True_|_EPROSARTAN MESYLATE_|_1997.0_|_4.0_|_CHEMBL813_|_False_|_True_|_['Eprosartan mesylate' 'Teveten']_|_['Eprosartan mesilate' 'Eprosartan mesylate'
 'Eprosartan monomethanesulfonate' 'SK&F 108566-J' 'SK&F-108566-J']_|_[('DailyMed', array(['eprosartan%20mesylate'], dtype=object)), ('PubChem', array(['144205739', '170465071'], dtype=object)), ('chEBI', array(['48409'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001134', 'EFO_0000537'], dtype=object), 'count': 2}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1201295,"Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1_|_FZGVEKPRDOIXJY-UHFFFAOYSA-N_|_Small molecule_|_False_|_BITOLTEROL_|_1984.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bitolterol']_|_[('PubChem', array(['170465239'], dtype=object)), ('Wikipedia', array(['Bitolterol'], dtype=object)), ('drugbank', array(['DB00901'], dtype=object)), ('chEBI', array(['3133'], dtype=object))]_|_['CHEMBL1200405']_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for airway obstruction."
CHEMBL1237044,"COc1cccc(C2(O)CCCCC2CN(C)C)c1_|_TVYLLZQTGLZFBW-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRAMADOL_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Amanda' 'CG-315E' 'E-265' 'ETS-6103' 'ETS6103' 'Tramadol' 'U-26255A'
 'Ultracet' 'Ultram']_|_[('chEBI', array(['75722'], dtype=object))]_|_['CHEMBL1237065']_|_{'rows': array(['HP_0012532', 'HP_0003419', 'EFO_1001250', 'HP_0002027',
       'EFO_0000181', 'EFO_0803321', 'EFO_0003964', 'EFO_0005762',
       'EFO_0005800', 'EFO_0003843', 'HP_0012532', 'MONDO_0002009',
       'MONDO_0005178', 'EFO_1000783', 'EFO_1000652', 'MONDO_0007254',
       'EFO_0010072', 'HP_0003419', 'EFO_0005611', 'EFO_0003843',
       'EFO_0005687', 'EFO_0004616', 'EFO_0003890', 'MONDO_0004992',
       'EFO_0000546'], dtype=object), 'count': 25}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1237099,"COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-]_|_APADFLLAXHIMFU-UHFFFAOYSA-L_|_Small molecule_|_False_|_DOXACURIUM CHLORIDE_|_1991.0_|_4.0_|_CHEMBL1237123_|_False_|_True_|_['Nuromax']_|_['BW A938U DICHLORIDE' 'BW-A938U' 'Doxacurium chloride'
 'Doxacurium chloride, meso-' 'Meso doxacurium chloride']_|_nan_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991."
CHEMBL1257040,"CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl_|_BXDAOUXDMHXPDI-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRIFLUOPERAZINE HYDROCHLORIDE_|_1959.0_|_4.0_|_CHEMBL422_|_False_|_True_|_['Stelazine' 'Trifluoperazine hydrochloride']_|_['NSC-757369' 'Trifluoperazine HCl' 'Trifluoperazine dihydrochloride'
 'Trifluoperazine hcl' 'Trifluoperazine hydrochloride'
 'Trifluoperazine maleate']_|_[('DailyMed', array(['trifluoperazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144203568', '170465265', '26747694', '26747695', '50107169'],
      dtype=object)), ('chEBI', array(['9710'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006788', 'MONDO_0005090', 'EFO_0000677'], dtype=object), 'count': 3}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL1267,"CC(O)c1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1_|_OXVFDZYQLGRLCD-UHFFFAOYSA-N_|_Small molecule_|_False_|_LERIGLITAZONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Hydroxypioglitazone' 'Leriglitazone' 'MIN-102' 'Min-102']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LERIGLITAZONE/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15021'], dtype=object)), ('chEBI', array(['82937'], dtype=object))]_|_['CHEMBL4298170']_|_{'rows': array(['Orphanet_43', 'MONDO_0100339', 'Orphanet_43', 'MONDO_0018544'],
      dtype=object), 'count': 4}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL18442,"c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1_|_YIQPUIGJQJDJOS-UHFFFAOYSA-N_|_Small molecule_|_False_|_PLERIXAFOR_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Mozobil']_|_['AMD 3100' 'AMD3100' 'JM 3100' 'Plerixafor' 'Plerixafor hydrochloride'
 'Plerixafor octahydrochloride' 'SID 791']_|_[('DailyMed', array(['plerixafor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil'],
      dtype=object)), ('PubChem', array(['174007494', '29217477'], dtype=object)), ('Wikipedia', array(['Plerixafor'], dtype=object)), ('drugbank', array(['DB06809'], dtype=object))]_|_['CHEMBL1788331' 'CHEMBL2311028' 'CHEMBL554014' 'CHEMBL2088494'
 'CHEMBL2373140' 'CHEMBL2311089']_|_{'rows': array(['MONDO_0003783', 'EFO_0001378', 'EFO_0000095', 'EFO_0000222',
       'MONDO_0000870', 'EFO_0000198', 'MONDO_0015760', 'EFO_1001311',
       'EFO_1001996', 'EFO_0000717', 'EFO_0000565', 'MONDO_0018305',
       'MONDO_0001475', 'MONDO_0011382', 'EFO_0000403', 'EFO_0000220',
       'EFO_0002618', 'EFO_0000691', 'EFO_1001465', 'EFO_0003086',
       'MONDO_0018906', 'MONDO_0019391', 'EFO_1001469', 'MONDO_0044881',
       'MONDO_0019460', 'EFO_0000574', 'EFO_0000220', 'EFO_0000616',
       'EFO_0006859', 'EFO_0005952', 'EFO_0000183', 'EFO_1001459',
       'MONDO_0005147', 'Orphanet_848', 'EFO_1000654', 'EFO_0004599'],
      dtype=object), 'count': 36}_|_[ENSG00000121966]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 30 investigational indications."
CHEMBL2104753,"COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1_|_XMSXOLDPMGMWTH-UHFFFAOYSA-N_|_Small molecule_|_False_|_RIVOGLITAZONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CS-011' 'DE-101' 'R 106056' 'R-106056' 'Rivoglitazone']_|_[('drugbank', array(['DB09200'], dtype=object))]_|_['CHEMBL3526906' 'CHEMBL3527103' 'CHEMBL3526905']_|_{'rows': array(['EFO_1000906', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108621,"nan_|_nan_|_Antibody_|_False_|_MAPATUMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HGS-1012' 'HGS-ETR1' 'HGS1012' 'Mapatumumab' 'TRAIL-R 1MAB'
 'TRAIL-R1 MAB' 'TRM-1' 'TRM-1 HGS-ETR1']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0002974', 'EFO_0005952', 'EFO_0001378',
       'EFO_0000182'], dtype=object), 'count': 5}_|_[ENSG00000104689]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2109496,nan_|_nan_|_Antibody_|_False_|_MLN-01_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MLN-01']_|_nan_|_nan_|_nan_|_[ENSG00000160255]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2397450,"OC[C@H]1O[C@@H](c2cc(Cc3cc4cccccc-4c3)ccc2O)[C@H](O)[C@@H](O)[C@@H]1O_|_AGJJCLBOHJQGFA-ZQGJOIPISA-N_|_Small molecule_|_False_|_YM-543_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_nan_|_['CHEMBL4297452']_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3187503,"CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1_|_AYJRTVVIBJSSKN-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-1292263_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK-1292263' 'GSK-1292263A' 'GSK-263A' 'GSK1292263' 'Gsk 1292263'
 'Gsk-1292263' 'Gsk1292263']_|_[('PubChem', array(['174006808'], dtype=object)), ('drugbank', array(['DB12627'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000147262]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545316,"nan_|_nan_|_Antibody_|_False_|_RINUCUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['REGN-2176' 'REGN2176' 'Rinucumab']_|_nan_|_nan_|_{'rows': array(['EFO_0001365'], dtype=object), 'count': 1}_|_[ENSG00000113721]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4101487,"O=C(O)c1ccc([C@H]2C[C@@H](NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c3ccc(OC(F)F)cc3O2)cc1_|_QVDYQHXNAQHIKH-TZIWHRDSSA-N_|_Small molecule_|_False_|_GALICAFTOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-2222' 'GLPG-2222' 'GLPG2222' 'Galicaftor' 'Glpg2222']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GALICAFTOR/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14894'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061'], dtype=object), 'count': 1}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297756,"nan_|_nan_|_Antibody_|_False_|_FREMANEZUMAB_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Ajovy']_|_['Fremanezumab' 'Fremanezumab vfrm' 'LBR-101' 'LBR101' 'PF-04472429'
 'PF04472429' 'RN-307' 'RN307' 'TEV-48125' 'TEV48125' 'Tev-48125']_|_[('DailyMed', array(['fremanezumab-vfrm'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'EFO_0005687', 'EFO_0008507', 'EFO_0003843'],
      dtype=object), 'count': 4}_|_[ENSG00000110680,ENSG00000175868]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 3 investigational indications."
CHEMBL4297792,"nan_|_nan_|_Unknown_|_False_|_MYRCLUDEX B_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Hbvpres2-48myr' 'Myrcludex b']_|_nan_|_nan_|_{'rows': array(['EFO_0007304', 'EFO_0004239', 'EFO_0004197'], dtype=object), 'count': 3}_|_[ENSG00000100652]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL447,"C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O_|_KQPKPCNLIDLUMF-UHFFFAOYSA-N_|_Small molecule_|_False_|_SECOBARBITAL_|_1950.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['(rs)-secobarbital' 'Evronal' 'Hypotrol' 'Immenox' 'Meballymal'
 'Quinalbarbital' 'Secobarbital' 'Secobarbital cii'
 'Secobarbital sodium free acid' 'Secobarbitone' 'Somatarax']_|_[('Wikipedia', array(['Secobarbital'], dtype=object)), ('drugbank', array(['DB00418'], dtype=object)), ('chEBI', array(['9073'], dtype=object))]_|_['CHEMBL1200903']_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950."
CHEMBL4594338,"nan_|_nan_|_Oligonucleotide_|_False_|_NEDOSIRAN SODIUM_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Rivfloza']_|_['DCR-PHXC' 'Dcr-phxc' 'Nedosiran sodium']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NEDOSIRAN%20SODIUM/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009823', 'MONDO_0002474'], dtype=object), 'count': 2}_|_[ENSG00000134333]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for primary hyperoxaluria type 1 and primary hyperoxaluria."
CHEMBL473417,"CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1_|_BPQMGSKTAYIVFO-UHFFFAOYSA-N_|_Small molecule_|_True_|_VISMODEGIB_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Erivedge']_|_['GDC-0449' 'NSC-747691' 'NSC-755986' 'Vismodegib']_|_[('DailyMed', array(['vismodegib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge'],
      dtype=object)), ('drugbank', array(['DB08828'], dtype=object)), ('chEBI', array(['66903'], dtype=object))]_|_['CHEMBL4129312' 'CHEMBL4125998' 'CHEMBL4127241']_|_{'rows': array(['MONDO_0007254', 'EFO_0000702', 'MONDO_0008170', 'EFO_0002618',
       'EFO_0002939', 'MONDO_0008315', 'MONDO_0003684', 'EFO_0000222',
       'EFO_1001465', 'EFO_0005537', 'MONDO_0004992', 'MONDO_0005184',
       'EFO_0000768', 'EFO_0000673', 'EFO_0000616', 'EFO_0003897',
       'MONDO_0020547', 'EFO_0004193', 'MONDO_0044903', 'MONDO_0005341',
       'EFO_0000326', 'MONDO_0007187', 'EFO_0001378', 'EFO_0000519',
       'EFO_1001041', 'MONDO_0016642'], dtype=object), 'count': 26}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 22 investigational indications. This drug has a black box warning from the FDA."
CHEMBL497939,"O=c1cccc2n1C[C@@H]1CNC[C@H]2C1_|_ANJTVLIZGCUXLD-DTWKUNHWSA-N_|_Small molecule_|_False_|_CYTISINICLINE_|_nan_|_3.0_|_nan_|_False_|_False_|_['Tabex']_|_['6039 Sopharma' 'Baptitoxine' 'Cytisine' 'Cytisinicline' 'Cytiton'
 'NSC-407282' 'Sophorine' 'Ulexine']_|_[('PubChem', array(['11112361', '11114058', '26752181', '477069', '56463106'],
      dtype=object)), ('Wikipedia', array(['Cytisine'], dtype=object)), ('drugbank', array(['DB09028'], dtype=object)), ('chEBI', array(['4055'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004319', 'EFO_0003768', 'EFO_0003086'], dtype=object), 'count': 3}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL5095036,"C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)[C@@](O)(CC)CC2_|_OXTSYWDBUVRXFF-GDLZYMKVSA-N_|_Small molecule_|_False_|_AZENOSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azenosertib' 'ZN-C3' 'Zn-c3']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000616', 'MONDO_0008170', 'MONDO_0002158',
       'EFO_0000637'], dtype=object), 'count': 5}_|_[ENSG00000166483]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL56337,"CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1_|_CHNUOJQWGUIOLD-NFZZJPOKSA-N_|_Small molecule_|_False_|_EPALRESTAT_|_1992.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Aldonil' 'Aldorin' 'Epalrestat' 'Kinedak' 'Tanglin']_|_[('PubChem', array(['26664249', '26758035'], dtype=object)), ('Wikipedia', array(['Epalrestat'], dtype=object)), ('drugbank', array(['DB15293'], dtype=object)), ('chEBI', array(['31539'], dtype=object))]_|_['CHEMBL4297277']_|_{'rows': array(['EFO_1000783', 'MONDO_0007254', 'MONDO_0015626'], dtype=object), 'count': 3}_|_[ENSG00000085662]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 3 investigational indications."
CHEMBL812,"CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-]_|_VNYBTNPBYXSMOO-UHFFFAOYSA-M_|_Small molecule_|_True_|_PYRIDOSTIGMINE BROMIDE_|_1955.0_|_4.0_|_CHEMBL1115_|_False_|_True_|_['Kalymin' 'Mestinon' 'Mestinon 10' 'Mestinon ret'
 'Pyridostigmine bromide' 'Regonal' 'Regonol']_|_['Kalimin' 'Kalymin' 'NSC-679759' 'NSC-758435' 'Pyridostigmine Bromide'
 'Pyridostigmine bromide' 'Pyridostigmini bromidum' 'RO-1-5130']_|_[('DailyMed', array(['pyridostigmine%20bromide'], dtype=object)), ('PubChem', array(['144204818', '170464878', '26747656', '50106936', '518187',
       '56422100', '855974'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003144', 'EFO_0005251', 'MONDO_0009672', 'MONDO_0100096',
       'MONDO_0004567', 'MONDO_0005180', 'Orphanet_365', 'EFO_0004991',
       'EFO_0005252'], dtype=object), 'count': 9}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1070,"COc1ccc2cc(CCC(C)=O)ccc2c1_|_BLXXJMDCKKHMKV-UHFFFAOYSA-N_|_Small molecule_|_True_|_NABUMETONE_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Nabumetone' 'Relafen' 'Relifex']_|_['BRL 14777' 'BRL-14777' 'NSC-758623' 'Nabumetone']_|_[('DailyMed', array(['nabumetone'], dtype=object)), ('PubChem', array(['11112767', '124882597', '144204198', '170464970', '26748824',
       '8139968'], dtype=object)), ('Wikipedia', array(['Nabumetone'], dtype=object)), ('drugbank', array(['DB00461'], dtype=object)), ('chEBI', array(['7443'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005178', 'EFO_0005755', 'EFO_0000685'], dtype=object), 'count': 3}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 3 approved indications. This drug has a black box warning from the FDA."
CHEMBL1200865,"CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_DMKSVUSAATWOCU-HROMYWEYSA-N_|_Small molecule_|_False_|_LOTEPREDNOL ETABONATE_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Alrex' 'Eysuvis' 'Inveltys' 'Lotemax' 'Lotemax sm']_|_['CDDD 5604' 'CDDD-5604' 'CDDD5604' 'HGP-1' 'KPI-121' 'Loteprednol'
 'Loteprednol etabonate' 'P-5604']_|_[('DailyMed', array(['loteprednol%20etabonate'], dtype=object)), ('PubChem', array(['144205772', '170465195', '26758016'], dtype=object)), ('drugbank', array(['DB14596'], dtype=object)), ('chEBI', array(['31784'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000811', 'EFO_0009536', 'MP_0001845', 'EFO_0007141',
       'EFO_0005752', 'EFO_1000906', 'MONDO_0005129', 'HP_0200026'],
      dtype=object), 'count': 8}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 3 investigational indications."
CHEMBL1200952,"CN[C@@H](C)Cc1ccccc1.Cl_|_TWXDDNPPQUTEOV-FVGYRXGTSA-N_|_Small molecule_|_True_|_METHAMPHETAMINE HYDROCHLORIDE_|_1943.0_|_4.0_|_CHEMBL1201201_|_False_|_True_|_['Desoxyn' 'Methampex' 'Methamphetamine hydrochloride']_|_['Desoxyephedrine hydrochloride' 'Metamfetamine hydrochloride'
 'Methamphetamine hcl' 'Methamphetamine hydrochloride'
 'Methamphetamine hydrochloride cii' 'Methylamfetamine hydrochloride'
 'NSC-169505']_|_[('DailyMed', array(['methamphetamine%20hydrochloride'], dtype=object)), ('PubChem', array(['144206409'], dtype=object)), ('chEBI', array(['35340'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1943 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA."
CHEMBL1201575,"nan_|_nan_|_Antibody_|_False_|_EFALIZUMAB_|_2003.0_|_4.0_|_nan_|_True_|_True_|_['Raptiva']_|_['ANTI-CD11A' 'Efalizumab' 'HU-1124' 'HU1124']_|_[('DrugCentral', array(['4959'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/raptiva'],
      dtype=object)), ('Wikipedia', array(['Efalizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001365', 'EFO_1000710', 'EFO_0003778', 'MONDO_0019080',
       'EFO_0003884', 'EFO_0000699', 'EFO_0000274', 'MONDO_0005147',
       'EFO_0000540', 'EFO_0000676', 'EFO_0000685'], dtype=object), 'count': 11}_|_[ENSG00000005844,ENSG00000160255]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and psoriasis and has 9 investigational indications. It was withdrawn in at least one region."
CHEMBL1201638,nan_|_nan_|_Protein_|_False_|_INSULIN SUSP PROTAMINE ZINC PURIFIED PORK_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Protamine zinc and iletin ii (pork)']_|_['Insulin susp protamine zinc purified pork']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1979.
CHEMBL1230122,"Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21_|_KKKRKRMVJRHDMG-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-1487_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_[]_|_[('PubChem', array(['103905625', '174007011'], dtype=object)), ('drugbank', array(['DB06518'], dtype=object))]_|_['CHEMBL1766582']_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL1358,"C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O_|_VWUXBMIQPBEWFH-WCCTWKNTSA-N_|_Small molecule_|_False_|_FULVESTRANT_|_2002.0_|_4.0_|_nan_|_False_|_True_|_['Faslodex']_|_['Faslodex' 'Fulvestrant' 'ICI 182,780' 'ICI-182780' 'NSC-759879'
 'ZD-9238' 'ZD9238']_|_[('DailyMed', array(['fulvestrant'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex'],
      dtype=object)), ('PubChem', array(['144204490', '144209802', '144213958', '170464917', '90341164'],
      dtype=object)), ('Wikipedia', array(['Fulvestrant'], dtype=object)), ('drugbank', array(['DB00947'], dtype=object)), ('chEBI', array(['31638'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0008528', 'MONDO_0011962', 'EFO_0003869',
       'EFO_0001075', 'MONDO_0007915', 'EFO_0007532', 'MONDO_0008903',
       'EFO_0000673', 'EFO_1001951', 'MONDO_0000088', 'EFO_0000432',
       'EFO_0002618', 'EFO_1000919', 'EFO_1000251', 'EFO_0000313',
       'EFO_0009708', 'MONDO_0018919', 'EFO_0000305', 'EFO_0000553',
       'EFO_0001361', 'Orphanet_145', 'EFO_0005952', 'EFO_0006318',
       'EFO_0000588', 'MONDO_0008315', 'EFO_0000616', 'EFO_1000294',
       'MONDO_0007254', 'EFO_1001512', 'MONDO_0008170', 'EFO_0000574',
       'EFO_0000181', 'EFO_0000702', 'EFO_1001331', 'EFO_0003060'],
      dtype=object), 'count': 36}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and has 6 approved and 30 investigational indications."
CHEMBL1770916,"CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(C(C)(C)CNCC(C)(C)C)cn1_|_VFCRKLWBYMDAED-REWPJTCUSA-N_|_Small molecule_|_False_|_NIROGACESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Nirogacestat' 'PF 03084014' 'PF 3084014' 'PF-03084014' 'PF-3084014']_|_[('drugbank', array(['DB12005'], dtype=object))]_|_['CHEMBL4298153']_|_{'rows': array(['EFO_0001378', 'EFO_0003869', 'EFO_0000616', 'EFO_0002618',
       'EFO_0009907', 'EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 7}_|_[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL1879463,"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21_|_JOGKUKXHTYWRGZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_DACTOLISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BEZ-235' 'BEZ235' 'Bez-235' 'Dactolisib' 'NSC-751249' 'NVP-BEZ235'
 'NVP-BEZ235-NX' 'Nvp-bez-235' 'RTB-101' 'RTB101' 'Rtb101']_|_[('PubChem', array(['103905146', '124898663', '124898665', '99460876'], dtype=object)), ('drugbank', array(['DB11651'], dtype=object)), ('chEBI', array(['71952'], dtype=object))]_|_['CHEMBL3039506' 'CHEMBL1911126']_|_{'rows': array(['MONDO_0004992', 'EFO_0000616', 'MONDO_0007254', 'MONDO_0100096',
       'MONDO_0008315', 'EFO_1000045', 'EFO_0000544', 'MONDO_0002367',
       'MONDO_0011962', 'EFO_1000601'], dtype=object), 'count': 10}_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461,ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL2062276,"C=CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13.O=C(O)C(O)C(O)C(=O)O_|_FWMLYVACGDQRFU-MBHUSPCXSA-N_|_Small molecule_|_False_|_LEVALLORPHAN TARTRATE_|_1982.0_|_4.0_|_CHEMBL1254682_|_False_|_True_|_['Lorfan']_|_['Levallorphan tartrate' 'Naloxiphane tartrate']_|_nan_|_nan_|_nan_|_[ENSG00000112038,ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL2105732,"CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN.Cl_|_XNCDYJFPRPDERF-NQQJLSKUSA-N_|_Small molecule_|_True_|_LEVOMILNACIPRAN HYDROCHLORIDE_|_2013.0_|_4.0_|_CHEMBL99946_|_False_|_True_|_['Fetzima']_|_['(1s,2r)-milnacipran hydrochloride' 'F 2695 HYDROCHLORIDE'
 'F-2695 HYDROCHLORIDE' 'F2695' 'F2695 HYDROCHLORIDE'
 'Levomilnacipran hydrochloride']_|_[('DailyMed', array(['levomilnacipran%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'EFO_0005687', 'HP_0002140', 'MONDO_0002009'],
      dtype=object), 'count': 4}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for major depressive disorder and fibromyalgia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2108144,nan_|_nan_|_Antibody_|_False_|_TENELIXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-224819' 'Teneliximab']_|_nan_|_nan_|_nan_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108324,"nan_|_nan_|_Oligonucleotide_|_False_|_OBLIMERSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Oblimersen']_|_[('DrugCentral', array(['4792'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000171791]_|_Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2364649,"nan_|_nan_|_Antibody_|_True_|_MARGETUXIMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Margenza']_|_['MGAH-22' 'MGAH22' 'Margetuximab' 'Margetuximab cmkb']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0007254'], dtype=object), 'count': 2}_|_[ENSG00000141736]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for neoplasm and breast cancer. This drug has a black box warning from the FDA."
CHEMBL238465,"Clc1cc(N2C[C@@H]3CN[C@@H]3C2)cnc1Cl_|_MBQYQLWSBRANKQ-IMTBSYHQSA-N_|_Small molecule_|_False_|_SOFINICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['A-422894.0' 'ABT-894' 'Sofinicline']_|_[('drugbank', array(['DB12527'], dtype=object))]_|_['CHEMBL2105654']_|_{'rows': array(['EFO_0003888', 'EFO_0005762', 'EFO_0000401', 'MONDO_0001583'],
      dtype=object), 'count': 4}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL245019,"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O_|_HZQDCMWJEBCWBR-UUOKFMHZSA-N_|_Small molecule_|_False_|_MIZORIBINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bredinin' 'Mizoribine' 'NSC-289637']_|_[('PubChem', array(['11532986', '170466027', '50106568', '50106569', '90340602'],
      dtype=object)), ('drugbank', array(['DB12617'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000685', 'EFO_0005761', 'EFO_0004255'], dtype=object), 'count': 3}_|_[ENSG00000106348,ENSG00000178035,ENSG00000163655]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL316561,"CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1_|_DGMKFQYCZXERLX-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROGLUMIDE_|_nan_|_4.0_|_nan_|_True_|_True_|_['Milid']_|_['Binoside' 'CR-242' 'Dl-proglumide' 'Gastrotopic' 'Midelid' 'NSC-757841'
 'Proglumide' 'Promid' 'Ulcutin' 'W-5219' 'Xylamide']_|_[('PubChem', array(['144204108', '170465774', '26747589', '50106676', '56463359',
       '90341320'], dtype=object)), ('Wikipedia', array(['Proglumide'], dtype=object)), ('drugbank', array(['DB13431'], dtype=object)), ('chEBI', array(['32058'], dtype=object))]_|_['CHEMBL1345380']_|_{'rows': array(['EFO_0002618', 'EFO_0003948', 'HP_0004398', 'EFO_0001422',
       'EFO_1001249'], dtype=object), 'count': 5}_|_[ENSG00000110148,ENSG00000163394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastroesophageal reflux disease and peptic ulcer and has 3 investigational indications. It was withdrawn in at least one region."
CHEMBL3301621,"c1ccc2cc([C@]34CNC[C@H]3C4)ccc2c1_|_HKHCSWPSUSWGLI-CABCVRRESA-N_|_Small molecule_|_False_|_CENTANAFADINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Centanafadine' 'DOV 216,419' 'DOV 216,419 free base' 'DOV-216419'
 'EB-1020' 'EB-1020 free base']_|_[('drugbank', array(['DB14841'], dtype=object))]_|_['CHEMBL3301615']_|_{'rows': array(['EFO_0004319', 'MONDO_0002009', 'EFO_0003888', 'EFO_0003888',
       'EFO_0005203'], dtype=object), 'count': 5}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3647536,"CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21_|_PTTQXDBPTFOCMT-UHFFFAOYSA-N_|_Small molecule_|_False_|_DARIGABAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CVL-865' 'Cvl-865' 'Darigabat' 'PF-06372865' 'Pf-06372865']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DARIGABAT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004262', 'HP_0001250', 'HP_0001250', 'HP_0003419',
       'EFO_1001892', 'EFO_1001146'], dtype=object), 'count': 6}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL3989944,"COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O_|_YIMYDTCOUQIDMT-SNAWJCMRSA-N_|_Small molecule_|_False_|_DIROXIMEL FUMARATE_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Vumerity']_|_['ALKS 8700' 'ALKS-8700' 'ALKS8700' 'Alks 8700' 'BIIB-098' 'BIIB098'
 'Diroximel fumarate' 'RDC-5108' 'RDC5108']_|_[('DailyMed', array(['diroximel%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/vumerity'],
      dtype=object)), ('drugbank', array(['DB14783'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000540', 'EFO_0003929', 'MONDO_0005301'], dtype=object), 'count': 3}_|_[ENSG00000079999]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved indications."
CHEMBL4297601,"COc1cc(F)c(C(C)C)cc1C1=C(CN2C(=O)O[C@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H]2C)CC(C)(C)CC1_|_GBHPDJQHZADVAA-SOKVYYICSA-N_|_Small molecule_|_False_|_ROCACETRAPIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CKD-519' 'Ckd-519' 'Rocacetrapib']_|_[('drugbank', array(['DB15437'], dtype=object))]_|_nan_|_{'rows': array(['Orphanet_309005'], dtype=object), 'count': 1}_|_[ENSG00000087237]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297686,"nan_|_nan_|_Protein_|_False_|_IZOKIBEP_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ABY-035' 'Aby-035' 'Aby-035/afo2' 'Aby035' 'IMG-020' 'Izokibep']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IZOKIBEP/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001231', 'EFO_0000676', 'EFO_1000710', 'EFO_0003898',
       'EFO_0003778'], dtype=object), 'count': 5}_|_[ENSG00000112115]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297995,"nan_|_nan_|_Unknown_|_False_|_BAZLITORAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bazlitoran' 'IMO-8400' 'Imo-8400']_|_nan_|_nan_|_{'rows': array(['EFO_0009441', 'EFO_0000403', 'EFO_0000676', 'EFO_0000398'],
      dtype=object), 'count': 4}_|_[ENSG00000101916,ENSG00000196664,ENSG00000239732]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL429876,"CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C_|_AMLYAMJWYAIXIA-VWNVYAMZSA-N_|_Protein_|_False_|_CILENGITIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cilengitide' 'EMD 121974' 'EMD-12192' 'EMD-121974']_|_[('Wikipedia', array(['Cilengitide'], dtype=object)), ('drugbank', array(['DB11890'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006861', 'MONDO_0008315', 'EFO_0000198', 'EFO_0000756',
       'EFO_1000026', 'MONDO_0021633', 'EFO_0000519', 'EFO_0002428',
       'EFO_1001465', 'EFO_0003086', 'EFO_0003060', 'EFO_0000326',
       'EFO_0001378', 'EFO_0002499', 'EFO_0000707', 'EFO_0002501',
       'EFO_0000565', 'EFO_1000158', 'EFO_0000691', 'EFO_0000616'],
      dtype=object), 'count': 20}_|_[ENSG00000259207,ENSG00000138448,ENSG00000082781]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 20 investigational indications."
CHEMBL4650284,"O=C1Nc2cc3[nH]nc(-c4ccncc4)c3cc2CN1Cc1ccccc1_|_ODIUJYZERXVGEI-UHFFFAOYSA-N_|_Small molecule_|_False_|_KO-947_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['KO-947' 'Ko-947']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000102882,ENSG00000100030]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4802157,"Cc1cc(F)ccc1-c1cc(N2C[C@H]3COCCN3C[C@H]2CO)ncc1N(C)C(=O)C(C)(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_DWRIJNIPBUFCQS-DQEYMECFSA-N_|_Small molecule_|_False_|_ELINZANETANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BAY-3427080' 'BAY3427080' 'Bay3427080' 'Elinzanetant' 'NT-814']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELINZANETANT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['GO_0042697', 'HP_0031217', 'EFO_0010702', 'MONDO_0007079'],
      dtype=object), 'count': 4}_|_[ENSG00000115353,ENSG00000169836]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL781,"OC1(c2ccc(Cl)cc2)c2ccccc2C2=NCCN21_|_ZPXSCAKFGYXMGA-UHFFFAOYSA-N_|_Small molecule_|_False_|_MAZINDOL_|_1973.0_|_4.0_|_nan_|_False_|_True_|_['Mazanor' 'Sanorex' 'Teronac']_|_['42-548' 'AN-448' 'Magrilon' 'Mazildene' 'Mazindol' 'Mazindol civ'
 'SAH-42548' 'Terenac']_|_[('Wikipedia', array(['Mazindol'], dtype=object)), ('drugbank', array(['DB00579'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0002610', 'MONDO_0016158', 'EFO_0003888', 'EFO_0001073'],
      dtype=object), 'count': 4}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and is indicated for obesity and has 3 investigational indications."
CHEMBL1046,"NCCCCCC(=O)O_|_SLXKOJJOQWFEFD-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMINOCAPROIC ACID_|_1964.0_|_4.0_|_nan_|_False_|_True_|_['Amicar' 'Aminocaproic' 'Aminocaproic acid' 'Epsikapron']_|_['.epsilon.-aminocaproic acid' '177 J.D' '177 J.D.' '177 JD' '177-JD'
 '6-aminocaproic acid' 'Aminocaproic acid' 'CL 10304' 'CL-10304' 'CY-116'
 'EACA' 'Epsilcapramin' 'Epsilon-aminocaproic acid'
 'Hexanoic acid, 6-amino-' 'NSC-26154' 'NSC-400230']_|_[('DailyMed', array(['aminocaproic%20acid'], dtype=object)), ('PubChem', array(['11110778', '11110779', '144203632', '170465057', '174007004',
       '26747439', '26747440', '50105811', '50105812', '57260392',
       '85230919', '90341441'], dtype=object)), ('Wikipedia', array(['Aminocaproic_acid'], dtype=object)), ('drugbank', array(['DB00513'], dtype=object)), ('chEBI', array(['16586'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005775', 'MP_0001914', 'EFO_1000760', 'MONDO_0015469',
       'MP_0001845'], dtype=object), 'count': 5}_|_[ENSG00000104368,ENSG00000122194]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for hemorrhage and has 4 investigational indications."
CHEMBL1200440,"Cc1cccc(C)c1NC(=O)C1CCCCN1C.Cl_|_RETIMRUQNCDCQB-UHFFFAOYSA-N_|_Small molecule_|_False_|_MEPIVACAINE HYDROCHLORIDE_|_1960.0_|_4.0_|_CHEMBL1087_|_False_|_True_|_['Arestocaine hydrochloride' 'Carbocaine' 'Isocaine hydrochloride'
 'Mepivacaine hydrochloride' 'Polocaine' 'Polocaine-mpf' 'Scandicaine'
 'Scandonest' 'Scandonest plain']_|_['Mepivacaine hcl' 'Mepivacaine hydrochloride'
 'Mepivacaine monohydrochloride' 'NSC-758674' 'Optocain' 'Scandicain']_|_[('DailyMed', array(['mepivacaine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204977', '26748921', '56424124'], dtype=object)), ('chEBI', array(['6760'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1237122,"CCCCC[C@](C)(O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O_|_DLJKPYFALUEJCK-IIELGFQLSA-N_|_Small molecule_|_True_|_CARBOPROST_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Hemabate']_|_['(15s)-15-methyl-pgf2.alpha.' '15-methyl-pgf2.alpha.'
 '15-methylprostaglandin f2.alpha.' 'Carboprost' 'U-32,921' 'U-32921']_|_nan_|_['CHEMBL1237105']_|_{'rows': array(['EFO_0000731', 'EFO_0009579', 'MP_0001914'], dtype=object), 'count': 3}_|_[ENSG00000122420]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and is indicated for postpartum hemorrhage and hemorrhage and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1256,"FC(F)OC(Cl)C(F)(F)F_|_PIWKPBJCKXDKJR-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOFLURANE_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Aerrane' 'Forane' 'Isoflurane']_|_['COMPOUND 469' 'COMPOUND-469' 'Isoflurane']_|_[('DailyMed', array(['isoflurane'], dtype=object)), ('PubChem', array(['144206238', '144208029', '50125772'], dtype=object)), ('Wikipedia', array(['Isoflurane'], dtype=object)), ('drugbank', array(['DB00753'], dtype=object)), ('chEBI', array(['6015'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005611', 'HP_0000023', 'EFO_0009686', 'MONDO_0100096',
       'EFO_0000713', 'EFO_0003777'], dtype=object), 'count': 6}_|_[ENSG00000100433,ENSG00000169427,ENSG00000082482,ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863,ENSG00000171303,ENSG00000145888,ENSG00000109738,ENSG00000186795]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 6 investigational indications."
CHEMBL1274,"CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O_|_XWXYUMMDTVBTOU-UHFFFAOYSA-N_|_Small molecule_|_True_|_NILUTAMIDE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Anadron' 'Nilandron' 'Nilutamide']_|_['NSC-758683' 'Nilutamide' 'RU 23908' 'RU-23908']_|_[('DailyMed', array(['nilutamide'], dtype=object)), ('PubChem', array(['104171203', '11111555', '11111556', '11114201', '124880925',
       '124880926', '144203764', '144211906', '170465021', '174007285',
       '26747174', '26747175', '26752242', '50104947', '50104948',
       '50104949', '50104950', '56463082', '85231160', '90341288'],
      dtype=object)), ('Wikipedia', array(['Nilutamide'], dtype=object)), ('drugbank', array(['DB00665'], dtype=object)), ('chEBI', array(['7573'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0008315', 'EFO_0000196', 'EFO_0000673',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1532,"CCC1NC(=O)c2cc(S(N)(=O)=O)c(Cl)cc2N1_|_AGMMTXLNIQSRCG-UHFFFAOYSA-N_|_Small molecule_|_False_|_QUINETHAZONE_|_1963.0_|_4.0_|_nan_|_False_|_True_|_['Hydromox']_|_['Chinethazone' 'NSC-759904' 'Quinethazone']_|_[('PubChem', array(['144203917', '170465167', '56463176'], dtype=object)), ('Wikipedia', array(['Quinethazone'], dtype=object)), ('drugbank', array(['DB01325'], dtype=object)), ('chEBI', array(['8717'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319'], dtype=object), 'count': 1}_|_[ENSG00000070915]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1963 and is indicated for cardiovascular disease."
CHEMBL1651956,"C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(CC)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C_|_OLROWHGDTNFZBH-XEMWPYQTSA-N_|_Protein_|_False_|_ALISPORIVIR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['(d-meala)3-(etval)4-csa' 'Alisporivir' 'DEB 025' 'DEB-025' 'DEB025'
 'DEBIO 025' 'DEBIO-025' 'DEBIO025' 'Debio 025' 'UNIL 025' 'UNIL-025'
 'UNIL025']_|_[('Wikipedia', array(['Alisporivir'], dtype=object)), ('drugbank', array(['DB12139'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0004220', 'MONDO_0100096', 'EFO_0003884',
       'EFO_0003047'], dtype=object), 'count': 5}_|_[ENSG00000196262]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL1683590,"C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@@H]3[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]3C[C@H]3O[C@@H](CC[C@@H]1O2)C[C@@H](C)C3=C_|_UFNVPOGXISZXJD-JBQZKEIOSA-N_|_Small molecule_|_False_|_ERIBULIN_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Halaven']_|_['ER-086526' 'Eribulin']_|_[('drugbank', array(['DB08871'], dtype=object)), ('chEBI', array(['63587'], dtype=object))]_|_['CHEMBL1683544' 'CHEMBL3526882']_|_{'rows': array(['MONDO_0001187', 'EFO_0000569', 'MONDO_0004992', 'EFO_0008528',
       'MONDO_0004669', 'EFO_0006859', 'Orphanet_145', 'EFO_1001968',
       'EFO_0000681', 'EFO_0002617', 'MONDO_0004192', 'EFO_0000691',
       'EFO_1000251', 'MONDO_0015523', 'MONDO_0002974', 'EFO_0000389',
       'EFO_0000305', 'MONDO_0007254', 'EFO_0005537', 'MONDO_0007254',
       'EFO_0001075', 'MONDO_0004992', 'EFO_0003968', 'EFO_0003060',
       'EFO_0000616', 'EFO_0000574', 'EFO_0000637', 'EFO_1000984',
       'EFO_0000616', 'EFO_0000673', 'EFO_0006861', 'MONDO_0021632',
       'MONDO_0016238', 'EFO_1000613', 'EFO_0000305', 'EFO_0003869',
       'EFO_0003060', 'EFO_0005537', 'MONDO_0008315'], dtype=object), 'count': 39}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 6 approved and 33 investigational indications."
CHEMBL1938400,"CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1_|_VGEXRDWWPSGZDH-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-03715455_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-03715455' 'Pf-03715455' 'Pf-3715455']_|_[('drugbank', array(['DB12138'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004979'], dtype=object), 'count': 2}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1963684,nan_|_nan_|_Protein_|_True_|_PEGINESATIDE ACETATE_|_2012.0_|_4.0_|_nan_|_True_|_True_|_['Omontys' 'Omontys preservative free']_|_['AF37702' 'Hematide acetate' 'Peginesatide acetate']_|_nan_|_nan_|_nan_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2012. It was withdrawn in at least one region. This drug has a black box warning from the FDA.
CHEMBL2109300,"nan_|_nan_|_Antibody_|_False_|_GSK933776_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK933776' 'Gsk933776']_|_nan_|_nan_|_{'rows': array(['EFO_1001492', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000142192]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3040440,"CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F_|_IGUBBWJDMLCRIK-UHFFFAOYSA-N_|_Small molecule_|_False_|_VS-4718_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PND-1186' 'SR-2516' 'VS-4718' 'Vs-4718']_|_[('drugbank', array(['DB15273'], dtype=object))]_|_['CHEMBL2430358']_|_{'rows': array(['EFO_0000094', 'EFO_0000222', 'EFO_0002618'], dtype=object), 'count': 3}_|_[ENSG00000169398]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3137309,"CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1_|_LQBVNQSMGBZMKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_VENETOCLAX_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Venclexta' 'Venclyxto']_|_['ABT-199' 'GDC-0199' 'RG-7601' 'RG7601' 'Venetoclax']_|_[('DailyMed', array(['venetoclax'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto'],
      dtype=object)), ('drugbank', array(['DB11581'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001023', 'EFO_0000616', 'EFO_0000224', 'EFO_0000574',
       'EFO_1000560', 'MONDO_0015540', 'EFO_0000221', 'MONDO_0007254',
       'EFO_0000198', 'EFO_0003032', 'EFO_1001469', 'EFO_0002913',
       'EFO_0009441', 'EFO_0000095', 'EFO_0004251', 'EFO_0000096',
       'EFO_0000702', 'EFO_0000209', 'MONDO_0004992', 'EFO_0000196',
       'MONDO_0044881', 'EFO_0000222', 'EFO_0005952', 'EFO_0004289',
       'EFO_0000565', 'EFO_0000339', 'EFO_0001378', 'EFO_0000231',
       'MONDO_0019438', 'MONDO_0044917', 'EFO_0003086', 'EFO_0000094',
       'EFO_0003869', 'MONDO_0000870', 'MONDO_0000873', 'EFO_0000220',
       'EFO_0000180', 'MONDO_0018906', 'EFO_0003060', 'EFO_0000309',
       'EFO_1000131', 'MONDO_0019460', 'EFO_0000403'], dtype=object), 'count': 43}_|_[ENSG00000171791]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 40 investigational indications."
CHEMBL3137343,"nan_|_nan_|_Antibody_|_False_|_PEMBROLIZUMAB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Keytruda']_|_['KEYLYNK-010 COMPONENT PEMBROLIZUMAB' 'Lambrolizumab' 'MK-3475'
 'PEMBROLIZUMAB COMPONENT OF KEYLYNK-010' 'Pembrolizumab' 'SCH-900475']_|_[('DailyMed', array(['pembrolizumab'], dtype=object)), ('DrugCentral', array(['4924'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001471', 'EFO_0000588', 'EFO_0009708', 'EFO_0000673',
       'EFO_0000707', 'MONDO_0003660', 'EFO_0000181', 'EFO_0005540',
       'EFO_1001951', 'EFO_1000251', 'EFO_0000519', 'MONDO_0018531',
       'MONDO_0005411', 'EFO_0000183', 'EFO_0000094', 'EFO_0003851',
       'MONDO_0002363', 'MONDO_0002108', 'MONDO_0002120', 'MONDO_0003659',
       'MONDO_0021148', 'EFO_0000305', 'EFO_1000613', 'MONDO_0021063',
       'EFO_1000601', 'EFO_1001469', 'EFO_0000681', 'EFO_0000571',
       'EFO_0000294', 'EFO_0000558', 'MONDO_0002367', 'MONDO_0011962',
       'EFO_0003893', 'EFO_0005543', 'EFO_0001416', 'EFO_0000182',
       'EFO_1000465', 'EFO_0000228', 'MONDO_0021117', 'EFO_1000581',
       'MONDO_0015277', 'EFO_0007541', 'EFO_0005537', 'EFO_0003968',
       'EFO_0000403', 'EFO_0003073', 'EFO_0000095', 'MONDO_0021310',
       'EFO_0000222', 'EFO_0000231', 'EFO_0000708', 'EFO_0000760',
       'EFO_0002913', 'MONDO_0002715', 'EFO_0000621', 'MONDO_0001528',
       'MONDO_0003199', 'EFO_1000785', 'EFO_0000574', 'EFO_0000764',
       'EFO_0003869', 'EFO_1000984', 'MONDO_0020634', 'MONDO_0004180',
       'EFO_0009259', 'MONDO_0001879', 'MONDO_0016642', 'MONDO_0002158',
       'EFO_0009441', 'Orphanet_145', 'EFO_0005952', 'MONDO_0002038',
       'EFO_0001061', 'EFO_1001968', 'EFO_0002617', 'MONDO_0004992',
       'EFO_0006859', 'MONDO_0002898', 'EFO_0000717', 'EFO_0000313',
       'EFO_1001931', 'MONDO_0100342', 'MONDO_0100096', 'MONDO_0024474',
       'EFO_0004284', 'EFO_0000096', 'EFO_0001378', 'EFO_0001663',
       'MONDO_0008315', 'EFO_0000691', 'EFO_0000365', 'EFO_0002921',
       'EFO_0000432', 'MONDO_0008170', 'EFO_1001513', 'HP_0002745',
       'MONDO_0017387', 'MONDO_0000521', 'MONDO_0018906', 'MONDO_0004658',
       'EFO_0001376', 'EFO_0000640', 'MONDO_0044881', 'EFO_0005950',
       'EFO_0002499', 'EFO_0003891', 'EFO_0000272', 'MONDO_0007576',
       'EFO_0007532', 'EFO_1001465', 'EFO_0000174', 'EFO_0001668',
       'MONDO_0004700', 'EFO_0003833', 'MONDO_0001657', 'EFO_0000565',
       'EFO_0003863', 'EFO_0000770', 'EFO_0003060', 'EFO_0002618',
       'MONDO_0000430', 'MONDO_0021251', 'EFO_0004230', 'MONDO_0011719',
       'MONDO_0004986', 'EFO_0000702', 'EFO_0006861', 'EFO_1001901',
       'EFO_0000196', 'EFO_0002918', 'EFO_0001642', 'EFO_1000576',
       'EFO_1000657', 'EFO_0000637', 'EFO_0004142', 'MONDO_0005184',
       'MONDO_0001056', 'EFO_1001512', 'EFO_0001071', 'EFO_0000220',
       'EFO_0000756', 'MONDO_0002974', 'EFO_0006352', 'EFO_0004252',
       'EFO_0000349', 'MONDO_0019472', 'EFO_0004198', 'EFO_0000616',
       'EFO_0002916', 'EFO_0003897', 'EFO_0004289', 'EFO_0005221',
       'MONDO_0009348', 'MONDO_0005341', 'EFO_0000389', 'EFO_0009709',
       'MONDO_0043243', 'EFO_0000503', 'EFO_1001100', 'MONDO_0018944',
       'EFO_0002892', 'EFO_0005922', 'EFO_1000796', 'EFO_1001051',
       'MONDO_0005575', 'EFO_0003868', 'MONDO_0003060', 'MONDO_0002087',
       'EFO_0000198', 'EFO_0008528', 'MONDO_0001187', 'MONDO_0021054',
       'EFO_0007143', 'EFO_0004243', 'MONDO_0002928', 'EFO_1000595',
       'MONDO_0007254', 'EFO_0001075', 'EFO_0003860', 'EFO_1001012',
       'MONDO_0044926', 'MONDO_0024503', 'MONDO_0008903'], dtype=object), 'count': 183}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 22 approved and 161 investigational indications."
CHEMBL3265032,"c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1_|_XSMSNFMDVXXHGJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENTOSPLETINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Entospletinib' 'GS-9973' 'SYK INHIBITOR GS-9973']_|_[('drugbank', array(['DB12121'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'MONDO_0018906', 'EFO_1001469', 'EFO_0005952',
       'EFO_0000095', 'EFO_0000220', 'EFO_0000403', 'MONDO_0004992'],
      dtype=object), 'count': 8}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL3544960,"NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1_|_IIRWNGPLJQXWFJ-KRWDZBQOSA-N_|_Small molecule_|_False_|_AT-13148_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AT13148' 'At-13148']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000162889,ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545091,nan_|_nan_|_Small molecule_|_False_|_XEN403_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Xen403']_|_nan_|_nan_|_nan_|_[ENSG00000169432]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545232,"Cc1ccc(-c2ccc(OC3CN4CCC3CC4)cn2)cc1_|_NPDLTEZXGWRMLQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_AQW051_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Aqw051']_|_nan_|_nan_|_{'rows': array(['MONDO_0005090', 'HP_0100543', 'MONDO_0004975'], dtype=object), 'count': 3}_|_[ENSG00000175344]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545357,nan_|_nan_|_Small molecule_|_False_|_JTE-151_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Jte-151']_|_nan_|_nan_|_nan_|_[ENSG00000143365]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3694769,"Nc1nc(-n2cccn2)nc(-n2cccn2)c1Br_|_ATFXVNUWQOXRRU-UHFFFAOYSA-N_|_Small molecule_|_False_|_PBF-509_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Pbf-509']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180', 'EFO_0003060'], dtype=object), 'count': 2}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3833307,"nan_|_nan_|_Antibody_|_False_|_SATRALIZUMAB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Enspryng']_|_['RG6168' 'SA-237' 'SA237' 'Sapelizumab' 'Satralizumab'
 'Satralizumab mwge' 'Satralizumab-mwge']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/enspryng'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000540', 'EFO_0004991', 'EFO_0004256', 'EFO_0001361',
       'EFO_0007332'], dtype=object), 'count': 5}_|_[ENSG00000160712,ENSG00000134352]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for immune system disease and neuromyelitis optica and has 3 investigational indications."
CHEMBL3990031,"nan_|_nan_|_Antibody_|_False_|_ROSMANTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['OMP-131R10' 'Rosmantuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000146374,ENSG00000205213]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL4072833,"C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1_|_QUIWHXQETADMGN-UHFFFAOYSA-N_|_Small molecule_|_False_|_EVOBRUTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Evobrutinib' 'M-2951' 'M2951' 'Msc-2364447c' 'Msc2364447c']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/EVOBRUTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15170'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'EFO_0000685', 'MONDO_0005301', 'EFO_0003086',
       'MONDO_0007915'], dtype=object), 'count': 5}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL428690,"CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1_|_BIIVYFLTOXDAOV-YVEFUNNKSA-N_|_Small molecule_|_False_|_ALVOCIDIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Alvocidib' 'Alvocidib freebase' 'Flavopiridol' 'HL 275' 'HL-275'
 'HMR 1275' 'HMR-1275' 'L 86 8275' 'L-868275' 'L86-8275' 'MDL 107,826A'
 'MDL-107826A' 'NSC-649890']_|_[('Wikipedia', array(['Alvocidib'], dtype=object)), ('drugbank', array(['DB03496'], dtype=object))]_|_['CHEMBL2105698']_|_{'rows': array(['EFO_0001378', 'MONDO_0007254', 'EFO_1001469', 'EFO_0009441',
       'EFO_0000095', 'EFO_0000222', 'MONDO_0018906', 'EFO_0000616',
       'EFO_0000222', 'EFO_0000691', 'EFO_0000191', 'EFO_0000565',
       'EFO_0006861', 'MONDO_0008315', 'MONDO_0001023', 'EFO_0001642',
       'MONDO_0007576', 'MONDO_0002691', 'EFO_0000403', 'EFO_0000389',
       'EFO_0001378', 'EFO_0000095', 'EFO_0000574', 'MONDO_0001023',
       'MONDO_0002367', 'MONDO_0011962'], dtype=object), 'count': 26}_|_[ENSG00000123374,ENSG00000170312,ENSG00000136807,ENSG00000105810,ENSG00000135446,ENSG00000134058]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications."
CHEMBL4297268,"COC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C_|_AHXICHPPXIGCBN-GPWPDEGDSA-N_|_Small molecule_|_False_|_BMS-275183_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bms 275183' 'Bms-275183']_|_[('drugbank', array(['DB12144'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL589583,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(=O)O)C1Cc2ccccc2C1_|_WOUOLAUOZXOLJQ-MBSDFSHPSA-N_|_Small molecule_|_False_|_DELAPRIL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Delapril']_|_[('drugbank', array(['DB13312'], dtype=object))]_|_['CHEMBL2106126']_|_{'rows': array(['EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 2}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL667,"CC(=O)OCC[N+](C)(C)C_|_OIPILFWXSMYKGL-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACETYLCHOLINE_|_1973.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Acetylcholine']_|_[('PubChem', array(['124883320', '26756572'], dtype=object)), ('Wikipedia', array(['Acetylcholine'], dtype=object)), ('drugbank', array(['DB03128'], dtype=object)), ('chEBI', array(['15355'], dtype=object))]_|_['CHEMBL1184' 'CHEMBL1736587' 'CHEMBL1427664' 'CHEMBL60457']_|_{'rows': array(['EFO_0004272', 'EFO_0000764', 'MONDO_0005148', 'HP_0000616',
       'MONDO_0005041', 'MP_0001845', 'MONDO_0011382', 'EFO_0000668',
       'EFO_0000556', 'EFO_0001645', 'MONDO_0005129'], dtype=object), 'count': 11}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 8 investigational indications."
CHEMBL1096896,"CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NCC(c4ccccc4)c4ccccc4)nc(C(=O)NCCNC(=O)NC4CCN(c5ccccn5)CC4)nc32)[C@H](O)[C@@H]1O_|_ZOTHAEBAWXWVID-HXEFRTELSA-N_|_Small molecule_|_False_|_UK432097_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Uk432097']_|_[('drugbank', array(['DB12691'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1201190,"Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1_|_PGLIUCLTXOYQMV-GHVWMZMZSA-N_|_Small molecule_|_False_|_LEVOCETIRIZINE DIHYDROCHLORIDE_|_2007.0_|_4.0_|_CHEMBL1201191_|_False_|_True_|_['Levocetirizine dihydrochloride' 'Xusal' 'Xyzal' 'Xyzal allergy 24hr'
 'Xyzall']_|_['Cetirizine (r)-form dihydrochloride' 'Cetirizine hydrochloride (r)-'
 'Levocetirizine dihydrochloride' 'Levocetirizine hydrochloride'
 'Levocetirizine monohydrochloride' 'NSC-758898' 'UCB 28556' 'UCB-28556']_|_[('DailyMed', array(['levocetirizine%20dihydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001417', 'EFO_0008521', 'EFO_0000701', 'EFO_0005531',
       'HP_0012735', 'EFO_0003956', 'Orphanet_79292'], dtype=object), 'count': 7}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 4 approved and 3 investigational indications."
CHEMBL1201263,"CCN(CC)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_FWFVLWGEFDIZMJ-FOMYWIRZSA-N_|_Small molecule_|_False_|_HYDROCORTAMATE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hydrocortamate']_|_[('PubChem', array(['170465314'], dtype=object)), ('drugbank', array(['DB00769'], dtype=object)), ('chEBI', array(['50851'], dtype=object))]_|_['CHEMBL1200635']_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL1201550,"nan_|_nan_|_Protein_|_True_|_DENILEUKIN DIFTITOX_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Ontak']_|_['DAB(SUB 389)IL2' 'DAB-389IL2' 'DAB389 IL2' 'DAB389IL2' 'Denileukin'
 'Denileukin diftitox' 'E-7272' 'E-7777' 'E7272' 'E7777' 'LY-335348'
 'LY335348']_|_[('DrugCentral', array(['5087'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DENILEUKIN%20DIFTITOX/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['Denileukin_diftitox', 'Resimmune'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'MONDO_0002367', 'EFO_0000756', 'EFO_0002913',
       'EFO_1000043', 'EFO_0000211', 'EFO_0000222', 'EFO_1000251',
       'EFO_0000389', 'EFO_0005952', 'EFO_0002618', 'EFO_0000095',
       'EFO_0000209', 'EFO_0000466', 'MONDO_0002087', 'EFO_0001378',
       'MONDO_0008170', 'EFO_0000565', 'EFO_0000616', 'MONDO_0013730',
       'MONDO_0002158', 'EFO_0006861'], dtype=object), 'count': 22}_|_[ENSG00000167658,ENSG00000134460,ENSG00000147168,ENSG00000100385]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for cutaneous t-cell lymphoma and neoplasm and has 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201621,"nan_|_nan_|_Protein_|_False_|_SOMATROPIN_|_1976.0_|_4.0_|_nan_|_False_|_True_|_['Accretropin' 'Asellacrin 10' 'Asellacrin 2' 'Bio-tropin' 'Crescormon'
 'Genotropin' 'Genotropin [Rdna Origin]' 'Genotropin goquick'
 'Genotropin kabipen' 'Genotropin kabiquick' 'Genotropin kabivial'
 'Genotropin miniquick' 'Genotropin preservative free' 'Humatrope'
 'Humatropen' 'Norditropin' 'Norditropin flexpro' 'Norditropin nordiflex'
 'Norditropin penset' 'Norditropin simplexx' 'Nutropin' 'Nutropin aq'
 'Nutropin aq nuspin' 'Nutropin aq pen' 'Nutropin depot' 'Nutropinaq'
 'Omnitrope' 'Omnitrope pen 10' 'Omnitrope pen 5' 'Omnitrope surepal 10'
 'Omnitrope surepal 15' 'Omnitrope surepal 5' 'Saizen' 'Saizen click.easy'
 'Saizen easyject' 'Serostim' 'Serostim lq' 'Tev-Tropin' 'Valtropin'
 'Zomacton' 'Zorbtive']_|_['CB-311' 'DA-3002' 'Genotonorm' 'Growth hormone' 'Growth hormone (human)'
 'Hsb-hgh' 'Human growth hormone' 'Hypertropin' 'LY-137998' 'LY137998'
 'R-hgh' 'Recombinant human growth hormone' 'Rh-polypeptide-7'
 'Somatotropin' 'Somatotropin (human)' 'Somatotropin human'
 'Somatotropin human growth hormone' 'Somatropin'
 'Somatropin (rdna origin)' 'Somatropin biopartners'
 'Somatropin for injection' 'Tev-tropin' 'Tevtropin' 'Vexxon-hgh']_|_[('DailyMed', array(['somatropin'], dtype=object)), ('DrugCentral', array(['4848'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0019019', 'Orphanet_665', 'EFO_0003944', 'EFO_0000319',
       'EFO_0001379', 'EFO_0001380', 'EFO_0000400', 'EFO_0000180',
       'HP_0100543', 'EFO_0700081', 'MONDO_0010674', 'MONDO_0009061',
       'EFO_0000495', 'Orphanet_269', 'MONDO_0015183', 'HP_0001510',
       'MONDO_0007078', 'EFO_0000545', 'MONDO_0008300', 'EFO_0001073',
       'EFO_0000764', 'EFO_0001379', 'MONDO_0043510', 'EFO_0003884',
       'EFO_1001434', 'MONDO_0007793', 'MONDO_0001967', 'EFO_0009607',
       'HP_0004326', 'MONDO_0015514', 'EFO_0008560', 'EFO_0007312',
       'EFO_1001919', 'MONDO_0019499', 'EFO_0001422', 'EFO_0009516',
       'MONDO_0009661', 'EFO_1000653', 'EFO_1001109', 'EFO_0003095',
       'EFO_0003144', 'MONDO_0004976', 'EFO_0000384', 'EFO_0004616',
       'MONDO_0018997', 'EFO_0008525'], dtype=object), 'count': 46}_|_[ENSG00000112964]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 14 approved and 32 investigational indications."
CHEMBL1201670,"nan_|_nan_|_Protein_|_False_|_SARGRAMOSTIM_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Leukine']_|_['B1 61.012' 'B1-61012'
 'Granulocyte-macrophage colony-stimulating factor sargramostim'
 'RHU GM-CSF' 'RHU-GM-CSF' 'Sargramostim' 'Sargramostim rdna']_|_[('DailyMed', array(['sargramostim'], dtype=object)), ('DrugCentral', array(['5025'], dtype=object)), ('Wikipedia', array(['Sargramostim'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001469', 'EFO_0000199', 'EFO_0006475', 'EFO_1001465',
       'HP_0001945', 'EFO_0003869', 'EFO_0003060', 'MONDO_0008315',
       'EFO_0000673', 'EFO_0000756', 'MONDO_0018906', 'EFO_0004142',
       'EFO_0000681', 'EFO_0001378', 'EFO_1000657', 'MONDO_0005180',
       'EFO_0004239', 'EFO_0000198', 'MONDO_0002158', 'EFO_1000251',
       'EFO_0001075', 'EFO_0000313', 'MONDO_0015667', 'MONDO_0002087',
       'EFO_0002618', 'EFO_0005543', 'EFO_0000685', 'EFO_0000095',
       'EFO_0000389', 'MONDO_0004975', 'MONDO_0021063', 'MONDO_0001475',
       'EFO_1001042', 'EFO_0000649', 'EFO_0002428', 'MONDO_0004643',
       'MONDO_0044881', 'MONDO_0004992', 'EFO_0000502', 'EFO_0004265',
       'MONDO_0007254', 'EFO_0000565', 'EFO_0000574', 'EFO_1001951',
       'EFO_0000183', 'EFO_0003811', 'EFO_0000309', 'EFO_0001663',
       'EFO_0000339', 'MONDO_0007576', 'EFO_0000621', 'MONDO_0005411',
       'EFO_0003086', 'MONDO_0008170', 'MONDO_0005575', 'EFO_0000384',
       'EFO_0000180', 'EFO_0000544', 'EFO_1000043', 'HP_0100806',
       'EFO_0000220', 'EFO_0000616', 'EFO_0000403', 'EFO_0005046',
       'EFO_1000984', 'EFO_0003921', 'EFO_0002918', 'MONDO_0100096',
       'EFO_0000228', 'EFO_0004991', 'EFO_0005537', 'EFO_0002617',
       'EFO_0000519', 'MONDO_0001437', 'EFO_0000764', 'EFO_1001302',
       'EFO_0000637', 'EFO_0000694', 'EFO_0000691', 'MONDO_0001187',
       'MONDO_0002691', 'EFO_0009708', 'MONDO_0100130', 'Orphanet_264675',
       'MONDO_0013730', 'MONDO_0020077', 'MONDO_0100342', 'EFO_1000158',
       'MONDO_0008903', 'EFO_0000466', 'EFO_0003891', 'MONDO_0011962',
       'MONDO_0002367', 'EFO_0003893', 'EFO_0001064', 'EFO_0003833',
       'MONDO_0001056', 'HP_0001871', 'EFO_0000222', 'EFO_0005952',
       'EFO_0000181', 'EFO_0000432', 'EFO_0006861', 'EFO_0000182'],
      dtype=object), 'count': 104}_|_[ENSG00000198223,ENSG00000292357,ENSG00000100368]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 4 approved and 100 investigational indications."
CHEMBL1419,"CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1_|_UNAANXDKBXWMLN-UHFFFAOYSA-N_|_Small molecule_|_False_|_SIBUTRAMINE_|_1997.0_|_4.0_|_nan_|_True_|_True_|_['Reductil']_|_['Butramin' 'Cf-alli' 'Medaria' 'Racemic sibutramine' 'Sibutramine']_|_[('PubChem', array(['174007250', '49732001'], dtype=object)), ('Wikipedia', array(['Sibutramine'], dtype=object)), ('drugbank', array(['DB01105'], dtype=object)), ('chEBI', array(['9137'], dtype=object))]_|_['CHEMBL3989830' 'CHEMBL1200765']_|_{'rows': array(['EFO_0001073', 'EFO_0001073'], dtype=object), 'count': 2}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for obesity and has 1 investigational indication. It was withdrawn in at least one region."
CHEMBL1633,"CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1.O=C(O)/C=C/C(=O)O_|_YNQQEYBLVYAWNX-WLHGVMLRSA-N_|_Small molecule_|_False_|_KETOTIFEN FUMARATE_|_1999.0_|_4.0_|_CHEMBL534_|_False_|_True_|_['Acuvue theravision with ketotifen' 'Alaway' ""Children's alaway""
 'Ketotifen fumarate' 'Zaditen' 'Zaditor']_|_['HC 20,511 FUMARATE' 'HC-20511 FUMARATE' 'Ketotifen (as fumarate)'
 'Ketotifen fumarate' 'Ketotifen hydrogen fumarate' 'NSC-757415']_|_[('DailyMed', array(['ketotifen%20fumarate'], dtype=object)), ('PubChem', array(['26719657', '26747554', '26747555', '49731996', '50106521',
       '50106522', '50106523', '56424131', '855752'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002406', 'EFO_0000274', 'EFO_0007141', 'HP_0012532',
       'EFO_0003931', 'EFO_1001417'], dtype=object), 'count': 6}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 6 investigational indications."
CHEMBL2010601,"CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O_|_PURKAOJPTOLRMP-UHFFFAOYSA-N_|_Small molecule_|_False_|_IVACAFTOR_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Kalydeco']_|_['Ivacaftor' 'VX-770']_|_[('DailyMed', array(['ivacaftor'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco'],
      dtype=object)), ('PubChem', array(['124950685'], dtype=object)), ('drugbank', array(['DB08820'], dtype=object)), ('chEBI', array(['66901'], dtype=object))]_|_['CHEMBL4297603']_|_{'rows': array(['EFO_0007486', 'MONDO_0016575', 'EFO_0001421', 'EFO_0000341',
       'MONDO_0009061', 'EFO_0006505', 'EFO_0000684', 'MONDO_0009061'],
      dtype=object), 'count': 8}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for respiratory system disease and cystic fibrosis and has 6 investigational indications."
CHEMBL2064032,"CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1.O=C(O)/C=C/C(=O)O_|_ROGSHYHKHPCCJW-WLHGVMLRSA-N_|_Small molecule_|_False_|_VONOPRAZAN FUMARATE_|_2022.0_|_4.0_|_CHEMBL2079130_|_False_|_True_|_[]_|_['TAK-438' 'TAK-438 monofumarate' 'Tak 438' 'Vonoprazan fumarate'
 'Vonoprazan monofumarate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/VONOPRAZAN%20FUMARATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0009454', 'MONDO_0001409', 'EFO_0003948', 'EFO_1000961',
       'EFO_0004607'], dtype=object), 'count': 5}_|_[ENSG00000105675,ENSG00000186009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 5 investigational indications."
CHEMBL2108404,"nan_|_nan_|_Antibody_|_False_|_EPRATUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Lymphocide']_|_['AMG-412' 'Epratuzumab' 'IMMU-HLL2' 'hLL2']_|_nan_|_nan_|_{'rows': array(['MONDO_0000870', 'EFO_0009441', 'MONDO_0007915', 'EFO_0000403',
       'EFO_0005952', 'EFO_0000220', 'MONDO_0004992', 'EFO_0000094',
       'EFO_0000574', 'EFO_0000565'], dtype=object), 'count': 10}_|_[ENSG00000012124]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL2109398,"nan_|_nan_|_Antibody_|_False_|_KB-004_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['KB-004' 'Kb-004']_|_nan_|_nan_|_{'rows': array(['EFO_0002430', 'EFO_0000198', 'EFO_0000519'], dtype=object), 'count': 3}_|_[ENSG00000044524]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL3301574,"nan_|_nan_|_Cell_|_True_|_TISAGENLECLEUCEL_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Kymriah']_|_['CART-19' 'CART19' 'CTL-019' 'CTL019' 'Car.cd19-redirected t cells'
 'Kymriah' 'Tisagenlecleucel' 'Tisagenlecleucel-t']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000094', 'EFO_0000403', 'EFO_0002618', 'EFO_0000183',
       'EFO_0000096', 'EFO_0001378', 'EFO_0005952', 'MONDO_0000873',
       'EFO_0000222', 'EFO_0000565', 'EFO_0000220', 'MONDO_0018906',
       'EFO_0000574', 'EFO_0000094', 'EFO_0000095'], dtype=object), 'count': 15}_|_[ENSG00000177455]_|_Cell drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for b-cell acute lymphoblastic leukemia and diffuse large b-cell lymphoma and has 13 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3545204,"nan_|_nan_|_Small molecule_|_False_|_QAF805_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Qaf805']_|_nan_|_nan_|_nan_|_[ENSG00000170425,ENSG00000282608]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3707401,"nan_|_nan_|_Small molecule_|_False_|_MK-8777_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-8777' 'Org-26576']_|_nan_|_nan_|_{'rows': array(['EFO_0003888', 'MONDO_0002050'], dtype=object), 'count': 2}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3948730,"CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F_|_IUVCFHHAEHNCFT-INIZCTEOSA-N_|_Small molecule_|_False_|_UMBRALISIB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['RP-5264' 'RP5264' 'TGR-1202 FREE BASE' 'TGR-1202 base' 'Tgr 1202'
 'Umbralisib']_|_[('drugbank', array(['DB14989'], dtype=object))]_|_['CHEMBL3989869']_|_{'rows': array(['EFO_0000095', 'EFO_0000183', 'MONDO_0044903', 'MONDO_0001056',
       'EFO_0000095', 'EFO_1000630', 'MONDO_0018906', 'MONDO_0007576',
       'EFO_1001469', 'EFO_1001469', 'EFO_1001951', 'EFO_0002618',
       'MONDO_0011719', 'EFO_0000183', 'EFO_0000616', 'EFO_0000403',
       'EFO_1000657', 'EFO_0002429', 'EFO_0000096', 'EFO_0000403',
       'EFO_0009441', 'EFO_0000211', 'MONDO_0018906'], dtype=object), 'count': 23}_|_[ENSG00000097007,ENSG00000213923,ENSG00000171608]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 3 approved and 19 investigational indications."
CHEMBL4297392,"O=C(NCc1ccc(Oc2ccccc2)cc1)c1nc(-c2cc(Br)c(O)c(Br)c2)no1_|_DSFNLJXHXBIKDS-UHFFFAOYSA-N_|_Small molecule_|_False_|_IOWH-032_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Iowh-032' 'Iowh032']_|_[('drugbank', array(['DB12959'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000001626]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4650215,"C[C@H](Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O_|_SGEUNORSOZVTOL-CABZTGNLSA-N_|_Small molecule_|_False_|_INAVOLISIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['GDC-0077' 'GDC0077' 'Gdc-0077' 'Inavolisib' 'RG-6114' 'RG6114'
 'RO-7113755' 'RO7113755']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/INAVOLISIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0011962', 'MONDO_0008170', 'EFO_0000616',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4650368,"COc1ncc(C)c(-c2ccc3c(c2)[nH]c(=O)c2cnn([C@H]4CCOC4)c23)c1C_|_CKJDCNZBABIEBZ-HNNXBMFYSA-N_|_Small molecule_|_False_|_IRSENONTRINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['E-2027' 'E2027' 'ER-592221-00' 'Irsenontrine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IRSENONTRINE/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650224']_|_{'rows': array(['HP_0000726', 'EFO_0006792', 'HP_0000726', 'MONDO_0005180',
       'EFO_0006792', 'MONDO_0005180'], dtype=object), 'count': 6}_|_[ENSG00000160191]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL477772,"Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O_|_CUIHSIWYWATEQL-UHFFFAOYSA-N_|_Small molecule_|_True_|_PAZOPANIB_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Votrient']_|_['GW786034' 'NSC-752782' 'Pazopanib']_|_[('PubChem', array(['103905642', '144206725', '170465625', '50100102'], dtype=object)), ('Wikipedia', array(['Pazopanib'], dtype=object)), ('drugbank', array(['DB06589'], dtype=object)), ('chEBI', array(['71219'], dtype=object))]_|_['CHEMBL1201733']_|_{'rows': array(['EFO_1001465', 'EFO_0000182', 'MONDO_0004986', 'EFO_0005543',
       'MONDO_0002087', 'EFO_0003016', 'EFO_0000681', 'EFO_0007143',
       'MONDO_0011719', 'MONDO_0015277', 'EFO_1001465', 'EFO_0003869',
       'MONDO_0008903', 'EFO_1000613', 'MONDO_0004192', 'MONDO_0008170',
       'MONDO_0002158', 'MONDO_0019297', 'MONDO_0004986', 'MONDO_0000521',
       'EFO_0003893', 'EFO_1001968', 'EFO_0000637', 'EFO_0000691',
       'MONDO_0001056', 'MONDO_0008315', 'EFO_0000333', 'EFO_0002618',
       'EFO_0003968', 'MONDO_0008667', 'EFO_0000564', 'MONDO_0002367',
       'MONDO_0007254', 'EFO_1001100', 'EFO_0000616', 'EFO_0000519',
       'MONDO_0011934', 'EFO_0006861', 'MONDO_0007254', 'MONDO_0019180',
       'MONDO_0004992', 'EFO_0003060', 'EFO_0000574', 'EFO_0000702',
       'EFO_0000222', 'EFO_0000501', 'EFO_0002892', 'MONDO_0001187',
       'MONDO_0001187', 'EFO_0000181', 'EFO_0000349', 'EFO_0003968',
       'MONDO_0002087', 'EFO_0000349', 'MONDO_0008315', 'EFO_0000588',
       'EFO_0001663', 'EFO_0009606', 'EFO_0000691', 'EFO_0000641',
       'MONDO_0002974', 'EFO_0000365', 'EFO_0000616', 'EFO_0000640',
       'MONDO_0002158', 'EFO_0000681', 'MONDO_0016238', 'EFO_1000880',
       'EFO_1001968', 'MONDO_0008903', 'EFO_0000756', 'EFO_0000569',
       'EFO_0000673', 'EFO_0000514', 'EFO_0000676', 'EFO_1001901',
       'EFO_0000335', 'EFO_0000389', 'MONDO_0008170'], dtype=object), 'count': 79}_|_[ENSG00000113721,ENSG00000134853,ENSG00000182866,ENSG00000068078,ENSG00000157404,ENSG00000182578,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000077782,ENSG00000113263]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 7 approved and 66 investigational indications. This drug has a black box warning from the FDA."
CHEMBL5314390,"CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4.Cl.Cl_|_PBEVPBFDKPJIOM-RHIKYVLPSA-N_|_Small molecule_|_False_|_CEP-2563 DIHYDROCHLORIDE_|_nan_|_1.0_|_CHEMBL5316170_|_False_|_False_|_[]_|_['Cep-2563' 'KT-8391']_|_nan_|_nan_|_nan_|_[ENSG00000198400,ENSG00000148053,ENSG00000140538,ENSG00000122025,ENSG00000165731,ENSG00000113721,ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL598797,"C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1_|_PLIVFNIUGLLCEK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CUDC-101_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CUDC-101' 'Cudc 101' 'Cudc-101']_|_[('PubChem', array(['137276021'], dtype=object)), ('drugbank', array(['DB12174'], dtype=object))]_|_['CHEMBL3922781' 'CHEMBL3957601' 'CHEMBL3983283' 'CHEMBL3913031']_|_{'rows': array(['EFO_0000616', 'EFO_0006859', 'EFO_0003060', 'MONDO_0002691',
       'MONDO_0001056', 'MONDO_0007254', 'MONDO_0004992'], dtype=object), 'count': 7}_|_[ENSG00000146648,ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications."
CHEMBL608533,"CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4_|_BMGQWWVMWDBQGC-IIFHNQTCSA-N_|_Small molecule_|_False_|_MIDOSTAURIN_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Rydapt']_|_['CGP 41251' 'CGP-41251' 'Midostaurin' 'NSC-656576' 'NVP-PKC412' 'PKC 412'
 'PKC-412' 'Pkc-412']_|_[('DailyMed', array(['midostaurin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt'],
      dtype=object)), ('PubChem', array(['124950161'], dtype=object)), ('Wikipedia', array(['Midostaurin'], dtype=object)), ('drugbank', array(['DB06595'], dtype=object)), ('chEBI', array(['63452'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000131', 'EFO_0001421', 'EFO_0000220', 'EFO_0009001',
       'EFO_0000616', 'MONDO_0016586', 'EFO_0007359', 'EFO_0000198',
       'EFO_0000565', 'EFO_0000222', 'EFO_1000657'], dtype=object), 'count': 11}_|_[ENSG00000115825,ENSG00000163558,ENSG00000154229,ENSG00000126583,ENSG00000163932,ENSG00000166501,ENSG00000067606,ENSG00000171132,ENSG00000027075,ENSG00000184304,ENSG00000065675,ENSG00000113721,ENSG00000134853,ENSG00000157404,ENSG00000122025,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 6 investigational indications."
CHEMBL652,"O=C(NCC1CCCCN1)c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F_|_DJBNUMBKLMJRSA-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLECAINIDE_|_1985.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Flecainide' 'NSC-719273' 'THN-102 COMPONENT FLECAINIDE']_|_[('PubChem', array(['104171159', '124880129', '144203702', '170464874', '26752195'],
      dtype=object)), ('Wikipedia', array(['Flecainide'], dtype=object)), ('drugbank', array(['DB01195'], dtype=object)), ('chEBI', array(['75984'], dtype=object))]_|_['CHEMBL4591096' 'CHEMBL1200822']_|_{'rows': array(['EFO_0004269', 'EFO_0000275', 'Orphanet_247', 'HP_0004308',
       'EFO_0003843', 'EFO_0000275'], dtype=object), 'count': 6}_|_[ENSG00000183873]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for cardiac arrhythmia and ventricular arrhythmia and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL673,"C#CCN(C)Cc1ccccc1_|_DPWPWRLQFGFJFI-UHFFFAOYSA-N_|_Small molecule_|_False_|_PARGYLINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Eutonyl' 'Eutron' 'Pargyline']_|_[('PubChem', array(['11111668', '11111669', '90340843'], dtype=object)), ('Wikipedia', array(['Pargyline'], dtype=object)), ('drugbank', array(['DB01626'], dtype=object)), ('chEBI', array(['7930'], dtype=object))]_|_['CHEMBL1200425']_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000189221,ENSG00000069535]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for hypertension."
CHEMBL768,"COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1_|_AQNDDEOPVVGCPG-UHFFFAOYSA-N_|_Small molecule_|_False_|_ESMOLOL_|_1986.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['ASL-8052-001' 'Esmolol']_|_[('Wikipedia', array(['Esmolol'], dtype=object)), ('drugbank', array(['DB00187'], dtype=object)), ('chEBI', array(['88206'], dtype=object))]_|_['CHEMBL1201115']_|_{'rows': array(['EFO_0000319', 'EFO_0003870', 'EFO_0000275', 'EFO_0002687',
       'HP_0100543', 'EFO_0003843', 'EFO_0000537', 'HP_0000138',
       'EFO_0003833', 'EFO_0006834', 'EFO_0001645', 'EFO_0007486',
       'EFO_1001459', 'EFO_0006834'], dtype=object), 'count': 14}_|_[ENSG00000169252,ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for cardiovascular disease and hypertension and has 12 investigational indications."
CHEMBL86715,"OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1_|_WYDUSKDSKCASEF-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROCYCLIDINE_|_1955.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Elorine' 'Kemadrine' 'Lergine' 'NSC-169103' 'Procyclidine' 'Tricoloid'
 'Vagosin']_|_[('drugbank', array(['DB00387'], dtype=object)), ('chEBI', array(['8448'], dtype=object))]_|_['CHEMBL1761']_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1955 and is indicated for parkinson disease."
CHEMBL973,"C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1_|_UTNUDOFZCWSZMS-YFHOEESVSA-N_|_Small molecule_|_True_|_TERIFLUNOMIDE_|_2012.0_|_4.0_|_nan_|_False_|_True_|_['Aubagio' 'Teriflunomide mylan']_|_['A77 1726' 'HMR-1726' 'HMR1726' 'Leflunomide related compound b'
 'Leflunomide related compound b rs' 'Teriflunomide']_|_[('DailyMed', array(['teriflunomide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-mylan'],
      dtype=object)), ('Wikipedia', array(['Teriflunomide'], dtype=object)), ('drugbank', array(['DB08880'], dtype=object)), ('chEBI', array(['68540'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'MONDO_0005301', 'EFO_0001060', 'EFO_0007527',
       'EFO_0000540', 'EFO_0003086'], dtype=object), 'count': 6}_|_[ENSG00000102967]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1029,"CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO_|_UQRORFVVSGFNRO-UTINFBMNSA-N_|_Small molecule_|_False_|_MIGLUSTAT_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Miglustat dipharma' 'Zavesca']_|_['Butyldeoxynojirimycin' 'Miglustat' 'N-butyldeoxynojirimycin' 'OGT 918'
 'OGT-918']_|_[('DailyMed', array(['miglustat'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/miglustat-dipharma'],
      dtype=object)), ('PubChem', array(['144204381', '170464950'], dtype=object)), ('Wikipedia', array(['Miglustat'], dtype=object)), ('drugbank', array(['DB00419'], dtype=object)), ('chEBI', array(['50381'], dtype=object))]_|_['CHEMBL1329690']_|_{'rows': array(['EFO_0000764', 'HP_0002014', 'Orphanet_365', 'Orphanet_77259',
       'MONDO_0019262', 'MONDO_0017720', 'MONDO_0018150', 'MONDO_0002412',
       'MONDO_0018982', 'MONDO_0010006', 'MONDO_0009061', 'MONDO_0019064'],
      dtype=object), 'count': 12}_|_[ENSG00000148154]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for gaucher disease type 1 and gaucher disease and has 10 investigational indications."
CHEMBL1104,"CC[N+](C)(C)c1cccc(O)c1_|_VWLHWLSRQJQWRG-UHFFFAOYSA-O_|_Small molecule_|_False_|_EDROPHONIUM_|_1951.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ENLON-PLUS' 'Edrophonium' 'Edrophonium cation' 'Edrophonium ion' 'Enlon'
 'Reversol' 'Tensilon']_|_[('PubChem', array(['11111143', '11111144', '50100235', '50104222', '90341680'],
      dtype=object)), ('drugbank', array(['DB01010'], dtype=object)), ('chEBI', array(['251408'], dtype=object))]_|_['CHEMBL60745' 'CHEMBL1128']_|_{'rows': array(['EFO_1000645', 'EFO_0005252'], dtype=object), 'count': 2}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and has 2 investigational indications."
CHEMBL1144,"CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21_|_TUZYXOIXSAXUGO-PZAWKZKUSA-N_|_Small molecule_|_False_|_PRAVASTATIN_|_1991.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['C10AA03' 'Pravachol' 'Pravastatin' 'Pravator']_|_[('Wikipedia', array(['Pravastatin'], dtype=object)), ('drugbank', array(['DB00175'], dtype=object)), ('chEBI', array(['63618'], dtype=object))]_|_['CHEMBL690']_|_{'rows': array(['EFO_0000319', 'EFO_1001496', 'EFO_0004705', 'HP_0001919',
       'MONDO_0005147', 'EFO_0000668', 'MONDO_0008310', 'EFO_1000049',
       'EFO_0003929', 'EFO_0000685', 'EFO_0001645', 'EFO_0004911',
       'MONDO_0018473', 'HP_0003124', 'EFO_0000565', 'EFO_0000764',
       'MONDO_0007915', 'EFO_0000612', 'Orphanet_79211', 'EFO_0000182',
       'EFO_0000612', 'EFO_0000180', 'MONDO_0021187', 'EFO_0000319',
       'MONDO_0007254', 'MONDO_0021661', 'EFO_0000537', 'EFO_0000400',
       'EFO_1000727', 'HP_0003124', 'EFO_0004255', 'EFO_0000318',
       'EFO_0003884', 'EFO_0000400', 'EFO_0003914', 'Orphanet_79211',
       'MONDO_0020732', 'EFO_0003144', 'MONDO_0008903', 'EFO_0004246',
       'EFO_0006890', 'Orphanet_309005', 'MONDO_0018076', 'EFO_0000565',
       'EFO_0000764', 'EFO_0003106', 'EFO_0000313', 'MONDO_0002691',
       'HP_0002140', 'EFO_1001375'], dtype=object), 'count': 50}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 38 investigational indications."
CHEMBL1200330,"CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C.Cl_|_RNAICSBVACLLGM-GNAZCLTHSA-N_|_Small molecule_|_False_|_PILOCARPINE HYDROCHLORIDE_|_1984.0_|_4.0_|_CHEMBL550_|_False_|_True_|_['Isopto carpine' 'Ocusert' 'Piloc hcl' 'Pilocarpine hydrochloride'
 'Pilogel' 'Pilopine hs' 'Salagen' 'Sno pilo' 'Vuity']_|_['Pilocarpine hcl' 'Pilocarpine hydrochloride'
 'Pilocarpine monohydrochloride' 'Pilocarpini hydrochloridum'
 'Pilocarpinum muriaticum' 'Salagen' 'Vistacarpin n' 'Vuity']_|_[('DailyMed', array(['pilocarpine%20hydrochloride'], dtype=object)), ('PubChem', array(['26719685', '50106827', '539062', '855931'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001330', 'EFO_0006859'], dtype=object), 'count': 2}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 2 investigational indications."
CHEMBL1201466,"nan_|_nan_|_Small molecule_|_True_|_ESTROGENS, CONJUGATED SYNTHETIC A_|_1999.0_|_4.0_|_nan_|_False_|_True_|_['Cenestin' 'Synthetic conjugated estrogens a']_|_['Estrogens, conjugated synthetic a' 'Estrogens,conjugated synthetic a'
 'Synthetic conjugated estrogens, a']_|_[('DailyMed', array(['estrogens,%20conjugated%20synthetic%20a'], dtype=object))]_|_nan_|_{'rows': array(['GO_0042697', 'EFO_1000096'], dtype=object), 'count': 2}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for menopause and atrophy. This drug has a black box warning from the FDA."
CHEMBL1201605,"nan_|_nan_|_Antibody_|_False_|_DACLIZUMAB_|_1997.0_|_4.0_|_nan_|_True_|_True_|_['Zenapax' 'Zinbryta']_|_['Daclizumab' 'Daclizumab beta' 'RO 24-7375' 'RO-24-7375']_|_[('DrugCentral', array(['4953'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zinbryta'],
      dtype=object)), ('Wikipedia', array(['Daclizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198', 'EFO_0001378', 'MONDO_0004979', 'EFO_0000574',
       'EFO_0000616', 'MONDO_0001705', 'EFO_0000676', 'HP_0012410',
       'EFO_0004683', 'EFO_0000764', 'MONDO_0013730', 'EFO_0000756',
       'EFO_0003929', 'MONDO_0018923', 'MONDO_0005301', 'EFO_0003086',
       'EFO_0000729', 'EFO_0003884', 'EFO_0000540', 'EFO_0000400',
       'HP_0001873', 'EFO_0005297', 'EFO_1001231', 'EFO_0000565',
       'HP_0001915', 'MONDO_0005147'], dtype=object), 'count': 26}_|_[ENSG00000134460,ENSG00000147168,ENSG00000100385]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 23 investigational indications. It was withdrawn in at least one region."
CHEMBL1201649,"nan_|_nan_|_Unknown_|_True_|_ESTROGENS, CONJUGATED_|_1942.0_|_4.0_|_nan_|_False_|_True_|_['Cenestin' 'Oestrogen' 'Premarin' 'Premarin Cream']_|_['Conjugated estrogens' 'Estrogen, conjugated (class)'
 'Estrogens conjugated' 'Estrogens, conjugated' 'Estrogens,conjugated'
 'G03CA57' 'Oestrogens conjugated']_|_[('DailyMed', array(['estrogens,%20conjugated'], dtype=object)), ('DrugCentral', array(['4855'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000938', 'MONDO_0008315', 'EFO_0000612', 'MONDO_0007915',
       'EFO_0000712', 'MONDO_0004975', 'EFO_0004288', 'MONDO_0001410',
       'EFO_0000400', 'EFO_0001072', 'EFO_1000781', 'HP_0030016',
       'GO_0042697', 'MONDO_0002146', 'EFO_0000537', 'HP_0031217',
       'MONDO_0043510', 'HP_0031273', 'EFO_1000985', 'EFO_0001663',
       'EFO_1001375', 'EFO_0002687', 'EFO_1000096', 'MONDO_0011962',
       'EFO_0003869', 'EFO_0008507', 'MONDO_0000831', 'EFO_0001645',
       'EFO_0003882', 'HP_0003124', 'MONDO_0007254', 'MONDO_0019499',
       'EFO_0004266', 'MONDO_0005351', 'EFO_0003854'], dtype=object), 'count': 35}_|_[ENSG00000140009,ENSG00000091831]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1942 and has 10 approved and 25 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2105613,"CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]_|_MSRILKIQRXUYCT-UHFFFAOYSA-M_|_Small molecule_|_True_|_DIVALPROEX SODIUM_|_1983.0_|_4.0_|_CHEMBL109_|_False_|_True_|_['Depakote' 'Depakote cp' 'Depakote er' 'Divalproex sodium']_|_['ABBOTT 50711' 'ABBOTT-50711' 'Divalproex' 'Divalproex sodium'
 'Semisodium valproate' 'Valproate semisodium'
 'Valproic acid sodium salt (2:1)']_|_[('DailyMed', array(['divalproex%20sodium'], dtype=object)), ('chEBI', array(['4667'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007079', 'EFO_0000474', 'HP_0000713', 'HP_0001250',
       'EFO_0000616', 'EFO_0000717', 'EFO_0001358', 'HP_0010865',
       'EFO_0004247', 'EFO_1000877', 'MONDO_0004975', 'HP_0002013',
       'MONDO_0002009', 'EFO_0003758', 'MONDO_0005090', 'EFO_0009963',
       'MONDO_0004985', 'HP_0000726', 'MONDO_0005277', 'HP_0007359',
       'HP_0002121', 'HP_0002039', 'MONDO_0007739'], dtype=object), 'count': 23}_|_[ENSG00000112294]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 11 approved and 12 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108570,"nan_|_nan_|_Unknown_|_True_|_ABOBOTULINUMTOXINA_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Abobotulinumtoxina' 'RTI-150' 'RTI150']_|_[('DailyMed', array(['abobotulinumtoxina'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006346', 'EFO_1001896', 'HP_0003419'], dtype=object), 'count': 3}_|_[ENSG00000132639]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109437,"nan_|_nan_|_Antibody_|_False_|_KHK-2866_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['KHK-2866' 'KHK2866' 'Khk-2866']_|_nan_|_nan_|_{'rows': array(['EFO_1001100', 'EFO_1000251', 'EFO_0003893'], dtype=object), 'count': 3}_|_[ENSG00000113070]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 3 investigational indications."
CHEMBL2109602,"nan_|_nan_|_Antibody_|_False_|_IMC-3C5_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IMC-3C5' 'Imc-3c5']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000037280]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2110824,"CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1_|_CUWODFFVMXJOKD-UVLQAERKSA-N_|_Protein_|_False_|_BUSERELIN_|_nan_|_4.0_|_nan_|_False_|_True_|_['Suprecur' 'Suprefact']_|_['Buserelin']_|_nan_|_['CHEMBL2106198']_|_{'rows': array(['EFO_0000545', 'EFO_0000616', 'MONDO_0008315', 'EFO_0000673',
       'EFO_0000196', 'EFO_0000545'], dtype=object), 'count': 6}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 5 investigational indications."
CHEMBL2219536,"COCCO[C@@H]1[C@H](SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(N)ncnc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)C[C@@H]2SP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)[C@H](OCCOC)[C@@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cnc4c(N)ncnc43)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2SP(=O)(O)OC[C@@H]2O[C@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)[C@H]2O)[C@@H](COP(=O)(O)S[C@H]2[C@@H](OCCOC)[C@H](n3cc(C)c(N)nc3=O)O[C@@H]2COP(=O)(O)S[C@H]2[C@@H](OCCOC)[C@H](n3cnc4c(=O)[nH]c(N)nc43)O[C@@H]2CO)O[C@H]1n1cc(C)c(N)nc1=O_|_TZRFSLHOCZEXCC-HIVFKXHNSA-N_|_Oligonucleotide_|_True_|_MIPOMERSEN_|_2013.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Mipomersen']_|_[('DrugCentral', array(['4747'], dtype=object))]_|_['CHEMBL502097']_|_{'rows': array(['EFO_0000319', 'EFO_0004911', 'HP_0003124'], dtype=object), 'count': 3}_|_[ENSG00000084674]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for cardiovascular disease and familial hypercholesterolemia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2323775,"Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1_|_VMJFTOSOFDEKTM-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-8033_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MK-8033' 'MK8033' 'Mk-8033']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000164078,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3099695,"N#Cc1ccc([C@H]2CCc3cncn32)c(F)c1_|_USUZGMWDZDXMDG-CYBMUJFWSA-N_|_Small molecule_|_False_|_OSILODROSTAT_|_2020.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['LCI-699-NX' 'LCI699-NX' 'Lci-699' 'Lci699' 'Osilodrostat']_|_[('drugbank', array(['DB11837'], dtype=object))]_|_['CHEMBL3707393']_|_{'rows': array(['EFO_0003086', 'EFO_0000537', 'EFO_0005539', 'HP_0011736',
       'EFO_1001110', 'EFO_0001421', 'MONDO_0001134', 'EFO_0003099',
       'EFO_0003099', 'EFO_1001110'], dtype=object), 'count': 10}_|_[ENSG00000160882]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 3 approved and 7 investigational indications."
CHEMBL3353410,"C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C_|_DUYJMQONPNNFPI-UHFFFAOYSA-N_|_Small molecule_|_False_|_OSIMERTINIB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Tagrisso']_|_['AZD-9291' 'AZD-9291 FREE BASE' 'AZD9291' 'Azd-9291' 'Mereletinib'
 'Osimertinib']_|_[('drugbank', array(['DB09330'], dtype=object))]_|_['CHEMBL4741340' 'CHEMBL4754013' 'CHEMBL3545063' 'CHEMBL4472934'
 'CHEMBL4784911']_|_{'rows': array(['EFO_0000313', 'MONDO_0005575', 'MONDO_0004992', 'EFO_0000707',
       'MONDO_0021117', 'EFO_0000571', 'EFO_0000519', 'EFO_0003060',
       'MONDO_0008903', 'MONDO_0008903', 'EFO_0003833', 'EFO_0000228',
       'EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 14}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 3 approved and 11 investigational indications."
CHEMBL3545331,nan_|_nan_|_Small molecule_|_False_|_RPR749_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Rpr749']_|_nan_|_nan_|_nan_|_[ENSG00000163485]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3989931,"CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O_|_ORZHZQZYWXEDDL-UHFFFAOYSA-N_|_Small molecule_|_True_|_ENASIDENIB MESYLATE_|_2017.0_|_4.0_|_CHEMBL3989908_|_False_|_True_|_['Idhifa']_|_['AG-221 mesylate' 'CC-90007' 'Enasidenib mesilate' 'Enasidenib mesylate'
 'Enasidenib methanesulfonate']_|_[('DailyMed', array(['enasidenib%20mesylate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000182054]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for acute myeloid leukemia. This drug has a black box warning from the FDA."
CHEMBL4298202,"nan_|_nan_|_Oligonucleotide_|_False_|_PELACARSEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AKCEA-APO(a)-LRx' 'ISIS 681257' 'ISIS-681257 FREE ACID'
 'Ionis-apo(a)-lrx' 'Pelacarsen']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PELACARSEN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0001645', 'MONDO_0037748', 'EFO_0003086',
       'EFO_0001421', 'EFO_0000266'], dtype=object), 'count': 6}_|_[ENSG00000198670]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL4650216,"COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1.Cl_|_HJVGDXBEMFHGKI-BQAIUKQQSA-N_|_Small molecule_|_False_|_DARIDOREXANT HYDROCHLORIDE_|_2022.0_|_4.0_|_CHEMBL4297590_|_False_|_True_|_['Quviviq']_|_['ACT-541468A' 'Daridorexant hydrochloride' 'Nemorexant hydrochloride'
 'Quviviq']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/DARIDOREXANT%20HYDROCHLORIDE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698'], dtype=object), 'count': 1}_|_[ENSG00000121764,ENSG00000137252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2022 and is indicated for insomnia."
CHEMBL467,"NC(=O)NO_|_VSNHCAURESNICA-UHFFFAOYSA-N_|_Small molecule_|_True_|_HYDROXYUREA_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Droxia' 'Hydrea' 'Hydroxyurea' 'Siklos']_|_['Hydroxycarbamide' 'Hydroxyurea' 'NSC-32065' 'SQ 1089' 'SQ-1089']_|_[('DailyMed', array(['hydroxyurea'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/siklos'],
      dtype=object)), ('PubChem', array(['11111283', '144210638', '170465025', '174007362', '26747533',
       '50106399', '57260119', '85231078', '90341681', '90752'],
      dtype=object)), ('Wikipedia', array(['Hydroxycarbamide'], dtype=object)), ('drugbank', array(['DB01005'], dtype=object)), ('chEBI', array(['44423'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000313', 'MONDO_0008903', 'EFO_0000198', 'EFO_0002430',
       'MONDO_0005301', 'EFO_0000616', 'EFO_0006859', 'EFO_1001465',
       'EFO_0000181', 'EFO_1000642', 'EFO_0000519', 'HP_0001871',
       'EFO_1000158', 'MONDO_0016487', 'EFO_0000764', 'EFO_0004251',
       'EFO_0005577', 'EFO_0000712', 'MONDO_0007576', 'EFO_0000707',
       'EFO_0002429', 'EFO_1001797', 'MONDO_0016642', 'EFO_0003866',
       'EFO_1001996', 'EFO_0000222', 'EFO_0000479', 'MONDO_0001056',
       'EFO_0000220', 'EFO_0000574', 'EFO_0003817', 'EFO_0008525',
       'EFO_0000339', 'Orphanet_848', 'EFO_0000756', 'EFO_0009907',
       'MONDO_0044903', 'EFO_0005570', 'MONDO_0005149', 'EFO_0000565',
       'EFO_0000224', 'MONDO_0011382'], dtype=object), 'count': 42}_|_[ENSG00000167325,ENSG00000048392,ENSG00000171848]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 6 approved and 36 investigational indications. This drug has a black box warning from the FDA."
CHEMBL515914,"CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O_|_QQOBRRFOVWGIMD-OJAKKHQRSA-N_|_Small molecule_|_False_|_AZARIBINE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['Azaribine' 'CB 304' 'CB-304' 'NSC-67239']_|_[('PubChem', array(['144204429', '170466075', '29215005', '855722'], dtype=object))]_|_nan_|_nan_|_[ENSG00000114491]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL5315122,"CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1O[C@H]([C@H](O)CO)[C@@H]([C@H](O)CO)O1_|_QDMRNLRJDHCHLB-DNNBANOASA-N_|_Small molecule_|_False_|_BORTEZOMIB D-MANNITOL_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Bortezomib accord']_|_['Bortezomib d-mannitol ester']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-accord'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000173692,ENSG00000126067,ENSG00000008018,ENSG00000100804,ENSG00000204264,ENSG00000240065,ENSG00000142507,ENSG00000115233,ENSG00000129084,ENSG00000106588,ENSG00000100567,ENSG00000041357,ENSG00000143106,ENSG00000100902,ENSG00000101182,ENSG00000154611,ENSG00000205220,ENSG00000222028,ENSG00000277791,ENSG00000159377,ENSG00000136930,ENSG00000130706,ENSG00000161057,ENSG00000100764,ENSG00000013275,ENSG00000100519,ENSG00000165916,ENSG00000087191,ENSG00000175166,ENSG00000108344,ENSG00000197170,ENSG00000108671,ENSG00000163636,ENSG00000103035,ENSG00000185627,ENSG00000159352,ENSG00000099341,ENSG00000127922]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2015."
CHEMBL550755,"Cl.O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12_|_WEIAMZKHBCLFOG-QPAIBFMUSA-N_|_Small molecule_|_False_|_FORODESINE HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL218291_|_False_|_False_|_[]_|_['BCX-1777' 'Forodesine hcl' 'Forodesine hydrochloride']_|_nan_|_nan_|_{'rows': array(['EFO_0000095', 'MONDO_0000430', 'EFO_0004289', 'EFO_0000574',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000198805]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL646,"Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2_|_JOFWLTCLBGQGBO-UHFFFAOYSA-N_|_Small molecule_|_True_|_TRIAZOLAM_|_1978.0_|_4.0_|_nan_|_True_|_True_|_['Halcion' 'Kention' 'Triazolam']_|_['N05CD05' 'Triazolam' 'Triazolam civ' 'U-33,030' 'U-33030']_|_[('DailyMed', array(['triazolam'], dtype=object)), ('PubChem', array(['144206170', '50113071'], dtype=object)), ('TG-GATEs', array(['120'], dtype=object)), ('Wikipedia', array(['Triazolam'], dtype=object)), ('drugbank', array(['DB00897'], dtype=object)), ('chEBI', array(['9674'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'MONDO_0002050', 'EFO_0003890',
       'MONDO_0005090', 'EFO_0004698'], dtype=object), 'count': 6}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and is indicated for insomnia and has 5 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1200328,"CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl_|_BFFSMCNJSOPUAY-LMOVPXPDSA-N_|_Small molecule_|_True_|_DULOXETINE HYDROCHLORIDE_|_2004.0_|_4.0_|_CHEMBL1175_|_False_|_True_|_['Ariclaim' 'Cymbalta' 'Drizalma sprinkle' 'Duciltia'
 'Duloxetine hydrochloride' 'Duloxetine zentiva' 'Yentreve']_|_['Ariclaim' 'Duloxetine (as hydrochloride)' 'Duloxetine hcl'
 'Duloxetine hydrochloride' 'Duloxetine mylan' 'LY-248686' 'LY-248686 HCL'
 'LY248686 HCL' 'NSC-759112' 'Xeristar']_|_[('DailyMed', array(['duloxetine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-zentiva'],
      dtype=object)), ('PubChem', array(['144205741', '170465319', '49681598'], dtype=object)), ('chEBI', array(['31526'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012532', 'EFO_0002970', 'HP_0000020', 'MONDO_0002009',
       'EFO_0005230', 'EFO_0005762', 'EFO_1001951', 'MONDO_0002009',
       'MONDO_0005301', 'EFO_0003843', 'MONDO_0002050', 'EFO_0001358',
       'MONDO_0005178', 'EFO_1000783', 'EFO_0005687', 'EFO_0006788'],
      dtype=object), 'count': 16}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 6 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200912,"CC(C)(N)Cc1ccccc1.Cl_|_NCAIGTHBQTXTLR-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENTERMINE HYDROCHLORIDE_|_1973.0_|_4.0_|_CHEMBL1574_|_False_|_True_|_['Adipex-p' 'Fastin' 'Lomaira' 'Obestin-30' 'Oby-trim' 'Ona-mast'
 'Phentermine hydrochloride' 'Suprenza' 'Tora' 'Wilpo']_|_['NSC-44090' 'Phentermine hcl' 'Phentermine hydrochloride'
 'Phentermine hydrochloride civ' 'Zantryl']_|_[('DailyMed', array(['phentermine%20hydrochloride'], dtype=object)), ('chEBI', array(['50506'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001073'], dtype=object), 'count': 1}_|_[ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1973 and is indicated for obesity."
CHEMBL1201081,"C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)COC(=O)CCC(=O)[O-])[C@@]2(C)C=CC(=O)C=C12.[Na+]_|_FQISKWAFAHGMGT-SGJOWKDISA-M_|_Small molecule_|_False_|_METHYLPREDNISOLONE SODIUM SUCCINATE_|_1959.0_|_4.0_|_CHEMBL1201265_|_False_|_True_|_['A-methapred' 'Methylprednisolone sodium succinate' 'Min-i-mix'
 'Solu-medrol' 'Solu-medrone' 'Urbasone']_|_['Methylprednisolone 21-succinate sodium salt'
 'Methylprednisolone sodium succinate' 'NSC-48989']_|_[('DailyMed', array(['methylprednisolone%20sodium%20succinate'], dtype=object)), ('PubChem', array(['144207076'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000694', 'EFO_0000768', 'MONDO_0007915', 'MONDO_0002280',
       'EFO_0008522', 'EFO_0000095', 'EFO_0000685', 'EFO_1001222',
       'EFO_0000540', 'MONDO_0002406', 'MONDO_0100096', 'MONDO_0013730',
       'EFO_0000220', 'MONDO_0005301', 'EFO_0003106', 'EFO_0003843',
       'MONDO_0002462', 'EFO_0003840', 'EFO_0000198', 'EFO_0004194',
       'EFO_1001272', 'EFO_0000574', 'MONDO_0004979', 'EFO_0004599',
       'EFO_0000565', 'EFO_0005952', 'EFO_0007359', 'EFO_0007332',
       'EFO_0007537', 'EFO_0004228', 'EFO_0001378', 'EFO_0000222',
       'EFO_0000474', 'EFO_0001063'], dtype=object), 'count': 34}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 8 approved and 26 investigational indications."
CHEMBL1201545,"nan_|_nan_|_Protein_|_False_|_INSULIN SUSP ISOPHANE BEEF_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Nph insulin']_|_['Insulin susp isophane beef']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'EFO_0004593'], dtype=object), 'count': 3}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and has 3 investigational indications."
CHEMBL1201585,"nan_|_nan_|_Antibody_|_True_|_TRASTUZUMAB_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Herceptin' 'Herzuma' 'Kadcyla']_|_['4D5V8' 'ABP 980' 'ABP-980' 'ABP980' 'Abp-980 (trastuzumab biosimilar)'
 'Bmab-200' 'Canhera' 'DMB-3111 (TRASTUZUMAB BIOSIMILAR)' 'Dmb-3111'
 'EG-12014' 'EG12014' 'Eg-12014 (trastuzumab biosimilar)'
 'Eg12014 trastuzumab biosimilar' 'HLX-02' 'Herzuma' 'Hlx 02'
 'Hlx-02 trastuzumab biosimilar' 'Hlx02' 'Kanjinti' 'Ogivri' 'Ontruzant'
 'Pf-05280014' 'R-597' 'RO-0452317' 'RO0452317' 'Rhumab her2' 'SYD-977'
 'SYD977' 'Sb-3 (trastuzumab biosimilar)' 'Trastuzumab'
 'Trastuzumab (herceptin)' 'Trastuzumab anns' 'Trastuzumab beta'
 'Trastuzumab biosimilar (abp-980)' 'Trastuzumab biosimilar (amgen)'
 'Trastuzumab biosimilar (ct-p6)' 'Trastuzumab biosimilar (sb-3)'
 'Trastuzumab dkst' 'Trastuzumab dttb' 'Trastuzumab pkrb'
 'Trastuzumab qyyp' 'Trastuzumab-anns' 'Trastuzumab-dkst'
 'Trastuzumab-dttb' 'Trastuzumab-pfizer' 'Trastuzumab-pkrb'
 'Trastuzumab-qyyp' 'Trastuzumab-zzxf' 'Trazimera' 'Zercepac']_|_[('DailyMed', array(['trastuzumab', 'trastuzumab-anns', 'trastuzumab-dkst',
       'trastuzumab-pkrb'], dtype=object)), ('DrugCentral', array(['4979'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/herzuma'],
      dtype=object)), ('Wikipedia', array(['Trastuzumab'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018364', 'MONDO_0004192', 'EFO_1000796', 'EFO_0009637',
       'EFO_0005774', 'MONDO_0001056', 'MONDO_0002974', 'MONDO_0003060',
       'MONDO_0021311', 'EFO_0000691', 'MONDO_0004992', 'EFO_0005922',
       'MONDO_0003510', 'EFO_0000183', 'MONDO_0002158', 'EFO_0007532',
       'EFO_0000616', 'EFO_0003869', 'MONDO_0003196', 'MONDO_0005411',
       'EFO_0005537', 'MONDO_0001402', 'EFO_0000305', 'EFO_0000222',
       'EFO_1001187', 'EFO_0000641', 'EFO_1001951', 'EFO_1001512',
       'MONDO_0001528', 'EFO_0002916', 'MONDO_0008315', 'EFO_1001051',
       'EFO_0003968', 'MONDO_0021165', 'MONDO_0011962', 'EFO_0005221',
       'EFO_0000501', 'MONDO_0004669', 'MONDO_0004986', 'EFO_0000549',
       'EFO_0003863', 'MONDO_0000521', 'EFO_0000503', 'EFO_0000701',
       'EFO_0000637', 'EFO_1000028', 'EFO_0006861', 'MONDO_0001370',
       'EFO_0000228', 'MONDO_0001879', 'EFO_0009708', 'EFO_0000432',
       'EFO_0006859', 'EFO_1000984', 'EFO_0006352', 'EFO_0002618',
       'MONDO_0007254', 'MONDO_0007576', 'MONDO_0002087', 'EFO_0003060',
       'MONDO_0044926', 'MONDO_0001187', 'EFO_0003897', 'EFO_0008549',
       'EFO_0001642', 'EFO_0001663', 'EFO_1000294', 'EFO_0000313',
       'EFO_0004142', 'MONDO_0008903', 'MONDO_0008170', 'EFO_0000565',
       'EFO_0006318', 'EFO_0003891', 'EFO_0005952'], dtype=object), 'count': 75}_|_[ENSG00000141736]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 9 approved and 66 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1237021,"O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1_|_PQXKDMSYBGKCJA-CVTJIBDQSA-N_|_Small molecule_|_True_|_LURASIDONE_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Latuda']_|_['Lurasidone']_|_[('Wikipedia', array(['Lurasidone'], dtype=object)), ('drugbank', array(['DB08815'], dtype=object)), ('chEBI', array(['70735'], dtype=object))]_|_['CHEMBL1615372']_|_{'rows': array(['EFO_0009963', 'EFO_0005411', 'MONDO_0005090', 'MONDO_0004985',
       'MONDO_0002009', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0009963',
       'MONDO_0004985', 'EFO_0003758', 'EFO_0005407'], dtype=object), 'count': 11}_|_[ENSG00000149295,ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1497,"CCCCC(=O)O[C@]1(C(=O)CO)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_SNHRLVCMMWUAJD-SUYDQAKGSA-N_|_Small molecule_|_True_|_BETAMETHASONE VALERATE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_['Audavate' 'Audavate rd' 'Beta-val' 'Betacap' 'Betaderm'
 'Betameth val in coal tar' 'Betamethasone valerate' 'Betatrex' 'Betesil'
 'Betnovate rd' 'Betnovate-c' 'Betnovate-n' 'Bettamousse' 'Bextasol'
 'Dermabet' 'Fucibet' 'Luxiq' 'Valisone' 'Valnac' 'Xemacort']_|_['Betamethasone (as valerate)' 'Betamethasone 17-valerate'
 'Betamethasone valerate' 'Betamethasoni valeras' 'NSC-755912'
 'Rinderon v' 'Stanoval' 'Tokuderm']_|_[('DailyMed', array(['betamethasone%20valerate'], dtype=object)), ('PubChem', array(['144212605'], dtype=object)), ('Wikipedia', array(['Betamethasone_17-valerate'], dtype=object)), ('chEBI', array(['31277'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001818', 'EFO_0000274', 'EFO_0000701', 'EFO_1001494',
       'EFO_0000676'], dtype=object), 'count': 5}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for skin disease and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1615369,"CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O_|_XETBXHPXHHOLOE-UHFFFAOYSA-N_|_Small molecule_|_True_|_DABIGATRAN ETEXILATE MESYLATE_|_2008.0_|_4.0_|_CHEMBL539697_|_False_|_True_|_['Pradaxa']_|_['BIBR 1048 MS' 'BIBR-1048-MS' 'Dabigatran etexilate mesilate'
 'Dabigatran etexilate mesylate']_|_[('DailyMed', array(['dabigatran%20etexilate%20mesylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa'],
      dtype=object)), ('chEBI', array(['70743'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0010726', 'EFO_0000275', 'EFO_0003827', 'EFO_0000712',
       'EFO_0004286', 'EFO_1000652', 'EFO_0003907'], dtype=object), 'count': 7}_|_[ENSG00000180210]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 6 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL19449,"CC(C)C(=O)c1c(C(C)C)nn2ccccc12_|_ZJVFLBOZORBYFE-UHFFFAOYSA-N_|_Small molecule_|_False_|_IBUDILAST_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AV-411' 'AV411' 'Ibudilast' 'Ketas' 'MN-166']_|_[('PubChem', array(['11114182', '124880396', '124880398', '144207052', '170466049',
       '46500478', '50104937', '90341511'], dtype=object)), ('Wikipedia', array(['Ibudilast'], dtype=object)), ('drugbank', array(['DB05266'], dtype=object))]_|_nan_|_{'rows': array(['HP_0006536', 'EFO_1000783', 'MONDO_0004976', 'MONDO_0007079',
       'EFO_0003843', 'EFO_0004701', 'EFO_0000519', 'EFO_0003840',
       'EFO_0007541', 'EFO_0005611', 'MONDO_0005277', 'HP_0002196',
       'MONDO_0002491'], dtype=object), 'count': 13}_|_[ENSG00000138735,ENSG00000112541,ENSG00000172572,ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1989 and has 13 investigational indications."
CHEMBL2036958,"CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1_|_ARJKMWXLIHZLQZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SCH-900271_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SCH 900271' 'Sch 900271' 'Sch-900271']_|_[('drugbank', array(['DB12433'], dtype=object))]_|_nan_|_nan_|_[ENSG00000182782]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2103797,"Cc1cn([C@H]2C[C@H](OP(=O)([O-])OC[C@H]3O[C@@H](n4cc(C)c(=O)[nH]c4=O)C[C@@H]3O)[C@@H](COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(=O)[nH]c4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4ccc(N)nc4=O)O[C@@H]3COP(=O)([O-])O[C@H]3[C@@H](O)[C@H](n4cnc5c(N)ncnc54)O[C@@H]3CO)O2)c(=O)[nH]c1=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]_|_JKXXLIACMWFHSH-FIIWBELYSA-A_|_Oligonucleotide_|_False_|_BEVASIRANIB SODIUM_|_nan_|_-1.0_|_CHEMBL2110581_|_False_|_False_|_[]_|_['Bevasiranib sodium' 'CAND5']_|_nan_|_nan_|_nan_|_[ENSG00000164342,ENSG00000112715]_|_Oligonucleotide drug."
CHEMBL2109367,"nan_|_nan_|_Antibody drug conjugate_|_False_|_LMB-2_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LMB-2' 'Lmb-2']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000565', 'EFO_1000956', 'MONDO_0019471'],
      dtype=object), 'count': 4}_|_[ENSG00000134460]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2158685,"O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2_|_CAOTVXGYTWCKQE-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABC-294640_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABC 294640' 'Abc-294640' 'Abc294640' 'Opaganib']_|_[('PubChem', array(['174006706'], dtype=object)), ('drugbank', array(['DB12764'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_0002618', 'MONDO_0008315', 'EFO_0005221',
       'EFO_0000403', 'EFO_0001378', 'EFO_0007224'], dtype=object), 'count': 7}_|_[ENSG00000063176]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL256087,"CC1CCC(C(C)C)C(O)C1_|_NOOLISFMXDJSKH-UHFFFAOYSA-N_|_Small molecule_|_False_|_MENTHOL_|_2008.0_|_4.0_|_nan_|_False_|_True_|_['Aqua-cool' 'Aquasoothe' 'Arjun' 'Catarrh' 'Dermacool' 'Halls' 'Karvol'
 'Lockets' 'Meggezones' 'Muirs' 'Tixylix decongestant inh' 'Vocalzone']_|_['Dl-menthol' 'FEMA NO. 2665' 'Meggezone' 'Menthol' 'Menthol racemate'
 'Menthol, cis-1,3,trans-1,4-' 'Menthol, dl-' 'NSC-2603' 'Rac-menthol'
 'Racementhol']_|_[('PubChem', array(['144207208', '144213774', '26754473', '29215309'], dtype=object)), ('chEBI', array(['25187'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005856', 'HP_0000989', 'MONDO_0004979', 'EFO_0003958',
       'EFO_1001347', 'HP_0002015', 'EFO_0009846', 'EFO_0003843',
       'EFO_0009552', 'MONDO_0002471', 'MONDO_0005178', 'HP_0003326',
       'EFO_0009516', 'EFO_0009582', 'EFO_1001434', 'HP_0003394',
       'HP_0001742', 'EFO_0003768', 'MONDO_0001056', 'HP_0012735',
       'HP_0003418', 'EFO_0000546', 'MONDO_0002258', 'HP_0000155',
       'MONDO_0004857', 'EFO_0000537', 'EFO_0009661', 'MONDO_0021201',
       'EFO_0007214', 'HP_0002315', 'EFO_1000941', 'HP_0002829',
       'EFO_1000783'], dtype=object), 'count': 33}_|_[ENSG00000104321,ENSG00000144481]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 28 approved and 5 investigational indications."
CHEMBL278462,"CC(C)(C)CCC#C[C@@H]1C[C@H]1c1c[nH]cn1_|_CVKJAXCQPFOAIN-VXGBXAGGSA-N_|_Small molecule_|_False_|_CIPRALISANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-GT-2331' 'Cipralisant' 'Cipralisant, (-)-' 'GT-2331']_|_[('Wikipedia', array(['Cipralisant'], dtype=object))]_|_['CHEMBL2106003']_|_nan_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL298406,"CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21_|_DMJWENQHWZZWDF-PKOBYXMFSA-N_|_Small molecule_|_False_|_ECOPIPAM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ecopipam' 'SCH-39166']_|_[('PubChem', array(['144204748', '170466462'], dtype=object)), ('drugbank', array(['DB12273'], dtype=object))]_|_['CHEMBL1535402' 'CHEMBL1822916']_|_{'rows': array(['EFO_0004270', 'MONDO_0002182', 'MONDO_0010298', 'EFO_0004895',
       'EFO_0004895', 'EFO_0004699'], dtype=object), 'count': 6}_|_[ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL3287218,"Cc1cc(-c2ccc3c(c2)CC[C@H]3N2CC3(CCN(C(=O)Cc4cn5cc(C)sc5n4)CC3)C2)ncn1_|_ZIUDADZJCKGWKR-AREMUKBSSA-N_|_Small molecule_|_False_|_PF-5190457_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['PF-5190457' 'Pf-05190457' 'Pf-5190457']_|_[('drugbank', array(['DB14870'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004329', 'MONDO_0007079', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000121853]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3544930,nan_|_nan_|_Small molecule_|_False_|_SC-80036_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Sc-80036']_|_nan_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545132,"nan_|_nan_|_Antibody drug conjugate_|_False_|_MIRVETUXIMAB SORAVTANSINE_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Elahere']_|_['Elahere' 'IMGN-853' 'IMGN853' 'Mirvetuximab soravtansine'
 'Mirvetuximab soravtansine gynx' 'Mirvetuximab soravtansine-gynx']_|_nan_|_nan_|_{'rows': array(['EFO_1001100', 'MONDO_0011962', 'MONDO_0018364', 'MONDO_0007254',
       'EFO_0000616', 'MONDO_0002158', 'MONDO_0008170', 'EFO_0005537',
       'MONDO_0021092'], dtype=object), 'count': 9}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000110195]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 4 approved and 5 investigational indications."
CHEMBL3545381,"nan_|_nan_|_Small molecule_|_False_|_PLX-7486_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Plx-7486']_|_nan_|_nan_|_{'rows': array(['MONDO_0002171'], dtype=object), 'count': 1}_|_[ENSG00000198400,ENSG00000140538,ENSG00000182578,ENSG00000148053]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL4297232,"nan_|_nan_|_Unknown_|_False_|_DICLOFENAC ETALHYALURONATE SODIUM_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Diclofenac etalhyaluronate sodium' 'SI-613 SODIUM']_|_nan_|_nan_|_nan_|_[ENSG00000073756,ENSG00000095303]_|_Unknown drug."
CHEMBL4297632,"COCCOCCOCCOCCOCCOCCO[C@H]1CCC2(O)[C@H]3Cc4ccc(OC)c5c4[C@@]2(CCN3C)[C@H]1O5_|_RQHILGKAOIGUHU-BUCMUWKRSA-N_|_Small molecule_|_False_|_OXYCODEGOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Loxicodegol' 'NKTR-181' 'Nktr-181' 'Oxicodegol' 'Oxycodegol']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OXYCODEGOL/relevant/1/'],
      dtype=object))]_|_['CHEMBL4298154']_|_{'rows': array(['HP_0012532', 'EFO_0004616', 'HP_0003419', 'HP_0003419'],
      dtype=object), 'count': 4}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297728,"nan_|_nan_|_Antibody_|_False_|_CIRMTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cirmtuzumab' 'UC-961' 'Zilovertamab']_|_nan_|_nan_|_{'rows': array(['MONDO_0001056', 'EFO_0002618', 'EFO_0003060', 'MONDO_0008170',
       'EFO_0008528', 'EFO_0000096', 'MONDO_0008315', 'EFO_0005537',
       'EFO_0000403', 'EFO_0000095'], dtype=object), 'count': 10}_|_[ENSG00000185483]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL4298212,"nan_|_nan_|_Antibody_|_False_|_RAVAGALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-323' 'PR-1629977' 'Ravagalimab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/RAVAGALIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000699', 'EFO_0005809', 'MP_0001845'],
      dtype=object), 'count': 4}_|_[ENSG00000102245]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL45,"COc1ccc2[nH]cc(CCNC(C)=O)c2c1_|_DRLFMBDRBRZALE-UHFFFAOYSA-N_|_Small molecule_|_False_|_MELATONIN_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Circadin' 'General nutrit' 'Health aid' 'Heidadouppi' 'Icenia'
 'Life ext' 'Melapure' 'Melatonin neurim' 'Natrol' ""Nature's blend""
 'Natures bounty' 'Quality health' 'S.gard' 'Travelag' 'Vespro'
 'Vytalonin']_|_['5-methoxy n-acetyl-tryptamine' 'BCI-049' 'J5.258B' 'Melatol' 'Melatonin'
 'Melatonine' 'Melovine' 'N-(2-(5-Methoxy-1H-Indol-3-Yl)Ethyl)Acetamide'
 'N-Acetyl-5-Methoxytryptamine' 'NSC-113928' 'NSC-302012' 'NSC-56423'
 'Regulin' 'Tartrol']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/melatonin-neurim'],
      dtype=object)), ('PubChem', array(['104171188', '105815', '11111468', '124880734', '124880739',
       '144208725', '144213243', '170465589', '17388930', '17389536',
       '26747238', '26752764', '46500483', '50105414', '85231137',
       '90340716'], dtype=object)), ('Wikipedia', array(['Melatonin'], dtype=object)), ('drugbank', array(['DB01065'], dtype=object)), ('chEBI', array(['16796'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0000195', 'EFO_0000555', 'MONDO_0001134',
       'HP_0001919', 'MONDO_0100096', 'EFO_0000589', 'MONDO_0005090',
       'EFO_0000616', 'EFO_0005800', 'EFO_0003888', 'EFO_0005687',
       'EFO_0000729', 'EFO_0002496', 'EFO_0000546', 'HP_0000303',
       'HP_0100806', 'EFO_0003758', 'EFO_1000824', 'EFO_0000275',
       'EFO_0000280', 'EFO_0003918', 'HP_0012378', 'MONDO_0002050',
       'EFO_0002687', 'HP_0040187', 'EFO_0000474', 'EFO_0003756',
       'EFO_0008583', 'MP_0001914', 'EFO_1001216', 'EFO_0000701',
       'MONDO_0002009', 'EFO_1001904', 'EFO_0008568', 'HP_0100543',
       'EFO_0000649', 'EFO_0009267', 'EFO_0006859', 'EFO_0003948',
       'EFO_0003928', 'EFO_1001121', 'EFO_0009516', 'EFO_0005230',
       'MONDO_0024290', 'HP_0000726', 'MONDO_0005277', 'MONDO_0043510',
       'EFO_0000756', 'EFO_0000274', 'HP_0031217', 'EFO_0003929',
       'EFO_0001666', 'MONDO_0005180', 'HP_0000938', 'EFO_0005547',
       'EFO_0004698', 'EFO_0000400', 'EFO_0000712', 'EFO_0003958',
       'MONDO_0021698', 'MONDO_0004992', 'MONDO_0005301', 'EFO_0009579',
       'EFO_0000199', 'EFO_0003060', 'MONDO_0007254', 'MONDO_0002635',
       'MONDO_0005299', 'EFO_0000537'], dtype=object), 'count': 70}_|_[ENSG00000168412,ENSG00000134640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for insomnia and has 69 investigational indications."
CHEMBL4577523,"COc1nn(C)cc1Nc1nccc(-c2c[nH]c3c(NC(=O)[C@@H](C)N4CCN(C)CC4)cccc23)n1_|_CVCVOSPZEVINRM-MRXNPFEDSA-N_|_Small molecule_|_False_|_GOLIDOCITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-4205' 'AZD4205' 'AZD4205 free base' 'Azd4205' 'Golidocitinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GOLIDOCITINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000211', 'EFO_0003060', 'EFO_0005809', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000162434]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4594311,"nan_|_nan_|_Gene_|_False_|_BETIBEGLOGENE AUTOTEMCEL_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Zynteglo']_|_['BB-305' 'Betibeglogene autotemcel' 'LentiGlobin BB305' 'Zynteglo']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011382', 'Orphanet_848', 'MONDO_0016486'], dtype=object), 'count': 3}_|_[ENSG00000244734]_|_Gene drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for beta-thalassemia and beta-thalassemia major and has 1 investigational indication."
CHEMBL4650230,"CN1CCC2(CC1)NCC(=O)N2Cc1ccccc1_|_BSQPTZYKCAULBH-UHFFFAOYSA-N_|_Small molecule_|_False_|_SIMUFILAM_|_nan_|_3.0_|_nan_|_False_|_False_|_['Filora']_|_['C-0105' 'C0105' 'C0105M' 'PTI-125' 'PTI-910' 'Simufilam']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIMUFILAM/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650231']_|_{'rows': array(['MONDO_0004975', 'MONDO_0004975', 'EFO_0000616', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000196924]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL522892,"CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1_|_PIQCTGMSNWUMAF-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOVITINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CHIR-258' 'Dovitinib' 'GFKI-258' 'NVP-TKI258' 'TKI-258' 'Tki-258']_|_[('PubChem', array(['103904684', '137275871', '50100092'], dtype=object)), ('drugbank', array(['DB05928'], dtype=object))]_|_['CHEMBL4297063']_|_{'rows': array(['EFO_0000182', 'MONDO_0008667', 'EFO_0000222', 'MONDO_0008315',
       'EFO_1001465', 'MONDO_0011719', 'MONDO_0005184', 'EFO_0001378',
       'MONDO_0007254', 'MONDO_0001187', 'EFO_0003060', 'EFO_0000231',
       'EFO_1000796', 'EFO_0003060', 'MONDO_0002108', 'EFO_0000519',
       'EFO_0000756', 'MONDO_0001056', 'EFO_0000770', 'EFO_0000349',
       'MONDO_0011962', 'MONDO_0004992', 'EFO_0000681', 'EFO_0003863',
       'EFO_0000616'], dtype=object), 'count': 25}_|_[ENSG00000157404,ENSG00000122025,ENSG00000113721,ENSG00000134853,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000068078]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 25 investigational indications."
CHEMBL5315056,"C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.Cl.O.O_|_TXMZWEASFRBVKY-IOQDSZRYSA-N_|_Small molecule_|_False_|_NALOXONE HYDROCHLORIDE DIHYDRATE_|_2017.0_|_4.0_|_CHEMBL80_|_False_|_True_|_['Nyxoid']_|_['Naloxone chlorhydrate' 'Naloxoni hydrochloridum dihydrate']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0005611'], dtype=object), 'count': 1}_|_[ENSG00000082556,ENSG00000116329,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2017 and is indicated for opioid dependence."
CHEMBL551813,"CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O_|_XEOSTBFUCNZKGS-UHFFFAOYSA-N_|_Small molecule_|_False_|_BI-671800_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Actimis' 'BI 671800' 'BI671800' 'Bi 671800' 'Bi-671800']_|_[('PubChem', array(['174006824'], dtype=object)), ('drugbank', array(['DB12524'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1098,"CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C_|_LEBVLXFERQHONN-UHFFFAOYSA-N_|_Small molecule_|_True_|_BUPIVACAINE_|_1972.0_|_4.0_|_nan_|_False_|_True_|_['Anekain' 'Exparel' 'Exparel liposomal' 'Marcaine' 'Posimir'
 'Sensorcaine']_|_['Bucaine' 'Bupivacaine' 'Bupivacaine liposome' 'LIQ-865' 'LIQ865'
 'Liposomal bupivacaine' 'Marcaine'
 'Ropivacaine hydrochloride impurity, bupivacaine-' 'SKY-0402' 'SKY0402'
 'Sensorcaine']_|_[('DailyMed', array(['bupivacaine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal'],
      dtype=object)), ('PubChem', array(['160644527'], dtype=object)), ('Wikipedia', array(['Bupivacaine'], dtype=object)), ('drugbank', array(['DB00297'], dtype=object)), ('chEBI', array(['77431'], dtype=object))]_|_['CHEMBL1200396']_|_{'rows': array(['EFO_0003833', 'HP_0002315', 'HP_0001623', 'EFO_0000546',
       'EFO_1001866', 'EFO_0005251', 'MONDO_0000728', 'HP_0000175',
       'EFO_0007490', 'MONDO_0005277', 'EFO_0003060', 'MONDO_0007254',
       'EFO_0002950', 'HP_0000023', 'MONDO_0005178', 'EFO_1001792',
       'EFO_1000994', 'EFO_0004229', 'EFO_0009615', 'EFO_1000786',
       'EFO_1001250', 'EFO_0000342', 'EFO_1001267', 'HP_0001537',
       'EFO_1001909', 'EFO_0003869', 'EFO_0009676', 'EFO_0003964',
       'MONDO_0002087', 'EFO_0003931', 'HP_0012227', 'EFO_0010072',
       'EFO_0005762', 'MONDO_0041052', 'HP_0012532', 'HP_0000023',
       'EFO_0004888', 'EFO_1001331', 'HP_0009926', 'MONDO_0005277',
       'EFO_0004209', 'EFO_0002618', 'EFO_0003818', 'MONDO_0004992',
       'EFO_0001358', 'HP_0030834', 'MONDO_0021117', 'EFO_0000691',
       'EFO_1001139', 'MONDO_0008315', 'HP_0001822', 'HP_0002027',
       'EFO_0004616', 'EFO_0009620', 'EFO_0003843', 'MONDO_0004567',
       'EFO_0000764', 'HP_0000175', 'EFO_1001087', 'HP_0100790',
       'HP_0012735', 'EFO_0003843', 'EFO_0000275', 'HP_0012532',
       'MONDO_0007254', 'MONDO_0002959', 'EFO_0004616', 'HP_0001822',
       'EFO_0009314', 'HP_0031217', 'EFO_0001074', 'EFO_0001421',
       'MONDO_0004992', 'EFO_0007149', 'EFO_0009552', 'EFO_0000616',
       'MP_0001914', 'EFO_1001968', 'EFO_0009552', 'EFO_0000546',
       'EFO_0007486', 'HP_0003419', 'EFO_0000764', 'EFO_1001898'],
      dtype=object), 'count': 84}_|_[ENSG00000007314]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and is indicated for pain and hernia and has 76 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200771,"CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1.[Cl-]_|_XJGONMZLEDGBRM-UHFFFAOYSA-M_|_Small molecule_|_False_|_TRIDIHEXETHYL CHLORIDE_|_1954.0_|_4.0_|_CHEMBL1201354_|_False_|_True_|_['Pathilon']_|_['Tridihexethyl chloride']_|_[('PubChem', array(['144204284', '56463141'], dtype=object)), ('chEBI', array(['9703'], dtype=object))]_|_nan_|_nan_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954."
CHEMBL1201182,"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C_|_CBPNZQVSJQDFBE-FUXHJELOSA-N_|_Small molecule_|_False_|_TEMSIROLIMUS_|_2007.0_|_4.0_|_nan_|_False_|_True_|_['Torisel']_|_['CCI-779' 'Temsirolimus']_|_[('DailyMed', array(['temsirolimus'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/torisel'],
      dtype=object)), ('PubChem', array(['144206068'], dtype=object)), ('Wikipedia', array(['Temsirolimus'], dtype=object)), ('drugbank', array(['DB06287'], dtype=object)), ('chEBI', array(['79699'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000437', 'EFO_0000403', 'EFO_1000292', 'EFO_0000632',
       'EFO_0000702', 'EFO_0000181', 'EFO_0000685', 'EFO_1000026',
       'EFO_0000756', 'EFO_0003929', 'MONDO_0004992', 'MONDO_0004192',
       'EFO_0000565', 'EFO_0000222', 'EFO_0001378', 'MONDO_0002691',
       'EFO_0000616', 'EFO_0003869', 'EFO_0003833', 'MONDO_0001187',
       'MONDO_0002367', 'EFO_0003060', 'MONDO_0002974', 'EFO_0000313',
       'EFO_0007416', 'EFO_1000251', 'EFO_1001187', 'EFO_1001469',
       'EFO_0000182', 'EFO_0000305', 'MONDO_0003268', 'EFO_0000232',
       'EFO_0000248', 'EFO_0000681', 'EFO_0000228', 'MONDO_0016693',
       'EFO_0004265', 'EFO_1001512', 'EFO_1001968', 'EFO_0002501',
       'MONDO_0016691', 'MONDO_0008903', 'MONDO_0002087', 'MONDO_0002158',
       'MONDO_0024677', 'MONDO_0002108', 'EFO_0000183', 'EFO_0000574',
       'EFO_0000349', 'EFO_0000673', 'MONDO_0008315', 'EFO_0005952',
       'EFO_0000707', 'EFO_0000466', 'EFO_1000158', 'EFO_0000637',
       'EFO_0000502', 'EFO_0000621', 'EFO_1001465', 'EFO_0000556',
       'EFO_0009708', 'MONDO_0007254', 'EFO_0000519', 'EFO_0002499',
       'EFO_0007532', 'MONDO_0008170', 'EFO_0000339', 'EFO_1001331',
       'EFO_0000691', 'EFO_1000613', 'EFO_0000365', 'EFO_0006861',
       'EFO_0000389', 'MONDO_0021063', 'MONDO_0011962', 'EFO_0000198'],
      dtype=object), 'count': 76}_|_[ENSG00000088832]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 71 investigational indications."
CHEMBL1467,"Oc1ncnc2[nH]ncc12_|_OFCNXPDARWKPPY-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALLOPURINOL_|_1966.0_|_4.0_|_nan_|_False_|_True_|_['Allopurinol' 'Aloral' 'Aluline 100' 'Aluline 300' 'Caplenal' 'Cosuric'
 'Hamarin 100' 'Hamarin 300' 'Ledopur' 'Lopurin' 'Uricto' 'Xanthomax-100'
 'Xanthomax-300' 'Zyloprim' 'Zyloric' 'Zyloric-300']_|_['Allopurinol' 'Allopurinolum' 'BW 56-158' 'BW-56-158' 'NSC-101655'
 'NSC-1390' 'Suspendol' 'Takanarumin']_|_[('DailyMed', array(['allopurinol'], dtype=object)), ('PubChem', array(['11110781', '144203633', '144208120', '170464935', '17389550',
       '174007214', '26747845', '50105533', '56424020', '8139898',
       '90341357'], dtype=object)), ('TG-GATEs', array(['28'], dtype=object)), ('Wikipedia', array(['Allopurinol'], dtype=object)), ('drugbank', array(['DB00437'], dtype=object)), ('chEBI', array(['40279'], dtype=object))]_|_['CHEMBL1200477']_|_{'rows': array(['MONDO_0002087', 'EFO_0000319', 'EFO_0009104', 'EFO_1001893',
       'EFO_1001793', 'EFO_0005044', 'EFO_0003913', 'EFO_0000195',
       'MONDO_0005148', 'EFO_0000198', 'EFO_0000729', 'EFO_0005952',
       'EFO_0005207', 'EFO_0004274', 'EFO_0000565', 'EFO_0000574',
       'EFO_0000400', 'EFO_0000095', 'EFO_0004251', 'EFO_0000220',
       'EFO_0000702', 'EFO_0000537', 'EFO_0001422', 'MONDO_0001134',
       'EFO_0003777', 'MONDO_0004992', 'MONDO_0002158', 'EFO_0003884',
       'EFO_0000373', 'EFO_0003767', 'EFO_0001073', 'EFO_0001378',
       'EFO_0004253', 'MONDO_0005178', 'EFO_1001479', 'MONDO_0018076',
       'EFO_0000094', 'EFO_0003144', 'MONDO_0008170', 'MONDO_0004985',
       'EFO_0009582', 'EFO_0000222'], dtype=object), 'count': 42}_|_[ENSG00000158125]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1966 and has 4 approved and 38 investigational indications."
CHEMBL1569487,"CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O_|_WLHQHAUOOXYABV-UHFFFAOYSA-N_|_Small molecule_|_False_|_LORNOXICAM_|_nan_|_4.0_|_nan_|_False_|_True_|_['Xefo']_|_['CTX' 'Lorcam' 'Lornoxicam' 'NSC-759620' 'RO 13-9297' 'RO-13-9297'
 'RO-139297']_|_[('PubChem', array(['49666507'], dtype=object)), ('drugbank', array(['DB06725'], dtype=object)), ('chEBI', array(['31783'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005755', 'MONDO_0005277', 'EFO_0003843', 'MONDO_0004975'],
      dtype=object), 'count': 4}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for rheumatic disease and has 3 investigational indications."
CHEMBL1623,"Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1_|_OCJYIGYOJCODJL-UHFFFAOYSA-N_|_Small molecule_|_False_|_MECLIZINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Meclizine' 'Meclozine' 'NSC-169189']_|_[('Wikipedia', array(['Meclozine'], dtype=object)), ('drugbank', array(['DB00737'], dtype=object)), ('chEBI', array(['6709'], dtype=object))]_|_['CHEMBL1200590' 'CHEMBL1324020' 'CHEMBL3989555' 'CHEMBL1085765']_|_{'rows': array(['MONDO_0005271', 'HP_0002013', 'EFO_0006928', 'HP_0002321',
       'HP_0002018', 'EFO_0004319', 'HP_0002321', 'EFO_0000182',
       'HP_0002017', 'EFO_0006928'], dtype=object), 'count': 10}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved and 4 investigational indications."
CHEMBL1670,"Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1_|_JWBOIMRXGHLCPP-UHFFFAOYSA-N_|_Small molecule_|_True_|_MITOTANE_|_1970.0_|_4.0_|_nan_|_False_|_True_|_['Lysodren' 'Opddd']_|_['CB 313' 'CB-313' 'Chloditan' 'Chlodithane' 'Mitotan' 'Mitotane'
 'NSC-38721' ""O,p'-ddd"" ""O,p'-ddd,o p'-tde"" ""O,p'-tde"" 'Opeprim']_|_[('DailyMed', array(['mitotane'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lysodren'],
      dtype=object)), ('PubChem', array(['104171128', '144203654', '144213121', '170464927', '17389949',
       '174007193', '26747348', '26752984', '50105583', '56462780',
       '85230966', '90341596', '94579'], dtype=object)), ('Wikipedia', array(['Mitotane'], dtype=object)), ('drugbank', array(['DB00648'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000313', 'MONDO_0036591', 'EFO_1000796', 'MONDO_0008315',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000140459,ENSG00000160882]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743082,"nan_|_nan_|_Antibody drug conjugate_|_True_|_TRASTUZUMAB EMTANSINE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Kadcyla']_|_['PRO-132365' 'RG-3502' 'TRASTUZUMAB-MCC-DM1 T-DM1'
 'Trastuzumab emtansine']_|_[('DailyMed', array(['ado-trastuzumab%20emtansine'], dtype=object)), ('DrugCentral', array(['4990'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000294', 'EFO_1000984', 'MONDO_0000521', 'EFO_0001378',
       'EFO_0003869', 'EFO_0000305', 'MONDO_0008170', 'EFO_0009708',
       'EFO_0003060', 'MONDO_0004992', 'MONDO_0004669', 'MONDO_0001056',
       'MONDO_0011962', 'MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 15}_|_[ENSG00000141736,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and has 6 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103867,"CC(C)C[C@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)O_|_NSPHQWLKCGGCQR-DLJDZFDSSA-N_|_Protein_|_True_|_PLECANATIDE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Trulance']_|_['Guanilib' 'Plecanatide' 'SP-304' 'SP-304 (SYNERGY)']_|_[('drugbank', array(['DB13170'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002019', 'EFO_0000555'], dtype=object), 'count': 2}_|_[ENSG00000070019]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for constipation and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL2108359,"nan_|_nan_|_Antibody_|_False_|_NIMOTUZUMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_['Theraloc theracim']_|_['HR3' 'Nimotuzumab' 'OSAG 101' 'THERACIM-HR3' 'THERALOC']_|_nan_|_nan_|_{'rows': array(['EFO_0007331', 'EFO_0003060', 'MONDO_0002974', 'EFO_0002916',
       'MONDO_0001325', 'EFO_0000181', 'EFO_0000326', 'EFO_1001931',
       'MONDO_0005575', 'EFO_0003897', 'EFO_0000228', 'EFO_1000657',
       'MONDO_0007254', 'EFO_0000199', 'EFO_0000313', 'EFO_0006859',
       'EFO_0000616', 'EFO_1000026', 'EFO_0000707', 'EFO_0005922',
       'MONDO_0007576', 'EFO_0002618', 'MONDO_0001056', 'EFO_0002938',
       'EFO_1001951', 'MONDO_0004992', 'MONDO_0002914', 'EFO_0000519',
       'MONDO_0008903', 'EFO_0004252'], dtype=object), 'count': 30}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 30 investigational indications."
CHEMBL2109072,"nan_|_nan_|_Unknown_|_False_|_FIBRINOGEN, HUMAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Evarrest' 'Factor i (fibrinogen)' 'Factor i human' 'Fibrinogen'
 'Fibrinogen (human)' 'Fibrinogen concentrate (human)'
 'Fibrinogen concentrate human' 'Fibrinogen human'
 'Fibrinogen human plasma-derived' 'Fibrinogen, human' 'Haemocomplettan p'
 'Human fibrinogen' 'Parenogen' 'Raplixa']_|_nan_|_nan_|_{'rows': array(['EFO_0001421', 'EFO_0005207', 'EFO_0009579', 'EFO_0010282',
       'EFO_0003777', 'MONDO_0008737', 'HP_0001871', 'HP_0031273',
       'EFO_0000546', 'MP_0001914', 'HP_0002647'], dtype=object), 'count': 11}_|_[ENSG00000171560,ENSG00000171564,ENSG00000171557]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 11 investigational indications."
CHEMBL2170582,"CNC(=O)COc1cccc(Nc2ncc(F)c(Nc3ccc4c(c3)NC(=O)C(F)(F)O4)n2)c1_|_MOXXQFNQDDSJHT-UHFFFAOYSA-N_|_Small molecule_|_False_|_R-343_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['R-343']_|_nan_|_['CHEMBL3545340']_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000165025]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL298734,"NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1_|_DHMTURDWPRKSOA-RUZDIDTESA-N_|_Small molecule_|_False_|_LONAFARNIB_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Zokinvy']_|_['Lonafarnib' 'SCH 66336' 'SCH-66336' 'SCH66336' 'Sarasar']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy'],
      dtype=object)), ('Wikipedia', array(['Lonafarnib'], dtype=object)), ('drugbank', array(['DB06448'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001779', 'MONDO_0004192', 'EFO_0007304', 'MONDO_0007254',
       'EFO_0000339', 'EFO_0006859', 'EFO_0009708', 'EFO_0002499',
       'EFO_0000574', 'EFO_0000198', 'EFO_1000158', 'MONDO_0001187',
       'MONDO_0008310', 'MONDO_0002691', 'MONDO_0008170', 'EFO_0003060',
       'MONDO_0020732', 'EFO_1001951', 'EFO_1001465'], dtype=object), 'count': 19}_|_[ENSG00000168522,ENSG00000257365]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for hutchinson-gilford progeria syndrome and progeria and has 17 investigational indications."
CHEMBL3182733,"CCCN[C@H]1CCc2nc(N)sc2C1.Cl.Cl.O_|_APVQOOKHDZVJEX-QTPLPEIMSA-N_|_Small molecule_|_False_|_PRAMIPEXOLE DIHYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL301265_|_False_|_True_|_['Mirapex' 'Mirapex Extended Release' 'Mirapex er' 'Oprymea'
 'Pramipexole dihydrochloride']_|_['Daquiran' 'PNU-98528E' 'Pramipexole accord'
 'Pramipexole dihydrochloride' 'Pramipexole dihydrochloride anhydrous'
 'Pramipexole dihydrochloride monohydrate' 'Pramipexole hydrochloride'
 'Pramipexole hydrochloride hydrate' 'Pramipexole teva' 'SND-919CL2Y'
 'SND919CL2Y' 'Sifrol']_|_[('DailyMed', array(['pramipexole%20dihydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/oprymea'],
      dtype=object)), ('PubChem', array(['144212633'], dtype=object)), ('chEBI', array(['51147'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004270', 'MONDO_0004976', 'MONDO_0005180', 'MONDO_0004985'],
      dtype=object), 'count': 4}_|_[ENSG00000149295,ENSG00000151577,ENSG00000069696]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for restless legs syndrome and parkinson disease and has 2 investigational indications."
CHEMBL3304244,"Cc1nn(-c2ncccc2CO)cc1CN1CCC2(CC1)OCC(F)(F)c1cc(Cl)sc12_|_NKQHBJNRBKHUQR-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY-2940094_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BTRX-246040' 'Btrx-246040' 'J3.309.394B' 'Ly-2940094']_|_nan_|_['CHEMBL3236487']_|_{'rows': array(['MONDO_0005180', 'MONDO_0002009'], dtype=object), 'count': 2}_|_[ENSG00000125510]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3545376,"COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1_|_OLAHOMJCDNXHFI-UHFFFAOYSA-N_|_Small molecule_|_False_|_ERDAFITINIB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Balversa']_|_['Erdafitinib' 'JNJ-42756493' 'Jnj-42756493']_|_[('DailyMed', array(['erdafitinib'], dtype=object)), ('drugbank', array(['DB12147'], dtype=object))]_|_['CHEMBL3918638' 'CHEMBL3919709' 'CHEMBL3975791' 'CHEMBL3948043']_|_{'rows': array(['EFO_0000519', 'EFO_0003863', 'EFO_0008528', 'MONDO_0004992',
       'EFO_0003060', 'MONDO_0007254', 'EFO_0000574', 'EFO_0001421',
       'EFO_0001378', 'EFO_0000196', 'MONDO_0001187', 'EFO_0000294',
       'EFO_0000616', 'EFO_0000708', 'EFO_0000673', 'EFO_0000182'],
      dtype=object), 'count': 16}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 11 investigational indications."
CHEMBL359164,"Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1_|_RXRGZNYSEHTMHC-BQBZGAKWSA-N_|_Small molecule_|_False_|_TROXACITABINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(-)-ODDC' 'BCH-4556' 'Lamivudine impurity i' 'Lamivudine impurity i rs'
 'Troxacitabine' 'Troxatyl']_|_[('Wikipedia', array(['Troxacitabine'], dtype=object)), ('drugbank', array(['DB04961'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565'], dtype=object), 'count': 1}_|_[ENSG00000101868,ENSG00000175482,ENSG00000077514,ENSG00000062822,ENSG00000106628,ENSG00000177084,ENSG00000014138,ENSG00000198056,ENSG00000146143,ENSG00000100479,ENSG00000148229]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3707317,"nan_|_nan_|_Small molecule_|_False_|_LOREDIPLON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gf-015535-00' 'Lorediplon']_|_nan_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3707331,"C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_FIVSJYGQAIEMOC-ZGNKEGEESA-N_|_Small molecule_|_False_|_ROLAPITANT_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Varuby']_|_['Rolapitant']_|_[('drugbank', array(['DB09291'], dtype=object))]_|_['CHEMBL3707330']_|_{'rows': array(['EFO_0006911', 'EFO_0004888', 'HP_0002018', 'EFO_0000691',
       'EFO_0006911'], dtype=object), 'count': 5}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for chemotherapy-induced nausea and vomiting and has 4 investigational indications."
CHEMBL3989521,"CC(C)NCC(O)c1ccc(O)c(O)c1.CC(C)NCC(O)c1ccc(O)c(O)c1.O.O.O=S(=O)(O)O_|_CUQPTVCVZLUXJB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ISOPROTERENOL SULFATE_|_1956.0_|_4.0_|_CHEMBL434_|_False_|_True_|_['Medihaler-iso' 'Norisodrine']_|_['Aludrin' 'Isomist' 'Isoprenaline sulfate'
 'Isoprenaline sulfate dihydrate' 'Isoprenaline sulphate'
 'Isoprenalini sulfas' 'Isopropylarterenol sulfate'
 'Isoproterenol sulfate' 'Isoproterenol sulfate anhydrous'
 'Isoproterenol sulfate dihydrate' 'Isoproterenol sulphate' 'Propal']_|_nan_|_nan_|_nan_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL4297480,"O=C(Nc1ccc(F)cc1)c1cnc(SCc2cc(OC(F)(F)F)ccc2B(O)O)nc1_|_SDUDZBCEHIZMFZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SX-682_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SX-682' 'SX682' 'Sx-682']_|_nan_|_nan_|_{'rows': array(['MONDO_0005184', 'EFO_0000756', 'EFO_0002618', 'EFO_0000198',
       'EFO_1001949', 'EFO_1000657', 'EFO_0003060'], dtype=object), 'count': 7}_|_[ENSG00000163464,ENSG00000180871]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4297701,"nan_|_nan_|_Unknown_|_False_|_BIO-11006_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIO-11006' 'Bio-11006']_|_nan_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0003060', 'MONDO_0100130'], dtype=object), 'count': 3}_|_[ENSG00000277443]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297842,"nan_|_nan_|_Antibody_|_False_|_TOMUZOTUXIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tomuzotuximab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298172,"O=C(c1cccnc1-c1ccncc1)N1CCC(O)(Cc2ccccc2)CC1_|_XKUZMIUSBMCVPP-UHFFFAOYSA-N_|_Small molecule_|_False_|_SOTICLESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['OV-935' 'OV935' 'Soticlestat' 'TAK-935' 'TAK935']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SOTICLESTAT/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001998', 'MONDO_0016532', 'HP_0001250', 'EFO_0001421',
       'EFO_0000474'], dtype=object), 'count': 5}_|_[ENSG00000036530]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL490665,"CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl_|_DJSFYNINGIMKAG-FQJQBBMWSA-N_|_Small molecule_|_False_|_NALFURAFINE HYDROCHLORIDE_|_2009.0_|_4.0_|_CHEMBL267495_|_False_|_True_|_[]_|_['Nalfurafine hcl' 'Nalfurafine hydrochloride' 'Nopicor' 'Remitch'
 'TRK-820']_|_nan_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0001421'], dtype=object), 'count': 2}_|_[ENSG00000082556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 2 investigational indications."
CHEMBL5314407,"Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]_|_HXINDCTZKGGRDE-JPKZNVRTSA-L_|_Small molecule_|_False_|_ARQ-736_|_nan_|_1.0_|_CHEMBL5316167_|_False_|_False_|_[]_|_['ARQ-736' 'Arq 736' 'Arq-736']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000132155,ENSG00000157764]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL563,"CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1_|_SYTBZMRGLBWNTM-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLURBIPROFEN_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Ansaid' 'Cebutid' 'Flurbiprofen' 'Froben' 'Froben sr' 'Strefen'
 'Transact']_|_['BTS 18,322' 'BTS-18322' 'Flubiprofen' 'Flurbiprofen' 'NSC-757037'
 'Ocufen' 'U-27,182' 'U-27182']_|_[('DailyMed', array(['flurbiprofen'], dtype=object)), ('PubChem', array(['144204098', '144212670', '174007327', '26747178', '49732000',
       '520771', '855731', '860839'], dtype=object)), ('Wikipedia', array(['Flurbiprofen'], dtype=object)), ('drugbank', array(['DB00712'], dtype=object)), ('chEBI', array(['5130'], dtype=object))]_|_['CHEMBL3989754' 'CHEMBL1200990']_|_{'rows': array(['HP_0003419', 'MONDO_0044970', 'EFO_0005752', 'EFO_0000649',
       'EFO_0000685', 'HP_0000616', 'EFO_0000764', 'MONDO_0002258',
       'EFO_0003843', 'HP_0003326', 'MONDO_0005148', 'HP_0002829',
       'EFO_0003931', 'EFO_0005755', 'EFO_0004272'], dtype=object), 'count': 15}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL691,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C_|_BFPYWIDHMRZLRN-SLHNCBLASA-N_|_Small molecule_|_False_|_ETHINYL ESTRADIOL_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Estinyl' 'Etinestryl' 'Feminone' 'Follicoral' 'Lynoral']_|_['17-ethinylestradiol' '17alpha-ethinylestradiol' 'Enovid' 'Enovid-E'
 'Ethinyl Estradiol' 'Ethinyl estradiol' 'Ethinylestradiol'
 'Ethinylestradiolum' 'Ethinyloestradiol' 'Ethynylestradiol' 'Ginestrene'
 'NSC-10973' 'Norinyl' 'Ovulen' 'Ovulen-21' 'Ovulen-28']_|_[('DailyMed', array(['ethinyl%20estradiol'], dtype=object)), ('PubChem', array(['144204698', '144208489', '144210731', '170464983', '26753042',
       '76025'], dtype=object)), ('TG-GATEs', array(['55'], dtype=object)), ('drugbank', array(['DB00977'], dtype=object)), ('chEBI', array(['4903'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000660', 'EFO_0005924', 'MONDO_0005148', 'HP_0100608',
       'HP_0100607', 'MONDO_0009061', 'EFO_0000616', 'EFO_0010269',
       'MONDO_0004992', 'HP_0000938', 'MONDO_0002050', 'EFO_0008560',
       'EFO_1000710', 'EFO_0003047', 'MONDO_0019499', 'MONDO_0007254',
       'MONDO_0011962', 'EFO_0003882', 'EFO_0003894', 'MONDO_0004169',
       'EFO_0000764', 'MONDO_0005277', 'EFO_0004220', 'EFO_0009006',
       'MONDO_0018075', 'EFO_0000095', 'EFO_0004239', 'EFO_1001249',
       'EFO_0005204', 'EFO_0000180', 'EFO_0002950', 'MONDO_0005351'],
      dtype=object), 'count': 32}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 29 investigational indications."
CHEMBL81,"O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12_|_GZUITABIAKMVPG-UHFFFAOYSA-N_|_Small molecule_|_True_|_RALOXIFENE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Eviden' 'Evista' 'J22.982B' 'Keoxifene' 'LY-139481' 'NSC-747974'
 'Raloxifene' 'Raloxiphene' 'Raxeto']_|_[('PubChem', array(['104171230', '11111733', '11111734', '144209801', '174007256',
       '26755239', '50105675', '90341181'], dtype=object)), ('Wikipedia', array(['Raloxifene'], dtype=object)), ('drugbank', array(['DB00481'], dtype=object)), ('chEBI', array(['8772'], dtype=object))]_|_['CHEMBL1116']_|_{'rows': array(['GO_0042697', 'MONDO_0007254', 'EFO_0003854', 'HP_0100543',
       'MONDO_0004975', 'EFO_0000660', 'EFO_0000673', 'EFO_0003882',
       'EFO_0003882', 'EFO_0005411', 'EFO_0000673', 'MONDO_0011962',
       'EFO_0000694', 'MONDO_0007254', 'HP_0000938', 'MONDO_0005090',
       'EFO_0003854'], dtype=object), 'count': 17}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL827,"COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1_|_DUGOZIWVEXMGBE-CHWSQXEVSA-N_|_Small molecule_|_False_|_DEXMETHYLPHENIDATE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dexmethylphenidate' 'Methylphenidate d-threo-form']_|_[('Wikipedia', array(['Dexmethylphenidate'], dtype=object)), ('drugbank', array(['DB06701'], dtype=object)), ('chEBI', array(['51860'], dtype=object))]_|_['CHEMBL904']_|_{'rows': array(['EFO_0003888', 'EFO_0003888'], dtype=object), 'count': 2}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for attention deficit hyperactivity disorder."
CHEMBL877,"NC[C@H]1CC[C@H](C(=O)O)CC1_|_GYDJEQRTZSCIOI-LJGSYFOKSA-N_|_Small molecule_|_False_|_TRANEXAMIC ACID_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Cyklo-f heavy period relief' 'Cyklokapron' 'Exacyl' 'Lysteda'
 'Menstralite' 'Tranexamic acid']_|_['Amcha' 'CL 65336' 'CL-65336' 'CL65336' 'Cyclo-f' 'Cyclocapron'
 'Cyclokapron' 'Espercil' 'Femstrual' 'Haematrix' 'LB-1148' 'LB1148'
 'NSC-291305' 'RP-18429' 'Rikavarin' 'TRANS AMCHA' 'TRANS-AMCHA'
 'Tranexamic acid' 'Trans AMCHA' 'Transamin']_|_[('DailyMed', array(['tranexamic%20acid'], dtype=object)), ('Wikipedia', array(['Tranexamic_acid'], dtype=object)), ('drugbank', array(['DB00302'], dtype=object)), ('chEBI', array(['48669'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003418', 'EFO_0004273', 'EFO_0009579', 'EFO_1000391',
       'EFO_0009516', 'MONDO_0007254', 'EFO_0006834', 'MONDO_0004992',
       'EFO_0005669', 'EFO_0000731', 'EFO_0000546', 'EFO_0004272',
       'HP_0100806', 'MONDO_0005178', 'EFO_0001645', 'EFO_0007440',
       'EFO_1000999', 'EFO_0004214', 'MONDO_0010602', 'MP_0001914',
       'MONDO_0021148', 'EFO_0001642', 'EFO_0003843', 'MONDO_0044881',
       'EFO_0000756', 'MONDO_0008315', 'MONDO_0043510', 'EFO_0003895',
       'EFO_0004710', 'EFO_1001792', 'EFO_1000350', 'EFO_0003833',
       'MONDO_0016642', 'MP_0001845', 'HP_0002239', 'EFO_0003931',
       'EFO_0003963', 'EFO_0004198', 'EFO_0007442', 'HP_0000132',
       'HP_0031273', 'EFO_0009314', 'MONDO_0004567', 'EFO_0004616',
       'EFO_0004284', 'EFO_0010680', 'EFO_0000713', 'EFO_0000326',
       'MONDO_0019623', 'MONDO_0001187', 'HP_0003040', 'EFO_0000272',
       'EFO_1001178', 'HP_0008419', 'HP_0002105', 'EFO_0005251',
       'EFO_0003964', 'MONDO_0019180', 'MONDO_0100096', 'EFO_1001801',
       'HP_0001873'], dtype=object), 'count': 61}_|_[ENSG00000122194]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved and 58 investigational indications."
CHEMBL1090771,"NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(-c2ncon2)cc1F)S(=O)(=O)c1ccc(Cl)cc1_|_XEAOPVUAMONVLA-QGZVFWFLSA-N_|_Small molecule_|_False_|_AVAGACESTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Avagacestat' 'BMS 708163' 'BMS-708163' 'BMS-708163-01' 'BMS-70816301'
 'BMS708163']_|_[('drugbank', array(['DB11893'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL119549,O=C(Nc1ccc(-c2nnn[nH]2)cc1)c1ccc(-c2nnn[nH]2)cc1_|_VXEBMQZDPONDFB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ANDOLAST_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Andolast' 'Cr2039']_|_nan_|_nan_|_nan_|_[ENSG00000156113]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL1200845,"CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1_|_MUQNGPZZQDCDFT-JNQJZLCISA-N_|_Small molecule_|_False_|_HALCINONIDE_|_1974.0_|_4.0_|_nan_|_False_|_True_|_['Halog' 'Halog-e']_|_['Halcinonide' 'NSC-758413' 'SO 18566' 'SO-18566' 'SQ 18566' 'SQ-18566']_|_[('DailyMed', array(['halcinonide'], dtype=object)), ('PubChem', array(['144204081', '170465389', '56463097'], dtype=object)), ('Wikipedia', array(['Halcinonide'], dtype=object)), ('drugbank', array(['DB06786'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000701'], dtype=object), 'count': 1}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for skin disease."
CHEMBL1200914,"CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl_|_ZZIZZTHXZRDOFM-XFULWGLBSA-N_|_Small molecule_|_False_|_TAMSULOSIN HYDROCHLORIDE_|_1997.0_|_4.0_|_CHEMBL836_|_False_|_True_|_['Alphacard mr' 'Bazetham mr' 'Contiflo xl' 'Cositam xl' 'Diffundox'
 'Faramsil' 'Flectone xl' 'Flomax' 'Flomax mr' 'Flomax relief mr'
 'Flomaxtra xl' 'Galebon' 'Losinate mr' 'Maxtron' 'Morvesin xl' 'Omnic mr'
 'Pamsvax xl' 'Petyme' 'Pinexel pr' 'Prosurin xl' 'Stronazon' 'Tabphyn mr'
 'Tamfrex xl' 'Tamsulosin hydrochloride' 'Tamurex']_|_['Harnal' 'LY-253351' 'LY253351' 'R-(-)-YM-12617' 'Tamsulosin hcl'
 'Tamsulosin hydrochloride' 'YM-12617-1' 'YM-617' 'YM617']_|_[('DailyMed', array(['tamsulosin%20hydrochloride'], dtype=object)), ('PubChem', array(['144205999', '170464826'], dtype=object)), ('chEBI', array(['9399'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000016', 'EFO_0000284', 'EFO_0005323', 'EFO_0000537',
       'HP_0000011', 'EFO_0003830', 'EFO_0001663'], dtype=object), 'count': 7}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for benign prostatic hyperplasia and prostate carcinoma and has 5 investigational indications."
CHEMBL1201528,"nan_|_nan_|_Protein_|_False_|_VASOPRESSIN TANNATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Pitressin tannate']_|_['Vasopressin tannate']_|_nan_|_nan_|_nan_|_[ENSG00000198049,ENSG00000166148,ENSG00000126895]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1208155,"COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F_|_HEAUOKZIVMZVQL-VWLOTQADSA-N_|_Small molecule_|_False_|_ELAGOLIX_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Elagolix' 'NBI-56418']_|_[('drugbank', array(['DB11979'], dtype=object))]_|_['CHEMBL502182']_|_{'rows': array(['EFO_0000660', 'EFO_0001065', 'EFO_0001065'], dtype=object), 'count': 3}_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for endometriosis and has 2 investigational indications."
CHEMBL1756,"C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O_|_ADFOJJHRTBFFOF-RBRWEJTLSA-N_|_Small molecule_|_False_|_ESTRAMUSTINE PHOSPHATE_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Estracyt']_|_['Estramustine 17-(dihydrogen phosphate)' 'Estramustine phosphate'
 'Ls 299' 'Ls-299' 'NSC-89199']_|_[('PubChem', array(['144206584'], dtype=object)), ('drugbank', array(['DB14674'], dtype=object)), ('chEBI', array(['68643'], dtype=object))]_|_['CHEMBL1200721']_|_{'rows': array(['MONDO_0008315', 'EFO_0000673', 'MONDO_0008315', 'EFO_0000574',
       'MONDO_0002367', 'MONDO_0007254', 'EFO_0000313'], dtype=object), 'count': 7}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and is indicated for carcinoma and has 6 investigational indications."
CHEMBL2017179,"Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1_|_IHIUGIVXARLYHP-YBXDKENTSA-N_|_Small molecule_|_False_|_EVACETRAPIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Evacetrapib' 'LY-2484595' 'LY2484595']_|_[('Wikipedia', array(['Evacetrapib'], dtype=object)), ('drugbank', array(['DB11655'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'HP_0003124', 'MONDO_0021187', 'Orphanet_309005'],
      dtype=object), 'count': 4}_|_[ENSG00000087237]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2079587,"C[C@]12Cc3c[nH]nc3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O_|_LKAJKIOFIWVMDJ-IYRCEVNGSA-N_|_Small molecule_|_False_|_STANOZOLOL_|_1962.0_|_4.0_|_nan_|_False_|_True_|_['Stromba' 'Tevabolin' 'Winstrol']_|_['Androstanazol' 'Androstanazole' 'NSC-233046' 'NSC-43193' 'Stanozolol'
 'Stanozolol ciii' 'WIN 14833' 'WIN-14833' 'Winstrol' 'Winstrol Depot']_|_[('PubChem', array(['170465251'], dtype=object)), ('drugbank', array(['DB06718'], dtype=object)), ('chEBI', array(['9249'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000198'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962 and has 1 investigational indication."
CHEMBL2104745,"CC(C)CCC(=O)CC1c2ccccc2C(=O)N1c1ccc2ccc(Cl)nc2n1_|_HIUPRQPBWVEQJJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PAGOCLONE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CI-1043' 'IP 456' 'IP-456' 'Pagoclone' 'RP 62955' 'RP-62955']_|_[('drugbank', array(['DB04903'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0803321', 'HP_0025268'], dtype=object), 'count': 2}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2106798,"CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O_|_CLUKHUGGXSIGRX-UHFFFAOYSA-N_|_Small molecule_|_False_|_NERAMEXANE MESYLATE_|_nan_|_3.0_|_CHEMBL2110954_|_False_|_False_|_[]_|_['Neramexane mesilate' 'Neramexane mesylate']_|_nan_|_nan_|_{'rows': array(['HP_0000360'], dtype=object), 'count': 1}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000174343,ENSG00000129749]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108035,"nan_|_nan_|_Unknown_|_True_|_INCOBOTULINUMTOXINA_|_2010.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Incobotulinumtoxina' 'RTI-150' 'RTI150']_|_nan_|_nan_|_{'rows': array(['HP_0025267', 'EFO_0003108', 'HP_0012076', 'EFO_0003843',
       'MONDO_0005180', 'EFO_0004191', 'EFO_0003877', 'HP_0000473',
       'MONDO_0000396', 'MONDO_0003441', 'EFO_1001219', 'EFO_0000712',
       'MONDO_0011728', 'Orphanet_93955', 'HP_0001257', 'HP_0001337',
       'EFO_1000783', 'EFO_1000781', 'EFO_1000760'], dtype=object), 'count': 19}_|_[ENSG00000132639]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 18 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3707223,"CCOC(=O)C[N+]1(C)CC[C@@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1.[Br-]_|_FIAFMTCUJCWADZ-JOFREBOKSA-M_|_Small molecule_|_False_|_SOFPIRONIUM BROMIDE_|_nan_|_3.0_|_CHEMBL3707224_|_False_|_False_|_[]_|_['BBI-4000' 'Sofpironium bromide']_|_nan_|_nan_|_{'rows': array(['HP_0000975'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3989682,"CN(CP(=O)(O)O)c1cc([N+](=O)[O-])cc2[nH]c(=O)c(=O)[nH]c12_|_DDOAQMGXVXFNSH-UHFFFAOYSA-N_|_Small molecule_|_False_|_BECAMPANEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMP-397' 'AMP397' 'Becampanel']_|_nan_|_nan_|_nan_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL4297333,"CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O_|_JGGNOCUEWOGWPL-MUUNZHRXSA-N_|_Small molecule_|_False_|_VB-201_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Vb 201' 'Vb-201']_|_[('drugbank', array(['DB15259'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000729', 'MONDO_0100096'], dtype=object), 'count': 3}_|_[ENSG00000137462,ENSG00000170458]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297951,"nan_|_nan_|_Unknown_|_False_|_COAGULATION FACTOR X HUMAN_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Coagadex']_|_['Coagulation factor x' 'Coagulation factor x human'
 'Coagulation factor x, human' 'Factor x' 'Human coagulation factor x'
 'Human factor x']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/coagadex'],
      dtype=object))]_|_nan_|_{'rows': array(['MP_0001914', 'MONDO_0002247'], dtype=object), 'count': 2}_|_[ENSG00000126218]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for hemorrhage and factor x deficiency."
CHEMBL4297987,"nan_|_nan_|_Antibody drug conjugate_|_False_|_ENAPOTAMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Axl-107-mmae' 'Enapotamab vedotin' 'Humax axl adc' 'Humax-axl-adc']_|_nan_|_nan_|_nan_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000167601]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II."
CHEMBL4594265,"nan_|_nan_|_Oligonucleotide_|_False_|_GIVOSIRAN SODIUM_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Givlaari']_|_[]_|_[('DailyMed', array(['givosiran%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari'],
      dtype=object))]_|_nan_|_{'rows': array(['Orphanet_95157', 'EFO_0001421'], dtype=object), 'count': 2}_|_[ENSG00000023330]_|_Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for acute hepatic porphyria and liver disease."
CHEMBL513909,"CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1_|_XQVVPGYIWAGRNI-JOCHJYFZSA-N_|_Small molecule_|_False_|_BI-2536_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BI-2536' 'BI2536' 'Bi 2536' 'Bi-2536']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000222', 'EFO_0000616', 'EFO_0003860',
       'EFO_0003060', 'EFO_0000673', 'EFO_0000702'], dtype=object), 'count': 7}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL571546,"O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1_|_HUNGUWOZPQBXGX-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIRBANIBULIN_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Klisyri']_|_['KX-01' 'KX-2-391' 'KX-2391' 'KX2-391' 'KX2391' 'Kx2-391' 'Tirbanibulin']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri'],
      dtype=object)), ('PubChem', array(['164339429'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TIRBANIBULIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06137'], dtype=object))]_|_['CHEMBL4594279']_|_{'rows': array(['EFO_0000574', 'EFO_0000222', 'EFO_0000616', 'EFO_0004193',
       'EFO_0002496', 'EFO_0000616', 'MONDO_0008315'], dtype=object), 'count': 7}_|_[ENSG00000197122]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and is indicated for actinic keratosis and has 5 investigational indications."
CHEMBL576982,"CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1_|_CVWXJKQAOSCOAB-UHFFFAOYSA-N_|_Small molecule_|_True_|_QUIZARTINIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AC-010220' 'AC-220' 'AC010220' 'AC220' 'ASP-2689' 'Ac-220' 'Quizartinib']_|_[('PubChem', array(['137275856'], dtype=object)), ('drugbank', array(['DB12874'], dtype=object)), ('chEBI', array(['90217'], dtype=object))]_|_['CHEMBL2105709']_|_{'rows': array(['EFO_0001421', 'EFO_0000220', 'EFO_0000198', 'EFO_0000222',
       'EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 6}_|_[ENSG00000122025,ENSG00000157404,ENSG00000182578,ENSG00000165731,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for acute myeloid leukemia and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL783,"CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1_|_OELFLUMRDSZNSF-BRWVUGGUSA-N_|_Small molecule_|_False_|_NATEGLINIDE_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Nateglinide' 'Starlix' 'Starsis']_|_['A-4166' 'AY-4166' 'AY4166' 'D-nateglinide' 'DJN 608' 'DJN-608'
 'NSC-758695' 'Nateglinide' 'SDZ DJN 608' 'SDZ-DJN-608' 'Senaglinide']_|_[('DailyMed', array(['nateglinide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/starlix'],
      dtype=object)), ('PubChem', array(['144204985', '170464822', '26719880'], dtype=object)), ('drugbank', array(['DB00731'], dtype=object)), ('chEBI', array(['31897'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000400'], dtype=object), 'count': 2}_|_[ENSG00000187486,ENSG00000006071]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for type 2 diabetes mellitus and diabetes mellitus."
CHEMBL1200946,"CCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C_|_JKWKMORAXJQQSR-MOPIKTETSA-N_|_Small molecule_|_False_|_NANDROLONE DECANOATE_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Deca-durabolin' 'Nandrolone decanoate']_|_['Nandrolone decanoate' 'Nandrolone decanoate ciii']_|_[('PubChem', array(['144205191', '170464711', '29215336'], dtype=object)), ('drugbank', array(['DB08804'], dtype=object)), ('chEBI', array(['7467'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003964', 'EFO_0008572', 'EFO_0007312'], dtype=object), 'count': 3}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1983 and has 3 investigational indications."
CHEMBL169896,"Cc1nc2ccc3ccc(CNc4ccc5c(c4)CN([C@@H](CCC(=O)O)C(=O)O)C5=O)cc3c2c(=O)[nH]1_|_BRVFNEZMTRVUGW-QFIPXVFZSA-N_|_Small molecule_|_False_|_OSI-7904_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gw-1843' 'OSI-7904L' 'Osi 7904' 'Osi 7904l' 'Osi-7904' 'Osi-7904l'
 'TCMDC-131928']_|_nan_|_nan_|_{'rows': array(['EFO_0006859', 'EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 3}_|_[ENSG00000176890]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1742987,"nan_|_nan_|_Antibody_|_False_|_ATINUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ATI-355' 'Atinumab']_|_nan_|_nan_|_{'rows': array(['EFO_1001919'], dtype=object), 'count': 1}_|_[ENSG00000115310]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL1743010,"nan_|_nan_|_Antibody_|_False_|_ELOTUZUMAB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Empliciti']_|_['BMS-901608' 'Elotuzumab' 'Empliciti' 'HULUC63' 'PDL-063' 'PDL063']_|_[('DailyMed', array(['elotuzumab'], dtype=object)), ('DrugCentral', array(['5072'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/empliciti'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0044881', 'EFO_0000616', 'EFO_0003073', 'MONDO_0017287',
       'EFO_0006475', 'MONDO_0019438', 'EFO_0001378'], dtype=object), 'count': 7}_|_[ENSG00000026751]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neoplasm and multiple myeloma and has 5 investigational indications."
CHEMBL18901,"Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(=O)O)cc2)c1_|_BNFRJXLZYUTIII-UHFFFAOYSA-N_|_Small molecule_|_False_|_EFAPROXIRAL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Efaproxiral' 'RSR-13' 'RSR13']_|_[('Wikipedia', array(['Efaproxiral'], dtype=object)), ('drugbank', array(['DB08486'], dtype=object))]_|_['CHEMBL2107744']_|_{'rows': array(['MONDO_0008903', 'EFO_0000616', 'EFO_1000158', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000206172,ENSG00000188536,ENSG00000244734]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL192,"CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12_|_BNRNXUUZRGQAQC-UHFFFAOYSA-N_|_Small molecule_|_False_|_SILDENAFIL_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Nipatra' 'Revatio' 'Viagra' 'Vizarsin']_|_['Aphrodil' 'HIP-0908' 'HIP0908' 'Patrex' 'Sildenafil'
 'Sildenafil actavis' 'Sildenafil ratiopharm' 'Sildenafil teva' 'UK-92480']_|_[('PubChem', array(['26748898', '50085897'], dtype=object)), ('drugbank', array(['DB00203'], dtype=object)), ('chEBI', array(['9139'], dtype=object))]_|_['CHEMBL1737' 'CHEMBL5276310']_|_{'rows': array(['HP_0000802', 'EFO_0000198', 'EFO_0002950', 'EFO_0004225',
       'EFO_1001893', 'MONDO_0004933', 'MONDO_0043510', 'EFO_0001422',
       'EFO_0009441', 'Orphanet_848', 'EFO_1001017', 'EFO_0004265',
       'EFO_1001145', 'HP_0001919', 'MONDO_0043510', 'EFO_0009085',
       'EFO_0803321', 'MONDO_0100096', 'EFO_0003144', 'EFO_0003917',
       'EFO_0008560', 'MONDO_0019091', 'EFO_0000545', 'HP_0200023',
       'EFO_1001134', 'EFO_0000537', 'MONDO_0100096', 'EFO_0000712',
       'HP_0001655', 'EFO_0001361', 'EFO_0004714', 'EFO_0000495',
       'EFO_0000284', 'HP_0200042', 'EFO_0000701', 'EFO_0003777',
       'EFO_1001134', 'MONDO_0005475', 'MONDO_0006058', 'EFO_0009429',
       'MONDO_0010679', 'EFO_0000341', 'EFO_1000824', 'EFO_0004234',
       'MONDO_0008315', 'EFO_0000668', 'EFO_1001103', 'MONDO_0005041',
       'EFO_0000400', 'EFO_1001145', 'MONDO_0005180', 'MONDO_0005149',
       'EFO_0003144', 'EFO_1001827', 'EFO_0003833', 'EFO_0000404',
       'EFO_0003060', 'HP_0001298', 'EFO_0000668', 'EFO_0000545',
       'EFO_0000519', 'EFO_0000717', 'EFO_0000373', 'MONDO_0005149',
       'EFO_0000768', 'EFO_0000464', 'EFO_1001986', 'EFO_0003047',
       'HP_0002140', 'EFO_1000824', 'HP_0100607', 'EFO_0001365',
       'EFO_0000537', 'MONDO_0011382', 'EFO_0011023', 'EFO_0008493',
       'HP_0000020', 'EFO_0009200', 'EFO_0000616', 'EFO_0004234',
       'EFO_0000495', 'MONDO_0010311', 'EFO_1001993', 'MONDO_0009061',
       'EFO_0003818', 'MONDO_0002013', 'EFO_0001361', 'EFO_1001103',
       'EFO_0001645', 'EFO_0003827'], dtype=object), 'count': 90}_|_[ENSG00000138735]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 5 approved and 79 investigational indications."
CHEMBL2095222,"nan_|_nan_|_Protein_|_False_|_OCRIPLASMIN_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Jetrea']_|_['Jetrea' 'MICROPLASMIN' 'Microplasmin (synthetic human)' 'Ocriplasmin'
 'Plasmin, micro- (synthetic human)' 'Recombinant human microplasmin']_|_[('DrugCentral', array(['5004'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000479', 'EFO_0009606', 'EFO_1001028', 'EFO_0003966',
       'EFO_0003907', 'EFO_0000712', 'EFO_1001231', 'EFO_1001157'],
      dtype=object), 'count': 8}_|_[ENSG00000164692,ENSG00000108821,ENSG00000139219,ENSG00000168542,ENSG00000187498,ENSG00000130635,ENSG00000142156,ENSG00000060718,ENSG00000204291,ENSG00000182871,ENSG00000171502,ENSG00000196739,ENSG00000215018,ENSG00000134871,ENSG00000204262,ENSG00000142173,ENSG00000204248,ENSG00000169031,ENSG00000080573,ENSG00000163359,ENSG00000081052,ENSG00000188153,ENSG00000172752,ENSG00000197565,ENSG00000206384,ENSG00000101680,ENSG00000196569,ENSG00000053747,ENSG00000112769,ENSG00000130702,ENSG00000091136,ENSG00000172037,ENSG00000196878,ENSG00000091128,ENSG00000135862,ENSG00000058085,ENSG00000050555,ENSG00000115414]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for abnormal retinal morphology and eye disease and has 6 investigational indications."
CHEMBL2107884,"nan_|_nan_|_Antibody_|_True_|_RESLIZUMAB_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Cinqaero' 'Cinqair' 'Cinquil']_|_['CEP-38072' 'DCP 835' 'DCP-835' 'Reslizumab' 'SCH 55700' 'SCH-55700'
 'SCH55700']_|_[('DailyMed', array(['reslizumab'], dtype=object)), ('DrugCentral', array(['5093'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cinqaero'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000729', 'MONDO_0004979', 'EFO_0007486', 'EFO_1001467',
       'EFO_0009661', 'EFO_0004232', 'MONDO_0004938', 'HP_0006536'],
      dtype=object), 'count': 8}_|_[ENSG00000113525]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for asthma and airway obstruction and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108499,"nan_|_nan_|_Enzyme_|_False_|_LANOTEPLASE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['7-l-glutamine-245-l-methionine' 'BMS-200980' 'Lanoteplase' 'SUN 9216'
 'SUN-9216']_|_nan_|_nan_|_nan_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of II."
CHEMBL2109229,"nan_|_nan_|_Oligonucleotide_|_False_|_OBLIMERSEN SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Augmerosen' 'D-G3139' 'G-3139' 'G3139' 'Oblimersen' 'Oblimersen sodium']_|_nan_|_nan_|_{'rows': array(['EFO_0000403', 'MONDO_0008170', 'EFO_0000095', 'EFO_1001471',
       'MONDO_0008903', 'EFO_0003086', 'EFO_0000756', 'EFO_0000681',
       'MONDO_0002691', 'EFO_0001378', 'MONDO_0002367', 'EFO_0006861',
       'EFO_0000339', 'EFO_1001951', 'EFO_1001469', 'EFO_0000574',
       'EFO_0009441', 'MONDO_0008315', 'MONDO_0011719', 'MONDO_0018906',
       'EFO_0000389', 'MONDO_0007576', 'MONDO_0007254', 'EFO_0000702',
       'EFO_0006859', 'MONDO_0001187', 'EFO_0000616', 'EFO_0000565'],
      dtype=object), 'count': 28}_|_[ENSG00000171791]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 28 investigational indications."
CHEMBL2109357,"nan_|_nan_|_Antibody_|_False_|_VELIGROTUG_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AVE-1642' 'AVE1642' 'Ave 1642' 'Ave-1642' 'Veligrotug']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-128'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003869', 'MONDO_0018531', 'EFO_0001378'], dtype=object), 'count': 3}_|_[ENSG00000140443]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2364652,"nan_|_nan_|_Antibody_|_False_|_VANTICTUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['OMP-18R5' 'Vantictumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0007254', 'EFO_0002618'], dtype=object), 'count': 3}_|_[ENSG00000163251,ENSG00000180340,ENSG00000155760,ENSG00000177283,ENSG00000157240]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545020,"nan_|_nan_|_Small molecule_|_False_|_MBX-2044_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mbx-2044']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545210,"CCN(CC)Cc1ccc(OCC[C@H]2CCC3C4C(CC[C@@]32C)c2ccc(O)cc2C[C@H]4C)c(OC)c1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_VOHOCSJONOJOSD-RQIKCBEZSA-N_|_Small molecule_|_False_|_SR16234_|_nan_|_2.0_|_CHEMBL3545211_|_False_|_False_|_[]_|_['HLX-801' 'SR-16234' 'Sr16234' 'TAS-108' 'TS-108']_|_nan_|_nan_|_{'rows': array(['MONDO_0007254'], dtype=object), 'count': 1}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL363392,"CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O_|_STPKWKPURVSAJF-LJEWAXOPSA-N_|_Small molecule_|_False_|_MARALIXIBAT_|_2021.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['LUM-001 CATION' 'LUM001 CATION' 'Lopixibat' 'Maralixibat'
 'Maralixibat cation']_|_nan_|_['CHEMBL17879']_|_{'rows': array(['EFO_0001421', 'MONDO_0007318', 'EFO_0004268', 'HP_0000989',
       'EFO_1001486', 'MONDO_0007318', 'MONDO_0008867'], dtype=object), 'count': 7}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alagille syndrome and pruritus and has 5 investigational indications."
CHEMBL3918017,"CC[C@@H](C(N)=O)N1C[C@H](C=C(F)F)CC1=O_|_ANWPENAPCIFDSZ-RQJHMYQMSA-N_|_Small molecule_|_False_|_SELETRACETAM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Seletracetam' 'UCB 44212' 'UCB-44212']_|_[('drugbank', array(['DB05885'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474', 'EFO_0004263'], dtype=object), 'count': 2}_|_[ENSG00000159164]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3989512,"CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C_|_DZMVCVHATYROOS-ZBFGKEHZSA-N_|_Small molecule_|_False_|_SOBLIDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Auristatin pe' 'Soblidotin' 'TZT-1027']_|_[('drugbank', array(['DB12677'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000691', 'MONDO_0008903'], dtype=object), 'count': 3}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4072756,"COc1cccc([C@@H](Oc2ccc3c(cnn3-c3ccc(F)cc3)c2)[C@H](C)NC(=O)C(F)(F)F)c1_|_FCNQMDSJHADDFT-WNSKOXEYSA-N_|_Small molecule_|_False_|_AZD-5423_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD5423' 'Azd 5423' 'Azd-5423' 'Azd5423']_|_[('drugbank', array(['DB12280'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'EFO_0000341'], dtype=object), 'count': 2}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297630,"CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)O)C(C)C)C(=O)O_|_YEKUUBPJRPXMBM-PTCFZACGSA-N_|_Protein_|_False_|_COTADUTIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cotadutide' 'MEDI-0382' 'MEDI0382' 'Medi 0382' 'Medi0382']_|_[('drugbank', array(['DB15194'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000083', 'EFO_0001421', 'EFO_0003095', 'EFO_0000400',
       'MONDO_0005148', 'EFO_0001073'], dtype=object), 'count': 6}_|_[ENSG00000215644,ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL5314400,"FC(F)(F)c1cccnc1-c1ccc(-c2nc3ccc(Br)cc3[nH]2)nc1_|_WGAVAOCYBMNWID-UHFFFAOYSA-N_|_Small molecule_|_False_|_DWP05195_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['DWP-05195' 'Dwp05195']_|_nan_|_nan_|_{'rows': array(['MONDO_0041052'], dtype=object), 'count': 1}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL564829,"CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2_|_RXZMYLDMFYNEIM-UHFFFAOYSA-N_|_Small molecule_|_False_|_MILCICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Milciclib' 'PHA 848125' 'PHA-848125' 'Pha-848125']_|_nan_|_['CHEMBL4297668' 'CHEMBL561564']_|_{'rows': array(['EFO_1000576', 'EFO_1000581', 'EFO_0000616', 'EFO_0000182'],
      dtype=object), 'count': 4}_|_[ENSG00000135446,ENSG00000198400,ENSG00000123374,ENSG00000170312]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1200601,"CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1.Cl_|_AWEZYKMQFAUBTD-UHFFFAOYSA-N_|_Small molecule_|_False_|_NARATRIPTAN HYDROCHLORIDE_|_1998.0_|_4.0_|_CHEMBL1278_|_False_|_True_|_['Amerge' 'Naramig' 'Naratriptan']_|_['GR 85548A' 'GR-85548A' 'Naratriptan hcl' 'Naratriptan hydrochloride']_|_[('DailyMed', array(['naratriptan%20hydrochloride'], dtype=object)), ('PubChem', array(['144207166', '170465423'], dtype=object)), ('chEBI', array(['7479'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277', 'HP_0002315'], dtype=object), 'count': 2}_|_[ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for migraine disorder and has 1 investigational indication."
CHEMBL1200893,CC(Cc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(O)c1.Cl_|_LOVXREQUMZKFCM-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROTOKYLOL HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1201273_|_False_|_True_|_['Ventaire']_|_['NSC-113490' 'Protokylol HCl' 'Protokylol hcl' 'Protokylol hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1201543,nan_|_nan_|_Protein_|_False_|_INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN_|_1983.0_|_4.0_|_nan_|_False_|_True_|_['Novolin l']_|_['Insulin zinc susp semisynthetic purified human']_|_nan_|_nan_|_nan_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 1983.
CHEMBL1201627,"nan_|_nan_|_Protein_|_False_|_INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN_|_1985.0_|_4.0_|_nan_|_False_|_True_|_['Insulatard nph human' 'Novolin n']_|_['Insulin susp isophane semisynthetic purified human']_|_nan_|_nan_|_{'rows': array(['EFO_0003914', 'MONDO_0005148', 'HP_0003074', 'EFO_0000537',
       'EFO_0001645', 'HP_0003124'], dtype=object), 'count': 6}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 6 investigational indications."
CHEMBL1615374,"Cl.N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1_|_RPZBRGFNBNQSOP-UHFFFAOYSA-N_|_Small molecule_|_True_|_VILAZODONE HYDROCHLORIDE_|_2011.0_|_4.0_|_CHEMBL439849_|_False_|_True_|_['Viibryd']_|_['EMD 68 843' 'EMD-68843' 'SB-659746-A' 'SB659746-A' 'Vilazodone hcl'
 'Vilazodone hydrochloride']_|_[('DailyMed', array(['vilazodone%20hydrochloride'], dtype=object)), ('chEBI', array(['70705'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2011 and is indicated for major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL1783282,"CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N_|_KYDURMHFWXCKMW-UHFFFAOYSA-N_|_Small molecule_|_False_|_AZD7325_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd7325']_|_[('drugbank', array(['DB13994'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010383', 'EFO_0005230', 'EFO_0003756'], dtype=object), 'count': 3}_|_[ENSG00000011677,ENSG00000151834]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL1963502,C[C@@H](Nc1ncnc2[nH]c(-c3ccc(O)cc3)cc12)c1ccccc1_|_XRYJULCDUUATMC-CYBMUJFWSA-N_|_Small molecule_|_False_|_PKI-166_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['CGP-75166' 'NVP-PKI166' 'PKI-166' 'Pki 166' 'Pki-166']_|_nan_|_['CHEMBL1914653']_|_nan_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2107723,"COc1cc(O)c(C(=O)Nc2nc(C(=O)NCCN(C(C)C)C(C)C)cs2)cc1OC_|_TWHZNAUBXFZMCA-UHFFFAOYSA-N_|_Small molecule_|_False_|_ACOTIAMIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Acotiamide']_|_[('drugbank', array(['DB12482'], dtype=object)), ('chEBI', array(['34523'], dtype=object))]_|_['CHEMBL2107308']_|_{'rows': array(['EFO_0008533', 'EFO_0010282'], dtype=object), 'count': 2}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109370,nan_|_nan_|_Antibody_|_False_|_T84.66_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['T84.66']_|_nan_|_nan_|_nan_|_[ENSG00000105388]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109456,"nan_|_nan_|_Antibody_|_False_|_QUILIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ANTI-M1' 'Anti-M1 prime' ""Anti-M1'"" 'MEMP-1972A' 'MEMP1972A' 'MEP-1972A'
 'MEP1972A' 'Quilizumab' 'RG-7449']_|_nan_|_nan_|_{'rows': array(['EFO_0005854', 'EFO_0005531', 'MONDO_0004979'], dtype=object), 'count': 3}_|_[ENSG00000211891]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2364651,"nan_|_nan_|_Antibody_|_False_|_TOVETUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MEDI-575' 'Tovetumab']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992', 'EFO_0000519'], dtype=object), 'count': 3}_|_[ENSG00000134853]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL279785,"CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C_|_OCSMOTCMPXTDND-OUAUKWLOSA-N_|_Small molecule_|_False_|_MARIMASTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BB 2516' 'BB-2516' 'GI 5712' 'GI-5712' 'KB-R 8898' 'Marimastat'
 'NSC-719333' 'TA 2516' 'TA-2516']_|_[('PubChem', array(['136949642'], dtype=object)), ('Wikipedia', array(['Marimastat'], dtype=object)), ('drugbank', array(['DB00786'], dtype=object)), ('chEBI', array(['50662'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'MONDO_0008903'], dtype=object), 'count': 2}_|_[ENSG00000100985,ENSG00000149968,ENSG00000196611,ENSG00000087245,ENSG00000137673,ENSG00000262406]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3989780,"O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O=S(=O)(OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O)O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O_|_WXOMTJVVIMOXJL-BOBFKVMVSA-A_|_Unknown_|_False_|_SUCRALFATE_|_1981.0_|_4.0_|_CHEMBL2367706_|_False_|_True_|_['Antepsin' 'Carafate' 'Sucralfate' 'Ulcerlmin']_|_['Aluminum sucrose octasulfate' 'Citogel' 'Hexagastron' 'Succosa'
 'Sucralfate' 'Sucralfate hydrate' 'Sucralfin' 'Sucrate' 'Sugast'
 'Sulcrate' 'Ulcar' 'Ulcermin' 'Ulcogant' 'Ulsanic' 'Urbal' 'Venter']_|_nan_|_nan_|_{'rows': array(['EFO_0004607', 'EFO_0003948', 'HP_0004398'], dtype=object), 'count': 3}_|_[ENSG00000256713]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved indications."
CHEMBL3989861,"CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)/C=C/C(=O)O_|_YETWCSLOYUZBLK-JITBQSAISA-N_|_Small molecule_|_True_|_DESVENLAFAXINE FUMARATE_|_2013.0_|_4.0_|_CHEMBL1118_|_False_|_True_|_[]_|_['Desvenlafaxine fumarate anhydrous' 'O-desmethylvenlafaxine fumarate']_|_nan_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2013 and is indicated for major depressive disorder. This drug has a black box warning from the FDA."
CHEMBL4297328,"O=C(CN1CCOCC1)Nc1ccc(OC2CCN(C3CCC3)CC2)cc1_|_LNXDUSQEXVQFGP-UHFFFAOYSA-N_|_Small molecule_|_False_|_SUVN-G3031_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SUVN-G3031 FREE BASE' 'Samelisant' 'Suvn-g3031']_|_[('drugbank', array(['DB14835'], dtype=object))]_|_['CHEMBL4593911']_|_{'rows': array(['HP_0100543', 'MONDO_0021107'], dtype=object), 'count': 2}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594406,"nan_|_nan_|_Small molecule_|_False_|_LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN_|_2022.0_|_4.0_|_CHEMBL4594730_|_False_|_True_|_['Pluvicto']_|_['177LU-LABELED PSMA-617' '177Lu-PSMA-617' '177lu-psma-617'
 'Lutetium (177lu) vipivotide tetraxetan'
 'Lutetium lu 177 vipivotide tetraxetan' 'Pluvicto' 'Psma-617 lu-177'
 'Vipivotide tetraxetan lu-177' 'Vipivotide tetraxetan lutetium lu-177']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUTETIUM%20LU%20177%20VIPIVOTIDE%20TETRAXETAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0008315', 'MONDO_0021259', 'EFO_0000616',
       'EFO_0001663', 'EFO_0003863', 'EFO_0000673'], dtype=object), 'count': 7}_|_[ENSG00000086205]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for prostate cancer and prostate neoplasm and has 5 investigational indications."
CHEMBL5315076,"nan_|_nan_|_Protein_|_False_|_ALBUTREPENONACOG ALFA_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Idelvion']_|_['CSL-654' 'Csl654']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010604'], dtype=object), 'count': 1}_|_[ENSG00000101981]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for hemophilia b."
CHEMBL571,"CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1_|_DKYWVDODHFEZIM-UHFFFAOYSA-N_|_Small molecule_|_True_|_KETOPROFEN_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Actron' 'Alrheumat' 'Axorid' 'Fenoket 200' 'Jomethid xl' 'Ketocid 200'
 'Ketonal' 'Ketoprofen' 'Ketotard 200 xl' 'Ketovail' 'Ketozip 200 xl'
 'Larafen' 'Larafen cr' 'Nexcede' 'Orudis' 'Orudis 100' 'Orudis kt'
 'Oruvail' 'Oruvail 100' 'Oruvail 150' 'Oruvail 200' 'Oruvail im'
 'Powergel' 'Tiloket' 'Tiloket cr' 'Valket 200 retard']_|_['(rs)-ketoprofen' '19583RP' 'Actron ketoprofen' 'Aneol' 'Capisten'
 'Hydratropic acid, m-benzoyl-' 'IDEA-033' 'Iso-k' 'Ketoprofen' 'Ketorin'
 'NSC-758144' 'R.P. 19,583' 'R.P. 19583' 'RP-19583' 'RU-4733' 'Sector']_|_[('DailyMed', array(['ketoprofen'], dtype=object)), ('PubChem', array(['11532908', '144204145', '144208045', '170465449', '26747548',
       '50086520', '50106498', '85231099', '857801', '90341309'],
      dtype=object)), ('Wikipedia', array(['Ketoprofen'], dtype=object)), ('drugbank', array(['DB01009'], dtype=object)), ('chEBI', array(['6128'], dtype=object))]_|_['CHEMBL4650345' 'CHEMBL341922']_|_{'rows': array(['EFO_0000685', 'EFO_0000649', 'MONDO_0005178', 'HP_0003326',
       'EFO_0000546', 'EFO_0002970', 'EFO_1001412', 'HP_0003419',
       'MONDO_0005277', 'EFO_0000512', 'HP_0100607', 'MONDO_0002471',
       'HP_0002829', 'EFO_0005755', 'EFO_0003843', 'EFO_0009582',
       'EFO_0004888', 'MONDO_0004857', 'EFO_0004616', 'MP_0001845',
       'EFO_0004253'], dtype=object), 'count': 21}_|_[ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 7 approved and 14 investigational indications. This drug has a black box warning from the FDA."
CHEMBL601719,"C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl_|_KTEIFNKAUNYNJU-GFCCVEGCSA-N_|_Small molecule_|_False_|_CRIZOTINIB_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Xalkori']_|_['Crizotinib' 'NSC-756645' 'PF-02341066' 'PF-2341066' 'Pf-2341066']_|_[('DailyMed', array(['crizotinib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori'],
      dtype=object)), ('Wikipedia', array(['Crizotinib'], dtype=object)), ('drugbank', array(['DB08865'], dtype=object)), ('chEBI', array(['64310'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_1000026', 'EFO_0000707', 'MONDO_0008903',
       'MONDO_0011962', 'EFO_0000571', 'EFO_0000228', 'EFO_0000222',
       'MONDO_0007254', 'EFO_0001378', 'MONDO_0001056', 'EFO_0003060',
       'MONDO_0015798', 'MONDO_0004992', 'EFO_0000519', 'EFO_0003086',
       'MONDO_0007039', 'EFO_0003032', 'MONDO_0008315', 'EFO_0000616',
       'EFO_0000640', 'EFO_0000403'], dtype=object), 'count': 22}_|_[ENSG00000171094,ENSG00000181163,ENSG00000143924,ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 4 approved and 18 investigational indications."
CHEMBL870,"NCCCC(O)(P(=O)(O)O)P(=O)(O)O_|_OGSPWJRAVKPPFI-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALENDRONIC ACID_|_1995.0_|_4.0_|_nan_|_False_|_True_|_['Binosto' 'Fosamax']_|_['Alendronate' 'Alendronic Acid' 'Alendronic acid' 'Fosamax']_|_[('Wikipedia', array(['Alendronic_acid'], dtype=object)), ('drugbank', array(['DB00630'], dtype=object)), ('chEBI', array(['2567'], dtype=object))]_|_['CHEMBL675' 'CHEMBL2367465']_|_{'rows': array(['MONDO_0005178', 'EFO_0004260', 'EFO_0003882', 'EFO_0000649',
       'EFO_0004261', 'HP_0000938', 'EFO_0003762', 'EFO_0003854',
       'EFO_0000589', 'EFO_0000764', 'EFO_0004261', 'MONDO_0006715',
       'MONDO_0004979', 'EFO_0003854', 'EFO_0000266', 'MONDO_0007254',
       'EFO_0004197', 'EFO_0003882', 'EFO_0000673', 'EFO_0003869',
       'MONDO_0008170', 'MONDO_0008274'], dtype=object), 'count': 22}_|_[ENSG00000160752]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 5 approved and 17 investigational indications."
CHEMBL108,"NC(=O)N1c2ccccc2C=Cc2ccccc21_|_FFGPTBGBLSHEPO-UHFFFAOYSA-N_|_Small molecule_|_True_|_CARBAMAZEPINE_|_1968.0_|_4.0_|_nan_|_False_|_True_|_['Arbil mr' 'Carbagen sr' 'Carbamazepine' 'Carbatrol' 'Carnexiv' 'Epimaz'
 'Epimaz ret' 'Epitol' 'Equetro' 'Sirtal ret' 'Tegretol' 'Tegretol Xr'
 'Tegretol chewtab' 'Tegretol prolonged release' 'Tegretol-xr' 'Teril'
 'Teril ret' 'Timonil 200 ret' 'Timonil 400 ret']_|_['Biston' 'Carbamazepine' 'Carbamazepine anhydrous'
 'Carbamazepine extended release' 'Carbamazepinum' 'Finlepsin' 'G-32883'
 'GEIGY 32883' 'Karbamazepin' 'Karbelex' 'NSC-169864' 'Neurotol'
 'Neurotop' 'Sirtal' 'Stazepine' 'Tegretal' 'Telesmin' 'Timonil']_|_[('DailyMed', array(['carbamazepine'], dtype=object)), ('PubChem', array(['11110939', '11110940', '124879629', '144203655', '144209471',
       '144210515', '170464712', '17389547', '26751576', '50104203',
       '56314829', '56422193', '855967', '90341617'], dtype=object)), ('TG-GATEs', array(['18'], dtype=object)), ('Wikipedia', array(['Carbamazepine'], dtype=object)), ('drugbank', array(['DB00564'], dtype=object)), ('chEBI', array(['3387'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'EFO_0005230', 'MONDO_0002050', 'MONDO_0015643',
       'MONDO_0005090', 'EFO_0009963', 'EFO_0006911', 'MONDO_0100096',
       'HP_0000726', 'HP_0001250', 'EFO_0004263', 'MONDO_0005180',
       'EFO_0002610', 'EFO_1001219', 'MONDO_0004985', 'EFO_0000474',
       'EFO_0004197'], dtype=object), 'count': 17}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 6 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201354,"CC[N+](CC)(CC)CCC(O)(c1ccccc1)C1CCCCC1_|_NPRHVSBSZMAEIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIDIHEXETHYL_|_1954.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Tridihexethyl' 'Tridihexethyl cation' 'Tridihexethyl ion']_|_[('Wikipedia', array(['Tridihexethyl'], dtype=object)), ('drugbank', array(['DB00505'], dtype=object)), ('chEBI', array(['9701'], dtype=object))]_|_['CHEMBL2107686' 'CHEMBL1200771']_|_{'rows': array(['EFO_0010282'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1954 and is indicated for gastrointestinal disease."
CHEMBL1201604,"nan_|_nan_|_Antibody_|_True_|_TOSITUMOMAB_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Bexxar']_|_['Tositumomab']_|_[('Wikipedia', array(['Tositumomab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0005952', 'MONDO_0018906', 'EFO_0000096',
       'EFO_1001469', 'EFO_0000095'], dtype=object), 'count': 6}_|_[ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201753,"O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1_|_VGYFMXBACGZSIL-MCBHFWOFSA-N_|_Small molecule_|_False_|_PITAVASTATIN_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Itavastatin' 'NSC-760423' 'Pitavastatin']_|_[('Wikipedia', array(['Pitavastatin'], dtype=object)), ('drugbank', array(['DB08860'], dtype=object)), ('chEBI', array(['32020'], dtype=object))]_|_['CHEMBL3989923' 'CHEMBL1237061' 'CHEMBL3989920']_|_{'rows': array(['MONDO_0005148', 'MONDO_0005147', 'Orphanet_309005',
       'MONDO_0021187', 'EFO_0001645', 'EFO_0007328', 'HP_0003119',
       'MONDO_0021187', 'HP_0000083', 'MONDO_0007254', 'HP_0003119',
       'EFO_0000195', 'Orphanet_309005', 'HP_0003119', 'HP_0003124',
       'EFO_0004911', 'MONDO_0021187', 'HP_0003124', 'MONDO_0021187',
       'EFO_0000319', 'HP_0003124'], dtype=object), 'count': 21}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 5 approved and 10 investigational indications."
CHEMBL1551724,"NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N_|_RTRQQBHATOEIAF-UUOKFMHZSA-N_|_Small molecule_|_False_|_ACADESINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Acadesine' 'GP-1-110' 'NSC-105823']_|_[('PubChem', array(['124893186', '144205104', '170465608', '29217492'], dtype=object)), ('drugbank', array(['DB04944'], dtype=object)), ('chEBI', array(['28498'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000319', 'EFO_0000095'], dtype=object), 'count': 2}_|_[ENSG00000162409,ENSG00000131791,ENSG00000181929,ENSG00000106617,ENSG00000111725,ENSG00000132356,ENSG00000115592]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2001019,"OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1_|_PDMUGYOXRHVNMO-UHFFFAOYSA-N_|_Small molecule_|_False_|_PF-04217903_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MET TYROSINE KINASE INHIBITOR PF-04217903' 'PF-04217903' 'PF-4217903'
 'Pf-04217903']_|_[('PubChem', array(['103905666', '137276005'], dtype=object)), ('drugbank', array(['DB12848'], dtype=object))]_|_['CHEMBL2170804']_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2108882,"nan_|_nan_|_Antibody_|_False_|_SIBROTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Sibrotuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000078098]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2109323,"nan_|_nan_|_Antibody_|_False_|_IMC-CS4_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['IMC-CS4' 'Imc-cs4']_|_nan_|_nan_|_{'rows': array(['EFO_0002618', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000182578]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL2219421,"O=C(O)c1ccc(/C=C/S(=O)(=O)Cc2ccc(Cl)cc2)cc1_|_KBEKQQJUNVQLDZ-MDZDMXLPSA-N_|_Small molecule_|_False_|_RECILISIB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Ex-rad']_|_['ON 01210' 'ON 01210.Na' 'ON01210' 'On-01210' 'Recilisib']_|_nan_|_['CHEMBL2219410']_|_nan_|_[ENSG00000145675,ENSG00000051382,ENSG00000105851,ENSG00000121879,ENSG00000105647,ENSG00000171608,ENSG00000141506,ENSG00000117461]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL225411,"O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F_|_TWQYWUXBZHPIIV-UHFFFAOYSA-N_|_Small molecule_|_False_|_GW842166X_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW 842166' 'GW 842166X' 'GW-842166' 'GW842166' 'GW842166X' 'Gw-842,166x'
 'Gw842166x']_|_[('PubChem', array(['174007169'], dtype=object)), ('Wikipedia', array(['GW-842,166X'], dtype=object)), ('drugbank', array(['DB11903'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004616', 'MONDO_0005178', 'EFO_0003843'], dtype=object), 'count': 3}_|_[ENSG00000188822]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2368925,"O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12_|_UKTAZPQNNNJVKR-KJGYPYNMSA-N_|_Small molecule_|_False_|_DOLASETRON_|_1997.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dolasetron']_|_[('drugbank', array(['DB00757'], dtype=object))]_|_['CHEMBL2373322' 'CHEMBL2368924']_|_{'rows': array(['HP_0002018', 'MONDO_0004992', 'EFO_0004888', 'EFO_0005687',
       'EFO_0006911', 'HP_0002017'], dtype=object), 'count': 6}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 1 investigational indication."
CHEMBL281872,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1_|_YBTGTVGEKMZEQX-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZD-4190_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ZD-4190']_|_nan_|_['CHEMBL3544937']_|_nan_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545134,"nan_|_nan_|_Small molecule_|_False_|_LY-2780301_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ly-2780301']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0009708'], dtype=object), 'count': 2}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208,ENSG00000175634,ENSG00000108443]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL3545289,C[C@@H](NC(=O)Cc1c(Cl)ccc(NCC(F)(F)c2cccc[n+]2O)[n+]1O)c1cccc(Cl)c1_|_GNYWBETUYIZBHL-CQSZACIVSA-P_|_Small molecule_|_False_|_AZD2207_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd2207']_|_nan_|_nan_|_nan_|_[ENSG00000118432]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3659497,"CC(C)Oc1cc(-n2cnc3ccc(N[C@@H](C)c4ncc(F)cn4)nc32)n[nH]1_|_AYOOGWWGECJQPI-NSHDSACASA-N_|_Small molecule_|_False_|_AZD-7451_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Azd-7451' 'Utatrectinib']_|_nan_|_nan_|_{'rows': array(['EFO_0000519'], dtype=object), 'count': 1}_|_[ENSG00000140538,ENSG00000148053,ENSG00000198400]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3678958,"CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21_|_WSOHOUHPUOAXIN-UHFFFAOYSA-N_|_Small molecule_|_False_|_RUSERONTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ruserontinib' 'SKLB-1028' 'Sklb 1028' 'Sklb1028']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000122025,ENSG00000146648,ENSG00000097007]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL370805,"COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C_|_ZPUCINDJVBIVPJ-LJISPDSOSA-N_|_Small molecule_|_True_|_COCAINE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(r)-(-)-cocaine' 'Benzoylmethylecgonine' 'Cocaine' 'Cocainum'
 'IDS-NC-004' 'Neurocaine' 'RX-0041' 'RX0041']_|_[('drugbank', array(['DB00907'], dtype=object)), ('chEBI', array(['27958'], dtype=object))]_|_['CHEMBL529437']_|_{'rows': array(['EFO_0005800', 'EFO_0005611', 'MONDO_0005271', 'EFO_0002610',
       'EFO_0002610'], dtype=object), 'count': 5}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3833330,"nan_|_nan_|_Antibody_|_False_|_CINPANEMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB-054' 'BIIB054' 'Cinpanemab' 'Ni-202']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000145335]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3989820,"Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1.O=C(O)C(O)C(O)C(=O)O_|_VXRDAMSNTXUHFX-UHFFFAOYSA-N_|_Small molecule_|_True_|_ZOLPIDEM TARTRATE_|_1992.0_|_4.0_|_CHEMBL911_|_False_|_True_|_['Ambien' 'Ambien cr' 'Edluar' 'Intermezzo' 'Stilnoct' 'Tovalt odt'
 'Zolpidem tartrate' 'Zolpimist']_|_['Ivadal' 'Myslee' 'Niotal' 'SL 80.0750-23N' 'SL-80.0750' 'SL-80.0750-23N'
 'Stilnox' 'Tovalt' 'Zolpidem hemitartrate' 'Zolpidem tartrate'
 'Zolpidem tartrate civ']_|_[('DailyMed', array(['zolpidem%20tartrate'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_0001073', 'EFO_0008568'], dtype=object), 'count': 3}_|_[ENSG00000022355,ENSG00000113327,ENSG00000163288]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL4297626,"Cn1nc(C(=O)N(Cc2ccccc2)Cc2ccc(C(=O)O)cc2)c2c1-c1cc(Cl)ccc1OC2_|_JYTIXGYXBIBOMN-UHFFFAOYSA-N_|_Small molecule_|_False_|_NIDUFEXOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LMB763' 'Lmb763' 'Nidufexor']_|_nan_|_nan_|_{'rows': array(['EFO_0003095', 'EFO_0000401'], dtype=object), 'count': 2}_|_[ENSG00000012504]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL5095050,"CCCCCCCCCCCCOS(=O)(=O)O.CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1_|_XTLZVNMZICNQBB-UHFFFAOYSA-N_|_Small molecule_|_False_|_FINGOLIMOD LAURYL SULFATE_|_2021.0_|_4.0_|_CHEMBL314854_|_False_|_True_|_['Tascenso odt']_|_['Tascenso']_|_nan_|_nan_|_nan_|_[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021."
CHEMBL5170587,"N#Cc1ccc(N2CCC[C@@H]2[C@@H](O)C(F)(F)F)cc1C(F)(F)F_|_OPSIVAKKLQRWKC-VXGBXAGGSA-N_|_Small molecule_|_False_|_VK5211_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LGD-4033' 'Ligandrol' 'Vk 5211' 'Vk-5211' 'Vk5211']_|_nan_|_nan_|_{'rows': array(['EFO_0003964'], dtype=object), 'count': 1}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL837,"CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC_|_FJHBVJOVLFPMQE-QFIPXVFZSA-N_|_Small molecule_|_False_|_7-ETHYL-10-HYDROXYCAMPTOTHECIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['7-Ethyl-10-Hydroxy-Camptothecin' '7-ethyl-10-hydroxycamptothecin'
 'Camptothecin, 7-ethyl-10-hydroxy-' 'IT-141'
 'Irinotecan related compound b' 'It-141' 'NK 012' 'NK-012' 'NK012'
 'Nk012' 'SN 38' 'SN-38']_|_[('PubChem', array(['515301'], dtype=object)), ('Wikipedia', array(['SN-38'], dtype=object)), ('drugbank', array(['DB05482'], dtype=object)), ('chEBI', array(['8988'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0000702', 'MONDO_0008903', 'EFO_1001951',
       'MONDO_0007254'], dtype=object), 'count': 5}_|_[ENSG00000198900]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL844,"Brc1c(NC2=NCCN2)ccc2nccnc12_|_XYLJNLCSTIOKRM-UHFFFAOYSA-N_|_Small molecule_|_False_|_BRIMONIDINE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AGN-190342 FREE BASE' 'Brimonidine' 'NSC-318825' 'UK-14304'
 'UK-1430418 FREE BASE']_|_[('PubChem', array(['104171261', '11111939', '11113354', '144203850', '170464941',
       '26751556', '50104157', '85231282', '855898', '90340645'],
      dtype=object)), ('Wikipedia', array(['Brimonidine'], dtype=object)), ('drugbank', array(['DB00484'], dtype=object)), ('chEBI', array(['3175'], dtype=object))]_|_['CHEMBL1200389' 'CHEMBL2062257']_|_{'rows': array(['EFO_0003770', 'MONDO_0001330', 'EFO_1001069', 'EFO_0004190',
       'EFO_1000906', 'MONDO_0021698', 'EFO_0000537', 'EFO_1001893',
       'MONDO_0001330', 'MONDO_0005041', 'EFO_0003822', 'HP_0000951',
       'EFO_1000879', 'MONDO_0005041', 'HP_0010783', 'EFO_1000760',
       'EFO_1000906', 'HP_0031284', 'EFO_0005751', 'EFO_1001069',
       'EFO_0007141', 'EFO_1000760', 'EFO_0004190'], dtype=object), 'count': 23}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 8 approved and 14 investigational indications."
CHEMBL16476,"CC(C)NCC(O)c1ccc2ccccc2c1_|_HRSANNODOVBCST-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRONETALOL_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['AY 6204 [AS HYDROCHLORIDE]' 'AY-6204 HCL' 'Dl-pronethalol' 'GNF-PF-2670'
 'ICI 38174 [AS HYDROCHLORIDE]' 'Inetol' 'Naphthylisoproterenol'
 'Nethalide' 'Pronetalol' 'Pronethalol']_|_[('PubChem', array(['144204478', '170466606', '26751909'], dtype=object)), ('chEBI', array(['8463'], dtype=object))]_|_['CHEMBL1876082']_|_nan_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL1743022,"nan_|_nan_|_Antibody_|_False_|_FRESOLIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fresolimumab' 'GC-1008' 'GC1008' 'GZ-402669' 'GZ402669']_|_nan_|_nan_|_{'rows': array(['EFO_0003833', 'EFO_0003060', 'EFO_0004236', 'EFO_0000770',
       'EFO_0000768', 'EFO_0000404', 'MONDO_0019019', 'EFO_0000681',
       'MONDO_0007254'], dtype=object), 'count': 9}_|_[ENSG00000105329,ENSG00000119699,ENSG00000092969]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL1801204,"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO_|_KVLFRAWTRWDEDF-IRXDYDNUSA-N_|_Small molecule_|_False_|_AZD-8055_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['AZ-12600000' 'AZD 8055' 'AZD-8055' 'AZD8055' 'Azd-8055']_|_[('drugbank', array(['DB12774'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0004992', 'EFO_0002499', 'EFO_0002501',
       'EFO_0000182', 'EFO_0000574', 'EFO_0000519'], dtype=object), 'count': 7}_|_[ENSG00000198793]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications."
CHEMBL2109387,"nan_|_nan_|_Antibody_|_False_|_PARSATUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MEGF-0444A' 'MEGF0444A' 'Parsatuzumab' 'RG-741' 'RG-7414' 'RG7414'
 'anti-EGFL7 monoclonal antibody']_|_nan_|_nan_|_{'rows': array(['EFO_0003060', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000172889]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109548,"nan_|_nan_|_Antibody_|_False_|_MK-4721_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AGS-1C4D4' 'AGS-PSCA' 'Ags 1c4d4' 'MK-4721' 'Mk-4721']_|_nan_|_nan_|_{'rows': array(['MONDO_0005184', 'MONDO_0008315', 'EFO_0010282'], dtype=object), 'count': 3}_|_[ENSG00000167653]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2308782,"C[N+]1(C)[C@@H]2CC[C@H]1C[C@H](CC(C#N)(c1ccccc1)c1ccccc1)C2.[Br-]_|_CWRNUVNMUYSOFQ-ABHLOGGPSA-M_|_Small molecule_|_False_|_DAROTROPIUM BROMIDE_|_nan_|_2.0_|_CHEMBL2365940_|_False_|_False_|_[]_|_['Darotropium bromide' 'GSK-233705' 'GSK-233705B' 'GSK233705' 'GSK233705B']_|_nan_|_nan_|_{'rows': array(['EFO_0000341'], dtype=object), 'count': 1}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2347655,"CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1_|_LLXISKGBWFTGEI-FQEVSTJZSA-N_|_Small molecule_|_False_|_FILANESIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARRY-520' 'Filanesib']_|_[('drugbank', array(['DB06040'], dtype=object))]_|_['CHEMBL3544920']_|_{'rows': array(['EFO_0000222', 'EFO_0001378', 'EFO_0000198', 'EFO_0006475',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000138160]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL3545406,"nan_|_nan_|_Small molecule_|_False_|_LY2940094_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ly2940094']_|_nan_|_nan_|_{'rows': array(['MONDO_0002050', 'MONDO_0007079', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000125510]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3989871,"Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F_|_PUKBOVABABRILL-YZNIXAGQSA-N_|_Small molecule_|_False_|_AVACOPAN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Tavneos']_|_['Avacopan' 'CCX-168' 'CCX168' 'Ccx168']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos'],
      dtype=object)), ('drugbank', array(['DB15011'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000784', 'EFO_0004826', 'EFO_0005297', 'EFO_0006803',
       'EFO_1000710', 'EFO_0000540', 'MONDO_0015492', 'EFO_0004194',
       'MONDO_0016244'], dtype=object), 'count': 9}_|_[ENSG00000197405]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 5 approved and 4 investigational indications."
CHEMBL4298045,"nan_|_nan_|_Antibody drug conjugate_|_False_|_INDUSATUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Indusatumab vedotin' 'MLN-0264' 'MLN0264' 'Mln0264' 'TAK-264']_|_nan_|_nan_|_{'rows': array(['EFO_0000503', 'MONDO_0004992'], dtype=object), 'count': 2}_|_[ENSG00000070019,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4594503,"nan_|_nan_|_Antibody_|_False_|_TALQUETAMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Talvey']_|_['JNJ-63483043' 'JNJ-64407564' 'Talquetamab']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TALQUETAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0001642'], dtype=object), 'count': 2}_|_[ENSG00000111291,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for multiple myeloma and has 1 investigational indication."
CHEMBL467084,"N[C@@H](Cc1ccccn1)c1ccccc1_|_FWUQWDCOOWEXRY-ZDUSSCGKSA-N_|_Small molecule_|_False_|_LANICEMINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AR-R15896AR' 'AZD-6765' 'AZD6765' 'Azd6765' 'Lanicemine']_|_[('drugbank', array(['DB11889'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009', 'MONDO_0002050'], dtype=object), 'count': 2}_|_[ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL484785,"N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1_|_USZAGAREISWJDP-UHFFFAOYSA-N_|_Small molecule_|_False_|_CRISABOROLE_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Eucrisa' 'Staquis']_|_['AN-2728' 'AN2728' 'Crisaborole']_|_[('DailyMed', array(['crisaborole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/staquis'],
      dtype=object)), ('PubChem', array(['174007043'], dtype=object)), ('drugbank', array(['DB05219'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000676', 'MONDO_0002406', 'HP_0000964', 'EFO_0004208',
       'EFO_0000274', 'EFO_1001361', 'EFO_0004192'], dtype=object), 'count': 7}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for eczematoid dermatitis and atopic eczema and has 5 investigational indications."
CHEMBL502835,"COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1_|_XZXHXSATPCNXJR-ZIADKAODSA-N_|_Small molecule_|_False_|_NINTEDANIB_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Ofev' 'Vargatef']_|_['BIBF 1120' 'BIBF-1120' 'BIBF1120' 'Bibf-1120' 'Intedanib' 'Nintedanib']_|_[('drugbank', array(['DB09079'], dtype=object)), ('chEBI', array(['85164'], dtype=object))]_|_['CHEMBL3039504']_|_{'rows': array(['MONDO_0019180', 'EFO_1001331', 'MONDO_0044937', 'EFO_0004244',
       'MONDO_0011705', 'EFO_1001949', 'EFO_0000222', 'EFO_0003893',
       'MONDO_0011962', 'EFO_0000691', 'EFO_0000503', 'EFO_0001378',
       'EFO_1001465', 'EFO_0000768', 'MONDO_0007254', 'EFO_0000681',
       'EFO_0000588', 'EFO_0007183', 'EFO_0009448', 'EFO_0000571',
       'MONDO_0100096', 'MONDO_0008903', 'EFO_0000616', 'EFO_0008528',
       'EFO_0000708', 'EFO_0004284', 'EFO_0000182', 'EFO_0002618',
       'EFO_0000717', 'EFO_0000770', 'EFO_0002499', 'EFO_0000519',
       'EFO_0001416', 'MONDO_0001235', 'EFO_0000702', 'MONDO_0015277',
       'MONDO_0004669', 'MONDO_0002158', 'EFO_0000717', 'EFO_0004142',
       'EFO_1001951', 'EFO_0000768', 'MONDO_0002087', 'MONDO_0008170',
       'EFO_0000673', 'EFO_0003060', 'EFO_0004243', 'EFO_0000389',
       'EFO_0002501'], dtype=object), 'count': 49}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468,ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000113721,ENSG00000134853]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for systemic scleroderma and idiopathic pulmonary fibrosis and has 47 investigational indications."
CHEMBL539423,"CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1_|_WRFHGDPIDHPWIQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_SPARSENTAN_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Filspari']_|_['Filspari' 'PS-433540' 'PS433540' 'RE-021' 'Sparsentan']_|_[('drugbank', array(['DB12548'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004236', 'EFO_0000537', 'EFO_0004194'], dtype=object), 'count': 3}_|_[ENSG00000151617,ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for iga glomerulonephritis and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL79,"CCN(CC)CC(=O)Nc1c(C)cccc1C_|_NNJVILVZKWQKPM-UHFFFAOYSA-N_|_Small molecule_|_True_|_LIDOCAINE_|_1948.0_|_4.0_|_nan_|_False_|_True_|_['Alphacaine' 'Anestacon' 'Dentipatch' 'Lidocaine' 'Lidoderm'
 'Lignocaine Hcl' 'Lignostab' 'Lmx 4' 'Oraqix' 'Vagisil' 'Xylocaine'
 'Xylodase' 'Xylotox' 'Ztlido']_|_['ALGRX 3268' 'ALGRX-3268' 'Anestacon' 'Embolex' 'Iontocaine' 'Lidocaine'
 'Lidocainum' 'Lidocaton' 'Lidopen' 'Lignocaine' 'NSC-40030' 'Octocaine'
 'Solarcaine' 'Xylestesin']_|_[('DailyMed', array(['lidocaine'], dtype=object)), ('PubChem', array(['104171182', '11111384', '11111385', '144203734', '170464729',
       '26751483', '26751484', '56422194', '855682', '90340642'],
      dtype=object)), ('Wikipedia', array(['Lidocaine'], dtype=object)), ('drugbank', array(['DB00281'], dtype=object)), ('chEBI', array(['6456'], dtype=object))]_|_['CHEMBL3278065' 'CHEMBL541521' 'CHEMBL1200409']_|_{'rows': array(['EFO_0003943', 'MONDO_0008903', 'EFO_0004273', 'EFO_0009364',
       'EFO_1001097', 'MONDO_0001572', 'EFO_0001074', 'Orphanet_365',
       'EFO_0002610', 'HP_0003418', 'EFO_0001663', 'EFO_1000941',
       'EFO_0003843', 'MONDO_0005178', 'EFO_0008507', 'EFO_0009688',
       'HP_0100543', 'HP_0000989', 'EFO_1001434', 'HP_0003419',
       'EFO_1001993', 'EFO_0000555', 'EFO_0005856', 'EFO_0009552',
       'EFO_0003878', 'EFO_1001896', 'EFO_0004616', 'HP_0002315',
       'EFO_0003958', 'EFO_0007214', 'EFO_1001250', 'EFO_1000249',
       'MONDO_0004992', 'EFO_0006346', 'EFO_0005230', 'EFO_0000668',
       'EFO_0009660', 'EFO_1001139', 'EFO_1001087', 'EFO_0002970',
       'EFO_1001178', 'HP_0003394', 'EFO_1001998', 'MONDO_0007254',
       'EFO_0000712', 'EFO_0002618', 'EFO_1001412', 'EFO_0009430',
       'EFO_0003917', 'MP_0001845', 'HP_0002315', 'EFO_0001073',
       'EFO_0004143', 'EFO_0000546', 'EFO_0009620', 'EFO_0007490',
       'MONDO_0004567', 'HP_0001907', 'EFO_1001951', 'EFO_0003888',
       'HP_0000360', 'EFO_0010582', 'MONDO_0100096', 'EFO_0000519',
       'EFO_0003902', 'EFO_1001898', 'EFO_0004142', 'EFO_0003833',
       'EFO_0000701', 'EFO_0009492', 'EFO_0009619', 'EFO_0000537',
       'EFO_0006834', 'EFO_0005762', 'EFO_0003100', 'HP_0030834',
       'EFO_1001492', 'HP_0000020', 'HP_0100607', 'EFO_0803321',
       'EFO_0005279', 'EFO_0003777', 'MP_0001914', 'MONDO_0002258',
       'EFO_0003957', 'EFO_1001996', 'EFO_0005687', 'EFO_0003103',
       'EFO_0009516', 'EFO_1001219', 'EFO_0000545', 'HP_0012532',
       'EFO_0005754', 'EFO_0009552', 'EFO_1001054', 'EFO_0801084',
       'HP_0003418', 'EFO_0009846', 'EFO_0000616', 'EFO_0000400',
       'EFO_0000546', 'MONDO_0005277', 'HP_0004308', 'EFO_0001069',
       'HP_0003326', 'EFO_1001255', 'EFO_1000910', 'EFO_1000781',
       'MONDO_0004992', 'MONDO_0002691', 'EFO_0003843', 'EFO_1001904',
       'EFO_0004198', 'EFO_1000783', 'EFO_0003901', 'EFO_0000707',
       'HP_0000989', 'EFO_0002950', 'EFO_0002950', 'EFO_0001361',
       'EFO_1000889', 'HP_0012532', 'EFO_0009582', 'EFO_0007486',
       'EFO_0000305', 'MONDO_0005277', 'HP_0012735', 'EFO_0004269',
       'EFO_0003854', 'EFO_0000313', 'EFO_1001887', 'EFO_0002496',
       'MONDO_0041052'], dtype=object), 'count': 133}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 23 approved and 105 investigational indications. This drug has a black box warning from the FDA."
CHEMBL964,"CCN(CC)C(=S)SSC(=S)N(CC)CC_|_AUZONCFQVSMFAP-UHFFFAOYSA-N_|_Small molecule_|_True_|_DISULFIRAM_|_1951.0_|_4.0_|_nan_|_False_|_True_|_['Antabuse' 'Disulfiram' 'Esperal']_|_['Disulfiram' 'NSC-25953' 'ORA-102' 'ORA102']_|_[('DailyMed', array(['disulfiram'], dtype=object)), ('PubChem', array(['104171249', '11111859', '11111860', '11533044', '123060006',
       '124881563', '124881565', '124881567', '124881570', '144203831',
       '144210721', '144214033', '170464767', '26747681', '26747682',
       '26753660', '26753661', '50107088', '50107089', '56422197',
       '85231246', '90340564'], dtype=object)), ('TG-GATEs', array(['109'], dtype=object)), ('Wikipedia', array(['Disulfiram'], dtype=object)), ('drugbank', array(['DB00822'], dtype=object)), ('chEBI', array(['4659'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0002610', 'EFO_0000519', 'EFO_0005611',
       'EFO_0001067', 'EFO_0001073', 'EFO_0002617', 'MONDO_0004992',
       'EFO_0003060', 'EFO_0004701', 'MONDO_0019118', 'EFO_0002618',
       'EFO_0000756', 'MONDO_0008315', 'HP_0012378', 'EFO_0000691',
       'EFO_0000764', 'MONDO_0021698', 'MONDO_0007254', 'MONDO_0007079',
       'MONDO_0100096', 'EFO_0000514'], dtype=object), 'count': 22}_|_[ENSG00000111275]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for parasitic infection and alcohol dependence and has 20 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1083659,"Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1_|_JYTNQNCOQXFQPK-MRXNPFEDSA-N_|_Small molecule_|_False_|_SUVOREXANT_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Belsomra']_|_['MK-4305' 'MK4305' 'Suvorexant']_|_[('DailyMed', array(['suvorexant'], dtype=object)), ('drugbank', array(['DB09034'], dtype=object)), ('chEBI', array(['82698'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009267', 'EFO_0003768', 'MONDO_0004975', 'EFO_0003877',
       'EFO_0003758', 'EFO_0004698', 'EFO_0004319', 'EFO_0004270',
       'EFO_0008568', 'MONDO_0007079', 'EFO_0010702'], dtype=object), 'count': 11}_|_[ENSG00000137252,ENSG00000121764]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for insomnia and has 10 investigational indications."
CHEMBL1201231,"C[C@]12C=CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O_|_JDOZJEUDSLGTLU-VWUMJDOOSA-N_|_Small molecule_|_False_|_PREDNISOLONE PHOSPHORIC ACID_|_1973.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Prednisolone phosphate' 'Prednisolone phosphoric acid']_|_[('drugbank', array(['DB14631'], dtype=object))]_|_['CHEMBL1201014']_|_{'rows': array(['MONDO_0005301', 'MONDO_0002280', 'EFO_1001231', 'EFO_0003929',
       'MP_0001845', 'EFO_0007126', 'MONDO_0004979', 'EFO_1001226',
       'EFO_0000768', 'EFO_0000341', 'HP_0000559', 'EFO_0009448',
       'EFO_0000565', 'EFO_0007308', 'EFO_0005854', 'EFO_0007141',
       'EFO_0004255', 'EFO_0007415'], dtype=object), 'count': 18}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 14 approved and 4 investigational indications."
CHEMBL1201747,"CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1_|_MWTBKTRZPHJQLH-UHFFFAOYSA-N_|_Small molecule_|_False_|_ALCAFTADINE_|_2010.0_|_4.0_|_nan_|_False_|_True_|_['Lastacaft']_|_['Alcaftadine' 'R 89674' 'R-89674']_|_[('DailyMed', array(['alcaftadine'], dtype=object)), ('Wikipedia', array(['Alcaftadine'], dtype=object)), ('drugbank', array(['DB06766'], dtype=object)), ('chEBI', array(['71023'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007141', 'EFO_0005751'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for allergic conjunctivitis and eye allergy."
CHEMBL1218,"CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3_|_YLXDSYKOBKBWJQ-LBPRGKRZSA-N_|_Small molecule_|_False_|_RAMELTEON_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Ramelteon' 'Rozerem']_|_['Ramelteon' 'TAK-375' 'TAK375']_|_[('DailyMed', array(['ramelteon'], dtype=object)), ('drugbank', array(['DB00980'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'MONDO_0004985', 'EFO_0004698', 'EFO_0003768',
       'EFO_0008568', 'MONDO_0005475', 'MONDO_0100096', 'EFO_0009516',
       'MONDO_0100431', 'EFO_0003890', 'MONDO_0002050', 'EFO_0007191',
       'EFO_0003918'], dtype=object), 'count': 13}_|_[ENSG00000168412,ENSG00000134640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for insomnia and has 12 investigational indications."
CHEMBL1360,"COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC_|_YXSLJKQTIDHPOT-UHFFFAOYSA-N_|_Small molecule_|_False_|_ATRACURIUM_|_1983.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Atracurium' 'Atracurium cation' 'Atracurium ion' 'Tracrium']_|_[('Wikipedia', array(['Atracurium_besilate'], dtype=object)), ('chEBI', array(['2914'], dtype=object))]_|_['CHEMBL4584552' 'CHEMBL1200527']_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983."
CHEMBL1614725,"CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21_|_ZYQXEVJIFYIBHZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_TAK-285_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['TAK-285' 'Tak 285' 'Tak-285' 'Tak285']_|_nan_|_nan_|_{'rows': array(['MONDO_0004992'], dtype=object), 'count': 1}_|_[ENSG00000141736,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1754,"CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O_|_XFDJYSQDBULQSI-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXAPRAM_|_1965.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Docatone' 'Doxapram']_|_[('PubChem', array(['50112713'], dtype=object)), ('Wikipedia', array(['Doxapram'], dtype=object)), ('drugbank', array(['DB00561'], dtype=object)), ('chEBI', array(['681848'], dtype=object))]_|_['CHEMBL1200876' 'CHEMBL3989519']_|_{'rows': array(['EFO_0000684', 'EFO_0004262', 'EFO_0003818'], dtype=object), 'count': 3}_|_[ENSG00000171303,ENSG00000169427]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for respiratory system disease and lung disease and has 1 investigational indication."
CHEMBL17879,"CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]_|_POMVPJBWDDJCMP-RUKDTIIFSA-M_|_Small molecule_|_False_|_MARALIXIBAT CHLORIDE_|_2021.0_|_4.0_|_CHEMBL363392_|_False_|_True_|_['Livmarli']_|_['LUM-001' 'LUM001' 'Lopixibat chloride' 'Maralixibat chloride']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007318', 'EFO_0004268', 'HP_0000989', 'EFO_1001486'],
      dtype=object), 'count': 4}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alagille syndrome and pruritus and has 2 investigational indications."
CHEMBL2107455,"CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1_|_ANMATWQYLIFGOK-UHFFFAOYSA-N_|_Small molecule_|_False_|_IGURATIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Careram' 'Iguratimod' 'Kolbet' 'T-614']_|_[('PubChem', array(['144206972'], dtype=object)), ('drugbank', array(['DB12233'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007160', 'EFO_0000699', 'EFO_0005761', 'EFO_0000685'],
      dtype=object), 'count': 4}_|_[ENSG00000240972,ENSG00000073756,ENSG00000056972]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2135460,"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O_|_BENFXAYNYRLAIU-QSVFAHTRSA-N_|_Protein_|_True_|_TERLIPRESSIN_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Terlivaz' 'Variquel']_|_['Glycylpressin' 'Glypressin' 'Terlipressin' 'Terlipressin acetate']_|_[('PubChem', array(['124896640', '144206925'], dtype=object)), ('drugbank', array(['DB02638'], dtype=object))]_|_['CHEMBL4088899']_|_{'rows': array(['HP_0000083', 'EFO_0001422', 'MONDO_0001382', 'HP_0001399',
       'MP_0001914', 'HP_0002105', 'EFO_0006834', 'EFO_1002048'],
      dtype=object), 'count': 8}_|_[ENSG00000126895,ENSG00000166148,ENSG00000198049]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL272621,"C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C_|_DGABKXLVXPYZII-SIBKNCMHSA-N_|_Small molecule_|_False_|_HYODEOXYCHOLIC_ACID_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['.alpha.-hyodeoxycholic acid' 'AHRO-001' 'HDCA' 'Hyodeoxycholic acid'
 'Hyodeoxycholic_acid' 'Hyodesoxycholic acid' 'NSC-60672']_|_[('Wikipedia', array(['Hyodeoxycholic_acid'], dtype=object)), ('drugbank', array(['DB11789'], dtype=object)), ('chEBI', array(['52023'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003124'], dtype=object), 'count': 1}_|_[ENSG00000025434,ENSG00000131408]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL3545269,"nan_|_nan_|_Small molecule_|_False_|_SAR425899_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Sar425899']_|_nan_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000215644]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545313,"CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O_|_HYHMLYSLQUKXKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_BEMPEDOIC ACID_|_2020.0_|_4.0_|_nan_|_False_|_True_|_['Nexletol' 'Nilemdo']_|_['Bempedoic acid' 'ESP-55016' 'ETC-1002' 'ETC1002']_|_[('DailyMed', array(['bempedoic%20acid'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nilemdo'],
      dtype=object)), ('drugbank', array(['DB11936'], dtype=object))]_|_nan_|_{'rows': array(['HP_0003124', 'EFO_0000319', 'EFO_0004911', 'MONDO_0021187',
       'HP_0003119', 'Orphanet_309005', 'EFO_0001645', 'EFO_0003914',
       'MONDO_0005148'], dtype=object), 'count': 9}_|_[ENSG00000131473]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 6 approved and 3 investigational indications."
CHEMBL3647420,"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C_|_SADXACCFNXBCFY-IYNHSRRRSA-N_|_Small molecule_|_False_|_PYROTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Pyrotinib' 'SHR-1258']_|_[('drugbank', array(['DB14993'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008549', 'MONDO_0001056', 'EFO_0000339', 'EFO_0003060',
       'EFO_1001951', 'MONDO_0007254', 'EFO_0000616', 'EFO_0000182',
       'EFO_0003869', 'EFO_0005537'], dtype=object), 'count': 10}_|_[ENSG00000141736,ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL4297545,"nan_|_nan_|_Protein_|_False_|_LUTETIUM OXODOTREOTIDE LU-177_|_2018.0_|_4.0_|_CHEMBL4302409_|_False_|_True_|_['Lutathera']_|_['(177)lu-dotatate' '177lu-dota-tyr3-octreotate' '177lu-dotatate'
 'Dota-octreotate lutetium lu-177' 'Dotatate lutenium lu-177'
 'Dotatate lutetium lu-177' 'Lutetium (177lu) dotatate'
 'Lutetium (177lu) oxodotreotide' 'Lutetium dotatate lu-177'
 'Lutetium dotatate, lu-177' 'Lutetium lu 177 dotatate'
 'Lutetium lu-177 dotatate' 'Oxodotreotide lutetium lu-177'
 'Oxodotreotide lutetium, lu-177']_|_[('DailyMed', array(['lutetium%20lu%20177%20dotatate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000045', 'MONDO_0002120', 'EFO_0000305', 'MONDO_0020634',
       'EFO_0000621', 'MONDO_0016642', 'EFO_1001471', 'MONDO_0024503',
       'EFO_1001901', 'EFO_0007416'], dtype=object), 'count': 10}_|_[ENSG00000162009,ENSG00000180616,ENSG00000132671,ENSG00000139874,ENSG00000278195]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for pancreatic neuroendocrine tumor and neuroendocrine neoplasm and has 8 investigational indications."
CHEMBL5314396,"CNC1CN(c2cc(N)nc(CC(C)C)n2)C1_|_QRBVUFXEMHNIDB-UHFFFAOYSA-N_|_Small molecule_|_False_|_UR-63325_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Seliforant' 'UR-63325' 'Ur-63325']_|_nan_|_nan_|_{'rows': array(['EFO_0003956'], dtype=object), 'count': 1}_|_[ENSG00000134489]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL813,"CCCCc1ncc(/C=C(\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1_|_OROAFUQRIXKEMV-LDADJPATSA-N_|_Small molecule_|_True_|_EPROSARTAN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Teveten']_|_['Eprosartan' 'SK&F 108566' 'SK&F-108566' 'SK-108566' 'Teveten']_|_[('Wikipedia', array(['Eprosartan'], dtype=object)), ('drugbank', array(['DB00876'], dtype=object)), ('chEBI', array(['4814'], dtype=object))]_|_['CHEMBL1200987']_|_{'rows': array(['EFO_0003086', 'MONDO_0100096', 'MONDO_0001134', 'EFO_0000694',
       'EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 6}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and hypertension and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL865,"Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1_|_LNPDTQAFDNKSHK-UHFFFAOYSA-N_|_Small molecule_|_True_|_VALDECOXIB_|_2001.0_|_4.0_|_nan_|_True_|_True_|_['Bextra']_|_['NSC-759846' 'SC-65872' 'Valdecoxib' 'Valdyn']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/bextra'],
      dtype=object)), ('PubChem', array(['144204991', '170465163', '26748964', '49665731'], dtype=object)), ('Wikipedia', array(['Valdecoxib'], dtype=object)), ('drugbank', array(['DB00580'], dtype=object)), ('chEBI', array(['63634'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002258', 'MONDO_0005178', 'HP_0100607', 'EFO_0003843',
       'EFO_0004616', 'EFO_0000685', 'EFO_0000278', 'EFO_0005755'],
      dtype=object), 'count': 8}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 4 approved and 4 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL904,"COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1.Cl_|_JUMYIBMBTDDLNG-OJERSXHUSA-N_|_Small molecule_|_True_|_DEXMETHYLPHENIDATE HYDROCHLORIDE_|_2001.0_|_4.0_|_CHEMBL827_|_False_|_True_|_['Dexmethylphenidate hydrochloride' 'Focalin' 'Focalin xr']_|_['Dex-methylphenidate hydrochloride' 'Dexmethylphenidate hcl'
 'Dexmethylphenidate hydrochloride'
 'Methylphenidate d-threo-form hydrochloride']_|_[('DailyMed', array(['dexmethylphenidate%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003888'], dtype=object), 'count': 1}_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA."
CHEMBL1159,"CC(N/C(=N\C#N)Nc1ccncc1)C(C)(C)C_|_IVVNZDGDKPTYHK-UHFFFAOYSA-N_|_Small molecule_|_False_|_PINACIDIL ANHYDROUS_|_1989.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(r,s)-pinacidil' 'P-1134' 'Pinacidil anhydrous' 'S-1230']_|_[('PubChem', array(['11532877', '124881033', '26749106', '26752206', '50104869',
       '56463565', '90341497'], dtype=object)), ('Wikipedia', array(['Pinacidil'], dtype=object)), ('drugbank', array(['DB06762'], dtype=object))]_|_['CHEMBL1200338']_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000187486,ENSG00000069431]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for hypertension."
CHEMBL1200335,"CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C_|_VOCBWIIFXDYGNZ-IXKNJLPQSA-N_|_Small molecule_|_True_|_TESTOSTERONE ENANTHATE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_['Delatestryl' 'Primoteston depot' 'Testosterone enanthate'
 'Xyosted (autoinjector)']_|_['Androtardyl' 'NSC-17591' 'Testosterone enantate'
 'Testosterone enanthate' 'Testosterone enanthate ciii'
 'Testosterone heptanoate' 'Testosteroni enantas' 'Xyosted']_|_[('DailyMed', array(['testosterone%20enanthate'], dtype=object)), ('drugbank', array(['DB13944'], dtype=object)), ('chEBI', array(['9464'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000341', 'EFO_0000673', 'EFO_1001078', 'HP_0000044',
       'MONDO_0008315', 'EFO_0000196', 'EFO_0000616', 'MONDO_0002146',
       'EFO_0007312', 'HP_0001824', 'Orphanet_269'], dtype=object), 'count': 11}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 4 approved and 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200432,"CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1.Cl_|_QSRVZCCJDKYRRF-YDALLXLXSA-N_|_Small molecule_|_False_|_METHYLDOPATE HYDROCHLORIDE_|_1962.0_|_4.0_|_CHEMBL1201233_|_False_|_True_|_['Aldomet' 'Methyldopate hydrochloride']_|_['Methyldopa l-form ethyl ester hydrochloride' 'Methyldopate hcl'
 'Methyldopate hydrochloride' 'NSC-760088']_|_[('PubChem', array(['144204076', '170466856'], dtype=object))]_|_nan_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962."
CHEMBL1201208,"CC1NCCOC1c1ccccc1_|_OOBHFESNSZDWIU-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENMETRAZINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Phenmetrazine' 'Preludin' 'Trans-phenmetrazine']_|_[('Wikipedia', array(['Phenmetrazine'], dtype=object)), ('drugbank', array(['DB00830'], dtype=object)), ('chEBI', array(['8067'], dtype=object))]_|_['CHEMBL1200483']_|_nan_|_[ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1230165,"O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12_|_MUOKSQABCJCOPU-UHFFFAOYSA-N_|_Small molecule_|_False_|_SILMITASERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CX 4945' 'CX-4945' 'CX4945' 'Cx-4945' 'Cx-4945 free acid'
 'Silmitasertib']_|_[('PubChem', array(['137276036'], dtype=object)), ('drugbank', array(['DB15408'], dtype=object))]_|_['CHEMBL5305652']_|_{'rows': array(['EFO_0004193', 'EFO_0002939', 'EFO_0005221', 'MONDO_0100096',
       'EFO_0001378'], dtype=object), 'count': 5}_|_[ENSG00000101266]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2103741,"N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)[O-].O.[Na+]_|_ANMYAHDLKVNJJO-LTCKWSDVSA-M_|_Small molecule_|_True_|_LEVOTHYROXINE SODIUM_|_2000.0_|_4.0_|_CHEMBL1624_|_False_|_True_|_['Eltroxin' 'Ermeza' 'Euthyrox' 'Evotrox' 'L-thyroxine henning' 'Levo-t'
 'Levolet' 'Levothroid' 'Levothyroid' 'Levothyroxine sodium' 'Levoxine'
 'Levoxyl' 'Novothyrox' 'Soloxine' 'Synthroid' 'Thyquidity' 'Thyro-tabs'
 'Thyrol L' 'Thyroxine' 'Tirosint' 'Tirosint-sol' 'Unithroid']_|_['Eferox' 'Levaxin' 'Levothyrox' 'Levothyroxine sodium'
 'Levothyroxine sodium anhydrous' 'Levothyroxine sodium hydrate'
 'Levothyroxine sodium pentahydrate' 'Levothyroxinum natricum anhydrous'
 'Liotrix (t4)' 'Monosodium l-thyroxine hydrate' 'NSC-259940' 'Oroxine'
 'Sodium levothyroxine pentahydrate' 'Soloxine' 'T4' 'Thyroxine'
 'Thyroxine sodium' 'Thyroxine sodium salt']_|_[('DailyMed', array(['levothyroxine%20sodium'], dtype=object)), ('chEBI', array(['6447'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0018612', 'EFO_0002892', 'EFO_0004705', 'EFO_0003843',
       'EFO_1002017', 'MONDO_0004985', 'MONDO_0002108'], dtype=object), 'count': 7}_|_[ENSG00000126351,ENSG00000151090]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 5 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103880,"CN(C)CCCOc1ccc2[nH]nc(S(=O)(=O)c3cccc4ccccc34)c2c1_|_NXQGEDVQXVTCDA-UHFFFAOYSA-N_|_Small molecule_|_False_|_CERLAPIRDINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Cerlapirdine' 'PF-05212365' 'SAM-531' 'SAM-531 FREE BASE' 'Sam-531'
 'WAY-262,531' 'WAY-262531']_|_[('drugbank', array(['DB12229'], dtype=object))]_|_['CHEMBL2105752']_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000158748]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2104262,"Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2_|_VTZPAJGVRWKMAG-UHFFFAOYSA-N_|_Small molecule_|_False_|_FADOLMIDINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fadolmidine' 'Radolmidine']_|_nan_|_['CHEMBL2106710']_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2107819,"CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C_|_SJDDOCKBXFJEJB-MOKWFATOSA-N_|_Small molecule_|_False_|_BELNACASAN_|_nan_|_2.0_|_nan_|_False_|_False_|_['Vx-765']_|_['Belnacasan' 'VX-765' 'VX765']_|_nan_|_nan_|_{'rows': array(['EFO_0000676', 'EFO_0000474', 'MONDO_0100096', 'EFO_0004263'],
      dtype=object), 'count': 4}_|_[ENSG00000137752]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2108119,"nan_|_nan_|_Antibody_|_False_|_PASCOLIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ANTI-IL4' 'Anti-il-4 antibody' 'Pascolizumab' 'SB-240683']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979', 'MONDO_0018076'], dtype=object), 'count': 2}_|_[ENSG00000113520]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2109519,nan_|_nan_|_Antibody_|_False_|_ABX-MA1_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['ABX-MA1']_|_nan_|_nan_|_nan_|_[ENSG00000076706]_|_Antibody drug with a maximum clinical trial phase of I.
CHEMBL2109575,"nan_|_nan_|_Antibody drug conjugate_|_False_|_BIIB-015_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BIIB-015' 'Biib-015']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000241186]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109591,"nan_|_nan_|_Antibody_|_False_|_TOL-101_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TOL-101' 'TOL101' 'Tol-101']_|_nan_|_nan_|_{'rows': array(['EFO_0003884'], dtype=object), 'count': 1}_|_[ENSG00000211810,ENSG00000277734,ENSG00000278030,ENSG00000211699]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545042,"CC(C)c1cc2[nH]c(=O)n(NS(C)(=O)=O)c(=O)c2cc1-c1ccnn1C_|_MCECSFFXUPEPDB-UHFFFAOYSA-N_|_Small molecule_|_False_|_SELURAMPANEL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BGG-492' 'BGG492' 'Bgg492' 'Selurampanel']_|_[('drugbank', array(['DB12367'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0015643', 'HP_0001250', 'HP_0001257', 'MONDO_0005277',
       'EFO_0000474', 'HP_0000360', 'MONDO_0005301'], dtype=object), 'count': 7}_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511,ENSG00000171189,ENSG00000105737,ENSG00000149403,ENSG00000164418,ENSG00000163873]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL39541,"CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C_|_OFDNQWIFNXBECV-VFSYNPLYSA-N_|_Small molecule_|_False_|_DOLASTATIN-10_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dolastatin 10' 'Dolastatin-10' 'Dolostatin 10']_|_[('drugbank', array(['DB12730'], dtype=object)), ('chEBI', array(['67357'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0002618', 'MONDO_0008170', 'EFO_0000574',
       'MONDO_0005411', 'EFO_0000198', 'EFO_0000565', 'MONDO_0002367',
       'EFO_0000691'], dtype=object), 'count': 9}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."
CHEMBL4297763,"nan_|_nan_|_Unknown_|_False_|_GTI-2040_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gti 2040' 'Gti-2040']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000616', 'MONDO_0008315', 'EFO_0006861'],
      dtype=object), 'count': 4}_|_[ENSG00000171848]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297819,"nan_|_nan_|_Unknown_|_False_|_ROPEGINTERFERON ALFA-2B_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Besremi']_|_['Aop2014' 'Besremi' 'P-1101' 'P1101' 'Ropeginterferon alfa-2b'
 'Ropeginterferon alfa-2b njft' 'Ropeginterferon alfa-2b-njft']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/besremi'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004239', 'EFO_0000616', 'MONDO_0044903', 'MONDO_0100096',
       'EFO_0000182', 'EFO_0000339', 'EFO_0002429', 'EFO_0007304',
       'EFO_0000479', 'EFO_0004220'], dtype=object), 'count': 10}_|_[ENSG00000142166,ENSG00000159110]_|_Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for neoplasm and polycythemia vera and has 8 investigational indications."
CHEMBL4297990,"nan_|_nan_|_Protein_|_False_|_TEBENTAFUSP_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Kimmtrak']_|_['IMCGP-100' 'IMCGP100' 'IMCgp 100' 'IMMTAC IMCGP100' 'Imcgp100'
 'ImmTAC IMCgpgp 100' 'Kimmtrak' 'Tebentafusp' 'Tebentafusp tebn'
 'Tebentafusp-tebn']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TEBENTAFUSP/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001230', 'EFO_0000616', 'EFO_0000756'], dtype=object), 'count': 3}_|_[ENSG00000185664]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved indications."
CHEMBL4594614,"nan_|_nan_|_Antibody_|_False_|_SIBEPRENLIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Sibeprenlimab' 'VIS-649' 'VIS649' 'Vis-649' 'Vis649']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SIBEPRENLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004194'], dtype=object), 'count': 1}_|_[ENSG00000161955]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL460702,"CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1_|_VNBRGSXVFBYQNN-UHFFFAOYSA-N_|_Small molecule_|_False_|_BMS-777607_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ASLAN-002' 'ASLAN002' 'BMS-777607' 'Bms-777607']_|_[('PubChem', array(['137276001'], dtype=object)), ('drugbank', array(['DB12064'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL46740,"Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12_|_UCJGJABZCDBEDK-UHFFFAOYSA-N_|_Small molecule_|_False_|_BAZEDOXIFENE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Bazedoxifene']_|_[('PubChem', array(['124893775'], dtype=object)), ('Wikipedia', array(['Bazedoxifene'], dtype=object)), ('drugbank', array(['DB06401'], dtype=object))]_|_['CHEMBL2106615']_|_{'rows': array(['EFO_0000432', 'EFO_0003854', 'MONDO_0007254', 'GO_0042697',
       'EFO_0003929', 'EFO_0003882', 'EFO_0003882', 'EFO_0003854',
       'GO_0042697'], dtype=object), 'count': 9}_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for postmenopausal osteoporosis and has 7 investigational indications."
CHEMBL5314379,"C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C_|_BICRTLVBTLFLRD-PTWUADNWSA-N_|_Protein_|_True_|_VOCLOSPORIN_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Lupkynis']_|_['ISA-247' 'ISA247' 'ISATX-247' 'ISATX247' 'LX-211' 'LX211' 'Voclosporin']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1000986', 'EFO_0005761', 'EFO_1000811', 'EFO_1001082',
       'EFO_1001119', 'EFO_1000906', 'EFO_0003086', 'EFO_1001231',
       'MONDO_0007915', 'EFO_0004236', 'EFO_0000540', 'EFO_0000676'],
      dtype=object), 'count': 12}_|_[ENSG00000138814]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for lupus nephritis and immune system disease and has 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL5314380,"NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O.N[C@@H](CC(=O)O)C(=O)O.N[C@@H](CC(=O)O)C(=O)O_|_NEEFMPSSNFRRNC-HQUONIRXSA-N_|_Protein_|_False_|_PASIREOTIDE DIASPARTATE_|_2012.0_|_4.0_|_CHEMBL3349607_|_False_|_True_|_['Signifor']_|_['Pasireotide (as diaspartate)']_|_[('DailyMed', array(['pasireotide%20diaspartate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/signifor'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000278195,ENSG00000139874,ENSG00000162009,ENSG00000180616]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2012."
CHEMBL70418,"CN1C(=O)CC(=O)N(c2ccccc2)c2cc(Cl)ccc21_|_CXOXHMZGEKVPMT-UHFFFAOYSA-N_|_Small molecule_|_True_|_CLOBAZAM_|_2005.0_|_4.0_|_nan_|_False_|_True_|_['Frisium' 'Onfi' 'Perizam' 'Sympazan' 'Tapclob' 'Urbanyl']_|_['Clobazam' 'Colbazam' 'H 4723' 'H-4723' 'HR 376' 'HR-376' 'LM 2717'
 'LM-2717' 'Mystan' 'NSC-336279' 'Urbadan']_|_[('DailyMed', array(['clobazam'], dtype=object)), ('PubChem', array(['144206161'], dtype=object)), ('Wikipedia', array(['Clobazam'], dtype=object)), ('drugbank', array(['DB00349'], dtype=object)), ('chEBI', array(['31413'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'MONDO_0016532', 'HP_0001250', 'HP_0000726',
       'EFO_0000474', 'EFO_0005762', 'EFO_0005230', 'MONDO_0002050',
       'MONDO_0005090', 'EFO_1000924', 'HP_0003419'], dtype=object), 'count': 11}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved and 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL802,"Nc1cc(N2CCCCC2)nc(N)[n+]1[O-]_|_ZFMITUMMTDLWHR-UHFFFAOYSA-N_|_Small molecule_|_True_|_MINOXIDIL_|_1979.0_|_4.0_|_nan_|_False_|_True_|_['Loniten' 'Lonolox' ""Men's rogaine"" 'Minodyl' 'Minoxidil'
 'Minoxidil (for men)' 'Minoxidil (for women)'
 'Minoxidil extra strength (for men)' 'Regaine for men'
 'Regaine for women' 'Rogaine (for men)' 'Rogaine (for women)'
 'Rogaine extra strength (for men)' 'Theroxidil' ""Women's rogaine""]_|_['Alopexil' 'Alostil' 'Minoxidil' 'Minoximen' 'Mintop' 'NSC-757106'
 'Normoxidil' 'Pierminox' 'Prexidil' 'Tricoxidil' 'U-10,858' 'U-10858']_|_[('DailyMed', array(['minoxidil'], dtype=object)), ('PubChem', array(['104171187', '11111457', '11111458', '11113580', '144203744',
       '170464704', '26751784', '26751785', '46500395', '50104471',
       '85231134', '90340717'], dtype=object)), ('Wikipedia', array(['Minoxidil'], dtype=object)), ('drugbank', array(['DB00350'], dtype=object)), ('chEBI', array(['6942'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008170', 'EFO_0004191', 'EFO_0000537', 'MONDO_0004907',
       'MONDO_0003037'], dtype=object), 'count': 5}_|_[ENSG00000187486,ENSG00000069431]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1979 and has 4 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL862,"N=C(N)NC(=O)Cc1c(Cl)cccc1Cl_|_INJOMKTZOLKMBF-UHFFFAOYSA-N_|_Small molecule_|_False_|_GUANFACINE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Intuniv']_|_['Guanfacine' 'NSC-759121' 'Tenex']_|_[('PubChem', array(['104171166', '11111221', '11111222', '11113866', '124880211',
       '26752038', '90341397'], dtype=object)), ('Wikipedia', array(['Guanfacine'], dtype=object)), ('drugbank', array(['DB01018'], dtype=object)), ('chEBI', array(['5558'], dtype=object))]_|_['CHEMBL1200494']_|_{'rows': array(['EFO_0004895', 'MONDO_0004975', 'EFO_0003890', 'EFO_0001358',
       'EFO_0002610', 'EFO_0004319', 'EFO_1001219', 'EFO_0003768',
       'EFO_0007191', 'EFO_0004329', 'EFO_0003888', 'MONDO_0007079',
       'EFO_0000712', 'EFO_0000537', 'EFO_0009267', 'MONDO_0001087',
       'EFO_0003888', 'EFO_0000537'], dtype=object), 'count': 18}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for attention deficit hyperactivity disorder and hypertension and has 15 investigational indications."
CHEMBL1085699,"COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1_|_ANEBWFXPVPTEET-UHFFFAOYSA-N_|_Small molecule_|_False_|_MANIDIPINE 6300_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Artedil' 'Franidipine' 'Manidipine' 'Manidipine 6300'
 'Manidipine hydrochloride']_|_[('PubChem', array(['174006297', '50112746'], dtype=object)), ('drugbank', array(['DB09238'], dtype=object))]_|_['CHEMBL2362693']_|_{'rows': array(['EFO_0000319', 'EFO_0000537'], dtype=object), 'count': 2}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1200491,"Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12_|_VKXSGUIOOQPGAF-UHFFFAOYSA-N_|_Small molecule_|_False_|_EPINASTINE HYDROCHLORIDE_|_2003.0_|_4.0_|_CHEMBL1106_|_False_|_True_|_['Elestat' 'Epinastine hydrochloride' 'Relestat']_|_['Alesion' 'DE-114' 'Epinastine HCl' 'Epinastine hcl'
 'Epinastine hydrochloride' 'WAL 801 CL' 'WAL-801CL' 'WAL-802-CL']_|_[('DailyMed', array(['epinastine%20hydrochloride'], dtype=object)), ('PubChem', array(['144205816', '170465284'], dtype=object)), ('chEBI', array(['51037'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007141'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003 and is indicated for allergic conjunctivitis."
CHEMBL1200885,"Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O.Cl_|_FNYQZOVOVDSGJH-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALOSETRON HYDROCHLORIDE_|_2000.0_|_4.0_|_CHEMBL1110_|_False_|_True_|_['Alosetron hydrochloride' 'Lotronex']_|_['Alosetron hcl' 'Alosetron hydrochloride' 'GR 68755C' 'GR-68755C'
 'Lotrpnex']_|_[('DailyMed', array(['alosetron%20hydrochloride'], dtype=object)), ('PubChem', array(['144206078', '170465416', '49681825'], dtype=object)), ('chEBI', array(['53783'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555'], dtype=object), 'count': 1}_|_[ENSG00000166736]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2000 and is indicated for irritable bowel syndrome. This drug has a black box warning from the FDA."
CHEMBL1200968,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]_|_RYJIRNNXCHOUTQ-OJJGEMKLSA-L_|_Small molecule_|_False_|_HYDROCORTISONE SODIUM PHOSPHATE_|_1960.0_|_4.0_|_CHEMBL1641_|_False_|_True_|_['Efcortesol' 'Hydrocortone']_|_['Cortisol 21-(disodium phosphate)' 'Hydrocortisone sodium phosphate']_|_[('PubChem', array(['144206021'], dtype=object)), ('chEBI', array(['5781'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1201060,"CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1.Cl_|_JSXBVMKACNEMKY-UHFFFAOYSA-N_|_Small molecule_|_False_|_LOXAPINE HYDROCHLORIDE_|_1976.0_|_4.0_|_CHEMBL831_|_False_|_True_|_['Loxitane c' 'Loxitane im']_|_['Loxapine hcl']_|_nan_|_nan_|_nan_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976."
CHEMBL1201156,"CNCCC=C1c2ccccc2CCc2ccccc21.Cl_|_SHAYBENGXDALFF-UHFFFAOYSA-N_|_Small molecule_|_True_|_NORTRIPTYLINE HYDROCHLORIDE_|_1964.0_|_4.0_|_CHEMBL445_|_False_|_True_|_['Aventyl' 'Aventyl hydrochloride' 'Nortriptyline hydrochloride' 'Pamelor'
 'Psychostyl']_|_['38489' 'NSC-169453' 'Nortriptyline hcl' 'Nortriptyline hydrochloride']_|_[('DailyMed', array(['nortriptyline%20hydrochloride'], dtype=object)), ('PubChem', array(['144203599', '50106715', '50106716', '562776', '56423135',
       '855575'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008524', 'EFO_0000676', 'EFO_1000948', 'MONDO_0002009',
       'EFO_0000274'], dtype=object), 'count': 5}_|_[ENSG00000103546,ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for major depressive disorder and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1206690,"CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1_|_TZRHLKRLEZJVIJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_PARECOXIB_|_2002.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Parecoxib' 'Rayzon' 'SC-69124' 'Xapit']_|_[('Wikipedia', array(['Parecoxib'], dtype=object)), ('drugbank', array(['DB08439'], dtype=object)), ('chEBI', array(['73038'], dtype=object))]_|_['CHEMBL296913']_|_{'rows': array(['EFO_0003843', 'EFO_0009620', 'MONDO_0005178', 'EFO_1001412',
       'EFO_0003843', 'HP_0030834', 'EFO_0005755'], dtype=object), 'count': 7}_|_[ENSG00000073756]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for pain and rheumatic disease and has 5 investigational indications."
CHEMBL1236924,"O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl_|_NMRWDFUZLLQSBN-UHFFFAOYSA-N_|_Small molecule_|_False_|_INT131_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AMG-131' 'CHS-131' 'INT-131' 'Ibrigampar' 'Int131' 'T-0903131'
 'T0903131' 'T131']_|_[('drugbank', array(['DB05490'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003929', 'MONDO_0005148'], dtype=object), 'count': 2}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1256818,"Br.COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3.O_|_STTADZBLEUMJRG-IKNOHUQMSA-N_|_Small molecule_|_False_|_DEXTROMETHORPHAN HYDROBROMIDE_|_1984.0_|_4.0_|_CHEMBL52440_|_False_|_True_|_['Beecham coughcaps' 'Brontyl' 'Contac coughcaps' 'Delsym' 'Franolyn dry'
 'Franolyn sed' 'Tussabron' 'Tuxium']_|_['Dextromethorphan Hydrobromide Monohydrate'
 'Dextromethorphan hydrobromide' 'NSC-756723']_|_[('DailyMed', array(['dextromethorphan%20hydrobromide'], dtype=object)), ('PubChem', array(['11112982', '26732619', '49731998'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007214', 'EFO_0007486', 'MONDO_0005271', 'MONDO_0004976',
       'MONDO_0002009', 'HP_0001945', 'EFO_0003843', 'EFO_0000616',
       'MONDO_0002050', 'HP_0002315', 'HP_0001742', 'HP_0012735',
       'MONDO_0005277', 'EFO_0001663', 'MONDO_0005148'], dtype=object), 'count': 15}_|_[ENSG00000183454,ENSG00000147955]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and has 7 approved and 8 investigational indications."
CHEMBL1473,"CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_WMWTYOKRWGGJOA-CENSZEJFSA-N_|_Small molecule_|_False_|_FLUTICASONE PROPIONATE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_['Aerivio spiromax' 'Airflusal forspiro' 'Armonair digihaler'
 'Armonair respiclick' 'Cutivate' 'Flixonase' 'Flixotide' 'Flonase'
 'Flonase allergy relief' 'Flovent' 'Flovent diskus 100'
 'Flovent diskus 250' 'Flovent diskus 50' 'Flovent hfa'
 'Fluticasone propionate' 'Flutiform' 'Nasofan' 'Pirinase' 'Sereflo'
 'Seretide 100' 'Seretide 125' 'Seretide 250' 'Seretide 50' 'Seretide 500'
 'Sirdupla' 'Xhance']_|_['CCI 18781' 'CCI-18781' 'CCI18781' 'FLOVENT' 'Fluticaps' 'Fluticasone'
 'Fluticasone propionate' 'Fluticasone propionate '
 'Fluticasone-17-propionate' 'NSC-759889' 'Opn-375' 'Optinose'
 'PF-00241939' 'R01AD08']_|_[('DailyMed', array(['fluticasone%20propionate'], dtype=object)), ('Wikipedia', array(['Fluticasone_propionate'], dtype=object)), ('drugbank', array(['DB00588'], dtype=object)), ('chEBI', array(['31441'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004232', 'MONDO_0100096', 'EFO_1001942', 'EFO_0006505',
       'EFO_0000341', 'HP_0001742', 'EFO_0007486', 'EFO_1000024',
       'EFO_0005854', 'EFO_0000464', 'EFO_0003956', 'EFO_0007227',
       'HP_0011950', 'EFO_0000274', 'EFO_0000400', 'EFO_0000701',
       'EFO_0008521', 'EFO_1001417', 'HP_0100582', 'EFO_1000391',
       'EFO_0003918', 'HP_0010307', 'MONDO_0004979', 'EFO_0009536',
       'EFO_0000662', 'EFO_0007183', 'HP_0006536'], dtype=object), 'count': 27}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 12 approved and 15 investigational indications."
CHEMBL1641,"C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@@]2(C)[C@H]1CC[C@]2(O)C(=O)COP(=O)(O)O_|_BGSOJVFOEQLVMH-VWUMJDOOSA-N_|_Small molecule_|_False_|_HYDROCORTISONE PHOSPHORIC ACID_|_1960.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Hydrocortisone phosphate']_|_[('PubChem', array(['50112718'], dtype=object)), ('drugbank', array(['DB14542'], dtype=object)), ('chEBI', array(['68634'], dtype=object))]_|_['CHEMBL1200968']_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1960."
CHEMBL1768,"CC(C[N+](C)(C)C)OC(N)=O.[Cl-]_|_XXRMYXBSBOVVBH-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETHANECHOL CHLORIDE_|_1948.0_|_4.0_|_CHEMBL1482_|_False_|_True_|_['Bethanechol chloride' 'Duvoid' 'Myocholine' 'Myotonachol' 'Myotonine'
 'Urecholine']_|_['Bethanechol Chloride' 'Bethanechol chloride'
 'Carbamylmethylcholine chloride' 'NSC-30783']_|_[('DailyMed', array(['bethanechol%20chloride'], dtype=object)), ('PubChem', array(['144205581', '26747481', '50106064', '56422417', '855684'],
      dtype=object)), ('chEBI', array(['3085'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000016'], dtype=object), 'count': 1}_|_[ENSG00000181072,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1948 and is indicated for urinary retention."
CHEMBL1789843,"nan_|_nan_|_Antibody_|_False_|_BELIMUMAB_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Benlysta' 'Lymphostat-b benlysta']_|_['BEL-114333' 'BEL114333' 'Belimumab'
 'Belimumab (genetical recombination)' 'GSK-1550188' 'GSK1550188'
 'HGS-1006' 'HGS1006']_|_[('DailyMed', array(['belimumab'], dtype=object)), ('DrugCentral', array(['4949'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0000685', 'EFO_0006803', 'MONDO_0003783',
       'EFO_0002689', 'EFO_0000464', 'MONDO_0005301', 'EFO_0000783',
       'EFO_0000699', 'EFO_0005761', 'EFO_0004254', 'EFO_0007160',
       'EFO_0004256', 'MONDO_0007915', 'EFO_0000095', 'EFO_0000540',
       'EFO_0000717', 'EFO_0004255'], dtype=object), 'count': 18}_|_[ENSG00000102524]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 15 investigational indications."
CHEMBL2105804,"Cc1cc(C)c2c3ccccc3n(Cc3cccc([C@@H](C(=O)N[C@@H](CO)c4ccccc4)C4CCCC4)c3)c2n1_|_AMNXBQPRODZJQR-DITALETJSA-N_|_Small molecule_|_False_|_IMPLITAPIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY-13-9952' 'Implitapide']_|_[('drugbank', array(['DB04852'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004911', 'EFO_0004211'], dtype=object), 'count': 2}_|_[ENSG00000138823,ENSG00000185624]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2142592,"CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1_|_SZBGQDXLNMELTB-UHFFFAOYSA-N_|_Small molecule_|_False_|_TALADEGIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['LY-2940680' 'LY2940680' 'Taladegib']_|_[('PubChem', array(['137276014'], dtype=object)), ('drugbank', array(['DB12550'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000768', 'EFO_0009708', 'EFO_0000702', 'MONDO_0004992',
       'EFO_0000616'], dtype=object), 'count': 5}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL2364607,"O=C(O)/C=C/C(=O)O.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1.O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1_|_RESIMIUSNACMNW-BXRWSSRYSA-N_|_Small molecule_|_False_|_COBIMETINIB FUMARATE_|_2015.0_|_4.0_|_CHEMBL2146883_|_False_|_True_|_['Cotellic']_|_['Cobimetinib fumarate' 'Cobimetinib hemifumarate' 'Gdc-0973 hemifumarate'
 'Xl-518 hemifumarate']_|_[('DailyMed', array(['cobimetinib%20fumarate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000756', 'EFO_0002617'], dtype=object), 'count': 2}_|_[ENSG00000169032,ENSG00000126934]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for melanoma and metastatic melanoma."
CHEMBL3301610,"CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1_|_UZWDCWONPYILKI-UHFFFAOYSA-N_|_Small molecule_|_False_|_ABEMACICLIB_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Verzenio' 'Verzenios']_|_['Abemaciclib' 'LY-2835219' 'LY2835219' 'Ly-2835219']_|_[('DailyMed', array(['abemaciclib'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios'],
      dtype=object)), ('drugbank', array(['DB12001'], dtype=object))]_|_['CHEMBL4290012' 'CHEMBL4560869' 'CHEMBL4534140' 'CHEMBL4474565']_|_{'rows': array(['EFO_0000616', 'EFO_0000182', 'EFO_0003060', 'EFO_0004284',
       'EFO_0000588', 'MONDO_0008903', 'EFO_0002618', 'MONDO_0008170',
       'EFO_0009708', 'EFO_0000702', 'EFO_0000305', 'MONDO_0008315',
       'EFO_0000349', 'EFO_0000632', 'MONDO_0001187', 'EFO_0000181',
       'EFO_0003825', 'EFO_0005701', 'MONDO_0100342', 'EFO_0005543',
       'EFO_0001378', 'EFO_0003869', 'MONDO_0011962', 'EFO_1001951',
       'EFO_0005537', 'EFO_0000574', 'MONDO_0002108', 'EFO_0003085',
       'EFO_0006861', 'EFO_1001469', 'EFO_0000637', 'EFO_0005952',
       'EFO_0002918', 'EFO_0000196', 'EFO_0000174', 'EFO_0001075',
       'EFO_0000673', 'MONDO_0004992', 'MONDO_0005184', 'EFO_0000389',
       'MONDO_0003060', 'EFO_1000294', 'MONDO_0007254', 'EFO_0003833',
       'EFO_0000756', 'EFO_1000045', 'EFO_1000026', 'EFO_0000558',
       'EFO_0000621', 'EFO_0000519', 'EFO_0003968', 'EFO_1001331',
       'MONDO_0016642', 'MONDO_0018975'], dtype=object), 'count': 54}_|_[ENSG00000135446,ENSG00000105810]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 6 approved and 48 investigational indications."
CHEMBL3544984,"O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1_|_CAVRKWRKTNINFF-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRADIPITANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-686017' 'LY686017' 'Ly686017' 'Tradipitant' 'VLY-686']_|_[('drugbank', array(['DB12580'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_1000948', 'HP_0000989', 'MONDO_0007079',
       'EFO_1001917', 'MONDO_0100096', 'EFO_0008533', 'EFO_0006928'],
      dtype=object), 'count': 8}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."
CHEMBL385517,"N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2_|_QGJUIPDUBHWZPV-SGTAVMJGSA-N_|_Small molecule_|_False_|_SAXAGLIPTIN ANHYDROUS_|_2009.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BMS-477118' 'SBMS-477118']_|_[('PubChem', array(['144206461'], dtype=object)), ('Wikipedia', array(['Saxagliptin'], dtype=object)), ('drugbank', array(['DB06335'], dtype=object)), ('chEBI', array(['71272'], dtype=object))]_|_['CHEMBL2103745' 'CHEMBL1201743' 'CHEMBL3542376']_|_{'rows': array(['MONDO_0005148', 'EFO_0008583', 'EFO_0000660', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0005147', 'EFO_0002546', 'EFO_0003940'],
      dtype=object), 'count': 8}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for type 2 diabetes mellitus and has 7 investigational indications."
CHEMBL4213970,"CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1_|_KPQQGHGDBBJGFA-QNGWXLTQSA-N_|_Small molecule_|_False_|_MK-8353_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Mk-8353' 'SCH-900353']_|_nan_|_['CHEMBL4204280']_|_{'rows': array(['EFO_0000616', 'EFO_1001951'], dtype=object), 'count': 2}_|_[ENSG00000102882,ENSG00000100030]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."
CHEMBL4297736,"nan_|_nan_|_Antibody drug conjugate_|_False_|_PRALUZATAMAB RAVTANSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Anti-cd166-dm4 cx-2009' 'CX-2009' 'Cx 2009' 'Cx-2009'
 'Praluzatamab ravtansine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PRALUZATAMAB%20RAVTANSINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616'], dtype=object), 'count': 2}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000170017]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL457,"Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1_|_HEMJJKBWTPKOJG-UHFFFAOYSA-N_|_Small molecule_|_False_|_GEMFIBROZIL_|_1981.0_|_4.0_|_nan_|_False_|_True_|_['Emfib' 'Gemfibrozil' 'Lopid']_|_['CI-719' 'Gemfibrozil' 'NSC-757024']_|_[('DailyMed', array(['gemfibrozil'], dtype=object)), ('PubChem', array(['11112705', '144204164', '144209195', '144213101', '170464998',
       '17389870', '174007259', '26751515', '49718189', '855780'],
      dtype=object)), ('TG-GATEs', array(['31'], dtype=object)), ('Wikipedia', array(['Gemfibrozil'], dtype=object)), ('drugbank', array(['DB01241'], dtype=object)), ('chEBI', array(['5296'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'MONDO_0004975', 'EFO_0004319', 'EFO_0004211',
       'MONDO_0004992', 'EFO_0003768', 'MONDO_0007079', 'EFO_0000764',
       'HP_0002027', 'EFO_0001645', 'EFO_1001375', 'EFO_0004272',
       'EFO_0000319'], dtype=object), 'count': 13}_|_[ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 3 approved and 10 investigational indications."
CHEMBL4650405,"nan_|_nan_|_Protein_|_False_|_LERODALCIBEP_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Lerodalcibep']_|_nan_|_nan_|_{'rows': array(['MONDO_0018328', 'EFO_0004911', 'HP_0003124', 'EFO_0000319'],
      dtype=object), 'count': 4}_|_[ENSG00000169174]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL467888,"C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1_|_HWLLYFXDDGGHOE-BCSUUIJWSA-N_|_Small molecule_|_False_|_LGD-2941_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LGD-122941' 'LGD122941' 'Lgd-2941']_|_[('drugbank', array(['DB05234'], dtype=object))]_|_nan_|_nan_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL830,"NCCCC(N)(C(=O)O)C(F)F_|_VLCYCQAOQCDTCN-UHFFFAOYSA-N_|_Small molecule_|_False_|_EFLORNITHINE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Eflornithine' 'Ornidyl' 'Vaniqa']_|_[('PubChem', array(['174006789', '575150', '90341137'], dtype=object)), ('Wikipedia', array(['Eflornithine'], dtype=object)), ('drugbank', array(['DB06243'], dtype=object)), ('chEBI', array(['41948'], dtype=object))]_|_['CHEMBL536971' 'CHEMBL1201037']_|_{'rows': array(['DOID_10113', 'MONDO_0007576', 'MONDO_0021074', 'EFO_0004142',
       'EFO_0000621', 'EFO_0000313', 'EFO_0002499', 'EFO_0000519',
       'Orphanet_733', 'MONDO_0001056', 'MONDO_0001187', 'Orphanet_733',
       'MONDO_0100342', 'EFO_0005225', 'EFO_0005044', 'EFO_1001951',
       'MONDO_0005147', 'EFO_0000621', 'MONDO_0002974', 'MONDO_0008315'],
      dtype=object), 'count': 20}_|_[ENSG00000115758]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 18 investigational indications."
CHEMBL1185,"CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12_|_ULSDMUVEXKOYBU-ZDUSSCGKSA-N_|_Small molecule_|_False_|_ZOLMITRIPTAN_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Zolmitriptan' 'Zomig' 'Zomig-zmt']_|_['311-C-90' '311C90' 'Cvt-427' 'NSC-760383' 'Zolmitriptan']_|_[('DailyMed', array(['zolmitriptan'], dtype=object)), ('PubChem', array(['144205008', '170464875'], dtype=object)), ('Wikipedia', array(['Zolmitriptan'], dtype=object)), ('drugbank', array(['DB00315'], dtype=object)), ('chEBI', array(['10124'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005277'], dtype=object), 'count': 1}_|_[ENSG00000135312,ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1997 and is indicated for migraine disorder."
CHEMBL1200384,"CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C_|_CIWBQSYVNNPZIQ-XYWKZLDCSA-N_|_Small molecule_|_False_|_BETAMETHASONE DIPROPIONATE_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Alphatrex' 'Betamethasone dipropionate' 'Diprolene' 'Diprolene af'
 'Diprosone' 'Sernivo']_|_['Betamethasone (as dipropionate)' 'Betamethasone 17,21-dipropionate'
 'Betamethasone dipropionate' 'Diprospan' 'Maxivate' 'NSC-758415'
 'Rinderon dp' 'SCH 11460' 'SCH-11460']_|_[('DailyMed', array(['betamethasone%20dipropionate'], dtype=object)), ('PubChem', array(['144206894', '29215385'], dtype=object)), ('Wikipedia', array(['Betamethasone_dipropionate'], dtype=object)), ('chEBI', array(['31276'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000274', 'EFO_0000676', 'EFO_1001097', 'EFO_0000544',
       'EFO_0000701', 'EFO_0008517', 'EFO_0007486', 'EFO_1001494'],
      dtype=object), 'count': 8}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 4 approved and 4 investigational indications."
CHEMBL1201273,"CC(Cc1ccc2c(c1)OCO2)NCC(O)c1ccc(O)c(O)c1_|_LUMAEVHDZXIGEP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROTOKYLOL_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Asmeti' 'Caytine' 'Palisan' 'Protokylol' 'Ventaire']_|_[('Wikipedia', array(['Protokylol'], dtype=object)), ('drugbank', array(['DB06814'], dtype=object))]_|_['CHEMBL1200893']_|_nan_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201274,"CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1_|_NWIUTZDMDHAVTP-KRWDZBQOSA-N_|_Small molecule_|_False_|_LEVOBETAXOLOL_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betaxolol, (s)-' 'Levobetaxolol']_|_[('Wikipedia', array(['Levobetaxolol'], dtype=object)), ('drugbank', array(['DB09351'], dtype=object)), ('chEBI', array(['59254'], dtype=object))]_|_['CHEMBL1200837']_|_{'rows': array(['MONDO_0005041', 'EFO_1001069'], dtype=object), 'count': 2}_|_[ENSG00000043591]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications."
CHEMBL1201569,"nan_|_nan_|_Protein_|_True_|_RIMABOTULINUMTOXINB_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Myobloc' 'Neurobloc']_|_['AN-0772' 'AN0772' 'BTX-8\t' 'BTX-B' 'Botulin b' 'Botulinum b toxin'
 'Botulinum neurotoxin type b' 'Botulinum toxin type b'
 'Rimabotulinumtoxinb']_|_[('DailyMed', array(['botulinum%20toxin%20type%20b'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/neurobloc'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004143', 'HP_0000975', 'HP_0000473', 'HP_0000726',
       'EFO_1000632', 'EFO_0000275', 'HP_0001257', 'HP_0200042',
       'HP_0002307'], dtype=object), 'count': 9}_|_[ENSG00000220205]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and is indicated for torticollis and has 8 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201731,"Cl.OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1_|_JWEXHQAEWHKGCW-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEBIVOLOL HYDROCHLORIDE_|_2007.0_|_4.0_|_CHEMBL434394_|_False_|_True_|_['Bystolic' 'Nebivolol hydrochloride']_|_['Nebivolol hcl' 'Nebivolol hydrochloride' 'R-067555' 'R067555' 'RO67555']_|_[('DailyMed', array(['nebivolol%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537', 'EFO_0000712'], dtype=object), 'count': 2}_|_[ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for hypertension and stroke."
CHEMBL1732,"CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21_|_LUZRJRNZXALNLM-JGRZULCMSA-N_|_Small molecule_|_True_|_DIHYDROERGOTAMINE_|_1946.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['9,10-dihydroergotamine' 'Dihydroergotamine' 'MAP-0004' 'MAP0004'
 'Neomigran']_|_[('PubChem', array(['104171355', '124883195', '144204372', '170465012', '26751735',
       '50104427', '90341683'], dtype=object)), ('Wikipedia', array(['Dihydroergotamine'], dtype=object)), ('drugbank', array(['DB00320'], dtype=object)), ('chEBI', array(['4562'], dtype=object))]_|_['CHEMBL1200517']_|_{'rows': array(['MONDO_0100431', 'MONDO_0005277', 'MONDO_0005277', 'MONDO_0005475'],
      dtype=object), 'count': 4}_|_[ENSG00000179546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and is indicated for migraine disorder and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1743005,"nan_|_nan_|_Antibody_|_False_|_DACETUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Dacetuzumab' 'HU-S2C6' 'HUS2C6' 'SGN-40']_|_nan_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_0005952', 'EFO_0001378', 'EFO_0000403'],
      dtype=object), 'count': 4}_|_[ENSG00000101017]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL1771,"COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1_|_GKTWGGQPFAXNFI-HNNXBMFYSA-N_|_Small molecule_|_True_|_CLOPIDOGREL_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Grepid' 'Iscover' 'Plavix']_|_['Clopidogrel' 'Clopidogrel 1a-pharma' 'Clopidogrel acino'
 'Clopidogrel apotex' 'Clopidogrel benzenesulfonate'
 'Clopidogrel besilate' 'Clopidogrel besylate' 'Clopidogrel hexal'
 'Clopidogrel sandoz' 'Clopidogrel-ratiopharm' 'NSC-758613' 'R 130964'
 'R-130964' 'SR 25990' 'SR-25990' 'Zyllt']_|_[('PubChem', array(['49666065', '49666423'], dtype=object)), ('Wikipedia', array(['Clopidogrel'], dtype=object)), ('drugbank', array(['DB00758'], dtype=object)), ('chEBI', array(['37941'], dtype=object))]_|_['CHEMBL1083385']_|_{'rows': array(['EFO_0000712', 'MONDO_0000831', 'EFO_0003777', 'EFO_0003764',
       'HP_0002140', 'EFO_0000612', 'EFO_1000985', 'EFO_0000764',
       'EFO_0008583', 'EFO_0003106', 'EFO_0005672', 'EFO_0003144',
       'EFO_1000860', 'EFO_0001645', 'EFO_0007328', 'EFO_0006859',
       'EFO_0000275', 'EFO_0002615', 'EFO_0004265', 'EFO_0004264',
       'EFO_0002950', 'EFO_0000180', 'EFO_0000717', 'EFO_0000612',
       'EFO_0003914', 'EFO_0004277', 'EFO_0003869', 'MONDO_0004979',
       'EFO_0009315', 'HP_0030680', 'EFO_0004265', 'MONDO_0002009',
       'EFO_0003875', 'EFO_0008585', 'EFO_0001645', 'EFO_0000556',
       'EFO_0000712', 'EFO_0003870', 'EFO_0000266', 'EFO_0003913',
       'EFO_0002429', 'EFO_0004286', 'EFO_0000319', 'EFO_0009686',
       'MONDO_0007915', 'EFO_0005672', 'EFO_0009086', 'MONDO_0100096',
       'EFO_1001375', 'MP_0001914', 'EFO_0007541', 'HP_0002239',
       'EFO_0003876', 'EFO_0003884', 'EFO_0001361', 'EFO_0000556',
       'HP_0002140', 'HP_0004419', 'MONDO_0005148'], dtype=object), 'count': 59}_|_[ENSG00000169313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 8 approved and 50 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1950553,"Nc1nc(OCCc2ccc(Cl)cc2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O_|_WUCQGGOGHZRELS-LSCFUAHRSA-N_|_Small molecule_|_False_|_SONEDENOSON_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MRE-0094' 'MRE0094' 'Mre0094' 'Sonedenoson']_|_[('drugbank', array(['DB12443'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1001459'], dtype=object), 'count': 1}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL206834,"Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1_|_ZGBAJMQHJDFTQJ-DEOSSOPVSA-N_|_Small molecule_|_False_|_BAFETINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bafetinib' 'CNS-9' 'INNO-406' 'NS-187']_|_[('drugbank', array(['DB11851'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008315', 'EFO_0000095'], dtype=object), 'count': 2}_|_[ENSG00000097007,ENSG00000254087]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2107859,"nan_|_nan_|_Unknown_|_False_|_ROZROLIMUPAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Rozrolimupab' 'SYM-001' 'SYM001']_|_nan_|_nan_|_{'rows': array(['EFO_0007160'], dtype=object), 'count': 1}_|_[ENSG00000187010]_|_Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2107885,"nan_|_nan_|_Enzyme_|_False_|_RETEPLASE_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Rapilysin' 'Retavase']_|_['BM 06.022' 'BM-06.022' 'BM-06022' 'Ecokinase' 'Retavase' 'Reteplase'
 'Reteplase, recombinant' 'Reteplase,recombinant' 'Retevase']_|_[('DailyMed', array(['reteplase'], dtype=object)), ('DrugCentral', array(['5044'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rapilysin'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000712', 'EFO_0008585', 'EFO_0003144', 'EFO_0000612',
       'HP_0004419'], dtype=object), 'count': 5}_|_[ENSG00000104368]_|_Enzyme drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 1 investigational indication."
CHEMBL2108290,"nan_|_nan_|_Protein_|_False_|_EPOETIN THETA_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Biopoin' 'Eporatio']_|_['Epoetin theta']_|_[('DrugCentral', array(['5007'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0004272'], dtype=object), 'count': 2}_|_[ENSG00000187266]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for chronic kidney disease and anemia (phenotype)."
CHEMBL2108594,"nan_|_nan_|_Protein_|_False_|_EPTOTERMIN ALFA_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Osigraft']_|_['Bmp-7' 'Bone morphogenetic protein 7' 'Eptotermin alfa' 'Hbmp7'
 'Opgenra' 'Osigraft' 'Osteogenic protein 1' 'Rh-polypeptide-52']_|_[('DrugCentral', array(['5175'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/osigraft'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004260', 'EFO_0004616', 'EFO_0003944'], dtype=object), 'count': 3}_|_[ENSG00000138696,ENSG00000204217,ENSG00000115170,ENSG00000107779]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for bone disease and tibia fracture and has 1 investigational indication."
CHEMBL2108708,"nan_|_nan_|_Antibody drug conjugate_|_False_|_YTTRIUM Y 90 CLIVATUZUMAB TETRAXETAN_|_nan_|_3.0_|_nan_|_False_|_False_|_['Hpam4-cide']_|_['90HY-PAM4' '90Y-HPAM4' '90Y-HPAMA4' 'HPAM-4-DOTA' 'HPAM-DOTA HY-PAM4'
 'HPAM4-DOTA' 'IMMU-107' 'S9S0HY-PAM4'
 'Yttrium (90y) clivatuzumab tetraxetan'
 'Yttrium y 90 clivatuzumab tetraxetan']_|_nan_|_nan_|_{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}_|_[ENSG00000215182]_|_Antibody drug conjugate drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL214796,"FC(F)(F)c1ccc(Nc2ncnc3cc(-c4ncccc4C(F)(F)F)ccc23)cc1_|_VTANGSDRFFLTSQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_NGD-8243_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['MK-2295' 'MK-2295-005' 'Ngd-8243']_|_nan_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000196689]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2325741,"NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1_|_JDUBGYFRJFOXQC-KRWDZBQOSA-N_|_Small molecule_|_False_|_CAPIVASERTIB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Truqap']_|_['AZC5363' 'AZD-5363' 'AZD5363' 'Azd 5363' 'Azd-5363' 'Capivasertib']_|_[('drugbank', array(['DB12218'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011962', 'EFO_0005537', 'EFO_0003060', 'EFO_0000707',
       'EFO_0000096', 'MONDO_0008170', 'MONDO_0008315', 'EFO_0000673',
       'MONDO_0001056', 'MONDO_0002974', 'MONDO_0007254', 'EFO_1000251',
       'EFO_0000616', 'EFO_0001378', 'MONDO_0004992', 'EFO_0000503',
       'EFO_0000228', 'EFO_0003869', 'EFO_0001642', 'EFO_0007532',
       'MONDO_0016642', 'Orphanet_145'], dtype=object), 'count': 22}_|_[ENSG00000105221,ENSG00000117020,ENSG00000142208]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and has 22 investigational indications."
CHEMBL317094,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@H]1C(=O)O_|_KLZWOWYOHUKJIG-BPUTZDHNSA-N_|_Small molecule_|_False_|_IMIDAPRIL_|_1993.0_|_4.0_|_nan_|_False_|_True_|_['Tanatril']_|_['Hipertene' 'Imidapril' 'Imidapril hcl' 'Imidapril hydrochloride'
 'Imidapril monohydrochloride' 'TA 6366' 'TA-6366']_|_[('Wikipedia', array(['Imidapril'], dtype=object)), ('drugbank', array(['DB11783'], dtype=object))]_|_['CHEMBL3183293']_|_{'rows': array(['EFO_1001496', 'EFO_0000319', 'MONDO_0001134'], dtype=object), 'count': 3}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for cardiovascular disease and has 2 investigational indications."
CHEMBL361812,"O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2_|_LDXDSHIEDAPSSA-OAHLLOKOSA-N_|_Small molecule_|_False_|_RAMATROBAN_|_2000.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BAY U 3405' 'BAY-U-3405' 'Baynas' 'EN 137774' 'EN-137774' 'Ramatroban']_|_[('PubChem', array(['144206069', '170465980'], dtype=object)), ('Wikipedia', array(['Ramatroban'], dtype=object)), ('drugbank', array(['DB13036'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000006638,ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 2 investigational indications."
CHEMBL3707243,"C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1.Cc1ccc(S(=O)(=O)[O-])cc1.O_|_UOWOLENSDISMPG-UHFFFAOYSA-M_|_Small molecule_|_False_|_GLYCOPYRRONIUM TOSYLATE_|_2018.0_|_4.0_|_CHEMBL1201335_|_False_|_True_|_['Qbrexza']_|_['DRM-04' 'DRM04' 'Glycopyrronium tosilate hydrate'
 'Glycopyrronium tosylate']_|_nan_|_nan_|_{'rows': array(['EFO_1000632', 'HP_0000975', 'EFO_0004269', 'EFO_0000341',
       'MONDO_0004247'], dtype=object), 'count': 5}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved indications."
CHEMBL3707399,"nan_|_nan_|_Small molecule_|_False_|_CX1739_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CX-1739' 'Cx1739']_|_nan_|_nan_|_nan_|_[ENSG00000152578,ENSG00000125675,ENSG00000120251,ENSG00000155511]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL3833368,"CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)O)C(=O)C2.CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1_|_INBJJAFXHQQSRW-STOWLHSFSA-N_|_Small molecule_|_False_|_RUCAPARIB CAMSYLATE_|_2016.0_|_4.0_|_CHEMBL1173055_|_False_|_True_|_['Rubraca']_|_['C0-338' 'CO-338' 'PF-1367338-BW' 'Rucaparib camsylate']_|_[('DailyMed', array(['rucaparib%20camsylate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003893', 'EFO_0000673', 'MONDO_0008170',
       'EFO_0001075'], dtype=object), 'count': 5}_|_[ENSG00000143799,ENSG00000041880,ENSG00000129484]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 3 approved and 2 investigational indications."
CHEMBL4297598,"C[C@@H](C(=O)Nc1ccc(Cl)cc1)C1CCC(c2ccnc3ccc(F)cc23)CC1_|_KRTIYQIPSAGSBP-KLAILNCOSA-N_|_Small molecule_|_False_|_LINRODOSTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS 986205' 'BMS-986205' 'Bms-986205' 'F 001287' 'F-001287' 'F001287'
 'Linrodostat' 'ONO 7701' 'ONO-7701' 'ONO7701']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINRODOSTAT/relevant/1/'],
      dtype=object))]_|_['CHEMBL4298147']_|_{'rows': array(['MONDO_0002334', 'EFO_0003060', 'MONDO_0001056', 'EFO_0000756',
       'MONDO_0002334', 'MONDO_0002898', 'MONDO_0004992', 'EFO_0000616',
       'EFO_0000616', 'EFO_0006859', 'EFO_0000519', 'EFO_0000294',
       'EFO_0000199', 'EFO_0000182'], dtype=object), 'count': 14}_|_[ENSG00000131203]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."
CHEMBL4298124,"nan_|_nan_|_Antibody_|_False_|_DOSTARLIMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Jemperli']_|_['Dostarlimab' 'Dostarlimab gxly' 'GSK-4057190' 'GSK4057190' 'TSR-042'
 'Tsr 042' 'Tsr-042' 'WBP-285']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0018944', 'EFO_1000465', 'EFO_0000181',
       'EFO_0006859', 'EFO_0002618', 'MONDO_0011962', 'EFO_1001951',
       'MONDO_0002165', 'EFO_0005537', 'MONDO_0004992', 'EFO_0001378',
       'MONDO_0002691', 'Orphanet_145', 'EFO_0000756', 'MONDO_0007254',
       'EFO_1000657', 'MONDO_0002974', 'EFO_0003893', 'MONDO_0005184',
       'EFO_0000691', 'EFO_0000702', 'EFO_0004288', 'MONDO_0008170',
       'MONDO_0021251', 'EFO_0003968', 'EFO_0001061', 'EFO_0003060',
       'MONDO_0021063', 'EFO_0000588'], dtype=object), 'count': 30}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 26 investigational indications."
CHEMBL517140,"CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1_|_WROHEWWOCPRMIA-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK189254_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GSK189254' 'Gsk189254']_|_[('Wikipedia', array(['GSK-189,254'], dtype=object))]_|_['CHEMBL2031739']_|_{'rows': array(['MONDO_0021107'], dtype=object), 'count': 1}_|_[ENSG00000101180]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL656,"COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314_|_BRUQQQPBMZOVGD-XFKAJCMBSA-N_|_Small molecule_|_True_|_OXYCODONE_|_1950.0_|_4.0_|_nan_|_True_|_True_|_['Proladone' 'Xtampza er']_|_['(-)-14-hydroxydihydrocodeinone' '14-hydroxydihydrocodeinone' 'Dihydrone'
 'IDS-NO-002' 'N02AA05' 'NSC-19043' 'Oxicone' 'Oxycodone' 'Oxycodone cii'
 'Oxymorphone 3-methyl ether' 'PF-00345439' 'PTI-821' 'Pavinal' 'Pti 821'
 'Remoxy' 'Xtampza']_|_[('DailyMed', array(['oxycodone'], dtype=object)), ('Wikipedia', array(['Oxycodone'], dtype=object)), ('drugbank', array(['DB00497'], dtype=object)), ('chEBI', array(['7852'], dtype=object))]_|_['CHEMBL1200890' 'CHEMBL3989826']_|_{'rows': array(['HP_0030833', 'EFO_0801084', 'EFO_0003890', 'EFO_0004253',
       'EFO_0004616', 'EFO_0003843', 'EFO_0004270', 'EFO_0010072',
       'MONDO_0002491', 'EFO_1000786', 'HP_0012532', 'HP_0003419',
       'EFO_0000668', 'HP_0012532', 'EFO_0010702', 'MONDO_0004992',
       'HP_0003418', 'MONDO_0005180', 'MONDO_0001583', 'EFO_0005611',
       'HP_0000989', 'HP_0003419', 'EFO_1001951', 'EFO_0005762',
       'EFO_0007486', 'EFO_1000999', 'EFO_1001919', 'EFO_0006859',
       'EFO_0003890', 'EFO_0001069', 'EFO_1000786', 'EFO_1001331',
       'HP_0008419', 'EFO_0004616', 'MONDO_0005178', 'EFO_0004209',
       'EFO_0003843', 'EFO_0009842', 'MONDO_0002367', 'EFO_0003843'],
      dtype=object), 'count': 40}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and has 4 approved and 29 investigational indications. This drug has a black box warning from the FDA."
CHEMBL704,"Nc1ccc(O)c(C(=O)O)c1_|_KBOPZPXVLCULAV-UHFFFAOYSA-N_|_Small molecule_|_False_|_MESALAMINE_|_1987.0_|_4.0_|_nan_|_False_|_True_|_['Apriso' 'Asacol' 'Asacol hd' 'Canasa' 'Coltec ec' 'Delzicol' 'Ipocol'
 'Lialda' 'Mesalamine' 'Mesren mr' 'Mezavant xl' 'Octasa' 'Pentasa'
 'Pentasa sr' 'Rowasa' 'Salofalk' 'Sfrowasa']_|_['Benzoic acid, 5-amino-2-hydroxy-' 'Fisalamine' 'Iialda' 'MAX-002'
 'Mesalamine' 'Mesalazine' 'Mesalazine ' 'NSC-38877']_|_[('DailyMed', array(['mesalamine'], dtype=object)), ('PubChem', array(['104171289', '11112235', '144203935', '144208808', '144213442',
       '170464840', '17389224', '26752847', '49681712'], dtype=object)), ('Wikipedia', array(['Mesalazine'], dtype=object)), ('drugbank', array(['DB00244'], dtype=object)), ('chEBI', array(['6775'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005628', 'EFO_0007168', 'EFO_1001293', 'EFO_0003767',
       'MONDO_0005835', 'EFO_0008572', 'EFO_0009959', 'HP_0002253',
       'EFO_1001951', 'EFO_0000729', 'EFO_0000555', 'EFO_0004232',
       'EFO_0003872', 'EFO_0000384', 'EFO_0005406', 'EFO_1001294',
       'EFO_0000764', 'MONDO_0004235'], dtype=object), 'count': 18}_|_[ENSG00000132170,ENSG00000012779,ENSG00000073756,ENSG00000095303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and is indicated for proctitis and ulcerative colitis and has 16 investigational indications."
CHEMBL1092,"Cl.OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1_|_QDWJJTJNXAKQKD-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIHEXYPHENIDYL HYDROCHLORIDE_|_1949.0_|_4.0_|_CHEMBL1490_|_False_|_True_|_['Agitane' 'Artane' 'Bentex' 'Broflex' 'Tremin'
 'Trihexyphenidyl hydrochloride']_|_['Aparkane' 'Benzhexol' 'Benzhexol hydrochloride' 'Cyclodol' 'Cyclodolum'
 'NSC-757357' 'Parcopane' 'Romparkin' 'Sedrina' 'Trihexyphenidyl HCl'
 'Trihexyphenidyl hcl' 'Trihexyphenidyl hydrochloride'
 'Trihexyphenidyli hydrochloridum' 'Triphedinon']_|_[('DailyMed', array(['trihexyphenidyl%20hydrochloride'], dtype=object)), ('PubChem', array(['144204826', '170464756', '26747667', '26747668', '50107036',
       '50107037', '50107038', '56422445', '855814'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1949."
CHEMBL1201020,"CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C.O=P(O)(O)O_|_CGDDQFMPGMYYQP-UHFFFAOYSA-N_|_Small molecule_|_True_|_DISOPYRAMIDE PHOSPHATE_|_1977.0_|_4.0_|_CHEMBL517_|_False_|_True_|_['Dirythmin' 'Dirythmin-sa' 'Disopyramide phosphate' 'Isomide cr'
 'Norpace' 'Norpace cr' 'Rythmodan ret']_|_['Dirythmin sa' 'Diso-duriles' 'Disopyramide phosphate' 'NSC-756744'
 'Rythmodan' 'SC-13957' 'SC-7031 PHOSPHATE']_|_[('DailyMed', array(['disopyramide%20phosphate'], dtype=object)), ('PubChem', array(['50106185', '855629'], dtype=object)), ('chEBI', array(['4658'], dtype=object))]_|_nan_|_{'rows': array(['HP_0004308', 'EFO_0004269', 'EFO_0003144', 'EFO_0000275'],
      dtype=object), 'count': 4}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and is indicated for ventricular arrhythmia and cardiac arrhythmia and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1707,"CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl_|_PGYPOBZJRVSMDS-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOPERAMIDE HYDROCHLORIDE_|_1976.0_|_4.0_|_CHEMBL841_|_False_|_True_|_['Arret' 'Diah-limit' 'Diaquitte' 'Diareze' 'Diarrhoea relief' 'Diasorb'
 'Diocalm' 'Diocaps' 'Dioraleze' 'Entrocalm' 'Gppe pack' 'Imodium'
 'Imodium Advanced' 'Imodium a-d' 'Imodium a-d ez chews' 'Imodium classic'
 'Imodium ibs relief' 'Imodium instant melts' 'Imodium instants'
 'Imodium liquicaps' 'Lodiar' 'Loperagen' 'Loperamide hydrochloride'
 'Norimode' 'Normaloe']_|_['Loperamide hcl' 'Loperamide hydrochloride' 'Loperamidi hydrochloridum'
 'NSC-696356' 'R 18,553' 'R-18553']_|_[('DailyMed', array(['loperamide%20hydrochloride'], dtype=object)), ('PubChem', array(['11533030', '26747556', '26747557', '50106525', '50125622',
       '56422888'], dtype=object)), ('chEBI', array(['6533'], dtype=object))]_|_nan_|_{'rows': array(['HP_0002014'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and is indicated for diarrhea. This drug has a black box warning from the FDA."
CHEMBL1738758,"CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1_|_QHLVBNKYJGBCQJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ONVANSERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['NMS-1286937' 'NMS-P937' 'Nms-1286937' 'Onvansertib' 'PCM-075']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ONVANSERTIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15110'], dtype=object))]_|_['CHEMBL4298158' 'CHEMBL1774489']_|_{'rows': array(['EFO_0000616', 'EFO_1000984', 'EFO_0000702', 'EFO_0000222',
       'EFO_1001779', 'MONDO_0008315', 'EFO_0000616', 'MONDO_0005184'],
      dtype=object), 'count': 8}_|_[ENSG00000166851]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL2028987,"CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O.CC(=O)O_|_AUTFSFUMNFDPLH-KYMMNHPFSA-N_|_Protein_|_False_|_DEGARELIX ACETATE_|_2008.0_|_4.0_|_CHEMBL415606_|_False_|_True_|_['Firmagon']_|_['Degarelix (as acetate)' 'Degarelix acetate' 'Degarelix acetate hydrate'
 'FE-200486' 'FE200486' 'FE200486 (FREE BASE)']_|_[('DailyMed', array(['degarelix%20acetate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001663', 'MONDO_0008315', 'MONDO_0008315', 'EFO_0000673'],
      dtype=object), 'count': 4}_|_[ENSG00000109163]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 1 investigational indication."
CHEMBL2103883,"O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1_|_OFZJKCQENFPZBH-UHFFFAOYSA-N_|_Small molecule_|_False_|_AVATROMBOPAG_|_2018.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Akr-501' 'Avatrombopag' 'E-5501' 'E5501' 'YM-301477' 'YM-477']_|_[('drugbank', array(['DB11995'], dtype=object))]_|_['CHEMBL2105758']_|_{'rows': array(['HP_0001873', 'EFO_0006927', 'EFO_0007160', 'HP_0001915',
       'EFO_0001421', 'MP_0001914', 'HP_0001873', 'MONDO_0002245',
       'EFO_0001421'], dtype=object), 'count': 9}_|_[ENSG00000117400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 6 investigational indications."
CHEMBL2106710,"Cl.Oc1ccc2c(c1)C(Cc1c[nH]cn1)CC2_|_OYKZVKWXOWICFI-UHFFFAOYSA-N_|_Small molecule_|_False_|_FADOLMIDINE HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL2104262_|_False_|_False_|_[]_|_['Fadolmidine hcl' 'Fadolmidine hydrochloride' 'MPV-2426'
 'Radolmidine hydrochloride']_|_nan_|_nan_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL2108253,"nan_|_nan_|_Antibody_|_False_|_ARCITUMOMAB_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Cea-scan']_|_['Arcitumomab' 'IMMU 4' 'IMMU-4']_|_[('DrugCentral', array(['5127'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/cea-scan'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004142', 'EFO_0006887'], dtype=object), 'count': 2}_|_[ENSG00000105388]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for colorectal neoplasm and radiologic finding."
CHEMBL2109516,"nan_|_nan_|_Antibody_|_False_|_SS1(DSFV)-PE38_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['SS1(DSFV)-PE38' 'Ss1(dsfv)-pe38']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0002618', 'MONDO_0002087', 'MONDO_0008903',
       'MONDO_0008170', 'MONDO_0002974', 'EFO_0006859', 'EFO_0000588',
       'MONDO_0002158'], dtype=object), 'count': 9}_|_[ENSG00000102854]_|_Antibody drug with a maximum clinical trial phase of I (across all indications) and has 9 investigational indications."
CHEMBL2110774,"CN(C)CCOC(C)(c1ccccc1)c1ccc(Cl)cc1_|_KKHPNPMTPORSQE-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORPHENOXAMINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Chlorphenoxamine']_|_[('drugbank', array(['DB09007'], dtype=object))]_|_['CHEMBL2105980']_|_{'rows': array(['HP_0000989', 'MONDO_0005271'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for pruritus and allergic disease."
CHEMBL255863,"Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1_|_HHZIURLSWUIHRB-UHFFFAOYSA-N_|_Small molecule_|_True_|_NILOTINIB_|_2007.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['AMN 107' 'AMN-107' 'AMN107' 'NSC-747599' 'Nilotinib']_|_[('PubChem', array(['124894351', '124894352', '99460838'], dtype=object)), ('Wikipedia', array(['Nilotinib'], dtype=object)), ('drugbank', array(['DB04868'], dtype=object)), ('chEBI', array(['52172'], dtype=object))]_|_['CHEMBL1201740']_|_{'rows': array(['MONDO_0005180', 'EFO_0002617', 'MONDO_0005180', 'EFO_0000565',
       'EFO_0001075', 'EFO_0000220', 'MONDO_0004992', 'EFO_0005543',
       'MONDO_0000437', 'EFO_0000756', 'MONDO_0004643', 'EFO_1000251',
       'MONDO_0007739', 'EFO_1001968', 'MONDO_0021063', 'MONDO_0004975',
       'MONDO_0013730', 'EFO_0000339', 'EFO_0001361', 'EFO_0000222',
       'MONDO_0007254', 'HP_0009588', 'EFO_0000717', 'EFO_0000616',
       'EFO_0000389', 'MONDO_0008978', 'EFO_1001106', 'EFO_1001512',
       'EFO_0000616', 'MONDO_0020547', 'EFO_0000339', 'MONDO_0002171',
       'MONDO_0011719'], dtype=object), 'count': 33}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and is indicated for chronic myelogenous leukemia and has 30 investigational indications. This drug has a black box warning from the FDA."
CHEMBL3301668,"CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O_|_NSTRIRCPWQHTIA-DTRKZRJBSA-N_|_Protein_|_False_|_CARBETOCIN_|_nan_|_4.0_|_nan_|_False_|_True_|_['Duratocin' 'Duratocin long acting' 'Pabal']_|_['Carbetocin' 'FE 992097' 'FE-992097' 'LV-101']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CARBETOCIN/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB01282'], dtype=object)), ('chEBI', array(['59204'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009579', 'MONDO_0008300', 'EFO_1001863'], dtype=object), 'count': 3}_|_[ENSG00000180914]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and has 3 investigational indications."
CHEMBL343448,"C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O_|_OHRURASPPZQGQM-GCCNXGTGSA-N_|_Protein_|_False_|_ROMIDEPSIN_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Istodax']_|_['Depsipeptide' 'FK-228' 'FK228' 'FR-901228' 'FR901228' 'NSC-630176'
 'Romidepsin']_|_[('DailyMed', array(['romidepsin'], dtype=object)), ('PubChem', array(['144206460'], dtype=object)), ('drugbank', array(['DB06176'], dtype=object)), ('chEBI', array(['61080'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0006861', 'EFO_0000183', 'EFO_1001951', 'EFO_0000224',
       'EFO_0000403', 'EFO_0002499', 'EFO_1001051', 'EFO_0000565',
       'EFO_1000785', 'MONDO_0004192', 'EFO_0003032', 'MONDO_0008170',
       'EFO_0000569', 'EFO_0000764', 'EFO_1001465', 'EFO_0000255',
       'EFO_0003060', 'EFO_1000984', 'EFO_1001469', 'EFO_0000641',
       'EFO_0005537', 'EFO_0000095', 'EFO_0000180', 'EFO_0002913',
       'EFO_0000574', 'EFO_0000211', 'EFO_0001378', 'EFO_0000616',
       'EFO_0002618', 'EFO_0000702', 'MONDO_0001187', 'MONDO_0018906',
       'EFO_0000503', 'MONDO_0004992', 'MONDO_0015760', 'EFO_0000756',
       'EFO_0000501', 'MONDO_0008315', 'EFO_0005952', 'MONDO_0000430',
       'EFO_0002501', 'MONDO_0005184'], dtype=object), 'count': 42}_|_[ENSG00000116478,ENSG00000171720,ENSG00000094631,ENSG00000196591,ENSG00000108840,ENSG00000061273,ENSG00000147099,ENSG00000163517,ENSG00000068024,ENSG00000048052,ENSG00000100429]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 6 approved and 36 investigational indications."
CHEMBL3707297,"nan_|_nan_|_Antibody_|_False_|_CG250 177LU_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CG250' 'Cg250 (177lu)' 'Cg250 177lu']_|_nan_|_nan_|_{'rows': array(['EFO_0000681'], dtype=object), 'count': 1}_|_[ENSG00000107159]_|_Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3707354,"nan_|_nan_|_Small molecule_|_False_|_ABT-560_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['Abt-560']_|_nan_|_nan_|_nan_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug."
CHEMBL3989978,"nan_|_nan_|_Oligonucleotide_|_False_|_PREXIGEBERSEN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BP-100-1.01/L-Grb2' 'BP-1001' 'L-grb-2 antisense' 'Prexigebersen']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000177885]_|_Oligonucleotide drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4297235,"nan_|_nan_|_Unknown_|_False_|_OMBIPEPIMUT-S_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['DSP-7888' 'Ombipepimut-s']_|_nan_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000198', 'EFO_0000519', 'EFO_1000026'],
      dtype=object), 'count': 4}_|_[ENSG00000184937]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297290,"C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(C3CCOCC3)ncc2c(=O)[nH]1_|_GWGNPYYVGANHRJ-GDBMZVCRSA-N_|_Small molecule_|_False_|_TOVINONTRINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['68722' 'AF-68722' 'AF68722' 'CK-1598' 'CK1598' 'IMR-687' 'Imr-687'
 'Tovinontrine']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TOVINONTRINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011382', 'Orphanet_848', 'EFO_0003144'], dtype=object), 'count': 3}_|_[ENSG00000160191]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4303525,"CC1(C)CC[C@]2(NC(=O)C(C)(F)F)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1_|_RJCWBNBKOKFWNY-IDPLTSGASA-N_|_Small molecule_|_False_|_OMAVELOXOLONE_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Skyclarys']_|_['Omaveloxolone' 'RTA 408' 'RTA-408' 'Skyclarys']_|_nan_|_nan_|_{'rows': array(['EFO_0001421', 'MONDO_0007254', 'MONDO_0100339', 'EFO_0000756'],
      dtype=object), 'count': 4}_|_[ENSG00000116044]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for friedreich ataxia and has 3 investigational indications."
CHEMBL4650290,"nan_|_nan_|_Antibody_|_False_|_GC1118_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GC1118' 'Gc1118']_|_nan_|_nan_|_{'rows': array(['EFO_0000503', 'EFO_0000519'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL6318,"CC/C(=C(\c1ccc(I)cc1)c1ccc(OCCN2CCCC2)cc1)c1ccccc1_|_JJKOTMDDZAJTGQ-DQSJHHFOSA-N_|_Small molecule_|_False_|_IDOXIFENE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CB 7432' 'CB-7432' 'Idoxifene' 'SB-223030']_|_[('Wikipedia', array(['Idoxifene'], dtype=object))]_|_nan_|_nan_|_[ENSG00000140009,ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1168,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21_|_HDACQVRGBOVJII-JBDAPHQKSA-N_|_Small molecule_|_True_|_RAMIPRIL_|_1991.0_|_4.0_|_nan_|_False_|_True_|_['Altace' 'Lopace' 'Ramipril' 'Ranace' 'Tritace']_|_['C09AA05' 'Cardace' 'Corpril' 'Delix' 'Ecator' 'HOE 498' 'HOE-498'
 'Hopace' 'NSC-758933' 'Pramace' 'Ramace' 'Ramipres' 'Ramipril' 'Triatec'
 'Unipril' 'Vesdil']_|_[('DailyMed', array(['ramipril'], dtype=object)), ('PubChem', array(['144204259', '170464731', '49664947'], dtype=object)), ('Wikipedia', array(['Ramipril'], dtype=object)), ('drugbank', array(['DB00178'], dtype=object)), ('chEBI', array(['8774'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0000401', 'EFO_0000400', 'EFO_0004285',
       'EFO_0001645', 'EFO_0003914', 'EFO_0000319', 'EFO_0000195',
       'MONDO_0002462', 'EFO_0003911', 'EFO_0008583', 'EFO_0003777',
       'EFO_0003086', 'EFO_0000685', 'MONDO_0100096', 'EFO_0000712',
       'EFO_0000589', 'EFO_0000537', 'EFO_0000275', 'MONDO_0007915',
       'EFO_1001375', 'EFO_0000612', 'HP_0003124', 'EFO_0000373',
       'EFO_0002546', 'EFO_0003144', 'MONDO_0005147', 'MONDO_0005148'],
      dtype=object), 'count': 28}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 9 approved and 19 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1182833,"COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2_|_ILVYCEVXHALBSC-OTBYEXOQSA-N_|_Small molecule_|_False_|_MIVACURIUM_|_1992.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BW B109OU' 'BW-B109OU' 'Mivacurium' 'Mivacurium cation' 'Mivacurium ion']_|_[('PubChem', array(['144206462', '50112723'], dtype=object)), ('drugbank', array(['DB01226'], dtype=object)), ('chEBI', array(['6958'], dtype=object))]_|_['CHEMBL984']_|_{'rows': array(['HP_0001410'], dtype=object), 'count': 1}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and has 1 investigational indication."
CHEMBL1200376,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccccc1)C(=O)CO_|_SOQJPQZCPBDOMF-YCUXZELOSA-N_|_Small molecule_|_False_|_BETAMETHASONE BENZOATE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_['Uticort']_|_['Betamethasone 17-benzoate' 'Betamethasone benzoate' 'W 5975' 'W-5975']_|_nan_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982.
CHEMBL1200569,"Cn1c(=O)c2c(ncn2C)n(C)c1=O.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_RCQXSQPPHJPGOF-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAFFEINE CITRATE_|_1999.0_|_4.0_|_CHEMBL113_|_False_|_True_|_['Cafcit' 'Caffeine citrate' 'Gencebok' 'Peyona'
 'Peyona (previously nymusa)']_|_['Caffeine citrate' 'Caffeine mixture with citric acid'
 'Caffeine, citrated' 'Citrated caffeine']_|_[('DailyMed', array(['caffeine%20citrate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/gencebok',
       'https://www.ema.europa.eu/en/medicines/human/EPAR/peyona-previously-nymusa'],
      dtype=object)), ('PubChem', array(['144203650', '170464929'], dtype=object))]_|_nan_|_{'rows': array(['HP_0001298', 'EFO_0003917', 'EFO_0003843', 'MONDO_0004567',
       'EFO_0001421', 'EFO_1001158', 'MONDO_0005299', 'HP_0002104'],
      dtype=object), 'count': 8}_|_[ENSG00000163485,ENSG00000170425,ENSG00000282608,ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for apnea and has 7 investigational indications."
CHEMBL1275,"CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21.CS(=O)(=O)O_|_UWCVGPLTGZWHGS-ZORIOUSZSA-N_|_Small molecule_|_False_|_PERGOLIDE MESYLATE_|_1988.0_|_4.0_|_CHEMBL531_|_True_|_True_|_['Celance' 'Pergolide mesylate' 'Permax']_|_['LY 127809' 'LY-127809' 'NSC-319773' 'NSC-758442' 'Pergolide mesilate'
 'Pergolide mesylate' 'Pergolide methanesulfonate']_|_[('PubChem', array(['11533039', '144204371', '170465250', '50106872', '56422469'],
      dtype=object)), ('chEBI', array(['8021'], dtype=object))]_|_nan_|_nan_|_[ENSG00000149295,ENSG00000151577,ENSG00000169676,ENSG00000069696,ENSG00000184845]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1988. It was withdrawn in at least one region."
CHEMBL128,"CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1_|_KQKPFRSPSRPDEB-UHFFFAOYSA-N_|_Small molecule_|_False_|_SUMATRIPTAN_|_1992.0_|_4.0_|_nan_|_False_|_True_|_['Imitrex' 'Sumatriptan' 'Tosymra']_|_['Dfn-11' 'Dfn-11 (sumatriptan injection)' 'N02CC01' 'Sumatriptan']_|_[('DailyMed', array(['sumatriptan'], dtype=object)), ('PubChem', array(['144205081', '170465377', '49679316'], dtype=object)), ('Wikipedia', array(['Sumatriptan'], dtype=object)), ('drugbank', array(['DB00669'], dtype=object)), ('chEBI', array(['10650'], dtype=object))]_|_['CHEMBL1201150']_|_{'rows': array(['EFO_0001073', 'EFO_0003843', 'MONDO_0005475', 'MONDO_0005475',
       'MONDO_0005277', 'MONDO_0100431', 'MONDO_0005277'], dtype=object), 'count': 7}_|_[ENSG00000179546,ENSG00000135312]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for migraine disorder and has 4 investigational indications."
CHEMBL1743081,"nan_|_nan_|_Antibody_|_False_|_TRALOKINUMAB_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Adbry' 'Adtralza']_|_['CAT-354' 'Tralokinumab']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0000274', 'EFO_0000768', 'HP_0000964',
       'EFO_0002618', 'MONDO_0004979', 'EFO_0004192'], dtype=object), 'count': 7}_|_[ENSG00000169194]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for atopic eczema and eczematoid dermatitis and has 5 investigational indications."
CHEMBL1888176,"O=C(O[C@H]1C[C@H]2CC[C@@H](C1)[N+]21CCCC1)C(O)(c1ccccc1)c1ccccc1_|_OYYDSUSKLWTMMQ-JKHIJQBDSA-N_|_Small molecule_|_False_|_TROSPIUM_|_2004.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Trospium' 'Trospium cation' 'Trospium ion']_|_[('PubChem', array(['50112692'], dtype=object)), ('drugbank', array(['DB00209'], dtype=object))]_|_['CHEMBL3084748']_|_{'rows': array(['EFO_0006865', 'EFO_0000341', 'EFO_1000781', 'HP_0000103',
       'MONDO_0005090', 'HP_0000020', 'EFO_1000781'], dtype=object), 'count': 7}_|_[ENSG00000133019,ENSG00000181072]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 4 approved and 3 investigational indications."
CHEMBL1929396,"Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1_|_LDXYBEHACFJIEL-HNNXBMFYSA-N_|_Small molecule_|_False_|_ANAGLIPTIN_|_2012.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Anagliptin' 'CWP-403' 'SK-0403' 'Sk-0403' 'Suiny']_|_[('drugbank', array(['DB12417'], dtype=object))]_|_['CHEMBL1929387']_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2012 and has 1 investigational indication."
CHEMBL2106195,"Cc1cccc([C@H](C)c2c[nH]cn2)c1C.Cl_|_VPNGEIHDPSLNMU-MERQFXBCSA-N_|_Small molecule_|_False_|_DEXMEDETOMIDINE HYDROCHLORIDE_|_1999.0_|_4.0_|_CHEMBL778_|_False_|_True_|_['Dexmedetomidine accord' 'Dexmedetomidine hydrochloride' 'Igalmi'
 'Precedex']_|_['Cepedex' 'Dexdomitor' 'Dexdor' 'Dexmedetomidine hcl'
 'Dexmedetomidine hydrochloride' 'Igalmi' 'Sedadex' 'Sileo']_|_[('DailyMed', array(['dexmedetomidine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/dexmedetomidine-accord'],
      dtype=object)), ('chEBI', array(['31472'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000713', 'MONDO_0005090', 'MONDO_0003544', 'EFO_0005411',
       'EFO_0003843', 'MONDO_0043510', 'EFO_1001454', 'EFO_0009267'],
      dtype=object), 'count': 8}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 8 investigational indications."
CHEMBL2107830,"OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O_|_OBWASQILIWPZMG-QZMOQZSNSA-N_|_Small molecule_|_False_|_EMPAGLIFLOZIN_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Bi 10773' 'Jardiance']_|_['BI 10773' 'BI-10773' 'Bi10773' 'Empagliflozin']_|_[('DailyMed', array(['empagliflozin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance'],
      dtype=object)), ('drugbank', array(['DB09038'], dtype=object)), ('chEBI', array(['82720'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000982', 'EFO_0004593', 'HP_0002902', 'MONDO_0005147',
       'EFO_0000660', 'HP_0031273', 'EFO_0003144', 'EFO_0000474',
       'Orphanet_364', 'EFO_0000195', 'MONDO_0002009', 'EFO_0000694',
       'EFO_0000666', 'HP_0001919', 'EFO_1001121', 'EFO_0000400',
       'HP_0001943', 'EFO_0003086', 'EFO_0008583', 'EFO_0003095',
       'EFO_0000612', 'MONDO_0017147', 'EFO_1001482', 'EFO_0003884',
       'EFO_0000384', 'EFO_0000729', 'HP_0001541', 'EFO_0002614',
       'MONDO_0005148', 'EFO_0000401', 'EFO_0004253', 'EFO_1001496'],
      dtype=object), 'count': 32}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 30 investigational indications."
CHEMBL2107842,"nan_|_nan_|_Protein_|_False_|_ALBINTERFERON ALFA-2B_|_nan_|_3.0_|_nan_|_False_|_False_|_['Albuferon']_|_['Albinterferon alfa-2b' 'Interferon-alfa-2b']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003047', 'EFO_0004239', 'EFO_0004220'],
      dtype=object), 'count': 4}_|_[ENSG00000142166,ENSG00000159110]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL2108724,"nan_|_nan_|_Protein_|_True_|_SEMAGLUTIDE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Ozempic' 'Rybelsus' 'Wegovy']_|_['NN-9535' 'NN9535' 'NNC 0113-0217' 'NNC-0113-0217' 'Nn9535' 'Semaglutide']_|_[('DailyMed', array(['semaglutide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0003095', 'EFO_0000660', 'MONDO_0004979', 'EFO_0000712',
       'MONDO_0005180', 'EFO_0000401', 'EFO_0001645', 'HP_0000938',
       'EFO_1001006', 'MONDO_0005147', 'MONDO_0002009', 'EFO_0003768',
       'MONDO_0005148', 'MONDO_0007079', 'HP_0002140', 'EFO_0000400',
       'MONDO_0004975', 'EFO_0001073', 'EFO_1001249'], dtype=object), 'count': 19}_|_[ENSG00000112164]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for type 2 diabetes mellitus and diabetes mellitus and has 17 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109604,"nan_|_nan_|_Antibody_|_False_|_CAMOTESKIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AEVI-007' 'Aevi-007' 'CERC-007' 'Camoteskimab' 'MEDI-2338' 'MEDI2338']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-126'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007135', 'EFO_0000341', 'EFO_0001378', 'EFO_0000616'],
      dtype=object), 'count': 4}_|_[ENSG00000150782]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL290352,"CCSCc1ccc2c(c1)c1c3c(c4c5cc(CSCC)ccc5n5c4c1n2[C@H]1C[C@](O)(C(=O)OC)[C@]5(C)O1)CNC3=O_|_SCMLRESZJCKCTC-KMYQRJGFSA-N_|_Small molecule_|_False_|_CEP-1347_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CEP-1347' 'Cep-1347' 'KT-1575' 'KT-7515' 'KT7515']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000073803,ENSG00000130758,ENSG00000139625,ENSG00000006432,ENSG00000173327]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL3039545,"nan_|_nan_|_Protein_|_False_|_LUSPATERCEPT_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Reblozyl']_|_['ACE-536' 'Luspatercept' 'Luspatercept aamt']_|_[('DailyMed', array(['luspatercept-aamt'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004272', 'Orphanet_848', 'EFO_1001996', 'HP_0001915',
       'EFO_0004251', 'EFO_0000198', 'MONDO_0002280', 'EFO_1001996'],
      dtype=object), 'count': 8}_|_[ENSG00000105329,ENSG00000092969,ENSG00000119699]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 5 approved and 3 investigational indications."
CHEMBL305660,"CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1_|_MJJALKDDGIKVBE-UHFFFAOYSA-N_|_Small molecule_|_False_|_EBASTINE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Ebastine' 'LAS W-090' 'LAS-W-090' 'RP 64305' 'RP-64305']_|_[('PubChem', array(['144205778', '170465995', '26758025', '90340626'], dtype=object)), ('Wikipedia', array(['Ebastine'], dtype=object)), ('drugbank', array(['DB11742'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000555', 'MONDO_0005271'], dtype=object), 'count': 2}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 2 investigational indications."
CHEMBL328560,"NS(=O)(=O)c1ccc(N2CCCCS2(=O)=O)cc1_|_HMHVCUVYZFYAJI-UHFFFAOYSA-N_|_Small molecule_|_False_|_SULTHIAME_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ospolot']_|_['RIKER 594' 'RIKER-594' 'Sulthiame' 'Sultiame']_|_[('PubChem', array(['170465788'], dtype=object)), ('Wikipedia', array(['Sultiame'], dtype=object)), ('drugbank', array(['DB08329'], dtype=object)), ('chEBI', array(['32171'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003918', 'EFO_0000474'], dtype=object), 'count': 2}_|_[ENSG00000104267,ENSG00000168748,ENSG00000133742,ENSG00000164879,ENSG00000131686,ENSG00000074410,ENSG00000118298,ENSG00000107159,ENSG00000167434,ENSG00000185015,ENSG00000169239,ENSG00000174990]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for epilepsy and has 1 investigational indication."
CHEMBL3301585,"nan_|_nan_|_Antibody drug conjugate_|_False_|_PINATUZUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ACD-22-VCMMAE' 'ACD-22VCMMAE' 'ACD22-VCMMAE' 'DCDT-2980S' 'DCDT2980S'
 'FCU-2703' 'FCU2703' 'Pinatuzumab vedotin' 'RG-7593' 'RO-5541072-000'
 'RO-5541072000' 'RO5541072-000']_|_nan_|_nan_|_{'rows': array(['MONDO_0018906', 'EFO_0000095', 'EFO_0000403'], dtype=object), 'count': 3}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014,ENSG00000012124]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3545388,CCN1CCC(c2cc(F)cc(S(C)(=O)=O)c2)CC1_|_PHRDGRSMZPOCAB-UHFFFAOYSA-N_|_Small molecule_|_False_|_SERIDOPIDINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Acr343' 'Seridopidine']_|_nan_|_nan_|_nan_|_[ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3707294,"nan_|_nan_|_Antibody_|_False_|_DEPATUXIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABT-806' 'Anti-egfr mab abt-806' 'Anti-egfr moab abt-806'
 'Depatuxizumab']_|_nan_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0000228'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4068611,"Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1_|_WANIDIGFXJFFEL-SANMLTNESA-N_|_Small molecule_|_False_|_RELACORILANT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CORT125134' 'Cort 125134' 'Cort-125134' 'Relacorilant']_|_[('drugbank', array(['DB14976'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_1000796', 'EFO_0000673', 'EFO_1000797',
       'MONDO_0008170', 'MONDO_0008315', 'EFO_1000251', 'EFO_0003099',
       'MONDO_0005184'], dtype=object), 'count': 9}_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL4298085,"nan_|_nan_|_Antibody_|_False_|_FIANLIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Fianlimab' 'REGN-3767' 'REGN3767' 'Regn3767']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FIANLIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0003060', 'EFO_0003968', 'EFO_0000616',
       'EFO_0000756', 'MONDO_0004992', 'EFO_0005537'], dtype=object), 'count': 7}_|_[ENSG00000089692]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL4594505,"nan_|_nan_|_Antibody_|_True_|_TECLISTAMAB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Tecvayli']_|_['BCMAxCD3' 'JNJ-64007957' 'Jnj 64007957' 'Teclistamab' 'Teclistamab cqyv']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TECLISTAMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0001642', 'MONDO_0004992', 'EFO_0001378'], dtype=object), 'count': 3}_|_[ENSG00000048462,ENSG00000198851,ENSG00000160654,ENSG00000167286]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for multiple myeloma and has 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL538867,"CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C_|_HZLFFNCLTRVYJG-WWGOJCOQSA-N_|_Small molecule_|_False_|_PATIDEGIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['FIN-5' 'IP-9' 'IP9 FREE BASE' 'IPI 926' 'IPI-926' 'IPI-926 FREE BASE'
 'Ipi-926' 'Patidegib' 'Saridegib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PATIDEGIB/relevant/1/'],
      dtype=object)), ('Wikipedia', array(['IPI-926'], dtype=object)), ('drugbank', array(['DB12655'], dtype=object))]_|_['CHEMBL2105764']_|_{'rows': array(['EFO_0000616', 'EFO_0004193', 'EFO_0000333', 'MONDO_0007187',
       'EFO_0002618', 'EFO_0004193'], dtype=object), 'count': 6}_|_[ENSG00000128602]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL9194,"CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1_|_MOTJMGVDPWRKOC-QPVYNBJUSA-N_|_Small molecule_|_False_|_ATRASENTAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-127722' 'Atrasentan']_|_[('Wikipedia', array(['Atrasentan'], dtype=object)), ('drugbank', array(['DB06199'], dtype=object))]_|_['CHEMBL2106068']_|_{'rows': array(['MONDO_0008315', 'EFO_0000673', 'MONDO_0002367', 'MONDO_0008315',
       'EFO_0000401', 'EFO_0004194', 'EFO_1000158', 'MONDO_0002087',
       'MONDO_0002158', 'MONDO_0008170'], dtype=object), 'count': 10}_|_[ENSG00000151617]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL932,"OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1_|_IZEKFCXSFNUWAM-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPYRIDAMOLE_|_1961.0_|_4.0_|_nan_|_False_|_True_|_['Attia' 'Cerebrovase 100' 'Cerebrovase 25' 'Dipyridamole' 'Iv persantine'
 'Modaplate' 'Ofcram pr' 'Persantin' 'Persantin ret' 'Persantine'
 'Pyridantin' 'Vasyrol']_|_['B01AC07' 'Dipyridamole' 'NSC-515776' 'RA-8']_|_[('DailyMed', array(['dipyridamole'], dtype=object)), ('PubChem', array(['104171148', '11111116', '11111117', '11113358', '124879978',
       '124879980', '124879984', '144203684', '170464694', '26747068',
       '26751580', '26751581', '489152', '50104213', '50104215',
       '56423153', '85231021', '855977', '90340971'], dtype=object)), ('Wikipedia', array(['Dipyridamole'], dtype=object)), ('drugbank', array(['DB00975'], dtype=object)), ('chEBI', array(['4653'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001645', 'MONDO_0100096', 'EFO_1001375', 'EFO_1002000',
       'EFO_0000685', 'MONDO_0008170', 'MONDO_0011382', 'EFO_0000764',
       'EFO_0003777', 'EFO_0000712', 'EFO_0003913', 'EFO_0002615',
       'EFO_1000965', 'EFO_0000537', 'HP_0004419', 'EFO_0002618'],
      dtype=object), 'count': 16}_|_[ENSG00000138735,ENSG00000065989,ENSG00000172572,ENSG00000139053,ENSG00000185527,ENSG00000186642,ENSG00000205268,ENSG00000115252,ENSG00000160191,ENSG00000133256,ENSG00000113448,ENSG00000184588,ENSG00000156973,ENSG00000132915,ENSG00000152270,ENSG00000095464,ENSG00000113231,ENSG00000112541,ENSG00000123360,ENSG00000105650,ENSG00000154678,ENSG00000073417,ENSG00000171408,ENSG00000112759]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1961 and has 3 approved and 13 investigational indications."
CHEMBL1090089,"Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21_|_JYYLVUFNAHSSFE-UHFFFAOYSA-N_|_Small molecule_|_False_|_PAMAPIMOD_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pamapimod' 'R-1503' 'R1503' 'RO 4402257' 'Ro-4402257']_|_[('chEBI', array(['90685'], dtype=object))]_|_nan_|_nan_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1200612,"CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1.Cl_|_IVHBBMHQKZBJEU-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIBUCAINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1086_|_False_|_True_|_['Heavy solution nupercaine' 'Nupercainal' 'Nupercaine']_|_['Cincaine chloride' 'Cinchocaine hydrochloride' 'Dibucaine hcl'
 'Dibucaine hydrochloride' 'NSC-756724']_|_[('PubChem', array(['26747981', '26747982', '50107328', '56422129', '855998'],
      dtype=object)), ('chEBI', array(['59735'], dtype=object))]_|_nan_|_nan_|_[ENSG00000183873,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200757,"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1.[Br-].[Br-]_|_NPIJXCQZLFKBMV-YTGGZNJNSA-L_|_Small molecule_|_False_|_PANCURONIUM BROMIDE_|_1972.0_|_4.0_|_CHEMBL185073_|_False_|_True_|_['Mioblock' 'Pancuronium bromide' 'Pavulon']_|_['Bromurex' 'Mioblock' 'NSC-293162' 'ORG NA 97' 'ORG-NA 97' 'ORG-NA-97'
 'Pancuronium bromide']_|_[('PubChem', array(['144205586', '50106734'], dtype=object)), ('chEBI', array(['7908'], dtype=object))]_|_nan_|_nan_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972."
CHEMBL1201506,"nan_|_nan_|_Antibody drug conjugate_|_True_|_GEMTUZUMAB OZOGAMICIN_|_2000.0_|_4.0_|_nan_|_False_|_True_|_['Mylotarg']_|_['CDP-771' 'CMA-676' 'CMC-676' 'Gemtuzumab ozogamicin'
 'Gemtuzumab ozogamicin recombinant' 'L01XC05' 'WAY-CMA-676']_|_[('DailyMed', array(['gemtuzumab%20ozogamicin'], dtype=object)), ('DrugCentral', array(['4980'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0'],
      dtype=object)), ('Wikipedia', array(['Gemtuzumab_ozogamicin'], dtype=object))]_|_nan_|_{'rows': array(['EFO_1000309', 'EFO_0000095', 'EFO_0000222', 'EFO_0000565',
       'MONDO_0004643', 'EFO_0000224', 'EFO_0000616', 'EFO_0000198',
       'EFO_0000220'], dtype=object), 'count': 9}_|_[ENSG00000105383]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2000 and has 3 approved and 6 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1215,"CNC[C@H](O)c1cccc(O)c1_|_SONNWYBIRXJNDC-VIFPVBQESA-N_|_Small molecule_|_False_|_PHENYLEPHRINE_|_1952.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-phenylephrine' '(r)-phenylephrine' 'AB-101 (PHENYLEPHRINE)'
 'Cyclomydril' 'Duo-Medihaler' 'J8.601K' 'M-oxedrine' 'M-sympathol'
 'M-sympatol' 'M-synephrine' 'Meta-synephrine' 'Metasynephrine'
 'Phenylephrine' 'Phenylephrine minims' 'Phenylephrine, (r)-'
 'R(-)-mezaton']_|_[('PubChem', array(['11111644', '90340906'], dtype=object)), ('Wikipedia', array(['Phenylephrine'], dtype=object)), ('drugbank', array(['DB00388'], dtype=object)), ('chEBI', array(['8093'], dtype=object))]_|_['CHEMBL2062264' 'CHEMBL1200339']_|_{'rows': array(['EFO_0009688', 'EFO_1001069', 'EFO_0007328', 'EFO_0007214',
       'HP_0000989', 'EFO_0007486', 'HP_0001742', 'EFO_0005751',
       'EFO_0000712', 'HP_0001742', 'EFO_0006834', 'EFO_0006834',
       'HP_0002315', 'EFO_0007214', 'EFO_0007533', 'EFO_0008521',
       'EFO_0000319', 'EFO_0001073', 'EFO_0000178', 'EFO_0005251',
       'HP_0011499', 'EFO_0005252', 'EFO_0005251', 'EFO_0000537',
       'EFO_0009552', 'MONDO_0005129', 'HP_0100543', 'MONDO_0005271',
       'EFO_0004269', 'EFO_0009523', 'EFO_0003843', 'EFO_0003966',
       'HP_0002140', 'EFO_0003956', 'EFO_0004610', 'HP_0011950',
       'HP_0000138', 'EFO_0000616', 'HP_0012735', 'HP_0001742',
       'EFO_1000645', 'MONDO_0024355', 'EFO_1001898', 'EFO_0007214',
       'EFO_0000544', 'EFO_0000319', 'EFO_0004264', 'MONDO_0024355',
       'EFO_0003956', 'EFO_0001358'], dtype=object), 'count': 50}_|_[ENSG00000120907,ENSG00000171873,ENSG00000170214]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 13 approved and 33 investigational indications."
CHEMBL1289601,"COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O_|_WOSKHXYHFSIKNG-UHFFFAOYSA-N_|_Small molecule_|_False_|_LENVATINIB_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Kisplyx' 'Lenvima']_|_['E-7080' 'ER-203492-00' 'Lenvatinib']_|_[('PubChem', array(['137276042'], dtype=object)), ('Wikipedia', array(['Lenvatinib'], dtype=object)), ('drugbank', array(['DB09078'], dtype=object)), ('chEBI', array(['85994'], dtype=object))]_|_['CHEMBL3527309' 'CHEMBL2105704']_|_{'rows': array(['EFO_1001961', 'MONDO_0004992', 'EFO_1000158', 'MONDO_0002108',
       'MONDO_0002120', 'EFO_0000501', 'MONDO_0007576', 'EFO_0005221',
       'EFO_0000182', 'EFO_0000558', 'MONDO_0002367', 'EFO_0000231',
       'EFO_1000576', 'EFO_0001421', 'EFO_0000681', 'EFO_1001512',
       'EFO_0000349', 'EFO_0005922', 'EFO_0004142', 'EFO_0000228',
       'EFO_0000641', 'EFO_0000616', 'EFO_0000574', 'MONDO_0002974',
       'EFO_0001061', 'MONDO_0003060', 'EFO_1000796', 'MONDO_0008315',
       'EFO_0003891', 'MONDO_0001056', 'EFO_0000756', 'MONDO_0003060',
       'MONDO_0004992', 'MONDO_0024477', 'EFO_0002617', 'MONDO_0008170',
       'EFO_0003086', 'MONDO_0001528', 'EFO_0000702', 'MONDO_0002108',
       'EFO_1001471', 'EFO_0004230', 'EFO_0000637', 'EFO_0003060',
       'MONDO_0005184', 'EFO_0000178', 'EFO_0000691', 'EFO_1001961',
       'EFO_0000616', 'EFO_0003060', 'EFO_1001901', 'EFO_0000181',
       'EFO_0000681', 'EFO_0002892', 'EFO_0005543', 'EFO_0008528',
       'EFO_0000503', 'EFO_0000571', 'MONDO_0011962', 'MONDO_0005184',
       'EFO_0000588', 'EFO_1001012', 'EFO_1000657', 'MONDO_0007254',
       'EFO_1000613'], dtype=object), 'count': 65}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 58 investigational indications."
CHEMBL142635,"COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1_|_HRRBJVNMSRJFHQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_NAFTOPIDIL_|_1999.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Flivas' 'NSC-759293' 'Naftopidil']_|_[('PubChem', array(['104171197', '144203756', '170466026', '26719853', '26751791',
       '49681769', '50104483', '90340768'], dtype=object)), ('drugbank', array(['DB12092'], dtype=object))]_|_['CHEMBL1257069' 'CHEMBL1532139' 'CHEMBL1593765']_|_{'rows': array(['EFO_0000536'], dtype=object), 'count': 1}_|_[ENSG00000171873]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1999 and has 1 investigational indication."
CHEMBL1492,"CN1CCC(OC(c2ccccc2)c2ccccc2)CC1_|_OWQUZNMMYNAXSL-UHFFFAOYSA-N_|_Small molecule_|_False_|_DIPHENYLPYRALINE_|_1982.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Diphenylpyraline']_|_[('PubChem', array(['11112289', '50123603', '50123604'], dtype=object)), ('Wikipedia', array(['Diphenylpyraline'], dtype=object)), ('drugbank', array(['DB01146'], dtype=object)), ('chEBI', array(['59788'], dtype=object))]_|_['CHEMBL1564']_|_{'rows': array(['MONDO_0005271'], dtype=object), 'count': 1}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for allergic disease."
CHEMBL27810,"CCN(CC)C(=O)Nc1ccc(OCC(O)CNC(C)(C)C)c(C(C)=O)c1_|_JOATXPAWOHTVSZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CELIPROLOL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Celiprolol' 'Celiprolol pch']_|_[('Wikipedia', array(['Celiprolol'], dtype=object)), ('drugbank', array(['DB04846'], dtype=object))]_|_['CHEMBL1742424']_|_{'rows': array(['EFO_0000319', 'MONDO_0020066'], dtype=object), 'count': 2}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286,ENSG00000043591,ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."
CHEMBL3707276,"nan_|_nan_|_Protein_|_False_|_VOSORITIDE_|_2021.0_|_4.0_|_nan_|_False_|_True_|_['Voxzogo']_|_['BMN 111' 'BMN-111' 'Bmn 111' 'Vosoritide' 'Voxzogo']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009659', 'MONDO_0007037', 'EFO_0004260'], dtype=object), 'count': 3}_|_[ENSG00000159899]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for achondroplasia and bone disease and has 1 investigational indication."
CHEMBL403989,"Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12_|_JMGXJHWTVBGOKG-UHFFFAOYSA-N_|_Small molecule_|_False_|_TG100-801_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['TG100-801' 'Tg100-801']_|_[('drugbank', array(['DB05075'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009606', 'EFO_0003770', 'EFO_0004683'], dtype=object), 'count': 3}_|_[ENSG00000010810,ENSG00000197122,ENSG00000182866,ENSG00000176105,ENSG00000136573,ENSG00000101336,ENSG00000254087,ENSG00000111816,ENSG00000000938,ENSG00000125508,ENSG00000066468,ENSG00000128052,ENSG00000102755,ENSG00000113721,ENSG00000196411,ENSG00000077782]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4594288,"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl.O=C(O)/C=C\C(=O)O_|_TZNOWAJJWCGILX-HNUXRKMMSA-N_|_Small molecule_|_False_|_LEVAMLODIPINE MALEATE_|_2019.0_|_4.0_|_CHEMBL2111097_|_False_|_True_|_['Conjupri']_|_['Amlodipine maleate, s-' 'Levamlodipine maleate']_|_[('DailyMed', array(['levamlodipine%20maleate'], dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LEVAMLODIPINE%20MALEATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000537'], dtype=object), 'count': 1}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hypertension."
CHEMBL4650322,"C[C@H]([C@H](C(=O)Nc1cc([C@@H](CC(=O)O)C2CC2)ccc1Cl)c1ccc(Cl)cc1)C(F)(F)F_|_NCRMKIWHFXSBGZ-CNBXIYLPSA-N_|_Small molecule_|_False_|_RUNCACIGUAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Runcaciguat']_|_nan_|_nan_|_{'rows': array(['EFO_0003884', 'EFO_0003770'], dtype=object), 'count': 2}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4802154,"Cn1ccc2c([C@H](Nc3cc(Cl)c4ncc(C#N)c(NCC(C)(C)C)c4c3)c3cn(C45CC(C4)C5)nn3)cccc2c1=O_|_VFGSKBLZRDRHOI-ZAGPDIDGSA-N_|_Small molecule_|_False_|_TILPISERTIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tilpisertib']_|_nan_|_nan_|_{'rows': array(['EFO_0000729'], dtype=object), 'count': 1}_|_[ENSG00000107968]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL511099,"Cc1ccc(C23CNCC2C3)cc1_|_OFYVIGTWSQPCLF-UHFFFAOYSA-N_|_Small molecule_|_False_|_BICIFADINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Bicifadine']_|_[('drugbank', array(['DB04889'], dtype=object))]_|_['CHEMBL544862']_|_{'rows': array(['HP_0003419', 'EFO_1000783'], dtype=object), 'count': 2}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL5315118,"CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O.NC(CO)(CO)CO_|_KZSSWXACMCYLBM-RMWNCEGRSA-N_|_Small molecule_|_False_|_ILOPROST TROMETHAMINE_|_2003.0_|_4.0_|_CHEMBL494_|_False_|_True_|_['Ventavis']_|_['Ciloprost trometamol' 'Trometamol iloprost']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ventavis'],
      dtype=object))]_|_nan_|_nan_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2003."
CHEMBL551466,"O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-]_|_XLAKJQPTOJHYDR-QTQXQZBYSA-M_|_Small molecule_|_False_|_ACLIDINIUM BROMIDE_|_2012.0_|_4.0_|_CHEMBL1194325_|_False_|_True_|_['Eklira' 'Eklira genuair' 'Tudorza pressair']_|_['14115700' 'Aclidinium bromide' 'Genuair' 'LAS 34273'
 'LAS 34273 MICRONIZED' 'LAS W-330' 'LAS-34273' 'LAS-34273 MICRONIZED'
 'LAS-W-330' 'LAS34273']_|_[('DailyMed', array(['aclidinium%20bromide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair'],
      dtype=object)), ('Wikipedia', array(['Aclidinium_bromide'], dtype=object)), ('chEBI', array(['65344'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000464', 'EFO_0000341', 'EFO_0006505', 'MONDO_0004979',
       'HP_0006536', 'EFO_0003768'], dtype=object), 'count': 6}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 5 approved and 1 investigational indication."
CHEMBL63,"COc1ccc(C2CNC(=O)C2)cc1OC1CCCC1_|_HJORMJIFDVBMOB-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROLIPRAM_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(r,s)-rolipram' 'NSC-760125' 'Rolipram' 'SB-95952' 'ZK 62 711'
 'ZK-62711' 'ZK-62771']_|_[('PubChem', array(['144204223', '170465962', '26719663', '26719664', '26752319',
       '26752320', '50105263', '56422401', '85231212', '855869',
       '90341367'], dtype=object)), ('Wikipedia', array(['Rolipram'], dtype=object)), ('drugbank', array(['DB01954'], dtype=object)), ('chEBI', array(['104872'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007739', 'MONDO_0005301', 'EFO_0000618', 'MONDO_0002009'],
      dtype=object), 'count': 4}_|_[ENSG00000065989,ENSG00000113448,ENSG00000184588,ENSG00000105650]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL954,"CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1_|_GKIRPKYJQBWNGO-OCEACIFDSA-N_|_Small molecule_|_False_|_ENCLOMIPHENE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cisclomiphene' 'Clomiphene trans-form' 'Enclomifene' 'Enclomiphene'
 'ICI-46476' 'ISOMER B' 'ISOMER-B' 'Isomer B' 'Milophene' 'RMI 16,289'
 'RMI-16289' 'Rmi-16,289' 'Serophene']_|_[('PubChem', array(['50085975'], dtype=object)), ('drugbank', array(['DB06735'], dtype=object))]_|_['CHEMBL1200667']_|_{'rows': array(['MONDO_0002146', 'MONDO_0018555', 'EFO_0001073', 'EFO_0000660',
       'MONDO_0002146', 'EFO_0000545'], dtype=object), 'count': 6}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."
CHEMBL1196,"CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N_|_KCLANYCVBBTKTO-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROPARACAINE_|_1953.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Alcaine' 'Kainair' 'Ophthaine' 'Ophthetic' 'Paracaine' 'Proparacaine'
 'Proxymetacaine']_|_[('PubChem', array(['11112907', '124882712', '174006303'], dtype=object)), ('Wikipedia', array(['Proxymetacaine'], dtype=object)), ('drugbank', array(['DB00807'], dtype=object)), ('chEBI', array(['8485'], dtype=object))]_|_['CHEMBL1200464']_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1953 and has 1 investigational indication."
CHEMBL1200814,"CC(=O)Nc1nnc(S([NH-])(=O)=O)s1.[Na+]_|_MRSXAJAOWWFZJJ-UHFFFAOYSA-M_|_Small molecule_|_False_|_ACETAZOLAMIDE SODIUM_|_1990.0_|_4.0_|_CHEMBL20_|_False_|_True_|_['Acetazolamide sodium' 'Diamox']_|_['Acetazolamide Sodium' 'Acetazolamide sodium' 'Acetazolamide sodium salt'
 'Sodium acetazolamide' 'Vetamox']_|_[('chEBI', array(['31163'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001744', 'EFO_0009373', 'MONDO_0005041', 'HP_0001250'],
      dtype=object), 'count': 4}_|_[ENSG00000074410,ENSG00000167434,ENSG00000133742,ENSG00000104267]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and has 4 approved indications."
CHEMBL1208829,"COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(C(C)(C)C)cc1NS(C)(=O)=O_|_UUROSJLZNDSXRF-UHFFFAOYSA-N_|_Small molecule_|_False_|_ITX-5061_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_[]_|_[('PubChem', array(['124360067'], dtype=object))]_|_['CHEMBL3402567']_|_{'rows': array(['EFO_0004719', 'EFO_0003047'], dtype=object), 'count': 2}_|_[ENSG00000112062]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL121,"CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1_|_YASAKCUCGLMORW-UHFFFAOYSA-N_|_Small molecule_|_True_|_ROSIGLITAZONE_|_1999.0_|_4.0_|_nan_|_True_|_True_|_['Avandia']_|_['Avandamet' 'Avandaryl' 'Avandia' 'BRL-49653' 'Gaudil' 'NSC-758698'
 'Rezult' 'Rosiglitazone' 'Rosiglizole' 'Rosvel' 'TDZ-01']_|_[('PubChem', array(['144204987', '170465417', '174007204', '26748954'], dtype=object)), ('Wikipedia', array(['Rosiglitazone'], dtype=object)), ('drugbank', array(['DB00412'], dtype=object)), ('chEBI', array(['50122'], dtype=object))]_|_['CHEMBL843' 'CHEMBL1704605']_|_{'rows': array(['MONDO_0004992', 'HP_0001952', 'EFO_1001373', 'MONDO_0004979',
       'EFO_0000400', 'MONDO_0007254', 'HP_0003124', 'MONDO_0005148',
       'EFO_0001068', 'EFO_1001051', 'EFO_0003914', 'EFO_0003914',
       'EFO_0000691', 'EFO_0000616', 'MONDO_0005148', 'EFO_0006911',
       'HP_0100543', 'EFO_0004236', 'Orphanet_309005', 'EFO_0000195',
       'EFO_0007444', 'EFO_0000764', 'EFO_1001110', 'EFO_0000373',
       'EFO_0000589', 'EFO_0002614', 'EFO_0004272', 'EFO_1000785',
       'HP_0002745', 'EFO_0000685', 'EFO_0004234', 'EFO_0000764',
       'EFO_1000158', 'EFO_0000729', 'EFO_0001065', 'EFO_0001645',
       'EFO_1001249', 'EFO_0000400', 'EFO_0002546', 'EFO_1001121',
       'EFO_1000783', 'EFO_0003095', 'MONDO_0004975', 'EFO_0000537',
       'EFO_0006859', 'EFO_0000673', 'EFO_0002614'], dtype=object), 'count': 47}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 43 investigational indications. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1578,"CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C.[Br-]_|_QSFKGMJOKUZAJM-CNKDKAJDSA-M_|_Small molecule_|_False_|_ANISOTROPINE METHYLBROMIDE_|_1962.0_|_4.0_|_CHEMBL1186610_|_False_|_True_|_['Anisotropine methylbromide' 'Valpin 50']_|_['Anisotropine methylbromide' 'Methyloctatropine bromide'
 'Octatropine methylbromide' 'Octatropone bromide'
 'Octotropine methylbromide']_|_[('PubChem', array(['144204422', '144207024', '56422429', '855548'], dtype=object))]_|_nan_|_nan_|_[ENSG00000168539,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962."
CHEMBL1697737,"CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl_|_CHBRHODLKOZEPZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOTIAZEPAM_|_nan_|_4.0_|_nan_|_False_|_True_|_['Clozan']_|_['Clotiazepam']_|_[('drugbank', array(['DB01559'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230'], dtype=object), 'count': 1}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for anxiety."
CHEMBL188462,"CN[C@@H](C)C/C=C/c1cncc(OC(C)C)c1_|_RPCVIAXDAUMJJP-PZBABLGHSA-N_|_Small molecule_|_False_|_ISPRONICLINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-3480' 'Azd3480' 'Ispronicline' 'TC-01734' 'TC-1734']_|_nan_|_nan_|_{'rows': array(['EFO_0001072', 'MONDO_0005090', 'MONDO_0004975', 'EFO_0003888'],
      dtype=object), 'count': 4}_|_[ENSG00000160716,ENSG00000101204]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2062154,C[C@](Cc1c[nH]c2ccccc12)(NC(=O)OC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2)C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1_|_FVQSSYMRZKLFDR-QRCSZXLUSA-N_|_Small molecule_|_False_|_CI-988_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Ci-988' 'PD-134308']_|_nan_|_nan_|_nan_|_[ENSG00000110148]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL2105708,"Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl_|_BWTNNZPNKQIADY-UHFFFAOYSA-N_|_Small molecule_|_True_|_PONATINIB HYDROCHLORIDE_|_2012.0_|_4.0_|_CHEMBL1171837_|_False_|_True_|_['Iclusig']_|_['AP-24534 HCL' 'AP24534 HCL' 'Ponatinib hydrochloride']_|_[('DailyMed', array(['ponatinib%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_1000131', 'EFO_0000220', 'EFO_0000339',
       'MONDO_0004992'], dtype=object), 'count': 5}_|_[ENSG00000097007,ENSG00000186716]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and is indicated for acute lymphoblastic leukemia and chronic myelogenous leukemia and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2105755,"CC(C)(NC(=O)C1=C(O)[C@@H]2Oc3c(O)ccc4c3[C@@]23CCN(CC2CC2)[C@H](C4)[C@]3(O)C1)c1nc(-c2ccccc2)no1_|_AXQACEQYCPKDMV-RZAWKFBISA-N_|_Small molecule_|_False_|_NALDEMEDINE_|_2017.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Naldemedine' 'S-297995']_|_[('drugbank', array(['DB11691'], dtype=object))]_|_['CHEMBL3039508']_|_{'rows': array(['EFO_0003843', 'EFO_0000278', 'HP_0002019', 'HP_0002019',
       'MONDO_0002203'], dtype=object), 'count': 5}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 3 approved and 1 investigational indication."
CHEMBL2107349,"C[C@H](CN(C(=O)c1ccc(C#N)cc1)c1ccccn1)N1CCN(c2cccc3c2OCCO3)CC1.Cl_|_GXYZREDEYDFJPT-ZMBIFBSDSA-N_|_Small molecule_|_False_|_LECOZOTAN HYDROCHLORIDE_|_nan_|_3.0_|_CHEMBL372205_|_False_|_False_|_[]_|_['Lecozotan hcl' 'Lecozotan hydrochloride' 'SRA-333']_|_nan_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2108361,nan_|_nan_|_Enzyme_|_False_|_AMEDIPLASE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Amediplase']_|_nan_|_nan_|_nan_|_[ENSG00000122194]_|_Enzyme drug with a maximum clinical trial phase of II.
CHEMBL2108723,"nan_|_nan_|_Protein_|_False_|_PEGINTERFERON LAMBDA-1A_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-914143' 'BMS914143' 'PEG-IL-29' 'PEG-RIL-29' 'PEG-RLL-29'
 'Peginterferon lambda-1a' 'Pegylated interferon lambda']_|_nan_|_nan_|_{'rows': array(['EFO_0000694', 'EFO_0004220', 'EFO_0007304', 'MONDO_0100096',
       'EFO_0004197', 'EFO_0004239', 'EFO_0003047'], dtype=object), 'count': 7}_|_[ENSG00000243646,ENSG00000185436]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."
CHEMBL2109526,"nan_|_nan_|_Antibody_|_False_|_PG-110_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PG-110' 'Pg-110']_|_nan_|_nan_|_{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}_|_[ENSG00000134259]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL218427,"Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)NC4(C(=O)N5CCN(C(=O)[C@@H](N)CCC[N+](C)(C)C)CC5)CCOCC4)c3Cl)c2n1_|_FQVSDHOWSLEEKJ-LJAQVGFWSA-N_|_Small molecule_|_False_|_FASITIBANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Fasitibant' 'Fasitibant cation' 'Fasitibant ion' 'MEN-16132'
 'MEN-16132 FREE BASE']_|_[('drugbank', array(['DB15646'], dtype=object))]_|_['CHEMBL541758']_|_{'rows': array(['EFO_0004616'], dtype=object), 'count': 1}_|_[ENSG00000168398]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL221326,"O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1_|_NMLMACJWHPHKGR-NCOIDOBVSA-N_|_Small molecule_|_False_|_DIQUAFOSOL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Diquafosol' 'INS-365']_|_[('Wikipedia', array(['Diquafosol'], dtype=object)), ('chEBI', array(['27791'], dtype=object))]_|_['CHEMBL1767408']_|_{'rows': array(['EFO_1000906'], dtype=object), 'count': 1}_|_[ENSG00000171631,ENSG00000186912,ENSG00000175591,ENSG00000169860]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL24441,"CNCCc1ccccn1_|_UUQMNUMQCIQDMZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BETAHISTINE_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['Betahistine']_|_[('Wikipedia', array(['Betahistine'], dtype=object)), ('drugbank', array(['DB06698'], dtype=object)), ('chEBI', array(['35677'], dtype=object))]_|_['CHEMBL4303472' 'CHEMBL1451277' 'CHEMBL1446813' 'CHEMBL1464589']_|_{'rows': array(['HP_0003124', 'EFO_0001073', 'EFO_0001073', 'HP_0002321',
       'EFO_0003888', 'EFO_0004566', 'MONDO_0002009'], dtype=object), 'count': 7}_|_[ENSG00000101180,ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for vertigo and has 6 investigational indications."
CHEMBL3183409,"CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F_|_HJBWBFZLDZWPHF-UHFFFAOYSA-N_|_Small molecule_|_False_|_APALUTAMIDE_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Erleada']_|_['ARN-509' 'Apalutamide' 'Arn-509' 'JNJ-56021927']_|_[('DailyMed', array(['apalutamide'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/erleada'],
      dtype=object)), ('PubChem', array(['174007290'], dtype=object)), ('drugbank', array(['DB11901'], dtype=object))]_|_['CHEMBL4082191' 'CHEMBL4105484' 'CHEMBL4100200' 'CHEMBL4062002']_|_{'rows': array(['EFO_0000196', 'EFO_0000616', 'EFO_0000673', 'MONDO_0004992',
       'EFO_0001421', 'EFO_0001663', 'MONDO_0008315', 'EFO_0003826'],
      dtype=object), 'count': 8}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 6 approved and 2 investigational indications."
CHEMBL3545221,"nan_|_nan_|_Small molecule_|_False_|_AZD2423_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Azd2423']_|_nan_|_nan_|_{'rows': array(['EFO_0003843', 'EFO_0000341', 'EFO_0005762'], dtype=object), 'count': 3}_|_[ENSG00000121807]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3989519,"CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O.Cl.O_|_ZOMBFZRWMLIDPX-UHFFFAOYSA-N_|_Small molecule_|_False_|_DOXAPRAM HYDROCHLORIDE_|_1965.0_|_4.0_|_CHEMBL1754_|_False_|_True_|_['Dopram' 'Doxapram hydrochloride' 'Stimulexin']_|_['AHR-619' 'Doxapram hcl' 'Doxapram hydrochloride'
 'Doxapram hydrochloride hydrate' 'Doxapram hydrochloride monohydrate'
 'NSC-170958' 'NSC-760347' 'Stimulexin']_|_[('DailyMed', array(['doxapram%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004262', 'EFO_0003818'], dtype=object), 'count': 2}_|_[ENSG00000169427,ENSG00000171303]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for lung disease and has 1 investigational indication."
CHEMBL3989970,"C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F_|_JYIUNVOCEFIUIU-GHMZBOCLSA-N_|_Small molecule_|_False_|_MAVELERTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Egfr t790m inhibitor pf-06747775' 'Mavelertinib' 'PF-06747775']_|_nan_|_nan_|_{'rows': array(['EFO_0003060'], dtype=object), 'count': 1}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4298079,"nan_|_nan_|_Unknown_|_False_|_SEPHB4-HSA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Recombinant ephb4-hsa fusion protein' 'Sephb4-hsa']_|_nan_|_nan_|_{'rows': array(['EFO_0000196', 'EFO_0000616', 'EFO_0008528', 'EFO_0000181',
       'MONDO_0004986', 'MONDO_0008315', 'EFO_0000558'], dtype=object), 'count': 7}_|_[ENSG00000125266]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4298171,"COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)[O-])c3c2=O)cc1OCc1c(OC)ccc(F)c1F.C[N+](C)(C)CCO_|_IAIVRTFCYOGNBW-UHFFFAOYSA-M_|_Small molecule_|_False_|_LINZAGOLIX CHOLINE_|_2022.0_|_4.0_|_CHEMBL3668014_|_False_|_True_|_['Yselty']_|_['KLH-2109 choline' 'Linzagolix choline' 'OBE2109 choline']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yselty'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LINZAGOLIX%20CHOLINE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000131', 'EFO_0001065'], dtype=object), 'count': 2}_|_[ENSG00000109163]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for uterine leiomyoma and has 1 investigational indication."
CHEMBL4594351,"Cc1c(Cc2ccc(-n3cccn3)cc2)cc2c(c1F)CN([C@H]1COCC[C@@H]1O)C2=O_|_WFSARWQASFQZMG-VXKWHMMOSA-N_|_Small molecule_|_False_|_TAK-071_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Tak-071']_|_nan_|_nan_|_{'rows': array(['MONDO_0005180', 'MONDO_0004975'], dtype=object), 'count': 2}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4742157,"CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl_|_BVAHPPKGOOJSPU-UHFFFAOYSA-N_|_Small molecule_|_False_|_GSK-2256098_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gsk-2256098' 'Gsk2256098']_|_nan_|_nan_|_{'rows': array(['EFO_0001361', 'MONDO_0004992', 'MONDO_0016642'], dtype=object), 'count': 3}_|_[ENSG00000169398]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL52939,"COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1_|_FFYNAVGJSYHHFO-UHFFFAOYSA-N_|_Small molecule_|_False_|_SARPOGRELATE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Sarpogrelate' 'Sarpogrelate hydrochloride']_|_[('PubChem', array(['124893325', '174006666', '50112742'], dtype=object)), ('drugbank', array(['DB12163'], dtype=object))]_|_['CHEMBL541829']_|_{'rows': array(['EFO_0004265', 'MONDO_0002679'], dtype=object), 'count': 2}_|_[ENSG00000102468]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL5315064,"nan_|_nan_|_Protein_|_False_|_FOLLITROPIN DELTA_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Rekovelle']_|_['FE 999049' 'FE-999049' 'Follitropin delta']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FOLLITROPIN%20DELTA/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002775'], dtype=object), 'count': 1}_|_[ENSG00000170820]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for anovulation."
CHEMBL605525,"C=C1[C@H](O)CC(=C/C=C2\CCC[C@]3(C)[C@@H]([C@@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O_|_UHMPCVGLSKFXHR-NAQZCRMNSA-N_|_Small molecule_|_False_|_DP001_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['2MD' 'Dp001']_|_nan_|_nan_|_{'rows': array(['EFO_0003854', 'EFO_1001173', 'EFO_0003882'], dtype=object), 'count': 3}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL6966,"COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC_|_SGTNSNPWRIOYBX-UHFFFAOYSA-N_|_Small molecule_|_False_|_VERAPAMIL_|_1981.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['CP-16,533-1' 'CP-16533-1' 'CP-165331' 'Calan' 'Covera-HS' 'D-365'
 'Iproveratril' 'Isoptin' 'NSC-272306NA' 'Tarka' 'Verapamil'
 'Verapamil slow release' 'Verelan']_|_[('PubChem', array(['104171262', '124881789', '124881790', '124881792', '124881795',
       '144203851', '170464904', '174316170', '26751825', '50104518',
       '50104519', '50104520', '90340771'], dtype=object)), ('Wikipedia', array(['Verapamil'], dtype=object)), ('drugbank', array(['DB00661'], dtype=object)), ('chEBI', array(['77733'], dtype=object))]_|_['CHEMBL1280' 'CHEMBL1707604' 'CHEMBL483787']_|_{'rows': array(['HP_0004308', 'EFO_0004616', 'MONDO_0005148', 'MP_0001914',
       'EFO_0000384', 'EFO_0000275', 'MONDO_0100096', 'EFO_0003843',
       'EFO_0003890', 'EFO_0000319', 'EFO_0004269', 'EFO_0000319',
       'EFO_1001413', 'EFO_0000400', 'EFO_0003144', 'EFO_0000183',
       'EFO_0000275', 'HP_0002140', 'MONDO_0005147', 'MONDO_0004985',
       'EFO_0000537'], dtype=object), 'count': 21}_|_[ENSG00000151067,ENSG00000081248,ENSG00000157388,ENSG00000102001]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 4 approved and 16 investigational indications."
CHEMBL1094966,"CC(C)(C)NCC(O)c1ccc(O)c(CO)n1_|_VQDBNKDJNJQRDG-UHFFFAOYSA-N_|_Small molecule_|_False_|_PIRBUTEROL_|_1986.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ARA-211' 'Pirbuterol']_|_[('Wikipedia', array(['Pirbuterol'], dtype=object)), ('drugbank', array(['DB01291'], dtype=object)), ('chEBI', array(['8245'], dtype=object))]_|_['CHEMBL1997417' 'CHEMBL3989646' 'CHEMBL1200444']_|_{'rows': array(['MONDO_0004979', 'HP_0006536'], dtype=object), 'count': 2}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for asthma and airway obstruction."
CHEMBL1096885,"CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O_|_ZOCKGBMQLCSHFP-KQRAQHLDSA-N_|_Small molecule_|_False_|_VALRUBICIN_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Valstar' 'Valstar preservative free']_|_['AD 32' 'AD-32' 'NSC-246131' 'Valrubicin']_|_[('PubChem', array(['144205810'], dtype=object)), ('Wikipedia', array(['Valrubicin'], dtype=object)), ('drugbank', array(['DB00385'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008528', 'EFO_0000616', 'EFO_0000313', 'MONDO_0001187',
       'MONDO_0004647'], dtype=object), 'count': 5}_|_[ENSG00000131747]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and is indicated for neoplasm and carcinoma and has 3 investigational indications."
CHEMBL1201222,"C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN_|_VOBHXZCDAVEXEY-JSGCOSHPSA-N_|_Small molecule_|_True_|_LISDEXAMFETAMINE_|_2007.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['L-lysine-dextroamphetamine' 'Lisdexamfetamine' 'Lisdexamphetamine']_|_[('Wikipedia', array(['Lisdexamfetamine'], dtype=object)), ('drugbank', array(['DB01255'], dtype=object))]_|_['CHEMBL1201178']_|_{'rows': array(['EFO_0004701', 'MONDO_0005090', 'MONDO_0002050', 'EFO_0005924',
       'EFO_0003888', 'EFO_0002610', 'MONDO_0005301', 'MONDO_0004985',
       'EFO_0001073', 'MONDO_0002009', 'MONDO_0002277', 'EFO_0005203',
       'EFO_0005203', 'EFO_0004698', 'EFO_0003890', 'EFO_0005204',
       'MONDO_0005041', 'EFO_0003888'], dtype=object), 'count': 18}_|_[ENSG00000103546,ENSG00000165646,ENSG00000142319]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2007 and has 5 approved and 11 investigational indications. This drug has a black box warning from the FDA."
CHEMBL135400,"CN1CCN(C(=O)OC2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1_|_GBBSUAFBMRNDJC-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZOPICLONE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Zileze 3.75' 'Zileze 7.5' 'Zimovane' 'Zimovane ls']_|_['Amoban' 'Imovane' 'NSC-758463' 'RP 27267' 'RP-27267' 'Zopiclone']_|_[('PubChem', array(['124881861', '26747152', '866104'], dtype=object)), ('Wikipedia', array(['Zopiclone'], dtype=object)), ('drugbank', array(['DB01198'], dtype=object)), ('chEBI', array(['32315'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005230', 'HP_0000726', 'EFO_0003918', 'EFO_0008568',
       'MONDO_0002009', 'MONDO_0002050', 'MONDO_0005090', 'EFO_0004698',
       'EFO_0004329'], dtype=object), 'count': 9}_|_[ENSG00000022355,ENSG00000145864,ENSG00000166206,ENSG00000109158,ENSG00000011677,ENSG00000163288,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 9 investigational indications."
CHEMBL1531,"C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC_|_GCKFUYQCUCGESZ-BPIQYHPVSA-N_|_Small molecule_|_False_|_ETONOGESTREL_|_2001.0_|_4.0_|_nan_|_False_|_True_|_['Implanon' 'Nexplanon']_|_['Etonogestrel' 'Implanon' 'ORG 3236' 'ORG-3236']_|_[('DailyMed', array(['etonogestrel'], dtype=object)), ('PubChem', array(['144206191', '50113279'], dtype=object)), ('Wikipedia', array(['Etonogestrel'], dtype=object)), ('drugbank', array(['DB00294'], dtype=object)), ('chEBI', array(['50777'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000764', 'MONDO_0007915', 'EFO_0000765', 'EFO_0002950',
       'EFO_0000284', 'HP_0100607'], dtype=object), 'count': 6}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 6 investigational indications."
CHEMBL160519,"CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12_|_FKNXQNWAXFXVNW-UHFFFAOYSA-N_|_Small molecule_|_False_|_PROCATEROL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Meptin' 'Procaterol']_|_nan_|_['CHEMBL1322218']_|_{'rows': array(['MONDO_0004979', 'HP_0006536'], dtype=object), 'count': 2}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL1626,"CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1_|_YNNUSGIPVFPVBX-NHCUHLMSSA-N_|_Small molecule_|_False_|_CLEMASTINE_|_1977.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Clemastin' 'Clemastine' 'HS-592' 'NSC-756685']_|_[('PubChem', array(['11111002', '11112618', '11114089', '124882478', '152146162'],
      dtype=object)), ('Wikipedia', array(['Clemastine'], dtype=object)), ('drugbank', array(['DB00283'], dtype=object)), ('chEBI', array(['3738'], dtype=object))]_|_['CHEMBL1200795']_|_{'rows': array(['MONDO_0005271', 'EFO_0005532', 'EFO_0005854', 'EFO_0005531',
       'EFO_0003956', 'HP_0000989', 'MONDO_0002406', 'EFO_0005531',
       'EFO_0003840', 'MONDO_0005271', 'EFO_0007405', 'EFO_0007214',
       'EFO_0003929', 'EFO_0003929', 'MONDO_0005301', 'MONDO_0005301'],
      dtype=object), 'count': 16}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 6 approved and 10 investigational indications."
CHEMBL1719,"CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl_|_HVRLZEKDTUEKQH-NOILCQHBSA-N_|_Small molecule_|_False_|_OLOPATADINE HYDROCHLORIDE_|_1996.0_|_4.0_|_CHEMBL1189432_|_False_|_True_|_['Olopatadine hydrochloride' 'Opatanol' 'Pataday'
 'Pataday once daily relief' 'Pataday twice daily relief' 'Patanase'
 'Patanol' 'Pazeo']_|_['ALO-4943A' 'ALO4943A' 'Allelock' 'KW-4679' 'KW4679'
 'Olopatadine (as hydrochloride)' 'Olopatadine hcl'
 'Olopatadine hydrochloride']_|_[('DailyMed', array(['olopatadine%20hydrochloride'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/opatanol'],
      dtype=object)), ('PubChem', array(['144205795', '170465181', '49681604'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005854', 'HP_0000989', 'EFO_0003956', 'EFO_0007141'],
      dtype=object), 'count': 4}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved indications."
CHEMBL2103822,"CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2_|_PTOIAAWZLUQTIO-GXFFZTMASA-N_|_Small molecule_|_False_|_TASIMELTEON_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Hetlioz' 'Hetlioz lq']_|_['BMS-214,778' 'BMS-214778' 'Tasimelteon' 'VEC-162']_|_[('DailyMed', array(['tasimelteon'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/hetlioz'],
      dtype=object)), ('drugbank', array(['DB09071'], dtype=object)), ('chEBI', array(['79042'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0003406', 'MONDO_0024361', 'MONDO_0008434', 'EFO_0001421',
       'EFO_0004698', 'Orphanet_68335', 'EFO_0003086', 'MONDO_0002009',
       'EFO_0007462'], dtype=object), 'count': 9}_|_[ENSG00000168412,ENSG00000134640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 4 approved and 5 investigational indications."
CHEMBL2107313,"CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O_|_JSKFWUPVIZYJMR-UDOAKELVSA-N_|_Small molecule_|_False_|_BECATECARIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-181176' 'BMY-27557' 'Becatecarin' 'Deae-rebeccamycin' 'NSC-655649'
 'XL-119' 'XL119 ']_|_[('drugbank', array(['DB06362'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002367', 'EFO_0000574', 'EFO_0006861', 'EFO_1001951',
       'MONDO_0008170', 'MONDO_0003060', 'MONDO_0008903', 'EFO_0000616',
       'EFO_0000702', 'EFO_0000621'], dtype=object), 'count': 10}_|_[ENSG00000198900,ENSG00000131747,ENSG00000077097]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL2107797,"C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC_|_WWYNJERNGUHSAO-CULCCENASA-N_|_Small molecule_|_False_|_NORGESTREL_|_1968.0_|_4.0_|_nan_|_False_|_True_|_['Opill' 'Ovrette']_|_['Dl-norgestrel' 'FH-122A' 'NSC-757251' 'Norgestrel' 'Prefest' 'Previfem'
 'SH-70850' 'SH-850' 'Sprintec' 'Tri-Previfem' 'Tri-Sprintec' 'WY-3707']_|_[('DailyMed', array(['norgestrel'], dtype=object)), ('PubChem', array(['144213928'], dtype=object))]_|_nan_|_{'rows': array(['MP_0001914', 'MONDO_0011962'], dtype=object), 'count': 2}_|_[ENSG00000082175]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and is indicated for hemorrhage and has 1 investigational indication."
CHEMBL2107822,"Cc1ccc(-c2ncccn2)c(C(=O)N2C[C@H](COc3ccc(F)cn3)CC[C@H]2C)c1_|_NPFDWHQSDBWQLH-QZTJIDSGSA-N_|_Small molecule_|_False_|_FILOREXANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Filorexant' 'MK-6096']_|_[('drugbank', array(['DB12158'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0004698', 'EFO_1000783', 'MONDO_0002009'], dtype=object), 'count': 3}_|_[ENSG00000137252,ENSG00000121764]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL2107874,"nan_|_nan_|_Antibody_|_True_|_ROMOSOZUMAB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Evenity']_|_['AMG 785' 'AMG-785' 'CDP-7851' 'CDP7851' 'Romosozumab' 'Romosozumab aqqg']_|_[('DailyMed', array(['romosozumab-aqqg'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/evenity'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0000938', 'MONDO_0019019', 'EFO_0003931', 'EFO_0003882',
       'EFO_0004260', 'EFO_0003854'], dtype=object), 'count': 6}_|_[ENSG00000167941]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved and 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108747,nan_|_nan_|_Antibody_|_False_|_TORALIZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ANTI-CD154' 'ANTI-CD40L' 'ANTI-GP39' 'E-6040' 'IDEC-131' 'Toralizumab']_|_nan_|_nan_|_nan_|_[ENSG00000102245]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108964,"nan_|_nan_|_Protein_|_False_|_INSULIN, ISOPHANE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Ins hum insulat' 'Ins hum protaphane' 'Ins humulin i'
 'Ins hypurin bov isop' 'Ins hypurin pore isop' 'Ins innolet insulat'
 'Ins insulat' 'Ins insulat novolet' 'Ins insuman basal'
 'Ins insuman basal optiset' 'Ins insuman basal solostar'
 'Ins novolet hum protaphane' 'Ins pork insulat' 'Ins pur-in hum isop'
 'Penfill']_|_['Insulin injection' 'Insulin, isophane' 'Isophane (aqueous suspension)'
 'Isophane insulin']_|_nan_|_nan_|_{'rows': array(['MONDO_0005147', 'EFO_0000400', 'MONDO_0005148', 'HP_0003419'],
      dtype=object), 'count': 4}_|_[ENSG00000171105]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) and has 4 investigational indications."
CHEMBL2109267,nan_|_nan_|_Antibody_|_False_|_M195_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['M195']_|_nan_|_nan_|_nan_|_[ENSG00000105383]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL3185958,"CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_PYTMYKVIJXPNBD-UHFFFAOYSA-N_|_Small molecule_|_False_|_CLOMIPHENE CITRATE_|_1967.0_|_4.0_|_CHEMBL2355051_|_False_|_True_|_['Clomid' 'Clomiphene citrate' 'Clophene' 'Milophene' 'Serophene']_|_['Chloramiphene' 'Clomid' 'Clomifene citrate' 'Clomifeni citras'
 'Clomiphene citrate' 'Clomiphene citrate (1:1)' 'Clostilbegyt'
 'Ikaclomine' 'MER-41' 'MRL-41' 'NSC-35770' 'Pergotime']_|_[('DailyMed', array(['clomiphene%20citrate'], dtype=object)), ('PubChem', array(['144212192'], dtype=object)), ('chEBI', array(['3753'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000660', 'EFO_0000545', 'MP_0001914', 'EFO_0008560'],
      dtype=object), 'count': 4}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and has 3 approved and 1 investigational indication."
CHEMBL3544909,"C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@]2(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]12.O_|_WRLFSJXJGJBFJQ-WPUCQFJDSA-N_|_Small molecule_|_False_|_CALCIFEDIOL_|_1980.0_|_4.0_|_CHEMBL1040_|_False_|_True_|_['Calderol' 'Rayaldee']_|_['CTAP101' 'Calcidiol' 'Calcifediol' 'Calcifediol hydrate'
 'Calcifediol monohydrate' 'Ctap-101' 'Didrogyl' 'Hidroferol' 'Rayaldy'
 'U-32,070E' 'U-32070E']_|_[('DailyMed', array(['calcifediol'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0003884', 'HP_0001919', 'EFO_0000612',
       'EFO_0005754', 'EFO_0003918', 'EFO_1001173', 'EFO_0003762'],
      dtype=object), 'count': 8}_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1980 and has 3 approved and 5 investigational indications."
CHEMBL3545208,"nan_|_nan_|_Small molecule_|_False_|_AZD3161_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Azd3161']_|_nan_|_nan_|_{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}_|_[ENSG00000169432]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL371064,"CCCN1CCN(c2ccc(C(=O)NC3(C(=O)NCC#N)CCCCC3)cc2)CC1_|_LLCRBOWRJOUJAE-UHFFFAOYSA-N_|_Small molecule_|_False_|_BALICATIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AAE-581' 'AAE581' 'Balicatib']_|_[('drugbank', array(['DB12239'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003882', 'EFO_0004616'], dtype=object), 'count': 2}_|_[ENSG00000143387]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL3989921,"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C.O=C(O)/C=C\C(=O)O_|_VXZCUHNJXSIJIM-MEBGWEOYSA-N_|_Small molecule_|_False_|_NERATINIB MALEATE_|_2017.0_|_4.0_|_CHEMBL180022_|_False_|_True_|_['Nerlynx']_|_['Neratinib maleate' 'Neratinib maleate anhydrous']_|_[('DailyMed', array(['neratinib%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0000305'], dtype=object), 'count': 3}_|_[ENSG00000178568,ENSG00000146648,ENSG00000141736]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for breast cancer and breast carcinoma and has 1 investigational indication."
CHEMBL3990039,"nan_|_nan_|_Antibody_|_False_|_MARSTACIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Marstacimab' 'PF-06741086']_|_nan_|_nan_|_{'rows': array(['MONDO_0010602', 'MONDO_0018660', 'MONDO_0010604'], dtype=object), 'count': 3}_|_[ENSG00000003436]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297404,"COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1_|_ORZMUVMQJPGFOM-UHFFFAOYSA-N_|_Small molecule_|_False_|_MK-0767_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['MK 0767' 'Mk-0767' 'Mk0767']_|_[('drugbank', array(['DB12055'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148', 'EFO_0000400', 'EFO_0000195'], dtype=object), 'count': 3}_|_[ENSG00000186951,ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4298207,"nan_|_nan_|_Protein_|_False_|_ZILUCOPLAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['RA101495' 'Zilucoplan']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ZILUCOPLAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0004991', 'MONDO_0100244', 'MONDO_0100096', 'MONDO_0004976',
       'MONDO_0100244'], dtype=object), 'count': 5}_|_[ENSG00000106804]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4650343,"Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1_|_DADAEARVGOQWHV-OSYLJGHBSA-N_|_Small molecule_|_False_|_IZENCITINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Izencitinib' 'TD-1473' 'TD1473' 'Td-1473']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/IZENCITINIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000729', 'EFO_0003767', 'EFO_0000384'], dtype=object), 'count': 3}_|_[ENSG00000105639,ENSG00000162434,ENSG00000096968,ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL5315071,"nan_|_nan_|_Protein_|_False_|_TUROCTOCOG ALFA PEGOL_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Esperoct']_|_['N8-gp']_|_[('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010602'], dtype=object), 'count': 1}_|_[ENSG00000185010]_|_Protein drug with a maximum clinical trial phase of IV that was first approved in 2019 and is indicated for hemophilia a."
CHEMBL703,"C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C_|_AXOIZCJOOAYSMI-UHFFFAOYSA-N_|_Small molecule_|_True_|_SUXAMETHONIUM_|_1952.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Anectine' 'Quelicin' 'Succinylcholine' 'Succinylcholine cation'
 'Succinylcholine ion' 'Sucostrin' 'Suxamethonium' 'Suxamethonium cation'
 'Suxamethonium ion']_|_[('PubChem', array(['11111825', '90341285'], dtype=object)), ('drugbank', array(['DB00202'], dtype=object)), ('chEBI', array(['45652'], dtype=object))]_|_['CHEMBL2104486' 'CHEMBL3391771' 'CHEMBL983']_|_{'rows': array(['EFO_0000712', 'HP_0001662', 'HP_0003326'], dtype=object), 'count': 3}_|_[ENSG00000138435,ENSG00000196811,ENSG00000170175,ENSG00000135902,ENSG00000108556]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 3 investigational indications. This drug has a black box warning from the FDA."
CHEMBL902,"NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1_|_XUFQPHANEAPEMJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_FAMOTIDINE_|_1986.0_|_4.0_|_nan_|_False_|_True_|_['Famotidine' 'Famotidine preservative free'
 'Famotidine preservative free (pharmacy bulk)' 'Fluxid' 'Pepcid'
 'Pepcid ac' 'Pepcid preservative free' 'Pepcid rpd']_|_['Amfamox' 'Fadul' 'Famodil' 'Famosan' 'Famotidine' 'Famoxal' 'Ganor'
 'Gastridin' 'Gastropen' 'L 643341' 'Lecedil' 'MK-208' 'Motiax' 'Muclox'
 'NSC-757810' 'Pepcidac' 'Pepdine' 'Pepdul' 'YM-11170']_|_[('DailyMed', array(['famotidine'], dtype=object)), ('PubChem', array(['11111194', '11111195', '144203704', '144212144', '170464877',
       '26748463', '26753575', '49681730', '50106279', '85231052',
       '855518'], dtype=object)), ('TG-GATEs', array(['85'], dtype=object)), ('Wikipedia', array(['Famotidine'], dtype=object)), ('drugbank', array(['DB00927'], dtype=object)), ('chEBI', array(['4975'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'MONDO_0011382', 'EFO_0009454', 'HP_0002239',
       'EFO_1001951', 'MONDO_0004992', 'EFO_0000180', 'MONDO_0043839',
       'EFO_0000676', 'EFO_0000764', 'EFO_0004607', 'HP_0100633',
       'MONDO_0004658', 'EFO_0004232', 'EFO_0006890', 'EFO_0000641',
       'MONDO_0005178', 'HP_0004398', 'EFO_0000616', 'HP_0100749',
       'MONDO_0001056', 'MONDO_0009291', 'EFO_0000756', 'MONDO_0017287',
       'EFO_0004280', 'EFO_0000685', 'MONDO_0005090', 'EFO_0003060',
       'EFO_0003948'], dtype=object), 'count': 29}_|_[ENSG00000113749]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 9 approved and 20 investigational indications."
CHEMBL1159717,"CC(C)(C)NCC(O)c1ccccc1Cl_|_YREYLAVBNPACJM-UHFFFAOYSA-N_|_Small molecule_|_False_|_TULOBUTEROL_|_nan_|_4.0_|_nan_|_False_|_True_|_['Brelomax' 'Respacal']_|_['Atenos' 'Berachin' 'Bremax' 'Chlibamol' 'Hokunalin' 'Lobuterol'
 'NSC-758643' 'Tulobuterol' 'Tulobuterol hcl' 'Tulobuterol hydrochloride']_|_[('PubChem', array(['90340621'], dtype=object)), ('Wikipedia', array(['Tulobuterol'], dtype=object)), ('drugbank', array(['DB12248'], dtype=object))]_|_['CHEMBL1256478']_|_{'rows': array(['HP_0006536'], dtype=object), 'count': 1}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV and is indicated for airway obstruction."
CHEMBL1200395,"Cc1ccccc1C(OCCN(C)C)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)O_|_MMMNTDFSPSQXJP-UHFFFAOYSA-N_|_Small molecule_|_False_|_ORPHENADRINE CITRATE_|_1959.0_|_4.0_|_CHEMBL900_|_False_|_True_|_['Norflex' 'Orphenadrine citrate']_|_['NSC-757238' 'Orphenadine citrate' 'Orphenadrine (citrate)'
 'Orphenadrine Citrate' 'Orphenadrine citrate'
 'Orphenadrine dihydrogen citrate']_|_[('DailyMed', array(['orphenadrine%20citrate'], dtype=object)), ('PubChem', array(['11532864', '144204876', '144207092', '144211396', '170464910',
       '26748176'], dtype=object)), ('chEBI', array(['7790'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843'], dtype=object), 'count': 1}_|_[ENSG00000103546,ENSG00000176884,ENSG00000183454,ENSG00000273079,ENSG00000105464,ENSG00000116032,ENSG00000161509,ENSG00000198785,ENSG00000196639,ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for pain."
CHEMBL1200927,"CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O_|_DBAKFASWICGISY-DASCVMRKSA-N_|_Small molecule_|_False_|_DEXCHLORPHENIRAMINE MALEATE_|_1981.0_|_4.0_|_CHEMBL1201353_|_False_|_True_|_['Dexchlorpheniramine maleate' 'Polaramine']_|_['Chlorpheniramine d-form maleate' 'Chlorpheniramine maleate, (s)-'
 'D-chlorpheniramine maleate' 'Dexchlorpheniramine maleate' 'NSC-759156']_|_[('DailyMed', array(['dexchlorpheniramine%20maleate'], dtype=object)), ('PubChem', array(['26747471', '26747472', '49681543', '50106017'], dtype=object)), ('drugbank', array(['DB09555'], dtype=object)), ('chEBI', array(['4465'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0005531', 'EFO_0007141', 'EFO_1001417', 'MONDO_0005271',
       'EFO_0005854', 'EFO_0003958', 'MONDO_0005301', 'EFO_0003956',
       'EFO_0005532', 'EFO_0007533'], dtype=object), 'count': 10}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1981 and has 7 approved and 3 investigational indications."
CHEMBL1201067,"CC(O)C(=O)O.OC(CCN1CCCCC1)(c1ccccc1)C1CC2C=CC1C2_|_GLPUBCPQWZZFNJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_BIPERIDEN LACTATE_|_1961.0_|_4.0_|_CHEMBL1101_|_False_|_True_|_['Akineton']_|_['Biperiden lactate']_|_nan_|_nan_|_{'rows': array(['MONDO_0043510'], dtype=object), 'count': 1}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and has 1 investigational indication."
CHEMBL1201269,"CC(C)(N)Cc1ccc(Cl)cc1_|_ZCKAMNXUHHNZLN-UHFFFAOYSA-N_|_Small molecule_|_False_|_CHLORPHENTERMINE_|_1982.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Chlorphentermine']_|_[('PubChem', array(['29216103'], dtype=object)), ('Wikipedia', array(['Chlorphentermine'], dtype=object)), ('drugbank', array(['DB01556'], dtype=object)), ('chEBI', array(['3646'], dtype=object))]_|_['CHEMBL1200595']_|_nan_|_[ENSG00000108576]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1201589,"nan_|_nan_|_Antibody_|_True_|_OMALIZUMAB_|_2003.0_|_4.0_|_nan_|_False_|_True_|_['Xolair']_|_['CT-P39' 'Ct-p39' 'GBR 310' 'Gbr-310' 'Hs632' 'IGE25' 'OLIZUMAB'
 'Omalizumab' 'Omalizumab biosimilar - synermore' 'RG-3648' 'RHUMAB-E25'
 'SYN-008' 'Syn008']_|_[('DailyMed', array(['omalizumab'], dtype=object)), ('DrugCentral', array(['4972'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/xolair'],
      dtype=object)), ('Wikipedia', array(['Omalizumab'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0007486', 'MONDO_0021063', 'EFO_0007187', 'EFO_0009482',
       'Orphanet_2314', 'MONDO_0001085', 'EFO_1001890', 'MONDO_0004979',
       'MONDO_0100096', 'EFO_1000685', 'EFO_0000540', 'EFO_0009661',
       'EFO_0000274', 'EFO_0005532', 'EFO_0007425', 'MONDO_0005271',
       'EFO_0007369', 'EFO_0008507', 'EFO_0005854', 'EFO_1001881',
       'MONDO_0007915', 'EFO_0003956', 'EFO_0005531', 'HP_0006536',
       'EFO_1001463', 'EFO_0000341', 'EFO_0004232'], dtype=object), 'count': 27}_|_[ENSG00000211891]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 24 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1490,"OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1_|_HWHLPVGTWGOCJO-UHFFFAOYSA-N_|_Small molecule_|_False_|_TRIHEXYPHENIDYL_|_1949.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Apo-trihex' 'NSC-12268' 'Trihexyphenidyl']_|_[('PubChem', array(['50105266', '90341555'], dtype=object)), ('Wikipedia', array(['Trihexyphenidyl'], dtype=object)), ('drugbank', array(['DB00376'], dtype=object)), ('chEBI', array(['9720'], dtype=object))]_|_['CHEMBL1092']_|_{'rows': array(['MONDO_0005180', 'MONDO_0003441'], dtype=object), 'count': 2}_|_[ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and is indicated for parkinson disease and has 1 investigational indication."
CHEMBL2105646,"CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C_|_ORFLZNAGUTZRLQ-ZMBVWFSWSA-N_|_Protein_|_False_|_LARAZOTIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AT-2347' 'Larazotide']_|_[('drugbank', array(['DB05645'], dtype=object))]_|_['CHEMBL2103815']_|_{'rows': array(['EFO_0001060', 'EFO_0001060'], dtype=object), 'count': 2}_|_[ENSG00000117971,ENSG00000080644]_|_Protein drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2106155,"COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1.Cl_|_OJIIZIWOLTYOBS-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENCAINIDE HYDROCHLORIDE_|_1986.0_|_4.0_|_CHEMBL315838_|_True_|_True_|_[]_|_['Encainide hcl' 'Encainide hydrochloride' 'MJ 9067-1' 'MJ-9067'
 'MJ-9067-1']_|_[('PubChem', array(['144207047'], dtype=object)), ('chEBI', array(['59880'], dtype=object))]_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1986. It was withdrawn in at least one region."
CHEMBL2107862,"nan_|_nan_|_Oligonucleotide_|_False_|_RINTATOLIMOD_|_nan_|_3.0_|_nan_|_False_|_False_|_['Ampligen']_|_['Atvogen' 'Poly i : poly c12u' 'Poly i: poly c12u' 'Rintatolimod']_|_nan_|_nan_|_{'rows': array(['EFO_0000756', 'MONDO_0044881', 'MONDO_0100096', 'EFO_0005537',
       'EFO_0004540', 'EFO_0001423', 'EFO_0000673', 'MONDO_0007254',
       'EFO_0006861', 'EFO_0000764', 'MONDO_0002158', 'EFO_0002618',
       'MONDO_0008170', 'MONDO_0004658'], dtype=object), 'count': 14}_|_[ENSG00000164342]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."
CHEMBL2108131,"nan_|_nan_|_Unknown_|_False_|_PLASMINOGEN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Human plasminogen' 'Plasma trypsinogen' 'Plasminogen' 'Profibrinolysin']_|_nan_|_nan_|_{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}_|_[ENSG00000171560,ENSG00000171564,ENSG00000171557]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2109288,"nan_|_nan_|_Antibody drug conjugate_|_False_|_BIVATUZUMAB MERTANSINE_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['BIWA-1-DM1' 'Bivatuzumab mertansine' 'Biwa-4 mertansine']_|_nan_|_nan_|_nan_|_[ENSG00000026508,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of I."
CHEMBL2109667,"nan_|_nan_|_Antibody_|_False_|_SIMTUZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AB-0024' 'AB0024' 'GS-6624' 'Simtuzumab']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0001422', 'EFO_0002618', 'EFO_0004268',
       'MONDO_0044903', 'EFO_0000616', 'EFO_0000768'], dtype=object), 'count': 7}_|_[ENSG00000134013]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL2109678,"nan_|_nan_|_Antibody_|_False_|_HUJ591 177LU_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['HUJ591' 'Huj591 (177lu)' 'Huj591 177lu']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315'], dtype=object), 'count': 1}_|_[ENSG00000086205]_|_Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL2110730,"CSCC[C@H](N)C(=O)N[C@@]1(C(=O)O)CS(=O)(=O)[C@H]2[C@H](C(=O)O)[C@H]21_|_VOYCNOJFAJAILW-CAMHOICYSA-N_|_Small molecule_|_False_|_POMAGLUMETAD METHIONIL ANHYDROUS_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-2140023' 'LY2140023' 'Ly2140023' 'Pomaglumetad methionil anhydrous']_|_nan_|_['CHEMBL2105707']_|_{'rows': array(['MONDO_0005090', 'EFO_0004701', 'EFO_0005407', 'EFO_0001358'],
      dtype=object), 'count': 4}_|_[ENSG00000198822,ENSG00000164082]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL278020,"CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1_|_ALWKGYPQUAPLQC-UHFFFAOYSA-N_|_Small molecule_|_False_|_NEOSTIGMINE_|_2013.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Miostin' 'Neostigmine' 'Neostigmine (cation)' 'Neostigmine cation'
 'Neostigmine hydroxide' 'Neostigmine ion']_|_[('PubChem', array(['11111527', '11111528', '26756597', '90340848'], dtype=object)), ('drugbank', array(['DB01400'], dtype=object)), ('chEBI', array(['7514'], dtype=object))]_|_['CHEMBL211471' 'CHEMBL54126']_|_{'rows': array(['EFO_0004209', 'EFO_0004991', 'EFO_1000948', 'EFO_0005323',
       'MONDO_0007254', 'HP_0025267', 'EFO_0001074', 'EFO_0009516',
       'HP_0002315', 'MONDO_0005041', 'EFO_0004888', 'EFO_0003843'],
      dtype=object), 'count': 12}_|_[ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for myasthenia gravis and glaucoma and has 10 investigational indications."
CHEMBL4113131,"C[C@@H]1CN(C(=O)c2ccc(NC(=O)c3cc(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(N)nn3)cc2)C[C@H](C)N1_|_GLYMPHUVMRFTFV-QLFBSQMISA-N_|_Small molecule_|_False_|_ENSARTINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Ensartinib' 'X-396']_|_[('drugbank', array(['DB14860'], dtype=object))]_|_['CHEMBL4297219']_|_{'rows': array(['MONDO_0008903', 'EFO_0003060', 'EFO_0003060', 'EFO_0000756'],
      dtype=object), 'count': 4}_|_[ENSG00000171094]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4297190,"Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1_|_TTZSNFLLYPYKIL-UHFFFAOYSA-N_|_Small molecule_|_False_|_SURUFATINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['HMPL-012' 'Hmpl-012' 'Sulfatinib' 'Surufatinib']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/SURUFATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15106'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000503', 'EFO_0001421', 'EFO_0003086', 'EFO_0003860',
       'EFO_0005537', 'EFO_0003060', 'EFO_0000702', 'EFO_0000616',
       'EFO_0002618', 'EFO_0000637', 'EFO_0006859', 'MONDO_0007254',
       'EFO_0004142', 'MONDO_0005184', 'EFO_1001901', 'EFO_0000691',
       'EFO_1001951', 'EFO_0002892', 'MONDO_0005575', 'EFO_1001968',
       'MONDO_0003060', 'MONDO_0002120', 'EFO_0000182', 'EFO_0004252',
       'MONDO_0008170', 'MONDO_0002108'], dtype=object), 'count': 26}_|_[ENSG00000077782,ENSG00000102755,ENSG00000037280,ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 26 investigational indications."
CHEMBL4297509,"CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1_|_SIFNOOUKXBRGGB-AREMUKBSSA-N_|_Small molecule_|_False_|_ELACESTRANT_|_2023.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['ER-306323' 'Elacestrant' 'RAD-1901' 'RAD1901' 'Rad1901']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ELACESTRANT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB06374'], dtype=object))]_|_['CHEMBL4594273']_|_{'rows': array(['HP_0031217', 'EFO_0006861', 'EFO_0003869', 'EFO_0000305',
       'EFO_0003869', 'MONDO_0007254'], dtype=object), 'count': 6}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for male breast carcinoma and breast neoplasm and has 4 investigational indications."
CHEMBL4594298,"COc1cc2c(cc1OC)CN(CCc1ccc(-n3nnc(-c4cc(OC)c(OC)cc4NC(=O)c4cc(=O)c5ccccc5o4)n3)cc1)CC2_|_AHJUHHDDCJQACA-UHFFFAOYSA-N_|_Small molecule_|_False_|_ENCEQUIDAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Encequidar' 'HM-30181' 'HM30181' 'HM30181AK' 'Pgp inhibitor hm30181ak']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ENCEQUIDAR/relevant/1/'],
      dtype=object))]_|_['CHEMBL4594299']_|_{'rows': array(['MONDO_0007254', 'EFO_0000616', 'EFO_0000616', 'EFO_0003968',
       'EFO_0005537', 'EFO_0003968'], dtype=object), 'count': 6}_|_[ENSG00000085563]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL716,"OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1_|_URKOMYMAXPYINW-UHFFFAOYSA-N_|_Small molecule_|_True_|_QUETIAPINE_|_1997.0_|_4.0_|_nan_|_False_|_True_|_['Atrolak xl' 'Biquelle xl' 'Brancico xl' 'Ebesque xl' 'Mintreleq xl'
 'Psyquet xl' 'Seotiapim xl' 'Seroquel' 'Seroquel xl' 'Sondate xl'
 'Tenprolide xl' 'Zaluron xl']_|_['NSC-758918' 'Norsic' 'Quetiapine' 'Quetiapine extended release']_|_[('PubChem', array(['144205090', '170465146', '26749928', '29215183', '49666155'],
      dtype=object)), ('Wikipedia', array(['Quetiapine'], dtype=object)), ('drugbank', array(['DB01224'], dtype=object)), ('chEBI', array(['8707'], dtype=object))]_|_['CHEMBL1200911' 'CHEMBL3188993']_|_{'rows': array(['MONDO_0002009', 'MONDO_0005301', 'EFO_0004242', 'EFO_0002610',
       'EFO_0004698', 'EFO_0005411', 'EFO_0009963', 'EFO_0007191',
       'EFO_0003918', 'EFO_0009854', 'MONDO_0005351', 'EFO_0009963',
       'HP_0000726', 'MONDO_0005180', 'MONDO_0002009', 'MONDO_0002050',
       'EFO_0005407', 'Orphanet_79292', 'EFO_0004247', 'EFO_0003888',
       'MONDO_0002050', 'MONDO_0007079', 'EFO_0000677', 'MONDO_0004985',
       'EFO_1001892', 'MONDO_0005090', 'EFO_0005230', 'EFO_0005411',
       'EFO_0003884', 'MONDO_0002046', 'EFO_0004242', 'HP_0012076',
       'EFO_1001917', 'HP_0000713', 'MONDO_0002009', 'EFO_1000904',
       'MONDO_0005090', 'EFO_0009267', 'EFO_0009964', 'EFO_0005230',
       'EFO_0005407', 'EFO_0004701', 'MONDO_0007079', 'HP_0000726',
       'MONDO_0004985', 'HP_0012076', 'EFO_1001917', 'EFO_0004257',
       'MONDO_0002009', 'EFO_0001358', 'EFO_0007453', 'HP_0100543'],
      dtype=object), 'count': 52}_|_[ENSG00000147246,ENSG00000102468,ENSG00000149295]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 7 approved and 38 investigational indications. This drug has a black box warning from the FDA."
CHEMBL109,"CCCC(CCC)C(=O)O_|_NIJJYAXOARWZEE-UHFFFAOYSA-N_|_Small molecule_|_True_|_VALPROIC ACID_|_1978.0_|_4.0_|_nan_|_False_|_True_|_['Convulex' 'Depakene' 'Depakote' 'Stavzor' 'Valproic acid']_|_['44089' 'NSC-93819' 'Pentanoic acid, 2-propyl' 'Valproate'
 'Valproic acid' 'Valproic acid extended release']_|_[('DailyMed', array(['valproic%20acid'], dtype=object)), ('PubChem', array(['144204642', '144209161', '144210920', '170465446', '17389523',
       '26752921', '399407', '90341449'], dtype=object)), ('TG-GATEs', array(['5'], dtype=object)), ('Wikipedia', array(['Valproic_acid'], dtype=object)), ('drugbank', array(['DB00313'], dtype=object)), ('chEBI', array(['39867'], dtype=object))]_|_['CHEMBL2315212' 'CHEMBL2105613' 'CHEMBL433']_|_{'rows': array(['HP_0000713', 'EFO_0002939', 'HP_0001250', 'MONDO_0019200',
       'EFO_0004247', 'MONDO_0007254', 'MONDO_0019188', 'MONDO_0001187',
       'EFO_1000158', 'HP_0001250', 'EFO_0005762', 'MONDO_0002009',
       'MONDO_0004985', 'EFO_0004252', 'EFO_0005762', 'EFO_0000095',
       'EFO_0000181', 'MONDO_0019037', 'EFO_0005230', 'MONDO_0100342',
       'EFO_0000616', 'EFO_0000717', 'MONDO_0044970', 'EFO_0009430',
       'EFO_0000519', 'MONDO_0002050', 'EFO_0008526', 'MONDO_0004975',
       'EFO_0003833', 'EFO_0004263', 'EFO_0000095', 'EFO_0000691',
       'EFO_0008525', 'MONDO_0010604', 'EFO_0006859', 'MONDO_0004976',
       'EFO_0009267', 'MONDO_0010826', 'HP_0000713', 'MONDO_0005277',
       'EFO_1001951', 'MONDO_0005277', 'HP_0007359', 'HP_0002121',
       'HP_0001250', 'EFO_0000180', 'MONDO_0007079', 'EFO_0000546',
       'MONDO_0004975', 'EFO_0004191', 'EFO_0001358', 'EFO_1000877',
       'Orphanet_83419', 'EFO_0002618', 'EFO_0003758', 'EFO_0000198',
       'EFO_0002499', 'EFO_1000877', 'MONDO_0008170', 'MONDO_0005277',
       'EFO_0000616', 'EFO_1001968', 'EFO_0008526', 'MONDO_0043510',
       'MONDO_0008903', 'EFO_0000519', 'MONDO_0004992', 'EFO_0003758',
       'EFO_0008525', 'HP_0000726', 'EFO_0000574', 'MONDO_0002974',
       'EFO_0000403', 'MONDO_0018105', 'EFO_0000616', 'EFO_0000474',
       'MONDO_0007254', 'MONDO_0004975', 'HP_0002121', 'MONDO_0007739',
       'EFO_0000565', 'MONDO_0004985', 'EFO_0007527', 'MONDO_0007079',
       'EFO_0000474', 'EFO_0000474', 'EFO_0000198', 'EFO_0000756',
       'EFO_0009963', 'EFO_0000702', 'EFO_0000764', 'MONDO_0005090',
       'HP_0010865', 'EFO_0003841', 'EFO_0003060', 'MONDO_0003478',
       'HP_0002013', 'MONDO_0008315', 'EFO_0004192', 'MONDO_0009293',
       'MONDO_0005090', 'EFO_0009963', 'HP_0031273', 'EFO_0001075',
       'EFO_0000222', 'MONDO_0004985', 'EFO_0000339', 'HP_0000726',
       'EFO_0000309', 'HP_0002039', 'EFO_1001469', 'EFO_0000403'],
      dtype=object), 'count': 112}_|_[ENSG00000112294]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1978 and has 13 approved and 84 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1186610,"CCCC(CCC)C(=O)O[C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C_|_XGGHHHBGPSNXFE-ZSHCYNCHSA-N_|_Small molecule_|_False_|_ANISOTROPINE_|_1962.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Anisotropine' 'Octatropine']_|_[('PubChem', array(['50103910', '50103911'], dtype=object)), ('Wikipedia', array(['Octatropine_methylbromide'], dtype=object))]_|_['CHEMBL1578']_|_nan_|_[ENSG00000133019,ENSG00000168539]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962."
CHEMBL1200532,"CN1CCC(CN2c3ccccc3Sc3ccccc32)C1.Cl_|_IEISBKIVLDXSMZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_METHDILAZINE HYDROCHLORIDE_|_1982.0_|_4.0_|_CHEMBL1200959_|_False_|_True_|_['Methdilazine hydrochloride' 'Tacaryl']_|_['Methdilazine hcl' 'Methdilazine hydrochloride' 'NSC-169091']_|_[('PubChem', array(['144203598', '562732'], dtype=object))]_|_nan_|_nan_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."
CHEMBL1200825,"CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl_|_FJQXCDYVZAHXNS-UHFFFAOYSA-N_|_Small molecule_|_True_|_METHADONE HYDROCHLORIDE_|_1947.0_|_4.0_|_CHEMBL651_|_False_|_True_|_['Dolophine hydrochloride' 'Eptadone' 'Martindale'
 'Methadone hydrochloride' 'Methadone hydrochloride intensol' 'Methadose'
 'Metharose' 'Methex' 'Physeptone' 'Pinadone' 'Synastone' 'Westadone']_|_['AN-148' 'Butalgin' 'Dolofin hydrochloride' 'Dolophine' 'Fenadone'
 'Heptadon' 'Ketalgin hydrochloride' 'Mecodin' 'Methadone hcl'
 'Methadone hydrochloride' 'Methadone hydrochloride cii'
 'Methadonium chloride' 'NSC-19600' 'Phenadone hydrochloride']_|_[('DailyMed', array(['methadone%20hydrochloride'], dtype=object)), ('PubChem', array(['144206448', '144209224', '144210950'], dtype=object)), ('chEBI', array(['50140'], dtype=object))]_|_nan_|_{'rows': array(['HP_0008419', 'EFO_0005611', 'EFO_0003843', 'EFO_0000764',
       'EFO_0003890'], dtype=object), 'count': 5}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1947 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1232461,"CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21_|_AAAQFGUYHFJNHI-SFHVURJKSA-N_|_Small molecule_|_False_|_MOLIBRESIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bet inhibitor gsk525762' 'GSK-525762' 'GSK-525762A' 'GSK525762'
 'GSK525762A' 'I-BET 762' 'Molibresib']_|_nan_|_['CHEMBL4297217']_|_{'rows': array(['EFO_0000616', 'EFO_0000313'], dtype=object), 'count': 2}_|_[ENSG00000204256,ENSG00000141867,ENSG00000137948,ENSG00000169925]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL1677,"Cl.Nc1c2c(nc3ccccc13)CCCC2_|_ZUFVXZVXEJHHBN-UHFFFAOYSA-N_|_Small molecule_|_False_|_TACRINE HYDROCHLORIDE_|_1993.0_|_4.0_|_CHEMBL95_|_False_|_True_|_['Alzyme' 'Cognex']_|_['CI-970' 'NSC-72108' 'Tacrine hcl' 'Tacrine hydrochloride']_|_[('PubChem', array(['11532943', '144207497', '17388697', '26747422', '49732004',
       '50105756'], dtype=object))]_|_nan_|_nan_|_[ENSG00000114200,ENSG00000087085]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1993."
CHEMBL2105659,"CCc1c(C(=O)C(N)=O)c2c(OCC(=O)OC)cccc2n1Cc1ccccc1_|_VJYDOJXJUCJUHL-UHFFFAOYSA-N_|_Small molecule_|_False_|_VARESPLADIB METHYL_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['A-002' 'LY-333013' 'LY333013' 'S-3013' 'Varespladib methyl'
 'Varespladib methyl ester']_|_[('drugbank', array(['DB05737'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003086', 'EFO_0005672', 'EFO_0001645'], dtype=object), 'count': 3}_|_[ENSG00000127472,ENSG00000188257,ENSG00000069764]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL2107870,"nan_|_nan_|_Oligonucleotide_|_False_|_PEGNIVACOGIN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Pegnivacogin' 'RB-006' 'RB006' 'REG-1' 'REG1']_|_nan_|_nan_|_{'rows': array(['EFO_0005672', 'EFO_0001645'], dtype=object), 'count': 2}_|_[ENSG00000101981]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL2108431,nan_|_nan_|_Antibody_|_False_|_METELIMUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CAT-192' 'Metelimumab']_|_nan_|_nan_|_nan_|_[ENSG00000105329]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL2108474,"nan_|_nan_|_Antibody_|_False_|_MASLIMOMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Maslimomab']_|_nan_|_nan_|_nan_|_[ENSG00000211810,ENSG00000277734,ENSG00000278030,ENSG00000211699]_|_Antibody drug with a maximum clinical trial phase of II."
CHEMBL2109351,"nan_|_nan_|_Antibody_|_False_|_FBT-A05_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['FBT-A05']_|_nan_|_nan_|_nan_|_[ENSG00000198851,ENSG00000160654,ENSG00000167286,ENSG00000156738]_|_Antibody drug with a maximum clinical trial phase of I."
CHEMBL2109372,"nan_|_nan_|_Antibody_|_False_|_MEDI-565_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['MEDI-565' 'Medi-565']_|_nan_|_nan_|_{'rows': array(['EFO_0000228'], dtype=object), 'count': 1}_|_[ENSG00000105388,ENSG00000198851]_|_Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL2109430,"nan_|_nan_|_Antibody_|_False_|_GIMSILUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Gimsilumab' 'MORAb-022']_|_nan_|_nan_|_{'rows': array(['EFO_0000685', 'MONDO_0100096'], dtype=object), 'count': 2}_|_[ENSG00000164400]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2159122,"COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O_|_QFNHIDANIVGXPE-FNZWTVRRSA-N_|_Small molecule_|_False_|_ELUXADOLINE_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Truberzi' 'Viberzi']_|_['Eluxadoline' 'JNJ-27018966']_|_[('DailyMed', array(['eluxadoline'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi'],
      dtype=object)), ('drugbank', array(['DB09272'], dtype=object)), ('chEBI', array(['85980'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001673', 'EFO_0000555'], dtype=object), 'count': 2}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for diarrheal disease and irritable bowel syndrome."
CHEMBL2364619,"C[N@+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13_|_ATCVVCBJNHXIEX-ZAHKBLQYSA-O_|_Small molecule_|_False_|_METHYLSAMIDORPHAN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ALKS 37' 'ALKS-37 CATION' 'ALKS37' 'Methylsamidorphan'
 'Methylsamidorphan cation' 'Methylsamidorphan ion' 'RDC-1036 CATION'
 'RDC-1036-00' 'RDC-103600' 'RDC-103603' 'Rdc-1036']_|_[('drugbank', array(['DB15241'], dtype=object))]_|_['CHEMBL2364620']_|_{'rows': array(['HP_0002019'], dtype=object), 'count': 1}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3301577,"nan_|_nan_|_Protein_|_False_|_IPAFRICEPT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Ipafricept' 'OMP-54F28']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000177283]_|_Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545173,"nan_|_nan_|_Small molecule_|_False_|_IRX4310_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['Irx4310']_|_nan_|_nan_|_nan_|_[ENSG00000172819,ENSG00000077092,ENSG00000131759]_|_Small molecule drug with a maximum clinical trial phase of I."
CHEMBL3707222,"CCCC[C@]1(CC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2cccc(NC(=O)N[C@@H]3O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](OCc4ccccc4)[C@H]3O)c2)[C@H]1O_|_ULVBLFBUTQMAGZ-RTNCXNSASA-N_|_Small molecule_|_False_|_VOLIXIBAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SAR-548304 FREE ACID' 'Volixibat']_|_[('drugbank', array(['DB13914'], dtype=object))]_|_['CHEMBL3956446' 'CHEMBL3707221']_|_{'rows': array(['EFO_0004268', 'MONDO_0019072', 'EFO_1001486'], dtype=object), 'count': 3}_|_[ENSG00000125255]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL378544,"CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O_|_KDQAABAKXDWYSZ-PNYVAJAMSA-N_|_Small molecule_|_False_|_VINBLASTINE SULFATE_|_1965.0_|_4.0_|_CHEMBL159_|_False_|_True_|_['Velban' 'Velbe' 'Vinblast,lederle' 'Vinblastine sulfate']_|_['29060-LE' '29060LE' 'Alkaban-aq' 'NSC-49842' 'Vinblastine sulfate'
 'Vinblastine sulphate' 'Vinblastini sulfas' 'Vincaleukoblastine sulfate'
 'Vlb monosulfate']_|_[('DailyMed', array(['vinblastine%20sulfate'], dtype=object)), ('PubChem', array(['144205051', '144206288', '170464976', '170464977', '26663016',
       '56462989', '855758'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000588', 'MONDO_0002041', 'MONDO_0008170', 'EFO_0000691',
       'EFO_0000574', 'MONDO_0008903', 'MONDO_0002367', 'MONDO_0004986',
       'EFO_0000756', 'MONDO_0001187', 'EFO_0004281', 'MONDO_0003751',
       'MONDO_0008315', 'EFO_0009907', 'EFO_0001642', 'MONDO_0009348',
       'EFO_0000183', 'MONDO_0004192', 'MONDO_0002974', 'EFO_0000389'],
      dtype=object), 'count': 20}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and has 5 approved and 15 investigational indications."
CHEMBL3809489,"Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2_|_KXMZDGSRSGHMMK-VWLOTQADSA-N_|_Small molecule_|_False_|_BEMCENTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BGB 324' 'BGB-324' 'BGB324' 'Bemcentinib' 'CS-1046' 'HY-15150'
 'KB-80319' 'QC-11751' 'R 428' 'R-428' 'R428' 'SYN-1131' 'SYN1131'
 'W-5845']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BEMCENTINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB12411'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_0000571', 'EFO_0002618', 'EFO_1000984',
       'EFO_0000756', 'EFO_0003060', 'EFO_0000222', 'EFO_0000198',
       'EFO_0000616', 'EFO_0000588', 'EFO_1000158'], dtype=object), 'count': 11}_|_[ENSG00000167601]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 11 investigational indications."
CHEMBL4297455,"O=C(O)Cc1nn(Cc2nc3cc(C(F)(F)F)ccc3s2)c(=O)c2nccnc12_|_YRGPAXAVTDMKDK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CAFICRESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AT-001' 'Aldose reductase-in-1' 'At-001' 'Caficrestat']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CAFICRESTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15121'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_1001458'], dtype=object), 'count': 2}_|_[ENSG00000085662]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL4297573,"nan_|_nan_|_Protein_|_True_|_TAGRAXOFUSP_|_2018.0_|_4.0_|_nan_|_False_|_True_|_['Elzonris']_|_['DT-3881L3' 'DT388IL3' 'MOLECULE-129' 'Molecule 129' 'SL-401' 'Sl-401'
 'Tagraxofusp' 'Tagraxofusp erzs']_|_[('DailyMed', array(['tagraxofusp-erzs'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/elzonris'],
      dtype=object)), ('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/TAGRAXOFUSP/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001779', 'EFO_0000222', 'EFO_0000616', 'EFO_0000574',
       'EFO_0000198'], dtype=object), 'count': 5}_|_[ENSG00000292332,ENSG00000185291,ENSG00000167658]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."
CHEMBL441738,"CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C_|_UAHFGYDRQSXQEB-LEBBXHLNSA-N_|_Protein_|_False_|_AFAMELANOTIDE_|_2014.0_|_4.0_|_nan_|_False_|_True_|_['Scenesse']_|_['(nle4,d-phe7)-.alpha.-msh' 'Afamelanotide' 'CUV-1647' 'CUV1647'
 'Melanotan' 'Melanotan i' 'Melanotan-1' 'Ndp-alpha-msh']_|_[('DailyMed', array(['afamelanotide'], dtype=object)), ('Wikipedia', array(['Afamelanotide'], dtype=object)), ('drugbank', array(['DB04931'], dtype=object))]_|_['CHEMBL4297213']_|_{'rows': array(['EFO_0005531', 'EFO_0004208', 'MONDO_0019600', 'MONDO_0001676',
       'EFO_0003894', 'MONDO_0008297', 'HP_0002140'], dtype=object), 'count': 7}_|_[ENSG00000258839]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for erythropoietic protoporphyria and has 6 investigational indications."
CHEMBL4461070,"O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5ccc(F)cc5)nn34)cc2s1_|_ODIUNTQOXRXOIV-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAR-125844_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['SAR 125844' 'SAR-125844' 'SAR125844' 'Sar-125844']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000105976]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4594542,"nan_|_nan_|_Protein_|_False_|_EFLEPEDOCOKIN ALFA_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Eflepedocokin alfa' 'F 652' 'F-652' 'Il-22 dimer f-652' 'Promenakin']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096', 'EFO_1001345', 'MONDO_0013730'], dtype=object), 'count': 3}_|_[ENSG00000243646,ENSG00000142677]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4596392,"CNC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC_|_BZZKEPGENYLQSC-UHFFFAOYSA-N_|_Small molecule_|_False_|_CRAVACITINIB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_[]_|_[]_|_nan_|_['CHEMBL4435170']_|_{'rows': array(['EFO_0003778', 'EFO_0003834', 'EFO_0000729', 'EFO_0000540',
       'EFO_0003086', 'HP_0000999', 'EFO_0000676', 'MONDO_0007915',
       'EFO_0004192', 'EFO_0005761', 'HP_0001410', 'MP_0001845'],
      dtype=object), 'count': 12}_|_[ENSG00000105397]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for psoriasis and has 11 investigational indications."
CHEMBL463981,"O=S(=O)(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)c1ccc(Cl)s1_|_PSXOKXJMVRSARX-SCSAIBSYSA-N_|_Small molecule_|_False_|_BEGACESTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Begacestat' 'GSI-953']_|_[('drugbank', array(['DB12263'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL478858,"CCCCCCCCN1CCc2c(C)c(CC(=O)O)c(C)c(NC(=O)C(C)(C)C)c21_|_TXIIZHHIOHVWJD-UHFFFAOYSA-N_|_Small molecule_|_False_|_PACTIMIBE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Pactimibe']_|_[('drugbank', array(['DB12971'], dtype=object))]_|_['CHEMBL564483' 'CHEMBL447977']_|_{'rows': array(['EFO_0003914', 'EFO_0001645'], dtype=object), 'count': 2}_|_[ENSG00000057252,ENSG00000167780]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL918,"NC(=O)NC(=O)Cc1ccccc1_|_XPFRXWCVYUEORT-UHFFFAOYSA-N_|_Small molecule_|_False_|_PHENACEMIDE_|_1951.0_|_4.0_|_nan_|_False_|_True_|_['Phenurone']_|_['NSC-39458' 'Phenacemide']_|_[('PubChem', array(['144204878', '170465322', '26748194'], dtype=object)), ('Wikipedia', array(['Phenacemide'], dtype=object)), ('drugbank', array(['DB01121'], dtype=object)), ('chEBI', array(['8049'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000474'], dtype=object), 'count': 1}_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951 and is indicated for epilepsy."
CHEMBL1200659,"CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O_|_OYFJQPXVCSSHAI-QFPUQLAESA-N_|_Small molecule_|_True_|_ENALAPRIL MALEATE_|_1985.0_|_4.0_|_CHEMBL578_|_False_|_True_|_['Ednyt' 'Enalapril maleate' 'Enapren' 'Epaned' 'Epaned kit' 'Innovace'
 'Pralenal 10' 'Pralenal 2.5' 'Pralenal 20' 'Pralenal 5' 'Renitec'
 'Vasotec' 'Xanef']_|_['Amprace' 'Cardiovet' 'Enacard' 'Enalapril maleate' 'Glioten' 'Hipoartel'
 'MK-421' 'NSC-758143' 'Naprilene' 'Reniten' 'Renivace' 'Xanef']_|_[('DailyMed', array(['enalapril%20maleate'], dtype=object)), ('PubChem', array(['56424090', '855584'], dtype=object)), ('chEBI', array(['4785'], dtype=object))]_|_nan_|_{'rows': array(['HP_0000093', 'EFO_0005669', 'EFO_0003144', 'EFO_0000373',
       'EFO_0000537', 'EFO_0000668', 'EFO_0000685'], dtype=object), 'count': 7}_|_[ENSG00000159640]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1201581,"nan_|_nan_|_Antibody_|_True_|_INFLIXIMAB_|_1998.0_|_4.0_|_nan_|_False_|_True_|_['Inflectra' 'Remicade' 'Remsima']_|_['ABP 710' 'Abp-710' 'Avsola' 'BOW015' 'Bow-015' 'Ct p13' 'Ct-p-13'
 'Ct-p13' 'Infimab' 'Infliximab' 'Infliximab (janssen)'
 'Infliximab (remicade)' 'Infliximab abda' 'Infliximab axxq'
 'Infliximab biosimilar (amgen)' 'Infliximab biosimilar (celltrion)'
 'Infliximab biosimilar (pfizer)' 'Infliximab biosimilar (sb-2)'
 'Infliximab dyyb' 'Infliximab qbtx' 'Infliximab-abda' 'Infliximab-axxq'
 'Infliximab-dyyb' 'Infliximab-hjmt' 'Infliximab-pfizer' 'Infliximab-qbtx'
 'Ixifi' 'NI-071' 'Pf-06438179' 'TA-650' 'Zessly' 'cA2']_|_[('DailyMed', array(['infliximab', 'infliximab-abda', 'infliximab-axxq',
       'infliximab-dyyb'], dtype=object)), ('DrugCentral', array(['4974'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/remsima'],
      dtype=object)), ('Wikipedia', array(['Infliximab'], dtype=object))]_|_nan_|_{'rows': array(['HP_0012378', 'EFO_0007527', 'EFO_0003767', 'HP_0002039',
       'EFO_1001209', 'MONDO_0005041', 'EFO_0003047', 'EFO_0007168',
       'EFO_0000706', 'MONDO_0013730', 'EFO_1000784', 'EFO_0000685',
       'EFO_0000198', 'MONDO_0005178', 'EFO_0007460', 'EFO_0003780',
       'EFO_0000676', 'EFO_0003778', 'EFO_0002617', 'HP_0003419',
       'EFO_0005297', 'EFO_0003872', 'MONDO_0008903', 'MONDO_0001718',
       'EFO_0008518', 'EFO_0001065', 'EFO_0000398', 'EFO_0000341',
       'MONDO_0019338', 'EFO_0004232', 'MONDO_0005147', 'HP_0004326',
       'EFO_1000710', 'EFO_0004683', 'EFO_0000540', 'EFO_0000783',
       'EFO_0002687', 'EFO_0000384', 'EFO_0004599', 'EFO_0004246',
       'EFO_0002609', 'EFO_0003898', 'MONDO_0004985', 'MONDO_0100096',
       'MONDO_0018305', 'EFO_1000747', 'EFO_1001857', 'EFO_0004276',
       'EFO_0004775', 'EFO_0004220', 'EFO_0000729', 'EFO_1000749'],
      dtype=object), 'count': 52}_|_[ENSG00000232810]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1998 and has 7 approved and 45 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1236936,"O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1_|_WPYWMXNXEZFMAK-UHFFFAOYSA-N_|_Small molecule_|_False_|_CINACIGUAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY 58-2667' 'Cinaciguat']_|_nan_|_nan_|_{'rows': array(['EFO_0000373', 'EFO_0003144'], dtype=object), 'count': 2}_|_[ENSG00000061918,ENSG00000123201,ENSG00000152402,ENSG00000164116]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL135,"C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O_|_VOXZDWNPVJITMN-ZBRFXRBCSA-N_|_Small molecule_|_True_|_ESTRADIOL_|_1975.0_|_4.0_|_nan_|_False_|_True_|_['Adgyn estro' 'Alora' 'Aquagen' 'Bedol' 'Climara' 'Climara Pro'
 'Dermestril 100' 'Dermestril 25' 'Dermestril 50' 'Dermestril septem 25'
 'Dermestril septem 50' 'Dermestril septem 75' 'Divigel' 'E-Cypionate'
 'Elestrin' 'Elleste solo' 'Elleste solo mx 40' 'Elleste solo mx 80'
 'Esclim' 'Estrace' 'Estraderm' 'Estraderm mx 100' 'Estraderm mx 25'
 'Estraderm mx 50' 'Estraderm mx 75' 'Estraderm tts 100'
 'Estraderm tts 25' 'Estraderm tts 50' 'Estradiol' 'Estrasorb' 'Estring'
 'Estrogel' 'Evamist' 'Evorel 100' 'Evorel 25' 'Evorel 50' 'Evorel 75'
 'Fematrix 40' 'Fematrix 80' 'Fempatch' 'Femseven 100' 'Femseven 50'
 'Femseven 75' 'Gynodiol' 'Gynogen' 'Imvexxy' 'Innofem' 'Menorest 37.5'
 'Menorest 50' 'Menorest 75' 'Menoring 50' 'Menostar' 'Minivelle'
 'Oestradiol' 'Progynova ts' 'Sandrena' 'Vagifem' 'Vagifem 18' 'Vagifem 8'
 'Vivelle' 'Vivelle-dot' 'Zumenon']_|_['17-.beta.-oestradiol' '17-beta-oestradiol' '17.beta.-estradiol'
 '17beta-estradiol' 'Agofollin' 'Alfatradiol' 'Depo-Estradiol'
 'Destradiol' 'Dihydrotheelin' 'Dihydroxyestrin' 'Estradiol'
 'Estradiol 17-beta' 'Estradiol anhydrous' 'Estradiol hemihydrate'
 'Estradiol valerate metabolite e2' 'Estrasorb' 'Gynergon' 'Gynoestryl'
 'NSC-20293' 'NSC-9895' 'Oestradiol' 'WC-3011' 'WC3011']_|_[('DailyMed', array(['estradiol'], dtype=object)), ('PubChem', array(['144204699', '144209255', '144210608', '17389898', '26753050',
       '26753051', '26753052', '29215115', '29215116', '29215117',
       '50105619', '50105620', '50124031', '56422158', '8139865',
       '90341590'], dtype=object)), ('Wikipedia', array(['Estradiol'], dtype=object)), ('drugbank', array(['DB00783'], dtype=object)), ('chEBI', array(['16469'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003103', 'EFO_0009314', 'MONDO_0005147', 'MONDO_0005148',
       'EFO_0001358', 'MONDO_0005301', 'HP_0031217', 'EFO_0005204',
       'EFO_0000731', 'EFO_1000906', 'EFO_0000545', 'MONDO_0007254',
       'EFO_0003843', 'HP_0008209', 'EFO_0004714', 'GO_0042697',
       'EFO_0010269', 'HP_0030016', 'EFO_0003869', 'EFO_1001271',
       'MONDO_0005351', 'EFO_0005411', 'EFO_0004243', 'EFO_0004266',
       'EFO_1001249', 'EFO_1000859', 'EFO_0003854', 'EFO_1001375',
       'HP_0100607', 'MONDO_0002146', 'EFO_1000096', 'EFO_0000764',
       'MONDO_0002050', 'Orphanet_145', 'EFO_0001663', 'MONDO_0005090',
       'MONDO_0008315', 'MONDO_0005277', 'EFO_0000305', 'MONDO_0100096',
       'EFO_0001065', 'EFO_0005537', 'EFO_0000180', 'EFO_0001073',
       'EFO_0003914', 'EFO_0000660', 'MONDO_0001410', 'HP_0000938',
       'MONDO_0004975', 'EFO_0003882', 'EFO_0007453', 'MONDO_0019499'],
      dtype=object), 'count': 52}_|_[ENSG00000091831]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1975 and has 13 approved and 39 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1441059,"CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O_|_BNPSSFBOAGDEEL-UHFFFAOYSA-N_|_Small molecule_|_True_|_ALBUTEROL SULFATE_|_1982.0_|_4.0_|_CHEMBL714_|_False_|_True_|_['Accuneb' 'Albuterol sulfate' 'Proair digihaler' 'Proair hfa'
 'Proair respiclick' 'Proventil' 'Proventil-hfa' 'Ventolin' 'Ventolin hfa'
 'Ventolin rotacaps' 'Volmax' 'Vospire er']_|_['Albuterol sulfate' 'Albuterol sulphate' 'Buventol' 'Ecovent' 'Hexotonal'
 'Loftan' 'NSC-289928' 'R03AC02' 'R03CC02' 'SCH 13949W SULFATE'
 'SCH-13949W SULFATE' 'Salamol' 'Salbumol' 'Salbutamol (as sulfate)'
 'Salbutamol sulfate' 'Salbutamol sulphate' 'Salbutamoli sulfas'
 'Sch 13949w sulphate' 'Sch-13949w sulphate' 'Sulbutamol (as sulphate)'
 'Sultanol' 'Torpex' 'Venetlin' 'Ventilastin' 'Vospire']_|_[('DailyMed', array(['albuterol%20sulfate'], dtype=object)), ('PubChem', array(['50107002'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003818', 'MONDO_0100130', 'EFO_0000319', 'EFO_0000341',
       'MONDO_0004979', 'EFO_0008590'], dtype=object), 'count': 6}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for chronic obstructive pulmonary disease and asthma and has 4 investigational indications. This drug has a black box warning from the FDA."
CHEMBL146506,"C/C(=C\c1ccc(OCCN2CCOCC2)cc1)c1ccc2c(c1)C(C)(C)CCC2(C)C_|_OUQPTBCOEKUHBH-LSDHQDQOSA-N_|_Small molecule_|_False_|_MOFAROTENE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mofarotene' 'RO 40-8757' 'Ro-408757']_|_nan_|_nan_|_nan_|_[ENSG00000204231,ENSG00000172819,ENSG00000143171,ENSG00000077092,ENSG00000131759,ENSG00000186350]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1496,"CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O_|_BPRHUIZQVSMCRT-VEUZHWNKSA-N_|_Small molecule_|_False_|_ROSUVASTATIN_|_2003.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Creston' 'Rosuvastatin' 'X-plended' 'ZD-4522' 'ZD4522']_|_[('Wikipedia', array(['Rosuvastatin'], dtype=object)), ('drugbank', array(['DB01098'], dtype=object)), ('chEBI', array(['38545'], dtype=object))]_|_['CHEMBL1744447']_|_{'rows': array(['EFO_0003060', 'EFO_1001512', 'MONDO_0005147', 'EFO_1002048',
       'EFO_0009516', 'EFO_0009426', 'EFO_0000384', 'MONDO_0008170',
       'EFO_0000400', 'MONDO_0001583', 'EFO_0000668', 'EFO_0000319',
       'EFO_0001645', 'EFO_0001645', 'EFO_0000195', 'HP_0003124',
       'EFO_1001454', 'EFO_1001413', 'MONDO_0008315', 'EFO_0000537',
       'EFO_0003914', 'EFO_0000373', 'EFO_0000556', 'EFO_0002617',
       'MONDO_0005148', 'EFO_1000657', 'EFO_0000764', 'EFO_0003144',
       'EFO_1001150', 'MONDO_0100339', 'EFO_0000712', 'EFO_0003047',
       'EFO_0005672', 'EFO_0000729', 'EFO_0000540', 'EFO_0000589',
       'EFO_0004211', 'EFO_0000400', 'MONDO_0018473', 'MONDO_0004979',
       'MONDO_0004992', 'MONDO_0005180', 'MONDO_0019623', 'EFO_0000616',
       'EFO_1001951', 'MONDO_0021187', 'MONDO_0007915', 'EFO_0004272',
       'EFO_0004239', 'MONDO_0002050', 'MONDO_0021187', 'MONDO_0018328',
       'EFO_0600064', 'EFO_0003144', 'EFO_0000180', 'EFO_0008583',
       'EFO_0000649', 'EFO_0001068', 'MONDO_0018473', 'Orphanet_309005',
       'EFO_0000266', 'EFO_0000685', 'HP_0000083', 'EFO_1000049',
       'Orphanet_309005', 'EFO_0000537', 'EFO_0001073', 'EFO_0000701',
       'EFO_0003964', 'EFO_0004211', 'EFO_0005226', 'EFO_0000673',
       'EFO_0005669', 'HP_0003124', 'EFO_0005672', 'EFO_0004286',
       'Orphanet_79211', 'EFO_0003914', 'MONDO_0100096', 'EFO_0004911',
       'HP_0100806', 'MONDO_0021661', 'EFO_0000717', 'EFO_0009505',
       'EFO_0004911', 'EFO_0000612', 'EFO_0004826', 'EFO_1001249',
       'EFO_0000407', 'MONDO_0005148', 'MONDO_0007254', 'EFO_0000616',
       'EFO_0000341'], dtype=object), 'count': 93}_|_[ENSG00000113161]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 7 approved and 81 investigational indications."
CHEMBL1738757,"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1_|_WVXNSAVVKYZVOE-UHFFFAOYSA-N_|_Small molecule_|_False_|_REBASTINIB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Dp-1919']_|_['DCC-2036' 'DCC-2036 FREE BASE' 'DP-1919' 'Dcc-2036' 'Rebastinib']_|_[('PubChem', array(['137276016'], dtype=object)), ('drugbank', array(['DB13005'], dtype=object)), ('chEBI', array(['62166'], dtype=object))]_|_['CHEMBL2107833']_|_{'rows': array(['EFO_0000616', 'EFO_0000339'], dtype=object), 'count': 2}_|_[ENSG00000097007]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL285674,"Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2_|_CDCHDCWJMGXXRH-UHFFFAOYSA-N_|_Small molecule_|_True_|_ESTAZOLAM_|_1990.0_|_4.0_|_nan_|_False_|_True_|_['Estazolam' 'Eurodin' 'Prosom']_|_['ABBOTT-47631' 'Estazolam' 'Estazolam civ' 'NSC-290818']_|_[('DailyMed', array(['estazolam'], dtype=object)), ('PubChem', array(['144206162', '50113063'], dtype=object)), ('Wikipedia', array(['Estazolam'], dtype=object)), ('drugbank', array(['DB01215'], dtype=object)), ('chEBI', array(['4858'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0008568', 'EFO_0004698'], dtype=object), 'count': 2}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for insomnia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL3039529,"C#Cc1cnc2nc(O)n(C(CC)CC)c2n1_|_RSQGZEAXODVTOL-UHFFFAOYSA-N_|_Small molecule_|_False_|_TIRASEMTIV_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['CK-2017357' 'CK2017357' 'Tirasemtiv']_|_[('drugbank', array(['DB12209'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003876', 'EFO_0004265', 'EFO_0004991', 'MONDO_0004976'],
      dtype=object), 'count': 4}_|_[ENSG00000130598,ENSG00000130595,ENSG00000101470]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL3039531,"Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O_|_NGYNBSHYFOFVLS-LBPRGKRZSA-N_|_Small molecule_|_False_|_DANIRIXIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Danirixin' 'GSK-1325756B' 'GSK1325756' 'GSK1325756B' 'Gsk1325756']_|_[('drugbank', array(['DB11922'], dtype=object))]_|_['CHEMBL4560026']_|_{'rows': array(['MONDO_0024355', 'EFO_0000341', 'EFO_1001413', 'EFO_0000763'],
      dtype=object), 'count': 4}_|_[ENSG00000180871]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3301586,"nan_|_nan_|_Antibody drug conjugate_|_False_|_CLIVATUZUMAB TETRAXETAN_|_nan_|_2.0_|_nan_|_False_|_False_|_['Clivatucyn']_|_['Clivatuzumab tetraxetan' 'HPAM-4' 'IMMU-107' 'IgG-DOTA' 'hPAM4']_|_nan_|_nan_|_{'rows': array(['EFO_0002618'], dtype=object), 'count': 1}_|_[ENSG00000215182]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3301593,"Nc1ccc(C#Cc2cnn3c(C(F)(F)F)cc(-c4ccc(C(F)(F)F)cc4)nc23)cn1_|_DMJHZVARRXJSEG-UHFFFAOYSA-N_|_Small molecule_|_False_|_DECOGLURANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Decoglurant' 'RO-4995819' 'RO4995819' 'Rg1578']_|_[('drugbank', array(['DB11923'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002009'], dtype=object), 'count': 1}_|_[ENSG00000164082,ENSG00000198822]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3544937,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCCn1ccnn1.Cl_|_IOFHDGSCWJNVRZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ZD-4190_|_nan_|_1.0_|_CHEMBL281872_|_False_|_False_|_[]_|_['Zd-4190']_|_nan_|_nan_|_nan_|_[ENSG00000128052]_|_Small molecule drug with a maximum clinical trial phase of I.
CHEMBL3545031,"nan_|_nan_|_Small molecule_|_False_|_MK-1029_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Mk-1029']_|_nan_|_nan_|_{'rows': array(['MONDO_0004979'], dtype=object), 'count': 1}_|_[ENSG00000183134]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL3545076,"Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1_|_FYXRSVDHGLUMHB-UHFFFAOYSA-N_|_Small molecule_|_False_|_LY-2584702_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['LY 2584702' 'LY2584702' 'Ly-2584702']_|_[('drugbank', array(['DB12690'], dtype=object))]_|_['CHEMBL3911801' 'CHEMBL3909070']_|_{'rows': array(['EFO_0000681', 'MONDO_0004992', 'EFO_0003060', 'EFO_1001901',
       'EFO_0009708'], dtype=object), 'count': 5}_|_[ENSG00000108443]_|_Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications."
CHEMBL363295,"CC(CC(c1ccccc1)c1ccccc1)NC(C)(C)C_|_UISARWKNNNHPGI-UHFFFAOYSA-N_|_Small molecule_|_False_|_TERODILINE_|_1986.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['Terodiline']_|_[('Wikipedia', array(['Terodiline'], dtype=object)), ('drugbank', array(['DB13725'], dtype=object))]_|_['CHEMBL539770']_|_{'rows': array(['HP_0000020', 'HP_0000103'], dtype=object), 'count': 2}_|_[ENSG00000133019,ENSG00000180720,ENSG00000168539,ENSG00000181072,ENSG00000184984,ENSG00000196557,ENSG00000153956,ENSG00000151067,ENSG00000157445,ENSG00000081248,ENSG00000007402,ENSG00000157388,ENSG00000141837,ENSG00000148408,ENSG00000006283,ENSG00000151062,ENSG00000100346,ENSG00000102001,ENSG00000198216,ENSG00000182389,ENSG00000165995,ENSG00000067191,ENSG00000167535,ENSG00000105605,ENSG00000075429,ENSG00000166862,ENSG00000075461,ENSG00000142408,ENSG00000006116,ENSG00000130433,ENSG00000108878]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for urinary incontinence and polyuria."
CHEMBL4297904,"nan_|_nan_|_Unknown_|_False_|_BAY-1093884_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BAY-1093884' 'BAY1093884' 'Bay-1093884' 'Bay1093884' 'Befovacimab']_|_nan_|_nan_|_{'rows': array(['MONDO_0010604', 'MONDO_0010602', 'MONDO_0018660'], dtype=object), 'count': 3}_|_[ENSG00000003436]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4298001,"nan_|_nan_|_Antibody_|_False_|_CETRELIMAB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Cetrelimab' 'JNJ-63723283' 'JNJ63723283' 'Jnj 63723283' 'Jnj-63723283']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/CETRELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008528', 'EFO_0003060', 'EFO_0000616', 'EFO_0000673',
       'MONDO_0001187', 'EFO_0004239', 'EFO_0000294', 'EFO_0001378',
       'EFO_0001663'], dtype=object), 'count': 9}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of III (across all indications) and has 9 investigational indications."
CHEMBL447664,"Cc1cc(Cn2nnc3c(-c4ccco4)nc(N)nc32)ccc1N_|_HQSBCDPYXDGTCL-UHFFFAOYSA-N_|_Small molecule_|_False_|_VIPADENANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BIIB-014' 'BIIB014' 'Biib014' 'CEB-4520' 'V-2006' 'V2006' 'VER-11135'
 'VER-A-00-11' 'VER-A-00049' 'VER-A00-11' 'VER-A00049' 'VER-ADO-49'
 'Vipadenant']_|_[('drugbank', array(['DB06625'], dtype=object))]_|_['CHEMBL3216899' 'CHEMBL461006']_|_{'rows': array(['MONDO_0005180'], dtype=object), 'count': 1}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL459,"C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O_|_CJCSPKMFHVPWAR-JTQLQIEISA-N_|_Small molecule_|_False_|_METHYLDOPA_|_1962.0_|_4.0_|_nan_|_False_|_True_|_['Aldomet' 'Dopamet' 'Lederdopa' 'Medomet' 'Metalpha 250' 'Metalpha 500'
 'Methyldopa']_|_['(-)-.alpha.-methyldopa' '(s)-(-)-.alpha.-methyldopa'
 '.alpha.-methyl-l-dopa' 'Alpha-methyldopa' 'Anhydrous methyldopa'
 'BAYER-1440L' 'J9.247I' 'L-.alpha.-methyldopa' 'MK-351' 'Methyldopa'
 'Methyldopa (levorotatory)' 'Methyldopa anhydrous' 'Methyldopa hydrate'
 'Methyldopa sesquihydrate' 'Methyldopa, anhydrous' 'NSC-169916'
 'NSC-760080']_|_[('DailyMed', array(['methyldopa'], dtype=object)), ('PubChem', array(['11113581', '124886927', '144209808', '50104474', '8139902',
       '90341702'], dtype=object)), ('TG-GATEs', array(['56'], dtype=object)), ('Wikipedia', array(['Methyldopa'], dtype=object)), ('drugbank', array(['DB00968'], dtype=object)), ('chEBI', array(['61058'], dtype=object))]_|_['CHEMBL4063475' 'CHEMBL1591707']_|_{'rows': array(['EFO_0000668', 'EFO_0000537', 'MONDO_0005147'], dtype=object), 'count': 3}_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1962 and is indicated for hypertension and has 2 investigational indications."
CHEMBL4594293,"CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12.O=C(O)/C=C\C(=O)O_|_JWEQLWMZHJSMEC-AFJTUFCWSA-N_|_Small molecule_|_False_|_ACALABRUTINIB MALEATE_|_2022.0_|_4.0_|_CHEMBL3707348_|_False_|_True_|_['Calquence']_|_['Acalabrutinib maleate' 'Acalabrutinib maleate anhydrous'
 'Calquence maleate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/ACALABRUTINIB%20MALEATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000095', 'EFO_1001469'], dtype=object), 'count': 2}_|_[ENSG00000010671]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for chronic lymphocytic leukemia and mantle cell lymphoma."
CHEMBL4594417,"CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2F)C(=S)N1c1ccc(CCCc2ncco2)nc1_|_KCBJGVDOSBKVKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_PRUXELUTAMIDE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Gt-0918' 'Gt0918' 'Proxalutamide' 'Pruxelutamide']_|_nan_|_nan_|_{'rows': array(['MONDO_0100096', 'MONDO_0007254', 'MONDO_0008315', 'EFO_0000694'],
      dtype=object), 'count': 4}_|_[ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL4650398,"nan_|_nan_|_Protein_|_False_|_HEPALATIDE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Hepalatide']_|_nan_|_nan_|_{'rows': array(['EFO_0007304', 'MONDO_0005148', 'EFO_0004239'], dtype=object), 'count': 3}_|_[ENSG00000100652]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL470888,"COc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1_|_AJACDNCVEGIBNA-KQYNXXCUSA-N_|_Small molecule_|_False_|_BVT.115959_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bvt.115959' 'Spongosine']_|_nan_|_nan_|_{'rows': array(['EFO_0005762'], dtype=object), 'count': 1}_|_[ENSG00000128271]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL4802130,"CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1.CS(=O)(=O)O_|_ILQJXEIRBCHLOM-UHFFFAOYSA-N_|_Small molecule_|_False_|_BELUMOSUDIL MESYLATE_|_2021.0_|_4.0_|_CHEMBL2005186_|_False_|_True_|_['Rezurock']_|_['Belumosudil mesylate' 'KD025 mesylate']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/BELUMOSUDIL%20MESYLATE/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0013730', 'EFO_0005809'], dtype=object), 'count': 2}_|_[ENSG00000134318,ENSG00000067900]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for graft versus host disease and has 1 investigational indication."
CHEMBL522987,"Cc1cc(F)ccc1[C@H]1CNCCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1_|_SBBYBXSFWOLDDG-JLTOFOAXSA-N_|_Small molecule_|_False_|_VESTIPITANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['GW-597599' 'Gw597599' 'Vestipitant']_|_[('Wikipedia', array(['Vestipitant'], dtype=object)), ('drugbank', array(['DB11949'], dtype=object))]_|_['CHEMBL2104992']_|_{'rows': array(['EFO_0004888', 'MONDO_0002050', 'HP_0000360', 'MONDO_0002009',
       'EFO_1001917', 'EFO_0008568'], dtype=object), 'count': 6}_|_[ENSG00000115353]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL5314406,"COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1_|_MAFACRSJGNJHCF-UHFFFAOYSA-N_|_Small molecule_|_False_|_4SC-203_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['4sc 203' '4sc-203']_|_nan_|_nan_|_{'rows': array(['EFO_0000222'], dtype=object), 'count': 1}_|_[ENSG00000102755,ENSG00000037280,ENSG00000128052,ENSG00000122025]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL596,"CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1_|_PJMPHNIQZUBGLI-UHFFFAOYSA-N_|_Small molecule_|_True_|_FENTANYL_|_1968.0_|_4.0_|_nan_|_False_|_True_|_['Abstral' 'Actiq' 'Breakyl' 'Duragesic-100' 'Duragesic-12' 'Duragesic-25'
 'Duragesic-37' 'Duragesic-50' 'Duragesic-75' 'Durogesic'
 'Durogesic dtrans' 'Effentora' 'Fencino' 'Fentalis reservoir'
 'Fentanyl-100' 'Fentanyl-12' 'Fentanyl-25' 'Fentanyl-37' 'Fentanyl-50'
 'Fentanyl-62' 'Fentanyl-75' 'Fentanyl-87' 'Fentora' 'Ionsys' 'Leptanal'
 'Matrifen' 'Mezolar matrix' 'Mylafent' 'Opiodur' 'Oralet' 'Osmach'
 'Osmanil' 'Pecfent' 'Recivit' 'Sublimaze' 'Subsys' 'Tilofyl' 'Victanyl'
 'Yemex']_|_['AD 923' 'AD-923' 'Abstral-' 'Durogesic d-trans' 'EN-3267' 'En3267'
 'Fendrop' 'Fentanest' 'Fentanyl' 'Fentanyl cii' 'Fentora' 'IDS-NF-001'
 'Innovar' 'Ionsys' 'N02AB03' 'Phentanyl' 'R 4263' 'Recuvyra' 'Sublimase']_|_[('DailyMed', array(['fentanyl'], dtype=object)), ('PubChem', array(['144206164', '50113065'], dtype=object)), ('Wikipedia', array(['Fentanyl'], dtype=object)), ('drugbank', array(['DB00813'], dtype=object)), ('chEBI', array(['119915'], dtype=object))]_|_['CHEMBL688' 'CHEMBL1201159']_|_{'rows': array(['EFO_0005251', 'EFO_0009870', 'HP_0003419', 'MONDO_0007254',
       'HP_0012532', 'EFO_0005762', 'EFO_0801084', 'EFO_0005611',
       'EFO_0000713', 'EFO_0003843', 'EFO_0009267', 'EFO_0003931',
       'EFO_0002618', 'EFO_0004209', 'EFO_0003843', 'MONDO_0005277',
       'HP_0003419', 'EFO_0000232', 'EFO_0003843', 'EFO_0003884',
       'EFO_0002950', 'EFO_0000616', 'MONDO_0004992', 'MONDO_0001056',
       'MONDO_0004992', 'MONDO_0005277', 'EFO_0004273', 'EFO_1000637',
       'EFO_0003030', 'EFO_0801084', 'EFO_0001421', 'EFO_0001074',
       'EFO_0003918', 'MONDO_0100096', 'HP_0012532', 'EFO_1001139',
       'MONDO_0043510', 'MONDO_0005178', 'EFO_1000783', 'EFO_0009842',
       'HP_0002093', 'EFO_0004244', 'EFO_0000555', 'EFO_0001073',
       'HP_0002094', 'EFO_1001267', 'EFO_0009727', 'EFO_0000546'],
      dtype=object), 'count': 48}_|_[ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1968 and has 6 approved and 38 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200909,"CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C_|_HUMXXHTVHHLNRO-KAJVQRHHSA-N_|_Small molecule_|_False_|_PREDNISOLONE TEBUTATE_|_1956.0_|_4.0_|_nan_|_False_|_True_|_['Hydeltra-tba' 'Prednisolone tebutate']_|_['Anhydrous prednisolone tebutate' 'Prednisolone 21-tert-butylacetate'
 'Prednisolone butylacetate' 'Prednisolone tebutate']_|_[('PubChem', array(['170465430'], dtype=object)), ('drugbank', array(['DB14632'], dtype=object)), ('chEBI', array(['8381'], dtype=object))]_|_nan_|_nan_|_[ENSG00000113580]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1956."
CHEMBL1200916,"CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2.Cl_|_NZFNXWQNBYZDAQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_THIORIDAZINE HYDROCHLORIDE_|_1962.0_|_4.0_|_CHEMBL479_|_True_|_True_|_['Mellaril' 'Thioridazine hydrochloride'
 'Thioridazine hydrochloride intensol']_|_['NSC-186060' 'Thioridazine hcl' 'Thioridazine hydrochloride']_|_[('DailyMed', array(['thioridazine%20hydrochloride'], dtype=object)), ('PubChem', array(['144209999', '26747699', '26747700', '50107199', '50107200',
       '50107201', '56422406', '855568'], dtype=object)), ('chEBI', array(['48566'], dtype=object))]_|_nan_|_nan_|_[ENSG00000102468,ENSG00000149295,ENSG00000151577,ENSG00000069696,ENSG00000147246]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962. It was withdrawn in at least one region. This drug has a black box warning from the FDA."
CHEMBL1201233,"CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1_|_SVEBYYWCXTVYCR-LBPRGKRZSA-N_|_Small molecule_|_False_|_METHYLDOPATE_|_1962.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Methyldopate']_|_nan_|_['CHEMBL1200432']_|_nan_|_[ENSG00000150594,ENSG00000184160,ENSG00000274286]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1962."
CHEMBL1363,"COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1_|_BPZSYCZIITTYBL-YJYMSZOUSA-N_|_Small molecule_|_False_|_ARFORMOTEROL_|_2006.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['(-)-formoterol' '(r,r)-formoterol' 'Arformoterol' 'Formoterol r,r-form']_|_[('Wikipedia', array(['Formoterol'], dtype=object)), ('drugbank', array(['DB01274'], dtype=object)), ('chEBI', array(['408174'], dtype=object))]_|_['CHEMBL3184383' 'CHEMBL605993' 'CHEMBL1200811' 'CHEMBL1951071']_|_{'rows': array(['EFO_0009661', 'EFO_0006505', 'EFO_0000341', 'EFO_0000341',
       'EFO_0006505', 'EFO_0000464', 'MONDO_0004979', 'EFO_0000464'],
      dtype=object), 'count': 8}_|_[ENSG00000169252]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and has 3 approved and 5 investigational indications."
CHEMBL14762,"CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1_|_BTIHMVBBUGXLCJ-OAHLLOKOSA-N_|_Small molecule_|_False_|_SELICICLIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AL-39256' 'CYC-202' 'Cyc-202' 'NSC-701554' 'R-roscovitine' 'Roscovitin'
 'Roscovitine' 'Seliciclib']_|_[('PubChem', array(['124891685', '26753649', '26753650', '50100113', '50107006',
       '527377'], dtype=object)), ('Wikipedia', array(['Seliciclib'], dtype=object)), ('drugbank', array(['DB06195'], dtype=object)), ('chEBI', array(['45307'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0009061', 'MONDO_0007254', 'EFO_0003060', 'EFO_0000616',
       'EFO_1001110'], dtype=object), 'count': 5}_|_[ENSG00000134058,ENSG00000164885,ENSG00000136807,ENSG00000123374,ENSG00000170312]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."
CHEMBL1743028,"nan_|_nan_|_Antibody drug conjugate_|_False_|_GLEMBATUMUMAB VEDOTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['CDX-011' 'CR-011-VCMMAE' 'Glembatumumab vedotin']_|_nan_|_nan_|_{'rows': array(['EFO_0000637', 'EFO_0000756', 'EFO_0000708', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000136235,ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Antibody drug conjugate drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL198877,"Oc1ccc([C@H]2COc3cc(O)ccc3C2)cc1_|_ADFCQWZHKCXPAJ-GFCCVEGCSA-N_|_Small molecule_|_False_|_AUS-131_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['(S)-Equol' 'Aus-131']_|_[('Wikipedia', array(['Equol'], dtype=object)), ('drugbank', array(['DB11674'], dtype=object)), ('chEBI', array(['34741'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975', 'EFO_0000284', 'GO_0042697', 'MONDO_0007254'],
      dtype=object), 'count': 4}_|_[ENSG00000140009]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL2105758,"O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1.O=C(O)/C=C\C(=O)O_|_MISPBGHDNZYFNM-BTJKTKAUSA-N_|_Small molecule_|_False_|_AVATROMBOPAG MALEATE_|_2018.0_|_4.0_|_CHEMBL2103883_|_False_|_True_|_['Doptelet']_|_['Avatrombopag maleate' 'E-5501 MALEATE' 'E5501 MALEATE']_|_[('DailyMed', array(['avatrombopag%20maleate'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/doptelet'],
      dtype=object))]_|_nan_|_{'rows': array(['HP_0001873', 'EFO_0001421'], dtype=object), 'count': 2}_|_[ENSG00000117400]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for thrombocytopenia and liver disease."
CHEMBL2108611,"nan_|_nan_|_Antibody drug conjugate_|_True_|_INOTUZUMAB OZOGAMICIN_|_2017.0_|_4.0_|_nan_|_False_|_True_|_['Besponsa']_|_['CMC-544' 'Inotuzumab ozogamicin' 'PF-05208773' 'WAY-207294'
 'WAY-207294 CMC-544']_|_[('DailyMed', array(['inotuzumab%20ozogamicin'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000565', 'EFO_0000616', 'EFO_0000094', 'MONDO_0044881',
       'EFO_0000220', 'EFO_0000094', 'EFO_0000403', 'MONDO_0000873',
       'EFO_1000131', 'EFO_0004289', 'EFO_0000096', 'EFO_0005952',
       'MONDO_0018906', 'EFO_0000574', 'EFO_0000309'], dtype=object), 'count': 15}_|_[ENSG00000012124]_|_Antibody drug conjugate drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and has 5 approved and 10 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2108679,"nan_|_nan_|_Antibody_|_False_|_OZANEZUMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_['Gsk1223249']_|_['GSK-1223249' 'GSK1223249' 'Ozanezumab']_|_nan_|_nan_|_{'rows': array(['MONDO_0005301', 'MONDO_0004976', 'EFO_0003929'], dtype=object), 'count': 3}_|_[ENSG00000115310]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL254328,"C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(c3cccnc3)=CC[C@@H]12_|_GZOSMCIZMLWJML-VJLLXTKPSA-N_|_Small molecule_|_False_|_ABIRATERONE_|_nan_|_4.0_|_nan_|_False_|_True_|_['Zytiga']_|_['Abiraterone' 'CB 7598' 'CB-7598' 'NSC-741232']_|_[('Wikipedia', array(['Abiraterone'], dtype=object)), ('drugbank', array(['DB05812'], dtype=object)), ('chEBI', array(['68642'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004992', 'EFO_0001663', 'EFO_0000616', 'MONDO_0008315',
       'EFO_0000673', 'EFO_0000196'], dtype=object), 'count': 6}_|_[ENSG00000145545,ENSG00000277893,ENSG00000128039,ENSG00000148795,ENSG00000169083]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 4 investigational indications."
CHEMBL3137314,"CC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O_|_CTPOHARTNNSRSR-NOQAJONNSA-N_|_Small molecule_|_False_|_ESUBERAPROST_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['APS-314d' 'Aps-314d' 'Aps-314d free acid' 'BPS-314d' 'Esuberaprost']_|_nan_|_['CHEMBL3137337' 'CHEMBL4298145']_|_{'rows': array(['EFO_0001361', 'MONDO_0005149'], dtype=object), 'count': 2}_|_[ENSG00000160013]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3545224,"Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NCC2CCC(CNCCCNC3CCCCC3)CC2)n1_|_QLVSJMZJSABWRX-UHFFFAOYSA-N_|_Small molecule_|_False_|_BURIXAFOR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Burixafor' 'Tg-0054']_|_nan_|_nan_|_{'rows': array(['EFO_0000183', 'EFO_0005952', 'MONDO_0008315', 'EFO_0001378'],
      dtype=object), 'count': 4}_|_[ENSG00000121966]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL3701238,"C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1_|_KEIPNCCJPRMIAX-HNNXBMFYSA-N_|_Small molecule_|_False_|_FUTIBATINIB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Lytgobi']_|_['Fgfr-in-1' 'Futibatinib' 'TAS-120' 'Tas 120' 'Tas-120']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/FUTIBATINIB/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB15149'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000182', 'MONDO_0007254', 'MONDO_0004992', 'EFO_0003891',
       'EFO_1001968', 'EFO_0005221', 'EFO_0000616', 'EFO_0003060'],
      dtype=object), 'count': 8}_|_[ENSG00000068078,ENSG00000077782,ENSG00000160867,ENSG00000066468]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and has 3 approved and 5 investigational indications."
CHEMBL3833342,"nan_|_nan_|_Oligonucleotide_|_False_|_NUSINERSEN SODIUM_|_2016.0_|_4.0_|_nan_|_False_|_True_|_['Spinraza']_|_[]_|_[('DailyMed', array(['nusinersen%20sodium'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/spinraza'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0008525'], dtype=object), 'count': 1}_|_[ENSG00000205571]_|_Oligonucleotide drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for spinal muscular atrophy."
CHEMBL3989689,"CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O.C[C@H](O)C(=O)O.O_|_ZPYIELFRIYUVQP-BHBJEIPNSA-N_|_Small molecule_|_False_|_SQUALAMINE LACTATE_|_nan_|_3.0_|_CHEMBL444929_|_False_|_False_|_[]_|_['MSI-1256F' 'Squalamine lactate' 'Squalamine lactate hydrate']_|_nan_|_nan_|_{'rows': array(['MONDO_0008315', 'MONDO_0008170', 'EFO_0009606', 'EFO_0001365',
       'EFO_0003770'], dtype=object), 'count': 5}_|_[ENSG00000066230]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."
CHEMBL4297578,"nan_|_nan_|_Protein_|_False_|_PEGBELFERMIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ARX-618' 'BMS-986036' 'Bms-986036' 'Peg-fgf21' 'Pegbelfermin']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/PEGBELFERMIN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_1001249', 'MONDO_0005148', 'HP_0001395', 'EFO_0003095'],
      dtype=object), 'count': 4}_|_[ENSG00000113578,ENSG00000134962]_|_Protein drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."
CHEMBL4297610,"C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O_|_NEQYWYXGTJDAKR-JTQLQIEISA-N_|_Small molecule_|_True_|_OLUTASIDENIB_|_2022.0_|_4.0_|_nan_|_False_|_True_|_['Rezlidhia']_|_['FT-2102' 'Ft-2102' 'Olutasidenib' 'Rezlidhia']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/OLUTASIDENIB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000222', 'EFO_0000198'], dtype=object), 'count': 2}_|_[ENSG00000138413]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2022 and is indicated for acute myeloid leukemia and has 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL4297760,"nan_|_nan_|_Oligonucleotide_|_False_|_GIVOSIRAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ALN-AS1' 'Givosiran']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/GIVOSIRAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0008294', 'MONDO_0007369', 'Orphanet_95157'], dtype=object), 'count': 3}_|_[ENSG00000023330]_|_Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297858,"nan_|_nan_|_Antibody_|_False_|_BUDIGALIMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ABBV-181' 'ABBV181' 'Abbv-181' 'Budigalimab' 'PR-1648817']_|_nan_|_nan_|_{'rows': array(['EFO_0000182', 'EFO_1001951', 'EFO_0000764', 'EFO_0000180',
       'EFO_0000702', 'MONDO_0007254', 'EFO_0000616', 'MONDO_0008170',
       'MONDO_0004992', 'EFO_0006859'], dtype=object), 'count': 10}_|_[ENSG00000188389]_|_Antibody drug with a maximum clinical trial phase of II (across all indications) and has 10 investigational indications."
CHEMBL436,"COc1ccc2c(C(=S)N(C)CC(=O)O)cccc2c1C(F)(F)F_|_LUBHDINQXIHVLS-UHFFFAOYSA-N_|_Small molecule_|_False_|_TOLRESTAT_|_1989.0_|_4.0_|_nan_|_True_|_True_|_['Alderase' 'Alredase']_|_['AY-27,773' 'AY-27773' 'Tolrestat']_|_[('PubChem', array(['144206867'], dtype=object)), ('Wikipedia', array(['Tolrestat'], dtype=object)), ('drugbank', array(['DB02383'], dtype=object)), ('chEBI', array(['48549'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000400'], dtype=object), 'count': 1}_|_[ENSG00000085662]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989 and is indicated for diabetes mellitus. It was withdrawn in at least one region."
CHEMBL520733,"CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21_|_PKXWXXPNHIWQHW-RCBQFDQVSA-N_|_Small molecule_|_False_|_SEMAGACESTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['LY-450139' 'LY450139' 'Semagacestat']_|_[('Wikipedia', array(['Semagacestat'], dtype=object)), ('drugbank', array(['DB12463'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004975'], dtype=object), 'count': 1}_|_[ENSG00000117362,ENSG00000205155,ENSG00000138613,ENSG00000080815,ENSG00000162736,ENSG00000143801]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL968,"CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21_|_SAADBVWGJQAEFS-UHFFFAOYSA-N_|_Small molecule_|_True_|_FLURAZEPAM_|_1970.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Dalmane' 'Flurazepam' 'Insumin']_|_[('PubChem', array(['144205754', '170465018', '26757995'], dtype=object)), ('Wikipedia', array(['Flurazepam'], dtype=object)), ('drugbank', array(['DB00690'], dtype=object))]_|_['CHEMBL3989724']_|_{'rows': array(['EFO_0004698', 'EFO_0005230', 'EFO_0004698', 'HP_0000726',
       'MONDO_0002050', 'MONDO_0005090'], dtype=object), 'count': 6}_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1970 and is indicated for insomnia and has 5 investigational indications. This drug has a black box warning from the FDA."
CHEMBL1200341,"CC(C)NCCCC1(C(N)=O)c2ccccc2-c2ccccc21.Cl_|_NXNSCUZKMVYAJQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_INDECAINIDE HYDROCHLORIDE_|_1989.0_|_4.0_|_CHEMBL1201242_|_False_|_True_|_['Decabid']_|_['Indecainide hcl' 'Indecainide hydrochloride' 'LY 135837' 'LY-135837'
 'LY-135857' 'Ricainide']_|_nan_|_nan_|_nan_|_[ENSG00000144285,ENSG00000183873,ENSG00000007314,ENSG00000136546,ENSG00000136531,ENSG00000169432,ENSG00000153253,ENSG00000168356,ENSG00000196876,ENSG00000185313]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989."
CHEMBL1200473,"CN(C)CCOC(=O)C(c1ccccc1)C1(O)CCCC1.Cl_|_RHKZVMUBMXGOLL-UHFFFAOYSA-N_|_Small molecule_|_False_|_CYCLOPENTOLATE HYDROCHLORIDE_|_1974.0_|_4.0_|_CHEMBL1201338_|_False_|_True_|_['Ak-pentolate' 'Akpentolate' 'Alnide' 'Cyclogyl'
 'Cyclopentolate hydrochloride' 'Mydrilate' 'Pentolair']_|_['Cyclopentolate hcl' 'Cyclopentolate hydrochloride' 'Cylate' 'Cyplegin'
 'NSC-756706']_|_[('DailyMed', array(['cyclopentolate%20hydrochloride'], dtype=object)), ('PubChem', array(['170464720', '26747954', '56320713', '855558'], dtype=object)), ('Wikipedia', array(['Cyclopentolate'], dtype=object)), ('chEBI', array(['4025'], dtype=object))]_|_nan_|_{'rows': array(['HP_0011499'], dtype=object), 'count': 1}_|_[ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974 and is indicated for mydriasis."
CHEMBL1201758,"O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1_|_YWGDOWXRIALTES-NRFANRHFSA-N_|_Small molecule_|_False_|_BEPOTASTINE_|_2009.0_|_4.0_|_nan_|_False_|_True_|_['Bepreve']_|_['Bepotastine' 'Betotastine']_|_[('Wikipedia', array(['Bepotastine'], dtype=object)), ('chEBI', array(['71204'], dtype=object))]_|_['CHEMBL1201759']_|_{'rows': array(['EFO_1001417', 'EFO_0007141', 'HP_0000989', 'MONDO_0002406',
       'EFO_1001417', 'EFO_0003956', 'EFO_0007141'], dtype=object), 'count': 7}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated for allergic conjunctivitis and pruritus and has 4 investigational indications."
CHEMBL1404,"COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1_|_XKLMZUWKNUAPSZ-UHFFFAOYSA-N_|_Small molecule_|_False_|_RANOLAZINE_|_2006.0_|_4.0_|_nan_|_False_|_True_|_['Aspruzyo sprinkle' 'Ranexa' 'Ranexa (previously latixa)' 'Ranolazine']_|_['Aspruzyo' 'CVT-303' 'NSC-759100' 'RS-43285-003' 'Ran d' 'Ranolazine']_|_[('DailyMed', array(['ranolazine'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/ranexa-previously-latixa'],
      dtype=object)), ('PubChem', array(['104171232', '170465435', '174006299', '26749060', '26749061',
       '50107515', '56463697', '90340842'], dtype=object)), ('Wikipedia', array(['Ranolazine'], dtype=object)), ('drugbank', array(['DB00243'], dtype=object)), ('chEBI', array(['87690'], dtype=object))]_|_['CHEMBL1526084' 'CHEMBL537649']_|_{'rows': array(['EFO_0000319', 'MONDO_0004976', 'EFO_0000384', 'EFO_1001375',
       'MONDO_0005148', 'EFO_0001361', 'EFO_1000899', 'EFO_0003913',
       'EFO_0004264', 'EFO_0000275', 'EFO_0005672', 'MONDO_0008195',
       'EFO_0000407', 'EFO_0001645', 'EFO_0000555', 'EFO_0003086',
       'HP_0001657'], dtype=object), 'count': 17}_|_[ENSG00000007314,ENSG00000183873]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for cardiovascular disease and angina pectoris and has 15 investigational indications."
CHEMBL186179,"COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1_|_IRLWJILLXJGJTD-UHFFFAOYSA-N_|_Small molecule_|_False_|_MURAGLITAZAR_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS-298585' 'BMS-298585-01' 'MK-0478' 'MK0478' 'Muraglitazar']_|_[('PubChem', array(['170466259'], dtype=object)), ('drugbank', array(['DB06510'], dtype=object))]_|_['CHEMBL3527055' 'CHEMBL557580']_|_{'rows': array(['Orphanet_309005', 'EFO_0000400', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000132170,ENSG00000186951]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL1909285,"Cc1nc([N+](=O)[O-])cn1-c1ccc([N+](=O)[O-])cc1_|_NMTBSNPBIGRZBL-UHFFFAOYSA-N_|_Small molecule_|_False_|_NITREFAZOLE_|_nan_|_4.0_|_nan_|_True_|_True_|_[]_|_['EMD 15 700' 'EMD-15-700' 'Nitrefazole']_|_[('PubChem', array(['144206859'], dtype=object))]_|_nan_|_nan_|_[ENSG00000187758,ENSG00000198099,ENSG00000196616,ENSG00000248144,ENSG00000196344,ENSG00000197894,ENSG00000172955]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL191,"CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1_|_PSIFNNKUMBGKDQ-UHFFFAOYSA-N_|_Small molecule_|_True_|_LOSARTAN_|_1995.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Allisartan' 'Angizaar' 'Dup-89' 'E-3174' 'EXP3174' 'Exp-3174' 'HGP-1405'
 'HGP1405' 'Losartan' 'Losartan carboxylic acid' 'Losartic' 'Lozap'
 'NSC-758699']_|_[('PubChem', array(['144204988', '170465135', '26748956'], dtype=object)), ('Wikipedia', array(['Losartan'], dtype=object)), ('drugbank', array(['DB00678'], dtype=object)), ('chEBI', array(['6541'], dtype=object))]_|_['CHEMBL367465' 'CHEMBL995']_|_{'rows': array(['MP_0001845', 'EFO_0004265', 'EFO_0000319', 'EFO_1000637',
       'EFO_0006818', 'MONDO_0007254', 'EFO_0000693', 'EFO_0000546',
       'EFO_0002618', 'HP_0009588', 'EFO_0007148', 'MONDO_0002474',
       'MONDO_0005149', 'EFO_0003086', 'EFO_0002618', 'EFO_0003144',
       'MONDO_0005147', 'EFO_0004194', 'EFO_0004236', 'MONDO_0005148',
       'MONDO_0009061', 'MONDO_0001134', 'EFO_0003095', 'EFO_0000637',
       'EFO_0000401', 'EFO_1001249', 'EFO_0002617', 'MONDO_0007947',
       'HP_0000093', 'EFO_0004232', 'MONDO_0011382', 'EFO_0004212',
       'EFO_0000537', 'EFO_0000537', 'EFO_0000668', 'EFO_0000694',
       'MONDO_0007947', 'EFO_0000712', 'EFO_0003884', 'EFO_0003884',
       'EFO_0000538', 'EFO_0003086', 'EFO_0000519', 'EFO_1000653',
       'MONDO_0100096', 'EFO_0000764', 'MONDO_0005184', 'EFO_0000768',
       'MONDO_0001134', 'EFO_0006890', 'HP_0000093', 'EFO_0004616',
       'EFO_0003896', 'EFO_0001358'], dtype=object), 'count': 54}_|_[ENSG00000144891]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 6 approved and 46 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2048484,"Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1_|_XTNGUQKDFGDXSJ-ZXGKGEBGSA-N_|_Small molecule_|_True_|_CANAGLIFLOZIN ANHYDROUS_|_2011.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['JNJ-28431754' 'TA-7284']_|_[('drugbank', array(['DB08907'], dtype=object)), ('chEBI', array(['73274'], dtype=object))]_|_['CHEMBL4594217' 'CHEMBL2103841']_|_{'rows': array(['EFO_0000401', 'MONDO_0005147', 'HP_0000083', 'EFO_0000400',
       'MONDO_0005148', 'MONDO_0007254', 'EFO_0003144', 'EFO_0001073',
       'EFO_0000660'], dtype=object), 'count': 9}_|_[ENSG00000140675]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for diabetes mellitus and type 2 diabetes mellitus and has 7 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2103991,"Cn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O_|_IETKPTYAGKZLKY-UHFFFAOYSA-N_|_Small molecule_|_False_|_BALAGLITAZONE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Balaglitazone' 'DRF-2593' 'Drf-2593' 'NN-2344']_|_[('drugbank', array(['DB12781'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0005148'], dtype=object), 'count': 1}_|_[ENSG00000132170]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL2105760,"O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1_|_ZKIAIYBUSXZPLP-UHFFFAOYSA-N_|_Small molecule_|_True_|_BREXPIPRAZOLE_|_2015.0_|_4.0_|_nan_|_False_|_True_|_['Rexulti' 'Rxulti']_|_['Brexpiprazole' 'OPC-34712']_|_[('DailyMed', array(['brexpiprazole'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti'],
      dtype=object)), ('drugbank', array(['DB09128'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0002050', 'MONDO_0004985', 'MONDO_0005090', 'HP_0000713',
       'EFO_0009963', 'EFO_0008568', 'MONDO_0002009', 'HP_0012076',
       'MONDO_0004975', 'EFO_0005411', 'MONDO_0002009', 'EFO_0005407',
       'MONDO_0007079', 'EFO_0001358'], dtype=object), 'count': 14}_|_[ENSG00000149295,ENSG00000102468,ENSG00000178394]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 4 approved and 9 investigational indications. This drug has a black box warning from the FDA."
CHEMBL2109508,nan_|_nan_|_Antibody_|_False_|_IMMURAIT-LL2_|_nan_|_-1.0_|_nan_|_False_|_False_|_[]_|_['IMMURAIT-LL2']_|_nan_|_nan_|_nan_|_[ENSG00000012124]_|_Antibody drug.
CHEMBL2364614,"CN1Cc2cc(-c3ccc(N)nn3)ccc2[C@H](c2ccc3ccccc3c2)C1_|_VCIBGDSRPUOBOG-QFIPXVFZSA-N_|_Small molecule_|_False_|_LIAFENSINE_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['BMS-820836' 'Liafensine']_|_[('drugbank', array(['DB14878'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0009854', 'MONDO_0002050'], dtype=object), 'count': 2}_|_[ENSG00000108576,ENSG00000142319,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2364628,"O=C(CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1)NO_|_QGZYDVAGYRLSKP-UHFFFAOYSA-N_|_Small molecule_|_False_|_RICOLINOSTAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['ACY-1215' 'ACY-63' 'Ricolinostat']_|_[('drugbank', array(['DB12376'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0001378', 'EFO_0000095', 'EFO_1000783', 'EFO_0000305',
       'EFO_0000574', 'EFO_1001959', 'EFO_0009387'], dtype=object), 'count': 7}_|_[ENSG00000094631]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL27193,"C[C@H](CCc1ccccc1)NC[C@H](O)c1ccc(O)c(C(N)=O)c1_|_SGUAFYQXFOLMHL-ACJLOTCBSA-N_|_Small molecule_|_False_|_DILEVALOL_|_1990.0_|_4.0_|_nan_|_True_|_True_|_[]_|_['(r,r)-labetalol' 'Dilevalol' 'Labetalol (r,r)-form']_|_nan_|_['CHEMBL1204165']_|_nan_|_[ENSG00000043591,ENSG00000169252,ENSG00000188778]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990."
CHEMBL3545308,"C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1_|_HUFOZJXAKZVRNJ-UHFFFAOYSA-N_|_Small molecule_|_False_|_ROCILETINIB_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['AVL-301' 'CNX-419' 'CO-1686' 'CS-1631' 'Rociletinib']_|_[('drugbank', array(['DB11907'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'EFO_0003060'], dtype=object), 'count': 2}_|_[ENSG00000146648]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."
CHEMBL3707351,"Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1_|_FASLTMSUPQDLIB-MHZLTWQESA-N_|_Small molecule_|_False_|_ADOMEGLIVANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Adomeglivant' 'Adomeglivant, (-)-' 'LY-2409021' 'LY2409021' 'Ly2409021']_|_[('drugbank', array(['DB11704'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003884', 'MONDO_0005147', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000215644]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL3990029,"nan_|_nan_|_Antibody_|_False_|_RISANKIZUMAB_|_2019.0_|_4.0_|_nan_|_False_|_True_|_['Skyrizi']_|_['655066-01' 'ABBV-066' 'BI655066' 'Bi-655066' 'Risankizumab'
 'Risankizumab rzaa']_|_[('DailyMed', array(['risankizumab-rzaa'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0004979', 'MONDO_0002406', 'EFO_0000384', 'EFO_1000710',
       'EFO_0000676', 'EFO_0003778', 'EFO_0000729', 'EFO_0003898',
       'MONDO_0100096', 'MONDO_0015597', 'EFO_0000540'], dtype=object), 'count': 11}_|_[ENSG00000113302,ENSG00000110944]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 4 approved and 7 investigational indications."
CHEMBL4297960,"nan_|_nan_|_Unknown_|_False_|_DAVANAT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Davanat' 'GM-CT-01' 'Galactomannan c' 'Gm-ct-01']_|_nan_|_nan_|_{'rows': array(['EFO_1001951', 'EFO_0002617'], dtype=object), 'count': 2}_|_[ENSG00000100097,ENSG00000131981]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL4297994,"nan_|_nan_|_Unknown_|_False_|_TILSOTOLIMOD SODIUM_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['IMO-2125 sodium' 'TLR9 AGONIST IMO-2125' 'Tilsotolimod sodium']_|_nan_|_nan_|_{'rows': array(['EFO_0002617', 'EFO_0003047', 'EFO_0000756'], dtype=object), 'count': 3}_|_[ENSG00000239732]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4298086,"nan_|_nan_|_Antibody_|_False_|_POZELIMAB_|_2023.0_|_4.0_|_nan_|_False_|_True_|_['Veopoz']_|_['Pozelimab' 'REGN-3918' 'REGN3918' 'Regn3918']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/POZELIMAB/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0100244', 'HP_0002243', 'MONDO_0100244', 'EFO_0004991'],
      dtype=object), 'count': 4}_|_[ENSG00000106804]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2023 and is indicated for protein-losing enteropathy and has 3 investigational indications."
CHEMBL4650521,"C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N_|_UCJZOKGUEJUNIO-IINYFYTJSA-N_|_Small molecule_|_False_|_BATOPROTAFIB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Batoprotafib' 'Ptpn11 inhibitor tno155' 'Shp2 inhibitor tno155'
 'TNO-155' 'TNO155' 'Tno 155' 'Tno-155' 'Tno155']_|_[('INN', array(['https://www.who.int/publications/m/item/inn-pl-127'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000179295]_|_Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."
CHEMBL5315126,"nan_|_nan_|_Protein_|_False_|_FOLLITROPIN BETA_|_1996.0_|_4.0_|_nan_|_False_|_True_|_['Follistim' 'Follistim aq' 'Puregon']_|_['Fertavid' 'Follitropin beta']_|_[('DailyMed', array(['follitropin%20alfa/beta'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/puregon'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000545', 'HP_0000044'], dtype=object), 'count': 2}_|_[ENSG00000170820]_|_Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for infertility and hypogonadotropic hypogonadism."
CHEMBL538943,"CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O_|_CILBMBUYJCWATM-UDRBCWGGSA-N_|_Small molecule_|_True_|_VINORELBINE TARTRATE_|_1994.0_|_4.0_|_CHEMBL553025_|_False_|_True_|_['Navelbine' 'Vinorelbine tartrate']_|_['Liposomal vinorelbine tartrate' 'TLC-178' 'TLC178'
 'Vinorelbine (as tartrate)' 'Vinorelbine Ditartarate'
 'Vinorelbine ditartrate' 'Vinorelbine liposomal' 'Vinorelbine tartrate'
 'Vinorelbine tartrate (1:2)']_|_[('PubChem', array(['144205824', '170465330'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000571', 'EFO_0003060', 'EFO_0000211', 'EFO_0000691',
       'EFO_0006861', 'MONDO_0004992', 'MONDO_0002974', 'EFO_0000588',
       'EFO_0000183', 'MONDO_0021063', 'EFO_0000313', 'MONDO_0008315',
       'EFO_0000437', 'MONDO_0007254', 'MONDO_0002367', 'EFO_0000616',
       'EFO_0000621', 'EFO_0000248', 'EFO_1000158', 'MONDO_0001187',
       'EFO_0003869', 'EFO_0000565', 'MONDO_0008903', 'EFO_0001416',
       'MONDO_0001402', 'MONDO_0011962', 'EFO_0005952', 'EFO_0000574'],
      dtype=object), 'count': 28}_|_[ENSG00000188229,ENSG00000101162,ENSG00000198033,ENSG00000127824,ENSG00000258947,ENSG00000167552,ENSG00000104833,ENSG00000261456,ENSG00000196230,ENSG00000123416,ENSG00000167553,ENSG00000152086,ENSG00000137267,ENSG00000137285,ENSG00000176014]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 28 investigational indications. This drug has a black box warning from the FDA."
CHEMBL668,"CNCCCC1c2ccccc2C=Cc2ccccc21_|_BWPIARFWQZKAIA-UHFFFAOYSA-N_|_Small molecule_|_True_|_PROTRIPTYLINE_|_1967.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['Protriptyline']_|_[('PubChem', array(['11111679', '11111680', '50100330', '50104299', '90341254'],
      dtype=object)), ('Wikipedia', array(['Protriptyline'], dtype=object)), ('drugbank', array(['DB00344'], dtype=object)), ('chEBI', array(['8597'], dtype=object))]_|_['CHEMBL1200332']_|_{'rows': array(['MONDO_0002009', 'MONDO_0002050'], dtype=object), 'count': 2}_|_[ENSG00000108576,ENSG00000103546]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1967 and is indicated for major depressive disorder and depressive disorder. This drug has a black box warning from the FDA."
CHEMBL811,"CN(C)CCC(c1ccc(Br)cc1)c1ccccn1_|_ZDIGNSYAACHWNL-UHFFFAOYSA-N_|_Small molecule_|_False_|_BROMPHENIRAMINE_|_1957.0_|_4.0_|_nan_|_False_|_True_|_[]_|_['BPN' 'Bromfed' 'Bromfenex' 'Brompheniramine' 'Brotane' 'Dimetane'
 'Dimetapp' 'Lodrane']_|_[('PubChem', array(['90341200'], dtype=object)), ('Wikipedia', array(['Brompheniramine'], dtype=object)), ('drugbank', array(['DB00835'], dtype=object)), ('chEBI', array(['3183'], dtype=object))]_|_['CHEMBL1200961']_|_{'rows': array(['MONDO_0005271', 'HP_0001742', 'EFO_0007214', 'MONDO_0005271',
       'EFO_0003956', 'EFO_0007486', 'HP_0012735'], dtype=object), 'count': 7}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and has 6 approved indications."
CHEMBL859,"Oc1nc(O)c2cn[nH]c2n1_|_HXNFUBHNUDHIGC-UHFFFAOYSA-N_|_Small molecule_|_False_|_OXYPURINOL_|_nan_|_4.0_|_nan_|_False_|_True_|_[]_|_['NSC-76239' 'Oxipurinol' 'Oxypurinol']_|_[('PubChem', array(['144211537', '57264357'], dtype=object)), ('Wikipedia', array(['Oxypurinol'], dtype=object)), ('drugbank', array(['DB05262'], dtype=object)), ('chEBI', array(['28315'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0011382', 'EFO_0000373'], dtype=object), 'count': 2}_|_[ENSG00000158125]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 2 investigational indications."
CHEMBL86304,"O=C(NCCN1CCOCC1)c1ccc(Cl)cc1_|_YHXISWVBGDMDLQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_MOCLOBEMIDE_|_1990.0_|_4.0_|_nan_|_False_|_True_|_['Manerix']_|_['Aurorix' 'GNF-PF-695' 'Moclobemide' 'RO 11-1163/000' 'RO-111163000']_|_[('PubChem', array(['104171398', '144204522', '144207163', '170465663', '50086440',
       '50105006', '50105007', '846440', '90340853'], dtype=object)), ('Wikipedia', array(['Moclobemide'], dtype=object)), ('drugbank', array(['DB01171'], dtype=object)), ('chEBI', array(['83531'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003768', 'EFO_0005230', 'MONDO_0002009', 'HP_0000726',
       'MONDO_0005090', 'MONDO_0002050', 'EFO_0003890'], dtype=object), 'count': 7}_|_[ENSG00000189221]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for major depressive disorder and depressive disorder and has 5 investigational indications."
CHEMBL1086997,"CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO_|_UQRORFVVSGFNRO-XFWSIPNHSA-N_|_Small molecule_|_False_|_LUCERASTAT_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['ACT-434964' 'Lucerastat' 'N-N-Butyl Deoxygalactonojirimycin']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/LUCERASTAT/relevant/1/'],
      dtype=object)), ('drugbank', array(['DB14872'], dtype=object))]_|_nan_|_{'rows': array(['MONDO_0010526'], dtype=object), 'count': 1}_|_[ENSG00000148154]_|_Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."
CHEMBL1200903,"C=CCC1(C(C)CCC)C(=O)[N-]C(=O)NC1=O.[Na+]_|_AXXJTNXVUHVOJW-UHFFFAOYSA-M_|_Small molecule_|_False_|_SECOBARBITAL SODIUM_|_1950.0_|_4.0_|_CHEMBL447_|_True_|_True_|_['Secobarbital sodium' 'Seconal sodium' 'Seconesin' 'Tuinal']_|_['(rs)-secobarbital sodium' 'Barbosec' 'Evronal sodium' 'Immenoctal'
 'NSC-10818' 'Pramil' 'Quinalbarbitone sodium' 'Sebar'
 'Secobarbital sodium' 'Synate']_|_nan_|_nan_|_nan_|_[ENSG00000022355,ENSG00000145864,ENSG00000113327,ENSG00000166206,ENSG00000109158,ENSG00000182256,ENSG00000268089,ENSG00000011677,ENSG00000094755,ENSG00000187730,ENSG00000163285,ENSG00000163288,ENSG00000102287,ENSG00000151834,ENSG00000186297,ENSG00000145863]_|_Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950. It was withdrawn in at least one region."
CHEMBL1201777,"CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C.Cl_|_ZELFLGGRLLOERW-YECZQDJWSA-N_|_Small molecule_|_True_|_TAPENTADOL HYDROCHLORIDE_|_2008.0_|_4.0_|_CHEMBL1201776_|_False_|_True_|_['Nucynta' 'Nucynta er' 'Palexia']_|_['BN-200 HYDROCHLORIDE' 'CG-5503 HYDROCHLORIDE' 'CG5503 HYDROCHLORIDE'
 'Tapentadol hcl' 'Tapentadol hydrochloride']_|_[('DailyMed', array(['tapentadol%20hydrochloride'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003843', 'HP_0003419', 'HP_0012532', 'EFO_0005762'],
      dtype=object), 'count': 4}_|_[ENSG00000103546,ENSG00000112038]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 1 investigational indication. This drug has a black box warning from the FDA."
CHEMBL1254771,"COc1cc(C)c(S(=O)(=O)N(C)CCOCC(=O)N(C)Cc2ccc(C3=NCCN3)cc2)c(C)c1_|_AMTQCENHQIDBHQ-UHFFFAOYSA-N_|_Small molecule_|_False_|_SAFOTIBANT_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['FOV-2304' 'Fov2304' 'Fov2304 free base' 'LF22-0542' 'Lf 22-0542'
 'Lf-22-0542' 'Safotibant' 'Safotibant phosphate']_|_nan_|_nan_|_nan_|_[ENSG00000100739]_|_Small molecule drug with a maximum clinical trial phase of II."
CHEMBL1258517,"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1_|_WXUUCRLKXQMWRY-UHFFFAOYSA-N_|_Small molecule_|_False_|_PKI-179_|_nan_|_1.0_|_nan_|_False_|_False_|_[]_|_['PKI-179' 'Pki-179']_|_nan_|_nan_|_{'rows': array(['EFO_0000616'], dtype=object), 'count': 1}_|_[ENSG00000198793,ENSG00000121879]_|_Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."
CHEMBL1607273,"Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1_|_PGLIUCLTXOYQMV-UHFFFAOYSA-N_|_Small molecule_|_False_|_CETIRIZINE HYDROCHLORIDE_|_1995.0_|_4.0_|_CHEMBL1000_|_False_|_True_|_['Allacan' 'Allertek' 'Becoallergy' 'Cetec' 'Cetirizine hydrochloride'
 'Cetirizine hydrochloride allergy' 'Cetirizine hydrochloride hives'
 'Cetirizine hydrochloride hives relief' 'Cetirocol'
 ""Children's cetirizine hydrochloride allergy""
 ""Children's cetirizine hydrochloride hives relief""
 ""Children's zyrtec allergy"" ""Children's zyrtec hives relief"" 'Piriteze'
 'Pollenshield' 'Quzyttir' 'Zerviate' 'Ziralton' 'Zirtek' 'Zynor' 'Zyrtec'
 'Zyrtec allergy' 'Zyrtec hives relief']_|_['Cetirizine' 'Cetirizine dihydrochloride' 'Cetirizine hcl'
 'Cetirizine hydrochloride' 'Cetrine' 'NSC-759102' 'P 071' 'P-071'
 'Zyrtec']_|_[('DailyMed', array(['cetirizine%20hydrochloride'], dtype=object)), ('PubChem', array(['144204255', '144212578', '170465442', '26749066'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0003830', 'HP_0001742', 'HP_0000989', 'EFO_0007141',
       'MONDO_0005271', 'EFO_0005531', 'EFO_0005854', 'EFO_1001417',
       'EFO_0003956'], dtype=object), 'count': 9}_|_[ENSG00000196639]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 7 approved and 2 investigational indications."
CHEMBL1789844,"nan_|_nan_|_Antibody_|_False_|_IPILIMUMAB_|_2011.0_|_4.0_|_nan_|_False_|_True_|_['Yervoy']_|_['BMS-734016' 'BMS734016' 'Ipilimumab' 'MDX-010' 'MDX-010 MDX-CTLA4'
 'MDX-101' 'MDX-CTLA-4' 'MDX010']_|_[('DailyMed', array(['ipilimumab'], dtype=object)), ('DrugCentral', array(['4958'], dtype=object)), ('EMA', array(['https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy'],
      dtype=object))]_|_nan_|_{'rows': array(['MONDO_0001056', 'EFO_0007466', 'EFO_0000708', 'EFO_1000984',
       'EFO_1001950', 'EFO_0001416', 'EFO_0000365', 'EFO_0004251',
       'EFO_0001376', 'EFO_1001972', 'EFO_0005952', 'EFO_0001378',
       'MONDO_0002120', 'EFO_0004288', 'MONDO_0008315', 'MONDO_0002087',
       'MONDO_0007187', 'EFO_0000339', 'EFO_0009709', 'EFO_0008528',
       'EFO_0000096', 'EFO_0006859', 'EFO_0000403', 'EFO_0000389',
       'MONDO_0009348', 'MONDO_0002367', 'EFO_1001968', 'EFO_1000355',
       'EFO_0003085', 'EFO_1001471', 'EFO_0000621', 'EFO_0000181',
       'EFO_0004243', 'MONDO_0011719', 'EFO_1000359', 'EFO_0004284',
       'EFO_0003891', 'EFO_0002618', 'EFO_0000198', 'EFO_0000220',
       'EFO_1001951', 'EFO_0000228', 'EFO_0000702', 'EFO_0000616',
       'EFO_0001075', 'MONDO_0004992', 'MONDO_0001187', 'EFO_0000756',
       'EFO_0000519', 'EFO_1000657', 'EFO_0005543', 'EFO_0004142',
       'EFO_1001512', 'EFO_0000503', 'EFO_0000588', 'EFO_0001061',
       'EFO_0004193', 'EFO_0000196', 'MONDO_0011962', 'MONDO_0008903',
       'EFO_1000613', 'EFO_0005537', 'MONDO_0024503', 'EFO_0000673',
       'EFO_0004252', 'MONDO_0020634', 'EFO_0000707', 'MONDO_0005184',
       'EFO_0000222', 'MONDO_0008170', 'EFO_0000571', 'MONDO_0007254',
       'EFO_0000182', 'MONDO_0016642', 'MONDO_0004669', 'EFO_0000558',
       'MONDO_0002547', 'EFO_0000349', 'EFO_0000095', 'EFO_0003060',
       'EFO_1000251', 'MONDO_0007576', 'EFO_0000681', 'MONDO_0002898',
       'EFO_0002916', 'MONDO_0100342', 'MONDO_0017582', 'EFO_0001663',
       'EFO_0000313', 'EFO_0002617', 'MONDO_0021063', 'EFO_0000574',
       'EFO_0003863', 'EFO_0000770', 'MONDO_0002108', 'EFO_0000691',
       'EFO_0008524', 'EFO_0000305', 'EFO_1001465', 'EFO_0000764',
       'EFO_0000183', 'EFO_0005221'], dtype=object), 'count': 102}_|_[ENSG00000163599]_|_Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 12 approved and 90 investigational indications."
CHEMBL2103856,"CCOc1cc2c(c(F)c1OCC)C(=N)N(CC(=O)c1cc(N3CCOCC3)c(OC)c(C(C)(C)C)c1)C2_|_QWKAUGRRIXBIPO-UHFFFAOYSA-N_|_Small molecule_|_False_|_ATOPAXAR_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Atopaxar' 'E-5555' 'E5555' 'ER-172594-00']_|_[('drugbank', array(['DB12046'], dtype=object))]_|_['CHEMBL2105699']_|_{'rows': array(['EFO_0005672', 'EFO_0001645'], dtype=object), 'count': 2}_|_[ENSG00000181104]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
CHEMBL2108285,nan_|_nan_|_Antibody_|_False_|_CAPROMAB_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Capromab']_|_nan_|_nan_|_nan_|_[ENSG00000142515]_|_Antibody drug with a maximum clinical trial phase of II.
CHEMBL231616,"NC(=S)N/N=C/c1ncccc1N_|_XMYKNCNAZKMVQN-NYYWCZLTSA-N_|_Small molecule_|_False_|_TRIAPINE_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['3-AP' 'NSC-663249' 'OCX-0191' 'OCX-191' 'Ocx 191' 'PAN-811' 'Triapine']_|_[('PubChem', array(['510133'], dtype=object)), ('Wikipedia', array(['3-Aminopyridine-2-carboxaldehyde_thiosemicarbazone'], dtype=object)), ('drugbank', array(['DB11940'], dtype=object))]_|_nan_|_{'rows': array(['EFO_0000616', 'MONDO_0005411', 'EFO_1001901', 'MONDO_0008903',
       'MONDO_0024503', 'MONDO_0002367', 'EFO_0002618', 'MONDO_0008315',
       'EFO_0006861', 'EFO_0003060'], dtype=object), 'count': 10}_|_[ENSG00000167325,ENSG00000048392]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."
CHEMBL2355333,"CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1.Cl.Cl.O_|_WFUAVXYXJOQWAZ-GVKRCPFFSA-N_|_Small molecule_|_False_|_ZIMELDINE HYDROCHLORIDE_|_nan_|_4.0_|_CHEMBL37744_|_True_|_True_|_[]_|_['H 102/09 HYDROCHLORIDE' 'Zimeldine hcl' 'Zimeldine hydrochloride'
 'Zimelidine hydrochloride']_|_[('PubChem', array(['144204841', '170466366'], dtype=object))]_|_nan_|_nan_|_[ENSG00000179097,ENSG00000135914,ENSG00000164270,ENSG00000135312,ENSG00000166736,ENSG00000178394,ENSG00000179546,ENSG00000102468,ENSG00000147246,ENSG00000168830,ENSG00000148680,ENSG00000158748,ENSG00000157219,ENSG00000186038,ENSG00000149305,ENSG00000186090,ENSG00000178084]_|_Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region."
CHEMBL3545094,C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@@H](C)C/C=C/C(O)(CC)CC)=CCC23)C[C@@H](O)C[C@@H]1O_|_XDBOQJCMEXOPMU-BAHYQGKPSA-N_|_Small molecule_|_False_|_ELOCALCITOL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Bxl-628' 'Elocalcitol' 'Ro-26-9228']_|_nan_|_nan_|_nan_|_[ENSG00000111424]_|_Small molecule drug with a maximum clinical trial phase of II.
CHEMBL3707374,"CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F.Cl_|_GEDVJGOVRLHFQG-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMISELIMOD HYDROCHLORIDE_|_nan_|_2.0_|_CHEMBL3707375_|_False_|_False_|_[]_|_['Amiselimod hydrochloride' 'MT-1303']_|_nan_|_nan_|_{'rows': array(['EFO_0003767', 'EFO_0000676', 'EFO_0003929', 'EFO_0000384',
       'MONDO_0007915', 'EFO_0000729'], dtype=object), 'count': 6}_|_[ENSG00000180739,ENSG00000267534,ENSG00000125910,ENSG00000213694,ENSG00000170989]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."
CHEMBL376359,"Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O_|_ZSBOMTDTBDDKMP-OAHLLOKOSA-N_|_Small molecule_|_False_|_ALOGLIPTIN_|_2013.0_|_4.0_|_nan_|_False_|_True_|_['Vipidia']_|_['Alogliptin']_|_[('Wikipedia', array(['Alogliptin'], dtype=object)), ('drugbank', array(['DB06203'], dtype=object)), ('chEBI', array(['72323'], dtype=object))]_|_['CHEMBL227529' 'CHEMBL458537' 'CHEMBL459806']_|_{'rows': array(['EFO_0000400', 'MONDO_0005148', 'MONDO_0005148'], dtype=object), 'count': 3}_|_[ENSG00000197635]_|_Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for type 2 diabetes mellitus and has 2 investigational indications."
CHEMBL4112929,"C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O_|_FSWFYCYPTDLKON-CMJOXMDJSA-N_|_Small molecule_|_False_|_MILVEXIAN_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['BMS 986177' 'BMS-986177' 'Bms-986177' 'JNJ-70033093' 'Jnj-70033093'
 'Milvexian']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/MILVEXIAN/relevant/1/'],
      dtype=object))]_|_nan_|_{'rows': array(['EFO_0000275', 'MONDO_0000831', 'EFO_0005672'], dtype=object), 'count': 3}_|_[ENSG00000088926]_|_Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."
CHEMBL4297483,"CN(CCCn1nnc2cc(CNC[C@H](O)c3ccc(O)c4[nH]c(=O)ccc34)ccc21)[C@H]1CC[C@H](OC(=O)C(O)(c2cccs2)c2cccs2)CC1_|_ZNKWRAKPQQZLNX-ZDQHWEPJSA-N_|_Small molecule_|_False_|_NAVAFENTEROL_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['AZD-8871' 'AZD8871' 'Azd 8871' 'Azd8871' 'LAS-191351' 'LAS191351'
 'Navafenterol']_|_[('USAN', array(['https://searchusan.ama-assn.org/finder/usan/search/NAVAFENTEROL/relevant/1/'],
      dtype=object))]_|_['CHEMBL4650222']_|_{'rows': array(['EFO_0000341', 'EFO_0000341', 'MONDO_0004979', 'MONDO_0004979'],
      dtype=object), 'count': 4}_|_[ENSG00000169252,ENSG00000133019]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."
CHEMBL4297577,"nan_|_nan_|_Unknown_|_False_|_BELAPECTIN_|_nan_|_2.0_|_nan_|_False_|_False_|_[]_|_['Belapectin' 'GR-MD-02' 'Gr-md-02']_|_nan_|_nan_|_{'rows': array(['EFO_0003095', 'EFO_0000756', 'EFO_1001249', 'EFO_0001421',
       'EFO_0002617', 'EFO_0000666', 'EFO_0000676'], dtype=object), 'count': 7}_|_[ENSG00000131981]_|_Unknown drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."
CHEMBL4594536,"nan_|_nan_|_Unknown_|_False_|_CS-1003_|_nan_|_3.0_|_nan_|_False_|_False_|_[]_|_['Antibody cs1003' 'CS 1003' 'CS-1003' 'CS1003' 'Cs-1003' 'Cs1003'
 'Nofazinlimab' 'Recombinant pd-1 mab cs1003']_|_nan_|_nan_|_{'rows': array(['EFO_0000574', 'EFO_0000182', 'EFO_0000616', 'MONDO_0004992'],
      dtype=object), 'count': 4}_|_[ENSG00000188389]_|_Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."
CHEMBL5314421,"CCOc1cc(CN2CCOCC2)cc2[nH]c(=O)c3c(c12)NCCC3.Cl.Cl.O.O_|_RYWIWBIJBCNLMR-UHFFFAOYSA-N_|_Small molecule_|_False_|_AMELPARIB DIHYDROCHLORIDE DIHYDRATE_|_nan_|_2.0_|_CHEMBL3649803_|_False_|_False_|_[]_|_['Amelparib dihydrochloride dihydrate' 'JPI-289' 'Jpi-289']_|_nan_|_nan_|_{'rows': array(['EFO_0000712', 'HP_0002140'], dtype=object), 'count': 2}_|_[ENSG00000143799]_|_Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."
header,"['canonicalSmiles', 'inchiKey', 'drugType', 'blackBoxWarning', 'name', 'yearOfFirstApproval', 'maximumClinicalTrialPhase', 'parentId', 'hasBeenWithdrawn', 'isApproved', 'tradeNames', 'synonyms', 'crossReferences', 'childChemblIds', 'linkedDiseases', 'linkedTargets', 'description']"
